﻿FN Clarivate Analytics Web of Science
VR 1.0
PT J
AU Jo, DH
   Kim, JH
   Yang, W
   Kim, H
   Chang, S
   Kim, D
   Chang, M
   Lee, K
   Chung, J
   Kim, JH
AF Jo, Dong Hyun
   Kim, Jin Hyoung
   Yang, Wonjun
   Kim, Hyori
   Chang, Shinjae
   Kim, Dongjo
   Chang, Minseok
   Lee, Kihwang
   Chung, Junho
   Kim, Jeong Hun
TI Anti-complement component 5 antibody targeting MG4 domain inhibits
   choroidal neovascularization
SO ONCOTARGET
LA English
DT Article
DE age-related macular degeneration; choroidal neovascularization;
   complement component 5; MG4 domain; therapeutic antibody
ID PIGMENT EPITHELIAL-CELLS; MACULAR DEGENERATION; GENE-EXPRESSION;
   FACTOR-B; C5A; MACROPHAGE; ACTIVATION; C3A; POLARIZATION; POLYMORPHISM
AB Age-related macular degeneration (AMD) is one of the main causes of visual impairment in adults. Visual deterioration is more prominent in neovascular AMD with choroidal neovascularization (CNV). Clinical and postmortem studies suggested that complement system activation might induce CNV. In this study, we demonstrated that an anti-mouse complement component 5 (C5) antibody targeting MG4 domain of beta chain effectively inhibited CNV which was induced by laser photocoagulation in mice. The targeted epitope of this anti-C5 antibody was different from that of currently utilized anti-C5 antibody (eculizumab) in the MG7 domain in which a single nucleotide polymorphism (R885H/C) results in poor response to eculizumab. Even with targeting MG4 domain, this anti-C5 antibody reduced production of C5a, monocyte chemoattractant protein-1 and vascular endothelial growth factor to prevent infiltration of F4/80-positive cells into CNV lesions and formation of CNV. Furthermore, anti-C5 antibody targeting MG4 domain induced no definite toxicity in normal retina. These results demonstrated that anti-C5 antibody targeting MG4 domain inhibited CNV in neovascular AMD.
C1 [Jo, Dong Hyun; Kim, Jin Hyoung; Kim, Jeong Hun] Seoul Natl Univ Hosp, Clin Res Inst, Fight Angiogenesis Related Blindness FARB Lab, Seoul, South Korea.
   [Jo, Dong Hyun; Kim, Jeong Hun] Seoul Natl Univ, Coll Med, Med Res Ctr, Dept Biomed Sci & Prot Metab, Seoul, South Korea.
   [Yang, Wonjun; Chung, Junho] Seoul Natl Univ, Coll Med, Dept Biochem & Mol Biol, Seoul, South Korea.
   [Yang, Wonjun; Chung, Junho] Seoul Natl Univ, Coll Med, Dept Canc Biol, Seoul, South Korea.
   [Yang, Wonjun; Chung, Junho] Seoul Natl Univ, Coll Med, Canc Res Inst, Seoul, South Korea.
   [Kim, Hyori] Univ Ulsan, Coll Med, Asan Med Ctr, Asan Inst Life Sci, Seoul, South Korea.
   [Chang, Shinjae; Kim, Dongjo; Chang, Minseok] Celltrion Inc, Biotechnol Res Inst, Incheon, South Korea.
   [Lee, Kihwang] Ajou Univ, Sch Med, Dept Ophthalmol, Suwon, South Korea.
   [Kim, Jeong Hun] Seoul Natl Univ, Coll Med, Dept Ophthalmol, Seoul, South Korea.
C3 Seoul National University (SNU); Seoul National University Hospital;
   Seoul National University (SNU); Seoul National University (SNU); Seoul
   National University (SNU); Seoul National University (SNU); University
   of Ulsan; Asan Medical Center; Celltrion; Ajou University; Seoul
   National University (SNU)
RP Kim, JH (通讯作者)，Seoul Natl Univ Hosp, Clin Res Inst, Fight Angiogenesis Related Blindness FARB Lab, Seoul, South Korea.; Kim, JH (通讯作者)，Seoul Natl Univ, Coll Med, Med Res Ctr, Dept Biomed Sci & Prot Metab, Seoul, South Korea.; Chung, J (通讯作者)，Seoul Natl Univ, Coll Med, Dept Biochem & Mol Biol, Seoul, South Korea.; Chung, J (通讯作者)，Seoul Natl Univ, Coll Med, Dept Canc Biol, Seoul, South Korea.; Chung, J (通讯作者)，Seoul Natl Univ, Coll Med, Canc Res Inst, Seoul, South Korea.; Kim, JH (通讯作者)，Seoul Natl Univ, Coll Med, Dept Ophthalmol, Seoul, South Korea.
EM jjhchung@snu.ac.kr; steph25@snu.ac.kr
RI Jo, Dong Hyun/D-5962-2012
OI Jo, Dong Hyun/0000-0002-6320-6829; Kim, Jeong Hun/0000-0003-2957-1766
FU Pioneer Research Program of the National Research Foundation of
   Korea/Ministry of Education, Science and Technology [2012-0009544]; Bio
   & Medical Technology Development Program of the National Research
   Foundation - Korean government, MSIP [NRF-2015M3A9E6028949,
   NRF-2012M3A9A9055121]; Development of Platform Technology for Innovative
   Medical Measurements Program from the Korea Research Institute of
   Standards and Science [KRISS-2016-16011064]; Interdisciplinary Research
   Initiatives Program from College of Engineering and College of Medicine,
   Seoul National University [800-2016-0082]
FX This study was supported by the Pioneer Research Program of the National
   Research Foundation of Korea/Ministry of Education, Science and
   Technology (2012-0009544 to Je. H.K.), the Bio & Medical Technology
   Development Program of the National Research Foundation funded by the
   Korean government, MSIP (NRF-2015M3A9E6028949 to Je.H.K. and
   NRF-2012M3A9A9055121 to J.C.), the Development of Platform Technology
   for Innovative Medical Measurements Program from the Korea Research
   Institute of Standards and Science (KRISS-2016-16011064 to Je.H.K), and
   the Interdisciplinary Research Initiatives Program from College of
   Engineering and College of Medicine, Seoul National University
   (800-2016-0082 to Je.H.K.).
CR Albrecht EA, 2004, AM J PATHOL, V164, P849, DOI 10.1016/S0002-9440(10)63173-2
   Ambati J, 2003, NAT MED, V9, P1390, DOI 10.1038/nm950
   Barbas III C. F., 2001, PHAGE DISPLAY LAB MA
   Bora NS, 2006, J IMMUNOL, V177, P1872, DOI 10.4049/jimmunol.177.3.1872
   Brockmann C, 2015, GRAEF ARCH CLIN EXP, V253, P1695, DOI 10.1007/s00417-015-3041-z
   BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5
   Cortright DN, 2009, CURR EYE RES, V34, P57, DOI 10.1080/02713680802546658
   Coughlin B, 2016, SCI REP-UK, V6, DOI 10.1038/srep23794
   Czermak BJ, 1999, J IMMUNOL, V162, P2321
   Edgar R, 2002, NUCLEIC ACIDS RES, V30, P207, DOI 10.1093/nar/30.1.207
   Fukuoka Y, 2003, CLIN EXP IMMUNOL, V131, P248, DOI 10.1046/j.1365-2249.2003.02087.x
   Giles JL, 2015, J IMMUNOL, V194, P3029, DOI 10.4049/jimmunol.1402956
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Grossniklaus HE, 2002, MOL VIS, V8, P119
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   He LZ, 2014, J BIOL CHEM, V289, P8019, DOI 10.1074/jbc.M113.535765
   He LZ, 2013, AM J PATHOL, V182, P2407, DOI 10.1016/j.ajpath.2013.02.032
   Hu MJ, 2011, BRIT J OPHTHALMOL, V95, P1738, DOI 10.1136/bjophthalmol-2011-300235
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Jawad S, 2013, INVEST OPHTH VIS SCI, V54, P5959, DOI 10.1167/iovs.12-11380
   Jo DH, 2010, ARCH PHARM RES, V33, P1557, DOI 10.1007/s12272-010-1007-6
   Johnson LV, 2000, EXP EYE RES, V70, P441, DOI 10.1006/exer.1999.0798
   Jore MM, 2016, NAT STRUCT MOL BIOL, V23, P378, DOI 10.1038/nsmb.3196
   Kim H, 2013, EXP MOL MED, V45, DOI 10.1038/emm.2013.83
   Kim JH, 2008, J PHARMACOL EXP THER, V324, P643, DOI 10.1124/jpet.107.132720
   Kim JH, 2008, NEUROTOXICOLOGY, V29, P1131, DOI 10.1016/j.neuro.2008.06.006
   Kim MG, 2012, J BIOMED BIOTECHNOL, DOI 10.1155/2012/614146
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Krisinger MJ, 2012, BLOOD, V120, P1717, DOI 10.1182/blood-2012-02-412080
   Kurihara T, 2012, J CLIN INVEST, V122, P4213, DOI 10.1172/JCI65157
   Lambert V, 2013, NAT PROTOC, V8, P2197, DOI 10.1038/nprot.2013.135
   Lechner J, 2016, IMMUN AGEING, V13, DOI 10.1186/s12979-016-0060-5
   Leung LL, 2016, EBIOMEDICINE, V5, P20, DOI 10.1016/j.ebiom.2016.03.015
   Liu J., 2013, BIOMED RES INT, V2013, P1, DOI DOI 10.1109/BSN.2013.6575474
   Maller JB, 2007, NAT GENET, V39, P1200, DOI 10.1038/ng2131
   Morgan BP, 2015, NAT REV DRUG DISCOV, V14, P857, DOI 10.1038/nrd4657
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Nishimura J, 2014, NEW ENGL J MED, V370, P632, DOI 10.1056/NEJMoa1311084
   Nozaki M, 2006, P NATL ACAD SCI USA, V103, P2328, DOI 10.1073/pnas.0408835103
   Reynolds R, 2009, INVEST OPHTH VIS SCI, V50, P5818, DOI 10.1167/iovs.09-3928
   Ricklin D, 2008, ADV EXP MED BIOL, V632, P273, DOI 10.1007/978-0-387-78952-1_20
   Rohrer Barbel, 2011, Mol Immunol, V48, pe1, DOI 10.1016/j.molimm.2010.12.016
   Sakurai E, 2003, INVEST OPHTH VIS SCI, V44, P3578, DOI 10.1167/iovs.03-0097
   Sica A, 2012, J CLIN INVEST, V122, P787, DOI 10.1172/JCI59643
   Skeie JM, 2010, INVEST OPHTH VIS SCI, V51, P5336, DOI 10.1167/iovs.10-5322
   Thomas TC, 1996, MOL IMMUNOL, V33, P1389, DOI 10.1016/S0161-5890(96)00078-8
   Troutbeck R, 2012, CLIN EXP OPHTHALMOL, V40, P18, DOI 10.1111/j.1442-9071.2011.02581.x
   Tsutsumi-Miyahara C, 2004, BRIT J OPHTHALMOL, V88, P1217, DOI 10.1136/bjo.2003.036392
   Volk AL, 2016, SCI REP-UK, V6, DOI 10.1038/srep31365
   Williams MA, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009300.pub2
   Wolf-Schnurrbusch Ute E K, 2013, Ocul Immunol Inflamm, V21, P36, DOI 10.3109/09273948.2012.726393
NR 51
TC 9
Z9 9
U1 0
U2 0
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD JUL 11
PY 2017
VL 8
IS 28
BP 45506
EP 45516
DI 10.18632/oncotarget.17221
PG 11
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA FA5SS
UT WOS:000405504600046
PM 28477014
OA Green Submitted, Green Published, gold
DA 2022-11-30
ER

PT J
AU Smiley, S
   Nickerson, PE
   Comanita, L
   Daftarian, N
   El-Sehemy, A
   Tsai, ELS
   Matan-Lithwick, S
   Yan, KQ
   Thurig, S
   Touahri, Y
   Dixit, R
   Aavani, T
   De Repentingy, Y
   Baker, A
   Tsilfidis, C
   Biernaskie, J
   Sauve, Y
   Schuurmans, C
   Kothary, R
   Mears, AJ
   Wallace, VA
AF Smiley, Sheila
   Nickerson, Philip E.
   Comanita, Lacrimioara
   Daftarian, Narsis
   El-Sehemy, Ahmed
   Tsai, En Leh Samuel
   Matan-Lithwick, Stuart
   Yan, Keqin
   Thurig, Sherry
   Touahri, Yacine
   Dixit, Rajiv
   Aavani, Tooka
   De Repentingy, Yves
   Baker, Adam
   Tsilfidis, Catherine
   Biernaskie, Jeff
   Sauve, Yves
   Schuurmans, Carol
   Kothary, Rashmi
   Mears, Alan J.
   Wallace, Valerie A.
TI Establishment of a cone photoreceptor transplantation platform based on
   a novel cone-GFP reporter mouse line
SO SCIENTIFIC REPORTS
LA English
DT Article
ID PROTEIN-INTERACTION NETWORK; GREEN FLUORESCENT PROTEIN; RETINA;
   EXPRESSION; DEGENERATION; MICE; PRECURSORS; CELLS; GENE; NRL
AB We report successful retinal cone enrichment and transplantation using a novel cone-GFP reporter mouse line. Using the putative cone photoreceptor-enriched transcript Coiled-Coil Domain Containing 136 (Ccdc136) GFP-trapped allele, we monitored developmental reporter expression, facilitated the enrichment of cones, and evaluated transplanted GFP-labeled cones in wildtype and retinal degeneration mutant retinas. GFP reporter and endogenous Ccdc136 transcripts exhibit overlapping temporal and spatial expression patterns, both initiated in cone precursors of the embryonic retina and persisting to the adult stage in S and S/M opsin(+) cones as well as rod bipolar cells. The trapped allele does not affect cone function or survival in the adult mutant retina. When comparing the integration of GFP(+) embryonic cones and postnatal Nrl(-/-) 'cods' into retinas of adult wildtype and blind mice, both cell types integrated and exhibited a degree of morphological maturation that was dependent on donor age. These results demonstrate the amenability of the adult retina to cone transplantation using a novel transgenic resource that can advance therapeutic cone transplantation in models of age-related macular degeneration.
C1 [Smiley, Sheila; Yan, Keqin; Thurig, Sherry; De Repentingy, Yves; Baker, Adam; Tsilfidis, Catherine; Kothary, Rashmi; Mears, Alan J.; Wallace, Valerie A.] Ottawa Hosp Res Inst, 501 Smyth Rd, Ottawa, ON K1H 8L6, Canada.
   [Tsilfidis, Catherine; Wallace, Valerie A.] Univ Ottawa, Dept Ophthalmol, Ottawa, ON K1H 8M5, Canada.
   [Mears, Alan J.; Wallace, Valerie A.] Univ Ottawa, Dept Biochem, Ottawa, ON K1H 8M5, Canada.
   [Mears, Alan J.; Wallace, Valerie A.] Univ Ottawa, Dept Microbiol, Ottawa, ON K1H 8M5, Canada.
   [Mears, Alan J.; Wallace, Valerie A.] Univ Ottawa, Dept Immunol, Ottawa, ON K1H 8M5, Canada.
   [Smiley, Sheila; Tsilfidis, Catherine; Kothary, Rashmi] Univ Ottawa, Dept Cellular & Mol Med, Ottawa, ON K1H 8M5, Canada.
   [Kothary, Rashmi] Univ Ottawa, Dept Med, 451 Smyth Rd, Ottawa, ON K1H 8M5, Canada.
   [Smiley, Sheila; Nickerson, Philip E.; Comanita, Lacrimioara; El-Sehemy, Ahmed; Tsai, En Leh Samuel; Matan-Lithwick, Stuart; Wallace, Valerie A.] Univ Hlth Network, Div Vis Sci, Dept Ophthalmol & Vis Sci, Krembil Res Inst, Toronto, ON M5T 2S8, Canada.
   [El-Sehemy, Ahmed; Tsai, En Leh Samuel; Matan-Lithwick, Stuart; Wallace, Valerie A.] Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON M5S 2J4, Canada.
   [Daftarian, Narsis; Touahri, Yacine; Dixit, Rajiv; Aavani, Tooka; Schuurmans, Carol] Univ Calgary, Dept Biochem & Mol Biol, Hotchkiss Brain Inst, 3330 Hosp Dr NW, Calgary, AB T2N 4N1, Canada.
   [Daftarian, Narsis; Touahri, Yacine; Dixit, Rajiv; Aavani, Tooka; Biernaskie, Jeff; Schuurmans, Carol] Univ Calgary, Alberta Childrens Hosp Res Inst, 3330 Hosp Dr NW, Calgary, AB T2N 4N1, Canada.
   [Biernaskie, Jeff] Univ Calgary, Dept Comparat Biol & Expt Med, Hotchkiss Brain Inst, 3330 Hosp Dr NW, Calgary, AB T2N 4N1, Canada.
   [Sauve, Yves] Univ Alberta, Dept Ophthalmol & Visual Sci, Edmonton, AB T6G 2H7, Canada.
   [Daftarian, Narsis] Shahid Beheshti Univ Med Sci SBMU, Ocular Tissue Engn Res Ctr, Tehran, Iran.
C3 University of Ottawa; Ottawa Hospital Research Institute; University of
   Ottawa; University of Ottawa; University of Ottawa; University of
   Ottawa; University of Ottawa; University of Ottawa; Krembil Research
   Institute; University of Toronto; University Toronto Affiliates;
   University Health Network Toronto; University of Toronto; University of
   Calgary; University of Calgary; University of Calgary; University of
   Alberta; Shahid Beheshti University Medical Sciences
RP Wallace, VA (通讯作者)，Ottawa Hosp Res Inst, 501 Smyth Rd, Ottawa, ON K1H 8L6, Canada.; Wallace, VA (通讯作者)，Univ Ottawa, Dept Ophthalmol, Ottawa, ON K1H 8M5, Canada.; Wallace, VA (通讯作者)，Univ Ottawa, Dept Biochem, Ottawa, ON K1H 8M5, Canada.; Wallace, VA (通讯作者)，Univ Ottawa, Dept Microbiol, Ottawa, ON K1H 8M5, Canada.; Wallace, VA (通讯作者)，Univ Ottawa, Dept Immunol, Ottawa, ON K1H 8M5, Canada.; Wallace, VA (通讯作者)，Univ Hlth Network, Div Vis Sci, Dept Ophthalmol & Vis Sci, Krembil Res Inst, Toronto, ON M5T 2S8, Canada.; Wallace, VA (通讯作者)，Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON M5S 2J4, Canada.
EM vwallace@uhnresearch.ca
RI Daftarian, Narsis/AAW-5803-2020
OI Daftarian, Narsis/0000-0001-5846-8739; Tsai, En Leh
   Samuel/0000-0001-7553-9770; Kothary, Rashmi/0000-0002-9239-7310;
   Schuurmans, Carol/0000-0003-3567-0058
FU W. Garfield Weston Foundation/Brain Canada Foundation; Foundation
   Fighting Blindness; Krembil Foundation; Alberta Innovates [201201139]
   Funding Source: researchfish
FX We thank Dr. Cheryl Gregory Evans for antibodies and Anand Swaroop for
   the Nrl-EGFP mice. Valerie Wallace is the Donald K. Johnson Chair in
   Vision Research. This work was supported by operating grants to V. A.
   Wallace from The W. Garfield Weston Foundation/Brain Canada Foundation,
   The Foundation Fighting Blindness and The Krembil Foundation
CR Akimoto M, 2006, P NATL ACAD SCI USA, V103, P3890, DOI 10.1073/pnas.0508214103
   Barber AC, 2013, P NATL ACAD SCI USA, V110, P354, DOI 10.1073/pnas.1212677110
   Bartsch U, 2008, EXP EYE RES, V86, P691, DOI 10.1016/j.exer.2008.01.018
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Brooks MJ, 2011, MOL VIS, V17, P3034
   Camargo LM, 2007, MOL PSYCHIATR, V12, P74, DOI 10.1038/sj.mp.4001880
   Corbo JC, 2005, PLOS GENET, V1, P140, DOI 10.1371/journal.pgen.0010011
   Corbo JC, 2007, P NATL ACAD SCI USA, V104, P12069, DOI 10.1073/pnas.0705465104
   Daniele LL, 2005, INVEST OPHTH VIS SCI, V46, P2156, DOI 10.1167/iovs.04-1427
   Dekomien G, 2010, NEUROGENETICS, V11, P163, DOI 10.1007/s10048-009-0223-z
   Eberle D, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046305
   Fei YJ, 2001, VISUAL NEUROSCI, V18, P615, DOI 10.1017/S0952523801184117
   Furukawa T, 1999, NAT GENET, V23, P466, DOI 10.1038/70591
   Hattar S, 2003, NATURE, V424, P76, DOI 10.1038/nature01761
   Kinouchi R, 2003, NAT NEUROSCI, V6, P863, DOI 10.1038/nn1088
   Kunchithapautham K, 2009, INVEST OPHTH VIS SCI, V50, P4858, DOI 10.1167/iovs.08-3008
   Lakowski J, 2010, HUM MOL GENET, V19, P4545, DOI 10.1093/hmg/ddq378
   Lakowski J, 2015, STEM CELLS, V33, P2469, DOI 10.1002/stem.2051
   Lehner B, 2004, GENOME RES, V14, P1315, DOI 10.1101/gr.2122004
   Lim J, 2006, CELL, V125, P801, DOI 10.1016/j.cell.2006.03.032
   Lipinski DM, 2011, INVEST OPHTH VIS SCI, V52, P6617, DOI 10.1167/iovs.11-7932
   MacLaren RE, 2006, NATURE, V444, P203, DOI 10.1038/nature05161
   Mears AJ, 2001, NAT GENET, V29, P447, DOI 10.1038/ng774
   Ng L, 2001, NAT GENET, V27, P94, DOI 10.1038/83829
   Pacal M, 2012, DEV DYNAM, V241, P1525, DOI 10.1002/dvdy.23840
   Pearson RA, 2012, NATURE, V485, P99, DOI 10.1038/nature10997
   Rich KA, 1997, J COMP NEUROL, V388, P47
   Roberts MR, 2005, INVEST OPHTH VIS SCI, V46, P2897, DOI 10.1167/iovs.05-0093
   Samson M, 2009, DEV DYNAM, V238, P3218, DOI 10.1002/dvdy.22138
   Santos-Ferreira T, 2015, STEM CELLS, V33, P79, DOI 10.1002/stem.1824
   Schwartz SD, 2015, LANCET, V385, P509, DOI 10.1016/S0140-6736(14)61376-3
   Singh MS, 2013, P NATL ACAD SCI USA, V110, P1101, DOI 10.1073/pnas.1119416110
   Strettoi E, 2004, J NEUROSCI, V24, P7576, DOI 10.1523/JNEUROSCI.2245-04.2004
   Stuck MW, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032484
   Swaroop A, 2010, NAT REV NEUROSCI, V11, P563, DOI 10.1038/nrn2880
   Vinayagam A, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2001699
   Wang YP, 2005, DEVELOPMENT, V132, P5103, DOI 10.1242/dev.02096
   Warre-Cornish K, 2014, STEM CELLS DEV, V23, P941, DOI 10.1089/scd.2013.0471
   Zhang XM, 2004, WORLD J GASTROENTERO, V10, P1361
NR 39
TC 37
Z9 38
U1 0
U2 7
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD MAR 11
PY 2016
VL 6
AR 22867
DI 10.1038/srep22867
PG 14
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA DG0QW
UT WOS:000371771700001
PM 26965927
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Higgins, RD
AF Higgins, RD
TI Ocular neovascularization: Genomic implications
SO CURRENT GENOMICS
LA English
DT Article
DE angiogenesis; eye; gene; neovascularization; pigment epithelium derived
   factor (PEDF); retinopathy; vascular endothelial growth factor (VEGF)
ID ENDOTHELIAL GROWTH-FACTOR; EPITHELIUM-DERIVED FACTOR;
   VASCULAR-PERMEABILITY FACTOR; RETINAL NEOVASCULARIZATION; CHOROIDAL
   NEOVASCULARIZATION; FACTOR VEGF; PHOSPHOROTHIOATE OLIGONUCLEOTIDES;
   DIABETIC-RETINOPATHY; MACULAR DEGENERATION; CELL GROWTH
AB Ocular neovascularization in the form of retinopathy, choroidal neovascularization, and age-related macular degeneration can be sight-threatening. Therapies have been directed at tissue ablation consisting of laser surgery and cryotherapy as well as medical therapies to reduce intraocular pressure. These therapies Occur later in the course of many kinds of ocular neovascularization. Advances in the field of angiogenesis biology have been critical to understanding the biology of various forms of ocular neovascularization. Vascular endothelial growth factor (VEGF) is the prime candidate for target of new therapies. Basic cellular experiments, animal studies and studies in genetically altered mice have been extremely helpful in elucidating ocular vascular pathology. Identification of factors involved in neovascularization, such as VFGF, and modification of their expression are vital to moving the field of ocular angiogenesis forward for ultimate clinical benefit. Applications of genomics to neovascularization are being developed both for detection of populations at high risk and for potential therapeutic intervention. Molecular biologic tools such as angiostatic gene transfer may prove to be sight-saving in the near future.
C1 NICHD, Pregnancy & Perinatol Branch, Ctr Dev Biol & Perinatal Med, NIH, Bethesda, MD 20892 USA.
C3 National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver
   National Institute of Child Health & Human Development (NICHD)
RP Higgins, RD (通讯作者)，NICHD, Pregnancy & Perinatol Branch, Ctr Dev Biol & Perinatal Med, NIH, 6100 Execut Blvd,Room 4B03B,MSC 7510, Bethesda, MD 20892 USA.
EM higginsr@mail.nih.gov
CR AIELLO LP, 1995, P NATL ACAD SCI USA, V92, P10457, DOI 10.1073/pnas.92.23.10457
   Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Auricchio A, 2002, MOL THER, V6, P490, DOI 10.1006/mthe.2002.0702
   Barouch Fina C., 2004, International Ophthalmology Clinics, V44, P23, DOI 10.1097/00004397-200404430-00005
   Bhisitkul RB, 2005, ARCH OPHTHALMOL-CHIC, V123, P214, DOI 10.1001/archopht.123.2.214
   Campochiaro P A, 1999, Mol Vis, V5, P34
   CONNOLLY DT, 1989, J CLIN INVEST, V84, P1470, DOI 10.1172/JCI114322
   Dawson DW, 1999, SCIENCE, V285, P245, DOI 10.1126/science.285.5425.245
   FloresAguilar M, 1997, J INFECT DIS, V175, P1308, DOI 10.1086/516461
   Fong DS, 2004, DIABETES CARE, V27, P2540, DOI 10.2337/diacare.27.10.2540
   Frank RN, 1996, AM J OPHTHALMOL, V122, P393, DOI 10.1016/S0002-9394(14)72066-5
   Gao GQ, 2002, J BIOL CHEM, V277, P9492, DOI 10.1074/jbc.M108004200
   Garrett KL, 2001, J GENE MED, V3, P373, DOI 10.1002/jgm.197
   Hangai M, 1998, ARCH OPHTHALMOL-CHIC, V116, P342, DOI 10.1001/archopht.116.3.342
   Henry SP, 2004, TRENDS PHARMACOL SCI, V25, P523, DOI 10.1016/j.tips.2004.08.003
   Higgins RD, 2003, CURR EYE RES, V27, P123, DOI 10.1076/ceyr.27.2.123.15955
   Holekamp NM, 2002, AM J OPHTHALMOL, V134, P220, DOI 10.1016/S0002-9394(02)01549-0
   Kim SY, 2003, EXP EYE RES, V77, P433, DOI 10.1016/S0014-4835(03)00174-X
   LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986
   Lutty GA, 1996, ARCH OPHTHALMOL-CHIC, V114, P971, DOI 10.1001/archopht.1996.01100140179011
   Marwick C, 1998, JAMA-J AM MED ASSOC, V280, P871, DOI 10.1001/jama.280.10.871
   MILLER JW, 1994, AM J PATHOL, V145, P574
   Mori K, 2002, INVEST OPHTH VIS SCI, V43, P1994
   Ogata N, 2002, AM J OPHTHALMOL, V134, P348, DOI 10.1016/S0002-9394(02)01568-4
   Ogata N, 2001, AM J OPHTHALMOL, V132, P378, DOI 10.1016/S0002-9394(01)01008-X
   Ohno-Matsui K, 2001, J CELL PHYSIOL, V189, P323, DOI 10.1002/jcp.10026
   Ozaki H, 2000, AM J PATHOL, V156, P697, DOI 10.1016/S0002-9440(10)64773-6
   PEER J, 1995, LAB INVEST, V72, P638
   Phillips G D, 1994, In Vivo, V8, P961
   Pierce EA, 1996, ARCH OPHTHALMOL-CHIC, V114, P1219, DOI 10.1001/archopht.1996.01100140419009
   PIERCE EA, 1995, P NATL ACAD SCI USA, V92, P905, DOI 10.1073/pnas.92.3.905
   Renno RZ, 2002, INVEST OPHTH VIS SCI, V43, P1574
   Robinson GS, 1996, P NATL ACAD SCI USA, V93, P4851, DOI 10.1073/pnas.93.10.4851
   ROBINSON GS, 2001, FASEB J
   SENGER DR, 1983, SCIENCE, V219, P983, DOI 10.1126/science.6823562
   Shao CK, 2004, INVEST OPHTH VIS SCI, V45, P1758, DOI 10.1167/iovs.03-0882
   Shen WY, 2002, LAB INVEST, V82, P167, DOI 10.1038/labinvest.3780409
   Shen WY, 1999, BRIT J OPHTHALMOL, V83, P852, DOI 10.1136/bjo.83.7.852
   SHIMA DT, 1995, MOL MED, V1, P182, DOI 10.1007/BF03401566
   SMITH LEH, 1994, INVEST OPHTH VIS SCI, V35, P101
   Smith LEH, 2004, GROWTH HORM IGF RES, V14, pS140, DOI 10.1016/j.ghir.2004.03.030
   Smith Lois E H, 2003, Semin Neonatol, V8, P469, DOI 10.1016/S1084-2756(03)00119-2
   Smyth AP, 1997, J INVEST DERMATOL, V108, P523, DOI 10.1111/1523-1747.ep12289740
   Sone H, 1999, LIFE SCI, V65, P2573, DOI 10.1016/S0024-3205(99)00526-3
   Spranger J, 2001, DIABETES, V50, P2641, DOI 10.2337/diabetes.50.12.2641
   Stellmach V, 2001, P NATL ACAD SCI USA, V98, P2593, DOI 10.1073/pnas.031252398
   Stone J, 1996, INVEST OPHTH VIS SCI, V37, P290
   STONE J, 1995, J NEUROSCI, V15, P4738, DOI 10.1523/jneurosci.15-07-04738.1995
   Suzuma K, 1998, MICROVASC RES, V56, P183, DOI 10.1006/mvre.1998.2111
   Wells JA, 1996, BRIT J OPHTHALMOL, V80, P363, DOI 10.1136/bjo.80.4.363
NR 50
TC 0
Z9 0
U1 0
U2 1
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y26, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1389-2029
J9 CURR GENOMICS
JI Curr. Genomics
PD AUG
PY 2005
VL 6
IS 5
BP 315
EP 318
DI 10.2174/1389202054750185
PG 4
WC Biochemistry & Molecular Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA 959QU
UT WOS:000231533900002
DA 2022-11-30
ER

PT J
AU Kaiser, PK
AF Kaiser, PK
TI Verteporfin therapy in combination with triamcinolone: published studies
   investigating a potential synergistic effect
SO CURRENT MEDICAL RESEARCH AND OPINION
LA English
DT Review
DE age-related macular degeneration; choroidal neovascularization;
   triamcinolone acetonide; verteporfin therapy
ID ENDOTHELIAL GROWTH-FACTOR; EXUDATIVE MACULAR DEGENERATION;
   EPITHELIUM-DERIVED FACTOR; INTRAVITREAL TRIAMCINOLONE; PHOTODYNAMIC
   THERAPY; VISUAL IMPAIRMENT; CHOROIDAL NEOVASCULARIZATION; OLDER
   POPULATION; FACTOR VEGF; AGE
AB Evidence from randomized, placebo-controlled, double-masked studies has demonstrated that verteporfin (Visudyne*) therapy is effective in reducing the risk of visual acuity loss in selected groups of patients with choroidal neovascularization (CNV) due to age-related macular degeneration (AMD). Pilot studies of intravitreal triamcinolone acetonide monotherapy revealed promising results in patients with CNV due to AMD, but the visual acuity outcomes in a randomized, controlled study were lower than anticipated. Recently, however, there has been growing interest in the adjunctive use of triamcinolone to improve visual acuity and reduce regrowth of CNV in patients receiving verteporfin therapy. This review article surveys the currently available evidence, based on a Medline search covering the years 1980-2005 and abstracts from recent scientific meetings. A number of small-scale, uncontrolled pilot studies have indicated that the combination of triamcinolone acetonide with verteporfin therapy may be beneficial. Evidence is now needed from randomized, controlled studies to determine whether the potential benefits of combination therapy outweigh the possible risks of increased intraocular pressure, endophthalmitis, and progression of cataract that have been observed in trials of triamcinolone monotherapy.
C1 Cleveland Clin Fdn, Cole Eye Inst, Cleveland, OH 44195 USA.
C3 Cleveland Clinic Foundation
RP Kaiser, PK (通讯作者)，Cleveland Clin Fdn, Cole Eye Inst, 9500 Euclid Ave,i-22, Cleveland, OH 44195 USA.
EM pkkaiser@mac.com
OI Kaiser, Peter/0000-0001-5126-045X
CR *AG REL EY DIS STU, 2004, CURR OPIN OPHTHALMOL, V15, P181
   Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   [Anonymous], 1991, Arch Ophthalmol, V109, P1109
   [Anonymous], 1993, Arch Ophthalmol, V111, P1200
   ANTOSZYK AN, 1993, GRAEF ARCH CLIN EXP, V231, P34, DOI 10.1007/BF01681698
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Arnold JJ, 2004, AM J OPHTHALMOL, V137, P683, DOI 10.1016/j.ajo.2003.11.059
   Bakri SJ, 2003, OPHTHALMIC SUR LA IM, V34, P386
   BHATTACHERJEE P, 1983, INVEST OPHTH VIS SCI, V24, P1143
   BHAVSAR AR, 2004, AM AC OPHTH EUR SOC
   BHAVSAR AR, 2004, AM SOC RET SPEC 2004
   Blinder KJ, 2003, AM J OPHTHALMOL, V136, P407, DOI 10.1016/S0002-9394(03)00223-X
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bressler NM, 2002, ARCH OPHTHALMOL-CHIC, V120, P1443
   Bressler NM, 2005, RETINA-J RET VIT DIS, V25, P119
   Bressler NM, 2002, ARCH OPHTHALMOL-CHIC, V120, P1307
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Buch H, 2004, OPHTHALMOLOGY, V111, P53, DOI 10.1016/j.ophtha.2003.05.010
   Challa JK, 1998, AUST NZ J OPHTHALMOL, V26, P277, DOI 10.1111/j.1442-9071.1998.tb01330.x
   Ciulla TA, 2001, ARCH OPHTHALMOL-CHIC, V119, P399, DOI 10.1001/archopht.119.3.399
   *CMS US DEP HHHS, NAT COV AN NCA OC PH
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Cui JZ, 2000, GRAEF ARCH CLIN EXP, V238, P326, DOI 10.1007/s004170050360
   Danis RP, 1996, OPHTHALMOLOGY, V103, P2099, DOI 10.1016/S0161-6420(96)30383-7
   Danis RP, 2000, RETINA-J RET VIT DIS, V20, P244, DOI 10.1097/00006982-200003000-00004
   Dawson DW, 1999, SCIENCE, V285, P245, DOI 10.1126/science.285.5425.245
   Dimitrov PN, 2003, INVEST OPHTH VIS SCI, V44, P5075, DOI 10.1167/iovs.02-0457
   ELMATRI L, 2004, INVEST OPHTHALMOL VI, V45
   Eter N, 2004, OPHTHALMOLOGE, V101, P794, DOI 10.1007/s0034-004-1052-y
   Fischer S, 2001, EUR J PHARMACOL, V411, P231, DOI 10.1016/S0014-2999(00)00915-8
   Foran S, 2003, OPHTHALMIC EPIDEMIOL, V10, P215, DOI 10.1076/opep.10.4.215.15906
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gillies MC, 2003, ARCH OPHTHALMOL-CHIC, V121, P667, DOI 10.1001/archopht.121.5.667
   Gillies MC, 2004, ARCH OPHTHALMOL-CHIC, V122, P336, DOI 10.1001/archopht.122.3.336
   Gollnick SO, 2003, BRIT J CANCER, V88, P1772, DOI 10.1038/sj.bjc.6600864
   Hassan SE, 2002, OPTOMETRY VISION SCI, V79, P697, DOI 10.1097/00006324-200211000-00007
   INGBER DE, 1986, ENDOCRINOLOGY, V119, P1768, DOI 10.1210/endo-119-4-1768
   Ishibashi T, 1997, GRAEF ARCH CLIN EXP, V235, P159, DOI 10.1007/BF00941723
   JOHNSON RN, 2004, AM AC OPHTH EUR SOC
   Jonas JB, 2005, EYE, V19, P163, DOI 10.1038/sj.eye.6701438
   Jonas JB, 2004, ARCH OPHTHALMOL-CHIC, V122, P218, DOI 10.1001/archopht.122.2.218
   Jonas JB, 2003, BRIT J OPHTHALMOL, V87, P462, DOI 10.1136/bjo.87.4.462
   JONAS JB, 2004, AM AC OPHTH EUR SOC
   KAISER PK, 2003, INVEST OPHTHALMOL VI, V44
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Klein BEK, 2003, OPHTHALMOLOGY, V110, P644, DOI 10.1016/S0161-6420(02)01935-8
   Kuyk T, 1999, J REHABIL RES DEV, V36, P303
   Kvanta A, 1996, INVEST OPHTH VIS SCI, V37, P1929
   LEWIS GD, 1986, ENDOCRINOLOGY, V119, P62, DOI 10.1210/endo-119-1-62
   LI R, 2004, INVEST OPHTHALMOL VI, V45
   LOPEZ PF, 1991, AM J OPHTHALMOL, V112, P647, DOI 10.1016/S0002-9394(14)77270-8
   Lopez PF, 1996, INVEST OPHTH VIS SCI, V37, P855
   McGwin G, 2000, ACCIDENT ANAL PREV, V32, P735, DOI 10.1016/S0001-4575(99)00123-2
   Mori K, 2001, J CELL PHYSIOL, V188, P253, DOI 10.1002/jcp.1114
   MOSHFEGHI A, 2004, 2004 M RET SOC M 26
   Moshfeghi DM, 2003, AM J OPHTHALMOL, V136, P791, DOI 10.1016/S0002-9394(03)00483-5
   Nelson ML, 2003, RETINA-J RET VIT DIS, V23, P686, DOI 10.1097/00006982-200310000-00014
   Owsley C, 2001, OPTOMETRY VISION SCI, V78, P350, DOI 10.1097/00006324-200105000-00019
   PECK RE, 2004, AM AC OPHTH EUR SOC
   Penfold PL, 1995, AUST NZ J OPHTHALMOL, V23, P293, DOI 10.1111/j.1442-9071.1995.tb00179.x
   Penfold PL, 2000, CLIN EXP IMMUNOL, V121, P458, DOI 10.1046/j.1365-2249.2000.01316.x
   Penfold PL, 2002, INVEST OPHTH VIS SCI, V43, P3125
   Ranson NT, 2002, BRIT J OPHTHALMOL, V86, P527, DOI 10.1136/bjo.86.5.527
   Rechtman E, 2004, BRIT J OPHTHALMOL, V88, P344, DOI 10.1136/bjo.2003.027177
   Rogers AH, 2002, AM J OPHTHALMOL, V134, P566, DOI 10.1016/S0002-9394(02)01566-0
   ROGERS DL, 2004, INVEST OPHTHALMOL VI, V45
   ROTH DB, 2004, AM AC OPHTH EUR SOC
   RUBIN GS, 1994, OPTOMETRY VISION SCI, V71, P750, DOI 10.1097/00006324-199412000-00005
   Sackett Catherine Stewart, 2002, Insight, V27, P5
   SCHACHAT AP, 1994, ARCH OPHTHALMOL-CHIC, V112, P500
   Schlotzer-Schrehardt U, 2002, GRAEF ARCH CLIN EXP, V240, P748, DOI 10.1007/s00417-002-0517-4
   Schmidt-Erfurth U, 2000, SURV OPHTHALMOL, V45, P195, DOI 10.1016/S0039-6257(00)00158-2
   Schmidt-Erfurth U, 2002, INVEST OPHTH VIS SCI, V43, P830
   Schmidt-Erfurth U, 2003, INVEST OPHTH VIS SCI, V44, P4473, DOI 10.1167/iovs.02-1115
   SCHMIDTERFURTH U, 1994, OPHTHALMOLOGY, V101, P1953
   SCHMIDTERFURTH U, 1995, LASER SURG MED, V17, P178, DOI 10.1002/lsm.1900170207
   SEREGARD S, 1994, GRAEF ARCH CLIN EXP, V232, P325, DOI 10.1007/BF00175983
   Spaide RF, 2005, OPHTHALMOLOGY, V112, P301, DOI 10.1016/j.ophtha.2004.08.012
   Spaide RF, 2003, OPHTHALMOLOGY, V110, P1517, DOI 10.1016/S0161-6420(03)00544-X
   SPAIDE RF, 2004, AM AC OPHTH EUR SOC
   Spilsbury K, 2000, AM J PATHOL, V157, P135, DOI 10.1016/S0002-9440(10)64525-7
   TAP and VIP Study Group, 2002, RETINA, V22, P6
   *TAP STUD GROUP, IN PRESS ARCH OPHTHA
   *TAP VIP STUD GROU, 2004, RETINA, V24, P1
   Umland SP, 1997, J ALLERGY CLIN IMMUN, V100, P511, DOI 10.1016/S0091-6749(97)70144-1
   *VIM STUD GROUP, IN PRESS ARCH OPHTHA
   Wang YS, 2002, GRAEF ARCH CLIN EXP, V240, P42, DOI 10.1007/s00417-001-0398-y
   WILSON CA, 1992, ARCH OPHTHALMOL-CHIC, V110, P1155, DOI 10.1001/archopht.1992.01080200135041
   Wood JM, 2002, HUM FACTORS, V44, P482, DOI 10.1518/0018720024497664
NR 89
TC 23
Z9 26
U1 1
U2 1
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 0300-7995
EI 1473-4877
J9 CURR MED RES OPIN
JI Curr. Med. Res. Opin.
PD MAY
PY 2005
VL 21
IS 5
BP 705
EP 713
DI 10.1185/030079905X43659
PG 9
WC Medicine, General & Internal; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine; Research & Experimental Medicine
GA 931PZ
UT WOS:000229498700008
PM 15969870
DA 2022-11-30
ER

PT J
AU Chen, MN
   Rong, R
   Xia, XB
AF Chen, Meini
   Rong, Rong
   Xia, Xiaobo
TI Spotlight on pyroptosis: role in pathogenesis and therapeutic potential
   of ocular diseases
SO JOURNAL OF NEUROINFLAMMATION
LA English
DT Review
DE Caspase-1; Caspase-4; 5; 11; Eye; Gasdermin; Inflammasome; Pyroptosis
ID NONCANONICAL-INFLAMMASOME ACTIVATION; NLRP3 INFLAMMASOME; CELL-DEATH;
   MACULAR DEGENERATION; CYTOMEGALOVIRUS RETINITIS; DEPENDENT PYROPTOSIS;
   DIABETIC-RETINOPATHY; IL-1-BETA PRODUCTION; PROTECTIVE ROLE;
   AMYLOID-BETA
AB Pyroptosis is a programmed cell death characterized by swift plasma membrane disruption and subsequent release of cellular contents and pro-inflammatory mediators (cytokines), including IL-1 beta and IL-18. It differs from other types of programmed cell death such as apoptosis, autophagy, necroptosis, ferroptosis, and NETosis in terms of its morphology and mechanism. As a recently discovered form of cell death, pyroptosis has been demonstrated to be involved in the progression of multiple diseases. Recent studies have also suggested that pyroptosis is linked to various ocular diseases. In this review, we systematically summarized and discussed recent scientific discoveries of the involvement of pyroptosis in common ocular diseases, including diabetic retinopathy, age-related macular degeneration, AIDS-related human cytomegalovirus retinitis, glaucoma, dry eye disease, keratitis, uveitis, and cataract. We also organized new and emerging evidence suggesting that pyroptosis signaling pathways may be potential therapeutic targets in ocular diseases, hoping to provide a summary of overall intervention strategies and relevant multi-dimensional evaluations for various ocular diseases, as well as offer valuable ideas for further research and development from the perspective of pyroptosis.
C1 [Chen, Meini; Rong, Rong; Xia, Xiaobo] Cent South Univ, Eye Ctr, Xiangya Hosp, Changsha 410008, Hunan, Peoples R China.
   [Chen, Meini; Rong, Rong; Xia, Xiaobo] Hunan Key Lab Ophthalmol, Changsha 410008, Hunan, Peoples R China.
   [Chen, Meini; Rong, Rong; Xia, Xiaobo] Xiangya Hosp, Natl Clin Res Ctr Geriatr Dis, Changsha 410008, Hunan, Peoples R China.
C3 Central South University; Central South University
RP Xia, XB (通讯作者)，Cent South Univ, Eye Ctr, Xiangya Hosp, Changsha 410008, Hunan, Peoples R China.
EM xbxia21@csu.edu.cn
FU National Natural Science Foundation of China [81974134, 81400442,
   82171058]; Hunan Natural Science Foundation [2019JJ40474]; Key R&D plan
   of Hunan Province of China [2020SK2076]; National key research and
   development program of China [2020YFC2008205]
FX This work was supported by grants from the National Natural Science
   Foundation of China (Grant Nos. 81974134, 81400442, 82171058), the Hunan
   Natural Science Foundation (No. 2019JJ40474) and Key R&D plan of Hunan
   Province of China (No. 2020SK2076), National key research and
   development program of China (2020YFC2008205).
CR Adornetto A, 2019, NEURAL REGEN RES, V14, P391, DOI 10.4103/1673-5374.245465
   Al Mamun A, 2021, EUR J PHARMACOL, V904, DOI 10.1016/j.ejphar.2021.174166
   Anderson OA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067263
   Antonetti DA, 2021, NAT REV ENDOCRINOL, V17, P195, DOI 10.1038/s41574-020-00451-4
   Ardeljan CP, 2014, J CLIN MED, V3, P1542, DOI 10.3390/jcm3041542
   Bai J, 2021, OXID MED CELL LONGEV, V2021, DOI 10.1155/2021/8043299
   Bauer R, 2020, MOL ASPECTS MED, V76, DOI 10.1016/j.mam.2020.100863
   Bedoui S, 2020, NAT REV MOL CELL BIO, V21, P678, DOI 10.1038/s41580-020-0270-8
   Bhattarai N, 2021, CELLS-BASEL, V10, DOI 10.3390/cells10061405
   Bigger JE, 2000, INVEST OPHTH VIS SCI, V41, P2248
   Brandstetter C, 2016, J PHOTOCH PHOTOBIO B, V161, P177, DOI 10.1016/j.jphotobiol.2016.05.018
   Brito BE, 1999, INVEST OPHTH VIS SCI, V40, P2583
   Broz P, 2020, NAT REV IMMUNOL, V20, P143, DOI 10.1038/s41577-019-0228-2
   Burgener SS, 2019, CELL REP, V27, P3646, DOI 10.1016/j.celrep.2019.05.065
   Burillo-Sanz S, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-39113-5
   Burillo-Sanz S, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-09164-7
   Burkholder BM, 2021, BMJ-BRIT MED J, V372, DOI 10.1136/bmj.m4979
   Cai BX, 2022, J BIOL CHEM, V298, DOI 10.1016/j.jbc.2021.101553
   Cai MY, 2022, NEUROCHEM INT, V152, DOI 10.1016/j.neuint.2021.105221
   Carter JJ, 2021, EXP EYE RES, V209, DOI 10.1016/j.exer.2021.108651
   Carter JJ, 2020, PLOS PATHOG, V16, DOI 10.1371/journal.ppat.1009032
   Celkova L, 2015, J CLIN MED, V4, P172, DOI 10.3390/jcm4010172
   Chavarria-Smith J, 2015, IMMUNOL REV, V265, P22, DOI 10.1111/imr.12283
   Che H, 2020, FASEB J, V34, P14042, DOI 10.1096/fj.202001328R
   Chen H, 2020, OCUL SURF, V18, P783, DOI 10.1016/j.jtos.2020.07.001
   Chen H, 2020, MOL NEURODEGENER, V15, DOI 10.1186/s13024-020-00372-w
   Chen H, 2018, EXP EYE RES, V176, P59, DOI 10.1016/j.exer.2018.07.001
   Chen J., 2021, FASEB J, V35
   Chen KW, 2020, EMBO J, V39, DOI 10.15252/embj.2019103397
   Chen SW, 2020, J AM HEART ASSOC, V9, DOI 10.1161/JAHA.119.015513
   Chi W, 2017, J AUTOIMMUN, V80, P65, DOI 10.1016/j.jaut.2017.02.006
   Chi W, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0360-2
   Chi W, 2014, P NATL ACAD SCI USA, V111, P11181, DOI 10.1073/pnas.1402819111
   Chien H, 2012, J VIROL, V86, P10961, DOI 10.1128/JVI.01275-12
   Cho Y, 2022, PHARMACOL THERAPEUT, V235, DOI 10.1016/j.pharmthera.2022.108122
   Chu CJ, 2012, OCUL IMMUNOL INFLAMM, V20, P394, DOI 10.3109/09273948.2012.726392
   Clarke J, 2020, NAT REV RHEUMATOL, V16, P248, DOI 10.1038/s41584-020-0415-3
   Coll RC, 2019, NAT CHEM BIOL, V15, P556, DOI 10.1038/s41589-019-0277-7
   Cookson BT, 2001, TRENDS MICROBIOL, V9, P113, DOI 10.1016/S0966-842X(00)01936-3
   Corcoran SE, 2021, PHARMACOL REV, V73, P968, DOI 10.1124/pharmrev.120.000171
   Coulon PG, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01631
   Coyle S, 2021, BIOMOLECULES, V11, DOI 10.3390/biom11081239
   Craig JP, 2017, OCUL SURF, V15, P276, DOI 10.1016/j.jtos.2017.05.008
   Dai YQ, 2019, REDOX BIOL, V21, DOI 10.1016/j.redox.2018.101093
   Danesh-Meyer HV, 2016, PROG RETIN EYE RES, V51, P41, DOI 10.1016/j.preteyeres.2015.09.004
   Dempsey C, 2017, BRAIN BEHAV IMMUN, V61, P306, DOI 10.1016/j.bbi.2016.12.014
   Deng J, 2019, MOL IMMUNOL, V107, P142, DOI 10.1016/j.molimm.2018.12.024
   Deng WY, 2022, NATURE, V602, P496, DOI 10.1038/s41586-021-04384-4
   Deng Y, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.669696
   Dong N, 2019, CURR EYE RES, V44, P1236, DOI 10.1080/02713683.2019.1632350
   Doyle SL, 2012, NAT MED, V18, P791, DOI 10.1038/nm.2717
   Du JX, 2020, EXP EYE RES, V196, DOI 10.1016/j.exer.2020.108065
   Eissa LD, 2021, EUR J PHARMACOL, V901, DOI 10.1016/j.ejphar.2021.174061
   El-Sisi AEE, 2021, TOXICOL APPL PHARM, V410, DOI 10.1016/j.taap.2020.115340
   Ezquerro S, 2019, J CLIN ENDOCR METAB, V104, P21, DOI 10.1210/jc.2018-01171
   Fabiani C, 2020, OCUL IMMUNOL INFLAMM, V28, P298, DOI 10.1080/09273948.2018.1511810
   Fabiani C, 2017, CLIN RHEUMATOL, V36, P191, DOI 10.1007/s10067-016-3506-4
   Faiq MA, 2019, PROG RETIN EYE RES, V72, DOI 10.1016/j.preteyeres.2019.06.003
   Fan R, 2021, FREE RADICAL BIO MED, V173, P29, DOI 10.1016/j.freeradbiomed.2021.07.009
   Fang Y, 2020, BIOMED PHARMACOTHER, V121, DOI 10.1016/j.biopha.2019.109595
   Feng JH, 2021, PHYTOMEDICINE, V88, DOI 10.1016/j.phymed.2021.153604
   Fidler TP, 2021, NATURE, V592, P296, DOI 10.1038/s41586-021-03341-5
   Fricker M, 2018, PHYSIOL REV, V98, P813, DOI 10.1152/physrev.00011.2017
   Fritsch M, 2019, NATURE, V575, P683, DOI 10.1038/s41586-019-1770-6
   Galletti JG, 2017, IMMUNOLOGY, V150, P397, DOI 10.1111/imm.12716
   Gan JH, 2020, BIOMED RES INT, V2020, DOI 10.1155/2020/4510628
   Gao JY, 2018, J NEUROINFLAMM, V15, DOI 10.1186/s12974-018-1062-3
   Gao JY, 2015, MEDIAT INFLAMM, V2015, DOI 10.1155/2015/690243
   Ge KK, 2022, MICROVASC RES, V139, DOI 10.1016/j.mvr.2021.104265
   Gehrke N, 2018, J HEPATOL, V68, P986, DOI 10.1016/j.jhep.2018.01.008
   Gimenez F, 2016, J LEUKOCYTE BIOL, V99, P647, DOI 10.1189/jlb.3HI0715-321R
   Gnanaguru G, 2016, INVEST OPHTH VIS SCI, V57, P4704, DOI 10.1167/iovs.15-18663
   Gu CF, 2019, INVEST OPHTH VIS SCI, V60, P4215, DOI 10.1167/iovs.19-27825
   Guo LT, 2017, INT J MOL MED, V40, P898, DOI 10.3892/ijmm.2017.3077
   Haldar S, 2015, J BIOL CHEM, V290, P6574, DOI 10.1074/jbc.M114.617886
   Han JH, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22073318
   Hao JF, 2019, OCUL IMMUNOL INFLAMM, V27, P836, DOI 10.1080/09273948.2018.1450516
   Harun-Or-Rashid M, 2018, J NEUROINFLAMM, V15, DOI 10.1186/s12974-018-1346-7
   He Y, 2016, TRENDS BIOCHEM SCI, V41, P1012, DOI 10.1016/j.tibs.2016.09.002
   He Y, 2013, J IMMUNOL, V190, P334, DOI 10.4049/jimmunol.1202737
   Hirano M, 2015, J OPHTHALMIC INFLAMM, V5, DOI 10.1186/s12348-015-0065-9
   Hou CC, 2021, CLIN RHEUMATOL, V40, P4143, DOI 10.1007/s10067-021-05755-y
   Hou JW, 2020, NAT CELL BIOL, V22, P1264, DOI 10.1038/s41556-020-0575-z
   Hu JJ, 2020, NAT IMMUNOL, V21, P736, DOI 10.1038/s41590-020-0669-6
   Hu L, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-2476-2
   Hu YC, 2022, J MOL BIOL, V434, DOI 10.1016/j.jmb.2021.167379
   Hu ZZ, 2019, J CELL PHYSIOL, V234, P18849, DOI 10.1002/jcp.28523
   Huang LB, 2021, ARQ BRAS OFTALMOL, V84, P67, DOI 10.5935/0004-2749.20210010
   Huang PR, 2020, CELL BIOL INT, V44, P2213, DOI 10.1002/cbin.11429
   Huang YX, 2021, ANN ANAT, V235, DOI 10.1016/j.aanat.2020.151672
   Hytti M, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22136800
   Ildefonso CJ, 2016, ADV EXP MED BIOL, V854, P59, DOI 10.1007/978-3-319-17121-0_9
   Ildefonso CJ, 2015, HUM GENE THER, V26, P59, DOI 10.1089/hum.2014.089
   Jassim AH, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.699623
   Ji QS, 2021, INFLAMMATION, V44, P682, DOI 10.1007/s10753-020-01367-x
   Jiang MX, 2021, INT J CANCER, V149, P1408, DOI 10.1002/ijc.33698
   Jiang MX, 2020, CELL DEATH DISCOV, V6, DOI 10.1038/s41420-020-00349-0
   Jiang SQ, 2021, J STEROID BIOCHEM, V206, DOI 10.1016/j.jsbmb.2020.105789
   Jiang YD, 2019, J INFLAMM RES, V12, P153, DOI 10.2147/JIR.S210441
   Jin X, 2018, MOL MED REP, V18, P2277, DOI 10.3892/mmr.2018.9188
   Kaarniranta K, 2020, AGING DIS, V11, P851, DOI 10.14336/AD.2019.0809
   Kambara H, 2018, CELL REP, V22, P2924, DOI 10.1016/j.celrep.2018.02.067
   Kar S, 2019, ANTIOXIDANTS-BASEL, V8, DOI 10.3390/antiox8120638
   Kar S, 2019, AM J PHYSIOL-HEART C, V316, pH1237, DOI 10.1152/ajpheart.00004.2019
   Kast RE, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00280
   Kauppinen A, 2016, CELL MOL LIFE SCI, V73, P1765, DOI 10.1007/s00018-016-2147-8
   Kayagaki N, 2015, NATURE, V526, P666, DOI 10.1038/nature15541
   Kayagaki N, 2011, NATURE, V479, P117, DOI 10.1038/nature10558
   KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33
   Kerur N, 2018, NAT MED, V24, P50, DOI 10.1038/nm.4450
   Kerur N, 2013, INVEST OPHTH VIS SCI, V54, P7395, DOI 10.1167/iovs.13-12500
   Korhonen E, 2020, FASEB J, V34, P6437, DOI 10.1096/fj.201902355RR
   Kovacs SB, 2017, TRENDS CELL BIOL, V27, P673, DOI 10.1016/j.tcb.2017.05.005
   Kumar B, 2018, MOL THER, V26, P1568, DOI 10.1016/j.ymthe.2018.03.012
   Kumari P, 2020, IMMUNOL REV, V297, P83, DOI 10.1111/imr.12903
   Lammert CR, 2020, NATURE, V580, P647, DOI 10.1038/s41586-020-2174-3
   Lee EJ, 2022, J NEUROINFLAMM, V19, DOI 10.1186/s12974-022-02425-x
   Lee EJ, 2015, CLIN EXP OPHTHALMOL, V43, P349, DOI 10.1111/ceo.12438
   Lee YJ, 2006, HUM IMMUNOL, V67, P812, DOI 10.1016/j.humimm.2006.07.012
   Li AS, 2021, AM J OPHTHALMOL, V221, P246, DOI 10.1016/j.ajo.2020.07.021
   Li D, 2022, FRONT GENET, V13, DOI 10.3389/fgene.2022.867492
   Li HS, 2021, J BIOCHEM MOL TOXIC, V35, DOI 10.1002/jbt.22845
   Li J, 2021, ECOTOX ENVIRON SAFE, V219, DOI 10.1016/j.ecoenv.2021.112351
   Li L, 2016, SCI REP-UK, V6, DOI 10.1038/srep20098
   Li LP, 2021, PART FIBRE TOXICOL, V18, DOI 10.1186/s12989-021-00403-4
   Li S, 2019, EXP ANIM TOKYO, V68, P221, DOI 10.1538/expanim.18-0146
   Li WD, 2020, NEUROPEPTIDES, V82, DOI 10.1016/j.npep.2020.102057
   Li XM, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.8.31
   Li Y, 2018, BIOCHEM BIOPH RES CO, V501, P351, DOI 10.1016/j.bbrc.2018.03.148
   Li ZH, 2021, OXID MED CELL LONGEV, V2021, DOI 10.1155/2021/8868361
   Liao Y, 2019, INVEST OPHTH VIS SCI, V60, P3034, DOI 10.1167/iovs.18-26360
   Lim RR, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21030899
   Lin KM, 2014, P NATL ACAD SCI USA, V111, P775, DOI 10.1073/pnas.1320294111
   Ling CB, 2019, EYE, V33, P777, DOI 10.1038/s41433-018-0318-6
   Liu BH, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.667644
   Liu F, 2021, INFECT DRUG RESIST, V14, P859, DOI 10.2147/IDR.S292413
   Liu F, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.01320
   Liu J., 2020, CELL PROLIFERAT, V53
   Liu RZT, 2014, EXP EYE RES, V127, P49, DOI 10.1016/j.exer.2014.07.003
   Liu ZY, 2021, FREE RADICAL BIO MED, V168, P142, DOI 10.1016/j.freeradbiomed.2021.03.037
   Liu ZR, 2022, INT J BIOL SCI, V18, P717, DOI 10.7150/ijbs.64350
   Long QX, 2020, NAT MED, V26, P845, DOI 10.1038/s41591-020-0897-1
   Lu FF, 2020, J CELL PHYSIOL, V235, P3207, DOI 10.1002/jcp.29268
   Lu L, 2021, FRONT MED-LAUSANNE, V8, DOI 10.3389/fmed.2021.736316
   Lu L, 2018, J DIABETES RES, V2018, DOI 10.1155/2018/8193523
   Luger D, 2008, J EXP MED, V205, P799, DOI 10.1084/jem.20071258
   Macchioni L, 2021, ANTIOXIDANTS-BASEL, V10, DOI 10.3390/antiox10010025
   Mahendra CK, 2020, OXID MED CELL LONGEV, V2020, DOI 10.1155/2020/1904178
   Malik A, 2017, J CELL SCI, V130, P3955, DOI 10.1242/jcs.207365
   Man SM, 2017, IMMUNOL REV, V277, P61, DOI 10.1111/imr.12534
   Mangan MSJ, 2018, NAT REV DRUG DISCOV, V17, P588, DOI [10.1038/nrd.2018.97, 10.1038/nrd.2018.149]
   Masters SL, 2011, TRENDS MOL MED, V17, P276, DOI 10.1016/j.molmed.2011.01.005
   Matsubara JA, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00574
   McClellan SA, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0185718
   Meng CR, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.763092
   Menini S, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9081812
   Miyake S, 2020, BIOCHEM BIOPH RES CO, V527, P839, DOI 10.1016/j.bbrc.2020.04.127
   Moreno MC, 2005, FASEB J, V19, P1161, DOI 10.1096/fj.04-3313fje
   Mugisho OO, 2018, BBA-GEN SUBJECTS, V1862, P385, DOI 10.1016/j.bbagen.2017.11.015
   Nebel C, 2017, BIOCHEM BIOPH RES CO, V484, P681, DOI 10.1016/j.bbrc.2017.01.176
   Ni JD, 2021, LIFE SCI, V284, DOI 10.1016/j.lfs.2021.119466
   Niu LL, 2021, ECOTOX ENVIRON SAFE, V207, DOI 10.1016/j.ecoenv.2020.111306
   Niu LL, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0126277
   Nor MNM, 2020, NEUROTHERAPEUTICS, V17, P371, DOI 10.1007/s13311-019-00786-5
   Oh JJ, 2021, PATHOGENS, V10, DOI 10.3390/pathogens10070850
   Orning P, 2021, J LEUKOCYTE BIOL, V109, P121, DOI 10.1002/JLB.3MR0420-305R
   Orning P, 2018, SCIENCE, V362, P1064, DOI 10.1126/science.aau2818
   Orzalli MH, 2021, IMMUNITY, V54, P1447, DOI 10.1016/j.immuni.2021.04.012
   Ou AT, 2021, ACTA PHARMACOL SIN, V42, P1913, DOI 10.1038/s41401-021-00770-w
   Pan WW, 2021, PROG RETIN EYE RES, V84, DOI 10.1016/j.preteyeres.2021.100940
   Park B, 2019, NUTRIENTS, V11, DOI 10.3390/nu11112792
   Pepple KL, 2015, INVEST OPHTH VIS SCI, V56, P8438, DOI 10.1167/iovs.15-17523
   Perez VL, 2015, TRENDS IMMUNOL, V36, P354, DOI 10.1016/j.it.2015.04.003
   Planck SR, 2012, ANN RHEUM DIS, V71, P753, DOI 10.1136/annrheumdis-2011-200556
   Prasinou M, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102613
   Pronin A, 2019, FRONT MOL NEUROSCI, V12, DOI 10.3389/fnmol.2019.00036
   Qu WT, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01121
   Rajan S, 2020, NAT CHEM BIOL, V16, P876, DOI 10.1038/s41589-020-0553-6
   Ridker PM, 2017, NEW ENGL J MED, V377, P1119, DOI 10.1056/NEJMoa1707914
   Rogers C, 2019, MOL CELL ONCOL, V6, DOI 10.1080/23723556.2019.1621501
   Rogers C, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09397-2
   Rogers C, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14128
   Rosenzweig HL, 2012, INFLAMM RES, V61, P225, DOI 10.1007/s00011-011-0404-8
   Sarhan J, 2018, P NATL ACAD SCI USA, V115, pE10888, DOI 10.1073/pnas.1809548115
   Schafer N, 2020, ANTIOXIDANTS-BASEL, V9, DOI 10.3390/antiox9090793
   Schnappauf O, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01745
   Schneider KS, 2017, CELL REP, V21, P3846, DOI 10.1016/j.celrep.2017.12.018
   Seok JK, 2021, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.618231
   Shao BZ, 2015, FRONT PHARMACOL, V6, DOI 10.3389/fphar.2015.00262
   Shao XF, 2020, INT IMMUNOPHARMACOL, V79, DOI 10.1016/j.intimp.2019.106175
   Shestopalov VI, 2021, CELLS-BASEL, V10, DOI 10.3390/cells10081973
   Shi FS, 2022, MBIO, V13, DOI 10.1128/mbio.02739-21
   Shi HL, 2020, INT IMMUNOPHARMACOL, V81, DOI 10.1016/j.intimp.2020.106195
   Shi JJ, 2015, NATURE, V526, P660, DOI 10.1038/nature15514
   Shi YH, 2021, INT IMMUNOPHARMACOL, V92, DOI 10.1016/j.intimp.2020.107358
   Shome A, 2021, DRUG DISCOV TODAY, V26, P2839, DOI 10.1016/j.drudis.2021.06.017
   Shu B, 2021, CELL DEATH DISCOV, V7, DOI 10.1038/s41420-021-00756-x
   Sobolewska B, 2016, J RHEUMATOL, V43, P1101, DOI 10.3899/jrheum.150681
   Stein JD, 2021, JAMA-J AM MED ASSOC, V325, P164, DOI 10.1001/jama.2020.21899
   Su Q, 2021, MEDIAT INFLAMM, V2021, DOI 10.1155/2021/8086253
   Sun HJ, 2020, PHARMACOLOGY, V105, P28, DOI 10.1159/000502614
   Sun JR, 2020, THERANOSTICS, V10, P11637, DOI 10.7150/thno.48064
   Sun LZ, 2020, REDOX BIOL, V37, DOI 10.1016/j.redox.2020.101759
   Sun Y, 2018, J IMMUNOL, V201, P2767, DOI 10.4049/jimmunol.1701195
   Sun Y, 2020, BIOCHEM BIOPH RES CO, V532, P159, DOI 10.1016/j.bbrc.2020.07.028
   Swanson KV, 2019, NAT REV IMMUNOL, V19, P477, DOI 10.1038/s41577-019-0165-0
   Taabazuing CY, 2020, IMMUNOL REV, V297, P13, DOI 10.1111/imr.12884
   Tajima T, 2019, KIDNEY INT, V95, P1120, DOI 10.1016/j.kint.2018.11.034
   Tang W, 2021, ASIAN J PHARM SCI, V16, P459, DOI 10.1016/j.ajps.2021.03.005
   Tezel G, 2012, INVEST OPHTH VIS SCI, V53, P4220, DOI 10.1167/iovs.11-9101
   Thaiss CA, 2016, NATURE, V535, P65, DOI 10.1038/nature18847
   Thulasi P, 2017, OPHTHALMOLOGY, V124, pS27, DOI 10.1016/j.ophtha.2017.07.022
   Trittibach P, 2008, GENE THER, V15, P1478, DOI 10.1038/gt.2008.109
   Trotta MC, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0211005
   Tsuchiya K, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22010426
   Ugurel E, 2019, IN VIVO, V33, P1493, DOI 10.21873/invivo.11629
   Vakrakou AG, 2020, J AUTOIMMUN, V108, DOI 10.1016/j.jaut.2019.102381
   Vande Walle L, 2016, CURR BIOL, V26, pR568, DOI 10.1016/j.cub.2016.02.019
   Voet S, 2019, EMBO MOL MED, V11, DOI 10.15252/emmm.201810248
   Wan PX, 2020, CELL DEATH DIFFER, V27, P176, DOI 10.1038/s41418-019-0351-4
   Wang B, 2017, J STRUCT BIOL, V200, P279, DOI 10.1016/j.jsb.2017.08.001
   Wang CC, 2022, BIOCHEM PHARMACOL, V200, DOI 10.1016/j.bcp.2022.115042
   Wang KK, 2020, FRONT NEUROSCI-SWITZ, V14, DOI 10.3389/fnins.2020.00848
   Wang K, 2017, J BIOCHEM MOL TOXIC, V31, DOI 10.1002/jbt.21887
   Wang K, 2020, CELL, V180, P941, DOI 10.1016/j.cell.2020.02.002
   Wang LP, 2019, J MOL MED, V97, P523, DOI 10.1007/s00109-019-01753-5
   Wang P, 2019, MEDIAT INFLAMM, V2019, DOI 10.1155/2019/8908960
   Wang SL, 2015, INT J OPHTHALMOL-CHI, V8, P46, DOI 10.3980/j.issn.2222-3959.2015.01.08
   Wang S, 2020, IUBMB LIFE, V72, P1433, DOI 10.1002/iub.2267
   Wang XH, 2021, EXP EYE RES, V212, DOI 10.1016/j.exer.2021.108786
   Wang YM, 2020, BMC OPHTHALMOL, V20, DOI 10.1186/s12886-020-01565-z
   Wang YJ, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17010073
   Wang YP, 2017, NATURE, V547, P99, DOI 10.1038/nature22393
   Willermain F, 2012, PROG RETIN EYE RES, V31, P182, DOI 10.1016/j.preteyeres.2011.11.004
   Wooff Y, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-58849-z
   Wu JX, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.780142
   Wu XQ, 2021, NEUROSCIENCE, V478, P1, DOI 10.1016/j.neuroscience.2021.09.018
   Xi XT, 2020, BIOMED PHARMACOTHER, V125, DOI 10.1016/j.biopha.2020.109924
   Xiao WJ, 2021, ISCIENCE, V24, DOI 10.1016/j.isci.2021.103518
   Xie J, 2021, EXP EYE RES, V209, DOI 10.1016/j.exer.2021.108640
   Xu JY, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.753660
   Xu JX, 2018, MOL VIS, V24, P379
   Xu QY, 2021, EXP EYE RES, V208, DOI 10.1016/j.exer.2021.108618
   Xu S, 2021, EXP EYE RES, V211, DOI 10.1016/j.exer.2021.108750
   Xue YS, 2019, TRENDS IMMUNOL, V40, P1035, DOI 10.1016/j.it.2019.09.005
   Yan HJ, 2022, INT IMMUNOPHARMACOL, V102, DOI 10.1016/j.intimp.2021.108401
   Yanez-Soto B, 2014, OCUL SURF, V12, P178, DOI 10.1016/j.jtos.2014.01.004
   Yang F, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-1029-4
   Yang F, 2020, BIOCHEM BIOPH RES CO, V526, P553, DOI 10.1016/j.bbrc.2020.02.149
   Yang K, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.603689
   Yang M, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21197279
   Yang M, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21134658
   Yang MZ, 2021, OXID MED CELL LONGEV, V2021, DOI 10.1155/2021/5520644
   Yang XJ, 2019, CURR EYE RES, V44, P716, DOI 10.1080/02713683.2019.1584321
   Yang YT, 2021, ACUPUNCT MED, DOI 10.1177/09645284211039235
   Yao K, 2021, EXP EYE RES, V203, DOI 10.1016/j.exer.2020.108388
   YOSHIDA M, 1994, INVEST OPHTH VIS SCI, V35, P1107
   Yu P, 2021, SIGNAL TRANSDUCT TAR, V6, DOI 10.1038/s41392-021-00507-5
   Yu XY, 2021, EXP EYE RES, V202, DOI 10.1016/j.exer.2020.108300
   Yuan ZH, 2019, MOL VIS, V25, P359
   Yuksel S, 2014, INT IMMUNOL, V26, P71, DOI 10.1093/intimm/dxt046
   Yumnamcha T, 2019, FRONT NEUROSCI-SWITZ, V13, DOI 10.3389/fnins.2019.01065
   Zeng ZL, 2019, CELL PROLIFERAT, V52, DOI 10.1111/cpr.12563
   Zha X, 2020, AGING-US, V12, P8137, DOI 10.18632/aging.103130
   Zhang HS, 2021, NEUROCHEM RES, V46, P1747, DOI 10.1007/s11064-021-03285-2
   Zhang JY, 2021, CELL RES, V31, P980, DOI 10.1038/s41422-021-00506-9
   Zhang J, 2021, J INFLAMM RES, V14, P2955, DOI 10.2147/JIR.S310116
   Zhang XL, 2021, ARCH BIOCHEM BIOPHYS, V705, DOI 10.1016/j.abb.2021.108894
   Zhang YY, 2020, AM J PHYSIOL-CELL PH, V318, pC346, DOI 10.1152/ajpcell.00053.2019
   Zhang Y, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.308
   Zhang Y, 2018, J PINEAL RES, V64, DOI 10.1111/jpi.12449
   Zhang Y, 2021, CNS NEUROL DISORD-DR, V20, P285, DOI 10.2174/1871527319666201012125149
   Zhang YJ, 2019, EXP EYE RES, V188, DOI 10.1016/j.exer.2019.107771
   Zhang ZB, 2020, NATURE, V579, P415, DOI 10.1038/s41586-020-2071-9
   Zhao BB, 2015, EXP EYE RES, V138, P80, DOI 10.1016/j.exer.2015.06.018
   Zhao T, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0337-1
   Zhao WY, 2021, EXP EYE RES, V202, DOI 10.1016/j.exer.2020.108375
   Zheng QX, 2015, EXP EYE RES, V134, P133, DOI 10.1016/j.exer.2015.02.013
   Zheng QX, 2014, EXP EYE RES, V125, P1, DOI 10.1016/j.exer.2014.05.001
   Zheng XT, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.711939
   Zhou ZW, 2020, SCIENCE, V368, P965, DOI 10.1126/science.aaz7548
   Zhu B, 2020, DIABETES METAB SYNDR, V13, P365, DOI 10.2147/DMSO.S225791
   Zou J, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.751533
   Zou WJ, 2021, INT J MOL MED, V47, P732, DOI 10.3892/ijmm.2020.4833
   ZYCHLINSKY A, 1992, NATURE, V358, P167, DOI 10.1038/358167a0
NR 285
TC 0
Z9 0
U1 19
U2 19
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1742-2094
J9 J NEUROINFLAMM
JI J. Neuroinflamm.
PD JUL 14
PY 2022
VL 19
IS 1
AR 183
DI 10.1186/s12974-022-02547-2
PG 31
WC Immunology; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Immunology; Neurosciences & Neurology
GA 2X8EG
UT WOS:000825431800004
PM 35836195
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Leung, HH
   Leung, KS
   Durand, T
   Galano, JM
   Lee, JCY
AF Leung, Ho Hang
   Leung, Kin Sum
   Durand, Thierry
   Galano, Jean-Marie
   Lee, Jetty Chung-Yung
TI Measurement of Enzymatic and Nonenzymatic Polyunsaturated Fatty Acid
   Oxidation Products in Plasma and Urine of Macular Degeneration
   UsingLC-QTOF-MS/MS
SO LIPIDS
LA English
DT Article
DE Age-related macular degeneration; HETE; Isoprostanes; Lipid mediators;
   QTOF
ID LC-MS/MS; MASS-SPECTROMETRY; IN-VIVO; OXYGENATED METABOLITES; REACTIVE
   OXYGEN; CHROMATOGRAPHY; BIOMARKERS; F-2-ISOPROSTANES; ISOPROSTANES; CELL
AB Oxidized polyunsaturated fatty acids (PUFA) are associated to pathogenesis of diseases including cardiovascular and neurodegeneration. The novel products are not only biomarkers but also lipid mediators in gene regulation and signaling pathways. Herein, simultaneous quantitation of 28 products derived from nonenzymatic and enzymatic oxidation of PUFAi.e.5-, 15-F-2t-isoprostanes, 7-, 17-F-2t-dihomo-isoprostanes, 7-, 17-F-2t-dihomo-isofurans, 5-, 8-, 18-F-3t-isoprostanes, 4-, 10-, 13-, 14-, 20-F-4t-neuroprostanes, 5-, 8-, 9-, 11-,12-, 15-, 20-HETE, 4-, 7-, 11-, 14-, 17-HDHA, RvE1, and NPD1 using LC-(ESI)-QTOF-MS/MS was developed. These products were measurable in a single sample and the analytical time was relative short (similar to 15 min). Furthermore, we showed that the use of internal standards is a requisite to normalize matrix effects and preparation loss for the quantitation. Validation assays indicated the method to be robust for plasma and mid-stream urine sample analysis in particular from those of age-related macular degeneration subjects, where the accuracy of quantitation displayed good repeatability.
C1 [Leung, Ho Hang; Leung, Kin Sum; Lee, Jetty Chung-Yung] Univ Hong Kong, Sch Biol Sci, Pokfulam Rd, Hong Kong, Peoples R China.
   [Durand, Thierry; Galano, Jean-Marie] Univ Montpellier, Inst Biomol Max Mousseron, CNRS, UMR 5247,ENSCM, 5 Av Charles Flahault, F-34093 Montpellier 05, France.
C3 University of Hong Kong; Centre National de la Recherche Scientifique
   (CNRS); Universite de Montpellier
RP Lee, JCY (通讯作者)，Univ Hong Kong, Sch Biol Sci, Pokfulam Rd, Hong Kong, Peoples R China.
EM jettylee@hku.hk
RI Lee, Jetty Chung-Yung/S-1443-2019; Lee, Jetty Chung-Yung/E-1475-2011
OI Lee, Jetty Chung-Yung/0000-0002-8175-7069; Lee, Jetty
   Chung-Yung/0000-0002-8175-7069
CR Basu S, 2005, ANTIOXID REDOX SIGN, V7, P221, DOI 10.1089/ars.2005.7.221
   Bauer J, 2014, BRIT J PHARMACOL, V171, P3115, DOI 10.1111/bph.12677
   Bazan NG, 2005, BRAIN PATHOL, V15, P159
   Bessard J, 2001, J CHROMATOGR B, V754, P333, DOI 10.1016/S0378-4347(00)00621-6
   Dayaker G, 2014, CHEM-EUR J, V20, P2879, DOI 10.1002/chem.201304526
   de Carvalho C., 2018, MOLECULES, V23, P2853
   de la Torre A, 2015, CHEM-EUR J, V21, P2442, DOI 10.1002/chem.201405497
   de La Torre A, 2014, ANGEW CHEM INT EDIT, V53, P6249, DOI 10.1002/anie.201402440
   Dupuy A, 2016, ANAL CHIM ACTA, V921, P46, DOI 10.1016/j.aca.2016.03.024
   Forman HJ, 2008, ARCH BIOCHEM BIOPHYS, V477, P183, DOI 10.1016/j.abb.2008.06.011
   Galano JM, 2017, PROG LIPID RES, V68, P83, DOI 10.1016/j.plipres.2017.09.004
   Galano JM, 2015, BBA-MOL CELL BIOL L, V1851, P446, DOI 10.1016/j.bbalip.2014.11.004
   Geng CM, 2017, BIOSCI TRENDS, V11, P202, DOI 10.5582/bst.2017.01029
   Guy A, 2014, CHEM-EUR J, V20, P6374, DOI 10.1002/chem.201400380
   Halliwell B., 2015, FREE RADICAL BIO MED, P411
   Hayashi G, 2014, HUM MOL GENET, V23, P6838, DOI 10.1093/hmg/ddu407
   Ikei KN, 2012, J LIPID RES, V53, P2546, DOI 10.1194/jlr.M026385
   Janicka M, 2013, INT J MOL SCI, V14, P6157, DOI 10.3390/ijms14036157
   Janssen LJ, 2004, CHEM PHYS LIPIDS, V128, P101, DOI 10.1016/j.chemphyslip.2003.10.009
   Lee CYJ, 2008, FREE RADICAL BIO MED, V44, P1314, DOI 10.1016/j.freeradbiomed.2007.12.026
   Lee CYJ, 2009, ANTIOXID REDOX SIGN, V11, P407, DOI [10.1089/ars.2008.2179, 10.1089/ARS.2008.2179]
   Lee CYJ, 2004, BIOCHEM BIOPH RES CO, V320, P696, DOI 10.1016/j.bbrc.2004.06.015
   Lee YY, 2018, METHODS MOL BIOL, V1730, P83, DOI 10.1007/978-1-4939-7592-1_6
   Leung HH, 2019, FREE RADICAL BIO MED, V145, P349, DOI 10.1016/j.freeradbiomed.2019.10.007
   Lewis GD, 2008, J AM COLL CARDIOL, V52, P117, DOI 10.1016/j.jacc.2008.03.043
   Liang YL, 2003, FREE RADICAL BIO MED, V34, P409, DOI 10.1016/S0891-5849(02)01018-3
   Liu JB, 2014, CHEST, V146, P670, DOI 10.1378/chest.13-2568
   Mallet A. I., 2018, QUANTITATIVE BIOL CL
   Milne GL, 2007, NAT PROTOC, V2, P221, DOI 10.1038/nprot.2006.375
   Morrow JD, 2005, ARTERIOSCL THROM VAS, V25, P279, DOI 10.1161/01.ATV.0000152605.64964.c0
   MORROW JD, 1990, P NATL ACAD SCI USA, V87, P9383, DOI 10.1073/pnas.87.23.9383
   Oger C, 2010, CHEM-EUR J, V16, P13976, DOI 10.1002/chem.201002304
   Roberts LJ, 2000, FREE RADICAL BIO MED, V28, P505, DOI 10.1016/S0891-5849(99)00264-6
   Roy J, 2017, FREE RADICAL BIO MED, V102, P229, DOI 10.1016/j.freeradbiomed.2016.12.005
   Rund KM, 2018, ANAL CHIM ACTA, V1037, P63, DOI 10.1016/j.aca.2017.11.002
   Sanchez-Illana A, 2017, ANAL CHIM ACTA, V996, P88, DOI 10.1016/j.aca.2017.09.026
   Schwanke RC, 2016, EUR J PHARMACOL, V785, P156, DOI 10.1016/j.ejphar.2015.08.050
   Serhan CN, 2008, NAT REV IMMUNOL, V8, P349, DOI 10.1038/nri2294
   SHAH VP, 1991, EUR J DRUG METAB PH, V16, P249
   Signorini C, 2018, FREE RADICAL BIO MED, V115, P261, DOI 10.1016/j.freeradbiomed.2017.12.009
   SPECTOR AA, 1985, J LIPID RES, V26, P1015
   Thakare R, 2018, BIOMED CHROMATOGR, V32, DOI 10.1002/bmc.4102
   Toewe A, 2018, ANAL CHIM ACTA, V1031, P185, DOI 10.1016/j.aca.2018.05.020
   Tsikas D, 2014, J CHROMATOGR B, V964, P79, DOI 10.1016/j.jchromb.2014.03.017
   Wishart DS, 2008, DRUGS R&D, V9, P307, DOI 10.2165/00126839-200809050-00002
   Yucel K, 2018, CLIN LAB, V64, P69, DOI 10.7754/Clin.Lab.2017.170612
   Zmijewski JW, 2005, BIOCHEM SOC T, V33, P1385, DOI 10.1042/BST0331385
   Zu LY, 2016, THROMB RES, V144, P192, DOI 10.1016/j.thromres.2016.06.031
NR 48
TC 1
Z9 1
U1 1
U2 8
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0024-4201
EI 1558-9307
J9 LIPIDS
JI Lipids
PD NOV
PY 2020
VL 55
IS 6
BP 693
EP 706
DI 10.1002/lipd.12264
EA JUN 2020
PG 14
WC Biochemistry & Molecular Biology; Nutrition & Dietetics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Nutrition & Dietetics
GA OQ2VF
UT WOS:000544007600001
PM 32602621
DA 2022-11-30
ER

PT J
AU Abdullah, AS
   Rahebi, J
   Ozok, YE
   Aljanabi, M
AF Abdullah, Ahmad S.
   Rahebi, Javad
   Ozok, Yasa Eksioglu
   Aljanabi, Mohanad
TI A new and effective method for human retina optic disc segmentation with
   fuzzy clustering method based on active contour model
SO MEDICAL & BIOLOGICAL ENGINEERING & COMPUTING
LA English
DT Article
DE Retinal image analysis; Optic disc; Fuzzy clustering; Active contour;
   Optic disc segmentation
ID AUTOMATIC DETECTION; BLOOD-VESSELS; FUNDUS IMAGES; DIABETIC-RETINOPATHY;
   LOCALIZATION; DIAGNOSIS; BOUNDARY; LOCATION; NERVE
AB In this paper, a new approach is proposed for localization and segmentation of the optic disc in human retina images. This new approach can find the boundary of the optic disc by an initial fuzzy clustering means algorithm. The proposed approach uses active contour model evolution based on a fuzzy clustering algorithm. The robustness of the proposed approach was evaluated with retinal imaging medical databases, such as DRIVE, STARE, DIARETDB1, and DRIONS. These bases contained images affected by different abnormalities, for example, diabetes, retinitis pigmentosa, and age-related macular degeneration AMD. A success detection rate with 100% accuracy was achieved for the DRIVE, DIRATEDB1, and DRIONS-DB databases, and 97.53% for the STARE database. For the optic disc segmentation, the method achieved an average accuracy and overlap in the range of 97.01-99.46% and 78.35-84.56% in these four databases. The result was compared with various methods in the literature, and it was concluded that the proposed method is more accurate than the other existing methods.
C1 [Abdullah, Ahmad S.; Ozok, Yasa Eksioglu; Aljanabi, Mohanad] Altinbas Univ, Istanbul, Turkey.
   [Abdullah, Ahmad S.] Univ Diyala, Baqubah, Diyala, Iraq.
   [Rahebi, Javad] Univ Turkish Aeronaut Assoc, Ankara, Turkey.
   [Aljanabi, Mohanad] Al Furat Al Awsat Tech Univ, Kufa, Iraq.
C3 Altinbas University; University of Diyala; Turk Hava Kurumu University;
   Turkish Aeronautical Association; Al-Furat Al-Awsat Technical University
RP Abdullah, AS (通讯作者)，Altinbas Univ, Istanbul, Turkey.; Abdullah, AS (通讯作者)，Univ Diyala, Baqubah, Diyala, Iraq.
EM Ahmed.alogaidi28@gmail.com; jrahebi@thk.edu.tr;
   yasa.eksioglu@altinbas.edu.tr; mohanad.aljanabi@ogr.altinbas.edu.tr
RI ali, mohanad H./A-8527-2019; ABDULLAH, AHMED SULAIMAN/N-2545-2017
OI ali, mohanad H./0000-0001-5333-6825; ABDULLAH, AHMED
   SULAIMAN/0000-0002-8578-1760
CR Abdullah AS, 2018, MED BIOL ENG COMPUT, V56, P2015, DOI 10.1007/s11517-018-1840-1
   Abdullah M, 2016, PEERJ, V4, DOI 10.7717/peerj.2003
   Akram MU, 2010, LECT NOTES COMPUT SC, V6112, P40, DOI 10.1007/978-3-642-13775-4_5
   [Anonymous], 2007, BMVC 2007 P BR MACH, DOI DOI 10.5244/C.21.15
   Balazs H, 2010, I S BIOMED IMAGING, P1329, DOI 10.1109/ISBI.2010.5490242
   Bharkad S, 2017, BIOMED SIGNAL PROCES, V31, P483, DOI 10.1016/j.bspc.2016.09.009
   Carmona EJ, 2008, ARTIF INTELL MED, V43, P243, DOI 10.1016/j.artmed.2008.04.005
   CHAUDHURI S, 1989, IEEE T MED IMAGING, V8, P263, DOI 10.1109/42.34715
   Fleming AD, 2007, PHYS MED BIOL, V52, P331, DOI 10.1088/0031-9155/52/2/002
   Gonzalez R, 2006, RE WOODS DIGITAL IMA
   Gonzalez RC, 1977, DIGITAL IMAGE PROCES, P451, DOI DOI 10.1109/CVPR.2014.81
   Haleem MS, 2013, COMPUT MED IMAG GRAP, V37, P581, DOI 10.1016/j.compmedimag.2013.09.005
   Hoover A, 2003, IEEE T MED IMAGING, V22, P951, DOI 10.1109/TMI.2003.815900
   Kande GB, 2008, 2008 6 IND C COMP VI
   KASS M, 1987, INT J COMPUT VISION, V1, P321, DOI 10.1007/BF00133570
   Lu SJ, 2011, IEEE T BIO-MED ENG, V58, P88, DOI 10.1109/TBME.2010.2086455
   Lupascu CA, 2008, COMP MED SY, P17, DOI 10.1109/CBMS.2008.15
   Mahfouz AE, 2010, IEEE T IMAGE PROCESS, V19, P3285, DOI 10.1109/TIP.2010.2052280
   Meng XJ, 2018, NEUROCOMPUTING, V312, P285, DOI 10.1016/j.neucom.2018.05.114
   Morales S, 2013, IEEE T MED IMAGING, V32, P786, DOI 10.1109/TMI.2013.2238244
   Muangnak N, 2018, MED BIOL ENG COMPUT, V56, P583, DOI 10.1007/s11517-017-1705-z
   OTSU N, 1979, IEEE T SYST MAN CYB, V9, P62, DOI 10.1109/TSMC.1979.4310076
   Perez-Rovira A, 2010, J MOD OPTIC, V57, P136, DOI 10.1080/09500340903434526
   Rahebi J, 2016, MED BIOL ENG COMPUT, V54, P453, DOI 10.1007/s11517-015-1330-7
   Ramakanth SA, 2014, COMPUT MED IMAG GRAP, V38, P49, DOI 10.1016/j.compmedimag.2013.10.007
   Reza MN, 2018, BIOMED SIGNAL PROCES, V45, P274, DOI 10.1016/j.bspc.2018.05.027
   Roychowdhury S, 2016, IEEE J BIOMED HEALTH, V20, P1562, DOI 10.1109/JBHI.2015.2473159
   Salazar-Gonzalez A, 2014, IEEE J BIOMED HEALTH, V18, P1874, DOI 10.1109/JBHI.2014.2302749
   Seo JM, 2004, P ANN INT IEEE EMBS, V26, P1711
   Sinthanayothin C, 1999, BRIT J OPHTHALMOL, V83, P902, DOI 10.1136/bjo.83.8.902
   Staal J, 2004, IEEE T MED IMAGING, V23, P501, DOI 10.1109/TMI.2004.825627
   Stapor K, 2004, LECT NOTES COMPUT SC, V3039, P41
   Tan JH, 2017, J COMPUT SCI-NETH, V20, P70, DOI 10.1016/j.jocs.2017.02.006
   Walter T, 2002, IEEE T MED IMAGING, V21, P1236, DOI 10.1109/TMI.2002.806290
   Welfer D, 2013, PATTERN RECOGN LETT, V34, P476, DOI 10.1016/j.patrec.2012.12.011
   Welfer D, 2010, COMPUT BIOL MED, V40, P124, DOI 10.1016/j.compbiomed.2009.11.009
   Xu J, 2007, IEEE T BIO-MED ENG, V54, P473, DOI 10.1109/TBME.2006.888831
   Youssif AAHAR, 2008, IEEE T MED IMAGING, V27, P11, DOI 10.1109/TMI.2007.900326
   Zou BJ, 2018, COMPUT GRAPH-UK, V70, P281, DOI 10.1016/j.cag.2017.07.031
NR 39
TC 13
Z9 13
U1 0
U2 13
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 0140-0118
EI 1741-0444
J9 MED BIOL ENG COMPUT
JI Med. Biol. Eng. Comput.
PD JAN
PY 2020
VL 58
IS 1
BP 25
EP 37
DI 10.1007/s11517-019-02032-8
EA DEC 2019
PG 13
WC Computer Science, Interdisciplinary Applications; Engineering,
   Biomedical; Mathematical & Computational Biology; Medical Informatics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Computer Science; Engineering; Mathematical & Computational Biology;
   Medical Informatics
GA KH7NC
UT WOS:000499979800002
PM 31444623
DA 2022-11-30
ER

PT J
AU Hu, ZZ
   Lv, XH
   Chen, L
   Gu, XY
   Qian, HM
   Fransisca, S
   Zhang, ZY
   Liu, QH
   Xie, P
AF Hu, Zizhong
   Lv, Xuehua
   Chen, Lu
   Gu, Xunyi
   Qian, Huiming
   Fransisca, Silvia
   Zhang, Zhengyu
   Liu, Qinghuai
   Xie, Ping
TI Protective effects of microRNA-22-3p against retinal pigment epithelial
   inflammatory damage by targeting NLRP3 inflammasome
SO JOURNAL OF CELLULAR PHYSIOLOGY
LA English
DT Article
DE miR-22-3p; NLRP3; retinal pigment epithelia; retinopathy
ID OXIDATIVE STRESS; CELL-DEATH; ALU RNA; IL-1-BETA; INTERLEUKIN-1-BETA;
   DEGENERATION; PATHOGENESIS; INHIBITION; ACTIVATION; EXPRESSION
AB NLRP3, as a crucial inflammasome component, plays important roles in age-related macular degeneration. Though some activators of NLRP3 have been studied, microRNAs (miRNAs) which potentially regulate NLRP3 messenger RNA (mRNA) have not been fully explored in retinal pigment epithelial (RPE) cells and retinopathy. In this study, by miRNA microarray profiling and bioinformatic analysis, we identified that four miRNAs, miR-4286, miR-223-3p, miR-365a, miR-22-3p, may target NLRP3 mRNA in RPE inflammatory damage in vivo. Further, real-time polymerase chain reaction verified that only miR-22-3p was significantly decreased, which was associated with NLRP3 upregulation in blue-light-induced retinopathy. Mechanistically, the dual-fluorescent reporter suggested miR-22-3p directly binds NLRP3 mRNA. Moreover, overexpression of miR-22-3p could significantly reduce whereas inhibition miR-22-3p could increase the mRNA and protein expressions of NLRP3, Caspase-1, and mature IL-1 beta. Collectively, our results indicate that miR-22-3p plays a suppressive role in RPE damage by targeting NLRP3, which provides new insights into the future intervention to retinopathy.
C1 [Hu, Zizhong; Lv, Xuehua; Chen, Lu; Gu, Xunyi; Qian, Huiming; Fransisca, Silvia; Zhang, Zhengyu; Liu, Qinghuai; Xie, Ping] Nanjing Med Univ, Dept Ophthalmol, Affiliated Hosp 1, Nanjing, Jiangsu, Peoples R China.
   [Lv, Xuehua] Nanjing Med Univ, Dept Ophthalmol, Childrens Hosp, Nanjing, Jiangsu, Peoples R China.
C3 Nanjing Medical University; Nanjing Medical University
RP Liu, QH; Xie, P (通讯作者)，300 Guangzhou Rd, Nanjing 210029, Jiangsu, Peoples R China.
EM liuqh@njmu.edu.cn; xieping9@126.com
OI Liu, Qinghuai/0000-0003-1605-1964; hu, zizhong/0000-0001-6289-1804
FU General Project of the National Natural Science [81870669]; Key Project
   of Research and Development Plan [2017YFA0104101]; General Project of
   Jiangsu Natural Science [BK20171503]
FX General Project of the National Natural Science, Grant/Award Number:
   81870669; Key Project of Research and Development Plan, Grant/Award
   Number: 2017YFA0104101; General Project of Jiangsu Natural Science,
   Grant/Award Number: BK20171503
CR Ameres SL, 2013, NAT REV MOL CELL BIO, V14, P475, DOI 10.1038/nrm3611
   Anderson OA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067263
   Chen QQ, 2019, FREE RADICAL BIO MED, V130, P48, DOI 10.1016/j.freeradbiomed.2018.10.419
   Datta S, 2017, PROG RETIN EYE RES, V60, P201, DOI 10.1016/j.preteyeres.2017.03.002
   Fang Y, 2016, SCI REP-UK, V6, DOI 10.1038/srep21018
   Friedlander RM, 1996, J EXP MED, V184, P717, DOI 10.1084/jem.184.2.717
   Gnanaguru G, 2016, INVEST OPHTH VIS SCI, V57, P4704, DOI 10.1167/iovs.15-18663
   Guo L, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/168358
   Howell JC, 2013, MOL VIS, V19, P544
   Hu ZZ, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.363
   Huang WQ, 2017, CELL PHYSIOL BIOCHEM, V43, P1346, DOI 10.1159/000481846
   Kerur N, 2018, NAT MED, V24, P50, DOI 10.1038/nm.4450
   Kim Y, 2014, P NATL ACAD SCI USA, V111, P16082, DOI 10.1073/pnas.1403814111
   Kowluru RA, 2004, BRIT J OPHTHALMOL, V88, P1343, DOI 10.1136/bjo.2003.038133
   Lee SY, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.266
   Lei CY, 2017, NEUROSCIENCE, V360, P48, DOI 10.1016/j.neuroscience.2017.07.053
   Li S, 2018, ONCOGENE, V37, P884, DOI 10.1038/onc.2017.381
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Lukiw Walter J, 2012, Int J Biochem Mol Biol, V3, P105
   Mao XY, 2018, BIOMED PHARMACOTHER, V103, P517, DOI 10.1016/j.biopha.2018.04.038
   Mao XY, 2016, DISCOV MED, V22, P337
   Miller JW, 2013, OPHTHALMOLOGY, V120, P106, DOI 10.1016/j.ophtha.2012.07.038
   Ming GF, 2016, BIOCHEM BIOPH RES CO, V478, P1382, DOI 10.1016/j.bbrc.2016.08.133
   Piccini A, 2008, P NATL ACAD SCI USA, V105, P8067, DOI 10.1073/pnas.0709684105
   Pogue AI, 2018, CELL MOL NEUROBIOL, V38, P1021, DOI 10.1007/s10571-017-0572-3
   Shi HQ, 2015, BIOCHEM BIOPH RES CO, V463, P1071, DOI 10.1016/j.bbrc.2015.06.060
   Song YX, 2019, BIOCHEM BIOPH RES CO, V509, P359, DOI 10.1016/j.bbrc.2018.12.139
   Tarallo V, 2012, CELL, V149, P847, DOI 10.1016/j.cell.2012.03.036
   Tian B, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0160887
   Villegas VM, 2017, EXPERT OPIN DRUG DEL, V14, P273, DOI 10.1080/17425247.2016.1213240
   Wen XF, 2018, PROG RETIN EYE RES, V64, P84, DOI 10.1016/j.preteyeres.2018.01.001
   Xiao LF, 2017, CELL PHYSIOL BIOCHEM, V42, P901, DOI 10.1159/000478645
   Xie XJ, 2017, MOL PAIN, V13, DOI 10.1177/1744806917706582
   Yerramothu P, 2018, EYE, V32, P491, DOI 10.1038/eye.2017.241
   Zhang Y, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.308
   Zhou QB, 2011, P NATL ACAD SCI USA, V108, P8287, DOI 10.1073/pnas.1105254108
   Zhou T, 2018, CELL PHYSIOL BIOCHEM, V49, P798, DOI 10.1159/000493042
NR 37
TC 27
Z9 30
U1 1
U2 32
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0021-9541
EI 1097-4652
J9 J CELL PHYSIOL
JI J. Cell. Physiol.
PD OCT
PY 2019
VL 234
IS 10
BP 18849
EP 18857
DI 10.1002/jcp.28523
PG 9
WC Cell Biology; Physiology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Physiology
GA IH7ML
UT WOS:000474688200179
PM 30927257
DA 2022-11-30
ER

PT J
AU Flores, T
   Huang, T
   Bhuckory, M
   Ho, E
   Chen, ZJ
   Dalal, R
   Galambos, L
   Kamins, T
   Mathieson, K
   Palanker, D
AF Flores, Thomas
   Huang, Tiffany
   Bhuckory, Mohajeet
   Ho, Elton
   Chen, Zhijie
   Dalal, Roopa
   Galambos, Ludwig
   Kamins, Theodore
   Mathieson, Keith
   Palanker, Daniel
TI Honeycomb-shaped electro-neural interface enables cellular-scale pixels
   in subretinal prosthesis
SO SCIENTIFIC REPORTS
LA English
DT Article
ID RETINAL PROSTHESIS; STIMULATION; CELLS; MICROGLIA; ANIMALS; VISION;
   DESIGN; SIGHT; VIVO
AB High-resolution visual prostheses require small, densely packed pixels, but limited penetration depth of the electric field formed by a planar electrode array constrains such miniaturization. We present a novel honeycomb configuration of an electrode array with vertically separated active and return electrodes designed to leverage migration of retinal cells into voids in the subretinal space. Insulating walls surrounding each pixel decouple the field penetration depth from the pixel width by aligning the electric field vertically, enabling a decrease of the pixel size down to cellular dimensions. We demonstrate that inner retinal cells migrate into the 25 mu m deep honeycomb wells as narrow as 18 mu m, resulting in more than half of these cells residing within the electrode cavities. Immune response to honeycombs is comparable to that with planar arrays. Modeled stimulation threshold current density with honeycombs does not increase substantially with reduced pixel size, unlike quadratic increase with planar arrays. This 3-D electrode configuration may enable functional restoration of central vision with acuity better than 20/100 for millions of patients suffering from age-related macular degeneration.
C1 [Flores, Thomas] Stanford Univ, Dept Appl Phys, Stanford, CA 94305 USA.
   [Flores, Thomas; Bhuckory, Mohajeet; Ho, Elton; Chen, Zhijie; Kamins, Theodore; Palanker, Daniel] Stanford Univ, Hansen Expt Phys Lab, Stanford, CA 94305 USA.
   [Huang, Tiffany; Chen, Zhijie; Galambos, Ludwig; Kamins, Theodore] Stanford Univ, Dept Elect Engn, Stanford, CA 94305 USA.
   [Bhuckory, Mohajeet; Dalal, Roopa; Palanker, Daniel] Stanford Univ, Dept Ophthalmol, Stanford, CA 94305 USA.
   [Ho, Elton] Stanford Univ, Dept Phys, Stanford, CA 94305 USA.
   [Mathieson, Keith] Univ Strathclyde, Inst Photon, Glasgow, Lanark, Scotland.
C3 Stanford University; Stanford University; Stanford University; Stanford
   University; Stanford University; University of Strathclyde
RP Flores, T (通讯作者)，Stanford Univ, Dept Appl Phys, Stanford, CA 94305 USA.; Flores, T (通讯作者)，Stanford Univ, Hansen Expt Phys Lab, Stanford, CA 94305 USA.
EM tomflo@stanford.edu
RI Mathieson, Keith/G-6308-2011
OI Mathieson, Keith/0000-0002-9517-8076; Palanker,
   Daniel/0000-0002-0480-3025; Kamins, Theodore/0000-0001-8319-1161; Chen,
   Zhijie/0000-0003-2705-065X
FU National Institutes of Health [R01-EY-018608, R01-EY-027786]; Department
   of Defense [W81XWH-15-1-0009]; Stanford Institute of Neuroscience;
   Research to Prevent Blindness; National Science Foundation
   [ECCS-1542152]; NATIONAL EYE INSTITUTE [R01EY027786, R01EY018608]
   Funding Source: NIH RePORTER
FX We would like to thank Dr. Xin Lei for her advice regarding fabrication
   of the implants and Dr. Henri Lorach for his help with training for
   surgeries. Studies were supported by the National Institutes of Health
   (Grants R01-EY-018608, R01-EY-027786), the Department of Defense (Grant
   W81XWH-15-1-0009), Stanford Institute of Neuroscience, and Research to
   Prevent Blindness. Fabrication of the silicon implants was performed at
   the Stanford Nanofabrication Facility (SNF) and Stanford Nano Shared
   Facilities (SNSF), supported by the National Science Foundation (Award
   ECCS-1542152).
CR Adekunle AN, 2015, TRANSL VIS SCI TECHN, V4, DOI 10.1167/tvst.4.4.5
   [Anonymous], FRONT NEUROENG
   Barriga-Rivera A, 2017, SCI REP-UK, V7, DOI 10.1038/srep42682
   Boinagrov D, 2012, J NEUROPHYSIOL, V108, P3233, DOI 10.1152/jn.01058.2011
   Boinagrov D, 2010, J NEUROPHYSIOL, V104, P2236, DOI 10.1152/jn.00343.2010
   Butterwick A, 2009, EXP EYE RES, V88, P22, DOI 10.1016/j.exer.2008.09.018
   Chichilnisky EJ, 2001, NETWORK-COMP NEURAL, V12, P199, DOI 10.1088/0954-898X/12/2/306
   Cogan SF, 2009, J BIOMED MATER RES B, V89B, P353, DOI 10.1002/jbm.b.31223
   Eiber CD, 2017, IEEE T NEUR SYS REH, V25, P2490, DOI 10.1109/TNSRE.2017.2730880
   EMERSON RC, 1992, BIOL CYBERN, V66, P291, DOI 10.1007/BF00203665
   Fernandez-Arjona MD, 2017, FRONT CELL NEUROSCI, V11, DOI 10.3389/fncel.2017.00235
   Flores T, 2018, J NEURAL ENG, V15, DOI 10.1088/1741-2552/aaac39
   Flores T, 2016, J NEURAL ENG, V13, DOI 10.1088/1741-2560/13/3/036010
   Goetz GA, 2016, REP PROG PHYS, V79, DOI 10.1088/0034-4885/79/9/096701
   Ho AC, 2015, OPHTHALMOLOGY, V122, P1547, DOI 10.1016/j.ophtha.2015.04.032
   Ho E., INVEST OPHTHALMOL VI, V59, P3977
   Jensen RJ, 2005, INVEST OPHTH VIS SCI, V46, P1486, DOI 10.1167/iovs.04-1018
   Jonas V., 2017, INVEST OPHTH VIS SCI, V58, P4190
   Kane SR, 2013, IEEE T BIO-MED ENG, V60, P2153, DOI 10.1109/TBME.2013.2248152
   KARWOSKI CJ, 1986, ANN NY ACAD SCI, V481, P365, DOI 10.1111/j.1749-6632.1986.tb27166.x
   Kezic JM, 2013, INVEST OPHTH VIS SCI, V54, P854, DOI 10.1167/iovs.12-10876
   Lee JE, 2008, INVEST OPHTH VIS SCI, V49, P4169, DOI 10.1167/iovs.08-2076
   Lee YK, 2017, ACS NANO, V11, P12562, DOI 10.1021/acsnano.7b06697
   Loizos K, 2016, PHYS MED BIOL, V61, P4491, DOI 10.1088/0031-9155/61/12/4491
   Lorach H, 2015, INVEST OPHTH VIS SCI, V56, P7444, DOI 10.1167/iovs.15-17521
   Lorach H, 2015, VISION RES, V111, P142, DOI 10.1016/j.visres.2014.09.007
   Lorach H, 2015, NAT MED, V21, P476, DOI 10.1038/nm.3851
   Loudin JD, 2007, J NEURAL ENG, V4, pS72, DOI 10.1088/1741-2560/4/1/S09
   Mathieson K, 2012, NAT PHOTONICS, V6, P391, DOI [10.1038/nphoton.2012.104, 10.1038/NPHOTON.2012.104]
   Matteucci PB, 2016, INVEST OPHTH VIS SCI, V57, P1031, DOI 10.1167/iovs.15-18400
   Matteucci PB, 2013, INVEST OPHTH VIS SCI, V54, P4307, DOI 10.1167/iovs.13-11653
   Palanker D, 2004, INVEST OPHTH VIS SCI, V45, P3266, DOI 10.1167/iovs.03-1327
   Palanker D. V., NEW ENGLAND J MED
   Palanker D, 2005, J NEURAL ENG, V2, pS105, DOI 10.1088/1741-2560/2/1/012
   Pan YL, 2013, IEEJ T ELECTR ELECTR, V8, P310, DOI 10.1002/tee.21860
   Ransohoff RM, 2009, ANNU REV IMMUNOL, V27, P119, DOI 10.1146/annurev.immunol.021908.132528
   Schindelin J, 2012, NAT METHODS, V9, P676, DOI [10.1038/NMETH.2019, 10.1038/nmeth.2019]
   Stingl K, 2017, FRONT NEUROSCI-SWITZ, V11, DOI 10.3389/fnins.2017.00445
   Stingl K, 2015, VISION RES, V111, P149, DOI 10.1016/j.visres.2015.03.001
   Stutzki H, 2016, J NEUROPHYSIOL, V116, P1684, DOI 10.1152/jn.01095.2015
   Wang BH, 2015, IEEE ENG MED BIO, P1650, DOI 10.1109/EMBC.2015.7318692
   Wang LL, 2012, J NEURAL ENG, V9, DOI 10.1088/1741-2560/9/4/046014
   Weiland JD, 2016, ANNU REV VIS SCI, V2, P273, DOI 10.1146/annurev-vision-111815-114425
   Werginz P, 2015, VISION RES, V111, P170, DOI 10.1016/j.visres.2014.12.002
   Werginz P, 2016, J NEURAL ENG, V13, DOI 10.1088/1741-2560/13/4/046013
   Westheimer G, 2008, P ROY SOC B-BIOL SCI, V275, P2777, DOI 10.1098/rspb.2008.0712
   Wilke RGH, 2011, J NEURAL ENG, V8, DOI 10.1088/1741-2560/8/4/046016
   Zrenner E, 2011, P ROY SOC B-BIOL SCI, V278, P1489, DOI 10.1098/rspb.2010.1747
NR 48
TC 24
Z9 24
U1 1
U2 2
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD JUL 23
PY 2019
VL 9
AR 10657
DI 10.1038/s41598-019-47082-y
PG 12
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA IK6SP
UT WOS:000476718900043
PM 31337815
OA gold, Green Accepted, Green Published
DA 2022-11-30
ER

PT J
AU Corso-Diaz, X
   Jaeger, C
   Chaitankar, V
   Swaroop, A
AF Corso-Diaz, Ximena
   Jaeger, Catherine
   Chaitankar, Vijender
   Swaroop, Anand
TI Epigenetic control of gene regulation during development and disease: A
   view from the retina
SO PROGRESS IN RETINAL AND EYE RESEARCH
LA English
DT Review
DE Chromatin; DNA methylation; Histone modification; Next generation
   sequencing; Neuronal differentiation; Photoreceptor; Retina
   neurodegeneration
ID DNA METHYLATION LANDSCAPE; HISTONE DEMETHYLASE JMJD3; CELLULAR METABOLIC
   MEMORY; PIGMENT EPITHELIAL-CELLS; H3 LYSINE-9 METHYLATION; NUCLEAR
   RECEPTOR NR2E3; EMBRYONIC STEM-CELLS; DE-NOVO METHYLATION; CPG BINDING
   DOMAIN; LEUCINE-ZIPPER NRL
AB Complex biological processes, such as organogenesis and homeostasis, are stringently regulated by genetic programs that are fine-tuned by epigenetic factors to establish cell fates and/or to respond to the micro-environment. Gene regulatory networks that guide cell differentiation and function are modulated and stabilized by modifications to DNA, RNA and proteins. In this review, we focus on two key epigenetic changes - DNA methylation and histone modifications - and discuss their contribution to retinal development, aging and disease, especially in the context of age-related macular degeneration (AMD) and diabetic retinopathy. We highlight less-studied roles of DNA methylation and provide the RNA expression profiles of epigenetic enzymes in human and mouse retina in comparison to other tissues. We also review computational tools and emergent technologies to profile, analyze and integrate epigenetic information. We suggest implementation of editing tools and single-cell technologies to trace and perturb the epigenome for delineating its role in transcriptional regulation. Finally, we present our thoughts on exciting avenues for exploring epigenome in retinal metabolism, disease modeling, and regeneration.
C1 [Corso-Diaz, Ximena; Jaeger, Catherine; Chaitankar, Vijender; Swaroop, Anand] NEI, Neurobiol Neurodegenerat & Repair Lab, NIH, Bldg 6-338,6 Ctr Dr, Bethesda, MD 20892 USA.
C3 National Institutes of Health (NIH) - USA; NIH National Eye Institute
   (NEI)
RP Swaroop, A (通讯作者)，NEI, Neurobiol Neurodegenerat & Repair Lab, NIH, Bldg 6-338,6 Ctr Dr, Bethesda, MD 20892 USA.
EM swaroopa@nei.nih.gov
OI Swaroop, Anand/0000-0002-1975-1141; Jaeger,
   Catherine/0000-0001-8519-8893
FU National Eye Institute, National Institutes of Health, Bethesda, MD, USA
   [EY000450, EY000546]; NATIONAL EYE INSTITUTE [Z01EY000450, ZIAEY000474,
   ZIAEY000546, ZIAEY000450] Funding Source: NIH RePORTER
FX We are grateful to Hyunjin Yang and Jung-woong Kim for discussions, and
   to Colin Barnstable, Valerie Wallace, Tiziana Cogliati, and Freekje van
   Asten for constructive comments on the manuscript. We acknowledge the
   contribution of Adrien Gontier with two of the illustrations. Our
   research is supported by the Intramural Research program (EY000450,
   EY000546) of the National Eye Institute, National Institutes of Health,
   Bethesda, MD, USA.
CR Aapola U, 2002, NUCLEIC ACIDS RES, V30, P3602, DOI 10.1093/nar/gkf474
   Agathocleous M, 2009, ANNU REV CELL DEV BI, V25, P45, DOI 10.1146/annurev.cellbio.042308.113259
   Akiyama T, 2016, DEVELOPMENT, V143, P3674, DOI 10.1242/dev.139360
   Albini S, 2013, CELL REP, V3, P661, DOI 10.1016/j.celrep.2013.02.012
   Aldiri I, 2017, NEURON, V94, P550, DOI 10.1016/j.neuron.2017.04.022
   Aldiri I, 2015, DEVELOPMENT, V142, P4092, DOI 10.1242/dev.124800
   Aldiri I, 2013, DEVELOPMENT, V140, P2867, DOI 10.1242/dev.088096
   Allis CD, 2007, CELL, V131, P633, DOI 10.1016/j.cell.2007.10.039
   Anderson K, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0118839
   Andzelm MM, 2015, NEURON, V86, P247, DOI 10.1016/j.neuron.2015.02.038
   Ardeljan D, 2013, PROG RETIN EYE RES, V37, P68, DOI 10.1016/j.preteyeres.2013.07.003
   Atilano SR, 2015, HUM MOL GENET, V24, P4491, DOI 10.1093/hmg/ddv173
   Azad GK, 2014, MOL BIOL REP, V41, P2717, DOI 10.1007/s11033-014-3181-y
   Ball MP, 2009, NAT BIOTECHNOL, V27, P361, DOI 10.1038/nbt.1533
   Bannister AJ, 2005, J BIOL CHEM, V280, P17732, DOI 10.1074/jbc.M500796200
   Bar-Nur O, 2011, CELL STEM CELL, V9, P17, DOI 10.1016/j.stem.2011.06.007
   Barabino A, 2016, DEVELOPMENT, V143, P1571, DOI 10.1242/dev.125351
   Barres R, 2011, AM J CLIN NUTR, V93, p897S, DOI 10.3945/ajcn.110.001933
   Bartke T, 2010, CELL, V143, P470, DOI 10.1016/j.cell.2010.10.012
   Bassett EA, 2012, TRENDS NEUROSCI, V35, P565, DOI 10.1016/j.tins.2012.05.004
   Becker PB, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a017905
   Bell AC, 2000, NATURE, V405, P482, DOI 10.1038/35013100
   Benayoun BA, 2015, NAT REV MOL CELL BIO, V16, P593, DOI 10.1038/nrm4048
   Berger S. L., 2016, COLD SPRING HARB PER, V8
   Bernstein BE, 2006, CELL, V125, P315, DOI 10.1016/j.cell.2006.02.041
   Bessant DAR, 1999, NAT GENET, V21, P355, DOI 10.1038/7678
   Bhattacharya S, 2012, INVEST OPHTH VIS SCI, V53, P8350, DOI 10.1167/iovs.12-10495
   Bintu L, 2016, SCIENCE, V351, P720, DOI 10.1126/science.aab2956
   Bird A, 2007, NATURE, V447, P396, DOI 10.1038/nature05913
   Black JC, 2012, MOL CELL, V48, P491, DOI 10.1016/j.molcel.2012.11.006
   Blackledge NP, 2010, MOL CELL, V38, P179, DOI 10.1016/j.molcel.2010.04.009
   Boatright JH, 2000, BRAIN RES, V887, P211, DOI 10.1016/S0006-8993(00)02990-5
   Bock C, 2012, NAT REV GENET, V13, P705, DOI 10.1038/nrg3273
   Bonasio R, 2010, SCIENCE, V330, P612, DOI 10.1126/science.1191078
   Bonnel S, 2003, EXP GERONTOL, V38, P825, DOI 10.1016/S0531-5565(03)00093-7
   Booij JC, 2010, PROG RETIN EYE RES, V29, P1, DOI 10.1016/j.preteyeres.2009.08.003
   Boulard M, 2015, NAT GENET, V47, P479, DOI 10.1038/ng.3272
   Brunner AL, 2009, GENOME RES, V19, P1044, DOI 10.1101/gr.088773.108
   Brzezinski JA, 2015, DEVELOPMENT, V142, P3263, DOI 10.1242/dev.127043
   Buenostro JD, 2015, NATURE, V523, P486, DOI 10.1038/nature14590
   Cai H, 2012, FRONT AGING NEUROSCI, V4, DOI 10.3389/fnagi.2012.00008
   Campos EI, 2009, ANNU REV GENET, V43, P559, DOI 10.1146/annurev.genet.032608.103928
   Cao YA, 2014, INVEST OPHTH VIS SCI, V55, P7321, DOI 10.1167/iovs.14-15167
   Carrozza MJ, 2003, TRENDS GENET, V19, P321, DOI 10.1016/S0168-9525(03)00115-X
   CARTERDAWSON LD, 1979, J COMP NEUROL, V188, P263, DOI 10.1002/cne.901880205
   Cavallotti C, 2004, CAN J OPHTHALMOL, V39, P61, DOI 10.1016/S0008-4182(04)80054-1
   Cepko C, 2014, NAT REV NEUROSCI, V15, P615, DOI 10.1038/nrn3767
   Chader GJ, 2013, INVEST OPHTH VIS SCI, V54, DOI 10.1167/iovs.13-12993
   Chaitankar V, 2016, PROG RETIN EYE RES, V55, P1, DOI 10.1016/j.preteyeres.2016.06.001
   Chan N, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0120587
   Chatoo W, 2010, STEM CELLS, V28, P1412, DOI 10.1002/stem.462
   Chatterjee A, 2012, NUCLEIC ACIDS RES, V40, DOI 10.1093/nar/gks150
   Chen B, 2007, BMC DEV BIOL, V7, DOI 10.1186/1471-213X-7-78
   Chen B, 2009, SCIENCE, V323, P256, DOI 10.1126/science.1166226
   Chen HY, 2016, MOL VIS, V22, P1077
   Cheng HL, 2003, P NATL ACAD SCI USA, V100, P10794, DOI 10.1073/pnas.1934713100
   Cheng H, 2011, HUM MOL GENET, V20, P4102, DOI 10.1093/hmg/ddr334
   Cheng X., 2014, COLD SPRING HERB PER, V6
   Cheung I, 2010, P NATL ACAD SCI USA, V107, P8824, DOI 10.1073/pnas.1001702107
   Chinchore Y, 2017, ELIFE, V6, DOI 10.7554/eLife.25946
   Chisholm NC, 2015, EPIGENETICS-US, V10, P142, DOI 10.1080/15592294.2014.1001219
   Choi SH, 2011, NUCLEIC ACIDS RES, V39, P104, DOI 10.1093/nar/gkq774
   Christiansen L, 2016, AGING CELL, V15, P149, DOI 10.1111/acel.12421
   Clevers H, 2016, CELL, V165, P1586, DOI 10.1016/j.cell.2016.05.082
   Corbo JC, 2005, PLOS GENET, V1, P140, DOI 10.1371/journal.pgen.0010011
   Cusanovich DA, 2015, SCIENCE, V348, P910, DOI 10.1126/science.aab1601
   Das AV, 2007, J BIOL CHEM, V282, P35187, DOI 10.1074/jbc.M706742200
   Das AV, 2006, DEV BIOL, V299, P283, DOI 10.1016/j.ydbio.2006.07.029
   Derrien T, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030377
   Dhalluin C, 1999, NATURE, V399, P491, DOI 10.1038/20974
   Dhayalan A, 2010, J BIOL CHEM, V285, P26114, DOI 10.1074/jbc.M109.089433
   Dion MF, 2005, P NATL ACAD SCI USA, V102, P5501, DOI 10.1073/pnas.0500136102
   Dixon JR, 2012, NATURE, V485, P376, DOI 10.1038/nature11082
   Domcke S, 2015, NATURE, V528, P575, DOI 10.1038/nature16462
   Du JM, 2015, NAT REV MOL CELL BIO, V16, P519, DOI 10.1038/nrm4043
   Duarte DA, 2015, J NUTR BIOCHEM, V26, P64, DOI 10.1016/j.jnutbio.2014.09.003
   Eberhart A, 2013, CHROMOSOME RES, V21, P535, DOI 10.1007/s10577-013-9375-7
   Elsner VR, 2013, EXP GERONTOL, V48, P136, DOI 10.1016/j.exger.2012.11.011
   Epsztejn-Litman S, 2008, NAT STRUCT MOL BIOL, V15, P1176, DOI 10.1038/nsmb.1476
   Ernst J, 2012, NAT METHODS, V9, P215, DOI 10.1038/nmeth.1906
   Fan GP, 2005, DEVELOPMENT, V132, P3345, DOI 10.1242/dev.01912
   Farlik M, 2015, CELL REP, V10, P1386, DOI 10.1016/j.celrep.2015.02.001
   Feng J, 2005, J NEUROSCI RES, V79, P734, DOI 10.1002/jnr.20404
   Ferreira RC, 2017, J BIOL CHEM, V292, P2422, DOI 10.1074/jbc.M116.756643
   Filion GJP, 2006, MOL CELL BIOL, V26, P169, DOI 10.1128/MCB.26.1.169-181.2006
   Fischer AJ, 2001, NAT NEUROSCI, V4, P247, DOI 10.1038/85090
   Fischle W, 2012, EPIGENOMICS-UK, V4, P641, DOI [10.2217/EPI.12.56, 10.2217/epi.12.56]
   Frith MC, 2012, NUCLEIC ACIDS RES, V40, DOI 10.1093/nar/gks275
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Fritsche LG, 2014, ANNU REV GENOM HUM G, V15, P151, DOI 10.1146/annurev-genom-090413-025610
   Fujimura N, 2018, DEV BIOL, V433, P47, DOI 10.1016/j.ydbio.2017.11.004
   Fuks F, 2001, EMBO J, V20, P2536, DOI 10.1093/emboj/20.10.2536
   Fuks F, 2000, NAT GENET, V24, P88, DOI 10.1038/71750
   Fuks F, 2003, NUCLEIC ACIDS RES, V31, P2305, DOI 10.1093/nar/gkg332
   Gangwani R, 2014, GRAEF ARCH CLIN EXP, V252, P723, DOI 10.1007/s00417-013-2530-1
   Geiman TM, 2004, BIOCHEM BIOPH RES CO, V318, P544, DOI 10.1016/j.bbrc.2004.04.058
   Gemenetzi M, 2014, EYE, V28, P1407, DOI 10.1038/eye.2014.225
   Golestaneh N, 2016, J TRANSL MED, V14, DOI 10.1186/s12967-016-1101-8
   Goll MG, 2005, ANNU REV BIOCHEM, V74, P481, DOI 10.1146/annurev.biochem.74.010904.153721
   Goll MG, 2006, SCIENCE, V311, P395, DOI 10.1126/science.1120976
   Gong H, 2015, ONCOTARGET, V6, P15882, DOI 10.18632/oncotarget.4137
   Govindarajan G, 2017, MITOCHONDRION, V36, P150, DOI 10.1016/j.mito.2017.07.007
   Gregory-Evans CY, 2013, PROG RETIN EYE RES, V33, P40, DOI 10.1016/j.preteyeres.2012.10.003
   Groman-Lupa S, 2017, INVEST OPHTH VIS SCI, V58, P5421, DOI 10.1167/iovs.17-22442
   Guarente L, 2013, GENE DEV, V27, P2072, DOI 10.1101/gad.227439.113
   Guenther MG, 2007, CELL, V130, P77, DOI 10.1016/j.cell.2007.05.042
   Guo HS, 2015, NAT PROTOC, V10, P645, DOI 10.1038/nprot.2015.039
   Guo JJU, 2011, NAT NEUROSCI, V14, P1345, DOI 10.1038/nn.2900
   Guo JU, 2011, CELL, V145, P423, DOI 10.1016/j.cell.2011.03.022
   Guo WL, 2013, BMC GENOMICS, V14, DOI 10.1186/1471-2164-14-774
   Guo XZ, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9005
   Hahn MA, 2013, CELL REP, V3, P291, DOI 10.1016/j.celrep.2013.01.011
   Hahn O, 2017, GENOME BIOL, V18, DOI 10.1186/s13059-017-1187-1
   Han YX, 2012, AGING CELL, V11, P1055, DOI 10.1111/acel.12007
   Hao H, 2012, PLOS GENET, V8, P380, DOI 10.1371/journal.pgen.1002649
   Hao H, 2011, J BIOL CHEM, V286, P34893, DOI 10.1074/jbc.M111.271072
   Harris EY, 2012, BIOINFORMATICS, V28, P1795, DOI 10.1093/bioinformatics/bts264
   Heavner W, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a008391
   Helmlinger D, 2006, PLOS BIOL, V4, P432, DOI 10.1371/journal.pbio.0040067
   Hendrich B, 2003, TRENDS GENET, V19, P269, DOI 10.1016/S0168-9525(03)00080-5
   Hendrich B, 1998, MOL CELL BIOL, V18, P6538, DOI 10.1128/MCB.18.11.6538
   Henikoff S, 2015, CSH PERSPECT BIOL, V7, DOI 10.1101/cshperspect.a019364
   Henikoff S, 2011, TRENDS GENET, V27, P389, DOI 10.1016/j.tig.2011.06.006
   Hennig AK, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069721
   Hiler D, 2015, CELL STEM CELL, V17, P101, DOI 10.1016/j.stem.2015.05.015
   Ho L, 2010, NATURE, V463, P474, DOI 10.1038/nature08911
   HOLLIDAY R, 1975, SCIENCE, V187, P226, DOI 10.1126/science.1111098
   Holoch D, 2015, NAT REV GENET, V16, P71, DOI 10.1038/nrg3863
   Hon G, 2009, PLOS COMPUT BIOL, V5, DOI 10.1371/journal.pcbi.1000566
   Horvath S, 2016, AGING-US, V8, P1485, DOI 10.18632/aging.101005
   Horvath S, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-10-r115
   Hoshino A, 2017, DEV CELL, V43, P763, DOI 10.1016/j.devcel.2017.10.029
   HOTCHKISS RD, 1948, J BIOL CHEM, V175, P315
   Hu SH, 2013, ELIFE, V2, DOI 10.7554/eLife.00726
   Huang B, 2014, EPIGENOMICS-UK, V6, P73, DOI 10.2217/epi.13.72
   Hughes AEO, 2017, SCI REP-UK, V7, DOI 10.1038/srep43184
   Hunter A, 2012, INVEST OPHTH VIS SCI, V53, P2089, DOI 10.1167/iovs.11-8449
   Hurley JB, 2015, J NEUROSCI RES, V93, P1079, DOI 10.1002/jnr.23583
   Hutchinson JN, 2014, HUM HERED, V78, P59, DOI 10.1159/000362814
   Hyun K, 2017, EXP MOL MED, V49, DOI 10.1038/emm.2017.11
   Iida A, 2015, DEV NEUROBIOL, V75, P947, DOI 10.1002/dneu.22261
   Iida A, 2014, P NATL ACAD SCI USA, V111, P3751, DOI 10.1073/pnas.1311480111
   Illingworth RS, 2009, FEBS LETT, V583, P1713, DOI 10.1016/j.febslet.2009.04.012
   Ito S, 2011, SCIENCE, V333, P1300, DOI 10.1126/science.1210597
   Jackson GR, 2002, AGEING RES REV, V1, P381, DOI 10.1016/S1568-1637(02)00007-7
   Jeltsch A, 2017, RNA BIOL, V14, P1108, DOI 10.1080/15476286.2016.1191737
   Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127
   Jones PA, 2012, NAT REV GENET, V13, P484, DOI 10.1038/nrg3230
   Jorstad NL, 2017, NATURE, V548, P103, DOI 10.1038/nature23283
   Jung CC, 2015, P NATL ACAD SCI USA, V112, pE3010, DOI 10.1073/pnas.1505870112
   Kadiyala CSR, 2012, J BIOL CHEM, V287, P25869, DOI 10.1074/jbc.M112.375204
   Kaelin WG, 2013, CELL, V153, P56, DOI 10.1016/j.cell.2013.03.004
   Kaewkhaw R, 2015, STEM CELLS, V33, P3504, DOI 10.1002/stem.2122
   Kanda A, 2007, HUM MUTAT, V28, P589, DOI 10.1002/humu.20488
   Kandpal RP, 2012, MOL VIS, V18, P1123
   Karimzadeh M., 2016, BIORXIV
   Katoh K, 2012, J NEUROSCI, V32, P17658, DOI 10.1523/JNEUROSCI.1869-12.2012
   Kaur H, 2006, DIABETES, V55, P3104, DOI 10.2337/db06-0519
   Kawashima M, 2013, EXP GERONTOL, V48, P1096, DOI 10.1016/j.exger.2013.04.002
   Kim C, 2006, MOL VIS, V12, P1640
   Kim CH, 2017, BIOCHEM BIOPH RES CO, V482, P735, DOI 10.1016/j.bbrc.2016.11.103
   Kim CH, 2012, BIOCHEM BIOPH RES CO, V424, P427, DOI 10.1016/j.bbrc.2012.06.126
   Kim DY, 2014, HEPAT ONCOL, V1, P3, DOI [10.2217/hep.13.1, 10.2217/HEP.13.1]
   Kim Dongho, 2015, J VIB CONTROL, V1, P1, DOI DOI 10.1155/2015/617919
   Kim JW, 2016, CELL REP, V17, P2460, DOI 10.1016/j.celrep.2016.10.074
   Kim JW, 2016, DEV CELL, V37, P520, DOI 10.1016/j.devcel.2016.05.023
   Kim JW, 2012, MOL CELL BIOL, V32, P1720, DOI 10.1128/MCB.06440-11
   Kim K, 2010, NATURE, V467, P285, DOI 10.1038/nature09342
   Kim KY, 2004, NEUROBIOL AGING, V25, P491, DOI 10.1016/j.neurobiolaging.2003.07.005
   Kinde B, 2015, P NATL ACAD SCI USA, V112, P6800, DOI 10.1073/pnas.1411269112
   King AD, 2016, CELL REP, V17, P289, DOI 10.1016/j.celrep.2016.08.083
   Kizilyaprak C, 2011, NUCLEUS-AUSTIN, V2, P444, DOI 10.4161/nucl.2.5.17843
   Kizilyaprak C, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011039
   Kohli RM, 2013, NATURE, V502, P472, DOI 10.1038/nature12750
   Kong YXG, 2012, NEUROBIOL AGING, V33, DOI 10.1016/j.neurobiolaging.2011.11.026
   Kooistra SM, 2012, NAT REV MOL CELL BIO, V13, P297, DOI 10.1038/nrm3327
   Kooragayala K, 2015, INVEST OPHTH VIS SCI, V56, P8428, DOI 10.1167/iovs.15-17901
   Kouzarides T, 2007, CELL, V128, P693, DOI 10.1016/j.cell.2007.02.005
   Kowluru RA, 2017, VISION RES, V139, P30, DOI 10.1016/j.visres.2017.02.011
   Kowluru RA, 2015, PROG RETIN EYE RES, V48, P40, DOI 10.1016/j.preteyeres.2015.05.001
   Kozhevnikova OS, 2013, CELL CYCLE, V12, P1745, DOI 10.4161/cc.24825
   Kriaucionis S, 2009, SCIENCE, V324, P929, DOI 10.1126/science.1169786
   Krueger F, 2011, BIOINFORMATICS, V27, P1571, DOI 10.1093/bioinformatics/btr167
   Lamba DA, 2008, DEV DYNAM, V237, P3016, DOI 10.1002/dvdy.21697
   Lamoke F, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0139664
   Landt SG, 2012, GENOME RES, V22, P1813, DOI 10.1101/gr.136184.111
   Langmead Ben, 2010, Curr Protoc Bioinformatics, VChapter 11, DOI 10.1002/0471250953.bi1107s32
   Laszlo AH, 2013, P NATL ACAD SCI USA, V110, P18904, DOI 10.1073/pnas.1310240110
   Lee JH, 2015, BMC GENOMICS, V16, DOI 10.1186/1471-2164-16-S12-S14
   Lehnertz B, 2003, CURR BIOL, V13, P1192, DOI 10.1016/S0960-9822(03)00432-9
   Levine ME, 2015, AGING-US, V7, P1198, DOI 10.18632/aging.100864
   Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324
   Li YY, 2011, BMC MED, V9, DOI 10.1186/1741-7015-9-98
   LIOU GI, 1994, DEV BIOL, V161, P345, DOI 10.1006/dbio.1994.1036
   Lister R, 2013, SCIENCE, V341, P629, DOI 10.1126/science.1237905
   Lister R, 2009, NATURE, V462, P315, DOI 10.1038/nature08514
   Liu XS, 2016, CELL, V167, P233, DOI 10.1016/j.cell.2016.08.056
   Lizardi P. M., 2017, COLD SPRING HARB PRO, V2017
   Lluch-Senar M, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003191
   Lorthongpanich C, 2013, SCIENCE, V341, P1110, DOI 10.1126/science.1240617
   Lu AT, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15353
   Ludwig AK, 2016, FRONT GENET, V7, DOI 10.3389/fgene.2016.00115
   Ma DK, 2009, SCIENCE, V323, P1074, DOI 10.1126/science.1166859
   Macosko EZ, 2015, CELL, V161, P1202, DOI 10.1016/j.cell.2015.05.002
   Maegawa S, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00607-3
   Mangold CA, 2017, J GERONTOL A-BIOL, V72, P16, DOI 10.1093/gerona/glv232
   Marbach D, 2012, GENOME RES, V22, P1334, DOI 10.1101/gr.127191.111
   Margueron R, 2011, NATURE, V469, P343, DOI 10.1038/nature09784
   Marmorstein R, 2014, CSH PERSPECT BIOL, V6, DOI 10.1101/cshperspect.a018762
   Martinowich K, 2003, SCIENCE, V302, P890, DOI 10.1126/science.1090842
   Martins-Taylor K, 2012, EPIGENETICS-US, V7, P71, DOI 10.4161/epi.7.1.18750
   Masland RH, 2012, NEURON, V76, P266, DOI 10.1016/j.neuron.2012.10.002
   Maunakea AK, 2010, NATURE, V466, P253, DOI 10.1038/nature09165
   Mears AJ, 2001, NAT GENET, V29, P447, DOI 10.1038/ng774
   Meissner A, 2005, NUCLEIC ACIDS RES, V33, P5868, DOI 10.1093/nar/gki901
   Merbs SL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032602
   Mikkelsen TS, 2007, NATURE, V448, P553, DOI 10.1038/nature06008
   Mimura T, 2013, EXP EYE RES, V116, P17, DOI 10.1016/j.exer.2013.07.017
   Mitteldorf Josh, 2015, Curr Aging Sci, V8, P69
   Mo A, 2016, ELIFE, V5, DOI 10.7554/eLife.11613
   Mohan RD, 2014, GENE DEV, V28, P259, DOI 10.1101/gad.225151.113
   Mohn Fabio, 2009, V507, P55, DOI 10.1007/978-1-59745-522-0_5
   Morse Sarah J., 2015, Biology-Basel, V4, P298, DOI 10.3390/biology4020298
   Mortuza R, 2015, J CELL MOL MED, V19, P1857, DOI 10.1111/jcmm.12557
   Mortuza R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054514
   Mutskov VJ, 2002, GENE DEV, V16, P1540, DOI 10.1101/gad.988502
   Nagano T, 2013, NATURE, V502, P59, DOI 10.1038/nature12593
   NANNEY DL, 1958, P NATL ACAD SCI USA, V44, P712, DOI 10.1073/pnas.44.7.712
   Nasonkin IO, 2013, DEVELOPMENT, V140, P1330, DOI 10.1242/dev.086603
   Nasonkin IO, 2011, J COMP NEUROL, V519, P1914, DOI 10.1002/cne.22613
   Ng L, 2011, J NEUROSCI, V31, P11118, DOI 10.1523/JNEUROSCI.1709-11.2011
   Nguyen' S, 2007, DEV DYNAM, V236, P1663, DOI 10.1002/dvdy.21176
   Oh ECT, 2008, BRAIN RES, V1236, P16, DOI 10.1016/j.brainres.2008.01.028
   Ohki I, 2001, CELL, V105, P487, DOI 10.1016/S0092-8674(01)00324-5
   Okano M, 1999, CELL, V99, P247, DOI 10.1016/S0092-8674(00)81656-6
   Oliver VF, 2015, EPIGENETICS-US, V10, P698, DOI 10.1080/15592294.2015.1060388
   Oliver VF, 2013, CELL REP, V5, P1527, DOI 10.1016/j.celrep.2013.11.042
   Oliver VF, 2013, EPIGENET CHROMATIN, V6, DOI 10.1186/1756-8935-6-17
   Olkhov-Mitsel E, 2012, CANCER MED-US, V1, P237, DOI 10.1002/cam4.22
   Omori Y, 2017, P NATL ACAD SCI USA, V114, pE8264, DOI 10.1073/pnas.1707021114
   Ooi SKT, 2007, NATURE, V448, P714, DOI 10.1038/nature05987
   Orsi G. A., 2015, CURRENT PROTOCOLS MO, V110, P21
   Owsley C, 2016, ANNU REV VIS SCI, V2, P255, DOI 10.1146/annurev-vision-111815-114550
   Owsley C, 2014, INVEST OPHTH VIS SCI, V55, P4776, DOI 10.1167/iovs.14-14502
   Pal S, 2016, SCI ADV, V2, DOI 10.1126/sciadv.1600584
   Palhan VB, 2005, P NATL ACAD SCI USA, V102, P8472, DOI 10.1073/pnas.0503505102
   Parapuram SK, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013885
   Park PJ, 2009, NAT REV GENET, V10, P669, DOI 10.1038/nrg2641
   Pedersen B, 2011, BIOINFORMATICS, V27, P2435, DOI 10.1093/bioinformatics/btr394
   Peleg S, 2010, SCIENCE, V328, P753, DOI 10.1126/science.1186088
   Pelzel HR, 2010, BMC NEUROSCI, V11, DOI 10.1186/1471-2202-11-62
   Peng CH, 2011, BIOMATERIALS, V32, P9077, DOI 10.1016/j.biomaterials.2011.08.008
   Peng CH, 2010, SENSORS-BASEL, V10, P6172, DOI 10.3390/s100606172
   Peng GH, 2007, HUM MOL GENET, V16, P2433, DOI 10.1093/hmg/ddm200
   Perera A, 2015, CELL REP, V11, P283, DOI 10.1016/j.celrep.2015.03.020
   Pervouchine DD, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms6903
   Petkova TD, 2011, VISION RES, V51, P260, DOI 10.1016/j.visres.2010.09.022
   Pinna A, 2016, CURR EYE RES, V41, P88, DOI 10.3109/02713683.2014.1002044
   Pirrotta V, 2016, CSH PERSPECT BIOL, V8, DOI 10.1101/cshperspect.a019547
   Popova EY, 2016, MOL NEUROBIOL, V53, P4563, DOI 10.1007/s12035-015-9395-8
   Popova EY, 2013, J BIOL CHEM, V288, P17895, DOI 10.1074/jbc.M113.452144
   Popova EY, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046867
   Powell C, 2013, P NATL ACAD SCI USA, V110, P19814, DOI 10.1073/pnas.1312009110
   Powell C, 2012, J NEUROSCI, V32, P1096, DOI 10.1523/JNEUROSCI.5603-11.2012
   Quenneville S, 2011, MOL CELL, V44, P361, DOI 10.1016/j.molcel.2011.08.032
   Rai K, 2007, GENE DEV, V21, P261, DOI 10.1101/gad.1472907
   Rai K, 2010, J BIOL CHEM, V285, P4110, DOI 10.1074/jbc.M109.073676
   Ramachandran R, 2010, NAT CELL BIOL, V12, P1101, DOI 10.1038/ncb2115
   Rando OJ, 2012, CURR OPIN GENET DEV, V22, P148, DOI 10.1016/j.gde.2012.02.013
   Rapaport DH, 2004, J COMP NEUROL, V474, P304, DOI 10.1002/cne.20134
   Raymond PA, 2006, BMC DEV BIOL, V6, DOI 10.1186/1471-213X-6-36
   Reddington JP, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-3-r25
   Reese BE, 2016, PROG RETIN EYE RES, V55, P246, DOI 10.1016/j.preteyeres.2016.07.003
   Rhee HS, 2011, CELL, V147, P1408, DOI 10.1016/j.cell.2011.11.013
   Rhee KD, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.165
   Richer S, 2014, NUTRIENTS, V6, P4404, DOI 10.3390/nu6104404
   Richer S, 2013, NUTRIENTS, V5, P1989, DOI 10.3390/nu5061989
   RIDEOUT WM, 1990, SCIENCE, V249, P1288, DOI 10.1126/science.1697983
   RIGGS AD, 1975, CYTOGENET CELL GENET, V14, P9, DOI 10.1159/000130315
   Rishi V, 2010, P NATL ACAD SCI USA, V107, P20311, DOI 10.1073/pnas.1008688107
   Robinson MD, 2012, GENOME RES, V22, P2489, DOI 10.1101/gr.139055.112
   Rodrigues HF, 2014, J CELL BIOCHEM, V115, P659, DOI 10.1002/jcb.24705
   Roesch K, 2008, J COMP NEUROL, V509, P225, DOI 10.1002/cne.21730
   Roessler R, 2014, STEM CELL REP, V2, P520, DOI 10.1016/j.stemcr.2014.03.001
   Roh TY, 2005, GENE DEV, V19, P542, DOI 10.1101/gad.1272505
   Rosenfeld JA, 2009, BMC GENOMICS, V10, DOI 10.1186/1471-2164-10-143
   Ross SE, 2012, NEURON, V73, P292, DOI 10.1016/j.neuron.2011.09.035
   Rountree MR, 2000, NAT GENET, V25, P269, DOI 10.1038/77023
   Ruiz MA, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0123987
   Ruthenburg AJ, 2011, CELL, V145, P692, DOI 10.1016/j.cell.2011.03.053
   Ryan DP, 2014, BMC BIOINFORMATICS, V15, DOI 10.1186/1471-2105-15-337
   Ryu SH, 2011, EXP GERONTOL, V46, P811, DOI 10.1016/j.exger.2011.07.001
   Sajgo S, 2017, P NATL ACAD SCI USA, V114, pE3974, DOI 10.1073/pnas.1618551114
   Sanchez R, 2009, CURR OPIN DRUG DISC, V12, P659
   Sanes JR, 2010, NEURON, V66, P15, DOI 10.1016/j.neuron.2010.01.018
   Sasai Y, 2013, CELL STEM CELL, V12, P520, DOI 10.1016/j.stem.2013.04.009
   Schaub MA, 2012, GENOME RES, V22, P1748, DOI 10.1101/gr.136127.111
   Schil K, 2016, SCI REP-UK, V6, DOI 10.1038/srep21307
   Schotta G, 2004, GENE DEV, V18, P1251, DOI 10.1101/gad.300704
   Schwartzman O, 2015, NAT REV GENET, V16, P716, DOI 10.1038/nrg3980
   Seto E, 2014, CSH PERSPECT BIOL, V6, DOI 10.1101/cshperspect.a018713
   Shin Hyunjin, 2013, Quant Biol, V1, P54
   Shlyueva D, 2014, NAT REV GENET, V15, P272, DOI 10.1038/nrg3682
   Shukla S, 2011, NATURE, V479, P74, DOI 10.1038/nature10442
   Siegert S, 2012, NAT NEUROSCI, V15, P487, DOI 10.1038/nn.3032
   Siegert S, 2009, NAT NEUROSCI, V12, P1197, DOI 10.1038/nn.2370
   Sifuentes CJ, 2016, INVEST OPHTH VIS SCI, V57, P5148, DOI 10.1167/iovs.16-19973
   Silberman DM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098831
   Simon JA, 2013, MOL CELL, V49, P808, DOI 10.1016/j.molcel.2013.02.013
   Singh RK, 2017, EXP EYE RES, V159, P132, DOI 10.1016/j.exer.2016.11.014
   Skene PJ, 2017, ELIFE, V6, DOI 10.7554/eLife.21856
   Skowronska-Krawczyk D, 2004, DEVELOPMENT, V131, P4447, DOI 10.1242/dev.01302
   Smallwood SA, 2014, NAT METHODS, V11, P817, DOI [10.1038/NMETH.3035, 10.1038/nmeth.3035]
   Smith ZD, 2013, NAT REV GENET, V14, P204, DOI 10.1038/nrg3354
   Snigdha S, 2016, J NEUROSCI, V36, P3611, DOI 10.1523/JNEUROSCI.2693-15.2016
   Sobrin L, 2014, PROG RETIN EYE RES, V40, P1, DOI 10.1016/j.preteyeres.2013.12.004
   Solovei I, 2009, CELL, V137, P356, DOI 10.1016/j.cell.2009.01.052
   Song JK, 2011, SCIENCE, V331, P1036, DOI 10.1126/science.1195380
   Soshnev AA, 2016, MOL CELL, V62, P681, DOI 10.1016/j.molcel.2016.05.004
   Spruijt CG, 2013, CELL, V152, P1146, DOI 10.1016/j.cell.2013.02.004
   Stadler MB, 2011, NATURE, V480, P490, DOI 10.1038/nature10716
   Stelzer Y, 2015, CELL, V163, P218, DOI 10.1016/j.cell.2015.08.046
   Storvall H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053822
   Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599
   Stubbs TM, 2017, GENOME BIOL, V18, DOI 10.1186/s13059-017-1203-5
   Swaroop A, 2010, NAT REV NEUROSCI, V11, P563, DOI 10.1038/nrn2880
   Swaroop A, 2009, ANNU REV GENOM HUM G, V10, P19, DOI 10.1146/annurev.genom.9.081307.164350
   Syreeni A, 2011, DIABETES, V60, P3073, DOI 10.2337/db11-0073
   Tahiliani M, 2009, SCIENCE, V324, P930, DOI 10.1126/science.1170116
   Telese F, 2013, NEURON, V77, P606, DOI 10.1016/j.neuron.2013.01.034
   Thu Kelsie L, 2009, J Vis Exp, DOI 10.3791/935
   Torres IO, 2015, CURR OPIN STRUC BIOL, V35, P68, DOI 10.1016/j.sbi.2015.09.007
   Treangen TJ, 2012, NAT REV GENET, V13, P36, DOI 10.1038/nrg3117
   Ueno K., 2016, SCI REP, V6
   Ueno K, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-03874-8
   Usui A, 2013, FEBS LETT, V587, P358, DOI 10.1016/j.febslet.2012.12.017
   Vakoc CR, 2005, MOL CELL, V19, P381, DOI 10.1016/j.molcel.2005.06.011
   Volkner M, 2016, STEM CELL REP, V6, P525, DOI 10.1016/j.stemcr.2016.03.001
   Voigt P, 2013, GENE DEV, V27, P1318, DOI 10.1101/gad.219626.113
   Voigt P, 2012, CELL, V151, P181, DOI 10.1016/j.cell.2012.09.002
   Waddington CH, 2012, INT J EPIDEMIOL, V41, P10, DOI 10.1093/ije/dyr184
   Waddington C. H, 1940, ORG AND GENES
   Wallace DM, 2006, INVEST OPHTH VIS SCI, V47, P2765, DOI 10.1167/iovs.05-1383
   Wan J, 2015, BMC GENOMICS, V16, DOI 10.1186/s12864-015-1271-4
   Wan J, 2013, NUCLEIC ACIDS RES, V41, P8503, DOI 10.1093/nar/gkt652
   Wang AH, 2001, MOL CELL BIOL, V21, P5992, DOI 10.1128/MCB.21.17.5992-6005.2001
   Wang JT, 2007, J NEUROSCI, V27, P8593, DOI 10.1523/JNEUROSCI.4488-06.2007
   Wang JY, 2016, TRENDS GENET, V32, P284, DOI 10.1016/j.tig.2016.02.005
   Wang S, 2011, GENET EPIDEMIOL, V35, P686, DOI 10.1002/gepi.20619
   Wang WJ, 2017, SCI REP-UK, V7, DOI 10.1038/srep45103
   Wang ZB, 2009, CELL, V138, P1019, DOI 10.1016/j.cell.2009.06.049
   Watanabe K, 2013, EUR ARCH OTO-RHINO-L, V270, P1823, DOI 10.1007/s00405-012-2222-1
   Wei L, 2012, CELL REP, V2, P1151, DOI 10.1016/j.celrep.2012.10.013
   Wen B, 2009, NAT GENET, V41, P246, DOI 10.1038/ng.297
   Wiench M, 2011, EMBO J, V30, P3028, DOI 10.1038/emboj.2011.210
   Wong TY, 2016, NAT REV DIS PRIMERS, V2, DOI 10.1038/nrdp.2016.12
   Wu H, 2014, CELL, V156, P45, DOI 10.1016/j.cell.2013.12.019
   Wu H, 2010, SCIENCE, V329, P444, DOI 10.1126/science.1190485
   Wu TP, 2016, NATURE, V532, P329, DOI 10.1038/nature17640
   Xie MY, 2014, MOL VIS, V20, P1411
   Yamaguchi M, 2005, DEVELOPMENT, V132, P3027, DOI 10.1242/dev.01881
   Yan NH, 2016, SCI REP-UK, V6, DOI 10.1038/srep33887
   Yang HJ, 2015, PROG RETIN EYE RES, V46, P1, DOI 10.1016/j.preteyeres.2015.01.005
   Yasuda H, 2016, J CLIN BIOCHEM NUTR, V59, P174, DOI 10.3164/jcbn.16-26
   Yoshida S, 2002, INVEST OPHTH VIS SCI, V43, P2554
   Young MD, 2011, NUCLEIC ACIDS RES, V39, P7415, DOI 10.1093/nar/gkr416
   YOUNG RW, 1985, DEV BRAIN RES, V21, P229, DOI 10.1016/0165-3806(85)90211-1
   Yu M, 2012, CELL, V149, P1368, DOI 10.1016/j.cell.2012.04.027
   Zelinger L, 2018, TRENDS GENET, V34, P341, DOI 10.1016/j.tig.2018.01.002
   Zemach A, 2010, SCIENCE, V328, P916, DOI 10.1126/science.1186366
   Zeng Y, 2016, EXP EYE RES, V151, P203, DOI 10.1016/j.exer.2016.05.002
   Zeng Y, 2015, BIOCHEM BIOPH RES CO, V468, P167, DOI 10.1016/j.bbrc.2015.10.139
   Zentner GE, 2013, NAT STRUCT MOL BIOL, V20, P259, DOI 10.1038/nsmb.2470
   Zhang JM, 2015, DEV BIOL, V403, P128, DOI 10.1016/j.ydbio.2015.05.010
   Zhang L, 2015, CELL STEM CELL, V17, P735, DOI 10.1016/j.stem.2015.09.012
   Zhang TY, 2015, EMBO REP, V16, P1467, DOI 10.15252/embr.201540945
   Zhang Y, 2011, NUCLEIC ACIDS RES, V39, DOI 10.1093/nar/gkr053
   Zhang Y, 2010, NUCLEIC ACIDS RES, V38, P4246, DOI 10.1093/nar/gkq147
   Zhang Y, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-9-r137
   Zhao SZ, 2016, DIABETOLOGIA, V59, P644, DOI 10.1007/s00125-015-3832-0
   Zhao SZ, 2015, MOL MED REP, V12, P6112, DOI 10.3892/mmr.2015.4164
   Zhao YM, 2015, CSH PERSPECT BIOL, V7, DOI 10.1101/cshperspect.a025064
   Zhong Q, 2010, J CELL BIOCHEM, V110, P1306, DOI 10.1002/jcb.22644
   Zhu H, 2016, NAT REV GENET, V17, P551, DOI 10.1038/nrg.2016.83
   Zhuang J, 2012, BMC BIOINFORMATICS, V13, DOI 10.1186/1471-2105-13-59
   Zhuge CC, 2014, INVEST OPHTH VIS SCI, V55, P4628, DOI 10.1167/iovs.13-13732
   Ziller MJ, 2013, NATURE, V500, P477, DOI 10.1038/nature12433
   Zorrilla-Zubilete MA, 2018, J NEUROCHEM, V144, P128, DOI 10.1111/jnc.14243
NR 388
TC 65
Z9 66
U1 0
U2 39
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 1350-9462
EI 1873-1635
J9 PROG RETIN EYE RES
JI Prog. Retin. Eye Res.
PD JUL
PY 2018
VL 65
BP 1
EP 27
DI 10.1016/j.preteyeres.2018.03.002
PG 27
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA GP4ZO
UT WOS:000440881100001
PM 29544768
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Luckoff, A
   Caramoy, A
   Scholz, R
   Prinz, M
   Kalinke, U
   Langmann, T
AF Lueckoff, Anika
   Caramoy, Albert
   Scholz, Rebecca
   Prinz, Marco
   Kalinke, Ulrich
   Langmann, Thomas
TI Interferon-beta signaling in retinal mononuclear phagocytes attenuates
   pathological neovascularization
SO EMBO MOLECULAR MEDICINE
LA English
DT Article
DE age-related macular degeneration; choroidal neovascularization;
   interferon-beta signaling; macrophages; microglia
ID EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; CHOROIDAL NEOVASCULARIZATION;
   MACULAR DEGENERATION; MICROGLIA; CELLS; INFLAMMATION; MACROPHAGES;
   PROGRESS; THERAPY
AB Age-related macular degeneration (AMD) is a leading cause of vision loss among the elderly. AMD pathogenesis involves chronic activation of the innate immune system including complement factors and microglia/macrophage reactivity in the retina. Here, we show that lack of interferon- signaling in the retina accelerates mononuclear phagocyte reactivity and promotes choroidal neovascularization (CNV) in the laser model of neovascular AMD. Complete deletion of interferon-/ receptor (Ifnar) using Ifnar1(-/-) mice significantly enhanced early microglia and macrophage activation in lesion areas. This triggered subsequent vascular leakage and CNV at later stages. Similar findings were obtained in laser-treated Cx3cr1(CreER):Ifnar1(fl/fl) animals that allowed the tamoxifen-induced conditional depletion of Ifnar in resident mononuclear phagocytes only. Conversely, systemic IFN- therapy of laser-treated wild-type animals effectively attenuated microgliosis and macrophage responses in the early stage of disease and significantly reduced CNV size in the late phase. Our results reveal a protective role of Ifnar signaling in retinal immune homeostasis and highlight a potential use for IFN- therapy in the eye to limit chronic inflammation and pathological angiogenesis in AMD.
C1 [Lueckoff, Anika; Caramoy, Albert; Scholz, Rebecca; Langmann, Thomas] Univ Cologne, Dept Ophthalmol, RIL, Cologne, Germany.
   [Prinz, Marco] Univ Freiburg, Inst Neuropathol, Freiburg, Germany.
   [Prinz, Marco] Univ Freiburg, BIOSS Ctr Biol Signaling Studies, Freiburg, Germany.
   [Kalinke, Ulrich] TWINCORE Ctr Expt & Clin Infect Res, Inst Expt Infect Res, Hannover, Germany.
C3 University of Cologne; University of Freiburg; University of Freiburg;
   Helmholtz Association; Helmholtz-Center for Infection Research
RP Langmann, T (通讯作者)，Univ Cologne, Dept Ophthalmol, RIL, Cologne, Germany.
EM thomas.langmann@uk-koeln.de
OI Kalinke, Ulrich/0000-0003-0503-9564
FU Graduate Program in Pharmacology and Experimental Therapeutics at the
   University of Cologne; Bayer AG; DFG [LA1203/6-2, LA1203/9-1,
   LA1203/10-1, FOR2240]; ProRetina Foundation; Hans and Marlies Stock
   Foundation
FX The authors thank Prof. Thomas Wunderlich, Max Planck Institute for
   Metabolism Research, and Institute for Genetics, University of Cologne,
   for providing R26<SUP>tomato</SUP> mice. We also thank Prof. Andrew
   Dick, Unit of Ophthalmology, School of Clinical Sciences and School of
   Cellular and Molecular Medicine, University of Bristol, for helpful
   discussion and Khalid Rashid for critical reading of the manuscript.
   This work was supported by grants from the Graduate Program in
   Pharmacology and Experimental Therapeutics at the University of Cologne
   in collaboration with Bayer AG, the DFG (LA1203/6-2, LA1203/9-1,
   LA1203/10-1, and FOR2240), the ProRetina Foundation, and the Hans and
   Marlies Stock Foundation.
CR Augood CA, 2006, ARCH OPHTHALMOL-CHIC, V124, P529, DOI 10.1001/archopht.124.4.529
   Axtell RC, 2008, IMMUNITY, V28, P600, DOI 10.1016/j.immuni.2008.04.006
   Bruttger J, 2015, IMMUNITY, V43, P92, DOI 10.1016/j.immuni.2015.06.012
   Chen M, 2012, GLIA, V60, P833, DOI 10.1002/glia.22315
   Cirino AC, 2006, RETINA-J RET VIT DIS, V26, P1091, DOI 10.1097/01.iae.0000254891.48272.13
   Combadiere C, 2007, J CLIN INVEST, V117, P2920, DOI 10.1172/JCI31692
   Damani MR, 2011, AGING CELL, V10, P263, DOI 10.1111/j.1474-9726.2010.00660.x
   Dann A, 2012, NAT NEUROSCI, V15, P98, DOI 10.1038/nn.2964
   Detje CN, 2009, J IMMUNOL, V182, P2297, DOI 10.4049/jimmunol.0800596
   Goldmann T, 2013, NAT NEUROSCI, V16, P1618, DOI 10.1038/nn.3531
   Gupta N, 2003, EXP EYE RES, V76, P463, DOI 10.1016/S0014-4835(02)00332-9
   Inoue M, 2013, IMMUNOLOGY, V139, P11, DOI 10.1111/imm.12081
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Jin S, 2007, BRAIN RES, V1179, P140, DOI 10.1016/j.brainres.2007.08.055
   Kamphuis E, 2006, BLOOD, V108, P3253, DOI 10.1182/blood-2006-06-027599
   Karlstetter M, 2015, PROG RETIN EYE RES, V45, P30, DOI 10.1016/j.preteyeres.2014.11.004
   Kettenmann H, 2011, PHYSIOL REV, V91, P461, DOI 10.1152/physrev.00011.2010
   Kierdorf K, 2013, NAT NEUROSCI, V16, P273, DOI 10.1038/nn.3318
   Kimoto T, 2002, JPN J OPHTHALMOL, V46, P160, DOI 10.1016/S0021-5155(01)00492-0
   Lambert V, 2013, NAT PROTOC, V8, P2197, DOI 10.1038/nprot.2013.135
   Langmann T, 2007, J LEUKOCYTE BIOL, V81, P1345, DOI 10.1189/jlb.0207114
   Levy O, 2015, EMBO MOL MED, V7, P211, DOI 10.15252/emmm.201404524
   McMenamin PG, 1999, BRIT J OPHTHALMOL, V83, P598, DOI 10.1136/bjo.83.5.598
   MULLER U, 1994, SCIENCE, V264, P1918, DOI 10.1126/science.8009221
   Nimmerjahn A, 2005, SCIENCE, V308, P1314, DOI 10.1126/science.1110647
   Noel A, 2007, TRENDS MOL MED, V13, P345, DOI 10.1016/j.molmed.2007.06.005
   Prinz M, 2008, IMMUNITY, V28, P675, DOI 10.1016/j.immuni.2008.03.011
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Sadler AJ, 2008, NAT REV IMMUNOL, V8, P559, DOI 10.1038/nri2314
   Sene A, 2015, TRENDS MOL MED, V21, P43, DOI 10.1016/j.molmed.2014.10.005
   Sierra A, 2007, GLIA, V55, P412, DOI 10.1002/glia.20468
   Soriano P, 1999, NAT GENET, V21, P70, DOI 10.1038/5007
   Steinman L, 2012, NAT MED, V18, P59, DOI 10.1038/nm.2625
   Sun M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019870
   Teige I, 2003, J IMMUNOL, V170, P4776, DOI 10.4049/jimmunol.170.9.4776
   Tobe Takao, 1995, Nippon Ganka Gakkai Zasshi, V99, P571
   Touil T, 2006, J IMMUNOL, V177, P7505, DOI 10.4049/jimmunol.177.11.7505
   Wieghofer P, 2015, GLIA, V63, P1, DOI 10.1002/glia.22727
   Yasukawa T, 2002, INVEST OPHTH VIS SCI, V43, P842
   Yona S, 2013, IMMUNITY, V38, P79, DOI 10.1016/j.immuni.2012.12.001
   Zhao L, 2015, EMBO MOL MED, V7, P1179, DOI 10.15252/emmm.201505298
NR 41
TC 51
Z9 51
U1 0
U2 8
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1757-4676
EI 1757-4684
J9 EMBO MOL MED
JI EMBO Mol. Med.
PD JUN
PY 2016
VL 8
IS 6
BP 670
EP 678
DI 10.15252/emmm.201505994
PG 9
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA DR5SZ
UT WOS:000379964000009
PM 27137488
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Cho, A
   Ratliff, C
   Sampath, A
   Weiland, J
AF Cho, Alice
   Ratliff, Charles
   Sampath, Alapakkam
   Weiland, James
TI Changes in ganglion cell physiology during retinal degeneration
   influence excitability by prosthetic electrodes
SO JOURNAL OF NEURAL ENGINEERING
LA English
DT Article
DE retinal prostheses; retinal ganglion cells; retinal degeneration
ID ELECTRICAL-STIMULATION; PHOTORECEPTOR DEGENERATION; SYNAPTIC INPUT;
   MOUSE MODEL; RD1 MOUSE; RAT; PRESERVATION; MORPHOLOGY; MICE;
   OSCILLATIONS
AB Objective. Here we investigate ganglion cell physiology in healthy and degenerating retina to test its influence on threshold to electrical stimulation. Approach. Age-related Macular Degeneration and Retinitis Pigmentosa cause blindness via outer retinal degeneration. Inner retinal pathways that transmit visual information to the central brain remain intact, so direct electrical stimulation from prosthetic devices offers the possibility for visual restoration. Since inner retinal physiology changes during degeneration, we characterize physiological properties and responses to electrical stimulation in retinal ganglion cells (RGCs) of both wild type mice and the rd10 mouse model of retinal degeneration. Main results. Our aggregate results support previous observations that elevated thresholds characterize diseased retinas. However, a physiology-driven classification scheme reveals distinct sub-populations of ganglion cells with thresholds either normal or strongly elevated compared to wild-type. When these populations are combined, only a weakly elevated threshold with large variance is observed. The cells with normal threshold are more depolarized at rest and exhibit periodic oscillations. Significance. During degeneration, physiological changes in RGCs affect the threshold stimulation currents required to evoke action potentials.
C1 [Cho, Alice; Weiland, James] Univ So Calif, Viterbi Sch Engn, Dept Biomed Engn, Los Angeles, CA 90033 USA.
   [Ratliff, Charles; Sampath, Alapakkam] Univ Calif Los Angeles, David Geffen Sch Med, Stein Eye Inst, Los Angeles, CA 90095 USA.
   [Weiland, James] Univ So Calif, Keck Sch Med, Dept Ophthalmol, Los Angeles, CA 90033 USA.
C3 University of Southern California; University of California System;
   University of California Los Angeles; University of California Los
   Angeles Medical Center; David Geffen School of Medicine at UCLA;
   University of Southern California
RP Weiland, J (通讯作者)，Univ So Calif, Viterbi Sch Engn, Dept Biomed Engn, Los Angeles, CA 90033 USA.; Sampath, A (通讯作者)，Univ Calif Los Angeles, David Geffen Sch Med, Stein Eye Inst, Los Angeles, CA 90095 USA.; Weiland, J (通讯作者)，Univ So Calif, Keck Sch Med, Dept Ophthalmol, Los Angeles, CA 90033 USA.
EM asampath@jsei.ucla.edu; jweiland@med.usc.edu
OI Weiland, James/0000-0003-3453-9074
FU National Eye Institute [R01EY022931]; National Science Foundation
   Division of Engineering Education and Centers [EEC-0310723]; Research to
   Prevent Blindness; NATIONAL EYE INSTITUTE [P30EY000331, R01EY022931]
   Funding Source: NIH RePORTER
FX This work was supported by the National Eye Institute (R01EY022931),
   National Science Foundation Division of Engineering Education and
   Centers (EEC-0310723), and Research to Prevent Blindness.
CR Ahuja AK, 2013, TRANSL VIS SCI TECHN, V2, DOI 10.1167/tvst.2.4.1
   Ahuja AK, 2008, IEEE T BIO-MED ENG, V55, P1744, DOI 10.1109/TBME.2008.919126
   Ayton LN, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0115239
   Biswas S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099075
   Boinagrov D, 2014, J NEURAL ENG, V11, DOI 10.1088/1741-2560/11/2/026008
   Chan LLH, 2011, J NEUROPHYSIOL, V105, P2687, DOI 10.1152/jn.00619.2010
   Chang B, 2007, VISION RES, V47, P624, DOI 10.1016/j.visres.2006.11.020
   Cho AK, 2011, IEEE ENG MED BIO, P1081, DOI 10.1109/IEMBS.2011.6090252
   Choi H, 2014, J NEUROPHYSIOL, V112, P1491, DOI 10.1152/jn.00437.2014
   da Cruz L, 2013, BRIT J OPHTHALMOL, V97, P632, DOI 10.1136/bjophthalmol-2012-301525
   de Balthasar C, 2008, INVEST OPHTH VIS SCI, V49, P2303, DOI 10.1167/iovs.07-0696
   Dorn JD, 2013, JAMA OPHTHALMOL, V131, P183, DOI 10.1001/2013.jamaophthalmol.221
   Freeman DK, 2011, J NEURAL ENG, V8, DOI 10.1088/1741-2560/8/3/035005
   Gargini C, 2007, J COMP NEUROL, V500, P222, DOI 10.1002/cne.21144
   Haq W, 2014, FRONT NEURAL CIRCUIT, V8, DOI 10.3389/fncir.2014.00108
   Humayun MS, 2012, OPHTHALMOLOGY, V119, P779, DOI 10.1016/j.ophtha.2011.09.028
   Husain S, 2012, INVEST OPHTH VIS SCI, V53, P4289, DOI 10.1167/iovs.12-9467
   Jensen RJ, 2012, EXP EYE RES, V99, P71, DOI 10.1016/j.exer.2012.03.016
   Jensen RJ, 2009, J NEURAL ENG, V6, DOI 10.1088/1741-2560/6/3/035004
   Jepson LH, 2014, J NEUROSCI, V34, P4871, DOI 10.1523/JNEUROSCI.2882-13.2014
   Keseru M, 2012, ACTA OPHTHALMOL, V90, pE1, DOI 10.1111/j.1755-3768.2011.02288.x
   Lapicque L, 1931, J PHYSIOL-LONDON, V73, P189, DOI 10.1113/jphysiol.1931.sp002806
   LAVAIL MM, 1992, P NATL ACAD SCI USA, V89, P11249, DOI 10.1073/pnas.89.23.11249
   Margolis DJ, 2008, J NEUROSCI, V28, P6526, DOI 10.1523/JNEUROSCI.1533-08.2008
   Margolis DJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0086253
   Mazzoni F, 2008, J NEUROSCI, V28, P14282, DOI 10.1523/JNEUROSCI.4968-08.2008
   Medeiros NE, 2001, INVEST OPHTH VIS SCI, V42, P795
   Menzler J, 2011, J NEUROSCI, V31, P2280, DOI 10.1523/JNEUROSCI.4238-10.2011
   Okawa H, 2010, J GEN PHYSIOL, V136, P443, DOI 10.1085/jgp.201010477
   Sekirnjak C, 2011, J NEUROPHYSIOL, V105, P2560, DOI 10.1152/jn.01061.2010
   Sekirnjak C, 2009, J NEUROPHYSIOL, V102, P3260, DOI 10.1152/jn.00663.2009
   Sieving PA, 2006, P NATL ACAD SCI USA, V103, P3896, DOI 10.1073/pnas.0600236103
   Stasheff SF, 2008, J NEUROPHYSIOL, V99, P1408, DOI 10.1152/jn.00144.2007
   Stasheff SF, 2011, J NEUROPHYSIOL, V105, P3002, DOI 10.1152/jn.00704.2010
   Stingl K, 2013, P ROY SOC B-BIOL SCI, V280, DOI 10.1098/rspb.2013.0077
   Strettoi E, 2003, VISION RES, V43, P867, DOI 10.1016/S0042-6989(02)00594-1
   Trenholm S, 2012, J PHYSIOL-LONDON, V590, P2501, DOI 10.1113/jphysiol.2011.225060
   Yamazaki H, 2002, INVEST OPHTH VIS SCI, V43, P919
   Ye JH, 2007, PHYSIOL MEAS, V28, P1079, DOI 10.1088/0967-3334/28/9/009
   Yee CW, 2014, J COMP NEUROL, V522, P4085, DOI 10.1002/cne.23660
NR 40
TC 25
Z9 25
U1 0
U2 17
PU IOP PUBLISHING LTD
PI BRISTOL
PA TEMPLE CIRCUS, TEMPLE WAY, BRISTOL BS1 6BE, ENGLAND
SN 1741-2560
EI 1741-2552
J9 J NEURAL ENG
JI J. Neural Eng.
PD APR
PY 2016
VL 13
IS 2
AR 025001
DI 10.1088/1741-2560/13/2/025001
PG 11
WC Engineering, Biomedical; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Engineering; Neurosciences & Neurology
GA DL5NM
UT WOS:000375683800005
PM 26905177
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Walsh, DI
   Sommer, GJ
   Schaff, UY
   Hahn, PS
   Jaffe, GJ
   Murthy, SK
AF Walsh, David I., III
   Sommer, Gregory J.
   Schaff, Ulrich Y.
   Hahn, Paul S.
   Jaffe, Glenn J.
   Murthy, Shashi K.
TI A centrifugal fluidic immunoassay for ocular diagnostics with an
   enzymatically hydrolyzed fluorogenic substrate
SO LAB ON A CHIP
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; AQUEOUS-HUMOR LEVELS; DIABETIC-RETINOPATHY;
   CARE DIAGNOSTICS; VITREOUS LEVELS; MACULAR EDEMA; BEVACIZUMAB; POINT
AB We present a novel "Lab-on-a-Disk" platform and demonstrate its capability for rapid and sensitive measurement of vascular endothelial growth factor (VEGF) intended for patients suffering from diabetic retinopathy (DR) and age-related macular degeneration (AND). This approach combines sedimentation principles applied to microspheres under centrifugal force with signal amplification using an enzyme and a fluorogenic substrate for readout. The simple single channel per assay platform separates, washes and concentrates antibody-coated microspheres from excess label to produce a sensitive fluorogenic response proportional to the amount of VEGF in the sample. This platform has comparable sensitivity to conventional ELISA and can generate a readout within 16-18 min with no sample preparation beyond mixing assay reagents and loading on the disk. In the context of ocular diagnostics, this device has the potential to facilitate accurate dosing of anti-VEGF medications utilized to treat DR and AMD, as well as identify patients whose ocular VEGF levels are not elevated and who would therefore not benefit from standard anti-VEGF medications.
C1 [Walsh, David I., III] Northeastern Univ, Dept Bioengn, Boston, MA 02115 USA.
   [Sommer, Gregory J.; Schaff, Ulrich Y.] Sandstone Diagnost Inc, Livermore, CA USA.
   [Hahn, Paul S.; Jaffe, Glenn J.] Duke Univ, Ctr Eye, Durham, NC USA.
   [Murthy, Shashi K.] Northeastern Univ, Dept Chem Engn, Boston, MA 02115 USA.
   [Murthy, Shashi K.] Northeastern Univ, Barnett Inst Chem & Biol Anal, Boston, MA 02115 USA.
C3 Northeastern University; Duke University; Northeastern University;
   Northeastern University
RP Murthy, SK (通讯作者)，Northeastern Univ, Dept Chem Engn, Boston, MA 02115 USA.
EM s.murthy@neu.edu
FU National Science Graduate Research Fellowship awarded [NSF/DGE-0946746]
FX This material is based upon work supported by the National Science
   Graduate Research Fellowship awarded to D.I.W. under grant number
   NSF/DGE-0946746. Any opinion, findings and conclusions or
   recommendations expressed in this material are of those of the author(s)
   and do not necessarily reflect the views of the National Science
   Foundation. The authors also gratefully acknowledge Erica M. Bortoff and
   Aaron J. Medley for their assistance with the experiments.
CR AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203
   Burger R, 2012, CURR OPIN CHEM BIOL, V16, P409, DOI 10.1016/j.cbpa.2012.06.002
   Funatsu H, 2005, GRAEF ARCH CLIN EXP, V243, P3, DOI 10.1007/s00417-004-0950-7
   Funk M, 2010, RETINA-J RET VIT DIS, V30, P1412, DOI 10.1097/IAE.0b013e3181e095c0
   Gorkin R, 2010, LAB CHIP, V10, P1758, DOI 10.1039/b924109d
   Klein BEK, 2007, OPHTHAL EPIDEMIOL, V14, P179, DOI 10.1080/09286580701396720
   Lee BS, 2011, LAB CHIP, V11, P70, DOI [10.1039/c0lc00205d, 10.1039/c01c00205d]
   Mark D, 2010, CHEM SOC REV, V39, P1153, DOI 10.1039/b820557b
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Noma H, 2010, EUR J OPHTHALMOL, V20, P402, DOI 10.1177/112067211002000222
   Park J, 2012, ANAL CHEM, V84, P2133, DOI 10.1021/ac203163u
   Ramachandraiah H, 2013, LAB CHIP, V13, P1578, DOI 10.1039/c3lc41360h
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Rissin DM, 2013, LAB CHIP, V13, P2902, DOI 10.1039/c3lc50416f
   Rissin DM, 2010, NAT BIOTECHNOL, V28, P595, DOI 10.1038/nbt.1641
   Schaff UY, 2011, CLIN CHEM, V57, P753, DOI 10.1373/clinchem.2011.162206
   Schlingemann RO, 2009, PROG BRAIN RES, V175, P253, DOI 10.1016/S0079-6123(09)17517-9
   Selim KM, 2010, INDIAN J OPHTHALMOL, V58, P375, DOI 10.4103/0301-4738.67042
   Sheybani A, 2010, EXPERT REV OPHTHALMO, V5, P35, DOI 10.1586/EOP.09.67
   Tian, 2008, MICROFLUIDICS BIOL A, P1, DOI DOI 10.1007/19/8018/69480-41_1.
   Tong JP, 2006, AM J OPHTHALMOL, V141, P456, DOI 10.1016/j.ajo.2005.10.012
   Wakabayashi T., 2013, OPHTHALMOLOGY
   Yager P, 2008, ANNU REV BIOMED ENG, V10, P107, DOI 10.1146/annurev.bioeng.10.061807.160524
NR 23
TC 13
Z9 14
U1 0
U2 39
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 1473-0197
EI 1473-0189
J9 LAB CHIP
JI Lab Chip
PD AUG 7
PY 2014
VL 14
IS 15
BP 2673
EP 2680
DI 10.1039/c4lc00279b
PG 8
WC Biochemical Research Methods; Chemistry, Multidisciplinary; Chemistry,
   Analytical; Nanoscience & Nanotechnology; Instruments & Instrumentation
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry; Science & Technology -
   Other Topics; Instruments & Instrumentation
GA AL7IF
UT WOS:000339306700011
PM 24806296
DA 2022-11-30
ER

PT J
AU Goldstein, M
   Heilweil, G
   Barak, A
   Loewenstein, A
AF Goldstein, M
   Heilweil, G
   Barak, A
   Loewenstein, A
TI Retinal pigment epithelial tear following photodynamic therapy for
   choroidal neovascularization secondary to AMD
SO EYE
LA English
DT Article
DE choroidal neovascularization; retinal pigment epithelial tear;
   photodynamic therapy
ID NATURAL-HISTORY; VERTEPORFIN; DETACHMENTS
AB Purpose To describe retinal pigment epithelial tear following photodynamic therapy (PDT) for subfoveal choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD). Design Retrospective interventional case series.
   Methods A retrospective study in an institutional practice. We describe seven cases of retinal pigment epithelial (RPE) tear, which developed in seven eyes of seven patients following PDT. All eyes had subfoveal CNV secondary to AMD.
   Results Six eyes had occult subfoveal CNV, and one eye had recurrent classic subfoveal CNV. In five patients, the eye that developed the tear was the second eye, whereas the first eye had a disciform scar. In four eyes, the RPE tear developed after one PDT, in one eye the RPE tear developed after the second PDT, and in two eyes the RPE tear developed after the third PDT. In five of seven cases, there was a significant visual deterioration following the RPE tear.
   Conclusions RPE tear is a complication that may occur following PDT in particular when the PDT is applied to an occult subfoveal CNV.
C1 Sackler Sch Med, Tel Aviv Med Ctr, Dept Ophthalmol, IL-64239 Tel Aviv, Israel.
C3 Tel Aviv University; Sackler Faculty of Medicine
RP Goldstein, M (通讯作者)，Sackler Sch Med, Tel Aviv Med Ctr, Dept Ophthalmol, 6 Weizman St, IL-64239 Tel Aviv, Israel.
EM michgold@netvision.net.il
CR Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Bressler NM, 2002, ARCH OPHTHALMOL-CHIC, V120, P1307
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   COSCAS G, 1990, ARCH OPHTHALMOL-CHIC, V108, P1687, DOI 10.1001/archopht.1990.01070140041025
   ELMAN MJ, 1986, OPHTHALMOLOGY, V93, P224
   GASS JDM, 1984, AM J OPHTHALMOL, V98, P700
   GASS JDM, 1984, BRIT J OPHTHALMOL, V68, P513, DOI 10.1136/bjo.68.8.513
   Gelisken F, 2001, AM J OPHTHALMOL, V131, P518, DOI 10.1016/S0002-9394(00)00813-8
   Haimovici R, 1997, CURR EYE RES, V16, P83, DOI 10.1076/ceyr.16.2.83.5088
   HOSKIN A, 1981, BRIT J OPHTHALMOL, V65, P417, DOI 10.1136/bjo.65.6.417
   Husain D, 1999, INVEST OPHTH VIS SCI, V40, P2322
   Kramer M, 1996, OPHTHALMOLOGY, V103, P427
   MEREDITH TA, 1979, AM J OPHTHALMOL, V88, P643, DOI 10.1016/0002-9394(79)90659-7
   Michels S, 2003, INVEST OPHTH VIS SCI, V44, P2147, DOI 10.1167/iovs.02-0604
   Pece A, 2001, RETINA-J RET VIT DIS, V21, P661, DOI 10.1097/00006982-200112000-00017
   POLINER LS, 1986, OPHTHALMOLOGY, V93, P543
   Reinke MH, 1999, OPHTHALMOLOGY, V106, P1915, DOI 10.1016/S0161-6420(99)90401-3
   Schmidt-Erfurth U, 2000, SURV OPHTHALMOL, V45, P195, DOI 10.1016/S0039-6257(00)00158-2
   Schmidt-Erfurth U, 2002, INVEST OPHTH VIS SCI, V43, P830
   Srivastava SK, 2002, RETINA-J RET VIT DIS, V22, P669, DOI 10.1097/00006982-200210000-00027
   *TREATM AG REL MAC, 2001, ARCH OPHTHALMOL-CHIC, V19, P198
   YEO JH, 1988, OPHTHALMOLOGY, V95, P8
NR 22
TC 43
Z9 50
U1 2
U2 4
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-222X
EI 1476-5454
J9 EYE
JI Eye
PD DEC
PY 2005
VL 19
IS 12
BP 1315
EP 1324
DI 10.1038/sj.eye.6701765
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 992AX
UT WOS:000233857300014
PM 15803179
OA Bronze
DA 2022-11-30
ER

PT J
AU Qi, JH
   Ebrahem, Q
   Yeow, K
   Edwards, DR
   Fox, PL
   Anand-Apte, B
AF Qi, JH
   Ebrahem, Q
   Yeow, K
   Edwards, DR
   Fox, PL
   Anand-Apte, B
TI Expression of sorsby's fundus dystrophy mutations in human retinal
   pigment epithelial cells reduces matrix metalloproteinase inhibition and
   may promote angiogenesis
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID CHOROIDAL ENDOTHELIAL-CELLS; TISSUE INHIBITOR; IN-VITRO; BRUCHS
   MEMBRANE; MELANOMA-CELLS; NEOVASCULARIZATION; TIMP-3; INVASION;
   OVEREXPRESSION; APOPTOSIS
AB Sorsby's fundus dystrophy (SFD) is an autosomal dominant degenerative disease of the macula caused by mutations in the tissue inhibitor of metalloproteinase-3 (TIMP-3) gene. Choroidal neovascularization is a hallmark of this disease, which closely resembles the exudative form of age-related macular degeneration. However, the mechanism by which TIMP-3 mutations induce the disease phenotype in SFD remains unknown. To address this question we established human retinal pigment epithelial cell lines expressing wild type or S156C (Ser(156) changed to cysteine) mutant TIMP-3. S156C TIMP-3 had reduced matrix metalloproteinase (MMP) inhibitory activity in retinal pigment epithelial cells and resulted in increased secretion and activation of gelatinase A and B. The conditioned medium from these cells induced angiogenesis in "in vivo" chick chorioallantoic membrane assays that could be reversed with recombinant wild type TIMP-3. Our data indicate that the choroidal neovascularization in SFD may be a result of increased MMP activity, which could lead to the stimulation of angiogenesis. These results also suggest the potential therapeutic use of TIMP-3 or synthetic MMP inhibitors in this disease.
C1 Cleveland Clin Fdn, Dept Ophthalm Res, Cole Dye Inst I131, Cleveland, OH 44195 USA.
   Cleveland Clin Fdn, Dept Cell Biol, Lerner Res Inst, Cleveland, OH 44195 USA.
   Univ E Anglia, Sch Biol Sci, Norwich NR4 7TJ, Norfolk, England.
C3 Cleveland Clinic Foundation; Cleveland Clinic Foundation; University of
   East Anglia
RP Anand-Apte, B (通讯作者)，Cleveland Clin Fdn, Dept Ophthalm Res, Cole Dye Inst I131, 9500 Euclid Ave, Cleveland, OH 44195 USA.
RI Edwards, Dylan R/B-4734-2009
OI Edwards, Dylan R/0000-0002-3292-2064
FU NATIONAL CANCER INSTITUTE [R01CA106415] Funding Source: NIH RePORTER;
   NATIONAL EYE INSTITUTE [R01EY016490, R29EY012109] Funding Source: NIH
   RePORTER; NCI NIH HHS [R01 CA106415] Funding Source: Medline; NEI NIH
   HHS [R01 EY016490, 1 R29 EY12109-01, R29 EY012109] Funding Source:
   Medline
CR Ahonen M, 1998, CANCER RES, V58, P2310
   Ahonen M, 1998, ADV EXP MED BIOL, V451, P69
   AnandApte B, 1997, INVEST OPHTH VIS SCI, V38, P817
   Baker AH, 1999, BRIT J CANCER, V79, P1347, DOI 10.1038/sj.bjc.6690217
   Baker AH, 1998, J CLIN INVEST, V101, P1478, DOI 10.1172/JCI1584
   Banyard J, 2000, ONCOGENE, V19, P580, DOI 10.1038/sj.onc.1203338
   Blaauwgeers HGT, 1999, AM J PATHOL, V155, P421, DOI 10.1016/S0002-9440(10)65138-3
   Bond M, 2000, J BIOL CHEM, V275, P41358, DOI 10.1074/jbc.M007929200
   Brooks PC, 1996, CANCER METAST REV, V15, P187, DOI 10.1007/BF00437471
   Campochiaro P.A., 1999, MOL VIS, V5, P24
   Campochiaro PA, 2000, J CELL PHYSIOL, V184, P301, DOI 10.1002/1097-4652(200009)184:3<301::AID-JCP3>3.0.CO;2-H
   CAPON MRC, 1989, OPHTHALMOLOGY, V96, P1769
   DAMORE PA, 1994, INVEST OPHTH VIS SCI, V35, P3974
   Fariss RN, 1998, BRIT J OPHTHALMOL, V82, P1329, DOI 10.1136/bjo.82.11.1329
   Fariss RN, 1997, AM J PATHOL, V150, P323
   Fata JE, 2001, J CLIN INVEST, V108, P831, DOI 10.1172/JCI200113171
   George SJ, 2000, CIRCULATION, V101, P296, DOI 10.1161/01.CIR.101.3.296
   Hiraoka N, 1998, CELL, V95, P365, DOI 10.1016/S0092-8674(00)81768-7
   HOLZ FG, 1994, RETINA-J RET VIT DIS, V14, P329, DOI 10.1097/00006982-199414040-00006
   Itoh T, 1998, CANCER RES, V58, P1048
   JACOBSON SG, 1995, NAT GENET, V11, P27, DOI 10.1038/ng0995-27
   KALMUS H, 1976, J MED GENET, V13, P271, DOI 10.1136/jmg.13.4.271
   Kamei M, 1999, INVEST OPHTH VIS SCI, V40, P2367
   KORTE GE, 1986, ACTA ANAT, V127, P171
   Langton KP, 1998, J BIOL CHEM, V273, P16778, DOI 10.1074/jbc.273.27.16778
   Langton KP, 2000, J BIOL CHEM, V275, P27027
   Leco KJ, 2001, J CLIN INVEST, V108, P817, DOI 10.1172/JCI200112067
   MILLER H, 1986, INVEST OPHTH VIS SCI, V27, P1644
   NGUYEN M, 1994, MICROVASC RES, V47, P31, DOI 10.1006/mvre.1994.1003
   PAVLOFF N, 1992, J BIOL CHEM, V267, P17321
   POLKINGHORNE PJ, 1989, OPHTHALMOLOGY, V96, P1763
   SAKAMOTO T, 1995, ARCH OPHTHALMOL-CHIC, V113, P512, DOI 10.1001/archopht.1995.01100040134039
   SAKAMOTO T, 1995, CURR EYE RES, V14, P621, DOI 10.3109/02713689508998488
   SORSBY A, 1949, BRIT J OPHTHALMOL, V33, P67, DOI 10.1136/bjo.33.2.67
   Stetler-Stevenson W G, 2001, Surg Oncol Clin N Am, V10, P383
   Stetler-Stevenson WG, 2001, SEMIN CANCER BIOL, V11, P143, DOI 10.1006/scbi.2000.0365
   Tabata Y, 1998, HUM GENET, V103, P179, DOI 10.1007/s004390050803
   Vu TH, 1998, CELL, V93, P411, DOI 10.1016/S0092-8674(00)81169-1
   WEBER BHF, 1994, NAT GENET, V8, P352, DOI 10.1038/ng1294-352
   Werb Z, 1999, APMIS, V107, P11, DOI 10.1111/j.1699-0463.1999.tb01521.x
   Will H, 1996, J BIOL CHEM, V271, P17119, DOI 10.1074/jbc.271.29.17119
   Woessner JF, 2001, J CLIN INVEST, V108, P799, DOI 10.1172/JCI13709
   Xu JS, 2001, J CELL BIOL, V154, P1069, DOI 10.1083/jcb.200103111
   Yeow KM, 2002, MATRIX BIOL, V21, P75, DOI 10.1016/S0945-053X(01)00180-9
   YU M, 1995, CANCER RES, V55, P3272
   Yu WH, 2000, J BIOL CHEM, V275, P31226, DOI 10.1074/jbc.M000907200
NR 46
TC 36
Z9 39
U1 0
U2 0
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0021-9258
J9 J BIOL CHEM
JI J. Biol. Chem.
PD APR 19
PY 2002
VL 277
IS 16
BP 13394
EP 13400
DI 10.1074/jbc.M110870200
PG 7
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA 543HR
UT WOS:000175096000008
PM 11821400
OA hybrid
DA 2022-11-30
ER

PT J
AU Tan, CS
   Lim, TH
   Hariprasad, SM
AF Tan, Colin S.
   Lim, Tock Han
   Hariprasad, Seenu M.
TI Current Management of Polypoidal Choroidal Vasculopathy
SO OPHTHALMIC SURGERY LASERS & IMAGING RETINA
LA English
DT Article
ID OPTICAL COHERENCE TOMOGRAPHY; PHOTODYNAMIC THERAPY; MACULAR
   DEGENERATION; INTRAVITREAL RANIBIZUMAB; VASCULAR NETWORK;
   HEALTHY-ADULTS; FOLLOW-UP; VERTEPORFIN; THICKNESSES; INJECTIONS
C1 [Tan, Colin S.; Lim, Tock Han] Tan Tock Seng Hosp, Natl Healthcare Grp Eye Inst, 11 Jalan Tan Tock Seng, Singapore 308433, Singapore.
   [Hariprasad, Seenu M.] Univ Chicago, Dept Ophthalmol & Visual Sci, Chicago, IL 60637 USA.
C3 Tan Tock Seng Hospital; University of Chicago
RP Tan, CS (通讯作者)，Tan Tock Seng Hosp, Natl Healthcare Grp Eye Inst, 11 Jalan Tan Tock Seng, Singapore 308433, Singapore.
EM Colintan_eye@yahoo.com.sg; tock_han_lim@nhg.com.sg; retina@uchicago.edu
RI Tan, Colin S/K-8972-2012
OI Tan, Colin S/0000-0003-3088-5690
CR Akaza E, 2008, RETINA-J RET VIT DIS, V28, P717, DOI 10.1097/IAE.0b013e31816577cb
   Akaza E, 2011, JPN J OPHTHALMOL, V55, P39, DOI 10.1007/s10384-010-0886-x
   Cheng CK, 2011, RETINA-J RET VIT DIS, V31, P846, DOI 10.1097/IAE.0b013e3181f84fdf
   Cho HJ, 2012, EYE, V26, P426, DOI 10.1038/eye.2011.324
   Chuah CT, 2003, CLIN EXP OPHTHALMOL, V31, P163, DOI 10.1046/j.1442-9071.2003.00627.x
   Fan NW, 2014, J CHIN MED ASSOC, V77, P101, DOI 10.1016/j.jcma.2013.10.012
   Gomi F, 2015, RETINA-J RET VIT DIS, V35, P1569, DOI 10.1097/IAE.0000000000000526
   Hata M, 2015, GRAEF ARCH CLIN EXP, V253, P189, DOI 10.1007/s00417-014-2675-6
   Hatz K, 2014, BRIT J OPHTHALMOL, V98, P188, DOI 10.1136/bjophthalmol-2013-303444
   Heussen FM, 2012, INVEST OPHTH VIS SCI, V53, P6526, DOI 10.1167/iovs.12-9909
   Hosokawa M, 2015, BRIT J OPHTHALMOL, V99, P1087, DOI 10.1136/bjophthalmol-2014-305275
   Imasawa M, 2011, JPN J OPHTHALMOL, V55, P241, DOI 10.1007/s10384-011-0006-6
   Jia YL, 2014, OPHTHALMOLOGY, V121, P1435, DOI 10.1016/j.ophtha.2014.01.034
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Koizumi H, 2015, BRIT J OPHTHALMOL, V99, P1284, DOI 10.1136/bjophthalmol-2014-306432
   Koizumi H, 2011, BRIT J OPHTHALMOL, V95, P1555, DOI 10.1136/bjophthalmol-2011-300285
   Lafaut BA, 2000, GRAEF ARCH CLIN EXP, V238, P752, DOI 10.1007/s004170000180
   Leal S, 2010, RETINA-J RET VIT DIS, V30, P1197, DOI 10.1097/IAE.0b013e3181d37486
   Lee MW, 2009, EYE, V23, P1417, DOI 10.1038/eye.2008.265
   Lim TH, 2010, EYE, V24, P483, DOI 10.1038/eye.2009.323
   Mauget-Faysse M, 2006, EUR J OPHTHALMOL, V16, P695, DOI 10.1177/112067210601600506
   Oishi A, 2011, EYE, V25, P1020, DOI 10.1038/eye.2011.110
   Oishi A, 2013, AM J OPHTHALMOL, V156, P644, DOI 10.1016/j.ajo.2013.05.024
   Sakurai M, 2014, CLIN OPHTHALMOL, V8, P235, DOI 10.2147/OPTH.S54578
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   Silva RM, 2005, GRAEF ARCH CLIN EXP, V243, P973, DOI 10.1007/s00417-005-1139-4
   Song MH, 2011, OPHTHALMOLOGICA, V226, DOI 10.1159/000329466
   Spaide RF, 2015, JAMA OPHTHALMOL, V133, P45, DOI 10.1001/jamaophthalmol.2014.3616
   STERN RM, 1985, AM J OPHTHALMOL, V100, P560, DOI 10.1016/0002-9394(85)90682-8
   Tan CSH, 2007, EYE, V21, P132, DOI 10.1038/sj.eye.6702455
   Tan CS, 2015, BRIT J OPHTHALMOL, V99, P624, DOI 10.1136/bjophthalmol-2014-305674
   Tan CS, 2014, OSLI RETINA, V45, P363, DOI 10.3928/23258160-20140909-07
   Tan CS, 2014, BRIT J OPHTHALMOL, V98, P997, DOI 10.1136/bjophthalmol-2014-305318
   Tan CS, 2013, OPHTHALMOLOGY, V120, P1271, DOI 10.1016/j.ophtha.2012.12.002
   Tan CS, 2012, INVEST OPHTH VIS SCI, V53, P261, DOI 10.1167/iovs.11-8782
   Tan CSH, 2015, BRIT J OPHTHALMOL, V99, P354, DOI 10.1136/bjophthalmol-2014-305331
   Tan CSH, 2014, BRIT J OPHTHALMOL, V98, P1528, DOI 10.1136/bjophthalmol-2014-305059
   Tan CSH, 2014, INVEST OPHTH VIS SCI, V55, P6452, DOI 10.1167/iovs.13-13771
   Tan CSH, 2014, BRIT J OPHTHALMOL, V98, P339, DOI 10.1136/bjophthalmol-2013-304000
   Tan CSH, 2013, ACTA OPHTHALMOL, V91, pE578, DOI 10.1111/aos.12214
   Tateiwa H, 2002, GRAEF ARCH CLIN EXP, V240, P354, DOI 10.1007/s00417-002-0459-x
   Toyama T, 2014, EYE, V28, P992, DOI 10.1038/eye.2014.132
   Ueta T, 2009, OPHTHALMOLOGY, V116, P2400, DOI 10.1016/j.ophtha.2009.06.013
   Uyama M, 2002, AM J OPHTHALMOL, V133, P639, DOI 10.1016/S0002-9394(02)01404-6
   Uyama M, 1999, ARCH OPHTHALMOL-CHIC, V117, P1035
   Yamamoto A, 2015, OPHTHALMOLOGY, V122, P1866, DOI 10.1016/j.ophtha.2015.05.024
   Yamaoka S, 2010, OPHTHALMOLOGICA, V224, P147, DOI 10.1159/000236040
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
NR 48
TC 15
Z9 15
U1 0
U2 0
PU SLACK INC
PI THOROFARE
PA 6900 GROVE RD, THOROFARE, NJ 08086 USA
SN 2325-8160
EI 2325-8179
J9 OSLI RETINA
JI Ophthalmic Surg. Lasers Imag. Retin.
PD SEP
PY 2015
VL 46
IS 8
BP 786
EP 791
DI 10.3928/23258160-20150909-02
PG 6
WC Ophthalmology; Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Surgery
GA DP9UD
UT WOS:000378842000003
PM 26431293
DA 2022-11-30
ER

PT J
AU Jacobo-Albavera, L
   Dominguez-Perez, M
   Medina-Leyte, DJ
   Gonzalez-Garrido, A
   Villarreal-Molina, T
AF Jacobo-Albavera, Leonor
   Dominguez-Perez, Mayra
   Medina-Leyte, Diana Jhoseline
   Gonzalez-Garrido, Antonia
   Villarreal-Molina, Teresa
TI The Role of the ATP-Binding Cassette A1 (ABCA1) in Human Disease
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Review
DE ATP-binding cassette transporter A1 (ABCA1); cholesterol homeostasis;
   reverse cholesterol transport; HDL-C; dyslipidemia; type 2 diabetes;
   microparticles
AB Cholesterol homeostasis is essential in normal physiology of all cells. One of several proteins involved in cholesterol homeostasis is the ATP-binding cassette transporter A1 (ABCA1), a transmembrane protein widely expressed in many tissues. One of its main functions is the efflux of intracellular free cholesterol and phospholipids across the plasma membrane to combine with apolipoproteins, mainly apolipoprotein A-I (Apo A-I), forming nascent high-density lipoprotein-cholesterol (HDL-C) particles, the first step of reverse cholesterol transport (RCT). In addition, ABCA1 regulates cholesterol and phospholipid content in the plasma membrane affecting lipid rafts, microparticle (MP) formation and cell signaling. Thus, it is not surprising that impaired ABCA1 function and altered cholesterol homeostasis may affect many different organs and is involved in the pathophysiology of a broad array of diseases. This review describes evidence obtained from animal models, human studies and genetic variation explaining how ABCA1 is involved in dyslipidemia, coronary heart disease (CHD), type 2 diabetes (T2D), thrombosis, neurological disorders, age-related macular degeneration (AMD), glaucoma, viral infections and in cancer progression.
C1 [Jacobo-Albavera, Leonor; Dominguez-Perez, Mayra; Medina-Leyte, Diana Jhoseline; Gonzalez-Garrido, Antonia; Villarreal-Molina, Teresa] Inst Nacl Med Genom INMEGEN, Lab Genom Enfermedades Cardiovasc, Direcc Invest, Mexico City 14610, DF, Mexico.
   [Medina-Leyte, Diana Jhoseline] Univ Nacl Autonoma Mexico, Posgrad Ciencias Biol, Mexico City 04510, DF, Mexico.
C3 Instituto Nacional de Medicina Genomica; Universidad Nacional Autonoma
   de Mexico
RP Villarreal-Molina, T (通讯作者)，Inst Nacl Med Genom INMEGEN, Lab Genom Enfermedades Cardiovasc, Direcc Invest, Mexico City 14610, DF, Mexico.
EM ljacobo@inmegen.gob.mx; mdominguez@inmegen.gob.mx;
   dianajhos18@gmail.com; agonzalezg@uchicago.edu;
   mvillareal@inmegen.gob.mx
RI Domínguez-Pérez, Mayra/AAB-3264-2020
OI Domínguez-Pérez, Mayra/0000-0002-6049-0430; Jacobo-Albavera,
   Leonor/0000-0001-5129-8108; Gonzalez-Garrido,
   Antonia/0000-0003-2578-3155; VILLARREAL MOLINA,
   TERESA/0000-0003-4450-7690; Medina Leyte, Diana
   Jhoseline/0000-0003-1620-9928
CR Acuna-Alonzo V, 2010, HUM MOL GENET, V19, P2877, DOI 10.1093/hmg/ddq173
   Adzhubei AA, 2018, AIDS, V32, P2103, DOI 10.1097/QAD.0000000000001951
   Aguirre-Portoles C, 2018, MOL ONCOL, V12, P1735, DOI 10.1002/1878-0261.12367
   Ahn J, 2009, CANCER EPIDEM BIOMAR, V18, P2814, DOI 10.1158/1055-9965.EPI-08-1248
   Aiello RJ, 2003, ARTERIOSCL THROM VAS, V23, P972, DOI 10.1161/01.ATV.0000054661.21499.FB
   Aizawa Y, 2015, WORLD J GASTROENTERO, V21, P10299, DOI 10.3748/wjg.v21.i36.10299
   Gamboa-Melendez MA, 2015, ARCH MED RES, V46, P495, DOI 10.1016/j.arcmed.2015.07.008
   Albrecht C, 2005, BLOOD, V106, P542, DOI 10.1182/blood-2004-05-2056
   Alharbi KK, 2013, J BIOSCIENCES, V38, P893, DOI 10.1007/s12038-013-9384-x
   Alshaikhli A, 2020, STATPEARLS
   Aly ASI, 2009, ANNU REV MICROBIOL, V63, P195, DOI 10.1146/annurev.micro.091208.073403
   Andrikovics H, 2006, CEREBROVASC DIS, V21, P254, DOI 10.1159/000091223
   [Anonymous], 2016, ENSANUT ENCUESTA NAC
   Asztalos BF, 2010, J INFECT DIS, V202, P614, DOI 10.1086/654817
   Babashamsi Mohammad Mahdi, 2017, Avicenna Journal of Medical Biotechnology, V9, P38
   Babatunde KA, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00022
   Ban N, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.120824
   BANCHER C, 1989, BRAIN RES, V477, P90, DOI 10.1016/0006-8993(89)91396-6
   Bellentani S, 2017, LIVER INT, V37, P81, DOI 10.1111/liv.13299
   Below JE, 2016, SCI REP-UK, V6, DOI 10.1038/srep19429
   Bevers EM, 2016, PHYSIOL REV, V96, P605, DOI 10.1152/physrev.00020.2015
   Bi DP, 2016, ONCOL REP, V35, P2873, DOI 10.3892/or.2016.4631
   Bocchetta S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092140
   Bochem AE, 2013, EUR HEART J, V34, P286, DOI 10.1093/eurheartj/ehs376
   Bodzioch M, 1999, NAT GENET, V22, P347, DOI 10.1038/11914
   Boehm-Cagan A, 2016, J ALZHEIMERS DIS, V54, P1219, DOI 10.3233/JAD-160467
   Bogan JS, 2012, TRAFFIC, V13, P1466, DOI 10.1111/j.1600-0854.2012.01407.x
   Braak H, 1997, NEUROBIOL AGING, V18, pS85, DOI 10.1016/S0197-4580(97)00062-6
   Braak H, 2006, ACTA NEUROPATHOL, V112, P389, DOI 10.1007/s00401-006-0127-z
   Brooks-Wilson A, 1999, NAT GENET, V22, P336, DOI 10.1038/11905
   Brunham LR, 2008, J CLIN INVEST, V118, P403, DOI 10.1172/JCI33296
   Brunham LR, 2007, NAT MED, V13, P340, DOI 10.1038/nm1546
   Brunham LR, 2006, J CLIN INVEST, V116, P1052, DOI 10.1172/JCI27352
   Buendia P, 2015, FASEB J, V29, P173, DOI 10.1096/fj.14-249706
   Burger D, 2013, CLIN SCI, V124, P423, DOI 10.1042/CS20120309
   Burnett JR, 1993, GENEREVIEWS
   Campbell DD, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033570
   Canfran-Duque A, 2014, CARDIOVASC RES, V103, P414, DOI 10.1093/cvr/cvu140
   Castranio EL, 2018, ACTA NEUROPATHOL COM, V6, DOI 10.1186/s40478-018-0569-2
   Cenarro A, 2003, J MED GENET, V40, P163, DOI 10.1136/jmg.40.3.163
   Chalasani N, 2018, HEPATOLOGY, V67, P328, DOI 10.1002/hep.29367
   Chang TY, 2017, J LIPID RES, V58, P2239, DOI 10.1194/jlr.R075630
   Chen W, 2010, P NATL ACAD SCI USA, V107, P7401, DOI 10.1073/pnas.0912702107
   Cheng J, 2020, ARTERIOSCL THROM VAS, V40, P412, DOI 10.1161/ATVBAHA.119.313633
   Cheung CMG, 2017, J LIPID RES, V58, P1785, DOI 10.1194/jlr.M073684
   Chou JL, 2015, CLIN EPIGENETICS, V7, DOI 10.1186/s13148-014-0036-2
   Christiansen-Weber TA, 2000, AM J PATHOL, V157, P1017, DOI 10.1016/S0002-9440(10)64614-7
   Clee SM, 2001, CIRCULATION, V103, P1198
   Clee SM, 2000, J CLIN INVEST, V106, P1263, DOI 10.1172/JCI10727
   Coban N, 2014, ANATOL J CARDIOL, V14, P18, DOI 10.5152/akd.2013.234
   Combes V, 2005, AM J PATHOL, V166, P295, DOI 10.1016/S0002-9440(10)62253-5
   Combes V, 2006, INT J PARASITOL, V36, P541, DOI 10.1016/j.ijpara.2006.02.005
   Corona AW, 2016, J NEUROIMMUNE PHARM, V11, P61, DOI 10.1007/s11481-015-9627-8
   Crompton M, 2000, J PHYSIOL-LONDON, V529, P11, DOI 10.1111/j.1469-7793.2000.00011.x
   Cui HL, 2012, J LIPID RES, V53, P696, DOI 10.1194/jlr.M023119
   Cui X, 2015, STROKE, V46, P827, DOI 10.1161/STROKEAHA.114.007145
   Curcio CA, 2013, RETINA-J RET VIT DIS, V33, P265, DOI 10.1097/IAE.0b013e31827e25e0
   Curcio CA, 2011, BRIT J OPHTHALMOL, V95, P1638, DOI 10.1136/bjophthalmol-2011-300344
   Daimon M, 2005, BIOCHEM BIOPH RES CO, V329, P205, DOI 10.1016/j.bbrc.2005.01.119
   de Haan W, 2014, J LIPID RES, V55, P516, DOI 10.1194/jlr.M045294
   de Vries PS, 2019, AM J EPIDEMIOL, V188, P1033, DOI 10.1093/aje/kwz005
   DeFronzo RA, 2009, DIABETES, V58, P773, DOI 10.2337/db09-9028
   Delgado-Lista J, 2010, ARTERIOSCL THROM VAS, V30, P1051, DOI 10.1161/ATVBAHA.109.202580
   Desmarchelier C, 2014, J CLIN ENDOCR METAB, V99, pE484, DOI 10.1210/jc.2013-3962
   DESSI S, 1994, CANCER, V73, P253, DOI 10.1002/1097-0142(19940115)73:2<253::AID-CNCR2820730204>3.0.CO;2-F
   Dietschy JM, 2004, J LIPID RES, V45, P1375, DOI 10.1194/jlr.R400004-JLR200
   Dietze J., 2020, STATPEARLS
   Dietzel M, 2014, GRAEF ARCH CLIN EXP, V252, P1273, DOI 10.1007/s00417-014-2690-7
   Ditiatkovski M, 2020, J BIOL CHEM, V295, P13377, DOI 10.1074/jbc.RA120.014642
   Do R, 2013, NAT GENET, V45, P1345, DOI 10.1038/ng.2795
   Dominguez-Perez M, 2019, J CELL PHYSIOL, V234, P7213, DOI 10.1002/jcp.27474
   Donkin JJ, 2010, J BIOL CHEM, V285, P34144, DOI 10.1074/jbc.M110.108100
   Drew BG, 2004, P NATL ACAD SCI USA, V101, P6999, DOI 10.1073/pnas.0306266101
   Drew BG, 2009, CIRCULATION, V119, P2103, DOI 10.1161/CIRCULATIONAHA.108.843219
   Dumitrescu L, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002138
   Duncan KG, 2009, BRIT J OPHTHALMOL, V93, P1116, DOI 10.1136/bjo.2008.144006
   Duong PT, 2006, J LIPID RES, V47, P832, DOI 10.1194/jlr.M500531-JLR200
   Egana-Gorrono L, 2013, AIDS, V27, P529, DOI 10.1097/QAD.0b013e32835d0da1
   Eliseeva N V, 2020, Vestn Oftalmol, V136, P129, DOI 10.17116/oftalma2020136051129
   Ergen HA, 2012, BIOCHEM MEDICA, V22, P114
   Evans D, 2003, J MOL MED-JMM, V81, P264, DOI 10.1007/s00109-003-0426-y
   Fan JJ, 2018, J LIPID RES, V59, P830, DOI 10.1194/jlr.M081851
   Fasano T, 2012, MOL GENET METAB, V107, P534, DOI 10.1016/j.ymgme.2012.08.005
   Feher A, 2018, NEUROSCI LETT, V664, P79, DOI 10.1016/j.neulet.2017.11.027
   Fitz NF, 2017, J ALZHEIMERS DIS, V56, P1075, DOI 10.3233/JAD-161056
   Frikke-Schmidt R, 2004, J CLIN INVEST, V114, P1343, DOI 10.1172/JCI200420361
   Fryirs M, 2009, CURR OPIN LIPIDOL, V20, P159, DOI 10.1097/MOL.0b013e32832ac180
   Funfschilling U, 2007, BMC NEUROSCI, V8, DOI 10.1186/1471-2202-8-1
   Fukuchi J, 2004, CANCER RES, V64, P7682, DOI 10.1158/0008-5472.CAN-04-2647
   Furney SJ, 2011, MOL PSYCHIATR, V16, P1130, DOI 10.1038/mp.2010.123
   Genvigir FDV, 2008, CLIN CHIM ACTA, V389, P79, DOI 10.1016/j.cca.2007.11.029
   Gillotte KL, 1999, J BIOL CHEM, V274, P2021, DOI 10.1074/jbc.274.4.2021
   Goedeke L, 2015, NAT MED, V21, P1280, DOI 10.1038/nm.3949
   Graff JR, 2000, J BIOL CHEM, V275, P24500, DOI 10.1074/jbc.M003145200
   Grau Georges E., 2005, Journal de la Societe de Biologie, V199, P199, DOI 10.1051/jbio:2005020
   Greferath U, 2016, OPHTHALMOLOGY, V123, P1320, DOI 10.1016/j.ophtha.2016.02.009
   Guevara-Cruz M, 2010, MOL GENET METAB, V101, P268, DOI 10.1016/j.ymgme.2010.08.007
   Guo ZG, 2002, J HUM GENET, V47, P325, DOI 10.1007/s100380200044
   Gusareva ES, 2014, NEUROBIOL AGING, V35, P2436, DOI 10.1016/j.neurobiolaging.2014.05.014
   Hafiane A, 2017, ATHEROSCLEROSIS, V257, P90, DOI 10.1016/j.atherosclerosis.2017.01.013
   Han R, 2007, DIABETOLOGIA, V50, P1960, DOI 10.1007/s00125-007-0752-7
   Hao M, 2007, DIABETES, V56, P2328, DOI 10.2337/db07-0056
   Hapugaswatta H, 2020, J BIOMED SCI, V27, DOI 10.1186/s12929-020-0620-z
   Harada T, 2003, ATHEROSCLEROSIS, V169, P105, DOI 10.1016/S0021-9150(03)00135-7
   Hassan HH, 2007, J LIPID RES, V48, P2428, DOI 10.1194/jlr.M700206-JLR200
   Heaton NS, 2011, TRENDS MICROBIOL, V19, P368, DOI 10.1016/j.tim.2011.03.007
   Hedditch EL, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/dju149
   Hirsch-Reinshagen V, 2005, J BIOL CHEM, V280, P43243, DOI 10.1074/jbc.M508781200
   Hirsch-Reinshagen V, 2004, J BIOL CHEM, V279, P41197, DOI 10.1074/jbc.M407962200
   Hooper AJ, 2020, CURR OPIN LIPIDOL, V31, P80, DOI 10.1097/MOL.0000000000000669
   Horie T, 2010, P NATL ACAD SCI USA, V107, P17321, DOI 10.1073/pnas.1008499107
   Hu CC, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.5.33
   Hunegnaw R, 2016, ARTERIOSCL THROM VAS, V36, P1758, DOI 10.1161/ATVBAHA.116.307997
   Hwang J, 2019, ANTIMICROB AGENTS CH, V63, DOI 10.1128/AAC.01220-19
   Hysi PG, 2014, NAT GENET, V46, P1126, DOI 10.1038/ng.3087
   Ishigami M, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-24428-6
   Ishikawa M, 2008, J LIPID RES, V49, P2524, DOI 10.1194/jlr.M800238-JLR200
   Jacob D, 2014, BIOCHEM BIOPH RES CO, V444, P19, DOI 10.1016/j.bbrc.2013.12.141
   Jacobo-Albavera L, 2015, NUTR METAB, V12, DOI 10.1186/s12986-015-0040-3
   Jafri H, 2010, J AM COLL CARDIOL, V55, P2846, DOI 10.1016/j.jacc.2009.12.069
   Jennelle L, 2014, J BIOL CHEM, V289, P28870, DOI 10.1074/jbc.M114.583591
   Jensen Majken K, 2007, Atherosclerosis, V195, pe172, DOI 10.1016/j.atherosclerosis.2007.01.025
   Jiang M, 2012, GENE, V510, P147, DOI 10.1016/j.gene.2012.09.009
   Jiang Q, 2008, NEURON, V58, P681, DOI 10.1016/j.neuron.2008.04.010
   Jiang S, 2019, CURR ALZHEIMER RES, V16, P753, DOI 10.2174/1567205016666190823124724
   Jung D, 2018, HORM METAB RES, V50, P308, DOI 10.1055/a-0583-0201
   Kamboh MI, 2012, TRANSL PSYCHIAT, V2, DOI 10.1038/tp.2012.45
   Kathiresan S, 2008, NAT GENET, V40, P189, DOI 10.1038/ng.75
   Katzov H, 2004, HUM MUTAT, V23, P358, DOI 10.1002/humu.20012
   Key CCC, 2017, CELL REP, V19, P2116, DOI 10.1016/j.celrep.2017.05.032
   Khan KN, 2016, PROG RETIN EYE RES, V53, P70, DOI 10.1016/j.preteyeres.2016.04.008
   Kim DS, 2018, DIABETES-METAB RES, V34, DOI 10.1002/dmrr.2944
   Kim J, 2015, J NEUROSCI, V35, P14717, DOI 10.1523/JNEUROSCI.2053-15.2015
   Kim J, 2012, EXP NEUROL, V235, P476, DOI 10.1016/j.expneurol.2011.11.010
   Klarin D, 2018, NAT GENET, V50, P1514, DOI 10.1038/s41588-018-0222-9
   Kolanjiappan K, 2003, CLIN BIOCHEM, V36, P61, DOI 10.1016/S0009-9120(02)00421-6
   Koldamova RP, 2003, J BIOL CHEM, V278, P13244, DOI 10.1074/jbc.M300044200
   Koldamova T, 2005, J BIOL CHEM, V280, P4079, DOI 10.1074/jbc.M411420200
   Kolovou G, 2003, J CLIN PATHOL, V56, P937, DOI 10.1136/jcp.56.12.937
   Kolovou V, 2012, LIPIDS HEALTH DIS, V11, DOI 10.1186/1476-511X-11-62
   Kolsch H, 2006, INT J MOL MED, V17, P791
   Koseki M, 2009, J ATHEROSCLER THROMB, V16, P292, DOI 10.5551/jat.E599
   Kruit JK, 2011, DIABETES, V60, P3186, DOI 10.2337/db11-0081
   Kuivenhoven JA, 2003, ATHEROSCLEROSIS, V171, P311, DOI 10.1016/j.atherosclerosis.2003.08.014
   Lambert JC, 2013, NAT GENET, V45, P1452, DOI 10.1038/ng.2802
   Landry YD, 2006, J BIOL CHEM, V281, P36091, DOI 10.1074/jbc.M602247200
   Langsted A, 2008, CIRCULATION, V118, P2047, DOI 10.1161/CIRCULATIONAHA.108.804146
   Lara-Riegos JC, 2015, GENE, V565, P68, DOI 10.1016/j.gene.2015.03.065
   Larsson S, 2008, BIOCHEM BIOPH RES CO, V376, P558, DOI 10.1016/j.bbrc.2008.09.045
   Lee BH, 2013, CANCER RES, V73, P1211, DOI 10.1158/0008-5472.CAN-12-3128
   Lee HJ, 2016, SCI REP-UK, V6, DOI 10.1038/srep36746
   Lefterov I, 2009, ASN NEURO, V1, DOI 10.1042/AN20090015
   Leroyer AS, 2009, CIRCULATION, V119, P2808, DOI 10.1161/CIRCULATIONAHA.108.816710
   Li BW, 2020, CELL MOL LIFE SCI, V77, P2751, DOI 10.1007/s00018-020-03453-7
   Li CY, 2018, BIOSCIENCE REP, V38, DOI [10.1042/BSR20171632, 10.1042/bsr20171632]
   Liu MX, 2017, BBA-MOL CELL BIOL L, V1862, P1035, DOI 10.1016/j.bbalip.2017.07.001
   Lo J, 2014, OPEN FORUM INFECT DI, V1, DOI 10.1093/ofid/ofu108
   Loane DJ, 2011, J NEUROTRAUM, V28, P225, DOI 10.1089/neu.2010.1595
   Lopez-Miranda J, 2007, BRIT J NUTR, V98, P458, DOI 10.1017/S000711450774268X
   Low H, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0215620
   Low H, 2016, CELL REP, V16, P186, DOI 10.1016/j.celrep.2016.05.070
   Lu Z, 2018, MEDICINE, V97, DOI 10.1097/MD.0000000000013521
   Lupton MK, 2014, J ALZHEIMERS DIS, V38, P897, DOI 10.3233/JAD-131121
   Lutucuta S, 2001, CIRC RES, V88, P969, DOI 10.1161/hh0901.090301
   Macauley SL, 2015, J CLIN INVEST, V125, P2463, DOI 10.1172/JCI79742
   Mahley RW, 2016, ARTERIOSCL THROM VAS, V36, P1305, DOI 10.1161/ATVBAHA.116.307023
   Maitra U, 2013, ARTERIOSCL THROM VAS, V33, P24, DOI 10.1161/ATVBAHA.112.300049
   Marco A, 2014, THROMB RES, V134, P1363, DOI 10.1016/j.thromres.2014.09.019
   Marin-Palma D, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0214245
   Marques LR, 2018, FRONT PHYSIOL, V9, DOI 10.3389/fphys.2018.00526
   Martinelli LM, 2020, J CELL MOL MED, V24, P10636, DOI 10.1111/jcmm.15682
   Martinez MC, 2011, TRENDS PHARMACOL SCI, V32, P659, DOI 10.1016/j.tips.2011.06.005
   McCaffrey K, 2016, ESSAYS BIOCHEM, V60, P227, DOI 10.1042/EBC20160003
   McManus RM, 2014, NEUROBIOL AGING, V35, P109, DOI 10.1016/j.neurobiolaging.2013.07.025
   McMurray HR, 2008, NATURE, V453, P1112, DOI 10.1038/nature06973
   McNamara RP, 2018, MBIO, V9, DOI 10.1128/mBio.02344-17
   McNeish J, 2000, P NATL ACAD SCI USA, V97, P4245, DOI 10.1073/pnas.97.8.4245
   Mercan M, 2018, J PERIPHER NERV SYST, V23, P88, DOI 10.1111/jns.12265
   Merle BMJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079848
   Minuz P, 2017, CLIN SCI, V131, P2095, DOI 10.1042/CS20170195
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Mora S, 2008, CIRCULATION, V118, P993, DOI 10.1161/CIRCULATIONAHA.108.777334
   Mujawar Z, 2006, PLOS BIOL, V4, P1970, DOI 10.1371/journal.pbio.0040365
   Mujawar Z, 2010, BIOCHEMISTRY-US, V49, P8338, DOI 10.1021/bi100466q
   Mukhamedova N, 2019, PLOS PATHOG, V15, DOI 10.1371/journal.ppat.1007907
   Muratsu J, 2018, J ATHEROSCLER THROMB, V25, P1076, DOI 10.5551/jat.43257
   Nagao K, 2011, FEBS J, V278, P3190, DOI 10.1111/j.1742-4658.2011.08170.x
   Najafi-Shoushtari SH, 2010, SCIENCE, V328, P1566, DOI 10.1126/science.1189123
   Nandi S, 2009, J LIPID RES, V50, P456, DOI 10.1194/jlr.M800345-JLR200
   Neale BM, 2010, P NATL ACAD SCI USA, V107, P7395, DOI 10.1073/pnas.0912019107
   Nobili S, 2020, SEMIN CANCER BIOL, V60, P72, DOI 10.1016/j.semcancer.2019.08.006
   Nordestgaard BG, 2007, JAMA-J AM MED ASSOC, V298, P299, DOI 10.1001/jama.298.3.299
   Nordestgaard LT, 2015, ALZHEIMERS DEMENT, V11, P1430, DOI 10.1016/j.jalz.2015.04.006
   Obirikorang C, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0227779
   Okamoto Y, 2020, BIOSCI BIOTECH BIOCH, V84, P764, DOI 10.1080/09168451.2019.1700775
   Olivetta E, 2016, CURR DRUG TARGETS, V17, P46, DOI 10.2174/1389450116666151001110126
   Oram JF, 2000, CURR OPIN LIPIDOL, V11, P253, DOI 10.1097/00041433-200006000-00005
   Oram JF, 2000, BBA-MOL CELL BIOL L, V1529, P321, DOI 10.1016/S1388-1981(00)00157-8
   Oram JF, 2006, CIRC RES, V99, P1031, DOI 10.1161/01.RES.0000250171.54048.5c
   Orso E, 2000, NAT GENET, V24, P192, DOI 10.1038/72869
   Pals P, 2004, ANN NEUROL, V56, P591, DOI 10.1002/ana.20268
   Pan HL, 2019, ONCOL REP, V42, P1869, DOI 10.3892/or.2019.7279
   Pappa E, 2020, CURR MED CHEM, V27, P2964, DOI 10.2174/0929867326666190201142321
   Parolini C, 2012, LIVER INT, V32, P1363, DOI 10.1111/j.1478-3231.2012.02855.x
   PATSCH JR, 1992, ARTERIOSCLER THROMB, V12, P1336, DOI 10.1161/01.ATV.12.11.1336
   Peloso GM, 2010, J LIPID RES, V51, P3524, DOI 10.1194/jlr.P008268
   Perez-Martinez P, 2008, ATHEROSCLEROSIS SUPP, V9, P49, DOI 10.1016/j.atherosclerosissup.2008.05.005
   Piccin A, 2007, BLOOD REV, V21, P157, DOI 10.1016/j.blre.2006.09.001
   Piconi S, 2013, AIDS, V27, P381, DOI 10.1097/QAD.0b013e32835abcc9
   Pirillo A, 2015, HANDB EXP PHARMACOL, V224, P483, DOI 10.1007/978-3-319-09665-0_15
   Pou J, 2008, EXP BIOL MED, V233, P1572, DOI 10.3181/0805-RM-144
   Proust C, 2015, CIRC-CARDIOVASC GENE, V8, P628, DOI 10.1161/CIRCGENETICS.114.000979
   Puntoni M, 2012, AM J CARDIOVASC DRUG, V12, P303, DOI 10.2165/11634140-000000000-00000
   Qi LP, 2015, GENET TEST MOL BIOMA, V19, P347, DOI 10.1089/gtmb.2015.0011
   Quigley HA, 2006, BRIT J OPHTHALMOL, V90, P262, DOI 10.1136/bjo.2005.081224
   Ramirez CM, 2013, CIRC RES, V112, P1592, DOI 10.1161/CIRCRESAHA.112.300626
   Ramirez CM, 2011, ARTERIOSCL THROM VAS, V31, P2707, DOI 10.1161/ATVBAHA.111.232066
   Rayner KJ, 2010, SCIENCE, V328, P1570, DOI 10.1126/science.1189862
   Richardson TG, 2020, PLOS MED, V17, DOI 10.1371/journal.pmed.1003062
   Ridger VC, 2017, THROMB HAEMOSTASIS, V117, P1296, DOI 10.1160/TH16-12-0943
   Ripatti P, 2020, CIRC-GENOM PRECIS ME, V13, DOI 10.1161/CIRCGEN.119.002725
   Rodriguez-Rodriguez E, 2007, AM J MED GENET B, V144B, P964, DOI 10.1002/ajmg.b.30552
   Romero-Hidalgo S, 2012, J NUTR, V142, P278, DOI 10.3945/jn.111.152421
   Rose H, 2008, ATHEROSCLEROSIS, V199, P79, DOI 10.1016/j.atherosclerosis.2007.10.018
   Rudkowska I, 2013, BRIT J NUTR, V109, P953, DOI 10.1017/S0007114512002231
   Sahu U, 2013, INFECT IMMUN, V81, P1287, DOI 10.1128/IAI.01175-12
   Saito Mieko, 2002, Nihon Naika Gakkai Zasshi, V91, P2762
   Sanchez V, 2010, VIROLOGY, V404, P71, DOI 10.1016/j.virol.2010.04.026
   Santilli F, 2016, THROMB HAEMOSTASIS, V116, P220, DOI 10.1160/TH16-03-0176
   Sarlak Z, 2019, IRAN J BASIC MED SCI, V22, P399, DOI 10.22038/ijbms.2018.32911.7860
   Saulle I, 2020, AIDS, V34, P1593, DOI 10.1097/QAD.0000000000002591
   Saxena R, 2007, SCIENCE, V316, P1331, DOI 10.1126/science.1142358
   Schaefer EJ, 2001, ATHEROSCLEROSIS, V159, P231, DOI 10.1016/S0021-9150(01)00688-8
   Schimanski S, 2010, HORM METAB RES, V42, P102, DOI 10.1055/s-0029-1241859
   Schott JM, 2016, ALZHEIMERS DEMENT, V12, P862, DOI 10.1016/j.jalz.2016.01.010
   Schou J, 2012, DIABETES CARE, V35, P2600, DOI 10.2337/dc12-0082
   Sears NC, 2019, EXP EYE RES, V186, DOI 10.1016/j.exer.2019.107702
   Selitsky SR, 2015, MBIO, V6, DOI 10.1128/mBio.01500-15
   Sene A, 2015, TRENDS MOL MED, V21, P43, DOI 10.1016/j.molmed.2014.10.005
   Sene A, 2014, TRENDS ENDOCRIN MET, V25, P107, DOI 10.1016/j.tem.2013.10.007
   SERFATYLACROSNIERE C, 1994, ATHEROSCLEROSIS, V107, P85, DOI 10.1016/0021-9150(94)90144-9
   Shen X, 2020, MOL MED, V26, DOI 10.1186/s10020-020-00213-y
   Shiga Y, 2018, HUM MOL GENET, V27, P1486, DOI 10.1093/hmg/ddy053
   Shinohara M, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20061488
   Shirasaki T, 2013, J VIROL, V87, P5270, DOI 10.1128/JVI.03022-12
   Siegel MO, 2015, ATHEROSCLEROSIS, V243, P19, DOI 10.1016/j.atherosclerosis.2015.08.036
   Simons K, 2000, SCIENCE, V290, P1721, DOI 10.1126/science.290.5497.1721
   Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052
   Sladek R, 2007, NATURE, V445, P881, DOI 10.1038/nature05616
   Slatter TL, 2008, CLIN GENET, V73, P179, DOI 10.1111/j.1399-0004.2007.00940.x
   Smith B, 2012, CELL REP, V2, P580, DOI 10.1016/j.celrep.2012.08.011
   Song C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060454
   Sorci-Thomas MG, 2012, J LIPID RES, V53, P1890, DOI 10.1194/jlr.M026674
   Soto-Acosta R, 2013, VIROLOGY, V442, P132, DOI 10.1016/j.virol.2013.04.003
   Souverein OW, 2005, EUR J HUM GENET, V13, P445, DOI 10.1038/sj.ejhg.5201362
   Spaide RF, 2018, SURV OPHTHALMOL, V63, P782, DOI 10.1016/j.survophthal.2018.05.005
   Steinthorsdottir V, 2007, NAT GENET, V39, P770, DOI 10.1038/ng2043
   Storti F, 2019, ELIFE, V8, DOI 10.7554/eLife.45100
   Suidan GL, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20092161
   Sun YM, 2012, AM J GERIAT PSYCHIAT, V20, P603, DOI 10.1097/JGP.0b013e3182423b6a
   Sundar PD, 2007, NEUROBIOL AGING, V28, P856, DOI 10.1016/j.neurobiolaging.2006.04.005
   Sviridov D, 2020, AIDS, V34, P1, DOI 10.1097/QAD.0000000000002385
   Sviridov D, 2014, CURR OPIN LIPIDOL, V25, P333, DOI 10.1097/MOL.0000000000000106
   Tabas I, 2002, J CLIN INVEST, V110, P905, DOI 10.1172/JCI200216452
   Tan JHH, 2003, HUM GENET, V113, P106, DOI 10.1007/s00439-003-0943-3
   Tanaka Akira, 2004, J Atheroscler Thromb, V11, P322
   Tang SD, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-018-38014-3
   Tao F, 2018, CLIN APPL THROMB-HEM, V24, P771, DOI 10.1177/1076029617725601
   Teslovich TM, 2010, NATURE, V466, P707, DOI 10.1038/nature09270
   Thangavel S, 2018, ANTIOXID REDOX SIGN, V28, P324, DOI 10.1089/ars.2016.6830
   Timmins JM, 2005, J CLIN INVEST, V115, P1333, DOI 10.1172/JCI200523915
   Trees MO, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-42803-9
   Tregouet DA, 2004, ARTERIOSCL THROM VAS, V24, P775, DOI 10.1161/01.ATV.0000121573.29550.1a
   Vallim TQD, 2013, CIRC RES, V112, P1602, DOI 10.1161/CIRCRESAHA.112.300648
   van 't Wout AB, 2005, J VIROL, V79, P10053, DOI 10.1128/JVI.79.15.10053-10058.2005
   Vargas T, 2015, ONCOTARGET, V6, P7348, DOI 10.18632/oncotarget.3130
   Vedhachalam C, 2007, ARTERIOSCL THROM VAS, V27, P1603, DOI 10.1161/ATVBAHA.107.145789
   Vega-Badillo J, 2016, LIVER INT, V36, P1383, DOI 10.1111/liv.13109
   Vergeer M, 2010, DIABETES CARE, V33, P869, DOI 10.2337/dc09-1562
   Viaud M, 2020, CELL REP, V30, P3397, DOI 10.1016/j.celrep.2020.02.056
   Vikman J, 2009, FASEB J, V23, P58, DOI 10.1096/fj.08-105734
   Villarreal-Molina MT, 2008, DIABETES, V57, P509, DOI 10.2337/db07-0484
   Villarreal-Molina MT, 2007, DIABETES, V56, P1881, DOI 10.2337/db06-0905
   Villarreal-Molina T, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049285
   Vion AC, 2013, CIRC RES, V112, P1323, DOI 10.1161/CIRCRESAHA.112.300818
   Vitali C, 2014, CARDIOVASC RES, V103, P405, DOI 10.1093/cvr/cvu148
   Voight BF, 2012, LANCET, V380, P572, DOI 10.1016/S0140-6736(12)60312-2
   Wager CML, 2019, PLOS PATHOG, V15, DOI 10.1371/journal.ppat.1007585
   Wah ST, 2019, MOL GENET GENOM MED, V7, DOI 10.1002/mgg3.529
   Wahrle SE, 2005, J BIOL CHEM, V280, P43236, DOI 10.1074/jbc.M508780200
   Wahrle SE, 2008, J CLIN INVEST, V118, P671, DOI 10.1172/JCI33622
   Wang B, 2018, NAT REV ENDOCRINOL, V14, P452, DOI 10.1038/s41574-018-0037-x
   Wang XF, 2013, MOL BIOL REP, V40, P779, DOI 10.1007/s11033-012-2115-9
   Wang XH, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19113368
   Wang YF, 2016, GRAEF ARCH CLIN EXP, V254, P323, DOI 10.1007/s00417-015-3211-z
   Wavrant-De Vrieze F, 2007, NEUROSCI LETT, V416, P180, DOI 10.1016/j.neulet.2007.02.010
   Weissglas-Volkov D, 2013, J MED GENET, V50, P298, DOI 10.1136/jmedgenet-2012-101461
   Wildsmith KR, 2013, ALZHEIMERS RES THER, V5, DOI 10.1186/alzrt187
   Wilflingseder D, 2007, FRONT BIOSCI-LANDMRK, V12, P2124, DOI 10.2741/2216
   Willer CJ, 2013, NAT GENET, V45, P1274, DOI 10.1038/ng.2797
   Wiser O, 1999, P NATL ACAD SCI USA, V96, P248, DOI 10.1073/pnas.96.1.248
   Xia FZ, 2004, J BIOL CHEM, V279, P24685, DOI 10.1074/jbc.M314314200
   Xiao ZJ, 2012, LIPIDS HEALTH DIS, V11, DOI 10.1186/1476-511X-11-163
   Xu GB, 2019, NEUROTHERAPEUTICS, V16, P505, DOI 10.1007/s13311-018-00704-1
   Xu MQ, 2020, BMC OPHTHALMOL, V20, DOI 10.1186/s12886-020-01661-0
   Ya LG, 2017, MED SCI MONITOR, V23, P4591, DOI 10.12659/MSM.903636
   Yang JL, 2017, BRAIN BEHAV IMMUN, V65, P262, DOI 10.1016/j.bbi.2017.05.012
   Yang Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069824
   Yao JQ, 2012, J EXP MED, V209, P2501, DOI 10.1084/jem.20121239
   YEAGLE PL, 1991, BIOCHIMIE, V73, P1303, DOI 10.1016/0300-9084(91)90093-G
   Yu Y, 2011, INVEST OPHTH VIS SCI, V52, P4663, DOI 10.1167/iovs.10-7070
   Zamanian-Daryoush M, 2017, ONCOTARGET, V8, P71965, DOI 10.18632/oncotarget.18666
   Zhang J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075786
   Zhang M, 2014, ATHEROSCLEROSIS, V234, P54, DOI 10.1016/j.atherosclerosis.2014.02.008
   Zhang Z, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027305
   Zhu ZZ, 2019, HUM GENET, V138, P271, DOI 10.1007/s00439-019-01988-9
   Zukerman R, 2021, GENES-BASEL, V12, DOI 10.3390/genes12010055
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P303, DOI 10.1016/j.ophtha.2009.07.014
NR 318
TC 31
Z9 31
U1 7
U2 26
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1422-0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD FEB
PY 2021
VL 22
IS 4
AR 1593
DI 10.3390/ijms22041593
PG 30
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA QP4UH
UT WOS:000623831500001
PM 33562440
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Bekmez, S
   Cakmak, H
   Kocaturk, T
   Cantas, F
   Dundar, S
AF Bekmez, Sinan
   Cakmak, Harun
   Kocaturk, Tolga
   Cantas, Fulden
   Dundar, Sema
TI Biomechanical properties of the cornea following intravitreal
   ranibizumab injection
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Intravitreal injection; Ranibizumab; Ocular Response Analyzer;
   Intraocular pressure; Corneal biomechanical properties
ID INTRAOCULAR-PRESSURE ELEVATION; GROWTH-FACTOR AGENTS; BEVACIZUMAB
   INJECTION; RISK-FACTOR; HYSTERESIS; SAFETY
AB Objective To evaluate intraocular pressure (IOP) and corneal biomechanical properties changes after intravitreal ranibizumab injection (IVRI).
   Methods One hundred twenty eyes of 120 patients who underwent IVRI between January and March 2018 in Adnan Menderes University Ophthalmology Clinic were included in study. Corneal hysteresis (CH), corneal resistance factor (CRF), Goldmann-correlated intraocular pressure (IOPg), and corneal-compensated intraocular pressure (IOPcc) were measured by Ocular Response Analyzer (ORA) by the same specialist preoperatively (preop), postoperative 1st (postop-1st), postoperative 3rd (postop-3rd), and postoperative 24th hours (postop-24th) after single-dose IVRI.
   Results Among the 120 wet age-related macular degeneration subjects, 58 (48.3%) were female and 62 (51.7%) were male. The mean age was 64.8 +/- 10.4 years. Postop-1st hour IOP cc and IOPg measurements were statistically different from all other measurements (p < 0.001). Postop-1st hour CH measurements were statistically different from preop and postop-3rd (p = 0.022 and p = 0.008, respectively).
   Conclusion After intravitreal injection, IOP pressures significantly increased. But, CH and CRF values were significantly decreased. All these changes were temporary.
C1 [Bekmez, Sinan] Univ Hlth Sci, Izmir Dr Behcet Uz Childrens Dis & Surg Training, Dept Ophthalmol, Izmir, Turkey.
   [Cakmak, Harun; Kocaturk, Tolga; Dundar, Sema] Adnan Menderes Univ, Fac Med, Dept Ophthalmol, Aydin, Turkey.
   [Cantas, Fulden] Adnan Menderes Univ, Fac Med, Dept Biostat, Aydin, Turkey.
C3 University of Health Sciences Turkey; Adnan Menderes University; Adnan
   Menderes University
RP Bekmez, S (通讯作者)，Univ Hlth Sci, Izmir Dr Behcet Uz Childrens Dis & Surg Training, Dept Ophthalmol, Izmir, Turkey.
EM sinanbekmez@gmail.com
RI kocaturk, tolga/AAB-5890-2021
OI kocaturk, tolga/0000-0001-5187-227X
CR Almubrad TM, 2007, CLIN OPHTHALMOL, V1, P305
   Ambati J, 2013, NAT REV IMMUNOL, V13, P438, DOI 10.1038/nri3459
   Arslan GD, 2019, CUTAN OCUL TOXICOL, V38, P344, DOI 10.1080/15569527.2019.1616749
   Bakri SJ, 2009, EYE, V23, P181, DOI 10.1038/sj.eye.6702938
   Bakri SJ, 2007, OPHTHALMOLOGY, V114, P2179, DOI 10.1016/j.ophtha.2007.09.012
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Congdon NG, 2006, AM J OPHTHALMOL, V141, P868, DOI 10.1016/j.ajo.2005.12.007
   ElMallah MK, 2008, CURR OPIN OPHTHALMOL, V19, P122, DOI 10.1097/ICU.0b013e3282f391ae
   Fontes BM, 2011, ARQ BRAS OFTALMOL, V74, P13, DOI 10.1590/S0004-27492011000100003
   Gismondi M, 2009, J GLAUCOMA, V18, P658, DOI 10.1097/IJG.0b013e31819c4893
   Hoang QV, 2012, OPHTHALMOLOGY, V119, P321, DOI 10.1016/j.ophtha.2011.08.011
   Hollands H, 2007, CAN J OPHTHALMOL, V42, P807, DOI 10.3129/i07-172
   Kahook MY, 2009, OPHTHAL SURG LAS IM, V40, P293, DOI 10.3928/15428877-20090430-12
   Kamiya K, 2008, GRAEF ARCH CLIN EXP, V246, P1491, DOI 10.1007/s00417-008-0864-x
   Kirgiz A, 2019, EYE CONTACT LENS, V45, P83, DOI 10.1097/ICL.0000000000000541
   Ladas ID, 2009, RETINA-J RET VIT DIS, V29, P313, DOI 10.1097/IAE.0b013e31819a5f98
   Luce DA, 2005, J CATARACT REFR SURG, V31, P156, DOI 10.1016/j.jcrs.2004.10.044
   McCannel CA, 2011, RETINA-J RET VIT DIS, V31, P654, DOI 10.1097/IAE.0b013e31820a67e4
   Medeiros FA, 2013, OPHTHALMOLOGY, V120, P1533, DOI 10.1016/j.ophtha.2013.01.032
   Mitchell P, 2010, BRIT J OPHTHALMOL, V94, P2, DOI 10.1136/bjo.2009.159160
   Park J, 2018, BMC OPHTHALMOL, V18, DOI 10.1186/s12886-018-0682-9
   Peden MC, 2015, OPHTHALMOLOGY, V122, P803, DOI 10.1016/j.ophtha.2014.11.018
   Pepose JS, 2007, AM J OPHTHALMOL, V143, P39, DOI 10.1016/j.ajo.2006.09.036
   Qin VL, 2018, RETINA-J RET VIT DIS, V38, P1500, DOI 10.1097/IAE.0000000000001753
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Shoeibi N, 2019, J OPHTHAL VIS RES, V14, P151, DOI 10.4103/jovr.jovr_257_17
   Sniegowski M, 2010, OPEN OPHTHALMOL J, V4, P28, DOI 10.2174/1874364101004010028
   SooHoo JR, 2014, CURR OPIN OPHTHALMOL, V25, P127, DOI 10.1097/ICU.0000000000000036
   Sternfeld A, 2020, INT J OPHTHALMOL-CHI, V13, P79, DOI 10.18240/ijo.2020.01.12
   Susanna CN, 2018, AM J OPHTHALMOL, V187, P148, DOI 10.1016/j.ajo.2017.12.018
   Tolentino M, 2011, SURV OPHTHALMOL, V56, P95, DOI 10.1016/j.survophthal.2010.08.006
   Wasielica-Poslednik J, 2010, GRAEF ARCH CLIN EXP, V248, P1617, DOI 10.1007/s00417-010-1471-1
   WHITACRE MM, 1993, SURV OPHTHALMOL, V38, P1, DOI 10.1016/0039-6257(93)90053-A
   Zhang CW, 2016, AM J OPHTHALMOL, V166, P29, DOI 10.1016/j.ajo.2016.02.034
NR 34
TC 0
Z9 0
U1 1
U2 3
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD MAR
PY 2021
VL 259
IS 3
BP 691
EP 696
DI 10.1007/s00417-020-05001-2
EA NOV 2020
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA QM0ZA
UT WOS:000587926900001
PM 33165643
DA 2022-11-30
ER

PT J
AU Marie, M
   Gondouin, P
   Pagan, D
   Barrau, C
   Villette, T
   Sahel, J
   Picaud, S
AF Marie, Melanie
   Gondouin, Pauline
   Pagan, Delphine
   Barrau, Coralie
   Villette, Thierry
   Sahel, Jose
   Picaud, Serge
TI Blue-violet light decreases VEGFa production in an in vitro model of AMD
SO PLOS ONE
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; PIGMENT EPITHELIAL-CELLS; AGE-RELATED
   MACULOPATHY; MACULAR DEGENERATION; SUNLIGHT EXPOSURE; OXIDATIVE STRESS;
   INTRAOCULAR-LENS; RPE LIPOFUSCIN; INDUCED DAMAGE; VISIBLE-LIGHT
AB Blue light is an identified risk factor for age-related macular degeneration (AMD). The production of vascular endothelial growth factor (VEGF), leading to neovascularization, is a major complication of the wet form of this disease. We investigated how blue light affects VEGF expression and secretion using A2E-loaded retinal pigment epithelium (RPE) cells, a cell model of AMD. Incubation of RPE cells with A2E resulted in a significant increase in VEGF mRNA and, intracellular and secreted VEGF protein levels, but not mRNA levels of VEGFR1 or VEGFR2. Blue light exposure of A2E-loaded RPE cells resulted in a decrease in VEGF mRNA and protein levels, but an increase in VEGFR1 levels. The toxicity of 440 nm light on A2E-loaded RPE cells was enhanced by VEGF supplementation. Our results suggest that age-related A2E accumulation may result in VEGF synthesis and release. This synthesis of VEGF, which enhances blue light toxicity for the RPE cells, is itself suppressed by blue light. Anti-VEGF therapy may therefore improve RPE survival in AMD.
C1 [Marie, Melanie; Gondouin, Pauline; Pagan, Delphine; Sahel, Jose; Picaud, Serge] Sorbonne Univ, INSERM, CNRS, Inst Vis, Paris, France.
   [Barrau, Coralie; Villette, Thierry] Essilor Int R&D, Charenton Le Pont, France.
   [Sahel, Jose] Univ Pittsburgh, Sch Med, Dept Ophthalmol, Pittsburgh, PA 15261 USA.
C3 Centre National de la Recherche Scientifique (CNRS); Institut National
   de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research
   Universities; Sorbonne Universite; Universite Paris Cite; Essilor
   International; Pennsylvania Commonwealth System of Higher Education
   (PCSHE); University of Pittsburgh
RP Picaud, S (通讯作者)，Sorbonne Univ, INSERM, CNRS, Inst Vis, Paris, France.
EM serge.picaud@inserm.fr
RI ; Picaud, Serge/H-4012-2014
OI MARIE, Melanie/0000-0003-3516-3582; Picaud, Serge/0000-0002-0548-5145;
   Villette, Thierry/0000-0003-3354-8155
FU Essilor International; INSERM, Sorbonne Universite; LabEx LIFESENSES,
   the first Investissements d'Avenir program - French state funds
   [ANR-10-LABX-65, ANR-11-IDEX-0004-02]; IHU FOReSIGHT - French state
   funds [ANR-18-IAHU-0001]
FX This work was financially supported by research grants from the
   following: Essilor International, INSERM, Sorbonne Universite, the LabEx
   LIFESENSES (ANR-10-LABX-65), as part of the first Investissements
   d'Avenir program (ANR-11-IDEX-0004-02) and IHU FOReSIGHT
   (ANR-18-IAHU-0001), both supported by French state funds managed by the
   Agence Nationale de la Recherche within the Investissements d'Avenir
   program. The funders had no role in study design, data collection and
   analysis, decision to publish, or preparation of the manuscript. CB and
   TV received support in the form of a salary from Essilor. The specific
   roles of these authors are articulated in the `author contributions'
   section.
CR Akiyama H, 2005, AM J PHYSIOL-CELL PH, V288, pC913, DOI 10.1152/ajpcell.00116.2004
   Arnault E, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071398
   Atienzar-Aroca S, 2016, J CELL MOL MED, V20, P1457, DOI 10.1111/jcmm.12834
   Augood CA, 2006, ARCH OPHTHALMOL-CHIC, V124, P529, DOI 10.1001/archopht.124.4.529
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Boulton M, 2001, J PHOTOCH PHOTOBIO B, V64, P144, DOI 10.1016/S1011-1344(01)00227-5
   Butt AL, 2011, OPHTHALMOLOGY, V118, P1380, DOI 10.1016/j.ophtha.2010.11.007
   Byeon SH, 2010, INVEST OPHTH VIS SCI, V51, P1190, DOI 10.1167/iovs.09-4144
   Cachafeiro M, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.303
   Cruickshanks KJ, 2001, ARCH OPHTHALMOL-CHIC, V119, P246
   Davies S, 2001, FREE RADICAL BIO MED, V31, P256, DOI 10.1016/S0891-5849(01)00582-2
   Endo A, 2003, J RECEPT SIG TRANSD, V23, P239, DOI 10.1081/RRS-120025567
   Ferrari G, 2006, P NATL ACAD SCI USA, V103, P17260, DOI 10.1073/pnas.0605556103
   Ferrari G, 2009, J CELL PHYSIOL, V219, P449, DOI 10.1002/jcp.21706
   Fletcher AE, 2008, ARCH OPHTHALMOL-CHIC, V126, P1396, DOI 10.1001/archopht.126.10.1396
   Froger N, 2019, SCI REPORTS
   Holmes DIR, 2008, CELL SIGNAL, V20, P569, DOI 10.1016/j.cellsig.2007.11.009
   Hui S, 2009, PHOTOCHEM PHOTOBIOL, V85, P966, DOI 10.1111/j.1751-1097.2008.00506.x
   Iriyama A, 2008, J BIOL CHEM, V283, P11947, DOI 10.1074/jbc.M708989200
   Iriyama A, 2009, J CELL PHYSIOL, V220, P469, DOI 10.1002/jcp.21792
   Jia YP, 2017, MOLECULES, V22, DOI 10.3390/molecules22040610
   Junghans A, 2001, ARCH BIOCHEM BIOPHYS, V391, P160, DOI 10.1006/abbi.2001.2411
   Kernt M, 2010, BRIT J OPHTHALMOL, V94, P1533, DOI 10.1136/bjo.2010.182162
   Kernt M, 2009, J CATARACT REFR SURG, V35, P354, DOI 10.1016/j.jcrs.2008.10.052
   Kijlstra A, 2012, PROG RETIN EYE RES, V31, P303, DOI 10.1016/j.preteyeres.2012.03.002
   Kim I, 1999, INVEST OPHTH VIS SCI, V40, P2115
   Lambert NG, 2016, PROG RETIN EYE RES, V54, P64, DOI 10.1016/j.preteyeres.2016.04.003
   Lima Veronica Castro, 2016, Int J Retina Vitreous, V2, P19
   Liu YX, 2012, BRIT J NUTR, V108, P16, DOI 10.1017/S000711451100523X
   Loane E, 2008, BRIT J OPHTHALMOL, V92, P1163, DOI 10.1136/bjo.2007.135566
   Loskutova E, 2013, NUTRIENTS, V5, P1962, DOI 10.3390/nu5061962
   Mainster MA, 2010, SURV OPHTHALMOL, V55, P272, DOI 10.1016/j.survophthal.2009.07.006
   Marazita MC, 2016, REDOX BIOL, V7, P78, DOI 10.1016/j.redox.2015.11.011
   Marie M, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0331-5
   Marie M, 2015, INVEST OPHTH VIS SCI, V56
   Miller JW, 2016, INVEST OPHTH VIS SCI, V57, P6911, DOI 10.1167/iovs.16-21201
   Miller JW, 2016, TRANSL VIS SCI TECHN, V5, DOI 10.1167/tvst.5.2.9
   Murphy MP, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2003386
   Nilsson SEG, 2003, DOC OPHTHALMOL, V106, P13, DOI 10.1023/A:1022419606629
   Penn JS, 2008, PROG RETIN EYE RES, V27, P331, DOI 10.1016/j.preteyeres.2008.05.001
   Rahimi N, 2006, FRONT BIOSCI-LANDMRK, V11, P818
   Rahimi N, 2006, EXP EYE RES, V83, P1005, DOI 10.1016/j.exer.2006.03.019
   Rozanowska M, 2004, INVEST OPHTH VIS SCI, V45, P1052, DOI 10.1167/iovs.03-0277
   Saint-Geniez M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003554
   Schick T, 2016, RETINA-J RET VIT DIS, V36, P787, DOI 10.1097/IAE.0000000000000756
   Schutt F, 2000, INVEST OPHTH VIS SCI, V41, P2303
   Shih SC, 2003, J CLIN INVEST, V112, P50, DOI 10.1172/JCI200317808
   SNODDERLY DM, 1995, AM J CLIN NUTR, V62, P1448
   Sparrow JR, 2005, EXP EYE RES, V80, P595, DOI 10.1016/j.exer.2005.01.007
   Sparrow JR, 2003, ADV EXP MED BIOL, V533, P205
   Sparrow JR, 2001, INVEST OPHTH VIS SCI, V42, P1356
   Sparrow JR, 2000, INVEST OPHTH VIS SCI, V41, P1981
   Stuttfeld E, 2009, IUBMB LIFE, V61, P915, DOI 10.1002/iub.234
   Sui GY, 2013, BRIT J OPHTHALMOL, V97, P389, DOI 10.1136/bjophthalmol-2012-302281
   Suter M, 2000, J BIOL CHEM, V275, P39625, DOI 10.1074/jbc.M007049200
   TAYLOR HR, 1992, ARCH OPHTHALMOL-CHIC, V110, P99, DOI 10.1001/archopht.1992.01080130101035
   van der Burght Barbro W, 2013, Acta Ophthalmol, V91, pe537, DOI 10.1111/aos.12146
   Westlund B, 2009, APOPTOSIS, V14, P31, DOI 10.1007/s10495-008-0285-7
   Whittles CE, 2002, MICROCIRCULATION, V9, P513, DOI 10.1038/sj.mn.7800164
   Wihlmark U, 1997, FREE RADICAL BIO MED, V22, P1229, DOI 10.1016/S0891-5849(96)00555-2
   Yanagi Y, 2006, J CATARACT REFR SURG, V32, P1540, DOI 10.1016/j.jcrs.2006.04.012
   YOUNG RW, 1992, J NATL MED ASSOC, V84, P353
   Zhang J, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.330
   Zhou JL, 2005, EXP EYE RES, V80, P567, DOI 10.1016/j.exer.2004.11.009
NR 64
TC 10
Z9 11
U1 1
U2 7
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD OCT 23
PY 2019
VL 14
IS 10
AR e0223839
DI 10.1371/journal.pone.0223839
PG 14
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA LM9XB
UT WOS:000532599700038
PM 31644596
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Sahle, FF
   Kim, S
   Niloy, KK
   Tahia, F
   Fili, CV
   Cooper, E
   Hamilton, DJ
   Lowe, TL
AF Sahle, Fitsum Feleke
   Kim, Sangyoon
   Niloy, Kumar Kulldeep
   Tahia, Faiza
   Fili, Cameron, V
   Cooper, Emily
   Hamilton, David J.
   Lowe, Tao L.
TI Nanotechnology in regenerative ophthalmology
SO ADVANCED DRUG DELIVERY REVIEWS
LA English
DT Review
DE Ocular regeneration; Nanoscaffolds; Electrospun nanofibers;
   Self-assembled peptides; Nanotopography; Stem cells; Cell reprogramming;
   Immunomodulators
ID RETINAL-PIGMENT EPITHELIUM; PLURIPOTENT STEM-CELLS; CORNEAL
   ENDOTHELIAL-CELLS; NERVE GROWTH-FACTOR; GENE DELIVERY;
   DIABETIC-RETINOPATHY; BRUCHS MEMBRANE; NANOFIBROUS SCAFFOLDS; TARGETED
   DELIVERY; NEURAL APOPTOSIS
AB In recent years, regenerative medicine is gaining momentum and is giving hopes for restoring function of diseased, damaged, and aged tissues and organs and nanotechnology is serving as a catalyst. In the ophthalmology field, various types of allogenic and autologous stem cells have been investigated to treat some ocular diseases due to age-related macular degeneration, glaucoma, retinitis pigmentosa, diabetic retinopathy, and corneal and lens traumas. Nanomaterials have been utilized directly as nanoscaffolds for these stem cells to promote their adhesion, proliferation and differentiation or indirectly as vectors for various genes, tissue growth factors, cytokines and immunosuppressants to facilitate cell reprogramming or ocular tissue regeneration. In this review, we reviewed various nanomaterials used for retina, cornea, and lens regenerations, and discussed the current status and future perspectives of nanotechnology in tracking cells in the eye and personalized regenerative ophthalmology. The purpose of this review is to provide comprehensive and timely insights on the emerging field of nanotechnology for ocular tissue engineering and regeneration. (C) 2019 Elsevier B.V. All rights reserved.
C1 [Sahle, Fitsum Feleke; Kim, Sangyoon; Niloy, Kumar Kulldeep; Tahia, Faiza; Cooper, Emily; Lowe, Tao L.] Univ Tennessee, Hlth Sci Ctr, Dept Pharmaceut Sci, Memphis, TN 38163 USA.
   [Fili, Cameron, V; Hamilton, David J.] Univ Tennessee, Hlth Sci Ctr, Dept Comparat Med, Memphis, TN 38163 USA.
C3 University of Tennessee System; University of Tennessee Health Science
   Center; University of Tennessee System; University of Tennessee Health
   Science Center
RP Lowe, TL (通讯作者)，Univ Tennessee, Hlth Sci Ctr, Dept Pharmaceut Sci, Memphis, TN 38163 USA.
EM tlowe4@uthsc.edu
RI Niloy, Kumar Kulldeep/ABA-1938-2021; Sahle, Fitsum/AAI-4642-2020
OI Sahle, Fitsum/0000-0003-3287-7475; Niloy, Kumar
   Kulldeep/0000-0001-9307-7899
FU NIH [R01EY023853]; NATIONAL EYE INSTITUTE [R01EY023853] Funding Source:
   NIH RePORTER
FX This work was financially supported by NIH R01EY023853.
CR Accomasso L, 2016, STEM CELLS INT, V2016, DOI 10.1155/2016/7920358
   Akhshabi S, 2018, INT J NANOMED, V13, P4405, DOI 10.2147/IJN.S165739
   Alaminos M, 2006, INVEST OPHTH VIS SCI, V47, P3311, DOI 10.1167/iovs.05-1647
   Anitua E, 2016, CURR EYE RES, V41, P875, DOI 10.3109/02713683.2015.1104362
   Antonetti DA, 1998, DIABETES, V47, P1953, DOI 10.2337/diabetes.47.12.1953
   Antonetti DA, 2006, DIABETES, V55, P2401, DOI 10.2337/db05-1635
   Arabpour Z, 2019, J BIOMED MATER RES A, V107, P2340, DOI 10.1002/jbm.a.36742
   Aslan B, 2018, J BIOMED MATER RES B, V106, P2157, DOI 10.1002/jbm.b.34022
   Baradaran-Rafii A, 2016, CURR EYE RES, V41, P326, DOI 10.3109/02713683.2015.1019004
   Barber AJ, 2000, INVEST OPHTH VIS SCI, V41, P3561
   Barber AJ, 2003, INVEST OPHTH VIS SCI, V44, P5410, DOI 10.1167/iovs.03-0244
   Barber AJ, 1998, J CLIN INVEST, V102, P783, DOI 10.1172/JCI2425
   Barber AJ, 2011, INVEST OPHTH VIS SCI, V52, P1156, DOI 10.1167/iovs.10-6293
   Bearse MA, 2006, PROG RETIN EYE RES, V25, P425, DOI 10.1016/j.preteyeres.2006.07.001
   Bi YL, 2013, MOL MED REP, V7, P1767, DOI 10.3892/mmr.2013.1418
   Borah R, 2018, ACS BIOMATER SCI ENG, V4, P3327, DOI 10.1021/acsbiomaterials.8b00624
   Bulte JWM, 2001, NAT BIOTECHNOL, V19, P1141, DOI 10.1038/nbt1201-1141
   Cai YN, 2015, DIAGN PATHOL, V10, DOI 10.1186/s13000-015-0263-7
   Calkins DJ, 2017, EXP EYE RES, V157, P28, DOI 10.1016/j.exer.2017.01.007
   Cao BR, 2013, MICROSC RES TECHNIQ, V76, P936, DOI 10.1002/jemt.22251
   CAPUTO S, 1990, DIABETES CARE, V13, P412, DOI 10.2337/diacare.13.4.412
   Cardarelli F, 2016, SCI REP-UK, V6, DOI 10.1038/srep25879
   Chang JH, 2017, J MATER CHEM B, V5, P3012, DOI 10.1039/c7tb00351j
   Chang YC, 2017, ACS APPL MATER INTER, V9, P37623, DOI 10.1021/acsami.7b12567
   Chen J, 2015, INT J NANOMED, V10, P3337, DOI 10.2147/IJN.S77706
   Chieruzzi M, 2016, NANOMATERIALS-BASEL, V6, DOI 10.3390/nano6070134
   Chou SF, 2017, MAT SCI ENG C-MATER, V71, P1145, DOI 10.1016/j.msec.2016.11.105
   Chung L, 2017, ADV DRUG DELIVER REV, V114, P184, DOI 10.1016/j.addr.2017.07.006
   Connor E.E., 2005, GOLD NANOPARTICLES A
   Cruz-Maya I, 2019, J BIOMED MATER RES A, V107, P1803, DOI 10.1002/jbm.a.36699
   da Silva ER, 2015, BIOMACROMOLECULES, V16, P3180, DOI 10.1021/acs.biomac.5b00820
   Daftarian Narsis, 2010, J Ophthalmic Vis Res, V5, P250
   Daliri K, 2017, INT J STEM CELLS, V10, P119, DOI 10.15283/ijsc17029
   Delgado D, 2011, EUR J PHARM BIOPHARM, V79, P495, DOI 10.1016/j.ejpb.2011.06.005
   Dove A, 2002, NAT BIOTECHNOL, V20, P339, DOI 10.1038/nbt0402-339
   Eguchi G, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1389
   Ellis-Behnke RG, 2006, P NATL ACAD SCI USA, V103, P5054, DOI 10.1073/pnas.0600559103
   Ellis-Behnke R, 2011, ACTA OPHTHALMOL, V89, pE108, DOI 10.1111/j.1755-3768.2010.01982.x
   Fagerholm P, 2014, BIOMATERIALS, V35, P2420, DOI 10.1016/j.biomaterials.2013.11.079
   Fagerholm P, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3001022
   Fischak C, 2017, J OPHTHALMOL, V2017, DOI 10.1155/2017/5192924
   Gandra N, 2013, ANGEW CHEM INT EDIT, V52, P11278, DOI 10.1002/anie.201301113
   Gao HS, 2012, REGEN MED, V7, P865, DOI [10.2217/RME.12.97, 10.2217/rme.12.97]
   Gardner TW, 2002, SURV OPHTHALMOL, V47, pS253, DOI 10.1016/S0039-6257(02)00387-9
   Gastinger MJ, 2008, INVEST OPHTH VIS SCI, V49, P2635, DOI 10.1167/iovs.07-0683
   Gastinger MJ, 2001, INVEST OPHTH VIS SCI, V42, P2679
   Ghezzi CE, 2015, TISSUE ENG PART B-RE, V21, P278, DOI [10.1089/ten.TEB.2014.0397, 10.1089/ten.teb.2014.0397]
   Giordano GG, 1997, J BIOMED MATER RES, V34, P87, DOI 10.1002/(SICI)1097-4636(199701)34:1<87::AID-JBM12>3.0.CO;2-M
   Gong NQ, 2007, INVEST OPHTH VIS SCI, V48, P1043, DOI 10.1167/iovs.06-1084
   Gonzalez G, 2018, WILEY INTERDISCIP RE, V7
   Gordon K, 2019, NAT REV DRUG DISCOV, V18, P415, DOI 10.1038/d41573-018-00016-1
   Gouveia RM, 2017, ADV BIOSYST, V1, DOI 10.1002/adbi.201700135
   Gouveia RM, 2017, BIOMATERIALS, V121, P205, DOI 10.1016/j.biomaterials.2016.12.023
   Gouveia RM, 2015, TISSUE ENG PT A, V21, P1772, DOI [10.1089/ten.tea.2014.0671, 10.1089/ten.TEA.2014.0671]
   Gouveia RM, 2013, J MATER CHEM B, V1, P6157, DOI 10.1039/c3tb21031f
   Gregory K.G., 1995, AGE RELATED MACULAR
   Griffith M, 2012, OCUL SURF, V10, P170, DOI 10.1016/j.jtos.2012.04.004
   HAMMES HP, 1995, MOL MED, V1, P527, DOI 10.1007/BF03401589
   He XM, 2013, REGEN MED, V8, P425, DOI 10.2217/rme.13.29
   Hernandez C, 2012, CURR DIABETES REP, V12, P329, DOI 10.1007/s11892-012-0284-5
   Ho CPS, 2018, INDIAN J OPHTHALMOL, V66, P1727, DOI 10.4103/ijo.IJO_975_18
   Ho D, 2011, NANOSCALE, V3, P907, DOI 10.1039/c0nr00666a
   Hoffman T, 2019, TISSUE ENG PT A, V25, P679, DOI [10.1089/ten.TEA.2019.0032, 10.1089/ten.tea.2019.0032]
   Hotaling NA, 2016, J OCUL PHARMACOL TH, V32, P272, DOI 10.1089/jop.2015.0157
   Hu XJ, 2005, TISSUE ENG, V11, P1710, DOI 10.1089/ten.2005.11.1710
   Hunziker R., 2010, FACT SHEET REGENERAT, P2
   Hunziker R., 2010, NIH FACT SHEET REGEN, P2
   Hynes SR, 2010, GRAEF ARCH CLIN EXP, V248, P763, DOI 10.1007/s00417-009-1263-7
   Ilmarinen T, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0143669
   Imai H, 2015, INVEST OPHTH VIS SCI, V56, P7839, DOI 10.1167/iovs.15-16998
   Inoue T, 2010, STEM CELLS, V28, P489, DOI 10.1002/stem.279
   Ip MS, 2012, ARCH OPHTHALMOL-CHIC, V130, P1145, DOI 10.1001/archophthalmol.2012.1043
   Jafari S, 2017, J DRUG DELIV SCI TEC, V37, P61, DOI 10.1016/j.jddst.2016.11.006
   Jahani H, 2012, CELL J, V14, P31
   Janagam DR, 2017, ADV DRUG DELIVER REV, V122, P31, DOI 10.1016/j.addr.2017.04.001
   Jing Y, 2007, BIOTECHNOL BIOENG, V96, P1139, DOI 10.1002/bit.21202
   Johnson H.J., 2017, PHARMACOTHERAPY PATH, p10e
   Jones RR, 2013, MOL PHARMACEUT, V10, P1063, DOI 10.1021/mp300549d
   Julien S, 2011, BIOMATERIALS, V32, P3890, DOI 10.1016/j.biomaterials.2011.02.016
   Kador KE, 2016, TISSUE ENG PT A, V22, P286, DOI [10.1089/ten.tea.2015.0373, 10.1089/ten.TEA.2015.0373]
   Kamaleddin MA, 2017, NANOMED-NANOTECHNOL, V13, P1459, DOI 10.1016/j.nano.2017.02.007
   Karamichos D, 2015, J FUNCT BIOMATER, V6, P77, DOI 10.3390/jfb6010077
   Karl MO, 2010, TRENDS MOL MED, V16, P193, DOI 10.1016/j.molmed.2010.02.003
   Khristov V., 2017, CELLULAR THERAPIES R, P33
   Kim JI, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-21618-0
   Koirala A, 2013, J CONTROL RELEASE, V172, P745, DOI 10.1016/j.jconrel.2013.08.299
   Kong B, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-01072-0
   Koo S, 2014, ACTA BIOMATER, V10, P1975, DOI 10.1016/j.actbio.2014.01.015
   Koss KM, 2016, ACTA BIOMATER, V44, P2, DOI 10.1016/j.actbio.2016.08.026
   Koss KM, 2018, MATERIALS, V11, DOI 10.3390/ma11091539
   Kutsuzawa K, 2006, BIOCHEM BIOPH RES CO, V350, P514, DOI 10.1016/j.bbrc.2006.09.081
   Lallemand F, 2003, EUR J PHARM BIOPHARM, V56, P307, DOI 10.1016/S0939-6411(03)00138-3
   Lamba DA, 2009, PROG BRAIN RES, V175, P23, DOI 10.1016/S0079-6123(09)17502-7
   Lee CH, 2011, BIOMATERIALS, V32, P6683, DOI 10.1016/j.biomaterials.2011.05.070
   Lee JO, 2017, MICROSYST NANOENG, V3, DOI 10.1038/micronano.2017.57
   Leow N.S., 2017, INT J MOL SCI, V18
   Li GC, 2011, CYTOKINE, V56, P208, DOI 10.1016/j.cyto.2011.06.020
   Li JC, 2016, NANOSCALE, V8, P7992, DOI 10.1039/c5nr08808a
   Li Q, 2014, EUR J PHARM SCI, V62, P115, DOI 10.1016/j.ejps.2014.05.020
   Li S, 1998, GENE THER, V5, P930, DOI 10.1038/sj.gt.3300683
   Li S, 1997, GENE THER, V4, P891, DOI 10.1038/sj.gt.3300482
   Li Wan-Ju, 2009, Curr Protoc Cell Biol, VChapter 25, DOI 10.1002/0471143030.cb2502s42
   Liang Y, 2011, J MATER SCI-MATER M, V22, P175, DOI 10.1007/s10856-010-4190-6
   Lin HT, 2016, NATURE, V531, P323, DOI 10.1038/nature17181
   LIN TP, 1966, SCIENCE, V151, P333, DOI 10.1126/science.151.3708.333
   Liu WH, 2015, CELL TRANSPLANT, V24, P2185, DOI 10.3727/096368914X685113
   Liu YZ, 2013, ASIA-PAC J OPHTHALMO, V2, P111, DOI 10.1097/APO.0b013e31828615b7
   Liu ZP, 2014, BIOMATERIALS, V35, P2837, DOI 10.1016/j.biomaterials.2013.12.069
   Long J, 2017, J MATER CHEM B, V5, P2375, DOI [10.1039/c6tb03130g, 10.1039/C6TB03130G]
   Lu JT, 2007, BIOMATERIALS, V28, P1486, DOI 10.1016/j.biomaterials.2006.11.023
   Lu TL, 2013, INT J NANOMED, V8, P337, DOI 10.2147/IJN.S38635
   Ma K, 2013, ADV FUNCT MATER, V23, P1172, DOI 10.1002/adfm.201102963
   Ma WJ, 2018, ACS APPL MATER INTER, V10, P7892, DOI 10.1021/acsami.8b00833
   Mao AS, 2015, P NATL ACAD SCI USA, V112, P14452, DOI 10.1073/pnas.1508520112
   Martin AD, 2018, ACS APPL MATER INTER, V10, P25127, DOI 10.1021/acsami.8b07560
   Marx V, 2015, NATURE, V522, P373, DOI 10.1038/522373a
   McHugh KJ, 2014, INVEST OPHTH VIS SCI, V55, P1754, DOI 10.1167/iovs.13-12833
   Mclaughlin S, 2016, FRONT MATER, V3, DOI 10.3389/fmats.2016.00027
   Meek KM, 2015, PROG RETIN EYE RES, V49, P1, DOI 10.1016/j.preteyeres.2015.07.001
   Mertsch K, 2001, J COMP NEUROL, V431, P217
   Misra GP, 2009, BIOMATERIALS, V30, P6541, DOI 10.1016/j.biomaterials.2009.08.025
   Misra GR, 2011, AAPS ADV PHARM SCI, V2, P291, DOI 10.1007/978-1-4419-9920-7_12
   Mitra RN, 2014, FREE RADICAL BIO MED, V75, P140, DOI 10.1016/j.freeradbiomed.2014.07.013
   Mitra RN, 2016, WIRES NANOMED NANOBI, V8, P160, DOI 10.1002/wnan.1356
   Mizutani M, 1996, J CLIN INVEST, V97, P2883, DOI 10.1172/JCI118746
   Moore AN, 2018, BIOMATERIALS, V161, P154, DOI 10.1016/j.biomaterials.2018.01.033
   Muhammad R, 2015, ACTA BIOMATER, V19, P138, DOI 10.1016/j.actbio.2015.03.016
   Nadri S, 2013, MOL BIOL REP, V40, P3883, DOI 10.1007/s11033-012-2360-y
   Nguyen PK, 2018, ACS APPL BIO MATER, V1, P865, DOI 10.1021/acsabm.8b00283
   Nibourg LM, 2016, EXP EYE RES, V143, P60, DOI 10.1016/j.exer.2015.10.001
   Nicoara SD, 2016, STEM CELLS INT, V2016, DOI 10.1155/2016/1236721
   Niloy K.K., 2019, REGEN ENG TRANSL MED, V10
   Niu GG, 2014, BIOMATERIALS, V35, P4005, DOI 10.1016/j.biomaterials.2014.01.033
   Noorani B, 2018, INT J POLYM MATER PO, V67, P754, DOI 10.1080/00914037.2017.1362639
   Obata H, 2007, CORNEA, V26, pS82, DOI 10.1097/ICO.0b013e31812f6f1b
   Oh B, 2013, EXPERT OPIN DRUG DEL, V10, P1565, DOI 10.1517/17425247.2013.830608
   Olsen TW, 2011, INVEST OPHTH VIS SCI, V52, P4749, DOI 10.1167/iovs.10-6291
   Ong FS, 2013, J PERS MED, V3, P40, DOI 10.3390/jpm3010040
   Ovando-Roche P, 2017, CURR STEM CELL REP, V3, P112, DOI 10.1007/s40778-017-0078-4
   Pan Q, 2015, J CONTROL RELEASE, V201, P32, DOI 10.1016/j.jconrel.2015.01.009
   Parekh M, 2016, STEM CELL TRANSL MED, V5, P258, DOI 10.5966/sctm.2015-0181
   Pashneh-Tala S, 2016, TISSUE ENG PART B-RE, V22, P68, DOI 10.1089/ten.teb.2015.0100
   Patel S, 2015, ANGEW CHEM INT EDIT, V54, P11983, DOI 10.1002/anie.201504902
   Pellegrini G, 1997, LANCET, V349, P990, DOI 10.1016/S0140-6736(96)11188-0
   Phu D, 2011, TISSUE ENG PT A, V17, P799, DOI 10.1089/ten.TEA.2009.0724
   Pieramici DJ, 2008, EYE, V22, P1330, DOI 10.1038/eye.2008.88
   Pillai RG, 2011, CURR TOP MED CHEM, V11, P1606
   PODUSLO JF, 1994, P NATL ACAD SCI USA, V91, P5705, DOI 10.1073/pnas.91.12.5705
   Polykandriotis E, 2010, J CELL MOL MED, V14, P2350, DOI 10.1111/j.1582-4934.2010.01169.x
   Popelka S, 2015, BIOMED MATER, V10, DOI 10.1088/1748-6041/10/4/045022
   Pritchard CD, 2010, BIOMATERIALS, V31, P2153, DOI 10.1016/j.biomaterials.2009.11.074
   Pushp P, 2013, ADV POLYM SCI, V254, P51, DOI 10.1007/12_2012_194
   Qiu F, 2018, INT J NANOMED, V13, P5003, DOI 10.2147/IJN.S166403
   Rajala A, 2014, NANO LETT, V14, P5257, DOI 10.1021/nl502275s
   Rakoczy EP, 2014, INT J BIOCHEM CELL B, V56, P153, DOI 10.1016/j.biocel.2014.09.022
   Ramanna K., 2009, SSRN ELECT J, P1, DOI [https://doi.org/10.2139/ssrn.1460763, DOI 10.2139/SSRN.1460763]
   Raveendran S., 2017, MAT BASEL SWITZERLAN, V10
   Reichl S, 2011, BIOMATERIALS, V32, P3375, DOI 10.1016/j.biomaterials.2011.01.052
   Ricles LM, 2011, INT J NANOMED, V6, P407, DOI 10.2147/IJN.S16354
   Rizwan M, 2017, BIOMATERIALS, V120, P139, DOI 10.1016/j.biomaterials.2016.12.026
   Rose JB, 2014, MATERIALS, V7, P3106, DOI 10.3390/ma7043106
   Rowe-Rendleman CL, 2014, INVEST OPHTH VIS SCI, V55, P2714, DOI 10.1167/iovs.13-13707
   Roybal CN, 2018, AM J OPHTHALMOL, V186, P152, DOI 10.1016/j.ajo.2017.11.025
   Ruan J, 2011, INT J NANOMED, V6, P425, DOI 10.2147/IJN.S16498
   Sadtler K, 2016, NAT REV MATER, V1, DOI 10.1038/natrevmats.2016.40
   Sahle F.F., 2019, DRUG DISCOVERY TODAY
   Sahle FF, 2018, DRUG DISCOV TODAY, V23, P992, DOI 10.1016/j.drudis.2018.04.003
   Salehi S, 2017, ACTA BIOMATER, V50, P370, DOI 10.1016/j.actbio.2017.01.013
   Sarao V., 2014, THESCIENTIFICWORLDJO, V2014, P14
   Sarkar K, 2010, ELECTROSPINNING FORC
   Schmidt N, 2010, FEBS LETT, V584, P1806, DOI 10.1016/j.febslet.2009.11.046
   Selmeczi D, 2011, BIOMED MICRODEVICES, V13, P383, DOI 10.1007/s10544-010-9507-1
   Shahmoradi S, 2017, MAT SCI ENG C-MATER, V73, P300, DOI 10.1016/j.msec.2016.11.076
   Shirali AC, 2011, AM J TRANSPLANT, V11, P2582, DOI 10.1111/j.1600-6143.2011.03725.x
   Sivaraman KR, 2016, OCUL SURF, V14, P393, DOI 10.1016/j.jtos.2016.04.003
   Smith IO, 2009, WIRES NANOMED NANOBI, V1, P226, DOI 10.1002/wnan.26
   Sorkio A, 2015, TISSUE ENG PT A, V21, P2301, DOI [10.1089/ten.tea.2014.0640, 10.1089/ten.TEA.2014.0640]
   Sorkio AE, 2015, BIOMATERIALS, V51, P257, DOI 10.1016/j.biomaterials.2015.02.005
   Sridhar MS, 2018, INDIAN J OPHTHALMOL, V66, P190, DOI 10.4103/ijo.IJO_646_17
   Stafiej P, 2017, MAT SCI ENG C-MATER, V71, P764, DOI 10.1016/j.msec.2016.10.058
   Starzl T E, 1994, JAMA, V272, P1705, DOI 10.1001/jama.272.21.1705
   Stern JH, 2018, CELL STEM CELL, V22, P834, DOI 10.1016/j.stem.2018.05.013
   Surrao DC, 2017, ACTA BIOMATER, V64, P357, DOI 10.1016/j.actbio.2017.09.032
   T.N.E. Institute, 2016, FACTS CORN CORN DIS
   Tan YSE, 2018, BRIT J OPHTHALMOL, V102, P1182, DOI 10.1136/bjophthalmol-2017-311390
   Teichmann J, 2013, J FUNCT BIOMATER, V4, P178, DOI 10.3390/jfb4040178
   Teo BKK, 2012, ACTA BIOMATER, V8, P2941, DOI 10.1016/j.actbio.2012.04.020
   Thieltges F, 2011, OPHTHALMIC RES, V46, P133, DOI 10.1159/000324045
   Tiera MJ, 2011, CURR GENE THER, V11, P288
   Torbet J, 2007, BIOMATERIALS, V28, P4268, DOI 10.1016/j.biomaterials.2007.05.024
   Uzunalli G, 2014, ACTA BIOMATER, V10, P1156, DOI 10.1016/j.actbio.2013.12.002
   Vacanti CA, 2006, J CELL MOL MED, V10, P569, DOI 10.1111/j.1582-4934.2006.tb00421.x
   VanGuilder HD, 2008, EUR J NEUROSCI, V28, P1, DOI 10.1111/j.1460-9568.2008.06322.x
   Vasita R, 2006, INT J NANOMED, V1, P15, DOI 10.2147/nano.2006.1.1.15
   VB Lu, 2009, J VIS EXP, V34, P1614
   Velez G, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.97818
   Walter MNM, 2016, BIOMATER SCI-UK, V4, P346, DOI 10.1039/c5bm00428d
   Wang HY, 2008, BIOTECHNOL BIOENG, V100, P579, DOI 10.1002/bit.21784
   Wang YH, 2015, J FUNCT BIOMATER, V6, P379, DOI 10.3390/jfb6020379
   Wang Z, 2009, NANOSCALE RES LETT, V4, P593, DOI 10.1007/s11671-009-9292-z
   Warnke PH, 2013, ACTA BIOMATER, V9, P9414, DOI 10.1016/j.actbio.2013.07.029
   White CE, 2017, J TISSUE ENG, V8, DOI 10.1177/2041731417720841
   Whitmire W, 2011, MOL VIS, V17, P300
   Wilson SL, 2012, J FUNCT BIOMATER, V3, P642, DOI 10.3390/jfb3030642
   Wood EH, 2019, RETINA-J RET VIT DIS, V39, P820, DOI 10.1097/IAE.0000000000002449
   Wray LS, 2009, TISSUE ENG PT A, V15, P1463, DOI 10.1089/ten.tea.2008.0239
   Wu HH, 2018, ENVIRON SCI-NANO, V5, P1567, DOI 10.1039/c8en00323h
   Wu ZJ, 2018, NANOMATERIALS-BASEL, V8, DOI 10.3390/nano8020124
   Xi YL, 2013, ACS APPL MATER INTER, V5, P4821, DOI 10.1021/am4004683
   Xiang P, 2014, BIOMATERIALS, V35, P9777, DOI 10.1016/j.biomaterials.2014.08.040
   Yan L, 2016, ACS APPL MATER INTER, V8, P6834, DOI 10.1021/acsami.5b12843
   Yanez-Soto B, 2013, BIOMATERIALS, V34, P9244, DOI 10.1016/j.biomaterials.2013.08.042
   Yang F, 2005, BIOMATERIALS, V26, P2603, DOI 10.1016/j.biomaterials.2004.06.051
   Yang TC, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18092013
   Yao K, 2018, NATURE, V560, P484, DOI 10.1038/s41586-018-0425-3
   Yao K, 2016, CELL REP, V17, P165, DOI 10.1016/j.celrep.2016.08.078
   Yi H, 2016, BONE RES, V4, DOI 10.1038/boneres.2016.50
   Yuan XB, 2008, INT J PHARM, V349, P241, DOI 10.1016/j.ijpharm.2007.07.045
   Zarbin MA, 2013, MAYO CLIN PROC, V88, P1480, DOI 10.1016/j.mayocp.2013.05.025
   Zarbin MA, 2012, WIRES NANOMED NANOBI, V4, P113, DOI 10.1002/wnan.167
   Zarbin MA, 2010, CAN J OPHTHALMOL, V45, P457, DOI 10.3129/i10-090
   Zeng HY, 2008, ARCH OPHTHALMOL-CHIC, V126, P227, DOI 10.1001/archophthalmol.2007.65
   Zhang JX, 2015, INT J OPHTHALMOL-CHI, V8, P622, DOI 10.3980/j.issn.2222-3959.2015.03.33
   Zhang SG, 2017, INTERFACE FOCUS, V7, DOI 10.1098/rsfs.2017.0028
   Zhang SG, 2012, AMINO ACIDS PEP PROT, V37, P40, DOI 10.1039/9781849734677-00040
   Zhang WY, 2017, EXP EYE RES, V154, P22, DOI 10.1016/j.exer.2016.11.006
   Zhang XM, 2010, MOL VIS, V16, P2867
   Zhao JJ, 2014, J BIOL CHEM, V289, P11945, DOI 10.1074/jbc.M113.532671
   Zhou X, 2018, RSC ADV, V8, P17656, DOI 10.1039/c8ra02424c
NR 229
TC 19
Z9 20
U1 4
U2 32
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0169-409X
EI 1872-8294
J9 ADV DRUG DELIVER REV
JI Adv. Drug Deliv. Rev.
PD AUG 1
PY 2019
VL 148
BP 290
EP 307
DI 10.1016/j.addr.2019.10.006
PG 18
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA JU8QU
UT WOS:000501935400013
PM 31707052
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Gong, LL
   Liu, FY
   Xiong, Z
   Qi, RL
   Luo, ZW
   Gong, XD
   Nie, Q
   Sun, Q
   Liu, YF
   Qing, WJ
   Wang, L
   Zhang, L
   Tang, XC
   Huang, S
   Li, G
   Ouyang, H
   Xiang, MQ
   Nguyen, QD
   Liu, YZ
   Li, DWC
AF Gong, Lili
   Liu, Fangyuan
   Xiong, Zhen
   Qi, Ruili
   Luo, Zhongwen
   Gong, Xiaodong
   Nie, Qian
   Sun, Qian
   Liu, Yun-Fei
   Qing, Wenjie
   Wang, Ling
   Zhang, Lan
   Tang, Xiangcheng
   Huang, Shan
   Li, Gen
   Ouyang, Hong
   Xiang, Mengqing
   Quan Dong Nguyen
   Liu, Yizhi
   Li, David Wan-Cheng
TI Heterochromatin protects retinal pigment epithelium cells from oxidative
   damage by silencing p53 target genes
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
DE age-related macular degeneration; oxidative stress; RPE;
   heterochromatin; p53
ID TUMOR-SUPPRESSOR; CHROMATIN RELAXATION; MACULAR DEGENERATION; SATELLITE
   REPEATS; STRESS; MODEL; METHYLTRANSFERASES; DEGRADATION; ACTIVATION;
   SUV39H1
AB Oxidative stress (OS)-induced retinal pigment epithelium (RPE) cell apoptosis is critically implicated in the pathogenesis of age-related macular degeneration (AMD), a leading cause of blindness in the elderly. Heterochromatin, a compact and transcriptional inert chromatin structure, has been recently shown to be dynamically regulated in response to stress stimuli. The functional mechanism of heterochromatin on OS exposure is unclear, however. Here we show that OS increases heterochromatin formation both in vivo and in vitro, which is essential for protecting RPE cells from oxidative damage. Mechanistically, OS-induced heterochromatin selectively accumulates at p53-regulated proapoptotic target promoters and inhibits their transcription. Furthermore, OS-induced desumoylation of p53 promotes p53-heterochromatin interaction and regulates p53 promoter selection, resulting in the locus-specific recruitment of heterochromatin and transcription repression. Together, our findings demonstrate a protective function of OS-induced heterochromatin formation in which p53 desumoylation-guided promoter selection and subsequent heterochromatin recruitment play a critical role. We propose that targeting heterochromatin provides a plausible therapeutic strategy for the treatment of AMD.
C1 [Gong, Lili; Liu, Fangyuan; Xiong, Zhen; Qi, Ruili; Luo, Zhongwen; Gong, Xiaodong; Nie, Qian; Sun, Qian; Liu, Yun-Fei; Qing, Wenjie; Wang, Ling; Zhang, Lan; Tang, Xiangcheng; Huang, Shan; Li, Gen; Ouyang, Hong; Xiang, Mengqing; Liu, Yizhi; Li, David Wan-Cheng] Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, State Key Lab Ophthalmol, Guangzhou 510060, Guangdong, Peoples R China.
   [Nie, Qian; Qing, Wenjie; Wang, Ling; Li, David Wan-Cheng] Hunan Normal Univ, Coll Life Sci, Key Lab Prot Chem & Dev Biol, Changsha 410081, Hunan, Peoples R China.
   [Wang, Ling; Li, David Wan-Cheng] Univ Nebraska Med Ctr, Truhlsen Eye Inst, Omaha, NE 68198 USA.
   [Xiang, Mengqing] Rutgers Robert Wood Johnson Med Sch, Ctr Adv Biotechnol & Med, Piscataway, NJ 08854 USA.
   [Xiang, Mengqing] Rutgers Robert Wood Johnson Med Sch, Dept Pediat, Piscataway, NJ 08854 USA.
   [Quan Dong Nguyen] Stanford Univ, Sch Med, Byers Eye Inst, Palo Alto, CA 94303 USA.
C3 Sun Yat Sen University; Hunan Normal University; University of Nebraska
   System; University of Nebraska Medical Center; Rutgers State University
   New Brunswick; Rutgers State University Medical Center; Rutgers State
   University New Brunswick; Rutgers State University Medical Center;
   Stanford University
RP Gong, LL; Liu, YZ; Li, DWC (通讯作者)，Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, State Key Lab Ophthalmol, Guangzhou 510060, Guangdong, Peoples R China.; Li, DWC (通讯作者)，Hunan Normal Univ, Coll Life Sci, Key Lab Prot Chem & Dev Biol, Changsha 410081, Hunan, Peoples R China.; Li, DWC (通讯作者)，Univ Nebraska Med Ctr, Truhlsen Eye Inst, Omaha, NE 68198 USA.
EM gonglili@mail.sysu.edu.cn; yzliu62@yahoo.com; liwancheng@gzzoc.com
RI Li, David/AAN-9205-2021; LIU, Fangyuan/GRX-8688-2022; liu,
   yi/GXE-9662-2022
OI Liu, Yizhi/0000-0002-2067-2707; Huang, Shan/0000-0003-3038-5688; Huang,
   Shan/0000-0001-8492-9658; Ouyang, Hong/0000-0002-7622-7733; Liu,
   Yizhi/0000-0003-4108-9593; Gong, Lili/0000-0002-3129-3868
FU National Natural Science Foundation of China [81500738, 81570824,
   81500707]; National Basic Research Program (973 Program) of China
   [2015CB964600]; State Key Laboratory of Ophthalmology, Zhongshan
   Ophthalmic Center, Sun Yat-sen University
FX We thank Hebi Liu, Mingyi Zhou, and Jianfa Huang of the Zhongshan
   Ophthalmic Center's flow cytometry and cellular imaging facility for
   assisting with confocal microscopy and the flow cytometry-based cell
   apoptosis assays. This work was supported by the National Natural
   Science Foundation of China (Grants 81500738, 81570824, and 81500707),
   the National Basic Research Program (973 Program) of China (Grant
   2015CB964600), and the Fundamental Research Fund of the State Key
   Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen
   University.
CR Bosch-Presegue L, 2011, MOL CELL, V42, P210, DOI 10.1016/j.molcel.2011.02.034
   Cai JY, 2000, PROG RETIN EYE RES, V19, P205, DOI 10.1016/S1350-9462(99)00009-9
   Chen LH, 2010, EMBO J, V29, P2538, DOI 10.1038/emboj.2010.140
   Enzmann V, 2006, EXP EYE RES, V82, P441, DOI 10.1016/j.exer.2005.08.002
   Frost B, 2014, NAT NEUROSCI, V17, P357, DOI 10.1038/nn.3639
   Fuhrmann S, 2014, EXP EYE RES, V123, P141, DOI 10.1016/j.exer.2013.09.003
   Gong LL, 2015, CELL CYCLE, V14, P2323, DOI 10.1080/15384101.2015.1044174
   Gostissa M, 1999, EMBO J, V18, P6462, DOI 10.1093/emboj/18.22.6462
   Greiner D, 2005, NAT CHEM BIOL, V1, P143, DOI 10.1038/nchembio721
   Grewal SIS, 2007, NAT REV GENET, V8, P35, DOI 10.1038/nrg2008
   Guenatri M, 2004, J CELL BIOL, V166, P493, DOI 10.1083/jcb.200403109
   Gupta S, 2001, J BIOL CHEM, V276, P10585, DOI 10.1074/jbc.C100025200
   Ijima R, 2014, INVEST OPHTH VIS SCI, V55, DOI 10.1167/iovs.14-15367
   Imamura Y, 2006, P NATL ACAD SCI USA, V103, P11282, DOI 10.1073/pnas.0602131103
   Kaczara P, 2010, FREE RADICAL BIO MED, V48, P1064, DOI 10.1016/j.freeradbiomed.2010.01.022
   Kaneko H, 2011, NATURE, V471, P325, DOI 10.1038/nature09830
   Lachner M, 2001, NATURE, V410, P116, DOI 10.1038/35065132
   Lagouge M, 2006, CELL, V127, P1109, DOI 10.1016/j.cell.2006.11.013
   Langmead B, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-3-r25
   Le Cam L, 2006, CELL, V127, P775, DOI 10.1016/j.cell.2006.09.031
   Mayo LD, 2005, J BIOL CHEM, V280, P25953, DOI 10.1074/jbc.M503026200
   Montero J, 2013, CELL DEATH DIFFER, V20, P1465, DOI 10.1038/cdd.2013.52
   Mungamuri SK, 2016, CELL REP, V14, P2528, DOI 10.1016/j.celrep.2016.02.049
   Mungamuri SK, 2012, NAT STRUCT MOL BIOL, V19, P478, DOI 10.1038/nsmb.2271
   Plafker SM, 2012, INT REV CEL MOL BIO, V298, P135, DOI 10.1016/B978-0-12-394309-5.00004-3
   Rea S, 2000, NATURE, V406, P593, DOI 10.1038/35020506
   Rodriguez MS, 1999, EMBO J, V18, P6455, DOI 10.1093/emboj/18.22.6455
   Sablina AA, 2005, NAT MED, V11, P1306, DOI 10.1038/nm1320
   Sen N, 2013, MOL CELL, V52, P406, DOI 10.1016/j.molcel.2013.09.003
   Sheu SJ, 2013, INVEST OPHTH VIS SCI, V54, P6426, DOI 10.1167/iovs.13-12024
   Soria C, 2010, NATURE, V466, P1076, DOI 10.1038/nature09307
   Tarallo V, 2012, CELL, V149, P847, DOI 10.1016/j.cell.2012.03.036
   Ting DT, 2011, SCIENCE, V331, P593, DOI 10.1126/science.1200801
   Wang JY, 2016, TRENDS GENET, V32, P284, DOI 10.1016/j.tig.2016.02.005
   Wu SY, 2009, EMBO J, V28, P1246, DOI 10.1038/emboj.2009.83
   Yu GC, 2015, BIOINFORMATICS, V31, P2382, DOI 10.1093/bioinformatics/btv145
   Zhang WQ, 2015, SCIENCE, V348, P1160, DOI 10.1126/science.aaa1356
   Zhang Y, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-9-r137
   Zhu Q, 2011, NATURE, V477, P179, DOI 10.1038/nature10371
   Ziv Y, 2006, NAT CELL BIOL, V8, P870, DOI 10.1038/ncb1446
NR 40
TC 21
Z9 21
U1 0
U2 4
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD APR 24
PY 2018
VL 115
IS 17
BP E3987
EP E3995
DI 10.1073/pnas.1715237115
PG 9
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA GD7MZ
UT WOS:000430697500018
PM 29622681
OA Green Published, hybrid
DA 2022-11-30
ER

PT J
AU Toomey, CB
   Johnson, LV
   Rickman, CB
AF Toomey, Christopher B.
   Johnson, Lincoln V.
   Rickman, Catherine Bowes
TI Complement factor H in AMD: Bridging genetic associations and
   pathobiology
SO PROGRESS IN RETINAL AND EYE RESEARCH
LA English
DT Article
ID C-REACTIVE PROTEIN; AGE-RELATED MACULOPATHY; RETINAL-PIGMENT EPITHELIUM;
   HEMOLYTIC-UREMIC SYNDROME; INDUCED CHOROIDAL NEOVASCULARIZATION;
   SUBRETINAL DRUSENOID DEPOSITS; LIPOPROTEIN-LIKE PARTICLES; MEDIATED
   DARK-ADAPTATION; MEMBRANE ATTACK COMPLEX; GENOME-WIDE ASSOCIATION
AB Age-Related Macular Degeneration (AMD) is a complex multifactorial disease characterized in its early stages by lipoprotein accumulations in Bruch's Membrane (BrM), seen on fundoscopic exam as drusen, and in its late forms by neovascularization ("wet") or geographic atrophy of the Retinal Pigmented Epithelial (RPE) cell layer ("dry"). Genetic studies have strongly supported a relationship between the alternative complement cascade, in particular the common H402 variant in Complement Factor H (CFH) and development of AMD. However, the functional significance of the CFH Y402H polymorphism remains elusive. In this article, we critically review the literature surrounding the functional significance of this polymorphism. Furthermore, based on our group's studies we propose a model in which CFH H402 affects CFH binding to heparan sulfate proteoglycans leading to accelerated lipoprotein accumulation in BrM and drusen progression. We also review the literature on the role of other complement components in AMD pathobiologies, including C3a, C5a and the membrane attack complex (MAC), and on transgenic mouse models developed to interrogate in vivo the effects of the CFH Y402H polymorphism. (C) 2017 Elsevier Ltd. All rights reserved.
C1 [Toomey, Christopher B.; Rickman, Catherine Bowes] Duke Univ, Duke Eye Ctr, Dept Ophthalmol, Durham, NC 27710 USA.
   [Toomey, Christopher B.; Rickman, Catherine Bowes] Duke Univ, Dept Cell Biol, Durham, NC 27710 USA.
   [Johnson, Lincoln V.] Univ Calif Santa Barbara, Neurosci Res Inst, Ctr Study Macular Degenerat, Santa Barbara, CA 93106 USA.
   [Toomey, Christopher B.] Univ Calif San Diego, Shiley Eye Inst, Dept Ophthalmol, La Jolla, CA 92093 USA.
C3 Duke University; Duke University; University of California System;
   University of California Santa Barbara; University of California System;
   University of California San Diego
RP Rickman, CB (通讯作者)，Duke Eye Ctr, Box 3802 AERI Rm 5010, Durham, NC 27710 USA.
EM bowes007@duke.edu
OI Bowes Rickman, Catherine/0000-0002-8555-9596
FU National Institutes of Health [EY026161, P30 EY005722]; Medical
   Scientist Training Program [T32 GM007171]; Research to Prevent
   Blindness; Foundation Fighting Blindness (CBR) [BR-CMM-0615-0681-DUKE];
   NATIONAL EYE INSTITUTE [P30EY005722, R01EY026161] Funding Source: NIH
   RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007171]
   Funding Source: NIH RePORTER
FX The authors acknowledge the funding support from the National Institutes
   of Health (EY026161 to CBR, P30 EY005722 to V. Arshaysky), and T32
   GM007171-Medical Scientist Training Program (to CBT), an unrestricted
   grant from Research to Prevent Blindness (to the Duke Eye Center), and a
   grant from the Foundation Fighting Blindness (CBR)
   (BR-CMM-0615-0681-DUKE).
CR Abecasis GR, 2004, AM J HUM GENET, V74, P403, DOI 10.1086/381713
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   Ansari M, 2013, HUM MOL GENET, V22, P4857, DOI 10.1093/hmg/ddt336
   Aredo B, 2015, INVEST OPHTH VIS SCI, V56, P3427, DOI 10.1167/iovs.14-16089
   Augood CA, 2006, ARCH OPHTHALMOL-CHIC, V124, P529, DOI 10.1001/archopht.124.4.529
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Black JRM, 2016, GENET MED, V18, P283, DOI 10.1038/gim.2015.70
   Black S, 2004, J BIOL CHEM, V279, P48487, DOI 10.1074/jbc.R400025200
   Blaum BS, 2015, NAT CHEM BIOL, V11, P77, DOI [10.1038/NCHEMBIO.1696, 10.1038/nchembio.1696]
   Bora NS, 2006, J IMMUNOL, V177, P1872, DOI 10.4049/jimmunol.177.3.1872
   Bora PS, 2005, J IMMUNOL, V174, P491, DOI 10.4049/jimmunol.174.1.491
   Bretillon L, 2008, EXP EYE RES, V87, P521, DOI 10.1016/j.exer.2008.08.010
   Buddles MRH, 2000, AM J HUM GENET, V66, P1721, DOI 10.1086/302877
   BUTKOWSKI RJ, 1989, KIDNEY INT, V35, P1195, DOI 10.1038/ki.1989.110
   Calippe B, 2017, IMMUNITY, V46, P261, DOI 10.1016/j.immuni.2017.01.006
   Caprioli J, 2003, HUM MOL GENET, V12, P3385, DOI 10.1093/hmg/ddg363
   Chen L, 2003, BRIT J OPHTHALMOL, V87, P212, DOI 10.1136/bjo.87.2.212
   Chen W, 2010, P NATL ACAD SCI USA, V107, P7401, DOI 10.1073/pnas.0912702107
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Chirco KR, 2016, J PATHOL, V240, P173, DOI 10.1002/path.4766
   Christen WG, 1996, JAMA-J AM MED ASSOC, V276, P1147, DOI 10.1001/jama.276.14.1147
   CHURCH DF, 1985, ENVIRON HEALTH PERSP, V64, P111, DOI 10.2307/3430003
   Clark SJ, 2006, J BIOL CHEM, V281, P24713, DOI 10.1074/jbc.M605083200
   Clark SJ, 2013, J IMMUNOL, V190, P2049, DOI 10.4049/jimmunol.1201751
   Clark SJ, 2010, J BIOL CHEM, V285, P30192, DOI 10.1074/jbc.M110.103986
   Coffey PJ, 2007, P NATL ACAD SCI USA, V104, P16651, DOI 10.1073/pnas.0705079104
   Colville D, 2003, AM J KIDNEY DIS, V42, DOI 10.1016/S0272-6386(03)00665-6
   Coughlin B, 2016, SCI REP-UK, V6, DOI 10.1038/srep23794
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Curcio C.A., 2013, RETINA-J RET VIT DIS, VVolume 1, P465
   Curcio CA, 2005, EXP EYE RES, V81, P731, DOI 10.1016/j.exer.2005.04.012
   Curcio CA, 2001, INVEST OPHTH VIS SCI, V42, P265
   Curcio CA, 2011, BRIT J OPHTHALMOL, V95, P1638, DOI 10.1136/bjophthalmol-2011-300344
   Datta S, 2017, PROG RETIN EYE RES, V60, P201, DOI 10.1016/j.preteyeres.2017.03.002
   de Cordoba SR, 2004, MOL IMMUNOL, V41, P355, DOI 10.1016/j.molimm.2004.02.005
   Delcourt C, 2011, INVEST OPHTH VIS SCI, V52, P5955, DOI 10.1167/iovs.10-6235
   Dentchev T, 2003, MOL VIS, V9, P184
   Devaraj S, 2004, J MOL CELL CARDIOL, V36, P405, DOI 10.1016/j.yjmcc.2003.12.005
   Dietzel M, 2014, GRAEF ARCH CLIN EXP, V252, P1273, DOI 10.1007/s00417-014-2690-7
   Ding JD, 2015, AM J PATHOL, V185, P29, DOI 10.1016/j.ajpath.2014.08.026
   Donders FC., 1855, ARCH OPHTHALMOL-CHIC, V1, P139
   Eagerness J. A., 2009, EUR J HUM GENET
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Eisenhardt SU, 2009, TRENDS CARDIOVAS MED, V19, P232, DOI 10.1016/j.tcm.2010.02.002
   Eisenhardt SU, 2009, CIRC RES, V105, P128, DOI 10.1161/CIRCRESAHA.108.190611
   Ennis S, 2007, BRIT J OPHTHALMOL, V91, P966, DOI 10.1136/bjo.2007.114090
   Ethier CR, 2004, ANNU REV BIOMED ENG, V6, P249, DOI 10.1146/annurev.bioeng.6.040803.140055
   FEARON DT, 1978, P NATL ACAD SCI USA, V75, P1971, DOI 10.1073/pnas.75.4.1971
   Feng SJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073715
   Fernandez-Godino R, 2015, HUM MOL GENET, V24, P5555, DOI 10.1093/hmg/ddv287
   Ferrara D, 2015, JAMA OPHTHALMOL, V133, P785, DOI 10.1001/jamaophthalmol.2015.0814
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   FISHER RF, 1987, EYE, V1, P184, DOI 10.1038/eye.1987.35
   Francis PJ, 2006, J ROY SOC MED, V99, P189, DOI 10.1258/jrsm.99.4.189
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Fujihara M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003119
   Gangnon RE, 2012, ARCH OPHTHALMOL-CHIC, V130, P1169, DOI 10.1001/archophthalmol.2012.693
   Garland DL, 2014, HUM MOL GENET, V23, P52, DOI 10.1093/hmg/ddt395
   Gass J D, 1972, Trans Am Ophthalmol Soc, V70, P409
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Grossniklaus HE, 2010, PROG RETIN EYE RES, V29, P500, DOI 10.1016/j.preteyeres.2010.05.003
   Guymer R, 1999, PROG RETIN EYE RES, V18, P59, DOI 10.1016/S1350-9462(98)00012-3
   Hageman GS, 1999, FASEB J, V13, P477, DOI 10.1096/fasebj.13.3.477
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hakobyan S, 2008, J BIOL CHEM, V283, P30451, DOI 10.1074/jbc.M803648200
   HAMLIN CR, 1971, BIOCHIM BIOPHYS ACTA, V236, P458, DOI 10.1016/0005-2795(71)90226-1
   Hammond CJ, 2002, OPHTHALMOLOGY, V109, P730, DOI 10.1016/S0161-6420(01)01049-1
   Handa JT, 1999, INVEST OPHTH VIS SCI, V40, P775
   Harboe M, 2004, CLIN EXP IMMUNOL, V138, P439, DOI 10.1111/j.1365-2249.2004.02627.x
   Harboe M, 2009, MOL IMMUNOL, V47, P373, DOI 10.1016/j.molimm.2009.09.005
   Harvey SJ, 1998, KIDNEY INT, V54, P1857, DOI 10.1046/j.1523-1755.1998.00188.x
   Hawse J, 2003, MOL VIS, V9, P515
   Hecker LA, 2010, HUM MOL GENET, V19, P209, DOI 10.1093/hmg/ddp472
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Heurich M, 2011, P NATL ACAD SCI USA, V108, P8761, DOI 10.1073/pnas.1019338108
   Hogan MJ, 1971, HISTOLOGY HUMAN EYE
   Holliday EG, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0082305, 10.1371/journal.pone.0053830]
   Hollyfield JG, 2008, NAT MED, V14, P194, DOI 10.1038/nm1709
   HOLZ FG, 1994, ARCH OPHTHALMOL-CHIC, V112, P402, DOI 10.1001/archopht.1994.01090150132035
   Huang JD, 2007, EXP EYE RES, V85, P202, DOI 10.1016/j.exer.2007.03.011
   Huang YX, 2008, J IMMUNOL, V181, P8068, DOI 10.4049/jimmunol.181.11.8068
   ISHIBASHI T, 1987, INVEST OPHTH VIS SCI, V28, P1116
   Ishibashi T, 1998, ARCH OPHTHALMOL-CHIC, V116, P1629, DOI 10.1001/archopht.116.12.1629
   Iyengar SK, 2004, AM J HUM GENET, V74, P20, DOI 10.1086/380912
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   JENNE DE, 1991, J BIOL CHEM, V266, P11030
   Ji SR, 2007, FASEB J, V21, P284, DOI 10.1096/fj.06-6722com
   Johnson LV, 2011, P NATL ACAD SCI USA, V108, P18277, DOI 10.1073/pnas.1109703108
   Johnson LV, 2000, EXP EYE RES, V70, P441, DOI 10.1006/exer.1999.0798
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Johnson LV, 2002, P NATL ACAD SCI USA, V99, P11830, DOI 10.1073/pnas.192203399
   Johnson PT, 2006, P NATL ACAD SCI USA, V103, P17456, DOI 10.1073/pnas.0606234103
   Kam JH, 2016, EXP EYE RES, V149, P116, DOI 10.1016/j.exer.2016.07.002
   Kam JH, 2013, AM J PATHOL, V183, P480, DOI 10.1016/j.ajpath.2013.04.008
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kavanagh D, 2015, HUM MOL GENET, V24, P3861, DOI 10.1093/hmg/ddv091
   Keenan TDL, 2014, INVEST OPHTH VIS SCI, V55, P5370, DOI 10.1167/iovs.14-14126
   Kelly U, 2010, J IMMUNOL, V185, P5486, DOI 10.4049/jimmunol.0903596
   KEW RR, 1985, J CLIN INVEST, V75, P1000, DOI 10.1172/JCI111760
   Klaver CCW, 1998, AM J HUM GENET, V63, P200, DOI 10.1086/301901
   Klein BEK, 2002, OPHTHALMOLOGY, V109, P2052, DOI 10.1016/S0161-6420(02)01249-6
   Klein BEK, 2001, AM J EPIDEMIOL, V154, P207, DOI 10.1093/aje/154.3.207
   Klein ML, 1998, ARCH OPHTHALMOL-CHIC, V116, P1082, DOI 10.1001/archopht.116.8.1082
   KLEIN ML, 1994, ARCH OPHTHALMOL-CHIC, V112, P932, DOI 10.1001/archopht.1994.01090190080025
   KLEIN R, 1993, AM J EPIDEMIOL, V137, P190, DOI 10.1093/oxfordjournals.aje.a116659
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klein R, 2013, JAMA OPHTHALMOL, V131, P383, DOI 10.1001/jamaophthalmol.2013.713
   Kunchithapautham K, 2014, J BIOL CHEM, V289, P14534, DOI 10.1074/jbc.M114.564674
   Kurihara T, 2016, ELIFE, V5, DOI 10.7554/eLife.14319
   Laine M, 2007, J IMMUNOL, V178, P3831, DOI 10.4049/jimmunol.178.6.3831
   Lambert V, 2013, NAT PROTOC, V8, P2197, DOI 10.1038/nprot.2013.135
   Lauer N, 2011, J IMMUNOL, V187, P4374, DOI 10.4049/jimmunol.1002488
   LeBedis CA, 2008, RADIOGRAPHICS, V28, P1741, DOI 10.1148/rg.286085515
   LESKE MC, 1994, ARCH OPHTHALMOL-CHIC, V112, P821, DOI 10.1001/archopht.1994.01090180121046
   Li CM, 2007, EXP EYE RES, V85, P192, DOI 10.1016/j.exer.2007.04.002
   Li CM, 2005, INVEST OPHTH VIS SCI, V46, P2576, DOI 10.1167/iovs.05-0034
   Li J, 2001, BRIT J OPHTHALMOL, V85, P287, DOI 10.1136/bjo.85.3.287
   LOFFLER KU, 1995, INVEST OPHTH VIS SCI, V36, P24
   Lommatzsch A, 2008, GRAEF ARCH CLIN EXP, V246, P803, DOI 10.1007/s00417-007-0749-4
   Loyet KM, 2012, INVEST OPHTH VIS SCI, V53, P6628, DOI 10.1167/iovs.12-9587
   Lyzogubov VV, 2010, AM J PATHOL, V177, P1870, DOI 10.2353/ajpath.2010.091168
   Magnusson KP, 2006, PLOS MED, V3, P109, DOI 10.1371/journal.pmed.0030005
   Majewski J, 2003, AM J HUM GENET, V73, P540, DOI 10.1086/377701
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   Maller JB, 2007, NAT GENET, V39, P1200, DOI 10.1038/ng2131
   MEYERS SM, 1995, AM J OPHTHALMOL, V120, P757, DOI 10.1016/S0002-9394(14)72729-1
   MILIS L, 1993, CLIN EXP IMMUNOL, V92, P114
   MOLD C, 1984, J IMMUNOL, V133, P882
   Molins B, 2016, SCI REP-UK, V6, DOI 10.1038/srep22889
   Mullins RF, 2001, EYE, V15, P390, DOI 10.1038/eye.2001.142
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Mullins RF, 2014, AM J PATHOL, V184, P3142, DOI 10.1016/j.ajpath.2014.07.017
   Mullins RF, 2011, EXP EYE RES, V93, P565, DOI 10.1016/j.exer.2011.06.015
   Myers CE, 2014, OPHTHALMOLOGY, V121, P1949, DOI 10.1016/j.ophtha.2014.04.040
   Neale BM, 2010, P NATL ACAD SCI USA, V107, P7395, DOI 10.1073/pnas.0912019107
   Neary JJ, 2002, J AM SOC NEPHROL, V13, P2052, DOI 10.1097/01.ASN.0000022006.49966.F8
   Nolasco L, 2013, ARTERIOSCL THROM VAS, V33, P2524, DOI 10.1161/ATVBAHA.113.302280
   Nozaki M, 2006, P NATL ACAD SCI USA, V103, P2328, DOI 10.1073/pnas.0408835103
   OBRIEN C, 1993, BRIT J OPHTHALMOL, V77, P778, DOI 10.1136/bjo.77.12.778
   Okemefuna AI, 2010, J BIOL CHEM, V285, P1053, DOI 10.1074/jbc.M109.044529
   Okubo A, 1999, INVEST OPHTH VIS SCI, V40, P443
   Ormsby RJ, 2008, INVEST OPHTH VIS SCI, V49, P1763, DOI 10.1167/iovs.07-1297
   Owsley C, 2001, OPHTHALMOLOGY, V108, P1196, DOI 10.1016/S0161-6420(01)00580-2
   Owsley C, 2016, CURR EYE RES, V41, P266, DOI 10.3109/02713683.2015.1011282
   Owsley C, 2016, OPHTHALMOLOGY, V123, P344, DOI 10.1016/j.ophtha.2015.09.041
   PANGBURN MK, 1983, ANN NY ACAD SCI, V421, P291, DOI 10.1111/j.1749-6632.1983.tb18116.x
   Pasceri V, 2000, CIRCULATION, V102, P2165
   PAULEIKHOFF D, 1990, OPHTHALMOLOGY, V97, P171
   Pauleikhoff D., 1994, Ophthalmologe, V91, P730
   Peters S, 2006, OPHTHAL RES, V38, P83, DOI 10.1159/000090268
   Pickering MC, 2007, J EXP MED, V204, P1249, DOI 10.1084/jem.20070301
   Pickering MC, 2002, NAT GENET, V31, P424, DOI 10.1038/ng912
   Pilgrim MG, 2017, INVEST OPHTH VIS SCI, V58, DOI 10.1167/iovs.16-21060
   Poor SH, 2014, INVEST OPHTH VIS SCI, V55, P6525, DOI 10.1167/iovs.14-15067
   Prosser BE, 2007, J EXP MED, V204, P2277, DOI 10.1084/jem.20071069
   Raychaudhuri S, 2011, NAT GENET, V43, P1232, DOI 10.1038/ng.976
   Raychaudhuri S, 2011, CELL, V147, P57, DOI 10.1016/j.cell.2011.09.011
   Recalde S, 2016, J AM SOC NEPHROL, V27, P1305, DOI 10.1681/ASN.2015050580
   Remuzzi G, 2002, BLOOD, V100, P778, DOI 10.1182/blood-2001-12-0166
   Reynolds R, 2009, INVEST OPHTH VIS SCI, V50, P5818, DOI 10.1167/iovs.09-3928
   Ristau T, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093459
   ROBBINS RA, 1991, AM J PHYSIOL, V260, pL254, DOI 10.1152/ajplung.1991.260.4.L254
   Rohrer B, 2012, J OCUL PHARMACOL TH, V28, P402, DOI 10.1089/jop.2011.0212
   Rohrer B, 2009, INVEST OPHTH VIS SCI, V50, P3056, DOI 10.1167/iovs.08-2222
   Rohrer Barbel, 2011, Mol Immunol, V48, pe1, DOI 10.1016/j.molimm.2010.12.016
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2011, NEW ENGL J MED, V364, P1966, DOI 10.1056/NEJMe1103334
   Rudolf M, 2008, EXP EYE RES, V87, P402, DOI 10.1016/j.exer.2008.07.010
   Rudolf M, 2008, INVEST OPHTH VIS SCI, V49, P1200, DOI 10.1167/iovs.07-1466
   RUNGGERBRANDLE E, 1987, INVEST OPHTH VIS SCI, V28, P2026
   SanGiovanni JP, 2007, ARCH OPHTHALMOL-CHIC, V125, P671, DOI 10.1001/archopht.125.5.671
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   SARKS JP, 1994, EYE, V8, P269, DOI 10.1038/eye.1994.57
   SARKS SH, 1976, BRIT J OPHTHALMOL, V60, P324, DOI 10.1136/bjo.60.5.324
   Sarks S, 2007, INVEST OPHTH VIS SCI, V48, P968, DOI 10.1167/iovs.06-0443
   Sarma JV, 2011, CELL TISSUE RES, V343, P227, DOI 10.1007/s00441-010-1034-0
   Schmidt CQ, 2008, J IMMUNOL, V181, P2610, DOI 10.4049/jimmunol.181.4.2610
   Schmidt CQ, 2010, J MOL BIOL, V395, P105, DOI 10.1016/j.jmb.2009.10.010
   Schnabolk G, 2015, INVEST OPHTH VIS SCI, V56, P1850, DOI 10.1167/iovs.14-15910
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P321, DOI 10.1001/archopht.123.3.321
   Seddon JM, 2004, JAMA-J AM MED ASSOC, V291, P704, DOI 10.1001/jama.291.6.704
   Seddon JM, 2003, AM J HUM GENET, V73, P780, DOI 10.1086/378505
   Seddon JM, 1996, JAMA-J AM MED ASSOC, V276, P1141, DOI 10.1001/jama.276.14.1141
   Seddon JM, 1997, AM J OPHTHALMOL, V123, P199, DOI 10.1016/S0002-9394(14)71036-0
   SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413
   Seddon JM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1191, DOI 10.1001/archopht.119.8.1191
   Seddon JM, 2006, ARCH OPHTHALMOL-CHIC, V124, P995, DOI 10.1001/archopht.124.7.995
   Seddon JM, 2013, NAT GENET, V45, P1366, DOI 10.1038/ng.2741
   Shaw PX, 2012, P NATL ACAD SCI USA, V109, P13757, DOI 10.1073/pnas.1121309109
   Shenoy SK, 2010, INDIAN J PATHOL MICR, V53, P329, DOI 10.4103/0377-4929.64316
   Silva AS, 2012, MOL VIS, V18, P2288
   Singh U, 2006, ARTERIOSCL THROM VAS, V26, P2469, DOI 10.1161/01.ATV.0000241572.05292.fb
   Skeie JM, 2010, INVEST OPHTH VIS SCI, V51, P5336, DOI 10.1167/iovs.10-5322
   Smailhodzic D, 2012, OPHTHALMOLOGY, V119, P339, DOI 10.1016/j.ophtha.2011.07.056
   Souied EH, 1998, AM J OPHTHALMOL, V125, P353, DOI 10.1016/S0002-9394(99)80146-9
   Spaide RF, 2013, RETINA-J RET VIT DIS, V33, P1800, DOI 10.1097/IAE.0b013e31829c3765
   Spencer KL, 2008, HUM MOL GENET, V17, P1821, DOI 10.1093/hmg/ddn075
   STANGOS N, 1995, OPHTHALMOLOGICA, V209, P194, DOI 10.1159/000310612
   Thiele JR, 2014, CIRCULATION, V130, P35, DOI 10.1161/CIRCULATIONAHA.113.007124
   Thurman JM, 2013, J CLIN INVEST, V123, P2218, DOI 10.1172/JCI65861
   Toomey CB, 2015, P NATL ACAD SCI USA, V112, pE3040, DOI 10.1073/pnas.1424391112
   Triebwasser MP, 2015, INVEST OPHTH VIS SCI, V56, P6873, DOI 10.1167/iovs.15-17432
   Tserentsoodol N, 2006, MOL VIS, V12, P1319
   Tserentsoodol N, 2006, MOL VIS, V12, P1306
   Ufret-Vincenty RL, 2010, INVEST OPHTH VIS SCI, V51, P5878, DOI 10.1167/iovs.09-4457
   Varma R, 2004, OPHTHALMOLOGY, V111, P1288, DOI 10.1016/j.ophtha.2004.01.023
   VATER CA, 1979, BIOCHEM J, V181, P639, DOI 10.1042/bj1810639
   Veyradier A, 2003, J PEDIATR-US, V142, P310, DOI 10.1067/mpd.2003.79
   Vingerling JR, 1996, ARCH OPHTHALMOL-CHIC, V114, P1193, DOI 10.1001/archopht.1996.01100140393005
   Volanakis JE, 2001, MOL IMMUNOL, V38, P189, DOI 10.1016/S0161-5890(01)00042-6
   von Leithner PL, 2009, AM J PATHOL, V175, P412, DOI 10.2353/ajpath.2009.080927
   Wang AL, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005304
   Wang L, 2009, INVEST OPHTH VIS SCI, V50, P870, DOI 10.1167/iovs.08-2376
   Wang L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010329
   Weeks DE, 2004, AM J HUM GENET, V75, P174, DOI 10.1086/422476
   Weismann D, 2011, NATURE, V478, P76, DOI 10.1038/nature10449
   Whitmore SS, 2015, PROG RETIN EYE RES, V45, P1, DOI 10.1016/j.preteyeres.2014.11.005
   WOLTER JR, 1962, ARCH OPHTHALMOL-CHIC, V68, P219
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Woodell A, 2016, INVEST OPHTH VIS SCI, V57, P1728, DOI 10.1167/iovs.15-18471
   Woodell A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067894
   Yang P, 2009, INVEST OPHTH VIS SCI, V50, P3473, DOI 10.1167/iovs.08-3202
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Ying LH, 1999, AM J HUM GENET, V65, P1538, DOI 10.1086/302673
   Yu Y, 2014, HUM MOL GENET, V23, P5283, DOI 10.1093/hmg/ddu226
   Zipfel PF, 2009, NAT REV IMMUNOL, V9, P729, DOI 10.1038/nri2620
   Zipfel PF, 2001, INT IMMUNOPHARMACOL, V1, P461, DOI 10.1016/S1567-5769(00)00047-3
   Zipfel PF, 2001, TRENDS IMMUNOL, V22, P345, DOI 10.1016/S1471-4906(01)01972-X
NR 233
TC 69
Z9 72
U1 2
U2 17
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 1350-9462
EI 1873-1635
J9 PROG RETIN EYE RES
JI Prog. Retin. Eye Res.
PD JAN
PY 2018
VL 62
BP 38
EP 57
DI 10.1016/j.preteyeres.2017.09.001
PG 20
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA FV6WP
UT WOS:000424723100003
PM 28928087
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Fan, WP
   Huang, P
   Chen, XY
AF Fan, Wenpei
   Huang, Peng
   Chen, Xiaoyuan
TI Overcoming the Achilles' heel of photodynamic therapy
SO CHEMICAL SOCIETY REVIEWS
LA English
DT Review
ID UP-CONVERSION NANOPARTICLES; MESOPOROUS SILICA NANOPARTICLES; SINGLET
   OXYGEN GENERATION; INTRANUCLEAR DRUG-DELIVERY; RESONANCE
   ENERGY-TRANSFER; IN-VITRO DEMONSTRATION; X-RAY LUMINESCENCE; 2-PHOTON
   ABSORPTION; INDOCYANINE-GREEN; CANCER-CELLS
AB Photodynamic therapy (PDT) has been applied to treat a wide range of medical conditions, including wet age-related macular degeneration psoriasis, atherosclerosis, viral infection and malignant cancers. However, the tissue penetration limitation of excitation light hinders the widespread clinical use of PDT. To overcome this "Achilles'heel'', deep PDT, a novel type of phototherapy, has been developed for the efficient treatment of deep-seated diseases. Based on the different excitation sources, including near-infrared (NIR) light, X-ray radiation, and internal self-luminescence, a series of deep PDT techniques have been explored to demonstrate the advantages of deep cancer therapy over conventional PDT excited by ultraviolet-visible (UV-Vis) light. In particular, the featured applications of deep PDT, such as organelle-targeted deep PDT, hypoxic deep PDT and deep PDT-involved multimodal synergistic therapy are discussed. Finally, the future development and potential challenges of deep PDT are also elucidated for clinical translation. It is highly expected that deep PDT will be developed as a versatile, depth/oxygen-independent and minimally invasive strategy for treating a variety of malignant tumours at deep locations.
C1 [Fan, Wenpei; Huang, Peng] Shenzhen Univ, Sch Med, Dept Biomed Engn, Guangdong Key Lab Biomed Measurements & Ultrasoun, Shenzhen 518060, Peoples R China.
   [Fan, Wenpei] Shenzhen Univ, Coll Optoelect Engn, Key Lab Optoelect Devices & Syst, Minist Educ & Guangdong Prov, Shenzhen 518060, Peoples R China.
   [Fan, Wenpei; Chen, Xiaoyuan] Natl Inst Biomed Imaging & Bioengn, Lab Mol Imaging & Nanomed, NIH, Bethesda, MD 20892 USA.
C3 Shenzhen University; Shenzhen University; National Institutes of Health
   (NIH) - USA; NIH National Institute of Biomedical Imaging &
   Bioengineering (NIBIB)
RP Huang, P (通讯作者)，Shenzhen Univ, Sch Med, Dept Biomed Engn, Guangdong Key Lab Biomed Measurements & Ultrasoun, Shenzhen 518060, Peoples R China.; Chen, XY (通讯作者)，Natl Inst Biomed Imaging & Bioengn, Lab Mol Imaging & Nanomed, NIH, Bethesda, MD 20892 USA.
EM peng.huang@szu.edu.cn; shawn.chen@nih.gov
RI Huang, Peng/R-2480-2016; Chen, Xiaoyuan/D-1860-2014
OI Huang, Peng/0000-0003-3651-7813; Chen, Xiaoyuan/0000-0002-9622-0870
FU Shenzhen University; National Science Foundation of China [81401465,
   51573096, 51602203]; Postdoctoral Science Foundation of China
   [2016M590808]; Intramural Research Program (IRP) of the NIBIB, NIH
FX This project is financially supported by the startup fund from the
   Shenzhen University, the National Science Foundation of China (81401465,
   51573096, 51602203), the Postdoctoral Science Foundation of China
   (2016M590808), and the Intramural Research Program (IRP) of the NIBIB,
   NIH.
CR Agostinis P, 2011, CA-CANCER J CLIN, V61, P250, DOI 10.3322/caac.20114
   Al Zaki A, 2014, ACS NANO, V8, P104, DOI 10.1021/nn405701q
   Allison RR, 2010, PHOTODIAGN PHOTODYN, V7, P61, DOI 10.1016/j.pdpdt.2010.02.001
   Arnbjerg J, 2007, J AM CHEM SOC, V129, P5188, DOI 10.1021/ja0688777
   Balaz M, 2009, ORG BIOMOL CHEM, V7, P874, DOI 10.1039/b814789b
   Barolet D, 2008, SEMIN CUTAN MED SURG, V27, P227, DOI 10.1016/j.sder.2008.08.003
   Barth BM, 2011, ACS NANO, V5, P5325, DOI 10.1021/nn2005766
   Bashkatov AN, 2005, J PHYS D APPL PHYS, V38, P2543, DOI 10.1088/0022-3727/38/15/004
   Baumler W, 1999, BRIT J CANCER, V80, P360, DOI 10.1038/sj.bjc.6690363
   Bessiere A, 2014, CHEM MATER, V26, P1365, DOI 10.1021/cm403050q
   Bisland SK, 1999, BIOCONJUGATE CHEM, V10, P982, DOI 10.1021/bc990020u
   Brancaleon L, 2002, LASER MED SCI, V17, P173, DOI 10.1007/s101030200027
   BROWN JM, 1993, BRIT J CANCER, V67, P1163, DOI 10.1038/bjc.1993.220
   Bulin AL, 2013, J PHYS CHEM C, V117, P21583, DOI 10.1021/jp4077189
   Cai XJ, 2015, ADV MATER, V27, P6382, DOI 10.1002/adma.201503381
   Cao X, 2015, ACS APPL MATER INTER, V7, P11775, DOI 10.1021/acsami.5b00432
   CARPENTER S, 1994, P NATL ACAD SCI USA, V91, P12273, DOI 10.1073/pnas.91.25.12273
   Castano AP, 2005, PHOTODIAGN PHOTODYN, V2, P91, DOI 10.1016/S1572-1000(05)00060-8
   Castano AP, 2004, PHOTODIAGN PHOTODYN, V1, P279, DOI 10.1016/S1572-1000(05)00007-4
   Chen D, 2009, ADV MATER, V21, P3804, DOI 10.1002/adma.200900599
   Chen F, 2012, CHEM-EUR J, V18, P7082, DOI 10.1002/chem.201103611
   Chen F, 2011, ADV FUNCT MATER, V21, P4285, DOI 10.1002/adfm.201101663
   Chen GY, 2015, CHEM SOC REV, V44, P1680, DOI 10.1039/c4cs00170b
   Chen GY, 2014, CHEM REV, V114, P5161, DOI 10.1021/cr400425h
   Chen GY, 2012, ACS NANO, V6, P8280, DOI 10.1021/nn302972r
   Chen GY, 2010, ACS NANO, V4, P3163, DOI 10.1021/nn100457j
   Chen HM, 2015, NANO LETT, V15, P2249, DOI 10.1021/nl504044p
   Chen H, 2013, ACS NANO, V7, P1178, DOI 10.1021/nn304369m
   Chen HB, 2014, J AM CHEM SOC, V136, P157, DOI 10.1021/ja406992w
   Chen HC, 2015, J AM CHEM SOC, V137, P1539, DOI 10.1021/ja511420n
   Chen NT, 2014, THERANOSTICS, V4, P798, DOI 10.7150/thno.8934
   Chen Q, 2014, BIOMATERIALS, V35, P2915, DOI 10.1016/j.biomaterials.2013.12.046
   Chen TC, 2012, PROCESS BIOCHEM, V47, P1903, DOI 10.1016/j.procbio.2012.06.025
   Chen XL, 2015, DYES PIGMENTS, V114, P93, DOI 10.1016/j.dyepig.2014.11.002
   Chen X, 2015, ADV FUNCT MATER, V25, P5462, DOI 10.1002/adfm.201502419
   Chen Y, 2013, ADV MATER, V25, P3144, DOI 10.1002/adma.201205292
   Chen Y, 2012, BIOMATERIALS, V33, P2388, DOI 10.1016/j.biomaterials.2011.11.086
   Chen Y, 2012, BIOMATERIALS, V33, P7126, DOI 10.1016/j.biomaterials.2012.06.059
   Cheng L, 2014, BIOMATERIALS, V35, P9844, DOI 10.1016/j.biomaterials.2014.09.004
   Cheng LA, 2011, J PHYS CHEM C, V115, P2686, DOI 10.1021/jp111006z
   Cheng SH, 2011, NANO TODAY, V6, P552, DOI 10.1016/j.nantod.2011.10.003
   Chou KL, 2013, J MATER CHEM B, V1, P4584, DOI 10.1039/c3tb20928h
   Clement S, 2016, SCI REP-UK, V6, DOI 10.1038/srep19954
   Couleaud P, 2010, NANOSCALE, V2, P1083, DOI 10.1039/c0nr00096e
   Cui SS, 2013, ACS NANO, V7, P676, DOI 10.1021/nn304872n
   Dai X, 2015, ADV DRUG DELIVER REV, V81, P184, DOI 10.1016/j.addr.2014.09.010
   de Chermont QL, 2007, P NATL ACAD SCI USA, V104, P9266, DOI 10.1073/pnas.0702427104
   DeRosa MC, 2002, COORDIN CHEM REV, V233, P351, DOI 10.1016/S0010-8545(02)00034-6
   Derycke ASL, 2004, ADV DRUG DELIVER REV, V56, P17, DOI 10.1016/j.addr.2003.07.014
   Dichtel WR, 2004, J AM CHEM SOC, V126, P5380, DOI 10.1021/ja031647x
   Dou QQ, 2015, SCI REP-UK, V5, DOI 10.1038/srep08252
   Duan XP, 2013, ACS NANO, V7, P5858, DOI 10.1021/nn4010796
   Durr NJ, 2007, NANO LETT, V7, P941, DOI 10.1021/nl062962v
   Elmenoufy AH, 2015, CHEM COMMUN, V51, P12247, DOI 10.1039/c5cc04135j
   Ethirajan M, 2011, CHEM SOC REV, V40, P340, DOI 10.1039/b915149b
   Fan WP, 2015, ANGEW CHEM INT EDIT, V54, P14026, DOI 10.1002/anie.201504536
   Fan WP, 2015, BIOMATERIALS, V69, P89, DOI 10.1016/j.biomaterials.2015.08.017
   Fan WP, 2015, ADV MATER, V27, P4155, DOI 10.1002/adma.201405141
   Fan WP, 2014, BIOMATERIALS, V35, P8992, DOI 10.1016/j.biomaterials.2014.07.024
   Feng W, 2013, ADV MATER, V25, P5287, DOI 10.1002/adma.201301946
   Fickweiler S, 1997, J PHOTOCH PHOTOBIO B, V38, P178, DOI 10.1016/S1011-1344(96)07453-2
   FIREY PA, 1987, PHOTOCHEM PHOTOBIOL, V45, P535, DOI 10.1111/j.1751-1097.1987.tb05414.x
   FOOTE CS, 1991, PHOTOCHEM PHOTOBIOL, V54, P659, DOI 10.1111/j.1751-1097.1991.tb02071.x
   Fowley C, 2013, CHEM COMMUN, V49, P8934, DOI 10.1039/c3cc45181j
   Fowley C, 2012, J MATER CHEM, V22, P6456, DOI 10.1039/c2jm00096b
   Frederiksen PK, 2005, J AM CHEM SOC, V127, P255, DOI 10.1021/ja0452020
   Gai SL, 2014, CHEM REV, V114, P2343, DOI 10.1021/cr4001594
   Gao D, 2006, NANO LETT, V6, P2383, DOI 10.1021/nl0617179
   Gao L, 2012, ACS NANO, V6, P8030, DOI 10.1021/nn302634m
   Gao Y, 2011, ACS NANO, V5, P9788, DOI 10.1021/nn2033105
   Gary-Bobo M, 2012, INT J PHARMACEUT, V423, P509, DOI 10.1016/j.ijpharm.2011.11.045
   Gary-Bobo M, 2011, ANGEW CHEM INT EDIT, V50, P11425, DOI 10.1002/anie.201104765
   Ge YL, 2013, RSC ADV, V3, P12839, DOI 10.1039/c3ra41647j
   Gu ZJ, 2013, ADV MATER, V25, P3758, DOI 10.1002/adma.201301197
   Guo M, 2014, BIOMATERIALS, V35, P4656, DOI 10.1016/j.biomaterials.2014.02.018
   Guo WS, 2015, ACS NANO, V9, P488, DOI 10.1021/nn505660r
   Hainfeld JF, 2008, J PHARM PHARMACOL, V60, P977, DOI 10.1211/jpp.60.8.0005
   Han K, 2015, ACS NANO, V9, P10268, DOI 10.1021/acsnano.5b04243
   Hatz S, 2007, PHOTOCH PHOTOBIO SCI, V6, P1106, DOI 10.1039/b707313e
   He CB, 2015, ACS NANO, V9, P991, DOI 10.1021/nn506963h
   He GS, 2008, CHEM REV, V108, P1245, DOI 10.1021/cr050054x
   He M, 2011, ADV FUNCT MATER, V21, P4470, DOI 10.1002/adfm.201101040
   He QJ, 2011, BIOMATERIALS, V32, P7711, DOI 10.1016/j.biomaterials.2011.06.066
   He XX, 2009, BIOMATERIALS, V30, P5601, DOI 10.1016/j.biomaterials.2009.06.030
   Hervella P, 2008, J BIOMED NANOTECHNOL, V4, P276, DOI 10.1166/jbn.2008.339
   Hockel M, 1996, CANCER RES, V56, P4509
   Hofman JW, 2008, PHARM RES-DORDR, V25, P2065, DOI 10.1007/s11095-008-9590-7
   Hogle William P, 2006, Semin Oncol Nurs, V22, P212, DOI 10.1016/j.soncn.2006.07.004
   Hou BB, 2015, J MATER CHEM B, V3, P3531, DOI 10.1039/c5tb00240k
   Hou ZY, 2015, ACS NANO, V9, P2584, DOI 10.1021/nn506107c
   Hsu CY, 2013, BIOMATERIALS, V34, P1204, DOI 10.1016/j.biomaterials.2012.08.044
   Hu H, 2014, BIOMATERIALS, V35, P9868, DOI 10.1016/j.biomaterials.2014.08.038
   Hu ZH, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8560
   Huang P, 2015, ACS NANO, V9, P9517, DOI 10.1021/acsnano.5b03874
   Huang Peng, 2013, Angew Chem Int Ed Engl, V52, P13958, DOI 10.1002/anie.201308986
   Huang P, 2014, ADV MATER, V26, P6401, DOI 10.1002/adma.201400914
   Huang P, 2014, J AM CHEM SOC, V136, P8307, DOI 10.1021/ja503115n
   Huang P, 2013, BIOMATERIALS, V34, P4643, DOI 10.1016/j.biomaterials.2013.02.063
   Huang P, 2012, ADV MATER, V24, P5104, DOI 10.1002/adma.201200650
   Huang P, 2011, BIOMATERIALS, V32, P9796, DOI 10.1016/j.biomaterials.2011.08.086
   Huang P, 2011, THERANOSTICS, V1, P240, DOI 10.7150/thno/v01p0240
   Huang P, 2011, BIOMATERIALS, V32, P3447, DOI 10.1016/j.biomaterials.2011.01.032
   Huang Z, 2005, LASER SURG MED, V36, P390, DOI 10.1002/lsm.20177
   Ichikawa K, 2004, CANCER LETT, V205, P39, DOI 10.1016/j.canlet.2003.10.001
   Idris NM, 2014, J MATER CHEM B, V2, P7017, DOI 10.1039/c4tb01169d
   Idris NM, 2012, NAT MED, V18, P1580, DOI 10.1038/nm.2933
   Idris NM, 2009, BIOMATERIALS, V30, P5104, DOI 10.1016/j.biomaterials.2009.05.062
   Imura K, 2009, J PHYS CHEM C, V113, P11756, DOI 10.1021/jp9018074
   Iohara D, 2012, J PHARM SCI-US, V101, P3390, DOI 10.1002/jps.23045
   Ishi-I T, 2007, J MATER CHEM, V17, P3341, DOI 10.1039/b704499b
   Jacques SL, 2013, PHYS MED BIOL, V58, pR37, DOI 10.1088/0031-9155/58/11/R37
   Jain PK, 2006, J PHYS CHEM B, V110, P7238, DOI 10.1021/jp057170o
   Janczyk A, 2006, J AM CHEM SOC, V128, P15574, DOI 10.1021/ja065970m
   Jiang BP, 2014, J MATER CHEM B, V2, P7141, DOI 10.1039/c4tb01038h
   Jin CS, 2013, ACS NANO, V7, P2541, DOI 10.1021/nn3058642
   Jin S, 2013, NANOSCALE, V5, P11910, DOI 10.1039/c3nr03515h
   Josefsen LB, 2012, THERANOSTICS, V2, P916, DOI 10.7150/thno.4571
   KAISER W, 1961, PHYS REV LETT, V7, P229, DOI 10.1103/PhysRevLett.7.229
   Kalluru P, 2013, ANGEW CHEM INT EDIT, V52, P12332, DOI 10.1002/anie.201307358
   Kamkaew A, 2013, CHEM SOC REV, V42, P77, DOI 10.1039/c2cs35216h
   Kang Z, 2015, NANO RES, V8, P2004, DOI 10.1007/s12274-015-0712-3
   Kantonis G, 2007, J PHOTOCH PHOTOBIO A, V185, P62, DOI 10.1016/j.jphotochem.2006.05.012
   Karnkaew A, 2016, ACS NANO, V10, P3918, DOI 10.1021/acsnano.6b01401
   Karotki A, 2006, PHOTOCHEM PHOTOBIOL, V82, P443, DOI 10.1562/2005-08-24-RA-657
   Karunakaran SC, 2013, ACS CHEM BIOL, V8, P127, DOI 10.1021/cb3004622
   Kascakova S, 2015, NANO RES, V8, P2373, DOI 10.1007/s12274-015-0747-5
   Khurana M, 2007, PHOTOCHEM PHOTOBIOL, V83, P1441, DOI 10.1111/j.1751-1097.2007.00185.x
   Kim S, 2007, J AM CHEM SOC, V129, P2669, DOI 10.1021/ja0680257
   Kim S, 2009, J PHYS CHEM C, V113, P12641, DOI 10.1021/jp900573s
   Kim YR, 2015, THERANOSTICS, V5, P805, DOI 10.7150/thno.11520
   Kojima C, 2007, BIOCONJUGATE CHEM, V18, P663, DOI 10.1021/bc060244u
   Koo H, 2010, CHEM COMMUN, V46, P5668, DOI 10.1039/c0cc01413c
   Kotagiri N, 2015, NAT NANOTECHNOL, V10, P370, DOI [10.1038/NNAN0.2015.17, 10.1038/nnano.2015.17]
   Kotagiri N, 2013, ANGEW CHEM INT EDIT, V52, P7756, DOI 10.1002/anie.201302564
   Kuang YY, 2011, J AM CHEM SOC, V133, P19278, DOI 10.1021/ja2073824
   Kunjachan S, 2015, CHEM REV, V115, P10907, DOI 10.1021/cr500314d
   Lagopati N, 2010, J PHOTOCH PHOTOBIO A, V214, P215, DOI 10.1016/j.jphotochem.2010.06.031
   Lee N, 2013, ADV MATER, V25, P2641, DOI 10.1002/adma.201300081
   Li LL, 2010, ACS NANO, V4, P6874, DOI 10.1021/nn100918a
   Li Y, 2012, ACS NANO, V6, P5164, DOI 10.1021/nn300934k
   Li YS, 2014, ADV MATER, V26, P3176, DOI 10.1002/adma.201305319
   Li Z, 2015, PHOTOCH PHOTOBIO SCI, V14, P1197, DOI 10.1039/c5pp00097a
   Li ZM, 2010, MOL PHARMACEUT, V7, P94, DOI 10.1021/mp9001415
   Lim HJ, 2011, PHOTODIAGN PHOTODYN, V8, P337, DOI 10.1016/j.pdpdt.2011.06.002
   Lin J, 2016, ADV MATER, V28, P3273, DOI 10.1002/adma.201505700
   Lin J, 2013, ACS NANO, V7, P5320, DOI 10.1021/nn4011686
   Liu HL, 2016, ADV FUNCT MATER, V26, P2561, DOI 10.1002/adfm.201504939
   Liu JN, 2012, BIOMATERIALS, V33, P7282, DOI 10.1016/j.biomaterials.2012.06.035
   Liu JP, 2015, BIOMATERIALS, V56, P140, DOI 10.1016/j.biomaterials.2015.04.002
   Liu K, 2012, ACS NANO, V6, P4054, DOI 10.1021/nn300436b
   Liu XM, 2013, CHEM COMMUN, V49, P3224, DOI 10.1039/c3cc41013g
   Liu YL, 2012, ANGEW CHEM INT EDIT, V51, P1437, DOI 10.1002/anie.201106686
   Liu YY, 2015, ANGEW CHEM INT EDIT, V54, P8105, DOI 10.1002/anie.201500478
   Liu YY, 2015, BIOMATERIALS, V49, P1, DOI 10.1016/j.biomaterials.2015.01.028
   Liu YS, 2013, CHEM SOC REV, V42, P6924, DOI 10.1039/c3cs60060b
   Liu YS, 2008, J APPL PHYS, V104, DOI 10.1063/1.2966456
   Liu YF, 2008, J APPL PHYS, V103, DOI 10.1063/1.2890148
   Lopez-Lazaro M, 2006, FASEB J, V20, P828, DOI 10.1096/fj.05-5168hyp
   Lucky SS, 2015, ACS NANO, V9, P191, DOI 10.1021/nn503450t
   Luo SL, 2011, BIOMATERIALS, V32, P7127, DOI 10.1016/j.biomaterials.2011.06.024
   Lv RC, 2015, CHEM MATER, V27, P1751, DOI 10.1021/cm504566f
   Lv RC, 2015, ACS NANO, V9, P1630, DOI 10.1021/nn5063613
   Ma L, 2014, APPL PHYS LETT, V105, DOI 10.1063/1.4890105
   Ma L, 2014, J MATER CHEM C, V2, P4239, DOI 10.1039/c4tc00114a
   Ma L, 2010, NANOTECHNOLOGY, V21, DOI 10.1088/0957-4484/21/38/385604
   Ma X, 2015, ACS APPL MATER INTER, V7, P10671, DOI 10.1021/acsami.5b03087
   MacDonald IJ, 2001, J PORPHYR PHTHALOCYA, V5, P105, DOI 10.1002/jpp.328
   Mang TS, 2004, PHOTODIAGN PHOTODYN, V1, P43, DOI 10.1016/S1572-1000(04)00012-2
   Mitrasinovic PM, 2008, CURR RADIOPHARM, V1, P22, DOI 10.2174/1874471010801010022
   MOAN J, 1985, CANCER RES, V45, P1608
   Montazerabadi AR, 2012, J PHOTOCH PHOTOBIO B, V109, P42, DOI 10.1016/j.jphotobiol.2012.01.004
   Moore TL, 2014, ADV FUNCT MATER, V24, P5815, DOI 10.1002/adfm.201400949
   Morgan J, 2001, ADV DRUG DELIVER REV, V49, P71, DOI 10.1016/S0169-409X(01)00126-0
   MOULDER JE, 1987, CANCER METAST REV, V5, P313, DOI 10.1007/BF00055376
   Muli DK, 2014, BIOORG MED CHEM LETT, V24, P4496, DOI 10.1016/j.bmcl.2014.07.082
   Muthu MS, 2014, THERANOSTICS, V4, P660, DOI 10.7150/thno.8698
   Namiki Y, 2011, ACCOUNTS CHEM RES, V44, P1080, DOI 10.1021/ar200011r
   Nishiyama N, 2009, ADV DRUG DELIVER REV, V61, P327, DOI 10.1016/j.addr.2009.01.004
   O'Connor AE, 2009, PHOTOCHEM PHOTOBIOL, V85, P1053, DOI 10.1111/j.1751-1097.2009.00585.x
   Ogawa K, 2006, J MED CHEM, V49, P2276, DOI 10.1021/jm051072+
   Ogawa K, 2005, J PHYS CHEM B, V109, P22003, DOI 10.1021/jp054444z
   Ogawa K, 2003, J AM CHEM SOC, V125, P13356, DOI 10.1021/ja035056i
   Ogawa K, 2009, ORG BIOMOL CHEM, V7, P2241, DOI 10.1039/b901422e
   Pan LM, 2013, BIOMATERIALS, V34, P2719, DOI 10.1016/j.biomaterials.2012.12.040
   Pan LM, 2012, J AM CHEM SOC, V134, P5722, DOI 10.1021/ja211035w
   Pan XB, 2015, COLLOID SURFACE B, V130, P292, DOI 10.1016/j.colsurfb.2015.04.028
   Pan ZW, 2012, NAT MATER, V11, P58, DOI [10.1038/NMAT3173, 10.1038/nmat3173]
   Park YI, 2015, CHEM SOC REV, V44, P1302, DOI 10.1039/c4cs00173g
   Park Y, 2012, ADV MATER, V24, P5755, DOI 10.1002/adma.201202433
   Paszko E, 2011, PHOTODIAGN PHOTODYN, V8, P14, DOI 10.1016/j.pdpdt.2010.12.001
   Paudel HP, 2011, J PHYS CHEM C, V115, P19028, DOI 10.1021/jp206053f
   Pawlicki M, 2009, ANGEW CHEM INT EDIT, V48, P3244, DOI 10.1002/anie.200805257
   Plaetzer K, 2009, LASER MED SCI, V24, P259, DOI 10.1007/s10103-008-0539-1
   Prasad P, 2014, ACS NANO, V8, P3202, DOI 10.1021/nn405773r
   Punjabi A, 2014, ACS NANO, V8, P10621, DOI 10.1021/nn505051d
   Qi ZD, 2011, J MATER CHEM, V21, P2455, DOI 10.1039/c0jm03229h
   Qian HS, 2009, SMALL, V5, P2285, DOI 10.1002/smll.200900692
   Qiao XF, 2012, NANOSCALE, V4, P4611, DOI 10.1039/c2nr30938f
   Rong PF, 2015, NANOSCALE, V7, P16330, DOI 10.1039/c5nr04428f
   Rosenkranz AA, 2000, IMMUNOL CELL BIOL, V78, P452, DOI 10.1046/j.1440-1711.2000.00925.x
   Rozhkova EA, 2009, NANO LETT, V9, P3337, DOI 10.1021/nl901610f
   Saboktakin M, 2012, ACS NANO, V6, P8758, DOI 10.1021/nn302466r
   Samia ACS, 2003, J AM CHEM SOC, V125, P15736, DOI 10.1021/ja0386905
   Saxena V, 2006, INT J PHARMACEUT, V308, P200, DOI 10.1016/j.ijpharm.2005.11.003
   Scaffidi JP, 2011, ACS NANO, V5, P4679, DOI 10.1021/nn200511m
   Schietinger S, 2010, NANO LETT, V10, P134, DOI 10.1021/nl903046r
   Schmitt J, 2015, ANGEW CHEM INT EDIT, V54, P169, DOI 10.1002/anie.201407537
   Secret E, 2014, ADV MATER, V26, P7643, DOI 10.1002/adma.201403415
   Seong DY, 2015, J PHOTOCH PHOTOBIO B, V146, P34, DOI 10.1016/j.jphotobiol.2015.02.022
   Shan JN, 2011, ADV FUNCT MATER, V21, P2488, DOI 10.1002/adfm.201002516
   Sharman WM, 2004, ADV DRUG DELIVER REV, V56, P53, DOI 10.1016/j.addr.2003.08.015
   Sharman WM, 1999, DRUG DISCOV TODAY, V4, P507, DOI 10.1016/S1359-6446(99)01412-9
   Shemesh CS, 2015, PHARM RES-DORDR, V32, P1604, DOI 10.1007/s11095-014-1560-7
   Shen JN, 2011, NANOSCALE, V3, P4314, DOI 10.1039/c1nr10580a
   Shen J, 2013, ADV DRUG DELIVER REV, V65, P744, DOI 10.1016/j.addr.2012.05.007
   Shi SK, 2012, J MATER CHEM, V22, P23461, DOI 10.1039/c2jm34950g
   Simpson CR, 1998, PHYS MED BIOL, V43, P2465, DOI 10.1088/0031-9155/43/9/003
   Song JB, 2015, ACCOUNTS CHEM RES, V48, P2506, DOI 10.1021/acs.accounts.5b00059
   Spinelli AE, 2015, PHYS MEDICA, V31, P120, DOI 10.1016/j.ejmp.2014.12.003
   Spyratou E, 2012, CANCER LETT, V327, P111, DOI 10.1016/j.canlet.2011.12.039
   Starkewolf ZB, 2013, CHEM COMMUN, V49, P2545, DOI 10.1039/c3cc38100e
   Starkey JR, 2008, CLIN CANCER RES, V14, P6564, DOI 10.1158/1078-0432.CCR-07-4162
   Starkey JR, 2013, BBA-GEN SUBJECTS, V1830, P4594, DOI 10.1016/j.bbagen.2013.05.043
   Sudheendra L, 2014, CHEM MATER, V26, P1881, DOI 10.1021/cm404044n
   Sun Y, 2013, ACS NANO, V7, P11290, DOI 10.1021/nn405082y
   SZATROWSKI TP, 1991, CANCER RES, V51, P794
   Tanabe K, 2012, BIOORG MED CHEM LETT, V22, P7045, DOI 10.1016/j.bmcl.2012.09.090
   Tanabe K, 2012, BIOCONJUGATE CHEM, V23, P1909, DOI 10.1021/bc3002985
   Tang CQ, 2015, DYES PIGMENTS, V117, P7, DOI 10.1016/j.dyepig.2015.01.019
   Tang YH, 2015, ADV FUNCT MATER, V25, P1024, DOI 10.1002/adfm.201402930
   Tang YG, 2015, ACS APPL MATER INTER, V7, P12261, DOI 10.1021/acsami.5b03067
   Taratula O, 2013, MOL PHARMACEUT, V10, P3946, DOI 10.1021/mp400397t
   Terenziani F, 2008, ADV MATER, V20, P4641, DOI 10.1002/adma.200800402
   Theodossiou T, 2003, CANCER RES, V63, P1818
   Tian B, 2011, ACS NANO, V5, P7000, DOI 10.1021/nn201560b
   Tian G, 2015, ADV MATER, V27, P7692, DOI 10.1002/adma.201503280
   Tian G, 2013, SMALL, V9, P1929, DOI 10.1002/smll.201201437
   Tian G, 2012, ADV MATER, V24, P1226, DOI 10.1002/adma.201104741
   Tian JW, 2013, J AM CHEM SOC, V135, P18850, DOI 10.1021/ja408286k
   Triesscheijn M, 2006, ONCOLOGIST, V11, P1034, DOI 10.1634/theoncologist.11-9-1034
   Tu HL, 2009, ADV MATER, V21, P172, DOI 10.1002/adma.200800548
   Ullah MF, 2008, ASIAN PAC J CANCER P, V9, P1
   van Nostrum CF, 2004, ADV DRUG DELIVER REV, V56, P9, DOI 10.1016/j.addr.2003.07.013
   Vankayala R, 2015, ADV FUNCT MATER, V25, P5934, DOI 10.1002/adfm.201502650
   Vankayala R, 2014, BIOMATERIALS, V35, P5527, DOI 10.1016/j.biomaterials.2014.03.065
   Vankayala R, 2014, SMALL, V10, P1612, DOI 10.1002/smll.201302719
   Vankayala R, 2011, ANGEW CHEM INT EDIT, V50, P10640, DOI 10.1002/anie.201105236
   Vaupel P, 2001, MED ONCOL, V18, P243, DOI 10.1385/MO:18:4:243
   Vijayaraghavan P, 2014, ADV MATER, V26, P6689, DOI 10.1002/adma.201400703
   Voon SH, 2014, SMALL, V10, P4993, DOI 10.1002/smll.201401416
   Wan H, 2015, ACS APPL MATER INTER, V7, P9608, DOI 10.1021/acsami.5b01165
   Wang C, 2013, ADV FUNCT MATER, V23, P3077, DOI 10.1002/adfm.201202992
   Wang C, 2013, THERANOSTICS, V3, P317, DOI 10.7150/thno.5284
   Wang C, 2011, BIOMATERIALS, V32, P6145, DOI 10.1016/j.biomaterials.2011.05.007
   Wang C, 2011, MOL BIOL REP, V38, P523, DOI 10.1007/s11033-010-0136-9
   Wang D, 2015, NANOSCALE, V7, P190, DOI 10.1039/c4nr04953e
   Wang F, 2010, ANGEW CHEM INT EDIT, V49, P7456, DOI 10.1002/anie.201003959
   Wang HJ, 2014, ACS APPL MATER INTER, V6, P3219, DOI 10.1021/am500097f
   Wang HF, 2005, P NATL ACAD SCI USA, V102, P15752, DOI 10.1073/pnas.0504892102
   Wang J, 2012, ACS NANO, V6, P5070, DOI 10.1021/nn300694v
   Wang L, 2014, NANOSCALE, V6, P4642, DOI 10.1039/c3nr06835h
   Wang M, 2014, NANOSCALE, V6, P8274, DOI 10.1039/c4nr01826e
   Wang M, 2012, J MED CHEM, V55, P4274, DOI 10.1021/jm3000664
   Wang SJ, 2013, ADV MATER, V25, P3055, DOI 10.1002/adma.201204623
   Wang YH, 2013, BIOMATERIALS, V34, P7715, DOI 10.1016/j.biomaterials.2013.06.045
   Wang ZT, 2016, ACS NANO, V10, P3453, DOI 10.1021/acsnano.5b07521
   Wang ZG, 2015, CHEM COMMUN, V51, P11587, DOI 10.1039/c5cc04376j
   Wen AM, 2012, CHEM COMMUN, V48, P9044, DOI 10.1039/c2cc34695h
   WILSON BC, 1985, PHOTOCHEM PHOTOBIOL, V42, P153, DOI 10.1111/j.1751-1097.1985.tb01554.x
   Wohrle D, 1998, RUSS CHEM B+, V47, P807, DOI 10.1007/BF02498146
   Xia L, 2014, BIOMATERIALS, V35, P4146, DOI 10.1016/j.biomaterials.2014.01.068
   Xiao QF, 2013, J AM CHEM SOC, V135, P13041, DOI 10.1021/ja404985w
   Xiao QF, 2012, BIOMATERIALS, V33, P7530, DOI 10.1016/j.biomaterials.2012.06.028
   Xie J, 2010, ADV DRUG DELIVER REV, V62, P1064, DOI 10.1016/j.addr.2010.07.009
   Xing HY, 2013, SCI REP-UK, V3, DOI 10.1038/srep01751
   Xu JS, 2014, SMALL, V10, P3750, DOI 10.1002/smll.201400437
   Xu YD, 2012, J NUCL MED, V53, P312, DOI 10.2967/jnumed.111.094623
   Yaghini E, 2009, NANOMEDICINE-UK, V4, P353, DOI 10.2217/NNM.09.9
   Yan XF, 2015, NANOSCALE, V7, P2520, DOI 10.1039/c4nr06868h
   Yan XF, 2015, BIOMATERIALS, V42, P94, DOI 10.1016/j.biomaterials.2014.11.040
   Yang CN, 2014, ANALYST, V139, P6414, DOI 10.1039/c4an01642d
   Yang K, 2013, CHEM SOC REV, V42, P530, DOI 10.1039/c2cs35342c
   Yang K, 2012, ADV MATER, V24, P1868, DOI 10.1002/adma.201104964
   Yang K, 2010, NANO LETT, V10, P3318, DOI 10.1021/nl100996u
   Yang PP, 2012, CHEM SOC REV, V41, P3679, DOI 10.1039/c2cs15308d
   Yang YM, 2014, CHEM COMMUN, V50, P7287, DOI 10.1039/c4cc02376e
   Yang YM, 2012, ANGEW CHEM INT EDIT, V51, P3125, DOI 10.1002/anie.201107919
   Yang YN, 2015, NANOSCALE, V7, P11894, DOI 10.1039/c5nr02769a
   Yao XM, 2015, J MATER CHEM B, V3, P4707, DOI 10.1039/c5tb00256g
   Yermolayeva YV, 2011, RADIAT MEAS, V46, P551, DOI 10.1016/j.radmeas.2011.02.020
   Yi GS, 2007, CHEM MATER, V19, P341, DOI 10.1021/cm062447y
   Yong Y, 2014, NANOSCALE, V6, P10394, DOI 10.1039/c4nr02453b
   Yu Q, 2014, CHEM COMMUN, V50, P12150, DOI 10.1039/c4cc05867d
   Yu ZZ, 2015, ACS NANO, V9, P11064, DOI 10.1021/acsnano.5b04501
   Yuan HX, 2012, J AM CHEM SOC, V134, P13184, DOI 10.1021/ja304986t
   Yuan PY, 2012, NANOSCALE, V4, P5132, DOI [10.1039/c2nr31241g, 10.1039/c2nr31241]
   Zeng LY, 2015, BIOMATERIALS, V57, P93, DOI 10.1016/j.biomaterials.2015.04.006
   Zhan QQ, 2011, ACS NANO, V5, P3744, DOI 10.1021/nn200110j
   Zhang C, 2015, ANGEW CHEM INT EDIT, V54, P1770, DOI 10.1002/anie.201408472
   Zhang D, 2015, ACS APPL MATER INTER, V7, P8176, DOI 10.1021/acsami.5b01027
   Zhang L, 2015, BIOMATERIALS, V67, P323, DOI 10.1016/j.biomaterials.2015.07.037
   Zhang LE, 2015, BIOMATERIALS, V44, P82, DOI 10.1016/j.biomaterials.2014.12.040
   Zhang M, 2008, P NATL ACAD SCI USA, V105, P14773, DOI 10.1073/pnas.0801349105
   Zhang YR, 2014, ANAL CHEM, V86, P3092, DOI 10.1021/ac404201s
   Zhao JZ, 2013, CHEM SOC REV, V42, P5323, DOI 10.1039/c3cs35531d
   Zhao L, 2015, ACTA BIOMATER, V20, P155, DOI 10.1016/j.actbio.2015.03.036
   Zhao TT, 2014, ACS APPL MATER INTER, V6, P2700, DOI 10.1021/am405214w
   Zhao TT, 2012, NANOSCALE, V4, P7712, DOI 10.1039/c2nr32196c
   Zhao ZX, 2012, CHEM-ASIAN J, V7, P830, DOI 10.1002/asia.201100879
   Zhou AG, 2012, MOL PHARMACEUT, V9, P1580, DOI 10.1021/mp200590y
   Zhou J, 2015, CHEM REV, V115, P395, DOI 10.1021/cr400478f
   Zhou J, 2012, CHEM SOC REV, V41, P1323, DOI 10.1039/c1cs15187h
   Zhou J, 2011, BIOMATERIALS, V32, P1148, DOI 10.1016/j.biomaterials.2010.09.071
   Zhou L, 2013, BIOORG MED CHEM LETT, V23, P5317, DOI 10.1016/j.bmcl.2013.07.064
   Zhou L, 2012, J PHYS CHEM B, V116, P12744, DOI 10.1021/jp305137j
   Zijlstra P, 2009, NATURE, V459, P410, DOI 10.1038/nature08053
NR 316
TC 934
Z9 947
U1 91
U2 1114
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 0306-0012
EI 1460-4744
J9 CHEM SOC REV
JI Chem. Soc. Rev.
PY 2016
VL 45
IS 23
BP 6488
EP 6519
DI 10.1039/c6cs00616g
PG 32
WC Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Chemistry
GA EE1CJ
UT WOS:000389318100006
PM 27722560
HC Y
HP N
DA 2022-11-30
ER

PT J
AU Peptu, CA
   Popa, M
   Savin, C
   Popa, RF
   Ochiuz, L
AF Peptu, Catalina A.
   Popa, Marcel
   Savin, Corina
   Popa, Radu F.
   Ochiuz, Lacramioara
TI Modern Drug Delivery Systems for Targeting the Posterior Segment of the
   Eye
SO CURRENT PHARMACEUTICAL DESIGN
LA English
DT Article
DE Drug delivery; posterior segment of the eye; micro- and nanoparticles;
   sustained release; intravitreal; implants; hydrogels; liposomes
ID LOADED CHITOSAN NANOPARTICLES; FLUOCINOLONE ACETONIDE; OCULAR DELIVERY;
   IN-VIVO; THERMOSENSITIVE HYDROGEL; TRIAMCINOLONE ACETONIDE; INTRAVITREAL
   IMPLANT; MACULAR DEGENERATION; LIPID NANOPARTICLES; RETINAL DISEASES
AB Some of the most dangerous diseases of the eye are related to the posterior segment. Diseases such as age-related macular degeneration, cytomegalovirus retinitis, diabetic retinopathy, posterior uveitis and retinitis pigmentosa are difficult to treat using classical methods because of the many internal barriers of the eye which affect the drug efficiency. In this review, we will summarize the main research directions in the field of medicamentous treatment of posterior eye disorders belonging to the controlled drug delivery concept.
   The review is starting with the most important knowledge regarding anatomy and pathology of the posterior segment of the eye and is continuing with the current treatment methods of the eye posterior segment illnesses and drawbacks of these methods, the drugs administration pathways to the posterior segment of the eye. The last three sections present the state of the art regarding the latest discoveries including the commercial products in the modern drug delivery systems; the main classes of materials treated in the present review are implants, hydrogels and nano- microparticulate systems.
C1 [Peptu, Catalina A.; Popa, Marcel; Savin, Corina] Gheorghe Asachi Tech Univ Iasi, Fac Chem Engn & Protect Environm, Dept Nat & Synthet Polymers, Iasi 700050, Romania.
   [Popa, Radu F.] Grigore T Popa Univ Med & Pharm, Dept Surg, Fac Med, Iasi 700115, Romania.
   [Ochiuz, Lacramioara] Grigore T Popa Univ Med & Pharm, Fac Pharm, Dept Pharmaceut Technol, Iasi 700115, Romania.
   [Popa, Marcel] Acad Romanian Sci, Bucharest 050094, Romania.
C3 GH Asachi Technical University; Grigore T Popa University of Medicine &
   Pharmacy; Grigore T Popa University of Medicine & Pharmacy; Romanian
   Academy of Sciences
RP Popa, M (通讯作者)，Gheorghe Asachi Tech Univ Iasi, Fac Chem Engn & Protect Environm, Dept Nat & Synthet Polymers, Prof Dr Docent Dimitrie Mangeron Str 73, Iasi 700050, Romania.
EM marpopa2001@yahoo.fr
RI Peptu, Catalina A/C-4813-2012; Popa, Radu Florin/AAG-1453-2019; Logigan
   (Savin), Corina Lenuta/AAP-6220-2020
OI Peptu, Catalina Anisoara/0000-0002-1682-0682
FU MEN -UEFISCDI authority [PN-II-PT-PCCA-2013-4-1570, 218/2014]
FX This work has been performed in the frame of the Partnership Program in
   priority areas-PN II, under MEN -UEFISCDI authority, project code
   PN-II-PT-PCCA-2013-4-1570 (project number 218/2014).
CR Abrishami M, 2009, RETINA-J RET VIT DIS, V29, P699, DOI 10.1097/IAE.0b013e3181a2f42a
   Achouri D, 2013, DRUG DEV IND PHARM, V39, P1599, DOI 10.3109/03639045.2012.736515
   Ambati J, 2000, INVEST OPHTH VIS SCI, V41, P1186
   Amrite AC, 2006, NANOPARTICLES OCULAR
   Araujo J, 2010, INT J PHARMACEUT, V393, P167, DOI 10.1016/j.ijpharm.2010.03.034
   Asik Mehmet Dogan, 2013, HACETTEPE JOURNAL OF BIOLOGY AND CHEMISTRY, V41, P81
   Attama AA, 2008, INT J PHARM, V355, P307, DOI 10.1016/j.ijpharm.2007.12.007
   Avitabile T, 2001, BIOMATERIALS, V22, P195, DOI 10.1016/S0142-9612(00)00169-1
   BANGHAM AD, 1965, J MOL BIOL, V13, P238, DOI 10.1016/S0022-2836(65)80093-6
   Birch DG, 2007, INT J NANOMED, V2, P65, DOI 10.2147/nano.2007.2.1.65
   Bonacucina G, 2011, POLYMERS-BASEL, V3, P779, DOI 10.3390/polym3020779
   Bourges JL, 2006, ADV DRUG DELIVER REV, V58, P1182, DOI 10.1016/j.addr.2006.07.026
   Cabrera M, 2014, J OPHTHALMOL, V2014, DOI 10.1155/2014/164692
   Carcaboso AM, 2010, INVEST OPHTH VIS SCI, V51, P2126, DOI 10.1167/iovs.09-4050
   Chang HI, 2012, INT J NANOMED, V7, P49, DOI 10.2147/IJN.S26766
   Chen XW, 2012, J BIOMATER APPL, V27, P391, DOI 10.1177/0885328211406563
   Cholkar Kishore, 2012, Recent Pat Nanomed, V2, P82
   Choonara YE, 2007, AAPS PHARMSCITECH, V8, DOI 10.1208/pt0804118
   Choonara YE, 2010, J PHARM SCI-US, V99, P2219, DOI 10.1002/jps.21987
   Christie JG, 2008, DRUG DISCOV TODAY, V13, P124, DOI 10.1016/j.drudis.2007.12.005
   Conway Barbara R, 2008, Recent Pat Drug Deliv Formul, V2, P1, DOI 10.2174/187221108783331410
   Cunha-Vaz JG, 2004, EXP EYE RES, V78, P715, DOI 10.1016/S0014-4835(03)00213-6
   da Silva GR, 2010, BRAZ J PHARM SCI, V46, P585, DOI 10.1590/S1984-82502010000300024
   de Campos AM, 2004, PHARM RES-DORDR, V21, P803, DOI 10.1023/B:PHAM.0000026432.75781.cb
   del Amo EM, 2008, DRUG DISCOV TODAY, V13, P135, DOI 10.1016/j.drudis.2007.11.002
   Ding XY, 2009, PROG RETIN EYE RES, V28, P1, DOI 10.1016/j.preteyeres.2008.10.001
   Driot JY, 2004, J OCUL PHARMACOL TH, V20, P269, DOI 10.1089/1080768041223611
   Dugel PU, 2009, P ASS RES VIS OPHTH
   Ebrahim S, 2005, SURV OPHTHALMOL, V50, P167, DOI 10.1016/j.survophthal.2004.12.006
   Edelhauser HF, 2010, INVEST OPHTH VIS SCI, V51, P5403, DOI 10.1167/iovs.10-5392
   Eljarrat-Binstock E, 2010, PHARM RES-DORDR, V27, P530, DOI 10.1007/s11095-009-0042-9
   Emerich DF, 2008, CURR OPIN MOL THER, V10, P506
   Gao YA, 2010, DRUG DEV IND PHARM, V36, P1131, DOI 10.3109/03639041003680826
   Gaudana R, 2010, AAPS J, V12, P348, DOI 10.1208/s12248-010-9183-3
   Ghate Deepta, 2006, Expert Opin Drug Deliv, V3, P275, DOI 10.1517/17425247.3.2.275
   Gomez-Graete C, 2007, INT J PHARMACEUT, V331, P153, DOI 10.1016/j.ijpharm.2006.11.028
   Guidetti B., 2008, Current Drug Delivery, V5, P7, DOI 10.2174/156720108783331050
   Gupta SK, 2014, TXB CLIN OCULAR PHAR, P65
   Guse C, 2006, INT J PHARMACEUT, V314, P153, DOI 10.1016/j.ijpharm.2005.12.050
   Haghjou Nahid, 2011, J Ophthalmic Vis Res, V6, P317
   Hao JF, 2014, COLLOID SURFACE B, V114, P111, DOI 10.1016/j.colsurfb.2013.09.059
   Herrero-Vanrell R, 2010, OCULAR PHARM DRUG BI, P60
   Hoffman AS, 2012, ADV DRUG DELIVER REV, V64, P18, DOI 10.1016/j.addr.2012.09.010
   Hughes PM, 2005, ADV DRUG DELIVER REV, V57, P2010, DOI 10.1016/j.addr.2005.09.004
   Hunter RS, 2011, CLIN OPHTHALMOL, V5, P1613, DOI 10.2147/OPTH.S17419
   Hwang YS, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067495
   Inoue M, 2004, AM J OPHTHALMOL, V138, P1046, DOI 10.1016/j.ajo.2004.05.028
   Jaffe GJ, 2000, RETINA-J RET VIT DIS, V20, P402, DOI 10.1097/00006982-200004000-00015
   Jaffe GJ, 2006, OPHTHALMOLOGY, V113, P1020, DOI 10.1016/j.ophtha.2006.02.021
   Jaffe GJ, 2000, OPHTHALMOLOGY, V107, P2024, DOI 10.1016/S0161-6420(00)00466-8
   Jaffe GJ, 2008, AM J OPHTHALMOL, V145, P667, DOI 10.1016/j.ajo.2007.11.008
   Janoria KG, 2007, EXPERT OPIN DRUG DEL, V4, P371, DOI 10.1517/17425247.4.4.371
   Janoria KG, 2007, INT J PHARM, V338, P133, DOI 10.1016/j.ijpharm.2007.01.038
   Kang DJJ, 2008, T AM OPHTHAL SOC, V106, P206
   Katiyar S, 2014, CARBOHYD POLYM, V102, P117, DOI 10.1016/j.carbpol.2013.10.079
   Kaur IP, 2014, J CONTROL RELEASE, V193, P100, DOI 10.1016/j.jconrel.2014.05.031
   Kiernan D.F., 2010, RETINA TODAY, V48, P48
   Kim YC, 2014, J CONTROL RELEASE, V190, P172, DOI 10.1016/j.jconrel.2014.06.043
   Kompella UB, 2010, THER DELIV, V1, P435, DOI 10.4155/TDE.10.40
   Kuno N, 2012, RETINA TODAY, P54
   Kuno N, 2010, DRUG AGING, V27, P117, DOI 10.2165/11530970-000000000-00000
   Lajunen T, 2014, EUR J PHARM SCI, V62, P23, DOI 10.1016/j.ejps.2014.04.018
   Lee SS, 2010, PHARM RES-DORDR, V27, P2043, DOI 10.1007/s11095-010-0159-x
   Lee SS, 2009, OPHTHALMIC RES, V41, P124, DOI 10.1159/000209665
   Liu CH, 2014, J OPHTHALMOL, V2014, DOI 10.1155/2014/304694
   Liu Y, 2013, TISSUE ENG PT A, V19, P135, DOI [10.1089/ten.tea.2012.0209, 10.1089/ten.TEA.2012.0209]
   Loftsson T, 2008, PHARMAZIE, V63, P171, DOI 10.1691/ph.2008.7322
   Loftsson T, 2000, INVEST OPHTH VIS SCI, V41
   Lovett ML, 2015, EUR J PHARM BIOPHARM, V95, P271, DOI 10.1016/j.ejpb.2014.12.029
   Mains J, 2013, J OCUL PHARMACOL TH, V29, P143, DOI 10.1089/jop.2012.0138
   Mannermaa E, 2006, ADV DRUG DELIVER REV, V58, P1136, DOI 10.1016/j.addr.2006.07.024
   Marx JL, 1996, ARCH OPHTHALMOL-CHIC, V114, P815, DOI 10.1001/archopht.1996.01100140029003
   Maurice D, 2001, J OCUL PHARMACOL TH, V17, P393, DOI 10.1089/108076801753162807
   Mazumder MAJ, 2012, J BIOMED MATER RES A, V100A, P1877, DOI 10.1002/jbm.a.34021
   Mikhail Michael, 2013, Med Hypothesis Discov Innov Ophthalmol, V2, P113
   Misra GP, 2009, BIOMATERIALS, V30, P6541, DOI 10.1016/j.biomaterials.2009.08.025
   Mitra AK, 2013, TREATISE OCULAR DRUG, P96
   Montero JA, 2009, CURR DIABETES REV, V5, P26, DOI 10.2174/157339909787314211
   Motwani SK, 2008, EUR J PHARM BIOPHARM, V68, P513, DOI 10.1016/j.ejpb.2007.09.009
   Nagai N, 2014, ACTA BIOMATER, V10, P680, DOI 10.1016/j.actbio.2013.11.004
   Nagarwal RC, 2012, EUR J PHARM SCI, V47, P678, DOI 10.1016/j.ejps.2012.08.008
   Okabe J, 2003, INVEST OPHTH VIS SCI, V44, P740, DOI 10.1167/iovs.02-0375
   Okabe K, 2003, INVEST OPHTH VIS SCI, V44, P2702, DOI 10.1167/iovs.02-0956
   Pahuja P, 2012, EXPERT OPIN DRUG DEL, V9, P837, DOI 10.1517/17425247.2012.690733
   Patel Ashaben, 2013, World J Pharmacol, V2, P47
   Patel SR, 2011, PHARM RES-DORDR, V28, P166, DOI 10.1007/s11095-010-0271-y
   Pirmoradi FN, 2011, LAB CHIP, V11, P2744, DOI 10.1039/c1lc20134d
   Prager F, 2009, BRIT J OPHTHALMOL, V93, P452, DOI 10.1136/bjo.2008.141085
   Prestwich GD, 2012, ACTA BIOMATER, V8, P4200, DOI 10.1016/j.actbio.2012.06.043
   Prestwich GD, 2011, J CONTROL RELEASE, V155, P193, DOI 10.1016/j.jconrel.2011.04.007
   Qian LL, 2013, BIOMATERIALS, V34, P8968, DOI 10.1016/j.biomaterials.2013.07.097
   Qian Y, 2010, DRUG DEV IND PHARM, V36, P1340, DOI 10.3109/03639041003801893
   Rajendran NN, 2010, ASIAN J PHARM, V4, DOI 10.4103/0973-8398.76749
   Rajoria G., 2012, AJPTR, V2, P24
   Ranta VP, 2010, J CONTROL RELEASE, V148, P42, DOI 10.1016/j.jconrel.2010.08.028
   Rauck BM, 2014, INVEST OPHTH VIS SCI, V55, P469, DOI 10.1167/iovs.13-13120
   Rieke ER, 2010, J OCUL PHARMACOL TH, V26, P55, DOI 10.1089/jop.2009.0059
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Russel R, 2004, PHARM TECHNOL, V28, P223
   Sahoo SK, 2008, DRUG DISCOV TODAY, V13, P144, DOI 10.1016/j.drudis.2007.10.021
   SANBORN GE, 1992, ARCH OPHTHALMOL-CHIC, V110, P188, DOI 10.1001/archopht.1992.01080140044023
   Sanford M, 2013, DRUGS, V73, P187, DOI 10.1007/s40265-013-0010-x
   Sarao V, 2014, SCI WORLD J, DOI 10.1155/2014/989501
   Sasaki H, 2013, EUR J PHARM BIOPHARM, V83, P364, DOI 10.1016/j.ejpb.2012.10.014
   Schultz C, 2011, CLIN EXP OPTOM, V94, P212, DOI 10.1111/j.1444-0938.2010.00553.x
   Shah SS, 2010, EXPERT REV OPHTHALMO, V5, P75, DOI 10.1586/EOP.09.70
   Sheardown H, 2006, OPHTHAL RES, P393, DOI 10.1007/978-1-59745-047-8_22
   Siddique SS, 2011, EXPERT OPIN INV DRUG, V20, P1497, DOI 10.1517/13543784.2011.617741
   Sigurdsson HH, 2007, ACTA OPHTHALMOL SCAN, V85, P598, DOI 10.1111/j.1600-0420.2007.00885.x
   Silva NC, 2015, DRUG DELIV, V22, P885, DOI 10.3109/10717544.2013.858195
   Souto EB, 2010, CURR EYE RES, V35, P537, DOI 10.3109/02713681003760168
   Su YC, 2004, J MICROELECTROMECH S, V13, P75, DOI 10.1109/JMEMS.2003.823215
   Suri S, 2013, CHAPTER 1 2 19 MICRO, P360, DOI 10.1016/B978-0-08-087780-8.00034-6
   Tamaddon L, 2014, JUNDISHAPUR J NAT PH, V9, DOI 10.17795/jjnpp-16414
   Thrimawithana TR, 2011, DRUG DISCOV TODAY, V16, P270, DOI 10.1016/j.drudis.2010.12.004
   Thrimawithana TR, 2011, DRUG DELIV LETT, V1, P40
   Tsukamoto T, 2013, ASIAN J PHARM SCI, V8, P104, DOI 10.1016/j.ajps.2013.07.013
   Turturro SB, 2011, BIOMATERIALS, V32, P3620, DOI 10.1016/j.biomaterials.2011.01.058
   Urtti A, 2006, ADV DRUG DELIVER REV, V58, P1131, DOI 10.1016/j.addr.2006.07.027
   van Wijngaarden P, 2008, CLIN EXP OPTOM, V91, P427, DOI 10.1111/j.1444-0938.2008.00305.x
   Wadhwa S, 2010, J DRUG TARGET, V18, P292, DOI 10.3109/10611860903450023
   Wang CH, 2012, BIOMACROMOLECULES, V13, P40, DOI 10.1021/bm2009558
   Wang JL, 2013, MEDIAT INFLAMM, V2013, DOI 10.1155/2013/780634
   Yang CS, 1998, ARCH OPHTHALMOL-CHIC, V116, P69, DOI 10.1001/archopht.116.1.69
   Yasin MN, 2014, J CONTROL RELEASE, V196, P208, DOI 10.1016/j.jconrel.2014.09.030
   Yasukawa T, 2005, ADV DRUG DELIVER REV, V57, P2033, DOI 10.1016/j.addr.2005.09.005
   Yasukawa T, 2001, ADV DRUG DELIVER REV, V52, P25, DOI 10.1016/S0169-409X(01)00192-2
   Zarembinski TI, 2014, ACTA BIOMATER, V10, P94, DOI 10.1016/j.actbio.2013.09.029
   Zhang XZ, 2005, POLYMER, V46, P9664, DOI 10.1016/j.polymer.2005.08.055
NR 129
TC 19
Z9 19
U1 1
U2 29
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1381-6128
EI 1873-4286
J9 CURR PHARM DESIGN
JI Curr. Pharm. Design
PY 2015
VL 21
IS 42
BP 6055
EP 6069
DI 10.2174/1381612821666151027151847
PG 15
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA CY1VS
UT WOS:000366196700003
PM 26503152
DA 2022-11-30
ER

PT J
AU Evans, SM
   Kim, K
   Moore, CE
   Uddin, MI
   Capozzi, ME
   Craft, JR
   Sulikowski, GA
   Jayagopal, A
AF Evans, Stephanie M.
   Kim, Kwangho
   Moore, Chauca E.
   Uddin, Md Imam
   Capozzi, Megan E.
   Craft, Jason R.
   Sulikowski, Gary A.
   Jayagopal, Ashwath
TI Molecular Probes for Imaging of Hypoxia in the Retina
SO BIOCONJUGATE CHEMISTRY
LA English
DT Article
ID OXYGEN-INDUCED RETINOPATHY; CHOROIDAL BLOOD-FLOW; FLUORESCENT-PROBES;
   TUMOR HYPOXIA; PIMONIDAZOLE; CARCINOMA; OXIMETRY; MARKER; METABOLISM;
   NORMOXIA
AB Hypoxia has been associated with retinal diseases which lead the causes of irreversible vision loss, including diabetic retinopathy, retinopathy of prematurity, and age-related macular degeneration. Therefore, technologies for imaging hypoxia in the retina are needed for early disease detection, monitoring of disease progression, and assessment of therapeutic responses in the patient. Toward this goal, we developed two hypoxia-sensitive imaging agents based on nitroimidazoles which are capable of accumulating in hypoxic cells in vivo. 2-nitroimidazole or Pimonidazole was conjugated to fluorescent dyes to yield the imaging agents HYPOX-1 and HYPOX-2. Imaging agents were characterized in cell culture and animal models of retinal vascular diseases which exhibit hypoxia. Both HYPOX-1 and -2 were capable of detecting hypoxia in cell culture models with >10:1 signal-to-noise ratios without acute toxicity. Furthermore, intraocular administration of contrast agents in mouse models of retinal hypoxia enabled ex vivo detection of hypoxic tissue. These imaging agents are a promising step toward translation of hypoxia-sensitive molecular imaging agents in preclinical animal models and patients.
C1 [Evans, Stephanie M.; Moore, Chauca E.; Uddin, Md Imam; Craft, Jason R.; Jayagopal, Ashwath] Vanderbilt Eye Inst, Dept Ophthalmol & Visual Sci, Nashville, TN 37232 USA.
   [Kim, Kwangho; Sulikowski, Gary A.] Vanderbilt Univ, Dept Chem, Nashville, TN 37235 USA.
   [Kim, Kwangho; Sulikowski, Gary A.] Vanderbilt Univ, Dept Biochem, Nashville, TN 37235 USA.
   [Capozzi, Megan E.; Jayagopal, Ashwath] Vanderbilt Univ, Dept Mol Physiol & Biophys, Nashville, TN 37235 USA.
C3 Vanderbilt University; Vanderbilt University; Vanderbilt University;
   Vanderbilt University
RP Jayagopal, A (通讯作者)，Vanderbilt Eye Inst, Dept Ophthalmol & Visual Sci, Nashville, TN 37232 USA.
EM ash.jayagopal@vanderbilt.edu
OI Capozzi, Megan/0000-0002-7587-0663; Uddin, MD Imam/0000-0001-5611-9666
FU National Institutes of Health [R01EY23397, P30008126]; American Diabetes
   Association [7-12-JF-30]; Brightfocus Foundation; International Retinal
   Research Foundation; Research to Prevent Blindness; NATIONAL EYE
   INSTITUTE [R01EY023397, P30EY008126] Funding Source: NIH RePORTER
FX This work was supported in part by National Institutes of Health
   (R01EY23397, P30008126), the American Diabetes Association (7-12-JF-30),
   the Brightfocus Foundation, the International Retinal Research
   Foundation, and Research to Prevent Blindness (Unrestricted Grant to
   Vanderbilt Eye Institute, and a Dolly Green Special Scholar Award
   (A.J.)).
CR Arteel GE, 1998, EUR J BIOCHEM, V253, P743, DOI 10.1046/j.1432-1327.1998.2530743.x
   Capozzi ME, 2014, INVEST OPHTH VIS SCI, V55, P4253, DOI 10.1167/iovs.14-14216
   Cunha-Vaz JG, 2004, EXP EYE RES, V78, P715, DOI 10.1016/S0014-4835(03)00213-6
   Dai CX, 2013, INVEST OPHTH VIS SCI, V54, P7998, DOI 10.1167/iovs.13-12318
   Dai Y, 2011, INT J RADIAT ONCOL, V81, P521, DOI 10.1016/j.ijrobp.2011.04.027
   GASS JDM, 1967, ARCH OPHTHALMOL-CHIC, V78, P455
   Grunwald JE, 2005, INVEST OPHTH VIS SCI, V46, P1033, DOI 10.1167/iovs.04-1050
   Hammer M, 2008, J BIOMED OPT, V13, DOI 10.1117/1.2976032
   Hardarson SH, 2013, ACTA OPHTHALMOL, V91, P189, DOI 10.1111/j.1755-3768.2012.02393.x
   Hardarson SH, 2006, INVEST OPHTH VIS SCI, V47, P5011, DOI 10.1167/iovs.06-0039
   Kiyose K, 2010, J AM CHEM SOC, V132, P15846, DOI 10.1021/ja105937q
   Kristjansdottir JV, 2013, INVEST OPHTH VIS SCI, V54, P3234, DOI 10.1167/iovs.12-10507
   Linsenmeier RA, 1998, INVEST OPHTH VIS SCI, V39, P1647
   Ljungkvist ASE, 2000, INT J RADIAT ONCOL, V48, P1529, DOI 10.1016/S0360-3016(00)00787-2
   Metelitsina TI, 2006, BRIT J OPHTHALMOL, V90, P342, DOI 10.1136/bjo.2005.082974
   Mezu-Ndubuisi OJ, 2014, EXP EYE RES, V122, P119, DOI 10.1016/j.exer.2014.03.010
   Mowat FM, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011103
   Nordsmark M, 2001, INT J RADIAT ONCOL, V49, P581, DOI 10.1016/S0360-3016(00)01493-0
   Nordsmark M, 2003, RADIOTHER ONCOL, V67, P35, DOI 10.1016/S0167-8140(03)00010-0
   Penn JS, 2008, PROG RETIN EYE RES, V27, P331, DOI 10.1016/j.preteyeres.2008.05.001
   Piao W, 2013, ANGEW CHEM INT EDIT, V52, P13028, DOI 10.1002/anie.201305784
   Poulaki V, 2002, J CLIN INVEST, V109, P805, DOI 10.1172/JCI200213776
   Seigel GM, 1997, IN VITRO CELL DEV-AN, V33, P499
   Seigel GM, 1996, IN VITRO CELL DEV-AN, V32, P66
   SMITH LEH, 1994, INVEST OPHTH VIS SCI, V35, P101
   Takahashi S, 2012, J AM CHEM SOC, V134, P19588, DOI 10.1021/ja310049d
   Traustason S, 2013, INVEST OPHTH VIS SCI, V54, P2746, DOI 10.1167/iovs.12-11284
   Varia MA, 1998, GYNECOL ONCOL, V71, P270, DOI 10.1006/gyno.1998.5163
   Wanek J, 2013, INVEST OPHTH VIS SCI, V54, P5012, DOI 10.1167/iovs.13-11887
   Yaromina A, 2006, RADIOTHER ONCOL, V81, P122, DOI 10.1016/j.radonc.2006.08.010
   Yu SJ, 2011, ACTA PHARMACOL SIN, V32, P912, DOI 10.1038/aps.2011.24
NR 31
TC 28
Z9 31
U1 0
U2 59
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1043-1802
J9 BIOCONJUGATE CHEM
JI Bioconjugate Chem.
PD NOV
PY 2014
VL 25
IS 11
BP 2030
EP 2037
DI 10.1021/bc500400z
PG 8
WC Biochemical Research Methods; Biochemistry & Molecular Biology;
   Chemistry, Multidisciplinary; Chemistry, Organic
WE Science Citation Index Expanded (SCI-EXPANDED); Index Chemicus (IC)
SC Biochemistry & Molecular Biology; Chemistry
GA AU0JK
UT WOS:000345309000014
PM 25250692
OA Green Published, hybrid
DA 2022-11-30
ER

PT J
AU Nitoda, E
   Moschos, MM
   Mavragani, CP
   Koutsilieris, M
AF Nitoda, Eirini
   Moschos, Marilita M.
   Mavragani, Clio P.
   Koutsilieris, Michael
TI Ocular actions of platelet-activating factor: clinical implications
SO EXPERT OPINION ON THERAPEUTIC TARGETS
LA English
DT Review
DE inflammatory mediators; ocular inflammation; PAF; PAF antagonists
ID NECROSIS-FACTOR-ALPHA; EXPERIMENTAL ALLERGIC CONJUNCTIVITIS; FACTOR
   RECEPTOR ANTAGONIST; FACTOR ACETYLHYDROLASE; FACTOR PAF;
   SIGNAL-TRANSDUCTION; OXIDATIVE STRESS; LIPID MEDIATORS; GUINEA-PIGS;
   PROINFLAMMATORY CYTOKINES
AB Introduction: To summarize the currently available evidence of platelet-activating factor (PAF) implication in the pathogenesis of inflammatory ocular diseases.
   Areas covered: PAF is a potent mediator of inflammation, implicated in the pathogenesis of chronic inflammatory disorders, allergic reactions, oncogenic transformation, wound repair and hypoxia-induced angiogenesis. It seems to be involved in the protection of ocular surface against various harmful agents through inflammatory processes, which can lead to chronic allergic reactions or even corneal neovascularization and haze, if they do not undergo regulation. Pathogenesis of uveitis, which is significant cause for the blurring of the visual system, has also been associated with PAF's activity. The hypoxia and the breakdown of the blood-retina barrier, observed in severe vascular retinal diseases, such as age-related macular degeneration and diabetic retinopathy, are associated with PAF ocular activity.
   Expert opinion: Understanding the pathophysiology of vision threatening diseases could enhance clinical treatment and encourage experimental studies, which could be based on potential beneficial effects of new agents, such as PAF antagonists.
C1 [Mavragani, Clio P.; Koutsilieris, Michael] Univ Athens, Sch Med, Dept Expt Physiol, Goudi 11527, Greece.
   [Nitoda, Eirini] Univ Athens, Sch Med, Dept Ophthalmol, Dept Expt Physiol, Athens 15125, Greece.
   [Moschos, Marilita M.] Univ Athens, Sch Med, Dept Ophthalmol, Athens 14578, Greece.
C3 National & Kapodistrian University of Athens; Athens Medical School;
   National & Kapodistrian University of Athens; Athens Medical School;
   National & Kapodistrian University of Athens
RP Koutsilieris, M (通讯作者)，Univ Athens, Sch Med, Dept Expt Physiol, 75 Micras Asias, Goudi 11527, Greece.
EM mkoutsil@med.uoa.gr
RI Koutsilieris, Michael/AAD-3648-2019; Mavrogeni, Sophie/AAV-2105-2021
CR Adachi H, 1997, BIOCHEM BIOPH RES CO, V233, P10, DOI 10.1006/bbrc.1997.6383
   Arai H, 2002, PROSTAG OTH LIPID M, V68-9, P83, DOI 10.1016/S0090-6980(02)00023-0
   Bazan HEP, 2005, EXP EYE RES, V80, P453, DOI 10.1016/j.exer.2004.12.023
   Bazan HEP, 2002, PROG RETIN EYE RES, V21, P449, DOI 10.1016/S1350-9462(02)00011-3
   Bazan NG, 2005, MOL NEUROBIOL, V32, P89, DOI 10.1385/MN:32:1:089
   Beauchamp MH, 2002, INVEST OPHTH VIS SCI, V43, P3327
   Berkhoff M, 1997, NERVENARZT, V68, P792, DOI 10.1007/s001150050196
   Bhatia M, 2005, SCAND J SURG, V94, P97, DOI 10.1177/145749690509400203
   Bhattacherjee P, 1989, Prog Clin Biol Res, V312, P211
   Bora NS, 2008, SEMIN IMMUNOPATHOL, V30, P85, DOI 10.1007/s00281-008-0110-y
   BUSSOLINO F, 1989, J LIPID MEDIATOR, V1, P283
   BUSSOLINO F, 1988, J NEUROCHEM, V51, P1755, DOI 10.1111/j.1471-4159.1988.tb01155.x
   Calonge M, 2010, OCUL IMMUNOL INFLAMM, V18, P244, DOI 10.3109/09273941003721926
   Chandrasekher G, 2002, INVEST OPHTH VIS SCI, V43, P1422
   CHAO W, 1993, BIOCHEM J, V292, P617, DOI 10.1042/bj2920617
   Chen C, 2008, WORLD J GASTROENTERO, V14, P4735, DOI 10.3748/wjg.14.4735
   Cheng L, 2009, AM J PHYSIOL-ENDOC M, V297, pE1276, DOI 10.1152/ajpendo.00475.2009
   CLUZEL J, 1995, OPHTHALMIC RES, V27, P153, DOI 10.1159/000267654
   Crane IJ, 2008, SEMIN IMMUNOPATHOL, V30, P165, DOI 10.1007/s00281-008-0106-7
   de la Cruz JP, 1998, EUR J PHARMACOL, V360, P37, DOI 10.1016/S0014-2999(98)00664-5
   Denizot Y, 2004, LEUKEMIA LYMPHOMA, V45, P515, DOI 10.1080/1042819032000141293
   Derewenda ZS, 1998, CELL MOL LIFE SCI, V54, P446, DOI 10.1007/s000180050172
   DHARMA S, 1991, CURR EYE RES, V10, P1031, DOI 10.3109/02713689109020341
   DOLY M, 1987, INT J TISSUE REACT, V9, P33
   Doly M, 1992, Lens Eye Toxic Res, V9, P529
   DOLY M, 1993, OPHTHALMIC RES, V25, P314, DOI 10.1159/000267331
   Droy-Lefaix M T, 1992, Lens Eye Toxic Res, V9, P521
   Edwards Laura J., 2009, Inflammation & Allergy Drug Targets, V8, P182
   Esquenazi S, 2004, J CATARACT REFR SURG, V30, P884, DOI 10.1016/j.jcrs.2003.09.069
   Esquenazi S, 2010, MOL NEUROBIOL, V42, P32, DOI 10.1007/s12035-010-8129-1
   Esquenazi S, 2009, CLIN DEV IMMUNOL, P1, DOI 10.1155/2009/138513
   Fernandes Caraciolo J, 2006, Curr Hematol Rep, V5, P76
   FLEISHER LN, 1991, INVEST OPHTH VIS SCI, V32, P2393
   Fragel-Madeira L, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016058
   Garland RC, 2011, FASEB J, V25, P1284, DOI 10.1096/fj.10-160051
   Garweg JG, 2009, MEM I OSWALDO CRUZ, V104, P211, DOI 10.1590/S0074-02762009000200014
   Hardy P, 2005, PROSTAG LEUKOTR ESS, V72, P301, DOI 10.1016/j.plefa.2005.02.004
   He JC, 2006, INVEST OPHTH VIS SCI, V47, P883, DOI 10.1167/iovs.05-0581
   He JC, 2006, ARCH OPHTHALMOL-CHIC, V124, P70, DOI 10.1001/archopht.124.1.70
   He JC, 2010, CURR EYE RES, V35, P1063, DOI 10.3109/02713683.2010.513797
   He YG, 2009, CURR EYE RES, V34, P957, DOI 10.3109/02713680903231135
   Ho YS, 1997, NATURE, V385, P89, DOI 10.1038/385089a0
   Ianopol N, 1998, Oftalmologia, V42, P5
   Irani AMA, 2008, IMMUNOL ALLERGY CLIN, V28, P25, DOI 10.1016/j.iac.2007.12.006
   Kato M, 2004, J PHARMACOL SCI, V95, P435, DOI 10.1254/jphs.FP0040265
   Kato M, 2003, J OCUL PHARMACOL TH, V19, P315, DOI 10.1089/108076803322279372
   Kenchegowda S, 2010, J LIPID RES, V51, P879, DOI 10.1194/jlr.R001347
   Kitagawa D, 2007, ONCOLOGY-BASEL, V72, P381, DOI 10.1159/000113149
   Leonardi A, 2008, CLIN EXP IMMUNOL, V153, P17, DOI 10.1111/j.1365-2249.2008.03716.x
   LIN NG, 1991, CURR EYE RES, V10, P19, DOI 10.3109/02713689109007607
   Ma X, 2004, INVEST OPHTH VIS SCI, V45, P2915, DOI 10.1167/iovs.04-0128
   Ma X, 2000, INVEST OPHTH VIS SCI, V41, P1696
   Malesinski Roman, 2007, Klin Oczna, V109, P345
   Marques M, 2002, J INVEST DERMATOL, V119, P913, DOI 10.1046/j.1523-1747.2002.01859.x
   McManus LM, 2000, CRIT REV ORAL BIOL M, V11, P240, DOI 10.1177/10454411000110020701
   Menerath JM, 1997, J OCUL PHARMACOL TH, V13, P81, DOI 10.1089/jop.1997.13.81
   Mertens A, 2001, FASEB J, V15, P2073, DOI 10.1096/fj.01-0273rev
   MEYNIEL G, 1992, CR ACAD SCI III-VIE, V314, P61
   Neoptolemos JP, 1998, GUT, V42, P886, DOI 10.1136/gut.42.6.886
   Noto H, 2003, ARTERIOSCL THROM VAS, V23, P829, DOI 10.1161/01.ATV.0000067701.09398.18
   Okumura N, 2006, J OCUL PHARMACOL TH, V22, P347, DOI 10.1089/jop.2006.22.347
   Ottino P, 2005, INVEST OPHTH VIS SCI, V46, P487, DOI 10.1167/iovs.04-0852
   Pisella Pierre-Jean, 2006, Rev Prat, V56, P1226
   Ramana KV, 2010, INT J BIOCHEM CELL B, V42, P1076, DOI 10.1016/j.biocel.2010.03.011
   REME C, 1992, GRAEF ARCH CLIN EXP, V230, P580, DOI 10.1007/BF00181782
   Reynaud S, 2007, LEUKEMIA RES, V31, P399, DOI 10.1016/j.leukres.2006.06.002
   ROSENBAUM JT, 1991, ARCH OPHTHALMOL-CHIC, V109, P410, DOI 10.1001/archopht.1991.01080030112049
   Rosenbaum JT, 1999, CURR EYE RES, V18, P342, DOI 10.1076/ceyr.18.5.342.5346
   Serhan CN, 1996, FASEB J, V10, P1147, DOI 10.1096/fasebj.10.10.8751717
   Sharif NA, 2009, MOL VIS, V15, P1153
   SHUKLA SD, 1992, FASEB J, V6, P2296, DOI 10.1096/fasebj.6.6.1312046
   SMITH D, 1994, EXP EYE RES, V59, P425, DOI 10.1006/exer.1994.1127
   Sohn Jeong-Hyeon, 2007, Chem Immunol Allergy, V92, P105, DOI 10.1159/000099261
   Spalton DJ, 1998, CLIN ANATOMY EYE
   Sreevidya CS, 2010, J INVEST DERMATOL, V130, P1428, DOI 10.1038/jid.2009.329
   Stafforini DM, 1997, J BIOL CHEM, V272, P17895, DOI 10.1074/jbc.272.29.17895
   Stern ME, 2010, MUCOSAL IMMUNOL, V3, P425, DOI 10.1038/mi.2010.26
   Sweeney KJ, 2000, MECH DEVELOP, V92, P263, DOI 10.1016/S0925-4773(00)00242-2
   Taheri F, 2007, INVEST OPHTH VIS SCI, V48, P1931, DOI 10.1167/iovs.06-1008
   Thakur A, 1998, EXP EYE RES, V67, P9, DOI 10.1006/exer.1998.0480
   Thakur A, 1998, J CLIN IMMUNOL, V18, P61, DOI 10.1023/A:1023291921695
   THIERRY A, 1989, EUR J PHARMACOL, V163, P97, DOI 10.1016/0014-2999(89)90400-7
   Tsuji F, 1998, CURR EYE RES, V17, P501, DOI 10.1076/ceyr.17.5.501.5194
   Tunc SE, 2005, RHEUMATOL INT, V25, P326, DOI 10.1007/s00296-004-0450-4
   Umemura K, 2007, STROKE, V38, P1063, DOI 10.1161/01.STR.0000257981.09329.d2
   VANE J, 1987, FASEB J, V1, P89, DOI 10.1096/fasebj.1.2.3111928
   Vinores SA, 2007, J NEUROIMMUNOL, V182, P73, DOI 10.1016/j.jneuroim.2006.09.015
   Wakamatsu TH, 2010, MOL VIS, V16, P2465
   Wakamatsu TH, 2008, ARQ BRAS OFTALMOL, V71, P72, DOI 10.1590/S0004-27492008000700015
   WAKEFIELD D, 1992, CYTOKINE, V4, P1, DOI 10.1016/1043-4666(92)90028-P
   Wallace GR, 2004, PROG RETIN EYE RES, V23, P435, DOI 10.1016/j.preteyeres.2004.04.004
   Wierzbicki M, 2008, POSTEP HIG MED DOSW, V62, P642
   Yadav UCS, 2011, CURR MED CHEM, V18, P931
   Yadav UCS, 2010, CURR MOL MED, V10, P540
   Yang D, 2007, EXP EYE RES, V85, P462, DOI 10.1016/j.exer.2007.06.013
   YOUSUFZAI SYK, 1985, BIOCHEM J, V228, P697, DOI 10.1042/bj2280697
   Zhou G, 2011, J BIOL CHEM, V286, P34820, DOI 10.1074/jbc.M111.267161
   Zinchuk O, 2005, MOL VIS, V11, P114
NR 98
TC 9
Z9 9
U1 1
U2 11
PU INFORMA HEALTHCARE
PI LONDON
PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND
SN 1472-8222
J9 EXPERT OPIN THER TAR
JI Expert Opin. Ther. Targets
PD SEP
PY 2012
VL 16
IS 10
BP 1027
EP 1039
DI 10.1517/14728222.2012.712961
PG 13
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA 008HC
UT WOS:000308947000007
PM 22924390
DA 2022-11-30
ER

PT J
AU Beri, A
   Sural, N
   Mahajan, SB
AF Beri, Abhimanyu
   Sural, Neethi
   Mahajan, Snigdha B.
TI Non-Atheroprotective Effects of Statins A Systematic Review
SO AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS
LA English
DT Review
ID CONVERTING ENZYME-INHIBITORS; POSTOPERATIVE ATRIAL-FIBRILLATION;
   ANGIOTENSIN RECEPTOR BLOCKERS; CONTRAST-INDUCED NEPHROPATHY; COA
   REDUCTASE INHIBITORS; C-REACTIVE PROTEIN; LONG-TERM RISK; HEART-FAILURE;
   COGNITIVE FUNCTION; PREOPERATIVE STATINS
AB Since the introduction of HMG-CoA reductase inhibitors (statins) for lowering lipids, a large amount of data has been published demonstrating their potential benefits in conditions as varied as cancer, osteoporosis, and Alzheimer's dementia. We reviewed the published literature on MEDLINE from articles between 1950 and 2008 on the non-atheroprotective effects of statins and noted consistent benefits of statin use in improving outcomes of ventricular arrhythmias, sudden cardiac death, cardiac transplant rejection, chronic obstructive pulmonary disease, and sepsis. However, for these conditions, the level of evidence was inadequate to recommend statin use. The evidence for improving outcomes in atrial fibrillation, mortality in heart failure, contrast-induced nephropathy, cataract, age-related macular degeneration, sub-arachnoid hemorrhage, osteoporosis, dementia, and cancer incidence was conflicting and inconclusive. Furthermore, we found that most of the literature consists of small observational studies and their conclusions are often not corroborated by results from larger or randomized studies. Pending large, well designed, randomized trials, we conclude that there is no definite evidence for the use of statins in any condition besides hyperlipidemia and atherosclerosis.
C1 [Beri, Abhimanyu; Sural, Neethi] Michigan State Univ, Dept Internal Med, E Lansing, MI 48824 USA.
   [Mahajan, Snigdha B.] Guru Nanak Mission Hosp, Dept Ophthalmol, Jalandhar, India.
C3 Michigan State University
RP Beri, A (通讯作者)，B301 Clin Ctr, 138 Serv Rd, E Lansing, MI 48824 USA.
EM abhiberi@gmail.com
OI Mahajan, Snigdha/0000-0001-9427-3613
CR Adabag AS, 2007, AM HEART J, V154, P1140, DOI 10.1016/j.ahj.2007.07.018
   Alexeeff SE, 2007, AM J RESP CRIT CARE, V176, P742, DOI 10.1164/rccm.200705-656OC
   Almog Y, 2003, CHEST, V124, P740, DOI 10.1378/chest.124.2.740
   Almog Y, 2004, CIRCULATION, V110, P880, DOI 10.1161/01.CIR.0000138932.17956.F1
   Almog Y, 2007, CRIT CARE MED, V35, P372, DOI 10.1097/01.CCM.0000253397.42079.D5
   Amar D, 2005, CHEST, V128, P3421, DOI 10.1378/chest.128.5.3421
   Antonini-Canterin F, 2003, AM J CARDIOL, V92, P1479, DOI 10.1016/j.amjcard.2003.08.066
   Arvanitakis Z, 2008, NEUROLOGY, V70, P1795, DOI 10.1212/01.wnl.0000288181.00826.63
   Asselbergs FW, 2004, CIRCULATION, V110, P2809, DOI 10.1161/01.CIR.0000146378.65439.7A
   Atar S, 2006, AM HEART J, V151, DOI 10.1016/j.ahj.2006.02.013
   Atkins D, 2004, BMJ-BRIT MED J, V328, P1490
   Bauer DC, 2004, ARCH INTERN MED, V164, P146, DOI 10.1001/archinte.164.2.146
   Bernick C, 2005, NEUROLOGY, V65, P1388, DOI 10.1212/01.wnl.0000182897.18229.ec
   Bjerre LM, 2001, AM J MED, V110, P716, DOI 10.1016/S0002-9343(01)00705-7
   Blanco M, 2007, NEUROLOGY, V69, P904, DOI 10.1212/01.wnl.0000269789.09277.47
   Bone HG, 2007, J CLIN ENDOCR METAB, V92, P4671, DOI 10.1210/jc.2006-1909
   Bonovas S, 2007, CAN MED ASSOC J, V176, P649, DOI 10.1503/cmaj.060803
   Chiu JH, 2005, AM J CARDIOL, V95, P490, DOI 10.1016/j.amjcard.2004.10.017
   Chung YS, 2000, J CLIN ENDOCR METAB, V85, P1137, DOI 10.1210/jc.85.3.1137
   Cowell SJ, 2005, NEW ENGL J MED, V352, P2389, DOI 10.1056/NEJMoa043876
   Cramer C, 2008, NEUROLOGY, V71, P344, DOI 10.1212/01.wnl.0000319647.15752.7b
   Cyrus-David MS, 2005, J UROLOGY, V173, P1923, DOI 10.1097/01.ju.0000158044.94188.88
   Dickinson MG, 2007, AM HEART J, V153, P573, DOI 10.1016/j.ahj.2007.02.002
   Domanski M, 2007, AM J CARDIOL, V99, P1448, DOI 10.1016/j.amjcard.2006.12.080
   Domanski MJ, 2007, NEW ENGL J MED, V357, P1543, DOI 10.1056/NEJMe078183
   Douketis JD, 2007, AM J MED, V120, DOI 10.1016/j.amjmed.2006.06.008
   Efron DT, 2008, J TRAUMA, V64, P66, DOI 10.1097/TA.0b013e31815b842a
   Endo A, 2004, ATHEROSCLEROSIS SUPP, V5, P125, DOI 10.1016/j.atherosclerosissup.2004.08.033
   Fauchier L, 2008, J AM COLL CARDIOL, V51, P828, DOI 10.1016/j.jacc.2007.09.063
   Frost FJ, 2007, CHEST, V131, P1006, DOI 10.1378/chest.06-1997
   Fukuta H, 2005, CIRCULATION, V112, P357, DOI 10.1161/CIRCULATIONAHA.104.519876
   Go AS, 2006, JAMA-J AM MED ASSOC, V296, P2105, DOI 10.1001/jama.296.17.2105
   Goldberger JJ, 2006, J AM COLL CARDIOL, V48, P1228, DOI 10.1016/j.jacc.2006.05.053
   Gupta A, 2004, AM J OPHTHALMOL, V137, P675, DOI 10.1016/j.ajo.2003.11.017
   Gupta R, 2007, JAMA-J AM MED ASSOC, V297, P1455, DOI 10.1001/jama.297.13.1455
   Hackam DG, 2006, LANCET, V367, P413, DOI 10.1016/S0140-6736(06)68041-0
   Hajjar L, 2002, J GERONTOL A-BIOL, V57, pM414, DOI 10.1093/gerona/57.7.M414
   Hong SK, 2007, J UROLOGY, V178, P613, DOI 10.1016/j.juro.2007.03.132
   Horwich TB, 2004, J AM COLL CARDIOL, V43, P642, DOI 10.1016/j.jacc.2003.07.049
   Humphries KH, 2007, AM HEART J, V154, P908, DOI 10.1016/j.ahj.2007.07.015
   Jenkins GH, 1996, AM J CARDIOL, V78, P1453, DOI 10.1016/S0002-9149(96)00637-6
   Jick H, 2000, LANCET, V356, P1627, DOI 10.1016/S0140-6736(00)03155-X
   Jo SH, 2008, AM HEART J, V155, DOI 10.1016/j.ahj.2007.11.042
   Johnson BA, 2003, AM J RESP CRIT CARE, V167, P1271, DOI 10.1164/rccm.200205-410OC
   Karp I, 2008, AM J MED, V121, P302, DOI 10.1016/j.amjmed.2007.12.011
   Keddissi JI, 2007, CHEST, V132, P1764, DOI 10.1378/chest.07-0298
   Khanal S, 2005, AM J MED, V118, P843, DOI 10.1016/j.amjmed.2005.03.031
   Khurana V, 2007, CHEST, V131, P1282, DOI 10.1378/chest.06-0931
   Khush KK, 2007, CIRCULATION, V115, P576, DOI 10.1161/CIRCULATIONAHA.106.625574
   Kjekshus J, 2007, NEW ENGL J MED, V357, P2248, DOI 10.1056/NEJMoa0706201
   Klein BEK, 2006, JAMA-J AM MED ASSOC, V295, P2752, DOI 10.1001/jama.295.23.2752
   Klein R, 2003, ARCH OPHTHALMOL-CHIC, V121, P1151, DOI 10.1001/archopht.121.8.1151
   Klein R, 2007, AM J OPHTHALMOL, V144, P1, DOI 10.1016/j.ajo.2007.02.047
   KOBASHIGAWA JA, 1995, NEW ENGL J MED, V333, P621, DOI 10.1056/NEJM199509073331003
   Kourliouros A, 2008, ANN THORAC SURG, V85, P1515, DOI 10.1016/j.athoracsur.2008.01.040
   LaCroix AZ, 2008, J GERONTOL A-BIOL, V63, P369, DOI 10.1093/gerona/63.4.369
   LaCroix AZ, 2003, ANN INTERN MED, V139, P97, DOI 10.7326/0003-4819-139-2-200307150-00009
   Lai HM, 2008, AM J CARDIOL, V102, P77, DOI 10.1016/j.amjcard.2008.02.103
   Lee TM, 2008, AM J CARDIOL, V101, P530, DOI 10.1016/j.amjcard.2007.09.102
   Lertsburapa K, 2008, J THORAC CARDIOV SUR, V135, P405, DOI 10.1016/j.jtcvs.2007.08.049
   Levantesi G, 2007, AM J CARDIOL, V100, P1644, DOI 10.1016/j.amjcard.2007.07.015
   Li G, 2007, NEUROLOGY, V69, P878, DOI 10.1212/01.wnl.0000277657.95487.1c
   Li G, 2004, NEUROLOGY, V63, P1624, DOI 10.1212/01.WNL.0000142963.90204.58
   Maki-Petaja KM, 2007, J AM COLL CARDIOL, V50, P852, DOI 10.1016/j.jacc.2007.04.076
   Majumdar SR, 2006, BMJ-BRIT MED J, V333, P999, DOI 10.1136/BMJ.38992.565972.7C
   Mancini GBJ, 2006, J AM COLL CARDIOL, V47, P2554, DOI 10.1016/j.jacc.2006.04.039
   Marin F, 2006, AM J CARDIOL, V97, P55, DOI 10.1016/j.amjcard.2005.07.124
   Mariscalco G, 2007, ANN THORAC SURG, V84, P1158, DOI 10.1016/j.athoracsur.2007.05.021
   McCarey DW, 2004, LANCET, V363, P2015, DOI 10.1016/S0140-6736(04)16449-0
   McGirt MJ, 2006, J NEUROSURG, V105, P671, DOI 10.3171/jns.2006.105.5.671
   McGwin G, 2004, ARCH OPHTHALMOL-CHIC, V122, P822, DOI 10.1001/archopht.122.6.822
   McLean DS, 2008, AM HEART J, V155, P298, DOI 10.1016/j.ahj.2007.10.024
   Mehra MR, 2002, J AM COLL CARDIOL, V40, P1609, DOI 10.1016/S0735-1097(02)02340-9
   Meier CR, 2001, JAMA-J AM MED ASSOC, V286, P669, DOI 10.1001/jama.286.6.669
   Menzies D, 2007, J ALLERGY CLIN IMMUN, V119, P328, DOI 10.1016/j.jaci.2006.10.014
   Merx MW, 2004, CIRCULATION, V109, P2560, DOI 10.1161/01.CIR.0000129774.09737.5B
   Muldoon MF, 2000, AM J MED, V108, P538, DOI 10.1016/S0002-9343(00)00353-3
   Muldoon MF, 2004, AM J MED, V117, P823, DOI 10.1016/j.amjmed.2004.07.041
   Nadrous HF, 2004, CHEST, V126, P438, DOI 10.1016/S0012-3692(15)31155-7
   Ovbiagele B, 2007, NEUROLOGY, V68, P2129, DOI 10.1212/01.wnl.0000264931.34941.f0
   Ozaydin M, 2006, AM J CARDIOL, V97, P1490, DOI 10.1016/j.amjcard.2005.11.082
   Pasco JA, 2002, ARCH INTERN MED, V162, P537, DOI 10.1001/archinte.162.5.537
   Patti G, 2008, AM J CARDIOL, V101, P279, DOI 10.1016/j.amjcard.2007.08.030
   Patti G, 2006, CIRCULATION, V114, P1455, DOI 10.1161/CIRCULATIONAHA.106.621763
   PEDERSEN TR, 1994, LANCET, V344, P1383
   Pocobelli G, 2008, CANCER-AM CANCER SOC, V112, P27, DOI 10.1002/cncr.23129
   Poynter JN, 2005, NEW ENGL J MED, V352, P2184, DOI 10.1056/NEJMoa043792
   Pritchett JW, 2001, CLIN ORTHOP RELAT R, P173
   Ramani G, 2007, AM J CARDIOL, V100, P404, DOI 10.1016/j.amjcard.2007.03.034
   Ray JG, 2005, ARCH INTERN MED, V165, P62, DOI 10.1001/archinte.165.1.62
   Ray JG, 2001, ARCH INTERN MED, V161, P1405, DOI 10.1001/archinte.161.11.1405
   Rea TD, 2005, ARCH NEUROL-CHICAGO, V62, P1047, DOI 10.1001/archneur.62.7.1047
   Richter B, 2007, AM HEART J, V153, P113, DOI 10.1016/j.ahj.2006.09.006
   Rinfret S, 2008, AM HEART J, V155, P316, DOI 10.1016/j.ahj.2007.09.004
   Rosenhek R, 2004, CIRCULATION, V110, P1291, DOI 10.1161/01.CIR.0000140723.15274.53
   Schlienger RG, 2001, ARCH INTERN MED, V161, P2021, DOI 10.1001/archinte.161.16.2021
   Schouten O, 2006, AM J CARDIOL, V97, P1383, DOI 10.1016/j.amjcard.2005.11.063
   Scranton RE, 2005, ARCH INTERN MED, V165, P2007, DOI 10.1001/archinte.165.17.2007
   Sen K, 2002, DIABETES RES CLIN PR, V56, P1, DOI 10.1016/S0168-8227(01)00341-2
   Setoguchi S, 2007, CIRCULATION, V115, P27, DOI 10.1161/CIRCULATIONAHA.106.650176
   Shah R, 2008, AM J CARDIOL, V101, P217, DOI 10.1016/j.amjcard.2007.08.050
   Simon A, 2004, CLIN PHARMACOL THER, V75, P476, DOI 10.1016/j.clpt.2004.01.012
   Singhal AB, 2005, NEUROLOGY, V64, P1008, DOI 10.1212/01.WNL.0000154523.21633.0E
   Siu CW, 2003, AM J CARDIOL, V92, P1343, DOI 10.1016/j.amjcard.2003.08.023
   Song YB, 2008, AM HEART J, V156, DOI 10.1016/j.ahj.200804.020
   Sparks DL, 2005, ARCH NEUROL-CHICAGO, V62, P753, DOI 10.1001/archneur.62.5.753
   Stewart RA, 2000, ARCH INTERN MED, V160, P3144, DOI 10.1001/archinte.160.20.3144
   Strandberg TE, 2004, LANCET, V364, P771, DOI 10.1016/S0140-6736(04)16936-5
   Sukhija R, 2008, AM J CARDIOL, V101, P975, DOI 10.1016/j.amjcard.2007.11.042
   Szwast SJ, 2007, NEUROLOGY, V69, P1873, DOI 10.1212/01.wnl.0000279333.77404.d7
   Tabata M, 2007, AM J CARDIOL, V100, P442, DOI 10.1016/j.amjcard.2007.03.071
   Tan JSL, 2007, AM J OPHTHALMOL, V143, P687, DOI 10.1016/j.ajo.2006.11.027
   Tan JSL, 2007, AM J OPHTHALMOL, V143, P685, DOI 10.1016/j.ajo.2006.11.021
   Tavazzi L, 2008, LANCET, V372, P1231, DOI 10.1016/S0140-6736(08)61240-4
   Thomsen RW, 2006, CRIT CARE MED, V34, P1080, DOI 10.1097/01.CCM.0000207345.92928.E4
   Tonelli M, 2005, CIRCULATION, V112, P171, DOI 10.1161/CIRCULATIONAHA.104.517565
   Tsai CT, 2008, AM HEART J, V156, P65, DOI 10.1016/j.ahj.2008.01.028
   Tseng MY, 2007, J NEUROSURG, V107, P1092, DOI 10.3171/JNS-07/12/1092
   Tveit A, 2004, AM J CARDIOL, V93, P780, DOI 10.1016/j.amjcard.2003.12.009
   *US FDA, EL OR BOOK APPR DRUG
   Van Leeuwen R, 2004, OPHTHALMOLOGY, V111, P1169, DOI 10.1016/j.ophtha.2003.10.024
   van Staa TP, 2001, JAMA-J AM MED ASSOC, V285, P1850, DOI 10.1001/jama.285.14.1850
   Verma A, 2005, AM J CARDIOL, V96, P1290, DOI 10.1016/j.amjcard.2005.06.074
   Vidt DG, 2006, AM J CARDIOL, V97, P1602, DOI 10.1016/j.amjcard.2005.12.052
   Vinogradova Y, 2007, GASTROENTEROLOGY, V133, P393, DOI 10.1053/j.gastro.2007.05.023
   Virani SS, 2008, AM HEART J, V155, P541, DOI 10.1016/j.ahj.2007.10.027
   Vollmer T, 2004, LANCET, V363, P1607, DOI 10.1016/S0140-6736(04)16205-3
   Vyas AK, 2006, J AM COLL CARDIOL, V47, P769, DOI 10.1016/j.jacc.2005.09.053
   Wahner AD, 2008, NEUROLOGY, V70, P1418, DOI 10.1212/01.wnl.0000286942.14552.51
   Wang PS, 2000, JAMA-J AM MED ASSOC, V283, P3211, DOI 10.1001/jama.283.24.3211
   Williams TM, 2008, ANN SURG, V247, P30, DOI 10.1097/SLA.0b013e3181492c0d
   Wu AH, 2005, AM J CARDIOL, V95, P367, DOI 10.1016/j.amjcard.2004.09.035
   Yaffe K, 2002, ARCH NEUROL-CHICAGO, V59, P378, DOI 10.1001/archneur.59.3.378
   Yamada T, 2007, AM HEART J, V153, DOI 10.1016/j.ahj.2007.03.027
   Young-Xu Y, 2003, J AM COLL CARDIOL, V42, P690, DOI 10.1016/S0735-1097(03)00785-X
   Young-Xu YN, 2003, AM J CARDIOL, V92, P1379, DOI 10.1016/j.amjcard.2003.08.040
   Zandi PP, 2005, ARCH GEN PSYCHIAT, V62, P217, DOI 10.1001/archpsyc.62.2.217
NR 137
TC 30
Z9 34
U1 0
U2 6
PU ADIS INT LTD
PI NORTHCOTE
PA 5 THE WAREHOUSE WAY, NORTHCOTE 0627, AUCKLAND, NEW ZEALAND
SN 1175-3277
EI 1179-187X
J9 AM J CARDIOVASC DRUG
JI Am. J. Cardiovasc. Drugs
PY 2009
VL 9
IS 6
BP 361
EP 370
DI 10.2165/11315710-000000000-00000
PG 10
WC Cardiac & Cardiovascular Systems; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cardiovascular System & Cardiology; Pharmacology & Pharmacy
GA 541ZC
UT WOS:000273459500002
PM 19929034
DA 2022-11-30
ER

PT J
AU Montero, JA
   Ruiz-Moreno, JM
   Sanchez-de Castro, MJ
   Fabiani, C
AF Montero, J. A.
   Ruiz-Moreno, J. M.
   Sanchez-de Castro, M. J.
   Fabiani, C.
TI Low vision aid in exudative macular degeneration treated by photodynamic
   therapy and thermal laser photocoagulation
SO INTERNATIONAL JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE age-related macular degeneration; photodynamic therapy; thermal laser;
   low vision rehabilitation
AB AIM: To determine the efficacy of low vision rehabilitation (LVR) in patients with age-related macular degeneration (AMD) treated by photodynamic therapy (PDT) compared to those treated by thermal laser photocoagulation (TLP).
   METHODS: A retrospective study was performed examining the files of 42 patients (42 eyes) with AMD who had been treated either by TLP (Group 1) and PDT (Group 2). Once AMD was considered to be inactive they underwent visual rehabilitation in the LVR Unit in order to increase their ability for distant and near vision.
   RESULTS: Eighteen eyes had received PDT and 24 had received TLP. Average corrected visual acuity after laser therapy was 0.14 in Group 1, and 0.16 in Group 2. No statistically significant differences were found between both groups before and after laser therapy. Both groups showed improvement after LVR; however, statistically significant differences between both groups were found only for near vision.
   CONCLUSION: Our findings suggest that even though both PDT and TLP are associated to a decreased visual acuity after treatment, LVR may be more successful for near vision among patients treated by PDT
C1 [Montero, J. A.; Ruiz-Moreno, J. M.; Fabiani, C.] Inst Oftalmol Alicante, Vitreoretinal Unit, Alicante, Spain.
   [Ruiz-Moreno, J. M.] Miguel Hernndez Univ, Sch Med, Dept Ophthalmol, Alicante, Spain.
   [Sanchez-de Castro, M. J.] Inst Oftalmol Alicante, Low Vis Unit, Alicante, Spain.
RP Montero, JA (通讯作者)，Inst Oftalmol Alicante, Vitreoretinal Unit, Alicante, Spain.
EM msm02va@wanadoo.es
RI Ruiz-Moreno, José M/E-4644-2016
CR Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   COSCAS G, 1991, ARCH OPHTHALMOL-CHIC, V109, P1258, DOI 10.1001/archopht.1991.01080090082028
   CUSTIS PH, 1993, CURR OPIN OPHTHALMOL, V4, P7, DOI 10.1097/00055735-199306000-00003
   Ergun E, 2003, OPHTHALMOLOGY, V110, P65, DOI 10.1016/S0161-6420(02)01566-X
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   HAWKINS BS, 1991, ARCH OPHTHALMOL-CHIC, V109, P1109
   la Cour M, 2002, DRUG AGING, V19, P101, DOI 10.2165/00002512-200219020-00003
   *LOW VIS SERV CONS, 1999, REC FUT SERV DEL UK
   MAGUIRE MG, 1994, ARCH OPHTHALMOL-CHIC, V112, P489
   Mainster M A, 2001, Semin Ophthalmol, V16, P55, DOI 10.1076/soph.16.2.55.4213
   Pawlak D, 2004, AM J OPHTHALMOL, V137, P880, DOI 10.1016/j.ajo.2003.12.041
   Postelmans L, 2004, AM J OPHTHALMOL, V138, P803, DOI 10.1016/j.ajo.2004.06.033
   Schmidt-Erfurth UM, 2004, OPHTHALMOLOGY, V111, P931, DOI 10.1016/j.ophtha.2003.12.025
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1242
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1220
   TIMBERLAKE GT, 1986, INVEST OPHTH VIS SCI, V27, P1137
   Tzekov R, 2006, INVEST OPHTH VIS SCI, V47, P377, DOI 10.1167/iovs.05-0838
   Verma Lalit, 2004, Indian Journal of Ophthalmology, V52, P35
NR 18
TC 0
Z9 0
U1 0
U2 0
PU IJO PRESS
PI XI AN
PA NO 269 YOUYI EAST RD, XI AN, 710054, PEOPLES R CHINA
SN 2222-3959
EI 2227-4898
J9 INT J OPHTHALMOL-CHI
JI Int. J. Ophthalmol.
PD DEC 18
PY 2008
VL 1
IS 4
BP 359
EP 361
PG 3
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA V13QZ
UT WOS:000207682600017
DA 2022-11-30
ER

PT J
AU Leitritz, M
   Gelisken, F
   Inhoffen, W
   Voelker, M
   Ziemssen, F
AF Leitritz, M.
   Gelisken, F.
   Inhoffen, W.
   Voelker, M.
   Ziemssen, F.
TI Can the risk of retinal pigment epithelium tears after bevacizumab
   treatment be predicted? An optical coherence tomography study
SO EYE
LA English
DT Article
DE Bevazicumab; anti-VEGF; pigment epithelial tear; age-related macular
   degeneration; pigment epithelium detachment; optical coherence
   tomography
ID MACULAR DEGENERATION; INTRAVITREAL INJECTION; DETACHMENTS; AVASTIN;
   PRETEAR
AB Background Retinal pigment epithelium (RPE) tears after bevacizumab treatment for neovascular age-related macular degeneration accompanied by a pigment epithelial detachment (PED) might be caused by stretching forces on the already weakened RPE. The purpose of this study was to evaluate whether simple measurements of optical coherence tomography (OCT) can predict the individual risk of an RPE tear in preoperative candidates.
   Methods A retrospective chart review study of 393 consecutive patients with neovascular agerelated macular degeneration evaluated OCT images (Stratus-OCT Zeiss, Jena, Germany). The height of the PED, the central retinal thickness, and the maximum retinal thickness were determined by two independent observers and retrospectively analysed.
   Results Fifteen patients with an RPE tear had a significant higher PED than the remaining study population. In contrast, no correlation was seen with the central retinal thickness. In a linear regression model, the probability of an RPE tear exponentially increased in dependence of the extent of PED.
   Conclusion The risk of an RPE tear can be estimated by simple measurement of the height of the PED on OCT.
C1 [Leitritz, M.; Gelisken, F.; Inhoffen, W.; Voelker, M.; Ziemssen, F.] Univ Eye Hosp, Dept Ophthalmol, D-72076 Tubingen, Germany.
C3 Eberhard Karls University of Tubingen; Eberhard Karls University
   Hospital
RP Ziemssen, F (通讯作者)，Univ Eye Hosp, Dept Ophthalmol, Schleichstr 12, D-72076 Tubingen, Germany.
EM Focke.Ziemssen@med.uni-tuebingen.de
RI Ziemssen, Focke/AAY-1686-2021; , Ziemssen/B-9564-2009
OI , Ziemssen/0000-0002-3873-0581; Leitritz, Martin/0000-0001-5179-2536
CR Chan CK, 2007, RETINA-J RET VIT DIS, V27, P541, DOI 10.1097/IAE.0b013e3180cc2612
   COSCAS G, 1990, ARCH OPHTHALMOL-CHIC, V108, P1687, DOI 10.1001/archopht.1990.01070140041025
   GELISKEN F, 2008, EYE
   Gelisken F, 2006, ACTA OPHTHALMOL SCAN, V84, P833, DOI 10.1111/j.1600-0420.2006.00765.x
   Kunze C, 1999, OPHTHALMOLOGY, V106, P1830, DOI 10.1016/S0161-6420(99)90364-0
   Lafaut BA, 2001, BRIT J OPHTHALMOL, V85, P454, DOI 10.1136/bjo.85.4.454
   Mathews JP, 2007, EYE, V21, P1004, DOI 10.1038/sj.eye.6702805
   Meyer CH, 2006, BRIT J OPHTHALMOL, V90, P1207, DOI 10.1136/bjo.2006.093732
   Nicolo M, 2006, EUR J OPHTHALMOL, V16, P770, DOI 10.1177/112067210601600521
   Pauleikhoff D, 2002, GRAEF ARCH CLIN EXP, V240, P533, DOI 10.1007/s00417-002-0505-8
NR 10
TC 38
Z9 40
U1 0
U2 1
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-222X
EI 1476-5454
J9 EYE
JI Eye
PD DEC
PY 2008
VL 22
IS 12
BP 1504
EP 1507
DI 10.1038/eye.2008.145
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 382EY
UT WOS:000261589200011
PM 18535608
OA Bronze
DA 2022-11-30
ER

PT J
AU Kelly, J
   Khan, AA
   Yin, J
   Ferguson, TA
   Apte, RS
AF Kelly, Jennifer
   Khan, Aslarn Ali
   Yin, Jiyi
   Ferguson, Thomas A.
   Apte, Rajendra S.
TI Senescence regulates macrophage activation and angiogenic fate at sites
   of tissue injury in mice
SO JOURNAL OF CLINICAL INVESTIGATION
LA English
DT Article
ID EXPERIMENTAL CHOROIDAL NEOVASCULARIZATION; MACULAR DEGENERATION; AGE;
   MODEL; EPIDEMIOLOGY; SEVERITY
AB Abnormal angiogenesis plays a key role in diseases of aging such as heart disease, certain cancers, and eye diseases including age-related macular degeneration. Macrophages have been shown previously to be both anti- and proangiogenic, and their role in regulating angiogenesis at sites of tissue injury is critical and complex. In this study, we analyzed cytokine gene expression patterns of mouse macrophages by real-time quantitative PCR and tested the functional effects of senescence on gene expression and macrophage polarization. Following laser injury to the retina, IL-10 was upregulated and Fas ligand (FasL), IL-12, and TNF-alpha were downregulated in ocular macrophages of old mice (>18 months of age). Downregulation of FasL on macrophages led to a loss of the antiangiogenic phenotype, as evidenced by the inability of these macrophages to inhibit vascular endothelial cells. Our results demonstrate that senescence, FasL, and IL-10 are key determinants of macrophage function that alter the growth of abnormal postdevelopmental blood vessels in disease processes including blinding eye disease.
C1 Washington Univ, Sch Med, Dept Ophthalmol & Visual Sci, St Louis, MO 63110 USA.
C3 Washington University (WUSTL)
RP Kelly, J (通讯作者)，Washington Univ, Sch Med, Dept Ophthalmol & Visual Sci, 660 S Euclid Ave,Box 8096, St Louis, MO 63110 USA.
RI Mohammed, Imran/J-8271-2012
OI Mohammed, Imran/0000-0002-8412-0768
FU NATIONAL EYE INSTITUTE [F32EY006765, K08EY016139, P30EY002687,
   R01EY006765, R01EY012826] Funding Source: NIH RePORTER; NATIONAL
   INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P60DK020579]
   Funding Source: NIH RePORTER; NEI NIH HHS [P30 EY002687, K08EY016139,
   F32 EY006765, R01 EY012826, K08 EY016139, R01 EY006765, EY12826,
   EY02687, EY06765] Funding Source: Medline; NIDDK NIH HHS [P60 DK020579,
   5 P60 DK20579] Funding Source: Medline
CR Ambati J, 2003, NAT MED, V9, P1390, DOI 10.1038/nm950
   Apte RS, 2006, PLOS MED, V3, P1371, DOI 10.1371/journal.pmed.0030310
   Espinosa-Heidmann DG, 2003, INVEST OPHTH VIS SCI, V44, P3586, DOI 10.1167/iovs.03-0038
   Espinosa-Heidmann DG, 2002, INVEST OPHTH VIS SCI, V43, P1567
   Gomez CR, 2005, CURR OPIN IMMUNOL, V17, P457, DOI 10.1016/j.coi.2005.07.013
   Hansson GK, 2005, NEW ENGL J MED, V352, P1685, DOI 10.1056/NEJMra043430
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Lamagna C, 2006, J LEUKOCYTE BIOL, V80, P705, DOI 10.1189/jlb.1105656
   Lobov IB, 2005, NATURE, V437, P417, DOI 10.1038/nature03928
   Mantovani A, 2005, IMMUNITY, V23, P344, DOI 10.1016/j.immuni.2005.10.001
   Mosser DM, 2003, J LEUKOCYTE BIOL, V73, P209, DOI 10.1189/jlb.0602325
   Nakamori T, 2001, ISL ARC, V10, P1, DOI 10.1046/j.1440-1738.2001.00276.x
   Sica A, 2006, EUR J CANCER, V42, P717, DOI 10.1016/j.ejca.2006.01.003
   Taylor PR, 2005, ANNU REV IMMUNOL, V23, P901, DOI 10.1146/annurev.immunol.23.021704.115816
   van Leeuwen R, 2003, EUR J EPIDEMIOL, V18, P845, DOI 10.1023/A:1025643303914
NR 15
TC 170
Z9 180
U1 0
U2 3
PU AMER SOC CLINICAL INVESTIGATION INC
PI ANN ARBOR
PA 35 RESEARCH DR, STE 300, ANN ARBOR, MI 48103 USA
SN 0021-9738
J9 J CLIN INVEST
JI J. Clin. Invest.
PD NOV
PY 2007
VL 117
IS 11
BP 3421
EP 3426
DI 10.1172/JCI32430
PG 6
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA 227RR
UT WOS:000250676000034
PM 17975672
OA Green Published, Bronze, Green Submitted
DA 2022-11-30
ER

PT J
AU Jacko, JA
   Moloney, KP
   Kongnakorn, T
   Barnard, L
   Edwards, PJ
   Leonard, VK
   Sainfort, F
AF Jacko, JA
   Moloney, KP
   Kongnakorn, T
   Barnard, L
   Edwards, PJ
   Leonard, VK
   Sainfort, F
TI Multimodal feedback as a solution to ocular disease-based user
   performance decrements in the absence of functional visual loss
SO INTERNATIONAL JOURNAL OF HUMAN-COMPUTER INTERACTION
LA English
DT Article
ID FUNCTION QUESTIONNAIRE; DESIGN PRINCIPLES; SPATIAL ATTENTION; TACTILE;
   VISION; LINKS
AB This study examines effects of the most common cause of blindness in persons over the age of 55 in the United States, age-related macular degeneration (AMD), on the performance of older adults when completing a simple computer-based task. Older users with normal vision (n = 6) and with AMD (n = 6) performed a series of drag-and-drop tasks that incorporated a variety of different feedback modalities. The user groups were equivalent with respect to traditional visual function parameters (i.e., visual acuity,. contrast sensitivity, and color vision) and measured subject cofactors, aside from the presence or absence of AMD (i.e., drusen and retinal pigment epithelial mottling). Task performance was assessed with measures of time (trial time and feedback exposure time) and accuracy (error frequency). Results indicate that users with AMD exhibited decreased performance with respect to required feedback exposure time, total trial time, and errors committed. Some nonvisual and multimodal feedback forms show potential as solutions for enhanced performance, for those with AMD as well as for visually healthy older adults.
C1 Georgia Inst Technol, Sch Ind & Syst Engn, Atlanta, GA 30332 USA.
   Univ Miami, Sch Med, Bascom Palmer Eye Inst, Coral Gables, FL 33124 USA.
C3 University System of Georgia; Georgia Institute of Technology; Bascom
   Palmer Eye Institute; University of Miami
RP Jacko, JA (通讯作者)，Georgia Inst Technol, Sch Ind & Syst Engn, Atlanta, GA 30332 USA.
EM jacko@isye.gatech.edu
OI Scott, Ingrid/0000-0002-3908-7153
CR Adler FH, 2003, ADLERS PHYSL EYE CLI
   AKAMATSU M, 1995, ERGONOMICS, V38, P816, DOI 10.1080/00140139508925152
   ALBERTI WE, 2000, AGE RELATED DEGENERA
   *AM FDN BLIND, 2000, STAT SOURC PROF PREV
   *AM MAC DEG FDN, 2003, WHAT MAC DEG
   ANDERSON JD, 1993, WIDE ANGLE, V15, P30
   BAILEY IL, 1976, AM J OPTOM PHYS OPT, V53, P740
   Belz SM, 1999, HUM FACTORS, V41, P608, DOI 10.1518/001872099779656734
   Biggs SJ, 2002, HUM FAC ER, P93
   BIGLAN AW, 1988, HDB DEV PHYS DISABIL, P471
   Brewster S., 1998, P INT C AUD DISPL IC, P1
   Brewster SA, 1999, BEHAV INFORM TECHNOL, V18, P165, DOI 10.1080/014492999119066
   BREWSTER SA, 1994, HUMAN FACTORS IN COMPUTING SYSTEMS, CHI '94 CONFERENCE PROCEEDINGS - CELEBRATING INTERDEPENDENCE, P173
   Burdea Grigore C, 1996, FORCE TOUCH FEEDBACK
   Clemons TE, 2003, ARCH OPHTHALMOL-CHIC, V121, P211
   *CTR AG SOC, 2002, VIS IMP
   Deibert E, 1999, NEUROLOGY, V52, P1413, DOI 10.1212/WNL.52.7.1413
   DIX AJ, 1998, HUMAN COMPUTER INTER
   Driver J, 2000, CURR BIOL, V10, pR731, DOI 10.1016/S0960-9822(00)00740-5
   Dyson BJ, 2002, J EXP PSYCHOL HUMAN, V28, P1483, DOI 10.1037//0096-1523.28.6.1483
   Eimer M, 2000, PSYCHOPHYSIOLOGY, V37, P697, DOI 10.1111/1469-8986.3750697
   ETSI, 2002, HUM FACT HF GUID MUL
   Farnsworth D, 1947, FARNSWORTH DICHOTOMO
   FARRELL FE, 1991, VISION VISUAL DYSFUN, V15, P7
   FERRIS FL, 1982, AM J OPHTHALMOL, V94, P91, DOI 10.1016/0002-9394(82)90197-0
   Feygin D, 2002, 10TH SYMPOSIUM ON HAPTIC INTERFACES FOR VIRTUAL ENVIRONMENT AND TELEOPERATOR SYSTEMS, PROCEEDINGS, P40, DOI 10.1109/HAPTIC.2002.998939
   Fitts P.M., 1967, HUM PERFORM
   Fraser J., 2000, P 4 INT ACM C ASS TE, P9
   Gaver W. W., 1989, Human-Computer Interaction, V4, P67, DOI 10.1207/s15327051hci0401_3
   Gerber E, 2001, J VISUAL IMPAIR BLIN, V95, P176, DOI 10.1177/0145482X0109500308
   Giard MH, 1999, J COGNITIVE NEUROSCI, V11, P473, DOI 10.1162/089892999563544
   HEDGE A, 1999, HUMAN INFORMATION PR
   Inkpen K. M., 2001, ACM Transactions on Computer-Human Interaction, V8, P1, DOI 10.1145/371127.371146
   Jacko J., 2003, P SIGCHI C HUM FACT, P33, DOI DOI 10.1145/642611.642619
   Jacko J. A., 2001, Universal Access in the Information Society, V1, P56
   Jacko J. A., 2002, Universal Access in the Information Society, V1, P197, DOI 10.1007/s102090100015
   Jacko J. A., 2000, P 4 INT ACM C ASS TE, P1
   Jacko JA, 2003, LECT NOTES COMPUT SC, V2615, P3
   Jacko JA, 2000, INT J HUM-COMPUT INT, V12, P135, DOI 10.1207/S15327590IJHC1201_6
   Jacko JA, 2000, INT J HUM-COMPUT INT, V12, P151, DOI 10.1207/S15327590IJHC1201_7
   JACKO JA, 2004, LETTERS, V6, P311
   JACKO JA, 2000, ACM EYE TRACKING RES, P112
   JACKO JA, 2000, P 14 TRIENN C INT ER, P116
   JACKO JA, 1999, P 9 ANN INT C HUM CO, P975
   JACKO JA, 2001, P 9 INT C HUM COMP I, P423
   Joiner R, 1998, COMPUT HUM BEHAV, V14, P513, DOI 10.1016/S0747-5632(98)00021-1
   Kennett S, 2001, J COGNITIVE NEUROSCI, V13, P462, DOI 10.1162/08989290152001899
   King AJ, 2001, CURR BIOL, V11, pR322, DOI 10.1016/S0960-9822(01)00175-0
   KLATZKY RL, 1993, J EXP PSYCHOL HUMAN, V19, P726
   KOHLRAUSCH A, 1999, P IS T SPIE 99 C HUM, V4, P34
   Lundberg L, 1999, MED DECIS MAKING, V19, P128, DOI 10.1177/0272989X9901900203
   *MAC DEG PARTN, 2004, WHAT AMD
   Mackenzie I. S., 2001, P SIGCHI C HUM FACT, P9
   MacKenzie I.S., 1991, P CHI 91 C HUM FACT, P161, DOI DOI 10.1145/108844.108868
   Mangione CM, 1998, ARCH OPHTHALMOL-CHIC, V116, P227
   Mangione CM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1050, DOI 10.1001/archopht.119.7.1050
   MARKS LE, 1982, J EXPT PSYCHOL HUMAN, V14, P726
   MCGEE MR, 1999, P 1 PHANTOM US RES S, P17
   MEREDITH MA, 1986, J NEUROPHYSIOL, V56, P640, DOI 10.1152/jn.1986.56.3.640
   *NAT EYE I, 2004, AG REL MAC DEG WHAT
   Neter J., 1990, APPL LINEAR STAT MOD
   OAKLEY I, 2000, P CHI 2000, P415, DOI DOI 10.1145/332040.332467
   Pappas C.J, 1999, P ASS COMP MACH C HU, P330
   PELLI DG, 1988, CLIN VISION SCI, V2, P187
   Popescu GV, 2002, HUM FAC ER, P435
   Quillen DA, 1999, AM FAM PHYSICIAN, V60, P99
   RICHARD P, 1994, P ICAT 94 C, P49
   ROCK I, 1964, SCIENCE, V143, P594, DOI 10.1126/science.143.3606.594
   *SCHEP EYE RES I, 2002, EYE DIS INF RES AMD
   Scott IU, 2002, AM J OPHTHALMOL, V133, P350, DOI 10.1016/S0002-9394(01)01406-4
   Sellen A. J., 1992, Human-Computer Interaction, V7, P141, DOI 10.1207/s15327051hci0702_1
   SELLEN AJ, 1990, HUMAN COMPUTER INTER, V90, P667
   Stanney K, 2004, INT J HUM-COMPUT INT, V17, P229, DOI 10.1207/s15327590ijhc1702_7
   Stephen I. O., 2001, P 2001 ACM C HUM FAC, P357
   Storms RL, 2002, HUM FAC ER, P455
   Tiffin J, 1948, J APPL PSYCHOL, V32, P234, DOI 10.1037/h0061266
   Vitense HS, 2003, ERGONOMICS, V46, P68, DOI 10.1080/00140130303534
   WARE J, 1995, SF12 SCORE SF12 PHYS
   Welch R, 1986, HDB PERCEPTION HUMAN, V1
   Wickens C.D., 1992, ENG PSYCHOL HUMAN PE, V2nd ed.
   2005, MACULAR DEGENERATION
   [No title captured]
   2004, WHAT MACULAR DEGENER
   2002, PHOTODYNAMIC THERAPY
NR 84
TC 13
Z9 13
U1 0
U2 2
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1044-7318
EI 1532-7590
J9 INT J HUM-COMPUT INT
JI Int. J. Hum.-Comput. Interact.
PY 2005
VL 18
IS 2
BP 183
EP 218
DI 10.1207/s15327590ijhc1802_4
PG 36
WC Computer Science, Cybernetics; Ergonomics
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Computer Science; Engineering
GA 922DO
UT WOS:000228816500004
DA 2022-11-30
ER

PT J
AU Caban, M
   Owczarek, K
   Lewandowska, U
AF Caban, Milosz
   Owczarek, Katarzyna
   Lewandowska, Urszula
TI The Role of Metalloproteinases and Their Tissue Inhibitors on Ocular
   Diseases: Focusing on Potential Mechanisms
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Review
DE ocular diseases; matrix metalloproteinases; tissue inhibitor of matrix;
   metalloproteinases; gelatinases
ID TRANSFORMING-GROWTH-FACTOR; LENS EPITHELIAL-CELLS; OPEN-ANGLE GLAUCOMA;
   GLUCOCORTICOID-INDUCIBLE MMP1; HUMAN TRABECULAR MESHWORK; DRY EYE
   DISEASE; MATRIX METALLOPROTEINASES; EXTRACELLULAR-MATRIX; AQUEOUS-HUMOR;
   DIABETIC-RETINOPATHY
AB Eye diseases are associated with visual impairment, reduced quality of life, and may even lead to vision loss. The efficacy of available treatment of eye diseases is not satisfactory. The unique environment of the eye related to anatomical and physiological barriers and constraints limits the bioavailability of existing agents. In turn, complex ethiopathogenesis of ocular disorders that used drugs generally are non-disease specific and do not act causally. Therefore, there is a need for the development of a new therapeutic and preventive approach. It seems that matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) have a significant role in the development and progression of eye diseases and could be used in the therapy of these disorders as pharmacological targets. MMPs and TIMPs play an important role in the angiogenesis, epithelial-mesenchymal transition, cell invasion, and migration, which occur in ocular diseases. In this review, we aim to describe the participation of MMPs and TIMPs in the eye diseases, such as age-related macular degeneration, cataract, diabetic retinopathy, dry eye syndrome, glaucoma, and ocular cancers, posterior capsule opacification focusing on potential mechanisms.
C1 [Caban, Milosz; Owczarek, Katarzyna; Lewandowska, Urszula] Med Univ Lodz, Dept Biochem, PL-92215 Lodz, Poland.
C3 Medical University Lodz
RP Lewandowska, U (通讯作者)，Med Univ Lodz, Dept Biochem, PL-92215 Lodz, Poland.
EM milosz.caban@stud.umed.lodz.pl; katarzyna.owczarek@umed.lodz.pl;
   urszula.lewandowska@umed.lodz.pl
OI Caban, Milosz/0000-0002-3894-3990
FU Medical University of Lodz, Poland [503/1-156-04/503-11-001-19-00]
FX The study was supported by grant No. 503/1-156-04/503-11-001-19-00 from
   the Medical University of Lodz, Poland.
CR Abu El-Asrar AM, 2022, FRONT PHYSIOL, V12, DOI 10.3389/fphys.2021.807747
   Abu El-Asrar AM, 2018, MOL VIS, V24, P394
   Abu El-Asrar AM, 2018, ACTA OPHTHALMOL, V96, pE27, DOI 10.1111/aos.13451
   Abu El-Asrar AM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0085857
   Acott TS, 2014, J OCUL PHARMACOL TH, V30, P94, DOI 10.1089/jop.2013.0185
   Adithi M, 2007, J PEDIAT HEMATOL ONC, V29, P399, DOI 10.1097/MPH.0b013e3180683bf1
   Alapure BV, 2012, MOL VIS, V18, P64
   Alapure BV, 2008, J CATARACT REFR SURG, V34, P2063, DOI 10.1016/j.jcrs.2008.08.016
   Alcazar O, 2007, INVEST OPHTH VIS SCI, V48, P5662, DOI 10.1167/iovs.07-0392
   Alge-Priglinger CS, 2009, INVEST OPHTH VIS SCI, V50, P5495, DOI 10.1167/iovs.08-3193
   Alyahya GA, 2008, INVEST OPHTH VIS SCI, V49, P2806, DOI 10.1167/iovs.07-1436
   Ancona-Lezama D, 2020, INDIAN J OPHTHALMOL, V68, P2356, DOI 10.4103/ijo.IJO_721_20
   Anfuso CD, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21155557
   Aragona P, 2015, OPHTHALMOLOGY, V122, P62, DOI 10.1016/j.ophtha.2014.07.048
   Astuti GDN, 2018, GENES-BASEL, V9, DOI 10.3390/genes9010021
   Awasthi N, 2008, INVEST OPHTH VIS SCI, V49, P1998, DOI 10.1167/iovs.07-0624
   Bachu RD, 2018, PHARMACEUTICS, V10, DOI 10.3390/pharmaceutics10010028
   Bailey TA, 2001, EXP EYE RES, V73, P851, DOI 10.1006/exer.2001.1089
   Bajenaru ML, 2010, INVEST OPHTH VIS SCI, V51, P2860, DOI 10.1167/iovs.09-4500
   Bi MC, 2016, J OPHTHALMOL, V2016, DOI 10.1155/2016/8734309
   Bian F, 2016, J CELL PHYSIOL, V231, P2506, DOI 10.1002/jcp.25364
   Briggs ELA, 2015, MOL VIS, V21, P1162
   Bron AJ, 2017, OCUL SURF, V15, P438, DOI 10.1016/j.jtos.2017.05.011
   Burugula B, 2011, INVEST OPHTH VIS SCI, V52, P4263, DOI 10.1167/iovs.10-7103
   Buttacavoli M, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms222212389
   Caban M, 2021, FOOD REV INT, DOI 10.1080/87559129.2021.2012792
   Caban M, 2021, J FUNCT FOODS, V87, DOI 10.1016/j.jff.2021.104761
   Caban M, 2021, FOOD REV INT, DOI 10.1080/87559129.2021.1874412
   Cabral-Pacheco GA, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21249739
   Chang JH, 2016, SURV OPHTHALMOL, V61, P478, DOI 10.1016/j.survophthal.2015.11.006
   Chang KC, 2015, INVEST OPHTH VIS SCI, V56, P4198, DOI 10.1167/iovs.15-16557
   Chau KY, 2007, EYE, V21, P1511, DOI [10.1038/sj.eye.6702722, 10.1038/sj.eye.6702722x]
   Chen B, 2017, EXP THER MED, V14, P6022, DOI 10.3892/etm.2017.5275
   Chen LX, 2011, CANCER BIOL THER, V11, P229, DOI 10.4161/cbt.11.2.13842
   Chen ML, 2017, MOL MED REP, V16, P4577, DOI 10.3892/mmr.2017.7151
   Chen Y, 2021, OPHTHALMIC RES, V64, P62, DOI 10.1159/000507762
   Chen Y, 2015, INT J CLIN EXP PATHO, V8, P10452
   Cheng SC, 2019, CYTOKINE, V116, P48, DOI 10.1016/j.cyto.2019.01.001
   Cheng Y, 2019, CELL SIGNAL, V63, DOI 10.1016/j.cellsig.2019.109386
   Cheng Y, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0177337
   Chojnacka K, 2020, J PHYSIOL PHARMACOL, V71, DOI 10.26402/jpp.2020.6.07
   Chojnacka K, 2020, J PHYSIOL PHARMACOL, V71, DOI 10.26402/jpp.2020.2.05
   Chojnacka K, 2018, J FUNCT FOODS, V46, P295, DOI 10.1016/j.jff.2018.05.001
   Clark AF, 2001, INVEST OPHTH VIS SCI, V42, P1769
   Clemens DL, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19124078
   Craig JP, 2017, OCUL SURF, V15, P276, DOI 10.1016/j.jtos.2017.05.008
   Cui N, 2017, PROG MOL BIOL TRANSL, V147, P1, DOI 10.1016/bs.pmbts.2017.02.005
   De Groef L, 2016, INVEST OPHTH VIS SCI, V57, P5984, DOI 10.1167/iovs.16-19734
   De Groef L, 2015, MEDIAT INFLAMM, V2015, DOI 10.1155/2015/108617
   DeLeon-Pennell KY, 2017, PROG MOL BIOL TRANSL, V147, P75, DOI 10.1016/bs.pmbts.2017.02.001
   Ding CB, 2016, J EXP CLIN CANC RES, V35, DOI 10.1186/s13046-015-0280-0
   Djordjevic B, 2018, EUR J PHARMACOL, V833, P290, DOI 10.1016/j.ejphar.2018.06.011
   Drankowska J, 2019, LIFE SCI, V229, P149, DOI 10.1016/j.lfs.2019.05.038
   Dwivedi DJ, 2006, AM J PATHOL, V168, P69, DOI 10.2353/ajpath.2006.041089
   Ecker SM, 2012, MOL VIS, V18, P1658
   El-Shabrawi Y, 2000, EYE, V14, P375, DOI 10.1038/eye.2000.92
   Elhadidy MG, 2021, LIFE SCI, V273, DOI 10.1016/j.lfs.2021.119297
   Epitropoulos AT, 2016, CORNEA, V35, P1185, DOI 10.1097/ICO.0000000000000940
   Fernandez-Godino R, 2018, HUM MOL GENET, V27, P147, DOI 10.1093/hmg/ddx392
   Filla MS, 2017, EXP EYE RES, V165, P7, DOI 10.1016/j.exer.2017.08.017
   Fountoulakis N, 2013, BMC OPHTHALMOL, V13, DOI 10.1186/1471-2415-13-69
   Fu ZJ, 2017, INVEST OPHTH VIS SCI, V58, P3862, DOI 10.1167/iovs.17-21796
   Garcia-Onrubia L, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21165934
   Gaton DD, 1999, INVEST OPHTH VIS SCI, V40, P363
   Gerometta R, 2010, INVEST OPHTH VIS SCI, V51, P3042, DOI 10.1167/iovs.09-4920
   Ghasemi H, 2019, INT IMMUNOPHARMACOL, V77, DOI 10.1016/j.intimp.2019.105812
   Giebel SJ, 2005, LAB INVEST, V85, P597, DOI 10.1038/labinvest.3700251
   Grossniklaus HE, 2016, HUM PATHOL, V57, P165, DOI 10.1016/j.humpath.2016.07.012
   Hazra S, 2012, MOL VIS, V18, P1701
   He SQ, 2018, J OCUL PHARMACOL TH, V34, P85, DOI 10.1089/jop.2017.0041
   Heo JY, 2020, EXP EYE RES, V194, DOI 10.1016/j.exer.2020.108019
   Hoffmann S, 2006, RETINA-J RET VIT DIS, V26, P454, DOI 10.1097/00006982-200604000-00012
   Hollborn M, 2007, INVEST OPHTH VIS SCI, V48, P4360, DOI 10.1167/iovs.06-1234
   Hou Q, 2019, INVEST OPHTH VIS SCI, V60, P4503, DOI 10.1167/iovs.18-26477
   Hsu KS, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-48438-0
   Hu DN, 2018, EXP EYE RES, V175, P181, DOI 10.1016/j.exer.2018.06.023
   Hussain AA, 2011, INVEST OPHTH VIS SCI, V52, P4459, DOI 10.1167/iovs.10-6678
   Jackson HW, 2017, NAT REV CANCER, V17, P38, DOI 10.1038/nrc.2016.115
   Jamerson EC, 2020, EYE CONTACT LENS, V46, pS57, DOI 10.1097/ICL.0000000000000668
   Jia Y, 2017, CURR EYE RES, V42, P600, DOI 10.1080/02713683.2016.1223317
   Kaarniranta K, 2017, CELL BIOL TOXICOL, V33, P113, DOI 10.1007/s10565-016-9371-8
   Kamei M, 1999, INVEST OPHTH VIS SCI, V40, P2367
   Kang JM, 2021, MED CLIN N AM, V105, P493, DOI 10.1016/j.mcna.2021.01.004
   Kapoor C, 2016, J CANCER RES THER, V12, P28, DOI 10.4103/0973-1482.157337
   Kehlet SN, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0194458
   Khan AH, 2022, EYE, V36, P2192, DOI 10.1038/s41433-021-01824-3
   Kiani A, 2020, MOL BIOL REP, V47, P9373, DOI 10.1007/s11033-020-05968-5
   Kim EC, 2013, CLIN EXP OPHTHALMOL, V41, P694, DOI 10.1111/ceo.12085
   Kim JH, 2010, INVEST OPHTH VIS SCI, V51, P1783, DOI 10.1167/iovs.09-3990
   Kim ML, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.5.29
   Kinuthia UM, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.564077
   Kook Kyung Yun, 2020, Korean J Ophthalmol, V34, P179, DOI 10.3341/kjo.2019.0145
   Korol A, 2014, AM J PATHOL, V184, P2001, DOI 10.1016/j.ajpath.2014.03.013
   Kowluru R.A., 2017, REGULATION MATRIX ME, V148
   Kowluru RA, 2014, INVEST OPHTH VIS SCI, V55, P5653, DOI 10.1167/iovs.14-14383
   Kubo E, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19103093
   Kwon JW, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0159720
   Lai K, 2008, EXP EYE RES, V86, P936, DOI 10.1016/j.exer.2008.03.010
   Lam D, 2015, NAT REV DIS PRIMERS, V1, DOI 10.1038/nrdp.2015.14
   Lamouille S, 2014, NAT REV MOL CELL BIO, V15, P178, DOI 10.1038/nrm3758
   Lanza NL, 2016, OCUL SURF, V14, P216, DOI 10.1016/j.jtos.2015.12.007
   Lechner J, 2017, VISION RES, V139, P7, DOI 10.1016/j.visres.2017.04.003
   Lee CM, 2017, CURR OPIN OPHTHALMOL, V28, P98, DOI 10.1097/ICU.0000000000000340
   Lee HS, 2014, MOLECULES, V19, P12150, DOI 10.3390/molecules190812150
   Lee H, 2017, INVEST OPHTH VIS SCI, V58, P1682, DOI 10.1167/iovs.16-20843
   Lee JI, 2020, Z NATURFORSCH C, V75, P113, DOI 10.1515/znc-2019-0163
   Lee YH, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0258203
   Leu ST, 2002, EXP EYE RES, V74, P141, DOI 10.1006/exer.2001.1112
   Li J, 2016, SCI REP-UK, V6, DOI 10.1038/srep19408
   Li K, 2019, EXP THER MED, V17, P4522, DOI 10.3892/etm.2019.7471
   Liao ZY, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21155541
   Lin FL, 2019, PHYTOMEDICINE, V56, P207, DOI 10.1016/j.phymed.2018.11.002
   Liu J, 2017, PROG MOL BIOL TRANSL, V148, P355, DOI 10.1016/bs.pmbts.2017.04.003
   Liu NN, 2012, ONCOL REP, V28, P961, DOI 10.3892/or.2012.1905
   Liu Y, 2018, J MOL CELL CARDIOL, V121, P36, DOI 10.1016/j.yjmcc.2018.06.006
   Long H, 2011, INT J OPHTHALMOL-CHI, V4, P489, DOI 10.3980/j.issn.2222-3959.2011.05.06
   Lu B, 2020, CYTOKINE, V127, DOI 10.1016/j.cyto.2019.154943
   Luke J, 2016, BMC OPHTHALMOL, V16, DOI 10.1186/s12886-016-0222-4
   Maacha S, 2016, INVEST OPHTH VIS SCI, V57, P1982, DOI 10.1167/iovs.15-18780
   Maatta M, 2005, J GLAUCOMA, V14, P64
   Maddineni P, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms221810095
   Manabe S, 2005, INVEST OPHTH VIS SCI, V46, P4747, DOI 10.1167/iovs.05-0128
   Mannello F, 2001, APOPTOSIS, V6, P479, DOI 10.1023/A:1012493808790
   Markiewicz L, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/812503
   Medina-Ortiz WE, 2013, INVEST OPHTH VIS SCI, V54, P6779, DOI 10.1167/iovs.13-12298
   Meng NN, 2020, J OPHTHALMOL, V2020, DOI 10.1155/2020/4912347
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Miyata Y, 2019, BIOL PHARM BULL, V42, P1658, DOI 10.1248/bpb.b19-00244
   Mousa SA, 1999, J CELL BIOCHEM, V74, P135, DOI 10.1002/(SICI)1097-4644(19990701)74:1<135::AID-JCB15>3.0.CO;2-#
   Mu YT, 2020, INT OPHTHALMOL, V40, P2435, DOI 10.1007/s10792-020-01406-4
   Nareyeck G, 2005, OPHTHAL RES, V37, P23, DOI 10.1159/000082940
   Nashine S, 2021, CELLS-BASEL, V10, DOI 10.3390/cells10092483
   Nathu Z, 2009, EXP EYE RES, V88, P323, DOI 10.1016/j.exer.2008.08.014
   Nga ADC, 2014, BMC OPHTHALMOL, V14, DOI 10.1186/1471-2415-14-33
   Nielsen MK, 2019, ACTA OPHTHALMOL, V97, P84, DOI 10.1111/aos.13894
   Nita M, 2014, MED SCI MONITOR, V20, P1003, DOI 10.12659/MSM.889887
   O'Callaghan J, 2017, EXPERT OPIN THER TAR, V21, P1037, DOI 10.1080/14728222.2017.1386174
   O'Callaghan J, 2017, HUM MOL GENET, V26, P1230, DOI 10.1093/hmg/ddx028
   Pan H, 2017, INT J CLIN EXP PATHO, V10, P7325
   Park J, 2021, BRIT J OPHTHALMOL, V105, P1504, DOI 10.1136/bjophthalmol-2020-317164
   Peck TJ, 2021, CURR OPIN OPHTHALMOL, V32, P62, DOI 10.1097/ICU.0000000000000727
   Peeters SA, 2015, CARDIOVASC DIABETOL, V14, DOI 10.1186/s12933-015-0195-2
   Pflugfelder SC, 2017, OPHTHALMOLOGY, V124, pS4, DOI 10.1016/j.ophtha.2017.07.010
   Pflugfelder SC, 2011, AM J OPHTHALMOL, V152, P900, DOI 10.1016/j.ajo.2011.08.023
   Plantner JJ, 1998, EXP EYE RES, V67, P637, DOI 10.1006/exer.1998.0552
   Pons M, 2011, AM J PATHOL, V178, P2665, DOI 10.1016/j.ajpath.2011.02.006
   Qian TW, 2020, AM J OPHTHALMOL, V212, P144, DOI 10.1016/j.ajo.2019.12.014
   Rahmawaty S, 2017, J HUM NUTR DIET, V30, P429, DOI 10.1111/jhn.12439
   Rajashekhar G, 2014, EXP EYE RES, V122, P77, DOI 10.1016/j.exer.2014.03.004
   Rangasamy S, 2012, MIDDLE EAST AFR J OP, V19, P52, DOI 10.4103/0974-9233.92116
   Razali N, 2018, EUR J PHARMACOL, V838, P1, DOI 10.1016/j.ejphar.2018.08.035
   Razali N, 2016, EXP EYE RES, V143, P9, DOI 10.1016/j.exer.2015.09.014
   Reinhard J, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21124322
   Rivera S, 2019, CELL MOL LIFE SCI, V76, P3167, DOI 10.1007/s00018-019-03178-2
   Robertson JV, 2013, MOL VIS, V19, P684
   Rodrigues M, 2013, DIABETES, V62, P3863, DOI 10.2337/db13-0014
   Ronkko S, 2007, GRAEF ARCH CLIN EXP, V245, P697, DOI 10.1007/s00417-006-0440-1
   Rossi S, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0982-1
   Sahay P, 2017, INVEST OPHTH VIS SCI, V58, pBIO106, DOI 10.1167/iovs.17-21723
   Sahin A, 2007, JPN J OPHTHALMOL, V51, P325, DOI 10.1007/s10384-007-0456-z
   Saleem S, 2021, NEUROSCIENCE, V460, P120, DOI 10.1016/j.neuroscience.2021.01.003
   Sambursky R, 2013, JAMA OPHTHALMOL, V131, P24, DOI 10.1001/jamaophthalmol.2013.561
   Santibanez JF, 2018, DEV DYNAM, V247, P382, DOI 10.1002/dvdy.24554
   Saucedo L, 2021, MEDIAT INFLAMM, V2021, DOI 10.1155/2021/9811361
   Schargus M, 2015, CORNEA, V34, P739, DOI 10.1097/ICO.0000000000000449
   Scheau C, 2019, ANAL CELL PATHOL, V2019, DOI 10.1155/2019/9423907
   Schlotzer-Schrehardt U, 2003, INVEST OPHTH VIS SCI, V44, P1117, DOI 10.1167/iovs.02-0365
   Schuster AK, 2020, DTSCH ARZTEBL INT, V117, P225, DOI 10.3238/arztebl.2020.0225
   Seo MJ, 2010, CURR EYE RES, V35, P165, DOI 10.3109/02713680903453494
   Shanmuganathan S, 2018, VASC PHARMACOL, V108, P23, DOI 10.1016/j.vph.2018.04.005
   Shen GL, 2016, J OPHTHALMOL, V2016, DOI 10.1155/2016/2415867
   Shim W, 2019, J CONTROL RELEASE, V307, P413, DOI 10.1016/j.jconrel.2019.04.016
   Shimada A, 2014, CURR EYE RES, V39, P460, DOI 10.3109/02713683.2013.853194
   Shoari A, 2021, EXP EYE RES, V205, DOI 10.1016/j.exer.2021.108523
   SNYDER RW, 1993, EXP EYE RES, V57, P461, DOI 10.1006/exer.1993.1148
   Spiga MG, 2010, INVEST OPHTH VIS SCI, V51, P3029, DOI 10.1167/iovs.09-4918
   Steinmetz JD, 2021, LANCET GLOB HEALTH, V9, pE144, DOI 10.1016/S2214-109X(20)30489-7
   Striker GE, 2008, AM J PHYSIOL-CELL PH, V295, pC1633, DOI 10.1152/ajpcell.00092.2008
   Suri R, 2020, MED HYPOTHESES, V136, DOI 10.1016/j.mehy.2019.109518
   Suzumura A, 2020, ANTIOXIDANTS-BASEL, V9, DOI 10.3390/antiox9100920
   Tabak S, 2021, J CELL MOL MED, V25, P3339, DOI 10.1111/jcmm.16408
   Taiyab A, 2016, INVEST OPHTH VIS SCI, V57, P5736, DOI 10.1167/iovs.16-20162
   Tamhane M, 2019, PHARM RES-DORDR, V36, DOI 10.1007/s11095-019-2569-8
   Tatar O, 2007, BRIT J OPHTHALMOL, V91, P1183, DOI 10.1136/bjo.2007.114769
   Theocharis AD, 2016, ADV DRUG DELIVER REV, V97, P4, DOI 10.1016/j.addr.2015.11.001
   Thompson J, 2015, PRIMARY CARE, V42, P409, DOI 10.1016/j.pop.2015.05.012
   Tong Y, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.591067
   Turan M, 2022, EUR J OPHTHALMOL, V32, P255, DOI 10.1177/1120672120966559
   Ucgun NI, 2020, MOL VIS, V26, P718
   VanDerMeid KR, 2012, INVEST OPHTH VIS SCI, V53, P1512, DOI 10.1167/iovs.11-7627
   Venkatesan N, 2012, MOL VIS, V18, P2420
   Wang JX, 2018, J CELL PHYSIOL, V233, P6986, DOI 10.1002/jcp.26621
   Wang TY, 2021, BMC CANCER, V21, DOI 10.1186/s12885-021-08788-3
   Webb AH, 2017, BMC CANCER, V17, DOI 10.1186/s12885-017-3418-y
   Weinreb RN, 2020, J OCUL PHARMACOL TH, V36, P208, DOI 10.1089/jop.2019.0146
   Wen S, 2021, J HEALTHC ENG, V2021, DOI 10.1155/2021/6091585
   Wen YL, 2015, GENET MOL RES, V14, P19342, DOI 10.4238/2015.December.29.44
   Wiechmann AF, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0113810
   Wu T, 2017, GENE THER, V24, P399, DOI 10.1038/gt.2017.31
   Xiao F, 2018, SAUDI J BIOL SCI, V25, P832, DOI 10.1016/j.sjbs.2016.11.016
   Xu HM, 2018, AM J TRANSL RES, V10, P1703
   Xu J, 2012, ANGIOGENESIS, V15, P213, DOI 10.1007/s10456-012-9254-4
   Xue MJ, 2019, J CANCER, V10, P4921, DOI 10.7150/jca.30618
   Yao J, 2012, MOL MED REP, V5, P1509, DOI 10.3892/mmr.2012.827
   Zaleska-Zmijewska A, 2019, J OPHTHALMOL, V2019, DOI 10.1155/2019/1240537
   Zalewska R, 2016, ADV MED SCI-POLAND, V61, P6, DOI 10.1016/j.advms.2015.07.007
   Zeng RP, 2013, MOL VIS, V19, P729
   Zeng SM, 2016, J PATHOL, V238, P446, DOI 10.1002/path.4669
   Zhang D, 2018, EUR REV MED PHARMACO, V22, P5071, DOI 10.26355/eurrev_201808_15699
   Zhang MG, 2018, PHARMACOL RES, V129, P365, DOI 10.1016/j.phrs.2017.11.033
   Zhang XB, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18071398
   Zhang YH, 2020, TRANSL VIS SCI TECHN, V9, DOI 10.1167/tvst.9.8.41
   Zhou JF, 2017, THERANOSTICS, V7, P1447, DOI 10.7150/thno.17451
   Zhou L, 2021, EXP MOL PATHOL, V118, DOI 10.1016/j.yexmp.2020.104594
   Zhou M, 2014, ONCOL LETT, V8, P1933, DOI 10.3892/ol.2014.2462
   Zhu JY, 2019, J TRANSL MED, V17, DOI 10.1186/s12967-019-1975-3
   Zhu SH, 2017, INFLAMMATION, V40, P1475, DOI 10.1007/s10753-017-0571-z
NR 217
TC 0
Z9 0
U1 4
U2 6
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1422-0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD APR
PY 2022
VL 23
IS 8
AR 4256
DI 10.3390/ijms23084256
PG 29
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA 0T1GC
UT WOS:000786721400001
PM 35457074
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Leveillard, T
   Klipfel, L
AF Leveillard, Thierry
   Klipfel, Laurence
TI Mechanisms Underlying the Visual Benefit of Cell Transplantation for the
   Treatment of Retinal Degenerations
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Review
DE photoreceptors; retinal pigmented epithelium; retinitis pigmentosa;
   age-related macular degeneration; cytoplasmic material transfer;
   induced-pluripotent stem cells
ID PIGMENT EPITHELIAL-CELLS; MACULAR DEGENERATION; STEM-CELLS; RCS RATS;
   PHOTORECEPTOR CELLS; HOST PHOTORECEPTORS; IN-VITRO; CONE; RESTORATION;
   INTEGRATE
AB The transplantation of retinal cells has been studied in animals to establish proof of its potential benefit for the treatment of blinding diseases. Photoreceptor precursors have been grafted in animal models of Mendelian-inherited retinal degenerations, and retinal pigmented epithelial cells have been used to restore visual function in animal models of age-related macular degeneration (AMD) and recently in patients. Cell therapy over corrective gene therapy in inherited retinal degeneration can overcome the genetic heterogeneity by providing one treatment for all genetic forms of the diseases. In AMD, the existence of multiple risk alleles precludes a priori the use of corrective gene therapy. Mechanistically, the experiments of photoreceptor precursor transplantation reveal the importance of cytoplasmic material exchange between the grafted cells and the host cells for functional rescue, an unsuspected mechanism and novel concept. For transplantation of retinal pigmented epithelial cells, the mechanisms behind the therapeutic benefit are only partially understood, and clinical trials are ongoing. The fascinating studies that describe the development of methodologies to produce cells to be grafted and demonstrate the functional benefit for vision are reviewed.
C1 [Leveillard, Thierry; Klipfel, Laurence] Sorbonne Univ, Inst Vis, CNRS, Dept Genet,INSERM, 17 Rue Moreau, F-75012 Paris, France.
C3 Centre National de la Recherche Scientifique (CNRS); Institut National
   de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research
   Universities; Sorbonne Universite; Universite Paris Cite
RP Leveillard, T (通讯作者)，Sorbonne Univ, Inst Vis, CNRS, Dept Genet,INSERM, 17 Rue Moreau, F-75012 Paris, France.
EM thierry.leveillard@inserm.fr; laurence.klipfel@inserm.fr
RI Léveillard, Thierry/AAR-1804-2020
OI Léveillard, Thierry/0000-0001-5692-8770
FU INSERM; Sorbonne University; SATT-LUTECH; ANR; Labex Lifesenses; la
   Fondation Voir Entendre
FX The work was supported by INSERM, Sorbonne University, SATT-LUTECH, ANR,
   Labex Lifesenses, and la Fondation Voir & Entendre.
CR Ait-Ali N, 2015, CELL, V161, P817, DOI 10.1016/j.cell.2015.03.023
   Barber AC, 2013, P NATL ACAD SCI USA, V110, P354, DOI 10.1073/pnas.1212677110
   Belinsky GS, 2016, FASEB J, V30, P2837, DOI 10.1096/fj.201500027R
   Ben M'Barek K, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aai7471
   Bertolotti E, 2014, PROG RETIN EYE RES, V42, P130, DOI 10.1016/j.preteyeres.2014.06.002
   Bi AD, 2006, NEURON, V50, P23, DOI 10.1016/j.neuron.2006.02.026
   Boudreau-Pinsonneault C, 2018, DEV DYNAM, V247, P10, DOI 10.1002/dvdy.24535
   Bracha P, 2017, EXPERT OPIN BIOL TH, V17, P1113, DOI 10.1080/14712598.2017.1346079
   Burnight ER, 2017, MOL THER, V25, P1999, DOI 10.1016/j.ymthe.2017.05.015
   Bush RA, 2015, CSH PERSPECT MED, V5, DOI 10.1101/cshperspect.a017368
   Byrne LC, 2015, J CLIN INVEST, V125, P105, DOI 10.1172/JCI65654
   Calippe B, 2017, IMMUNITY, V46, P261, DOI 10.1016/j.immuni.2017.01.006
   Carr AJ, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008152
   CEHAJICKAPETANO.J, 2015, HUMAN, V25, P2111, DOI DOI 10.1016/J.CUB.2015.07.029
   Cepko C, 2014, NAT REV NEUROSCI, V15, P615, DOI 10.1038/nrn3767
   Chao JR, 2017, TRANSL VIS SCI TECHN, V6, DOI 10.1167/tvst.6.3.4
   Chedotal A, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a001917
   Chinchore Y, 2017, ELIFE, V6, DOI 10.7554/eLife.25946
   Coffey PJ, 2002, NAT NEUROSCI, V5, P53, DOI 10.1038/nn782
   Comitato A, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0613-y
   da Cruz L, 2007, PROG RETIN EYE RES, V26, P598, DOI 10.1016/j.preteyeres.2007.07.001
   Daniele LL, 2008, AM J PHYSIOL-CELL PH, V295, pC451, DOI 10.1152/ajpcell.00124.2008
   Daruwalla A, 2018, BIOCHEM J, V475, P3171, DOI 10.1042/BCJ20180193
   Davis RJ, 2017, STEM CELL REP, V9, P42, DOI 10.1016/j.stemcr.2017.05.016
   DeAngelis MM, 2017, HUM MOL GENET, V26, pR45, DOI 10.1093/hmg/ddx228
   Decembrini S, 2017, MOL THER, V25, P634, DOI 10.1016/j.ymthe.2016.12.015
   Delyfer MN, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028791
   Dhar-Chowdhury P, 2007, CELL MOL LIFE SCI, V64, P3069, DOI 10.1007/s00018-007-7332-3
   Doll JA, 2003, NAT MED, V9, P774, DOI 10.1038/nm870
   Duncan JL, 2018, TRANSL VIS SCI TECHN, V7, DOI 10.1167/tvst.7.4.6
   Eldred KC, 2018, SCIENCE, V362, P200, DOI 10.1126/science.aau6348
   FISHER C, 2018, AMD, V59, pAMD41, DOI DOI 10.1167/IOVS.18-24289
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Fritsche LG, 2014, ANNU REV GENOM HUM G, V15, P151, DOI 10.1146/annurev-genom-090413-025610
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Gagliardi G, 2018, STEM CELL REP, V11, P665, DOI 10.1016/j.stemcr.2018.07.005
   Gasparini S.J., 2018, PROG RETIN EYE RES, DOI [10.1016/j.preteyeres.2018, DOI 10.1016/J.PRETEYERES.2018]
   Gerkema MP, 2013, P ROY SOC B-BIOL SCI, V280, DOI 10.1098/rspb.2013.0508
   Gonzalez-Cordero A, 2013, NAT BIOTECHNOL, V31, P741, DOI 10.1038/nbt.2643
   Guillonneau X, 2017, PROG RETIN EYE RES, V61, P98, DOI 10.1016/j.preteyeres.2017.06.002
   Haruta M, 2004, INVEST OPHTH VIS SCI, V45, P1020, DOI 10.1167/iovs.03-1034
   Homan EP, 2011, J BONE MINER RES, V26, P2798, DOI 10.1002/jbmr.487
   Javed A, 2017, FRONT NEURAL CIRCUIT, V11, DOI 10.3389/fncir.2017.00105
   Jin ZB, 2019, PROG RETIN EYE RES, V69, P38, DOI 10.1016/j.preteyeres.2018.11.003
   Jonasson F, 2011, OPHTHALMOLOGY, V118, P825, DOI 10.1016/j.ophtha.2010.08.044
   Kalluri R, 2016, J CLIN INVEST, V126, P1208, DOI 10.1172/JCI81135
   Kanemura H, 2013, SCI REP-UK, V3, DOI 10.1038/srep02334
   Kanow MA, 2017, ELIFE, V6, DOI 10.7554/eLife.28899
   Kole C, 2018, MOL THER, V26, P219, DOI 10.1016/j.ymthe.2017.09.007
   Kolesnikov AV, 2011, J NEUROSCI, V31, P7900, DOI 10.1523/JNEUROSCI.0438-11.2011
   Kolomeyer AM, 2011, INVEST OPHTH VIS SCI, V52, P5973, DOI 10.1167/iovs.10-6965
   Kominami A, 2016, INVEST OPHTH VIS SCI, V57, P1604, DOI 10.1167/iovs.15-19030
   Lagali PS, 2008, NAT NEUROSCI, V11, P667, DOI 10.1038/nn.2117
   Lakowski J, 2011, STEM CELLS, V29, P1391, DOI 10.1002/stem.694
   Lakowski J, 2015, STEM CELLS, V33, P2469, DOI 10.1002/stem.2051
   Leveillard T, 2017, CELL MOL LIFE SCI, V74, P3649, DOI 10.1007/s00018-016-2318-7
   Leveillard T, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000866
   Levin LA, 2017, OPHTHALMOLOGY, V124, P926, DOI 10.1016/j.ophtha.2017.02.017
   Lu B, 2009, STEM CELLS, V27, P2126, DOI 10.1002/stem.149
   Lund RD, 2001, P NATL ACAD SCI USA, V98, P9942, DOI 10.1073/pnas.171266298
   Luo ZM, 2018, STEM CELLS INT, V2018, DOI 10.1155/2018/9437041
   MacLaren RE, 2006, NATURE, V444, P203, DOI 10.1038/nature05161
   Maeda T, 2013, J BIOL CHEM, V288, P34484, DOI 10.1074/jbc.M113.518571
   Mandai Michiko, 2017, N Engl J Med, V377, P792, DOI 10.1056/NEJMc1706274
   Mandai M, 2017, STEM CELL REP, V8, P69, DOI 10.1016/j.stemcr.2016.12.008
   McLelland BT, 2018, INVEST OPHTH VIS SCI, V59, P2586, DOI 10.1167/iovs.17-23646
   Mehat MS, 2018, OPHTHALMOLOGY, V125, P1765, DOI 10.1016/j.ophtha.2018.04.037
   Mittal R, 2019, J CELL PHYSIOL, V234, P1130, DOI 10.1002/jcp.27072
   Molthagen M, 1996, J NEUROCYTOL, V25, P243, DOI 10.1007/BF02284800
   Nandrot E, 2000, NEUROBIOL DIS, V7, P586, DOI 10.1006/nbdi.2000.0328
   Neves J, 2016, SCIENCE, V353, DOI 10.1126/science.aaf3646
   Nickerson PEB, 2018, FRONT NEURAL CIRCUIT, V12, DOI 10.3389/fncir.2018.00017
   Omri S, 2010, CLIN OPHTHALMOL, V4, P183
   Ortin-Martinez A, 2017, STEM CELLS, V35, P932, DOI 10.1002/stem.2552
   Paolicelli RC, 2019, NEUROSCIENCE, V405, P148, DOI 10.1016/j.neuroscience.2018.04.003
   Pearson RA, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13029
   Pearson RA, 2012, NATURE, V485, P99, DOI 10.1038/nature10997
   Petrus-Reurer S, 2017, INVEST OPHTH VIS SCI, V58, DOI 10.1167/iovs.16-20738
   Pinilla I, 2009, VISION RES, V49, P2067, DOI 10.1016/j.visres.2009.05.014
   Plossl K, 2017, MOL BIOL CELL, V28, P2178, DOI 10.1091/mbc.E17-01-0064
   Reh TA, 2006, NATURE, V444, P156, DOI 10.1038/444156a
   Reich DE, 2001, NATURE, V411, P199, DOI 10.1038/35075590
   Roman D, 2018, EXP EYE RES, V176, P219, DOI 10.1016/j.exer.2018.07.014
   Roska B, 2018, NATURE, V557, P359, DOI 10.1038/s41586-018-0076-4
   Sergouniotis PI, 2011, AM J HUM GENET, V89, P183, DOI 10.1016/j.ajhg.2011.06.002
   SHEEDLO HJ, 1989, EXP EYE RES, V48, P841, DOI 10.1016/0014-4835(89)90067-5
   Shirai H, 2016, P NATL ACAD SCI USA, V113, pE81, DOI 10.1073/pnas.1512590113
   Singh MS, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13537
   Song CG, 2018, NEURAL REGEN RES, V13, P1294, DOI 10.4103/1673-5374.235085
   Subramanian P, 2013, J BIOL CHEM, V288, P23928, DOI 10.1074/jbc.M113.487884
   Sugita S, 2016, STEM CELL REP, V7, P635, DOI 10.1016/j.stemcr.2016.08.010
   Swaroop A, 2010, NAT REV NEUROSCI, V11, P563, DOI 10.1038/nrn2880
   Tan PL, 2016, HUM GENOMICS, V10, DOI 10.1186/s40246-016-0079-x
   Tomita H, 2007, INVEST OPHTH VIS SCI, V48, P3821, DOI 10.1167/iovs.06-1501
   van Niel G, 2018, NAT REV MOL CELL BIO, V19, P213, DOI 10.1038/nrm.2017.125
   Verbakel SK, 2018, PROG RETIN EYE RES, V66, P157, DOI 10.1016/j.preteyeres.2018.03.005
   Waldron PV, 2018, STEM CELL REP, V10, P406, DOI 10.1016/j.stemcr.2017.12.008
   Wang W, 2016, CELL REP, V15, P372, DOI 10.1016/j.celrep.2016.03.022
   Welby E, 2017, STEM CELL REP, V9, P1898, DOI 10.1016/j.stemcr.2017.10.018
   West EL, 2012, STEM CELLS, V30, P1424, DOI 10.1002/stem.1123
   West EL, 2010, STEM CELLS, V28, P1997, DOI 10.1002/stem.520
   Wittig D, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033195
   Yao K, 2018, NATURE, V560, P484, DOI 10.1038/s41586-018-0425-3
   Ying GX, 2018, J BIOL CHEM, V293, P17546, DOI 10.1074/jbc.RA118.005484
   Zarbin M, 2016, TRENDS MOL MED, V22, P115, DOI 10.1016/j.molmed.2015.12.007
   Zhang Y, 2017, INVEST OPHTH VIS SCI, V58, P5616, DOI 10.1167/iovs.17-22471
   Zhao YJ, 2018, TRANSL VIS SCI TECHN, V7, DOI 10.1167/tvst.7.3.6
NR 107
TC 2
Z9 2
U1 1
U2 7
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
SN 1422-0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD FEB 1
PY 2019
VL 20
IS 3
AR 557
DI 10.3390/ijms20030557
PG 16
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA HQ4WR
UT WOS:000462412500101
PM 30696106
OA Green Published, Green Submitted, gold
DA 2022-11-30
ER

PT J
AU Liaskos, M
   Asvestas, PA
   Matsopoulos, GK
   Charonis, A
   Anastassopoulos, V
AF Liaskos, Meletios
   Asvestas, Pantelis A.
   Matsopoulos, George K.
   Charonis, Alexander
   Anastassopoulos, Vassilis
TI Detection of retinal pigment epithelium detachment from OCT images using
   multiscale Gaussian filtering
SO TECHNOLOGY AND HEALTH CARE
LA English
DT Article
DE Optical coherence tomography (OCT); retinal pigment epithelium
   detachment; segmentation; Gaussian filtering
ID COHERENCE TOMOGRAPHY IMAGES; MACULAR DEGENERATION; LAYER SEGMENTATION
AB Macular diseases, including neovascular age-related macular degeneration (nvAMD), are leading causes of irreversible blindness and visual impairment. One prominent feature of nvAMD is the detachment of the retinal pigment epithelium. The aim of this study is to implement an automated method for the segmentation of the pigment epithelial detachment (PED) using optical coherence tomography (OCT). OCT datasets from 8 patients with nvAMD were acquired during multiple sessions. At each session, 17 images with a resolution of 1020 x 640 pixels were obtained. The images were segmented using Gaussian filtering and template matching for the detection of the upper and lower border of the PED, respectively. The results of the method were compared with the ones obtained from the manual segmentation of the images by an expert. Four well-known metrics were used to evaluate the performance of the method with respect to the manual segmentation, resulting in high scores of consistency. Furthermore, the proposed method was also compared with four other well-known methods providing similar or superior performance.
C1 [Liaskos, Meletios; Anastassopoulos, Vassilis] Univ Patras, Phys Dept, Patras, Greece.
   [Asvestas, Pantelis A.] Univ West Attica, Dept Biomed Engn, Agiou Spyridonos St,122 43 Egaleo, Athens, Greece.
   [Liaskos, Meletios; Matsopoulos, George K.] Natl Tech Univ Athens, Sch Elect & Comp Engn, Athens, Greece.
   [Charonis, Alexander] Athens Vis Eye Inst, Athens, Greece.
C3 University of Patras; University of West Attica; National Technical
   University of Athens
RP Asvestas, PA (通讯作者)，Univ West Attica, Dept Biomed Engn, Agiou Spyridonos St,122 43 Egaleo, Athens, Greece.
EM pasv@uniwa.gr
RI Asvestas, Pantelis/U-8912-2019
CR Adrian GP, 2012, J MICROSCOPY, P1365
   Chiu SJ, 2010, OPT EXPRESS, V18, P19413, DOI 10.1364/OE.18.019413
   Cukras C, 2010, EYE, V24, P775, DOI 10.1038/eye.2009.211
   Garvin MK, 2008, IEEE T MED IMAGING, V27, P1495, DOI 10.1109/TMI.2008.923966
   Holz FG, 2014, J CLIN INVEST, V124, P1430, DOI 10.1172/JCI71029
   Kafieh R, 2013, MED IMAGE ANAL, V17, P907, DOI 10.1016/j.media.2013.05.006
   Kato Z, 2011, FOUND TRENDS SIGNAL, V5, P1, DOI 10.1561/2000000035
   Lay KL, 2015, ADV COMPUTER COMMUNI
   Lokesh M, 2014, IJRST, V4, P51
   Lommatzsch A, 2009, EYE, V23, P2163, DOI 10.1038/eye.2008.425
   Lowe DG, 2004, INT J COMPUT VISION, V60, P91, DOI 10.1023/B:VISI.0000029664.99615.94
   Makoto I, 2015, J OPHTHALMOLOGY
   NAJMAN L, 1994, SIGNAL PROCESS, V38, P99, DOI 10.1016/0165-1684(94)90059-0
   Ng HP, 2006, 7TH IEEE SOUTHWEST SYMPOSIUM ON IMAGE ANALYSIS AND INTERPRETATION, P61
   Penha FM, 2012, AM J OPHTHALMOL, V153, P515, DOI 10.1016/j.ajo.2011.08.031
   Pereyra M, 2017, IEEE T IMAGE PROCESS, V26, P2577, DOI 10.1109/TIP.2017.2675165
   Pham DL, 2000, ANNU REV BIOMED ENG, P2315
   Qian XH, 2013, MED PHYS, V40, DOI 10.1118/1.4774359
   Rueda S, 2015, MED IMAGE ANAL, V26, P30, DOI 10.1016/j.media.2015.07.002
   Schmidt-Erfurth U, 2014, BRIT J OPHTHALMOL, V98, P1144, DOI 10.1136/bjophthalmol-2014-305702
   Shi F, 2015, IEEE T MED IMAGING, V34, P441, DOI 10.1109/TMI.2014.2359980
   Staal J, 2004, IEEE T MED IMAGING, V23, P501, DOI 10.1109/TMI.2004.825627
   Steger C, 1998, IEEE T PATTERN ANAL, V20, P113, DOI 10.1109/34.659930
   Sundelin SP, 2001, FREE RADICAL BIO MED, V30, P74, DOI 10.1016/S0891-5849(00)00444-5
   Taha AA, 2015, BMC MED IMAGING, V15, DOI 10.1186/s12880-015-0068-x
   William K., 2007, DIGITAL IMAGE PROCES, V4th ed
   Wu ML, 2017, BIOMED OPT EXPRESS, V8, P4257, DOI 10.1364/BOE.8.004257
   Xin J, 2012, PHYS PROCEDIA, P33840
   Xu YP, 2017, BIOMED OPT EXPRESS, V8, P4061, DOI 10.1364/BOE.8.004061
   Zayit-Soudry S, 2007, SURV OPHTHALMOL, V52, P227, DOI 10.1016/j.survophthal.2007.02.008
   Zheng YL, 2013, AM J OPHTHALMOL, V155, P277, DOI 10.1016/j.ajo.2012.07.030
   Zhuli S, 2016, SCI REP
NR 32
TC 1
Z9 2
U1 0
U2 1
PU IOS PRESS
PI AMSTERDAM
PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS
SN 0928-7329
EI 1878-7401
J9 TECHNOL HEALTH CARE
JI Technol. Health Care
PY 2019
VL 27
IS 3
BP 301
EP 316
DI 10.3233/THC-181501
PG 16
WC Health Care Sciences & Services; Engineering, Biomedical
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Health Care Sciences & Services; Engineering
GA HY1XV
UT WOS:000467911700005
PM 30829626
DA 2022-11-30
ER

PT J
AU Jia, J
   Li, K
   Liu, XW
   Zhong, J
   Xiang, Y
AF Jia, Jun
   Li, Ke
   Liu, Xiaowen
   Zhong, Jie
   Xiang, Yi
TI Crocin protects retinal pigment epithelial cells from oxidative stress
   through suppression of the MAPK signaling pathway
SO INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE
LA English
DT Article
DE Crocin; retinal pigment epithelial (RPE) cells; oxidative stress;
   apoptosis
ID MITOCHONDRIAL-DNA DAMAGE; INDUCED APOPTOSIS; GANGLION-CELLS; ACTIVATION;
   RESPONSES; KINASES
AB Oxidative stress damage to retinal pigment epithelial (RPE) cells is thought to play a critical role in the pathogenesis of age-related macular degeneration (AMD). Crocin, a pharmacologically active component of Crocus sativus L., was reported to have anti-antioxidant and anti-apoptotic properties. However, whether crocin protects against oxidative stress-induced retinal damage in RPE cells is still unknown. Therefore, in this study, we investigated the protective effect of crocin against oxidative stress-induced cell death in ARPE-19 cells and its underlying mechanism. Our results demonstrated that crocin significantly attenuated H2O2-induced ARPE-19 cell injury by suppressing LDH release. Crocin also decreased H2O2-induced oxidative stress though scavenging ROS accumulation and MDA peroxidation. Furthermore, crocin reversed H2O2-induced Bcl-2 down-regulation and Bax overexpression, inhibited caspase-3 activation, p38 MAPK and JNK phosphorylation in ARPE-19 cells. In conclusion, these data suggest that crocin protects against H2O2-induced oxidative stress through suppression of the MAPK signaling pathway in ARPE-19 cells. Thus, crocin may be useful for the prevention or treatment of AMD.
C1 [Jia, Jun; Li, Ke; Liu, Xiaowen; Zhong, Jie; Xiang, Yi] Wuhan Cent Hosp, Dept Ophthalmol, 26 Sheng Li Rd, Wuhan 430014, Peoples R China.
RP Xiang, Y (通讯作者)，Wuhan Cent Hosp, Dept Ophthalmol, 26 Sheng Li Rd, Wuhan 430014, Peoples R China.
EM xiangyiwh@163.com
CR Alge CS, 2002, INVEST OPHTH VIS SCI, V43, P3575
   Amin A, 2015, INT J MOL SCI, V16, P1544, DOI 10.3390/ijms16011544
   Bakhtiary Zahra, 2014, Vet Res Forum, V5, P213
   Ballinger SW, 1999, EXP EYE RES, V68, P765, DOI 10.1006/exer.1998.0661
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Cano M, 2010, VISION RES, V50, P652, DOI 10.1016/j.visres.2009.08.018
   Chichili GR, 2006, BRIT J NUTR, V96, P643, DOI 10.1079/BJN20061843
   Cowan KJ, 2003, J EXP BIOL, V206, P1107, DOI 10.1242/jeb.00220
   Ding QH, 2013, INFLAMM RES, V62, P17, DOI 10.1007/s00011-012-0546-3
   Finkel T, 2000, NATURE, V408, P239, DOI 10.1038/35041687
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Ho TC, 2006, APOPTOSIS, V11, P1899, DOI 10.1007/s10495-006-9403-6
   Jin GF, 2001, CURR EYE RES, V23, P11, DOI 10.1076/ceyr.23.1.11.5423
   Jin GF, 2001, CURR EYE RES, V22, P165, DOI 10.1076/ceyr.22.3.165.5517
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kim JH, 2014, MEDIAT INFLAMM, V2014, DOI 10.1155/2014/728709
   Kook D, 2008, INVEST OPHTH VIS SCI, V49, P1712, DOI 10.1167/iovs.07-0477
   LEBEL CP, 1992, CHEM RES TOXICOL, V5, P227, DOI 10.1021/tx00026a012
   Levonen AL, 2001, ANTIOXID REDOX SIGN, V3, P215, DOI 10.1089/152308601300185188
   Lv BC, 2016, INT J MOL MED, V37, P225, DOI 10.3892/ijmm.2015.2418
   Martindale JL, 2002, J CELL PHYSIOL, V192, P1, DOI 10.1002/jcp.10119
   Pocrnich CE, 2009, CAN J OPHTHALMOL, V44, P431, DOI 10.3129/i09-109
   Qi Y, 2013, EXP EYE RES, V107, P44, DOI 10.1016/j.exer.2012.11.011
   Thushara RM, 2014, J THROMB THROMBOLYS, V38, P321, DOI 10.1007/s11239-014-1056-7
   Wang ZY, 2009, FREE RADICAL BIO MED, V46, P1032, DOI 10.1016/j.freeradbiomed.2008.11.027
   Winkler BS, 1999, MOL VIS, V5
   Zhang HR, 2015, NEUROCHEM RES, V40, P1583, DOI 10.1007/s11064-015-1632-z
   Zhang W, 2002, CELL RES, V12, P9, DOI 10.1038/sj.cr.7290105
NR 28
TC 1
Z9 1
U1 0
U2 3
PU E-CENTURY PUBLISHING CORP
PI MADISON
PA 40 WHITE OAKS LN, MADISON, WI 53711 USA
SN 1940-5901
J9 INT J CLIN EXP MED
JI Int. J. Clin. Exp. Med.
PY 2016
VL 9
IS 6
BP 11016
EP 11022
PG 7
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA DQ4ES
UT WOS:000379157300024
DA 2022-11-30
ER

PT J
AU Maaijwee, K
   Koolen, T
   Rosenbrand, D
   Jacobs, E
   Kleinheerenbrink, S
   Knulst, A
   Bos, J
   Holland, WP
   Brouwer, A
   van Meurs, JC
   Schutte, S
AF Maaijwee, Kristel
   Koolen, Twan
   Rosenbrand, Dagmar
   Jacobs, Elmer
   Kleinheerenbrink, Sander
   Knulst, Arjan
   Bos, Joop
   Holland, Wim P.
   Brouwer, Alex
   van Meurs, Jan C.
   Schutte, Sander
TI Threshold amplitude and frequency for ocular tissue release from a
   vibrating instrument: An experimental study
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID RETINAL-PIGMENT EPITHELIUM; CHOROID TRANSLOCATION; MACULAR DEGENERATION
AB PURPOSE. During retinal pigment epithelium (RPE) and choroid graft translocation in the treatment of patients with exudative age-related macular degeneration, the adhesion of the graft to the translocation instrument complicated its submacular release. Vibration of the instrument improved the release of the graft. This study was conducted to validate the effectiveness of the principle of vibration and to determine the threshold amplitude and frequency required for development of an optimized instrument.
   METHODS. An experimental in vitro model with fresh porcine RPE-choroid grafts was used. Release of the graft was studied by a masked observer for amplitudes in the range of 0.05 to 1.2 mm and frequencies in the range of 25 to 200 Hz in the horizontal plane.
   RESULTS. The minimum threshold amplitude required to release the graft was approximately 0.15 mm from a frequency of 100 Hz and higher.
   CONCLUSIONS. This study confirmed the clinical experience that vibration of an instrument induces the release of the RPE-choroid graft. The minimum threshold amplitude and frequency needed for optimum tissue release were estimated.
C1 [Maaijwee, Kristel; van Meurs, Jan C.] Rotterdam Eye Hosp, Dept Vitreoretinal Surg, Rotterdam, Netherlands.
   [Koolen, Twan; Rosenbrand, Dagmar; Jacobs, Elmer; Kleinheerenbrink, Sander; Knulst, Arjan; Schutte, Sander] Delft Univ Technol, Dept BioMech Engn, Delft, Netherlands.
   [Bos, Joop; Holland, Wim P.; Brouwer, Alex] Erasmus Univ, Med Ctr, Dept Expt Med Instrumentat, Rotterdam, Netherlands.
   [van Meurs, Jan C.] Erasmus MC, Rotterdam, Netherlands.
C3 Rotterdam Eye Hospital; Delft University of Technology; Erasmus
   University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus
   MC
RP Maaijwee, K (通讯作者)，Schiedamse Vest 180, NL-3011 BH Rotterdam, Netherlands.
EM kmaaijwee@hotmail.com
RI Knulst, Arjan J/A-2585-2009; Knulst, Arjan/ABB-7786-2020
OI Knulst, Arjan/0000-0002-3610-0877
CR Maaijwee K, 2008, INVEST OPHTH VIS SCI, V49, P758, DOI 10.1167/iovs.07-0510
   Maaijwee K, 2007, GRAEF ARCH CLIN EXP, V245, P1681, DOI 10.1007/s00417-007-0607-4
   Van Meurs JC, 2003, AM J OPHTHALMOL, V136, P688, DOI 10.1016/S0002-9394(03)00384-2
NR 3
TC 6
Z9 6
U1 0
U2 0
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD APR
PY 2008
VL 49
IS 4
BP 1629
EP 1632
DI 10.1167/iovs.07-1220
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 282ON
UT WOS:000254577200046
PM 18385084
DA 2022-11-30
ER

PT J
AU Dewell, TE
   Gjoni, K
   Liu, AZ
   Libby, ARG
   Moore, AT
   So, PL
   Conklin, BR
AF Dewell, Tessa E.
   Gjoni, Ketrin
   Liu, Angela Z.
   Libby, Ashley R. G.
   Moore, Anthony T.
   So, Po-Lin
   Conklin, Bruce R.
TI Transcription factor overexpression drives reliable differentiation of
   retinal pigment epithelium from human induced pluripotent stem cells
SO STEM CELL RESEARCH
LA English
DT Article
DE Retinal Pigment Epithelium; Induced Pluripotent Stem Cells; iPSC;
   Transcription Factors; Cell Differentiation; Retinal Diseases
ID DIRECTED DIFFERENTIATION; IPS CELLS; EXPRESSION; DISEASE; MUTATIONS;
   EYE; SPECIFICATION; PROTOCOL; REGIONS; PACKAGE
AB Age-related macular degeneration and genetic forms of blindness such as Best Disease and Retinitis Pigmentosa can be caused by degeneration of the Retinal Pigment Epithelium (RPE). RPE generated from patient-derived induced pluripotent stem cells (iPSCs) is valuable for both the study of disease mechanisms and development of therapeutic strategies. However, protocols to produce iPSC-derived RPE in vitro are often inefficient, laborintensive, low-throughput, and highly variable between cell lines and within batches. Here, we report a robust, scalable method to generate iPSC-RPE using doxycycline-inducible expression of eye field transcription factors OTX2, PAX6 and MITF paired with RPE-permissive culture media. Doxycycline addition induces exogenous expression of these transcription factors in Best Disease patient- and wildtype iPSCs to efficiently produce monolayers of RPE with characteristic morphology and gene expression. Further, these RPE monolayers display functionality features including light absorption via pigmentation, polarity-driven fluid transport, and phagocytosis. With this method, we achieve a highly efficient and easily scalable differentiation without the need for mechanical isolation or enrichment methods, generating RPE cultures applicable for in vitro studies.
C1 [Dewell, Tessa E.; Gjoni, Ketrin; Liu, Angela Z.; Libby, Ashley R. G.; So, Po-Lin; Conklin, Bruce R.] Gladstone Inst, 1650 Owens St, San Francisco, CA 94158 USA.
   [Libby, Ashley R. G.] Univ Calif San Francisco, Dev & Stem Cell Biol Program, 1675 Owens St, San Francisco, CA 94158 USA.
   [Moore, Anthony T.; Conklin, Bruce R.] UCSF Dept Ophthalmol, 10 Koret Way, San Francisco, CA 94143 USA.
   [So, Po-Lin; Conklin, Bruce R.] Innovat Genom Inst, 2151 Berkeley Way, Berkeley, CA 94720 USA.
   [So, Po-Lin] Gladstone Inst Stem Cell Core, 1650 Owens St, San Francisco, CA 94158 USA.
   [Conklin, Bruce R.] UCSF Dept Med, 535 Mission Bay Blvd South, San Francisco, CA 94158 USA.
C3 University of California System; University of California San Francisco;
   The J David Gladstone Institutes; University of California System;
   University of California San Francisco
RP Conklin, BR (通讯作者)，Gladstone Inst, 1650 Owens St, San Francisco, CA 94158 USA.
EM bconklin@gladstone.ucsf.edu
RI Libby, Ashley/GLN-7460-2022
OI Libby, Ashley/0000-0002-8139-8844
FU National Institutes of Health [EY028249, EY027789]; Claire Giannini
   Fund; That Man May See; Gladstone Institutes; Roddenberry Foundation
FX This work was supported by grants to B.R.C. from the National Institutes
   of Health: EY028249 and EY027789. B.R.C. and A.T.M. received support
   from the Claire Giannini Fund, and That Man May See. The stem cell work
   was also supported by Gladstone Institutes, and the Roddenberry
   Foundation.
CR ACAMPORA D, 1995, DEVELOPMENT, V121, P3279
   Ashery-Padan R, 2001, CURR OPIN CELL BIOL, V13, P706, DOI 10.1016/S0955-0674(00)00274-X
   Audo I, 2018, HUM MUTAT, V39, P887, DOI 10.1002/humu.23431
   BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x
   Bharti K, 2006, PIGM CELL RES, V19, P380, DOI 10.1111/j.1600-0749.2006.00318.x
   Bharti K, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002757
   Boergermann JH, 2010, INT J BIOCHEM CELL B, V42, P1802, DOI 10.1016/j.biocel.2010.07.018
   BOK D, 1993, J CELL SCI, P189
   Boulton M, 2001, EYE, V15, P384, DOI 10.1038/eye.2001.141
   Buchholz DE, 2013, STEM CELL TRANSL MED, V2, P384, DOI 10.5966/sctm.2012-0163
   Buschini E, 2015, CLIN OPHTHALMOL, V9, P563, DOI 10.2147/OPTH.S59724
   Carr AJ, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008152
   Carter DA, 2016, SCI REP-UK, V6, DOI 10.1038/srep33792
   Cerbini T, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0116032
   Chambers SM, 2009, NAT BIOTECHNOL, V27, P275, DOI 10.1038/nbt.1529
   Choudhary P, 2017, STEM CELL TRANSL MED, V6, P490, DOI 10.5966/sctm.2016-0088
   Das AT, 2016, CURR GENE THER, V16, P156, DOI 10.2174/1566523216666160524144041
   Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635
   Evans JR, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000254.pub4
   Ewels P., 2019, ZENODO, DOI 10.5281/zenodo.3503887
   Farkas MH, 2014, AM J PATHOL, V184, P2641, DOI 10.1016/j.ajpath.2014.06.026
   Fernandes TG, 2015, BIOTECHNOL J, V10, P1578, DOI 10.1002/biot.201400751
   Fernandopulle Michael S, 2018, Curr Protoc Cell Biol, V79, pe51, DOI 10.1002/cpcb.51
   Ferrer M, 2014, STEM CELL TRANSL MED, V3, P911, DOI 10.5966/sctm.2013-0192
   Fotiadis D, 2003, NATURE, V421, P127, DOI 10.1038/421127a
   Halder SK, 2005, NEOPLASIA, V7, P509, DOI 10.1593/neo.04640
   Heavner W, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a008391
   Hu YQ, 2019, PLOS BIOL, V17, DOI 10.1371/journal.pbio.3000365
   Idelson M, 2009, CELL STEM CELL, V5, P396, DOI 10.1016/j.stem.2009.07.002
   Khandhadia S, 2012, ADV EXP MED BIOL, V724, P15, DOI 10.1007/978-1-4614-0653-2_2
   Klimanskaya I, 2004, CLONING STEM CELLS, V6, P217, DOI 10.1089/1536230042323420
   Kreitzer FR, 2013, AM J STEM CELLS, V2, P119
   Lane A, 2014, STEM CELL TRANSL MED, V3, P1295, DOI 10.5966/sctm.2014-0094
   Larson MH, 2013, NAT PROTOC, V8, P2180, DOI 10.1038/nprot.2013.132
   Liao Y, 2014, BIOINFORMATICS, V30, P923, DOI 10.1093/bioinformatics/btt656
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   LIU ISC, 1994, NEURON, V13, P377, DOI 10.1016/0896-6273(94)90354-9
   Lun ATL, 2016, METHODS MOL BIOL, V1418, P391, DOI 10.1007/978-1-4939-3578-9_19
   Mandegar MA, 2016, CELL STEM CELL, V18, P541, DOI 10.1016/j.stem.2016.01.022
   Marlhens F, 1997, NAT GENET, V17, P139, DOI 10.1038/ng1097-139
   Martinez-Morales JR, 2003, J BIOL CHEM, V278, P21721, DOI 10.1074/jbc.M301708200
   Maruotti J, 2013, STEM CELL TRANSL MED, V2, P341, DOI 10.5966/sctm.2012-0106
   MATSUO I, 1995, GENE DEV, V9, P2646, DOI 10.1101/gad.9.21.2646
   Miyaoka Y, 2014, NAT METHODS, V11, P291, DOI 10.1038/nmeth.2840
   Molday RS, 2009, BBA-MOL CELL BIOL L, V1791, P573, DOI 10.1016/j.bbalip.2009.02.004
   Nguyen MTT, 2000, DEVELOPMENT, V127, P3581
   Nishihara D, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048879
   Okita K, 2013, STEM CELLS, V31, P458, DOI 10.1002/stem.1293
   Petrukhin K, 1998, NAT GENET, V19, P241, DOI 10.1038/915
   Quinn JC, 1996, GENE DEV, V10, P435, DOI 10.1101/gad.10.4.435
   Ramsden CM, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-00142-7
   Raviv S, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004360
   Regent F, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-47123-6
   Reyes AP, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15326-5
   Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616
   Seymour T, 2015, INT J MOL SCI, V16, P27288, DOI 10.3390/ijms161126024
   Singh R, 2013, HUM MOL GENET, V22, P593, DOI 10.1093/hmg/dds469
   Sinha D, 2020, AM J HUM GENET, V107, P278, DOI 10.1016/j.ajhg.2020.06.011
   Smith JR, 2008, STEM CELLS, V26, P496, DOI 10.1634/stemcells.2007-0039
   Sonoda S, 2009, NAT PROTOC, V4, P662, DOI 10.1038/nprot.2009.33
   Sparrrow JR, 2010, CURR MOL MED, V10, P802
   STONE EM, 1992, NAT GENET, V1, P246, DOI 10.1038/ng0792-246
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Strunnikova NV, 2010, HUM MOL GENET, V19, P2468, DOI 10.1093/hmg/ddq129
   Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024
   Thompson DA, 2001, NAT GENET, V28, P123, DOI 10.1038/88828
   Toops KA, 2014, EXP EYE RES, V124, P74, DOI 10.1016/j.exer.2014.05.003
   van der Laan M.J., 2001, HYBRID CLUSTERING GE
   Wang C, 2017, STEM CELL REP, V9, P1221, DOI 10.1016/j.stemcr.2017.08.019
   Whitmore SS, 2014, EXP EYE RES, V129, P93, DOI 10.1016/j.exer.2014.11.001
   Wienert B, 2019, SCIENCE, V364, P286, DOI 10.1126/science.aav9023
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yu GC, 2012, OMICS, V16, P284, DOI 10.1089/omi.2011.0118
   Zhang ZY, 2012, MOL VIS, V18, P2961
   Zhu PX, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000533
   Zhu Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054552
   Zou CJ, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002924
NR 77
TC 4
Z9 4
U1 0
U2 1
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1873-5061
EI 1876-7753
J9 STEM CELL RES
JI Stem Cell Res.
PD MAY
PY 2021
VL 53
AR 102368
DI 10.1016/j.scr.2021.102368
EA MAY 2021
PG 11
WC Cell & Tissue Engineering; Biotechnology & Applied Microbiology; Cell
   Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Biotechnology & Applied Microbiology
GA SU9GR
UT WOS:000663438800005
PM 34087997
OA gold
DA 2022-11-30
ER

PT J
AU Wright, CB
   Uehara, H
   Kim, Y
   Yasuma, T
   Yasuma, R
   Hirahara, S
   Makin, RD
   Apicella, I
   Pereira, F
   Nagasaka, Y
   Narendran, S
   Fukuda, S
   Albuquerque, R
   Fowler, BJ
   Bastos-Carvalho, A
   Georgel, P
   Hatada, I
   Chang, B
   Kerur, N
   Ambati, BK
   Ambati, J
   Gelfand, BD
AF Wright, Charles B.
   Uehara, Hironori
   Kim, Younghee
   Yasuma, Tetsuhiro
   Yasuma, Reo
   Hirahara, Shuichiro
   Makin, Ryan D.
   Apicella, Ivana
   Pereira, Felipe
   Nagasaka, Yosuke
   Narendran, Siddharth
   Fukuda, Shinichi
   Albuquerque, Romulo
   Fowler, Benjamin J.
   Bastos-Carvalho, Ana
   Georgel, Philippe
   Hatada, Izuho
   Chang, Bo
   Kerur, Nagaraj
   Ambati, Balamurali K.
   Ambati, Jayakrishna
   Gelfand, Bradley D.
TI Chronic Dicer1 deficiency promotes atrophic and neovascular outer
   retinal pathologies in mice
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
DE Dicer; retina; inflammasome; choroidal; neovascularization
ID MICRORNA TARGET PREDICTION; CHOROIDAL NEOVASCULARIZATION; MACULAR
   DEGENERATION; ALU RNA; INFLAMMASOME ACTIVATION; GEOGRAPHIC ATROPHY;
   NLRP3 INFLAMMASOME; GENE-THERAPY; MOUSE MODEL; IN-VIVO
AB Degeneration of the retinal pigmented epithelium (RPE) and aberrant blood vessel growth in the eye are advanced-stage processes in blinding diseases such as age-related macular degeneration (AMD), which affect hundreds of millions of people worldwide. Loss of the RNase DICER1, an essential factor in micro-RNA biogenesis, is implicated in RPE atrophy. However, the functional implications of DICER1 loss in choroidal and retinal neovascularization are unknown. Here, we report that two independent hypomorphic mouse strains, as well as a separate model of postnatal RPE-specific DICER1 ablation, all presented with spontaneous RPE degeneration and choroidal and retinal neovascularization. DICER1 hypomorphic mice lacking critical inflammasome components or the innate immune adaptor MyD88 developed less severe RPE atrophy and pathological neovascularization. DICER1 abundance was also reduced in retinas of the JR5558 mouse model of spontaneous choroidal neovascularization. Finally, adenoassociated vector-mediated gene delivery of a truncated DICER1 variant (OptiDicer) reduced spontaneous choroidal neovascularization in JR5558 mice. Collectively, these findings significantly expand the repertoire of DICER1 in preserving retinal homeostasis by preventing both RPE degeneration and pathological neovascularization.
C1 [Wright, Charles B.; Yasuma, Tetsuhiro; Albuquerque, Romulo; Fowler, Benjamin J.; Bastos-Carvalho, Ana] Univ Kentucky, Dept Ophthalmol & Visual Sci, Lexington, KY 40506 USA.
   [Uehara, Hironori; Ambati, Balamurali K.] Loma Linda Univ, Dept Ophthalmol, Loma Linda, CA 92350 USA.
   [Kim, Younghee; Yasuma, Reo; Hirahara, Shuichiro; Makin, Ryan D.; Apicella, Ivana; Pereira, Felipe; Nagasaka, Yosuke; Narendran, Siddharth; Fukuda, Shinichi; Kerur, Nagaraj; Ambati, Jayakrishna; Gelfand, Bradley D.] Univ Virginia, Sch Med, Ctr Adv Vis Sci, Charlottesville, VA 22903 USA.
   [Kim, Younghee; Yasuma, Reo; Hirahara, Shuichiro; Makin, Ryan D.; Apicella, Ivana; Pereira, Felipe; Nagasaka, Yosuke; Narendran, Siddharth; Fukuda, Shinichi; Kerur, Nagaraj; Ambati, Jayakrishna; Gelfand, Bradley D.] Univ Virginia, Sch Med, Dept Ophthalmol, Charlottesville, VA 22903 USA.
   [Makin, Ryan D.] Univ Virginia, Sch Med, Mol & Cellular Basis Dis Grad Program, Charlottesville, VA 22903 USA.
   [Pereira, Felipe] Univ Fed Sao Paulo, Dept Oftalmol & Ciencias Visuais, Escola Paulista Med, BR-04039032 Sao Paulo, Brazil.
   [Narendran, Siddharth] Aravind Med Res Fdn, Aravind Eye Care Syst, Madurai 625020, Tamil Nadu, India.
   [Fukuda, Shinichi] Univ Tsukuba, Dept Ophthalmol, Ibaraki 3058575, Japan.
   [Georgel, Philippe] Univ Strasbourg, Federat Med Translat Strasbourg, Lab ImmunoRhumatol Mol, INSERM,LabEx Transplantex,UMR S1109, F-67085 Strasbourg, France.
   [Georgel, Philippe] Univ Strasbourg, Federat Hosp Univ OMICARE, F-67085 Strasbourg, France.
   [Hatada, Izuho] Gunma Univ, Inst Mol & Cellular Regulat, Biosignal Genome Resource Ctr, Lab Genome Sci, Maebashi, Gunma 3718512, Japan.
   [Chang, Bo] Jackson Lab, 600 Main St, Bar Harbor, ME 04609 USA.
   [Ambati, Jayakrishna] Univ Virginia, Dept Pathol, Sch Med, Charlottesville, VA 22903 USA.
   [Ambati, Jayakrishna] Univ Virginia, Sch Med, Dept Microbiol Immunol & Canc Biol, Charlottesville, VA 22903 USA.
   [Gelfand, Bradley D.] Univ Virginia, Dept Biomed Engn, Sch Engn, Charlottesville, VA 22904 USA.
   [Kim, Younghee] OliX Pharmaceut Inc, Suwon 16226, Gyeonggi Do, South Korea.
   [Albuquerque, Romulo] Vistar Eye Ctr, Roanoke, VA 24019 USA.
C3 University of Kentucky; Loma Linda University; University of Virginia;
   University of Virginia; University of Virginia; Universidade Federal de
   Sao Paulo (UNIFESP); University of Tsukuba; Institut National de la
   Sante et de la Recherche Medicale (Inserm); UDICE-French Research
   Universities; Universites de Strasbourg Etablissements Associes;
   Universite de Strasbourg; UDICE-French Research Universities;
   Universites de Strasbourg Etablissements Associes; Universite de
   Strasbourg; Gunma University; Jackson Laboratory; University of
   Virginia; University of Virginia; University of Virginia
RP Gelfand, BD (通讯作者)，Univ Virginia, Sch Med, Ctr Adv Vis Sci, Charlottesville, VA 22903 USA.; Gelfand, BD (通讯作者)，Univ Virginia, Sch Med, Dept Ophthalmol, Charlottesville, VA 22903 USA.; Gelfand, BD (通讯作者)，Univ Virginia, Dept Biomed Engn, Sch Engn, Charlottesville, VA 22904 USA.
EM gelfand@virginia.edu
RI Narendran, Siddharth/AAV-1944-2020; georgel, philippe/P-5676-2016
OI georgel, philippe/0000-0001-6853-7080; Chang, Bo/0000-0001-8259-7290
FU NIH [R01EY019943, R01EY028027, DP1GM114862, R01EY022238, R01EY024068,
   R01EY029799, K99EY024336, R00EY024336, T32 HL007284, R01EY017950,
   R01EY017182]; American Heart Association [13SDG16770008]; John Templeton
   Foundation [60763]; DuPont Guerry, III, Professorship
FX We thank G. Pattison, K. Langberg, D. Robertson, X. Zhou, K. Atwood, and
   H. Hall for their technical assistance. These studies were supported by
   NIH Grant R01EY028027 and American Heart Association Grant 13SDG16770008
   (B.D.G.); J.A. was supported by NIH Grants DP1GM114862, R01EY022238,
   R01EY024068, R01EY028027, and R01EY029799; John Templeton Foundation
   Grant 60763; and the DuPont Guerry, III, Professorship; N.K. by NIH
   Grants K99EY024336 and R00EY024336; R.D.M. by NIH Grant T32 HL007284;
   B.K.A. and H. U. by NIH Grants R01EY017950 and R01EY017182; and B.C. by
   NIH Grant R01EY019943. The content is solely the responsibility of the
   authors and does not necessarily represent the official views of the
   NIH.
CR Alsaleh G, 2016, ARTHRITIS RHEUMATOL, V68, P1839, DOI 10.1002/art.39641
   Ambati J, 2003, NAT MED, V9, P1390, DOI 10.1038/nm950
   Babiarz JE, 2008, GENE DEV, V22, P2773, DOI 10.1101/gad.1705308
   Bainbridge JWB, 2008, NEW ENGL J MED, V358, P2231, DOI 10.1056/NEJMoa0802268
   Barker SE, 2009, J GENE MED, V11, P486, DOI 10.1002/jgm.1327
   Bernstein E, 2003, NAT GENET, V35, P215, DOI 10.1038/ng1253
   Bernstein E, 2001, NATURE, V409, P363, DOI 10.1038/35053110
   Carido M, 2014, INVEST OPHTH VIS SCI, V55, P5431, DOI 10.1167/iovs.14-14325
   Chang B, 2018, INVEST OPHTH VIS SCI, V59, P5127, DOI 10.1167/iovs.18-25046
   Chen SD, 2014, GENE DEV, V28, P1054, DOI 10.1101/gad.239681.114
   Chen YS, 2016, ONCOTARGET, V7, P84299, DOI 10.18632/oncotarget.12520
   Dong JY, 1996, HUM GENE THER, V7, P2101, DOI 10.1089/hum.1996.7.17-2101
   Dridi S, 2012, P NATL ACAD SCI USA, V109, P13781, DOI 10.1073/pnas.1206494109
   Du Z, 2008, P NATL ACAD SCI USA, V105, P2391, DOI 10.1073/pnas.0711506105
   Fan Y, 2016, ONCOTARGET, V7, P18280, DOI 10.18632/oncotarget.7807
   Fareh M, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13694
   Flemr M, 2013, CELL, V155, P807, DOI 10.1016/j.cell.2013.10.001
   Forman JJ, 2008, P NATL ACAD SCI USA, V105, P14879, DOI 10.1073/pnas.0803230105
   Fowler BJ, 2014, SCIENCE, V346, P1000, DOI 10.1126/science.1261754
   Foxton R, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.110
   Fukasawa M, 2006, CYTOGENET GENOME RES, V113, P138, DOI 10.1159/000090825
   Gan JH, 2006, CELL, V124, P355, DOI 10.1016/j.cell.2005.11.034
   Gelfand BD, 2015, CELL REP, V11, P1686, DOI 10.1016/j.celrep.2015.05.023
   Grunin M, 2012, INVEST OPHTH VIS SCI, V53, P5292, DOI 10.1167/iovs.11-9165
   Gurtan AM, 2012, RNA, V18, P1116, DOI 10.1261/rna.032680.112
   Hanna JA, 2017, CANCER RES, V77, P6109, DOI 10.1158/0008-5472.CAN-17-1262
   Harfe BD, 2005, P NATL ACAD SCI USA, V102, P10898, DOI 10.1073/pnas.0504834102
   Hasegawa E, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0106507
   Hoerster R, 2012, GRAEF ARCH CLIN EXP, V250, P1579, DOI 10.1007/s00417-012-1990-z
   Hu QD, 2012, NAT STRUCT MOL BIOL, V19, P1168, DOI 10.1038/nsmb.2400
   Imamura Y, 2006, P NATL ACAD SCI USA, V103, P11282, DOI 10.1073/pnas.0602131103
   Kaneko H, 2011, NATURE, V471, P325, DOI 10.1038/nature09830
   Kaszubski P, 2016, OPHTHALMIC RES, V55, P185, DOI 10.1159/000443209
   Kennedy EM, 2015, P NATL ACAD SCI USA, V112, pE6945, DOI 10.1073/pnas.1513421112
   Kerur N, 2018, NAT MED, V24, P50, DOI 10.1038/nm.4450
   Kerur N, 2013, INVEST OPHTH VIS SCI, V54, P7395, DOI 10.1167/iovs.13-12500
   Kim YK, 2016, P NATL ACAD SCI USA, V113, pE1881, DOI 10.1073/pnas.1602532113
   Kim Y, 2014, P NATL ACAD SCI USA, V111, P16082, DOI 10.1073/pnas.1403814111
   Kuehbacher A, 2007, CIRC RES, V101, P59, DOI 10.1161/CIRCRESAHA.107.153916
   KUIDA K, 1995, SCIENCE, V267, P2000, DOI 10.1126/science.7535475
   Lai CM, 2005, MOL THER, V12, P659, DOI 10.1016/j.ymthe.2005.04.022
   Lee SH, 2018, MOL THER-METH CLIN D, V9, P90, DOI 10.1016/j.omtm.2018.01.008
   Li YA, 2015, SCI REP-UK, V5, DOI 10.1038/srep13316
   Liang XH, 2013, BBA-GENE REGUL MECH, V1829, P455, DOI 10.1016/j.bbagrm.2013.01.011
   Luo L, 2013, ELIFE, V2, DOI 10.7554/eLife.00324
   Ma E, 2008, J MOL BIOL, V380, P237, DOI 10.1016/j.jmb.2008.05.005
   Ma JB, 2004, NATURE, V429, P318, DOI 10.1038/nature02519
   MacRae IJ, 2007, NAT STRUCT MOL BIOL, V14, P934, DOI 10.1038/nsmb1293
   Maguire AM, 2008, NEW ENGL J MED, V358, P2240, DOI 10.1056/NEJMoa0802315
   Mattapallil MJ, 2012, INVEST OPHTH VIS SCI, V53, P2921, DOI 10.1167/iovs.12-9662
   Morita S, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004212
   Murchison EP, 2007, GENE DEV, V21, P682, DOI 10.1101/gad.1521307
   Nagai N, 2015, AM J PATHOL, V185, P2534, DOI 10.1016/j.ajpath.2015.04.029
   Nagai N, 2014, INVEST OPHTH VIS SCI, V55, P3709, DOI 10.1167/iovs.14-13989
   Ohnishi Y, 2012, MOL BIOL REP, V39, P903, DOI 10.1007/s11033-011-0815-1
   Ostermann E, 2015, VIRUSES-BASEL, V7, P2308, DOI 10.3390/v7052308
   Ostermann E, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043744
   Otsuka M, 2008, J CLIN INVEST, V118, P1944, DOI 10.1172/JCI33680
   Otsuka M, 2007, IMMUNITY, V27, P123, DOI 10.1016/j.immuni.2007.05.014
   Paneghetti L, 2016, VASC CELL, V8, DOI 10.1186/s13221-016-0036-4
   Park JE, 2011, NATURE, V475, P201, DOI 10.1038/nature10198
   Plummer PN, 2013, CANCER RES, V73, P341, DOI 10.1158/0008-5472.CAN-12-0271
   Ren YF, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040705
   Schnabolk G, 2018, MOL THER-METH CLIN D, V9, P1, DOI 10.1016/j.omtm.2017.11.003
   Schultz R, 2018, INVEST OPHTH VIS SCI, V59
   Suarez Y, 2008, P NATL ACAD SCI USA, V105, P14082, DOI 10.1073/pnas.0804597105
   Sun Y, 2017, J EXP MED, V214, P1753, DOI 10.1084/jem.20161645
   Sun Y, 2017, EBIOMEDICINE, V18, P281, DOI 10.1016/j.ebiom.2017.03.026
   Sundermeier TR, 2017, J BIOL CHEM, V292, P3366, DOI 10.1074/jbc.M116.770024
   Sunness JS, 1999, OPHTHALMOLOGY, V106, P910, DOI 10.1016/S0161-6420(99)00509-6
   Tarallo V, 2012, CELL, V149, P847, DOI 10.1016/j.cell.2012.03.036
   Wang JM, 2014, INVEST OPHTH VIS SCI, V55, P1941, DOI 10.1167/iovs.13-13075
   Wang XW, 2008, RNA, V14, P1012, DOI 10.1261/rna.965408
   Wei H, 2016, EXP EYE RES, V145, P450, DOI 10.1016/j.exer.2015.09.015
   Wong N, 2015, NUCLEIC ACIDS RES, V43, pD146, DOI 10.1093/nar/gku1104
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wu ZJ, 2010, MOL THER, V18, P80, DOI 10.1038/mt.2009.255
   Yang WJ, 2005, J BIOL CHEM, V280, P9330, DOI 10.1074/jbc.M413394200
   Yu HG, 2008, INVEST OPHTH VIS SCI, V49, P2599, DOI 10.1167/iovs.07-1508
   Zhang XH, 2015, MOL THER, V23, P226, DOI 10.1038/mt.2014.199
NR 80
TC 20
Z9 21
U1 0
U2 8
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD FEB 4
PY 2020
VL 117
IS 5
BP 2579
EP 2587
DI 10.1073/pnas.1909761117
PG 9
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA KJ8YB
UT WOS:000512340900051
PM 31964819
OA Green Published, hybrid
DA 2022-11-30
ER

PT J
AU Wang, DP
   Wang, LJ
AF Wang, Depeng
   Wang, Liejun
TI On OCT Image Classification via Deep Learning
SO IEEE PHOTONICS JOURNAL
LA English
DT Article
DE Deep learning; optical coherence tomography; diabetic macular edema;
   age-related macular degeneration automated diagnosis; computer-aided
   diagnosis
ID DIABETIC MACULAR EDEMA; CONVOLUTIONAL NEURAL-NETWORKS; DEGENERATION;
   CARE
AB Computer-aided diagnosis of retinopathy is a research hotspot in the field of medical image classification. Diabetic macular edema (DME) and age-related macular degeneration (AMD) are two common ocular diseases that can result in partial or complete loss of vision. Optical coherence tomography imaging (OCT) is widely applied to the diagnosis of ocular diseases including DME and AMD. In this paper, an automatic method based on deep learning is proposed to detect AME and AMD lesions, in which two publicly available OCT datasets of retina were adopted and a network model with effective feature of reuse feature was applied to solve the problem of small datasets and enhance the adaptation to the difference of different datasets of the approach. Several network models with effective feature of reusable feature were compared and the transfer learning on networks with pre-trained models was realized. CliqueNet achieves better, classification results compared with other network models with a more than 0.98 accuracy and 0.99 of area under the curve (AUC) value finally.
C1 [Wang, Depeng] Xinjiang Univ, Coll Software Engn, Urumqi 830046, Peoples R China.
   [Wang, Liejun] Xinjiang Univ, Coll Informat Sci & Engn, Urumqi 830046, Peoples R China.
C3 Xinjiang University; Xinjiang University
RP Wang, LJ (通讯作者)，Xinjiang Univ, Coll Informat Sci & Engn, Urumqi 830046, Peoples R China.
EM wljxju@xju.edu.cn
OI Wang, Depeng/0000-0003-4310-0469
FU National Science Foundation of China [61771416]; Creative Research
   Groups of Higher Education of Xinjiang Uygur Autonomous Region
   [XJEDU2017T002]; CERNET Innovation Project [NGII20180201, NGII20170325,
   NGII20180320]
FX This work was supported in part by the National Science Foundation of
   China under Grant 61771416, in part by the Creative Research Groups of
   Higher Education of Xinjiang Uygur Autonomous Region under Grant
   XJEDU2017T002, and in part by the CERNET Innovation Project under Grants
   NGII20180201, NGII20170325, and NGII20180320.
CR Bourne RRA, 2014, BRIT J OPHTHALMOL, V98, P629, DOI 10.1136/bjophthalmol-2013-304033
   Bressler Neil M, 2002, J Am Board Fam Pract, V15, P142
   Chen Y., 2017, ADV NEURAL INFORM PR, P4470
   Cheng H, 2019, IEEE ACCESS, V7, P29989, DOI 10.1109/ACCESS.2019.2897799
   Cheng SL, 2019, IEEE ACCESS, V7, P78942, DOI 10.1109/ACCESS.2019.2922738
   Davis J., 2006, P 23 INT C MACH LEAR, P233
   Friedman D S, 2014, ARCH OPHTHALMOL-CHIC, V122, P564
   Gomez-Valverde JJ, 2019, BIOMED OPT EXPRESS, V10, P892, DOI 10.1364/BOE.10.000892
   He K., 2016, P IEEE COMPUTER SOC, P630, DOI DOI 10.1109/CVPR.2016.90
   Hendra TJ, 1997, AGE AGEING, V26, P3, DOI 10.1093/ageing/26.1.3
   HUANG D, 1991, SCIENCE, V254, P1178, DOI 10.1126/science.1957169
   Huang G, 2017, PROC CVPR IEEE, P2261, DOI 10.1109/CVPR.2017.243
   JAVITT JC, 1994, DIABETES CARE, V17, P909, DOI 10.2337/diacare.17.8.909
   Karri SPK, 2017, BIOMED OPT EXPRESS, V8, P579, DOI 10.1364/BOE.8.000579
   Kollias AN, 2010, DTSCH ARZTEBL INT, V107, P75, DOI 10.3238/arztebl.2010.0075
   Kraus H.M.J., 1992, DIABETES METAB, V18, P334
   Li F, 2019, GRAEF ARCH CLIN EXP, V257, P495, DOI 10.1007/s00417-018-04224-8
   Litjens G, 2017, MED IMAGE ANAL, V42, P60, DOI 10.1016/j.media.2017.07.005
   Oulhaj H, 2012, INT CONF MULTIMED, P344, DOI 10.1109/ICMCS.2012.6320218
   Platt JC, 1999, ADVANCES IN KERNEL METHODS, P185
   Rasti R, 2018, IEEE T MED IMAGING, V37, P1024, DOI 10.1109/TMI.2017.2780115
   Romero-Aroca P, 2013, WORLD J DIABETES, V4, P165, DOI 10.4239/wjd.v4.i5.165
   Simonyan K., 2014, PREPRINT, DOI DOI 10.48550/ARXIV.1409.1556
   Srinivasan PP, 2014, BIOMED OPT EXPRESS, V5, P3568, DOI 10.1364/BOE.5.003568
   Sutskever I., 2013, INT C MACH LEARN, V3, P1139, DOI DOI 10.1007/S00287-015-0911-Z
   Szegedy C., 2016, 2016 IEEE C COMPUTER, P2818, DOI DOI 10.1109/CVPR.2016.308
   Wang Y, 2016, BIOMED OPT EXPRESS, V7, P4928, DOI 10.1364/BOE.7.004928
   Xie SN, 2017, PROC CVPR IEEE, P5987, DOI 10.1109/CVPR.2017.634
   Yang YB, 2018, PROC CVPR IEEE, P2413, DOI 10.1109/CVPR.2018.00256
NR 29
TC 13
Z9 13
U1 7
U2 24
PU IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC
PI PISCATAWAY
PA 445 HOES LANE, PISCATAWAY, NJ 08855-4141 USA
SN 1943-0655
EI 1943-0647
J9 IEEE PHOTONICS J
JI IEEE Photonics J.
PD OCT
PY 2019
VL 11
IS 5
AR 3900714
DI 10.1109/JPHOT.2019.2934484
PG 14
WC Engineering, Electrical & Electronic; Optics; Physics, Applied
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Engineering; Optics; Physics
GA IV3SM
UT WOS:000484194500001
OA gold
DA 2022-11-30
ER

PT J
AU Bakker, NAM
   de Boer, R
   Marie, C
   Scherman, D
   Haanen, JBAG
   Beijnen, JH
   Nuijen, B
   van den Berg, JH
AF Bakker, Noor A. M.
   de Boer, Renate
   Marie, Corinne
   Scherman, Daniel
   Haanen, John B. A. G.
   Beijnen, Jos H.
   Nuijen, Bastiaan
   van den Berg, Joost H.
TI Small-scale GMP production of plasmid DNA using a simplified and fully
   disposable production method
SO JOURNAL OF BIOTECHNOLOGY
LA English
DT Article
DE Small scale plasmid production; RNase; GMP; fully disposable;
   antibiotic-free gene vectors; miniplasmids
AB In the past years, the demand for small batches of clinical grade plasmid DNA has been growing. For that purpose, we designed and qualified a scaled-down Good Manufacturing Practices (GMP) production method, able to produce small batches (1-4 mg) of plasmid. The developed method does not require any complex production equipment and utilizes only disposable production materials, which makes it easy to implement and simplifies line-clearance. We have successfully used this method to produce several small batches of two different plasmids. The produced plasmids, both formulated in an Electroporation Buffer, are mixed and filled into small, single-use, aliquots. Quality control confirmed the robustness of the developed method and a stability study showed that the final formulation is stable for at least two years. The final patient formulation will be subsequently used in a phase I/II clinical trial in which retina cells of patients with Age Related Macular Degeneration, are transfected. The presented production method can be generically used for other plasmid constructs and final formulation designs.
C1 [Bakker, Noor A. M.; de Boer, Renate; Haanen, John B. A. G.; van den Berg, Joost H.] Netherlands Canc Inst Antoni van Leeuwenhoek, Div Immunol, Plesmanslaan 121, NL-1066 CX Amsterdam, Netherlands.
   [Bakker, Noor A. M.; de Boer, Renate; Haanen, John B. A. G.; Beijnen, Jos H.; Nuijen, Bastiaan; van den Berg, Joost H.] Netherlands Canc Inst Antoni van Leeuwenhoek, Div Pharm, Plesmanslaan 121, NL-1066 CX Amsterdam, Netherlands.
   [Bakker, Noor A. M.; de Boer, Renate; Haanen, John B. A. G.; Beijnen, Jos H.; Nuijen, Bastiaan; van den Berg, Joost H.] Netherlands Canc Inst Antoni van Leeuwenhoek, Div Clin Pharmacol, Plesmanslaan 121, NL-1066 CX Amsterdam, Netherlands.
   [Bakker, Noor A. M.; de Boer, Renate; van den Berg, Joost H.] Amsterdam Biotherapeut Unit, Louwesweg 6, NL-1066 EC Amsterdam, Netherlands.
   [Scherman, Daniel; Haanen, John B. A. G.] Netherlands Canc Inst Antoni van Leeuwenhoek, Div Med Oncol, Plesmanslaan 121, NL-1066 CX Amsterdam, Netherlands.
   [Marie, Corinne] CNRS, Unite Technol Chim & Biol Sante UTCBS, UMR 8258, F-75006 Paris, France.
   [Marie, Corinne; Scherman, Daniel] INSERM, UTCBS U1022, F-75006 Paris, France.
   [Marie, Corinne; Scherman, Daniel] Univ Paris 05, Sorbonne Paris Cite, UTCBS, F-75006 Paris, France.
   [Marie, Corinne; Scherman, Daniel] PSL Res Univ, Chim ParisTech, UTCBS, F-75005 Paris, France.
C3 Netherlands Cancer Institute; Netherlands Cancer Institute; Netherlands
   Cancer Institute; Netherlands Cancer Institute; Centre National de la
   Recherche Scientifique (CNRS); CNRS - Institute of Chemistry (INC);
   UDICE-French Research Universities; Universite Paris Cite; Institut
   National de la Sante et de la Recherche Medicale (Inserm); UDICE-French
   Research Universities; Universite Paris Cite; UDICE-French Research
   Universities; Universite Paris Cite; UDICE-French Research Universities;
   PSL Research University Paris; Chimie ParisTech; Universite Paris Cite
RP van den Berg, JH (通讯作者)，Netherlands Canc Inst Antoni van Leeuwenhoek, Div Immunol, Plesmanslaan 121, NL-1066 CX Amsterdam, Netherlands.; van den Berg, JH (通讯作者)，Netherlands Canc Inst Antoni van Leeuwenhoek, Div Pharm, Plesmanslaan 121, NL-1066 CX Amsterdam, Netherlands.; van den Berg, JH (通讯作者)，Netherlands Canc Inst Antoni van Leeuwenhoek, Div Clin Pharmacol, Plesmanslaan 121, NL-1066 CX Amsterdam, Netherlands.; van den Berg, JH (通讯作者)，Amsterdam Biotherapeut Unit, Louwesweg 6, NL-1066 EC Amsterdam, Netherlands.
EM jh.vd.berg@nki.nl
RI Haanen, John/AAD-8578-2022; Haanen, John/AAD-8534-2022
OI Haanen, John/0000-0001-5884-7704; Scherman, Daniel/0000-0003-1207-1298;
   MARIE, Corinne/0000-0001-9619-5700; Bakker, Noor/0000-0002-7167-581X
FU QC and QA department of the Pharmacy of The Netherlands Cancer
   Institute-Antoni van Leeuwenhoek; European Union Seventh Framework
   Program [305134]
FX The authors would like to thank Edith Vermeij for preparing most of the
   buffers, and the QC and QA department of the Pharmacy of The Netherlands
   Cancer Institute-Antoni van Leeuwenhoek for the generous support. The
   research leading to these results has received funding from the European
   Union Seventh Framework Program under grant agreement n~305134.
CR Barnstable CJ, 2004, PROG RETIN EYE RES, V23, P561, DOI 10.1016/j.preteyeres.2004.05.002
   Eon-Duval A, 2004, J CHROMATOGR B, V804, P327, DOI 10.1016/j.jchromb.2004.01.033
   Eon-Duval A, 2003, ANAL BIOCHEM, V316, P66, DOI 10.1016/S0003-2697(03)00050-2
   Ferreira GNM, 1999, BIOTECHNOL PROGR, V15, P725, DOI 10.1021/bp990065+
   Ginn SL, 2013, J GENE MED, V15, P65, DOI 10.1002/jgm.2698
   Gorabi AM, 2018, J CELL BIOCHEM, V119, P9645, DOI 10.1002/jcb.27303
   Melero I, 2014, NAT REV CLIN ONCOL, V11, P509, DOI 10.1038/nrclinonc.2014.111
   Pastor M, 2018, MOL THER-NUCL ACIDS, V11, P57, DOI 10.1016/j.omtn.2017.12.017
   Quaak SGL, 2008, EUR J PHARM BIOPHARM, V70, P429, DOI 10.1016/j.ejpb.2008.05.002
   Russell S.a., 1989, MOL CLONING LAB MANU
   Samuels S, 2017, CANCER IMMUNOL IMMUN, V66, P1163, DOI 10.1007/s00262-017-2006-y
   Subramanian P, 2013, J BIOL CHEM, V288, P23928, DOI 10.1074/jbc.M113.487884
   Thumann G, 2017, MOL THER-NUCL ACIDS, V6, P302, DOI 10.1016/j.omtn.2017.02.002
NR 13
TC 6
Z9 6
U1 1
U2 6
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0168-1656
EI 1873-4863
J9 J BIOTECHNOL
JI J. Biotechnol.
PY 2019
VL 306
SU S
AR 100007
DI 10.1016/j.btecx.2019.100007
PG 8
WC Biotechnology & Applied Microbiology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology
GA VK3XY
UT WOS:000687469200005
PM 34112376
OA hybrid, Green Published
DA 2022-11-30
ER

PT J
AU Huang, WY
   Wu, H
   Li, DJ
   Song, JF
   Xiao, YD
   Liu, CQ
   Zhou, JZ
   Sui, ZQ
AF Huang, Wu-Yang
   Wu, Han
   Li, Da-Jing
   Song, Jiang-Feng
   Xiao, Ya-Dong
   Liu, Chun-Quan
   Zhou, Jian-Zhong
   Sui, Zhong-Quan
TI Protective Effects of Blueberry Anthocyanins against H2O2-Induced
   Oxidative Injuries in Human Retinal Pigment Epithelial Cells
SO JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY
LA English
DT Article
DE age-related macular degeneration; antioxidant; blueberry anthocyanins;
   oxidative stress; retinal pigment epithelial cells
ID ANTIOXIDANT ACTIVITY; IN-VITRO; DAMAGE; AGE; STRESS; VEGF;
   IDENTIFICATION; ANGIOGENESIS; POLYPHENOLS; CYANIDIN
AB Blueberry anthocyanins are considered protective of eye health because of their recognized antioxidant properties. In this study, blueberry anthocyanin extract (BAE), malvidin (Mv), malvidin-3-glucoside (Mv-3-glc), and malvidin-3-galactoside (Mv-3-gal) all reduced H2O2-induced oxidative stress by decreasing the levels of reactive oxygen species and malondialdehyde and increasing the levels of superoxide dismutase, catalase, and glutathione peroxidase in human retinal pigment epithelial cells. BAE and the anthocyanin standards enhanced cell viability from 63.69 +/- 3.36 to 86.57 +/- 6.92% (BAE), 115.72 +/- 23.41% (Mv), 98.15 +/- 9.39% (Mv-3-glc), and 127.97 +/- 20.09% (Mv-3-gal) and significantly inhibited cell apoptosis (P < 0.01 for all). Mitogen-activated-protein-kinase pathways, including ERK1/2 and p38, were involved in the bioactivities. In addition, the anthocyanins decreased vascular-endothelial-cell-growth-factor levels and activated Akt-signal pathways. These combined results supported the hypothesis that blueberry anthocyanins could inhibit the induction and progression of age-related macular degeneration (AMD) through antioxidant mechanisms.
C1 [Huang, Wu-Yang; Wu, Han; Li, Da-Jing; Song, Jiang-Feng; Xiao, Ya-Dong; Liu, Chun-Quan; Zhou, Jian-Zhong] Jiangsu Acad Agr Sci, Inst Farm Prod Proc, Nanjing 210014, Jiangsu, Peoples R China.
   [Huang, Wu-Yang] Jiangsu Acad Agr Sci, Jiangsu Key Lab Hort Crop Genet Improvement, Nanjing 210014, Jiangsu, Peoples R China.
   [Sui, Zhong-Quan] Shanghai Jiao Tong Univ, Sch Agr & Biol, Bor S Luh Food Safety Res Ctr, Key Lab Urban Agr South,Dept Food Sci & Engn, Shanghai 200240, Peoples R China.
C3 Jiangsu Academy of Agricultural Sciences; Jiangsu Academy of
   Agricultural Sciences; Shanghai Jiao Tong University
RP Zhou, JZ (通讯作者)，Jiangsu Acad Agr Sci, Inst Farm Prod Proc, Nanjing 210014, Jiangsu, Peoples R China.; Sui, ZQ (通讯作者)，Shanghai Jiao Tong Univ, Sch Agr & Biol, Bor S Luh Food Safety Res Ctr, Key Lab Urban Agr South,Dept Food Sci & Engn, Shanghai 200240, Peoples R China.
EM zjzluck@126.com; springsui@gmail.com
RI HUANG, Wuyang/ABH-5066-2020
OI HUANG, Wuyang/0000-0002-3038-0636; , Han/0000-0003-0684-5461
FU Natural Science Foundation Program of Jiangsu Province [BK20161376];
   Jiangsu Agriculture Science and Technology Innovation Fund [CX(15)1026];
   Institute Science Research Fund of the Jiangsu Academy of Agricultural
   Sciences [013036611703]
FX This work was supported by the Natural Science Foundation Program of
   Jiangsu Province (BK20161376), the Jiangsu Agriculture Science and
   Technology Innovation Fund (CX(15)1026), and the Institute Science
   Research Fund of the Jiangsu Academy of Agricultural Sciences
   (013036611703).
CR Bar-Gill AB, 2013, BBA-MOL CELL RES, V1833, P2070, DOI 10.1016/j.bbamcr.2013.04.016
   Bhabak KP, 2010, ACCOUNTS CHEM RES, V43, P1408, DOI 10.1021/ar100059g
   Boulton M, 2001, EYE, V15, P384, DOI 10.1038/eye.2001.141
   Brentnall M, 2013, BMC CELL BIOL, V14, DOI 10.1186/1471-2121-14-32
   Cai JY, 2000, PROG RETIN EYE RES, V19, P205, DOI 10.1016/S1350-9462(99)00009-9
   Cano M, 2014, FREE RADICAL BIO MED, V69, P1, DOI 10.1016/j.freeradbiomed.2014.01.004
   Chen R, 2014, MOL VIS, V20, P242
   Ding XY, 2009, PROG RETIN EYE RES, V28, P1, DOI 10.1016/j.preteyeres.2008.10.001
   Fernandes I, 2014, J FUNCT FOODS, V7, P54, DOI 10.1016/j.jff.2013.05.010
   Giorgio M, 2007, NAT REV MOL CELL BIO, V8, p722A
   Green DR, 2000, CELL, V102, P1, DOI 10.1016/S0092-8674(00)00003-9
   Huang W. Y., 2016, OXID MED CELL LONGEV, P1, DOI DOI 10.1155/2016/1591803
   Huang WY, 2014, MOLECULES, V19, P12827, DOI 10.3390/molecules190812827
   Hyun JW, 2004, J AGR FOOD CHEM, V52, P2213, DOI 10.1021/jf030370h
   Kaczara P, 2010, FREE RADICAL BIO MED, V48, P1064, DOI 10.1016/j.freeradbiomed.2010.01.022
   Kalt W, 2008, J AGR FOOD CHEM, V56, P705, DOI 10.1021/jf071998l
   Kalt W, 2010, J AGR FOOD CHEM, V58, P4001, DOI 10.1021/jf903038r
   Karkkainen MJ, 2000, ONCOGENE, V19, P5598, DOI 10.1038/sj.onc.1203855
   Khodapasand Ehsan, 2015, Iranian Biomedical Journal, V19, P69, DOI 10.6091/ibj.1366.2015
   Kich DM, 2017, MOL CELL BIOCHEM, V424, P35, DOI 10.1007/s11010-016-2840-9
   Ku HJ, 2017, REDOX REP, V22, P35, DOI 10.1080/13510002.2015.1135581
   Li CY, 2013, J AGR FOOD CHEM, V61, P523, DOI 10.1021/jf3046158
   Li J, 2016, SCI REP-UK, V6, DOI 10.1038/srep19408
   Liu YX, 2016, J AGR FOOD CHEM, V64, P416, DOI 10.1021/acs.jafc.5b05436
   Liu YX, 2015, J AGR FOOD CHEM, V63, P9295, DOI 10.1021/acs.jafc.5b04341
   Liu YX, 2011, J AGR FOOD CHEM, V59, P356, DOI 10.1021/jf103852s
   London DS, 2015, NUTR RES, V35, P107, DOI 10.1016/j.nutres.2014.12.007
   Manning BD, 2007, CELL, V129, P1261, DOI 10.1016/j.cell.2007.06.009
   Marazita MC, 2016, REDOX BIOL, V7, P78, DOI 10.1016/j.redox.2015.11.011
   Matsumoto H, 2006, EXP EYE RES, V83, P348, DOI 10.1016/j.exer.2005.12.019
   MICELI MV, 1994, EXP CELL RES, V214, P242, DOI 10.1006/excr.1994.1254
   Milbury PE, 2010, J NUTR, V140, P1099, DOI 10.3945/jn.109.117168
   Olmedilla-Alonso B, 2014, NUTR J, V13, DOI 10.1186/1475-2891-13-52
   Olsson AK, 2006, NAT REV MOL CELL BIO, V7, P359, DOI 10.1038/nrm1911
   Qiu ZK, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0151067
   Rickman CB, 2013, INVEST OPHTH VIS SCI, V54, pORSF68, DOI 10.1167/iovs.13-12757
   Segales J, 2016, FRONT CELL DEV BIOL, V4, DOI 10.3389/fcell.2016.00091
   Sen Raychaudhuri S, 2000, BOT REV, V66, P89, DOI 10.1007/BF02857783
   Sene A, 2015, TRENDS MOL MED, V21, P43, DOI 10.1016/j.molmed.2014.10.005
   Shaul YD, 2007, BBA-MOL CELL RES, V1773, P1213, DOI 10.1016/j.bbamcr.2006.10.005
   Shih PH, 2005, FOOD CHEM TOXICOL, V43, P1557, DOI 10.1016/j.fct.2005.05.001
   Singh N, 2007, INDIAN J CLIN BIOCHE, V22, P6, DOI 10.1007/BF02913307
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Teng H, 2017, TRENDS FOOD SCI TECH, V66, P153, DOI 10.1016/j.tifs.2017.05.015
   Veljkovic M, 2017, PHYTOTHER RES, V31, P115, DOI 10.1002/ptr.5738
   Wang KJ, 2015, BIOCHEM BIOPH RES CO, V468, P541, DOI 10.1016/j.bbrc.2015.10.117
   Wang LY, 2008, J IMMUNOL, V180, P3072, DOI 10.4049/jimmunol.180.5.3072
   Wang Y, 2015, J SCI FOOD AGR, V95, P936, DOI 10.1002/jsfa.6765
   Xu Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072528
   Yang B, 2013, EXPERT OPIN THER TAR, V17, P255, DOI 10.1517/14728222.2013.745513
   Yu CC, 2012, FREE RADICAL BIO MED, V52, P660, DOI 10.1016/j.freeradbiomed.2011.11.021
   Yun JW, 2010, FOOD CHEM TOXICOL, V48, P903, DOI 10.1016/j.fct.2009.12.031
   Zhao CL, 2014, MOL DIVERS, V18, P687, DOI 10.1007/s11030-014-9520-z
   Zhu C, 2017, BIOMED PHARMACOTHER, V88, P124, DOI 10.1016/j.biopha.2016.11.089
NR 54
TC 51
Z9 60
U1 13
U2 122
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0021-8561
EI 1520-5118
J9 J AGR FOOD CHEM
JI J. Agric. Food Chem.
PD FEB 21
PY 2018
VL 66
IS 7
BP 1638
EP 1648
DI 10.1021/acs.jafc.7b06135
PG 11
WC Agriculture, Multidisciplinary; Chemistry, Applied; Food Science &
   Technology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Agriculture; Chemistry; Food Science & Technology
GA FX5TV
UT WOS:000426144200005
PM 29393642
DA 2022-11-30
ER

PT J
AU Jin, HL
   Choung, SY
   Jeong, KW
AF Jin, Hong Lan
   Choung, Se-Young
   Jeong, Kwang Won
TI Protective mechanisms of polyphenol-enriched fraction of Vaccinium
   uliginosum L. Against blue light-induced cell death of human retinal
   pigmented epithelial cells
SO JOURNAL OF FUNCTIONAL FOODS
LA English
DT Article
DE Vaccinium uliginosum L.; A2E; Blue light; Age-related macular
   degeneration; ARPE-19
ID MACULAR DEGENERATION; INDUCED DAMAGE; A2E; LIPOFUSCIN; EXPRESSION;
   FLUORESCENCE; ACTIVATION; ZEAXANTHIN; APOPTOSIS; EXTRACT
AB Accumulation of N-retinylidene-N-retinylethanolamine (A2E) in retinal pigment epithelial cells is implicated in the pathogenesis of age-related macular degeneration (AMD). A recent study has demonstrated that the polyphenol-enriched fraction of Vaccinium uliginosum L. (FH) reduces retinal damage induced by blue light in a mouse model. However, the underlying mechanism of its protective effect remains unclear. Here, we revealed that blue light irradiation of A2E-laden ARPE-19 cells can alter the transcription of genes belonging to TNF alpha signaling, UV response, complement, p53, and apoptosis pathways. FH treatment of ARPE-19 cells inhibited blue light-induced transcriptional activity of NF-kB and AP1 and activation of C3 complement. Additionally, FH protected ARPE-19 cells from blue light-induced apoptosis. Finally, we showed that FH inhibits the intracellular accumulation of A2E and induces the removal of A2E from retinal pigment cells. Taken together, our study revealed the protective mechanisms of FH against blue light-induced damage of A2E-laden RPE cells. (C) 2017 Elsevier Ltd. All rights reserved.
C1 [Jin, Hong Lan; Jeong, Kwang Won] Gachon Univ, Coll Pharm, Gachon Inst Pharmaceut Sci, 191 Hambakmoero, Incheon 21936, South Korea.
   [Choung, Se-Young] Kyung Hee Univ, Coll Pharm, Dept Life & Nanopharmaceut Sci Pharm, Dept Prevent Pharm & Toxicol, Seoul 130701, South Korea.
C3 Gachon University; Kyung Hee University
RP Jeong, KW (通讯作者)，Gachon Univ, Coll Pharm, Gachon Inst Pharmaceut Sci, 191 Hambakmoero, Incheon 21936, South Korea.; Choung, SY (通讯作者)，Kyung Hee Univ, Coll Pharm, Dept Life & Nanopharmaceut Sci Pharm, Dept Prevent Pharm & Toxicol, Seoul 130701, South Korea.
EM sychoung@khu.ac.kr; kwjeong@gachon.ac.kr
RI Choung, Young/AAH-9208-2020
FU technology Innovation Industrial Program - Ministry of Trade, Industry
   and Energy (MOTIE, Korea) [10048028]; Korea Evaluation Institute of
   Industrial Technology (KEIT)
FX This work was supported by the technology Innovation Industrial Program
   (10048028) funded by the Ministry of Trade, Industry and Energy (MOTIE,
   Korea) & Korea Evaluation Institute of Industrial Technology (KEIT).
CR Ablonczy Z, 2013, INVEST OPHTH VIS SCI, V54, P5535, DOI 10.1167/iovs.13-12250
   Ablonczy Z, 2011, INVEST OPHTH VIS SCI, V52, P8614, DOI 10.1167/iovs.11-8021
   Alge CS, 2006, J PROTEOME RES, V5, P862, DOI 10.1021/pr050420t
   Algvere PV, 2002, ACTA OPHTHALMOL SCAN, V80, P136, DOI 10.1034/j.1600-0420.2002.800204.x
   Boulton ME, 2014, EXP EYE RES, V126, P61, DOI 10.1016/j.exer.2014.01.016
   Brauns SC, 2005, ANTICANCER RES, V25, P4197
   Cai H, 2006, MOL VIS, V12, P1
   Chaitanya GV, 2010, CELL COMMUN SIGNAL, V8, DOI 10.1186/1478-811X-8-31
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   DAVIS AA, 1995, INVEST OPHTH VIS SCI, V36, P955
   Dinasarapu A. R., 2012, UCSD MOL, V1
   Dunn KC, 1996, EXP EYE RES, V62, P155, DOI 10.1006/exer.1996.0020
   Dwyer MA, 2011, MOL ENDOCRINOL, V25, P360, DOI 10.1210/me.2010-0392
   Gehrs KM, 2006, ANN MED, V38, P450, DOI 10.1080/07853890600946724
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Jin HL, 2016, J PHARMACEUT BIOMED, V117, P560, DOI 10.1016/j.jpba.2015.10.010
   Kennedy CJ, 1995, EYE, V9, P763, DOI 10.1038/eye.1995.192
   Kim YH, 2009, J MED FOOD, V12, P885, DOI 10.1089/jmf.2008.1127
   Kinnunen K, 2012, ACTA OPHTHALMOL, V90, P299, DOI 10.1111/j.1755-3768.2011.02179.x
   Kuznetsova AV, 2014, J OPHTHALMOL, V2014, DOI 10.1155/2014/801787
   Lee BL, 2016, NUTR RES, V36, P1402, DOI 10.1016/j.nutres.2016.11.008
   Newman AM, 2012, GENOME MED, V4, DOI [10.1186/PREACCEPT-1418491035586234, 10.1186/gm315]
   Nociari MM, 2014, P NATL ACAD SCI USA, V111, pE1402, DOI 10.1073/pnas.1400530111
   Pallitto P, 2015, PHOTOCH PHOTOBIO SCI, V14, P1888, DOI 10.1039/c5pp00170f
   Parish CA, 1998, P NATL ACAD SCI USA, V95, P14609, DOI 10.1073/pnas.95.25.14609
   Ramkumar HL, 2013, J NUTR, V143, P1129, DOI 10.3945/jn.112.169649
   Rickman CB, 2013, INVEST OPHTH VIS SCI, V54, pORSF68, DOI 10.1167/iovs.13-12757
   Rozanowski B, 2008, INVEST OPHTH VIS SCI, V49, P2838, DOI 10.1167/iovs.08-1700
   Shaban H, 2002, EXP EYE RES, V75, P99, DOI 10.1006/exer.2001.1192
   Sparrow JR, 2008, ADV EXP MED BIOL, V613, P393, DOI 10.1007/978-0-387-74904-4_46
   Sparrow JR, 2003, VISION RES, V43, P2983, DOI 10.1016/S0042-6989(03)00475-9
   Sparrow JR, 2003, J BIOL CHEM, V278, P18207, DOI 10.1074/jbc.M300457200
   Sparrow JR, 2002, INVEST OPHTH VIS SCI, V43, P1222
   Suter M, 2000, J BIOL CHEM, V275, P39625, DOI 10.1074/jbc.M007049200
   Thao MT, 2014, PHOTOCHEM PHOTOBIOL, V90, P329, DOI 10.1111/php.12200
   Thapliyal A., 2014, INT J CELL BIOL, V2014
   van der Burght Barbro W, 2013, Acta Ophthalmol, V91, pe537, DOI 10.1111/aos.12146
   Wang Y, 2015, J SCI FOOD AGR, V95, P936, DOI 10.1002/jsfa.6765
   Yin L, 2012, CHIN J INTEGR MED, V18, P299, DOI 10.1007/s11655-011-0901-1
   Yoon SM, 2016, ARCH PHARM RES, V39, P21, DOI 10.1007/s12272-015-0683-7
   Zhou JL, 2006, P NATL ACAD SCI USA, V103, P16182, DOI 10.1073/pnas.0604255103
   Zhu C, 2017, BIOMED PHARMACOTHER, V88, P124, DOI 10.1016/j.biopha.2016.11.089
NR 42
TC 13
Z9 13
U1 2
U2 16
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1756-4646
EI 2214-9414
J9 J FUNCT FOODS
JI J. Funct. Food.
PD DEC
PY 2017
VL 39
BP 28
EP 36
DI 10.1016/j.jff.2017.10.009
PG 9
WC Food Science & Technology; Nutrition & Dietetics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Food Science & Technology; Nutrition & Dietetics
GA FQ2RW
UT WOS:000418206000004
DA 2022-11-30
ER

PT J
AU Jia, YL
   Bailey, ST
   Hwang, TS
   McClintic, SM
   Gao, SS
   Pennesi, ME
   Flaxel, CJ
   Lauer, AK
   Wilson, DJ
   Hornegger, J
   Fujimoto, JG
   Huang, D
AF Jia, Yali
   Bailey, Steven T.
   Hwang, Thomas S.
   McClintic, Scott M.
   Gao, Simon S.
   Pennesi, Mark E.
   Flaxel, Christina J.
   Lauer, Andreas K.
   Wilson, David J.
   Hornegger, Joachim
   Fujimoto, James G.
   Huang, David
TI Quantitative optical coherence tomography angiography of vascular
   abnormalities in the living human eye
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
DE optical coherence tomography angiography; ophthalmic imaging; ocular
   circulation
ID SOURCE OCT ANGIOGRAPHY; MACULAR DEGENERATION; VELOCITY;
   MICROVASCULATURE; CHORIOCAPILLARIS; VISUALIZATION; RETINA; FLOW
AB Retinal vascular diseases are important causes of vision loss. A detailed evaluation of the vascular abnormalities facilitates diagnosis and treatment in these diseases. Optical coherence tomography (OCT) angiography using the highly efficient split-spectrum amplitude decorrelation angiography algorithm offers an alternative to conventional dye-based retinal angiography. OCT angiography has several advantages, including 3D visualization of retinal and choroidal circulations (including the choriocapillaris) and avoidance of dye injection-related complications. Results from six illustrative cases are reported. In diabetic retinopathy, OCT angiography can detect neovascularization and quantify ischemia. In age-related macular degeneration, choroidal neovascularization can be observed without the obscuration of details caused by dye leakage in conventional angiography. Choriocapillaris dysfunction can be detected in the nonneovascular form of the disease, furthering our understanding of pathogenesis. In choroideremia, OCT's ability to show choroidal and retinal vascular dysfunction separately may be valuable in predicting progression and assessing treatment response. OCT angiography shows promise as a noninvasive alternative to dye-based angiography for highly detailed, in vivo, 3D, quantitative evaluation of retinal vascular abnormalities.
C1 [Jia, Yali; Bailey, Steven T.; Hwang, Thomas S.; McClintic, Scott M.; Gao, Simon S.; Pennesi, Mark E.; Flaxel, Christina J.; Lauer, Andreas K.; Wilson, David J.; Huang, David] Oregon Hlth & Sci Univ, Casey Eye Inst, Portland, OR 97239 USA.
   [Hornegger, Joachim] Univ Erlangen Nurnberg, Pattern Recognit Lab, D-91058 Erlangen, Germany.
   [Hornegger, Joachim] Univ Erlangen Nurnberg, Sch Adv Opt Technol, D-91058 Erlangen, Germany.
   [Fujimoto, James G.] MIT, Dept Elect Engn & Comp Sci, Cambridge, MA 02139 USA.
   [Fujimoto, James G.] MIT, Elect Res Lab, Cambridge, MA 02139 USA.
C3 Oregon Health & Science University; University of Erlangen Nuremberg;
   University of Erlangen Nuremberg; Massachusetts Institute of Technology
   (MIT); Massachusetts Institute of Technology (MIT)
RP Huang, D (通讯作者)，Oregon Hlth & Sci Univ, Casey Eye Inst, Portland, OR 97239 USA.
EM huangd@ohsu.edu
RI Hwang, Thomas S./AAW-6618-2020; Hwang, Thomas/AAV-5146-2020; Hornegger,
   Joachim/H-2465-2017
OI Hwang, Thomas S./0000-0002-0535-4823; Hornegger,
   Joachim/0000-0002-1834-8844; Gao, Simon/0000-0002-7020-037X
FU National Institutes of Health [R01-EY023285, R01-EY024544, DP3 DK104397,
   R01-EY11289, K08-EY021186, T32-EY23211, P30-EY010572]; Clinical and
   Translational Science Award Grant [UL1TR000128]; Research to Prevent
   Blindness [CD-NMT-0914-0659-OHSU]; AFOSR from Foundation Fighting
   Blindness [FA9550-10-1-0551]; German Research Foundation
   [DFG-HO-1791/11-1, DFG-GSC80-SAOT]; NATIONAL CENTER FOR ADVANCING
   TRANSLATIONAL SCIENCES [UL1TR000128] Funding Source: NIH RePORTER;
   NATIONAL EYE INSTITUTE [K08EY021186, R01EY024544, P30EY010572,
   T32EY023211, R01EY023285, R01EY011289] Funding Source: NIH RePORTER;
   NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES
   [DP3DK104397] Funding Source: NIH RePORTER
FX This work was supported by National Institutes of Health Grants
   R01-EY023285, R01-EY024544, DP3 DK104397, R01-EY11289, K08-EY021186,
   T32-EY23211, and P30-EY010572; Clinical and Translational Science Award
   Grant UL1TR000128; unrestricted Grant and Career Development Award
   CD-NMT-0914-0659-OHSU from Research to Prevent Blindness; enhanced
   Career Development Award AFOSR FA9550-10-1-0551 from Foundation Fighting
   Blindness; and German Research Foundation Grants DFG-HO-1791/11-1 and
   DFG-GSC80-SAOT.
CR Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   [Anonymous], 1991, OPHTHALMOLOGY, V98, P807
   [Anonymous], 1981, OPHTHALMOLOGY, V88, P583
   [Anonymous], 2007, AM NATL STANDARD SAF
   Antonetti DA, 2012, NEW ENGL J MED, V366, P1227, DOI 10.1056/NEJMra1005073
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Blatter C, 2012, J BIOMED OPT, V17, DOI 10.1117/1.JBO.17.7.070505
   Braaf B, 2012, OPT EXPRESS, V20, P20516, DOI 10.1364/OE.20.020516
   Choi W, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081499
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Coussa RG, 2012, OPHTHALMIC GENET, V33, P57, DOI 10.3109/13816810.2011.620056
   Drexler W, 2008, PROG RETIN EYE RES, V27, P45, DOI 10.1016/j.preteyeres.2007.07.005
   Enfield J, 2011, BIOMED OPT EXPRESS, V2, P1184, DOI 10.1364/BOE.2.001184
   Fingler J, 2009, OPT EXPRESS, V17, P22190, DOI 10.1364/OE.17.022190
   Frank RN, 2004, NEW ENGL J MED, V350, P48, DOI 10.1056/NEJMra021678
   Gass J, 1997, STEREOSCOPIC ATLAS M, P24
   Grulkowski I, 2009, OPT EXPRESS, V17, P23736, DOI 10.1364/OE.17.023736
   Grunwald JE, 2005, INVEST OPHTH VIS SCI, V46, P1033, DOI 10.1167/iovs.04-1050
   Hee MR, 1996, OPHTHALMOLOGY, V103, P1260, DOI 10.1016/S0161-6420(96)30512-5
   Hendargo HC, 2011, BIOMED OPT EXPRESS, V2, P2175, DOI 10.1364/BOE.2.002175
   Jia YL, 2014, OPHTHALMOLOGY, V121, P1435, DOI 10.1016/j.ophtha.2014.01.034
   Jia YL, 2014, OPHTHALMOLOGY, V121, P1322, DOI 10.1016/j.ophtha.2014.01.021
   Jia YL, 2012, OPT EXPRESS, V20, P4710, DOI 10.1364/OE.20.004710
   Kim DY, 2013, P NATL ACAD SCI USA, V110, P14354, DOI 10.1073/pnas.1307315110
   Kraus MF, 2012, BIOMED OPT EXPRESS, V3, P1182, DOI 10.1364/BOE.3.001182
   Liu GJ, 2012, BIOMED OPT EXPRESS, V3, P2669, DOI 10.1364/BOE.3.002669
   Lopez-Saez MP, 1998, ANN ALLERG ASTHMA IM, V81, P428, DOI 10.1016/S1081-1206(10)63140-7
   MacLaren RE, 2014, LANCET, V383, P1129, DOI 10.1016/S0140-6736(13)62117-0
   Makita S, 2011, OPT EXPRESS, V19, P1271, DOI 10.1364/OE.19.001271
   Mariampillai A, 2008, OPT LETT, V33, P1530, DOI 10.1364/OL.33.001530
   McLeod DS, 2009, INVEST OPHTH VIS SCI, V50, P4982, DOI 10.1167/iovs.09-3639
   Miura M, 2011, INVEST OPHTH VIS SCI, V52, P2689, DOI 10.1167/iovs.10-6282
   Motaghiannezam R, 2012, BIOMED OPT EXPRESS, V3, P503, DOI 10.1364/BOE.3.000503
   Moult E, 2014, OSLI RETINA, V45, P496, DOI 10.3928/23258160-20141118-03
   Mrejen S, 2013, SURV OPHTHALMOL, V58, P387, DOI 10.1016/j.survophthal.2012.12.001
   Mullins RE, 2011, INVEST OPHTH VIS SCI, V52, P1606, DOI 10.1167/iovs.10-6476
   RIVA CE, 1980, J OPT SOC AM, V70, P1234, DOI 10.1364/JOSA.70.001234
   Schwartz DM, 2014, OPHTHALMOLOGY, V121, P180, DOI 10.1016/j.ophtha.2013.09.002
   Spaide RF, 2015, JAMA OPHTHALMOL, V133, P66, DOI 10.1001/jamaophthalmol.2014.3950
   Tam J, 2011, BIOMED OPT EXPRESS, V2, P781, DOI 10.1364/BOE.2.000781
   Thorell MR, 2014, OSLI RETINA, V45, P369, DOI 10.3928/23258160-20140909-06
   Wang RK, 2007, OPT EXPRESS, V15, P4083, DOI 10.1364/OE.15.004083
   Ying GS, 2013, OPHTHALMOLOGY, V120, P122, DOI 10.1016/j.ophtha.2012.07.042
   Yu LF, 2010, J BIOMED OPT, V15, DOI 10.1117/1.3302806
   Zotter S, 2011, OPT EXPRESS, V19, P1217, DOI 10.1364/OE.19.001217
NR 45
TC 464
Z9 491
U1 3
U2 80
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD MAY 5
PY 2015
VL 112
IS 18
BP E2395
EP E2402
DI 10.1073/pnas.1500185112
PG 8
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA CH3TS
UT WOS:000353953800019
PM 25897021
OA Green Published, hybrid
HC Y
HP N
DA 2022-11-30
ER

PT J
AU Ahn, JH
   Lee, SM
   Hong, SJ
   Yoo, HJ
   Jung, SW
   Park, SK
   Ko, HH
   Cho, DI
AF Ahn, Jae-Hyun
   Lee, Sang-Min
   Hong, Seok-June
   Yoo, Hyung-Jung
   Jung, Suk-Won
   Park, Sun-Kil
   Ko, Hyoung-Ho
   Cho, Dong-il ''Dan''
TI Multi-Channel Stimulator IC Using a Channel Sharing Method for Retinal
   Prostheses
SO JOURNAL OF BIOMEDICAL NANOTECHNOLOGY
LA English
DT Article
DE Retinal Prostheses; Channel Sharing Technique; Current Stimulator;
   Simultaneous Stimulation; Integrated Circuit
ID PIXELIZED VISION SYSTEM; MACULAR DEGENERATION; RETINITIS-PIGMENTOSA;
   PERFORMANCE
AB A retinal stimulator is an implantable device restoring vision by supplying a controlled, stimulating electrical signal to people blinded by retinal diseases such as age-related macular degeneration (AMD) and retinitis pigmentosa (RP). The resolution requirements of artificial retina systems become increasingly significant in their design as well as their usefulness. At least 32 x 32 pixels are required to provide a minimal visual function. However, a retinal stimulator with a high resolution imposes severe constraints on interface electronics. In this paper, a new stimulator IC (integrated chip) using a channel sharing technique is developed to minimize the circuit size, power consumption, as well as overheating of retina tissues. The proposed current-mode stimulator is fabricated by a 0.35 mu m 2-poly/4-metal BCDMOS technology. Attention is given to minimizing the silicon area so that higher channel numbers can be implemented. The stimulator for each channel can provide output current in the range of 0-350 mu A. The effective chip area excluding the pads is 1.2 mm x 1.2 mm.
C1 [Ahn, Jae-Hyun; Lee, Sang-Min; Hong, Seok-June; Yoo, Hyung-Jung; Jung, Suk-Won; Park, Sun-Kil; Cho, Dong-il ''Dan''] Seoul Natl Univ, Sch Elect Engn & Comp Sci, ASRI ISRC, Seoul 151742, South Korea.
   [Ko, Hyoung-Ho] Chungnam Natl Univ, Dept Elect Engn, Taejon 305764, South Korea.
C3 Seoul National University (SNU); Chungnam National University
RP Cho, DI (通讯作者)，Seoul Natl Univ, Sch Elect Engn & Comp Sci, ASRI ISRC, Seoul 151742, South Korea.
EM dicho@snu.ac.kr
OI Cho, Dong-il/0000-0002-8040-5803; Ko, Hyoungho/0000-0001-5348-3585
FU National Research Foundation of Korea (NRF); Ministry of Education,
   Science and Technology [2010-0020852]; IC Design Education Center (IDEC)
FX This research was supported by the Happy tech. program through the
   National Research Foundation of Korea (NRF) funded by the Ministry of
   Education, Science and Technology (2010-0020852). This work was also
   supported by IC Design Education Center (IDEC).
CR BERSON EL, 1993, INVEST OPHTH VIS SCI, V34, P1659
   CHA K, 1992, VISION RES, V32, P1367, DOI 10.1016/0042-6989(92)90229-C
   CHA K, 1992, J OPT SOC AM A, V9, P673, DOI 10.1364/JOSAA.9.000673
   CHA KH, 1992, ANN BIOMED ENG, V20, P439, DOI 10.1007/BF02368135
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Hayes JS, 2003, ARTIF ORGANS, V27, P1016, DOI 10.1046/j.1525-1594.2003.07309.x
   Humayun MS, 1999, INVEST OPHTH VIS SCI, V40, P143
   Liu W., 2001, ARVO P FLOR
   Liu WT, 2004, ISSCC DIG TECH PAP I, V47, P218, DOI 10.1109/ISSCC.2004.1332672
   Medeiros NE, 2001, INVEST OPHTH VIS SCI, V42, P795
   Shah S, 2007, J NEURAL ENG, V4, pS24, DOI 10.1088/1741-2560/4/1/S04
NR 11
TC 9
Z9 9
U1 0
U2 11
PU AMER SCIENTIFIC PUBLISHERS
PI VALENCIA
PA 26650 THE OLD RD, STE 208, VALENCIA, CA 91381-0751 USA
SN 1550-7033
J9 J BIOMED NANOTECHNOL
JI J. Biomed. Nanotechnol.
PD APR
PY 2013
VL 9
IS 4
BP 621
EP 625
DI 10.1166/jbn.2013.1524
PG 5
WC Nanoscience & Nanotechnology; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics; Materials Science
GA 211NS
UT WOS:000323915600010
PM 23621021
DA 2022-11-30
ER

PT J
AU Dimitrova, G
   Kato, S
AF Dimitrova, Galina
   Kato, Satoshi
TI Color Doppler Imaging of Retinal Diseases
SO SURVEY OF OPHTHALMOLOGY
LA English
DT Review
DE age-related macular degeneration; blood flow; color Doppler imaging;
   diabetic retinopathy; myopia; retina; retinal artery occlusion; retinal
   detachment; retinal vein occlusion; retinitis pigmentosa
ID OCULAR BLOOD-FLOW; PROLIFERATIVE DIABETIC-RETINOPATHY; RETROBULBAR
   CIRCULATION; VEIN OCCLUSION; ORBITAL VESSELS; CHOROIDAL
   NEOVASCULARIZATION; ARTERY-OCCLUSION; FOLLOW-UP; VELOCITY; HEMODYNAMICS
AB Color Doppler imaging (CDI) is a widely used method for evaluating ocular circulation that has been used in a number of studies on retinal diseases. CDI assesses blood velocity parameters by using ultrasound waves. In ophthalmology, these assessments are mainly performed on the retrobulbar blood vessels: the ophthalmic, the central retinal, and the short posterior ciliary arteries. In this review, we discuss CDI use for the assessment of retinal diseases classified into the following: vascular diseases, degenerations, dystrophies, and detachment. The retinal vascular diseases that have been investigated by CDI include diabetic retinopathy, retinal vein occlusions, retinal artery occlusions, ocular ischemic conditions, and retinopathy of prematurity. Degenerations and dystrophies included in this review are age-related macular degeneration, myopia, and retinitis pigmentosa. CDI has been used for the differential diagnosis of retinal detachment, as well as the evaluation of retrobulbar circulation in this condition. CDI is valuable for research and is a potentially useful diagnostic tool in the clinical setting. (Surv Ophthalmol 55:193-214, 2010. (C) 2010 Elsevier Inc. All rights reserved.)
C1 [Dimitrova, Galina] Ctr Eye Dis OKO, Skopje, Macedonia.
   [Kato, Satoshi] Tokyo Univ Hosp, Dept Ophthalmol, Tokyo 113, Japan.
C3 University of Tokyo
RP Dimitrova, G (通讯作者)，Ctr Eye Dis OKO, Dame Gruev 5, Skopje, Macedonia.
EM galina@sonet.com.mk
RI Dimitrova, Galina/I-4820-2019
OI Dimitrova, Galina/0000-0003-3537-4363
CR AKYOL N, 1995, CAN J OPHTHALMOL, V30, P28
   Akyol N, 1996, CAN J OPHTHALMOL, V31, P113
   Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Arai T, 1998, J ULTRAS MED, V17, P675, DOI 10.7863/jum.1998.17.11.675
   Arsene S, 2002, BRIT J OPHTHALMOL, V86, P1243, DOI 10.1136/bjo.86.11.1243
   ASHTON N, 1974, BRIT J OPHTHALMOL, V58, P344, DOI 10.1136/bjo.58.4.344
   Avunduk AM, 1999, BRIT J OPHTHALMOL, V83, P50, DOI 10.1136/bjo.83.1.50
   BAXTER GM, 1993, RADIOLOGY, V187, P847, DOI 10.1148/radiology.187.3.8497643
   Baxter GM, 1996, CLIN RADIOL, V51, P411, DOI 10.1016/S0009-9260(96)80159-0
   Baydar S, 2007, AUSTRALAS RADIOL, V51, P230, DOI 10.1111/j.1440-1673.2007.01717.x
   Bek T, 1996, ACTA OPHTHALMOL SCAN, V74, P36
   Bek T., 2000, DIABETIC RETINOPATHY, P169
   BERGER J, 1999, AAP NEWS        0401, P17
   Berger R W, 1991, Fortschr Ophthalmol, V88, P690
   BERTRAM B, 1991, BRIT J OPHTHALMOL, V75, P462, DOI 10.1136/bjo.75.8.462
   BISCHOFF PM, 1983, AM J OPHTHALMOL, V96, P398, DOI 10.1016/S0002-9394(14)77839-0
   BRESSLER SB, 2000, ALBERT JAKOBIECS PRI, V6, P1992
   Cekic Osman, 2007, International Ophthalmology, V27, P313, DOI 10.1007/s10792-007-9080-7
   Cellini M, 1997, J FR OPHTALMOL, V20, P659
   Chao AC, 2007, STROKE, V38, P1377, DOI 10.1161/01.STR.0000260188.51784.6e
   Chung Tze-Wen, 1994, Proceedings of the National Science Council Republic of China Part B Life Sciences, V18, P30
   Ciulla TA, 1999, AM J OPHTHALMOL, V128, P75, DOI 10.1016/S0002-9394(99)00061-6
   Ciulla TA, 2001, INVEST OPHTH VIS SCI, V42, P3337
   COHEN HL, 1993, J ULTRAS MED, V12, P411
   Cuypers MHM, 2000, GRAEF ARCH CLIN EXP, V238, P935, DOI 10.1007/s004170000207
   Dimitrova G, 2003, BRIT J OPHTHALMOL, V87, P622, DOI 10.1136/bjo.87.5.622
   Dimitrova G, 2002, EYE, V16, P580, DOI 10.1038/sj.eye.6700161
   Dimitrova G, 2002, BRIT J OPHTHALMOL, V86, P771, DOI 10.1136/bjo.86.7.771
   Dimitrova G, 2001, EYE, V15, P602, DOI 10.1038/eye.2001.193
   Dimitrova G, 2009, GRAEF ARCH CLIN EXP, V247, P53, DOI 10.1007/s00417-008-0925-1
   DOWLER J, 2000, DIABETIC RETINOPATHY, V1, P1
   Evans DW, 1999, BRIT J OPHTHALMOL, V83, P809, DOI 10.1136/bjo.83.7.809
   Evans DW, 1997, BRIT J OPHTHALMOL, V81, P279, DOI 10.1136/bjo.81.4.279
   FEKE GT, 1985, OPHTHALMOLOGY, V92, P1517
   Findl O, 2000, BRIT J OPHTHALMOL, V84, P493, DOI 10.1136/bjo.84.5.493
   Foroozan R, 2002, OPHTHALMOLOGY, V109, P744, DOI 10.1016/S0161-6420(01)01011-9
   FRIEDMAN E, 1995, OPHTHALMOLOGY, V102, P640, DOI 10.1016/S0161-6420(95)30974-8
   Fujioka S, 2004, JPN J OPHTHALMOL, V48, P59, DOI 10.1007/s10384-003-0005-3
   Fujioka S, 2006, JPN J OPHTHALMOL, V50, P312, DOI 10.1007/s10384-005-0338-1
   GARNER A, 1972, T OPHTHAL SOC UK, V7, P101
   Geyer O, 1999, ACTA OPHTHALMOL SCAN, V77, P522, DOI 10.1034/j.1600-0420.1999.770507.x
   GOEBEL W, 1995, INVEST OPHTH VIS SCI, V36, P864
   Gracner T, 2004, OPHTHALMOLOGICA, V218, P237, DOI 10.1159/000078613
   GREAVES M, 2000, DIABETIC RETINOPATHY, P201
   GRUNWALD JE, 1986, ARCH OPHTHALMOL-CHIC, V104, P991
   Guven D, 1996, OPHTHALMOLOGY, V103, P1245
   Han SS, 2001, KOREAN J RADIOL, V2, P197, DOI 10.3348/kjr.2001.2.4.197
   Hanutsaha P, 1998, OPHTHALMOLOGY, V105, P1632, DOI 10.1016/S0161-6420(98)99030-3
   Harris A, 2000, ARCH OPHTHALMOL-CHIC, V118, P1076, DOI 10.1001/archopht.118.8.1076
   HARRIS A, 2003, ATLAS OCULAR BLOOD F, P19
   Harris Alon, 2000, Harefuah, V138, P812
   HARUYAMA M, 2000, J JPN OPHTHALMOL SOC, V104, P805
   HIDAYAT AA, 1985, OPHTHALMOLOGY, V92, P512
   HO AC, 1992, OPHTHALMOLOGY, V99, P1453
   Holland DR, 1999, J AAPOS, V3, P194, DOI 10.1016/S1091-8531(99)70002-9
   HSUEH WA, 1992, HYPERTENSION, V20, P253, DOI 10.1161/01.HYP.20.2.253
   Ido M, 2007, EYE, V21, P1375, DOI 10.1038/sj.eye.6702442
   Ino-ue M, 2000, ACTA OPHTHALMOL SCAN, V78, P173, DOI 10.1034/j.1600-0420.2000.078002173.x
   Kaeser P, 2005, BRIT J OPHTHALMOL, V89, P1302, DOI 10.1136/bjo.2005.067884
   Kaiser HJ, 1997, BRIT J OPHTHALMOL, V81, P133, DOI 10.1136/bjo.81.2.133
   KAWAGISHI T, 1995, DIABETES CARE, V18, P1544, DOI 10.2337/diacare.18.12.1544
   Kawaguchi S, 2001, NEUROSURGERY, V48, P328, DOI 10.1097/00006123-200102000-00016
   Kawaguchi S, 2006, CEREBROVASC DIS, V22, P402, DOI 10.1159/000094859
   KEYSER BJ, 1994, OPHTHALMOLOGY, V101, P1357
   Kiseleva T N, 2006, Vestn Oftalmol, V122, P4
   KLEIN BEK, 1990, INVEST OPHTH VIS SCI, V31, P805
   KNAPP MEP, 1992, OPHTHALMOLOGY, V99, P238
   Krepler K, 2003, RETINA-J RET VIT DIS, V23, P192, DOI 10.1097/00006982-200304000-00009
   LANGHAM ME, 1991, EXP EYE RES, V52, P167, DOI 10.1016/0014-4835(91)90256-E
   LIEB WE, 1991, ARCH OPHTHALMOL-CHIC, V109, P527, DOI 10.1001/archopht.1991.01080040095036
   LIEB WE, 1991, OPHTHALMOLOGY, V98, P548
   LIEB WE, 1992, ACTA OPHTHALMOL, V70, P50
   LIPING S, 1997, CHIN OCULAR FUNDUS D, V13, P210
   MacKinnon JR, 1997, ACTA OPHTHALMOL SCAN, V75, P661
   MacKinnon JR, 2000, ACTA OPHTHALMOL SCAN, V78, P386, DOI 10.1034/j.1600-0420.2000.078004386.x
   Maguire MG, 1997, ARCH OPHTHALMOL-CHIC, V115, P741
   MENDIVIL A, 1995, BRIT J OPHTHALMOL, V79, P413, DOI 10.1136/bjo.79.5.413
   Mendivil A, 1997, SURV OPHTHALMOL, V42, pS89, DOI 10.1016/S0039-6257(97)80031-8
   Michelson G, 1997, OPHTHALMOLOGY, V104, P659, DOI 10.1016/S0161-6420(97)30255-3
   Michelson G, 1997, OPHTHALMOLOGY, V104, P664, DOI 10.1016/S0161-6420(97)30254-1
   Modrzejewska M, 2008, MED SCI MONITOR, V14, pM147
   Mori F, 2001, BRIT J OPHTHALMOL, V85, P531, DOI 10.1136/bjo.85.5.531
   MOSS SE, 1994, OPHTHALMOLOGY, V101, P77
   Nagahara M, 2002, AM J OPHTHALMOL, V133, P270, DOI 10.1016/S0002-9394(01)01312-5
   Niwa Y, 1998, JPN J OPHTHALMOL, V42, P389, DOI 10.1016/S0021-5155(98)00025-2
   Niwald Anna, 2006, Klin Oczna, V108, P32
   Nowak Izabela, 2005, Klin Oczna, V107, P63
   OGASAWARA H, 1992, BRIT J OPHTHALMOL, V76, P275, DOI 10.1136/bjo.76.5.275
   Ovali GY, 2008, DIABETES RES CLIN PR, V79, P243, DOI 10.1016/j.diabres.2007.09.001
   Ozbek Z, 2002, OPHTHALMOLOGICA, V216, P231, DOI 10.1159/000063851
   Ozkiris A, 2007, BRIT J OPHTHALMOL, V91, P69, DOI 10.1136/bjo.2006.098285
   Paivansalo M, 2004, ACTA RADIOL, V45, P404, DOI 10.1080/02841850410005246
   PATEL V, 1992, BMJ-BRIT MED J, V305, P678, DOI 10.1136/bmj.305.6855.678
   PAULEIKHOFF D, 1990, AM J OPHTHALMOL, V109, P211, DOI 10.1016/S0002-9394(14)75989-6
   Pichot O, 1996, J FR OPHTALMOL, V19, P19
   Rankin SJA, 1999, SURV OPHTHALMOL, V43, pS176, DOI 10.1016/S0039-6257(99)00043-0
   Rechtman E, 2007, OPHTHAL SURG LAS IM, V38, P219, DOI 10.3928/15428877-20070501-06
   REGILLO CD, 1993, OPHTHALMOLOGY, V100, P1044
   REMULLA JFC, 1995, BRIT J OPHTHALMOL, V79, P558, DOI 10.1136/bjo.79.6.558
   RIMMER T, 1989, BRIT J OPHTHALMOL, V73, P1, DOI 10.1136/bjo.73.1.1
   Roldan Pallares M, 2001, Arch Soc Esp Oftalmol, V76, P351
   Roldan-Pallares M, 2008, RETINA-J RET VIT DIS, V28, P111, DOI 10.1097/IAE.0b013e31809ffad0
   Ross RD, 1998, AM J OPHTHALMOL, V125, P71, DOI 10.1016/S0002-9394(99)80237-2
   SANTOS L, 1994, GRAEF ARCH CLIN EXP, V232, P666, DOI 10.1007/BF00171381
   Schmetterer L, 1997, GRAEF ARCH CLIN EXP, V235, P283, DOI 10.1007/BF01739637
   Schmidt KG, 2000, BRIT J OPHTHALMOL, V84, P1282, DOI 10.1136/bjo.84.11.1282
   Senn BC, 1997, GER J OPHTHALMOL, V5, P386
   Sergott R C, 1992, Trans Am Ophthalmol Soc, V90, P383
   Stearne MR, 1998, BMJ-BRIT MED J, V317, P703
   Steigerwalt RD, 1998, RETINA-J RET VIT DIS, V18, P539
   Suzuki A, 2000, JPN J OPHTHALMOL, V44, P685, DOI 10.1016/S0021-5155(00)00271-9
   TAMAKI Y, 1993, JPN J OPHTHALMOL, V37, P385
   Taner Pelin, 2004, International Ophthalmology, V25, P95, DOI 10.1023/B:INTE.0000031743.67336.b5
   Tranquart F, 2003, J CLIN ULTRASOUND, V31, P258, DOI 10.1002/jcu.10169
   Tranquart F, 1998, J CLIN ULTRASOUND, V26, P119, DOI 10.1002/(SICI)1097-0096(199803/04)26:3<119::AID-JCU2>3.0.CO;2-P
   Tranquart F, 2000, J CLIN ULTRASOUND, V28, P28, DOI 10.1002/(SICI)1097-0096(200001)28:1<28::AID-JCU4>3.0.CO;2-5
   Turkcuoglu P, 2008, CLIN EXP OPHTHALMOL, V36, P39, DOI 10.1111/j.1442-9071.2007.01644.x
   Urban Beata, 2004, Klin Oczna, V106, P318
   Uretmen O, 2003, OPHTHALMOLOGICA, V217, P137, DOI 10.1159/000068559
   Vecsei PV, 1996, ANN HEMATOL, V73, P29, DOI 10.1007/s002770050195
   Vecsei PV, 1999, ACTA OPHTHALMOL SCAN, V77, P19, DOI 10.1034/j.1600-0420.1999.770104.x
   WILLIAMSON TH, 1995, GRAEF ARCH CLIN EXP, V233, P80, DOI 10.1007/BF00241476
   WILLIAMSON TH, 1994, OPHTHALMOLOGY, V101, P1362
   Williamson TH, 1996, SURV OPHTHALMOL, V40, P255, DOI 10.1016/S0039-6257(96)82001-7
   WILLIAMSON TH, 1993, OPHTHALMOLOGY, V100, P312
   Williamson TH, 2007, BRIT J OPHTHALMOL, V91, P1190, DOI 10.1136/bjo.2006.102798
   WOLF S, 1991, OPHTHALMOLOGY, V98, P996
   WOLF S, 1994, HYPERTENSION, V23, P464, DOI 10.1161/01.HYP.23.4.464
   WONG AD, 1991, RADIOLOGY, V178, P429, DOI 10.1148/radiology.178.2.1987604
   YANOFF M, 1969, AM J OPHTHALMOL, V67, P21, DOI 10.1016/0002-9394(69)90004-X
   YOH M, 2000, ATARASHII GANKA, V17, P1433
NR 131
TC 56
Z9 61
U1 0
U2 15
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0039-6257
EI 1879-3304
J9 SURV OPHTHALMOL
JI Surv. Ophthalmol.
PD MAY-JUN
PY 2010
VL 55
IS 3
BP 193
EP 214
DI 10.1016/j.survophthal.2009.06.010
PG 22
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 592HR
UT WOS:000277369700001
PM 20385332
DA 2022-11-30
ER

PT J
AU Guma, M
   Rius, J
   Duong-Polk, KX
   Haddad, GG
   Lindsey, JD
   Karin, M
AF Guma, Monica
   Rius, Jordi
   Duong-Polk, Karen X.
   Haddad, Gabriel G.
   Lindsey, James D.
   Karin, Michael
TI Genetic and pharmacological inhibition of JNK ameliorates
   hypoxia-induced retinopathy through interference with VEGF expression
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
DE neoangiogenesis; retinopathy of prematurity
ID ENDOTHELIAL GROWTH-FACTOR; OXYGEN-INDUCED RETINOPATHY; C-JUN;
   INTRAVITREAL INJECTION; CHOROIDAL NEOVASCULARIZATION; RETINAL
   NEOVASCULARIZATION; TRANSCRIPTIONAL REGULATION; VASCULAR-PERMEABILITY;
   INDUCIBLE FACTOR-1; RESPONSE ELEMENT
AB Many ocular pathologies, including retinopathy of prematurity (ROP), diabetic retinopathy, and age-related macular degeneration, result in vision loss because of aberrant neoangiogenesis. A common feature of these conditions is the presence of hypoxic areas and overexpression of the proangiogenic vascular endothelial growth factor (VEGF). The prevailing current treatment, laser ablation of the retina, is destructive and only partially effective. Preventive and less destructive therapies are much more desirable. Here, we show that mice lacking c-Jun N-terminal kinase 1 (JNK1) exhibit reduced pathological angiogenesis and lower levels of retinal VEGF production in a murine model of ROP. We found that hypoxia induces JNK activation and regulates VEGF expression by enhancing the binding of phospho-c-Jun to the VEGF promoter. Intravitreal injection of a specific JNK inhibitor decreases retinal VEGF expression and reduces pathological retinal neovascularization without obvious side effects. These results strongly suggest that JNK1 plays a key role in retinal neoangiogenesis and that it represents a new pharmacological target for treatment of diseases where excessive neoangiogenesis is the underlying pathology.
C1 [Guma, Monica; Rius, Jordi; Karin, Michael] Univ Calif San Diego, Lab Gene Regulat & Signal Transduct, La Jolla, CA 92093 USA.
   [Guma, Monica; Rius, Jordi; Karin, Michael] Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA.
   [Guma, Monica; Rius, Jordi; Karin, Michael] Univ Calif San Diego, Dept Pathol, La Jolla, CA 92093 USA.
   [Haddad, Gabriel G.] Univ Calif San Diego, Dept Pediat, Sch Med, La Jolla, CA 92093 USA.
   [Duong-Polk, Karen X.; Lindsey, James D.] Univ Calif San Diego, Hamilton Glaucoma Ctr, La Jolla, CA 92093 USA.
C3 University of California System; University of California San Diego;
   University of California System; University of California San Diego;
   University of California System; University of California San Diego;
   University of California System; University of California San Diego;
   University of California System; University of California San Diego
RP Karin, M (通讯作者)，Univ Calif San Diego, Lab Gene Regulat & Signal Transduct, 9500 Gilman Dr, La Jolla, CA 92093 USA.
EM mkarin@ucsd.edu
OI guma, monica/0000-0003-1951-9411
FU National Institutes of Health; Spanish Ministry of Education and
   Science; Spanish Society of Rheumatology; NATIONAL INSTITUTE OF
   ENVIRONMENTAL HEALTH SCIENCES [R01ES006376] Funding Source: NIH RePORTER
FX We thank Dr. Samuel J. Leibovich for providing VEGF promoter-luciferase
   reporters, Dr. Jonathan H. Lin for examination of tissue histology, and
   Dr. Randall S. Johnson for the use of his hypoxia chamber. This work was
   supported by National Institutes of Health grants (to M. K., J. D. L.,
   and G. G. H. laboratories). M. K. is an American Cancer Society Research
   Professor. J. R. and M. G. were supported by postdoctoral fellowships
   from the Spanish Ministry of Education and Science. M. G. was also
   supported by the Spanish Society of Rheumatology.
CR ALON T, 1995, NAT MED, V1, P1024, DOI 10.1038/nm1095-1024
   Andreoli CM, 2007, CURR OPIN OPHTHALMOL, V18, P502, DOI 10.1097/ICU.0b013e3282f0ca54
   Banin E, 2006, INVEST OPHTH VIS SCI, V47, P2125, DOI 10.1167/iovs.05-1096
   Behrens A, 1999, NAT GENET, V21, P326, DOI 10.1038/6854
   Borsello T, 2003, NAT MED, V9, P1180, DOI 10.1038/nm911
   Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0
   Chandel NS, 1998, P NATL ACAD SCI USA, V95, P11715, DOI 10.1073/pnas.95.20.11715
   Chen Jing, 2007, Angiogenesis, V10, P133, DOI 10.1007/s10456-007-9066-0
   Dafer Rima M, 2007, Semin Ophthalmol, V22, P201, DOI 10.1080/08820530701543024
   Dorrell M, 2007, SURV OPHTHALMOL, V52, pS3, DOI 10.1016/j.survophthal.2006.10.017
   Ema M, 1997, P NATL ACAD SCI USA, V94, P4273, DOI 10.1073/pnas.94.9.4273
   Ferrandi C, 2004, BRIT J PHARMACOL, V142, P953, DOI 10.1038/sj.bjp.0705873
   Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0
   Ferrara N, 2005, NATURE, V438, P967, DOI 10.1038/nature04483
   Fleck BW, 2008, EARLY HUM DEV, V84, P83, DOI 10.1016/j.earlhumdev.2007.11.008
   Forsythe JA, 1996, MOL CELL BIOL, V16, P4604
   Gardiner TA, 2005, AM J PATHOL, V166, P637, DOI 10.1016/S0002-9440(10)62284-5
   Hreniuk D, 2001, MOL PHARMACOL, V59, P867, DOI 10.1124/mol.59.4.867
   Hui LJ, 2008, J CLIN INVEST, V118, P3943, DOI 10.1172/JCI37156
   Inan UU, 2007, INVEST OPHTH VIS SCI, V48, P1773, DOI 10.1167/iovs.06-0828
   Ishibashi T, 1997, GRAEF ARCH CLIN EXP, V235, P159, DOI 10.1007/BF00941723
   Jiang J, 2009, J CELL PHYSIOL, V218, P66, DOI 10.1002/jcp.21566
   Kaelin WG, 2008, MOL CELL, V30, P393, DOI 10.1016/j.molcel.2008.04.009
   Kallunki T, 1996, CELL, V87, P929, DOI 10.1016/S0092-8674(00)81999-6
   Kamata H, 2005, CELL, V120, P649, DOI 10.1016/j.cell.2004.12.041
   Kaneto H, 2004, NAT MED, V10, P1128, DOI 10.1038/nm1111
   Karin M, 2005, IUBMB LIFE, V57, P283, DOI 10.1080/15216540500097111
   Kim JH, 2008, NEUROTOXICOLOGY, V29, P1131, DOI 10.1016/j.neuro.2008.06.006
   Kusaka S, 2008, BRIT J OPHTHALMOL, V92, P1450, DOI 10.1136/bjo.2008.140657
   Lee YJ, 1999, MOL CELL BIOCHEM, V202, P1, DOI 10.1023/A:1007059806016
   Mason JO, 2006, AM J OPHTHALMOL, V142, P685, DOI 10.1016/j.ajo.2006.04.058
   Minet E, 2001, EXP CELL RES, V265, P114, DOI 10.1006/excr.2001.5180
   Naug HL, 2000, CLIN EXP OPHTHALMOL, V28, P48, DOI 10.1046/j.1442-9071.2000.00226.x
   Oosthuyse B, 2001, NAT GENET, V28, P131, DOI 10.1038/88842
   Pages G, 2000, J BIOL CHEM, V275, P26484, DOI 10.1074/jbc.M002104200
   Pages G, 2005, CARDIOVASC RES, V65, P564, DOI 10.1016/j.cardiores.2004.09.032
   PIERCE EA, 1995, P NATL ACAD SCI USA, V92, P905, DOI 10.1073/pnas.92.3.905
   Rius J, 2008, NATURE, V453, P807, DOI 10.1038/nature06905
   Schmidt D, 2007, EMBO J, V26, P710, DOI 10.1038/sj.emboj.7601539
   Shaulian E, 2002, NAT CELL BIOL, V4, pE131, DOI 10.1038/ncb0502-e131
   SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0
   SMITH LEH, 1994, INVEST OPHTH VIS SCI, V35, P101
   Stone J, 1996, INVEST OPHTH VIS SCI, V37, P290
   Takeda AL, 2007, BRIT J OPHTHALMOL, V91, P1177, DOI 10.1136/bjo.2007.118562
   Vinores SA, 2006, J CELL PHYSIOL, V206, P749, DOI 10.1002/jcp.20525
   Weis SM, 2005, NATURE, V437, P497, DOI 10.1038/nature03987
   Young T L, 1997, J AAPOS, V1, P105, DOI 10.1016/S1091-8531(97)90008-2
   Zachary I, 2005, NEUROSIGNALS, V14, P207, DOI 10.1159/000088637
NR 48
TC 56
Z9 59
U1 0
U2 3
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD MAY 26
PY 2009
VL 106
IS 21
BP 8760
EP 8765
DI 10.1073/pnas.0902659106
PG 6
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 450WS
UT WOS:000266432700063
PM 19433784
OA Green Published, Bronze
DA 2022-11-30
ER

PT J
AU Funakoshi, T
   Birsner, AE
   D'Amato, RJ
AF Funakoshi, Taisaku
   Birsner, Amy E.
   D'Amato, Robert J.
TI Antiangiogenic effect of oral 2-methoxyestradiol on choroidal
   neovascularization in mice
SO EXPERIMENTAL EYE RESEARCH
LA English
DT Article
DE antiangiogenesis; choroidal neovascularization; 2-methoxyestradiol;
   age-related macular degeneration; mouse; drug; laser
ID ENDOGENOUS ESTROGEN METABOLITE; MULTIPLE-MYELOMA CELLS; MACULAR
   DEGENERATION; TRANSPUPILLARY THERMOTHERAPY; INHIBITS ANGIOGENESIS;
   PHOTODYNAMIC THERAPY; TUMOR-GROWTH; APOPTOSIS; RESISTANCE; MEMBRANES
AB We evaluated the efficacy of systemic 2-methoxyestradiol (2ME2) in a laser-induced murime model of choroidal neovascularization (CNV). C57BL/6J mice (8 week old males) were used in this study and divided into four groups. After laser treatment, daily oral treatment with vehicle control, and 30, 50, and 75 mg/kg of 2ME2 was started. Two weeks after laser treatment, digital images of CNV were obtained from fluorescein isothiocyanate-dextran (FITC-dextran) angiography and choroidal flat mount after FITC-dextran perfusion. These images were quantified by NIH image software. Analysis of images from both FITC-dextran angiography and choroidal flat mount with FITC-dextran perfusion demonstrated that the 2ME2 treated groups showed a statistically significant, dose-dependent decrease in CNV. No toxicity or weight loss was observed during the treatment. Significant antiangiogenic effects of oral 2ME2 on laser induced CNV were observed. Since 2ME2 (Panzem (R)) has demonstrated good safety in phase I/II trials for cancer, it has the potential to be used as a novel oral treatment for age-related macular degeneration. (c) 2006 Elsevier Ltd. All rights reserved.
C1 Harvard Univ, Sch Med, Vasc Biol Program, Childrens Hosp, Boston, MA 02115 USA.
   Harvard Univ, Sch Med, Dept Ophthalmol, Boston, MA 02115 USA.
C3 Harvard University; Boston Children's Hospital; Harvard Medical School;
   Harvard University; Harvard Medical School
RP D'Amato, RJ (通讯作者)，Harvard Univ, Sch Med, Vasc Biol Program, Childrens Hosp, 300 Longwood Ave,Karp 11-210, Boston, MA 02115 USA.
EM robert.damato@childrens.harvard.edu
CR Chauhan D, 2004, APOPTOSIS, V9, P149, DOI 10.1023/B:APPT.0000018797.66067.6c
   Chauhan D, 2003, ONCOGENE, V22, P6296, DOI 10.1038/sj.onc.1206734
   Dahut WL, 2006, CANCER BIOL THER, V5, P22, DOI 10.4161/cbt.5.1.2349
   DAMATO RJ, 1994, P NATL ACAD SCI USA, V91, P3964, DOI 10.1073/pnas.91.9.3964
   FOTSIS T, 1994, NATURE, V368, P237, DOI 10.1038/368237a0
   Gokmen-Polar Y, 2005, CANCER RES, V65, P9406, DOI 10.1158/0008-5472.CAN-05-0088
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   HEIER JS, 2006, OPHTHALMOLOGY, V113, P642
   Klauber N, 1997, CANCER RES, V57, P81
   LAMBERT HM, 1992, AM J OPHTHALMOL, V113, P257, DOI 10.1016/S0002-9394(14)71576-4
   LaVallee TM, 2003, CANCER RES, V63, P468
   LaVallee TM, 2002, CANCER RES, V62, P3691
   Mabjeesh NJ, 2003, CANCER CELL, V3, P363, DOI 10.1016/S1535-6108(03)00077-1
   MILLER JW, 1995, ARCH OPHTHALMOL-CHIC, V113, P810, DOI 10.1001/archopht.1995.01100060136048
   Newsom RSB, 2001, BRIT J OPHTHALMOL, V85, P173, DOI 10.1136/bjo.85.2.173
   Ninomiya Y, 1996, AM J OPHTHALMOL, V122, P613, DOI 10.1016/S0002-9394(14)70479-9
   Poulaki V, 2002, J CLIN INVEST, V109, P805, DOI 10.1172/JCI200213776
   Pribluda VS, 2000, CANCER METAST REV, V19, P173, DOI 10.1023/A:1026543018478
   Reichel E, 1999, OPHTHALMOLOGY, V106, P1908, DOI 10.1016/S0161-6420(99)90400-1
   Robinson MR, 2002, EXP EYE RES, V74, P309, DOI 10.1006/exer.2001.1132
   Schmidt-Erfurth U, 1999, ARCH OPHTHALMOL-CHIC, V117, P1177
   Sibonga JD, 2003, ENDOCRINOLOGY, V144, P785, DOI 10.1210/en.2002-220632
   Sica DA, 2006, J CLIN ONCOL, V24, P1329, DOI 10.1200/JCO.2005.04.5740
   Turner RT, 2000, CALCIFIED TISSUE INT, V66, P465, DOI 10.1007/s002230010093
   Yue TL, 1997, MOL PHARMACOL, V51, P951, DOI 10.1124/mol.51.6.951
   Zondor SD, 2004, ANN PHARMACOTHER, V38, P1258, DOI 10.1345/aph.1D470
NR 26
TC 14
Z9 15
U1 0
U2 2
PU ACADEMIC PRESS LTD ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0014-4835
J9 EXP EYE RES
JI Exp. Eye Res.
PD NOV
PY 2006
VL 83
IS 5
BP 1102
EP 1107
DI 10.1016/j.exer.2006.05.016
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 093WZ
UT WOS:000241202300012
PM 16828472
DA 2022-11-30
ER

PT J
AU Geruschat, DR
   Hassan, SE
   Turano, KA
   Quigley, HA
   Congdon, NG
AF Geruschat, Duane R.
   Hassan, Shirin E.
   Turano, Kathleen A.
   Quigley, Harry A.
   Congdon, Nathan G.
TI Gaze behavior of the visually impaired during street crossing
SO OPTOMETRY AND VISION SCIENCE
LA English
DT Article
DE orientation and mobility; low vision; eye movements; gaze direction;
   street crossing
ID EYE-MOVEMENTS; WATERLOO VISION; DIRECTION; STRATEGIES; MOBILITY;
   WALKING; ADULTS
AB Purpose. This study explored the gaze patterns of fully sighted and visually impaired subjects during the high-risk activity of crossing the street.
   Methods. Gaze behavior of 12 fully sighted subjects, nine with visual impairment resulting from age-related macular degeneration and 12 with impairment resulting from glaucoma, was monitored using a portable eye tracker as they crossed at two unfamiliar intersections.
   Results. All subject groups fixated primarily on vehicles and crossing elements but changed their fixation behavior as they moved from "walking to the curb" to "standing at the curb" and to "crossing the street." A comparison of where subjects fixated in the 4-second time period before crossing showed that the fully sighted who waited for the light to change fixated on the light, whereas the fully sighted who crossed early fixated primarily on vehicles. Visually impaired subjects crossing early or waiting for the light fixate primarily on vehicles.
   Conclusions. Vision status affects fixation allocation while performing the high-risk activity of street crossing. Crossing decision-making strategy corresponds to fixation behavior only for the fully sighted subjects.
C1 Maryland Sch Blind, Baltimore, MD USA.
   Johns Hopkins Sch Med, Wilmer Eye Inst, Baltimore, MD USA.
C3 Johns Hopkins University; Johns Hopkins Medicine
RP Geruschat, DR (通讯作者)，Lions Vis Res Ctr, 550 N Broadway,6th Floor, Baltimore, MD 21205 USA.
EM dgeruschat@jhmi.edu
FU NEI NIH HHS [EY12984] Funding Source: Medline; NATIONAL EYE INSTITUTE
   [R01EY012984] Funding Source: NIH RePORTER
CR CONOVER WJ, 1981, AM STAT, V35, P124, DOI 10.2307/2683975
   De l'Aune WR, 2000, J VISUAL IMPAIR BLIN, V94, P281, DOI 10.1177/0145482X0009400505
   ELLIOTT DB, 1995, OPHTHAL PHYSL OPT, V15, P553, DOI 10.1016/0275-5408(95)00025-9
   Geruschat DR, 2003, OPTOMETRY VISION SCI, V80, P515, DOI 10.1097/00006324-200307000-00013
   Guse Clare E, 2003, WMJ, V102, P37
   Hayhoe M, 2005, TRENDS COGN SCI, V9, P188, DOI 10.1016/j.tics.2005.02.009
   Hayhoe MM, 2003, J VISION, V3, P49, DOI 10.1167/3.1.6
   Hollands MA, 2002, EXP BRAIN RES, V143, P221, DOI 10.1007/s00221-001-0983-7
   HOLLANDS MA, 1995, J MOTOR BEHAV, V27, P155, DOI 10.1080/00222895.1995.9941707
   *INS I HIGHW SAF, 2002, FAT FACTS 2003
   Ivers RQ, 1998, J AM GERIATR SOC, V46, P58
   Land M, 1999, PERCEPTION, V28, P1311, DOI 10.1068/p2935
   LAND MF, 1994, NATURE, V369, P742, DOI 10.1038/369742a0
   Land MF, 2000, INVEST OPHTH VIS SCI, V41, pS815
   Patla AE, 1997, NEUROREPORT, V8, P3661, DOI 10.1097/00001756-199712010-00002
   Shabana N, 2005, CLIN EXP OPHTHALMOL, V33, P264, DOI 10.1111/j.1442-9071.2005.01003.x
   SPAULDING SJ, 1994, OPTOMETRY VISION SCI, V71, P770, DOI 10.1097/00006324-199412000-00007
   Turano KA, 2003, VISION RES, V43, P333, DOI 10.1016/S0042-6989(02)00498-4
   Turano KA, 2002, VISION RES, V42, P2635, DOI 10.1016/S0042-6989(02)00299-7
   Turano KA, 2001, OPTOMETRY VISION SCI, V78, P667, DOI 10.1097/00006324-200109000-00012
NR 20
TC 22
Z9 22
U1 0
U2 6
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1040-5488
EI 1538-9235
J9 OPTOMETRY VISION SCI
JI Optom. Vis. Sci.
PD AUG
PY 2006
VL 83
IS 8
BP 550
EP 558
DI 10.1097/01.opx.0000232219.23362.a6
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Ophthalmology
GA 074XT
UT WOS:000239846400003
PM 16909081
DA 2022-11-30
ER

PT J
AU Zhu, XM
   Chen, ZY
   Wang, L
   Ou, QJ
   Feng, Z
   Xiao, HL
   Shen, Q
   Li, YG
   Jin, CX
   Xu, JY
   Gao, FR
   Wang, J
   Zhang, JF
   Zhang, JP
   Xu, ZG
   Xu, GT
   Lu, LX
   Tian, HB
AF Zhu, Xiaoman
   Chen, Zhiyang
   Wang, Li
   Ou, Qingjian
   Feng, Zhong
   Xiao, Honglei
   Shen, Qi
   Li, Yingao
   Jin, Caixia
   Xu, Jing-Ying
   Gao, Furong
   Wang, Juan
   Zhang, Jingfa
   Zhang, Jieping
   Xu, Zhiguo
   Xu, Guo-Tong
   Lu, Lixia
   Tian, Haibin
TI Direct conversion of human umbilical cord mesenchymal stem cells into
   retinal pigment epithelial cells for treatment of retinal degeneration
SO CELL DEATH & DISEASE
LA English
DT Article
ID TRANSCRIPTION FACTORS; MACULAR DEGENERATION; NEOVASCULAR MEMBRANES;
   RODENT MODEL; SYNTENIN; FIELD; GENE; PHOSPHATASE; EXPRESSION; ARPE-19
AB Age-related macular degeneration (AMD) is a major vision-threatening disease. Although mesenchymal stem cells (MSCs) exhibit beneficial neural protective effects, their limited differentiation capacity in vivo attenuates their therapeutic function. Therefore, the differentiation of MSCs into retinal pigment epithelial (RPE) cells in vitro and their subsequent transplantation into the subretinal space is expected to improve the outcome of cell therapy. Here, we transdifferentiated human umbilical cord MSCs (hUCMSCs) into induced RPE (iRPE) cells using a cocktail of five transcription factors (TFs): CRX, NR2E1, C-MYC, LHX2, and SIX6. iRPE cells exhibited RPE specific properties, including phagocytic ability, epithelial polarity, and gene expression profile. In addition, high expression of PTPN13 in iRPE cells endows them with an epithelial-to-mesenchymal transition (EMT)-resistant capacity through dephosphorylating syntenin1, and subsequently promoting the internalization and degradation of transforming growth factor-beta receptors. After grafting into the subretinal space of the sodium iodate-induced rat AMD model, iRPE cells demonstrated a better therapeutic function than hUCMSCs. These results suggest that hUCMSC-derived iRPE cells may be promising candidates to reverse AMD pathophysiology.
C1 [Zhu, Xiaoman; Chen, Zhiyang; Wang, Li; Ou, Qingjian; Feng, Zhong; Xiao, Honglei; Shen, Qi; Li, Yingao; Jin, Caixia; Xu, Jing-Ying; Gao, Furong; Wang, Juan; Zhang, Jieping; Xu, Guo-Tong; Lu, Lixia; Tian, Haibin] Tongji Univ, Sch Med, Tongji Hosp, Dept Ophthalmol,Tongji Eye Inst, Shanghai 200065, Peoples R China.
   [Zhang, Jingfa] Shanghai Jiao Tong Univ, Shanghai Peoples Hosp 1, Shanghai Gen Hosp, Dept Ophthalmol, Shanghai 200080, Peoples R China.
   [Zhang, Jieping; Xu, Guo-Tong] TUSM, Dept Physiol & Pharmacol, Shanghai 200092, Peoples R China.
   [Xu, Zhiguo] Huzhou Coll, Huzhou 313000, Zhejiang, Peoples R China.
   [Xu, Guo-Tong] Tongji Univ, Collaborat Innovat Ctr Brain Sci, Shanghai 200092, Peoples R China.
   [Zhu, Xiaoman; Chen, Zhiyang; Wang, Li; Ou, Qingjian; Feng, Zhong; Xiao, Honglei; Shen, Qi; Li, Yingao; Jin, Caixia; Xu, Jing-Ying; Gao, Furong; Wang, Juan; Zhang, Jieping; Xu, Guo-Tong; Lu, Lixia; Tian, Haibin] Tongji Univ, Sch Med, Tongji Eye Inst, Lab Clin & Visual Sci, Shanghai 200065, Peoples R China.
C3 Tongji University; Shanghai Jiao Tong University; Tongji University;
   Tongji University
RP Xu, GT; Lu, LX; Tian, HB (通讯作者)，Tongji Univ, Sch Med, Tongji Hosp, Dept Ophthalmol,Tongji Eye Inst, Shanghai 200065, Peoples R China.; Xu, GT; Lu, LX; Tian, HB (通讯作者)，Tongji Univ, Sch Med, Tongji Eye Inst, Lab Clin & Visual Sci, Shanghai 200065, Peoples R China.
EM gtxu@tongji.edu.cn; lulixia@tongji.edu.cn; tianhb@tongji.edu.cn
OI Ou, Qingjian/0000-0002-6881-8680
FU Ministry of Science and Technology of China [2020YFA0113102,
   2017YFA0104100, 2016YFA0101302]; National Natural Science Foundation
   [81770942, 81670867]
FX This work was supported by grants obtained from the Ministry of Science
   and Technology of China (2020YFA0113102, 2017YFA0104100, and
   2016YFA0101302), National Natural Science Foundation (81770942 and
   81670867).
CR AMIN R, 1994, INVEST OPHTH VIS SCI, V35, P3178
   Ark AV, 2018, CELL SIGNAL, V52, P112, DOI 10.1016/j.cellsig.2018.09.002
   Baietti MF, 2012, NAT CELL BIOL, V14, P677, DOI 10.1038/ncb2502
   Barzelay A, 2018, STEM CELLS INT, V2018, DOI 10.1155/2018/9682856
   Beekman JM, 2008, J CELL SCI, V121, P1349, DOI 10.1242/jcs.026401
   Chen GK, 2011, NAT METHODS, V8, P424, DOI [10.1038/NMETH.1593, 10.1038/nmeth.1593]
   Chen Y, 2021, INVEST OPHTH VIS SCI, V62, DOI 10.1167/iovs.62.4.21
   Chen Z, 2017, EXP THER MED, V14, P4951, DOI 10.3892/etm.2017.5187
   Cheng D, 2008, INSECT BIOCHEM MOLEC, V38, P1130, DOI 10.1016/j.ibmb.2008.09.013
   D'Alessio AC, 2015, STEM CELL REP, V5, P763, DOI 10.1016/j.stemcr.2015.09.016
   da Cruz L, 2018, NAT BIOTECHNOL, V36, P1, DOI 10.1038/nbt.4114
   Dunn KC, 1996, EXP EYE RES, V62, P155, DOI 10.1006/exer.1996.0020
   Furukawa T, 1997, CELL, V91, P531, DOI 10.1016/S0092-8674(00)80439-0
   Glondu-Lassis M, 2010, CANCER RES, V70, P5116, DOI 10.1158/0008-5472.CAN-09-4368
   Guan Y, 2013, CURR MOL MED, V13, P1419
   Guidry C, 2002, INVEST OPHTH VIS SCI, V43, P267
   Hadziahmetovic M, 2021, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.612812
   Hamyeh M, 2020, THERANOSTICS, V10, P1016, DOI 10.7150/thno.38537
   Heikkinen PT, 2010, J BIOL CHEM, V285, P3740, DOI 10.1074/jbc.M109.042978
   Hoover AC, 2009, ONCOGENE, V28, P3960, DOI 10.1038/onc.2009.251
   Hu CY, 2020, STEM CELLS INT, V2020, DOI 10.1155/2020/9625798
   Huang Q, 2021, CURR MED SCI, V41, P145, DOI 10.1007/s11596-021-2329-y
   Hwangbo C, 2016, ONCOGENE, V35, P389, DOI 10.1038/onc.2015.100
   Jonas JB, 2017, ASIA-PAC J OPHTHALMO, V6, P493, DOI 10.22608/APO.2017251
   Kadkhodaeian HA, 2019, TISSUE CELL, V56, P52, DOI 10.1016/j.tice.2018.12.003
   Kadkhodaeian HA, 2018, EXP CLIN TRANSPLANT, V16, P204, DOI 10.6002/ect.2016.0235
   Kamijyo A, 2015, GENE, V555, P73, DOI 10.1016/j.gene.2014.10.003
   Kawakami K, 2000, BIOESSAYS, V22, P616, DOI 10.1002/1521-1878(200007)22:7<616::AID-BIES4>3.0.CO;2-R
   Koroll M, 2001, J BIOL CHEM, V276, P10646, DOI 10.1074/jbc.M010647200
   Kuriyan AE, 2017, NEW ENGL J MED, V376, P1047, DOI 10.1056/NEJMoa1609583
   Li Z, 2016, CURR MOL MED, V16, P553, DOI 10.2174/1566524016666160607090538
   Lin X, 2006, CELL, V125, P915, DOI 10.1016/j.cell.2006.03.044
   Liu T, 2010, BIOCHEM J, V430, P191, DOI 10.1042/BJ20100427
   Liu Y, 2018, CELL DISCOV, V4, DOI 10.1038/s41421-018-0053-y
   Long QZ, 2020, EXP CELL RES, V396, DOI 10.1016/j.yexcr.2020.112286
   Lu B, 2010, EXP EYE RES, V91, P449, DOI 10.1016/j.exer.2010.06.024
   Lund RD, 2007, STEM CELLS, V25, P602, DOI 10.1634/stemcells.2006-0308
   Masuda T, 2014, J BIOL CHEM, V289, P12908, DOI 10.1074/jbc.M114.556738
   Mcheik S, 2020, BIOMOLECULES, V10, DOI 10.3390/biom10121659
   Mehat MS, 2018, OPHTHALMOLOGY, V125, P1765, DOI 10.1016/j.ophtha.2018.04.037
   Miao JY, 2021, J INTERF CYTOK RES, V41, P365, DOI 10.1089/jir.2021.0094
   Michelis G, 2021, J NEUROCHEM, V159, P840, DOI 10.1111/jnc.15454
   OLSEN KJ, 1979, ACTA PHARMACOL TOX, V44, P241
   REDDY VM, 1995, AM J OPHTHALMOL, V120, P291, DOI 10.1016/S0002-9394(14)72158-0
   Rong JB, 2011, BIOCHEM BIOPH RES CO, V407, P605, DOI 10.1016/j.bbrc.2011.03.080
   Sadda SR, 2018, OPHTHALMOLOGY, V125, P537, DOI 10.1016/j.ophtha.2017.09.028
   Sadelain M, 2012, NAT REV CANCER, V12, P51, DOI 10.1038/nrc3179
   Schwartz SD, 2015, LANCET, V385, P509, DOI 10.1016/S0140-6736(14)61376-3
   Shi WB, 2004, J CELL BIOL, V164, P291, DOI 10.1083/jcb.200307151
   Soucek L, 2010, CURR OPIN GENET DEV, V20, P91, DOI 10.1016/j.gde.2009.11.001
   Sugita S, 2020, J CLIN MED, V9, DOI 10.3390/jcm9072217
   Takagi S, 2019, OPHTHALMOL RETINA, V3, P850, DOI 10.1016/j.oret.2019.04.021
   Tetreault N, 2009, DEV BIOL, V327, P541, DOI 10.1016/j.ydbio.2008.12.022
   Tian HB, 2018, EXP EYE RES, V177, P160, DOI 10.1016/j.exer.2018.08.005
   Wang L, 2017, CURR MOL MED, V17, P421, DOI 10.2174/1566524018666171205140806
   Wang SM, 2005, INVEST OPHTH VIS SCI, V46, P2552, DOI 10.1167/iovs.05-0279
   WOLFF J, 1963, BIOCHIM BIOPHYS ACTA, V69, P58, DOI 10.1016/0006-3002(63)91225-3
   Yang S, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.727870
   Zanzottera EC, 2015, INVEST OPHTH VIS SCI, V56, P3269, DOI 10.1167/iovs.15-16432
   Zhang H, 2012, INT J OPHTHALMOL-CHI, V5, P307, DOI 10.3980/j.issn.2222-3959.2012.03.11
   Zhang KJ, 2014, PROTEIN CELL, V5, P48, DOI 10.1007/s13238-013-0011-2
   Zuber ME, 2003, DEVELOPMENT, V130, P5155, DOI 10.1242/dev.00723
NR 62
TC 0
Z9 0
U1 4
U2 4
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
SN 2041-4889
J9 CELL DEATH DIS
JI Cell Death Dis.
PD SEP 12
PY 2022
VL 13
IS 9
AR 785
DI 10.1038/s41419-022-05199-5
PG 15
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA 4M9PD
UT WOS:000853649300002
PM 36096985
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Szalai, I
   Palya, F
   Csorba, A
   Toth, M
   Somfai, GM
AF Szalai, Iren
   Palya, Fanni
   Csorba, Anita
   Toth, Miklos
   Somfai, Gabor Mark
TI The Effect of Physical Exercise on the Retina and Choroid
SO KLINISCHE MONATSBLATTER FUR AUGENHEILKUNDE
LA English
DT Article
DE choroid; retina; optical coherence tomography; physical exercise
ID COHERENCE TOMOGRAPHY ANGIOGRAPHY; OPTIC-NERVE HEAD; BLOOD-FLOW;
   INTRAOCULAR-PRESSURE; ISOMETRIC-EXERCISE; DYNAMIC EXERCISE; THICKNESS;
   PROTECTS; AUTOREGULATION; DEGENERATION
AB There is only limited information available on the effects of physical exercise on the posterior pole. Retinal circulation is autoregulated similarly to the brain vasculature in order to provide constant flow and thus constant nutrition of the inner retinal structures while the choroid is mostly controlled by the sympathetic nervous system. The available data show that physical exercise may indeed have a positive effect on the retina and visual function. The assessment of retinal structure could serve as a marker in sports medicine, whereas physical activity could exert a positive protective effect against diseases such as diabetic retinopathy or age-related macular degeneration. According to our theory, similar to the term "trained heart" used in cardiology and sports medicine, the term "trained eye" could also be coined. This latter term would help to further emphasize the beneficial effects of physical exercise that works protectively not only for the cardiovascular but for the visual system as well, and thus could further help in the fight against avoidable blindness worldwide.
C1 [Szalai, Iren; Palya, Fanni; Csorba, Anita; Somfai, Gabor Mark] Semmelweis Univ, Dept Ophthalmol, Fac Med, Budapest, Hungary.
   [Toth, Miklos] Univ Phys Educ, Inst Hlth Sci & Sports Med, Budapest, Hungary.
   [Somfai, Gabor Mark] Pallas Kliniken AG, Retinol Unit, Louis Giroud Str 20, CH-4600 Olten, Switzerland.
C3 Semmelweis University; University of Physical Education
RP Somfai, GM (通讯作者)，Pallas Kliniken AG, Retinol Unit, Louis Giroud Str 20, CH-4600 Olten, Switzerland.
EM somfaigm@yahoo.com
CR Alnawaiseh M, 2017, RETINA-J RET VIT DIS, V37, P1642, DOI 10.1097/IAE.0000000000001419
   Alten F, 2019, OPHTHALMOLOGE, V116, P722, DOI 10.1007/s00347-019-0897-z
   Alwassia AA, 2013, RETINA-J RET VIT DIS, V33, P160, DOI 10.1097/IAE.0b013e3182618c22
   [Anonymous], 2010, GLOB REC PHYS ACT HL
   Boltz A, 2013, J CEREBR BLOOD F MET, V33, P1850, DOI 10.1038/jcbfm.2013.137
   Braun G, 2018, MICROVASC RES, V120, P36, DOI 10.1016/j.mvr.2018.06.001
   Chrysostomou V, 2014, NEUROBIOL AGING, V35, P1722, DOI 10.1016/j.neurobiolaging.2014.01.019
   Guthold R, 2008, AM J PREV MED, V34, P486, DOI 10.1016/j.amepre.2008.02.013
   Hulke SM, 2012, J RES MED SCI, V17, P649
   Kim DY, 2013, MOL MED REP, V7, P1745, DOI 10.3892/mmr.2013.1439
   Kim SV, 2019, INVEST OPHTH VIS SCI, V60, P1412, DOI 10.1167/iovs.18-24389
   Kinoshita T, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0168336
   Koller A, 2012, J VASC RES, V49, P375, DOI 10.1159/000338747
   Lawson EC, 2014, J NEUROSCI, V34, P2406, DOI 10.1523/JNEUROSCI.2062-13.2014
   Leasher JL, 2016, DIABETES CARE, V39, P1643, DOI 10.2337/dc15-2171
   Lundberg K, 2018, SCAND J MED SCI SPOR, V28, P1897, DOI 10.1111/sms.13204
   Lundberg K, 2018, ACTA OPHTHALMOL, V96, P371, DOI 10.1111/aos.13640
   Lundberg K, 2018, ACTA OPHTHALMOL, V96, P134, DOI 10.1111/aos.13513
   Metelitsina TI, 2010, BRIT J OPHTHALMOL, V94, P1629, DOI 10.1136/bjo.2009.176859
   Nemeth J, 2002, GRAEF ARCH CLIN EXP, V240, P835, DOI 10.1007/s00417-002-0552-1
   Nussbaumer M, 2014, AGE, V36, P1249, DOI 10.1007/s11357-014-9650-3
   Pardue MT, 2015, PROG MOL BIOL TRANSL, V134, P491, DOI 10.1016/bs.pmbts.2015.06.011
   Popa-Cherecheanu A, 2019, INVEST OPHTH VIS SCI, V60, P176, DOI 10.1167/iovs.18-24992
   Pressler A, 2011, ATHEROSCLEROSIS, V219, P864, DOI 10.1016/j.atherosclerosis.2011.08.052
   Sayin N, 2015, INDIAN J OPHTHALMOL, V63, P445, DOI 10.4103/0301-4738.159884
   Schmitz B, 2018, ATHEROSCLEROSIS, V274, P8, DOI 10.1016/j.atherosclerosis.2018.04.028
   Williams PT, 2009, INVEST OPHTH VIS SCI, V50, P101, DOI 10.1167/iovs.08-2165
   Zhang X, 2019, MOL VIS, V25, P462
NR 28
TC 2
Z9 2
U1 0
U2 8
PU GEORG THIEME VERLAG KG
PI STUTTGART
PA RUDIGERSTR 14, D-70469 STUTTGART, GERMANY
SN 0023-2165
EI 1439-3999
J9 KLIN MONATSBL AUGENH
JI Klinische Monatsblat. Augenheilkunde
PD APR
PY 2020
VL 237
IS 4
BP 446
EP 449
DI 10.1055/a-1101-9288
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA LJ6UT
UT WOS:000530298700024
PM 32131128
DA 2022-11-30
ER

PT J
AU Ben M'Barek, K
   Monville, C
AF Ben M'Barek, Karim
   Monville, Christelle
TI Cell Therapy for Retinal Dystrophies: From Cell Suspension Formulation
   to Complex Retinal Tissue Bioengineering
SO STEM CELLS INTERNATIONAL
LA English
DT Review
ID PLURIPOTENT STEM-CELLS; PIGMENT EPITHELIAL-CELLS; HUMAN NEURAL
   PROGENITORS; HUMAN IPS CELLS; MACULAR DEGENERATION; HUMAN FETAL; HUMAN
   RPE; VISUAL FUNCTION; ROYAL-COLLEGE; RAT MODEL
AB Retinal degeneration is an irreversible phenomenon caused by various disease conditions including age-related macular degeneration (AMD) and retinitis pigmentosa (RP). During the course of these diseases, photoreceptors (PRs) are susceptible to degeneration due to their malfunctions or to a primary dysfunction of the retinal pigment epithelium (RPE). Once lost, these cells could not be endogenously regenerated in humans, and cell therapy to replace the lost cells is one of the promising strategies to recover vision. Depending on the nature of the primary defect and the stage of the disease, RPE cells, PRs, or both might be transplanted to achieve therapeutic effects. We describe in this review the current knowledge and recent progress to develop such approaches. The different cell sources proposed for cell therapy including human pluripotent stem cells are presented with their advantages and limits. Another critical aspect described herein is the pharmaceutical formulation of the end product to be delivered into the eye of patients. Finally, we also outline the future research directions in order to develop a complex multilayered retinal tissue for end-stage patients.
C1 [Ben M'Barek, Karim; Monville, Christelle] I Stem, U861, INSERM, AFM,Inst Stem Cell Therapy & Explorat Monogen Dis, F-91100 Corbeil Essonnes, France.
   [Ben M'Barek, Karim; Monville, Christelle] I Stem, U861, UEVE, AFM,Inst Stem Cell Therapy & Explorat Monogen Dis, F-91100 Corbeil Essonnes, France.
   [Ben M'Barek, Karim] I Stem, CECS, AFM, Inst Stem Cell Therapy & Explorat Monogen Dis, F-91100 Corbeil Essonnes, France.
C3 Institut National de la Sante et de la Recherche Medicale (Inserm);
   UDICE-French Research Universities; Universite Paris Saclay;
   UDICE-French Research Universities; Universite Paris Saclay;
   UDICE-French Research Universities; Universite Paris Saclay
RP Monville, C (通讯作者)，I Stem, U861, INSERM, AFM,Inst Stem Cell Therapy & Explorat Monogen Dis, F-91100 Corbeil Essonnes, France.; Monville, C (通讯作者)，I Stem, U861, UEVE, AFM,Inst Stem Cell Therapy & Explorat Monogen Dis, F-91100 Corbeil Essonnes, France.
EM cmonville@istem.fr
RI M'BAREK, Karim BEN/K-1389-2019
OI M'BAREK, Karim BEN/0000-0002-2556-0325; Monville,
   Christelle/0000-0003-1256-5140
FU ANR (SightREPAIR) [ANR-16-CE17-008-02]; Fondation pour la Recherche
   Medicale (Bioengineering program) [DBS20140930777]; LabEx Revive
   [ANR-10-LABX-73]; NeurATRIS, a translational research infrastructure
   (Investissements d'Avenir) for biotherapies in neurosciences
   [ANR-11-INBS-0011]; INGESTEM, the national infrastructure
   (Investissements d'Avenir) engineering for pluripotent and
   differentiated stem cells [ANR-11-INBS-000]; Association Francaise
   contre les Myopathies-(AFM-) Telethon
FX This work was supported by grants from the ANR (SightREPAIR:
   ANR-16-CE17-008-02), the Fondation pour la Recherche Medicale
   (Bioengineering program: DBS20140930777), and the LabEx Revive
   (ANR-10-LABX-73) to Christelle Monville. It was supported by NeurATRIS,
   a translational research infrastructure (Investissements d'Avenir) for
   biotherapies in neurosciences (ANR-11-INBS-0011), and INGESTEM, the
   national infrastructure (Investissements d'Avenir) engineering for
   pluripotent and differentiated stem cells (ANR-11-INBS-000), to
   Christelle Monville. I-Stem is part of the Biotherapies Institute for
   Rare Diseases supported by the Association Francaise contre les
   Myopathies-(AFM-) Telethon.
CR Abe T, 2000, TOHOKU J EXP MED, V191, P7, DOI 10.1620/tjem.191.7
   Abe T, 2007, PROG RETIN EYE RES, V26, P302, DOI 10.1016/j.preteyeres.2007.01.003
   Achberger K., 2018, ADV DRUG DELIVERY RE
   Ahmad I, 2000, BIOCHEM BIOPH RES CO, V270, P517, DOI 10.1006/bbrc.2000.2473
   Akimoto M, 2006, P NATL ACAD SCI USA, V103, P3890, DOI 10.1073/pnas.0508214103
   Algvere PV, 1999, EUR J OPHTHALMOL, V9, P217, DOI 10.1177/112067219900900310
   ALGVERE PV, 1994, GRAEF ARCH CLIN EXP, V232, P707, DOI 10.1007/BF00184273
   Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Andrews PW, 2015, REGEN MED, V10, P1, DOI [10.2217/RME.14.93, 10.2217/rme.14.93]
   [Anonymous], 2001, B WORLD HEALTH ORGAN, V79, P373
   Arnhold S, 2006, INVEST OPHTH VIS SCI, V47, P4121, DOI 10.1167/iovs.04-1501
   Assawachananont J, 2014, STEM CELL REP, V2, P662, DOI 10.1016/j.stemcr.2014.03.011
   Audo I, 2018, HUM MUTAT, V39, P887, DOI 10.1002/humu.23431
   Ballios BG, 2012, BIOL OPEN, V1, P237, DOI 10.1242/bio.2012027
   Barber AC, 2013, P NATL ACAD SCI USA, V110, P354, DOI 10.1073/pnas.1212677110
   Barnea-Cramer AO, 2016, SCI REP-UK, V6, DOI 10.1038/srep29784
   Ben M'Barek K, 2018, M S-MED SCI, V34, P383, DOI 10.1051/medsci/20183405004
   Ben M'Barek K, 2018, ADV EXP MED BIOL, V1074, P625, DOI 10.1007/978-3-319-75402-4_76
   Ben M'Barek K, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aai7471
   Ben M'Barek K, 2015, WORLD J STEM CELLS, V7, P596, DOI 10.4252/wjsc.v7.i3.596
   Berger AS, 2003, OPHTHALMOLOGY, V110, P383, DOI 10.1016/S0161-6420(02)01738-4
   Bharti K, 2014, INVEST OPHTH VIS SCI, V55, P1191, DOI 10.1167/iovs.13-13481
   BHATT NS, 1994, AM J OPHTHALMOL, V117, P214, DOI 10.1016/S0002-9394(14)73079-X
   Binder S, 2002, AM J OPHTHALMOL, V133, P215, DOI 10.1016/S0002-9394(01)01373-3
   Binder S, 2007, PROG RETIN EYE RES, V26, P516, DOI 10.1016/j.preteyeres.2007.02.002
   BIRD AC, 1995, AM J OPHTHALMOL, V119, P543, DOI 10.1016/S0002-9394(14)70212-0
   Brzezinski JA, 2015, DEVELOPMENT, V142, P3263, DOI 10.1242/dev.127043
   Buchholz DE, 2013, STEM CELL TRANSL MED, V2, P384, DOI 10.5966/sctm.2012-0163
   Carr AJF, 2013, TRENDS NEUROSCI, V36, P385, DOI 10.1016/j.tins.2013.03.006
   Casarosa Simona, 2014, Mol Cell Ther, V2, P31, DOI 10.1186/2052-8426-2-31
   Castillo BV, 1997, EXP NEUROL, V146, P1, DOI 10.1006/exnr.1997.6534
   Chen Y, 2008, INT J BIOCHEM CELL B, V40, P815, DOI 10.1016/j.biocel.2008.01.007
   Chiba C, 2014, EXP EYE RES, V123, P107, DOI 10.1016/j.exer.2013.07.009
   Choudhary P, 2017, STEM CELL TRANSL MED, V6, P490, DOI 10.5966/sctm.2016-0088
   Cicero SA, 2009, P NATL ACAD SCI USA, V106, P6685, DOI 10.1073/pnas.0901596106
   Coffey PJ, 2002, NAT NEUROSCI, V5, P53, DOI 10.1038/nn782
   Coles BLK, 2004, P NATL ACAD SCI USA, V101, P15772, DOI 10.1073/pnas.0401596101
   Crafoord S, 2000, ACTA OPHTHALMOL SCAN, V78, P122, DOI 10.1034/j.1600-0420.2000.078002122.x
   Crombie DE, 2017, SLAS DISCOV, V22, P1016, DOI 10.1177/2472555217696797
   Croze RH, 2014, STEM CELL TRANSL MED, V3, P1066, DOI 10.5966/sctm.2014-0079
   Cuenca N, 2013, INVEST OPHTH VIS SCI, V54, P6745, DOI 10.1167/iovs.13-12860
   da Cruz L, 2007, PROG RETIN EYE RES, V26, P598, DOI 10.1016/j.preteyeres.2007.07.001
   da Cruz L, 2018, NAT BIOTECHNOL, V36, P1, DOI 10.1038/nbt.4114
   Davis RJ, 2017, STEM CELL REP, V9, P42, DOI 10.1016/j.stemcr.2017.05.016
   Davis RJ, 2016, J OCUL PHARMACOL TH, V32, P304, DOI 10.1089/jop.2015.0162
   Diniz B, 2013, INVEST OPHTH VIS SCI, V54, P5087, DOI 10.1167/iovs.12-11239
   Fernandes Rodrigo A Brant, 2017, Int J Retina Vitreous, V3, P41, DOI 10.1186/s40942-017-0095-6
   Forest DL, 2015, DIS MODEL MECH, V8, P421, DOI 10.1242/dmm.017236
   Francis PJ, 2009, INVEST OPHTH VIS SCI, V50, P3425, DOI 10.1167/iovs.08-2908
   Froen R, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/531579
   Gagliardi G, 2018, STEM CELL REP, V11, P665, DOI 10.1016/j.stemcr.2018.07.005
   Gamm DM, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000338
   Garber K, 2015, NAT BIOTECHNOL, V33, P890, DOI 10.1038/nbt0915-890
   Gonzalez-Cordero A, 2013, NAT BIOTECHNOL, V31, P741, DOI 10.1038/nbt.2643
   GOURAS P, 1984, AN ACAD BRAS CIENC, V56, P431
   Gouras P., 2009, CURRENT EYE RES, V4, P253
   Hartong DT, 2006, LANCET, V368, P1795, DOI 10.1016/S0140-6736(06)69740-7
   Heavner W, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a008391
   Hsiung J, 2015, STEM CELL TRANSL MED, V4, P10, DOI 10.5966/sctm.2014-0205
   Hu YT, 2012, OPHTHALMIC RES, V48, P186, DOI 10.1159/000338749
   Huang YM, 2011, STEM CELL REV REP, V7, P434, DOI 10.1007/s12015-010-9192-8
   Hynes SR, 2010, GRAEF ARCH CLIN EXP, V248, P763, DOI 10.1007/s00417-009-1263-7
   Idelson M, 2009, CELL STEM CELL, V5, P396, DOI 10.1016/j.stem.2009.07.002
   Ilmarinen T, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0143669
   Inoue Y, 2007, EXP EYE RES, V85, P234, DOI 10.1016/j.exer.2007.04.007
   Iraha S, 2018, STEM CELL REP, V10, P1059, DOI 10.1016/j.stemcr.2018.01.032
   Jung YH, 2018, ADV MATER, V30, DOI 10.1002/adma.201803550
   Kador KE, 2012, EXPERT REV OPHTHALMO, V7, P459, DOI 10.1586/EOP.12.56
   Kamao H, 2014, STEM CELL REP, V2, P205, DOI 10.1016/j.stemcr.2013.12.007
   Kashani AH, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aao4097
   Keegan DJ, 2003, INVEST OPHTH VIS SCI, V44, P3526, DOI 10.1167/iovs.02-0097
   Kiilgaard Jens Folke, 2012, Stem Cells Int, V2012, P716968, DOI 10.1155/2012/716968
   Kuriyan AE, 2017, NEW ENGL J MED, V376, P1047, DOI 10.1056/NEJMoa1609583
   Kuwahara A, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7286
   Lakowski J, 2018, STEM CELLS, V36, P709, DOI 10.1002/stem.2775
   Lakowski J, 2015, STEM CELLS, V33, P2469, DOI 10.1002/stem.2051
   Lamba DA, 2006, P NATL ACAD SCI USA, V103, P12769, DOI 10.1073/pnas.0601990103
   Lamba DA, 2009, CELL STEM CELL, V4, P73, DOI 10.1016/j.stem.2008.10.015
   Lawrence JM, 2000, INVEST OPHTH VIS SCI, V41, P518
   Leach LL, 2015, STEM CELLS, V33, P2363, DOI 10.1002/stem.2010
   Leach LL, 2015, INVEST OPHTH VIS SCI, V56, P1002, DOI 10.1167/iovs.14-15835
   Liao JL, 2010, HUM MOL GENET, V19, P4229, DOI 10.1093/hmg/ddq341
   Lidgerwood GE, 2016, STEM CELL REV REP, V12, P179, DOI 10.1007/s12015-015-9636-2
   Little CW, 1996, INVEST OPHTH VIS SCI, V37, P204
   LOPEZ R, 1989, INVEST OPHTH VIS SCI, V30, P586
   Lu B, 2009, STEM CELLS, V27, P2126, DOI 10.1002/stem.149
   Lund RD, 2007, STEM CELLS, V25, P602, DOI 10.1634/stemcells.2006-0308
   Lund RD, 2006, CLONING STEM CELLS, V8, P189, DOI 10.1089/clo.2006.8.189
   Lustremant C, 2013, CELL REPROGRAM, V15, P233, DOI 10.1089/cell.2012.0076
   MacLaren RE, 2006, NATURE, V444, P203, DOI 10.1038/nature05161
   Maminishkis A, 2006, INVEST OPHTH VIS SCI, V47, P3612, DOI 10.1167/iovs.05-1622
   Mandai M, 2017, NEW ENGL J MED, V376, P1038, DOI 10.1056/NEJMoa1608368
   Mandai M, 2017, STEM CELL REP, V8, P69, DOI 10.1016/j.stemcr.2016.12.008
   Maruotti J, 2015, P NATL ACAD SCI USA, V112, P10950, DOI 10.1073/pnas.1422818112
   McGill TJ, 2012, EUR J NEUROSCI, V35, P468, DOI 10.1111/j.1460-9568.2011.07970.x
   Melville H, 2013, J TRANSL MED, V11, DOI 10.1186/1479-5876-11-53
   MULLEN RJ, 1976, SCIENCE, V192, P799, DOI 10.1126/science.1265483
   Nakano T, 2012, CELL STEM CELL, V10, P771, DOI 10.1016/j.stem.2012.05.009
   Nandrot EF, 2010, ADV EXP MED BIOL, V664, P133, DOI 10.1007/978-1-4419-1399-9_16
   Nazari H, 2015, PROG RETIN EYE RES, V48, P1, DOI 10.1016/j.preteyeres.2015.06.004
   Ohlemacher S. K., 2015, CURR PROTOC STEM CEL, V32, DOI DOI 10.1002/9780470151808.SC01H08S32
   Parfitt DA, 2016, CELL STEM CELL, V18, P769, DOI 10.1016/j.stem.2016.03.021
   Pearson RA, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13029
   Pearson RA, 2012, NATURE, V485, P99, DOI 10.1038/nature10997
   Pennington BO, 2016, J OCUL PHARMACOL TH, V32, P261, DOI 10.1089/jop.2015.0153
   Phillips S. J., 2009, CURRENT EYE RES, V26, P81
   Pinilla I, 2007, EXP EYE RES, V85, P381, DOI 10.1016/j.exer.2007.06.002
   Radtke ND, 2002, AM J OPHTHALMOL, V133, P544, DOI 10.1016/S0002-9394(02)01322-3
   Radtke ND, 2008, AM J OPHTHALMOL, V146, P172, DOI 10.1016/j.ajo.2008.04.009
   Ramsden CM, 2013, DEVELOPMENT, V140, P2576, DOI 10.1242/dev.092270
   Reichman S, 2017, STEM CELLS, V35, P1176, DOI 10.1002/stem.2586
   Reichman S, 2014, P NATL ACAD SCI USA, V111, P8518, DOI 10.1073/pnas.1324212111
   Riera M, 2016, MOL THER-METH CLIN D, V3, DOI 10.1038/mtm.2016.10
   Russell S, 2017, LANCET, V390, P849, DOI 10.1016/S0140-6736(17)31868-8
   Sahel J. A., 2015, COLD SPRING HARB PER, V5
   Salero E, 2012, CELL STEM CELL, V10, P88, DOI 10.1016/j.stem.2011.11.018
   Santos-Ferreira T, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13028
   Santos-Ferreira T, 2016, INVEST OPHTH VIS SCI, V57, P3509, DOI 10.1167/iovs.16-19087
   Santos-Ferreira TF, 2017, FRONT SYST NEUROSCI, V10, DOI 10.3389/fnsys.2016.00105
   Schraermeyer U, 1997, EXP EYE RES, V65, P277, DOI 10.1006/exer.1997.0339
   Schraermeyer U, 1999, INVEST OPHTH VIS SCI, V40, P1545
   Schwartz SD, 2016, INVEST OPHTH VIS SCI, V57, DOI 10.1167/iovs.15-18681
   Schwartz SD, 2015, LANCET, V385, P509, DOI 10.1016/S0140-6736(14)61376-3
   Schwartz SD, 2012, LANCET, V379, P713, DOI 10.1016/S0140-6736(12)60028-2
   SHENG Y, 1995, INVEST OPHTH VIS SCI, V36, P381
   Shirai H, 2016, P NATL ACAD SCI USA, V113, pE81, DOI 10.1073/pnas.1512590113
   Singh MS, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13537
   Singh MS, 2013, P NATL ACAD SCI USA, V110, P1101, DOI 10.1073/pnas.1119416110
   Singh RK, 2015, STEM CELLS DEV, V24, P2778, DOI 10.1089/scd.2015.0144
   Singh R, 2013, INVEST OPHTH VIS SCI, V54, P6767, DOI 10.1167/iovs.13-11943
   Sohn EH, 2015, SCI REP-UK, V5, DOI 10.1038/srep11791
   Song MJ, 2016, BRAIN RES, V1638, P2, DOI 10.1016/j.brainres.2015.12.011
   Song WK, 2015, STEM CELL REP, V4, P860, DOI 10.1016/j.stemcr.2015.04.005
   Sonoda S, 2010, AGING-US, V2, P28, DOI 10.18632/aging.100111
   Sparrrow JR, 2010, CURR MOL MED, V10, P802
   Stanzel BV, 2014, STEM CELL REP, V2, P64, DOI 10.1016/j.stemcr.2013.11.005
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Streilein JW, 2002, VISION RES, V42, P487, DOI 10.1016/S0042-6989(01)00185-7
   Takahashi K, 2007, CELL, V131, P861, DOI 10.1016/j.cell.2007.11.019
   Taylor CJ, 2005, LANCET, V366, P2019, DOI 10.1016/S0140-6736(05)67813-0
   Taylor CJ, 2012, CELL STEM CELL, V11, P147, DOI 10.1016/j.stem.2012.07.014
   Tezel TH, 2004, INVEST OPHTH VIS SCI, V45, P3337, DOI 10.1167/iovs.04-0193
   Thackaberry EA, 2017, INVEST OPHTH VIS SCI, V58, P4274, DOI 10.1167/iovs.16-21334
   Thomson JA, 1998, SCIENCE, V282, P1145, DOI 10.1126/science.282.5391.1145
   Thumann G., 2009, CURRENT EYE RES, V16, P1236
   Thumann G, 2009, GRAEF ARCH CLIN EXP, V247, P363, DOI 10.1007/s00417-008-0998-x
   Tropepe V, 2000, SCIENCE, V287, P2032, DOI 10.1126/science.287.5460.2032
   Tsukamoto A, 2013, STEM CELL RES THER, V4, DOI [10.1186/1757-6512-4-102, 10.1186/scrt313]
   Verbakel SK, 2018, PROG RETIN EYE RES, V66, P157, DOI 10.1016/j.preteyeres.2018.03.005
   Vugler A, 2008, EXP NEUROL, V214, P347, DOI 10.1016/j.expneurol.2008.09.007
   Wang JJ, 1998, BRIT J OPHTHALMOL, V82, P743, DOI 10.1136/bjo.82.7.743
   Wang SM, 2008, INVEST OPHTH VIS SCI, V49, P3201, DOI 10.1167/iovs.08-1831
   Weisz JM, 1999, RETINA-J RET VIT DIS, V19, P540, DOI 10.1097/00006982-199911000-00011
   Welby E, 2017, STEM CELL REP, V9, P1898, DOI 10.1016/j.stemcr.2017.10.018
   Wilmut I, 2015, REGEN MED, V10, P235, DOI [10.2217/rme.15.1, 10.2217/RME.15.1]
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wu J, 2016, CELL, V166, P1371, DOI 10.1016/j.cell.2016.08.008
   Xu HP, 2009, PROG RETIN EYE RES, V28, P348, DOI 10.1016/j.preteyeres.2009.06.001
   Xu RM, 1996, P NATL ACAD SCI USA, V93, P6308, DOI 10.1073/pnas.93.13.6308
   Zarbin M, 2016, TRENDS MOL MED, V22, P115, DOI 10.1016/j.molmed.2015.12.007
   Zarbin MA, 2010, RETINA-J RET VIT DIS, V30, P1350, DOI 10.1097/IAE.0b013e3181f57e30
   Zhang XY, 1998, INVEST OPHTH VIS SCI, V39, P1021
   Zhong XF, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5047
   Zhou SF, 2015, DEVELOPMENT, V142, P3294, DOI 10.1242/dev.125385
   Zhu M, 1998, AUST NZ J OPHTHALMOL, V26, pS50, DOI 10.1111/j.1442-9071.1998.tb01371.x
NR 165
TC 18
Z9 19
U1 0
U2 5
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1687-966X
EI 1687-9678
J9 STEM CELLS INT
JI Stem Cells Int.
PD JAN 23
PY 2019
VL 2019
AR 4568979
DI 10.1155/2019/4568979
PG 14
WC Cell & Tissue Engineering
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA IS4CP
UT WOS:000482101200001
PM 30809263
OA Green Published, gold, Green Submitted
DA 2022-11-30
ER

PT J
AU Wang, J
   Gong, HM
   Zou, HH
   Liang, L
   Wu, XY
AF Wang, Jing
   Gong, Hui-Min
   Zou, Hui-Hui
   Liang, Ling
   Wu, Xin-Yi
TI Isorhamnetin prevents H2O2-induced oxidative stress in human retinal
   pigment epithelial cells
SO MOLECULAR MEDICINE REPORTS
LA English
DT Article
DE age-related macular degeneration; isorhamnetin; retinal pigment
   epithelium cells; oxidative stress
ID PROTECTS ARPE-19 CELLS; MACULAR DEGENERATION; ERK INACTIVATION;
   UP-REGULATION; RPE CELLS; APOPTOSIS; DAMAGE; ACTIVATION; PI3K/AKT;
   EXPRESSION
AB Isorhamnetin, a 3-O-methylated metabolite of quercetin, exhibits antioxidant effects. However, to the best of our knowledge, no study to date has focused on the effects of isorhamnetin on retinal pigment epithelium (RPE) cells, and its underlying molecular mechanisms. Therefore, the present study aimed to examine the potential protective effect of isorhamnetin against oxidative stress in human RPE cells. The results demonstrated that pretreatment of RPE cells with isorhamnetin significantly protected cell viability against oxidative stress. In addition, isorhamnetin pretreatment inhibited hydrogen peroxide (H2O2)-induced reactive oxygen species (ROS) production and caspase-3 activation in RPE cells. Furthermore, isorhamnetin pretreatment significantly increased the phosphorylation of phosphoinositide 3-kinase (PI3K) and AKT serine/threonine kinase 1 (Akt) in RPE cells exposed to H2O2, compared with cells treated with H2O2 alone. Taken together, the present results demonstrated that isorhamnetin protected human RPE cells from oxidative stress-induced cell death, and this effect was associated with activation of the PI3K/Akt signaling pathway. Thus, isorhamnetin may be considered as a potential antioxidant useful for the prevention of age-related macular degeneration.
C1 [Wang, Jing; Wu, Xin-Yi] Shandong Univ, Dept Ophthalmol, Qi Lu Hosp, 107 Culture West Rd, Jinan 250012, Shandong, Peoples R China.
   [Wang, Jing; Zou, Hui-Hui; Liang, Ling] Dezhou Peoples Hosp, Dept Ophthalmol, Dezhou 253014, Shandong, Peoples R China.
   [Gong, Hui-Min] Qingdao Municipal Hosp, Ophthalm Ctr, Qingdao 266000, Shandong, Peoples R China.
C3 Shandong University; Qingdao Municipal Hospital
RP Wu, XY (通讯作者)，Shandong Univ, Dept Ophthalmol, Qi Lu Hosp, 107 Culture West Rd, Jinan 250012, Shandong, Peoples R China.
EM wuxyoph@163.com
CR Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Bouhlel I, 2009, DRUG CHEM TOXICOL, V32, P258, DOI 10.1080/01480540902882192
   Cai JY, 2000, PROG RETIN EYE RES, V19, P205, DOI 10.1016/S1350-9462(99)00009-9
   Chen TL, 2015, INT J CLIN EXP PATHO, V8, P2311
   Choi YH, 2016, GEN PHYSIOL BIOPHYS, V35, P145, DOI 10.4149/gpb_2015034
   Congdon NG, 2003, JAMA-J AM MED ASSOC, V290, P2057, DOI 10.1001/jama.290.15.2057
   Curcio CA, 2015, INVEST OPHTH VIS SCI, V56
   Drobek-Slowik Monika, 2007, Postepy Hig Med Dosw (Online), V61, P28
   Faghiri Z, 2010, EXP EYE RES, V90, P718, DOI 10.1016/j.exer.2010.03.002
   Hanneken A, 2006, INVEST OPHTH VIS SCI, V47, P3164, DOI 10.1167/iovs.04-1369
   Janicke RU, 1998, J BIOL CHEM, V273, P9357, DOI 10.1074/jbc.273.16.9357
   Jarrett SG, 2012, MOL ASPECTS MED, V33, P399, DOI 10.1016/j.mam.2012.03.009
   Kim Min-Ho, 2003, Korean J Ophthalmol, V17, P19
   Kong CS, 2009, FOOD CHEM TOXICOL, V47, P1914, DOI 10.1016/j.fct.2009.05.002
   Kook D, 2008, INVEST OPHTH VIS SCI, V49, P1712, DOI 10.1167/iovs.07-0477
   Li ZR, 2013, MOL VIS, V19, P1656
   Liang FQ, 2003, EXP EYE RES, V76, P397, DOI 10.1016/S0014-4835(03)00023-X
   Luo Y, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0120259
   /Ophthalmology and the Ageing Society, 2013, OPHTHALMOLOGY AGEING, P1, DOI DOI 10.1007/978-3-642-36324-5_1
   PARK JC, 1995, PLANTA MED, V61, P377, DOI 10.1055/s-2006-958110
   Porter AG, 1999, CELL DEATH DIFFER, V6, P99, DOI 10.1038/sj.cdd.4400476
   Saud SM, 2013, CANCER RES, V73, P5473, DOI 10.1158/0008-5472.CAN-13-0525
   Sreekumar PG, 2005, BIOCHEM BIOPH RES CO, V334, P245, DOI 10.1016/j.bbrc.2005.06.081
   Sun B, 2012, J CELL BIOCHEM, V113, P473, DOI 10.1002/jcb.23371
   Wang RK, 2015, INT J MOL SCI, V16, P22350, DOI 10.3390/ijms160922350
   Yang JH, 2014, TOXICOL APPL PHARM, V274, P293, DOI 10.1016/j.taap.2013.10.026
   Yang P, 2006, INVEST OPHTH VIS SCI, V47, P4598, DOI 10.1167/iovs.06-0140
   Zha X, 2015, CELL PHYSIOL BIOCHEM, V36, P2217, DOI 10.1159/000430186
   Zhang NJ, 2011, EXP TOXICOL PATHOL, V63, P33, DOI 10.1016/j.etp.2009.09.005
NR 29
TC 16
Z9 21
U1 2
U2 10
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1791-2997
EI 1791-3004
J9 MOL MED REP
JI Mol. Med. Rep.
PD JAN
PY 2018
VL 17
IS 1
BP 648
EP 652
DI 10.3892/mmr.2017.7916
PG 5
WC Oncology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Research & Experimental Medicine
GA FT8WG
UT WOS:000423433300085
PM 29115489
OA Bronze
DA 2022-11-30
ER

PT J
AU Al-Nawaiseh, S
   Thieltges, F
   Liu, ZP
   Strack, C
   Brinken, R
   Braun, N
   Wolschendorf, M
   Maminishkis, A
   Eter, N
   Stanzel, BV
AF Al-Nawaiseh, Sami
   Thieltges, Fabian
   Liu, Zengping
   Strack, Claudine
   Brinken, Ralf
   Braun, Norbert
   Wolschendorf, Marc
   Maminishkis, Arvydas
   Eter, Nicole
   Stanzel, Boris V.
TI A Step by Step Protocol for Subretinal Surgery in Rabbits
SO JOVE-JOURNAL OF VISUALIZED EXPERIMENTS
LA English
DT Article
DE Medicine; Issue 115; age-related macular degeneration; cell carrier;
   cell replacement; SD-OCT; pluripotent stem cells; rabbit; retinal
   pigment epithelium; vitreoretinal surgery; transplantation; tissue
   engineering; vitrectomy
ID ARTIFICIAL RETINAL-DETACHMENT; PIGMENT EPITHELIAL-CELLS; BRUCHS
   MEMBRANE; TRANSPLANTATION; RPE; SPACE; SHEETS; FLUID; IMPLANTATION;
   SCAFFOLDS
AB Age related macular degeneration (AMD), retinitis pigmentosa, and other RPE related diseases are the most common causes for irreversible loss of vision in adults in industrially developed countries. RPE transplantation appears to be a promising therapy, as it may replace dysfunctional RPE, restore its function, and thereby vision.
   Here we describe a method for transplanting a cultured RPE monolayer on a scaffold into the subretinal space (SRS) of rabbits. After vitrectomy xenotransplants were delivered into the SRS using a custom made shooter consisting of a 20-gauge metallic nozzle with a polytetrafluoroethylene (PTFE) coated plunger. The current technique evolved in over 150 rabbit surgeries over 6 years. Post-operative follow-up can be obtained using non-invasive and repetitive in vivo imaging such as spectral domain optical coherence tomography (SD-OCT) followed by perfusion-fixed histology.
   The method has well-defined steps for easy learning and high success rate. Rabbits are considered a large eye animal model useful in preclinical studies for clinical translation. In this context rabbits are a cost-efficient and perhaps convenient alternative to other large eye animal models.
C1 [Al-Nawaiseh, Sami; Thieltges, Fabian; Liu, Zengping; Strack, Claudine; Brinken, Ralf; Stanzel, Boris V.] Boston Univ, Dept Ophthalmol, Boston, MA 02215 USA.
   [Liu, Zengping] Natl Univ Singapore, Dept Ophthalmol, Singapore 117548, Singapore.
   [Braun, Norbert; Wolschendorf, Marc] Geuder AG, Heidelberg, Germany.
   [Eter, Nicole] Univ Munster, Dept Ophthalmol, Munster, Germany.
   [Maminishkis, Arvydas] NEI, Sect Epithelial & Retinal Physiol & Dis, NIH, Bethesda, MD 20892 USA.
   [Stanzel, Boris V.] Singapore Natl Eye Ctr, Surg Retina Dept, Singapore, Singapore.
C3 Boston University; National University of Singapore; University of
   Munster; National Institutes of Health (NIH) - USA; NIH National Eye
   Institute (NEI); Singapore National Eye Center
RP Stanzel, BV (通讯作者)，Boston Univ, Dept Ophthalmol, Boston, MA 02215 USA.; Stanzel, BV (通讯作者)，Singapore Natl Eye Ctr, Surg Retina Dept, Singapore, Singapore.
EM stanzel@uni-bonn.de
RI Stanzel, Boris/ADP-9221-2022; Liu, Zengping/GQO-9030-2022; Stanzel,
   Boris/AAG-7010-2022
OI Stanzel, Boris/0000-0002-4316-1539; Stanzel, Boris/0000-0002-4316-1539;
   Liu, Zengping/0000-0002-2578-293X; Maminishkis,
   Arvydas/0000-0003-3345-3375
FU Rudiger Foundation; BONFOR/Gerok Scholarship [O-137.0015, O-137.0019];
   Deutsche Forschungsgemeinschaft/DFG [STA 1135/2-1]; Chinese Scholarship
   Council [2008627116]; Geuder AG, Heidelberg; NATIONAL EYE INSTITUTE
   [ZIAEY000456] Funding Source: NIH RePORTER
FX Supported by Rudiger Foundation grants in 2008 & 2010 (BVS),
   BONFOR/Gerok Scholarship O-137.0015 (BVS), BONFOR/Gerok Scholarship
   O-137.0019 (FT), Deutsche Forschungsgemeinschaft/DFG (BVS) STA 1135/2-1,
   Chinese Scholarship Council No. 2008627116 (ZL) and an unrestricted
   grant by Geuder AG, Heidelberg (Fig. 2). Members of H. Skottman's
   laboratory, University of Tampere Finland are gratefully acknowledged
   for providing hES derived RPE shown in Fig 2.
CR AORN Recommended Practices Committee, 2006, AORN J, V83, P402
   BHATT NS, 1994, AM J OPHTHALMOL, V117, P214, DOI 10.1016/S0002-9394(14)73079-X
   Binder S, 2007, PROG RETIN EYE RES, V26, P516, DOI 10.1016/j.preteyeres.2007.02.002
   Blenkinsop TA, 2012, REGEN MED, V7, P32, DOI [10.2217/RME.12.77, 10.2217/rme.12.77]
   Boochoon KS, 2014, J BIOMECH, V47, P3237, DOI 10.1016/j.jbiomech.2014.06.021
   Brantfernandes R. A., 2012, INVEST OPHTH VIS SCI, V53, P312
   Carr AJF, 2013, TRENDS NEUROSCI, V36, P385, DOI 10.1016/j.tins.2013.03.006
   da Cruz L, 2007, PROG RETIN EYE RES, V26, P598, DOI 10.1016/j.preteyeres.2007.07.001
   Del Priore LV, 2006, PROG RETIN EYE RES, V25, P539, DOI 10.1016/j.preteyeres.2006.08.001
   Del Priore LV, 2004, INVEST OPHTH VIS SCI, V45, P985, DOI 10.1167/iovs.03-0662
   Fang XY, 2001, AM J OPHTHALMOL, V131, P481, DOI 10.1016/S0002-9394(00)00899-0
   Faude F, 2001, INVEST OPHTH VIS SCI, V42, P1328
   FINE AM, 1986, ARCH OPHTHALMOL-CHIC, V104, P513
   FRAMBACH DA, 1982, INVEST OPHTH VIS SCI, V22, P292
   Gouras P., 1998, RETINAL PIGMENT EPIT, P492
   Hirami Y, 2009, NEUROSCI LETT, V458, P126, DOI 10.1016/j.neulet.2009.04.035
   Holz FG, 2014, OPHTHALMOLOGY, V121, P1079, DOI 10.1016/j.ophtha.2013.11.023
   Hong SB, 2002, ANESTH ANALG, V94, P157, DOI 10.1097/00000539-200201000-00030
   Hynes SR, 2010, GRAEF ARCH CLIN EXP, V248, P763, DOI 10.1007/s00417-009-1263-7
   IVERSON DA, 1991, ARCH OPHTHALMOL-CHIC, V109, P405, DOI 10.1001/archopht.1991.01080030107048
   Ivert L, 2002, GRAEF ARCH CLIN EXP, V240, P232, DOI 10.1007/s00417-001-0392-4
   Jha B. S., 2015, CURR STEM CELL REP, P1
   Kamao H, 2014, STEM CELL REP, V2, P205, DOI 10.1016/j.stemcr.2013.12.007
   KITA M, 1992, INVEST OPHTH VIS SCI, V33, P23
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Liu ZP, 2014, BIOMATERIALS, V35, P2837, DOI 10.1016/j.biomaterials.2013.12.069
   Los LI, 1999, EXP EYE RES, V69, P343, DOI 10.1006/exer.1999.0708
   Lu B, 2012, BIOMED MICRODEVICES, V14, P659, DOI 10.1007/s10544-012-9645-8
   Lund RD, 2001, PROG RETIN EYE RES, V20, P415, DOI 10.1016/S1350-9462(01)00003-9
   MACHEMER R, 1995, GRAEF ARCH CLIN EXP, V233, P453, DOI 10.1007/BF00183425
   MARMOR MF, 1990, EYE, V4, P340, DOI 10.1038/eye.1990.46
   MARMOR MF, 1980, INVEST OPHTH VIS SCI, V19, P893
   Montezuma SR, 2006, INVEST OPHTH VIS SCI, V47, P3514, DOI 10.1167/iovs.06-0106
   Nicolini J, 2000, ACTA OPHTHALMOL SCAN, V78, P527, DOI 10.1034/j.1600-0420.2000.078005527.x
   Pritchard CD, 2010, BIOMATERIALS, V31, P7978, DOI 10.1016/j.biomaterials.2010.07.026
   Schwartz SD, 2015, LANCET, V385, P509, DOI 10.1016/S0140-6736(14)61376-3
   Seiler MJ, 1998, INVEST OPHTH VIS SCI, V39, P2121
   Stanzel BV, 2010, INVEST OPHTH VIS SCI, V51
   Stanzel BV, 2014, STEM CELL REP, V2, P64, DOI 10.1016/j.stemcr.2013.11.005
   Stanzel BV, 2012, INVEST OPHTH VIS SCI, V53, P490, DOI 10.1167/iovs.11-8260
   Szurman P, 2005, ARCH OPHTHALMOL-CHIC, V123, P964, DOI 10.1001/archopht.123.7.964
   Szurman P, 2006, INVEST OPHTH VIS SCI, V47, P4983, DOI 10.1167/iovs.06-0491
   Thieltges F, 2015, INVEST OPHTH VIS SCI, V56
   Thumann G, 2009, BIOMATERIALS, V30, P287, DOI 10.1016/j.biomaterials.2008.09.039
   Vaajasaari H, 2011, MOL VIS, V17, P558
NR 45
TC 15
Z9 18
U1 1
U2 5
PU JOURNAL OF VISUALIZED EXPERIMENTS
PI CAMBRIDGE
PA 1 ALEWIFE CENTER, STE 200, CAMBRIDGE, MA 02140 USA
SN 1940-087X
J9 JOVE-J VIS EXP
JI J. Vis. Exp.
PD SEP
PY 2016
IS 115
AR e53927
DI 10.3791/53927
PG 8
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA EP3GC
UT WOS:000397269800040
PM 27684952
OA Green Published
DA 2022-11-30
ER

PT J
AU Kam, JH
   Morgan, JE
   Jeffery, G
AF Kam, Jaimie Hoh
   Morgan, James E.
   Jeffery, Glen
TI Aged complement factor H knockout mice kept in a clean barriered
   environment have reduced retinal pathology
SO EXPERIMENTAL EYE RESEARCH
LA English
DT Article
DE Age-related macular degeneration; Factor H; Pathogens; Inflammation
ID TUMOR-NECROSIS-FACTOR; C-REACTIVE PROTEIN; PHOTORECEPTOR CELL LOSS;
   MACULAR DEGENERATION; ALZHEIMERS-DISEASE; AMYLOID-BETA;
   BACTERIAL-INFECTION; SYNAPTIC PLASTICITY; BRUCHS MEMBRANE; ROD TERMINALS
AB Age-related macular degeneration (AMD) is the largest cause of visual loss in those over 60 years in the West and is a condition increasing in prevalence. Many diseases result from genetic/environmental interactions and 50% of AMD cases have an association with polymorphisms of the complement system including complement factor H. Here we explore interactions between genetic predisposition and environmental conditions in triggering retinal pathology in two groups of aged complement factor H knock out (Cfh(-/-)) mice. Mice were maintained over 9 months in either a conventional open environment or a barriered pathogen free environment. Open environment Cfh(-/-) mice had significant increases in subretinal macrophage numbers, inflammatory and stress responses and reduced photoreceptor numbers over mice kept in a pathogen free environment. Hence, environmental factors can drive retinal disease in these mice when linked to complement deficits impairing immune function. Both groups of mice had similar levels of retinal amyloid beta accumulation. Consequently there is no direct link between this and inflammation in Cfh(-/-) mice. (C) 2016 Elsevier Ltd. All rights reserved.
C1 [Kam, Jaimie Hoh; Jeffery, Glen] UCL, Inst Ophthalmol, 11-43 Bath St, London EC1V 9EL, England.
   [Morgan, James E.] Cardiff Univ, Sch Optometry & Visual Sci, Cardiff CF10 3AX, S Glam, Wales.
C3 University of London; University College London; Cardiff University
RP Jeffery, G (通讯作者)，UCL, Inst Ophthalmol, 11-43 Bath St, London EC1V 9EL, England.
EM g.jeffery@ucl.ac.uk
RI Morgan, James/GRO-2905-2022
OI Morgan, James/0000-0002-8920-1065
FU Rosetrees Trust; BBSRC [BB/N000250/1]; Biotechnology and Biological
   Sciences Research Council [BB/N000250/1] Funding Source: researchfish
FX This research was supported by The Rosetrees Trust and the BBSRC No.
   BB/N000250/1. We thank Ian Catchpole for his assistance with this
   project. We would also like to thank GSK and Matthew Pickering for the
   genotype information and the provision of some of the mice used in this
   study.
CR Aartsen WM, 2006, HUM MOL GENET, V15, P1291, DOI 10.1093/hmg/ddl047
   Alexander JJ, 2005, J AM SOC NEPHROL, V16, P52, DOI 10.1681/ASN.2004090778
   Arora T, 2009, CYTOKINE, V45, P124, DOI 10.1016/j.cyto.2008.11.008
   Barker RA, 1996, EXP NEUROL, V141, P79, DOI 10.1006/exnr.1996.0141
   Bian ZM, 1999, CURR EYE RES, V18, P349, DOI 10.1076/ceyr.18.5.349.5353
   BLANKS JC, 1983, J COMP NEUROL, V221, P31, DOI 10.1002/cne.902210103
   Booij JC, 2010, PROG RETIN EYE RES, V29, P1, DOI 10.1016/j.preteyeres.2009.08.003
   BROUCKAERT P, 1993, IMMUNOBIOLOGY, V187, P317, DOI 10.1016/S0171-2985(11)80347-5
   CARTERDAWSON LD, 1979, J COMP NEUROL, V188, P263, DOI 10.1002/cne.901880205
   CARTERDAWSON LD, 1979, J COMP NEUROL, V188, P245, DOI 10.1002/cne.901880204
   Catchpole I, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065518
   Chiang PK, 2008, CURR MOL MED, V8, P580, DOI 10.2174/156652408785747951
   Cipriani V, 2012, IMMUNOBIOLOGY, V217, P158, DOI 10.1016/j.imbio.2011.09.002
   Coffey PJ, 2007, P NATL ACAD SCI USA, V104, P16651, DOI 10.1073/pnas.0705079104
   Cunea A., 2014, NEROBIOL AGING
   Cunea A, 2007, VISUAL NEUROSCI, V24, P151, DOI 10.1017/S0952523807070204
   Curcio CA, 2013, STRUCTURE FUNCTION P
   Dinarello CA, 1996, BLOOD, V87, P2095, DOI 10.1182/blood.V87.6.2095.bloodjournal8762095
   Ding JD, 2008, VISION RES, V48, P339, DOI 10.1016/j.visres.2007.07.025
   Ding JD, 2011, P NATL ACAD SCI USA, V108, pE279, DOI 10.1073/pnas.1100901108
   Dunaief JL, 2002, ARCH OPHTHALMOL-CHIC, V120, P1435, DOI 10.1001/archopht.120.11.1435
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   ELNER SG, 1991, LAB INVEST, V64, P819
   Cestari JAF, 2016, J ALZHEIMERS DIS, V52, P1479, DOI 10.3233/JAD-160212
   Fisher SK, 2005, PROG RETIN EYE RES, V24, P395, DOI 10.1016/j.preteyeres.2004.10.004
   Francis PJ, 2011, CLIN OPHTHALMOL, V5, P1127, DOI 10.2147/OPTH.S11627
   Francis PJ, 2005, BRIT J OPHTHALMOL, V89, P70, DOI 10.1136/bjo.2004.042416
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Graymore C., 1969, BIOCH EYE
   Guymer R, 1999, PROG RETIN EYE RES, V18, P59, DOI 10.1016/S1350-9462(98)00012-3
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Harris SA, 2015, J ALZHEIMERS DIS, V48, P319, DOI 10.3233/JAD-142853
   Haverkamp S, 2006, J NEUROSCI, V26, P5248, DOI 10.1523/JNEUROSCI.4483-05.2006
   Hippert C, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0120415
   Ho T, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029892
   Holder GE, 2005, BRIT J OPHTHALMOL, V89, P709, DOI 10.1136/bjo.2004.047837
   Holmes C, 2009, CNS DRUGS, V23, P993, DOI 10.2165/11310910-000000000-00000
   Ide M, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0151081
   Itzhaki RF, 2016, J ALZHEIMERS DIS, V51, P979, DOI 10.3233/JAD-160152
   JANSEN HG, 1992, J COMP NEUROL, V316, P117, DOI 10.1002/cne.903160110
   Jekabsone A, 2006, J NEUROINFLAMM, V3, DOI 10.1186/1742-2094-3-24
   Johnson LV, 2002, P NATL ACAD SCI USA, V99, P11830, DOI 10.1073/pnas.192203399
   Johnson PT, 2006, P NATL ACAD SCI USA, V103, P17456, DOI 10.1073/pnas.0606234103
   Kam JH, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013127
   Kaymakcalan Z, 2009, CLIN IMMUNOL, V131, P308, DOI 10.1016/j.clim.2009.01.002
   Kim S.-Y., 2015, MACROPHAGE, V2, pe698
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klein R, 2008, OPHTHALMOLOGY, V115, P1742, DOI 10.1016/j.ophtha.2008.03.021
   Lesne S, 2006, NATURE, V440, P352, DOI 10.1038/nature04533
   Lotz M, 2005, J NEUROCHEM, V94, P289, DOI 10.1111/j.1471-4159.2005.03188.x
   Maheshwari P, 2015, J ALZHEIMERS DIS, V43, P957, DOI 10.3233/JAD-140621
   Mander PK, 2006, J IMMUNOL, V176, P1046, DOI 10.4049/jimmunol.176.2.1046
   Mantel I, 2008, EXP MOL PATHOL, V84, P90, DOI 10.1016/j.yexmp.2007.10.006
   MARCH CJ, 1985, NATURE, V315, P641, DOI 10.1038/315641a0
   McGraw J, 2001, J NEUROSCI RES, V63, P109, DOI 10.1002/1097-4547(20010115)63:2<109::AID-JNR1002>3.0.CO;2-J
   McGwin G, 2005, BRIT J OPHTHALMOL, V89, P1166, DOI 10.1136/bjo.2005.067397
   Medeiros R, 2013, EXP NEUROL, V239, P133, DOI 10.1016/j.expneurol.2012.10.007
   Miklossy J, 2016, AGING-US, V8, P575, DOI 10.18632/aging.100921
   Mitoma H, 2004, GASTROENTEROLOGY, V126, P934, DOI 10.1053/j.gastro.2004.01.036
   Mitoma H, 2008, ARTHRITIS RHEUM-US, V58, P1248, DOI 10.1002/art.23447
   MOCHIZUKI DY, 1987, P NATL ACAD SCI USA, V84, P5267, DOI 10.1073/pnas.84.15.5267
   Neniskyte U, 2014, FEBS LETT, V588, P2952, DOI 10.1016/j.febslet.2014.05.046
   OPPENHEIM JJ, 1986, IMMUNOL TODAY, V7, P45, DOI 10.1016/0167-5699(86)90124-6
   Parihar MS, 2010, J ALZHEIMERS DIS, V22, P741, DOI 10.3233/JAD-2010-101020
   PENFOLD PL, 1985, GRAEF ARCH CLIN EXP, V223, P69, DOI 10.1007/BF02150948
   PEREZ C, 1990, CELL, V63, P251, DOI 10.1016/0092-8674(90)90158-B
   Perry VH, 2010, NAT REV NEUROL, V6, P193, DOI 10.1038/nrneurol.2010.17
   Pisa D, 2015, J ALZHEIMERS DIS, V43, P613, DOI 10.3233/JAD-141386
   Puzzo D, 2012, NEUROBIOL AGING, V33, DOI 10.1016/j.neurobiolaging.2011.12.020
   Robman L, 2010, OPHTHALMOLOGY, V117, P1982, DOI 10.1016/j.ophtha.2010.02.003
   Rodrigues EB, 2007, OPHTHALMOLOGICA, V221, P143, DOI 10.1159/000099293
   SANYAL S, 1992, DEVELOPMENT, V114, P797
   Sasaki Y, 2001, BIOCHEM BIOPH RES CO, V286, P292, DOI 10.1006/bbrc.2001.5388
   Schaumberg DA, 2006, INVEST OPHTH VIS SCI, V47, P2336, DOI 10.1167/iovs.05-1456
   Scholl HPN, 2000, SURV OPHTHALMOL, V45, P29, DOI 10.1016/S0039-6257(00)00125-9
   Schroder K, 2010, CELL, V140, P821, DOI 10.1016/j.cell.2010.01.040
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P774, DOI 10.1001/archopht.123.6.774
   Seddon JM, 2004, JAMA-J AM MED ASSOC, V291, P704, DOI 10.1001/jama.291.6.704
   Steel AJ, 2015, J ALZHEIMERS DIS, V47, P351, DOI 10.3233/JAD-140822
   Teeling JL, 2009, NEUROSCIENCE, V158, P1062, DOI 10.1016/j.neuroscience.2008.07.031
   Vingerling JR, 1996, ARCH OPHTHALMOL-CHIC, V114, P1193, DOI 10.1001/archopht.1996.01100140393005
   von Leithner PL, 2009, AM J PATHOL, V175, P412, DOI 10.2353/ajpath.2009.080927
   Walter S, 2007, CELL PHYSIOL BIOCHEM, V20, P947, DOI 10.1159/000110455
NR 86
TC 8
Z9 8
U1 0
U2 2
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0014-4835
EI 1096-0007
J9 EXP EYE RES
JI Exp. Eye Res.
PD AUG
PY 2016
VL 149
BP 116
EP 125
DI 10.1016/j.exer.2016.07.002
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DT1HB
UT WOS:000381231200014
PM 27397653
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Pekel, G
   Acer, S
   Cetin, EN
   Yagci, R
   Kasikci, A
   Cevik, A
AF Pekel, Gokhan
   Acer, Semra
   Cetin, Ebru Nevin
   Yagci, Ramazan
   Kasikci, Alper
   Cevik, Ali
TI Ocular pulse amplitude and retinal vessel caliber changes after
   intravitreal ranibizumab
SO INTERNATIONAL OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; Intraocular pressure; Intravitreal
   injection; Ocular pulse amplitude; Ranibizumab; Retinal vessel caliber
ID BLOOD-FLOW; MACULAR DEGENERATION; BEVACIZUMAB AVASTIN(R); INJECTIONS
AB The purpose of the present study was to examine the effects of intravitreal ranibizumab on ocular pulse amplitude (OPA) and retinal vessel caliber (RVC) in wet age-related macular degeneration (AMD). Thirty-two eyes of 32 wet AMD patients were included in this case series. Three consecutive monthly injections of ranibizumab were performed. The OPA was measured with the Pascal dynamic contour tonometer. RVC measurements were taken with spectral-domain optical coherence tomography. Pre-injection mean OPA value was 2.55 +/- A 0.76 mmHg and post-injections mean OPA value was 2.79 +/- A 0.88 mmHg at the last visit (p = 0.10). Pre-injection mean arteriole and venule RVC were 96.7 +/- A 9.4 and 125.9 +/- A 8.4 A mu m; while post-injections arteriole and venule RVC were 96.0 +/- A 8.7 and 125.6 +/- A 8.9 A mu m, respectively (p > 0.05). OPA and RVC are unchanged after triple intravitreal ranibizumab injections, indicating that this treatment does not significantly alter gross retina-choroidal vasculature and hemodynamics.
C1 [Pekel, Gokhan; Acer, Semra; Cetin, Ebru Nevin; Yagci, Ramazan; Kasikci, Alper] Pamukkale Univ, Dept Ophthalmol, TR-20070 Denizli, Turkey.
   [Cevik, Ali] Tatvan State Hosp, Eye Clin, Bitlis, Turkey.
C3 Pamukkale University; Tatvan State Hospital
RP Pekel, G (通讯作者)，Pamukkale Univ, Dept Ophthalmol, TR-20070 Denizli, Turkey.
EM gkhanpekel@yahoo.com
RI cetin, ebru/AAF-2986-2020; Pekel, Gökhan/AAW-3343-2021
OI Acer, Semra/0000-0002-4956-3774
CR Adelman RA, 2010, J OCUL PHARMACOL TH, V26, P105, DOI 10.1089/jop.2009.0076
   Bonnin P, 2010, ACTA OPHTHALMOL, V88, P641, DOI 10.1111/j.1755-3768.2009.01526.x
   Chen SJ, 2001, BRIT J OPHTHALMOL, V85, P1411, DOI 10.1136/bjo.85.12.1411
   Chen YX, 2012, THER CLIN RISK MANAG, V8, P343, DOI 10.2147/TCRM.S32801
   Costagliola C, 2012, EXPERT OPIN BIOL TH, V12, P1299, DOI 10.1517/14712598.2012.707176
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Gaudreault J, 2005, INVEST OPHTH VIS SCI, V46, P726, DOI 10.1167/iovs.04-0601
   Good TJ, 2011, BRIT J OPHTHALMOL, V95, P1111, DOI 10.1136/bjo.2010.180729
   Hoffmann Esther M, 2004, BMC Ophthalmol, V4, P4
   Hosseini H, 2012, RETINA-J RET VIT DIS, V32, P967, DOI 10.1097/IAE.0b013e31822c28d6
   Jaffe GJ, 2013, OPHTHALMOLOGY, V120, P1860, DOI 10.1016/j.ophtha.2013.01.073
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Kaiser PK, 2007, AM J OPHTHALMOL, V144, P850, DOI 10.1016/j.ajo.2007.08.012
   Kovach JL, 2012, J OPHTHALMOL, V2012, DOI 10.1155/2012/786870
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Mendrinos E, 2013, ACTA OPHTHALMOL, V91, pE184, DOI 10.1111/aos.12008
   Mori F, 2001, BRIT J OPHTHALMOL, V85, P531, DOI 10.1136/bjo.85.5.531
   Panos GD, 2013, DRUG DES DEV THER, V7, P565, DOI 10.2147/DDDT.S46610
   Pemp B, 2008, CAN J OPHTHALMOL, V43, P295, DOI 10.3129/i08-049
   Pierro L, 2012, CLIN OPHTHALMOL, V6, P219, DOI 10.2147/OPTH.S27656
   Punjabi OS, 2006, CLIN EXP OPHTHALMOL, V34, P837, DOI 10.1111/j.1442-9071.2006.01389.x
   Rechtman E, 2011, CLIN OPHTHALMOL, V5, P37, DOI 10.2147/OPTH.S15810
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sandhu R, 2007, EYE, V21, P506, DOI 10.1038/sj.eye.6702242
   Semeraro F, 2011, CURR VASC PHARMACOL, V9, P629, DOI 10.2174/157016111796642670
   Sobaci G, 2013, INT J OPHTHALMOL-CHI, V6, P211, DOI 10.3980/j.issn.2222-3959.2013.02.20
   Wickremasinghe SS, 2012, EYE, V26, P958, DOI 10.1038/eye.2012.72
   Wickremasinghe SS, 2012, CLIN EXP OPHTHALMOL, V40, P59, DOI 10.1111/j.1442-9071.2011.02613.x
NR 29
TC 5
Z9 5
U1 0
U2 2
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0165-5701
EI 1573-2630
J9 INT OPHTHALMOL
JI Int. Ophthalmol.
PD OCT
PY 2015
VL 35
IS 5
BP 657
EP 662
DI 10.1007/s10792-014-9991-z
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CQ1UV
UT WOS:000360386500011
PM 25186317
DA 2022-11-30
ER

PT J
AU Charvet, CD
   Saadane, A
   Wang, MY
   Salomon, RG
   Brunengraber, H
   Turko, IV
   Pikuleva, IA
AF Charvet, Casey D.
   Saadane, Aicha
   Wang, Meiyao
   Salomon, Robert G.
   Brunengraber, Henri
   Turko, Illarion V.
   Pikuleva, Irina A.
TI Pretreatment with Pyridoxamine Mitigates Isolevuglandin-associated
   Retinal Effects in Mice Exposed to Bright Light
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID INDUCED PHOTORECEPTOR DEGENERATION; 4-HYDROXYNONENAL PROTEIN ADDUCTS;
   LIPID-PEROXIDATION; GAMMA-KETOALDEHYDES; ISOPROSTANE PATHWAY;
   LIPOXIDATION REACTIONS; MOLECULAR-MECHANISMS; PIGMENT EPITHELIUM;
   ADVANCED GLYCATION; OXIDATIVE DAMAGE
AB The benefits of antioxidant therapy for treating age-related macular degeneration, a devastating retinal disease, are limited. Perhaps species other than reactive oxygen intermediates should be considered as therapeutic targets. These could be lipid peroxidation products, including isolevuglandins (isoLGs), prototypical and extraordinarily reactive gamma-ketoaldehydes that avidly bind to proteins, phospholipids, and DNA and modulate the properties of these biomolecules. We found isoLG adducts in aged human retina but not in the retina of mice kept under dim lighting. Hence, to test whether scavenging of isoLGs could complement or supplant antioxidant therapy, we exposed mice to bright light and found that this insult leads to retinal isoLG-adduct formation. We then pretreated mice with pyridoxamine, a B-6 vitamer and efficient scavenger of gamma-ketoaldehydes, and found that the levels of retinal isoLG adducts are decreased, and morphological changes in photoreceptor mitochondria are not as pronounced as in untreated animals. Our study demonstrates that preventing the damage to biomolecules by lipid peroxidation products, a novel concept in vision research, is a viable strategy to combat oxidative stress in the retina.
C1 [Charvet, Casey D.; Saadane, Aicha; Pikuleva, Irina A.] Case Western Reserve Univ, Dept Ophthalmol & Visual Sci, Cleveland, OH 44106 USA.
   [Salomon, Robert G.] Case Western Reserve Univ, Dept Chem, Cleveland, OH 44106 USA.
   [Brunengraber, Henri] Case Western Reserve Univ, Dept Nutr, Cleveland, OH 44106 USA.
   [Wang, Meiyao; Turko, Illarion V.] Inst Biosci & Biotechnol Res, Rockville, MD 20850 USA.
   [Wang, Meiyao; Turko, Illarion V.] NIST, Div Analyt Chem, Gaithersburg, MD 20899 USA.
C3 Case Western Reserve University; Case Western Reserve University; Case
   Western Reserve University; National Institute of Standards & Technology
   (NIST) - USA
RP Pikuleva, IA (通讯作者)，Case Western Reserve Univ, Dept Ophthalmol & Visual Sci, 2085 Adelbert Rd,Rm 303, Cleveland, OH 44106 USA.
EM iap8@case.edu
OI Saadane, Aicha/0000-0001-9985-2147; Salomon, Robert/0000-0001-9456-3557;
   Pikuleva, Irina/0000-0001-9742-6232
FU National Institutes of Health [EY018383, GM21249, R33DK070291,
   T32-EY007157]; Visual Sciences Research Center [P30 EY11373]; Jules and
   Doris Stein Research Professorship from Research to Prevent Blindness;
   NATIONAL EYE INSTITUTE [R01EY018383, R01EY016813, P30EY011373,
   T32EY007157] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF
   DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R33DK070291] Funding Source:
   NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES
   [R01GM021249] Funding Source: NIH RePORTER
FX This work was supported, in whole or in part, by National Institutes of
   Health Grants EY018383 (to I.A.P.), GM21249 (to R.G.S.), and R33DK070291
   (to H.B.), and Visual Sciences Research Center Core Grant P30 EY11373.
   This work was also supported by the Jules and Doris Stein Research
   Professorship from Research to Prevent Blindness (to I.A.P.).; Recipient
   of a fellowship from the National Institutes of Health (Training Grant
   T32-EY007157).
CR Bachmanov AA, 2002, BEHAV GENET, V32, P435, DOI 10.1023/A:1020884312053
   Bacot S, 2003, J LIPID RES, V44, P917, DOI 10.1194/jlr.M200450-JLR200
   BASU AK, 1984, MUTAT RES, V129, P39, DOI 10.1016/0027-5107(84)90121-0
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Ben-Shabat S, 2002, J BIOL CHEM, V277, P7183, DOI 10.1074/jbc.M108981200
   Brame CJ, 1999, J BIOL CHEM, V274, P13139, DOI 10.1074/jbc.274.19.13139
   Caldes C, 2011, CHEM BIODIVERS, V8, P1318, DOI 10.1002/cbdv.201000296
   Charvet C, 2011, J BIOL CHEM, V286, P20413, DOI 10.1074/jbc.M111.232546
   Charvet CD, 2013, J LIPID RES, V54, P1421, DOI 10.1194/jlr.M035790
   Chen L, 2004, EXP EYE RES, V79, P239, DOI 10.1016/j.exer.2004.05.002
   Chew EY, 2009, ARCH OPHTHALMOL-CHIC, V127, P1678, DOI 10.1001/archophthalmol.2009.312
   Clayton PT, 2006, J INHERIT METAB DIS, V29, P317, DOI 10.1007/s10545-005-0243-2
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Dalle-Donne I, 2006, CLIN CHEM, V52, P601, DOI 10.1373/clinchem.2005.061408
   Davies SS, 2006, BIOCHEMISTRY-US, V45, P15756, DOI 10.1021/bi061860g
   Davies SS, 2011, J ALZHEIMERS DIS, V27, P49, DOI 10.3233/JAD-2011-102118
   Davies SS, 2004, CHEM PHYS LIPIDS, V128, P85, DOI 10.1016/j.chemphyslip.2003.10.007
   Degenhardt TP, 2002, KIDNEY INT, V61, P939, DOI 10.1046/j.1523-1755.2002.00207.x
   DEXTER DT, 1989, J NEUROCHEM, V52, P381, DOI 10.1111/j.1471-4159.1989.tb09133.x
   DIFRANCO E, 1995, CHEM RES TOXICOL, V8, P61, DOI 10.1021/tx00043a008
   Donovan M, 2001, J BIOL CHEM, V276, P23000, DOI 10.1074/jbc.M005359200
   Ebrahem Q, 2006, P NATL ACAD SCI USA, V103, P13480, DOI 10.1073/pnas.0601552103
   EDER E, 1990, ENVIRON HEALTH PERSP, V88, P99, DOI 10.2307/3431058
   ELDRED GE, 1993, NATURE, V364, P396
   ESTERBAUER H, 1993, AM J CLIN NUTR, V57, P779, DOI 10.1093/ajcn/57.5.779S
   ESTERBAUER H, 1991, FREE RADICAL BIO MED, V11, P81, DOI 10.1016/0891-5849(91)90192-6
   Feher J, 2006, NEUROBIOL AGING, V27, P983, DOI 10.1016/j.neurobiolaging.2005.05.012
   FLIESLER SJ, 1983, PROG LIPID RES, V22, P79
   Fukuda K, 2005, CIRC RES, V97, P1262, DOI 10.1161/01.RES.0000195844.31466.e9
   Galluzzi L, 2013, ONCOGENE, V32, P4995, DOI 10.1038/onc.2012.623
   Govindarajan B, 2008, BIOCHEMISTRY-US, V47, P817, DOI 10.1021/bi701517m
   Govindarajan B, 2009, MOL VIS, V15, P1079
   Gu XR, 2003, J BIOL CHEM, V278, P42027, DOI 10.1074/jbc.M305460200
   GULCAN HG, 1993, INVEST OPHTH VIS SCI, V34, P3187
   HABERLAND ME, 1988, SCIENCE, V241, P215, DOI 10.1126/science.2455346
   Hahn P, 2004, MOL VIS, V10, P598
   HENNIG B, 1988, FREE RADICAL BIO MED, V4, P99, DOI 10.1016/0891-5849(88)90070-6
   Hirai K, 2001, J NEUROSCI, V21, P3017, DOI 10.1523/JNEUROSCI.21-09-03017.2001
   Hoang QV, 2002, VISUAL NEUROSCI, V19, P395, DOI 10.1017/S0952523802194028
   Hollyfield JG, 2008, NAT MED, V14, P194, DOI 10.1038/nm1709
   HOUGLUM K, 1990, J CLIN INVEST, V86, P1991, DOI 10.1172/JCI114934
   HUNT RC, 1992, J CELL PHYSIOL, V152, P102, DOI 10.1002/jcp.1041520114
   Imanishi Y, 2008, J BIOL CHEM, V283, P25091, DOI 10.1074/jbc.M802981200
   Jump DB, 2012, J LIPID RES, V53, P2525, DOI 10.1194/jlr.R027904
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kaur K, 1997, CHEM RES TOXICOL, V10, P1387, DOI 10.1021/tx970112c
   Keeney PM, 2006, J NEUROSCI, V26, P5256, DOI 10.1523/JNEUROSCI.0984-06.2006
   Kris-Etherton PM, 2004, CIRCULATION, V110, P637, DOI 10.1161/01.CIR.0000137822.39831.F1
   Krishnadev N, 2010, CURR OPIN OPHTHALMOL, V21, P184, DOI 10.1097/ICU.0b013e32833866ee
   Lambert AJ, 2009, METHODS MOL BIOL, V554, P165, DOI 10.1007/978-1-59745-521-3_11
   LAVAIL MM, 1987, CURR EYE RES, V6, P825, DOI 10.3109/02713688709034850
   Levin L. A., 2011, ADLERS PHYSL EYE CLI, P243
   Lewis EJ, 2012, J AM SOC NEPHROL, V23, P131, DOI 10.1681/ASN.2011030272
   Li W, 2009, FREE RADICAL BIO MED, V47, P1539, DOI 10.1016/j.freeradbiomed.2009.09.003
   Liao WL, 2008, ANAL BIOCHEM, V377, P55, DOI 10.1016/j.ab.2008.03.016
   Liton PB, 2008, INVEST OPHTH VIS SCI, V49, P3961, DOI 10.1167/iovs.08-1915
   Maeda A, 2008, J BIOL CHEM, V283, P26684, DOI 10.1074/jbc.M804505200
   Maeda A, 2012, NAT CHEM BIOL, V8, P170, DOI 10.1038/nchembio.759
   Malek G, 2003, AM J PATHOL, V162, P413, DOI 10.1016/S0002-9440(10)63836-9
   Marchette LD, 2010, FREE RADICAL BIO MED, V48, P16, DOI 10.1016/j.freeradbiomed.2009.08.005
   Markesbery WR, 1998, NEUROBIOL AGING, V19, P33, DOI 10.1016/S0197-4580(98)00009-8
   Metz TO, 2003, ARCH BIOCHEM BIOPHYS, V419, P41, DOI 10.1016/j.abb.2003.08.021
   Morris MC, 2002, JAMA-J AM MED ASSOC, V287, P3230, DOI 10.1001/jama.287.24.3230
   Noell W K, 1966, Invest Ophthalmol, V5, P450
   Ohishi K, 2005, FREE RADICAL RES, V39, P875, DOI 10.1080/10715760500177807
   Ohishi K, 2006, FREE RADICAL RES, V40, P799, DOI 10.1080/10715760600555027
   Omarova S, 2012, J CLIN INVEST, V122, P3012, DOI 10.1172/JCI63816
   Onorato JM, 2000, J BIOL CHEM, V275, P21177, DOI 10.1074/jbc.M003263200
   Ortega-Castro J, 2012, J PHYS CHEM A, V116, P2961, DOI 10.1021/jp210188w
   Pascolini D, 2004, OPHTHAL EPIDEMIOL, V11, P67, DOI 10.1076/opep.11.2.67.28158
   Poliakov E, 2003, FASEB J, V17, P2209, DOI 10.1096/fj.03-0086com
   RIMINGTON C, 1965, LANCET, V1, P624
   Roca A, 2004, NEUROSCIENCE, V129, P779, DOI 10.1016/j.neuroscience.2004.08.021
   Rodriguez IR, 2009, PHOTOCHEM PHOTOBIOL, V85, P1116, DOI 10.1111/j.1751-1097.2009.00568.x
   Sakai N, 1996, J AM CHEM SOC, V118, P1559, DOI 10.1021/ja953480g
   Salomon R G, 1985, Adv Prostaglandin Thromboxane Leukot Res, V15, P323
   Salomon RG, 1999, J BIOL CHEM, V274, P20271, DOI 10.1074/jbc.274.29.20271
   Salomon RG, 2000, TRENDS CARDIOVAS MED, V10, P53, DOI 10.1016/S1050-1738(00)00040-2
   Salomon RG, 1997, CHEM RES TOXICOL, V10, P750, DOI 10.1021/tx970016b
   Sayre LM, 1997, J NEUROCHEM, V68, P2092
   Sha W, 2000, J ORG CHEM, V65, P5315, DOI 10.1021/jo000537v
   Siems WG, 1996, FREE RADICAL BIO MED, V20, P215, DOI 10.1016/0891-5849(95)02041-1
   Smith RS, 2002, RES METH MUT M SER, P25
   Song DL, 2012, FREE RADICAL BIO MED, V53, P64, DOI 10.1016/j.freeradbiomed.2012.04.020
   Stavrovskaya IG, 2010, FREE RADICAL BIO MED, V49, P567, DOI 10.1016/j.freeradbiomed.2010.04.037
   Stitt A, 2002, DIABETES, V51, P2826, DOI 10.2337/diabetes.51.9.2826
   Stone J, 2008, BRAIN RES, V1189, P58, DOI 10.1016/j.brainres.2007.10.083
   Subbanagounder G, 1997, J ORG CHEM, V62, P7658, DOI 10.1021/jo970858f
   Sullivan CB, 2010, J LIPID RES, V51, P999, DOI 10.1194/jlr.M001040
   TANDLER B, 1972, ANAT REC, V173, P309, DOI 10.1002/ar.1091730306
   Tanito M, 2005, INVEST OPHTH VIS SCI, V46, P3859, DOI 10.1167/iovs.05-0672
   van der Ham M, 2012, ANAL CHIM ACTA, V712, P108, DOI 10.1016/j.aca.2011.11.018
   Wenzel A, 2005, PROG RETIN EYE RES, V24, P275, DOI 10.1016/j.preteyeres.2004.08.002
   Wenzel A, 2001, J NEUROSCI, V21, P53, DOI 10.1523/JNEUROSCI.21-01-00053.2001
   Williams ME, 2007, AM J NEPHROL, V27, P605, DOI 10.1159/000108104
   Xu LB, 2009, J AM CHEM SOC, V131, P13037, DOI 10.1021/ja9029076
   Yefimova MG, 2000, INVEST OPHTH VIS SCI, V41, P2343
   Yoritaka A, 1996, P NATL ACAD SCI USA, V93, P2696, DOI 10.1073/pnas.93.7.2696
   Yu DY, 2001, PROG RETIN EYE RES, V20, P175, DOI 10.1016/S1350-9462(00)00027-6
   Zagol-Ikapitte I, 2005, J NEUROCHEM, V94, P1140, DOI 10.1111/j.1471-4159.2005.03264.x
NR 100
TC 21
Z9 21
U1 0
U2 3
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
EI 1083-351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD OCT 11
PY 2013
VL 288
IS 41
BP 29267
EP 29280
DI 10.1074/jbc.M113.498832
PG 14
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA 302OT
UT WOS:000330615300007
PM 23970548
OA hybrid, Green Published
DA 2022-11-30
ER

PT J
AU Hyttinen, JMT
   Niittykoski, M
   Salminen, A
   Kaarniranta, K
AF Hyttinen, Juha M. T.
   Niittykoski, Minna
   Salminen, Antero
   Kaarniranta, Kai
TI Maturation of autophagosomes and endosomes: A key role for Rab7
SO BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH
LA English
DT Review
DE Rab7; Autophagy; Endocytosis; Trafficking; Maturation
ID SACCHAROMYCES-CEREVISIAE; ENDOCYTIC TRAFFICKING; GROWTH-FACTOR; PROTEIN;
   FUSION; GTPASE; PATHWAY; CELL; RECEPTOR; TARGET
AB Macroautophagy is an important route in cellular maintenance, in the breakdown and reuse of intracellular materials. It is closely related to endocytosis, the means by which the cell can absorb extracellular material, as both macroautophagy and endocytosis have converging steps and common participating molecules. The point where autophagosomes and endosomes fuse with lysosomes to permit for the final degradation of their contents is important. One of the most substantial molecules in the maturation of autophagosomes/endosomes is Rab7, a member of small GTPases. Rab7 designates the maturation of endosomes and also autophagosomes, directing the trafficking of cargos along microtubules, and finally, participating in the fusion step with lysosomes. Rab7 is an effective multifunctional regulator of autophagy and endocytosis. Since many aggregation-based diseases, e.g. age-related macular degeneration of the eye (AMD) and Alzheimer's disease are due of malfunctioning in the autophagic process, the management of Rab7 activity might hold potential as a therapeutic target against these diseases. (C) 2012 Elsevier B.V. All rights reserved.
C1 [Hyttinen, Juha M. T.; Kaarniranta, Kai] Univ Eastern Finland, Inst Clin Med, Dept Ophthalmol, FI-70211 Kuopio, Finland.
   [Niittykoski, Minna] Univ Eastern Finland, AI Virtanen Inst Mol Sci, Dept Biotechnol & Mol Med, FI-70211 Kuopio, Finland.
   [Salminen, Antero] Univ Eastern Finland, Inst Clin Med, Dept Neurol, FI-70211 Kuopio, Finland.
   [Salminen, Antero] Kuopio Univ Hosp, Dept Neurol, SF-70210 Kuopio, Finland.
   [Kaarniranta, Kai] Kuopio Univ Hosp, Dept Ophthalmol, SF-70210 Kuopio, Finland.
C3 University of Eastern Finland; University of Eastern Finland; University
   of Eastern Finland; Kuopio University Hospital; University of Eastern
   Finland; Kuopio University Hospital; University of Eastern Finland
RP Hyttinen, JMT (通讯作者)，Univ Eastern Finland, Inst Clin Med, Dept Ophthalmol, POB 1627, FI-70211 Kuopio, Finland.
EM Juha.Hyttinen@uef.fi
OI Hyttinen, Juha/0000-0002-3414-4032; Kaarniranta,
   Kai/0000-0003-2600-8679; Niittykoski, Minna/0000-0002-2816-9874
CR Agola JO, 2011, CLIN GENET, V80, P305, DOI 10.1111/j.1399-0004.2011.01724.x
   Agola JO, 2012, ACS CHEM BIOL, V7, P1095, DOI 10.1021/cb3001099
   Babst M, 2005, TRAFFIC, V6, P2, DOI 10.1111/j.1600-0854.2004.00246.x
   Berg TO, 1998, J BIOL CHEM, V273, P21883, DOI 10.1074/jbc.273.34.21883
   Binder B, 2012, CELL BIOCHEM BIOPHYS, V63, P59, DOI 10.1007/s12013-012-9341-6
   Brech A, 2009, MOL ONCOL, V3, P366, DOI 10.1016/j.molonc.2009.05.007
   Bridges D, 2012, J BIOL CHEM, V287, P20913, DOI 10.1074/jbc.M111.334060
   Bright NA, 2005, CURR BIOL, V15, P360, DOI 10.1016/j.cub.2005.01.049
   Bucci C, 2000, MOL BIOL CELL, V11, P467, DOI 10.1091/mbc.11.2.467
   Bug M, 2012, J STRUCT BIOL, V179, P78, DOI 10.1016/j.jsb.2012.03.003
   Cai QA, 2010, NEURON, V68, P73, DOI 10.1016/j.neuron.2010.09.022
   Cao Y, 2007, CELL RES, V17, P839, DOI 10.1038/cr.2007.78
   Ceresa BP, 2006, J BIOL CHEM, V281, P1099, DOI 10.1074/jbc.M504175200
   CHAVRIER P, 1990, CELL, V62, P317, DOI 10.1016/0092-8674(90)90369-P
   Chen W, 2005, J BIOL CHEM, V280, P40985, DOI 10.1074/jbc.M502190200
   Christoforidis S, 1999, NATURE, V397, P621, DOI 10.1038/17618
   Chua CEL, 2011, CELL MOL LIFE SCI, V68, P3349, DOI 10.1007/s00018-011-0748-9
   Eskelinen EL, 2005, AUTOPHAGY, V1, P1, DOI 10.4161/auto.1.1.1270
   Eskelinen EL, 2009, BBA-MOL CELL RES, V1793, P664, DOI 10.1016/j.bbamcr.2008.07.014
   Fader CM, 2008, TRAFFIC, V9, P230, DOI 10.1111/j.1600-0854.2007.00677.x
   FENG Y, 1995, J CELL BIOL, V131, P1435, DOI 10.1083/jcb.131.6.1435
   Fingar DC, 2004, ONCOGENE, V23, P3151, DOI 10.1038/sj.onc.1207542
   Flinn RJ, 2010, MOL BIOL CELL, V21, P833, DOI 10.1091/mbc.E09-09-0756
   Furuta N, 2010, MOL BIOL CELL, V21, P1001, DOI 10.1091/mbc.E09-08-0693
   Ganley IG, 2011, MOL CELL, V42, P731, DOI 10.1016/j.molcel.2011.04.024
   Gutierrez MG, 2004, J CELL SCI, V117, P2687, DOI 10.1242/jcs.01114
   HAAS A, 1995, EMBO J, V14, P5258, DOI 10.1002/j.1460-2075.1995.tb00210.x
   Harrison RE, 2003, MOL CELL BIOL, V23, P6494, DOI 10.1128/MCB.23.18.6494-6506.2003
   Hennig KM, 2006, J CELL BIOL, V173, P963, DOI 10.1083/jcb.200511140
   Huotari J, 2011, EMBO J, V30, P3481, DOI 10.1038/emboj.2011.286
   Hyttinen JMT, 2011, REJUV RES, V14, P651, DOI 10.1089/rej.2011.1220
   Jager S, 2004, J CELL SCI, V117, P4837, DOI 10.1242/jcs.01370
   Johansson M, 2005, MOL BIOL CELL, V16, P5480, DOI 10.1091/mbc.E05-03-0189
   Johansson M, 2007, J CELL BIOL, V176, P459, DOI 10.1083/jcb.200606077
   Kaarniranta K, 2011, J ALZHEIMERS DIS, V24, P615, DOI 10.3233/JAD-2011-101908
   Kaarniranta Kai, 2010, Front Biosci (Elite Ed), V2, P1374
   Kardon JR, 2009, NAT REV MOL CELL BIO, V10, P854, DOI 10.1038/nrm2804
   Kinchen JM, 2010, NATURE, V464, P778, DOI 10.1038/nature08853
   Klionsky DJ, 2011, AUTOPHAGY, V7, P1273, DOI 10.4161/auto.7.11.17661
   Klionsky DJ, 2000, SCIENCE, V290, P1717, DOI 10.1126/science.290.5497.1717
   Kroemer G, 2010, MOL CELL, V40, P280, DOI 10.1016/j.molcel.2010.09.023
   Kucharczyk R, 2009, FEMS YEAST RES, V9, P565, DOI 10.1111/j.1567-1364.2009.00515.x
   Kundu M, 2008, ANNU REV PATHOL-MECH, V3, P427, DOI 10.1146/annurev.pathmechdis.2.010506.091842
   Liang CY, 2008, AUTOPHAGY, V4, P817, DOI 10.4161/auto.6496
   Lin Mary Grace, 2011, Small GTPases, V2, P85
   Lin WJ, 2012, BIOCHEM BIOPH RES CO, V417, P35, DOI 10.1016/j.bbrc.2011.11.043
   Lindmo K, 2006, J CELL SCI, V119, P605, DOI 10.1242/jcs.02855
   Liou W, 1997, J CELL BIOL, V136, P61, DOI 10.1083/jcb.136.1.61
   Liu TT, 2012, MOL BIOL CELL, V23, P2505, DOI 10.1091/mbc.E11-11-0915
   Luzio JP, 2009, BIOCHEM SOC T, V37, P1019, DOI 10.1042/BST0371019
   Maday S, 2012, J CELL BIOL, V196, P407, DOI 10.1083/jcb.201106120
   McGough IJ, 2011, TRAFFIC, V12, P963, DOI 10.1111/j.1600-0854.2011.01201.x
   Mitra S, 2011, SEMIN CELL DEV BIOL, V22, P57, DOI 10.1016/j.semcdb.2010.12.005
   Mizuno K, 2003, MOL BIOL CELL, V14, P3741, DOI 10.1091/mbc.E02-08-0495
   Mizushima N, 2010, CELL, V140, P313, DOI 10.1016/j.cell.2010.01.028
   Ng EL, 2012, CELL BIOCHEM FUNCT, V30, P515, DOI 10.1002/cbf.2827
   Noda T, 2009, CELL DEATH DIFFER, V16, P984, DOI 10.1038/cdd.2009.54
   Nordmann M, 2010, CURR BIOL, V20, P1654, DOI 10.1016/j.cub.2010.08.002
   Ostrowicz CW, 2008, AUTOPHAGY, V4, P5, DOI 10.4161/auto.5054
   Pankiv S, 2010, J CELL BIOL, V188, P253, DOI 10.1083/jcb.200907015
   Pawelec A, 2010, EUKARYOT CELL, V9, P602, DOI 10.1128/EC.00286-09
   Peralta ER, 2010, J BIOL CHEM, V285, P16814, DOI 10.1074/jbc.M110.111633
   Poteryaev D, 2010, CELL, V141, P497, DOI 10.1016/j.cell.2010.03.011
   Press B, 1998, J CELL BIOL, V140, P1075, DOI 10.1083/jcb.140.5.1075
   Ravikumar B, 2008, J CELL SCI, V121, P1649, DOI 10.1242/jcs.025726
   Rink J, 2005, CELL, V122, P735, DOI 10.1016/j.cell.2005.06.043
   Rocha N, 2009, J CELL BIOL, V185, P1209, DOI 10.1083/jcb.200811005
   Russell MRG, 2006, CURR OPIN CELL BIOL, V18, P422, DOI 10.1016/j.ceb.2006.06.002
   Rusten TE, 2012, NAT CELL BIOL, V14, P38, DOI 10.1038/ncb2381
   Sancak Y, 2008, SCIENCE, V320, P1496, DOI 10.1126/science.1157535
   Scheffzek K, 2005, CELL MOL LIFE SCI, V62, P3014, DOI 10.1007/s00018-005-5136-x
   Schwartz SL, 2007, J CELL SCI, V120, P3905, DOI 10.1242/jcs.015909
   Shin HW, 2005, J CELL BIOL, V170, P607, DOI 10.1083/jcb.200505128
   Son JH, 2012, EXP MOL MED, V44, P89, DOI 10.3858/emm.2012.44.2.031
   Spang A, 2009, BIOL CHEM, V390, P753, DOI 10.1515/BC.2009.056
   Su HB, 2011, CIRCULATION, V124, P2117, DOI 10.1161/CIRCULATIONAHA.111.048934
   Su WC, 2011, J VIROL, V85, P10561, DOI 10.1128/JVI.00173-11
   Sun QM, 2010, P NATL ACAD SCI USA, V107, P19338, DOI 10.1073/pnas.1010554107
   Tabata K, 2010, MOL BIOL CELL, V21, P4162, DOI 10.1091/mbc.E10-06-0495
   Takahashi Y, 2012, BIOCHEM BIOPH RES CO, V417, P1151, DOI 10.1016/j.bbrc.2011.12.082
   Tong JJ, 2010, PROTEIN CELL, V1, P907, DOI 10.1007/s13238-010-0121-z
   Vale RD, 2003, CELL, V112, P467, DOI 10.1016/S0092-8674(03)00111-9
   Vanlandingham PA, 2009, J BIOL CHEM, V284, P12110, DOI 10.1074/jbc.M809277200
   Vieira OV, 2003, MOL CELL BIOL, V23, P2501, DOI 10.1128/MCB.23.7.2501-2514.2003
   Wang CW, 2002, J BIOL CHEM, V277, P47917, DOI 10.1074/jbc.M208191200
   Wang TL, 2006, BIOCHEM BIOPH RES CO, V350, P413, DOI 10.1016/j.bbrc.2006.09.064
   Wang TL, 2011, CELL SIGNAL, V23, P516, DOI 10.1016/j.cellsig.2010.09.012
   Wedaman KP, 2003, MOL BIOL CELL, V14, P1204, DOI 10.1091/mbc.E02-09-0609
   Wong E, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a006734
   Wurmser AE, 2000, J CELL BIOL, V151, P551, DOI 10.1083/jcb.151.3.551
   Zerial M, 2001, NAT REV MOL CELL BIO, V2, P107, DOI 10.1038/35052055
   Zhang XM, 2005, BIOCHEM BIOPH RES CO, V335, P154, DOI 10.1016/j.bbrc.2005.07.070
   Zucchi PC, 2011, MOL BIOL CELL, V22, P4635, DOI 10.1091/mbc.E11-08-0680
NR 93
TC 261
Z9 266
U1 3
U2 60
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0167-4889
EI 1879-2596
J9 BBA-MOL CELL RES
JI Biochim. Biophys. Acta-Mol. Cell Res.
PD MAR
PY 2013
VL 1833
IS 3
BP 503
EP 510
DI 10.1016/j.bbamcr.2012.11.018
PG 8
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA 095AY
UT WOS:000315308100008
PM 23220125
OA Bronze
DA 2022-11-30
ER

PT J
AU Liu, AH
   Lin, YH
   Terry, R
   Nelson, K
   Bernstein, PS
AF Liu, Aihua
   Lin, Yanhua
   Terry, Ryan
   Nelson, Kelly
   Bernstein, Paul S.
TI Role of long-chain and very-long-chain polyunsaturated fatty acids in
   macular degenerations and dystrophies
SO CLINICAL LIPIDOLOGY
LA English
DT Review
DE age-related macular degeneration (AMD); autosomal dominant Stargardt
   disease-3 (STGD3); elongation of very-long-chain fatty acids-like 4
   (ELOVL4); long-chain polyunsaturated fatty acid (LCPUFA);
   very-long-chain polyunsaturated fatty acid (VLCPUFA)
ID PERMEABILITY BARRIER FUNCTION; DIETARY DOCOSAHEXAENOIC ACID; AGE-RELATED
   MACULOPATHY; ELOVL4 TRANSGENIC MICE; APOPTOTIC CELL-DEATH;
   ARACHIDONIC-ACID; RETINAL DEGENERATION; NEUROPROTECTIN D1;
   EICOSAPENTAENOIC ACID; SYNAPTIC-TRANSMISSION
AB Macular degeneration is a progressive, bilateral eye disorder that damages the macula of the human eye. The most common form of macular degeneration is age-related macular degeneration (AMD), which is the leading cause of irreversible blindness in people older than 50 years in developed countries. Autosomal dominant Stargardt disease-3 (STGD3) is an inherited macular dystrophy that has clinical features similar to dry AMD, but occurs at a much earlier age. It is caused by a mutation in the elongation of very-long-chain fatty acids-like 4 (ELOVL4) gene, which is responsible for encoding the elongase enzyme that converts shorter chain fatty acids into C-28-C-38 very long-chain polyunsaturated fatty acids (VLCPUFAs, total number of carbons >= 24). Diets rich in long-chain polyunsaturated fatty acids (LCPUFAs) have inverse associations with the progression of AMD and STGD3, and a deficiency in retinal LCPUFAs and VLCPUFAs has been detected in AMD retinas and STGD3 animal models. This article systematically summarizes the roles of LCPUFAs and VLCPUFAs in AMD and STGD3, and discusses future research directions.
C1 [Liu, Aihua; Lin, Yanhua; Terry, Ryan; Nelson, Kelly; Bernstein, Paul S.] Univ Utah, Sch Med, Dept Ophthalmol & Visual Sci, Moran Eye Ctr, Salt Lake City, UT 84132 USA.
C3 Utah System of Higher Education; University of Utah
RP Bernstein, PS (通讯作者)，Univ Utah, Sch Med, Dept Ophthalmol & Visual Sci, Moran Eye Ctr, 65 Mario Capecchi Dr, Salt Lake City, UT 84132 USA.
EM paul.bernstein@hsc.utah.edu
FU Steinbach Foundation; Macula Vision Research Foundation; Foundation
   Fighting Blindness; Research to Prevent Blindness; NATIONAL EYE
   INSTITUTE [P30EY014800] Funding Source: NIH RePORTER
FX This work was supported by grants from the Steinbach Foundation, the
   Macula Vision Research Foundation, the Foundation Fighting Blindness,
   and a departmental grant from Research to Prevent Blindness. The authors
   have no other relevant affiliations or financial involvement with any
   organization or entity with a financial interest in or financial
   conflict with the subject matter or materials discussed in the
   manuscript apart from those disclosed.
CR Agbaga MP, 2008, P NATL ACAD SCI USA, V105, P12843, DOI 10.1073/pnas.0802607105
   Agbaga MP, 2010, ADV EXP MED BIOL, V664, P233, DOI 10.1007/978-1-4419-1399-9_27
   Ambasudhan R, 2004, GENOMICS, V83, P615, DOI 10.1016/j.ygeno.2003.10.004
   Ambati J, 2003, NAT MED, V9, P1390, DOI 10.1038/nm950
   Arita M, 2005, J EXP MED, V201, P713, DOI 10.1084/jem.20042031
   Augood C, 2008, AM J CLIN NUTR, V88, P398, DOI 10.1093/ajcn/88.2.398
   AVELDANO MI, 1992, ADV EXP MED BIOL, V318, P231
   AVELDANO MI, 1987, J BIOL CHEM, V262, P1172
   Barabas P, 2011, ASS RES VIS OPHTH 20
   Bazan NG, 2005, ANN NY ACAD SCI, V1053, P137, DOI 10.1196/annals.1344.011
   Bazan NG, 2005, MOL NEUROBIOL, V32, P89, DOI 10.1385/MN:32:1:089
   BAZAN NG, 1970, BIOCHIM BIOPHYS ACTA, V218, P1, DOI 10.1016/0005-2760(70)90086-X
   BAZAN NG, 1986, BIOCHEM BIOPH RES CO, V141, P600, DOI 10.1016/S0006-291X(86)80215-7
   Bazan NG, 2007, INVEST OPHTH VIS SCI, V48, P4866, DOI 10.1167/iovs.07-0918
   Bazan NG, 2007, CURR OPIN CLIN NUTR, V10, P136, DOI 10.1097/MCO.0b013e32802b7030
   Beatty S, 1999, BRIT J OPHTHALMOL, V83, P867, DOI 10.1136/bjo.83.7.867
   Bernstein PS, 2001, INVEST OPHTH VIS SCI, V42, P3331
   Bernstein PS., 1999, AGE RELATED MACULAR, V1
   Blom HM, 1997, CLIN EXP ALLERGY, V27, P796, DOI 10.1111/j.1365-2222.1997.tb01214.x
   Cameron DJ, 2007, INT J BIOL SCI, V3, P111
   CHAN PH, 1980, J NEUROCHEM, V35, P1004, DOI 10.1111/j.1471-4159.1980.tb07100.x
   Cho E, 2001, AM J CLIN NUTR, V73, P209
   Choudhary S, 2005, TOXICOL APPL PHARM, V204, P122, DOI 10.1016/j.taap.2004.08.023
   Chua B, 2006, ARCH OPHTHALMOL-CHIC, V124, P981, DOI 10.1001/archopht.124.7.981
   Conley YP, 2005, HUM MOL GENET, V14, P1991, DOI 10.1093/hmg/ddi204
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   DeAngelis MM, 2007, ARCH OPHTHALMOL-CHIC, V125, P49, DOI 10.1001/archopht.125.1.49
   Denic V, 2007, CELL, V130, P663, DOI 10.1016/j.cell.2007.06.031
   Edwards AO, 2001, INVEST OPHTH VIS SCI, V42, P2652
   Elner Victor M, 2002, Trans Am Ophthalmol Soc, V100, P301
   FLIESLER SJ, 1983, PROG LIPID RES, V22, P79
   FRASER DD, 1993, NEURON, V11, P633, DOI 10.1016/0896-6273(93)90075-3
   Gilroy DW, 1999, NAT MED, V5, P698, DOI 10.1038/9550
   Grayson C, 2005, J BIOL CHEM, V280, P32521, DOI 10.1074/jbc.M503411200
   Grimm C, 2000, NAT GENET, V25, P63, DOI 10.1038/75614
   Gu Hong, 2010, Zhonghua Yan Ke Za Zhi, V46, P125
   Gu XR, 2003, J BIOL CHEM, V278, P42027, DOI 10.1074/jbc.M305460200
   Hafezi F, 1997, NAT MED, V3, P346, DOI 10.1038/nm0397-346
   Hampton GR, 1992, PRINCIPLES PRACTICE
   Hanna N, 1997, FREE RADICAL BIO MED, V23, P885, DOI 10.1016/S0891-5849(97)00083-X
   Hubbard AF, 2006, ARCH OPHTHALMOL-CHIC, V124, P257, DOI 10.1001/archopht.124.2.257
   Ishikado A, 2010, BIOCHEM BIOPH RES CO, V402, P99, DOI 10.1016/j.bbrc.2010.09.124
   Kang JX, 2004, NATURE, V427, P504, DOI 10.1038/427504a
   Karan G, 2005, P NATL ACAD SCI USA, V102, P4164, DOI 10.1073/pnas.0407698102
   KEYSER DO, 1990, NEURON, V5, P545, DOI 10.1016/0896-6273(90)90092-T
   Koto T, 2007, INVEST OPHTH VIS SCI, V48, P4328, DOI 10.1167/iovs.06-1148
   Ladewig MS, 2005, PROSTAG LEUKOTR ESS, V72, P251, DOI 10.1016/j.plefa.2004.11.006
   Lai Z, 2005, J CELL MOL MED, V9, P961, DOI 10.1111/j.1582-4934.2005.tb00392.x
   Lewin AS, 1998, NAT MED, V4, P967, DOI 10.1038/nm0898-967
   Li F, 2001, EXP EYE RES, V73, P569, DOI 10.1006/exer.2001.1068
   Li F, 2009, MOL VIS, V15, P1185
   Li WM, 2007, INT J BIOL SCI, V3, P120
   Li WM, 2007, VISION RES, V47, P714, DOI 10.1016/j.visres.2006.10.023
   Liu AH, 2010, J LIPID RES, V51, P3217, DOI 10.1194/jlr.M007518
   Long EK, 2008, J NEUROCHEM, V105, P714, DOI 10.1111/j.1471-4159.2007.05175.x
   Lukiw WJ, 2005, J CLIN INVEST, V115, P2774, DOI 10.1172/JCI25420
   MacDonald IM, 2004, BRIT J OPHTHALMOL, V88, P305, DOI 10.1136/bjo.2003.024299
   Manev H, 1998, RESTOR NEUROL NEUROS, V12, P81
   MARESPERLMAN JA, 1995, ARCH OPHTHALMOL-CHIC, V113, P743, DOI 10.1001/archopht.1995.01100060069034
   Marmorstein AD, 2007, TRENDS GENET, V23, P225, DOI 10.1016/j.tig.2007.03.001
   Maugeri A, 2004, INVEST OPHTH VIS SCI, V45, P4263, DOI 10.1167/iovs.04-0078
   McMahon A, 2007, FEBS LETT, V581, P5459, DOI 10.1016/j.febslet.2007.10.050
   McMahon A, 2007, MOL VIS, V13, P258
   McMahon A, 2011, J LIPID RES, V52, P1128, DOI 10.1194/jlr.M014415
   McMahon A, 2010, BRIT J OPHTHALMOL, V94, P1127, DOI 10.1136/bjo.2008.149286
   MILLER B, 1992, NATURE, V355, P722, DOI 10.1038/355722a0
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Miyata T, 1998, FEBS LETT, V437, P24, DOI 10.1016/S0014-5793(98)01079-5
   Mizota A, 2001, INVEST OPHTH VIS SCI, V42, P216
   Monroig O, 2010, BBA-MOL CELL BIOL L, V1801, P1145, DOI 10.1016/j.bbalip.2010.06.005
   Mukherjee PK, 2004, P NATL ACAD SCI USA, V101, P8491, DOI 10.1073/pnas.0402531101
   Mukherjee PK, 2007, P NATL ACAD SCI USA, V104, P13152, DOI 10.1073/pnas.0705949104
   Musiek ES, 2008, J BIOL CHEM, V283, P19927, DOI 10.1074/jbc.M803625200
   Nanda BL, 2007, CURR TOP MED CHEM, V7, P765, DOI 10.2174/156802607780487623
   Okuda A, 2010, MOL VIS, V16, P2438
   OKUDA S, 1994, NEUROSCIENCE, V63, P691, DOI 10.1016/0306-4522(94)90515-0
   Organisciak DT, 1996, INVEST OPHTH VIS SCI, V37, P2243
   Orr SK, 2008, CURR OPIN INVEST DR, V9, P735
   Ouchi M, 2002, OPHTHALMOLOGICA, V216, P363, DOI 10.1159/000066178
   POULOS A, 1986, BIOCHEM J, V235, P607, DOI 10.1042/bj2350607
   POULOS A, 1986, BIOCHEM J, V240, P891, DOI 10.1042/bj2400891
   Raz-Prag D, 2006, INVEST OPHTH VIS SCI, V47, P3603, DOI 10.1167/iovs.05-1527
   Reichenbach A, 2007, GRAEF ARCH CLIN EXP, V245, P627, DOI 10.1007/s00417-006-0516-y
   Reme CE, 1998, PROG RETIN EYE RES, V17, P443, DOI 10.1016/S1350-9462(98)00009-3
   Roqueta-Rivera M, 2010, J LIPID RES, V51, P360, DOI 10.1194/jlr.M001180
   SANDERS TAB, 1993, AM J CLIN NUTR, V57, P428, DOI 10.1093/ajcn/57.3.428
   SanGiovanni JP, 2008, ARCH OPHTHALMOL-CHIC, V126, P1274, DOI 10.1001/archopht.126.9.1274
   SanGiovanni JP, 2007, ARCH OPHTHALMOL-CHIC, V125, P1225, DOI 10.1001/archopht.125.9.1225
   SanGiovanni JP, 2007, ARCH OPHTHALMOL-CHIC, V125, P671, DOI 10.1001/archopht.125.5.671
   SanGiovanni JP, 2009, AM J CLIN NUTR, V90, P1601, DOI 10.3945/ajcn.2009.27594
   SanGiovanni JP, 2005, PROG RETIN EYE RES, V24, P87, DOI 10.1016/j.preteyeres.2004.06.002
   Scholl S, 2010, OPHTHALMOLOGICA, V224, P8, DOI 10.1159/000315155
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1728, DOI 10.1001/archopht.121.12.1728
   Seddon JM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1191, DOI 10.1001/archopht.119.8.1191
   Seddon JM, 2006, ARCH OPHTHALMOL-CHIC, V124, P995, DOI 10.1001/archopht.124.7.995
   Seitsonen S, 2006, MOL VIS, V12, P796
   Serhan CN, 2004, LIPIDS, V39, P1125, DOI 10.1007/s11745-004-1339-7
   Serhan CN, 2005, CURR OPIN CLIN NUTR, V8, P115, DOI 10.1097/00075197-200503000-00003
   Serhan CN, 2002, J EXP MED, V196, P1025, DOI 10.1084/jem.20020760
   Simonian NA, 1996, ANNU REV PHARMACOL, V36, P83, DOI 10.1146/annurev.pa.36.040196.000503
   Smith W, 2000, ARCH OPHTHALMOL-CHIC, V118, P401, DOI 10.1001/archopht.118.3.401
   SNODDERLY DM, 1995, AM J CLIN NUTR, V62, P1448
   Song WL, 2008, J BIOL CHEM, V283, P6, DOI 10.1074/jbc.M706124200
   Suh M, 2005, CURR EYE RES, V30, P959, DOI 10.1080/02713680500246957
   Tan JSL, 2009, ARCH OPHTHALMOL-CHIC, V127, P656, DOI 10.1001/archophthalmol.2009.76
   Tang DG, 1996, P NATL ACAD SCI USA, V93, P5241, DOI 10.1073/pnas.93.11.5241
   Tian HB, 2009, INVEST OPHTH VIS SCI, V50, P3613, DOI 10.1167/iovs.08-3146
   Topol EJ, 2006, HUM MOL GENET, V15, pR117, DOI 10.1093/hmg/ddl183
   Tuo JS, 2009, AM J PATHOL, V175, P799, DOI 10.2353/ajpath.2009.090089
   Uchida Y, 2008, J DERMATOL SCI, V51, P77, DOI 10.1016/j.jdermsci.2008.01.002
   Vasireddy V, 2007, HUM MOL GENET, V16, P471, DOI 10.1093/hmg/ddl480
   Vasireddy V, 2006, INVEST OPHTH VIS SCI, V47, P4558, DOI 10.1167/iovs.06-0353
   Vasireddy V, 2010, PROG RETIN EYE RES, V29, P191, DOI 10.1016/j.preteyeres.2010.01.001
   VOLTERRA A, 1992, J NEUROCHEM, V59, P600, DOI 10.1111/j.1471-4159.1992.tb09411.x
   Vrabec TR, 2003, AM J OPHTHALMOL, V136, P542, DOI 10.1016/S0002-9394(03)00227-7
   WILLIAMS JH, 1989, NATURE, V341, P739, DOI 10.1038/341739a0
   Zack DJ, 1999, MOL VIS, V5, pU37
   Zhang K, 2001, NAT GENET, V27, P89, DOI 10.1038/83817
   Zhang XM, 2003, MOL VIS, V9, P301
NR 119
TC 6
Z9 6
U1 0
U2 13
PU FUTURE MEDICINE LTD
PI LONDON
PA UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3
   1QB, ENGLAND
SN 1758-4299
EI 1758-4302
J9 CLIN LIPIDOL
JI Clin. Lipidol.
PD OCT
PY 2011
VL 6
IS 5
BP 593
EP 613
DI 10.2217/CLP.11.41
PG 21
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA 847NH
UT WOS:000296979100013
PM 25324899
OA Bronze, Green Accepted
DA 2022-11-30
ER

PT J
AU Loh, A
   Hadziahmetovic, M
   Dunaief, JL
AF Loh, Allison
   Hadziahmetovic, Majda
   Dunaief, Joshua L.
TI Iron homeostasis and eye disease
SO BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS
LA English
DT Review
DE Iron; Retina; Cornea; Lens; Chelator; Oxidative stress
ID HYPERFERRITINEMIA CATARACT SYNDROME; HEREDITARY OPTIC NEUROPATHY;
   RETINAL GANGLION-CELLS; LENS EPITHELIAL-CELLS; FACTOR-H POLYMORPHISM;
   HUDSON-STAHLI LINE; OXIDATIVE STRESS; MACULAR DEGENERATION;
   LIPID-PEROXIDATION; ISCHEMIA-REPERFUSION
AB Background: Iron is necessary for life, but excess iron can be toxic to tissues. Iron is thought to damage tissues primarily by generating oxygen free radicals through the Fenton reaction.
   Methods: We present an overview of the evidence supporting iron's potential contribution to a broad range of eye disease using an anatomical approach.
   Results: Iron can be visualized in the cornea as iron lines in the normal aging cornea as well as in diseases like keratoconus and pterygium. In the lens, we present the evidence for the role of oxidative damage in cataractogenesis. Also, we review the evidence that iron may play a role in the pathogenesis of the retinal disease age-related macular degeneration. Although currently there is no direct link between excess iron and development of optic neuropathies, ferrous iron's ability to form highly reactive oxygen species may play a role in optic nerve pathology. Lastly, we discuss recent advances in prevention and therapeutics for eye disease with antioxidants and iron chelators.
   General significance: Iron homeostasis is important for ocular health. (C) 2008 Elsevier B.V. All rights reserved.
C1 [Loh, Allison; Hadziahmetovic, Majda; Dunaief, Joshua L.] Univ Penn, Scheie Eye Inst, FM Kirby Ctr Mol Ophthalmol, Philadelphia, PA 19104 USA.
C3 University of Pennsylvania; Pennsylvania Medicine
RP Dunaief, JL (通讯作者)，Univ Penn, Scheie Eye Inst, FM Kirby Ctr Mol Ophthalmol, 305 Stellar Chance Labs,422 Curie Blvd, Philadelphia, PA 19104 USA.
EM jdunaief@mail.med.upenn.edu
FU Research to Prevent Blindness; International Retina Research Foundation
   Alston Callahan, MD Award; NIH [EY015240]; Macula Vision Research
   Foundation; F.M. Kirby Foundation; Paul and Evanina Bell MacKall
   Foundation Trust; NATIONAL EYE INSTITUTE [R01EY015240] Funding Source:
   NIH RePORTER
FX This work was supported by Research to Prevent Blindness (William and
   Mary Greve Scholar Award), International Retina Research Foundation
   Alston Callahan, MD Award, NIH EY015240, the Macula Vision Research
   Foundation, F.M. Kirby Foundation, and the Paul and Evanina Bell MacKall
   Foundation Trust. We would also like to thank Sinauer Associates,
   Investigative Ophthalmology and Visual Sciences, Blackwell Synergy,
   SpringerLink, Nature Publishing Group, British Medical journal
   Publishing Group, American Medical Association for kindly granting
   permission to reprint figures for use in this article.
CR Abboud S, 2000, J BIOL CHEM, V275, P19906, DOI 10.1074/jbc.M000713200
   Abu-Amero KK, 2006, BRIT J OPHTHALMOL, V90, P823, DOI 10.1136/bjo.2006.090332
   Aisen P, 2001, INT J BIOCHEM CELL B, V33, P940, DOI 10.1016/S1357-2725(01)00063-2
   ALLAIN P, 1987, BRIT J CLIN PHARMACO, V24, P207, DOI 10.1111/j.1365-2125.1987.tb03163.x
   AMADO D, 2006, INVEST OPHTHALMOL VI, V47
   Anderson GJ, 2007, AM J HEMATOL, V82, P1128, DOI 10.1002/ajh.21075
   ASSIL KK, 1993, AM J OPHTHALMOL, V116, P350, DOI 10.1016/S0002-9394(14)71353-4
   Atanasiu V, 2007, EUR J HAEMATOL, V78, P1, DOI 10.1111/j.1600-0609.2006.00772.x
   Balcer LJ, 2006, NEW ENGL J MED, V354, P1273, DOI 10.1056/NEJMcp053247
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Beutler E, 2006, ANNU REV MED, V57, P331, DOI 10.1146/annurev.med.57.121304.131310
   Beutler E, 2007, BLOOD CELL MOL DIS, V39, P140, DOI 10.1016/j.bcmd.2007.03.009
   BHUYAN KC, 1986, LIFE SCI, V38, P1463, DOI 10.1016/0024-3205(86)90559-X
   Brooks DG, 2002, INVEST OPHTH VIS SCI, V43, P1121
   Burdo JR, 2003, BIOMETALS, V16, P63, DOI 10.1023/A:1020718718550
   Cai CX, 1997, J BIOL CHEM, V272, P12831, DOI 10.1074/jbc.272.19.12831
   CANNON DJ, 1978, INVEST OPHTH VIS SCI, V171, P63
   Celebi S, 2002, EUR J OPHTHALMOL, V12, P77, DOI 10.1177/112067210201200201
   Charkoudian LK, 2006, J AM CHEM SOC, V128, P12424, DOI 10.1021/ja064806w
   Cheah JH, 2006, NEURON, V51, P431, DOI 10.1016/j.neuron.2006.07.011
   COATS G, 1912, T OPHTHAL SOC UK, V32, P53
   Danielson SR, 2002, J BIOL CHEM, V277, P5810, DOI 10.1074/jbc.M110119200
   Das S, 2005, CORNEA, V24, P772, DOI 10.1097/01.ico.0000153100.74033.ef
   DECLERCQ SS, 1977, ARCH OPHTHALMOL-CHIC, V95, P1051, DOI 10.1001/archopht.1977.04450060138014
   Dentchev T, 2005, ARCH OPHTHALMOL-CHIC, V123, P1745, DOI 10.1001/archopht.123.12.1745
   Dogru M, 2007, OPHTHALMOLOGY, V114, P2366, DOI 10.1016/j.ophtha.2007.06.027
   Donovan A, 2000, NATURE, V403, P776, DOI 10.1038/35001596
   Dunaief JL, 2005, OPHTHALMOLOGY, V112, P1062, DOI 10.1016/j.ophtha.2004.12.029
   Dunaief JL, 2006, INVEST OPHTH VIS SCI, V47, P4660, DOI 10.1167/iovs.06-0568
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   EDWARDS CQ, 1993, NEW ENGL J MED, V328, P1616
   ELLISON RT, 1994, ADV EXP MED BIOL, V357, P71
   EVERY S, 2005, INVEST OPHTHALMOL VI, V46
   Farkas RH, 2004, INVEST OPHTH VIS SCI, V45, P1410, DOI 10.1167/iovs.03-0872
   FERRY AP, 1968, ARCH OPHTHALMOL-CHIC, V79, P142, DOI 10.1001/archopht.1968.03850040144005
   Fleming MD, 1997, NAT GENET, V16, P383, DOI 10.1038/ng0897-383
   FOSTER CS, 2004, CORNEA SCI FDN CLIN
   Fujihara T, 1998, J OCUL PHARMACOL TH, V14, P99, DOI 10.1089/jop.1998.14.99
   GALIN MA, 1965, ARCH OPHTHALMOL-CHIC, V74, P674
   GANZ T, 2006, HEMATOL-AM SOC HEMAT, V507, P29, DOI DOI 10.1182/ASHEDUCATION-2006.1.29
   GARCIAVALENZUELA E, 1994, J NEUROBIOL, V25, P431, DOI 10.1002/neu.480250408
   GASS JDM, 1964, ARCH OPHTHALMOL-CHIC, V71, P348, DOI 10.1001/archopht.1964.00970010364010
   GAY S, 1978, COLLAGEN PHYSL PATHO, P106
   Germundsson J, 2004, ACTA OPHTHALMOL SCAN, V82, P148, DOI 10.1111/j.1600-0420.2004.00228.x
   GIRELLI D, 1995, BLOOD, V86, P4050, DOI 10.1182/blood.V86.11.4050.bloodjournal86114050
   Glickstein H, 2005, BLOOD, V106, P3242, DOI 10.1182/blood-2005-02-0460
   Goralska M, 2005, INVEST OPHTH VIS SCI, V46, P3521, DOI 10.1167/iovs.05-0358
   Goralska M, 2003, J BIOL CHEM, V278, P42920, DOI 10.1074/jbc.M305827200
   Goralska M, 2001, INVEST OPHTH VIS SCI, V42, P1721
   GUY J, 1993, OPHTHALMIC RES, V25, P253, DOI 10.1159/000267321
   GUY J, 1994, INVEST OPHTH VIS SCI, V35, P1114
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Hahn P, 2004, P NATL ACAD SCI USA, V101, P13850, DOI 10.1073/pnas.0405146101
   Hahn P, 2003, ARCH OPHTHALMOL-CHIC, V121, P1099, DOI 10.1001/archopht.121.8.1099
   HALMAY O, 1965, BRIT J OPHTHALMOL, V49, P87, DOI 10.1136/bjo.49.2.87
   Harmatz P, 2007, BRIT J HAEMATOL, V138, P374, DOI 10.1111/j.1365-2141.2007.06651.x
   Harris ZL, 1998, AM J CLIN NUTR, V67, p972S, DOI 10.1093/ajcn/67.5.972S
   He XN, 2007, PROG RETIN EYE RES, V26, P649, DOI 10.1016/j.preteyeres.2007.07.004
   Hiratsuka Y, 2000, JPN J OPHTHALMOL, V44, P381, DOI 10.1016/S0021-5155(00)00179-9
   HOLLY FJ, 1977, SURV OPHTHALMOL, V22, P69, DOI 10.1016/0039-6257(77)90087-X
   HOPEROSS M, 1993, EYE, V7, P419, DOI 10.1038/eye.1993.83
   Horackova M, 2000, CARDIOVASC RES, V47, P529, DOI 10.1016/S0008-6363(00)00088-2
   IWAMOTO T, 1976, ARCH OPHTHALMOL-CHIC, V94, P1579
   Jacques PF, 2005, ARCH OPHTHALMOL-CHIC, V123, P517, DOI 10.1001/archopht.123.4.517
   Kalinowski DS, 2005, PHARMACOL REV, V57, P547, DOI 10.1124/pr.57.4.2
   Kalman B, 2003, NEUROMOL MED, V3, P147, DOI 10.1385/NMM:3:3:147
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Khoo J, 1998, INT OPHTHALMOL, V22, P293, DOI 10.1023/A:1006340822308
   KLEIN R, 1995, INVEST OPHTH VIS SCI, V36, P182
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klimtova Ivona, 2003, Acta Medica (Hradec Kralove), V46, P163
   Klocker N, 1998, J NEUROSCI, V18, P1038
   Ko ML, 2000, INVEST OPHTH VIS SCI, V41, P2967
   KOENIG SB, 1983, ARCH OPHTHALMOL-CHIC, V101, P1862
   Krinsky NI, 2003, ANNU REV NUTR, V23, P171, DOI 10.1146/annurev.nutr.23.011702.073307
   KUIZENGA A, 1987, INVEST OPHTH VIS SCI, V28, P305
   Kymionis GD, 2003, AM J OPHTHALMOL, V136, P378, DOI 10.1016/S0002-9394(03)00224-1
   LAWLESS M, 1989, AUST NZ J OPHTHALMOL, V17, P33
   Lee IK, 2003, PLANTA MED, V69, P513, DOI 10.1055/s-2003-40650
   Lee W, 2007, J CATARACT REFR SURG, V33, P550, DOI 10.1016/j.jcrs.2006.09.043
   Lesbordes-Brion JC, 2006, BLOOD, V108, P1402, DOI 10.1182/blood-2006-02-003376
   LEVAY PF, 1995, HAEMATOLOGICA, V80, P252
   Levin LA, 1996, INVEST OPHTH VIS SCI, V37, P2744
   Levin LA, 1998, INVEST OPHTH VIS SCI, V39, P157
   Lieven CJ, 2003, ANTIOXID REDOX SIGN, V5, P641, DOI 10.1089/152308603770310310
   Liu Q, 2007, INVEST OPHTH VIS SCI, V48, P4580, DOI 10.1167/iovs.07-0170
   Liu ZD, 2002, J MED CHEM, V45, P631, DOI 10.1021/jm010817i
   Lu M, 2007, ARCH OPHTHALMOL-CHIC, V125, P1581, DOI 10.1001/archopht.125.11.1581
   MACKENZIE FD, 1992, OPHTHALMOLOGY, V99, P1056, DOI 10.1016/s0161-6420(92)31850-0
   MASCIULLI L, 1972, AM J OPHTHALMOL, V74, P638, DOI 10.1016/0002-9394(72)90826-4
   MCGUINNESS R, 1968, BRIT J OPHTHALMOL, V52, P777, DOI 10.1136/bjo.52.10.777
   MEMARZADEH F, 2006, EYE
   Millholland JM, 2003, J BIOL CHEM, V278, P23963, DOI 10.1074/jbc.M210050200
   MOISEYEV G, 2005, J BIOL CHEM
   MORAN D, 1994, BR J OPHTHALMOL, V68, P343
   Moreno MC, 2004, FREE RADICAL BIO MED, V37, P803, DOI 10.1016/j.freeradbiomed.2004.06.001
   Mumford AD, 2000, BRIT J OPHTHALMOL, V84, P697, DOI 10.1136/bjo.84.7.697
   Nakamura S, 2007, INVEST OPHTH VIS SCI, V48, P1552, DOI 10.1167/iovs.06-1027
   Neufeld EJ, 2006, BLOOD, V107, P3436, DOI 10.1182/blood-2006-02-002394
   NEVINS RC, 1969, ARCH OPHTHALMOL-CHIC, V82, P457
   Nguyen SM, 2003, ANTIOXID REDOX SIGN, V5, P629, DOI 10.1089/152308603770310293
   Nicolas G, 2002, P NATL ACAD SCI USA, V99, P4596, DOI 10.1073/pnas.072632499
   NORN MS, 1968, ACTA OPHTHALMOL, V46, P119
   PARTRIDGE E, 1977, ORIGINS SHORT ETYMOL, P992
   Picard E, 2008, MOL VIS, V14, P928
   PRYDAL JI, 1992, INVEST OPHTH VIS SCI, V33, P1996
   Purves D., 2019, NEUROSCIENCE
   Qi XP, 2007, ARCH OPHTHALMOL-CHIC, V125, P268, DOI 10.1001/archopht.125.2.268
   Qi XP, 2007, INVEST OPHTH VIS SCI, V48, P681, DOI 10.1167/iovs.06-0553
   REINACH NW, 1981, AM J OPHTHALMOL, V91, P677, DOI 10.1016/0002-9394(81)90072-6
   REITER RJ, 1995, FRONT NEUROENDOCRIN, V16, P383, DOI 10.1006/frne.1995.1014
   Reitz C, 1998, GRAEF ARCH CLIN EXP, V236, P894, DOI 10.1007/s004170050177
   Riordan-Eva P, 2007, VAUGHAN ASBURYS GEN
   ROSE GE, 1987, EYE, V1, P475, DOI 10.1038/eye.1987.71
   ROSE GE, 1987, EYE, V1, P466, DOI 10.1038/eye.1987.69
   Rouault TA, 2001, NAT GENET, V28, P299, DOI 10.1038/91036
   Rozanowski B, 2008, INVEST OPHTH VIS SCI, V49, P2838, DOI 10.1167/iovs.08-1700
   SanGiovanni JP, 2007, ARCH OPHTHALMOL-CHIC, V125, P1225, DOI 10.1001/archopht.125.9.1225
   SCHICHI H, 1969, MICROSOMAL ELECT
   Shen JK, 2007, HISTOL HISTOPATHOL, V22, P1301, DOI 10.14670/HH-22.1301
   Shimmura S, 1996, EXP EYE RES, V63, P519, DOI 10.1006/exer.1996.0142
   Simunek T, 2005, J MOL CELL CARDIOL, V39, P345, DOI 10.1016/j.yjmcc.2005.05.008
   Singh PK, 2002, NATURE, V417, P552, DOI 10.1038/417552a
   SNEED SR, 1990, OPHTHALMOLOGY, V97, P375
   SPECTOR A, 1995, FASEB J, V9, P1173, DOI 10.1096/fasebj.9.12.7672510
   STARK WJ, 1989, ARCH OPHTHALMOL-CHIC, V107, P1441, DOI 10.1001/archopht.1989.01070020515030
   STEINBERG EB, 1984, AM J OPHTHALMOL, V98, P416, DOI 10.1016/0002-9394(84)90122-3
   Sureda A, 2005, FREE RADICAL RES, V39, P817, DOI 10.1080/10715760500164045
   Swanson KI, 2005, INVEST OPHTH VIS SCI, V46, P3737, DOI 10.1167/iovs.05-0155
   Szabo ME, 2001, EUR J PHARMACOL, V428, P277, DOI 10.1016/S0014-2999(01)01196-7
   TASMAN W, 1992, DUANES CLIN OPHTHALM, V4, P1
   TAYLOR HR, 1989, ARCH OPHTHALMOL-CHIC, V107, P1481, DOI 10.1001/archopht.1989.01070020555039
   Taylor VL, 1996, INVEST OPHTH VIS SCI, V37, P1396
   Threlfall TJ, 1999, AM J OPHTHALMOL, V128, P280, DOI 10.1016/S0002-9394(99)00161-0
   TRIPATHI RC, 1992, INVEST OPHTH VIS SCI, V33, P2866
   Tseng SCG, 1997, AM J OPHTHALMOL, V124, P825, DOI 10.1016/S0002-9394(14)71700-3
   Tuomainen TP, 1998, CIRCULATION, V97, P1461
   Tuomainen TP, 1997, BRIT MED J, V314, P793, DOI 10.1136/bmj.314.7083.793
   Uyama Y, 1936, ARCH OPHTHALMOL-CHIC, V15, P309
   VITALI C, 1994, ANN RHEUM DIS, V53, P637, DOI 10.1136/ard.53.10.637
   Wang YP, 2005, ANTIOXID REDOX SIGN, V7, P1513, DOI 10.1089/ars.2005.7.1513
   Ward PP, 2005, CELL MOL LIFE SCI, V62, P2540, DOI 10.1007/s00018-005-5369-8
   Weinreb RN, 2004, LANCET, V363, P1711, DOI 10.1016/S0140-6736(04)16257-0
   WEST S, 1992, JAMA-J AM MED ASSOC, V268, P1025, DOI 10.1001/jama.268.8.1025
   WEST SK, 1989, ARCH OPHTHALMOL-CHIC, V107, P875, DOI 10.1001/archopht.1989.01070010897038
   Wong RW, 2007, RETINA-J RET VIT DIS, V27, P997, DOI 10.1097/IAE.0b013e318074c290
   Yang FM, 2002, AM J PHYSIOL-LUNG C, V283, pL932, DOI 10.1152/ajplung.00114.2002
   Yanoff M., 2004, OPHTHALMOLOGY
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
   Zheng HL, 2005, BIOORGAN MED CHEM, V13, P773, DOI 10.1016/j.bmc.2004.10.037
   ZIGLER JS, 1989, FREE RADICAL BIO MED, V7, P499
NR 151
TC 72
Z9 73
U1 0
U2 6
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0304-4165
EI 1872-8006
J9 BBA-GEN SUBJECTS
JI Biochim. Biophys. Acta-Gen. Subj.
PD JUL
PY 2009
VL 1790
IS 7
SI SI
BP 637
EP 649
DI 10.1016/j.bbagen.2008.11.001
PG 13
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA 463XJ
UT WOS:000267467100009
PM 19059309
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Zhang, D
   Mihai, DM
   Washington, I
AF Zhang, Dan
   Mihai, Doina M.
   Washington, Ilyas
TI Vitamin A cycle byproducts explain retinal damage and molecular changes
   thought to initiate retinal degeneration
SO BIOLOGY OPEN
LA English
DT Article
DE Vitamin A; Retina; A2E; Age-related macular degeneration; Stargardt
   disease
ID PIGMENT EPITHELIAL-CELLS; LIGHT-INDUCED DAMAGE; LIPOFUSCIN FLUOROPHORE;
   MACULAR DEGENERATION; COMPLEMENT ACTIVATION; OXIDATION-PRODUCTS; RPE
   LIPOFUSCIN; ELLIPSOID ZONE; A2E OXIDATION; AGE
AB In the most prevalent retinal diseases, including Stargardt disease and age-related macular degeneration (AMD), byproducts of vitamin A form in the retina abnormally during the vitamin A cycle. Despite evidence of their toxicity, whether these vitamin A cycle byproducts contribute to retinal disease, are symptoms, beneficial, or benign has been debated. We delivered a representative vitamin A byproduct, A2E, to the rat's retina and monitored electrophysiological, histological, proteomic, and transcriptomic changes. We show that the vitamin A cycle byproduct is sufficient alone to damage the RPE, photoreceptor inner and outer segments, and the outer plexiform layer, cause the formation of sub-retinal debris, alter transcription and protein synthesis, and diminish retinal function. The presented data are consistent with the theory that the formation of vitamin A byproducts during the vitamin A cycle is neither benign nor beneficial but may be sufficient alone to cause the most prevalent forms of retinal disease. Retarding the formation of vitamin A byproducts could potentially address the root cause of several retinal diseases to eliminate the threat of irreversible blindness for millions of people.
C1 [Zhang, Dan; Mihai, Doina M.; Washington, Ilyas] Columbia Univ, Ophthalmol, Med Ctr, New York, NY 10032 USA.
   [Washington, Ilyas] biOOrg3 14, Buffalo, WY 82834 USA.
C3 Columbia University
RP Washington, I (通讯作者)，Columbia Univ, Ophthalmol, Med Ctr, New York, NY 10032 USA.; Washington, I (通讯作者)，biOOrg3 14, Buffalo, WY 82834 USA.
EM publications@bioorg314.com
OI W, I/0000-0002-2238-7918
FU U.S. National Institutes of Health, National Eye Institute
   [1R01EY021207]; Research to Prevent Blindness (RPB) Inc., NY, USA
FX U.S. National Institutes of Health, National Eye Institute
   [1R01EY021207] and Research to Prevent Blindness (RPB) Inc., NY, USA.
CR Adini I, 2014, J CLIN INVEST, V124, P425, DOI 10.1172/JCI69404
   Anderson OA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067263
   Avalle LB, 2004, EXP EYE RES, V78, P895, DOI 10.1016/j.exer.2003.10.023
   Beattie JR, 2010, FASEB J, V24, P4816, DOI 10.1096/fj.10-166090
   Ben-Shabat S, 2002, ANGEW CHEM INT EDIT, V41, P814, DOI 10.1002/1521-3773(20020301)41:5<814::AID-ANIE814>3.0.CO;2-2
   Ben-Shabat S, 2002, J BIOL CHEM, V277, P7183, DOI 10.1074/jbc.M108981200
   Bermann M, 2001, EXP EYE RES, V72, P191
   Bertolotto M, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/741538
   Biesemeier A, 2014, NEUROBIOL AGING, V35, P2562, DOI 10.1016/j.neurobiolaging.2014.05.003
   Bird A, 2021, BRIT J OPHTHALMOL, V105, P1469, DOI 10.1136/bjophthalmol-2020-317447
   BIRNBACH CD, 1994, OPHTHALMOLOGY, V101, P1211
   Bora NS, 2015, MOL IMMUNOL, V63, P176, DOI 10.1016/j.molimm.2014.07.012
   Cai CX, 2018, AM J OPHTHALMOL, V186, P1, DOI 10.1016/j.ajo.2017.10.032
   Camelo S, 2014, AUTOIMMUN DIS, V2014, DOI 10.1155/2014/532487
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Curcio CA, 2017, INVEST OPHTH VIS SCI, V58, P211, DOI 10.1167/iovs.17-21872
   Dai GL, 2005, MOL PHARMACOL, V68, P1590, DOI 10.1124/mol.105.013680
   De S, 2002, J GEN PHYSIOL, V120, P147, DOI 10.1085/jgp.20028566
   Dontsov AE, 2009, DOKL BIOCHEM BIOPHYS, V425, P98, DOI 10.1134/S1607672909020112
   EAGLE RC, 1980, OPHTHALMOLOGY, V87, P1189
   ELDRED GE, 1988, EXP EYE RES, V47, P71, DOI 10.1016/0014-4835(88)90025-5
   ELDRED GE, 1993, NATURE, V361, P724, DOI 10.1038/361724a0
   ERTEL W, 1995, BLOOD, V85, P1341, DOI 10.1182/blood.V85.5.1341.bloodjournal8551341
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Finnemann SC, 2002, P NATL ACAD SCI USA, V99, P3842, DOI 10.1073/pnas.052025899
   Fishkin N, 2003, ORG BIOMOL CHEM, V1, P1101, DOI 10.1039/b212213h
   Fishkin NE, 2005, P NATL ACAD SCI USA, V102, P7091, DOI 10.1073/pnas.0501266102
   GARTNER S, 1981, BRIT J OPHTHALMOL, V65, P23, DOI 10.1136/bjo.65.1.23
   Harris VK, 2013, MULT SCLER J, V19, P1462, DOI 10.1177/1352458513477923
   HOGAN M J, 1972, Transactions of the American Academy of Ophthalmology and Oto-Laryngology, V76, P64
   Holz FG, 1999, OPHTHALMOLOGE, V96, P781, DOI 10.1007/s003470050496
   Iriyama A, 2008, J BIOL CHEM, V283, P11947, DOI 10.1074/jbc.M708989200
   Iriyama A, 2009, J CELL PHYSIOL, V220, P469, DOI 10.1002/jcp.21792
   Kaarniranta K, 2013, AUTOPHAGY, V9, P973, DOI 10.4161/auto.24546
   Kanofsky JR, 2003, PHOTOCHEM PHOTOBIOL, V77, P235, DOI 10.1562/0031-8655(2003)077<0235:SOGFA>2.0.CO;2
   Katz ML, 1999, INVEST OPHTH VIS SCI, V40, P175
   Katz ML, 1996, MECH AGEING DEV, V92, P159, DOI 10.1016/S0047-6374(96)01817-9
   Kenney MC, 2013, BMC MED GENET, V14, DOI 10.1186/1471-2350-14-4
   Lakkaraju A, 2007, P NATL ACAD SCI USA, V104, P11026, DOI 10.1073/pnas.0702504104
   Lamin A, 2019, EYE, V33, P428, DOI 10.1038/s41433-018-0234-9
   LOW JC, 1987, GRAEF ARCH CLIN EXP, V225, P413, DOI 10.1007/BF02334167
   Lukiw WJ, 2006, CURR EYE RES, V31, P259, DOI 10.1080/02713680600556974
   Ma L, 2011, J BIOL CHEM, V286, P7966, DOI 10.1074/jbc.M110.178657
   Ma WX, 2013, NEUROBIOL AGING, V34, P943, DOI 10.1016/j.neurobiolaging.2012.06.010
   Machalinska A, 2010, NEUROCHEM RES, V35, P1819, DOI 10.1007/s11064-010-0248-6
   Maeda H, 1998, GRAEF ARCH CLIN EXP, V236, P207, DOI 10.1007/s004170050066
   McGill T. J., 2017, LONG TERM CHARACTERI
   Mihai DM, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.314
   Moiseyev G, 2010, P NATL ACAD SCI USA, V107, P17551, DOI 10.1073/pnas.1008769107
   Murdaugh LS, 2011, J MASS SPECTROM, V46, P90, DOI 10.1002/jms.1865
   Murdaugh LS, 2010, J MASS SPECTROM, V45, P1139, DOI 10.1002/jms.1795
   Murdaugh LS, 2010, EXP EYE RES, V90, P564, DOI 10.1016/j.exer.2010.01.014
   Murdaugh LS, 2009, EXP EYE RES, V89, P187, DOI 10.1016/j.exer.2009.03.021
   Nordgaard CL, 2006, INVEST OPHTH VIS SCI, V47, P815, DOI 10.1167/iovs.05-0976
   Nowak JZ, 2013, PHARMACOL REP, V65, P288, DOI 10.1016/S1734-1140(13)71005-3
   Penn J, 2015, DIS MODEL MECH, V8, P131, DOI 10.1242/dmm.017194
   Radu RA, 2004, P NATL ACAD SCI USA, V101, P5928, DOI 10.1073/pnas.0308302101
   Reinboth JJ, 1997, EXP EYE RES, V65, P639, DOI 10.1006/exer.1997.0367
   Roberts JE, 2002, PHOTOCHEM PHOTOBIOL, V75, P184, DOI 10.1562/0031-8655(2002)075<0184:TROAIP>2.0.CO;2
   Sakai N, 1996, J AM CHEM SOC, V118, P1559, DOI 10.1021/ja953480g
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   SARKS SH, 1976, BRIT J OPHTHALMOL, V60, P324, DOI 10.1136/bjo.60.5.324
   Sokolov VS, 2007, J PHOTOCH PHOTOBIO B, V86, P177, DOI 10.1016/j.jphotobiol.2006.09.006
   Sparrow JR, 2010, ADV EXP MED BIOL, V703, P63, DOI 10.1007/978-1-4419-5635-4_5
   Sparrow JR, 2006, ADV EXP MED BIOL, V572, P63
   Sparrow JR, 1999, INVEST OPHTH VIS SCI, V40, P2988
   Sparrow JR, 2003, J BIOL CHEM, V278, P18207, DOI 10.1074/jbc.M300457200
   Sparrow JR, 2003, INVEST OPHTH VIS SCI, V44, P2245, DOI 10.1167/iovs.02-0746
   Sparrow JR, 2002, INVEST OPHTH VIS SCI, V43, P1222
   Sparrow JR, 2001, INVEST OPHTH VIS SCI, V42, P1356
   Sparrow JR, 2000, INVEST OPHTH VIS SCI, V41, P1981
   TABATABAY CA, 1987, INVEST OPHTH VIS SCI, V28, P1783
   Tezel TH, 2009, INVEST OPHTH VIS SCI, V50, P1911, DOI 10.1167/iovs.07-1372
   Thao MT, 2014, PHOTOCHEM PHOTOBIOL, V90, P329, DOI 10.1111/php.12200
   Tomography, INVEST OPHTH VIS SCI, V58, P1378, DOI [10.1167/iovs.16-20363, DOI 10.1167/IOVS.16-20363]
   Toprak I, 2017, INT OPHTHALMOL, V37, P801, DOI 10.1007/s10792-016-0331-3
   Ueda K, 2016, P NATL ACAD SCI USA, V113, P6904, DOI 10.1073/pnas.1524774113
   Ugurlu N, 2013, CURR EYE RES, V38, P497, DOI 10.3109/02713683.2013.774023
   van der Burght Barbro W, 2013, Acta Ophthalmol, V91, pe537, DOI 10.1111/aos.12146
   Vives-Bauza C, 2008, J BIOL CHEM, V283, P24770, DOI 10.1074/jbc.M800706200
   Wang Z, 2006, PHOTOCHEM PHOTOBIOL, V82, P1251, DOI 10.1562/2006-04-01-RA-864
   Washington I, 2005, ANGEW CHEM INT EDIT, V44, P7097, DOI 10.1002/anie.200501346
   Washington I, 2007, PHOTOCH PHOTOBIO SCI, V6, P775, DOI 10.1039/b618104j
   Washington I, 2006, PHOTOCHEM PHOTOBIOL, V82, P1394, DOI 10.1562/2006-02-28-RA-828
   Whitmore SS, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-73645-5
   Wielgus AR, 2010, PHOTOCH PHOTOBIO SCI, V9, P1505, DOI 10.1039/c0pp00133c
   Wu YL, 2010, P NATL ACAD SCI USA, V107, P7275, DOI 10.1073/pnas.0913112107
   Yasukawa T, 2007, GRAEF ARCH CLIN EXP, V245, P1475, DOI 10.1007/s00417-007-0571-z
   Yoon KD, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041309
   Yoon KD, 2011, MOL VIS, V17, P1839
   Zhang D, 2021, J BIOL CHEM, V297, DOI 10.1016/j.jbc.2021.101074
   Zhou JL, 2006, P NATL ACAD SCI USA, V103, P16182, DOI 10.1073/pnas.0604255103
NR 92
TC 1
Z9 1
U1 0
U2 1
PU COMPANY BIOLOGISTS LTD
PI CAMBRIDGE
PA BIDDER BUILDING, STATION RD, HISTON, CAMBRIDGE CB24 9LF, ENGLAND
SN 2046-6390
J9 BIOL OPEN
JI Biol. Open
PD NOV
PY 2021
VL 10
IS 11
AR bio058600
DI 10.1242/bio.058600
PG 10
WC Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Life Sciences & Biomedicine - Other Topics
GA XK1ZT
UT WOS:000727272600001
PM 34842275
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Dorion, MF
   Mulumba, M
   Kasai, S
   Itoh, K
   Lubell, WD
   Ong, H
AF Dorion, Marie-France
   Mulumba, Mukandila
   Kasai, Shuya
   Itoh, Ken
   Lubell, William D.
   Ong, Huy
TI The CD36 Ligand-Promoted Autophagy Protects Retinal Pigment Epithelial
   Cells from Oxidative Stress
SO OXIDATIVE MEDICINE AND CELLULAR LONGEVITY
LA English
DT Article
ID MITOCHONDRIAL-LYSOSOMAL AXIS; MACULAR DEGENERATION; CROSS-TALK; RPE;
   DIFFERENTIATION; RECEPTOR; INFLAMMATION; ANTIOXIDANT; ACTIVATION;
   PEPTIDE
AB The retinal pigment epithelium (RPE) performs many functions that maintain photoreceptor health. Oxidative damage to the RPE is a critical component in the pathogenesis of eye diseases such as age-related macular degeneration (AMD). Ligands of the cluster of differentiation 36 (CD36) have previously preserved photoreceptor integrity in mouse models of AMD. The cytoprotective effect of the CD36 ligand MPE-001 on RPE cells has now been elucidated employing a model of oxidative stress. Sodium iodate (NaIO3) induced formation of reactive oxygen species and apoptosis in human RPE cells, which were decreased by MPE-001 without affecting antioxidant enzyme transcription. Immunoblotting and immunostaining assays showed a restorative effect of MPE-001 on the autophagic flux disrupted by NaIO3, which was associated with an increase in syntaxin 17-positive mature autophagosomes. The cytoprotective effect of MPE-001 was completely abolished by the autophagy inhibitors wortmannin and bafilomycin A1. In conclusion, we report for the first time an autophagy-dependent protection of RPE cells from oxidative stress by a CD36 ligand.
C1 [Dorion, Marie-France] McGill Univ, Montreal Neurol Inst, Dept Neurol & Neurosurg, 3801 Univ St, Montreal, PQ H3A 2B4, Canada.
   [Dorion, Marie-France; Mulumba, Mukandila; Ong, Huy] Univ Montreal, Fac Pharm, 2940 Chemin Polytech, Montreal, PQ H3T 1J4, Canada.
   [Kasai, Shuya; Itoh, Ken] Hirosaki Univ, Ctr Adv Med Res, Grad Sch Med, Dept Stress Response Sci, 5 Zaifu Cho, Hirosaki, Aomori 0368562, Japan.
   [Lubell, William D.] Univ Montreal, Dept Chem, 2900 Blvd Edouard Montpetit, Montreal, PQ H3T 1J4, Canada.
C3 McGill University; Universite de Montreal; Hirosaki University;
   Universite de Montreal
RP Ong, H (通讯作者)，Univ Montreal, Fac Pharm, 2940 Chemin Polytech, Montreal, PQ H3T 1J4, Canada.
EM huy.ong@umontreal.ca
RI Kasai, Shuya/AAL-2157-2021; Itoh, Ken/B-9506-2013
OI Kasai, Shuya/0000-0001-7171-4885; Itoh, Ken/0000-0002-5518-0729; Lubell,
   William/0000-0002-3080-2712; Dorion, Marie-France/0000-0003-1285-6087
FU Canadian Institutes of Health Research (CIHR) [PPP-90157]; Natural
   Sciences and Engineering Research Council (NSERC)-CIHR Collaborative
   Health Research Project "Azacyclopeptide Modulators of Immuno-metabolism
   to Treat Age-Related Macular Degeneration" [163973]; CIHR; Fonds de
   recherche Sante du Quebec (FRQS); Japan Society for the Promotion of
   Science (JSPS); Mitacs Globalink
FX This work was supported by the Canadian Institutes of Health Research
   (CIHR) (PPP-90157) and the Natural Sciences and Engineering Research
   Council (NSERC)-CIHR Collaborative Health Research Project
   "Azacyclopeptide Modulators of Immuno-metabolism to Treat Age-Related
   Macular Degeneration" (163973). M-FD received financial supports from
   CIHR, Fonds de recherche Sante du Quebec (FRQS), the Japan Society for
   the Promotion of Science (JSPS), and Mitacs Globalink.
CR ABUMRAD NA, 1993, J BIOL CHEM, V268, P17665
   Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Armento A., 2020, LOSS COMPLEMENT FACT, V2020, DOI [10.1101/2020.01.08.898551, DOI 10.1101/2020.01.08.898551]
   Baek A, 2017, AUTOPHAGY, V13, P248, DOI 10.1080/15548627.2016.1256932
   Brunk UT, 2002, EUR J BIOCHEM, V269, P1996, DOI 10.1046/j.1432-1033.2002.02869.x
   Chan CM, 2019, J BIOMED SCI, V26, DOI 10.1186/s12929-019-0531-z
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Datta S, 2017, PROG RETIN EYE RES, V60, P201, DOI 10.1016/j.preteyeres.2017.03.002
   Decanini A, 2007, AM J OPHTHALMOL, V143, P607, DOI 10.1016/j.ajo.2006.12.006
   Dikalov S, 2011, FREE RADICAL BIO MED, V51, P1289, DOI 10.1016/j.freeradbiomed.2011.06.033
   Evans J, 2008, EYE, V22, P751, DOI 10.1038/eye.2008.100
   Fang CC, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/8495160
   Feher J, 2006, NEUROBIOL AGING, V27, P983, DOI 10.1016/j.neurobiolaging.2005.05.012
   Hernandez-Zimbron LF, 2018, OXID MED CELL LONGEV, V2018, DOI 10.1155/2018/8374647
   Ferrington DA, 2017, REDOX BIOL, V13, P255, DOI 10.1016/j.redox.2017.05.015
   Golestaneh N, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2016.453
   Hanus J, 2016, CELL DEATH DISCOV, V2, DOI 10.1038/cddiscovery.2016.54
   Hazim RA, 2019, EXP EYE RES, V179, P18, DOI 10.1016/j.exer.2018.10.009
   Houssier M, 2008, PLOS MED, V5, P323, DOI 10.1371/journal.pmed.0050039
   Howes KA, 2004, INVEST OPHTH VIS SCI, V45, P3713, DOI 10.1167/iovs.04-0404
   Iannaccone A, 2017, EXP EYE RES, V155, P64, DOI 10.1016/j.exer.2016.12.006
   Imamura Y, 2006, P NATL ACAD SCI USA, V103, P11282, DOI 10.1073/pnas.0602131103
   Ishiyama M, 1997, TALANTA, V44, P1299, DOI 10.1016/S0039-9140(97)00017-9
   Itakura E, 2012, CELL, V151, P1256, DOI 10.1016/j.cell.2012.11.001
   Johnson LV, 2002, P NATL ACAD SCI USA, V99, P11830, DOI 10.1073/pnas.192203399
   Justilien V, 2007, INVEST OPHTH VIS SCI, V48, P4407, DOI 10.1167/iovs.07-0432
   Karunadharma PP, 2010, INVEST OPHTH VIS SCI, V51, P5470, DOI 10.1167/iovs.10-5429
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kelso GF, 2001, J BIOL CHEM, V276, P4588, DOI 10.1074/jbc.M009093200
   Khan JC, 2006, BRIT J OPHTHALMOL, V90, P75, DOI 10.1136/bjo.2005.073643
   Kobayashi M, 2006, ADV ENZYME REGUL, V46, P113, DOI 10.1016/j.advenzreg.2006.01.007
   Lee J, 2012, BIOCHEM J, V441, P523, DOI 10.1042/BJ20111451
   Li JJ, 2020, EXP THER MED, V19, P2588, DOI 10.3892/etm.2020.8497
   Lin H., 2018, BLOCKING NECROPTOSIS, V2018, article 387068, DOI [10.1101/387068, DOI 10.1101/387068]
   Lin YC, 2018, J OCUL PHARMACOL TH, V34, P500, DOI 10.1089/jop.2017.0073
   Mao XY, 2018, BIOMED PHARMACOTHER, V103, P517, DOI 10.1016/j.biopha.2018.04.038
   Mellal K, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-49472-8
   Mitter SK, 2014, AUTOPHAGY, V10, P1989, DOI 10.4161/auto.36184
   Pascolini D, 2012, BRIT J OPHTHALMOL, V96, P614, DOI 10.1136/bjophthalmol-2011-300539
   Picard E, 2010, AGING-US, V2, P981, DOI 10.18632/aging.100218
   Proulx C, 2020, BIOMEDICINES, V8, DOI 10.3390/biomedicines8080241
   Proulx C, 2012, J MED CHEM, V55, P6502, DOI 10.1021/jm300557t
   Sachdeva MM, 2014, EXP EYE RES, V119, P111, DOI 10.1016/j.exer.2013.10.024
   Saito Y, 2018, REDOX BIOL, V19, P354, DOI 10.1016/j.redox.2018.09.004
   Sanjurjo L, 2015, AUTOPHAGY, V11, P487, DOI 10.1080/15548627.2015.1017183
   Satish S, 2018, OXID MED CELL LONGEV, V2018, DOI 10.1155/2018/9248640
   Silverstein RL, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.272re3
   Sorsby A, 1941, Br J Ophthalmol, V25, P58, DOI 10.1136/bjo.25.2.58
   STERNBERG P, 1993, INVEST OPHTH VIS SCI, V34, P3661
   Uchiyama A, 2008, HEPATOLOGY, V48, P1644, DOI 10.1002/hep.22498
   Wang AL, 2009, AUTOPHAGY, V5, P1190, DOI 10.4161/auto.5.8.10087
   Wang CX, 2009, ANNU REV GENET, V43, P95, DOI 10.1146/annurev-genet-102108-134850
   Yamada Y, 2008, J NEUROCHEM, V105, P1187, DOI 10.1111/j.1471-4159.2008.05211.x
   Yoshii SR, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18091865
   Zhang XY, 2016, SCI REP-UK, V6, DOI 10.1038/srep37279
   Zhang Y, 2017, MOL VIS, V23, P228
   Zhao ZY, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019456
NR 57
TC 1
Z9 1
U1 1
U2 2
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1942-0900
EI 1942-0994
J9 OXID MED CELL LONGEV
JI Oxidative Med. Cell. Longev.
PD MAR 28
PY 2021
VL 2021
AR 6691402
DI 10.1155/2021/6691402
PG 14
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA RJ1WC
UT WOS:000637391100001
PM 33854697
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Petrus-Reurer, S
   Winblad, N
   Kumar, P
   Gorchs, L
   Chrobok, M
   KathleenWagner, A
   Bartuma, H
   Lardner, E
   Aronsson, M
   Reyes, AP
   Andre, H
   Alici, E
   Kaipe, H
   Kvanta, A
   Lanner, F
AF Petrus-Reurer, Sandra
   Winblad, Nerges
   Kumar, Pankaj
   Gorchs, Laia
   Chrobok, Michael
   KathleenWagner, Arnika
   Bartuma, Hammurabi
   Lardner, Emma
   Aronsson, Monica
   Reyes, Alvaro Plaza
   Andre, Helder
   Alici, Evren
   Kaipe, Helen
   Kvanta, Anders
   Lanner, Fredrik
TI Generation of Retinal Pigment Epithelial Cells Derived from Human
   Embryonic Stem Cells Lacking Human Leukocyte Antigen Class I and II
SO STEM CELL REPORTS
LA English
DT Article
ID XENO-FREE; MACULAR DEGENERATION; IMMUNE-RESPONSE; TRANSPLANTATION; RPE;
   DIFFERENTIATION; CYTOTOXICITY; DERIVATION; MOLECULES
AB Human embryonic stem cell-derived retinal pigment epithelial (hESC-RPE) cells could serve as a replacement therapy in advanced stages of age-related macular degeneration. However, allogenic hESC-RPE transplants trigger immune rejection, supporting a strategy to evade their immune recognition. We established single-knockout beta-2 microglobulin (SKO-B2M), class II major histocompatibility complex transactivator (SKO-CIITA) and double-knockout (DKO) hESC lines that were further differentiated into corresponding hESC-RPE lines lacking either surface human leukocyte antigen class I (HLA-I) or HLA-II, or both. Activation of CD4+ and CD8+ T-cells was markedly lower by hESC-RPE DKO cells, while natural killer cell cytotoxic response was not increased. After transplantation of SKO-B2M, SKO-CIITA, or DKO hESC-RPEs in a preclinical rabbit model, donor cell rejection was reduced and delayed. In conclusion, we have developed cell lines that lack both HLA-I and -II antigens, which evoke reduced T-cell responses in vitro together with reduced rejection in a large-eyed animal model.
C1 [Petrus-Reurer, Sandra; Bartuma, Hammurabi; Lardner, Emma; Aronsson, Monica; Andre, Helder; Kvanta, Anders] Karolinska Inst, St Erik Eye Hosp, Sect Ophtalmol & Vis, Clin Neurosci, S-11282 Stockholm, Sweden.
   [Petrus-Reurer, Sandra; Winblad, Nerges; Kumar, Pankaj; Reyes, Alvaro Plaza; Lanner, Fredrik] Karolinska Insitutet, Dept Clin Sci Intervent & Technol, S-17177 Stockholm, Sweden.
   [Petrus-Reurer, Sandra; Winblad, Nerges; Kumar, Pankaj; Reyes, Alvaro Plaza; Lanner, Fredrik] Karolinska Univ Sjukhuset, Gynecol & Reprod Med, S-14186 Stockholm, Sweden.
   [Lanner, Fredrik] Karolinska Inst, Stockholm Node, Ming Wai Lau Ctr Reparat Med, S-17177 Stockholm, Sweden.
   [Gorchs, Laia; Kaipe, Helen] Karolinska Inst, Dept Lab Med, S-14152 Stockholm, Sweden.
   [Chrobok, Michael; KathleenWagner, Arnika; Alici, Evren] Karolinska Inst, Dept Med Huddinge, Ctr Hematol & Regenerat Med, S-17177 Stockholm, Sweden.
   [Kaipe, Helen] Karolinska Univ Hosp, Clin Immunol & Transfus Med, S-14186 Stockholm, Sweden.
C3 Karolinska Institutet; Karolinska Institutet; Karolinska Institutet;
   Karolinska Institutet; Karolinska Institutet; Karolinska Institutet;
   Karolinska University Hospital
RP Lanner, F (通讯作者)，Karolinska Insitutet, Dept Clin Sci Intervent & Technol, S-17177 Stockholm, Sweden.; Lanner, F (通讯作者)，Karolinska Univ Sjukhuset, Gynecol & Reprod Med, S-14186 Stockholm, Sweden.; Lanner, F (通讯作者)，Karolinska Inst, Stockholm Node, Ming Wai Lau Ctr Reparat Med, S-17177 Stockholm, Sweden.
EM fredrik.lanner@ki.se
RI Kaipe, Helen/J-2301-2012; Plaza Reyes, Alvaro/AAC-1723-2022; Reyes,
   Alvaro Plaza/AAX-7992-2020
OI Kaipe, Helen/0000-0001-7391-1137; Reyes, Alvaro
   Plaza/0000-0003-1167-6316; Lanner, Fredrik/0000-0002-2771-7445; Wagner,
   Arnika/0000-0002-0339-8259; Andre, Helder/0000-0002-2926-2376;
   Petrus-Reurer, Sandra/0000-0002-7051-1741; Alici,
   Evren/0000-0001-5307-6648; KUMAR, PANKAJ/0000-0002-8411-1634
FU Swedish Research Council; Ragnar Soderberg Foundation; Ming Wai Lau
   Center for Reparative Medicine; Center for Innovative Medicine;
   Stockholm County Council (ALF project); Karolinska Institute; Crown
   Princess Margareta's Foundation for the Visually Impaired; Strategic
   Research Area (SRA) Stem Cells and Regenerative Medicine; ARMEC
   Lindeberg Foundation; Ulla och Ingemar Dahlberg Foundation; King Gustav
   V and Queen Victoria Foundation; Cronqvist Foundation; Knut and Alice
   Wallenberg Foundation; Centre for Innovative Medicine; Jonasson
   donation; Knut and AliceWallenberg Foundation; Wallenberg Academy
FX This work was supported by grants from the Swedish Research Council,
   Ragnar Soderberg Foundation, Ming Wai Lau Center for Reparative
   Medicine, Center for Innovative Medicine, Wallenberg Academy Fellow,
   Stockholm County Council (ALF project), Karolinska Institute, Crown
   Princess Margareta's Foundation for the Visually Impaired, Strategic
   Research Area (SRA) Stem Cells and Regenerative Medicine, Ragnar
   Soderberg Foundation, ARMEC Lindeberg Foundation, the Ulla och Ingemar
   Dahlberg Foundation, the King Gustav V and Queen Victoria Foundation,
   and the Cronqvist Foundation. This study was performed at the Live Cell
   Imaging unit/Nikon Center of Excellence, BioNut, KI, supported by Knut
   and Alice Wallenberg Foundation, Swedish Research Council, Centre for
   Innovative Medicine and the Jonasson donation. Flow cytometry analysis
   and cell sorting were performed at the MedH Flow Cytometry core
   facility, supported by KI/SLL. Sequencing was performed at National
   Genomics Infrastructure in Stockholm at Science for Life Laboratory
   (funded by the Knut and AliceWallenberg Foundation and the Swedish
   Research Council) with assistance from SNIC/Uppsala Multidisciplinary
   Center for Advanced Computational Science with massively parallel
   sequencing and access to the UPPMAX computational infrastructure.
   Authors report no financial interest related to this work.
CR Bae S, 2014, BIOINFORMATICS, V30, P1473, DOI 10.1093/bioinformatics/btu048
   Bradley JA, 2002, NAT REV IMMUNOL, V2, P859, DOI 10.1038/nri934
   Choudhary P, 2017, STEM CELL TRANSL MED, V6, P490, DOI 10.5966/sctm.2016-0088
   da Cruz L, 2018, NAT BIOTECHNOL, V36, P1, DOI 10.1038/nbt.4114
   de Rham C, 2011, SEMIN IMMUNOPATHOL, V33, P525, DOI 10.1007/s00281-011-0262-z
   Deuse T, 2019, NAT BIOTECHNOL, V37, P252, DOI 10.1038/s41587-019-0016-3
   Diniz B, 2013, INVEST OPHTH VIS SCI, V54, P5087, DOI 10.1167/iovs.12-11239
   FINBERG RW, 1992, J IMMUNOL, V149, P2055
   Fox A, 2001, J IMMUNOL, V166, P2133, DOI 10.4049/jimmunol.166.3.2133
   Gehrs KM, 2006, ANN MED, V38, P450, DOI 10.1080/07853890600946724
   Gornalusse GG, 2017, NAT BIOTECHNOL, V35, P765, DOI 10.1038/nbt.3860
   Hawthorne WJ, 2016, CURR OPIN ORGAN TRAN, V21, P476, DOI 10.1097/MOT.0000000000000353
   Heigwer F, 2014, NAT METHODS, V11, P122, DOI 10.1038/nmeth.2812
   Hongisto H, 2017, STEM CELL RES THER, V8, DOI 10.1186/s13287-017-0738-4
   Idelson M, 2009, CELL STEM CELL, V5, P396, DOI 10.1016/j.stem.2009.07.002
   Ilmarinen T, 2019, ACTA OPHTHALMOL, V97, pE688, DOI 10.1111/aos.14004
   Ilmarinen T, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0143669
   Jonas JB, 2017, ASIA-PAC J OPHTHALMO, V6, P493, DOI 10.22608/APO.2017251
   Kamao H, 2014, STEM CELL REP, V2, P205, DOI 10.1016/j.stemcr.2013.12.007
   KARRE K, 1986, NATURE, V319, P675, DOI 10.1038/319675a0
   Kashani AH, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aao4097
   Klimanskaya I, 2004, CLONING STEM CELLS, V6, P217, DOI 10.1089/1536230042323420
   Lane A, 2014, STEM CELL TRANSL MED, V3, P1295, DOI 10.5966/sctm.2014-0094
   Liang Q, 2018, NATURE, V563, P701, DOI 10.1038/s41586-018-0733-7
   LJUNGGREN HG, 1990, IMMUNOL TODAY, V11, P237, DOI 10.1016/0167-5699(90)90097-S
   Lu B, 2009, STEM CELLS, V27, P2126, DOI 10.1002/stem.149
   Lund RD, 2006, CLONING STEM CELLS, V8, P189, DOI 10.1089/clo.2006.8.189
   Mandai M, 2017, NEW ENGL J MED, V376, P1038, DOI 10.1056/NEJMoa1608368
   Marcenaro E, 2003, EUR J IMMUNOL, V33, P3367, DOI 10.1002/eji.200324425
   Maruotti J, 2015, P NATL ACAD SCI USA, V112, P10950, DOI 10.1073/pnas.1422818112
   Masternak K, 2000, GENE DEV, V14, P1156
   McGill TJ, 2018, INVEST OPHTH VIS SCI, V59, P1374, DOI 10.1167/iovs.17-22467
   NATHENSON SG, 1981, ANNU REV BIOCHEM, V50, P1025, DOI 10.1146/annurev.bi.50.070181.005113
   Osakada F, 2009, J CELL SCI, V122, P3169, DOI 10.1242/jcs.050393
   Pegram HJ, 2011, IMMUNOL CELL BIOL, V89, P216, DOI 10.1038/icb.2010.78
   Pennington BO, 2015, STEM CELL TRANSL MED, V4, P165, DOI 10.5966/sctm.2014-0179
   Petrus-Reurer S, 2017, INVEST OPHTH VIS SCI, V58, DOI 10.1167/iovs.16-20738
   Reyes AP, 2016, STEM CELL REP, V6, P9, DOI 10.1016/j.stemcr.2015.11.008
   Rodin S, 2014, NAT PROTOC, V9, P2354, DOI 10.1038/nprot.2014.159
   Rodin S, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4195
   Schwartz SD, 2016, INVEST OPHTH VIS SCI, V57, DOI 10.1167/iovs.15-18681
   Sharma R, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aat5580
   Sohn EH, 2015, SCI REP-UK, V5, DOI 10.1038/srep11791
   Song WK, 2015, STEM CELL REP, V4, P860, DOI 10.1016/j.stemcr.2015.04.005
   Stanzel BV, 2014, STEM CELL REP, V2, P64, DOI 10.1016/j.stemcr.2013.11.005
   Sugita S, 2018, INVEST OPHTH VIS SCI, V59, P1719, DOI 10.1167/iovs.17-22703
   Sugita S, 2017, STEM CELL REP, V9, P1501, DOI 10.1016/j.stemcr.2017.10.003
   Sugita S, 2016, STEM CELL REP, V7, P619, DOI 10.1016/j.stemcr.2016.08.011
   Sugita S, 2016, STEM CELL REP, V7, P635, DOI 10.1016/j.stemcr.2016.08.010
   Taylor CJ, 2012, CELL STEM CELL, V11, P147, DOI 10.1016/j.stem.2012.07.014
   Vaajasaari H, 2011, MOL VIS, V17, P558
   Vugler A, 2008, EXP NEUROL, V214, P347, DOI 10.1016/j.expneurol.2008.09.007
   Xu HG, 2019, CELL STEM CELL, V24, P566, DOI 10.1016/j.stem.2019.02.005
   Zhang XY, 1998, INVEST OPHTH VIS SCI, V39, P1021
NR 54
TC 17
Z9 17
U1 2
U2 5
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 2213-6711
J9 STEM CELL REP
JI Stem Cell Rep.
PD APR 14
PY 2020
VL 14
IS 4
BP 648
EP 662
DI 10.1016/j.stemcr.2020.02.006
PG 15
WC Cell & Tissue Engineering; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA LE7YV
UT WOS:000526941200012
PM 32197113
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Jandorf, S
   Nielsen, MK
   Sorensen, K
   Sorensen, TL
AF Jandorf, Sofie
   Nielsen, Marie Krogh
   Sorensen, Kristine
   Sorensen, Torben Lykke
TI Low health literacy levels in patients with chronic retinal disease
SO BMC OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; Diabetic macular edema; Health
   literacy; Retinal vein occlusion
ID ASSOCIATION; GLAUCOMA
AB Background A patient's health literacy is fundamental for navigating the health system and managing disease. This study aimed to compare the health literacy levels of patients with chronic retinal disease in Denmark. Methods This cross-sectional questionnaire study used the validated HLS-EU-Q16 questionnaire to determine the health literacy of 225 patients with age-related macular degeneration (AMD), diabetic macular edema (DME) or retinal vein occlusion (RVO), receiving intravitreal treatment at the retinal clinic, Zealand University Hospital, Denmark. Patients were consecutively included as participants for the study. All patients had the option of having the survey read aloud to them. Results Health literacy levels between the patient groups did not differ significantly, however, the proportion of patients with poor health literacy was high-65% of AMD patients, 73% of DME patients, and 63% of patients with RVO. Conclusions Low health literacy of patients with retinal disease signify a need for more health literacy research in the field of retinal diseases, to secure that patients have the timely and appropriate knowledge and competencies to manage their condition.
C1 [Jandorf, Sofie; Nielsen, Marie Krogh; Sorensen, Torben Lykke] Zealand Univ Hosp, Dept Ophthalmol, Clin Eye Res Div, Vestermarksvej 23, DK-4000 Roskilde, Denmark.
   [Sorensen, Kristine] Global Hlth Literacy Acad, Risskov, Denmark.
   [Sorensen, Torben Lykke] Univ Copenhagen, Fac Hlth & Med Sci, Copenhagen, Denmark.
C3 University of Copenhagen
RP Nielsen, MK (通讯作者)，Zealand Univ Hosp, Dept Ophthalmol, Clin Eye Res Div, Vestermarksvej 23, DK-4000 Roskilde, Denmark.
EM mrrm@regionsjaelland.dk
RI Sørensen, Kristine/ABD-6128-2021
OI Sørensen, Kristine/0000-0002-6179-7004; Krogh Nielsen,
   Marie/0000-0003-3804-7296; Jandorf, Sofie/0000-0002-5879-8321
CR Agriculture and fisheries, DAN RUR DEV PROGR 20, V2012, P8
   Beck RW, 2003, AM J OPHTHALMOL, V135, P194, DOI 10.1016/S0002-9394(02)01825-1
   Berens EM, 2016, BMC PUBLIC HEALTH, V16, DOI 10.1186/s12889-016-3810-6
   Chahardah-Cherik Shima MS, 2018, Int J Community Based Nurs Midwifery, V6, P65
   CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8
   Juzych MS, 2008, ARCH OPHTHALMOL-CHIC, V126, P718, DOI 10.1001/archopht.126.5.718
   Kaiser Peter K, 2009, Trans Am Ophthalmol Soc, V107, P311
   Lassen AT, 2016, CLIN EPIDEMIOL, V8, P469, DOI 10.2147/CLEP.S99505
   Levin-Zamir D, 2016, J HEALTH COMMUN, V21, P61, DOI 10.1080/10810730.2016.1207115
   Maindal HT, 2016, SPRINGERPLUS, V5, DOI 10.1186/s40064-016-2887-9
   Mann Baldeep K, 2019, Clin Diabetes, V37, P172, DOI 10.2337/cd18-0068
   Ministry of Higher Education and Science, 2016, DAN ED SYST
   Muir KW, 2006, AM J OPHTHALMOL, V142, P223, DOI 10.1016/j.ajo.2006.03.018
   Muir KW, 2013, CURR OPIN OPHTHALMOL, V24, P119, DOI 10.1097/ICU.0b013e32835c8b0e
   Muir KW, 2010, SURV OPHTHALMOL, V55, P454, DOI 10.1016/j.survophthal.2010.03.005
   Parker R, 2010, J HEALTH COMMUN, V15, P20, DOI 10.1080/10810730.2010.501094
   Schillinger D, 2002, JAMA-J AM MED ASSOC, V288, P475, DOI 10.1001/jama.288.4.475
   Sorensen K, 2015, EUR J PUBLIC HEALTH, V25, P1053, DOI 10.1093/eurpub/ckv043
   Sorensen K, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-948
   Sorensen K, 2012, BMC PUBLIC HEALTH, V12, DOI 10.1186/1471-2458-12-80
   Warren Mary, 2016, Am J Occup Ther, V70, p7003270010p1, DOI 10.5014/ajot.2016.017400
   Wittenberg E, 2018, CLIN J ONCOL NURS, V22, P53, DOI 10.1188/18.CJON.53-61
NR 22
TC 16
Z9 16
U1 1
U2 3
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1471-2415
J9 BMC OPHTHALMOL
JI BMC Ophthalmol.
PD AUG 8
PY 2019
VL 19
IS 1
AR 174
DI 10.1186/s12886-019-1191-1
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA IQ0WX
UT WOS:000480472900001
PM 31395040
OA Green Published, Green Submitted, gold
DA 2022-11-30
ER

PT J
AU Wang, ZX
   Liu, CS
   Huang, S
   Chen, J
AF Wang, Zhongxiao
   Liu, Chi-Hsiu
   Huang, Shuo
   Chen, Jing
TI Wnt Signaling in vascular eye diseases
SO PROGRESS IN RETINAL AND EYE RESEARCH
LA English
DT Review
DE Wnt; Development; Angiogenesis; Norrie disease; FEVR; AMD; DR; ROP
ID ENDOTHELIAL GROWTH-FACTOR; FAMILIAL EXUDATIVE VITREORETINOPATHY;
   BLOOD-BRAIN-BARRIER; OXYGEN-INDUCED RETINOPATHY; WNT/BETA-CATENIN
   PATHWAY; DENSITY-LIPOPROTEIN RECEPTOR; OPTICAL COHERENCE TOMOGRAPHY;
   EMBRYONIC STEM-CELLS; BETA-CATENIN; NORRIE-DISEASE
AB The Wnt signaling pathway plays a pivotal role in vascular morphogenesis in various organs including the eye. Wnt ligands and receptors are key regulators of ocular angiogenesis both during the eye development and in vascular eye diseases. Wnt signaling participates in regulating multiple vascular beds in the eye including regression of the hyaloid vessels, and development of structured layers of vasculature in the retina. Loss-of-function mutations in Wnt signaling components cause rare genetic eye diseases in humans such as Norrie disease, and familial exudative vitreoretinopathy (FEVR) with defective ocular vasculature. On the other hand, experimental studies in more prevalent vascular eye diseases, such as wet age-related macular degeneration (AMD), diabetic retinopathy (DR), retinopathy of prematurity (ROP), and corneal neovascularization, suggest that aberrantly increased Wnt signaling is one of the causations for pathological ocular neovascularization, indicating the potential of modulating Wnt signaling to ameliorate pathological angiogenesis in eye diseases. This review recapitulates the key roles of the Wnt signaling pathway during ocular vascular development and in vascular eye diseases, and pharmaceutical approaches targeting the Wnt signaling as potential treatment options.
C1 [Wang, Zhongxiao; Liu, Chi-Hsiu; Huang, Shuo; Chen, Jing] Harvard Med Sch, Boston Childrens Hosp, Dept Ophthalmol, 300 Longwood Ave, Boston, MA 02115 USA.
C3 Harvard University; Boston Children's Hospital; Harvard Medical School
RP Chen, J (通讯作者)，Harvard Med Sch, Boston Childrens Hosp, Dept Ophthalmol, 300 Longwood Ave, Boston, MA 02115 USA.
EM Jing.Chen@childrens.harvard.edu
FU NIH [R01 EY028100, EY024963]; Mass Lions Eye Research Fund Inc.;
   BrightFocus Foundation; Research to Prevent Blindness; Knights Templar
   Eye Foundation Pediatric Ophthalmology Career Starter Awards; NATIONAL
   EYE INSTITUTE [R01EY024963, R01EY028100] Funding Source: NIH RePORTER
FX This work was supported by NIH R01 EY028100 and EY024963, Mass Lions Eye
   Research Fund Inc., BrightFocus Foundation, and Research to Prevent
   Blindness (to JC). ZW and CL were supported by Knights Templar Eye
   Foundation Pediatric Ophthalmology Career Starter Awards. We thank
   William Britton and Jane Patrick for their excellent assistance with
   language editing.
CR Abdelfattah NS, 2015, INT J OPHTHALMOL-CHI, V8, P182, DOI 10.3980/j.issn.2222-3959.2015.01.32
   Ai MR, 2005, AM J HUM GENET, V77, P741, DOI 10.1086/497706
   AIELLO LP, 1995, P NATL ACAD SCI USA, V92, P10457, DOI 10.1073/pnas.92.23.10457
   Alexander CM, 2012, COLD SPRING HARB PER, V4
   Allinson KR, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039336
   Ambati BK, 2006, NATURE, V443, P993, DOI 10.1038/nature05249
   Anai M, 2005, J BIOL CHEM, V280, P18525, DOI 10.1074/jbc.M500586200
   Anand-Apte B., 2011, RETINA ITS DISORDERS
   Anastas JN, 2013, NAT REV CANCER, V13, P11, DOI 10.1038/nrc3419
   ANDERSEN SR, 1961, ARCH OPHTHALMOL-CHIC, V66, P614, DOI 10.1001/archopht.1961.00960010616003
   Antonetti DA, 2012, NEW ENGL J MED, V366, P1227, DOI 10.1056/NEJMra1005073
   Ardeljan D, 2013, PROG RETIN EYE RES, V37, P68, DOI 10.1016/j.preteyeres.2013.07.003
   Arnold TD, 2012, J NEUROSCI, V32, P1197, DOI 10.1523/JNEUROSCI.5648-11.2012
   Bafico A, 2001, NAT CELL BIOL, V3, P683, DOI 10.1038/35083081
   Bai YJ, 2013, J OCUL PHARMACOL TH, V29, P619, DOI 10.1089/jop.2012.0225
   Barnstable CJ, 2004, PROG RETIN EYE RES, V23, P561, DOI 10.1016/j.preteyeres.2004.05.002
   Baron R, 2013, NAT MED, V19, P179, DOI 10.1038/nm.3074
   Bass AJ, 2011, NAT GENET, V43, P964, DOI 10.1038/ng.936
   Bassnett S, 2017, PROG RETIN EYE RES, V60, P181, DOI 10.1016/j.preteyeres.2017.04.001
   Beck SC, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0178753
   Beebe DC, 2008, SEMIN CELL DEV BIOL, V19, P125, DOI 10.1016/j.semcdb.2007.08.014
   Benedito R, 2009, CELL, V137, P1124, DOI 10.1016/j.cell.2009.03.025
   BERGER W, 1992, NAT GENET, V1, P199, DOI 10.1038/ng0692-199
   Bharadwaj AS, 2013, PROG RETIN EYE RES, V32, P102, DOI 10.1016/j.preteyeres.2012.08.004
   Birdsey GM, 2015, DEV CELL, V32, P82, DOI 10.1016/j.devcel.2014.11.016
   Biswal MR, 2014, INVEST OPHTH VIS SCI, V55, P8044, DOI 10.1167/iovs.14-13932
   Black GCM, 1999, HUM MOL GENET, V8, P2031, DOI 10.1093/hmg/8.11.2031
   Blanco R, 2013, CSH PERSPECT MED, V3, DOI 10.1101/cshperspect.a006569
   BLEEKERWAGEMAKERS LM, 1985, HUM GENET, V71, P211, DOI 10.1007/BF00284575
   Boyden LM, 2002, NEW ENGL J MED, V346, P1513, DOI 10.1056/NEJMoa013444
   Brancato R, 2002, EUR J OPHTHALMOL, V12, P467, DOI 10.5301/EJO.2008.2283
   Bucher Felicitas, 2018, Oncotarget, V9, P33244, DOI 10.18632/oncotarget.26102
   Bucher F, 2017, CIRCULATION, V136, P180, DOI 10.1161/CIRCULATIONAHA.116.025604
   Burke JM, 2008, PROG RETIN EYE RES, V27, P579, DOI 10.1016/j.preteyeres.2008.08.002
   Campochiaro PA, 2015, PROG RETIN EYE RES, V49, P67, DOI 10.1016/j.preteyeres.2015.06.002
   Cattelino A, 2003, J CELL BIOL, V162, P1111, DOI 10.1083/jcb.200212157
   Chan Ling T, 1995, INVEST OPHTH VIS SCI, V36, P1201
   Chan-Ling T, 2018, PROG RETIN EYE RES, V62, P77, DOI 10.1016/j.preteyeres.2017.09.002
   Chang JL, 2017, NAT MED, V23, P450, DOI 10.1038/nm.4309
   Chang TH, 2015, ELIFE, V4, DOI 10.7554/eLife.06554
   Chen J, 2012, PARASITE VECTOR, V5, DOI 10.1186/1756-3305-5-279
   Chen J, 2008, J CLIN INVEST, V118, P526, DOI [10.1172/JC133813, 10.1172/JCI33813]
   Chen Jing, 2007, Angiogenesis, V10, P133, DOI 10.1007/s10456-007-9066-0
   Chen J, 2015, SCI REP-UK, V5, DOI 10.1038/srep11438
   Chen J, 2011, CURR OPIN PEDIATR, V23, P173, DOI 10.1097/MOP.0b013e3283423f35
   Chen J, 2011, CIRCULATION, V124, P1871, DOI 10.1161/CIRCULATIONAHA.111.040337
   Chen J, 2009, INVEST OPHTH VIS SCI, V50, P1329, DOI 10.1167/iovs.08-2521
   Chen Q, 2017, VISION RES, V139, P47, DOI 10.1016/j.visres.2017.02.007
   Chen Q, 2016, MOL CELL BIOL, V36, P2645, DOI 10.1128/MCB.00235-16
   Chen Y, 2007, J BIOL CHEM, V282, P34420, DOI 10.1074/jbc.M611289200
   Chen Y, 2013, DIABETES, V62, P261, DOI 10.2337/db11-0413
   Chen Y, 2009, AM J PATHOL, V175, P2676, DOI 10.2353/ajpath.2009.080945
   CHEN ZY, 1993, NAT GENET, V5, P180, DOI 10.1038/ng1093-180
   CHEN ZY, 1992, NAT GENET, V1, P204, DOI 10.1038/ng0692-204
   Cheng R, 2016, DIABETES, V65, P3730, DOI 10.2337/db16-0426
   Chenga CW, 2003, EXP CELL RES, V291, P415, DOI 10.1016/S0014-4827(03)00411-7
   Cheung N, 2010, LANCET, V376, P124, DOI 10.1016/S0140-6736(09)62124-3
   Cho C, 2017, NEURON, V95, P1221, DOI 10.1016/j.neuron.2017.08.032
   Chu Y, 2001, FASEB J, V15, P2013, DOI 10.1096/fj.00-0868fje
   Clevers H, 2014, SCIENCE, V346, P54, DOI 10.1126/science.1248012
   Cole MF, 2008, GENE DEV, V22, P746, DOI 10.1101/gad.1642408
   Connor KM, 2009, NAT PROTOC, V4, P1565, DOI 10.1038/nprot.2009.187
   Corada M, 2010, DEV CELL, V18, P938, DOI 10.1016/j.devcel.2010.05.006
   CRISWICK VG, 1969, AM J OPHTHALMOL, V68, P578, DOI 10.1016/0002-9394(69)91237-9
   Cui YJ, 2011, NAT MED, V17, P684, DOI 10.1038/nm.2388
   Cursiefen C, 2006, P NATL ACAD SCI USA, V103, P11405, DOI 10.1073/pnas.0506112103
   Dailey WA, 2017, DATA BRIEF, V15, P491, DOI 10.1016/j.dib.2017.09.075
   Dailey WA, 2017, EXP EYE RES, V164, P129, DOI 10.1016/j.exer.2017.08.012
   Dailey WA, 2015, OPHTHALMOLOGY, V122, P1917, DOI 10.1016/j.ophtha.2015.05.036
   Daneman R, 2009, P NATL ACAD SCI USA, V106, P641, DOI 10.1073/pnas.0805165106
   Das A, 2003, PROG RETIN EYE RES, V22, P721, DOI 10.1016/j.preteyeres.2003.08.001
   Davis J, 2011, INVEST OPHTH VIS SCI, V52, P4158, DOI 10.1167/iovs.10-6726
   de Crecchio G, 1998, CLIN GENET, V54, P315, DOI 10.1034/j.1399-0004.1998.5440409.x
   De Ferrari GV, 2007, P NATL ACAD SCI USA, V104, P9434, DOI 10.1073/pnas.0603523104
   de Iongh RU, 2006, FRONT BIOSCI-LANDMRK, V11, P2442, DOI 10.2741/1982
   de La Coste A, 1998, P NATL ACAD SCI USA, V95, P8847
   Dejana E, 2010, CIRC RES, V107, P943, DOI 10.1161/CIRCRESAHA.110.223750
   Deng GT, 2017, INVEST OPHTH VIS SCI, V58, P5030, DOI 10.1167/iovs.16-21402
   Dickinson JL, 2006, CLIN EXP OPHTHALMOL, V34, P682, DOI 10.1111/j.1442-9071.2006.01314.x
   Ding LX, 2014, AM J PATHOL, V184, P2709, DOI 10.1016/j.ajpath.2014.06.021
   Dixelius J, 2003, CANCER LETT, V196, P1, DOI 10.1016/S0304-3835(03)00267-2
   Dorrell MI, 2002, INVEST OPHTH VIS SCI, V43, P3500
   Dorrell MI, 2006, PROG RETIN EYE RES, V25, P277, DOI 10.1016/j.preteyeres.2006.01.001
   Drenser KA, 2007, RETINA-J RET VIT DIS, V27, P243, DOI 10.1097/01.iae.0000231380.29644.c3
   Drenser KA, 2016, EYE BRAIN, V8, P141, DOI 10.2147/EB.S94452
   Dufourcq P, 2008, AM J PATHOL, V172, P37, DOI 10.2353/ajpath.2008.070130
   Durham JT, 2011, CURR DIABETES REP, V11, P253, DOI 10.1007/s11892-011-0204-0
   Ellenberg D, 2010, PROG RETIN EYE RES, V29, P208, DOI 10.1016/j.preteyeres.2010.01.002
   Ells A, 2010, OPHTHALMIC GENET, V31, P37, DOI 10.3109/13816810903479834
   Enomoto A, 2005, DEV CELL, V9, P389, DOI 10.1016/j.devcel.2005.08.001
   Esen E, 2013, CELL METAB, V17, P745, DOI 10.1016/j.cmet.2013.03.017
   Eubelen M, 2018, SCIENCE, V361, P663, DOI 10.1126/science.aat1178
   Fahiminiya S, 2013, J MED GENET, V50, P345, DOI 10.1136/jmedgenet-2013-101567
   Florez JC, 2006, NEW ENGL J MED, V355, P241, DOI 10.1056/NEJMoa062418
   Forsdahl S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102559
   Fragoso MA, 2011, CELL MOL NEUROBIOL, V31, P163, DOI 10.1007/s10571-010-9603-z
   Franco CA, 2016, ELIFE, V5, DOI 10.7554/eLife.07727
   Franco CA, 2009, CURR OPIN GENET DEV, V19, P476, DOI 10.1016/j.gde.2009.09.004
   Frey JL, 2015, MOL CELL BIOL, V35, P1979, DOI 10.1128/MCB.01343-14
   Fruttiger Marcus, 2007, Angiogenesis, V10, P77, DOI 10.1007/s10456-007-9065-1
   Fujimura N, 2016, FRONT CELL DEV BIOL, V4, DOI 10.3389/fcell.2016.00138
   Fujimura N, 2015, DEV GENES EVOL, V225, P121, DOI 10.1007/s00427-015-0493-4
   FULLWOOD P, 1993, BRIT J OPHTHALMOL, V77, P168, DOI 10.1136/bjo.77.3.168
   Fulton AB, 2009, PROG RETIN EYE RES, V28, P452, DOI 10.1016/j.preteyeres.2009.06.003
   Gal M, 2014, AM J MED GENET A, V164, P2996, DOI 10.1002/ajmg.a.36739
   Gao S, 2017, SCI REP-UK, V7, DOI 10.1038/srep42846
   Gao XX, 2015, MOL VIS, V21, P665
   Gariano RF, 2005, NATURE, V438, P960, DOI 10.1038/nature04482
   Gariano RF, 1996, INVEST OPHTH VIS SCI, V37, P2367
   Gehrs KM, 2006, ANN MED, V38, P450, DOI 10.1080/07853890600946724
   Gerhardt H, 2003, J CELL BIOL, V161, P1163, DOI 10.1083/jcb.200302047
   Gong YQ, 2001, CELL, V107, P513, DOI 10.1016/S0092-8674(01)00571-2
   Goodwin AM, 2007, GROWTH FACTORS, V25, P25, DOI 10.1080/08977190701272933
   Goodwin AM, 2006, DEV DYNAM, V235, P3110, DOI 10.1002/dvdy.20939
   Grant SFA, 2006, NAT GENET, V38, P320, DOI 10.1038/ng1732
   Green W R, 1999, Mol Vis, V5, P27
   Grisanti S, 2008, PROG RETIN EYE RES, V27, P372, DOI 10.1016/j.preteyeres.2008.05.002
   Grossniklaus HE, 2010, PROG RETIN EYE RES, V29, P500, DOI 10.1016/j.preteyeres.2010.05.003
   Gurney A, 2012, P NATL ACAD SCI USA, V109, P11717, DOI 10.1073/pnas.1120068109
   Hackam AS, 2005, IUBMB LIFE, V57, P381, DOI 10.1080/15216540500137586
   Hackett SF, 2002, J CELL PHYSIOL, V192, P182, DOI 10.1002/jcp.10128
   Hansen RM, 2017, PROG RETIN EYE RES, V56, P32, DOI 10.1016/j.preteyeres.2016.09.004
   Hartnett M. E., 2013, PEDIAT RETINA
   Hartnett ME, 2012, NEW ENGL J MED, V367, P2515, DOI 10.1056/NEJMra1208129
   Hatzis P, 2008, MOL CELL BIOL, V28, P2732, DOI 10.1128/MCB.02175-07
   He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509
   He XM, 2017, KIDNEY INT, V91, P642, DOI 10.1016/j.kint.2016.09.036
   Hellstrom M, 2007, NATURE, V445, P776, DOI 10.1038/nature05571
   Hellstrom A, 2013, LANCET, V382, P1445, DOI 10.1016/S0140-6736(13)60178-6
   Henkind P, 1979, PHYSL HUMAN EYE VISU, P98
   Hildebrand GD., 2011, PEDIAT RETINA
   Hiraoka M, 2001, J HUM GENET, V46, P178, DOI 10.1007/s100380170085
   Hobbs R. P., 2013, HYALOIDAL VASCULATUR
   Hoeflich KP, 2000, NATURE, V406, P86, DOI 10.1038/35017574
   Hombrebueno JR, 2018, DIABETOLOGIA, V61, P2433, DOI 10.1007/s00125-018-4682-3
   Howe LR, 2003, CANCER RES, V63, P1906
   Hsieh JC, 1999, NATURE, V398, P431, DOI 10.1038/18899
   Hsieh M, 2005, BIOL REPROD, V73, P1135, DOI 10.1095/biolreprod.105.042739
   Hu Y, 2013, INVEST OPHTH VIS SCI, V54, P141, DOI 10.1167/iovs.12-10281
   Huang H, 1999, AM J PATHOL, V155, P1795, DOI 10.1016/S0002-9440(10)65496-X
   Huang S, 2017, CANCER RES, V77, P6562, DOI 10.1158/0008-5472.CAN-17-1570
   Huang YL, 2015, P NATL ACAD SCI USA, V112, P5732, DOI 10.1073/pnas.1423533112
   Huelsken J, 2000, J CELL BIOL, V148, P567, DOI 10.1083/jcb.148.3.567
   Humphries AC, 2018, CURR OPIN CELL BIOL, V51, P110, DOI 10.1016/j.ceb.2017.12.005
   Hutcheson KA, 2005, MOL VIS, V11, P501
   Ito M, 1999, ANAT EMBRYOL, V200, P403, DOI 10.1007/s004290050289
   Ito T, 2013, AM J PATHOL, V182, P586, DOI 10.1016/j.ajpath.2012.10.012
   Iwai-Takekoshi L, 2018, DEVELOPMENT, V145, DOI 10.1242/dev.163212
   Iyer LM, 2018, NUCLEIC ACIDS RES, V46, P2850, DOI 10.1093/nar/gky049
   Jiao XD, 2004, AM J HUM GENET, V75, P878, DOI 10.1086/425080
   Joyal JS, 2018, PROG RETIN EYE RES, V64, P131, DOI 10.1016/j.preteyeres.2017.11.002
   Joyal JS, 2016, NAT MED, V22, P439, DOI 10.1038/nm.4059
   Ju R, 2010, P NATL ACAD SCI USA, V107, P6906, DOI 10.1073/pnas.1001075107
   Junge HJ, 2009, CELL, V139, P299, DOI 10.1016/j.cell.2009.07.048
   Kato M, 2002, J CELL BIOL, V157, P303, DOI 10.1083/jcb.200201089
   Katoh M, 2017, INT J MOL MED, V40, P587, DOI 10.3892/ijmm.2017.3071
   Kawano Y, 2003, J CELL SCI, V116, P2627, DOI 10.1242/jcs.00623
   KENDALL RL, 1993, P NATL ACAD SCI USA, V90, P10705, DOI 10.1073/pnas.90.22.10705
   Kim JS, 2010, CURR EYE RES, V35, P274, DOI 10.3109/02713680903528345
   Kimelman D, 2006, ONCOGENE, V25, P7482, DOI 10.1038/sj.onc.1210055
   KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562
   Kitamura T, 2008, NAT CELL BIOL, V10, P329, DOI 10.1038/ncb1695
   Klein D, 2008, HEPATOLOGY, V47, P1018, DOI 10.1002/hep.22084
   Koch S, 2015, CELL, V163, P1225, DOI 10.1016/j.cell.2015.10.029
   Korinek V, 1998, NAT GENET, V19, P379, DOI 10.1038/1270
   Korn C, 2014, DEVELOPMENT, V141, P1757, DOI 10.1242/dev.104422
   Kretzschmar K, 2017, DEV BIOL, V428, P273, DOI 10.1016/j.ydbio.2017.05.015
   Krishnamurthy N, 2018, CANCER TREAT REV, V62, P50, DOI 10.1016/j.ctrv.2017.11.002
   Krzystolik MG, 2002, ARCH OPHTHALMOL-CHIC, V120, P338
   Kwiatkowski S, 2013, DEV DYNAM, V242, P738, DOI 10.1002/dvdy.23956
   Lafaut BA, 2000, BRIT J OPHTHALMOL, V84, P1269, DOI 10.1136/bjo.84.11.1269
   Lai MB, 2017, CELL REP, V19, P2809, DOI 10.1016/j.celrep.2017.06.004
   Lammi L, 2004, AM J HUM GENET, V74, P1043, DOI 10.1086/386293
   Landgraf P, 2007, CELL, V129, P1401, DOI 10.1016/j.cell.2007.04.040
   LAQUA H, 1980, A GRAEF ARCH KLIN EX, V213, P121, DOI 10.1007/BF00413539
   Lara-Castillo N, 2015, REV ENDOCR METAB DIS, V16, P141, DOI 10.1007/s11154-015-9315-2
   Lee H, 2013, ACTA HISTOCHEM, V115, P447, DOI 10.1016/j.acthis.2012.10.008
   Lee K, 2014, J CELL SCI, V127, P4857, DOI 10.1242/jcs.149302
   Lee K, 2012, DIABETES, V61, P2948, DOI 10.2337/db11-0300
   Li J, 2014, INVEST OPHTH VIS SCI, V55, P8267, DOI 10.1167/iovs.14-15623
   Li XF, 2005, J BIOL CHEM, V280, P19883, DOI 10.1074/jbc.M413274200
   Liebner S, 2008, J CELL BIOL, V183, P409, DOI 10.1083/jcb.200806024
   Lim X., 2013, COLD SPRING HERB PER, V5
   Lin JB, 2018, EXP EYE RES, V174, P107, DOI 10.1016/j.exer.2018.05.033
   Lin S, 2009, MOL VIS, V15, P26
   Little RD, 2002, AM J HUM GENET, V70, P11, DOI 10.1086/338450
   Liu CH, 2017, FASEB J, V31, P4665, DOI 10.1096/fj.201700336R
   Liu CH, 2015, P NATL ACAD SCI USA, V112, P12163, DOI 10.1073/pnas.1508426112
   Liu H, 2003, DEV DYNAM, V227, P323, DOI 10.1002/dvdy.10315
   Liu H, 2006, INVEST OPHTH VIS SCI, V47, P5088, DOI 10.1167/iovs.06-0403
   Liu PT, 1999, NAT GENET, V22, P361, DOI 10.1038/11932
   Liu WG, 2000, NAT GENET, V26, P146, DOI 10.1038/79859
   Liu XC, 2013, DIABETES, V62, P4228, DOI 10.2337/db12-1710
   Liu XC, 2013, INVEST OPHTH VIS SCI, V54, P7386, DOI 10.1167/iovs.13-13163
   Lobov IB, 2005, NATURE, V437, P417, DOI 10.1038/nature03928
   Logan CY, 2004, ANNU REV CELL DEV BI, V20, P781, DOI 10.1146/annurev.cellbio.20.010403.113126
   London A, 2013, NAT REV NEUROL, V9, P44, DOI 10.1038/nrneurol.2012.227
   Longeras R, 2012, EXP DIABETES RES, DOI 10.1155/2012/518426
   Luhmann UFO, 2005, INVEST OPHTH VIS SCI, V46, P3372, DOI 10.1167/iovs.05-0174
   Lutty GA, 2018, PROG RETIN EYE RES, V62, P58, DOI 10.1016/j.preteyeres.2017.10.001
   Ma B, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00378
   Ma DHK, 2006, PROG RETIN EYE RES, V25, P563, DOI 10.1016/j.preteyeres.2006.09.001
   Ma SC, 2017, CNS NEUROSCI THER, V23, P947, DOI 10.1111/cns.12764
   MacDonald BT, 2009, DEV CELL, V17, P9, DOI 10.1016/j.devcel.2009.06.016
   Mani A, 2007, SCIENCE, V315, P1278, DOI 10.1126/science.1136370
   Mao BY, 2002, NATURE, V417, P664, DOI 10.1038/nature756
   Massink MPG, 2015, AM J HUM GENET, V97, P621, DOI 10.1016/j.ajhg.2015.08.014
   Mastropasqua R, 2014, PROG RETIN EYE RES, V43, P92, DOI 10.1016/j.preteyeres.2014.07.003
   Maye P, 2004, J BIOL CHEM, V279, P24659, DOI 10.1074/jbc.M311724200
   McBride JD, 2017, INT J HEMATOL, V105, P748, DOI 10.1007/s12185-017-2205-5
   McBride JD, 2014, J INVEST DERMATOL, V134, P1725, DOI 10.1038/jid.2014.40
   McClung MR, 2014, NEW ENGL J MED, V370, P412, DOI 10.1056/NEJMoa1305224
   McKenna CC, 2014, DEV BIOL, V391, P241, DOI 10.1016/j.ydbio.2014.04.017
   MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092-8674(90)90385-R
   MEITINGER T, 1993, NAT GENET, V5, P376, DOI 10.1038/ng1293-376
   Mikels AJ, 2006, PLOS BIOL, V4, P570, DOI 10.1371/journal.pbio.0040115
   Min JK, 2011, J CLIN INVEST, V121, P1882, DOI 10.1172/JCI42556
   Mizukami M, 2009, EXP EYE RES, V89, P462, DOI 10.1016/j.exer.2009.04.011
   Monkley SJ, 1996, DEVELOPMENT, V122, P3343
   Moran E, 2014, INVEST OPHTH VIS SCI, V55, P4568, DOI 10.1167/iovs.13-13127
   Moran EP, 2016, AM J PHYSIOL-HEART C, V311, pH738, DOI 10.1152/ajpheart.00005.2016
   Moran EP, 2015, PPAR RES, V2015, DOI 10.1155/2015/595426
   Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787
   Nakatsu MN, 2011, INVEST OPHTH VIS SCI, V52, P4734, DOI 10.1167/iovs.10-6486
   Nayak G, 2018, DEVELOPMENT, V145, DOI 10.1242/dev.154898
   NEUHAUSER G, 1976, CLIN GENET, V9, P324
   Niehrs C, 2006, ONCOGENE, V25, P7469, DOI 10.1038/sj.onc.1210054
   Niemann S, 2004, AM J HUM GENET, V74, P558, DOI 10.1086/382196
   Nikopoulos K, 2010, AM J HUM GENET, V86, P240, DOI 10.1016/j.ajhg.2009.12.016
   Nimmagadda S, 2007, DEV BIOL, V305, P421, DOI 10.1016/j.ydbio.2007.02.031
   NISHISHO I, 1991, SCIENCE, V253, P665, DOI 10.1126/science.1651563
   Nitta T, 2003, J CELL BIOL, V161, P653, DOI 10.1083/jcb.200302070
   NODEN DM, 1989, AM REV RESPIR DIS, V140, P1097, DOI 10.1164/ajrccm/140.4.1097
   NUSSE R, 1992, CELL, V69, P1073, DOI 10.1016/0092-8674(92)90630-U
   NUSSE R, 1982, CELL, V31, P99, DOI 10.1016/0092-8674(82)90409-3
   Nusse R, 2017, CELL, V169, P985, DOI 10.1016/j.cell.2017.05.016
   Ohlmann A, 2005, J NEUROSCI, V25, P1701, DOI 10.1523/JNEUROSCI.4756-04.2005
   Ohlmann A, 2012, PROG RETIN EYE RES, V31, P243, DOI 10.1016/j.preteyeres.2012.02.002
   Ohlmann A, 2010, J NEUROSCI, V30, P183, DOI 10.1523/JNEUROSCI.3210-09.2010
   Ohlmann AV, 2004, INVEST OPHTH VIS SCI, V45, P2384, DOI 10.1167/iovs.03-1214
   Okabe K, 2014, CELL, V159, P584, DOI 10.1016/j.cell.2014.09.025
   Ouyang H, 2014, NATURE, V511, P358, DOI 10.1038/nature13465
   Paes KT, 2011, INVEST OPHTH VIS SCI, V52, P6452, DOI 10.1167/iovs.10-7146
   Palacios J, 1998, CANCER RES, V58, P1344
   PARDANAUD L, 1989, DEVELOPMENT, V105, P473
   Park K, 2011, MOL CELL BIOL, V31, P3038, DOI 10.1128/MCB.01211-10
   Park KH, 2014, INVEST OPHTH VIS SCI, V55, P5522, DOI 10.1167/iovs.14-14566
   Parmalee NL, 2008, CURR DRUG TARGETS, V9, P558, DOI 10.2174/138945008784911822
   PARSONS MA, 1992, GRAEF ARCH CLIN EXP, V230, P248, DOI 10.1007/BF00176299
   Patel AK, 2015, NEUROPHARMACOLOGY, V91, P1, DOI 10.1016/j.neuropharm.2014.11.015
   Peghaire C, 2016, ARTERIOSCL THROM VAS, V36, P2369, DOI 10.1161/ATVBAHA.116.307926
   Penn JS, 2008, PROG RETIN EYE RES, V27, P331, DOI 10.1016/j.preteyeres.2008.05.001
   Perez VADJ, 2009, J CELL BIOL, V184, P83, DOI 10.1083/jcb.200806049
   Person AD, 2010, DEV DYNAM, V239, P327, DOI 10.1002/dvdy.22156
   Piccolo S, 1999, NATURE, V397, P707, DOI 10.1038/17820
   PIERCE EA, 1995, P NATL ACAD SCI USA, V92, P905, DOI 10.1073/pnas.92.3.905
   Poulter JA, 2010, AM J HUM GENET, V86, P248, DOI 10.1016/j.ajhg.2010.01.012
   Pyott SM, 2013, AM J HUM GENET, V92, P590, DOI 10.1016/j.ajhg.2013.02.009
   Qin MH, 2005, HUM MUTAT, V26, P104, DOI 10.1002/humu.20191
   Qiu F, 2014, EYE, V28, P402, DOI 10.1038/eye.2013.229
   Qiu FF, 2018, MICROVASC RES, V119, P29, DOI 10.1016/j.mvr.2018.03.011
   Qiu FF, 2017, INVEST OPHTH VIS SCI, V58, P5065, DOI 10.1167/iovs.17-22091
   Qiu FF, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-01119-2
   Rattner A, 2014, INVEST OPHTH VIS SCI, V55, P8614, DOI 10.1167/iovs.14-15693
   REDMOND RM, 1993, OPHTHALMIC PAED GEN, V14, P1, DOI 10.3109/13816819309087615
   Rehm HL, 2002, J NEUROSCI, V22, P4286, DOI 10.1523/JNEUROSCI.22-11-04286.2002
   Reis M, 2013, EXP CELL RES, V319, P1317, DOI 10.1016/j.yexcr.2012.12.023
   Reis M, 2012, J EXP MED, V209, P1611, DOI 10.1084/jem.20111580
   Richter M, 1998, INVEST OPHTH VIS SCI, V39, P2450
   Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0
   Robanus-Maandag EC, 2010, CARCINOGENESIS, V31, P946, DOI 10.1093/carcin/bgq046
   Robitaille J, 2002, NAT GENET, V32, P326, DOI 10.1038/ng957
   Robitaille JM, 2011, BRIT J OPHTHALMOL, V95, P574, DOI 10.1136/bjo.2010.190116
   Rodilla V, 2009, P NATL ACAD SCI USA, V106, P6315, DOI 10.1073/pnas.0813221106
   Rodrigues EB, 2009, PROG RETIN EYE RES, V28, P117, DOI 10.1016/j.preteyeres.2008.11.005
   Saint-Geniez M, 2004, INT J DEV BIOL, V48, P1045, DOI 10.1387/ijdb.041895ms
   Sakabe M, 2017, P NATL ACAD SCI USA, V114, P10918, DOI 10.1073/pnas.1704030114
   Sato N, 2004, NAT MED, V10, P55, DOI 10.1038/nm979
   Satoh S, 2000, NAT GENET, V24, P245, DOI 10.1038/73448
   Schafer NF, 2009, INVEST OPHTH VIS SCI, V50, P906, DOI 10.1167/iovs.08-1731
   Schmidt KG, 2008, CURR NEUROPHARMACOL, V6, P164, DOI 10.2174/157015908784533851
   Schmidt-Erfurth UM, 2007, PROG RETIN EYE RES, V26, P437, DOI 10.1016/j.preteyeres.2007.03.002
   Schuijers J, 2014, EMBO J, V33, P146, DOI 10.1002/embj.201385358
   Scott A, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011863
   Seitz R, 2018, INVEST OPHTH VIS SCI, V59, P2240, DOI 10.1167/iovs.17-23403
   Seitz R, 2010, J NEUROSCI, V30, P5998, DOI 10.1523/JNEUROSCI.0730-10.2010
   Selvam S, 2018, PROG RETIN EYE RES, V63, P1, DOI 10.1016/j.preteyeres.2017.11.001
   Semenov MV, 2006, J BIOL CHEM, V281, P38276, DOI 10.1074/jbc.M609509200
   Shastry BS, 2010, J BIOMED SCI, V17, DOI 10.1186/1423-0127-17-69
   Shastry BS, 2009, CLIN EXP OPHTHALMOL, V37, P884, DOI 10.1111/j.1442-9071.2009.02150.x
   SHASTRY BS, 1995, GENOMICS, V27, P341, DOI 10.1006/geno.1995.1052
   Shastry BS, 1997, ARCH OPHTHALMOL-CHIC, V115, P651, DOI 10.1001/archopht.1997.01100150653015
   Shimomura Y, 2010, NATURE, V464, P1043, DOI 10.1038/nature08875
   SMITH LEH, 1994, INVEST OPHTH VIS SCI, V35, P101
   Staal FJT, 2004, J IMMUNOL, V172, P1099, DOI 10.4049/jimmunol.172.2.1099
   Stahl A, 2010, INVEST OPHTH VIS SCI, V51, P2813, DOI 10.1167/iovs.10-5176
   Stefater JA, 2011, NATURE, V474, P511, DOI 10.1038/nature10085
   Stenman JM, 2008, SCIENCE, V322, P1247, DOI 10.1126/science.1164594
   Sun Y, 2018, ANNU REV VIS SCI, V4, P101, DOI 10.1146/annurev-vision-091517-034018
   Sun Y, 2017, J EXP MED, V214, P1753, DOI 10.1084/jem.20161645
   Sunaga N, 2001, GENE CHROMOSOME CANC, V30, P316, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1097>3.0.CO;2-9
   Takahashi K, 2003, FASEB J, V17, P896, DOI 10.1096/fj.02-0824fje
   Takahashi M, 2002, CANCER RES, V62, P5651
   Takahashi Y, 2015, FEBS LETT, V589, P1143, DOI 10.1016/j.febslet.2015.03.010
   Takeda H, 2006, NAT MED, V12, P395, DOI 10.1038/nm1386
   Takemaru KI, 2003, NATURE, V422, P905, DOI 10.1038/nature01570
   Tanaka Y, 2001, CANCER RES, V61, P8401
   ten Berge D, 2008, CELL STEM CELL, V3, P508, DOI 10.1016/j.stem.2008.09.013
   Ten Berge D, 2011, NAT CELL BIOL, V13, P1070, DOI 10.1038/ncb2314
   Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884
   Tokunaga CC, 2013, INVEST OPHTH VIS SCI, V54, P222, DOI 10.1167/iovs.12-10127
   Toomes C, 2004, AM J HUM GENET, V74, P721, DOI 10.1086/383202
   Tuo JS, 2015, J TRANSL MED, V13, DOI 10.1186/s12967-015-0683-x
   Vallee A, 2017, J MOL NEUROSCI, V62, P368, DOI 10.1007/s12031-017-0947-4
   Vallon M, 2018, CELL REP, V25, P339, DOI 10.1016/j.celrep.2018.09.045
   van de Schans VAM, 2008, EUR J PHARMACOL, V585, P338, DOI 10.1016/j.ejphar.2008.02.093
   Van Raay TJ, 2005, NEURON, V46, P23, DOI 10.1016/j.neuron.2005.02.023
   Van Wesenbeeck L, 2003, AM J HUM GENET, V72, P763, DOI 10.1086/368277
   Varelas X, 2010, DEV CELL, V18, P579, DOI 10.1016/j.devcel.2010.03.007
   Wang H, 2007, J BIOL CHEM, V282, P782, DOI 10.1074/jbc.M606610200
   Wang H, 2006, CIRC RES, V98, P1331, DOI 10.1161/01.RES.0000220650.26555.1d
   Wang HB, 2017, MOL MED REP, V16, P3351, DOI 10.3892/mmr.2017.6971
   Wang YS, 2012, CELL, V151, P1332, DOI 10.1016/j.cell.2012.10.042
   Wang YK, 1997, HUM MOL GENET, V6, P465, DOI 10.1093/hmg/6.3.465
   Wang ZX, 2016, AM J PATHOL, V186, P2588, DOI 10.1016/j.ajpath.2016.06.015
   Wang ZX, 2015, ARTERIOSCL THROM VAS, V35, P855, DOI 10.1161/ATVBAHA.114.304627
   Wang ZX, 2014, INVEST OPHTH VIS SCI, V55, P3820, DOI 10.1167/iovs.13-13396
   Watanabe D, 2005, NEW ENGL J MED, V353, P782, DOI 10.1056/NEJMoa041773
   WATANABE T, 1988, NATURE, V332, P834, DOI 10.1038/332834a0
   Watson MG, 2012, J R SOC INTERFACE, V9, P2351, DOI 10.1098/rsif.2012.0067
   Weidemann A, 2010, GLIA, V58, P1177, DOI 10.1002/glia.20997
   West-Mays JA, 2010, PROG RETIN EYE RES, V29, P135, DOI 10.1016/j.preteyeres.2009.12.001
   White J, 2015, AM J HUM GENET, V96, P612, DOI 10.1016/j.ajhg.2015.02.015
   White JJ, 2018, AM J HUM GENET, V102, P27, DOI 10.1016/j.ajhg.2017.10.002
   White JJ, 2016, AM J HUM GENET, V98, P553, DOI 10.1016/j.ajhg.2016.01.005
   Willert Jennifer, 2002, BMC Dev Biol, V2, P8, DOI 10.1186/1471-213X-2-8
   Williams BO, 2017, BONE, V102, P26, DOI 10.1016/j.bone.2017.03.044
   Wirostko B, 2008, PROG RETIN EYE RES, V27, P608, DOI 10.1016/j.preteyeres.2008.09.002
   Witmer AN, 2003, PROG RETIN EYE RES, V22, P1, DOI 10.1016/S1350-9462(02)00043-5
   Wright M, 1999, BIOCHEM BIOPH RES CO, V263, P384, DOI 10.1006/bbrc.1999.1344
   Wu JH, 2016, HUM MOL GENET, V25, P1637, DOI 10.1093/hmg/ddw041
   Wu LH, 2017, FETAL PEDIATR PATHOL, V36, P240, DOI 10.1080/15513815.2017.1307474
   Xia CH, 2008, HUM MOL GENET, V17, P1605, DOI 10.1093/hmg/ddn047
   Xia CH, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011676
   Xu C, 2009, CELL CYCLE, V8, P4032, DOI 10.4161/cc.8.24.10111
   Xu Q, 2004, CELL, V116, P883, DOI 10.1016/S0092-8674(04)00216-8
   Xu SB, 2009, PROG RETIN EYE RES, V28, P87, DOI 10.1016/j.preteyeres.2008.11.003
   Xu SH, 2012, PLOS BIOL, V10, DOI 10.1371/journal.pbio.1001286
   Yao K, 2018, NATURE, V560, P484, DOI 10.1038/s41586-018-0425-3
   Yao K, 2016, CELL REP, V17, P165, DOI 10.1016/j.celrep.2016.08.078
   Ye X, 2011, GENE EXPR PATTERNS, V11, P151, DOI 10.1016/j.gep.2010.10.007
   Ye X, 2010, TRENDS MOL MED, V16, P417, DOI 10.1016/j.molmed.2010.07.003
   Ye X, 2009, CELL, V139, P285, DOI 10.1016/j.cell.2009.07.047
   Yi H, 2007, INVEST OPHTH VIS SCI, V48, P5733, DOI 10.1167/iovs.07-0097
   Yonekawa Y, 2017, RETINA-J RET VIT DIS, V37, P2208, DOI 10.1097/IAE.0000000000001719
   Yonekawa Y, 2015, OPHTHALMOLOGY, V122, P2270, DOI 10.1016/j.ophtha.2015.07.024
   Yoshikawa Y, 2016, J EXP MED, V213, P1175, DOI 10.1084/jem.20151966
   Zeilbeck LF, 2016, EXP EYE RES, V145, P317, DOI 10.1016/j.exer.2015.12.001
   Zeng L, 1997, CELL, V90, P181, DOI 10.1016/S0092-8674(00)80324-4
   Zerlin M, 2008, ANGIOGENESIS, V11, P63, DOI 10.1007/s10456-008-9095-3
   Zhang B, 2010, PROTEIN CELL, V1, P898, DOI 10.1007/s13238-010-0112-0
   Zhang B, 2010, DIABETES, V59, P1809, DOI 10.2337/db09-1056
   Zhang B, 2010, P NATL ACAD SCI USA, V107, P6900, DOI 10.1073/pnas.0906764107
   Zhang B, 2009, INVEST OPHTH VIS SCI, V50, P3943, DOI 10.1167/iovs.08-2954
   Zhang C, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms16050
   Zhang JM, 2013, MOL CELL BIOCHEM, V379, P295, DOI 10.1007/s11010-013-1654-2
   Zhang LH, 2017, CIRCULATION, V135, P2505, DOI 10.1161/CIRCULATIONAHA.116.025722
   Zhang SX, 2007, PROG RETIN EYE RES, V26, P1, DOI 10.1016/j.preteyeres.2006.09.002
   Zhang XB, 2001, CANCER RES, V61, P6050
   Zhang YK, 2017, INT J OPHTHALMOL-CHI, V10, P1791, DOI 10.18240/ijo.2017.12.01
   Zhang YJ, 2015, DEVELOPMENT, V142, P3383, DOI 10.1242/dev.125393
   Zheng XL, 2017, INVEST OPHTH VIS SCI, V58, P2874, DOI 10.1167/iovs.17-21544
   Zhou KG, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0095020
   Zhou T, 2010, INVEST OPHTH VIS SCI, V51, P4371, DOI 10.1167/iovs.09-4278
   Zhou T, 2014, INVEST OPHTH VIS SCI, V55, P4863, DOI 10.1167/iovs.14-14023
   Zhou YS, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0116095
   Zhou YL, 2014, DEV CELL, V31, P248, DOI 10.1016/j.devcel.2014.08.018
   Zhu CP, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0108859
   Zong RR, 2016, INVEST OPHTH VIS SCI, V57, P1398, DOI 10.1167/iovs.15-17417
   Zurawel RH, 1998, CANCER RES, V58, P896
NR 380
TC 65
Z9 68
U1 5
U2 37
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 1350-9462
EI 1873-1635
J9 PROG RETIN EYE RES
JI Prog. Retin. Eye Res.
PD MAY
PY 2019
VL 70
BP 110
EP 133
DI 10.1016/j.preteyeres.2018.11.008
PG 24
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA IE9IO
UT WOS:000472688300006
PM 30513356
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Karlstetter, M
   Kopatz, J
   Aslanidis, A
   Shahraz, A
   Caramoy, A
   Linnartz-Gerlach, B
   Lin, YC
   Luckoff, A
   Fauser, S
   Duker, K
   Claude, J
   Wang, YN
   Ackermann, J
   Schmidt, T
   Hornung, V
   Skerka, C
   Langmann, T
   Neumann, H
AF Karlstetter, Marcus
   Kopatz, Jens
   Aslanidis, Alexander
   Shahraz, Anahita
   Caramoy, Albert
   Linnartz-Gerlach, Bettina
   Lin, Yuchen
   Lueckoff, Anika
   Fauser, Sascha
   Dueker, Katharina
   Claude, Janine
   Wang, Yiner
   Ackermann, Johannes
   Schmidt, Tobias
   Hornung, Veit
   Skerka, Christine
   Langmann, Thomas
   Neumann, Harald
TI Polysialic acid blocks mononuclear phagocyte reactivity, inhibits
   complement activation, and protects from vascular damage in the retina
SO EMBO MOLECULAR MEDICINE
LA English
DT Article
DE age-related macular degeneration; complement; microglia; polysialic
   acid; SIGLEC
ID EXPERIMENTAL CHOROIDAL NEOVASCULARIZATION; MACULAR DEGENERATION;
   MICROGLIAL CELLS; EPITHELIAL-CELLS; HUMAN SIGLEC-11; C3 CONVERTASE;
   MACROPHAGES; NEUROTOXICITY; VISUALIZATION; MECHANISMS
AB Age-related macular degeneration (AMD) is a major cause of blindness in the elderly population. Its pathophysiology is linked to reactive oxygen species (ROS) and activation of the complement system. Sialic acid polymers prevent ROS production of human mononuclear phagocytes via the inhibitory sialic acid-binding immunoglobulin-like lectin-11 (SIGLEC11) receptor. Here, we show that low-dose intravitreal injection of low molecular weight polysialic acid with average degree of polymerization 20 (polySia avDP20) in humanized transgenic mice expressing SIGLEC11 on mononuclear phagocytes reduced their reactivity and vascular leakage induced by laser coagulation. Furthermore, polySia avDP20 prevented deposition of the membrane attack complex in both SIGLEC11 transgenic and wild-type animals. In vitro, polySia avDP20 showed two independent, but synergistic effects on the innate immune system. First, polySia avDP20 prevented tumor necrosis factor-, vascular endothelial growth factor A, and superoxide production by SIGLEC11-positive phagocytes. Second, polySia avDP20 directly interfered with complement activation. Our data provide evidence that polySia avDP20 ameliorates laser-induced damage in the retina and thus is a promising candidate to prevent AMD-related inflammation and angiogenesis.
C1 [Karlstetter, Marcus; Aslanidis, Alexander; Caramoy, Albert; Lueckoff, Anika; Fauser, Sascha; Langmann, Thomas] Univ Cologne, Dept Ophthalmol, Lab Expt Immunol Eye, Cologne, Germany.
   [Karlstetter, Marcus] Bayer Pharma AG, Therapeut Res Grp Ophthalmol, Wuppertal, Germany.
   [Kopatz, Jens; Shahraz, Anahita; Linnartz-Gerlach, Bettina; Dueker, Katharina; Claude, Janine; Wang, Yiner; Ackermann, Johannes; Neumann, Harald] Univ Bonn, Univ Hosp Bonn, Inst Reconstruct Neurobiol, Bonn, Germany.
   [Lin, Yuchen; Skerka, Christine] Leibniz Inst Nat Prod Res & Infect Biol, Jena, Germany.
   [Schmidt, Tobias; Hornung, Veit] Univ Bonn, Univ Hosp Bonn, Inst Mol Med, Bonn, Germany.
   [Hornung, Veit] Ludwig Maximilians Univ Munchen, Gene Ctr, Munich, Germany.
   [Hornung, Veit] Ludwig Maximilians Univ Munchen, Dept Biochem, Munich, Germany.
C3 University of Cologne; Bayer AG; Bayer Healthcare Pharmaceuticals;
   University of Bonn; Hans Knoll Institute (HKI); University of Bonn;
   University of Munich; University of Munich
RP Langmann, T (通讯作者)，Univ Cologne, Dept Ophthalmol, Lab Expt Immunol Eye, Cologne, Germany.; Neumann, H (通讯作者)，Univ Bonn, Univ Hosp Bonn, Inst Reconstruct Neurobiol, Bonn, Germany.
EM thomas.langmann@uk-koeln.de; hneuman1@uni-bonn.de
RI Linnartz-Gerlach, Bettina/B-9428-2011; Neumann, Harald/A-9718-2010;
   Hornung, Veit/C-3565-2012
OI Linnartz-Gerlach, Bettina/0000-0003-4485-684X; Neumann,
   Harald/0000-0002-5071-5202; Hornung, Veit/0000-0002-4150-194X; Dueker,
   Katharina/0000-0003-0426-468X; Schmidt, Tobias/0000-0003-3102-3515
FU Deutsche Forschungsgemeinschaft [DFG-KFO177, DFG-SFB704, DFG-NE507/14-1,
   DFG-FOR2240, DFG-LA1203/9-1, DFG-Sk46/2-2]; Hertie Foundation; Hans und
   Marlies Stock-Foundation; DFG [EXC 1023]; Koeln Fortune Program/Faculty
   of Medicine, University of Cologne; Bayer Pharma AG [2014-08-1139];
   governmental grant (NRW-Patent-Validierung); governmental grant (BMBF
   VIP+) [03VP00271]
FX This project was supported by the Deutsche Forschungsgemeinschaft
   (DFG-KFO177, DFG-SFB704, DFG-NE507/14-1, DFG-FOR2240, DFG-LA1203/9-1,
   DFG-Sk46/2-2), the Hertie Foundation, and the Hans und Marlies
   Stock-Foundation. HN and BL-G are members of the DFG-funded excellence
   cluster ImmunoSensation (EXC 1023). MK received support by the Koeln
   Fortune Program/Faculty of Medicine, University of Cologne. This project
   was kindly supported by a grant from Bayer Pharma AG ("from targets to
   novel drugs" 2014-08-1139) and by governmental grants
   (NRW-Patent-Validierung; BMBF VIP+ 03VP00271). We thank Jessica
   Reinartz, Rita Jietou, and Eva Scheiffert for excellent technical
   support of cultures and molecular biology. Furthermore, we thank Prof.
   Thomas Scheper for polysialic acids and Prof. Volkmar Gieselmann for his
   support in the isolation of polysialic acids. Iba1 promoter (Hirasawa et
   al, 2005) was kindly provided by Dr. S. Kohsaka (kohsaka@ncnp.go.jp),
   Department of Neurochemistry, National Institute of Neuroscience, Tokyo,
   Japan. We thank Dr. A. Varki for helpful discussions.
CR Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   Angata T, 2002, J BIOL CHEM, V277, P24466, DOI 10.1074/jbc.M202833200
   [Anonymous], 2017, EMBO MOL MED, V9, P154
   Augood CA, 2006, ARCH OPHTHALMOL-CHIC, V124, P529, DOI 10.1001/archopht.124.4.529
   BARTSCH U, 1990, J NEUROCYTOL, V19, P550, DOI 10.1007/BF01257243
   Beutner C, 2013, GLIA, V61, P1429, DOI 10.1002/glia.22524
   Beutner C, 2010, NAT PROTOC, V5, P1481, DOI 10.1038/nprot.2010.90
   Blaum BS, 2015, NAT CHEM BIOL, V11, P77, DOI [10.1038/NCHEMBIO.1696, 10.1038/nchembio.1696]
   Block ML, 2007, NAT REV NEUROSCI, V8, P57, DOI 10.1038/nrn2038
   Bodea LG, 2014, J NEUROSCI, V34, P8546, DOI 10.1523/JNEUROSCI.5002-13.2014
   Bradley DT, 2011, EYE, V25, P683, DOI 10.1038/eye.2011.37
   Claude J, 2013, J NEUROSCI, V33, P18270, DOI 10.1523/JNEUROSCI.2211-13.2013
   Eberhardt HU, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078617
   Espinosa-Heidmann DG, 2003, INVEST OPHTH VIS SCI, V44, P3586, DOI 10.1167/iovs.03-0038
   Eter N, 2008, INVEST OPHTH VIS SCI, V49, P3649, DOI 10.1167/iovs.07-1322
   FEARON DT, 1978, P NATL ACAD SCI USA, V75, P1971, DOI 10.1073/pnas.75.4.1971
   Ferreira VP, 2010, MOL IMMUNOL, V47, P2187, DOI 10.1016/j.molimm.2010.05.007
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Fritsche LG, 2014, ANNU REV GENOM HUM G, V15, P151, DOI 10.1146/annurev-genom-090413-025610
   Gao HM, 2012, TRENDS PHARMACOL SCI, V33, P295, DOI 10.1016/j.tips.2012.03.008
   Gupta N, 2003, EXP EYE RES, V76, P463, DOI 10.1016/S0014-4835(02)00332-9
   Hayakawa T, 2005, SCIENCE, V309, P1693, DOI 10.1126/science.1114321
   Hildebrandt H, 2015, TOP CURR CHEM, V366, P55, DOI 10.1007/128_2013_446
   Hirasawa T, 2005, J NEUROSCI RES, V81, P357, DOI 10.1002/jnr.20480
   KILLINGSWORTH MC, 1990, EYE, V4, P613, DOI 10.1038/eye.1990.86
   Linnartz-Gerlach B, 2014, GLYCOBIOLOGY, V24, P794, DOI 10.1093/glycob/cwu044
   Liu J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072935
   Luckoff A, 2016, EMBO MOL MED, V8, P670, DOI 10.15252/emmm.201505994
   Luo C, 2013, EXP EYE RES, V112, P93, DOI 10.1016/j.exer.2013.04.016
   Ma WX, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007945
   McHarg S, 2015, MOL IMMUNOL, V67, P43, DOI 10.1016/j.molimm.2015.02.032
   Monnier PP, 2001, DEV BIOL, V229, P1, DOI 10.1006/dbio.2000.9970
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   PANGBURN MK, 1978, P NATL ACAD SCI USA, V75, P2416, DOI 10.1073/pnas.75.5.2416
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Sakurai E, 2003, INVEST OPHTH VIS SCI, V44, P3578, DOI 10.1167/iovs.03-0097
   Sato C, 2013, J BIOCHEM, V154, P115, DOI 10.1093/jb/mvt057
   Sawaguchi A, 1999, J HISTOCHEM CYTOCHEM, V47, P919, DOI 10.1177/002215549904700709
   Schwarz F, 2015, ELIFE, V4, DOI 10.7554/eLife.06184
   Shahraz A, 2015, SCI REP-UK, V5, DOI 10.1038/srep16800
   Varki A, 2011, GLYCOBIOLOGY, V21, P1121, DOI 10.1093/glycob/cwr087
   Wang Y, 2010, J NEUROSCI, V30, P3482, DOI 10.1523/JNEUROSCI.3940-09.2010
NR 42
TC 47
Z9 48
U1 0
U2 18
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1757-4676
EI 1757-4684
J9 EMBO MOL MED
JI EMBO Mol. Med.
PD FEB
PY 2017
VL 9
IS 2
BP 154
EP 166
DI 10.15252/emmm.201606627
PG 13
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA EL5JM
UT WOS:000394657400004
PM 28003336
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU de Smet, MD
   Elkareem, AMG
   Zwinderman, AH
AF de Smet, Marc D.
   Elkareem, Ashraf M. Gad
   Zwinderman, Aeilko H.
TI The Vitreous, the Retinal Interface in Ocular Health and Disease
SO OPHTHALMOLOGICA
LA English
DT Review
DE Meta-analysis; Syneresis; Synchysis; Vitreous; Macular hole; Macular
   pucker; Posterior vitreous detachment; Odds ratio; Diabetic retinopathy;
   Neovascularization; Age-related macular degeneration; Proliferative
   diabetic retinopathy; Macular edema
ID OPTICAL-COHERENCE-TOMOGRAPHY; DIABETIC MACULAR EDEMA; VITREOMACULAR
   TRACTION SYNDROME; VEIN OCCLUSION; VITREORETINAL INTERFACE; SPONTANEOUS
   RESOLUTION; HOLE FORMATION; HUMAN-EYE; POSTERIOR VITREOSCHISIS; ASSISTED
   VITRECTOMY
AB The vitreous is a complex structure whose composition and appearance change with age. Anomalous adhesions between the posterior vitreous face and the retinal surface are the cause of numerous vitreoretinal complications, while the presence of an intact posterior hyaloid provides a scaffold for vascular growth and anteroposterior traction. This review summarizes what is known about the biochemistry of the vitreous, the process of posterior vitreous detachment (PVD) development, and the available clinical approaches to examining the vitreous and its interface. A pooled analysis of studies looking at the presence of a complete, partial or absent PVD in a number of macular and retinal diseases allows us to establish odds ratios for these various states. From this emerge both protective and disease-associated states in conditions such as proliferative diabetic retinopathy, macular edema, and age-related macular degeneration. With the emergence of pharmacological means to separate the posterior hyaloid, a better understanding of the possible role of the vitreous in tractional syndromes is required. Copyright (C) 2013 S. Karger AG, Basel
C1 [de Smet, Marc D.; Elkareem, Ashraf M. Gad] Univ Amsterdam, Acad Med Ctr, Dept Ophthalmol, NL-1105 AZ Amsterdam, Netherlands.
   [Zwinderman, Aeilko H.] Univ Amsterdam, Acad Med Ctr, Dept Clin Epidemiol Biostat & Bioinfornnat, NL-1105 AZ Amsterdam, Netherlands.
   [de Smet, Marc D.] MIOS, Retina & Ocular Inflammat Serv, CH-1005 Lausanne, Switzerland.
   [Elkareem, Ashraf M. Gad] Al Azhar Univ, Fac Med, Assiut Branch, Dept Ophthalmol, Assiut, Egypt.
C3 University of Amsterdam; Academic Medical Center Amsterdam; University
   of Amsterdam; Academic Medical Center Amsterdam; Egyptian Knowledge Bank
   (EKB); Al Azhar University; Assiut University
RP de Smet, MD (通讯作者)，MIOS, Retina & Ocular Inflammat Serv, Ave Leman 32, CH-1005 Lausanne, Switzerland.
EM mddesmet1@mac.com
RI De Smet, Marc D./E-2451-2013
OI De Smet, Marc D./0000-0002-9217-5603
CR AKIBA J, 1993, OPHTHALMOLOGY, V100, P1384
   AKIBA J, 1990, OPHTHALMOLOGY, V97, P889
   AKIBA J, 1990, ARCH OPHTHALMOL-CHIC, V108, P1088, DOI 10.1001/archopht.1990.01070100044031
   AKIBA J, 1990, OPHTHALMOLOGY, V97, P1610
   AKIBA J, 1991, OPHTHALMIC SURG LAS, V22, P498
   ARZABE CW, 1991, GRAEF ARCH CLIN EXP, V229, P66, DOI 10.1007/BF00172264
   Avunduk AM, 1997, ACTA OPHTHALMOL SCAN, V75, P441
   BALAZS EA, 1964, EXP EYE RES, V3, P57, DOI 10.1016/S0014-4835(64)80008-7
   Barak Y, 2012, J OPHTHALMOL, V2012, DOI 10.1155/2012/876472
   Bertelmann T, 2011, ACTA OPHTHALMOL, V89, pE327, DOI 10.1111/j.1755-3768.2010.02101.x
   Bishop P, 1996, EYE, V10, P664, DOI 10.1038/eye.1996.159
   BISHOP PN, 1994, BIOCHEM J, V299, P497, DOI 10.1042/bj2990497
   Bishop PN, 2004, INVEST OPHTH VIS SCI, V45, P1041, DOI 10.1167/iovs.03-1017
   Bishop PN, 2000, PROG RETIN EYE RES, V19, P323, DOI 10.1016/S1350-9462(99)00016-6
   Bottos JM, 2012, CURR OPIN OPHTHALMOL, V23, P195, DOI 10.1097/ICU.0b013e328352404c
   Carpineto P, 2004, EUR J OPHTHALMOL, V14, P67, DOI 10.1177/112067210401400113
   Chauhan DS, 2000, ARCH OPHTHALMOL-CHIC, V118, P32
   Cheng CL, 2003, CLIN EXP OPHTHALMOL, V31, P161, DOI 10.1046/j.1442-9071.2003.00626.x
   Chu TG, 1996, OPHTHALMOLOGY, V103, P315
   COMPER WD, 1978, PHYSIOL REV, V58, P255, DOI 10.1152/physrev.1978.58.1.255
   de Smet MD, 2009, OPHTHALMOLOGY, V116, P1349, DOI 10.1016/j.ophtha.2009.03.051
   de Smet MD, 2009, INVEST OPHTH VIS SCI, V50, P814, DOI 10.1167/iovs.08-2185
   DeCroos FC, 2012, INVEST OPHTH VIS SCI, V53, P6504, DOI 10.1167/iovs.12-10370
   Ebato K, 2000, OPHTHALMIC SURG LAS, V31, P245
   Edwards AO, 2008, EYE, V22, P1233, DOI 10.1038/eye.2008.38
   Elkareem AMG, 2014, ACTA OPHTHALMOL, V92, P47, DOI 10.1111/j.1755-3768.2012.02568.x
   Falkner-Radler CI, 2010, OPHTHALMOLOGY, V117, P798, DOI 10.1016/j.ophtha.2009.08.034
   Folgar FA, 2012, INVEST OPHTH VIS SCI, V53, P7395, DOI 10.1167/iovs.12-10379
   FOOS R Y, 1972, Transactions of the American Academy of Ophthalmology and Oto-Laryngology, V76, P480
   FOOS RY, 1972, INVEST OPHTH VISUAL, V11, P801
   FOOS RY, 1980, OPHTHALMOLOGY, V87, P122
   FOOS RY, 1975, A GRAEF ARCH KLIN EX, V196, P103, DOI 10.1007/BF00414796
   FOOS RY, 1982, OPHTHALMOLOGY, V89, P1502
   Gallemore RP, 2000, RETINA-J RET VIT DIS, V20, P115, DOI 10.1097/00006982-200003000-00001
   Gandorfer A, 2004, INVEST OPHTH VIS SCI, V45, P641, DOI 10.1167/iovs.03-0930
   GASS JDM, 1988, ARCH OPHTHALMOL-CHIC, V106, P629, DOI 10.1001/archopht.1988.01060130683026
   Gaucher D, 2005, AM J OPHTHALMOL, V139, P807, DOI 10.1016/j.ajo.2004.12.084
   Goodfellow JFB, 2010, OPHTHAL PHYSL OPT, V30, P20, DOI 10.1111/j.1475-1313.2009.00685.x
   GRABNER G, 1980, INVEST OPHTH VIS SCI, V19, P333
   Gupta P, 2008, RETINA-J RET VIT DIS, V28, P447, DOI 10.1097/IAE.0b013e318160a754
   Haouchine B, 2001, OPHTHALMOLOGY, V108, P15, DOI 10.1016/S0161-6420(00)00519-4
   Hayreh SS, 2004, OPHTHALMOLOGICA, V218, P333, DOI 10.1159/000079476
   HEEGAARD S, 1988, GRAEF ARCH CLIN EXP, V226, P377, DOI 10.1007/BF02172971
   HEEGAARD S, 1986, GRAEF ARCH CLIN EXP, V224, P355, DOI 10.1007/BF02150029
   HIKICHI T, 1995, RETINA-J RET VIT DIS, V15, P29, DOI 10.1097/00006982-199515010-00006
   HIKICHI T, 1995, AM J OPHTHALMOL, V119, P55, DOI 10.1016/S0002-9394(14)73813-9
   HIKICHI T, 1993, AM J OPHTHALMOL, V116, P273, DOI 10.1016/S0002-9394(14)71343-1
   Hikichi T, 1997, OPHTHALMOLOGY, V104, P473, DOI 10.1016/S0161-6420(97)30289-9
   Hikichi T, 1997, JPN J OPHTHALMOL, V41, P154, DOI 10.1016/S0021-5155(97)00033-6
   HIKICHI T, 1993, AM J OPHTHALMOL, V116, P401, DOI 10.1016/S0002-9394(14)71395-9
   HIKICHI T, 1994, AM J OPHTHALMOL, V117, P593, DOI 10.1016/S0002-9394(14)70065-0
   Hillenkamp J, 2007, BRIT J OPHTHALMOL, V91, P1445, DOI 10.1136/bjo.2007.115642
   HIROKAWA H, 1985, ARCH OPHTHALMOL-CHIC, V103, P1704
   HOGAN MJ, 1963, INVEST OPHTH VISUAL, V2, P418
   Hosseini H, 2009, EUR J OPHTHALMOL, V19, P263, DOI 10.1177/112067210901900214
   Hruby K, 1960, IMPORTANCE VITREOUS, P94
   HYAMS SW, 1975, BRIT J OPHTHALMOL, V59, P483, DOI 10.1136/bjo.59.9.483
   Ikeda T, 1999, OPHTHALMOLOGY, V106, P1081, DOI 10.1016/S0161-6420(99)90268-3
   Itakura H, 2011, RETINA-J RET VIT DIS, V31, P1400, DOI 10.1097/IAE.0b013e318206cb43
   Ito Y, 2003, AM J OPHTHALMOL, V135, P351, DOI 10.1016/S0002-9394(02)01944-X
   Jaffe N S, 1967, Trans Am Acad Ophthalmol Otolaryngol, V71, P642
   JAFFE NS, 1968, ARCH OPHTHALMOL-CHIC, V79, P568
   JALKH A, 1982, ARCH OPHTHALMOL-CHIC, V100, P432
   JERDAN J A, 1986, Investigative Ophthalmology and Visual Science, V27, P230
   Johnson Mark W, 2005, Trans Am Ophthalmol Soc, V103, P537
   Johnson MW, 2013, AM J OPHTHALMOL, V155, P203, DOI 10.1016/j.ajo.2012.10.016
   Johnson Mark W, 2012, Retina, V32 Suppl 2, pS174, DOI 10.1097/IAE.0b013e31825bef62
   Johnson MW, 2010, AM J OPHTHALMOL, V149, P371, DOI 10.1016/j.ajo.2009.11.022
   JOHNSON RN, 1988, OPHTHALMOLOGY, V95, P917
   KADO M, 1990, OPHTHALMIC SURG LAS, V21, P544
   KADO M, 1988, AM J OPHTHALMOL, V105, P20, DOI 10.1016/0002-9394(88)90115-8
   Kakehashi A, 1996, GRAEF ARCH CLIN EXP, V234, P425, DOI 10.1007/BF02539408
   Kakehashi A, 1997, BRIT J OPHTHALMOL, V81, P527, DOI 10.1136/bjo.81.7.527
   KAKEHASHI A, 1993, OPHTHALMIC SURG LAS, V24, P846
   KAMEI A, 1982, BIOCHEM BIOPH RES CO, V109, P881, DOI 10.1016/0006-291X(82)92022-8
   Kicova N, 2012, ACTA OPHTHALMOL, V90, pE264, DOI 10.1111/j.1755-3768.2011.02330.x
   KISHI S, 1986, INT OPHTHALMOL, V9, P253, DOI 10.1007/BF00137539
   Kita T, 2007, DIABETES, V56, P1421, DOI 10.2337/db06-1644
   KLOTI R, 1967, EXP EYE RES, V6, P393, DOI 10.1016/S0014-4835(67)80014-9
   KOHNO T, 1987, INVEST OPHTH VIS SCI, V28, P506
   KOHNO T, 1987, INVEST OPHTH VIS SCI, V28, P515
   Koizumi H, 2008, AM J OPHTHALMOL, V145, P509, DOI 10.1016/j.ajo.2007.10.014
   Kraus CL, 2011, CAN J OPHTHALMOL, V46, P186, DOI 10.3129/i10-100
   Krebs I, 2007, AM J OPHTHALMOL, V144, P741, DOI 10.1016/j.ajo.2007.07.024
   Krebs I, 2011, BRIT J OPHTHALMOL, V95, P1415, DOI 10.1136/bjo.2010.192385
   Lai MM, 2006, AM J OPHTHALMOL, V141, P210, DOI 10.1016/j.ajo.2005.07.074
   LARSSON L, 1985, GRAEF ARCH CLIN EXP, V223, P92, DOI 10.1007/BF02150952
   Legarreta JE, 2008, AM J OPHTHALMOL, V145, P1023, DOI 10.1016/j.ajo.2008.01.014
   Levy Jaime, 2004, Int Ophthalmol, V25, P247, DOI 10.1007/s10792-005-8249-1
   Li XX, 2002, GRAEF ARCH CLIN EXP, V240, P56, DOI 10.1007/s004170100351
   Linder B, 1966, ACTA OPHTHALMOL    S, V87, P5
   Los LI, 2003, INVEST OPHTH VIS SCI, V44, P2828, DOI 10.1167/iovs.02-0588
   Martinez MR, 2011, GRAEF ARCH CLIN EXP, V249, P811, DOI 10.1007/s00417-011-1666-0
   Massin P, 2003, AM J OPHTHALMOL, V135, P169, DOI 10.1016/S0002-9394(02)01837-8
   MATSUMOTO B, 1984, INVEST OPHTH VIS SCI, V25, P71
   MCDONNELL PJ, 1985, OPHTHALMOLOGY, V92, P1208
   Michalewska Z, 2009, CLIN EXP OPHTHALMOL, V37, P373, DOI 10.1111/j.1442-9071.2009.02041.x
   Mirza RG, 2007, SURV OPHTHALMOL, V52, P397, DOI 10.1016/j.survophthal.2007.04.007
   Mitry D, 2011, OPHTHALMOLOGY, V118, P1429, DOI 10.1016/j.ophtha.2010.11.031
   Mojana F, 2010, AM J OPHTHALMOL, V149, P641, DOI 10.1016/j.ajo.2009.11.016
   MOORE RF, 1947, BRIT J OPHTHALMOL, V31, P46, DOI 10.1136/bjo.31.1.46
   Murakami T, 2007, RETINA-J RET VIT DIS, V27, P1031, DOI 10.1097/IAE.0b013e318074bc39
   NASRALLAH FP, 1988, OPHTHALMOLOGY, V95, P1335
   NASRALLAH FP, 1989, OPHTHALMOLOGY, V96, P1511
   Nomura Y, 2011, OPHTHALMOLOGY, V118, P853, DOI 10.1016/j.ophtha.2010.09.001
   NOVAK MA, 1984, AM J OPHTHALMOL, V97, P308, DOI 10.1016/0002-9394(84)90628-7
   Oliveira LB, 2001, RETINA, V21, P342
   Ondes F, 2000, JPN J OPHTHALMOL, V44, P91, DOI 10.1016/S0021-5155(99)00174-4
   Ono Ryuichiro, 2005, International Ophthalmology, V26, P15, DOI 10.1007/s10792-005-5389-2
   OSTERLIN S, 1977, ACTA OPHTHALMOL, V55, P353
   PISCHEL DK, 1952, T AM OPHTHAL SOC, V50, P329
   Quaranta-El Maftouhi M, 2006, EUR J OPHTHALMOL, V16, P134
   Robison CD, 2009, AM J OPHTHALMOL, V148, P79, DOI 10.1016/j.ajo.2009.01.014
   ROLDAN M, 1989, ANN OPHTHALMOL, V21, P141
   Rosen RB, 2007, SPEKTRUM AUGENHEILKD, V21, P17, DOI 10.1007/s00717-007-0182-4
   SCHUBERT HD, 1985, ARCH OPHTHALMOL-CHIC, V103, P1538
   Sebag J, 2008, GRAEF ARCH CLIN EXP, V246, P329, DOI 10.1007/s00417-007-0743-x
   Sebag J, 2005, Trans Am Ophthalmol Soc, V103, P473
   SEBAG J, 1992, ARCH OPHTHALMOL-CHIC, V110, P1472, DOI 10.1001/archopht.1992.01080220134035
   SEBAG J, 1993, GRAEF ARCH CLIN EXP, V231, P257, DOI 10.1007/BF00919101
   Sebag J, 2004, GRAEF ARCH CLIN EXP, V242, P690, DOI 10.1007/s00417-004-0980-1
   SEBAG J, 1987, EYE, V1, P254, DOI 10.1038/eye.1987.45
   Sebag J, 2002, EYE, V16, P429, DOI 10.1038/sj.eye.6700201
   Sebag J, 2009, Trans Am Ophthalmol Soc, V107, P35
   Sebag J, 1998, PROG POLYM SCI, V23, P415, DOI 10.1016/S0079-6700(97)00035-X
   SEBAG J, 1984, SURV OPHTHALMOL, V28, P493, DOI 10.1016/0039-6257(84)90231-5
   SEBAG J, 1992, EYE, V6, P541, DOI 10.1038/eye.1992.119
   Sebag J, 2000, EUR J OPHTHALMOL, V10, P1
   Sebag J, 1989, VITREOUS STRUCTURE F
   Serpetopoulos C, 1997, SURV OPHTHALMOL, V42, P92, DOI 10.1016/S0039-6257(97)84046-5
   Simpson ARH, 2012, SURV OPHTHALMOL, V57, P498, DOI 10.1016/j.survophthal.2012.01.011
   SIREK OV, 1977, ATHEROSCLEROSIS, V27, P227, DOI 10.1016/0021-9150(77)90060-0
   Staubach F, 2004, CURR EYE RES, V29, P261, DOI 10.1080/02713680490516747
   STICKLER GB, 1965, MAYO CLIN PROC, V40, P433
   TAGAWA H, 1986, OPHTHALMOLOGY, V93, P596
   Takahashi A, 2012, AM J OPHTHALMOL, V154, P881, DOI 10.1016/j.ajo.2012.05.024
   TAKAHASHI M, 1981, ARCH OPHTHALMOL-CHIC, V99, P241, DOI 10.1001/archopht.1981.03930010243003
   Takahashi MK, 1997, OPHTHALMIC SURG LAS, V28, P294
   Takezawa M, 2011, CLIN OPHTHALMOL, V5, P101, DOI 10.2147/OPTH.S16549
   Tammewar AM, 2009, BRIT J OPHTHALMOL, V93, P366, DOI 10.1136/bjo.2007.132290
   Tan HS, 2009, AM J OPHTHALMOL, V148, P427, DOI 10.1016/j.ajo.2009.04.002
   THEOPOLD H, 1980, A GRAEF ARCH KLIN EX, V214, P33, DOI 10.1007/BF00414534
   TREMPE CL, 1981, OPHTHALMOLOGY, V88, P681
   TREMPE CL, 1986, ARCH OPHTHALMOL-CHIC, V104, P93, DOI 10.1001/archopht.1986.01050130103031
   Uchino E, 2001, ARCH OPHTHALMOL-CHIC, V119, P1475
   Uemura A, 2005, ARCH OPHTHALMOL-CHIC, V123, P209, DOI 10.1001/archopht.123.2.209
   UENO N, 1987, EXP EYE RES, V44, P863, DOI 10.1016/S0014-4835(87)80048-9
   Van Newkirk M R, 2000, Trans Am Ophthalmol Soc, V98, P163
   van Overdam KA, 2005, ARCH OPHTHALMOL-CHIC, V123, P479, DOI 10.1001/archopht.123.4.479
   van Overdam KA, 2001, ARCH OPHTHALMOL-CHIC, V119, P1483
   van Velthoven MEJ, 2005, BRIT J OPHTHALMOL, V89, P1483, DOI 10.1136/bjo.2005.073056
   Van Velthoven MEJ, 2006, RETINA-J RET VIT DIS, V26, P129, DOI 10.1097/00006982-200602000-00001
   van Velthoven MEJ, 2007, PROG RETIN EYE RES, V26, P57, DOI 10.1016/j.preteyeres.2006.10.002
   Wang MY, 2009, RETINA-J RET VIT DIS, V29, P644, DOI 10.1097/IAE.0b013e31819e0d92
   Weber-Krause Brigitte, 1996, Ophthalmologe, V93, P660, DOI 10.1007/s003470050054
   Williamson TH, 2009, EYE, V23, P1477, DOI 10.1038/eye.2008.209
   Wu PC, 2009, EYE, V23, P356, DOI 10.1038/sj.eye.6703038
   Yamaguchi Y, 2003, AM J OPHTHALMOL, V135, P116, DOI 10.1016/S0002-9394(02)01855-X
   Yamashita T, 2002, AM J OPHTHALMOL, V133, P230, DOI 10.1016/S0002-9394(01)01303-4
   YONEMOTO J, 1994, GRAEF ARCH CLIN EXP, V232, P67, DOI 10.1007/BF00171665
NR 160
TC 42
Z9 43
U1 0
U2 13
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3755
EI 1423-0267
J9 OPHTHALMOLOGICA
JI Ophthalmologica
PY 2013
VL 230
IS 4
BP 165
EP 178
DI 10.1159/000353447
PG 14
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 253TO
UT WOS:000327112400001
PM 23989078
OA Bronze
DA 2022-11-30
ER

PT J
AU Liu, XC
   Liu, XF
   Jian, CX
   Li, CJ
   He, SZ
AF Liu, Xiao-Cui
   Liu, Xiao-Fei
   Jian, Cong-Xiang
   Li, Chen-Jun
   He, Shou-Zhi
TI IL-33 Is Induced by Amyloid-beta Stimulation and Regulates Inflammatory
   Cytokine Production in Retinal Pigment Epithelium Cells
SO INFLAMMATION
LA English
DT Article
DE age-related macular degeneration; IL-33; inflammation; retinal pigment
   epithelium cells; pathogenesis
ID MACULAR DEGENERATION; BRUCHS MEMBRANE; MAST-CELLS; AGE; DRUSEN;
   DEPOSITS; RECEPTOR; DISEASE; ST2; PATHOGENESIS
AB Age-related macular degeneration (AMD) is the predominant cause of irreversible blindness in the elderly population. Despite intensive basic and clinical research, its pathogenesis remains unclear. However, evidence suggests that immunological and inflammatory factors contribute to the pathogenesis of AMD. A newly identified cytokine, IL-33, appears to be an important pro-inflammatory cytokine promoting tissue inflammation. In this study, IL-33 was increased through amyloid-beta(1-40) (A beta(1-40)) stimulation and regulated inflammatory cytokines including IL-6, IL-8, IL-1 beta, and TNF-alpha secretion using different signaling pathways in retinal pigment epithelium (RPE) cells. Furthermore, ST2L, the important component of the IL-33 receptor, was significantly increased following recombinant human IL-33 stimulation in RPE cells. These findings suggest that IL-33-mediated inflammatory responses in RPE cells are involved in the pathogenesis of AMD. Greater understanding of the inflammatory effect of IL-33 and its role in RPE cells should aid the development of future clinical therapeutics and enable novel pharmacological approaches towards the prevention of AMD.
C1 [Jian, Cong-Xiang; Li, Chen-Jun] PLA Gen Hosp Chengdu Mil Reg, Dept Stomatolog, Chengdu 610083, Sichuan Provinc, Peoples R China.
   [Liu, Xiao-Cui; He, Shou-Zhi] Chinese PLA Peoples Liberat Army Gen Hosp, Dept Ophthalmol, Beijing 100853, Peoples R China.
   [Liu, Xiao-Fei] Gen Hosp Jinan Mil Reg PLA, Dept Lab Med, Jinan 250031, Shandong, Peoples R China.
C3 Chinese People's Liberation Army General Hospital
RP Li, CJ (通讯作者)，PLA Gen Hosp Chengdu Mil Reg, Dept Stomatolog, Chengdu 610083, Sichuan Provinc, Peoples R China.
EM Lichenjun65@163.com; heshouzhi@sina.com
CR Anderson DH, 2004, EXP EYE RES, V78, P243, DOI 10.1016/j.exer.2003.10.011
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Beltran CJ, 2010, INFLAMM BOWEL DIS, V16, P1097, DOI 10.1002/ibd.21175
   BRESSLER SB, 1990, ARCH OPHTHALMOL-CHIC, V108, P1442, DOI 10.1001/archopht.1990.01070120090035
   Chackerian AA, 2007, J IMMUNOL, V179, P2551, DOI 10.4049/jimmunol.179.4.2551
   Dentchev T, 2003, MOL VIS, V9, P184
   Dinarello CA, 2009, ANNU REV IMMUNOL, V27, P519, DOI 10.1146/annurev.immunol.021908.132612
   Donoso LA, 2006, SURV OPHTHALMOL, V51, P137, DOI 10.1016/j.survophthal.2005.12.001
   Eikelenboom P, 2010, NEURODEGENER DIS, V7, P38, DOI 10.1159/000283480
   Funakoshi-Tago M, 2011, CELL SIGNAL, V23, P363, DOI 10.1016/j.cellsig.2010.10.006
   Handa JT, 1999, INVEST OPHTH VIS SCI, V40, P775
   He FQ, 2011, INT IMMUNOPHARMACOL, V11, P1220, DOI 10.1016/j.intimp.2011.03.023
   Iikura M, 2007, LAB INVEST, V87, P971, DOI 10.1038/labinvest.3700663
   Kijlstra A, 2005, OCUL IMMUNOL INFLAMM, V13, P3, DOI 10.1080/09273940590909185
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Kuehn BM, 2005, JAMA-J AM MED ASSOC, V293, P1841, DOI 10.1001/jama.293.15.1841
   Kunes Pavel, 2010, Acta Medica (Hradec Kralove), V53, P125
   Kurji KH, 2010, INVEST OPHTH VIS SCI, V51, P1151, DOI 10.1167/iovs.09-3622
   Lindberg C, 2005, J MOL NEUROSCI, V27, P1, DOI 10.1385/JMN:27:1:001
   Liu B, 2003, J PHARMACOL EXP THER, V304, P1, DOI 10.1124/jpet.102.035048
   Luibl V, 2006, J CLIN INVEST, V116, P378, DOI 10.1172/JCI25843
   Manetti M, 2010, ANN RHEUM DIS, V69, P598, DOI 10.1136/ard.2009.119321
   Marvie P, 2010, J CELL MOL MED, V14, P1726, DOI 10.1111/j.1582-4934.2009.00801.x
   Mato Naoko, 2010, Nihon Kokyuki Gakkai Zasshi, V48, P419
   Matsuyama Y, 2010, J RHEUMATOL, V37, P18, DOI 10.3899/jrheum.090492
   Meda L, 1999, J NEUROIMMUNOL, V93, P45, DOI 10.1016/S0165-5728(98)00188-X
   Mok MY, 2010, RHEUMATOLOGY, V49, P520, DOI 10.1093/rheumatology/kep402
   Moulin D, 2007, CYTOKINE, V40, P216, DOI 10.1016/j.cyto.2007.09.013
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Ning A, 2008, INVEST OPHTH VIS SCI, V49, P5136, DOI 10.1167/iovs.08-1849
   O'Neill LAJ, 2008, IMMUNOL REV, V226, P10, DOI 10.1111/j.1600-065X.2008.00701.x
   Oboki Keisuke, 2010, Allergology International, V59, P143, DOI 10.2332/allergolint.10-RAI-0186
   PAULEIKHOFF D, 1992, OPHTHALMOLOGY, V99, P1548
   Prefontaine D, 2010, J ALLERGY CLIN IMMUN, V125, P752, DOI 10.1016/j.jaci.2009.12.935
   Rodrigues EB, 2007, OPHTHALMOLOGICA, V221, P143, DOI 10.1159/000099293
   Schmitz J, 2005, IMMUNITY, V23, P479, DOI 10.1016/j.immuni.2005.09.015
   Seidelin JB, 2010, IMMUNOL LETT, V128, P80, DOI 10.1016/j.imlet.2009.11.001
   Stolarski B, 2010, J IMMUNOL, V185, P3472, DOI 10.4049/jimmunol.1000730
   Suzukawa M, 2008, J IMMUNOL, V181, P5981, DOI 10.4049/jimmunol.181.9.5981
   Veerhuis R, 2005, NEUROBIOL DIS, V19, P273, DOI 10.1016/j.nbd.2005.01.005
   VINDING T, 1990, ACTA OPHTHALMOL, V68, P410
   Yagami A, 2010, J IMMUNOL, V185, P5743, DOI 10.4049/jimmunol.0903818
   Yoshida T, 2005, J CLIN INVEST, V115, P2793, DOI 10.1172/JCI24635
NR 43
TC 30
Z9 33
U1 0
U2 8
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0360-3997
J9 INFLAMMATION
JI Inflammation
PD APR
PY 2012
VL 35
IS 2
BP 776
EP 784
DI 10.1007/s10753-011-9379-4
PG 9
WC Cell Biology; Immunology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Immunology
GA 933SG
UT WOS:000303382200044
PM 21898270
DA 2022-11-30
ER

PT J
AU Xu, JY
   Wu, LY
   Zheng, XQ
   Lu, JL
   Wu, MY
   Liang, YR
AF Xu, Jing-Yi
   Wu, Liang-Yu
   Zheng, Xin-Qiang
   Lu, Jian-Liang
   Wu, Ming-Yan
   Liang, Yue-Rong
TI Green Tea Polyphenols Attenuating Ultraviolet B-Induced Damage to Human
   Retinal Pigment Epithelial Cells In Vitro
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID OXIDATIVE STRESS; MACULAR DEGENERATION; CYCLE ARREST; LIGHT DAMAGE;
   DNA-DAMAGE; RPE CELLS; APOPTOSIS; SURVIVIN; EXPRESSION; MITOCHONDRIA
AB PURPOSE. To examine the protective effect of green tea polyphenols against ultraviolet B (UVB)-induced damage to retinal pigment epithelial (RPE) cells.
   METHODS. Green tea polyphenols (GTP) was used to treat RPE cells before or after exposure to UVB. Viability of RPE cells was tested by 3,(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide (MTT) assay. Survivin gene expression was examined by real-time PCR analysis. Ultrastructure of RPE cells was examined by transmission electron microscopy.
   RESULTS. GTP effectively suppressed the decrease in viability of the UVB stressed RPE cells and the UVB suppression of survivin gene expression level. GTP alleviated mitochondria dysfunction and DNA fragmentation induced by UVB.
   CONCLUSIONS. GTP protected RPE cells from UVB damage through its increase in the survivin gene expression and its attenuation of mitochondria dysfunction and DNA fragmentation. GTP is a potential candidate for further development as a chemoprotective factor for the primary prevention of age-related eye diseases such as age-related macular degeneration. (Invest Ophthalmol Vis Sci. 2010; 51: 6665-6670) DOI:10.1167/iovs.10-5698
C1 [Xu, Jing-Yi; Wu, Liang-Yu; Lu, Jian-Liang; Wu, Ming-Yan; Liang, Yue-Rong] Zhejiang Univ, Tea Res Inst, Hangzhou 310029, Zhejiang, Peoples R China.
   [Zheng, Xin-Qiang] Agr Minist China, Key Lab Hort Plants Growth Dev & Biotechnol, Hangzhou, Zhejiang, Peoples R China.
C3 Chinese Academy of Agricultural Sciences; Tea Research Institute, CAAS;
   Zhejiang University
RP Liang, YR (通讯作者)，Zhejiang Univ, Tea Res Inst, Hangzhou 310029, Zhejiang, Peoples R China.
EM yrliang@zju.edu.cn
RI , jllu/GZL-3912-2022
FU Science Foundation of Chinese University [2009QNA6031]
FX Supported by Science Foundation of Chinese University Grant 2009QNA6031.
CR Abe I, 2000, FEBS LETT, V483, P131, DOI 10.1016/S0014-5793(00)02100-1
   Altieri DC, 2008, NAT REV CANCER, V8, P61, DOI 10.1038/nrc2293
   Anderson RF, 2001, CARCINOGENESIS, V22, P1189, DOI 10.1093/carcin/22.8.1189
   Bantseev V, 2006, ANN NY ACAD SCI, V1091, P17, DOI 10.1196/annals.1378.051
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Biesemeier A, 2008, J PHOTOCH PHOTOBIO B, V90, P113, DOI 10.1016/j.jphotobiol.2007.11.005
   Cai JY, 2000, PROG RETIN EYE RES, V19, P205, DOI 10.1016/S1350-9462(99)00009-9
   Chen QY, 2010, ONCOL REP, V23, P397, DOI 10.3892/or_00000648
   Chirico F, 2007, EXP DERMATOL, V16, P429, DOI 10.1111/j.1600-0625.2007.00545.x
   da Costa BLDA, 2008, BRAIN RES BULL, V76, P412, DOI 10.1016/j.brainresbull.2008.01.022
   Dallaglio K, 2009, EXP DERMATOL, V18, P464, DOI 10.1111/j.1600-0625.2008.00819.x
   Dohi T, 2004, J BIOL CHEM, V279, P34087, DOI 10.1074/jbc.C400236200
   Du YY, 2009, J HORTIC SCI BIOTECH, V84, P365, DOI 10.1080/14620316.2009.11512533
   Esposito E, 2002, NEUROBIOL AGING, V23, P719, DOI 10.1016/S0197-4580(02)00078-7
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   GODAR DE, 1993, PHOTOCHEM PHOTOBIOL, V57, P1018, DOI 10.1111/j.1751-1097.1993.tb02965.x
   GORGELS T, 1995, INVEST OPHTH VIS SCI, V36, pS517
   Grossman D, 2001, J CLIN INVEST, V108, P991, DOI 10.1172/JCI200113345
   Haga N, 2003, ONCOGENE, V22, P5579, DOI 10.1038/sj.onc.1206576
   Hervouet E, 2007, BIOCHIMIE, V89, P1080, DOI 10.1016/j.biochi.2007.03.010
   Higdon JV, 2003, CRIT REV FOOD SCI, V43, P89, DOI 10.1080/10408690390826464
   Huang Q, 2006, J ASIAN NAT PROD RES, V8, P61, DOI 10.1080/10286020500209087
   Johnson ME, 2004, VET PATHOL, V41, P599, DOI 10.1354/vp.41-6-599
   Kalfon L, 2007, J NEUROCHEM, V100, P992, DOI 10.1111/j.1471-4159.2006.04265.x
   Kanofsky JR, 2006, EXP EYE RES, V82, P907, DOI 10.1016/j.exer.2005.10.015
   Karbowski M, 2003, CELL DEATH DIFFER, V10, P870, DOI 10.1038/sj.cdd.4401260
   Kelly MR, 2001, J CELL BIOCHEM, V81, P647, DOI 10.1002/jcb.1097
   KERR JB, 1993, SCIENCE, V262, P1032, DOI 10.1126/science.262.5136.1032
   KHAN SG, 1992, CANCER RES, V52, P4050
   Kim GJ, 2010, APPL PHYS LETT, V96, DOI 10.1063/1.3292206
   Law YL, 2009, RADIAT MEAS, V44, P1069, DOI 10.1016/j.radmeas.2009.10.030
   Lens SMA, 2006, CURR OPIN CELL BIOL, V18, P616, DOI 10.1016/j.ceb.2006.08.016
   Li FZ, 1998, NATURE, V396, P580, DOI 10.1038/25141
   Li WY, 1999, MECH AGEING DEV, V110, P137, DOI 10.1016/S0047-6374(99)00047-0
   Liang FQ, 2003, EXP EYE RES, V76, P397, DOI 10.1016/S0014-4835(03)00023-X
   Matangkasombut O, 2010, INFECT IMMUN, V78, P783, DOI 10.1128/IAI.00857-09
   McCarty CA, 1996, INVEST OPHTH VIS SCI, V37, P1720
   ORGANISCIAK DT, 1985, INVEST OPHTH VIS SCI, V26, P1580
   Patton WP, 1999, INVEST OPHTH VIS SCI, V40, pS928
   Paul B, 2005, CARCINOGENESIS, V26, P119, DOI 10.1093/carcin/bgh281
   Rhone M, 2008, NUTR REV, V66, P465, DOI 10.1111/j.1753-4887.2008.00078.x
   Sah NK, 2006, CANCER LETT, V244, P164, DOI 10.1016/j.canlet.2006.03.007
   Weinreb O, 2003, ANN NY ACAD SCI, V993, P351, DOI 10.1111/j.1749-6632.2003.tb07544.x
   Weinreb O, 2009, GENES NUTR, V4, P283, DOI 10.1007/s12263-009-0143-4
   WEITER J, 1987, CLIN LIGHT DAMAGE EY, P79
   Wu LY, 2009, HUM CELL, V22, P18, DOI 10.1111/j.1749-0774.2008.00063.x
   Yoo K, 2009, J FOOD SCI, V74, pC419, DOI 10.1111/j.1750-3841.2009.01191.x
   Youn HY, 2007, J PHOTOCH PHOTOBIO B, V88, P21, DOI 10.1016/j.jphotobiol.2007.04.012
   Yu XR, 2005, MECH AGEING DEV, V126, P1135, DOI 10.1016/j.mad.2005.05.005
   ZUCLICH JA, 1989, HEALTH PHYS, V56, P671, DOI 10.1097/00004032-198905000-00012
NR 50
TC 33
Z9 35
U1 1
U2 21
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD DEC
PY 2010
VL 51
IS 12
BP 6665
EP 6670
DI 10.1167/iovs.10-5698
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 688GJ
UT WOS:000284837500075
PM 20702817
DA 2022-11-30
ER

PT J
AU Saper, RB
   Rash, R
AF Saper, Robert B.
   Rash, Rebecca
TI Zinc: An Essential Micronutrient
SO AMERICAN FAMILY PHYSICIAN
LA English
DT Article
ID CHRONIC LEG ULCERS; DOUBLE-BLIND; COMMON COLD; MACULAR DEGENERATION;
   DIETARY ANTIOXIDANTS; WILSONS-DISEASE; ORAL ZINC; SUPPLEMENTATION;
   METAANALYSIS; GLUCONATE
AB Zinc is an essential micronutrient for human metabolism that catalyzes more than 100 enzymes, facilitates protein folding, and helps regulate gene expression. Patients with malnutrition, alcoholism, inflammatory bowel disease, and malabsorption syndromes are at an increased risk of zinc deficiency. Symptoms of zinc deficiency are nonspecific, including growth retardation, diarrhea, alopecia, glossitis, nail dystrophy, decreased immunity, and hypogonadism in males. In developing countries, zinc supplementation may be effective for the prevention of upper respiratory infection and diarrhea, and as an adjunct treatment for diarrhea in malnourished children. Zinc in combination with antioxidants may be modestly effective in slowing the progression of intermediate and advanced age-related macular degeneration. Zinc is an effective treatment for Wilson disease. Current data do not support zinc supplementation as effective for upper respiratory infection, wound healing, or human immunodeficiency virus. Zinc is well tolerated at recommended dosages. Adverse effects of long-term high-dose zinc use include suppressed immunity, decreased high-density lipoprotein cholesterol levels, anemia, copper deficiency, and possible genitourinary complications. (Am Fam Physician. 2009;79(9):768-772. Copyright (C) 2009 American Academy of Family Physicians.)
C1 [Saper, Robert B.] Boston Med Ctr, Dept Family Med, Boston, MA 02118 USA.
   [Rash, Rebecca] Boston Univ, Sch Med, Dept Family Med, Boston, MA 02118 USA.
C3 Boston Medical Center; Boston University
RP Saper, RB (通讯作者)，Boston Med Ctr, Dept Family Med, 1 Boston Med Ctr Pl,Dowling 5 S, Boston, MA 02118 USA.
EM robert.saper@bmc.org
RI Saper, Robert B/Y-4598-2018
OI Saper, Robert B/0000-0002-0992-6198
FU NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE [K07AT002915]
   Funding Source: NIH RePORTER; NCCIH NIH HHS [K07 AT002915, K07
   AT002915-04] Funding Source: Medline
CR Age-Related Eye Disease Study Research Group, 2008, ARCH OPHTHALMOL-CHIC, V126, P1251
   Aggarwal R, 2007, PEDIATRICS, V119, P1120, DOI 10.1542/peds.2006-3481
   Agren MS, 2006, WOUND REPAIR REGEN, V14, P526, DOI 10.1111/j.1743-6109.2006.00159.x
   Alpha-Tocopherol Beta Carotene Cancer Prevention Study Group, 1994, N Engl J Med, V330, P1029, DOI 10.1056/NEJM199404143301501
   Bobat R, 2005, LANCET, V366, P1862, DOI 10.1016/S0140-6736(05)67756-2
   Brewer GJ, 1998, J LAB CLIN MED, V132, P264, DOI 10.1016/S0022-2143(98)90039-7
   Brown KH, 2002, AM J CLIN NUTR, V75, P1062, DOI 10.1093/ajcn/75.6.1062
   Cario E, 2000, EUR J CLIN INVEST, V30, P419
   Chong EWT, 2007, BMJ-BRIT MED J, V335, P755, DOI 10.1136/bmj.39350.500428.47
   COUSINS RJ, 1989, ZINC HUMAN BIOL, P79
   Czlonkowska A, 1996, J NEUROL, V243, P269, DOI 10.1007/BF00868525
   Dreno B, 2001, DERMATOLOGY, V203, P135, DOI 10.1159/000051728
   Evans JR, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000253.pub2
   Evans JR, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000254.pub2
   FOSMIRE GJ, 1990, AM J CLIN NUTR, V51, P225, DOI 10.1093/ajcn/51.2.225
   Grahn BH, 2001, J AM COLL NUTR, V20, P106, DOI 10.1080/07315724.2001.10719022
   Institute of Medicine (U.S.), 2001, DRI DIET REF INT VIT
   Iwata M, 1999, HISTOCHEM CELL BIOL, V112, P283, DOI 10.1007/s004180050449
   Jackson JL, 2000, J NUTR, V130, p1512S, DOI 10.1093/jn/130.5.1512S
   Johnson AR, 2007, J UROLOGY, V177, P639, DOI 10.1016/j.juro.2006.09.047
   Jones CY, 2006, JAIDS-J ACQ IMM DEF, V43, P475, DOI 10.1097/01.qai.0000243096.27029.fe
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   King J., 2006, MODERN NUTR HLTH DIS, P271
   Kurugol Z, 2006, ACTA PAEDIATR, V95, P1175, DOI 10.1080/08035250600603024
   Leitzmann MF, 2003, J NATL CANCER I, V95, P1004, DOI 10.1093/jnci/95.13.1004
   Lukacik M, 2008, PEDIATRICS, V121, P326, DOI 10.1542/peds.2007-0921
   Macknin ML, 1998, JAMA-J AM MED ASSOC, V279, P1962, DOI 10.1001/jama.279.24.1962
   *MERCK RES LAB, 2006, MERCK MANUAL DIAGNOS, P55
   MOCCHEGIANI E, 1995, INT J IMMUNOPHARMACO, V17, P703, DOI 10.1016/0192-0561(95)00059-B
   Mossad SB, 2003, QJM-INT J MED, V96, P35, DOI 10.1093/qjmed/hcg004
   Prasad AS, 2007, AM J CLIN NUTR, V85, P837, DOI 10.1093/ajcn/85.3.837
   Prasad AS, 2000, ANN INTERN MED, V133, P245, DOI 10.7326/0003-4819-133-4-200008150-00006
   Rojas AI, 1999, DERMATOL SURG, V25, P601, DOI 10.1046/j.1524-4725.1999.99074.x
   Tan JSL, 2008, OPHTHALMOLOGY, V115, P334, DOI 10.1016/j.ophtha.2007.03.083
   Timbo BB, 2006, J AM DIET ASSOC, V106, P1966, DOI 10.1016/j.jada.2006.09.002
   Turner RB, 2000, CLIN INFECT DIS, V31, P1202, DOI 10.1086/317437
   Villamor E, 2006, EUR J CLIN NUTR, V60, P862, DOI 10.1038/sj.ejcn.1602391
   WALRAVENS PA, 1989, PEDIATRICS, V83, P532
   Wananukul Siriwan, 2006, Journal of the Medical Association of Thailand, V89, P1654
   Wilkinson EAJ, 1998, ARCH DERMATOL, V134, P1556, DOI 10.1001/archderm.134.12.1556
   World Health Organization, 2013, WORLD HLTH REPORT 20
   2000, ADV NUTR HUMAN METAB, P401
NR 42
TC 107
Z9 112
U1 0
U2 17
PU AMER ACAD FAMILY PHYSICIANS
PI KANSAS CITY
PA 8880 WARD PARKWAY, KANSAS CITY, MO 64114-2797 USA
SN 0002-838X
EI 1532-0650
J9 AM FAM PHYSICIAN
JI Am. Fam. Physician
PD MAY 1
PY 2009
VL 79
IS 9
BP 768
EP 772
PG 5
WC Primary Health Care; Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA 439ID
UT WOS:000265619900006
PM 20141096
DA 2022-11-30
ER

PT J
AU Kaiser, PK
   Do, DV
AF Kaiser, P. K.
   Do, D. V.
TI Ranibizumab for the treatment of neovascular AMD
SO INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; INTRAVITREAL TRIAMCINOLONE ACETONIDE;
   COHERENCE TOMOGRAPHY FINDINGS; MACULAR DEGENERATION; PHOTODYNAMIC
   THERAPY; CHOROIDAL NEOVASCULARIZATION; VASCULAR-PERMEABILITY;
   BEVACIZUMAB AVASTIN(R); INCREASED EXPRESSION; TUMOR-CELLS
AB Age-related macular degeneration (AMD) is the leading cause of adult blindness among individuals aged 50 and older in the Western world, with the neovascular form of AMD responsible for the most severe and rapid visual loss. Although monotherapy with currently available treatments can slow the rate of loss of vision in eyes with neovascular AMD, they do not significantly improve vision. Vascular endothelial growth factor-A (VEGF-A) plays a critical role in the pathogenesis of neovascular AMD, and ranibizumab is a promising new treatment that targets all VEGF-A isoforms and their biologically active degradation products. Clinical trials have reported that ranibizumab treatment resulted in greater proportions of patients achieving a < 15 letter loss of visual acuity and improved vision at 12 and 24 months than control groups. The incidence of serious ocular and systemic adverse events was low in all ranibizumab trials to date. Currently, ranibizumab is the only treatment for neovascular AMD to demonstrate significant improvement in vision for many patients and represents a major advance in treating neovascular AMD.
C1 Johns Hopkins Univ, Sch Med, Wilmer Eye Inst, Baltimore, MD 21205 USA.
   Cleveland Clin Fdn, Cole Eye Inst, Cleveland, OH 44195 USA.
C3 Johns Hopkins University; Johns Hopkins Medicine; Cleveland Clinic
   Foundation
RP Do, DV (通讯作者)，Johns Hopkins Univ, Sch Med, Wilmer Eye Inst, 550 N Broadway,Suite 902, Baltimore, MD 21205 USA.
EM ddo@jhmi.edu
OI Kaiser, Peter/0000-0001-5126-045X
CR Adamis AP, 1996, ARCH OPHTHALMOL-CHIC, V114, P66, DOI 10.1001/archopht.1996.01100130062010
   Akiyama H, 2005, MOL PHARMACOL, V68, P1543, DOI 10.1124/mol.105.015628
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Augustin AJ, 2006, AM J OPHTHALMOL, V141, P638, DOI 10.1016/j.ajo.2005.11.058
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Chen Y, 1999, J MOL BIOL, V293, P865, DOI 10.1006/jmbi.1999.3192
   Ding XM, 2005, CHINESE MED J-PEKING, V118, P1644
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Ergun E, 2006, AM J OPHTHALMOL, V142, P10, DOI 10.1016/j.ajo.2006.02.048
   Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gaudreault J, 2005, INVEST OPHTH VIS SCI, V46, P726, DOI 10.1167/iovs.04-0601
   *GEN INC, 2006, LUC RAN INJ PRESCR I
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Gonzales CR, 2005, RETINA-J RET VIT DIS, V25, P815
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Heier JS, 2006, ARCH OPHTHALMOL-CHIC, V124, P1532, DOI 10.1001/archopht.124.11.1532
   HEIER JS, 2006, OPHTHALMOLOGY, V113
   Hera R, 2005, AM J OPHTHALMOL, V139, P589, DOI 10.1016/j.ajo.2004.11.064
   HOUCK KA, 1991, MOL ENDOCRINOL, V5, P1806, DOI 10.1210/mend-5-12-1806
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Keyt BA, 1996, J BIOL CHEM, V271, P7788, DOI 10.1074/jbc.271.13.7788
   Kim KJ, 1992, GROWTH FACTORS, V7, P53, DOI 10.3109/08977199209023937
   Kliffen M, 1997, BRIT J OPHTHALMOL, V81, P154, DOI 10.1136/bjo.81.2.154
   Krzystolik MG, 2002, ARCH OPHTHALMOL-CHIC, V120, P338
   Kvanta A, 1996, INVEST OPHTH VIS SCI, V37, P1929
   Lebherz C, 2005, DIABETES, V54, P1141, DOI 10.2337/diabetes.54.4.1141
   Lei JX, 1998, BBA-GENE STRUCT EXPR, V1443, P400, DOI 10.1016/S0167-4781(98)00240-1
   LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986
   Maier P, 2005, GRAEF ARCH CLIN EXP, V243, P593, DOI 10.1007/s00417-004-1021-9
   Martin DF, 2002, RETINA-J RET VIT DIS, V22, P143
   Michels S, 2005, OPHTHALMOLOGY, V112, P1035, DOI 10.1016/j.ophtha.2005.02.007
   Nguyen QD, 2005, BRIT J OPHTHALMOL, V89, P1368, DOI 10.1136/bjo.2005.066431
   Nozaki M, 2006, J CLIN INVEST, V116, P422, DOI 10.1172/JCI26316
   Olofsson B, 1998, P NATL ACAD SCI USA, V95, P11709, DOI 10.1073/pnas.95.20.11709
   Oner A, 2005, DOC OPHTHALMOL, V111, P83, DOI 10.1007/s10633-005-4410-4
   Oshima Y, 2004, J CELL PHYSIOL, V201, P393, DOI 10.1002/jcp.20110
   Ozdemir H, 2006, AM J OPHTHALMOL, V141, P574, DOI 10.1016/j.ajo.2005.09.031
   Rakic JM, 2003, INVEST OPHTH VIS SCI, V44, P3186, DOI 10.1167/iovs.02-1092
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2005, OPHTHALMOLOGY, V112, P1048, DOI 10.1016/j.ophtha.2005.01.043
   Rosenfeld PJ, 2006, OPHTHALMOLOGY, V113, P623, DOI 10.1016/j.ophtha.2006.01.027
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P336, DOI 10.3928/1542-8877-20050701-15
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
   Ruckman J, 1998, J BIOL CHEM, V273, P20556, DOI 10.1074/jbc.273.32.20556
   Schmidt S, 2005, MOL VIS, V11, P941
   SENGER DR, 1983, SCIENCE, V219, P983, DOI 10.1126/science.6823562
   SENGER DR, 1990, CANCER RES, V50, P1774
   Slakter JS, 2006, OPHTHALMOLOGY, V113, P3, DOI 10.1016/j.ophtha.2005.10.019
   Soker S, 1998, CELL, V92, P735, DOI 10.1016/S0092-8674(00)81402-6
   Sutter FK, 2006, KLIN MONATSBL AUGENH, V223, P376, DOI 10.1055/s-2006-926564
   Takahashi H, 2005, CLIN SCI, V109, P227, DOI 10.1042/CS20040370
   Tzekov R, 2006, INVEST OPHTH VIS SCI, V47, P377, DOI 10.1167/iovs.05-0838
   Yourey PA, 2000, J NEUROSCI, V20, P6781, DOI 10.1523/JNEUROSCI.20-18-06781.2000
   Zhang HT, 2000, BRIT J CANCER, V83, P63
NR 58
TC 21
Z9 21
U1 0
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1368-5031
EI 1742-1241
J9 INT J CLIN PRACT
JI Int. J. Clin. Pract.
PD MAR
PY 2007
VL 61
IS 3
BP 501
EP 509
DI 10.1111/j.1742-1241.2007.01299.x
PG 9
WC Medicine, General & Internal; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine; Pharmacology & Pharmacy
GA 136SD
UT WOS:000244243500030
PM 17313620
DA 2022-11-30
ER

PT J
AU Zhang, XY
   Zhu, XQ
   Wang, DS
   Xu, L
   Jonas, JB
AF Zhang, Xinyuan
   Zhu, Xiaoqing
   Wang, Dongsheng
   Xu, Liang
   Jonas, Jost B.
TI Low-power transpupillary thermotherapy combined with intravitreal
   triamcinolone acetonide for subfoveal choroidal neovascularization
SO OPHTHALMIC RESEARCH
LA English
DT Article
DE transpupillary thermotherapy; intravitreal steroids; age-related macular
   degeneration; myopic macular degeneration; choroidal neovascularization;
   visual impairment; low vision
ID MACULAR DEGENERATION; PHOTODYNAMIC THERAPY; VERTEPORFIN
AB Purpose: To examine transpupillary thermotherapy combined with intravitreal triamcinolone for treatment of subfoveal choroidal neovascularization. Methods: The clinical interventional, noncomparative, case series study included 14 patients (14 eyes) with choroidal neovascularization (age-related macular degeneration, n = 11; high myopia, n = 2; unknown reason, n = 1), who underwent transpupillary thermotherapy (75-150 mW, 60 s, 500-3,000 mu m), followed by an intravitreal triamcinolone injection ( 10 mg). Follow-up was at least 6 months. Results: Visual acuity increased by 3 lines in 3 (21%) eyes at 3 months, and in 3 (21%) eyes at 6 months of follow-up. None of the patients experienced a visual acuity loss of 3 or more lines. At the 6-month followup, mean visual acuity was improved by 1.36 +/- 1.16 lines. Retreatment by transpupillary thermotherapy was performed for 3 (21%) eyes at 3 months, and for 1 (7%) eye at 6 months of follow-up. Conclusions: Transpupillary thermotherapy combined with intravitreal triamcinolone may be a therapeutic option for choroidal neovascularization particularly if other treatment modalities are not available. Copyright (C) 2007 S. Karger AG, Basel
C1 Capital Univ Med Sci, Tongren Hosp, Beijing Inst Ophthalmol, Dept Ophthalmol, Beijing, Peoples R China.
   Capital Univ Med Sci, Tongren Hosp, Eye Hosp, Beijing, Peoples R China.
   Univ Heidelberg, Dept Ophthalmol, Fac Clin Med, D-6800 Mannheim, Germany.
C3 Capital Medical University; Capital Medical University; Ruprecht Karls
   University Heidelberg
RP Jonas, JB (通讯作者)，Univ Augenklin, Theodor Kutzer Ufer 1-3, D-68167 Mannheim, Germany.
EM Jost.Jonas@augen.ma.uni-heidelberg.de
OI Zhang, Xinyuan/0000-0002-3372-0798
CR Augustin AJ, 2006, OPHTHALMOLOGY, V113, P14, DOI 10.1016/j.ophtha.2005.09.002
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Jonas JB, 2003, ARCH OPHTHALMOL-CHIC, V121, P1663, DOI 10.1001/archopht.121.11.1663-b
   Reichel E, 1999, OPHTHALMOLOGY, V106, P1908, DOI 10.1016/S0161-6420(99)90400-1
   Schmidt-Erfurth U, 2003, INVEST OPHTH VIS SCI, V44, P4473, DOI 10.1167/iovs.02-1115
   Stolba U, 2006, BRIT J OPHTHALMOL, V90, P158, DOI 10.1136/bjo.2005.076422
   Thompson JT, 2001, AM J OPHTHALMOL, V131, P662, DOI 10.1016/S0002-9394(00)00879-5
NR 7
TC 4
Z9 4
U1 0
U2 2
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3747
J9 OPHTHAL RES
JI Ophthalmic Res.
PY 2007
VL 39
IS 4
BP 241
EP 242
DI 10.1159/000104833
PG 2
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 192XR
UT WOS:000248237700008
PM 17622745
DA 2022-11-30
ER

PT J
AU Ranta, VP
   Urtti, A
AF Ranta, Veli-Pekka
   Urtti, Arto
TI Transscleral drug delivery to the posterior eye: Prospects of
   pharmacokinetic modeling
SO ADVANCED DRUG DELIVERY REVIEWS
LA English
DT Review
DE ocular drug delivery; pharmacokinetic simulation; permeability; sclera;
   choroid; retina; vitreous
ID SUBFOVEAL CHOROIDAL NEOVASCULARIZATION; RETINAL-PIGMENT EPITHELIUM;
   MOLECULAR-WEIGHT; VITREOUS-HUMOR; BLOOD-FLOW; IN-VITRO; INTRAOCULAR
   PENETRATION; CAPILLARY-PERMEABILITY; INTRAVITREAL INJECTION; ANECORTAVE
   ACETATE
AB Basic biological research has provided new approaches to treat severe diseases of the retina and choroid, such as age related macular degeneration. Although it is possible to deliver drugs from a subconjunctival drug depot to the retina and choroid, the barriers and kinetics of this route of drug administration are not well known. In this review we investigate the pharmacokinetic aspects of transscleral drug delivery into the posterior eye with emphasis on pharmacokinetic modeling. The existing simulation models related to the transscleral drug delivery are reviewed and future directions for the model development are discussed. In addition, a new simulation model for the transscleral drug delivery based on permeability data is introduced. This compartmental model contains several ocular tissues (sclera, choroid, retinal pigment epithelium and vitreous) and it takes into account the clearance of the drug via choroidal circulation. The model is used to simulate the vitreous delivery of macromolecules based on the available data on FITC-dextran 70 kDa. (c) 2006 Elsevier B.V. All rights reserved.
C1 Univ Kuopio, Dept Pharmaceut, FIN-70211 Kuopio, Finland.
   Univ Helsinki, Fac Pharm, Drug Discovery & Dev Technol Ctr, FIN-00014 Helsinki, Finland.
C3 University of Eastern Finland; University of Helsinki
RP Ranta, VP (通讯作者)，Univ Kuopio, Dept Pharmaceut, POB 1627, FIN-70211 Kuopio, Finland.
EM velipekka.ranta@uku.fi
CR AHMED I, 1987, J PHARM SCI, V76, P583, DOI 10.1002/jps.2600760802
   ALM A, 1973, EXP EYE RES, V15, P15, DOI 10.1016/0014-4835(73)90185-1
   Ambati J, 2000, INVEST OPHTH VIS SCI, V41, P1181
   Ambati J, 2000, INVEST OPHTH VIS SCI, V41, P1186
   Amrite AC, 2005, J PHARM PHARMACOL, V57, P1555, DOI 10.1211/jpp.57.12.0005
   ARAIE M, 1991, EXP EYE RES, V52, P27, DOI 10.1016/0014-4835(91)90125-X
   Augustin AJ, 2005, GRAEF ARCH CLIN EXP, V243, P9, DOI 10.1007/s00417-004-0961-4
   AULA P, 1988, J OCUL PHARMACOL, V4, P29, DOI 10.1089/jop.1988.4.29
   Ayalasomayajula SP, 2005, EUR J PHARMACOL, V511, P191, DOI 10.1016/j.ejphar.2005.02.019
   Ayalasomayajula SP, 2004, PHARM RES-DORDR, V21, P1797, DOI 10.1023/B:PHAM.0000045231.51924.e8
   Bakri SJ, 2006, EXPERT OPIN INV DRUG, V15, P163, DOI 10.1517/13543784.15.2.163
   Barza M, 1989, Infect Dis Clin North Am, V3, P533
   BARZA M, 1993, ARCH OPHTHALMOL-CHIC, V111, P121, DOI 10.1001/archopht.1993.01090010125038
   BELLHORN RW, 1981, INVEST OPHTH VIS SCI, V21, P282
   BILL A, 1965, ARCH OPHTHALMOL-CHIC, V74, P248
   BILL A, 1968, ACTA PHYSIOL SCAND, V73, P204, DOI 10.1111/j.1748-1716.1968.tb04097.x
   BILL A, 1983, INT OPHTHALMOL, V6, P101, DOI 10.1007/BF00127638
   BILL A, 1980, T OPHTHAL SOC UK, V100, P332
   BILL A, 1964, EXP EYE RES, V3, P179, DOI 10.1016/S0014-4835(64)80033-6
   BOXENBAUM H, 1992, DRUG METAB REV, V24, P89, DOI 10.3109/03602539208996291
   BUNTMILAM AH, 1985, INVEST OPHTH VIS SCI, V26, P1377
   Buszman E, 2003, PHARMAZIE, V58, P507
   Campochiaro PA, 2006, GENE THER, V13, P559, DOI 10.1038/sj.gt.3302653
   Candia OA, 2005, INVEST OPHTH VIS SCI, V46, P939, DOI 10.1167/iovs.04-0950
   Centofanti M, 2000, BRIT J OPHTHALMOL, V84, P786, DOI 10.1136/bjo.84.7.786
   CONRAD JM, 1980, J PHARM SCI, V69, P875, DOI 10.1002/jps.2600690806
   Cruysberg LPJ, 2005, CURR EYE RES, V30, P653, DOI 10.1080/02713680590968600
   CUNHAVAZ JG, 1967, J PHYSIOL-LONDON, V191, P467, DOI 10.1113/jphysiol.1967.sp008262
   DELAMAZA MS, 1995, DUANES FDN CLIN OPHT, V1, P1
   Edwards A, 1998, AICHE J, V44, P214, DOI 10.1002/aic.690440123
   Eljarrat-Binstock E, 2006, J CONTROL RELEASE, V110, P479, DOI 10.1016/j.jconrel.2005.09.049
   Flower RW, 2001, AM J OPHTHALMOL, V132, P85, DOI 10.1016/S0002-9394(01)00872-8
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Friedrich S, 1997, ANN BIOMED ENG, V25, P303, DOI 10.1007/BF02648045
   Friedrich S, 1997, J OCUL PHARMACOL TH, V13, P445, DOI 10.1089/jop.1997.13.445
   Friedrich S, 1997, CURR EYE RES, V16, P663, DOI 10.1076/ceyr.16.7.663.5061
   Gan IM, 2001, BRIT J OPHTHALMOL, V85, P1289, DOI 10.1136/bjo.85.11.1289
   Gilbert JA, 2003, J CONTROL RELEASE, V89, P409, DOI 10.1016/S0168-3659(03)00151-2
   Hamalainen KM, 1997, INVEST OPHTH VIS SCI, V38, P627
   Hillenkamp J, 2004, INVEST OPHTH VIS SCI, V45, P4099, DOI 10.1167/iovs.04-0624
   Horibe Y, 1997, PHARMACEUT RES, V14, P1246, DOI 10.1023/A:1012123411343
   HUANG AJW, 1989, INVEST OPHTH VIS SCI, V30, P684
   Hughes PM, 2005, ADV DRUG DELIVER REV, V57, P2010, DOI 10.1016/j.addr.2005.09.004
   Hussain AA, 2002, J OPT SOC AM A, V19, P166, DOI 10.1364/JOSAA.19.000166
   Jackson TL, 2003, INVEST OPHTH VIS SCI, V44, P2141, DOI 10.1167/iovs.02-1027
   Jiang J, 2006, INVEST OPHTH VIS SCI, V47, P3011, DOI 10.1167/iovs.05-1464
   JOHNSON F, 1984, EXP EYE RES, V39, P791, DOI 10.1016/0014-4835(84)90078-2
   Kato A, 2004, INVEST OPHTH VIS SCI, V45, P238, DOI 10.1167/iovs.02-1258
   Kim H, 2005, ANN BIOMED ENG, V33, P150, DOI 10.1007/s10439-005-8974-7
   Kim H, 2004, INVEST OPHTH VIS SCI, V45, P2722, DOI 10.1167/iovs.04-0091
   KINSEY VE, 1960, CIRCULATION, V21, P968, DOI 10.1161/01.CIR.21.5.968
   Kompella UB, 2003, INVEST OPHTH VIS SCI, V44, P1192, DOI 10.1167/iovs.02-0791
   KONDO M, 1994, CURR EYE RES, V13, P251, DOI 10.3109/02713689408995785
   KOYANO S, 1993, INVEST OPHTH VIS SCI, V34, P531
   Lee TWY, 2001, J OCUL PHARMACOL TH, V17, P565, DOI 10.1089/10807680152729257
   Lee TWY, 2004, J OCUL PHARMACOL TH, V20, P43, DOI 10.1089/108076804772745455
   Lee TWY, 2004, J OCUL PHARMACOL TH, V20, P55, DOI 10.1089/108076804772745464
   LEVINE ND, 1970, ARCH OPHTHALMOL-CHIC, V83, P599
   Li SK, 2004, PHARM RES-DORDR, V21, P2175, DOI 10.1007/s11095-004-7669-3
   Mannermaa E, 2006, ADV DRUG DELIVER REV, V58, P1136, DOI 10.1016/j.addr.2006.07.024
   MARMOR MF, 1985, EXP EYE RES, V40, P687, DOI 10.1016/0014-4835(85)90138-1
   Maurice D. M., 1984, HANDB EXP PHARM, P19
   MENON IA, 1992, J OCUL PHARMACOL, V8, P35, DOI 10.1089/jop.1992.8.35
   Missel PJ, 2002, PHARMACEUT RES, V19, P1636, DOI 10.1023/A:1020940927675
   Missel PJ, 2002, ANN BIOMED ENG, V30, P1128, DOI 10.1114/1.1521417
   Missel PJ, 2004, PHARM DEV TECHNOL, V9, P453, DOI 10.1081/PDT-200035808
   Moore DJ, 2001, INVEST OPHTH VIS SCI, V42, P2970
   Morlet N, 1996, BRIT J OPHTHALMOL, V80, P214, DOI 10.1136/bjo.80.3.214
   Ng EWM, 2005, CAN J OPHTHALMOL, V40, P352, DOI 10.1016/S0008-4182(05)80078-X
   Okabe J, 2003, INVEST OPHTH VIS SCI, V44, P740, DOI 10.1167/iovs.02-0375
   Okabe K, 2005, INVEST OPHTH VIS SCI, V46, P703, DOI 10.1167/iovs.03-0934
   Okabe K, 2003, INVEST OPHTH VIS SCI, V44, P2702, DOI 10.1167/iovs.02-0956
   OLSEN TW, 1995, INVEST OPHTH VIS SCI, V36, P1893
   Pitkanen L, 2005, INVEST OPHTH VIS SCI, V46, P641, DOI 10.1167/iovs.04-1051
   Pospisil H, 2001, ATLA-ALTERN LAB ANIM, V29, P347, DOI 10.1177/026119290102900318
   Prausnitz MR, 1998, IND ENG CHEM RES, V37, P2903, DOI 10.1021/ie9800952
   Prausnitz MR, 1998, J PHARM SCI, V87, P1479, DOI 10.1021/js9802594
   Raghava Swita, 2004, Expert Opin Drug Deliv, V1, P99, DOI 10.1517/17425247.1.1.99
   RAVIOLA G, 1983, INVEST OPHTH VIS SCI, V24, P725
   RECORDS RE, 1995, DUANES FDN CLIN OPHT, V2, P1
   Robinson MR, 2006, EXP EYE RES, V82, P479, DOI 10.1016/j.exer.2005.08.007
   Sasaki H, 1999, BIOL PHARM BULL, V22, P961
   Savage HI, 2004, INVEST OPHTH VIS SCI, V45, P4504, DOI 10.1167/iovs.04-0077
   Simpson AE, 2002, ARCH OPHTHALMOL-CHIC, V120, P1069
   Stay MS, 2003, PHARM RES-DORDR, V20, P96, DOI 10.1023/A:1022207026982
   Steuer H, 2005, INVEST OPHTH VIS SCI, V46, P1047, DOI 10.1167/iovs.04-0925
   TAKEUCHI A, 1995, INVEST OPHTH VIS SCI, V36, P1298
   Tojo K, 1999, EUR J PHARM BIOPHARM, V47, P99, DOI 10.1016/S0939-6411(98)00073-3
   Tojo K, 2004, CHEM PHARM BULL, V52, P1290, DOI 10.1248/cpb.52.1290
   TOJO KJ, 1994, MATH BIOSCI, V123, P59, DOI 10.1016/0025-5564(94)90018-3
   Tolentino MJ, 2000, ARCH OPHTHALMOL-CHIC, V118, P78
   TORCZYNSKI E, 1995, DUANES FDN CLIN OPHT, V1, P1
   TORNQUIST P, 1979, ACTA PHYSIOL SCAND, V106, P425, DOI 10.1111/j.1748-1716.1979.tb06421.x
   TSUJI A, 1988, OPHTHALMIC RES, V20, P31, DOI 10.1159/000266253
   Urtti A, 2006, ADV DRUG DELIVER REV, V58, P1131, DOI 10.1016/j.addr.2006.07.027
   WANG W, 1991, CURR EYE RES, V10, P571, DOI 10.3109/02713689109001766
   Weijtens O, 2002, OPHTHALMOLOGY, V109, P1887, DOI 10.1016/S0161-6420(02)01176-4
   Weijtens O, 1998, AM J OPHTHALMOL, V125, P673, DOI 10.1016/S0002-9394(98)00003-8
   Weijtens O, 1999, AM J OPHTHALMOL, V128, P192, DOI 10.1016/S0002-9394(99)00129-4
   Weijtens O, 1997, AM J OPHTHALMOL, V123, P358, DOI 10.1016/S0002-9394(14)70131-X
   Yasukawa T, 2004, PROG RETIN EYE RES, V23, P253, DOI 10.1016/j.preteyeres.2004.02.003
   Yu LX, 2000, DRUGS PHARM SCI, V102, P23
   Zhang WS, 2006, AM J PHYSIOL-RENAL, V290, pF87, DOI 10.1152/ajprenal.00168.2005
NR 103
TC 104
Z9 115
U1 2
U2 46
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0169-409X
EI 1872-8294
J9 ADV DRUG DELIVER REV
JI Adv. Drug Deliv. Rev.
PD NOV 15
PY 2006
VL 58
IS 11
BP 1164
EP 1181
DI 10.1016/j.addr.2006.07.025
PG 18
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA 118FL
UT WOS:000242927700004
PM 17069929
DA 2022-11-30
ER

PT J
AU Arthur, P
   Muok, L
   Nathani, A
   Zeng, EZ
   Sun, L
   Li, Y
   Singh, M
AF Arthur, Peggy
   Muok, Laureana
   Nathani, Aakash
   Zeng, Eric Z.
   Sun, Li
   Li, Yan
   Singh, Mandip
TI Bioengineering Human Pluripotent Stem Cell-Derived Retinal Organoids and
   Optic Vesicle-Containing Brain Organoids for Ocular Diseases
SO CELLS
LA English
DT Review
DE human induced pluripotent stem cells; retinal organoids; assembled
   organoids; ocular diseases; extracellular vesicles
ID HUMAN IPS CELLS; X-LINKED RETINOSCHISIS; RETINITIS-PIGMENTOSA;
   USHER-SYNDROME; IN-VITRO; VISUAL FUNCTION; NERVE HEAD; PHOTORECEPTOR
   DIFFERENTIATION; CLINICAL-FEATURES; NEURAL RETINA
AB Retinal organoids are three-dimensional (3D) structures derived from human pluripotent stem cells (hPSCs) that mimic the retina's spatial and temporal differentiation, making them useful as in vitro retinal development models. Retinal organoids can be assembled with brain organoids, the 3D self-assembled aggregates derived from hPSCs containing different cell types and cytoarchitectures that resemble the human embryonic brain. Recent studies have shown the development of optic cups in brain organoids. The cellular components of a developing optic vesicle-containing organoids include primitive corneal epithelial and lens-like cells, retinal pigment epithelia, retinal progenitor cells, axon-like projections, and electrically active neuronal networks. The importance of retinal organoids in ocular diseases such as age-related macular degeneration, Stargardt disease, retinitis pigmentosa, and diabetic retinopathy are described in this review. This review highlights current developments in retinal organoid techniques, and their applications in ocular conditions such as disease modeling, gene therapy, drug screening and development. In addition, recent advancements in utilizing extracellular vesicles secreted by retinal organoids for ocular disease treatments are summarized.
C1 [Arthur, Peggy; Nathani, Aakash; Singh, Mandip] Florida A&M Univ, Coll Pharm & Pharmaceut Sci, Tallahassee, FL 32307 USA.
   [Muok, Laureana; Zeng, Eric Z.; Sun, Li; Li, Yan] Florida State Univ, FAMU FSU Coll Engn, Dept Chem & Biomed Engn, Tallahassee, FL 32306 USA.
   [Sun, Li] Florida State Univ, Coll Med, Dept Biomed Sci, Tallahassee, FL 32306 USA.
C3 State University System of Florida; Florida A&M University; State
   University System of Florida; Florida A&M University; Florida State
   University; State University System of Florida; Florida State University
RP Singh, M (通讯作者)，Florida A&M Univ, Coll Pharm & Pharmaceut Sci, Tallahassee, FL 32307 USA.; Li, Y (通讯作者)，Florida State Univ, FAMU FSU Coll Engn, Dept Chem & Biomed Engn, Tallahassee, FL 32306 USA.
EM yli@eng.famu.fsu.edu; mandip.sachdeva@famu.edu
FU FAMU title III funding; McKnight Doctorial Fellowship
FX L.M. held the McKnight Doctorial Fellowship and was also supported in
   part by FAMU title III funding.
CR Adamson PC, 2001, CLIN CANCER RES, V7, P3034
   Adelmann H.B, 1966, EVOLUTION EMBRYOLOGY
   Ader M, 2014, CURR OPIN CELL BIOL, V31, P23, DOI 10.1016/j.ceb.2014.06.013
   Aerts I, 2006, ORPHANET J RARE DIS, V1, DOI 10.1186/1750-1172-1-31
   Akhtar T, 2019, STEM CELL RES, V39, DOI 10.1016/j.scr.2019.101491
   Allikmets R, 1997, NAT GENET, V15, P236, DOI 10.1038/ng0397-236
   Andersen J, 2020, CELL, V183, P1913, DOI 10.1016/j.cell.2020.11.017
   ANDERSON KL, 1995, AM J HUM GENET, V57, P1351
   Apte RS, 2018, CELL, V173, P5, DOI 10.1016/j.cell.2018.03.021
   Archibald NK, 2009, BRAIN, V132, P1128, DOI 10.1093/brain/awp068
   Arthur P, 2022, PHARM RES-DORDR, DOI 10.1007/s11095-022-03350-7
   Arthur P, 2020, TOXICOL APPL PHARM, V401, DOI 10.1016/j.taap.2020.115112
   Ashok A, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21197290
   Assawachananont J, 2014, STEM CELL REP, V2, P662, DOI 10.1016/j.stemcr.2014.03.011
   Bailey T.J., 2005, PROGRAM DEV BIOL
   Baixauli F, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00403
   Barishak Y., 2001, EMBRYOLOGY EYE ITS A, V2nd ed., DOI [10.1159/isbn.978-3-318-00662-9, DOI 10.1159/ISBN.978-3-318-00662-9]
   Bartsch U, 2008, EXP EYE RES, V86, P691, DOI 10.1016/j.exer.2008.01.018
   Ben M'Barek K, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aai7471
   Berber P., 2021, J TRANSL GENET GENOM, V5, P292, DOI [10.20517/jtgg.2021.35, DOI 10.20517/JTGG.2021.35]
   Birey F, 2017, NATURE, V545, P54, DOI 10.1038/nature22330
   Boland MV, 2007, J GLAUCOMA, V16, P406, DOI 10.1097/IJG.0b013e31806540a1
   Brookmeyer R, 2018, ALZHEIMERS DEMENT, V14, P121, DOI 10.1016/j.jalz.2017.10.009
   Bujakowska K, 2012, HUM MUTAT, V33, P306, DOI 10.1002/humu.21653
   Burgoyne CF, 2005, PROG RETIN EYE RES, V24, P39, DOI 10.1016/j.preteyeres.2004.06.001
   Buskin A, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06448-y
   Cakir B, 2019, NAT METHODS, V16, P1169, DOI 10.1038/s41592-019-0586-5
   Capowski EE, 2019, DEVELOPMENT, V146, DOI 10.1242/dev.171686
   Carr AJ, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008152
   Centanin L, 2014, DEVELOPMENT, V141, P241, DOI 10.1242/dev.083642
   Chen D, 2004, CANCER CELL, V5, P539, DOI 10.1016/j.ccr.2004.05.025
   Chichagova Valeria, 2019, Curr Protoc Stem Cell Biol, V50, pe95, DOI 10.1002/cpsc.95
   Choi H, 2020, AGING CELL, V19, DOI 10.1111/acel.13081
   CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0
   Clevers H, 2016, CELL, V165, P1586, DOI 10.1016/j.cell.2016.05.082
   Collin J, 2019, STEM CELLS, V37, P593, DOI 10.1002/stem.2963
   Cong L, 2013, SCIENCE, V339, P819, DOI 10.1126/science.1231143
   Corro C, 2020, AM J PHYSIOL-CELL PH, V319, pC151, DOI 10.1152/ajpcell.00120.2020
   Cowan CS, 2020, CELL, V182, P1623, DOI 10.1016/j.cell.2020.08.013
   Crair MC, 2016, J NEUROSCI, V36, P10707, DOI 10.1523/JNEUROSCI.1711-16.2016
   Cui ZK, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.3.6
   Cunningham CL, 2013, J NEUROSCI, V33, P4216, DOI 10.1523/JNEUROSCI.3441-12.2013
   Cvekl A, 2009, EXP EYE RES, V89, P280, DOI 10.1016/j.exer.2009.04.012
   De La Camara CMF, 2018, EXPERT OPIN ORPHAN D, V6, P167, DOI 10.1080/21678707.2018.1444476
   De Roach JN, 2013, CLIN EXP OPHTHALMOL, V41, P476, DOI 10.1111/ceo.12020
   den Hollander AI, 2008, PROG RETIN EYE RES, V27, P391, DOI 10.1016/j.preteyeres.2008.05.003
   Deng WL, 2018, STEM CELL REP, V10, P1267, DOI 10.1016/j.stemcr.2018.02.003
   Deutman A.F., 1971, HEREDITARY DYSTROPHI
   Dimaras H, 2015, NAT REV DIS PRIMERS, V1, DOI 10.1038/nrdp.2015.21
   DiStefano T, 2018, STEM CELL REP, V10, P300, DOI 10.1016/j.stemcr.2017.11.001
   Dong ZM, 2016, INVEST OPHTH VIS SCI, V57, pOCT556, DOI 10.1167/iovs.16-19933
   Dunn KC, 1996, EXP EYE RES, V62, P155, DOI 10.1006/exer.1996.0020
   Eade K, 2021, JOVE-J VIS EXP, DOI 10.3791/62269
   Eastlake K, 2019, STEM CELL TRANSL MED, V8, P775, DOI 10.1002/sctm.18-0263
   Eiraku M, 2011, NATURE, V472, P51, DOI 10.1038/nature09941
   El-Amraoui A, 2014, CR BIOL, V337, P167, DOI 10.1016/j.crvi.2013.12.004
   Eldred KC, 2018, SCIENCE, V362, P200, DOI 10.1126/science.aau6348
   Elliott RO, 2021, PHARMACEUTICS, V13, DOI 10.3390/pharmaceutics13010122
   Fagerlund I, 2022, CELLS-BASEL, V11, DOI 10.3390/cells11010124
   Fereshtehnejad SM, 2017, BRAIN, V140, P1959, DOI 10.1093/brain/awx118
   Fernando M, 2022, STEM CELL REP, V17, P1476, DOI 10.1016/j.stemcr.2022.04.003
   Finlay BL, 2008, BRAIN RES, V1192, P5, DOI 10.1016/j.brainres.2007.07.005
   Fligor CM, 2021, STEM CELL REP, V16, P2228, DOI 10.1016/j.stemcr.2021.05.009
   Flores-Bellver M, 2021, J EXTRACELL VESICLES, V10, DOI 10.1002/jev2.12165
   FORSIUS H, 1973, CAN J OPHTHALMOL, V8, P385
   FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0
   Furukawa T, 1999, NAT GENET, V23, P466, DOI 10.1038/70591
   Fuster-Matanzo A, 2015, STEM CELL RES THER, V6, DOI 10.1186/s13287-015-0232-9
   Gabriel E, 2021, CELL STEM CELL, V28, P1740, DOI 10.1016/j.stem.2021.07.010
   Gabriel E, 2016, EMBO J, V35, P803, DOI 10.15252/embj.201593679
   Gagliardi G, 2018, STEM CELL REP, V11, P665, DOI 10.1016/j.stemcr.2018.07.005
   Gao ML, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.00128
   Garreta E, 2021, NAT MATER, V20, P145, DOI 10.1038/s41563-020-00804-4
   George NDL, 1996, ARCH OPHTHALMOL-CHIC, V114, P274, DOI 10.1001/archopht.1996.01100130270007
   German OL, 2008, J NEUROSCI RES, V86, P3503, DOI 10.1002/jnr.21813
   Ginhoux F, 2010, SCIENCE, V330, P841, DOI 10.1126/science.1194637
   Gitler AD, 2017, DIS MODEL MECH, V10, P499, DOI 10.1242/dmm.030205
   Gonzalez-Cordero A, 2017, STEM CELL REP, V9, P820, DOI 10.1016/j.stemcr.2017.07.022
   Graziotto JJ, 2011, INVEST OPHTH VIS SCI, V52, P190, DOI 10.1167/iovs.10-5194
   Green ES, 2003, DEVELOPMENT, V130, P539, DOI 10.1242/dev.00275
   Greenfield DS, 2008, AM J OPHTHALMOL, V145, P598, DOI 10.1016/j.ajo.2007.12.018
   Gregory CD, 2010, APOPTOSIS, V15, P1029, DOI 10.1007/s10495-010-0485-9
   Grytz R, 2014, J MECH BEHAV BIOMED, V29, P602, DOI 10.1016/j.jmbbm.2013.03.027
   Guo YL, 2019, FRONT CELL NEUROSCI, V13, DOI 10.3389/fncel.2019.00361
   Ha D, 2016, ACTA PHARM SIN B, V6, P287, DOI 10.1016/j.apsb.2016.02.001
   Hallam D, 2018, STEM CELLS, V36, P1535, DOI 10.1002/stem.2883
   Hamel C, 2006, ORPHANET J RARE DIS, V1, DOI 10.1186/1750-1172-1-40
   Han C, 2016, STEM CELLS INT, V2016, DOI 10.1155/2016/7653489
   Harding P, 2019, J DEV BIOL, V7, DOI 10.3390/jdb7030016
   Hartong DT, 2006, LANCET, V368, P1795, DOI 10.1016/S0140-6736(06)69740-7
   HENDRICKSON A, 1992, BEHAV BRAIN RES, V49, P21, DOI 10.1016/S0166-4328(05)80191-3
   Hendrickson A, 2016, AM J OPHTHALMOL, V161, P29, DOI 10.1016/j.ajo.2015.09.023
   HEYMAN RA, 1992, CELL, V68, P397, DOI 10.1016/0092-8674(92)90479-V
   Hiler D, 2015, CELL STEM CELL, V17, P101, DOI 10.1016/j.stem.2015.05.015
   Hirami Y, 2009, NEUROSCI LETT, V458, P126, DOI 10.1016/j.neulet.2009.04.035
   Horsford DJ, 2005, DEVELOPMENT, V132, P177, DOI 10.1242/dev.01571
   Hoshino A, 2017, DEV CELL, V43, P763, DOI 10.1016/j.devcel.2017.10.029
   Huang KC, 2019, STEM CELL REP, V13, P906, DOI 10.1016/j.stemcr.2019.09.010
   Huang LL, 2018, EYE, V32, P1608, DOI 10.1038/s41433-018-0130-3
   Huch M, 2015, DEVELOPMENT, V142, P3113, DOI 10.1242/dev.118570
   Huschke E., 1835, OPHTHALMOLOGY, V4, P273
   Hyatt GA, 1996, P NATL ACAD SCI USA, V93, P13298, DOI 10.1073/pnas.93.23.13298
   Ikeda H, 2005, P NATL ACAD SCI USA, V102, P11331, DOI 10.1073/pnas.0500010102
   Indovina P, 2015, ONCOTARGET, V6, P17873, DOI 10.18632/oncotarget.4286
   JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0
   Jeske R, 2020, TISSUE ENG PART B-RE, V26, P129, DOI [10.1089/ten.teb.2019.0252, 10.1089/ten.TEB.2019.0252]
   Jin N, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.741368
   Kamao H, 2014, STEM CELL REP, V2, P205, DOI 10.1016/j.stemcr.2013.12.007
   Kaplan HJ, 1997, ARCH OPHTHALMOL-CHIC, V115, P1168, DOI 10.1001/archopht.1997.01100160338012
   KAWANO K, 1981, A GRAEF ARCH KLIN EX, V217, P315, DOI 10.1007/BF00429292
   Kaya KD, 2019, MOL VIS, V25, P663
   Kelley MW, 1999, NEUROREPORT, V10, P2389, DOI 10.1097/00001756-199908020-00031
   KELLNER U, 1990, GRAEF ARCH CLIN EXP, V228, P432, DOI 10.1007/BF00927256
   Khanna H, 2006, J BIOL CHEM, V281, P27327, DOI 10.1074/jbc.M605500200
   Kierdorf K, 2013, NAT NEUROSCI, V16, P273, DOI 10.1038/nn.3318
   Kim J, 2020, NAT REV MOL CELL BIO, V21, P571, DOI 10.1038/s41580-020-0259-3
   Kim S, 2019, P NATL ACAD SCI USA, V116, P10824, DOI 10.1073/pnas.1901572116
   Kimberling WJ, 2010, GENET MED, V12, P512, DOI 10.1097/GIM.0b013e3181e5afb8
   Klingeborn M, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-05102-9
   Knudsen ES, 2006, CURR MOL MED, V6, P749
   Kooijmans SAA, 2012, INT J NANOMED, V7, P1525, DOI 10.2147/IJN.S29661
   Kruczek K, 2020, STEM CELLS, V38, P1206, DOI 10.1002/stem.3239
   Kumaran N, 2017, BRIT J OPHTHALMOL, V101, P1147, DOI 10.1136/bjophthalmol-2016-309975
   Lakkaraju A, 2020, PROG RETIN EYE RES, V78, DOI 10.1016/j.preteyeres.2020.100846
   Lamba DA, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008763
   Lamba DA, 2009, CELL STEM CELL, V4, P73, DOI 10.1016/j.stem.2008.10.015
   Lancaster MA, 2014, SCIENCE, V345, DOI 10.1126/science.1247125
   Lancaster MA, 2013, NATURE, V501, P373, DOI 10.1038/nature12517
   Lane A, 2020, STEM CELL REP, V15, P67, DOI 10.1016/j.stemcr.2020.05.007
   Langer KB, 2018, STEM CELL REP, V10, P1282, DOI 10.1016/j.stemcr.2018.02.010
   LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0
   Li HS, 1997, DEVELOPMENT, V124, P603
   Li LH, 2005, ANNU REV CELL DEV BI, V21, P605, DOI 10.1146/annurev.cellbio.21.012704.131525
   Li SF, 2020, INT J OPHTHALMOL-CHI, V13, P1493, DOI 10.18240/ijo.2020.09.23
   Li ZQ, 2012, BIOMATERIALS, V33, P5914, DOI 10.1016/j.biomaterials.2012.05.012
   Limb GA, 2002, INVEST OPHTH VIS SCI, V43, P864
   Liu J, 2020, INT J NANOMED, V15, P10519, DOI 10.2147/IJN.S277190
   Lukovic D, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-62047-2
   MacLaren RE, 2006, NATURE, V444, P203, DOI 10.1038/nature05161
   Mansour AA, 2018, NAT BIOTECHNOL, V36, P432, DOI 10.1038/nbt.4127
   Marzano M, 2021, ACS BIOMATER SCI ENG, V7, P1111, DOI 10.1021/acsbiomaterials.0c01286
   Marzano M, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8090993
   Mathers PH, 2000, CELL MOL LIFE SCI, V57, P186, DOI 10.1007/PL00000683
   McLelland BT, 2018, INVEST OPHTH VIS SCI, V59, P2586, DOI 10.1167/iovs.17-23646
   Mellough CB, 2019, STEM CELL TRANSL MED, V8, P694, DOI 10.1002/sctm.18-0267
   Meyer JS, 2009, P NATL ACAD SCI USA, V106, P16698, DOI 10.1073/pnas.0905245106
   Milman N, 2019, DRUG RESIST UPDATE, V45, P1, DOI 10.1016/j.drup.2019.07.003
   Miltner AM, 2019, DEV DYNAM, V248, P118, DOI 10.1002/dvdy.24672
   Miyamoto A, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12540
   Molday LL, 2001, INVEST OPHTH VIS SCI, V42, P816
   Morrison SJ, 2008, CELL, V132, P598, DOI 10.1016/j.cell.2008.01.038
   Muffat J, 2016, CURR OPIN CELL BIOL, V43, P96, DOI 10.1016/j.ceb.2016.10.001
   Nakano T, 2012, CELL STEM CELL, V10, P771, DOI 10.1016/j.stem.2012.05.009
   Neidhardt J, 2008, MOL VIS, V14, P1081
   Norman RE, 2011, EXP EYE RES, V93, P4, DOI 10.1016/j.exer.2010.09.014
   Norrie JL, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-24781-7
   Ootani A, 2009, NAT MED, V15, P1, DOI 10.1038/nm.1951
   Osakada F, 2008, NAT BIOTECHNOL, V26, P215, DOI 10.1038/nbt1384
   Osakada F, 2009, J CELL SCI, V122, P3169, DOI 10.1242/jcs.050393
   Osaki T, 2018, SCI ADV, V4, DOI 10.1126/sciadv.aat5847
   PAGON RA, 1988, SURV OPHTHALMOL, V33, P137, DOI 10.1016/0039-6257(88)90085-9
   Pander C.H., 1817, BEITRAGE ENTWICKELUN
   Patel N, 2021, INT J PHARMACEUT, V607, DOI 10.1016/j.ijpharm.2021.120943
   Peng C, 2020, NAT REV NEUROL, V16, P199, DOI 10.1038/s41582-020-0333-7
   Phillips MJ, 2018, STEM CELLS, V36, P313, DOI 10.1002/stem.2755
   Phillips MJ, 2014, STEM CELLS, V32, P1480, DOI 10.1002/stem.1667
   Phillips MJ, 2012, INVEST OPHTH VIS SCI, V53, P2007, DOI 10.1167/iovs.11-9313
   Poon A, 2017, NEW BIOTECHNOL, V39, P190, DOI 10.1016/j.nbt.2017.05.009
   Quadrato G, 2017, NATURE, V545, P48, DOI 10.1038/nature22047
   Quigley HA, 2006, BRIT J OPHTHALMOL, V90, P262, DOI 10.1136/bjo.2005.081224
   QUIGLEY HA, 1993, NEW ENGL J MED, V328, P1097, DOI 10.1056/NEJM199304153281507
   QUIGLEY HA, 1995, INVEST OPHTH VIS SCI, V36, P774
   QUIGLEY HA, 1981, ARCH OPHTHALMOL-CHIC, V99, P635, DOI 10.1001/archopht.1981.03930010635009
   QUIGLEY HA, 1989, AM J OPHTHALMOL, V107, P453, DOI 10.1016/0002-9394(89)90488-1
   Radtke ND, 1999, AM J OPHTHALMOL, V128, P384, DOI 10.1016/S0002-9394(99)00250-0
   Ragge N, 2007, EYE, V21, P1290, DOI 10.1038/sj.eye.6702858
   Dezfuly AR, 2021, STEM CELL RES THER, V12, DOI 10.1186/s13287-021-02588-z
   Regent F, 2020, MOL VIS, V26, P97
   Reichman S, 2017, STEM CELLS, V35, P1176, DOI 10.1002/stem.2586
   Reichman S, 2014, P NATL ACAD SCI USA, V111, P8518, DOI 10.1073/pnas.1324212111
   Reiners J, 2006, EXP EYE RES, V83, P97, DOI 10.1016/j.exer.2005.11.010
   Renner M, 2017, EMBO J, V36, P1316, DOI 10.15252/embj.201694700
   Richardson R, 2017, EUR J HUM GENET, V25, DOI 10.1038/ejhg.2016.201
   Rowan S, 2004, DEVELOPMENT, V131, P5139, DOI 10.1242/dev.01300
   Saengwimol D, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-34037-y
   Sasai Y, 2012, SCI AM, V307, P44, DOI 10.1038/scientificamerican1112-44
   Sasai Y, 2013, CELL STEM CELL, V12, P520, DOI 10.1016/j.stem.2013.04.009
   Sasai Y, 2012, DEVELOPMENT, V139, P4111, DOI 10.1242/dev.079590
   Sato T, 2009, NATURE, V459, P262, DOI 10.1038/nature07935
   Sauer CG, 1997, NAT GENET, V17, P164, DOI 10.1038/ng1097-164
   Schiller M, 2008, CELL DEATH DIFFER, V15, P183, DOI 10.1038/sj.cdd.4402239
   Sears AE, 2017, TRANSL VIS SCI TECHN, V6, DOI 10.1167/tvst.6.5.6
   Seigel G, 1999, MOL VIS, V5
   Sercombe L, 2015, FRONT PHARMACOL, V6, DOI 10.3389/fphar.2015.00286
   Shah SP, 2011, INVEST OPHTH VIS SCI, V52, P558, DOI 10.1167/iovs.10-5263
   Shirai H, 2016, P NATL ACAD SCI USA, V113, pE81, DOI 10.1073/pnas.1512590113
   Sigal IA, 2005, INVEST OPHTH VIS SCI, V46, P4189, DOI 10.1167/iovs.05-0541
   Sigal IA, 2011, INVEST OPHTH VIS SCI, V52, P1896, DOI 10.1167/iovs.10-5500
   Stevens B, 2007, CELL, V131, P1164, DOI 10.1016/j.cell.2007.10.036
   Stratoulias V, 2019, EMBO J, V38, DOI 10.15252/embj.2019101997
   Su PY, 2021, INVEST OPHTH VIS SCI, V62
   Sun TY, 2018, INVEST OPHTH VIS SCI, V59, P1229, DOI 10.1167/iovs.17-23312
   Takahashi K, 2007, CELL, V131, P861, DOI 10.1016/j.cell.2007.11.019
   Talbot K, 2018, J NEUROL, V265, P2454, DOI 10.1007/s00415-018-8983-8
   Tan A, 2013, ADV DRUG DELIVER REV, V65, P357, DOI 10.1016/j.addr.2012.06.014
   Tantri A, 2004, SURV OPHTHALMOL, V49, P214, DOI 10.1016/j.survophthal.2003.12.007
   Thomson JA, 1998, SCIENCE, V282, P1145, DOI 10.1126/science.282.5391.1145
   Tucker BA, 2013, ELIFE, V2, DOI 10.7554/eLife.00824
   Tucker BA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018992
   VanderWall KB, 2020, STEM CELL REP, V15, P52, DOI 10.1016/j.stemcr.2020.05.009
   Velasco S, 2019, NATURE, V570, P523, DOI 10.1038/s41586-019-1289-x
   Veleri S, 2015, DIS MODEL MECH, V8, P109, DOI 10.1242/dmm.017913
   Verma AS, 2007, ORPHANET J RARE DIS, V2, DOI 10.1186/1750-1172-2-47
   Vugler A, 2008, EXP NEUROL, V214, P347, DOI 10.1016/j.expneurol.2008.09.007
   Wahlin KJ, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-00774-9
   Wang J, 2021, J CONTROL RELEASE, V329, P894, DOI 10.1016/j.jconrel.2020.10.020
   Welby E, 2017, STEM CELL REP, V9, P1898, DOI 10.1016/j.stemcr.2017.10.018
   Westeneng-van Haaften SC, 2012, OPHTHALMOLOGY, V119, P1199, DOI 10.1016/j.ophtha.2012.01.005
   Xiao M, 2000, J COMP NEUROL, V425, P545
   Xu HX, 2018, EXP HEMATOL ONCOL, V7, DOI 10.1186/s40164-018-0122-9
   Xu J, 2018, J CELL SCI, V131, DOI 10.1242/jcs.215210
   Yu Y, 2022, STEM CELL RES THER, V13, DOI 10.1186/s13287-021-02685-z
   Zhang JK, 2004, CELL CYCLE, V3, P952
   Zhang JK, 2004, NAT GENET, V36, P351, DOI 10.1038/ng1318
   Zhang ZY, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.643680
   Zhong XF, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5047
   Zhou J, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-00542-w
   Zhu J, 2018, STEM CELL TRANSL MED, V7, P210, DOI 10.1002/sctm.17-0205
   Zhu Y, 2017, STEM CELL RES THER, V8, DOI 10.1186/s13287-017-0510-9
NR 229
TC 0
Z9 0
U1 2
U2 2
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2073-4409
J9 CELLS-BASEL
JI Cells
PD NOV
PY 2022
VL 11
IS 21
AR 3429
DI 10.3390/cells11213429
PG 30
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA 6B0TE
UT WOS:000881055900001
PM 36359825
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Ortolan, D
   Sharma, R
   Volkov, A
   Maminishkis, A
   Hotaling, NA
   Huryn, LA
   Cukras, C
   Di Marco, S
   Bisti, S
   Bharti, K
AF Ortolan, Davide
   Sharma, Ruchi
   Volkov, Andrei
   Maminishkis, Arvydas
   Hotaling, Nathan A.
   Huryn, Laryssa A.
   Cukras, Catherine
   Di Marco, Stefano
   Bisti, Silvia
   Bharti, Kapil
TI Single-cell-resolution map of human retinal pigment epithelium helps
   discover subpopulations with differential disease sensitivity
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
DE cell morphometry; retinal degeneration; artificial intelligence; data
   science; AMD
ID LYSOSOMAL-ENZYMES; STEM-CELL; REGIONAL DISTRIBUTION; METABOLIC-RATE;
   AGE; RPE; DEGENERATION; DRUSEN; MACULA; SIZE
AB Regional phenotypic and functional differences in the retinal pigment epithelium (RPE) monolayer have been suggested to account for regional susceptibility in ocular diseases such as age-related macular degeneration (AMD), late-onset retinal degeneration (L-ORD), and choroideremia (CHM). However, a comprehensive description of human topographical RPE diversity is not yet available, thus limiting the understanding of regional RPE diversity and degenerative disease sensitivity in the eye. To develop a complete morphometric RPE map of the human eye, artificial intelligence-based software was trained to recognize, segment, and analyze RPE borders. Five statistically different, concentric RPE subpopulations (P1 to P5) were identified using cell area as a parameter, including a subpopulation (P4) with cell area comparable to that of macular cells in the far periphery of the eye. This work provides a complete reference map of human RPE subpopulations and their location in the eye. In addition, the analysis of cadaver non-AMD and AMD eyes and ultra-widefield fundus images of patients revealed differential vulnerability of the five RPE subpopulations to different retinal diseases.
C1 [Ortolan, Davide; Sharma, Ruchi; Volkov, Andrei; Maminishkis, Arvydas; Bharti, Kapil] NEI, Ocular & Stem Cell Translat Res Sect, NIH, Bethesda, MD 20892 USA.
   [Hotaling, Nathan A.] NIH, Informat Resources Technol Branch, Natl Ctr Adv Translat Sci, Bethesda, MD 20892 USA.
   [Huryn, Laryssa A.] NEI, Ophthalm Clin Genet Sect, NIH, Bethesda, MD 20892 USA.
   [Cukras, Catherine] NEI, Unit Clin Invest Retinal Dis, NIH, Bethesda, MD 20892 USA.
   [Di Marco, Stefano; Bisti, Silvia] Ist Italiano Tecnol, Ctr Synapt Neurosci & Technol, I-16132 Genoa, Italy.
   [Bisti, Silvia] Biostruct & Biosyst Natl Inst, I-00136 Rome, Italy.
C3 National Institutes of Health (NIH) - USA; NIH National Eye Institute
   (NEI); National Institutes of Health (NIH) - USA; NIH National Center
   for Advancing Translational Sciences (NCATS); National Institutes of
   Health (NIH) - USA; NIH National Eye Institute (NEI); National
   Institutes of Health (NIH) - USA; NIH National Eye Institute (NEI);
   Istituto Italiano di Tecnologia - IIT
RP Bharti, K (通讯作者)，NEI, Ocular & Stem Cell Translat Res Sect, NIH, Bethesda, MD 20892 USA.
EM kapil.bharti@nih.gov
RI Ortolan, Davide/AFP-8878-2022
OI Ortolan, Davide/0000-0002-8236-9391; BISTI, Silvia/0000-0003-4157-111X
FU NEI IRP funds [ZIA EY000533-04]
FX We thank the National Eye Institute (NEI) histology core for the use of
   the Zeiss Axio Scan.Z1; Jorge Ferrari Escoto for helping with the
   isolation of RPE subpopulations; and the donors, their families, the
   Advancing Sight Network, and the Lions Eye Institute for their
   generosity. We also thank Michael B. Gorin for the invaluable comments
   on the manuscript. This work was supported by NEI IRP funds (grant
   number ZIA EY000533-04).
CR Al-Hussaini H, 2008, MOL VIS, V14, P1784
   Ben M'Barek K, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aai7471
   Bharti K, 2011, PIGM CELL MELANOMA R, V24, P21, DOI 10.1111/j.1755-148X.2010.00772.x
   Bhatia SK, 2016, MOL VIS, V22, P898
   Bortner CD, 2002, CELL DEATH DIFFER, V9, P1307, DOI 10.1038/sj.cdd.4401126
   BOULTON M, 1994, BRIT J OPHTHALMOL, V78, P125, DOI 10.1136/bjo.78.2.125
   BURKE JM, 1991, INVEST OPHTH VIS SCI, V32, P2042
   BURKE JM, 1988, INVEST OPHTH VIS SCI, V29, P1789
   CABRAL L, 1990, INVEST OPHTH VIS SCI, V31, P670
   Chong NHV, 2005, AM J PATHOL, V166, P241, DOI 10.1016/S0002-9440(10)62248-1
   Classen AK, 2005, DEV CELL, V9, P805, DOI 10.1016/j.devcel.2005.10.016
   Coussa RG, 2012, OPHTHALMIC GENET, V33, P57, DOI 10.3109/13816810.2011.620056
   CURCIO CA, 1990, J COMP NEUROL, V292, P497, DOI 10.1002/cne.902920402
   da Cruz L, 2018, NAT BIOTECHNOL, V36, P1, DOI 10.1038/nbt.4114
   Elmore S, 2007, TOXICOL PATHOL, V35, P495, DOI 10.1080/01926230701320337
   Foltz LP, 2017, JOVE-J VIS EXP, DOI 10.3791/56274
   Galloway CA, 2018, INVEST OPHTH VIS SCI, V59, P2792, DOI 10.1167/iovs.17-23157
   Galloway CA, 2017, P NATL ACAD SCI USA, V114, pE8214, DOI 10.1073/pnas.1710430114
   Ginzberg MB, 2015, SCIENCE, V348, DOI 10.1126/science.1245075
   Gomez-Angelats M, 2002, TOXICOL PATHOL, V30, P541, DOI 10.1080/01926230290105820
   Greeff R., 1900, HDB GESAMTEN AUGENHE, P74
   Hannezo E, 2014, P NATL ACAD SCI USA, V111, P27, DOI 10.1073/pnas.1312076111
   Harman AM, 1997, INVEST OPHTH VIS SCI, V38, P2016
   HAYASAKA S, 1981, A GRAEF ARCH KLIN EX, V216, P269, DOI 10.1007/BF00455034
   Ishibashi K, 2004, INVEST OPHTH VIS SCI, V45, P3291, DOI 10.1167/iovs.04-0168
   Jacobson SG, 2001, INVEST OPHTH VIS SCI, V42, P1882
   Kamao H, 2014, STEM CELL REP, V2, P205, DOI 10.1016/j.stemcr.2013.12.007
   Kim YK, 2021, INVEST OPHTH VIS SCI, V62, DOI 10.1167/iovs.62.2.32
   Kuntz CA, 1996, INVEST OPHTH VIS SCI, V37, P1772
   Leach LL, 2016, J OCUL PHARMACOL TH, V32, P317, DOI 10.1089/jop.2016.0022
   Li B, 2020, ISCIENCE, V23, DOI 10.1016/j.isci.2020.101672
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   MacDonald IM, 2009, SURV OPHTHALMOL, V54, P401, DOI 10.1016/j.survophthal.2009.02.008
   Marshall WF, 2015, TRENDS CELL BIOL, V25, P760, DOI 10.1016/j.tcb.2015.08.008
   Miettinen TP, 2017, TRENDS CELL BIOL, V27, P393, DOI 10.1016/j.tcb.2017.02.006
   Miettinen TP, 2016, DEV CELL, V39, P370, DOI 10.1016/j.devcel.2016.09.004
   MILLER SS, 1978, J MEMBRANE BIOL, V44, P259, DOI 10.1007/BF01944224
   Mollon JD, 1998, EYE, V12, P548, DOI 10.1038/eye.1998.144
   Mullins RE, 2011, INVEST OPHTH VIS SCI, V52, P1606, DOI 10.1167/iovs.10-6476
   Osakada F, 2009, J CELL SCI, V122, P3169, DOI 10.1242/jcs.050393
   Osterberg G, 1935, TOPOGRAPHY LAYER ROD
   Pennesi ME, 2019, RETINA-J RET VIT DIS, V39, P2059, DOI 10.1097/IAE.0000000000002553
   Pennington BO, 2015, STEM CELL TRANSL MED, V4, P165, DOI 10.5966/sctm.2014-0179
   Radeke MJ, 2007, EXP EYE RES, V85, P366, DOI 10.1016/j.exer.2007.05.006
   Salero E, 2012, CELL STEM CELL, V10, P88, DOI 10.1016/j.stem.2011.11.018
   Savage VM, 2007, P NATL ACAD SCI USA, V104, P4718, DOI 10.1073/pnas.0611235104
   Schaub NJ, 2020, J CLIN INVEST, V130, P1010, DOI 10.1172/JCI131187
   Sharma R, 2020, ANNU REV PHARMACOL, V60, P553, DOI 10.1146/annurev-pharmtox-010919-023245
   Sharma R, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aat5580
   Singh R, 2013, INVEST OPHTH VIS SCI, V54, P6767, DOI 10.1167/iovs.13-11943
   Singh R, 2013, HUM MOL GENET, V22, P593, DOI 10.1093/hmg/dds469
   Snodderly DM, 2002, INVEST OPHTH VIS SCI, V43, P2815
   Styles CJ, 2003, EYE, V17, P530, DOI 10.1038/sj.eye.6700408
   van Soest SS, 2007, MOL VIS, V13, P1608
   WATZKE RC, 1993, CURR EYE RES, V12, P133, DOI 10.3109/02713689308999481
   West GB, 2002, P NATL ACAD SCI USA, V99, P2473, DOI 10.1073/pnas.012579799
   Whitmore SS, 2014, EXP EYE RES, V129, P93, DOI 10.1016/j.exer.2014.11.001
   WILLIAMS RW, 1991, VISUAL NEUROSCI, V6, P403, DOI 10.1017/S0952523800006647
   Zhang Q, 2019, MOL VIS, V25, P70
NR 59
TC 3
Z9 3
U1 1
U2 1
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
EI 1091-6490
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD MAY 10
PY 2022
VL 119
IS 19
AR e2117553119
DI 10.1073/pnas.2117553119
PG 12
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 4N4SP
UT WOS:000854009500007
PM 35522714
OA hybrid, Green Published
DA 2022-11-30
ER

PT J
AU Schottenhamml, J
   Moult, EM
   Ploner, SB
   Chen, SY
   Novais, E
   Husvogt, L
   Duker, JS
   Waheed, NK
   Fujimoto, JG
   Maier, AK
AF Schottenhamml, Julia
   Moult, Eric M.
   Ploner, Stefan B.
   Chen, Siyu
   Novais, Eduardo
   Husvogt, Lennart
   Duker, Jay S.
   Waheed, Nadia K.
   Fujimoto, James G.
   Maier, Andreas K.
TI OCT-OCTA segmentation: combining structural and blood flow information
   to segment Bruch's membrane
SO BIOMEDICAL OPTICS EXPRESS
LA English
DT Article
ID OPTICAL COHERENCE TOMOGRAPHY; RETINAL-PIGMENT EPITHELIUM; AUTOMATIC
   SEGMENTATION; GEOGRAPHIC ATROPHY; CHORIOCAPILLARIS ALTERATIONS;
   MORPHOMETRIC-ANALYSIS; MACULAR DEGENERATION; LAYER SEGMENTATION; MOTION
   CORRECTION; ULTRAHIGH-SPEED
AB In this paper we present a fully automated graph-based segmentation algorithm that jointly uses optical coherence tomography (OCT) and OCT angiography (OCTA) data to segment Bruch's membrane (BM). This is especially valuable in cases where the spatial correlation between BM, which is usually not visible on OCT scans, and the retinal pigment epithelium (RPE), which is often used as a surrogate for segmenting BM, is distorted by pathology. We validated the performance of our proposed algorithm against manual segmentation in a total of 18 eyes from healthy controls and patients with diabetic retinopathy (DR), non-exudative age-related macular degeneration (AMD) (early/intermediate AMID, nascent geographic atrophy (nGA) and drusen-associated geographic atrophy (DAGA) and geographic atrophy (GA)), and choroidal neovascularization (CNV) with a mean absolute error of similar to 0.91 pixel (similar to 4.1 mu m). This paper suggests that OCT-OCTA segmentation may be a useful framework to complement the growing usage of OCTA in ophthalmic research and clinical communities. (C) 2020 Optical Society of America under the terms of the OSA Open Access Publishing Agreement
C1 [Schottenhamml, Julia; Ploner, Stefan B.; Husvogt, Lennart; Maier, Andreas K.] Friedrich Alexander Univ Erlangen Nurnberg, Pattern Recognit Lab, D-91058 Erlangen, Germany.
   [Moult, Eric M.; Chen, Siyu; Husvogt, Lennart; Fujimoto, James G.] MIT, Dept Elect Engn & Comp Sci, Res Lab Elect, Cambridge, MA 02139 USA.
   [Novais, Eduardo; Duker, Jay S.; Waheed, Nadia K.] Tufts Med Ctr, New England Eye Ctr, Boston, MA 02116 USA.
   [Novais, Eduardo] Univ Fed Sao Paulo, Sch Med, BR-04021001 Sao Paulo, SP, Brazil.
C3 University of Erlangen Nuremberg; Massachusetts Institute of Technology
   (MIT); Tufts Medical Center; Universidade Federal de Sao Paulo (UNIFESP)
RP Schottenhamml, J (通讯作者)，Friedrich Alexander Univ Erlangen Nurnberg, Pattern Recognit Lab, D-91058 Erlangen, Germany.
EM julia.schottenhamml@fau.de
RI Maier, Andreas/AAV-6505-2021; CHEN, SI/GZL-4800-2022
OI Maier, Andreas/0000-0002-9550-5284; Ploner, Stefan/0000-0003-4286-8687
FU Deutsche Forschungsgemeinschaft [MA 4898/12-1]; National Institutes of
   Health [5-R01EY011289-31]; Air Force Office of Scientific Research
   [FA9550-15-1-0473]; Macula Vision Research Foundation; Champalimaud
   Vision Award; Beckman-Argyros Award in Vision Research
FX Deutsche Forschungsgemeinschaft (MA 4898/12-1); National Institutes of
   Health (5-R01EY011289-31); Air Force Office of Scientific Research
   (FA9550-15-1-0473); Macula Vision Research Foundation; Champalimaud
   Vision Award; Beckman-Argyros Award in Vision Research.
CR Baumann B, 2010, J BIOMED OPT, V15, DOI 10.1117/1.3499420
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Biesemeier A, 2014, NEUROBIOL AGING, V35, P2562, DOI 10.1016/j.neurobiolaging.2014.05.003
   Blatter C, 2012, J BIOMED OPT, V17, DOI 10.1117/1.JBO.17.7.070505
   Borrelli E, 2018, AM J OPHTHALMOL, V196, P34, DOI 10.1016/j.ajo.2018.08.014
   Boulton M, 2001, EYE, V15, P384, DOI 10.1038/eye.2001.141
   Chen Q, 2015, OPT EXPRESS, V23, P8974, DOI 10.1364/OE.23.008974
   Chen Q, 2013, MED IMAGE ANAL, V17, P1058, DOI 10.1016/j.media.2013.06.003
   Chiu SJ, 2012, INVEST OPHTH VIS SCI, V53, P53, DOI 10.1167/iovs.11-7640
   Chiu SJ, 2010, OPT EXPRESS, V18, P19413, DOI 10.1364/OE.18.019413
   Choi W, 2017, RETINA-J RET VIT DIS, V37, P11, DOI 10.1097/IAE.0000000000001250
   Choi W, 2015, OPHTHALMOLOGY, V122, P2532, DOI 10.1016/j.ophtha.2015.08.029
   Choi W, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081499
   Choi W, 2013, OPT LETT, V38, P338, DOI 10.1364/OL.38.000338
   Curcio C.A., 2013, RETINA-J RET VIT DIS, VVolume 1, P465
   Curcio CA, 1999, ARCH OPHTHALMOL-CHIC, V117, P329, DOI 10.1001/archopht.117.3.329
   Curcio Christine A, 2018, Invest Ophthalmol Vis Sci, V59, pAMD160, DOI 10.1167/iovs.18-24882
   Danesh H, 2014, COMPUT MATH METHODS, V2014, P1
   Dijkstra E. W., 1959, NUMER MATH, V1, P269, DOI [10.1007/BF01386390, DOI 10.1007/BF01386390]
   Fang LY, 2017, BIOMED OPT EXPRESS, V8, P2732, DOI 10.1364/BOE.8.002732
   Farsiu S, 2008, PROC SPIE, V6844, DOI 10.1117/12.768624
   Fingler J, 2007, OPT EXPRESS, V15, P12636, DOI 10.1364/OE.15.012636
   Gass JD., 1997, STEREOSCOPIC ATLAS M, V1
   Gregori G, 2011, OPHTHALMOLOGY, V118, P1373, DOI 10.1016/j.ophtha.2010.11.013
   He KM, 2015, IEEE I CONF COMP VIS, P1026, DOI 10.1109/ICCV.2015.123
   Jia YL, 2012, OPT EXPRESS, V20, P4710, DOI 10.1364/OE.20.004710
   Jonathan E, 2011, P SOC PHOTO-OPT INS, V7898, DOI 10.1117/12.879812
   Kajic V, 2012, BIOMED OPT EXPRESS, V3, P86, DOI 10.1364/BOE.3.000086
   Ko F, 2017, OPHTHALMOLOGY, V124, P105, DOI 10.1016/j.ophtha.2016.07.033
   Kraus MF, 2014, BIOMED OPT EXPRESS, V5, P2591, DOI 10.1364/BOE.5.002591
   Kraus MF, 2012, BIOMED OPT EXPRESS, V3, P1182, DOI 10.1364/BOE.3.001182
   Kurokawa K, 2017, BIOMED OPT EXPRESS, V8, P1803, DOI 10.1364/BOE.8.001803
   Lang A, 2013, PROC SPIE, V8669, DOI 10.1117/12.2006649
   Lutty G, 1999, MOL VIS, V5
   Makita S, 2006, OPT EXPRESS, V14, P7821, DOI 10.1364/OE.14.007821
   Mariampillai A, 2008, OPT LETT, V33, P1530, DOI 10.1364/OL.33.001530
   McLeod DS, 2009, INVEST OPHTH VIS SCI, V50, P4982, DOI 10.1167/iovs.09-3639
   Migacz JV, 2019, BIOMED OPT EXPRESS, V10, P50, DOI 10.1364/BOE.10.000050
   Mishra A, 2009, OPT EXPRESS, V17, P23719, DOI 10.1364/OE.17.023719
   Moult EM, 2016, RETINA-J RET VIT DIS, V36, pS2, DOI 10.1097/IAE.0000000000001287
   OLVER JM, 1990, EYE, V4, P262, DOI 10.1038/eye.1990.38
   Ploner S. B., 2020, ARXIV201006931
   RAMRATTAN RS, 1994, INVEST OPHTH VIS SCI, V35, P2857
   Ronneberger O, 2015, LECT NOTES COMPUT SC, V9351, P234, DOI 10.1007/978-3-319-24574-4_28
   SARKS JP, 1994, EYE, V8, P269, DOI 10.1038/eye.1994.57
   SARKS SH, 1980, AUST J OPHTHALMOL, V8, P117, DOI 10.1111/j.1442-9071.1980.tb01670.x
   Schachat A. P., 2017, RYANS RETINA E BOOK
   Schlanitz FG, 2011, INVEST OPHTH VIS SCI, V52, P4571, DOI 10.1167/iovs.10-6846
   Schwartz DM, 2014, OPHTHALMOLOGY, V121, P180, DOI 10.1016/j.ophtha.2013.09.002
   Spaide RF, 2018, PROG RETIN EYE RES, V64, P1, DOI 10.1016/j.preteyeres.2017.11.003
   Spaide RF, 2016, AM J OPHTHALMOL, V170, P58, DOI 10.1016/j.ajo.2016.07.023
   Sui XD, 2017, NEUROCOMPUTING, V237, P332, DOI 10.1016/j.neucom.2017.01.023
   Szegedy C, 2015, PROC CVPR IEEE, P1, DOI 10.1109/CVPR.2015.7298594
   Tao YK, 2008, OPT EXPRESS, V16, P12350, DOI 10.1364/OE.16.012350
   Thulliez M, 2019, OPHTHALMOL RETINA, V3, P478, DOI 10.1016/j.oret.2019.01.024
   Tomasi C, 1998, SIXTH INTERNATIONAL CONFERENCE ON COMPUTER VISION, P839, DOI 10.1109/ICCV.1998.710815
   Yang Q, 2011, BIOMED OPT EXPRESS, V2, P2493, DOI 10.1364/BOE.2.002493
   Yang Q, 2010, OPT EXPRESS, V18, P21293, DOI 10.1364/OE.18.021293
   Yi K, 2009, BRIT J OPHTHALMOL, V93, P176, DOI 10.1136/bjo.2008.137356
   Zadeh SG, 2017, LECT NOTES COMPUT SC, V10553, P65, DOI 10.1007/978-3-319-67558-9_8
   Zhang L, 2012, INVEST OPHTH VIS SCI, V53, P7510, DOI 10.1167/iovs.12-10311
   Zheng F, 2019, AM J OPHTHALMOL, V200, P110, DOI 10.1016/j.ajo.2018.12.025
NR 62
TC 4
Z9 4
U1 2
U2 5
PU OPTICAL SOC AMER
PI WASHINGTON
PA 2010 MASSACHUSETTS AVE NW, WASHINGTON, DC 20036 USA
SN 2156-7085
J9 BIOMED OPT EXPRESS
JI Biomed. Opt. Express
PD JAN 1
PY 2021
VL 12
IS 1
BP 84
EP 99
DI 10.1364/BOE.398222
PG 16
WC Biochemical Research Methods; Optics; Radiology, Nuclear Medicine &
   Medical Imaging
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Optics; Radiology, Nuclear Medicine &
   Medical Imaging
GA PO1FY
UT WOS:000604917800006
PM 33520378
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Kurth, T
   Witt, S
   Bolten, S
   Waniek, JJ
   Kortmann, C
   Lavrentieva, A
   Scheper, T
   Walter, JG
AF Kurth, Tracy
   Witt, Sandra
   Bolten, Svenja
   Waniek, Janice-Joy
   Kortmann, Carlotta
   Lavrentieva, Antonina
   Scheper, Thomas
   Walter, Johanna-Gabriela
TI Development of Aptamer-Based TID Assays Using Thermophoresis and
   Microarrays
SO BIOSENSORS-BASEL
LA English
DT Article
DE Aptamer; microarray; protein detection; target-induced dissociation
   (TID); biosensor; thermophoresis; vascular endothelial growth factor
   (VEGF)
ID VEGF APTAMER; DNA APTAMERS; SELECTION; APTASENSORS; IMPROVEMENT;
   MOLECULES; BIOLOGY
AB Aptamers are single-stranded oligonucleotides which can be used as alternative recognition elements for protein detection, because aptamers bind their targets with a high affinity similar to antibodies. Due to the target-induced conformational changes of aptamers, these oligonucleotides can be applied in various biosensing platforms. In this work, aptamers directed against the vascular endothelial growth factor (VEGF) were used as a model system. VEGF plays a key role in physiological angiogenesis and vasculogenesis. Furthermore, VEGF is involved in the development and growth of cancer and other diseases like age-related macular degeneration, rheumatoid arthritis, diabetes mellitus, and neurodegenerative disorders. Detecting the protein biomarker VEGF is therefore of great importance for medical research and diagnostics. In this research, VEGF-binding aptamers were investigated for the systematic development of a target-induced dissociation (TID) assay utilizing thermophoresis and microarrays. The established aptamer-microarray allowed for the detection of 0.1 nM of VEGF. Furthermore, the systematic development of the TID method using the VEGF model protein could help to develop further TID assays for the detection of various protein biomarkers.
C1 [Kurth, Tracy; Witt, Sandra; Bolten, Svenja; Waniek, Janice-Joy; Kortmann, Carlotta; Lavrentieva, Antonina; Scheper, Thomas; Walter, Johanna-Gabriela] Leibniz Univ Hannover, Inst Tech Chem, Callinstr 5, D-30167 Hannover, Germany.
C3 Leibniz University Hannover
RP Walter, JG (通讯作者)，Leibniz Univ Hannover, Inst Tech Chem, Callinstr 5, D-30167 Hannover, Germany.
EM walter@iftc.uni-hannover.de
OI Scheper, Thomas/0000-0003-1535-4584; Lavrentieva,
   Antonina/0000-0003-0003-5572
FU German Research Foundation (DFG); Max Buchner Research Foundation;
   Leibniz Universitat Hannover
FX Parts of this work were funded by German Research Foundation (DFG) and
   by the Max Buchner Research Foundation. The publication of this article
   was funded by the Open Access fund of Leibniz Universitat Hannover.
CR Barbulovic-Nad I, 2006, CRIT REV BIOTECHNOL, V26, P237, DOI 10.1080/07388550600978358
   Cerchia L, 2010, TRENDS BIOTECHNOL, V28, P517, DOI 10.1016/j.tibtech.2010.07.005
   Chiarelli F, 2000, DIABETIC MED, V17, P650, DOI 10.1046/j.1464-5491.2000.00350.x
   Dehghani S, 2018, BIOSENS BIOELECTRON, V110, P23, DOI 10.1016/j.bios.2018.03.037
   Deng B, 2014, ANAL CHIM ACTA, V837, P1, DOI 10.1016/j.aca.2014.04.055
   Freeman R, 2012, ANAL CHEM, V84, P6192, DOI 10.1021/ac3011473
   Hamula CLA, 2006, TRAC-TREND ANAL CHEM, V25, P681, DOI 10.1016/j.trac.2006.05.007
   Hasegawa H, 2008, BIOTECHNOL LETT, V30, P829, DOI 10.1007/s10529-007-9629-6
   Heilkenbrinker A, 2015, ANAL CHEM, V87, P677, DOI 10.1021/ac5034819
   Kaur H, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031196
   Lago S, 2017, BBA-GEN SUBJECTS, V1861, P1371, DOI 10.1016/j.bbagen.2016.11.036
   Levicky R, 2005, TRENDS BIOTECHNOL, V23, P143, DOI 10.1016/j.tibtech.2005.01.004
   Lonne Maren, 2015, Biotechnol Rep (Amst), V8, P16, DOI 10.1016/j.btre.2015.08.006
   Lubbecke M, 2012, ENG LIFE SCI, V12, P144, DOI 10.1002/elsc.201100100
   Marras SAE, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/gnf121
   Marusic M, 2013, NUCLEIC ACIDS RES, V41, P9524, DOI 10.1093/nar/gkt697
   Modh H, 2018, SENSORS-BASEL, V18, DOI 10.3390/s18041041
   Modh H, 2017, ENG LIFE SCI, V17, P923, DOI 10.1002/elsc.201700048
   Modh H, 2017, TALANTA, V172, P199, DOI 10.1016/j.talanta.2017.05.037
   Neidle S, 2009, CURR OPIN STRUC BIOL, V19, P239, DOI 10.1016/j.sbi.2009.04.001
   Ng EWM, 2006, NAT REV DRUG DISCOV, V5, P123, DOI 10.1038/nrd1955
   Nonaka Y, 2013, ANAL CHEM, V85, P1132, DOI 10.1021/ac303023d
   Nonaka Y, 2010, MOLECULES, V15, P215, DOI 10.3390/molecules15010215
   Radom F, 2013, BIOTECHNOL ADV, V31, P1260, DOI 10.1016/j.biotechadv.2013.04.007
   Roy H, 2006, FEBS LETT, V580, P2879, DOI 10.1016/j.febslet.2006.03.087
   Schax E, 2015, BIOTECHNOL BIOPROC E, V20, P1016, DOI 10.1007/s12257-015-0486-1
   Schuling T, 2018, AIMS BIOENG, V5, P78, DOI 10.3934/bioeng.2018.2.78
   Shim JW, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19010275
   Song YL, 2013, ANAL CHEM, V85, P4141, DOI 10.1021/ac400366b
   Tan WH, 2011, TRENDS BIOTECHNOL, V29, P634, DOI 10.1016/j.tibtech.2011.06.009
   Taylor JN, 2008, BIOCHEM BIOPH RES CO, V373, P213, DOI 10.1016/j.bbrc.2008.05.191
   Tombelli S, 2005, BIOSENS BIOELECTRON, V20, P2424, DOI 10.1016/j.bios.2004.11.006
   Walter JG, 2008, ANAL CHEM, V80, P7372, DOI 10.1021/ac801081v
   Walter JG, 2012, Z NATURFORSCH B, V67, P976, DOI 10.5560/ZNB.2012-0147
   Walter JG, 2012, ENG LIFE SCI, V12, P496, DOI 10.1002/elsc.201100197
   Wang CY, 2016, INT J CANCER, V138, P918, DOI 10.1002/ijc.29826
   Witt Martin, 2015, Microarrays (Basel), V4, P115, DOI 10.3390/microarrays4020115
   Yla-Herttuala S, 2007, J AM COLL CARDIOL, V49, P1015, DOI 10.1016/j.jacc.2006.09.053
   Zhu GH, 2011, CHEM ENG TECHNOL, V34, P2022, DOI 10.1002/ceat.201000551
NR 39
TC 5
Z9 6
U1 0
U2 8
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2079-6374
J9 BIOSENSORS-BASEL
JI Biosensors-Basel
PD DEC
PY 2019
VL 9
IS 4
AR 124
DI 10.3390/bios9040124
PG 15
WC Chemistry, Analytical; Nanoscience & Nanotechnology; Instruments &
   Instrumentation
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Chemistry; Science & Technology - Other Topics; Instruments &
   Instrumentation
GA KA3ZD
UT WOS:000505735900006
PM 31615077
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Shin, EY
   Park, JH
   Shin, ME
   Song, JE
   Thangavelu, M
   Carlomagno, C
   Motta, A
   Migliaresi, C
   Khang, G
AF Shin, Eun Yeong
   Park, Jong Ho
   Shin, Myeong Eun
   Song, Jeong Eun
   Thangavelu, Muthukumar
   Carlomagno, Cristiano
   Motta, Antonella
   Migliaresi, Claudio
   Khang, Gilson
TI Injectable taurine-loaded alginate hydrogels for retinal pigment
   epithelium (RPE) regeneration
SO MATERIALS SCIENCE & ENGINEERING C-MATERIALS FOR BIOLOGICAL APPLICATIONS
LA English
DT Article
DE Taurine; Sodium alginate; Injectable hydrogel; Retinal pigment
   epithelium; Tissue engineering
ID STEM-CELL THERAPY; MECHANICAL-PROPERTIES; MACULAR DEGENERATION
AB The purpose of this study is to produce injectable taurine (Tr)-loaded alginate (Agn) hydrogel for age-related macular degeneration (AMD) treatment by inducing the regeneration of RPE (retinal pigment epithelium) cells. Porosity and swelling ratio were measured to evaluate the mechanical properties of the hydrogels, and Fourier transform infrared spectroscopy (FTIR) was used to evaluate the physical and chemical properties. RPE cells extracted from the pigmented epithelium of rabbits were encapsulated in the Tr/Agn hydrogels. Cells proliferation and migration were improved in Tr/Agn hydrogels with an enhanced expression of RPE-specific genes including RPE65, CRALBP, NPR-A, MITE and collagen type I and II. In vivo tests demonstrated the excellent biocompatibility and biodegradability without inflammatory response by the host when implanted with the hydrogel. Moreover, when the Tr/Agn hydrogels were injected into the sub-retinal space, high adhesion of RPE cells and retinal regeneration were confirmed. These results demonstrated a potential role of injectable Tr/Agn hydrogels as potential therapeutic tools for the treatment of retinal diseases, including AMD.
C1 [Shin, Eun Yeong; Park, Jong Ho; Shin, Myeong Eun; Song, Jeong Eun; Thangavelu, Muthukumar; Khang, Gilson] Chonbuk Natl Univ, Dept Polymer Nano Sci & Technol, Dept BIN Convergence Technol, 567 Baekje Daero, Jeonju Si 54896, Jeollabuk Do, South Korea.
   [Shin, Eun Yeong; Park, Jong Ho; Shin, Myeong Eun; Song, Jeong Eun; Thangavelu, Muthukumar; Khang, Gilson] Chonbuk Natl Univ, Polymer Mat Fus Res Ctr, 567 Baekje Daero, Jeonju Si 54896, Jeollabuk Do, South Korea.
   [Carlomagno, Cristiano; Motta, Antonella; Migliaresi, Claudio] Univ Trento, Dept Ind Engn, Via Sommar 9, Trento, Italy.
   [Carlomagno, Cristiano; Motta, Antonella; Migliaresi, Claudio] Univ Trento, BIOTech Res Ctr, Via Regole 101, Trento, Italy.
   [Motta, Antonella; Migliaresi, Claudio] European Inst Excellence Tissue Engn & Regenerat, Trento, Italy.
C3 Jeonbuk National University; Jeonbuk National University; University of
   Trento; University of Trento
RP Khang, G (通讯作者)，Chonbuk Natl Univ, Dept Polymer Nano Sci & Technol, Dept BIN Convergence Technol, 567 Baekje Daero, Jeonju Si 54896, Jeollabuk Do, South Korea.; Khang, G (通讯作者)，Chonbuk Natl Univ, Polymer Mat Fus Res Ctr, 567 Baekje Daero, Jeonju Si 54896, Jeollabuk Do, South Korea.
EM gskhang@jbnu.ac.kr
RI Thangavelu, Muthukumar/E-3891-2016; Carlomagno, Cristiano/ABD-5080-2021;
   Motta, Antonella/E-2554-2014; song, jeong eun/P-9106-2015
OI Thangavelu, Muthukumar/0000-0002-4449-6015; Carlomagno,
   Cristiano/0000-0002-5543-0505; Motta, Antonella/0000-0003-4893-6863;
   song, jeong eun/0000-0001-6879-7616
FU Basic Science Research Program through the National Research Foundation
   of Korea (NRF) - Ministry of Science, ICT and Future Planning
   [2017R1A2B3010270]; International Research & Development Program through
   the National Research Foundation of Korea (NRF) - Ministry of Science,
   ICT and Future Planning [2017K1A3A7A03089427]
FX This research was supported by Basic Science Research Program
   (2017R1A2B3010270) and the International Research & Development Program
   (2017K1A3A7A03089427) through the National Research Foundation of Korea
   (NRF) funded by the Ministry of Science, ICT and Future Planning.
CR Ahmed EM, 2015, J ADV RES, V6, P105, DOI 10.1016/j.jare.2013.07.006
   Baek YY, 2012, EUR J PHARMACOL, V674, P188, DOI 10.1016/j.ejphar.2011.11.022
   Baker PS, 2009, CURR OPIN OPHTHALMOL, V20, P175, DOI 10.1097/ICU.0b013e328329b5f2
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Bidarra SJ, 2014, ACTA BIOMATER, V10, P1646, DOI 10.1016/j.actbio.2013.12.006
   Chesney R W, 1985, Adv Pediatr, V32, P1
   Cong LD, 2008, INVEST OPHTH VIS SCI, V49, P4115, DOI 10.1167/iovs.08-1976
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Drury JL, 2003, BIOMATERIALS, V24, P4337, DOI 10.1016/S0142-9612(03)00340-5
   Giordano GG, 1997, J BIOMED MATER RES, V34, P87, DOI 10.1002/(SICI)1097-4636(199701)34:1<87::AID-JBM12>3.0.CO;2-M
   Hanus J, 2016, CELL DEATH DISCOV, V2, DOI 10.1038/cddiscovery.2016.54
   HAYES KC, 1975, SCIENCE, V188, P949, DOI 10.1126/science.1138364
   Heljak Marcin K., 2014, Journal of Applied Polymer Science, V131, DOI 10.1002/app.40280
   Ho E, 2006, BIOMACROMOLECULES, V7, P3223, DOI 10.1021/bm0602536
   Holz FG, 1999, GRAEF ARCH CLIN EXP, V237, P145, DOI 10.1007/s004170050209
   Kannan R, 2014, NEURAL REGEN RES, V9, P2044, DOI 10.4103/1673-5374.147927
   Kloxin AM, 2010, ADV MATER, V22, P3484, DOI 10.1002/adma.200904179
   KORTE GE, 1984, INVEST OPHTH VIS SCI, V25, P1135
   Kuo CK, 2001, BIOMATERIALS, V22, P511, DOI 10.1016/S0142-9612(00)00201-5
   Landa N, 2008, CIRCULATION, V117, P1388, DOI 10.1161/CIRCULATIONAHA.107.727420
   Leibowitz H M, 1980, Surv Ophthalmol, V24, P335
   Li XW, 2017, NUTR NEUROSCI, V20, P409, DOI [10.1080/1028415X.2016.1152004, 10.1080/1028415x.2016.1152004]
   Liao JL, 2010, HUM MOL GENET, V19, P4229, DOI 10.1093/hmg/ddq341
   Lu LC, 2001, BIOMATERIALS, V22, P3345, DOI 10.1016/S0142-9612(01)00172-7
   McGuinness MB, 2017, OPHTHAL EPIDEMIOL, V24, P141, DOI 10.1080/09286586.2016.1259422
   OHNO K, 1992, J MOL STRUCT, V268, P41, DOI 10.1016/0022-2860(92)85058-O
   Okubo A, 1999, INVEST OPHTH VIS SCI, V40, P443
   Ong JM, 2012, BRIT MED BULL, V102, P133, DOI 10.1093/bmb/lds013
   Park H, 2009, BIOMACROMOLECULES, V10, P541, DOI 10.1021/bm801197m
   PASANTESMORALES H, 1984, J NEUROSCI RES, V11, P303, DOI 10.1002/jnr.490110310
   Rao KM, 2013, INT J POLYM MATER PO, V62, P565, DOI 10.1080/00914037.2013.769160
   Redmond TM, 1998, NAT GENET, V20, P344, DOI 10.1038/3813
   Ripps H, 2012, MOL VIS, V18, P2673
   Rizzolo LJ, 2014, EXP EYE RES, V126, P16, DOI 10.1016/j.exer.2013.12.018
   Simo R, 2010, J BIOMED BIOTECHNOL, DOI 10.1155/2010/190724
   Sridharan Gokul, 2012, J Oral Maxillofac Pathol, V16, P251, DOI 10.4103/0973-029X.99081
   Tibbitt MW, 2009, BIOTECHNOL BIOENG, V103, P655, DOI 10.1002/bit.22361
   van Leeuwen R, 2005, JAMA-J AM MED ASSOC, V294, P3101, DOI 10.1001/jama.294.24.3101
   Wen B., 2016, SCI REP UK, V6
   Wikstrom J, 2008, BIOMATERIALS, V29, P869, DOI 10.1016/j.biomaterials.2007.10.056
   Worthington KS, 2014, EXP EYE RES, V121, P194, DOI 10.1016/j.exer.2014.02.020
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Yu L, 2008, CHEM SOC REV, V37, P1473, DOI 10.1039/b713009k
   Zhang XY, 1998, INVEST OPHTH VIS SCI, V39, P1021
NR 44
TC 15
Z9 15
U1 3
U2 40
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0928-4931
EI 1873-0191
J9 MAT SCI ENG C-MATER
JI Mater. Sci. Eng. C-Mater. Biol. Appl.
PD OCT
PY 2019
VL 103
AR 109787
DI 10.1016/j.msec.2019.109787
PG 10
WC Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Materials Science
GA IQ3PZ
UT WOS:000480664900124
PM 31349479
DA 2022-11-30
ER

PT J
AU Pyakurel, A
   Balmer, D
   Saba-El-Leil, MK
   Kizilyaprak, C
   Daraspe, J
   Humbel, BM
   Voisin, L
   Le, YZ
   von Lintig, J
   Meloche, S
   Roduit, R
AF Pyakurel, Aswin
   Balmer, Delphine
   Saba-El-Leil, Marc K.
   Kizilyaprak, Caroline
   Daraspe, Jean
   Humbel, Bruno M.
   Voisin, Laure
   Le, Yun Z.
   von Lintig, Johannes
   Meloche, Sylvain
   Roduit, Raphael
TI Loss of Extracellular Signal-Regulated Kinase 1/2 in the Retinal Pigment
   Epithelium Leads to RPE65 Decrease and Retinal Degeneration
SO MOLECULAR AND CELLULAR BIOLOGY
LA English
DT Article
DE AP-1; ERK1/2; photoreceptors; RPE65; retinal degeneration; retinoid;
   electron microscopy
ID ORAL MEK INHIBITOR; DOWN-REGULATION; CONE PHOTORECEPTORS;
   GENE-EXPRESSION; CELL LUNG; VITAMIN-A; PHASE-II; LIPOFUSCIN; PATHWAYS;
   ERK1/2
AB Recent work suggested that the activity of extracellular signal-regulated kinase 1/2 (ERK1/2) is increased in the retinal pigment epithelium (RPE) of age-related macular degeneration (ARMD) patients and therefore could be an attractive therapeutic target. Notably, ERK1/2 pathway inhibitors are used in cancer therapy, with severe and noncharacterized ocular side effects. To decipher the role of ERK1/2 in RPE cells, we conditionally disrupted the Erk1 and Erk2 genes in mouse RPE. The loss of ERK1/2 activity resulted in a significant decrease in the level of RPE65 expression, a decrease in ocular retinoid levels concomitant with low visual function, and a rapid disorganization of RPE cells, ultimately leading to retinal degeneration. Our results identify the ERK1/2 pathway as a direct regulator of the visual cycle and a critical component of the viability of RPE and photoreceptor cells. Moreover, our results caution about the need for a very fine adjustment of kinase inhibition in cancer or ARMD treatment in order to avoid ocular side effects.
C1 [Pyakurel, Aswin; Roduit, Raphael] Univ Lausanne, Fdn Asile Aveugles, Jules Gonin Eye Hosp, Dept Ophthalmol, Lausanne, Switzerland.
   [Pyakurel, Aswin; Balmer, Delphine; Roduit, Raphael] Inst Res Ophthalmol, Sion, Switzerland.
   [Le, Yun Z.] Univ Oklahoma, Hlth Sci Ctr, Endocrinol & Harold Hamm Diabet Ctr, Dept Med Endocrinol, Oklahoma City, OK USA.
   [Le, Yun Z.] Univ Oklahoma, Hlth Sci Ctr, Endocrinol & Harold Hamm Diabet Ctr, Harold Hamm Diabet Ctr, Oklahoma City, OK USA.
   [Saba-El-Leil, Marc K.; Voisin, Laure; Meloche, Sylvain] Univ Montreal, Inst Res Immunol & Canc, Dept Pharmacol, Montreal, PQ, Canada.
   [Saba-El-Leil, Marc K.; Voisin, Laure; Meloche, Sylvain] Univ Montreal, Program Mol Biol, Montreal, PQ, Canada.
   [Kizilyaprak, Caroline; Daraspe, Jean; Humbel, Bruno M.] Univ Lausanne, Electron Microscopy Facil, Lausanne, Switzerland.
   [von Lintig, Johannes] Case Western Reserve Univ, Sch Med, Dept Pharmacol, Cleveland, OH 44106 USA.
C3 University of Lausanne; University of Oklahoma System; University of
   Oklahoma Health Sciences Center; University of Oklahoma System;
   University of Oklahoma Health Sciences Center; Universite de Montreal;
   Universite de Montreal; University of Lausanne; Case Western Reserve
   University
RP Roduit, R (通讯作者)，Univ Lausanne, Fdn Asile Aveugles, Jules Gonin Eye Hosp, Dept Ophthalmol, Lausanne, Switzerland.; Roduit, R (通讯作者)，Inst Res Ophthalmol, Sion, Switzerland.
EM raphael.roduit@fa2.ch
RI Roduit, Raphael/AAC-3890-2021
OI Roduit, Raphael/0000-0001-7440-2799
FU Gelbert Foundation; Art Vie Foundation
FX This work was supported by grants from the Gelbert Foundation and the
   Art & Vie Foundation to A.P. and R.R.
CR Ablonczy Z, 2013, INVEST OPHTH VIS SCI, V54, P5535, DOI 10.1167/iovs.13-12250
   Amengual J, 2014, HUM MOL GENET, V23, P5402, DOI 10.1093/hmg/ddu258
   Amengual J, 2012, J BIOL CHEM, V287, P24216, DOI 10.1074/jbc.M112.353979
   Balmer D, 2017, FRONT AGING NEUROSCI, V9, DOI 10.3389/fnagi.2017.00043
   Bharti K, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002757
   Bisel B, 2008, J CELL BIOL, V182, P837, DOI 10.1083/jcb.200805045
   Boulanger A, 2000, J BIOL CHEM, V275, P31274, DOI 10.1074/jbc.M003441200
   Cargnello M, 2011, MICROBIOL MOL BIOL R, V75, P50, DOI 10.1128/MMBR.00031-10
   Cervenka I, 2011, MOL CELL BIOL, V31, P179, DOI 10.1128/MCB.00550-10
   Chen M, 2016, AGING CELL, V15, P436, DOI 10.1111/acel.12447
   Chen Y, 2003, MOL VIS, V9, P345
   DAVIS RJ, 1995, MOL REPROD DEV, V42, P459, DOI 10.1002/mrd.1080420414
   Donovan M, 2011, J NEUROCHEM, V116, P33, DOI 10.1111/j.1471-4159.2010.07056.x
   Dridi S, 2012, P NATL ACAD SCI USA, V109, P13781, DOI 10.1073/pnas.1206494109
   Duncan KE, 2015, EYE, V29, P1003, DOI 10.1038/eye.2015.82
   ELDRED GE, 1993, NATURE, V361, P724, DOI 10.1038/361724a0
   Fremin C, 2010, J HEMATOL ONCOL, V3, DOI 10.1186/1756-8722-3-8
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Haura EB, 2010, CLIN CANCER RES, V16, P2450, DOI 10.1158/1078-0432.CCR-09-1920
   Hecquet C, 2002, INVEST OPHTH VIS SCI, V43, P3091
   Holz FG, 1999, INVEST OPHTH VIS SCI, V40, P737
   Huang J, 2009, MOL VIS, V15, P223
   Iriyama A, 2008, J BIOL CHEM, V283, P11947, DOI 10.1074/jbc.M708989200
   Katz ML, 2001, INVEST OPHTH VIS SCI, V42, P3023
   Kim EK, 2010, BBA-MOL BASIS DIS, V1802, P396, DOI 10.1016/j.bbadis.2009.12.009
   Kokkinopoulos I, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018921
   Kyriakis JM, 2012, PHYSIOL REV, V92, P689, DOI 10.1152/physrev.00028.2011
   Lampert JM, 2003, DEVELOPMENT, V130, P2173, DOI 10.1242/dev.00437
   Lawrence MC, 2008, CELL RES, V18, P436, DOI 10.1038/cr.2008.37
   Le YZ, 2008, INVEST OPHTH VIS SCI, V49, P1248, DOI 10.1167/iovs.07-1105
   Lemieux E, 2015, ONCOGENE, V34, P4914, DOI 10.1038/onc.2014.416
   Li SH, 2013, J NEUROSCI, V33, P3178, DOI 10.1523/JNEUROSCI.2428-12.2013
   Ling SZ, 2011, CANCER RES, V71, P3812, DOI 10.1158/0008-5472.CAN-10-3072
   Longbottom R, 2009, P NATL ACAD SCI USA, V106, P18728, DOI 10.1073/pnas.0902593106
   Lorenz B, 2000, INVEST OPHTH VIS SCI, V41, P2735
   Madisen L, 2010, NAT NEUROSCI, V13, P133, DOI 10.1038/nn.2467
   Martinez-Garcia M, 2012, CLIN CANCER RES, V18, P4806, DOI 10.1158/1078-0432.CCR-12-0742
   Masuda T, 2014, J BIOL CHEM, V289, P12908, DOI 10.1074/jbc.M114.556738
   Meloche S, 2007, ONCOGENE, V26, P3227, DOI 10.1038/sj.onc.1210414
   Metrailler S, 2013, EXP EYE RES, V116, P86, DOI 10.1016/j.exer.2013.08.015
   Morimura H, 1998, P NATL ACAD SCI USA, V95, P3088, DOI 10.1073/pnas.95.6.3088
   Nicoletti A, 1998, INVEST OPHTH VIS SCI, V39, P637
   Niro A, 2015, AM J OPHTHALMOL, V160, P959, DOI 10.1016/j.ajo.2015.07.035
   Plotnikov A, 2011, BBA-MOL CELL RES, V1813, P1619, DOI 10.1016/j.bbamcr.2010.12.012
   Pyakurel A, 2015, MOL CELL, V58, P244, DOI 10.1016/j.molcel.2015.02.021
   Qin SF, 2006, INVEST OPHTH VIS SCI, V47, P5098, DOI 10.1167/iovs.06-0318
   Rando RR, 2001, CHEM REV, V101, P1881, DOI 10.1021/cr960141c
   Rauen KA, 2013, ANNU REV GENOM HUM G, V14, P355, DOI 10.1146/annurev-genom-091212-153523
   Redmond TM, 1998, NAT GENET, V20, P344, DOI 10.1038/3813
   Redmond TM, 2005, P NATL ACAD SCI USA, V102, P13658, DOI 10.1073/pnas.0504167102
   Renouf DJ, 2012, J CLIN ONCOL, V30, P3277, DOI 10.1200/JCO.2011.41.5851
   REYNOLDS ES, 1963, J CELL BIOL, V17, P208, DOI 10.1083/jcb.17.1.208
   Rinehart J, 2004, J CLIN ONCOL, V22, P4456, DOI 10.1200/JCO.2004.01.185
   Rodrigues EB, 2007, OPHTHALMOLOGICA, V221, P143, DOI 10.1159/000099293
   Roduit R, 2008, APOPTOSIS, V13, P343, DOI 10.1007/s10495-008-0179-8
   Rohrer B, 2005, INVEST OPHTH VIS SCI, V46, P3876, DOI 10.1167/iovs.05-0533
   Samatar AA, 2014, NAT REV DRUG DISCOV, V13, P928, DOI 10.1038/nrd4281
   Schoenberger SD, 2013, CASE REP OPHTHALMOL, V2013, DOI 10.1155/2013/673796
   Schubbert S, 2007, NAT REV CANCER, V7, P295, DOI 10.1038/nrc2109
   Sparrow JR, 2005, EXP EYE RES, V80, P595, DOI 10.1016/j.exer.2005.01.007
   Spence JR, 2007, MOL VIS, V13, P57
   Starnes AC, 2016, VISUAL NEUROSCI, V33, DOI 10.1017/S0952523815000310
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Subramaniam S, 2010, FEBS J, V277, P22, DOI 10.1111/j.1742-4658.2009.07367.x
   Sun D, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.456
   Tang PH, 2010, INVEST OPHTH VIS SCI, V51, P5958, DOI 10.1167/iovs.10-5766
   Voisin L, 2010, MOL CELL BIOL, V30, P2918, DOI 10.1128/MCB.00131-10
   Wang CXZ, 2012, EXP EYE RES, V102, P1, DOI 10.1016/j.exer.2012.06.003
   Wei H, 2016, EXP EYE RES, V145, P450, DOI 10.1016/j.exer.2015.09.015
   Wenzel A, 2007, INVEST OPHTH VIS SCI, V48, P534, DOI 10.1167/iovs.06-0652
   Westenskow P, 2009, DEVELOPMENT, V136, P2505, DOI 10.1242/dev.032136
   Yoshikawa T, 2012, PIGM CELL MELANOMA R, V25, P66, DOI 10.1111/j.1755-148X.2011.00935.x
   Zhou JL, 2006, P NATL ACAD SCI USA, V103, P16182, DOI 10.1073/pnas.0604255103
   Znoiko SL, 2005, INVEST OPHTH VIS SCI, V46, P1473, DOI 10.1167/iovs.04-0653
   Zolfaghari R, 2009, ARCH BIOCHEM BIOPHYS, V489, P1, DOI 10.1016/j.abb.2009.08.001
NR 75
TC 5
Z9 5
U1 0
U2 3
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0270-7306
EI 1098-5549
J9 MOL CELL BIOL
JI Mol. Cell. Biol.
PD DEC
PY 2017
VL 37
IS 24
AR e00295-17
DI 10.1128/MCB.00295-17
PG 19
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA FN9SU
UT WOS:000416383100006
PM 29038159
OA hybrid, Green Published, Green Submitted
DA 2022-11-30
ER

PT J
AU Ma, WX
   Cojocaru, R
   Gotoh, N
   Gieser, L
   Villasmil, R
   Cogliati, T
   Swaroop, A
   Wong, WT
AF Ma, Wenxin
   Cojocaru, Radu
   Gotoh, Norimoto
   Gieser, Linn
   Villasmil, Rafael
   Cogliati, Tiziana
   Swaroop, Anand
   Wong, Wai T.
TI Gene expression changes in aging retinal microglia: relationship to
   microglial support functions and regulation of activation
SO NEUROBIOLOGY OF AGING
LA English
DT Article
DE Aging; Microglia; Retina; Microarray; Gene expression; Complement;
   Activation; Angiogenesis; Neurotrophic factors; Senescence
ID AGE-RELATED ALTERATIONS; MACULAR DEGENERATION; VISUAL IMPAIRMENT;
   COMPLEMENT ACTIVATION; RECIPROCAL REGULATION; GLIAL RESPONSES;
   MESSENGER-RNA; MOUSE RETINA; ADULT BRAIN; CELLS
AB Microglia, the resident immune cells of the central nervous system (CNS), are thought to contribute to the pathogenesis of age-related neurodegenerative disorders. It has been hypothesized that microglia undergo age-related changes in gene expression patterns that give rise to pathogenic phenotypes. We compared the gene expression profiles in microglia isolated ex vivo from the retinas of mice ranging from early adulthood to late senescence. We discovered that microglial gene expression demonstrated progressive change with increasing age, and involved genes that regulate microglial supportive functions and immune activation. Molecular pathways involving immune function and regulation, angiogenesis, and neurotrophin signaling demonstrated age-related change. In particular, expression levels of complement genes, C3 and CFB, previously associated with age-related macular degeneration (AMD), increased with aging, suggesting that senescent microglia may contribute to complement dysregulation during disease pathogenesis. Taken together, senescent microglia demonstrate age-related gene expression changes capable of altering their constitutive support functions and regulation of their activation status in ways relating to neuroinflammation and neurodegeneration in the CNS. Published by Elsevier Inc.
C1 [Ma, Wenxin; Wong, Wai T.] NEI, Unit Neuron Glia Interact Retinal Dis, NIH, Bethesda, MD 20892 USA.
   [Cojocaru, Radu; Gotoh, Norimoto; Gieser, Linn; Cogliati, Tiziana; Swaroop, Anand] NEI, Neurobiol Neurodegenerat & Repair Lab, NIH, Bethesda, MD 20892 USA.
   [Villasmil, Rafael] NEI, Flow Cytometry Core Facil, NIH, Bethesda, MD 20892 USA.
C3 National Institutes of Health (NIH) - USA; NIH National Eye Institute
   (NEI); National Institutes of Health (NIH) - USA; NIH National Eye
   Institute (NEI); National Institutes of Health (NIH) - USA; NIH National
   Eye Institute (NEI)
RP Wong, WT (通讯作者)，NEI, Unit Neuron Glia Interact Retinal Dis, NIH, Bldg 6,Room 215, Bethesda, MD 20892 USA.
EM wongw@nei.nih.gov
RI Wong, Wai/B-6118-2017
OI Wong, Wai/0000-0003-0681-4016; Swaroop, Anand/0000-0002-1975-1141
FU NEI Intramural; National Eye Institute Intramural Research Program;
   American Health Assistance Foundation (AHAF); program of the American
   Health Assistance Foundation; NATIONAL EYE INSTITUTE [ZICEY000457,
   ZIAEY000463, ZIAEY000473] Funding Source: NIH RePORTER
FX This study was supported by the NEI Intramural by the National Eye
   Institute Intramural Research Program and a grant from the American
   Health Assistance Foundation (AHAF). Acknowledgement is made to the
   donors of ADR, a program of the American Health Assistance Foundation,
   for support of this research. The funders had no role in study design,
   data collection and analysis, decision to publish, or preparation of the
   manuscript. The data in this manuscript is published or submitted
   elsewhere, and has been approved by all contributing authors. Procedures
   involving animals here have been previously approved by institutional
   review boards.
CR Ajami B, 2007, NAT NEUROSCI, V10, P1538, DOI 10.1038/nn2014
   Alvarez E., 2013, MULT SCLERO IN PRESS
   Bakalash S, 2011, INVEST OPHTH VIS SCI, V52, P9033, DOI 10.1167/iovs.11-7498
   Bauman DR, 2009, P NATL ACAD SCI USA, V106, P16764, DOI 10.1073/pnas.0909142106
   Bosco A, 2008, INVEST OPHTH VIS SCI, V49, P1437, DOI 10.1167/iovs.07-1337
   Bosco A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043602
   Bosco A, 2011, J COMP NEUROL, V519, P599, DOI 10.1002/cne.22516
   Brand C, 2005, MOL VIS, V11, P309
   Brantley MA, 2008, J NEUROSCI, V28, P4123, DOI 10.1523/JNEUROSCI.0249-08.2008
   Brewer G, 2002, AGEING RES REV, V1, P607, DOI 10.1016/S1568-1637(02)00023-5
   Buschini E, 2011, PROG NEUROBIOL, V95, P14, DOI 10.1016/j.pneurobio.2011.05.011
   Cao JN, 2010, AGING CELL, V9, P19, DOI 10.1111/j.1474-9726.2009.00534.x
   Chen HY, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002339
   Chen M, 2010, INVEST OPHTH VIS SCI, V51, P5888, DOI 10.1167/iovs.09-5103
   Chen M, 2008, EXP EYE RES, V87, P543, DOI 10.1016/j.exer.2008.09.005
   Chesarone MA, 2010, NAT REV MOL CELL BIO, V11, P62, DOI 10.1038/nrm2816
   Chung AS, 2011, ANNU REV CELL DEV BI, V27, P563, DOI 10.1146/annurev-cellbio-092910-154002
   Collier RJ, 2011, INVEST OPHTH VIS SCI, V52, P8108, DOI 10.1167/iovs.10-6418
   Combadiere C, 2007, J CLIN INVEST, V117, P2920, DOI 10.1172/JCI31692
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Congdon NG, 2003, JAMA-J AM MED ASSOC, V290, P2057, DOI 10.1001/jama.290.15.2057
   Damani MR, 2011, AGING CELL, V10, P263, DOI 10.1111/j.1474-9726.2010.00660.x
   Davalos D, 2005, NAT NEUROSCI, V8, P752, DOI 10.1038/nn1472
   de Fraipont F, 2001, TRENDS MOL MED, V7, P401, DOI 10.1016/S1471-4914(01)02102-5
   De Haas AH, 2008, GLIA, V56, P888, DOI 10.1002/glia.20663
   Diczfalusy U, 2009, J LIPID RES, V50, P2258, DOI 10.1194/jlr.M900107-JLR200
   Dilger RN, 2008, J LEUKOCYTE BIOL, V84, P932, DOI 10.1189/jlb.0208108
   Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148
   Fantin A, 2010, BLOOD, V116, P829, DOI 10.1182/blood-2009-12-257832
   Fischer F., 2011, PLOS ONE, V8, P120
   Franceschi C, 2000, ANN NY ACAD SCI, V908, P244
   Friedle SA, 2011, GLIA, V59, P1, DOI 10.1002/glia.21071
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P532
   Godbout JP, 2005, FASEB J, V19, P1329, DOI 10.1096/fj.05-3776fje
   Gottfried-Blackmore A, 2010, GLIA, V58, P1257, DOI 10.1002/glia.21007
   Gupta N, 2003, EXP EYE RES, V76, P463, DOI 10.1016/S0014-4835(02)00332-9
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Harada T, 2002, J NEUROSCI, V22, P9228, DOI 10.1523/jneurosci.22-21-09228.2002
   Hecker LA, 2010, HUM MOL GENET, V19, P209, DOI 10.1093/hmg/ddp472
   Herdegen T, 2001, ONCOGENE, V20, P2424, DOI 10.1038/sj.onc.1204387
   Hiscott P, 2006, PROG RETIN EYE RES, V25, P1, DOI 10.1016/j.preteyeres.2005.05.001
   Howell GR, 2011, J CLIN INVEST, V121, P1429, DOI 10.1172/JCI44646
   Irizarry RA, 2003, BIOSTATISTICS, V4, P249, DOI 10.1093/biostatistics/4.2.249
   Joseph SB, 2003, NAT MED, V9, P213, DOI 10.1038/nm820
   Joseph SB, 2004, CELL, V119, P299, DOI 10.1016/j.cell.2004.09.032
   Jung S, 2000, MOL CELL BIOL, V20, P4106, DOI 10.1128/MCB.20.11.4106-4114.2000
   Kawanokuchi J, 2008, J NEUROIMMUNOL, V194, P54, DOI 10.1016/j.jneuroim.2007.11.006
   Kim SH, 2004, NEUROBIOL AGING, V25, P431, DOI 10.1016/S0197-4580(03)00126-X
   Koistinaho M, 2002, GLIA, V40, P175, DOI 10.1002/glia.10151
   Krady JK, 2005, DIABETES, V54, P1559, DOI 10.2337/diabetes.54.5.1559
   Lalor SJ, 2010, J NEUROIMMUNOL, V224, P56, DOI 10.1016/j.jneuroim.2010.05.017
   Langmann T, 2009, NEUROMOL MED, V11, P87, DOI 10.1007/s12017-009-8061-6
   Lapointe S, 2010, J CELL PHYSIOL, V224, P127, DOI 10.1002/jcp.22106
   Lee JE, 2008, INVEST OPHTH VIS SCI, V49, P4169, DOI 10.1167/iovs.08-2076
   Lee K, 2010, SCIENCE, V329, P1341, DOI 10.1126/science.1191710
   Li Y, 2012, DEV CELL, V23, P1189, DOI 10.1016/j.devcel.2012.10.027
   Lommatzsch A, 2008, GRAEF ARCH CLIN EXP, V246, P803, DOI 10.1007/s00417-007-0749-4
   Luo C, 2011, MOL VIS, V17, P1588
   Lv M, 2011, NEUROSCIENCE, V176, P162, DOI 10.1016/j.neuroscience.2010.11.066
   Ma WX, 2013, NEUROBIOL AGING, V34, P943, DOI 10.1016/j.neurobiolaging.2012.06.010
   Mattapallil MJ, 2012, INVEST OPHTH VIS SCI, V53, P2921, DOI 10.1167/iovs.12-9662
   Mildner A, 2007, NAT NEUROSCI, V10, P1544, DOI 10.1038/nn2015
   Moeller G, 2009, MOL CELL ENDOCRINOL, V301, P7, DOI 10.1016/j.mce.2008.10.040
   Montes T, 2009, P NATL ACAD SCI USA, V106, P4366, DOI 10.1073/pnas.0812584106
   Mrak RE, 2005, NEUROBIOL AGING, V26, P349, DOI 10.1016/j.neurobiolaging.2004.05.010
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Murakami M, 1997, CRIT REV IMMUNOL, V17, P225, DOI 10.1615/CritRevImmunol.v17.i3-4.10
   Nimmerjahn A, 2005, SCIENCE, V308, P1314, DOI 10.1126/science.1110647
   Njie EG, 2012, NEUROBIOL AGING, V33, DOI 10.1016/j.neurobiolaging.2010.05.008
   ONeill LAJ, 1997, TRENDS NEUROSCI, V20, P252, DOI 10.1016/S0166-2236(96)01035-1
   Paolicelli RC, 2011, SCIENCE, V333, P1456, DOI 10.1126/science.1202529
   PERRY VH, 1993, GLIA, V7, P60, DOI 10.1002/glia.440070111
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Ruiperez V, 2009, J IMMUNOL, V182, P3877, DOI 10.4049/jimmunol.0804003
   Rutar M, 2011, INVEST OPHTH VIS SCI, V52, P5347, DOI 10.1167/iovs.10-7119
   Saijo K, 2011, CELL, V145, P584, DOI 10.1016/j.cell.2011.03.050
   Sakane A, 2010, MOL CELL BIOL, V30, P1077, DOI 10.1128/MCB.01067-09
   Sandhir R, 2008, EXP NEUROL, V213, P372, DOI 10.1016/j.expneurol.2008.06.013
   Schafer DP, 2013, GLIA, V61, P24, DOI 10.1002/glia.22389
   Schafer DP, 2012, NEURON, V74, P691, DOI 10.1016/j.neuron.2012.03.026
   Scholl HPN, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002593
   Seckl JR, 2001, ENDOCRINOLOGY, V142, P1371, DOI 10.1210/en.142.4.1371
   Sharma YV, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031371
   Sheehan B, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-468
   Sheng JG, 1998, ACTA NEUROPATHOL, V95, P229, DOI 10.1007/s004010050792
   Sierra A, 2008, GLIA, V56, P659, DOI 10.1002/glia.20644
   Sierra A, 2007, GLIA, V55, P412, DOI 10.1002/glia.20468
   Streit WJ, 2009, J NEUROIMMUNE PHARM, V4, P371, DOI 10.1007/s11481-009-9163-5
   Sugama S, 2003, BRAIN RES, V964, P288, DOI 10.1016/S0006-8993(02)04085-4
   Swaroop A, 2009, ANNU REV GENOM HUM G, V10, P19, DOI 10.1146/annurev.genom.9.081307.164350
   Tang J, 2011, PROG RETIN EYE RES, V30, P343, DOI 10.1016/j.preteyeres.2011.05.002
   Tremblay ME, 2012, GLIA, V60, P541, DOI 10.1002/glia.22287
   Van Kirk CA, 2011, MOL VIS, V17, P1261
   Vinet J, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-27
   von Bernhardi R, 2010, J NEUROCHEM, V112, P1099, DOI 10.1111/j.1471-4159.2009.06537.x
   Wake H, 2009, J NEUROSCI, V29, P3974, DOI 10.1523/JNEUROSCI.4363-08.2009
   Wasserman JK, 2008, EUR J NEUROSCI, V28, P1316, DOI 10.1111/j.1460-9568.2008.06442.x
   Wax MB, 2009, EXP EYE RES, V88, P825, DOI 10.1016/j.exer.2009.02.005
   Witmer AN, 2003, PROG RETIN EYE RES, V22, P1, DOI 10.1016/S1350-9462(02)00043-5
   Xie Z, 2003, EXP NEUROL, V182, P135, DOI 10.1016/S0014-4886(03)00057-8
   Xu HP, 2009, PROG RETIN EYE RES, V28, P348, DOI 10.1016/j.preteyeres.2009.06.001
   Yan J, 2012, J NEUROCHEM, V120, P721, DOI 10.1111/j.1471-4159.2011.07619.x
   Yang CS, 2009, GLIA, V57, P1091, DOI 10.1002/glia.20832
   Ye SM, 1999, J NEUROIMMUNOL, V93, P139, DOI 10.1016/S0165-5728(98)00217-3
   Yoshida S, 2002, INVEST OPHTH VIS SCI, V43, P2554
   Yuan LY, 2001, J NEUROSCI RES, V64, P523, DOI 10.1002/jnr.1104
   Zeng HY, 2008, ARCH OPHTHALMOL-CHIC, V126, P227, DOI 10.1001/archophthalmol.2007.65
NR 108
TC 65
Z9 65
U1 0
U2 17
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0197-4580
EI 1558-1497
J9 NEUROBIOL AGING
JI Neurobiol. Aging
PD OCT
PY 2013
VL 34
IS 10
BP 2310
EP 2321
DI 10.1016/j.neurobiolaging.2013.03.022
PG 12
WC Geriatrics & Gerontology; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Geriatrics & Gerontology; Neurosciences & Neurology
GA 187JM
UT WOS:000322113800010
PM 23608111
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Meyer, CH
   Brinkmann, CK
   Helb, HM
AF Meyer, Carsten H.
   Brinkmann, Christian K.
   Helb, Hans-Martin
TI Choroidal Detachment After an Uneventful Intravitreal Injection
SO JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS
LA English
DT Article
ID COMPLICATIONS; BEVACIZUMAB; NEEDLES
AB Purpose: The purpose of this report was to describe a case of choroidal detachment after an uneventful intravitreal injection using a 30-gauge needle.
   Methods: An 88-year-old patient with acute onset of neovascular age-related macular degeneration developed a choroidal detachment after an uneventful intravitreal injection in the infero-temporal aspect of the fundus.
   Results: The patient described no symptoms related to the chorioretinal detachment. Additional intravitreal injections were required to treat an active subfoveal choroidal neovascularization. These injections were placed at the contralateral side in the supero-nasal quadrant. She was closely watched on a 2-week follow-up schedule. The choroidal detachment remained asymptomatic for the patient and resolved spontaneously, and the best corrected visual acuity improved from 0.2 to 0.63 during a 6-month follow-up. A mild hyperpigmentation remained at this location.
   Conclusion: Asymptomatic choroidal detachments may occur after intravitreal injection. Although treatment was not needed, additional injections should be avoided in the same quadrant until the detachment has resolved.
C1 [Meyer, Carsten H.; Brinkmann, Christian K.; Helb, Hans-Martin] Univ Bonn, Dept Ophthalmol, D-53127 Bonn, Germany.
C3 University of Bonn
RP Meyer, CH (通讯作者)，Univ Bonn, Dept Ophthalmol, Ernst Abbe St 2, D-53127 Bonn, Germany.
EM meyer_eye@yahoo.com
RI Meyer, Carsten/A-3981-2017
OI Meyer, Carsten/0000-0002-0530-5298
CR Brouzas D, 2009, CLIN OPHTHALMOL, V3, P457
   Charles S, 2007, RETINA-J RET VIT DIS, V27, P813, DOI 10.1097/IAE.0b013e318154b9f2
   Fung AE, 2006, BRIT J OPHTHALMOL, V90, P1344, DOI 10.1136/bjo.2006.099598
   Kaderli B, 2006, EUR J OPHTHALMOL, V16, P718, DOI 10.1177/112067210601600509
   Kozak I, 2006, RETINA-J RET VIT DIS, V26, P679, DOI 10.1097/00006982-200607000-00015
   Meyer CH, 2008, OPHTHALMOLOGE, V105, P143, DOI 10.1007/s00347-008-1701-7
   Pulido JS, 2007, EYE, V21, P829, DOI 10.1038/sj.eye.6702514
   Rodrigues EB, 2007, AM J OPHTHALMOL, V143, P1035, DOI 10.1016/j.ajo.2007.01.035
   Shima C, 2008, ACTA OPHTHALMOL, V86, P372, DOI 10.1111/j.1600-0420.2007.01067.x
NR 9
TC 2
Z9 2
U1 0
U2 0
PU MARY ANN LIEBERT INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1080-7683
J9 J OCUL PHARMACOL TH
JI J. Ocular Pharmacol. Ther.
PD JUN
PY 2010
VL 26
IS 3
BP 305
EP 307
DI 10.1089/jop.2009.0128
PG 3
WC Ophthalmology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Pharmacology & Pharmacy
GA 614CW
UT WOS:000279033800015
PM 20565320
DA 2022-11-30
ER

PT J
AU Kaluzny, JJ
   Wojtkowski, M
   Sikorski, BL
   Szkulmowski, M
   Szkulmowska, A
   Bajraszewski, T
   Fujimoto, JG
   Duker, JS
   Schuman, JS
   Kowalczyk, A
AF Kaluzny, Jakub J.
   Wojtkowski, Maciej
   Sikorski, Bartosz L.
   Szkulmowski, Maciej
   Szkulmowska, Anna
   Bajraszewski, Tomasz
   Fujimoto, James G.
   Duker, Jay S.
   Schuman, Joel S.
   Kowalczyk, Andrzej
TI Analysis of the outer retina reconstructed by high-resolution,
   three-dimensional spectral domain optical coherence tomography
SO OPHTHALMIC SURGERY LASERS & IMAGING
LA English
DT Article
ID ULTRAHIGH-RESOLUTION
AB BACKGROUND AND OBJECTIVE: A retrospective cross-sectional study was conducted to demonstrate an analysis of an outer retinal layer reconstructed by the three-dimensional and high-speed spectral domain optical coherence tomography (SD-OCT) instrument.
   PATIENTS AND METHODS: New measurement protocols for SD-OCT and methods of analysis and visualization of the individual segmented retinal layer reconstructed by SD-OCT were proposed. Three contour maps representing mutual distances between the basal part of the retinal pigment epithelium, the junction between the inner and outer segments of photoreceptors, and a reference contour representing the shape of a healthy retina were introduced.
   RESULTS: The analysis of the outer retina was performed on pathological eyes. Three cases of central sero us chorioretinopathy, age-related macular degeneration, and acute zonal occult outer retinopathy are demonstrated.
   CONCLUSION: Three contour maps reconstructed for clinical cases demonstrate high variability of observed patterns depending on analyzed pathology. The authors believe this can help to present OCT data simultaneously in a more comprehensive and convenient way to assist in everyday clinical diagnosis.
C1 [Wojtkowski, Maciej; Szkulmowski, Maciej; Szkulmowska, Anna; Bajraszewski, Tomasz; Kowalczyk, Andrzej] Nicholas Copernicus Univ, Inst Phys, PL-87100 Torun, Poland.
   [Kaluzny, Jakub J.; Sikorski, Bartosz L.] Nicholas Copernicus Univ, Coll Med, Dept Ophthalmol, Bydgoszcz, Poland.
   [Fujimoto, James G.] MIT, Dept Elect Engn & Comp Sci, Cambridge, MA 02139 USA.
   [Fujimoto, James G.] MIT, Elect Res Lab, Cambridge, MA 02139 USA.
   [Duker, Jay S.] Tufts Univ, New England Med Ctr, New England Eye Ctr, Boston, MA 02111 USA.
   [Schuman, Joel S.] Univ Pittsburgh, Sch Med, Dept Ophthalmol, UPMC Eye Ctr, Pittsburgh, PA 15261 USA.
C3 Nicolaus Copernicus University; Nicolaus Copernicus University; Ludwik
   Rydygier Collegium Medicum; Massachusetts Institute of Technology (MIT);
   Massachusetts Institute of Technology (MIT); Tufts Medical Center; Tufts
   University; Pennsylvania Commonwealth System of Higher Education
   (PCSHE); University of Pittsburgh
RP Wojtkowski, M (通讯作者)，Nicholas Copernicus Univ, Inst Phys, Ul Grudziadzka 5, PL-87100 Torun, Poland.
RI Sikorski, Bartosz L/AHD-2057-2022; Szkulmowski, Maciej/D-6244-2014;
   Schuman, Joel/K-7304-2012
OI Sikorski, Bartosz L/0000-0001-5357-9560; Szkulmowski,
   Maciej/0000-0002-2006-0524; Schuman, Joel/0000-0002-8885-3766; Kaluzny,
   Jakub/0000-0003-1908-2141; Wojtkowski, Maciej/0000-0003-0599-0878;
   Szkulmowska, Anna/0000-0002-2939-0829
CR ANSI,, 2000, AM NAT STAND CENTR P
   Jiao SL, 2005, OPT EXPRESS, V13, P444, DOI 10.1364/OPEX.13.000444
   Ko TH, 2004, OPT EXPRESS, V12, P2112, DOI 10.1364/OPEX.12.002112
   Ko TH, 2004, OPHTHALMOLOGY, V111, P2033, DOI 10.1016/j.ophtha.2004.05.021
   POLSKIE N, 1992, PN91T06700 WYD NORM
   Srinivasan VJ, 2006, OPHTHALMOLOGY, V113, P2054, DOI 10.1016/j.ophtha.2006.05.046
   Szkulmowski M, 2007, J BIOMED OPT, V12, DOI 10.1117/1.2771569
   Wojtkowski M, 2005, OPHTHALMOLOGY, V112, P1734, DOI 10.1016/j.ophtha.2005.05.023
NR 8
TC 3
Z9 3
U1 0
U2 3
PU SLACK INC
PI THOROFARE
PA 6900 GROVE RD, THOROFARE, NJ 08086 USA
SN 1542-8877
EI 1938-2375
J9 OPHTHAL SURG LAS IM
JI Ophthalmic Surg. Lasers Imaging
PD JUL-AUG
PY 2008
VL 39
IS 4
SU S
BP S30
EP S36
PG 7
WC Ophthalmology; Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Surgery
GA 335IC
UT WOS:000258283000005
DA 2022-11-30
ER

PT J
AU Kowanetz, M
   Ferrara, N
AF Kowanetz, Marcin
   Ferrara, Napoleone
TI Vascular endothelial growth factor signaling pathways: Therapeutic
   perspective
SO CLINICAL CANCER RESEARCH
LA English
DT Article
ID TUMOR ANGIOGENESIS; FACTOR RECEPTOR-1; VEGF RECEPTOR-2; ACTIVATION;
   MIGRATION; PROTEIN; CELLS; PHOSPHORYLATION; RECRUITMENT; EXPRESSION
AB The establishment of a vascular supply is one of the earliest and most important events occurring during embryonic development. Growth and maturation of a functional vascular network are complex and still incompletely understood processes involving orchestrated activation of vascular progenitors in the early stages of embryonic development followed by vasculogenesis and angiogenesis. These processes require a tightly regulated activation of several growth factors and their receptors. The role of vascular endothelial growth factors (VEGF) and their receptors has been studied extensively due to their prominent role during blood vessel formation. Mice deficient in various VEGF ligands or receptors show serious defects in vascular formation and maturation. Moreover, members of the VEGF family are involved in other significant biological processes, including lymphangiogenesis, vascular permeability, and hematopoiesis. Importantly, VEGF is released by tumor cells and induces tumor neovascularization. It is now well established that the VEGF axis represents an important target for antitumor therapy. Aberrant VEGF signaling is also a feature of several other pathologic conditions, such as age-related macular degeneration and rheumatoid arthritis.
C1 Genentech Inc, San Francisco, CA 94080 USA.
C3 Roche Holding; Genentech
RP Ferrara, N (通讯作者)，Genentech Inc, 1 DNA Way, San Francisco, CA 94080 USA.
EM nf@gene.com
CR Abedi H, 1997, J BIOL CHEM, V272, P15442, DOI 10.1074/jbc.272.24.15442
   Alitalo K, 2005, NATURE, V438, P946, DOI 10.1038/nature04480
   Barleon B, 1996, BLOOD, V87, P3336, DOI 10.1182/blood.V87.8.3336.bloodjournal8783336
   Bressler NM, 2005, RETINA-J RET VIT DIS, V25, P119
   Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0
   Cebe-Suarez S, 2006, CELL MOL LIFE SCI, V63, P601, DOI 10.1007/s00018-005-5426-3
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Cross MJ, 2003, TRENDS BIOCHEM SCI, V28, P488, DOI 10.1016/S0968-0004(03)00193-2
   Dunaif A, 2001, ANNU REV MED, V52, P401, DOI 10.1146/annurev.med.52.1.401
   Fan F, 2005, ONCOGENE, V24, P2647, DOI 10.1038/sj.onc.1208246
   FAVA RA, 1994, J EXP MED, V180, P341, DOI 10.1084/jem.180.1.341
   Ferrara N, 2002, NAT REV CANCER, V2, P795, DOI 10.1038/nrc909
   Ferrara N, 2004, NAT REV DRUG DISCOV, V3, P391, DOI 10.1038/nrd1381
   Ferrara N, 2004, ENDOCR REV, V25, P581, DOI 10.1210/er.2003-0027
   Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669
   Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0
   Ferrara N, 1997, ENDOCR REV, V18, P4, DOI 10.1210/er.18.1.4
   Ferrara N, 2005, NATURE, V438, P967, DOI 10.1038/nature04483
   FERRARA N, 2006, IN PRESS ANN REV MED
   FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182
   FOURNIER E, 1995, ONCOGENE, V11, P921
   Gasparini G, 2005, NAT CLIN PRACT ONCOL, V2, P562, DOI 10.1038/ncponc0342
   Gerber HP, 2002, NATURE, V417, P954, DOI 10.1038/nature00821
   Gille H, 2000, EMBO J, V19, P4064, DOI 10.1093/emboj/19.15.4064
   Hicklin DJ, 2005, J CLIN ONCOL, V23, P1011, DOI 10.1200/JCO.2005.06.081
   Hiratsuka S, 2002, CANCER CELL, V2, P289, DOI 10.1016/S1535-6108(02)00153-8
   Holmqvist K, 2004, J BIOL CHEM, V279, P22267, DOI 10.1074/jbc.M312729200
   HOUCK KA, 1991, MOL ENDOCRINOL, V5, P1806, DOI 10.1210/mend-5-12-1806
   Jain RK, 2006, NAT CLIN PRACT ONCOL, V3, P24, DOI 10.1038/ncponc0403
   Kaplan RN, 2005, NATURE, V438, P820, DOI 10.1038/nature04186
   KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0
   Lamalice L, 2004, ONCOGENE, V23, P434, DOI 10.1038/sj.onc.1207034
   LeCouter J, 2003, SCIENCE, V299, P890, DOI 10.1126/science.1079562
   Lesslie DP, 2006, BRIT J CANCER, V94, P1710, DOI 10.1038/sj.bjc.6603143
   Lyden D, 2001, NAT MED, V7, P1194, DOI 10.1038/nm1101-1194
   Makinen T, 2001, EMBO J, V20, P4762, DOI 10.1093/emboj/20.17.4762
   Matsumoto T, 2005, EMBO J, V24, P2342, DOI 10.1038/sj.emboj.7600709
   MILLAUER B, 1994, NATURE, V367, P576, DOI 10.1038/367576a0
   MURAKAMI M, 2006, BLOOD
   Ng EWM, 2006, NAT REV DRUG DISCOV, V5, P123, DOI 10.1038/nrd1955
   Olsson AK, 2006, NAT REV MOL CELL BIO, V7, P359, DOI 10.1038/nrm1911
   Presta LG, 1997, CANCER RES, V57, P4593
   Roccaro Aldo M., 2005, Current Drug Targets - Inflammation and Allergy, V4, P27, DOI 10.2174/1568010053622911
   Schlessinger Joseph, 2003, Sci STKE, V2003, pRE12, DOI 10.1126/stke.2003.191.re12
   SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0
   Shen J, 2006, GENE THER, V13, P225, DOI 10.1038/sj.gt.3302641
   Shibuya M, 2006, EXP CELL RES, V312, P549, DOI 10.1016/j.yexcr.2005.11.012
   Su JL, 2006, CANCER CELL, V9, P209, DOI 10.1016/j.ccr.2006.02.018
   Takahashi H, 2005, CLIN SCI, V109, P227, DOI 10.1042/CS20040370
   Takahashi T, 2001, EMBO J, V20, P2768, DOI 10.1093/emboj/20.11.2768
   TISCHER E, 1991, J BIOL CHEM, V266, P11947
   Tolentino MJ, 2004, RETINA-J RET VIT DIS, V24, P660, DOI 10.1097/00006982-200408000-00039
   WU Y, 2006, INT J CANC
   Yamaoka-Tojo M, 2004, CIRC RES, V95, P276, DOI 10.1161/01.RES.0000136522.58649.60
NR 54
TC 456
Z9 481
U1 0
U2 25
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1078-0432
EI 1557-3265
J9 CLIN CANCER RES
JI Clin. Cancer Res.
PD SEP 1
PY 2006
VL 12
IS 17
BP 5018
EP 5022
DI 10.1158/1078-0432.CCR-06-1520
PG 5
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 082MX
UT WOS:000240392000006
PM 16951216
DA 2022-11-30
ER

PT J
AU Cui, KX
   Liu, J
   Huang, LL
   Qin, B
   Yang, XW
   Li, LL
   Liu, Y
   Gu, JY
   Wu, WL
   Yu, Y
   Sang, AM
AF Cui, Kaixuan
   Liu, Jian
   Huang, Lili
   Qin, Bai
   Yang, Xiaowei
   Li, Lele
   Liu, Yu
   Gu, Jiayi
   Wu, Wenli
   Yu, Ying
   Sang, Aimin
TI Andrographolide attenuates choroidal neovascularization by inhibiting
   the HIF-1 alpha/VEGF signaling pathway
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE Andrographolide (Andro); Choroidal neovascularization (CNV); Age-related
   macular degeneration (AMD); HIF-1 alpha/VEGF signaling Pathway
ID MACULAR DEGENERATION; RETINAL ANGIOGENESIS; DOWN-REGULATION; MECHANISMS;
   INFLAMMATION; INVOLVEMENT; THERAPY; ANALOGS; CANCER; CELLS
AB Choroidal neovascularization (CNV), a characteristic of wet age-related macular degeneration (AMD), leads to severe vision loss amongst the elderly in the developed countries. Currently, the premier treatment for AMD is anti-VEGF therapy, which has limited efficacy, and is still controversial. Previous studies have showed that Andrographolide (Andro) had various biological effects, including anti-angiogenesis, anti- inflammation, and antioxidant. However, the effect of Andro on the formation of CNV has not been studied thus far. Here our results showed that Andro reduced the expression levels of HIF-1 alpha and VEGF in the RF/6A cells chemical hypoxia model and the laser-induced CNV mouse model. Moreover, Andro inhibited the tube formation activity of RF/6A cells under hypoxic conditions. Furthermore, intraperitoneal injection of Andro reduced the severity of choroidal vascular leakage and the size of CNV in the laser-induced CNV mouse model, indicating that Andro attenuated the development of CNV by inhibiting the HIF-1 alpha/VEGF signaling pathway. These results suggest that Andro could be a potential novel therapeutic agent for AMD. (C) 2020 Elsevier Inc. All rights reserved.
C1 [Cui, Kaixuan; Qin, Bai; Yang, Xiaowei; Li, Lele; Liu, Yu; Gu, Jiayi; Yu, Ying; Sang, Aimin] Nantong Univ, Dept Ophthalmol, Affiliated Hosp, Nantong 226001, Peoples R China.
   [Liu, Jian] Nantong Univ, Xinglin Coll, Nantong 226001, Peoples R China.
   [Huang, Lili] First Peoples Hosp Nantong, Dept Ophthalmol, Nantong 226001, Jiangsu, Peoples R China.
   [Wu, Wenli] Nantong Univ, Coll Med, Nantong, Jiangsu, Peoples R China.
C3 Nantong University; Nantong University; Nantong University
RP Yu, Y; Sang, AM (通讯作者)，Nantong Univ, Dept Ophthalmol, Affiliated Hosp, Nantong 226001, Peoples R China.
EM yuying.2009@163.com; sangam@ntu.edu.cn
FU National Natural Science Foundation of China [81700853]; China
   Postdoctoral Science Foundation [2019M651927]
FX This project has been funded in part by grants from National Natural
   Science Foundation of China 81700853, China Postdoctoral Science
   Foundation 2019M651927.
CR Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   Bae JH, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0180482
   Bhattarai D, 2018, MED RES REV, V38, P1404, DOI 10.1002/med.21477
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Cabrera D, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-03675-z
   Campochiaro PA, 2015, PROG RETIN EYE RES, V49, P67, DOI 10.1016/j.preteyeres.2015.06.002
   Chen HW, 2011, J NAT PROD, V74, P2408, DOI 10.1021/np200631v
   Chen YH, 2010, MOL INTERV, V10, P271, DOI 10.1124/mi.10.5.4
   Dai JW, 2017, INT J BIOL SCI, V13, P660, DOI 10.7150/ijbs.19194
   Du HJ, 2013, P NATL ACAD SCI USA, V110, P2377, DOI 10.1073/pnas.1221729110
   Gao ZF, 2018, INT IMMUNOPHARMACOL, V57, P82, DOI 10.1016/j.intimp.2018.02.012
   Gupta S, 2018, INFLAMMOPHARMACOLOGY, V26, P447, DOI 10.1007/s10787-017-0375-7
   Hua ZY, 2015, PATHOG DIS, V73, DOI 10.1093/femspd/ftu022
   Kishore V, 2017, CURR TOP MED CHEM, V17, P845, DOI 10.2174/1568026616666160927150452
   Klettner A, 2013, INT J BIOCHEM CELL B, V45, P1457, DOI 10.1016/j.biocel.2013.04.013
   Kou W, 2014, INFLAMMATION, V37, P1738, DOI 10.1007/s10753-014-9902-5
   Li J, 2015, ONCOTARGETS THER, V8, P427, DOI 10.2147/OTT.S76116
   Li Y, 2017, EVID-BASED COMPL ALT, V2017, DOI 10.1155/2017/8248142
   Liang ES, 2018, OXID MED CELL LONGEV, V2018, DOI 10.1155/2018/9086747
   Lim JCW, 2012, CLIN EXP PHARMACOL P, V39, P300, DOI 10.1111/j.1440-1681.2011.05633.x
   Lin HH, 2011, TOXICOL APPL PHARM, V250, P336, DOI 10.1016/j.taap.2010.11.014
   Lin MK, 2012, INVEST OPHTH VIS SCI, V53, P6197, DOI 10.1167/iovs.11-8936
   Liu JW, 2019, J CELL PHYSIOL, V234, P9631, DOI 10.1002/jcp.27650
   Moore NA, 2017, EXPERT OPIN BIOL TH, V17, P1235, DOI 10.1080/14712598.2017.1356817
   Park YH, 2010, CLIN EXP OPHTHALMOL, V38, P718, DOI 10.1111/j.1442-9071.2010.02328.x
   Peng S, 2016, ONCOTARGET, V7, P80262, DOI 10.18632/oncotarget.12918
   Pilu S, 2008, AM J OPHTHALMOL, V145, P879, DOI 10.1016/j.ajo.2007.12.036
   Pratheeshkumar P, 2011, J ENVIRON PATHOL TOX, V30, P33, DOI 10.1615/JEnvironPatholToxicolOncol.v30.i1.40
   Ren J, 2016, J PHARMACOL EXP THER, V356, P137, DOI 10.1124/jpet.115.227934
   Rey S, 2010, CARDIOVASC RES, V86, P236, DOI 10.1093/cvr/cvq045
   Shao J, 2016, DEV OPHTHALMOL, V55, P125, DOI 10.1159/000438969
   Shen KK, 2014, CHEM-BIOL INTERACT, V218, P99, DOI 10.1016/j.cbi.2014.04.020
   Shi L, 2017, CHEM-BIOL INTERACT, V273, P228, DOI 10.1016/j.cbi.2017.06.024
   Wakusawa R, 2011, INVEST OPHTH VIS SCI, V52, P3272, DOI 10.1167/iovs.10-6295
   Wu JM, 2016, INT J BIOL SCI, V12, P1363, DOI 10.7150/ijbs.16334
   Xu Y, 2018, J PINEAL RES, V64, DOI 10.1111/jpi.12473
   Yan H, 2016, CURR PHARM DESIGN, V22, P499, DOI 10.2174/1381612821666150921110716
   Yang CH, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18081638
   Yang SQ, 2016, DRUG DES DEV THER, V10, P1857, DOI 10.2147/DDDT.S97653
   Yang W, 2017, TOXICOL APPL PHARM, V327, P1, DOI 10.1016/j.taap.2017.04.022
   Yang Y, 2016, SCI REP-UK, V6, DOI 10.1038/srep30933
   Yu ZY, 2015, BBA-GEN SUBJECTS, V1850, P824, DOI 10.1016/j.bbagen.2015.01.014
NR 42
TC 3
Z9 4
U1 3
U2 9
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0006-291X
EI 1090-2104
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD SEP 10
PY 2020
VL 530
IS 1
BP 60
EP 66
DI 10.1016/j.bbrc.2020.06.130
PG 7
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA NI2KL
UT WOS:000565184300011
PM 32828316
DA 2022-11-30
ER

PT J
AU Mandadi, SKR
   Iovino, C
   Sacconi, R
   Querques, G
   Peiretti, E
   Singh, SR
   Chhablani, J
AF Mandadi, Spoorti Krishna Reddy
   Iovino, Claudio
   Sacconi, Riccardo
   Querques, Giuseppe
   Peiretti, Enrico
   Singh, Sumit Randhir
   Chhablani, Jay
TI Outer retinal tubulations in central serous chorioretinopathy associated
   with choroidal neovascularisation
SO EUROPEAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Central serous chorioretinopathy; outer retinal tubulation; OCT;
   choroidal neovascularization; CNV; CSCR
AB Aim
   To report the prevalence and characteristics of outer retinal tubulations in eyes with choroidal neovascularisation associated with chronic central serous chorioretinopathy.
   Methods
   Retrospective case series which included evaluation of optical coherence tomography B-scans and enface optical coherence tomography scans of eyes with choroidal neovascularisation associated with chronic central serous chorioretinopathy. The characteristics of outer retinal tubulations such as number, shape and distribution were noted. The location of the outer retinal tubulations was correlated with autofluorescence.
   Results
   Outer retinal tubulations were detected in 9.1% of the eyes (9 out of 87 eyes). The average number of outer retinal tubulations in each eye was 4.7 +/- 4.6. Spheroidal outer retinal tubulations were more common than the branching tubules. Although presence of outer retinal tubulations was mostly associated with inactive disease, two eyes had coexistent subretinal fluid.
   Conclusion
   Outer retinal tubulations associated with choroidal neovascularisation in chronic central serous chorioretinopathy, though less frequent, when present are more numerous, mostly extrafoveal and more spheroidal in shape compared to outer retinal tubulations associated with age-related macular degeneration and other degenerative conditions.
C1 [Mandadi, Spoorti Krishna Reddy; Singh, Sumit Randhir; Chhablani, Jay] LV Prasad Eye Inst, Smt Kanuri Santhamma Ctr Vitreoretinal Dis, Banjara Hills, Hyderabad 500034, India.
   [Iovino, Claudio; Peiretti, Enrico] Univ Cagliari, Dept Surg Sci, Eye Clin, Cagliari, Italy.
   [Sacconi, Riccardo; Querques, Giuseppe] Osped San Raffaele, Ophthalmol, Milan, Italy.
   [Chhablani, Jay] Univ Pittsburgh, UPMC Eye Ctr, Pittsburgh, PA USA.
C3 L. V. Prasad Eye Institute; University of Cagliari; Vita-Salute San
   Raffaele University; IRCCS Ospedale San Raffaele; Pennsylvania
   Commonwealth System of Higher Education (PCSHE); University of
   Pittsburgh
RP Chhablani, J (通讯作者)，LV Prasad Eye Inst, Smt Kanuri Santhamma Ctr Vitreoretinal Dis, Banjara Hills, Hyderabad 500034, India.
EM jay.chhablani@gmail.com
RI Iovino, Claudio/O-7680-2019
OI Iovino, Claudio/0000-0003-1984-0555; Chhablani, Jay/0000-0003-1772-3558;
   Sacconi, Riccardo/0000-0003-2891-2012; Querques,
   Giuseppe/0000-0002-3292-9581
CR Braimah IZ, 2017, RETINA-J RET VIT DIS, V37, P578, DOI 10.1097/IAE.0000000000001220
   Chhablani J, 2015, RETINA-J RET VIT DIS, V35, P2489, DOI 10.1097/IAE.0000000000000655
   Costanzo E, 2015, J OPHTHALMOL, V2015, DOI 10.1155/2015/134783
   Gallego-Pinazo R, 2013, GRAEF ARCH CLIN EXP, V251, P1655, DOI 10.1007/s00417-012-2151-0
   Giachetti Filho Richard Geraldo, 2016, Int J Retina Vitreous, V2, P6, DOI 10.1186/s40942-016-0029-8
   유성, 2014, [Journal of The Korean Ophthalmological Society, 대한안과학회지], V55, P1642
   Lee JY, 2014, OPHTHALMOLOGY, V121, P2423, DOI 10.1016/j.ophtha.2014.06.013
   Litts KM, 2015, JAMA OPHTHALMOL, V133, P609, DOI 10.1001/jamaophthalmol.2015.126
   Loo RH, 2002, RETINA-J RET VIT DIS, V22, P19, DOI 10.1097/00006982-200202000-00004
   Peiretti E, 2019, RETINA-J RET VIT DIS, V39, P1693, DOI 10.1097/IAE.0000000000002234
   Quaranta-El Maftouhi M, 2015, AM J OPHTHALMOL, V160, P581, DOI 10.1016/j.ajo.2015.06.016
   Sahoo NK, 2019, BRIT J OPHTHALMOL, V103, P1615, DOI 10.1136/bjophthalmol-2018-313048
   Wolff B, 2012, J OPHTHALMOL, V2012, DOI 10.1155/2012/542417
   Zweifel SA, 2009, ARCH OPHTHALMOL-CHIC, V127, P1596, DOI 10.1001/archophthalmol.2009.326
NR 14
TC 1
Z9 1
U1 0
U2 1
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1120-6721
EI 1724-6016
J9 EUR J OPHTHALMOL
JI Eur. J. Ophthalmol.
PD MAY
PY 2021
VL 31
IS 3
BP 1225
EP 1230
AR 1120672120921369
DI 10.1177/1120672120921369
EA MAY 2020
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA TZ2CF
UT WOS:000533980600001
PM 32370611
DA 2022-11-30
ER

PT J
AU Sastre-Ibanez, M
   Martinez-Rubio, C
   Molina-Pallete, R
   Martinez-Lopez-Corell, P
   Wu, L
   Arevalo, JF
   Gallego-Pinazo, R
AF Sastre-Ibanez, M.
   Martinez-Rubio, C.
   Molina-Pallete, R.
   Martinez-Lopez-Corell, P.
   Wu, L.
   Arevalo, J. F.
   Gallego-Pinazo, R.
TI Retinal pigment epithelial tears
SO JOURNAL FRANCAIS D OPHTALMOLOGIE
LA English
DT Review
DE Retinal pigment epithelial (RPE) tear; Age-related macular degeneration;
   Retinal pigment epithelial detachments; Anti-angiogenics; Risk factors
   for retinal pigment epithelial tear
ID OPTICAL COHERENCE TOMOGRAPHY; INTRAVITREAL BEVACIZUMAB INJECTION;
   ANTI-VEGF THERAPY; CHOROIDAL NEOVASCULARIZATION SECONDARY; GROWTH-FACTOR
   THERAPY; PHOTODYNAMIC THERAPY; RISK-FACTORS; RPE TEARS; RANIBIZUMAB
   INJECTION; DOSE RANIBIZUMAB
AB A retinal pigment epithelial (RPE) tear is a well-known complication of retinal pigment epithelial detachments (PED) and may cause a significant visual impairment. The most common cause is a vascularized PED in patients with exudative age-related macular degeneration (AMD). The development of diagnostic imaging techniques brings us closer to the etiology and pathophysiological mechanisms of this entity, offering us new strategies for treatment and follow-up. The advent of intravitreal antiangiogenic treatment (anti-VEGF) has led to an increase in the number of reported cases of RPE tears, which are an important vision-limiting factor during treatment. However, RPE tears may occur spontaneously or as a consequence of thermal laser treatment, photodynamic therapy or anti-VEGF therapy. It is accepted that the mechanism of RPE tears is multifactorial. The optimization of the functional outcome of this complication has been described with continuous treatment with antiangiogenic drugs. The goal of the present review is to evaluate the incidence, risk factors and treatment of RPE tears. (C) 2018 Published by Elsevier Masson SAS.
C1 [Sastre-Ibanez, M.] Clin San Carlos Hosp Madrid, Dept Ophthalmol, Gran Via Este 80, Madrid 28031, Spain.
   [Martinez-Rubio, C.; Martinez-Lopez-Corell, P.] Univ & Politecn La Fe Hosp, Dept Ophthalmol, Valencia, Spain.
   [Molina-Pallete, R.] Macula Vitreous & Retina Associates Costa Rica, San Jose, Costa Rica.
   [Wu, L.] Johns Hopkins Univ, Sch Med, Wilmer Eye Inst, Retina Div, Baltimore, MD 21205 USA.
   [Arevalo, J. F.; Gallego-Pinazo, R.] Oftalvist Clin, Macula Dept, Valencia, Spain.
   [Gallego-Pinazo, R.] Carlos III Hlth Inst, RETICS Ocular Dis Prevent Early Detect Treatment, Madrid, Spain.
C3 Hospital Universitari i Politecnic La Fe; Johns Hopkins University;
   Johns Hopkins Medicine
RP Sastre-Ibanez, M (通讯作者)，Clin San Carlos Hosp Madrid, Dept Ophthalmol, Gran Via Este 80, Madrid 28031, Spain.
EM marinasastre@yahoo.es
RI Ibáñez, Marina Sastre-/R-1346-2019
OI Sastre Ibanez, Marina/0000-0003-0640-894X; Martinez-Rubio,
   Clara/0000-0001-8838-7497; Arevalo Suarez, Fernando
   Antonio/0000-0002-4114-5949
CR Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Arnold JJ, 2004, AM J OPHTHALMOL, V137, P683, DOI 10.1016/j.ajo.2003.11.059
   Bakri SJ, 2007, AM J OPHTHALMOL, V143, P505, DOI 10.1016/j.ajo.2006.11.047
   Bartels S, 2014, OPHTHALMOLOGE, V111, P460, DOI 10.1007/s00347-013-2883-1
   BIRD AC, 1991, EYE, V5, P1
   Bloch SB, 2011, ACTA OPHTHALMOL, V89, pe665, DOI 10.1111/j.1755-3768.2010.02023.x
   Caramoy A, 2012, BRIT J OPHTHALMOL, V96, P1211, DOI 10.1136/bjophthalmol-2012-301750
   Carvounis PE, 2007, AM J OPHTHALMOL, V143, P504, DOI 10.1016/j.ajo.2006.11.028
   CASSWELL AG, 1985, BRIT J OPHTHALMOL, V69, P397, DOI 10.1136/bjo.69.6.397
   Chalam KV, 2011, INDIAN J OPHTHALMOL, V59, P47, DOI 10.4103/0301-4738.73712
   Chan CK, 2007, EUR J OPHTHALMOL, V17, P674, DOI 10.1177/112067210701700432
   Chan CK, 2015, EYE, V29, P80, DOI 10.1038/eye.2014.233
   Chan CK, 2007, RETINA-J RET VIT DIS, V27, P541, DOI 10.1097/IAE.0b013e3180cc2612
   Chan CK, 2010, RETINA-J RET VIT DIS, V30, P203, DOI 10.1097/IAE.0b013e3181babda5
   Chang LK, 2007, RETINA-J RET VIT DIS, V27, P857, DOI 10.1097/IAE.0b013e3180342c42
   Chang LK, 2007, RETINA-J RET VIT DIS, V27, P523, DOI 10.1097/IAE.0b013e3180a032db
   Chiang A, 2008, RETINA-J RET VIT DIS, V28, P1265, DOI 10.1097/IAE.0b013e31817d5d03
   Cho HJ, 2016, RETINA-J RET VIT DIS, V36, P1851, DOI 10.1097/IAE.0000000000001009
   Cho HJ, 2015, AM J OPHTHALMOL, V160, P1000, DOI 10.1016/j.ajo.2015.07.023
   CHUANG EL, 1988, EYE, V2, P106, DOI 10.1038/eye.1988.22
   Clemens CR, 2016, OPHTHALMOLOGICA, V235, P1, DOI 10.1159/000439445
   Coscas F, 2007, AM J OPHTHALMOL, V144, P592, DOI 10.1016/j.ajo.2007.06.014
   Cunningham ET, 2011, OPHTHALMOLOGY, V118, P2447, DOI 10.1016/j.ophtha.2011.05.026
   Dhalla MS, 2006, AM J OPHTHALMOL, V141, P752, DOI 10.1016/j.ajo.2005.10.053
   Doguizi S, 2014, RETINA-J RET VIT DIS, V34, P1156, DOI 10.1097/IAE.0000000000000056
   Empeslidis T, 2014, OPEN OPHTHALMOL J, V8, P101, DOI 10.2174/1874364101408010101
   Garg S, 2008, CLIN EXP OPHTHALMOL, V36, P252, DOI 10.1111/j.1442-9071.2008.01710.x
   GASS JDM, 1981, ARCH OPHTHALMOL-CHIC, V99, P1016, DOI 10.1001/archopht.1981.03930011016006
   GASS JDM, 1984, AM J OPHTHALMOL, V98, P700
   GASS JDM, 1984, BRIT J OPHTHALMOL, V68, P513, DOI 10.1136/bjo.68.8.513
   Gelisken F, 2001, AM J OPHTHALMOL, V131, P518, DOI 10.1016/S0002-9394(00)00813-8
   Gelisken F, 2006, ACTA OPHTHALMOL SCAN, V84, P833, DOI 10.1111/j.1600-0420.2006.00765.x
   Giovannini A, 2000, RETINA-J RET VIT DIS, V20, P37, DOI 10.1097/00006982-200001000-00007
   Goldstein M, 2005, EYE, V19, P1315, DOI 10.1038/sj.eye.6701765
   Guber J, 2014, KLIN MONATSBL AUGENH, V231, P432, DOI 10.1055/s-0034-1368219
   Gutfleisch M, 2011, EYE, V25, P1181, DOI 10.1038/eye.2011.146
   Heimes B, 2016, RETINA-J RET VIT DIS, V36, P868, DOI 10.1097/IAE.0000000000000823
   HOSKIN A, 1981, BRIT J OPHTHALMOL, V65, P417, DOI 10.1136/bjo.65.6.417
   Kiss C, 2007, ACTA OPHTHALMOL SCAN, V85, P902, DOI 10.1111/j.1600-0420.2007.00928.x
   Konstantinidis L, 2010, ACTA OPHTHALMOL, V88, P736, DOI 10.1111/j.1755-3768.2009.01547.x
   Kook D, 2008, OPHTHALMOLOGE, V105, P158, DOI 10.1007/s00347-007-1561-6
   Lee GKY, 2007, GRAEF ARCH CLIN EXP, V245, P1225, DOI 10.1007/s00417-007-0536-2
   Leitritz M, 2008, EYE, V22, P1504, DOI 10.1038/eye.2008.145
   Leon PE, 2014, INT J OPHTHALMOL-CHI, V7, P681, DOI 10.3980/j.issn.2222-3959.2014.04.18
   Lesniak SP, 2011, EUR J OPHTHALMOL, V21, P73, DOI 10.5301/EJO.2010.2285
   LOPEZ PF, 1995, ARCH OPHTHALMOL-CHIC, V113, P1437, DOI 10.1001/archopht.1995.01100110097032
   Maaijwee K, 2008, BRIT J OPHTHALMOL, V92, P526, DOI 10.1136/bjo.2007.131383
   Mendis R, 2014, GRAEF ARCH CLIN EXP, V252, P1059, DOI 10.1007/s00417-013-2549-3
   Meyer CH, 2006, BRIT J OPHTHALMOL, V90, P1207, DOI 10.1136/bjo.2006.093732
   Michels S, 2006, AM J OPHTHALMOL, V141, P396, DOI 10.1016/j.ajo.2005.08.046
   Mones J, 2013, CLIN OPHTHALMOL, V7, P1089, DOI 10.2147/OPTH.S45155
   Moroz I, 2009, OPHTHAL SURG LAS IM, V40, P570, DOI 10.3928/15428877-20091030-06
   Mouallem A, 2016, RETINA-J RET VIT DIS, V36, P2197, DOI 10.1097/IAE.0000000000001062
   Mukai R, 2014, ACTA OPHTHALMOL, V92, pE407, DOI 10.1111/aos.12350
   Nagiel A, 2013, AM J OPHTHALMOL, V156, P981, DOI 10.1016/j.ajo.2013.06.024
   Nicolo M, 2006, EUR J OPHTHALMOL, V16, P770, DOI 10.1177/112067210601600521
   Oishi A., 2017, RETINA-J RET VIT DIS, V0, P1
   Pece A, 2001, RETINA-J RET VIT DIS, V21, P661, DOI 10.1097/00006982-200112000-00017
   Pece A, 2010, OPHTHALMOLOGICA, V224, P159, DOI 10.1159/000236910
   Pepple K, 2011, SEMIN OPHTHALMOL, V26, P198, DOI 10.3109/08820538.2011.570850
   Polito A, 2011, BRIT J OPHTHALMOL, V95, P74, DOI 10.1136/bjo.2009.170381
   Saito M, 2013, CLIN OPHTHALMOL, V7, P1287, DOI 10.2147/OPTH.S47735
   Salz D, 2010, REV OPHTHALMOL, V18, P66
   Sarraf David, 2014, Trans Am Ophthalmol Soc, V112, P142
   Sarraf D, 2013, RETINA-J RET VIT DIS, V33, P1551, DOI 10.1097/IAE.0b013e31828992f5
   Sarraf D, 2010, RETINA-J RET VIT DIS, V30, P1039, DOI 10.1097/IAE.0b013e3181cdf366
   Sato T, 2015, OSLI RETINA, V46, P87, DOI 10.3928/23258160-20150101-16
   Shah CP, 2006, AM J OPHTHALMOL, V142, P1070, DOI 10.1016/j.ajo.2006.07.037
   Shin JY, 2015, GRAEF ARCH CLIN EXP, V253, P2151, DOI 10.1007/s00417-015-2977-3
   Singh RP, 2006, AM J OPHTHALMOL, V142, P160, DOI 10.1016/j.ajo.2006.03.051
   Smith BT, 2009, RETINA-J RET VIT DIS, V29, P335, DOI 10.1097/IAE.0b013e318195cad5
   Spaide RF, 2009, AM J OPHTHALMOL, V147, P644, DOI 10.1016/j.ajo.2008.10.005
   Spandau UHM, 2006, AM J OPHTHALMOL, V142, P1068, DOI 10.1016/j.ajo.2006.06.048
   Starita C, 1997, INVEST OPHTH VIS SCI, V38, P762
   Sutter FK, 2007, KLIN MONATSBL AUGENH, V224, P297, DOI 10.1055/s-2007-962949
   VALENTINO TL, 1995, ARCH OPHTHALMOL-CHIC, V113, P932, DOI 10.1001/archopht.1995.01100070106033
   Yeh B, 2011, OPTOMETRY, V82, P152, DOI 10.1016/j.optm.2010.09.010
   YEO JH, 1988, OPHTHALMOLOGY, V95, P8
NR 78
TC 4
Z9 7
U1 0
U2 5
PU MASSON EDITEUR
PI MOULINEAUX CEDEX 9
PA 21 STREET CAMILLE DESMOULINS, ISSY, 92789 MOULINEAUX CEDEX 9, FRANCE
SN 0181-5512
EI 1773-0597
J9 J FR OPHTALMOL
JI J. Fr. Ophthamol.
PD JAN
PY 2019
VL 42
IS 1
BP 63
EP 72
DI 10.1016/j.jfo.2018.04.017
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA HH4BN
UT WOS:000455665200016
PM 30594420
DA 2022-11-30
ER

PT J
AU Anwary, M
   Kumar, P
   du Toit, LC
   Choonara, YE
   Pillay, V
AF Anwary, Muhammed
   Kumar, Pradeep
   du Toit, Lisa C.
   Choonara, Yahya E.
   Pillay, Viness
TI Polymeric, injectable, intravitreal hydrogel devices for posterior
   segment applications and interventions
SO ARTIFICIAL CELLS NANOMEDICINE AND BIOTECHNOLOGY
LA English
DT Article
DE Ocular drug delivery; posterior segment; intravitreal devices;
   injectable hydrogels; injectable intravitreal devices; biodegradable
   hydrogels
ID OCULAR DRUG-DELIVERY; THERMORESPONSIVE HYDROGELS; SUSTAINED-RELEASE;
   IN-VITRO; SILK; AVASTIN(R); BEHAVIOR
AB Posterior segment diseases are commonly implicated in the occurrence of curable as well as incurable diseases which could lead to blindness. An example of one such disease is age-related macular degeneration, which would require chronic treatment over an extended period and as such the development of an intravitreal drug delivery system that would optimize patient outcomes is essential. The major contributor of the difficulty in treating diseases in the posterior segment is the structure of the eye, particularly the blood-ocular barriers. This review will focus on the various biodegradable and non-biodegradable injectable intravitreal polymeric hydrogel devices, such as poly(ethylene glycol), poly(lactic-co-glycolic acid), silica, hyaluronic acid/dextran, silk, chitosan/alginate and poly(N-isopropylacrylamide)-based polymers, their compositions as well as the effects and results of these polymeric components on the device as a whole. Furthermore, it will briefly discuss therapeutic agents used in these devices, such as ranibizumab, dexamethasone, Avastin (R)/bevacizumab and aflibercept, and a potential way forward by employing intelligent polymeric systems.
C1 [Anwary, Muhammed; Kumar, Pradeep; du Toit, Lisa C.; Choonara, Yahya E.; Pillay, Viness] Univ Witwatersrand, Wits Adv Drug Delivery Platform Res Unit, Fac Hlth Sci, Dept Pharm & Pharmacol,Sch Therapeut Sci, Johannesburg, South Africa.
C3 University of Witwatersrand
RP Pillay, V (通讯作者)，Univ Witwatersrand, Wits Adv Drug Delivery Platform Res Unit, Fac Hlth Sci, Dept Pharm & Pharmacol,Sch Therapeut Sci, 7 York Rd, ZA-2193 Parktown, South Africa.
EM viness.pillay@wits.ac.za
RI Choonara, Yahya E./B-2955-2013; Kumar, Pradeep/C-9424-2013; Kumar,
   Pradeep/GQA-7930-2022; Kumar, Pradeep/GQV-5790-2022; Pillay,
   Viness/C-1569-2010
OI Choonara, Yahya E./0000-0002-3889-1529; Kumar,
   Pradeep/0000-0002-8640-4350; Pillay, Viness/0000-0002-8119-3347;
   /0000-0002-2042-6338
FU National Research Foundation (NRF) of South Africa
FX This work was funded by the National Research Foundation (NRF) of South
   Africa.
CR Adamson P, 2016, J CONTROL RELEASE, V244, P1, DOI 10.1016/j.jconrel.2016.10.026
   Ahmadi F, 2015, RES PHARM SCI, V10, P1
   Asghari F, 2017, ARTIF CELL NANOMED B, V45, P185, DOI 10.3109/21691401.2016.1146731
   Bora M, 2016, COGENT MED, V3, P1
   Choonara YE, 2010, J PHARM SCI-US, V99, P2219, DOI 10.1002/jps.21987
   Drapala PW, 2014, PHARM RES-DORDR, V31, P742, DOI 10.1007/s11095-013-1195-0
   Drapala PW, 2011, J BIOMAT SCI-POLYM E, V22, P59, DOI 10.1163/092050609X12578498952315
   du Toit LCA., 2013, THESIS
   du Toit LC, 2014, PHARM RES-DORDR, V31, P607, DOI 10.1007/s11095-013-1184-3
   Ekenseair AK, 2012, BIOMACROMOLECULES, V13, P1908, DOI 10.1021/bm300429e
   Fathi M, 2015, BIOIMPACTS, V5, P159, DOI 10.15171/bi.2015.31
   Floren M, 2016, J FUNCT BIOMATER, V7, DOI 10.3390/jfb7030026
   Gandhi A, 2015, ASIAN J PHARM SCI, V10, P99, DOI 10.1016/j.ajps.2014.08.010
   Ghormade V, 2017, INT J BIOL MACROMOL, V104, P1415, DOI 10.1016/j.ijbiomac.2017.01.112
   Haghjou Nahid, 2011, J Ophthalmic Vis Res, V6, P317
   Hayashi K, 2017, NAT BIOMED ENG, V1, DOI 10.1038/s41551-017-0044
   Henise J, 2015, BIOCONJUGATE CHEM, V26, P270, DOI 10.1021/bc5005476
   Hu CC, 2014, BIO-MED MATER ENG, V24, P1941, DOI 10.3233/BME-141003
   Huang X, 2003, CHEM ENG COMMUN, V190, P519, DOI 10.1080/00986440302081
   Hutanu D., 2014, MOD CHEM APPL, V2, P1, DOI [10.4172/2329-6798.1000132, DOI 10.4172/2329-6798.1000132]
   Ilyin SO, 2016, COLLOID J+, V78, P608, DOI 10.1134/S1061933X16050070
   Imam S, 2017, ARTIF CELL NANOMED B, P1
   Jokinen M, 2016, ONDRUGDELIVERY, V63, P28
   Jokinen M, 2008, KEY ENG MATER, V377, P195, DOI 10.4028/www.scientific.net/KEM.377.195
   Kang-Mieler JJ, 2014, EXPERT OPIN DRUG DEL, V11, P1647, DOI 10.1517/17425247.2014.935338
   Khalil HEM, 2016, J OPHTHALMOL, V2016, DOI 10.1155/2016/1678495
   Klouda L, 2008, EUR J PHARM BIOPHARM, V68, P34, DOI 10.1016/j.ejpb.2007.02.025
   Klouda L, 2015, EUR J PHARM BIOPHARM, V97, P338, DOI 10.1016/j.ejpb.2015.05.017
   Kumar K, 2014, ARTIF CELL NANOMED B, V42, P274, DOI 10.3109/21691401.2013.815194
   Lee DJ, 2015, J FUNCT BIOMATER, V6, P650, DOI 10.3390/jfb6030650
   Lee KY, 2012, PROG POLYM SCI, V37, P106, DOI 10.1016/j.progpolymsci.2011.06.003
   Li YR, 2018, AMYOTROPH LAT SCL FR, V19, P516, DOI 10.1080/21678421.2018.1457057
   Li YL, 2012, CHEM SOC REV, V41, P2193, DOI 10.1039/c1cs15203c
   Lovett ML, 2015, EUR J PHARM BIOPHARM, V95, P271, DOI 10.1016/j.ejpb.2014.12.029
   Lu CH, 2014, J PHARM SCI-US, V103, P216, DOI 10.1002/jps.23777
   Mahlumba P, 2016, MOLECULES, V21, DOI 10.3390/molecules21081002
   Ming JF, 2016, MAT SCI ENG C-MATER, V59, P185, DOI 10.1016/j.msec.2015.10.013
   Ohya Shoji, 2004, J Artif Organs, V7, P181
   Osswald CR, 2017, CURR EYE RES, V42, P1293, DOI 10.1080/02713683.2017.1302590
   Osswald CR, 2016, CURR EYE RES, V41, P1216, DOI 10.3109/02713683.2015.1101140
   Pandit J, 2017, ARTIF CELL NANOMED B, V45, P1397, DOI 10.1080/21691401.2016.1243545
   Pelton R, 2010, J COLLOID INTERF SCI, V348, P673, DOI 10.1016/j.jcis.2010.05.034
   Peng KT, 2016, BMC MUSCULOSKEL DIS, V17, DOI 10.1186/s12891-016-1131-7
   Pillay V, 2016, NANOBIOMATERIALS OPH, P407, DOI [10.1007/978-3-319-29346-2_18, DOI 10.1007/978-3-319-29346-2_18]
   Ren ZW, 2015, ACS APPL MATER INTER, V7, P19006, DOI 10.1021/acsami.5b02821
   Singh NK, 2014, J CONTROL RELEASE, V193, P214, DOI 10.1016/j.jconrel.2014.04.056
   Stoddart A., 2017, NAT REV MATER, V2, P17018
   Trimaille T, 2016, CR CHIM, V19, P157, DOI 10.1016/j.crci.2015.03.016
   Unsal Erkan, 2017, Korean J Ophthalmol, V31, P115, DOI 10.3341/kjo.2017.31.2.115
   Vasquez J.M.G., 2015, 11 ENG RES DEV TECHN, V5, P60
   Vepari C, 2007, PROG POLYM SCI, V32, P991, DOI 10.1016/j.progpolymsci.2007.05.013
   Widjaja LK, 2014, J BIOMED MATER RES A, V102, P3056, DOI 10.1002/jbm.a.34976
   Xie BB, 2015, INT J PHARMACEUT, V490, P375, DOI 10.1016/j.ijpharm.2015.05.071
   Xu X, 2013, INT J BIOL MACROMOL, V60, P272, DOI 10.1016/j.ijbiomac.2013.05.034
   Yin ZP, 2017, RSC ADV, V7, P24085, DOI 10.1039/c7ra02682j
   Yu J, 2014, INT J PHARMACEUT, V470, P151, DOI 10.1016/j.ijpharm.2014.04.053
   Yu L, 2007, J POLYM SCI POL CHEM, V45, P1122, DOI 10.1002/pola.21876
   Yu Y, 2015, TRANSL VIS SCI TECHN, V4, DOI 10.1167/tvst.4.2.5
   Yuan L, 2016, ARTIF CELL NANOMED B, V45, P76
   Zhang L, 2015, ACTA BIOMATER, V23, P271, DOI 10.1016/j.actbio.2015.05.005
   Zhao W, 2013, J CHEM TECHNOL BIOT, V88, P327, DOI 10.1002/jctb.3970
NR 61
TC 11
Z9 11
U1 4
U2 36
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 2169-1401
EI 2169-141X
J9 ARTIF CELL NANOMED B
JI Artif. Cell. Nanomed. Biotechnol.
PY 2018
VL 46
SU 2
BP 1074
EP 1081
DI 10.1080/21691401.2018.1478845
PG 8
WC Biotechnology & Applied Microbiology; Engineering, Biomedical; Materials
   Science, Biomaterials
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Engineering; Materials Science
GA HM1BA
UT WOS:000459181400103
PM 29916734
OA Bronze
DA 2022-11-30
ER

PT J
AU Penn, J
   Mihai, DM
   Washington, I
AF Penn, Jackie
   Mihai, Doina M.
   Washington, Ilyas
TI Morphological and physiological retinal degeneration induced by
   intravenous delivery of vitamin A dimers in rabbits
SO DISEASE MODELS & MECHANISMS
LA English
DT Article
DE Vitamin A; Neurodegeneration; Bisretinoids; A2E; RPE; Vitamin A dimer;
   Age-related macular degeneration; AMD; Stargardt
ID PIGMENT EPITHELIAL-CELLS; AGE-RELATED MACULOPATHY; LIGHT-INDUCED DAMAGE;
   LIPOFUSCIN FLUOROPHORE; COMPLEMENT ACTIVATION; MACULAR DEGENERATION;
   OXIDATION-PRODUCTS; RPE LIPOFUSCIN; A2E OXIDATION; BISRETINOIDS
AB The eye uses vitamin A as a cofactor to sense light and, during this process, some vitamin A molecules dimerize, forming vitamin A dimers. A striking chemical signature of retinas undergoing degeneration in major eye diseases such as age-related macular degeneration (AMD) and Stargardt disease is the accumulation of these dimers in the retinal pigment epithelium (RPE) and Bruch's membrane (BM). However, it is not known whether dimers of vitamin A are secondary symptoms or primary insults that drive degeneration. Here, we present a chromatography-free method to prepare gram quantities of the vitamin A dimer, A2E, and show that intravenous administration of A2E to the rabbit results in retinal degeneration. A2E-damaged photoreceptors and RPE cells triggered inflammation, induced remolding of the choroidal vasculature and triggered a decline in the retina's response to light. Data suggest that vitamin A dimers are not bystanders, but can be primary drivers of retinal degeneration. Thus, preventing dimer formation could be a preemptive strategy to address serious forms of blindness.
C1 [Penn, Jackie; Mihai, Doina M.; Washington, Ilyas] Columbia Univ, Med Ctr, New York, NY 10032 USA.
C3 Columbia University
RP Washington, I (通讯作者)，Columbia Univ, Med Ctr, New York, NY 10032 USA.
EM iw2101@columbia.edu
OI W, I/0000-0002-2238-7918
FU U.S. National Institutes of Health, National Eye Institute
   [1R01EY021207, 5P30EY019007]; Research to Prevent Blindness (RPB) Inc.,
   New York, NY; NATIONAL EYE INSTITUTE [P30EY019007, R01EY021207] Funding
   Source: NIH RePORTER
FX We thank the U.S. National Institutes of Health, National Eye Institute
   (grant number 1R01EY021207 and 5P30EY019007) and Research to Prevent
   Blindness (RPB) Inc., New York, NY.
CR Anderson OA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067263
   ASHBURN FS, 1980, INVEST OPHTH VIS SCI, V19, P1427
   Augustin AJ, 2009, EXPERT OPIN THER TAR, V13, P641, DOI 10.1517/14728220902942322
   Avalle LB, 2004, EXP EYE RES, V78, P895, DOI 10.1016/j.exer.2003.10.023
   Ben-Shabat S, 2002, ANGEW CHEM INT EDIT, V41, P814, DOI 10.1002/1521-3773(20020301)41:5<814::AID-ANIE814>3.0.CO;2-2
   Ben-Shabat S, 2002, J BIOL CHEM, V277, P7183, DOI 10.1074/jbc.M108981200
   Bermann M, 2001, EXP EYE RES, V72, P191
   BRANDTZAEG P, 1988, J CLIN PATHOL, V41, P963, DOI 10.1136/jcp.41.9.963
   Bressler SB, 2009, OPHTHALMOLOGY, V116, pS1, DOI 10.1016/j.ophtha.2009.06.045
   CAMPOCHIARO PA, 1988, ARCH OPHTHALMOL-CHIC, V106, P676
   CURCIO CA, 1993, INVEST OPHTH VIS SCI, V34, P3278
   Curcio CA, 2011, BRIT J OPHTHALMOL, V95, P1638, DOI 10.1136/bjophthalmol-2011-300344
   Curcio CA, 2009, PROG RETIN EYE RES, V28, P393, DOI 10.1016/j.preteyeres.2009.08.001
   De S, 2002, J GEN PHYSIOL, V120, P147, DOI 10.1085/jgp.20028566
   Del Priore LV, 2002, INVEST OPHTH VIS SCI, V43, P3312
   Dontsov AE, 2009, DOKL BIOCHEM BIOPHYS, V425, P98, DOI 10.1134/S1607672909020112
   Dunaief JL, 2002, ARCH OPHTHALMOL-CHIC, V120, P1435, DOI 10.1001/archopht.120.11.1435
   Eldred GE, 1995, GERONTOLOGY, V41, P15
   ELDRED GE, 1988, EXP EYE RES, V47, P71, DOI 10.1016/0014-4835(88)90025-5
   ELDRED GE, 1993, NATURE, V361, P724, DOI 10.1038/361724a0
   Finnemann SC, 2002, P NATL ACAD SCI USA, V99, P3842, DOI 10.1073/pnas.052025899
   GAO H, 1992, INVEST OPHTH VIS SCI, V33, P1
   Harman AM, 1997, INVEST OPHTH VIS SCI, V38, P2016
   HEWITT CD, 1989, CLIN CHEM, V35, P1777
   Holz FG, 1999, OPHTHALMOLOGE, V96, P781, DOI 10.1007/s003470050496
   Iriyama A, 2008, J BIOL CHEM, V283, P11947, DOI 10.1074/jbc.M708989200
   Iriyama A, 2009, J CELL PHYSIOL, V220, P469, DOI 10.1002/jcp.21792
   Jackson GR, 2006, VISION RES, V46, P1422, DOI 10.1016/j.visres.2005.09.003
   Jackson GR, 2004, INVEST OPHTH VIS SCI, V45, P3271, DOI 10.1167/iovs.04-0019
   Jackson GR, 1999, VISION RES, V39, P3975, DOI 10.1016/S0042-6989(99)00092-9
   Jager Martine J, 2014, J Ophthalmic Vis Res, V9, P1
   Julien S, 2012, NEUROBIOL AGING, V33, P2390, DOI 10.1016/j.neurobiolaging.2011.12.009
   Kaarniranta K, 2013, AUTOPHAGY, V9, P973, DOI 10.4161/auto.24546
   Kanda A, 2008, BRIT J OPHTHALMOL, V92, P448, DOI 10.1136/bjo.2007.131581
   Kanofsky JR, 2003, PHOTOCHEM PHOTOBIOL, V77, P235, DOI 10.1562/0031-8655(2003)077<0235:SOGFA>2.0.CO;2
   Karunadharma PP, 2010, INVEST OPHTH VIS SCI, V51, P5470, DOI 10.1167/iovs.10-5429
   KILLINGSWORTH MC, 1990, EYE, V4, P613, DOI 10.1038/eye.1990.86
   Kliffen M, 1997, MICROSC RES TECHNIQ, V36, P106, DOI 10.1002/(SICI)1097-0029(19970115)36:2<106::AID-JEMT4>3.0.CO;2-N
   LACHAPELLE P, 1990, DOC OPHTHALMOL, V75, P7, DOI 10.1007/BF00142588
   Lakkaraju A, 2007, P NATL ACAD SCI USA, V104, P11026, DOI 10.1073/pnas.0702504104
   LOW JC, 1987, GRAEF ARCH CLIN EXP, V225, P413, DOI 10.1007/BF02334167
   Lukiw WJ, 2006, CURR EYE RES, V31, P259, DOI 10.1080/02713680600556974
   Ma L, 2011, J BIOL CHEM, V286, P7966, DOI 10.1074/jbc.M110.178657
   Ma WX, 2013, NEUROBIOL AGING, V34, P943, DOI 10.1016/j.neurobiolaging.2012.06.010
   Mihai DM, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.314
   Moiseyev G, 2010, P NATL ACAD SCI USA, V107, P17551, DOI 10.1073/pnas.1008769107
   Murdaugh LS, 2010, EXP EYE RES, V90, P564, DOI 10.1016/j.exer.2010.01.014
   Murdaugh LS, 2009, EXP EYE RES, V89, P187, DOI 10.1016/j.exer.2009.03.021
   Ng EWM, 2005, CAN J OPHTHALMOL, V40, P352, DOI 10.1016/S0008-4182(05)80078-X
   Nociari MM, 2014, P NATL ACAD SCI USA, V111, pE1402, DOI 10.1073/pnas.1400530111
   NOELL WK, 1954, AM J OPHTHALMOL, V38, P78, DOI 10.1016/0002-9394(54)90012-4
   Nowak JZ, 2013, PHARMACOL REP, V65, P288, DOI 10.1016/S1734-1140(13)71005-3
   Owsley C, 2001, OPHTHALMOLOGY, V108, P1196, DOI 10.1016/S0161-6420(01)00580-2
   PandaJonas S, 1996, AM J OPHTHALMOL, V121, P181, DOI 10.1016/S0002-9394(14)70583-5
   Parish CA, 1998, P NATL ACAD SCI USA, V95, P14609, DOI 10.1073/pnas.95.25.14609
   Pikuleva IA, 2014, PROG RETIN EYE RES, V41, P64, DOI 10.1016/j.preteyeres.2014.03.002
   Radu RA, 2004, P NATL ACAD SCI USA, V101, P5928, DOI 10.1073/pnas.0308302101
   Radu RA, 2014, J BIOL CHEM, V289, P9113, DOI 10.1074/jbc.M114.548669
   Ren RXF, 1997, J AM CHEM SOC, V119, P3619, DOI 10.1021/ja9700414
   Roberts JE, 2002, PHOTOCHEM PHOTOBIOL, V75, P184, DOI 10.1562/0031-8655(2002)075<0184:TROAIP>2.0.CO;2
   Rodrigues EB, 2007, OPHTHALMOLOGICA, V221, P143, DOI 10.1159/000099293
   Ryan S J, 1979, Trans Am Ophthalmol Soc, V77, P707
   Sakai N, 1996, J AM CHEM SOC, V118, P1559, DOI 10.1021/ja953480g
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   SEREGARD S, 1994, GRAEF ARCH CLIN EXP, V232, P325, DOI 10.1007/BF00175983
   Sicre C, 2005, ORG LETT, V7, P5737, DOI 10.1021/ol052512u
   Sokolov VS, 2007, J PHOTOCH PHOTOBIO B, V86, P177, DOI 10.1016/j.jphotobiol.2006.09.006
   Sorsby A, 1941, Br J Ophthalmol, V25, P58, DOI 10.1136/bjo.25.2.58
   Spaide RF, 2003, RETINA-J RET VIT DIS, V23, P595, DOI 10.1097/00006982-200310000-00001
   Sparrow JR, 2010, ADV EXP MED BIOL, V703, P63, DOI 10.1007/978-1-4419-5635-4_5
   Sparrow JR, 2006, ADV EXP MED BIOL, V572, P63
   Sparrow JR, 1999, INVEST OPHTH VIS SCI, V40, P2988
   Sparrow JR, 2003, J BIOL CHEM, V278, P18207, DOI 10.1074/jbc.M300457200
   Sparrow JR, 2003, INVEST OPHTH VIS SCI, V44, P2245, DOI 10.1167/iovs.02-0746
   Sparrow JR, 2002, INVEST OPHTH VIS SCI, V43, P1222
   Sparrow JR, 2001, INVEST OPHTH VIS SCI, V42, P1356
   Sparrow JR, 2000, INVEST OPHTH VIS SCI, V41, P1981
   Swaroop A, 2009, ANNU REV GENOM HUM G, V10, P19, DOI 10.1146/annurev.genom.9.081307.164350
   Tanaka K, 2000, ORG LETT, V2, P373, DOI 10.1021/ol991320u
   Thao MT, 2014, PHOTOCHEM PHOTOBIOL, V90, P329, DOI 10.1111/php.12200
   TSO MOM, 1967, ARCH OPHTHALMOL-CHIC, V78, P641, DOI 10.1001/archopht.1967.00980030643016
   van der Burght Barbro W, 2013, Acta Ophthalmol, V91, pe537, DOI 10.1111/aos.12146
   Vives-Bauza C, 2008, J BIOL CHEM, V283, P24770, DOI 10.1074/jbc.M800706200
   Walter P, 1999, GRAEF ARCH CLIN EXP, V237, P962, DOI 10.1007/s004170050331
   Wang Z, 2006, PHOTOCHEM PHOTOBIOL, V82, P1251, DOI 10.1562/2006-04-01-RA-864
   Washington I, 2005, ANGEW CHEM INT EDIT, V44, P7097, DOI 10.1002/anie.200501346
   Washington I, 2007, PHOTOCH PHOTOBIO SCI, V6, P775, DOI 10.1039/b618104j
   Wielgus AR, 2010, PHOTOCH PHOTOBIO SCI, V9, P1505, DOI 10.1039/c0pp00133c
   Wu YL, 2010, P NATL ACAD SCI USA, V107, P7275, DOI 10.1073/pnas.0913112107
   Yoon KD, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041309
   Yoon KD, 2011, MOL VIS, V17, P1839
   YOUNG RW, 1987, SURV OPHTHALMOL, V31, P291, DOI 10.1016/0039-6257(87)90115-9
   Zhou JL, 2006, P NATL ACAD SCI USA, V103, P16182, DOI 10.1073/pnas.0604255103
NR 93
TC 12
Z9 13
U1 0
U2 11
PU COMPANY BIOLOGISTS LTD
PI CAMBRIDGE
PA BIDDER BUILDING, STATION RD, HISTON, CAMBRIDGE CB24 9LF, ENGLAND
SN 1754-8403
EI 1754-8411
J9 DIS MODEL MECH
JI Dis. Model. Mech.
PD FEB
PY 2015
VL 8
IS 2
BP 131
EP 138
DI 10.1242/dmm.017194
PG 8
WC Cell Biology; Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Pathology
GA CB0SL
UT WOS:000349337200003
PM 25504631
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Al-Shamekh, S
   Goldberg, JL
AF Al-Shamekh, Shomoukh
   Goldberg, Jeffrey L.
TI Retinal repair with induced pluripotent stem cells
SO TRANSLATIONAL RESEARCH
LA English
DT Review
ID IN-VITRO DIFFERENTIATION; GANGLION-LIKE CELLS; PIGMENT EPITHELIUM;
   DIRECTED DIFFERENTIATION; MACULAR DEGENERATION; PROGENITOR CELLS; VISUAL
   FUNCTION; MOUSE; GENERATION; TRANSPLANTATION
AB Retinal degeneration such as age-related macular degeneration and other inherited forms, such as Stargardt's disease and retinitis pigmentosa, and optic neuropathies including glaucoma and ischemic optic neuropathy are major causes of vision loss and blindness worldwide. Damage to retinal pigment epithelial cells and photoreceptors in the former, and to retinal ganglion cell axons in the optic nerve and their cell bodies in the retina in the latter diseases lead to the eventual death of these retinal cells, and in humans there is no endogenous replacement or repair. Cell replacement therapies provide 1 avenue to restore function in these diseases, particularly in the case of retinal repair, although there are considerable issues to overcome, including the differentiation and integration of the transplanted cells. What stem cell sources could be used for such therapies? One promising source is induced pluripotent stem cells (iPSCs), which could be drawn from an individual patient needing therapy, or generated and banked from select donors. We review developing research in the use of iPSCs for retinal cell replacement therapy.
C1 [Goldberg, Jeffrey L.] Univ Calif San Diego, Shiley Eye Ctr, La Jolla, CA 92093 USA.
   Univ Miami, Miller Sch Med, Bascom Palmer Eye Inst, Miami, FL 33136 USA.
   King Saud Univ, King Abdulaziz Univ Hosp, Dept Ophthalmol, Riyadh, Saudi Arabia.
C3 University of California System; University of California San Diego;
   Bascom Palmer Eye Institute; University of Miami; King Abdulaziz
   University; King Saud University; King Abdulaziz University Hospital -
   Riyadh
RP Goldberg, JL (通讯作者)，Univ Calif San Diego, Shiley Eye Ctr, 9415 Campus Point Dr 0946, La Jolla, CA 92093 USA.
EM jlgoldberg@ucsd.edu
OI Goldberg, Jeffrey/0000-0002-1390-7360
FU National Eye Institute [P30- EY022589]; Department of Ophthalmology King
   Saud University; Prevent Blindness, Inc.; NATIONAL EYE INSTITUTE
   [P30EY022589] Funding Source: NIH RePORTER
FX Conflicts of Interest: All authors have read the journal's policy on
   conflicts of interest and have none to declare. The authors' work was
   funded by the National Eye Institute (P30- EY022589 to Shiley Eye
   Center, University of California at San Diego), the Department of
   Ophthalmology King Saud University (S. Al-Shamekh), and an unrestricted
   grant from Research to Prevent Blindness, Inc.
CR Aoki H, 2006, EXP EYE RES, V82, P265, DOI 10.1016/j.exer.2005.06.021
   Aoki H, 2008, GRAEF ARCH CLIN EXP, V246, P255, DOI 10.1007/s00417-007-0710-6
   Banin E, 2006, STEM CELLS, V24, P246, DOI 10.1634/stemcells.2005-0009
   Barber AC, 2013, P NATL ACAD SCI USA, V110, P354, DOI 10.1073/pnas.1212677110
   Bhatia B, 2010, OPEN OPHTHALMOL J, V4, P30, DOI 10.2174/1874364101004010030
   Blenkinsop Timothy A, 2013, Methods Mol Biol, V945, P45, DOI 10.1007/978-1-62703-125-7_4
   Boucherie C, 2013, STEM CELLS, V31, P408, DOI 10.1002/stem.1268
   Brown NL, 2001, DEVELOPMENT, V128, P2497
   Buchholz DE, 2013, STEM CELL TRANSL MED, V2, P384, DOI 10.5966/sctm.2012-0163
   Buchholz DE, 2009, STEM CELLS, V27, P2427, DOI 10.1002/stem.189
   Carr AJ, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008152
   Chen MF, 2010, INVEST OPHTH VIS SCI, V51, P5970, DOI 10.1167/iovs.09-4504
   Cimadamore F, 2009, STEM CELLS, V27, P1772, DOI 10.1002/stem.107
   DELPRIORE LV, 1995, OPHTHALMOLOGY, V102, P1125, DOI 10.1016/S0161-6420(95)30903-7
   Dunaief JL, 2002, ARCH OPHTHALMOL-CHIC, V120, P1435, DOI 10.1001/archopht.120.11.1435
   Eiraku M, 2012, NAT PROTOC, V7, P69, DOI 10.1038/nprot.2011.429
   EISENFELD AJ, 1985, INVEST OPHTH VIS SCI, V26, P775
   Gamm DM, 2013, NAT BIOTECHNOL, V31, P712, DOI 10.1038/nbt.2648
   Gamm DM, 2010, REGEN MED, V5, P315, DOI 10.2217/RME.10.28
   Gehrs KM, 2006, ANN MED, V38, P450, DOI 10.1080/07853890600946724
   Gonzalez F, 2009, P NATL ACAD SCI USA, V106, P8918, DOI 10.1073/pnas.0901471106
   Gonzalez-Cordero A, 2013, NAT BIOTECHNOL, V31, P741, DOI 10.1038/nbt.2643
   Hambright D, 2012, MOL VIS, V18, P920
   Hertz J, 2013, NOVEL REGULATORY MEC
   Hertz J, 2013, CELL TRANSPLANT
   Hertz J, 2013, ACTA BIOMATER, V9, P7622, DOI 10.1016/j.actbio.2013.04.048
   Hirami Y, 2009, NEUROSCI LETT, V458, P126, DOI 10.1016/j.neulet.2009.04.035
   Hou PP, 2013, SCIENCE, V341, P651, DOI 10.1126/science.1239278
   Hu QR, 2010, STEM CELLS, V28, P1981, DOI 10.1002/stem.531
   Humayun MS, 2000, INVEST OPHTH VIS SCI, V41, P3100
   Idelson M, 2009, CELL STEM CELL, V5, P396, DOI 10.1016/j.stem.2009.07.002
   Jagatha B, 2009, BIOCHEM BIOPH RES CO, V380, P230, DOI 10.1016/j.bbrc.2009.01.038
   Jiang Y, 2013, J BIOL CHEM, V288, P18429, DOI 10.1074/jbc.M113.478503
   Jin ZB, 2012, STEM CELL TRANSL MED, V1, P503, DOI 10.5966/sctm.2012-0005
   Jin ZB, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017084
   Johnson TV, 2011, EXP EYE RES, V93, P196, DOI 10.1016/j.exer.2010.05.016
   Kador KE, 2013, BIOMATERIALS, V34, P4242, DOI 10.1016/j.biomaterials.2013.02.027
   Kayama M, 2010, OPHTHALMIC RES, V43, P79, DOI 10.1159/000247592
   Klassen H, 2006, EXPERT OPIN BIOL TH, V6, P443, DOI 10.1517/14712598.6.5.443
   Kokkinaki M, 2011, STEM CELLS, V29, P825, DOI 10.1002/stem.635
   Lamba DA, 2006, P NATL ACAD SCI USA, V103, P12769, DOI 10.1073/pnas.0601990103
   Lamba DA, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008763
   Lamba DA, 2009, CELL STEM CELL, V4, P73, DOI 10.1016/j.stem.2008.10.015
   Li XH, 2013, P NATL ACAD SCI USA, V110, pE2279, DOI 10.1073/pnas.1305987110
   Li YQ, 2011, CELL RES, V21, P196, DOI 10.1038/cr.2010.142
   Liao JL, 2010, HUM MOL GENET, V19, P4229, DOI 10.1093/hmg/ddq341
   Lu B, 2009, STEM CELLS, V27, P2126, DOI 10.1002/stem.149
   Lund RD, 2006, CLONING STEM CELLS, V8, P189, DOI 10.1089/clo.2006.8.189
   MacLaren RE, 2006, NATURE, V444, P203, DOI 10.1038/nature05161
   Marmorstein AD, 1998, ANN NY ACAD SCI, V857, P1, DOI 10.1111/j.1749-6632.1998.tb10102.x
   Maruotti J, 2013, STEM CELL TRANSL MED, V2, P341, DOI 10.5966/sctm.2012-0106
   Meir YJJ, 2013, FASEB J, V27, P4429, DOI 10.1096/fj.12-223586
   Merkl C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055170
   Meyer JS, 2011, STEM CELLS, V29, P1206, DOI 10.1002/stem.674
   Meyer JS, 2009, P NATL ACAD SCI USA, V106, P16698, DOI 10.1073/pnas.0905245106
   Okamoto S, 2011, INVEST OPHTH VIS SCI, V52, P8785, DOI 10.1167/iovs.11-8129
   Osakada F, 2008, NAT BIOTECHNOL, V26, P215, DOI 10.1038/nbt1384
   Osakada F, 2009, J CELL SCI, V122, P3169, DOI 10.1242/jcs.050393
   Osakada F, 2009, NAT PROTOC, V4, P811, DOI 10.1038/nprot.2009.51
   Parameswaran S, 2010, STEM CELLS, V28, P695, DOI 10.1002/stem.320
   Purves D, 2001, RETINA NEUROSCIENCE
   Radtke ND, 2002, AM J OPHTHALMOL, V133, P544, DOI 10.1016/S0002-9394(02)01322-3
   Radtke ND, 2008, AM J OPHTHALMOL, V146, P172, DOI 10.1016/j.ajo.2008.04.009
   Rowland TJ, 2013, J TISSUE ENG REGEN M, V7, P642, DOI 10.1002/term.1458
   Salero E, 2012, CELL STEM CELL, V10, P88, DOI 10.1016/j.stem.2011.11.018
   Schwartz SD, 2012, LANCET, V379, P713, DOI 10.1016/S0140-6736(12)60028-2
   Sridhar A, 2013, STEM CELL TRANSL MED, V2, P255, DOI 10.5966/sctm.2012-0101
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Subrizi A, 2012, BIOMATERIALS, V33, P8047, DOI 10.1016/j.biomaterials.2012.07.033
   Takahashi K, 2007, CELL, V131, P861, DOI 10.1016/j.cell.2007.11.019
   Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024
   Thomson JA, 1998, SCIENCE, V282, P1145, DOI 10.1126/science.282.5391.1145
   Tucker BA, 2013, STEM CELL TRANSL MED, V2, P16, DOI 10.5966/sctm.2012-0040
   Tucker BA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018992
   TURNER DL, 1987, NATURE, V328, P131, DOI 10.1038/328131a0
   Vugler A, 2008, EXP NEUROL, V214, P347, DOI 10.1016/j.expneurol.2008.09.007
   Wang NK, 2010, TRANSPLANTATION, V89, P911, DOI 10.1097/TP.0b013e3181d45a61
   West EL, 2012, STEM CELLS, V30, P1424, DOI 10.1002/stem.1123
   Young MJ, 2005, APMIS, V113, P845, DOI 10.1111/j.1600-0463.2005.apm_334.x
   Yu JY, 2007, SCIENCE, V318, P1917, DOI 10.1126/science.1151526
   Yu JY, 2009, SCIENCE, V324, P797, DOI 10.1126/science.1172482
   Zahabi A, 2012, STEM CELLS DEV, V21, P2262, DOI 10.1089/scd.2011.0599
NR 82
TC 28
Z9 29
U1 0
U2 37
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1931-5244
EI 1878-1810
J9 TRANSL RES
JI Transl. Res.
PD APR
PY 2014
VL 163
IS 4
BP 377
EP 386
DI 10.1016/j.trsl.2013.11.002
PG 10
WC Medical Laboratory Technology; Medicine, General & Internal; Medicine,
   Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Medical Laboratory Technology; General & Internal Medicine; Research &
   Experimental Medicine
GA AF3YL
UT WOS:000334648500011
PM 24291154
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Tetz, M
   Rizzo, S
   Augustin, AJ
AF Tetz, Manfred
   Rizzo, Stanislao
   Augustin, Albert J.
TI Safety of Submacular Suprachoroidal Drug Administration via a
   Microcatheter: Retrospective Analysis of European Treatment Results
SO OPHTHALMOLOGICA
LA English
DT Article
DE Drug administration, submacular suprachoroidal; Microcatheter;
   Age-related macular degeneration
ID OPEN-ANGLE GLAUCOMA; RETINA STUDY-GROUP; CIRCUMFERENTIAL VISCODILATION;
   INTRAVITREAL BEVACIZUMAB; FLEXIBLE MICROCATHETER; CANALOPLASTY;
   INJECTION; ADULTS; SPACE
AB Purpose: To investigate the safety and feasibility of using a microcatheter for drug delivery in the suprachoroidal space in eyes with advanced, exudative, age-related macular degeneration (AMD) unresponsive to conventional therapy.
   Procedures: A unique microcatheter was used to deliver a drug combination consisting of bevacizumab and triamcinolone to the submacular suprachoroidal space. Twenty-one eyes of 21 patients with choroidal neovascularization (CNV) secondary to advanced, exudative AMD were followed over a 6-month postprocedure period.
   Results: The microcatheter was successfully and atraumatically inserted into the suprachoroidal space of all eyes. No serious intraoperative or postoperative complications including suprachoroidal hemorrhages were encountered. Postsurgically, complications consisted of 1 eye experiencing a transient elevation in intraocular pressure at 3 months, which was medically controlled, and 2 eyes (10.5%) with an apparent increase in nuclear sclerotic cataracts.
   Conclusions: Suprachoroidal drug administration was achieved without serious complication using a novel microcatheter. Direct drug delivery to the choroid can potentially increase local tissue drug levels and drug efficacy for the treatment of AMD and other diseases associated with CNV. Copyright (C) 2012 S. Karger AG, Basel
C1 [Tetz, Manfred] Berlin Eye Res Inst, DE-10559 Berlin, Germany.
   [Augustin, Albert J.] Klinikum Karlsruhe, Karlsruhe, Germany.
   [Rizzo, Stanislao] Azienda Osped Univ Pisana, Pisa, Italy.
C3 Municipal Hospital Karlsruhe; University of Pisa; Azienda Ospedaliero
   Universitaria Pisana
RP Tetz, M (通讯作者)，Berlin Eye Res Inst, Alt Moabit 101 B, DE-10559 Berlin, Germany.
EM manfred.tetz@atk-spreebogen.de
OI RIZZO, Stanislao/0000-0001-6302-063X; Augustin, Prof. Dr. Albert
   J./0000-0003-1591-0536
FU iScience Interventional Corporation, Menlo Park, Calif., USA
FX The sponsor, iScience Interventional Corporation, Menlo Park, Calif.,
   USA, provided funding for the study.
CR Artunay O, 2009, EYE, V23, P2187, DOI 10.1038/eye.2009.7
   Azad Rajvardhan, 2007, Indian Journal of Ophthalmology, V55, P441
   Beer PM, 2003, OPHTHALMOLOGY, V110, P681, DOI 10.1016/S0161-6420(02)01969-3
   Bocco MCA, 2008, J FR OPHTALMOL, V31, P693
   Einmahl S, 2002, INVEST OPHTH VIS SCI, V43, P1533
   Guyer D.R., 2006, RETINA-J RET VIT DIS, Vfourth, P33
   HAWKINS BS, 1991, ARCH OPHTHALMOL-CHIC, V109, P1109
   Lewis RA, 2007, J CATARACT REFR SURG, V33, P1217, DOI 10.1016/j.jcrs.2007.03.051
   Lewis RA, 2011, J CATARACT REFR SURG, V37, P682, DOI 10.1016/j.jcrs.2010.10.055
   Lewis RA, 2009, J CATARACT REFR SURG, V35, P814, DOI 10.1016/j.jcrs.2009.01.010
   Lommatzsch AP, 2008, KLIN MONATSBL AUGENH, V225, P874, DOI 10.1055/s-2008-1027454
   Nigam N, 2008, BRIT J OPHTHALMOL, V92, P864
   Olsen TW, 2006, AM J OPHTHALMOL, V142, P777, DOI 10.1016/j.ajo.2006.05.045
   Wu L, 2008, GRAEF ARCH CLIN EXP, V246, P81, DOI 10.1007/s00417-007-0660-z
   Wu L, 2010, RETINA-J RET VIT DIS, V30, P1002, DOI 10.1097/IAE.0b013e3181cea68d
   Zhu Q, 2008, OPHTHALMOLOGY, V115, P1750, DOI 10.1016/j.ophtha.2008.04.023
NR 16
TC 29
Z9 34
U1 1
U2 5
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3755
J9 OPHTHALMOLOGICA
JI Ophthalmologica
PY 2012
VL 227
IS 4
BP 183
EP 189
DI 10.1159/000336045
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 934JO
UT WOS:000303440600002
PM 22354263
DA 2022-11-30
ER

PT J
AU Keating, AM
   Jacobs, DS
AF Keating, Anne M.
   Jacobs, Deborah S.
TI Anti-VEGF Treatment of Corneal Neovascularization
SO OCULAR SURFACE
LA English
DT Article
DE anti-VEGF agents; bevacizumab; corneal neovascularization; intravitreal
   injection; ranibizumab; subconjunctival injection; vascular endothelial
   growth factor (VEGF); VEGF inhibitors
ID ENDOTHELIAL GROWTH-FACTOR; SCLERAL CONTACT-LENS; SUBCONJUNCTIVAL
   BEVACIZUMAB; TOPICAL BEVACIZUMAB; MACULAR DEGENERATION; GRAFT FAILURE;
   SOLID TUMORS; THERAPY; ANGIOGENESIS; DISEASE
AB Vascular endothelial growth factor (VEGF) is an angiogenic factor shown to be a critical secreted cytokine in tumorigenesis and retinal neovascularization (NV). Currently, there are two anti-VEGF agents, pegaptanib and ranizumab, approved by the United States Food and Drug Administration (FDA) for intravitreal use in the treatment of wet age-related macular degeneration (AMD). Bevacizumab is FDA-approved for intravenous administration in the treatment of several cancers and is in widespread use, off-label, as an intravitreal injection to treat a variety of retinal pathologies. Animal studies demonstrate the role of VEGF in corneal NV. There are now a number of human case series reporting the use of anti-VEGF agents, primarily bevacizumab, to treat corneal NV. This review summarizes reports to date on the use of anti-VEGF agents in the treatment of corneal NV in humans, noting the limitations of current data and the need for further studies. The experience of one clinician with the use of an anti-VEGF drug in the treatment of active corneal NV is presented.
C1 [Jacobs, Deborah S.] Boston Fdn Sight, Needham, MA 02494 USA.
   [Keating, Anne M.] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Boston, MA USA.
C3 Harvard University; Harvard Medical School; Massachusetts Eye & Ear
   Infirmary
RP Jacobs, DS (通讯作者)，Boston Fdn Sight, 464 Hillside Ave,Suite 205, Needham, MA 02494 USA.
EM djacobs@bostonsight.org
OI Jacobs, Deborah/0000-0002-8587-1184
FU Boston Foundation for Sight
FX Financial Disclosures: None. Dr. Jacobs is a salaried, full-time
   employee of 501(c)3 Boston Foundation for Sight. Dr. Keating is employed
   by Essentia Health, Department of Ophthalmology, Fargo, ND. Neither
   author has any financial or proprietary interest in any contact lens or
   prosthetic device, or in any concept or product discussed in this
   article.
CR Adamis AP, 1996, ARCH OPHTHALMOL-CHIC, V114, P66, DOI 10.1001/archopht.1996.01100130062010
   Andreoli CM, 2007, CURR OPIN OPHTHALMOL, V18, P502, DOI 10.1097/ICU.0b013e3282f0ca54
   Awadein A, 2007, J CATARACT REFR SURG, V33, P1991, DOI 10.1016/j.jcrs.2007.07.012
   Bachmann B, 2010, OPHTHALMOLOGY, V117, P1300, DOI 10.1016/j.ophtha.2010.01.039
   Bahar I, 2008, CORNEA, V27, P142, DOI 10.1097/ICO.0b013e318159019f
   BenEzra D, 1997, INVEST OPHTH VIS SCI, V38, P1954
   Benjamin LE, 1998, DEVELOPMENT, V125, P1591
   Bock F, 2008, GRAEF ARCH CLIN EXP, V246, P281, DOI 10.1007/s00417-007-0684-4
   Bock F, 2009, INVEST OPHTH VIS SCI, V50, P2095, DOI 10.1167/iovs.07-1129
   BOISJOLY HM, 1993, OPHTHALMOLOGY, V100, P1728
   Carrasco MA, 2008, CORNEA, V27, P743, DOI 10.1097/QAI.0b013e31815b833a
   Chang JH, 2001, CURR OPIN OPHTHALMOL, V12, P242, DOI 10.1097/00055735-200108000-00002
   Ciulla TA, 2009, CURR OPIN OPHTHALMOL, V20, P158, DOI 10.1097/ICU.0b013e32832d25b3
   Cursiefen C, 2000, CORNEA, V19, P526, DOI 10.1097/00003226-200007000-00025
   Cursiefen C, 2006, P NATL ACAD SCI USA, V103, P11405, DOI 10.1073/pnas.0506112103
   Dastjerdi MH, 2010, INVEST OPHTH VIS SCI, V51, P2411, DOI 10.1167/iovs.09-3745
   Dastjerdi MH, 2009, ARCH OPHTHALMOL-CHIC, V127, P381, DOI 10.1001/archophthalmol.2009.18
   DeStafeno JJ, 2007, ARCH OPHTHALMOL-CHIC, V125, P834, DOI 10.1001/archopht.125.6.834
   Doctor PP, 2008, CORNEA, V27, P992, DOI 10.1097/ICO.0b013e31817786ad
   Erdurmus M, 2007, GRAEF ARCH CLIN EXP, V245, P1577, DOI 10.1007/s00417-007-0587-4
   Flach Allan J, 2008, Trans Am Ophthalmol Soc, V106, P138
   Folkman J, 2003, CURR MOL MED, V3, P643, DOI 10.2174/1566524033479465
   Galor Anat, 2010, Ophthalmic Surg Lasers Imaging, P1, DOI 10.3928/15428877-20100215-07
   Harooni H, 2007, OPHTHALMOLOGY, V114, P1950, DOI 10.1016/j.ophtha.2007.05.016
   Hosny MH, 2009, J OCUL PHARMACOL TH, V25, P513, DOI 10.1089/jop.2009.0056
   Jacobs DS, 2007, CORNEA, V26, P1195, DOI 10.1097/ICO.0b013e318155743d
   Jacobs DS, 2009, OPHTHALMOLOGY, V116, P592, DOI 10.1016/j.ophtha.2008.10.011
   Kerbel R, 2002, NAT REV CANCER, V2, P727, DOI 10.1038/nrc905
   KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0
   Kim Sang Woo, 2008, Ophthalmology, V115, pe33, DOI 10.1016/j.ophtha.2008.02.013
   Lee P, 1998, SURV OPHTHALMOL, V43, P245, DOI 10.1016/S0039-6257(98)00035-6
   Lim M, 2009, SEMIN OPHTHALMOL, V24, P149, DOI 10.1080/08820530902802013
   Lu JF, 2008, CANCER CHEMOTH PHARM, V62, P779, DOI 10.1007/s00280-007-0664-8
   Mandalos A, 2010, CORNEA, V29, P1373, DOI 10.1097/ICO.0b013e3181d927b9
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Oh JY, 2009, CORNEA, V28, P1070, DOI 10.1097/ICO.0b013e31819839f9
   Oliveira HB, 2010, EUR J OPHTHALMOL, V20, P48, DOI 10.1177/112067211002000106
   Philipp W, 2000, INVEST OPHTH VIS SCI, V41, P2514
   Piltonen M, 2011, NEUROSCIENCE    0714
   Presta LG, 1997, CANCER RES, V57, P4593
   Romero-Rangel T, 2000, AM J OPHTHALMOL, V130, P25, DOI 10.1016/S0002-9394(00)00378-0
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
   SCHEIN OD, 1990, AM J OPHTHALMOL, V109, P318, DOI 10.1016/S0002-9394(14)74558-1
   Schucker C, 2011, BR J OPHTHALMOL, V95, P308
   Shalam KV, 2009, CORNEA, V28, P328, DOI 10.1097/ICO.0b013e31818b8be0
   Stason WB, 2010, AM J OPHTHALMOL, V149, P54, DOI 10.1016/j.ajo.2009.07.037
   Symes RJ, 2010, CORNEA, V29, P691, DOI 10.1097/ICO.0b013e3181ba0ae2
   Uy HS, 2008, CORNEA, V27, P70, DOI 10.1097/ICO.0b013e318158f6ad
NR 48
TC 45
Z9 48
U1 1
U2 11
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1542-0124
EI 1937-5913
J9 OCUL SURF
JI Ocul. Surf.
PD OCT
PY 2011
VL 9
IS 4
BP 227
EP 238
DI 10.1016/S1542-0124(11)70035-0
PG 12
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 841CF
UT WOS:000296489200005
PM 22023817
DA 2022-11-30
ER

PT J
AU Chen, JQ
   Sun, JR
   Hu, YF
   Wan, XL
   Wang, YW
   Gao, M
   Liang, J
   Liu, T
   Sun, XD
AF Chen, Jieqiong
   Sun, Junran
   Hu, Yifan
   Wan, Xiaoling
   Wang, Yuwei
   Gao, Min
   Liang, Jian
   Liu, Te
   Sun, Xiaodong
TI MicroRNA-191-5p ameliorates amyloid-beta(1-40)-mediated retinal pigment
   epithelium cell injury by suppressing the NLRP3 inflammasome pathway
SO FASEB JOURNAL
LA English
DT Article
DE A beta; C/EBP beta; miR-191-5P; NLRP3; retinal pigment epithelium
AB Amyloid beta (A beta) is a crucial component of drusen, the hallmark of the early stage of age-related macular degeneration (AMD), and can cause retinal pigment epithelium (RPE) cell damage through activation of the inflammatory response. MicroRNAs play a critical role in inflammation. However, the mechanism underlying the effect of microRNAs on the NLRP3 inflammasome induced by A beta remains poorly understood. In the present study, we demonstrated that A beta(1-)(40) -mediated RPE damage by inducing a decrease in endogenous miR-191-5p expression. This led to the upregulation of its target gene, C/EBP beta, C/EBP beta acts as a transcription factor for NLRP3, promotes its transcription, and upregulates the downstream inflammatory factors Caspase-1 and IL-1 beta. Correspondingly, overexpression of miR-191-5p alleviated RPE cell injury by suppressing inflammation. The present study elucidates a novel transcriptional regulatory mechanism of the NLRP3 inflammasome. Our findings suggest an anti-inflammatory effect of miR-191-5p in A beta(1-40)-induced RPE impairment, shedding light on novel preventive or therapeutic approaches for AMD-associated RPE impairment.
C1 [Chen, Jieqiong; Sun, Junran; Hu, Yifan; Wan, Xiaoling; Wang, Yuwei; Gao, Min; Liang, Jian; Sun, Xiaodong] Shanghai Gen Hosp, Dept Ophthalmol,Shanghai Engn Ctr Precise Diag &, Shanghai First Peoples Hosp,Shanghai Engn Ctr Vis, Natl Clin Res Ctr Eye Dis,Shanghai Key Lab Ocular, Shanghai, Peoples R China.
   [Chen, Jieqiong; Hu, Yifan; Wang, Yuwei; Gao, Min; Sun, Xiaodong] Shanghai Jiao Tong Univ, Sch Med, Shanghai, Peoples R China.
   [Liu, Te] Shanghai Univ Tradit Chinese Med, Shanghai Geriatr Inst Chinese Med, 365 South Xiangyang Rd, Shanghai 200031, Peoples R China.
C3 Shanghai Jiao Tong University; Shanghai University of Traditional
   Chinese Medicine
RP Liu, T (通讯作者)，Shanghai Univ Tradit Chinese Med, Shanghai Geriatr Inst Chinese Med, 365 South Xiangyang Rd, Shanghai 200031, Peoples R China.; Sun, XD (通讯作者)，Shanghai Gen Hosp, Natl Clin Res Ctr Eye Dis, Shanghai Key Lab Ocular Fundus Dis, Shanghai Engn Ctr Visual Sci & Photomed,Shanghai, 100 Haining Rd, Shanghai 200080, Peoples R China.
EM 0721160004@mail.tongji.edu.cn; xdsun@sjtu.edu.cn
FU National Natural Science Foundation of China [81730026, 81700843];
   National Key RD Program [2017YFA0105301]; Science and Technology
   Commission of Shanghai Municipality [17411953000]; Shanghai Sailing
   Program [19YF1439600, 19YF1439200, BJ-LM2018001J]; National Key R&D
   Program of China [2016YFC0904800, 2019YFC0840607]; National Science and
   Technology Major Project of China [2017ZX09304010]
FX National Natural Science Foundation of China, Grant/Award Number:
   81730026 and 81700843; National Key R&D Program, Grant/Award Number:
   2017YFA0105301; Science and Technology Commission of Shanghai
   Municipality, Grant/Award Number: 17411953000; Shanghai Sailing Program,
   Grant/Award Number: 19YF1439600 and 19YF1439200; Bethune-Langmu,
   Grant/Award Number: BJ-LM2018001J; National Key R&D Program of China,
   Grant/Award Number: 2016YFC0904800 and 2019YFC0840607; National Science
   and Technology Major Project of China, Grant/Award Number:
   2017ZX09304010
CR Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   Calvente CJ, 2019, J CLIN INVEST, V129, P4091, DOI 10.1172/JCI122258
   Chen J, 2018, J GENE MED, V20, DOI 10.1002/jgm.3014
   Chen M, 2008, INVEST OPHTH VIS SCI, V49, P3699, DOI 10.1167/iovs.07-1522
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Cunningham C, 2013, GLIA, V61, P71, DOI 10.1002/glia.22350
   Doyle SL, 2012, NAT MED, V18, P791, DOI 10.1038/nm.2717
   Foster A, 2005, EYE, V19, P1133, DOI 10.1038/sj.eye.6701973
   Friedman RC, 2009, GENOME RES, V19, P92, DOI 10.1101/gr.082701.108
   Gao JY, 2018, J NEUROINFLAMM, V15, DOI 10.1186/s12974-018-1062-3
   Ge QM, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0173292
   Gilam A, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12868
   Glass CK, 2010, CELL, V140, P918, DOI 10.1016/j.cell.2010.02.016
   Guduric-Fuchs J, 2012, J CELL BIOCHEM, V113, P2098, DOI 10.1002/jcb.24084
   Gurung P, 2014, J IMMUNOL, V192, P1835, DOI 10.4049/jimmunol.1302839
   Ha YJ, 2016, EXP MOL MED, V48, DOI 10.1038/emm.2016.47
   Hong Y, 2019, INT IMMUNOPHARMACOL, V74, DOI 10.1016/j.intimp.2019.05.054
   HOOD DC, 1990, INVEST OPHTH VIS SCI, V31, P2070
   Huang PR, 2017, INVEST OPHTH VIS SCI, V58, P1726, DOI 10.1167/iovs.16-20043
   Isas JM, 2010, INVEST OPHTH VIS SCI, V51, P1304, DOI 10.1167/iovs.09-4207
   Ji SY, 2014, BIOCHEM BIOPH RES CO, V451, P329, DOI 10.1016/j.bbrc.2014.07.130
   Johnson LV, 2002, P NATL ACAD SCI USA, V99, P11830, DOI 10.1073/pnas.192203399
   Judge AD, 2005, NAT BIOTECHNOL, V23, P457, DOI 10.1038/nbt1081
   Karali M, 2016, NUCLEIC ACIDS RES, V44, P1525, DOI 10.1093/nar/gkw039
   Kauppinen A, 2016, CELL MOL LIFE SCI, V73, P1765, DOI 10.1007/s00018-016-2147-8
   Kauppinen A, 2012, IMMUNOL LETT, V147, P29, DOI 10.1016/j.imlet.2012.05.005
   Kutty RK, 2010, MOL VIS, V16, P1475
   La Rosa F, 2019, J ALZHEIMERS DIS, V72, P401, DOI 10.3233/JAD-181259
   Lei CY, 2017, NEUROSCIENCE, V360, P48, DOI 10.1016/j.neuroscience.2017.07.053
   Li FL, 2019, EXP THER MED, V18, P1175, DOI 10.3892/etm.2019.7668
   Liu JD, 2008, CURR OPIN CELL BIOL, V20, P214, DOI 10.1016/j.ceb.2008.01.006
   Liu RT, 2013, INVEST OPHTH VIS SCI, V54, P2225, DOI 10.1167/iovs.12-10849
   Luciunaite A, 2020, J NEUROCHEM, V155, P650, DOI 10.1111/jnc.14945
   McCulloch DL, 2019, DOC OPHTHALMOL, V138, P205, DOI 10.1007/s10633-019-09685-8
   Morquette B, 2019, BRAIN, V142, P2979, DOI 10.1093/brain/awz245
   Nagpal N, 2014, FRONT GENET, V5, DOI 10.3389/fgene.2014.00099
   Nakanishi A, 2018, INFLAMM REGEN, V38, DOI 10.1186/s41232-018-0085-6
   O'Connell RM, 2010, NAT REV IMMUNOL, V10, P111, DOI 10.1038/nri2708
   Pecot CV, 2011, NAT REV CANCER, V11, P59, DOI 10.1038/nrc2966
   Pulido-Salgado M, 2015, PROG NEUROBIOL, V132, P1, DOI 10.1016/j.pneurobio.2015.06.003
   Rahman SM, 2012, J BIOL CHEM, V287, P34349, DOI 10.1074/jbc.M112.410613
   Saba R, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003652
   Samuels IS, 2015, J NEUROPHYSIOL, V113, P1085, DOI 10.1152/jn.00761.2014
   Shang P, 2018, JOVE-J VIS EXP, DOI 10.3791/56997
   Sun JR, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.502
   Tarallo V, 2012, CELL, V149, P847, DOI 10.1016/j.cell.2012.03.036
   Tejera D, 2019, EMBO J, V38, DOI 10.15252/embj.2018101064
   Teodori L, 2019, MECH AGEING DEV, V182, DOI 10.1016/j.mad.2019.111127
   Tseng WA, 2013, INVEST OPHTH VIS SCI, V54, P110, DOI 10.1167/iovs.12-10655
   Vistbakka J, 2018, ACTA NEUROL SCAND, V138, P130, DOI 10.1111/ane.12921
   Wang K, 2017, EXP CELL RES, V357, P335, DOI 10.1016/j.yexcr.2017.05.030
   Wang K, 2017, J BIOCHEM MOL TOXIC, V31, DOI 10.1002/jbt.21887
   Wilkins HM, 2017, BRAIN RES BULL, V133, P71, DOI 10.1016/j.brainresbull.2016.08.009
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wu JH, 2012, OPHTHALMIC RES, V47, P195, DOI 10.1159/000331992
   Yang HY, 2016, IMMUNITY, V45, P83, DOI 10.1016/j.immuni.2016.06.022
   Yu SS, 2019, ARTHRITIS RES THER, V21, DOI 10.1186/s13075-019-1861-7
   Zampetaki A, 2010, CIRC RES, V107, P810, DOI 10.1161/CIRCRESAHA.110.226357
   Zhang XF, 2015, ONCOTARGET, V6, P4144, DOI 10.18632/oncotarget.2864
   Zhao T, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0337-1
NR 60
TC 5
Z9 5
U1 0
U2 3
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0892-6638
EI 1530-6860
J9 FASEB J
JI Faseb J.
PD APR
PY 2021
VL 35
IS 4
AR e21184
DI 10.1096/fj.202000645RR
PG 16
WC Biochemistry & Molecular Biology; Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
   Topics; Cell Biology
GA RG0GY
UT WOS:000635216100086
PM 33715208
DA 2022-11-30
ER

PT J
AU Badar, M
   Haris, M
   Fatima, A
AF Badar, Maryam
   Haris, Muhammad
   Fatima, Anam
TI Application of deep learning for retinal image analysis: A review
SO COMPUTER SCIENCE REVIEW
LA English
DT Review
DE Deep learning; Deep neural network; Convolutional neural network;
   Auto-encoder; Sparse stacked auto-encoder; De-noised sparse
   auto-encoder; Softmax; Random forest; Rectified linear unit; Hidden
   layers
ID BLOOD-VESSEL SEGMENTATION; DIABETIC-RETINOPATHY; NEURAL-NETWORKS;
   FEATURES; PROGRESS; LESIONS
AB Retinal image analysis holds an imperative position for the identification and classification of retinal diseases such as Diabetic Retinopathy (DR), Age Related Macular Degeneration (AMD), Macular Bunker, Retinoblastoma, Retinal Detachment, and Retinitis Pigmentosa. Automated identification of retinal diseases is a big step towards early diagnosis and prevention of exacerbation of the disease. A number of state-of-the-art methods have been developed in the past that helped in the automatic segmentation and identification of retinal landmarks and pathologies. However, the current unprecedented advancements in deep learning and modern imaging modalities in ophthalmology have opened a whole new arena for researchers. This paper is a review of deep learning techniques applied to 2-D fundus and 3-D Optical Coherence Tomography (OCT) retinal images for automated classification of retinal landmarks, pathology, and disease classification. The methodologies are analyzed in terms of sensitivity, specificity, Area under ROC curve, accuracy, and F score on publicly available datasets which includes DRIVE, STARE, CHASE_DB1, DRiDB, NIH AREDS, ARIA, MESSIDOR-2, E-OPTHA, EyePACS-1 DIARETDB and OCT image datasets. (C) 2019 Elsevier Inc. All rights reserved.
C1 [Badar, Maryam; Haris, Muhammad] Natl Univ Sci & Technol, Sch Elect Engn & Comp Sci, Islamabad, Pakistan.
   [Fatima, Anam] Univ Engn & Technol, Lahore, Pakistan.
C3 National University of Sciences & Technology - Pakistan; University of
   Engineering & Technology Lahore
RP Haris, M (通讯作者)，Natl Univ Sci & Technol, Sch Elect Engn & Comp Sci, Islamabad, Pakistan.
EM mharis.msit15seecs@seecs.edu.pk
OI Haris, Muhammad/0000-0002-5071-1658
CR Abbasi-Sureshjani S, 2017, LECT NOTES COMPUT SC, V10554, P210, DOI 10.1007/978-3-319-67561-9_24
   Abramoff Michael D, 2010, IEEE Rev Biomed Eng, V3, P169, DOI 10.1109/RBME.2010.2084567
   Abramoff MD, 2016, INVEST OPHTH VIS SCI, V57, P5200, DOI 10.1167/iovs.16-19964
   ALBERT DM, 1973, AM J OPHTHALMOL, V76, P494, DOI 10.1016/0002-9394(73)90737-X
   Angelov P, 2016, P 24 EUR S ART NEUR
   [Anonymous], INT S MED DAT AN
   [Anonymous], ANN C MED IM UND AN
   [Anonymous], SPIE MED IM
   [Anonymous], MED IM UND AN
   [Anonymous], IM SIGN PROC AN ISPA
   [Anonymous], 2006, MACHINE VISION PATTE
   [Anonymous], ENG MED BIOL SOC EMB
   [Anonymous], EUR C BIOM OPT
   [Anonymous], CONN HLTH APPL SYST
   [Anonymous], J OPHTHALMIC PHOTOGR
   [Anonymous], 2016, ADAPT COMPUT MACH LE, DOI DOI 10.5555/3086952HTTPS://WWW.DEEPLEARNINGBOOK.ORG
   [Anonymous], COMP INT DES ISCID 2
   [Anonymous], ADV NEUR INF PROC SY
   [Anonymous], 2006, AGE RELATED MACULAR
   [Anonymous], 2013 8 INT S IM SIGN
   [Anonymous], 1998, INT C MED IM COMP CO
   [Anonymous], 2016, INT C MED IM COMP CO
   [Anonymous], INT SYST BRACIS 2015
   [Anonymous], ENG MED BIOL SOC EMB
   [Anonymous], COMPUT BIOL MED
   [Anonymous], BIOM IM ISBI 2017 20
   [Anonymous], J COMPUT SCI
   [Anonymous], ANN C MED IM UND AN
   [Anonymous], 2016, INT C MED IM COMP CO
   [Anonymous], IM SIGN PROC CISP 20
   Arunkumar R, 2017, NEURAL COMPUT APPL, V28, P329, DOI 10.1007/s00521-015-2059-9
   Badrinarayanan V, 2017, IEEE T PATTERN ANAL, V39, P2481, DOI 10.1109/TPAMI.2016.2644615
   Beagley J, 2014, DIABETES RES CLIN PR, V103, P150, DOI 10.1016/j.diabres.2013.11.001
   Bennett TJ, 2009, CLIN EXP OPHTHALMOL, V37, P2, DOI 10.1111/j.1442-9071.2008.01812.x
   Burlina P, 2016, I S BIOMED IMAGING, P184, DOI 10.1109/ISBI.2016.7493240
   Burlina P, 2017, COMPUT BIOL MED, V82, P80, DOI 10.1016/j.compbiomed.2017.01.018
   Choi JY, 2017, PLOS ONE, V12, DOI [10.1371/journal.pone.0187338, 10.1371/journal.pone.0187336]
   Colas E., 2016, ACTA OPHTHALMOL, V94
   Costa P, 2017, PROCEEDINGS OF THE FIFTEENTH IAPR INTERNATIONAL CONFERENCE ON MACHINE VISION APPLICATIONS - MVA2017, P165, DOI 10.23919/MVA.2017.7986827
   Decenciere E, 2014, IMAGE ANAL STEREOL, V33, P231, DOI 10.5566/ias.1155
   Drexler W, 2008, BIOL MED PHYS BIOMED, P1, DOI 10.1007/978-3-540-77550-8
   ENGERMAN RL, 1989, DIABETES, V38, P1203, DOI 10.2337/diabetes.38.10.1203
   Fraz MM, 2012, COMPUT METH PROG BIO, V108, P407, DOI 10.1016/j.cmpb.2012.03.009
   Fraz MM, 2012, IEEE T BIO-MED ENG, V59, P2538, DOI 10.1109/TBME.2012.2205687
   Gargeya R, 2017, OPHTHALMOLOGY, V124, P962, DOI 10.1016/j.ophtha.2017.02.008
   Glorot X., 2010, J MACH LEARN RES, V9, P249, DOI DOI 10.1109/CVPR.2016.90
   Gulshan V, 2016, JAMA-J AM MED ASSOC, V316, P2402, DOI 10.1001/jama.2016.17216
   Hirohara Y, 2007, OPT REV, V14, P151, DOI 10.1007/BF02919416
   Hoover A, 2000, IEEE T MED IMAGING, V19, P203, DOI 10.1109/42.845178
   Hsu F, 2002, DEEP BLUE BUILDING C
   HUANG D, 1991, SCIENCE, V254, P1178, DOI 10.1126/science.1957169
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Kanagasingam Y, 2014, PROG RETIN EYE RES, V38, P20, DOI 10.1016/j.preteyeres.2013.10.002
   Kanski J.J., 2011, CLIN OPHTHALMOLOGY S, V7th
   Klein R, 2009, OPHTHALMOLOGY, V116, P497, DOI 10.1016/j.ophtha.2008.10.016
   Kowluru RA, 2008, CONTEMP DIABETES, P265, DOI 10.1007/978-1-59745-563-3_11
   Lam C, 2018, INVEST OPHTH VIS SCI, V59, P590, DOI 10.1167/iovs.17-22721
   LeCun Y., 2015, NATURE, V521, P436, DOI DOI 10.1038/NATURE14539
   Lee CS, 2017, OPHTHALMOL RETINA, V1, P322, DOI 10.1016/j.oret.2016.12.009
   Li QL, 2016, IEEE T MED IMAGING, V35, P109, DOI 10.1109/TMI.2015.2457891
   Liew G, 2011, REV ESP CARDIOL, V64, P515, DOI [10.1016/j.recesp.2011.02.014, 10.1016/j.rec.2011.02.017]
   Liskowski P, 2016, IEEE T MED IMAGING, V35, P2369, DOI 10.1109/TMI.2016.2546227
   Marin D, 2011, IEEE T MED IMAGING, V30, P146, DOI 10.1109/TMI.2010.2064333
   Melinscak M., 2015, VISAPP 2015 10 INT C
   NESTEROV IE, 1983, DOKL AKAD NAUK SSSR+, V269, P543
   Ng EYK, 2014, OPHTHALMOLOGICAL IMAGING AND APPLICATIONS, pV
   Niemeijer M, 2004, METHODS EVALUATING S
   Otalora S, 2017, LECT NOTES COMPUT SC, V10552, P146, DOI 10.1007/978-3-319-67534-3_16
   Patton N, 2006, PROG RETIN EYE RES, V25, P99, DOI 10.1016/j.preteyeres.2005.07.001
   Pratt H, 2016, PROCEDIA COMPUT SCI, V90, P200, DOI 10.1016/j.procs.2016.07.014
   Prentasic P, 2016, COMPUT METH PROG BIO, V137, P281, DOI 10.1016/j.cmpb.2016.09.018
   Quellec G, 2008, IEEE T MED IMAGING, V27, P1230, DOI 10.1109/TMI.2008.920619
   Quigley HA, 2006, BRIT J OPHTHALMOL, V90, P262, DOI 10.1136/bjo.2005.081224
   Raman V., 2016, COMM SOFTW NETW ICCS
   Roorda A, 2002, OPT EXPRESS, V10, P405, DOI 10.1364/OE.10.000405
   Sidibe D, 2015, COMPUT BIOL MED, V62, P175, DOI 10.1016/j.compbiomed.2015.04.026
   Sivaswamy J, 2014, I S BIOMED IMAGING, P53, DOI 10.1109/ISBI.2014.6867807
   Slakter J S, 1995, Curr Opin Ophthalmol, V6, P25
   Sopharak A, 2008, COMPUT MED IMAG GRAP, V32, P720, DOI 10.1016/j.compmedimag.2008.08.009
   Szegedy C, 2016, PROC CVPR IEEE, P2818, DOI 10.1109/CVPR.2016.308
   Tan JH, 2017, INFORM SCIENCES, V420, P66, DOI 10.1016/j.ins.2017.08.050
   Thomas Ravi, 2006, Community Eye Health, V19, P36
   Torczynski E., 1982, OCULAR ANATOMY EMBRY
   Varma R, 2014, JAMA OPHTHALMOL, V132, P1334, DOI 10.1001/jamaophthalmol.2014.2854
   Venkatesh P, 2015, INT OPHTHALMOL, V35, P635, DOI 10.1007/s10792-012-9620-7
   Walter T, 2002, IEEE T MED IMAGING, V21, P1236, DOI 10.1109/TMI.2002.806290
   Wang SL, 2015, NEUROCOMPUTING, V149, P708, DOI 10.1016/j.neucom.2014.07.059
   WEBB RH, 1981, IEEE T BIO-MED ENG, V28, P488, DOI 10.1109/TBME.1981.324734
   Worrall DE, 2016, LECT NOTES COMPUT SC, V10008, P68, DOI 10.1007/978-3-319-46976-8_8
   Xie SN, 2015, IEEE I CONF COMP VIS, P1395, DOI 10.1109/ICCV.2015.164
   Zilly J, 2017, COMPUT MED IMAG GRAP, V55, P28, DOI 10.1016/j.compmedimag.2016.07.012
NR 91
TC 51
Z9 51
U1 8
U2 40
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1574-0137
EI 1876-7745
J9 COMPUT SCI REV
JI Comput. Sci. Rev.
PD FEB
PY 2020
VL 35
AR 100203
DI 10.1016/j.cosrev.2019.100203
PG 18
WC Computer Science, Information Systems; Computer Science, Software
   Engineering; Computer Science, Theory & Methods
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Computer Science
GA KN4OL
UT WOS:000514817900001
DA 2022-11-30
ER

PT J
AU Lee, S
   Kim, S
   Fuchsberger, C
AF Lee, Seunggeun
   Kim, Sehee
   Fuchsberger, Christian
TI Improving power for rare-variant tests by integrating external controls
SO GENETIC EPIDEMIOLOGY
LA English
DT Article
DE Rare-variant test; external controls; next-generation sequencing
ID KERNEL MACHINE REGRESSION; PHENOTYPE ASSOCIATION; LINEAR-MODELS; GENE
   LEVEL; TRAITS; EQUIVALENCE
AB Due to the drop in sequencing cost, the number of sequenced genomes is increasing rapidly. To improve power of rare-variant tests, these sequenced samples could be used as external control samples in addition to control samples from the study itself. However, when using external controls, possible batch effects due to the use of different sequencing platforms or genotype calling pipelines can dramatically increase type I error rates. To address this, we propose novel summary statistics based single and gene-or region-based rare-variant tests that allow the integration of external controls while controlling for type I error. Our approach is based on the insight that batch effects on a given variant can be assessed by comparing odds ratio estimates using internal controls only vs. using combined control samples of internal and external controls. From simulation experiments and the analysis of data from age-related macular degeneration and type 2 diabetes studies, we demonstrate that our method can substantially improve power while controlling for type I error rate.
C1 [Lee, Seunggeun; Kim, Sehee; Fuchsberger, Christian] Univ Michigan, Dept Biostat, Ann Arbor, MI 48109 USA.
   [Lee, Seunggeun; Fuchsberger, Christian] Univ Michigan, Ctr Stat Genet, Ann Arbor, MI 48109 USA.
   [Fuchsberger, Christian] Univ Lubeck, European Acad Bolzano Bozen, Ctr Biomed, Bolzano, Italy.
C3 University of Michigan System; University of Michigan; University of
   Michigan System; University of Michigan; European Academy of
   Bozen-Bolzano
RP Lee, S (通讯作者)，M4148 SPH 2,1415 Washington Hts, Ann Arbor, MI 48109 USA.
EM leeshawn@umich.edu
RI Fuchsberger, Christian/ABD-7127-2021
OI Fuchsberger, Christian/0000-0002-5918-8947
FU Austrian Science Fund (FWF) [J-3401];  [R01 HG008773]; NATIONAL HUMAN
   GENOME RESEARCH INSTITUTE [R01HG008773] Funding Source: NIH RePORTER
FX This work was supported by grants R01 HG008773 (S.L.) and the Austrian
   Science Fund (FWF) grant J-3401 (C.F.). We would like to thank
   investigators of GoT2D project for access to the whole exome sequence
   data, and Dr. Goncalo Abecasis for access to the ESP data. The dataset
   used for the AMD analysis described in this manuscript were obtained
   from the NEI Study of Age-Related Macular Degeneration (NEI-AMD).
   Database found at https://dbgap.ncbi.nlm.nih.gov through dbGaP accession
   number [phs000684.v1.p1].
CR Colantuoni C, 2011, NATURE, V478, P519, DOI 10.1038/nature10524
   ESCOUFIER Y, 1973, BIOMETRICS, V29, P751, DOI 10.2307/2529140
   Escoufier Y, 1970, ECHANTILLONNAGE POPU
   Fan R, 2016, GENET EPIDEMIOL, V40, P702, DOI 10.1002/gepi.21984
   He ZH, 2015, BIOMETRICS, V71, P606, DOI 10.1111/biom.12310
   Hua WY, 2015, BIOMETRICS, V71, P812, DOI 10.1111/biom.12314
   Josse J., 2014, MEASURES DEPENDENCE
   Kanehisa M, 2016, NUCLEIC ACIDS RES, V44, pD457, DOI 10.1093/nar/gkv1070
   Kim JH, 2016, GENETICS, V203, P715, DOI 10.1534/genetics.115.186502
   LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.1093/biomet/73.1.13
   Maity A, 2012, GENET EPIDEMIOL, V36, P686, DOI 10.1002/gepi.21663
   MANTEL N, 1967, CANCER RES, V27, P209
   Minas C, 2013, BIOINFORMATICS, V29, P2555, DOI 10.1093/bioinformatics/btt450
   Sejdinovic D, 2013, ANN STAT, V41, P2263, DOI 10.1214/13-AOS1140
   Spearman C, 1904, AM J PSYCHOL, V15, P72, DOI 10.2307/1412159
   Szekely GJ, 2007, ANN STAT, V35, P2769, DOI 10.1214/009053607000000505
   Wang XF, 2013, GENET EPIDEMIOL, V37, P778, DOI 10.1002/gepi.21763
   Wang YF, 2015, GENET EPIDEMIOL, V39, P259, DOI 10.1002/gepi.21895
   Wang Z, 2017, GENET EPIDEMIOL, V41, P81, DOI 10.1002/gepi.22016
   Xu GJ, 2016, BIOMETRIKA, V103, P609, DOI 10.1093/biomet/asw029
NR 20
TC 9
Z9 9
U1 0
U2 3
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0741-0395
EI 1098-2272
J9 GENET EPIDEMIOL
JI Genet. Epidemiol.
PD NOV
PY 2017
VL 41
IS 7
BP 610
EP 619
DI 10.1002/gepi.22057
PG 10
WC Genetics & Heredity; Mathematical & Computational Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity; Mathematical & Computational Biology
GA FJ8QZ
UT WOS:000413035000004
PM 28657150
OA Green Accepted, Green Published, Green Submitted
DA 2022-11-30
ER

PT J
AU Liu, CH
   Wang, ZX
   Sun, Y
   Chen, J
AF Liu, Chi-Hsiu
   Wang, Zhongxiao
   Sun, Ye
   Chen, Jing
TI Animal models of ocular angiogenesis: from development to pathologies
SO FASEB JOURNAL
LA English
DT Review
DE choroidal neovascularization; corneal angiogenesis; macular
   degeneration; retinal vasculature; retinopathy
ID ENDOTHELIAL GROWTH-FACTOR; DENSITY-LIPOPROTEIN RECEPTOR; RETINAL
   VASCULAR DEVELOPMENT; OXYGEN-INDUCED RETINOPATHY; EXPERIMENTAL CHOROIDAL
   NEOVASCULARIZATION; TISSUE-SPECIFIC EXPRESSION; MOUSE MODEL; MACULAR
   DEGENERATION; DIABETIC-RETINOPATHY; SUBRETINAL NEOVASCULARIZATION
AB Pathological angiogenesis in the eye is an important feature in the pathophysiology of many vision-threatening diseases, including retinopathy of prematurity, diabetic retinopathy, and age-related macular degeneration, as well as corneal diseases with abnormal angiogenesis. Development of reproducible and reliable animal models of ocular angiogenesis has advanced our understanding of both the normal development and the pathobiology of ocular neovascularization. These models have also proven to be valuable experimental tools with which to easily evaluate potential antiangiogenic therapies beyond eye research. This review summarizes the current available animal models of ocular angiogenesis. Models of retinal and choroidal angiogenesis, including oxygen-induced retinopathy, laser-induced choroidal neovascularization, and transgenic mouse models with deficient or spontaneous retinal/choroidal neovascularization, as well as models with induced corneal angiogenesis, are widely used to investigate the molecular and cellular basis of angiogenic mechanisms. Theoretical concepts and experimental protocols of these models are outlined, as well as their advantages and potential limitations, which may help researchers choose the most suitable models for their investigative work.
C1 [Liu, Chi-Hsiu; Wang, Zhongxiao; Sun, Ye; Chen, Jing] Harvard Med Sch, Boston Childrens Hosp, Dept Ophthalmol, 300 Longwood Ave, Boston, MA 02115 USA.
C3 Harvard University; Boston Children's Hospital; Harvard Medical School
RP Chen, J (通讯作者)，Harvard Med Sch, Boston Childrens Hosp, Dept Ophthalmol, 300 Longwood Ave, Boston, MA 02115 USA.
EM jing.chen@childrens.harvard.edu
OI Sun, Ye/0000-0002-7674-9056
FU U.S. National Institutes of Health (NIH), National Eye Institute
   [R01-EY024963]; Boston Children's Hospital Ophthalmology Foundation;
   Massachusetts Lions Eye Research Fund, Inc.; BrightFocus Foundation;
   Knights Templar Eye Foundation Pediatric Ophthalmology Career-Starter
   Research Grants; Boston Children's Hospital Faculty Career Development
   Grant OFD/BTREC/CTREC; NATIONAL EYE INSTITUTE [R01EY024963] Funding
   Source: NIH RePORTER
FX This study was supported by U.S. National Institutes of Health (NIH),
   National Eye Institute Grant R01-EY024963, the Boston Children's
   Hospital Ophthalmology Foundation, Massachusetts Lions Eye Research
   Fund, Inc. and BrightFocus Foundation (to J.C.), Knights Templar Eye
   Foundation Pediatric Ophthalmology Career-Starter Research Grants (to
   C.-H.L.), and Boston Children's Hospital Faculty Career Development
   Grant OFD/BTREC/CTREC (to Y.S.). All animal work was approved by the
   Boston Children's Hospital Animal Care and Use Committee and adhered to
   the Association for Research in Vision and Ophthalmology Statement for
   the Use of Animals in Ophthalmic and Vision Research. The authors
   declare no conflicts of interest.
CR Afzal A, 2007, MICROVASC RES, V74, P131, DOI 10.1016/j.mvr.2007.04.011
   Ahmad S, 2012, STEM CELL TRANSL MED, V1, P110, DOI 10.5966/sctm.2011-0037
   AIELLO LP, 1995, P NATL ACAD SCI USA, V92, P10457, DOI 10.1073/pnas.92.23.10457
   AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203
   Al-Latayfeh M, 2012, CSH PERSPECT MED, V2, DOI 10.1101/cshperspect.a006411
   Albuquerque RJC, 2009, NAT MED, V15, P1023, DOI 10.1038/nm.2018
   Ambati BK, 2006, NATURE, V443, P993, DOI 10.1038/nature05249
   AMIN R, 1994, INVEST OPHTH VIS SCI, V35, P3178
   Anai M, 2005, J BIOL CHEM, V280, P18525, DOI 10.1074/jbc.M500586200
   Anand-Apte J. G. H. Bela, 2011, RETINA ITS DISORDERS
   ANDERSEN SR, 1961, ARCH OPHTHALMOL-CHIC, V66, P614, DOI 10.1001/archopht.1961.00960010616003
   ARCHER DB, 1981, AM J OPHTHALMOL, V91, P433, DOI 10.1016/0002-9394(81)90230-0
   ASHTON N, 1954, BRIT J OPHTHALMOL, V38, P397, DOI 10.1136/bjo.38.7.397
   Azar Dimitri T, 2006, Trans Am Ophthalmol Soc, V104, P264
   Barber AJ, 2005, INVEST OPHTH VIS SCI, V46, P2210, DOI 10.1167/iovs.04-1340
   BAUM JULES L., 1965, TRANS AMER OPHTHALMOL SOC, V63, P91
   Bermig J, 2002, GRAEF ARCH CLIN EXP, V240, P169, DOI 10.1007/s00417-001-0378-2
   Bock F, 2013, PROG RETIN EYE RES, V34, P89, DOI 10.1016/j.preteyeres.2013.01.001
   Bottoni F, 2005, ARCH OPHTHALMOL-CHIC, V123, P1644, DOI 10.1001/archopht.123.12.1644
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2013, OPHTHALMOLOGY, V120, P2013, DOI 10.1016/j.ophtha.2013.02.034
   Campochiaro PA, 2015, PROG RETIN EYE RES, V49, P67, DOI 10.1016/j.preteyeres.2015.06.002
   Cao JT, 2010, INVEST OPHTH VIS SCI, V51, P6009, DOI 10.1167/iovs.09-4956
   Cao RH, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002748
   Cao ZQ, 2010, NAT PROTOC, V5, P1903, DOI 10.1038/nprot.2010.149
   Carmeliet P, 1998, INT J BIOCHEM CELL B, V30, P661, DOI 10.1016/S1357-2725(97)00121-0
   Chang JH, 2001, CURR OPIN OPHTHALMOL, V12, P242, DOI 10.1097/00055735-200108000-00002
   Chen J, 2012, PARASITE VECTOR, V5, DOI 10.1186/1756-3305-5-279
   Chen J, 2008, J CLIN INVEST, V118, P526, DOI [10.1172/JC133813, 10.1172/JCI33813]
   Chen Jing, 2007, Angiogenesis, V10, P133, DOI 10.1007/s10456-007-9066-0
   Chen J, 2014, INVEST OPHTH VIS SCI, V55, P6535, DOI 10.1167/iovs.14-15615
   Chen J, 2011, CURR OPIN PEDIATR, V23, P173, DOI 10.1097/MOP.0b013e3283423f35
   Chen J, 2011, CIRCULATION, V124, P1871, DOI 10.1161/CIRCULATIONAHA.111.040337
   Chen J, 2009, INVEST OPHTH VIS SCI, V50, P1329, DOI 10.1167/iovs.08-2521
   Chen Y, 2009, MICROVASC RES, V78, P119, DOI 10.1016/j.mvr.2009.02.005
   Chiang H.H., 2013, AM ACAD OPTHALMOL, V1, P35, DOI 10.1016/j.asoc.2020.106210
   Connor KM, 2007, NAT MED, V13, P868, DOI 10.1038/nm1591
   Connor KM, 2009, NAT PROTOC, V4, P1565, DOI 10.1038/nprot.2009.187
   Crawford TN, 2009, CURR DIABETES REV, V5, P8, DOI 10.2174/157339909787314149
   Crawford Y, 2009, CELL TISSUE RES, V335, P261, DOI 10.1007/s00441-008-0675-8
   CRISWICK VG, 1969, AM J OPHTHALMOL, V68, P578, DOI 10.1016/0002-9394(69)91237-9
   CUNNINGHAM S, 1995, LANCET, V346, P1464, DOI 10.1016/S0140-6736(95)92475-2
   Cursiefen C, 2005, AM J PATHOL, V166, P1367, DOI 10.1016/S0002-9440(10)62355-3
   Cursiefen C, 2006, P NATL ACAD SCI USA, V103, P11405, DOI 10.1073/pnas.0506112103
   DAMATO RJ, 1994, P NATL ACAD SCI USA, V91, P4082, DOI 10.1073/pnas.91.9.4082
   Davis J, 2011, INVEST OPHTH VIS SCI, V52, P4158, DOI 10.1167/iovs.10-6726
   Dejana E, 2010, CIRC RES, V107, P943, DOI 10.1161/CIRCRESAHA.110.223750
   DOBI ET, 1989, ARCH OPHTHALMOL-CHIC, V107, P264, DOI 10.1001/archopht.1989.01070010270035
   Donati MC, 2006, OPHTHALMOLOGICA, V220, P31, DOI 10.1159/000089272
   Dorrell MI, 2002, INVEST OPHTH VIS SCI, V43, P3500
   Dorrell MI, 2009, J CLIN INVEST, V119, P611, DOI 10.1172/JCI35977
   Doyle SL, 2015, INVEST OPHTH VIS SCI, V56, P5424, DOI 10.1167/iovs.15-17264
   ELDIRINI AA, 1991, RETINA-J RET VIT DIS, V11, P244, DOI 10.1097/00006982-199111020-00010
   Ellenberg D, 2010, PROG RETIN EYE RES, V29, P208, DOI 10.1016/j.preteyeres.2010.01.002
   Elman MJ, 2010, OPHTHALMOLOGY, V117, P1064, DOI 10.1016/j.ophtha.2010.02.031
   Enomoto A, 2005, DEV CELL, V9, P389, DOI 10.1016/j.devcel.2005.08.001
   Ferrari G, 2016, BRIT J OPHTHALMOL, V100, P1005, DOI 10.1136/bjophthalmol-2015-307901
   FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27
   Foxton R, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.110
   Fruttiger Marcus, 2007, Angiogenesis, V10, P77, DOI 10.1007/s10456-007-9065-1
   FRYKMAN PK, 1995, P NATL ACAD SCI USA, V92, P8453, DOI 10.1073/pnas.92.18.8453
   Fulton AB, 2009, DOC OPHTHALMOL, V118, P55, DOI 10.1007/s10633-008-9127-8
   Gal M, 2014, AM J MED GENET A, V164, P2996, DOI 10.1002/ajmg.a.36739
   Gerhardt H, 2003, J CELL BIOL, V161, P1163, DOI 10.1083/jcb.200302047
   Giacomini C, 2014, EXP EYE RES, V121, P1, DOI 10.1016/j.exer.2014.02.005
   GIMBRONE MA, 1974, J NATL CANCER I, V52, P413, DOI 10.1093/jnci/52.2.413
   Gong Y, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132643
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Grossniklaus HE, 2010, PROG RETIN EYE RES, V29, P500, DOI 10.1016/j.preteyeres.2010.05.003
   Gu XL, 2002, INVEST OPHTH VIS SCI, V43, P496
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hahn N, 2012, INVEST OPHTH VIS SCI, V53, P3260, DOI 10.1167/iovs.12-9676
   Haines JL, 2006, INVEST OPHTH VIS SCI, V47, P329, DOI 10.1167/iovs.05-0116
   Han ZC, 2013, INVEST OPHTH VIS SCI, V54, P574, DOI 10.1167/iovs.12-10959
   Hartnett M. E., 2013, PEDIAT RETINA
   Hartnett ME, 2012, NEW ENGL J MED, V367, P2515, DOI 10.1056/NEJMra1208129
   Hasegawa E, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0106507
   Heckenlively JR, 2003, RETINA-J RET VIT DIS, V23, P518, DOI 10.1097/00006982-200308000-00012
   Henkind P., 1979, OCULAR CIRCULATION, P98
   Holz FG, 2004, AM J OPHTHALMOL, V137, P504, DOI 10.1016/j.ajo.2003.11.026
   Hsu CC, 2015, J CHIN MED ASSOC, V78, P323, DOI 10.1016/j.jcma.2014.10.002
   Hu WZ, 2008, INVEST OPHTH VIS SCI, V49, P407, DOI 10.1167/iovs.07-0870
   Hua J, 2011, INVEST OPHTH VIS SCI, V52, P2809, DOI 10.1167/iovs.10-6496
   Ishikawa K, 2016, EXP EYE RES, V142, P19, DOI 10.1016/j.exer.2015.03.009
   Ito T, 2013, AM J PATHOL, V182, P586, DOI 10.1016/j.ajpath.2012.10.012
   Joyal JS, 2016, NAT MED, V22, P439, DOI 10.1038/nm.4059
   Junge HJ, 2009, CELL, V139, P299, DOI 10.1016/j.cell.2009.07.048
   JUNOD A, 1969, J CLIN INVEST, V48, P2129, DOI 10.1172/JCI106180
   Kather JN, 2014, INVEST OPHTH VIS SCI, V55, P7637, DOI 10.1167/iovs.14-15430
   Kato M, 2002, J CELL BIOL, V157, P303, DOI 10.1083/jcb.200201089
   KENDALL RL, 1993, P NATL ACAD SCI USA, V90, P10705, DOI 10.1073/pnas.90.22.10705
   Kenyon BM, 1996, INVEST OPHTH VIS SCI, V37, P1625
   Kiel JW., 2010, OCULAR CIRCULATION, VChapter 4
   Kinnunen K, 2012, ANN MED, V44, P1, DOI 10.3109/07853890.2010.532150
   KINSEY VE, 1956, ARCH OPHTHALMOL-CHIC, V56, P481, DOI 10.1001/archopht.1956.00930040489001
   Kitamura T, 2008, NAT CELL BIOL, V10, P329, DOI 10.1038/ncb1695
   Krzystolik MG, 2002, ARCH OPHTHALMOL-CHIC, V120, P338
   Ksander BR, 2014, NATURE, V511, P353, DOI 10.1038/nature13426
   Kurihara T, 2012, J CLIN INVEST, V122, P4213, DOI 10.1172/JCI65157
   Kvanta A, 1996, INVEST OPHTH VIS SCI, V37, P1929
   Kwak N, 2000, INVEST OPHTH VIS SCI, V41, P3158
   Kyosseva SV, 2013, EXP EYE RES, V116, P63, DOI 10.1016/j.exer.2013.08.003
   Lafaut BA, 2000, BRIT J OPHTHALMOL, V84, P1269, DOI 10.1136/bjo.84.11.1269
   Lai AKW, 2013, J DIABETES RES, V2013, DOI 10.1155/2013/106594
   Lambert V, 2013, NAT PROTOC, V8, P2197, DOI 10.1038/nprot.2013.135
   Lange C, 2009, GRAEF ARCH CLIN EXP, V247, P1205, DOI 10.1007/s00417-009-1116-4
   Lee H, 2014, INVEST OPHTH VIS SCI, V55, P2885, DOI 10.1167/iovs.14-14093
   Li C, 2007, ARCH OPHTHALMOL-CHIC, V125, P795, DOI 10.1001/archopht.125.6.795
   Li YW, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017106
   Liu CH, 2015, P NATL ACAD SCI USA, V112, P12163, DOI 10.1073/pnas.1508426112
   Lobov IB, 2005, NATURE, V437, P417, DOI 10.1038/nature03928
   Lopez PF, 1996, INVEST OPHTH VIS SCI, V37, P855
   Luhmann UFO, 2005, INVEST OPHTH VIS SCI, V46, P3372, DOI 10.1167/iovs.05-0174
   MacDonald BT, 2009, DEV CELL, V17, P9, DOI 10.1016/j.devcel.2009.06.016
   Madan A, 2003, FRONT BIOSCI-LANDMRK, V8, pD1030, DOI 10.2741/1056
   McLeod DS, 1998, INVEST OPHTH VIS SCI, V39, P1918
   McLeod DS, 1996, INVEST OPHTH VIS SCI, V37, P1322
   McLeod DS, 1996, INVEST OPHTH VIS SCI, V37, P300
   MIDENA E, 1989, OPHTHALMIC RES, V21, P106, DOI 10.1159/000266787
   MILLER H, 1986, INVEST OPHTH VIS SCI, V27, P1644
   Mintz-Hittner HA, 2011, NEW ENGL J MED, V364, P603, DOI 10.1056/NEJMoa1007374
   Montezuma SR, 2009, SEMIN OPHTHALMOL, V24, P52, DOI 10.1080/08820530902800017
   Moore KL, 2009, CLIN ORIENTED ANATOM
   Mwaikambo BR, 2008, CORNEA, V27, P1037, DOI 10.1097/ICO.0b013e31817780b6
   Nagai N, 2015, AM J PATHOL, V185, P2534, DOI 10.1016/j.ajpath.2015.04.029
   Nagai N, 2014, INVEST OPHTH VIS SCI, V55, P3709, DOI 10.1167/iovs.14-13989
   Netter FH, 2006, ATLAS HUMAN ANATOMY
   Neufeld G, 1999, FASEB J, V13, P9, DOI 10.1096/fasebj.13.1.9
   NIEDERKORN JY, 1990, INVEST OPHTH VIS SCI, V31, P948
   Ning X, 2004, INT J MOL MED, V13, P87
   Ohlmann A, 2005, J NEUROSCI, V25, P1701, DOI 10.1523/JNEUROSCI.4756-04.2005
   OKA K, 1994, EUR J BIOCHEM, V224, P975, DOI 10.1111/j.1432-1033.1994.00975.x
   Okamoto N, 1997, AM J PATHOL, V151, P281
   ORMEROD LD, 1989, INVEST OPHTH VIS SCI, V30, P2148
   Ouyang H, 2014, NATURE, V511, P358, DOI 10.1038/nature13465
   Paneghetti L, 2016, VASC CELL, V8, DOI 10.1186/s13221-016-0036-4
   Penn JS, 2008, PROG RETIN EYE RES, V27, P331, DOI 10.1016/j.preteyeres.2008.05.001
   PENN JS, 1993, INVEST OPHTH VIS SCI, V34, P576
   Penn JS, 2001, INVEST OPHTH VIS SCI, V42, P283
   Pennesi ME, 2012, MOL ASPECTS MED, V33, P487, DOI 10.1016/j.mam.2012.06.003
   PHELPS DL, 1984, PEDIATRICS, V73, P1
   PIERCE EA, 1995, P NATL ACAD SCI USA, V92, P905, DOI 10.1073/pnas.92.3.905
   Poor SH, 2014, INVEST OPHTH VIS SCI, V55, P6525, DOI 10.1167/iovs.14-15067
   Potente M, 2011, CELL, V146, P873, DOI 10.1016/j.cell.2011.08.039
   Rattner A, 2014, INVEST OPHTH VIS SCI, V55, P8614, DOI 10.1167/iovs.14-15693
   RERUP C C, 1970, Pharmacological Reviews, V22, P485
   Riordan-Eva E. T. C. Paul, 2011, VAUGHAN ASBURYS GEN
   Robinson GS, 2001, FASEB J, V15, P1215, DOI 10.1096/fj.00-0598fje
   Robinson R, 2012, DIS MODEL MECH, V5, P444, DOI 10.1242/dmm.009597
   Rogers MS, 2007, NAT PROTOC, V2, P2545, DOI 10.1038/nprot.2007.368
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Ross M. H., 2005, HISTOLOGY TEXT ATLAS
   Ryan S J, 1979, Trans Am Ophthalmol Soc, V77, P707
   Sapieha P, 2010, J CLIN INVEST, V120, P3022, DOI 10.1172/JCI42142
   Sene A, 2015, TRENDS MOL MED, V21, P43, DOI 10.1016/j.molmed.2014.10.005
   Shaw SG, 2006, EXP BIOL MED, V231, P1101
   Singh Parul, 2013, Oman J Ophthalmol, V6, P83, DOI 10.4103/0974-620X.116624
   SMITH LEH, 1994, INVEST OPHTH VIS SCI, V35, P101
   Smith LEH, 1999, NAT MED, V5, P1390, DOI 10.1038/70963
   Smith LEH, 2008, INVEST OPHTH VIS SCI, V49, P5177, DOI 10.1167/iovs.08-2584
   Stahl A, 2009, ANGIOGENESIS, V12, P297, DOI 10.1007/s10456-009-9155-3
   Stahl A, 2010, INVEST OPHTH VIS SCI, V51, P2813, DOI 10.1167/iovs.10-5176
   Stalmans I, 2002, J CLIN INVEST, V109, P327, DOI 10.1172/jci0214362
   Standring S, 2008, GRAYS ANATOMY
   Steen B, 1998, INVEST OPHTH VIS SCI, V39, P2194
   Stenman JM, 2008, SCIENCE, V322, P1247, DOI 10.1126/science.1164594
   STONE J, 1995, J NEUROSCI, V15, P4738, DOI 10.1523/jneurosci.15-07-04738.1995
   Sun Y, 2017, J EXP MED, V214, P1753, DOI 10.1084/jem.20161645
   Sun Y, 2015, P NATL ACAD SCI USA, V112, P10401, DOI 10.1073/pnas.1504387112
   Sun Y, 2013, BMC CELL BIOL, V14, DOI 10.1186/1471-2121-14-8
   Takahashi T, 2000, AM J OPHTHALMOL, V130, P774, DOI 10.1016/S0002-9394(00)00772-8
   Tang ZS, 2011, JOVE-J VIS EXP, DOI 10.3791/3077
   Tiebel O, 1999, ATHEROSCLEROSIS, V145, P239, DOI 10.1016/S0021-9150(99)00068-4
   Tobe T, 1998, AM J PATHOL, V153, P1641, DOI 10.1016/S0002-9440(10)65753-7
   Tobe T, 1998, INVEST OPHTH VIS SCI, V39, P180
   TOIVONEN J, 1991, ACTA ANAESTH SCAND, V35, P496, DOI 10.1111/j.1399-6576.1991.tb03336.x
   Toomes C, 2004, AM J HUM GENET, V74, P721, DOI 10.1086/383202
   Vahatupa M, 2016, INVEST OPHTH VIS SCI, V57, P4898, DOI 10.1167/iovs.16-19212
   Wacker A, 2011, CURR OPIN CELL BIOL, V23, P676, DOI 10.1016/j.ceb.2011.10.002
   Wang ZX, 2016, AM J PATHOL, V186, P2588, DOI 10.1016/j.ajpath.2016.06.015
   Wang ZX, 2015, ARTERIOSCL THROM VAS, V35, P855, DOI 10.1161/ATVBAHA.114.304627
   Wang ZX, 2014, CORNEA, V33, P405, DOI 10.1097/ICO.0000000000000032
   WARBURG M, 1975, ACTA OPHTHALMOL, V53, P217
   Weis SM, 2005, NATURE, V437, P497, DOI 10.1038/nature03987
   Westenskow PD, 2013, J CLIN INVEST, V123, P4900, DOI 10.1172/JCI70230
   Won JY, 2011, J OPHTHALMOL, V2011, DOI 10.1155/2011/391384
   Wu YC, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0126750
   Wyne KL, 1996, ARTERIOSCL THROM VAS, V16, P407, DOI 10.1161/01.ATV.16.3.407
   Xia CH, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011676
   Xu Q, 2004, CELL, V116, P883, DOI 10.1016/S0092-8674(04)00216-8
   Xu QW, 2001, INVEST OPHTH VIS SCI, V42, P789
   Yanagi Y, 2002, INVEST OPHTH VIS SCI, V43, P3495
   Ye X, 2010, TRENDS MOL MED, V16, P417, DOI 10.1016/j.molmed.2010.07.003
   Ye X, 2009, CELL, V139, P285, DOI 10.1016/j.cell.2009.07.047
   York Jackie R, 2004, J Perinatol, V24, P82, DOI 10.1038/sj.jp.7211040
   Yoshida J, 2015, J OPHTHALMOL, V2015, DOI 10.1155/2015/137136
   Zhou YL, 2014, J CLIN INVEST, V124, P3825, DOI 10.1172/JCI76431
NR 197
TC 77
Z9 82
U1 2
U2 20
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0892-6638
EI 1530-6860
J9 FASEB J
JI Faseb J.
PD NOV
PY 2017
VL 31
IS 11
BP 4665
EP 4681
DI 10.1096/fj.201700336R
PG 17
WC Biochemistry & Molecular Biology; Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
   Topics; Cell Biology
GA FK3PP
UT WOS:000413398500002
PM 28739642
OA Green Published
DA 2022-11-30
ER

PT J
AU Choudhary, P
   Whiting, PJ
AF Choudhary, Parul
   Whiting, Paul John
TI A strategy to ensure safety of stem cell-derived retinal pigment
   epithelium cells
SO STEM CELL RESEARCH & THERAPY
LA English
DT Article
DE Retinal pigment epithelium; Embryonic stem cells; Flow sorting;
   Age-related macular degeneration; Cell surface markers
ID MACULAR DEGENERATION; TRANSPLANTATION; CD59; AGE; ACTIVATION; EXPRESSION
AB Cell replacement and regenerative therapy using embryonic stem cell-derived material holds promise for the treatment of several pathologies. However, the safety of this approach is of prime importance given the teratogenic potential of residual stem cells, if present in the differentiated cell product. Using the example of embryonic stem cell-derived retinal pigment epithelium (RPE) for the treatment of age-related macular degeneration, we present a novel strategy for ensuring the absence of stem cells in the RPE population. Based on an unbiased screening approach, we identify and validate the expression of CD59, a cell surface marker expressed on RPE but absent on stem cells. We further demonstrate that flow sorting on the basis of CD59 expression can effectively purify RPE and deplete stem cells, resulting in a population free from stem cell impurity. This purification helps to ensure removal of stem cells and hence increases the safety of cells that may be used for clinical transplantation. This strategy can potentially be applied to other pluripotent stem cell-derived material and help mitigate concerns of using such cells for therapy.
C1 [Choudhary, Parul] Pfizer Neurosci & Pain Res Unit, The Portway,Granta Pk, Cambridge CB21 6GS, England.
   [Whiting, Paul John] UCL, AR UK Drug Discovery Inst, London WC1E 6BT, England.
C3 Pfizer; University of London; University College London
RP Choudhary, P (通讯作者)，Pfizer Neurosci & Pain Res Unit, The Portway,Granta Pk, Cambridge CB21 6GS, England.
EM parulc83@gmail.com
OI Whiting, Paul/0000-0002-4121-1379
CR Cashman SM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019078
   CHOUDHARY P, 2016, STEM CELLS IN PRESS
   DAVIES A, 1993, IMMUNOL RES, V12, P258, DOI 10.1007/BF02918257
   DAVIES A, 1989, J EXP MED, V170, P637, DOI 10.1084/jem.170.3.637
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P532
   Goldring CEP, 2011, CELL STEM CELL, V8, P618, DOI 10.1016/j.stem.2011.05.012
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Herrmann P, 2015, NEUROBIOL AGING, V36, P2637, DOI 10.1016/j.neurobiolaging.2015.05.019
   Heslop JA, 2015, STEM CELL TRANSL MED, V4, P389, DOI 10.5966/sctm.2014-0110
   Juel HB, 2011, EXP EYE RES, V92, P180, DOI 10.1016/j.exer.2011.01.003
   Kanuga N, 2002, INVEST OPHTH VIS SCI, V43, P546
   Kuroda T, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037342
   Lang P, 1999, BONE MARROW TRANSPL, V24, P583, DOI 10.1038/sj.bmt.1701961
   Leach LL, 2015, STEM CELLS, V33, P2363, DOI 10.1002/stem.2010
   Liversidge J, 1996, J IMMUNOL, V156, P3696
   Luo C, 2013, EXP EYE RES, V112, P93, DOI 10.1016/j.exer.2013.04.016
   Schwartz SD, 2015, LANCET, V385, P509, DOI 10.1016/S0140-6736(14)61376-3
   Schwartz SD, 2012, LANCET, V379, P713, DOI 10.1016/S0140-6736(12)60028-2
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Vugler A, 2008, EXP NEUROL, V214, P347, DOI 10.1016/j.expneurol.2008.09.007
   Wang XY, 2016, MOL THER-ONCOLYTICS, V3, DOI 10.1038/mto.2016.15
   Whiting P, 2015, PHILOS T R SOC B, V370, DOI 10.1098/rstb.2014.0375
   Yang P, 2009, INVEST OPHTH VIS SCI, V50, P3473, DOI 10.1167/iovs.08-3202
NR 23
TC 4
Z9 5
U1 1
U2 9
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1757-6512
J9 STEM CELL RES THER
JI Stem Cell Res. Ther.
PD SEP 2
PY 2016
VL 7
AR 127
DI 10.1186/s13287-016-0380-6
PG 8
WC Cell & Tissue Engineering; Cell Biology; Medicine, Research &
   Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Research & Experimental Medicine
GA DX7UW
UT WOS:000384595900001
PM 27590276
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Calaza, KC
   Kam, JH
   Hogg, C
   Jeffery, G
AF Calaza, Karin C.
   Kam, Jaimie Hoh
   Hogg, Chris
   Jeffery, Glen
TI Mitochondrial decline precedes phenotype development in the complement
   factor H mouse model of retinal degeneration but can be corrected by
   near infrared light
SO NEUROBIOLOGY OF AGING
LA English
DT Article
DE 670 nm; Aging; Retina; AMD; ATP
ID AGE; HSP60; DYNAMICS; ROD; ABSORPTION; LOCATIONS; INCREASES; FISSION;
   FUSION; ATP
AB Mitochondria produce adenosine triphosphate (ATP), critical for cellular metabolism. ATP declines with age, which is associated with inflammation. Here, we measure retinal and brain ATP in normal C57BL/6 and complement factor H knockout mice (Cfh(-/-)), which are proposed as a model of age-related macular degeneration. We show a significant premature 30% decline in retinal ATP in Cfh(-/-) mice and a subsequent shift in expression of a heat shock protein that is predominantly mitochondrial (Hsp60). Changes in Hsp60 are associated with stress and neuroprotection. We find no differences in brain ATP between C57BL/6 and Cfh(-/-) mice. Near infrared (NIR) increases ATP and reduces inflammation. ATP decline in Cfh(-/-) mice was corrected with NIR which also shifted Hsp60 labeling patterns. ATP decline in Cfh(-/-) mice occurs before inflammation becomes established and photoreceptor loss occurs and may relate to disease etiology. However, ATP levels were corrected with NIR. In summary, we provide evidence for a mitochondrial basis for this disease in mice and correct this with simple light exposure known to improve mitochondrial function. (C) 2015 The Authors. Published by Elsevier Inc.
C1 [Calaza, Karin C.] Univ Fed Fluminense, Inst Biol, Program Neurosci, Rio De Janeiro, Brazil.
   [Calaza, Karin C.; Kam, Jaimie Hoh; Jeffery, Glen] UCL, Inst Ophthalmol, London EC1V 9EL, England.
   [Hogg, Chris] Moorfields Eye Hosp, London, England.
C3 Universidade Federal Fluminense; University of London; University
   College London; University of London; University College London;
   Moorfields Eye Hospital NHS Foundation Trust
RP Jeffery, G (通讯作者)，UCL, Inst Ophthalmol, Bath St, London EC1V 9EL, England.
EM g.jeffery@ucl.ac.uk
RI Calaza, Karin/AAE-4669-2019
OI Calaza, Karin/0000-0003-1199-1826
FU Rosetrees Trust
FX This research was supported by The Rosetrees Trust. Karin C. Calaza was
   a research fellow from CAPES (Proc. No 18134/12-2).
CR Archer SL, 2013, NEW ENGL J MED, V369, P2236, DOI 10.1056/NEJMra1215233
   Balaban RS, 2005, CELL, V120, P483, DOI 10.1016/j.cell.2005.02.001
   Barot M, 2011, CURR EYE RES, V36, P1069, DOI 10.3109/02713683.2011.607536
   Begum R, 2015, BIOL LETTERS, V11, DOI 10.1098/rsbl.2015.0073
   Begum R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057828
   Binns AM, 2007, INVEST OPHTH VIS SCI, V48, P2806, DOI 10.1167/iovs.06-0392
   Brocchieri L, 2000, PROTEIN SCI, V9, P476
   Cappello F, 2008, CANCER BIOL THER, V7, P801, DOI 10.4161/cbt.7.6.6281
   CARTERDAWSON LD, 1979, J COMP NEUROL, V188, P245, DOI 10.1002/cne.901880204
   Caspari R, 2004, P NATL ACAD SCI USA, V101, P10895, DOI 10.1073/pnas.0402857101
   Catchpole I, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065518
   Chen HC, 2009, HUM MOL GENET, V18, pR169, DOI 10.1093/hmg/ddp326
   Chew EY, 2012, OPHTHALMOLOGY, V119, P2282, DOI 10.1016/j.ophtha.2012.05.027
   Coffey PJ, 2007, P NATL ACAD SCI USA, V104, P16651, DOI 10.1073/pnas.0705079104
   Cunea A, 2007, VISUAL NEUROSCI, V24, P151, DOI 10.1017/S0952523807070204
   Cunea A, 2014, NEUROBIOL AGING, V35, P2584, DOI 10.1016/j.neurobiolaging.2014.05.012
   Curcio CA, 2001, EYE, V15, P376, DOI 10.1038/eye.2001.140
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Fitzgerald M, 2013, REV NEUROSCIENCE, V24, P205, DOI 10.1515/revneuro-2012-0086
   FOX DA, 1989, EXP EYE RES, V48, P237, DOI 10.1016/S0014-4835(89)80073-9
   Gkotsi D, 2014, EXP EYE RES, V122, P50, DOI 10.1016/j.exer.2014.02.023
   GRIFFITHS D, 1961, BIOCHEM BIOPH RES CO, V4, P151, DOI 10.1016/0006-291X(61)90366-7
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hansen JJ, 2003, HUM GENET, V112, P71, DOI 10.1007/s00439-002-0837-9
   HARMAN D, 1972, J AM GERIATR SOC, V20, P145, DOI 10.1111/j.1532-5415.1972.tb00787.x
   Jarrett SG, 2008, PROG RETIN EYE RES, V27, P596, DOI 10.1016/j.preteyeres.2008.09.001
   Jeon CJ, 1998, J NEUROSCI, V18, P8936
   Johnson JE, 2007, MOL VIS, V13, P887
   Jonas JB, 2014, LANCET GLOB HEALTH, V2, pE65, DOI 10.1016/S2214-109X(13)70163-3
   Kam JH, 2013, AM J PATHOL, V183, P480, DOI 10.1016/j.ajpath.2013.04.008
   Kam JH, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013127
   Kaufman BA, 2003, J CELL BIOL, V163, P457, DOI 10.1083/jcb.200306132
   Keane PC, 2011, PARKINSONS DIS-US, V2011, DOI 10.4061/2011/716871
   Kokkinopoulos I, 2013, NEUROBIOL AGING, V34, P602, DOI 10.1016/j.neurobiolaging.2012.04.014
   Kolesnikov AV, 2010, J NEUROSCI, V30, P11222, DOI 10.1523/JNEUROSCI.4239-09.2010
   Lane N., 2005, POWER SEX SUICIDE MI
   Lopez-Otin C, 2013, CELL, V153, P1194, DOI 10.1016/j.cell.2013.05.039
   Moro C, 2014, J NEUROSURG, V120, P670, DOI 10.3171/2013.9.JNS13423
   Nordgaard CL, 2008, INVEST OPHTH VIS SCI, V49, P2848, DOI 10.1167/iovs.07-1352
   OSTERMANN J, 1989, NATURE, V341, P125, DOI 10.1038/341125a0
   Radermacher P, 2013, INTENS CARE MED EXP, V1, DOI 10.1186/2197-425X-1-7
   Saibil H, 2013, NAT REV MOL CELL BIO, V14, P630, DOI 10.1038/nrm3658
   Schon EA, 2003, J CLIN INVEST, V111, P303, DOI 10.1172/JCI200317741
   Seok J, 2013, P NATL ACAD SCI USA, V110, P3507, DOI 10.1073/pnas.1222878110
   Speakman JR, 2005, J EXP BIOL, V208, P1717, DOI 10.1242/jeb.01556
   Stone J, 2008, BRAIN RES, V1189, P58, DOI 10.1016/j.brainres.2007.10.083
   Szundi I, 2001, BIOCHEMISTRY-US, V40, P2332, DOI 10.1021/bi002220v
   Udar N, 2009, INVEST OPHTH VIS SCI, V50, P2966, DOI 10.1167/iovs.08-2646
   von Leithner PL, 2009, AM J PATHOL, V175, P412, DOI 10.2353/ajpath.2009.080927
   Wang ZM, 2010, AM J CLIN NUTR, V92, P1369, DOI 10.3945/ajcn.2010.29885
   WILSON M, 1970, BIOCHEM J, V116, pP17, DOI 10.1042/bj1160017P
   Yu DY, 2001, PROG RETIN EYE RES, V20, P175, DOI 10.1016/S1350-9462(00)00027-6
   Zipfel PF, 2010, ADV EXP MED BIOL, V703, P9, DOI 10.1007/978-1-4419-5635-4_2
   Zolfaghari PS, 2013, INTENS CARE MED EXP, V1, DOI 10.1186/2197-425X-1-6
NR 54
TC 34
Z9 35
U1 0
U2 11
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0197-4580
EI 1558-1497
J9 NEUROBIOL AGING
JI Neurobiol. Aging
PD OCT
PY 2015
VL 36
IS 10
BP 2869
EP 2876
DI 10.1016/j.neurobiolaging.2015.06.010
PG 8
WC Geriatrics & Gerontology; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Geriatrics & Gerontology; Neurosciences & Neurology
GA CQ9JA
UT WOS:000360929100024
PM 26149919
OA hybrid
DA 2022-11-30
ER

PT J
AU Kanesa-Thasan, A
   Grewal, DS
   Gill, MK
   Lyon, AT
   Mirza, RG
AF Kanesa-Thasan, Aditya
   Grewal, Dilraj S.
   Gill, Manjot K.
   Lyon, Alice T.
   Mirza, Rukhsana G.
TI Quantification of Change in Pigment Epithelial Detachment Volume and
   Morphology After Transition to Intravitreal Aflibercept in Eyes With
   Recalcitrant Neovascular AMD: 18-Month Results
SO OPHTHALMIC SURGERY LASERS & IMAGING RETINA
LA English
DT Article
ID ANATOMICAL OUTCOMES; RANIBIZUMAB; FLUID
AB BACKGROUND AND OBJECTIVE: To quantitatively evaluate the change in pigment epithelial detachment (PED) morphology on spectral-domain optical coherence tomography (SD-OCT) 18 months after the transition to intravitreal aflibercept in patients with neovascular age-related macular degeneration (AMD) with PED recalcitrant to monthly intravitreal bevacizumab or ranibizumab.
   PATIENTS AND METHODS: Retrospective case series examining patients with neovascular AMD who had a persistent fibrovascular or serous PED on SD-OCT. PED volume was calculated by manually outlining the PED on individual OCT slices of the raster scan and multiplying by the pixel dimensions.
   RESULTS: Eleven eyes of 10 patients who had received an average of 25.7 +/- 20.1 (range: 6 to 70) prior bevacizumab or ranibizumab injections over a period of 26.6 +/- 19.8 months (range: 4 to 63) were included. PED volume decreased with aflibercept from 0.687 +/- 0.837 mm(3) to 0.562 +/- 0.705 mm(3) (P = .02), a decrease of 19% +/- 12.27%.
   CONCLUSION: After 18 months of aflibercept, recalcitrant PED volumes were reduced by 19% while preserving visual acuity in eyes with neovascular AMD.
C1 [Kanesa-Thasan, Aditya; Grewal, Dilraj S.; Gill, Manjot K.; Lyon, Alice T.; Mirza, Rukhsana G.] Northwestern Univ, Feinberg Sch Med, Dept Ophthalmol, Chicago, IL 60611 USA.
   [Grewal, Dilraj S.] Duke Eye Ctr, Durham, NC USA.
C3 Northwestern University; Feinberg School of Medicine; Duke University
RP Mirza, RG (通讯作者)，Northwestern Univ, Feinberg Sch Med, Dept Ophthalmol, 645 N Michigan Ave,Suite 440, Chicago, IL 60611 USA.
EM r-mirza@northwestern.edu
OI Grewal, Dilraj/0000-0002-2229-5343
FU Research to Prevent Blindness; Heed Ophthalmic Foundation
FX Supported in part by an unrestricted grant from Research to Prevent
   Blindness and the Heed Ophthalmic Foundation.
CR Bakall B, 2013, AM J OPHTHALMOL, V156, P15, DOI 10.1016/j.ajo.2013.02.017
   Chang AA, 2014, OPHTHALMOLOGY, V121, P188, DOI 10.1016/j.ophtha.2013.08.035
   Cho H, 2013, BRIT J OPHTHALMOL, V97, P1032, DOI 10.1136/bjophthalmol-2013-303344
   Ferrone PJ, 2014, BRIT J OPHTHALMOL, V98, P17, DOI 10.1136/bjophthalmol-2013-304474
   Grewal DS, 2014, EYE, V28, P895, DOI 10.1038/eye.2014.101
   Grossniklaus HE, 2002, MOL VIS, V8, P119
   Ho VY, 2013, AM J OPHTHALMOL, V156, P23, DOI 10.1016/j.ajo.2013.02.009
   Kumar N, 2013, RETINA-J RET VIT DIS, V33, P1605, DOI 10.1097/IAE.0b013e31828e8551
   Patel KH, 2013, EYE, V27, P664, DOI 10.1038/eye.2013.31
   Penha FM, 2013, RETINA-J RET VIT DIS, V33, P459, DOI 10.1097/IAE.0b013e31827d2657
   Rahimy E, 2014, RETINA-J RET VIT DIS, V34, P1289, DOI 10.1097/IAE.0000000000000130
   Schlingemann RO, 2004, GRAEF ARCH CLIN EXP, V242, P91, DOI 10.1007/s00417-003-0828-0
   Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089
   Yamashita M, 2014, CLIN OPHTHALMOL, V8, P343, DOI 10.2147/OPTH.S56539
   Zayit-Soudry S, 2007, SURV OPHTHALMOL, V52, P227, DOI 10.1016/j.survophthal.2007.02.008
NR 15
TC 21
Z9 22
U1 0
U2 3
PU SLACK INC
PI THOROFARE
PA 6900 GROVE RD, THOROFARE, NJ 08086 USA
SN 2325-8160
EI 2325-8179
J9 OSLI RETINA
JI Ophthalmic Surg. Lasers Imag. Retin.
PD JUN
PY 2015
VL 46
IS 6
BP 638
EP 641
DI 10.3928/23258160-20150610-07
PG 4
WC Ophthalmology; Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Surgery
GA CO6US
UT WOS:000359292700007
PM 26114844
DA 2022-11-30
ER

PT J
AU Maeda, T
   Golczak, M
   Maeda, A
AF Maeda, Tadao
   Golczak, Marcin
   Maeda, Akiko
TI Retinal Photodamage Mediated by All-trans-retinal
SO PHOTOCHEMISTRY AND PHOTOBIOLOGY
LA English
DT Review
ID CASSETTE TRANSPORTER ABCA4; LIGHT-INDUCED DAMAGE; ROD OUTER SEGMENTS;
   FUNDUS AUTOFLUORESCENCE; MACULAR DEGENERATION; STARGARDT-DISEASE; VISUAL
   CYCLE; LIPOFUSCIN ACCUMULATION; GEOGRAPHIC ATROPHY; PIGMENT EPITHELIUM
AB Accumulation of all-trans-retinal (all-trans-RAL), reactive vitamin A aldehyde, is one of the key factors in initiating retinal photodamage. This photodamage is characterized by progressive retinal cell death evoked by light exposure in both an acute and chronic fashion. Photoactivated rhodopsin releases all-trans-RAL, which is subsequently transported by ATP-binding cassette transporter 4 and reduced to all-trans-retinol by all-trans-retinol dehydrogenases located in photoreceptor cells. Any interruptions in the clearing of all-trans-RAL in the photoreceptors can cause an accumulation of this reactive aldehyde and its toxic condensation products. This accumulation may result in the manifestation of retinal dystrophy including human retinal degenerative diseases such as Stargardts disease and age-related macular degeneration. Herein, we discuss the mechanisms of all-trans-RAL clearance in photoreceptor cells by sequential enzymatic reactions, the visual (retinoid) cycle, and potential molecular pathways of retinal photodamage. We also review recent imaging technologies to monitor retinal health status as well as novel therapeutic strategies preventing all-trans-RAL-associated retinal photodamage.
C1 [Maeda, Tadao; Maeda, Akiko] Case Western Reserve Univ, Dept Ophthalmol & Visual Sci, Cleveland, OH 44106 USA.
   [Maeda, Tadao; Golczak, Marcin; Maeda, Akiko] Case Western Reserve Univ, Dept Pharmacol, Cleveland, OH 44106 USA.
C3 Case Western Reserve University; Case Western Reserve University
RP Maeda, A (通讯作者)，Case Western Reserve Univ, Dept Ophthalmol & Visual Sci, Cleveland, OH 44106 USA.
EM aam19@case.edu
FU National Institutes of Health [EY019031, EY019880, EY009339, EY 021126,
   P30 EY11373]; Research to Prevent Blindness Foundation; Foundation
   Fighting Blindness; Fight for Sight; Ohio Lions Eye Research Foundation;
   NATIONAL EYE INSTITUTE [R01EY009339, K08EY019880, R24EY021126,
   R01EY022658, P30EY011373, K08EY019031] Funding Source: NIH RePORTER
FX We specially thank Dr. Krzysztof Palczewski (Case Western Reserve
   University) for his generous support. We also thank Drs. S. Howell, H.
   Fujioka. M. Hitomi, S. Roos and L. Perusek (Case Western Reserve
   University), G. Palczewska and Z. Dong (Polgenix Inc.) for technical
   support. This work was supported in part by funding from the National
   Institutes of Health (EY019031, EY019880, EY009339, EY 021126, P30
   EY11373); the Research to Prevent Blindness Foundation; Foundation
   Fighting Blindness; Fight for Sight and the Ohio Lions Eye Research
   Foundation.
CR Abdelsalam A, 1999, SURV OPHTHALMOL, V44, P1, DOI 10.1016/S0039-6257(99)00072-7
   Allikmets R, 1997, NAT GENET, V15, P236, DOI 10.1038/ng0397-236
   Allikmets R, 1997, SCIENCE, V277, P1805, DOI 10.1126/science.277.5333.1805
   Allikmets R., 2007, RETINAL DEGENERATION, P105
   Arshavsky VY, 2012, J BIOL CHEM, V287, P1620, DOI 10.1074/jbc.R111.305243
   Batten ML, 2004, J BIOL CHEM, V279, P10422, DOI 10.1074/jbc.M312410200
   Baylor D, 1996, P NATL ACAD SCI USA, V93, P560, DOI 10.1073/pnas.93.2.560
   Bennett J, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3002865
   BOULTON M, 1989, INVEST OPHTH VIS SCI, V30, P82
   Burke TR, 2011, INVEST OPHTH VIS SCI, V52, P8006, DOI 10.1167/iovs.11-7693
   Cao HB, 2011, PROTEIN CELL, V2, P973, DOI 10.1007/s13238-011-1126-y
   Chen Y, 2012, J BIOL CHEM, V287, P5059, DOI 10.1074/jbc.M111.315432
   Chrispell JD, 2009, J BIOL CHEM, V284, P21468, DOI 10.1074/jbc.M109.020966
   Davies S, 2001, FREE RADICAL BIO MED, V31, P256, DOI 10.1016/S0891-5849(01)00582-2
   Davis J, 2011, AM J OPHTHALMOL, V152, P509, DOI 10.1016/j.ajo.2011.07.004
   DELORI FC, 1995, INVEST OPHTH VIS SCI, V36, P2327
   Delori FC, 2001, INVEST OPHTH VIS SCI, V42, P1855
   DOREY CK, 1989, INVEST OPHTH VIS SCI, V30, P1691
   ELDRED GE, 1993, NATURE, V361, P724, DOI 10.1038/361724a0
   ELDRED GE, 1993, NATURE, V364, P396
   FEENEYBURNS L, 1984, INVEST OPHTH VIS SCI, V25, P195
   FEENEYBURNS L, 1983, T OPHTHAL SOC UK, V103, P416
   Fleckenstein M, 2008, INVEST OPHTH VIS SCI, V49, P4137, DOI 10.1167/iovs.08-1967
   GAILLARD ER, 1995, PHOTOCHEM PHOTOBIOL, V61, P448, DOI 10.1111/j.1751-1097.1995.tb02343.x
   Golczak M, 2005, P NATL ACAD SCI USA, V102, P8162, DOI 10.1073/pnas.0503318102
   Gollapalli DR, 2004, P NATL ACAD SCI USA, V101, P10030, DOI 10.1073/pnas.0401936101
   Gomes NL, 2009, INVEST OPHTH VIS SCI, V50, P3953, DOI 10.1167/iovs.08-2657
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Grey AC, 2011, INVEST OPHTH VIS SCI, V52, P3926, DOI 10.1167/iovs.10-7020
   Grimm C, 2000, NAT GENET, V25, P63, DOI 10.1038/75614
   Han M, 2006, J BIOMED OPT, V11, DOI 10.1117/1.2171649
   HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435
   Holz FG, 1999, INVEST OPHTH VIS SCI, V40, P737
   Holz FG, 2007, AM J OPHTHALMOL, V143, P463, DOI 10.1016/j.ajo.2006.11.041
   Illing M, 1997, J BIOL CHEM, V272, P10303, DOI 10.1074/jbc.272.15.10303
   Kiser PD, 2012, BBA-MOL CELL BIOL L, V1821, P137, DOI 10.1016/j.bbalip.2011.03.005
   Kos V, 2009, CELL MOL LIFE SCI, V66, P3111, DOI 10.1007/s00018-009-0064-9
   Linton KJ, 2007, PFLUG ARCH EUR J PHY, V453, P555, DOI 10.1007/s00424-006-0126-x
   Liu JH, 2000, J BIOL CHEM, V275, P29354, DOI 10.1074/jbc.M910191199
   LOCHNER JE, 1986, P NATL ACAD SCI USA, V83, P7673, DOI 10.1073/pnas.83.20.7673
   LOPEZ PF, 1990, OPHTHALMOLOGY, V97, P798
   Maeda A, 2005, J BIOL CHEM, V280, P18822, DOI 10.1074/jbc.M501757200
   Maeda A, 2008, J BIOL CHEM, V283, P26684, DOI 10.1074/jbc.M804505200
   Maeda A, 2006, MOL PHARMACOL, V70, P1220, DOI 10.1124/mol.106.026823
   Maeda A, 2006, J BIOL CHEM, V281, P37697, DOI 10.1074/jbc.M608375200
   Maeda A, 2012, NAT CHEM BIOL, V8, P170, DOI 10.1038/nchembio.759
   Maeda A, 2009, J BIOL CHEM, V284, P15173, DOI 10.1074/jbc.M900322200
   Martras S, 2004, EUR J BIOCHEM, V271, P1660, DOI 10.1111/j.1432-1033.2004.04058.x
   Maugeri A, 2000, AM J HUM GENET, V67, P960, DOI 10.1086/303079
   McBee JK, 2001, PROG RETIN EYE RES, V20, P469, DOI 10.1016/S1350-9462(01)00002-7
   Molday LL, 2000, NAT GENET, V25, P257, DOI 10.1038/77004
   Molday RS, 2007, J BIOENERG BIOMEMBR, V39, P507, DOI 10.1007/s10863-007-9118-6
   Murdaugh LS, 2011, J MASS SPECTROM, V46, P90, DOI 10.1002/jms.1865
   Ng KP, 2008, MOL CELL PROTEOMICS, V7, P1397, DOI 10.1074/mcp.M700525-MCP200
   Nickell S, 2007, J CELL BIOL, V177, P917, DOI 10.1083/jcb.200612010
   Oppermann U, 2003, CHEM-BIOL INTERACT, V143, P247, DOI 10.1016/S0009-2797(02)00164-3
   Palczewska G, 2010, NAT MED, V16, P1444, DOI 10.1038/nm.2260
   PALCZEWSKI K, 1994, BIOCHEMISTRY-US, V33, P13741, DOI 10.1021/bi00250a027
   Palczewski K, 2012, J BIOL CHEM, V287, P1612, DOI 10.1074/jbc.R111.301150
   Palczewski K, 2010, TRENDS PHARMACOL SCI, V31, P284, DOI 10.1016/j.tips.2010.03.001
   PAPERMASTER DS, 1978, J CELL BIOL, V78, P415, DOI 10.1083/jcb.78.2.415
   PARES X, 1985, ALCOHOL, V2, P43, DOI 10.1016/0741-8329(85)90013-8
   Parker RO, 2010, EXP EYE RES, V91, P788, DOI 10.1016/j.exer.2010.08.013
   Paskowitz DM, 2006, BRIT J OPHTHALMOL, V90, P1060, DOI 10.1136/bjo.2006.097436
   RABB MF, 1986, OPHTHALMOLOGY, V93, P1443
   Radu RA, 2005, INVEST OPHTH VIS SCI, V46, P4393, DOI 10.1167/iovs.05-0820
   Radu RA, 2003, P NATL ACAD SCI USA, V100, P4742, DOI 10.1073/pnas.0737855100
   Radu RA, 2011, J BIOL CHEM, V286, P18593, DOI 10.1074/jbc.M110.191866
   Rattner A, 2000, J BIOL CHEM, V275, P11034, DOI 10.1074/jbc.275.15.11034
   Rattner A, 2006, NAT REV NEUROSCI, V7, P860, DOI 10.1038/nrn2007
   Redmond TM, 2007, MOL VIS, V13, P1813
   Redmond TM, 1998, NAT GENET, V20, P344, DOI 10.1038/3813
   Rivera A, 2000, AM J HUM GENET, V67, P800, DOI 10.1086/303090
   Rossi EA, 2011, EYE, V25, P301, DOI 10.1038/eye.2010.221
   Rozanowska M, 2005, PHOTOCHEM PHOTOBIOL, V81, P1305, DOI 10.1562/2004-11-13-IR-371
   Schmitz-Valckenberg S, 2008, RETINA-J RET VIT DIS, V28, P385, DOI 10.1097/IAE.0b013e318164a907
   Schmitz-Valckenberg S, 2008, AM J OPHTHALMOL, V146, P183, DOI 10.1016/j.ajo.2008.04.006
   Schmitz-Valckenberg S, 2011, INVEST OPHTH VIS SCI, V52, P1, DOI 10.1167/iovs.10-5619
   Schmitz-Valckenberg S, 2009, SURV OPHTHALMOL, V54, P96, DOI 10.1016/j.survophthal.2008.10.004
   Shiose S, 2011, J BIOL CHEM, V286, P15543, DOI 10.1074/jbc.M111.228551
   Sieving PA, 2001, P NATL ACAD SCI USA, V98, P1835, DOI 10.1073/pnas.041606498
   Smith RT, 2009, INVEST OPHTH VIS SCI, V50, P3907, DOI 10.1167/iovs.08-2448
   Sparrow JR, 2008, ADV EXP MED BIOL, V613, P393, DOI 10.1007/978-0-387-74904-4_46
   Sparrow JR, 2010, PHOTOCH PHOTOBIO SCI, V9, P1480, DOI 10.1039/c0pp00207k
   Sparrow JR, 1999, INVEST OPHTH VIS SCI, V40, P2988
   Sparrow JR, 2000, INVEST OPHTH VIS SCI, V41, P1981
   Sun H, 2001, J BIOL CHEM, V276, P11766, DOI 10.1074/jbc.M010152200
   Sun H, 2000, NAT GENET, V26, P242, DOI 10.1038/79994
   Tawa P, 2001, CELL DEATH DIFFER, V8, P30, DOI 10.1038/sj.cdd.4400769
   Travis GH, 2007, ANNU REV PHARMACOL, V47, P469, DOI 10.1146/annurev.pharmtox.47.120505.105225
   Tsybovsky Y, 2011, BIOCHEMISTRY-US, V50, P6855, DOI 10.1021/bi200774w
   Tsybovsky Y, 2010, ADV EXP MED BIOL, V703, P105, DOI 10.1007/978-1-4419-5635-4_8
   Vasiliou Vasilis, 2009, Human Genomics, V3, P281
   Vives-Bauza C, 2008, J BIOL CHEM, V283, P24770, DOI 10.1074/jbc.M800706200
   Walia S, 2009, OPHTHALMIC GENET, V30, P63, DOI 10.1080/13816810802695550
   Wang XY, 2010, CURR BIOL, V20, P93, DOI 10.1016/j.cub.2009.12.022
   WEINGEIST TA, 1982, ARCH OPHTHALMOL-CHIC, V100, P1108
   WEITER JJ, 1986, INVEST OPHTH VIS SCI, V27, P145
   WELEBER RG, 1994, ARCH OPHTHALMOL-CHIC, V112, P752, DOI 10.1001/archopht.1994.01090180050033
   WING GL, 1978, INVEST OPHTH VIS SCI, V17, P601
   Yasukawa T, 2007, GRAEF ARCH CLIN EXP, V245, P1475, DOI 10.1007/s00417-007-0571-z
NR 101
TC 52
Z9 54
U1 0
U2 18
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0031-8655
EI 1751-1097
J9 PHOTOCHEM PHOTOBIOL
JI Photochem. Photobiol.
PD NOV-DEC
PY 2012
VL 88
IS 6
BP 1309
EP 1319
DI 10.1111/j.1751-1097.2012.01143.x
PG 11
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA 030IB
UT WOS:000310563300002
PM 22428905
OA Bronze, Green Accepted
DA 2022-11-30
ER

PT J
AU Xu, HM
   Wei, J
   Pan, L
   Lin, HY
   Wang, WQ
   Zhang, YH
   Shen, ZL
AF Xu, Han-Mei
   Wei, Jin
   Pan, Li
   Lin, Hongying
   Wang, Weiqiang
   Zhang, Yihua
   Shen, Zilong
TI The Mechanism of (R,R) ZX-5 on Increasing NO Release
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE (R,R) ZX-5; iNOS; eNOS; ERK; Akt
ID NITRIC-OXIDE SYNTHASE; ENDOTHELIAL GROWTH-FACTOR; ACTIVATION; PATHWAY;
   AKT; NEOVASCULARIZATION; EPIDEMIOLOGY; ISCHEMIA
AB (R,R) ZX-5 has been proven to have positive effects on choroidal blood flow without affecting the sclera and ciliary bodies in New Zealand white rabbits. This study was designed to investigate the mechanisms of (R,R) ZX-5 on improving the choroidal blood flow and promoting NO production. HUVECs (human umbilical vein endothelial cells) were used to determine the production of eNOS, p-eNOS, AKT and Erk1/2 by Western blot analysis. iNOS and eNOS mRNA levels were investigated by RT-PCR and the effect of (R,R) ZX-5 on NO production were determined by eNOS activity assay. We found (R,R) ZX-5 upregulated protein expression of eNOS and iNOS, increased NO production, and reduced ERK and Akt protein level. Therefore, (R,R) ZX-5 may promote the choroidal blood flow in New Zealand white rabbits without affecting the blood flow in the iris or ciliary bodies via increasing NO production. These results suggest that (R,R) ZX-5 may function to cure and prevent Age-related macular degeneration (AMD).
C1 [Xu, Han-Mei; Wei, Jin; Pan, Li; Lin, Hongying; Wang, Weiqiang; Shen, Zilong] China Pharmaceut Univ, Coll Life Sci & Technol, Dept Marine Pharm, Nanjing 210009, Jiangsu, Peoples R China.
   [Zhang, Yihua] China Pharmaceut Univ, Dept Pharm, Nanjing 210009, Jiangsu, Peoples R China.
C3 China Pharmaceutical University; China Pharmaceutical University
RP Shen, ZL (通讯作者)，China Pharmaceut Univ, Coll Life Sci & Technol, Dept Marine Pharm, Nanjing 210009, Jiangsu, Peoples R China.
EM xuhanmei@yahoo.com.cn; tiandezhijian@126.com; panli0225@163.com;
   hongyin7719@sina.com; wwq1979@163.com; zyhtgd@sohu.com;
   zilongshe@sina.com
FU National Science Foundation of China (NSFC) [30472085, 30873073];
   Natural Science Foundation of Jiangsu Province of China [BK2004108]
FX The authors want to thank National Science Foundation of China (NSFC,
   No. 30472085,30873073) and the Natural Science Foundation of Jiangsu
   Province of China (No. BK2004108) for the funding.
CR Albrecht EWJA, 2003, J PATHOL, V199, P8, DOI 10.1002/path.1250
   Bernier SG, 2000, J BIOL CHEM, V275, P30707, DOI 10.1074/jbc.M005116200
   Cale JM, 2006, BIOCHEM J, V398, P279, DOI 10.1042/BJ20060371
   Cha MS, 2001, BIOCHEM BIOPH RES CO, V282, P1061, DOI 10.1006/bbrc.2001.4682
   Chiou GCY, 2001, J OCUL PHARMACOL TH, V17, P189, DOI 10.1089/10807680151125555
   Goetze S, 2002, HYPERTENSION, V40, P748, DOI 10.1161/01.HYP.0000035522.63647.D3
   Igarashi J, 2001, J BIOL CHEM, V276, P36281, DOI 10.1074/jbc.M105628200
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Knowles RG, 1998, METH MOL B, V100, P67
   Korkmaz Y, 2006, J DENT RES, V85, P536, DOI 10.1177/154405910608500611
   Kou RQ, 2002, BIOCHEMISTRY-US, V41, P4982, DOI 10.1021/bi016017r
   Lorenz M, 2004, J BIOL CHEM, V279, P6190, DOI 10.1074/jbc.M309114200
   Miller JW, 1997, AM J PATHOL, V151, P13
   Mineo C, 2003, J BIOL CHEM, V278, P9142, DOI 10.1074/jbc.M211394200
   Schmidt K, 2002, BIOCHEM PHARMACOL, V63, P1137, DOI 10.1016/S0006-2952(01)00936-4
   Smith LEH, 1997, SCIENCE, V276, P1706, DOI 10.1126/science.276.5319.1706
   Song SJ, 2008, OPHTHALMIC RES, V40, P35, DOI 10.1159/000111157
   van Leeuwen R, 2003, EUR J EPIDEMIOL, V18, P845, DOI 10.1023/A:1025643303914
   Wei ZH, 2001, AM J PHYSIOL-HEART C, V281, pH2226, DOI 10.1152/ajpheart.2001.281.5.H2226
   Wyatt AW, 2002, FASEB J, V16, P1584, DOI 10.1096/fasebj.16.12.1584
   Xuan B, 2003, J OCUL PHARMACOL TH, V19, P247, DOI 10.1089/108076803321908365
   Yang XM, 2009, INVEST OPHTH VIS SCI, V50, P1873, DOI 10.1167/iovs.08-2591
NR 22
TC 2
Z9 2
U1 1
U2 7
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1422-0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD SEP
PY 2010
VL 11
IS 9
BP 3323
EP 3333
DI 10.3390/ijms11093323
PG 11
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA 655DK
UT WOS:000282223500019
PM 20957097
OA Green Published, Green Submitted, gold
DA 2022-11-30
ER

PT J
AU Lundmark, PO
   Pandi-Perumal, SR
   Srinivasan, V
   Cardinali, DP
   Rosenstein, RE
AF Lundmark, Per O.
   Pandi-Perumal, S. R.
   Srinivasan, V.
   Cardinali, D. P.
   Rosenstein, R. E.
TI Melatonin in the eye: Implications for glaucoma
SO EXPERIMENTAL EYE RESEARCH
LA English
DT Review
DE melatonin; glaucoma; intraocular pressure; antioxidant properties;
   glutamate excitotoxicity; free radicals
ID SEROTONIN N-ACETYLTRANSFERASE; RETINAL GANGLION-CELLS; NITRIC-OXIDE
   SYNTHASE; OPEN-ANGLE GLAUCOMA; CARBONIC-ANHYDRASE INHIBITOR;
   XENOPUS-LAEVIS RETINA; BEAVER DAM EYE; INTRAOCULAR-PRESSURE; RAT RETINA;
   MACULAR DEGENERATION
AB Melatonin synthesis occurs in the retina of most animals as well as in humans. Circadian oscillators that control retinal melatonin synthesis have been identified in the eyes of different animal species. The presence of melatonin receptors is demonstrable by immunocytochemical studies of ocular tissues. These receptors may have different functional roles in different parts of the eye. In view that melatonin is a potent antioxidant molecule, it can be effective in scavenging free radicals that are generated in ocular tissues. By this mechanism melatonin could protect the ocular tissues against disorders like glaucoma, age-related macular degeneration, retinopathy of prematurity, photo-keratitis and cataracts. Although an increased intraocular pressure is an important risk factor in glaucoma, other concomitant phenomena like increased glutamate levels, altered nitric oxide metabolism and increased free radical generation seem to play a significant role in its pathogenesis. Data are discussed indicating that melatonin, being an efficient antioxidant with antinitridergic properties, has a promising role in the treatment and management of glaucoma. (c) 2006 Elsevier Ltd. All rights reserved.
C1 Buskerud Univ Hosp, Dept Optometry & Vis Sci, NO-3601 Kongsberg, Norway.
   Mt Sinai Sch Med, Comprehens Ctr Sleep Med, Dept Pulm Crit Care & Sleep Med, New York, NY 10029 USA.
   Univ Sains Malaysia, Sch Med Sci, Dept Physiol, Kelanta 16150, Malaysia.
   Univ Buenos Aires, Fac Med, Dept Fis, RA-1121 Buenos Aires, DF, Argentina.
   Univ Buenos Aires, Fac Med, Dept Bioquim Humana, RA-1121 Buenos Aires, DF, Argentina.
C3 Icahn School of Medicine at Mount Sinai; Universiti Sains Malaysia;
   University of Buenos Aires; University of Buenos Aires
RP Pandi-Perumal, SR (通讯作者)，Buskerud Univ Hosp, Dept Optometry & Vis Sci, NO-3601 Kongsberg, Norway.
EM pandiperumal2006@gmail.com
RI Pandi-Perumal, Seithikurippu R/HDM-2070-2022; Ratnas, Pandi-Perumal
   Seithikurippu/C-6767-2008; Pandi-Perumal, Seithikurippu R./Q-8281-2016
OI Ratnas, Pandi-Perumal Seithikurippu/0000-0002-8686-7259; Pandi-Perumal,
   Seithikurippu R./0000-0002-8686-7259
CR Acuna Castroviejo Dario, 2002, Curr Top Med Chem, V2, P133
   ALDER VA, 1985, CURR EYE RES, V4, P121, DOI 10.3109/02713688508999977
   ALONSOGOMEZ AL, 1995, J NEUROCHEM, V65, P1054
   Avery RL, 1996, RETINA-J RET VIT DIS, V16, P183, DOI 10.1097/00006982-199616030-00001
   Bailey MJ, 2002, FEBS LETT, V513, P169, DOI 10.1016/S0014-5793(02)02276-7
   Benozzi J, 2002, INVEST OPHTH VIS SCI, V43, P2196
   Bernard M, 1999, REPROD NUTR DEV, V39, P325, DOI 10.1051/rnd:19990305
   Brainard GC, 2001, J CLIN ENDOCR METAB, V86, P433, DOI 10.1210/jc.86.1.433
   Brainard GC, 2001, J NEUROSCI, V21, P6405
   BUBENIK GA, 1980, CAN J PHYSIOL PHARM, V58, P1457, DOI 10.1139/y80-220
   BUNIN AY, 1992, VESTN OFTALMOL, V108, P13
   CAHILL GM, 1993, NEURON, V10, P573, DOI 10.1016/0896-6273(93)90160-S
   Cai JY, 2000, PROG RETIN EYE RES, V19, P205, DOI 10.1016/S1350-9462(99)00009-9
   CARDINAL.DP, 1971, ENDOCRINOLOGY, V89, P301, DOI 10.1210/endo-89-1-301
   CARDINALI DP, 1971, J NEUROCHEM, V18, P1769, DOI 10.1111/j.1471-4159.1971.tb03752.x
   Chan DKL, 1999, J PERINAT MED, V27, P395, DOI 10.1515/JPM.1999.054
   Chew SJ, 1997, J GLAUCOMA, V6, P263
   Ciuffi M, 2003, J PHOTOCH PHOTOBIO B, V71, P59, DOI 10.1016/j.jphotobiol.2003.07.004
   Claustrat B, 2005, SLEEP MED REV, V9, P11, DOI 10.1016/j.smrv.2004.08.001
   CRUICKSHANKS KJ, 1993, ARCH OPHTHALMOL-CHIC, V111, P514, DOI 10.1001/archopht.1993.01090040106042
   Cruickshanks KJ, 2001, ARCH OPHTHALMOL-CHIC, V119, P246
   Dinet V, 2006, EXP EYE RES, V83, P276, DOI 10.1016/j.exer.2005.12.011
   DOREY CK, 1990, CURR EYE RES, V9, P549, DOI 10.3109/02713689008999595
   Doyle SE, 2002, VISUAL NEUROSCI, V19, P593, DOI 10.1017/S0952523802195058
   DREYER EB, 1994, NEUROREPORT, V5, P629, DOI 10.1097/00001756-199401000-00024
   Dreyer EB, 1996, ARCH OPHTHALMOL-CHIC, V114, P299, DOI 10.1001/archopht.1996.01100130295012
   Dubocovich M. L., 2000, IUPHAR COMPENDIUM RE, P271
   Dubocovich ML, 1997, N-S ARCH PHARMACOL, V355, P365, DOI 10.1007/PL00004956
   DUBOCOVICH ML, 1987, P NATL ACAD SCI USA, V84, P3916, DOI 10.1073/pnas.84.11.3916
   Foster RG, 2002, PROG RETIN EYE RES, V21, P507, DOI 10.1016/S1350-9462(02)00036-8
   FRAMPTON P, 1987, AM J OPTOM PHYS OPT, V64, P54
   Fujieda H, 1999, NEUROSCIENCE, V93, P793, DOI 10.1016/S0306-4522(99)00111-6
   Fujieda H, 2000, VISUAL NEUROSCI, V17, P63, DOI 10.1017/S0952523800171068
   Fukuhara C, 2004, J NEUROSCI, V24, P1803, DOI 10.1523/JNEUROSCI.4988-03.2004
   Fukuhara C, 2001, NEUROREPORT, V12, P3833, DOI 10.1097/00001756-200112040-00046
   GAN JW, 1995, NEUROCHEM INT, V27, P147, DOI 10.1016/0197-0186(95)00035-7
   Garbarino-Pico E, 2004, J BIOL CHEM, V279, P51172, DOI 10.1074/jbc.M309248200
   Green W R, 1977, Trans Am Ophthalmol Soc, V75, P180
   Greve P, 1999, J NEUROCHEM, V73, P1894
   Guenther AL, 2005, J PINEAL RES, V39, P251, DOI 10.1111/j.1600-079X.2005.00242.x
   HADRELAND R, 2006, CELL BIOL, V38, P313
   HAMM HE, 1980, P NATL ACAD SCI-BIOL, V77, P4998, DOI 10.1073/pnas.77.8.4998
   Hammond BR, 1996, VISION RES, V36, P3003, DOI 10.1016/0042-6989(96)00008-9
   Haque R, 2002, NEUROREPORT, V13, P2247, DOI 10.1097/00001756-200212030-00016
   HARDELAND R, 1995, J PINEAL RES, V18, P104, DOI 10.1111/j.1600-079X.1995.tb00147.x
   Hardeland R, 2005, ENDOCRINE, V27, P119, DOI 10.1385/ENDO:27:2:119
   Isorna E, 2004, GEN COMP ENDOCR, V135, P259, DOI 10.1016/j.ygcen.2003.10.003
   Iuvone PM, 2002, INVEST OPHTH VIS SCI, V43, P564
   Ivanova TN, 2003, BRAIN RES, V973, P56, DOI 10.1016/S0006-8993(03)02540-X
   IWONE PM, 1995, J NEUROCHEM, V64, P1892
   Kaushik S, 2003, J Postgrad Med, V49, P90
   KITAZAWA Y, 1975, AM J OPHTHALMOL, V79, P557, DOI 10.1016/0002-9394(75)90792-8
   KLEIN BE, 1982, ARCH OPHTHALMOL-CHIC, V100, P571
   Kvetnoy I, 2002, NEUROENDOCRINOL LETT, V23, P92
   LEE PY, 1987, ARCH OPHTHALMOL-CHIC, V105, P249
   Leon J, 2004, LIFE SCI, V75, P765, DOI 10.1016/j.lfs.2004.03.003
   Liang FQ, 2004, EXP EYE RES, V78, P1069, DOI 10.1016/j.exer.2004.02.003
   Liang FQ, 2003, EXP EYE RES, V76, P397, DOI 10.1016/S0014-4835(03)00023-X
   Liu CM, 2004, CELL TISSUE RES, V315, P197, DOI 10.1007/s00441-003-0822-1
   LIU W, 1999, P AS C SIGN SYST COM, V1, P32
   LUNDMARK PO, IN PRESS VIS NEUROSC
   Marchiafava PL, 1999, J PINEAL RES, V26, P184, DOI 10.1111/j.1600-079X.1999.tb00582.x
   Martin X D, 1992, Eur J Ophthalmol, V2, P67
   Meyer P, 2002, BRIT J OPHTHALMOL, V86, P1053, DOI 10.1136/bjo.86.9.1053
   MHATRE MC, 1988, BIOCHEM BIOPH RES CO, V153, P1186, DOI 10.1016/S0006-291X(88)81353-6
   Militante J, 2004, NEUROCHEM RES, V29, P151, DOI 10.1023/B:NERE.0000010444.97959.1b
   Moore CG, 1996, CURR EYE RES, V15, P185, DOI 10.3109/02713689608997412
   Moore RY, 1997, ANNU REV MED, V48, P253, DOI 10.1146/annurev.med.48.1.253
   Moreno MC, 2005, FASEB J, V19, P1161, DOI 10.1096/fj.04-3313fje
   Moreno MC, 2005, EXP EYE RES, V81, P71, DOI 10.1016/j.exer.2005.01.008
   Moreno MC, 2004, FREE RADICAL BIO MED, V37, P803, DOI 10.1016/j.freeradbiomed.2004.06.001
   Namihira M, 2001, NEUROREPORT, V12, P471, DOI 10.1097/00001756-200103050-00010
   Natesan AK, 2002, VISUAL NEUROSCI, V19, P265, DOI 10.1017/S0952523802192042
   NETLAND PA, 1993, AM J OPHTHALMOL, V115, P608, DOI 10.1016/S0002-9394(14)71458-8
   Neufeld AH, 2004, BRAIN RES BULL, V62, P455, DOI 10.1016/j.brainresbull.2003.07.005
   Neufeld AH, 1997, ARCH OPHTHALMOL-CHIC, V115, P497, DOI 10.1001/archopht.1997.01100150499009
   Niki T, 1998, BIOCHEM BIOPH RES CO, V248, P115, DOI 10.1006/bbrc.1998.8916
   Nohl H, 2005, BIOCHEM PHARMACOL, V69, P719, DOI 10.1016/j.bcp.2004.12.002
   Nosjean O, 2000, J BIOL CHEM, V275, P31311, DOI 10.1074/jbc.M005141200
   Nosjean O, 2001, BIOCHEM PHARMACOL, V61, P1369, DOI 10.1016/S0006-2952(01)00615-3
   Osborne N N, 1999, Curr Opin Ophthalmol, V10, P82, DOI 10.1097/00055735-199904000-00002
   Osborne Neville N., 1994, Acta Neurobiologiae Experimentalis (Warsaw), V54, P57
   OSBORNE NN, 1994, EXP EYE RES, V59, P3, DOI 10.1006/exer.1994.1076
   Pandi-Perumal SR, 2006, FEBS J, V273, P2813, DOI 10.1111/j.1742-4658.2006.05322.x
   PANG SF, 1980, J ENDOCRINOL, V87, P89, DOI 10.1677/joe.0.0870089
   Papp A, 1999, FREE RADICAL BIO MED, V27, P738, DOI 10.1016/S0891-5849(99)00041-6
   PIERCE ME, 1985, J GEN PHYSIOL, V86, P671, DOI 10.1085/jgp.86.5.671
   Pintor J, 2001, EUR J PHARMACOL, V416, P251, DOI 10.1016/S0014-2999(01)00864-0
   POEGGELER B, 1993, J PINEAL RES, V14, P151, DOI 10.1111/j.1600-079X.1993.tb00498.x
   Rada JAS, 2006, INVEST OPHTH VIS SCI, V47, P25, DOI 10.1167/iovs.05-0195
   Reiter RJ, 1998, PROG NEUROBIOL, V56, P359, DOI 10.1016/S0301-0082(98)00052-5
   Reiter RJ, 1997, HORM METAB RES, V29, P363, DOI 10.1055/s-2007-979057
   REPPERT SM, 1995, P NATL ACAD SCI USA, V92, P8734, DOI 10.1073/pnas.92.19.8734
   Ritch R, 2000, Curr Opin Ophthalmol, V11, P78, DOI 10.1097/00055735-200004000-00002
   Rufiange M, 2002, INVEST OPHTH VIS SCI, V43, P2491
   Saenz DA, 2002, J PINEAL RES, V33, P31, DOI 10.1034/j.1600-079X.2002.01880.x
   SAMPLES JR, 1988, CURR EYE RES, V7, P649, DOI 10.3109/02713688809033192
   Savaskan E, 2002, J HISTOCHEM CYTOCHEM, V50, P519, DOI 10.1177/002215540205000408
   Scher J, 2003, EXP EYE RES, V77, P375, DOI 10.1016/S0014-4835(03)00123-4
   Scher J, 2002, INVEST OPHTH VIS SCI, V43, P889
   Serle JB, 2004, J GLAUCOMA, V13, P385, DOI 10.1097/01.ijg.0000133150.44686.0b
   Serle JB, 1998, JPN J OPHTHALMOL, V42, P95, DOI 10.1016/S0021-5155(97)00128-7
   Shareef S, 1999, INVEST OPHTH VIS SCI, V40, P2884
   SILIPRANDI R, 1992, VISUAL NEUROSCI, V8, P567, DOI 10.1017/S0952523800005666
   Siu AW, 1999, J PINEAL RES, V27, P122, DOI 10.1111/j.1600-079X.1999.tb00606.x
   Siu AW, 2006, J PINEAL RES, V40, P101, DOI 10.1111/j.1600-079X.2005.00304.x
   Siu AW, 2002, EXP EYE RES, V75, P401, DOI 10.1006/exer.2002.2029
   SMITH SD, 1989, INVEST OPHTH VIS SCI, V30, P775
   Srinivasan V, 2006, Behav Brain Funct, V2, P15, DOI 10.1186/1744-9081-2-15
   Srinivasan V, 2005, NEUROTOX RES, V7, P293, DOI 10.1007/BF03033887
   SUCHER NJ, 1991, BRAIN RES, V551, P297, DOI 10.1016/0006-8993(91)90944-Q
   Sugawara T, 1998, INVEST OPHTH VIS SCI, V39, P2458
   Tan DX, 2003, J PINEAL RES, V34, P249, DOI 10.1034/j.1600-079X.2003.00037.x
   Thompson CL, 2004, MOL BRAIN RES, V122, P158, DOI 10.1016/j.molbrainres.2003.12.006
   Tosini G, 2000, CHRONOBIOL INT, V17, P599, DOI 10.1081/CBI-100101067
   Tosini G, 1996, SCIENCE, V272, P419, DOI 10.1126/science.272.5260.419
   Tosini G, 1998, BRAIN RES, V789, P221, DOI 10.1016/S0006-8993(97)01446-7
   Uchida K, 1999, MOL VIS, V5, pU1
   VIGGIANO SR, 1994, OPHTHALMOLOGY, V101, P326
   Vorwerk CK, 1996, INVEST OPHTH VIS SCI, V37, P1618
   WANG RF, 1990, CURR EYE RES, V9, P163, DOI 10.3109/02713689008995202
   WANG RF, 1990, ARCH OPHTHALMOL-CHIC, V108, P511, DOI 10.1001/archopht.1990.01070060059049
   Weinreb RN, 1999, ARCH OPHTHALMOL-CHIC, V117, P1540
   Wiechmann AF, 2004, EXP EYE RES, V79, P585, DOI 10.1016/j.exer.2004.07.004
   WIECHMANN AF, 1986, EXP EYE RES, V42, P507, DOI 10.1016/0014-4835(86)90042-4
   WIECHMANN AF, 1991, J PINEAL RES, V10, P174, DOI 10.1111/j.1600-079X.1991.tb00812.x
   WIECHMANN AF, 1992, INVEST OPHTH VIS SCI, V33, P1894
   Wiechmann AF, 2003, INVEST OPHTH VIS SCI, V44, P4522, DOI 10.1167/iovs.03-0329
   Wiechmann AF, 2003, EXP EYE RES, V77, P219, DOI 10.1016/S0014-4835(03)00126-X
   Wiechmann AF, 2001, VISUAL NEUROSCI, V18, P695, DOI 10.1017/S0952523801185032
   Wiechmann AF, 1999, MOL BRAIN RES, V63, P297, DOI 10.1016/S0169-328X(98)00292-7
   Wiechmann AF, 2001, MOL BRAIN RES, V91, P104, DOI 10.1016/S0169-328X(01)00134-6
   WIECHMANN AF, 1994, BRAIN BEHAV EVOLUT, V43, P26, DOI 10.1159/000113622
   Witkovsky P, 2003, J NEUROSCI, V23, P7670
   Yi CX, 2005, ANN NY ACAD SCI, V1057, P384, DOI 10.1196/annals.1356.029
   YU HS, 1990, NEUROSCI LETT, V116, P309, DOI 10.1016/0304-3940(90)90092-N
   ZAWILSKA J, 1989, Acta Physiologica Polonica, V40, P28
   Zisapel N, 2001, CELL MOL NEUROBIOL, V21, P605, DOI 10.1023/A:1015187601628
NR 138
TC 48
Z9 49
U1 1
U2 10
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0014-4835
EI 1096-0007
J9 EXP EYE RES
JI Exp. Eye Res.
PD JUN
PY 2007
VL 84
IS 6
BP 1021
EP 1030
DI 10.1016/j.exer.2006.10.018
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 179HC
UT WOS:000247279300002
PM 17174303
DA 2022-11-30
ER

PT J
AU Takahashi, H
   Obata, R
   Tamaki, Y
AF Takahashi, Hidenori
   Obata, Ryo
   Tamaki, Yasuhiro
TI A novel vascular endothelial growth factor receptor 2 inhibitor,
   SU11248, suppresses choroidal neovascularization in vivo
SO JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS
LA English
DT Article
ID TYROSINE KINASE INHIBITOR; CELL SURVIVAL; VEGF; EXPRESSION; PATHWAY;
   PDGF
AB Aim: An oral, multitargeted receptor tyrosine kinase inhibitor, SU11248, inhibits vascular endothelial growth factor receptor 2 (VEG FR2, kinase domain receptor F1K1), platelet-derived growth factor receptor, stem cell factor receptor (Kit), and fetal liver tyrosine kinase 3. In this study, we administered SU11248 beyond the completion of an experimental choroidal neovascularization (CNV) model to determine whether CNV growth can be inhibited in vivo.
   Methods: C57B6J mice were treated with daily oral administration (40, 80, and 150 mg/kg) of SU11248 during 5 days after diode laser endophotocoagulation and subjected to angiographic examination and histological analysis.
   Results: Intensity of fluorescein leakage from the experimental CNV decreased significantly compared to the control eyes. Histological study also revealed that the volume of CNV membrane was significantly reduced in the SU11248-treated eyes.
   Conclusions: Oral administration of this compound is potentially beneficial in treating CNV caused by age-related macular degeneration (AMD) and other causal diseases. Considering the tolerance the clinical studies for malignant tumors previously demonstrated, further studies to evaluate the clinical efficacy of the drug for AMD might be indicated.
C1 Univ Tokyo, Sch Med, Dept Ophthalmol, Bunkyo Ku, Tokyo 1138655, Japan.
C3 University of Tokyo
RP Takahashi, H (通讯作者)，Univ Tokyo, Sch Med, Dept Ophthalmol, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138655, Japan.
EM takahah-tky@umin.ac.jp
RI Takahashi, Hidenori/H-2945-2019
OI Takahashi, Hidenori/0000-0001-5331-4730; Obata, Ryo/0000-0002-1762-0797
CR [Anonymous], 1993, Arch Ophthalmol, V111, P1200
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Bergers G, 2003, J CLIN INVEST, V111, P1287, DOI 10.1172/JCI200317929
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Cui JZ, 2000, GRAEF ARCH CLIN EXP, V238, P326, DOI 10.1007/s004170050360
   DAngelo G, 1997, J CELL BIOCHEM, V67, P353, DOI 10.1002/(SICI)1097-4644(19971201)67:3<353::AID-JCB7>3.3.CO;2-2
   Erber R, 2003, FASEB J, V17, P338, DOI 10.1096/fj.03-0271fje
   Espinosa-Heidmann DG, 2003, INVEST OPHTH VIS SCI, V44, P4914, DOI 10.1167/iovs.03-0371
   Ferrara N, 2001, AM J PHYSIOL-CELL PH, V280, pC1358, DOI 10.1152/ajpcell.2001.280.6.C1358
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Gerber HP, 1998, J BIOL CHEM, V273, P30336, DOI 10.1074/jbc.273.46.30336
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Heissig B, 2003, THROMB HAEMOSTASIS, V90, P570, DOI 10.1160/TH03-03-0188
   Ishibashi T, 1997, GRAEF ARCH CLIN EXP, V235, P159, DOI 10.1007/BF00941723
   Iwashita Kenshiro, 1999, Nippon Ganka Gakkai Zasshi, V103, P415
   Kinose F, 2005, MOL VIS, V11, P366
   Kwak N, 2000, INVEST OPHTH VIS SCI, V41, P3158
   Mendel DB, 2003, CLIN CANCER RES, V9, P327
   O'Farrell AM, 2003, BLOOD, V101, P3597, DOI 10.1182/blood-2002-07-2307
   Rousseau S, 1997, ONCOGENE, V15, P2169, DOI 10.1038/sj.onc.1201380
   Sengupta N, 2003, INVEST OPHTH VIS SCI, V44, P4908, DOI 10.1167/iovs.03-0342
   Shen WY, 1998, BRIT J OPHTHALMOL, V82, P1063, DOI 10.1136/bjo.82.9.1063
   Sun JZ, 2005, ONCOGENE, V24, P4701, DOI 10.1038/sj.onc.1208391
   Takahashi H, 2004, BIOCHEM BIOPH RES CO, V325, P461, DOI 10.1016/j.bbrc.2004.10.054
   Takahashi H, 2004, BIOCHEM BIOPH RES CO, V320, P372, DOI 10.1016/j.bbrc.2004.05.177
   Takahashi T, 1999, ONCOGENE, V18, P2221, DOI 10.1038/sj.onc.1202527
   Takeda A, 2003, GRAEF ARCH CLIN EXP, V241, P765, DOI 10.1007/s00417-003-0688-7
   van Wijngaarden P, 2005, JAMA-J AM MED ASSOC, V293, P1509, DOI 10.1001/jama.293.12.1509
   Yi XJ, 1997, GRAEF ARCH CLIN EXP, V235, P313, DOI 10.1007/BF01739641
   Yu MJT, 2000, GROWTH FACTORS, V17, P301, DOI 10.3109/08977190009028973
   Yuzawa Mitsuko, 2000, Nippon Ganka Gakkai Zasshi, V104, P875
NR 31
TC 40
Z9 43
U1 1
U2 7
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1080-7683
EI 1557-7732
J9 J OCUL PHARMACOL TH
JI J. Ocular Pharmacol. Ther.
PD AUG
PY 2006
VL 22
IS 4
BP 213
EP 218
DI 10.1089/jop.2006.22.213
PG 6
WC Ophthalmology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Pharmacology & Pharmacy
GA 075MK
UT WOS:000239888900001
PM 16910860
DA 2022-11-30
ER

PT J
AU Lee, JH
   Canny, MD
   De Erkenez, A
   Krilleke, D
   Ng, YS
   Shima, DT
   Pardi, A
   Jucker, F
AF Lee, JH
   Canny, MD
   De Erkenez, A
   Krilleke, D
   Ng, YS
   Shima, DT
   Pardi, A
   Jucker, F
TI A therapeutic aptamer inhibits angiogenesis by specifically targeting
   the heparin binding domain of VEGF(165)
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
DE age-related macular degeneration; Macugen; RNA; NMR
ID ENDOTHELIAL GROWTH-FACTOR; MACULAR DEGENERATION; RECEPTOR-BINDING;
   VASCULAR-PERMEABILITY; RNA LIGANDS; IN-VITRO; VEGF; COMPLEX; NMR;
   NEUROPILIN-1
AB Aptamers recognize their targets with extraordinary affinity and specificity. The aptamer-based therapeutic, Macugen, is derived from a modified 2'fluoro pyrimidine RNA inhibitor to vascular endothelial growth factor (VEGF) and is now being used to treat the wet form of age-related macular degeneration. This VEGF(165) aptamer binds specifically to the VEGF(165) isoform, a dimeric protein with a receptor-binding domain and a heparin-binding domain (HBD). To understand the molecular recognition between VEGF and this aptamer, binding experiments were used to show that the HBD contributes the majority of binding energy in the VEGF(165)-aptamer complex. A tissue culture-based competition assay demonstrated that the HBD effectively competes with VEGF(165) for aptamer binding in vivo. Comparison of NMR spectra revealed that structural features of the smaller HBD-aptamer complex are present in the full-length VEGF(164)-aptamer complex. These data show that the HBD provides the binding site for the aptamer and is the primary determinant for the affinity and specificity in the VEGF(165)-aptamer complex.
C1 Univ Colorado, Dept Chem & Biochem, Boulder, CO 80309 USA.
   Eyetech Res Ctr, Lexington, MA USA.
C3 University of Colorado System; University of Colorado Boulder
RP Jucker, F (通讯作者)，Dharmacon Inc, Lafayette, CO 80026 USA.
EM fiona.jucker@dharmacon.com
RI Lee, Joon-Hwa/G-1686-2010
OI Ng, Yin Shan/0000-0002-4982-1999; Lee, Joon-Hwa/0000-0003-3137-4585
FU NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR011969, S10RR016649]
   Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND
   INFECTIOUS DISEASES [R01AI033098, R56AI033098] Funding Source: NIH
   RePORTER; NCRR NIH HHS [S10 RR011969, RR16649, S10 RR016649] Funding
   Source: Medline; NIAID NIH HHS [R01 AI033098, R56 AI033098] Funding
   Source: Medline
CR Bell C, 1999, IN VITRO CELL DEV-AN, V35, P533
   Burmeister PE, 2005, CHEM BIOL, V12, P25, DOI 10.1016/j.chembiol.2004.10.017
   Castagne C, 2000, EUR J BIOCHEM, V267, P1223, DOI 10.1046/j.1432-1327.2000.01124.x
   CUMMINS LL, 1995, NUCLEIC ACIDS RES, V23, P2019, DOI 10.1093/nar/23.11.2019
   DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809
   Farmer BT, 1996, NAT STRUCT BIOL, V3, P995, DOI 10.1038/nsb1296-995
   Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669
   Fine SL, 2005, NAT REV DRUG DISCOV, V4, P187, DOI 10.1038/nrd1677
   GODDARD TD, 2003, SPARKY
   Golden MC, 2000, J BIOTECHNOL, V81, P167, DOI 10.1016/S0168-1656(00)00290-X
   Gorenstein D.G., 1984, PHOSPHOROUS 31 NMR P
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   GREEN LS, 1995, CHEM BIOL, V2, P683, DOI 10.1016/1074-5521(95)90032-2
   GUERON M, 1975, P NATL ACAD SCI USA, V72, P3482, DOI 10.1073/pnas.72.9.3482
   Hermann T, 2000, SCIENCE, V287, P820, DOI 10.1126/science.287.5454.820
   Heroult M, 2004, ONCOGENE, V23, P1745, DOI 10.1038/sj.onc.1206879
   Inoki I, 2001, FASEB J, V15, P219, DOI 10.1096/fj.01-0332fje
   Ishida S, 2003, J EXP MED, V198, P483, DOI 10.1084/jem.20022027
   JELLINEK D, 1994, BIOCHEMISTRY-US, V33, P10450, DOI 10.1021/bi00200a028
   Lucerna M, 2003, J BIOL CHEM, V278, P11433, DOI 10.1074/jbc.M204937200
   Luque A, 2003, J BIOL CHEM, V278, P23656, DOI 10.1074/jbc.M212964200
   Ng EWM, 2005, CAN J OPHTHALMOL, V40, P352, DOI 10.1016/S0008-4182(05)80078-X
   Nimjee SM, 2005, ANNU REV MED, V56, P555, DOI 10.1146/annurev.med.56.062904.144915
   Pan B, 2002, J BIOMOL NMR, V22, P189, DOI 10.1023/A:1014297525543
   Pervushin K, 1997, P NATL ACAD SCI USA, V94, P12366, DOI 10.1073/pnas.94.23.12366
   Ruckman J, 1998, J BIOL CHEM, V273, P20556, DOI 10.1074/jbc.273.32.20556
   Schachat AP, 2005, OPHTHALMOLOGY, V112, P531, DOI 10.1016/j.ophtha.2005.01.018
   Soker S, 1998, CELL, V92, P735, DOI 10.1016/S0092-8674(00)81402-6
   Stauffer ME, 2002, J BIOMOL NMR, V23, P57, DOI 10.1023/A:1015346504499
   Tammela T, 2005, CARDIOVASC RES, V65, P550, DOI 10.1016/j.cardiores.2004.12.002
   TUERK C, 1990, SCIENCE, V249, P505, DOI 10.1126/science.2200121
   Whitaker GB, 2001, J BIOL CHEM, V276, P25520, DOI 10.1074/jbc.M102315200
   Wiesmann C, 1997, CELL, V91, P695, DOI 10.1016/S0092-8674(00)80456-0
   Williamson JR, 2000, NAT STRUCT BIOL, V7, P834, DOI 10.1038/79575
   Witmer AN, 2003, PROG RETIN EYE RES, V22, P1, DOI 10.1016/S1350-9462(02)00043-5
NR 35
TC 182
Z9 198
U1 4
U2 57
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD DEC 27
PY 2005
VL 102
IS 52
BP 18902
EP 18907
DI 10.1073/pnas.0509069102
PG 6
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 998WG
UT WOS:000234350000024
PM 16357200
OA Green Published
DA 2022-11-30
ER

PT J
AU Chen, JT
   Liang, JB
   Chou, CL
   Shyu, RC
   Lu, DW
AF Chen, JT
   Liang, JB
   Chou, CL
   Shyu, RC
   Lu, DW
TI Retinoic acid induces VEGF gene expression in human retinal pigment
   epithelial cells (ARPE-19)
SO JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; SMOOTH-MUSCLE-CELLS; DIFFERENTIATION;
   INDUCTION; DEGENERATION; LETHALITY; MICE
AB Purpose: The aim of this study was to evaluate the expression of vascular endothelial growth factor (VEGF) in response to retinoic acid (RA) in human retinal pigment epithelial cells.
   Methods: Expression of VEGF in human ARPE-19 cells was determined by a semiquantitative reverse transcription-polymerase chain reaction (RT-PCR) and enzyme-linked immunosorbent assay (ELISA). mRNA stability was assessed after the administration of actinomycin D. The induction of the VEGF gene by various RAS was also determined by semiquantitative RT-PCR.
   Results: All-trans retinoic acid (atRA) time-dependently increased VEGF mRNA levels. The effect of atRA was dose-dependent in a range between 10(-7) M and 10(-6) M. Treatment with actinomycin D revealed that atRA induces the VEGF gene at the transcriptional level. Of the various RAS tested, atRA was the most potent inducer of the VEGF gene.
   Conclusions: We demonstrated that atRA stimulates the induction of the VEGF gene in ARPE-19 cells, suggesting a novel pathway for the development of age-related macular degeneration.
C1 Tri Serv Gen Hosp, Dept Ophthalmol, Taipei, Taiwan.
   Natl Def Med Ctr, Inst Aerosp Med, Taipei, Taiwan.
C3 Tri-Service General Hospital; National Defense Medical Center
RP Chen, JT (通讯作者)，Tri Serv Gen Hosp, Dept Ophthalmol, Taipei, Taiwan.
EM jt66chen@ms32.hinet.net
CR AIELLO LP, 1995, ARCH OPHTHALMOL-CHIC, V113, P1538, DOI 10.1001/archopht.1995.01100120068012
   AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203
   AKIYAMA H, 2002, INVEST OPHTH VIS SCI, V40, P1624
   BROGI E, 1994, CIRCULATION, V90, P649, DOI 10.1161/01.CIR.90.2.649
   Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0
   CLAFFEY KP, 1992, J BIOL CHEM, V267, P16317
   FERRARA N, 1989, BIOCHEM BIOPH RES CO, V161, P851, DOI 10.1016/0006-291X(89)92678-8
   Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0
   GARRIDO C, 1993, GROWTH FACTORS, V8, P109, DOI 10.3109/08977199309046931
   Goodman D.S., 1994, RETINOIDS BIOL CHEM
   Grondona JM, 1996, DEVELOPMENT, V122, P2173
   GUDAS LJ, 1992, CELL GROWTH DIFFER, V3, P655
   HARADA S, 1994, J CLIN INVEST, V93, P2490, DOI 10.1172/JCI117258
   Hera R, 2005, AM J OPHTHALMOL, V139, P589, DOI 10.1016/j.ajo.2004.11.064
   Hirata C, 1997, BIOCHEM BIOPH RES CO, V236, P712, DOI 10.1006/bbrc.1997.7036
   Hyatt GA, 1996, P NATL ACAD SCI USA, V93, P13298, DOI 10.1073/pnas.93.23.13298
   KELLEY MW, 1995, INVEST OPHTH VIS SCI, V36, P1280
   LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986
   LI J, 1995, J BIOL CHEM, V270, P308, DOI 10.1074/jbc.270.1.308
   LIU Y, 1995, CIRC RES, V77, P639
   Lutty GA, 1996, ARCH OPHTHALMOL-CHIC, V114, P971, DOI 10.1001/archopht.1996.01100140179011
   McCaffery P, 2000, CYTOKINE GROWTH F R, V11, P233, DOI 10.1016/S1359-6101(00)00002-2
   McCaffery P, 1996, P NATL ACAD SCI USA, V93, P12570, DOI 10.1073/pnas.93.22.12570
   MINCHENKO A, 1994, CELL MOL BIOL RES, V40, P35
   Pal S, 2000, MICROVASC RES, V60, P112, DOI 10.1006/mvre.2000.2246
   Pe'er J, 1998, OPHTHALMOLOGY, V105, P412, DOI 10.1016/S0161-6420(98)93020-2
   PERTOVAARA L, 1994, J BIOL CHEM, V269, P6271
   Ryuto M, 1996, J BIOL CHEM, V271, P28220, DOI 10.1074/jbc.271.45.28220
   SHIMA DT, 1995, MOL MED, V2, P64
   SHWEIKI D, 1992, NATURE, V359, P845
   Soderpalm AK, 2000, INVEST OPHTH VIS SCI, V41, P937
   STONE J, 1995, J NEUROSCI, V15, P4738, DOI 10.1523/jneurosci.15-07-04738.1995
   Suzuki Y, 1999, BLOOD, V93, P4264, DOI 10.1182/blood.V93.12.4264.412k27_4264_4276
   WOLFGANG W, 1998, J INVEST DERMATOL, V111, P907
   Yao AW, 1999, DNA SEQUENCE, V10, P55, DOI 10.3109/10425179909033937
   Yoshida A, 1999, INVEST OPHTH VIS SCI, V40, P1624
NR 36
TC 13
Z9 15
U1 0
U2 10
PU MARY ANN LIEBERT INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1080-7683
J9 J OCUL PHARMACOL TH
JI J. Ocular Pharmacol. Ther.
PD DEC
PY 2005
VL 21
IS 6
BP 413
EP 419
DI 10.1089/jop.2005.21.413
PG 7
WC Ophthalmology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Pharmacology & Pharmacy
GA 001FJ
UT WOS:000234518700001
PM 16386082
DA 2022-11-30
ER

PT J
AU Kahana, A
   Gottlieb, JL
AF Kahana, A
   Gottlieb, JL
TI Ophthalmology on the Internet - What do our patients find?
SO ARCHIVES OF OPHTHALMOLOGY
LA English
DT Article
ID HEALTH INFORMATION; WEB
AB The Internet has become a favorite source of medical information for a growing number of patients. At the same time, content on the Internet represents an amalgamation of viewpoints, commercial interests, and various biases. A common way to access Internet information is through commercial portals with proprietary search engines. Often these search engines prioritize their rank list based on commercial interests. We evaluated whether Internet searches of ophthalmic issues are slanted toward commercial sites and whether any differences exist among the various search engines. We used age-related macular degeneration as an example. In this study, we found that some search engines are heavily tilted toward commercial partnerships, whereas others emphasize sites run by nonprofit and educational organizations. Our findings may guide physicians in recommending to their patients some internet portals rather than others. This type of evaluation can be conducted intermittently by physicians and other health care professionals to assess the type of information that reaches their patients and what biases may be influencing patient knowledge and decision making.
C1 Univ Wisconsin Hosp, Dept Ophthalmol & Visual Sci, Madison, WI USA.
C3 University of Wisconsin System; University of Wisconsin Madison
RP Gottlieb, JL (通讯作者)，Univ Wisconsin, 2870 Univ Ave,Suite 206, Madison, WI 53705 USA.
EM jlgottlieb@wisc.edu
OI Kahana, Alon/0000-0002-5667-2274
CR *ASK JEEV INC, MAC DEG
   Crocco AG, 2002, JAMA-J AM MED ASSOC, V287, P2869, DOI 10.1001/jama.287.21.2869
   Eysenbach G, 2002, JAMA-J AM MED ASSOC, V287, P2691, DOI 10.1001/jama.287.20.2691
   Slater MD, 2002, JAMA-J AM MED ASSOC, V288, P316, DOI 10.1001/jama.288.3.316
   Stone TW, 2001, SOUTHERN MED J, V94, P22
   TEDESCHI B, 2003, NY TIMES        0224, pC7
NR 6
TC 14
Z9 14
U1 0
U2 1
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0003-9950
EI 1538-3601
J9 ARCH OPHTHALMOL-CHIC
JI Arch. Ophthalmol.
PD MAR
PY 2004
VL 122
IS 3
BP 380
EP 382
DI 10.1001/archopht.122.3.380
PG 3
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 801CY
UT WOS:000220075200016
PM 15006856
OA Bronze
DA 2022-11-30
ER

PT J
AU Ishida, BY
   Bailey, KR
   Duncan, KG
   Chalkley, RJ
   Burlingame, AL
   Kane, JP
   Schwartz, DM
AF Ishida, BY
   Bailey, KR
   Duncan, KG
   Chalkley, RJ
   Burlingame, AL
   Kane, JP
   Schwartz, DM
TI Regulated expression of apolipoprotein E by human retinal pigment
   epithelial cells
SO JOURNAL OF LIPID RESEARCH
LA English
DT Article
DE age-related macular degeneration; Bruch's membrane; retina; high density
   lipoprotein; thyroid hormone
ID AGE-RELATED MACULOPATHY; LIVER X-RECEPTOR; BRUCHS MEMBRANE; CHOLESTEROL
   EFFLUX; MACULAR DEGENERATION; E GENE; POLYACRYLAMIDE GELS; NERVE
   DEGENERATION; APOE EXPRESSION; DEFICIENT MICE
AB In early age-related macular degeneration (AMD), lipid-containing deposits (drusen) accumulate in Bruch's membrane underlying the retinal pigment epithelium (RPE). Recent studies indicate that apolipoprotein E (apoE) may play a role in lipid trafficking in AMD. Compared with the apoE3 allele, the apoE4 and apoE2 alleles are associated with decreased and increased risk for AMD, respectively; drusen contain high levels of apoE, and apoE null mice develop lipid deposits in Bruch's membrane similar to those observed in AMD. Primary cultures of human RPE cells expressing the apoE3 allele were grown on Transwell(R) culture plates. Western blotting, ELISA assay, and mass spectrometry confirmed that apoE3 was secreted into the apical and basal chambers and that secretion was upregulated by thyroid hormone, 9-cis-retinoic acid, and 22(R)-hydroxycholesterol. In addition, basally secreted apoE associated with exogenously added HDL. These results indicate that apoE secretion can be regulated by specific hormones and that apoE associates with HDL. The findings are consistent with a role for apoE in lipid trafficking through Bruch's membrane and may be relevant to AMD.
C1 Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA 94143 USA.
   Univ Calif San Francisco, Dept Ophthalmol, San Francisco, CA 94143 USA.
   Univ Calif San Francisco, Dept Pharmaceut Chem, Mass Spectrometry Facil, San Francisco, CA 94143 USA.
   Vet Affairs Med Ctr, San Francisco, CA 94121 USA.
C3 University of California System; University of California San Francisco;
   University of California System; University of California San Francisco;
   University of California System; University of California San Francisco;
   US Department of Veterans Affairs; Veterans Health Administration (VHA)
RP Schwartz, DM (通讯作者)，Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA 94143 USA.
EM schwartz7@mindspring.com
OI Chalkley, Robert/0000-0002-9757-7302
FU NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR014606, S10RR012961]
   Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE
   [R01HL031210] Funding Source: NIH RePORTER
CR Anderson DH, 2001, AM J OPHTHALMOL, V131, P767, DOI 10.1016/S0002-9394(00)00961-2
   BELLOSTA S, 1995, J CLIN INVEST, V96, P2170, DOI 10.1172/JCI118271
   BLUE ML, 1983, P NATL ACAD SCI-BIOL, V80, P283, DOI 10.1073/pnas.80.1.283
   BLUM H, 1987, ELECTROPHORESIS, V8, P93, DOI 10.1002/elps.1150080203
   BROWNING PJ, 1994, J EXP MED, V180, P1949, DOI 10.1084/jem.180.5.1949
   CURCIO CA, 2002, ASS RES VIS OPHTH AR
   DAWSON PA, 1986, J BIOL CHEM, V261, P5681
   DeMattos RB, 1998, J BIOL CHEM, V273, P4206, DOI 10.1074/jbc.273.7.4206
   Dithmar S, 2000, INVEST OPHTH VIS SCI, V41, P2035
   Duncan KG, 1999, OPHTHALMIC RES, V31, P399, DOI 10.1159/000055564
   Fazio S, 1997, P NATL ACAD SCI USA, V94, P4647, DOI 10.1073/pnas.94.9.4647
   FEENEYBURNS L, 1984, INVEST OPHTH VIS SCI, V25, P195
   Hasty AH, 1999, CIRCULATION, V99, P2571, DOI 10.1161/01.CIR.99.19.2571
   HERSCOVITZ H, 1992, J LIPID RES, V33, P791
   HOLZ FG, 1994, ARCH OPHTHALMOL-CHIC, V112, P402, DOI 10.1001/archopht.1994.01090150132035
   IGNATIUS MJ, 1986, P NATL ACAD SCI USA, V83, P1125, DOI 10.1073/pnas.83.4.1125
   Inatani M, 2002, PROG RETIN EYE RES, V21, P429, DOI 10.1016/S1350-9462(02)00009-5
   KELLY ME, 1994, CELL IMMUNOL, V159, P124, DOI 10.1006/cimm.1994.1302
   KENNEDY CJ, 1995, EYE, V9, P262
   Klaver CCW, 1998, AM J HUM GENET, V63, P200, DOI 10.1086/301901
   Kliffen M, 2000, BRIT J OPHTHALMOL, V84, P1415, DOI 10.1136/bjo.84.12.1415
   Laffitte BA, 2001, P NATL ACAD SCI USA, V98, P507, DOI 10.1073/pnas.021488798
   Langer C, 2000, J MOL MED, V78, P217, DOI 10.1007/s001090000096
   Lin CY, 1999, J LIPID RES, V40, P1618
   Lin CY, 1998, J LIPID RES, V39, P293
   Lin CY, 2001, J LIPID RES, V42, P1125
   Mak PA, 2002, J BIOL CHEM, V277, P31900, DOI 10.1074/jbc.M202993200
   Malek G, 2003, AM J PATHOL, V162, P413, DOI 10.1016/S0002-9440(10)63836-9
   MAZZONE T, 1994, J LIPID RES, V35, P1345
   MAZZONE T, 1992, CIRCULATION S1, V86, P1
   MOORE DJ, 1995, INVEST OPHTH VIS SCI, V36, P1290
   Moore DJ, 2001, INVEST OPHTH VIS SCI, V42, P2970
   Murthy S, 2002, J LIPID RES, V43, P1054, DOI 10.1194/jlr.M100358-JLR200
   Muscat GEO, 2002, J BIOL CHEM, V277, P40722, DOI 10.1074/jbc.M206681200
   PAULEIKHOFF D, 1990, OPHTHALMOLOGY, V97, P171
   Ruberti JW, 2003, INVEST OPHTH VIS SCI, V44, P1753, DOI 10.1167/iovs.02-0496
   SHERAIDAH G, 1993, OPHTHALMOLOGY, V100, P47
   SHIMANO H, 1995, J CLIN INVEST, V95, P469, DOI 10.1172/JCI117687
   Simonelli F, 2001, OPHTHALMIC RES, V33, P325, DOI 10.1159/000055688
   SONG MK, 1990, J CELL PHYSIOL, V143, P196, DOI 10.1002/jcp.1041430127
   Souied EH, 1998, AM J OPHTHALMOL, V125, P353, DOI 10.1016/S0002-9394(99)80146-9
   Spaide RF, 1999, RETINA-J RET VIT DIS, V19, P141, DOI 10.1097/00006982-199902000-00010
   Starita C, 1996, EXP EYE RES, V62, P565, DOI 10.1006/exer.1996.0066
   STEWART JM, 2003, ASS RES VIS OPHTH AR
   SWAIN M, 1995, ELECTROPHORESIS, V16, P948, DOI 10.1002/elps.11501601159
   Tangirala RK, 2001, J BIOL CHEM, V276, P261, DOI 10.1074/jbc.M003324200
   Taylor HR, 2001, BRIT J OPHTHALMOL, V85, P261, DOI 10.1136/bjo.85.3.261
   VANDENBROUCK Y, 1994, EUR J BIOCHEM, V224, P463, DOI 10.1111/j.1432-1033.1994.00463.x
   VanNewkirk MR, 2000, OPHTHALMOLOGY, V107, P1593, DOI 10.1016/S0161-6420(00)00175-5
   VARNER HH, 1987, EXP EYE RES, V44, P633, DOI 10.1016/S0014-4835(87)80135-5
   WEISGRABER KH, 1982, J BIOL CHEM, V257, P2518
   WILLIAMS DL, 1985, J BIOL CHEM, V260, P2444
   Zhang YY, 2002, MOL GENET METAB, V77, P150, DOI 10.1016/S1096-7192(02)00111-7
NR 53
TC 73
Z9 79
U1 0
U2 2
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0022-2275
EI 1539-7262
J9 J LIPID RES
JI J. Lipid Res.
PD FEB
PY 2004
VL 45
IS 2
BP 263
EP 271
DI 10.1194/jlr.M300306-JLR200
PG 9
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA 776JM
UT WOS:000189112900007
PM 14594998
OA hybrid
DA 2022-11-30
ER

PT J
AU Ou, KP
   Li, YJ
   Liu, L
   Li, H
   Cox, K
   Wu, JH
   Liu, J
   Dick, AD
AF Ou, Kepeng
   Li, Youjian
   Liu, Ling
   Li, Hua
   Cox, Katherine
   Wu, Jiahui
   Liu, Jian
   Dick, Andrew D.
TI Recent developments of neuroprotective agents for degenerative retinal
   disorders
SO NEURAL REGENERATION RESEARCH
LA English
DT Review
DE antioxidants; autophagy enhancers; complement inhibitors; exosomes;
   neuropeptides; neuroprotective agents; retinal degeneration; senolytics
ID EPITHELIUM-DERIVED FACTOR; OXIDATIVE STRESS; MACULAR DEGENERATION;
   DIABETIC-RETINOPATHY; PIGMENT EPITHELIUM; SUBSTANCE-P; CELLULAR
   SENESCENCE; EYE TISSUES; RAT RETINA; GLAUCOMA
AB Retinal degeneration is a debilitating ocular complication characterized by the progressive loss of photoreceptors and other retinal neurons, which are caused by a group of retinal diseases affecting various age groups, and increasingly prevalent in the elderly. Age-related macular degeneration, diabetic retinopathy and glaucoma are among the most common complex degenerative retinal disorders, posing significant public health problems worldwide largely due to the aging society and the lack of effective therapeutics. Whilst pathoetiologies vary, if left untreated, loss of retinal neurons can result in an acquired degeneration and ultimately severe visual impairment. Irrespective of underlined etiology, loss of neurons and supporting cells including retinal pigment epithelium, microvascular endothelium, and glia, converges as the common endpoint of retinal degeneration and therefore discovery or repurposing of therapies to protect retinal neurons directly or indirectly are under intensive investigation. This review overviews recent developments of potential neuroprotectants including neuropeptides, exosomes, mitochondrial-derived peptides, complement inhibitors, senolytics, autophagy enhancers and antioxidants either still experimentally or in clinical trials. Effective treatments that possess direct or indirect neuroprotective properties would significantly lift the burden of visual handicap.
C1 [Ou, Kepeng; Li, Youjian] Chongqing Univ Arts & Sci, Coll Pharm, Natl & Local Joint Engn Res Ctr Targeted & Innova, IATTI, Chongqing, Peoples R China.
   [Ou, Kepeng; Li, Youjian; Cox, Katherine; Wu, Jiahui; Liu, Jian; Dick, Andrew D.] Univ Bristol, Bristol Med Sch, Translat Hlth Sci, Bristol, Avon, England.
   [Liu, Ling; Li, Hua] Chongqing Med Univ, Yongchuan Hosp, Dept Ophthalmol, Chongqing, Peoples R China.
   [Wu, Jiahui] Shanghai Jiao Tong Univ, Sch Med, Shanghai Peoples Hosp 1, Dept Ophthalmol,Shanghai Gen Hosp, Shanghai, Peoples R China.
   [Dick, Andrew D.] UCL, Inst Ophthalmol, London, England.
   [Dick, Andrew D.] Moorfields Eye Hosp, Natl Inst Hlth Res Biomed Res Ctr, London, England.
C3 Chongqing University of Arts & Sciences; University of Bristol;
   Chongqing Medical University; Shanghai Jiao Tong University; University
   of London; University College London; University of London; University
   College London; Moorfields Eye Hospital NHS Foundation Trust
RP Wu, JH (通讯作者)，Univ Bristol, Bristol Med Sch, Translat Hlth Sci, Bristol, Avon, England.; Wu, JH (通讯作者)，Shanghai Jiao Tong Univ, Sch Med, Shanghai Peoples Hosp 1, Dept Ophthalmol,Shanghai Gen Hosp, Shanghai, Peoples R China.
EM Jiahui.Wu@bristol.ac.uk
RI Wu, Jane/CAI-7607-2022
CR Abu-Amero K, 2015, INT J MOL SCI, V16, P28886, DOI 10.3390/ijms161226135
   Ahlqvist E, 2018, LANCET DIABETES ENDO, V6, P361, DOI 10.1016/S2213-8587(18)30051-2
   Alvaro AR, 2008, NEUROSCIENCE, V152, P97, DOI 10.1016/j.neuroscience.2007.12.027
   Alvaro AR, 2007, NEUROCHEM INT, V50, P757, DOI 10.1016/j.neuint.2007.01.010
   Alvaro AR, 2009, J NEUROCHEM, V109, P1508, DOI 10.1111/j.1471-4159.2009.06079.x
   Ammar MJ, 2020, CURR OPIN OPHTHALMOL, V31, P215, DOI 10.1097/ICU.0000000000000657
   Bian BSJ, 2020, J EXTRACELL VESICLES, V9, DOI 10.1080/20013078.2020.1748931
   Biasutto L, 2013, EXP CELL RES, V319, P2113, DOI 10.1016/j.yexcr.2013.05.005
   Boia R, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21072262
   Bonds DE, 2014, JAMA INTERN MED, V174, P763, DOI 10.1001/jamainternmed.2014.328
   Brownlee M, 2005, DIABETES, V54, P1615, DOI 10.2337/diabetes.54.6.1615
   Cabrera AP, 2016, INVEST OPHTH VIS SCI, V57, P5910, DOI 10.1167/iovs.16-19727
   Barbosa MC, 2019, FRONT ENDOCRINOL, V9, DOI 10.3389/fendo.2018.00790
   Chan CM, 2015, INT J MOL SCI, V16, P5789, DOI 10.3390/ijms16035789
   Chaum E, 2015, MAMM GENOME, V26, P210, DOI 10.1007/s00335-015-9568-9
   Chen J, 2005, BIOCHEM BIOPH RES CO, V330, P1062, DOI 10.1016/j.bbrc.2005.03.095
   Chen LJ, 2012, MOL VIS, V18, P1763
   Chen M, 2017, MOL MED REP, V15, P2179, DOI 10.3892/mmr.2017.6271
   Chitranshi N, 2018, CURR NEUROPHARMACOL, V16, P1018, DOI 10.2174/1570159X16666180419121247
   Cobb LJ, 2016, AGING-US, V8, P796, DOI 10.18632/aging.100943
   Copland DA, 2018, INVEST OPHTH VIS SCI, V59, pAMD83, DOI 10.1167/iovs.18-23893
   Cremers FPM, 2020, PROG RETIN EYE RES, V79, DOI 10.1016/j.preteyeres.2020.100861
   Crespo-Garcia S, 2021, CELL METAB, V33, P818, DOI 10.1016/j.cmet.2021.01.011
   D'Alessandro A, 2014, MOL BIOSYST, V10, P1290, DOI 10.1039/c3mb70362b
   Damani MR, 2011, AGING CELL, V10, P263, DOI 10.1111/j.1474-9726.2010.00660.x
   Datta S, 2017, PROG RETIN EYE RES, V60, P201, DOI 10.1016/j.preteyeres.2017.03.002
   de la Lastra CA, 2005, MOL NUTR FOOD RES, V49, P405
   DeBosch BJ, 2016, SCI SIGNAL, V9, DOI 10.1126/scisignal.aac5472
   Dekeyster E, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0142067
   Ding JD, 2011, P NATL ACAD SCI USA, V108, pE279, DOI 10.1073/pnas.1100901108
   Du XL, 2000, P NATL ACAD SCI USA, V97, P12222, DOI 10.1073/pnas.97.22.12222
   El-Nimri NW, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-78802-4
   El-Remessy AB, 2006, AM J PATHOL, V168, P235, DOI 10.2353/ajpath.2006.050500
   El-Remessy AB, 2003, AM J PATHOL, V163, P1997, DOI 10.1016/S0002-9440(10)63558-4
   Erlich H, 2008, DIABETES, V57, P1084, DOI 10.2337/db07-1331
   Hernandez-Zimbron LF, 2018, OXID MED CELL LONGEV, V2018, DOI 10.1155/2018/8374647
   Ferreira R, 2010, J BIOL CHEM, V285, P41921, DOI 10.1074/jbc.M110.164020
   Gabriel R, 2013, BRIT J CLIN PHARMACO, V75, P1189, DOI 10.1111/bcp.12003
   Gahlaut N, 2015, EUR J PHARM BIOPHARM, V95, P323, DOI 10.1016/j.ejpb.2015.05.001
   Garcia-Layana A, 2017, CLIN INTERV AGING, V12, P1579, DOI 10.2147/CIA.S142685
   Garway-Heath DF, 2015, LANCET, V385, P1295, DOI 10.1016/S0140-6736(14)62111-5
   Gassel CJ, 2020, CELL TISSUE RES, V382, P293, DOI 10.1007/s00441-020-03240-7
   Golestaneh N, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2016.453
   Gurunathan S, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8040307
   Han J, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0193031
   Hanus J, 2015, AGEING RES REV, V24, P286, DOI 10.1016/j.arr.2015.09.002
   Harder JM, 2017, P NATL ACAD SCI USA, V114, pE3839, DOI 10.1073/pnas.1608769114
   He Y, 2014, INVEST OPHTH VIS SCI, V55, DOI 10.1167/iovs.14-14696
   Heesterbeek TJ, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.3.18
   Alves CH, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9051217
   Himawan E, 2019, DRUG DISCOV TODAY, V24, P1637, DOI 10.1016/j.drudis.2019.03.004
   Ho TC, 2006, BIOCHEM BIOPH RES CO, V342, P372, DOI 10.1016/j.bbrc.2006.01.164
   Holekamp NM, 2002, AM J OPHTHALMOL, V134, P220, DOI 10.1016/S0002-9394(02)01549-0
   Holz FG, 2018, JAMA OPHTHALMOL, V136, P666, DOI 10.1001/jamaophthalmol.2018.1544
   Huang DD, 2020, BIOMED PHARMACOTHER, V125, DOI 10.1016/j.biopha.2019.109767
   Hubens WHG, 2021, EXP EYE RES, V204, DOI 10.1016/j.exer.2021.108460
   Jaffe GJ, 2021, OPHTHALMOLOGY, V128, P576, DOI 10.1016/j.ophtha.2020.08.027
   Josifovska N, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21030813
   Kaarniranta K, 2020, PROG RETIN EYE RES, V79, DOI 10.1016/j.preteyeres.2020.100858
   Kassa E, 2019, EXPERT OPIN BIOL TH, V19, P335, DOI 10.1080/14712598.2019.1575358
   Khandhadia S, 2010, EXPERT REV MOL MED, V12, DOI 10.1017/S146239941000164X
   Khatib TZ, 2020, CURR EYE RES, V45, P327, DOI 10.1080/02713683.2019.1663385
   Khawaja AP, 2018, NAT GENET, V50, P778, DOI 10.1038/s41588-018-0126-8
   Kim BJ, 2021, PROG RETIN EYE RES, V83, DOI 10.1016/j.preteyeres.2020.100936
   Kim YS, 2018, BIOCHEM BIOPH RES CO, V503, P1307, DOI 10.1016/j.bbrc.2018.07.041
   Klingeborn M, 2018, ADV EXP MED BIOL, V1074, P539, DOI 10.1007/978-3-319-75402-4_65
   Kubota S, 2011, INVEST OPHTH VIS SCI, V52, P9142, DOI 10.1167/iovs.11-8041
   Kumar S, 2021, INVEST OPHTH VIS SCI, V62, DOI 10.1167/iovs.62.9.35
   Kumar-Singh R, 2019, EXP EYE RES, V184, P266, DOI 10.1016/j.exer.2019.05.006
   Kumari R, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0142199
   Lee HJ, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0749-9
   Lee KS, 2021, J NEUROINFLAMM, V18, DOI 10.1186/s12974-021-02088-0
   Lee R, 2015, EYE VISION, V2, DOI 10.1186/s40662-015-0026-2
   Levkovitch-Verbin H, 2015, PROG BRAIN RES, V220, P37, DOI 10.1016/bs.pbr.2015.05.005
   Li XR, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.01038
   Liou GI, 2008, INVEST OPHTH VIS SCI, V49, P5526, DOI 10.1167/iovs.08-2196
   Liton PB, 2005, EXP GERONTOL, V40, P745, DOI 10.1016/j.exger.2005.06.005
   Liu CQ, 2015, INT J MOL MED, V35, P169, DOI 10.3892/ijmm.2014.1993
   Liu HH, 2020, INT J OPHTHALMOL-CHI, V13, P176, DOI 10.18240/ijo.2020.01.24
   Liu J, 2016, SCI REP-UK, V6, DOI 10.1038/srep20639
   Liu K, 2019, EYE VISION, V6, DOI 10.1186/s40662-019-0161-2
   Lorenz K, 2017, TRIALS, V18, DOI 10.1186/s13063-017-1861-3
   Lotfi P, 2018, AUTOPHAGY, V14, P1419, DOI 10.1080/15548627.2018.1474313
   Loukovaara S, 2015, J PROTEOME RES, V14, P5131, DOI 10.1021/acs.jproteome.5b00900
   Luo HD, 2018, INVEST OPHTH VIS SCI, V59, P3879, DOI 10.1167/iovs.18-23806
   Lusthaus J, 2019, MED J AUSTRALIA, V210, P180, DOI 10.5694/mja2.50020
   Ma N, 2021, OXID MED CELL LONGEV, V2021, DOI 10.1155/2021/8847844
   Ma ZW, 2018, ACTA PHARMACOL SIN, V39, P1012, DOI 10.1038/aps.2017.169
   Madeira MH, 2015, MEDIAT INFLAMM, V2015, DOI 10.1155/2015/673090
   Matias I, 2006, PROSTAG LEUKOTR ESS, V75, P413, DOI 10.1016/j.plefa.2006.08.002
   Mayer AL, 2016, SCI REP-UK, V6, DOI 10.1038/srep38586
   Menon M, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-12780-8
   Menzies FM, 2017, NEURON, V93, P1015, DOI 10.1016/j.neuron.2017.01.022
   Michelis G, 2021, J NEUROCHEM, V159, P840, DOI 10.1111/jnc.15454
   Mikitsh JL, 2014, PERSPECT MED CHEM, V6, P11, DOI 10.4137/PMC.S13384
   Minasyan L, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/1675230
   Nashine S, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-33290-5
   Nojima H, 2016, J HEPATOL, V64, P60, DOI 10.1016/j.jhep.2015.07.030
   Noristani R, 2016, J MOL NEUROSCI, V58, P470, DOI 10.1007/s12031-015-0707-2
   Nozaki M, 2006, P NATL ACAD SCI USA, V103, P2328, DOI 10.1073/pnas.0408835103
   Ogata N, 2002, AM J OPHTHALMOL, V134, P348, DOI 10.1016/S0002-9394(02)01568-4
   Ortega A, 2021, PHARMACEUTICS, V13, DOI 10.3390/pharmaceutics13010003
   Ou KP, 2020, J CELL MOL MED, V24, P3958, DOI 10.1111/jcmm.15016
   Ou KP, 2019, EXP CELL RES, V380, P115, DOI 10.1016/j.yexcr.2019.04.008
   Palmieri M, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14338
   Park DH, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01007
   Patrick David M, 2006, BMC Physiol, V6, P2, DOI 10.1186/1472-6793-6-2
   Peng JJ, 2019, EUR J PHARMACOL, V853, P381, DOI 10.1016/j.ejphar.2019.04.038
   Qu SC, 2020, OXID MED CELL LONGEV, V2020, DOI 10.1155/2020/1740943
   Rapino C, 2018, CURR NEUROPHARMACOL, V16, P959, DOI 10.2174/1570159X15666170724104305
   Rochette L, 2015, CAN J PHYSIOL PHARM, V93, P1021, DOI 10.1139/cjpp-2014-0353
   Rother RP, 2007, NAT BIOTECHNOL, V25, P1256, DOI 10.1038/nbt1344
   Ruan Y, 2020, ANTIOXIDANTS-BASEL, V9, DOI 10.3390/antiox9080761
   Sacks D, 2018, AM J NEURORADIOL, V39, pE61, DOI 10.3174/ajnr.A5638
   Sahajpal NS, 2019, CURR PROTEIN PEPT SC, V20, P92, DOI 10.2174/1389203719666180928123449
   Santos-Carvalho A, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.160
   Shahulhameed S, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00154
   Silva KC, 2009, DIABETES, V58, P1382, DOI 10.2337/db09-0166
   Simo R, 2002, DIABETES CARE, V25, P2282, DOI 10.2337/diacare.25.12.2282
   Simo-Servat O, 2018, ENDOCRINE, V60, P1, DOI 10.1007/s12020-018-1561-0
   Solomon SD, 2017, DIABETES CARE, V40, P412, DOI 10.2337/dc16-2641
   Song DL, 2017, MOL VIS, V23, P210
   Sreekumar PG, 2020, OXID MED CELL LONGEV, V2020, DOI 10.1155/2020/2583601
   Sreekumar PG, 2016, INVEST OPHTH VIS SCI, V57, P1238, DOI 10.1167/iovs.15-17053
   Stitt AW, 2010, INVEST OPHTH VIS SCI, V51, P4867, DOI 10.1167/iovs.10-5881
   Takano K, 2014, EXCLI J, V13, P1145
   Thomas CC, 2015, MED CLIN N AM, V99, P1, DOI 10.1016/j.mcna.2014.08.015
   Toomey CB, 2018, PROG RETIN EYE RES, V62, P38, DOI 10.1016/j.preteyeres.2017.09.001
   Troger J, 2001, INVEST OPHTH VIS SCI, V42, P1045
   Uckermann O, 2006, J NEUROSCI RES, V83, P538, DOI 10.1002/jnr.20760
   Upadhyay RK, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/869269
   Voigt AP, 2019, P NATL ACAD SCI USA, V116, P24100, DOI 10.1073/pnas.1914143116
   Wang MTM, 2021, SURV OPHTHALMOL, V66, P327, DOI 10.1016/j.survophthal.2020.07.002
   Wang SB, 2019, OXID MED CELL LONGEV, V2019, DOI 10.1155/2019/3632169
   Wang W, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19061816
   Wang YG, 2021, DRUG DELIV, V28, P218, DOI 10.1080/10717544.2020.1870584
   Weinreb RN, 2014, JAMA-J AM MED ASSOC, V311, P1901, DOI 10.1001/jama.2014.3192
   Williams PA, 2016, MOL NEURODEGENER, V11, DOI 10.1186/s13024-016-0091-6
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wubben TJ, 2019, CURR OPIN OPHTHALMOL, V30, P199, DOI 10.1097/ICU.0000000000000558
   Xu HP, 2016, EUR J PHARMACOL, V787, P94, DOI 10.1016/j.ejphar.2016.03.001
   Yang JH, 2013, REGUL PEPTIDES, V187, P12, DOI 10.1016/j.regpep.2013.09.001
   Yang ST, 2020, BIOMED PHARMACOTHER, V132, DOI 10.1016/j.biopha.2020.110818
   Yang X, 2019, BIOMED RES INT, V2019, DOI 10.1155/2019/5763658
   Yang YX, 2019, BIOMED PHARMACOTHER, V117, DOI 10.1016/j.biopha.2019.109075
   Yi L, 2018, TRANSL RES, V201, P13, DOI 10.1016/j.trsl.2018.07.009
   Yuan LY, 2001, J NEUROSCI RES, V64, P523, DOI 10.1002/jnr.1104
   Zantut PRA, 2020, CUTAN OCUL TOXICOL, V39, P1, DOI 10.1080/15569527.2019.1685534
   Zhang LJ, 2016, J LEUKOCYTE BIOL, V99, P447, DOI 10.1189/jlb.3A0415-157R
   Zhu Y, 2015, AGING CELL, V14, P644, DOI 10.1111/acel.12344
NR 150
TC 1
Z9 1
U1 5
U2 6
PU WOLTERS KLUWER MEDKNOW PUBLICATIONS
PI MUMBAI
PA WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2
   VILLAGE MAROL, ANDHERI EAST, MUMBAI, Maharashtra, INDIA
SN 1673-5374
EI 1876-7958
J9 NEURAL REGEN RES
JI Neural Regen. Res.
PD SEP
PY 2022
VL 17
IS 9
BP 1919
EP 1928
DI 10.4103/1673-5374.335140
PG 10
WC Cell Biology; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Neurosciences & Neurology
GA 1P7KU
UT WOS:000802184600010
PM 35142668
OA Green Published, Green Submitted, gold
DA 2022-11-30
ER

PT J
AU Jhanji, V
   Billig, I
   Yam, GHF
AF Jhanji, Vishal
   Billig, Isabelle
   Yam, Gary Hin-Fai
TI Cell-Free Biological Approach for Corneal Stromal Wound Healing
SO FRONTIERS IN PHARMACOLOGY
LA English
DT Review
DE cornea; wound healing; fibrosis; protein therapy; microRNAs
ID PLATELET-RICH PLASMA; EPITHELIAL BASEMENT-MEMBRANE; HEPATOCYTE
   GROWTH-FACTOR; FACTOR-BETA ISOFORMS; MITOMYCIN-C; TGF-BETA; AMNIOTIC
   MEMBRANE; RENAL FIBROSIS; EXTRACELLULAR-MATRIX; CHEMOKINE RECEPTOR
AB Corneal opacification is the fourth most common cause of blindness globally behind cataracts, glaucoma, and age-related macular degeneration. The standard treatment of serious corneal scarring is corneal transplantation. Though it is effective for restoring vision, the treatment outcome is not optimal, due to limitations such as long-term graft survival, lifelong use of immunosuppressants, and a loss of corneal strength. Regulation of corneal stromal wound healing, along with inhibition or downregulation of corneal scarring is a promising approach to prevent corneal opacification. Pharmacological approaches have been suggested, however these are fraught with side effects. Tissue healing is an intricate process that involves cell death, proliferation, differentiation, and remodeling of the extracellular matrix. Current research on stromal wound healing is focused on corneal characteristics such as the immune response, angiogenesis, and cell signaling. Indeed, promising new technologies with the potential to modulate wound healing are under development. In this review, we provide an overview of cell-free strategies and some approaches under development that have the potential to control stromal fibrosis and scarring, especially in the context of early intervention.
C1 [Jhanji, Vishal; Billig, Isabelle; Yam, Gary Hin-Fai] Univ Pittsburgh, Dept Ophthalmol, Pittsburgh, PA 15260 USA.
C3 Pennsylvania Commonwealth System of Higher Education (PCSHE); University
   of Pittsburgh
RP Yam, GHF (通讯作者)，Univ Pittsburgh, Dept Ophthalmol, Pittsburgh, PA 15260 USA.
EM yamg@pitt.edu
FU NIH CORE Grant [P30 EY08098]; Eye and Ear Foundation of Pittsburgh;
   Research to Prevent Blindness, New York, NY; UPMC Immune Transplant
   Immunotherapy Centre, University of Pittsburgh, Pittsburgh, PA
   [04.29889]
FX Supported in part by NIH CORE Grant P30 EY08098 to the Department of
   Ophthalmology, the Eye and Ear Foundation of Pittsburgh, and from an
   unrestricted grant from Research to Prevent Blindness, New York, NY.
   Pilot experiment funded by UPMC Immune Transplant Immunotherapy Centre,
   University of Pittsburgh, Pittsburgh, PA (Grant number 04.29889).
CR Ahmed Z, 2014, NEUROBIOL DIS, V64, P163, DOI 10.1016/j.nbd.2013.12.008
   del Barrio JLA, 2021, SURV OPHTHALMOL, V66, P20, DOI 10.1016/j.survophthal.2020.10.003
   del Barrio JLA, 2018, EYE VISION, V5, DOI 10.1186/s40662-018-0122-1
   Alio JL, 2017, J OPHTHALMOL, V2017, DOI 10.1155/2017/2457620
   Alio JL, 2012, CURR PHARM BIOTECHNO, V13, P1257
   Gomez LA, 2015, CLIN LAB, V61, P973, DOI 10.7754/Clin.Lab.2015.141141
   Androulidaki A, 2009, IMMUNITY, V31, P220, DOI 10.1016/j.immuni.2009.06.024
   Anumanthan G, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0192145
   Arundhati A, 2021, AM J OPHTHALMOL, V224, P207, DOI 10.1016/j.ajo.2020.11.006
   Bamdad S, 2017, J CURR OPHTHALMOL, V29, P28, DOI 10.1016/j.joco.2016.10.006
   Bardin P, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.01113
   Basu S, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3009644
   BEUERMAN RW, 1980, EXP NEUROL, V69, P196, DOI 10.1016/0014-4886(80)90154-5
   Bian EB, 2014, GENE, V544, P259, DOI 10.1016/j.gene.2014.04.076
   Boomiraj H, 2015, INVEST OPHTH VIS SCI, V56, P7939, DOI 10.1167/iovs.15-17619
   Bourcier T, 2003, MOL VIS, V9, P96
   Burgess HA, 2005, AM J PHYSIOL-LUNG C, V288, pL1146, DOI 10.1152/ajplung.00383.2004
   Carlson EC, 2003, MOL VIS, V9, P615
   Chamberlain WD, 2019, CURR OPIN OPHTHALMOL, V30, P256, DOI 10.1097/ICU.0000000000000574
   Chan TCY, 2015, J OPHTHALMOL, V2015, DOI 10.1155/2015/891582
   Chen J, 2009, INVEST OPHTH VIS SCI, V50, P3662, DOI 10.1167/iovs.08-3276
   Cho YW, 2014, MEDICINE, V93, DOI 10.1097/MD.0000000000000125
   Chung JK, 2017, INT J OPHTHALMOL-CHI, V10, P329, DOI 10.18240/ijo.2017.03.01
   Ciechomska M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0115596
   Cushing L, 2011, AM J RESP CELL MOL, V45, P287, DOI 10.1165/rcmb.2010-0323OC
   Dawson K, 2013, CIRCULATION, V127, P1466, DOI 10.1161/CIRCULATIONAHA.112.001207
   de Oliveira RC, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.2.28
   Deng ZJ, 2017, MOL DIAGN THER, V21, P285, DOI 10.1007/s40291-016-0253-9
   Deshmukh R, 2020, INDIAN J OPHTHALMOL, V68, P2856, DOI 10.4103/ijo.IJO_1524_20
   Divakaran V, 2009, CIRC-HEART FAIL, V2, P633, DOI 10.1161/CIRCHEARTFAILURE.108.823070
   Doherty T, 2007, CURR OPIN IMMUNOL, V19, P676, DOI 10.1016/j.coi.2007.07.017
   Du YQ, 2009, STEM CELLS, V27, P1635, DOI 10.1002/stem.91
   Dua HS, 2004, SURV OPHTHALMOL, V49, P51, DOI 10.1016/j.survophthal.2003.10.004
   El Zarif M, 2021, CORNEA, V40, P741, DOI 10.1097/ICO.0000000000002646
   Eslami A, 2009, J HISTOCHEM CYTOCHEM, V57, P543, DOI 10.1369/jhc.2009.952572
   Espana EM, 2003, INVEST OPHTH VIS SCI, V44, P5136, DOI 10.1167/iovs.03-0484
   Etxebarria J, 2017, ACTA OPHTHALMOL, V95, pe693, DOI 10.1111/aos.13371
   Faraoni I, 2009, BBA-MOL BASIS DIS, V1792, P497, DOI 10.1016/j.bbadis.2009.02.013
   Fenner BJ, 2019, EYE VISION, V6, DOI 10.1186/s40662-019-0155-0
   Fini ME, 1999, PROG RETIN EYE RES, V18, P529, DOI 10.1016/S1350-9462(98)00033-0
   Fuentes-Mattei E, 2020, JCI INSIGHT, V5, DOI 10.1172/jci.insight.121781
   Fuest M, 2016, REGEN MED, V11, P601, DOI 10.2217/rme-2016-0054
   Gabison EE, 2005, AM J PATHOL, V166, P209, DOI 10.1016/S0002-9440(10)62245-6
   Gain P, 2016, JAMA OPHTHALMOL, V134, P167, DOI 10.1001/jamaophthalmol.2015.4776
   Gallant-Behm CL, 2019, J INVEST DERMATOL, V139, P1073, DOI 10.1016/j.jid.2018.11.007
   Gilbert RWD, 2016, J DEV BIOL, V4, DOI 10.3390/jdb4020021
   Gondaliya P, 2020, J DIABETES METAB DIS, V19, P13, DOI 10.1007/s40200-019-00469-0
   Grisanti S, 2005, INVEST OPHTH VIS SCI, V46, P191, DOI 10.1167/iovs.04-0902
   Grobe GM, 2013, CELLS TISSUES ORGANS, V197, P283, DOI 10.1159/000346172
   Gulias-Canizo R, 2019, BURNS, V45, P398, DOI 10.1016/j.burns.2018.08.021
   Helbig G, 2003, J BIOL CHEM, V278, P21631, DOI 10.1074/jbc.M300609200
   Hennessy EJ, 2011, J BIOL CHEM, V286, P25531, DOI 10.1074/jbc.M111.256206
   Herretes S, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005430.pub3
   Hill LJ, 2018, NPJ REGEN MED, V3, DOI 10.1038/s41536-018-0061-4
   Hill LJ, 2015, INVEST OPHTH VIS SCI, V56, P3743, DOI 10.1167/iovs.14-15622
   Hos D, 2019, PROG RETIN EYE RES, V73, DOI 10.1016/j.preteyeres.2019.07.001
   Huang CL, 2013, DIABETES, V62, P2923, DOI 10.2337/db13-0135
   Huet E, 2011, AM J PATHOL, V179, P1278, DOI 10.1016/j.ajpath.2011.05.036
   Huxlin KR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070785
   Huynh LK, 2019, BIOMOLECULES, V9, DOI 10.3390/biom9110743
   Hwang HW, 2007, SCIENCE, V315, P97, DOI 10.1126/science.1136235
   Imai Y, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-10227-y
   Iorio MV, 2012, CANCER J, V18, P215, DOI 10.1097/PPO.0b013e318250c001
   Jafarinejad-Farsangi S, 2015, AUTOIMMUNITY, V48, P369, DOI 10.3109/08916934.2015.1030616
   Jamilloux Y, 2019, AUTOIMMUN REV, V18, DOI 10.1016/j.autrev.2019.102390
   Jeon KI, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-30964-y
   Jester JV, 1999, J CELL SCI, V112, P613
   Jhanji V, 2012, CURR OPIN OPHTHALMOL, V23, P324, DOI 10.1097/ICU.0b013e32835484a1
   Jiang X, 2010, FEBS J, V277, P2015, DOI 10.1111/j.1742-4658.2010.07632.x
   Joung C, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21082990
   Kalamajski S, 2010, MATRIX BIOL, V29, P248, DOI 10.1016/j.matbio.2010.01.001
   Kam KW, 2015, CORNEA, V34, P530, DOI 10.1097/ICO.0000000000000400
   Kamran F, 2015, MOL ENDOCRINOL, V29, P921, DOI 10.1210/me.2015-1047
   Karamichos D, 2011, J TISSUE ENG REGEN M, V5, pE228, DOI 10.1002/term.429
   Karamichos D, 2013, INVEST OPHTH VIS SCI, V54, P6612, DOI 10.1167/iovs.13-12861
   Kaur H, 2009, EXP EYE RES, V89, P152, DOI 10.1016/j.exer.2009.03.001
   Kawakita T, 2005, J BIOL CHEM, V280, P27085, DOI 10.1074/jbc.M409567200
   Kesar V, 2014, LIVER INT, V34, P184, DOI 10.1111/liv.12315
   Koh KP, 2011, CELL STEM CELL, V8, P200, DOI 10.1016/j.stem.2011.01.008
   Komajda M, 2010, EUR HEART J, V31, P824, DOI 10.1093/eurheartj/ehp604
   Koulikovska M, 2015, CURR EYE RES, V40, P1102, DOI 10.3109/02713683.2014.978478
   Kumar M, 2011, J ALLERGY CLIN IMMUN, V128, P1077, DOI 10.1016/j.jaci.2011.04.034
   Kurowska-Stolarska M, 2011, P NATL ACAD SCI USA, V108, P11193, DOI 10.1073/pnas.1019536108
   Kwiecinski M, 2012, LAB INVEST, V92, P978, DOI 10.1038/labinvest.2012.70
   Kwok SS, 2019, EYE CONTACT LENS, V45, P347, DOI 10.1097/ICL.0000000000000584
   Kwon JJ, 2019, MOL THER-ONCOLYTICS, V12, P173, DOI 10.1016/j.omto.2018.12.011
   Lam FW, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0118950
   Lee HS, 2011, CORNEA, V30, P1465, DOI 10.1097/ICO.0b013e31821c9b5a
   Lee MY, 2012, CORNEA, V31, P1165, DOI 10.1097/ICO.0b013e318241433b
   Lee SWL, 2019, J CONTROL RELEASE, V313, P80, DOI 10.1016/j.jconrel.2019.10.007
   Lennikov A, 2018, ANGIOGENESIS, V21, P267, DOI 10.1007/s10456-018-9594-9
   Li M, 2016, GENE, V585, P44, DOI 10.1016/j.gene.2016.03.015
   Liu Y, 2010, HYPERTENSION, V55, P974, DOI 10.1161/HYPERTENSIONAHA.109.144428
   Lopez MJ, 2018, INVEST OPHTH VIS SCI, V59, P5671, DOI 10.1167/iovs.18-25084
   Luengo-Gimeno F, 2011, OCUL SURF, V9, P98, DOI 10.1016/S1542-0124(11)70017-9
   Marino GK, 2017, J REFRACT SURG, V33, P337, DOI 10.3928/1081597X-20170126-02
   Matsumoto Y, 2016, MOL THER, V24, P1848, DOI 10.1038/mt.2016.127
   Matthaei M, 2020, INVEST OPHTH VIS SCI, V61
   Maurer B, 2010, ARTHRITIS RHEUM-US, V62, P1733, DOI 10.1002/art.27443
   McKenna E, 2012, CELL CYCLE, V11, P3132, DOI 10.4161/cc.21506
   Meek KM, 2015, PROG RETIN EYE RES, V49, P1, DOI 10.1016/j.preteyeres.2015.07.001
   Mittal SK, 2016, STEM CELL REP, V7, P583, DOI 10.1016/j.stemcr.2016.09.001
   Miyagawa T, 2020, PHARMACEUTICS, V12, DOI 10.3390/pharmaceutics12050404
   Miyagi H, 2018, EXP EYE RES, V166, P49, DOI 10.1016/j.exer.2017.10.006
   Mizuno S, 2005, FASEB J, V19, P580, DOI 10.1096/fj.04-1535fje
   Mohan RR, 2011, CURR MOL MED, V11, P110
   Montastier E, 2019, INT J OBESITY, V43, P1485, DOI 10.1038/s41366-018-0260-5
   Mott JL, 2010, J CELL BIOCHEM, V110, P1155, DOI 10.1002/jcb.22630
   Mukwaya A, 2019, OCUL SURF, V17, P400, DOI 10.1016/j.jtos.2019.04.002
   Murri MS, 2018, CLIN OPHTHALMOL, V12, P1105, DOI 10.2147/OPTH.S165553
   Nassiri N, 2008, J CATARACT REFR SURG, V34, P902, DOI 10.1016/j.jcrs.2008.03.007
   Tran N, 2016, TRENDS CANCER, V2, P329, DOI 10.1016/j.trecan.2016.05.008
   Nur Akkaya P., 2019, J TRANSPLANT, V4, P1, DOI [10.5606/dsufnjt.2019.001, DOI 10.5606/DSUFNJT.2019.001]
   O'Brien J, 2018, FRONT ENDOCRINOL, V9, DOI 10.3389/fendo.2018.00402
   O'Connell RM, 2007, P NATL ACAD SCI USA, V104, P1604, DOI 10.1073/pnas.0610731104
   O'Connell RM, 2012, ANNU REV IMMUNOL, V30, P295, DOI 10.1146/annurev-immunol-020711-075013
   O'Connell RM, 2010, IMMUNITY, V33, P607, DOI 10.1016/j.immuni.2010.09.009
   O'Reilly S, 2016, ARTHRITIS RES THER, V18, DOI 10.1186/s13075-016-0929-x
   Ogawa T, 2010, BIOCHEM BIOPH RES CO, V391, P316, DOI 10.1016/j.bbrc.2009.11.056
   Okayama K, 2012, HYPERTENSION, V59, P958, DOI 10.1161/HYPERTENSIONAHA.111.183905
   Park JK, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0134853
   Patel V, 2012, CURR OPIN NEPHROL HY, V21, P410, DOI 10.1097/MNH.0b013e328354e559
   Penn JW, 2012, INT J BURNS TRAUMA, V2, P18
   Pflugfelder SC, 2013, EXP EYE RES, V117, P118, DOI 10.1016/j.exer.2013.08.013
   Pinel K, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8020083
   Prabhasawat P, 2005, CORNEA, V24, P443, DOI 10.1097/01.ico.0000148314.86557.6a
   Qin W, 2011, J AM SOC NEPHROL, V22, P1462, DOI 10.1681/ASN.2010121308
   Recchioni R, 2013, BIOMARKERS, V18, P547, DOI 10.3109/1354750X.2013.833294
   Rechichi Miguel, 2020, Am J Ophthalmol Case Rep, V20, P100838, DOI 10.1016/j.ajoc.2020.100838
   Reid G, 2016, EPIGENOMICS-UK, V8, P1079, DOI 10.2217/epi-2016-0035
   Roach KM, 2015, FIBROGENESIS TISSUE, V8, DOI 10.1186/s13069-015-0022-0
   Robinson PM, 2013, INVEST OPHTH VIS SCI, V54, P6944, DOI 10.1167/iovs.13-12621
   Rodriguez A, 2007, SCIENCE, V316, P608, DOI 10.1126/science.1139253
   Saika S, 2005, LAB INVEST, V85, P474, DOI 10.1038/labinvest.3700247
   Saika S, 2007, AM J PHYSIOL-CELL PH, V293, pC75, DOI 10.1152/ajpcell.00332.2006
   Salah Z, 2019, CURR GENE THER, V19, P342, DOI 10.2174/1566523219666191108103739
   Sanchez-Huerta V, 2011, MED HYPOTHESES, V76, P311, DOI 10.1016/j.mehy.2010.09.020
   Santhanam A, 2017, MOL VIS, V23, P39
   Sarkar J, 2013, INVEST OPHTH VIS SCI, V54, P5920, DOI 10.1167/iovs.13-12237
   Satish L, 2010, DERMAT RES PRACT, V2010, DOI 10.1155/2010/790234
   Schrementi ME, 2008, WOUND REPAIR REGEN, V16, P80, DOI 10.1111/j.1524-475X.2007.00320.x
   Scott KA, 2015, EXPERT OPIN INV DRUG, V24, P529, DOI 10.1517/13543784.2014.997873
   Segal M, 2020, MOL THER-NUCL ACIDS, V19, P267, DOI 10.1016/j.omtn.2019.11.008
   Seyed-Razavi Y, 2014, INVEST OPHTH VIS SCI, V55, P1313, DOI 10.1167/iovs.13-12995
   Shaheen BS, 2014, SURV OPHTHALMOL, V59, P263, DOI 10.1016/j.survophthal.2013.09.002
   Shay E, 2011, INVEST OPHTH VIS SCI, V52, P2669, DOI 10.1167/iovs.10-5888
   Shojaati G, 2019, STEM CELL TRANSL MED, V8, P1192, DOI 10.1002/sctm.18-0297
   Shojaati G, 2018, STEM CELL TRANSL MED, V7, P487, DOI 10.1002/sctm.17-0258
   Sloniecka M, 2016, MOL PHARMACOL, V89, P215, DOI 10.1124/mol.115.101014
   Sole C, 2015, NEPHROL DIAL TRANSPL, V30, P1488, DOI 10.1093/ndt/gfv128
   Stojanovic A, 2003, J REFRACT SURG, V19, P338
   Sun XY, 2015, J CLIN NEUROSCI, V22, P570, DOI 10.1016/j.jocn.2014.08.018
   Sun ZQ, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0897-7
   Tandon A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066434
   Tanidir ST, 2010, CORNEA, V29, P664, DOI 10.1097/ICO.0b013e3181c29633
   Teus MA, 2009, SURV OPHTHALMOL, V54, P487, DOI 10.1016/j.survophthal.2009.04.002
   Torricelli AAM, 2016, EXP EYE RES, V142, P110, DOI 10.1016/j.exer.2014.09.012
   Toyono T, 2016, CORNEA, V35, P1466, DOI 10.1097/ICO.0000000000000954
   Tseng SCG, 1999, J CELL PHYSIOL, V179, P325, DOI 10.1002/(SICI)1097-4652(199906)179:3<325::AID-JCP10>3.0.CO;2-X
   TUFT SJ, 1993, BRIT J OPHTHALMOL, V77, P243, DOI 10.1136/bjo.77.4.243
   van Rooij E, 2008, P NATL ACAD SCI USA, V105, P13027, DOI 10.1073/pnas.0805038105
   Vettori Serena, 2012, Open Rheumatol J, V6, P130, DOI 10.2174/1874312901206010130
   Walton KL, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00461
   Wang H, 2008, CANCER CELL, V14, P369, DOI 10.1016/j.ccr.2008.10.006
   Wang QM, 2016, CELL PHYSIOL BIOCHEM, V39, P2308, DOI 10.1159/000447923
   Wangoo A, 1997, INT J EXP PATHOL, V78, P33, DOI 10.1046/j.1365-2613.1997.d01-241.x
   Weijtens O, 2002, OPHTHALMOLOGY, V109, P1887, DOI 10.1016/S0161-6420(02)01176-4
   Wen FQ, 2002, INFLAMMATION, V26, P279, DOI 10.1023/A:1021412601538
   Weng L, 2020, EYE VISION, V7, DOI 10.1186/s40662-020-00217-z
   Williams KA, 2008, TRANSPLANTATION, V86, P1720, DOI 10.1097/TP.0b013e3181903b0a
   Williams K, 2011, NATURE, V473, P343, DOI 10.1038/nature10066
   Wilson SE, 2007, EXP EYE RES, V85, P305, DOI 10.1016/j.exer.2007.06.009
   Wilson SE, 2019, J REFRACT SURG, V35, P506, DOI 10.3928/1081597X-20190625-02
   Wilson SE, 2017, MATRIX BIOL, V64, P17, DOI 10.1016/j.matbio.2017.06.003
   Wilson SE, 2012, EXP EYE RES, V99, P78, DOI 10.1016/j.exer.2012.03.018
   Xu ZH, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/849475
   Yam GHF, 2020, EXP EYE RES, V196, DOI 10.1016/j.exer.2020.108062
   Yam GHF, 2015, CELL TRANSPLANT, V24, P1845, DOI 10.3727/096368914X685069
   Yang RL, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04464-6
   Ye YM, 2010, CARDIOVASC RES, V87, P535, DOI 10.1093/cvr/cvq053
   Young AL, 2013, OPHTHALMOLOGY, V120, P2390, DOI 10.1016/j.ophtha.2013.05.033
   Yu HR, 2018, CANCER LETT, V433, P99, DOI 10.1016/j.canlet.2018.06.014
   Yulish M, 2012, ISR MED ASSOC J, V14, P382
   Zarrin AA, 2021, NAT REV DRUG DISCOV, V20, P39, DOI 10.1038/s41573-020-0082-8
   Zhang GY, 2016, CLIN EXP DERMATOL, V41, P341, DOI 10.1111/ced.12734
   Zhou L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033766
   Zirm, 1906, ALBRECHTVGRAEFES ARC, V64, P580, DOI [10.1007/BF01949227, DOI 10.1007/BF01949227]
NR 187
TC 4
Z9 4
U1 1
U2 3
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1663-9812
J9 FRONT PHARMACOL
JI Front. Pharmacol.
PD MAY 28
PY 2021
VL 12
AR 671405
DI 10.3389/fphar.2021.671405
PG 15
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA SQ0JZ
UT WOS:000660049000001
PM 34122095
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Meng, QQ
   Zuo, C
   Shi, F
   Zhu, WF
   Xiang, DH
   Chen, HY
   Chen, XJ
AF Meng, Qingquan
   Zuo, Chang
   Shi, Fei
   Zhu, Weifang
   Xiang, Dehui
   Chen, Haoyu
   Chen, Xinjian
TI Three-dimensional choroid neovascularization growth prediction from
   longitudinal retinal OCT images based on a hybrid model
SO PATTERN RECOGNITION LETTERS
LA English
DT Article
DE Choroid neovascularization; Growth prediction; Reaction-diffusion model;
   Hyperelastic biomechanical model; Optical coherence tomography
ID SEGMENTATION; DIFFUSION; VEGF
AB Choroid neovascularization (CNV) is a pathological manifestation of retinal-choroidal diseases such as age-related macular degeneration and pathological myopia, which can cause permanent loss of central vision. Prediction of its growth is important in treatment planning. In this paper, based on longitudinal optical coherence tomography (OCT) volumes, a three-dimensional CNV growth prediction framework is proposed. A hybrid model which combines the reaction-diffusion model and the hyperelastic biomechan-ical model through mass effect is adopted to characterize the growth of CNV region and its reaction with surround tissues. A treatment factor is also included so that the model can adjust to different treatment plan each patient receives. Tested on a dataset with 6 subjects, each with 12 longitudinal 3D images, the proposed method achieved average true positive rate (TPR), false positive rate (FPR) and Dice coefficient (DC) of 80.0 ? 7.62%, 23.4 ? 8.36% and 78.9 ? 7.54%, respectively, in predicting the future CNV regions, and outperforms those achieved by the single reaction-diffusion model. ? 2021 Elsevier B.V. All rights reserved.
C1 [Meng, Qingquan; Zuo, Chang; Shi, Fei; Zhu, Weifang; Xiang, Dehui; Chen, Xinjian] Soochow Univ, Sch Elect & Informat Engn, Suzhou 215006, Peoples R China.
   [Chen, Xinjian] Soochow Univ, State Key Lab Radiat Med & Protect, Suzhou 215123, Peoples R China.
   [Chen, Haoyu] Shantou Univ, Joint Shantou Int Eye Ctr, Shantou, Peoples R China.
   [Chen, Haoyu] Chinese Univ Hong Kong, Shantou, Peoples R China.
C3 Soochow University - China; Soochow University - China; Shantou
   University
RP Chen, XJ (通讯作者)，Soochow Univ, Sch Elect & Informat Engn, Suzhou 215006, Peoples R China.; Chen, XJ (通讯作者)，Soochow Univ, State Key Lab Radiat Med & Protect, Suzhou 215123, Peoples R China.
EM xjchen@suda.edu.cn
RI Chen, Haoyu/A-7432-2013
OI Chen, Haoyu/0000-0003-0676-4610; Chen, Xinjian/0000-0002-0871-293X
FU National Key R&D Program of China [2018YFA0701700]; National Natural
   Science Foundation of China (NSFC) [61622114, 61971298, 61771326]
FX This work was supported in part by the National Key R&D Program of China
   under Grant 2018YFA0701700, and in part by the National Natural Science
   Foundation of China (NSFC) under Grant 61622114, 61971298, 61771326 .
CR Ahn SJ, 2013, INVEST OPHTH VIS SCI, V54, P2115, DOI 10.1167/iovs.12-11542
   Bathe KJ., 2014, FINITE ELEMENT PROCE
   Bogunovic H., 2014, MICCAI WORKSH OPHTH, P129, DOI DOI 10.17077/OMIA.1018
   Bogunovic H, 2017, INVEST OPHTH VIS SCI, V58, P3240, DOI 10.1167/iovs.16-21053
   Chen XJ, 2013, IEEE T BIO-MED ENG, V60, P169, DOI 10.1109/TBME.2012.2222027
   Chen XJ, 2012, IEEE T MED IMAGING, V31, P1521, DOI 10.1109/TMI.2012.2191302
   Chen XJ, 2011, IEEE T BIO-MED ENG, V58, P463, DOI 10.1109/TBME.2010.2089522
   Clatz O, 2005, IEEE T MED IMAGING, V24, P1334, DOI 10.1109/TMI.2005.857217
   Deb K, 2002, IEEE T EVOLUT COMPUT, V6, P182, DOI 10.1109/4235.996017
   Fang Q., 2016, ISO2MESH 3D SURFACE
   Friedman J, 2000, ANN STAT, V28, P337, DOI 10.1214/aos/1016218223
   Hogea C, 2008, J MATH BIOL, V56, P793, DOI 10.1007/s00285-007-0139-x
   Holzapfel GA., 2002, MECCANICA, V37, P489, DOI [10.1023/A:1020843529530, DOI 10.1023/A:1020843529530]
   HUANG D, 1991, SCIENCE, V254, P1178, DOI 10.1126/science.1957169
   Kwak N, 2000, INVEST OPHTH VIS SCI, V41, P3158
   Luo CZ, 2018, IEEE T IMAGE PROCESS, V27, P637, DOI 10.1109/TIP.2017.2745109
   Luo CZ, 2016, IEEE T MULTIMEDIA, V18, P40, DOI 10.1109/TMM.2015.2495248
   Martin DF, 2002, RETINA-J RET VIT DIS, V22, P143
   Mohamed A., 2005, LNCS, V3749
   Oubraham H, 2011, RETINA-J RET VIT DIS, V31, P26, DOI 10.1097/IAE.0b013e3181de5609
   PERKKIO J, 1982, J THEOR BIOL, V98, P675, DOI 10.1016/0022-5193(82)90145-X
   Rosenfeld P.J., 2006, INVEST OPHTH VIS SCI, V47
   Schmidt-Erfurth U, 2018, OPHTHALMOL RETINA, V2, P24, DOI 10.1016/j.oret.2017.03.015
   Shi F, 2015, IEEE T MED IMAGING, V34, P441, DOI 10.1109/TMI.2014.2359980
   Spilsbury K, 2000, AM J PATHOL, V157, P135, DOI 10.1016/S0002-9440(10)64525-7
   Wang M, 2015, IEEE T KNOWL DATA EN, V27, P2564, DOI 10.1109/TKDE.2015.2415497
   Wang M, 2013, IEEE T IMAGE PROCESS, V22, P1395, DOI 10.1109/TIP.2012.2231088
   Wong KCL, 2014, LECT NOTES COMPUT SC, V8674, P25, DOI 10.1007/978-3-319-10470-6_4
   Zhu S., 2016, SPIE MED IMAG, V9788
   Zhu SX, 2017, IEEE J BIOMED HEALTH, V21, P1667, DOI 10.1109/JBHI.2017.2702603
   Zuo C., 2017, 3D CHOROID NEOVASCUL, P142
NR 31
TC 0
Z9 0
U1 4
U2 9
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0167-8655
EI 1872-7344
J9 PATTERN RECOGN LETT
JI Pattern Recognit. Lett.
PD JUN
PY 2021
VL 146
BP 108
EP 114
DI 10.1016/j.patrec.2021.03.006
EA MAR 2021
PG 7
WC Computer Science, Artificial Intelligence
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Computer Science
GA RV7OX
UT WOS:000646018400015
DA 2022-11-30
ER

PT J
AU Tang, MM
   Zhang, L
   Song, B
   Ji, XY
   Wang, CY
   Wang, HY
   Xu, H
   Su, YY
   He, Y
AF Tang, Miaomiao
   Zhang, Lu
   Song, Bin
   Ji, Xiaoyuan
   Wang, Chenyu
   Wang, Houyu
   Xu, Hua
   Su, Yuanyuan
   He, Yao
TI Long-term fundus fluorescence angiography and real-time diagnosis of
   retinal diseases in non-human primate-animal models
SO NANO RESEARCH
LA English
DT Article
DE fluorescent silicon nanoparticles; long-term; real-time; bioimaging;
   retinal diseases
ID INDOCYANINE GREEN ANGIOGRAPHY; OPTICAL COHERENCE TOMOGRAPHY; CYSTOID
   MACULAR EDEMA; CHOROIDAL NEOVASCULARIZATION; SILICON NANOPARTICLES;
   NANOMATERIALS; DOXORUBICIN; NANOPROBES; MEDICINE; FEATURES
AB Fluorescein angiography (FA) is a standard imaging modality for evaluating vascular abnormalities in retina-related diseases, which is recognized as the major cause of vision loss. Long-term and real-time fundus angiography is of great importance in preclinical research, nevertheless remaining big challenges up to present. In this study, we demonstrate that long-term fluorescence imaging of retinal vessels is enabled through a kind of fluorescent nanoagents, which is made of small-sized (hydrodynamic diameter: similar to 3 nm) silicon nanoparticles (SiNPs) featuring strong fluorescence, robust photostability, lengthened blood residency and negligible toxicity. In particular, the presented SiNPs-based nanoagents are capable of imaging retinal capillaries in similar to 10 min, which is around 10-fold longer than that (similar to 1 min) of fluorescein sodium (FS, known as the most widely used contrast agents for FA in clinic). Taking cynomolgus macaques as non-human primate-animal model, we further demonstrate the feasibility of real-time diagnosis of retinal diseases (e.g., age-related macular degeneration (AMD)) through dynamic monitoring of vascular dysfunction.
C1 [Tang, Miaomiao; Zhang, Lu; Song, Bin; Ji, Xiaoyuan; Wang, Chenyu; Wang, Houyu; Su, Yuanyuan; He, Yao] Soochow Univ, Inst Funct Nano & Soft Mat FUNSOM, Lab Nanoscale Biochem Anal, Suzhou 215123, Peoples R China.
   [Tang, Miaomiao; Zhang, Lu; Song, Bin; Ji, Xiaoyuan; Wang, Chenyu; Wang, Houyu; Su, Yuanyuan; He, Yao] Soochow Univ, Collaborat Innovat Ctr Suzhou Nano Sci & Technol, Suzhou 215123, Peoples R China.
   [Xu, Hua] Soochow Univ, Childrens Hosp, Dept Ophthalmol, Suzhou 215123, Peoples R China.
   [Su, Yuanyuan] Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Med Res Ctr, Guangdong Prov Key Lab Malignant Tumor Epigenet &, Guangzhou 510120, Peoples R China.
C3 Soochow University - China; Soochow University - China; Soochow
   University - China; Sun Yat Sen University
RP He, Y (通讯作者)，Soochow Univ, Inst Funct Nano & Soft Mat FUNSOM, Lab Nanoscale Biochem Anal, Suzhou 215123, Peoples R China.; He, Y (通讯作者)，Soochow Univ, Collaborat Innovat Ctr Suzhou Nano Sci & Technol, Suzhou 215123, Peoples R China.
EM yaohe@suda.edu.cn
RI song, bin/HCI-0974-2022
FU National Natural Science Foundation of China [21825402, 31400860,
   21575096, 21605109]; Natural Science Foundation of Jiangsu Province of
   China [BK20191417, BK20170061]; Program for Jiangsu Specially-Appointed
   Professors - Priority Academic Program Development of Jiangsu Higher
   Education Institutions (PAPD)
FX We appreciate financial support from National Natural Science Foundation
   of China (Nos. 21825402, 31400860, 21575096, and 21605109), Natural
   Science Foundation of Jiangsu Province of China (Nos. BK20191417 and
   BK20170061) and the Program for Jiangsu Specially-Appointed Professors
   to Prof. Yao He, a project funded by the Priority Academic Program
   Development of Jiangsu Higher Education Institutions (PAPD).
CR Antcliff RJ, 2000, OPHTHALMOLOGY, V107, P593, DOI 10.1016/S0161-6420(99)00087-1
   Antonelli A, 2017, NANO RES, V10, P731, DOI 10.1007/s12274-016-1342-0
   Aydin P, 2000, EYE, V14, P211, DOI 10.1038/eye.2000.56
   Chen F, 2019, SCI ADV, V5, DOI 10.1126/sciadv.aax5208
   Cui MY, 2019, NANO-MICRO LETT, V11, DOI 10.1007/s40820-019-0306-9
   Cursiefen C, 2006, P NATL ACAD SCI USA, V103, P11405, DOI 10.1073/pnas.0506112103
   Fan Y, 2018, NAT NANOTECHNOL, V13, P941, DOI 10.1038/s41565-018-0221-0
   Fardeau C, 2009, AM J OPHTHALMOL, V147, P886, DOI 10.1016/j.ajo.2008.12.025
   Ghosh JG, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14837
   Goody RJ, 2011, EXP EYE RES, V92, P464, DOI 10.1016/j.exer.2011.03.006
   Guo DX, 2019, NANO-MICRO LETT, V11, DOI 10.1007/s40820-019-0257-1
   Haarhaus M, 2017, NAT REV NEPHROL, V13, P429, DOI 10.1038/nrneph.2017.60
   Hauck TS, 2010, SMALL, V6, P138, DOI 10.1002/smll.200900626
   Huang JG, 2019, NAT MATER, V18, P1133, DOI 10.1038/s41563-019-0378-4
   Ji XY, 2018, NANO RES, V11, P5629, DOI 10.1007/s12274-018-1976-1
   Jia YL, 2015, P NATL ACAD SCI USA, V112, pE2395, DOI 10.1073/pnas.1500185112
   Kim DY, 2013, P NATL ACAD SCI USA, V110, P14354, DOI 10.1073/pnas.1307315110
   Kulkarni AD, 2005, ADV DRUG DELIVER REV, V57, P1994, DOI 10.1016/j.addr.2005.09.003
   Kwon J, 2019, SCI ADV, V5, DOI 10.1126/sciadv.aay0044
   Laginha KM, 2005, CLIN CANCER RES, V11, P6944, DOI 10.1158/1078-0432.CCR-05-0343
   Lambert V, 2013, NAT PROTOC, V8, P2197, DOI 10.1038/nprot.2013.135
   Liu Z, 2009, ANGEW CHEM INT EDIT, V48, P7668, DOI 10.1002/anie.200902612
   Luo L, 2013, ACS NANO, V7, P3264, DOI 10.1021/nn305958y
   Miao QQ, 2017, NAT BIOTECHNOL, V35, P1102, DOI 10.1038/nbt.3987
   Munson MC, 2019, SCI ADV, V5, DOI 10.1126/sciadv.aax6363
   Nakayama-Ratchford N, 2007, J AM CHEM SOC, V129, P2448, DOI 10.1021/ja068684j
   Nicholson B, 2013, SURV OPHTHALMOL, V58, P103, DOI 10.1016/j.survophthal.2012.07.004
   Park J, 2004, ADV MATER, V16, P520, DOI 10.1002/adma.200306181
   Pearlman JD, 2002, CURR PHARM DESIGN, V8, P1467, DOI 10.2174/1381612023394395
   Peng F, 2014, ACCOUNTS CHEM RES, V47, P612, DOI 10.1021/ar400221g
   Shen JK, 2020, SCI ADV, V6, DOI 10.1126/sciadv.aba1606
   Shinojima A, 2014, RETINA-J RET VIT DIS, V34, P1407, DOI 10.1097/IAE.0000000000000108
   Sidman RL, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aac4882
   SPAIDE RF, 1993, OPHTHALMIC SURG LAS, V24, P262
   Stanga PE, 2003, OPHTHALMOLOGY, V110, P15, DOI 10.1016/S0161-6420(02)01563-4
   Su YY, 2016, ADV MATER, V28, P10567, DOI 10.1002/adma.201601173
   Takahashi K, 1998, AM J OPHTHALMOL, V126, P91, DOI 10.1016/S0002-9394(98)00069-5
   Tang MM, 2018, ANAL CHEM, V90, P8188, DOI 10.1021/acs.analchem.8b01580
   Wang JH, 2020, NANO RES, V13, P1614, DOI 10.1007/s12274-020-2781-1
   Wang R, 2014, ANGEW CHEM INT EDIT, V53, P12086, DOI 10.1002/anie.201407420
   Wang YF, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-08690-4
   Weng YH, 2018, ADV SCI, V5, DOI 10.1002/advs.201700455
   Wolfensberger TJ, 1999, OPHTHALMOLOGY, V106, P285, DOI 10.1016/S0161-6420(99)90067-2
   YANNUZZI LA, 1984, SURV OPHTHALMOL, V28, P540, DOI 10.1016/0039-6257(84)90238-8
   Yao J, 2014, CHEM REV, V114, P6130, DOI 10.1021/cr200359p
   Ye L, 2012, NAT NANOTECHNOL, V7, P453, DOI [10.1038/nnano.2012.74, 10.1038/NNANO.2012.74]
   Yong KT, 2013, CHEM SOC REV, V42, P1236, DOI 10.1039/c2cs35392j
   Zhai X, 2018, NANO RES, V11, P6417, DOI 10.1007/s12274-018-2166-x
   Zhang K, 2012, NAT REV DRUG DISCOV, V11, P541, DOI 10.1038/nrd3745
   Zhang L, 2021, NANO RES, V14, P52, DOI 10.1007/s12274-020-3039-7
   Zhong YL, 2019, CHEM COMMUN, V55, P365, DOI 10.1039/c8cc07340f
   Zhou J, 2015, CHEM REV, V115, P395, DOI 10.1021/cr400478f
   Zhou L, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7938
NR 53
TC 1
Z9 1
U1 3
U2 25
PU TSINGHUA UNIV PRESS
PI BEIJING
PA B605D, XUE YAN BUILDING, BEIJING, 100084, PEOPLES R CHINA
SN 1998-0124
EI 1998-0000
J9 NANO RES
JI Nano Res.
PD NOV
PY 2021
VL 14
IS 11
BP 3840
EP 3847
DI 10.1007/s12274-021-3302-6
EA JAN 2021
PG 8
WC Chemistry, Physical; Nanoscience & Nanotechnology; Materials Science,
   Multidisciplinary; Physics, Applied
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Chemistry; Science & Technology - Other Topics; Materials Science;
   Physics
GA WF5XA
UT WOS:000610025400003
DA 2022-11-30
ER

PT J
AU Wang, J
   Hormel, TT
   Gao, LQ
   Zang, PX
   Guo, YK
   Wang, XG
   Bailey, ST
   Jia, YL
AF Wang, Jie
   Hormel, Tristan T.
   Gao, Liqin
   Zang, Pengxiao
   Guo, Yukun
   Wang, Xiaogang
   Bailey, Steven T.
   Jia, Yali
TI Automated diagnosis and segmentation of choroidal neovascularization in
   OCT angiography using deep learning
SO BIOMEDICAL OPTICS EXPRESS
LA English
DT Article
ID OPTICAL COHERENCE TOMOGRAPHY; RETINAL LAYER BOUNDARIES; MACULAR
   DEGENERATION; ARTIFACTS; ALGORITHM; NETWORKS; AREA
AB Accurate identification and segmentation of choroidal neovascularization (CNV) is essential for the diagnosis and management of exudative age-related macular degeneration (AMD). Projection-resolved optical coherence tomographic angiography (PR-OCTA) enables both cross-sectional and en face visualization of CNV. However, CNV identification and segmentation remains difficult even with PR-OCTA due to the presence of residual artifacts. In this paper, a fully automated CNV diagnosis and segmentation algorithm using convolutional neural networks (CNNs) is described. This study used a clinical dataset, including both scans with and without CNV, and scans of eyes with different pathologies. Furthermore, no scans were excluded due to image quality. In testing, all CNV cases were diagnosed from non-CNV controls with 100% sensitivity and 95% specificity. The mean intersection over union of CNV membrane segmentation was as high as 0.88. By enabling fully automated categorization and segmentation, the proposed algorithm should offer benefits for CNV diagnosis, visualization monitoring. (C) 2020 Optical Society of America under the terms of the OSA Open Access Publishing Agreement
C1 [Wang, Jie; Hormel, Tristan T.; Gao, Liqin; Zang, Pengxiao; Guo, Yukun; Bailey, Steven T.; Jia, Yali] Oregon Hlth & Sci Univ, Casey Eye Inst, Portland, OR 97239 USA.
   [Wang, Jie; Zang, Pengxiao; Jia, Yali] Oregon Hlth & Sci Univ, Dept Biomed Engn, Portland, OR 97239 USA.
   [Gao, Liqin] Capital Med Univ, Beijing Tongren Hosp, Beijing Tongren Eye Ctr, Beijing Key Lab Ophthalmol & Visual Sci, Beijing, Peoples R China.
   [Wang, Xiaogang] Shanxi Eye Hosp, Taiyuan, Shanxi, Peoples R China.
C3 Oregon Health & Science University; Oregon Health & Science University;
   Capital Medical University; Shanxi Medical University
RP Jia, YL (通讯作者)，Oregon Hlth & Sci Univ, Casey Eye Inst, Portland, OR 97239 USA.; Jia, YL (通讯作者)，Oregon Hlth & Sci Univ, Dept Biomed Engn, Portland, OR 97239 USA.
EM jiaya@ohsu.edu
RI Guo, Yukun/AAB-6902-2020
OI Guo, Yukun/0000-0002-6784-2355; Bailey, Steven/0000-0003-4949-1464; Jia,
   Yali/0000-0002-2784-1905
FU National Institutes of Health [P30 EY010572, R01 EY024544, R01
   EY027833]; National Natural Science Foundation of China [81971697];
   Research to Prevent Blindness
FX National Institutes of Health (P30 EY010572, R01 EY024544, R01
   EY027833); National Natural Science Foundation of China (81971697);
   Research to Prevent Blindness (unrestricted departmental funding grant,
   William & Mary Greve Special Scholar Award).
CR Al-Sheikh M, 2018, RETINA-J RET VIT DIS, V38, P220, DOI 10.1097/IAE.0000000000001628
   [Anonymous], 2017, ARXIV PREPRINT ARXIV
   Bailey ST, 2019, OPHTHALMOL RETINA, V3, P629, DOI 10.1016/j.oret.2019.03.008
   Bhavsar Kavita V, 2017, Am J Ophthalmol Case Rep, V8, P53, DOI 10.1016/j.ajoc.2017.10.001
   Bonini MA, 2015, JAMA OPHTHALMOL, V133, P899, DOI 10.1001/jamaophthalmol.2015.1320
   Camino A, 2017, BIOMED OPT EXPRESS, V8, P3053, DOI 10.1364/BOE.8.003053
   Chen LC, 2018, IEEE T PATTERN ANAL, V40, P834, DOI 10.1109/TPAMI.2017.2699184
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Dasgupta A, 2017, I S BIOMED IMAGING, P248, DOI 10.1109/ISBI.2017.7950512
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   Donoso LA, 2006, SURV OPHTHALMOL, V51, P137, DOI 10.1016/j.survophthal.2005.12.001
   Fang LY, 2017, BIOMED OPT EXPRESS, V8, P2732, DOI 10.1364/BOE.8.002732
   Grossniklaus HE, 2004, AM J OPHTHALMOL, V137, P496, DOI 10.1016/j.ajo.2003.09.042
   Gu YK, 2018, BIOMED OPT EXPRESS, V9, P5147, DOI 10.1364/BOE.9.005147
   Guo YK, 2019, BIOMED OPT EXPRESS, V10, P3257, DOI 10.1364/BOE.10.003257
   Guo YK, 2018, BIOMED OPT EXPRESS, V9, P4429, DOI 10.1364/BOE.9.004429
   Hee MR, 1996, OPHTHALMOLOGY, V103, P1260, DOI 10.1016/S0161-6420(96)30512-5
   Huang G, 2017, PROC CVPR IEEE, P2261, DOI 10.1109/CVPR.2017.243
   Huazhu Fu, 2016, Medical Image Computing and Computer-Assisted Intervention - MICCAI 2016. 19th International Conference. Proceedings: LNCS 9901, P132, DOI 10.1007/978-3-319-46723-8_16
   Inoue M, 2015, RETINA-J RET VIT DIS, V35, P2265, DOI 10.1097/IAE.0000000000000777
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Jia YL, 2015, P NATL ACAD SCI USA, V112, pE2395, DOI 10.1073/pnas.1500185112
   Jia YL, 2014, OPHTHALMOLOGY, V121, P1435, DOI 10.1016/j.ophtha.2014.01.034
   Jia YL, 2012, OPT EXPRESS, V20, P4710, DOI 10.1364/OE.20.004710
   Kuehlewein L, 2015, AM J OPHTHALMOL, V160, P739, DOI 10.1016/j.ajo.2015.06.030
   Liu L, 2015, BIOMED OPT EXPRESS, V6, P3564, DOI 10.1364/BOE.6.003564
   Lopez-Saez MP, 1998, ANN ALLERG ASTHMA IM, V81, P428, DOI 10.1016/S1081-1206(10)63140-7
   Maetschke S, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0219126
   Mo J, 2017, INT J COMPUT ASS RAD, V12, P2181, DOI 10.1007/s11548-017-1619-0
   Nesper PL, 2018, INVEST OPHTH VIS SCI, V59, P1944, DOI 10.1167/iovs.17-23361
   Patel R, 2018, INVEST OPHTH VIS SCI, V59, P4285, DOI 10.1167/iovs.18-24624
   Patel RC, 2018, OPHTHALMOL RETINA, V2, P816, DOI 10.1016/j.oret.2017.11.010
   Perfetti R, 2007, IEEE T CIRCUITS-II, V54, P141, DOI 10.1109/TCSII.2006.886244
   Schmidt-Erfurth U, 2018, PROG RETIN EYE RES, V67, P1, DOI 10.1016/j.preteyeres.2018.07.004
   Spaide RF, 2015, RETINA-J RET VIT DIS, V35, P2163, DOI 10.1097/IAE.0000000000000765
   Stanga PE, 2003, OPHTHALMOLOGY, V110, P15, DOI 10.1016/S0161-6420(02)01563-4
   The Eye Diseases Prevalence Research Group, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Treister AD, 2018, TRANSL VIS SCI TECHN, V7, DOI 10.1167/tvst.7.5.19
   Wang J, 2017, BIOMED OPT EXPRESS, V8, P1536, DOI 10.1364/BOE.8.001536
   Wei X, 2018, OPT LETT, V43, P2204, DOI 10.1364/OL.43.002204
   Wu AR, 2016, I S BIOMED IMAGING, P1363, DOI 10.1109/ISBI.2016.7493520
   Xue J, 2018, BIOMED OPT EXPRESS, V9, P3208, DOI 10.1364/BOE.9.003208
   Zang PX, 2019, BIOMED OPT EXPRESS, V10, P4340, DOI 10.1364/BOE.10.004340
   Zhang AQ, 2015, BIOMED OPT EXPRESS, V6, P4130, DOI 10.1364/BOE.6.004130
   Zhang M, 2016, BIOMED OPT EXPRESS, V7, P816, DOI 10.1364/BOE.7.000816
   Zhang M, 2015, BIOMED OPT EXPRESS, V6, P4661, DOI 10.1364/BOE.6.004661
   Zhang QQ, 2017, INVEST OPHTH VIS SCI, V58, P1506, DOI 10.1167/iovs.16-20977
   Zhang YH, 2019, OSA CONTINUUM, V2, P1011, DOI 10.1364/OSAC.2.001011
   Zhu CZ, 2017, COMPUT MED IMAG GRAP, V55, P68, DOI 10.1016/j.compmedimag.2016.05.004
NR 49
TC 29
Z9 29
U1 9
U2 22
PU OPTICAL SOC AMER
PI WASHINGTON
PA 2010 MASSACHUSETTS AVE NW, WASHINGTON, DC 20036 USA
SN 2156-7085
J9 BIOMED OPT EXPRESS
JI Biomed. Opt. Express
PD FEB 1
PY 2020
VL 11
IS 2
BP 927
EP 944
DI 10.1364/BOE.379977
PG 18
WC Biochemical Research Methods; Optics; Radiology, Nuclear Medicine &
   Medical Imaging
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Optics; Radiology, Nuclear Medicine &
   Medical Imaging
GA KT5QQ
UT WOS:000519069700029
PM 32133230
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Melo, E
   Oertle, P
   Trepp, C
   Meistermann, H
   Burgoyne, T
   Sborgi, L
   Cabrera, AC
   Chen, CY
   Hoflack, JC
   Kam-Thong, T
   Schmucki, R
   Badi, L
   Flint, N
   Ghiani, ZE
   Delobel, F
   Stucki, C
   Gromo, G
   Einhaus, A
   Hornsperger, B
   Golling, S
   Siebourg-Polster, J
   Gerber, F
   Bohrmann, B
   Futter, C
   Dunkley, T
   Hiller, S
   Schilling, O
   Enzmann, V
   Fauser, S
   Plodinec, M
   Iacone, R
AF Melo, Esther
   Oertle, Philipp
   Trepp, Carolyn
   Meistermann, Helene
   Burgoyne, Thomas
   Sborgi, Lorenzo
   Cabrera, Alvaro Cortes
   Chen, Chia-yi
   Hoflack, Jean-Christophe
   Kam-Thong, Tony
   Schmucki, Roland
   Badi, Laura
   Flint, Nicholas
   Ghiani, Zeynep Eren
   Delobel, Frederic
   Stucki, Corinne
   Gromo, Giulia
   Einhaus, Alfred
   Hornsperger, Benoit
   Golling, Sabrina
   Siebourg-Polster, Juliane
   Gerber, Francoise
   Bohrmann, Bernd
   Futter, Clare
   Dunkley, Tom
   Hiller, Sebastian
   Schilling, Oliver
   Enzmann, Volker
   Fauser, Sascha
   Plodinec, Marija
   Iacone, Roberto
TI HtrA1 Mediated Intracellular Effects on Tubulin Using a Polarized RPE
   Disease Model
SO EBIOMEDICINE
LA English
DT Article
DE Age-related macular degeneration; Polarized human retinal, pigmented
   epithelium; HtrA serine peptidase 1; Disease modelling; Mechanical
   properties; Cell stiffness; Phagocytic activity
ID SERINE-PROTEASE HTRA1; RETINAL-PIGMENT EPITHELIUM; MACULAR DEGENERATION;
   PROMOTER POLYMORPHISM; INCREASED EXPRESSION; AGE; CELLS; GENE;
   SUSCEPTIBILITY; MICROTUBULES
AB Age-related macular degeneration (AMD) is the leading cause of irreversible vision loss. The protein HtrA1 is enriched in retinal pigment epithelial (RPE) cells isolated from AMD patients and in drusen deposits. However, it is poorly understood how increased levels of HtrA1 affect the physiological function of the RPE at the intracellular level. Here, we developed hfRPE (human fetal retinal pigment epithelial) cell culturemodelwhere cells fully differentiated into a polarized functional monolayer. In this model, we fine-tuned the cellular levels of HtrA1 by targeted overexpression. Our data show that HtrA1 enzymatic activity leads to intracellular degradation of tubulin with a corresponding reduction in the number of microtubules, and consequently to an altered mechanical cell phenotype. HtrA1 overexpression further leads to impaired apical processes and decreased phagocytosis, an essential function for photoreceptor survival. These cellular alterations correlate with the AMD phenotype and thus highlight HtrA1 as an intracellular target for therapeutic interventions towards AMD treatment. (C) 2017 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license.
C1 [Melo, Esther; Meistermann, Helene; Cabrera, Alvaro Cortes; Hoflack, Jean-Christophe; Kam-Thong, Tony; Schmucki, Roland; Badi, Laura; Flint, Nicholas; Ghiani, Zeynep Eren; Delobel, Frederic; Stucki, Corinne; Gromo, Giulia; Einhaus, Alfred; Hornsperger, Benoit; Golling, Sabrina; Siebourg-Polster, Juliane; Gerber, Francoise; Bohrmann, Bernd; Dunkley, Tom; Fauser, Sascha; Iacone, Roberto] Roche Innovat Ctr Basel, Roche Pharma Res & Early Dev, CH-4070 Basel, Switzerland.
   [Trepp, Carolyn; Enzmann, Volker] Univ Bern, Univ Hosp Bern, Dept Clin Res, Dept Ophthalmol, CH-3010 Bern, Switzerland.
   [Oertle, Philipp; Sborgi, Lorenzo; Hiller, Sebastian; Plodinec, Marija] Univ Basel, Biozentrum, CH-4056 Basel, Switzerland.
   [Oertle, Philipp; Sborgi, Lorenzo; Hiller, Sebastian; Plodinec, Marija] Univ Basel, Swiss Nanosci Inst, CH-4056 Basel, Switzerland.
   [Burgoyne, Thomas; Futter, Clare] UCL, Inst Ophthalmol, London EC1V 9EL, England.
   [Chen, Chia-yi; Schilling, Oliver] Univ Freiburg, Inst Mol Med & Cell Res, D-79104 Freiburg, Germany.
   [Schilling, Oliver] Univ Freiburg, BIOSS Ctr Biol Signaling Studies, D-79104 Freiburg, Germany.
C3 Roche Holding; University of Bern; University Hospital of Bern;
   University of Basel; University of Basel; University of London;
   University College London; University of Freiburg; University of
   Freiburg
RP Melo, E; Iacone, R (通讯作者)，Roche Innovat Ctr Basel, Roche Pharma Res & Early Dev, CH-4070 Basel, Switzerland.; Plodinec, M (通讯作者)，Univ Basel, Biozentrum, CH-4056 Basel, Switzerland.; Plodinec, M (通讯作者)，Univ Basel, Swiss Nanosci Inst, CH-4056 Basel, Switzerland.
EM esther.melo@roche.com; marija.plodinec@unibas.ch;
   roberto.iacone47@gmail.com
RI Burgoyne, Thomas/HCI-9054-2022; Schilling, O/AAC-8302-2019; Cortes
   Cabrera, Alvaro/B-3748-2016
OI Burgoyne, Thomas/0000-0002-8428-720X; Schilling,
   Oliver/0000-0001-7678-7653; Cortes Cabrera, Alvaro/0000-0003-4635-6267;
   Siebourg, Juliane/0000-0002-1759-3223
FU Swiss National Science Foundation Nanotera Project; MRC [MR/P010091/1]
   Funding Source: UKRI
FX Work of MP and PO was supported by the Swiss National Science Foundation
   Nanotera Project awarded to the PATLiSci II Consortium.
CR Augustin A, 2013, MOL CANCER THER, V12, P520, DOI 10.1158/1535-7163.MCT-12-0880
   Barturen G., 2014, METHODS NEXT GENERAT, V1, P21, DOI [10.2478/mngs-2014-0001, DOI 10.2478/MNGS-2014-0001]
   Bonilha VL, 2008, CLIN OPHTHALMOL, V2, P413
   Booij JC, 2010, PROG RETIN EYE RES, V29, P1, DOI 10.1016/j.preteyeres.2009.08.003
   Cabrera AC, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-14208-z
   Canfield AE, 2007, BIOCHEM SOC T, V35, P669, DOI 10.1042/BST0350669
   Cheng Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053665
   Chien J, 2004, ONCOGENE, V23, P1636, DOI 10.1038/sj.onc.1207271
   Chien J, 2009, MOL CELL BIOL, V29, P4177, DOI 10.1128/MCB.00035-09
   Chien J, 2009, J CELL BIOCHEM, V107, P253, DOI 10.1002/jcb.22121
   Coleman HR, 2008, LANCET, V372, P1835, DOI 10.1016/S0140-6736(08)61759-6
   De Luca A, 2003, J HISTOCHEM CYTOCHEM, V51, P1279, DOI 10.1177/002215540305101004
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Dugel PU, 2016, OSLI RETINA, V47, P134, DOI 10.3928/23258160-20160126-06
   Dunn KC, 1996, EXP EYE RES, V62, P155, DOI 10.1006/exer.1996.0020
   Eigenbrot C, 2012, STRUCTURE, V20, P1040, DOI 10.1016/j.str.2012.03.021
   Friedrich U, 2015, HUM MOL GENET, V24, P6361, DOI 10.1093/hmg/ddv346
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Fritsche LG, 2014, ANNU REV GENOM HUM G, V15, P151, DOI 10.1146/annurev-genom-090413-025610
   Grassmann F, 2017, GENETICS, V205, P919, DOI 10.1534/genetics.116.195966
   Griffiths-Jones S, 2004, NUCLEIC ACIDS RES, V32, pD109, DOI 10.1093/nar/gkh023
   Haase K, 2015, J R SOC INTERFACE, V12, DOI 10.1098/rsif.2014.0970
   Hu SI, 1998, J BIOL CHEM, V273, P34406, DOI 10.1074/jbc.273.51.34406
   Iejima D, 2015, J BIOL CHEM, V290, P2784, DOI 10.1074/jbc.M114.593384
   Jones A, 2011, P NATL ACAD SCI USA, V108, P14578, DOI 10.1073/pnas.1102853108
   Koczorowska MM, 2016, MOL ONCOL, V10, P40, DOI 10.1016/j.molonc.2015.08.001
   Kumar S, 2014, INVEST OPHTH VIS SCI, V55, P3842, DOI 10.1167/iovs.13-13111
   Langmead B, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-3-r25
   Lehmann GL, 2014, EXP EYE RES, V126, P5, DOI 10.1016/j.exer.2014.04.021
   Li WB, 2012, INVEST OPHTH VIS SCI, V53, P5334, DOI 10.1167/iovs.12-8303
   Maminishkis A, 2006, INVEST OPHTH VIS SCI, V47, P3612, DOI 10.1167/iovs.05-1622
   Marmorstein AD, 1998, ANN NY ACAD SCI, V857, P1, DOI 10.1111/j.1749-6632.1998.tb10102.x
   Meistermann H, 2014, MOL CELL PROTEOMICS, V13, P3040, DOI 10.1074/mcp.M113.028977
   Milton RC, 2005, OPHTHALMOLOGY, V112, P533, DOI 10.1016/j.ophtha.2004.10.047
   Mortazavi A, 2008, NAT METHODS, V5, P621, DOI 10.1038/nmeth.1226
   Nakayama M, 2014, INVEST OPHTH VIS SCI, V55, P6514, DOI 10.1167/iovs.14-14453
   Nandrot EE, 2004, J EXP MED, V200, P1539, DOI 10.1084/jem.20041447
   Ng TK, 2017, LAB INVEST, V97, P43, DOI 10.1038/labinvest.2016.117
   Ohana R, 2015, DEVELOPMENT, V142, P2487, DOI 10.1242/dev.121533
   Pandi SPS, 2013, INVEST OPHTH VIS SCI, V54, P8140, DOI 10.1167/iovs.13-12631
   Pei XT, 2015, GRAEF ARCH CLIN EXP, V253, P565, DOI 10.1007/s00417-014-2901-2
   Plodinec M, 2012, NAT NANOTECHNOL, V7, P757, DOI [10.1038/NNANO.2012.167, 10.1038/nnano.2012.167]
   Radu RA, 2004, P NATL ACAD SCI USA, V101, P5928, DOI 10.1073/pnas.0308302101
   Reyes AP, 2016, STEM CELL REP, V6, P9, DOI 10.1016/j.stemcr.2015.11.008
   Ruggiero L, 2014, ADV EXP MED BIOL, V801, P91, DOI 10.1007/978-1-4614-3209-8_12
   Saini JS, 2017, CELL STEM CELL, V20, P635, DOI 10.1016/j.stem.2016.12.015
   Sarna M., 2016, NANOMEDICINE, V13, P801
   Schaedel L, 2015, NAT MATER, V14, P1156, DOI [10.1038/NMAT4396, 10.1038/nmat4396]
   Schick T, 2016, RETINA-J RET VIT DIS, V36, P787, DOI 10.1097/IAE.0000000000000756
   Schmidt N, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2425-8
   Schraermeyer U, 1997, EXP EYE RES, V65, P277, DOI 10.1006/exer.1997.0339
   Shawky JH, 2015, DEV BIOL, V401, P152, DOI 10.1016/j.ydbio.2014.12.005
   Shirinifard A, 2012, PLOS COMPUT BIOL, V8, DOI 10.1371/journal.pcbi.1002440
   Shu XH, 2006, ADV EXP MED BIOL, V572, P41
   Sloboda RD, 2007, J CELL BIOL, V179, P575, DOI 10.1083/jcb.200709039
   SLOT JW, 1991, J CELL BIOL, V113, P123, DOI 10.1083/jcb.113.1.123
   Smyth, 2004, STAT APPL GENET MOL, V3, P1, DOI DOI 10.2202/1544-6115.1027
   Sonoda S, 2009, NAT PROTOC, V4, P662, DOI 10.1038/nprot.2009.33
   Stamenovic D, 2005, J BIOMECH, V38, P1728, DOI 10.1016/j.jbiomech.2004.07.016
   Strunnikova NV, 2010, HUM MOL GENET, V19, P2468, DOI 10.1093/hmg/ddq129
   Supanji, 2013, EXP EYE RES, V112, P79, DOI 10.1016/j.exer.2013.04.013
   Tosi GM, 2017, INVEST OPHTH VIS SCI, V58, P162, DOI 10.1167/iovs.16-20922
   Truebestein L, 2011, NAT STRUCT MOL BIOL, V18, P386, DOI 10.1038/nsmb.2013
   Tsang WY, 2008, DEV CELL, V15, P187, DOI 10.1016/j.devcel.2008.07.004
   Tuo J, 2008, OPHTHALMOLOGY, V115, P1891, DOI 10.1016/j.ophtha.2008.05.021
   Vierkotten S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022959
   Wang HC, 2014, CANCER INFORM, V13, P25, DOI 10.4137/CIN.S14074
   Wu TD, 2005, BIOINFORMATICS, V21, P1859, DOI 10.1093/bioinformatics/bti310
   Wu TD, 2010, BIOINFORMATICS, V26, P873, DOI 10.1093/bioinformatics/btq057
   Yamashiro K, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-09632-0
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
NR 71
TC 11
Z9 12
U1 0
U2 4
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 2352-3964
J9 EBIOMEDICINE
JI EBioMedicine
PD JAN
PY 2018
VL 27
BP 258
EP 274
DI 10.1016/j.ebiom.2017.12.011
PG 17
WC Medicine, General & Internal; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine; Research & Experimental Medicine
GA FX2FR
UT WOS:000425875400031
PM 29269042
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Oshima, Y
   Apte, RS
   Nakao, S
   Yoshida, S
   Ishibashi, T
AF Oshima, Yuji
   Apte, Rajendra S.
   Nakao, Shintaro
   Yoshida, Shigeo
   Ishibashi, Tatsuro
TI Full thickness macular hole case after intravitreal aflibercept
   treatment
SO BMC OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; Tear of retinal pigment epithelium;
   Macular hole; Aflibercept
ID RETINAL-PIGMENT EPITHELIUM; TEARS; DETACHMENT; RANIBIZUMAB; INJECTION;
   DEGENERATION
AB Background: The pathogenesis of macular hole formation is widely accepted as a tractional force at the vitreo-retinal interface in fovea. We report a case of macular hole after intravitreous aflibercept injection for age-related macular degeneration (AMD) associated with contraction of the retinal pigment epithelium (RPE) at the edge of a fibrovascular pigment epithelial detachment (PED).
   Case presentation: A 94-year old man with neovascular AMD affecting his left eye accompanied by a fibrovascular PED was examined for severe vision loss. Although RPE tear in his left eye was identified before the first aflibercept intravitreous injection performed in order to treat neovascular AMD, he received three aflibercept injections as induction treatment. After induction treatment, a full thickness macular hole was identified associated with the contracted rolled RPE edge beneath the retina.
   Conclusion: Macular hole is commonly formed associated with tangential vitreous traction. Current report suggests that rapid contraction of the RPE underneath the retina can be one of the causes of a macular hole, and one of the side effects of anti-VEGF therapy for neovascular AMD.
C1 [Oshima, Yuji; Nakao, Shintaro; Yoshida, Shigeo; Ishibashi, Tatsuro] Kyushu Univ, Grad Sch Med Sci, Dept Ophthalmol, Higashi Ku, Fukuoka 8128582, Japan.
   [Apte, Rajendra S.] Washington Univ, Sch Med, Dept Ophthalmol & Visual Sci, St Louis, MO 63110 USA.
C3 Kyushu University; Washington University (WUSTL)
RP Oshima, Y (通讯作者)，Kyushu Univ, Grad Sch Med Sci, Dept Ophthalmol, Higashi Ku, 3-1-1 Maidashi, Fukuoka 8128582, Japan.
EM yuji@eye.med.kyushu-u.ac.jp
OI Yoshida, Shigeo/0000-0003-1049-8909
FU JSPS KAKENHI [Kiban C26462641]
FX This work was supported in part by JSPS KAKENHI Grant # Kiban C26462641.
   The authors acknowledge the MD members of Kyushu University Hospital for
   the AMD case work, and co-medical staff for assisting the medical
   procedures.
CR Chang LK, 2007, RETINA-J RET VIT DIS, V27, P857, DOI 10.1097/IAE.0b013e3180342c42
   Chang LK, 2007, RETINA-J RET VIT DIS, V27, P523, DOI 10.1097/IAE.0b013e3180a032db
   Cunningham ET, 2011, OPHTHALMOLOGY, V118, P2447, DOI 10.1016/j.ophtha.2011.05.026
   Doguizi S, 2014, RETINA-J RET VIT DIS, V34, P1156, DOI 10.1097/IAE.0000000000000056
   Grigoropoulos V, 2010, EUR J OPHTHALMOL, V20, P469, DOI 10.1177/112067211002000235
   Guber J, 2013, BRIT J OPHTHALMOL, V97, P1486, DOI 10.1136/bjophthalmol-2013-303978
   Moisseiev E, 2010, CASE REP OPHTHALM, V1, P36, DOI 10.1159/000319827
   Nagiel A, 2013, AM J OPHTHALMOL, V156, P981, DOI 10.1016/j.ajo.2013.06.024
   Okamoto T, 2014, BMC OPHTHALMOL, V14, DOI 10.1186/1471-2415-14-114
   Pauleikhoff D, 2002, GRAEF ARCH CLIN EXP, V240, P533, DOI 10.1007/s00417-002-0505-8
   Raiji Veena R, 2013, Retin Cases Brief Rep, V7, P91, DOI 10.1097/ICB.0b013e31826f090d
   Saito M, 2013, CLIN OPHTHALMOL, V7, P1287, DOI 10.2147/OPTH.S47735
   Shah CP, 2006, AM J OPHTHALMOL, V142, P1070, DOI 10.1016/j.ajo.2006.07.037
   Smiddy WE, 2004, AM J OPHTHALMOL, V137, P525, DOI 10.1016/j.ajo.2003.12.011
   Steel DHW, 2013, EYE, V27, pS1, DOI 10.1038/eye.2013.212
NR 15
TC 18
Z9 18
U1 1
U2 5
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1471-2415
J9 BMC OPHTHALMOL
JI BMC Ophthalmol.
PD MAR 29
PY 2015
VL 15
AR 30
DI 10.1186/s12886-015-0021-3
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CE5VB
UT WOS:000351902700001
PM 25881212
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Krishnan, MMR
   Laude, A
AF Krishnan, M. Muthu Rama
   Laude, Augustinus
TI An Integrated Diabetic Retinopathy Index for the Diagnosis of
   Retinopathy Using Digital Fundus Image Features
SO JOURNAL OF MEDICAL IMAGING AND HEALTH INFORMATICS
LA English
DT Article
DE Diabetic Retinopathy; Computer-Aided Diagnosis; Fundus Imaging; Local
   Binary Pattern; Index
ID AUTOMATED DETECTION; RETINAL IMAGES; RED LESIONS; CLASSIFICATION;
   TEXTURE; ULTRASOUND; IDENTIFICATION; SYSTEM; FILTER
AB Retinal fundus images may provide useful insights into the visual system and increasingly, provide additional indicators of systemic health. Many important eye and systemic diseases and conditions may manifest themselves as morphological changes that may be observed and recorded in the retina. Some of the most prevalent causes of blindness in the world include age-related macular degeneration, Diabetic Retinopathy (DR), and glaucoma. As many of these conditions are often asymptomatic till the more advanced stages, systematic screening of targetted individuals may help to identify the cases for early and appropriate intervention. This paper proposes a system for an automated identification of normal and abnormal DR classes using digital fundus images. Local Binary Pattern (LBP), Entropies and Invariant moments were used to extract the salient features. In this work, we have proposed a novel integrated index called Diabetic Retinopathy Index (DRI) which is made up of different features, to diagnose the unknown class using a single number. We hope that this DRI can aid clinicians towards faster screening of people with diabetes.
C1 [Krishnan, M. Muthu Rama] Ngee Ann Polytech, Dept Elect & Comp Engn, Singapore 599489, Singapore.
   [Laude, Augustinus] Tan Tock Seng Hosp, Nat Healthcare Grp Eye Inst, Singapore 308433, Singapore.
C3 Tan Tock Seng Hospital
RP Krishnan, MMR (通讯作者)，Ngee Ann Polytech, Dept Elect & Comp Engn, Singapore 599489, Singapore.
RI Mookiah, Muthu Rama Krishnan/G-4033-2011
OI Mookiah, Muthu Rama Krishnan/0000-0001-6437-1482
FU Social Innovation Research Fund (SIRF), Singapore
FX Authors thank Social Innovation Research Fund (SIRF), Singapore for
   providing grant for this research.
CR Acharya R, 2003, COMPUT BIOL MED, V33, P303, DOI 10.1016/S0010-4825(02)00083-5
   Acharya RU, 2012, J MED SYST, V36, P1861, DOI 10.1007/s10916-010-9645-2
   Acharya U., 2012, INT J NEURAL SYST, V22
   Acharya UR, 2009, P I MECH ENG H, V223, P545, DOI 10.1243/09544119JEIM486
   Acharya U. R., 2013, MED BIOL ENG COMPUTI, V1
   Acharya UR, 2013, COMPUT METHOD BIOMEC, V16, P222, DOI 10.1080/10255842.2011.616945
   Acharya UR, 2013, IEEE T INSTRUM MEAS, V62, P392, DOI 10.1109/TIM.2012.2217651
   Acharya UR, 2012, TECHNOL CANCER RES T, V11, P543, DOI 10.7785/tcrt.2012.500272
   Acharya UR, 2012, COMPUT METH PROG BIO, V107, P233, DOI 10.1016/j.cmpb.2011.10.001
   Acharya UR, 2012, BIOMED SIGNAL PROCES, V7, P401, DOI 10.1016/j.bspc.2011.07.007
   Acharya UR, 2012, ULTRASOUND MED BIOL, V38, P899, DOI 10.1016/j.ultrasmedbio.2012.01.015
   Acharya UR, 2012, ULTRASONICS, V52, P508, DOI 10.1016/j.ultras.2011.11.003
   Acharya UR, 2011, INT J NEURAL SYST, V21, P403, DOI 10.1142/S0129065711002912
   Acharya UR, 2011, IEEE T INF TECHNOL B, V15, P449, DOI 10.1109/TITB.2011.2119322
   Acharya UR, 2012, J MED SYST, V36, P2011, DOI 10.1007/s10916-011-9663-8
   Acharya R, 2010, INT J NEURAL SYST, V20, P509, DOI 10.1142/S0129065710002589
   Acharya UR, 2001, IEEE T INF TECHNOL B, V5, P320, DOI 10.1109/4233.966107
   Agurto C, 2010, IEEE T MED IMAGING, V29, P502, DOI 10.1109/TMI.2009.2037146
   Al-Rawi M, 2007, COMPUT BIOL MED, V37, P262, DOI 10.1016/j.compbiomed.2006.03.003
   Alghadyan AA, 2011, SAUDI J OPHTHALMOL, V25, P99, DOI 10.1016/j.sjopt.2011.01.009
   CHAUDHURI S, 1989, IEEE T MED IMAGING, V8, P263, DOI 10.1109/42.34715
   Chua KC, 2010, MED ENG PHYS, V32, P679, DOI 10.1016/j.medengphy.2010.04.009
   Das DK, 2013, ADVANCES IN THERAPEUTIC ENGINEERING, P419
   Das DK, 2013, MICRON, V45, P97, DOI 10.1016/j.micron.2012.11.002
   Dua S, 2012, IEEE T INF TECHNOL B, V16, P80, DOI 10.1109/TITB.2011.2176540
   Gardner GG, 1996, BRIT J OPHTHALMOL, V80, P940, DOI 10.1136/bjo.80.11.940
   Gun A.M., 2005, OUTLINE STAT THEORY
   HU M, 1962, IRE T INFORM THEOR, V8, P179, DOI 10.1109/TIT.1962.1057692
   Kahai P, 2006, INT J BIOMED IMAGING, V2006, DOI 10.1155/IJBI/2006/45806
   Krishnan MMR, 2011, TECHNOL CANCER RES T, V10, P443, DOI 10.7785/tcrt.2012.500221
   Krishnan MMR, 2011, TISSUE CELL, V43, P318, DOI 10.1016/j.tice.2011.06.005
   Krishnan MMR, 2012, J MED SYST, V36, P865, DOI 10.1007/s10916-010-9550-8
   Larsen M, 2003, INVEST OPHTH VIS SCI, V44, P761, DOI 10.1167/iovs.02-0418
   Larsen N, 2003, INVEST OPHTH VIS SCI, V44, P767, DOI 10.1167/iovs.02-0417
   Laude A., 2012, AM AC OPHTH AS PAC A, P184
   Mookiah MRK, 2013, KNOWL-BASED SYST, V39, P9, DOI 10.1016/j.knosys.2012.09.008
   Mookiah M. R. K., 2013, J MECH MED BIOL, V13
   Mookiah MRK, 2012, KNOWL-BASED SYST, V33, P73, DOI 10.1016/j.knosys.2012.02.010
   Mookiah MRK, 2011, ANAL QUANT CYTOL, V33, P158
   Nayak J, 2008, J MED SYST, V32, P107, DOI 10.1007/s10916-007-9113-9
   Nayak J, 2004, BIOMED ENG ONLINE, V3, DOI 10.1186/1475-925X-3-17
   Nayak J, 2009, J MED SYST, V33, P337, DOI 10.1007/s10916-008-9195-z
   Niemeijer M, 2005, IEEE T MED IMAGING, V24, P584, DOI 10.1109/TMI.2005.843738
   Niemeijer M, 2007, INVEST OPHTH VIS SCI, V48, P2260, DOI 10.1167/iovs.06-0996
   Noronha K., 2012, P I MECH ENG H
   Ojala T, 2002, IEEE T PATTERN ANAL, V24, P971, DOI 10.1109/TPAMI.2002.1017623
   Olson JA, 2003, DIABETIC MED, V20, P528, DOI 10.1046/j.1464-5491.2003.00969.x
   Osareh A, 2002, LECT NOTES COMPUT SC, V2353, P502
   Pharwaha APS, 2009, P WORLD C ENG COMP S, V3, P1
   Quellec G., 2006, EMBS 06 28 ANN INT C, P2618
   Quellec G, 2011, IEEE T MED IMAGING, V30, P523, DOI 10.1109/TMI.2010.2089383
   Reza AW, 2011, J MED SYST, V35, P17, DOI 10.1007/s10916-009-9337-y
   Singh, 2010, LECT NOTES ELECT ENG, P341
   Sinthanayothin C, 2003, ISPA 2003: PROCEEDINGS OF THE 3RD INTERNATIONAL SYMPOSIUM ON IMAGE AND SIGNAL PROCESSING AND ANALYSIS, PTS 1 AND 2, P915
   Tan JH, 2010, INFRARED PHYS TECHN, V53, P120, DOI 10.1016/j.infrared.2009.10.006
   Tan JH, 2009, INFRARED PHYS TECHN, V52, P97, DOI 10.1016/j.infrared.2009.05.002
   U RA, 2008, J MED SYST, V32, P481, DOI 10.1007/s10916-008-9154-8
   Usher D, 2004, DIABETIC MED, V21, P84, DOI 10.1046/j.1464-5491.2003.01085.x
   Yun WL, 2008, INFORM SCIENCES, V178, P106, DOI 10.1016/j.ins.2007.07.020
NR 59
TC 19
Z9 19
U1 2
U2 12
PU AMER SCIENTIFIC PUBLISHERS
PI VALENCIA
PA 26650 THE OLD RD, STE 208, VALENCIA, CA 91381-0751 USA
SN 2156-7018
EI 2156-7026
J9 J MED IMAG HEALTH IN
JI J. Med. Imaging Health Inform.
PD JUN
PY 2013
VL 3
IS 2
BP 306
EP 313
DI 10.1166/jmihi.2013.1165
PG 8
WC Mathematical & Computational Biology; Radiology, Nuclear Medicine &
   Medical Imaging
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Mathematical & Computational Biology; Radiology, Nuclear Medicine &
   Medical Imaging
GA 194BD
UT WOS:000322605100022
DA 2022-11-30
ER

PT J
AU Mullins, RF
   Dewald, AD
   Streb, LM
   Wang, K
   Kuehn, MH
   Stone, EM
AF Mullins, Robert F.
   Dewald, Aaron D.
   Streb, Luan M.
   Wang, Kai
   Kuehn, Markus H.
   Stone, Edwin M.
TI Elevated membrane attack complex in human choroid with high risk
   complement factor H genotypes
SO EXPERIMENTAL EYE RESEARCH
LA English
DT Article
DE macular degeneration; complement; choroid; choriocapillaris
ID VARIANT; POLYMORPHISM; INDIVIDUALS; GENES
AB Data from human genetics, histopathology, and animal models reveal a major role for the complement system in the development of age-related macular degeneration (AMD). Genetic variations in the complement factor H (CFH) gene are associated with an elevated risk of AMD. In this study we sought to determine whether eyes from donors with a high-risk genotype (homozygosity for the histidine allele at codon 402) exhibit altered levels of membrane attack complex (MAC) in the choroid, compared to eyes with a low risk genotype (homozygosity for tyrosine). Proteins were extracted from the RPE/choroid of 18 donors (10 low risk and 8 high risk) and levels of MAC were assessed using an ELISA assay. Eyes from donors homozygous for the histidine allele showed 69% higher levels of MAC than those homozygous for the tyrosine allele (p < 0.05), independent of whether the eyes showed signs of early AMD. Our results provide evidence that high-risk CFH genotypes may affect AMD risk by increased deposition of MAC around the aging choriocapillaris. (C) 2011 Elsevier Ltd. All rights reserved.
C1 [Mullins, Robert F.; Dewald, Aaron D.; Streb, Luan M.; Wang, Kai; Kuehn, Markus H.; Stone, Edwin M.] Univ Iowa, Iowa City, IA 52242 USA.
C3 University of Iowa
RP Mullins, RF (通讯作者)，Univ Iowa, 4135E MERE,375 Newton Rd, Iowa City, IA 52242 USA.
EM robert-mullins@uiowa.edu
RI Mullins, Robert F/I-6717-2013
OI Mullins, Robert/0000-0002-5006-0891; Kuehn, Markus/0000-0003-3940-198X;
   Stone, Edwin M./0000-0003-3343-4414
FU NEI [EY017451, 016822]; Foundation Fighting Blindness; Macula Vision
   Research Foundation; Hansjoerg E.J.W. Kolder Professorship for Best
   Disease Research; Howard Hughes Medical Institute; NATIONAL EYE
   INSTITUTE [R01EY019485, R01EY016822, R01EY017451] Funding Source: NIH
   RePORTER
FX Supported in part by NEI EY017451 (RFM), NEI 016822 (EMS), Foundation
   Fighting Blindness (RFM), the Macula Vision Research Foundation (RFM),
   the Hansjoerg E.J.W. Kolder Professorship for Best Disease Research
   (RFM) and the Howard Hughes Medical Institute (EMS). RM is co-inventor
   on patents related to complement and AMD.
CR Abrera-Abeleda MA, 2006, J MED GENET, V43, P582, DOI 10.1136/jmg.2005.038315
   Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Ethen CM, 2006, INVEST OPHTH VIS SCI, V47, P2280, DOI 10.1167/iovs.05-1395
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hecker LA, 2010, ADV EXP MED BIOL, V703, P49, DOI 10.1007/978-1-4419-5635-4_4
   Johnson PT, 2006, P NATL ACAD SCI USA, V103, P17456, DOI 10.1073/pnas.0606234103
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Maller JB, 2007, NAT GENET, V39, P1200, DOI 10.1038/ng2131
   Mullins RE, 2011, INVEST OPHTH VIS SCI, V52, P1606, DOI 10.1167/iovs.10-6476
   Nozaki M., 2006, P NATL ACAD SCI US
   Seth A, 2008, INVEST OPHTH VIS SCI, V49, P743, DOI 10.1167/iovs.07-1072
   Sivaprasad S, 2007, ARCH OPHTHALMOL-CHIC, V125, P515, DOI 10.1001/archopht.125.4.515
   Skeie JM, 2010, INVEST OPHTH VIS SCI, V51, P5336, DOI 10.1167/iovs.10-5322
   Streitberg R., 1986, STAT SOFTW NEWSLETT, V12, P10
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Yehoshua Z, 2011, SEMIN OPHTHALMOL, V26, P167, DOI 10.3109/08820538.2011.577132
NR 19
TC 89
Z9 92
U1 0
U2 5
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0014-4835
EI 1096-0007
J9 EXP EYE RES
JI Exp. Eye Res.
PD OCT
PY 2011
VL 93
IS 4
BP 565
EP 567
DI 10.1016/j.exer.2011.06.015
PG 3
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 853TZ
UT WOS:000297449900028
PM 21729696
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Marneros, AG
   Fan, J
   Yokoyama, Y
   Gerber, HP
   Ferrara, N
   Crouch, RK
   Olsen, BR
AF Marneros, AG
   Fan, J
   Yokoyama, Y
   Gerber, HP
   Ferrara, N
   Crouch, RK
   Olsen, BR
TI Vascular endothelial growth factor expression in the retinal pigment
   epithelium is essential for choriocapillaris development and visual
   function
SO AMERICAN JOURNAL OF PATHOLOGY
LA English
DT Article
ID VEGF; PERMEABILITY; SECRETION; HIF-1-ALPHA; DEFECTS; HYPOXIA; CELLS;
   EYES; RPE
AB The choroid in the eye provides vascular support for the retinal pigment epithelium (RPE) and the photoreceptors. Vascular endothelial growth factor (VEGF) derived from the RPE has been implicated in the physiological regulation of the choroidal vasculature, and overexpression of VEGF in this epithelium has been considered an important factor in the pathogenesis of choroidal neovascularization in age-related macular degeneration. Here, we demonstrate that RPE-derived VEGF is essential for choriocapillaris development. Conditional inactivation of VEGF expression in the RPE (in VEGF(rpe-/-) mice) results in the absence of choriocapillaris, occurrence of microphthalmia, and the loss of visual function. Severe abnormalities of RPE cells are already observed when VEGF expression in the RPE is only reduced (in VEGF(rpe+/-) mice), despite the formation of choroidal vessels at these VEGF levels. Finally, using Hif1a(rpe-/-) mice we demonstrate that these roles of VEGF are not dependent on hypoxia-inducible factor-1 alpha-mediated transcriptional regulation of VEGF expression in the RPE. Thus, hypoxia-inducible factor-1 alpha-independent expression of VEGF is essential for choroid development.
C1 Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA.
   Harvard Univ, Sch Dent, Dept Oral & Dev Biol, Boston, MA 02115 USA.
   Med Univ S Carolina, Dept Ophthalmol, Charleston, SC 29425 USA.
   Genentech Inc, Dept Mol Oncol, San Francisco, CA 94080 USA.
C3 Harvard University; Harvard Medical School; Harvard University; Medical
   University of South Carolina; Roche Holding; Genentech
RP Marneros, AG (通讯作者)，Harvard Univ, Sch Dent, Dept Oral Biol, 188 Longwood Ave, Boston, MA 02115 USA.
EM alexmarneros@hotmail.com
OI Marneros, Alexander/0000-0003-3866-020X
FU NIAMS NIH HHS [AR36820, R01 AR036820] Funding Source: Medline; NATIONAL
   INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES
   [R01AR036820, R37AR036820] Funding Source: NIH RePORTER
CR ADAMIS AP, 1993, BIOCHEM BIOPH RES CO, V193, P631, DOI 10.1006/bbrc.1993.1671
   Blaauwgeers HGT, 1999, AM J PATHOL, V155, P421, DOI 10.1016/S0002-9440(10)65138-3
   DELPRIORE LV, 1995, OPHTHALMOLOGY, V102, P1125, DOI 10.1016/S0161-6420(95)30903-7
   Ding K, 2005, INVEST OPHTH VIS SCI, V46, P1010, DOI 10.1167/iovs.04-0788
   Etchevers HC, 2001, DEVELOPMENT, V128, P1059
   Fan J, 2003, P NATL ACAD SCI USA, V100, P13662, DOI 10.1073/pnas.2234461100
   Gerber HP, 1999, DEVELOPMENT, V126, P1149
   Gogat K, 2004, INVEST OPHTH VIS SCI, V45, P7, DOI 10.1167/iovs.02-1096
   Harris WA, 1998, INT J DEV BIOL, V42, P299
   Hoffmann S, 2000, INVEST OPHTH VIS SCI, V41, P2389
   KORTE GE, 1989, ACTA ANAT, V134, P144
   Kotch LE, 1999, DEV BIOL, V209, P254, DOI 10.1006/dbio.1999.9253
   Leonard DS, 1997, INVEST OPHTH VIS SCI, V38, P1094
   LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986
   Marneros AG, 2004, EMBO J, V23, P89, DOI 10.1038/sj.emboj.7600014
   Martin G, 2004, GRAEF ARCH CLIN EXP, V242, P321, DOI 10.1007/s00417-003-0838-y
   McLeod DS, 2002, INVEST OPHTH VIS SCI, V43, P1986
   Miquerol L, 1999, DEV BIOL, V212, P307, DOI 10.1006/dbio.1999.9355
   Mori M, 2002, INVEST OPHTH VIS SCI, V43, P1384
   Ortega S, 1998, P NATL ACAD SCI USA, V95, P5672, DOI 10.1073/pnas.95.10.5672
   Ozaki H, 1998, AM J PATHOL, V153, P757, DOI 10.1016/S0002-9440(10)65619-2
   RAYMOND SM, 1995, CURR BIOL, V5, P1286, DOI 10.1016/S0960-9822(95)00255-7
   Reh TA, 1998, J NEUROBIOL, V36, P206, DOI 10.1002/(SICI)1097-4695(199808)36:2<206::AID-NEU8>3.0.CO;2-5
   ROBERTS WG, 1995, J CELL SCI, V108, P2369
   Rousseau B, 2000, EXP EYE RES, V71, P395, DOI 10.1006/exer.2000.0892
   Rousseau B, 2003, EXP EYE RES, V77, P147, DOI 10.1016/S0014-4835(03)00127-1
   SAKAMOTO T, 1995, ARCH OPHTHALMOL-CHIC, V113, P512, DOI 10.1001/archopht.1995.01100040134039
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   SARKS SH, 1976, BRIT J OPHTHALMOL, V60, P324, DOI 10.1136/bjo.60.5.324
   Schipani E, 2001, GENE DEV, V15, P2865
   Semenza GL, 2002, TRENDS MOL MED, V8, pS62, DOI 10.1016/S1471-4914(02)02317-1
   Slomiany MG, 2004, INVEST OPHTH VIS SCI, V45, P2838, DOI 10.1167/iovs.03-0565
   Torczynski E, 1982, Prog Clin Biol Res, V82, P35
   Yi XJ, 1998, EXP BRAIN RES, V118, P155, DOI 10.1007/s002210050267
   YOUNG RW, 1987, SURV OPHTHALMOL, V31, P291, DOI 10.1016/0039-6257(87)90115-9
   Zhao SL, 2001, MOL VIS, V7, P277
NR 36
TC 270
Z9 274
U1 0
U2 15
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9440
EI 1525-2191
J9 AM J PATHOL
JI Am. J. Pathol.
PD NOV
PY 2005
VL 167
IS 5
BP 1451
EP 1459
DI 10.1016/S0002-9440(10)61231-X
PG 9
WC Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pathology
GA 979UK
UT WOS:000232970200026
PM 16251428
OA Green Published
DA 2022-11-30
ER

PT J
AU Ghazi, NG
   Conway, BP
AF Ghazi, NG
   Conway, BP
TI Retinal angiomatous proliferation with a cilioretinal artery
   anastomosis: an unusual presentation
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
ID VEIN OCCLUSION; BLOOD-FLOW
AB Purpose: To report an unusual phenotype of retinal angiomatous proliferation (RAP) in age-related macular degeneration (AMD) and its short-term response to laser photocoagulation. Methods: Case report. Results: An 85-year-old woman was found to have an unusual RAP with a major feeder vessel originating from a cilioretinal artery and associated with a cilioretinal-oretinal anastomosis (C-RRA). Diffuse cystoid macular edema (CME), intraretinal hard exudates in a circinate pattern, and a fibrovascular pigment epithelial detachment (PED) were present. Laser photocoagulation was performed and led to occlusion of the cilioretinal feeder vessel and angiomatous lesion, with less CME. The other (retinal) arm of the C-RRA became more engorged and a new cilioretinal feeder developed, and both were associated with intraretinal hemorrhages. Visual acuity was stable and the PED persisted throughout follow-up. Conclusions: We report an unusual phenotype of RAP that is associated with a major cilioretinal feeder vessel and comment on the possible effect of such an association on the response to laser treatment.
C1 Univ Virginia Hlth Syst, Dept Ophthalmol, Charlottesville, VA 22908 USA.
C3 University of Virginia
RP Ghazi, NG (通讯作者)，Univ Virginia Hlth Syst, Dept Ophthalmol, Charlottesville, VA 22908 USA.
EM nghazi@eyeweb.org
RI Ghazi, Nicola/AAH-4169-2020
OI Ghazi, Nicola/0000-0001-9255-8025
CR ALM A, 1972, ACTA PHYSIOL SCAND, V84, P306, DOI 10.1111/j.1748-1716.1972.tb05182.x
   BLUMENTHAL M, 1971, AM J OPHTHALMOL, V71, P819, DOI 10.1016/0002-9394(71)90247-9
   Borrillo JL, 2003, ARCH OPHTHALMOL-CHIC, V121, P558, DOI 10.1001/archopht.121.4.558
   BROWN GC, 1983, RETINA-J RET VIT DIS, V3, P182, DOI 10.1097/00006982-198300330-00007
   Ghazi NG, 2002, RETINA-J RET VIT DIS, V22, P509, DOI 10.1097/00006982-200208000-00023
   MCLEOD D, 1976, BRIT J OPHTHALMOL, V60, P419, DOI 10.1136/bjo.60.6.419
   SCHATZ H, 1991, OPHTHALMOLOGY, V98, P594
   WISE NG, 1971, RETINAL CIRCULATION, P59
   Yannuzzi LA, 2001, RETINA-J RET VIT DIS, V21, P416, DOI 10.1097/00006982-200110000-00003
NR 9
TC 7
Z9 7
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING STREET, NEW YORK, NY 10013 USA
SN 0721-832X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD MAY
PY 2005
VL 243
IS 5
BP 493
EP 496
DI 10.1007/s00417-004-1034-4
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 932UB
UT WOS:000229577900019
PM 15931547
DA 2022-11-30
ER

PT J
AU Jiang, LB
   Jin, CJ
   Wen, F
   Huang, SZ
   Wu, DZ
   Wu, LZ
AF Jiang, LB
   Jin, CJ
   Wen, F
   Huang, SZ
   Wu, DZ
   Wu, LZ
TI The changes of multifocal electroretinography in the early stage of
   photodynamic therapy for choroidal neovascularization
SO DOCUMENTA OPHTHALMOLOGICA
LA English
DT Article
DE age-related macular degeneration; choroidal neovascularization;
   multifocal electroretinography; photodynamic therapy
ID MACULAR DEGENERATION; VERTEPORFIN
AB To investigate short-term changes in the multifocal electroretinography (ERG) recordings after photodynamic therapy (PDT) for choroidal neovascularization (CNV), 16 patients (17 eyes) with classic CNV confirmed by fluorescein angiography (FA) and indocyanine green angiography (ICGA), including 11 cases (12 eyes) of exudative age-related macular degeneration (AMD), two cases (two eyes) of pathological myopia and three cases (three eyes) of idiopathic causes, were treated using PDT with verteporfin. The multifocal ERGs of these patients were tested with VERIS Science(TM)4.0 imaging system. The latencies and average response densities of all six ring retinal regions were measured and compared before PDT and 3 or 7 days after PDT. The latencies and amplitude densities of the N-1 and P-1 waves in all six rings remained unchanged at 3 or 7 days post-treatment (p > 0.05). Therefore, there is no significant evidence to suggest an adverse effect from PDT for classic CNV on the outer retinal function in the early stage of treatment, with the aid of the multifocal ERG recordings.
C1 Capital Univ Med Sci, Beijing Tongren Hosp, Dept Ophthalmol, Beijing 100730, Peoples R China.
   Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, Guangzhou 510060, Peoples R China.
C3 Capital Medical University; Sun Yat Sen University
RP Jiang, LB (通讯作者)，Capital Univ Med Sci, Beijing Tongren Hosp, Dept Ophthalmol, 2 Chongnei St, Beijing 100730, Peoples R China.
EM jlb-jlb@sina.com
CR Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Bearse MA, 1996, J OPT SOC AM A, V13, P634
   Ghazi NG, 2001, RETINA-J RET VIT DIS, V21, P478, DOI 10.1097/00006982-200110000-00010
   Haimovici R, 1997, CURR EYE RES, V16, P83, DOI 10.1076/ceyr.16.2.83.5088
   Husain D, 1999, INVEST OPHTH VIS SCI, V40, P2322
   Husain D, 1996, ARCH OPHTHALMOL-CHIC, V114, P978, DOI 10.1001/archopht.1996.01100140186012
   Kramer M, 1996, OPHTHALMOLOGY, V103, P427
   Palmowski AM, 2002, OPHTHALMOLOGY, V109, P1788, DOI 10.1016/S0161-6420(02)01147-8
   Schmidt-Erfurth U, 2000, SURV OPHTHALMOL, V45, P195, DOI 10.1016/S0039-6257(00)00158-2
   Schnurrbusch UEK, 2001, BRIT J OPHTHALMOL, V85, P1086, DOI 10.1136/bjo.85.9.1086
   SEERLIGER M, 1998, AM J OPHTHALMOL, V125, P214
   Sickenberg M, 2000, ARCH OPHTHALMOL-CHIC, V118, P327, DOI 10.1001/archopht.118.3.327
NR 12
TC 13
Z9 17
U1 0
U2 2
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0012-4486
EI 1573-2622
J9 DOC OPHTHALMOL
JI Doc. Ophthalmol.
PD SEP
PY 2003
VL 107
IS 2
BP 165
EP 170
DI 10.1023/A:1026215221569
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 749JV
UT WOS:000186917300010
PM 14661906
DA 2022-11-30
ER

PT J
AU Zheng, RZ
   Zhang, YH
   Zhang, K
   Yuan, Y
   Jia, ST
   Liu, J
AF Zheng, Runzi
   Zhang, Yanghuan
   Zhang, Ke
   Yuan, Yang
   Jia, Shuting
   Liu, Jing
TI The Complement System, Aging, and Aging-Related Diseases
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Review
DE complement system; C3; aging
ID C5A RECEPTOR ANTAGONISTS; MACULAR DEGENERATION; SENESCENT CELLS; MOUSE
   MODELS; RISK-FACTORS; SERUM C3; ACTIVATION; COMPONENT; INFLAMMATION;
   INHIBITION
AB The complement system is a part of the immune system and consists of multiple complement components with biological functions such as defense against pathogens and immunomodulation. The complement system has three activation pathways: the classical pathway, the lectin pathway, and the alternative pathway. Increasing evidence indicates that the complement system plays a role in aging. Complement plays a role in inflammatory processes, metabolism, apoptosis, mitochondrial function, and Wnt signaling pathways. In addition, the complement system plays a significant role in aging-related diseases, including Alzheimer's disease, age-related macular degeneration, and osteoarthritis. However, the effect of complement on aging and aging-related diseases is still unclear. Thus, a better understanding of the potential relationship between complement, aging, and aging-related diseases will provide molecular targets for treating aging, while focusing on the balance of complement in during treatment. Inhibition of a single component does not result in a good outcome. In this review, we discussed the research progress and effects of complement in aging and aging-related diseases.
C1 [Zheng, Runzi; Zhang, Yanghuan; Zhang, Ke; Yuan, Yang; Jia, Shuting; Liu, Jing] Kunming Univ Sci & Technol, Med Sch, Lab Mol Genet Aging & Tumor, 727 South Jing Ming Rd, Kunming 650500, Yunnan, Peoples R China.
C3 Kunming University of Science & Technology
RP Jia, ST; Liu, J (通讯作者)，Kunming Univ Sci & Technol, Med Sch, Lab Mol Genet Aging & Tumor, 727 South Jing Ming Rd, Kunming 650500, Yunnan, Peoples R China.
EM shutingjia@kust.edu.cn; jingliu1437@163.com
OI Runzi, Zheng/0000-0001-8514-692X; Jia, Shuting/0000-0003-0452-260X
FU National Natural Science Foundation of China [82060660]; Yunnan
   Fundamental Research Project [202201AS070074, 202101AT070086]
FX The National Natural Science Foundation of China (Grant No. 82060660) to
   J.L. and the Yunnan Fundamental Research Project (Grant No.
   202201AS070074, 202101AT070086) to S.J. and J.L.
CR Al-Sofiani ME, 2019, J DIABETES COMPLICAT, V33, P451, DOI 10.1016/j.jdiacomp.2019.03.007
   Amarilyo G, 2010, EUR J IMMUNOL, V40, P699, DOI 10.1002/eji.200838951
   Armento A, 2021, CELL MOL LIFE SCI, V78, P4487, DOI 10.1007/s00018-021-03796-9
   Asgari E, 2013, BLOOD, V122, P3473, DOI 10.1182/blood-2013-05-502229
   Assirelli E, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.535010
   Barbu A, 2015, MOL IMMUNOL, V67, P101, DOI 10.1016/j.molimm.2015.02.027
   Barna J, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-40788-z
   Bhutto IA, 2016, BRIT J OPHTHALMOL, V100, P720, DOI 10.1136/bjophthalmol-2015-308290
   Bongrazio M, 2003, MOL IMMUNOL, V39, P669, DOI 10.1016/S0161-5890(02)00215-8
   Borodkina AV, 2018, ACTA NATURAE, V10, P4, DOI 10.32607/20758251-2018-10-1-4-14
   Brinkmann CR, 2013, J BIOL CHEM, V288, P8016, DOI 10.1074/jbc.M112.430249
   Cao WJ, 2020, AGING-US, V12, P10676, DOI 10.18632/aging.103286
   Cashman SM, 2011, INVEST OPHTH VIS SCI, V52, P3436, DOI 10.1167/iovs.10-6002
   Castellano G, 2019, AGING-US, V11, P4382, DOI 10.18632/aging.102059
   Chandra P, 2019, AM J NEPHROL, V49, P81, DOI 10.1159/000496059
   Cohen D, 2012, KIDNEY INT, V81, P628, DOI 10.1038/ki.2011.497
   Davalli P, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/3565127
   Delanghe JR, 2014, PATHOLOGY, V46, P1, DOI 10.1097/PAT.0000000000000042
   Dodig S, 2019, BIOCHEM MEDICA, V29, DOI 10.11613/BM.2019.030501
   Dong ZC, 2021, EXP THER MED, V22, DOI 10.3892/etm.2021.10169
   Dos Santos RS, 2017, ENDOCRINOLOGY, V158, P2503, DOI 10.1210/en.2017-00104
   ELSNER J, 1994, EUR J IMMUNOL, V24, P518, DOI 10.1002/eji.1830240304
   ELSNER J, 1994, BLOOD, V83, P3324
   Engstrom G, 2005, DIABETES, V54, P570, DOI 10.2337/diabetes.54.2.570
   Faget DV, 2019, NAT REV CANCER, V19, P439, DOI 10.1038/s41568-019-0156-2
   Felson DT, 2009, ARTHRITIS RES THER, V11, DOI 10.1186/ar2531
   Fonseca MI, 2004, J NEUROSCI, V24, P6457, DOI 10.1523/JNEUROSCI.0901-04.2004
   Franceschi C, 2014, J GERONTOL A-BIOL, V69, pS4, DOI 10.1093/gerona/glu057
   Friscic J, 2021, IMMUNITY, V54, P1002, DOI 10.1016/j.immuni.2021.03.003
   Fu SH, 2020, CELL MOL IMMUNOL, V17, P1196, DOI 10.1038/s41423-020-0386-y
   Fu SH, 2018, J TRANSL MED, V16, DOI 10.1186/s12967-018-1691-4
   Gadjeva M, 2004, MOL IMMUNOL, V41, P113, DOI 10.1016/j.molimm.2004.03.015
   Geyer M, 2018, CURR RHEUMATOL REV, V14, P98, DOI 10.2174/1573397113666170807122312
   Goetzl EJ, 2018, ANN NEUROL, V83, P544, DOI 10.1002/ana.25172
   Hai J.Z., 2010, J CHIN J MOD MED, V20, P548
   Heesterbeek TJ, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.3.18
   Hertle E, 2014, MOL IMMUNOL, V61, P135, DOI 10.1016/j.molimm.2014.06.031
   Hettmann T, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-60319-5
   Hoppel CL, 2017, ADV EXP MED BIOL, V982, P451, DOI 10.1007/978-3-319-55330-6_24
   Horii N, 2018, FASEB J, V32, P3547, DOI 10.1096/fj.201700772RRR
   Hou YJ, 2019, NAT REV NEUROL, V15, P565, DOI 10.1038/s41582-019-0244-7
   Huber-Lang M, 2006, NAT MED, V12, P682, DOI 10.1038/nm1419
   Iltumur K, 2005, APMIS, V113, P167, DOI 10.1111/j.1600-0463.2005.apm1130303.x
   Ishii M, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.628062
   Izzo C, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19020481
   Jang JH, 2010, PAIN, V148, P343, DOI 10.1016/j.pain.2009.11.021
   Janssen BJC, 2005, NATURE, V437, P505, DOI 10.1038/nature04005
   Jha P, 2011, MOL IMMUNOL, V48, P2151, DOI 10.1016/j.molimm.2011.07.012
   Jura M, 2016, AGE, V38, DOI 10.1007/s11357-016-9884-3
   Kam JH, 2013, AM J PATHOL, V183, P480, DOI 10.1016/j.ajpath.2013.04.008
   Kassa E, 2019, EXPERT OPIN BIOL TH, V19, P335, DOI 10.1080/14712598.2019.1575358
   Keshavjee S, 2005, J THORAC CARDIOV SUR, V129, P423, DOI 10.1016/j.jtcvs.2004.06.048
   Khaltourina D, 2020, MECH AGEING DEV, V189, DOI 10.1016/j.mad.2020.111230
   Khan SS, 2017, AGING CELL, V16, P624, DOI 10.1111/acel.12601
   Khandhadia S, 2012, IMMUNOBIOLOGY, V217, P127, DOI 10.1016/j.imbio.2011.07.019
   King B, 2019, AUTOPHAGY, V15, P919, DOI 10.1080/15548627.2019.1580515
   Kostner KM, 2006, CLIN CHIM ACTA, V365, P129, DOI 10.1016/j.cca.2005.08.028
   Kumar V, 2020, ACS OMEGA, V5, P2345, DOI 10.1021/acsomega.9b03735
   Lagrand WK, 1997, CIRCULATION, V95, P97, DOI 10.1161/01.CIR.95.1.97
   Lech M, 2013, J AM SOC NEPHROL, V24, P1357, DOI 10.1681/ASN.2013010026
   Lee JD, 2017, BRIT J PHARMACOL, V174, P689, DOI 10.1111/bph.13730
   Lohman RJ, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00414-w
   Lopez-Otin C, 2013, CELL, V153, P1194, DOI 10.1016/j.cell.2013.05.039
   Markiewski MM, 2004, J IMMUNOL, V173, P747, DOI 10.4049/jimmunol.173.2.747
   Martinus RD, 2011, NEUROREPORT, V22, P581, DOI 10.1097/WNR.0b013e32834901d9
   Mastellos D, 2001, J IMMUNOL, V166, P2479, DOI 10.4049/jimmunol.166.4.2479
   McGeer EG, 2005, NEUROBIOL AGING, V26, pS94, DOI 10.1016/j.neurobiolaging.2005.08.008
   McGeer PL, 2017, NEUROBIOL AGING, V52, P12, DOI 10.1016/j.neurobiolaging.2016.12.017
   Merle NS, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00262
   Merle NS, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00257
   MURAKAMI Y, 1993, IMMUNOLOGY, V79, P633
   Muscari A, 2005, INT J CARDIOL, V100, P217, DOI 10.1016/j.ijcard.2004.07.024
   Muscari A, 2000, EUR HEART J, V21, P1081, DOI 10.1053/euhj.1999.2013
   Naito AT, 2012, CELL, V149, P1298, DOI 10.1016/j.cell.2012.03.047
   Nesargikar PN, 2012, EUR J MICROBIOL IMMU, V2, P103, DOI 10.1556/EuJMI.2.2012.2.2
   Nozaki M, 2006, P NATL ACAD SCI USA, V103, P2328, DOI 10.1073/pnas.0408835103
   Onat A, 2011, CLIN CHIM ACTA, V412, P1171, DOI 10.1016/j.cca.2011.03.005
   Onat A, 2010, METABOLISM, V59, P628, DOI 10.1016/j.metabol.2009.09.006
   Pandya PH, 2014, AM J RESP CELL MOL, V51, P467, DOI 10.1165/rcmb.2013-0485TR
   Pierre AF, 1998, TRANSPLANTATION, V66, P723, DOI 10.1097/00007890-199809270-00006
   Postmus AC, 2019, CURR OPIN LIPIDOL, V30, P177, DOI 10.1097/MOL.0000000000000602
   Qin XB, 2006, CELL MOL IMMUNOL, V3, P333
   Quadros AU, 2016, PHARMACOL RES, V112, P58, DOI 10.1016/j.phrs.2016.02.004
   ROGERS J, 1992, P NATL ACAD SCI USA, V89, P10016, DOI 10.1073/pnas.89.21.10016
   Salminen A, 2011, CELL MOL LIFE SCI, V68, P1021, DOI 10.1007/s00018-010-0597-y
   Schaefer N, 2022, PEPTIDES, V154, DOI 10.1016/j.peptides.2022.170815
   Schmid RA, 1998, J THORAC CARDIOV SUR, V116, P90, DOI 10.1016/S0022-5223(98)70246-6
   Shah AK, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms222413647
   Shen Liang-xian, 2011, Zhongguo Yaolixue Tongbao, V27, P1245
   Sho T, 2019, BIOTECHNOL APPL BIOC, V66, P4, DOI 10.1002/bab.1700
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Stammberger U, 2000, J THORAC CARDIOV SUR, V120, P1078, DOI 10.1067/mtc.2000.111175
   Stevens B, 2007, CELL, V131, P1164, DOI 10.1016/j.cell.2007.10.036
   Strey CW, 2003, J EXP MED, V198, P913, DOI 10.1084/jem.20030374
   Struglics A, 2016, ARTHRITIS RES THER, V18, DOI 10.1186/s13075-016-1123-x
   Sullivan Kathleen E., 1998, Current Opinion in Pediatrics, V10, P600
   Szeplaki G, 2004, ATHEROSCLEROSIS, V177, P383, DOI 10.1016/j.atherosclerosis.2004.07.022
   Takabayashi T, 1996, J IMMUNOL, V156, P3455
   Tan PL, 2016, HUM GENOMICS, V10, DOI 10.1186/s40246-016-0079-x
   Tan SM, 2020, DIABETES, V69, P83, DOI 10.2337/db19-0043
   Tenner AJ, 2020, J IMMUNOL, V204, P306, DOI 10.4049/jimmunol.1901068
   Toapanta FR, 2006, IMMUNOL RES, V36, P197, DOI 10.1385/IR:36:1:197
   Trouw LA, 2003, MOL IMMUNOL, V40, P125, DOI 10.1016/S0161-5890(03)00105-6
   Veerhuis R, 2011, CURR ALZHEIMER RES, V8, P34, DOI 10.2174/156720511794604589
   Vergunst CE, 2007, RHEUMATOLOGY, V46, P1773, DOI 10.1093/rheumatology/kem222
   Vignesh P, 2017, CLIN CHIM ACTA, V465, P123, DOI 10.1016/j.cca.2016.12.017
   WALKER DG, 1992, MOL BRAIN RES, V14, P109, DOI 10.1016/0169-328X(92)90017-6
   Wang HB, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.694928
   Wang Q, 2011, NAT MED, V17, P1674, DOI 10.1038/nm.2543
   Wang XD, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0084852
   Woodruff TM, 2006, FASEB J, V20, P1407, DOI 10.1096/fj.05-5814com
   Wu MCL, 2013, P NATL ACAD SCI USA, V110, P9439, DOI 10.1073/pnas.1218815110
   Wu T, 2019, CELL REP, V28, P2111, DOI 10.1016/j.celrep.2019.07.060
   Wu XT, 2020, LIFE SCI, V260, DOI 10.1016/j.lfs.2020.118370
   WUNDER GC, 1992, J AM DENT ASSOC, V123, P129, DOI 10.14219/jada.archive.1992.0278
   Xing Y, 2021, ANIM SCI J, V92, DOI 10.1111/asj.13527
   YASUDA M, 1990, CIRCULATION, V81, P156, DOI 10.1161/01.CIR.81.1.156
   Zeng W, 2021, PHARMACOL RES, V170, DOI 10.1016/j.phrs.2021.105697
   Zhang C, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01543
   Zheng QY, 2020, INT IMMUNOPHARMACOL, V85, DOI 10.1016/j.intimp.2020.106692
NR 120
TC 0
Z9 0
U1 10
U2 10
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1422-0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD AUG
PY 2022
VL 23
IS 15
AR 8689
DI 10.3390/ijms23158689
PG 14
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA 3R7UF
UT WOS:000839112400001
PM 35955822
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Nishida, M
   Tanaka, Y
   Tanaka, Y
   Amaya, S
   Tanaka, N
   Uyama, H
   Masuda, T
   Onishi, A
   Sho, J
   Yokota, S
   Takahashi, M
   Mandai, M
AF Nishida, Mitsuhiro
   Tanaka, Yuji
   Tanaka, Yo
   Amaya, Satoshi
   Tanaka, Nobuyuki
   Uyama, Hirofumi
   Masuda, Tomohiro
   Onishi, Akishi
   Sho, Junki
   Yokota, Satoshi
   Takahashi, Masayo
   Mandai, Michiko
TI Human iPS cell derived RPE strips for secure delivery of graft cells at
   a target place with minimal surgical invasion
SO SCIENTIFIC REPORTS
LA English
DT Article
ID PLURIPOTENT STEM-CELLS; MACULAR DEGENERATION; DRIVEN
AB Several clinical studies have been conducted into the practicality and safety of regenerative therapy using hESC/iPSC-retinal pigment epithelium (RPE) as a treatment for the diseases including age-related macular degeneration. These studies used either suspensions of RPE cells or an RPE cell sheet. The cells can be injected using a minimally invasive procedure but the delivery of an intended number of cells at an exact target location is difficult; cell sheets take a longer time to prepare, and the surgical procedure is invasive but can be placed at the target area. In the research reported here, we combined the advantages of the two approaches by producing a quickly formed hiPSC-RPE strip in as short as 2 days. The strip readily expanded into a monolayer sheet on the plate, and after transplantation in nude rats, it showed a potency to partly expand with the correct apical/basal polarity in vivo, although limited in expansion area in the presence of healthy host RPE. The strip could be injected into a target area in animal eyes using a 24G canula tip.
C1 [Nishida, Mitsuhiro; Tanaka, Yuji; Uyama, Hirofumi; Masuda, Tomohiro; Onishi, Akishi; Sho, Junki; Yokota, Satoshi; Takahashi, Masayo; Mandai, Michiko] RIKEN Ctr Biosyst Dynam Res, Lab Retinal Regenerat, Chuo Ku, 2-2-3 Minatojima Minamimachi, Kobe, Hyogo 6500047, Japan.
   [Tanaka, Yuji] Univ Yamanashi, Interdisciplinary Grad Sch Med & Engn, Div Med, Kofu, Yamanashi, Japan.
   [Tanaka, Yo; Amaya, Satoshi; Tanaka, Nobuyuki] RIKEN Ctr Biosyst Dynam Res, Lab Integrated Biodevice, Kobe, Hyogo, Japan.
   [Uyama, Hirofumi; Yokota, Satoshi; Takahashi, Masayo; Mandai, Michiko] Kobe City Eye Hosp, Dept Ophthalmol, Kobe, Hyogo, Japan.
   [Sho, Junki; Takahashi, Masayo] Vis Care Inc, Kobe, Hyogo, Japan.
   [Masuda, Tomohiro; Takahashi, Masayo] Vis Care Cell Therapy Inc, Kobe, Hyogo, Japan.
C3 RIKEN; University of Yamanashi; RIKEN
RP Mandai, M (通讯作者)，RIKEN Ctr Biosyst Dynam Res, Lab Retinal Regenerat, Chuo Ku, 2-2-3 Minatojima Minamimachi, Kobe, Hyogo 6500047, Japan.; Mandai, M (通讯作者)，Kobe City Eye Hosp, Dept Ophthalmol, Kobe, Hyogo, Japan.
EM michiko.mandai@riken.jp
RI Tanaka, Yo/ABE-5075-2020
OI Tanaka, Yo/0000-0003-1034-5718
CR da Cruz L, 2018, NAT BIOTECHNOL, V36, P1, DOI 10.1038/nbt.4114
   Fernandes Rodrigo A Brant, 2017, Int J Retina Vitreous, V3, P41, DOI 10.1186/s40942-017-0095-6
   Kamei K, 2015, BIOMED MICRODEVICES, V17, DOI 10.1007/s10544-015-9928-y
   Kashani AH, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aao4097
   Kitahata S, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-018-38065-6
   Kuwahara A, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-55130-w
   Kuwahara A, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7286
   Mandai M, 2017, NEW ENGL J MED, V376, P1038, DOI 10.1056/NEJMoa1608368
   Nakagawa M, 2008, NAT BIOTECHNOL, V26, P101, DOI 10.1038/nbt1374
   Nakano T, 2012, CELL STEM CELL, V10, P771, DOI 10.1016/j.stem.2012.05.009
   Ni Y, 2017, CURR MOL MED, V17, P637, DOI 10.2174/1566524018666180316150936
   Oceguera-Yanez F, 2016, METHODS, V101, P43, DOI 10.1016/j.ymeth.2015.12.012
   Okita K, 2011, NAT METHODS, V8, P409, DOI [10.1038/NMETH.1591, 10.1038/nmeth.1591]
   Schwartz SD, 2015, LANCET, V385, P509, DOI 10.1016/S0140-6736(14)61376-3
   Schwartz SD, 2012, LANCET, V379, P713, DOI 10.1016/S0140-6736(12)60028-2
   Song WK, 2015, STEM CELL REP, V4, P860, DOI 10.1016/j.stemcr.2015.04.005
   Sugita S, 2020, J CLIN MED, V9, DOI 10.3390/jcm9072217
   Takagi S, 2019, OPHTHALMOL RETINA, V3, P850, DOI 10.1016/j.oret.2019.04.021
   Takahashi K, 2007, CELL, V131, P861, DOI 10.1016/j.cell.2007.11.019
   Takebe T, 2015, CELL STEM CELL, V16, P556, DOI 10.1016/j.stem.2015.03.004
   Tanaka N, 2019, SENSOR ACTUAT B-CHEM, V293, P256, DOI 10.1016/j.snb.2019.04.087
   Xia YN, 1998, ANNU REV MATER SCI, V28, P153, DOI 10.1146/annurev.matsci.28.1.153
   Xia YN, 1998, ANGEW CHEM INT EDIT, V37, P550, DOI 10.1002/(SICI)1521-3773(19980316)37:5<550::AID-ANIE550>3.0.CO;2-G
   Yamashita T, 2016, ACTA BIOMATER, V45, P85, DOI 10.1016/j.actbio.2016.08.044
NR 24
TC 4
Z9 4
U1 1
U2 3
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD NOV 2
PY 2021
VL 11
IS 1
AR 21421
DI 10.1038/s41598-021-00703-x
PG 14
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA WS1MO
UT WOS:000714953500078
PM 34728664
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Li, XM
   Hu, XW
   Qi, XJ
   Yu, LQ
   Zhao, W
   Heng, PA
   Xing, L
AF Li, Xiaomeng
   Hu, Xiaowei
   Qi, Xiaojuan
   Yu, Lequan
   Zhao, Wei
   Heng, Pheng-Ann
   Xing, Lei
TI Rotation-Oriented Collaborative Self-Supervised Learning for Retinal
   Disease Diagnosis
SO IEEE TRANSACTIONS ON MEDICAL IMAGING
LA English
DT Article
DE Task analysis; Retina; Diseases; Medical diagnosis; Medical diagnostic
   imaging; Feature extraction; Annotations; Self-supervised learning;
   retinal disease classification
ID MACULAR DEGENERATION
AB The automatic diagnosis of various conventional ophthalmic diseases from fundus images is important in clinical practice. However, developing such automatic solutions is challenging due to the requirement of a large amount of training data and the expensive annotations for medical images. This paper presents a novel self-supervised learning framework for retinal disease diagnosis to reduce the annotation efforts by learning the visual features from the unlabeled images. To achieve this, we present a rotation-oriented collaborative method that explores rotation-related and rotation-invariant features, which capture discriminative structures from fundus images and also explore the invariant property used for retinal disease classification. We evaluate the proposed method on two public benchmark datasets for retinal disease classification. The experimental results demonstrate that our method outperforms other self-supervised feature learning methods (around 4.2% area under the curve (AUC)). With a large amount of unlabeled data available, our method can surpass the supervised baseline for pathologic myopia (PM) and is very close to the supervised baseline for age-related macular degeneration (AMD), showing the potential benefit of our method in clinical practice.
C1 [Li, Xiaomeng] Hong Kong Univ Sci & Technol, Dept Elect & Comp Engn, Hong Kong, Peoples R China.
   [Li, Xiaomeng; Yu, Lequan; Zhao, Wei; Xing, Lei] Stanford Univ, Dept Radiat Oncol, Stanford, CA 94305 USA.
   [Hu, Xiaowei; Heng, Pheng-Ann] Chinese Univ Hong Kong, Dept Comp Sci & Engn, Hong Kong, Peoples R China.
   [Qi, Xiaojuan] Univ Hong Kong, Dept Elect & Elect Engn, Hong Kong, Peoples R China.
   [Yu, Lequan] Univ Hong Kong, Dept Stat & Actuarial Sci, Hong Kong, Peoples R China.
C3 Hong Kong University of Science & Technology; Stanford University;
   Chinese University of Hong Kong; University of Hong Kong; University of
   Hong Kong
RP Li, XM (通讯作者)，Hong Kong Univ Sci & Technol, Dept Elect & Comp Engn, Hong Kong, Peoples R China.; Xing, L (通讯作者)，Stanford Univ, Dept Radiat Oncol, Stanford, CA 94305 USA.
EM eexmli@ust.hk; lei@stanford.edu
OI Xing, Lei/0000-0003-2536-5359; Hu, Xiaowei/0000-0002-5708-7018; Li,
   Xiaomeng/0000-0003-1105-8083; Zhao, Wei/0000-0002-6182-4746; Heng, Pheng
   Ann/0000-0003-3055-5034
FU Hong Kong University of Science and Technology
FX This work was supported in part by a start-up research grant at The Hong
   Kong University of Science and Technology.
CR Almazroa A, 2018, PROC SPIE, V10579, DOI 10.1117/12.2293584
   Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Badar M, 2020, COMPUT SCI REV, V35, DOI 10.1016/j.cosrev.2019.100203
   Bai WJ, 2019, LECT NOTES COMPUT SC, V11765, P541, DOI 10.1007/978-3-030-32245-8_60
   BLENDOWSKI M, 2019, P INT C MED IM COMP, P649
   Burlina P, 2016, I S BIOMED IMAGING, P184, DOI 10.1109/ISBI.2016.7493240
   Burlina PM, 2017, JAMA OPHTHALMOL, V135, P1170, DOI 10.1001/jamaophthalmol.2017.3782
   Chen L, 2019, MED IMAGE ANAL, V58, DOI 10.1016/j.media.2019.101539
   Chen T, 2020, PR MACH LEARN RES, V119
   Chen XY, 2015, IEEE ENG MED BIO, P715, DOI 10.1109/EMBC.2015.7318462
   Chen XC, 2020, IEEE IJCNN
   Cheng G, 2019, IEEE T IMAGE PROCESS, V28, P265, DOI 10.1109/TIP.2018.2867198
   Cheng G, 2016, PROC CVPR IEEE, P2884, DOI 10.1109/CVPR.2016.315
   Cheng G, 2016, IEEE T GEOSCI REMOTE, V54, P7405, DOI 10.1109/TGRS.2016.2601622
   Cheng J, 2019, ELS MIC SOC BOOK SER, P199, DOI 10.1016/B978-0-08-102816-2.00011-3
   Cheng J, 2013, IEEE T MED IMAGING, V32, P1019, DOI 10.1109/TMI.2013.2247770
   Chollet F, 2017, PROC CVPR IEEE, P1800, DOI 10.1109/CVPR.2017.195
   COX DR, 1958, J R STAT SOC B, V20, P215
   de Jong EK, 2020, GENETICS AND GENOMICS OF EYE DISEASE: ADVANCING TO PRECISION MEDICINE, P155, DOI 10.1016/B978-0-12-816222-4.00010-1
   Doersch C, 2017, IEEE I CONF COMP VIS, P2070, DOI 10.1109/ICCV.2017.226
   Doersch C, 2015, IEEE I CONF COMP VIS, P1422, DOI 10.1109/ICCV.2015.167
   Dosovitskiy A., 2014, P NIPS, P766, DOI [10.48550/arXiv.1406.6909, DOI 10.1109/TPAMI.2015.2496141]
   Dosovitskiy A, 2016, IEEE T PATTERN ANAL, V38, P1734, DOI 10.1109/TPAMI.2015.2496141
   Feng ZY, 2019, PROC CVPR IEEE, P10356, DOI 10.1109/CVPR.2019.01061
   Ferrara N, 2010, NAT MED, V16, P1107, DOI 10.1038/nm1010-1107
   Freire C. R., 2020, ARXIV200206382
   Fu Huazhu, 2018, IEEE Trans Med Imaging, V37, P2493, DOI 10.1109/TMI.2018.2837012
   Garnier M, 2014, PROC SPIE, V9035, DOI 10.1117/12.2043099
   Gidaris S., 2018, ARXIV180307728
   Grassmann F, 2018, OPHTHALMOLOGY, V125, P1410, DOI 10.1016/j.ophtha.2018.02.037
   Grill J., 2020, ADV NEUR IN
   Guo Y, 2020, I S BIOMED IMAGING, P1242, DOI 10.1109/ISBI45749.2020.9098669
   He K., 2020, CVPR, P9729, DOI DOI 10.1109/CVPR42600.2020.00975
   He KM, 2016, PROC CVPR IEEE, P770, DOI 10.1109/CVPR.2016.90
   Jamaludin A, 2017, LECT NOTES COMPUT SC, V10553, P294, DOI 10.1007/978-3-319-67558-9_34
   King DB, 2015, ACS SYM SER, V1214, P1
   KLEIN BEK, 1992, OPHTHALMOLOGY, V99, P1499
   Li XM, 2020, IEEE T MED IMAGING, V39, P4023, DOI 10.1109/TMI.2020.3008871
   Li XM, 2020, IEEE T MED IMAGING, V39, P1483, DOI 10.1109/TMI.2019.2951844
   Milea D, 2020, NEW ENGL J MED, V382, P1687, DOI 10.1056/NEJMoa1917130
   Morgan IG, 2012, LANCET, V379, P1739, DOI 10.1016/S0140-6736(12)60272-4
   Noroozi M, 2016, LECT NOTES COMPUT SC, V9910, P69, DOI 10.1007/978-3-319-46466-4_5
   Paszke A, 2019, ADV NEUR IN, V32
   Pathak D, 2016, PROC CVPR IEEE, P2536, DOI 10.1109/CVPR.2016.278
   Peng YF, 2019, OPHTHALMOLOGY, V126, P565, DOI 10.1016/j.ophtha.2018.11.015
   Qiu L, 2019, ARXIV190800410
   Saba T, 2018, MICROSC RES TECHNIQ, V81, P1105, DOI 10.1002/jemt.23094
   Sakaguchi A., 2019, P 2019 9 INT C BIOME, P190
   Selvaraju RR, 2017, IEEE I CONF COMP VIS, P618, DOI 10.1109/ICCV.2017.74
   Spitzer H, 2018, LECT NOTES COMPUT SC, V11072, P663, DOI 10.1007/978-3-030-00931-1_76
   Springenberg J.T., 2014, ICLR WORKSHOP TRACK, DOI DOI 10.48550/ARXIV.1412.6806
   Tajbakhsh N, 2019, I S BIOMED IMAGING, P1251, DOI 10.1109/ISBI.2019.8759553
   Taleb A, 2020, ADV NEUR IN, V33
   Virmani J., 2019, SENS HLTH MONIT, V5, P215
   Waseem Saima, 2014, 7th International Conference on Information and Automation for Sustainability (ICIAfS), P1, DOI 10.1109/ICIAFS.2014.7069581
   Wu ZR, 2018, PROC CVPR IEEE, P3733, DOI 10.1109/CVPR.2018.00393
   Xia XL, 2017, 2017 2ND INTERNATIONAL CONFERENCE ON IMAGE, VISION AND COMPUTING (ICIVC 2017), P783, DOI 10.1109/ICIVC.2017.7984661
   Ye M, 2019, PROC CVPR IEEE, P6203, DOI 10.1109/CVPR.2019.00637
   Yin PS, 2019, LECT NOTES COMPUT SC, V11764, P129, DOI 10.1007/978-3-030-32239-7_15
   Zhang R, 2016, LECT NOTES COMPUT SC, V9907, P649, DOI 10.1007/978-3-319-46487-9_40
   Zhe Wang, 2017, Medical Image Computing and Computer Assisted Intervention - MICCAI 2017. 20th International Conference. Proceedings: LNCS 10435, P267, DOI 10.1007/978-3-319-66179-7_31
   Zhou Y, 2019, PROC CVPR IEEE, P2074, DOI 10.1109/CVPR.2019.00218
   Zhou ZW, 2019, LECT NOTES COMPUT SC, V11767, P384, DOI 10.1007/978-3-030-32251-9_42
   Zhu JW, 2020, MED IMAGE ANAL, V64, DOI 10.1016/j.media.2020.101746
   Zhuang XR, 2019, LECT NOTES COMPUT SC, V11767, P420, DOI 10.1007/978-3-030-32251-9_46
NR 65
TC 7
Z9 7
U1 5
U2 16
PU IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC
PI PISCATAWAY
PA 445 HOES LANE, PISCATAWAY, NJ 08855-4141 USA
SN 0278-0062
EI 1558-254X
J9 IEEE T MED IMAGING
JI IEEE Trans. Med. Imaging
PD SEP
PY 2021
VL 40
IS 9
BP 2284
EP 2294
DI 10.1109/TMI.2021.3075244
PG 11
WC Computer Science, Interdisciplinary Applications; Engineering,
   Biomedical; Engineering, Electrical & Electronic; Imaging Science &
   Photographic Technology; Radiology, Nuclear Medicine & Medical Imaging
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Computer Science; Engineering; Imaging Science & Photographic
   Technology; Radiology, Nuclear Medicine & Medical Imaging
GA UK8IN
UT WOS:000692208500009
PM 33891550
DA 2022-11-30
ER

PT J
AU Low, SWY
   Connor, TB
   Kassem, IS
   Costakos, DM
   Chaurasia, SS
AF Low, Shermaine W. Y.
   Connor, Thomas B.
   Kassem, Iris S.
   Costakos, Deborah M.
   Chaurasia, Shyam S.
TI Small Leucine-Rich Proteoglycans (SLRPs) in the Retina
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Review
DE retina; small leucine rich proteoglycans (SLRP); biglycan; decorin;
   fibromodulin; lumican; PRELP; opticin; osteoglycin; mimecan;
   chondroadherin; tsukushi; nyctalopin
ID STATIONARY NIGHT BLINDNESS; RESTORES VISUAL FUNCTION; ADULT HUMAN
   RETINA; EXTRACELLULAR-MATRIX; MOUSE MODEL; PROLIFERATIVE
   VITREORETINOPATHY; DIFFERENTIAL DISTRIBUTION; SULFATE PROTEOGLYCANS;
   SIGNALING PATHWAYS; PIGMENT EPITHELIUM
AB Retinal diseases such as age-related macular degeneration (AMD), retinopathy of prematurity (ROP), and diabetic retinopathy (DR) are the leading causes of visual impairment worldwide. There is a critical need to understand the structural and cellular components that play a vital role in the pathophysiology of retinal diseases. One potential component is the family of structural proteins called small leucine-rich proteoglycans (SLRPs). SLRPs are crucial in many fundamental biological processes involved in the maintenance of retinal homeostasis. They are present within the extracellular matrix (ECM) of connective and vascular tissues and contribute to tissue organization and modulation of cell growth. They play a vital role in cell-matrix interactions in many upstream signaling pathways involved in fibrillogenesis and angiogenesis. In this comprehensive review, we describe the expression patterns and function of SLRPs in the retina, including Biglycan and Decorin from class I; Fibromodulin, Lumican, and a Proline/arginine-rich end leucine-rich repeat protein (PRELP) from class II; Opticin and Osteoglycin/Mimecan from class III; and Chondroadherin (CHAD), Tsukushi and Nyctalopin from class IV.
C1 [Low, Shermaine W. Y.; Connor, Thomas B.; Kassem, Iris S.; Costakos, Deborah M.; Chaurasia, Shyam S.] Med Coll Wisconsin, Dept Ophthalmol & Visual Sci, Ocular Immunol & Angiogenesis Lab, Milwaukee, WI 53226 USA.
C3 Medical College of Wisconsin
RP Chaurasia, SS (通讯作者)，Med Coll Wisconsin, Dept Ophthalmol & Visual Sci, Ocular Immunol & Angiogenesis Lab, Milwaukee, WI 53226 USA.
EM wlow@mcw.edu; tconnor@mcw.edu; ikassem@mcw.edu; dcostakos@mcw.edu;
   schaurasia@mcw.edu
RI Chaurasia, Shyam/AAB-4709-2019
OI Chaurasia, Shyam/0000-0001-8725-676X
FU National Eye Institute, NIH, Bethesda, Maryland [RO1EY029795]; Research
   Facilities Improvement Program from the National Center for Research
   Resources, NIH [C06RR016511]
FX This research was funded by National Eye Institute, NIH, Bethesda,
   Maryland grant number RO1EY029795 to S.S.C. This investigation was
   conducted in part in a facility constructed with support from a Research
   Facilities Improvement Program, grant number C06RR016511 from the
   National Center for Research Resources, NIH. Its contents are solely the
   responsibility of the authors and do not necessarily represent the
   official views of the NIH.
CR Abdullatif AM, 2018, GRAEF ARCH CLIN EXP, V256, P2473, DOI 10.1007/s00417-018-4105-7
   Ali SAM, 2011, J VET MED SCI, V73, P13, DOI 10.1292/jvms.10-0201
   Ali SAM, 2011, J VET MED SCI, V73, P439, DOI 10.1292/jvms.10-0464
   An E, 2010, INVEST OPHTH VIS SCI, V51, P3379, DOI 10.1167/iovs.09-4853
   Ball SL, 2003, VISUAL NEUROSCI, V20, P267, DOI 10.1017/S0952523803203059
   Bech-Hansen NT, 2000, NAT GENET, V26, P319, DOI 10.1038/81619
   Bech-Hansen NT, 2005, MAMM GENOME, V16, P815, DOI 10.1007/s00335-005-0018-y
   Begum G, 2018, INVEST OPHTH VIS SCI, V59, P4929, DOI 10.1167/iovs.18-24299
   Bengtsson E, 2000, J BIOL CHEM, V275, P40695, DOI 10.1074/jbc.M007917200
   Birke MT, 2014, GENE THER, V21, P507, DOI 10.1038/gt.2014.24
   Bishop PN, 2002, EYE, V16, P454, DOI 10.1038/sj.eye.6700199
   Bishop PN, 2000, PROG RETIN EYE RES, V19, P323, DOI 10.1016/S1350-9462(99)00016-6
   Bojang P, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033137
   Cao Y, 2011, J NEUROSCI, V31, P11521, DOI 10.1523/JNEUROSCI.1682-11.2011
   Chakravarti S, 2003, INVEST OPHTH VIS SCI, V44, P2422, DOI 10.1167/iovs.02-0783
   Chen SJ, 2013, FEBS J, V280, P2120, DOI 10.1111/febs.12136
   Clark SJ, 2011, INVEST OPHTH VIS SCI, V52, P6511, DOI 10.1167/iovs.11-7909
   Csordas G, 2000, J BIOL CHEM, V275, P32879, DOI 10.1074/jbc.M005609200
   Davies JE, 2006, J NEUROTRAUM, V23, P397, DOI 10.1089/neu.2006.23.397
   Dellett M, 2012, DEV GROWTH DIFFER, V54, P327, DOI 10.1111/j.1440-169X.2012.01339.x
   Demas J, 2006, NEURON, V50, P247, DOI 10.1016/j.neuron.2006.03.033
   Du SS, 2013, EXP EYE RES, V116, P151, DOI 10.1016/j.exer.2013.08.019
   Fincham GS, 2018, OPHTHALMOLOGY, V125, P227, DOI 10.1016/j.ophtha.2017.08.001
   Friedman JS, 2002, HUM MOL GENET, V11, P1333, DOI 10.1093/hmg/11.11.1333
   Goldoni S, 2009, J CELL BIOL, V185, P743, DOI 10.1083/jcb.200901129
   Gregg RG, 2003, INVEST OPHTH VIS SCI, V44, P378, DOI 10.1167/iovs.02-0501
   Gregg RG, 2007, J NEUROPHYSIOL, V98, P3023, DOI 10.1152/jn.00608.2007
   Grover J, 2001, MATRIX BIOL, V20, P555, DOI 10.1016/S0945-053X(01)00165-2
   Guler SD, 2021, INDIAN J OPHTHALMOL, V69, P369, DOI 10.4103/ijo.IJO_1739_20
   Happonen KE, 2012, J BIOL CHEM, V287, P8092, DOI 10.1074/jbc.M111.291476
   Hasan N, 2020, ENEURO, V7, DOI 10.1523/ENEURO.0002-20.2020
   HEDBOM E, 1993, J BIOL CHEM, V268, P27307
   Hill LJ, 2015, INVEST OPHTH VIS SCI, V56, P3743, DOI 10.1167/iovs.14-15622
   Hobby P, 2000, MOL VIS, V6, P72
   Holmstrom G, 2018, ACTA OPHTHALMOL, V96, P142, DOI 10.1111/aos.13549
   Ichijo H, 2004, MOL NEUROBIOL, V30, P23, DOI 10.1385/MN:30:1:023
   Inatani M, 1999, INVEST OPHTH VIS SCI, V40, P1783
   Iozzo RV, 2011, J BIOL CHEM, V286, P34712, DOI 10.1074/jbc.M111.262766
   Iozzo RV, 2011, BIOL EXTRACELL MATR, P197, DOI 10.1007/978-3-642-16555-9_6
   Iozzo RV, 1999, J BIOL CHEM, V274, P18843, DOI 10.1074/jbc.274.27.18843
   Jonas JB, 2017, ASIA-PAC J OPHTHALMO, V6, P493, DOI 10.22608/APO.2017251
   Kaji T, 2004, BIOL PHARM BULL, V27, P1763, DOI 10.1248/bpb.27.1763
   Kalamajski S, 2010, MATRIX BIOL, V29, P248, DOI 10.1016/j.matbio.2010.01.001
   Kardideh B, 2019, CELL BIOSCI, V9, DOI 10.1186/s13578-019-0327-6
   Keenan TDL, 2012, INVEST OPHTH VIS SCI, V53, P7528, DOI 10.1167/iovs.12-10797
   Khan GA, 2011, MOL ENDOCRINOL, V25, P1431, DOI 10.1210/me.2010-0426
   Khan NW, 2005, J NEUROPHYSIOL, V93, P481, DOI 10.1152/jn.00365.2004
   Kinsella MG, 1997, J BIOL CHEM, V272, P318
   Kiranmayee PS, 2019, INDIAN J OPHTHALMOL, V67, P726, DOI 10.4103/ijo.IJO_700_18
   LAZARUS HS, 1992, INVEST OPHTH VIS SCI, V33, P364
   Le Goff MM, 2012, J BIOL CHEM, V287, P28027, DOI 10.1074/jbc.M111.331157
   Le Goff MM, 2012, INVEST OPHTH VIS SCI, V53, P228, DOI 10.1167/iovs.11-8514
   Lee Na Eun, 2011, Korean J Ophthalmol, V25, P42, DOI 10.3341/kjo.2011.25.1.42
   Lindahl U., 2015, PROTEOGLYCANS SULFAT
   Liu LY, 2012, BRAIN RES BULL, V87, P534, DOI 10.1016/j.brainresbull.2012.02.009
   Ma J, 2012, CYTOKINE, V59, P100, DOI 10.1016/j.cyto.2012.03.025
   McEwan PA, 2006, J STRUCT BIOL, V155, P294, DOI 10.1016/j.jsb.2006.01.016
   Monfort J, 2008, OSTEOARTHR CARTILAGE, V16, P749, DOI 10.1016/j.joca.2007.11.007
   Morgans CW, 2006, EUR J NEUROSCI, V23, P1163, DOI 10.1111/j.1460-9568.2006.04647.x
   Nassar K, 2011, GRAEF ARCH CLIN EXP, V249, P1649, DOI 10.1007/s00417-011-1730-9
   Neill T, 2012, AM J PATHOL, V181, P380, DOI 10.1016/j.ajpath.2012.04.029
   Nobl M, 2016, EXP EYE RES, V146, P107, DOI 10.1016/j.exer.2016.01.001
   O'Brien KD, 1998, CIRCULATION, V98, P519, DOI 10.1161/01.CIR.98.6.519
   O'Connor E, 2005, HUM MOL GENET, V14, P1877, DOI 10.1093/hmg/ddi194
   Ohta K, 2008, DEV GROWTH DIFFER, V50, P253, DOI [10.1111/j.1440-169x.2008.01006.x, 10.1111/j.1440-169X.2008.01006.x]
   Pardue MT, 2008, INVEST OPHTH VIS SCI, V49, P706, DOI 10.1167/iovs.07-0643
   Park H, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-599
   Park YJ, 2010, CURR EYE RES, V35, P657, DOI 10.3109/02713681003760143
   Pavelic SK, 2015, BBA-MOL BASIS DIS, V1852, P1833, DOI 10.1016/j.bbadis.2015.06.006
   Pearring JN, 2011, J NEUROSCI, V31, P10060, DOI 10.1523/JNEUROSCI.1014-11.2011
   Pellegrini B, 2002, GENE, V282, P121, DOI 10.1016/S0378-1119(01)00842-3
   Pesch K, 2003, INVEST OPHTH VIS SCI, V44, P2260, DOI 10.1167/iovs.02-0115
   Pinto F, 2021, CANCERS, V13, DOI 10.3390/cancers13061330
   Pusch CM, 2000, NAT GENET, V26, P324, DOI 10.1038/81627
   Ramesh S, 2004, BRIT J OPHTHALMOL, V88, P697, DOI 10.1136/bjo.2003.031989
   Reardon AJ, 2000, J BIOL CHEM, V275, P2123, DOI 10.1074/jbc.275.3.2123
   Saika S, 2004, LAB INVEST, V84, P1245, DOI 10.1038/labinvest.3700156
   Saika S, 2003, INVEST OPHTH VIS SCI, V44, P2094, DOI 10.1167/iovs.02-1059
   Sallo FB, 2009, EXP EYE RES, V89, P178, DOI 10.1016/j.exer.2009.03.006
   Sanders EJ, 2003, INVEST OPHTH VIS SCI, V44, P5404, DOI 10.1167/iovs.03-0500
   Scalabrino ML, 2015, HUM MOL GENET, V24, P6229, DOI 10.1093/hmg/ddv341
   Schaefer L, 2008, J BIOL CHEM, V283, P21305, DOI 10.1074/jbc.R800020200
   Scholl HPN, 2001, INVEST OPHTH VIS SCI, V42, P2728
   Schroeter EH, 2006, VISUAL NEUROSCI, V23, P833, DOI 10.1017/S0952523806230219
   Sjoberg A, 2005, J BIOL CHEM, V280, P32301, DOI 10.1074/jbc.M504828200
   Steinhart MR, 2014, EXP EYE RES, V119, P54, DOI 10.1016/j.exer.2013.12.008
   Takanosu M, 2001, INVEST OPHTH VIS SCI, V42, P2202
   Tasheva E, 2005, MOL VIS, V11, P452
   Tasheva E, 2004, MOL VIS, V10, P544
   Tasheva ES, 2004, MOL VIS, V10, P403
   Tio L, 2014, JOINT BONE SPINE, V81, P137, DOI 10.1016/j.jbspin.2013.05.007
   Wang S, 2015, INVEST OPHTH VIS SCI, V56, P2971, DOI 10.1167/iovs.14-15874
   Wang XL, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-10124-4
   Yang S, 2015, DISCOV MED, V20, P207
   Yau JWY, 2012, DIABETES CARE, V35, P556, DOI 10.2337/dc11-1909
   Zhang GY, 2006, J CELL BIOCHEM, V98, P1436, DOI 10.1002/jcb.20776
   Zhang QJ, 2007, MOL VIS, V13, P330
   Zhu W., 2008, OSTEOPOROSIS 2 VOLUM
NR 98
TC 7
Z9 7
U1 5
U2 10
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1422-0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD JUL
PY 2021
VL 22
IS 14
AR 7293
DI 10.3390/ijms22147293
PG 18
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA TN5RL
UT WOS:000676291400001
PM 34298915
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Singh, RK
   Binette, F
   Seiler, M
   Petersen-Jones, SM
   Nasonkin, IO
AF Singh, Ratnesh K.
   Binette, Francois
   Seiler, Magdalene
   Petersen-Jones, Simon M.
   Nasonkin, Igor O.
TI Pluripotent Stem Cell-Based Organoid Technologies for Developing
   Next-Generation Vision Restoration Therapies of Blindness
SO JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS
LA English
DT Article
DE blindness; retina; organoids; photoreceptors; vision; retinal
   degeneration; cell therapy
ID GENE-THERAPY; CONGENITAL AMAUROSIS; MACULAR DEGENERATION;
   RETINITIS-PIGMENTOSA; RETINAL DEVELOPMENT; ECTOPIC EXPRESSION; AXON
   REGENERATION; VISUAL FUNCTION; TRANSPLANTATION; GROWTH
AB Blindness, associated with death of retinal cells at the back of the eye, is caused by a number of conditions with high prevalence such as glaucoma, age-related macular degeneration, and diabetic retinopathy. In addition, a large number of orphan inherited (mostly monogenic) conditions, such as retinitis pigmentosa and Leber Congenital Amaurosis, add to the overall number of patients with blinding retinal degenerative diseases. Blindness caused by deterioration and loss of retina is so far incurable. Modern biomedical research leveraging molecular and regenerative medicine approaches had a number of groundbreaking discoveries and proof-of-principle treatments of blindness in animals. However, these methods are slow to be standardized and commercialized as therapies to benefit people losing their eyesight due to retinal degenerative conditions. In this review, we will outline major regenerative medicine approaches, which are emerging as promising for preserving or/and restoring vision. We discuss the potential of each of these approaches to reach commercialization step and be converted to treatments, which could at least ameliorate blindness caused by retinal cell death.
C1 [Singh, Ratnesh K.; Binette, Francois; Nasonkin, Igor O.] Lineage Cell Therapeut Inc, 1010 Atlantic Ave, Alameda, CA 94501 USA.
   [Seiler, Magdalene] Univ Calif Irvine, Stem Cell Res Ctr, Irvine, CA USA.
   [Seiler, Magdalene] Univ Calif Irvine, Dept Phys Med & Rehabil, Irvine, CA USA.
   [Seiler, Magdalene] Univ Calif Irvine, Dept Ophthalmol, Irvine, CA USA.
   [Seiler, Magdalene] Univ Calif Irvine, Dept Anat & Neurobiol, Irvine, CA 92717 USA.
   [Petersen-Jones, Simon M.] Michigan State Univ, Coll Vet Med, Dept Small Anim Clin Sci, E Lansing, MI 48824 USA.
C3 University of California System; University of California Irvine;
   University of California System; University of California Irvine;
   University of California System; University of California Irvine;
   University of California System; University of California Irvine;
   Michigan State University
RP Nasonkin, IO (通讯作者)，Lineage Cell Therapeut Inc, 1010 Atlantic Ave, Alameda, CA 94501 USA.
EM inasonkin@lineagecell.com
RI Seiler, Magdalene J./I-2942-2019
OI Seiler, Magdalene J./0000-0002-0869-9923
FU National Eye Institute Fast Track SBIR grants [5R44EY027654-01,
   5R44EY027654-02, 3R44 EY 027654-02 S1]; California Institute of
   Regenerative Medicine (CIRM) [TRAN1-10995, TR4-06648]
FX This work was supported, in part, by the National Eye Institute Fast
   Track SBIR grants 5R44EY027654-01 (I.O.N.), 5R44EY027654-02 (I.O.N.),
   and 3R44 EY 027654-02 S1 (I.O.N.). The project described was supported
   by the California Institute of Regenerative Medicine (CIRM), through
   grant number TRAN1-10995 and linked to grant number TR4-06648. The
   content is solely the responsibility of the authors and does not
   necessarily represent the official views of CIRM.
CR Aijaz A, 2018, NAT BIOMED ENG, V2, P362, DOI 10.1038/s41551-018-0246-6
   Annear MJ, 2013, HUM GENE THER, V24, P883, DOI 10.1089/hum.2013.146
   [Anonymous], 2014, DIALOGUES, V3, P4
   Aramant RB, 2002, EXP EYE RES, V75, P115, DOI 10.1006/exer.2002.2001
   Aramant RB, 2002, PROG RETIN EYE RES, V21, P57, DOI 10.1016/S1350-9462(01)00020-9
   Baghbaderani BA, 2016, STEM CELL REV REP, V12, P394, DOI 10.1007/s12015-016-9662-8
   Baker CK, 2018, FRONT CELL NEUROSCI, V12, DOI 10.3389/fncel.2018.00316
   Balaratnasingam C, 2015, CLIN OPHTHALMOL, V9, P2355, DOI 10.2147/OPTH.S80040
   Barrett JM, 2016, SCI REP-UK, V6, DOI 10.1038/srep33565
   Bassuk AG, 2016, SCI REP-UK, V6, DOI 10.1038/srep19969
   Bennett J, 2000, MOL THER, V1, P501, DOI 10.1006/mthe.2000.0080
   Benowitz LI, 2017, EXP NEUROL, V287, P365, DOI 10.1016/j.expneurol.2015.12.015
   Benowitz LI, 2011, CURR OPIN NEUROL, V24, P577, DOI 10.1097/WCO.0b013e32834c208d
   Bhisitkul RB, 2006, BRIT J OPHTHALMOL, V90, P1542, DOI 10.1136/bjo.2006.098426
   Bi AD, 2006, NEURON, V50, P23, DOI 10.1016/j.neuron.2006.02.026
   Blenkinsop TA, 2015, INVEST OPHTH VIS SCI, V56, P7085, DOI 10.1167/iovs.14-16246
   Blenkinsop Timothy A, 2013, Methods Mol Biol, V945, P45, DOI 10.1007/978-1-62703-125-7_4
   Cai Y, 2019, SCI ADV, V5, DOI 10.1126/sciadv.aav3335
   Campagne MV, 2014, J PATHOL, V232, P151, DOI 10.1002/path.4266
   Capowski EE, 2019, DEVELOPMENT, V146, DOI 10.1242/dev.171686
   Capowski EE, 2016, STEM CELLS, V34, P2625, DOI 10.1002/stem.2414
   CHEN XY, 2019, INVEST OPHTH VIS SCI, V60
   Cideciyan AV, 2018, P NATL ACAD SCI USA, V115, pE8547, DOI 10.1073/pnas.1805055115
   Cooper AE, 2016, J OCUL PHARMACOL TH, V32, P296, DOI 10.1089/jop.2015.0134
   Cuzzani O., 2018, RETIN PHYS, V15, P44
   Daiger SP, 2014, INVEST OPHTH VIS SCI, V55
   Deisseroth K, 2017, SCIENCE, V357, DOI 10.1126/science.aan5544
   DiCarlo JE, 2018, J CLIN INVEST, V128, P2177, DOI 10.1172/JCI120429
   Dodson BP, 2015, BMC BIOTECHNOL, V15, DOI 10.1186/s12896-015-0190-4
   Duebel J, 2015, CURR OPIN OPHTHALMOL, V26, P226, DOI 10.1097/ICU.0000000000000140
   Eldred KC, 2018, SCIENCE, V362, P200, DOI 10.1126/science.aau6348
   Elverum K, 2019, GENE THER
   Galvao J, 2018, INVEST OPHTH VIS SCI, V59, P2736, DOI 10.1167/iovs.17-23319
   Gamm DM, 2019, AM J OPHTHALMOL, V206, P113, DOI 10.1016/j.ajo.2019.04.033
   Hambright D, 2012, MOL VIS, V18, P920
   Hochedlinger K, 2005, CELL, V121, P465, DOI 10.1016/j.cell.2005.02.018
   Humayun MS, 2009, IEEE ENG MED BIO, P4566, DOI 10.1109/IEMBS.2009.5332695
   Humayun MS, 2000, INVEST OPHTH VIS SCI, V41, P3100
   Idelson M, 2018, STEM CELL REP, V11, P681, DOI 10.1016/j.stemcr.2018.07.009
   Jacobson SG, 2012, ARCH OPHTHALMOL-CHIC, V130, P9, DOI 10.1001/archophthalmol.2011.298
   Jorstad NL, 2017, NATURE, V548, P103, DOI 10.1038/nature23283
   Karl MO, 2008, P NATL ACAD SCI USA, V105, P19508, DOI 10.1073/pnas.0807453105
   Kashani AH, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aao4097
   Katschke KJ, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-30162-w
   Khanani AM, 2020, RETIN PHYS, V17, P36
   Klassen H, 2007, VET OPHTHALMOL, V10, P245, DOI 10.1111/j.1463-5224.2007.00547.x
   Klassen H, 2016, EXPERT OPIN BIOL TH, V16, P7, DOI 10.1517/14712598.2016.1093110
   Kramer J, 2019, ADV EXP MED BIOL, V1186, P99, DOI 10.1007/978-3-030-28471-8_4
   Kuppermann BD, 2018, INVEST OPHTH VIS SCI, V59
   Kurimoto T, 2010, J NEUROSCI, V30, P15654, DOI 10.1523/JNEUROSCI.4340-10.2010
   Lamba DA, 2009, CELL STEM CELL, V4, P73, DOI 10.1016/j.stem.2008.10.015
   Ledford H, 2020, NATURE, V579, P185, DOI 10.1038/d41586-020-00655-8
   Ledley FD, 2014, GENE THER, V21, P188, DOI 10.1038/gt.2013.72
   Lewin AS, 2014, CSH PERSPECT MED, V4, DOI 10.1101/cshperspect.a017400
   Lorach H, 2015, M S-MED SCI, V31, P830, DOI 10.1051/medsci/20153110006
   Lu Y., 2019, REVERSAL AGEING INJU
   Mathieson K, 2012, NAT PHOTONICS, V6, P391, DOI [10.1038/nphoton.2012.104, 10.1038/NPHOTON.2012.104]
   McGill TJ, 2017, TRANSL VIS SCI TECHN, V6, DOI 10.1167/tvst.6.3.17
   McLelland BT, 2018, INVEST OPHTH VIS SCI, V59, P2586, DOI 10.1167/iovs.17-23646
   Mendes HF, 2008, HUM MOL GENET, V17, P3043, DOI 10.1093/hmg/ddn202
   Meyer JS, 2011, STEM CELLS, V29, P1206, DOI 10.1002/stem.674
   Meyer JS, 2009, P NATL ACAD SCI USA, V106, P16698, DOI 10.1073/pnas.0905245106
   Mowat FM, 2017, FRONT NEUROSCI-SWITZ, V11, DOI 10.3389/fnins.2017.00342
   Mullen Patrick, 2007, Biotechnol Healthc, V4, P48
   Murray SF, 2015, INVEST OPHTH VIS SCI, V56, P6362, DOI 10.1167/iovs.15-16400
   Neves J, 2016, SCIENCE, V353, DOI 10.1126/science.aaf3646
   Ocampo A, 2016, TRENDS MOL MED, V22, P725, DOI 10.1016/j.molmed.2016.06.005
   Ostergaard ME, 2013, NUCLEIC ACIDS RES, V41, P9634, DOI 10.1093/nar/gkt725
   Pao PW, 2014, MOL THER, V22, P854, DOI 10.1038/mt.2013.276
   Pasqualetti G, 2007, PHARMACOGENOMICS, V8, P49, DOI 10.2217/14622416.8.1.49
   Petersen-Jones SM, 2019, ADV EXP MED BIOL, V1185, P103, DOI 10.1007/978-3-030-27378-1_17
   Petersen-Jones SM, 2018, J CLIN INVEST, V128, P190, DOI 10.1172/JCI95161
   Phillips MJ, 2014, STEM CELLS, V32, P1480, DOI 10.1002/stem.1667
   Pierce E, 2018, OPHTHALMOLOGY, V125, P1431, DOI 10.1016/j.ophtha.2018.06.008
   Radke ND, 2004, ARCH OPHTHALMOL-CHIC, V122, P1159, DOI 10.1001/archopht.122.8.1159
   Radtke ND, 2008, AM J OPHTHALMOL, V146, P172, DOI 10.1016/j.ajo.2008.04.009
   Sadaka A, 2017, OSLI RETINA, V48, P1022, DOI 10.3928/23258160-20171130-11
   Sanjurjo-Soriano C, 2018, NEURAL PLAST, V2018, DOI 10.1155/2018/5056279
   Sardone V, 2017, MOLECULES, V22, DOI 10.3390/molecules22040563
   Sasai Y, 2012, DEVELOPMENT, V139, P4111, DOI 10.1242/dev.079590
   Schwartz SD, 2015, LANCET, V385, P509, DOI 10.1016/S0140-6736(14)61376-3
   Schwartz SD, 2012, LANCET, V379, P713, DOI 10.1016/S0140-6736(12)60028-2
   Seiler MJ, 2014, GRAEF ARCH CLIN EXP, V252, P1079, DOI 10.1007/s00417-014-2638-y
   Seiler MJ, 2012, PROG RETIN EYE RES, V31, P661, DOI 10.1016/j.preteyeres.2012.06.003
   Seiler MJ, 1998, INVEST OPHTH VIS SCI, V39, P2121
   Sharma R, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aat5580
   Sheu J, 2014, DEV OPHTHALMOL, V53, P178, DOI 10.1159/000357362
   Sieving PA, 2012, INVEST OPHTH VIS SCI, V53, P7149, DOI 10.1167/iovs.12-11069
   Simonelli F, 2010, MOL THER, V18, P643, DOI 10.1038/mt.2009.277
   Singh R, 2018, STEM CELL REV REP, V14, P463, DOI 10.1007/s12015-018-9802-4
   Singh RK, 2019, STEM CELLS DEV, V28, P1151, DOI 10.1089/scd.2019.0090
   Singh RK, 2015, STEM CELLS DEV, V24, P2778, DOI 10.1089/scd.2015.0144
   Singh R, 2015, MOL THER, V23, P1700, DOI 10.1038/mt.2015.141
   Sridhar A, 2020, CELL REP, V30, P1644, DOI 10.1016/j.celrep.2020.01.007
   Stern JH, 2018, CELL STEM CELL, V22, P834, DOI 10.1016/j.stem.2018.05.013
   Thompson DA, 2015, INVEST OPHTH VIS SCI, V56, P918, DOI 10.1167/iovs.14-16049
   Van Norman Gail A, 2016, JACC Basic Transl Sci, V1, P170, DOI 10.1016/j.jacbts.2016.03.002
   Veleri S, 2015, DIS MODEL MECH, V8, P109, DOI 10.1242/dmm.017913
   Wahlin KJ, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-00774-9
   Wahlin KJ, 2014, ADV EXP MED BIOL, V801, P157, DOI 10.1007/978-1-4614-3209-8_20
   West MD, 2019, REGEN MED, V14, P867, DOI 10.2217/rme-2019-0062
   Xia T. Y., 2018, THESIS
   Yancopoulos GD, 2000, NATURE, V407, P242, DOI 10.1038/35025215
   Yang R, 2017, SCI REP-UK, V7, DOI 10.1038/srep40035
   Yao K, 2018, NATURE, V560, P484, DOI 10.1038/s41586-018-0425-3
   Yaspan BL, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aaf1443
   Yin YQ, 2006, NAT NEUROSCI, V9, P843, DOI 10.1038/nn1701
   Zhao C., 2017, JOVE-J VIS EXP, V126, P55220
   Zhong XF, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5047
   Zhu J, 2018, STEM CELL TRANSL MED, V7, P210, DOI 10.1002/sctm.17-0205
   Zhu J, 2017, CELL STEM CELL, V20, P374, DOI 10.1016/j.stem.2016.11.019
   2010, SB ACAD REV, V7, P31
NR 112
TC 4
Z9 4
U1 1
U2 6
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1080-7683
EI 1557-7732
J9 J OCUL PHARMACOL TH
JI J. Ocular Pharmacol. Ther.
PD APR 1
PY 2021
VL 37
IS 3
BP 147
EP 156
DI 10.1089/jop.2020.0016
EA OCT 2020
PG 10
WC Ophthalmology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Pharmacology & Pharmacy
GA RK4YC
UT WOS:000581187200001
PM 33052761
OA Green Submitted, Green Published
DA 2022-11-30
ER

PT J
AU Dai, L
   Elich, J
   Jacobson, F
AF Dai, Lu
   Elich, Joseph
   Jacobson, Fred
TI Development of a Size-Exclusion Chromatography Method to Characterize a
   Multimeric PEG-Protein Conjugate
SO LC GC NORTH AMERICA
LA English
DT Article
ID PEGYLATION
AB Conjugation of poly(ethylene glycol) (PEG) to therapeutic molecules is a widely used technique to increase in vivo half-life of therapeutics. A multimeric PEG protein conjugate, which contains eight antigen-binding fragments (Fabs) conjugated to an 8-arm PEG core, was developed as a therapeutic candidate for age-related macular degeneration (AMD). The increased molecular size of the conjugate, compared to the Fab alone, produces a significant longer half-life, and requires less frequent intravitreal (ITV) injections, which can greatly benefit the patient. Due to the major impact that molecular size has on in vitreous half-life, it is crucial to have an analytical method to monitor the size attribute of the conjugate. Here we report a simple and robust size-exclusion chromatography (SEC) method that was developed for the conjugate. A wide range of size variants of the conjugate, ranging from 50 kDa to >1000 kDa, can be resolved and quantitated. The method was evaluated for precision, accuracy, linearity, and robustness, and was deemed suitable for routine use in product quality control.
C1 [Dai, Lu; Jacobson, Fred] Genentech Inc, Prot Analyt Chem Grp, San Francisco, CA 94080 USA.
   [Elich, Joseph] Genentech Inc, San Francisco, CA USA.
C3 Roche Holding; Genentech; Roche Holding; Genentech
RP Dai, L (通讯作者)，Genentech Inc, Prot Analyt Chem Grp, San Francisco, CA 94080 USA.
EM dai.lu@gene.com
CR ABUCHOWSKI A, 1984, CANCER BIOCHEM BIOPH, V7, P175
   Greenwald RB, 2003, ADV DRUG DELIVER REV, V55, P217, DOI 10.1016/S0169-409X(02)00180-1
   Harris JM, 2003, NAT REV DRUG DISCOV, V2, P214, DOI 10.1038/nrd1033
   Li WJ, 2013, PROG POLYM SCI, V38, P421, DOI 10.1016/j.progpolymsci.2012.07.006
   Minko Tamara, 2005, Drug Discov Today Technol, V2, P15, DOI 10.1016/j.ddtec.2005.05.005
   Shatz W, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0218613
   Shatz W, 2016, MOL PHARMACEUT, V13, P2996, DOI 10.1021/acs.molpharmaceut.6b00345
   Swierczewska M, 2015, EXPERT OPIN EMERG DR, V20, P531, DOI 10.1517/14728214.2015.1113254
   Veronese FM, 2005, DRUG DISCOV TODAY, V10, P1451, DOI 10.1016/S1359-6446(05)03575-0
   Yumioka R, 2010, J PHARM SCI-US, V99, P618, DOI 10.1002/jps.21857
   Zhao H, 2008, BIOCONJUGATE CHEM, V19, P849, DOI 10.1021/bc700333s
NR 11
TC 0
Z9 0
U1 1
U2 2
PU ADVANSTAR COMMUNICATIONS INC
PI DULUTH
PA 131 W 1ST STREET, DULUTH, MN 55802 USA
SN 1527-5949
EI 1939-1889
J9 LC GC N AM
JI LC GC N. AM.
PD NOV
PY 2019
VL 37
IS 11
SU S
BP 40
EP +
PG 6
WC Chemistry, Analytical
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Chemistry
GA JU0TY
UT WOS:000501393300007
DA 2022-11-30
ER

PT J
AU Lee, CS
   Larson, EB
   Gibbons, LE
   Lee, AY
   McCurry, SM
   Bowen, JD
   McCormick, WC
   Crane, PK
AF Lee, Cecilia S.
   Larson, Eric B.
   Gibbons, Laura E.
   Lee, Aaron Y.
   McCurry, Susan M.
   Bowen, James D.
   McCormick, Wayne C.
   Crane, Paul K.
TI Associations between recent and established ophthalmic conditions and
   risk of Alzheimer's disease
SO ALZHEIMERS & DEMENTIA
LA English
DT Article
DE Alzheimer's disease; Adult Changes in Thought (ACT); Ophthalmology;
   Diabetic retinopathy; Age-related macular degeneration; Glaucoma;
   Cataract
ID OPEN-ANGLE GLAUCOMA; MACULAR DEGENERATION; VASCULAR DEMENTIA; ADULT
   CHANGES; AGE; THOUGHT; BRAIN; EVENT; MODEL
AB Introduction: Identifying ophthalmic diseases associated with increased risk of Alzheimer's disease (AD) may enable better screening and understanding of those at risk of AD.
   Methods: Diagnoses of glaucoma, age-related macular degeneration (AMD), and diabetic retinopathy (DR) were based on International Classification of Diseases, 9th revision, codes for 3877 participants from the Adult Changes in Thought study. The adjusted hazard ratio for developing probable or possible AD for recent (within 5 years) and established (>5 years) diagnoses were assessed.
   Results: Over 31,142 person-years of follow-up, 792 AD cases occurred. The recent and established hazard ratio were 1.46 (P = .01) and 0.87 (P = .19) for glaucoma, 1.20 (P = .12) and 1.50 (P < .001) for AMD, and 1.50 (P = .045) and 1.50 (P = .03) for DR.
   Discussion: Increased AD risk was found for recent glaucoma diagnoses, established AMD diagnoses, and both recent and established DR. People with certain ophthalmic conditions may have increased AD risk. (C) 2018 the Alzheimer's Association. Published by Elsevier Inc. All rights reserved.
C1 [Lee, Cecilia S.; Lee, Aaron Y.] Univ Washington, Dept Ophthalmol, Seattle, WA 98195 USA.
   [Larson, Eric B.; Gibbons, Laura E.; McCormick, Wayne C.; Crane, Paul K.] Univ Washington, Dept Med, Seattle, WA USA.
   [Larson, Eric B.] Kaiser Permanente Washington Hlth Res Inst, Seattle, WA USA.
   [McCurry, Susan M.] Univ Washington, Sch Nursing, Seattle, WA 98195 USA.
   [Bowen, James D.] Swedish Med Ctr, Dept Neurol, Seattle, WA USA.
C3 University of Washington; University of Washington Seattle; University
   of Washington; University of Washington Seattle; Kaiser Permanente;
   University of Washington; University of Washington Seattle; Swedish
   Medical Center
RP Lee, CS (通讯作者)，Univ Washington, Dept Ophthalmol, Seattle, WA 98195 USA.
EM leecs2@uw.edu
RI Melief, Erica/M-6436-2019; McCurry, Susan M/E-4731-2015; Lee,
   Aaron/AAT-2839-2020
OI McCurry, Susan M/0000-0001-8624-3772; Lee, Aaron/0000-0002-7452-1648
FU NEI NIH HHS [K23 EY029246, K23 EY024921] Funding Source: Medline; NIA
   NIH HHS [P50 AG005136] Funding Source: Medline; NATIONAL EYE INSTITUTE
   [K23EY029246, K23EY024921] Funding Source: NIH RePORTER; NATIONAL
   INSTITUTE ON AGING [P50AG005136] Funding Source: NIH RePORTER
CR Al-Salem Khalil M, 2014, Retina, V34, P868, DOI 10.1097/IAE.0000000000000006
   Alzheimers Assoc, 2015, ALZHEIMERS DEMENT, V11, P332, DOI 10.1016/j.jalz.2015.02.003
   [Anonymous], 2004, ARCH OPHTHALMOL-CHIC, V122, P532
   APA, 1994, DIAGNOSTIC STAT MANU
   Chung SD, 2015, EYE, V29, P1340, DOI 10.1038/eye.2015.120
   Chung SD, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0120003
   Crane PK, 2017, ALZHEIMERS DEMENT, V13, P1307, DOI 10.1016/j.jalz.2017.04.011
   Crane PK, 2016, ALZHEIMERS DEMENT, V12, P419, DOI 10.1016/j.jalz.2015.10.007
   Crane PK, 2013, NEW ENGL J MED, V369, P540, DOI [10.1056/NEJMoa1215740, 10.1056/NEJMc1311765]
   Ermilov VV, 2016, ADV EXP MED BIOL, V854, P119, DOI 10.1007/978-3-319-17121-0_17
   Exalto LG, 2012, EXP GERONTOL, V47, P858, DOI 10.1016/j.exger.2012.07.014
   Exalto LG, 2014, J ALZHEIMERS DIS, V42, pS109, DOI 10.3233/JAD-132570
   Exalto LG, 2013, LANCET DIABETES ENDO, V1, P183, DOI 10.1016/S2213-8587(13)70048-2
   Fine JP, 1999, J AM STAT ASSOC, V94, P496, DOI 10.2307/2670170
   Gupta N, 2007, CURR OPIN OPHTHALMOL, V18, P110, DOI 10.1097/ICU.0b013e3280895aea
   Helmer C, 2013, ANN NEUROL, V74, P171, DOI 10.1002/ana.23926
   Heringa SM, 2013, J CEREBR BLOOD F MET, V33, P983, DOI 10.1038/jcbfm.2013.58
   Jack CR, 2010, LANCET NEUROL, V9, P119, DOI 10.1016/S1474-4422(09)70299-6
   Keenan TDL, 2015, BRIT J OPHTHALMOL, V99, P524, DOI 10.1136/bjophthalmol-2014-305863
   Kim DD, 2000, ARCH OPHTHALMOL-CHIC, V118, P1132
   Klaver CCW, 1999, AM J EPIDEMIOL, V150, P963
   Korn EL, 1997, AM J EPIDEMIOL, V145, P72
   Kukull WA, 2002, ARCH NEUROL-CHICAGO, V59, P1737, DOI 10.1001/archneur.59.11.1737
   Larson EB, 2006, ANN INTERN MED, V144, P73, DOI 10.7326/0003-4819-144-2-200601170-00004
   London A, 2013, NAT REV NEUROL, V9, P44, DOI 10.1038/nrneurol.2012.227
   MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939
   Montine TJ, 2012, CURR ALZHEIMER RES, V9, P718
   Ou Y, 2012, OPHTHAL EPIDEMIOL, V19, P285, DOI 10.3109/09286586.2011.649228
   Rozzini L, 2014, AM J ALZHEIMERS DIS, V29, P256, DOI 10.1177/1533317513517032
   Santos Claudia Y, 2017, Alzheimers Dement (Amst), V7, P69, DOI 10.1016/j.dadm.2017.01.005
   Sivak JM, 2013, INVEST OPHTH VIS SCI, V54, P871, DOI 10.1167/iovs.12-10827
   Sonnen JA, 2009, J ALZHEIMERS DIS, V18, P703, DOI 10.3233/JAD-2009-1180
   Teng E L, 1994, Int Psychogeriatr, V6, P45, DOI 10.1017/S1041610294001602
   Tomsak RL, 2003, BRIT J OPHTHALMOL, V87, P917, DOI 10.1136/bjo.87.7.917
   Tsai DC, 2015, OPHTHALMOLOGY, V122, P2327, DOI 10.1016/j.ophtha.2015.07.033
   Villarroel M, 2010, WORLD J DIABETES, V1, P57, DOI 10.4239/wjd.v1.i2.57
   Whitmer R, 2012, ALZHEIMERS DEMENT, V8, pP256
NR 37
TC 67
Z9 69
U1 1
U2 12
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1552-5260
EI 1552-5279
J9 ALZHEIMERS DEMENT
JI Alzheimers. Dement.
PD JAN
PY 2019
VL 15
IS 1
BP 34
EP 41
DI 10.1016/j.jalz.2018.06.2856
PG 8
WC Clinical Neurology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA HH1PV
UT WOS:000455493000005
PM 30098888
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Wang, K
   Yao, Y
   Zhu, X
   Zhang, K
   Zhou, FF
   Zhu, L
AF Wang, Ke
   Yao, Yong
   Zhu, Xue
   Zhang, Kai
   Zhou, Fanfan
   Zhu, Ling
TI Amyloid beta induces NLRP3 inflammasome activation in retinal pigment
   epithelial cells via NADPH oxidase- and mitochondria-dependent ROS
   production
SO JOURNAL OF BIOCHEMICAL AND MOLECULAR TOXICOLOGY
LA English
DT Article
DE age-related macular degeneration; amyloid beta; NLRP3 inflammasome;
   reactive oxygen species
ID NF-KAPPA-B; MACULAR DEGENERATION; A-BETA; ALZHEIMERS-DISEASE; DRUSEN
   DEPOSITS; PATHOGENESIS; IL-1-BETA; DAMAGE; AMD
AB Amyloid beta (A beta)-induced chronic inflammation is believed to be a key pathogenic process in early-stage age-related macular degeneration (AMD). Nucleotide oligomerization domain (NOD)-like receptor family, pyrin domain containing 3 (NLRP3) inflammasome activation triggered by A beta is responsible for retinal pigment epithelium (RPE) dysfunction in the onset of AMD; however, the detailed molecular mechanism remains unclear. In this study, we investigated the involvement of NADPH oxidase- and mitochondria-derived reactive oxygen species (ROS) in the process of A beta(1-40)-induced NLRP3 inflammasome activation in LPS-primed ARPE-19 cells. The results showed that A beta(1-40) could induce excessive ROS generation, MAPK/NF-kappa B signaling activation and subsequently NLRP3 inflammasome activation in LPS-primed ARPE-19 cells. Furthermore, the inductive effect of A beta(1-40) on NLRP3 inflammasome activation was mediated in a manner dependent on NADPH oxidase- and mitochondria-derived ROS. Our findings may provide a novel insight into the molecular mechanism by which A beta contributes to the early-stage AMD.
C1 [Wang, Ke; Zhu, Xue; Zhang, Kai] Minist Hlth, Key Lab Nucl Med, Jiangsu Key Lab Mol Nucl Med, Jiangsu Inst Nucl Med, Wuxi 214063, Jiangsu, Peoples R China.
   [Yao, Yong] Nanjing Med Univ, Wuxi Peoples Hosp, Dept Ophthalmol, Wuxi 214023, Jiangsu, Peoples R China.
   [Zhou, Fanfan] Univ Sydney, Fac Pharm, Sydney, NSW 2006, Australia.
   [Zhu, Ling] Univ Sydney, Save Sight Inst, Sydney, NSW 2000, Australia.
C3 Jiangnan University; Nanjing Medical University; University of Sydney;
   University of Sydney
RP Yao, Y (通讯作者)，Nanjing Med Univ, Wuxi Peoples Hosp, Dept Ophthalmol, Wuxi 214023, Jiangsu, Peoples R China.
RI Zhu, Xue/AAR-9416-2020; Zhou, Fanfan/M-4404-2013; Zhou,
   Fanfan/J-2327-2019; Zhu, Ling/M-3887-2013; Zhang, Kai/AGI-6985-2022
OI Zhou, Fanfan/0000-0002-1982-1541; Zhou, Fanfan/0000-0002-1982-1541; Zhu,
   Ling/0000-0003-0776-1630; Zhang, Kai/0000-0002-7021-5395
FU National Natural Science Foundation [81300787]; Natural Science
   Foundation of Jiangsu Province [BK20141103]; Wuxi Municipal Health
   Bureau [ZS201401, Z201508]; Wuxi Municipal Science and Technology Bureau
   [CSE31N1520]
FX National Natural Science Foundation.; 81300787.; Natural Science
   Foundation of Jiangsu Province.; BK20141103.; Major Project of Wuxi
   Municipal Health Bureau.; ZS201401, Z201508.; Project of Wuxi Municipal
   Science and Technology Bureau.; CSE31N1520.
CR Abais JM, 2015, ANTIOXID REDOX SIGN, V22, P1111, DOI 10.1089/ars.2014.5994
   Abdelsalam A, 1999, SURV OPHTHALMOL, V44, P1, DOI 10.1016/S0039-6257(99)00072-7
   Bruban J, 2011, NEUROBIOL DIS, V42, P55, DOI 10.1016/j.nbd.2011.01.004
   Bruban J, 2009, AGING CELL, V8, P162, DOI 10.1111/j.1474-9726.2009.00456.x
   Cao LN, 2013, INVEST OPHTH VIS SCI, V54, P3738, DOI 10.1167/iovs.13-11612
   Davis BK, 2011, ANNU REV IMMUNOL, V29, P707, DOI 10.1146/annurev-immunol-031210-101405
   Dinarello CA, 2011, EUR J IMMUNOL, V41, P1203, DOI 10.1002/eji.201141550
   Garai K, 2013, P NATL ACAD SCI USA, V110, P3321, DOI 10.1073/pnas.1222478110
   Gold M, 2015, SEMIN IMMUNOPATHOL, V37, P607, DOI 10.1007/s00281-015-0518-0
   Hammond J B, 1988, Methods Mol Biol, V3, P25, DOI 10.1385/0-89603-126-8:25
   Heid ME, 2013, J IMMUNOL, V191, P5230, DOI 10.4049/jimmunol.1301490
   Isas JM, 2010, INVEST OPHTH VIS SCI, V51, P1304, DOI 10.1167/iovs.09-4207
   Kauppinen A, 2016, CELL MOL LIFE SCI, V73, P1765, DOI 10.1007/s00018-016-2147-8
   Khansari N, 2009, RECENT PATENTS INFLA, V3, P73, DOI 10.2174/187221309787158371
   Kurji KH, 2010, INVEST OPHTH VIS SCI, V51, P1151, DOI 10.1167/iovs.09-3622
   Leemans JC, 2011, IMMUNOL REV, V243, P152, DOI 10.1111/j.1600-065X.2011.01043.x
   Liu RZT, 2014, EXP EYE RES, V127, P49, DOI 10.1016/j.exer.2014.07.003
   Luibl V, 2006, J CLIN INVEST, V116, P378, DOI 10.1172/JCI25843
   Masters SL, 2009, ANNU REV IMMUNOL, V27, P621, DOI 10.1146/annurev.immunol.25.022106.141627
   Nakano H, 2006, CELL DEATH DIFFER, V13, P730, DOI 10.1038/sj.cdd.4401830
   Nita Malgorzata, 2016, Oxid Med Cell Longev, V2016, P3164734, DOI 10.1155/2016/3164734
   Parajuli B, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.503
   Prakasam A, 2010, J ALZHEIMERS DIS, V20, P1243, DOI 10.3233/JAD-2010-100210
   Ratnapriya R, 2013, CLIN GENET, V84, P160, DOI 10.1111/cge.12206
   Shao BZ, 2015, FRONT PHARMACOL, V6, DOI 10.3389/fphar.2015.00262
   Son Y, 2013, METHOD ENZYMOL, V528, P27, DOI 10.1016/B978-0-12-405881-1.00002-1
   Sparrrow JR, 2010, CURR MOL MED, V10, P802
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Thannickal VJ, 2000, AM J PHYSIOL-LUNG C, V279, pL1005
   Torres MA, 2006, PLANT PHYSIOL, V141, P373, DOI 10.1104/pp.106.079467
   Wang K, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17071109
   Yoshida T, 2005, J CLIN INVEST, V115, P2793, DOI 10.1172/JCI24635
   Zajac-Pytrus HM, 2015, ADV CLIN EXP MED, V24, P1099, DOI 10.17219/acem/27093
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
NR 34
TC 34
Z9 37
U1 0
U2 19
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1095-6670
EI 1099-0461
J9 J BIOCHEM MOL TOXIC
JI J. Biochem. Mol. Toxicol.
PD JUN
PY 2017
VL 31
IS 6
AR e21887
DI 10.1002/jbt.21887
PG 5
WC Biochemistry & Molecular Biology; Toxicology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Toxicology
GA EX3QT
UT WOS:000403147800001
PM 28004443
DA 2022-11-30
ER

PT J
AU Song, DL
   Wilson, B
   Zhao, LL
   Bhuyan, R
   Bandyopadhyay, M
   Lyubarsky, A
   Yu, C
   Li, YF
   Kanu, L
   Miwa, T
   Song, WC
   Finnemann, SC
   Rohrer, B
   Dunaief, JL
AF Song, Delu
   Wilson, Brooks
   Zhao, Liangliang
   Bhuyan, Rupak
   Bandyopadhyay, Mausumi
   Lyubarsky, Arkady
   Yu, Chen
   Li, Yafeng
   Kanu, Levi
   Miwa, Takashi
   Song, Wen-Chao
   Finnemann, Silvia C.
   Rohrer, Barbel
   Dunaief, Joshua L.
TI Retinal Pre-Conditioning by CD59a Knockout Protects against
   Light-Induced Photoreceptor Degeneration
SO PLOS ONE
LA English
DT Article
ID PAROXYSMAL-NOCTURNAL HEMOGLOBINURIA; PIGMENT EPITHELIAL-CELLS;
   COMPLEMENT REGULATORY PROTEINS; CHELATOR DEFERIPRONE PROTECTS;
   DECAY-ACCELERATING FACTOR; FACTOR-H DEFICIENCY; MACULAR DEGENERATION;
   CHOROIDAL NEOVASCULARIZATION; FUNCTIONAL-CHARACTERIZATION; OXIDATIVE
   STRESS
AB Complement dysregulation plays a key role in the pathogenesis of age-related macular degeneration (AMD), but the specific mechanisms are incompletely understood. Complement also potentiates retinal degeneration in the murine light damage model. To test the retinal function of CD59a, a complement inhibitor, CD59a knockout (KO) mice were used for light damage (LD) experiments. Retinal degeneration and function were compared in WT versus KO mice following light damage. Gene expression changes, endoplasmic reticulum (ER) stress, and glial cell activation were also compared. At baseline, the ERG responses and rhodopsin levels were lower in CD59aKO compared to wild-type (WT) mice. Following LD, the ERG responses were better preserved in CD59aKO compared to WT mice. Correspondingly, the number of photoreceptors was higher in CD59aKO retinas than WT controls after LD. Under normal light conditions, CD59aKO mice had higher levels than WT for GFAP immunostaining in Muller cells, mRNA and protein levels of two ER-stress markers, and neurotrophic factors. The reduction in photon capture, together with the neurotrophic factor upregulation, may explain the structural and functional protection against LD in the CD59aKO.
C1 [Song, Delu; Zhao, Liangliang; Bhuyan, Rupak; Lyubarsky, Arkady; Li, Yafeng; Kanu, Levi; Dunaief, Joshua L.] Univ Penn, Perelman Sch Med, Scheie Eye Inst, FM Kirby Ctr Mol Ophthalmol, Philadelphia, PA 19104 USA.
   [Wilson, Brooks; Bandyopadhyay, Mausumi; Rohrer, Barbel] Med Univ South Carolina, Dept Ophthalmol, 171 Ashley Ave, Charleston, SC 29425 USA.
   [Zhao, Liangliang] Jilin Univ, Hosp 2, Dept Ophthalmol, Changchun, Jilin, Peoples R China.
   [Yu, Chen; Finnemann, Silvia C.] Fordham Univ, Dept Biol Sci, Ctr Canc Genet Dis & Gene Regulat, Bronx, NY 10458 USA.
   [Miwa, Takashi; Song, Wen-Chao] Univ Penn, Perelman Sch Med, Dept Pharmacol & Translat Therapeut, Philadelphia, PA 19104 USA.
   [Rohrer, Barbel] Ralph H Johnson VA Med Ctr, Res Serv, Charleston, SC 29401 USA.
C3 University of Pennsylvania; Pennsylvania Medicine; Medical University of
   South Carolina; Jilin University; Fordham University; University of
   Pennsylvania; Pennsylvania Medicine; US Department of Veterans Affairs;
   Veterans Health Administration (VHA); Ralph H Johnson VA Medical Center
RP Dunaief, JL (通讯作者)，Univ Penn, Perelman Sch Med, Scheie Eye Inst, FM Kirby Ctr Mol Ophthalmol, Philadelphia, PA 19104 USA.; Rohrer, B (通讯作者)，Med Univ South Carolina, Dept Ophthalmol, 171 Ashley Ave, Charleston, SC 29425 USA.; Rohrer, B (通讯作者)，Ralph H Johnson VA Med Ctr, Res Serv, Charleston, SC 29401 USA.
EM rohrer@musc.edu; jdunaief@upenn.edu
RI Yu, Chen/GPG-1530-2022
OI Yu, Chen/0000-0001-9651-9875; Kanu, Levi/0000-0001-6428-4696; Song,
   Delu/0000-0002-9030-7211
FU NIH [EY015240, CO6RR015455]; Research to Prevent Blindness; FM Kirby
   Foundation; Paul and Evanina Bell Mackall Foundation Trust; National
   Center for Advancing Translational Sciences of the NIH [KL2TR001879];
   National Institutes of Health [NIH R01EY019320, R01EY013295]; Department
   for Veteran Affairs merit award [RX000444]; Beckman Initiative for
   Macular Research; Research to Prevent Blindness (RPB), New York, NY;
   NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [KL2TR001879]
   Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES
   [C06RR015455] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE
   [R01EY015240, R01EY019320, R01EY013295, P30EY001583] Funding Source: NIH
   RePORTER; Veterans Affairs [I01RX000444] Funding Source: NIH RePORTER
FX This work was supported in the laboratory of J.D. by NIH EY015240,
   Research to Prevent Blindness, the FM Kirby Foundation, the Paul and
   Evanina Bell Mackall Foundation Trust, a gift in memory of Dr. Lee F.
   Mauger, and grant KL2TR001879 from the National Center for Advancing
   Translational Sciences of the NIH; in the laboratory of B.R. in part by
   the National Institutes of Health (NIH R01EY019320), a Department for
   Veteran Affairs merit award RX000444, the Beckman Initiative for Macular
   Research, an unrestricted grant to MUSC from Research to Prevent
   Blindness (RPB), New York, NY; and in the laboratory of S.C.F. by grants
   from the National Institutes of Health (R01EY013295) and the Beckman
   Initiative for Macular Research. B.R.'s animal studies were conducted in
   a facility constructed with support from the NIH CO6RR015455. The
   funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.; This work was
   supported in the laboratory of J.L.D. by NIH EY015240, Research to
   Prevent Blindness, the FM Kirby Foundation, the Paul and Evanina Bell
   Mackall Foundation Trust, a gift in memory of Dr. Lee F. Mauger, and
   grant KL2TR001879 from the National Center for Advancing Translational
   Sciences of the NIH; in the laboratory of B.R. in part by the National
   Institutes of Health (NIH R01EY019320), a Department for Veteran Affairs
   merit award RX000444, the Beckman Initiative for Macular Research, an
   unrestricted grant to MUSC from Research to Prevent Blindness (RPB), New
   York, NY; and in the laboratory of S.C.F. by grants from the National
   Institutes of Health (R01EY013295) and the Beckman Initiative for
   Macular Research. B.R.'s animal studies were conducted in a facility
   constructed with support from the NIH C06RR015455.
CR ADAMUS G, 1991, VISION RES, V31, P17, DOI 10.1016/0042-6989(91)90069-H
   Bandyopadhyay M, 2010, MOL VIS, V16, P1178
   Bayer AU, 2001, VISION RES, V41, P2173, DOI 10.1016/S0042-6989(01)00103-1
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   BENZAQUEN LR, 1994, J EXP MED, V179, P985, DOI 10.1084/jem.179.3.985
   BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911
   BORA NS, 1993, INVEST OPHTH VIS SCI, V34, P3579
   Campochiaro PA, 2000, J CELL PHYSIOL, V184, P301, DOI 10.1002/1097-4652(200009)184:3<301::AID-JCP3>3.0.CO;2-H
   Chollangi S, 2009, NEUROBIOL DIS, V34, P535, DOI 10.1016/j.nbd.2009.03.012
   Chucair-Elliott AJ, 2012, J BIOL CHEM, V287, P24092, DOI 10.1074/jbc.M112.378240
   Coffey PJ, 2007, P NATL ACAD SCI USA, V104, P16651, DOI 10.1073/pnas.0705079104
   Collier RJ, 2011, INVEST OPHTH VIS SCI, V52, P8108, DOI 10.1167/iovs.10-6418
   Ebrahimi KB, 2014, ADV EXP MED BIOL, V801, P259, DOI 10.1007/978-1-4614-3209-8_33
   Faber C, 2012, INVEST OPHTH VIS SCI, V53, P6324, DOI 10.1167/iovs.12-10385
   Feathers KL, 2008, INVEST OPHTH VIS SCI, V49, P1126, DOI 10.1167/iovs.07-1234
   Gresh J, 2003, VISUAL NEUROSCI, V20, P211, DOI 10.1017/S0952523803202108
   Hadziahmetovic M, 2012, INVEST OPHTH VIS SCI, V53, P5231, DOI 10.1167/iovs.12-10204
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   HALPERIN JA, 1993, J CLIN INVEST, V91, P1974, DOI 10.1172/JCI116418
   Herrmann P, 2015, NEUROBIOL AGING, V36, P2637, DOI 10.1016/j.neurobiolaging.2015.05.019
   Holt DS, 2001, BLOOD, V98, P442, DOI 10.1182/blood.V98.2.442
   Jones SE, 2002, INT J BIOCHEM CELL B, V34, P427, DOI 10.1016/S1357-2725(01)00155-8
   Kunchithapautham K, 2011, J BIOL CHEM, V286, P23717, DOI 10.1074/jbc.M110.214593
   Liu CD, 1998, J NEUROSCI, V18, P1337
   Lueck K, 2011, EYE, V25, P1074, DOI 10.1038/eye.2011.109
   Lyubarsky AL, 2004, VISION RES, V44, P3235, DOI 10.1016/j.visres.2004.09.019
   MEDOF ME, 1985, P NATL ACAD SCI USA, V82, P2980, DOI 10.1073/pnas.82.9.2980
   Miwa T, 2002, BLOOD, V99, P3707, DOI 10.1182/blood.V99.10.3707
   Nandrot EF, 2007, P NATL ACAD SCI USA, V104, P12005, DOI 10.1073/pnas.0704756104
   NICHOLSONWELLER A, 1983, P NATL ACAD SCI-BIOL, V80, P5066, DOI 10.1073/pnas.80.16.5066
   Noell W K, 1966, Invest Ophthalmol, V5, P450
   Ohlsson M, 2006, NEUROSCI LETT, V394, P179, DOI 10.1016/j.neulet.2005.10.037
   PANGBURN MK, 1983, P NATL ACAD SCI-BIOL, V80, P5430, DOI 10.1073/pnas.80.17.5430
   PODACK ER, 1984, ACTA PATH MICRO IM C, V92, P89
   Powell MB, 1997, J IMMUNOL, V158, P1692
   Qian YM, 2000, J IMMUNOL, V165, P2528, DOI 10.4049/jimmunol.165.5.2528
   Radu RA, 2014, J BIOL CHEM, V289, P9113, DOI 10.1074/jbc.M114.548669
   Rohrer B, 2007, INVEST OPHTH VIS SCI, V48, P5282, DOI 10.1167/iovs.07-0282
   ROSSE WF, 1985, CLIN HAEMATOL, V14, P105
   Schnabolk G, 2014, EXP EYE RES, V129, P18, DOI 10.1016/j.exer.2014.10.005
   Sethna Saumil, 2013, Methods Mol Biol, V935, P245, DOI 10.1007/978-1-62703-080-9_17
   SHAHINFAR S, 1991, CURR EYE RES, V10, P47, DOI 10.3109/02713689109007610
   Song DL, 2014, AM J PATHOL, V184, P2721, DOI 10.1016/j.ajpath.2014.06.010
   Song DL, 2014, INVEST OPHTH VIS SCI, V55, P4525, DOI 10.1167/iovs.14-14568
   Song DL, 2012, FREE RADICAL BIO MED, V53, P64, DOI 10.1016/j.freeradbiomed.2012.04.020
   Sulewski M., 2015, ARVO
   Thurman JM, 2009, J BIOL CHEM, V284, P16939, DOI 10.1074/jbc.M808166200
   Torres PMM, 2001, J NEUROIMMUNOL, V117, P43, DOI 10.1016/S0165-5728(01)00303-4
   VANDERSCHAFT TL, 1993, BRIT J OPHTHALMOL, V77, P657, DOI 10.1136/bjo.77.10.657
   Vogt SD, 2006, EXP EYE RES, V83, P834, DOI 10.1016/j.exer.2006.04.002
   Wen R, 2006, J NEUROSCI, V26, P13523, DOI 10.1523/JNEUROSCI.4021-06.2006
   Wenzel A, 2005, PROG RETIN EYE RES, V24, P275, DOI 10.1016/j.preteyeres.2004.08.002
   Wilson RB, 2007, INVEST OPHTH VIS SCI, V48, P2877, DOI 10.1167/iovs.06-1079
   Wong P, 2001, CURR EYE RES, V23, P157, DOI 10.1076/ceyr.23.3.157.5463
   Woodell A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067894
   Yang P, 2009, INVEST OPHTH VIS SCI, V50, P3473, DOI 10.1167/iovs.08-3202
   Yu MZ, 2012, INVEST OPHTH VIS SCI, V53, P7684, DOI 10.1167/iovs.12-10069
NR 57
TC 3
Z9 3
U1 0
U2 1
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD NOV 28
PY 2016
VL 11
IS 11
AR e0166348
DI 10.1371/journal.pone.0166348
PG 19
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA EE3FE
UT WOS:000389472400022
PM 27893831
OA Green Published, Green Submitted, gold
DA 2022-11-30
ER

PT J
AU Zhu, XY
   Xia, B
   Liu, HC
   Xu, YQ
   Huang, CJ
   Gao, JM
   Dong, QX
   Li, CQ
AF Zhu, Xiao-Yu
   Xia, Bo
   Liu, Hong-Cui
   Xu, Yi-Qiao
   Huang, Chang-Jiang
   Gao, Ji-Min
   Dong, Qiao-Xiang
   Li, Chun-Qi
TI Closantel Suppresses Angiogenesis and Cancer Growth in Zebrafish Models
SO ASSAY AND DRUG DEVELOPMENT TECHNOLOGIES
LA English
DT Article
ID STRATEGIES; OVERDOSAGE; INHIBITORS; BLINDNESS; DRUGS; MILK; VEGF
AB Angiogenesis has emerged as an important therapeutic target in several major diseases, including cancer and age-related macular degeneration. The zebrafish offer the potential for high-throughput drug discovery in a whole vertebrate system. In this study, we have taken advantage of the transgenic Tg (fli1a:EGFP) zebrafish line to screen the U.S. Drug Collection Library and identified 11 old drugs with antiangiogenic activity, including Closantel, an FDA-approved broad-spectrum salicylanilide antiparasitic drug for a variety of types of animals. Closantel was confirmed to have antiangiogenic activity in zebrafish with a half-inhibitory concentration (IC50) at 1.69 mu M on the intersegmental vessels and 1.45 mu M on the subintestinal vessels. Closantel also markedly suppressed cancer growth in zebrafish xenotransplanted with human lymphoma, cervical cancer, pancreatic cancer, and liver cancer cells, generally in a dose-dependent manner. These data reveal that Closantel has antiangiogenesis and anticancer effects and could be a potential drug candidate for animal and human cancer treatments. Further study is needed to clarify the mechanisms involved in the antiangiogenesis and anticancer effects of Closantel.
C1 [Zhu, Xiao-Yu; Huang, Chang-Jiang; Gao, Ji-Min; Dong, Qiao-Xiang; Li, Chun-Qi] Wenzhou Med Univ, Zhejiang Prov Key Lab Technol & Applicat Model Or, Wenzhou, Peoples R China.
   [Zhu, Xiao-Yu; Xia, Bo; Liu, Hong-Cui; Xu, Yi-Qiao; Li, Chun-Qi] Hunter Biotechnol Inc, F1A,Bldg 5,88 Jiangling Rd, Hangzhou 311231, Zhejiang, Peoples R China.
   [Huang, Chang-Jiang; Li, Chun-Qi] Wenzhou Med Univ, Inst Watershed Sci & Environm Ecol, Wenzhou, Peoples R China.
C3 Wenzhou Medical University; Wenzhou Medical University
RP Li, CQ (通讯作者)，Hunter Biotechnol Inc, F1A,Bldg 5,88 Jiangling Rd, Hangzhou 311231, Zhejiang, Peoples R China.
EM chunqili@wzmc.edu.cn
RI Dong, Qiaoxiang/F-1918-2010; Huang, Changjiang/F-2644-2010
FU Zhejiang Provincial Major Research Program [2014C03009]
FX This work was sponsored in part by the Zhejiang Provincial Major
   Research Program (2014C03009).
CR Auerbach R, 2003, CLIN CHEM, V49, P32, DOI 10.1373/49.1.32
   Barlow AM, 2002, VET REC, V151, P25, DOI 10.1136/vr.151.1.25
   Borges AS, 1999, VET HUM TOXICOL, V41, P378
   BUTTON C, 1987, AUST VET J, V64, P226, DOI 10.1111/j.1751-0813.1987.tb15193.x
   Cao YH, 2009, SEMIN CANCER BIOL, V19, P338, DOI 10.1016/j.semcancer.2009.05.001
   Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220
   Carmeliet P, 2009, NAT REV CLIN ONCOL, V6, P315, DOI 10.1038/nrclinonc.2009.64
   Chan J, 2002, CANCER CELL, V1, P257, DOI 10.1016/S1535-6108(02)00042-9
   Choueiri TK, 2010, J CLIN ONCOL, V28, P2280, DOI 10.1200/JCO.2009.27.2757
   Cook KM, 2010, CA-CANCER J CLIN, V60, P222, DOI 10.3322/caac.20075
   Cross LM, 2003, ARTERIOSCL THROM VAS, V23, P911, DOI 10.1161/01.ATV.0000068685.72914.7E
   Depasquale I, 2006, CANCER CELL INT, V6, DOI 10.1186/1475-2867-6-9
   Devreese M, 2014, J CHROMATOGR A, V1353, P106, DOI 10.1016/j.chroma.2014.02.090
   Folkman J, 2007, NAT REV DRUG DISCOV, V6, P273, DOI 10.1038/nrd2115
   Garner AL, 2011, J MED CHEM, V54, P3963, DOI 10.1021/jm200364n
   Gooyit M, 2014, J MED CHEM, V57, P5792, DOI 10.1021/jm5006435
   Haldi Maryann, 2006, Angiogenesis, V9, P139, DOI 10.1007/s10456-006-9040-2
   Hasan Jurjees, 2004, Angiogenesis, V7, P1, DOI 10.1023/B:AGEN.0000037338.51851.d1
   He JH, 2013, J PHARMACOL TOX MET, V67, P25, DOI 10.1016/j.vascn.2012.10.003
   HO RK, 1990, NATURE, V348, P728, DOI 10.1038/348728a0
   Iezzi S, 2014, J VET PHARMACOL THER, V37, P589, DOI 10.1111/jvp.12135
   Isogai S, 2001, DEV BIOL, V230, P278, DOI 10.1006/dbio.2000.9995
   Ivy SP, 2009, NAT REV CLIN ONCOL, V6, P569, DOI 10.1038/nrclinonc.2009.130
   KIMMEL CB, 1995, DEV DYNAM, V203, P253, DOI 10.1002/aja.1002030302
   Laschke MW, 2012, HUM REPROD UPDATE, V18, P682, DOI 10.1093/humupd/dms026
   Lawson ND, 2002, DEV BIOL, V248, P307, DOI 10.1006/dbio.2002.0711
   Liang D, 2001, MECH DEVELOP, V108, P29, DOI 10.1016/S0925-4773(01)00468-3
   Lyons MS, 1998, DEV DYNAM, V212, P133, DOI 10.1002/(SICI)1097-0177(199805)212:1<133::AID-AJA12>3.3.CO;2-3
   MCENTEE K, 1995, VET HUM TOXICOL, V37, P234
   McGrath P, 2008, DRUG DISCOV TODAY, V13, P394, DOI 10.1016/j.drudis.2008.03.002
   Rajmohan R, 2014, PLOS ONE, V9
   Segura-Cabrera A, 2011, J COMPUT AID MOL DES, V25, P1107, DOI 10.1007/s10822-011-9489-y
   Seng Wen Lin, 2004, Angiogenesis, V7, P243, DOI 10.1007/s10456-004-4181-7
   Wang CY, 2010, EUR UROL, V58, P418, DOI 10.1016/j.eururo.2010.05.024
   Westerfield M., 1993, ZEBRAFISH BOOK GUIDE
   Xu M, 2014, NAT PROD RES, V28, P932, DOI 10.1080/14786419.2014.883395
   Yabu T, 2005, BLOOD, V106, P125, DOI 10.1182/blood-2004-09-3679
   Yang R, 2015, J APPL TOXICOL, V35, P295, DOI 10.1002/jat.3069
   Zhao TT, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012563
   Zhou J, 2014, NEUROGASTROENT MOTIL, V26, P589, DOI 10.1111/nmo.12306
   Zhu JJ, 2014, J APPL TOXICOL, V34, P139, DOI 10.1002/jat.2843
NR 41
TC 16
Z9 18
U1 0
U2 6
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1540-658X
EI 1557-8127
J9 ASSAY DRUG DEV TECHN
JI ASSAY DRUG DEV. TECHNOL.
PD JUN-JUL
PY 2016
VL 14
IS 5
BP 282
EP 290
DI 10.1089/adt.2015.679
PG 9
WC Biochemical Research Methods; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy
GA DS4LL
UT WOS:000380752500003
PM 27045536
DA 2022-11-30
ER

PT J
AU Yi, J
   Liu, WZ
   Chen, SY
   Backman, V
   Sheibani, N
   Sorenson, CM
   Fawzi, AA
   Linsenmeier, RA
   Zhang, HF
AF Yi, Ji
   Liu, Wenzhong
   Chen, Siyu
   Backman, Vadim
   Sheibani, Nader
   Sorenson, Christine M.
   Fawzi, Amani A.
   Linsenmeier, Robert A.
   Zhang, Hao F.
TI Visible light optical coherence tomography measures retinal oxygen
   metabolic response to systemic oxygenation
SO LIGHT-SCIENCE & APPLICATIONS
LA English
DT Article
DE oxygen metabolism; retinal circulation; visible light optical coherence
   tomography
ID BLOOD-FLOW; RAT RETINA; PHOTOACOUSTIC OPHTHALMOSCOPY;
   DIABETIC-RETINOPATHY; IN-VIVO; HYPOXIA; OXIMETRY; DISEASE; NORMOXIA;
   HEALTH
AB The lack of capability to quantify oxygen metabolism noninvasively impedes both fundamental investigation and clinical diagnosis of a wide spectrum of diseases including all the major blinding diseases such as age-related macular degeneration, diabetic retinopathy, and glaucoma. Using visible light optical coherence tomography (vis-OCT), we demonstrated accurate and robust measurement of retinal oxygen metabolic rate (rMRO(2)) noninvasively in rat eyes. We continuously monitored the regulatory response of oxygen consumption to a progressive hypoxic challenge. We found that both oxygen delivery, and rMRO(2) increased from the highly regulated retinal circulation (RC) under hypoxia, by 0.28 +/- 0.08 mu L min(-1) (p < 0.001), and 0.20 +/- 0.04 mu L min(-1) (p < 0.001) per 100 mmHg systemic pO(2) reduction, respectively. The increased oxygen extraction compensated for the deficient oxygen supply from the poorly regulated choroidal circulation. Results from an oxygen diffusion model based on previous oxygen electrode measurements corroborated our in vivo observations. We believe that vis-OCT has the potential to reveal the fundamental role of oxygen metabolism in various retinal diseases.
C1 [Yi, Ji; Liu, Wenzhong; Chen, Siyu; Backman, Vadim; Linsenmeier, Robert A.; Zhang, Hao F.] Northwestern Univ, Dept Biomed Engn, Evanston, IL 60208 USA.
   [Sheibani, Nader; Sorenson, Christine M.] Univ Wisconsin, McPherson Eye Res Inst, Madison, WI 53705 USA.
   [Fawzi, Amani A.; Linsenmeier, Robert A.; Zhang, Hao F.] Northwestern Univ, Dept Ophthalmol, Chicago, IL 60611 USA.
   [Linsenmeier, Robert A.] Northwestern Univ, Dept Neurobiol, Evanston, IL 60208 USA.
C3 Northwestern University; University of Wisconsin System; University of
   Wisconsin Madison; Northwestern University; Northwestern University
RP Zhang, HF (通讯作者)，Northwestern Univ, Dept Biomed Engn, Evanston, IL 60208 USA.
EM hfzhang@northwestern.edu
RI Chen, Siyu/I-9386-2019; Zhang, Hao F F/C-2451-2015; fawzi,
   amani/AAA-9199-2021; Sheibani, Nader/AAG-2379-2020; Zhang,
   Hao/H-6199-2012; Zhang, Hao F/D-1695-2011; Backman, Vadim/B-6689-2009;
   Linsenmeier, Robert A/B-7625-2009
OI Chen, Siyu/0000-0003-0336-3627; Zhang, Hao F F/0000-0001-5089-1196;
   fawzi, amani/0000-0002-9568-3558; Sheibani, Nader/0000-0003-2723-9217;
   Yi, Ji/0000-0001-6583-7192
FU NIH [1R01EY019951, 1R24EY022883]; NSF [CBET-1055379, CBET-1066776]; HHMI
   graduate student fellowship; Illinois Society for Blindness Prevention;
   Juvenile Diabetes Research Foundation (JDRF)
FX We would like to acknowledge the generous financial support from the NIH
   (Grant Nos 1R01EY019951 and 1R24EY022883) and NSF (Grant Nos
   CBET-1055379 and CBET-1066776). Wenzhong Liu is supported by a HHMI
   graduate student fellowship. Ji Yi is supported by a Seed Grant from the
   Illinois Society for Blindness Prevention and a post-doctoral fellowship
   award from the Juvenile Diabetes Research Foundation (JDRF).
CR AHMED J, 1993, INVEST OPHTH VIS SCI, V34, P516
   Arjamaa O, 2006, EXP EYE RES, V83, P473, DOI 10.1016/j.exer.2006.01.016
   Berkowitz BA, 1999, INVEST OPHTH VIS SCI, V40, P2100
   BOETTNER EA, 1962, INVEST OPHTH VISUAL, V1, P776
   Bosschaart N, 2014, LASER MED SCI, V29, P453, DOI 10.1007/s10103-013-1446-7
   BRAUN RD, 1995, INVEST OPHTH VIS SCI, V36, P542
   Bursell SE, 1996, INVEST OPHTH VIS SCI, V37, P886
   Caprara C, 2012, PROG RETIN EYE RES, V31, P89, DOI 10.1016/j.preteyeres.2011.11.003
   Choi W, 2012, BIOMED OPT EXPRESS, V3, P1047, DOI 10.1364/BOE.3.001047
   Crosson LA, 2009, MOL VIS, V15, P296
   DEVILLOTA ED, 1981, BRIT J ANAESTH, V53, P1325, DOI 10.1093/bja/53.12.1325
   Faber DJ, 2004, PHYS REV LETT, V93, DOI 10.1103/PhysRevLett.93.028102
   FEKE GT, 1994, INVEST OPHTH VIS SCI, V35, P2968
   Flammer J, 2002, PROG RETIN EYE RES, V21, P359, DOI 10.1016/S1350-9462(02)00008-3
   Hammes HP, 2005, HORM METAB RES, V37, pS39, DOI 10.1055/s-2005-861361
   Hardarson SH, 2006, INVEST OPHTH VIS SCI, V47, P5011, DOI 10.1167/iovs.06-0039
   Harris A, 2003, OPHTHAL SURG LAS IM, V34, P152, DOI 10.3928/1542-8877-20030301-16
   Hill AV, 1913, BIOCHEM J, V7, P471, DOI 10.1042/bj0070471
   Jiao SL, 2010, OPT EXPRESS, V18, P3967, DOI 10.1364/OE.18.003967
   Kaur C, 2006, INVEST OPHTH VIS SCI, V47, P1126, DOI 10.1167/iovs.05-0518
   KOHNER EM, 1995, DIABETES, V44, P603, DOI 10.2337/diabetes.44.6.603
   KOHNER EM, 1975, DIABETOLOGIA, V11, P27, DOI 10.1007/BF00422814
   Kristjansdottir JV, 2014, INVEST OPHTH VIS SCI, V55, P3120, DOI 10.1167/iovs.13-13255
   Kur J, 2012, PROG RETIN EYE RES, V31, P377, DOI 10.1016/j.preteyeres.2012.04.004
   Lange CAK, 2012, OPHTHALMOLOGICA, V227, P115, DOI 10.1159/000331418
   Lau JCM, 2012, EXP EYE RES, V102, P50, DOI 10.1016/j.exer.2012.07.004
   Linsenmeier RA, 1998, INVEST OPHTH VIS SCI, V39, P1647
   LINSENMEIER RA, 1992, J GEN PHYSIOL, V99, P177, DOI 10.1085/jgp.99.2.177
   Mozaffarieh M, 2008, MOL VIS, V14, P224
   Nagaoka T, 2002, INVEST OPHTH VIS SCI, V43, P3037
   Newman EA, 2013, J CEREBR BLOOD F MET, V33, P1685, DOI 10.1038/jcbfm.2013.145
   Nowak JZ, 2006, PHARMACOL REP, V58, P353
   Palkovits S, 2014, AM J PHYSIOL-HEART C, V307, pH1412, DOI 10.1152/ajpheart.00479.2014
   Palkovits S, 2014, INVEST OPHTH VIS SCI, V55, P4707, DOI 10.1167/iovs.14-14593
   Palsson O, 2012, INVEST OPHTH VIS SCI, V53, P1729, DOI 10.1167/iovs.11-8621
   Pournaras CJ, 2008, PROG RETIN EYE RES, V27, P284, DOI 10.1016/j.preteyeres.2008.02.002
   RIVA CE, 1986, INVEST OPHTH VIS SCI, V27, P1706
   Riva CE, 2000, KLIN MONATSBL AUGENH, V216, P309, DOI 10.1055/s-2000-10990
   Robles FE, 2011, NAT PHOTONICS, V5, P744, DOI 10.1038/nphoton.2011.257
   SCHWINN DA, 1990, ANESTH ANALG, V71, P451
   Shahidi M, 2010, INVEST OPHTH VIS SCI, V51, P4766, DOI 10.1167/iovs.09-4710
   Song W, 2014, SCI REP-UK, V4, DOI 10.1038/srep06525
   Srinivasan VJ, 2013, J BIOMED OPT, V18, DOI 10.1117/1.JBO.18.7.076025
   Suzuki H, 2004, NAT GENET, V36, P417, DOI 10.1038/ng1330
   Teng PY, 2014, INVEST OPHTH VIS SCI, V55, P6055, DOI 10.1167/iovs.13-13811
   Wanek J, 2013, INVEST OPHTH VIS SCI, V54, P5012, DOI 10.1167/iovs.13-11887
   Wang YM, 2007, J BIOMED OPT, V12, DOI 10.1117/1.2772871
   Wang YM, 2011, INVEST OPHTH VIS SCI, V52, P840, DOI 10.1167/iovs.10-5985
   Wang YM, 2008, J BIOMED OPT, V13, DOI 10.1117/1.2998480
   Wright WS, 2011, EXP EYE RES, V93, P437, DOI 10.1016/j.exer.2011.06.003
   Yazdanfar S, 2000, OPT LETT, V25, P1448, DOI 10.1364/OL.25.001448
   Yi J, 2013, OPT LETT, V38, P1796, DOI 10.1364/OL.38.001796
   Yi J, 2010, OPT LETT, V35, P2094, DOI 10.1364/OL.35.002094
   Zhao YH, 2000, OPT LETT, V25, P114, DOI 10.1364/OL.25.000114
   Zhi ZW, 2011, BIOMED OPT EXPRESS, V2, P579, DOI 10.1364/BOE.2.000579
NR 55
TC 107
Z9 111
U1 0
U2 25
PU CHINESE ACAD SCIENCES, CHANGCHUN INST OPTICS FINE MECHANICS AND PHYSICS
PI CHANGCHUN
PA 3888, DONGNANHU ROAD, CHANGCHUN, 130033, PEOPLES R CHINA
SN 2047-7538
J9 LIGHT-SCI APPL
JI Light-Sci. Appl.
PD SEP
PY 2015
VL 4
AR e334
DI 10.1038/lsa.2015.107
PG 10
WC Optics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Optics
GA CS1EQ
UT WOS:000361805800006
PM 26658555
OA gold, Green Accepted
DA 2022-11-30
ER

PT J
AU Akhtar, S
   Patnaik, SR
   Raghupathy, RK
   Al-Mubrad, TM
   Craft, JA
   Shu, XH
AF Akhtar, Saeed
   Patnaik, Sarita Rani
   Raghupathy, Rakesh Kotapati
   Al-Mubrad, Turki M.
   Craft, John A.
   Shu, Xinhua
TI Histological Characterization of the Dicer1 Mutant Zebrafish Retina
SO JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID FACTOR-H POLYMORPHISM; MACULAR DEGENERATION; EXPRESSION; RNAS
AB DICER1, a multidomain RNase III endoribonuclease, plays a critical role in microRNA (miRNA) and RNA-interference (RNAi) functional pathways. Loss of Dicer1 affects different developmental processes. Dicer1 is essential for retinal development and maintenance. DICER1 was recently shown to have another function of silencing the toxicity of Alu RNAs in retinal pigment epithelium (RPE) cells, which are involved in the pathogenesis of age related macular degeneration. In this study, we characterized a Dicer1 mutant fish line, which carries a nonsense mutation (W1457Ter) induced by N-ethyl-N-nitrosourea mutagenesis. Zebrafish DICER1 protein is highly conserved in the evolution. Zebrafish Dicer1 is expressed at the earliest stages of zebrafish development and persists into late developmental stages; it is widely expressed in adult tissues. Homozygous Dicer1 mutant fish (DICER1(W1457Ter/W1457Ter)) have an arrest in early growth with significantly smaller eyes and are dead at 14-18 dpf. Heterozygous Dicer1 mutant fish have similar retinal structure to that of control fish; the retinal pigment epithelium (RPE) cells are normal with no sign of degeneration at the age of 20 months.
C1 [Akhtar, Saeed; Al-Mubrad, Turki M.] King Saud Univ, Dept Optometry, Cornea Res Chair, Riyadh 11433, Saudi Arabia.
   [Patnaik, Sarita Rani; Raghupathy, Rakesh Kotapati; Craft, John A.; Shu, Xinhua] Glasgow Caledonian Univ, Dept Life Sci, Glasgow G4 0BA, Lanark, Scotland.
C3 King Saud University; Glasgow Caledonian University
RP Shu, XH (通讯作者)，Glasgow Caledonian Univ, Dept Life Sci, Glasgow G4 0BA, Lanark, Scotland.
EM xinhua.shu@gcu.ac.uk
RI Akhtar, Saeed/AGY-3605-2022
OI Kotapati Raghupathy, Rakesh/0000-0001-6956-7564
FU Royal Society of London; TENOVUS Scotland; National Eye Research Centre;
   Visual Research Trust; W. H. Ross Foundation; Rosetrees Trust; Fight for
   Sight; Carnegie Trust for the Universities of Scotland; Deanship of
   Scientific Research at King Saud University [RGP-VPP-219]; EU INTERREG
   NEW noPILLS programme
FX The authors would like to thank the Royal Society of London, TENOVUS
   Scotland, National Eye Research Centre, Visual Research Trust, the W. H.
   Ross Foundation, the Rosetrees Trust, Fight for Sight, and the Carnegie
   Trust for the Universities of Scotland for supporting this work. The
   authors also would like to extend their sincere appreciation to the
   Deanship of Scientific Research at King Saud University for its funding
   of this research through the Research Project (RGP-VPP-219). The
   maintenance of GCU Zebrafish Facility was funded by the EU INTERREG NEW
   noPILLS programme.
CR Bernstein E, 2003, NAT GENET, V35, P215, DOI 10.1038/ng1253
   Damiani D, 2008, J NEUROSCI, V28, P4878, DOI 10.1523/JNEUROSCI.0828-08.2008
   de Bruijn Ewart, 2009, V546, P3, DOI 10.1007/978-1-60327-977-2_1
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Fritsche LG, 2014, ANNU REV GENOM HUM G, V15, P151, DOI 10.1146/annurev-genom-090413-025610
   Georgi SA, 2010, J NEUROSCI, V30, P4048, DOI 10.1523/JNEUROSCI.4982-09.2010
   Giraldez AJ, 2005, SCIENCE, V308, P833, DOI 10.1126/science.1109020
   Grishok A, 2001, CELL, V106, P23, DOI 10.1016/S0092-8674(01)00431-7
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Ho JJD, 2008, J AM SOC NEPHROL, V19, P2043, DOI 10.1681/ASN.2008090986
   Iida A, 2011, INVEST OPHTH VIS SCI, V52, P3008, DOI 10.1167/iovs.10-6428
   Jaskiewicz L, 2008, CURR TOP MICROBIOL, V320, P77
   Jinek M, 2009, NATURE, V457, P405, DOI 10.1038/nature07755
   Kaneko H, 2011, NATURE, V471, P325, DOI 10.1038/nature09830
   Kanellopoulou C, 2005, GENE DEV, V19, P489, DOI 10.1101/gad.1248505
   Kim VN, 2009, NAT REV MOL CELL BIO, V10, P126, DOI 10.1038/nrm2632
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   La Torre A, 2013, P NATL ACAD SCI USA, V110, pE2362, DOI 10.1073/pnas.1301837110
   MacRae IJ, 2006, SCIENCE, V311, P195, DOI 10.1126/science.1121638
   Raghupathy RK, 2013, ZEBRAFISH, V10, P62, DOI 10.1089/zeb.2012.0761
   Shu XH, 2010, HUM MOL GENET, V19, P657, DOI 10.1093/hmg/ddp533
   Stowe HM, 2012, GENE, V501, P198, DOI 10.1016/j.gene.2012.03.058
   Sundermeier T. R., 2004, J FEDERATION AM SOC, V28, P3780
   Tarallo V, 2012, CELL, V149, P847, DOI 10.1016/j.cell.2012.03.036
   Tarboush R, 2012, TISSUE CELL, V44, P264, DOI 10.1016/j.tice.2012.04.004
   Wienholds E, 2003, NAT GENET, V35, P217, DOI 10.1038/ng1251
   Zhang HD, 2004, CELL, V118, P57, DOI 10.1016/j.cell.2004.06.017
NR 27
TC 9
Z9 9
U1 0
U2 4
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2090-004X
EI 2090-0058
J9 J OPHTHALMOL
JI J. Ophthalmol.
PY 2015
VL 2015
AR 309510
DI 10.1155/2015/309510
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CK5QD
UT WOS:000356279700001
PM 26124959
OA gold, Green Published, Green Submitted
DA 2022-11-30
ER

PT J
AU Zheng, WC
   Mast, N
   Saadane, A
   Pikuleva, IA
AF Zheng, Wenchao
   Mast, Natalia
   Saadane, Aicha
   Pikuleva, Irina A.
TI Pathways of cholesterol homeostasis in mouse retina responsive to
   dietary and pharmacologic treatments
SO JOURNAL OF LIPID RESEARCH
LA English
DT Article
DE cytochrome P450; transcriptional regulation; posttranslational
   regulation; 3-hydroxy-3-methyl-glutaryl-CoA reductase; liver X receptor;
   sterol-regulatory element binding protein; RPE65; age-related macular
   degeneration
ID HMG-COA REDUCTASE; DENSITY-LIPOPROTEIN RECEPTOR; STEROL 27-HYDROXYLASE
   GENE; LIVER-X-RECEPTORS; MACULAR DEGENERATION; PIGMENT EPITHELIUM;
   LIPID-METABOLISM; APOLIPOPROTEIN-D; DIABETIC-RETINOPATHY;
   FEEDBACK-REGULATION
AB Effects of serum cholesterol on cholesterol content in the retina are currently unknown. It is also unclear how cholesterol levels are controlled in the retina. High-cholesterol diet and oral administrations of simvastatin were used to modulate serum cholesterol in mice. These treatments only modestly affected cholesterol content in the retina and had no significant effect on retinal expression of the major cholesterol-and vision-related genes; the sterol-regulatory element binding protein pathway of transcriptional regulation does not seem to be operative in the retina under the experimental conditions used. Evidence is obtained that posttranslational mechanisms play a role in the control of retinal cholesterol. Retinal genes were only up-regulated by oral administrations of TO901317 activating liver X receptors. Three of the upregulated genes could be of particular importance (apoD, Idol, and Rpe65) and have not yet been considered in the context of cholesterol homeostasis in the retina. Collectively, the data obtained identify specific features of retinal cholesterol maintenance and suggest additional therapies for age-related macular degeneration, a blinding disease characterized by cholesterol and lipid accumulations in chorioretinal tissues.
C1 [Zheng, Wenchao; Mast, Natalia; Saadane, Aicha; Pikuleva, Irina A.] Case Western Reserve Univ, Dept Ophthalmol & Visual Sci, Cleveland, OH 44106 USA.
C3 Case Western Reserve University
RP Pikuleva, IA (通讯作者)，Case Western Reserve Univ, Dept Ophthalmol & Visual Sci, Cleveland, OH 44106 USA.
EM iap8@case.edu
OI Pikuleva, Irina/0000-0001-9742-6232; Saadane, Aicha/0000-0001-9985-2147
FU National Institutes of Health [EY018383, EY11373]; Ohio Lions Eye
   Research Foundation; Research to Prevent Blindness; Jules and Doris
   Stein Professorship from the Research to Prevent Blindness Foundation;
   NATIONAL EYE INSTITUTE [R01EY018383, P30EY011373] Funding Source: NIH
   RePORTER
FX This work was supported in part by National Institutes of Health Grants
   EY018383 (I.A.P.) and Core grant EY11373, funds from the Ohio Lions Eye
   Research Foundation, and unrestricted grants from Research to Prevent
   Blindness. I.A.P. is a recipient of the Jules and Doris Stein
   Professorship from the Research to Prevent Blindness Foundation.
CR Albert AD, 2005, PROG LIPID RES, V44, P99, DOI 10.1016/j.plipres.2005.02.001
   Amaratunga A, 1996, J BIOL CHEM, V271, P5628, DOI 10.1074/jbc.271.10.5628
   Anderson DH, 2001, AM J OPHTHALMOL, V131, P767, DOI 10.1016/S0002-9394(00)00961-2
   Barathi VA, 2014, INVEST OPHTH VIS SCI, V55, P460, DOI 10.1167/iovs.13-11636
   Bavner A, 2010, J LIPID RES, V51, P2722, DOI 10.1194/jlr.M008326
   BJORKHEM I, 1987, J LIPID RES, V28, P1137
   Bretillon L, 2007, CURR EYE RES, V32, P361, DOI 10.1080/02713680701231857
   Brown MS, 2009, J LIPID RES, V50, pS15, DOI 10.1194/jlr.R800054-JLR200
   Burg JS, 2011, PROG LIPID RES, V50, P403, DOI 10.1016/j.plipres.2011.07.002
   Calabro P, 2005, CURR OPIN CARDIOL, V20, P541, DOI 10.1097/01.hco.0000181482.99067.bf
   Cartharius K, 2005, BIOINFORMATICS, V21, P2933, DOI 10.1093/bioinformatics/bti473
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Curcio CA, 2011, BRIT J OPHTHALMOL, V95, P1638, DOI 10.1136/bjophthalmol-2011-300344
   DeBose-Boyd RA, 2008, CELL RES, V18, P609, DOI 10.1038/cr.2008.61
   Dubrac S, 2005, J LIPID RES, V46, P76, DOI 10.1194/jlr.M400219-JLR200
   Duncan KG, 2009, BRIT J OPHTHALMOL, V93, P1116, DOI 10.1136/bjo.2008.144006
   Eichinger A, 2007, J BIOL CHEM, V282, P31068, DOI 10.1074/jbc.M703552200
   Elner Victor M, 2002, Trans Am Ophthalmol Soc, V100, P301
   Evans BA, 2009, DEMENT GERIATR COGN, V27, P519, DOI 10.1159/000221835
   FLIESLER SJ, 1995, BIOCHEM BIOPH RES CO, V210, P695, DOI 10.1006/bbrc.1995.1715
   FLIESLER SJ, 1993, FEBS LETT, V335, P234, DOI 10.1016/0014-5793(93)80736-E
   Fliesler SJ, 2010, J LIPID RES, V51, P3399, DOI 10.1194/jlr.R010538
   Guymer RH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0083759
   HAMEL CP, 1993, J BIOL CHEM, V268, P15751
   Hazra S, 2012, DIABETES, V61, P3270, DOI 10.2337/db11-1596
   Heo GY, 2012, ARCH BIOCHEM BIOPHYS, V518, P119, DOI 10.1016/j.abb.2011.12.016
   Hoeke MO, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088011
   Hong C, 2010, J BIOL CHEM, V285, P19720, DOI 10.1074/jbc.M110.123729
   Horton JD, 2002, J CLIN INVEST, V109, P1125, DOI 10.1172/JCI200215593
   Hu CY, 2001, J NEUROCYTOL, V30, P209, DOI 10.1023/A:1012797623620
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Jakobsson T, 2012, TRENDS PHARMACOL SCI, V33, P394, DOI 10.1016/j.tips.2012.03.013
   Janowski BA, 1999, P NATL ACAD SCI USA, V96, P266, DOI 10.1073/pnas.96.1.266
   Jansen PJ, 2009, J ALZHEIMERS DIS, V18, P319, DOI 10.3233/JAD-2009-1150
   Jin MH, 2005, CELL, V122, P449, DOI 10.1016/j.cell.2005.06.042
   Jo Y, 2010, CRIT REV BIOCHEM MOL, V45, P185, DOI 10.3109/10409238.2010.485605
   Kalaany NY, 2006, ANNU REV PHYSIOL, V68, P159, DOI 10.1146/annurev.physiol.68.033104.152158
   KEMPEN HJM, 1988, J LIPID RES, V29, P1149
   Kiser PD, 2010, PROG RETIN EYE RES, V29, P428, DOI 10.1016/j.preteyeres.2010.03.002
   Kuhrt H, 1997, J BRAIN RES, V38, P223
   Li MY, 2014, HUM MOL GENET, V23, P4001, DOI 10.1093/hmg/ddu114
   Li XL, 2010, EXPERT OPIN THER PAT, V20, P535, DOI 10.1517/13543771003621269
   Liao JK, 2005, ANNU REV PHARMACOL, V45, P89, DOI 10.1146/annurev.pharmtox.45.120403.095748
   Liao WL, 2011, J PROTEOME RES, V10, P241, DOI 10.1021/pr1008898
   LUND E, 1989, SCAND J CLIN LAB INV, V49, P165, DOI 10.3109/00365518909105417
   Lund EG, 1999, P NATL ACAD SCI USA, V96, P7238, DOI 10.1073/pnas.96.13.7238
   Mak PA, 2002, J LIPID RES, V43, P2037, DOI 10.1194/jlr.C200014-JLR200
   Mast N, 2014, J BIOL CHEM, V289, P3529, DOI 10.1074/jbc.M113.532846
   Mast N, 2012, MOL PHARMACOL, V82, P824, DOI 10.1124/mol.112.080424
   Mast N, 2011, INVEST OPHTH VIS SCI, V52, P594, DOI 10.1167/iovs.10-6021
   Moiseyev G, 2005, P NATL ACAD SCI USA, V102, P12413, DOI 10.1073/pnas.0503460102
   NAN W, 1993, INVEST OPHTH VIS SCI, V34, P101
   Omarova S, 2012, J CLIN INVEST, V122, P3012, DOI 10.1172/JCI63816
   Park Paul Shin-Hyun, 2014, Adv Pharmacol, V70, P1, DOI 10.1016/B978-0-12-417197-8.00001-8
   Perdomo G, 2009, AGING-US, V1, P17
   Pfrieger FW, 2011, PROG LIPID RES, V50, P357, DOI 10.1016/j.plipres.2011.06.002
   Pikuleva IA, 2014, PROG RETIN EYE RES, V41, P64, DOI 10.1016/j.preteyeres.2014.03.002
   Redmond TM, 2005, P NATL ACAD SCI USA, V102, P13658, DOI 10.1073/pnas.0504167102
   Repa JJ, 2000, ANNU REV CELL DEV BI, V16, P459, DOI 10.1146/annurev.cellbio.16.1.459
   Repa JJ, 2000, J BIOL CHEM, V275, P39685, DOI 10.1074/jbc.M007653200
   Rosen H, 1998, J BIOL CHEM, V273, P14805, DOI 10.1074/jbc.273.24.14805
   Saadane A, 2014, AM J PATHOL, V184, P2403, DOI 10.1016/j.ajpath.2014.05.024
   Schultz JR, 2000, GENE DEV, V14, P2831, DOI 10.1101/gad.850400
   Scotti E, 2013, MOL CELL BIOL, V33, P1503, DOI 10.1128/MCB.01716-12
   Sene A, 2013, CELL METAB, V17, P549, DOI 10.1016/j.cmet.2013.03.009
   Shanmugaratnam J, 1997, MOL BRAIN RES, V50, P113, DOI 10.1016/S0169-328X(97)00176-9
   Sierra S, 2011, J ALZHEIMERS DIS, V23, P307, DOI 10.3233/JAD-2010-101179
   Skerra A, 2000, BBA-PROTEIN STRUCT M, V1482, P337, DOI 10.1016/S0167-4838(00)00145-X
   Song BL, 2004, J BIOL CHEM, V279, P28798, DOI 10.1074/jbc.M402442200
   Spann NJ, 2012, CELL, V151, P138, DOI 10.1016/j.cell.2012.06.054
   Tang J, 2011, PROG RETIN EYE RES, V30, P343, DOI 10.1016/j.preteyeres.2011.05.002
   Tserentsoodol N, 2006, MOL VIS, V12, P1319
   Tserentsoodol N, 2006, MOL VIS, V12, P1306
   Walczak R, 2004, J BIOL CHEM, V279, P9905, DOI 10.1074/jbc.M310587200
   Wang MY, 2012, ANAL CHEM, V84, P5186, DOI 10.1021/ac300587v
   WIKVALL K, 1984, J BIOL CHEM, V259, P3800
   Yang CD, 2006, J BIOL CHEM, V281, P27816, DOI 10.1074/jbc.M603781200
   Yang HX, 2014, INVEST OPHTH VIS SCI, V55, P2795, DOI 10.1167/iovs.13-13323
   Zelcer N, 2009, SCIENCE, V325, P100, DOI 10.1126/science.1168974
   Zhang L, 2012, ARTERIOSCL THROM VAS, V32, P2541, DOI 10.1161/ATVBAHA.112.250571
   Zheng WC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037926
NR 81
TC 49
Z9 49
U1 1
U2 9
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0022-2275
EI 1539-7262
J9 J LIPID RES
JI J. Lipid Res.
PD JAN
PY 2015
VL 56
IS 1
BP 81
EP 97
DI 10.1194/jlr.M053439
PG 17
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA AX5KB
UT WOS:000346963600009
PM 25293590
OA Green Published, hybrid
DA 2022-11-30
ER

PT J
AU Zhang, Z
   Srivastava, R
   Liu, HY
   Chen, XY
   Duan, LX
   Wong, DWK
   Kwoh, CK
   Wong, TY
   Liu, J
AF Zhang, Zhuo
   Srivastava, Ruchir
   Liu, Huiying
   Chen, Xiangyu
   Duan, Lixin
   Wong, Damon Wing Kee
   Kwoh, Chee Keong
   Wong, Tien Yin
   Liu, Jiang
TI A survey on computer aided diagnosis for ocular diseases
SO BMC MEDICAL INFORMATICS AND DECISION MAKING
LA English
DT Article
DE Computer Aided Diagnosis (CAD); Ocular diseases; Review; Clinical data;
   Ocular imaging; Genetic information
ID OPTICAL COHERENCE TOMOGRAPHY; RETINAL FUNDUS IMAGES; TO-DISC RATIO;
   SCANNING LASER POLARIMETRY; GENOME-WIDE ASSOCIATION; OPEN-ANGLE
   GLAUCOMA; BIOLOGICALLY INSPIRED FEATURE; DECISION-SUPPORT-SYSTEM;
   ANTERIOR-CHAMBER DEPTH; DIABETIC-RETINOPATHY
AB Background: Computer Aided Diagnosis (CAD), which can automate the detection process for ocular diseases, has attracted extensive attention from clinicians and researchers alike. It not only alleviates the burden on the clinicians by providing objective opinion with valuable insights, but also offers early detection and easy access for patients.
   Method: We review ocular CAD methodologies for various data types. For each data type, we investigate the databases and the algorithms to detect different ocular diseases. Their advantages and shortcomings are analyzed and discussed.
   Result: We have studied three types of data (i.e., clinical, genetic and imaging) that have been commonly used in existing methods for CAD. The recent developments in methods used in CAD of ocular diseases (such as Diabetic Retinopathy, Glaucoma, Age-related Macular Degeneration and Pathological Myopia) are investigated and summarized comprehensively.
   Conclusion: While CAD for ocular diseases has shown considerable progress over the past years, the clinical importance of fully automatic CAD systems which are able to embed clinical knowledge and integrate heterogeneous data sources still show great potential for future breakthrough.
C1 [Zhang, Zhuo; Srivastava, Ruchir; Liu, Huiying; Chen, Xiangyu; Duan, Lixin; Wong, Damon Wing Kee; Liu, Jiang] Inst Infocomm Res, Singapore, Singapore.
   [Zhang, Zhuo; Kwoh, Chee Keong] Nanyang Technol Univ, Singapore 639798, Singapore.
   [Wong, Tien Yin] Singapore Natl Eye Ctr, Singapore, Singapore.
C3 Agency for Science Technology & Research (A*STAR); A*STAR - Institute
   for Infocomm Research (I2R); Nanyang Technological University & National
   Institute of Education (NIE) Singapore; Nanyang Technological
   University; Singapore National Eye Center
RP Zhang, Z (通讯作者)，Inst Infocomm Res, 1 Fusionopolis Way, Singapore, Singapore.
EM zzhang@i2r.a-star.edu.sg
RI Wong, Tien Yin/AAC-9724-2020
OI Wong, Tien Yin/0000-0002-8448-1264; Srivastava,
   Rakesh/0000-0002-0065-4069; Wong, Damon/0000-0003-4601-9121; Srivastava,
   Rakesh/0000-0003-3112-4252; liu, jiang/0000-0001-6281-6505
FU Agency for Science, Technology and Research Singapore
FX Authors would like to express their appreciation to the Agency for
   Science, Technology and Research Singapore for providing research
   funding and facilities for this interdisciplinary research. The authors
   are also particular grateful to the Singapore Eye Research Institute for
   clinical advice and assistance.
CR Abramoff MD, 2007, INVEST OPHTH VIS SCI, V48, P1665, DOI 10.1167/iovs.06-1081
   Abramoff MD, 2013, JAMA OPHTHALMOL, V131, P351, DOI 10.1001/jamaophthalmol.2013.1743
   Abramoff Michael D, 2010, IEEE Rev Biomed Eng, V3, P169, DOI 10.1109/RBME.2010.2084567
   Abramoff MD, 2009, INVEST OPHTH VIS SCI, V50, P5778, DOI 10.1167/iovs.09-3790
   Acharya U. R., 2007, IRBM, V28, P35
   Acharya U Rajendra, 2006, Conf Proc IEEE Eng Med Biol Soc, V2006, P6121
   Agurto C, 2011, INVEST OPHTH VIS SCI, V52, P5862, DOI 10.1167/iovs.10-7075
   Agurto C, 2010, IEEE T MED IMAGING, V29, P502, DOI 10.1109/TMI.2009.2037146
   Ahmad HMH, 2011, RES DEV INTELLIGENT
   Akram MU, 2013, PATTERN RECOGN, V46, P107, DOI 10.1016/j.patcog.2012.07.002
   Allen D, 2006, BMJ-BRIT MED J, V333, P128, DOI 10.1136/bmj.333.7559.128
   Allingham R, 2004, SHIELDS TXB GLAUCOMA
   ALSBIRK PH, 1975, ACTA OPHTHALMOL, V53, P436
   Antal B, 2012, IEEE T BIO-MED ENG, V59, P1720, DOI 10.1109/TBME.2012.2193126
   Antal B, 2012, PATTERN RECOGN, V45, P264, DOI 10.1016/j.patcog.2011.06.010
   Antoniak Katarzyna, 2008, Klin Oczna, V110, P211
   Aronsky D, 2001, J AM MED INFORM ASSN, V8, P473, DOI 10.1136/jamia.2001.0080473
   Asakuma T, 2012, OPHTHALMOLOGY, V119, P1760, DOI 10.1016/j.ophtha.2012.02.034
   Asbell PA, 2005, LANCET, V365, P599
   Attebo K, 1996, OPHTHALMOLOGY, V103, P357
   Barriga E, 2009, IEEE INT S COMP BAS, P1
   BAUDOIN CE, 1984, REV EPIDEMIOL SANTE, V32, P254
   Ben Sbeh Z, 2001, IEEE T MED IMAGING, V20, P1321, DOI 10.1109/42.974927
   Bernardes R, 2011, OPHTHALMOLOGICA, V226, P161, DOI 10.1159/000329597
   Bizios D, 2011, BMC OPHTHALMOL, V11, DOI 10.1186/1471-2415-11-20
   Bock R, 2007, LECT NOTES COMPUT SC, V4713, P355
   Bock R, 2010, MED IMAGE ANAL, V14, P471, DOI 10.1016/j.media.2009.12.006
   Brandon L, 2003, LECT NOTES COMPUT SC, V2878, P618
   BRESSLER NM, 1988, SURV OPHTHALMOL, V32, P375, DOI 10.1016/0039-6257(88)90052-5
   Budai A, 2011, OPHTHALMOL VISUAL SC, P1345
   Burgansky-Eliash Z, 2007, OPHTHALMOLOGY, V114, P466, DOI 10.1016/j.ophtha.2006.08.022
   Burton PR, 2007, NATURE, V447, P661, DOI 10.1038/nature05911
   Carbonaro F, 2009, INVEST OPHTH VIS SCI, V50, P5115, DOI 10.1167/iovs.09-3577
   Caruana R, 1997, MACH LEARN, V28, P41, DOI 10.1023/A:1007379606734
   Chan KL, 2002, IEEE T BIO-MED ENG, V49, P963, DOI 10.1109/TBME.2002.802012
   Charlesworth J, 2010, INVEST OPHTH VIS SCI, V51, P3509, DOI 10.1167/iovs.09-4786
   Chauhan BC, 2000, INVEST OPHTH VIS SCI, V41, P775
   Chaum E, 2008, RETINA-J RET VIT DIS, V28, P1463, DOI 10.1097/IAE.0b013e31818356dd
   Chen SJ, 2012, INVEST OPHTH VIS SCI, V53, P4868, DOI 10.1167/iovs.12-9919
   Chen XJ, 2012, IEEE T MED IMAGING, V31, P1521, DOI 10.1109/TMI.2012.2191302
   Cheng J, 2012, P INT C PATT REC TSU, P2063
   Cheng J, 2013, LECT NOTES COMPUT SC, V8151, P421, DOI 10.1007/978-3-642-40760-4_53
   Cheng J, 2012, IEEE IMAGE PROC, P2805, DOI 10.1109/ICIP.2012.6467482
   Cheng J, 2013, IEEE T MED IMAGING, V32, P1019, DOI 10.1109/TMI.2013.2247770
   Cheng J, 2012, IEEE T MED IMAGING, V31, P2355, DOI 10.1109/TMI.2012.2218118
   Cheng J, 2011, LECT NOTES COMPUT SC, V6893, P91, DOI 10.1007/978-3-642-23626-6_12
   Cheng XG, 2012, IEEE ENG MED BIO, P4954, DOI 10.1109/EMBC.2012.6347104
   Cheung CYL, 2011, OPHTHALMOLOGY, V118, P812, DOI 10.1016/j.ophtha.2010.08.045
   Chow YC, 2011, IEEE ENG MED BIO, P5044, DOI 10.1109/IEMBS.2011.6091249
   Colenbrander A, 2009, MEASURING VISION VIS
   Complications of Age-Related Macular Degeneration Prevention Trial Study Group, 2004, Clin Trials, V1, P91
   Congdon N, 2005, OPHTHALMOLOGY, V112, P73, DOI 10.1016/j.ophtha.2004.07.012
   Cooper JD, 2008, NAT GENET, V40, P1399, DOI 10.1038/ng.249
   Corona E, 2002, IEEE T MED IMAGING, V21, P1244, DOI 10.1109/TMI.2002.806293
   Cree MJ, 1997, EYE, V11, P622, DOI 10.1038/eye.1997.166
   D'Angelo Gina M, 2009, BMC Proc, V3 Suppl 7, pS62
   DAMMS T, 1993, INVEST OPHTH VIS SCI, V34, P2246
   Damon WWK, 2012, 2012 9TH IEEE INTERNATIONAL SYMPOSIUM ON BIOMEDICAL IMAGING (ISBI), P1647, DOI 10.1109/ISBI.2012.6235893
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   Dirani M, 2008, INVEST OPHTH VIS SCI, V49, P1339, DOI 10.1167/iovs.07-1011
   Drent M, 1996, AM J RESP CRIT CARE, V153, P736, DOI 10.1164/ajrccm.153.2.8564126
   Duncan DD, 1997, J OPT SOC AM A, V14, P1197, DOI 10.1364/JOSAA.14.001197
   Esmaeili M, 2010, P IEEE INT C IM PROC
   Fajnkuchen F, 2008, J FR OPHTALMOL, V31, P630, DOI 10.1016/S0181-5512(08)75469-X
   Fan SH, 2003, LECT NOTES COMPUT SC, V2878, P592
   Fleming AD, 2006, IEEE T MED IMAGING, V25, P1223, DOI 10.1109/TMI.2006.879953
   Foong AWP, 2007, OPHTHAL EPIDEMIOL, V14, P25, DOI 10.1080/09286580600878844
   Forsman E, 2007, ACTA OPHTHALMOL SCAN, V85, P500, DOI 10.1111/j.1600-0420.2007.00978.x
   Freund DE, 2009, I S BIOMED IMAGING, P61, DOI 10.1109/ISBI.2009.5192983
   Fujimoto JG, 2003, NAT BIOTECHNOL, V21, P1361, DOI 10.1038/nbt892
   Fujita H, 2008, COMPUT METH PROG BIO, V92, P238, DOI 10.1016/j.cmpb.2008.04.003
   Fung HC, 2006, LANCET NEUROL, V5, P911, DOI 10.1016/S1474-4422(06)70578-6
   Gao X, 2012, P 11 AS C COMP VIS 2, P256, DOI DOI 10.1007/978-3-642-37444-9
   Gao XT, 2011, IEEE IMAGE PROC, P1565, DOI 10.1109/ICIP.2011.6115746
   Gardner GG, 1996, BRIT J OPHTHALMOL, V80, P940, DOI 10.1136/bjo.80.11.940
   Gershenzon A, 1999, AUST NZ J OPHTHALMOL, V27, P170, DOI 10.1046/j.1440-1606.1999.00201.x
   Gilmartin B, 2004, CLIN EXP OPHTHALMOL, V32, P305, DOI 10.1111/j.1442-9071.2004.00831.x
   Grulkowski I, 2012, BIOMED OPT EXPRESS, V3, P2733, DOI 10.1364/BOE.3.002733
   Guesalaga A, 2003, MEASUREMENT, V34, P207, DOI 10.1016/S0263-2241(03)00053-8
   Guyatt GH, 2000, JAMA-J AM MED ASSOC, V284, P1290, DOI 10.1001/jama.284.10.1290
   Hammond CJ, 2000, NEW ENGL J MED, V342, P1786, DOI 10.1056/NEJM200006153422404
   Hammond CJ, 2002, OPHTHALMOLOGY, V109, P730, DOI 10.1016/S0161-6420(01)01049-1
   Hammond CJ, 2001, INVEST OPHTH VIS SCI, V42, P601
   Hani AFM, 2010, IEEE ENG MED BIO, P5632, DOI 10.1109/IEMBS.2010.5628041
   Hansen AB, 2004, ACTA OPHTHALMOL SCAN, V82, P666, DOI 10.1111/j.1600-0420.2004.00350.x
   Harangi B, 2012, IEEE ENG MED BIO, P5951, DOI 10.1109/EMBC.2012.6347349
   Harizman N, 2006, ARCH OPHTHALMOL-CHIC, V124, P1579, DOI 10.1001/archopht.124.11.1579
   Hatanaka Y, 2010, LECT NOTES COMPUT SC, V6165, P64, DOI 10.1007/978-3-642-13923-9_7
   HAUG P, 1989, MED DECIS MAKING, V9, P84, DOI 10.1177/0272989X8900900203
   Hee MR, 1996, OPHTHALMOLOGY, V103, P1260, DOI 10.1016/S0161-6420(96)30512-5
   Heitmann M, 2005, VET OPHTHALMOL, V8, P145, DOI 10.1111/j.1463-5224.2005.00339.x
   Heneghan C, 2002, MED IMAGE ANAL, V6, P407, DOI 10.1016/S1361-8415(02)00058-0
   Herskind AM, 1996, HUM GENET, V97, P319, DOI 10.1007/BF02185763
   Hijazi MHA, 2010, P INT JOINT C NEUR N, P3501
   Hijazi MHA, 2012, KNOWL-BASED SYST, V29, P83, DOI 10.1016/j.knosys.2011.07.002
   Hijazi MHA, 2011, LECT NOTES ARTIF INT, V6912, P65, DOI 10.1007/978-3-642-23783-6_5
   Hofman A, 2011, EUR J EPIDEMIOL, V26, P657, DOI 10.1007/s10654-011-9610-5
   Hoggart CJ, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000130
   Holtzman NA, 1997, SCIENCE, V278, P602, DOI 10.1126/science.278.5338.602
   Hoover A, 2000, IEEE T MED IMAGING, V19, P203, DOI 10.1109/42.845178
   Hu Z, 2009, INVEST OPHTH VIS SCI, V50, P33
   Hu Z, 2009, P SPIE C MED IM
   Hu ZH, 2010, INVEST OPHTH VIS SCI, V51, P5708, DOI 10.1167/iovs.09-4838
   HUANG D, 1991, SCIENCE, V254, P1178, DOI 10.1126/science.1957169
   Huang W, 2011, IEEE T MED IMAGING, V30, P94, DOI 10.1109/TMI.2010.2062197
   Hunter A, 2011, IEEE ENG MED BIO, P3375, DOI 10.1109/IEMBS.2011.6090914
   Institute NHGR, 2013, FACT SHEET GEN WID A
   Jaafar HF, 2010, C P IEEE ENG MED BIO
   Jaafar HF, 2011, C P IEEE ENG MED BIO, P584
   Jablonski W, 1922, ARCH AUGENHEILKD, V91, P308
   Jain N, 2010, INVEST OPHTH VIS SCI, V51, P4875, DOI 10.1167/iovs.09-4962
   Jelinek HF, 2011, IEEE ENG MED BIO, P5951, DOI 10.1109/IEMBS.2011.6091471
   Jelinek HJ, 2006, CLIN EXP OPTOM, V89, P299, DOI 10.1111/j.1444-0938.2006.00071.x
   JONAS JB, 1992, ARCH OPHTHALMOL-CHIC, V110, P214, DOI 10.1001/archopht.1992.01080140070030
   Jonas JB, 2002, INVEST OPHTH VIS SCI, V43, P2956
   Joshi G D, 2010, Proceedings of the 2010 20th International Conference on Pattern Recognition (ICPR 2010), P2536, DOI 10.1109/ICPR.2010.621
   Joshi GD, 2012, IEEE T BIO-MED ENG, V59, P1523, DOI 10.1109/TBME.2012.2187293
   Joshi GD, 2011, IEEE T MED IMAGING, V30, P1192, DOI 10.1109/TMI.2011.2106509
   Kanthan GL, 2014, CLIN EXP OPHTHALMOL, V42, P347, DOI 10.1111/ceo.12206
   Karasik D, 2005, J GERONTOL A-BIOL, V60, P574, DOI 10.1093/gerona/60.5.574
   Karnowski TP, 2008, IEEE ENG MED BIO, P5433, DOI 10.1109/IEMBS.2008.4650443
   Kauppi T, 2006, MACHINE VISION PATTE
   Kauppi T, 2007, P BRIT MACH VIS C WA, P15
   Klein BEK, 2004, INVEST OPHTH VIS SCI, V45, P59, DOI 10.1167/iovs.03-0516
   KLEIN BEK, 1990, OPHTHALMOLOGY, V97, P1428
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kochner B, 1988, P SPIE C MED IMG, P755
   Kooperberg C, 2010, GENET EPIDEMIOL, V34, P643, DOI 10.1002/gepi.20509
   Kose C, 2010, J MED SYST, V34, P1, DOI 10.1007/s10916-008-9210-4
   Kourkoutas D, 2012, COMPUT METH PROG BIO, V108, P1149, DOI 10.1016/j.cmpb.2012.08.004
   Kulikowski CA, 1982, ARTIF INTELL MED, V51
   Kwon YH, 2010, AM GLAUC SOC 20 ANN
   Larsen N, 2003, INVEST OPHTH VIS SCI, V44, P767, DOI 10.1167/iovs.02-0417
   Larson MG, 2007, BMC MED GENET, V8, DOI 10.1186/1471-2350-8-S1-S5
   Lauterwald F, 2011, CS201102 U ERL DEP C
   Lay B, 1984, P SOC PHOTO-OPT INS, P165, DOI DOI 10.1117/12.936655
   Lee K, 2009, P SPIE C MED IM, P7262
   Lee K, 2010, IEEE T MED IMAGING, V29, P159, DOI 10.1109/TMI.2009.2031324
   Lee MK, 2012, OPHTHALMOLOGY, V119, P450, DOI 10.1016/j.ophtha.2011.09.016
   Lee N, 2010, IEEE ENG MED BIO, P5363, DOI 10.1109/IEMBS.2010.5626463
   Lee PJ, 2010, AM J OPHTHALMOL, V149, P817, DOI 10.1016/j.ajo.2009.12.007
   Li C, 2008, HUM HERED, V65, P129, DOI 10.1159/000109730
   Li H, 2010, IEEE ENG MED BIO, P5359, DOI 10.1109/IEMBS.2010.5626467
   Li HQ, 2010, IEEE T BIO-MED ENG, V57, P1690, DOI 10.1109/TBME.2010.2041454
   Liang ZY, 2010, IEEE ENG MED BIO, P4100, DOI 10.1109/IEMBS.2010.5627289
   Lim LS, 2014, EYE, V28, P488, DOI 10.1038/eye.2013.308
   Liu J, 2009, IFMBE PROC, V23, P559
   Liu J, 2010, P SPIE C MED IM
   Liu J, 2013, J IRON STEEL RES INT, V20, P20, DOI 10.1016/S1006-706X(13)60136-3
   Liu J, 2010, J HEALTHC ENG, V1, P1, DOI 10.1260/2040-2295.1.1.1
   Lowe DG, 2004, INT J COMPUT VISION, V60, P91, DOI 10.1023/B:VISI.0000029664.99615.94
   Lowell J, 2004, IEEE T MED IMAGING, V23, P1196, DOI 10.1109/TMI.2004.830524
   Lowell J, 2004, IEEE T MED IMAGING, V23, P256, DOI 10.1109/TMI.2003.823261
   Lu SJ, 2009, IEEE ENG MED BIO, P1453, DOI 10.1109/IEMBS.2009.5332917
   Lyhne N, 2001, BRIT J OPHTHALMOL, V85, P1470, DOI 10.1136/bjo.85.12.1470
   Makeeva OA, 2009, PERS MED, V6, P329, DOI [10.2217/pme.09.14, 10.2217/PME.09.14]
   Marchini J, 2010, NAT REV GENET, V11, P499, DOI 10.1038/nrg2796
   Marrugo AG, 2012, SPIE PHOTONICS EUROP
   Martins CIO, 2009, P IEEE INT C IM PROC
   MATSUI M, 1973, Nippon Ganka Gakkai Zasshi, V77, P907
   MCCALLY RL, 1994, P SOC PHOTO-OPT INS, V2126, P161, DOI 10.1117/12.178552
   McCally RL, 1993, OELASE 93 BIOMEDICAL, P20
   McIntyre AR, 2004, 1ST CANADIAN CONFERENCE ON COMPUTER AND ROBOT VISION, PROCEEDINGS, P265, DOI 10.1109/CCCRV.2004.1301454
   Medeiros FA, 2004, ARCH OPHTHALMOL-CHIC, V122, P827, DOI 10.1001/archopht.122.6.827
   Medhi JP, 2012, PROCEEDINGS OF THE 2012 WORLD CONGRESS ON INFORMATION AND COMMUNICATION TECHNOLOGIES, P511, DOI 10.1109/WICT.2012.6409131
   Meier J, 2007, LECT NOTES COMPUT SC, V4673, P165
   Merickel MB, 2006, P SPIE MED IMAG, P1031
   Michael D., 1999, CLIN EYE VIS CARE, V11, P59, DOI DOI 10.1016/S0953-4431(99)00012-0
   Michelson G, 2008, DTSCH AERZTEBLATT IN, V105, P34
   Miglior S, 2003, AM J OPHTHALMOL, V136, P26, DOI 10.1016/S0002-9394(03)00084-9
   Mihalkova L., 2007, AAAI, V7, P608
   MILLER GA, 1956, PSYCHOL REV, V63, P81, DOI 10.1037/h0043158
   MILLER RA, 1982, NEW ENGL J MED, V307, P468, DOI 10.1056/NEJM198208193070803
   Mookiah MRK, 2013, P I MECH ENG H, V227, P37, DOI 10.1177/0954411912458740
   Mookiah MRK, 2012, KNOWL-BASED SYST, V33, P73, DOI 10.1016/j.knosys.2012.02.010
   MORI G, 2004, P IEEE C COMP VIS PA
   Mubbashar M, 2011, INT C INF COMM TECHN, P1
   Munch IC, 2007, INVEST OPHTH VIS SCI, V48, P833, DOI 10.1167/iovs.06-0529
   Muramatsu C, 2009, P SPIE C MED IM, P603
   Murray V, 2012, IEEE IMAGE PROC, P525, DOI 10.1109/ICIP.2012.6466912
   Mustacchi G, 2013, INT J MOL SCI, V14, P9686, DOI 10.3390/ijms14059686
   Narasimha-Iyer H, 2006, IEEE T BIO-MED ENG, V53, P1084, DOI 10.1109/TBME.2005.863971
   National Eye Institute, 2004, NIH PUBL, V04, P3252
   Nidek Co. Ltd, 1991, ANT EYE SEGM AN SYST
   Niemeijer M, 2005, IEEE T MED IMAGING, V24, P584, DOI 10.1109/TMI.2005.843738
   Niemeijer M, 2007, INVEST OPHTH VIS SCI, V48, P2260, DOI 10.1167/iovs.06-0996
   Niemeijer M, 2010, IEEE T MED IMAGING, V29, P185, DOI 10.1109/TMI.2009.2033909
   Niemeijer M, 2009, IEEE T MED IMAGING, V28, P775, DOI 10.1109/TMI.2008.2012029
   Noronha K, 2013, P I MECH ENG H, V227, P251, DOI 10.1177/0954411912470240
   Nyul LG, 2009, P SPIE C MED IM
   Ohno-Matsui K, 2012, INVEST OPHTH VIS SCI, V53, P6046, DOI 10.1167/iovs.12-10161
   Ohno-Matsui K, 2012, OPHTHALMOLOGY, V119, P1685, DOI 10.1016/j.ophtha.2012.01.047
   Ohwada H, 1998, LECT NOTES ARTIF INT, V1531, P494
   Oloumi F, 2012, IEEE ENG MED BIO, P1438, DOI 10.1109/EMBC.2012.6346210
   Pan CW, 2011, INVEST OPHTH VIS SCI, V52, P6636, DOI 10.1167/iovs.10-7148
   Pardianto G, 2005, MIMBAR ILMIAH OFTALM, V2, P65
   Perumalsamy N, 2007, DIABETES CARE, V30, P2302, DOI 10.2337/dc07-0225
   Plomin R., 2001, BEHAV GENETICS
   Potsaid B, 2010, OPT EXPRESS, V18, P20029, DOI 10.1364/OE.18.020029
   Priya R., 2011, 2011 3rd International Conference on Electronics Computer Technology (ICECT 2011), P227, DOI 10.1109/ICECTECH.2011.5941690
   Pulst SM, 1999, ARCH NEUROL-CHICAGO, V56, P667, DOI 10.1001/archneur.56.6.667
   Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795
   Quellec G, 2008, IEEE T MED IMAGING, V27, P1230, DOI 10.1109/TMI.2008.920619
   Quellec G, 2011, IEEE T MED IMAGING, V30, P523, DOI 10.1109/TMI.2010.2089383
   Quellec G, 2010, IEEE T MED IMAGING, V29, P1321, DOI 10.1109/TMI.2010.2047023
   Radhakrishna A, 2010, 149300 FPFI
   Ram K, 2011, IEEE T BIO-MED ENG, V58, P664, DOI 10.1109/TBME.2010.2096223
   Rapantzikos K, 2003, MED IMAGE ANAL, V7, P95, DOI 10.1016/S1361-8415(02)00093-2
   Ravishankar S, 2009, P IEEE C COMP VIS PA
   Raza SH, 2009, IEEE ENG MED BIO, P6687, DOI 10.1109/IEMBS.2009.5334009
   Ren XF, 2003, NINTH IEEE INTERNATIONAL CONFERENCE ON COMPUTER VISION, VOLS I AND II, PROCEEDINGS, P10
   Robinson BE, 2003, CAN J OPTOM, V65, P175
   Rocha A, 2012, IEEE T BIO-MED ENG, V59, P2244, DOI 10.1109/TBME.2012.2201717
   Ryan S.J., 2012, RETINA-J RET VIT DIS
   Saine P, 2004, OPHTHALMIC PHOTOGRAP
   Sanfilippo PG, 2010, SURV OPHTHALMOL, V55, P561, DOI 10.1016/j.survophthal.2010.07.003
   Saw SM, 1996, EPIDEMIOL REV, V18, P175, DOI 10.1093/oxfordjournals.epirev.a017924
   Schnoll Robert A, 2007, Curr Psychiatry Rep, V9, P349, DOI 10.1007/s11920-007-0045-3
   Scholl HPN, 2007, MOL VIS, V13, P196
   Scuteri A, 2007, PLOS GENET, V3, P1200, DOI 10.1371/journal.pgen.0030115
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P321, DOI 10.1001/archopht.123.3.321
   Sehi M, 2007, AM J OPHTHALMOL, V143, P272, DOI 10.1016/j.ajo.2006.09.049
   Sharma A, 2010, J CURR GLAUCOMA PRAC, V4, P240
   Shortliffe E. H., 1977, The First Annual Symposium on Computer Application in Medical Care, P66
   Sinthanayothin C, 2002, DIABETIC MED, V19, P105, DOI 10.1046/j.1464-5491.2002.00613.x
   Smith RT, 2005, ARCH OPHTHALMOL-CHIC, V123, P200, DOI 10.1001/archopht.123.2.200
   Sng CC, 2012, OPHTHALMOLOGY, V119, P1143, DOI 10.1016/j.ophtha.2012.01.011
   Soliz P, 2008, 2008 IEEE SOUTHWEST SYMPOSIUM ON IMAGE ANALYSIS & INTERPRETATION, P65, DOI 10.1109/SSIAI.2008.4512286
   SOMMER A, 1991, ARCH OPHTHALMOL-CHIC, V109, P1090, DOI 10.1001/archopht.1991.01080080050026
   Spaide RF, 2012, RETINA-J RET VIT DIS, V32, P1037, DOI 10.1097/IAE.0b013e318242b9c0
   Taboada J, 2001, PROC SPIE, V4245, P7, DOI 10.1117/12.429274
   Taboada J, 2000, PROC SPIE, V3908, P50, DOI 10.1117/12.387510
   TAMURA S, 1988, PATTERN RECOGN, V21, P227, DOI 10.1016/0031-3203(88)90057-X
   Tan NM, 2009, IEEE ENG MED BIO, P3609, DOI 10.1109/IEMBS.2009.5333517
   Tang L, 2013, IEEE T MED IMAGING, V32, P364, DOI 10.1109/TMI.2012.2227119
   TEIKARI J, 1990, ACTA GENET MED GEMEL, V39, P133, DOI 10.1017/S0001566000005651
   TEIKARI JM, 1987, ACTA OPHTHALMOL, V65, P715
   Thrun S, 1996, ADV NEUR IN, V8, P640
   Tibshirani R, 1996, J ROY STAT SOC B MET, V58, P267, DOI 10.1111/j.2517-6161.1996.tb02080.x
   Tobin KW, 2007, P ANN INT IEEE EMBS, P6744
   Toh TY, 2005, INVEST OPHTH VIS SCI, V46, P3718, DOI 10.1167/iovs.04-1497
   Tsai MY, 2009, JPN J OPHTHALMOL, V53, P615, DOI 10.1007/s10384-009-0724-1
   Tu YS, 2008, OPHTHALMIC GENET, V29, P171, DOI 10.1080/13816810802324532
   Ujjwal K, 2013, IEEE 10 INT S BIOM I, P1428
   VARMA R, 1988, GRAEF ARCH CLIN EXP, V226, P435, DOI 10.1007/BF02170004
   Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040
   Vermeer KA, 2011, COMPUT BIOL MED, V41, P857, DOI 10.1016/j.compbiomed.2011.06.022
   Vink J, 2005, BEHAV GENET, V35, P397, DOI 10.1007/s10519-004-1327-8
   Wagholikar KB, 2012, J MED SYST, V36, P3029, DOI 10.1007/s10916-011-9780-4
   Walter T, 2002, LECT NOTES COMPUT SC, V2526, P210
   Walter T, 2007, MED IMAGE ANAL, V11, P555, DOI 10.1016/j.media.2007.05.001
   Wan XA, 2010, AM J HUM GENET, V87, P325, DOI 10.1016/j.ajhg.2010.07.021
   WEISS SM, 1978, ARTIF INTELL, V11, P145, DOI 10.1016/0004-3702(78)90015-2
   Wilkins GR, 2012, IEEE T BIO-MED ENG, V59, P1109, DOI 10.1109/TBME.2012.2184759
   Wollstein G, 1998, OPHTHALMOLOGY, V105, P1557, DOI 10.1016/S0161-6420(98)98047-2
   Wong D, 2009, P SPIE C MED IM, V7260
   Wong DWK, 2008, IEEE ENG MED BIO, P2266, DOI 10.1109/IEMBS.2008.4649648
   Wong DWK, 2013, I S BIOMED IMAGING, P884
   Wong TY, 2004, OPHTHALMOLOGY, V111, P1183, DOI 10.1016/j.ophtha.2003.09.039
   Wong TY, 2001, SURV OPHTHALMOL, V46, P59, DOI 10.1016/S0039-6257(01)00234-X
   World Health Organization, 2014, BLIND TRACH FACT SHE
   World Health Organization, 2014, ONCH FACT SHEET
   Wu J, 2010, GENET EPIDEMIOL, V34, P275, DOI 10.1002/gepi.20459
   Wu TT, 2009, BIOINFORMATICS, V25, P714, DOI 10.1093/bioinformatics/btp041
   Wu Zheyang, 2009, BMC Proc, V3 Suppl 7, pS29
   Xu J, 2007, PATTERN RECOGN, V40, P2063, DOI 10.1016/j.patcog.2006.10.015
   Xu YW, 2012, LECT NOTES COMPUT SC, V7510, P58, DOI 10.1007/978-3-642-33415-3_8
   Xu YW, 2013, LECT NOTES COMPUT SC, V8150, P468, DOI 10.1007/978-3-642-40763-5_58
   Xu YW, 2013, LECT NOTES COMPUT SC, V8151, P445, DOI 10.1007/978-3-642-40760-4_56
   Xu YW, 2013, I S BIOMED IMAGING, P888
   XU YW, 2011, P INT C MICCAI, V6893, P1
   Young TL, 1998, AM J HUM GENET, V63, P1419, DOI 10.1086/302111
   Yu J, 2005, COMP MED SY, P97
   Yuliang Wang, 2010, Proceedings 3rd International Congress on Image and Signal Processing (CISP 2010), P2747, DOI 10.1109/CISP.2010.5647550
   Yun SH, 2008, BIOL MED PHYS BIOMED, P359, DOI 10.1007/978-3-540-77550-8_11
   Zhang Bob, 2010, Proceedings of the 2010 20th International Conference on Pattern Recognition (ICPR 2010), P277, DOI 10.1109/ICPR.2010.77
   Zhang B, 2010, PATTERN RECOGN, V43, P2237, DOI 10.1016/j.patcog.2009.12.017
   Zhang X, 2010, BIOINFORMATICS, V26, pi217, DOI 10.1093/bioinformatics/btq186
   Zhang Z, 2010, C P IEEE ENG MED BIO
   Zhang Z, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065736
   Zhao L, 2013, ACTA OPHTHALMOLOGICA
   Zheng YL, 2012, INVEST OPHTH VIS SCI, V53, P8310, DOI 10.1167/iovs.12-9576
   Zheng YJ, 2013, I S BIOMED IMAGING, P1448
   Zuiderveld K., 1994, GRAPHICS GEMS, VIV, P474, DOI [10.1016/b978-0-12-336156-1.50061-6, DOI 10.1016/B978-0-12-336156-1.50061-6]
NR 285
TC 51
Z9 58
U1 2
U2 32
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1472-6947
J9 BMC MED INFORM DECIS
JI BMC Med. Inform. Decis. Mak.
PD AUG 31
PY 2014
VL 14
AR 80
DI 10.1186/1472-6947-14-80
PG 29
WC Medical Informatics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Medical Informatics
GA AP5CB
UT WOS:000342096200001
PM 25175552
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Jin, QX
   Dong, XR
   Chen, JM
   Yao, K
   Wu, YL
AF Jin, Qiu-xia
   Dong, Xin-ran
   Chen, Jing-meng
   Yao, Ke
   Wu, Ya-lin
TI Effects of organic solvents on two retinal pigment epithelial lipofuscin
   fluorophores, A2E and all-trans-retinal dimer
SO JOURNAL OF ZHEJIANG UNIVERSITY-SCIENCE B
LA English
DT Article
DE N-retinylidene-N-retinyl-ethanolamine (A2E); All-trans-retinal dimer;
   Lipofuscin; Organic solvents; Retinal pigment epithelial
ID STARGARDT MACULAR DYSTROPHY; TRANSPORTER GENE; RPE LIPOFUSCIN; VISUAL
   CYCLE; MOUSE MODEL; CELLS; DISEASE; ABCR; DEGENERATION; THERAPY
AB Gene and drug therapies are being developed to alleviate vision loss in patients with Stargardt's disease and age-related macular degeneration (AMD). To evaluate the therapeutic effects of these treatments, organic solvents are routinely used to extract and quantify bisretinoid lipofuscin constituents, such as N-retinylidene-N-retinyl-ethanolamine (A2E) and all-trans-retinal dimer (ATR-dimer). By high-performance liquid chromatography (HPLC), we found that A2E and ATR-dimer were both altered by tetrahydrofuran (THF) and chloroform, but were stable in dimethyl sulfoxide (DMSO) or methanol (MeOH). In addition, cyclohexane and ethanol (EtOH) did not alter ATR-dimer, whereas an alteration of A2E occurred in EtOH. On the basis of these findings, we designed processes II-IV, generated by modifications of process I, a routine method to measure bisretinoid compounds in vivo. Extra amounts of either ATR-dimer or A2E in mouse eyecups were released by processes II-IV versus process I. Efforts to clarify the effects of organic solvents on lipofuscin pigments are important because such studies can guide the handling of these fluorophores in related experiments.
C1 [Jin, Qiu-xia; Wu, Ya-lin] Zhejiang Univ, Coll Pharmaceut Sci, Hangzhou 310058, Zhejiang, Peoples R China.
   [Dong, Xin-ran; Yao, Ke; Wu, Ya-lin] Zhejiang Univ, Sch Med, Ctr Eye, Affiliated Hosp 2, Hangzhou 310009, Zhejiang, Peoples R China.
   [Chen, Jing-meng] Zhejiang Univ City Coll, Sch Med, Hangzhou 310015, Zhejiang, Peoples R China.
C3 Zhejiang University; Zhejiang University; Zhejiang University City
   College
RP Wu, YL (通讯作者)，Zhejiang Univ, Coll Pharmaceut Sci, Hangzhou 310058, Zhejiang, Peoples R China.
EM yalinw@zju.edu.cn
RI Yao, Ke/AAM-6866-2021
OI Yao, Ke/0000-0002-6764-7365
FU National Natural Science Foundation of China [21202146, 81271018];
   Fundamental Research Funds for the Central Universities; Zhejiang
   Scientific Research Foundation for the Returned Overseas Chinese
   Scholars [J20120556]; Zhejiang Key Laboratory Fund of China [2011E10006]
FX Project supported by the National Natural Science Foundation of China
   (Nos. 21202146 and 81271018), the Fundamental Research Funds for the
   Central Universities, the Zhejiang Scientific Research Foundation for
   the Returned Overseas Chinese Scholars (No. J20120556), and the Zhejiang
   Key Laboratory Fund of China (No. 2011E10006)
CR Ahn J, 2000, J BIOL CHEM, V275, P20399, DOI 10.1074/jbc.M000555200
   Allikmets R, 1997, NAT GENET, V15, P236, DOI 10.1038/ng0397-236
   Allocca M, 2008, J CLIN INVEST, V118, P1955, DOI 10.1172/JCI34316
   Ben-Shabat S, 2002, J BIOL CHEM, V277, P7183, DOI 10.1074/jbc.M108981200
   Chrispell JD, 2009, J BIOL CHEM, V284, P21468, DOI 10.1074/jbc.M109.020966
   Fishkin NE, 2005, P NATL ACAD SCI USA, V102, P7091, DOI 10.1073/pnas.0501266102
   Holz FG, 1999, INVEST OPHTH VIS SCI, V40, P737
   Kim SR, 2007, P NATL ACAD SCI USA, V104, P19273, DOI 10.1073/pnas.0708714104
   Kong J, 2008, GENE THER, V15, P1311, DOI 10.1038/gt.2008.78
   Liu JH, 2000, J BIOL CHEM, V275, P29354, DOI 10.1074/jbc.M910191199
   Maeda A, 2007, P NATL ACAD SCI USA, V104, P19565, DOI 10.1073/pnas.0707477104
   Maiti P, 2006, BIOCHEMISTRY-US, V45, P852, DOI 10.1021/bi0518545
   Parish CA, 1998, P NATL ACAD SCI USA, V95, P14609, DOI 10.1073/pnas.95.25.14609
   Radu RA, 2005, INVEST OPHTH VIS SCI, V46, P4393, DOI 10.1167/iovs.05-0820
   Radu RA, 2003, P NATL ACAD SCI USA, V100, P4742, DOI 10.1073/pnas.0737855100
   Shroyer NF, 1999, VISION RES, V39, P2537, DOI 10.1016/S0042-6989(99)00037-1
   Sieving PA, 2001, P NATL ACAD SCI USA, V98, P1835, DOI 10.1073/pnas.041606498
   Sparrow JR, 2008, ADV EXP MED BIOL, V613, P393, DOI 10.1007/978-0-387-74904-4_46
   Sparrow JR, 1999, INVEST OPHTH VIS SCI, V40, P2988
   Sparrow JR, 2005, EXP EYE RES, V80, P595, DOI 10.1016/j.exer.2005.01.007
   Sparrow JR, 2003, J BIOL CHEM, V278, P18207, DOI 10.1074/jbc.M300457200
   Sparrow JR, 2000, INVEST OPHTH VIS SCI, V41, P1981
   Sun H, 1999, J BIOL CHEM, V274, P8269, DOI 10.1074/jbc.274.12.8269
   Suter M, 2000, J BIOL CHEM, V275, P39625, DOI 10.1074/jbc.M007049200
   Vasireddy V, 2009, EXP EYE RES, V89, P905, DOI 10.1016/j.exer.2009.07.021
   Weng J, 1999, CELL, V98, P13, DOI 10.1016/S0092-8674(00)80602-9
   Wielgus AR, 2010, PHOTOCHEM PHOTOBIOL, V86, P781, DOI 10.1111/j.1751-1097.2010.00750.x
   Wu L, 2010, ADV EXP MED BIOL, V664, P533, DOI 10.1007/978-1-4419-1399-9_61
   Wu YL, 2013, J ZHEJIANG UNIV-SC B, V14, P763, DOI 10.1631/jzus.B1300051
   Yamamoto K, 2011, INVEST OPHTH VIS SCI, V52, P9084, DOI 10.1167/iovs.11-8632
NR 30
TC 0
Z9 0
U1 0
U2 8
PU ZHEJIANG UNIV
PI HANGZHOU
PA EDITORIAL BOARD, 20 YUGU RD, HANGZHOU, 310027, PEOPLES R CHINA
SN 1673-1581
EI 1862-1783
J9 J ZHEJIANG UNIV-SC B
JI J. Zhejiang Univ.-SCI. B
PD JUL
PY 2014
VL 15
IS 7
BP 661
EP 669
DI 10.1631/jzus.B1300194
PG 9
WC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Research & Experimental Medicine
GA AL5EG
UT WOS:000339155700006
PM 25001225
OA Bronze, Green Published
DA 2022-11-30
ER

PT J
AU Todorich, B
   Yiu, G
   Hahn, P
AF Todorich, Bozho
   Yiu, Glenn
   Hahn, Paul
TI Current and investigational pharmacotherapeutic approaches for
   modulating retinal angiogenesis
SO EXPERT REVIEW OF CLINICAL PHARMACOLOGY
LA English
DT Review
DE aflibercept; age-related macular degeneration; bevacizumab; choroidal
   neovascularization; diabetic retinopathy; ranizbizumab; retinal
   neovascularization
ID ENDOTHELIAL GROWTH-FACTOR; INTRAVITREAL BEVACIZUMAB AVASTIN; OPTICAL
   COHERENCE TOMOGRAPHY; EXPERIMENTAL CHOROIDAL NEOVASCULARIZATION;
   VERTEPORFIN PLUS RANIBIZUMAB; LEBER CONGENITAL AMAUROSIS; RECEPTOR
   TYROSINE KINASE; DIABETIC MACULAR EDEMA; ANKYRIN REPEAT PROTEIN;
   ANTI-VEGF ANTIBODY
AB Retinal vascular development is a carefully orchestrated developmental process during which retinal and choroidal vasculature form to provide a dual vascular supply to the neurosensory retina and retinal pigment epithelium. The most common causes of vision loss in children and adults involve at least in part perturbation of the normal vascular physiology or development. Vascular endothelial growth factor has emerged as a key molecular regulator of retinal vascular development as well as retinal and choroidal neovascularization, which underlie the pathophysiology of many retinal diseases. Over the past decade, the advent of injectable pharmacotherapeutic agents into the vitreous cavity of the eye has revolutionized our management of neovascular age-related macular degeneration and other retinal diseases and has, for the first time, offered an opportunity to improve vision rather than just slow the progression of disease processes. The transient duration of these agents, however, requires chronic treatment with repeated intraocular injections and significant treatment burden for patients and the healthcare system. Novel treatments modulating retinal angiogenesis offer the promise of improved efficacy, decreased treatment burden and improved cost-effectiveness.
C1 [Todorich, Bozho; Yiu, Glenn; Hahn, Paul] Duke Univ, Ctr Eye, Durham, NC 27710 USA.
C3 Duke University
RP Hahn, P (通讯作者)，Duke Univ, Ctr Eye, Erwin Rd,DUMC 3802, Durham, NC 27710 USA.
EM paul.s.hahn@duke.edu
RI Yiu, Glenn/AAF-2858-2020
OI Yiu, Glenn/0000-0003-3061-3310
CR Abraham P, 2010, AM J OPHTHALMOL, V150, P315, DOI 10.1016/j.ajo.2010.04.011
   ADAMIS AP, 1994, AM J OPHTHALMOL, V118, P445, DOI 10.1016/S0002-9394(14)75794-0
   Adamis AP, 1996, ARCH OPHTHALMOL-CHIC, V114, P66, DOI 10.1001/archopht.1996.01100130062010
   Aggio FB, 2007, GRAEF ARCH CLIN EXP, V245, P215, DOI 10.1007/s00417-006-0412-5
   Aging. USSSCo, 2011, STAT J BLUM DEP ADM
   Aguilar E, 2008, METHOD ENZYMOL, V444, P115, DOI 10.1016/S0076-6879(08)02806-1
   AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203
   [Anonymous], 1999, Arch Ophthalmol, V117, P1329
   [Anonymous], 2014, REDUCED FLUENCE VISU
   ANSEM RPJ, 1987, DOC OPHTHALMOL, V67, P19, DOI 10.1007/BF00142693
   Antoszyk AN, 2008, AM J OPHTHALMOL, V145, P862, DOI 10.1016/j.ajo.2007.12.029
   ARCHER D B, 1991, Eye (London), V5, P239
   Arevalo JF, 2008, BRIT J OPHTHALMOL, V92, P213, DOI 10.1136/bjo.2007.127142
   Arevalo JF, 2008, RETINA-J RET VIT DIS, V28, P1387, DOI 10.1097/IAE.0b013e3181884ff4
   Arnold J, 2001, OPHTHALMOLOGY, V108, P841
   Avery RL, 2006, OPHTHALMOLOGY, V113, P1695, DOI 10.1016/j.ophtha.2006.05.064
   Avery RL, 2006, RETINA-J RET VIT DIS, V26, P352, DOI 10.1097/00006982-200603000-00016
   Awh CC, 2013, AM AC OPHTH ANN M 16
   Bakall B, 2013, AM J OPHTHALMOL, V156, P15, DOI 10.1016/j.ajo.2013.02.017
   Bakri SJ, 2006, EYE, V20, P1474, DOI 10.1038/sj.eye.6702364
   Barakat MR, 2009, EXPERT OPIN INV DRUG, V18, P637, DOI [10.1517/13543780902855316 , 10.1517/13543780902855316]
   Bashshur ZF, 2006, AM J OPHTHALMOL, V142, P1, DOI 10.1016/j.ajo.2006.02.037
   Benjamin LE, 1998, DEVELOPMENT, V125, P1591
   Bergers G, 2003, J CLIN INVEST, V111, P1287, DOI 10.1172/JCI200317929
   Binz HK, 2004, NAT BIOTECHNOL, V22, P575, DOI 10.1038/nbt962
   Binz HK, 2003, J MOL BIOL, V332, P489, DOI 10.1016/S0022-2836(03)00896-9
   Blaauwgeers HGT, 1999, AM J PATHOL, V155, P421, DOI 10.1016/S0002-9440(10)65138-3
   Boyer DS, 2009, OPHTHALMOLOGY, V116, P1731, DOI 10.1016/j.ophtha.2009.05.024
   Boyer DS, 2009, INVEST OPHTH VIS SCI, V50, P1260
   Breier G, 1997, THROMB HAEMOSTASIS, V78, P678
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Campochiaro PA, 2000, J CELL PHYSIOL, V184, P301, DOI 10.1002/1097-4652(200009)184:3<301::AID-JCP3>3.0.CO;2-H
   Campochiaro PA, 2013, AM J OPHTHALMOL, V155, P697, DOI 10.1016/j.ajo.2012.09.032
   Carmeliet P, 2000, NAT MED, V6, P389, DOI 10.1038/74651
   Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0
   CHAKRAVARTHY U, 1989, CURR EYE RES, V8, P337, DOI 10.3109/02713688908996381
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Chen E, 2006, RETINA-J RET VIT DIS, V26, P699, DOI 10.1097/01.iae.0000225351.87205.69
   Chen Y, 1999, J MOL BIOL, V293, P865, DOI 10.1006/jmbi.1999.3192
   Cideciyan AV, 2009, HUM GENE THER, V20, P999, DOI 10.1089/hum.2009.086
   Ciulla TA, 2001, CURR OPIN OPHTHALMOL, V12, P442, DOI 10.1097/00055735-200112000-00009
   Clarkson JC, 1997, ARCH OPHTHALMOL-CHIC, V115, P486
   D'Amico DJ., 2005, INVEST OPHTH VIS SCI, V46
   DASTGHEIB K, 1994, ARCH OPHTHALMOL-CHIC, V112, P813, DOI 10.1001/archopht.1994.01090180111045
   David B, 2013, AM AC OPHTH ANN M NE
   Davidorf FH, 2006, RETINA-J RET VIT DIS, V26, P354, DOI 10.1097/00006982-200603000-00017
   Delyfer MN, 2004, ACTA OPHTHALMOL SCAN, V82, P236, DOI 10.1111/j.1600-0420.2004.00231.x
   DOBI ET, 1989, ARCH OPHTHALMOL-CHIC, V107, P264, DOI 10.1001/archopht.1989.01070010270035
   Dorrell M.I., 2007, RETINAL VASCULAR DIS, P24
   Duda DG, 2007, TRENDS MOL MED, V13, P223, DOI 10.1016/j.molmed.2007.04.001
   Dugel PU, 2013, OPHTHALMOLOGY, V120, P317, DOI 10.1016/j.ophtha.2012.07.068
   Dugel PU, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.01.014
   DUMONT DJ, 1994, GENE DEV, V8, P1897, DOI 10.1101/gad.8.16.1897
   Erber R, 2003, FASEB J, V17, P338, DOI 10.1096/fj.03-0271fje
   Eyetech Pharmaceuticals Inc; Pfizer Inc, 2004, PEG SOD INJ TREATM N
   Ferrara N, 2004, NAT REV DRUG DISCOV, V3, P391, DOI 10.1038/nrd1381
   Forsythe JA, 1996, MOL CELL BIOL, V16, P4604
   FRANK RN, 1989, CURR EYE RES, V8, P239, DOI 10.3109/02713688908997565
   Friberg TR, 2014, VEGF INHIBITION STUD
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Gariano RF, 2005, NATURE, V438, P960, DOI 10.1038/nature04482
   Gariano RF, 2003, PROG RETIN EYE RES, V22, P295, DOI 10.1016/S1350-9462(02)00062-9
   Gaudreault J, 2005, INVEST OPHTH VIS SCI, V46, P726, DOI 10.1167/iovs.04-0601
   Gerber HP, 1997, J BIOL CHEM, V272, P23659, DOI 10.1074/jbc.272.38.23659
   GlaxoSmithKline, 2013, SAF STUD EV PAZ EYE
   Gokce G, 2013, POSTGRAD MED, V125, P51, DOI 10.3810/pgm.2013.09.2699
   GOLDBERG MF, 1977, T AM ACAD OPHTHALMOL, V83, P409
   Goldberg RA, 2012, AM J OPHTHALMOL, V153, P204, DOI 10.1016/j.ajo.2011.11.035
   Gonzalez S, 2012, AM J OPHTHALMOL, V153, P196, DOI 10.1016/j.ajo.2011.11.023
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   GREEN LS, 1995, CHEM BIOL, V2, P683, DOI 10.1016/1074-5521(95)90032-2
   GREEN WR, 1993, OPHTHALMOLOGY, V100, P1519
   GYLLENSTEN L J, 1954, Acta Paediatr Suppl, V43, P131, DOI 10.1111/j.1651-2227.1954.tb15463.x
   Hall AP, 2006, TOXICOL PATHOL, V34, P763, DOI 10.1080/01926230600936290
   Hanahan D, 1997, SCIENCE, V277, P48, DOI 10.1126/science.277.5322.48
   Hauswirth WW, 2008, HUM GENE THER, V19, P979, DOI 10.1089/hum.2008.107
   HAWKINS BS, 1990, ARCH OPHTHALMOL-CHIC, V108, P832
   HAWKINS BS, 1991, ARCH OPHTHALMOL-CHIC, V109, P1109
   HAYREH SS, 1982, ARCH OPHTHALMOL-CHIC, V100, P1585, DOI 10.1001/archopht.1982.01030040563002
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Holz FG, 2011, OPHTHALMOLOGY, V118, P663, DOI 10.1016/j.ophtha.2010.12.019
   Honda S, 2008, GRAEF ARCH CLIN EXP, V246, P1061, DOI 10.1007/s00417-008-0786-7
   Hospital UU, 2013, LUC COMP AV STUD RAN
   Hudson PJ, 2003, NAT MED, V9, P129, DOI 10.1038/nm0103-129
   Ishikawa K, 2009, EYE, V23, P108, DOI 10.1038/sj.eye.6702983
   Iturralde D, 2006, RETINA-J RET VIT DIS, V26, P279, DOI 10.1097/00006982-200603000-00005
   Jackson TL, 2013, OPHTHALMOLOGY, V120, P1597, DOI 10.1016/j.ophtha.2013.01.074
   Jackson TL, 2003, INVEST OPHTH VIS SCI, V44, P2141, DOI 10.1167/iovs.02-1027
   Jager RD, 2004, RETINA-J RET VIT DIS, V24, P676, DOI 10.1097/00006982-200410000-00002
   JANZER RC, 1987, NATURE, V325, P253, DOI 10.1038/325253a0
   JIANG B, 1995, GLIA, V15, P1, DOI 10.1002/glia.440150102
   Jumper JM, 2012, ASRS PREF TRENDS PAT
   Kaiser PK, 2006, AM J OPHTHALMOL, V142, P660, DOI 10.1016/j.ajo.2006.05.061
   Kaiser PK, 2012, OPHTHALMOLOGY, V119, P1001, DOI 10.1016/j.ophtha.2012.02.003
   Katsura Y, 2005, DIABETES CARE, V28, P2252, DOI 10.2337/diacare.28.9.2252
   KAUFMAN SC, 1989, INVEST OPHTH VIS SCI, V30, P23
   Keane PA, 2008, INVEST OPHTH VIS SCI, V49, P3115, DOI 10.1167/iovs.08-1689
   KILLINGSWORTH MC, 1990, EYE, V4, P613, DOI 10.1038/eye.1990.86
   Kodjikian L, 2013, OPHTHALMOLOGY, V120, P2300, DOI 10.1016/j.ophtha.2013.06.020
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Konner Jason, 2004, Clin Colorectal Cancer, V4 Suppl 2, pS81
   KRISHNAN L, 1988, INT J RADIAT ONCOL, V15, P147, DOI 10.1016/0360-3016(88)90359-8
   Krzystolik MG, 2002, ARCH OPHTHALMOL-CHIC, V120, P338
   Kychenthal Andres, 2010, Retina, V30, pS32, DOI 10.1097/IAE.0b013e3181ca146b
   Lalwani GA, 2008, RETINA-J RET VIT DIS, V28, pS13, DOI 10.1097/IAE.0b013e3181644ad2
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Larsen M, 2012, OPHTHALMOLOGY, V119, P992, DOI 10.1016/j.ophtha.2012.02.002
   Lee J, 2001, BRIT J OPHTHALMOL, V85, P1309, DOI 10.1136/bjo.85.11.1309
   Lee JY, 2010, GRAEF ARCH CLIN EXP, V248, P1257, DOI 10.1007/s00417-010-1375-0
   Lucena DD, 2009, BRIT J OPHTHALMOL, V93, P688, DOI 10.1136/bjo.2008.151233
   Lukason M, 2011, MOL THER, V19, P260, DOI 10.1038/mt.2010.230
   Luna J, 1996, LAB INVEST, V75, P563
   Madan A, 2003, FRONT BIOSCI-LANDMRK, V8, pD1030, DOI 10.2741/1056
   Magdelaine-Beuzelin C, 2010, MABS-AUSTIN, V2, P176, DOI 10.4161/mabs.2.2.11205
   Maguire AM, 2008, NEW ENGL J MED, V358, P2240, DOI 10.1056/NEJMoa0802315
   Maisonpierre PC, 1997, SCIENCE, V277, P55, DOI 10.1126/science.277.5322.55
   Maloney SC, 2009, RETINA-J RET VIT DIS, V29, P176, DOI 10.1097/IAE.0b013e3181884fa6
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Mason JO, 2006, AM J OPHTHALMOL, V142, P685, DOI 10.1016/j.ajo.2006.04.058
   McLaughlin MM, 2013, JAMA OPHTHALMOL, V131, P1595, DOI 10.1001/jamaophthalmol.2013.5002
   Michels S, 2005, OPHTHALMOLOGY, V112, P1035, DOI 10.1016/j.ophtha.2005.02.007
   Micieli JA, 2009, AM J OPHTHALMOL, V148, P536, DOI 10.1016/j.ajo.2009.05.031
   Mimoun G, 2013, RETINA-J RET VIT DIS, V33, P513, DOI 10.1097/IAE.0b013e3182753adb
   Mintz-Hittner HA, 2008, RETINA-J RET VIT DIS, V28, P831, DOI 10.1097/IAE.0b013e318177f934
   Mintz-Hittner HA, 2011, NEW ENGL J MED, V364, P603, DOI 10.1056/NEJMoa1007374
   Mousa SA, 1999, J CELL BIOCHEM, V74, P135, DOI 10.1002/(SICI)1097-4644(19990701)74:1<135::AID-JCB15>3.0.CO;2-#
   Myers AL, 2010, J PEDIATR SURG, V45, P1080, DOI 10.1016/j.jpedsurg.2010.02.068
   Nakagawa S, 2013, RETINA-J RET VIT DIS, V33, P825, DOI 10.1097/IAE.0b013e31826b0bbe
   Neelam K, 2012, PROG RETIN EYE RES, V31, P495, DOI 10.1016/j.preteyeres.2012.04.001
   Ng EWM, 2006, ANN NY ACAD SCI, V1082, P151, DOI 10.1196/annals.1348.062
   Ng EWM, 2006, NAT REV DRUG DISCOV, V5, P123, DOI 10.1038/nrd1955
   Nieder C, 2006, CANCER TREAT REV, V32, P348, DOI 10.1016/j.ctrv.2006.03.006
   Novartis NCI, 2013, SAF EFF OR PTK787 PA
   Okamoto N, 1997, AM J PATHOL, V151, P281
   Olofsson B, 1998, P NATL ACAD SCI USA, V95, P11709, DOI 10.1073/pnas.95.20.11709
   Ozaki H, 1997, EXP EYE RES, V64, P505, DOI 10.1006/exer.1996.0239
   Papadopoulos N, 2012, ANGIOGENESIS, V15, P171, DOI 10.1007/s10456-011-9249-6
   Patan S, 2000, J NEURO-ONCOL, V50, P1, DOI 10.1023/A:1006493130855
   Pechan P, 2009, GENE THER, V16, P10, DOI 10.1038/gt.2008.115
   PEER J, 1995, LAB INVEST, V72, P638
   Peters S, 2008, BRIT J OPHTHALMOL, V92, P541, DOI 10.1136/bjo.2007.133496
   PIERCE EA, 1995, P NATL ACAD SCI USA, V92, P905, DOI 10.1073/pnas.92.3.905
   Punglia RS, 1997, DIABETES, V46, P1619, DOI 10.2337/diabetes.46.10.1619
   PURI MC, 1995, EMBO J, V14, P5884, DOI 10.1002/j.1460-2075.1995.tb00276.x
   Rahimi N, 2006, FRONT BIOSCI-LANDMRK, V11, P818
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rezaei KA, 2011, INVEST OPHTH VIS SCI, V52, P701, DOI 10.1167/iovs.10-6319
   Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0
   Robinson GS, 1996, P NATL ACAD SCI USA, V93, P4851, DOI 10.1073/pnas.93.10.4851
   ROSENBERG N, 1986, ARCH OPHTHALMOL-CHIC, V104, P34
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2005, OPHTHALMOLOGY, V112, P1048, DOI 10.1016/j.ophtha.2005.01.043
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
   Ross RD, 1998, AM J OPHTHALMOL, V125, P71, DOI 10.1016/S0002-9394(99)80237-2
   Ruckman J, 1998, J BIOL CHEM, V273, P20556, DOI 10.1074/jbc.273.32.20556
   Rudkin AK, 2010, EUR J OPHTHALMOL, V20, P1042, DOI 10.1177/112067211002000603
   Russo A, 2013, MEDIAT INFLAMM, V2013, DOI 10.1155/2013/476525
   RYAN SJ, 1982, ARCH OPHTHALMOL-CHIC, V100, P1804, DOI 10.1001/archopht.1982.01030040784015
   Saint-Geniez M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003554
   Saito Y, 2010, AM J OPHTHALMOL, V149, P964, DOI 10.1016/j.ajo.2010.01.008
   Sandercoe TM, 1999, EXP EYE RES, V69, P511, DOI 10.1006/exer.1999.0730
   Sandner P, 1997, KIDNEY INT, V51, P448, DOI 10.1038/ki.1997.60
   Saric B, 2014, EUR J OPHTHALMOL, V24, P221, DOI 10.5301/ejo.5000358
   Sawada O, 2007, ARCH OPHTHALMOL-CHIC, V125, P1363, DOI 10.1001/archopht.125.10.1363
   Schaal S, 2008, OPHTHALMOLOGY, V115, P2199, DOI 10.1016/j.ophtha.2008.07.007
   Schoenberger SD, 2013, INT J INFLAMM, V2013, DOI 10.1155/2013/281981
   Sepp T, 2006, INVEST OPHTH VIS SCI, V47, P536, DOI 10.1167/iovs.05-1143
   Simo R, 2006, CURR DIABETES REV, V2, P71, DOI 10.2174/157339906775473671
   Singer MA, 2012, OPHTHALMOLOGY, V119, P1175, DOI 10.1016/j.ophtha.2011.12.016
   Smith LEH, 2004, GROWTH HORM IGF RES, V14, pS140, DOI 10.1016/j.ghir.2004.03.030
   Sondell M, 1999, BRAIN RES, V846, P219, DOI 10.1016/S0006-8993(99)02056-9
   Sondell M, 1999, J NEUROSCI, V19, P5731, DOI 10.1523/JNEUROSCI.19-14-05731.1999
   Sonpavde G, 2008, EXPERT OPIN INV DRUG, V17, P253, DOI 10.1517/13543784.17.2.253
   Spaide RF, 2002, RETINA-J RET VIT DIS, V22, P545, DOI 10.1097/00006982-200210000-00003
   Spaide RF, 2002, AM J OPHTHALMOL, V134, P62, DOI 10.1016/S0002-9394(02)01452-6
   Spaide RF, 2006, RETINA-J RET VIT DIS, V26, P275, DOI 10.1097/00006982-200603000-00004
   Stacker SA, 2001, NAT MED, V7, P186, DOI 10.1038/84635
   Stahl A, 2013, ANGIOGENESIS, V16, P101, DOI 10.1007/s10456-012-9302-0
   Stahl A, 2010, INVEST OPHTH VIS SCI, V51, P2813, DOI 10.1167/iovs.10-5176
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1242
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1220
   Stewart MW, 2012, CLIN OPHTHALMOL, V6, P1175, DOI 10.2147/OPTH.S33372
   STONE J, 1995, J NEUROSCI, V15, P4738, DOI 10.1523/jneurosci.15-07-04738.1995
   Terelak-Borys B, 2012, MED SCI MONITOR, V18, pRA138, DOI 10.12659/MSM.883260
   The Diabetic Retinopathy Study Research Group, 1987, INT OPHTHALMOL CLIN, V27, P239, DOI DOI 10.1097/00004397-198702740-00004
   Tolentino MJ, 1996, ARCH OPHTHALMOL-CHIC, V114, P964, DOI 10.1001/archopht.1996.01100140172010
   Tolentino MJ, 1996, OPHTHALMOLOGY, V103, P1820, DOI 10.1016/S0161-6420(96)30420-X
   Tripathi RC, 1998, OPHTHALMOLOGY, V105, P232, DOI 10.1016/S0161-6420(98)92782-8
   Vavilala DT, 2013, BIOCHEM BIOPH RES CO, V438, P697, DOI 10.1016/j.bbrc.2013.07.118
   Wakabayashi T, 2008, OPHTHALMOLOGY, V115, P1571, DOI 10.1016/j.ophtha.2008.02.026
   Wells JA, 1996, BRIT J OPHTHALMOL, V80, P363, DOI 10.1136/bjo.80.4.363
   Willett CG, 2007, ONCOLOGY-NY, V21, P1055
   Willett CG, 2006, SEMIN ONCOL, V33, pS35, DOI 10.1053/j.seminoncol.2006.08.007
   Yanni SE, 2009, INVEST OPHTH VIS SCI, V50, P5479, DOI 10.1167/iovs.09-3652
   Yoshida T, 2010, FASEB J, V24, P1759, DOI 10.1096/fj.09-145664
   Zou LH, 2011, THERANOSTICS, V1, P395, DOI 10.7150/thno/v01p0395
NR 197
TC 19
Z9 19
U1 0
U2 3
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1751-2433
EI 1751-2441
J9 EXPERT REV CLIN PHAR
JI Expert Rev. Clin. Pharmacol.
PD MAY
PY 2014
VL 7
IS 3
BP 375
EP 391
DI 10.1586/17512433.2014.890047
PG 17
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA CB9YE
UT WOS:000349989700014
PM 24580084
DA 2022-11-30
ER

PT J
AU Heinen, S
   Hartmann, A
   Lauer, N
   Wiehl, U
   Dahse, HM
   Schirmer, S
   Gropp, K
   Enghardt, T
   Wallich, R
   Halbich, S
   Mihlan, M
   Schlotzer-Schrehardt, U
   Zipfel, PF
   Skerka, C
AF Heinen, Stefan
   Hartmann, Andrea
   Lauer, Nadine
   Wiehl, Ulrike
   Dahse, Hans-Martin
   Schirmer, Sylvia
   Gropp, Katharina
   Enghardt, Tina
   Wallich, Reinhard
   Haelbich, Steffi
   Mihlan, Michael
   Schloetzer-Schrehardt, Ursula
   Zipfel, Peter F.
   Skerka, Christine
TI Factor H-related protein 1 (CFHR-1) inhibits complement C5 convertase
   activity and terminal complex formation
SO BLOOD
LA English
DT Article
ID HEMOLYTIC-UREMIC SYNDROME; DENSE DEPOSIT DISEASE; MACULAR DEGENERATION;
   ALTERNATIVE PATHWAY; RECOGNITION FUNCTIONS; MOLECULAR-CLONING;
   BINDING-PROTEIN; 2 PARTS; SURFACE; AUTOANTIBODIES
AB Homozygous deletion of a 84-kb genomic fragment in human chromosome 1 that encompasses the CFHR1 and CFHR3 genes represents a risk factor for hemolytic uremic syndrome (HUS) but has a protective effect in age-related macular degeneration (AMD). Here we identify CFHR1 as a novel inhibitor of the complement pathway that blocks C5 convertase activity and interferes with C5b surface deposition and MAC formation. This activity is distinct from complement factor H, and apparently factor H and CFHR1 control complement activation in a sequential manner. As both proteins bind to the same or similar sites at the cellular surfaces, the gain of CFHR1 activity presumably is at the expense of CFH-mediated function (inhibition of the C3 convertase). In HUS, the absence of CFHR1 may result in reduced inhibition of terminal complex formation and in reduced protection of endothelial cells upon complement attack. These findings provide new insights into complement regulation on the cell surface and biosurfaces and likely define the role of CFHR1 in human diseases. (Blood. 2009; 114: 2439-2447)
C1 [Heinen, Stefan; Hartmann, Andrea; Lauer, Nadine; Wiehl, Ulrike; Dahse, Hans-Martin; Schirmer, Sylvia; Gropp, Katharina; Enghardt, Tina; Haelbich, Steffi; Mihlan, Michael; Zipfel, Peter F.; Skerka, Christine] Hans Knoell Inst, Dept Infect Biol, Leibniz Inst Nat Prod Res & Infect Biol, D-07745 Jena, Germany.
   [Wallich, Reinhard] Heidelberg Univ, Inst Immunol, D-6900 Heidelberg, Germany.
   [Schloetzer-Schrehardt, Ursula] Univ Erlangen Nurnberg, Dept Ophthalmol, D-8520 Erlangen, Germany.
   [Zipfel, Peter F.] Univ Jena, Jena, Germany.
C3 Hans Knoll Institute (HKI); Ruprecht Karls University Heidelberg;
   University of Erlangen Nuremberg; Friedrich Schiller University of Jena
RP Skerka, C (通讯作者)，Hans Knoell Inst, Dept Infect Biol, Leibniz Inst Nat Prod Res & Infect Biol, Beutenbergstr 11, D-07745 Jena, Germany.
EM christine.skerka@hki-jena.de
OI Heinen, Stefan/0000-0001-5800-6593; Mihlan, Michael/0000-0002-3946-6583
FU German Research Foundation (DFG, Bonn, Germany) [Sk/2-1, Zi 432]; Pro
   Retina (Aachen, Germany)
FX We especially acknowledge the patients and their family members for
   participating in this study. We thank Wolfgang Schmidt-Heck (Leibniz
   Institute for Natural Product Research and Infection Biology) for the
   statistical analysis of data.; The work of the authors is supported by
   the German Research Foundation (DFG, Bonn, Germany; Sk/2-1, Zi 432) and
   Pro Retina (Aachen, Germany).
CR Appel GB, 2005, J AM SOC NEPHROL, V16, P1392, DOI 10.1681/ASN.2005010078
   Atkinson JP, 2007, J EXP MED, V204, P1245, DOI 10.1084/jem.20070664
   Behnsen J, 2008, INFECT IMMUN, V76, P820, DOI 10.1128/IAI.01037-07
   de Cordoba SR, 2008, CLIN EXP IMMUNOL, V151, P1, DOI 10.1111/j.1365-2249.2007.03574.x
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   Guo RF, 2005, ANNU REV IMMUNOL, V23, P821, DOI 10.1146/annurev.immunol.23.021704.115835
   Haas PJ, 2007, IMMUNOL RES, V37, P161, DOI 10.1007/BF02697367
   Heinen S, 2007, J AM SOC NEPHROL, V18, P506, DOI 10.1681/ASN.2006091069
   Heinen Stefan, 2006, Hum Mutat, V27, P292, DOI 10.1002/humu.9408
   Hughes AE, 2006, NAT GENET, V38, P1173, DOI 10.1038/ng1890
   Janeway CA, 2002, ANNU REV IMMUNOL, V20, P197, DOI 10.1146/annurev.immunol.20.083001.084359
   JENNE DE, 1992, TRENDS BIOCHEM SCI, V17, P154, DOI 10.1016/0968-0004(92)90325-4
   Jozsi M, 2008, BLOOD, V111, P1512, DOI 10.1182/blood-2007-09-109876
   Jozsi M, 2007, BLOOD, V110, P1516, DOI 10.1182/blood-2007-02-071472
   Jozsi M, 2006, J AM SOC NEPHROL, V17, P170, DOI 10.1681/ASN.2005080868
   Kunert A, 2007, J IMMUNOL, V179, P2979, DOI 10.4049/jimmunol.179.5.2979
   LEHMANN EL, 1975, NONPARAMETRICS STAT, P233
   Male DA, 2000, MOL IMMUNOL, V37, P41, DOI 10.1016/S0161-5890(00)00024-9
   Manuelian T, 2003, J CLIN INVEST, V111, P1181, DOI 10.1172/JCI200316651
   Morgan B. P., 1999, COMPLEMENT REGULATOR
   Oppermann M, 2006, CLIN EXP IMMUNOL, V144, P342, DOI 10.1111/j.1365-2249.2006.03071.x
   Pangburn MK, 2002, J IMMUNOL, V169, P4702, DOI 10.4049/jimmunol.169.9.4702
   Park CT, 1996, J BIOL CHEM, V271, P18054, DOI 10.1074/jbc.271.30.18054
   PODACK ER, 1984, ACTA PATH MICRO IM C, V92, P89
   Poltermann S, 2007, J BIOL CHEM, V282, P37537, DOI 10.1074/jbc.M707280200
   Rawal N, 1998, J BIOL CHEM, V273, P16828, DOI 10.1074/jbc.273.27.16828
   Rawal N, 2001, J IMMUNOL, V166, P2635, DOI 10.4049/jimmunol.166.4.2635
   Saunders RE, 2007, HUM MUTAT, V28, P222, DOI 10.1002/humu.20435
   SCHWAEBLE W, 1991, IMMUNOBIOLOGY, V182, P307, DOI 10.1016/S0171-2985(11)80665-0
   Sethi S, 2009, KIDNEY INT, V75, P952, DOI 10.1038/ki.2008.657
   SKERKA C, 1991, J BIOL CHEM, V266, P12015
   Skerka C, 2008, VACCINE, V26, pI9, DOI 10.1016/j.vaccine.2008.11.021
   Skerka C, 2007, MOL IMMUNOL, V44, P3398, DOI 10.1016/j.molimm.2007.02.012
   Stahl AL, 2008, BLOOD, V111, P5307, DOI 10.1182/blood-2007-08-106153
   TIMMANN C, 1991, J IMMUNOL, V146, P1265
   Walport MJ, 2001, NEW ENGL J MED, V344, P1058, DOI 10.1056/NEJM200104053441406
   Walport MJ, 2001, NEW ENGL J MED, V344, P1140, DOI 10.1056/NEJM200104123441506
   Zipfel PF, 2007, PLOS GENET, V3, P387, DOI 10.1371/journal.pgen.0030041
   Zipfel PF, 2006, MOL IMMUNOL, V43, P97, DOI 10.1016/j.molimm.2005.06.015
NR 39
TC 208
Z9 220
U1 0
U2 6
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD SEP 17
PY 2009
VL 114
IS 12
BP 2439
EP 2447
DI 10.1182/blood-2009-02-205641
PG 9
WC Hematology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Hematology
GA 495WD
UT WOS:000269925000012
PM 19528535
DA 2022-11-30
ER

PT J
AU Rovner, BW
AF Rovner, Barry W.
TI The Charles Bonnet syndrome: a review of recent research
SO CURRENT OPINION IN OPHTHALMOLOGY
LA English
DT Article
DE Charles Bonnet syndrome; vision loss; visual hallucinations
ID COMPLEX VISUAL HALLUCINATIONS
AB Purpose of review
   The Charles Bonnet syndrome is a disorder of visual hallucinations typically occurring in older persons with vision impairment or deafferentation of the visual cortex. This review cites recent studies on Charles Bonnet syndrome and discusses treatment options. The numbers of affected persons will increase with aging of the population, making recognition and treatment important components of ophthalmologic care.
   Recent findings
   The etiology of the Charles Bonnet syndrome is varied; most often it involves direct damage to the visual system (e.g. age-related macular degeneration, glaucoma) but it may also result from cerebral pathology interrupting connections between the eye and the occipital cortex. Case reports of different management approaches demonstrate the range of treatment options.
   Summary
   This review suggests that the Charles Bonnet syndrome will affect an increasingly large number of older persons as the population ages and the occurrence of vision and cerebral disorders. Clinical trials of antipsychotic and other medications, as well as low-vision rehabilitation, are necessary to establish valid treatments for this disorder.
C1 Thomas Jefferson Univ, Jefferson Med Coll, Philadelphia, PA 19107 USA.
C3 Jefferson University
RP Rovner, BW (通讯作者)，Jefferson Hosp Neurosci, Dept Neurol & Psychiat, 900 Walnut St,Room 405-1, Philadelphia, PA 19107 USA.
EM barry.rovner@jefferson.edu
CR Alao AO, 2003, INT J PSYCHIAT MED, V33, P195, DOI 10.2190/0NUQ-Y5Q9-TA6H-RJHH
   Choi EJ, 2005, ARCH NEUROL-CHICAGO, V62, P481, DOI 10.1001/archneur.62.3.481
   Cohen SY, 2003, BRIT J OPHTHALMOL, V87, P977, DOI 10.1136/bjo.87.8.977
   Eperjesi Frank, 2004, Clin Exp Optom, V87, P149
   Freiman TM, 2004, J NEUROSURG, V101, P846, DOI 10.3171/jns.2004.101.5.0846
   Menon GJ, 2005, ARCH OPHTHALMOL-CHIC, V123, P349, DOI 10.1001/archopht.123.3.349
   Menon GJ, 2003, SURV OPHTHALMOL, V48, P58, DOI 10.1016/S0039-6257(02)00414-9
   Moja MC, 2005, NEUROL SCI, V26, P168, DOI 10.1007/s10072-005-0455-0
   Plesnicar BK, 2004, WIEN KLIN WOCHENSCHR, V116, P75
   Pliskin NH, 1996, J AM GERIATR SOC, V44, P1055, DOI 10.1111/j.1532-5415.1996.tb02937.x
   RABINS PV, 1994, INT J GERIATR PSYCH, V9, P775, DOI 10.1002/gps.930091002
   Razavi M, 2004, J NEUROPSYCH CLIN N, V16, P505, DOI 10.1176/appi.neuropsych.16.4.505
   Tan CSH, 2004, BRIT J OPHTHALMOL, V88, P1325, DOI 10.1136/bjo.2004.041947
   Teunisse RJ, 1996, LANCET, V347, P794, DOI 10.1016/S0140-6736(96)90869-7
   Ukai S, 2004, INT CLIN PSYCHOPHARM, V19, P355, DOI 10.1097/00004850-200411000-00008
NR 15
TC 47
Z9 47
U1 0
U2 15
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1040-8738
EI 1531-7021
J9 CURR OPIN OPHTHALMOL
JI Curr. Opin. Ophthalmol.
PD JUN
PY 2006
VL 17
IS 3
BP 275
EP 277
DI 10.1097/01.icu.0000193100.13551.ac
PG 3
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 055XC
UT WOS:000238483500009
PM 16794440
DA 2022-11-30
ER

PT J
AU Wang, J
   Li, ML
   Geng, ZY
   Khattak, S
   Ji, XY
   Wu, DD
   Dang, YL
AF Wang, Jun
   Li, Mengling
   Geng, Ziyue
   Khattak, Saadullah
   Ji, Xinying
   Wu, Dongdong
   Dang, Yalong
TI Role of Oxidative Stress in Retinal Disease and the Early Intervention
   Strategies: A Review
SO OXIDATIVE MEDICINE AND CELLULAR LONGEVITY
LA English
DT Review
ID CONE CELL-DEATH; MACULAR DEGENERATION; DIABETIC-RETINOPATHY;
   FREE-RADICALS; MITOCHONDRIAL DYSFUNCTION; MOUSE MODEL; DNA-DAMAGE;
   INTRAOCULAR-PRESSURE; PHOTOCHEMICAL DAMAGE; DIETARY ANTIOXIDANTS
AB The retina, owing to its cellular anatomy and physical location, is susceptible to generating reactive oxygen species (ROS), which are associated with several major retinal diseases. When ROS exceeds the body's natural antioxidants, the retina is in a state of oxidative stress, which is recognized as the pathogenesis of retinal diseases. The early stage of the pathogenic process is an adaptive change in which oxidative stress and endogenous defense mechanisms occur. If no treatment is applied, the retinal diseases will progress to the pathological stage with neuronal and vascular dysfunction or damage and even blindness. This review summarizes the role of oxidative stress in several common retinal diseases, including retinitis pigmentosa, age-related macular degeneration, diabetic retinopathy, glaucoma, and retinopathy of prematurity. In addition, we discuss the early intervention strategies for these diseases. An outline is provided to identify potential intervention targets for further research. Early intervention for retinal diseases is necessary and urgent and may offer hope to improve patients' quality of life through functional vision.
C1 [Wang, Jun] Henan Univ, Sch Basic Med Sci, Kaifeng, Peoples R China.
   [Wang, Jun; Khattak, Saadullah; Ji, Xinying; Wu, Dongdong; Dang, Yalong] Henan Univ, Henan Int Joint Lab Nucl Prot Regulat, Kaifeng, Peoples R China.
   [Li, Mengling] Shaanxi Univ Chinese Med, Coll Acu Moxibust & Massage, Xianyang, Peoples R China.
   [Geng, Ziyue] Henan Univ, Sch Clin Med, Kaifeng, Henan, Peoples R China.
   [Dang, Yalong] Sanmenxia Cent Hosp, Sanmenxia, Henan, Peoples R China.
C3 Henan University; Henan University; Shaanxi University of Chinese
   Medicine; Henan University
RP Wang, J (通讯作者)，Henan Univ, Sch Basic Med Sci, Kaifeng, Peoples R China.; Wang, J; Wu, DD; Dang, YL (通讯作者)，Henan Univ, Henan Int Joint Lab Nucl Prot Regulat, Kaifeng, Peoples R China.; Dang, YL (通讯作者)，Sanmenxia Cent Hosp, Sanmenxia, Henan, Peoples R China.
EM whb21c@vip.henu.edu.cn; 873788450@qq.com; 2421535070@qq.com;
   saadullah271@gmail.com; 10190096@vip.henu.edu.cn;
   ddwubiomed2010@163.com; dangyalong@haust.edu.cn
RI Wu, Dongdong/GPX-6051-2022
OI Wu, Dongdong/0000-0001-6739-8437
FU Key R&D and Promotion Projects of Henan Province;  [182102410099]; 
   [182102310452]
FX AcknowledgmentsThe authors thank Editage Editing Service for editing the
   English text of a draft of this manuscript. This study was supported by
   the Key R&D and Promotion Projects of Henan Province No. 182102410099
   and No. 182102310452.
CR Abokyi S, 2020, OXID MED CELL LONGEV, V2020, DOI 10.1155/2020/7901270
   Ahsan H, 2015, DIABETES METAB SYND, V9, P51, DOI 10.1016/j.dsx.2014.09.011
   Alge CS, 2002, INVEST OPHTH VIS SCI, V43, P3575
   Alqawlaq S, 2012, NANOMEDICINE-UK, V7, P1067, DOI [10.2217/NNM.12.69, 10.2217/nnm.12.69]
   Amarowicz Ryszard, 2020, Adv Food Nutr Res, V93, P251, DOI 10.1016/bs.afnr.2020.04.002
   Amoaku WM, 2015, EYE, V29, P721, DOI 10.1038/eye.2015.48
   Appukuttan B, 2018, CLIN EXP OPHTHALMOL, V46, P652, DOI 10.1111/ceo.13155
   Domenech EB, 2020, ANTIOXIDANTS-BASEL, V9, DOI 10.3390/antiox9040347
   Banjac L, 2018, ACTA CLIN CROAT, V57, P458, DOI 10.20471/acc.2018.57.03.08
   Barot M, 2011, CURR EYE RES, V36, P1069, DOI 10.3109/02713683.2011.607536
   Baudouin C, 2021, PROG RETIN EYE RES, V83, DOI 10.1016/j.preteyeres.2020.100916
   Bek T, 2017, MITOCHONDRION, V36, P4, DOI 10.1016/j.mito.2016.07.011
   Bourne RRA, 2021, LANCET GLOB HEALTH, V9, pE130, DOI 10.1016/S2214-109X(20)30425-3
   Bungau S, 2019, OXID MED CELL LONGEV, V2019, DOI 10.1155/2019/9783429
   Buonocore G, 2002, PEDIATR RES, V52, P46, DOI 10.1203/01.PDR.0000016664.46604.01
   Calderon GD, 2017, EYE, V31, P1122, DOI 10.1038/eye.2017.64
   Campochiaro PA, 2020, J CLIN INVEST, V130, P1527, DOI 10.1172/JCI132990
   Campochiaro PA, 2018, PROG RETIN EYE RES, V62, P24, DOI 10.1016/j.preteyeres.2017.08.004
   Campochiaro PA, 2015, ANTIOXID REDOX SIGN, V23, P643, DOI 10.1089/ars.2015.6327
   Cayabyab R, 2016, NEONATOLOGY, V109, P369, DOI 10.1159/000444901
   Chalke SD, 2021, CURR DRUG TARGETS, V22, P1810, DOI 10.2174/1389450122666210319113136
   Chan TCW, 2020, EXP EYE RES, V201, DOI 10.1016/j.exer.2020.108255
   Chen QQ, 2019, FREE RADICAL BIO MED, V130, P48, DOI 10.1016/j.freeradbiomed.2018.10.419
   Chew EY, 2013, OPHTHALMOLOGY, V120, P1604, DOI 10.1016/j.ophtha.2013.01.021
   Chou SF, 2017, SCI REP-UK, V7, DOI 10.1038/srep42344
   Chrysostomou V, 2016, AGING CELL, V15, P1082, DOI 10.1111/acel.12512
   Cook R, 2019, BMJ-BRIT MED J, V366, DOI 10.1136/bmj.l4235
   Cooper ML, 2016, EXP EYE RES, V150, P22, DOI 10.1016/j.exer.2015.11.016
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Daiger SP, 2013, CLIN GENET, V84, P132, DOI 10.1111/cge.12203
   Dani Carlo, 2012, J Matern Fetal Neonatal Med, V25, P523, DOI 10.3109/14767058.2011.629252
   Davis JM, 2010, SEMIN FETAL NEONAT M, V15, P191, DOI 10.1016/j.siny.2010.04.001
   Mesquita LMD, 2021, NUTR REV, V79, P76, DOI 10.1093/nutrit/nuaa075
   Deliyanti D, 2018, INVEST OPHTH VIS SCI, V59, P815, DOI 10.1167/iovs.17-22920
   Demontis GC, 2002, INVEST OPHTH VIS SCI, V43, P2421
   Di Marco E, 2015, CLIN SCI, V129, P199, DOI 10.1042/CS20150093
   Di Meo S, 2020, OXID MED CELL LONGEV, V2020, DOI 10.1155/2020/9829176
   Du Y, 2013, P NATL ACAD SCI USA, V110, P16586, DOI 10.1073/pnas.1314575110
   Eells JT, 2019, BIOLOGY-BASEL, V8, DOI 10.3390/biology8020031
   Fahmideh F, 2022, SURV OPHTHALMOL, V67, P675, DOI 10.1016/j.survophthal.2021.09.002
   Hernandez-Zimbron LF, 2018, OXID MED CELL LONGEV, V2018, DOI 10.1155/2018/8374647
   Finkel T, 2000, NATURE, V408, P239, DOI 10.1038/35041687
   Fleck BW, 2013, CLIN PERINATOL, V40, P229, DOI 10.1016/j.clp.2013.02.010
   FREI B, 1991, American Journal of Clinical Nutrition, V54, p1113S, DOI 10.1093/ajcn/54.6.1113s
   FROYSAKER T, 1972, Scandinavian Journal of Thoracic and Cardiovascular Surgery, V6, P227, DOI 10.3109/14017437209134804
   Garg U, 2012, INDIAN J CLIN BIOCHE, V27, P196, DOI 10.1007/s12291-011-0180-9
   Gaskin JCF, 2021, ANTIOXIDANTS-BASEL, V10, DOI 10.3390/antiox10020238
   Golestaneh N, 2016, J TRANSL MED, V14, DOI 10.1186/s12967-016-1101-8
   Good WV, 2005, PEDIATRICS, V116, P15, DOI 10.1542/peds.2004-1413
   Gupta Madhur M, 2005, Indian J Physiol Pharmacol, V49, P187
   Halliwell B, 1996, ANNU REV NUTR, V16, P33, DOI 10.1146/annurev.nu.16.070196.000341
   Halliwell B, 2007, BIOCHEM SOC T, V35, P1147, DOI 10.1042/BST0351147
   HALLIWELL B, 1985, MOL ASPECTS MED, V8, P89, DOI 10.1016/0098-2997(85)90001-9
   Halliwell B, 2006, PLANT PHYSIOL, V141, P312, DOI 10.1104/pp.106.077073
   Hanif AM, 2015, INVEST OPHTH VIS SCI, V56, P6839, DOI 10.1167/iovs.15-16792
   Hanson C, 2019, CLIN NUTR, V38, P934, DOI 10.1016/j.clnu.2018.02.003
   Hartnett ME, 2017, SURV OPHTHALMOL, V62, P257, DOI 10.1016/j.survophthal.2016.12.004
   Hellstrom A, 2013, LANCET, V382, P1445, DOI 10.1016/S0140-6736(13)60178-6
   Ho L, 2011, ARCH OPHTHALMOL-CHIC, V129, P758, DOI 10.1001/archophthalmol.2011.141
   Holekamp NM, 2019, AM J MANAG CARE, V25, pS172
   Hondur G, 2017, INVEST OPHTH VIS SCI, V58, P4078, DOI 10.1167/iovs.17-22242
   Hunter JJ, 2012, PROG RETIN EYE RES, V31, P28, DOI 10.1016/j.preteyeres.2011.11.001
   Hurley JB, 2015, J NEUROSCI RES, V93, P1079, DOI 10.1002/jnr.23583
   Izzotti A, 2006, MUTAT RES-REV MUTAT, V612, P105, DOI 10.1016/j.mrrev.2005.11.001
   Izzotti A, 2003, AM J MED, V114, P638, DOI 10.1016/S0002-9343(03)00114-1
   Jabbehdari S, 2021, SURV OPHTHALMOL, V66, P423, DOI 10.1016/j.survophthal.2020.09.002
   Jayaram H, 2020, TAIWAN J OPHTHALMOL, V10, P255, DOI 10.4103/tjo.tjo_63_20
   Jiao WZ, 2019, MOL MED REP, V19, P667, DOI 10.3892/mmr.2018.9637
   Jo H, 2015, BMB REP, V48, P271, DOI 10.5483/BMBRep.2015.48.5.131
   Kalita D, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0191025
   Kang QZ, 2020, REDOX BIOL, V37, DOI 10.1016/j.redox.2020.101799
   Kikuchi K, 2020, J OPHTHALMOL, V2020, DOI 10.1155/2020/9539681
   Kim J, 2021, OPHTHALMOLOGY, V128, P866, DOI 10.1016/j.ophtha.2020.12.009
   Kolko M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132048
   Komeima K, 2007, J CELL PHYSIOL, V213, P809, DOI 10.1002/jcp.21152
   Kowluru RA, 2005, ANTIOXID REDOX SIGN, V7, P1581, DOI 10.1089/ars.2005.7.1581
   Kozlowska Aleksandra, 2014, Rocz Panstw Zakl Hig, V65, P79
   Kruk J, 2016, MINI-REV MED CHEM, V16, P241, DOI 10.2174/1389557516666151120114605
   Laddha AP, 2019, PHYTOMEDICINE, V56, P229, DOI 10.1016/j.phymed.2018.10.026
   Landers M B 3rd, 1978, Trans Am Ophthalmol Soc, V76, P528
   Lanzi C, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20040981
   Law SM, 2018, EYE, V32, P716, DOI 10.1038/eye.2017.292
   Lee Jason E, 2003, Surv Ophthalmol, V48, P234, DOI 10.1016/S0039-6257(02)00455-1
   Li JM, 2010, DIABETES, V59, P1528, DOI 10.2337/db09-1057
   Li Qiu-ping, 2012, Zhonghua Yan Ke Za Zhi, V48, P903
   Liu QP, 2018, MOL CELL BIOCHEM, V445, P105, DOI 10.1007/s11010-017-3256-x
   Liu Q, 2007, INVEST OPHTH VIS SCI, V48, P4580, DOI 10.1167/iovs.07-0170
   Loprinzi PD, 2016, JAMA OPHTHALMOL, V134, P1197, DOI 10.1001/jamaophthalmol.2016.2400
   Lushchak VI, 2014, CHEM-BIOL INTERACT, V224, P164, DOI 10.1016/j.cbi.2014.10.016
   Mahalingam K, 2018, INDIAN J OPHTHALMOL, V66, P1104, DOI 10.4103/ijo.IJO_108_18
   Mahmoud AM, 2017, EUR J NUTR, V56, P1671, DOI 10.1007/s00394-016-1214-0
   Maia SB, 2019, NUTRIENTS, V11, DOI 10.3390/nu11030681
   Masihzadeh O, 2011, EXP EYE RES, V93, P316, DOI 10.1016/j.exer.2011.02.012
   Matsuura T, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/9548767
   McGuinness MB, 2016, BRIT J OPHTHALMOL, V100, P1353, DOI 10.1136/bjophthalmol-2015-307663
   Meyer JG, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-51777-7
   Morizane Y, 2019, JPN J OPHTHALMOL, V63, P26, DOI 10.1007/s10384-018-0623-4
   Murakami Y, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21197170
   Murakami Y, 2012, AM J PATHOL, V181, P1378, DOI 10.1016/j.ajpath.2012.06.026
   Murphy MP, 2009, BIOCHEM J, V417, P1, DOI 10.1042/BJ20081386
   Nebbioso M, 2022, SURV OPHTHALMOL, V67, P168, DOI 10.1016/j.survophthal.2021.04.003
   Nishimura Y, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/4076518
   Nita M, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/3164734
   Noro T, 2015, INVEST OPHTH VIS SCI, V56, P5012, DOI 10.1167/iovs.15-17142
   Oikawa K, 2020, MOL NEUROBIOL, V57, P2620, DOI 10.1007/s12035-020-01910-9
   Oishi A, 2020, BRAIN COMMUN, V2, DOI 10.1093/braincomms/fcaa117
   Ortega AL, 2021, ANTIOXIDANTS-BASEL, V10, DOI 10.3390/antiox10010050
   Palsamy P, 2011, BBA-MOL BASIS DIS, V1812, P719, DOI 10.1016/j.bbadis.2011.03.008
   Pardue MT, 2018, PROG RETIN EYE RES, V65, P50, DOI 10.1016/j.preteyeres.2018.02.002
   Park JH, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-76472-w
   Park SW, 2012, INVEST OPHTH VIS SCI, V53, P7718, DOI 10.1167/iovs.11-8790
   Payne AJ, 2014, INT J MOL SCI, V15, P1865, DOI 10.3390/ijms15021865
   Payne Andrew J, 2013, Mo Med, V110, P429
   Perez CI, 2019, CURR OPIN OPHTHALMOL, V30, P82, DOI 10.1097/ICU.0000000000000553
   Robles-Rivera RR, 2020, OXID MED CELL LONGEV, V2020, DOI 10.1155/2020/3096470
   Rodriguez ML, 2019, OXID MED CELL LONGEV, V2019, DOI 10.1155/2019/4940825
   Rodriguez SH, 2020, J AAPOS, V24, DOI 10.1016/j.jaapos.2020.03.003
   Rohowetz LJ, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19113362
   Ross JA, 2002, ANNU REV NUTR, V22, P19, DOI 10.1146/annurev.nutr.22.111401.144957
   Sacca SC, 2005, ARCH OPHTHALMOL-CHIC, V123, P458, DOI 10.1001/archopht.123.4.458
   Sacca SC, 2013, MUTAT RES-REV MUTAT, V752, P153, DOI 10.1016/j.mrrev.2013.01.001
   Sacca SC, 2016, AGEING RES REV, V29, P26, DOI 10.1016/j.arr.2016.05.012
   Sahnoun Z, 1998, THERAPIE, V53, P315
   Saito Y, 2007, J CLIN BIOCHEM NUTR, V41, P43, DOI 10.3164/jcbn.2007006
   Sapienza A, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0509-7
   Saugstad OD, 2006, J PERINATOL, V26, pS46, DOI 10.1038/sj.jp.7211475
   Schwartz L, 2003, MED HYPOTHESES, V60, P644, DOI 10.1016/S0306-9877(02)00391-2
   Seen S, 2018, ACTA OPHTHALMOL, V96, pE412, DOI 10.1111/aos.13526
   Shaw PX, 2016, AIMS MOL SCI, V3, P196, DOI 10.3934/molsci.2016.2.196
   Sies H, 2020, NAT REV MOL CELL BIO, V21, P363, DOI 10.1038/s41580-020-0230-3
   Singh A, 2019, MOLECULES, V24, DOI 10.3390/molecules24081583
   Singh JK, 2019, J AAPOS, V23, P209, DOI 10.1016/j.jaapos.2019.02.008
   Smith LE, 2013, CLIN PERINATOL, V40, P201, DOI 10.1016/j.clp.2013.02.002
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Sreekumar PG, 2020, OXID MED CELL LONGEV, V2020, DOI 10.1155/2020/2583601
   Stone WL, 2016, FRONT BIOSCI-LANDMRK, V21, P165, DOI 10.2741/4382
   Tham YC, 2014, OPHTHALMOLOGY, V121, P2081, DOI 10.1016/j.ophtha.2014.05.013
   Tsang JKW, 2021, LIFE-BASEL, V11, DOI 10.3390/life11020079
   Usui S, 2009, MOL THER, V17, P778, DOI 10.1038/mt.2009.47
   Usui S, 2009, J NEUROCHEM, V110, P1028, DOI 10.1111/j.1471-4159.2009.06195.x
   Valko M, 2006, CHEM-BIOL INTERACT, V160, P1, DOI 10.1016/j.cbi.2005.12.009
   van der Meer AM, 2020, TRANSL VIS SCI TECHN, V9, DOI 10.1167/tvst.9.9.21
   Vander JF, 2005, ARCH OPHTHALMOL-CHIC, V123, P406, DOI 10.1001/archopht.123.3.406-b
   Velilla S, 2013, J OPHTHALMOL, V2013, DOI 10.1155/2013/895147
   Verbakel SK, 2018, PROG RETIN EYE RES, V66, P157, DOI 10.1016/j.preteyeres.2018.03.005
   Wang AL, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005304
   Wang JJ, 2014, OPHTHALMOLOGY, V121, P667, DOI 10.1016/j.ophtha.2013.10.017
   Wang MH, 2020, ANTIOXIDANTS-BASEL, V9, DOI 10.3390/antiox9060520
   Wang W, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19061816
   Wang Y, 2015, MOLECULES, V20, P22395, DOI 10.3390/molecules201219785
   Wei QQ, 2019, DISCOV MED, V27, P189
   Williams PA, 2017, SCIENCE, V355, P756, DOI 10.1126/science.aal0092
   Wong WT, 2010, INVEST OPHTH VIS SCI, V51, P6131, DOI 10.1167/iovs.10-5637
   Wu JM, 2006, SURV OPHTHALMOL, V51, P461, DOI 10.1016/j.survophthal.2006.06.009
   Xia N, 2010, J PHARMACOL EXP THER, V335, P149, DOI 10.1124/jpet.110.168724
   Ye L, 2013, OXID MED CELL LONGEV, V2013, DOI 10.1155/2013/413024
   Zhang D, 2018, EUR REV MED PHARMACO, V22, P5071, DOI 10.26355/eurrev_201808_15699
   Zhang Q J, 2001, Space Med Med Eng (Beijing), V14, P50
   Zhao J, 2016, INT J MOL MED, V38, P995, DOI 10.3892/ijmm.2016.2714
   Zhou LL, 1999, J CELL PHYSIOL, V180, P182, DOI 10.1002/(SICI)1097-4652(199908)180:2<182::AID-JCP6>3.0.CO;2-X
   Zhou TWE, 2016, AM J PATHOL, V186, P3100, DOI 10.1016/j.ajpath.2016.08.004
NR 161
TC 0
Z9 0
U1 0
U2 0
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1942-0900
EI 1942-0994
J9 OXID MED CELL LONGEV
JI Oxidative Med. Cell. Longev.
PD OCT 14
PY 2022
VL 2022
AR 7836828
DI 10.1155/2022/7836828
PG 13
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA 5U2XY
UT WOS:000876417500004
PM 36275903
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Pouw, AE
   Greiner, MA
   Coussa, RG
   Jiao, CH
   Han, IC
   Skeie, JM
   Fingert, JH
   Mullins, RF
   Sohn, EH
AF Pouw, Andrew E.
   Greiner, Mark A.
   Coussa, Razek G.
   Jiao, Chunhua
   Han, Ian C.
   Skeie, Jessica M.
   Fingert, John H.
   Mullins, Robert F.
   Sohn, Elliott H.
TI Cell-Matrix Interactions in the Eye: From Cornea to Choroid
SO CELLS
LA English
DT Review
DE TGF-beta; descemet membrane; collagen; metalloproteinases; AMD;
   interphotoreceptor matrix; MMP-9; VEGF; MMP-14; TIMP-3; bruch&#8217; s
   membrane; choroid
ID ENDOTHELIAL GROWTH-FACTOR; EPITHELIUM-DERIVED FACTOR; HUMAN TRABECULAR
   MESHWORK; OPTIC-NERVE HEAD; PROLIFERATIVE DIABETIC-RETINOPATHY; GLAUCOMA
   FILTRATION SURGERY; LAMINA-CRIBROSA CELLS; HUMAN BRUCHS MEMBRANE;
   AGE-RELATED-CHANGES; EXTRACELLULAR-MATRIX
AB The extracellular matrix (ECM) plays a crucial role in all parts of the eye, from maintaining clarity and hydration of the cornea and vitreous to regulating angiogenesis, intraocular pressure maintenance, and vascular signaling. This review focuses on the interactions of the ECM for homeostasis of normal physiologic functions of the cornea, vitreous, retina, retinal pigment epithelium, Bruch's membrane, and choroid as well as trabecular meshwork, optic nerve, conjunctiva and tenon's layer as it relates to glaucoma. A variety of pathways and key factors related to ECM in the eye are discussed, including but not limited to those related to transforming growth factor-beta, vascular endothelial growth factor, basic-fibroblastic growth factor, connective tissue growth factor, matrix metalloproteinases (including MMP-2 and MMP-9, and MMP-14), collagen IV, fibronectin, elastin, canonical signaling, integrins, and endothelial morphogenesis consistent of cellular activation-tubulogenesis and cellular differentiation-stabilization. Alterations contributing to disease states such as wound healing, diabetes-related complications, Fuchs endothelial corneal dystrophy, angiogenesis, fibrosis, age-related macular degeneration, retinal detachment, and posteriorly inserted vitreous base are also reviewed.
C1 [Pouw, Andrew E.; Greiner, Mark A.; Coussa, Razek G.; Jiao, Chunhua; Han, Ian C.; Skeie, Jessica M.; Fingert, John H.; Mullins, Robert F.; Sohn, Elliott H.] Univ Iowa Hosp & Clin, Carver Coll Med, Dept Ophthalmol & Visual Sci, Iowa City, IA 52242 USA.
   [Pouw, Andrew E.; Greiner, Mark A.; Coussa, Razek G.; Jiao, Chunhua; Han, Ian C.; Fingert, John H.; Mullins, Robert F.; Sohn, Elliott H.] Univ Iowa, Inst Vis Res, Iowa City, IA 52242 USA.
C3 University of Iowa; University of Iowa
RP Sohn, EH (通讯作者)，Univ Iowa Hosp & Clin, Carver Coll Med, Dept Ophthalmol & Visual Sci, Iowa City, IA 52242 USA.; Sohn, EH (通讯作者)，Univ Iowa, Inst Vis Res, Iowa City, IA 52242 USA.
EM andrew-pouw@uiowa.edu; mark-greiner@uiowa.edu;
   razekgeorges-coussa@uiowa.edu; chunhua-jiao@uiowa.edu;
   ian-han@uiowa.edu; jessica-skeie@uiowa.edu; john-fingert@uiowa.edu;
   robert-mullins@uiowa.edu; elliott.sohn@gmail.com
RI Fingert, John/AAX-4750-2021
OI Fingert, John/0000-0002-0377-0479; Mullins, Robert/0000-0002-5006-0891;
   Han, Ian/0000-0002-2371-727X; Sohn, Elliott/0000-0002-3778-9362; Pouw,
   Andrew/0000-0001-8594-7612
FU NEI [R01 EY026547, P30 EY025580]
FX This work is supported by NEI R01 EY026547, P30 EY025580.
CR Acott TS, 2008, EXP EYE RES, V86, P543, DOI 10.1016/j.exer.2008.01.013
   Adams JC, 2018, CURR TOP DEV BIOL, V130, P39, DOI 10.1016/bs.ctdb.2018.02.003
   ADLER AJ, 1981, EXP EYE RES, V32, P755, DOI 10.1016/0014-4835(81)90025-7
   AKIYAMA SK, 1989, J CELL BIOL, V109, P863, DOI 10.1083/jcb.109.2.863
   Al-Ubaidi MR, 2013, INVEST OPHTH VIS SCI, V54, P8119, DOI 10.1167/iovs.13-13536
   Albon J, 2000, BRIT J OPHTHALMOL, V84, P318, DOI 10.1136/bjo.84.3.318
   Aldrich BT, 2017, INVEST OPHTH VIS SCI, V58, P2130, DOI 10.1167/iovs.16-21094
   Alexander JP, 1998, CURR EYE RES, V17, P276, DOI 10.1076/ceyr.17.3.276.5219
   ALEXANDER JP, 1991, INVEST OPHTH VIS SCI, V32, P172
   Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   Anitua E, 2015, EXP EYE RES, V135, P118, DOI 10.1016/j.exer.2015.02.016
   Aoudjit F, 2001, J CELL BIOL, V152, P633, DOI 10.1083/jcb.152.3.633
   Ardi VC, 2007, P NATL ACAD SCI USA, V104, P20262, DOI 10.1073/pnas.0706438104
   AUSPRUNK DH, 1977, MICROVASC RES, V14, P53, DOI 10.1016/0026-2862(77)90141-8
   Bakall B, 2013, AM J OPHTHALMOL, V156, P15, DOI 10.1016/j.ajo.2013.02.017
   Barthelmes D, 2015, BRIT J OPHTHALMOL, V99, P359, DOI 10.1136/bjophthalmol-2014-305514
   Bayless KJ, 2003, BIOCHEM BIOPH RES CO, V312, P903, DOI 10.1016/j.bbrc.2003.11.017
   Becerra SP, 2006, EXP EYE RES, V82, P739, DOI 10.1016/j.exer.2005.10.016
   Bergers G, 2000, NAT CELL BIOL, V2, P737, DOI 10.1038/35036374
   Bhutto IA, 2008, ARCH OPHTHALMOL-CHIC, V126, P670, DOI 10.1001/archopht.126.5.670
   Binder S, 2012, BRIT J OPHTHALMOL, V96, P1, DOI 10.1136/bjophthalmol-2011-301236
   Bishop PN, 2015, EXP EYE RES, V133, P30, DOI 10.1016/j.exer.2014.10.021
   BISHOP PN, 1994, BIOCHEM J, V299, P497, DOI 10.1042/bj2990497
   Bishop PN, 2004, INVEST OPHTH VIS SCI, V45, P1041, DOI 10.1167/iovs.03-1017
   BISHOP PN, 1994, BIOCHEM BIOPH RES CO, V203, P289, DOI 10.1006/bbrc.1994.2180
   Bishop PN, 2000, PROG RETIN EYE RES, V19, P323, DOI 10.1016/S1350-9462(99)00016-6
   Bollinger KE, 2011, INVEST OPHTH VIS SCI, V52, P8287, DOI 10.1167/iovs.11-8218
   Booij JC, 2010, PROG RETIN EYE RES, V29, P1, DOI 10.1016/j.preteyeres.2009.08.003
   Bos KJ, 2001, MICRON, V32, P301, DOI 10.1016/S0968-4328(00)00035-4
   Bos KJ, 2001, J MOL BIOL, V306, P1011, DOI 10.1006/jmbi.2000.4429
   Bourne WM, 1997, INVEST OPHTH VIS SCI, V38, P779
   Bradley JMB, 2003, INVEST OPHTH VIS SCI, V44, P5174, DOI 10.1167/iovs.03-0213
   Bradley JMB, 1998, INVEST OPHTH VIS SCI, V39, P2649
   Bradley JMB, 2001, INVEST OPHTH VIS SCI, V42, P1505
   Brown DM, 2013, RETINA-J RET VIT DIS, V33, P23, DOI 10.1097/IAE.0b013e318263cedf
   BULLER C, 1990, INVEST OPHTH VIS SCI, V31, P2156
   Burg-Roderfeld M, 2007, INT J ONCOL, V30, P985
   Burgoyne CF, 2005, PROG RETIN EYE RES, V24, P39, DOI 10.1016/j.preteyeres.2004.06.001
   Butler GS, 1999, J BIOL CHEM, V274, P10846, DOI 10.1074/jbc.274.16.10846
   Buys ES, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060156
   Candiello J, 2010, MATRIX BIOL, V29, P402, DOI 10.1016/j.matbio.2010.03.004
   Cavet ME, 2014, INVEST OPHTH VIS SCI, V55, P5005, DOI 10.1167/iovs.14-14515
   Chang JH, 1998, OPHTHALMIC GENET, V19, P123, DOI 10.1076/opge.19.3.123.2185
   Chang JH, 2016, SURV OPHTHALMOL, V61, P478, DOI 10.1016/j.survophthal.2015.11.006
   Chang W, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0191285
   Chau KY, 2007, EYE, V21, P1511, DOI [10.1038/sj.eye.6702722, 10.1038/sj.eye.6702722x]
   Chen L, 2003, BRIT J OPHTHALMOL, V87, P212, DOI 10.1136/bjo.87.2.212
   Chen WS, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.00302
   Chong NHV, 2005, AM J PATHOL, V166, P241, DOI 10.1016/S0002-9440(10)62248-1
   Chudgar SM, 2006, MOL VIS, V12, P1117
   Clark SJ, 2011, INVEST OPHTH VIS SCI, V52, P6511, DOI 10.1167/iovs.11-7909
   Curcio CA., 2012, RETINA-J RET VIT DIS, V1, P466
   Curcio CA, 2011, BRIT J OPHTHALMOL, V95, P1638, DOI 10.1136/bjophthalmol-2011-300344
   Cursiefen C, 1998, CORNEA, V17, P611, DOI 10.1097/00003226-199811000-00008
   Daniels JT, 1998, MICROSC RES TECHNIQ, V42, P317, DOI 10.1002/(SICI)1097-0029(19980901)42:5<317::AID-JEMT3>3.0.CO;2-M
   Davis AS, 2012, ARCH OPHTHALMOL-CHIC, V130, P1073, DOI 10.1001/archophthalmol.2012.465
   Davis GE, 2005, CIRC RES, V97, P1093, DOI 10.1161/01.RES.0000191547.64391.e3
   Davis GE, 2003, MICROCIRCULATION, V10, P27, DOI 10.1038/sj.mn.7800175
   Davis GE, 2002, ANAT RECORD, V268, P252, DOI 10.1002/ar.10159
   Dawson DW, 1999, SCIENCE, V285, P245, DOI 10.1126/science.285.5425.245
   de Smet MD, 2013, OPHTHALMOLOGICA, V230, P165, DOI 10.1159/000353447
   Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745
   Erkenbrack EM, 2017, J EXP ZOOL PART B, V328, P423, DOI 10.1002/jez.b.22743
   Esson DW, 2004, INVEST OPHTH VIS SCI, V45, P485, DOI 10.1167/iovs.03-0485
   Faralli JA, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8121518
   Faralli JA, 2009, EXP EYE RES, V88, P689, DOI 10.1016/j.exer.2008.08.019
   Fariss RN, 1997, AM J PATHOL, V150, P323
   Fassina G, 2000, CLIN EXP METASTAS, V18, P111, DOI 10.1023/A:1006797522521
   Filla MS, 2017, EXP EYE RES, V158, P124, DOI 10.1016/j.exer.2016.05.011
   Fiotti N, 2005, GENET MED, V7, P272, DOI 10.1097/01.GIM.0000159903.69597.73
   FOOS R Y, 1972, Transactions of the American Academy of Ophthalmology and Oto-Laryngology, V76, P480
   FOOS RY, 1967, AM J OPHTHALMOL, V64, P643
   Forooghian F, 2009, RETINA-J RET VIT DIS, V29, P723, DOI 10.1097/IAE.0b013e3181a2c1c3
   FOUSER L, 1991, J BIOL CHEM, V266, P18345
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Fuchshofer R, 2012, CELL TISSUE RES, V347, P279, DOI 10.1007/s00441-011-1274-7
   Gasperini JL, 2012, BRIT J OPHTHALMOL, V96, P14, DOI 10.1136/bjo.2011.204685
   Gehlbach P, 2003, GENE THER, V10, P637, DOI 10.1038/sj.gt.3301931
   Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028
   Giraudo E, 2004, J CLIN INVEST, V114, P623, DOI 10.1172/JCI200422087
   Greiner MA, 2014, CORNEA, V33, P1129, DOI 10.1097/ICO.0000000000000262
   Guo L, 1999, INVEST OPHTH VIS SCI, V40, P2676
   Haddadin RI, 2012, INVEST OPHTH VIS SCI, V53, P6708, DOI 10.1167/iovs.11-9013
   Haddadin RI, 2009, INVEST OPHTH VIS SCI, V50, P3771, DOI 10.1167/iovs.08-2489
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haimovici R, 2001, INVEST OPHTH VIS SCI, V42, P1592
   Hausman RE, 2007, PROG RETIN EYE RES, V26, P162, DOI 10.1016/j.preteyeres.2006.11.001
   Heimark RL, 2002, CURR EYE RES, V25, P299, DOI 10.1076/ceyr.25.5.299.13495
   Heissig B, 2003, CURR OPIN HEMATOL, V10, P136, DOI 10.1097/00062752-200303000-00007
   Heng LZ, 2013, DIABETIC MED, V30, P640, DOI 10.1111/dme.12089
   Hernandez MR, 2000, PROG RETIN EYE RES, V19, P297, DOI 10.1016/S1350-9462(99)00017-8
   Hindson VJ, 2005, INVEST OPHTH VIS SCI, V46, P4417, DOI 10.1167/iovs.05-0883
   Hiscott P, 1996, HUM PATHOL, V27, P1255, DOI 10.1016/S0046-8177(96)90333-0
   HOGAN MJ, 1963, INVEST OPHTH VISUAL, V2, P418
   Holderfield MT, 2008, CIRC RES, V102, P637, DOI 10.1161/CIRCRESAHA.107.167171
   Hollborn M, 2007, INVEST OPHTH VIS SCI, V48, P4360, DOI 10.1167/iovs.06-1234
   Hopkins AA, 2020, AM J PHYSIOL-CELL PH, V319, pC611, DOI 10.1152/ajpcell.00054.2020
   HOSODA Y, 1992, OPHTHALMIC RES, V24, P260, DOI 10.1159/000267176
   Hubmacher D, 2013, CURR OPIN RHEUMATOL, V25, P65, DOI 10.1097/BOR.0b013e32835b137b
   Hussain AA, 2010, EXP EYE RES, V90, P703, DOI 10.1016/j.exer.2010.02.013
   Hussain AA, 2011, INVEST OPHTH VIS SCI, V52, P4459, DOI 10.1167/iovs.10-6678
   HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S
   Jiao CH, 2019, RETINA-J RET VIT DIS, V39, P265, DOI 10.1097/IAE.0000000000001952
   Johnson LV, 2004, NEW ENGL J MED, V351, P320, DOI 10.1056/NEJMp048131
   Jonas JB, 2012, ACTA OPHTHALMOL, V90, pe381, DOI 10.1111/j.1755-3768.2012.02414.x
   Junglas B, 2009, EXP EYE RES, V88, P1065, DOI 10.1016/j.exer.2009.01.008
   Kamei M, 1999, INVEST OPHTH VIS SCI, V40, P2367
   Kang MH, 2013, INVEST OPHTH VIS SCI, V54, P2523, DOI 10.1167/iovs.12-11474
   KARWATOWSKI WSS, 1995, BRIT J OPHTHALMOL, V79, P944, DOI 10.1136/bjo.79.10.944
   Keane PA, 2008, INVEST OPHTH VIS SCI, V49, P3115, DOI 10.1167/iovs.08-1689
   Keller KE, 2013, INVEST OPHTH VIS SCI, V54, P5613, DOI 10.1167/iovs.13-11620
   Kessenbrock K, 2010, CELL, V141, P52, DOI 10.1016/j.cell.2010.03.015
   KHAW PT, 1994, EYE, V8, P188, DOI 10.1038/eye.1994.44
   KIELTY CM, 1992, J CELL BIOL, V118, P979, DOI 10.1083/jcb.118.4.979
   King N, 2008, NATURE, V451, P783, DOI 10.1038/nature06617
   Kirwan RP, 2005, MOL VIS, V11, P798
   Knupp C, 2002, J STRUCT BIOL, V137, P31, DOI 10.1006/jsbi.2002.4449
   Kocaba V, 2018, JAMA OPHTHALMOL, V136, P886, DOI 10.1001/jamaophthalmol.2018.2031
   Krebs I, 2013, BRIT J OPHTHALMOL, V97, P1443, DOI 10.1136/bjophthalmol-2013-303513
   Kubota T, 2010, RETINA-J RET VIT DIS, V30, P468, DOI 10.1097/IAE.0b013e3181bd2d7b
   Kuiper EJ, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002675
   Kvanta A, 2000, CURR EYE RES, V21, P684, DOI 10.1076/0271-3683(200009)21:3;1-R;FT684
   Kvanta A, 2000, EXP EYE RES, V70, P419, DOI 10.1006/exer.1999.0790
   Lambert V, 2003, FASEB J, V17, P2290, DOI 10.1096/fj.03-0113fje
   Lambert V, 2002, AM J PATHOL, V161, P1247, DOI 10.1016/S0002-9440(10)64401-X
   Lass JH, 2019, JAMA OPHTHALMOL, V137, P185, DOI 10.1001/jamaophthalmol.2018.5669
   Le Goff MM, 2012, J BIOL CHEM, V287, P28027, DOI 10.1074/jbc.M111.331157
   Le Goff MM, 2003, J BIOL CHEM, V278, P45280, DOI 10.1074/jbc.M303117200
   Lengyel I, 2004, INVEST OPHTH VIS SCI, V45, P2886, DOI 10.1167/iovs.03-1083
   Li GR, 2019, P NATL ACAD SCI USA, V116, P1714, DOI 10.1073/pnas.1814889116
   Liaboe CA, 2017, CORNEA, V36, P561, DOI 10.1097/ICO.0000000000001174
   Liu YQ, 2004, FASEB J, V18, P457, DOI 10.1096/fj.03-0948com
   Liutkeviciene R, 2015, OPHTHALMIC GENET, V36, P149, DOI 10.3109/13816810.2013.838274
   Lund LR, 1999, EMBO J, V18, P4645, DOI 10.1093/emboj/18.17.4645
   Maatta M, 2007, GRAEF ARCH CLIN EXP, V245, P74, DOI 10.1007/s00417-006-0281-y
   MARANO RPC, 1995, EXP EYE RES, V60, P5, DOI 10.1016/S0014-4835(05)80079-X
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   MATSUMOTO B, 1984, INVEST OPHTH VIS SCI, V25, P71
   McLeod D, 2007, BRIT J OPHTHALMOL, V91, P677, DOI 10.1136/bjo.2006.109199
   Meredith JE, 1997, TRENDS CELL BIOL, V7, P146, DOI 10.1016/S0962-8924(97)01002-7
   Mitry D, 2010, RETINA-J RET VIT DIS, V30, P1561, DOI 10.1097/IAE.0b013e3181f669e6
   MONTESANO R, 1983, J CELL BIOL, V97, P1648, DOI 10.1083/jcb.97.5.1648
   Mullins RE, 2011, INVEST OPHTH VIS SCI, V52, P1606, DOI 10.1167/iovs.10-6476
   Mullins RF, 2019, OPHTHALMOLOGY, V126, P591, DOI 10.1016/j.ophtha.2018.10.037
   Mullins RF, 2014, AM J PATHOL, V184, P3142, DOI 10.1016/j.ajpath.2014.07.017
   Mullins RF, 2014, ADV EXP MED BIOL, V801, P283, DOI 10.1007/978-1-4614-3209-8_36
   Murphy-Ullrich JE, 2015, J OCUL PHARMACOL TH, V31, P371, DOI 10.1089/jop.2015.0016
   Nakao S, 2013, RETINA-J RET VIT DIS, V33, P957, DOI 10.1097/IAE.0b013e3182753b41
   Nanda GG, 2019, MOL VIS, V25, P295
   Nasir Normie Aida Mohd, 2020, Journal of Basic and Clinical Physiology and Pharmacology, V31, P20190373, DOI 10.1515/jbcpp-2019-0373
   Nelissen I, 2003, BRAIN, V126, P1371, DOI 10.1093/brain/awg129
   Netto MV, 2005, CORNEA, V24, P509, DOI 10.1097/01.ico.0000151544.23360.17
   Ng EWM, 2005, CAN J OPHTHALMOL, V40, P352, DOI 10.1016/S0008-4182(05)80078-X
   Nichols SA, 2012, P NATL ACAD SCI USA, V109, P13046, DOI 10.1073/pnas.1120685109
   NikhalaShree S, 2019, INVEST OPHTH VIS SCI, V60, P4661, DOI 10.1167/iovs.19-27091
   Nussenblatt RB, 2007, AM J OPHTHALMOL, V144, P618, DOI 10.1016/j.ajo.2007.06.025
   Ogata N, 2002, INVEST OPHTH VIS SCI, V43, P1168
   Okumura N, 2015, LAB INVEST, V95, P1291, DOI 10.1038/labinvest.2015.111
   Onguchi T, 2009, AM J PATHOL, V174, P1564, DOI 10.2353/ajpath.2009.080452
   Oshima Y, 2004, J CELL PHYSIOL, V201, P393, DOI 10.1002/jcp.20110
   Oster SF, 2003, BRIT J OPHTHALMOL, V87, P639, DOI 10.1136/bjo.87.5.639
   Otey C A, 1990, Semin Cell Biol, V1, P391
   Overall CM, 2002, NAT REV CANCER, V2, P657, DOI 10.1038/nrc884
   Overby DR, 2014, INVEST OPHTH VIS SCI, V55, P4922, DOI 10.1167/iovs.14-14429
   Page-McCaw A, 2007, NAT REV MOL CELL BIO, V8, P221, DOI 10.1038/nrm2125
   PARSHLEY DE, 1995, CURR EYE RES, V14, P537, DOI 10.3109/02713689508998400
   Pasquale LR, 2016, CURR OPIN OPHTHALMOL, V27, P94, DOI 10.1097/ICU.0000000000000245
   Pattwell DM, 2010, RETINA-J RET VIT DIS, V30, P1012, DOI 10.1097/IAE.0b013e3181cb463a
   Pepper MS, 2001, ARTERIOSCL THROM VAS, V21, P1104, DOI 10.1161/hq0701.093685
   Pires-Neto MA, 1999, BRAZ J MED BIOL RES, V32, P633, DOI 10.1590/S0100-879X1999000500017
   Porter K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068668
   Porter KM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034792
   Qiao H, 2005, BRIT J OPHTHALMOL, V89, P513, DOI 10.1136/bjo.2004.050658
   Qu J, 2015, INVEST OPHTH VIS SCI, V56, P7821, DOI 10.1167/iovs.15-17848
   Quinlan R, 2004, TRENDS NEUROSCI, V27, P241, DOI 10.1016/j.tins.2004.02.009
   Rahman N, 2020, BRIT J OPHTHALMOL, V104, P451, DOI 10.1136/bjophthalmol-2019-315086
   Ramesh S, 2004, BRIT J OPHTHALMOL, V88, P697, DOI 10.1136/bjo.2003.031989
   Rehany U, 2000, CORNEA, V19, P534, DOI 10.1097/00003226-200007000-00026
   Reinhard J, 2015, EXP EYE RES, V133, P132, DOI 10.1016/j.exer.2014.07.001
   Rhee DJ, 2003, EXP EYE RES, V77, P601, DOI 10.1016/S0014-4835(03)00190-8
   Roovers K, 2000, BIOESSAYS, V22, P818, DOI 10.1002/1521-1878(200009)22:9<818::AID-BIES7>3.0.CO;2-6
   Roychoudhury J, 2010, INVEST OPHTH VIS SCI, V51, P3560, DOI 10.1167/iovs.09-3890
   Rudolf M, 2009, J HISTOCHEM CYTOCHEM, V57, P731, DOI 10.1369/jhc.2009.953448
   Salvesen GS, 1999, APMIS, V107, P73, DOI 10.1111/j.1699-0463.1999.tb01528.x
   Samtani S, 2009, INVEST OPHTH VIS SCI, V50, P5098, DOI 10.1167/iovs.08-3174
   Sarnicola C, 2019, EYE CONTACT LENS, V45, P1, DOI 10.1097/ICL.0000000000000469
   Saunders WB, 2006, J CELL BIOL, V175, P179, DOI 10.1083/jcb.200603176
   Schaal S, 2008, OPHTHALMOLOGY, V115, P2199, DOI 10.1016/j.ophtha.2008.07.007
   SCHEPENS CL, 1954, AM J OPHTHALMOL, V38, P8, DOI 10.1016/0002-9394(54)90004-5
   Schwarz C, 2016, EXP EYE RES, V153, P152, DOI 10.1016/j.exer.2016.10.015
   Schwesinger C, 2001, AM J PATHOL, V158, P1161, DOI 10.1016/S0002-9440(10)64063-1
   Seet LF, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009415
   Seth A, 2008, INVEST OPHTH VIS SCI, V49, P743, DOI 10.1167/iovs.07-1072
   Shapiro SD, 1998, CURR OPIN CELL BIOL, V10, P602, DOI 10.1016/S0955-0674(98)80035-5
   Short SM, 1998, MOL BIOL CELL, V9, P1969, DOI 10.1091/mbc.9.8.1969
   Shukla D., 2020, CORRES RETINA, V40, P68, DOI [10.1097/IAE.0000000000002957, DOI 10.1097/IAE.0000000000002957]
   Sivaprasad S, 2008, AM J OPHTHALMOL, V146, P228, DOI 10.1016/j.ajo.2008.03.024
   Skeie JM, 2012, MATRIX BIOL, V31, P113, DOI 10.1016/j.matbio.2011.11.003
   SKUTA GL, 1987, SURV OPHTHALMOL, V32, P149, DOI 10.1016/0039-6257(87)90091-9
   Sohn E.H., 2020, OPHTHALMOLOGY, V1, DOI [10.1016/j.xops.2020.100002, DOI 10.1016/J.XOPS.2020.100002]
   Sohn EH, 2020, RETINA-J RET VIT DIS, V40, pE68, DOI 10.1097/IAE.0000000000002958
   Sohn EH, 2019, AM J PATHOL, V189, P1473, DOI 10.1016/j.ajpath.2019.04.005
   Sohn EH, 2020, RETINA-J RET VIT DIS, V40, P943, DOI 10.1097/IAE.0000000000002482
   Sohn EH, 2015, RETINA-J RET VIT DIS, V35, P48, DOI 10.1097/IAE.0000000000000263
   Sohn EH, 2014, INVEST OPHTH VIS SCI, V55, P1352, DOI 10.1167/iovs.13-13754
   Sohn EH, 2012, ARCH OPHTHALMOL-CHIC, V130, P1127, DOI 10.1001/archophthalmol.2012.1611
   Sohn EH, 2011, ARCH OPHTHALMOL-CHIC, V129, P1626, DOI 10.1001/archophthalmol.2011.338
   Sounni NE, 2011, FRONT PHARMACOL, V2, DOI 10.3389/fphar.2011.00111
   Spraul CW, 1999, SURV OPHTHALMOL, V44, pS10, DOI 10.1016/S0039-6257(99)00086-7
   Steen B, 1998, INVEST OPHTH VIS SCI, V39, P2194
   STRAATSM.BR, 1974, AM J OPHTHALMOL, V77, P619, DOI 10.1016/0002-9394(74)90525-X
   STREETEN BW, 1972, AM J OPHTHALMOL, V74, P1201, DOI 10.1016/0002-9394(72)90743-X
   Suga H, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3325
   Sun JF, 2009, AM J PHYSIOL-HEART C, V296, pH1344, DOI 10.1152/ajpheart.01246.2008
   Sura AA, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.13.19
   Sweeney SM, 1998, P NATL ACAD SCI USA, V95, P7275, DOI 10.1073/pnas.95.13.7275
   Tamm ER, 2009, EXP EYE RES, V88, P648, DOI 10.1016/j.exer.2009.02.007
   Tatar O, 2007, BRIT J OPHTHALMOL, V91, P1183, DOI 10.1136/bjo.2007.114769
   TENG CC, 1957, AM J OPHTHALMOL, V44, P335, DOI 10.1016/0002-9394(57)92766-6
   Terry MA, 2018, OPHTHALMOLOGY, V125, P1700, DOI 10.1016/j.ophtha.2018.08.002
   Tian BH, 2005, EXP EYE RES, V80, P215, DOI 10.1016/j.exer.2004.09.002
   Tio L, 2014, JOINT BONE SPINE, V81, P137, DOI 10.1016/j.jbspin.2013.05.007
   Tiozzo S, 2008, DEV BIOL, V315, P243, DOI 10.1016/j.ydbio.2007.12.035
   Tomarev SI, 2003, INVEST OPHTH VIS SCI, V44, P2588, DOI 10.1167/iovs.02-1099
   Tozer K, 2013, OPHTHALMOLOGY, V120, P2029, DOI 10.1016/j.ophtha.2013.03.016
   TRIPATHI BJ, 1991, INVEST OPHTH VIS SCI, V32, P181
   Tshionyi M, 2012, CORNEA, V31, P74, DOI 10.1097/ICO.0b013e31821dd986
   Uno K, 2006, BRIT J OPHTHALMOL, V90, P48, DOI 10.1136/bjo.2005.074005
   Van Geest RJ, 2012, BRIT J OPHTHALMOL, V96, P587, DOI 10.1136/bjophthalmol-2011-301005
   Vedana G, 2016, CLIN OPHTHALMOL, V10, P321, DOI 10.2147/OPTH.S83467
   Vega-Macaya F, 2016, GENETICS, V204, P1139, DOI 10.1534/genetics.116.189548
   Vinals F, 1999, MOL CELL BIOL, V19, P2763
   Vittal V, 2005, INVEST OPHTH VIS SCI, V46, P2857, DOI 10.1167/iovs.05-0075
   VOGEL HG, 1980, MECH AGEING DEV, V14, P283, DOI 10.1016/0047-6374(80)90002-0
   Voigt AP, 2019, P NATL ACAD SCI USA, V116, P24100, DOI 10.1073/pnas.1914143116
   Vorotnikova E, 2010, MATRIX BIOL, V29, P690, DOI 10.1016/j.matbio.2010.08.007
   Vranka JA, 2015, EXP EYE RES, V133, P112, DOI 10.1016/j.exer.2014.07.014
   Vu TH, 1998, CELL, V93, P411, DOI 10.1016/S0092-8674(00)81169-1
   Wallace DM, 2016, EXP EYE RES, V142, P102, DOI 10.1016/j.exer.2014.12.006
   Wallace DM, 2014, MATRIX BIOL, V37, P174, DOI 10.1016/j.matbio.2014.03.007
   Wallace DM, 2013, INVEST OPHTH VIS SCI, V54, P7836, DOI 10.1167/iovs.13-12494
   Wang J, 2003, INVEST OPHTH VIS SCI, V44, P1793, DOI 10.1167/iovs.02-0802
   Wang JM, 2011, INT J OPHTHALMOL-CHI, V4, P480, DOI 10.3980/j.issn.2222-3959.2011.05.04
   Wang SJ, 2009, ARCH OPHTHALMOL-CHIC, V127, P507, DOI 10.1001/archophthalmol.2009.53
   Warejcka D, 2005, MOL VIS, V11, P859
   Weinreb RN, 2015, BRIT J OPHTHALMOL, V99, P738, DOI 10.1136/bjophthalmol-2014-305908
   Whelan MC, 2003, J BIOL CHEM, V278, P327, DOI 10.1074/jbc.M207554200
   Whitmore SS, 2015, PROG RETIN EYE RES, V45, P1, DOI 10.1016/j.preteyeres.2014.11.005
   Williams F, 2014, MATRIX BIOL, V37, P60, DOI 10.1016/j.matbio.2014.02.002
   Wissink S, 1997, J BIOL CHEM, V272, P22278, DOI 10.1074/jbc.272.35.22278
   Witjas FMR, 2019, STEM CELL TRANSL MED, V8, P375, DOI 10.1002/sctm.18-0155
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wu NX, 2020, MOL CELL BIOCHEM, V470, P175, DOI 10.1007/s11010-020-03760-4
   Yan Q, 2000, EXP EYE RES, V71, P81, DOI 10.1006/exer.2000.0853
   Yan XM, 2000, ARCH OPHTHALMOL-CHIC, V118, P666, DOI 10.1001/archopht.118.5.666
   Yana I, 2007, J CELL SCI, V120, P1607, DOI 10.1242/jcs.000679
   Yu M, 2008, J OCUL PHARMACOL TH, V24, P373, DOI 10.1089/jop.2008.0029
   Yuan Hui-ping, 2009, Zhonghua Yan Ke Za Zhi, V45, P168
   Yuan LY, 2001, J NEUROSCI RES, V64, P523, DOI 10.1002/jnr.1104
   Yue Beatrice, 2014, J Glaucoma, V23, pS20, DOI 10.1097/IJG.0000000000000108
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
   Zeng RP, 2014, OPHTHALMIC GENET, V35, P235, DOI 10.3109/13816810.2014.952832
   Zeng SM, 2016, J PATHOL, V238, P446, DOI 10.1002/path.4669
NR 264
TC 12
Z9 12
U1 5
U2 12
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2073-4409
J9 CELLS-BASEL
JI Cells
PD MAR
PY 2021
VL 10
IS 3
AR 687
DI 10.3390/cells10030687
PG 27
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA RD5BB
UT WOS:000633492200001
PM 33804633
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU He, ZB
   Yu, JG
   Li, J
   Han, QL
   Luo, GC
   Li, YS
AF He, Zaobo
   Yu, Jiguo
   Li, Ji
   Han, Qilong
   Luo, Guangchun
   Li, Yingshu
TI Inference Attacks and Controls on Genotypes and Phenotypes for
   Individual Genomic Data
SO IEEE-ACM TRANSACTIONS ON COMPUTATIONAL BIOLOGY AND BIOINFORMATICS
LA English
DT Article
DE Genomics; Bioinformatics; Data privacy; Diseases; DNA; Belief
   propagation; SNP-trait association; belief propagation; factor graph;
   data-sanitization
ID IMPUTATION
AB The rapid growth of DNA-sequencing technologies motivates more personalized and predictive genetic-oriented services, which further attract individuals to increasingly release their genome information to learn about personalized medicines, disease predispositions, genetic compatibilities, etc. Individual genome information is notoriously privacy-sensitive and highly associated with relatives. In this paper, we present an inference attack algorithm to predict target genotypes and phenotypes based on belief propagation in factor graphs. With this algorithm, an attacker can effectively predict the target genotypes and phenotypes of target individuals based on genome information shared by individuals or their relatives, and genotype and phenotype association from genome-wide association study (GWAS). To address the privacy threats resulted from such inference attacks, we elaborate the metrics to evaluate data utility and privacy and then present a data sanitization method. We evaluate our inference attack algorithm and data sanitization method on real GWAS dataset: Age-related macular degeneration (AMD) case/control dataset. The evaluation results show that our work can effectively defense against genome threats while guaranteeing data utility.
C1 [He, Zaobo; Li, Ji; Li, Yingshu] Georgia State Univ, Dept Comp Sci, Atlanta, GA 30303 USA.
   [Yu, Jiguo] Qufu Normal Univ, Sch Informat Sci & Engn, Rizhao 276826, Shandong, Peoples R China.
   [Han, Qilong] Harbin Engn Univ, Coll Comp Sci & Technol, Harbin 150001, Peoples R China.
   [Luo, Guangchun] Univ Elect Sci & Technol China, Sch Comp Sci & Engn, Chengdu 610054, Sichuan, Peoples R China.
C3 University System of Georgia; Georgia State University; Qufu Normal
   University; Harbin Engineering University; University of Electronic
   Science & Technology of China
RP He, ZB (通讯作者)，Georgia State Univ, Dept Comp Sci, Atlanta, GA 30303 USA.
EM zhe4@student.gsu.edu; jiguoyu@sina.com; jli30@student.gsu.edu;
   hanqilong@hrbeu.edu.cn; gcluo@uestc.edu.cn; yili@gsu.edu
RI He, Zaobo/Y-7594-2018; Yu, Jiguo/I-5242-2014
OI Yu, Jiguo/0000-0001-6451-1158; han, qilong/0000-0002-5185-8387
FU US National Science Foundation (NSF) [1252292, 1741277, 1704287];
   Foundation of Science AMP; Technology Department of Sichuan province
   [2017JZ0031]; NSF of Shandong Province [ZR2012FM023]; National Science
   Foundation (NSF) of China [61771289, 61672321, 61373027, 61502116,
   61370084, 61632010, 61602129]
FX This work is partly supported by the US National Science Foundation
   (NSF) under grants NOs 1252292, 1741277, 1704287, the Foundation of
   Science & Technology Department of Sichuan province (NO. 2017JZ0031),
   and the NSF of Shandong Province under Contract ZR2012FM023. This work
   is partly supported by the National Science Foundation (NSF) of China
   under grants 61771289, 61672321, 61373027, 61502116, 61370084, 61632010
   and 61602129.
CR [Anonymous], 2014, P 13 WORKSHOP PRIVAC
   Ayday E, 2015, COMPUTER, V48, P58, DOI 10.1109/MC.2015.59
   Cai ZP, 2018, IEEE T DEPEND SECURE, V15, P577, DOI 10.1109/TDSC.2016.2613521
   Dwork C, 2006, LECT NOTES COMPUT SC, V4052, P1
   Erlich Y, 2014, NAT REV GENET, V15, P409, DOI 10.1038/nrg3723
   Fishelson M, 2002, Bioinformatics, V18 Suppl 1, pS189
   Guo X, 2015, LECT N BIOINFORMAT, V9096, P96, DOI 10.1007/978-3-319-19048-8_9
   Guo X, 2014, BMC BIOINFORMATICS, V15, DOI 10.1186/1471-2105-15-102
   Gymrek M, 2013, SCIENCE, V339, P321, DOI 10.1126/science.1229566
   He ZB, 2017, PERS UBIQUIT COMPUT, V21, P43, DOI 10.1007/s00779-016-0972-2
   He ZB, 2016, PERS UBIQUIT COMPUT, V20, P833, DOI 10.1007/s00779-016-0952-6
   Howie B, 2012, NAT GENET, V44, P955, DOI 10.1038/ng.2354
   Humbert M., 2015, PROC 1 ENHANCING TEC, V2015, P99, DOI [10.1515/popets-2015-0020, DOI 10.1515/POPETS-2015-0020]
   Humbert M., 2013, P ACM SIGSAC C COMP
   Johnson A, 2013, 19TH ACM SIGKDD INTERNATIONAL CONFERENCE ON KNOWLEDGE DISCOVERY AND DATA MINING (KDD'13), P1079
   Marchini J, 2010, NAT REV GENET, V11, P499, DOI 10.1038/nrg2796
   Mourad R, 2012, BRIEF BIOINFORM, V13, P20, DOI 10.1093/bib/bbr015
   Nyholt DR, 2009, EUR J HUM GENET, V17, P147, DOI 10.1038/ejhg.2008.198
   O'Connell J, 2016, NAT GENET, V48, P817, DOI 10.1038/ng.3583
   Sviridenko M, 2004, OPER RES LETT, V32, P41, DOI 10.1016/S0167-6377(03)00062-2
   Sweeney L, 2013, CISC VIS NETW IND GL
   Wang Y, 2013, INT CONF ACOUST SPEE, P1041, DOI 10.1109/ICASSP.2013.6637808
   Zhang LC, 2016, IEEE T NETW SERV MAN, V13, P335, DOI 10.1109/TNSM.2016.2559448
   Zhang L, 2016, IEEE INT C BIOINFORM, P529, DOI 10.1109/BIBM.2016.7822576
NR 24
TC 5
Z9 5
U1 4
U2 10
PU IEEE COMPUTER SOC
PI LOS ALAMITOS
PA 10662 LOS VAQUEROS CIRCLE, PO BOX 3014, LOS ALAMITOS, CA 90720-1314 USA
SN 1545-5963
EI 1557-9964
J9 IEEE ACM T COMPUT BI
JI IEEE-ACM Trans. Comput. Biol. Bioinform.
PD MAY-JUN
PY 2020
VL 17
IS 3
BP 930
EP 937
DI 10.1109/TCBB.2018.2810180
PG 8
WC Biochemical Research Methods; Computer Science, Interdisciplinary
   Applications; Mathematics, Interdisciplinary Applications; Statistics &
   Probability
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Computer Science; Mathematics
GA MB9WK
UT WOS:000542948000021
PM 29994587
OA hybrid
DA 2022-11-30
ER

PT J
AU Smallfield, S
   Kaldenberg, J
AF Smallfield, Stacy
   Kaldenberg, Jennifer
TI Occupational Therapy Interventions for Older Adults With Low Vision
SO AMERICAN JOURNAL OF OCCUPATIONAL THERAPY
LA English
DT Article
ID REHABILITATION OUTCOMES
AB Evidence Connection articles provide clinical application of systematic reviews developed in conjunction with the American Occupational Therapy Association's (AOTA's) Evidence-Based Practice Project. Findings from the systematic review of occupational therapy for older adults with low vision were published in the Jan uary/February 2020 issue of the American Journal of Occupational Therapy (AJOT) and in AOTA's Occupational Therapy Practice Guidelines for Older Adults With Loth Vision. published in the March/April 2020 issue of AJOT. In this article, we describe a case report of an older adult with low vision who was referred to outpatient occupational therapy services because of a recent progression of her age-related macular degeneration that led to a decline in functional independence. Each article H the Evidence Connection series summarizes the evidence from the published reviews on a given topic and presents an application of the evidence to a related clinical case. These articles illustrate how the research evidence from the reviews can be used to inform and guide clinical decision making.
C1 [Smallfield, Stacy] Washington Univ, Sch Med, Occupat Therapy & Med, St Louis, MO 63130 USA.
   [Smallfield, Stacy] Washington Univ, Sch Med, Occupat Therapy Entry Level Profess Program, St Louis, MO 63130 USA.
   [Kaldenberg, Jennifer] Boston Univ, Coll Hlth & Rehabil Sci, Sargent Coll, Occupat Therapy, Boston, MA 02215 USA.
C3 Washington University (WUSTL); Washington University (WUSTL); Boston
   University
RP Smallfield, S (通讯作者)，Washington Univ, Sch Med, Occupat Therapy & Med, St Louis, MO 63130 USA.; Smallfield, S (通讯作者)，Washington Univ, Sch Med, Occupat Therapy Entry Level Profess Program, St Louis, MO 63130 USA.
EM stacy.smallfield@wustl.edu
OI Smallfield, Stacy/0000-0002-8070-5451
CR American Macular Degeneration Foundation, AMSL CHART TEST YOUR
   [Anonymous], 2017, Am J Occup Ther, V71, p7112420030p1, DOI 10.5014/ajot.2017.716S12
   Chung STL, 2011, INVEST OPHTH VIS SCI, V52, P1164, DOI 10.1167/iovs.10-6034
   Coulmont M, 2013, HEALTH CARE MANAG, V32, P154, DOI 10.1097/HCM.0b013e31828ef643
   Gill K, 2013, EYE, V27, P639, DOI 10.1038/eye.2013.14
   Goldstein JE, 2015, JAMA OPHTHALMOL, V133, P762, DOI 10.1001/jamaophthalmol.2015.0693
   Kaldenberg J., 2013, OCCUPATIONAL THERAPY
   Kaldenberg J, 2017, BRIT J OCCUP THER, V80, P117, DOI 10.1177/0308022616648172
   Law M., 2019, COPM MANUAL CANADIAN
   Liu CJ, 2020, AM J OCCUP THER, V74, DOI 10.5014/ajot.2020.038372
   Mansfield J, 1994, MNREAD ACUITY CHARTS
   Nastasi JA, 2020, AM J OCCUP THER, V74, DOI 10.5014/ajot.2020.038521
   Palmer S, 2010, BRIT J OPHTHALMOL, V94, P494, DOI 10.1136/bjo.2008.152231
   Pearce E, 2011, BRIT J OPHTHALMOL, V95, P105, DOI 10.1136/bjo.2009.175703
   Renieri G, 2013, INT J REHABIL RES, V36, P48, DOI 10.1097/MRR.0b013e328357885b
   Rovner BW, 2013, OPHTHALMOLOGY, V120, P1649, DOI 10.1016/j.ophtha.2013.01.022
   Ryan B, 2013, BRIT J OPHTHALMOL, V97, P487, DOI 10.1136/bjophthalmol-2012-302416
   Seiple W, 2011, INVEST OPHTH VIS SCI, V52, P2938, DOI 10.1167/iovs.10-6137
   SMALLFIELD S, 2020, AM J OCCUPATIONAL TH, V74
   Smallfield S, 2020, AM J OCCUP THER, V74, DOI 10.5014/ajot.2020.038380
   Snow M, 2018, AM J OCCUP THER, V72, DOI 10.5014/ajot.2018.030205
   Stelmack JA, 2012, ARCH OPHTHALMOL-CHIC, V130, P1162, DOI 10.1001/archophthalmol.2012.1820
   Warren M., 2006, BRAIN INJURY VISUAL
   YESAVAGE JA, 1983, J PSYCHIATR RES, V17, P37, DOI 10.1016/0022-3956(82)90033-4
NR 24
TC 1
Z9 1
U1 1
U2 7
PU AMER OCCUPATIONAL THERAPY ASSOC, INC
PI BETHESDA
PA 4720 MONTGOMERY LANE, BETHESDA, MD 20814-3425 USA
SN 0272-9490
EI 1943-7676
J9 AM J OCCUP THER
JI Am. J. Occup. Ther.
PD MAR-APR
PY 2020
VL 74
IS 2
AR 7402390010
DI 10.5014/ajot.2020.742004
PG 5
WC Rehabilitation
WE Social Science Citation Index (SSCI)
SC Rehabilitation
GA LF8NO
UT WOS:000527671600022
PM 32204789
OA Bronze
DA 2022-11-30
ER

PT J
AU Liu, L
   Li, Y
   Zhang, GS
   Wu, JY
   Majithia, S
   Tham, YC
   Zhang, H
   Chen, L
AF Liu, Lei
   Li, Yan
   Zhang, Gui-Sen
   Wu, Jing-Yang
   Majithia, Shivani
   Tham, Yih-Chung
   Zhang, Han
   Chen, Lei
TI Top 100 cited articles in ophthalmic epidemiology between 2006 and 2016
SO INTERNATIONAL JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE epidemiology; ophthalmology; article; citation; bibliometric analysis
ID CITATION ANALYSIS; TRENDS; BLINDNESS; SURGERY
AB AIM: To identify the most-cited articles in ophthalmic epidemiology over the last decade.
   METHODS: We performed a cited reference search on articles that were included in the ISI Web of Science database using the terms "Epidemi*" AND "ophthalm*" AND "population*" during year 2006 to 2016. TOP 100 most cited articles (T100) in ophthalmic epidemiology were short listed and analysed using bibliometrics.
   RESULTS: These top 100 articles in ophthalmic epidemiology were cited between 61 to 333 times. Of these T100 articles, 36% originated from United States, and 34% were published in the Ophthalmology journal. The three major topics identified were age-related macular degeneration (AMD, n=23), glaucoma (n=16) and visual impairment (n=12). The top-cited article was a study on outdoor activities and its association with the prevalence of myopia in school-aged children, published in 2008.
   CONCLUSION: This bibliometric analysis provides useful insights into the current development in ophthalmic epidemiology in the past decade and can help recognizing the quality of the researches, discoveries, and trends steering ophthalmic epidemiology.
C1 [Liu, Lei; Wu, Jing-Yang; Zhang, Han; Chen, Lei] China Med Univ, Affiliated Hosp 1, Dept Ophthalmol, 155 Nanjing North St, Shenyang 110001, Liaoning, Peoples R China.
   [Liu, Lei] China Med Univ, Affiliated Hosp 1, Dept Publ Serv, Shenyang 110001, Liaoning, Peoples R China.
   [Liu, Lei; Majithia, Shivani; Tham, Yih-Chung] Singapore Natl Eye Ctr, Singapore Eye Res Inst, Singapore 168751, Singapore.
   [Li, Yan] China Med Univ, Sch Fundamental Sci, Dept English, Shenyang 110122, Liaoning, Peoples R China.
   [Zhang, Gui-Sen] Hohhot Chao Ju Eye Hosp, Dept Ophthalmol, Hohhot 010052, Inner Mongolia, Peoples R China.
   [Chen, Lei] Liaoning Diabet Eye Ctr, Shenyang 110001, Liaoning, Peoples R China.
C3 China Medical University; China Medical University; National University
   of Singapore; Singapore National Eye Center; China Medical University
RP Liu, L (通讯作者)，China Med Univ, Affiliated Hosp 1, Dept Ophthalmol, 155 Nanjing North St, Shenyang 110001, Liaoning, Peoples R China.
EM China.liuleijiao@163.com
RI Chung, Yih/AIF-2414-2022
OI Chung, Yih/0000-0002-6752-797X; Zhang, Han/0000-0002-9338-0051
FU National Natural Science Foundation of China [81300783]; Scientific
   Research Project of Liaoning Provincial Department of Education
   [LQNK201703]
FX Supported by National Natural Science Foundation of China (No.
   81300783); Scientific Research Project of Liaoning Provincial Department
   of Education (No. LQNK201703).
CR Barlow P, 2017, GLOBALIZATION HEALTH, V13, DOI 10.1186/s12992-017-0240-x
   Barnes KL, 2017, J CLIN EPIDEMIOL, V86, P153, DOI 10.1016/j.jclinepi.2017.03.003
   Bressler NM, 2013, JAMA OPHTHALMOL, V131, P839, DOI 10.1001/jamaophthalmol.2013.5420
   Dabi Y, 2016, OBES SURG, V26, P2691, DOI 10.1007/s11695-016-2160-x
   GARFIELD E, 1975, SCIENCE, V189, P397, DOI 10.1126/science.189.4200.397
   GARFIELD E, 1987, JAMA-J AM MED ASSOC, V257, P52, DOI 10.1001/jama.257.1.52
   GARFIELD E, 1972, SCIENCE, V178, P471, DOI 10.1126/science.178.4060.471
   Iftikhar M, 2018, AM J OPHTHALMOL, V185, P101, DOI 10.1016/j.ajo.2017.10.014
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Krishnan T, 2015, CLIN EXP OPHTHALMOL, V43, P282, DOI 10.1111/ceo.12409
   Lin ZN, 2017, INT J OPHTHALMOL-CHI, V10, P1586, DOI 10.18240/ijo.2017.10.17
   Pagel PS, 2015, ANESTHESIOLOGY, V123, P683, DOI 10.1097/ALN.0000000000000737
   Ramke J, 2018, OPHTHAL EPIDEMIOL, V25, P13, DOI 10.1080/09286586.2017.1328067
   Rangel JC, 2017, MED EDUC, V51, P918, DOI 10.1111/medu.13349
   Schulz CB, 2016, INT J OPHTHALMOL-CHI, V9, P1669, DOI 10.18240/ijo.2016.11.22
   TODD MM, 1993, ANESTHESIOLOGY, V78, P615, DOI 10.1097/00000542-199303000-00043
   Turki H, 2018, J CLIN EPIDEMIOL, V97, P124, DOI 10.1016/j.jclinepi.2017.11.002
   Vainer I, 2016, INDIAN J OPHTHALMOL, V64, P668, DOI 10.4103/0301-4738.194324
   Wilson MR, 2001, ARCH OPHTHALMOL-CHIC, V119, P1374
   Wong TY, 2008, AM J OPHTHALMOL, V146, P656, DOI 10.1016/j.ajo.2008.07.048
   Xu LA, 2007, OPHTHALMOLOGY, V114, P216, DOI 10.1016/j.ophtha.2006.06.050
   Xu L, 2006, OPHTHALMOLOGY, V113, P1134, DOI 10.1016/j.ophtha.2006.01.035
NR 22
TC 5
Z9 5
U1 5
U2 14
PU IJO PRESS
PI XI AN
PA NO 269 YOUYI EAST RD, XI AN, 710054, PEOPLES R CHINA
SN 2222-3959
EI 2227-4898
J9 INT J OPHTHALMOL-CHI
JI Int. J. Ophthalmol.
PD DEC 18
PY 2018
VL 11
IS 12
BP 1994
EP 1998
DI 10.18240/ijo.2018.12.19
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA HD8SU
UT WOS:000452830000019
PM 30588435
OA Green Published, gold, Green Submitted
DA 2022-11-30
ER

PT J
AU Pozarowska, D
   Pozarowski, P
AF Pozarowska, Dorota
   Pozarowski, Piotr
TI The era of anti-vascular endothelial growth factor (VEGF) drugs in
   ophthalmology, VEGF and anti-VEGF therapy
SO CENTRAL EUROPEAN JOURNAL OF IMMUNOLOGY
LA English
DT Review
DE safety; VEGF; macular oedema; anti-VEGF therapy; AMD
ID INTRAOCULAR-PRESSURE CHANGES; GLAUCOMA FILTRATION SURGERY; INTRAVITREAL
   INJECTION; SUSTAINED ELEVATION; NEOVASCULAR GLAUCOMA; BEVACIZUMAB;
   RANIBIZUMAB; ANGIOGENESIS; AGENTS; MANAGEMENT
AB Angiogenesis is a clue process for tissue development and function, both in normal and pathological conditions. This process is regulated by multiple molecular systems. One of the most potent is vascular endothelial growth factor (VEGF) and its receptor (VEGFR) system. Members of this family are involved in new vessel formation in embryogenesis and maturation, as well as in reparative or pathological reactions in later stages. They play a substantial role in regeneration, inflammation, wound healing, as well as in cancer pathology. Nowadays it is possible to modulate VEGF-VEGFR interactions in many pathological conditions using anti-VEGF therapy. This therapy has already achieved a grounded position in the management of rheumatological disorders, tumour progression, and metastasis. Such drugs as bevacizumab, ranibizumab, aflibercept, and pegaptanib have also proven to be very effective in the treatment of several ocular diseases, such as age-related macular degeneration (AMD), macular oedema, or proliferative retinopathies and iris neovascularisation. The indications for the application of this therapy in ophthalmology are becoming wider and wider. It may also be used for corneal pathologies and in anti-glaucoma procedures.
C1 [Pozarowska, Dorota] Med Univ Lublin, Dept Diagnost & Microsurg Glaucoma, Chair Ophthalmol, Lublin, Poland.
   [Pozarowski, Piotr] Med Univ Lublin, Dept Clin Immunol, Chodzki 4 A, PL-20093 Lublin, Poland.
C3 Medical University of Lublin; Medical University of Lublin
RP Pozarowski, P (通讯作者)，Med Univ Lublin, Dept Clin Immunol, Chodzki 4 A, PL-20093 Lublin, Poland.
EM ppozarowski@yahoo.com
OI Pozarowski, Piotr/0000-0002-0526-510X
CR Akpek EK, 2013, AM J MANAG CARE, V19, pS76
   Al-Latayfeh M, 2012, CSH PERSPECT MED, V2, DOI 10.1101/cshperspect.a006411
   Andreoli CM, 2007, CURR OPIN OPHTHALMOL, V18, P502, DOI 10.1097/ICU.0b013e3282f0ca54
   Aref AA, 2012, CURR OPIN OPHTHALMOL, V23, P105, DOI 10.1097/ICU.0b013e32834ff41d
   Aspelund A, 2014, J CLIN INVEST, V124, P3975, DOI 10.1172/JCI75395
   Bahar I, 2012, CURR OPIN OPHTHALMOL, V23, P303, DOI 10.1097/ICU.0b013e3283548459
   Bakri SJ, 2008, RETINA-J RET VIT DIS, V28, P996, DOI 10.1097/IAE.0b013e31816c6868
   Bakri SJ, 2008, GRAEF ARCH CLIN EXP, V246, P955, DOI 10.1007/s00417-008-0819-2
   Bakri SJ, 2008, GRAEF ARCH CLIN EXP, V246, P779, DOI 10.1007/s00417-007-0754-7
   Bakri SJ, 2014, OPHTHALMOLOGY, V121, P1102, DOI 10.1016/j.ophtha.2013.11.029
   Cacciamani A, 2013, JPN J OPHTHALMOL, V57, P63, DOI 10.1007/s10384-012-0194-8
   Cardarelli WJ, 2013, AM J MANAG CARE, V19, pS85
   Chalam KV, 2014, JAMA OPHTHALMOL, V132, P1350, DOI 10.1001/jamaophthalmol.2014.2356
   Chang JH, 2012, SURV OPHTHALMOL, V57, P415, DOI 10.1016/j.survophthal.2012.01.007
   Chen SD, 2015, ACTA OPHTHALMOL, V93, pE556, DOI 10.1111/aos.12624
   Choi DY, 2011, RETINA-J RET VIT DIS, V31, P1028, DOI 10.1097/IAE.0b013e318217ffde
   Daneshvar Ramin, 2013, J Ophthalmic Vis Res, V8, P182
   Dedania VS, 2015, RETINA-J RET VIT DIS, V35, P841, DOI 10.1097/IAE.0000000000000520
   Foxton RH, 2013, AM J PATHOL, V182, P1379, DOI 10.1016/j.ajpath.2012.12.032
   Gismondi M, 2009, J GLAUCOMA, V18, P658, DOI 10.1097/IJG.0b013e31819c4893
   Good TJ, 2011, BRIT J OPHTHALMOL, V95, P1111, DOI 10.1136/bjo.2010.180729
   Higashide T, 2012, GRAEF ARCH CLIN EXP, V250, P603, DOI 10.1007/s00417-011-1865-8
   Hoang QV, 2012, OPHTHALMOLOGY, V119, P321, DOI 10.1016/j.ophtha.2011.08.011
   Hollands H, 2007, CAN J OPHTHALMOL, V42, P807, DOI 10.3129/i07-172
   Horsley MB, 2010, CURR OPIN OPHTHALMOL, V21, P112, DOI 10.1097/ICU.0b013e3283360aad
   Kahook MY, 2010, J GLAUCOMA, V19, P437, DOI 10.1097/IJG.0b013e3181ca74de
   Kahook MY, 2010, RETINA-J RET VIT DIS, V30, P887, DOI 10.1097/IAE.0b013e3181d50cea
   Kahook MY, 2009, OPHTHAL SURG LAS IM, V40, P293, DOI 10.3928/15428877-20090430-12
   Karpinich NO, 2014, J CLIN INVEST, V124, P3701, DOI 10.1172/JCI77507
   Kaur C, 2006, INVEST OPHTH VIS SCI, V47, P1126, DOI 10.1167/iovs.05-0518
   Kaur C, 2008, CLIN OPHTHALMOL, V2, P879, DOI 10.2147/opth.s3361
   Kiddee W, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0137833
   Kim JE, 2008, AM J OPHTHALMOL, V146, P930, DOI 10.1016/j.ajo.2008.07.007
   Kim M, 2015, SURV OPHTHALMOL, V60, P524, DOI 10.1016/j.survophthal.2015.04.003
   Kim YJ, 2014, AM J OPHTHALMOL, V157, P1266, DOI 10.1016/j.ajo.2014.02.035
   Kimoto K, 2012, J OPHTHALMOL, V2012, DOI 10.1155/2012/852183
   Klein A, 2016, DEV OPHTHALMOL, V55, P232, DOI 10.1159/000431199
   Mansour AM, 2012, CLIN OPHTHALMOL, V6, P343, DOI 10.2147/OPTH.S29075
   Noma H, 2014, OPHTHALMOLOGICA, V232, P102, DOI 10.1159/000360303
   Osaadon P, 2014, EYE, V28, P510, DOI 10.1038/eye.2014.13
   Park SC, 2012, EXPERT OPIN BIOL TH, V12, P1641, DOI 10.1517/14712598.2012.721772
   Popescu V, 2015, J Med Life, V8, P8
   Rusovici R, 2011, MOL VIS, V17, P3339
   Ryu CL, 2014, J OPHTHALMOL, V2014, DOI 10.1155/2014/317694
   Sampat KM, 2010, CURR OPIN OPHTHALMOL, V21, P178, DOI 10.1097/ICU.0b013e328338679a
   Shibuya M, 2014, BIOMOL THER, V22, P1, DOI 10.4062/biomolther.2013.113
   Shibuya M, 2013, J BIOCHEM, V153, P13, DOI 10.1093/jb/mvs136
   Shibuya Masabumi, 2011, Genes Cancer, V2, P1097, DOI 10.1177/1947601911423031
   Simha A, 2013, REV COCHRANE DATABAS, V10
   Singh RSJ, 2012, DRUG AGING, V29, P949, DOI 10.1007/s40266-012-0031-2
   Skalicky SE, 2012, OPHTHAL SURG LAS IM, V43, P328, DOI 10.3928/15428877-20120618-01
   Sniegowski M, 2010, OPEN OPHTHALMOL J, V4, P28, DOI 10.2174/1874364101004010028
   SooHoo JR, 2014, CURR OPIN OPHTHALMOL, V25, P127, DOI 10.1097/ICU.0000000000000036
   SooHoo JR, 2013, SEMIN OPHTHALMOL, V28, P165, DOI 10.3109/08820538.2012.730103
   Tolentino M, 2011, SURV OPHTHALMOL, V56, P95, DOI 10.1016/j.survophthal.2010.08.006
   Tseng JJ, 2012, J GLAUCOMA, V21, P241, DOI 10.1097/IJG.0b013e31820d7d19
   Ueta T, 2009, OPHTHALMOLOGY, V116, P362, DOI 10.1016/j.ophtha.2008.09.046
   Van Bergen T, 2011, EXP EYE RES, V93, P689, DOI 10.1016/j.exer.2011.08.016
   Wilhelm A, 2015, OPHTHALMOLOGE, V112, P346, DOI 10.1007/s00347-014-3116-y
   Wu L, 2008, GRAEF ARCH CLIN EXP, V246, P81, DOI 10.1007/s00417-007-0660-z
   Xiong Q, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088403
   Zheng W, 2014, J CLIN INVEST, V124, P878, DOI 10.1172/JCI71603
NR 62
TC 50
Z9 57
U1 1
U2 11
PU TERMEDIA PUBLISHING HOUSE LTD
PI POZNAN
PA KLEEBERGA ST 2, POZNAN, 61-615, POLAND
SN 1426-3912
EI 1644-4124
J9 CENT EUR J IMMUNOL
JI Central Eur. J. Immunol.
PY 2016
VL 41
IS 3
BP 311
EP 316
DI 10.5114/ceji.2016.63132
PG 6
WC Immunology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Immunology
GA EA3WF
UT WOS:000386539300013
PM 27833450
OA Green Published, Green Submitted, gold
DA 2022-11-30
ER

PT J
AU Pearson, RA
AF Pearson, Rachael A.
TI Advances in repairing the degenerate retina by rod photoreceptor
   transplantation
SO BIOTECHNOLOGY ADVANCES
LA English
DT Review
DE Photoreceptor; Transplantation; Gliosis; Degeneration; Stem cells; Eye;
   Visual function; Development; Neural retina
ID PLURIPOTENT STEM-CELLS; NEURAL PROGENITOR CELLS; LEBERS CONGENITAL
   AMAUROSIS; CILIARY EPITHELIAL-CELLS; ADULT MAMMALIAN EYE; IN-VITRO;
   MACULAR DEGENERATION; VISUAL FUNCTION; MULLER GLIA; MORPHOLOGICAL
   INTEGRATION
AB Despite very different aetiologies, age-related macular degeneration (AMD) and most inherited retinal disorders culminate in the same final common pathway, loss of the light-sensitive photoreceptors. There are few clinical treatments and none can reverse the loss of vision. Photoreceptor replacement by transplantation is proposed as a broad treatment strategy applicable to all degenerations. The past decade has seen a number of landmark achievements in this field, which together provide strong justification for continuing investigation into photoreceptor replacement strategies. These include proof of principle for restoring vision by rod-photoreceptor transplantation in mice with congenital stationary night blindness and advances in stem cell biology, which have led to the generation of complete optic structures in vitro from embryonic stem cells. The latter represents enormous potential for generating suitable and renewable donor cells with which to achieve the former. However, there are still challenges presented by the degenerating recipient retinal environment that must be addressed as we move to translating these technologies towards clinical application. (C) 2014 The Author. Published by Elsevier Inc. All rights reserved.
C1 UCL Inst Ophthalmol, Dept Genet, London EC1V 9EL, England.
C3 University of London; University College London
RP Pearson, RA (通讯作者)，UCL Inst Ophthalmol, Dept Genet, 11-43 Bath St, London EC1V 9EL, England.
EM rachael.pearson@ucl.ac.uk
RI Pearson, Rachael/Y-3339-2018
OI Pearson, Rachael/0000-0002-1107-1969
FU Medical Research Council [G03000341, mr/j004553/1, 6HAT/DENR]; Wellcome
   Trust [086128/Z/08/Z]; BBSRC [BB/I013636/1]; RP Fighting Blindness
   [GR566]; Fight for Sight [1448/1449]; MRC [MR/J004553/1] Funding Source:
   UKRI; Biotechnology and Biological Sciences Research Council
   [BB/I013636/1] Funding Source: researchfish; Medical Research Council
   [MR/J004553/1] Funding Source: researchfish; National Institute for
   Health Research [NF-SI-0513-10074, NF-SI-0508-10130] Funding Source:
   researchfish; Fight for Sight [1448/49] Funding Source: researchfish
FX RAP is a Royal Society University Research Fellow (RG080398) and is
   generously supported by grants from the Medical Research Council
   (G03000341; mr/j004553/1; 6HAT/DENR), the Wellcome Trust (086128/Z/08/Z;
   4 yr PhD Neuroscience scheme), BBSRC (BB/I013636/1), RP Fighting
   Blindness (GR566) and Fight for Sight (1448/1449).
CR Ahmad I, 2000, BIOCHEM BIOPH RES CO, V270, P517, DOI 10.1006/bbrc.2000.2473
   Akimoto M, 2006, P NATL ACAD SCI USA, V103, P3890, DOI 10.1073/pnas.0508214103
   Bainbridge JWB, 2008, NEW ENGL J MED, V358, P2231, DOI 10.1056/NEJMoa0802268
   Barber AC, 2013, P NATL ACAD SCI USA, V110, P354, DOI 10.1073/pnas.1212677110
   Bartsch U, 2008, EXP EYE RES, V86, P691, DOI 10.1016/j.exer.2008.01.018
   Bernardos RL, 2007, J NEUROSCI, V27, P7028, DOI 10.1523/JNEUROSCI.1624-07.2007
   BIGNAMI A, 1979, EXP EYE RES, V28, P63
   Bull ND, 2011, STEM CELLS, V29, P1170, DOI 10.1002/stem.676
   Calame M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023782
   Chader GJ, 2009, PROG BRAIN RES, V175, P317, DOI 10.1016/S0079-6123(09)17522-2
   Chen LF, 2012, EXP NEUROL, V234, P488, DOI 10.1016/j.expneurol.2012.01.023
   Cicero SA, 2009, P NATL ACAD SCI USA, V106, P6685, DOI 10.1073/pnas.0901596106
   Coles BLK, 2004, P NATL ACAD SCI USA, V101, P15772, DOI 10.1073/pnas.0401596101
   Eberle D, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046305
   Eiraku M, 2011, NATURE, V472, P51, DOI 10.1038/nature09941
   ENG LF, 1994, BRAIN PATHOL, V4, P229, DOI 10.1111/j.1750-3639.1994.tb00838.x
   Fang Y, 2013, STEM CELLS, V31, P349, DOI 10.1002/stem.1283
   Fischer AJ, 2000, DEV BIOL, V220, P197, DOI 10.1006/dbio.2000.9640
   Fischer AJ, 2002, DEVELOPMENT, V129, P2283
   Ghosh F, 2004, RETINA-J RET VIT DIS, V24, P98, DOI 10.1097/00006982-200402000-00014
   Ghosh F, 1999, EXP EYE RES, V68, P67, DOI 10.1006/exer.1998.0582
   Giordano F, 2007, MOL VIS, V13, P1842
   Gonzalez-Cordero A, 2013, NAT BIOTECHNOL, V31, P741, DOI 10.1038/nbt.2643
   Gouras P, 2003, GRAEF ARCH CLIN EXP, V241, P403, DOI 10.1007/s00417-003-0648-2
   Gualdoni S, 2010, STEM CELLS, V28, P1048, DOI 10.1002/stem.423
   Gust J, 2011, INVEST OPHTH VIS SCI, V52, P5266, DOI 10.1167/iovs.10-6329
   Hirami Y, 2009, NEUROSCI LETT, V458, P126, DOI 10.1016/j.neulet.2009.04.035
   Howden SE, 2011, P NATL ACAD SCI USA, V108, P6537, DOI 10.1073/pnas.1103388108
   Humayun MS, 2000, INVEST OPHTH VIS SCI, V41, P3100
   Ikeda H, 2005, P NATL ACAD SCI USA, V102, P11331, DOI 10.1073/pnas.0500010102
   Inatani M, 2000, INVEST OPHTH VIS SCI, V41, P2748
   Jin ZB, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017084
   Karl MO, 2010, TRENDS MOL MED, V16, P193, DOI 10.1016/j.molmed.2010.02.003
   Karl MO, 2008, P NATL ACAD SCI USA, V105, P19508, DOI 10.1073/pnas.0807453105
   Kinouchi R, 2003, NAT NEUROSCI, V6, P863, DOI 10.1038/nn1088
   Kiyama T, 2012, J NEUROSCI, V32, P12797, DOI 10.1523/JNEUROSCI.0118-12.2012
   Klassen H, 2007, VET OPHTHALMOL, V10, P245, DOI 10.1111/j.1463-5224.2007.00547.x
   Lakowski J, 2010, HUM MOL GENET, V19, P4545, DOI 10.1093/hmg/ddq378
   Lamba DA, 2006, P NATL ACAD SCI USA, V103, P12769, DOI 10.1073/pnas.0601990103
   Lamba DA, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008763
   Lamba DA, 2009, CELL STEM CELL, V4, P73, DOI 10.1016/j.stem.2008.10.015
   LANDERS RA, 1994, J NEUROCHEM, V63, P737
   LAYER PG, 1989, CELL TISSUE RES, V258, P233
   MacLaren RE, 2006, NATURE, V444, P203, DOI 10.1038/nature05161
   MacNeil A, 2007, STEM CELLS, V25, P2430, DOI 10.1634/stemcells.2007-0035
   Maguire AM, 2008, NEW ENGL J MED, V358, P2240, DOI 10.1056/NEJMoa0802315
   Mellough CB, 2007, RESTOR NEUROL NEUROS, V25, P177
   Meyer JS, 2009, P NATL ACAD SCI USA, V106, P16698, DOI 10.1073/pnas.0905245106
   Osakada F, 2009, NAT PROTOC, V4, P811, DOI 10.1038/nprot.2009.51
   Owen CG, 2012, BRIT J OPHTHALMOL, V96, P752, DOI 10.1136/bjophthalmol-2011-301109
   Pearson RA, 2012, NATURE, V485, P99, DOI 10.1038/nature10997
   Pearson RA, 2010, CELL TRANSPLANT, V19, P487, DOI 10.3727/096368909X486057
   PEDERSEN OO, 1979, EXP EYE RES, V28, P569, DOI 10.1016/0014-4835(79)90044-7
   Qiu GT, 2005, EXP EYE RES, V80, P515, DOI 10.1016/j.exer.2004.11.001
   Radtke ND, 1999, AM J OPHTHALMOL, V128, P384, DOI 10.1016/S0002-9394(99)00250-0
   Radtke ND, 2008, AM J OPHTHALMOL, V146, P172, DOI 10.1016/j.ajo.2008.04.009
   Ramachandran R, 2012, NAT CELL BIOL, V14, P1013, DOI 10.1038/ncb2586
   Ramachandran R, 2010, NAT CELL BIOL, V12, P1101, DOI 10.1038/ncb2115
   Raymond PA, 2006, BMC DEV BIOL, V6, DOI 10.1186/1471-213X-6-36
   Reh TA, 1998, J NEUROBIOL, V36, P206, DOI 10.1002/(SICI)1097-4695(199808)36:2<206::AID-NEU8>3.0.CO;2-5
   Roesch Karin, 2012, Mol Vis, V18, P1197
   Sakaguchi DS, 2005, ANN NY ACAD SCI, V1049, P118, DOI 10.1196/annals.1334.012
   Sakaguchi DS, 2004, DEV NEUROSCI-BASEL, V26, P336, DOI 10.1159/000082275
   Sakaguchi DS, 2003, ANN NY ACAD SCI, V995, P127, DOI 10.1111/j.1749-6632.2003.tb03216.x
   Sam TN, 2006, CELL TRANSPLANT, V15, P147, DOI 10.3727/000000006783982098
   Schwartz SD, 2012, LANCET, V379, P713, DOI 10.1016/S0140-6736(12)60028-2
   Seiler MJ, 2008, EUR J NEUROSCI, V28, P208, DOI 10.1111/j.1460-9568.2008.06279.x
   Singh MS CIP, 2013, P NATL ACAD SCI US, V110
   Singh R, 2013, HUM MOL GENET, V22, P593, DOI 10.1093/hmg/dds469
   Singhal S, 2008, STEM CELLS, V26, P1074, DOI 10.1634/stemcells.2007-0898
   Suzuki T, 2007, CELL TRANSPLANT, V16, P493, DOI 10.3727/000000007783464966
   Suzuki T, 2006, STEM CELLS, V24, P2406, DOI 10.1634/stemcells.2005-0587
   Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024
   Tropepe V, 2000, SCIENCE, V287, P2032, DOI 10.1126/science.287.5460.2032
   TURNER JE, 1988, PROG BRAIN RES, V78, P131
   Van Hoffelen SJ, 2003, INVEST OPHTH VIS SCI, V44, P426, DOI 10.1167/iovs.02-0269
   Warre-Cornish K, 2013, STEM CELLS DEV
   Watanabe K, 2005, NAT NEUROSCI, V8, P288, DOI 10.1038/nn1402
   West EL, 2008, EXP EYE RES, V86, P601, DOI 10.1016/j.exer.2008.01.004
   West EL, 2012, STEM CELLS, V30, P1424, DOI 10.1002/stem.1123
   West EL, 2010, STEM CELLS, V28, P1997, DOI 10.1002/stem.520
   WILLBOLD E, 1992, EUR J NEUROSCI, V4, P210, DOI 10.1111/j.1460-9568.1992.tb00869.x
   Yang P, 2002, J NEUROSCI RES, V69, P466, DOI 10.1002/jnr.10320
   Yao J, 2011, BIOMATERIALS, V32, P1041, DOI 10.1016/j.biomaterials.2010.09.063
   Young MJ, 2000, MOL CELL NEUROSCI, V16, P197, DOI 10.1006/mcne.2000.0869
   Zhang Y, 2007, J NEUROSCI, V27, P4499, DOI 10.1523/JNEUROSCI.0200-07.2007
   Zhang YQ, 2003, INVEST OPHTH VIS SCI, V44, P4936, DOI 10.1167/iovs.02-0640
NR 87
TC 37
Z9 38
U1 1
U2 12
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0734-9750
EI 1873-1899
J9 BIOTECHNOL ADV
JI Biotechnol. Adv.
PD MAR-APR
PY 2014
VL 32
IS 2
BP 485
EP 491
DI 10.1016/j.biotechadv.2014.01.001
PG 7
WC Biotechnology & Applied Microbiology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology
GA AR5RE
UT WOS:000343640400019
PM 24412415
OA Green Published, hybrid
DA 2022-11-30
ER

PT J
AU Subczynski, WK
   Wisniewska, A
   Widomska, J
AF Subczynski, Witold K.
   Wisniewska, Anna
   Widomska, Justyna
TI Location of macular xanthophylls in the most vulnerable regions of
   photoreceptor outer-segment membranes
SO ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS
LA English
DT Review
DE Macular xanthophylls; Lutein; Zeaxanthin; Membrane; AMD; POS
ID ALKYL-CHAIN-LENGTH; LIPID-BILAYERS; BETA-CAROTENE; POLAR CAROTENOIDS;
   BINDING-PROTEIN; FATTY-ACIDS; RADICALS RELATIONSHIP; BIOLOGIC
   MECHANISMS; OXIDATIVE DAMAGE; OPTICAL-DENSITY
AB Lutein and zeaxanthin are two dietary carotenoids that compose the macular pigment of the primate retina. Another carotenoid, meso-zeaxanthin, is formed from lutein in the retina. A membrane location is one possible site where these dipolar, terminally dihydroxylated carotenoids, named macular xanthophylls, are accumulated in the nerve fibers and photoreceptor outer segments. Macular xanthophylls are oriented perpendicular to the membrane surface, which ensures their high solubility, stability, and significant effects on membrane properties. It was recently shown that they are selectively accumulated in membrane domains that contain unsaturated phospholipids, and thus are located in the most vulnerable regions of the membrane. This location is ideal if they are to act as lipid antioxidants, which is the most accepted mechanism through which lutein and zeaxanthin protect the retina from age-related macular degeneration. In this mini-review, we examine published data on carotenoid-membrane interactions and present our hypothesis that the specific orientation and location of macular xanthophylls maximize their protective action in membranes of the eye retina. (C) 2010 Elsevier Inc. All rights reserved.
C1 [Subczynski, Witold K.; Wisniewska, Anna; Widomska, Justyna] Med Coll Wisconsin, Dept Biophys, Milwaukee, WI 53226 USA.
   [Wisniewska, Anna] Jagiellonian Univ, Dept Biophys, Fac Biochem Biophys & Biotechnol, Krakow, Poland.
   [Widomska, Justyna] Jagiellonian Univ, Dept Plant Physiol & Biochem, Fac Biochem Biophys & Biotechnol, Krakow, Poland.
   [Widomska, Justyna] Med Univ, Dept Biophys, Lublin, Poland.
C3 Medical College of Wisconsin; Jagiellonian University; Jagiellonian
   University; Medical University of Lublin
RP Subczynski, WK (通讯作者)，Med Coll Wisconsin, Dept Biophys, 8701 Watertown Plank Rd, Milwaukee, WI 53226 USA.
EM subczyn@mcw.edu
RI Wisniewska, Anna M/J-4339-2017
OI Wisniewska, Anna M/0000-0001-7076-5445; Widomska,
   Justyna/0000-0003-2358-4099
FU National Institutes of Health [EY015526, EB002052, EB001980]; Polish
   Ministry of Higher Education and Science [PBZ/MNiSW/07/2006/01]; FOGARTY
   INTERNATIONAL CENTER [R03TW008052] Funding Source: NIH RePORTER;
   NATIONAL EYE INSTITUTE [R01EY015526] Funding Source: NIH RePORTER;
   NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING
   [R01EB002052, P41EB001980] Funding Source: NIH RePORTER
FX This work was supported by Grants EY015526, EB002052, and EB001980 of
   the National Institutes of Health and by the POL-POSTDOC III
   PBZ/MNiSW/07/2006/01 Grant of the Polish Ministry of Higher Education
   and Science.
CR ANDERSON RE, 1974, EXP EYE RES, V18, P205, DOI 10.1016/0014-4835(74)90149-3
   ANWAR M, 1977, NATURE, V270, P538, DOI 10.1038/270538a0
   AVELDANO MI, 1988, BIOCHEMISTRY-US, V27, P1229, DOI 10.1021/bi00404a024
   Beatty S, 2004, ARCH BIOCHEM BIOPHYS, V430, P70, DOI 10.1016/j.abb.2004.03.015
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Benting J, 1999, FEBS LETT, V462, P47, DOI 10.1016/S0014-5793(99)01501-X
   Bhosale P, 2005, BBA-MOL BASIS DIS, V1740, P116, DOI 10.1016/j.bbadis.2005.02.002
   Bhosale P, 2004, J BIOL CHEM, V279, P49447, DOI 10.1074/jbc.M405334200
   Bhosale P, 2007, ARCH BIOCHEM BIOPHYS, V458, P121, DOI 10.1016/j.abb.2006.10.005
   Bhosale P, 2009, BIOCHEMISTRY-US, V48, P4798, DOI 10.1021/bi9004478
   Boesze-Battaglia K, 1997, J EXP BIOL, V200, P2927
   Boesze-Battaglia K, 2002, J BIOL CHEM, V277, P41843, DOI 10.1074/jbc.M207111200
   BONE RA, 1992, VISION RES, V32, P105, DOI 10.1016/0042-6989(92)90118-3
   BONE RA, 1985, VISION RES, V25, P1531, DOI 10.1016/0042-6989(85)90123-3
   BONE RA, 1988, INVEST OPHTH VIS SCI, V29, P843
   BONE RA, 1984, VISION RES, V24, P103, DOI 10.1016/0042-6989(84)90094-4
   Britton G, 1995, FASEB J, V9, P1551, DOI 10.1096/fasebj.9.15.8529834
   Brown DA, 1998, J MEMBRANE BIOL, V164, P103, DOI 10.1007/s002329900397
   Cantrell A, 2003, ARCH BIOCHEM BIOPHYS, V412, P47, DOI 10.1016/S0003-9861(03)00014-6
   Cho EY, 2004, ARCH OPHTHALMOL-CHIC, V122, P883, DOI 10.1001/archopht.122.6.883
   CORNELL BA, 1983, BIOCHIM BIOPHYS ACTA, V733, P189, DOI 10.1016/0005-2736(83)90106-2
   de Almeida RFM, 2003, BIOPHYS J, V85, P2406, DOI 10.1016/S0006-3495(03)74664-5
   DELMELLE M, 1978, PHOTOCHEM PHOTOBIOL, V27, P731, DOI 10.1111/j.1751-1097.1978.tb07671.x
   During A, 2002, J LIPID RES, V43, P1086, DOI 10.1194/jlr.M200068-JLR200
   Edge R, 1997, J PHOTOCH PHOTOBIO B, V41, P189, DOI 10.1016/S1011-1344(97)00092-4
   Gabrielska J, 1996, BBA-BIOMEMBRANES, V1285, P167, DOI 10.1016/S0005-2736(96)00152-6
   Gale CR, 2003, INVEST OPHTH VIS SCI, V44, P2461, DOI 10.1167/iovs.02-0929
   Gruszecki WI, 2005, BBA-MOL BASIS DIS, V1740, P108, DOI 10.1016/j.bbadis.2004.11.015
   GRUSZECKI WI, 1991, BIOCHIM BIOPHYS ACTA, V1060, P310, DOI 10.1016/S0005-2728(05)80322-6
   Gruszecki WI, 1999, ADV PHOTOSYNTH, V8, P363
   GRUSZECKI WI, 1990, BIOCHIM BIOPHYS ACTA, V1023, P405, DOI 10.1016/0005-2736(90)90133-9
   Gruszecki WI, 2010, CAROTENOIDS: PHYSICAL, CHEMICAL, AND BIOLOGICAL FUNCTIONS AND PROPERTIES, P19
   Hammond BR, 1997, INVEST OPHTH VIS SCI, V38, P1795
   Ikonen E, 2001, CURR OPIN CELL BIOL, V13, P470, DOI 10.1016/S0955-0674(00)00238-6
   Janes PW, 1999, J CELL BIOL, V147, P447, DOI 10.1083/jcb.147.2.447
   KENNEDY TA, 1992, J BIOL CHEM, V267, P4658
   Khachik F, 1997, ANAL CHEM, V69, P1873, DOI 10.1021/ac961085i
   Kim SR, 2006, EXP EYE RES, V82, P828, DOI 10.1016/j.exer.2005.10.004
   KIRSCHFELD K, 1982, PROC R SOC SER B-BIO, V216, P71, DOI 10.1098/rspb.1982.0061
   Krinsky NI, 2003, ANNU REV NUTR, V23, P171, DOI 10.1146/annurev.nutr.23.011702.073307
   Krinsky NI, 2002, J NUTR, V132, p540S, DOI 10.1093/jn/132.3.540S
   KRINSKY NI, 1989, FREE RADICAL BIO MED, V7, P617, DOI 10.1016/0891-5849(89)90143-3
   Landrum JT, 1997, EXP EYE RES, V65, P57, DOI 10.1006/exer.1997.0309
   Landrum JT, 2004, OXIDAT STRESS DIS, V13, P445
   Landrum JT, 1999, METHOD ENZYMOL, V299, P457
   Lincoln JE, 2006, INVEST OPHTH VIS SCI, V47, P2172, DOI 10.1167/iovs.05-1167
   Litman BJ, 1996, LIPIDS, V31, pS193, DOI 10.1007/BF02637075
   Loane E, 2008, SURV OPHTHALMOL, V53, P68, DOI 10.1016/j.survophthal.2007.10.008
   London E, 2000, BBA-BIOMEMBRANES, V1508, P182, DOI 10.1016/S0304-4157(00)00007-1
   Mares JA, 2004, OXIDAT STRESS DIS, V13, P427
   Mares-Perlman JA, 2002, J NUTR, V132, p518S, DOI 10.1093/jn/132.3.518S
   Mares-Perlman JA, 2002, J NUTR, V132, p517S, DOI 10.1093/jn/132.3.517S
   Martin HD, 1999, PURE APPL CHEM, V71, P2253, DOI 10.1351/pac199971122253
   Martin RE, 2005, INVEST OPHTH VIS SCI, V46, P1147, DOI 10.1167/iovs.04-1207
   McNulty HP, 2007, BBA-BIOMEMBRANES, V1768, P167, DOI 10.1016/j.bbamem.2006.09.010
   Milanowska J, 2003, J PHOTOCH PHOTOBIO B, V72, P1, DOI 10.1016/j.jphotobiol.2003.08.009
   MILON A, 1986, BIOCHIM BIOPHYS ACTA, V859, P1, DOI 10.1016/0005-2736(86)90311-1
   MITCHELL DC, 1992, BIOCHEMISTRY-US, V31, P662, DOI 10.1021/bi00118a005
   Moffett S, 2000, J BIOL CHEM, V275, P2191, DOI 10.1074/jbc.275.3.2191
   Nair KS, 2002, CURR BIOL, V12, P421, DOI 10.1016/S0960-9822(02)00691-7
   Palozza P, 2006, CARCINOGENESIS, V27, P2383, DOI 10.1093/carcin/bgl074
   Parker RS, 1996, FASEB J, V10, P542, DOI 10.1096/fasebj.10.5.8621054
   Polozova A, 2000, BIOPHYS J, V79, P2632, DOI 10.1016/S0006-3495(00)76502-7
   Rapp LM, 2000, INVEST OPHTH VIS SCI, V41, P1200
   Ridyard MS, 2003, J BIOL CHEM, V278, P13803, DOI 10.1074/jbc.M210245200
   ROHMER M, 1979, P NATL ACAD SCI USA, V76, P847, DOI 10.1073/pnas.76.2.847
   ROIANOWSKA M, 2005, PHOTOCHEM PHOTOBIOL, V81, P1305
   Seno K, 2001, J BIOL CHEM, V276, P20813, DOI 10.1074/jbc.C100032200
   Sharma P, 2004, CELL, V116, P577, DOI 10.1016/S0092-8674(04)00167-9
   Simons K, 2000, SCIENCE, V290, P1721, DOI 10.1126/science.290.5497.1721
   Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052
   Socaciu C, 2000, CHEM PHYS LIPIDS, V106, P79, DOI 10.1016/S0009-3084(00)00135-3
   Sommerburg O, 1999, CURR EYE RES, V19, P491, DOI 10.1076/ceyr.19.6.491.5276
   Stahl W, 1998, FEBS LETT, V427, P305, DOI 10.1016/S0014-5793(98)00434-7
   STINSON AM, 1991, EXP EYE RES, V52, P213, DOI 10.1016/0014-4835(91)90261-C
   Subczynski W.K., 1998, CURR TOP BIOPHYS, V22, P44
   SUBCZYNSKI WK, 1993, BIOCHIM BIOPHYS ACTA, V1150, P173, DOI 10.1016/0005-2736(93)90087-G
   SUBCZYNSKI WK, 1992, BIOCHIM BIOPHYS ACTA, V1105, P97, DOI 10.1016/0005-2736(92)90167-K
   SUBCZYNSKI WK, 1991, BIOCHIM BIOPHYS ACTA, V1068, P68, DOI 10.1016/0005-2736(91)90061-C
   SUBCZYNSKI WK, 1994, BIOCHEMISTRY-US, V33, P7670, DOI 10.1021/bi00190a022
   Suh M, 2005, CURR EYE RES, V30, P959, DOI 10.1080/02713680500246957
   Sujak A, 1999, ARCH BIOCHEM BIOPHYS, V371, P301, DOI 10.1006/abbi.1999.1437
   Sujak A, 2002, J PHOTOCH PHOTOBIO B, V68, P39, DOI 10.1016/S1011-1344(02)00330-5
   Sujak A, 2000, BBA-BIOMEMBRANES, V1509, P255, DOI 10.1016/S0005-2736(00)00299-6
   Thomson LR, 2002, INVEST OPHTH VIS SCI, V43, P3538
   VANDEVEN M, 1984, BIOPHYS J, V45, P1203, DOI 10.1016/S0006-3495(84)84269-1
   Wang Q, 2008, J BIOL CHEM, V283, P30015, DOI 10.1074/jbc.M803953200
   Widomska J, 2008, BBA-BIOMEMBRANES, V1778, P10, DOI 10.1016/j.bbamem.2007.08.021
   Wisniewska A, 1998, BBA-BIOMEMBRANES, V1368, P235, DOI 10.1016/S0005-2736(97)00182-X
   Wisniewska A, 2003, CELL MOL BIOL LETT, V8, P147
   Wisniewska A, 2006, ACTA BIOCHIM POL, V53, P475
   Wisniewska A, 2006, FREE RADICAL BIO MED, V41, P1257, DOI 10.1016/j.freeradbiomed.2006.07.003
   Wisniewska A, 2006, FREE RADICAL BIO MED, V40, P1820, DOI 10.1016/j.freeradbiomed.2006.01.016
   Woodall AA, 1997, BBA-GEN SUBJECTS, V1336, P33, DOI 10.1016/S0304-4165(97)00006-8
   Woodall AA, 1997, BBA-GEN SUBJECTS, V1336, P575, DOI 10.1016/S0304-4165(97)00007-X
   WOODALL AA, 1995, BIOCHEM SOC T, V23, pS133, DOI 10.1042/bst023133s
   Wooten BR, 2002, PROG RETIN EYE RES, V21, P225, DOI 10.1016/S1350-9462(02)00003-4
   Yeum KJ, 2002, ANNU REV NUTR, V22, P483, DOI 10.1146/annurev.nutr.22.010402.102834
   Yin JJ, 1996, BIOPHYS J, V71, P832, DOI 10.1016/S0006-3495(96)79284-6
   YOKOYAMA A, 1995, TETRAHEDRON LETT, V36, P4901
   Young RM, 2005, J BIOL CHEM, V280, P1230, DOI 10.1074/jbc.M408339200
NR 101
TC 44
Z9 49
U1 0
U2 17
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0003-9861
EI 1096-0384
J9 ARCH BIOCHEM BIOPHYS
JI Arch. Biochem. Biophys.
PD DEC 1
PY 2010
VL 504
IS 1
SI SI
BP 61
EP 66
DI 10.1016/j.abb.2010.05.015
PG 6
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA 673OR
UT WOS:000283673300010
PM 20494651
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Schalnus, R
   Aulmann, G
   Hellenbrecht, A
   Hagele, M
   Ohrloff, C
   Luchtenberg, M
AF Schalnus, Rainer
   Aulmann, Georg
   Hellenbrecht, Anja
   Haegele, Michael
   Ohrloff, Christian
   Luechtenberg, Marc
TI Content Quality of Ophthalmic Information on the Internet
SO OPHTHALMOLOGICA
LA English
DT Article
DE Internet, health information; Eye diseases; Age-related macular
   degeneration; Visually impaired persons
ID WORLD-WIDE-WEB; HEALTH INFORMATION; ACCESSIBILITY; SITES; EDUCATION;
   WEBSITES
AB Purpose: Little is known whether information about eye conditions on the Internet is complete and accurate to support patient or layman decision making. Methods: Quality of content modules about age-related macular degeneration (AMD) was analyzed on 20 web sites. Content analysis covered 72 criteria in 11 groups. Each single criterion was rated with '1' or '0' (yes/no answer). Results: The interrater reliability between two observers was almost perfect (kappa = 0.86). On average, 25.6% (+/-15.6) of the criteria were fulfilled. In the categories diagnostic procedures, therapy, preventive checkups, prevention and prognosis of AMD, only 12.7, 18.3, 20.0, 25.0 and 30.0%, respectively, of the required content was given. Conclusion: Our study shows, based upon the example of university eye hospitals, that the full potential to provide laymen with firsthand and up-to-date information has by far not yet been achieved. Further research is needed on how the Internet influences the communication between patient and ophthalmologist. Copyright (C) 2009 S. Karger AG, Basel
C1 [Schalnus, Rainer; Aulmann, Georg; Hellenbrecht, Anja; Haegele, Michael; Ohrloff, Christian; Luechtenberg, Marc] Goethe Univ Frankfurt, Dept Ophthalmol, DE-60590 Frankfurt, Germany.
C3 Goethe University Frankfurt
RP Schalnus, R (通讯作者)，Goethe Univ Frankfurt, Dept Ophthalmol, Theodor Stern Kai 7, DE-60590 Frankfurt, Germany.
EM schalnus@schalnus.com
CR Al-Bahrani A, 2004, Colorectal Dis, V6, P323, DOI 10.1111/j.1463-1318.2004.00604.x
   [Anonymous], [No title captured]
   Baur C, 2000, MedGenMed, V2, pE35
   *BER AUG DEUTSCHL, LEITL BVA DOG
   *BER AUG DEUTSCHL, ALT MAK PAT
   *BER AUG DEUTSCHL, INTR INJ OP MED AUG
   Berland GK, 2001, JAMA-J AM MED ASSOC, V285, P2612, DOI 10.1001/jama.285.20.2612
   Charnock D, 1999, J EPIDEMIOL COMMUN H, V53, P105, DOI 10.1136/jech.53.2.105
   COHEN J, 1968, PSYCHOL BULL, V70, P213, DOI 10.1037/h0026256
   Commission of the European Communities Brussels, 2002, J Med Internet Res, V4, pE15
   Croft DR, 2002, CHEST, V121, P1301, DOI 10.1378/chest.121.4.1301
   England CY, 2004, J HUM NUTR DIET, V17, P547, DOI 10.1111/j.1365-277X.2004.00561.x
   Eysenbach G, 2000, J AM MED INFORM ASSN, P230
   Fox S, 2006, ONLINE HLTH SEARCH 2
   Kim P, 1999, BMJ-BRIT MED J, V318, P647, DOI 10.1136/bmj.318.7184.647
   LANDIS JR, 1977, BIOMETRICS, V33, P174
   Luchtenberg M, 2008, OPHTHALMOLOGICA, V222, P187, DOI 10.1159/000126082
   Maloney S, 2005, RHEUMATOLOGY, V44, P382, DOI 10.1093/rheumatology/keh498
   Martins EN, 2005, BRIT J OPHTHALMOL, V89, P565, DOI 10.1136/bjo.2004.055111
   Norman F, 1998, MED INFORM, V23, P43, DOI 10.3109/14639239809001390
   Pennekamp PH, 2006, Z ORTHOP GRENZGEB, V144, P218, DOI 10.1055/s-2006-921418
   Saithna A, 2008, SURG-J R COLL SURG E, V6, P85, DOI 10.1016/S1479-666X(08)80070-4
   Sambandam SN, 2007, ARTHROSCOPY, V23, P509, DOI 10.1016/j.arthro.2006.12.007
   SAWYER P, 1996, P C HUM FACT COMP SY, P375
   SCHALNUS R, 2001, INFORM BIOM EPIDEMIO, V32, P267
   Schriver K. A., 1989, IEEE Transactions on Professional Communications, V32, P238, DOI 10.1109/47.44536
   Winker MA, 2000, JAMA-J AM MED ASSOC, V283, P1600, DOI 10.1001/jama.283.12.1600
   2007, OPHTHALMOLOGE, V104, P628
NR 28
TC 7
Z9 7
U1 0
U2 4
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3755
EI 1423-0267
J9 OPHTHALMOLOGICA
JI Ophthalmologica
PY 2010
VL 224
IS 1
BP 30
EP 37
DI 10.1159/000233233
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 503SU
UT WOS:000270560900006
PM 19684426
DA 2022-11-30
ER

PT J
AU Liew, SHM
   Gilbert, CE
   Spector, TD
   Mellerio, J
   Van Kuijk, FJ
   Beatty, S
   Fitzke, F
   Marshall, J
   Hammond, CJ
AF Liew, S. H. Melissa
   Gilbert, Clare E.
   Spector, Tim D.
   Mellerio, John
   Van Kuijk, Frederik J.
   Beatty, Stephen
   Fitzke, Fred
   Marshall, John
   Hammond, Christopher J.
TI Central retinal thickness is positively correlated with macular pigment
   optical density
SO EXPERIMENTAL EYE RESEARCH
LA English
DT Article
DE macular pigment; lutein; carotenoids; retinal thickness; xanthophylls
ID COHERENCE TOMOGRAPHY; LUTEIN SUPPLEMENTATION; PRIMATE RETINAS; AGE;
   DEGENERATION; AUTOFLUORESCENCE; ZEAXANTHIN; IDENTIFICATION; INSTRUMENT;
   PHOTOMETRY
AB Macular pigment (MP) has been suggested to have a protective role in age-related macular degeneration by reducing the amount of oxidative stress on the retina. MP levels peak at the foveal center, where it is found predominantly in the receptor axon and inner plexiform layers of the retina. The purpose of this study was to investigate the relationship between central retinal thickness and macular pigment optical density in a group of healthy subjects. We report that macular pigment optical density (MPOD) has a significant and positive relationship with central retinal thickness as measured by optical coherence tomography. The strength of the observed relationship (r similar to 0.30) was independent of the technique used to measure MPOD, whether heterochromatic flicker photometry (HFP) or 2-wavelength autofluorescence (AF). Of note, there was no statistically demonstrable relationship between MPOD at an eccentricity of 1- or 2-degrees and central retinal thickness. This finding has important implications for future studies investigating MPOD, and its response to dietary modification/supplementation. (c) 2005 Elsevier Ltd. All rights reserved.
C1 St Thomas Hosp, Twin Res & Genet Epidemiol Unit, London SE1 7EH, England.
   Univ London, London Sch Hyg & Trop Med, Int Ctr Eye Hlth, London, England.
   Univ Westminster, Sch Biosci, London W1R 8AL, England.
   Univ Texas, Dept Ophthalmol & Visual Sci, Med Branch, Galveston, TX 77555 USA.
   Waterford Inst Technol, Dept Chem & Life Sci, Waterford, Ireland.
   Inst Ophthalmol, London, England.
   St Thomas Hosp, Rayne Inst, London SE1 7EH, England.
   Princess Royal Univ Hosp, W Kent Eye Ctr, Orpington, England.
C3 Guy's & St Thomas' NHS Foundation Trust; University of London; London
   School of Hygiene & Tropical Medicine; University of Westminster;
   University of Texas System; University of Texas Medical Branch
   Galveston; South East Technological University (SETU); University of
   London; University College London; Guy's & St Thomas' NHS Foundation
   Trust; University of London; King's College London
RP Hammond, CJ (通讯作者)，St Thomas Hosp, Twin Res & Genet Epidemiol Unit, Lambeth Palace Rd, London SE1 7EH, England.
EM chammond@btopenworld.com
FU Wellcome Trust Funding Source: Medline
CR Alamouti B, 2003, BRIT J OPHTHALMOL, V87, P899, DOI 10.1136/bjo.87.7.899
   Aleman TS, 2001, INVEST OPHTH VIS SCI, V42, P1873
   Andrew T, 2001, Twin Res, V4, P464, DOI 10.1375/1369052012803
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Beatty S, 2000, OPHTHAL PHYSL OPT, V20, P105, DOI 10.1016/S0275-5408(99)00039-3
   Beatty S, 2001, INVEST OPHTH VIS SCI, V42, P439
   BONE RA, 1985, VISION RES, V25, P1531, DOI 10.1016/0042-6989(85)90123-3
   Boulton M, 2001, J PHOTOCH PHOTOBIO B, V64, P144, DOI 10.1016/S1011-1344(01)00227-5
   Delori FC, 2004, ARCH BIOCHEM BIOPHYS, V430, P156, DOI 10.1016/j.abb.2004.05.016
   Delori FC, 2001, J OPT SOC AM A, V18, P1212, DOI 10.1364/JOSAA.18.001212
   DELORI FC, 1995, INVEST OPHTH VIS SCI, V36, P718
   Duncan JL, 2002, EXP EYE RES, V74, P371, DOI 10.1006/exer.2001.1126
   Gale CR, 2003, INVEST OPHTH VIS SCI, V44, P2461, DOI 10.1167/iovs.02-0929
   Guedes V, 2003, OPHTHALMOLOGY, V110, P177, DOI 10.1016/S0161-6420(02)01564-6
   Hammond BR, 1997, INVEST OPHTH VIS SCI, V38, P1795
   Hammond BR, 1997, J OPT SOC AM A, V14, P1187, DOI 10.1364/JOSAA.14.001187
   HEE MR, 1995, ARCH OPHTHALMOL-CHIC, V113, P325, DOI 10.1001/archopht.1995.01100030081025
   Johnson EJ, 2000, AM J CLIN NUTR, V71, P1555
   Khachik F, 1997, INVEST OPHTH VIS SCI, V38, P1802
   Landrum JT, 1997, EXP EYE RES, V65, P57, DOI 10.1006/exer.1997.0309
   Liew SHM, 2005, INVEST OPHTH VIS SCI, V46, P4430, DOI 10.1167/iovs.05-0519
   Lim MCC, 2005, INVEST OPHTH VIS SCI, V46, P974, DOI 10.1167/iovs.04-0828
   Margrain TH, 2004, PROG RETIN EYE RES, V23, P523, DOI 10.1016/j.preteyeres.2004.05.001
   Massin P, 2002, EUR J OPHTHALMOL, V12, P102, DOI 10.1177/112067210201200205
   Mellerio J, 2002, CURR EYE RES, V25, P37, DOI 10.1076/ceyr.25.1.37.9961
   Robson AG, 2003, VISION RES, V43, P1765, DOI 10.1016/S0042-6989(03)00280-3
   SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413
   SNODDERLY DM, 1984, INVEST OPHTH VIS SCI, V25, P660
   SNODDERLY DM, 1984, INVEST OPHTH VIS SCI, V25, P674
   WERNER JS, 1987, VISION RES, V27, P257, DOI 10.1016/0042-6989(87)90188-X
   Wustemeyer H, 2003, GRAEF ARCH CLIN EXP, V241, P647, DOI 10.1007/s00417-003-0730-9
NR 31
TC 53
Z9 57
U1 0
U2 5
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0014-4835
EI 1096-0007
J9 EXP EYE RES
JI Exp. Eye Res.
PD MAY
PY 2006
VL 82
IS 5
BP 915
EP 920
DI 10.1016/j.exer.2005.10.014
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 041FU
UT WOS:000237440300021
PM 16380117
DA 2022-11-30
ER

PT J
AU Sivaprakasam, M
   Liu, WT
   Humayun, MS
   Weiland, JD
AF Sivaprakasam, M
   Liu, WT
   Humayun, MS
   Weiland, JD
TI A variable range bi-phasic current stimulus driver circuitry for an
   implantable retinal prosthetic device
SO IEEE JOURNAL OF SOLID-STATE CIRCUITS
LA English
DT Article
DE biomedical; functional electrical stimulation (FES); implantable
   devices; microstimulator; retinal prosthesis
ID ELECTRICAL-STIMULATION; VISUAL-PERCEPTION; PERFORMANCE
AB This paper reports a driver circuitry to generate bi-phasic (anodic and cathodic) current pulses for stimulating the retinal layer through electrodes which is part of a retinal prosthetic device for implants in blind patients affected by retinitis pigmentosa (RP) and age-related macular degeneration (AMD). Dual voltage architecture is used to halve the number of interface leads from the chip to the stimulation sites compared to a single voltage supply. The driver circuitry is designed to deliver currents with six bit resolution for a wide range of full scale currents up to 600 mu A. To cater to the varying stimulus requirements among patients and different regions of the retina, variable gain architecture is used to achieve fine resolution even for a narrow range of stimulus. 1:8 demultiplexing feature is embedded within the output stage thus allowing one DAC for eight outputs. A novel charge cancellation circuitry with current limiting capability is implemented to discharge the electrodes for medical safety. Measurement results of a prototype chip fabricated in 1.5-mu m CMOS technology are presented.
C1 Univ Calif Santa Cruz, Dept Elect Engn, Santa Cruz, CA 95064 USA.
   Univ So Calif, Keck Sch Med, Dept Ophthalmol, Los Angeles, CA 90089 USA.
C3 University of California System; University of California Santa Cruz;
   University of Southern California
RP Sivaprakasam, M (通讯作者)，Univ Calif Santa Cruz, Dept Elect Engn, Santa Cruz, CA 95064 USA.
EM mohan@soe.ucsc.edu
OI Sivaprakasam, Mohanasankar/0000-0002-6714-9147; Weiland,
   James/0000-0003-3453-9074
CR BASHIRULLAH R, 2006, P IEEE INT S CIRC SY, V5, P5
   BouRabee F, 1997, ENVIRON INT, V23, P5, DOI 10.1016/S0160-4120(96)00073-6
   CHA K, 1992, VISION RES, V32, P1367, DOI 10.1016/0042-6989(92)90229-C
   CHA K, 1992, J OPT SOC AM A, V9, P673, DOI 10.1364/JOSAA.9.000673
   CHA KH, 1992, ANN BIOMED ENG, V20, P439, DOI 10.1007/BF02368135
   DeMarco SC, 2003, IEEE J SOLID-ST CIRC, V38, P1679, DOI 10.1109/JSSC.2003.817264
   Ghovanloo M, 2004, ISSCC DIG TECH PAP I, V47, P226, DOI 10.1109/ISSCC.2004.1332676
   Ghovanloo M, 2003, P ANN INT IEEE EMBS, V25, P1979
   HASTINGS A, 2001, ART ANALOG LAYOUT, P427
   Hayes JS, 2003, ARTIF ORGANS, V27, P1016, DOI 10.1046/j.1525-1594.2003.07309.x
   HUMAYUN M, 2003, ARVO ANN M APR
   Humayun MS, 1999, VISION RES, V39, P2569, DOI 10.1016/S0042-6989(99)00052-8
   Humayun MS, 1996, ARCH OPHTHALMOL-CHIC, V114, P40, DOI 10.1001/archopht.1996.01100130038006
   Humayun MS, 2003, VISION RES, V43, P2573, DOI 10.1016/S0042-6989(03)00457-7
   HYMEN L, 1987, EYE, V1, P1330
   JOHNS DA, 1997, ANALOG INTEGR CIRC S, P475
   Kagawa K, 2003, ELECTRON LETT, V39, P419, DOI 10.1049/el:20030325
   Kendir GA, 2004, 2004 IEEE INTERNATIONAL SYMPOSIUM ON CIRCUITS AND SYSTEMS, VOL 4, PROCEEDINGS, P41
   KENDIR GA, IN PRESS IEEE T CIRC
   Kim C, 1996, IEEE J SOLID-ST CIRC, V31, P1230, DOI 10.1109/4.535406
   LIU W, 2005, P IEEE INT S CIRC SY
   Liu WT, 2004, ISSCC DIG TECH PAP I, V47, P218, DOI 10.1109/ISSCC.2004.1332672
   Majji AB, 1999, INVEST OPHTH VIS SCI, V40, P2073
   MOKAWA W, 2003, P IEEE SENSORS, V2, P980
   RAZAVI B, 2001, DESIGN ANALOG CMOS I, P139
   Rizzo JF, 2003, INVEST OPHTH VIS SCI, V44, P5355, DOI 10.1167/iovs.02-0819
   Rizzo JF, 2001, OPHTHALMOLOGY, V108, P13, DOI 10.1016/S0161-6420(00)00430-9
   Schmitt D, 1997, 1997 INTERNATIONAL SYMPOSIUM ON LOW POWER ELECTRONICS AND DESIGN, PROCEEDINGS, P110, DOI 10.1109/LPE.1997.621253
   Wang SJ, 2004, PROD PRACT QUAL ASSE, V4, P17
   Weiland JD, 1999, GRAEF ARCH CLIN EXP, V237, P1007, DOI 10.1007/s004170050337
   Wong LSY, 2004, ISSCC DIG TECH PAP I, V47, P318, DOI 10.1109/ISSCC.2004.1332722
   Zrenner E, 1999, VISION RES, V39, P2555, DOI 10.1016/S0042-6989(98)00312-5
NR 32
TC 104
Z9 124
U1 0
U2 7
PU IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC
PI PISCATAWAY
PA 445 HOES LANE, PISCATAWAY, NJ 08855-4141 USA
SN 0018-9200
EI 1558-173X
J9 IEEE J SOLID-ST CIRC
JI IEEE J. Solid-State Circuit
PD MAR
PY 2005
VL 40
IS 3
BP 763
EP 771
DI 10.1109/JSSC.2005.843630
PG 9
WC Engineering, Electrical & Electronic
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Engineering
GA 907IZ
UT WOS:000227711600021
DA 2022-11-30
ER

PT J
AU Jacobson, SG
   Cideciyan, AV
   Bennett, J
   Kingsley, RM
   Sheffield, VC
   Stone, EM
AF Jacobson, SG
   Cideciyan, AV
   Bennett, J
   Kingsley, RM
   Sheffield, VC
   Stone, EM
TI Novel mutation in the TIMP3 gene causes sorsby fundus dystrophy
SO ARCHIVES OF OPHTHALMOLOGY
LA English
DT Article
ID TISSUE INHIBITOR; MACULAR DEGENERATION; BRUCHS MEMBRANE; VITAMIN-A;
   METALLOPROTEINASES-3; AGE
AB Objective: To determine the molecular basis of a retinopathy previously described as dominant macular subretinal neovascularization with peripheral retinal degeneration.
   Methods: The TIMP3 gene was analyzed in family members, and 4 mutation-positive patients were studied using psychophysics and electroretinography.
   Results: Cosegregating with disease in the family was a single base pair change in the TIMP3 gene, altering a conserved tyrosine to cysteine at amino acid position 172 (Y172C). There was psychophysical and electroretinographic evidence of rod dysfunction greater than cone dysfunction. Dark adaptometry showed abnormalities with regional retinal variation in degree.
   Conclusions: The Y172C mutation in the TIMP3 gene is another cause of Sorsby fundus dystrophy. The expression of this form of the disease, as in other C-terminal TIMP3 mutations, is speculated to be secondary to mutant TIMP-3, causing a decreased turnover of the extracellular matrix.
   Clinical Relevance: The molecular clarification of inherited retinal degeneration involving abnormal extracellular matrix turnover in and around Bruch's membrane should provide clues to the pathogenesis of not only these particular diseases but also forms of age-related macular degeneration.
C1 Univ Penn, Scheie Eye Inst, Dept Ophthalmol, Philadelphia, PA 19104 USA.
   Univ Oklahoma, Hlth Sci Ctr, Dean A McGee Eye Inst, Dept Ophthalmol, Oklahoma City, OK USA.
   Univ Iowa, Coll Med, Dept Ophthalmol, Iowa City, IA 52242 USA.
   Univ Iowa, Coll Med, Dept Pediat, Iowa City, IA 52242 USA.
   Univ Iowa, Coll Med, Howard Hughes Med Inst, Iowa City, IA 52242 USA.
C3 University of Pennsylvania; Pennsylvania Medicine; University of
   Oklahoma System; University of Oklahoma Health Sciences Center;
   University of Iowa; University of Iowa; Howard Hughes Medical Institute;
   University of Iowa
RP Jacobson, SG (通讯作者)，Univ Penn, Scheie Eye Inst, Dept Ophthalmol, 51 N 39th St, Philadelphia, PA 19104 USA.
RI Cideciyan, Artur V/A-1075-2007
OI Cideciyan, Artur V/0000-0002-2018-0905; Jacobson,
   Samuel/0000-0003-2122-169X; Sheffield, Val/0000-0002-6282-0835; Stone,
   Edwin M./0000-0003-3343-4414
FU NEI NIH HHS [EY13203, EY-05627, EY12156] Funding Source: Medline;
   NATIONAL EYE INSTITUTE [R01EY005627, R01EY013203, R01EY012156] Funding
   Source: NIH RePORTER
CR BALYEAT RM, 1987, OPHTHALMOLOGY, V94, P1140
   CAPON MRC, 1989, OPHTHALMOLOGY, V96, P1769
   Cideciyan AV, 2000, METHOD ENZYMOL, V316, P611
   Cideciyan AV, 1996, VISION RES, V36, P2609, DOI 10.1016/0042-6989(95)00327-4
   Cideciyan AV, 1997, INVEST OPHTH VIS SCI, V38, P1786
   DelaPaz MA, 1997, INVEST OPHTH VIS SCI, V38, P1060
   Fariss RN, 1998, BRIT J OPHTHALMOL, V82, P1329, DOI 10.1136/bjo.82.11.1329
   Fariss RN, 1997, AM J PATHOL, V150, P323
   Felbor U, 1997, ARCH OPHTHALMOL-CHIC, V115, P1569, DOI 10.1001/archopht.1997.01100160739011
   Felbor U, 1997, INVEST OPHTH VIS SCI, V38, P1054
   HOSKIN A, 1981, BRIT J OPHTHALMOL, V65, P859, DOI 10.1136/bjo.65.12.859
   JACOBSON SG, 1986, OPHTHALMOLOGY, V93, P1604
   JACOBSON SG, 1995, NAT GENET, V11, P27, DOI 10.1038/ng0995-27
   Kamei M, 1999, INVEST OPHTH VIS SCI, V40, P2367
   Langton KP, 1998, J BIOL CHEM, V273, P16778, DOI 10.1074/jbc.273.27.16778
   Langton KP, 2000, J BIOL CHEM, V275, P27027
   Martignetti JA, 2001, NAT GENET, V28, P261, DOI 10.1038/90100
   Nishimura DY, 1998, NAT GENET, V19, P140, DOI 10.1038/493
   SORSBY A, 1949, BRIT J OPHTHALMOL, V33, P67, DOI 10.1136/bjo.33.2.67
   Vu TH, 2001, NAT GENET, V28, P202, DOI 10.1038/90023
   WEBER BHF, 1994, NAT GENET, V8, P352, DOI 10.1038/ng1294-352
   Zhang K, 1996, BRIT J OPHTHALMOL, V80, P1018, DOI 10.1136/bjo.80.11.1018
NR 22
TC 32
Z9 35
U1 1
U2 1
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60610 USA
SN 0003-9950
J9 ARCH OPHTHALMOL-CHIC
JI Arch. Ophthalmol.
PD MAR
PY 2002
VL 120
IS 3
SI SI
BP 376
EP 379
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 529LL
UT WOS:000174300900017
PM 11879143
DA 2022-11-30
ER

PT J
AU Edano, M
   Kanda, T
   Tarumoto, R
   Hamamoto, W
   Hasegawa, T
   Mae, Y
   Onoyama, T
   Takata, T
   Sugihara, T
   Isomoto, H
AF Edano, Mirai
   Kanda, Tsutomu
   Tarumoto, Ryohei
   Hamamoto, Wataru
   Hasegawa, Takashi
   Mae, Yukari
   Onoyama, Takumi
   Takata, Tomoaki
   Sugihara, Takaaki
   Isomoto, Hajime
TI Intracellular glutathione levels affect the outcomes of
   verteporfin-mediated photodynamic therapy in esophageal cancer cells
SO PHOTODIAGNOSIS AND PHOTODYNAMIC THERAPY
LA English
DT Article
DE Esophageal cancer; Verteporfin; Photodynamic therapy; Glutathione;
   Sulfasalazine
ID TALAPORFIN SODIUM; EXPRESSION; RECEPTOR
AB Photodynamic therapy (PDT) induces cancer cell death by generating reactive oxygen species (ROS). In this process, photosensitizers accumulate in cancer cells irradiated by laser light of a specific wavelength, leading to ROS generation. Verteporfin (VP), a second-generation photosensitizer, is used in PDT for age-related macular degeneration. However, the antitumor effects of VP-PDT remain poorly defined. This study investigated the antitumor effects of VP-PDT on esophageal cancer (EC) cell lines in vitro. Two types of EC cell lines, the KYSE30 cell line, derived from highly differentiated esophageal carcinoma, and the KYSE170 cell line, derived from moderately differentiated carcinoma, were used in this study. VP-PDT exerted effective anticancer effects in both cell lines. Our results revealed that the low-density lipoprotein receptor, albumin receptor, and heme carrier protein-1 in VP uptake were not involved in VP uptake. However, cells rich in intracellular glutathione were resistant to VP-PDT. Our study outcomes suggest that lowering intracellular glutathione via a glutathione syn-thesis inhibitor or sulfasalazine can increase the effectiveness of VP-PDT-mediated anticancer effects.
C1 [Edano, Mirai; Kanda, Tsutomu; Tarumoto, Ryohei; Hamamoto, Wataru; Hasegawa, Takashi; Mae, Yukari; Onoyama, Takumi; Takata, Tomoaki; Sugihara, Takaaki; Isomoto, Hajime] Tottori Univ, Fac Med, Div Gastroenterol & Nephrol, 36-1 Nishi Cho, Yonago, Tottori, Japan.
C3 Tottori University
RP Kanda, T (通讯作者)，Tottori Univ, Fac Med, Div Gastroenterol & Nephrol, 36-1 Nishi Cho, Yonago, Tottori, Japan.
EM tsutomu-k@tottori-u.ac.jp
CR Azzouzi AR, 2013, BJU INT, V112, P766, DOI 10.1111/bju.12265
   Ethirajan M, 2011, CHEM SOC REV, V40, P340, DOI 10.1039/b915149b
   Huggett MT, 2014, BRIT J CANCER, V110, P1698, DOI 10.1038/bjc.2014.95
   Ishimoto T, 2011, CANCER CELL, V19, P387, DOI 10.1016/j.ccr.2011.01.038
   Ito H, 2014, J CLIN BIOCHEM NUTR, V55, P67, DOI 10.3164/jcbn.14-27
   Kanda T, 2019, ONCOL LETT, V17, P3261, DOI 10.3892/ol.2019.10004
   Kitagawa Y, 2019, ESOPHAGUS-TOKYO, V16, P1, DOI 10.1007/s10388-018-0641-9
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Mae Y, 2020, MOL CLIN ONCOL, V13, DOI 10.3892/mco.2020.2081
   Messmer KJ, 2001, ANN PHARMACOTHER, V35, P1593
   Ogawa E, 2015, PHOTODIAGN PHOTODYN, V12, P252, DOI 10.1016/j.pdpdt.2015.02.001
   Seishinna R, 2016, CLIN RES HEPATOL GAS, V40, P487, DOI 10.1016/j.clinre.2015.11.007
   Shibata Y, 2001, CANCER LETT, V166, P79, DOI 10.1016/S0304-3835(00)00717-5
   Siegel RL, 2016, CA-CANCER J CLIN, V66, P7, DOI [10.3322/caac.21332, 10.3322/caac.21708, 10.3322/caac.21590]
   Tangutoori S, 2016, NANOMED-NANOTECHNOL, V12, P223, DOI 10.1016/j.nano.2015.08.007
   Timmerman LA, 2013, CANCER CELL, V24, P450, DOI 10.1016/j.ccr.2013.08.020
NR 16
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1572-1000
EI 1873-1597
J9 PHOTODIAGN PHOTODYN
JI Photodiagnosis Photodyn. Ther.
PD DEC
PY 2022
VL 40
AR 103090
DI 10.1016/j.pdpdt.2022.103090
PG 9
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 5R6PQ
UT WOS:000874630700006
PM 36031142
DA 2022-11-30
ER

PT J
AU Wang, J
   Tao, ZY
   Deng, HW
   Cui, YB
   Xu, ZR
   Lyu, QH
   Zhao, J
AF Wang, Jiao
   Tao, Zhengyang
   Deng, Hongwei
   Cui, Yubo
   Xu, Zhirong
   Lyu, Qinghua
   Zhao, Jun
TI Therapeutic implications of nanodrug and tissue engineering for retinal
   pigment epithelium-related diseases
SO NANOSCALE
LA English
DT Review
ID ENDOTHELIAL GROWTH-FACTOR; DOMINANT RETINITIS-PIGMENTOSA; CORE-SHELL
   LIPONANOPARTICLES; PLASMID DNA NANOPARTICLES; DRUG-DELIVERY SYSTEM; GENE
   DELIVERY; LONG-TERM; ANTI-VEGF; POLYMERIC NANOPARTICLES; VERSATILE
   PLATFORM
AB The retinal pigment epithelium (RPE), as a single layer of cells that performs multiple functions posteriorly in the eye, is a promising target site for the prevention and treatment of several clinical diseases, including proliferative diabetic retinopathy, age-related macular degeneration, chorionic neovascularization, and retinitis pigmentosa. In recent decades, several nanodrug delivery platforms and tissue-engineered RPE have been widely developed to treat RPE-related diseases. This work summarizes the recent advances in nanoplatforms and tissue engineering scaffolds developed in these fields. The diseases associated with pathological RPE and their common therapy strategies are first introduced. Then, the recent progress made with a variety of drug delivery systems is presented, with an emphasis on the modification strategies of nanomaterials for targeted delivery. Tissue engineering-mediated RPE transplantation for treating these diseases is subsequently described. Finally, the clinical translation challenges in these fields are discussed in depth. This article will offer readers a better understanding of emerging nanotechnology and tissue engineering related to the treatment of RPE-related diseases and could facilitate their widespread use in experiments in vivo and in clinical applications.
C1 [Wang, Jiao; Tao, Zhengyang; Deng, Hongwei; Lyu, Qinghua] Shenzhen Univ, Jinan Univ, Shenzhen Eye Hosp, Sch Optometry,Shenzhen Eye Inst, Shenzhen 518000, Peoples R China.
   [Cui, Yubo; Zhao, Jun] Jinan Univ, Clin Med Coll 2, Shenzhen Peoples Hosp, Dept Ophthalmol, Shenzhen 518020, Peoples R China.
   [Cui, Yubo; Zhao, Jun] Southern Univ Sci & Technol, Affiliated Hosp 1, Shenzhen 518020, Peoples R China.
   [Xu, Zhirong] Jinzhou Med Univ, Jinzhou 121000, Liaoning, Peoples R China.
   [Lyu, Qinghua] Shenzhen Univ, Coll Phys & Optoelect Engn, Inst Microscale Optoelect, Shenzhen 518060, Peoples R China.
C3 Jinan University; Shenzhen University; Jinan University; Southern
   University of Science & Technology; Jinzhou Medical University; Shenzhen
   University
RP Lyu, QH (通讯作者)，Shenzhen Univ, Jinan Univ, Shenzhen Eye Hosp, Sch Optometry,Shenzhen Eye Inst, Shenzhen 518000, Peoples R China.; Zhao, J (通讯作者)，Jinan Univ, Clin Med Coll 2, Shenzhen Peoples Hosp, Dept Ophthalmol, Shenzhen 518020, Peoples R China.; Zhao, J (通讯作者)，Southern Univ Sci & Technol, Affiliated Hosp 1, Shenzhen 518020, Peoples R China.; Lyu, QH (通讯作者)，Shenzhen Univ, Coll Phys & Optoelect Engn, Inst Microscale Optoelect, Shenzhen 518060, Peoples R China.
EM Lyuqh2020@163.com; doctorzhaofun@163.com
RI Deng, Hongwei/GVP-3581-2022
OI Zhao, Jun/0000-0002-4815-3183
FU Science, Technology and Innovation Commission of Shenzhen Municipality
   [JCYJ20210324113610029]; Sanming Project of Medicine in Shenzhen Grant
   [SZSM201812090]
FX This study was supported by Science, Technology and Innovation
   Commission of Shenzhen Municipality under grant (No.
   JCYJ20210324113610029), Sanming Project of Medicine in Shenzhen Grant
   (No. SZSM201812090).
CR Aguirre G D, 1998, Mol Vis, V4, P23
   Arden GB, 2012, DOC OPHTHALMOL, V124, P15, DOI 10.1007/s10633-011-9305-y
   Arima H, 2012, CANCER GENE THER, V19, P358, DOI 10.1038/cgt.2012.9
   Bailey T.J., 2004, DEVELOPMENT, V130, P5155
   Bainbridge JWB, 2015, NEW ENGL J MED, V372, P1887, DOI 10.1056/NEJMoa1414221
   Bakall B, 1999, HUM GENET, V104, P383, DOI 10.1007/s004390050972
   Balser C, 2019, J NEUROINFLAMM, V16, DOI 10.1186/s12974-019-1419-2
   Baltazar GC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049635
   Bao XF, 2018, ACS NANO, V12, P8882, DOI 10.1021/acsnano.8b04022
   Bastiaans J, 2013, INVEST OPHTH VIS SCI, V54, P8306, DOI 10.1167/iovs.13-12383
   Basuki JS, 2017, ANGEW CHEM INT EDIT, V56, P966, DOI 10.1002/anie.201610618
   Ben M'Barek K, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aai7471
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Bian ZM, 2007, INVEST OPHTH VIS SCI, V48, P2738, DOI 10.1167/iovs.06-1023
   Bishop PN, 2000, PROG RETIN EYE RES, V19, P323, DOI 10.1016/S1350-9462(99)00016-6
   Blasiak J, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/768026
   Bochot A, 2012, J CONTROL RELEASE, V161, P628, DOI 10.1016/j.jconrel.2012.01.019
   Boulton M, 2001, EYE, V15, P384, DOI 10.1038/eye.2001.141
   Bourges JL, 2003, INVEST OPHTH VIS SCI, V44, P3562, DOI 10.1167/iovs.02-1068
   Bower M, 2014, J CLIN ONCOL, V32, P409, DOI 10.1200/JCO.2013.51.6757
   De Paiva MRB, 2019, DOC OPHTHALMOL, V138, P3, DOI 10.1007/s10633-018-9664-8
   Bridges CC, 2001, HISTOCHEM J, V33, P149, DOI 10.1023/A:1017991925821
   Burke JM, 2005, MOL INTERV, V5, P241, DOI 10.1124/mi.5.4.7
   Cai X, 2016, ADV EXP MED BIOL, V854, P111, DOI 10.1007/978-3-319-17121-0_16
   Calejo MT, 2016, J BIOMED MATER RES A, V104, P1646, DOI 10.1002/jbm.a.35690
   Chaplot SP, 2014, J PHARM PHARMACOL, V66, P542, DOI 10.1111/jphp.12104
   Chen CW, 2011, INT J NANOMED, V6, P2567, DOI 10.2147/IJN.S24447
   Chen WS, 2018, ADV MATER, V30, DOI 10.1002/adma.201703458
   Cheng YY, 2008, J PHARM SCI-US, V97, P123, DOI 10.1002/jps.21079
   Chowers I, 2006, INVEST OPHTH VIS SCI, V47, P2135, DOI 10.1167/iovs.05-1135
   Christie JG, 2008, DRUG DISCOV TODAY, V13, P124, DOI 10.1016/j.drudis.2007.12.005
   Clark SJ, 2011, INVEST OPHTH VIS SCI, V52, P6511, DOI 10.1167/iovs.11-7909
   Cortie MB, 2011, CHEM REV, V111, P3713, DOI 10.1021/cr1002529
   CROSS HE, 1974, AM J OPHTHALMOL, V77, P46, DOI 10.1016/0002-9394(74)90603-5
   Diebold Y, 2010, PROG RETIN EYE RES, V29, P596, DOI 10.1016/j.preteyeres.2010.08.002
   Ding XQ, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007410
   Dong A, 2009, J CELL PHYSIOL, V219, P544, DOI 10.1002/jcp.21698
   Dong ZL, 2016, THERANOSTICS, V6, P1031, DOI 10.7150/thno.14431
   Drury JL, 2003, BIOMATERIALS, V24, P4337, DOI 10.1016/S0142-9612(03)00340-5
   Duvvuri S, 2003, EXPERT OPIN BIOL TH, V3, P45, DOI 10.1517/14712598.3.1.45
   Estevanato L, 2011, INT J NANOMED, V6, P1709, DOI 10.2147/IJN.S21323
   Fink TL, 2006, GENE THER, V13, P1048, DOI 10.1038/sj.gt.3302761
   Fredenberg S, 2011, INT J PHARMACEUT, V415, P34, DOI 10.1016/j.ijpharm.2011.05.049
   Friedlander M, 1996, P NATL ACAD SCI USA, V93, P9764, DOI 10.1073/pnas.93.18.9764
   Friedlander M, 2007, J CLIN INVEST, V117, P576, DOI 10.1172/JCI31030
   Fujii Y, 2010, BRIT J OPHTHALMOL, V94, P1074, DOI 10.1136/bjo.2009.161109
   Gabrielian K, 1999, GRAEF ARCH CLIN EXP, V237, P326, DOI 10.1007/s004170050240
   Gan L, 2013, BIOMATERIALS, V34, P5978, DOI 10.1016/j.biomaterials.2013.04.035
   Gao GQ, 2001, FEBS LETT, V489, P270, DOI 10.1016/S0014-5793(01)02110-X
   Gao SQ, 2012, INVEST OPHTH VIS SCI, V53, P6314, DOI 10.1167/iovs.12-10279
   Geroski DH, 2000, INVEST OPHTH VIS SCI, V41, P961
   Giannaccini M, 2014, INT J MOL SCI, V15, P1590, DOI 10.3390/ijms15011590
   GODEL V, 1986, Acta Ophthalmologica Supplementum, V175, P1
   Goncalves S, 2015, BIOMACROMOLECULES, V16, P1341, DOI 10.1021/acs.biomac.5b00129
   Grimm C, 2000, NAT GENET, V25, P63, DOI 10.1038/75614
   Han ZC, 2015, FASEB J, V29, P2535, DOI 10.1096/fj.15-270363
   Heidari R, 2015, APPL BIOCHEM BIOTECH, V175, P2399, DOI 10.1007/s12010-014-1431-z
   Hirani A., 2014, PHARM DEV TECHNOL, V26, P1
   Hirani A, 2016, PHARM DEV TECHNOL, V21, P61, DOI 10.3109/10837450.2014.965326
   Hollborn M, 2012, INVEST OPHTH VIS SCI, V53, P5930, DOI 10.1167/iovs.11-9214
   Hollborn M, 2009, INVEST OPHTH VIS SCI, V50, P4452, DOI 10.1167/iovs.08-3194
   Huang D, 2018, BIOMATERIALS, V168, P10, DOI 10.1016/j.biomaterials.2018.03.034
   Huang D, 2017, MOL PHARMACEUT, V14, P533, DOI 10.1021/acs.molpharmaceut.6b01029
   Hunt NC, 2018, ADV HEALTHC MATER, V7, DOI 10.1002/adhm.201800226
   Intra J, 2008, J CONTROL RELEASE, V130, P129, DOI 10.1016/j.jconrel.2008.04.014
   Ishida K, 2003, OCUL IMMUNOL INFLAMM, V11, P91, DOI 10.1076/ocii.11.2.91.15914
   Jiang PF, 2020, NANOSCALE, V12, P17298, DOI 10.1039/d0nr03710a
   Jin MH, 2009, J NEUROSCI, V29, P1486, DOI 10.1523/JNEUROSCI.3882-08.2009
   Kamaleddin MA, 2017, NANOMED-NANOTECHNOL, V13, P1459, DOI 10.1016/j.nano.2017.02.007
   Kamaly N, 2016, CHEM REV, V116, P2602, DOI 10.1021/acs.chemrev.5b00346
   Kambhampati SP, 2015, EUR J PHARM BIOPHARM, V95, P239, DOI 10.1016/j.ejpb.2015.02.013
   Kambhampati SP, 2013, J OCUL PHARMACOL TH, V29, P151, DOI 10.1089/jop.2012.0232
   Kang-Mieler JJ, 2020, EYE, V34, P1371, DOI 10.1038/s41433-020-0809-0
   Kashani AH, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aao4097
   Kaur IP, 2004, INT J PHARMACEUT, V269, P1, DOI 10.1016/j.ijpharm.2003.09.016
   Kesharwani P, 2014, PROG POLYM SCI, V39, P268, DOI 10.1016/j.progpolymsci.2013.07.005
   Kim HS, 2019, INT J BIOL MACROMOL, V130, P220, DOI 10.1016/j.ijbiomac.2019.01.078
   Kiser PD, 2015, NAT CHEM BIOL, V11, P409, DOI [10.1038/NCHEMBIO.1799, 10.1038/nchembio.1799]
   Klettner A, 2021, BIOMOLECULES, V11, DOI 10.3390/biom11010114
   Koirala A, 2011, BIOMATERIALS, V32, P9483, DOI 10.1016/j.biomaterials.2011.08.062
   Koo H, 2012, BIOMATERIALS, V33, P3485, DOI 10.1016/j.biomaterials.2012.01.030
   Koss MJ, 2016, GRAEF ARCH CLIN EXP, V254, P1553, DOI 10.1007/s00417-016-3386-y
   Kowluru RA, 2015, BBA-MOL BASIS DIS, V1852, P2474, DOI 10.1016/j.bbadis.2015.08.001
   KUPPNER MC, 1993, CURR EYE RES, V12, P923, DOI 10.3109/02713689309020399
   Lai KB, 2020, BIOMED PHARMACOTHER, V131, DOI 10.1016/j.biopha.2020.110737
   Lajunen T, 2014, EUR J PHARM SCI, V62, P23, DOI 10.1016/j.ejps.2014.04.018
   Lan DTP, 2020, CELL TRANSPLANT, V29, DOI 10.1177/0963689720964381
   Lee CC, 2005, NAT BIOTECHNOL, V23, P1517, DOI 10.1038/nbt1171
   Lee CJ, 2006, BIOMATERIALS, V27, P1670, DOI 10.1016/j.biomaterials.2005.09.008
   Li C, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/9702820
   LI L, 1991, EXP EYE RES, V52, P669, DOI 10.1016/0014-4835(91)90019-B
   Li QY, 2021, EXP EYE RES, V202, DOI 10.1016/j.exer.2020.108305
   Li QQ, 2016, COLLOID SURFACE B, V140, P278, DOI 10.1016/j.colsurfb.2015.12.053
   Lin TC, 2019, CELL TRANSPLANT, V28, P1345, DOI 10.1177/0963689719860130
   Liu NP, 1997, INVEST OPHTH VIS SCI, V38, P2027
   Liu YL, 2014, CHEM REV, V114, P5057, DOI 10.1021/cr400407a
   Lotery AJ, 2000, INVEST OPHTH VIS SCI, V41, P1291
   Lu XM, 2009, ANNU REV PHYS CHEM, V60, P167, DOI 10.1146/annurev.physchem.040808.090434
   Luo L, 2013, ACS NANO, V7, P3264, DOI 10.1021/nn305958y
   Lyu QH, 2021, BIOMATERIALS, V270, DOI 10.1016/j.biomaterials.2021.120682
   M'Barek K.B., 2018, JOVE-J VIS EXP, V139
   M'Barek K.B., 2020, BIOMATERIALS, V230
   Maier MM, 2009, KLIN MONATSBL AUGENH, V226, P496, DOI 10.1055/s-0028-1109463
   Mandai M, 2017, NEW ENGL J MED, V376, P1038, DOI 10.1056/NEJMoa1608368
   Mannisto M, 2002, J CONTROL RELEASE, V83, P169, DOI 10.1016/S0168-3659(02)00178-5
   Marano RJ, 2005, GENE THER, V12, P1544, DOI 10.1038/sj.gt.3302579
   Marmorstein AD, 2000, P NATL ACAD SCI USA, V97, P12758, DOI 10.1073/pnas.220402097
   Marmorstein LY, 2002, J BIOL CHEM, V277, P30591, DOI 10.1074/jbc.M204269200
   Marneros AG, 2005, AM J PATHOL, V167, P1451, DOI 10.1016/S0002-9440(10)61231-X
   MARTINSEN A, 1989, BIOTECHNOL BIOENG, V33, P79, DOI 10.1002/bit.260330111
   McKie AB, 2001, HUM MOL GENET, V10, P1555, DOI 10.1093/hmg/10.15.1555
   Mitra RN, 2017, ACS NANO, V11, P4669, DOI 10.1021/acsnano.7b00429
   MOORE DJ, 1995, INVEST OPHTH VIS SCI, V36, P1290
   Moreira EF, 2015, TRANSL VIS SCI TECHN, V4, DOI 10.1167/tvst.4.5.10
   Murugesan S, 2007, FEBS LETT, V581, P1157, DOI 10.1016/j.febslet.2007.02.022
   Nanjwade BK, 2009, EUR J PHARM SCI, V38, P185, DOI 10.1016/j.ejps.2009.07.008
   Nicolini J, 2000, ACTA OPHTHALMOL SCAN, V78, P527, DOI 10.1034/j.1600-0420.2000.078005527.x
   Ohno-Matsui K, 2005, MOL VIS, V11, P1
   Omstead DT, 2020, J HEMATOL ONCOL, V13, DOI 10.1186/s13045-020-00965-4
   Park JH, 2018, INT J BIOL MACROMOL, V117, P546, DOI 10.1016/j.ijbiomac.2018.05.127
   Parveen S, 2012, NANOMED-NANOTECHNOL, V8, P147, DOI 10.1016/j.nano.2011.05.016
   Pensado A, 2016, NANOMED-NANOTECHNOL, V12, P2251, DOI 10.1016/j.nano.2016.06.007
   Pescina S, 2015, CURR TOP MED CHEM, V15, P369, DOI 10.2174/1568026615666150108150217
   Pillai O, 2001, CURR OPIN CHEM BIOL, V5, P447, DOI 10.1016/S1367-5931(00)00227-1
   Pugh CW, 2003, NAT MED, V9, P677, DOI 10.1038/nm0603-677
   Rajala A, 2014, NANO LETT, V14, P5257, DOI 10.1021/nl502275s
   Redmond TM, 1998, NAT GENET, V20, P344, DOI 10.1038/3813
   Rim MA, 2020, ACS APPL BIO MATER, V3, P6079, DOI 10.1021/acsabm.0c00672
   Rosenthal R, 2005, FASEB J, V19, P178, DOI 10.1096/fj.05-4495fje
   Russ V, 2008, J CONTROL RELEASE, V132, P131, DOI 10.1016/j.jconrel.2008.09.003
   Rycenga M, 2011, CHEM REV, V111, P3669, DOI 10.1021/cr100275d
   Sapieha P, 2010, INT J BIOCHEM CELL B, V42, P5, DOI 10.1016/j.biocel.2009.10.006
   Schwartz SD, 2016, INVEST OPHTH VIS SCI, V57, DOI 10.1167/iovs.15-18681
   Schwartz SD, 2015, LANCET, V385, P509, DOI 10.1016/S0140-6736(14)61376-3
   Shen WY, 1998, BRIT J OPHTHALMOL, V82, P1063, DOI 10.1136/bjo.82.9.1063
   Singh SR, 2009, GENE THER, V16, P645, DOI 10.1038/gt.2008.185
   Skaf AR, 2011, SEMIN OPHTHALMOL, V26, P181, DOI 10.3109/08820538.2011.577133
   Smorenburg CH, 2014, ANN ONCOL, V25, P599, DOI 10.1093/annonc/mdt588
   Solanki A, 2019, CURR DRUG DELIV, V16, P226, DOI 10.2174/1567201815666181031163111
   Solomon SD, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005139.pub3
   Stohr H, 2002, EUR J HUM GENET, V10, P281, DOI 10.1038/sj.ejhg.5200796
   Strauss O, 2009, OPHTHALMOLOGE, V106, P299, DOI 10.1007/s00347-008-1869-x
   STREETEN BW, 1969, ARCH OPHTHALMOL-CHIC, V81, P383
   Su ZX, 2011, PHARM DEV TECHNOL, V16, P377, DOI 10.3109/10837451003739297
   Suen WLL, 2014, J PHARM PHARMACOL, V66, P564, DOI 10.1111/jphp.12134
   Sun D, 2017, MOL THER-NUCL ACIDS, V7, P42, DOI 10.1016/j.omtn.2017.02.005
   Sun K, 2007, MOL VIS, V13, P2310
   Sunshine JC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037543
   Svenson S, 2009, EUR J PHARM BIOPHARM, V71, P445, DOI 10.1016/j.ejpb.2008.09.023
   Takahashi K, 2019, CURR NEUROVASC RES, V16, P258, DOI 10.2174/1567202616666190619150956
   Thomas BB, 2016, INVEST OPHTH VIS SCI, V57, P2877, DOI 10.1167/iovs.16-19238
   Tibbitt MW, 2009, BIOTECHNOL BIOENG, V103, P655, DOI 10.1002/bit.22361
   Tombran-Tink J, 2003, NAT REV NEUROSCI, V4, P628, DOI 10.1038/nrn1176
   Trigueros S, 2019, GENES-BASEL, V10, DOI 10.3390/genes10040289
   Trivedi R, 2010, NANOMEDICINE-UK, V5, P485, DOI [10.2217/nnm.10.10, 10.2217/NNM.10.10]
   Nguyen VP, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-020-20276-z
   Vithana EN, 2001, MOL CELL, V8, P375, DOI 10.1016/S1097-2765(01)00305-7
   Wang YF, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-08690-4
   WEINGEIST TA, 1982, ARCH OPHTHALMOL-CHIC, V100, P1108
   Weng YH, 2017, ACTA PHARM SIN B, V7, P281, DOI 10.1016/j.apsb.2016.09.001
   White CE, 2017, J TISSUE ENG, V8, DOI 10.1177/2041731417720841
   Xian BK, 2015, STEM CELL RES THER, V6, DOI 10.1186/s13287-015-0167-1
   Xiang P, 2014, BIOMATERIALS, V35, P9777, DOI 10.1016/j.biomaterials.2014.08.040
   Xin G, 2020, ACS APPL MATER INTER, V12, P57710, DOI 10.1021/acsami.0c17296
   Yamashita M, 2005, INT J IMPACT ENG, V32, P618, DOI 10.1016/j.ijimpeng.2004.09.001
   Yu KY, 2018, INT J NANOMED, V13, P129, DOI 10.2147/IJN.S150319
   Yu Y, 2019, BIOENG TRANSL MED, V4, DOI 10.1002/btm2.10128
   Yu Y, 2015, TRANSL VIS SCI TECHN, V4, DOI 10.1167/tvst.4.2.5
   Yusuke T., 2011, FEBS J, V278, P2913
   Zeng XW, 2018, ADV SCI, V5, DOI 10.1002/advs.201800510
   Zhao H, 2018, NANOSCALE, V10, P6981, DOI 10.1039/c8nr00838h
   Zhao H, 2016, THERANOSTICS, V6, P1833, DOI 10.7150/thno.16047
   Zhao Ya-nan, 2014, Yaoxue Xuebao, V49, P711
NR 173
TC 0
Z9 0
U1 5
U2 7
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 2040-3364
EI 2040-3372
J9 NANOSCALE
JI Nanoscale
PD APR 14
PY 2022
VL 14
IS 15
BP 5657
EP 5677
DI 10.1039/d1nr08337f
EA MAR 2022
PG 21
WC Chemistry, Multidisciplinary; Nanoscience & Nanotechnology; Materials
   Science, Multidisciplinary; Physics, Applied
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Chemistry; Science & Technology - Other Topics; Materials Science;
   Physics
GA 0N6MZ
UT WOS:000774822200001
PM 35352082
DA 2022-11-30
ER

PT J
AU Chang, KC
   Liu, PF
   Chang, CH
   Lin, YC
   Chen, YJ
   Shu, CW
AF Chang, Kun-Che
   Liu, Pei-Feng
   Chang, Chia-Hsuan
   Lin, Ying-Cheng
   Chen, Yen-Ju
   Shu, Chih-Wen
TI The interplay of autophagy and oxidative stress in the pathogenesis and
   therapy of retinal degenerative diseases
SO CELL AND BIOSCIENCE
LA English
DT Review
DE Autophagy; Reactive oxygen species; Glaucoma; Age-related macular
   degeneration; Diabetic retinopathy; Optic nerve atrophy
ID CHAPERONE-MEDIATED AUTOPHAGY; CELL-DEATH; AXON REGENERATION; DNA-DAMAGE;
   MACULAR DEGENERATION; SELECTIVE AUTOPHAGY; CYTOSOLIC PROTEINS;
   RESPONSIVE ELEMENT; MITOCHONDRIAL-DNA; TUMOR-SUPPRESSOR
AB Oxidative stress is mainly caused by intracellular reactive oxygen species (ROS) production, which is highly associated with normal physiological homeostasis and the pathogenesis of diseases, particularly ocular diseases. Autophagy is a self-clearance pathway that removes oxidized cellular components and regulates cellular ROS levels. ROS can modulate autophagy activity through transcriptional and posttranslational mechanisms. Autophagy further triggers transcription factor activation and degrades impaired organelles and proteins to eliminate excessive ROS in cells. Thus, autophagy may play an antioxidant role in protecting ocular cells from oxidative stress. Nevertheless, excessive autophagy may cause autophagic cell death. In this review, we summarize the mechanisms of interaction between ROS and autophagy and their roles in the pathogenesis of several ocular diseases, including glaucoma, age-related macular degeneration (AMD), diabetic retinopathy (DR), and optic nerve atrophy, which are major causes of blindness. The autophagy modulators used to treat ocular diseases are further discussed. The findings of the studies reviewed here might shed light on the development and use of autophagy modulators for the future treatment of ocular diseases.
C1 [Chang, Kun-Che] Univ Pittsburgh, Sch Med, Dept Ophthalmol & Neurobiol, Louis J Fox Ctr Vis Restorat, Pittsburgh, PA USA.
   [Chang, Kun-Che] Kaohsiung Med Univ, Grad Inst Med, Coll Med, Kaohsiung, Taiwan.
   [Liu, Pei-Feng] Kaohsiung Med Univ, Coll Life Sci, PhD Program Life Sci, Dept Biomed Sci & Environm Biol, Kaohsiung, Taiwan.
   [Liu, Pei-Feng] Kaohsiung Med Univ Hosp, Dept Med Res, Kaohsiung, Taiwan.
   [Liu, Pei-Feng] Kaohsiung Med Univ, Ctr Canc Res, Kaohsiung, Taiwan.
   [Chang, Chia-Hsuan; Shu, Chih-Wen] Natl Sun Yat Sen Univ, Inst BioPharmaceut Sci, 70 Lianhai Rd, Kaohsiung 80424, Taiwan.
   [Lin, Ying-Cheng] Taichung Vet Gen Hosp, Dept Internal Med, Div Gastroenterol & Hepatol, Taichung, Taiwan.
   [Chen, Yen-Ju] Natl Yang Ming Chiao Tung Univ, Inst Clin Med, Taipei, Taiwan.
   [Chen, Yen-Ju] Taichung Vet Gen Hosp, Dept Med Res, Taichung, Taiwan.
   [Chen, Yen-Ju] Taichung Vet Gen Hosp, Dept Internal Med, Div Allergy Immunol & Rheumatol, Taichung, Taiwan.
C3 Pennsylvania Commonwealth System of Higher Education (PCSHE); University
   of Pittsburgh; Kaohsiung Medical University; Kaohsiung Medical
   University; Kaohsiung Medical University; Kaohsiung Medical University
   Hospital; Kaohsiung Medical University; National Sun Yat Sen University;
   Taichung Veterans General Hospital; National Yang Ming Chiao Tung
   University; Taichung Veterans General Hospital; Taichung Veterans
   General Hospital
RP Shu, CW (通讯作者)，Natl Sun Yat Sen Univ, Inst BioPharmaceut Sci, 70 Lianhai Rd, Kaohsiung 80424, Taiwan.
EM cwshu@g-mail.nsysu.edu.tw
OI Chang, Kun-Che/0000-0002-0871-5612; Shu, Chih-Wen/0000-0002-7774-0002
FU NIH CORE Grant P30 [EY008098]; Eye and Ear Foundation of Pittsburgh;
   Research to Prevent Blindness, New York, NY; Ministry of Science and
   Technology MOST [108-2320-B-110-008-MY3, 109-2320-B-037-015-MY3];
   National Sun Yatsen University-KCGMH Joint Research Project [110-05,
   111-05]
FX The work was supported by the NIH CORE Grant P30 (EY008098) to the
   Department of Ophthalmology University of Pittsburgh, the Eye and Ear
   Foundation of Pittsburgh, and from an unrestricted grant from Research
   to Prevent Blindness, New York, NY, Ministry of Science and Technology
   MOST (108-2320-B-110-008-MY3 and 109-2320-B-037-015-MY3) and the
   National Sun Yat-sen University-KCGMH Joint Research Project (110-05 and
   111-05).
CR Aihara M, 2021, JPN J OPHTHALMOL, V65, P581, DOI 10.1007/s10384-021-00844-6
   Al-Humimat Ghadeer, 2021, J Exp Pharmacol, V13, P197, DOI 10.2147/JEP.S259297
   Alers S, 2012, MOL CELL BIOL, V32, P2, DOI 10.1128/MCB.06159-11
   Alexander A, 2010, P NATL ACAD SCI USA, V107, P4153, DOI 10.1073/pnas.0913860107
   Amankwa CE, 2021, ANTIOXIDANTS-BASEL, V10, DOI 10.3390/antiox10040575
   Amato R, 2018, PHARMACOL RES, V128, P167, DOI 10.1016/j.phrs.2017.09.022
   Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   Anding AL, 2017, DEV CELL, V41, P10, DOI 10.1016/j.devcel.2017.02.016
   Arrigo A, 2021, PHARMACEUTICS, V13, DOI 10.3390/pharmaceutics13071102
   Banaee T, 2021, J OPHTHAL VIS RES, V16, P178, DOI 10.18502/jovr.v16i2.9081
   Bandyopadhyay U, 2008, MOL CELL BIOL, V28, P5747, DOI 10.1128/MCB.02070-07
   Beckers A, 2021, NEUROSCIENCE, V470, P52, DOI 10.1016/j.neuroscience.2021.07.009
   Bell K, 2020, CELL DEATH DISCOV, V6, DOI 10.1038/s41420-020-0257-4
   Bellot G, 2009, MOL CELL BIOL, V29, P2570, DOI 10.1128/MCB.00166-09
   Berrocal MH, 2021, CURR OPIN OPHTHALMOL, V32, P203, DOI 10.1097/ICU.0000000000000760
   Bialik S, 2018, J CELL SCI, V131, DOI 10.1242/jcs.215152
   Bikbov M M, 2020, Vestn Oftalmol, V136, P87, DOI 10.17116/oftalma202013603187
   Blasiak J, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22137194
   Bonekamp NA, 2009, BIOFACTORS, V35, P346, DOI 10.1002/biof.48
   Brown EE, 2019, REDOX BIOL, V24, DOI 10.1016/j.redox.2019.101201
   Brown EE, 2019, INVEST OPHTH VIS SCI, V60, P1470, DOI 10.1167/iovs.18-26422
   Callahan MK, 2002, J BIOL CHEM, V277, P33604, DOI 10.1074/jbc.M202890200
   Canovai E, 2020, TRANSPLANT DIRECT, V6, DOI 10.1097/TXD.0000000000000960
   Cao JX, 2009, EMBO J, V28, P1505, DOI 10.1038/emboj.2009.101
   Chan CM, 2019, J BIOMED SCI, V26, DOI 10.1186/s12929-019-0531-z
   Chang KC, 2021, ENEURO, V8, DOI 10.1523/ENEURO.0358-20.2020
   Chang KC, 2019, CURR BIOL, V29, P1963, DOI 10.1016/j.cub.2019.05.011
   Chang KC, 2018, ADV EXP MED BIOL, V1032, P173, DOI 10.1007/978-3-319-98788-0_13
   Chang KC, 2015, CHEM-BIOL INTERACT, V234, P254, DOI 10.1016/j.cbi.2014.10.007
   Chen Y, 2008, CELL DEATH DIFFER, V15, P171, DOI 10.1038/sj.cdd.4402233
   Chen Y, 2009, CELL DEATH DIFFER, V16, P1040, DOI 10.1038/cdd.2009.49
   Chen YQ, 2007, J CELL SCI, V120, P4155, DOI 10.1242/jcs.011163
   Chichan H, 2021, CLIN OPHTHALMOL, V15, P1887, DOI 10.2147/OPTH.S307671
   Cinik R, 2016, CURR EYE RES, V41, P1438, DOI 10.3109/02713683.2015.1125506
   CLARK SL, 1957, J BIOPHYS BIOCHEM CY, V3, P349, DOI 10.1083/jcb.3.3.349
   Cordani M, 2019, OXID MED CELL LONGEV, V2019, DOI 10.1155/2019/1283075
   Coucha M, 2015, MIDDLE EAST AFR J OP, V22, P135, DOI 10.4103/0974-9233.154386
   Dai Y, 2014, HUM MOL GENET, V23, P637, DOI 10.1093/hmg/ddt450
   Dasgupta B, 2005, CANCER RES, V65, P2755, DOI 10.1158/0008-5472.CAN-04-4058
   DEDUVE C, 1966, ANNU REV PHYSIOL, V28, P435, DOI 10.1146/annurev.ph.28.030166.002251
   Di Rosa M, 2016, CURR NEUROPHARMACOL, V14, P810, DOI 10.2174/1570159X14666160321122900
   Diao JJ, 2015, NATURE, V520, P563, DOI 10.1038/nature14147
   DICE JF, 1990, TRENDS BIOCHEM SCI, V15, P305, DOI 10.1016/0968-0004(90)90019-8
   Ditch S, 2012, TRENDS BIOCHEM SCI, V37, P15, DOI 10.1016/j.tibs.2011.10.002
   Duh EJ, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.93751
   Eiyama A, 2015, CURR OPIN CELL BIOL, V33, P95, DOI 10.1016/j.ceb.2015.01.002
   Faiq MA, 2019, PROG RETIN EYE RES, V72, DOI 10.1016/j.preteyeres.2019.06.003
   Fauzi YR, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0256320
   Filomeni G, 2015, CELL DEATH DIFFER, V22, P377, DOI 10.1038/cdd.2014.150
   Filomeni G, 2010, AUTOPHAGY, V6, P999, DOI 10.4161/auto.6.7.12754
   Fleckenstein M, 2021, NAT REV DIS PRIMERS, V7, DOI 10.1038/s41572-021-00265-2
   Fligor CM, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-32871-8
   Forrester SJ, 2018, CIRC RES, V122, P877, DOI 10.1161/CIRCRESAHA.117.311401
   Fransen M, 2012, BBA-MOL BASIS DIS, V1822, P1363, DOI 10.1016/j.bbadis.2011.12.001
   FRILING RS, 1992, P NATL ACAD SCI USA, V89, P668, DOI 10.1073/pnas.89.2.668
   Fu D, 2012, DIABETOLOGIA, V55, P3128, DOI 10.1007/s00125-012-2692-0
   Fujita Y, 2017, DIABETOL INT, V8, P4, DOI 10.1007/s13340-016-0300-0
   Fukai T, 2011, ANTIOXID REDOX SIGN, V15, P1583, DOI 10.1089/ars.2011.3999
   Gabbay Kenneth H, 2004, Curr Diab Rep, V4, P405, DOI 10.1007/s11892-004-0047-z
   Gao Q, 2019, ADV EXP MED BIOL, V1206, P179, DOI 10.1007/978-981-15-0602-4_9
   Gao Y, 2018, INVEST OPHTH VIS SCI, V59, P4307, DOI 10.1167/iovs.17-23747
   Ge P, 2020, MOL NEURODEGENER, V15, DOI 10.1186/s13024-020-00367-7
   Georgakopoulos ND, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-07679-7
   George SM, 2021, PROG RETIN EYE RES, V85, DOI 10.1016/j.preteyeres.2021.100969
   Golestaneh N, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2016.453
   Guo Z, 2010, CELL CYCLE, V9, P4805, DOI 10.4161/cc.9.24.14323
   Guo Z, 2010, SCIENCE, V330, P517, DOI 10.1126/science.1192912
   Ha S, 2015, MOL BRAIN, V8, DOI 10.1186/s13041-015-0119-9
   Hamano T, 2020, NEUROBIOL AGING, V89, P41, DOI 10.1016/j.neurobiolaging.2019.12.009
   Hassanpour M, 2020, CELL BIOSCI, V10, DOI 10.1186/s13578-020-00455-7
   Heo JM, 2015, MOL CELL, V60, P7, DOI 10.1016/j.molcel.2015.08.016
   Ichimura Y, 2000, NATURE, V408, P488, DOI 10.1038/35044114
   Ichimura Y, 2013, MOL CELL, V51, P618, DOI 10.1016/j.molcel.2013.08.003
   Incalza MA, 2018, VASC PHARMACOL, V100, P1, DOI 10.1016/j.vph.2017.05.005
   Ishikawa M, 2021, AUTOPHAGY, V17, P743, DOI 10.1080/15548627.2020.1731270
   Izzotti A, 2006, MUTAT RES-REV MUTAT, V612, P105, DOI 10.1016/j.mrrev.2005.11.001
   Jacot JL, 2011, J OPHTHALMOL, V2011, DOI 10.1155/2011/589813
   Jain A, 2010, J BIOL CHEM, V285, P22576, DOI 10.1074/jbc.M110.118976
   Jansook P, 2021, INT J PHARMACEUT, V606, DOI 10.1016/j.ijpharm.2021.120955
   Jiang P, 2014, MOL BIOL CELL, V25, P1327, DOI 10.1091/mbc.E13-08-0447
   Johannessen CM, 2005, P NATL ACAD SCI USA, V102, P8573, DOI 10.1073/pnas.0503224102
   Johansen T, 2011, AUTOPHAGY, V7, P279, DOI 10.4161/auto.7.3.14487
   Kaarniranta K, 2017, CELL BIOL TOXICOL, V33, P113, DOI 10.1007/s10565-016-9371-8
   Kabeya Y, 2004, J CELL SCI, V117, P2805, DOI 10.1242/jcs.01131
   Kageyama S, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-020-20185-1
   Kamsler A, 2001, CANCER RES, V61, P1849
   Kan E, 2018, INT OPHTHALMOL, V38, P1635, DOI 10.1007/s10792-017-0635-y
   Kan JTC, 2022, ACTA OPHTHALMOL, V100, pE617, DOI 10.1111/aos.14962
   Kang LH, 2019, INT J OPHTHALMOL-CHI, V12, P1395, DOI 10.18240/ijo.2019.09.04
   Kaspar JW, 2009, FREE RADICAL BIO MED, V47, P1304, DOI 10.1016/j.freeradbiomed.2009.07.035
   Kauppinen A, 2020, CELL MOL LIFE SCI, V77, P779, DOI 10.1007/s00018-019-03418-5
   Kaushik S, 2018, NAT REV MOL CELL BIO, V19, P365, DOI 10.1038/s41580-018-0001-6
   Kaushik S, 2012, TRENDS CELL BIOL, V22, P407, DOI 10.1016/j.tcb.2012.05.006
   Kawamata T, 2008, MOL BIOL CELL, V19, P2039, DOI 10.1091/mbc.E07-10-1048
   Kiffin R, 2004, MOL BIOL CELL, V15, P4829, DOI 10.1091/mbc.E04-06-0477
   Kim H, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms10025
   Kim J, 2013, CELL, V152, P290, DOI 10.1016/j.cell.2012.12.016
   Kim SH, 2008, J NEUROSCI RES, V86, P2943, DOI 10.1002/jnr.21738
   Kim YS, 2017, BIOCHEM BIOPH RES CO, V492, P397, DOI 10.1016/j.bbrc.2017.08.087
   Kimball SR, 2016, CELL SIGNAL, V28, P896, DOI 10.1016/j.cellsig.2016.03.008
   Kitaoka Y, 2020, JPN J OPHTHALMOL, V64, P298, DOI 10.1007/s10384-020-00731-6
   Kitaoka Y, 2017, INVEST OPHTH VIS SCI, V58, P5056, DOI 10.1167/iovs.17-22000
   Knoferle J, 2010, P NATL ACAD SCI USA, V107, P6064, DOI 10.1073/pnas.0909794107
   Kourelis TV, 2012, MED ONCOL, V29, P1314, DOI 10.1007/s12032-011-9846-7
   Kumar RR, 2016, J TRANSL MED, V14, DOI 10.1186/s12967-016-0839-3
   Kurihara Y, 2012, J BIOL CHEM, V287, P3265, DOI 10.1074/jbc.M111.280156
   Lamb CA, 2013, NAT REV MOL CELL BIO, V14, P759, DOI 10.1038/nrm3696
   Law BYK, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-56675-6
   Lee J, 2012, BIOCHEM J, V441, P523, DOI 10.1042/BJ20111451
   Lee JJ, 2020, BIOCHEM BIOPH RES CO, V521, P414, DOI 10.1016/j.bbrc.2019.10.138
   Lee JH, 2010, SCIENCE, V327, P1223, DOI 10.1126/science.1182228
   Liang CY, 2008, NAT CELL BIOL, V10, P776, DOI 10.1038/ncb1740
   Liegl R, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088203
   Lim J, 2015, PLOS GENET, V11, DOI 10.1371/journal.pgen.1004987
   Lin HC, 2015, JAMA OPHTHALMOL, V133, P915, DOI 10.1001/jamaophthalmol.2015.1440
   Lin WJ, 2014, AUTOPHAGY, V10, P1692, DOI 10.4161/auto.36076
   Liu J, 2016, SCI REP-UK, V6, DOI 10.1038/srep20639
   Liu PF, 2022, SEMIN CANCER BIOL, V83, P269, DOI 10.1016/j.semcancer.2020.10.009
   Losiewicz MK, 2020, EXP EYE RES, V197, DOI 10.1016/j.exer.2020.108131
   Luo ZM, 2021, ACTA BIOMATER, V134, P289, DOI 10.1016/j.actbio.2021.07.040
   Massey AC, 2006, P NATL ACAD SCI USA, V103, P5805, DOI 10.1073/pnas.0507436103
   Matloob S, 2011, J CLIN NEUROSCI, V18, P974, DOI 10.1016/j.jocn.2010.12.010
   Matoba K, 2020, NAT STRUCT MOL BIOL, V27, P1185, DOI [10.1038/s41594-020-00538-6, 10.1038/s41594-020-00518-w]
   Matsuki M, 2017, CANCER SCI, V108, P763, DOI 10.1111/cas.13169
   Matsuura A, 1997, GENE, V192, P245, DOI 10.1016/S0378-1119(97)00084-X
   Meng DL, 2018, DEVELOPMENT, V145, DOI 10.1242/dev.152595
   Metlagel Z, 2013, P NATL ACAD SCI USA, V110, P18844, DOI 10.1073/pnas.1314755110
   Miltner AM, 2019, DEV DYNAM, V248, P118, DOI 10.1002/dvdy.24672
   Mitter SK, 2014, AUTOPHAGY, V10, P1989, DOI 10.4161/auto.36184
   Mizushima N, 1998, NATURE, V395, P395, DOI 10.1038/26506
   Mizushima N, 2011, ANNU REV CELL DEV BI, V27, P107, DOI 10.1146/annurev-cellbio-092910-154005
   Mizushima N, 2010, CURR OPIN CELL BIOL, V22, P132, DOI 10.1016/j.ceb.2009.12.004
   Moore DL, 2009, SCIENCE, V326, P298, DOI 10.1126/science.1175737
   Morris Deanna H, 2015, Front Biol (Beijing), V10, P398
   Motoi Y, 2014, ACS CHEM NEUROSCI, V5, P434, DOI 10.1021/cn500056q
   Murata H, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0142438
   Murphy MP, 2009, BIOCHEM J, V417, P1, DOI 10.1042/BJ20081386
   Nettesheim A, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.10.31
   Nocentini A, 2019, EXPERT OPIN THER PAT, V29, P805, DOI 10.1080/13543776.2019.1665023
   NOVIKOFF AB, 1959, J BIOPHYS BIOCHEM CY, V6, P136, DOI 10.1083/jcb.6.1.136
   Obara K, 2008, AUTOPHAGY, V4, P952, DOI 10.4161/auto.6790
   Obara Keisuke, 2011, Int J Cell Biol, V2011, P713435, DOI 10.1155/2011/713435
   Ohsumi Y, 2014, CELL RES, V24, P9, DOI 10.1038/cr.2013.169
   Oku M, 2018, BIOESSAYS, V40, DOI 10.1002/bies.201800008
   Volpe CMO, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-017-0135-z
   Orenstein SJ, 2010, SEMIN CELL DEV BIOL, V21, P719, DOI 10.1016/j.semcdb.2010.02.005
   Otomo C, 2013, NAT STRUCT MOL BIOL, V20, P59, DOI 10.1038/nsmb.2431
   Pajares M, 2016, AUTOPHAGY, V12, P1902, DOI 10.1080/15548627.2016.1208889
   Pan Y, 2021, NATURE, V594, P277, DOI 10.1038/s41586-021-03580-6
   Papinski D, 2014, MOL CELL, V53, P471, DOI 10.1016/j.molcel.2013.12.011
   Park KK, 2008, SCIENCE, V322, P963, DOI 10.1126/science.1161566
   Parravano M, 2021, BIODRUGS, V35, P673, DOI 10.1007/s40259-021-00499-2
   Patel AK, 2020, P NATL ACAD SCI USA, V117, P33597, DOI 10.1073/pnas.2004683117
   Piano I, 2016, FRONT CELL NEUROSCI, V10, DOI 10.3389/fncel.2016.00042
   Pizzino G, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/8416763
   Porter K, 2015, BBA-MOL BASIS DIS, V1852, P379, DOI 10.1016/j.bbadis.2014.11.021
   Quigley HA, 2006, BRIT J OPHTHALMOL, V90, P262, DOI 10.1136/bjo.2005.081224
   Ragusa MJ, 2012, CELL, V151, P1501, DOI 10.1016/j.cell.2012.11.028
   Ran ZL, 2019, MOL MED REP, V19, P1024, DOI 10.3892/mmr.2018.9749
   Reichel C, 2020, TRANSL VIS SCI TECHN, V9, DOI 10.1167/tvst.9.9.42
   Reichenbach J, 2002, ANTIOXID REDOX SIGN, V4, P465, DOI 10.1089/15230860260196254
   Rena G, 2017, DIABETOLOGIA, V60, P1577, DOI 10.1007/s00125-017-4342-z
   Ribas V, 2014, FRONT PHARMACOL, V5, DOI 10.3389/fphar.2014.00151
   Riva I, 2017, ADV THER, V34, P834, DOI 10.1007/s12325-017-0503-1
   Roberts DJ, 2014, MOL CELL, V53, P521, DOI 10.1016/j.molcel.2013.12.019
   Rodriguez-Muela N, 2012, CELL DEATH DIFFER, V19, P162, DOI 10.1038/cdd.2011.88
   Rodriguez-Muela N, 2013, AGING CELL, V12, P478, DOI 10.1111/acel.12072
   Rodriguez-Muela N, 2012, AUTOPHAGY, V8, P286, DOI 10.4161/auto.8.2.18982
   Rogov V, 2014, MOL CELL, V53, P167, DOI 10.1016/j.molcel.2013.12.014
   Rose CM, 2016, CELL SYST, V3, P395, DOI 10.1016/j.cels.2016.08.009
   Ruiz-Pesini E, 2018, DRUG DISCOV TODAY, V23, P493, DOI 10.1016/j.drudis.2018.01.031
   RUSHMORE TH, 1991, J BIOL CHEM, V266, P11632
   Russo R, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-1044-5
   Russo R, 2013, CURR OPIN PHARMACOL, V13, P72, DOI 10.1016/j.coph.2012.09.004
   Sahu R, 2011, DEV CELL, V20, P131, DOI 10.1016/j.devcel.2010.12.003
   Sarraf SA, 2013, NATURE, V496, P372, DOI 10.1038/nature12043
   Sawa-Makarska J, 2020, SCIENCE, V369, P1206, DOI 10.1126/science.aaz7714
   Saxton RA, 2016, SCIENCE, V351, P53, DOI 10.1126/science.aad2087
   Sbardella D, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22115891
   Scherz-Shouval R, 2007, EMBO J, V26, P1749, DOI 10.1038/sj.emboj.7601623
   Schrader M, 2006, BBA-MOL CELL RES, V1763, P1755, DOI 10.1016/j.bbamcr.2006.09.006
   Schuck S, 2020, J CELL SCI, V133, DOI 10.1242/jcs.246322
   Settembre C, 2011, SCIENCE, V332, P1429, DOI 10.1126/science.1204592
   Shadel GS, 2015, CELL, V163, P560, DOI 10.1016/j.cell.2015.10.001
   Sheu SJ, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0213932
   Shi XD, 2016, NEUROBIOL DIS, V95, P111, DOI 10.1016/j.nbd.2016.07.016
   Shim MS, 2021, P NATL ACAD SCI USA, V118, DOI 10.1073/pnas.2021942118
   Shin BY, 2012, FREE RADICAL BIO MED, V53, P834, DOI 10.1016/j.freeradbiomed.2012.06.026
   Singh A, 2019, MOLECULES, V24, DOI 10.3390/molecules24081583
   Singh DK, 2019, RHEUMATOL ADV PRACT, V3, DOI 10.1093/rap/rkz009
   Skov AG, 2022, ACTA OPHTHALMOL, V100, P253, DOI 10.1111/aos.14926
   Skrzypczak T, 2021, CUREUS, V13, DOI 10.7759/cureus.15916
   Sluch VM, 2017, STEM CELL TRANSL MED, V6, P1972, DOI 10.1002/sctm.17-0059
   Song CJ, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0171940
   Sonowal H, 2021, CURR MED CHEM, V28, P3683, DOI 10.2174/0929867327666201027152737
   Sowter HM, 2001, CANCER RES, V61, P6669
   Su Q, 2018, CELL PHYSIOL BIOCHEM, V46, P1536, DOI 10.1159/000489198
   Su WR, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099719
   Sun XB, 2014, PHARMAZIE, V69, P889, DOI 10.1691/ph.2014.4672
   Suzen S, 2003, CURR MED CHEM, V10, P1329, DOI 10.2174/0929867033457377
   Suzuki K, 2007, GENES CELLS, V12, P209, DOI 10.1111/j.1365-2443.2007.01050.x
   Suzuki T, 2019, CELL REP, V28, P746, DOI 10.1016/j.celrep.2019.06.047
   Suzuki T, 2017, J BIOL CHEM, V292, P16817, DOI 10.1074/jbc.R117.800169
   Szatmari-Toth M, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.133
   Szatmari-Toth M, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20040926
   Tal MC, 2009, P NATL ACAD SCI USA, V106, P2770, DOI 10.1073/pnas.0807694106
   Tasset I, 2016, FEBS J, V283, P2403, DOI 10.1111/febs.13677
   TELAKOWSKIHOPKINS CA, 1988, P NATL ACAD SCI USA, V85, P1000, DOI 10.1073/pnas.85.4.1000
   Tooley AA, 2021, ORBIT-ABINGDON, V40, P30, DOI 10.1080/01676830.2020.1733027
   Toteberg-Harms M, 2021, CURR OPIN OPHTHALMOL, V32, P141, DOI 10.1097/ICU.0000000000000732
   Touhami S, 2014, TRANSPLANTATION, V98, pE102, DOI 10.1097/TP.0000000000000551
   Tripathi DN, 2013, P NATL ACAD SCI USA, V110, pE2950, DOI 10.1073/pnas.1307736110
   Uchida Junji, 2018, World J Transplant, V8, P150, DOI 10.5500/wjt.v8.i5.150
   Ung L, 2017, CLIN SCI, V131, P2865, DOI 10.1042/CS20171246
   Velasco-Miguel S, 1999, ONCOGENE, V18, P127, DOI 10.1038/sj.onc.1202274
   Wanders RJA, 2006, ANNU REV BIOCHEM, V75, P295, DOI 10.1146/annurev.biochem.74.082803.133329
   Wang AL, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004160
   Wang S, 2019, MOL MED REP, V19, P927, DOI 10.3892/mmr.2018.9759
   Wang YQ, 2012, AUTOPHAGY, V8, P1462, DOI 10.4161/auto.21211
   Weidberg H, 2010, EMBO J, V29, P1792, DOI 10.1038/emboj.2010.74
   Williams PR, 2020, ANNU REV VIS SCI, V6, P195, DOI 10.1146/annurev-vision-022720-094953
   Wolters JEJ, 2021, CURR OPIN OPHTHALMOL, V32, P148, DOI 10.1097/ICU.0000000000000729
   Wu JJ, 2009, AGING-US, V1, P425, DOI 10.18632/aging.100038
   Xiao B, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.463
   Xiao B, 2017, J BIOL CHEM, V292, P16697, DOI 10.1074/jbc.M117.787739
   Xie Lili, 2021, Proc Natl Acad Sci U S A, V118, DOI 10.1073/pnas.2017282118
   Yamada T, 2018, CELL METAB, V28, P588, DOI 10.1016/j.cmet.2018.06.014
   Yang SJ, 2014, REDOX BIOL, V3, P63, DOI 10.1016/j.redox.2014.04.001
   Yang X, 2019, BIOMED RES INT, V2019, DOI 10.1155/2019/5763658
   Yao J, 2014, CELL PHYSIOL BIOCHEM, V33, P107, DOI 10.1159/000356654
   Yarana C, 2017, ANTIOXIDANTS-BASEL, V6, DOI 10.3390/antiox6040075
   Yazdankhah M, 2021, AUTOPHAGY, V17, P3140, DOI 10.1080/15548627.2020.1871204
   Ying HY, 2016, EXP EYE RES, V144, P73, DOI 10.1016/j.exer.2015.06.029
   Yoshii SR, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18091865
   Youle RJ, 2011, NAT REV MOL CELL BIO, V12, P9, DOI 10.1038/nrm3028
   Yu L, 2018, AUTOPHAGY, V14, P207, DOI 10.1080/15548627.2017.1378838
   Zachari M, 2017, ESSAYS BIOCHEM, V61, P585, DOI 10.1042/EBC20170021
   Zeilbeck LF, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0095546
   Zhan ZY, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.10.55
   Zhang J, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.330
   Zhang JW, 2015, NAT CELL BIOL, V17, P1259, DOI 10.1038/ncb3230
   Zhang JW, 2013, NAT CELL BIOL, V15, P1186, DOI 10.1038/ncb2822
   Zhang L, 2014, TOXICOL LETT, V228, P248, DOI 10.1016/j.toxlet.2014.05.015
   Zhang ML, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-02951-7
   Zhang SQ, 2021, CELL DEATH DISCOV, V7, DOI 10.1038/s41420-021-00432-0
   Zhang XY, 2013, CELL SIGNAL, V25, P150, DOI 10.1016/j.cellsig.2012.09.004
   Zhang X, 2020, RESTOR NEUROL NEUROS, V38, P131, DOI 10.3233/RNN-190941
   Zhang ZY, 2020, OXID MED CELL LONGEV, V2020, DOI 10.1155/2020/2896036
   Zhong Y, 2009, NAT CELL BIOL, V11, P468, DOI 10.1038/ncb1854
   Zhou RB, 2011, NATURE, V469, P221, DOI 10.1038/nature09663
   Zuo L, 2013, INVEST OPHTH VIS SCI, V54, P5097, DOI 10.1167/iovs.13-12157
NR 251
TC 9
Z9 9
U1 17
U2 25
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 2045-3701
J9 CELL BIOSCI
JI Cell Biosci.
PD JAN 3
PY 2022
VL 12
IS 1
AR 1
DI 10.1186/s13578-021-00736-9
PG 20
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA XZ8YQ
UT WOS:000737933300001
PM 34980273
OA Green Published, gold
HC Y
HP N
DA 2022-11-30
ER

PT J
AU Wang, Y
   Xie, LQ
   Zhu, MH
   Guo, Y
   Tu, YY
   Zhou, YM
   Zeng, J
   Zhu, LL
   Du, S
   Wang, ZZ
   Zhang, YT
   Liu, XJ
   Song, E
AF Wang, Ying
   Xie, Laiqing
   Zhu, Manhui
   Guo, Yang
   Tu, Yuanyuan
   Zhou, Yamei
   Zeng, Jia
   Zhu, Linling
   Du, Shu
   Wang, Zhenzhen
   Zhang, Yuting
   Liu, Xiaojuan
   Song, E.
TI Shikonin alleviates choroidal neovascularization by inhibiting
   proangiogenic factor production from infiltrating macrophages
SO EXPERIMENTAL EYE RESEARCH
LA English
DT Article
DE Choroidal neovascularization (CNV); Shikonin (SHI); Pyruvate kinase M2
   (PKM2); Macrophage
ID GENE-TRANSCRIPTION; VEGF EXPRESSION; GLYCOLYSIS
AB Choroidal neovascularization (CNV), a feature of neovasular age-related macular degeneration (AMD), acts as a leading cause of vision loss in the elderly. Shikonin (SHI), a natural bioactive compound extracted from Chinese herb radix arnebiae, exerts anti-inflammatory and anti-angiogenic roles and also acts as a potential pyruvate kinase M2 (PKM2) inhibitor in macrophages. The major immune cells macrophages infiltrate the CNV lesions, where the production of pro-angiognic cytokines from macrophage facilitates the development of CNV. PKM2 contributes to the neovascular diseases. In this study, we found that SHI oral gavage alleviated the leakage, area and volume of mouse laser-induced CNV lesion and inhibited macrophage infiltration without ocular cytotoxicity. Moreover, SHI inhibited the secretion of pro-angiogenic cytokine, including basic fibroblast growth factor (FGF2), insulin-like growth factor-1 (IGF1), chemokine (C-C motif) ligand 2 (CCL2), placental growth factor and vascular endothelial growth factor (VEGF), from primary human macrophages by down-regulating PKM2/ STAT3/CD163 pathway, indicating a novel potential therapy strategy for CNV.
C1 [Wang, Ying; Zhu, Manhui; Tu, Yuanyuan; Zhu, Linling; Du, Shu; Wang, Zhenzhen; Zhang, Yuting; Song, E.] Soochow Univ, Dept Ophthalmol, Lixiang Eye Hosp, Suzhou, Jiangsu, Peoples R China.
   [Wang, Ying] Nanjing Med Univ, Suzhou Municipal Hosp, Dept Ophthalmol, Affiliated Suzhou Hosp, Suzhou, Jiangsu, Peoples R China.
   [Xie, Laiqing; Guo, Yang] Soochow Univ, Dept Ophthalmol, Affiliated Hosp 2, Suzhou, Jiangsu, Peoples R China.
   [Zhou, Yamei; Zeng, Jia; Liu, Xiaojuan] Nantong Univ, Med Coll, Dept Pathogen Biol, Nantong, Jiangsu, Peoples R China.
C3 Soochow University - China; Nanjing Medical University; Soochow
   University - China; Nantong University
RP Song, E (通讯作者)，Soochow Univ, Dept Ophthalmol, Lixiang Eye Hosp, Suzhou, Jiangsu, Peoples R China.; Liu, XJ (通讯作者)，Nantong Univ, Med Coll, Dept Pathogen Biol, Nantong, Jiangsu, Peoples R China.
EM lxj@ntu.edu.cn; songe@suda.edu.cn
RI 涂, 园园/AGE-3991-2022
FU Jiangsu Provincial Natural Science Foundation [BK20191177, BK20200209];
   National Natural Science Foundation of China [82000911]; Medical
   research project derived from Health Commission of Jiangsu Province
   [M2020053]; Pre-research of Natural Science Foundation of China
   [SDFEYGJ2011]; Suzhou Science and Technology Bureau [SYSD2020072,
   SYS2018005]
FX The study was partly financially supported by the Jiangsu Provincial
   Natural Science Foundation (No. BK20191177 & No. BK20200209) , the
   National Natural Science Foundation of China (No. 82000911) , the
   Medical research project derived from Health Commission of Jiangsu
   Province (No. M2020053) , Pre-research of Natural Science Foundation of
   China (No. SDFEYGJ2011) , and Suzhou Science and Technology Bureau (No.
   SYSD2020072 & No. SYS2018005) .
CR Alexandru Malciolu Radu, 2016, Rom J Ophthalmol, V60, P9
   Azoitei N, 2016, MOL CANCER, V15, DOI 10.1186/s12943-015-0490-2
   Balser C, 2019, J NEUROINFLAMM, V16, DOI 10.1186/s12974-019-1419-2
   Chen J, 2011, ONCOGENE, V30, P4297, DOI 10.1038/onc.2011.137
   Cheng ZG, 2017, ONCOTARGET, V8, P87244, DOI 10.18632/oncotarget.20244
   Falavarjani KG, 2013, EYE, V27, P787, DOI 10.1038/eye.2013.107
   Gao XL, 2012, MOL CELL, V45, P598, DOI 10.1016/j.molcel.2012.01.001
   Grossniklaus HE, 2010, PROG RETIN EYE RES, V29, P500, DOI 10.1016/j.preteyeres.2010.05.003
   Guo HL, 2019, BIOMED PHARMACOTHER, V112, DOI 10.1016/j.biopha.2019.108704
   Guo S., 2020, BIN LOSS HARD EXUDAT, V392
   Guo T, 2020, FRONT PHYSIOL, V11, DOI 10.3389/fphys.2020.570441
   Ho CPS, 2018, CURR PHARM DESIGN, V24, P4882, DOI 10.2174/1381612825666190206105943
   Kim JH, 2008, NEUROTOXICOLOGY, V29, P1131, DOI 10.1016/j.neuro.2008.06.006
   Komi Y, 2009, CANCER SCI, V100, P269, DOI 10.1111/j.1349-7006.2008.01049.x
   Leveziel N, 2012, INVEST OPHTH VIS SCI, V53, P5004, DOI 10.1167/iovs.12-9538
   Liu ZP, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.aay1371
   MARIE J, 1983, ISOZYMES-CURR T BIOL, V7, P221
   Marneros AG, 2007, FASEB J, V21, P3809, DOI 10.1096/fj.07-8422com
   Morohoshi K, 2012, EXP MOL PATHOL, V93, P193, DOI 10.1016/j.yexmp.2012.03.007
   Neumann J, 2019, NANOSCALE, V11, P9769, DOI 10.1039/c9nr00943d
   Sakurai E, 2003, INVEST OPHTH VIS SCI, V44, P3578, DOI 10.1167/iovs.03-0097
   Song J, 2018, INVEST OPHTH VIS SCI, V59, P3747, DOI 10.1167/iovs.18-23892
   Tahiri H, 2016, SCI REP-UK, V6, DOI 10.1038/srep37391
   Tsutsumi C, 2003, J LEUKOCYTE BIOL, V74, P25, DOI 10.1189/jlb.0902436
   Vallee A, 2017, J MOL NEUROSCI, V62, P368, DOI 10.1007/s12031-017-0947-4
   Wang HJ, 2014, P NATL ACAD SCI USA, V111, P279, DOI 10.1073/pnas.1311249111
   Weber ML, 2016, DEV OPHTHALMOL, V55, P167, DOI 10.1159/000431194
   Xie L., J CELL MOL MED, V25, P1700
   Xie M, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13280
   Xu YY, 2014, INT IMMUNOPHARMACOL, V19, P327, DOI 10.1016/j.intimp.2014.01.027
   Yang JT, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094180
   Yang LC, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5436
   Yang SQ, 2016, DRUG DES DEV THER, V10, P1857, DOI 10.2147/DDDT.S97653
   Yang WW, 2012, CELL, V150, P685, DOI 10.1016/j.cell.2012.07.018
   Zahra K, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.00159
   Zhang YL, 2018, BRIT J PHARMACOL, V175, P840, DOI 10.1111/bph.14129
   Zorman J, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0159826
NR 37
TC 1
Z9 1
U1 0
U2 4
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0014-4835
EI 1096-0007
J9 EXP EYE RES
JI Exp. Eye Res.
PD DEC
PY 2021
VL 213
AR 108823
DI 10.1016/j.exer.2021.108823
EA NOV 2021
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA WW7YO
UT WOS:000718127200004
PM 34752817
DA 2022-11-30
ER

PT J
AU Proulx, C
   Zhang, JQ
   Sabatino, D
   Chemtob, S
   Ong, H
   Lubell, WD
AF Proulx, Caroline
   Zhang, Jinqiang
   Sabatino, David
   Chemtob, Sylvain
   Ong, Huy
   Lubell, William D.
TI Synthesis and Biomedical Potential of Azapeptide Modulators of the
   Cluster of Differentiation 36 Receptor (CD36)
SO BIOMEDICINES
LA English
DT Review
DE semicarbazide; CD36; age-related macular degeneration; atherosclerosis;
   macrophage-driven inflammation; peptide
ID HORMONE-RELEASING PEPTIDE; DIVERSITY-ORIENTED SYNTHESIS; SCAVENGER
   RECEPTOR; BINDING-SITE; AMINO-ACIDS; AZA-LYSINE; AZAPROLINE;
   CONFORMATION; ADIPONECTIN; LIGANDS
AB The innovative development of azapeptide analogues of growth hormone releasing peptide-6 (GHRP-6) has produced selective modulators of the cluster of differentiation 36 receptor (CD36). The azapeptide CD36 modulators curb macrophage-driven inflammation and mitigate atherosclerotic and angiogenic pathology. In macrophages activated with Toll-like receptor-2 heterodimer agonist, they reduced nitric oxide production and proinflammatory cytokine release. In a mouse choroidal explant microvascular sprouting model, they inhibited neovascularization. In murine models of cardiovascular injury, CD36-selective azapeptide modulators exhibited cardioprotective and anti-atherosclerotic effects. In subretinal inflammation models, they altered activated mononuclear phagocyte metabolism and decreased immune responses to alleviate subsequent inflammation-dependent neuronal injury associated with retinitis pigmentosa, diabetic retinopathy and age-related macular degeneration. The translation of GHRP-6 to potent and selective linear and cyclic azapeptide modulators of CD36 is outlined in this review which highlights the relevance of turn geometry for activity and the biomedical potential of prototypes for the beneficial treatment of a wide range of cardiovascular, metabolic and immunological disorders.
C1 [Proulx, Caroline] North Carolina State Univ, Dept Chem, Raleigh, NC 27695 USA.
   [Zhang, Jinqiang] Chongqing Univ, Sch Pharmaceut Sci, Chongqing Key Lab Nat Prod Synth & Drug Res, Innovat Drug Res Ctr, Chongqing 401331, Peoples R China.
   [Sabatino, David] Seton Hall Univ, Dept Chem & Biochem, 400 South Orange Ave, S Orange, NJ 07079 USA.
   [Chemtob, Sylvain] Univ Montreal, Dept Ophtalmol, CP 6128,Succursale Ctr Ville, Montreal, PQ H3C 3J7, Canada.
   [Ong, Huy] Univ Montreal, Fac Pharm, CP 6128,Succursale Ctr Ville, Montreal, PQ H3C 3J7, Canada.
   [Lubell, William D.] Univ Montreal, Dept Chim, CP 6128,Succursale Ctr Ville, Montreal, PQ H3C 3J7, Canada.
C3 University of North Carolina; North Carolina State University; Chongqing
   University; Seton Hall University; Universite de Montreal; Universite de
   Montreal; Universite de Montreal
RP Lubell, WD (通讯作者)，Univ Montreal, Dept Chim, CP 6128,Succursale Ctr Ville, Montreal, PQ H3C 3J7, Canada.
EM cproulx@ncsu.edu; j.zhang1983@cqu.edu.cn; david.sabatino@shu.edu;
   sylvain.chemtob@umontreal.ca; huy.ong@umontreal.ca;
   william.lubell@umontreal.ca
OI Lubell, William/0000-0002-3080-2712; Sabatino, David/0000-0002-9797-0833
FU Natural Sciences and Engineering Research Council (NSERC) of Canada
   [04079]; Canadian Institutes of Health Research (CIHR) [MOP89716,
   PPP-90157]; NSERC-CIHR [163973]; Ministere du Developpement Economique,
   de l'Innovation et de l'Exportation du Gouvernement provincial du Quebec
   [PSVT3-21396]; Amorchem Holdings Inc.; Mperia Therapeutics Inc.
FX This project was supported by funding from the Natural Sciences and
   Engineering Research Council (NSERC) of Canada (Discovery Research
   Project #04079), the Canadian Institutes of Health Research (CIHR;
   MOP89716 and PPP-90157), the NSERC-CIHR for funding the Collaborative
   Health Research Project "Azacyclopeptide Modulators of Immuno-metabolism
   to Treat Age-Related Macular Degeneration" No. 163973, the Ministere du
   Developpement Economique, de l'Innovation et de l'Exportation du
   Gouvernement provincial du Quebec (PSVT3-21396) in partnership with
   Amorchem Holdings Inc., and Mperia Therapeutics Inc.
CR Abe T, 2010, STROKE, V41, P898, DOI 10.1161/STROKEAHA.109.572552
   Ahsanullah, 2019, PEPTIDE SCI, V111, DOI 10.1002/pep2.24102
   Avallone R, 2006, MOL ENDOCRINOL, V20, P3165, DOI 10.1210/me.2006-0146
   Bessi VL, 2012, CARDIOVASC RES, V96, P99, DOI 10.1093/cvr/cvs225
   Beutler B, 2006, ANNU REV IMMUNOL, V24, P353, DOI 10.1146/annurev.immunol.24.021605.090552
   Boeglin D, 2005, J COMB CHEM, V7, P864, DOI 10.1021/cc050043h
   Bolduc OR, 2011, ANALYST, V136, P3142, DOI 10.1039/c1an15235a
   Boutard N, 2010, CHEM BIOL DRUG DES, V75, P40, DOI 10.1111/j.1747-0285.2009.00913.x
   BUSH CA, 1978, BIOCHEMISTRY-US, V17, P4951, DOI 10.1021/bi00616a015
   Che Y, 2006, J MED CHEM, V49, P111, DOI 10.1021/jm0507072
   Che Y, 2004, J ORG CHEM, V69, P9030, DOI 10.1021/jo0487303
   Chingle R, 2019, J ORG CHEM, V84, P6006, DOI 10.1021/acs.joc.8b03283
   Chingle R, 2017, ACCOUNTS CHEM RES, V50, P1541, DOI 10.1021/acs.accounts.7b00114
   Danelius E, 2019, J MED CHEM, V62, P11071, DOI 10.1021/acs.jmedchem.9b00918
   Demers A, 2004, BIOCHEM J, V382, P417, DOI 10.1042/BJ20040036
   Didierjean C, 2000, J PEPT RES, V55, P308, DOI 10.1034/j.1399-3011.2000.00686.x
   ENDEMANN G, 1993, J BIOL CHEM, V268, P11811
   Febbraio M, 2001, J CLIN INVEST, V108, P785, DOI 10.1172/JCI14006
   Febbraio M, 2007, INT J BIOCHEM CELL B, V39, P2012, DOI 10.1016/j.biocel.2007.03.012
   Fregeau G, 2020, ATHEROSCLEROSIS, V307, P52, DOI 10.1016/j.atherosclerosis.2020.06.010
   FREIDINGER RM, 1980, SCIENCE, V210, P656, DOI 10.1126/science.7001627
   Freidinger RM, 2003, J MED CHEM, V46, P5553, DOI 10.1021/jm030484k
   Hajri T, 2007, DIABETES, V56, P1872, DOI 10.2337/db06-1699
   Hemmerlin C, 2001, TETRAHEDRON LETT, V42, P5009, DOI 10.1016/S0040-4039(01)00917-0
   Hoosdally SJ, 2009, J BIOL CHEM, V284, P16277, DOI 10.1074/jbc.M109.007849
   Huynh DN, 2018, FASEB J, V32, P807, DOI 10.1096/fj.201700505R
   Jimenez B, 2000, NAT MED, V6, P41, DOI 10.1038/71517
   Kar NS, 2008, J BIOL CHEM, V283, P8765, DOI 10.1074/jbc.M709195200
   LECOQ A, 1992, TETRAHEDRON LETT, V33, P5209, DOI 10.1016/S0040-4039(00)79134-9
   LECOQ A, 1993, BIOPOLYMERS, V33, P1051, DOI 10.1002/bip.360330707
   Lopaschuk GD, 2010, PHYSIOL REV, V90, P207, DOI 10.1152/physrev.00015.2009
   Lubell W.D., 2014, COMPREHENSIVE CHIRAL, P86
   Mellal K, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-49472-8
   Muller MN, 2019, J BIOL CHEM, V294, P14776, DOI 10.1074/jbc.REV119.006136
   Nagendran J, 2013, J MOL CELL CARDIOL, V63, P180, DOI 10.1016/j.yjmcc.2013.07.020
   Doan ND, 2015, BIOPOLYMERS, V104, P629, DOI 10.1002/bip.22646
   Doan ND, 2015, J PEPT SCI, V21, P387, DOI 10.1002/psc.2711
   Doan ND, 2014, ORG LETT, V16, P2232, DOI 10.1021/ol500739k
   Picard E, 2010, AGING-US, V2, P981, DOI 10.18632/aging.100218
   Possi KC, 2017, J MED CHEM, V60, P9263, DOI 10.1021/acs.jmedchem.7b01209
   Proulx C., 2009, PEPT BREAK AW P 21 A, P56
   Proulx C, 2012, J MED CHEM, V55, P6502, DOI 10.1021/jm300557t
   Proulx C, 2011, FUTURE MED CHEM, V3, P1139, DOI [10.4155/FMC.11.74, 10.4155/fmc.11.74]
   Proulx C, 2010, J ORG CHEM, V75, P5385, DOI 10.1021/jo100957z
   Proulx C, 2010, ORG LETT, V12, P2916, DOI 10.1021/ol100932m
   Qiao LP, 2011, DIABETES, V60, P1519, DOI 10.2337/db10-1017
   Reis A, 2014, DIABETES, V63, P3926, DOI 10.2337/db13-1673
   Sabatino D, 2011, J AM CHEM SOC, V133, P12493, DOI 10.1021/ja203007u
   Sabatino D, 2009, ORG LETT, V11, P3650, DOI 10.1021/ol901423c
   Shibata R, 2005, NAT MED, V11, P1096, DOI 10.1038/nm1295
   Silverstein RL, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.272re3
   St-Cyr D.J., 2017, TOPICS HETEROCYCLIC, P125, DOI DOI 10.1007/7081_2017_204
   Sun JF, 2009, AM J PHYSIOL-HEART C, V296, pH1344, DOI 10.1152/ajpheart.01246.2008
   Suzuki M, 2012, J CELL SCI, V125, P2407, DOI 10.1242/jcs.097683
   Traore M, 2014, ORG LETT, V16, P3588, DOI 10.1021/ol501586y
   Turcotte S, 2018, BIOMEDICINES, V6, DOI 10.3390/biomedicines6040098
   Turcotte S, 2015, BIOPOLYMERS, V104, P622, DOI 10.1002/bip.22632
   Vinogradov AA, 2019, J AM CHEM SOC, V141, P4167, DOI 10.1021/jacs.8b13178
   Wei CM, 2002, J AM CHEM SOC, V124, P5638, DOI 10.1021/ja026007t
   Weinberger H, 1997, ARCH PHARM, V330, P109, DOI 10.1002/ardp.19973300406
   Zhang JQ, 2017, ANGEW CHEM INT EDIT, V56, P6284, DOI 10.1002/anie.201611685
   Zhang JQ, 2014, ORG LETT, V16, P298, DOI 10.1021/ol403297v
   Zhang WJ, 2003, J AM CHEM SOC, V125, P1221, DOI 10.1021/ja020994o
   Zouikri M, 1998, J PEPT RES, V52, P19
NR 64
TC 8
Z9 8
U1 3
U2 12
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2227-9059
J9 BIOMEDICINES
JI Biomedicines
PD AUG
PY 2020
VL 8
IS 8
AR 241
DI 10.3390/biomedicines8080241
PG 25
WC Biochemistry & Molecular Biology; Medicine, Research & Experimental;
   Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Research & Experimental Medicine;
   Pharmacology & Pharmacy
GA OA5OE
UT WOS:000577833500001
PM 32717955
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Tom, I
   Pham, VC
   Katschke, KJ
   Li, W
   Liang, WC
   Gutierrez, J
   Young, AA
   Figueroa, I
   Eshghi, ST
   Lee, CV
   Kanodia, J
   Snipas, SJ
   Salvesen, GS
   Lai, P
   Honigberg, L
   Campagne, MV
   Kirchhofer, D
   Baruch, A
   Lill, JR
AF Tom, Irene
   Pham, Victoria C.
   Katschke, Kenneth J.
   Li, Wei
   Liang, Wei-Ching
   Gutierrez, Johnny
   Young, Andrew Ah
   Figueroa, Isabel
   Eshghi, Shadi Toghi
   Lee, ChingWei, V
   Kanodia, Jitendra
   Snipas, Scott J.
   Salvesen, Guy S.
   Lai, Phillip
   Honigberg, Lee
   Campagne, Menno van Lookeren
   Kirchhofer, Daniel
   Baruch, Amos
   Lill, Jennie R.
TI Development of a therapeutic anti-HtrA1 antibody and the identification
   of DKK3 as a pharmacodynamic biomarker in geographic atrophy
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
DE age-related macular degeneration (AMD); proteomics; biomarker
ID SERINE-PROTEASE HTRA1; ACTIVITY-BASED PROBES; MACULAR DEGENERATION;
   COMPLEX; ASSOCIATION; RETINOL; SCREEN
AB Genetic polymorphisms in the region of the trimeric serine hydrolase high-temperature requirement 1 (HTRA1) are associated with increased risk of age-related macular degeneration (AMD) and disease progression, but the precise biological function of HtrA1 in the eye and its contribution to disease etiologies remain undefined. In this study, we have developed an HtrA1-blocking Fab fragment to test the therapeutic hypothesis that HtrA1 protease activity is involved in the progression of AMD. Next, we generated an activity-based small-molecule probe (ABP) to track target engagement in vivo. In addition, we used N-terminomic proteomic profiling in preclinical models to elucidate the in vivo repertoire of HtrA1-specific substrates, and identified substrates that can serve as robust pharmacodynamic biomarkers of HtrA1 activity. One of these HtrA1 substrates, Dickkopf-related protein 3 (DKK3), was successfully used as a biomarker to demonstrate the inhibition of HtrA1 activity in patients with AMD who were treated with the HtrA1-blocking Fab fragment. This pharmacodynamic biomarker provides important information on HtrA1 activity and pharmacological inhibition within the ocular compartment.
C1 [Tom, Irene; Gutierrez, Johnny; Eshghi, Shadi Toghi; Honigberg, Lee] Genentech Inc, OMNI Biomarker Dev, San Francisco, CA 94080 USA.
   [Pham, Victoria C.; Lill, Jennie R.] Genentech Inc, Dept Microchem Prote & Lipid, San Francisco, CA 94080 USA.
   [Katschke, Kenneth J.] Genentech Inc, Dept Immunol, San Francisco, CA 94080 USA.
   [Li, Wei; Young, Andrew Ah; Kirchhofer, Daniel] Genentech Inc, Dept Early Discovery Biochem, San Francisco, CA 94080 USA.
   [Liang, Wei-Ching] Genentech Inc, Dept Antibody Discovery, San Francisco, CA 94080 USA.
   [Figueroa, Isabel] AbbVie, Drug Metab Pharmacokinet & Bioanal, San Francisco, CA 94090 USA.
   [Lee, ChingWei, V] Gilead Sci, Biol Core Support, Foster City, CA 94404 USA.
   [Kanodia, Jitendra] Theravance Biopharma Inc, Clin & Translat Pharmacol, San Francisco, CA 94080 USA.
   [Snipas, Scott J.; Salvesen, Guy S.] NCI, Designated Canc Ctr, Sanford Burnham Prebys Med Discovery Inst, La Jolla, CA 92037 USA.
   [Lai, Phillip] Genentech Inc, Early Clin Dev, OMNI Dept, San Francisco, CA 94080 USA.
   [Campagne, Menno van Lookeren] Amgen Inc, Inflammat & Oncol Res, San Francisco, CA 94080 USA.
   [Baruch, Amos] Cal Life Sci LLC, Biomarker Dev, San Francisco, CA 94080 USA.
C3 Roche Holding; Genentech; Roche Holding; Genentech; Roche Holding;
   Genentech; Roche Holding; Genentech; Roche Holding; Genentech; AbbVie;
   Gilead Sciences; Theravance; National Institutes of Health (NIH) - USA;
   NIH National Cancer Institute (NCI); Sanford Burnham Prebys Medical
   Discovery Institute; Roche Holding; Genentech; Amgen
RP Lill, JR (通讯作者)，Genentech Inc, Dept Microchem Prote & Lipid, San Francisco, CA 94080 USA.; Baruch, A (通讯作者)，Cal Life Sci LLC, Biomarker Dev, San Francisco, CA 94080 USA.
EM barucha@calicolabs.com; jennie@gene.com
FU NIGMS NIH HHS [R01 GM099040] Funding Source: Medline
CR An E, 2010, INVEST OPHTH VIS SCI, V51, P3379, DOI 10.1167/iovs.09-4853
   [Anonymous], 2011, GUIDE CARE USE LAB A, V8th, DOI [10.17226/12910, DOI 10.17226/12910]
   Bakalarski CE, 2008, J PROTEOME RES, V7, P4756, DOI 10.1021/pr800333e
   Beaufort N, 2014, P NATL ACAD SCI USA, V111, P16496, DOI 10.1073/pnas.1418087111
   Busceti CL, 2018, FRONT CELL NEUROSCI, V12, DOI 10.3389/fncel.2018.00292
   Campagne MV, 2014, J PATHOL, V232, P151, DOI 10.1002/path.4266
   Chen CY, 2018, MATRIX BIOL, V70, P84, DOI 10.1016/j.matbio.2018.03.013
   Chen CH, 2017, J BIOL CHEM, V292, P19356, DOI 10.1074/jbc.M117.795187
   Chien J, 2009, J CELL BIOCHEM, V107, P253, DOI 10.1002/jcb.22121
   CHOI NH, 1989, MOL IMMUNOL, V26, P835
   Ciferri C, 2015, BIOCHEM J, V472, P169, DOI 10.1042/BJ20150601
   Colaert N, 2009, NAT METHODS, V6, P786, DOI 10.1038/nmeth1109-786
   den Hollander AI, 2009, INVEST OPHTH VIS SCI, V50, P1864, DOI 10.1167/iovs.08-2497
   Eigenbrot C, 2012, STRUCTURE, V20, P1040, DOI 10.1016/j.str.2012.03.021
   Elias JE, 2010, METHODS MOL BIOL, V604, P55, DOI 10.1007/978-1-60761-444-9_5
   FONG SL, 1984, J BIOL CHEM, V259, P6534
   Fonovic M, 2007, CURR PHARM DESIGN, V13, P253, DOI 10.2174/138161207779313623
   Friedman JS, 2002, HUM MOL GENET, V11, P1333, DOI 10.1093/hmg/11.11.1333
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Gonzalez-Fernandez F, 2014, EXP EYE RES, V120, P167, DOI 10.1016/j.exer.2014.01.002
   Grau S, 2005, P NATL ACAD SCI USA, V102, P6021, DOI 10.1073/pnas.0501823102
   Hara K, 2009, NEW ENGL J MED, V360, P1729, DOI 10.1056/NEJMoa0801560
   Ishikawa M, 2015, EXP EYE RES, V133, P3, DOI 10.1016/j.exer.2015.02.017
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   JONES SE, 1992, FEBS LETT, V300, P279, DOI 10.1016/0014-5793(92)80863-C
   Karamariti E, 2018, ARTERIOSCL THROM VAS, V38, P425, DOI 10.1161/ATVBAHA.117.310079
   Kidd D, 2001, BIOCHEMISTRY-US, V40, P4005, DOI 10.1021/bi002579j
   Kleifeld O, 2010, NAT BIOTECHNOL, V28, P281, DOI 10.1038/nbt.1611
   Kortvely E, 2016, HUM MOL GENET, V25, P3143, DOI 10.1093/hmg/ddw162
   Melo E, 2018, EBIOMEDICINE, V27, P258, DOI 10.1016/j.ebiom.2017.12.011
   Menard C, 2016, ONCOTARGET, V7, P19171, DOI 10.18632/oncotarget.8280
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Mones J., INHIBITING VEGF PDGF
   Oka C, 2004, DEVELOPMENT, V131, P1041, DOI 10.1242/dev.00999
   Pan ZY, 2006, BIOORG MED CHEM LETT, V16, P2882, DOI 10.1016/j.bmcl.2006.03.012
   Risor MW, 2014, BIOCHEMISTRY-US, V53, P3851, DOI 10.1021/bi401633w
   Ruzafa N, 2018, PROTEOMICS, V18, DOI 10.1002/pmic.201700321
   Sohn EH, 2015, RETINA-J RET VIT DIS, V35, P48, DOI 10.1097/IAE.0000000000000263
   Tamhane M, 2019, PHARM RES-DORDR, V36, DOI 10.1007/s11095-019-2569-8
   Timmer JC, 2011, METHODS MOL BIOL, V753, P243, DOI 10.1007/978-1-61779-148-2_16
   Yu BQ, 2017, CIRCULATION, V136, P1022, DOI 10.1161/CIRCULATIONAHA.117.027690
NR 41
TC 17
Z9 17
U1 0
U2 4
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD MAY 5
PY 2020
VL 117
IS 18
BP 9952
EP 9963
DI 10.1073/pnas.1917608117
PG 12
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA LK7UR
UT WOS:000531067600047
PM 32345717
OA hybrid, Green Published
DA 2022-11-30
ER

PT J
AU Hosoda, Y
   Yoshikawa, M
   Miyake, M
   Tabara, Y
   Ahn, J
   Woo, SJ
   Honda, S
   Sakurada, Y
   Shiragami, C
   Nakanishi, H
   Oishi, A
   Ooto, S
   Miki, A
   Iida, T
   Iijima, H
   Nakamura, M
   Khor, CC
   Wong, TY
   Song, K
   Park, KH
   Yamada, R
   Matsuda, F
   Tsujikawa, A
   Yamashiro, K
AF Hosoda, Yoshikatsu
   Yoshikawa, Munemitsu
   Miyake, Masahiro
   Tabara, Yasuharu
   Ahn, Jeeyun
   Woo, Se Joon
   Honda, Shigeru
   Sakurada, Yoichi
   Shiragami, Chieko
   Nakanishi, Hideo
   Oishi, Akio
   Ooto, Sotaro
   Miki, Akiko
   Iida, Tomohiro
   Iijima, Hiroyuki
   Nakamura, Makoto
   Khor, Chiea Chuen
   Wong, Tien Yin
   Song, Kyuyoung
   Park, Kyu Hyung
   Yamada, Ryo
   Matsuda, Fumihiko
   Tsujikawa, Akitaka
   Yamashiro, Kenji
CA Nagahama Study Grp
TI CFH and VIPR2 as susceptibility loci in choroidal thickness and
   pachychoroid disease central serous chorioretinopathy
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
DE GWAS; choroidal thickness; CFH; VIPR2; central serous chorioretinopathy
ID COMPLEMENT FACTOR-H; OPTICAL COHERENCE TOMOGRAPHY; MACULAR DEGENERATION;
   HELICOBACTER-PYLORI; VASCULOPATHY; MYOPIA; GENE; POLYMORPHISMS;
   RETINOPATHY; POPULATION
AB Central serous chorioretinopathy (CSC) is a common disease affecting younger people and may lead to vision loss. CSC shares phenotypic overlap with age-related macular degeneration (AMD). As recent studies have revealed a characteristic increase of choroidal thickness in CSC, we conducted a genome-wide association study on choroidal thickness in 3,418 individuals followed by TaqMan assays in 2,692 subjects, and we identified two susceptibility loci: CFH rs800292, an established AMD susceptibility polymorphism, and VIPR2 rs3793217 (P = 2.05 x 10(-10) and 6.75 x 10(-8), respectively). Case-control studies using patients with CSC confirmed associations between both polymorphisms and CSC (P = 5.27 x 10(-5) and 5.14 x 10(-5), respectively). The CFH rs800292 G allele is reportedly a risk allele for AMD, whereas the A allele conferred risk for thicker choroid and CSC development. This study not only shows that susceptibility genes for CSC could be discovered using choroidal thickness as a defining variable but also, deepens the understanding of differences between CSC and AMD pathophysiology.
C1 [Hosoda, Yoshikatsu; Yoshikawa, Munemitsu; Miyake, Masahiro; Nakanishi, Hideo; Oishi, Akio; Ooto, Sotaro; Tsujikawa, Akitaka; Yamashiro, Kenji] Kyoto Univ, Grad Sch Med, Dept Ophthalmol & Visual Sci, Kyoto 6068507, Japan.
   [Hosoda, Yoshikatsu; Yoshikawa, Munemitsu; Miyake, Masahiro; Tabara, Yasuharu; Yamada, Ryo; Matsuda, Fumihiko] Kyoto Univ, Grad Sch Med, Ctr Genom Med, Kyoto 6068503, Japan.
   [Ahn, Jeeyun] Seoul Natl Univ, Coll Med, SMG SNU Boramae Med Ctr, Dept Ophthalmol, Seoul 07061, South Korea.
   [Woo, Se Joon; Park, Kyu Hyung] Seoul Natl Univ, Bundang Hosp, Coll Med Kyeonggi, Dept Ophthalmol, Seoul 13620, South Korea.
   [Honda, Shigeru; Miki, Akiko; Nakamura, Makoto] Kobe Univ, Grad Sch Med, Dept Surg, Div Ophthalmol, Kobe, Hyogo 6500017, Japan.
   [Sakurada, Yoichi; Iijima, Hiroyuki] Univ Yamanashi, Dept Ophthalmol, Yamanashi 4008510, Japan.
   [Shiragami, Chieko] Kagawa Univ, Dept Ophthalmol, Kagawa 7610793, Japan.
   [Iida, Tomohiro] Tokyo Womens Med Univ, Dept Ophthalmol, Tokyo 1628666, Japan.
   [Khor, Chiea Chuen; Wong, Tien Yin] Singapore Eye Res Inst, Singapore Natl Eye Ctr, Singapore 168751, Singapore.
   [Khor, Chiea Chuen] Genome Inst Singapore, Div Human Genet, Singapore 138672, Singapore.
   [Wong, Tien Yin] Natl Univ Singapore, Saw Swee Hock Sch Publ Hlth, Singapore 117549, Singapore.
   [Wong, Tien Yin] Natl Univ Hlth Syst, Singapore 117549, Singapore.
   [Wong, Tien Yin] Natl Univ Singapore, Duke NUS Med Sch, Ophthalmol & Visual Sci Acad Clin Program, Singapore 169857, Singapore.
   [Song, Kyuyoung] Univ Ulsan, Coll Med, Dept Biochem & Mol Biol, Seoul 138736, South Korea.
   [Yamashiro, Kenji] Otsu Red Cross Hosp, Dept Ophthalmol, Otsu, Shiga 5208511, Japan.
C3 Kyoto University; Kyoto University; Seoul National University (SNU);
   Seoul National University Hospital; Seoul National University (SNU);
   Kobe University; University of Yamanashi; Kagawa University; Tokyo
   Women's Medical University; National University of Singapore; Singapore
   National Eye Center; Agency for Science Technology & Research (A*STAR);
   A*STAR - Genome Institute of Singapore (GIS); National University of
   Singapore; National University of Singapore; National University of
   Singapore; University of Ulsan
RP Yamashiro, K (通讯作者)，Kyoto Univ, Grad Sch Med, Dept Ophthalmol & Visual Sci, Kyoto 6068507, Japan.; Yamashiro, K (通讯作者)，Otsu Red Cross Hosp, Dept Ophthalmol, Otsu, Shiga 5208511, Japan.
EM yamashro@kuhp.kyoto-u.ac.jp
RI Oishi, Akio/AAE-9996-2020; Wong, Tien Yin/AAC-9724-2020; Honda,
   Shigeru/W-4761-2019; Miyake, Masahiro/V-1261-2019
OI Oishi, Akio/0000-0002-0977-9458; Wong, Tien Yin/0000-0002-8448-1264;
   Miyake, Masahiro/0000-0001-7410-3764; Tsujikawa,
   Akitaka/0000-0003-0779-7799; Nakamura, Makoto/0000-0002-6464-4302; Ahn,
   Jeeyun/0000-0001-9017-1652; Yamashiro, Kenji/0000-0001-9354-8558;
   Yamada, Ryo/0000-0002-1587-630X
FU Kyoto University; Ministry of Education, Culture, Sports, Science &
   Technology in Japan; Center of Innovation Program from Japan Science and
   Technology Agency; Global University Project from Japan Science and
   Technology Agency; Practical Research Project for Rare/Intractable
   Diseases from Japan Agency for Medical Research and Development;
   Comprehensive Research on Aging and Health Science Research Grants for
   Dementia R&D from Japan Agency for Medical Research and Development;
   Takeda Science Foundation
FX We thank Ms. Hatsue Hamanaka for her assistance in genotyping. We also
   thank the Nagahama City Office and the nonprofit organization Zeroji
   Club for help in conducting the Nagahama Study. This study was supported
   by a University Grant from Kyoto University; a Grant-in-Aid for
   Scientific Research from the Ministry of Education, Culture, Sports,
   Science & Technology in Japan; the Center of Innovation Program and the
   Global University Project from Japan Science and Technology Agency; the
   Practical Research Project for Rare/Intractable Diseases and the
   Comprehensive Research on Aging and Health Science Research Grants for
   Dementia R&D from Japan Agency for Medical Research and Development; and
   a research grant from the Takeda Science Foundation.
CR Bernasconi P, 1998, GRAEF ARCH CLIN EXP, V236, P571, DOI 10.1007/s004170050123
   Bouzas EA, 2002, SURV OPHTHALMOL, V47, P431, DOI 10.1016/S0039-6257(02)00338-7
   Breukink MB, 2015, INVEST OPHTH VIS SCI, V56, P5608, DOI 10.1167/iovs.15-17343
   Bujarborua D, 2001, ACTA OPHTHALMOL SCAN, V79, P417, DOI 10.1034/j.1600-0420.2001.079004417.x
   Cotticelli L, 2006, EUR J OPHTHALMOL, V16, P274, DOI 10.1177/112067210601600213
   Daruich A, 2015, PROG RETIN EYE RES, V48, P82, DOI 10.1016/j.preteyeres.2015.05.003
   Das S, 2016, NAT GENET, V48, P1284, DOI 10.1038/ng.3656
   de Jong EK, 2015, OPHTHALMOLOGY, V122, P562, DOI 10.1016/j.ophtha.2014.09.026
   Gass J.D., 1967, AM J OPHTHALMOL, V63, P1
   Gemenetzi M, 2010, EYE, V24, P1743, DOI 10.1038/eye.2010.130
   Hayashi H, 2010, INVEST OPHTH VIS SCI, V51, P5914, DOI 10.1167/iovs.10-5554
   Henning RJ, 2001, CARDIOVASC RES, V49, P27, DOI 10.1016/S0008-6363(00)00229-7
   Imamura Y, 2009, RETINA-J RET VIT DIS, V29, P1469, DOI 10.1097/IAE.0b013e3181be0a83
   Jhoo JH, 2008, DEMENT GERIATR COGN, V26, P270, DOI 10.1159/000160960
   Kiefer AK, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003299
   Kim SW, 2011, RETINA-J RET VIT DIS, V31, P1904, DOI 10.1097/IAE.0b013e31821801c5
   Kitzmann AS, 2008, OPHTHALMOLOGY, V115, P169, DOI [10.1016/j.ophtha.2007.02.032, 10.1016/j.ophtha.2008.01.009]
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Lehmann M, 2015, RETINA-J RET VIT DIS, V35, P10, DOI 10.1097/IAE.0000000000000287
   Liu Shuang-zhen, 2005, Zhong Nan Da Xue Xue Bao Yi Xue Ban, V30, P456
   Loh PR, 2016, NAT GENET, V48, P1443, DOI 10.1038/ng.3679
   Miki A, 2014, OPHTHALMOLOGY, V121, P1067, DOI 10.1016/j.ophtha.2013.11.020
   Miyake M, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7689
   Moschos MM, 2016, RETINA-J RET VIT DIS, V36, P402, DOI 10.1097/IAE.0000000000000693
   Nakata I, 2015, SCI REP-UK, V5, DOI 10.1038/srep09345
   Nicholson B, 2013, SURV OPHTHALMOL, V58, P103, DOI 10.1016/j.survophthal.2012.07.004
   Nowak KW, 1999, BIOMED RES-TOKYO, V20, P127, DOI 10.2220/biomedres.20.127
   Nussdorfer GG, 1998, PEPTIDES, V19, P1443, DOI 10.1016/S0196-9781(98)00102-8
   Oosterhuis JA, 1996, GRAEF ARCH CLIN EXP, V234, P337, DOI 10.1007/BF00220710
   Pang CE, 2015, RETINA-J RET VIT DIS, V35, P1, DOI 10.1097/IAE.0000000000000331
   Park DW, 1998, EUR J OPHTHALMOL, V8, P42, DOI 10.1177/112067219800800110
   Rahbani-Nobar MB, 2011, MOL VIS, V17, P99
   Schubert C, 2014, HUM MUTAT, V35, P859, DOI 10.1002/humu.22551
   Shi Y, 2013, HUM MOL GENET, V22, P2325, DOI 10.1093/hmg/ddt066
   Tittl M, 2005, INVEST OPHTH VIS SCI, V46, P4717, DOI 10.1167/iovs.05-0268
   Toyama T, 2014, EYE, V28, P992, DOI 10.1038/eye.2014.132
   Ueta T, 2009, OPHTHALMOLOGY, V116, P2400, DOI 10.1016/j.ophtha.2009.06.013
   van Dijk EHC, 2017, JAMA OPHTHALMOL, V135, P446, DOI 10.1001/jamaophthalmol.2017.0245
   van Velthoven MEJ, 2005, BRIT J OPHTHALMOL, V89, P1483, DOI 10.1136/bjo.2005.073056
   Verhoeven VJM, 2013, NAT GENET, V45, P314, DOI 10.1038/ng.2554
   Wang M, 2008, ACTA OPHTHALMOL, V86, P126, DOI 10.1111/j.1600-0420.2007.00889.x
   Weenink AC, 2001, OPHTHALMOLOGICA, V215, P183, DOI 10.1159/000050855
   Wei WB, 2013, OPHTHALMOLOGY, V120, P175, DOI 10.1016/j.ophtha.2012.07.048
   Yiu WC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061805
NR 44
TC 56
Z9 56
U1 1
U2 8
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD JUN 12
PY 2018
VL 115
IS 24
BP 6261
EP 6266
DI 10.1073/pnas.1802212115
PG 6
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA GJ0HJ
UT WOS:000434933400056
PM 29844195
OA Green Published, Green Submitted, hybrid
DA 2022-11-30
ER

PT J
AU Molins, B
   Anna Pascual, M
   Llorenc, V
   Zarranz-Ventura, J
   Mesquida, M
   Adan, A
   Martorell, J
AF Molins, Blanca
   Anna Pascual, Mendez
   Llorenc, Victor
   Zarranz-Ventura, Javier
   Mesquida, Marina
   Adan, Alfredo
   Martorell, Jordi
TI C-reactive protein isoforms differentially affect outer blood-retinal
   barrier integrity and function
SO AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY
LA English
DT Article
DE blood-retinal barrier; C-reactive protein; macular degeneration; tight
   junctions
ID COMPLEMENT FACTOR-H; MACULAR DEGENERATION; ACTIVATED PLATELETS;
   ENDOTHELIAL-CELLS; RISK-FACTORS; IN-VIVO; INFLAMMATION; DRUSEN; VARIANT;
   GLUCOCORTICOIDS
AB The retinal pigment epithelium (RPE) forms the outer blood-retinal barrier (oBRB) and is the prime target of early age-related macular degeneration (AMD). C-reactive protein (CRP), a serum biomarker for chronic inflammation and AMD, presents two different isoforms, monomeric (mCRP) and pentameric (pCRP), that may have a different effect on inflammation and barrier function in the RPE. The results reported in this study suggest that mCRP but not pCRP impairs RPE functionality by increasing paracellular permeability and disrupting the tight junction proteins ZO-1 and occludin in RPE cells. Additionally, we evaluated the effect of drugs commonly used in clinical settings on mCRP-induced barrier dysfunction. We found that a corticosteroid (methylprednisolone) and an anti-VEGF agent (bevacizumab) prevented mCRP-induced ARPE-19 barrier disruption and IL-8 production. Furthermore, bevacizumab was also able to revert mCRP-induced IL-8 increase after mCRP stimulation. In conclusion, the presence of mCRP within retinal tissue may lead to disruption of the oBRB, an effect that may be modified in the presence of corticosteroids or anti-VEGF drugs.
C1 [Molins, Blanca; Anna Pascual, Mendez; Llorenc, Victor; Zarranz-Ventura, Javier; Mesquida, Marina; Adan, Alfredo] Hosp Clin Barcelona, Inst Invest Biomed Agusti Pi & Sunyer, Sabino de Arana 1, Barcelona 08028, Spain.
   [Molins, Blanca; Llorenc, Victor; Zarranz-Ventura, Javier; Mesquida, Marina; Adan, Alfredo] Hosp Clin Barcelona, Inst Clin Oftalmol, Barcelona, Spain.
   [Anna Pascual, Mendez; Martorell, Jordi] Univ Ramon Llull, IQS Sch Engn, Dept Chem Engn & Mat Sci, Barcelona, Spain.
C3 University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS;
   University of Barcelona; Hospital Clinic de Barcelona; Universitat Ramon
   Llull; Institut Quimic de Sarria
RP Molins, B (通讯作者)，Hosp Clin Barcelona, Inst Invest Biomed Agusti Pi & Sunyer, Sabino de Arana 1, Barcelona 08028, Spain.
EM bmolins@clinic.ub.es
RI Llorens Bellés, Víctor/V-3892-2019; Zarranz-Ventura,
   Javier/AAB-5390-2021; Martorell, Jordi/N-3657-2013
OI Llorens Bellés, Víctor/0000-0002-7375-1564; Zarranz-Ventura,
   Javier/0000-0003-2338-8143; Martorell, Jordi/0000-0002-2043-2762;
   Molins, Blanca/0000-0003-0941-9134; Mesquida, Marina/0000-0003-0270-0978
FU Ministry of Science and Innovation of Spain, Instituto de Salud Carlos
   III, Fondo de Investigacion Sanitaria [RD12/0034]
FX Support for this study was provided by Ministry of Science and
   Innovation of Spain, Instituto de Salud Carlos III, Fondo de
   Investigacion Sanitaria Grant RD12/0034.
CR Ablonczy Z, 2011, INVEST OPHTH VIS SCI, V52, P8614, DOI 10.1167/iovs.11-8021
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   ANDERSON JM, 1995, AM J PHYSIOL-GASTR L, V269, pG467, DOI 10.1152/ajpgi.1995.269.4.G467
   CALICETI C, 2014, BIOMED RES INT, V2014, DOI DOI 10.1155/2014/857504
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Donoso LA, 2006, SURV OPHTHALMOL, V51, P137, DOI 10.1016/j.survophthal.2005.12.001
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Eisenhardt SU, 2009, CIRC RES, V105, P128, DOI 10.1161/CIRCRESAHA.108.190611
   Goncalves A, 2013, TISSUE BARRIERS, V1, DOI 10.4161/tisb.24782
   Green W R, 1999, Mol Vis, V5, P27
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Ji SR, 2007, FASEB J, V21, P284, DOI 10.1096/fj.06-6722com
   Ji SR, 2009, FASEB J, V23, P1806, DOI 10.1096/fj.08-116962
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Johnson PT, 2006, P NATL ACAD SCI USA, V103, P17456, DOI 10.1073/pnas.0606234103
   Khreiss T, 2004, CIRCULATION, V109, P2016, DOI 10.1161/01.CIR.0000125527.41598.68
   Khreiss T, 2002, J BIOL CHEM, V277, P40775, DOI 10.1074/jbc.M205378200
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Kuhlmann CRW, 2009, STROKE, V40, P1458, DOI 10.1161/STROKEAHA.108.535930
   Lauer N, 2011, J IMMUNOL, V187, P4374, DOI 10.4049/jimmunol.1002488
   McLeod DS, 2002, INVEST OPHTH VIS SCI, V43, P1986
   Molins B, 2008, ARTERIOSCL THROM VAS, V28, P2239, DOI 10.1161/ATVBAHA.108.174359
   Molins B, 2016, SCI REP-UK, V6, DOI 10.1038/srep22889
   Molins B, 2011, CARDIOVASC RES, V92, P328, DOI 10.1093/cvr/cvr226
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Seddon JM, 2006, NUTRITION, V22, P441, DOI 10.1016/j.nut.2005.12.004
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P774, DOI 10.1001/archopht.123.6.774
   Seddon JM, 2004, JAMA-J AM MED ASSOC, V291, P704, DOI 10.1001/jama.291.6.704
   Thiele JR, 2014, CIRCULATION, V130, P35, DOI 10.1161/CIRCULATIONAHA.113.007124
   Van Laethem F, 2003, J IMMUNOL, V170, P2932, DOI 10.4049/jimmunol.170.6.2932
   van Leeuwen R, 2003, EUR J EPIDEMIOL, V18, P845, DOI 10.1023/A:1025643303914
   Vilahur G, 2009, J THROMB HAEMOST, V7, P485, DOI 10.1111/j.1538-7836.2008.03244.x
   Vine AK, 2005, OPHTHALMOLOGY, V112, P2076, DOI 10.1016/j.ophtha.2005.07.004
   Volanakis JE, 2001, MOL IMMUNOL, V38, P189, DOI 10.1016/S0161-5890(01)00042-6
   Yamagata S, 2012, CLIN EXP IMMUNOL, V170, P86, DOI 10.1111/j.1365-2249.2012.04636.x
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
NR 37
TC 11
Z9 12
U1 0
U2 9
PU AMER PHYSIOLOGICAL SOC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0363-6143
EI 1522-1563
J9 AM J PHYSIOL-CELL PH
JI Am. J. Physiol.-Cell Physiol.
PD MAR
PY 2017
VL 312
IS 3
BP C244
EP C253
DI 10.1152/ajpcell.00057.2016
PG 10
WC Cell Biology; Physiology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Physiology
GA EN0SQ
UT WOS:000395720300005
PM 28003224
OA Bronze
DA 2022-11-30
ER

PT J
AU Chong, CM
   Zheng, WH
AF Chong, Cheong-Meng
   Zheng, Wenhua
TI Artemisinin protects human retinal pigment epithelial cells from
   hydrogen peroxide-induced oxidative damage through activation of
   ERK/CREB signaling
SO REDOX BIOLOGY
LA English
DT Article
DE Retinal pigment epithelial cells; Age-related macular degeneration;
   Artemisinin; ROS; ERK
ID MACULAR DEGENERATION; STRESS; ANTIOXIDANTS; PATHOGENESIS; APOPTOSIS
AB The pathological increase in the levels of reactive oxygen species (ROS) in the retinal pigment epithelium (RPE), is implicated in the development of age-related macular degeneration (AMD). The discovery of drug candidates to effectively protect RPE cells from oxidative damage is required to resolve the pathological aspects and modify the process of AMD. In this study, a FDA-approved anti-malaria drug, Artemisinin was found to suppress hydrogen peroxide (H2O2)-induced cell death in human RPE cell D407 cells. Further study showed that Artemisinin significantly suppressed H2O2-induced D407 cell death by restoring abnormal changes in nuclear morphology, intracellular ROS, mitochondria) membrane potential and apoptotic biomarkers. Western blotting analysis showed that Artemisinin was able to activate extracellular regulated ERK/CREB survival signaling. Furthermore, Artemisinin failed to suppress H2O2-induced cytotoxicity and the increase of caspase 3/7 activity in the presence of the ERK inhibitor PD98059. Taken together, these results suggest that Artemisinin is a potential protectant with the pro survival effects against H2O2 insult through activation of the ERK/CREB pathway. (C) 2016 The Authors. Published by Elsevier B.V.
C1 [Chong, Cheong-Meng; Zheng, Wenhua] Univ Macau, Fac Hlth Sci, Macau, Peoples R China.
C3 University of Macau
RP Zheng, WH (通讯作者)，Univ Macau, Fac Hlth Sci, Macau, Peoples R China.
EM wenhuazheng@umac.mo
FU Guangdong Provincial Project of Science and Technology [2011B050200005];
   National Natural Science Foundation of China [31371088]; University of
   Macau [SRG2015-00004-FHS, MYRG2016-00052-FHS]; Science and Technology
   Development Fund (FDCT) of Macao [FDCT 021/2015/A1]
FX This research was financially supported by the Guangdong Provincial
   Project of Science and Technology (2011B050200005), the National Natural
   Science Foundation of China (31371088), SRG2015-00004-FHS and
   MYRG2016-00052-FHS from University of Macau, and the Science and
   Technology Development Fund (FDCT) of Macao (FDCT 021/2015/A1).
CR Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   BOK D, 1993, J CELL SCI, P189
   BOK D, 1990, EYE, V4, P326, DOI 10.1038/eye.1990.44
   Cheng C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020932
   Chong CM, 2013, NEUROSCI LETT, V543, P121, DOI 10.1016/j.neulet.2013.02.069
   Coleman AL, 2010, AM J OPHTHALMOL, V150, P683, DOI 10.1016/j.ajo.2010.05.030
   Curcio CA, 2000, OPHTHALMOLOGY, V107, P334, DOI 10.1016/S0161-6420(99)00037-8
   Das AK, 2015, ANN MED HEALTH SCI R, V5, P93, DOI 10.4103/2141-9248.153609
   Ding XY, 2009, PROG RETIN EYE RES, V28, P1, DOI 10.1016/j.preteyeres.2008.10.001
   Efferth T, 2008, CLIN INFECT DIS, V47, P804, DOI 10.1086/591195
   Fang YZ, 2002, NUTRITION, V18, P872, DOI 10.1016/S0899-9007(02)00916-4
   Grunwald JE, 1998, INVEST OPHTH VIS SCI, V39, P385
   Hytti M, 2015, EXP EYE RES, V132, P208, DOI 10.1016/j.exer.2015.02.001
   Karunadharma PP, 2010, INVEST OPHTH VIS SCI, V51, P5470, DOI 10.1167/iovs.10-5429
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kim Min-Ho, 2003, Korean J Ophthalmol, V17, P19
   Kim SH, 2008, EUR J PHARMACOL, V587, P65, DOI 10.1016/j.ejphar.2008.03.036
   Klein R, 2007, OPHTHAL EPIDEMIOL, V14, P184, DOI 10.1080/09286580701344381
   Klonis N, 2013, P NATL ACAD SCI USA, V110, P5157, DOI 10.1073/pnas.1217452110
   Kucuksayan E, 2014, FREE RADICAL BIO MED, V72, P113, DOI 10.1016/j.freeradbiomed.2014.04.013
   Lin HJ, 2011, INVEST OPHTH VIS SCI, V52, P3521, DOI 10.1167/iovs.10-6163
   Lin MT, 2006, NATURE, V443, P787, DOI 10.1038/nature05292
   Lu L, 2006, J CELL PHYSIOL, V206, P119, DOI 10.1002/jcp.20439
   Lux A, 2007, BRIT J OPHTHALMOL, V91, P1318, DOI 10.1136/bjo.2006.113902
   McGimpsey Stuart J, 2010, Expert Rev Clin Pharmacol, V3, P243, DOI 10.1586/ecp.10.6
   Mitra RN, 2016, ADV EXP MED BIOL, V854, P463, DOI 10.1007/978-3-319-17121-0_62
   Mitra RN, 2014, FREE RADICAL BIO MED, V75, P140, DOI 10.1016/j.freeradbiomed.2014.07.013
   Nicotera P, 2000, IUBMB LIFE, V49, P421, DOI 10.1080/152165400410272
   Nordgaard CL, 2008, INVEST OPHTH VIS SCI, V49, P2848, DOI 10.1167/iovs.07-1352
   Organisciak DT, 2010, PROG RETIN EYE RES, V29, P113, DOI 10.1016/j.preteyeres.2009.11.004
   Resnikoff S, 2008, ANN TROP MED PARASIT, V102, P3, DOI 10.1179/136485908X337409
   Salvesen GS, 2002, CELL DEATH DIFFER, V9, P3, DOI 10.1038/sj.cdd.4400963
   Sarina, 2013, BRAIN RES, V1490, P61, DOI 10.1016/j.brainres.2012.10.059
   Shi CC, 2015, MEDIAT INFLAMM, V2015, DOI 10.1155/2015/435713
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Sunderman F.W., 1929, CHLORIDE NITROGEN BA, P313
   Terluk MR, 2015, J NEUROSCI, V35, P7304, DOI 10.1523/JNEUROSCI.0190-15.2015
   Tokarz P, 2013, BIOGERONTOLOGY, V14, P461, DOI 10.1007/s10522-013-9463-2
   Tu YY, 2011, NAT MED, V17, P1217, DOI 10.1038/nm.2471
   Vurusaner B, 2014, FREE RADICAL BIO MED, V77, P376, DOI 10.1016/j.freeradbiomed.2014.07.026
   Yu DY, 2001, PROG RETIN EYE RES, V20, P175, DOI 10.1016/S1350-9462(00)00027-6
   Zheng WH, 2009, J BIOL CHEM, V284, P855, DOI 10.1074/jbc.M807914200
   Zheng WH, 2016, FREE RADICAL BIO MED, V97, P158, DOI 10.1016/j.freeradbiomed.2016.05.023
NR 43
TC 58
Z9 59
U1 0
U2 9
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 2213-2317
J9 REDOX BIOL
JI Redox Biol.
PD OCT
PY 2016
VL 9
BP 50
EP 56
DI 10.1016/j.redox.2016.06.002
PG 7
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA EA6RQ
UT WOS:000386757000007
PM 27372058
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Prineas, JW
   Parratt, JDE
   Kirwan, PD
AF Prineas, John W.
   Parratt, John D. E.
   Kirwan, Paul D.
TI Fibrosis of the Choroid Plexus Filtration Membrane
SO JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY
LA English
DT Article
DE Alzheimer disease; Choroid plexus; Complement; Macular degeneration;
   Multiple sclerosis
ID BLOOD-BRAIN-BARRIER; ALZHEIMERS-DISEASE; AMYLOID-BETA;
   NEUROMYELITIS-OPTICA; MACULAR DEGENERATION; MULTIPLE-SCLEROSIS; DRUSEN
   FORMATION; AGING EYE; CLEARANCE; RECEPTORS
AB We report a previously undescribed inflammatory lesion consisting of deposition of activated complement (C3d and C9neo) in association with major histocompatibility complex type II (MHC2)-positive activated microglia in choroid plexus villi exhibiting classical fibrous thickening of the pericapillary filtration membrane. The proportion of villi affected ranged from 5% to 90% in 56 adult subjects with diseases of the CNS and 11 subjects with no preexisting disease of the CNS. In 3 of the 4 children studied, 2% or less of examined villi showed stromal thickening, complement deposition, and the presence of MHC2-positive microglia; in adults, the proportion of villi affected increased with age. Other features of the lesion included loss of capillaries and failure by macrophages to clear extracellular particulate electron-dense material by clathrin-mediated phagocytosis. This choroid plexus lesion may relate pathogenetically to age-related macular degeneration and to Alzheimer disease, 2 other conditions with no known risk factors other than increasing age. All 3 conditions are characterized by the presence of damaged capillaries, inflammatory extracellular aggregates of mixed molecular composition and defective clearance of the deposits by macrophages.
C1 [Prineas, John W.; Parratt, John D. E.] Univ Sydney, Inst Clin Neurosci, Camperdown, NSW, Australia.
   [Prineas, John W.; Parratt, John D. E.] Univ Sydney, Nerve Res Fdn, Dept Med, Camperdown, NSW, Australia.
   [Parratt, John D. E.] Royal North Shore Hosp, Dept Neurol, Sydney, NSW, Australia.
   [Kirwan, Paul D.] Concord Repatriat Gen Hosp, Dept Anat Pathol, Electron Microscope Unit, Sydney, NSW, Australia.
C3 University of Sydney; University of Sydney; Royal North Shore Hospital;
   Concord Repatriation General Hospital
RP Prineas, JW (通讯作者)，Univ Sydney, Brain & Mind Res Inst, Room 711-MO2F,94 Mallet St, Camperdown, NSW 2050, Australia.
EM john.prineas@sydney.edu.au
CR Adams RD, 1968, INTRO NEUROPATHOLOGY
   Adams RD, 1982, HISTOL HISTOPATHOL, P641
   Banati Richard B., 1995, P1027
   Bargmann W, 1982, HISTOL HISTOPATHOL, P560
   BAUDOUIN C, 1992, JPN J OPHTHALMOL, V36, P443
   Bowman GL, 2007, NEUROLOGY, V68, P1809, DOI 10.1212/01.wnl.0000262031.18018.1a
   BRAATHEN LR, 1979, CLIN IMMUNOL IMMUNOP, V14, P284, DOI 10.1016/0090-1229(79)90154-5
   Cobb S., 1932, CYTOLOGY CELLULAR PA, P577
   Corsellis J. A. N, 1976, GREENFIELDS NEUROPAT, P796
   Curcio C. A., 2012, RETINA, V1, P465
   Daneman R, 2012, ANN NEUROL, V72, P648, DOI 10.1002/ana.23648
   DUNN J, 1955, P STAFF M MAYO CLIN, V30, P505
   El Khoury J, 1998, NEUROBIOL AGING, V19, pS81, DOI 10.1016/S0197-4580(98)00036-0
   ERIKSSON L, 1986, AM J PATHOL, V125, P124
   Esiri M. M., 1997, GREENFIELDS NEUROPAT, P153
   Glabe CG, 2006, NEUROLOGY, V66, pS74, DOI 10.1212/01.wnl.0000192103.24796.42
   Graeber MB, 2002, GREENFIELDS NEUROPAT, VI, P123
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Kress BT, 2014, ANN NEUROL, V76, P845, DOI 10.1002/ana.24271
   Krzyzanowska A, 2012, FRONT PHARMACOL, V3, DOI 10.3389/fphar.2012.00075
   LAMPERT PW, 1973, SCIENCE, V180, P408, DOI 10.1126/science.180.4084.408
   Liu RT, 2013, INVEST OPHTH VIS SCI, V54, P2225, DOI 10.1167/iovs.12-10849
   Lowe J, 2008, GREENFIELDS NEUROPAT, P1031
   Mawuenyega KG, 2010, SCIENCE, V330, P1774, DOI 10.1126/science.1197623
   MAY C, 1990, NEUROLOGY, V40, P500, DOI 10.1212/WNL.40.3_Part_1.500
   McGeer PL, 2006, ALZHEIMER'S DISEASE: A CENTURY OF SCIENTIFIC AND CLINICAL RESEARCH, P271
   MCGEER PL, 1993, GLIA, V7, P84, DOI 10.1002/glia.440070114
   Millen James Wilson, 1962, ANATOMY CEREBROSPINA
   MIRRA SS, 1993, ARCH PATHOL LAB MED, V117, P132
   Mirra SS, 2002, GREENFIELDS NEUROPAT, P212
   Misu T, 2007, BRAIN, V130, P1224, DOI 10.1093/brain/awm047
   Mrak RE, 1997, J NEUROPATH EXP NEUR, V56, P1269, DOI 10.1097/00005072-199712000-00001
   Nag S, 1991, TXB NEUROPATHOLOGY, P95
   NYLAND H, 1982, ACTA PATH MICRO IM C, V90, P171
   Ohno-Matsui K, 2011, PROG RETIN EYE RES, V30, P217, DOI 10.1016/j.preteyeres.2011.02.004
   Parratt JDE, 2010, MULT SCLER J, V16, P1156, DOI 10.1177/1352458510382324
   PERESS NS, 1981, ARTHRITIS RHEUM, V24, P520, DOI 10.1002/art.1780240312
   Peters A, 1976, NEURONS SUPPORTING C, P280
   Pluta R, 2006, NEUROL RES, V28, P665, DOI 10.1179/016164106X130399
   PRINEAS JW, 1979, SCIENCE, V203, P1123, DOI 10.1126/science.424741
   PRINEAS JW, 1978, LAB INVEST, V38, P409
   Redzic ZB, 2005, CURR TOP DEV BIOL, V71, P1, DOI 10.1016/S0070-2153(05)71001-2
   Reichenbach Andreas, 1995, P58
   Roberts KF, 2014, ANN NEUROL, V76, P837, DOI 10.1002/ana.24270
   Roemer SF, 2007, BRAIN, V130, P1194, DOI 10.1093/brain/awl371
   Rosenstock JL, 2003, KIDNEY INT, V63, P1450, DOI 10.1046/j.1523-1755.2003.00853.x
   Ryu JK, 2009, J CELL MOL MED, V13, P2911, DOI 10.1111/j.1582-4934.2008.00434.x
   Sarks SH, 1999, BRIT J OPHTHALMOL, V83, P358, DOI 10.1136/bjo.83.3.358
   Schwab C, 1996, BRAIN RES, V707, P196, DOI 10.1016/0006-8993(95)01257-5
   Shi J, 2012, ANN NEUROL, V72, P788, DOI 10.1002/ana.23677
   Silverberg GD, 2003, LANCET NEUROL, V2, P506, DOI 10.1016/S1474-4422(03)00487-3
   Sivak JM, 2013, INVEST OPHTH VIS SCI, V54, P871, DOI 10.1167/iovs.12-10827
   STEWART PA, 1992, LAB INVEST, V67, P734
   VANDERSCHAFT TL, 1993, BRIT J OPHTHALMOL, V77, P657, DOI 10.1136/bjo.77.10.657
   Vercellino M, 2008, J NEUROIMMUNOL, V199, P133, DOI 10.1016/j.jneuroim.2008.04.035
   Vinters HV, 2008, GREENFIELDS NEUROPAT, V1, P1
   Wang YJ, 2006, DRUG DISCOV TODAY, V11, P931, DOI 10.1016/j.drudis.2006.08.004
   Weller RO, 2008, BRAIN PATHOL, V18, P253, DOI 10.1111/j.1750-3639.2008.00133.x
NR 58
TC 6
Z9 6
U1 0
U2 2
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0022-3069
EI 1554-6578
J9 J NEUROPATH EXP NEUR
JI J. Neuropathol. Exp. Neurol.
PD SEP
PY 2016
VL 75
IS 9
BP 855
EP 867
DI 10.1093/jnen/nlw061
PG 13
WC Clinical Neurology; Neurosciences; Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology; Pathology
GA DX8WJ
UT WOS:000384671300004
PM 27444353
OA Green Published, hybrid
DA 2022-11-30
ER

PT J
AU Geringswald, F
   Herbik, A
   Hofmuller, W
   Hoffmann, MB
   Pollmann, S
AF Geringswald, Franziska
   Herbik, Anne
   Hofmueller, Wolfram
   Hoffmann, Michael B.
   Pollmann, Stefan
TI Visual Memory for Objects Following Foveal Vision Loss
SO JOURNAL OF EXPERIMENTAL PSYCHOLOGY-LEARNING MEMORY AND COGNITION
LA English
DT Article
DE visual attention; visual long-term memory for objects; age-related
   macular degeneration; macular scotoma
ID PREFERRED RETINAL LOCI; LONG-TERM-MEMORY; NATURAL SCENES; FIXATION
   CHARACTERISTICS; GEOGRAPHIC ATROPHY; WORKING-MEMORY; READING SPEED; EYE;
   PSYCHOPHYSICS; CAPACITY
AB Allocation of visual attention is crucial for encoding items into visual long-term memory. In free vision, attention is closely linked to the center of gaze, raising the question whether foveal vision loss entails suboptimal deployment of attention and subsequent impairment of object encoding. To investigate this question, we examined visual long-term memory for objects in patients suffering from foveal vision loss due to age-related macular degeneration. We measured patients' change detection sensitivity after a period of free scene exploration monocularly with their worse eye when possible, and under binocular vision, comparing sensitivity and eye movements to matched normal-sighted controls. A highly salient cue was used to capture attention to a nontarget location before a target change occurred in half of the trials, ensuring that change detection relied on memory. Patients' monocular and binocular sensitivity to object change was comparable to controls, even after more than 4 intervening fixations, and not significantly correlated with visual impairment. We conclude that extrafoveal vision suffices for efficient encoding into visual long-term memory.
C1 [Geringswald, Franziska; Pollmann, Stefan] Otto Von Guericke Univ, Dept Expt Psychol, Magdeburg, Germany.
   [Herbik, Anne; Hoffmann, Michael B.] Otto Von Guericke Univ, Ophthalm Dept, Visual Proc Lab, Magdeburg, Germany.
   [Hofmueller, Wolfram] Otto Von Guericke Univ, Ophthalm Dept, Magdeburg, Germany.
   [Hoffmann, Michael B.; Pollmann, Stefan] Ctr Behavi Brain Sci, Magdeburg, Germany.
C3 Otto von Guericke University; Otto von Guericke University; Otto von
   Guericke University
RP Geringswald, F (通讯作者)，Otto Von Guericke Univ, Inst Psychol 2, Postfach 4120, D-39016 Magdeburg, Germany.
EM franziska.geringswald@gmail.com
RI Pollmann, Stefan/AAH-5584-2020; Pollmann, Stefan/D-1999-2013; Hoffmann,
   Michael/E-9115-2010
OI Pollmann, Stefan/0000-0001-5840-5658; Pollmann,
   Stefan/0000-0001-5840-5658; Hoffmann, Michael/0000-0002-6452-9638
FU Deutsche Forschungsgemeinschaft [PO548/8-1, 14-1, HO2002/9-1]
FX This work was supported by the Deutsche Forschungsgemeinschaft
   (PO548/8-1 and 14-1 and HO2002/9-1). We thank Ina Maria Pohl and Katja
   Wilhelm for assistance in data acquisition. We thank Gisela Muller-Plath
   for providing us with the facilities and Carolin Wienrich for helpful
   assistance during testing one patient at Martin-Luther-University, Halle
   (Saale), Germany.
CR Alvarez GA, 2004, PSYCHOL SCI, V15, P106, DOI 10.1111/j.0963-7214.2004.01502006.x
   Arroyo JG, 2006, JAMA-J AM MED ASSOC, V295, P2394, DOI 10.1001/jama.295.20.2394
   Bach M, 1996, OPTOMETRY VISION SCI, V73, P49, DOI 10.1097/00006324-199601000-00008
   Bach M, 2007, GRAEF ARCH CLIN EXP, V245, P965, DOI 10.1007/s00417-006-0474-4
   Bellmann C, 2004, OPHTHALMOLOGY, V111, P2265, DOI 10.1016/j.ophtha.2004.06.019
   Bethlehem RAI, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0100171
   Brady TF, 2008, P NATL ACAD SCI USA, V105, P14325, DOI 10.1073/pnas.0803390105
   Brainard DH, 1997, SPATIAL VISION, V10, P433, DOI 10.1163/156856897X00357
   BULLIMORE MA, 1995, OPTOMETRY VISION SCI, V72, P125, DOI 10.1097/00006324-199502000-00011
   Cornelissen FW, 2002, BEHAV RES METH INS C, V34, P613, DOI 10.3758/BF03195489
   Crossland MD, 2004, OPHTHAL PHYSL OPT, V24, P327, DOI 10.1111/j.1475-1313.2004.00213.x
   Crossland MD, 2011, INVEST OPHTH VIS SCI, V52, P411, DOI 10.1167/iovs.10-5473
   Deruaz A, 2002, VISION RES, V42, P2947, DOI 10.1016/S0042-6989(02)00354-1
   Deubel H, 1996, VISION RES, V36, P1827, DOI 10.1016/0042-6989(95)00294-4
   Duret F, 1999, VISION RES, V39, P873, DOI 10.1016/S0042-6989(98)00179-5
   Faubert J, 2000, J AM GERIATR SOC, V48, P375, DOI 10.1111/j.1532-5415.2000.tb04693.x
   Fletcher DC, 1997, OPHTHALMOLOGY, V104, P632, DOI 10.1016/S0161-6420(97)30260-7
   Geringswald F, 2013, J VISION, V13, DOI 10.1167/13.3.28
   GUEZ JE, 1993, VISION RES, V33, P1271, DOI 10.1016/0042-6989(93)90213-G
   HOFFMAN JE, 1995, PERCEPT PSYCHOPHYS, V57, P787, DOI 10.3758/BF03206794
   Hollingworth A, 2005, J EXP PSYCHOL LEARN, V31, P396, DOI 10.1037/0278-7393.31.3.396
   Hollingworth A, 2004, J EXP PSYCHOL HUMAN, V30, P519, DOI 10.1037/0096-1523.30.3.519
   Hollingworth A, 2003, J EXP PSYCHOL HUMAN, V29, P388, DOI 10.1037/0096-1523.29.2.388
   Hollingworth A, 2002, J EXP PSYCHOL HUMAN, V28, P113, DOI 10.1037//0096-1523.28.1.113
   Hollingworth A, 2001, MEM COGNITION, V29, P296, DOI 10.3758/BF03194923
   Hollingworth A, 2006, VIS COGN, V14, P781, DOI 10.1080/13506280500193818
   HOLM S, 1979, SCAND J STAT, V6, P65
   Kwon MY, 2013, CURR BIOL, V23, P1663, DOI 10.1016/j.cub.2013.06.056
   Lindblad AS, 2009, ARCH OPHTHALMOL-CHIC, V127, P1168, DOI 10.1001/archophthalmol.2009.198
   Lingnau A, 2010, J VISION, V10, DOI 10.1167/10.11.13
   Luck SJ, 1997, NATURE, V390, P279, DOI 10.1038/36846
   Luck SJ, 2013, TRENDS COGN SCI, V17, P391, DOI 10.1016/j.tics.2013.06.006
   MCMAHON TT, 1991, INVEST OPHTH VIS SCI, V32, P567
   Nazemi PP, 2005, RETINA-J RET VIT DIS, V25, P446, DOI 10.1097/00006982-200506000-00009
   Neelam K, 2009, SURV OPHTHALMOL, V54, P167, DOI 10.1016/j.survophthal.2008.12.003
   NOORDEN GKV, 1962, AM J OPHTHALMOL, V53, P642, DOI 10.1016/0002-9394(62)91987-6
   Nystrom M, 2010, BEHAV RES METHODS, V42, P188, DOI 10.3758/BRM.42.1.188
   Pelli DG, 1997, SPATIAL VISION, V10, P437, DOI 10.1163/156856897X00366
   Pertzov Y, 2009, J VISION, V9, DOI 10.1167/9.10.2
   POSNER MI, 1980, Q J EXP PSYCHOL, V32, P3, DOI 10.1080/00335558008248231
   Prins N, 2007, PHASE SPECTRUM SCRAM
   Rensink RA, 2002, ANNU REV PSYCHOL, V53, P245, DOI 10.1146/annurev.psych.53.100901.135125
   Rensink RA, 1997, PSYCHOL SCI, V8, P368, DOI 10.1111/j.1467-9280.1997.tb00427.x
   Schuchard RA, 2005, CAN J OPHTHALMOL, V40, P303, DOI 10.1016/S0008-4182(05)80073-0
   Simons DJ, 2005, TRENDS COGN SCI, V9, P16, DOI 10.1016/j.tics.2004.11.006
   SNODGRASS JG, 1988, J EXP PSYCHOL GEN, V117, P34, DOI 10.1037/0096-3445.117.1.34
   STANDING L, 1973, Q J EXP PSYCHOL, V25, P207, DOI 10.1080/14640747308400340
   Stanislaw H, 1999, BEHAV RES METH INS C, V31, P137, DOI 10.3758/BF03207704
   Sunness JS, 2005, AM J OPHTHALMOL, V140, P1085, DOI 10.1016/j.ajo.2005.07.040
   Tarita-Nistor L, 2008, RETINA-J RET VIT DIS, V28, P125, DOI 10.1097/IAE.0b013e3180ed4571
   Tarita-Nistor L, 2013, CAN J OPHTHALMOL, V48, P443, DOI 10.1016/j.jcjo.2013.04.005
   Tatler BW, 2005, Q J EXP PSYCHOL-A, V58, P931, DOI 10.1080/02724980443000430
   Team RC, 2013, R LANG ENV STAT COMP
   Theeuwes J, 1998, PSYCHOL SCI, V9, P379, DOI 10.1111/1467-9280.00071
   Valberg A, 2002, J OPT SOC AM A, V19, P223, DOI 10.1364/JOSAA.19.000223
   Vogt S, 2007, EXP PSYCHOL, V54, P298, DOI 10.1027/1618-3169.54.4.298
   Walsh DV, 2014, VISION RES, V96, P75, DOI 10.1016/j.visres.2014.01.005
   WHITE JM, 1990, INVEST OPHTH VIS SCI, V31, P1149
   WHITTAKER SG, 1988, INVEST OPHTH VIS SCI, V29, P268
   WHITTAKER SG, 1991, VISION RES, V31, P2209, DOI 10.1016/0042-6989(91)90173-3
   [Anonymous], 2000, JAMA, V284, P3043, DOI 10.1001/jama.2013.281053
NR 61
TC 8
Z9 8
U1 1
U2 11
PU AMER PSYCHOLOGICAL ASSOC
PI WASHINGTON
PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA
SN 0278-7393
EI 1939-1285
J9 J EXP PSYCHOL LEARN
JI J. Exp. Psychol.-Learn. Mem. Cogn.
PD SEP
PY 2015
VL 41
IS 5
BP 1471
EP 1484
DI 10.1037/xlm0000112
PG 14
WC Psychology; Psychology, Experimental
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Psychology
GA CR0UO
UT WOS:000361038900015
PM 25893842
DA 2022-11-30
ER

PT J
AU Kavousanakis, ME
   Kalogeropoulos, NG
   Hatziavramidis, DT
AF Kavousanakis, Michail E.
   Kalogeropoulos, Nikolaos G.
   Hatziavramidis, Dimitrios T.
TI Computational modeling of drug delivery to the posterior eye
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Drug delivery; Posterior eye; Computational modeling; Age related
   macular degeneration; Intravitreal injection; Transcleral delivery
ID FLUORESCEIN; TRANSPORT; PHARMACOKINETICS; BLOOD; FLOW
AB Simulations of delivery of IgG1 Fab, an anti vascular epithelial growth factor (VEGF) macromolecular drug for the treatment of age related macular degeneration (AMD), from an episcleral thermally responsive-poly(N-isopolyacrylamide) (NIPAM)-gel implant, arc made to evaluate the effectiveness of sustained delivery.
   The model of the human eye used in the above simulations is validated as far as its anatomical and physiological features by the agreement observed in comparing results of simulations of intravitreal fluorescein delivery with relevant experimental data.
   Simulations of IgG1 Fab delivery from an episcleral NIPAM-gel implant to the posterior eye, with the previously validated anatomically and physiologically correct model of the human eye, show that drug therapeutic levels in the posterior eye are sustained for 8 weeks similarly to those associated with intravitreal injection of IgG1 Fab. Thus, delivery of the macromolecular anti-VEGF drug IgG1 Fab from an episcleral NIPAM-gel implant seems to be a viable alternative to more invasive, risk-related delivery by intravitreal injection, as effective and sustainable as the latter. (C) 2014 Elsevier Ltd. All rights reserved
C1 [Kavousanakis, Michail E.; Kalogeropoulos, Nikolaos G.; Hatziavramidis, Dimitrios T.] Natl Tech Univ Athens, Sch Chem Engn, Athens 15780, Greece.
C3 National Technical University of Athens
RP Hatziavramidis, DT (通讯作者)，Natl Tech Univ Athens, Sch Chem Engn, 9 Heroon Polytech, Athens 15780, Greece.
EM dhatz@chemeng.ntua.gr
RI Kavousanakis, Mihalis/V-3519-2019; Kavousanakis, Michail/AAO-1292-2020;
   Kavousanakis, Michail/AAS-6198-2020
OI Kavousanakis, Michail/0000-0001-6621-9249; HATZIAVRAMIDIS,
   DIMITRIS/0000-0002-6432-4114
CR Ambati J, 2000, INVEST OPHTH VIS SCI, V41, P1186
   [Anonymous], 2007, CHMP REV
   Balachandran RK, 2008, PHARM RES-DORDR, V25, P2685, DOI 10.1007/s11095-008-9691-3
   BLAIR NP, 1986, INVEST OPHTH VIS SCI, V27, P1107
   Blondeau P, 2001, J GLAUCOMA, V10, P18, DOI 10.1097/00061198-200102000-00005
   DALGAARD P, 1990, BIOMETRICS, V46, P1097, DOI 10.2307/2532451
   ENGLER CB, 1994, ACTA OPHTHALMOL, V72, P655
   FATT I, 1970, EXP EYE RES, V10, P243, DOI 10.1016/S0014-4835(70)80035-5
   KITANO S, 1986, INVEST OPHTH VIS SCI, V27, P998
   박재충, 2005, [Korean Journal of Ecology and Environment, 생태와 환경], V38, P105
   LUNDANDERSEN H, 1985, INVEST OPHTH VIS SCI, V26, P698
   MAURICE DM, 1959, AM J OPHTHALMOL, V47, P361, DOI 10.1016/S0002-9394(14)78042-0
   Missel PJ, 2012, PHARM RES-DORDR, V29, P3251, DOI 10.1007/s11095-012-0721-9
   Ninawe PR, 2010, CHEM ENG SCI, V65, P5170, DOI 10.1016/j.ces.2010.06.014
   Olejnik O, 2005, ADV DRUG DELIVER REV, V57, P1991, DOI 10.1016/j.addr.2005.09.002
   PALESTINE AG, 1981, INVEST OPHTH VIS SCI, V21, P542
   Steinbrook R, 2006, NEW ENGL J MED, V355, P1409, DOI 10.1056/NEJMp068185
   TSUBOI S, 1987, INVEST OPHTH VIS SCI, V28, P1776
   Xu J, 2000, PHARMACEUT RES, V17, P664, DOI 10.1023/A:1007517912927
NR 19
TC 17
Z9 17
U1 4
U2 25
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD APR 28
PY 2014
VL 108
BP 203
EP 212
DI 10.1016/j.ces.2014.01.005
PG 10
WC Engineering, Chemical
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Engineering
GA AC3CH
UT WOS:000332392100021
DA 2022-11-30
ER

PT J
AU Zhang, KJ
   Liu, GH
   Yi, F
   Montserrat, N
   Hishida, T
   Esteban, CR
   Belmonte, JCI
AF Zhang, Kejing
   Liu, Guang-Hui
   Yi, Fei
   Montserrat, Nuria
   Hishida, Tomoaki
   Esteban, Concepcion Rodriguez
   Izpisua Belmonte, Juan Carlos
TI Direct conversion of human fibroblasts into retinal pigment
   epithelium-like cells by defined factors
SO PROTEIN & CELL
LA English
DT Article
DE retinal pigment epithelium; fibroblasts; direct conversion
ID PLURIPOTENT STEM-CELLS; MOUSE FIBROBLASTS; TRANSCRIPTION FACTORS;
   MACULAR DEGENERATION; VERTEBRATE EYE; NEURONAL CELLS; IN-VITRO;
   DIFFERENTIATION; EXPRESSION; SPECIFICATION
AB The generation of functional retinal pigment epithelium (RPE) is of great therapeutic interest to the field of regenerative medicine and may provide possible cures for retinal degenerative diseases, including age-related macular degeneration (AMD). Although RPE cells can be produced from either embryonic stem cells or induced pluripotent stem cells, direct cell reprogramming driven by lineage-determining transcription factors provides an immediate route to their generation. By monitoring a human RPE specific Best1::GFP reporter, we report the conversion of human fibroblasts into RPE lineage using defined sets of transcription factors. We found that Best1::GFP positive cells formed colonies and exhibited morphological and molecular features of early stage RPE cells. Moreover, they were able to obtain pigmentation upon activation of Retinoic acid (RA) and Sonic Hedgehog (SHH) signaling pathways. Our study not only established an ideal platform to investigate the transcriptional network regulating the RPE cell fate determination, but also provided an alternative strategy to generate functional RPE cells that complement the use of pluripotent stem cells for disease modeling, drug screening, and cell therapy of retinal degeneration.
C1 [Zhang, Kejing; Hishida, Tomoaki; Esteban, Concepcion Rodriguez; Izpisua Belmonte, Juan Carlos] Salk Inst Biol Studies, Gene Express Lab, La Jolla, CA 92037 USA.
   [Liu, Guang-Hui] Chinese Acad Sci, Natl Lab Biomacromol, Inst Biophys, Beijing 100101, Peoples R China.
   [Yi, Fei] Stanford Univ, Dept Mol & Cellular Physiol, Sch Med, Stanford, CA 94305 USA.
   [Montserrat, Nuria; Izpisua Belmonte, Juan Carlos] Ctr Regenerat Med Barcelona, Barcelona 08003, Spain.
   [Montserrat, Nuria] Biomed Res Networking Ctr Bioengn Biomat & Nanome, Barcelona, Spain.
C3 Salk Institute; Chinese Academy of Sciences; Institute of Biophysics,
   CAS; Stanford University; Institut d'Investigacio Biomedica de Bellvitge
   (IDIBELL); Centro de Medicina Regenerativa de Barcelona; University of
   Barcelona; CIBER - Centro de Investigacion Biomedica en Red; CIBERBBN
RP Liu, GH (通讯作者)，Chinese Acad Sci, Natl Lab Biomacromol, Inst Biophys, Beijing 100101, Peoples R China.
EM ghliu@ibp.ac.cn; belmonte@salk.edu
RI Montserrat, Nuria/F-3136-2016
OI Montserrat, Nuria/0000-0002-1603-1755
FU Chinese Academy of Sciences [XDA01020312]; National Natural Science
   Foundation of China [81271266, 31222039, 31201111]; Thousand Young
   Talents program of China, National Laboratory of Biomacromolecules
   [2013kf05, 2013kf11]; State Key Laboratory of Drug Research
   [SIMM1302KF-17]; CIBER-BBN; MINECO; Fundacion Cellex; G. Harold and
   Leila Y. Mathers Charitable Foundation; Leona M. and Harry B. Helmsley
   Charitable Trust; Ellison Medical Foundation
FX G.H.L. is supported by the Strategic Priority Research Program of the
   Chinese Academy of Sciences (XDA01020312), National Natural Science
   Foundation of China (Grant Nos. 81271266, 31222039, and 31201111), the
   Thousand Young Talents program of China, National Laboratory of
   Biomacromolecules (2013kf05, and 2013kf11), and State Key Laboratory of
   Drug Research (SIMM1302KF-17). JCIB was supported by CIBER-BBN and
   grants from MINECO, Fundacion Cellex, G. Harold and Leila Y. Mathers
   Charitable Foundation, The Leona M. and Harry B. Helmsley Charitable
   Trust and The Ellison Medical Foundation.
CR Acland GM, 2005, MOL THER, V12, P1072, DOI 10.1016/j.ymthe.2005.08.008
   Ben-David U, 2011, NAT REV CANCER, V11, P268, DOI 10.1038/nrc3034
   Bharti K, 2006, PIGM CELL RES, V19, P380, DOI 10.1111/j.1600-0749.2006.00318.x
   Boucherie C, 2013, STEM CELLS, V31, P408, DOI 10.1002/stem.1268
   Boulanger A, 2000, J BIOL CHEM, V275, P31274, DOI 10.1074/jbc.M003441200
   Buchholz DE, 2009, STEM CELLS, V27, P2427, DOI 10.1002/stem.189
   Carr AJ, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008152
   Efe JA, 2011, NAT CELL BIOL, V13, P215, DOI 10.1038/ncb2164
   Esumi N, 2004, J BIOL CHEM, V279, P19064, DOI 10.1074/jbc.M309881200
   Esumi N, 2009, HUM MOL GENET, V18, P128, DOI 10.1093/hmg/ddn323
   Giorgetti A, 2012, P NATL ACAD SCI USA, V109, P12556, DOI 10.1073/pnas.1209523109
   Huang PY, 2011, NATURE, V475, P386, DOI 10.1038/nature10116
   Khandhadia S, 2012, ADV EXP MED BIOL, V724, P15, DOI 10.1007/978-1-4614-0653-2_2
   Kim J, 2011, P NATL ACAD SCI USA, V108, P7838, DOI 10.1073/pnas.1103113108
   Kurian L, 2013, NAT METHODS, V10, P77, DOI [10.1038/NMETH.2255, 10.1038/nmeth.2255]
   Liu GH, 2012, CELL RES, V22, P1087, DOI 10.1038/cr.2012.73
   Lu B, 2009, STEM CELLS, V27, P2126, DOI 10.1002/stem.149
   Martinez-Morales JR, 2004, BIOESSAYS, V26, P766, DOI 10.1002/bies.20064
   Meyer JS, 2009, P NATL ACAD SCI USA, V106, P16698, DOI 10.1073/pnas.0905245106
   Nakano T, 2012, CELL STEM CELL, V10, P771, DOI 10.1016/j.stem.2012.05.009
   Okada Y, 2004, DEV BIOL, V275, P124, DOI 10.1016/j.ydbio.2004.07.038
   Osakada F, 2009, NAT PROTOC, V4, P811, DOI 10.1038/nprot.2009.51
   Pang ZPP, 2011, NATURE, V476, P220, DOI 10.1038/nature10202
   Panopoulos AD, 2011, CELL STEM CELL, V8, P347, DOI 10.1016/j.stem.2011.03.003
   Salero E, 2012, CELL STEM CELL, V10, P88, DOI 10.1016/j.stem.2011.11.018
   Sancho-Martinez I, 2012, NAT CELL BIOL, V14, P892, DOI 10.1038/ncb2567
   Schwartz SD, 2012, LANCET, V379, P713, DOI 10.1016/S0140-6736(12)60028-2
   Sekiya S, 2011, NATURE, V475, P390, DOI 10.1038/nature10263
   Steingrimsson E, 2004, ANNU REV GENET, V38, P365, DOI 10.1146/annurev.genet.38.072902.092717
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Takahashi K, 2007, CELL, V131, P861, DOI 10.1016/j.cell.2007.11.019
   Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024
   Vierbuchen T, 2010, NATURE, V463, P1035, DOI 10.1038/nature08797
   Yi F, 2012, CELL RES, V22, P616, DOI 10.1038/cr.2012.33
   Zahabi A, 2012, STEM CELLS DEV, V21, P2262, DOI 10.1089/scd.2011.0599
   Zhang KJ, 2013, J MOL CELL BIOL, V5, P151, DOI 10.1093/jmcb/mjs060
   Zhang WQ, 2012, PROTEIN CELL, V3, P91, DOI 10.1007/s13238-012-2029-2
   Zhu Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054552
   Zuber ME, 2003, DEVELOPMENT, V130, P5155, DOI 10.1242/dev.00723
NR 39
TC 37
Z9 40
U1 0
U2 14
PU HIGHER EDUCATION PRESS
PI BEIJING
PA SHATANHOU ST 55, BEIJING 100009, PEOPLES R CHINA
SN 1674-800X
EI 1674-8018
J9 PROTEIN CELL
JI Protein Cell
PD JAN
PY 2014
VL 5
IS 1
BP 48
EP 58
DI 10.1007/s13238-013-0011-2
PG 11
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA AC3ZW
UT WOS:000332461300007
PM 24474194
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Ito, S
   Pilat, A
   Gerwat, W
   Skumatz, CMB
   Ito, M
   Kiyono, A
   Zadlo, A
   Nakanishi, Y
   Kolbe, L
   Burke, JM
   Sarna, T
   Wakamatsu, K
AF Ito, Shosuke
   Pilat, Anna
   Gerwat, Wolfram
   Skumatz, Christine M. B.
   Ito, Miho
   Kiyono, Atsumi
   Zadlo, Andrzej
   Nakanishi, Yukiko
   Kolbe, Ludger
   Burke, Janice M.
   Sarna, Tadeusz
   Wakamatsu, Kazumasa
TI Photoaging of human retinal pigment epithelium is accompanied by
   oxidative modifications of its eumelanin
SO PIGMENT CELL & MELANOMA RESEARCH
LA English
DT Article
DE eumelanin; pheomelanin; retinal pigment epithelium; UVA; blue light;
   photoaging; oxidative modifications
ID HYDROGEN-PEROXIDE; CHEMICAL-ANALYSIS; OCULAR MELANIN; BINDING-SITES;
   DNA-DAMAGE; HAIR; PHEOMELANIN; MELANOSOMES; IRON; RPE
AB Although photodegradation of the retinal pigment epithelium (RPE) melanin may contribute to the etiology of age-related macular degeneration, the molecular mechanisms of this phenomenon and the structural changes of the modified melanin remain unknown. Recently, we found that the ratio of pyrrole-2,3,4,5-tetracarboxylic acid (PTeCA) to pyrrole-2,3,5-tricarboxylic acid (PTCA) is a marker for the heat-induced cross-linking of eumelanin. In this study, we examined UVA-induced changes in synthetic eumelanins to confirm the usefulness of the PTeCA/PTCA ratio as an indicator of photo-oxidation and compared changes in various melanin markers and their ratios in human melanocytes exposed to UVA, in isolated bovine RPE melanosomes exposed to strong blue light and in human RPE cells from donors of various ages. The results indicate that the PTeCA/PTCA ratio is a sensitive marker for the oxidation of eumelanin exposed to UVA or blue light and that eumelanin and pheomelanin in human RPE cells undergo extensive structural modifications due to the life-long exposure to blue light.
C1 [Ito, Shosuke; Ito, Miho; Kiyono, Atsumi; Nakanishi, Yukiko; Wakamatsu, Kazumasa] Fujita Hlth Univ, Sch Hlth Sci, Dept Chem, Toyoake, Aichi, Japan.
   [Pilat, Anna; Zadlo, Andrzej; Sarna, Tadeusz] Jagiellonian Univ, Dept Biophys, Fac Biochem Biophys & Biotechnol, Krakow, Poland.
   [Gerwat, Wolfram; Kolbe, Ludger] Beiersdorf AG, R&D, Skin Res Ctr, Hamburg, Germany.
   [Skumatz, Christine M. B.; Burke, Janice M.] Med Coll Wisconsin, Dept Ophthalmol, Milwaukee, WI 53226 USA.
C3 Fujita Health University; Jagiellonian University; Beiersdorf AG;
   Medical College of Wisconsin
RP Ito, S (通讯作者)，Fujita Hlth Univ, Sch Hlth Sci, Dept Chem, Toyoake, Aichi, Japan.
EM sito@fujita-hu.ac.jp
RI Kolbe, Ludger/AAF-6978-2020; Wakamatsu, Kazumasa/AAZ-5877-2020
OI Wakamatsu, Kazumasa/0000-0003-1748-9001; Zadlo,
   Andrzej/0000-0001-7301-0013; Ito, Shosuke/0000-0001-9182-5144
FU Japan Society for the Promotion of Science (JSPS) [23591659]; Poland
   Ministry of Science and Higher Education [2661/B/P01/2010/3]; NEI in USA
   [R01EY013722, R01EY019664, P30EY01931]; NATIONAL EYE INSTITUTE
   [R01EY013722, P30EY001931, R01EY019664] Funding Source: NIH RePORTER
FX We thank Dr John D. Simon of University of Virginia for the generous
   gift of pyrrole-2,3,4,5-tetracarboxylic acid (PTeCA). This work was
   supported, in part, by a Japan Society for the Promotion of Science
   (JSPS) grant (No. 23591659), by the Poland Ministry of Science and
   Higher Education (grant 2661/B/P01/2010/3) and by research grants
   R01EY013722, R01EY019664, and P30EY01931 from the NEI in USA.
CR [Anonymous], 2010, 247305 ISOIEC, P1, DOI DOI 10.1109/IEEESTD.2010
   Borovansky J, 2011, MELANINS AND MELANOSOMES: BIOSYNTHESIS, BIOGENESIS, PHYSIOLOGICAL, AND PATHOLOGICAL FUNCTIONS, P1, DOI 10.1002/9783527636150
   BOULTON M, 1998, RETINAL PIGMENT EPIT, P68
   Brenner M, 2008, PHOTOCHEM PHOTOBIOL, V84, P539, DOI 10.1111/j.1751-1097.2007.00226.x
   Burke JM, 2011, MOL VIS, V17, P2864
   Burke JM, 2009, INVEST OPHTH VIS SCI, V50, P1940, DOI 10.1167/iovs.08-2671
   CHEDEKEL MR, 1978, P NATL ACAD SCI USA, V75, P5395, DOI 10.1073/pnas.75.11.5395
   Commo S, 2012, INT J COSMETIC SCI, V34, P102, DOI 10.1111/j.1468-2494.2011.00691.x
   FELIX CC, 1978, BIOCHEM BIOPH RES CO, V84, P335, DOI 10.1016/0006-291X(78)90175-4
   Glass K, 2012, P NATL ACAD SCI USA, V109, P10218, DOI 10.1073/pnas.1118448109
   Greco G, 2009, PIGM CELL MELANOMA R, V22, P319, DOI 10.1111/j.1755-148X.2009.00561.x
   Hahn P, 2003, ARCH OPHTHALMOL-CHIC, V121, P1099, DOI 10.1001/archopht.121.8.1099
   Haywood RM, 2008, PHOTOCHEM PHOTOBIOL, V84, P572, DOI 10.1111/j.1751-1097.2008.00343.x
   Hearing Vincent J, 2011, J Invest Dermatol, V131, pE8, DOI 10.1038/skinbio.2011.4
   Hong L, 2005, PHOTOCHEM PHOTOBIOL, V81, P517, DOI 10.1562/2005-03-02-RA-453.1
   Hong L, 2007, J PHYS CHEM B, V111, P7938, DOI 10.1021/jp071439h
   Hu DN, 2008, PHOTOCHEM PHOTOBIOL, V84, P639, DOI 10.1111/j.1751-1097.2008.00316.x
   ITO S, 1985, ANAL BIOCHEM, V144, P527, DOI 10.1016/0003-2697(85)90150-2
   Ito S, 2008, PHOTOCHEM PHOTOBIOL, V84, P582, DOI 10.1111/j.1751-1097.2007.00238.x
   Ito S, 2013, ANAL BIOCHEM, V434, P221, DOI 10.1016/j.ab.2012.12.005
   Ito S, 2011, PIGM CELL MELANOMA R, V24, P605, DOI 10.1111/j.1755-148X.2011.00864.x
   Ito S, 2011, PIGM CELL MELANOMA R, V24, P63, DOI 10.1111/j.1755-148X.2010.00755.x
   Kaczara P, 2012, PIGM CELL MELANOMA R, V25, P804, DOI 10.1111/pcmr.12008
   Kayatz P, 2001, INVEST OPHTH VIS SCI, V42, P241
   Kolbe L, 2012, J INVEST DERMATOL, V132, P1756, DOI 10.1038/jid.2012.148
   KORYTOWSKI W, 1990, J BIOL CHEM, V265, P12410
   KORYTOWSKI W, 1985, BIOCHEM BIOPH RES CO, V131, P659, DOI 10.1016/0006-291X(85)91288-4
   Liebel F, 2012, J INVEST DERMATOL, V132, P1901, DOI 10.1038/jid.2011.476
   Meredith P, 2006, PIGM CELL RES, V19, P572, DOI 10.1111/j.1600-0749.2006.00345.x
   Miyamura Y, 2011, PIGM CELL MELANOMA R, V24, P136, DOI 10.1111/j.1755-148X.2010.00764.x
   NECKEL H, 1984, SOL PHYS, V90, P205
   Noonan FP, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1893
   Ozeki H, 1996, PIGM CELL RES, V9, P265, DOI 10.1111/j.1600-0749.1996.tb00116.x
   Pezzella A, 1996, TETRAHEDRON, V52, P7913, DOI 10.1016/0040-4020(96)00362-6
   Rozanowska M, 1999, FREE RADICAL BIO MED, V26, P518, DOI 10.1016/S0891-5849(98)00234-2
   ROZANOWSKA M, 1995, J BIOL CHEM, V270, P18825, DOI 10.1074/jbc.270.32.18825
   Rozanowski B, 2008, PHOTOCHEM PHOTOBIOL, V84, P650, DOI 10.1111/j.1751-1097.2007.00259.x
   Rozanowski B, 2008, INVEST OPHTH VIS SCI, V49, P2838, DOI 10.1167/iovs.08-1700
   SARNA T, 1986, BIOCHIM BIOPHYS ACTA, V883, P162, DOI 10.1016/0304-4165(86)90147-9
   Sarna T, 2003, EXP EYE RES, V76, P89, DOI 10.1016/S0014-4835(02)00247-6
   SARNA T, 1980, ARCH BIOCHEM BIOPHYS, V202, P304, DOI 10.1016/0003-9861(80)90431-2
   SARNA T, 1992, J PHOTOCH PHOTOBIO B, V12, P215, DOI 10.1016/1011-1344(92)85027-R
   SARNA T, 1984, PHOTOCHEM PHOTOBIOL, V39, P69, DOI 10.1111/j.1751-1097.1984.tb03406.x
   SCHMIDT SY, 1986, INVEST OPHTH VIS SCI, V27, P1063
   Simon JD, 2010, ACCOUNTS CHEM RES, V43, P1452, DOI 10.1021/ar100079y
   Simon JD, 2009, PIGM CELL MELANOMA R, V22, P563, DOI 10.1111/j.1755-148X.2009.00610.x
   Swalwell H, 2012, FREE RADICAL BIO MED, V52, P626, DOI 10.1016/j.freeradbiomed.2011.11.019
   Szpoganicz B, 2002, J INORG BIOCHEM, V89, P45, DOI 10.1016/S0162-0134(01)00406-8
   Takeuchi S, 2004, P NATL ACAD SCI USA, V101, P15076, DOI 10.1073/pnas.0403994101
   TSUKAMOTO K, 1992, EMBO J, V11, P519, DOI 10.1002/j.1460-2075.1992.tb05082.x
   Wakamatsu K, 2002, PIGM CELL RES, V15, P225, DOI 10.1034/j.1600-0749.2002.02009.x
   Wakamatsu K, 2012, PIGM CELL MELANOMA R, V25, P434, DOI 10.1111/j.1755-148X.2012.01011.x
   Wakamatsu K, 2009, PIGM CELL MELANOMA R, V22, P474, DOI 10.1111/j.1755-148X.2009.00580.x
   Wenczl E, 1998, J INVEST DERMATOL, V111, P678, DOI 10.1046/j.1523-1747.1998.00357.x
   Wood SR, 2006, P NATL ACAD SCI USA, V103, P4111, DOI 10.1073/pnas.0511248103
   Ye T, 2006, PHOTOCHEM PHOTOBIOL, V82, P733, DOI 10.1562/2006-01-02-RA-762
   Zadlo A, 2007, PIGM CELL RES, V20, P52, DOI 10.1111/j.1600-0749.2006.00350.x
   Zadlo A, 2009, PHOTOCH PHOTOBIO SCI, V8, P830, DOI 10.1039/b901820d
   Zareba M, 2007, PHOTOCHEM PHOTOBIOL, V83, P925, DOI 10.1111/j.1751-1097.2007.00080.x
   Zareba M, 2006, PHOTOCHEM PHOTOBIOL, V82, P1024, DOI 10.1562/2006-03-08-RA-836
NR 60
TC 42
Z9 42
U1 2
U2 30
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1755-1471
EI 1755-148X
J9 PIGM CELL MELANOMA R
JI Pigment Cell Melanoma Res.
PD MAY
PY 2013
VL 26
IS 3
BP 357
EP 366
DI 10.1111/pcmr.12078
PG 10
WC Oncology; Cell Biology; Dermatology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology; Dermatology
GA 133CD
UT WOS:000318114100015
PM 23421783
DA 2022-11-30
ER

PT J
AU Leng, T
   Fishman, HA
AF Leng, Theodore
   Fishman, Harvey A.
TI Carbon Nanotube Bucky Paper as an Artificial Support Membrane for
   Retinal Cell Transplantation
SO OPHTHALMIC SURGERY LASERS & IMAGING
LA English
DT Article
ID PIGMENT-EPITHELIUM
AB BACKGROUND AND OBJECTIVE: Transplantation of epithelial cells on a substrate to rescue diseased retinal cells is an experimental therapy for age-related macular degeneration. Carbon nanotube bucky paper was tested for cell transplantation into the retina.
   MATERIALS AND METHODS: Bucky paper was prepared and human RPE cells cultured on its surface demonstrating its utility as a cell transplantation substrate. Bucky paper was implanted underneath 9 rabbit retinas using a standard 3-port pars plana vitrectomy and subretinal bleb. A 1 mm retinotomy was created through which Bucky paper precut to fit was inserted with the subretinal forceps, into the subretinal bleb. The retina was reattached by airfluid exchange.
   RESULTS: By light microscopy, RPE cells demonstrated normal morphology and growth patterns on the bucky paper surface. Scanning electron microscopy confirmed a confluent monolayer of cells, and indicated the formation of microvilli on the apical surface. Bucky paper remained flat in the subretinal space after 2 weeks, the retina fully attached without edema or inflammation.
   CONCLUSION: Bucky paper possesses the necessary attributes for therapeutic cell transplantation in the eye.
C1 [Leng, Theodore; Fishman, Harvey A.] Stanford Univ, Sch Med, Byers Eye Inst Stanford, Stanford, CA 94305 USA.
C3 Stanford University
RP Leng, T (通讯作者)，Byers Eye Inst Stanford, 2452 Watson Court, Palo Alto, CA 94303 USA.
EM tedleng@stanford.edu
RI Leng, Theodore/AAQ-7459-2020
OI Leng, Theodore/0000-0002-8461-3562
CR Dumee LF, 2010, J MEMBRANE SCI, V351, P36, DOI 10.1016/j.memsci.2010.01.025
   Durlu YK, 1997, CELL TRANSPLANT, V6, P149, DOI 10.1016/S0963-6897(96)00142-X
   Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669
   Gouras P., 1998, RETINAL PIGMENT EPIT, P492
   Ho TC, 1997, INVEST OPHTH VIS SCI, V38, P1110
   KLEIN R, 1999, AGE RELATED MACULAR, P31
   Lin T, 2003, AUST J CHEM, V56, P635, DOI 10.1071/CH02254
   Nicolini J, 2000, ACTA OPHTHALMOL SCAN, V78, P527, DOI 10.1034/j.1600-0420.2000.078005527.x
   Priglinger SG, 2005, ARCH OPHTHALMOL-CHIC, V123, P1412, DOI 10.1001/archopht.123.10.1412
   Thumann G, 1997, CURR EYE RES, V16, P1236, DOI 10.1076/ceyr.16.12.1236.5031
   Thumann G, 1999, TRANSPLANTATION, V68, P195, DOI 10.1097/00007890-199907270-00006
NR 11
TC 11
Z9 11
U1 0
U2 20
PU SLACK INC
PI THOROFARE
PA 6900 GROVE RD, THOROFARE, NJ 08086 USA
SN 1542-8877
J9 OPHTHAL SURG LAS IM
JI Ophthalmic Surg. Lasers Imaging
PD JAN-FEB
PY 2013
VL 44
IS 1
BP 73
EP 76
DI 10.3928/23258160-20121221-16
PG 4
WC Ophthalmology; Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Surgery
GA 172PG
UT WOS:000321016000013
PM 23410811
DA 2022-11-30
ER

PT J
AU Petropoulos, IK
   Matter, MA
   Katsimpris, JM
   Desmangles, PM
AF Petropoulos, I. K.
   Matter, M. A.
   Katsimpris, J. M.
   Desmangles, P. M.
TI The Role of Spectral-Domain Optical Coherence Tomography in the
   Diagnosis of Retinal Angiomatous Proliferation
SO KLINISCHE MONATSBLATTER FUR AUGENHEILKUNDE
LA English
DT Article
DE retinal angiomatous proliferation; optical coherence tomography;
   age-related macular degeneration; serous pigment epithelium detachment
ID TYPE-3 NEOVASCULARIZATION; MACULAR DEGENERATION
AB Background: We present the findings of spectral-domain optical coherence tomography (OCT) in 8 patients with retinal angiomatous proliferation.
   History and Signs: Eight patients with a known history of age-related macular degeneration presented with a recent decrease of visual acuity in one eye. On fundus examination, all patients showed an elevated macular lesion associated with intra- or subretinal hemorrhage and retinal hard exudates. Fluorescein and indocyanine-green (ICG) angiography, together with spectral-domain OCT (Optopol Copernicus SOCT), were performed.
   Therapy and Outcome: Fluorescein angiography showed early hyperfluorescence with late leakage in all cases. A serous pigment epithelium detachment was present in 6 cases. ICG angiography showed a hot spot in the macular area. The OCT showed a serous pigment epithelium detachment in 6 cases and intraretinal cysts in all cases. The line crossing the ICG visible hot spot showed a greatly hyperreflective intraretinal lesion located at various depths inside the retina.
   Conclusions: Spectral-domain OCT is a useful complementary tool to confirm the diagnosis of retinal angiomatous proliferation. Its high resolution and speed enables accurate localization of the angiomatous lesion.
C1 [Petropoulos, I. K.; Matter, M. A.; Desmangles, P. M.] Ophthalmol Ctr Terrassiere, CH-1207 Geneva, Switzerland.
   [Katsimpris, J. M.] Gen Hosp Patras Agios Andreas, Dept Ophthalmol, Patras, Greece.
RP Petropoulos, IK (通讯作者)，Ophthalmol Ctr Terrassiere, Rue Terrassiere 31, CH-1207 Geneva, Switzerland.
EM ipetropoulos@cot-ge.ch
CR Freund KB, 2008, RETINA-J RET VIT DIS, V28, P201, DOI 10.1097/IAE.0b013e3181669504
   Kerbs I, 2009, OPHTHAL SURG LAS IM, V40, P285, DOI [10.9999/15428877-20090430-10, 10.3928/15428877-20090430-10]
   Mendrinos E, 2009, KLIN MONATSBL AUGENH, V226, P284, DOI 10.1055/s-0028-1109311
   Polito A, 2006, ANN ACAD MED SINGAP, V35, P420
   Truong SN, 2007, RETINA-J RET VIT DIS, V27, P915, DOI 10.1097/IAE.0b013e31805468fd
   Yannuzzi LA, 2001, RETINA-J RET VIT DIS, V21, P416, DOI 10.1097/00006982-200110000-00003
   Yannuzzi LA, 2008, RETINA-J RET VIT DIS, V28, P375, DOI 10.1097/IAE.0b013e3181619c55
NR 7
TC 1
Z9 1
U1 0
U2 0
PU GEORG THIEME VERLAG KG
PI STUTTGART
PA RUDIGERSTR 14, D-70469 STUTTGART, GERMANY
SN 0023-2165
EI 1439-3999
J9 KLIN MONATSBL AUGENH
JI Klinische Monatsblat. Augenheilkunde
PD APR
PY 2010
VL 227
IS 4
BP 309
EP 311
DI 10.1055/s-0029-1245221
PG 3
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 585XH
UT WOS:000276863200019
PM 20408082
DA 2022-11-30
ER

PT J
AU Chan, A
   Blumenkranz, MS
   Wu, KHC
   Wang, G
   Berker, N
   Parast, LM
   Sanislo, SR
AF Chan, Annie
   Blumenkranz, Mark S.
   Wu, Kathy H. C.
   Wang, Gloria
   Berker, Nilufer
   Parast, Layla M.
   Sanislo, Steven R.
TI Photodynamic Therapy With and Without Adjunctive Intravitreal
   Triamcinolone Acetonide: A Retrospective Comparative Study
SO OPHTHALMIC SURGERY LASERS & IMAGING
LA English
DT Article
ID SUBFOVEAL CHOROIDAL NEOVASCULARIZATION; BLUE MOUNTAINS EYE; MACULAR
   DEGENERATION; VERTEPORFIN THERAPY; VISUAL IMPAIRMENT; RANIBIZUMAB;
   EXPRESSION; CELLS; CORTICOSTEROIDS; PREVALENCE
AB BACKGROUND AND OBJECTIVE: To compare photodynamic therapy (PDT) with and without adjunctive intravitreal triamcinolone acetonide (IVTA) in the treatment of choroidal neovascularization secondary to age-related macular degeneration.
   PATIENTS AND METHODS: Sixty-six eyes received PDT with IVTA and 73 eyes received PDT only. Outcome measures included changes In Visual acuity and greatest linear dimension (GLD), the presence of angiographic leakage, the re-treatment rate, and adverse events.
   RESULTS: Patients treated with PDT with IVTA had reduced mean GLD compared to patients treated with PDT only at all study time points (3 [P = .0049], 6 [P = .003], and 12 [P = .05] months). Forty-four percent of patients in the PDT with IVTA group and 22% of patients in the PDT only group achieved angiographic closure at 3 months (P = .027). There were no significant differences in the final visual acuity outcome or the re-treatment rate between the two groups.
   CONCLUSION: PDT with IVTA therapy has a favorable outcome on GLD. There is a modest improvement in visual acuity with PDT with IVTA therapy, which diminishes over time.
C1 [Sanislo, Steven R.] Stanford Univ, Ctr Med, Calif VitreoRetinal Ctr, Dept Ophthalmol, Menlo Pk, CA 94025 USA.
   [Parast, Layla M.] Stanford Univ, Dept Stat, Stanford, CA 94305 USA.
C3 Stanford University; Stanford University
RP Sanislo, SR (通讯作者)，Stanford Univ, Ctr Med, Calif VitreoRetinal Ctr, Dept Ophthalmol, 1225 Crane St, Menlo Pk, CA 94025 USA.
OI Parast, Layla/0000-0002-7288-1009
CR Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   [Anonymous], 1999, ARCH OPHTHALMOL, V117, P1329
   Arias L, 2006, OPHTHALMOLOGY, V113, P2243, DOI 10.1016/j.ophtha.2006.04.039
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Augustin AJ, 2006, AM J OPHTHALMOL, V141, P638, DOI 10.1016/j.ajo.2005.11.058
   Augustin AJ, 2006, OPHTHALMOLOGY, V113, P14, DOI 10.1016/j.ophtha.2005.09.002
   Augustin AJ, 2007, RETINA-J RET VIT DIS, V27, P133, DOI 10.1097/IAE.0b013e3180323de7
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Chakravarthy U, 2006, BMJ-BRIT MED J, V333, P869, DOI 10.1136/bmj.39009.366736.80
   Ergun E, 2006, AM J OPHTHALMOL, V142, P10, DOI 10.1016/j.ajo.2006.02.048
   FOLKMAN J, 1987, ANN SURG, V206, P374, DOI 10.1097/00000658-198709000-00016
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Gilson MM, 2007, OPHTHALMOLOGY, V114, P1713, DOI 10.1016/j.ophtha.2007.03.071
   Hopley C, 2004, BRIT J OPHTHALMOL, V88, P982, DOI 10.1136/bjo.2003.039131
   Kato A, 2005, RETINA-J RET VIT DIS, V25, P503, DOI 10.1097/00006982-200506000-00017
   Nauck M, 1998, EUR J PHARMACOL, V341, P309, DOI 10.1016/S0014-2999(97)01464-7
   Obata R, 2007, BRIT J OPHTHALMOL, V91, P100, DOI 10.1136/bjo.2006.098004
   Oh H, 1999, INVEST OPHTH VIS SCI, V40, P1891
   Penfold PL, 2000, CLIN EXP IMMUNOL, V121, P458, DOI 10.1046/j.1365-2249.2000.01316.x
   Penfold PL, 2001, CLIN EXP OPHTHALMOL, V29, P188, DOI 10.1046/j.1442-9071.2001.00407.x
   Rahmani B, 1996, OPHTHALMOLOGY, V103, P1721, DOI 10.1016/S0161-6420(96)30435-1
   Rechtman E, 2004, BRIT J OPHTHALMOL, V88, P344, DOI 10.1136/bjo.2003.027177
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Ruiz-Moreno JM, 2007, RETINA-J RET VIT DIS, V27, P458, DOI 10.1097/IAE.0b013e318030c77c
   Smiddy WE, 2007, OPHTHALMOLOGY, V114, P847, DOI 10.1016/j.ophtha.2006.10.038
   Spaide RF, 2003, OPHTHALMOLOGY, V110, P1517, DOI 10.1016/S0161-6420(03)00544-X
   Spaide RF, 2005, RETINA-J RET VIT DIS, V25, P685, DOI 10.1097/00006982-200509000-00001
   Wang JJ, 2007, OPHTHALMOLOGY, V114, P92, DOI 10.1016/j.ophtha.2006.07.017
   Wang JJ, 2000, CLIN EXP OPHTHALMOL, V28, P268, DOI 10.1046/j.1442-9071.2000.00315.x
   Wang YS, 2002, GRAEF ARCH CLIN EXP, V240, P42, DOI 10.1007/s00417-001-0398-y
   WILSON CA, 1992, ARCH OPHTHALMOL-CHIC, V110, P1155, DOI 10.1001/archopht.1992.01080200135041
   Zarbin M, 2006, ARCH OPHTHALMOL-CHIC, V124, P563, DOI 10.1001/archopht.124.4.563
NR 32
TC 9
Z9 9
U1 0
U2 0
PU SLACK INC
PI THOROFARE
PA 6900 GROVE RD, THOROFARE, NJ 08086 USA
SN 1542-8877
EI 1938-2375
J9 OPHTHAL SURG LAS IM
JI Ophthalmic Surg. Lasers Imaging
PD NOV-DEC
PY 2009
VL 40
IS 6
BP 561
EP 569
DI 10.3928/15428877-20091030-05
PG 9
WC Ophthalmology; Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Surgery
GA 529IY
UT WOS:000272510500006
PM 19928721
DA 2022-11-30
ER

PT J
AU Kaidzu, S
   Tanito, M
   Ohira, A
   Umeda, S
   Suzuki, M
   Yoshikawa, Y
   Iwata, T
AF Kaidzu, Sachiko
   Tanito, Masaki
   Ohira, Akihiro
   Umeda, Shinsuke
   Suzuki, Michihiro
   Yoshikawa, Yasuhiro
   Iwata, Takeshi
TI Immunohistochemical analysis of aldehyde-modified proteins in drusen in
   cynomolgus monkeys (Macaca fascicularis)
SO EXPERIMENTAL EYE RESEARCH
LA English
DT Article
DE aldehydes; 4-hydroxynonenal; 4-hydroxyhexenal; cynomolgus monkey;
   drusen; age-related macular degeneration; protein modification
ID MACULAR DEGENERATION; BRUCHS MEMBRANE; AGE; PATHOGENESIS; DISEASE;
   STRESS
AB Protein modifications resulting from reactive aldehydes are thought to be involved in the pathogenesis of various degenerative diseases. Aged cynomolgus monkey (Macaca fascicularis) spontaneously develop drusen in the macula, consistent with the phenotype observed in early-stage age-related macular degeneration (AMD), indicating that this animal is an optimum model for AMD. In retinal sections from three monkeys with macular degeneration, regardless of their size, drusen were consistently positive with immunohistochemical labeling against protein modifications by 4-hydroxynonenal and 4-hydroxyhexenal, end products of non-enzymatic oxidation of n-6 and n-3 polyunsaturated fatty acids, respectively. Positive labeling for both modifications was observed in the ganglion cell layer, the inner nuclear layer, the outer nuclear layer, and the retinal pigment epithelium. However, no consistent differences in location or intensity of the labeling were observed between monkeys with normal macula and macular degeneration. The results suggest a possible association between drusen formation and protein modifications by aldehydes in the pathogenesis of AMD. (c) 2008 Elsevier Ltd. All rights reserved.
C1 [Kaidzu, Sachiko; Tanito, Masaki; Ohira, Akihiro] Shimane Univ, Fac Med, Dept Ophthalmol, Izumo, Shimane 6938501, Japan.
   [Umeda, Shinsuke; Iwata, Takeshi] Natl Hosp Org, Natl Inst Sensory Organs, Tokyo Med Ctr, Tokyo, Japan.
   [Suzuki, Michihiro] Corp Product, Ibaraki, Japan.
   [Suzuki, Michihiro] Res Lab Primates, Ibaraki, Japan.
   [Yoshikawa, Yasuhiro] Univ Tokyo, Grad Sch Agr & Life Sci, Dept Biomed Sci, Tokyo, Japan.
C3 Shimane University; University of Tokyo
RP Tanito, M (通讯作者)，Shimane Univ, Fac Med, Dept Ophthalmol, 89-1 Enya, Izumo, Shimane 6938501, Japan.
EM tanito-oph@umin.ac.jp
RI ohira, akihiro/G-8352-2017
OI ohira, akihiro/0000-0002-1307-5592
CR Awasthi YC, 2004, FREE RADICAL BIO MED, V37, P607, DOI 10.1016/j.freeradbiomed.2004.05.033
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   ESTERBAUER H, 1993, AM J CLIN NUTR, V57, P779, DOI 10.1093/ajcn/57.5.779S
   Ethen CM, 2007, INVEST OPHTH VIS SCI, V48, P3469, DOI 10.1167/iovs.06-1058
   Fine SL, 2000, NEW ENGL J MED, V342, P483, DOI 10.1056/NEJM200002173420707
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Handa JT, 1999, INVEST OPHTH VIS SCI, V40, P775
   Ishibashi T, 1998, ARCH OPHTHALMOL-CHIC, V116, P1629, DOI 10.1001/archopht.116.12.1629
   ISHIBASHI T, 1986, INVEST OPHTH VIS SCI, V27, P184
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   STAFFORD TJ, 1984, OPHTHALMOLOGY, V91, P513
   Tanito M, 2005, INVEST OPHTH VIS SCI, V46, P3859, DOI 10.1167/iovs.05-0672
   Tanito M, 2006, FREE RADICAL BIO MED, V41, P1847, DOI 10.1016/j.freeradbiomed.2006.09.012
   UCHIDA K, 1993, P NATL ACAD SCI USA, V90, P8742, DOI 10.1073/pnas.90.18.8742
   UCHIDA K, 1992, P NATL ACAD SCI USA, V89, P4544, DOI 10.1073/pnas.89.10.4544
   Umeda S, 2005, FASEB J, V19, P1683, DOI 10.1096/fj.04-3525fje
NR 19
TC 6
Z9 6
U1 0
U2 1
PU ACADEMIC PRESS LTD ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0014-4835
J9 EXP EYE RES
JI Exp. Eye Res.
PD MAY
PY 2008
VL 86
IS 5
BP 856
EP 859
DI 10.1016/j.exer.2008.01.016
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 314PT
UT WOS:000256822000017
PM 18355809
DA 2022-11-30
ER

PT J
AU Jain, RK
   Finn, AV
   Kolodgie, FD
   Gold, HK
   Virmani, R
AF Jain, Rakesh K.
   Finn, Aloke V.
   Kolodgie, Frank D.
   Gold, Herman K.
   Virmani, Renu
TI Antiangiogenic therapy for normalization of atherosclerotic plaque
   vasculature: a potential strategy for plaque stabilization
SO NATURE CLINICAL PRACTICE CARDIOVASCULAR MEDICINE
LA English
DT Review
DE angiogenesis; atherosclerosis; cancer; hemorrhage; vascular
   normalization
ID ENDOTHELIAL GROWTH-FACTOR; SUDDEN CORONARY DEATH; INTRAPLAQUE
   HEMORRHAGE; TUMOR VASCULATURE; MAST-CELLS; IN-VIVO; ANGIOGENESIS;
   NEOVASCULARIZATION; RUPTURE; BEVACIZUMAB
AB Angiogenesis within human atherosclerotic plaques has an important role in plaque progression as immature blood vessels leak red blood cells and inflammatory mediators into the plaque center. Accumulation of free cholesterol from red blood cell membranes potentially increases the size of the necrotic core and triggers a chain of events that promote plaque destabilization. Antiangiogenic agents have been shown to prune some tumor vessels and 'normalize' the structure and function of the remaining vasculature, thereby improving the access of chemotherapeutic agents to tumors. We propose that antiangiogenic therapy can similarly stabilize vulnerable 'rupture-prone' plaques by pruning and normalizing immature intraplaque vessels, preventing further intraplaque hemorrhage. This normalization would limit necrotic core enlargement, further luminal narrowing and the degree of inflammation. Such normalization has been realized using vascular endothelial growth factor antagonists for the treatment of cancer and age-related macular degeneration. The development of this novel approach to prevent plaque progression might add to the armamentarium of preventive measures for acute myocardial infarction, stroke and sudden cardiac death.
C1 Harvard Univ, Sch Med, Boston, MA 02114 USA.
   Massachusetts Gen Hosp, Dept Radiat Oncol & Med, Director Edwin L Steele Lab Tumor Biol, Boston, MA USA.
   Massachusetts Gen Hosp, Boston, MA 02114 USA.
   Massachusetts Gen Hosp, Dept Med, Intervent Cardiol Cardiol Div, Boston, MA USA.
   CVPath Inst Inc, Gaithersburg, MD USA.
C3 Harvard University; Harvard Medical School; Harvard University;
   Massachusetts General Hospital; Harvard University; Massachusetts
   General Hospital; Harvard University; Massachusetts General Hospital;
   CVPath Institute
RP Jain, RK (通讯作者)，Harvard Univ, Sch Med, Cox 7 100 Blossom St, Boston, MA 02114 USA.
EM jain@steele.mgh.harvard.edu; hgold@partners.org
RI Jain, Rakesh K/I-1384-2017
OI Jain, Rakesh K/0000-0001-7571-3548
FU NCI NIH HHS [P01 CA080124] Funding Source: Medline; NATIONAL CANCER
   INSTITUTE [P01CA080124] Funding Source: NIH RePORTER
CR AIELLO LP, 1995, P NATL ACAD SCI USA, V92, P10457, DOI 10.1073/pnas.92.23.10457
   Autiero M, 2003, J THROMB HAEMOST, V1, P1356, DOI 10.1046/j.1538-7836.2003.00263.x
   Batchelor TT, 2007, CANCER CELL, V11, P83, DOI 10.1016/j.ccr.2006.11.021
   Burke AP, 1999, JAMA-J AM MED ASSOC, V281, P921, DOI 10.1001/jama.281.10.921
   Burke AP, 1997, NEW ENGL J MED, V336, P1276, DOI 10.1056/NEJM199705013361802
   Burke AP, 2001, CIRCULATION, V103, P934
   Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220
   Chen YX, 1999, ARTERIOSCL THROM VAS, V19, P131, DOI 10.1161/01.ATV.19.1.131
   DARBONNE WC, 1991, J CLIN INVEST, V88, P1362, DOI 10.1172/JCI115442
   DAVIS GE, 1992, EXP CELL RES, V200, P242, DOI 10.1016/0014-4827(92)90170-D
   Des Guetz G, 2006, BRIT J CANCER, V94, P1823, DOI 10.1038/sj.bjc.6603176
   Drimal J, 2006, NEUROENDOCRINOL LETT, V27, P176
   Dunmore BJ, 2007, J VASC SURG, V45, P155, DOI 10.1016/j.jvs.2006.08.072
   Ferrara N, 2006, RETINA-J RET VIT DIS, V26, P859, DOI 10.1097/01.iae.0000242842.14624.e7
   Fleiner M, 2004, CIRCULATION, V110, P2843, DOI 10.1161/01.CIR.0000146787.16297.E8
   FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182
   Fung AE, 2006, BRIT J OPHTHALMOL, V90, P1344, DOI 10.1136/bjo.2006.099598
   GERRITY RG, 1981, AM J PATHOL, V103, P191
   Gordon MS, 2005, ONCOLOGY-BASEL, V69, P25, DOI 10.1159/000088481
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Graversen JH, 2002, INT J BIOCHEM CELL B, V34, P309, DOI 10.1016/S1357-2725(01)00144-3
   Hansson GK, 2001, ARTERIOSCL THROM VAS, V21, P1876, DOI 10.1161/hq1201.100220
   HEISTAD DD, 1986, ARTERIOSCLEROSIS, V6, P326, DOI 10.1161/01.ATV.6.3.326
   HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S
   Inai T, 2004, AM J PATHOL, V165, P35, DOI 10.1016/S0002-9440(10)63273-7
   Jain RK, 2003, NAT MED, V9, P685, DOI 10.1038/nm0603-685
   Jain RK, 2006, NAT CLIN PRACT ONCOL, V3, P24, DOI 10.1038/ncponc0403
   Jain RK, 2001, NAT MED, V7, P987, DOI 10.1038/nm0901-987
   Jain RK, 2005, SCIENCE, V307, P58, DOI 10.1126/science.1104819
   Jeziorska M, 1999, J PATHOL, V188, P189
   Johnson J, 2005, CIRCULATION, V111, P1422, DOI 10.1161/01.CIR.0000158435.98035.8D
   Kamba T, 2006, AM J PHYSIOL-HEART C, V290, pH560, DOI 10.1152/ajpheart.00133.2005
   Khurana R, 2005, CIRCULATION, V112, P1813, DOI 10.1161/CIRCULATIONAHA.105.535294
   Kim-Shapiro DB, 2006, ARTERIOSCL THROM VAS, V26, P697, DOI 10.1161/01.ATV.0000204350.44226.9a
   Kockx MM, 2003, ARTERIOSCL THROM VAS, V23, P440, DOI 10.1161/01.ATV.0000057807.28754.7F
   KOHN S, 1992, LAB INVEST, V67, P596
   Kolodgie FD, 2003, NEW ENGL J MED, V349, P2316, DOI 10.1056/NEJMoa035655
   Laine P, 2000, CIRCULATION, V101, P1665
   Lappalainen H, 2004, ARTERIOSCL THROM VAS, V24, P1880, DOI 10.1161/01.ATV.0000140820.51174.8d
   Levy AP, 2007, ARTERIOSCL THROM VAS, V27, P134, DOI 10.1161/01.ATV.0000251020.24399.a2
   Liew G, 2007, NEW ENGL J MED, V356, P747
   Luttun A, 2002, NAT MED, V8, P831, DOI 10.1038/nm731
   Manegold C, 2007, J CLIN ONCOL, V25
   Melder RJ, 1996, NAT MED, V2, P992, DOI 10.1038/nm0996-992
   Milei J, 1998, AM HEART J, V136, P1096, DOI 10.1016/S0002-8703(98)70169-3
   Moreno PR, 2006, CIRCULATION, V113, P2245, DOI 10.1161/CIRCULATIONAHA.105.578955
   Moreno PR, 2004, CIRCULATION, V110, P2032, DOI 10.1161/01.CIR.0000143233.87854.23
   Moulton KS, 1999, CIRCULATION, V99, P1726, DOI 10.1161/01.CIR.99.13.1726
   Munoz-Najar UM, 2006, ONCOGENE, V25, P2379, DOI 10.1038/sj.onc.1209273
   OBrien KD, 1996, CIRCULATION, V93, P672, DOI 10.1161/01.CIR.93.4.672
   Philippidis P, 2004, CIRC RES, V94, P119, DOI 10.1161/01.RES.0000109414.78907.F9
   Ratner M, 2004, NAT BIOTECHNOL, V22, P1198, DOI 10.1038/nbt1004-1198
   Robertson AKL, 2003, J CLIN INVEST, V112, P1342, DOI 10.1172/JCI200318607
   Rosenfeld ME, 2000, ARTERIOSCL THROM VAS, V20, P2587, DOI 10.1161/01.ATV.20.12.2587
   Sasaki T, 2006, ARTERIOSCL THROM VAS, V26, P1304, DOI 10.1161/01.ATV.0000219687.71607.f7
   Schwartz SM, 2007, ARTERIOSCL THROM VAS, V27, P705, DOI 10.1161/01.ATV.0000261709.34878.20
   SHAH PK, 1995, CIRCULATION, V92, P1565
   Skillings JR, 2005, J CLIN ONCOL, V23, p196S
   Tabas I, 1996, J BIOL CHEM, V271, P22773, DOI 10.1074/jbc.271.37.22773
   Tabas I, 2000, BBA-MOL CELL BIOL L, V1529, P164, DOI 10.1016/S1388-1981(00)00146-3
   Takaya N, 2005, CIRCULATION, V111, P2768, DOI 10.1161/CIRCULATIONAHA.104.504167
   Tong RT, 2004, CANCER RES, V64, P3731, DOI 10.1158/0008-5472.CAN-04-0074
   Toth T, 2000, HUM PATHOL, V31, P955
   Van den Heuvel MM, 1999, J LEUKOCYTE BIOL, V66, P858, DOI 10.1002/jlb.66.5.858
   VANDENBRENK HAS, 1977, BRIT J EXP PATHOL, V58, P147
   Verheul HMW, 2007, NAT REV CANCER, V7, P475, DOI 10.1038/nrc2152
   Virmani R, 2005, ARTERIOSCL THROM VAS, V25, P2054, DOI 10.1161/01.ATV.0000178991.71605.18
   Virmani R, 1998, AM HEART J, V136, P937, DOI 10.1016/S0002-8703(98)70144-9
   Virmani R, 2000, ARTERIOSCL THROM VAS, V20, P1262, DOI 10.1161/01.ATV.20.5.1262
   Vlodavsky I, 2001, J CLIN INVEST, V108, P341, DOI 10.1172/JCI13662
   Weis M, 2002, CIRCULATION, V105, P739, DOI 10.1161/hc0602.103393
   WEISS MRD, 2007, ASS RES VIS OPHTH MA
   Willett CG, 2005, J CLIN ONCOL, V23, P8136, DOI 10.1200/JCO.2005.02.5635
   Willett CG, 2004, NAT MED, V10, P145, DOI 10.1038/nm988
   Winkler F, 2004, CANCER CELL, V6, P553, DOI 10.1016/S1535-6108(04)00305-8
   Yang JC, 2003, NEW ENGL J MED, V349, P427, DOI 10.1056/NEJMoa021491
   ZHANG Y, 1993, AM J PATHOL, V143, P164
NR 77
TC 104
Z9 109
U1 0
U2 11
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1743-4297
J9 NAT CLIN PRACT CARD
JI Nat. Clin. Pract. Cardiovasc. Med.
PD SEP
PY 2007
VL 4
IS 9
BP 491
EP 502
DI 10.1038/ncpcardio0979
PG 12
WC Cardiac & Cardiovascular Systems
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cardiovascular System & Cardiology
GA 203AZ
UT WOS:000248948800009
PM 17712362
DA 2022-11-30
ER

PT J
AU Guo, MC
   Schwartz, TD
   Dunaief, JL
   Cui, QN
AF Guo, Michellsdd
   Schwartz, Turner D.
   Dunaief, Joshua L.
   Cui, Qi N.
TI Myeloid cells in retinal and brain degeneration
SO FEBS JOURNAL
LA English
DT Review
DE age-related macular degeneration; Alzheimer's disease; glaucoma;
   inflammation; macrophages; microglia; monocytes; Parkinson's disease;
   retina; retinitis pigmentosa
ID OPTICAL COHERENCE TOMOGRAPHY; NECROSIS-FACTOR-ALPHA; AMYLOID-BETA
   PEPTIDE; C-REACTIVE PROTEIN; MACROPHAGE CHEMOATTRACTANT PROTEIN-1;
   CHRONIC INFLAMMATORY REACTION; COMPLEMENT FACTOR-H; MACULAR
   DEGENERATION; ALZHEIMERS-DISEASE; MOUSE MODEL
AB Retinal inflammation underlies multiple prevalent ocular and neurological diseases. Similar inflammatory processes are observed in glaucomatous optic neuropathy, age-related macular degeneration, retinitis pigmentosa, posterior uveitis, Alzheimer's disease, and Parkinson's disease. In particular, human and animal studies have demonstrated the important role microglia/macrophages play in initiating and maintaining a pro-inflammatory environment in degenerative processes impacting vision. On the other hand, microglia have also been shown to have a protective role in multiple central nervous system diseases. Identifying the mechanisms underlying cell dysfunction and death is the first step toward developing novel therapeutics for these diseases impacting the central nervous system. In addition to reviewing recent key studies defining important mediators of retinal inflammation, with an emphasis on translational studies that bridge this research from bench to bedside, we also highlight a promising therapeutic class of medications, the glucagon-like peptide-1 receptor agonists. Finally, we propose areas where additional research is necessary to identify mechanisms that can be modulated to shift the balance from a neurotoxic to a neuroprotective retinal environment.
C1 [Guo, Michellsdd; Schwartz, Turner D.; Dunaief, Joshua L.; Cui, Qi N.] Univ Penn, Dept Ophthalmol, Philadelphia, PA 19104 USA.
C3 University of Pennsylvania
RP Cui, QN (通讯作者)，Univ Penn, Scheie Eye Inst, Philadelphia, PA 19104 USA.
EM qi.cui@pennmedicine.upenn.edu
OI Guo, Michelle/0000-0003-4633-3997
FU Jeffrey W. Berger Memorial Medical Student Research Award; National
   Institutes of Health/National Eye Institute [R01EY015240, R01EY028916,
   K08EY029765, K12EY015398]; Glaucoma Research Foundation; Research to
   Prevent Blindness; F. M. Kirby Foundation; Paul and Evanina Bell Mackall
   Foundation Trust; Neuraly, Inc.
FX We wish to thank Amy Chen for assistance with figure design and F. Chris
   Bennett and Jacob K. Sterling for fruitful discussions and support. The
   authors are supported by the Jeffrey W. Berger Memorial Medical Student
   Research Award (MG); National Institutes of Health/National Eye
   Institute grants K08EY029765 and K12EY015398, Glaucoma Research
   Foundation, and Neuraly, Inc. (QNC); National Institutes of
   Health/National Eye Institute grants R01EY015240 and R01EY028916 (JLD);
   Research to Prevent Blindness; the F. M. Kirby Foundation; the Paul and
   Evanina Bell Mackall Foundation Trust; and a gift in memory of Dr. Lee
   F. Mauger.
CR Ahern T, 2013, J EUR ACAD DERMATOL, V27, P1440, DOI 10.1111/j.1468-3083.2012.04609.x
   Ajami B, 2007, NAT NEUROSCI, V10, P1538, DOI 10.1038/nn2014
   Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   [Anonymous], 2021, CLIN STUD NLY01 PAT
   Arakawa M, 2010, DIABETES, V59, P1030, DOI 10.2337/db09-1694
   Archibald NK, 2009, BRAIN, V132, P1128, DOI 10.1093/brain/awp068
   Aroda VR, 2019, DIABETES CARE, V42, P1724, DOI 10.2337/dc19-0749
   Askew K, 2017, CELL REP, V18, P391, DOI 10.1016/j.celrep.2016.12.041
   Athauda D, 2017, LANCET, V390, P1664, DOI 10.1016/S0140-6736(17)31585-4
   Athauda D, 2016, DRUG DISCOV TODAY, V21, P802, DOI 10.1016/j.drudis.2016.01.013
   Aviles-Olmos I, 2013, J CLIN INVEST, V123, P2730, DOI 10.1172/JCI68295
   Awh C, 2020, EYEWIKI
   BASSI CJ, 1993, OPTOMETRY VISION SCI, V70, P809, DOI 10.1097/00006324-199310000-00005
   Beguier F, 2020, IMMUNITY, V53, P429, DOI 10.1016/j.immuni.2020.07.021
   Bennett FC, 2018, NEURON, V98, P1170, DOI 10.1016/j.neuron.2018.05.014
   Bertilsson G, 2008, J NEUROSCI RES, V86, P326, DOI 10.1002/jnr.21483
   Biousse V, 2004, NEUROLOGY, V62, P177, DOI 10.1212/01.WNL.0000103444.45882.D8
   BLANKS JC, 1989, BRAIN RES, V501, P364, DOI 10.1016/0006-8993(89)90653-7
   Bodis-Wollner I, 2014, ANN NEUROL, V75, P964, DOI 10.1002/ana.24182
   Boland MV, 2007, J GLAUCOMA, V16, P406, DOI 10.1097/IJG.0b013e31806540a1
   Borucki DM, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.566892
   Bremer D, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00642
   Brown GC, 2014, NAT REV NEUROSCI, V15, P209, DOI 10.1038/nrn3710
   Bruttger J, 2015, IMMUNITY, V43, P92, DOI 10.1016/j.immuni.2015.06.012
   Cairns E, 2020, EVALUATE VANTAGE
   Calippe B, 2017, IMMUNITY, V46, P261, DOI 10.1016/j.immuni.2017.01.006
   Campochiaro PA, 2020, J CLIN INVEST, V130, P1527, DOI 10.1172/JCI132990
   Cao SW, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-259
   Chen L, 2020, RETINA-J RET VIT DIS, V40, P1644, DOI 10.1097/IAE.0000000000002893
   Chen M, 2015, J LEUKOCYTE BIOL, V98, P713, DOI 10.1189/jlb.3RI0615-239R
   Chen ST, 2003, NEUROCHEM RES, V28, P805, DOI 10.1023/A:1023298604347
   Chen W, 2009, EXP EYE RES, V89, P292, DOI 10.1016/j.exer.2008.10.017
   Chen XT, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0235-6
   Chen YH, 2021, J NEUROINFLAMM, V18, DOI 10.1186/s12974-021-02080-8
   Cheung CYL, 2015, J ALZHEIMERS DIS, V45, P45, DOI 10.3233/JAD-141659
   Chi W, 2014, P NATL ACAD SCI USA, V111, P11181, DOI 10.1073/pnas.1402819111
   Chichagova V, 2018, EYE, V32, P946, DOI 10.1038/s41433-018-0061-z
   Coleman AL, 2008, SURV OPHTHALMOL, V53, pS3, DOI 10.1016/j.survophthal.2008.08.006
   Condello C, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7176
   Croisier E, 2005, J NEUROINFLAMM, V2, DOI 10.1186/1742-2094-2-14
   CRONINGOLOMB A, 1991, ANN NEUROL, V29, P41, DOI 10.1002/ana.410290110
   Cuenca N, 2014, PROG RETIN EYE RES, V43, P17, DOI 10.1016/j.preteyeres.2014.07.001
   Cukierman-Yaffe T, 2020, LANCET NEUROL, V19, P582, DOI 10.1016/S1474-4422(20)30173-3
   Daftarian N, 2020, FASEB J, V34, P8001, DOI 10.1096/fj.201901902RR
   Danesh-Meyer HV, 2006, NEUROLOGY, V67, P1852, DOI 10.1212/01.wnl.0000244490.07925.8b
   Daniel E, 2014, OPHTHALMOLOGY, V121, P656, DOI 10.1016/j.ophtha.2013.10.019
   Dauer W, 2003, NEURON, V39, P889, DOI 10.1016/S0896-6273(03)00568-3
   DELAYE M, 1983, NATURE, V302, P415, DOI 10.1038/302415a0
   Diaz-Aparicio I, 2020, J NEUROSCI, V40, P1453, DOI 10.1523/JNEUROSCI.0993-19.2019
   Djamgoz MBA, 1997, VISION RES, V37, P3509, DOI 10.1016/S0042-6989(97)00129-6
   Doorn KJ, 2014, ACTA NEUROPATHOL COM, V2, DOI 10.1186/s40478-014-0090-1
   Duh EJ, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.93751
   Durrani OM, 2004, BRIT J OPHTHALMOL, V88, P1159, DOI 10.1136/bjo.2003.037226
   Eandi CM, 2016, ELIFE, V5, DOI 10.7554/eLife.16490
   Ebneter A, 2017, INVEST OPHTH VIS SCI, V58, DOI 10.1167/iovs.16-20474
   Eghrari AO, 2015, PROG MOL BIOL TRANSL, V134, P7, DOI 10.1016/bs.pmbts.2015.04.001
   Epelman S, 2014, IMMUNITY, V40, P91, DOI 10.1016/j.immuni.2013.11.019
   Fellner L, 2013, GLIA, V61, P349, DOI 10.1002/glia.22437
   Femminella GD, 2019, TRIALS, V20, DOI 10.1186/s13063-019-3259-x
   Ferreira D, 2017, SCI REP-UK, V7, DOI 10.1038/srep46263
   Filippatos Theodosios D, 2014, Rev Diabet Stud, V11, P202, DOI 10.1900/RDS.2014.11.202
   Forrester JV, 2018, AM J OPHTHALMOL, V189, P77, DOI 10.1016/j.ajo.2018.02.019
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Frost S, 2010, J ALZHEIMERS DIS, V22, P1, DOI 10.3233/JAD-2010-100819
   Garces K, 2020, J MOL NEUROSCI, V70, P968, DOI 10.1007/s12031-020-01503-0
   Garcia-Bermudez MY, 2021, FRONT NEUROL, V12, DOI 10.3389/fneur.2021.624983
   Garcia-Martin E, 2014, INVEST OPHTH VIS SCI, V55, P696, DOI 10.1167/iovs.13-13062
   Garcia-Martin ES, 2014, OPHTHALMOLOGY, V121, P1149, DOI 10.1016/j.ophtha.2013.12.023
   GeethaRamani R, 2018, COMPUT METH PROG BIO, V160, P153, DOI 10.1016/j.cmpb.2018.03.020
   Gejl M, 2016, FRONT AGING NEUROSCI, V8, DOI 10.3389/fnagi.2016.00108
   Gengler S, 2012, NEUROBIOL AGING, V33, P265, DOI 10.1016/j.neurobiolaging.2010.02.014
   George S, 2015, J PARKINSON DIS, V5, P413, DOI 10.3233/JPD-150630
   Gharbiya M, 2014, J ALZHEIMERS DIS, V40, P907, DOI 10.3233/JAD-132039
   Ginhoux F, 2010, SCIENCE, V330, P841, DOI 10.1126/science.1194637
   Gomes C, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-16
   Gong N, 2014, J NEUROSCI, V34, P5322, DOI 10.1523/JNEUROSCI.4703-13.2014
   Gonzalez H, 2014, J NEUROIMMUNOL, V274, P1, DOI 10.1016/j.jneuroim.2014.07.012
   Goto H, 2007, JPN J OPHTHALMOL, V51, P41, DOI 10.1007/s10384-006-0383-4
   Gramlich OW, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0542-6
   Graymore, 1991, BIOCH EYE, P291
   Grimaldi A, 2019, FRONT NEUROSCI-SWITZ, V13, DOI 10.3389/fnins.2019.00925
   Grimaldi A, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0740-5
   Grossniklaus HE, 2015, PROG MOL BIOL TRANSL, V134, P383, DOI 10.1016/bs.pmbts.2015.06.001
   Grus FH, 2007, PROTEOM CLIN APPL, V1, P876, DOI 10.1002/prca.200700105
   Gschwandtner M, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02759
   Guilliams M, 2021, NAT IMMUNOL, V22, P118, DOI 10.1038/s41590-020-00849-2
   Guilliams M, 2018, IMMUNITY, V49, P595, DOI 10.1016/j.immuni.2018.10.005
   Guillonneau X, 2017, PROG RETIN EYE RES, V61, P98, DOI 10.1016/j.preteyeres.2017.06.002
   Guo CR, 2012, EXP EYE RES, V104, P39, DOI 10.1016/j.exer.2012.08.013
   Guo L, 2018, MOVEMENT DISORD, V33, P1390, DOI 10.1002/mds.27454
   Gupta D, 2016, AM FAM PHYSICIAN, V93, P668
   Gupta N, 2003, EXP EYE RES, V76, P463, DOI 10.1016/S0014-4835(02)00332-9
   Guttenplan KA, 2020, CELL REP, V31, DOI 10.1016/j.celrep.2020.107776
   Han LN, 2012, DIABETES RES CLIN PR, V97, P453, DOI 10.1016/j.diabres.2012.04.001
   Han WN, 2013, NEUROBIOL AGING, V34, P576, DOI 10.1016/j.neurobiolaging.2012.04.009
   Harder JM, 2020, J NEUROINFLAMM, V17, DOI 10.1186/s12974-020-02011-z
   Harkavyi A, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-19
   Hayes MR, 2014, ANNU REV NUTR, V34, P237, DOI 10.1146/annurev-nutr-071812-161201
   Hebsgaard JB, 2018, DIABETES OBES METAB, V20, P2304, DOI 10.1111/dom.13339
   Hernandez C, 2016, DIABETES, V65, P172, DOI 10.2337/db15-0443
   Hernandez M, 2009, MOL VIS, V15, P2696
   Heuss ND, 2018, ACTA NEUROPATHOL COM, V6, DOI 10.1186/s40478-018-0571-8
   Hoeffel G, 2015, IMMUNITY, V42, P665, DOI 10.1016/j.immuni.2015.03.011
   Hohenstein-Blaul NVU, 2017, EYE, V31, P225, DOI 10.1038/eye.2016.300
   Hosoya K, 2005, BIOL PHARM BULL, V28, P1, DOI 10.1248/bpb.28.1
   Howell GR, 2014, NEUROBIOL DIS, V71, P44, DOI 10.1016/j.nbd.2014.07.016
   Hu SJ, 2015, J NEUROSCI, V35, P6987, DOI 10.1523/JNEUROSCI.3955-14.2015
   Huang HC, 2009, J ALZHEIMERS DIS, V16, P15, DOI 10.3233/JAD-2009-0960
   Huang YT, 2021, NAT IMMUNOL, V22, P586, DOI 10.1038/s41590-021-00913-5
   Hume DA, 2019, TRENDS IMMUNOL, V40, P98, DOI 10.1016/j.it.2018.11.007
   Italiani P, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00514
   Jabs DA, 2005, AM J OPHTHALMOL, V140, P509, DOI 10.1016/j.ajo.2005.03.057
   Jackson CR, 2012, J NEUROSCI, V32, P9359, DOI 10.1523/JNEUROSCI.0711-12.2012
   Karlstetter M, 2015, PROG RETIN EYE RES, V45, P30, DOI 10.1016/j.preteyeres.2014.11.004
   Kastin AJ, 2002, J MOL NEUROSCI, V18, P7, DOI 10.1385/JMN:18:1-2:07
   Keren-Shaul H, 2017, CELL, V169, P1276, DOI 10.1016/j.cell.2017.05.018
   Kielczewski JL, 2016, J IMMUNOL, V196, P1013, DOI 10.4049/jimmunol.1501570
   Kim BJ, 2017, NEUROLOGY, V89, P1604, DOI 10.1212/WNL.0000000000004500
   Kim S, 2009, J ENDOCRINOL, V202, P431, DOI 10.1677/JOE-09-0132
   Kokona D, 2018, J NEUROINFLAMM, V15, DOI 10.1186/s12974-018-1373-4
   KORETZ JF, 1988, SCI AM, V259, P92, DOI 10.1038/scientificamerican0788-92
   Koronyo Y, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.93621
   Krishnan A, 2019, J NEUROINFLAMM, V16, DOI 10.1186/s12974-019-1576-3
   Krishnan A, 2016, J IMMUNOL, V197, P4626, DOI 10.4049/jimmunol.1601488
   Kristensen SL, 2019, LANCET DIABETES ENDO, V7, P776, DOI 10.1016/S2213-8587(19)30249-9
   Kromer Robert, 2014, Front Psychiatry, V5, P22, DOI 10.3389/fpsyt.2014.00022
   La Morgia C, 2016, ANN NEUROL, V79, P90, DOI 10.1002/ana.24548
   Lakshminarayanan V, 1996, NEUROL RES, V18, P9, DOI 10.1080/01616412.1996.11740369
   Lambert WS, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-48054-y
   Lapenna A, 2018, NAT REV IMMUNOL, V18, P689, DOI 10.1038/s41577-018-0056-9
   Lardenoye CWTA, 2006, OPHTHALMOLOGY, V113, P1446, DOI 10.1016/j.ophtha.2006.03.027
   Lee HJ, 2010, J BIOL CHEM, V285, P9262, DOI 10.1074/jbc.M109.081125
   Lee NY, 2017, CURR EYE RES, V42, P1002, DOI 10.1080/02713683.2016.1276193
   Lee NY, 2012, CURR EYE RES, V37, P1121, DOI 10.3109/02713683.2012.725798
   Lee SJ, 2000, J IMMUNOL, V164, P1277, DOI 10.4049/jimmunol.164.3.1277
   Lee SY, 2011, J CELL PHYSIOL, V226, P1843, DOI 10.1002/jcp.22508
   Li YZ, 2010, J ALZHEIMERS DIS, V19, P1205, DOI 10.3233/JAD-2010-1314
   Li YZ, 2009, P NATL ACAD SCI USA, V106, P1285, DOI 10.1073/pnas.0806720106
   Liao SM, 2017, MOL VIS, V23, P318
   Liddelow SA, 2017, NATURE, V541, P481, DOI 10.1038/nature21029
   Little K, 2020, J NEUROINFLAMM, V17, DOI 10.1186/s12974-020-02033-7
   Liu BQ, 2009, AM J PATHOL, V175, P2099, DOI 10.2353/ajpath.2009.090159
   Liu W, 2015, NEUROSCIENCE, V303, P42, DOI 10.1016/j.neuroscience.2015.06.054
   Liu ZY, 2019, CELL, V178, P1509, DOI 10.1016/j.cell.2019.08.009
   London A, 2013, NAT REV NEUROL, V9, P44, DOI 10.1038/nrneurol.2012.227
   Lund H, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-07295-7
   Madeira MH, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-20733-2
   Maleki AF, 2019, FRONT CELL NEUROSCI, V13, DOI 10.3389/fncel.2019.00355
   Mammadova N, 2019, NEUROBIOL DIS, V121, P1, DOI 10.1016/j.nbd.2018.09.013
   Margeta MA, 2018, GRAEF ARCH CLIN EXP, V256, P2449, DOI 10.1007/s00417-018-4081-y
   Marina N, 2018, GLIA, V66, P1185, DOI 10.1002/glia.23283
   Markiewicz L, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/812503
   Marso SP, 2016, NEW ENGL J MED, V375, P311, DOI 10.1056/NEJMoa1603827
   Martinez Fernando O, 2014, F1000Prime Rep, V6, P13, DOI 10.12703/P6-13
   Martinez-Navarrete GC, 2007, MOL VIS, V13, P949
   Marziani E, 2013, INVEST OPHTH VIS SCI, V54, P5953, DOI 10.1167/iovs.13-12046
   Masland RH, 2001, NAT NEUROSCI, V4, P877, DOI 10.1038/nn0901-877
   McClean PL, 2011, J NEUROSCI, V31, P6587, DOI 10.1523/JNEUROSCI.0529-11.2011
   McGovern SFJ, 2012, BRAIN RES, V1473, P204, DOI 10.1016/j.brainres.2012.07.029
   McKhann GM, 2011, ALZHEIMERS DEMENT, V7, P263, DOI 10.1016/j.jalz.2011.03.005
   Miao HS, 2018, J NEUROPHYSIOL, V120, P1307, DOI 10.1152/jn.00234.2018
   Mills CD, 2000, J IMMUNOL, V164, P6166, DOI 10.4049/jimmunol.164.12.6166
   Morris DR, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21103541
   Morris JC, 2014, J INTERN MED, V275, P204, DOI 10.1111/joim.12199
   Moschos MM, 2011, EUR J OPHTHALMOL, V21, P24, DOI 10.5301/EJO.2010.1318
   Nadal-Nicolas FM, 2020, ELIFE, V9, DOI 10.7554/eLife.56840
   Nahrendorf M, 2016, CIRC RES, V119, P414, DOI 10.1161/CIRCRESAHA.116.309194
   Nakamura R, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8847
   Nakazawa T, 2006, J NEUROSCI, V26, P12633, DOI 10.1523/JNEUROSCI.2801-06.2006
   Nanda S, 2004, EXPERT OPIN PHARMACO, V5, P1175, DOI 10.1517/eoph.5.5.1175.31081
   NATHANS J, 1986, SCIENCE, V232, P193, DOI 10.1126/science.2937147
   Neufeld AH, 1999, ARCH OPHTHALMOL-CHIC, V117, P1050
   Newman E, 1996, TRENDS NEUROSCI, V19, P307, DOI 10.1016/0166-2236(96)10040-0
   Nilson AN, 2017, J ALZHEIMERS DIS, V55, P1083, DOI 10.3233/JAD-160912
   Nimmerjahn A, 2005, SCIENCE, V308, P1314, DOI 10.1126/science.1110647
   Ning A, 2008, INVEST OPHTH VIS SCI, V49, P5136, DOI 10.1167/iovs.08-1849
   Norris GT, 2018, J EXP MED, V215, P1789, DOI 10.1084/jem.20172244
   Nussbaum RL, 2003, NEW ENGL J MED, V348, P1356, DOI 10.1056/NEJM2003ra020003
   O'Koren EG, 2019, IMMUNITY, V50, P723, DOI 10.1016/j.immuni.2019.02.007
   Oikawa K, 2020, MOL NEUROBIOL, V57, P2620, DOI 10.1007/s12035-020-01910-9
   Okunuki Y, 2019, P NATL ACAD SCI USA, V116, P9989, DOI 10.1073/pnas.1820387116
   Okunuki Y, 2018, P NATL ACAD SCI USA, V115, pE6264, DOI 10.1073/pnas.1719601115
   Orr CF, 2002, PROG NEUROBIOL, V68, P325, DOI 10.1016/S0301-0082(02)00127-2
   Paraskevaidi M, 2020, J CLIN MED, V9, DOI 10.3390/jcm9061673
   Parisi V, 2001, CLIN NEUROPHYSIOL, V112, P1860, DOI 10.1016/S1388-2457(01)00620-4
   Park JS, 2021, ACTA NEUROPATHOL COM, V9, DOI 10.1186/s40478-021-01180-z
   Parkhurst CN, 2013, CELL, V155, P1596, DOI 10.1016/j.cell.2013.11.030
   Paschalis EI, 2018, AM J PATHOL, V188, P1580, DOI 10.1016/j.ajpath.2018.03.005
   Peng C, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00004
   Perdiguero EG, 2015, NATURE, V518, P547, DOI 10.1038/nature13989
   Perez SE, 2009, INVEST OPHTH VIS SCI, V50, P793, DOI 10.1167/iovs.08-2384
   Perry T, 2003, J NEUROSCI RES, V72, P603, DOI 10.1002/jnr.10611
   Pinero DP, 2016, CAN J OPHTHALMOL, V51, pE16, DOI 10.1016/j.jcjo.2015.09.009
   Polo V, 2017, EYE, V31, P1034, DOI 10.1038/eye.2017.23
   Polo V, 2014, EYE, V28, P680, DOI 10.1038/eye.2014.51
   Porter DW, 2010, DIABETES OBES METAB, V12, P891, DOI 10.1111/j.1463-1326.2010.01259.x
   Potts JE, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0126769
   Quigley HA, 2011, LANCET, V377, P1367, DOI 10.1016/S0140-6736(10)61423-7
   Ramiro S, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008886.pub2
   Ransohoff RM, 2016, NAT NEUROSCI, V19, P987, DOI 10.1038/nn.4338
   Rathnasamy G, 2019, PROG NEUROBIOL, V173, P18, DOI 10.1016/j.pneurobio.2018.05.006
   Reinehr S, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.01381
   Reiner DJ, 2016, J NEUROSCI, V36, P3531, DOI 10.1523/JNEUROSCI.3579-15.2016
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Robbins CB, 2021, JAMA OPHTHALMOL, V139, P182, DOI 10.1001/jamaophthalmol.2020.5730
   Roh M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040065
   Rojas B, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-133
   Rothova A, 1996, BRIT J OPHTHALMOL, V80, P332, DOI 10.1136/bjo.80.4.332
   Rutar M, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-221
   SADUN AA, 1987, AM J OPHTHALMOL, V104, P113, DOI 10.1016/0002-9394(87)90001-8
   Sanchez D, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-34577-3
   Sawada H, 2010, INVEST OPHTH VIS SCI, V51, P903, DOI 10.1167/iovs.09-4247
   Schon C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0053547
   Scholz R, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0431-4
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P774, DOI 10.1001/archopht.123.6.774
   Seddon JM, 2004, JAMA-J AM MED ASSOC, V291, P704, DOI 10.1001/jama.291.6.704
   Shan YL, 2019, J NEUROINFLAMM, V16, DOI 10.1186/s12974-019-1638-6
   Sheng JP, 2015, IMMUNITY, V43, P382, DOI 10.1016/j.immuni.2015.07.016
   Silverman SM, 2018, ANNU REV VIS SCI, V4, P45, DOI 10.1146/annurev-vision-091517-034425
   Solmaz V, 2015, EUR J PHARMACOL, V765, P482, DOI 10.1016/j.ejphar.2015.09.024
   Song DL, 2017, MOL VIS, V23, P210
   Spaide RF, 2010, RETINA-J RET VIT DIS, V30, P1441, DOI 10.1097/IAE.0b013e3181ee5ce8
   Stasi K, 2006, INVEST OPHTH VIS SCI, V47, P1024, DOI 10.1167/iovs.05-0830
   Sterling J, 2021, BRIT J OPHTHALMOL, DOI 10.1136/bjophthalmol-2021-319232
   Sterling JK, 2020, CELL REP, V33, DOI 10.1016/j.celrep.2020.108271
   Stevens B, 2007, CELL, V131, P1164, DOI 10.1016/j.cell.2007.10.036
   Tamm ER, 2015, PROG MOL BIOL TRANSL, V134, P301, DOI 10.1016/bs.pmbts.2015.06.007
   Tezel G, 2001, INVEST OPHTH VIS SCI, V42, P1787
   Tham Yih-Chung, 2014, Ophthalmology, V121, P2081, DOI 10.1016/j.ophtha.2014.05.013
   Timper K, 2020, CELL METAB, V31, P1189, DOI 10.1016/j.cmet.2020.05.001
   Tribble J, 2020, MOL BRAIN, V13, DOI 10.1186/s13041-020-00603-7
   Tribble JR, 2021, TRANSL VIS SCI TECHN, V10, DOI 10.1167/tvst.10.1.22
   Valenti DA, 2010, OPTOMETRY, V81, P12, DOI 10.1016/j.optm.2009.04.101
   Vargas JLC, 2015, J NEUROSCI, V35, P12088, DOI 10.1523/JNEUROSCI.1273-15.2015
   Vecino E, 2016, PROG RETIN EYE RES, V51, P1, DOI 10.1016/j.preteyeres.2015.06.003
   Volland S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125631
   Wakselman S, 2008, J NEUROSCI, V28, P8138, DOI 10.1523/JNEUROSCI.1006-08.2008
   Wang N, 2001, NAT MED, V7, P304, DOI 10.1038/85446
   Wang XH, 2010, NEUROSCIENCE, V170, P1239, DOI 10.1016/j.neuroscience.2010.08.028
   Wang X, 2017, J NEUROSCI, V37, P3294, DOI 10.1523/JNEUROSCI.2717-16.2017
   Wang X, 2016, J NEUROSCI, V36, P2827, DOI 10.1523/JNEUROSCI.3575-15.2016
   Wang YM, 2015, CELL, V160, P1061, DOI 10.1016/j.cell.2015.01.049
   Weinhard L, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03566-5
   Weinreb RN, 2014, JAMA-J AM MED ASSOC, V311, P1901, DOI 10.1001/jama.2014.3192
   Werner Y, 2020, NAT NEUROSCI, V23, P351, DOI 10.1038/s41593-020-0585-y
   Wiedemann J, 2018, BIOCHEM BIOPH RES CO, V501, P239, DOI 10.1016/j.bbrc.2018.04.223
   Wieghofer P, 2021, EMBO J, V40, DOI 10.15252/embj.2020105123
   Williams PA, 2019, MOL NEURODEGENER, V14, DOI 10.1186/s13024-018-0303-3
   Williams PA, 2016, MOL NEURODEGENER, V11, DOI 10.1186/s13024-016-0091-6
   Willoughby CE, 2010, CLIN EXP OPHTHALMOL, V38, P2, DOI 10.1111/j.1442-9071.2010.02363.x
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wong Winston, 2020, Am J Manag Care, V26, pS177, DOI 10.37765/ajmc.2020.88482
   Wooff Y, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01618
   Wynn TA, 2013, NATURE, V496, P445, DOI 10.1038/nature12034
   Xu HP, 2003, INVEST OPHTH VIS SCI, V44, P226, DOI 10.1167/iovs.01-1202
   Yan XM, 2000, ARCH OPHTHALMOL-CHIC, V118, P666, DOI 10.1001/archopht.118.5.666
   Yang XJ, 2020, J NEUROINFLAMM, V17, DOI 10.1186/s12974-020-01930-1
   Yoshida N, 2013, OPHTHALMOLOGY, V120, pE5, DOI 10.1016/j.ophtha.2012.07.008
   Yoshida N, 2013, OPHTHALMOLOGY, V120, P100, DOI 10.1016/j.ophtha.2012.07.006
   Yun SP, 2018, NAT MED, V24, P931, DOI 10.1038/s41591-018-0051-5
   Zeng HL, 2018, INT J OPHTHALMOL-CHI, V11, P143, DOI 10.18240/ijo.2018.01.22
   Zhang M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035446
   Zhang QS, 2017, TOXICOL LETT, V265, P30, DOI 10.1016/j.toxlet.2016.11.002
   Zhang S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047038
   Zhao L, 2015, EMBO MOL MED, V7, P1179, DOI 10.15252/emmm.201505298
   Zhao M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125150
   Zhou MW, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102972
   Zor RK, 2020, THER ADV OPHTHALMOL, V12, DOI 10.1177/2515841420951682
NR 268
TC 3
Z9 3
U1 2
U2 13
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1742-464X
EI 1742-4658
J9 FEBS J
JI FEBS J.
PD APR
PY 2022
VL 289
IS 8
SI SI
BP 2337
EP 2361
DI 10.1111/febs.16177
EA SEP 2021
PG 25
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA 0P4TX
UT WOS:000696106800001
PM 34478598
DA 2022-11-30
ER

PT J
AU Huang, PR
   Liu, WJ
   Chen, JQ
   Hu, YF
   Wang, YW
   Sun, JR
   Feng, JY
AF Huang, Peirong
   Liu, Wenjia
   Chen, Jieqiong
   Hu, Yifan
   Wang, Yuwei
   Sun, Junran
   Feng, Jingyang
TI TRIM31 inhibits NLRP3 inflammasome and pyroptosis of retinal pigment
   epithelial cells through ubiquitination of NLRP3
SO CELL BIOLOGY INTERNATIONAL
LA English
DT Article
DE NLRP3; retinal pigment epithelial cells; TRIM31
ID MACULAR DEGENERATION; ACTIVATION; INVASION; RPE
AB NOD-like receptor protein 3 (NLRP3) is associated with age-related macular degeneration (AMD). Retinal pigment epithelial (RPE) cells serve as the immune defense of macula, and their dysfunction causes clinically relevant changes in AMD. In the present study, oxidized low-density lipoprotein (ox-LDL) activated the NLRP3 inflammasome in human RPE cell line ARPE-19. Our data showed that the expression of NLRP3, interleukin-1 beta (IL-1 beta), and caspase-1 and the release of IL-1 beta in ARPE-19 cells were substantially increased by ox-LDL, whereas the addition of NLRP3 inhibitor INF39 dose-dependently reversed the effect of ox-LDL. Overexpression of tripartite motif-containing protein 31 (TRIM31) also suppressed the effect of ox-LDL in ARPE-19 cells. TRIM31 knockdown had similar effects with ox-LDL but INF39 could block the effect of TRIM31 knockdown. Moreover, TRIM31 could interact with NLRP3 in ARPE-19 cells. Overexpression of TRIM31 increased NLRP3 ubiquitination. In conclusion, the results propose that TRIM31 could enhance NLRP3 ubiquitination, therefore inhibiting NLRP3 inflammasome and pyroptosis in human RPE cells.
C1 [Huang, Peirong; Liu, Wenjia; Chen, Jieqiong; Hu, Yifan; Wang, Yuwei; Sun, Junran; Feng, Jingyang] Shanghai Jiao Tong Univ, Sch Med, Shanghai Peoples Hosp 1, Dept Ophthalmol,Shanghai Gen Hosp, 85 Wu Jin Rd, Shanghai 200080, Peoples R China.
   [Huang, Peirong; Liu, Wenjia; Chen, Jieqiong; Hu, Yifan; Wang, Yuwei; Sun, Junran; Feng, Jingyang] Shanghai Engn Ctr Visual Sci & Photomed, Photomed Div, Shanghai, Peoples R China.
   [Huang, Peirong; Liu, Wenjia; Hu, Yifan; Wang, Yuwei; Sun, Junran; Feng, Jingyang] Shanghai Key Lab Fundus Dis, Vitreoretina Div, Shanghai, Peoples R China.
C3 Shanghai Jiao Tong University
RP Feng, JY (通讯作者)，Shanghai Jiao Tong Univ, Sch Med, Shanghai Peoples Hosp 1, Dept Ophthalmol,Shanghai Gen Hosp, 85 Wu Jin Rd, Shanghai 200080, Peoples R China.
EM drfengjy@126.com
OI Feng, Jingyang/0000-0001-6031-7980
FU Bethune-Langmu eye research fund for the young and middle-aged
   ophthalmologist [BJ-LM2018001J]; Natural Science Foundation of China
   [81500732, 81700843]
FX Bethune-Langmu eye research fund for the young and middle-aged
   ophthalmologist, Grant/Award Number: BJ-LM2018001J; Natural Science
   Foundation of China, Grant/Award Number: 81500732 and 81700843
CR Aachoui Y, 2013, CURR OPIN MICROBIOL, V16, P319, DOI 10.1016/j.mib.2013.04.004
   Anand A, 2014, SCI REP-UK, V4, DOI 10.1038/srep04114
   Binder S, 2007, PROG RETIN EYE RES, V26, P516, DOI 10.1016/j.preteyeres.2007.02.002
   Brentnall M, 2013, BMC CELL BIOL, V14, DOI 10.1186/1471-2121-14-32
   Dunaief JL, 2002, ARCH OPHTHALMOL-CHIC, V120, P1435, DOI 10.1001/archopht.120.11.1435
   Gao Jiangyuan, 2015, MEDIAT INFLAMM, V2015, P1
   Grassmann F, 2015, EUR J PHARM BIOPHARM, V95, P194, DOI 10.1016/j.ejpb.2015.04.039
   Guo P, 2018, ONCOGENE, V37, P478, DOI 10.1038/onc.2017.349
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Holz FG, 2017, OPHTHALMOLOGY, V124, P464, DOI 10.1016/j.ophtha.2016.12.002
   Ildefonso CJ, 2016, ADV EXP MED BIOL, V854, P59, DOI 10.1007/978-3-319-17121-0_9
   Javadzadeh A, 2010, MOL VIS, V16, P2578
   Jiang YG, 2012, BIOCHEM BIOPH RES CO, V425, P121, DOI 10.1016/j.bbrc.2012.07.011
   Kaneko H, 2011, NATURE, V471, P325, DOI 10.1038/nature09830
   Li H, 2014, TUMOR BIOL, V35, P5747, DOI 10.1007/s13277-014-1763-x
   Liu BY, 2017, NAT IMMUNOL, V18, P214, DOI 10.1038/ni.3641
   Miao EA, 2011, IMMUNOL REV, V243, P206, DOI 10.1111/j.1600-065X.2011.01044.x
   Ooto S, 2014, JAMA OPHTHALMOL, V132, P806, DOI 10.1001/jamaophthalmol.2014.1871
   Pu ZC, 2019, AM J TRANSL RES, V11, P3992
   Rajamaki K, 2016, ARTERIOSCL THROM VAS, V36, P1937, DOI 10.1161/ATVBAHA.115.307312
   Rhoads JP, 2017, J IMMUNOL, V198, P2105, DOI 10.4049/jimmunol.1601563
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   Shao BZ, 2015, FRONT PHARMACOL, V6, DOI 10.3389/fphar.2015.00262
   Shi G, 2019, NEOPLASMA, V66, P727, DOI 10.4149/neo_2019_190106N21
   Song H, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13727
   Strowig T, 2012, NATURE, V481, P278, DOI 10.1038/nature10759
   Sugiura T, 2011, CELL BIOL INT, V35, P657, DOI 10.1042/CBI20100772
   Tan MS, 2013, MOL NEUROBIOL, V48, P875, DOI 10.1007/s12035-013-8475-x
   Tarallo V, 2012, CELL, V149, P847, DOI 10.1016/j.cell.2012.03.036
   Wang HY, 2018, AM J TRANSL RES, V10, P1247
   Wang L, 2016, ONCOTARGET, V7, P73229, DOI 10.18632/oncotarget.12302
   Yu AL, 2009, EXP EYE RES, V88, P495, DOI 10.1016/j.exer.2008.10.028
   Zanzottera EC, 2015, INVEST OPHTH VIS SCI, V56, P3253, DOI 10.1167/iovs.15-16431
   Zhou L, 2019, ONCOTARGETS THER, V12, P2289, DOI 10.2147/OTT.S183625
NR 34
TC 8
Z9 10
U1 0
U2 10
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1065-6995
EI 1095-8355
J9 CELL BIOL INT
JI Cell Biol. Int.
PD NOV
PY 2020
VL 44
IS 11
BP 2213
EP 2219
DI 10.1002/cbin.11429
EA AUG 2020
PG 7
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA OC2LZ
UT WOS:000555563500001
PM 32716108
DA 2022-11-30
ER

PT J
AU Sulaiman, RS
   Park, B
   Babu, SPSP
   Si, YB
   Kharwadkar, R
   Mitter, SK
   Lee, B
   Sun, W
   Qi, XP
   Boulton, ME
   Merouehli, SO
   Fei, X
   Seo, SY
   Corson, TW
AF Sulaiman, Rania S.
   Park, Bomina
   Babu, Sardar Pasha Sheik Pran
   Si, Yubing
   Kharwadkar, Rakshin
   Mitter, Sayak K.
   Lee, Bit
   Sun, Wei
   Qi, Xiaoping
   Boulton, Michael E.
   Merouehli, Samy O.
   Fei, Xiang
   Seo, Seung-Yong
   Corson, Timothy W.
TI Chemical Proteomics Reveals Soluble Epoxide Hydrolase as a Therapeutic
   Target for Ocular Neovascularization
SO ACS CHEMICAL BIOLOGY
LA English
DT Article
ID FATTY-ACIDS; BIOLOGICAL EVALUATION; LIPID METABOLITES; ANGIOGENESIS;
   INFLAMMATION; OMEGA-3-FATTY-ACIDS; EPOXYEICOSANOIDS; EXPRESSION;
   GENERATION
AB The standard-of-care therapeutics for the, treatment of ocular neovascular diseases like wet age-related macular degeneration (AMD) are biologics targeting vascular endothelial growth factor signaling. There are Currently no FDA approved small molecules for treating these blinding eye diseases. Therefore, therapeutic agents with novel mechanisms are critical to complement or combine with existing approaches. Here, we identified soluble epoxide hydrolase (sEH), a key enzyme for epoxy fatty acid metabolism, as a target of an antiangiogenic homoisoflavonoid, SH-11037. SH-11037 inhibits sEH in vitro and in vivo and docks to the substrate binding cleft in the sEH hydrolase domain. sEH levels and activity are up-regulated in the eyes of a choroidal neovascularization (CNV) mouse model. sEH is overexpressed in human wet AMD eyes, suggesting that sEH is relevant to neovascularization. Known sEH inhibitors delivered intraocularly suppressed CNV. Thus, by dissecting a bioactive compound's mechanism, we identified a new chemotype for sEH inhibition and characterized sEH as a target for blocking the CNV that underlies wet AMD.
C1 [Sulaiman, Rania S.; Park, Bomina; Babu, Sardar Pasha Sheik Pran; Mitter, Sayak K.; Qi, Xiaoping; Boulton, Michael E.; Corson, Timothy W.] Indiana Univ Sch Med, Dept Ophthalmol, Eugene & Marilyn Glick Eye Inst, 1160 West Michigan St, Indianapolis, IN 46202 USA.
   [Sulaiman, Rania S.; Park, Bomina; Corson, Timothy W.] Indiana Univ Sch Med, Dept Pharmacol & Toxicol, 1160 West Michigan St, Indianapolis, IN 46202 USA.
   [Si, Yubing; Kharwadkar, Rakshin; Merouehli, Samy O.; Corson, Timothy W.] Indiana Univ Sch Med, Dept Biochem & Mol Biol, 1160 West Michigan St, Indianapolis, IN 46202 USA.
   [Merouehli, Samy O.; Corson, Timothy W.] Indiana Univ Sch Med, Melvin & Bren Simon Canc Ctr, 1160 West Michigan St, Indianapolis, IN 46202 USA.
   [Sulaiman, Rania S.] Cairo Univ, Dept Biochem, Fac Pharm, Cairo 11562, Egypt.
   [Lee, Bit; Sun, Wei; Fei, Xiang; Seo, Seung-Yong] Gachon Univ, Coll Pharm, 191 Hambakoero, Incheon 21936, South Korea.
   [Mitter, Sayak K.; Qi, Xiaoping; Boulton, Michael E.] Univ Alabama Birmingham, Dept Ophthalmol, Birmingham, AL 35294 USA.
C3 Indiana University System; Indiana University Bloomington; Indiana
   University System; Indiana University Bloomington; Indiana University
   System; Indiana University Bloomington; Indiana University System;
   Indiana University Bloomington; Egyptian Knowledge Bank (EKB); Cairo
   University; Gachon University; University of Alabama System; University
   of Alabama Birmingham
RP Corson, TW (通讯作者)，Indiana Univ Sch Med, Dept Ophthalmol, Eugene & Marilyn Glick Eye Inst, 1160 West Michigan St, Indianapolis, IN 46202 USA.; Corson, TW (通讯作者)，Indiana Univ Sch Med, Dept Pharmacol & Toxicol, 1160 West Michigan St, Indianapolis, IN 46202 USA.; Corson, TW (通讯作者)，Indiana Univ Sch Med, Dept Biochem & Mol Biol, 1160 West Michigan St, Indianapolis, IN 46202 USA.; Corson, TW (通讯作者)，Indiana Univ Sch Med, Melvin & Bren Simon Canc Ctr, 1160 West Michigan St, Indianapolis, IN 46202 USA.; Seo, SY (通讯作者)，Gachon Univ, Coll Pharm, 191 Hambakoero, Incheon 21936, South Korea.
EM syseo@gachon.ac.kr; tcorson@iu.edu
RI PASHA, PRAN BABU SARDAR/AAS-7266-2020; Corson, Timothy W./B-6851-2009;
   Pasha, Pran Babu Sardar/AAH-8388-2019; Fei, Xiang/Z-1378-2019
OI PASHA, PRAN BABU SARDAR/0000-0001-8974-7562; Corson, Timothy
   W./0000-0002-1402-7875; Fei, Xiang/0000-0001-9637-1989; Kharwadkar,
   Rakshin/0000-0002-6303-1651
FU NIH/NCRR [S10RR027926]; International Retinal Research Foundation;
   Retina Research Foundation; BrightFocus Foundation; NIH/NEI
   [R01EY025641]; Research to Prevent Blindness, Inc.; Bio & Medical
   Technology Development Program of the National Research Foundation -
   Korean government, MSIP [NRF-2017M3A9C8027781]; Korea Health Technology
   R&D Project through the Korea Health Industry Development Institute
   [KHIDI-HI14C113.5]; NIH/NCATS [UL1TR001108, KL2TR001106]; 
   [R01EY018358]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES
   [KL2TR001106, UL1TR001108] Funding Source: NIH RePORTER; NATIONAL CENTER
   FOR RESEARCH RESOURCES [S10RR027926] Funding Source: NIH RePORTER;
   NATIONAL EYE INSTITUTE [R01EY025641, R01EY018358] Funding Source: NIH
   RePORTER
FX We thank M. Sturek for the porcine brain, and K. Maddipati at the Wayne
   State University Lipidomics Core, supported in part by NIH/NCRR
   S10RR027926. T.W.C. acknowledges support from the International Retinal
   Research Foundation, the Retina Research Foundation, the BrightFocus
   Foundation, NIH/NEI R01EY025641, and an unrestricted grant from Research
   to Prevent Blindness, Inc. S.-Y.S. was supported by the Bio & Medical
   Technology Development Program of the National Research Foundation
   funded by the Korean government, MSIP (NRF-2017M3A9C8027781) and the
   Korea Health Technology R&D Project through the Korea Health Industry
   Development Institute (KHIDI-HI14C113.5). This publication was also made
   possible in part by R01EY018358 (M.E.B.), NIH/NCATS UL1TR001108 and
   KL2TR001106.
CR Arterburn LM, 2006, AM J CLIN NUTR, V83, p1467S, DOI 10.1093/ajcn/83.6.1467S
   Basavarajappa HD, 2015, J MED CHEM, V58, P5015, DOI 10.1021/acs.jmedchem.5b00449
   BORHAN B, 1995, J BIOL CHEM, V270, P26923, DOI 10.1074/jbc.270.45.26923
   Connor KM, 2007, NAT MED, V13, P868, DOI 10.1038/nm1591
   Das A, 2003, PROG RETIN EYE RES, V22, P721, DOI 10.1016/j.preteyeres.2003.08.001
   Falavarjani KG, 2013, EYE, V27, P787, DOI 10.1038/eye.2013.107
   Fromel T, 2012, P NATL ACAD SCI USA, V109, P9995, DOI 10.1073/pnas.1206493109
   Gong Y, 2016, EBIOMEDICINE, V13, P201, DOI 10.1016/j.ebiom.2016.09.025
   Gong Y, 2016, ARTERIOSCL THROM VAS, V36, P1919, DOI 10.1161/ATVBAHA.116.307558
   Grossniklaus HE, 2010, PROG RETIN EYE RES, V29, P500, DOI 10.1016/j.preteyeres.2010.05.003
   Harris TR, 2013, GENE, V526, P61, DOI 10.1016/j.gene.2013.05.008
   Hasegawa E, 2017, P NATL ACAD SCI USA, V114, pE7545, DOI 10.1073/pnas.1620898114
   Hu J, 2014, J EXP MED, V211, P281, DOI 10.1084/jem.20131494
   Lazaar AL, 2016, BRIT J CLIN PHARMACO, V81, P971, DOI 10.1111/bcp.12855
   Lee B, 2016, BIOORG MED CHEM LETT, V26, P4277, DOI 10.1016/j.bmcl.2016.07.043
   Lux A, 2007, BRIT J OPHTHALMOL, V91, P1318, DOI 10.1136/bjo.2006.113902
   Merle BMJ, 2014, INVEST OPHTH VIS SCI, V55, P2010, DOI 10.1167/iovs.14-13916
   Moghaddam-Taaheri S., 2011, J CLIN EXP OPHTHALMO, V2, P187, DOI DOI 10.4172/2155-9570.1000187
   Morisseau C, 2013, ANNU REV PHARMACOL, V53, P37, DOI 10.1146/annurev-pharmtox-011112-140244
   Thao NP, 2016, BIOORGAN MED CHEM, V24, P3125, DOI 10.1016/j.bmc.2016.05.034
   Norwood S, 2010, AM J TRANSL RES, V2, P447
   Panigrahy D, 2012, J CLIN INVEST, V122, P178, DOI 10.1172/JCI58128
   Prasad PS, 2010, MATURITAS, V66, P46, DOI 10.1016/j.maturitas.2010.02.006
   Shao Z, 2014, ARTERIOSCL THROM VAS, V34, P581, DOI 10.1161/ATVBAHA.113.302927
   Shen HC, 2012, J MED CHEM, V55, P1789, DOI 10.1021/jm201468j
   Shen HC, 2009, BIOORG MED CHEM LETT, V19, P5716, DOI 10.1016/j.bmcl.2009.08.006
   Souied EH, 2013, OPHTHALMOLOGY, V120, P1619, DOI 10.1016/j.ophtha.2013.01.005
   Stahl A, 2010, CIRC RES, V107, P495, DOI 10.1161/CIRCRESAHA.110.221317
   Sulaiman RS, 2016, SCI REP-UK, V6, DOI 10.1038/srep25509
   Sura P, 2008, J HISTOCHEM CYTOCHEM, V56, P551, DOI 10.1369/jhc.2008.950659
   Wang WC, 2014, PROSTAG OTH LIPID M, V113, P13, DOI 10.1016/j.prostaglandins.2014.07.002
   Yanai R, 2014, P NATL ACAD SCI USA, V111, P9603, DOI 10.1073/pnas.1401191111
   Zhang GD, 2014, PROG LIPID RES, V53, P108, DOI 10.1016/j.plipres.2013.11.003
NR 33
TC 17
Z9 17
U1 1
U2 27
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1554-8929
EI 1554-8937
J9 ACS CHEM BIOL
JI ACS Chem. Biol.
PD JAN
PY 2018
VL 13
IS 1
BP 45
EP 52
DI 10.1021/acschembio.7b00854
PG 8
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA FT6GN
UT WOS:000423252600004
PM 29193961
OA Green Submitted, Green Accepted
DA 2022-11-30
ER

PT J
AU Hodge, R
   Narayanavari, SA
   Izsvak, Z
   Ivics, Z
AF Hodge, Russ
   Narayanavari, Suneel A.
   Izsvak, Zsuzsanna
   Ivics, Zoltan
TI Wide Awake and Ready to Move: 20 Years of Non-Viral Therapeutic Genome
   Engineering with the Sleeping Beauty Transposon System
SO HUMAN GENE THERAPY
LA English
DT Review
DE gene therapy vectors; chimeric antigen receptor; stable gene transfer;
   non-viral gene delivery; transposon/virus hybrid vectors; cell-specific
   targeting
ID STABLE GENE-TRANSFER; RETINAL-PIGMENT EPITHELIUM; LONG-TERM EXPRESSION;
   DNA-BINDING DOMAIN; CAR-T CELLS; MACULAR DEGENERATION; GERMLINE
   TRANSGENESIS; PHENOTYPIC CORRECTION; PIGGYBAC TRANSPOSONS; STEM-CELLS
AB Gene therapies will only become a widespread tool in the clinical treatment of human diseases with the advent of gene transfer vectors that integrate genetic information stably, safely, effectively, and economically. Two decades after the discovery of the Sleeping Beauty (SB) transposon, it has been transformed into a vector system that is fulfilling these requirements. SB may well overcome some of the limitations associated with viral gene transfer vectors and transient non-viral gene delivery approaches that are being used in the majority of ongoing clinical trials. The SB system has achieved a high level of stable gene transfer and sustained transgene expression in multiple primary human somatic cell types, representing crucial steps that may permit its clinical use in the near future. This article reviews the most important aspects of SB as a tool for gene therapy, including aspects of its vectorization and genomic integration. As an illustration, the clinical development of the SB system toward gene therapy of age-related macular degeneration and cancer immunotherapy is highlighted.
C1 [Hodge, Russ; Narayanavari, Suneel A.; Izsvak, Zsuzsanna] Helmholtz Assoc MDC, Max Delbruck Ctr Mol Med, Berlin, Germany.
   [Ivics, Zoltan] Paul Ehrlich Inst, Div Med Biotechnol, Langen, Germany.
C3 Helmholtz Association; Max Delbruck Center for Molecular Medicine; Paul
   Ehrlich Institute
RP Ivics, Z (通讯作者)，Paul Ehrlich Inst, Paul Ehrlich Str 51-59, D-63225 Langen, Germany.
EM zoltan.ivics@pei.de
RI Narayanavari, Suneel A./I-8063-2019
OI Narayanavari, Suneel A./0000-0002-6997-4829
FU European Union's Seventh Framework Programme for research, technological
   development, and demonstration [305134]; Deutsche Forschungsgemeinschaft
   (DFG) [IV 21/11-1, IV 21/13-1]; Center for Cell and Gene Therapy of
   LOEWE (Landes-Offensive zur Entwicklung Wissenschaftlich-okonomischer
   Exzellenz) program in Hessen, Germany
FX The TargetAMD project has received funding from the European Union's
   Seventh Framework Programme for research, technological development, and
   demonstration under grant agreement no 305134. Z. Ivics. has been funded
   by the Deutsche Forschungsgemeinschaft (DFG) under grants IV 21/11-1 and
   IV 21/13-1, and has been supported by the Center for Cell and Gene
   Therapy of the LOEWE (Landes-Offensive zur Entwicklung
   Wissenschaftlich-okonomischer Exzellenz) program in Hessen, Germany. We
   thank M. Kropp for the image presented in Fig. 3.
CR Abrusan G, 2016, MOL THER, V24, P1369, DOI 10.1038/mt.2016.110
   Aisenbrey S, 2006, ARCH OPHTHALMOL-CHIC, V124, P183, DOI 10.1001/archopht.124.2.183
   Aronovich EL, 2007, J GENE MED, V9, P403, DOI 10.1002/jgm.1028
   Aronovich EL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078161
   Aronovich EL, 2009, MOL THER, V17, P1136, DOI 10.1038/mt.2009.87
   Belay E, 2010, STEM CELLS, V28, P1760, DOI 10.1002/stem.501
   Belcher JD, 2010, J MOL MED, V88, P665, DOI 10.1007/s00109-010-0613-6
   Belur LR, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-14
   Belur LR, 2003, MOL THER, V8, P501, DOI 10.1016/S1525-0016(03)00211-9
   Bevacqua RJ, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0174025
   Binder S, 2004, INVEST OPHTH VIS SCI, V45, P4151, DOI 10.1167/iovs.04-0118
   Boehme P, 2016, MOL THER-NUCL ACIDS, V5, DOI 10.1038/mtna.2016.44
   Boehme P, 2015, CURR GENE THER, V15, P255, DOI 10.2174/1566523215666150126121353
   Boulanger-Scemama E, 2015, J FR OPHTALMOL, V38, P620, DOI 10.1016/j.jfo.2014.11.015
   Bowers WJ, 2006, MOL THER, V13, P580, DOI 10.1016/j.ymthe.2005.11.011
   Chabot S, 2013, GENE THER, V20, P62, DOI 10.1038/gt.2011.215
   Chen ZYJ, 2005, BIOCHEM BIOPH RES CO, V329, P646, DOI 10.1016/j.bbrc.2005.02.024
   Cooney AL, 2015, MOL THER, V23, P667, DOI 10.1038/mt.2014.254
   Cui ZB, 2002, J MOL BIOL, V318, P1221, DOI 10.1016/S0022-2836(02)00237-1
   Darquet AM, 1997, GENE THER, V4, P1341, DOI 10.1038/sj.gt.3300540
   Davila ML, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3008226
   de Silva S, 2010, GENE THER, V17, P424, DOI 10.1038/gt.2009.144
   Deniger DC, 2016, MOL THER, V24, P1078, DOI 10.1038/mt.2016.51
   Di Matteo M, 2014, MOL THER, V22, P1614, DOI 10.1038/mt.2014.131
   Doudna JA, 2014, SCIENCE, V346, P1077, DOI 10.1126/science.1258096
   Escobar H, 2016, MOL THER-NUCL ACIDS, V5, DOI 10.1038/mtna.2015.52
   Essner JJ, 2005, CURR OPIN PHARMACOL, V5, P513, DOI 10.1016/j.coph.2005.04.015
   Eyjolfsdottir H, 2016, ALZHEIMERS RES THER, V8, DOI 10.1186/s13195-016-0195-9
   Falkner-Radler CI, 2011, BRIT J OPHTHALMOL, V95, P370, DOI 10.1136/bjo.2009.176305
   Fernando S, 2006, BIODRUGS, V20, P219, DOI 10.2165/00063030-200620040-00003
   FRASER MJ, 1985, VIROLOGY, V145, P356, DOI 10.1016/0042-6822(85)90172-2
   Fung H, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020514
   Garrels W, 2016, SCI REP-UK, V6, DOI 10.1038/srep21953
   Geurts AM, 2003, MOL THER, V8, P108, DOI 10.1016/S1525-0016(03)00099-6
   Gogol-Doring A, 2016, MOL THER, V24, P592, DOI 10.1038/mt.2016.11
   Grossniklaus HE, 2010, PROG RETIN EYE RES, V29, P500, DOI 10.1016/j.preteyeres.2010.05.003
   Hackett PB, 2005, ADV GENET, V54, P189, DOI 10.1016/S0065-2660(05)54009-4
   Hackett PB, 2010, MOL THER, V18, P674, DOI 10.1038/mt.2010.2
   Hackett PB, 2011, CURR GENE THER, V11, P341
   Hartman ZC, 2008, VIRUS RES, V132, P1, DOI 10.1016/j.virusres.2007.10.005
   Hausl MA, 2010, MOL THER, V18, P1896, DOI 10.1038/mt.2010.169
   He CX, 2004, WORLD J GASTROENTERO, V10, P567, DOI 10.3748/wjg.v10/i4/567
   Henssen AG, 2015, ELIFE, V4, DOI 10.7554/eLife.10565
   Hockemeyer D, 2011, NAT BIOTECHNOL, V29, P731, DOI 10.1038/nbt.1927
   Hockemeyer D, 2009, NAT BIOTECHNOL, V27, P851, DOI 10.1038/nbt.1562
   Hollis RP, 2006, EXP HEMATOL, V34, P1333, DOI 10.1016/j.exphem.2006.05.023
   Hsu PD, 2014, CELL, V157, P1262, DOI 10.1016/j.cell.2014.05.010
   Huang X, 2008, MOL THER, V16, P580, DOI 10.1038/sj.mt.6300404
   Huang X, 2010, MOL THER, V18, P1803, DOI 10.1038/mt.2010.141
   Hudecek M, 2017, CRIT REV BIOCHEM MOL, V52, P355, DOI 10.1080/10409238.2017.1304354
   Hudecek M, 2015, CANCER IMMUNOL RES, V3, P125, DOI 10.1158/2326-6066.CIR-14-0127
   Hurton LV, 2016, P NATL ACAD SCI USA, V113, pE7788, DOI 10.1073/pnas.1610544113
   Hyland KA, 2011, J GENE MED, V13, P462, DOI 10.1002/jgm.1589
   Ivics Z, 1997, CELL, V91, P501, DOI 10.1016/S0092-8674(00)80436-5
   Ivics Z, 2007, MOL THER, V15, P1137, DOI 10.1038/sj.mt.6300169
   Ivics Z, 2006, CURR GENE THER, V6, P593, DOI 10.2174/156652306778520647
   Ivics Z, 2016, MOL THER, V24, P851, DOI 10.1038/mt.2016.76
   Ivics Z, 2014, NAT PROTOC, V9, P810, DOI 10.1038/nprot.2014.010
   Ivics Z, 2014, NAT PROTOC, V9, P794, DOI 10.1038/nprot.2014.009
   Ivics Z, 2014, NAT PROTOC, V9, P773, DOI 10.1038/nprot.2014.008
   Ivics Z, 2011, HUM GENE THER, V22, P1043, DOI 10.1089/hum.2011.143
   Ivics Z, 2010, MOBILE DNA-UK, V1, DOI 10.1186/1759-8753-1-25
   Ivics Z, 2009, NAT METHODS, V6, P415, DOI [10.1038/NMETH.1332, 10.1038/nmeth.1332]
   Izsvak Z, 2000, J MOL BIOL, V302, P93, DOI 10.1006/jmbi.2000.4047
   Izsvak Z, 2004, MOL THER, V9, P147, DOI 10.1016/j.ymthe.2003.11.009
   Izsvak Z, 2002, J BIOL CHEM, V277, P34581, DOI 10.1074/jbc.M204001200
   Izsvak Z, 2010, BIOESSAYS, V32, P756, DOI 10.1002/bies.201000027
   Izsvak Z, 2009, METHODS, V49, P287, DOI 10.1016/j.ymeth.2009.07.001
   Jin Z, 2011, GENE THER, V18, P849, DOI 10.1038/gt.2011.40
   Johnen S, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/863845
   Johnen S, 2012, INVEST OPHTH VIS SCI, V53, P4787, DOI 10.1167/iovs.12-9951
   Katter K, 2013, FASEB J, V27, P930, DOI 10.1096/fj.12-205526
   Kebriaei P, 2016, J CLIN INVEST, V126, P3363, DOI 10.1172/JCI86721
   Kochenderfer JN, 2015, J CLIN ONCOL, V33, P540, DOI 10.1200/JCO.2014.56.2025
   Kova A., 2017, CELL GENE THER INSIG, V3, P103, DOI [10.18609/cgti.2017.013, DOI 10.18609/CGTI.2017.013]
   Kren BT, 2009, J CLIN INVEST, V119, P2086, DOI 10.1172/JCI34332
   Lad EM, 2014, AM J OPHTHALMOL, V158, P537, DOI 10.1016/j.ajo.2014.05.014
   Lappas A, 2004, GRAEF ARCH CLIN EXP, V242, P638, DOI 10.1007/s00417-003-0764-z
   Latella MC, 2017, J INVEST DERMATOL, V137, P836, DOI 10.1016/j.jid.2016.11.038
   Lee DW, 2015, LANCET, V385, P517, DOI 10.1016/S0140-6736(14)61403-3
   Liu L, 2004, MOL THER, V10, P97, DOI 10.1016/j.ymthe.2004.04.006
   Liu L, 2006, FASEB J, V20, P2594, DOI 10.1096/fj.06-6254fje
   Liu L, 2006, MOL THER, V13, P1006, DOI 10.1016/j.ymthe.2005.11.021
   Loperfido M, 2016, NUCLEIC ACIDS RES, V44, P744, DOI 10.1093/nar/gkv1464
   Luo WY, 2012, GENE THER, V19, P844, DOI 10.1038/gt.2011.129
   Magnani CF, 2016, ONCOTARGET, V7, P51581, DOI 10.18632/oncotarget.9955
   Manuri PVR, 2010, HUM GENE THER, V21, P427, DOI 10.1089/hum.2009.114
   Marie C, 2010, J GENE MED, V12, P323, DOI 10.1002/jgm.1441
   Mates L, 2009, NAT GENET, V41, P753, DOI 10.1038/ng.343
   Maude SL, 2014, NEW ENGL J MED, V371, P1507, DOI 10.1056/NEJMoa1407222
   Moldt B, 2007, HUM GENE THER, V18, P1193, DOI 10.1089/hum.2007.099
   Moldt B, 2011, MOL THER, V19, P1499, DOI 10.1038/mt.2011.47
   Monjezi R, 2017, LEUKEMIA, V31, P186, DOI 10.1038/leu.2016.180
   Montini E, 2002, MOL THER, V6, P759, DOI 10.1006/mthe.2002.0812
   Muses S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024826
   Naldini L, 2011, NAT REV GENET, V12, P301, DOI 10.1038/nrg2985
   Narayanavari SA, 2017, CELL GENE THER INSIG, V3, P131
   Narayanavari SA, 2017, CRIT REV BIOCHEM MOL, V52, P18, DOI 10.1080/10409238.2016.1237935
   Nesmith BLW, 2014, RETINA-J RET VIT DIS, V34, P2423, DOI 10.1097/IAE.0000000000000247
   Ohlfest JR, 2005, MOL THER, V12, P778, DOI 10.1016/j.ymthe.2005.07.689
   Ohlfest JR, 2005, BLOOD, V105, P2691, DOI 10.1182/blood-2004-09-3496
   Ohno-Matsui K, 2001, J CELL PHYSIOL, V189, P323, DOI 10.1002/jcp.10026
   Orban TI, 2009, STEM CELLS, V27, P1077, DOI 10.1002/stem.45
   Ortiz-Urda S, 2003, GENE THER, V10, P1099, DOI 10.1038/sj.gt.3301978
   Ousterout DG, 2016, METHODS MOL BIOL, V1338, P27, DOI 10.1007/978-1-4939-2932-0_3
   Pan XJ, 2012, J INT MED RES, V40, P1850, DOI 10.1177/030006051204000523
   Papapetrou EP, 2011, NAT BIOTECHNOL, V29, P73, DOI 10.1038/nbt.1717
   Peng PD, 2009, GENE THER, V16, P1042, DOI 10.1038/gt.2009.54
   Ren JQ, 2016, BLOOD, V128, P2194, DOI 10.1182/blood-2016-09-736983
   Richter M, 2016, BLOOD, V128, P2206, DOI 10.1182/blood-2016-04-711580
   Sadelain M, 2013, CANCER DISCOV, V3, P388, DOI 10.1158/2159-8290.CD-12-0548
   Sadelain M, 2012, NAT REV CANCER, V12, P51, DOI 10.1038/nrc3179
   Saha S, 2012, JOVE-J VIS EXP, DOI 10.3791/4235
   Saint-Geniez M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003554
   Scott AW, 2013, CURR OPIN OPHTHALMOL, V24, P190, DOI 10.1097/ICU.0b013e32835fefee
   Sharma N, 2013, MOL THER-NUCL ACIDS, V2, DOI 10.1038/mtna.2013.1
   Singh H, 2008, CANCER RES, V68, P2961, DOI 10.1158/0008-5472.CAN-07-5600
   Singh H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064138
   Sjeklocha LM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080403
   Sommermeyer D, 2016, LEUKEMIA, V30, P492, DOI 10.1038/leu.2015.247
   Song JS, 2009, BIOSCI BIOTECH BIOCH, V73, P165, DOI 10.1271/bbb.80581
   Srivastava S, 2015, TRENDS IMMUNOL, V36, P494, DOI 10.1016/j.it.2015.06.004
   Staunstrup NH, 2009, MOL THER, V17, P1205, DOI 10.1038/mt.2009.10
   Sumiyoshi T, 2009, HUM GENE THER, V20, P1607, DOI 10.1089/hum.2009.109
   Thumann G, 2017, MOL THER-NUCL ACIDS, V6, P302, DOI 10.1016/j.omtn.2017.02.002
   Turtle CJ, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aaf8621
   Turtle CJ, 2016, EXPERT REV HEMATOL, V9, P719, DOI 10.1080/17474086.2016.1203251
   Turtle CJ, 2016, J CLIN INVEST, V126, P2123, DOI 10.1172/JCI85309
   Turunen TAK, 2014, J GENE MED, V16, P40, DOI 10.1002/jgm.2756
   Turuneni TAK, 2016, MOL THER, V24, P620, DOI 10.1038/mt.2015.221
   Urnov FD, 2010, NAT REV GENET, V11, P636, DOI 10.1038/nrg2842
   VandenDriessche T, 2009, BLOOD, V114, P1461, DOI 10.1182/blood-2009-04-210427
   Velez-Montoya R, 2014, RETINA-J RET VIT DIS, V34, P423, DOI 10.1097/IAE.0000000000000036
   Verhenne S, 2017, ARTERIOSCL THROM VAS, V37, P836, DOI 10.1161/ATVBAHA.116.308680
   Vink CA, 2009, MOL THER, V17, P1197, DOI 10.1038/mt.2009.94
   Voigt F, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11126
   Walisko O, 2006, P NATL ACAD SCI USA, V103, P4062, DOI 10.1073/pnas.0507683103
   Walisko O, 2008, MOL THER, V16, P359, DOI 10.1038/sj.mt.6300366
   Wang X, 2009, HEPATOLOGY, V50, P815, DOI 10.1002/hep.23060
   Wang YM, 2017, NUCLEIC ACIDS RES, V45, P311, DOI 10.1093/nar/gkw1164
   Wiehe JM, 2007, J CELL MOL MED, V11, P521, DOI 10.1111/j.1582-4934.2007.00038.x
   Wilber A, 2006, MOL THER, V13, P625, DOI 10.1016/j.ymthe.2005.10.014
   Wilber A, 2007, MOL THER, V15, P1280, DOI 10.1038/sj.mt.6300160
   Xiao J, 2012, MOL THER, V20, P1251, DOI 10.1038/mt.2012.36
   Xue XK, 2009, BLOOD, V114, P1319, DOI 10.1182/blood-2009-03-210005
   Yant SR, 2002, NAT BIOTECHNOL, V20, P999, DOI 10.1038/nbt738
   Yant SR, 2004, MOL CELL BIOL, V24, P9239, DOI 10.1128/MCB.24.20.9239-9247.2004
   Yant SR, 2000, NAT GENET, V25, P35, DOI 10.1038/75568
   Zayed H, 2004, MOL THER, V9, P292, DOI 10.1016/j.ymthe.2003.11.024
   Zayed H, 2007, MOL THER, V15, P1273, DOI 10.1038/sj.mt.6300178
   Zhang WL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076771
   Zhu JH, 2007, BIOCHEMISTRY-US, V46, P6844, DOI 10.1021/bi6024484
   Zou JZ, 2009, CELL STEM CELL, V5, P97, DOI 10.1016/j.stem.2009.05.023
NR 153
TC 11
Z9 11
U1 0
U2 25
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1043-0342
EI 1557-7422
J9 HUM GENE THER
JI Hum. Gene Ther.
PD OCT
PY 2017
VL 28
IS 10
SI SI
BP 842
EP 855
DI 10.1089/hum.2017.130
PN 1
PG 14
WC Biotechnology & Applied Microbiology; Genetics & Heredity; Medicine,
   Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Genetics & Heredity; Research &
   Experimental Medicine
GA FI3DA
UT WOS:000411835800006
PM 28870121
OA Green Accepted
DA 2022-11-30
ER

PT J
AU He, J
   Long, CD
   Huang, ZX
   Zhou, X
   Kuang, XL
   Liu, LY
   Liu, HJ
   Tang, Y
   Fan, YT
   Ning, J
   Ma, XQ
   Zhang, QJ
   Shen, HX
AF He, Jia
   Long, Chongde
   Huang, Zixin
   Zhou, Xin
   Kuang, Xielan
   Liu, Lanying
   Liu, Huijun
   Tang, Yan
   Fan, Yuting
   Ning, Jie
   Ma, Xinqi
   Zhang, Qingjiong
   Shen, Huangxuan
TI PTEN Reduced UVB-Mediated Apoptosis in Retinal Pigment Epithelium Cells
SO BIOMED RESEARCH INTERNATIONAL
LA English
DT Article
ID DNA-DAMAGE RESPONSE; MACULAR DEGENERATION; PHOSPHORYLATION; RISK; RARE
AB Age-related macular degeneration (AMD) is a leading cause of blindness and progressive loss of central vision in the elderly population. The important factor of AMD pathogenesis is the degeneration of retinal pigment epithelial (RPE) cells by oxidative stress. Inactivation of PTEN can disrupt intercellular adhesion in the RPE cells, but the mechanism of oxidative stress is less known. Here we presented evidence that UVB-mediated oxidative stress induced apoptosis in ARPE-19 cells. Downregulation of the expression of PTEN in UVB-irradiative RPE cells triggered DNA damage and increased the level of UVB-induced apoptosis by activating p53-dependent pathway. However, overexpression of PTEN increased cell survival by suppressing p-H2A in response to DNA damage and apoptosis. When using Pifithrin-alpha (one of p53 inhibitors), the level of p53-dependent apoptosis was significantly lower than untreated, which suggested that p53 was possibly involved in PTEN-dependent apoptosis. Thus, it elucidated the molecular mechanisms of UVB-induced damage in RPE cells and may offer an alternative therapeutic target in dry AMD.
C1 [He, Jia; Long, Chongde; Huang, Zixin; Zhou, Xin; Kuang, Xielan; Liu, Lanying; Liu, Huijun; Tang, Yan; Fan, Yuting; Ning, Jie; Ma, Xinqi; Zhang, Qingjiong; Shen, Huangxuan] Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, State Key Lab Ophthalmol, 54 Xianlie Rd, Guangzhou 510060, Guangdong, Peoples R China.
   [Kuang, Xielan; Shen, Huangxuan] Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, State Key Lab Ophthalmol, Biobank Eye, 54 Xianlie Rd, Guangzhou 510060, Guangdong, Peoples R China.
C3 Sun Yat Sen University; Sun Yat Sen University
RP Shen, HX (通讯作者)，Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, State Key Lab Ophthalmol, 54 Xianlie Rd, Guangzhou 510060, Guangdong, Peoples R China.; Shen, HX (通讯作者)，Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, State Key Lab Ophthalmol, Biobank Eye, 54 Xianlie Rd, Guangzhou 510060, Guangdong, Peoples R China.
EM shenhx@mail.sysu.edu.cn
RI Zhang, Qingjiong/AAR-6331-2021
OI Zhang, Qingjiong/0000-0001-7508-848X; Zhou, Xin/0000-0002-0480-3068
FU National Natural Science Foundation of China [81670874, 81270914]
FX The investigation was supported by the National Natural Science
   Foundation of China (81670874 and 81270914). The authors thank Professor
   Lizi Wu (Shands Cancer Center, University of Florida) for kindly
   providing some plasmids.
CR Balaiya S, 2010, CLIN OPHTHALMOL, V4, P33
   Chalam KV, 2011, EYE CONTACT LENS, V37, P225, DOI 10.1097/ICL.0b013e31821fbd3e
   Chen AJ, 2015, MED SCI MONIT BASIC, V21, P86, DOI 10.12659/MSMBR.893608
   Chen JH, 2015, AUTOPHAGY, V11, P239, DOI 10.1080/15548627.2015.1009767
   Chen ZR, 2012, BIOCHEM BIOPH RES CO, V422, P522, DOI 10.1016/j.bbrc.2012.05.068
   Chou WW, 2013, TOXICOL IN VITRO, V27, P1728, DOI 10.1016/j.tiv.2013.05.002
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Fritsche LG, 2014, ANNU REV GENOM HUM G, V15, P151, DOI 10.1146/annurev-genom-090413-025610
   Hollander MC, 2011, NAT REV CANCER, V11, P289, DOI 10.1038/nrc3037
   Jager R. D., 2008, NEW ENGL J MED, V358, P2544
   Kevany BM, 2010, PHYSIOLOGY, V25, P8, DOI 10.1152/physiol.00038.2009
   Khan JC, 2006, BRIT J OPHTHALMOL, V90, P29, DOI 10.1136/bjo.2005.073825
   Khan JC, 2006, BRIT J OPHTHALMOL, V90, P75, DOI 10.1136/bjo.2005.073643
   Kim JW, 2008, GENE DEV, V22, P3147, DOI 10.1101/gad.1700108
   Lai K, 2015, EXPERT REV CLIN PHAR, V8, P135, DOI 10.1586/17512433.2015.990379
   Lee EJ, 2011, BIOCHEM BIOPH RES CO, V414, P384, DOI 10.1016/j.bbrc.2011.09.083
   Lin S, 2013, ONCOGENE, V32, P4845, DOI 10.1038/onc.2012.482
   Lopez-Sanchez E, 2006, EUR J OPHTHALMOL, V16, P440, DOI 10.1177/112067210601600313
   McCabe N, 2015, CANCER RES, V75, P2159, DOI 10.1158/0008-5472.CAN-14-3502
   Ming M, 2011, CANCER RES, V71, P5287, DOI 10.1158/0008-5472.CAN-10-4614
   Nowak JZ, 2006, PHARMACOL REP, V58, P353
   Pennesi ME, 2012, MOL ASPECTS MED, V33, P487, DOI 10.1016/j.mam.2012.06.003
   Shen HX, 2006, GENE DEV, V20, P675, DOI 10.1101/gad.1383706
   Tendler Y, 2013, INT J MOL MED, V31, P540, DOI 10.3892/ijmm.2013.1247
   Vojnikovic B, 2007, COLLEGIUM ANTROPOL, V31, P29
   Vojnikovic B, 2010, COLLEGIUM ANTROPOL, V34, P5
   Wang XX, 2015, AGING-US, V7, P1032, DOI 10.18632/aging.100855
   Wong TY, 2007, LANCET, V370, P204, DOI 10.1016/S0140-6736(07)61104-0
   Wu KLH, 2013, ANTIOXID REDOX SIGN, V18, P36, DOI 10.1089/ars.2011.4457
   Yan S, 2014, CELL MOL LIFE SCI, V71, P3951, DOI 10.1007/s00018-014-1666-4
NR 30
TC 4
Z9 7
U1 2
U2 6
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2314-6133
EI 2314-6141
J9 BIOMED RES INT
JI Biomed Res. Int.
PY 2017
VL 2017
AR 3681707
DI 10.1155/2017/3681707
PG 11
WC Biotechnology & Applied Microbiology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Research & Experimental Medicine
GA EN8PO
UT WOS:000396262500001
PM 28321407
OA Green Published, Green Submitted, gold
DA 2022-11-30
ER

PT J
AU Morales, S
   Engan, K
   Naranjo, V
   Colomer, A
AF Morales, Sandra
   Engan, Kjersti
   Naranjo, Valery
   Colomer, Adrian
TI Retinal Disease Screening Through Local Binary Patterns
SO IEEE JOURNAL OF BIOMEDICAL AND HEALTH INFORMATICS
LA English
DT Article
DE Age-related macular degeneration (AMD); diabetic retinopathy (DR);
   diagnosis aid system; fundus image; local binary patterns (LBP); retinal
   image
ID MACULAR DEGENERATION; BLOOD-VESSELS
AB This paper investigates discrimination capabilities in the texture of fundus images to differentiate between pathological and healthy images. For this purpose, the performance of local binary patterns (LBP) as a texture descriptor for retinal images has been explored and compared with other descriptors such as LBP filtering and local phase quantization. The goal is to distinguish between diabetic retinopathy (DR), age-related macular degeneration (AMD), and normal fundus images analyzing the texture of the retina background and avoiding a previous lesion segmentation stage. Five experiments (separating DR from normal, AMD from normal, pathological from normal, DR from AMD, and the three different classes) were designed and validated with the proposed procedure obtaining promising results. For each experiment, several classifiers were tested. An average sensitivity and specificity higher than 0.86 in all the cases and almost of 1 and 0.99, respectively, for AMD detection were achieved. These results suggest that the method presented in this paper is a robust algorithm for describing retina texture and can be useful in a diagnosis aid system for retinal disease screening.
C1 [Morales, Sandra; Naranjo, Valery; Colomer, Adrian] Univ Politecn Valencia, Inst Interuniv Invest Bioingn & Tecnol Orientada, Valencia 46022, Spain.
   [Morales, Sandra; Naranjo, Valery; Colomer, Adrian] Unidad Conjunta UPV FISABIO, Grp Tecnol Informat Aplicadas Oftalmol, Valencia, Spain.
   [Engan, Kjersti] Univ Stavanger, Dept Elect Engn & Comp Sci, N-4036 Stavanger, Norway.
C3 Universitat Politecnica de Valencia; Universitetet i Stavanger
RP Morales, S (通讯作者)，Univ Politecn Valencia, Inst Interuniv Invest Bioingn & Tecnol Orientada, Valencia 46022, Spain.
EM smorales@labhuman.com; kjersti.engan@uis.no; vnaranjo@labhuman.com;
   acolomer@labhuman.com
RI Morales, Sandra/AAV-3633-2021; Colomer Granero, Adrián/GZM-7967-2022;
   Engan, Kjersti/AFU-6843-2022
OI Morales, Sandra/0000-0003-0763-1545; Colomer Granero,
   Adrián/0000-0002-7616-6029; Naranjo, Valery/0000-0002-0181-3412
FU NILS Science and Sustainability Programme [010-ABEL-IM-2013]; Ministerio
   de Economia y Competitividad of Spain, Project ACRIMA [TIN2013-46751-R];
   Spanish Government [BES-2014-067889]
FX This work was supported by NILS Science and Sustainability Programme
   (010-ABEL-IM-2013) and by the Ministerio de Economia y Competitividad of
   Spain, Project ACRIMA (TIN2013-46751-R). The work of A. Colomer was
   supported by the Spanish Government under the FPI Grant BES-2014-067889.
CR Ahonen T, 2006, IEEE T PATTERN ANAL, V28, P2037, DOI 10.1109/TPAMI.2006.244
   BREIMAN L, 2001, MACH LEARN, V0045
   Chang CC, 2011, ACM T INTEL SYST TEC, V2, DOI 10.1145/1961189.1961199
   Chawla NV, 2002, J ARTIF INTELL RES, V16, P321, DOI 10.1613/jair.953
   Chen J, 2010, IEEE T PATTERN ANAL, V32, P1705, DOI 10.1109/TPAMI.2009.155
   Decenciere E, 2013, IRBM, V34, P196, DOI 10.1016/j.irbm.2013.01.010
   Dhanushkodi S. S. R., 2013, Applied Medical Informatics, V33, P1
   Dudoit S., 2005, STAT METHODOL, V2, P131, DOI DOI 10.1016/J.STAMET.2005.02.003
   E-Ophtha, 2006, COL FUND IM DAT
   Farnell DJJ, 2008, J FRANKLIN I, V345, P748, DOI 10.1016/j.jfranklin.2008.04.009
   Freund Y., 1996, P 13 INT C MACH LEAR, P148, DOI DOI 10.5555/3091696.3091715
   Garnier M., 2014, P SOC PHOTO-OPT INS, V9035
   Guo ZH, 2010, IEEE T IMAGE PROCESS, V19, P1657, DOI 10.1109/TIP.2010.2044957
   Hall M., 2009, SIGKDD EXPLORATIONS, V11, P10, DOI [10.1145/1656274.1656278, DOI 10.1145/1656274.1656278]
   Hecht -Nielsen R., 1990, NEUROCOMPUTING
   Heikkila M, 2009, PATTERN RECOGN, V42, P425, DOI 10.1016/j.patcog.2008.08.014
   Hoover A, 2003, IEEE T MED IMAGING, V22, P951, DOI 10.1109/TMI.2003.815900
   Hoover A, 2000, IEEE T MED IMAGING, V19, P203, DOI 10.1109/42.845178
   John GH., 1995, P 11 C UNC ART INT, P338, DOI DOI 10.1109/TGRS.2004.834800
   Kohavi R, 1997, ARTIF INTELL, V97, P273, DOI 10.1016/S0004-3702(97)00043-X
   Kotu LP, 2012, EUR SIGNAL PR CONF, P2586
   Krishnan MMR, 2013, J MED IMAG HEALTH IN, V3, P306, DOI 10.1166/jmihi.2013.1165
   LECESSIE S, 1992, APPL STAT-J ROY ST C, V41, P191
   Liao S, 2009, IEEE T IMAGE PROCESS, V18, P1107, DOI 10.1109/TIP.2009.2015682
   Maenpaa T, 2003, LECT NOTES COMPUT SC, V2749, P885
   Mookiah MRK, 2013, KNOWL-BASED SYST, V39, P9, DOI 10.1016/j.knosys.2012.09.008
   Mookiah MRK, 2015, COMPUT BIOL MED, V63, P208, DOI 10.1016/j.compbiomed.2015.05.019
   Morales Sandra, 2012, Proceedings of the International Conference on Bio-inspired Systems and Signal Processing (BIOSIGNALS 2012), P321
   Morales S, 2013, IEEE T MED IMAGING, V32, P786, DOI 10.1109/TMI.2013.2238244
   Nanni L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0083554
   Nanni L, 2010, ARTIF INTELL MED, V49, P117, DOI 10.1016/j.artmed.2010.02.006
   Ojala T, 2002, IEEE T PATTERN ANAL, V24, P971, DOI 10.1109/TPAMI.2002.1017623
   Ojala T., 2001, Advances in Pattern Recognition - ICAPR 2001. Second International Conference. Proceedings (Lecture Notes in Computer Science Vol.2013), P397
   Ojansivu V, 2008, LECT NOTES COMPUT SC, V5099, P236, DOI 10.1007/978-3-540-69905-7_27
   Oppedal K, 2012, 2012 9TH IEEE INTERNATIONAL SYMPOSIUM ON BIOMEDICAL IMAGING (ISBI), P594, DOI 10.1109/ISBI.2012.6235618
   Paci M, 2013, CURR BIOINFORM, V8, P208, DOI 10.2174/1574893611308020009
   Quinlan J.R, 1993, C4 5 PROGRAMS MACHIN
   Rodriguez JJ, 2006, IEEE T PATTERN ANAL, V28, P1619, DOI 10.1109/TPAMI.2006.211
   Scheffer T., 1999, THESIS
   Song TC, 2014, IEEE SIGNAL PROC LET, V21, P93, DOI 10.1109/LSP.2013.2293335
   World Health Organization (WHO), 2010, ACT PLAN PREV AV BLI
   World Health Organization (WHO), 2013, UN EYE HLTH GLOB ACT
   Yang Z., 2007, P INT C ADV BIOM ICB, P464
   Zabidi S.A., 2010, INT C COMP COMM ENG, P1, DOI DOI 10.1109/IRANIANMVIP.2010.5941129
   Zhang X., 2012, P 9 IEEE INT S BIOM
   Zheng YL, 2012, INVEST OPHTH VIS SCI, V53, P8310, DOI 10.1167/iovs.12-9576
NR 46
TC 26
Z9 28
U1 0
U2 0
PU IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC
PI PISCATAWAY
PA 445 HOES LANE, PISCATAWAY, NJ 08855-4141 USA
SN 2168-2194
EI 2168-2208
J9 IEEE J BIOMED HEALTH
JI IEEE J. Biomed. Health Inform.
PD JAN
PY 2017
VL 21
IS 1
BP 184
EP 192
DI 10.1109/JBHI.2015.2490798
PG 9
WC Computer Science, Information Systems; Computer Science,
   Interdisciplinary Applications; Mathematical & Computational Biology;
   Medical Informatics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Computer Science; Mathematical & Computational Biology; Medical
   Informatics
GA EM8CJ
UT WOS:000395538500020
PM 26469792
OA Green Published
DA 2022-11-30
ER

PT J
AU Gorbatyuk, M
   Gorbatyuk, O
AF Gorbatyuk, Marina
   Gorbatyuk, Oleg
TI Review: Retinal degeneration: Focus on the unfolded protein response
SO MOLECULAR VISION
LA English
DT Article
ID ENDOPLASMIC-RETICULUM STRESS; ER-STRESS; MOUSE MODEL; OPTIC-NERVE;
   SODIUM 4-PHENYLBUTYRATE; MOLECULAR CHAPERONE; DOWN-REGULATION;
   QUALITY-CONTROL; ANIMAL-MODELS; ACTIVATION
AB Recently published literature has provided evidence that the unfolded protein response (UPR) is involved in the development of retinal degeneration. The scope of these studies encompassed diabetic retinopathy, retinopathy of prematurity, glaucoma, retinal detachment, light-induced retinal degeneration, age-related macular degeneration, and inherited retinal degeneration. Subsequent studies investigating the role of individual UPR markers in retinal pathogenesis and examining the therapeutic potential of reprogramming the UPR as a method for modulating the rate of retinal degeneration have been initiated. Manipulation of UPR markers has been made possible by the use of knockout mice, pharmacological agents, and viral vector-mediated augmentation of gene expression. Future research will aim at identifying specific inhibitors and/or inducers of UPR regulatory markers as well as expand the list of UPR-related animal models. Additionally, adeno-associated virus-mediated gene delivery is a safe and effective method for modulating gene expression, and thus is a useful research tool for manipulating individual UPR markers in affected retinas and a promising delivery vector for gene therapy in retinal degenerative disorders.
C1 [Gorbatyuk, Marina] Univ Alabama Birmingham, Dept Vis Sci, Birmingham, AL 35233 USA.
   [Gorbatyuk, Oleg] Univ Florida, Dept Mol Genet & Microbiol, Gainesville, FL 32610 USA.
C3 University of Alabama System; University of Alabama Birmingham; State
   University System of Florida; University of Florida
RP Gorbatyuk, M (通讯作者)，Univ Alabama Birmingham, Dept Vis Sci, Birmingham, AL 35233 USA.
EM mgortk@uab.edu
OI Gorbatyuk, Marina/0000-0001-9060-856X
FU NIH [R01EY020905]; Foundation Fighting Blindness; NATIONAL EYE INSTITUTE
   [R01EY020905] Funding Source: NIH RePORTER
FX The authors acknowledge support by the Foundation Fighting Blindness,
   and by NIH grant R01EY020905.
CR Athanasiou D, 2013, FEBS LETT, V587, P2008, DOI 10.1016/j.febslet.2013.05.020
   Athanasiou D, 2012, MOL BIOL CELL, V23, P3522, DOI 10.1091/mbc.E12-02-0168
   Bertolotti A, 2001, J CLIN INVEST, V107, P585, DOI 10.1172/JCI11476
   Bravo R, 2013, INT REV CEL MOL BIO, V301, P215, DOI 10.1016/B978-0-12-407704-1.00005-1
   Chai F, 2010, MOL VIS, V16, P1122
   Chakrabarti A, 2011, BIOTECHNOL BIOENG, V108, P2777, DOI 10.1002/bit.23282
   Chen Y, 2012, DIABETOLOGIA, V55, P2533, DOI 10.1007/s00125-012-2594-1
   Chiang WC, 2012, INVEST OPHTH VIS SCI, V53, P7159, DOI 10.1167/iovs.12-10222
   Chiang WC, 2012, MOL BIOL CELL, V23, P758, DOI 10.1091/mbc.E11-08-0663
   Choudhury S, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.34
   Csala M, 2012, ANTIOXID REDOX SIGN, V16, P1100, DOI 10.1089/ars.2011.4227
   Dalkara D, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005708
   Datta R, 2009, P NATL ACAD SCI USA, V106, P3437, DOI 10.1073/pnas.0813178106
   Ding XY, 2009, PROG RETIN EYE RES, V28, P1, DOI 10.1016/j.preteyeres.2008.10.001
   Duricka DL, 2012, BIOCHEM J, V441, P685, DOI 10.1042/BJ20111004
   Erdurmus M, 2011, CURR EYE RES, V36, P713, DOI 10.3109/02713683.2011.584370
   Fels DR, 2006, CANCER BIOL THER, V5, P723, DOI 10.4161/cbt.5.7.2967
   Gorbatyuk MS, 2010, P NATL ACAD SCI USA, V107, P5961, DOI 10.1073/pnas.0911991107
   Griciuc A, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1001075
   Haeri Mohammad, 2012, J Ophthalmic Vis Res, V7, P45
   Hagiwara M, 2012, ANTIOXID REDOX SIGN, V16, P1119, DOI 10.1089/ars.2011.4495
   He B, 2006, CELL DEATH DIFFER, V13, P393, DOI 10.1038/sj.cdd.4401833
   Ikesugi K, 2006, CURR EYE RES, V31, P947, DOI 10.1080/02713680600966785
   Inokuchi Y, 2009, INVEST OPHTH VIS SCI, V50, P334, DOI 10.1167/iovs.08-2123
   Iwawaki T, 2004, NAT MED, V10, P98, DOI 10.1038/nm970
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Jeng YY, 2007, EXP EYE RES, V84, P486, DOI 10.1016/j.exer.2006.11.001
   Kaur J, 2011, PLOS ONE, V6
   Kim R, 2006, APOPTOSIS, V11, P5, DOI 10.1007/s10495-005-3088-0
   Krebs J, 2011, NEUROCHEM RES, V36, P1198, DOI 10.1007/s11064-011-0431-4
   Krishnamoorthy RR, 1999, J BIOL CHEM, V274, P3734, DOI 10.1074/jbc.274.6.3734
   Krishnamoorthy T, 2001, MOL CELL BIOL, V21, P5018, DOI 10.1128/MCB.21.15.5018-5030.2001
   Kroeger H, 2012, INVEST OPHTH VIS SCI, V53, P7590, DOI 10.1167/iovs.12-10221
   Kunte MM, 2012, INVEST OPHTH VIS SCI, V53, P3792, DOI 10.1167/iovs.11-9235
   Li B, 2011, ACTA DIABETOL, V48, P103, DOI 10.1007/s00592-009-0170-z
   Li H, 2010, P NATL ACAD SCI USA, V107, P16113, DOI 10.1073/pnas.1010580107
   Li JM, 2009, FEBS LETT, V583, P1521, DOI 10.1016/j.febslet.2009.04.007
   Li Y, 2008, EXP GERONTOL, V43, P1114, DOI 10.1016/j.exger.2008.08.052
   Libby RT, 2010, ADV EXP MED BIOL, V664, P403, DOI 10.1007/978-1-4419-1399-9_46
   Liu H, 2010, EYE, V24, P137, DOI 10.1038/eye.2009.20
   Luo B, 2013, ONCOGENE, V32, P805, DOI 10.1038/onc.2012.130
   Ma YJ, 2004, J CHEM NEUROANAT, V28, P51, DOI 10.1016/j.jchemneu.2003.08.007
   MANSOURROBAEY S, 1994, P NATL ACAD SCI USA, V91, P1632, DOI 10.1073/pnas.91.5.1632
   Mantopoulos D, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024245
   Maurel M, 2013, AM J PHYSIOL-CELL PH, V304, pC1117, DOI 10.1152/ajpcell.00061.2013
   Mendes CS, 2009, EMBO J, V28, P1296, DOI 10.1038/emboj.2009.76
   Mockel A, 2012, J BIOL CHEM, V287, P37483, DOI 10.1074/jbc.M112.386821
   Nakamura S, 2013, PLOS ONE, V8
   Nakanishi T, 2013, J NEUROCHEM, V125, P111, DOI 10.1111/jnc.12116
   Nashine S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063205
   Naskar R, 2000, INVEST OPHTH VIS SCI, V41, P1940
   Nishitoh H, 1998, MOL CELL, V2, P389, DOI 10.1016/S1097-2765(00)80283-X
   Nishitoh H, 2002, GENE DEV, V16, P1345, DOI 10.1101/gad.992302
   Pennesi ME, 2012, MOL ASPECTS MED, V33, P487, DOI 10.1016/j.mam.2012.06.003
   Quigley HA, 2006, BRIT J OPHTHALMOL, V90, P262, DOI 10.1136/bjo.2005.081224
   Rao RV, 2001, J BIOL CHEM, V276, P33869, DOI 10.1074/jbc.M102225200
   Ron D, 2008, CELL, V132, P24, DOI 10.1016/j.cell.2007.12.017
   Rossmiller B, 2012, MOL VIS, V18, P2479
   Roth J, 2010, MOL CELLS, V30, P497, DOI 10.1007/s10059-010-0159-z
   Roy CR, 2006, NAT REV IMMUNOL, V6, P136, DOI 10.1038/nri1775
   Roybal CN, 2005, INVEST OPHTH VIS SCI, V46, P3973, DOI 10.1167/iovs.05-0070
   Rutkowski DT, 2007, MOL BIOL CELL, V18, P3681, DOI 10.1091/mbc.e07-03-0272
   Ryhanen T, 2009, J CELL MOL MED, V13, P3616, DOI 10.1111/j.1582-4934.2008.00577.x
   Ryoo HD, 2007, EMBO J, V26, P242, DOI 10.1038/sj.emboj.7601477
   Schonthal AH, 2013, BIOCHEM PHARMACOL, V85, P653, DOI 10.1016/j.bcp.2012.09.012
   Shimazawa M, 2007, MOL VIS, V13, P578
   Shinde VM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033266
   Sommer T, 2002, DEV CELL, V3, P1, DOI 10.1016/S1534-5807(02)00210-1
   Szegezdi E, 2006, EMBO REP, V7, P880, DOI 10.1038/sj.embor.7400779
   Tanaka J, 2011, J AGR FOOD CHEM, V59, P528, DOI 10.1021/jf103186a
   Tezel G, 2004, BRAIN RES BULL, V62, P473, DOI 10.1016/S0361-9230(03)00074-1
   Tezel G, 2004, ARCH OPHTHALMOL-CHIC, V122, P1348, DOI 10.1001/archopht.122.9.1348
   Tezel G, 2004, BRAIN RES, V996, P202, DOI 10.1016/j.brainres.2003.10.029
   Tezel Gulgun, 2004, Curr Opin Ophthalmol, V15, P80, DOI 10.1097/00055735-200404000-00003
   Urano F, 2000, J CELL SCI, V113, P3697
   Urano F, 2000, SCIENCE, V287, P664, DOI 10.1126/science.287.5453.664
   Vorwerk CK, 2001, VET OPHTHALMOL, V4, P201, DOI 10.1046/j.1463-5216.2001.00168.x
   Walter P, 2011, SCIENCE, V334, P1081, DOI 10.1126/science.1209038
   Wang XQ, 2013, INVEST OPHTH VIS SCI, V54, P5995, DOI 10.1167/iovs.13-12117
   Wei J, 2013, CHEST, V143, P1098, DOI 10.1378/chest.12-2133
   Yamamoto K, 2004, J BIOCHEM, V136, P343, DOI 10.1093/jb/mvh122
   Yamamoto K, 2007, DEV CELL, V13, P365, DOI 10.1016/j.devcel.2007.07.018
   Yang H, 2011, MOL VIS, V17, P78
   Yang LP, 2008, J NEUROSCI RES, V86, P910, DOI 10.1002/jnr.21535
   Yang LP, 2007, INVEST OPHTH VIS SCI, V48, P5191, DOI 10.1167/iovs.07-0512
   Yoneda T, 2001, J BIOL CHEM, V276, P13935, DOI 10.1074/jbc.M010677200
   Yoshikawa T, 2011, CURR EYE RES, V36, P1153, DOI 10.3109/02713683.2011.606592
   Zhang LH, 2010, J CELL BIOCHEM, V110, P1299, DOI 10.1002/jcb.22679
   Zhong Y, 2012, PLOS ONE, V7
   Zhong YM, 2012, DIABETES, V61, P492, DOI 10.2337/db11-0315
   Zhu H, 2013, PLOS ONE, V8
   Zode GS, 2012, INVEST OPHTH VIS SCI, V53, P1557, DOI 10.1167/iovs.11-8837
   Zode GS, 2011, J CLIN INVEST, V121, P3542, DOI 10.1172/JCI58183
   Zweifel LS, 2005, NAT REV NEUROSCI, V6, P615, DOI 10.1038/nrn1727
NR 94
TC 37
Z9 39
U1 0
U2 11
PU MOLECULAR VISION
PI ATLANTA
PA C/O JEFF BOATRIGHT, LAB B, 5500 EMORY EYE CENTER, 1327 CLIFTON RD, N E,
   ATLANTA, GA 30322 USA
SN 1090-0535
J9 MOL VIS
JI Mol. Vis.
PD SEP 20
PY 2013
VL 19
BP 1985
EP 1998
PG 14
WC Biochemistry & Molecular Biology; Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Ophthalmology
GA 221XK
UT WOS:000324693700001
PM 24068865
DA 2022-11-30
ER

PT J
AU Scheetz, TE
   Fingert, JH
   Wang, K
   Kuehn, MH
   Knudtson, KL
   Alward, WLM
   Boldt, HC
   Russell, SR
   Folk, JC
   Casavant, TL
   Braun, TA
   Clark, AF
   Stone, EM
   Sheffield, VC
AF Scheetz, Todd E.
   Fingert, John H.
   Wang, Kai
   Kuehn, Markus H.
   Knudtson, Kevin L.
   Alward, Wallace L. M.
   Boldt, H. Culver
   Russell, Stephen R.
   Folk, James C.
   Casavant, Thomas L.
   Braun, Terry A.
   Clark, Abbot F.
   Stone, Edwin M.
   Sheffield, Val C.
TI A Genome-Wide Association Study for Primary Open Angle Glaucoma and
   Macular Degeneration Reveals Novel Loci
SO PLOS ONE
LA English
DT Article
ID COMPLEMENT FACTOR-H; OCULAR HYPERTENSION TREATMENT; TRANSCRIPTION FACTOR
   GENE; COMMON VARIANTS; SEQUENCE VARIANTS; WDR36 GENE; ONSET; RISK;
   SUSCEPTIBILITY; MAPS
AB Glaucoma and age-related macular degeneration (AMD) are the two leading causes of visual loss in the United States. We utilized a novel study design to perform a genome-wide association for both primary open angle glaucoma (POAG) and AMD. This study design utilized a two-stage process for hypothesis generation and validation, in which each disease cohort was utilized as a control for the other. A total of 400 POAG patients and 400 AMD patients were ascertained and genotyped at 500,000 loci. This study identified a novel association of complement component 7 (C7) to POAG. Additionally, an association of central corneal thickness, a known risk factor for POAG, was found to be associated with ribophorin II (RPN2). Linked monogenic loci for POAG and AMD were also evaluated for evidence of association, none of which were found to be significantly associated. However, several yielded putative associations requiring validation. Our data suggest that POAG is more genetically complex than AMD, with no common risk alleles of large effect.
C1 [Scheetz, Todd E.; Fingert, John H.; Kuehn, Markus H.; Alward, Wallace L. M.; Boldt, H. Culver; Russell, Stephen R.; Folk, James C.; Casavant, Thomas L.; Braun, Terry A.; Stone, Edwin M.; Sheffield, Val C.] Univ Iowa, Dept Ophthalmol & Visual Sci, Iowa City, IA 52242 USA.
   [Scheetz, Todd E.; Casavant, Thomas L.; Braun, Terry A.] Univ Iowa, Dept Biomed Engn, Iowa City, IA 52242 USA.
   [Scheetz, Todd E.; Casavant, Thomas L.; Braun, Terry A.] Univ Iowa, Ctr Bioinformat & Computat Biol, Iowa City, IA USA.
   [Wang, Kai] Univ Iowa, Dept Biostat, Iowa City, IA USA.
   [Knudtson, Kevin L.] Univ Iowa, DNA Core Facil, Iowa City, IA USA.
   [Casavant, Thomas L.] Univ Iowa, Dept Elect & Comp Engn, Iowa City, IA 52242 USA.
   [Clark, Abbot F.] Univ Iowa, Dept Cell Biol & Anat, Iowa City, IA USA.
   [Clark, Abbot F.] Univ N Texas, Hlth Sci Ctr, North Texas Eye Res Inst, Ft Worth, TX USA.
   [Sheffield, Val C.] Univ Iowa, Howard Hughes Med Inst, Dept Pediat, Iowa City, IA 52242 USA.
   [Stone, Edwin M.; Sheffield, Val C.] Univ Iowa, Howard Hughes Med Inst, Iowa City, IA 52242 USA.
C3 University of Iowa; University of Iowa; University of Iowa; University
   of Iowa; University of Iowa; University of Iowa; University of Iowa;
   University of North Texas System; University of North Texas Health
   Science Center; Howard Hughes Medical Institute; University of Iowa;
   Howard Hughes Medical Institute; University of Iowa
RP Sheffield, VC (通讯作者)，Univ Iowa, Dept Ophthalmol & Visual Sci, Iowa City, IA 52242 USA.
EM val-sheffield@uiowa.edu
RI Fingert, John/AAX-4750-2021; Fingert, John/F-8787-2012; Alward,
   Wallace/AAY-4149-2020
OI Fingert, John/0000-0002-0377-0479; Fingert, John/0000-0002-0377-0479;
   Stone, Edwin M./0000-0003-3343-4414; Sheffield, Val/0000-0002-6282-0835;
   Russell, Stephen/0000-0003-3776-1367; Scheetz, Todd/0000-0002-1965-5811;
   Kuehn, Markus/0000-0003-3940-198X; Boldt, H. Culver/0000-0002-7292-2093;
   Folk, James/0000-0002-6271-2906; Alward, Wallace/0000-0001-6368-9018
FU National Institutes of Health [R01-EY-010564, R01-EY-016822,
   R01-EY-018825]; Carver Endowment for Molecular Ophthalmology; Research
   to Prevent Blindness (Department of Ophthalmology, University of Iowa);
   Foundation Fighting Blindness; Alcon Research, Ltd. (Ft. Worth, Texas);
   Alcon Research Ltd; NATIONAL EYE INSTITUTE [R01EY018825, R01EY019485,
   R01EY024259, R01EY010564, R01EY016822, R01EY022044] Funding Source: NIH
   RePORTER
FX This work was supported by the National Institutes of Health
   [R01-EY-010564 to VCS, R01-EY-016822 to EMS, R01-EY-018825 to JHF]; the
   Carver Endowment for Molecular Ophthalmology to EMS and VCS; Research to
   Prevent Blindness (Department of Ophthalmology, University of Iowa,
   Career Development Awards to TES and JHF, and the Lew Wasserman Award to
   WLMA); and Foundation Fighting Blindness. VCS and EMS are investigators
   of the Howard Hughes Medical Institute. Alcon Research, Ltd. (Ft. Worth,
   Texas) provided funds for the purchase of the SNP genotyping chips used
   in this study. The funders had no role in study design, data collection
   and analysis, decision to publish, or preparation of the manuscript.;
   This research was supported in part by Alcon Research Ltd, specifically
   in acquisition of the genotyping arrays. This does not alter the
   authors' adherence to all the PLOS ONE policies on sharing data and
   materials.
CR *AFF, 2007, BRLMM P GEN CALL MET
   Affymetrix, 2009, AFF POW TOOLS
   Akarsu AN, 1996, HUM MOL GENET, V5, P1199, DOI 10.1093/hmg/5.8.1199
   Ali M, 2009, AM J HUM GENET, V84, P664, DOI 10.1016/j.ajhg.2009.03.017
   Allingham RR, 2005, INVEST OPHTH VIS SCI, V46, P2002, DOI 10.1167/iovs.04-1477
   Alward WLM, 2003, AM J OPHTHALMOL, V136, P904, DOI 10.1016/S0002-9394(03)00577-4
   Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556
   Baas DC, 2010, OPHTHALMOLOGY, V117, P500, DOI 10.1016/j.ophtha.2009.08.032
   Baird PN, 2005, HUM GENET, V117, P249, DOI 10.1007/s00439-005-1296-x
   Burdon KP, 2011, NAT GENET, V43, P574, DOI 10.1038/ng.824
   Burton PR, 2007, NATURE, V447, P661, DOI 10.1038/nature05911
   Daiger S. P., 1998, IOVS, V39, pS295
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Ennis S, 2008, LANCET, V372, P1828, DOI 10.1016/S0140-6736(08)61348-3
   Fagerness JA, 2009, EUR J HUM GENET, V17, P100, DOI 10.1038/ejhg.2008.140
   Fan BJ, 2007, MOL VIS, V13, P779
   Fan BJ, 2011, INVEST OPHTH VIS SCI, V52, P1788, DOI 10.1167/iovs.10-6339
   Fingert JH, 2011, EYE, V25, P587, DOI 10.1038/eye.2011.97
   Fingert JH, 1999, HUM MOL GENET, V8, P899, DOI 10.1093/hmg/8.5.899
   Fingert JH, 2012, HUM MOL GENET
   Fingert JH, 2007, ARCH OPHTHALMOL-CHIC, V125, P434, DOI 10.1001/archopht.125.3.434-b
   Fingert JH, 2011, HUM MOL GENET, V20, P2482, DOI 10.1093/hmg/ddr123
   Firasat S, 2008, MOL VIS, V14, P1659
   Gibbs RA, 2003, NATURE, V426, P789, DOI 10.1038/nature02168
   Gibson J, 2010, BRIT J OPHTHALMOL, V94, P1382, DOI 10.1136/bjo.2010.182568
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Gordon MO, 1999, ARCH OPHTHALMOL-CHIC, V117, P573
   Gordon MO, 2002, ARCH OPHTHALMOL-CHIC, V120, P714
   Graber JJ, 2009, PHARMACOL THERAPEUT, V121, P147, DOI 10.1016/j.pharmthera.2008.10.001
   GRIMBERG J, 1989, NUCLEIC ACIDS RES, V17, P8390, DOI 10.1093/nar/17.20.8390
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hauser MA, 2006, INVEST OPHTH VIS SCI, V47, P2542, DOI 10.1167/iovs.05-1476
   Hewitt AW, 2006, AM J OPHTHALMOL, V142, P324, DOI 10.1016/j.ajo.2006.02.041
   Hewitt AW, 2006, CLIN EXP OPHTHALMOL, V34, P472, DOI 10.1111/j.1442-9071.2006.01268.x
   Hughes AE, 2006, NAT GENET, V38, P1173, DOI 10.1038/ng1890
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Kanda A, 2007, P NATL ACAD SCI USA, V104, P16227, DOI 10.1073/pnas.0703933104
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kawase K, 2012, EXP EYE RES, V96, P178, DOI 10.1016/j.exer.2011.12.021
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kuehn MH, 2008, EXP EYE RES, V87, P89, DOI 10.1016/j.exer.2008.04.012
   Kuehn MH, 2006, EXP EYE RES, V83, P620, DOI 10.1016/j.exer.2006.03.002
   LESKE MC, 1983, AM J EPIDEMIOL, V118, P166, DOI 10.1093/oxfordjournals.aje.a113626
   Libby RT, 2005, ANNU REV GENOM HUM G, V6, P15, DOI 10.1146/annurev.genom.6.080604.162209
   Liu Y, AM J HUM GENET, V86, P500
   Liu Y, AM J HUM GENET, V86, P498
   Mabuchi F, 2011, INVEST OPHTH VIS SCI, V52, P4626, DOI 10.1167/iovs.11-7382
   Meguro A, 2010, OPHTHALMOLOGY, V117, P1331, DOI 10.1016/j.ophtha.2009.12.001
   Monemi S, 2005, HUM MOL GENET, V14, P725, DOI 10.1093/hmg/ddi068
   MORGAN BP, 1989, BIOCHEM J, V264, P1
   Nakano M, 2009, P NATL ACAD SCI USA, V106, P12838, DOI 10.1073/pnas.0906397106
   Nishimura DY, 1998, NAT GENET, V19, P140, DOI 10.1038/493
   Pasutto F, 2012, HUM MOL GENET, V21, P1336, DOI 10.1093/hmg/ddr572
   Pasutto F, 2009, AM J HUM GENET, V85, P447, DOI 10.1016/j.ajhg.2009.08.016
   Rabbee N, 2006, BIOINFORMATICS, V22, P7, DOI 10.1093/bioinformatics/bti741
   Ramdas WD, 2011, HUM MOL GENET, V20, P2464, DOI 10.1093/hmg/ddr120
   Rezaie T, 2002, SCIENCE, V295, P1077, DOI 10.1126/science.1066901
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Sarfarazi M, 1998, AM J HUM GENET, V62, P641, DOI 10.1086/301767
   SARFARAZI M, 1995, GENOMICS, V30, P171, DOI 10.1006/geno.1995.9888
   Schulzer M, 1998, AM J OPHTHALMOL, V126, P487
   Semina EV, 1996, NAT GENET, V14, P392, DOI 10.1038/ng1296-392
   SHEFFIELD VC, 1993, NAT GENET, V4, P47, DOI 10.1038/ng0593-47
   Shepard AR, 2007, HUM MOL GENET, V16, P609, DOI 10.1093/hmg/ddm001
   Shibuya E, 2008, INVEST OPHTH VIS SCI, V49, P4453, DOI 10.1167/iovs.07-1575
   Stasi K, 2006, INVEST OPHTH VIS SCI, V47, P1024, DOI 10.1167/iovs.05-0830
   Stevens B, 2007, CELL, V131, P1164, DOI 10.1016/j.cell.2007.10.036
   Stoilov I, 1997, HUM MOL GENET, V6, P641, DOI 10.1093/hmg/6.4.641
   Stoilov I, 2002, 3 GENETIC LOCUS GLC3, P43
   Stoilova D, 1996, GENOMICS, V36, P142, DOI 10.1006/geno.1996.0434
   Stokowski RP, 2007, AM J HUM GENET, V81, P1119, DOI 10.1086/522235
   Stone EM, 1997, SCIENCE, V275, P668, DOI 10.1126/science.275.5300.668
   Stone EM, 2004, NEW ENGL J MED, V351, P346, DOI 10.1056/NEJMoa040833
   Thorleifsson G, 2007, SCIENCE, V317, P1397, DOI 10.1126/science.1146554
   Thorleifsson G, 2010, NAT GENET, V42, P906, DOI 10.1038/ng.661
   Trifan OC, 1998, AM J OPHTHALMOL, V126, P17, DOI 10.1016/S0002-9394(98)00073-7
   Ulmer M, 2012, INVEST OPHTHALMOL VI
   Wang DY, 2006, INVEST OPHTH VIS SCI, V47, P5315, DOI 10.1167/iovs.06-0179
   Wang K, 2009, GENET EPIDEMIOL, V33, P637, DOI 10.1002/gepi.20415
   Wiggs JL, 2012, PLOS GENET, V8, P413, DOI 10.1371/journal.pgen.1002654
   Wiggs JL, 2011, HUM MOL GENET, V20, P4707, DOI 10.1093/hmg/ddr382
   Wiggs JL, 2004, AM J HUM GENET, V74, P1314, DOI 10.1086/421533
   Wirtz MK, 1997, AM J HUM GENET, V60, P296
   Wirtz MK, 1999, ARCH OPHTHALMOL-CHIC, V117, P237
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Zareparsi S, 2005, AM J HUM GENET, V77, P149, DOI 10.1086/431426
   Zhang H, 2008, BMC MED GENET, V9, DOI 10.1186/1471-2350-9-51
NR 91
TC 27
Z9 29
U1 0
U2 9
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAR 11
PY 2013
VL 8
IS 3
AR e58657
DI 10.1371/journal.pone.0058657
PG 10
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 107WI
UT WOS:000316251100074
PM 23536807
OA gold, Green Published, Green Submitted
DA 2022-11-30
ER

PT J
AU Amos, CI
AF Amos, Christopher I.
TI Successful design and conduct of genome-wide association studies
SO HUMAN MOLECULAR GENETICS
LA English
DT Review
ID FACTOR-H POLYMORPHISM; MACULAR DEGENERATION; POPULATION STRATIFICATION;
   ADMIXTURE MAP; RISK LOCI; LINKAGE; POWER; SUSCEPTIBILITY; REPLICATION;
   EFFICIENT
AB Genome-wide association studies are becoming an increasingly effective tool for identifying genetic factors contributing to complex diseases. In this review, I discuss two sets of genome-wide association studies that identified novel genetic factors for age-related macular degeneration and genetic factors for type II diabetes. In reviewing these sets of studies, my goal is to identify factors that contributed to the success of these studies. Design-related factors include the selection of traits that show strong familiality, the selection of clinically homogeneous populations and the selection of cases that have a family history. Ethnic stratification within the study sample can lead to biases, and methods to control for stratification are briefly reviewed. Finally, the impact of single nucleotide polymorphism selection on the power of a study and procedures for improving power by inferring genotypes, by combining data across studies and by performing multistage analyses are discussed. The continuing success of genome-wide association studies depends on careful selection of populations for study and on collaborative analytical approaches.
C1 Univ Texas MD Anderson Canc Ctr, Dept Epidemiol & Bioinformat, Houston, TX 77030 USA.
   Univ Texas MD Anderson Canc Ctr, Dept Computat Biol, Houston, TX 77030 USA.
C3 University of Texas System; UTMD Anderson Cancer Center; University of
   Texas System; UTMD Anderson Cancer Center
RP Amos, CI (通讯作者)，Univ Texas MD Anderson Canc Ctr, Dept Epidemiol & Bioinformat, 1155 Pressler St, Houston, TX 77030 USA.
EM camos@manderson.org
RI Peng, Bo/A-6920-2009
OI Peng, Bo/0000-0001-8225-2284
FU NCI NIH HHS [R01 CA121197, P01 CA034936, 2 P01 CA34936, R01 CA121197-02]
   Funding Source: Medline; NIAMS NIH HHS [N01 AR 8 2232] Funding Source:
   Medline; NIEHS NIH HHS [R01 ES009912, ES09912] Funding Source: Medline;
   NATIONAL CANCER INSTITUTE [P01CA034936, R01CA121197] Funding Source: NIH
   RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES
   [R01ES009912] Funding Source: NIH RePORTER
CR Altshuler D, 2005, NATURE, V437, P1299, DOI 10.1038/nature04226
   Boulton SJ, 2006, BIOCHEM SOC T, V34, P633, DOI 10.1042/BST0340633
   Campbell CD, 2005, NAT GENET, V37, P868, DOI 10.1038/ng1607
   de Bakker PIW, 2005, NAT GENET, V37, P1217, DOI 10.1038/ng1669
   DEVLIN B, 1995, GENOMICS, V29, P311, DOI 10.1006/geno.1995.9003
   DEVLIN B, BIOSTATISTICS, V14, P369
   Dube C, 2005, GASTROENTEROLOGY, V128, pS57, DOI 10.1053/j.gastro.2005.02.014
   EASTON DF, 2007, NATURE
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Epstein MP, 2007, AM J HUM GENET, V80, P921, DOI 10.1086/516842
   Ferlay J, 2007, ANN ONCOL, V18, P581, DOI 10.1093/annonc/mdl498
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Jorgenson E, 2006, NAT REV GENET, V7, P885, DOI 10.1038/nrg1962
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P1646, DOI 10.1001/archopht.116.12.1646
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Li MY, 2005, AM J HUM GENET, V76, P934, DOI 10.1086/430277
   Lin DY, 2005, BIOINFORMATICS, V21, P781, DOI 10.1093/bioinformatics/bti053
   Montana G, 2004, AM J HUM GENET, V75, P771, DOI 10.1086/425281
   Nicolae DL, 2006, GENET EPIDEMIOL, V30, P718, DOI 10.1002/gepi.20182
   OKADA T, 2003, TRENDS CELL BIOL, V5, P222
   Price AL, 2007, AM J HUM GENET, V80, P1024, DOI 10.1086/518313
   Price AL, 2006, NAT GENET, V38, P904, DOI 10.1038/ng1847
   Pritchard JK, 2000, AM J HUM GENET, V67, P170, DOI 10.1086/302959
   Pritchard JK, 1999, AM J HUM GENET, V65, P220, DOI 10.1086/302449
   Purcell S, 2004, HUM HERED, V58, P93, DOI 10.1159/000083030
   PURCELL S, 2007, IN PRESS AM J HUM GE
   Redden DT, 2006, PLOS GENET, V2, P1254, DOI 10.1371/journal.pgen.0020137
   Risch N, 1996, SCIENCE, V273, P1516, DOI 10.1126/science.273.5281.1516
   Roeder K, 2006, AM J HUM GENET, V78, P243, DOI 10.1086/500026
   Rudd MF, 2006, GENOME RES, V16, P693, DOI 10.1101/gr.5120106
   Scott LJ, 2007, SCIENCE, V316, P1341, DOI 10.1126/science.1142382
   SELDIN MF, 2006, PLOS GENET, V15
   Skol AD, 2006, NAT GENET, V38, P209, DOI 10.1038/ng1706
   Slager SL, 2000, GENET EPIDEMIOL, V18, P143, DOI 10.1002/(SICI)1098-2272(200002)18:2<143::AID-GEPI4>3.0.CO;2-5
   Smith MW, 2004, AM J HUM GENET, V74, P1001, DOI 10.1086/420856
   Szatmari P, 2007, NAT GENET, V39, P319, DOI 10.1038/ng1985
   Taylor JA, 2006, CANCER EPIDEM BIOMAR, V15, P133, DOI 10.1158/1055-9965.EPI-05-0641
   Tian C, 2006, AM J HUM GENET, V79, P640, DOI 10.1086/507954
   Wang HS, 2006, GENET EPIDEMIOL, V30, P356, DOI 10.1002/gepi.20150
   Zeggini E, 2005, NAT GENET, V37, P1320, DOI 10.1038/ng1670
   Zeggini E, 2007, SCIENCE, V316, P1336, DOI 10.1126/science.1142364
NR 42
TC 58
Z9 59
U1 0
U2 12
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0964-6906
EI 1460-2083
J9 HUM MOL GENET
JI Hum. Mol. Genet.
PD OCT 15
PY 2007
VL 16
SI 2
BP R220
EP R225
DI 10.1093/hmg/ddm161
PG 6
WC Biochemistry & Molecular Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA 234LL
UT WOS:000251165500013
PM 17597095
OA Green Accepted, Bronze, Green Submitted
DA 2022-11-30
ER

PT J
AU Hadj-Slimane, R
   Lepelletier, Y
   Lopez, N
   Garbay, C
   Raynaud, F
AF Hadj-Slimane, Reda
   Lepelletier, Yves
   Lopez, Nicolas
   Garbay, Christiane
   Raynaud, Francoise
TI Short interfering RNA (siRNA), a novel therapeutic tool acting on
   angiogenesis
SO BIOCHIMIE
LA English
DT Review
DE angiogenesis; siRNA; age-related macular degeneration; cancer; VEGF
ID ENDOTHELIAL GROWTH-FACTOR; SUPPRESSES TUMOR-GROWTH; IN-VIVO;
   CANCER-CELLS; FACTOR VEGF; FACTOR RECEPTORS; PROTEIN EXPRESSION;
   SIGNALING PATHWAY; GENE-EXPRESSION; DOWN-REGULATION
AB The formation of new blood vessels, uncontrolled cell expansions and invasions are the common feature of cancer, neovascular inflammatory and ocular diseases, such as age-related macular degeneration (AMD). Short interfering RNA (siRNA) and short-hairpin RNA (shRNA) have recently helped extend our understanding of the mechanisms regulating angiogenesis and tumor developments. Moreover, the early success of these tools has reinforced the therapeutic hopes of preventing endogenous or exogenous gene translation. In vivo experiments using several animal tumor models and human pre-clinical trials augured many benefits to control protein expression and cell signaling. The high specificity of siRNA and shRNA to target a protein is crucial to design a new generation of therapeutic agents. At the present, several investigations are focused on the understanding of both gene function and the proof-of-concept for siRNA-mediated anti -angiogenesis. Taken together, in vitro and in vivo studies shed light on the efficiency of siRNA as a new alternative therapeutic agent, (c) 2007 Elsevier Masson SAS. All rights reserved.
C1 Univ Paris 05, Fac Med, Lab Pharmacochim Mol & Cellulaire, F-75270 Paris 06, France.
   INSERM, U648, F-75270 Paris 06, France.
   Univ Paris 05, Hop Necker Enfants Malad, AP HP, CNRS,UMR 8147, F-75015 Paris, France.
C3 UDICE-French Research Universities; Universite Paris Cite; Universite de
   Franche-Comte; Institut National de la Sante et de la Recherche Medicale
   (Inserm); Assistance Publique Hopitaux Paris (APHP); Hopital
   Universitaire Necker-Enfants Malades - APHP; Centre National de la
   Recherche Scientifique (CNRS); UDICE-French Research Universities;
   Universite Paris Cite
RP Garbay, C (通讯作者)，Univ Paris 05, Fac Med, Lab Pharmacochim Mol & Cellulaire, 45 Rue Saints Peres, F-75270 Paris 06, France.
EM christiane.garbay@univ-paris5.fr; francoise.raynaud@univ-paris5.fr
RI lepelletier, yves/AAF-1546-2020
OI lepelletier, yves/0000-0001-7746-5170
CR Akagi M, 2003, BRIT J CANCER, V88, P796, DOI 10.1038/sj.bjc.6600811
   Axelson H, 2005, SEMIN CELL DEV BIOL, V16, P554, DOI 10.1016/j.semcdb.2005.03.007
   Baba T, 2007, GYNECOL ONCOL, V105, P703, DOI 10.1016/j.ygyno.2007.02.005
   Bachelder RE, 2001, CANCER RES, V61, P5736
   Bumcrot D, 2006, NAT CHEM BIOL, V2, P711, DOI 10.1038/nchembio839
   Calipel A, 2003, J BIOL CHEM, V278, P42409, DOI 10.1074/jbc.M308709200
   Cao Y, 2003, MOL CELL BIOL, V23, P6725, DOI 10.1128/MCB.23.19.6725-6738.2003
   Cashman SM, 2006, INVEST OPHTH VIS SCI, V47, P3496, DOI 10.1167/iovs.05-1610
   Cejka D, 2006, CLIN SCI, V110, P47, DOI 10.1042/CS20050162
   Chetty C, 2006, MOL CANCER THER, V5, P2289, DOI 10.1158/1535-7163.MCT-06-0169
   CYKXHOORN DM, 2006, ANNU REV BIOMED ENG, V8, P377
   Das B, 2005, CANCER RES, V65, P7267, DOI 10.1158/0008-5472.CAN-04-4575
   Dekker RJ, 2005, AM J PATHOL, V167, P609, DOI 10.1016/S0002-9440(10)63002-7
   Detmar M, 2004, J INVEST DERMATOL, V122, pXIV, DOI 10.1046/j.0022-202X.2003.22140.x
   Ding H, 2000, INT J CANCER, V88, P584, DOI 10.1002/1097-0215(20001115)88:4<584::AID-IJC11>3.0.CO;2-T
   Ding Q, 2003, J BIOL CHEM, V278, P39882, DOI 10.1074/jbc.M304685200
   Dor V, 1997, CURR OPIN CARDIOL, V12, P533, DOI 10.1097/00001573-199711000-00006
   Dowds TA, 2004, J BIOL CHEM, V279, P21924, DOI 10.1074/jbc.M401178200
   Duxbury MS, 2004, ANN SURG, V240, P667, DOI 10.1097/01.sla.0000140755.97224.9a
   Duxbury MS, 2004, CANCER RES, V64, P3987, DOI 10.1158/0008-5472.CAN-04-0424
   Dvorak HF, 1999, CURR TOP MICROBIOL, V237, P97
   Eliceiri BP, 2001, CURR OPIN CELL BIOL, V13, P563, DOI 10.1016/S0955-0674(00)00252-0
   Eskandarpour M, 2005, INT J CANCER, V115, P65, DOI 10.1002/ijc.20873
   Fakhari M, 2002, CANCER-AM CANCER SOC, V94, P258, DOI 10.1002/cncr.10177
   Faltus T, 2004, NEOPLASIA, V6, P786, DOI 10.1593/neo.04313
   Fattal E, 2006, ADV DRUG DELIVER REV, V58, P1203, DOI 10.1016/j.addr.2006.07.020
   Favier B, 2006, BLOOD, V108, P1243, DOI 10.1182/blood-2005-11-4447
   Fischer B, 2007, CANCER TREAT REV, V33, P391, DOI 10.1016/j.ctrv.2007.01.006
   FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27
   Fu GF, 2005, CANCER BIOL THER, V4, P822, DOI 10.4161/cbt.4.8.1889
   Fuh G, 2000, J BIOL CHEM, V275, P26690
   Fujiwara S, 2007, INT J ONCOL, V30, P793
   Fukuda T, 2003, J BIOL CHEM, V278, P51324, DOI 10.1074/jbc.M309122200
   Funding AT, 2006, J INVEST DERMATOL, V126, P1784, DOI 10.1038/sj.jid.5700252
   Gaggioli C, 2007, J INVEST DERMATOL, V127, P400, DOI 10.1038/sj.jid.5700524
   Gregory RI, 2005, CELL, V123, P631, DOI 10.1016/j.cell.2005.10.022
   Halder J, 2006, CLIN CANCER RES, V12, P4916, DOI 10.1158/1078-0432.CCR-06-0021
   Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7
   Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9
   Handa A, 2000, INT J ONCOL, V17, P291
   Hirota K, 2006, CRIT REV ONCOL HEMAT, V59, P15, DOI 10.1016/j.critrevonc.2005.12.003
   Holmqvist K, 2004, J BIOL CHEM, V279, P22267, DOI 10.1074/jbc.M312729200
   Iliopoulos O, 1996, P NATL ACAD SCI USA, V93, P10595, DOI 10.1073/pnas.93.20.10595
   Ishida A, 2001, J CELL PHYSIOL, V188, P359, DOI 10.1002/jcp.1121
   Johansen C, 2006, J IMMUNOL, V176, P1431, DOI 10.4049/jimmunol.176.3.1431
   KAIPAINEN A, 1995, P NATL ACAD SCI USA, V92, P3566, DOI 10.1073/pnas.92.8.3566
   Kawaguchi N, 2003, J CELL SCI, V116, P3893, DOI 10.1242/jcs.00699
   Kendall RL, 1996, BIOCHEM BIOPH RES CO, V226, P324, DOI 10.1006/bbrc.1996.1355
   Kim B, 2004, AM J PATHOL, V165, P2177, DOI 10.1016/S0002-9440(10)63267-1
   Kim DH, 2007, NAT REV GENET, V8, P173, DOI 10.1038/nrg2006
   KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0
   Kim WU, 2006, J IMMUNOL, V177, P5727, DOI 10.4049/jimmunol.177.8.5727
   Klagsbrun M, 1999, CHEM BIOL, V6, pR217, DOI 10.1016/S1074-5521(99)80081-7
   Klemke M, 2007, J CELL PHYSIOL, V212, P368, DOI 10.1002/jcp.21029
   Kou RQ, 2005, BIOCHEMISTRY-US, V44, P15064, DOI 10.1021/bi0509898
   Lantuejoul S, 2003, J PATHOL, V200, P336, DOI 10.1002/path.1367
   Lapteva N, 2005, CANCER GENE THER, V12, P84, DOI 10.1038/sj.cgt.7700770
   Lee MS, 2004, INT J ONCOL, V24, P1229
   Lee TH, 2006, J BIOL CHEM, V281, P40450, DOI 10.1074/jbc.M607525200
   Lee YS, 2004, CELL, V117, P69, DOI 10.1016/S0092-8674(04)00261-2
   Li SF, 2007, MOL THER, V15, P515, DOI 10.1038/sj.mt.6300072
   Liang ZX, 2005, CANCER RES, V65, P967
   Lima RT, 2004, CANCER GENE THER, V11, P309, DOI 10.1038/sj.cgt.7700706
   Lipscomb EA, 2003, CLIN EXP METASTAS, V20, P569, DOI 10.1023/A:1025819521707
   List AF, 2004, EXP HEMATOL, V32, P526, DOI 10.1016/j.exphem.2004.03.005
   Lu PY, 2005, TRENDS MOL MED, V11, P104, DOI 10.1016/j.molmed.2005.01.005
   Lu PY, 2003, CURR OPIN MOL THER, V5, P225
   McManus DC, 2004, ONCOGENE, V23, P8105, DOI 10.1038/sj.onc.1207967
   McNamara JO, 2006, NAT BIOTECHNOL, V24, P1005, DOI 10.1038/nbt1223
   Meister B, 1999, EUR J CANCER, V35, P445, DOI 10.1016/S0959-8049(98)00387-6
   MILLAUER B, 1994, NATURE, V367, P576, DOI 10.1038/367576a0
   Minakuchi Y, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh093
   Miyashita T, 2003, BIOCHEM BIOPH RES CO, V312, P397, DOI 10.1016/j.bbrc.2003.10.141
   Moshfeghi AA, 2006, OPHTHALMOLOGY, V113, P2002, DOI 10.1016/j.ophtha.2006.05.070
   Muller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016
   Murai T, 2004, J BIOL CHEM, V279, P4541, DOI 10.1074/jbc.M307356200
   Murga M, 2005, BLOOD, V105, P1992, DOI 10.1182/blood-2004-07-2598
   Nagy P, 2003, EXP CELL RES, V285, P39, DOI 10.1016/S0014-4827(02)00050-2
   NAPOLI C, 1990, PLANT CELL, V2, P279, DOI 10.1105/tpc.2.4.279
   Neufeld G, 1999, FASEB J, V13, P9, DOI 10.1096/fasebj.13.1.9
   Ng EWM, 2006, ANN NY ACAD SCI, V1082, P151, DOI 10.1196/annals.1348.062
   Nickoloff BJ, 2000, J INVEST DERM SYMP P, V5, P67, DOI 10.1046/j.1087-0024.2000.00006.x
   Ning S, 2004, INT J ONCOL, V25, P1065
   Oliveira S, 2006, J BIOMED BIOTECHNOL, DOI 10.1155/JBB/2006/63675
   Parikh AA, 2003, CANCER, V98, P720, DOI 10.1002/cncr.11560
   Petrovic N, 2003, J BIOL CHEM, V278, P49358, DOI 10.1074/jbc.M308071200
   Price DJ, 2001, CELL GROWTH DIFFER, V12, P129
   Rana TM, 2007, NAT REV MOL CELL BIO, V8, P23, DOI 10.1038/nrm2085
   Reich S, 2003, MOL VIS, V9, P210
   Salvatore G, 2006, CLIN CANCER RES, V12, P1623, DOI 10.1158/1078-0432.CCR-05-2378
   Santel A, 2006, GENE THER, V13, P1222, DOI 10.1038/sj.gt.3302777
   Sawai H, 2005, MOL CANCER, V4, DOI 10.1186/1476-4598-4-37
   Schiffelers RM, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh140
   Schulze-Bergkamen H, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-232
   SCHWARTZ B, 2007, ONCOGENE
   Shu XD, 2002, MOL CELL BIOL, V22, P7758, DOI 10.1128/MCB.22.22.7758-7768.2002
   Soker S, 1998, CELL, V92, P735, DOI 10.1016/S0092-8674(00)81402-6
   Soker S, 2002, J CELL BIOCHEM, V85, P357, DOI 10.1002/jcb.10140
   Song EW, 2005, NAT BIOTECHNOL, V23, P709, DOI 10.1038/nbt1101
   Spagnuolo R, 2004, BLOOD, V103, P3005, DOI 10.1182/blood-2003-07-2459
   Stoeck A, 2006, BIOCHEM J, V393, P609, DOI 10.1042/BJ20051013
   Sumimoto H, 2004, ONCOGENE, V23, P6031, DOI 10.1038/sj.onc.1207812
   Sumimoto H, 2006, J EXP MED, V203, P1651, DOI 10.1084/jem.20051848
   Tan C, 2004, CANCER CELL, V5, P79, DOI 10.1016/S1535-6108(03)00281-2
   Tian XJ, 2001, BIOCHEM BIOPH RES CO, V286, P505, DOI 10.1006/bbrc.2001.5409
   Tomari Y, 2004, CELL, V116, P831, DOI 10.1016/S0092-8674(04)00218-1
   WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988
   Whitaker GB, 2001, J BIOL CHEM, V276, P25520, DOI 10.1074/jbc.M102315200
   Wu JB, 2004, CANCER RES, V64, P2238, DOI 10.1158/0008-5472.CAN-03-3044
   Xie FY, 2006, DRUG DISCOV TODAY, V11, P67, DOI 10.1016/S1359-6446(05)03668-8
   Yang G, 2003, ONCOGENE, V22, P5694, DOI 10.1038/sj.onc.1206858
   Zamore PD, 2006, CELL, V127, P1083, DOI 10.1016/j.cell.2006.12.001
NR 112
TC 28
Z9 30
U1 1
U2 10
PU ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI ISSY-LES-MOULINEAUX
PA 65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY-LES-MOULINEAUX, FRANCE
SN 0300-9084
EI 1638-6183
J9 BIOCHIMIE
JI Biochimie
PD OCT
PY 2007
VL 89
IS 10
BP 1234
EP 1244
DI 10.1016/j.biochi.2007.06.012
PG 11
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA 226UI
UT WOS:000250613600010
PM 17707573
DA 2022-11-30
ER

PT J
AU Kocur, I
   Resnikoff, S
AF Kocur, I
   Resnikoff, S
TI Visual impairment and blindness in Europe and their prevention
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Review
ID AGE-RELATED MACULOPATHY; CHILDHOOD BLINDNESS; NORDIC CHILDREN; MACULAR
   DEGENERATION; DIABETIC-RETINOPATHY; PARTIAL SIGHT; EPIDEMIOLOGY;
   PREVALENCE; CATARACT; POPULATION
AB The European region currently differs in many aspects, such as political, socioeconomic, and geographical. After substantial political changes at the beginning of the 1990s, the majority of central and eastern European countries started to rebuild their healthcare systems. It is apparent that eastern Europe represents a highly diverse region where the difference among countries broadens year after year. In highly industrialised countries of Europe, the leading causes of childhood serious visual loss are lesions of the central nervous system, congenital anomalies and retinal disorders. In the middle income countries of Europe, congenital cataract, glaucoma and, mainly, retinopathy of prematurity are highly expressed. The major cause of serious visual loss in adults in industrialised countries is age related macular degeneration. The other conditions comprise cataract, glaucoma, diabetic retinopathy, and uncorrected/uncorrectable refractive errors, along with low vision. In people of working age, diabetic retinopathy, retinopathy pigmentosa, and optic atrophy are the most frequently reported causes of serious visual loss. In the middle income countries of Europe, advanced cataract, glaucoma, and diabetic retinopathy are more frequently observed.
C1 Charles Univ Prague, Eye Clin, Prague 10034, Czech Republic.
   WHO, CH-1211 Geneva, Switzerland.
C3 Charles University Prague; World Health Organization
RP Kocur, I (通讯作者)，Charles Univ Prague, Eye Clin, Srobarova 50, Prague 10034, Czech Republic.
EM ivokocur@ti.cz
RI Resnikoff, Serge/N-2355-2019
OI Resnikoff, Serge/0000-0002-5866-4446
CR Abou-Gareeb I, 2001, Ophthalmic Epidemiol, V8, P39, DOI 10.1076/opep.8.1.39.1540
   ALBERT DM, 1994, PRINCIPLES PRACTICE, P782
   [Anonymous], 1991, Diabet Med, V8, P263
   BAILEY C, 2001, SCREENING DIABETIC R
   BASH PF, 1999, TXB INT HLTH, P370
   BILLSON F, 2001, P 6 IAPB GEN ASS HYD, P75
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Blohme J, 1997, ACTA OPHTHALMOL SCAN, V75, P681
   BRESSLER NM, 1995, OPHTHALMOLOGY, V102, P1206, DOI 10.1016/S0161-6420(95)30889-5
   BRYAS JH, 1997, T OPHTHAL SOC UK, V97, P26
   CALVOCORESSI P, 1997, WORLD POLITICS 1945, P207
   CHEW EY, 1995, DIABETES CARE, V18, P631, DOI 10.2337/diacare.18.5.631
   COFFEY M, 1993, BRIT J OPHTHALMOL, V77, P17, DOI 10.1136/bjo.77.1.17
   CONGDON N, 1992, SURV OPHTHALMOL, V36, P411, DOI 10.1016/S0039-6257(05)80022-0
   Czeizel A, 1991, Acta Paediatr Hung, V31, P365
   DOCI J, 1988, CS OFTALMOL, V4, P241
   DOLIN P, 1998, EPIDEMIOLOGY EYE DIS, P103
   DULDULAO EC, 2001, VISION FUTURE
   EVAN J, 1998, EPIDEMIOLOGY EYE DIS, P325
   Evans J, 1996, BRIT J OPHTHALMOL, V80, P9, DOI 10.1136/bjo.80.1.9
   FLEDELIUS HC, 1990, ACTA OPHTHALMOL, V68, P209
   Foster A, 1997, J CATARACT REFR SURG, V23, P601, DOI 10.1016/S0886-3350(97)80040-5
   FOSTER A, 1990, INT OPHTHALMOL, V14, P135, DOI 10.1007/BF00158310
   Foster A, 2001, BRIT J OPHTHALMOL, V85, P635, DOI 10.1136/bjo.85.6.635
   FOSTER A, 2001, P 6 IAPB GEN ASS HYD, P431
   FOSTER A, 1997, PAEDIAT OPHTHALMOLOG
   FREDERICK MA, 1992, INT J TECHNOL ASSESS, V8, P694
   GATLING W, 1995, DIABETIC MED, V12, P531, DOI 10.1111/j.1464-5491.1995.tb00536.x
   GERINEC A, 1990, CS OFTALMOL, V2, P121
   GHAFOUR IM, 1983, BRIT J OPHTHALMOL, V67, P209, DOI 10.1136/bjo.67.4.209
   GIESER SC, 1994, ARCH OPHTHALMOL-CHIC, V112, P687, DOI 10.1001/archopht.1994.01090170135036
   GIESER SC, 1993, CURR OPIN OPHTHALMOL, V4, P10, DOI 10.1097/00055735-199302000-00003
   GILBERT C, 1995, OPHTHALMIC GENET, V16, P1, DOI 10.3109/13816819509057847
   Gilbert C, 1997, LANCET, V350, P12, DOI 10.1016/S0140-6736(97)01107-0
   GILBERT C, 1993, B WORLD HEALTH ORGAN, V71, P485
   Gilbert C, 2001, B WORLD HEALTH ORGAN, V79, P227
   GILBERT C, 2001, P 6 IAPB GEN ASS HYD, P71
   Gilbert C E, 1999, Ophthalmic Epidemiol, V6, P73
   Gilbert CE, 1998, EPIDEMIOLOGY EYE DIS, P181
   Gillies M, 1998, ARCH OPHTHALMOL-CHIC, V116, P90, DOI 10.1001/archopht.116.1.90
   GOGGIN M, 1991, BRIT J OPHTHALMOL, V75, P425, DOI 10.1136/bjo.75.7.425
   Goldstein H, 1980, ADV OPHTHALMOL, V40, P1
   GRAHAM PA, 1968, BRIT J PREV SOC MED, V22, P238
   Gramer E, 1995, Curr Opin Ophthalmol, V6, P78
   GREY RHB, 1989, BRIT J OPHTHALMOL, V73, P88, DOI 10.1136/bjo.73.2.88
   HALLDORSSON S, 1980, ACTA OPHTHALMOL, V58, P237
   HANSEN E, 1992, ACTA OPHTHALMOL, V70, P597
   HANSEN S E, 1987, Ugeskrift for Laeger, V149, P1839
   Hornby S J, 2000, Ophthalmic Epidemiol, V7, P127
   *I TERC MUND, 1999, WORLD GUID 1999 2000
   JOHNS A, 1990, INT OPHTHALMOL, V14, P227, DOI 10.1007/BF00158323
   JOHNSON GJ, 1998, EPIDEMIOLOGY EYE DIS, P159
   JOHNSON GJ, 2001, P 6 IAPB GEN ASS HYD, P181
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P653, DOI 10.1001/archopht.116.5.653
   KLEIN BEK, 1992, OPHTHALMOLOGY, V99, P1499
   KLEIN BEK, 1998, EPIDEMIOLOGY EYE DIS, P311
   KLEIN R, 1994, ARCH OPHTHALMOL-CHIC, V112, P1217, DOI 10.1001/archopht.1994.01090210105023
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Kocur I, 2001, BRIT J OPHTHALMOL, V85, P1149, DOI 10.1136/bjo.85.10.1149
   KOHLER L, 1973, ACTA PAEDIATR SCAND, V62, P17, DOI 10.1111/j.1651-2227.1973.tb08060.x
   KOHLER L, 1984, PROGR CHILD HLTH, V1, P230
   KRAUT JA, 1994, PRINCIPLES PRACTICE
   KUPFER C, 2001, P 6 IAPB GEN ASS HYD, P421
   LAGA M, 1989, B WORLD HEALTH ORGAN, V67, P471
   LINDSTEDT E, 1975, DOC OPHTHALMOL, V39, P351, DOI 10.1007/BF00578767
   LINDSTEDT E, 1972, DOC OPHTHALMOL, V31, P173, DOI 10.1007/BF00167366
   MARAINI G, 1991, AM J EPIDEMIOL, V133, P541
   MCCABE P, 1994, PRINCIPLES PRACTICE
   Minassian DC, 2000, BRIT J OPHTHALMOL, V84, P4, DOI 10.1136/bjo.84.1.4
   MINASSIAN DC, 1988, EYE, V2, pS3, DOI 10.1038/eye.1988.128
   NG YK, 1988, LANCET, V2, P1235
   NICOLOSI A, 1994, INT J EPIDEMIOL, V23, P359, DOI 10.1093/ije/23.2.359
   NIELSEN NV, 1982, ACTA OPHTHALMOL, V60, P677
   NORRIE GORDON, 1927, ACTA OPHTHALMOLOGICA, V5, P357
   PHILLIPS CI, 1987, BRIT J OPHTHALMOL, V71, P578, DOI 10.1136/bjo.71.8.578
   PODGOR MJ, 1983, AM J EPIDEMIOL, V118, P206, DOI 10.1093/oxfordjournals.aje.a113628
   Quigley HA, 1996, BRIT J OPHTHALMOL, V80, P389, DOI 10.1136/bjo.80.5.389
   Rahi JS, 1999, BRIT J OPHTHALMOL, V83, P387, DOI 10.1136/bjo.83.4.387
   Rahi JS, 1998, ARCH DIS CHILD, V78, P381, DOI 10.1136/adc.78.4.381
   RIISE R, 1992, ACTA OPHTHALMOL, V70, P145
   RIISE R, 1992, ACTA OPHTHALMOL, V70, P605
   ROBINSON GC, 1987, AM J DIS CHILD, V141, P1321, DOI 10.1001/archpedi.1987.04460120087041
   ROBINSON R, 1994, BRIT J OPHTHALMOL, V78, P736, DOI 10.1136/bjo.78.10.736
   Rogers NK, 1999, EYE, V13, P65, DOI 10.1038/eye.1999.13
   ROHAN TE, 1989, BMJ-BRIT MED J, V299, P1198, DOI 10.1136/bmj.299.6709.1198
   ROSENBERG T, 1987, ACTA OPHTHALMOL, V65, P110
   ROSENBERG T, 1992, ACTA OPHTHALMOL, V70, P155
   Rosenberg T, 1996, BRIT J OPHTHALMOL, V80, P49, DOI 10.1136/bjo.80.1.49
   Rosenberg T, 1994, Arctic Med Res, V53, P91
   SARMA U, 1994, EUR J CLIN NUTR, V48, P1
   Sjolie AK, 1997, OPHTHALMOLOGY, V104, P252, DOI 10.1016/S0161-6420(97)30327-3
   STAYTE M, 1990, BRIT J OPHTHALMOL, V74, P465, DOI 10.1136/bjo.74.8.465
   Stefansson E, 2000, ACTA OPHTHALMOL SCAN, V78, P374, DOI 10.1034/j.1600-0420.2000.078004374.x
   STEWARTBROWN S, 1985, J EPIDEMIOL COMMUN H, V39, P107, DOI 10.1136/jech.39.2.107
   STEWARTBROWN SL, 1988, J EPIDEMIOL COMMUN H, V42, P17, DOI 10.1136/jech.42.1.17
   STOLL C, 1992, OPHTHALMIC PAED GEN, V13, P179, DOI 10.3109/13816819209046487
   SuttorpSchulten MSA, 1996, BRIT J OPHTHALMOL, V80, P844, DOI 10.1136/bjo.80.9.844
   TAYLOR D, 1975, CHILD CARE HLTH DEV, V1, P291, DOI 10.1111/j.1365-2214.1975.tb00210.x
   Taylor HR, 1999, EYE, V13, P445, DOI 10.1038/eye.1999.119
   Taylor HR, 2000, BRIT J OPHTHALMOL, V84, P1, DOI 10.1136/bjo.84.1.1
   TAYLOR HR, 2001, WORLD BLINDNESS ITS, P37
   THOMPSON A, 1989, BR J OPHTHALMOL, V73, P88
   THOMPSON JR, 1990, CURR OPIN OPHTHALMOL, V1, P649
   THOMPSON JR, 1991, PUBLIC HEALTH, V105, P455, DOI 10.1016/S0033-3506(05)80616-X
   Thylefors B, 1995, Ophthalmic Epidemiol, V2, P5, DOI 10.3109/09286589509071448
   Thylefors B, 1998, AM J OPHTHALMOL, V125, P90, DOI 10.1016/S0002-9394(99)80239-6
   THYLEFORS B, 1987, B WORLD HEALTH ORGAN, V65, P477
   THYLEFORS B, 1992, DOC OPHTHALMOL, V81, P339, DOI 10.1007/BF00161771
   THYLEFORS B, 1990, INT OPHTHALMOL, V14, P211, DOI 10.1007/BF00158321
   THYLEFORS B, 1982, INT OPHTHALMOL, V5, P129, DOI 10.1007/BF00149141
   THYLEFORS B, 2001, P 6 IAPB GEN ASS HYD, P25
   THYLEFORS B, 2000, LANCET, V354, pSIV44
   Trautner C, 1997, DIABETES CARE, V20, P1147, DOI 10.2337/diacare.20.7.1147
   Vassileva P, 1996, Ophthalmic Epidemiol, V3, P143, DOI 10.3109/09286589609080120
   VINDING T, 1990, ACTA OPHTHALMOL, V68, P162
   VINDING T, 1989, ACTA OPHTHALMOL, V67, P609
   Vingerling JR, 1995, EPIDEMIOL REV, V17, P347, DOI 10.1093/oxfordjournals.epirev.a036198
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   WEALE R, 1995, EXP EYE RES, V60, P49, DOI 10.1016/S0014-4835(05)80083-1
   WEST SK, 1995, SURV OPHTHALMOL, V39, P323
   *WHO, 1992, ICD10 WHO, V1, P457
   *WHO, 1999, EUR HLTH SER
   *WHO, 1998, WORLD HLTH REP 1998, P47
   Willshaw HE, 1996, BRIT J OPHTHALMOL, V80, P388, DOI 10.1136/bjo.80.5.388
   WILSON MR, 1996, GLAUCOMAS, P753
   World Bank, 1993, INV HLTH
   World Health Organisation (WHO), 1992, PREV CHILDH BLINDN
   World Health Organization, 2000, WORLD HLTH REP 2000
   World Health Organization, 1997, STRAT PREV BLINDN NA
   WORMALD R, 1994, BRIT J OPHTHALMOL, V78, P733, DOI 10.1136/bjo.78.10.733
   Wormald R P, 1995, J Med Screen, V2, P109
   WORMALD RPL, 1992, BRIT MED J, V304, P1226, DOI 10.1136/bmj.304.6836.1226
   YANNUZZI LA, 1992, ARCH OPHTHALMOL-CHIC, V110, P1701
NR 133
TC 159
Z9 171
U1 0
U2 22
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD JUL
PY 2002
VL 86
IS 7
BP 716
EP 722
DI 10.1136/bjo.86.7.716
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 570KX
UT WOS:000176658400005
PM 12084735
OA Green Published, Green Submitted, Bronze
DA 2022-11-30
ER

PT J
AU Amin, SV
   Khanna, S
   Parvar, SP
   Shaw, LT
   Dao, D
   Hariprasad, SM
   Skondra, D
AF Amin, Shivam, V
   Khanna, Saira
   Parvar, Seyedeh P.
   Shaw, Lincoln T.
   Dao, David
   Hariprasad, Seenu M.
   Skondra, Dimitra
TI Metformin and retinal diseases in preclinical and clinical studies:
   Insights and review of literature
SO EXPERIMENTAL BIOLOGY AND MEDICINE
LA English
DT Review
DE Metformin; retina; ophthalmology; glaucoma; diabetes
ID LIFE-STYLE INTERVENTION; GLAUCOMA; ACTIVATION; PREVENTION; CANCER
AB Metformin is one of the most prescribed drugs in the world giving potential health benefits beyond that of type 2 diabetes (T2DM). Emerging evidence suggests that it may have protective effects for retinal/posterior segment diseases including diabetic retinopathy (DR), age-related macular degeneration (AMD), inherited retinal degeneration such as retinitis pigmentosa (RP), primary open angle glaucoma (POAG), retinal vein occlusion (RVO), and uveitis. Metformin exerts potent anti-inflammatory, antiangiogenic, and antioxidative effects on the retina in response to pathologic stressors. In this review, we highlight the broad mechanism of action of metformin through key preclinical studies on animal models and cell lines used to simulate human retinal disease. We then explore the sparse but promising retrospective clinical data on metformin's potential protective role in DR, AMD, POAG, and uveitis. Prospective clinical data is needed to clarify metformin's role in management of posterior segment disorders. However, given metformin's proven broad biochemical effects, favorable safety profile, relatively low cost, and promising data to date, it may represent a new therapeutic preventive and strategy for retinal diseases.
C1 [Amin, Shivam, V; Khanna, Saira; Shaw, Lincoln T.; Dao, David; Hariprasad, Seenu M.; Skondra, Dimitra] Univ Chicago, Dept Ophthalmol & Visual Sci, Chicago, IL 60637 USA.
   [Parvar, Seyedeh P.] Islamic Azad Univ, Tehran Fac Med, Tehran QCGM X9, Tehran, Tehran Province, Iran.
C3 University of Chicago; Islamic Azad University
RP Skondra, D (通讯作者)，Univ Chicago, Dept Ophthalmol & Visual Sci, Chicago, IL 60637 USA.
EM dimitraskondra@gmail.com
OI Khanna, Saira/0000-0001-7373-9429
CR [Anonymous], 2016, METF MIN GEOGR ATR P
   Athanasiou D, 2017, HUM MOL GENET, V26, P305, DOI 10.1093/hmg/ddw387
   Berger NA, 2018, BRIT J PHARMACOL, V175, P192, DOI 10.1111/bph.13748
   Blitzer AL, 2021, JAMA OPHTHALMOL, V139, P302, DOI 10.1001/jamaophthalmol.2020.6331
   BOWES C, 1990, NATURE, V347, P677, DOI 10.1038/347677a0
   Bray GA, 2012, DIABETES CARE, V35, P731, DOI 10.2337/dc11-1299
   Brown EE, 2019, INVEST OPHTH VIS SCI, V60, P1470, DOI 10.1167/iovs.18-26422
   Buse JB, 2016, DIABETES CARE, V39, P198, DOI 10.2337/dc15-0488
   Campbell JM, 2017, AGEING RES REV, V40, P31, DOI 10.1016/j.arr.2017.08.003
   Case Medical Research, 2019, CASE MED RES, DOI [10.31525/ct1-nct04155164, DOI 10.31525/CT1-NCT04155164]
   Chen YY, 2019, J OPHTHALMOL, V2019, DOI 10.1155/2019/1649156
   Eton EA, 2022, EUR J OPHTHALMOL, V32, P417, DOI 10.1177/1120672121997288
   Fan YP, 2020, J DIABETES RES, V2020, DOI 10.1155/2020/9161039
   Gabriel R, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0231196
   GALUSKA D, 1991, DIABETES METAB, V17, P159
   Han J, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0193031
   Hawley SA, 2002, DIABETES, V51, P2420, DOI 10.2337/diabetes.51.8.2420
   Hurley DJ, 2021, CELLS-BASEL, V10, DOI 10.3390/cells10082131
   Iizuka K, 2017, BBA-MOL BASIS DIS, V1863, P474, DOI 10.1016/j.bbadis.2016.11.029
   Jiang T, 2014, BRIT J PHARMACOL, V171, P3146, DOI 10.1111/bph.12655
   Joe SG, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0119708
   Kalariya NM, 2012, INVEST OPHTH VIS SCI, V53, P3431, DOI 10.1167/iovs.12-9432
   Kasznicki J, 2014, ANN TRANSL MED, V2, DOI 10.3978/j.issn.2305-5839.2014.06.01
   Kim AJ, 2017, INVEST OPHTH VIS SCI, V58, P106, DOI 10.1167/iovs.16-20691
   Kim YS, 2017, BIOCHEM BIOPH RES CO, V492, P397, DOI 10.1016/j.bbrc.2017.08.087
   Knowler WC, 2002, NEW ENGL J MED, V346, P393, DOI 10.1056/NEJMoa012512
   LaMoia TE, 2021, ENDOCR REV, V42, P77, DOI 10.1210/endrev/bnaa023
   Lee H, 2019, YONSEI MED J, V60, P679, DOI 10.3349/ymj.2019.60.7.679
   Li Y, 2018, J DIABETES RES, V2018, DOI [10.1155/2018/2801450, 10.1155/2018/2801150]
   Lin HC, 2015, JAMA OPHTHALMOL, V133, P915, DOI 10.1001/jamaophthalmol.2015.1440
   Lipska KJ, 2011, DIABETES CARE, V34, P1431, DOI 10.2337/dc10-2361
   Luodan A, 2019, FRONT MOL NEUROSCI, V12, DOI 10.3389/fnmol.2019.00102
   Nahar N, 2021, N-S ARCH PHARMACOL, V394, P457, DOI 10.1007/s00210-020-01989-w
   Nathan DM, 2015, LANCET DIABETES ENDO, V3, P866, DOI 10.1016/S2213-8587(15)00291-0
   Oubaha M, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aaf9440
   Porceddu PF, 2016, NEUROTOX RES, V30, P101, DOI 10.1007/s12640-016-9633-5
   Poynter ME, 1998, J BIOL CHEM, V273, P32833, DOI 10.1074/jbc.273.49.32833
   Qu SC, 2020, OXID MED CELL LONGEV, V2020, DOI 10.1155/2020/1740943
   Quigley HA, 2006, BRIT J OPHTHALMOL, V90, P262, DOI 10.1136/bjo.2005.081224
   Rena G, 2017, DIABETOLOGIA, V60, P1577, DOI 10.1007/s00125-017-4342-z
   Romdhoniyyah DF, 2021, OPHTHALMOL THER, V10, P245, DOI 10.1007/s40123-021-00344-3
   Romero IL, 2012, OBSTET GYNECOL, V119, P61, DOI 10.1097/AOG.0b013e3182393ab3
   Romero R, 2017, AM J OBSTET GYNECOL, V217, P282, DOI 10.1016/j.ajog.2017.06.003
   Saeedi P, 2019, DIABETES RES CLIN PR, V157, DOI 10.1016/j.diabres.2019.107843
   Saisho Y, 2015, ENDOCR METAB IMMUNE, V15, P196, DOI 10.2174/1871530315666150316124019
   SMITH LEH, 1994, INVEST OPHTH VIS SCI, V35, P101
   Sobrin L, 2022, OCUL IMMUNOL INFLAMM, V30, P1334, DOI 10.1080/09273948.2021.1872650
   Stewart JM, 2020, OPHTHALMOL RETINA, V4, P1118, DOI 10.1016/j.oret.2020.06.003
   Weinreb RN, 2014, JAMA-J AM MED ASSOC, V311, P1901, DOI 10.1001/jama.2014.3192
   White J., 2008, MEDICATIONS TREATMEN, P5
   White John R Jr, 2014, Diabetes Spectr, V27, P82, DOI 10.2337/diaspect.27.2.82
   Xu L, 2020, REDOX BIOL, V37, DOI 10.1016/j.redox.2020.101700
   Xu L, 2018, P NATL ACAD SCI USA, V115, P10475, DOI 10.1073/pnas.1802724115
   Yi QY, 2016, AM J TRANSL RES, V8, P3947
   Ying Y, 2017, ONCOTARGET, V8, P32794, DOI 10.18632/oncotarget.15825
   Zhang Y, 2017, AM J TRANSL RES, V9, P5558
   Zhao X, 2020, OXID MED CELL LONGEV, V2020, DOI 10.1155/2020/2524174
   Zhou J, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19102863
   Zhu J, 2018, J AM HEART ASSOC, V7, DOI 10.1161/JAHA.117.008389
NR 59
TC 0
Z9 0
U1 2
U2 3
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1535-3702
EI 1535-3699
J9 EXP BIOL MED
JI Exp. Biol. Med.
PD FEB
PY 2022
VL 247
IS 4
BP 317
EP 329
AR 15353702211069986
DI 10.1177/15353702211069986
EA JAN 2022
PG 13
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA ZN1RS
UT WOS:000748928400001
PM 35068220
OA Green Published
DA 2022-11-30
ER

PT J
AU Kaur, G
   Singh, NK
AF Kaur, Geetika
   Singh, Nikhlesh K.
TI The Role of Inflammation in Retinal Neurodegeneration and Degenerative
   Diseases
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Review
DE retina; retinal degeneration; AMD
ID LEBER CONGENITAL AMAUROSIS; AGE-RELATED MACULOPATHY; CONE CELL-DEATH;
   MACULAR DEGENERATION; GENE-THERAPY; MOUSE MODEL; PHOTORECEPTOR
   DEGENERATION; MICROGLIAL PHAGOCYTOSIS; RETINITIS-PIGMENTOSA;
   MOLECULAR-GENETICS
AB Retinal neurodegeneration is predominantly reported as the apoptosis or impaired function of the photoreceptors. Retinal degeneration is a major causative factor of irreversible vision loss leading to blindness. In recent years, retinal degenerative diseases have been investigated and many genes and genetic defects have been elucidated by many of the causative factors. An enormous amount of research has been performed to determine the pathogenesis of retinal degenerative conditions and to formulate the treatment modalities that are the critical requirements in this current scenario. Encouraging results have been obtained using gene therapy. We provide a narrative review of the various studies performed to date on the role of inflammation in human retinal degenerative diseases such as age-related macular degeneration, inherited retinal dystrophies, retinitis pigmentosa, Stargardt macular dystrophy, and Leber congenital amaurosis. In addition, we have highlighted the pivotal role of various inflammatory mechanisms in the progress of retinal degeneration. This review also offers an assessment of various therapeutic approaches, including gene-therapies and stem-cell-based therapies, for degenerative retinal diseases.
C1 [Kaur, Geetika; Singh, Nikhlesh K.] Wayne State Univ, Integrat Biosci Ctr, Detroit, MI 48202 USA.
   [Kaur, Geetika; Singh, Nikhlesh K.] Wayne State Univ, Sch Med, Dept Ophthalmol Visual & Anat Sci, Detroit, MI 48202 USA.
C3 Wayne State University; Wayne State University
RP Singh, NK (通讯作者)，Wayne State Univ, Integrat Biosci Ctr, Detroit, MI 48202 USA.; Singh, NK (通讯作者)，Wayne State Univ, Sch Med, Dept Ophthalmol Visual & Anat Sci, Detroit, MI 48202 USA.
EM hj1044@wayne.edu; nsingh2@wayne.edu
OI Singh, Nikhlesh/0000-0002-3665-6023
FU National Institutes of Health [EY029709]; Research to Prevent Blindness;
   Kresge Eye Institute [P30EY04068]
FX The present work was supported by a grant from National Institutes of
   Health (EY029709 to NKS). Supported by a Research to Prevent Blindness
   unrestricted grant to Kresge Eye Institute, and by P30EY04068 (LDH) at
   Wayne State University.
CR Ahmed AU, 2015, BIOMOLECULES, V5, P3087, DOI 10.3390/biom5043087
   Akira S, 2004, NAT REV IMMUNOL, V4, P499, DOI 10.1038/nri1391
   Alikhan A, 2010, AM J CLIN DERMATOL, V11, P79, DOI 10.2165/11530200-000000000-00000
   Allikmets R, 1997, NAT GENET, V15, P236, DOI 10.1038/ng0397-236
   Altmann C, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19010110
   Amato A, 2021, FRONT MED-LAUSANNE, V8, DOI 10.3389/fmed.2021.750586
   Ambati J, 2013, NAT REV IMMUNOL, V13, P438, DOI 10.1038/nri3459
   Ammar MJ, 2020, CURR OPIN OPHTHALMOL, V31, P215, DOI 10.1097/ICU.0000000000000657
   Appelbaum T, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0177224
   Arroba AI, 2018, FRONT AGING NEUROSCI, V10, DOI 10.3389/fnagi.2018.00203
   Arroba AI, 2017, ACTA DIABETOL, V54, P527, DOI 10.1007/s00592-017-0984-z
   Augustine J, 2019, J NEUROINFLAMM, V16, DOI 10.1186/s12974-019-1625-y
   Bainbridge JWB, 2008, NEW ENGL J MED, V358, P2231, DOI 10.1056/NEJMoa0802268
   Behl T, 2016, DIABETES-METAB RES, V32, P251, DOI 10.1002/dmrr.2710
   Bennett JM, 2018, FRONT MED-LAUSANNE, V5, DOI 10.3389/fmed.2018.00316
   Blank T, 2018, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01930
   Bomotti S, 2018, INVEST OPHTH VIS SCI, V59, P4518, DOI 10.1167/iovs.18-23914
   Broadgate S, 2017, PROG RETIN EYE RES, V59, P53, DOI 10.1016/j.preteyeres.2017.03.003
   Brown EE, 2018, ADV EXP MED BIOL, V1074, P11, DOI 10.1007/978-3-319-75402-4_2
   Busskamp V, 2012, GENE THER, V19, P169, DOI 10.1038/gt.2011.155
   Calippe B, 2017, IMMUNITY, V46, P261, DOI 10.1016/j.immuni.2017.01.006
   Campochiaro PA, 2018, PROG RETIN EYE RES, V62, P24, DOI 10.1016/j.preteyeres.2017.08.004
   Carniglia L, 2017, MEDIAT INFLAMM, V2017, DOI 10.1155/2017/5048616
   Casey GA, 2020, J OPHTHAL VIS RES, V15, P396, DOI 10.18502/jovr.v15i3.7457
   Celkova L, 2015, J CLIN MED, V4, P172, DOI 10.3390/jcm4010172
   Chakarova CF, 2011, HUM MOL GENET, V20, P975, DOI 10.1093/hmg/ddq543
   Chaumet-Riffaud AE, 2017, AM J OPHTHALMOL, V177, P169, DOI 10.1016/j.ajo.2017.02.016
   Chen Y, 2020, CUTAN OCUL TOXICOL, V39, P36, DOI 10.1080/15569527.2019.1685535
   Chinnery HR, 2012, NEUROBIOL AGING, V33, P1769, DOI 10.1016/j.neurobiolaging.2011.03.010
   Choudhury S, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.34
   Cideciyan AV, 2013, P NATL ACAD SCI USA, V110, pE517, DOI 10.1073/pnas.1218933110
   Cideciyan AV, 2008, P NATL ACAD SCI USA, V105, P15112, DOI 10.1073/pnas.0807027105
   Comitato A, 2014, INVEST OPHTH VIS SCI, V55, P3555, DOI 10.1167/iovs.14-13917
   Copland DA, 2018, INVEST OPHTH VIS SCI, V59, pAMD83, DOI 10.1167/iovs.18-23893
   Cuenca N, 2014, PROG RETIN EYE RES, V43, P17, DOI 10.1016/j.preteyeres.2014.07.001
   de Jong EK, 2020, GENETICS AND GENOMICS OF EYE DISEASE: ADVANCING TO PRECISION MEDICINE, P155, DOI 10.1016/B978-0-12-816222-4.00010-1
   Peixoto RD, 2021, EYE, V35, P3333, DOI 10.1038/s41433-021-01414-3
   den Hollander AI, 2008, PROG RETIN EYE RES, V27, P391, DOI 10.1016/j.preteyeres.2008.05.003
   Dinarello CA, 2012, NAT REV DRUG DISCOV, V11, P633, DOI 10.1038/nrd3800
   Ding XY, 2009, PROG RETIN EYE RES, V28, P1, DOI 10.1016/j.preteyeres.2008.10.001
   Eandi CM, 2016, ELIFE, V5, DOI 10.7554/eLife.16490
   Ebihara N, 2007, OPHTHAL RES, V39, P155, DOI 10.1159/000103235
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Espinosa-Heidmann DG, 2006, INVEST OPHTH VIS SCI, V47, P729, DOI 10.1167/iovs.05-0719
   Fenwick EK, 2017, BRIT J OPHTHALMOL, V101, P686, DOI 10.1136/bjophthalmol-2016-308701
   Fernando N, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0514-x
   Friedman JS, 2009, AM J HUM GENET, V84, P792, DOI 10.1016/j.ajhg.2009.05.007
   Fritsche LG, 2014, ANNU REV GENOM HUM G, V15, P151, DOI 10.1146/annurev-genom-090413-025610
   Gallenga CE, 2021, ANTIOXIDANTS-BASEL, V10, DOI 10.3390/antiox10060848
   Garafalo AV, 2020, PROG RETIN EYE RES, V77, DOI 10.1016/j.preteyeres.2019.100827
   Gasparini SJ, 2019, PROG RETIN EYE RES, V69, P1, DOI 10.1016/j.preteyeres.2018.11.001
   Geerlings MJ, 2017, MOL IMMUNOL, V84, P65, DOI 10.1016/j.molimm.2016.11.016
   Genini S, 2014, BMC GENOMICS, V15, DOI 10.1186/1471-2164-15-172
   Ghasemi H, 2011, OCUL IMMUNOL INFLAMM, V19, P401, DOI 10.3109/09273948.2011.618902
   Gora IM, 2021, CELLS-BASEL, V10, DOI 10.3390/cells10020314
   Goverdhan SV, 2008, BRIT J OPHTHALMOL, V92, P537, DOI 10.1136/bjo.2007.123190
   Gudkov AV, 2016, CSH PERSPECT MED, V6, DOI 10.1101/cshperspect.a026161
   Hammond BR, 1996, VISION RES, V36, P3003, DOI 10.1016/0042-6989(96)00008-9
   Handa JT, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11262-1
   Hartong DT, 2006, LANCET, V368, P1795, DOI 10.1016/S0140-6736(06)69740-7
   Heesterbeek TJ, 2020, OPHTHAL PHYSL OPT, V40, P140, DOI 10.1111/opo.12675
   Alves CH, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9051217
   Holan V, 2021, CELLS-BASEL, V10, DOI 10.3390/cells10030588
   Ikeda Y, 2019, JPN J OPHTHALMOL, V63, P181, DOI 10.1007/s10384-018-00644-5
   Jablonski KA, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0159724
   Jackson ACW, 2016, J NEUROCHEM, V136, P63, DOI 10.1111/jnc.13388
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Jiao HH, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0143952
   Jozsef L, 2006, J IMMUNOL, V176, P1195, DOI 10.4049/jimmunol.176.2.1195
   Karlstetter M, 2015, PROG RETIN EYE RES, V45, P30, DOI 10.1016/j.preteyeres.2014.11.004
   Kauppinen A, 2016, CELL MOL LIFE SCI, V73, P1765, DOI 10.1007/s00018-016-2147-8
   Kim SJ, 2010, SURV OPHTHALMOL, V55, P108, DOI 10.1016/j.survophthal.2009.07.005
   Knudtson MD, 2006, BRIT J OPHTHALMOL, V90, P1461, DOI 10.1136/bjo.2006.103796
   Kohno H, 2014, J IMMUNOL, V192, P3816, DOI 10.4049/jimmunol.1301738
   Kohno H, 2013, J BIOL CHEM, V288, P15326, DOI 10.1074/jbc.M112.448712
   Kumaran N, 2017, BRIT J OPHTHALMOL, V101, P1147, DOI 10.1136/bjophthalmol-2016-309975
   Kunte MM, 2012, INVEST OPHTH VIS SCI, V53, P3792, DOI 10.1167/iovs.11-9235
   Kuzmich NN, 2017, VACCINES-BASEL, V5, DOI 10.3390/vaccines5040034
   Lambert NG, 2016, PROG RETIN EYE RES, V54, P64, DOI 10.1016/j.preteyeres.2016.04.003
   Leroy BP, 2021, RETINA-J RET VIT DIS, V41, P898, DOI 10.1097/IAE.0000000000003133
   Levy O, 2015, EMBO MOL MED, V7, P211, DOI 10.15252/emmm.201404524
   Li L, 2010, AM J HUM GENET, V87, P400, DOI 10.1016/j.ajhg.2010.08.003
   Lin JB, 2018, PROG RETIN EYE RES, V67, P118, DOI 10.1016/j.preteyeres.2018.06.002
   Liu HY, 2018, ONCOTARGET, V9, P2887, DOI 10.18632/oncotarget.20812
   Maguire AM, 2008, NEW ENGL J MED, V358, P2240, DOI 10.1056/NEJMoa0802315
   Maguire AM, 2019, OPHTHALMOLOGY, V126, P1273, DOI 10.1016/j.ophtha.2019.06.017
   Malsy J, 2020, ELIFE, V9, DOI 10.7554/eLife.60194
   de la Camara CMF, 2015, SCI REP-UK, V5, DOI 10.1038/srep11764
   McKay GJ, 2011, HUM MUTAT, V32, P1407, DOI 10.1002/humu.21577
   McMenamin PG, 2019, PROG RETIN EYE RES, V70, P85, DOI 10.1016/j.preteyeres.2018.12.002
   MELROSE MA, 1985, OPHTHALMIC SURG LAS, V16, P648
   Menghini M, 2020, EXPERT OPIN ORPHAN D, V8, P67, DOI 10.1080/21678707.2020.1735352
   Miller AM, 2008, J EXP MED, V205, P339, DOI 10.1084/jem.20071868
   Moldogazieva NT, 2019, OXID MED CELL LONGEV, V2019, DOI 10.1155/2019/3085756
   Morizane Y, 2019, JPN J OPHTHALMOL, V63, P26, DOI 10.1007/s10384-018-0623-4
   Murakami Y, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21197170
   Murakami Y, 2020, PROG RETIN EYE RES, V74, DOI 10.1016/j.preteyeres.2019.100778
   Murakami Y, 2012, P NATL ACAD SCI USA, V109, P14598, DOI 10.1073/pnas.1206937109
   Nassar K, 2015, GRAEF ARCH CLIN EXP, V253, P699, DOI 10.1007/s00417-014-2738-8
   Naz S, 2010, AM J OPHTHALMOL, V149, P861, DOI 10.1016/j.ajo.2009.12.034
   Nielsen MK, 2019, INVEST OPHTH VIS SCI, V60, P202, DOI 10.1167/iovs.18-25878
   Noailles A, 2014, J NEUROINFLAMM, V11, DOI 10.1186/s12974-014-0186-3
   Okita A, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.11.30
   Olivares-Gonzalez L, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22042096
   Olivares-Gonzalez L, 2020, FASEB J, V34, P13839, DOI 10.1096/fj.202000044RR
   Ong SR, 2018, EYE, V32, P1296, DOI 10.1038/s41433-018-0081-8
   Peng B, 2014, J NEUROSCI, V34, P8139, DOI 10.1523/JNEUROSCI.5200-13.2014
   Pereira Datson Marian, 2017, J Clin Diagn Res, V11, pNC01, DOI 10.7860/JCDR/2017/24496.9686
   Petrou PA, 2015, INVEST OPHTH VIS SCI, V56, P330, DOI 10.1167/iovs.14-15877
   Pinto SM, 2018, J CELL COMMUN SIGNAL, V12, P615, DOI 10.1007/s12079-018-0464-4
   Punzo C, 2009, NAT NEUROSCI, V12, P44, DOI 10.1038/nn.2234
   Qian YJ, 2020, MEDIAT INFLAMM, V2020, DOI 10.1155/2020/5230716
   Rashid K, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01975
   Riveiro-Alvarez R, 2013, OPHTHALMOLOGY, V120, P2332, DOI 10.1016/j.ophtha.2013.04.002
   Ronning KE, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-41141-0
   Rosenberg T, 2007, MOL VIS, V13, P1962
   Roshanipour N, 2019, J CURR OPHTHALMOL, V31, P292, DOI 10.1016/j.joco.2019.07.005
   Rutar M, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-014-0224-1
   Sahel JA, 2013, ANNU REV NEUROSCI, V36, P467, DOI 10.1146/annurev-neuro-062012-170304
   Sarks SH, 1999, BRIT J OPHTHALMOL, V83, P358, DOI 10.1136/bjo.83.3.358
   Sastry BVR, 1998, J OCUL PHARMACOL TH, V14, P447, DOI 10.1089/jop.1998.14.447
   Scholl HPN, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aaf2838
   Schwartz SD, 2014, PRINCIPLES OF TISSUE ENGINEERING, 4TH EDITION, P1427, DOI 10.1016/B978-0-12-398358-9.00068-9
   Seddon JM, 2004, JAMA-J AM MED ASSOC, V291, P704, DOI 10.1001/jama.291.6.704
   Sene A, 2018, ADV EXP MED BIOL, V1074, P203, DOI 10.1007/978-3-319-75402-4_25
   Sennlaub F, 2013, EMBO MOL MED, V5, P1775, DOI 10.1002/emmm.201302692
   Senthil MP, 2017, J PATIENT-REP OUTCOM, V1, DOI 10.1186/s41687-017-0023-4
   Sergejeva O, 2016, MEDICINA-LITHUANIA, V52, P79, DOI 10.1016/j.medici.2016.02.004
   Shanmugam N, 2008, DIABETES, V57, P879, DOI 10.2337/db07-1204
   Singh M, 2018, INT J OPHTHALMOL-CHI, V11, P117, DOI 10.18240/ijo.2018.01.20
   Smith SB, 2018, PROG RETIN EYE RES, V67, P130, DOI 10.1016/j.preteyeres.2018.07.003
   Streit WJ, 2004, J NEUROINFLAMM, V1, DOI 10.1186/1742-2094-1-14
   Sugita S, 2013, INVEST OPHTH VIS SCI, V54, P3240, DOI 10.1167/iovs.12-11483
   Takeuchi O, 2010, CELL, V140, P805, DOI 10.1016/j.cell.2010.01.022
   Tanna P, 2017, BRIT J OPHTHALMOL, V101, P25, DOI 10.1136/bjophthalmol-2016-308823
   ten Berge JC, 2019, ACTA OPHTHALMOL, V97, P185, DOI 10.1111/aos.13899
   Toomey CB, 2015, P NATL ACAD SCI USA, V112, pE3040, DOI 10.1073/pnas.1424391112
   Touhami S, 2018, J NEUROINFLAMM, V15, DOI 10.1186/s12974-018-1106-8
   Trifunovic D, 2012, CURR MOL MED, V12, P598, DOI 10.2174/156652412800620048
   Usui S, 2009, J NEUROCHEM, V110, P1028, DOI 10.1111/j.1471-4159.2009.06195.x
   Varela MD, 2022, BRIT J OPHTHALMOL, V106, P445, DOI 10.1136/bjophthalmol-2020-318483
   Vessey KA, 2015, INVEST OPHTH VIS SCI, V56, P1238, DOI 10.1167/iovs.14-15334
   Wang Y, 2011, EYE, V25, P127, DOI 10.1038/eye.2010.196
   Waugh N, 2018, HEALTH TECHNOL ASSES, V22, P1, DOI 10.3310/hta22270
   WEINBLATT ME, 1985, NEW ENGL J MED, V312, P818, DOI 10.1056/NEJM198503283121303
   Whitcup SM, 2013, INT J INFLAMM, V2013, DOI 10.1155/2013/724648
   Wong EKS, 2021, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.602284
   Woo SJ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132771
   Wooff Y, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01618
   Wykoff CC, 2017, CURR OPIN OPHTHALMOL, V28, P213, DOI 10.1097/ICU.0000000000000364
   Xiong WJ, 2015, J CLIN INVEST, V125, P1433, DOI 10.1172/JCI79735
   Yerramothu P, 2018, EYE, V32, P491, DOI 10.1038/eye.2017.241
   Yoshida N, 2013, OPHTHALMOLOGY, V120, P100, DOI 10.1016/j.ophtha.2012.07.006
   Zabel MK, 2016, GLIA, V64, P1479, DOI 10.1002/glia.23016
   Zareparsi S, 2005, HUM MOL GENET, V14, P1449, DOI 10.1093/hmg/ddi154
   Zeng HL, 2018, INT J OPHTHALMOL-CHI, V11, P143, DOI 10.18240/ijo.2018.01.22
   Zhang QJ, 2016, ASIA-PAC J OPHTHALMO, V5, P265, DOI 10.1097/APO.0000000000000227
   Zhao L, 2015, EMBO MOL MED, V7, P1179, DOI 10.15252/emmm.201505298
   Ziccardi L, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20225722
NR 159
TC 7
Z9 7
U1 3
U2 5
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1422-0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD JAN
PY 2022
VL 23
IS 1
AR 386
DI 10.3390/ijms23010386
PG 20
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA YV6VH
UT WOS:000752865000001
PM 35008812
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Manzar, H
   Abdulhussein, D
   Yap, TE
   Cordeiro, MF
AF Manzar, Haider
   Abdulhussein, Dalia
   Yap, Timothy E.
   Cordeiro, M. Francesca
TI Cellular Consequences of Coenzyme Q10 Deficiency in Neurodegeneration of
   the Retina and Brain
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Review
DE coenzyme Q10; neurodegeneration; reactive oxygen species; apoptosis
AB Coenzyme Q10 (CoQ10) is a ubiquitous cofactor in the body, operating in the inner mitochondrial membrane, where it plays a vital role in the generation of adenosine triphosphate (ATP) through the electron transport chain (ETC). In addition to this, CoQ10 serves as an antioxidant, protecting the cell from oxidative stress by reactive oxygen species (ROS) as well as maintaining a proton (H+) gradient across lysosome membranes to facilitate the breakdown of cellular waste products. Through the process of ageing, the body becomes deficient in CoQ10, resulting in several systemic manifestations. On a cellular level, one of the consequences of CoQ10 deficiency is apoptosis, which can be visualised in tissues of the central nervous system (CNS). Diseases affecting the retina and brain such as age-related macular degeneration (AMD), glaucoma, Alzheimer's disease (AD) and Parkinson's disease (PD) have shown defects in cellular biochemical reactions attributed to reduced levels of CoQ10. Through further research into the pathogenesis of such conditions, the effects of CoQ10 deficiency can be counteracted through supplementation, early detection and intervention.
C1 [Manzar, Haider; Abdulhussein, Dalia; Yap, Timothy E.; Cordeiro, M. Francesca] Western Eye Hosp, Imperial Coll Ophthalmol Res Grp, 153-173 Marylebone Rd, London NW1 5QH, England.
   [Cordeiro, M. Francesca] UCL, Inst Ophthalmol, Glaucoma & Retinal Neurodegenerat Res Grp, London EC1V 9EL, England.
C3 University of London; University College London
RP Cordeiro, MF (通讯作者)，Western Eye Hosp, Imperial Coll Ophthalmol Res Grp, 153-173 Marylebone Rd, London NW1 5QH, England.; Cordeiro, MF (通讯作者)，UCL, Inst Ophthalmol, Glaucoma & Retinal Neurodegenerat Res Grp, London EC1V 9EL, England.
EM haider.manzar@southend.nhs.uk; dalia.abdulhussein13@imperial.ac.uk;
   timothyedward.yap@nhs.net; m.cordeiro@imperial.ac.uk
OI Cordeiro, Maria Francesca/0000-0001-8663-6525
CR ABERG F, 1992, ARCH BIOCHEM BIOPHYS, V295, P230, DOI 10.1016/0003-9861(92)90511-T
   Acosta MJ, 2016, BBA-BIOENERGETICS, V1857, P1079, DOI 10.1016/j.bbabio.2016.03.036
   Al-Mahdawi S, 2006, GENOMICS, V88, P580, DOI 10.1016/j.ygeno.2006.06.015
   Babcock M, 1997, SCIENCE, V276, P1709, DOI 10.1126/science.276.5319.1709
   Beal MF, 2014, JAMA NEUROL, V71, P543, DOI 10.1001/jamaneurol.2014.131
   BEAL MF, 1994, ANN NEUROL, V36, P882, DOI 10.1002/ana.410360613
   Beal MF, 1998, BRAIN RES, V783, P109, DOI 10.1016/S0006-8993(97)01192-X
   Bergamasco B, 1994, Funct Neurol, V9, P161
   Bhagavan HN, 2006, FREE RADICAL RES, V40, P445, DOI 10.1080/10715760600617843
   Blasi MA, 2001, OPHTHALMOLOGICA, V215, P51, DOI 10.1159/000050826
   Braak H, 2000, J NEUROL, V247, P3
   Bradley JL, 2000, HUM MOL GENET, V9, P275, DOI 10.1093/hmg/9.2.275
   BRESOLIN N, 1990, J NEUROL SCI, V100, P70, DOI 10.1016/0022-510X(90)90015-F
   Burk Katrin, 2017, Cerebellum Ataxias, V4, P4, DOI 10.1186/s40673-017-0062-x
   CALNE DB, 1992, ANN NEUROL, V32, pS125, DOI 10.1002/ana.410320721
   Campuzano V, 1996, SCIENCE, V271, P1423, DOI 10.1126/science.271.5254.1423
   Campuzano V, 1997, HUM MOL GENET, V6, P1771, DOI 10.1093/hmg/6.11.1771
   Challem J., 1996, NUTR REPORTER
   Choi H, 2012, NEUROTOXICOLOGY, V33, P85, DOI 10.1016/j.neuro.2011.12.005
   Cooper JM, 2008, EUR J NEUROL, V15, P1371, DOI 10.1111/j.1468-1331.2008.02318.x
   Davis BM, 2017, MITOCHONDRION, V36, P114, DOI 10.1016/j.mito.2017.05.010
   de Barcelos IP, 2019, BIOLOGY-BASEL, V8, DOI 10.3390/biology8020028
   Desbats MA, 2016, HUM MOL GENET, V25, P4256, DOI 10.1093/hmg/ddw257
   DiMauro S, 2007, J CLIN INVEST, V117, P587, DOI 10.1172/JCI31423
   Dumont M, 2011, J ALZHEIMERS DIS, V27, P211, DOI 10.3233/JAD-2011-110209
   Durr A, 1996, NEW ENGL J MED, V335, P1169, DOI 10.1056/NEJM199610173351601
   Dusting GJ, 2005, VASC HEALTH RISK MAN, V1, P93, DOI 10.2147/vhrm.1.2.93.64080
   EDLUND C, 1992, BIOCHEM CELL BIOL, V70, P422, DOI 10.1139/o92-065
   Fahn S, 2006, J NEURAL TRANSM-SUPP, P1
   Feigin A, 1996, MOVEMENT DISORD, V11, P321, DOI 10.1002/mds.870110317
   Ferrante RJ, 2002, J NEUROSCI, V22, P1592, DOI 10.1523/JNEUROSCI.22-05-01592.2002
   Forno L.S, 1988, PROG PARKINSON RES, P11
   Foury F, 1997, FEBS LETT, V411, P373, DOI 10.1016/S0014-5793(97)00734-5
   Galasko DR, 2012, ARCH NEUROL-CHICAGO, V69, P836, DOI 10.1001/archneurol.2012.85
   Gempel K, 2007, BRAIN, V130, P2037, DOI 10.1093/brain/awm054
   HARDING AE, 1981, BRAIN, V104, P589, DOI 10.1093/brain/104.3.589
   Hart PE, 2005, ARCH NEUROL-CHICAGO, V62, P621, DOI 10.1001/archneur.62.4.621
   Heaton RA, 2020, J CLIN MED, V9, DOI 10.3390/jcm9061923
   Jenner P, 1996, PATHOL BIOL, V44, P57
   Kawamoto EM, 2005, NEUROBIOL AGING, V26, P857, DOI 10.1016/j.neurobiolaging.2004.08.011
   Kieburtz K, 2001, NEUROLOGY, V57, P397
   KNEKT P, 1992, BMJ-BRIT MED J, V305, P1392, DOI 10.1136/bmj.305.6866.1392
   Koroshetz WJ, 1997, ANN NEUROL, V41, P160, DOI 10.1002/ana.410410206
   Koutnikova H, 1997, NAT GENET, V16, P345, DOI 10.1038/ng0897-345
   KRIGE D, 1992, ANN NEUROL, V32, P782, DOI 10.1002/ana.410320612
   Kuhlbrandt W, 2015, BMC BIOL, V13, DOI 10.1186/s12915-015-0201-x
   Lagendijk J, 1996, J LIPID RES, V37, P67
   LANGSTON JW, 1983, SCIENCE, V219, P979, DOI 10.1126/science.6823561
   Lee D, 2014, INVEST OPHTH VIS SCI, V55, P993, DOI 10.1167/iovs.13-12564
   Lenaz G, 1998, BBA-BIOENERGETICS, V1366, P53, DOI 10.1016/S0005-2728(98)00120-0
   Lodi R, 2001, ANN NEUROL, V49, P590
   Lulli M, 2012, INVEST OPHTH VIS SCI, V53, P8295, DOI 10.1167/iovs.12-10374
   Mancini A, 2011, INT J MOL SCI, V12, P9216, DOI 10.3390/ijms12129216
   Mancino R, 2019, CURR MED CHEM, V26, P3754, DOI 10.2174/0929867325666180307114332
   Miles MV, 2003, CLIN CHIM ACTA, V332, P123, DOI 10.1016/S0009-8981(03)00137-2
   Mollet J, 2007, J CLIN INVEST, V117, P765, DOI 10.1172/JCI29089
   Nagase M, 2018, J CLIN BIOCHEM NUTR, V63, P129, DOI [10.3164/jcbn.17.124, 10.3164/jcbn.17-124]
   Nohl H., 2001, COENZYME Q MOL MECH, P99
   Nucci C, 2007, INT REV NEUROBIOL, V82, P397, DOI 10.1016/S0074-7742(07)82022-8
   Nucci C, 2016, EUR J PHARMACOL, V787, P119, DOI 10.1016/j.ejphar.2016.04.030
   Nunomura A., 2007, CNS & Neurological Disorders-Drug Targets, V6, P411, DOI 10.2174/187152707783399201
   Olanow CW, 1999, ANNU REV NEUROSCI, V22, P123, DOI 10.1002/mds.23732
   Ozates S, 2019, EUR J OPHTHALMOL, V29, P196, DOI 10.1177/1120672118779486
   Park HW., 2020, SCI REP-UK, V10, P1, DOI [10.1038/s41598-019-56847-4, DOI 10.1038/S41598-019-56847-4]
   PARKER WD, 1989, ANN NEUROL, V26, P719, DOI 10.1002/ana.410260606
   Popovic N, 2006, INT J PHARMACEUT, V314, P120, DOI 10.1016/j.ijpharm.2005.09.040
   Potgieter M, 2013, NUTR REV, V71, P180, DOI 10.1111/nure.12011
   Przedborski S, 1998, MOVEMENT DISORD, V13, P35
   Qu JF, 2009, INVEST OPHTH VIS SCI, V50, P1814, DOI 10.1167/iovs.08-2656
   Quaranta L, 2019, ADV THER, V36, P2506, DOI 10.1007/s12325-019-01023-3
   Quinzii CM, 2017, FRONT PHYSIOL, V8, DOI 10.3389/fphys.2017.00525
   Quinzii CM, 2011, BIOFACTORS, V37, P361, DOI 10.1002/biof.155
   Quinzii CM, 2010, FASEB J, V24, P3733, DOI 10.1096/fj.09-152728
   Rahman S, 2001, J PEDIATR-US, V139, P456, DOI 10.1067/mpd.2001.117575
   Rotig A, 2000, LANCET, V356, P391, DOI 10.1016/S0140-6736(00)02531-9
   Russo R, 2008, PROG BRAIN RES, V173, P575, DOI 10.1016/S0079-6123(08)01139-4
   Schapira AHV, 2008, LANCET NEUROL, V7, P97, DOI 10.1016/S1474-4422(07)70327-7
   SENIN U, 1992, ARCH GERONTOL GERIAT, V15, P249, DOI 10.1016/0167-4943(92)90060-H
   Sherer T., 2001, PATHOGENESIS PARKINS
   Shults CW, 2002, ARCH NEUROL-CHICAGO, V59, P1541, DOI 10.1001/archneur.59.10.1541
   Shults CW, 1998, NEUROLOGY, V50, P793, DOI 10.1212/WNL.50.3.793
   SHULTS CW, 1995, NEUROLOGY, V45, P344, DOI 10.1212/WNL.45.2.344
   Shults CW, 1997, ANN NEUROL, V42, P261, DOI 10.1002/ana.410420221
   SIAN J, 1994, ANN NEUROL, V36, P348, DOI 10.1002/ana.410360305
   Silverman H.M., 1993, VITAMIN BOOK
   SODERBERG M, 1990, J NEUROCHEM, V54, P415, DOI 10.1111/j.1471-4159.1990.tb01889.x
   Turner C, 2001, ADV EXP MED BIOL, V487, P229
   Vaughan JR, 2001, ANN HUM GENET, V65, P111, DOI 10.1017/S0003480001008557
   Wong A, 1999, HUM MOL GENET, V8, P425, DOI 10.1093/hmg/8.3.425
   Yamagishi K, 2014, ATHEROSCLEROSIS, V237, P400, DOI 10.1016/j.atherosclerosis.2014.09.017
   Yang XF, 2008, J MOL NEUROSCI, V34, P165, DOI 10.1007/s12031-007-9033-7
NR 91
TC 17
Z9 17
U1 0
U2 11
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1422-0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD DEC
PY 2020
VL 21
IS 23
AR 9299
DI 10.3390/ijms21239299
PG 13
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA PD1RP
UT WOS:000597471200001
PM 33291255
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Crisostomo, S
   Cardigos, J
   Fernandes, DH
   Luis, ME
   Figueiredo, R
   Moura-Coelho, N
   Cunha, JP
   Pinto, LA
   Ferreira, J
AF Crisostomo, Sara
   Cardigos, Joana
   Fernandes, Diogo Hipolito
   Luis, Maria Elisa
   Figueiredo, Ricardo
   Moura-Coelho, Nuno
   Cunha, Joao Paulo
   Pinto, Luis Abegao
   Ferreira, Joana
TI Choroidal binarization analysis: clinical application
SO INTERNATIONAL OPHTHALMOLOGY
LA English
DT Review
DE Choroid; Choroidal imaging; Binarization; Optic coherence tomography
ID OPTICAL COHERENCE TOMOGRAPHY; CENTRAL SEROUS CHORIORETINOPATHY;
   KOYANAGI-HARADA-DISEASE; MACULAR DEGENERATION; VASCULARITY INDEX;
   DIABETIC CHOROIDOPATHY; STRUCTURAL-CHANGES; STROMAL AREAS; NORMAL EYES;
   BLOOD-FLOW
AB IntroductionImage processing of optical coherence tomography scans through binarization techniques represent a non-invasive way to separately asses and measure choroidal components, in vivo. In this review, we systematically search the scientific literature regarding binarization studies published so far.MethodsA systematic research was conducted at PubMed database, including English literature articles for all of the following terms in various combinations: binarization, choroid/al, enhanced depth spectral domain/swept source optic coherence tomography, and latest publications up to November 2018 were reviewed.ResultsThirty-seven articles were included and analyzed regarding studied disease, binarization method, studied variables, and outcomes. Most of the studies have focused on the more common retinal pathologies, such as age-related macular degeneration, central serous chorioretinopathy and diabetic retinopathy but binarization techniques have also been applied to the study of choroidal characteristics in ocular inflammatory diseases, corneal dystrophies and in postsurgical follow-up. Advantages and disadvantages of binarization techniques are also discussed.ConclusionBinarization of choroidal images seems to represent a promising approach to study choroid subcomponents in an increasingly detailed manner.
C1 [Crisostomo, Sara; Cardigos, Joana; Fernandes, Diogo Hipolito; Luis, Maria Elisa; Moura-Coelho, Nuno; Cunha, Joao Paulo; Ferreira, Joana] Cent Lisbon Hosp Ctr, Dept Ophthalmol, Alameda Santo Antonio DOS Capuchos, P-1169050 Lisbon, Portugal.
   [Figueiredo, Ricardo] Evora Espirito Santo Hosp, Dept Ophthalmol, Evora, Portugal.
   [Pinto, Luis Abegao] North Lisbon Hosp Ctr, Dept Ophthalmol, Lisbon, Portugal.
   [Cunha, Joao Paulo; Ferreira, Joana] Univ Nova Lisboa, Fac Ciencias Med, NOVA Med Sch, Lisbon, Portugal.
   [Pinto, Luis Abegao] Univ Lisbon, Visual Sci Study Ctr, Fac Med, Lisbon, Portugal.
C3 Universidade Nova de Lisboa; Universidade de Lisboa
RP Crisostomo, S (通讯作者)，Cent Lisbon Hosp Ctr, Dept Ophthalmol, Alameda Santo Antonio DOS Capuchos, P-1169050 Lisbon, Portugal.
EM saralbcrisostomo@gmail.com
RI Fernandes, Diogo/GZM-2387-2022; Pinto, Luis Abegão/Y-7762-2018
OI Pinto, Luis Abegão/0000-0002-9960-7579; Cunha, Joao
   Paulo/0000-0002-3162-0531; Figueiredo, Ricardo/0000-0003-0264-7871;
   Tavares Ferreira, Joana/0000-0002-2237-3962
CR Agarwal A, 2018, OCUL IMMUNOL INFLAMM, V26, P838, DOI 10.1080/09273948.2017.1370650
   Agrawal R, 2016, SCI REP, V6, P1
   Agrawal R, 2017, ACTA OPHTHALMOL, V95, pe770, DOI 10.1111/aos.13442
   Agrawal R, 2016, TRANSL VIS SCI TECHN, V5, DOI 10.1167/tvst.5.4.7
   Agrawal R, 2016, RETINA-J RET VIT DIS, V36, P1646, DOI 10.1097/IAE.0000000000001040
   Agrawal R, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0146344
   ALM A, 1973, EXP EYE RES, V15, P15, DOI 10.1016/0014-4835(73)90185-1
   Alshareef RA, 2016, OPHTHALMIC SURG LASE
   atra D., 2017, RETINA
   Bakthavatsalam M, 2017, GRAEF ARCH CLIN EXP, V255, P935, DOI 10.1007/s00417-017-3591-3
   Balaratnasingam C, 2016, RETINA-J RET VIT DIS, V36, P1, DOI 10.1097/IAE.0000000000000774
   Bersen J., 1986, Eighth International Conference on Pattern Recognition. Proceedings (Cat. No.86CH2342-4), P1251
   BIRNBACH CD, 1994, OPHTHALMOLOGY, V101, P1211
   Branchini LA, 2013, OPHTHALMOLOGY, V120, P1901, DOI 10.1016/j.ophtha.2013.01.066
   CastroCorreia J, 1995, INT OPHTHALMOL, V19, P135
   Cho M, 2009, AM J OPHTHALMOL, V148, P70, DOI 10.1016/j.ajo.2009.02.012
   Chung SE, 2011, OPHTHALMOLOGY, V118, P840, DOI 10.1016/j.ophtha.2010.09.012
   Daizumoto E, 2017, BRIT J OPHTHALMOL, V101, P56, DOI 10.1136/bjophthalmol-2016-309694
   Dansingani KK, 2015, RETINA, V36, P499
   Donald J, 1967, AM J OPHTHALMOL, V63, p573/1
   Esmaeelpour M, 2018, INVEST OPHTH VIS SCI, V51, P5260
   Farias LB, 2014, OPHTHALMOLOGY, V121, P2071, DOI 10.1016/j.ophtha.2014.04.038
   Ferreira J, 2015, INVEST OPHTH VIS SCI, V56
   Ferreira JT, 2017, AM J OPHTHALMOL, V176, P15, DOI 10.1016/j.ajo.2016.12.023
   Flores-Moreno I, 2013, AM J OPHTHALMOL, V155, P314, DOI 10.1016/j.ajo.2012.07.015
   Fong AHC, 2011, RETINA-J RET VIT DIS, V31, P502, DOI 10.1097/IAE.0b013e3182083beb
   FRYCZKOWSKI AW, 1994, INT OPHTHALMOL, V18, P131, DOI 10.1007/BF00915961
   Fujiwara A, 2016, AM J OPHTHALMOL, V170, P1, DOI 10.1016/j.ajo.2016.07.006
   Fujiwara T, 2009, AM J OPHTHALMOL, V148, P445, DOI 10.1016/j.ajo.2009.04.029
   Gallego-Pinazo Roberto, 2014, Med Hypothesis Discov Innov Ophthalmol, V3, P111
   Gemenetzi M, 2010, EYE, V24, P1743, DOI 10.1038/eye.2010.130
   Gerendas BS, 2014, AM J OPHTHALMOL, V158, P1039, DOI 10.1016/j.ajo.2014.08.001
   Gomi F, 2008, CURR OPIN OPHTHALMOL, V19, P208, DOI 10.1097/ICU.0b013e3282fb7c33
   Grossniklaus HE, 2004, AM J OPHTHALMOL, V137, P496, DOI 10.1016/j.ajo.2003.09.042
   Gupta P, 2017, RETINA-J RET VIT DIS, V37, P2269, DOI 10.1097/IAE.0000000000001481
   Gupta P, 2017, AM J OPHTHALMOL, V177, P27, DOI 10.1016/j.ajo.2017.02.001
   Gupta P, 2015, AM J OPHTHALMOL, V159, P293, DOI 10.1016/j.ajo.2014.10.034
   HIDAYAT AA, 1985, OPHTHALMOLOGY, V92, P512
   Hirashima T, 2017, INVEST OPHTH VIS SCI, V58, P3871, DOI 10.1167/iovs.17-21515
   Imamura Y, 2009, RETINA-J RET VIT DIS, V29, P1469, DOI 10.1097/IAE.0b013e3181be0a83
   Jaisankar D, 2017, OCUL IMMUNOL INFLAMM, V14, P1, DOI DOI 10.1080/09273948.2017.1332231
   Jirarattanasopa P, 2016, SCIENCE
   Jonas JB, 2014, RETINA-J RET VIT DIS, V34, P1149, DOI 10.1097/IAE.0000000000000035
   Kawano H, 2016, GRAEF ARCH CLIN EXP, V254, P421, DOI 10.1007/s00417-016-3283-4
   Kim JT, 2013, INVEST OPHTH VIS SCI, V54, P3378, DOI 10.1167/iovs.12-11503
   Kim M, 2018, SCI REP
   Kinoshita T, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0163104
   Koh LHL, 2017, ACTA OPHTHALMOL, V95, pE597, DOI 10.1111/aos.13399
   Koizumi H, 2011, GRAEF ARCH CLIN EXP, V249, P1123, DOI 10.1007/s00417-011-1620-1
   Kur J, 2012, PROG RETIN EYE RES, V31, P377, DOI 10.1016/j.preteyeres.2012.04.004
   Kuroda Y, 2016, AM J OPHTHALMOL, V169, P199, DOI 10.1016/j.ajo.2016.06.043
   Lee Hyo Kyung, 2013, Korean J Ophthalmol, V27, P433, DOI 10.3341/kjo.2013.27.6.433
   Liu S, 2017, OCUL IMMUNOL INFLAMM, V3948, P1
   LOPEZ PF, 1990, OPHTHALMOLOGY, V97, P798
   Ma L, 2015, OPHTHALMOLOGY, V122, P1854, DOI 10.1016/j.ophtha.2015.05.012
   Mahajan NR, 2013, IEEE ENG MED BIO, P3355, DOI 10.1109/EMBC.2013.6610260
   Manjunath V, 2011, AM J OPHTHALMOL, V152, P663, DOI 10.1016/j.ajo.2011.03.008
   Maruko I, 2011, RETINA-J RET VIT DIS, V31, P510, DOI 10.1097/IAE.0b013e3181eef053
   Masuda N, 2017, CLIN OPHTHALMOL, V11, P791, DOI 10.2147/OPTH.S135160
   Ming C, 2015, GRAEFES ARCH CLIN EX
   MOORTHY RS, 1995, SURV OPHTHALMOL, V39, P265, DOI 10.1016/S0039-6257(05)80105-5
   Nakai K, 2012, GRAEF ARCH CLIN EXP, V250, P1089, DOI 10.1007/s00417-011-1910-7
   Neelam K, 2012, PROG RETIN EYE RES, V31, P495, DOI 10.1016/j.preteyeres.2012.04.001
   Ng DSC, 2017, INVEST OPHTH VIS SCI, V58, DOI 10.1167/iovs.16-20519
   Niblack W, 1986, ADV COMPUTER GRAPHIC
   Nicholson B, 2013, SURV OPHTHALMOL, V58, P103, DOI 10.1016/j.survophthal.2012.07.004
   Nickla DL, 2010, PROG RETIN EYE RES, V29, P144, DOI 10.1016/j.preteyeres.2009.12.002
   Nishida Y, 2012, RETINA-J RET VIT DIS, V32, P1229, DOI 10.1097/IAE.0b013e318242b990
   Onal S, 2018, RETINA-J RET VIT DIS, V38, P828, DOI 10.1097/IAE.0000000000001587
   Ozkaya A, 2016, EYE, V30, P958, DOI 10.1038/eye.2016.71
   Pang CE, 2015, RETINA-J RET VIT DIS, V35, P1, DOI 10.1097/IAE.0000000000000331
   Querques G, 2012, INVEST OPHTH VIS SCI, V53, P6017, DOI 10.1167/iovs.12-9692
   Rao NA, 2010, OPHTHALMOLOGY, V117, P591, DOI 10.1016/j.ophtha.2009.08.030
   Read RW, 2001, AM J OPHTHALMOL, V131, P647, DOI 10.1016/S0002-9394(01)00925-4
   Ruiz-Medrano J, 2014, INVEST OPHTH VIS SCI, V55, P3532, DOI 10.1167/iovs.14-13868
   Sansom LT, 2016, ACTA OPHTHALMOL, V94, pE157, DOI 10.1111/aos.12794
   Saw SM, 2005, OPHTHAL PHYSL OPT, V25, P381, DOI 10.1111/j.1475-1313.2005.00298.x
   Sonoda S, 2017, JPN J OPHTHALMOL
   Sonoda S, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0157190
   Sonoda S, 2015, AM J OPHTHALMOL, V159, P1123, DOI 10.1016/j.ajo.2015.03.005
   Sonoda S, 2014, INVEST OPHTH VIS SCI, V55, P3893, DOI 10.1167/iovs.14-14447
   Spaide RF, 1996, OPHTHALMOLOGY, V103, P2070, DOI 10.1016/S0161-6420(96)30386-2
   Spaide RF, 2008, AM J OPHTHALMOL, V146, P496, DOI 10.1016/j.ajo.2008.05.032
   Spaide RF, 2015, AM J OPHTHALMOL, V160, P1211, DOI 10.1016/j.ajo.2015.08.018
   Spraul CW, 2002, VISION RES, V42, P923, DOI 10.1016/S0042-6989(02)00022-6
   Tan KA, 2016, ACTA OPHTHALMOL, V94, pE612, DOI 10.1111/aos.13044
   Ting DSW, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-08276-4
   Unsal E, 2014, CLIN OPHTHALMOL, V8, P637, DOI 10.2147/OPTH.S59395
   Uppugunduri SR, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0193324
   Vupparaboina KK, 2016, 2016 INTERNATIONAL CONFERENCE ON SIGNAL AND INFORMATION PROCESSING (ICONSIP)
   Wang JC, 2017, AM J OPHTHALMOL, V184, P75, DOI 10.1016/j.ajo.2017.09.030
   Warrow DJ, 2013, RETINA-J RET VIT DIS, V33, P1659, DOI 10.1097/IAE.0b013e3182953df4
   Wei WB, 2013, OPHTHALMOLOGY, V120, P175, DOI 10.1016/j.ophtha.2012.07.048
   Wei X, 2016, RETINA, V37, P1120
   Ng WY, 2016, INVEST OPHTH VIS SCI, V57, P4933, DOI 10.1167/iovs.16-20191
   Wong TY, 2014, AM J OPHTHALMOL, V157, P9, DOI 10.1016/j.ajo.2013.08.010
   Zheng F, 2018, INVEST OPHTHALMOL VI
NR 97
TC 3
Z9 3
U1 0
U2 4
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0165-5701
EI 1573-2630
J9 INT OPHTHALMOL
JI Int. Ophthalmol.
PD DEC
PY 2019
VL 39
IS 12
BP 2947
EP 2973
DI 10.1007/s10792-019-01122-8
PG 27
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA JY0IH
UT WOS:000504108000029
PM 31140022
DA 2022-11-30
ER

PT J
AU Rathi, S
   Tsui, E
   Mehta, N
   Zahid, S
   Schuman, JS
AF Rathi, Siddarth
   Tsui, Edmund
   Mehta, Nitish
   Zahid, Sarwar
   Schuman, Joel S.
TI The Current State of Teleophthalmology in the United States
SO OPHTHALMOLOGY
LA English
DT Article
ID ACUTE-PHASE RETINOPATHY; DIABETIC-RETINOPATHY; MACULAR DEGENERATION;
   CARE QUALITY; TELEMEDICINE; PROGRAM; PREMATURITY; GLAUCOMA; SYSTEM;
   IMPROVEMENT
AB Telemedicine services facilitate the evaluation, diagnosis, and management of the remote patient. Telemedicine has rapidly flourished in the United States and has improved access to care, outcomes, and patient satisfaction. However, the use of telemedicine in ophthalmology is currently in its infancy and has yet to gain wide acceptance. Current models of telemedicine in ophthalmology are largely performed via "store and forward" methods, but remote monitoring and interactive modalities exist. Although studies have examined the effects of telemedicine, few reports have characterized its current status. We perform a descriptive analysis of the current state of teleophthalmology in the United States. We describe the use of teleophthalmology in the hospital and outpatient settings. We also review the applications to retinopathy of prematurity, diabetic retinopathy, age-related macular degeneration, and glaucoma, as well as anticipated barriers and hurdles for the future adoption of teleophthalmology. With ongoing advances in teleophthalmology, these models may provide earlier detection and more reliable monitoring of vision-threatening diseases. (C) 2017 by the American Academy of Ophthalmology
C1 [Rathi, Siddarth] Univ Miami, Miller Sch Med, Bascom Palmer Eye Inst, Miami, FL 33136 USA.
   [Tsui, Edmund; Mehta, Nitish; Zahid, Sarwar; Schuman, Joel S.] NYU, Langone Eye Ctr, Langone Med Ctr, Dept Ophthalmol,Sch Med, New York, NY 10016 USA.
   [Schuman, Joel S.] NYU, Langone Med Ctr, Dept Neurosci & Physiol, Sch Med, New York, NY 10016 USA.
   [Schuman, Joel S.] NYU, Tandon Sch Engn, Dept Elect & Comp Engn, Brooklyn, NY USA.
C3 Bascom Palmer Eye Institute; University of Miami; New York University;
   NYU Langone Medical Center; New York University; NYU Langone Medical
   Center; New York University; New York University Tandon School of
   Engineering
RP Schuman, JS (通讯作者)，NYU, Dept Ophthalmol, Sch Med, Langone Eye Ctr, 462 First Ave,NBV 5N3, New York, NY 10016 USA.
EM joel.schuman@nyu.edu
RI Schuman, Joel S/K-7304-2012; Schuman, Joel S/M-2389-2019
OI Schuman, Joel S/0000-0002-8885-3766; Schuman, Joel S/0000-0002-8885-3766
FU National Institutes of Health [R01-EY013178]; NATIONAL EYE INSTITUTE
   [R01EY013178] Funding Source: NIH RePORTER
FX Supported in part by National Institutes of Health (R01-EY013178).
CR [Anonymous], 2015, FREQUENCY OCULAR EXA
   Arora S, 2014, TELEMED E-HEALTH, V20, P439, DOI 10.1089/tmj.2013.0241
   Bergua A, 2009, TELEMED J E-HEALTH, V15, P439, DOI 10.1089/tmj.2008.0162
   Cavallerano Anthony A, 2008, J Diabetes Sci Technol, V2, P33
   Channa R, 2016, JAMA OPHTHALMOL, V134, P312, DOI 10.1001/jamaophthalmol.2015.5778
   Chew EY, 2014, OPHTHALMOLOGY, V121, P535, DOI 10.1016/j.ophtha.2013.10.027
   Chiang MF, 2012, OPHTHALMOLOGY, V119, P1272, DOI 10.1016/j.ophtha.2012.01.002
   Cook JA, 2012, OPHTHALMOLOGY, V119, P1552, DOI 10.1016/j.ophtha.2012.02.030
   Daniel E, 2015, JAMA OPHTHALMOL, V133, P675, DOI 10.1001/jamaophthalmol.2015.0460
   Dorsey ER, 2016, NEW ENGL J MED, V375, P154, DOI 10.1056/NEJMra1601705
   Fierson WM, 2015, PEDIATRICS, V135, pE238, DOI 10.1542/peds.2014-0978
   Gibson DM, 2012, AM J PREV MED, V43, P48, DOI 10.1016/j.amepre.2012.02.028
   Institute of Medicine (US), 1996, TELEMEDICINE
   Jampel HD, 2009, AM J OPHTHALMOL, V147, P39, DOI 10.1016/j.ajo.2008.07.023
   Kassam F, 2013, CLIN EXP OPTOM, V96, P577, DOI 10.1111/cxo.12065
   Kelly SP, 2011, CLIN OPHTHALMOL, V5, P1673, DOI 10.2147/OPTH.S26753
   Kemper A. R, 2016, PEDIATRICS, V137
   Kiage Dan, 2013, Middle East Afr J Ophthalmol, V20, P150, DOI 10.4103/0974-9233.110604
   Kirkizlar E, 2013, OPHTHALMOLOGY, V120, P2604, DOI 10.1016/j.ophtha.2013.06.029
   Legarreta JE, 2014, INVEST OPHTHALMOL VI, V55
   Li B, 2015, JAMA OPHTHALMOL, V133, P276, DOI 10.1001/jamaophthalmol.2014.5014
   Mansouri K, 2012, ARCH OPHTHALMOL-CHIC, V130, P1534, DOI [10.1001/archophthalmol.2012.2280, 10.1001/jamaophthalmol.2013.1350]
   Mines MJ, 2011, AM J OPHTHALMOL, V152, P126, DOI 10.1016/j.ajo.2011.01.028
   Mueller KJ, 2014, HEALTH AFFAIR, V33, P228, DOI 10.1377/hlthaff.2013.1016
   Owsley C, 2015, INT J EQUITY HEALTH, V14, DOI 10.1186/s12939-015-0213-8
   Parodi MB, 2014, ACTA OPHTHALMOL, V92, pE243, DOI [10.1111/aos.12255, 10.1111/aos.12108]
   Quinn GE, 2014, JAMA OPHTHALMOL, V132, P1178, DOI 10.1001/jamaophthalmol.2014.1604
   Sanchez CR, 2010, SEMIN OPHTHALMOL, V25, P218, DOI 10.3109/08820538.2010.518893
   Schoenfeld ER, 2001, OPHTHALMOLOGY, V108, P563, DOI 10.1016/S0161-6420(00)00600-X
   Shaw J., 2016, EYENET, V6, P41
   Silva PS, 2016, OPHTHALMOLOGY, V123, P1360, DOI 10.1016/j.ophtha.2016.01.043
   Sim D, 2008, EMERG MED J, V25, P76, DOI 10.1136/emj.2007.049999
   Sun JK, 2016, JAMA OPHTHALMOL, V134, P210, DOI 10.1001/jamaophthalmol.2015.5099
   Thomas M, 2015, JAMA OPHTHALMOL, V133, P1425, DOI 10.1001/jamaophthalmol.2015.3684
   Thomas S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0137913
   Thomas SM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0113779
   Walton OB, 2016, JAMA OPHTHALMOL, V134, P204, DOI 10.1001/jamaophthalmol.2015.5083
   Wang SK, 2015, CAN J OPHTHALMOL, V50, P101, DOI 10.1016/j.jcjo.2014.11.005
   Wright HR, 2015, BRIT J OPHTHALMOL, V99, P313, DOI 10.1136/bjophthalmol-2014-305588
   Zimmer-Galler IE, 2015, CURR OPIN OPHTHALMOL, V26, P167, DOI 10.1097/ICU.0000000000000142
NR 40
TC 133
Z9 138
U1 0
U2 13
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD DEC
PY 2017
VL 124
IS 12
BP 1729
EP 1734
DI 10.1016/j.ophtha.2017.05.026
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA FM9JZ
UT WOS:000415586000011
PM 28647202
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Schmidli, H
   Neuenschwander, B
   Friede, T
AF Schmidli, Heinz
   Neuenschwander, Beat
   Friede, Tim
TI Meta-analytic-predictive use of historical variance data for the design
   and analysis of clinical trials
SO COMPUTATIONAL STATISTICS & DATA ANALYSIS
LA English
DT Article
DE Bayesian approach; Between-trial heterogeneity; Evidence synthesis;
   Meta-analysis; Sample size; Standard deviation
ID SAMPLE-SIZE DETERMINATION; RANDOM-EFFECTS METAANALYSIS; MACULAR
   DEGENERATION; CONTROL INFORMATION; PILOT SAMPLE; PHASE-II;
   DISTRIBUTIONS; HETEROGENEITY; PRIORS
AB Continuous endpoints are common in clinical trials. The design and analysis of such trials is often based on models assuming normally distributed data, possibly after an appropriate transformation. When planning a new trial, information on the variance of the endpoint is usually available from historical trials. Although the idea to use historical data for a new trial is not new, literature on how to formally summarize and use these data on variances is scarce. The meta-analytic-predictive (MAP) approach consists of a random-effects meta analysis of the historical variance data and a prediction of the variance in the new clinical trial. Two applications that rely on the MAP approach are considered: first, the selection of the sample size in the new trial, guided by the prediction of the variance; and, second, the inclusion of the predicted variance in a Bayesian analysis of the new trial. A clinical trial in patients with wet age-related macular degeneration illustrates the methodology. (C) 2016 Elsevier B.V. All rights reserved.
C1 [Schmidli, Heinz] Novartis Pharma AG, Stat Methodol, Dev, Lichtstr 35, CH-4056 Basel, Switzerland.
   [Neuenschwander, Beat] Novartis Pharma AG, Biometr & Data Management, Oncol, Basel, Switzerland.
   [Friede, Tim] Univ Med Ctr Goettingen, Dept Med Stat, Gottingen, Germany.
C3 Novartis; Novartis; University of Gottingen
RP Schmidli, H (通讯作者)，Novartis Pharma AG, Stat Methodol, Dev, Lichtstr 35, CH-4056 Basel, Switzerland.
EM heinz.schmidli@novartis.com
RI Friede, Tim/ABF-1132-2021
OI Friede, Tim/0000-0001-5347-7441
CR Adcock CJ, 1997, J ROY STAT SOC D-STA, V46, P261
   [Anonymous], 2012, EVIDENCE SYNTHESIS D
   Baeten D, 2013, LANCET, V382, P1705, DOI 10.1016/S0140-6736(13)61134-4
   Bernardo JM, 1994, BAYESIAN THEORY
   Berry SM, 2010, CH CRC BIOSTAT SER, P1, DOI 10.1201/EBK1439825488
   Box G. E. P., 2011, BAYESIAN INFERENCE S
   Brown DM, 2011, OPHTHALMOLOGY, V118, P1089, DOI 10.1016/j.ophtha.2011.02.039
   BROWNE RH, 1995, STAT MED, V14, P1933, DOI 10.1002/sim.4780141709
   Charpentier E, 2016, BMC MED RES METHODOL, V16, DOI 10.1186/s12874-016-0107-5
   Cox D., 1978, J R STAT SOC B, V40, P29
   DALAL SR, 1983, J ROY STAT SOC B MET, V45, P278
   DeGroot M., 2013, PROBABILITY STAT PEA
   Diaconis P., 1985, BAYESIAN STAT, V2, P133
   Fisch R, 2015, THER INNOV REGUL SCI, V49, P155, DOI 10.1177/2168479014533970
   Follmann DA, 1999, BIOMETRICS, V55, P732, DOI 10.1111/j.0006-341X.1999.00732.x
   Friede T., 2016, BIOM J IN PRESS
   Friede T., 2016, RES SYN METH
   Friede T, 2006, BIOMETRICAL J, V48, P537, DOI 10.1002/bimj.200510238
   Garthwaite PH, 2005, J AM STAT ASSOC, V100, P680, DOI 10.1198/016214505000000105
   Gelman A., 2014, BAYESIAN DATA ANAL
   Gelman A, 2006, BAYESIAN ANAL, V1, P515, DOI 10.1214/06-BA117A
   Gsponer T, 2014, PHARM STAT, V13, P71, DOI 10.1002/pst.1593
   Gsteiger S, 2013, STAT MED, V32, P3609, DOI 10.1002/sim.5851
   Hartley AM, 2012, PHARM STAT, V11, P230, DOI 10.1002/pst.538
   Hartung J, 2001, STAT MED, V20, P1771, DOI 10.1002/sim.791
   Higgins JPT, 2009, J R STAT SOC A STAT, V172, P137, DOI 10.1111/j.1467-985X.2008.00552.x
   Hueber W, 2012, GUT, V61, P1693, DOI 10.1136/gutjnl-2011-301668
   Inoue LYT, 2005, AM STAT, V59, P79, DOI 10.1198/000313005X21069
   JOSEPH L, 1997, J R STAT SOC D-STAT, V46, P209
   Julious SA, 2004, PHARM STAT, V3, P261, DOI 10.1002/pst.139
   Julious SA, 2004, STAT MED, V23, P1921, DOI 10.1002/sim.1783
   Kieser M, 1996, BIOMETRICAL J, V38, P941, DOI 10.1002/bimj.4710380806
   Lindley DV, 1997, J ROY STAT SOC D-STA, V46, P129
   Malec D, 2001, STAT MED, V20, P1811, DOI 10.1002/sim.782
   Mittlbock M, 2006, STAT MED, V25, P4321, DOI 10.1002/sim.2692
   Morita S, 2008, BIOMETRICS, V64, P595, DOI 10.1111/j.1541-0420.2007.00888.x
   Neuenschwander B, 2010, CLIN TRIALS, V7, P5, DOI 10.1177/1740774509356002
   O'Hagan A, 2005, PHARM STAT, V4, P187, DOI 10.1002/pst.175
   O'Hagan A., 2004, KENDALLS ADV THEORY, V2B
   O'Hagan A, 2012, BRAZ J PROBAB STAT, V26, P372, DOI 10.1214/11-BJPS164
   Pennello G, 2008, J BIOPHARM STAT, V18, P81, DOI 10.1080/10543400701668274
   Pezeshk H, 2003, STAT METHODS MED RES, V12, P489, DOI 10.1191/0962280203sm345oa
   Pigott TD, 2008, PSYCHOL BULL, V134, P498, DOI 10.1037/0033-2909.134.4.498
   Pinheiro J.C., 1995, J COMPUTATIONAL GRAP, V4, P12, DOI DOI 10.2307/1390625
   POCOCK SJ, 1976, J CHRON DIS, V29, P175, DOI 10.1016/0021-9681(76)90044-8
   Rover C, 2016, BIOMETRICAL J, V58, P170, DOI 10.1002/bimj.201300288
   Rover C, 2015, BMC MED RES METHODOL, V15, DOI 10.1186/s12874-015-0091-1
   Schmidli H, 2014, BIOMETRICS, V70, P1023, DOI 10.1111/biom.12242
   Spiegelhalter DJ., 2004, BAYESIAN APPROACHES, DOI [10.1002/0470092602, DOI 10.1002/0470092602]
   Stallard N, 1998, BIOMETRICS, V54, P279, DOI 10.2307/2534014
   Szabo SM, 2015, CURR MED RES OPIN, V31, P2031, DOI 10.1185/03007995.2015.1084909
   Takeda K., 2015, JAPAN J BIOMETRICS, V36, P25
   Turner RM, 2015, STAT MED, V34, P984, DOI 10.1002/sim.6381
   Viele K, 2014, PHARM STAT, V13, P41, DOI 10.1002/pst.1589
   Weaver J, 2016, STAT BIOPHARM RES, V8, P106, DOI 10.1080/19466315.2015.1067252
NR 55
TC 9
Z9 9
U1 0
U2 11
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0167-9473
EI 1872-7352
J9 COMPUT STAT DATA AN
JI Comput. Stat. Data Anal.
PD SEP
PY 2017
VL 113
BP 100
EP 110
DI 10.1016/j.csda.2016.08.007
PG 11
WC Computer Science, Interdisciplinary Applications; Statistics &
   Probability
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Computer Science; Mathematics
GA EZ6IW
UT WOS:000404822600009
DA 2022-11-30
ER

PT J
AU Zhou, QB
   Frost, RJA
   Anderson, C
   Zhao, FK
   Ma, J
   Yu, B
   Wang, SS
AF Zhou, Qinbo
   Frost, Robert J. A.
   Anderson, Chastain
   Zhao, Fangkun
   Ma, Jing
   Yu, Bo
   Wang, Shusheng
TI let-7 Contributes to Diabetic Retinopathy but Represses Pathological
   Ocular Angiogenesis
SO MOLECULAR AND CELLULAR BIOLOGY
LA English
DT Article
DE let-7; endothelial cells; angiogenesis; diabetic retinopathy; choroidal;
   neovascularization; AMD
ID CHOROIDAL NEOVASCULARIZATION; RETINAL NEOVASCULARIZATION; MICRORNA
   EXPRESSION; RANIBIZUMAB; GROWTH; ACTIVATION; THERAPY; FAMILY
AB The in vivo function of microRNAs (miRs) in diabetic retinopathy (DR) and age-related macular degeneration (AMD) remains unclear. We report here that let-7 family members are expressed in retinal and choroidal endothelial cells (ECs). In ECs, overexpression of let-7 by adenovirus represses EC proliferation, migration, and networking in vitro, whereas inhibition of the let-7 family with a locked nucleic acid (LNA)-anti-miR has the opposite effect. Mechanistically, silencing of the let-7 target HMGA2 gene mimics the phenotype of let-7 overexpression in ECs. let-7 transgenic (let-7-Tg) mice show features of nonproliferative DR, including tortuous retinal vessels and defective pericyte coverage. However, these mice develop significantly less choroidal neovascularization (CNV) compared to wild-type controls after laser injury. Consistently, silencing of let-7 in the eye increased laser-induced CNV in wild-type mice. Together, our data establish a causative role of let-7 in nonproliferative diabetic retinopathy and a repressive function of let-7 in pathological angiogenesis, suggesting distinct implications of let-7 in the pathogenesis of DR and AMD.
C1 [Zhou, Qinbo; Anderson, Chastain; Zhao, Fangkun; Ma, Jing; Yu, Bo; Wang, Shusheng] Tulane Univ, Dept Cell & Mol Biol, New Orleans, LA 70118 USA.
   [Frost, Robert J. A.] Univ Texas Southwestern Med Ctr Dallas, Dept Mol Biol, Dallas, TX 75390 USA.
   [Zhao, Fangkun] China Med Univ, Eye Hosp, Dept Ophthalmol, Key Lens Res Lab Liaoning Prov,Affiliated Hosp 4, Shenyang, Liaoning, Peoples R China.
   [Wang, Shusheng] Tulane Univ, Dept Ophthalmol, New Orleans, LA 70118 USA.
C3 Tulane University; University of Texas System; University of Texas
   Southwestern Medical Center Dallas; China Medical University; Tulane
   University
RP Wang, SS (通讯作者)，Tulane Univ, Dept Cell & Mol Biol, New Orleans, LA 70118 USA.; Wang, SS (通讯作者)，Tulane Univ, Dept Ophthalmol, New Orleans, LA 70118 USA.
EM swang1@tulane.edu
FU NIH [EY021862, EY026069]; Research to Prevent Blindness foundation;
   BrightFocus Foundation; American Heart Association; Tulane University;
   NATIONAL EYE INSTITUTE [R01EY026069, R01EY021862] Funding Source: NIH
   RePORTER
FX S.W. was supported by a startup fund from Tulane University, NIH grants
   EY021862 and EY026069, a career development award from the Research to
   Prevent Blindness foundation, and a BrightFocus Foundation Award in
   Age-related Macular Degeneration. Q.Z. was supported by an American
   Heart Association Southeast Affiliate Postdoctoral fellowship.
CR Bai YY, 2011, EXP MOL PATHOL, V91, P471, DOI 10.1016/j.yexmp.2011.04.016
   Barh D, 2010, CURR ONCOL, V17, P70
   Boyerinas B, 2010, ENDOCR-RELAT CANCER, V17, pF19, DOI 10.1677/ERC-09-0184
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Cowan C, 2014, INVEST OPHTH VIS SCI, V55, P4944, DOI 10.1167/iovs.13-13631
   Falk MK, 2013, AM J OPHTHALMOL, V155, P89, DOI 10.1016/j.ajo.2012.06.031
   Feng BA, 2011, DIABETES, V60, P2975, DOI 10.2337/db11-0478
   Folk JC, 2010, NEW ENGL J MED, V363, P1648, DOI 10.1056/NEJMct1000495
   Frost RJA, 2011, P NATL ACAD SCI USA, V108, P21075, DOI 10.1073/pnas.1118922109
   Gardlik R, 2015, SEMIN OPHTHALMOL, V30, P252, DOI 10.3109/08820538.2013.859280
   Garofalo M, 2011, ANNU REV PHARMACOL, V51, P25, DOI 10.1146/annurev-pharmtox-010510-100517
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Jordan SD, 2011, NAT CELL BIOL, V13, P434, DOI 10.1038/ncb2211
   Karolina DS, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022839
   Kempen JH, 2004, ARCH OPHTHALMOL-CHIC, V122, P552
   Kovacs B, 2011, INVEST OPHTH VIS SCI, V52, P4402, DOI 10.1167/iovs.10-6879
   Kuehbacher A, 2007, CIRC RES, V101, P59, DOI 10.1161/CIRCRESAHA.107.153916
   Kumar MS, 2008, P NATL ACAD SCI USA, V105, P3903, DOI 10.1073/pnas.0712321105
   Lee YS, 2007, GENE DEV, V21, P1025, DOI 10.1101/gad.1540407
   Long JY, 2010, J BIOL CHEM, V285, P23455, DOI 10.1074/jbc.M110.136168
   Mastropasqua R, 2014, PROG RETIN EYE RES, V43, P92, DOI 10.1016/j.preteyeres.2014.07.003
   Mayr C, 2007, SCIENCE, V315, P1576, DOI 10.1126/science.1137999
   McArthur K, 2011, DIABETES, V60, P1314, DOI 10.2337/db10-1557
   Mortuza R, 2014, DIABETOLOGIA, V57, P1037, DOI 10.1007/s00125-014-3197-9
   Murray AR, 2013, INVEST OPHTH VIS SCI, V54, P1689, DOI 10.1167/iovs.12-10921
   Plaisance V, 2006, J BIOL CHEM, V281, P26932, DOI 10.1074/jbc.M601225200
   Poy MN, 2004, NATURE, V432, P226, DOI 10.1038/nature03076
   Reinhart BJ, 2000, NATURE, V403, P901, DOI 10.1038/35002607
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Roush S, 2008, TRENDS CELL BIOL, V18, P505, DOI 10.1016/j.tcb.2008.07.007
   RYAN SJ, 1982, ARCH OPHTHALMOL-CHIC, V100, P1804, DOI 10.1001/archopht.1982.01030040784015
   Sabatel C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016979
   Saint-Geniez M, 2004, INT J DEV BIOL, V48, P1045, DOI 10.1387/ijdb.041895ms
   Santulli G, 2016, J CELL PHYSIOL, V231, P1638, DOI 10.1002/jcp.25276
   Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089
   Shen JK, 2008, MOL THER, V16, P1208, DOI 10.1038/mt.2008.104
   Silva VAO, 2011, MOL VIS, V17, P2228
   Small EM, 2011, NATURE, V469, P336, DOI 10.1038/nature09783
   Stahl A, 2010, INVEST OPHTH VIS SCI, V51, P2813, DOI 10.1167/iovs.10-5176
   Trajkovski M, 2011, NATURE, V474, P649, DOI 10.1038/nature10112
   Wang SS, 2012, FUTURE MED CHEM, V4, P277, DOI 10.4155/fmc.11.176
   Wu JH, 2012, OPHTHALMIC RES, V47, P195, DOI 10.1159/000331992
   Yan LL, 2015, J BIOL CHEM, V290, P23264, DOI 10.1074/jbc.M115.646950
   Ye PP, 2014, INT J MED SCI, V11, P17, DOI 10.7150/ijms.7329
   Zaidi MR, 2006, CANCER RES, V66, P7453, DOI 10.1158/0008-5472.CAN-06-0931
   Zampros I, 2012, J OPHTHALMOL, V2012, DOI 10.1155/2012/319728
   Zhou QB, 2016, MOL THER, V24, P1823, DOI 10.1038/mt.2016.108
   Zhou QB, 2014, MOL THER, V22, P378, DOI 10.1038/mt.2013.243
   Zhou QB, 2011, P NATL ACAD SCI USA, V108, P8287, DOI 10.1073/pnas.1105254108
   ZHOU XJ, 1995, NATURE, V376, P771, DOI 10.1038/376771a0
   Zhu H, 2011, CELL, V147, P81, DOI 10.1016/j.cell.2011.08.033
   Zhu SK, 2013, CIRC RES, V112, P152, DOI 10.1161/CIRCRESAHA.112.280016
NR 52
TC 17
Z9 18
U1 0
U2 2
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0270-7306
EI 1098-5549
J9 MOL CELL BIOL
JI Mol. Cell. Biol.
PD AUG
PY 2017
VL 37
IS 16
AR e00001-17
DI 10.1128/MCB.00001-17
PG 14
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA FB9YC
UT WOS:000406494300001
PM 28584193
OA Green Published
DA 2022-11-30
ER

PT J
AU Cehofski, LJ
   Honore, B
   Vorum, H
AF Cehofski, Lasse Jorgensen
   Honore, Bent
   Vorum, Henrik
TI A Review: Proteomics in Retinal Artery Occlusion, Retinal Vein
   Occlusion, Diabetic Retinopathy and Acquired Macular Disorders
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Review
DE age-related macular degeneration; biological marker; diabetic
   retinopathy; mass spectrometry; proteomics; retina; retinal vein
   occlusion; vascular endothelial growth factor; vitreous body
ID ENDOTHELIAL GROWTH-FACTOR; PIGMENT EPITHELIAL ATROPHY; AQUEOUS-HUMOR;
   INFLAMMATORY FACTORS; VITREORETINAL DISEASES; DEXAMETHASONE IMPLANT;
   VITREOUS PROTEOME; PERIPHERAL RETINA; EDEMA; PROTEINS
AB Retinal artery occlusion (RAO), retinal vein occlusion (RVO), diabetic retinopathy (DR) and age-related macular degeneration (AMD) are frequent ocular diseases with potentially sight-threatening outcomes. In the present review we discuss major findings of proteomic studies of RAO, RVO, DR and AMD, including an overview of ocular proteome changes associated with anti-vascular endothelial growth factor (VEGF) treatments. Despite the severe outcomes of RAO, the proteome of the disease remains largely unstudied. There is also limited knowledge about the proteome of RVO, but proteomic studies suggest that RVO is associated with remodeling of the extracellular matrix and adhesion processes. Proteomic studies of DR have resulted in the identification of potential therapeutic targets such as carbonic anhydrase-I. Proliferative diabetic retinopathy is the most intensively studied stage of DR. Proteomic studies have established VEGF, pigment epithelium-derived factor (PEDF) and complement components as key factors associated with AMD. The aim of this review is to highlight the major milestones in proteomics in RAO, RVO, DR and AMD. Through large-scale protein analyses, proteomics is bringing new important insights into these complex pathological conditions.
C1 [Cehofski, Lasse Jorgensen; Vorum, Henrik] Aalborg Univ Hosp, Dept Ophthalmol, Hobrovej 18-22, DK-9000 Aalborg, Denmark.
   [Cehofski, Lasse Jorgensen; Honore, Bent; Vorum, Henrik] Aalborg Univ, Dept Clin Med, Sondre Skovvej 15, DK-9000 Aalborg, Denmark.
   [Honore, Bent] Aarhus Univ, Dept Biomed, Ole Worms Alle 3,Bldg 1182,024, DK-8000 Aarhus C, Denmark.
C3 Aalborg University; Aalborg University Hospital; Aalborg University;
   Aarhus University
RP Cehofski, LJ (通讯作者)，Aalborg Univ Hosp, Dept Ophthalmol, Hobrovej 18-22, DK-9000 Aalborg, Denmark.; Cehofski, LJ (通讯作者)，Aalborg Univ, Dept Clin Med, Sondre Skovvej 15, DK-9000 Aalborg, Denmark.
EM L.cehofski@rn.dk; bh@biomed.au.dk; henrik.vorum@rn.dk
RI Honoré, Bent/ABF-3650-2021
OI Honore, Bent/0000-0002-3459-7429; Jorgensen Cehofski,
   Lasse/0000-0002-2150-7754
FU Svend Andersen Foundation; Bagger-Sorensen Foundation; Obel Family
   Foundation; Fight for Sight Denmark; Herta Christensen Foudation; North
   Denmark Region; Heinrich Kopps Foundation
FX This work was supported by Svend Andersen Foundation, Bagger-Sorensen
   Foundation, Obel Family Foundation, Fight for Sight Denmark, Herta
   Christensen Foudation, North Denmark Region and Heinrich Kopps
   Foundation. Chief librarian Conni Skrubbeltrang and librarian Louise
   Stenholt, Medical Library Aalborg University Hospital, are thanked for
   assisting with the literature search.
CR Balasubramani M, 2010, MATRIX BIOL, V29, P471, DOI 10.1016/j.matbio.2010.04.002
   Bergua A, 2013, EXP EYE RES, V110, P142, DOI 10.1016/j.exer.2012.11.020
   Bhisitkul RB, 2015, AM J OPHTHALMOL, V159, P915, DOI 10.1016/j.ajo.2015.01.032
   Bolinger MT, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17091498
   Bressler NM, 2011, NEW ENGL J MED, V365, P1520, DOI 10.1056/NEJMct0908432
   Brown DM, 2015, OPHTHALMOLOGY, V122, P2044, DOI 10.1016/j.ophtha.2015.06.017
   Campochiaro PA, 2016, OPHTHALMOLOGY, V123, pS78, DOI 10.1016/j.ophtha.2016.04.056
   Campochiaro PA, 2015, PROG RETIN EYE RES, V49, P67, DOI 10.1016/j.preteyeres.2015.06.002
   Campochiaro PA, 2015, AM J OPHTHALMOL, V160, P313, DOI 10.1016/j.ajo.2015.04.025
   Campochiaro PA, 2015, OPHTHALMOLOGY, V122, P1426, DOI 10.1016/j.ophtha.2015.04.006
   Campochiaro PA, 2014, OPHTHALMOLOGY, V121, P209, DOI 10.1016/j.ophtha.2013.08.038
   Campochiaro PA, 2010, OPHTHALMOLOGY, V117, P1102, DOI 10.1016/j.ophtha.2010.02.021
   Cehofski LJ, 2016, EXP EYE RES, V152, P49, DOI 10.1016/j.exer.2016.09.002
   Cehofski LJ, 2015, EXP EYE RES, V138, P87, DOI 10.1016/j.exer.2015.06.011
   Cehofski LJ, 2015, J OPHTHALMOL, V2015, DOI 10.1155/2015/839137
   Chan CC, 2008, OPHTHALMIC RES, V40, P124, DOI 10.1159/000119862
   Chaturvedi N, 2008, LANCET, V372, P1394, DOI 10.1016/S0140-6736(08)61412-9
   Chiang SY, 2012, J PROTEOMICS, V75, P2950, DOI 10.1016/j.jprot.2011.12.006
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Decanini A, 2008, DIABETOLOGIA, V51, P1051, DOI 10.1007/s00125-008-0991-2
   Ethen CM, 2006, INVEST OPHTH VIS SCI, V47, P2280, DOI 10.1167/iovs.05-1395
   Fort PE, 2009, MOL CELL PROTEOMICS, V8, P767, DOI 10.1074/mcp.M800326-MCP200
   Funatsu H, 2012, BRIT J OPHTHALMOL, V96, P302, DOI 10.1136/bjo.2010.181222
   Gao BB, 2008, J PROTEOME RES, V7, P2516, DOI 10.1021/pr800112g
   Gao BB, 2007, NAT MED, V13, P181, DOI 10.1038/nm1534
   Gao BB, 2009, J PROTEOME RES, V8, P5541, DOI 10.1021/pr9006415
   Garcia-Ramirez M, 2007, DIABETOLOGIA, V50, P1294, DOI 10.1007/s00125-007-0627-y
   Gaudreault J, 2005, INVEST OPHTH VIS SCI, V46, P726, DOI 10.1167/iovs.04-0601
   Hauck SM, 2010, MOL CELL PROTEOMICS, V9, P2292, DOI 10.1074/mcp.M110.001073
   Hayreh SS, 2014, PROG RETIN EYE RES, V41, P1, DOI 10.1016/j.preteyeres.2014.04.001
   Hayreh SS, 2005, AM J OPHTHALMOL, V140, P376, DOI 10.1016/j.ajo.2005.03.038
   Hernandez C, 2013, DIABETES-METAB RES, V29, P499, DOI 10.1002/dmrr.2419
   Holz FG, 2016, EYE, V30, P1063, DOI 10.1038/eye.2016.90
   Kang GY, 2014, J PROTEOME RES, V13, P581, DOI 10.1021/pr400751k
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kaur C, 2008, PROG RETIN EYE RES, V27, P622, DOI 10.1016/j.preteyeres.2008.09.003
   Kim HJ, 2012, CLIN BIOCHEM, V45, P60, DOI 10.1016/j.clinbiochem.2011.10.006
   Kim K, 2013, J PROTEOME RES, V12, P1078, DOI 10.1021/pr3012073
   Kim K, 2010, J PROTEOME RES, V9, P689, DOI 10.1021/pr901013d
   Kim SJ, 2006, CURR EYE RES, V31, P231, DOI 10.1080/02713680600557030
   Kim TW, 2012, J PROTEOME RES, V11, P4034, DOI 10.1021/pr300080s
   Klaassen I, 2013, PROG RETIN EYE RES, V34, P19, DOI 10.1016/j.preteyeres.2013.02.001
   Kokotas H, 2011, CLIN CHEM LAB MED, V49, P601, DOI 10.1515/CCLM.2011.091
   Koss MJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096895
   Kunikata H, 2012, ACTA OPHTHALMOL, V90, P162, DOI 10.1111/j.1755-3768.2010.01892.x
   Kuroda Y, 2016, AM J OPHTHALMOL, V161, P94, DOI 10.1016/j.ajo.2015.09.032
   Lambert NG, 2016, PROG RETIN EYE RES, V54, P64, DOI 10.1016/j.preteyeres.2016.04.003
   Larsen M, 2016, OPHTHALMOLOGY, V123, P1101, DOI 10.1016/j.ophtha.2016.01.011
   Lee H, 2014, BMB REP, V47, P292, DOI 10.5483/BMBRep.2014.47.5.193
   Lee WJ, 2012, BRIT J OPHTHALMOL, V96, P1426, DOI 10.1136/bjophthalmol-2012-301913
   Loukovaara S, 2015, J PROTEOME RES, V14, P5131, DOI 10.1021/acs.jproteome.5b00900
   Lundkvist A, 2004, J CELL SCI, V117, P3481, DOI 10.1242/jcs.01221
   Ly A, 2014, DIABETOLOGIA, V57, P192, DOI 10.1007/s00125-013-3070-2
   Mandal N, 2010, BIOL PROCED ONLINE, V12, P56, DOI 10.1007/s12575-009-9019-7
   Maturi RK, 2016, RETINA-J RET VIT DIS, V36, P1143, DOI 10.1097/IAE.0000000000001004
   Mir TA, 2016, OPHTHALMOLOGY, V123, P625, DOI 10.1016/j.ophtha.2015.10.030
   Mukai N, 2008, ANN CLIN BIOCHEM, V45, P307, DOI 10.1258/acb.2007.007151
   Nag TC, 2012, MICRON, V43, P759, DOI 10.1016/j.micron.2012.01.011
   Nobl M, 2016, EXP EYE RES, V146, P107, DOI 10.1016/j.exer.2016.01.001
   Noma H, 2014, BMC OPHTHALMOL, V14, DOI 10.1186/1471-2415-14-67
   Noma H, 2013, JAMA OPHTHALMOL, V131, P160, DOI 10.1001/2013.jamaophthalmol.228
   Noma H, 2011, AM J OPHTHALMOL, V152, P669, DOI 10.1016/j.ajo.2011.04.006
   Noma H, 2010, GRAEF ARCH CLIN EXP, V248, P1559, DOI 10.1007/s00417-010-1486-7
   Nordgaard CL, 2008, INVEST OPHTH VIS SCI, V49, P2848, DOI 10.1167/iovs.07-1352
   Okamoto H, 2010, EXP ANIM TOKYO, V59, P171, DOI 10.1538/expanim.59.171
   Ouchi M, 2005, EXP EYE RES, V81, P176, DOI 10.1016/j.exer.2005.01.020
   Quin GJ, 2015, CLIN EXP OPHTHALMOL, V43, P180, DOI 10.1111/ceo.12372
   Reich M, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0158001
   Rezar-Dreindl S., 2016, RETINA
   Rezar-Dreindl S, 2017, ACTA OPHTHALMOL, V95, pE119, DOI 10.1111/aos.13152
   Rezar-Dreindl S, 2016, INVEST OPHTH VIS SCI, V57, P4144, DOI 10.1167/iovs.16-19772
   Rogers S, 2010, OPHTHALMOLOGY, V117, P313, DOI [10.1016/j.ophtha.2009.07.017, 10.1016/j.ophtha.2010.01.060]
   Rogers SL, 2010, OPHTHALMOLOGY, V117, P1094, DOI 10.1016/j.ophtha.2010.01.058
   Ryan SJ, 2001, RETINA, P2068
   Santarelli M, 2015, EXPERT OPIN PHARMACO, V16, P1769, DOI 10.1517/14656566.2015.1067679
   Sarwar S, 2016, COCHRANE DB SYST REV, V2
   Schutze C, 2015, AM J OPHTHALMOL, V159, P1100, DOI 10.1016/j.ajo.2015.02.020
   Sepah YJ, 2016, OPHTHALMOLOGY, V123, P2581, DOI 10.1016/j.ophtha.2016.08.040
   Sharma K, 2003, AM J PHYSIOL-RENAL, V284, pF1138, DOI 10.1152/ajprenal.00315.2002
   Shitama T, 2008, PROTEOM CLIN APPL, V2, P1265, DOI 10.1002/prca.200800017
   Simo R, 2008, ARCH OPHTHALMOL-CHIC, V126, P1076, DOI 10.1001/archopht.126.8.1076
   Simo R, 2015, PROG RETIN EYE RES, V48, P160, DOI 10.1016/j.preteyeres.2015.04.003
   Sjolie AK, 2008, LANCET, V372, P1385, DOI 10.1016/S0140-6736(08)61411-7
   Stitt AW, 2016, PROG RETIN EYE RES, V51, P156, DOI 10.1016/j.preteyeres.2015.08.001
   Takada M, 2010, BIOCHEM BIOPH RES CO, V399, P221, DOI 10.1016/j.bbrc.2010.07.058
   Tuo JS, 2007, INVEST OPHTH VIS SCI, V48, P3827, DOI 10.1167/iovs.07-0051
   Umeda S, 2005, FASEB J, V19, P1683, DOI 10.1096/fj.04-3525fje
   VanGuilder HD, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016271
   Walia S, 2010, SEMIN OPHTHALMOL, V25, P289, DOI 10.3109/08820538.2010.518912
   Wang HB, 2016, MOL VIS, V22, P189
   Wang H, 2013, EXP EYE RES, V108, P110, DOI 10.1016/j.exer.2012.11.023
   Wang H, 2012, PROTEOME SCI, V10, DOI 10.1186/1477-5956-10-15
   Wang YD, 2007, CURR EYE RES, V32, P891, DOI 10.1080/02713680701593702
   Wilkinson CP, 2003, OPHTHALMOLOGY, V110, P1677, DOI 10.1016/S0161-6420(03)00475-5
   Wong TY, 2016, NAT REV DIS PRIMERS, V2, DOI 10.1038/nrdp.2016.12
   Xu HP, 2016, EUR J PHARMACOL, V787, P94, DOI 10.1016/j.ejphar.2016.03.001
   Yamane K, 2003, MOL CELL PROTEOMICS, V2, P1177, DOI 10.1074/mcp.M300038-MCP200
   Yao JQ, 2013, INT J MOL MED, V32, P1421, DOI 10.3892/ijmm.2013.1509
   Yao JQ, 2013, PROTEOM CLIN APPL, V7, P550, DOI 10.1002/prca.201200012
   Yuan XL, 2010, MOL CELL PROTEOMICS, V9, P1031, DOI 10.1074/mcp.M900523-MCP200
   Zhang SY, 2013, MOL VIS, V19, P812
   Zhang Y, 2005, INVEST OPHTH VIS SCI, V46, P2133, DOI 10.1167/iovs.04-1235
NR 102
TC 29
Z9 30
U1 4
U2 27
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1422-0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD MAY
PY 2017
VL 18
IS 5
AR 907
DI 10.3390/ijms18050907
PG 24
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA EY6SQ
UT WOS:000404113900014
PM 28452939
OA Green Published, gold, Green Submitted
DA 2022-11-30
ER

PT J
AU Hajrasouliha, AR
   Jiang, GM
   Lu, QX
   Lu, HY
   Kaplan, HJ
   Zhang, HG
   Shao, H
AF Hajrasouliha, Amir Reza
   Jiang, Guomin
   Lu, Qingxian
   Lu, Huayi
   Kaplan, Henry J.
   Zhang, Huang-Ge
   Shao, Hui
TI Exosomes from Retinal Astrocytes Contain Antiangiogenic Components That
   Inhibit Laser-induced Choroidal Neovascularization
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID MACULAR DEGENERATION; COMPLEMENT ACTIVATION; T-CELLS; ANGIOGENESIS;
   PROTEINS; IMMUNOTHERAPY; PEPTIDE; GROWTH; MODEL; MICE
AB Exosomes released from different types of host cells have different biological effects. We report that exosomes released from retinal astroglial cells (RACs) suppress retinal vessel leakage and inhibit choroidal neovascularization (CNV) in a laser-induced CNV model, whereas exosomes released from retinal pigmental epithelium do not. RAC exosomes inhibit the migration of macrophages and the tubule forming of mouse retinal microvascular endothelial cells. Further, we analyzed antiangiogenic components in RAC exosomes using an angiogenesis array kit and detected several endogenous inhibitors of angiogenesis exclusively present in RAC exosomes, such as endostatin. Moreover, blockade of matrix metalloproteinases in the cleavage of collagen XVIII to form endostatin using FN-439 reverses RAC exosome-mediated retinal vessel leakage. This study demonstrates that exosomes released from retinal tissue cells have different angiogenic effects, with exosomes from RACs containing antiangiogenic components that might protect the eye from angiogenesis and maintain its functional integrity. In addition, by identifying additional components and their functions of RAC exosomes, we might improve the antiangiogenic therapy for CNV in age-related macular degeneration and diabetic retinopathy.
C1 [Hajrasouliha, Amir Reza; Jiang, Guomin; Lu, Qingxian; Lu, Huayi; Kaplan, Henry J.; Shao, Hui] Univ Louisville, Dept Ophthalmol & Visual Sci, Kentucky Lions Eye Ctr, Louisville, KY 40202 USA.
   [Zhang, Huang-Ge] Univ Louisville, Dept Res & Dev, Robley Rex Med Ctr, Louisville, KY 40202 USA.
C3 University of Louisville; University of Louisville
RP Shao, H (通讯作者)，Univ Louisville, Dept Ophthalmol & Vis Sci, Kentucky Lions Eye Ctr, 301 E Muhammad Ali Blvd, Louisville, KY 40202 USA.
EM h0shao01@louisville.edu
FU Research to Prevent Blindness Lew R. Wasserman merit award; Research to
   Prevent Blindness, New York; Commonwealth of Kentucky Research Challenge
   Trust Fund
FX This work was supported in part by a Research to Prevent Blindness Lew
   R. Wasserman merit award (to H. S.), an unrestricted grant from Research
   to Prevent Blindness (to H.J.K.), New York, and the Commonwealth of
   Kentucky Research Challenge Trust Fund (to H.J.K.).
CR Bora PS, 2003, P NATL ACAD SCI USA, V100, P2679, DOI 10.1073/pnas.0438014100
   Bussolati B, 2011, FASEB J, V25, P2874, DOI 10.1096/fj.10-180323
   Cao XG, 2011, PATHOL INT, V61, P528, DOI 10.1111/j.1440-1827.2011.02695.x
   Martinez MC, 2006, BLOOD, V108, P3012, DOI 10.1182/blood-2006-04-019109
   Chan CC, 2008, OPHTHALMIC RES, V40, P124, DOI 10.1159/000119862
   Cho YE, 2009, INVEST OPHTH VIS SCI, V50, P5614, DOI 10.1167/iovs.09-3688
   Couch SM, 2011, SEMIN OPHTHALMOL, V26, P114, DOI 10.3109/08820538.2011.577130
   Courrier HM, 2002, CRIT REV THER DRUG, V19, P425, DOI 10.1615/CritRevTherDrugCarrierSyst.v19.i45.40
   Delcayre A, 2006, CURR OPIN MOL THER, V8, P31
   Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745
   Ethen CM, 2007, INVEST OPHTH VIS SCI, V48, P3469, DOI 10.1167/iovs.06-1058
   Fujimoto T, 2010, INVEST OPHTH VIS SCI, V51, P4694, DOI 10.1167/iovs.09-4464
   Hao SG, 2007, CANCER BIOTHER RADIO, V22, P692, DOI 10.1089/cbr.2007.368-R
   Huber M, 2012, OPHTHALMOLOGICA, V228, P188, DOI 10.1159/000339952
   Jiang GM, 2008, INVEST OPHTH VIS SCI, V49, P282, DOI 10.1167/iovs.07-0371
   Jiang GM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040510
   Jiang GM, 2009, INVEST OPHTH VIS SCI, V50, P4769, DOI 10.1167/iovs.08-3303
   Johnson LV, 2002, P NATL ACAD SCI USA, V99, P11830, DOI 10.1073/pnas.192203399
   JOHNSON MD, 1994, J CELL PHYSIOL, V160, P194, DOI 10.1002/jcp.1041600122
   Lavalette S, 2011, AM J PATHOL, V178, P2416, DOI 10.1016/j.ajpath.2011.01.013
   Lebreton A, 2008, BBA-GENE REGUL MECH, V1779, P558, DOI 10.1016/j.bbagrm.2008.02.003
   Liao TJ, 2006, INVEST OPHTH VIS SCI, V47, P1543, DOI 10.1167/iovs.05-1238
   Liu CR, 2006, J IMMUNOL, V176, P1375, DOI 10.4049/jimmunol.176.3.1375
   Liu YQ, 2009, CELL STEM CELL, V4, P336, DOI 10.1016/j.stem.2009.02.015
   Lorentzen E, 2006, CELL, V125, P651, DOI 10.1016/j.cell.2006.05.002
   Luhmann UFO, 2009, INVEST OPHTH VIS SCI, V50, P5934, DOI 10.1167/iovs.09-3462
   Marneros AG, 2007, FASEB J, V21, P3809, DOI 10.1096/fj.07-8422com
   Martinez MC, 2011, CIRC RES, V109, P110, DOI 10.1161/CIRCRESAHA.110.233049
   Mirochnik Y, 2009, CLIN CANCER RES, V15, P1655, DOI 10.1158/1078-0432.CCR-08-2113
   Mullins RF, 2001, EYE, V15, P390, DOI 10.1038/eye.2001.142
   Park JE, 2010, MOL CELL PROTEOMICS, V9, P1085, DOI 10.1074/mcp.M900381-MCP200
   Patel M, 2008, SEMIN IMMUNOPATHOL, V30, P97, DOI 10.1007/s00281-008-0112-9
   Penfold PL, 2001, PROG RETIN EYE RES, V20, P385, DOI 10.1016/S1350-9462(00)00025-2
   Ray Avijit, 2010, J Vis Exp, DOI 10.3791/1488
   Shichita T, 2012, NAT MED, V18, P911, DOI 10.1038/nm.2749
   Takeda A, 2009, NATURE, V460, P225, DOI 10.1038/nature08151
   Thery C, 2002, NAT REV IMMUNOL, V2, P569, DOI 10.1038/nri855
   Totan Y, 2009, CURR EYE RES, V34, P1089, DOI 10.3109/02713680903353772
   Wang Y, 2011, EYE, V25, P127, DOI 10.1038/eye.2010.196
   Weismann D, 2011, NATURE, V478, P76, DOI 10.1038/nature10449
   Witmer AN, 2003, PROG RETIN EYE RES, V22, P1, DOI 10.1016/S1350-9462(02)00043-5
   Yang M, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-117
   Zhang HG, 2011, CLIN CANCER RES, V17, P959, DOI 10.1158/1078-0432.CCR-10-1489
   Zhuang XY, 2011, MOL THER, V19, P1769, DOI 10.1038/mt.2011.164
NR 44
TC 84
Z9 90
U1 0
U2 11
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
EI 1083-351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD SEP 27
PY 2013
VL 288
IS 39
BP 28058
EP 28067
DI 10.1074/jbc.M113.470765
PG 10
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA 302OB
UT WOS:000330612800031
PM 23926109
OA Green Published, hybrid
DA 2022-11-30
ER

PT J
AU Prasad, AS
AF Prasad, Ananda S.
TI Discovery of human zinc deficiency: 50 years later
SO JOURNAL OF TRACE ELEMENTS IN MEDICINE AND BIOLOGY
LA English
DT Article
DE Zinc; Immunity; IL-2; A-20; TNF-alpha
ID ACRODERMATITIS-ENTEROPATHICA; INFLAMMATORY CYTOKINES; OXIDATIVE STRESS;
   HUT-78 CELLS; KAPPA-B; HYPOGONADISM; GENERATION; DWARFISM; DISEASE;
   ANEMIA
AB Essentiality of zinc for humans and its deficiency was recognized in 1963. During the past 50 years, it has become apparent that deficiency of zinc in humans is prevalent. Nutritional deficiency of zinc may affect nearly 2 billion subjects in the developing world. Consumption of cereal proteins high in phytate decreases the availability of zinc for absorption. Conditioned deficiency of zinc is also very common. Growth retardation, hypogonadism in males, rough skin, impaired immunity, neuro-sensory disorder and cognitive impairment are some of the clinical manifestations of zinc deficiency. Zinc is involved in many biochemical functions. Over 300 enzymes require zinc for their activation and nearly 2000 transcription factors require zinc for gene expression. Zinc is essential for cell mediated immunity. Zinc is also an effective antioxidant and anti-inflammatory agent. In therapeutic dosages, zinc has been used for the treatment of acute diarrhea in infants and children, common cold, Wilson's disease, sickle cell disease and for prevention of blindness in patients with age related macular degeneration. (C) 2012 Elsevier GmbH. All rights reserved.
C1 [Prasad, Ananda S.] Wayne State Univ, Sch Med, Dept Oncol, Detroit, MI 48201 USA.
   [Prasad, Ananda S.] Wayne State Univ, Sch Med, Barbara Ann Karmanos Canc Ctr, Detroit, MI USA.
C3 Wayne State University; Barbara Ann Karmanos Cancer Institute; Wayne
   State University
RP Prasad, AS (通讯作者)，Wayne State Univ, Sch Med, Dept Oncol, 421 E Canfield, Detroit, MI 48201 USA.
EM prasada@kamanos.org
CR ARAKAWA T, 1976, AM J CLIN NUTR, V29, P197, DOI 10.1093/ajcn/29.2.197
   Bao B, 2008, TRANSL RES, V152, P67, DOI 10.1016/j.trsl.2008.06.001
   Bao B, 2011, BIOCHEM BIOPH RES CO, V407, P703, DOI 10.1016/j.bbrc.2011.03.084
   Bao B, 2010, AM J CLIN NUTR, V91, P1634, DOI 10.3945/ajcn.2009.28836
   BARNES PM, 1973, P ROY SOC MED, V66, P327, DOI 10.1177/003591577306600411
   Beck FWJ, 1997, AM J PHYSIOL-ENDOC M, V272, pE1002, DOI 10.1152/ajpendo.1997.272.6.E1002
   BREWER GJ, 1995, DRUGS, V50, P240, DOI 10.2165/00003495-199550020-00004
   Clemons TE, 2004, ARCH OPHTHALMOL-CHIC, V122, P716
   Fischer Walker CL, 2011, BIOMED HEALTH RES, V76, P234, DOI 10.3233/978-1-60750-816-8-234
   Fukada T, 2011, METALLOMICS, V3, P662, DOI 10.1039/c1mt00011j
   Haase H, 2011, BIOMED HEALTH RES, V76, P94, DOI 10.3233/978-1-60750-816-8-94
   HALSTED JA, 1972, AM J MED, V53, P277, DOI 10.1016/0002-9343(72)90169-6
   HAMBIDGE KM, 1972, PEDIATR RES, V6, P868, DOI 10.1203/00006450-197212000-00003
   KAY RG, 1975, LANCET, V2, P605
   MacMahon R A, 1968, Med J Aust, V2, P210
   ODELL BL, 1960, P SOC EXP BIOL MED, V103, P304, DOI 10.3181/00379727-103-25498
   OKADA A, 1976, SURGERY, V80, P629
   Prasad A.S., 1993, BIOCH ZINC, DOI 10.1007/978-1-4757-9444-1_2
   Prasad AS, 2008, J INFECT DIS, V197, P795, DOI 10.1086/528803
   Prasad AS, 2007, AM J CLIN NUTR, V85, P837, DOI 10.1093/ajcn/85.3.837
   Prasad AS, 2011, NUTRITION, V27, P816, DOI 10.1016/j.nut.2010.08.010
   PRASAD AS, 1978, ANN INTERN MED, V89, P483, DOI 10.7326/0003-4819-89-4-483
   PRASAD AS, 1988, J CLIN INVEST, V82, P1202, DOI 10.1172/JCI113717
   PRASAD AS, 1974, J LAB CLIN MED, V83, P634
   PRASAD AS, 1961, AM J MED, V31, P532, DOI 10.1016/0002-9343(61)90137-1
   PRASAD AS, 1963, J LAB CLIN MED, V61, P537
   Prasad AS, 2004, FREE RADICAL BIO MED, V37, P1182, DOI 10.1016/j.freeradbiomed.2004.07.007
   Prasad AS, 2002, J LAB CLIN MED, V140, P272, DOI 10.1067/mlc.2002.127908
   PRASAD AS, 1967, J CLIN INVEST, V46, P549, DOI 10.1172/JCI105556
   Prasad AS, 2001, J LAB CLIN MED, V138, P250, DOI 10.1067/mlc.2001.118108
   Raulin J., 1869, ANN SCI NAT BOT BIOL, V11, P93
   SANSTEAD HH, 1967, AM J CLIN NUTR, V20, P422, DOI 10.1093/ajcn/20.5.422
   Shankar AH, 1998, AM J CLIN NUTR, V68, p447S, DOI 10.1093/ajcn/68.2.447S
   Todd WR, 1934, AM J PHYSIOL, V107, P146, DOI 10.1152/ajplegacy.1933.107.1.146
   Wang K, 2002, AM J HUM GENET, V71, P66, DOI 10.1086/341125
NR 35
TC 197
Z9 219
U1 0
U2 53
PU ELSEVIER GMBH, URBAN & FISCHER VERLAG
PI JENA
PA OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY
SN 0946-672X
J9 J TRACE ELEM MED BIO
JI J. Trace Elem. Med. Biol.
PY 2012
VL 26
IS 2-3
BP 66
EP 69
DI 10.1016/j.jtemb.2012.04.004
PG 4
WC Biochemistry & Molecular Biology; Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Endocrinology & Metabolism
GA 991FP
UT WOS:000307687200003
PM 22664333
DA 2022-11-30
ER

PT J
AU Lecomte, J
   Louis, K
   Detry, B
   Blacher, S
   Lambert, V
   Bekaert, S
   Munaut, C
   Paupert, J
   Blaise, P
   Foidart, JM
   Rakic, JM
   Krane, SM
   Noel, A
AF Lecomte, Julie
   Louis, Krystel
   Detry, Benoit
   Blacher, Silvia
   Lambert, Vincent
   Bekaert, Sandrine
   Munaut, Carine
   Paupert, Jenny
   Blaise, Pierre
   Foidart, Jean-Michel
   Rakic, Jean-Marie
   Krane, Stephen M.
   Noel, Agnes
TI Bone marrow-derived mesenchymal cells and MMP13 contribute to
   experimental choroidal neovascularization
SO CELLULAR AND MOLECULAR LIFE SCIENCES
LA English
DT Article
DE CNV; MMP13; Angiogenesis; Bone marrow; Mesenchymal stem cells
ID MATRIX METALLOPROTEINASES; MACULAR DEGENERATION; CELLULAR MECHANISMS;
   GROWTH-FACTOR; GELATINASE-A; STEM-CELLS; ANGIOGENESIS; DEGRADATION;
   ACTIVATION; EXPRESSION
AB In this study, we evaluate the potential involvement of collagenase-3 (MMP13), a matrix metalloproteinase (MMP) family member, in the exudative form of age-related macular degeneration characterized by a neovascularisation into the choroid. RT-PCR analysis revealed that human neovascular membranes issued from patients with AMD expressed high levels of Mmp13. The contribution of MMP13 in choroidal neovascularization (CNV) formation was explored by using a murine model of laser-induced CNV and applying it to wild-type mice (WT) and Mmp13-deficient mice (Mmp13 (-/-) mice). Angiogenic and inflammatory reactions were explored by immunohistochemistry. The implication of bone marrow (BM)-derived cells was determined by BM engraftment into irradiated mice and by injecting mesenchymal stem cells (MSC) isolated from WT BM. The deficiency of Mmp13 impaired CNV formation which was fully restored by WT BM engraftment and partially rescued by several injections of WT MSC. The present study sheds light on a novel function of MMP13 during BM-dependent choroidal vascularization and provides evidence for a role for MSC in the pathogenesis of CNV.
C1 [Lecomte, Julie; Louis, Krystel; Detry, Benoit; Blacher, Silvia; Lambert, Vincent; Bekaert, Sandrine; Munaut, Carine; Paupert, Jenny; Foidart, Jean-Michel; Noel, Agnes] Univ Liege, Lab Tumor & Dev Biol, Grp Interdisciplinaire Genoprote Appl Res GIGA Ca, CHU B23, B-4000 Liege, Belgium.
   [Lambert, Vincent; Blaise, Pierre; Rakic, Jean-Marie] CHU, Dept Ophthalmol, B-4000 Liege, Belgium.
   [Krane, Stephen M.] Harvard Univ, Sch Med, Dept Med, Ctr Immunol & Inflammatory Dis, Boston, MA 02129 USA.
   [Krane, Stephen M.] Massachusetts Gen Hosp, Boston, MA 02129 USA.
C3 University of Liege; University of Liege; Harvard University; Harvard
   Medical School; Harvard University; Massachusetts General Hospital
RP Noel, A (通讯作者)，Univ Liege, Lab Tumor & Dev Biol, Grp Interdisciplinaire Genoprote Appl Res GIGA Ca, CHU B23, B-4000 Liege, Belgium.
EM agnes.noel@ulg.ac.be
RI Munaut, Carine/K-8138-2019
OI Noel, Agnes/0000-0002-7670-6179; Paupert, Jenny/0000-0001-9550-9296
FU European Union; Fonds de la Recherche Scientifique Medicale; Fonds
   National de la Recherche Scientifique (F.N.R.S., Belgium); Federation
   belge contre le Cancer; Fonds speciaux de la Recherche (University of
   Liege); Centre Anti-cancereux pres l'Universite de Liege; Fonds Leon
   Fredericq (University of Liege); D.G.T.R.E. from the "Region Wallonne"
   the Interuniversity Attraction Poles Program-Belgian Science Policy
   (Brussels, Belgium); Televie-FNRS; US National Institutes of Health
FX The authors acknowledge P. Gavitelli, F. Olivier, M.-R. Pignon, E.
   Feyereisen, L. Poma, G. Roland and N. Lefin for collaboration and
   technical assistance. They thank the GIGA imaging and flow cytometry
   platform for their help. This work was supported by grants from the
   European Union Framework Program projects (FP7, MICROENVIMET), the Fonds
   de la Recherche Scientifique Medicale, the Fonds National de la
   Recherche Scientifique (F.N.R.S., Belgium), the Federation belge contre
   le Cancer, the Fonds speciaux de la Recherche (University of Liege), the
   Centre Anti-cancereux pres l'Universite de Liege, the Fonds Leon
   Fredericq (University of Liege), the D.G.T.R.E. from the "Region
   Wallonne" the Interuniversity Attraction Poles Program-Belgian Science
   Policy (Brussels, Belgium). JL is recipient of a Televie-FNRS grant. SMK
   was supported by a grant from the US National Institutes of Health.
CR Asahara T, 1999, CIRC RES, V85, P221, DOI 10.1161/01.RES.85.3.221
   Ashworth JL, 1999, BIOCHEM J, V340, P171, DOI 10.1042/0264-6021:3400171
   Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   Cowell S, 1998, BIOCHEM J, V331, P453, DOI 10.1042/bj3310453
   Csaky KG, 2004, EXP EYE RES, V78, P1107, DOI 10.1016/j.exer.2004.01.010
   Das A, 1999, INVEST OPHTH VIS SCI, V40, P809
   El Hour M, 2010, ONCOGENE, V29, P3025, DOI 10.1038/onc.2010.49
   Espinosa-Heidmann DG, 2003, INVEST OPHTH VIS SCI, V44, P4914, DOI 10.1167/iovs.03-0371
   Ferrara N, 2005, NATURE, V438, P967, DOI 10.1038/nature04483
   Fosang AJ, 1996, FEBS LETT, V380, P17, DOI 10.1016/0014-5793(95)01539-6
   Higashiyama R, 2007, HEPATOLOGY, V45, P213, DOI 10.1002/hep.21477
   Inada M, 2004, P NATL ACAD SCI USA, V101, P17192, DOI 10.1073/pnas.0407788101
   Jost M, 2007, AM J PATHOL, V171, P1369, DOI 10.2353/ajpath.2007.070074
   Kadonosono K, 1999, AM J OPHTHALMOL, V128, P382, DOI 10.1016/S0002-9394(99)00135-X
   Knauper V, 1996, J BIOL CHEM, V271, P17124, DOI 10.1074/jbc.271.29.17124
   Knauper V, 1997, EUR J BIOCHEM, V248, P369, DOI 10.1111/j.1432-1033.1997.00369.x
   Kosaki N, 2007, BIOCHEM BIOPH RES CO, V354, P846, DOI 10.1016/j.bbrc.2006.12.234
   Lambert V, 2003, FASEB J, V17, P2290, DOI 10.1096/fj.03-0113fje
   Lambert V, 2002, AM J PATHOL, V161, P1247, DOI 10.1016/S0002-9440(10)64401-X
   Lambert V, 2001, FASEB J, V15, P1021, DOI 10.1096/fj.00-0393com
   Lederle W, 2010, CARCINOGENESIS, V31, P1175, DOI 10.1093/carcin/bgp248
   Leeman MF, 2002, CRIT REV BIOCHEM MOL, V37, P149, DOI 10.1080/10409230290771483
   Nielsen BS, 2001, CANCER RES, V61, P7091
   Noel A, 2007, TRENDS MOL MED, V13, P345, DOI 10.1016/j.molmed.2007.06.005
   Overall CM, 2002, NAT REV CANCER, V2, P657, DOI 10.1038/nrc884
   Peister A, 2004, BLOOD, V103, P1662, DOI 10.1182/blood-2003-09-3070
   Raffetto JD, 2008, BIOCHEM PHARMACOL, V75, P346, DOI 10.1016/j.bcp.2007.07.004
   Rakic JM, 2003, INVEST OPHTH VIS SCI, V44, P1732, DOI 10.1167/iovs.02-0809
   Rakic JM, 2003, CELL MOL LIFE SCI, V60, P463, DOI 10.1007/s000180300039
   Rakic JM, 2003, INVEST OPHTH VIS SCI, V44, P3186, DOI 10.1167/iovs.02-1092
   Rattner A, 2006, NAT REV NEUROSCI, V7, P860, DOI 10.1038/nrn2007
   Rundhaug JE, 2005, J CELL MOL MED, V9, P267, DOI 10.1111/j.1582-4934.2005.tb00355.x
   Sengupta N, 2003, INVEST OPHTH VIS SCI, V44, pU349
   Takaishi H, 2008, CURR PHARM BIOTECHNO, V9, P47, DOI 10.2174/138920108783497659
   Tomita M, 2004, STEM CELLS, V22, P21, DOI 10.1634/stemcells.22-1-21
   Udagawa T, 2007, CANCER RES, V67, P2040, DOI 10.1158/0008-5472.CAN-06-2877
   WEBER BHF, 1994, NAT GENET, V8, P352, DOI 10.1038/ng1294-352
   Whitelock JM, 1996, J BIOL CHEM, V271, P10079, DOI 10.1074/jbc.271.17.10079
   Zhang B, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-83
   Zijlstra A, 2004, J BIOL CHEM, V279, P27633, DOI 10.1074/jbc.M313617200
NR 40
TC 25
Z9 30
U1 0
U2 4
PU SPRINGER BASEL AG
PI BASEL
PA PICASSOPLATZ 4, BASEL, 4052, SWITZERLAND
SN 1420-682X
EI 1420-9071
J9 CELL MOL LIFE SCI
JI Cell. Mol. Life Sci.
PD FEB
PY 2011
VL 68
IS 4
BP 677
EP 686
DI 10.1007/s00018-010-0476-6
PG 10
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA 712JK
UT WOS:000286662700009
PM 20700625
OA Green Submitted
DA 2022-11-30
ER

PT J
AU Fernandez-Sevilla, JM
   Fernandez, FGA
   Grima, EM
AF Fernandez-Sevilla, Jose M.
   Acien Fernandez, F. G.
   Molina Grima, E.
TI Biotechnological production of lutein and its applications
SO APPLIED MICROBIOLOGY AND BIOTECHNOLOGY
LA English
DT Review
DE Lutein; Microalgae; Extraction; Photobioreactor; Mass production
ID SUPERCRITICAL-FLUID EXTRACTION; CHLORELLA-PROTOTHECOIDES; MURIELLOPSIS
   SP; SCENEDESMUS-ALMERIENSIS; HETEROTROPHIC CHLORELLA; OUTDOOR
   CULTIVATION; CARBON-DIOXIDE; CO2 EXTRACTION; CHLOROPHYLL-A; CAROTENOIDS
AB Lutein is an antioxidant that has gathered increasing attention due to its potential role in preventing or ameliorating age-related macular degeneration. Currently, it is produced from marigold oleoresin, but continuous reports of lutein-producing microalgae pose the question if those microorganisms can become an alternative source. Several microalgae have higher lutein contents than most marigold cultivars and have been shown to yield productivities hundreds of times higher than marigold crops on a per square meter basis. Microalgae and marigold are opposite alternatives in the use of resources such as land and labor and the prevalence of one or the other could change in the future as the lutein demand rises and if labor or land becomes more restricted or expensive in the producing countries. The potential of microalgae as a lutein source is analyzed and compared to marigold. It is suggested that, in the current state of the art, microalgae could compete with marigold even without counting on any of the improvements in microalgal technology that can be expected in the near future.
C1 [Fernandez-Sevilla, Jose M.; Acien Fernandez, F. G.; Molina Grima, E.] Univ Almeria, Dept Chem Engn, La Canada De San Urbano 04120, Almeria, Spain.
C3 Universidad de Almeria
RP Fernandez-Sevilla, JM (通讯作者)，Univ Almeria, Dept Chem Engn, La Canada De San Urbano 04120, Almeria, Spain.
EM jfernand@ual.es
RI Fernandez-Sevilla, Jose Maria/I-9830-2018; Acien, Gabriel/H-1894-2015;
   Molina-Grima, Emilio/A-6705-2018
OI Fernandez-Sevilla, Jose Maria/0000-0002-0290-5810; Acien,
   Gabriel/0000-0002-8434-0365; Molina Grima, Emilio/0000-0003-1361-0564
CR Arnal E, 2009, GRAEF ARCH CLIN EXP, V247, P115, DOI 10.1007/s00417-008-0935-z
   BENDICH A, 1989, FASEB J, V3, P1927, DOI 10.1096/fasebj.3.8.2656356
   Bermejo R, 2007, ENZYME MICROB TECH, V40, P927, DOI 10.1016/j.enzmictec.2006.07.027
   Blanco AM, 2007, APPL MICROBIOL BIOT, V73, P1259, DOI 10.1007/s00253-006-0598-9
   Carpentier S, 2009, CRIT REV FOOD SCI, V49, P313, DOI 10.1080/10408390802066979
   Ceron MC, 2008, J AGR FOOD CHEM, V56, P11761, DOI 10.1021/jf8025875
   Chiu CJ, 2007, EXP EYE RES, V84, P229, DOI 10.1016/j.exer.2006.05.015
   Coleman H, 2007, CURR OPIN OPHTHALMOL, V18, P220, DOI 10.1097/ICU.0b013e32814a586b
   CRNOBARAC J, 2009, NAT PROD COMMUN, V4, P35
   Del Campo JA, 2004, APPL MICROBIOL BIOT, V64, P848, DOI 10.1007/s00253-003-1510-5
   Del Campo JA, 2001, J BIOTECHNOL, V85, P289, DOI 10.1016/S0168-1656(00)00380-1
   Del Campo JA, 2000, J BIOTECHNOL, V76, P51, DOI 10.1016/S0168-1656(99)00178-9
   Del Campo JA, 2007, APPL MICROBIOL BIOT, V74, P1163, DOI 10.1007/s00253-007-0844-9
   Delgado-Vargas F, 2000, CRIT REV FOOD SCI, V40, P173, DOI 10.1080/10408690091189257
   Demmig-Adams B, 2002, SCIENCE, V298, P2149, DOI 10.1126/science.1078002
   DemmigAdams B, 1996, TRENDS PLANT SCI, V1, P21, DOI 10.1016/S1360-1385(96)80019-7
   Diaz-Avelar J, 2004, WATER SCI TECHNOL, V50, P33, DOI 10.2166/wst.2004.0528
   Macias-Sanchez MD, 2009, CHEM ENG J, V150, P104, DOI 10.1016/j.cej.2008.12.006
   Failla M., 2005, TECHNICAL MONOGRAPHS, V3
   Farrow W. M., 1966, U.S. Patent, Patent No. [3,280,502, 3280502]
   Fernandez-Sevilla J., 2008, LARGE SCALE PRODUCTI
   FERNANDEZSEVILLA JM, 2005, Patent No. 2006000072
   Gao YX, 2009, J SUPERCRIT FLUID, V49, P345, DOI 10.1016/j.supflu.2009.02.006
   Granado F, 2003, BRIT J NUTR, V90, P487, DOI 10.1079/BJN2003927
   Granado-Lorencio F, 2009, FOOD CHEM, V114, P747, DOI 10.1016/j.foodchem.2008.10.058
   Herrero M, 2005, FOOD CHEM, V93, P417, DOI 10.1016/j.foodchem.2004.09.037
   Hojnik M, 2008, LWT-FOOD SCI TECHNOL, V41, P2008, DOI 10.1016/j.lwt.2007.11.017
   Ishida BK, 2009, J AGR FOOD CHEM, V57, P1051, DOI 10.1021/jf8026292
   John JH, 2002, LANCET, V359, P1969, DOI 10.1016/S0140-6736(02)98858-6
   KHACHIK F, 2007, Patent No. 7173145
   Kitada K, 2009, J CHEM TECHNOL BIOT, V84, P657, DOI 10.1002/jctb.2096
   Krinsky NI, 2003, ANNU REV NUTR, V23, P171, DOI 10.1146/annurev.nutr.23.011702.073307
   LAHAYE M, 1991, J SCI FOOD AGR, V54, P587, DOI 10.1002/jsfa.2740540410
   Lakshminarayana R, 2006, MOL CELL BIOCHEM, V281, P103, DOI 10.1007/s11010-006-1337-3
   Li HB, 2002, J AGR FOOD CHEM, V50, P1070, DOI 10.1021/jf010220b
   Macias-Sanchez MD, 2009, TALANTA, V77, P948, DOI 10.1016/j.talanta.2008.07.032
   Macias-Sanchez MD, 2008, J SEP SCI, V31, P1352, DOI 10.1002/jssc.200700503
   Macias-Sanchez MD, 2005, J FOOD ENG, V66, P245, DOI 10.1016/j.jfoodeng.2004.03.021
   Matsukawa R, 2000, J APPL PHYCOL, V12, P263, DOI 10.1023/A:1008141414115
   Miguel F, 2008, CHEM ENG PROCESS, V47, P1594, DOI 10.1016/j.cep.2007.07.008
   MINGUEZMOSQUERA MI, 1992, J AGR FOOD CHEM, V40, P60, DOI 10.1021/jf00013a012
   Navarrete-Bolanos JL, 2005, FOOD RES INT, V38, P159, DOI 10.1016/j.foodres.2004.09.007
   Nonomura A. M., 1987, U.S. Patent, Patent No. [4,680,314, 4680314]
   O'Neill ME, 2001, BRIT J NUTR, V85, P499, DOI 10.1079/BJN2000284
   Piccaglia R, 1998, IND CROP PROD, V8, P45, DOI 10.1016/S0926-6690(97)10005-X
   Qingxiang Ma, 2008, International Journal of Food Science & Technology, V43, P1763, DOI 10.1111/j.1365-2621.2007.01694.x
   Ramesh K, 2008, IND CROP PROD, V27, P380, DOI 10.1016/j.indcrop.2007.08.004
   Roberts RL, 2009, CLIN DERMATOL, V27, P195, DOI 10.1016/j.clindermatol.2008.01.011
   Sanchez JF, 2008, APPL MICROBIOL BIOT, V79, P719, DOI 10.1007/s00253-008-1494-2
   Sanchez JF, 2008, PROCESS BIOCHEM, V43, P398, DOI 10.1016/j.procbio.2008.01.004
   Semba RD, 2003, MED HYPOTHESES, V61, P465, DOI 10.1016/S0306-9877(03)00198-1
   SEVILLA JMF, 2005, Patent No. 200500374
   Shen Y, 2009, J CHROMATOGR A, V1216, P5763, DOI 10.1016/j.chroma.2009.06.009
   Shi XM, 2006, MOL NUTR FOOD RES, V50, P763, DOI 10.1002/mnfr.200600037
   Shi XM, 2002, BIOTECHNOL PROGR, V18, P723, DOI 10.1021/bp0101987
   Shi XM, 2000, ENZYME MICROB TECH, V27, P312, DOI 10.1016/S0141-0229(00)00208-8
   Wei D, 2008, SCI CHINA SER C, V51, P1088, DOI 10.1007/s11427-008-0145-2
NR 57
TC 218
Z9 229
U1 4
U2 113
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0175-7598
EI 1432-0614
J9 APPL MICROBIOL BIOT
JI Appl. Microbiol. Biotechnol.
PD MAR
PY 2010
VL 86
IS 1
BP 27
EP 40
DI 10.1007/s00253-009-2420-y
PG 14
WC Biotechnology & Applied Microbiology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology
GA 555VC
UT WOS:000274543200004
PM 20091305
DA 2022-11-30
ER

PT J
AU Tolentino, MJ
AF Tolentino, Michael J.
TI Current Molecular Understanding and Future Treatment Strategies for
   Pathologic Ocular Neovascularization
SO CURRENT MOLECULAR MEDICINE
LA English
DT Review
DE Vascular Endothelial Growth Factor (VEGF); Age Related Macular
   Degeneration (AMD); Complement; Diabetic Retinopathy (DR); Complement;
   Ranibizumab; Pegaptanib; Bevacizumab; Bevasiranib; Integrins; Platelet
   Derived Growth Factor (PDGF)
ID ENDOTHELIAL GROWTH-FACTOR; DIABETIC MACULAR EDEMA; EXPERIMENTAL
   CHOROIDAL NEOVASCULARIZATION; VASCULAR-PERMEABILITY FACTOR; PIGMENT
   EPITHELIAL-CELLS; BLOOD-RETINAL BARRIER; FACTOR VEGF; IN-VIVO; IRIS
   NEOVASCULARIZATION; FACTOR EXPRESSION
AB The leading cause of blindness in the developed world results from several disorders that have pathologic ocular neovascularization as the common pathway leading to vision loss. These disorders include exudative age related macular degeneration (AMD), diabetic retinopathy (DR), retinopathy of prematurity (ROP), retinal vein occlusions (RVO) and ocular tumors. Because neovascularization is the common pathway to blindness in these highly prevalent conditions, the recent understanding of the cascade of angiogenesis has led to clinically available molecular therapeutics that have been proven to restore and preserve vision in patients that suffer from these blinding conditions. This article will summarize the emergence of vascular endothelial growth factor (VEGF) as a validated treatment target for and current understanding of the pathophysiology of ocular neovascularization. The article will then cover promising future strategies and therapeutic targets that are aimed at enhancing the efficacy and/or duration of effect of these clinically available anti-VEGF strategies. In particular molecules that target, VEGF, PDGF, Complement, Inflammation and Integrins that are entering or are currently in clinical trials will be reviewed.
C1 Ctr Retina & Macular Dis, Winter Haven, FL 33880 USA.
RP Tolentino, MJ (通讯作者)，Ctr Retina & Macular Dis, 250 Ave K SW, Winter Haven, FL 33880 USA.
EM MTolent95@aol.com
FU Regeneron; Opthotech; Novartis; Glaxo Smith Kline; Genentech; Pfizer;
   National Eye Institute; Lpath
FX Regeneron, Opthotech, Novartis, Glaxo Smith Kline, Genentech, Pfizer,
   National Eye Institute, Lpath.
CR Adamis AP, 2006, OPHTHALMOLOGY, V113, P23, DOI 10.1016/j.ophtha.2005.10.012
   Adamis AP, 1996, ARCH OPHTHALMOL-CHIC, V114, P66, DOI 10.1001/archopht.1996.01100130062010
   AIELLO LP, 1995, ARCH OPHTHALMOL-CHIC, V113, P1538, DOI 10.1001/archopht.1995.01100120068012
   AIELLO LP, 1995, P NATL ACAD SCI USA, V92, P10457, DOI 10.1073/pnas.92.23.10457
   AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203
   Antonetti D A, 1999, Semin Ophthalmol, V14, P240, DOI 10.3109/08820539909069543
   Avraamides CJ, 2008, NAT REV CANCER, V8, P604, DOI 10.1038/nrc2353
   Barleon B, 1996, BLOOD, V87, P3336, DOI 10.1182/blood.V87.8.3336.bloodjournal8783336
   Benjamin LE, 1999, J CLIN INVEST, V103, P159, DOI 10.1172/JCI5028
   Benjamin LE, 1998, DEVELOPMENT, V125, P1591
   Bhisitkul RB, 2005, ARCH OPHTHALMOL-CHIC, V123, P214, DOI 10.1001/archopht.123.2.214
   Bora NS, 2006, J IMMUNOL, V177, P1872, DOI 10.4049/jimmunol.177.3.1872
   Bora PS, 2005, J IMMUNOL, V174, P491, DOI 10.4049/jimmunol.174.1.491
   Brooks HL, 2004, ARCH OPHTHALMOL-CHIC, V122, P1801, DOI 10.1001/archopht.122.12.1801
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Campochiaro PA, 2004, INVEST OPHTH VIS SCI, V45, P922, DOI 10.1167/iovs.03-0955
   Cantor JM, 2008, IMMUNOL REV, V223, P236, DOI 10.1111/j.1600-065X.2008.00640.x
   Chun DW, 2006, OPHTHALMOLOGY, V113, P1706, DOI 10.1016/j.ophtha.2006.04.033
   Cunningham ET, 2005, OPHTHALMOLOGY, V112, P1747, DOI 10.1016/j.ophtha.2005.06.007
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Espinosa-Heidmann DG, 2003, INVEST OPHTH VIS SCI, V44, P3586, DOI 10.1167/iovs.03-0038
   Ferrara N, 2004, ENDOCR REV, V25, P581, DOI 10.1210/er.2003-0027
   Fong DS, 2004, DIABETES CARE, V27, P2540, DOI 10.2337/diacare.27.10.2540
   Fredriksson L, 2004, CYTOKINE GROWTH F R, V15, P197, DOI 10.1016/j.cytogfr.2004.03.007
   Funatsu H, 2003, OPHTHALMOLOGY, V110, P1690, DOI 10.1016/S0161-6420(03)00568-2
   Funatsu H, 2001, RETINA-J RET VIT DIS, V21, P469, DOI 10.1097/00006982-200110000-00009
   Funatsu H, 2002, AM J OPHTHALMOL, V133, P537, DOI 10.1016/S0002-9394(02)01323-5
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Grossniklaus HE, 2002, MOL VIS, V8, P119
   GUERRIN M, 1995, J CELL PHYSIOL, V164, P385, DOI 10.1002/jcp.1041640219
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Heldin CH, 1999, PHYSIOL REV, V79, P1283, DOI 10.1152/physrev.1999.79.4.1283
   Hellstrom M, 1999, DEVELOPMENT, V126, P3047
   Hiratsuka S, 2002, CANCER CELL, V2, P289, DOI 10.1016/S1535-6108(02)00153-8
   Honda M, 2000, GENE THER, V7, P978, DOI 10.1038/sj.gt.3301203
   Ishida S, 2003, J EXP MED, V198, P483, DOI 10.1084/jem.20022027
   Ishida S, 2003, NAT MED, V9, P781, DOI 10.1038/nm877
   Jo N, 2006, AM J PATHOL, V168, P2036, DOI 10.2353/ajpath.2006.050588
   Joussen AM, 2001, AM J PATHOL, V158, P147, DOI 10.1016/S0002-9440(10)63952-1
   Kleinman ME, 2008, NATURE, V452, P591, DOI 10.1038/nature06765
   Kliffen M, 1997, BRIT J OPHTHALMOL, V81, P154, DOI 10.1136/bjo.81.2.154
   Krzystolik MG, 2002, ARCH OPHTHALMOL-CHIC, V120, P338
   Kuroki M, 1996, J CLIN INVEST, V98, P1667, DOI 10.1172/JCI118962
   KVANTA A, 1995, CURR EYE RES, V14, P1015, DOI 10.3109/02713689508998523
   LeCouter J, 2003, SCIENCE, V299, P890, DOI 10.1126/science.1079562
   Lee S, 2005, J CELL BIOL, V169, P681, DOI 10.1083/jcb.200409115
   LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986
   Lopez PF, 1996, INVEST OPHTH VIS SCI, V37, P855
   Lu M, 1998, J CLIN INVEST, V101, P1219, DOI 10.1172/JCI1277
   Lynch SS, 2007, ANN PHARMACOTHER, V41, P614, DOI 10.1345/aph.1H316
   Maier AKB, 2007, CURR EYE RES, V32, P801, DOI 10.1080/02713680701553052
   Maller JB, 2007, NAT GENET, V39, P1200, DOI 10.1038/ng2131
   Markomichelakis NN, 2005, AM J OPHTHALMOL, V139, P537, DOI 10.1016/j.ajo.2004.09.058
   Matsumoto T, 2001, Sci STKE, V2001, pre21, DOI 10.1126/stke.2001.112.re21
   MILLER JW, 1994, AM J PATHOL, V145, P574
   Miyamoto K, 1999, P NATL ACAD SCI USA, V96, P10836, DOI 10.1073/pnas.96.19.10836
   Miyamoto K, 1998, INVEST OPHTH VIS SCI, V39, P2190
   Miyamoto K, 2000, AM J PATHOL, V156, P1733, DOI 10.1016/S0002-9440(10)65044-4
   Nguyen QD, 2006, OPHTHALMOLOGY, V113, P1522, DOI 10.1016/j.ophtha.2006.05.055
   Nguyen QD, 2006, AM J OPHTHALMOL, V142, P961, DOI 10.1016/j.ajo.2006.06.068
   Ohno-Matsui K, 2002, AM J PATHOL, V160, P711, DOI 10.1016/S0002-9440(10)64891-2
   Olson JL, 2007, ARCH OPHTHALMOL-CHIC, V125, P1221, DOI 10.1001/archopht.125.9.1221
   Papapetropoulos A, 1997, J CLIN INVEST, V100, P3131, DOI 10.1172/JCI119868
   PARK JE, 1993, MOL BIOL CELL, V4, P1317, DOI 10.1091/mbc.4.12.1317
   PEPPER MS, 1991, BIOCHEM BIOPH RES CO, V181, P902, DOI 10.1016/0006-291X(91)91276-I
   PLATE KH, 1992, NATURE, V359, P845, DOI 10.1038/359845a0
   Punglia RS, 1997, DIABETES, V46, P1619, DOI 10.2337/diabetes.46.10.1619
   Qaum T, 2001, INVEST OPHTH VIS SCI, V42, P2408
   Reich S, 2003, MOL VIS, V9, P210
   ROBERTS WG, 1995, J CELL SCI, V108, P2369
   Robinson CJ, 2001, J CELL SCI, V114, P853
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Saishin Y, 2003, J CELL PHYSIOL, V195, P241, DOI 10.1002/jcp.10246
   Seddon JM, 2004, JAMA-J AM MED ASSOC, V291, P704, DOI 10.1001/jama.291.6.704
   SENGER DR, 1983, SCIENCE, V219, P983, DOI 10.1126/science.6823562
   Shen J, 2006, GENE THER, V13, P225, DOI 10.1038/sj.gt.3302641
   Sonpavde Guru, 2007, Curr Oncol Rep, V9, P115, DOI 10.1007/s11912-007-0007-2
   Stewart MW, 2008, BRIT J OPHTHALMOL, V92, P667, DOI 10.1136/bjo.2007.134874
   TOLENTINO M, 2007, PRINCIPLE PRACTICE O
   Tolentino MJ, 1996, ARCH OPHTHALMOL-CHIC, V114, P964, DOI 10.1001/archopht.1996.01100140172010
   Tolentino MJ, 1996, OPHTHALMOLOGY, V103, P1820, DOI 10.1016/S0161-6420(96)30420-X
   Umeda N, 2006, MOL PHARMACOL, V69, P1820, DOI 10.1124/mol.105.020941
   Watanabe D, 2005, NEW ENGL J MED, V353, P782, DOI 10.1056/NEJMoa041773
   Watanabe D, 2005, AM J OPHTHALMOL, V139, P476, DOI 10.1016/j.ajo.2004.10.004
   Wilkinson-Berka JL, 2006, INVEST OPHTH VIS SCI, V47, P1600, DOI 10.1167/iovs.05-1314
   Yasukawa T, 2004, CURR EYE RES, V28, P359, DOI 10.1076/ceyr.28.5.359.28678
NR 86
TC 43
Z9 46
U1 0
U2 14
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1566-5240
EI 1875-5666
J9 CURR MOL MED
JI Curr. Mol. Med.
PD NOV
PY 2009
VL 9
IS 8
BP 973
EP 981
DI 10.2174/156652409789712783
PG 9
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA 514GC
UT WOS:000271381400007
PM 19925410
DA 2022-11-30
ER

PT J
AU Mahaling, B
   Low, SWY
   Beck, M
   Kumar, D
   Ahmed, S
   Connor, TB
   Ahmad, B
   Chaurasia, SS
AF Mahaling, Binapani
   Low, Shermaine W. Y.
   Beck, Molly
   Kumar, Devesh
   Ahmed, Simrah
   Connor, Thomas B.
   Ahmad, Baseer
   Chaurasia, Shyam S.
TI Damage-Associated Molecular Patterns (DAMPs) in Retinal Disorders
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE DAMPs; endophthalmitis; uveitis; glaucoma; ocular cancer; ischemic
   retinopathies; diabetic retinopathy; age-related macular degeneration;
   proliferative vitreoretinopathy; inherited retinal disorders
ID LEUKEMIA INHIBITORY FACTOR; MITOCHONDRIAL TRANSCRIPTION FACTOR;
   HEPARAN-SULFATE PROTEOGLYCAN; GROUP BOX-1 PROTEIN; TOLL-LIKE RECEPTORS;
   INCREASED URIC-ACID; TENASCIN-C LEVELS; AMYLOID-BETA; OPTIC-NERVE;
   AQUEOUS-HUMOR
AB Damage-associated molecular patterns (DAMPs) are endogenous danger molecules released from the extracellular and intracellular space of damaged tissue or dead cells. Recent evidence indicates that DAMPs are associated with the sterile inflammation caused by aging, increased ocular pressure, high glucose, oxidative stress, ischemia, mechanical trauma, stress, or environmental conditions, in retinal diseases. DAMPs activate the innate immune system, suggesting their role to be protective, but may promote pathological inflammation and angiogenesis in response to the chronic insult or injury. DAMPs are recognized by specialized innate immune receptors, such as receptors for advanced glycation end products (RAGE), toll-like receptors (TLRs) and the NOD-like receptor family (NLRs), and purine receptor 7 (P2X7), in systemic diseases. However, studies describing the role of DAMPs in retinal disorders are meager. Here, we extensively reviewed the role of DAMPs in retinal disorders, including endophthalmitis, uveitis, glaucoma, ocular cancer, ischemic retinopathies, diabetic retinopathy, age-related macular degeneration, rhegmatogenous retinal detachment, proliferative vitreoretinopathy, and inherited retinal disorders. Finally, we discussed DAMPs as biomarkers, therapeutic targets, and therapeutic agents for retinal disorders.
C1 [Mahaling, Binapani; Low, Shermaine W. Y.; Beck, Molly; Kumar, Devesh; Ahmed, Simrah; Connor, Thomas B.; Ahmad, Baseer; Chaurasia, Shyam S.] Med Coll Wisconsin, Froedtert & MCW Eye Inst, Dept Ophthalmol & Visual Sci, Ocular Immunol & Angiogenesis Lab, Milwaukee, WI USA.
   [Connor, Thomas B.; Ahmad, Baseer] Med Coll Wisconsin, Froedtert & MCW Eye Inst, Vitreoretinal Surg, Milwaukee, WI USA.
   [Chaurasia, Shyam S.] Med Coll Wisconsin, Dept Cell Biol Neurobiol & Anat, Milwaukee, WI USA.
C3 Medical College of Wisconsin; Medical College of Wisconsin; Medical
   College of Wisconsin
RP Chaurasia, SS (通讯作者)，Med Coll Wisconsin, Froedtert & MCW Eye Inst, Dept Ophthalmol & Visual Sci, Ocular Immunol & Angiogenesis Lab, Milwaukee, WI USA.; Chaurasia, SS (通讯作者)，Med Coll Wisconsin, Dept Cell Biol Neurobiol & Anat, Milwaukee, WI USA.
EM wlow@mcw.edu; mobeck@mcw.edu; dkumar@mcw.edu; schaurasia@mcw.edu;
   tconnor@mcw.edu; bahmad@mcw.edu; bahmad@mcw.edu; bmahaling@mcw.edu
RI Chaurasia, Shyam/AAB-4709-2019
OI Chaurasia, Shyam/0000-0001-8725-676X; Ahmad, Baseer/0000-0002-2216-4263;
   Kumar, Devesh/0000-0001-9202-6248
FU National Eye Institute, NIH, Bethesda, Maryland [RO1EY029795];
   Children's Wisconsin CRI Multi-Year Grant, Children's Research
   Institute, Milwaukee, WI; National Center for Research Resources, NIH
   [C06RR016511]
FX This research was funded by the National Eye Institute, NIH, Bethesda,
   Maryland, grant number RO1EY029795; and the Children's Wisconsin CRI
   Multi-Year Grant, Children's Research Institute, Milwaukee, WI to S.S.C.
   We would also like to thank the ARVO EyeFind Research Grant Program.
   This investigation was conducted, in part, in a facility constructed
   with support from a Research Facilities Improvement Program, grant
   number C06RR016511, from the National Center for Research Resources,
   NIH. Its contents are solely the responsibility of the authors and do
   not necessarily represent the official views of the NIH.
CR Abu El-Asrar AM, 2017, MOL VIS, V23, P853
   Abu El-Asrar AM, 2012, MEDIAT INFLAMM, V2012, DOI 10.1155/2012/493043
   Abu El-Asrar AM, 2011, MOL VIS, V17, P508
   Adachi K, 2018, INVEST OPHTH VIS SCI, V59
   Aguila M, 2016, ADV EXP MED BIOL, V854, P161, DOI 10.1007/978-3-319-17121-0_22
   Akhtar-Schafer I, 2018, EMBO MOL MED, V10, DOI 10.15252/emmm.201708259
   Akpek EK, 2003, EYE, V17, P949, DOI 10.1038/sj.eye.6700617
   Albakova Z, 2021, TRANSL ONCOL, V14, DOI 10.1016/j.tranon.2020.100995
   Allocca M, 2019, SCI SIGNAL, V12, DOI 10.1126/scisignal.aau9216
   Angeles-Han ST, 2021, OCUL IMMUNOL INFLAMM, V29, P1616, DOI 10.1080/09273948.2020.1758731
   Aplin FP, 2016, FRONT NEUROANAT, V10, DOI 10.3389/fnana.2016.00046
   Arckens L, 2003, EUR J NEUROSCI, V18, P61, DOI 10.1046/j.1460-9568.2003.02726.x
   Ardeljan CP, 2014, J CLIN MED, V3, P1542, DOI 10.3390/jcm3041542
   Arimura N, 2008, GRAEF ARCH CLIN EXP, V246, P1053, DOI 10.1007/s00417-008-0827-2
   Arimura N, 2009, LAB INVEST, V89, P278, DOI 10.1038/labinvest.2008.165
   Ash J, 2005, MOL VIS, V11, P298
   Atil A, 2018, VASCULAR, V26, P378, DOI 10.1177/1708538117742831
   Augustine J, 2019, J NEUROINFLAMM, V16, DOI 10.1186/s12974-019-1625-y
   Austin BA, 2009, INVEST OPHTH VIS SCI, V50, P2896, DOI 10.1167/iovs.08-2495
   Barbour M, 2014, EUR J IMMUNOL, V44, P3320, DOI 10.1002/eji.201444671
   Barile GR, 2007, CURR MOL MED, V7, P758, DOI 10.2174/156652407783220778
   Bauer D, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00708
   Begum G, 2018, INVEST OPHTH VIS SCI, V59, P4929, DOI 10.1167/iovs.18-24299
   Bek T, 1998, ACTA OPHTHALMOL SCAN, V76, P643, DOI 10.1034/j.1600-0420.1998.760601.x
   Bellini S, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18122709
   Berry JL, 2017, JAMA OPHTHALMOL, V135, P1221, DOI 10.1001/jamaophthalmol.2017.4097
   Bianchi ME, 2007, J LEUKOCYTE BIOL, V81, P1, DOI 10.1189/jlb.0306164
   Bresnick AR, 2015, NAT REV CANCER, V15, P96, DOI 10.1038/nrc3893
   Brown KR, 2018, CASE REP OPHTHALM, V9, P279, DOI 10.1159/000488931
   Brucklacher RM, 2008, BMC MED GENOMICS, V1, DOI 10.1186/1755-8794-1-26
   Burgoyne C, 2014, INVEST OPHTH VIS SCI, V55
   Campochiaro PA, 2018, PROG RETIN EYE RES, V62, P24, DOI 10.1016/j.preteyeres.2017.08.004
   Casola C, 2015, J MOL NEUROSCI, V56, P228, DOI 10.1007/s12031-014-0485-2
   Castellon R, 2002, INVEST OPHTH VIS SCI, V43, P2758
   Chang JH, 2012, CLIN EXP OPHTHALMOL, V40, P821, DOI 10.1111/j.1442-9071.2012.02797.x
   Chang YC, 2017, CELL SIGNAL, V40, P248, DOI 10.1016/j.cellsig.2017.09.019
   Chao AC, 2016, CNS NEUROSCI THER, V22, P291, DOI 10.1111/cns.12503
   Chauhan BC, 2008, CAN J OPHTHALMOL, V43, P356, DOI 10.3129/i08-060
   Chaurasia SS, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-21198-z
   Cheng G, 2016, EYE, V30, P877, DOI 10.1038/eye.2016.43
   Cheng GM, 2016, GRAEF ARCH CLIN EXP, V254, P97, DOI 10.1007/s00417-015-3158-0
   Chi W, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0360-2
   CHUSOVA G G, 1982, Byulleten' Eksperimental'noi Biologii i Meditsiny, V94, P21
   Coburn PS, 2018, BMC OPHTHALMOL, V18, DOI 10.1186/s12886-018-0764-8
   Crabb JW, 2014, CSH PERSPECT MED, V4, DOI 10.1101/cshperspect.a017194
   Curnow S. John, 2011, Current Immunology Reviews, V7, P350
   Dai ML, 2020, EYE, V34, P1672, DOI 10.1038/s41433-019-0740-4
   Deshmukh D, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0205292
   Dinet V, 2012, AGING CELL, V11, P683, DOI 10.1111/j.1474-9726.2012.00834.x
   Donato R, 2013, CURR MOL MED, V13, P24, DOI 10.2174/156652413804486214
   Dvoriantchikova G, 2011, INVEST OPHTH VIS SCI, V52, P7187, DOI 10.1167/iovs.11-7793
   Eagle RC, 2013, EYE, V27, P128, DOI 10.1038/eye.2012.237
   Faingold D, 2008, CLIN CANCER RES, V14, P847, DOI 10.1158/1078-0432.CCR-07-0926
   Faralli JA, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8121518
   Farjo R, 2008, INVEST OPHTH VIS SCI, V49, P511, DOI 10.1167/iovs.07-1013
   Feldman N, 2015, AGEING RES REV, V24, P29, DOI 10.1016/j.arr.2015.01.003
   Feng J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068149
   Frevert CW, 2018, J HISTOCHEM CYTOCHEM, V66, P213, DOI 10.1369/0022155417740880
   Gawecki M, 2020, LASER MED SCI, V35, P1663, DOI 10.1007/s10103-020-03036-9
   Gotte M, 2002, INVEST OPHTH VIS SCI, V43, P1135
   Grisanti S, 2005, INVEST OPHTH VIS SCI, V46, P191, DOI 10.1167/iovs.04-0902
   Guo L, 2007, P NATL ACAD SCI USA, V104, P13444, DOI 10.1073/pnas.0703707104
   Guo ZS, 2013, AM J CANCER RES, V3, P1
   Gupta V, 2016, CELL MOL LIFE SCI, V73, P4279, DOI 10.1007/s00018-016-2295-x
   Hagedorn M, 1993, Ger J Ophthalmol, V2, P28
   HANGAI M, 1995, INVEST OPHTH VIS SCI, V36, P571
   Haynes RJ, 2000, INVEST OPHTH VIS SCI, V41, P3026
   He C, 2013, ARTERIOSCL THROM VAS, V33, P330, DOI 10.1161/ATVBAHA.112.300679
   He RG, 2017, MOL IMMUNOL, V90, P42, DOI 10.1016/j.molimm.2017.06.249
   He SK, 2013, MOL VIS, V19, P665
   HE W, 1993, OPHTHALMOLOGICA, V206, P133, DOI 10.1159/000310378
   He WJ, 2021, CURR MOL MED, V21, P237, DOI 10.2174/1566524020666200413113107
   Hill LJ, 2015, INVEST OPHTH VIS SCI, V56, P3743, DOI 10.1167/iovs.14-15622
   Hokari M, 2010, NEUROPATHOLOGY, V30, P401, DOI 10.1111/j.1440-1789.2009.01086.x
   Hooper MJ, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-27479-x
   Hu QQ, 2015, MOL MED REP, V12, P6577, DOI 10.3892/mmr.2015.4287
   Hu W, 1998, EUR J IMMUNOL, V28, P2444, DOI 10.1002/(SICI)1521-4141(199808)28:08<2444::AID-IMMU2444>3.0.CO;2-N
   Huang J, 2015, AGEING RES REV, V24, P3, DOI 10.1016/j.arr.2014.10.004
   Ievdokimova N Iu, 2008, Ukr Biokhim Zh (1999), V80, P5
   Inatani M, 1999, INVEST OPHTH VIS SCI, V40, P1783
   Izzotti A, 2003, AM J MED, V114, P638, DOI 10.1016/S0002-9343(03)00114-1
   Jiang GM, 2014, J LEUKOCYTE BIOL, V95, P599, DOI 10.1189/jlb.0613337
   Jimenez-Mateos EM, 2019, BRAIN RES BULL, V151, P153, DOI 10.1016/j.brainresbull.2018.12.008
   Jin E, 2021, OCUL ONCOL PATHOL, V7, P1, DOI 10.1159/000508613
   Jin J, 2022, INT OPHTHALMOL, V42, P661, DOI 10.1007/s10792-021-02038-y
   Joachim SC, 2012, OPHTHALMIC RES, V48, P67, DOI 10.1159/000335965
   Joly S, 2008, J NEUROSCI, V28, P13765, DOI 10.1523/JNEUROSCI.5114-08.2008
   Joussen AM, 2001, INVEST OPHTH VIS SCI, V42, P3047
   Jovanovic P, 2013, INT J CLIN EXP PATHO, V6, P1230
   Kaarniranta K, 2009, AGEING RES REV, V8, P128, DOI 10.1016/j.arr.2009.01.001
   Kalesnykas G, 2008, NEUROSCIENCE, V155, P937, DOI 10.1016/j.neuroscience.2008.06.038
   Kam JH, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013127
   Kaneko H, 2011, NATURE, V471, P325, DOI 10.1038/nature09830
   KANMITCHELL J, 1990, INVEST OPHTH VIS SCI, V31, P1492
   Kanters SDJM, 2001, DIABETES CARE, V24, P323, DOI 10.2337/diacare.24.2.323
   Kaplan HJ, 2022, OCUL IMMUNOL INFLAMM, V30, P734, DOI 10.1080/09273948.2021.1954203
   Kaprinis K, 2016, EUR J OPHTHALMOL, V26, P633, DOI 10.5301/ejo.5000802
   Karim MM, 1997, OPHTHALMOLOGICA, V211, P351, DOI 10.1159/000310827
   Kataoka K, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.73
   Kawano H, 2014, LAB INVEST, V94, P569, DOI 10.1038/labinvest.2014.46
   Kayama M, 2011, AM J PATHOL, V178, P1080, DOI 10.1016/j.ajpath.2010.11.072
   Keijser S, 2006, BRIT J OPHTHALMOL, V90, P213, DOI 10.1136/bjo.2005.080390
   Keller KE, 2011, INVEST OPHTH VIS SCI, V52, P5049, DOI 10.1167/iovs.10-6948
   Kim SY, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.80
   Kobayashi Y, 2016, LAB INVEST, V96, P1178, DOI 10.1038/labinvest.2016.99
   Kobayashi Y, 2016, MOL VIS, V22, P436
   Kolseth IBM, 2017, J DIABETES COMPLICAT, V31, P245, DOI 10.1016/j.jdiacomp.2016.06.029
   Kothari P, 2020, CANCER MED-US, V9, P6093, DOI 10.1002/cam4.3144
   Krizova L, 2011, OPHTHALMIC RES, V46, P73, DOI 10.1159/000322994
   Kubo Y, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-66278-1
   Kumar A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0128423
   Kumar A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029830
   Kumar R, 2020, CUREUS, V12, DOI 10.7759/cureus.8960
   Kwong JMK, 2003, BRAIN RES, V970, P119, DOI 10.1016/S0006-8993(03)02298-4
   LAM KW, 1983, CURR EYE RES, V2, P645
   Land WG, 2020, MOL DIAGN THER, V24, P251, DOI 10.1007/s40291-020-00460-z
   LANDERS RA, 1994, J NEUROCHEM, V63, P737
   Le DSNT, 2008, DIABETES RES CLIN PR, V82, P317, DOI 10.1016/j.diabres.2008.08.019
   Lee D, 2014, APOPTOSIS, V19, P603, DOI 10.1007/s10495-013-0956-x
   Lee D, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047098
   Lee JJ, 2015, INT J BIOCHEM CELL B, V64, P1, DOI 10.1016/j.biocel.2015.03.002
   Leskova W, 2019, EXP EYE RES, V179, P125, DOI 10.1016/j.exer.2018.11.012
   Lewden O, 1998, OPHTHALMIC RES, V30, P291, DOI 10.1159/000055487
   Li P, 2022, EMBO MOL MED, V14, DOI 10.15252/emmm.202114511
   Li SJ, 2017, ONCOTARGET, V8, P2816, DOI 10.18632/oncotarget.13745
   Li XL, 2021, MOL VIS, V27, P438
   Li Y, 2003, INVEST OPHTH VIS SCI, V44, P1299, DOI 10.1167/iovs.02-0235
   Lim RR, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21030899
   Lim RR, 2019, DIABETES METAB SYND, V13, P1581, DOI 10.1016/j.dsx.2019.03.014
   Lin HJ, 2011, INVEST OPHTH VIS SCI, V52, P3521, DOI 10.1167/iovs.10-6163
   Lin MK, 2018, AGING CELL, V17, DOI 10.1111/acel.12710
   Little JP, 2014, MOL CELL NEUROSCI, V60, P88, DOI 10.1016/j.mcn.2014.04.003
   Liu K, 2014, AUTOPHAGY, V10, P442, DOI 10.4161/auto.27418
   Liu L, 2019, J CLIN MED, V8, DOI 10.3390/jcm8060772
   Liu L, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0178236
   Liu RZT, 2014, EXP EYE RES, V127, P49, DOI 10.1016/j.exer.2014.07.003
   Liu TL, 2018, INT J OPHTHALMOL-CHI, V11, P1600, DOI 10.18240/ijo.2018.10.05
   Liu Y, 2018, J OPHTHALMOL, V2018, DOI 10.1155/2018/5195290
   LOFFLER KU, 1995, INVEST OPHTH VIS SCI, V36, P24
   Lopalco G, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000001858
   Low SWY, 2021, LIFE-BASEL, V11, DOI 10.3390/life11121421
   Low SWY, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22147293
   Lu Ailing, 2020, Matrix Biol Plus, V8, P100034, DOI 10.1016/j.mbplus.2020.100034
   Luo C, 2010, INVEST OPHTH VIS SCI, V51, P5697, DOI 10.1167/iovs.10-5407
   Ma JHJ, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-02213-1
   Madic J, 2012, CLIN CANCER RES, V18, P3934, DOI 10.1158/1078-0432.CCR-12-0309
   Mahaling B, 2021, INT J PHARMACEUT, V606, DOI 10.1016/j.ijpharm.2021.120900
   Mahaling B, 2018, NANOSCALE, V10, DOI 10.1039/c8nr00058a
   Maiza A, 2018, FEBS LETT, V592, P3806, DOI 10.1002/1873-3468.13082
   Marola OJ, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-02990-0
   Mendelsohn M E, 1998, J AAPOS, V2, P369, DOI 10.1016/S1091-8531(98)90037-4
   Midwood K, 2009, NAT MED, V15, P774, DOI 10.1038/nm.1987
   Miller CG, 2017, EXP BIOL MED, V242, P1, DOI 10.1177/1535370216675245
   Miller FC, 2019, PROG RETIN EYE RES, V73, DOI 10.1016/j.preteyeres.2019.05.004
   Milner R, 2007, J IMMUNOL, V178, P8158, DOI 10.4049/jimmunol.178.12.8158
   Minhas G, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00444
   Missotten GS, 2007, TUMOR BIOL, V28, P63, DOI 10.1159/000099151
   Missotten GS, 2003, INVEST OPHTH VIS SCI, V44, P3059, DOI 10.1167/iovs.02-1038
   Mitamura Y, 2003, OPHTHALMOLOGICA, V217, P422, DOI 10.1159/000073073
   Mitamura Y, 2002, DIABETES CARE, V25, P1899, DOI 10.2337/diacare.25.10.1899
   Lazaldin MAM, 2020, EUR J NEUROSCI, V51, P2394, DOI 10.1111/ejn.14662
   Moreth K, 2012, CELL CYCLE, V11, P2084, DOI 10.4161/cc.20316
   Mulfaul K, 2018, ADV EXP MED BIOL, V1074, P19, DOI 10.1007/978-3-319-75402-4_3
   Murakami Y, 2015, CELL DEATH DISCOV, V1, DOI 10.1038/cddiscovery.2015.58
   Murakami Y, 2014, CELL DEATH DIFFER, V21, P270, DOI 10.1038/cdd.2013.109
   Myren M, 2016, MATRIX BIOL, V52-54, P141, DOI 10.1016/j.matbio.2016.03.008
   Nagai N, 2015, BIOL PHARM BULL, V38, P601, DOI 10.1248/bpb.b14-00819
   Nanini HF, 2018, WORLD J GASTROENTERO, V24, P4622, DOI 10.3748/wjg.v24.i41.4622
   Nassar K, 2015, GRAEF ARCH CLIN EXP, V253, P699, DOI 10.1007/s00417-014-2738-8
   Nassar K, 2011, GRAEF ARCH CLIN EXP, V249, P1649, DOI 10.1007/s00417-011-1730-9
   Nastase MV, 2012, J HISTOCHEM CYTOCHEM, V60, P963, DOI 10.1369/0022155412456380
   NI M, 1988, ARCH OPHTHALMOL-CHIC, V106, P392
   Niemi K, 2011, J IMMUNOL, V186, P6119, DOI 10.4049/jimmunol.1002843
   NikhalaShree S, 2019, INVEST OPHTH VIS SCI, V60, P4661, DOI 10.1167/iovs.19-27091
   Nishiguchi KM, 2013, MOL VIS, V19, P1125
   Nishiguchi KM, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013493
   Notomi S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053338
   Notomi S, 2011, AM J PATHOL, V179, P2798, DOI 10.1016/j.ajpath.2011.08.035
   Olivares-Gonzalez L, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22042096
   Oshitari T, 2006, DIABETES, V55, P86, DOI 10.2337/diabetes.55.01.06.db05-0186
   Osterbauer K.J., 2018, THESIS U WASHINGTON
   Ozacmak HS, 2014, J SURG RES, V191, P350, DOI 10.1016/j.jss.2014.04.040
   Pachydaki SI, 2006, EXP EYE RES, V82, P807, DOI 10.1016/j.exer.2005.09.022
   Pantalon A, 2019, INT J OPHTHALMOL-CHI, V12, P795, DOI 10.18240/ijo.2019.05.15
   Pardo M, 2004, J CELL BIOCHEM, V93, P708, DOI 10.1002/jcb.20230
   Pardo M, 2006, INT J CANCER, V119, P1014, DOI 10.1002/ijc.21942
   Park PJ, 2013, EXP EYE RES, V110, P1, DOI 10.1016/j.exer.2013.01.015
   Patel NB, 2019, INVEST OPHTH VIS SCI, V60
   Poulaki V, 2007, FASEB J, V21, P2113, DOI 10.1096/fj.06-7637com
   Probst K, 2004, BRIT J OPHTHALMOL, V88, P667, DOI 10.1136/bjo.2003.026542
   Pulukool SK, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-89137-z
   Qi Y, 2014, INVEST OPHTH VIS SCI, V55, P5466, DOI 10.1167/iovs.14-14380
   Qu X, 2014, MEDIAT INFLAMM, V2014, DOI 10.1155/2014/728673
   Quintyn JC, 2005, GRAEF ARCH CLIN EXP, V243, P1167, DOI 10.1007/s00417-005-1175-0
   Ramachandran S, 2014, CARDIOVASC DIABETOL, V13, DOI 10.1186/1475-2840-13-38
   Regatieri CV, 2010, BRAZ J MED BIOL RES, V43, P627, DOI 10.1590/S0100-879X2010007500043
   Reichelt J, 2008, CURR EYE RES, V33, P253, DOI 10.1080/02713680701871157
   Reinehr S, 2018, CELL TISSUE RES, V371, P237, DOI 10.1007/s00441-017-2710-0
   Reinehr S, 2016, J CELL MOL MED, V20, P2122, DOI 10.1111/jcmm.12909
   Reinhard J, 2021, BIOLOGY-BASEL, V10, DOI 10.3390/biology10030169
   Reinhard J, 2017, SCI REP-UK, V7, DOI 10.1038/srep43470
   Ricker LJAG, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019141
   Rivera-Perez J, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21103716
   Roesch Karin, 2012, Mol Vis, V18, P1197
   Roh JS, 2018, IMMUNE NETW, V18, DOI 10.4110/in.2018.18.e27
   Sahebari M, 2013, SCAND J IMMUNOL, V77, P476, DOI 10.1111/sji.12045
   Sakamoto K, 2015, EUR J PHARMACOL, V756, P52, DOI 10.1016/j.ejphar.2015.03.008
   Sakurada Y, 2015, OPHTHALMIC RES, V53, P2, DOI 10.1159/000365487
   Sanchez-Cruz A, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22157815
   SANO Y, 1992, JPN J OPHTHALMOL, V36, P76
   Saraheimo M, 2008, NEPHROL DIAL TRANSPL, V23, P914, DOI 10.1093/ndt/gfm711
   Sarker B, 2021, INVEST OPHTH VIS SCI, V62
   Schaefer L, 2001, FASEB J, V15, P559
   Scuderi S, 2015, J MOL NEUROSCI, V56, P431, DOI 10.1007/s12031-015-0505-x
   Secli L, 2021, CELL MOL LIFE SCI, V78, P4069, DOI 10.1007/s00018-021-03764-3
   Singh JA, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0199562
   Singh L.P., 2011, INVESTIG OPHTHALMOL, V52, P3579
   Singh Lalit P, 2017, JOJ Ophthalmol, V4, DOI 10.19080/jojo.2017.04.555643
   Singh MK, 2015, PATHOL ONCOL RES, V21, P1237, DOI 10.1007/s12253-015-9951-6
   Singh PK, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-33
   Smiley ST, 2001, J IMMUNOL, V167, P2887, DOI 10.4049/jimmunol.167.5.2887
   Smith W, 1998, ARCH OPHTHALMOL-CHIC, V116, P583, DOI 10.1001/archopht.116.5.583
   Song CJ, 2009, ATHEROSCLEROSIS, V207, P374, DOI 10.1016/j.atherosclerosis.2009.05.007
   Soto I, 2014, CSH PERSPECT MED, V4, DOI 10.1101/cshperspect.a017269
   Srethapakdi M, 2000, CANCER RES, V60, P3940
   STANFORD MR, 1994, CLIN EXP IMMUNOL, V97, P226
   Stein-Streilein J, 2013, INT REV IMMUNOL, V32, P42, DOI 10.3109/08830185.2012.740535
   Steinle JJ, 2020, CELL SIGNAL, V73, DOI 10.1016/j.cellsig.2020.109687
   Stowell C, 2018, INVEST OPHTH VIS SCI, V59
   Streilein JW, 2003, J LEUKOCYTE BIOL, V74, P179, DOI 10.1189/jlb.1102574
   Strunnikova N, 2001, INVEST OPHTH VIS SCI, V42, P2130
   Subramani S, 2010, Med J Malaysia, V65, P36
   Sugita J, 2014, INVEST OPHTH VIS SCI, V55
   Sun S, 2019, AGING-US, V11, P4323, DOI 10.18632/aging.102039
   Swaney JS, 2008, EXP EYE RES, V87, P367, DOI 10.1016/j.exer.2008.07.005
   Tachibana T, 2016, INVEST OPHTH VIS SCI, V57
   Takahashi T, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-22409-3
   Takeuchi M, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0178230
   Takeuchi M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0137358
   Tavianatou AG, 2019, FEBS J, V286, P2883, DOI 10.1111/febs.14777
   Tezel G, 1999, ARCH OPHTHALMOL-CHIC, V117, P917
   Theocharis IP, 2010, CLIN OPHTHALMOL, V4, P73
   Theodoropoulou S, 2017, J PATHOL, V241, P45, DOI 10.1002/path.4816
   Tong L, 2014, OCUL SURF, V12, P23, DOI 10.1016/j.jtos.2013.10.001
   Tosi GM, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.8.34
   Totan Yϋksel, 2015, J Ophthalmic Vis Res, V10, P151, DOI 10.4103/2008-322X.163765
   Tsai T, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20205160
   Tsering T, 2020, CANCERS, V12, DOI 10.3390/cancers12102923
   Tu LL, 2018, ANGIOGENESIS, V21, P95, DOI 10.1007/s10456-017-9591-4
   Urbak Larke, 2010, Int J Proteomics, V2010, P479571, DOI 10.1155/2010/479571
   Uruska A, 2017, CLIN BIOCHEM, V50, P1110, DOI 10.1016/j.clinbiochem.2017.09.023
   Vallejo-Garcia JL, 2012, MEDIAT INFLAMM, V2012, DOI 10.1155/2012/196094
   van Harten RM, 2018, VACCINES-BASEL, V6, DOI 10.3390/vaccines6030063
   Van Hove I, 2020, DIABETOLOGIA, V63, P2235, DOI 10.1007/s00125-020-05218-0
   Venkatesan N, 2016, CHEM-BIOL INTERACT, V252, P141, DOI 10.1016/j.cbi.2016.04.011
   Wakefield D, 2010, BRIT J OPHTHALMOL, V94, P271, DOI 10.1136/bjo.2008.146753
   Walscheid K, 2015, INVEST OPHTH VIS SCI, V56, P7653, DOI 10.1167/iovs.15-17066
   Wang JB, 2008, CURR EYE RES, V33, P101, DOI 10.1080/02713680701809272
   Wang L, 2020, ARCH PHYSIOL BIOCHEM, DOI 10.1080/13813455.2020.1792506
   Wang LL, 2017, INT J OPHTHALMOL-CHI, V10, P30, DOI 10.18240/ijo.2017.01.05
   Wang L, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22052360
   Wang S, 2015, INVEST OPHTH VIS SCI, V56, P2971, DOI 10.1167/iovs.14-15874
   Wang WH, 2008, INVEST OPHTH VIS SCI, V49, P1916, DOI 10.1167/iovs.07-1104
   Wang XL, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-10124-4
   Whiston EA, 2008, INFECT IMMUN, V76, P1781, DOI 10.1128/IAI.01285-07
   Whitlock NA, 2005, INVEST OPHTH VIS SCI, V46, P1092, DOI 10.1167/iovs.04-0043
   Wiemann S, 2021, FRONT NEUROSCI-SWITZ, V15, DOI 10.3389/fnins.2021.642176
   Wight TN, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00512
   Willermain F, 2012, PROG RETIN EYE RES, V31, P182, DOI 10.1016/j.preteyeres.2011.11.004
   Windisch BK, 2009, CLIN EXP OPHTHALMOL, V37, P299, DOI 10.1111/j.1442-9071.2009.02032.x
   Wooff Y, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01618
   Wu JH, 2015, NEUROBIOL DIS, V74, P167, DOI 10.1016/j.nbd.2014.11.014
   Wu MY, 2018, CELL PHYSIOL BIOCHEM, V46, P1650, DOI 10.1159/000489241
   Wu WC, 2007, EXP EYE RES, V85, P721, DOI 10.1016/j.exer.2007.08.005
   Xia C, 2018, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01908
   Xu D, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02025
   Xu J, 2021, INT J GEN MED, V14, P4639, DOI 10.2147/IJGM.S325846
   Yang JY, 2020, EXP EYE RES, V201, DOI 10.1016/j.exer.2020.108281
   Yang SY, 2011, CURR EYE RES, V36, P1037, DOI 10.3109/02713683.2011.594201
   Yang Y.-Y., 2019, INT EYE SCI, V12, P1738
   Yang Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080288
   Yenari MA, 2005, ANN NY ACAD SCI, V1053, P74, DOI 10.1196/annals.1344.007
   YEO JH, 1986, ARCH OPHTHALMOL-CHIC, V104, P417, DOI 10.1001/archopht.1986.01050150119041
   Yokoyama A, 2001, INVEST OPHTH VIS SCI, V42, P3283
   Yoneda S, 2005, JPN J OPHTHALMOL, V49, P106, DOI 10.1007/s10384-004-0156-x
   Yu P, 2017, CURR EYE RES, V42, P1319, DOI 10.1080/02713683.2017.1315142
   Yuki K, 2010, GRAEF ARCH CLIN EXP, V248, P243, DOI 10.1007/s00417-009-1183-6
   Yun J, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00142
   Zeiner J, 2019, J MOL MED, V97, P341, DOI 10.1007/s00109-018-01734-0
   Zhang YM, 2022, FREE RADICAL BIO MED, V181, P14, DOI 10.1016/j.freeradbiomed.2022.01.018
   Zhao Y, 2021, VIRULENCE, V12, P1362, DOI 10.1080/21505594.2021.1926649
   Zhu D., URIC ACID PROMOTES D, DOI [10.21203/rs.3.rs-566131/v1, DOI 10.21203/RS.3.RS-566131/V1]
   Zhu DD, 2018, BIOCHEM BIOPH RES CO, V503, P921, DOI 10.1016/j.bbrc.2018.06.097
   Zuliani-Alvarez L, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01718-7
NR 294
TC 1
Z9 1
U1 3
U2 4
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1422-0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD MAR
PY 2022
VL 23
IS 5
AR 2591
DI 10.3390/ijms23052591
PG 38
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA 0A0FD
UT WOS:000773636700001
PM 35269741
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Kim, KM
   Heo, TY
   Kim, A
   Kim, J
   Han, KJ
   Yun, J
   Min, JK
AF Kim, Kyoung Min
   Heo, Tae-Young
   Kim, Aesul
   Kim, Joohee
   Han, Kyu Jin
   Yun, Jaesuk
   Min, Jung Kee
TI Development of a Fundus Image-Based Deep Learning Diagnostic Tool for
   Various Retinal Diseases
SO JOURNAL OF PERSONALIZED MEDICINE
LA English
DT Article
DE artificial intelligence; class activation map; convolutional neural
   network; fundus photograph; retinal diseases
ID DIABETIC-RETINOPATHY; VEIN OCCLUSION; MORPHOLOGY; FEATURES
AB Artificial intelligence (AI)-based diagnostic tools have been accepted in ophthalmology. The use of retinal images, such as fundus photographs, is a promising approach for the development of AI-based diagnostic platforms. Retinal pathologies usually occur in a broad spectrum of eye diseases, including neovascular or dry age-related macular degeneration, epiretinal membrane, rhegmatogenous retinal detachment, retinitis pigmentosa, macular hole, retinal vein occlusions, and diabetic retinopathy. Here, we report a fundus image-based AI model for differential diagnosis of retinal diseases. We classified retinal images with three convolutional neural network models: ResNet50, VGG19, and Inception v3. Furthermore, the performance of several dense (fully connected) layers was compared. The prediction accuracy for diagnosis of nine classes of eight retinal diseases and normal control was 87.42% in the ResNet50 model, which added a dense layer with 128 nodes. Furthermore, our AI tool augments ophthalmologist's performance in the diagnosis of retinal disease. These results suggested that the fundus image-based AI tool is applicable for the medical diagnosis process of retinal diseases.
C1 [Kim, Kyoung Min] BEGAS Inc, Data Scientist Team, Sejong Daero 39, Seoul 04513, South Korea.
   [Heo, Tae-Young] Chungbuk Natl Univ, Dept Informat & Stat, Chungdae Ro 1, Cheongju 28644, Chungbuk, South Korea.
   [Kim, Aesul; Kim, Joohee; Yun, Jaesuk] Chungbuk Natl Univ, Coll Pharm, Pharmacol Lab, 194-31 Osongsaengmyeong 1 Ro, Cheongju 28160, Chungbuk, South Korea.
   [Kim, Aesul; Kim, Joohee; Yun, Jaesuk] Chungbuk Natl Univ, Med Res Ctr, 194-31 Osongsaengmyeong 1 Ro, Cheongju 28160, Chungbuk, South Korea.
   [Han, Kyu Jin; Min, Jung Kee] Univ Ulsan, Coll Med, Ulsan Univ Hosp, Dept Ophthalmol, 877 Bangeojinsunhwando Ro, Ulsan 44033, South Korea.
C3 Chungbuk National University; Chungbuk National University; Chungbuk
   National University; University of Ulsan; Ulsan University Hospital
RP Yun, J (通讯作者)，Chungbuk Natl Univ, Coll Pharm, Pharmacol Lab, 194-31 Osongsaengmyeong 1 Ro, Cheongju 28160, Chungbuk, South Korea.; Yun, J (通讯作者)，Chungbuk Natl Univ, Med Res Ctr, 194-31 Osongsaengmyeong 1 Ro, Cheongju 28160, Chungbuk, South Korea.; Min, JK (通讯作者)，Univ Ulsan, Coll Med, Ulsan Univ Hosp, Dept Ophthalmol, 877 Bangeojinsunhwando Ro, Ulsan 44033, South Korea.
EM ganaaml2002@naver.com; theo@cbnu.ac.kr; aeseulkim@daum.net;
   joohyee4u@naver.com; hankj229@hanmail.net; jyun@chungbuk.ac.kr;
   jkmin@uuh.ulsan.kr
OI Min, Jung Kee/0000-0002-8006-8560; heo, tae-young/0000-0002-0505-5559
FU National Research Foundation of Korea (NRF) - Korea government (MSIT)
   [2017R1C1B5017929]; National Research Foundation of Korea (NRF) -
   Ministry of Education [2017R1D1A3B03028084, 2019R1I1A3A01057696];
   Regional Innovation Strategy (RIS)
FX This work was supported by the National Research Foundation of Korea
   (NRF) grant, funded by the Korea government (MSIT) (No.
   2017R1C1B5017929). This research was also supported by "Regional
   Innovation Strategy (RIS)" and Basic Science Research Program through
   the National Research Foundation of Korea (NRF) funded by the Ministry
   of Education (2017R1D1A3B03028084, 2019R1I1A3A01057696).
CR Abramoff MD, 2018, NPJ DIGIT MED, V1, DOI 10.1038/s41746-018-0040-6
   Adhi M, 2013, JAMA OPHTHALMOL, V131, P1267, DOI 10.1001/jamaophthalmol.2013.4321
   Bernardes R, 2011, OPHTHALMOLOGICA, V226, P161, DOI 10.1159/000329597
   Chung H, 2017, SURV OPHTHALMOL, V62, P506, DOI 10.1016/j.survophthal.2017.03.003
   Coudray N, 2018, NAT MED, V24, P1559, DOI 10.1038/s41591-018-0177-5
   Donato L, 2020, ANTIOXIDANTS-BASEL, V9, DOI 10.3390/antiox9111158
   Falkner-Radler CI, 2010, OPHTHALMOLOGY, V117, P798, DOI 10.1016/j.ophtha.2009.08.034
   GASS JDM, 1988, ARCH OPHTHALMOL-CHIC, V106, P629, DOI 10.1001/archopht.1988.01060130683026
   Hall Anthony, 2011, Community Eye Health, V24, P5
   Heo TY, 2020, DIAGNOSTICS, V10, DOI 10.3390/diagnostics10050261
   Hillenkamp J, 2005, BRIT J OPHTHALMOL, V89, P437, DOI 10.1136/bjo.2004.051250
   Hwang TS, 2016, JAMA OPHTHALMOL, V134, P367, DOI 10.1001/jamaophthalmol.2015.5658
   Ip M, 2018, ASIA-PAC J OPHTHALMO, V7, P40, DOI 10.22608/APO.2017442
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1439, DOI 10.1001/archopht.119.10.1439
   Kuhn F, 2014, OPHTHALMIC RES, V51, P15, DOI 10.1159/000355077
   Levine AB, 2019, TRENDS CANCER, V5, P157, DOI 10.1016/j.trecan.2019.02.002
   MCDONALD HR, 1986, OPHTHALMOLOGY, V93, P978
   Muller P.L., 2019, HIGH RESOLUTION IMAG, P87
   Niwa T, 2003, INVEST OPHTH VIS SCI, V44, P1652, DOI 10.1167/iovs.02-0404
   Schadlu R, 2008, RETINA-J RET VIT DIS, V28, P853, DOI 10.1097/IAE.0b013e3181631962
   Scimone C, 2020, ANTIOXIDANTS-BASEL, V9, DOI 10.3390/antiox9111154
   Scott IU, 2017, JAMA-J AM MED ASSOC, V317, P2072, DOI 10.1001/jama.2017.4568
   Tremolada G, 2012, EXP DIABETES RES, DOI 10.1155/2012/728325
NR 23
TC 8
Z9 8
U1 1
U2 13
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2075-4426
J9 J PERS MED
JI J. Pers. Med.
PD MAY
PY 2021
VL 11
IS 5
AR 321
DI 10.3390/jpm11050321
PG 11
WC Health Care Sciences & Services; Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Health Care Sciences & Services; General & Internal Medicine
GA SH4QH
UT WOS:000654121300001
PM 33918998
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Cheng, XX
   He, DX
   Liao, CY
   Lin, SJ
   Tang, LY
   Wang, YL
   Hu, JY
   Li, W
   Liu, ZG
   Wu, YL
   Liao, Y
AF Cheng, Xinxuan
   He, Danxue
   Liao, Chunyan
   Lin, Sijie
   Tang, Liying
   Wang, Yuan-Liang
   Hu, Jiaoyue
   Li, Wei
   Liu, Zuguo
   Wu, Yalin
   Liao, Yi
TI IL-1/IL-1R signaling induced by all-trans-retinal contributes to
   complement alternative pathway activation in retinal pigment epithelium
SO JOURNAL OF CELLULAR PHYSIOLOGY
LA English
DT Article
DE all-trans-retinal; complement alternative pathway; complement factor B;
   interleukin-1 beta; retinal pigment epithelium
ID FACTOR-H POLYMORPHISM; MACULAR DEGENERATION; MOUSE MODEL; FACTOR-B; CELL
   LINE; INVOLVEMENT; RETINOPATHY; EXPRESSION; INHIBITOR; DISEASE
AB The underlying mechanisms of complement activation in Stargardt disease type 1 (STGD1) and age-related macular degeneration (AMD) are not fully understood. Overaccumulation of all-trans-retinal (atRAL) has been proposed as the pathogenic factor in both diseases. By incubating retinal pigment epithelium (RPE) cells with atRAL, we showed that C5b-9 membrane attack complexes (MACs) were generated mainly through complement alternative pathway. An increase in complement factor B (CFB) expression as well as downregulation of complement regulatory proteins CD46, CD55, CD59, and CFH were observed in RPE cells after atRAL treatment. Furthermore, interleukin-1 beta production was provoked in both atRAL-treated RPE cells and microglia/macrophages. Coincubation of RPE cells with interleukin-1 receptor antagonist (IL1Ra) and atRAL ameliorated complement activation and downregulated CFB expression by attenuating both p38 and c-Jun N-terminal kinase (JNK) signaling pathways. Our findings demonstrate that atRAL induces an autocrine/paracrine IL-1/IL-1R signaling to promote complement alternative pathway activation in RPE cells and provide a novel perspective on the pathomechanism of macular degeneration.
C1 [Cheng, Xinxuan; He, Danxue; Liao, Chunyan; Lin, Sijie; Tang, Liying; Hu, Jiaoyue; Li, Wei; Liu, Zuguo; Wu, Yalin; Liao, Yi] Xiamen Univ, Inst Eye, Sch Med, Fujian Prov Key Lab Ophthalmol & Visual Sci, 4th Floor,Chengyi Bldg,Xiangan Campus, Xiamen 361102, Fujian, Peoples R China.
   [Cheng, Xinxuan; He, Danxue; Liao, Chunyan; Lin, Sijie; Tang, Liying; Hu, Jiaoyue; Li, Wei; Liu, Zuguo; Wu, Yalin; Liao, Yi] Xiamen Univ, Dept Ophthalmol, Xiangan Hosp, Xiamen, Peoples R China.
   [Cheng, Xinxuan; He, Danxue; Liao, Chunyan; Lin, Sijie; Tang, Liying; Hu, Jiaoyue; Li, Wei; Liu, Zuguo; Wu, Yalin; Liao, Yi] Xiamen Univ, Dept Ophthalmol, Xiamen Eye Ctr, Xiamen, Peoples R China.
   [Wang, Yuan-Liang] Fujian Med Univ, Sch Publ Hlth, Dept Prevent Med, Fuzhou, Peoples R China.
   [Wang, Yuan-Liang] Univ Calif San Diego, Mol Biol Sect, La Jolla, CA 92093 USA.
C3 Xiamen University; Xiamen University; Xiamen University; Fujian Medical
   University; University of California System; University of California
   San Diego
RP Wu, YL; Liao, Y (通讯作者)，Xiamen Univ, Inst Eye, Sch Med, Fujian Prov Key Lab Ophthalmol & Visual Sci, 4th Floor,Chengyi Bldg,Xiangan Campus, Xiamen 361102, Fujian, Peoples R China.
EM yalinw@xmu.edu.cn; liaoyilori@xmu.edu.cn
RI Wang, Yu/GZL-9655-2022
FU National Key R&D Program of China [2018YFA0107301, 2019YFA0111200];
   National Natural Science Foundation of China [81700864]; Fujian Medical
   University Startup Fund [XRCZX2019007]
FX National Key R&D Program of China, Grant/Award Numbers: 2018YFA0107301,
   2019YFA0111200; National Natural Science Foundation of China,
   Grant/Award Number: 81700864; Fujian Medical University Startup Fund,
   Grant/Award Number: XRCZX2019007
CR Akhtar-Schafer I, 2018, EMBO MOL MED, V10, DOI 10.15252/emmm.201708259
   Ambati J, 2013, NAT REV IMMUNOL, V13, P438, DOI 10.1038/nri3459
   ANDOH A, 1993, J IMMUNOL, V151, P4239
   Berchuck JE, 2013, INVEST OPHTH VIS SCI, V54, P2669, DOI 10.1167/iovs.12-11020
   Bora NS, 2006, J IMMUNOL, V177, P1872, DOI 10.4049/jimmunol.177.3.1872
   Brandstetter C, 2015, J BIOL CHEM, V290, P31189, DOI 10.1074/jbc.M115.671180
   Chen M, 2008, EXP EYE RES, V87, P543, DOI 10.1016/j.exer.2008.09.005
   Doyle SL, 2012, NAT MED, V18, P791, DOI 10.1038/nm.2717
   Ebrahimi KB, 2013, J PATHOL, V229, P729, DOI 10.1002/path.4128
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Gao Z, 2018, J BIOL CHEM, V293, P14507, DOI 10.1074/jbc.RA118.002447
   Garlanda C, 2013, IMMUNITY, V39, P1003, DOI 10.1016/j.immuni.2013.11.010
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kohno H, 2013, J BIOL CHEM, V288, P15326, DOI 10.1074/jbc.M112.448712
   Kunchithapautham K, 2011, J BIOL CHEM, V286, P23717, DOI 10.1074/jbc.M110.214593
   Lenis TL, 2017, P NATL ACAD SCI USA, V114, P3987, DOI 10.1073/pnas.1620299114
   Li J, 2015, TOXICOL SCI, V143, P196, DOI 10.1093/toxsci/kfu223
   Liao Y, 2019, INVEST OPHTH VIS SCI, V60, P3034, DOI 10.1167/iovs.18-26360
   Luo C, 2013, EXP EYE RES, V112, P93, DOI 10.1016/j.exer.2013.04.016
   Maeda A, 2008, J BIOL CHEM, V283, P26684, DOI 10.1074/jbc.M804505200
   Maeda A, 2009, J BIOL CHEM, V284, P15173, DOI 10.1074/jbc.M900322200
   Martin M, 2016, IMMUNOL REV, V274, P218, DOI 10.1111/imr.12462
   Merle NS, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00262
   Natoli R, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01666
   Nilsson B, 2012, IMMUNOBIOLOGY, V217, P1106, DOI 10.1016/j.imbio.2012.07.008
   PERLMUTTER DH, 1989, J BIOL CHEM, V264, P7669
   Quazi F, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1927
   Radu RA, 2011, J BIOL CHEM, V286, P18593, DOI 10.1074/jbc.M110.191866
   Rathinam VAK, 2016, CELL, V165, P792, DOI 10.1016/j.cell.2016.03.046
   Rattner A, 2000, J BIOL CHEM, V275, P11034, DOI 10.1074/jbc.275.15.11034
   Ricklin D, 2016, IMMUNOL REV, V274, P33, DOI 10.1111/imr.12500
   Rohrer B, 2012, J OCUL PHARMACOL TH, V28, P402, DOI 10.1089/jop.2011.0212
   Rohrer B, 2009, INVEST OPHTH VIS SCI, V50, P3056, DOI 10.1167/iovs.08-2222
   Rohrer Barbel, 2011, Mol Immunol, V48, pe1, DOI 10.1016/j.molimm.2010.12.016
   Schnabolk G, 2015, INVEST OPHTH VIS SCI, V56, P1850, DOI 10.1167/iovs.14-15910
   Sears AE, 2017, TRANSL VIS SCI TECHN, V6, DOI 10.1167/tvst.6.5.6
   Sparrow JR, 2010, J LIPID RES, V51, P247, DOI 10.1194/jlr.R000687
   Tan PL, 2016, HUM GENOMICS, V10, DOI 10.1186/s40246-016-0079-x
   Toomey CB, 2018, PROG RETIN EYE RES, V62, P38, DOI 10.1016/j.preteyeres.2017.09.001
   Toomey CB, 2015, P NATL ACAD SCI USA, V112, pE3040, DOI 10.1073/pnas.1424391112
   WALD G, 1968, SCIENCE, V162, P230, DOI 10.1126/science.162.3850.230
   Wang L, 2016, J PATHOL, V240, P495, DOI 10.1002/path.4811
   Weber A, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.3105cm1
   Weng J, 1999, CELL, V98, P13, DOI 10.1016/S0092-8674(00)80602-9
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Woodell A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067894
   Zhou JL, 2006, P NATL ACAD SCI USA, V103, P16182, DOI 10.1073/pnas.0604255103
   Zhou J, 2009, INVEST OPHTH VIS SCI, V50, P1392, DOI 10.1167/iovs.08-2868
NR 50
TC 2
Z9 2
U1 1
U2 13
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0021-9541
EI 1097-4652
J9 J CELL PHYSIOL
JI J. Cell. Physiol.
PD MAY
PY 2021
VL 236
IS 5
BP 3660
EP 3674
DI 10.1002/jcp.30103
EA OCT 2020
PG 15
WC Cell Biology; Physiology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Physiology
GA QO7JN
UT WOS:000577940800001
PM 33034385
DA 2022-11-30
ER

PT J
AU Liu, Y
   Noda, K
   Murata, M
   Wu, D
   Kanda, A
   Ishida, S
AF Liu, Ye
   Noda, Kousuke
   Murata, Miyuki
   Wu, Di
   Kanda, Atsuhiro
   Ishida, Susumu
TI Blockade of Platelet-Derived Growth Factor Signaling Inhibits Choroidal
   Neovascularization and Subretinal Fibrosis in Mice
SO JOURNAL OF CLINICAL MEDICINE
LA English
DT Article
DE age-related macular degeneration; subretinal fibrosis; platelet derived
   growth factor receptor-beta; choroidal neovascularization; pericyte
ID MACULAR DEGENERATION; IN-VITRO; PERICYTES; CELLS; RANIBIZUMAB;
   FIBROBLASTS; BIOMARKERS; SCAR
AB Neovascular age related macular degeneration (nAMD) leads to severe vision loss worldwide and is characterized by the formation of choroidal neovascularization (CNV) and fibrosis. In the current study, we aimed to investigate the effect of blockade for platelet derived growth factor receptor-beta (PDGFR-beta) on the formation of choroidal neovascularization and fibrosis in the laser-induced CNV model in mice. Firstly, the presence of PDGFR-beta in CNV lesions were confirmed. Intravitreal injection of PDGFR-beta neutralizing antibody significantly reduced the size of CNV and subretinal fibrosis. Additionally, subretinal hyperreflective material (SHRM), a landmark feature on OCT as a risk factor for subretinal fibrosis formation in nAMD patients was also suppressed by PDGFR-beta blockade. Furthermore, pericytes were abundantly recruited to the CNV lesions during CNV formation, however, blockade of PDGFR-beta significantly reduced pericyte recruitment. In addition, PDGF-BB stimulation increased the migration of the rat retinal pericyte cell line, R-rPCT1, which was abrogated by the neutralization of PDGFR-beta. These results indicate that blockade of PDGFR-beta attenuates laser-induced CNV and fibrosis through the inhibition of pericyte migration.
C1 [Noda, Kousuke; Murata, Miyuki; Wu, Di; Kanda, Atsuhiro; Ishida, Susumu] Hokkaido Univ, Fac Med, Dept Ophthalmol, Lab Ocular Cell Biol & Visual Sci, Sapporo, Hokkaido 0608638, Japan.
   [Murata, Miyuki; Wu, Di; Kanda, Atsuhiro] Hokkaido Univ, Grad Sch Med, Sapporo, Hokkaido 0608638, Japan.
C3 Hokkaido University; Hokkaido University
RP Noda, K (通讯作者)，Hokkaido Univ, Fac Med, Dept Ophthalmol, Lab Ocular Cell Biol & Visual Sci, Sapporo, Hokkaido 0608638, Japan.
EM doctorliuye@zju.edu.cn; nodako@med.hokudai.ac.jp;
   miyukin@med.hokudai.ac.jp; cmueyewd@gmail.com; kanda@med.hokudai.ac.jp;
   ishidasu@med.hokudai.ac.jp
OI Kanda, Atsuhiro/0000-0001-7192-9974
FU Novartis Pharma K.K. [18K09393, 17K11442]; Japan Society for the
   Promotion of Science; Otsuka Toshimi Scholarship Foundation; China
   Scholarship Council [201508210220]
FX This research was funded by Novartis Pharma K.K. (K.N.), Grant-in-Aid
   for Scientific Research (C) (18K09393(K.N.) and 17K11442(M.M.)) of the
   Japan Society for the Promotion of Science, and Otsuka Toshimi
   Scholarship Foundation (D.W.). Y.L. is a recipient of a scholarship from
   the China Scholarship Council (Y.L., 201508210220).
CR Andrae J, 2008, GENE DEV, V22, P1276, DOI 10.1101/gad.1653708
   Armulik A, 2011, DEV CELL, V21, P193, DOI 10.1016/j.devcel.2011.07.001
   Bagley RG, 2005, CANCER RES, V65, P9741, DOI 10.1158/0008-5472.CAN-04-4337
   Barron L, 2016, AM J PATHOL, V186, P2519, DOI 10.1016/j.ajpath.2016.07.004
   Bloch SB, 2013, AM J OPHTHALMOL, V156, P116, DOI 10.1016/j.ajo.2013.02.012
   Casalino G, 2018, OPHTHALMOL RETINA, V2, P451, DOI 10.1016/j.oret.2017.08.019
   Chen YT, 2011, KIDNEY INT, V80, P1170, DOI 10.1038/ki.2011.208
   Daniel E, 2014, OPHTHALMOLOGY, V121, P656, DOI 10.1016/j.ophtha.2013.10.019
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   Dong A, 2014, ANGIOGENESIS, V17, P553, DOI 10.1007/s10456-013-9402-5
   Dunn EN, 2017, OSLI RETINA, V48, P100, DOI 10.3928/23258160-20170130-02
   Erber R, 2003, FASEB J, V17, P338, DOI 10.1096/fj.03-0271fje
   Friedlander M, 2007, J CLIN INVEST, V117, P576, DOI 10.1172/JCI31030
   Giddabasappa A, 2016, EXP EYE RES, V145, P373, DOI 10.1016/j.exer.2016.02.010
   Goritz C, 2011, SCIENCE, V333, P238, DOI 10.1126/science.1203165
   Greenhalgh Stephen N, 2013, F1000Prime Rep, V5, P37, DOI 10.12703/P5-37
   Grisanti S, 2008, PROG RETIN EYE RES, V27, P372, DOI 10.1016/j.preteyeres.2008.05.002
   Heldin CH, 1999, PHYSIOL REV, V79, P1283, DOI 10.1152/physrev.1999.79.4.1283
   Hughes S, 2004, INVEST OPHTH VIS SCI, V45, P2795, DOI 10.1167/iovs.03-1312
   Ishikawa K, 2016, EXP EYE RES, V142, P19, DOI 10.1016/j.exer.2015.03.009
   Jo N, 2006, AM J PATHOL, V168, P2036, DOI 10.2353/ajpath.2006.050588
   Klaassen I, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0187304
   Kondo T, 2003, CELL STRUCT FUNCT, V28, P145
   Lin SL, 2008, AM J PATHOL, V173, P1617, DOI 10.2353/ajpath.2008.080433
   Liu Y, 2019, MOL THER-NUCL ACIDS, V17, P113, DOI 10.1016/j.omtn.2019.05.012
   Luo XT, 2018, DIS MODEL MECH, V11, DOI 10.1242/dmm.032060
   Mabry R, 2010, MABS-AUSTIN, V2, P20, DOI 10.4161/mabs.2.1.10498
   Matsuda T, 2017, INVEST OPHTH VIS SCI, V58, P3254, DOI 10.1167/iovs.17-21555
   Nagai N, 2016, SCI REP-UK, V6, DOI 10.1038/srep29619
   Otsuji T, 2013, CLIN OPHTHALMOL, V7, P1487, DOI 10.2147/OPTH.S46317
   Ozerdem U, 2001, DEV DYNAM, V222, P218, DOI 10.1002/dvdy.1200
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   ROSS R, 1986, CELL, V46, P155, DOI 10.1016/0092-8674(86)90733-6
   Schmidt-Erfurth U, 2016, PROG RETIN EYE RES, V50, P1, DOI 10.1016/j.preteyeres.2015.07.007
   Willoughby AS, 2015, OPHTHALMOLOGY, V122, P1846, DOI 10.1016/j.ophtha.2015.05.042
   Zehetner C, 2014, INVEST OPHTH VIS SCI, V55, P337, DOI 10.1167/iovs.13-12978
NR 36
TC 4
Z9 4
U1 0
U2 2
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2077-0383
J9 J CLIN MED
JI J. Clin. Med.
PD JUL
PY 2020
VL 9
IS 7
AR 2242
DI 10.3390/jcm9072242
PG 13
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA MS4VJ
UT WOS:000554275400001
PM 32679740
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Allingham, MJ
   Mettu, PS
   Cousins, SW
AF Allingham, Michael J.
   Mettu, Priyatham S.
   Cousins, Scott W.
TI Aldosterone as a mediator of severity in retinal vascular disease:
   Evidence and potential mechanisms
SO EXPERIMENTAL EYE RESEARCH
LA English
DT Article
DE Aldosterone; Diabetic retinopathy; Retinal vein occlusion; Macular edema
ID CENTRAL SEROUS CHORIORETINOPATHY; MINERALOCORTICOID RECEPTOR ANTAGONISM;
   LONG-TERM OUTCOMES; VEIN OCCLUSION; MACULAR EDEMA; RISK-FACTORS;
   DIABETIC-RETINOPATHY; VISUAL-ACUITY; MULLER CELLS; TRAP-EYE
AB Diabetic retinopathy (DR) and retinal vein occlusion (RVO) are the two most common retinal vascular diseases and are major causes of vision loss and blindness worldwide. Recent and ongoing development of medical therapies including anti-vascular endothelial growth factor and corticosteroid drugs for treatment of these diseases have greatly improved the care of afflicted patients. However, severe manifestations of retinal vascular disease result in persistent macular edema, progressive retinal ischemia and incomplete visual recovery. Additionally, choroidal vascular diseases including neovascular age-related macular degeneration (NVAMD) and central serous chorioretinopathy (CSCR) cause vision loss for which current treatments are incompletely effective in some cases and highly burdensome in others. In recent years, aldosterone has gained attention as a contributor to the various deleterious effects of retinal and choroidal vascular diseases via a variety of mechanisms in several retinal cell types. The following is a review of the role of aldosterone in retinal and choroidal vascular diseases as well as our current understanding of the mechanisms by which aldosterone mediates these effects.
C1 [Allingham, Michael J.; Mettu, Priyatham S.; Cousins, Scott W.] Duke Univ, Med Ctr, Dept Ophthalmol, Durham, NC 27710 USA.
C3 Duke University
RP Allingham, MJ (通讯作者)，Duke Eye Ctr, 2351 Erwin Rd, Durham, NC 27710 USA.
EM mike.allingham@duke.edu
OI behar cohen, francine/0000-0001-8571-9513
FU National Institutes of Health [K08EY026627]; NATIONAL EYE INSTITUTE
   [K08EY026627] Funding Source: NIH RePORTER
FX MJA, National Institutes of Health K08EY026627.
CR Allingham MJ, 2018, INVEST OPHTH VIS SCI, V59, P3355, DOI 10.1167/iovs.17-23073
   Allingham MJ, 2017, TRANSL VIS SCI TECHN, V6, DOI 10.1167/tvst.6.2.7
   ARRIZA JL, 1987, SCIENCE, V237, P268, DOI 10.1126/science.3037703
   Atik A., 2017, RETIN CASES BRIEF RE, V1
   Berka JLW, 2009, CIRC RES, V104, P124, DOI 10.1161/CIRCRESAHA.108.176008
   BERKA JL, 1995, INVEST OPHTH VIS SCI, V36, P1450
   Biwer LA, 2019, AM J HYPERTENS, V32, P123, DOI 10.1093/ajh/hpy158
   Bousquet E, 2019, EXP EYE RES, V187, DOI 10.1016/j.exer.2019.107754
   Bousquet E, 2013, RETINA-J RET VIT DIS, V33, P2096, DOI 10.1097/IAE.0b013e318297a07a
   Boyer D.S., 2014, OPHTHALMOLOGY, P1
   Boyer D, 2012, OPHTHALMOLOGY, V119, P1024, DOI 10.1016/j.ophtha.2012.01.042
   Briet M, 2011, CURR HYPERTENS REP, V13, P163, DOI 10.1007/s11906-011-0182-2
   Caicedo A, 2005, J COMP NEUROL, V483, P263, DOI 10.1002/cne.20413
   Caicedo A, 2005, EXP EYE RES, V81, P38, DOI 10.1016/j.exer.2005.01.013
   Campochiaro PA, 2014, OPHTHALMOLOGY, V121, P209, DOI 10.1016/j.ophtha.2013.08.038
   Campochiaro PA, 2011, OPHTHALMOLOGY, V118, P626, DOI 10.1016/j.ophtha.2010.12.028
   Caprio M, 2008, CIRC RES, V102, P1359, DOI 10.1161/CIRCRESAHA.108.174235
   Clark D, 2012, CAN J CARDIOL, V28, P318, DOI 10.1016/j.cjca.2012.03.010
   CLARKSON JG, 1995, OPHTHALMOLOGY, V102, P1434
   Deliyanti D, 2012, HYPERTENSION, V59, P607, DOI 10.1161/HYPERTENSIONAHA.111.188136
   Do DV, 2011, OPHTHALMOLOGY, V118, P1819, DOI 10.1016/j.ophtha.2011.02.018
   Ebneter A, 2017, INVEST OPHTH VIS SCI, V58, DOI 10.1167/iovs.16-20474
   Elman MJ, 2010, OPHTHALMOLOGY, V117, P1064, DOI 10.1016/j.ophtha.2010.02.031
   FRANGIEH GT, 1982, ARCH OPHTHALMOL-CHIC, V100, P1132
   Funder JW, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18051032
   FUNDER JW, 1988, SCIENCE, V242, P583, DOI 10.1126/science.2845584
   Gomez-Sanchez EP, 2005, AM J PHYSIOL-ENDOC M, V288, pE342, DOI 10.1152/ajpendo.00355.2004
   Goodfriend TL, 1998, ENDOCR RES, V24, P789, DOI 10.3109/07435809809032689
   Green W R, 1981, Retina, V1, P27
   Gu HY, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-00461-9
   Haimovici R, 2004, OPHTHALMOLOGY, V111, P244, DOI 10.1016/j.ophtha.2003.09.024
   Hannemann A, 2012, EUR J ENDOCRINOL, V167, P7, DOI 10.1530/EJE-11-1013
   Hayreh SS, 2014, PROG RETIN EYE RES, V41, P1, DOI 10.1016/j.preteyeres.2014.04.001
   Hayreh SS, 2001, AM J OPHTHALMOL, V131, P61, DOI 10.1016/S0002-9394(00)00709-1
   Heier JS, 2014, OPHTHALMOLOGY, V121, P1414, DOI 10.1016/j.ophtha.2014.01.027
   Heier JS, 2012, OPHTHALMOLOGY, V119, P802, DOI 10.1016/j.ophtha.2011.12.005
   Herold TR, 2014, GRAEF ARCH CLIN EXP, V252, P1985, DOI 10.1007/s00417-014-2780-6
   Ip MS, 2012, ARCH OPHTHALMOL-CHIC, V130, P1145, DOI 10.1001/archophthalmol.2012.1043
   Jia GH, 2016, CIRC RES, V118, P935, DOI 10.1161/CIRCRESAHA.115.308269
   Joseph JJ, 2018, J AM HEART ASSOC, V7, DOI 10.1161/JAHA.118.009890
   Klein BEK, 2007, OPHTHAL EPIDEMIOL, V14, P179, DOI 10.1080/09286580701396720
   Korobelnik J., 2014, OPHTHALMOLOGY, P1
   Lad EM, 2015, GRAEF ARCH CLIN EXP, V253, P1941, DOI 10.1007/s00417-015-3094-z
   Lad EM, 2014, AM J OPHTHALMOL, V158, P537, DOI 10.1016/j.ajo.2014.05.014
   Martin-Fernandez B, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0145946
   Moss ME, 2015, FRONT ENDOCRINOL, V6, DOI 10.3389/fendo.2015.00153
   Nagata D, 2006, HYPERTENSION, V48, P165, DOI 10.1161/01.HYP.0000226054.53527.bb
   Nitta E, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.240
   Okada Y, 2001, JPN J OPHTHALMOL, V45, P585, DOI 10.1016/S0021-5155(01)00412-9
   Patel RD, 2011, SEMIN OPHTHALMOL, V26, P372, DOI 10.3109/08820538.2011.570845
   Peden MC, 2015, OPHTHALMOLOGY, V122, P803, DOI 10.1016/j.ophtha.2014.11.018
   Nguyen QD, 2012, OPHTHALMOLOGY, V119, P789, DOI 10.1016/j.ophtha.2011.12.039
   Ramchandran RS, 2008, AM J OPHTHALMOL, V146, P285, DOI 10.1016/j.ajo.2008.03.025
   Rangasamy S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0108508
   Reichenbach A, 2007, GRAEF ARCH CLIN EXP, V245, P627, DOI 10.1007/s00417-006-0516-y
   Reichenbach A, 2013, GLIA, V61, P651, DOI 10.1002/glia.22477
   Retinal E, 2009, ARCH OPHTHALMOL-CHIC, V127, P1101
   Robinson R, 2012, DIS MODEL MECH, V5, P444, DOI 10.1242/dmm.009597
   Rogers S, 2010, OPHTHALMOLOGY, V117, P313, DOI [10.1016/j.ophtha.2009.07.017, 10.1016/j.ophtha.2010.01.060]
   Satofuka S, 2009, DIABETES, V58, P1625, DOI 10.2337/db08-0254
   Schafer N, 2013, EUR HEART J, V34, P3515, DOI 10.1093/eurheartj/eht095
   Scott IU, 2017, JAMA-J AM MED ASSOC, V317, P2072, DOI 10.1001/jama.2017.4568
   Shannon H, 2000, NEW ENGL J MED, V342, P381
   Sharma S, 2016, OPHTHALMOLOGY, V123, P865, DOI 10.1016/j.ophtha.2015.12.002
   Sjolie AK, 2008, LANCET, V372, P1385, DOI 10.1016/S0140-6736(08)61411-7
   Stearne MR, 1998, BMJ-BRIT MED J, V317, P703
   Su EN, 2000, GRAEF ARCH CLIN EXP, V238, P163, DOI 10.1007/s004170050028
   Takasago Y., 2018, JRAAS, V19
   Taves MD, 2011, AM J PHYSIOL-ENDOC M, V301, pE11, DOI 10.1152/ajpendo.00100.2011
   Wang B, 2015, LANCET DIABETES ENDO, V3, P263, DOI 10.1016/S2213-8587(14)70256-6
   Wells JA, 2016, OPHTHALMOLOGY, V123, P1351, DOI 10.1016/j.ophtha.2016.02.022
   White AJR, 2015, J RENIN-ANGIO-ALDO S, V16, P59, DOI 10.1177/1470320314549791
   Wilkinson-Berka JL, 2012, PEPTIDES, V36, P142, DOI 10.1016/j.peptides.2012.04.008
   Wilkinson-Berka JL, 2006, INT J BIOCHEM CELL B, V38, P752, DOI 10.1016/j.biocel.2005.08.002
   Wykoff CC, 2015, RETINA-J RET VIT DIS, V35, P43, DOI 10.1097/IAE.0000000000000277
   Yannuzzi LA, 1996, ARCH OPHTHALMOL-CHIC, V114, P545
   YANNUZZI LA, 1993, AM J OPHTHALMOL, V116, P286
   Yau JWY, 2012, DIABETES CARE, V35, P556, DOI 10.2337/dc11-1909
   Zeng HY, 2008, ARCH OPHTHALMOL-CHIC, V126, P227, DOI 10.1001/archophthalmol.2007.65
   Zhao M, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-018-08125-6
   Zhao M, 2012, J CLIN INVEST, V122, P2672, DOI 10.1172/JCI61427
   Zhao M, 2010, FASEB J, V24, P3405, DOI 10.1096/fj.09-154344
NR 82
TC 5
Z9 5
U1 0
U2 5
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0014-4835
EI 1096-0007
J9 EXP EYE RES
JI Exp. Eye Res.
PD NOV
PY 2019
VL 188
AR 107788
DI 10.1016/j.exer.2019.107788
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA JJ9XC
UT WOS:000494503700027
PM 31479654
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Fanelli, G
   Gonzalez-Cordero, A
   Gardner, PJ
   Peng, Q
   Fernando, M
   Kloc, M
   Farrar, CA
   Naeem, A
   Garred, P
   Ali, RR
   Sacks, SH
AF Fanelli, Giorgia
   Gonzalez-Cordero, Anai
   Gardner, Peter J.
   Peng, Qi
   Fernando, Milan
   Kloc, Magdalena
   Farrar, Conrad A.
   Naeem, Arifa
   Garred, Peter
   Ali, Robin R.
   Sacks, Steven H.
TI Human stem cell-derived retinal epithelial cells activate complement via
   collectin 11 in response to stress
SO SCIENTIFIC REPORTS
LA English
DT Article
ID MEMBRANE ATTACK COMPLEX; MANNAN-BINDING LECTIN; FACTOR-H POLYMORPHISM;
   MACULAR-DEGENERATION; CHOROIDAL NEOVASCULARIZATION; REGULATORY PROTEINS;
   OXIDATIVE STRESS; BLOOD-FLOW; HIGH-RISK; FACTOR-B
AB Age-related macular degeneration (AMD) is a major cause of blindness and is associated with complement dysregulation. The disease is a potential target for stem cell therapy but success is likely to be limited by the inflammatory response. We investigated the innate immune properties of human induced-pluripotent stem cell (iPSC)-derived RPE cells, particularly with regard to the complement pathway. We focused on collectin-11 (CL-11), a pattern recognition molecule that can trigger complement activation in renal epithelial tissue. We found evidence of constitutive and hypoxia-induced expression of CL-11 in iPS-RPE cells, and in the extracellular fluid. Complement activation on the cell surface occurred in conjunction with CL-11 binding. CL-11 has been shown to activate inflammatory responses through recognition of L-fucose, which we confirmed by showing that fucosidase-treated cells, largely, failed to activate complement. The presence of CL-11 in healthy murine and human retinal tissues confirmed the biological relevance of CL-11. Our data describe a new trigger mechanism of complement activation that could be important in disease pathogenesis and therapeutic interventions.
C1 [Fanelli, Giorgia; Peng, Qi; Farrar, Conrad A.; Sacks, Steven H.] Kings Coll London, MRC Ctr Transplantat, London, England.
   [Fanelli, Giorgia; Peng, Qi; Farrar, Conrad A.; Sacks, Steven H.] Guys Hosp, KGuys & St Thomas NHS Trust, London, England.
   [Gonzalez-Cordero, Anai; Gardner, Peter J.; Fernando, Milan; Kloc, Magdalena; Naeem, Arifa; Ali, Robin R.] UCL, Inst Ophthalmol, London, England.
   [Garred, Peter] Univ Copenhagen, Rigshosp, Dept Clin Immunol, Lab Mol Med,Sect 7631, Copenhagen, Denmark.
C3 University of London; King's College London; Guy's & St Thomas' NHS
   Foundation Trust; University of London; University College London;
   Rigshospitalet; University of Copenhagen
RP Sacks, SH (通讯作者)，Kings Coll London, MRC Ctr Transplantat, London, England.; Sacks, SH (通讯作者)，Guys Hosp, KGuys & St Thomas NHS Trust, London, England.
EM steven.sacks@kcl.ac.uk
OI Sacks, Steven/0000-0001-6361-9095; Gardner, Pete/0000-0002-4940-2639;
   Gonzalez Cordero, Anai/0000-0002-1818-0375; Ali,
   Robin/0000-0003-3126-6517; Garred, Peter/0000-0002-2876-8586; fanelli,
   giorgia/0000-0002-2003-529X
FU UK Regenerative Medicine Platform, Department of Health through the NIHR
   comprehensive Biomedical Research Centre award; Medical Research Council
   UK [MR/J004553/1, MR/M007871/1, MR/L012758/1]; European Research Council
   [ERC-2012-ADG_20120314]; Department of Health's National Institute for
   Health Research Biomedical Research Centre at Moorfields Eye Hospital;
   Danish Research Council for Independent Research [DFF-6110-00489];
   King's College London; King's College Hospital NHS Foundation Trust;
   Medical Research Council [MR/J006742/1, MR/M007871/1, MR/M012263/1,
   G0600892, MR/J004553/1, MR/L012758/1] Funding Source: researchfish;
   National Institute for Health Research [NF-SI-0510-10142,
   NF-SI-0513-10074, NF-SI-0508-10130] Funding Source: researchfish; Novo
   Nordisk Fonden [NNF13SA0009309] Funding Source: researchfish; MRC
   [MR/J004553/1, MR/M012263/1, MR/L012758/1, G0600892] Funding Source:
   UKRI
FX The authors would like to thank Dr. Pablo D. Becker for constructive
   discussions and Dr. Marco Romano for technical support. We are grateful
   with Dr. Catey Bunce, Reader in Medical Statistics at King's College
   London and Honorary Statistician at the National Institute for Health
   Research (NIHR) Moorfields BRC for her help with statistical analysis.
   This work was funded by a grant from the UK Regenerative Medicine
   Platform, Department of Health through the NIHR comprehensive Biomedical
   Research Centre award to Guy's & St Thomas' NHS Foundation Trust in
   partnership with King's College London and King's College Hospital NHS
   Foundation Trust and grants from the Medical Research Council UK
   (MR/J004553/1; MR/M007871/1; MR/L012758/1) and European Research Council
   (ERC-2012-ADG_20120314). A.G.C. is a UCL Sensory systems and Therapies
   Fellow. R.R.A. is funded by the Department of Health's National
   Institute for Health Research Biomedical Research Centre at Moorfields
   Eye Hospital. P.G. is supported by a grant from the Danish Research
   Council for Independent Research (DFF-6110-00489). The views expressed
   are those of the authors and not necessarily those of the NHS, the NIHR,
   or the UK Department of Health.
CR Abe K, 2004, CLIN EXP IMMUNOL, V136, P60, DOI 10.1111/j.1365-2249.2004.02411.x
   Amadi-Obi A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045801
   Ambati J, 2013, NAT REV IMMUNOL, V13, P438, DOI 10.1038/nri3459
   Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   Arjamaa O, 2009, AGEING RES REV, V8, P349, DOI 10.1016/j.arr.2009.06.002
   Asgari E, 2014, FASEB J, V28, P3996, DOI 10.1096/fj.13-246306
   Boltz A, 2010, INVEST OPHTH VIS SCI, V51, P4220, DOI 10.1167/iovs.09-4968
   Bradley DT, 2011, EYE, V25, P683, DOI 10.1038/eye.2011.37
   Carr AJ, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008152
   Chen M, 2007, EXP EYE RES, V84, P635, DOI 10.1016/j.exer.2006.11.015
   Cho EYP, 2002, HISTOCHEM J, V34, P589, DOI 10.1023/A:1026032005521
   Collard CD, 1999, MOL IMMUNOL, V36, P941, DOI 10.1016/S0161-5890(99)00116-9
   CYBULSKY AV, 1989, AM J PHYSIOL, V257, pF826, DOI 10.1152/ajprenal.1989.257.5.F826
   Despriet DDG, 2009, OPHTHALMOLOGY, V116, P474, DOI 10.1016/j.ophtha.2008.09.055
   Dithmer M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089150
   Du ZJ, 2011, INVEST OPHTH VIS SCI, V52, P987, DOI 10.1167/iovs.10-5557
   Dunkelberger JR, 2010, CELL RES, V20, P34, DOI 10.1038/cr.2009.139
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Farrar CA, 2016, J CLIN INVEST, V126, P1911, DOI 10.1172/JCI83000
   Fett AL, 2012, HISTOL HISTOPATHOL, V27, P357, DOI 10.14670/HH-27.357
   Forooghian F, 2007, BRIT J OPHTHALMOL, V91, DOI 10.1136/bjo.2007.123125
   Garred P, 2016, IMMUNOL REV, V274, P74, DOI 10.1111/imr.12468
   Gehrs KM, 2006, ANN MED, V38, P450, DOI 10.1080/07853890600946724
   Gemenetzi M, 2016, EYE, V30, P1, DOI 10.1038/eye.2015.203
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hansen S, 2010, J IMMUNOL, V185, P6096, DOI 10.4049/jimmunol.1002185
   Johnson LV, 2000, EXP EYE RES, V70, P441, DOI 10.1006/exer.1999.0798
   Kaarniranta K, 2009, J MOL MED, V87, P117, DOI 10.1007/s00109-008-0418-z
   Kaur C, 2008, CLIN OPHTHALMOL, V2, P879, DOI 10.2147/opth.s3361
   Keshi H, 2006, MICROBIOL IMMUNOL, V50, P1001, DOI 10.1111/j.1348-0421.2006.tb03868.x
   Kimbrel EA, 2015, NAT REV DRUG DISCOV, V14, P681, DOI 10.1038/nrd4738
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kovach JL, 2012, J OPHTHALMOL, V2012, DOI 10.1155/2012/786870
   Kurihara T, 2016, ELIFE, V5, DOI 10.7554/eLife.14319
   Lechner J, 2016, IMMUN AGEING, V13, DOI 10.1186/s12979-016-0060-5
   Lee CA, 2016, CELL TRANSPLANT, V25, P1227, DOI 10.3727/096368916X691286
   Lewis EC, 2008, P NATL ACAD SCI USA, V105, P16236, DOI 10.1073/pnas.0807627105
   Luo C, 2013, EXP EYE RES, V112, P93, DOI 10.1016/j.exer.2013.04.016
   Ma YJ, 2013, J INNATE IMMUN, V5, P242, DOI 10.1159/000345356
   Maeda T, 2013, J BIOL CHEM, V288, P34484, DOI 10.1074/jbc.M113.518571
   Mandai M, 2017, NEW ENGL J MED, V376, P1038, DOI 10.1056/NEJMoa1608368
   MAYNARD Y, 1982, J BIOL CHEM, V257, P3788
   Metelitsina TI, 2008, INVEST OPHTH VIS SCI, V49, P358, DOI 10.1167/iovs.07-0526
   Motomura W, 2008, J HISTOCHEM CYTOCHEM, V56, P243, DOI 10.1369/jhc.7A7312.2007
   Mullins RF, 2014, AM J PATHOL, V184, P3142, DOI 10.1016/j.ajpath.2014.07.017
   Mullins RF, 2011, EXP EYE RES, V93, P565, DOI 10.1016/j.exer.2011.06.015
   Palazon A, 2014, IMMUNITY, V41, P518, DOI 10.1016/j.immuni.2014.09.008
   Petersen SV, 2001, MOL IMMUNOL, V38, P133
   Remsch H, 2000, GRAEF ARCH CLIN EXP, V238, P960, DOI 10.1007/s004170000202
   Reynolds R, 2009, INVEST OPHTH VIS SCI, V50, P5818, DOI 10.1167/iovs.09-3928
   Ricklin D, 2013, J IMMUNOL, V190, P3831, DOI 10.4049/jimmunol.1203487
   Rus HG, 1996, J IMMUNOL, V156, P4892
   Sacks SH, 2012, NAT REV IMMUNOL, V12, P431, DOI 10.1038/nri3225
   Schick T., 2017, EYE
   Schwaeble WJ, 2011, P NATL ACAD SCI USA, V108, P7523, DOI 10.1073/pnas.1101748108
   Schwartz SD, 2015, LANCET, V385, P509, DOI 10.1016/S0140-6736(14)61376-3
   Schwartz SD, 2012, LANCET, V379, P713, DOI 10.1016/S0140-6736(12)60028-2
   Seddon JM, 2013, NAT GENET, V45, P1366, DOI 10.1038/ng.2741
   Selman L, 2012, IMMUNOBIOLOGY, V217, P851, DOI 10.1016/j.imbio.2011.12.008
   Semenza GL, 2012, CELL, V148, P399, DOI 10.1016/j.cell.2012.01.021
   Sohn JH, 2000, INVEST OPHTH VIS SCI, V41, P3492
   Stanton CM, 2014, ADV EXP MED BIOL, V801, P251, DOI 10.1007/978-1-4614-3209-8_32
   Taube C, 2006, P NATL ACAD SCI USA, V103, P8084, DOI 10.1073/pnas.0602357103
   Thiel S, 2007, MOL IMMUNOL, V44, P3875, DOI 10.1016/j.molimm.2007.06.005
   Thurman JM, 2006, J CLIN INVEST, V116, P357, DOI 10.1172/JCI24521
   Thurman JM, 2009, J BIOL CHEM, V284, P16939, DOI 10.1074/jbc.M808166200
   Triantafilou K, 2013, J CELL SCI, V126, P2903, DOI 10.1242/jcs.124388
   Xu HP, 2009, PROG RETIN EYE RES, V28, P348, DOI 10.1016/j.preteyeres.2009.06.001
   Yaseen S, 2017, FASEB J, V31, P2210, DOI 10.1096/fj.201601306R
NR 71
TC 16
Z9 16
U1 0
U2 4
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD NOV 7
PY 2017
VL 7
AR 14625
DI 10.1038/s41598-017-15212-z
PG 13
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA FL9IA
UT WOS:000414565700005
PM 29116192
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Batabyal, S
   Cervenka, G
   Birch, D
   Kim, YT
   Mohanty, S
AF Batabyal, Subrata
   Cervenka, Gregory
   Birch, David
   Kim, Young-tae
   Mohanty, Samarendra
TI Broadband activation by white-opsin lowers intensity threshold for
   cellular stimulation
SO SCIENTIFIC REPORTS
LA English
DT Article
ID RESTORES VISUAL RESPONSES; ECTOPIC EXPRESSION; LIGHT RESPONSES; OPTICAL
   CONTROL; CHANNELRHODOPSIN-2; CELLS; CHANNELS; MODELS; MICE
AB Photoreceptors, which initiate the conversion of ambient light to action potentials via retinal circuitry, degenerate in retinal diseases such as retinitis pigmentosa and age related macular degeneration leading to loss of vision. Current prosthetic devices using arrays consisting of electrodes or LEDs (for optogenetic activation of conventional narrow-band opsins) have limited spatial resolution and can cause damage to retinal circuits by mechanical or photochemical (by absorption of intense narrow band light) means. Here, we describe a broad-band light activatable white-opsin for generating significant photocurrent at white light intensity levels close to ambient daylight conditions. White-opsin produced an order of magnitude higher photocurrent in response to white light as compared to narrow-band opsin channelrhodopsin-2, while maintaining the ms-channel kinetics. High fidelity of peak-photocurrent (both amplitude and latency) of white-opsin in response to repetitive white light stimulation of varying pulse width was observed. The significantly lower intensity stimulation required for activating white-opsin sensitized cells may facilitate ambient white light-based restoration of vision for patients with widespread photoreceptor degeneration.
C1 [Batabyal, Subrata; Cervenka, Gregory; Mohanty, Samarendra] Univ Texas Arlington, Biophys & Physiol Lab, Arlington, TX 76019 USA.
   [Birch, David] Retina Fdn SW, Dallas, TX USA.
   [Kim, Young-tae] Univ Texas Arlington, Dept Bioengn, Arlington, TX 76019 USA.
C3 University of Texas System; University of Texas Arlington; Retina
   Foundation of the Southwest; University of Texas System; University of
   Texas Arlington
RP Mohanty, S (通讯作者)，Univ Texas Arlington, Biophys & Physiol Lab, Arlington, TX 76019 USA.
EM smohanty@uta.edu
FU National Institute of Health [NS084311]; Office of President and
   Provost, The University of Texas at Arlington; NATIONAL INSTITUTE OF
   NEUROLOGICAL DISORDERS AND STROKE [R21NS084311] Funding Source: NIH
   RePORTER
FX The authors would like to thank Prof. Qing Lin, Saurabh Kokane,
   Christopher Cote, Kamal Dhakal, Sarmishtha Satpathy and Mary Nguyen
   (UTA) for their help in experiments. SM would like to thank K.
   Deisseroth (Stanford) for ChR2 and C1V1 plasmids, and J. Lin (UCSD) for
   the ReaChR constructs. SM would also like to acknowledge initial
   supports from the National Institute of Health (NS084311) and Office of
   President and Provost, The University of Texas at Arlington.
CR Baumgartner WA, 2000, MED HYPOTHESES, V54, P814, DOI 10.1054/mehy.1999.0957
   Bi AD, 2006, NEURON, V50, P23, DOI 10.1016/j.neuron.2006.02.026
   Boyden ES, 2005, NAT NEUROSCI, V8, P1263, DOI 10.1038/nn1525
   Buj R, 2013, BMC MOL BIOL, V14, DOI 10.1186/1471-2199-14-18
   Busskamp V, 2010, SCIENCE, V329, P413, DOI 10.1126/science.1190897
   Cao H, 2013, IEEE T BIO-MED ENG, V60, P225, DOI 10.1109/TBME.2012.2217395
   Chader GJ, 2002, VISION RES, V42, P393, DOI 10.1016/S0042-6989(01)00212-7
   Chow AY, 2002, J REHABIL RES DEV, V39, P313
   Curcio CA, 1996, INVEST OPHTH VIS SCI, V37, P1236
   Daiger SP, 2007, ARCH OPHTHALMOL-CHIC, V125, P151, DOI 10.1001/archopht.125.2.151
   de Balthasar C, 2008, INVEST OPHTH VIS SCI, V49, P2303, DOI 10.1167/iovs.07-0696
   Degenaar P, 2009, J NEURAL ENG, V6, DOI 10.1088/1741-2560/6/3/035007
   Delori FC, 2007, J OPT SOC AM A, V24, P1250, DOI 10.1364/JOSAA.24.001250
   Doroudchi MM, 2011, MOL THER, V19, P1220, DOI 10.1038/mt.2011.69
   Fohlmeister JF, 2010, J NEUROPHYSIOL, V103, P1357, DOI 10.1152/jn.00123.2009
   Grossman N, 2009, I IEEE EMBS C NEUR E, P68, DOI 10.1109/NER.2009.5109236
   Guo ZV, 2009, NAT METHODS, V6, P891, DOI 10.1038/nmeth.1397
   Hamel C, 2006, ORPHANET J RARE DIS, V1, DOI 10.1186/1750-1172-1-40
   Hartley JL, 2000, GENOME RES, V10, P1788, DOI 10.1101/gr.143000
   Hartong DT, 2006, LANCET, V368, P1795, DOI 10.1016/S0140-6736(06)69740-7
   Horsager A, 2009, INVEST OPHTH VIS SCI, V50, P1483, DOI 10.1167/iovs.08-2595
   Kleinlogel S, 2011, NAT METHODS, V8, P1083, DOI [10.1038/NMETH.1766, 10.1038/nmeth.1766]
   Lagali PS, 2008, NAT NEUROSCI, V11, P667, DOI 10.1038/nn.2117
   Lin JY, 2013, NAT NEUROSCI, V16, P1499, DOI 10.1038/nn.3502
   Mezer E, 2007, OPHTHALMIC GENET, V28, P9, DOI 10.1080/13816810701199423
   Miller G, 2006, SCIENCE, V314, P1674, DOI 10.1126/science.314.5806.1674
   Mohanty S., 2012, NAT PREC, DOI [10.1038/npre.2012.6869.1, DOI 10.1038/NPRE.2012.6869.1]
   Mohanty SK, 2008, BIOPHYS J, V95, P3916, DOI 10.1529/biophysj.108.130187
   Nagel G, 2003, P NATL ACAD SCI USA, V100, P13940, DOI 10.1073/pnas.1936192100
   Pan ZH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098924
   Prigge M, 2012, J BIOL CHEM, V287, P31804, DOI 10.1074/jbc.M112.391185
   Sliney DH, 2005, PHOTOCHEM PHOTOBIOL, V81, P483, DOI 10.1562/2005-02-14-RA-439.1
   Sugawara T, 2010, EYE, V24, P535, DOI 10.1038/eye.2009.176
   Thyagarajan S, 2010, J NEUROSCI, V30, P8745, DOI 10.1523/JNEUROSCI.4417-09.2010
   Tomita H, 2010, EXP EYE RES, V90, P429, DOI 10.1016/j.exer.2009.12.006
   Tomita H, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007679
   Warren EJ, 2003, EUR J NEUROSCI, V17, P1727, DOI 10.1046/j.1460-9568.2003.02594.x
   Zhang F, 2007, NAT REV NEUROSCI, V8, P577, DOI 10.1038/nrn2192
   Zhang F, 2006, NAT METHODS, V3, P785, DOI 10.1038/nmeth936
   Zhang Y, 2009, J NEUROSCI, V29, P9186, DOI 10.1523/JNEUROSCI.0184-09.2009
   Zrenner E, 2002, SCIENCE, V295, P1022, DOI 10.1126/science.1067996
   Zrenner E, 2011, P ROY SOC B-BIOL SCI, V278, P1489, DOI 10.1098/rspb.2010.1747
NR 42
TC 6
Z9 6
U1 0
U2 6
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD DEC 14
PY 2015
VL 5
AR 17857
DI 10.1038/srep17857
PG 9
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA CY3BW
UT WOS:000366284100001
PM 26658483
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Achiron, A
   Lagstein, O
   Glick, M
   Gur, Z
   Bartov, E
   Burgansky-Eliash, Z
AF Achiron, Asaf
   Lagstein, Oded
   Glick, Mirit
   Gur, Zvi
   Bartov, Elisha
   Burgansky-Eliash, Zvia
TI Quantifying metamorphopsia in patients with diabetic macular oedema and
   other macular abnormalities
SO ACTA OPHTHALMOLOGICA
LA English
DT Article
DE Anti-VEGF; diabetic retinopathy; macular oedema; M-chart;
   metamorphopsia; quantification
ID RETINAL VEIN OCCLUSION; EPIRETINAL MEMBRANE; VISUAL-ACUITY; M-CHARTS;
   DEGENERATION; QUANTIFICATION; LUCENTIS; SURGERY; TIME
AB Purpose: To quantify subjective visual metamorphopsia in newly diagnosed patients suffering from diabetic macular oedema (DME) and other macular abnormalities and to evaluate anti-VEGF treatment effect.
   Methods: Patients with DME, subfoveal choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD) or retinal venous occlusion (RVO) were recruited. Metamorphopsia score (Mscore) was calculated using M-Charts at baseline and at the end of a series of anti-VEGF injections.
   Results: Fifteen eyes of 10 patients with DME, 14 eyes of 13 patients with AMD-CNV and five patients with RVO were included in this study. At baseline, positive Mscore was observed in 46.6% of eyes with DME, 50% of eyes with AMD-CNV and four of five eyes with RVO. Treatment led to a complete metamorphopsia reduction (Mscore = 0) in 71.4% of DME patients, 35.7% of AMD and 0% of RVO patients.
   Conclusion: We suggest that the M-charts may serve as an additional test for diagnosis and follow-up, complementary to morphological evaluation by imaging, in diabetic patients facing their first anti-VEGF treatment.
C1 [Achiron, Asaf; Lagstein, Oded; Bartov, Elisha; Burgansky-Eliash, Zvia] Edith Wolfson Med Ctr, Dept Ophthalmol, IL-58100 Holon, Israel.
   [Achiron, Asaf; Lagstein, Oded; Glick, Mirit; Bartov, Elisha; Burgansky-Eliash, Zvia] Tel Aviv Univ, Sackler Fac Med, IL-69978 Tel Aviv, Israel.
   [Gur, Zvi] Soroka Univ, Med Ctr, Dept Ophthalmol, Beer Sheva, Israel.
C3 Tel Aviv University; Sackler Faculty of Medicine; Ben Gurion University;
   Soroka Medical Center
RP Achiron, A (通讯作者)，Edith Wolfson Med Ctr, Dept Ophthalmol, 62 Halochamim St, IL-58100 Holon, Israel.
EM AchironAsaf@gmail.com
FU Claire and Amedee Maratier Institute for the Study of Blindness and
   Visual Disorder, Sackler Faculty of Medicine, Tel-Aviv University,
   Israel
FX This study was supported by a grant from the Claire and Amedee Maratier
   Institute for the Study of Blindness and Visual Disorder, Sackler
   Faculty of Medicine, Tel-Aviv University, Israel.
CR AMSLER M, 1953, BRIT J OPHTHALMOL, V37, P521, DOI 10.1136/bjo.37.9.521
   Arimura E, 2011, INVEST OPHTH VIS SCI, V52, P128, DOI 10.1167/iovs.09-3535
   Bae SW, 2013, INDIAN J OPHTHALMOL, V61, P172, DOI 10.4103/0301-4738.112162
   Brown MM, 2006, CURR OPIN OPHTHALMOL, V17, P257
   Das R, 2009, RETINA-J RET VIT DIS, V29, P1013, DOI 10.1097/IAE.0b013e3181a91dbf
   dell'Omo R, 2013, INVEST OPHTH VIS SCI, V54, P7803, DOI 10.1167/iovs.13-12817
   Fletcher DC, 2006, OPTOMETRY VISION SCI, V83, P178, DOI 10.1097/01.opx.0000204510.08026.7f
   Fukuda S, 2009, BRIT J OPHTHALMOL, V93, P1595, DOI 10.1136/bjo.2008.155440
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Kinoshita T, 2012, INVEST OPHTH VIS SCI, V53, P3592, DOI 10.1167/iovs.12-9493
   Kroyer K, 2009, INVEST OPHTH VIS SCI, V50, P5511, DOI 10.1167/iovs.09-3530
   Matsumoto C, 2003, INVEST OPHTH VIS SCI, V44, P4012, DOI 10.1167/iovs.03-0117
   Mehdizadeh M, 2008, GRAEF ARCH CLIN EXP, V246, P1203, DOI 10.1007/s00417-008-0833-4
   Nakagawa Tomoya, 2007, Nippon Ganka Gakkai Zasshi, V111, P331
   Nowomiejska K, 2013, BMC OPHTHALMOL, V13, P13
   Provis Jan M, 2005, Clin Exp Optom, V88, P269
   Rahman R, 2014, EYE, V28, P410, DOI 10.1038/eye.2013.305
   Thach AB, 2014, OPHTHALMOLOGY, V121, P1059, DOI 10.1016/j.ophtha.2013.11.022
NR 18
TC 19
Z9 19
U1 0
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1755-375X
EI 1755-3768
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD DEC
PY 2015
VL 93
IS 8
BP E649
EP E653
DI 10.1111/aos.12735
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DA2VI
UT WOS:000367654500007
PM 25899144
OA Bronze
DA 2022-11-30
ER

PT J
AU Hutton, D
   Newman-Casey, PA
   Tavag, M
   Zacks, D
   Stein, J
AF Hutton, David
   Newman-Casey, Paula Anne
   Tavag, Mrinalini
   Zacks, David
   Stein, Joshua
TI Switching To Less Expensive Blindness Drug Could Save Medicare Part B
   $18 Billion Over A Ten-Year Period
SO HEALTH AFFAIRS
LA English
DT Article
ID RANIBIZUMAB PLUS PROMPT; MACULAR DEGENERATION; COST-EFFECTIVENESS;
   DIABETIC-RETINOPATHY; DEFERRED LASER; UNITED-STATES; PREVALENCE;
   BEVACIZUMAB; PROJECTION; DIFFUSION
AB The biologic drugs bevacizumab and ranibizumab have revolutionized treatment of diabetic macular edema and neovascular age-related macular degeneration, leading causes of blindness. Ophthalmologic use of these drugs has increased and now accounts for roughly one-sixth of the Medicare Part B drug budget. The two drugs have similar efficacy and potentially minor differences in adverse-event rates; however, at $2,023 per dose, ranibizumab costs forty times more than bevacizumab. Using modeling methods, we predict ten-year (2010-20) population-level costs and health benefits of using bevacizumab and ranibizumab. Our results show that if all patients were treated with the less expensive bevacizumab instead of current usage patterns, savings would amount to $18 billion for Medicare Part B and nearly $5 billion for patients. With an additional $6 billion savings in other health care expenses, the total savings would be almost $29 billion. Altering patterns of use with these therapies by encouraging bevacizumab use and hastening approval of biosimilar therapies would dramatically reduce spending without substantially affecting patient outcomes.
C1 [Hutton, David] Univ Michigan, Ann Arbor, MI 48109 USA.
   [Newman-Casey, Paula Anne; Zacks, David; Stein, Joshua] Univ Michigan, Sch Med, Dept Ophthalmol & Visual Sci, Ann Arbor, MI 48109 USA.
   [Tavag, Mrinalini] Univ Michigan, Dept Hlth Management & Policy, Ann Arbor, MI 48109 USA.
C3 University of Michigan System; University of Michigan; University of
   Michigan System; University of Michigan; University of Michigan System;
   University of Michigan
RP Hutton, D (通讯作者)，Univ Michigan, Ann Arbor, MI 48109 USA.
EM dwhutton@umich.edu
OI Zacks, David/0000-0001-8592-5165; Newman-Casey, Paula
   Anne/0000-0002-0847-1929; Stein, Joshua/0000-0003-2937-6987
FU National Eye Institute K23 Mentored Clinician Scientist Award
   [1K23EY019511-01]; NATIONAL EYE INSTITUTE [K23EY019511, K12EY022299]
   Funding Source: NIH RePORTER
FX This research was supported by a National Eye Institute K23 Mentored
   Clinician Scientist Award (No. 1K23EY019511-01).
CR Analysis Group, 2010, BIOL BIOS GEN
   Boyle JP, 2010, POPUL HEALTH METR, V8, DOI 10.1186/1478-7954-8-29
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Census Bureau, 2012, 2012 NAT POP PROJ
   Center for Medicare and Medicaid Services, 2011, NAT HLTH EXP PROJ 20
   Centers for Disease Control and Prevention, 2013, PERC CIV NON POP DIA
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Curtis LH, 2012, AM J OPHTHALMOL, V153, P1116, DOI 10.1016/j.ajo.2011.11.032
   Department of Health and Human Services Office of Inspector General, 2011, REV MED PART B AVAST
   Department of Health and Human Services Office of Inspector General, 2012, MED PAYM DRUGS US TR
   Drugs.com, 2013, AV SAL DAT
   Elman MJ, 2011, OPHTHALMOLOGY, V118, P609, DOI 10.1016/j.ophtha.2010.12.033
   Elman MJ, 2010, OPHTHALMOLOGY, V117, P1064, DOI 10.1016/j.ophtha.2010.02.031
   Elmendorf DW, 2011, CBOS ANAL MAJOR HLTH
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   GOLD M. R., 1996, COSTEFFECTIVENESS HL
   Grunwald JE, 2014, OPHTHALMOLOGY, V121, P150, DOI 10.1016/j.ophtha.2013.08.015
   Harrison C, 2012, NAT BIOTECHNOL, V30, P123, DOI 10.1038/nbt0212-123
   Hussey PS, 2009, NEW ENGL J MED, V361, P2109, DOI 10.1056/NEJMp0910315
   Klein R, 2006, OPHTHALMOLOGY, V113, P373, DOI 10.1016/j.ophtha.2005.12.013
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Mantone J., 2007, WSJ HLTH BLOG   1220
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Megerlin F, 2013, HEALTH AFFAIR, V32, P1803, DOI 10.1377/hlthaff.2009.0196
   *NAT ADV EY COUNC, 1993, VIS RES NAT PLAN 199
   Patel JJ, 2012, J EVAL CLIN PRACT, V18, P247, DOI 10.1111/j.1365-2753.2010.01546.x
   Pershing S, 2014, ANN INTERN MED, V160, P18, DOI 10.7326/M13-0768
   Pollack A., 2014, NY TIMES
   Pollack G., 2009, NY TIMES
   Nguyen QD, 2012, OPHTHALMOLOGY, V119, P789, DOI 10.1016/j.ophtha.2011.12.039
   Radley DC, 2006, ARCH INTERN MED, V166, P1021, DOI 10.1001/archinte.166.9.1021
   Raftery J, 2007, BRIT J OPHTHALMOL, V91, P1244, DOI 10.1136/bjo.2007.116616
   Rein DB, 2009, ARCH OPHTHALMOL-CHIC, V127, P533, DOI 10.1001/archophthalmol.2009.58
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Roux AVD, 2011, AM J PUBLIC HEALTH, V101, P1627, DOI 10.2105/AJPH.2011.300149
   Ruttan VW, 1996, SOCIOL RURALIS, V36, P51, DOI 10.1111/j.1467-9523.1996.tb00004.x
   Saaddine JB, 2008, ARCH OPHTHALMOL-CHIC, V126, P1740, DOI 10.1001/archopht.126.12.1740
   Schmucker C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042701
   Social Security Administration, 2014, MONTHL STAT SNAP MAR
   Stein JD, 2014, OPHTHALMOLOGY, V121, P936, DOI 10.1016/j.ophtha.2013.10.037
   Stein JD, 2013, OPHTHALMOLOGY, V120, P1835, DOI 10.1016/j.ophtha.2013.02.002
   Stein JD, 2013, AM J OPHTHALMOL, V155, P688, DOI 10.1016/j.ajo.2012.10.003
   Sterman J., 2010, BUSINESS DYNAMICS
   United States Patent and Trademark Office, 2012, PAT TERMS EXT 35 USC
   US Senate Special Committee on Aging, 2011, PRESCR SAV RED DRUG
   Varma R, 2004, OPHTHALMOLOGY, V111, P1288, DOI 10.1016/j.ophtha.2004.01.023
   Virgili G, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007419.pub3
   Whoriskey P., 2014, WASHINGTON POST
   Whoriskey P, 2013, WASHINGTON POST
   Yokota F, 2004, MED DECIS MAKING, V24, P287, DOI 10.1177/0272989X04263157
   Zhang XZ, 2010, JAMA-J AM MED ASSOC, V304, P649, DOI 10.1001/jama.2010.1111
NR 51
TC 62
Z9 62
U1 0
U2 2
PU PROJECT HOPE
PI BETHESDA
PA 7500 OLD GEORGETOWN RD, STE 600, BETHESDA, MD 20814-6133 USA
SN 0278-2715
J9 HEALTH AFFAIR
JI Health Aff.
PD JUN
PY 2014
VL 33
IS 6
BP 931
EP 939
DI 10.1377/hlthaff.2013.0832
PG 9
WC Health Care Sciences & Services; Health Policy & Services
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Health Care Sciences & Services
GA AK1PL
UT WOS:000338187200003
PM 24889941
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Anand, A
   Sharma, NK
   Singh, R
   Gupta, A
   Prabhakar, S
   Jindal, N
   Bhatt, AK
   Sharma, SK
   Gupta, PK
AF Anand, Akshay
   Sharma, Neel K.
   Singh, Ramandeep
   Gupta, Amod
   Prabhakar, Sudesh
   Jindal, Neeru
   Bhatt, Arvind K.
   Sharma, Suresh K.
   Gupta, Pawan K.
TI Does DcR1 (TNF-related apoptosis-inducing-ligand Receptor 3) have any
   role in human AMD pathogenesis?
SO SCIENTIFIC REPORTS
LA English
DT Article
ID MACULAR DEGENERATION; MOUSE MODEL; DRUSEN
AB It has been postulated that there is a link between age related degenerative diseases and cancer. The TNF-related apoptosis-inducing ligand (TRAIL) has been shown to selectively kill tumor cells by binding to pro-apoptotic and anti-apoptotic receptors. Our aim was to study the levels of anti-apoptotic receptor (DcR1) in age related macular degeneration (AMD) and controls. AMD patients (115) were classified into two groups: Dry and Wet AMD. Wet AMDs were further classified into occult, predominant classic and minimal classic. 61 healthy individuals were recruited as normal controls. After normalization with total protein, DcR1 levels were analyzed by ELISA. Mann Whitney U-statistic was used for analysis of DcR1 ELISA results. We have observed DcR1 levels in serum sample which were significantly lower in AMD patients as compared to controls (p = 0.001). On the other hand, we did not find difference in DcR1 levels between wet and dry AMD. The present study defines the plausible role of DcR1 in AMD pathology signifying a new therapeutic target for AMD.
C1 [Anand, Akshay; Sharma, Neel K.; Prabhakar, Sudesh; Gupta, Pawan K.] Post Grad Inst Med Educ & Res, Dept Neurol, Neurosci Res Lab, Chandigarh, India.
   [Singh, Ramandeep; Gupta, Amod; Jindal, Neeru] Post Grad Inst Med Educ & Res, Dept Ophthalmol, Chandigarh, India.
   [Bhatt, Arvind K.] Himachal Pradesh Univ, Dept Biotechnol, Shimla, India.
   [Sharma, Suresh K.] Panjab Univ, Dept Stat, Chandigarh 160014, India.
C3 Post Graduate Institute of Medical Education & Research (PGIMER),
   Chandigarh; Post Graduate Institute of Medical Education & Research
   (PGIMER), Chandigarh; Himachal Pradesh University; Panjab University
RP Anand, A (通讯作者)，Post Grad Inst Med Educ & Res, Dept Neurol, Neurosci Res Lab, Chandigarh, India.
EM akshay1anand@rediffmail.com
RI anand, Akshay/AAI-1586-2019; Gupta, Amod/V-7633-2017
OI Gupta, Amod/0000-0001-8427-5738
FU Indian Council of Medical research, India [45/11/2010-HUM/BMS]
FX The study was carried out at Department of Neurology, PGIMER,
   Chandigarh, India. We acknowledge Indian Council of Medical research,
   India for providing funds (45/11/2010-HUM/BMS). The funders had no role
   in study design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Anand A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049905
   Azad Rajvardhan, 2007, Indian Journal of Ophthalmology, V55, P441
   Bhattacharya S, 2012, INVEST OPHTH VIS SCI, V53, P8350, DOI 10.1167/iovs.12-10495
   Brown RC, 2005, ENVIRON HEALTH PERSP, V113, P1250, DOI 10.1289/ehp.7567
   Chang B, 2002, VISION RES, V42, P517, DOI 10.1016/S0042-6989(01)00146-8
   Chang B, 2008, HUM MOL GENET, V17, P3929, DOI 10.1093/hmg/ddn295
   Chavala SH, 2013, J CLIN INVEST, V123, P4170, DOI 10.1172/JCI67315
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Dunaief JL, 2002, ARCH OPHTHALMOL-CHIC, V120, P1435, DOI 10.1001/archopht.120.11.1435
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hawes NL, 2000, INVEST OPHTH VIS SCI, V41, P3149
   Johnstone RW, 2008, NAT REV CANCER, V8, P782, DOI 10.1038/nrc2465
   Johnstone RW, 2002, CELL, V108, P153, DOI 10.1016/S0092-8674(02)00625-6
   Kerrigan LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P1031, DOI 10.1001/archopht.1997.01100160201010
   Klein R, 2013, JAMA OPHTHALMOL, V131, P383, DOI 10.1001/jamaophthalmol.2013.713
   Li ZY, 1995, DEGENERATIVE DISEASES OF THE RETINA, P1
   Owen CG, 2003, BRIT J OPHTHALMOL, V87, P312, DOI 10.1136/bjo.87.3.312
   Ozoren N, 2003, SEMIN CANCER BIOL, V13, P135, DOI 10.1016/S1044-579X(02)00131-1
   Sharma NK, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070193
   Sharma NK, 2012, CURR NEUROVASC RES, V9, P256
   Sharma NK, 2012, DNA CELL BIOL, V31, P1618, DOI 10.1089/dna.2012.1786
   Toscano F, 2008, ONCOGENE, V27, P4161, DOI 10.1038/onc.2008.52
   Wang A. L., 2008, PLOS ONE, V4, pe4160
   Xu G Z, 1996, Trans Am Ophthalmol Soc, V94, P411
   Yamanaka T, 2000, HEPATOLOGY, V32, P482, DOI 10.1053/jhep.2000.16266
NR 25
TC 11
Z9 11
U1 0
U2 1
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD FEB 18
PY 2014
VL 4
AR 4114
DI 10.1038/srep04114
PG 5
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA AA9GB
UT WOS:000331400700001
PM 24534820
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Majumder, P
   Gomes, KN
   Ulrich, H
AF Majumder, Paromita
   Gomes, Katia N.
   Ulrich, Henning
TI Aptamers: from bench side research towards patented molecules with
   therapeutic applications
SO EXPERT OPINION ON THERAPEUTIC PATENTS
LA English
DT Review
DE aptamers; cancer; cardiovascular system; clinical applications; patents
ID ENDOTHELIAL GROWTH-FACTOR; IN-VITRO SELECTION; VASCULAR-PERMEABILITY
   FACTOR; VON-WILLEBRAND-FACTOR; ANTI-VEGF APTAMER; RNA MOLECULES;
   SYSTEMATIC EVOLUTION; MONOCLONAL-ANTIBODY; RECEPTOR-BINDING; DNA
   APTAMERS
AB Background: RNA and DNA aptamers recognize their targets with high specificity and affinity. These aptamers can be developed against almost any target protein through iterative cycles of in vitro screening of a combinatorial oligonucleotide library for target binding. Aptamer sequences from the final pool of in vitro selection are screened for pharmacological activity and possible medical applications. Methods: Chemical modifications and improvements of the identification of aptamer selection procedures made aptamers rival antibodies in diagnostic and therapeutic applications. This article reviews recent literature and patents and discusses the properties of aptamers as high-affinity and specificity target binders as well as their stability in biological fluids that turns them into therapeutic agents. Conclusion: The development of I aptamers into compounds with therapeutic and diagnostic compounds has resulted in patents protecting the sequences and the use of these oligonucleotides. Several of these patented aptamers are currently being tested in Phase I or II clinical trials. Moreover, an anti-VEGF aptamer has already been approved by the FDA for treatment of age-related macular degeneration in humans.
C1 [Majumder, Paromita; Gomes, Katia N.; Ulrich, Henning] Univ Sao Paulo, Inst Quim, Dept Bioquim, BR-05508900 Sao Paulo, Brazil.
C3 Universidade de Sao Paulo
RP Ulrich, H (通讯作者)，Univ Sao Paulo, Inst Quim, Dept Bioquim, BR-05508900 Sao Paulo, Brazil.
EM henning@iq.usp.br
RI Ulrich, Henning/AAX-8586-2021; Majumder, Paromita/AAK-9704-2020; Ulrich,
   Henning/C-5245-2013
OI Ulrich, Henning/0000-0002-2114-3815; Majumder,
   Paromita/0000-0002-1340-2290; Ulrich, Henning/0000-0002-2114-3815
FU FAPESP (Fundacao de Amparo Pesquisa do Estado de Sao Paulo); CNPq
   (Conselho Nacional de Desenvolvimento Cientifico e Tecnologico), Brazil;
   CAPES (Coordenacao do de Aperfeicoamento de Pessoal de Nivel Superior)
FX The authors state no conflict of interest and have received no payment
   in preparation of this manuscript. HU Ulrich received grant support from
   FAPESP (Fundacao de Amparo Pesquisa do Estado de Sao Paulo) and CNPq
   (Conselho Nacional de Desenvolvimento Cientifico e Tecnologico), Brazil.
   KG Neves' doctoral thesis research is supported by a fellowship from
   CAPES (Coordenacao do de Aperfeicoamento de Pessoal de Nivel Superior).
CR Akiyama H, 2006, J CELL PHYSIOL, V207, P407, DOI 10.1002/jcp.20583
   ALON T, 1995, NAT MED, V1, P1024, DOI 10.1038/nm1095-1024
   Asahara T, 1999, EMBO J, V18, P3964, DOI 10.1093/emboj/18.14.3964
   Avci-Adali M, 2008, BIOMATERIALS, V29, P3936, DOI 10.1016/j.biomaterials.2008.07.002
   Balasubrananian V, 1998, MOL PHARMACOL, V53, P926
   Bell C, 1999, IN VITRO CELL DEV-AN, V35, P533
   BENEDICT C, 2006, Patent No. 20060105980
   Bergers G, 2003, J CLIN INVEST, V111, P1287, DOI 10.1172/JCI200317929
   Beri A, 2008, CARDIOVASC DRUG THER, V22, P419, DOI 10.1007/s10557-008-6122-y
   Biesecker G, 1999, IMMUNOPHARMACOLOGY, V42, P219, DOI 10.1016/S0162-3109(99)00020-X
   Blank M, 2001, J BIOL CHEM, V276, P16464, DOI 10.1074/jbc.M100347200
   Bruno JG, 1999, BIOSENS BIOELECTRON, V14, P457, DOI 10.1016/S0956-5663(99)00028-7
   Chan MY, 2008, J THROMB HAEMOST, V6, P789, DOI 10.1111/j.1538-7836.2008.02932.x
   Chan MY, 2008, CIRCULATION, V117, P2865, DOI 10.1161/CIRCULATIONAHA.107.745687
   Chu TC, 2006, NUCLEIC ACIDS RES, V34, DOI 10.1093/nar/gkl388
   Chu TC, 2006, CANCER RES, V66, P5989, DOI 10.1158/0008-5472.CAN-05-4583
   *CLIN TRIALS, ONG CLIN TRIAL INF
   Cosmi B, 2009, CURR OPIN MOL THER, V11, P322
   Csaky KG, 2004, EXP EYE RES, V78, P1107, DOI 10.1016/j.exer.2004.01.010
   de Groot JF, 2008, CANCER J, V14, P279, DOI 10.1097/PPO.0b013e3181867bd6
   DESMIDT PC, 1991, NUCLEIC ACIDS RES, V19, P4695, DOI 10.1093/nar/19.17.4695
   DIENER JL, 2007, Patent No. 07025049
   DIENER JL, 2009, Patent No. 20090149643
   Dua Pooja, 2008, Recent Pat DNA Gene Seq, V2, P172, DOI 10.2174/187221508786241710
   Dyke CK, 2006, CIRCULATION, V114, P2490, DOI 10.1161/CIRCULATIONAHA.106.668434
   ELLINGTON AD, 1990, NATURE, V346, P818, DOI 10.1038/346818a0
   EPSTEIN D, 2007, Patent No. 07103549
   Eulberg D, 2003, CHEMBIOCHEM, V4, P979, DOI 10.1002/cbic.200300663
   Farokhzad OC, 2004, CANCER RES, V64, P7668, DOI 10.1158/0008-5472.CAN-04-2550
   Farokhzad OC, 2006, P NATL ACAD SCI USA, V103, P6315, DOI 10.1073/pnas.0601755103
   Ferrara N, 2004, ENDOCR REV, V25, P581, DOI 10.1210/er.2003-0027
   FRIEBE M, 2008, Patent No. 08028534
   GILBERT J, 2004, Patent No. 08150495
   Gilbert JC, 2007, CIRCULATION, V116, P2678, DOI 10.1161/CIRCULATIONAHA.107.724864
   Girvan AC, 2006, MOL CANCER THER, V5, P1790, DOI 10.1158/1535-7163.MCT-05-0361
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   GREEN C, 2009, Patent No. 20090131351
   GREEN LS, 1995, CHEM BIOL, V2, P683, DOI 10.1016/1074-5521(95)90032-2
   Guo KT, 2006, STEM CELLS, V24, P2220, DOI 10.1634/stemcells.2006-0015
   Healy JM, 2004, PHARM RES-DORDR, V21, P2234, DOI 10.1007/s11095-004-7676-4
   HICKE B, 2006, Patent No. 20060105378
   Hicke BJ, 2006, J NUCL MED, V47, P668
   Ireson CR, 2006, MOL CANCER THER, V5, P2957, DOI 10.1158/1535-7163.MCT-06-0172
   Ishida S, 2003, INVEST OPHTH VIS SCI, V44, P2155, DOI 10.1167/iovs.02-0807
   JANJIC N, 2005, Patent No. 20040224915
   Jayasena SD, 1999, CLIN CHEM, V45, P1628
   JELLINEK D, 1994, BIOCHEMISTRY-US, V33, P10450, DOI 10.1021/bi00200a028
   Jo N, 2006, AM J PATHOL, V168, P2036, DOI 10.2353/ajpath.2006.050588
   KECK PJ, 1989, SCIENCE, V246, P1309, DOI 10.1126/science.2479987
   Keefe AD, 2008, CURR OPIN PHARMACOL, V8, P147, DOI 10.1016/j.coph.2007.12.005
   Lamoreaux WJ, 1998, MICROVASC RES, V55, P29, DOI 10.1006/mvre.1997.2056
   Lee JF, 2006, CURR OPIN CHEM BIOL, V10, P282, DOI 10.1016/j.cbpa.2006.03.015
   Lee JF, 2004, NUCLEIC ACIDS RES, V32, pD95, DOI 10.1093/nar/gkh094
   LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986
   Li N, 2009, J PROTEOME RES, V8, P2438, DOI 10.1021/pr801048z
   Lupold SE, 2002, CANCER RES, V62, P4029
   LUPOLD SE, 2005, Patent No. 20050158780
   Martin DF, 2002, RETINA-J RET VIT DIS, V22, P143
   McNamara JO, 2006, NAT BIOTECHNOL, V24, P1005, DOI 10.1038/nbt1223
   Mendonsa SD, 2004, ANAL CHEM, V76, P5387, DOI 10.1021/ac049857v
   Miyamoto K, 2000, AM J PATHOL, V156, P1733, DOI 10.1016/S0002-9440(10)65044-4
   Neryl AA, 2009, J SEP SCI, V32, P1523, DOI 10.1002/jssc.200800695
   Ng EWM, 2005, CAN J OPHTHALMOL, V40, P352, DOI 10.1016/S0008-4182(05)80078-X
   Ng EWM, 2006, NAT REV DRUG DISCOV, V5, P123, DOI 10.1038/nrd1955
   Nimjee SM, 2006, MOL THER, V14, P408, DOI 10.1016/j.ymthe.2006.04.006
   Ostendorf T, 2001, J AM SOC NEPHROL, V12, P909, DOI 10.1681/ASN.V125909
   Perry CM, 1999, DRUGS, V57, P375, DOI 10.2165/00003495-199957030-00010
   PIEKEN WA, 1991, SCIENCE, V253, P314, DOI 10.1126/science.1857967
   Pietras K, 2002, CANCER RES, V62, P5476
   PIETRAS K, 2007, Patent No. 20070021327
   PREISS JR, 2009, Patent No. 20090053138
   Ruckman J, 1998, J BIOL CHEM, V273, P20556, DOI 10.1074/jbc.273.32.20556
   Rusconi CP, 2002, NATURE, V419, P90, DOI 10.1038/nature00963
   RUSCONI CP, 2009, Patent No. 20090163437
   RUSCONI CP, 2009, Patent No. 20090048193
   RUSCONI CP, 2008, Patent No. 20080153769
   SENGER DR, 1983, SCIENCE, V219, P983, DOI 10.1126/science.6823562
   Sennino B, 2007, CANCER RES, V67, P7358, DOI 10.1158/0008-5472.CAN-07-0293
   Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101
   Song S, 2005, NAT CELL BIOL, V7, P870, DOI 10.1038/ncb1288
   SULLENGER BA, 2008, Patent No. 20080051339
   Teng Y, 2007, CANCER RES, V67, P10491, DOI 10.1158/0008-5472.CAN-06-4206
   TRENT JO, 2008, Patent No. 20080318890
   Trujillo CA, 2007, CLIN OPHTHALMOL, V1, P393
   Tucker CE, 1999, J CHROMATOGR B, V732, P203, DOI 10.1016/S0378-4347(99)00285-6
   TUERK C, 1990, SCIENCE, V249, P505, DOI 10.1126/science.2200121
   Ulrich H, 1998, P NATL ACAD SCI USA, V95, P14051, DOI 10.1073/pnas.95.24.14051
   Ulrich H, 2004, CYTOM PART A, V59A, P220, DOI 10.1002/cyto.a.20056
   Ulrich H, 2002, J BIOL CHEM, V277, P20756, DOI 10.1074/jbc.M111859200
   ULRICH H, 2009, CYTOM PART A, DOI DOI 10.1002/CYT0.A.20766
   Ulrich H, 2006, COMB CHEM HIGH T SCR, V9, P619, DOI 10.2174/138620706778249695
   Vivekananda J., 2003, US Patent, Patent No. [6569630, US 6569630 B1]
   Vogel CL, 2002, J CLIN ONCOL, V20, P719, DOI 10.1200/JCO.20.3.719
   Weiner GJ, 2007, IMMUNOL RES, V39, P271, DOI 10.1007/s12026-007-0073-4
   Yoshida Y, 2008, ANAL BIOCHEM, V375, P217, DOI 10.1016/j.ab.2008.01.005
   CATALOG ALL AVAILABL
NR 96
TC 21
Z9 24
U1 0
U2 18
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1354-3776
EI 1744-7674
J9 EXPERT OPIN THER PAT
JI Expert Opin. Ther. Patents
PD NOV
PY 2009
VL 19
IS 11
BP 1603
EP 1613
DI 10.1517/13543770903313746
PG 11
WC Chemistry, Medicinal; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA 520OF
UT WOS:000271854100006
PM 19852719
DA 2022-11-30
ER

PT J
AU Dougherty, TJ
AF Dougherty, TJ
TI An update on photodynamic therapy applications
SO JOURNAL OF CLINICAL LASER MEDICINE & SURGERY
LA English
DT Review
ID CANCER; HEAD
AB Photodynamic therapy (PDT), following health agency approvals throughout the world for various cancers and other diseases, is slowly being accepted as a standard treatment to be added to the medical practitioner's armamentarium. This includes palliative treatments such as for obstructive esophageal and lung cancers as well as those intended for cure, early stage lung cancer, and actinic keratoses. A particularly new and important application is for the treatment of age-related macular degeneration (AMD), where PDT (Visudyne) has made a major impact on the outcome of this disease, the major cause of blindness in those over the age of 50. In the cancer field, while not yet approved (pending), the use of PDT in treatment of high-grade dysplasia (HGD) in Barrett's esophagus may well change bow this disease is currently treated (often esophagectomy). Mechanistically, the recognition of apoptosis as an important mode of cell death following PDT and the critical role of the inflammatory process and immunity has only recently been recognized. This review updates the current and future role of PDT in cancer and other diseases.
C1 New York State Dept Hlth, Roswell Pk Canc Inst, Photodynam Therapy Ctr, Buffalo, NY 14263 USA.
C3 Roswell Park Cancer Institute
RP Dougherty, TJ (通讯作者)，New York State Dept Hlth, Roswell Pk Canc Inst, Photodynam Therapy Ctr, Elm & Carlton St, Buffalo, NY 14263 USA.
CR Biel MA, 1998, LARYNGOSCOPE, V108, P1259, DOI 10.1097/00005537-199809000-00001
   CHOW T, 2001, 8 WORLD C PHOT PHOT, P29
   Diaz-Jimenez JP, 1999, EUR RESPIR J, V14, P800, DOI 10.1034/j.1399-3003.1999.14d13.x
   Fan KFM, 1997, INT J CANCER, V73, P25
   GLUCKMAN JL, 1991, LARYNGOSCOPE, V101, P36
   GOLINICK S, 2001, 8 WORLD C PHOT PHOT, P45
   KARRER S, 2001, 8 WORLD C PHOT PHOT, P34
   Korbelik M, 1996, CANCER RES, V56, P5647
   Lam S, 1998, CHEST, V113, P696, DOI 10.1378/chest.113.3.696
   Lam S., 1998, P 34 ANN M AM SOC CL
   LIGHTDALE CJ, 1995, GASTROINTEST ENDOSC, V42, P507, DOI 10.1016/S0016-5107(95)70002-1
   METZ J, 2001, 8 WORLD C PHOT PHOT, P27
   Moskal TL, 1998, ANN THORAC SURG, V66, P1128, DOI 10.1016/S0003-4975(98)00799-1
   MULLER P, 2001, PROG BIOMED OPTICS I, V2, P34
   Muller P J, 1996, J Clin Laser Med Surg, V14, P263
   MULLER PJ, 1995, SEMIN SURG ONCOL, V11, P346, DOI 10.1002/ssu.2980110504
   Nseyo UO, 1998, J CLIN LASER MED SUR, V16, P61, DOI 10.1089/clm.1998.16.61
   Ortner MAEJ, 1998, GASTROENTEROLOGY, V114, P536, DOI 10.1016/S0016-5085(98)70537-2
   Overholt BF, 1999, GASTROINTEST ENDOSC, V49, P1, DOI 10.1016/S0016-5107(99)70437-2
   PASS HI, 1994, ANN SURG ONCOL, V1, P28, DOI 10.1007/BF02303538
   Popovic E A, 1996, J Clin Laser Med Surg, V14, P251
   RENNER I, 2001, 8 WORLD C PHOT PHOT, P28
   SHIEH S, 2002, 8 WORLD C PHOT PHOT, P36
   Tochner Z A, 1994, Cancer Treat Res, V70, P83
   *VERT PHOT THER ST, 2000, AM J OPHTHALMOL, V131, P541
NR 25
TC 482
Z9 522
U1 2
U2 94
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1044-5471
J9 J CLIN LASER MED SUR
JI J. Clin. Laser Med. Sur.
PD FEB
PY 2002
VL 20
IS 1
BP 3
EP 7
DI 10.1089/104454702753474931
PG 5
WC Engineering, Biomedical; Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Engineering; Surgery
GA 526EZ
UT WOS:000174118000002
PM 11902352
DA 2022-11-30
ER

PT J
AU Bao, A
   Nashine, S
   Atilano, S
   Chwa, M
   Federoff, H
   Kenney, MC
AF Bao, Andrea
   Nashine, Sonali
   Atilano, Shari
   Chwa, Marilyn
   Federoff, Howard
   Kenney, M. Cristina
TI Differential responses of AMD mitochondrial DNA haplogroups to PU-91, a
   mitochondria-targeting drug
SO MITOCHONDRION
LA English
DT Article
DE AMD; PU-91; Age-related macular degeneration; Mitochondrial DNA
   haplogroup
AB Mitochondrial DNA (mtDNA) dysfunction and variation in mtDNA haplogroups play a key role in the etiology of Age-related Macular Degeneration (AMD). This study examined the response(s) of AMD ARPE-19 transmitochondrial cybrids having U, K, and J mtDNA haplogroups to treatment with a mitochondria-targeting PU-91 drug. PU-91 exerts its cytoprotective effects by upregulating PGC-1 alpha (Peroxisome proliferator-activated receptorgamma coactivator (PGC)-1alpha) which is a primary regulator of the mitochondrial biogenesis pathway. The effects of PU-91 drug were determined using cell-based assays and gene expression analyses. Our study revealed that AMD cybrids with different mtDNA haplogroups i.e., U, K, J haplogroups respond differentially to PU-91 drug treatment; and that the PU-91 drug increases viable cell number, improves mitochondrial health, and protects AMD cybrids against oxidative stress across the board irrespective of their haplogroup variation. This study suggests that mtDNA haplogroups may contribute to the differential responses of AMD cybrid cells to PU91 drug in vitro and may also influence AMD patients' responses to drug treatment.
C1 [Bao, Andrea; Nashine, Sonali; Atilano, Shari; Chwa, Marilyn; Kenney, M. Cristina] Univ Calif Irvine, Gavin Herbert Eye Inst, Dept Ophthalmol, Irvine, CA 92697 USA.
   [Federoff, Howard] Univ Calif Irvine, Dept Neurol, Irvine, CA 92717 USA.
   [Kenney, M. Cristina] Univ Calif Irvine, Dept Pathol & Lab Med, Irvine, CA USA.
C3 University of California System; University of California Irvine;
   University of California System; University of California Irvine;
   University of California System; University of California Irvine
RP Kenney, MC (通讯作者)，Univ Calif Irvine, Gavin Herbert Eye Inst, Ophthalmol Res Lab, Hewitt Hall,Room 2028,843 Hlth Sci Rd, Irvine, CA 92697 USA.
EM mkenney@uci.edu
FU NEI [1R01EY027363]; Discovery Eye Foundation; Polly and Michael Smith;
   Roy and Edith Carver; Iris and B. Gerald Cantor Foundation; Research to
   Prevent Blindness; Institute for Clinical and Translational Science
   (ICTS) at UC Irvine
FX NEI grant - R01grant (1R01EY027363) (MCK) ; Discovery Eye Foundation,
   Polly and Michael Smith, Roy and Edith Carver, Iris and B. Gerald Cantor
   Foundation; Research was supported in part by an Un-restricted
   Departmental Grant from Research to Prevent Blindness. We acknowledge
   the support of the Institute for Clinical and Translational Science
   (ICTS) at UC Irvine.
CR Chinnery PF, 2018, FRONT NEUROSCI-SWITZ, V12, DOI 10.3389/fnins.2018.00682
   Gonzalez AM, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-124
   Kaarniranta K, 2020, PROG RETIN EYE RES, V79, DOI 10.1016/j.preteyeres.2020.100858
   Kaarniranta K, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19082317
   Kenney MC, 2013, BMC MED GENET, V14, DOI 10.1186/1471-2350-14-4
   Kenney MC, 2010, INVEST OPHTH VIS SCI, V51, P4289, DOI 10.1167/iovs.09-4778
   Li HZ, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8060608
   Li JM, 2015, J DIABETES RES, V2015, DOI 10.1155/2015/963289
   Mueller EE, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030874
   Nashine S, 2020, AGING-US, V12, P9031, DOI 10.18632/aging.103164
   Nashine S, 2020, NUTRIENTS, V12, DOI 10.3390/nu12010159
   Nashine S, 2019, AGING-US, V11, P6691, DOI 10.18632/aging.102179
   Nashine S, 2019, EXP EYE RES, V189, DOI 10.1016/j.exer.2019.107701
   Nashine S, 2019, AGING-US, V11, P1177, DOI 10.18632/aging.101820
   Nashine S, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-33290-5
   Nashine S, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.348
   Nashine S, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0159828
   Terluk MR, 2015, J NEUROSCI, V35, P7304, DOI 10.1523/JNEUROSCI.0190-15.2015
   Udar N, 2009, INVEST OPHTH VIS SCI, V50, P2966, DOI 10.1167/iovs.08-2646
   van Oven M, 2009, HUM MUTAT, V30, pE386, DOI 10.1002/humu.20921
   Zorov DB, 2014, PHYSIOL REV, V94, P909, DOI 10.1152/physrev.00026.2013
NR 22
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1567-7249
EI 1872-8278
J9 MITOCHONDRION
JI Mitochondrion
PD SEP
PY 2021
VL 60
BP 189
EP 200
DI 10.1016/j.mito.2021.08.010
EA SEP 2021
PG 12
WC Cell Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Genetics & Heredity
GA WB7GY
UT WOS:000703738800001
PM 34400356
DA 2022-11-30
ER

PT J
AU Gour, N
   Khanna, P
AF Gour, Neha
   Khanna, Pritee
TI Multi-class multi-label ophthalmological disease detection using
   transfer learning based convolutional neural network
SO BIOMEDICAL SIGNAL PROCESSING AND CONTROL
LA English
DT Article
DE Ophthalmological Disease Detection; Multi-class Classification;
   Multi-label Classification; Fundus Imaging; Convolutional Neural
   Networks
ID RETINAL IMAGES; RISK
AB Fundus imaging is a retinal image modality for capturing anatomical structures and abnormalities in the human eye. Fundus images are the primary tool for observation and detection of a wide range of ophthalmological diseases. Changes in and around the anatomical structures like blood vessels, optic disc, fovea, and macula indicate the presence of disease like diabetic retinopathy, glaucoma, age-related macular degeneration (AMD), myopia, hypertension, and cataract. The patient may be suffering from more than one ophthalmological disease observed in either or both the eyes. Two models are proposed for multi-class multi-label fundus images classification of ophthalmological diseases using transfer learning based convolutional neural network (CNN) approaches. Ocular Disease Intelligent Recognition (ODIR) database having fundus images of left and right eye of patients for eight categories is used for experimentation. Four different pre-trained CNN architectures with two different optimizers are used and it is observed that VGG16 pre-trained architecture with SGD optimizer performs better for multi-class multi-label fundus images classification on ODIR database.
C1 [Gour, Neha; Khanna, Pritee] PDPM Indian Inst Informat Technol Design & Mfg, Jabalpur, India.
C3 Indian Institute of Information Technology Design & Manufacturing,
   Jabalpur
RP Khanna, P (通讯作者)，PDPM Indian Inst Informat Technol Design & Mfg, Jabalpur, India.
EM pkhanna@iiitdmj.ac.in
RI Khanna, Pritee/V-5418-2019
OI Khanna, Pritee/0000-0003-0518-2133
CR Abramoff Michael D, 2010, IEEE Rev Biomed Eng, V3, P169, DOI 10.1109/RBME.2010.2084567
   Adam H., 2017, ARXIV170404861
   Almazroa A, 2018, PROC SPIE, V10579, DOI 10.1117/12.2293584
   Almazroa A, 2015, J OPHTHALMOL, V2015, DOI 10.1155/2015/180972
   Amin J, 2016, SCIENTIFICA, V2016, DOI 10.1155/2016/6838976
   [Anonymous], 2015, KAGGLE DIABETIC RETI
   [Anonymous], 2020, PEKING U INT COMPETI
   Bravo MA, 2017, PROC SPIE, V10572, DOI 10.1117/12.2285939
   Chen H., 2019, INT C MEDICAL IMAGIN, P109
   Chua TS., 2009, P ACM INT C IM VID R, P1, DOI DOI 10.1145/1646396.1646452
   Ciulla TA, 2003, DIABETES CARE, V26, P2653, DOI 10.2337/diacare.26.9.2653
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   Decenciere E, 2014, IMAGE ANAL STEREOL, V33, P231, DOI 10.5566/ias.1155
   Faes L, 2019, LANCET DIGIT HEALTH, V1, pE232, DOI 10.1016/S2589-7500(19)30108-6
   Fraz MM, 2012, COMPUT METH PROG BIO, V108, P407, DOI 10.1016/j.cmpb.2012.03.009
   Graham B., KAGGLE DIABETIC RETI
   He KM, 2016, PROC CVPR IEEE, P770, DOI 10.1109/CVPR.2016.90
   Heijl A, 2002, ARCH OPHTHALMOL-CHIC, V120, P1268, DOI 10.1001/archopht.120.10.1268
   Holm S, 2017, J MED IMAGING, V4, DOI 10.1117/1.JMI.4.1.014503
   Hoover A, 2000, IEEE T MED IMAGING, V19, P203, DOI 10.1109/42.845178
   Hubbard LD, 1999, OPHTHALMOLOGY, V106, P2269, DOI 10.1016/S0161-6420(99)90525-0
   Orlando JI, 2017, PROC SPIE, V10160, DOI 10.1117/12.2255740
   Islam Md Tariqul, 2019, 2019 IEEE International Conference on Signal Processing, Information, Communication & Systems (SPICSCON), P59, DOI 10.1109/SPICSCON48833.2019.9065162
   Jordi C.C., 2019, OCULAR DIS INTELLIGE, P1
   Kauppi T, 2007, DIARETDB1 DIABETIC R
   Ke RM, 2020, TRANSPORT RES REC, V2674, P459, DOI 10.1177/0361198120911052
   Koh J. E. W., 2017, APPL INTELL, P1
   Krizhevsky A., 2012, ADV NEURAL INF PROCE, P1097, DOI DOI 10.1145/3065386
   Lecun Y, 1998, P IEEE, V86, P2278, DOI 10.1109/5.726791
   Li C, 2020, I S BIOMED IMAGING, P1250, DOI 10.1109/ISBI45749.2020.9098340
   Lin TY, 2014, LECT NOTES COMPUT SC, V8693, P740, DOI 10.1007/978-3-319-10602-1_48
   Loog M., METHODS EVALUATING S
   Mateen M, 2019, SYMMETRY-BASEL, V11, DOI 10.3390/sym11010001
   Meng Q., 2019, AS C PATT REC, P469
   Ng A, NUTS BOLTS BUILDING
   Porwal P., 2020, **DATA OBJECT**, DOI [10.21227/H25W98, DOI 10.21227/H25W98]
   Reyes-Aldasoro d.C.C., ARXIV PREPRINT ARXIV
   SAHU S, 2019, HDB MULTIMEDIA INFOR, P359, DOI DOI 10.1007/978-3-030-15887-3_16
   Simonyan K., 2014, PREPRINT, DOI DOI 10.48550/ARXIV.1409.1556
   Sivaswamy J., 2015, JSM BIOMED IMAGING D, V2, P1004, DOI 10.1109/ISBI.2014.6867807
   Sun Y, 2017, J ELECTR COMPUT ENG, V2017, DOI 10.1155/2017/9240407
   Szegedy C, 2015, PROC CVPR IEEE, P1, DOI 10.1109/CVPR.2015.7298594
   Thakur N, 2018, ADV INTELL SYST, V562, P91, DOI 10.1007/978-981-10-4603-2_10
   TIELSCH JM, 1991, AM J EPIDEMIOL, V134, P1102, DOI 10.1093/oxfordjournals.aje.a116013
   Wong TY, 2004, BMJ-BRIT MED J, V329, P79, DOI 10.1136/bmj.38124.682523.55
   Wu N, 2020, IEEE T MED IMAGING, V39, P1184, DOI 10.1109/TMI.2019.2945514
   Yannuzzi LA, 2004, AM J OPHTHALMOL, V137, P511, DOI 10.1016/j.ajo.2003.12.035
   Zhang Z, 2010, IEEE ENG MED BIO, P3065, DOI 10.1109/IEMBS.2010.5626137
NR 48
TC 21
Z9 21
U1 6
U2 28
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1746-8094
EI 1746-8108
J9 BIOMED SIGNAL PROCES
JI Biomed. Signal Process. Control
PD APR
PY 2021
VL 66
AR 102329
DI 10.1016/j.bspc.2020.102329
EA MAR 2021
PG 8
WC Engineering, Biomedical
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Engineering
GA RH5DX
UT WOS:000636240200005
DA 2022-11-30
ER

PT J
AU Jiao, JH
   Yu, HH
   Yao, LT
   Li, LH
   Yang, XH
   Liu, L
AF Jiao, Jinghua
   Yu, Honghua
   Yao, Litong
   Li, Lihua
   Yang, Xiaohong
   Liu, Lei
TI Recent Insights into the Role of Gut Microbiota in Diabetic Retinopathy
SO JOURNAL OF INFLAMMATION RESEARCH
LA English
DT Review
DE retinopathy; bacteria; microbiota; microbiota-gut-retina axis; mechanism
ID MITOCHONDRIAL DAMAGE; RISK-FACTORS; RETINA AXIS; INFLAMMATION;
   ACTIVATION; MARKERS; OBESITY; ANGIOGENESIS; PREVALENCE; EXPRESSION
AB The microbiome has become a hot issue in recent years. The composition, modification, alteration, and disturbance of gut microbiota were found to influence important physiological processes, including energy metabolism and microenvironmental homeostasis, and lead to various diseases, including obesity, type 2 diabetes mellitus and chronic kidney disease. Diabetic retinopathy (DR) is a major microvascular complication of diabetes mellitus and one of the leading causes of blindness and vision impairment. The underlying mechanisms in DR pathogenesis remain limited. Recently, important insights have been made regarding possible connections between gut microbiome dysbiosis and ocular disease including DR, uveitis, glaucoma, and age-related macular degeneration, and the concept of a "microbiota-gut-retina axis" has been put forward. Hence, we reviewed current under-standing of the relationship between DR and gut microbiota. We summarized potential pathophysiological mechanisms that contribute to the role of the gut microbiota on DR, including hyperglycemia, anti-diabetes drugs, microbial metabolites, and inflammatory prop-erties. We aimed to find novel effective therapeutic options to prevent the onset and development of DR.
C1 [Jiao, Jinghua] Cent Hosp, Shenyang Med Coll, Dept Anesthesiol, Shenyang 110024, Liaoning, Peoples R China.
   [Yu, Honghua; Yang, Xiaohong; Liu, Lei] Guangdong Acad Med Sci, Guangdong Eye Inst, Guangdong Prov Peoples Hosp, Dept Ophthalmol, Guangzhou 510120, Guangdong, Peoples R China.
   [Yao, Litong] China Med Univ, Dept Breast Surg, Affiliated Hosp 1, Shenyang 110001, Liaoning, Peoples R China.
   [Li, Lihua] Weifang Med Univ, Dept Ophthalmol, Affiliated Hosp, Weifang 261031, Shandong, Peoples R China.
C3 Shenyang Medical College; Guangdong Academy of Medical Sciences &
   Guangdong General Hospital; China Medical University; Weifang Medical
   University
RP Yang, XH; Liu, L (通讯作者)，Guangdong Acad Med Sci, Guangdong Eye Inst, Guangdong Prov Peoples Hosp, Dept Ophthalmol, Guangzhou 510120, Guangdong, Peoples R China.
EM syyangxh@scut.edu.cn; liuleijiao@163.com
FU Science and Technology Program of Guangzhou, China [202002020049];
   Project of Special Research on Cardiovascular Diseases [2020XXG007];
   National Natural Science Foundation of China [81300783, 82003882]; China
   Postdoctoral Science Foundation [2019TQ0358, 2019M661162]; Liaoning
   Revitalization Talents Program [XLYC1807082]; Shenyang Young and
   Middle-aged Science and Technology Innovation Talent Support Program
   [RC190146]
FX This work was supported by the Science and Technology Program of
   Guangzhou, China (No. 202002020049), Project of Special Research on
   Cardiovascular Diseases (No. 2020XXG007), National Natural Science
   Foundation of China (No. 81300783; 82003882), China Postdoctoral Science
   Foundation (No. 2019TQ0358; 2019M661162), Liaoning Revitalization
   Talents Program (No. XLYC1807082), Shenyang Young and Middle-aged
   Science and Technology Innovation Talent Support Program (grant number
   RC190146). The funders had no role in the design and conduct of the
   study; the collection, management, analysis, interpretation of the data;
   the pre-paration, review, or approval of the manuscript; or the decision
   to submit the manuscript for publication.
CR Abdel-Latif RG, 2018, N-S ARCH PHARMACOL, V391, P705, DOI 10.1007/s00210-018-1497-1
   Abdulaal M, 2016, SEMIN OPHTHALMOL, V31, P19, DOI 10.3109/08820538.2015.1114829
   Aiello LP, 2014, DIABETES CARE, V37, P17, DOI 10.2337/dc13-2251
   Al-Obaide MAI, 2017, J CLIN MED, V6, DOI 10.3390/jcm6090086
   Al-ofi EA, 2017, J REPROD IMMUNOL, V121, P26, DOI 10.1016/j.jri.2017.05.002
   Andriessen EMMA, 2016, EMBO MOL MED, V8, P1366, DOI 10.15252/emmm.201606531
   Antonetti DA, 2012, NEW ENGL J MED, V366, P1227, DOI 10.1056/NEJMra1005073
   Aoki A, 2016, SCI REP-UK, V6, DOI 10.1038/srep20723
   Behar-Cohen F, 2019, DRUG DISCOV TODAY, V24, P1436, DOI 10.1016/j.drudis.2019.05.034
   Beli E, 2018, DIABETES, V67, P1867, DOI 10.2337/db18-0158
   Boini KM, 2017, CELL PHYSIOL BIOCHEM, V44, P152, DOI 10.1159/000484623
   Braakhuis Andrea, 2017, Diseases, V5, DOI 10.3390/diseases5010003
   Cai XS, 2017, INT J MED SCI, V14, P1203, DOI 10.7150/ijms.20962
   Campo GM, 2010, BIOCHIMIE, V92, P204, DOI 10.1016/j.biochi.2009.10.006
   Cecilia OM, 2019, J DIABETES RES, V2019, DOI 10.1155/2019/8562408
   Chaiwiang N, 2019, ACTA MICROBIOL IMM H, V66, P541, DOI 10.1556/030.66.2019.038
   Chelakkot C, 2018, EXP MOL MED, V50, DOI 10.1038/emm.2017.282
   Chen H, 2018, INVEST OPHTH VIS SCI, V59, P978, DOI 10.1167/iovs.17-22816
   Chen ML, 2017, J AM HEART ASSOC, V6, DOI 10.1161/JAHA.117.006347
   Chen W, 2017, INFLAMM RES, V66, P157, DOI 10.1007/s00011-016-1002-6
   Cheung N, 2010, LANCET, V376, P124, DOI 10.1016/S0140-6736(09)62124-3
   CUMMINGS JH, 1987, GUT, V28, P1221, DOI 10.1136/gut.28.10.1221
   Cvitkovic K, 2020, SEMIN OPHTHALMOL, V35, P126, DOI 10.1080/08820538.2020.1755320
   Das T, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-82538-0
   de Groot P, 2021, GUT, V70, P92, DOI [10.1136/gutjnl-2020-323252, 10.1136/gutjnl-2020-322630]
   Egshatyan L, 2016, ENDOCR CONNECT, V5, P1, DOI 10.1530/EC-15-0094
   Gerstein HC, 2013, LANCET DIABETES ENDO, V1, P71, DOI 10.1016/S2213-8587(13)70025-1
   Goncalves A, 2016, INVEST OPHTH VIS SCI, V57, P2584, DOI 10.1167/iovs.15-19006
   Gronbeck KR, 2016, NEUROCRIT CARE, V25, P153, DOI 10.1007/s12028-015-0225-7
   Gu RP, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00331
   Hachana S, 2020, BRIT J PHARMACOL, V177, P1949, DOI 10.1111/bph.14962
   Hammond BR, 2014, INVEST OPHTH VIS SCI, V55, P8583, DOI 10.1167/iovs.14-15573
   Han J, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0193031
   Hayes AJ, 2013, DIABETOLOGIA, V56, P1925, DOI 10.1007/s00125-013-2940-y
   Herat LY, 2020, WORLD J GASTROENTERO, V26, DOI 10.3748/wjg.v26.i23.3225
   Huang YH, 2021, FRONT CELL INFECT MI, V11, DOI 10.3389/fcimb.2021.646348
   Karpova T, 2020, LIFE SCI, V245, DOI 10.1016/j.lfs.2020.117365
   Khangwal I, 2019, APPL MICROBIOL BIOT, V103, P3615, DOI 10.1007/s00253-019-09727-w
   Kim EJ, 2019, CURR DIABETES REP, V19, DOI 10.1007/s11892-019-1188-4
   Kowluru RA, 2015, BBA-MOL BASIS DIS, V1852, P2474, DOI 10.1016/j.bbadis.2015.08.001
   Kowluru RA, 2014, DIABETOLOGIA, V57, P1047, DOI 10.1007/s00125-014-3194-z
   Larsen N, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009085
   Layoun A, 2012, INFLAMMATION, V35, P1500, DOI 10.1007/s10753-012-9463-4
   Li J, 2017, MICROBIOME, V5, DOI 10.1186/s40168-016-0222-x
   Li Y, 2018, J DIABETES RES, V2018, DOI [10.1155/2018/2801450, 10.1155/2018/2801150]
   Liu QP, 2018, MOL CELL BIOCHEM, V445, P105, DOI 10.1007/s11010-017-3256-x
   Liu RX, 2017, NAT MED, V23, P859, DOI 10.1038/nm.4358
   Loukovaara S, 2017, ACTA OPHTHALMOL, V95, P803, DOI 10.1111/aos.13427
   Luo R, 2020, INFLAMM RES, V69, P255, DOI 10.1007/s00011-019-01312-1
   Maniadakis N, 2019, PHARMACOECONOMICS, V37, P995, DOI 10.1007/s40273-019-00800-w
   Mitamura Y, 2003, DIABETOLOGIA, V46, P699, DOI 10.1007/s00125-003-1084-x
   Mohammad G, 2019, MOL NEUROBIOL, V56, P8643, DOI 10.1007/s12035-019-01696-5
   Moubayed NMS, 2019, MICROB PATHOGENESIS, V129, P88, DOI 10.1016/j.micpath.2019.01.025
   Munipally PK, 2011, ARCH PHYSIOL BIOCHEM, V117, P254, DOI 10.3109/13813455.2011.623705
   Nadeem U., 2020, HIGH THROUGHPUT RNA, DOI [10.1101/2020.10.01.318949, DOI 10.1101/2020.10.01.318949]
   Niimi N, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22031031
   Nowinski A, 2018, NUTRITION, V46, P7, DOI 10.1016/j.nut.2017.08.001
   Ogura S, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.90905
   Ouyang H, 2018, EUR J PHARMACOL, V840, P20, DOI 10.1016/j.ejphar.2018.09.027
   Peng JN, 2019, FRONT CELL INFECT MI, V9, DOI 10.3389/fcimb.2019.00204
   Rajamani U, 2014, J DIABETES RES, V2014, DOI 10.1155/2014/790902
   Rinninella E, 2018, NUTRIENTS, V10, DOI 10.3390/nu10111677
   Rizk P, 2012, WIRES SYST BIOL MED, V4, P475, DOI 10.1002/wsbm.1176
   Rizzo G, 2010, MOL PHARMACOL, V78, P617, DOI 10.1124/mol.110.064501
   Rowan S, 2017, P NATL ACAD SCI USA, V114, pE4472, DOI 10.1073/pnas.1702302114
   Sahajpal N, 2019, J CLIN MED, V8, DOI 10.3390/jcm8070965
   Salarolli RT, 2021, INT UROL NEPHROL, V53, P1231, DOI 10.1007/s11255-020-02760-z
   Sapieha P, 2008, NAT MED, V14, P1067, DOI 10.1038/nm.1873
   Sayed KM, 2016, ACTA OPHTHALMOL, V94, pe361, DOI 10.1111/aos.12919
   Schoeler M, 2019, REV ENDOCR METAB DIS, V20, P461, DOI 10.1007/s11154-019-09512-0
   Scirocco A, 2016, J CELL PHYSIOL, V231, P295, DOI 10.1002/jcp.25105
   Shang JJ, 2021, PEERJ, V9, DOI 10.7717/peerj.11128
   Sharma A, 2017, DEV OPHTHALMOL, V60, P56, DOI 10.1159/000459690
   Singh V, 2016, CURR OPIN PHARMACOL, V27, P8, DOI 10.1016/j.coph.2016.01.002
   Sohail MU, 2017, J DIABETES RES, V2017, DOI 10.1155/2017/9631435
   Souied EH, 2013, OPHTHALMOLOGY, V120, P1619, DOI 10.1016/j.ophtha.2013.01.005
   Spilsbury K, 2000, AM J PATHOL, V157, P135, DOI 10.1016/S0002-9440(10)64525-7
   Kuwabara WMT, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-35809-2
   Turnbaugh PJ, 2009, NATURE, V457, P480, DOI 10.1038/nature07540
   Vagaja NN, 2013, BRIT J OPHTHALMOL, V97, P1343, DOI 10.1136/bjophthalmol-2013-303201
   Verma A, 2019, MOL THER-METH CLIN D, V14, P161, DOI 10.1016/j.omtm.2019.06.007
   Virgili G, 2018, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007419.pub6
   Wang M, 2019, DIABETOLOGIA, V62, P335, DOI 10.1007/s00125-018-4755-3
   Wang P, 2019, MEDIAT INFLAMM, V2019, DOI 10.1155/2019/8908960
   Wang S, 2020, IUBMB LIFE, V72, P1433, DOI 10.1002/iub.2267
   Wang XXX, 2018, J AM SOC NEPHROL, V29, P118, DOI 10.1681/ASN.2017020222
   Wang YX, 2018, HORM METAB RES, V50, P704, DOI 10.1055/a-0664-0699
   Wong TY, 2016, NAT REV DIS PRIMERS, V2, DOI 10.1038/nrdp.2016.12
   Wu H, 2017, NAT MED, V23, P850, DOI 10.1038/nm.4345
   Wu M, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.00223
   Yamaguchi Y, 2016, DIGESTION, V94, P66, DOI 10.1159/000447690
   Yang CY, 2021, CELLS-BASEL, V10, DOI 10.3390/cells10010114
   Yau JWY, 2012, DIABETES CARE, V35, P556, DOI 10.2337/dc11-1909
   Yu YB, 2018, HYPERTENS RES, V41, P1036, DOI 10.1038/s41440-018-0110-9
   Zaman Gaffar Sarwar, 2015, J Nat Sci Biol Med, V6, P89, DOI 10.4103/0976-9668.149098
   Zhang GH, 2017, BRIT J OPHTHALMOL, V101, P1591, DOI 10.1136/bjophthalmol-2017-310316
   Zhang L, 2018, PATHOG DIS, V76, DOI 10.1093/femspd/fty028
   Zhang QY, 2016, INVEST OPHTH VIS SCI, V57, P1276, DOI 10.1167/iovs.15-18637
   Zhao LJ, 2019, ENDOCRINE, V66, P526, DOI 10.1007/s12020-019-02103-8
   Zhao LP, 2018, SCIENCE, V359, P1151, DOI 10.1126/science.aao5774
   Zhou H, 2020, DNA CELL BIOL, V39, P441, DOI 10.1089/dna.2019.4942
   Zhu LL, 2020, LIPIDS HEALTH DIS, V19, DOI 10.1186/s12944-019-1167-4
   Zinkernagel MS, 2017, SCI REP-UK, V7, DOI 10.1038/srep40826
NR 103
TC 4
Z9 4
U1 2
U2 4
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
EI 1178-7031
J9 J INFLAMM RES
JI J. Inflamm. Res.
PY 2021
VL 14
BP 6929
EP 6938
DI 10.2147/JIR.S336148
PG 10
WC Immunology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Immunology
GA XT5QH
UT WOS:000733641500002
PM 34938095
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Han, SX
   Chen, JJ
   Hua, JJ
   Hu, XJ
   Jian, SH
   Zheng, GX
   Wang, J
   Li, HR
   Yang, JL
   Hejtmancik, JF
   Qu, J
   Ma, XY
   Hou, L
AF Han, Shuxian
   Chen, Jianjun
   Hua, Jiajia
   Hu, Xiaojuan
   Jian, Shuhui
   Zheng, Guoxiao
   Wang, Jing
   Li, Huirong
   Yang, Jinglei
   Hejtmancik, J. Fielding
   Qu, Jia
   Ma, Xiaoyin
   Hou, Ling
TI MITF protects against oxidative damage-induced retinal degeneration by
   regulating the NRF2 pathway in the retinal pigment epithelium
SO REDOX BIOLOGY
LA English
DT Article
DE Antioxidant; Retinal degeneration; NRF2; RPE; MITF
ID TRANSCRIPTION FACTOR NRF2; MICROPHTHALMIA; CELLS; MUTATIONS; RPE;
   STRESS; NEURODEGENERATION; PREDISPOSES; MELANOCYTES; AUTOPHAGY
AB Oxidative damage is one of the major contributors to retinal degenerative diseases such as age -related macular degeneration (AMD), while RPE mediated antioxidant defense plays an important role in preventing re-tinopathies. However, the regulatory mechanisms of antioxidant signaling in RPE cells are poorly understood. Here we show that transcription factor MITF regulates the antioxidant response in RPE cells, protecting the neural retina from oxidative damage. In the oxidative stress -induced retinal degeneration mouse model, retinal degeneration in Mitf+/- mice is signi ficantly aggravated compared to WT mice. In contrast, overexpression of Mitf in Dct-Mitf transgenic mice and AAV mediated overexpression in RPE cells protect the neural retina against oxidative damage. Mechanistically, MITF both directly regulates the transcription of NRF2, a master regulator of antioxidant signaling, and promotes its nuclear translocation. Furthermore, speci fic overexpression of NRF2 in Mitf+/- RPE cells activates antioxidant signaling and partially protects the retina from oxidative damage. Taken together, our findings demonstrate the regulation of NRF2 by MITF in RPE cells and provide new insights into potential therapeutic approaches for prevention of oxidative damage diseases.
C1 [Han, Shuxian; Hua, Jiajia; Hu, Xiaojuan; Jian, Shuhui; Zheng, Guoxiao; Wang, Jing; Li, Huirong; Ma, Xiaoyin; Hou, Ling] Wenzhou Med Univ, Sch Ophthalmol & Optometry, Lab Dev Cell Biol & Dis, Wenzhou, Peoples R China.
   [Han, Shuxian; Hua, Jiajia; Hu, Xiaojuan; Jian, Shuhui; Zheng, Guoxiao; Wang, Jing; Li, Huirong; Ma, Xiaoyin; Hou, Ling] Wenzhou Med Univ, Eye Hosp, Wenzhou, Peoples R China.
   [Han, Shuxian; Wang, Jing; Li, Huirong; Yang, Jinglei; Qu, Jia; Ma, Xiaoyin; Hou, Ling] Wenzhou Med Univ, State Key Lab Cultivat Base, Minist Hlth, Wenzhou 325003, Peoples R China.
   [Han, Shuxian; Wang, Jing; Li, Huirong; Yang, Jinglei; Qu, Jia; Ma, Xiaoyin; Hou, Ling] Wenzhou Med Univ, Minist Hlth, Key Lab Vis Sci, Wenzhou 325003, Peoples R China.
   [Han, Shuxian; Wang, Jing; Li, Huirong; Yang, Jinglei; Qu, Jia; Ma, Xiaoyin; Hou, Ling] Wenzhou Med Univ, Zhejiang Prov Key Lab Ophthalmol, Wenzhou 325003, Peoples R China.
   [Chen, Jianjun] Tongji Univ, Shanghai Peoples Hosp 4, Translat Res Inst Brain & Brain Intelligence, Birth Defect Grp,Sch Med, Shanghai 200081, Peoples R China.
   [Hua, Jiajia] Jining Med Univ, Affiliated Hosp, Dept Ophthalmol, Jining 272029, Shandong, Peoples R China.
   [Hejtmancik, J. Fielding] NEI, Ophthalm Genet & Visual Funct Branch, NIH, Bethesda, MD 20892 USA.
C3 Wenzhou Medical University; Wenzhou Medical University; Wenzhou Medical
   University; Wenzhou Medical University; Wenzhou Medical University;
   Tongji University; Jining Medical University; National Institutes of
   Health (NIH) - USA; NIH National Eye Institute (NEI)
RP Ma, XY (通讯作者)，Wenzhou Med Univ, Sch Ophthalmol & Optometry, Lab Dev Cell Biol & Dis, Wenzhou, Peoples R China.; Ma, XY (通讯作者)，Wenzhou Med Univ, Eye Hosp, Wenzhou, Peoples R China.; Qu, J (通讯作者)，Wenzhou Med Univ, State Key Lab Cultivat Base, Minist Hlth, Wenzhou 325003, Peoples R China.; Qu, J (通讯作者)，Wenzhou Med Univ, Minist Hlth, Key Lab Vis Sci, Wenzhou 325003, Peoples R China.; Qu, J (通讯作者)，Wenzhou Med Univ, Zhejiang Prov Key Lab Ophthalmol, Wenzhou 325003, Peoples R China.
EM jqu@wz.zj.cn; xyma2015@wmu.edu.cn
RI hua, jiajia/GVT-5178-2022
OI Hou, Ling/0000-0003-0705-8099; Hua, Jiajia/0000-0002-9152-7013; Ma,
   Xiaoyin/0000-0002-3564-1647
FU National Natural Science Foundation of China [81870664, 81770946,
   81570892, 81600748, 81800838]; Research Grant of Wenzhou Medical
   University Eye Hospital [KYQD151211, YNZD201605]; Project of State Key
   Laboratory of Ophthalmology, Optometry and Visual Science, Wenzhou
   Medical University [437201804G]
FX We would like to thank NIH Dr. Heinz Arnheiter and University of
   Maryland School of Medicine Dr. Thomas J. Hornyak for providing Mitf
   mi-vga9 mutant mice, plasmids and reagents. This work is supported by
   the National Natural Science Foundation of China (81870664, 81770946,
   81570892, 81600748 and 81800838), the Research Grant of Wenzhou Medical
   University Eye Hospital (KYQD151211, YNZD201605). This study was also
   supported by the Project of State Key Laboratory of Ophthalmology,
   Optometry and Visual Science, Wenzhou Medical University (437201804G).
CR Adijanto J, 2012, J BIOL CHEM, V287, P20491, DOI 10.1074/jbc.M112.354761
   Arjunan P, 2018, P NATL ACAD SCI USA, V115, P10351, DOI 10.1073/pnas.1801379115
   Baldelli S, 2013, BBA-GEN SUBJECTS, V1830, P4137, DOI 10.1016/j.bbagen.2013.04.006
   Bertolotto C, 2011, NATURE, V480, P94, DOI 10.1038/nature10539
   Bharti K, 2006, PIGM CELL RES, V19, P380, DOI 10.1111/j.1600-0749.2006.00318.x
   Bharti K, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002757
   Biswal MR, 2017, INVEST OPHTH VIS SCI, V58, DOI 10.1167/iovs.16-21272
   Blasiak J, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20010210
   Chen CM, 2018, INT J APPL METAHEUR, V9, P1, DOI 10.4018/IJAMC.2018070101
   Chen Y, 2019, DIS MODEL MECH, V12, DOI 10.1242/dmm.035642
   Datta S, 2017, PROG RETIN EYE RES, V60, P201, DOI 10.1016/j.preteyeres.2017.03.002
   Dias MF, 2018, PROG RETIN EYE RES, V63, P107, DOI 10.1016/j.preteyeres.2017.10.004
   Egger A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031272
   Enzmann V, 2006, EXP EYE RES, V82, P441, DOI 10.1016/j.exer.2005.08.002
   Fan YT, 2018, ARCH BIOCHEM BIOPHYS, V650, P1, DOI 10.1016/j.abb.2018.05.008
   Felszeghy S, 2019, REDOX BIOL, V20, P1, DOI 10.1016/j.redox.2018.09.011
   Garcia-Llorca A, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-51819-0
   Garcia-Ramirez M, 2011, CELL SIGNAL, V23, P1596, DOI 10.1016/j.cellsig.2011.05.011
   Ge ZD, 2019, INT HEART J, V60, P512, DOI 10.1536/ihj.18-476
   George A, 2016, AM J HUM GENET, V99, P1388, DOI 10.1016/j.ajhg.2016.11.004
   Gleyzer N, 2005, MOL CELL BIOL, V25, P1354, DOI 10.1128/MCB.25.4.1354-1366.2005
   Gong LL, 2018, P NATL ACAD SCI USA, V115, pE3987, DOI 10.1073/pnas.1715237115
   Hartong DT, 2006, LANCET, V368, P1795, DOI 10.1016/S0140-6736(06)69740-7
   HODGKINSON CA, 1993, CELL, V74, P395, DOI 10.1016/0092-8674(93)90429-T
   Hua JJ, 2018, EXP EYE RES, V170, P138, DOI 10.1016/j.exer.2018.02.023
   Hyttinen JMT, 2017, AGEING RES REV, V36, P64, DOI 10.1016/j.arr.2017.03.006
   Ichimura Y, 2013, MOL CELL, V51, P618, DOI 10.1016/j.molcel.2013.08.003
   Jadeja R.N., 2019, REDOX BIOL, V28
   Jaramillo MC, 2013, GENE DEV, V27, P2179, DOI 10.1101/gad.225680.113
   Kensler TW, 2007, ANNU REV PHARMACOL, V47, P89, DOI 10.1146/annurev.pharmtox.46.120604.141046
   Khandhadia S, 2010, EXPERT REV MOL MED, V12, DOI 10.1017/S146239941000164X
   Klettner Alexa, 2012, Front Biosci (Schol Ed), V4, P392
   Komatsu M, 2010, NAT CELL BIOL, V12, P213, DOI 10.1038/ncb2021
   Kong SS, 2013, CELL RES, V23, P835, DOI 10.1038/cr.2013.59
   Le Meur G, 2018, MOL THER, V26, P256, DOI 10.1016/j.ymthe.2017.09.014
   Li L, 2017, INVEST OPHTH VIS SCI, V58, P2218, DOI 10.1167/iovs.17-21424
   Liao RF, 2018, BRIT J PHARMACOL, V175, P125, DOI 10.1111/bph.14078
   Liu F, 2009, J INVEST DERMATOL, V129, P422, DOI 10.1038/jid.2008.255
   Lobanova ES, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04117-8
   Ma XY, 2019, PROG RETIN EYE RES, V73, DOI 10.1016/j.preteyeres.2019.06.002
   Ma XY, 2018, PIGM CELL MELANOMA R, V31, P411, DOI 10.1111/pcmr.12676
   Ma XY, 2012, EXP CELL RES, V318, P251, DOI 10.1016/j.yexcr.2011.11.002
   Michael HT, 2018, INVEST OPHTH VIS SCI, V59, P6067, DOI 10.1167/iovs.18-25186
   Mitsuishi Y, 2012, CANCER CELL, V22, P66, DOI 10.1016/j.ccr.2012.05.016
   Nakayama A, 1998, MECH DEVELOP, V70, P155, DOI 10.1016/S0925-4773(97)00188-3
   Paladino S, 2018, CELL PHYSIOL BIOCHEM, V47, P1951, DOI 10.1159/000491465
   Phelep A, 2017, PLOS GENET, V13, DOI 10.1371/journal.pgen.1007093
   Rosales M.A.B., 2019, LIFE SCI ALLIANCE, V2
   Sachdeva MM, 2014, EXP EYE RES, V119, P111, DOI 10.1016/j.exer.2013.10.024
   Saito Y, 2018, REDOX BIOL, V19, P354, DOI 10.1016/j.redox.2018.09.004
   Salazar G, 2020, AUTOPHAGY, V16, P1092, DOI 10.1080/15548627.2019.1659612
   Schmidlin CJ, 2019, FREE RADICAL BIO MED, V134, P702, DOI 10.1016/j.freeradbiomed.2019.01.016
   Shi Q, 2016, CELL DEATH DIFFER, V23, P496, DOI 10.1038/cdd.2015.117
   Simo R, 2010, J BIOMED BIOTECHNOL, DOI 10.1155/2010/190724
   SMITH LEH, 1994, INVEST OPHTH VIS SCI, V35, P101
   SMITH SB, 1995, EXP EYE RES, V60, P91, DOI 10.1016/S0014-4835(05)80086-7
   St-Pierre J, 2006, CELL, V127, P397, DOI 10.1016/j.cell.2006.09.024
   Steingrimsson E, 2003, GENETICS, V163, P267
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Strub T, 2011, ONCOGENE, V30, P2319, DOI 10.1038/onc.2010.612
   TASSABEHJI M, 1994, NAT GENET, V8, P251, DOI 10.1038/ng1194-251
   TASSABEHJI M, 1995, HUM MOL GENET, V4, P2131, DOI 10.1093/hmg/4.11.2131
   Tebay LE, 2015, FREE RADICAL BIO MED, V88, P108, DOI 10.1016/j.freeradbiomed.2015.06.021
   Tshori S, 2006, J CLIN INVEST, V116, P2673, DOI 10.1172/JCI27643
   Wen B, 2016, SCI REP-UK, V6, DOI 10.1038/srep21208
   Xiong WJ, 2015, J CLIN INVEST, V125, P1433, DOI 10.1172/JCI79735
   Yamawaki K, 2018, TOXICOL APPL PHARM, V360, P30, DOI 10.1016/j.taap.2018.09.030
   Yang YP, 2014, INVEST OPHTH VIS SCI, V55, P1696, DOI 10.1167/iovs.13-12477
   Yokoyama S, 2011, NATURE, V480, P99, DOI 10.1038/nature10630
   Yu DY, 2005, EXP EYE RES, V80, P745, DOI 10.1016/j.exer.2005.01.018
   Zhang Z, 2018, MOL MED REP, V17, P6054, DOI 10.3892/mmr.2018.8627
   Zhao ZY, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019456
NR 72
TC 9
Z9 10
U1 5
U2 20
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 2213-2317
J9 REDOX BIOL
JI Redox Biol.
PD JUL
PY 2020
VL 34
AR 101537
DI 10.1016/j.redox.2020.101537
PG 14
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA ME8MS
UT WOS:000544908000005
PM 32361183
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Reyes, AP
   Petrus-Reurer, S
   Sanchez, SP
   Kumar, P
   Douagi, I
   Bartuma, H
   Aronsson, M
   Westman, S
   Lardner, E
   Andre, H
   Falk, A
   Nandrot, EF
   Kvanta, A
   Lanner, F
AF Reyes, Alvaro Plaza
   Petrus-Reurer, Sandra
   Sanchez, Sara Padrell
   Kumar, Pankaj
   Douagi, Iyadh
   Bartuma, Hammurabi
   Aronsson, Monica
   Westman, Sofie
   Lardner, Emma
   Andre, Helder
   Falk, Anna
   Nandrot, Emeline F.
   Kvanta, Anders
   Lanner, Fredrik
TI Identification of cell surface markers and establishment of monolayer
   differentiation to retinal pigment epithelial cells
SO NATURE COMMUNICATIONS
LA English
DT Article
ID PLURIPOTENT STEM-CELLS; MACULAR DEGENERATION; XENO-FREE; DIRECTED
   DIFFERENTIATION; EYE DEVELOPMENT; EXPRESSION; DERIVATION
AB In vitro differentiation of human pluripotent stem cells into functional retinal pigment epithelial (RPE) cells provides a potentially unlimited source for cell based reparative therapy of age-related macular degeneration. Although the inherent pigmentation of the RPE cells have been useful to grossly evaluate differentiation efficiency and allowed manual isolation of pigmented structures, accurate quantification and automated isolation has been challenging. To address this issue, here we perform a comprehensive antibody screening and identify cell surface markers for RPE cells. We show that these markers can be used to isolate RPE cells during in vitro differentiation and to track, quantify and improve differentiation efficiency. Finally, these surface markers aided to develop a robust, direct and scalable monolayer differentiation protocol on human recombinant laminin-111 and -521 without the need for manual isolation. Whilst pigmentation has been used to identify retinal pigment epithelial (RPE) cells, surface markers for these cells remain unclear. Here, the authors define surface markers for the RPE including CD140b, which help produce hPSC-derived RPE cells at a large scale following a robust, direct and scalable monolayer differentiation protocol.
C1 [Reyes, Alvaro Plaza; Petrus-Reurer, Sandra; Sanchez, Sara Padrell; Kumar, Pankaj; Lanner, Fredrik] Karolinska Inst, Dept Clin Sci Intervent & Technol, Stockholm, Sweden.
   [Reyes, Alvaro Plaza; Petrus-Reurer, Sandra; Sanchez, Sara Padrell; Kumar, Pankaj; Lanner, Fredrik] Karolinska Inst, Ming Wai Lau Ctr Reparat Med, Stockholm Node, Stockholm, Sweden.
   [Reyes, Alvaro Plaza; Petrus-Reurer, Sandra; Sanchez, Sara Padrell; Kumar, Pankaj; Lanner, Fredrik] Karolinska Univ Sjukhuset, Div Obstet & Gynecol, Stockholm, Sweden.
   [Petrus-Reurer, Sandra; Bartuma, Hammurabi; Aronsson, Monica; Westman, Sofie; Lardner, Emma; Andre, Helder; Kvanta, Anders] St Erik Eye Hosp, Karolinska Inst, Dept Clin Neurosci, Div Eye & Vis, Stockholm, Sweden.
   [Douagi, Iyadh] Karolinska Inst, Ctr Hematol & Regenerat Med, Dept Med, Stockholm, Sweden.
   [Falk, Anna] Karolinska Inst, Dept Neurosci, Stockholm, Sweden.
   [Nandrot, Emeline F.] Sorbonne Univ, Inst Vis, CNRS, INSERM, F-75012 Paris, France.
C3 Karolinska Institutet; Karolinska Institutet; Karolinska Institutet;
   Karolinska Institutet; Karolinska Institutet; Centre National de la
   Recherche Scientifique (CNRS); Institut National de la Sante et de la
   Recherche Medicale (Inserm); UDICE-French Research Universities;
   Sorbonne Universite; Universite Paris Cite
RP Lanner, F (通讯作者)，Karolinska Inst, Dept Clin Sci Intervent & Technol, Stockholm, Sweden.; Lanner, F (通讯作者)，Karolinska Inst, Ming Wai Lau Ctr Reparat Med, Stockholm Node, Stockholm, Sweden.; Lanner, F (通讯作者)，Karolinska Univ Sjukhuset, Div Obstet & Gynecol, Stockholm, Sweden.
EM Fredrik.Lanner@ki.se
RI Plaza Reyes, Alvaro/AAC-1723-2022; Falk, Anna/GWV-1616-2022; Reyes,
   Alvaro Plaza/AAX-7992-2020
OI Reyes, Alvaro Plaza/0000-0003-1167-6316; Douagi,
   Iyadh/0000-0002-3221-8667; Lanner, Fredrik/0000-0002-2771-7445;
   Petrus-Reurer, Sandra/0000-0002-7051-1741; KUMAR,
   PANKAJ/0000-0002-8411-1634; Andre, Helder/0000-0002-2926-2376; Nandrot,
   Emeline/0000-0003-3087-078X
FU Ming Wai Lau Center for Reparative Medicine; Centre for Innovative
   Medicine; Swedish Research Council; Ragnar Soderberg Foundation;
   Stockholm County Council (ALF project); Karolinska Institute;
   Ogonfonden; Cronqvist Foundation; Strategic Research Area (SRA) Stem
   Cells and Regenerative Medicine, Crown Princess Margareta's Foundation
   for the Visually Impaired; Ulla och Ingemar Dahlberg Foundation; King
   Gustav V and Queen Victoria Foundation; Knut and Alice Wallenberg
   Foundation; KI/SLL - Knut and Alice Wallenberg Foundation; ARMEC
   Lindeberg Foundation
FX This work was supported by grants from the Ming Wai Lau Center for
   Reparative Medicine, Knut and Alice Wallenberg Foundation, Centre for
   Innovative Medicine, Swedish Research Council, Ragnar Soderberg
   Foundation, Wallenberg Academy Fellow, Swedish Foundation for Strategic
   Research, Stockholm County Council (ALF project), Karolinska Institute,
   Ogonfonden and Cronqvist Foundation, Strategic Research Area (SRA) Stem
   Cells and Regenerative Medicine, Crown Princess Margareta's Foundation
   for the Visually Impaired, The ARMEC Lindeberg Foundation, The Ulla och
   Ingemar Dahlberg Foundation, and King Gustav V and Queen Victoria
   Foundation. This study was performed at the Live Cell Imaging unit/Nikon
   Center of Excellence, BioNut, KI, supported by Knut and Alice Wallenberg
   Foundation, Swedish Research Council, Centre for Innovative Medicine and
   the Jonasson donation. Flow cytometry analysis and cell sorting were
   performed at the MedH Flow Cytometry core facility, supported by KI/SLL.
   Sequencing was performed at the ESCG at Science for Life Laboratory
   (funded by the Knut and Alice Wallenberg Foundation and the Swedish
   Research Council) with assistance from SNIC/Uppsala Multidisciplinary
   Center for Advanced Computational Science for assistance with massively
   parallel sequencing and access to the UPPMAX computational
   infrastructure. Open access funding provided by Karolinska Institute.
CR Aisenbrey S, 2006, INVEST OPHTH VIS SCI, V47, P5537, DOI 10.1167/iovs.05-1590
   Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Buchholz DE, 2013, STEM CELL TRANSL MED, V2, P384, DOI 10.5966/sctm.2012-0163
   Buettner F, 2015, NAT BIOTECHNOL, V33, P155, DOI 10.1038/nbt.3102
   Butler A, 2018, NAT BIOTECHNOL, V36, P411, DOI 10.1038/nbt.4096
   Choudhary P, 2017, STEM CELL TRANSL MED, V6, P490, DOI 10.5966/sctm.2016-0088
   Choudhary P, 2016, STEM CELL RES THER, V7, DOI 10.1186/s13287-016-0380-6
   Cogger KF, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00561-0
   Collier AJ, 2017, CELL STEM CELL, V20, P874, DOI 10.1016/j.stem.2017.02.014
   Darland DC, 1999, J CLIN INVEST, V103, P157, DOI 10.1172/JCI6127
   Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635
   Dowling J, 1996, J CELL BIOL, V134, P559, DOI 10.1083/jcb.134.2.559
   Dubois NC, 2011, NAT BIOTECHNOL, V29, P1011, DOI 10.1038/nbt.2005
   Fuhrmann S, 2000, DEVELOPMENT, V127, P4599
   Gehrs KM, 2006, ANN MED, V38, P450, DOI 10.1080/07853890600946724
   Hongisto H, 2017, STEM CELL RES THER, V8, DOI 10.1186/s13287-017-0738-4
   Idelson M, 2009, CELL STEM CELL, V5, P396, DOI 10.1016/j.stem.2009.07.002
   Klimanskaya I, 2004, CLONING STEM CELLS, V6, P217, DOI 10.1089/1536230042323420
   Lane A, 2014, STEM CELL TRANSL MED, V3, P1295, DOI 10.5966/sctm.2014-0094
   Leach LL, 2015, STEM CELLS, V33, P2363, DOI 10.1002/stem.2010
   Lehnen D, 2017, STEM CELL REP, V9, P1207, DOI 10.1016/j.stemcr.2017.08.016
   Libby RT, 1996, INVEST OPHTH VIS SCI, V37, P1651
   Macosko EZ, 2015, CELL, V161, P1202, DOI 10.1016/j.cell.2015.05.002
   Mandai M, 2017, NEW ENGL J MED, V376, P1038, DOI 10.1056/NEJMoa1608368
   Martinez-Morales JR, 2004, BIOESSAYS, V26, P766, DOI 10.1002/bies.20064
   Maruotti J, 2015, P NATL ACAD SCI USA, V112, P10950, DOI 10.1073/pnas.1422818112
   MUDHAR HS, 1993, DEVELOPMENT, V118, P539
   Osakada F, 2009, J CELL SCI, V122, P3169, DOI 10.1242/jcs.050393
   Parinot C, 2014, JOVE-J VIS EXP, DOI 10.3791/52100
   Pennington BO, 2015, STEM CELL TRANSL MED, V4, P165, DOI 10.5966/sctm.2014-0179
   Petrus-Reurer S, 2018, JOVE-J VIS EXP, DOI 10.3791/56702
   Petrus-Reurer S, 2017, INVEST OPHTH VIS SCI, V58, DOI 10.1167/iovs.16-20738
   Plaza Reyes A, 2020, NAT PROTOC, DOI [10.21203/rs.2.12256/v1, DOI 10.21203/RS.2.12256/V1]
   Reyes AP, 2016, STEM CELL REP, V6, P9, DOI 10.1016/j.stemcr.2015.11.008
   Rodin S, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4195
   Schwartz SD, 2015, LANCET, V385, P509, DOI 10.1016/S0140-6736(14)61376-3
   Schwartz SD, 2012, LANCET, V379, P713, DOI 10.1016/S0140-6736(12)60028-2
   Sharma R, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aat5580
   Sunness JS, 1999, MOL VIS, V5
   Tang C, 2011, NAT BIOTECHNOL, V29, P829, DOI 10.1038/nbt.1947
   Team RC. R, 2013, R CORE TEAM R LANGUA, DOI DOI 10.1890/0012-9658(2002)083[3097:CFHIWS]2.0.CO;2
   Vaajasaari H, 2011, MOL VIS, V17, P558
   van der Maaten L, 2008, J MACH LEARN RES, V9, P2579
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Zappia L, 2018, GIGASCIENCE, V7, DOI 10.1093/gigascience/giy083
NR 45
TC 14
Z9 14
U1 2
U2 7
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
EI 2041-1723
J9 NAT COMMUN
JI Nat. Commun.
PD MAR 30
PY 2020
VL 11
IS 1
AR 1609
DI 10.1038/s41467-020-15326-5
PG 15
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA MZ0XG
UT WOS:000558846000001
PM 32231223
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Gao, Y
   Teo, YCHK
   Beuerman, RW
   Wong, TY
   Zhou, L
   Cheung, CMG
AF Gao, Yan
   Teo, Yi C. Hong Kelvin
   Beuerman, Roger W.
   Wong, Tien Yin
   Zhou, Lei
   Cheung, Chui Ming Gemmy
TI A serum metabolomics study of patients with nAMD in response to
   anti-VEGF therapy
SO SCIENTIFIC REPORTS
LA English
DT Article
ID BASE-LINE PREDICTORS; MACULAR DEGENERATION; SUBGROUP ANALYSIS;
   LIPID-METABOLISM; VISUAL OUTCOMES; LYSOPHOSPHATIDYLCHOLINE; RANIBIZUMAB;
   LIPOPROTEIN; MEMBRANE; PHOSPHATIDYLSERINE
AB Intravitreal injection of anti-vascular endothelial growth factor (anti-VEGF) is the current standard of treatment for choroidal neovascularization (CNV) secondary to neovascular age-related macular degeneration (nAMD), but there are no diagnostic tools to predict response of these therapies. We hypothesize that differences in baseline metabolic profiles of patients with nAMD may influence responsiveness to anti-VEGF therapy, and thus provide prognosticating information for these patients. A prospective study was performed on 100 patients with nAMD treated with anti-VEGF therapy. We classified patients into two groups: responders (n = 54) and non-responders (n = 46). The expression levels of glycerophosphocholine,LysoPC (18:2) and PS (18:0/20:4) were higher in non-responders and these findings were verified in the validation cohort, implicating that reductions in these three metabolites can be used as predictors for responsiveness to anti-VEGF therapy during the initial loading phase for patients with nAMD. Our study also provided new insights into the pathophysiological changes and molecular mechanism of anti-VEGF therapy for nAMD patients.
C1 [Gao, Yan; Teo, Yi C. Hong Kelvin; Beuerman, Roger W.; Wong, Tien Yin; Zhou, Lei; Cheung, Chui Ming Gemmy] Singapore Eye Res Inst, Singapore, Singapore.
   [Teo, Yi C. Hong Kelvin; Wong, Tien Yin; Cheung, Chui Ming Gemmy] Singapore Natl Eye Ctr, Singapore, Singapore.
   [Beuerman, Roger W.; Wong, Tien Yin; Zhou, Lei] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Ophthalmol, Singapore, Singapore.
   [Beuerman, Roger W.; Wong, Tien Yin; Zhou, Lei; Cheung, Chui Ming Gemmy] Natl Univ Singapore, Ophthalmol & Visual Sci Acad Clin Res Program, Duke NUS Med Sch, Singapore, Singapore.
C3 National University of Singapore; Singapore National Eye Center;
   Singapore National Eye Center; National University of Singapore;
   National University of Singapore
RP Zhou, L; Cheung, CMG (通讯作者)，Singapore Eye Res Inst, Singapore, Singapore.; Cheung, CMG (通讯作者)，Singapore Natl Eye Ctr, Singapore, Singapore.; Zhou, L (通讯作者)，Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Ophthalmol, Singapore, Singapore.; Zhou, L; Cheung, CMG (通讯作者)，Natl Univ Singapore, Ophthalmol & Visual Sci Acad Clin Res Program, Duke NUS Med Sch, Singapore, Singapore.
EM zhou.lei@seri.com.sg; gemmy.cheung.c.m@singhealth.com.sg
RI Wong, Tien Yin/AAC-9724-2020
OI Wong, Tien Yin/0000-0002-8448-1264; Zhou, Lei/0000-0001-5893-6002;
   Cheung, Chui Ming Gemmy/0000-0003-3358-3516
FU A-STAR Strategic Positioning Fund [SPF2014/002]; SERI (Singapore Eye
   Research Institute) IMCB (Institute of Molecular and Cell Biology)
   Programme in Retinal Angiogenic Diseases; National Medical Research
   Council Open Fund Large Collaborative Grant [NMRC/LCG/004/2018];
   Singapore National Medical Research Council (NMRC)
FX This work was supported by an A-STAR Strategic Positioning Fund
   (SPF2014/002) to SIPRAD, SERI (Singapore Eye Research Institute) IMCB
   (Institute of Molecular and Cell Biology) Programme in Retinal
   Angiogenic Diseases and National Medical Research Council Open Fund
   Large Collaborative Grant: NMRC/LCG/004/2018. The authors would like to
   thank SingHealth Foundation for supporting the proteomics core facility
   at the Singapore Eye Research Institute and Centre Grant CG 2013 and CG
   2017 from Singapore National Medical Research Council (NMRC).
CR Abalain JH, 2002, CLIN CHIM ACTA, V326, P97, DOI 10.1016/S0009-8981(02)00288-7
   Adibhatla RM, 2008, BMB REP, V41, P560, DOI 10.5483/BMBRep.2008.41.8.560
   Baek HM, 2008, MAGN RESON IMAGING, V26, P523, DOI 10.1016/j.mri.2007.10.002
   Birge RB, 2016, CELL DEATH DIFFER, V23, P962, DOI 10.1038/cdd.2016.11
   Boyer DS, 2007, OPHTHALMOLOGY, V114, P246, DOI 10.1016/j.ophtha.2006.10.045
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Cao MD, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-39
   Chae B, 2015, INVEST OPHTH VIS SCI, V56, P5040, DOI 10.1167/iovs.15-16494
   Chen GB, 2017, ANAL CHEM, V89, P4897, DOI 10.1021/acs.analchem.6b05006
   Chen JH, 2011, NMR BIOMED, V24, P316, DOI 10.1002/nbm.1595
   Cheung CMG, 2014, J INTERN MED, V276, P140, DOI 10.1111/joim.12227
   Cheung CMG, 2012, CLIN EXP OPHTHALMOL, V40, P727, DOI 10.1111/j.1442-9071.2012.02765.x
   Cheung CMG, 2017, J LIPID RES, V58, P1785, DOI 10.1194/jlr.M073684
   Cheung CMG, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101057
   Choi J, 2011, CHEM RES TOXICOL, V24, P111, DOI 10.1021/tx100305b
   Curcio CA, 2010, J LIPID RES, V51, P451, DOI 10.1194/jlr.R002238
   Curcio CA, 2009, PROG RETIN EYE RES, V28, P393, DOI 10.1016/j.preteyeres.2009.08.001
   Daleau P, 1999, J MOL CELL CARDIOL, V31, P1391, DOI 10.1006/jmcc.1999.0973
   Dugel PU, 2020, OPHTHALMOLOGY, V127, P72, DOI 10.1016/j.ophtha.2019.04.017
   Fan Q, 2017, INT J EPIDEMIOL, V46, P1891, DOI 10.1093/ije/dyx189
   Farooqui AA, 2007, J NEUROSCI RES, V85, P1834, DOI 10.1002/jnr.21268
   Farshidfar F, 2016, BRIT J CANCER, V115, P848, DOI 10.1038/bjc.2016.243
   Fenwick EK, 2018, BRIT J OPHTHALMOL, V102, P377, DOI 10.1136/bjophthalmol-2017-310532
   Fukui M, 2008, METABOLISM, V57, P625, DOI 10.1016/j.metabol.2007.12.005
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Haug K, 2013, NUCLEIC ACIDS RES, V41, pD781, DOI 10.1093/nar/gks1004
   Ho J, 2018, BIORXIV, DOI [10.1101/377978, DOI 10.1101/377978]
   Iwase M, 2008, ATHEROSCLEROSIS, V196, P931, DOI 10.1016/j.atherosclerosis.2007.02.012
   Jaffe GJ, 2019, OPHTHALMOLOGY, V126, P252, DOI 10.1016/j.ophtha.2018.08.035
   Kaiser PK, 2007, AM J OPHTHALMOL, V144, P850, DOI 10.1016/j.ajo.2007.08.012
   Kersten E, 2018, SURV OPHTHALMOL, V63, P9, DOI 10.1016/j.survophthal.2017.05.003
   Khanani AM, 2018, 2018 AM AC OPHTH AAO
   Kiviat N. B, 2016, NEW ENGL J MED, V355, P1419
   Klein J, 2000, J NEURAL TRANSM, V107, P1027, DOI 10.1007/s007020070051
   Lains I, 2018, OPHTHALMOLOGY, V125, P245, DOI 10.1016/j.ophtha.2017.08.008
   Lains I, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0177749
   Latonen L, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03573-6
   Li T, 2015, INVEST OPHTH VIS SCI, V56, P7137, DOI 10.1167/iovs.15-17302
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Matsumoto T, 2007, CURR MED CHEM, V14, P3209, DOI 10.2174/092986707782793899
   Nowak M, 2005, CLIN EXP MED, V4, P183, DOI 10.1007/s10238-004-0054-z
   Osborn MP, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072737
   R Core Team, 2014, R LANG ENV STAT COMP
   Reynolds R, 2010, OPHTHALMOLOGY, V117, P1989, DOI 10.1016/j.ophtha.2010.07.009
   Sabanayagam C, 2017, INVEST OPHTH VIS SCI, V58, P2538, DOI 10.1167/iovs.16-21263
   Smith CA, 2005, THER DRUG MONIT, V27, P747, DOI 10.1097/01.ftd.0000179845.53213.39
   Spratlin JL, 2009, CLIN CANCER RES, V15, P431, DOI 10.1158/1078-0432.CCR-08-1059
   Tautenhahn R, 2012, ANAL CHEM, V84, P5035, DOI 10.1021/ac300698c
   Triba MN, 2015, MOL BIOSYST, V11, P13, DOI 10.1039/c4mb00414k
   Vance JE, 2013, BBA-MOL CELL BIOL L, V1831, P543, DOI 10.1016/j.bbalip.2012.08.016
   Vogl WD, 2017, INVEST OPHTH VIS SCI, V58, P4173, DOI 10.1167/iovs.17-21878
   Nguyen V, 2019, OPHTHALMOLOGY, V126, P64, DOI 10.1016/j.ophtha.2018.08.023
   Walter A, 2004, NEUROBIOL AGING, V25, P1299, DOI 10.1016/j.neurobiolaging.2004.02.016
   Wang L, 2009, INVEST OPHTH VIS SCI, V50, P870, DOI 10.1167/iovs.08-2376
   Wishart DS, 2013, NUCLEIC ACIDS RES, V41, pD801, DOI 10.1093/nar/gks1065
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Xia JG, 2015, NUCLEIC ACIDS RES, V43, pW251, DOI 10.1093/nar/gkv380
   Yang J, 2017, SCI REP-UK, V7, P1, DOI [10.1038/s41598-017-09018-2, 10.1038/s41598-017-16705-7]
   Ying GS, 2015, OPHTHALMOLOGY, V122, P2523, DOI 10.1016/j.ophtha.2015.08.015
   Ying GS, 2013, OPHTHALMOLOGY, V120, P122, DOI 10.1016/j.ophtha.2012.07.042
   ZABLOCKI K, 1991, P NATL ACAD SCI USA, V88, P7820, DOI 10.1073/pnas.88.17.7820
   Zinkernagel MS, 2017, SCI REP-UK, V7, DOI 10.1038/srep40826
   Zou Y, 2009, REJUV RES, V12, P15, DOI 10.1089/rej.2008.0807
NR 63
TC 5
Z9 5
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD JAN 28
PY 2020
VL 10
IS 1
AR 1341
DI 10.1038/s41598-020-58346-3
PG 10
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA NE8NU
UT WOS:000562863200004
PM 31992792
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Esteban, R
   Buezo, J
   Becerril, JM
   Garcia-Plazaola, JI
AF Esteban, Raquel
   Buezo, Javier
   Becerril, Jose M.
   Garcia-Plazaola, Jose I.
TI Modified Atmosphere Packaging and Dark/Light Refrigerated Storage in
   Green Leafy Vegetables Have an Impact on Nutritional Value
SO PLANT FOODS FOR HUMAN NUTRITION
LA English
DT Article
DE Carotenoids; Health; Fridge; Market; Modified atmosphere; Xanthophylls
ID PIGMENT COMPOSITION; QUALITY; PLANTS; ROCKET
AB The consumption of zeaxanthin (Z) through a vegetable-rich diet is recommended to reduce the progression of age-related macular degeneration. Due to Z's intrinsic dynamic character that results from its participation in the photoprotective xanthophyll cycle involving the carotenoids violaxanthin, antheraxanthin and zeaxanthin (VAZ), post-harvest handling practices and storage usually retain low amounts of this bioactive compound (compared to the rest of phytochemicals that are, in general, more stable). Thus, the aim of this work was to investigate in important consumed leafy vegetables the effects of different storage conditions on carotenoids (mainly Z) including i) packaging under three modified atmospheres (MAs), ii) light refrigerated supermarket storage and iii) dark refrigerated domestic storage. The results showed that an MA with low O-2 and high CO2 enhanced the Z content under light. Moreover, both light and dark refrigerated storage showed dynamic and circadian pigment changes that enhanced the total VAZ pool. These results can contribute to generating practical recommendations for industries, supermarkets, and consumers when high Z content is a nutritional target.
C1 [Esteban, Raquel; Becerril, Jose M.; Garcia-Plazaola, Jose I.] Univ Basque Country, UPV EHU, C Sarriena S-N,Apdo 644, Bilbao 48080, Spain.
   [Buezo, Javier] Univ Publ Navarra, Dept Sci, Inst Multidisciplinary Appl Biol Res IMAB, Mutilva, Spain.
C3 University of Basque Country; Universidad Publica de Navarra
RP Esteban, R (通讯作者)，Univ Basque Country, UPV EHU, C Sarriena S-N,Apdo 644, Bilbao 48080, Spain.
EM raquel.esteban@ehu.eus
RI Becerril, Jose/H-1560-2015; Buezo, Javier/AAB-2117-2021;
   Garcia-Plazaola, Jose Ignacio/B-8188-2009
OI Becerril, Jose/0000-0001-6216-3508; Garcia-Plazaola, Jose
   Ignacio/0000-0001-6498-975X; ESTEBAN, Raquel/0000-0003-2560-3310
FU Juan de la Cierva-incorporacion grant [IJCI-2014-21452]; Public
   University of Navarre; Ministry of Education and Science of Spain [BFU
   2010-15021, CTM2014-53902-C2-2-P]; ERDF (FEDER);  [UPV/EHU IT-1018-16]
FX RE received a Juan de la Cierva-incorporacion grant IJCI-2014-21452. JB
   is the holder of a PhD fellowship from the Public University of Navarre.
   This research was supported by the research grants BFU 2010-15021 and
   CTM2014-53902-C2-2-P from the Ministry of Education and Science of Spain
   and the ERDF (FEDER) as well as the research project UPV/EHU IT-1018-16.
   Technical and human support from Eroski supermarkets and the "Fundacion
   Tecnova" is gratefully acknowledged.
CR Ansari M, 2016, EUR J MED CHEM, V123, P141, DOI 10.1016/j.ejmech.2016.07.037
   Cohu CM, 2014, ACTA ASTRONAUT, V94, P799, DOI 10.1016/j.actaastro.2013.10.009
   Demmig-Adams B, 2012, PHOTOSYNTH RES, V113, P75, DOI 10.1007/s11120-012-9761-6
   Esteban R, 2015, ENVIRON EXP BOT, V119, P63, DOI 10.1016/j.envexpbot.2015.04.009
   Esteban R, 2015, NEW PHYTOL, V206, P268, DOI 10.1111/nph.13186
   Esteban R, 2014, FOOD RES INT, V65, P207, DOI 10.1016/j.foodres.2014.05.044
   Fanciullino AL, 2014, PLANT CELL ENVIRON, V37, P273, DOI 10.1111/pce.12153
   Garcia-Plazaola JI, 1999, PHYTOCHEM ANALYSIS, V10, P307, DOI 10.1002/(SICI)1099-1565(199911/12)10:6&lt;307::AID-PCA477&gt;3.0.CO;2-L
   Goodspeed D, 2013, CURR BIOL, V23, P1235, DOI 10.1016/j.cub.2013.05.034
   Garcia-Plazaola JI, 2017, PLANT CELL ENVIRON, V40, P1153, DOI 10.1111/pce.12909
   Jia CG, 2009, FOOD CHEM, V114, P28, DOI 10.1016/j.foodchem.2008.09.009
   Johnson EJ, 2010, CURR OPIN CLIN NUTR, V13, P28, DOI 10.1097/MCO.0b013e32833308ff
   Kaur P, 2011, J FOOD QUALITY, V34, P10, DOI 10.1111/j.1745-4557.2010.00361.x
   Latowski D, 2004, ACTA PHYSIOL PLANT, V26, P197, DOI 10.1007/s11738-004-0009-8
   Liu JD, 2015, BMC PLANT BIOL, V15, DOI 10.1186/s12870-015-0474-9
   Martinez-Sanchez A, 2006, POSTHARVEST BIOL TEC, V40, P26, DOI 10.1016/j.postharvbio.2005.12.015
   Moretti Celso L., 2003, Hortic. Bras., V21, P676, DOI 10.1590/S0102-05362003000400021
   Nath A, 2011, FOOD CHEM, V127, P1510, DOI 10.1016/j.foodchem.2011.02.007
   Sandhya, 2010, LWT-FOOD SCI TECHNOL, V43, P381, DOI 10.1016/j.lwt.2009.05.018
   Singh M, 2014, J FOOD SCI TECH MYS, V51, P1911, DOI 10.1007/s13197-012-0735-7
NR 20
TC 2
Z9 2
U1 2
U2 28
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0921-9668
EI 1573-9104
J9 PLANT FOOD HUM NUTR
JI Plant Food Hum. Nutr.
PD MAR
PY 2019
VL 74
IS 1
BP 99
EP 106
DI 10.1007/s11130-018-0705-y
PG 8
WC Plant Sciences; Chemistry, Applied; Food Science & Technology; Nutrition
   & Dietetics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Plant Sciences; Chemistry; Food Science & Technology; Nutrition &
   Dietetics
GA HP6RU
UT WOS:000461814400014
PM 30610553
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Hytti, M
   Korhonen, E
   Hyttinen, JMT
   Roehrich, H
   Kaarniranta, K
   Ferrington, DA
   Kauppinen, A
AF Hytti, Maria
   Korhonen, Eveliina
   Hyttinen, Juha M. T.
   Roehrich, Heidi
   Kaarniranta, Kai
   Ferrington, Deborah A.
   Kauppinen, Anu
TI Antimycin A-Induced Mitochondrial Damage Causes Human RPE Cell Death
   despite Activation of Autophagy
SO OXIDATIVE MEDICINE AND CELLULAR LONGEVITY
LA English
DT Article
AB Mitochondrial dysfunction has been implicated in a wide variety of degenerative diseases, including age-related macular degeneration. Damage to mitochondria and mitochondria' DNA accumulates with age in the postmitotic retinal pigment epithelium (RPE), which could lead to RPE cell death and trigger disease. One possible mechanism for cells to avoid cell death is mitophagy, the targeted clearance of damaged mitochondria by autophagy. Here, we induced mitochondria' damage in human RPE cells (ARPE-19 and hRPE), using antimycin A, an inhibitor of complex III of the electron transport chain, and investigated cellular viability, mitochondrial structure and function, and autophagy activity. We observed that antimycin A evoked dose-dependent cell death, a rapid loss in mitochondrial membrane potential, and a collapse of oxidative phosphorylation. Mitochondria appeared swollen and there was clear damage to their cristae structure. At the same time, cells were undergoing active autophagy and were sensitive to autophagy inhibition by hafilomycin Al or chloroquine. These results indicate that mitochondrial dysfunction can cause significant RPE damage and that autophagy is an important survival mechanism for cells suffering from mitochondrial damage.
C1 [Hytti, Maria; Korhonen, Eveliina; Hyttinen, Juha M. T.; Kauppinen, Anu] Univ Eastern Finland, Sch Pharm, Kuopio, Finland.
   [Hyttinen, Juha M. T.; Kaarniranta, Kai] Univ Eastern Finland, Inst Clin Med, Dept Ophthalmol, Kuopio, Finland.
   [Roehrich, Heidi] Univ Minnesota, Histol Core Vis Res, Minneapolis, MN USA.
   [Kaarniranta, Kai] Kuopio Univ Hosp, Dept Ophthalmol, Kuopio, Finland.
   [Ferrington, Deborah A.] Univ Minnesota, Dept Ophthalmol & Visual Neurosci, Minneapolis, MN USA.
C3 University of Eastern Finland; University of Eastern Finland; University
   of Minnesota System; University of Minnesota Twin Cities; Kuopio
   University Hospital; University of Eastern Finland; University of
   Minnesota System; University of Minnesota Twin Cities
RP Hytti, M (通讯作者)，Univ Eastern Finland, Sch Pharm, Kuopio, Finland.
EM maria.hytti@uef.fi
RI Hytti, Maria/AAE-4016-2019
OI Hytti, Maria/0000-0003-2150-6847; Korhonen,
   Eveliina/0000-0002-5360-7258; Ferrington, Deborah/0000-0003-2561-7464;
   Hyttinen, Juha/0000-0002-3414-4032
FU Finnish Cultural Foundation-North Savo Regional Fund; Academy of Finland
   (Health Research Council) [297267, 307341]; Emil Aaltonen Foundation;
   Elaine and Robert Larson Endowed Vision Research Chair; Lindsay Family
   Foundation; Research to Prevent Blindness
FX The authors wish to thank the University of Minnesota Imaging Center,
   St. Paul, MN, and Virpi Miettinen, UEF, Finland, for their excellent
   practical assistance in the preparation of the TEM samples and Ewen
   MacDonald for revising the language of the article. The authors also
   want to acknowledge the contribution of personnel from the Lions Gift of
   Sight for their assistance in procuring human donor eyes and Dr. Nathan
   Schuld and Professor M. Cristina Kenney for their advice with the
   Seahorse assays. This work was supported by the Finnish Cultural
   Foundation-North Savo Regional Fund (to MH), the Academy of Finland
   (Health Research Council projects 297267 and 307341), and the Emil
   Aaltonen Foundation. Work at the University of Minnesota was supported
   by the Elaine and Robert Larson Endowed Vision Research Chair (to DAF),
   the Lindsay Family Foundation, an anonymous donor for AMD research, and
   an unrestricted grant from the Research to Prevent Blindness to the
   Department of Ophthalmology.
CR Bender A, 2006, NAT GENET, V38, P515, DOI 10.1038/ng1769
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
   Chen JX, 2010, J ALZHEIMERS DIS, V20, pS569, DOI 10.3233/JAD-2010-100357
   Chen Y, 2009, CELL DEATH DIFFER, V16, P1040, DOI 10.1038/cdd.2009.49
   Choi EM, 2011, FOOD CHEM TOXICOL, V49, P2459, DOI 10.1016/j.fct.2011.04.037
   Feher J, 2006, NEUROBIOL AGING, V27, P983, DOI 10.1016/j.neurobiolaging.2005.05.012
   Ferrington DA, 2017, REDOX BIOL, V13, P255, DOI 10.1016/j.redox.2017.05.015
   Fukae J, 2007, MITOCHONDRION, V7, P58, DOI 10.1016/j.mito.2006.12.002
   Golestaneh N, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2016.453
   GREAVES L, 2002, THE JOURNAL OF PATHO, V226, P274, DOI DOI 10.1002/PATH.3028
   GUHA G, 2002, FOOD AND CHEMICAL TO, V48, P3449, DOI DOI 10.1016/J.FCT.2010.09.020
   Hyttinen JMT, 2018, CELL MOL LIFE SCI, V75, P2991, DOI 10.1007/s00018-018-2843-7
   Hyttinen JMT, 2017, AGEING RES REV, V36, P64, DOI 10.1016/j.arr.2017.03.006
   Jang YC, 2009, EXP GERONTOL, V44, P256, DOI 10.1016/j.exger.2008.12.006
   Jeppesen DK, 2011, PROG NEUROBIOL, V94, P166, DOI 10.1016/j.pneurobio.2011.04.013
   Kaarniranta K, 2013, AUTOPHAGY, V9, P973, DOI 10.4161/auto.24546
   Karunadharma PP, 2010, INVEST OPHTH VIS SCI, V51, P5470, DOI 10.1167/iovs.10-5429
   Kauppinen A., 2018, HDB IMMUNOSENESCENCE, P1
   Kauppinen A, 2016, CELL MOL LIFE SCI, V73, P1765, DOI 10.1007/s00018-016-2147-8
   Kenney MC, 2010, INVEST OPHTH VIS SCI, V51, P4289, DOI 10.1167/iovs.09-4778
   Lee SY, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.266
   Leuner K, 2012, ANTIOXID REDOX SIGN, V16, P1421, DOI 10.1089/ars.2011.4173
   Nordgaard CL, 2008, INVEST OPHTH VIS SCI, V49, P2848, DOI 10.1167/iovs.07-1352
   Park WH, 2016, INT J ONCOL, V48, P813, DOI 10.3892/ijo.2015.3276
   Pinto M, 2014, BBA-MOL BASIS DIS, V1842, P1198, DOI 10.1016/j.bbadis.2013.11.012
   Repetto G, 2008, NAT PROTOC, V3, P1125, DOI 10.1038/nprot.2008.75
   Rohrer B, 2016, ADV EXP MED BIOL, V854, P793, DOI 10.1007/978-3-319-17121-0_106
   Sheng BY, 2012, J NEUROCHEM, V120, P419, DOI 10.1111/j.1471-4159.2011.07581.x
   Srivastava S, 2017, GENES-BASEL, V8, DOI 10.3390/genes8120398
   TERLUK M, 2002, THE JOURNAL OF NEURO, V35, P7304, DOI DOI 10.1523/JNEUROSCI.0190-15.2015
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   Vakifahmetoglu-Norberg H, 2013, GENE DEV, V27, P1718, DOI 10.1101/gad.220897.113
   Yamaguchi O, 2016, J MOL CELL CARDIOL, V95, P50, DOI 10.1016/j.yjmcc.2016.03.010
   You BR, 2010, TOXICOL IN VITRO, V24, P1111, DOI 10.1016/j.tiv.2010.03.009
   Zhou RB, 2011, NATURE, V469, P221, DOI 10.1038/nature09663
NR 35
TC 22
Z9 23
U1 3
U2 7
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1942-0900
EI 1942-0994
J9 OXID MED CELL LONGEV
JI Oxidative Med. Cell. Longev.
PY 2019
VL 2019
AR 1583656
DI 10.1155/2019/1583656
PG 12
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA HS2ER
UT WOS:000463674400001
PM 31007832
OA Green Published, Green Submitted, gold
DA 2022-11-30
ER

PT J
AU Luo, WT
   Xie, F
   Zhang, ZY
   Sun, DW
AF Luo, Wenting
   Xie, Fang
   Zhang, Zhongyu
   Sun, Dawei
TI Vascular Adhesion Protein 1 in the Eye
SO JOURNAL OF OPHTHALMOLOGY
LA English
DT Review
ID EXPERIMENTAL AUTOIMMUNE UVEORETINITIS; ENDOTOXIN-INDUCED UVEITIS;
   SENSITIVE AMINE OXIDASE; MACULAR DEGENERATION; DIABETIC-RETINOPATHY;
   BRUCHS MEMBRANE; EXPRESSION; INFLAMMATION; PATHOGENESIS; MACROPHAGES
AB Semicarbazide-sensitive amine oxidase/vascular adhesion protein-1 (SSAO/VAP-1), a dual-function molecule with adhesive and enzymatic properties, is expressed on the surface of vascular endothelial cells of mammals. It also exists as a soluble form (sVAP-1), which is implicated in oxidative stress via its enzymatic activity and can be a prognostic biomarker. Recent evidence suggests that VAP-1 is an important therapeutic target for several inflammation-related ocular diseases, such as uveitis, age-related macular degeneration (AMD), and diabetic retinopathy (DR), by involving in the recruitment of leukocytes at sites of inflammation. Furthermore, VAP-1 plays an important role in the pathogenesis of conjunctival inflammatory diseases such as pyogenic granulomas and the progression of conjunctival lymphoma. VAP-1 may be an alternative therapeutic target in ocular diseases. The in vivo imaging of inflammation using VAP-1 as a target molecule is a novel approach with a potential for early detection and characterization of inflammatory diseases. This paper reviews the critical roles of VAP-1 in ophthalmological diseases which may provide a novel research direction or a potent therapeutic strategy.
C1 [Luo, Wenting; Zhang, Zhongyu; Sun, Dawei] Harbin Med Univ, Affiliated Hosp 2, Dept Ophthalmol, Harbin 150001, Peoples R China.
   [Luo, Wenting; Xie, Fang; Zhang, Zhongyu; Sun, Dawei] Harbin Med Univ, Key Lab Myocardial Ischemia, Chinese Minist Educ, Harbin 150001, Peoples R China.
   [Xie, Fang] Harbin Med Univ, Affiliated Hosp 1, Dept Ophthalmol, Harbin 150001, Peoples R China.
C3 Harbin Medical University; Harbin Medical University; Harbin Medical
   University
RP Sun, DW (通讯作者)，Harbin Med Univ, Affiliated Hosp 2, Dept Ophthalmol, 246 Xuefu Rd, Harbin 150001, Peoples R China.
EM dr.sundw@gmail.com
FU National Natural Science Foundation of China [81171381]; Heilongjiang
   Science Grant [LC2011C27]; Ministry of Education fund [20112307120019]
FX Support by National Natural Science Foundation of China Grant 81171381,
   Heilongjiang Science Grant LC2011C27, and Ministry of Education fund
   20112307120019 was granted to D. Sun.
CR Aalto K, 2011, BLOOD, V118, P3725, DOI 10.1182/blood-2010-09-311076
   Abbas AK, 2007, J AUTOIMMUN, V28, P59, DOI 10.1016/j.jaut.2007.02.002
   Airenne TT, 2005, PROTEIN SCI, V14, P1964, DOI 10.1110/ps.051438105
   Akin E, 2001, INFECT IMMUN, V69, P1774, DOI 10.1128/IAI.69.3.1774-1780.2001
   Almulki L, 2010, EXP EYE RES, V90, P26, DOI 10.1016/j.exer.2009.09.005
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Antonetti DA, 2006, DIABETES, V55, P2401, DOI 10.2337/db05-1635
   ATALLA L, 1990, INVEST OPHTH VIS SCI, V31, P1264
   Autio A, 2011, EJNMMI RES, V1, DOI 10.1186/2191-219X-1-10
   Belkhiri A, 1997, LAB INVEST, V77, P533
   BHATTACHERJEE P, 1980, METHOD FIND EXP CLIN, V2, P17
   Boomsma F, 1999, DIABETOLOGIA, V42, P233, DOI 10.1007/s001250051143
   CASPI RR, 1993, J NEUROIMMUNOL, V47, P177, DOI 10.1016/0165-5728(93)90028-W
   CHAN CC, 1990, J AUTOIMMUN, V3, P247, DOI 10.1016/0896-8411(90)90144-H
   Crocker PR, 2007, NAT REV IMMUNOL, V7, P255, DOI 10.1038/nri2056
   DASTGHEIB K, 1994, ARCH OPHTHALMOL-CHIC, V112, P813, DOI 10.1001/archopht.1994.01090180111045
   DEVOS AF, 1994, INVEST OPHTH VIS SCI, V35, P1100
   Donoso LA, 2006, SURV OPHTHALMOL, V51, P137, DOI 10.1016/j.survophthal.2005.12.001
   Durrani OM, 2004, BRIT J OPHTHALMOL, V88, P1159, DOI 10.1136/bjo.2003.037226
   Duyndam MCA, 2001, J BIOL CHEM, V276, P48066, DOI 10.1074/jbc.M106282200
   Ernberg K, 2010, ACTA CRYSTALLOGR F, V66, P1572, DOI 10.1107/S1744309110041515
   Espinosa-Heidmann DG, 2003, INVEST OPHTH VIS SCI, V44, P3586, DOI 10.1167/iovs.03-0038
   Forster-Horvath C, 2004, MELANOMA RES, V14, P135, DOI 10.1097/00008390-200404000-00010
   Fukuhara J, 2012, OPHTHALMIC RES, V48, P33, DOI 10.1159/000335983
   Gardner TW, 2002, SURV OPHTHALMOL, V47, pS253, DOI 10.1016/S0039-6257(02)00387-9
   Garland RC, 2011, FASEB J, V25, P1284, DOI 10.1096/fj.10-160051
   Garpenstrand H, 1999, DIABETIC MED, V16, P514, DOI 10.1046/j.1464-5491.1999.00103.x
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Grossniklaus HE, 2005, ARCH OPHTHALMOL-CHIC, V123, P914
   Grossniklaus HE, 2002, MOL VIS, V8, P119
   HUTCHINSON AK, 1993, ARCH OPHTHALMOL-CHIC, V111, P734, DOI 10.1001/archopht.1993.01090060020010
   Itoh T, 1998, CANCER RES, V58, P1048
   Izuta H, 2010, MOL VIS, V16, P130
   Jaakkola K, 2000, J AM COLL CARDIOL, V36, P122, DOI 10.1016/S0735-1097(00)00706-3
   Jaakkola K, 2000, AM J PATHOL, V157, P463, DOI 10.1016/S0002-9440(10)64558-0
   Jiang HR, 1999, INVEST OPHTH VIS SCI, V40, P3177
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Joussen AM, 2004, FASEB J, V18, P1450, DOI 10.1096/fj.03-1476fje
   Kemik O., 2010, WORLD J SURG ONCOLOG, V8
   KILLINGSWORTH MC, 1990, EYE, V4, P613, DOI 10.1038/eye.1990.86
   Kivi E, 2009, BLOOD, V114, P5385, DOI 10.1182/blood-2009-04-219253
   Koskinen K, 2004, BLOOD, V103, P3388, DOI 10.1182/blood-2003-09-3275
   Koto T, 2007, INVEST OPHTH VIS SCI, V48, P4328, DOI 10.1167/iovs.06-1148
   Kurkijarvi R, 1998, J IMMUNOL, V161, P1549
   Markomichelakis NN, 2005, AM J OPHTHALMOL, V139, P537, DOI 10.1016/j.ajo.2004.09.058
   Marttila-Ichihara F, 2010, J IMMUNOL, V184, P3164, DOI 10.4049/jimmunol.0901794
   Marttila-Ichihara F, 2009, CANCER RES, V69, P7875, DOI 10.1158/0008-5472.CAN-09-1205
   Moore TCB, 2003, INVEST OPHTH VIS SCI, V44, P4457, DOI 10.1167/iovs.02-1063
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Murata M, 2012, INVEST OPHTH VIS SCI, V53, P4055, DOI 10.1167/iovs.12-9857
   Nagai N, 2006, ARTERIOSCL THROM VAS, V26, P2252, DOI 10.1161/01.ATV.0000240050.15321.fe
   Nakao S, 2011, AM J PATHOL, V178, P1913, DOI 10.1016/j.ajpath.2011.01.011
   Noda K, 2008, FASEB J, V22, P2928, DOI 10.1096/fj.07-105346
   Noda K, 2008, FASEB J, V22, P1094, DOI 10.1096/fj.07-9377com
   Noda K, 2009, EXP EYE RES, V89, P774, DOI 10.1016/j.exer.2009.07.010
   Nozaki M, 2006, P NATL ACAD SCI USA, V103, P2328, DOI 10.1073/pnas.0408835103
   Oh H, 1999, INVEST OPHTH VIS SCI, V40, P1891
   OKUMURA A, 1990, INT OPHTHALMOL, V14, P31, DOI 10.1007/BF00131166
   PENFOLD PL, 1985, GRAEF ARCH CLIN EXP, V223, P69, DOI 10.1007/BF02150948
   Roivainen A, 2012, EUR J NUCL MED MOL I, V39, P68, DOI 10.1007/s00259-011-1987-6
   Rothova A, 2004, OPHTHALMOLOGY, V111, P954, DOI 10.1016/j.ophtha.2003.09.031
   Sakurai E, 2003, INVEST OPHTH VIS SCI, V44, P3578, DOI 10.1167/iovs.03-0097
   Salmi M, 1997, J CLIN INVEST, V99, P2165, DOI 10.1172/JCI119389
   SALMI M, 1992, SCIENCE, V257, P1407, DOI 10.1126/science.1529341
   SALMI M, 1993, J EXP MED, V178, P2255, DOI 10.1084/jem.178.6.2255
   Salmi M, 2011, FEBS LETT, V585, P1543, DOI 10.1016/j.febslet.2011.04.033
   SEREGARD S, 1994, GRAEF ARCH CLIN EXP, V232, P325, DOI 10.1007/BF00175983
   Sheetz MJ, 2002, JAMA-J AM MED ASSOC, V288, P2579, DOI 10.1001/jama.288.20.2579
   Shi X, 2006, EXP EYE RES, V83, P1325, DOI 10.1016/j.exer.2006.07.007
   Singh B, 2003, VIRCHOWS ARCH, V442, P491, DOI 10.1007/s00428-003-0802-6
   Sun DW, 2010, FASEB J, V24, P1532, DOI 10.1096/fj.09-148981
   Tadayoni R, 2003, EXP EYE RES, V77, P497, DOI 10.1016/S0014-4835(03)00155-6
   Tamura H, 2005, INVEST OPHTH VIS SCI, V46, P1440, DOI 10.1167/iovs.04-0905
   Tohka S, 2001, FASEB J, V15, P373, DOI 10.1096/fj.00-0240com
   Tsutsumi C, 2003, J LEUKOCYTE BIOL, V74, P25, DOI 10.1189/jlb.0902436
   Tugal-Tutkun I, 2004, AM J OPHTHALMOL, V138, P373, DOI 10.1016/j.ajo.2004.03.022
   Ujula T, 2009, NUCL MED BIOL, V36, P631, DOI 10.1016/j.nucmedbio.2009.04.008
   Vidovic-Valentincic N, 2009, BRIT J OPHTHALMOL, V93, P477, DOI 10.1136/bjo.2008.149039
   Vu TH, 1998, CELL, V93, P411, DOI 10.1016/S0092-8674(00)81169-1
   Xie F, 2010, AM J PATHOL, V177, P39, DOI 10.2353/ajpath.2010.100007
   Yasuda H, 2011, J SURG ONCOL, V103, P695, DOI 10.1002/jso.21877
   Yoong KF, 1998, J IMMUNOL, V160, P3978
   Yoshikawa N, 2012, MOL VIS, V18, P593
   Yu PH, 2003, BBA-PROTEINS PROTEOM, V1647, P193, DOI 10.1016/S1570-9639(03)00101-8
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
NR 85
TC 11
Z9 11
U1 0
U2 9
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2090-004X
EI 2090-0058
J9 J OPHTHALMOL
JI J. Ophthalmol.
PY 2013
VL 2013
AR 925267
DI 10.1155/2013/925267
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 166BV
UT WOS:000320530300001
PM 23840939
OA Green Submitted, gold, Green Published
DA 2022-11-30
ER

PT J
AU Barisic, F
   Sicaja, AJ
   Ravlic, MM
   Novak-Laus, K
   Ivekovic, R
   Mandic, Z
AF Barisic, Freja
   Sicaja, Ana Jurin
   Ravlic, Maja Malenica
   Novak-Laus, Katia
   Ivekovic, Renata
   Mandic, Zdravko
TI Macular Thickness and Volume Parameters Measured Using Optical Coherence
   Tomography (OCT) for Evaluation of Glaucoma Patients
SO COLLEGIUM ANTROPOLOGICUM
LA English
DT Article
DE macular thickness; glaucoma; optical coherence tomography
ID NERVE-FIBER LAYER; GANGLION-CELL COMPLEX; DOMAIN OCT; VISUAL-FIELD;
   EYES; DIAGNOSIS; NEUROPATHY; PERIMETRY; DAMAGE
AB The aim of this study was to evaluate macular thickness parameters in glaucoma patients and to compare them to normal subjects using Optical Coherence Tomography (OCT). This prospective, observational study included 20 primary open angle glaucoma patients (POAG) and 20 healthy subjects in control group. Exclusion criteria were diabetes and other macular pathology, like age-related macular degeneration, macular oedema, central serous retinopathy and high myopia >4.00 dsph. OCT imaging of peripapillar retina and macular area were performed using Cirrus HD OCT. In these two groups of patients we analyzed changes of macular thickness parameters (central subfield thickness, macular volume, and average macular thickness). The group of glaucoma patients had decreased values of the two macular thickness parameters: macular volume and average macular thickness, compared to control group. There was no difference in central macular thickness, presumably because of the absence of the ganglion cells in this layer Macular imaging can be a useful additional method to determine glaucoma status and has a potential for tracking glaucoma progression.
C1 [Barisic, Freja; Sicaja, Ana Jurin; Ravlic, Maja Malenica; Novak-Laus, Katia; Ivekovic, Renata; Mandic, Zdravko] Univ Zagreb, Sestre Milosrdnice Univ Hosp Ctr, Dept Ophthalmol, Zagreb 10000, Croatia.
C3 University of Zagreb; University of Zagreb, School of Dental Medicine
RP Barisic, F (通讯作者)，Univ Zagreb, Sestre Milosrdnice Univ Hosp Ctr, Dept Ophthalmol, Vinogradska 29, Zagreb 10000, Croatia.
EM frejabarisic@yahoo.com
CR Aref Ahmad A, 2010, Ophthalmic Surg Lasers Imaging, V41 Suppl, pS15, DOI 10.3928/15428877-20101031-01
   Bagga H, 2006, ARCH OPHTHALMOL-CHIC, V124, P169, DOI 10.1001/archopht.124.2.169
   Cvenkel B, 2011, GRAEF ARCH CLIN EXP, V249, P575, DOI 10.1007/s00417-010-1538-z
   Desatnik H, 1996, J GLAUCOMA, V5, P46
   DING Y, 2003, INVEST OPHTHALMOL VI, V44
   Giovannini A, 2002, ACTA OPHTHALMOL SCAN, V80, P34, DOI 10.1034/j.1600-0420.80.s236.44.x
   Greenfield DS, 2003, ARCH OPHTHALMOL-CHIC, V121, P41
   GREENFIELD DS, 2010, GLAUCOMA 2010 CURREN
   Guedes V, 2003, OPHTHALMOLOGY, V110, P177, DOI 10.1016/S0161-6420(02)01564-6
   Han IC, 2010, OPHTHALMOLOGY, V117, P1177, DOI 10.1016/j.ophtha.2009.10.029
   Harwerth RS, 2004, INVEST OPHTH VIS SCI, V45, P3152, DOI 10.1167/iovs.04-0227
   Hood DC, 2011, BIOMED OPT EXPRESS, V2, P1097, DOI 10.1364/BOE.2.001097
   Kim NR, 2010, INVEST OPHTH VIS SCI, V51, P4646, DOI 10.1167/iovs.09-5053
   Lederer DE, 2003, AM J OPHTHALMOL, V135, P838, DOI 10.1016/S0002-9394(02)02277-8
   Leung CKS, 2005, OPHTHALMOLOGY, V112, P391, DOI 10.1016/j.ophtha.2004.10.020
   Moreno PAM, 2011, CAN J OPHTHALMOL, V46, P543, DOI 10.1016/j.jcjo.2011.09.006
   Moreno-Montanes J, 2010, INVEST OPHTH VIS SCI, V51, P335, DOI 10.1167/iovs.08-2988
   Mori S, 2010, J GLAUCOMA, V19, P528, DOI 10.1097/IJG.0b013e3181ca7acf
   Mwanza JC, 2011, J GLAUCOMA, V20, P37, DOI 10.1097/IJG.0b013e3181ccb93b
   Mwanza JC, 2011, INVEST OPHTH VIS SCI, V52, P8323, DOI 10.1167/iovs.11-7962
   Na JH, 2012, GRAEF ARCH CLIN EXP, V250, P595, DOI 10.1007/s00417-011-1864-9
   Rao HL, 2010, OPHTHALMOLOGY, V117, P1692, DOI 10.1016/j.ophtha.2010.01.031
   Savini G, 2011, CURR OPIN OPHTHALMOL, V22, P115, DOI 10.1097/ICU.0b013e3283437222
   Schulze A, 2011, GRAEF ARCH CLIN EXP, V249, P1039, DOI 10.1007/s00417-010-1585-5
   Schuman Joel S, 2008, Trans Am Ophthalmol Soc, V106, P426
   Takagi ST, 2011, J OPHTHALMOL, V2011, DOI 10.1155/2011/914250
   Tan O, 2009, OPHTHALMOLOGY, V116, P2305, DOI 10.1016/j.ophtha.2009.05.025
   Wollstein G, 2004, AM J OPHTHALMOL, V138, P218, DOI 10.1016/j.ajo.2004.03.019
   Zeimer R, 1998, OPHTHALMOLOGY, V105, P224, DOI 10.1016/S0161-6420(98)92743-9
NR 29
TC 5
Z9 7
U1 0
U2 3
PU COLLEGIUM ANTROPOLOGICUM
PI ZAGREB
PA INST ANTHROPOLOGICAL RESEARCH, GAJEVA 32, PO BOX 290, HR-10000 ZAGREB,
   CROATIA
SN 0350-6134
J9 COLLEGIUM ANTROPOL
JI Coll. Anthropol.
PD JUN
PY 2012
VL 36
IS 2
BP 441
EP 445
PG 5
WC Anthropology
WE Social Science Citation Index (SSCI)
SC Anthropology
GA 977CS
UT WOS:000306634600014
PM 22856228
DA 2022-11-30
ER

PT J
AU Iyigun, E
   Bayer, A
   Tastan, S
   Demiralp, M
   Acikel, C
AF Iyigun, Emine
   Bayer, Atilla
   Tastan, Sevinc
   Demiralp, Meral
   Acikel, Cengizhan
TI Validity and reliability study for the NEI-VFO-39 scale in chronic
   ophthalmic diseases - Turkish version
SO ACTA OPHTHALMOLOGICA
LA English
DT Article
DE age-related macular degeneration; cataract; diabetic retinopathy;
   glaucoma; quality of life
ID VISUAL FUNCTION QUESTIONNAIRE; QUALITY-OF-LIFE; MACULAR DEGENERATION;
   GLAUCOMA PATIENTS; IMPACT; VALIDATION; VISION
AB Purpose:
   To test the reliability and validity of National Eye Institute Visual Function Questionnaire (NEI-VFQ-39) in patients with glaucoma, cataract, diabetic retinopathy and age-related macular degeneration.
   Methods:
   The study was carried out on 210 patients and 51 control subjects. The data were collected by using a data collection form and NEI-VFQ-39. Statistical analyses were performed with spss for Windows version 15.0.
   Results:
   Cronbach's alpha coefficient was 0.96 for the whole group. Cronbach's alpha coefficient was between 0.97 and 0.56 for the subscales. There was a strong relationship (r > 0.80) in 12.8% with dual correlation in NEI-VFQ-39 global scales and subscales and their correlations in all participant groups. There was a statistically significant difference for the NEI-VFn global and subscale scores between the control and patient groups except for general health and ocular pain.
   Conclusions:
   We found that the NEI-VFQ-39 was a valid and reliable scale to determine the quality of life in Turkish patients with chronic ophthalmic disease.
C1 [Iyigun, Emine; Tastan, Sevinc; Demiralp, Meral] Gulhane Mil Med Acad, Sch Nursing, Ankara, Turkey.
   [Bayer, Atilla] Gulhane Mil Med Acad, Dept Ophthalmol, Ankara, Turkey.
   [Acikel, Cengizhan] Gulhane Mil Med Acad, Dept Publ Hlth, Ankara, Turkey.
C3 Gulhane Military Medical Academy; Gulhane Military Medical Academy;
   Gulhane Military Medical Academy
RP Iyigun, E (通讯作者)，Gulhane Askeri Tip Akad Hemsirel, Yuksek Okulu, Ankara, Turkey.
EM eiyigun@yahoo.com
RI demiralp, meral/AAD-7456-2021; Bayer, Atilla/AAO-8926-2020; Tastan,
   Sevinc/AAN-6552-2021
OI Bayer, Atilla/0000-0002-0184-8033; Tastan, Sevinc/0000-0002-4187-0358;
   Iyigun, Emine/0000-0002-2276-615X; Demiralp, Meral/0000-0002-6988-4153
CR AVCI PY, 2005, THESIS GULHANE MILIT
   Baker RS, 2006, OPHTHALMOLOGY, V113, P1363, DOI 10.1016/j.ophtha.2006.01.073
   Berdeaux GH, 2005, AM J OPHTHALMOL, V139, P271, DOI 10.1016/j.ajo.2004.09.028
   Clemons TE, 2003, ARCH OPHTHALMOL-CHIC, V121, P211
   Cole SR, 2000, INVEST OPHTH VIS SCI, V41, P1017
   Cusick M, 2005, AM J OPHTHALMOL, V139, P1042, DOI 10.1016/j.ajo.2005.01.008
   Gupta V, 2005, BRIT J OPHTHALMOL, V89, P1241, DOI 10.1136/bjo.2005.068858
   Hassell JB, 2006, BRIT J OPHTHALMOL, V90, P593, DOI 10.1136/bjo.2005.086595
   Jampel HD, 2002, J GLAUCOMA, V11, P154, DOI 10.1097/00061198-200204000-00012
   Lau J, 2002, BRIT J OPHTHALMOL, V86, P12, DOI 10.1136/bjo.86.1.12
   Mangione CM, 1998, ARCH OPHTHALMOL-CHIC, V116, P227
   Mangione CM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1050, DOI 10.1001/archopht.119.7.1050
   Mangione CM, 1998, ARCH OPHTHALMOL-CHIC, V116, P1496, DOI 10.1001/archopht.116.11.1496
   Mitchell J, 2006, HEALTH QUAL LIFE OUT, V4, DOI 10.1186/1477-7525-4-97
   Nordmann JP, 2004, PHARMACOECONOMICS, V22, P197, DOI 10.2165/00019053-200422030-00005
   Odberg T, 2001, ACTA OPHTHALMOL SCAN, V79, P116, DOI 10.1034/j.1600-0420.2001.079002116.x
   Owsley C, 2004, OPHTHALMOLOGY, V111, P2259, DOI 10.1016/j.ophtha.2004.06.026
   Rossi GCM, 2003, J GLAUCOMA, V12, P213, DOI 10.1097/00061198-200306000-00006
   Sharma Sanjay, 2005, Curr Opin Ophthalmol, V16, P155, DOI 10.1097/01.icu.0000161227.21797.3d
   Slakter JS, 2005, SURV OPHTHALMOL, V50, P263, DOI 10.1016/j.survophthal.2005.02.007
   Spaeth GL, 2006, AM J OPHTHALMOL, V141, P147, DOI 10.1016/j.ajo.2005.08.026
   Suzukamo Yoshimi, 2005, Health Qual Life Outcomes, V3, P65, DOI 10.1186/1477-7525-3-65
   Swamy BN, 2009, ACTA OPHTHALMOL, V87, P335, DOI 10.1111/j.1755-3768.2008.01203.x
   Toprak AB, 2005, OPHTHAL EPIDEMIOL, V12, P259, DOI 10.1080/09286580590967763
   Wolffsohn JS, 2000, BRIT J OPHTHALMOL, V84, P1035, DOI 10.1136/bjo.84.9.1035
   Zhao JL, 1998, AM J OPHTHALMOL, V126, P515, DOI 10.1016/S0002-9394(98)00274-8
NR 26
TC 8
Z9 9
U1 0
U2 10
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1755-375X
EI 1755-3768
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD JUN
PY 2010
VL 88
IS 4
BP e115
EP e119
DI 10.1111/j.1755-3768.2009.01810.x
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 603BD
UT WOS:000278182000026
PM 20346083
OA Bronze
DA 2022-11-30
ER

PT J
AU Perry, A
   Rasmussen, H
   Johnson, EJ
AF Perry, Alisa
   Rasmussen, Helen
   Johnson, Elizabeth J.
TI Xanthophyll (lutein, zeaxanthin) content in fruits, vegetables and corn
   and egg products
SO JOURNAL OF FOOD COMPOSITION AND ANALYSIS
LA English
DT Article
DE Lutein; Zeaxanthin; Carotenoids; Corn products; Egg products; Food
   composition
ID GEOMETRICAL-ISOMERS; CAROTENOIDS; SUPPLEMENTATION; LYCOPENE; FOODS;
   JUICE
AB Lutein and zeaxanthin are carotenoids that are selectively taken up into the macula of the eye where they are thought to protect against the development of age-related macular degeneration. Current dietary databases make it difficult to ascertain their individual roles in eye health because their concentrations in foods are generally reported together. The objective of this work is to determine the concentrations of lutein and zeaxanthin, separately, within major food Sources of dietary xanthophylls as determined by NHANES 2001-2002 intakes. Corn and corn products were found to be major contributors of dietary zeaxanthin whereas green leafy vegetables were major contributors of dietary lutein. The predominant isomeric xanthophyll form was trans for all foods. processed foods contained more cis xanthophyll isomers than fruits and vegetables. These data will provide added information to the current databases for lutein and zeaxanthin content of commonly consumed foods as well as enhance the validity of estimates of dietary intake of these xanthophylls and their respective contributions to health. (C) 2008 Elsevier Inc. All rights reserved.
C1 [Perry, Alisa; Rasmussen, Helen; Johnson, Elizabeth J.] Tufts Univ, Jean Mayer US Dept Agr, Human Nutr Res Ctr Aging, Boston, MA 02111 USA.
C3 Tufts University; United States Department of Agriculture (USDA)
RP Johnson, EJ (通讯作者)，Tufts Univ, Jean Mayer US Dept Agr, Human Nutr Res Ctr Aging, 711 Washington St, Boston, MA 02111 USA.
EM elizabeth.johnson@tufts.edu
FU USDA [1950-5100-065]; Chrysantis, Inc.
FX Supported by USDA 1950-5100-065 and Chrysantis, Inc. Any opinions,
   findings, conclusions. or recommendations expressed in this publication
   are those of the author(s) and do not necessarily reflect the view of
   the U.S. Department of Agriculture.
CR Bermudez OI, 2005, J NUTR, V135, P1496, DOI 10.1093/jn/135.6.1496
   BONE RA, 1985, VISION RES, V25, P1531, DOI 10.1016/0042-6989(85)90123-3
   BONE RA, 1992, METHOD ENZYMOL, V213, P360
   Chung HY, 2004, J NUTR, V134, P1887, DOI 10.1093/jn/134.8.1887
   *FOOD SURV RES GRO, 2006, WER AR WHAT WE EAT A
   GAZIANO JM, 1995, AM J CLIN NUTR, V61, P1248, DOI 10.1093/ajcn/61.6.1248
   Granado F, 1996, EUR J CLIN NUTR, V50, P246
   Granado F, 2003, BRIT J NUTR, V90, P487, DOI 10.1079/BJN2003927
   HART DJ, 1995, FOOD CHEM, V54, P101, DOI 10.1016/0308-8146(95)92669-B
   Humphries JM, 2003, J AGR FOOD CHEM, V51, P1322, DOI 10.1021/jf026073e
   Johnson EJ, 2005, INVEST OPHTH VIS SCI, V46, P692, DOI 10.1167/iovs.02-1192
   Johson EJ, 1996, J AM COLL NUTR, V15, P620, DOI 10.1080/07315724.1996.10718639
   Lessin WJ, 1997, J AGR FOOD CHEM, V45, P3728, DOI 10.1021/jf960803z
   O'Neill ME, 2001, BRIT J NUTR, V85, P499, DOI 10.1079/BJN2000284
   Riso P, 1997, INT J VITAM NUTR RES, V67, P47
   SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413
   SNODDERLY DM, 1995, AM J CLIN NUTR, V62, P1448
   Sommerburg O, 1998, BRIT J OPHTHALMOL, V82, P907, DOI 10.1136/bjo.82.8.907
   STAHL W, 1992, J NUTR, V122, P2161, DOI 10.1093/jn/122.11.2161
   Torregrosa F, 2005, J AGR FOOD CHEM, V53, P9519, DOI 10.1021/jf051171w
   Unlu NZ, 2007, BRIT J NUTR, V98, P140, DOI 10.1017/S0007114507685201
   West C. E., 1993, CAROTENOID CONTENT F
   [No title captured]
NR 23
TC 225
Z9 240
U1 2
U2 74
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0889-1575
EI 1096-0481
J9 J FOOD COMPOS ANAL
JI J. Food Compos. Anal.
PD FEB
PY 2009
VL 22
IS 1
BP 9
EP 15
DI 10.1016/j.jfca.2008.07.006
PG 7
WC Chemistry, Applied; Food Science & Technology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Chemistry; Food Science & Technology
GA 430KW
UT WOS:000264989000002
DA 2022-11-30
ER

PT J
AU Pescosolido, N
   Imperatrice, B
   Karavitis, P
AF Pescosolido, Nicola
   Imperatrice, Barbara
   Karavitis, Panagiotis
TI The Aging Eye and the Role of L-Carnitine and its Derivatives
SO DRUGS IN R&D
LA English
DT Review
ID ACETYL-L-CARNITINE; SELENITE-INDUCED CATARACTOGENESIS; PERIPHERAL-BLOOD
   LYMPHOCYTES; RETINAL-PIGMENT EPITHELIUM; OPEN-ANGLE GLAUCOMA;
   AGE-RELATED NUCLEAR; FILM LIPID LAYER; MACULAR DEGENERATION; CERAMIDE
   GENERATION; RISK-FACTORS
AB The majority of ocular pathologies originate from a functional deterioration of intraocular tissues. This age-related deterioration often occurs as a result of changes within the eye. There is growing interest in the role of natural or synthetic compounds, such as carnitine, for blocking, or slowing, the progress of this deterioration. L-carnitine and its derivatives are involved in numerous physiological reactions, including sugar aerobic metabolism, oxidative phosphorylation, fatty acid oxidation and osmosis. While carnitine levels in human ocular tissue are unknown, animal studies indicate that carnitine is differentially distributed within the eye with the highest concentrations reported in the iris, ciliary body and the choroid-retina. In patients with age-related macular degeneration (AMD), acetyl-L-carnitine improved four parameters of visual function, including visual field mean defect, visual acuity, foveal sensitivity and ocular fundus alterations. L-carnitine has also demonstrated antioxidant properties in animal models of oxidative damage. This article reviews the potential use of L-carnitine and its derivatives in age-related ocular pathologies, such as AMD, cataract, glaucoma and dry eye syndrome.
C1 [Pescosolido, Nicola; Imperatrice, Barbara; Karavitis, Panagiotis] Univ Rome, Dept Ophthalmol, Ophthalm Neurosci Program, I-00161 Rome, Italy.
C3 Sapienza University Rome
RP Imperatrice, B (通讯作者)，Univ Rome, Fac Med & Chirurg, Dipartimento Sci Oftalmol, Sapienza 1,Viale Policlin 155, I-00161 Rome, Italy.
EM impabarbar@hotmail.com
CR Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Andrieu-Abadie N, 1999, FASEB J, V13, P1501, DOI 10.1096/fasebj.13.12.1501
   Bremer J., 1997, CARNITINE TODAY, P1, DOI [10.1007/978-1-4615-6005-0_1, DOI 10.1007/978-1-4615-6005-0_1]
   Bron AJ, 2004, EXP EYE RES, V78, P347, DOI 10.1016/j.exer.2003.09.019
   BROWN NAP, 1987, BRIT J OPHTHALMOL, V71, P405, DOI 10.1136/bjo.71.6.405
   BROWNLEE M, 1995, ANNU REV MED, V46, P223, DOI 10.1146/annurev.med.46.1.223
   Bucala R, 1992, Adv Pharmacol, V23, P1
   Calabrese V, 2005, J NEUROSCI RES, V79, P509, DOI 10.1002/jnr.20386
   Cammarata PR, 1999, INVEST OPHTH VIS SCI, V40, P1727
   CAMMARATA PR, 1994, INVEST OPHTH VIS SCI, V35, P1223
   CAPACCIOLI S, 1998, APOPTOSI OFTALMOLOGI, P44
   Chang BJ, 2002, ARCH BIOCHEM BIOPHYS, V405, P55, DOI 10.1016/S0003-9861(02)00342-9
   CHYLACK LT, 1993, ARCH OPHTHALMOL-CHIC, V111, P831, DOI 10.1001/archopht.1993.01090060119035
   Cifone MG, 1997, P ASSOC AM PHYSICIAN, V109, P146
   Cossarizza A, 1997, AIDS, V11, P19, DOI 10.1097/00002030-199701000-00004
   CREUZOTGARCHER C, 2001, INFLAMMATORY DIS CON, P8
   Cruess AF, 2008, PHARMACOECONOMICS, V26, P57, DOI 10.2165/00019053-200826010-00006
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   Di Marzio L, 1999, CLIN IMMUNOL, V92, P103, DOI 10.1006/clim.1999.4727
   DiMarzio L, 1997, P ASSOC AM PHYSICIAN, V109, P154
   Elanchezhian R, 2007, CURR EYE RES, V32, P961, DOI 10.1080/02713680701673470
   Feher J, 2005, OPHTHALMOLOGICA, V219, P154, DOI 10.1159/000085248
   Foulks GN, 2007, SURV OPHTHALMOL, V52, P369, DOI 10.1016/j.survophthal.2007.04.009
   FOULKS GN, 1981, OPHTHALMOLOGY, V88, P801
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P532
   GALLI G, 1993, EXP CELL RES, V204, P54, DOI 10.1006/excr.1993.1008
   Geraldine P, 2006, EXP EYE RES, V83, P1340, DOI 10.1016/j.exer.2006.07.009
   GILMARTIN B, 1995, OPHTHAL PHYSL OPT, V15, P431, DOI 10.1016/0275-5408(95)00095-U
   Gipson IK, 2004, EXP EYE RES, V78, P379, DOI 10.1016/S0014-4835(03)00204-5
   Gulcin I, 2006, LIFE SCI, V78, P803, DOI 10.1016/j.lfs.2005.05.103
   Hagen TM, 2002, P NATL ACAD SCI USA, V99, P7184
   HAMARD P, 1994, BRIT J OPHTHALMOL, V78, P449, DOI 10.1136/bjo.78.6.449
   Holly F J, 1985, J Ocul Pharmacol, V1, P327, DOI 10.1089/jop.1985.1.327
   Ishii T, 2000, JPN J PHARMACOL, V83, P119, DOI 10.1254/jjp.83.119
   Jackson GR, 1999, VISION RES, V39, P3975, DOI 10.1016/S0042-6989(99)00092-9
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   KAISER HJ, 1995, GRAEF ARCH CLIN EXP, V233, P484, DOI 10.1007/BF00183429
   Kashiwagi A, 2001, COMP BIOCHEM PHYS B, V130, P411, DOI 10.1016/S1096-4959(01)00458-4
   KLEIN BEK, 1992, OPHTHALMOLOGY, V99, P546
   Kocer I, 2007, GRAEF ARCH CLIN EXP, V245, P588, DOI 10.1007/s00417-005-0097-1
   KOVERECH A, 2007, USE 1 CARNITINE ALKA
   Leibowitz H M, 1980, Surv Ophthalmol, V24, P335
   Li DQ, 2001, EXP EYE RES, V73, P449, DOI 10.1006/exer.2001.1054
   LILES MR, 1991, ARCH OPHTHALMOL-CHIC, V109, P1285, DOI 10.1001/archopht.1991.01080090111033
   Linetsky M, 2008, BBA-MOL BASIS DIS, V1782, P22, DOI 10.1016/j.bbadis.2007.10.003
   Mathias RT, 1997, PHYSIOL REV, V77, P21, DOI 10.1152/physrev.1997.77.1.21
   Moretti S, 1998, BLOOD, V91, P3817, DOI 10.1182/blood.V91.10.3817.3817_3817_3824
   Moretti S, 2002, ANTIOXID REDOX SIGN, V4, P391, DOI 10.1089/15230860260196191
   Moss SE, 2000, ARCH OPHTHALMOL-CHIC, V118, P1264
   Mutomba MC, 2000, FEBS LETT, V478, P19, DOI 10.1016/S0014-5793(00)01817-2
   Nowak JZ, 2006, PHARMACOL REP, V58, P353
   Omoti A E, 2007, Niger J Clin Pract, V10, P79
   Orlandi A, 2002, ATHEROSCLEROSIS, V160, P81, DOI 10.1016/S0021-9150(01)00568-8
   Peluso C, 2000, J CELL BIOCHEM, V80, P1
   PESCOSOLIDO N, OPT VIS SCI IN PRESS
   PESCOSOLIDO N, 2002, ATT 17 RIUN AISG RAP
   PESSOTTO P, 1994, J OCUL PHARMACOL, V10, P643, DOI 10.1089/jop.1994.10.643
   Pessotto P, 1997, EXP EYE RES, V64, P195, DOI 10.1006/exer.1996.0188
   Pettegrew JW, 2000, MOL PSYCHIATR, V5, P616, DOI 10.1038/sj.mp.4000805
   Pisano C, 2003, CLIN CANCER RES, V9, P5756
   PISANO C, 1996, 24 M FED EUR BIOCH S
   Quigley HA, 2000, INVEST OPHTH VIS SCI, V41, P3460
   QUIGLEY HA, 1995, INVEST OPHTH VIS SCI, V36, P774
   RANKIN SJA, 1995, AM J OPHTHALMOL, V119, P685, DOI 10.1016/S0002-9394(14)72771-0
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   REVOLTELLA RP, 1994, BBA-MOL CELL RES, V1224, P333, DOI 10.1016/0167-4889(94)90265-8
   Rivera JL, 2008, CURR OPIN OPHTHALMOL, V19, P102, DOI 10.1097/ICU.0b013e3282f493b3
   Skulachev VP, 2007, BIOCHEMISTRY-MOSCOW+, V72, P1385, DOI 10.1134/S0006297907120139
   SLOANE ME, 1988, VISION RES, V28, P1235, DOI 10.1016/0042-6989(88)90039-9
   SPAGNOLI LG, 1995, ATHEROSCLEROSIS, V114, P29, DOI 10.1016/0021-9150(94)05460-Z
   Sperduto RD, 2001, OPHTHALMOLOGY, V108, P1400
   Swamy-Mruthinti S, 1999, EXP EYE RES, V69, P109, DOI 10.1006/exer.1999.0680
   Tan Ava Grace, 2006, BMC Ophthalmol, V6, P17, DOI 10.1186/1471-2415-6-17
   TATE DJ, 1993, INVEST OPHTH VIS SCI, V34, P2348
   Tomlinson A, 2006, INVEST OPHTH VIS SCI, V47, P4309, DOI 10.1167/iovs.05-1504
   Truscott RJW, 2005, EXP EYE RES, V80, P709, DOI 10.1016/j.exer.2004.12.007
   VANBUSKIRK EM, 1992, AM J OPHTHALMOL, V113, P447, DOI 10.1016/S0002-9394(14)76171-9
   VANHAERINGEN NJ, 1981, SURV OPHTHALMOL, V26, P84, DOI 10.1016/0039-6257(81)90145-4
   Vescovo G, 2002, AM J PHYSIOL-CELL PH, V283, pC802, DOI 10.1152/ajpcell.00046.2002
   Wax MB, 2000, BRIT J OPHTHALMOL, V84, P423, DOI 10.1136/bjo.84.4.423
NR 80
TC 13
Z9 14
U1 0
U2 8
PU SPRINGER INTERNATIONAL PUBLISHING AG
PI CHAM
PA GEWERBESTRASSE 11, CHAM, CH-6330, SWITZERLAND
SN 1174-5886
EI 1179-6901
J9 DRUGS R&D
JI Drugs R&D
PY 2008
VL 9
SU 1
BP 3
EP 14
DI 10.2165/0126839-200809001-00002
PG 12
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA 422QK
UT WOS:000264442600002
PM 19105587
DA 2022-11-30
ER

PT J
AU Paskowitz, DM
   Nune, G
   Yasumura, D
   Yang, HD
   Bhisitkul, RB
   Sharma, S
   Matthes, MT
   Zarbin, MA
   LaVail, MM
   Duncan, JL
AF Paskowitz, DM
   Nune, G
   Yasumura, D
   Yang, HD
   Bhisitkul, RB
   Sharma, S
   Matthes, MT
   Zarbin, MA
   LaVail, MM
   Duncan, JL
TI BDNF reduces the retinal toxicity of verteporfin photodynamic therapy
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID FIBROBLAST-GROWTH-FACTOR; SUBFOVEAL CHOROIDAL NEOVASCULARIZATION;
   RANDOMIZED CLINICAL-TRIALS; EPITHELIUM-DERIVED FACTOR; AGE-RELATED
   MACULOPATHY; LIGHT-DAMAGE; MULTIFOCAL ELECTRORETINOGRAM; PHOTORECEPTOR
   SURVIVAL; LASER PHOTOCOAGULATION; ROD PHOTORECEPTORS
AB Purpose. Verteporfin photodynamic therapy (PDT) is the most effective treatment for age-related macular degeneration, using laser activation of a photosensitizing dye to achieve closure of choroidal neovascularization. Although PDT preferentially affects pathologic vessels, it can also cause collateral damage to the overlying retina. In the current study, it was found that the neuroprotective agent brain-derived neurotrophic factor (BDNF) reduces this retinal damage.
   Methods. Normal adult rats received intravitreal BDNF in one eye and PBS or no injection in the other eye 2 days before PDT.
   Results. Control eyes exhibited choroidal hypofluorescence, moderate to severe photoreceptor loss, and depression of local retinal function measured using multifocal ERG in the laser-treated area. BDNF-injected eyes had more surviving photoreceptors and improved multifocal ERG responses 1 week after PDT. BDNF did not diminish the effect of PDT on the choroidal circulation as assessed by fluorescein angiography, and there was no evidence of retinal toxicity due to BDNF treatment.
   Conclusions. These results suggest that adjunctive neuroprotective therapy may reduce collateral damage to photoreceptors and improve visual outcome after PDT.
C1 Univ Calif San Francisco, Sch Med, Beckman Vis Ctr, Dept Ophthalmol, San Francisco, CA 94143 USA.
   Univ Calif San Francisco, Med Scientist Training Program, San Francisco, CA 94143 USA.
   Univ Calif San Francisco, Grad Program Neurosci, San Francisco, CA 94143 USA.
   Univ Calif San Francisco, Dept Anat, San Francisco, CA 94143 USA.
   Univ Med & Dent New Jersey, Inst Ophthalmol & Visual Sci, Newark, NJ 07103 USA.
C3 University of California System; University of California San Francisco;
   University of California System; University of California San Francisco;
   University of California System; University of California San Francisco;
   University of California System; University of California San Francisco;
   Rutgers State University New Brunswick; Rutgers State University Medical
   Center
RP Duncan, JL (通讯作者)，Univ Calif San Francisco, Sch Med, Beckman Vis Ctr, Dept Ophthalmol, 10 Koret Way,Room K-120, San Francisco, CA 94143 USA.
EM jduncan@itsa.ucsf.edu
OI Zarbin, Marco/0000-0002-7811-7132
FU NATIONAL EYE INSTITUTE [R37EY001919, R01EY006842, U01EY006842,
   R01EY001919, P30EY002162] Funding Source: NIH RePORTER; NEI NIH HHS
   [EY01919, EY02162, EY06842, EY00415] Funding Source: Medline
CR Arnold J, 2001, OPHTHALMOLOGY, V108, P841
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Arnold JJ, 2004, AM J OPHTHALMOL, V137, P683, DOI 10.1016/j.ajo.2003.11.059
   Azab M, 2004, RETINA-J RET VIT DIS, V24, P1
   Ball SL, 2000, INVEST OPHTH VIS SCI, V41, P610
   BEHBEHANI MM, 1984, RETINA-J RET VIT DIS, V4, P257, DOI 10.1097/00006982-198400440-00009
   Blinder KJ, 2003, OPHTHALMOLOGY, V110, P667, DOI 10.1016/S0161-6420(02)01998-X
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bressler NM, 2002, ARCH OPHTHALMOL-CHIC, V120, P1307
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Cao W, 2001, INVEST OPHTH VIS SCI, V42, P1646
   Cayouette M, 1999, NEUROBIOL DIS, V6, P523, DOI 10.1006/nbdi.1999.0263
   Chong NHV, 1999, INVEST OPHTH VIS SCI, V40, P1298
   Chu Y, 1998, AUST NZ J OPHTHALMOL, V26, P87, DOI 10.1046/j.1440-1606.1998.00068.x
   DOBI ET, 1989, ARCH OPHTHALMOL-CHIC, V107, P264, DOI 10.1001/archopht.1989.01070010270035
   FAKTOROVICH EG, 1992, J NEUROSCI, V12, P3554
   FRANK RN, 1989, CURR EYE RES, V8, P239, DOI 10.3109/02713688908997565
   Frasson M, 1999, INVEST OPHTH VIS SCI, V40, P2724
   Gilpin DA, 1996, BURNS, V22, P607, DOI 10.1016/S0305-4179(96)00064-2
   Hood DC, 1997, VISUAL NEUROSCI, V14, P533, DOI 10.1017/S0952523800012190
   HUMPHREY MF, 1993, CURR EYE RES, V12, P367, DOI 10.3109/02713689308999461
   Husain D, 1996, ARCH OPHTHALMOL-CHIC, V114, P978, DOI 10.1001/archopht.1996.01100140186012
   Ikeda K, 2003, J NEUROCHEM, V87, P290, DOI 10.1046/j.1471-4159.2003.01994.x
   Jiang LB, 2003, DOC OPHTHALMOL, V107, P165, DOI 10.1023/A:1026215221569
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein R, 2002, OPHTHALMOLOGY, V109, P1767, DOI 10.1016/S0161-6420(02)01146-6
   Kramer M, 1996, OPHTHALMOLOGY, V103, P427
   Lai TYY, 2004, AM J OPHTHALMOL, V137, P826, DOI 10.1016/j.ajo.2003.11.079
   Landy Jennifer, 2003, Curr Opin Ophthalmol, V14, P163, DOI 10.1097/00055735-200306000-00010
   LAVAIL MM, 1975, EXP EYE RES, V21, P167, DOI 10.1016/0014-4835(75)90080-9
   LAVAIL MM, 1992, P NATL ACAD SCI USA, V89, P11249, DOI 10.1073/pnas.89.23.11249
   LAVAIL MM, 1976, INVEST OPHTH VISUAL, V15, P64
   LaVail MM, 1998, INVEST OPHTH VIS SCI, V39, P592
   Machida S, 2001, INVEST OPHTH VIS SCI, V42, P1087
   Moschos MN, 2003, EUR J OPHTHALMOL, V13, P461, DOI 10.1177/112067210301300507
   Ogata N, 2002, INVEST OPHTH VIS SCI, V43, P1168
   Okoye G, 2003, J NEUROSCI, V23, P4164
   Palmowski AM, 2002, OPHTHALMOLOGY, V109, P1788, DOI 10.1016/S0161-6420(02)01147-8
   Peyman GA, 2000, OPHTHALMOLOGY, V107, P29, DOI 10.1016/S0161-6420(99)00012-3
   Reinke MH, 1999, OPHTHALMOLOGY, V106, P1915, DOI 10.1016/S0161-6420(99)90401-3
   Rohrer B, 1999, J NEUROSCI, V19, P8919, DOI 10.1523/JNEUROSCI.19-20-08919.1999
   RYAN SJ, 1982, ARCH OPHTHALMOL-CHIC, V100, P1804, DOI 10.1001/archopht.1982.01030040784015
   Sanftner LHM, 2001, MOL THER, V4, P622, DOI 10.1006/mthe.2001.0498
   Seeliger Mathias W., 2000, Documenta Ophthalmologica, V100, P167, DOI 10.1023/A:1002731703120
   Tobe T, 1998, AM J PATHOL, V153, P1641, DOI 10.1016/S0002-9440(10)65753-7
   Ugolini G, 1995, BRAIN RES, V704, P121, DOI 10.1016/0006-8993(95)01191-9
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   Vollrath D, 2001, P NATL ACAD SCI USA, V98, P12584, DOI 10.1073/pnas.221364198
   WILLIAMS TP, 1983, INVEST OPHTH VIS SCI, V24, P285
   Xiao M, 1998, INVEST OPHTH VIS SCI, V39, P618
   Yamada H, 2001, AM J PATHOL, V159, P1113, DOI 10.1016/S0002-9440(10)61787-7
   Zacks DN, 2002, INVEST OPHTH VIS SCI, V43, P2384
NR 52
TC 25
Z9 26
U1 0
U2 4
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD NOV
PY 2004
VL 45
IS 11
BP 4190
EP 4196
DI 10.1167/iovs.04-0676
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 865BT
UT WOS:000224678200047
PM 15505074
DA 2022-11-30
ER

PT J
AU Shapland, CY
   Zhao, QY
   Bowden, J
AF Shapland, Chin Yang
   Zhao, Qingyuan
   Bowden, Jack
TI Profile-likelihood Bayesian model averaging for two-sample summary data
   Mendelian randomization in the presence of horizontal pleiotropy
SO STATISTICS IN MEDICINE
LA English
DT Article
DE Bayesian model averaging; horizontal pleiotropy; InSIDE violation;
   two-sample summary data Mendelian randomization; weak instruments
ID INSTRUMENTAL VARIABLES; INVALID INSTRUMENTS; COMPLEX TRAITS;
   ASSOCIATION; REGRESSION
AB Two-sample summary data Mendelian randomization is a popular method for assessing causality in epidemiology, by using genetic variants as instrumental variables. If genes exert pleiotropic effects on the outcome not entirely through the exposure of interest, this can lead to heterogeneous and (potentially) biased estimates of causal effect. We investigate the use of Bayesian model averaging to preferentially search the space of models with the highest posterior likelihood. We develop a Metropolis-Hasting algorithm to perform the search using the recently developed MR-RAPS as the basis for defining a posterior distribution that efficiently accounts for pleiotropic and weak instrument bias. We demonstrate how our general modeling approach can be extended from a standard one-component causal model to a two-component model, which allows a large proportion of SNPs to violate the InSIDE assumption. We use Monte Carlo simulations to illustrate our methods and compare it to several related approaches. We finish by applying our approach to investigate the causal role of cholesterol on the development age-related macular degeneration.
C1 [Shapland, Chin Yang; Bowden, Jack] Univ Bristol, MRC Integrat Epidemiol Unit, Oakfield House, Bristol BS8 2BN, Avon, England.
   [Shapland, Chin Yang; Bowden, Jack] Univ Bristol, Populat Hlth Sci, Bristol, Avon, England.
   [Zhao, Qingyuan] Univ Cambridge, Dept Pure Math & Math Stat, Cambridge, England.
   [Bowden, Jack] Univ Exeter, Coll Med & Hlth, Exeter, Devon, England.
C3 University of Bristol; University of Bristol; University of Cambridge;
   University of Exeter
RP Shapland, CY (通讯作者)，Univ Bristol, MRC Integrat Epidemiol Unit, Oakfield House, Bristol BS8 2BN, Avon, England.
EM chinyang.shapland@bristol.ac.uk
OI Bowden, Jack/0000-0003-2628-3304
FU Expanding Excellence in England [E3]; Issac Newton Trust; Medical
   Research Council [MC_UU_00011/3]
FX Expanding Excellence in England (E3); Issac Newton Trust; Medical
   Research Council, Grant/Award Number: MC_UU_00011/3
CR Albert J, 2009, USE R, P1, DOI 10.1007/978-0-387-92298-0_1
   Bowden J., 2019, MR DATA CHALLENGE 20
   Bowden J, 2018, INT J EPIDEMIOL, V47, P1264, DOI [10.1093/ije/dyy101, 10.1093/ije/dyy265]
   Bowden J, 2019, INT J EPIDEMIOL, V48, P728, DOI 10.1093/ije/dyy258
   Bowden J, 2017, STAT MED, V36, P1783, DOI 10.1002/sim.7221
   Bowden J, 2016, GENET EPIDEMIOL, V40, P304, DOI 10.1002/gepi.21965
   Bowden J, 2015, INT J EPIDEMIOL, V44, P512, DOI 10.1093/ije/dyv080
   Boyle EA, 2017, CELL, V169, P1177, DOI 10.1016/j.cell.2017.05.038
   Burgess S, 2018, INT J EPIDEMIOL, V47, P1242, DOI 10.1093/ije/dyy080
   Burgess S, 2017, OPHTHALMOLOGY, V124, P1165, DOI 10.1016/j.ophtha.2017.03.042
   Burgess S, 2013, GENET EPIDEMIOL, V37, P658, DOI 10.1002/gepi.21758
   Colijn JM, 2019, OPHTHALMOLOGY, V126, P393, DOI 10.1016/j.ophtha.2018.09.045
   Davis JP, 2017, PLOS GENET, V13, DOI 10.1371/journal.pgen.1007079
   Del Greco MF, 2015, STAT MED, V34, P2926, DOI 10.1002/sim.6522
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Greenland S, 2000, INT J EPIDEMIOL, V29, P722, DOI 10.1093/ije/29.4.722
   Guo ZJ, 2018, J R STAT SOC B, V80, P793, DOI 10.1111/rssb.12275
   Hartigan J. A., 1979, Applied Statistics, V28, P100, DOI 10.2307/2346830
   Hartwig FP, 2017, INT J EPIDEMIOL, V46, P1985, DOI 10.1093/ije/dyx102
   Hemani G, 2018, ELIFE, V7, DOI 10.7554/eLife.34408
   Hemani G, 2018, HUM MOL GENET, V27, pR195, DOI 10.1093/hmg/ddy163
   Hoeting JA, 1999, STAT SCI, V14, P382, DOI 10.1214/ss/1009212519
   Inoue A, 2010, REV ECON STAT, V92, P557, DOI 10.1162/REST_a_00011
   Iong D., 2020, ARXIV PREPRINT ARXIV
   Jasra A, 2005, STAT SCI, V20, P50, DOI 10.1214/088342305000000016
   Kang H, 2022, BIOMETRICS, V78, P24, DOI 10.1111/biom.13415
   Karl A., 2012, ARXIV PREPRINT ARXIV
   Kettunen J, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11122
   Kolesar M, 2015, J BUS ECON STAT, V33, P474, DOI 10.1080/07350015.2014.978175
   Koop G, 2012, J ECONOMETRICS, V171, P237, DOI 10.1016/j.jeconom.2012.06.005
   Lawlor DA, 2016, INT J EPIDEMIOL, V45, P908, DOI 10.1093/ije/dyw127
   Lunn D., 2012, BUGS BOOK PRACTICAL
   Marin J. M., 2014, BAYESIAN ESSENTIALS
   Neyman J, 1948, ECONOMETRICA, V16, P1, DOI 10.2307/1914288
   O'Hara RB, 2009, BAYESIAN ANAL, V4, P85, DOI 10.1214/09-BA403
   Pearl J., 2000, CAUSALITY
   Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795
   Sanderson E, 2019, INT J EPIDEMIOL, V48, P713, DOI 10.1093/ije/dyy262
   Shapland CY, 2019, STAT MED, V38, P985, DOI 10.1002/sim.8029
   Shi H, 2016, AM J HUM GENET, V99, P139, DOI 10.1016/j.ajhg.2016.05.013
   Smith GD, 2003, INT J EPIDEMIOL, V32, P1, DOI 10.1093/ije/dyg070
   Staiger D, 1997, ECONOMETRICA, V65, P557, DOI 10.2307/2171753
   Thompson JR, 2017, STAT MED, V36, P4627, DOI 10.1002/sim.7442
   Thompson JR, 2016, INT J BIOSTAT, V12, DOI 10.1515/ijb-2015-0074
   van Leeuwen EM, 2018, PROG RETIN EYE RES, V67, P56, DOI 10.1016/j.preteyeres.2018.04.006
   Verbanck M, 2018, NAT GENET, V50, P693, DOI 10.1038/s41588-018-0099-7
   Visscher PM, 2017, AM J HUM GENET, V101, P5, DOI 10.1016/j.ajhg.2017.06.005
   Zhao QY, 2020, ANN STAT, V48, P1742, DOI 10.1214/19-AOS1866
   Zhao QY, 2019, INT J EPIDEMIOL, V48, P1478, DOI [10.1093/ije/dyz142, 10.1093/ije/]
   Zuber V, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-13870-3
NR 51
TC 1
Z9 1
U1 0
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0277-6715
EI 1097-0258
J9 STAT MED
JI Stat. Med.
PD MAR 15
PY 2022
VL 41
IS 6
BP 1100
EP 1119
DI 10.1002/sim.9320
EA JAN 2022
PG 20
WC Mathematical & Computational Biology; Public, Environmental &
   Occupational Health; Medical Informatics; Medicine, Research &
   Experimental; Statistics & Probability
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Mathematical & Computational Biology; Public, Environmental &
   Occupational Health; Medical Informatics; Research & Experimental
   Medicine; Mathematics
GA ZG3YP
UT WOS:000744675600001
PM 35060160
OA Green Submitted, Green Published, hybrid
DA 2022-11-30
ER

PT J
AU Tao, L
   He, DX
   Liao, CY
   Cai, BX
   Chen, C
   Wang, Y
   Chen, JM
   Liu, ZG
   Wu, YL
AF Tao, Lei
   He, Danxue
   Liao, Chunyan
   Cai, Binxiang
   Chen, Chao
   Wang, Yan
   Chen, Jingmeng
   Liu, Zuguo
   Wu, Yalin
TI Repressing c-Jun N-terminal kinase signaling mitigates retinal pigment
   epithelium degeneration in mice with failure to clear all-trans-retinal
SO EXPERIMENTAL EYE RESEARCH
LA English
DT Article
DE Macular degeneration; Stargardt 's disease; Retinal pigment epithelium;
   c-Jun N -Terminal kinase (JNK); Reactive oxygen species; Endoplasmic
   reticulum stress
ID INDUCED RETINOPATHY; STARGARDT DISEASE; GENE ABCR; JNK; ACTIVATION;
   APOPTOSIS; DAMAGE; INVOLVEMENT; INHIBITION; INDUCTION
AB Retinal pigment epithelium (RPE) cell apoptosis arising from all-trans-retinal (atRAL) is in close contact with the etiology of dry age-related macular degeneration (AMD) and autosomal recessive Stargardt's disease (STGD1), but its underlying mechanisms remain elusive. In this study, we reported that c-Jun N-terminal kinase (JNK) activation facilitated atRAL-induced apoptosis of RPE cells. Reactive oxygen species production and endoplasmic reticulum stress were identified as two of major upstream events responsible for activating JNK signaling in atRAL-loaded RPE cells. Inhibiting JNK signaling rescued RPE cells from apoptosis induced by atRAL through attenuating caspase-3 activation leading to poly-ADP-ribose polymerase (PARP) cleavage, and DNA damage response. Abca4-/-Rdh8-/- mice upon light exposure exhibit rapidly increased accumulation of atRAL in the retina, and display severe RPE degeneration, a primary attribute of dry AMD and STGD1. Reducing JNK signaling by intraperitoneally injected JNK-IN-8 was highly effective in preventing RPE atrophy and apoptosis in lightexposed Abca4- /-Rdh8-/- mice. These findings afford a further understanding for contribution of JNK activation by atRAL to retinal damage.
C1 [Tao, Lei; He, Danxue; Liao, Chunyan; Cai, Binxiang; Chen, Chao; Liu, Zuguo; Wu, Yalin] Xiamen Univ, Sch Med, Eye Inst,Fujian Prov Key Lab Ophthalmol & Visual, Xiangan Hosp,Dept Ophthalmol,Fujian Engn & Res Ct, Xiangan South Rd, Xiamen 361102, Fujian, Peoples R China.
   [Wang, Yan] Shenzhen Univ, South China Hosp, Hlth Sci Ctr, Dept Ophthalmol, Shenzhen, Guangdong, Peoples R China.
   [Chen, Jingmeng] Xiamen Univ, Sch Med, Xiamen, Fujian, Peoples R China.
   [Wu, Yalin] Xiamen Univ, Xiamen Eye Ctr, Xiamen, Fujian, Peoples R China.
   [Wu, Yalin] Xiamen Univ, Shenzhen Res Inst, Shenzhen, Guangdong, Peoples R China.
C3 Xiamen University; Shenzhen University; Xiamen University; Xiamen
   University; Xiamen University
RP Wu, YL (通讯作者)，Xiamen Univ, Sch Med, Eye Inst,Fujian Prov Key Lab Ophthalmol & Visual, Xiangan Hosp,Dept Ophthalmol,Fujian Engn & Res Ct, Xiangan South Rd, Xiamen 361102, Fujian, Peoples R China.
EM yalinw@xmu.edu.cn
FU China National Natural Science Foundation [82171064, 81870671];
   Guangdong Basic and Applied Basic Research Foundation [2021A1515011391];
   Basic Research Program of Shenzhen [JCYJ20180306173025004]; XMU Training
   Program of Innovation and Entrepreneurship for Undergraduates
FX This work was supported by grants from China National Natural Science
   Foundation (82171064 and 81870671 to Y.Wu) , Guangdong Basic and Applied
   Basic Research Foundation (2021A1515011391 to Y. Wu) , the Basic
   Research Program of Shenzhen (JCYJ20180306173025004 to Y.Wu) , and XMU
   Training Program of Innovation and Entrepreneurship for Undergraduates.
CR Allikmets R, 1997, NAT GENET, V15, P236, DOI 10.1038/ng0397-236
   Allikmets R, 2000, AM J HUM GENET, V67, P487, DOI 10.1086/303018
   Allikmets R, 1997, SCIENCE, V277, P1805, DOI 10.1126/science.277.5333.1805
   Berchuck JE, 2013, INVEST OPHTH VIS SCI, V54, P2669, DOI 10.1167/iovs.12-11020
   Bogoyevitch MA, 2006, MICROBIOL MOL BIOL R, V70, P1061, DOI 10.1128/MMBR.00025-06
   Boulares AH, 1999, J BIOL CHEM, V274, P22932, DOI 10.1074/jbc.274.33.22932
   Burma S, 2001, J BIOL CHEM, V276, P42462, DOI 10.1074/jbc.C100466200
   Cai JY, 2000, PROG RETIN EYE RES, V19, P205, DOI 10.1016/S1350-9462(99)00009-9
   Chen CH, 2012, J BIOL CHEM, V287, P24662, DOI 10.1074/jbc.M112.354514
   Chen Y, 2012, J BIOL CHEM, V287, P5059, DOI 10.1074/jbc.M111.315432
   Du HJ, 2013, P NATL ACAD SCI USA, V110, P2377, DOI 10.1073/pnas.1221729110
   Guma M, 2009, P NATL ACAD SCI USA, V106, P8760, DOI 10.1073/pnas.0902659106
   Henriksson JT, 2010, EXP EYE RES, V90, P382, DOI 10.1016/j.exer.2009.11.004
   Hughes D, 2019, FEBS J, V286, P342, DOI 10.1111/febs.14422
   Hunot S, 2004, P NATL ACAD SCI USA, V101, P665, DOI 10.1073/pnas.0307453101
   Li J, 2016, TOXICOLOGY, V371, P41, DOI 10.1016/j.tox.2016.10.005
   Li J, 2015, TOXICOL SCI, V143, P196, DOI 10.1093/toxsci/kfu223
   Li J, 2013, J BIOL CHEM, V288, P35671, DOI 10.1074/jbc.M113.511386
   Liao CY, 2020, J BIOL CHEM, V295, P6958, DOI 10.1074/jbc.RA120.013189
   Liao Y, 2019, INVEST OPHTH VIS SCI, V60, P3034, DOI 10.1167/iovs.18-26360
   Liu X, 2016, INVEST OPHTH VIS SCI, V57, P1017, DOI 10.1167/iovs.15-18429
   Lu CR, 2006, MOL CELL, V23, P121, DOI 10.1016/j.molcel.2006.05.023
   Maeda A, 2008, J BIOL CHEM, V283, P26684, DOI 10.1074/jbc.M804505200
   Maeda A, 2014, P NATL ACAD SCI USA, V111, pE1428, DOI 10.1073/pnas.1317986111
   Maeda A, 2009, J BIOL CHEM, V284, P15173, DOI 10.1074/jbc.M900322200
   Makelainen S, 2019, PLOS GENET, V15, DOI 10.1371/journal.pgen.1007873
   Meng QH, 2011, PROTEIN CELL, V2, P889, DOI 10.1007/s13238-011-1113-3
   Modesti M, 2001, CURR BIOL, V11, pR229, DOI 10.1016/S0960-9822(01)00112-9
   Nagata S, 2018, ANNU REV IMMUNOL, V36, P489, DOI 10.1146/annurev-immunol-042617-053010
   Rogakou EP, 1999, J CELL BIOL, V146, P905, DOI 10.1083/jcb.146.5.905
   Sawada O, 2014, EXP EYE RES, V123, P27, DOI 10.1016/j.exer.2014.04.003
   Shimada K, 2009, CANCER RES, V69, P3157, DOI 10.1158/0008-5472.CAN-08-3530
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Wang YP, 2017, NATURE, V547, P99, DOI 10.1038/nature22393
   Zeke A, 2016, MICROBIOL MOL BIOL R, V80, P793, DOI 10.1128/MMBR.00043-14
   Zhang T, 2012, CHEM BIOL, V19, P140, DOI 10.1016/j.chembiol.2011.11.010
   Zhu X, 2016, EXP CELL RES, V348, P87, DOI 10.1016/j.yexcr.2016.09.002
   Zhu XW, 2001, J NEUROCHEM, V76, P435, DOI 10.1046/j.1471-4159.2001.00046.x
NR 38
TC 0
Z9 0
U1 0
U2 6
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0014-4835
EI 1096-0007
J9 EXP EYE RES
JI Exp. Eye Res.
PD JAN
PY 2022
VL 214
AR 108877
DI 10.1016/j.exer.2021.108877
EA DEC 2021
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA XW4HL
UT WOS:000735582300002
PM 34863682
DA 2022-11-30
ER

PT J
AU Keenan, TD
   Agron, E
   Mares, JA
   Clemons, TE
   Asten, F
   Swaroop, A
   Chew, EY
AF Keenan, Tiarnan D.
   Agron, Elvira
   Mares, Julie A.
   Clemons, Traci E.
   Asten, Freekje
   Swaroop, Anand
   Chew, Emily Y.
CA AREDS Res Grp
   AREDS2 Res Grp
TI Adherence to a Mediterranean diet and cognitive function in the
   Age-Related Eye Disease Studies 1 & 2
SO ALZHEIMERS & DEMENTIA
LA English
DT Article
DE age-related macular degeneration; cognitive function; fish consumption;
   genetic interaction; Mediterranean diet
ID MACULAR DEGENERATION; ALZHEIMERS-DISEASE; DECLINE; DEMENTIA; RISK;
   OMEGA-3-FATTY-ACIDS; IMPAIRMENT; PATTERNS; BRAIN; AREDS
AB Introduction: The objective was to determine whether closer adherence to the alternative Mediterranean Diet (aMED) was associated with altered cognitive function.
   Methods: Observational analyses of participants (n = 7,756) enrolled in two randomized trials of nutritional supplements for age-related macular degeneration: Age-Related Eye Disease Study (AREDS) and AREDS2.
   Results: Odds ratios for cognitive impairment, in aMED tertile 3 (vs 1), were 0.36 (P = .0001) for Modified Mini-Mental State (<80) and 0.56 (P = .001) for composite score in AREDS, and 0.56 for Telephone Interview Cognitive Status-Modified (<30) and 0.48 for composite score (each P < .0001) in AREDS2. Fish intake was associated with higher cognitive function. In AREDS2, rate of cognitive decline over 5 to 10 years was not significantly different by aMED but was significantly slower (P = .019) with higher fish intake.
   Discussion: Closer Mediterranean diet adherence was associated with lower risk of cognitive impairment but not slower decline in cognitive function. Apolipoprotein E (APOE) haplotype did not influence these relationships.
C1 [Keenan, Tiarnan D.; Agron, Elvira; Chew, Emily Y.] NEI, Div Epidemiol & Clin Applicat, NIH, Bethesda, MD 20892 USA.
   [Mares, Julie A.] Univ Wisconsin, Dept Ophthalmol & Visual Sci, Sch Med & Publ Hlth, Madison, WI USA.
   [Clemons, Traci E.] Emmes Co LLC, Rockville, MD USA.
   [Asten, Freekje; Swaroop, Anand] NEI, Neurobiol Neurodegenerat & Repair Lab, NIH, Bethesda, MD 20892 USA.
C3 National Institutes of Health (NIH) - USA; NIH National Eye Institute
   (NEI); University of Wisconsin System; University of Wisconsin Madison;
   National Institutes of Health (NIH) - USA; NIH National Eye Institute
   (NEI)
RP Chew, EY (通讯作者)，NIH, CRC, Bldg 10,Room 3-2531,10 Ctr Dr,MSC 1204, Bethesda, MD 20892 USA.
EM echew@nei.nih.gov
FU AREDS [NOI-EY-0-2127]; National Eye Institute/National Institutes of
   Health; Department of Health and Human Services; AREDS2
   [HHS-N-260-2005-00007-C, N01-EY-5-0007]
FX AREDS, Grant/Award Number: NOI-EY-0-2127; AREDS2, Grant/Award Numbers:
   HHS-N-260-2005-00007-C, N01-EY-5-0007; National Eye Institute/National
   Institutes of Health; Department of Health and Human Services
CR Abondio P, 2019, GENES-BASEL, V10, DOI 10.3390/genes10030222
   Bakre AT, 2018, PUBLIC HEALTH NUTR, V21, P1921, DOI 10.1017/S136898001800037X
   Barberger-Gateau P, 2007, NEUROLOGY, V69, P1921, DOI 10.1212/01.wnl.0000278116.37320.52
   Buckley JS, 2015, DRUG AGING, V32, P453, DOI 10.1007/s40266-015-0266-9
   Cao L, 2016, MOL NEUROBIOL, V53, P6144, DOI 10.1007/s12035-015-9516-4
   Casaletto KB, 2015, J INT NEUROPSYCH SOC, V21, P378, DOI 10.1017/S1355617715000351
   Chew EY, 2015, JAMA-J AM MED ASSOC, V314, P791, DOI 10.1001/jama.2015.9677
   Chew EY, 2012, OPHTHALMOLOGY, V119, P2282, DOI 10.1016/j.ophtha.2012.05.027
   Clemons TE, 2006, ARCH OPHTHALMOL-CHIC, V124, P537
   Davis C, 2015, NUTRIENTS, V7, P9139, DOI 10.3390/nu7115459
   Esiri MM, 2007, J PATHOL, V211, P181, DOI 10.1002/path.2089
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Grassmann F, 2017, GENOME MED, V9, DOI 10.1186/s13073-017-0418-0
   Hardman RJ, 2016, FRONT NUTR, V3, DOI 10.3389/fnut.2016.00022
   Hedden T, 2004, NAT REV NEUROSCI, V5, P87, DOI 10.1038/nrn1323
   Inc. SI, SAS STAT SOFTW CAUSA
   Kassoff A, 1999, CONTROL CLIN TRIALS, V20, P573
   Kipnis V, 2003, AM J EPIDEMIOL, V158, P14, DOI 10.1093/aje/kwg091
   Kipnis V, 2003, AM J EPIDEMIOL, V158, P2
   Koyama A, 2015, J GERONTOL A-BIOL, V70, P352, DOI 10.1093/gerona/glu097
   Lee CS, 2019, ALZHEIMERS DEMENT, V15, P34, DOI 10.1016/j.jalz.2018.06.2856
   Li K, 2017, J ALZHEIMERS DIS, V58, P360, DOI 10.3233/JAD-161201
   Lopez-Garcia E, 2014, AM J CLIN NUTR, V99, P172, DOI 10.3945/ajcn.113.068106
   Manly JJ, 2008, ANN NEUROL, V63, P494, DOI 10.1002/ana.21326
   Martinez-Lapiscina EH, 2013, J NUTR HEALTH AGING, V17, P544, DOI 10.1007/s12603-013-0027-6
   Martinez-Lapiscina EH, 2014, GENES NUTR, V9, DOI 10.1007/s12263-014-0393-7
   Mattson MP, 2002, PHYSIOL REV, V82, P637, DOI 10.1152/physrev.00004.2002
   Mattson MP, 2004, AGEING RES REV, V3, P445, DOI 10.1016/j.arr.2004.08.001
   Menardi A, 2018, J ALZHEIMERS DIS, V66, P1341, DOI 10.3233/JAD-180549
   Michaud DS, 1998, CANCER EPIDEM BIOMAR, V7, P283
   Morris MC, 2016, ANN NY ACAD SCI, V1367, P31, DOI 10.1111/nyas.13047
   Morris MC, 2015, ALZHEIMERS DEMENT, V11, P1015, DOI 10.1016/j.jalz.2015.04.011
   Morris MC, 2015, ALZHEIMERS DEMENT, V11, P1007, DOI 10.1016/j.jalz.2014.11.009
   Nichols E, 2019, LANCET NEUROL, V18, P88, DOI 10.1016/S1474-4422(18)30403-4
   Norton S, 2014, LANCET NEUROL, V13, P788, DOI 10.1016/S1474-4422(14)70136-X
   Olsson E, 2015, J ALZHEIMERS DIS, V43, P109, DOI 10.3233/JAD-140867
   Prince M, 2013, ALZHEIMERS DEMENT, V9, P63, DOI 10.1016/j.jalz.2012.11.007
   Radd-Vagenas S, 2018, AM J CLIN NUTR, V107, P389, DOI 10.1093/ajcn/nqx070
   Rankin MW, 2005, OPHTHAL EPIDEMIOL, V12, P271, DOI 10.1080/09286580591003815
   Rezazadeh M, 2019, J CELL PHYSIOL, V234, P16873, DOI 10.1002/jcp.28372
   Riederer P, 2017, J NEURAL TRANSM, V124, P1431, DOI 10.1007/s00702-017-1763-2
   RIMM EB, 1992, AM J EPIDEMIOL, V135, P1114, DOI 10.1093/oxfordjournals.aje.a116211
   Roberts RO, 2010, DEMENT GERIATR COGN, V29, P413, DOI 10.1159/000305099
   Rong SS, 2019, BRIT J OPHTHALMOL, V103, P1777, DOI 10.1136/bjophthalmol-2018-313277
   Samieri C, 2018, AM J EPIDEMIOL, V187, P933, DOI 10.1093/aje/kwx330
   Samieri C, 2013, EPIDEMIOLOGY, V24, P490, DOI 10.1097/EDE.0b013e318294a065
   Samieri C, 2013, J NUTR, V143, P493, DOI 10.3945/jn.112.169896
   SanGiovanni JP, 2007, ARCH OPHTHALMOL-CHIC, V125, P671, DOI 10.1001/archopht.125.5.671
   Santos Claudia Y, 2017, Alzheimers Dement (Amst), V7, P69, DOI 10.1016/j.dadm.2017.01.005
   Scarmeas N, 2018, LANCET NEUROL, V17, P1006, DOI 10.1016/S1474-4422(18)30338-7
   Scarmeas N, 2006, ANN NEUROL, V59, P912, DOI 10.1002/ana.20854
   Scarmeas N, 2006, ARCH NEUROL-CHICAGO, V63, P1709, DOI 10.1001/archneur.63.12.noc60109
   Subar AF, 2003, AM J EPIDEMIOL, V158, P1, DOI 10.1093/aje/kwg092
   Tangney CC, 2011, AM J CLIN NUTR, V93, P601, DOI 10.3945/ajcn.110.007369
   Tangney CC, 2014, NEUROLOGY, V83, P1410, DOI 10.1212/WNL.0000000000000884
   TRICHOPOULOU A, 1995, BMJ-BRIT MED J, V311, P1457, DOI 10.1136/bmj.311.7018.1457
   Trichopoulou A, 2003, NEW ENGL J MED, V348, P2599, DOI 10.1056/NEJMoa025039
   Trichopoulou A, 2015, EUR J NUTR, V54, P1311, DOI 10.1007/s00394-014-0811-z
   Tsivgoulis G, 2013, NEUROLOGY, V80, P1684, DOI 10.1212/WNL.0b013e3182904f69
   van de Rest O, 2016, NEUROLOGY, V86, P2063, DOI 10.1212/WNL.0000000000002719
   VanderWeele TJ, 2010, AM J EPIDEMIOL, V172, P1339, DOI 10.1093/aje/kwq332
   Vercambre MN, 2012, J ACAD NUTR DIET, V112, P816, DOI 10.1016/j.jand.2012.02.023
   Wengreen H, 2013, AM J CLIN NUTR, V98, P1263, DOI 10.3945/ajcn.112.051276
   Wu SQ, 2015, NEUROSCI BIOBEHAV R, V48, P1, DOI 10.1016/j.neubiorev.2014.11.008
   Zeng LF, 2017, ONCOTARGET, V8, P39877, DOI 10.18632/oncotarget.16347
   Zhang Y, 2016, AM J CLIN NUTR, V103, P330, DOI 10.3945/ajcn.115.124081
NR 66
TC 16
Z9 17
U1 1
U2 9
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1552-5260
EI 1552-5279
J9 ALZHEIMERS DEMENT
JI Alzheimers. Dement.
PD JUN
PY 2020
VL 16
IS 6
BP 831
EP 842
DI 10.1002/alz.12077
PG 12
WC Clinical Neurology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA OA6CF
UT WOS:000577870000002
PM 32285590
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Hao, YM
   Liu, J
   Wang, ZY
   Yu, LL
   Wang, J
AF Hao, Yiming
   Liu, Jie
   Wang, Ziyuan
   Yu, Liangli (Lucy)
   Wang, Jing
TI Piceatannol Protects Human Retinal Pigment Epithelial Cells against
   Hydrogen Peroxide Induced Oxidative Stress and Apoptosis through
   Modulating PI3K/Akt Signaling Pathway
SO NUTRIENTS
LA English
DT Article
DE piceatannol; ARPE-19 cell; oxidative stress; apoptosis; PI3K; Akt
   signaling pathway
ID MACULAR DEGENERATION; GROWTH-FACTOR; VITAMIN-A; ACTIVATION; SURVIVAL;
   ACID
AB This study investigated the protective effect and the molecular mechanism of piceatannol on hydrogen peroxide (H2O2)-induced retinal pigment epithelium cell (ARPE-19) damage. Piceatannol treatment significantly inhibited H2O2-induced RPE cell death and reactive oxygen species (ROS) generation by 64.4% and 75.0%, respectively. Results of flow cytometry showed that H2O2-induced ARPE-19 cells apoptosis was ameliorated by piceatannol supplementation, along with decreased relative protein expressions of Bax/Bcl-2, Cleave-Caspase-3, and Cleave-PARP. Moreover, piceatannol treatment induced NF-E2-related factor 2 (Nrf2) signaling activation, which was evidenced by increased transcription of anti-oxidant genes, glutamate-cysteine ligase catalytic subunit (GCLc), SOD, and HO-1. Knockdown of Nrf2 through targeted siRNA alleviated piceatannol-mediated HO-1 transcription, and significantly abolished piceatannol-mediated cytoprotection. LY294002 (PI3K inhibitor) dramatically blocked piceatannol-mediated increasing of Nrf2 nuclear translocation, HO-1 expression, and cytoprotective activity, indicating the involvement of PI3K/Akt pathway in the cytoprotective effect of piceatannol. The results from this suggest the potential of piceatannol in reducing the risk of age-related macular degeneration.
C1 [Hao, Yiming; Liu, Jie; Wang, Ziyuan] Beijing Technol & Business Univ, China Canada Joint Lab Food Nutr & Hlth Beijing, Beijing 100048, Peoples R China.
   [Hao, Yiming; Wang, Jing] Beijing Technol & Business Univ, Beijing Adv Innovat Ctr Food Nutr & Human Hlth, Beijing 100048, Peoples R China.
   [Yu, Liangli (Lucy)] Univ Maryland, Dept Nutr & Food Sci, College Pk, MD 20742 USA.
C3 Beijing Technology & Business University; Beijing Technology & Business
   University; University System of Maryland; University of Maryland
   College Park
RP Liu, J (通讯作者)，Beijing Technol & Business Univ, China Canada Joint Lab Food Nutr & Hlth Beijing, Beijing 100048, Peoples R China.; Wang, J (通讯作者)，Beijing Technol & Business Univ, Beijing Adv Innovat Ctr Food Nutr & Human Hlth, Beijing 100048, Peoples R China.
EM liu_jie@btbu.edu.cn; wangjing@th.btbu.edu.cn
RI Liu, Jie/AAD-7665-2020
FU National Natural Science Foundation of China [31701640]; Beijing
   Excellent Talents Funding for Youth Scientist Innovation Team
   [2016000026833TD01]; Support Project of High-level Teachers in Beijing
   Municipal Universities [IDHT20180506]
FX This research was funded by National Natural Science Foundation of China
   (Grant 31701640), Beijing Excellent Talents Funding for Youth Scientist
   Innovation Team (2016000026833TD01), and Support Project of High-level
   Teachers in Beijing Municipal Universities (IDHT20180506).
CR Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Byeon SH, 2010, INVEST OPHTH VIS SCI, V51, P1190, DOI 10.1167/iovs.09-4144
   Cacho JI, 2013, J CHROMATOGR A, V1315, P21, DOI 10.1016/j.chroma.2013.09.045
   Chen XD, 2017, INT J OPHTHALMOL-CHI, V10, P507, DOI 10.18240/ijo.2017.04.02
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Danias J, 2001, BRIT J OPHTHALMOL, V85, P245
   Faghiri Z, 2010, EXP EYE RES, V90, P718, DOI 10.1016/j.exer.2010.03.002
   Fu Z, 2016, FOOD FUNCT, V7, P1014, DOI 10.1039/c5fo01124h
   Gong YQ, 2016, ONCOTARGET, V7, P60123, DOI 10.18632/oncotarget.11164
   Hanus J, 2015, INVEST OPHTH VIS SCI, V56, P5048, DOI 10.1167/iovs.15-16401
   Hu HT, 2018, BIOCHEM BIOPH RES CO, V495, P2171, DOI 10.1016/j.bbrc.2017.12.078
   Justilien V, 2007, INVEST OPHTH VIS SCI, V48, P4407, DOI 10.1167/iovs.07-0432
   Kenessey A, 2006, J BIOL CHEM, V281, P20666, DOI 10.1074/jbc.M512671200
   Kim EK, 2018, EUR J CLIN NUTR, V72, P161, DOI 10.1038/ejcn.2017.152
   Krook A, 1997, DIABETES, V46, P2110, DOI 10.2337/diabetes.46.12.2110
   Li YF, 2017, J AGR FOOD CHEM, V65, P4634, DOI 10.1021/acs.jafc.7b01567
   Lu B, 2016, J FUNCT FOODS, V26, P739, DOI 10.1016/j.jff.2016.08.046
   Moon I, 2017, B KOREAN CHEM SOC, V38, P342, DOI 10.1002/bkcs.11089
   Qiu F, 2018, MOL CELL BIOCHEM, V446, P127, DOI 10.1007/s11010-018-3280-5
   Shieh JM, 2009, J PINEAL RES, V47, P339, DOI 10.1111/j.1600-079X.2009.00720.x
   Song M, 2016, CELL MOL BIOL, V62, P50, DOI 10.14715/cmb/2016.62.6.9
   Lai TNH, 2014, SEP PURIF TECHNOL, V134, P139, DOI 10.1016/j.seppur.2014.07.032
   Vigano J, 2016, FOOD RES INT, V85, P51, DOI 10.1016/j.foodres.2016.04.015
   Wang KJ, 2015, BIOCHEM BIOPH RES CO, V468, P541, DOI 10.1016/j.bbrc.2015.10.117
   Wang WX, 2019, FOOD CHEM, V295, P10, DOI 10.1016/j.foodchem.2019.02.137
   Yan TQ, 2014, DIAGN PATHOL, V9, DOI 10.1186/s13000-014-0154-3
   Zhang H, 2014, FREE RADICAL BIO MED, V69, P219, DOI 10.1016/j.freeradbiomed.2014.01.025
   Zheng YZ, 2018, PHYTOCHEMISTRY, V156, P184, DOI 10.1016/j.phytochem.2018.10.004
NR 28
TC 19
Z9 20
U1 5
U2 19
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
SN 2072-6643
J9 NUTRIENTS
JI Nutrients
PD JUL
PY 2019
VL 11
IS 7
AR 1515
DI 10.3390/nu11071515
PG 13
WC Nutrition & Dietetics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Nutrition & Dietetics
GA IN7TT
UT WOS:000478885400166
PM 31277394
OA gold, Green Published, Green Submitted
DA 2022-11-30
ER

PT J
AU Tangvarasittichai, O
   Tangvarasittichai, S
AF Tangvarasittichai, Orathai
   Tangvarasittichai, Surapon
TI Oxidative Stress, Ocular Disease and Diabetes Retinopathy
SO CURRENT PHARMACEUTICAL DESIGN
LA English
DT Review
DE Oxidative stress; oxidative damage; ocular diseases; keratoconus;
   cataract; retinopathy
ID NITRIC-OXIDE SYNTHASE; LIPID-PEROXIDATION PRODUCTS; MITOCHONDRIAL-DNA
   DAMAGE; LONG-TERM INCIDENCE; AQUEOUS-HUMOR; DRY EYE; REACTIVE OXYGEN;
   TRABECULAR MESHWORK; FREE-RADICALS; CELL-DEATH
AB Background: Oxidative stress is caused by free radicals or oxidant productions, including lipid peroxidation, protein modification, DNA damage and apoptosis or cell death and results in cellular degeneration and neurodegeneration from damage to macromolecules.
   Results: Accumulation of the DNA damage (8HOdG) products and the end products of LPO (including aldehyde, diene, triene conjugates and Schiff's bases) were noted in the research studies. Significantly higher levels of these products in comparison with the controls were observed. Oxidative stress induced changes to ocular cells and tissues. Typical changes include ECM accumulation, cell dysfunction, cell death, advanced senescence, disarrangement or rearrangement of the cytoskeleton and released inflammatory cytokines. It is involved in ocular diseases, including keratoconus, Fuchs endothelial corneal dystrophy, and granular corneal dystrophy type 2, cataract, age-related macular degeneration, primary open-angle glaucoma, retinal light damage, and retinopathy of prematurity. These ocular diseases are the cause of irreversible blindness worldwide.
   Conclusions: Oxidative stress, inflammation and autophagy are implicated in biochemical and morphological changes in these ocular tissues. The development of therapy is a major target for the management care of these ocular diseases.
C1 [Tangvarasittichai, Orathai; Tangvarasittichai, Surapon] Naresuan Univ, Chron Dis Res Unit, Dept Med Technol, Fac Allied Hlth Sci, 99 Moo 9 Tambon Tha Pho, Muang Phitsanulok 65000, Thailand.
C3 Naresuan University
RP Tangvarasittichai, S (通讯作者)，Naresuan Univ, Chron Dis Res Unit, Dept Med Technol, Fac Allied Hlth Sci, 99 Moo 9 Tambon Tha Pho, Muang Phitsanulok 65000, Thailand.
EM surapon14t@yahoo.com
CR Acott TS, 1996, GLAUCOMAS, P281
   Adamis AP, 2002, BRIT J OPHTHALMOL, V86, P363, DOI 10.1136/bjo.86.4.363
   Agbaga MP, 2010, J LIPID RES, V51, P1624, DOI 10.1194/jlr.R005025
   Alvarado JA, 2005, BRIT J OPHTHALMOL, V89, P1500, DOI 10.1136/bjo.2005.081307
   Alves M, 2014, ARQ BRAS OFTALMOL, V77, P193, DOI 10.5935/0004-2749.20140050
   Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   AMES BN, 1992, ANN NY ACAD SCI, V663, P85, DOI 10.1111/j.1749-6632.1992.tb38652.x
   Andrade AS, 2014, EXP EYE RES, V120, P1, DOI 10.1016/j.exer.2013.12.014
   Antonetti DA, 2006, DIABETES, V55, P2401, DOI 10.2337/db05-1635
   Arnal E, 2011, INVEST OPHTH VIS SCI, V52, P8592, DOI 10.1167/iovs.11-7732
   Atilano SR, 2005, INVEST OPHTH VIS SCI, V46, P1256, DOI 10.1167/iovs.04-1395
   BABIZHAYEV MA, 1989, MECH AGEING DEV, V47, P145, DOI 10.1016/0047-6374(89)90017-1
   BABIZHAYEV MA, 1989, BIOCHIM BIOPHYS ACTA, V1004, P124, DOI 10.1016/0005-2760(89)90222-1
   Babizhayev MA, 2011, CELL BIOCHEM FUNCT, V29, P183, DOI 10.1002/cbf.1737
   Babizhayev Mark A, 2009, Recent Pat Drug Deliv Formul, V3, P229
   Baratz KH, 2010, NEW ENGL J MED, V363, P1016, DOI 10.1056/NEJMoa1007064
   BARKSDALE S, 1986, Investigative Ophthalmology and Visual Science, V27, P210
   Batista TM, 2012, MOL VIS, V18, P194
   Baudouin C, 1997, INVEST OPHTH VIS SCI, V38, P1458
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   BERNTHPETERSEN P, 1983, ACTA OPHTHALMOL, V61, P406
   Berthoud VM, 2009, ANTIOXID REDOX SIGN, V11, P339, DOI 10.1089/ars.2008.2119
   Betteridge DJ, 2000, METABOLISM, V49, P3, DOI 10.1016/S0026-0495(00)80077-3
   Bhattacharya S, 2011, J BIOCHEM MOL TOXIC, V25, P341, DOI 10.1002/jbt.20393
   Bhattacharyya S, 2012, FREE RADICAL RES, V46, P1296, DOI 10.3109/10715762.2012.712690
   BILL A, 1993, EYE, V7, P14, DOI 10.1038/eye.1993.4
   Bonanno JA, 2003, PROG RETIN EYE RES, V22, P69, DOI 10.1016/S1350-9462(02)00059-9
   BONE RA, 1988, INVEST OPHTH VIS SCI, V29, P843
   Boss JD, 2017, INVEST OPHTH VIS SCI, V58, P5594, DOI 10.1167/iovs.17-21973
   BOULTON M, 1991, PROG RETIN RES, V11, P125, DOI 10.1016/0278-4327(91)90027-Y
   BOULTON M, 1990, VISION RES, V30, P1291, DOI 10.1016/0042-6989(90)90003-4
   Brand MD, 2010, EXP GERONTOL, V45, P466, DOI 10.1016/j.exger.2010.01.003
   Brown DJ, 2004, MOL VIS, V10, P281
   BROWN MD, 1994, J BIOENERG BIOMEMBR, V26, P273, DOI 10.1007/BF00763099
   Brownlee M, 2005, DIABETES, V54, P1615, DOI 10.2337/diabetes.54.6.1615
   Brunk U.T., 1981, AGE PIGMENTS 1981, P243
   Bryan N, 2012, EUR CELLS MATER, V24, P249, DOI 10.22203/eCM.v024a18
   Buddi R, 2002, J HISTOCHEM CYTOCHEM, V50, P341, DOI 10.1177/002215540205000306
   Burdon KP, 2013, CLIN EXP OPTOM, V96, P146, DOI 10.1111/cxo.12024
   Cadenas E, 2000, FREE RADICAL BIO MED, V29, P222, DOI 10.1016/S0891-5849(00)00317-8
   Calcerrada P, 2011, CURR PHARM DESIGN, V17, P3905, DOI 10.2174/138161211798357719
   Cederbaum AI, 2015, REDOX BIOL, V4, P60, DOI 10.1016/j.redox.2014.11.008
   Cejkova J, 2002, HISTOL HISTOPATHOL, V17, P755, DOI 10.14670/HH-17.755
   Chalam KV, 2011, EYE CONTACT LENS, V37, P225, DOI 10.1097/ICL.0b013e31821fbd3e
   Charles I, 2005, INVEST OPHTH VIS SCI, V46, P1330, DOI 10.1167/iovs.04-0363
   CHEESEMAN KH, 1993, BRIT MED BULL, V49, P481, DOI 10.1093/oxfordjournals.bmb.a072625
   Choi SI, 2011, J PINEAL RES, V51, P94, DOI 10.1111/j.1600-079X.2011.00866.x
   Choi SI, 2009, AM J PATHOL, V175, P248, DOI 10.2353/ajpath.2009.081001
   Choi W, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/4727415
   Chwa M, 2008, INVEST OPHTH VIS SCI, V49, P4361, DOI 10.1167/iovs.08-1969
   Chwa M, 2006, INVEST OPHTH VIS SCI, V47, P1902, DOI 10.1167/iovs.05-0828
   Colin J, 2003, J CATARACT REFR SURG, V29, P379, DOI 10.1016/S0886-3350(02)01968-5
   Cossarizza A, 2009, NAT PROTOC, V4, P1790, DOI 10.1038/nprot.2009.189
   Cristina Kenney M, 2003, Cont Lens Anterior Eye, V26, P139
   Cui Hang, 2012, J Signal Transduct, V2012, P646354, DOI 10.1155/2012/646354
   Dahl BJ, 2012, OPTOMETRY, V83, P33, DOI 10.1016/j.optm.2011.09.011
   Davies MJ, 2001, J PHOTOCH PHOTOBIO B, V63, P114, DOI 10.1016/S1011-1344(01)00208-1
   Deng RZ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0126561
   Didion SP, 2001, AM J PHYSIOL-HEART C, V281, pH1697, DOI 10.1152/ajpheart.2001.281.4.H1697
   Dikalova AE, 2010, AM J PHYSIOL-HEART C, V299, pH673, DOI 10.1152/ajpheart.00242.2010
   Drobek-Slowik Monika, 2007, Postepy Hig Med Dosw (Online), V61, P28
   Droge W, 2002, PHYSIOL REV, V82, P47, DOI 10.1152/physrev.00018.2001
   Drummond GR, 2011, NAT REV DRUG DISCOV, V10, P453, DOI 10.1038/nrd3403
   Du XL, 2003, J CLIN INVEST, V112, P1049, DOI 10.1172/JCI200318127
   Duran-Jimenez B, 2009, DIABETES, V58, P2893, DOI 10.2337/db09-0320
   Edwards M, 2001, CLIN EXP OPHTHALMOL, V29, P345, DOI 10.1046/j.1442-9071.2001.d01-16.x
   ELDRED GE, 1993, NATURE, V361, P724, DOI 10.1038/361724a0
   Elhalis H, 2010, OCUL SURF, V8, P173, DOI 10.1016/S1542-0124(12)70232-X
   Enriquez-de-Salamanca A, 2010, MOL VIS, V16, P862
   Enzsoly A, 2014, INVEST OPHTH VIS SCI, V55, P3686, DOI 10.1167/iovs.13-13562
   Esquivel-Solis H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063464
   Evans MD, 2004, MUTAT RES-REV MUTAT, V567, P1, DOI 10.1016/j.mrrev.2003.11.001
   Feldman EL, 2003, J CLIN INVEST, V111, P431, DOI 10.1172/JCI200317863
   Fenton H.J.H., 1894, J CHEM SOC, V65, P899, DOI DOI 10.1039/CT8946500899
   Ferrara N, 1997, ENDOCR REV, V18, P4, DOI 10.1210/er.18.1.4
   Ferreira SM, 2004, AM J OPHTHALMOL, V137, P62, DOI 10.1016/S0002-9394(03)00788-8
   Figueira TR, 2013, ANTIOXID REDOX SIGN, V18, P2029, DOI 10.1089/ars.2012.4729
   Finkel T, 2000, NATURE, V408, P239, DOI 10.1038/35041687
   Finkel T, 2011, J CELL BIOL, V194, P7, DOI 10.1083/jcb.201102095
   Flammer J, 1994, Surv Ophthalmol, V38 Suppl, pS3, DOI 10.1016/0039-6257(94)90041-8
   Flammer J, 1999, J GLAUCOMA, V8, P212
   Fletcher EL, 2007, CURR PHARM DESIGN, V13, P2699, DOI 10.2174/138161207781662920
   Frank RN, 2004, NEW ENGL J MED, V350, P48, DOI 10.1056/NEJMra021678
   Frei B, 1994, NATURAL ANTIOXIDANTS
   Frey T, 2011, ANTIOXID REDOX SIGN, V15, P1271, DOI 10.1089/ars.2011.3906
   Galbis-Estrada C, 2013, CLIN INTERV AGING, V8, P711, DOI 10.2147/CIA.S43191
   Gherghel D, 2005, INVEST OPHTH VIS SCI, V46, P877, DOI 10.1167/iovs.04-0777
   Ghosh A, 2011, DRUG DELIV, V18, P451, DOI 10.3109/10717544.2011.577110
   Gipson IK, 2003, INVEST OPHTH VIS SCI, V44, P2496, DOI 10.1167/iovs.02-0851
   Gorlach A, 2006, ANTIOXID REDOX SIGN, V8, P1391, DOI 10.1089/ars.2006.8.1391
   GOLDSTEIN S, 1993, FREE RADICAL BIO MED, V15, P435, DOI 10.1016/0891-5849(93)90043-T
   GOTTSCH JD, 1993, ARCH OPHTHALMOL-CHIC, V111, P126, DOI 10.1001/archopht.1993.01090010130039
   Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309
   GUTTERIDGE JMC, 1995, CLIN CHEM, V41, P1819
   Haber F, 1932, NATURWISSENSCHAFTEN, V20, P948, DOI 10.1007/BF01504715
   Hager M, 2010, J INTERN MED, V268, P25, DOI 10.1111/j.1365-2796.2010.02237.x
   Halilovic A, 2016, ANTIOXID REDOX SIGN, V24, P1072, DOI 10.1089/ars.2015.6532
   HALLIWELL B, 1984, BIOCHEM J, V219, P1, DOI 10.1042/bj2190001
   HALLIWELL B, 1990, METHOD ENZYMOL, V186, P1
   Halliwell B., 2015, FREE RADICAL BIO MED, P199, DOI [10.1093/acprof:oso/9780198717478.001.0001, DOI 10.1093/ACPROF:OSO/9780198717478.001.0001]
   HONIGSMANN H, 1976, J INVEST DERMATOL, V66, P188, DOI 10.1111/1523-1747.ep12481938
   Hull D S, 1989, Lens Eye Toxic Res, V6, P87
   Hwang SH, 2016, JAMA OPHTHALMOL, V134, P503, DOI 10.1001/jamaophthalmol.2016.0139
   Hybertson BM, 2011, MOL ASPECTS MED, V32, P234, DOI 10.1016/j.mam.2011.10.006
   Ibrahim OMA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099328
   Ihnat MA, 2007, DIABETOLOGIA, V50, P1523, DOI 10.1007/s00125-007-0684-2
   Iliff BW, 2012, EXPERT REV OPHTHALMO, V7, P363, DOI 10.1586/EOP.12.39
   Izzotti A, 2009, INVEST OPHTH VIS SCI, V50, P5251, DOI 10.1167/iovs.09-3871
   Janik-Papis Katarzyna, 2009, Klin Oczna, V111, P168
   Jia LH, 2007, INVEST OPHTH VIS SCI, V48, P339, DOI 10.1167/iovs.06-0248
   Jiang SN, 2005, INVEST OPHTH VIS SCI, V46, P1054, DOI 10.1167/iovs.04-0949
   Jie Y, 2009, EYE, V23, P688, DOI 10.1038/sj.eye.6703101
   Johnson M, 2006, EXP EYE RES, V82, P545, DOI 10.1016/j.exer.2005.10.011
   Jomova K, 2011, TOXICOLOGY, V283, P65, DOI 10.1016/j.tox.2011.03.001
   Junqueira Virginia B. C., 2004, Molecular Aspects of Medicine, V25, P5, DOI 10.1016/j.mam.2004.02.003
   Jurkunas UV, 2008, INVEST OPHTH VIS SCI, V49, P2956, DOI 10.1167/iovs.07-1529
   Jurkunas UV, 2010, AM J PATHOL, V177, P2278, DOI 10.2353/ajpath.2010.100279
   KAHN MG, 1983, INVEST OPHTH VIS SCI, V24, P1283
   KATZ ML, 1994, INVEST OPHTH VIS SCI, V35, P3613
   KATZ ML, 1986, MECH AGEING DEV, V35, P291, DOI 10.1016/0047-6374(86)90131-4
   Kayankarnna W, 2013, IJTPR, V5, P102
   Kenney MC, 2005, INVEST OPHTH VIS SCI, V46, P823, DOI 10.1167/iovs.04-0549
   Kensler TW, 2000, ANN REV PHARM TOXICO, V47, P89
   Kern TS, 2007, EXP DIABETES RES, DOI 10.1155/2007/95103
   Khachik F, 1997, INVEST OPHTH VIS SCI, V38, P1802
   Khalfaoui T, 2008, J MOL HISTOL, V39, P243, DOI 10.1007/s10735-007-9159-5
   Kinugawa S, 2005, CIRC RES, V96, P355, DOI 10.1161/01.RES.0000155331.09458.A7
   Klein B E, 1995, Ophthalmic Epidemiol, V2, P49, DOI 10.3109/09286589509071451
   Klein R, 2002, ARCH OPHTHALMOL-CHIC, V120, P1551, DOI 10.1001/archopht.120.11.1551
   Klintworth GK, 2009, ORPHANET J RARE DIS, V4, P1, DOI DOI 10.1186/1750-1172-4-7
   Knapp LT, 2002, J NEUROSCI RES, V70, P1, DOI 10.1002/jnr.10371
   Kodydkova J, 2014, FOLIA BIOL-PRAGUE, V60, P153
   Kojima T, 2012, AM J PATHOL, V180, P1879, DOI 10.1016/j.ajpath.2012.01.019
   Korvatska E, 2000, J BIOL CHEM, V275, P11465, DOI 10.1074/jbc.275.15.11465
   Kowluru RA, 2009, FREE RADICAL BIO MED, V46, P1677, DOI 10.1016/j.freeradbiomed.2009.03.024
   Kruk J, 2016, MINI-REV MED CHEM, V16, P241, DOI 10.2174/1389557516666151120114605
   Labbe A, 2007, J FR OPHTALMOL, V30, P76, DOI 10.1016/S0181-5512(07)89557-X
   Landmesser U, 2003, J CLIN INVEST, V111, P1201, DOI 10.1172/JCI200314172
   Lee J, 2012, BIOCHEM J, V441, P523, DOI 10.1042/BJ20111451
   Lemp MA, 2007, OCUL SURF, V5, P75
   Liu CL, 2016, INVEST OPHTH VIS SCI, V57, P2319, DOI 10.1167/iovs.16-19097
   Liu H, 2015, INT J CLIN EXP PATHO, V8, P7644
   Luo LH, 2007, CORNEA, V26, P452, DOI 10.1097/ICO.0b013e318030d259
   Lutjen-Drecoll E, 2005, EXP EYE RES, V81, P1, DOI 10.1016/j.exer.2005.02.008
   Lutjen-Drecoll E, 1999, PROG RETIN EYE RES, V18, P91, DOI 10.1016/S1350-9462(98)00011-1
   Maatta M, 2006, CORNEA, V25, P341
   MAEPEA O, 1992, EXP EYE RES, V54, P879, DOI 10.1016/0014-4835(92)90151-H
   Mancino R, 2011, MOL VIS, V17, P1298
   Manda-Handzlik A, 2015, ADV EXP MED BIOL, V857, P51, DOI 10.1007/5584_2015_117
   Margrain TH, 2004, PROG RETIN EYE RES, V23, P523, DOI 10.1016/j.preteyeres.2004.05.001
   Matalia H, 2012, BRIT J OPHTHALMOL, V96, P1339, DOI 10.1136/bjophthalmol-2012-301811
   Matthaei M, 2014, EXP EYE RES, V129, P13, DOI 10.1016/j.exer.2014.10.011
   Mayne ST, 1996, FASEB J, V10, P690, DOI 10.1096/fasebj.10.7.8635686
   McCord JM, 1998, SEMIN HEMATOL, V35, P5
   Melo P, 2010, NEUROCHEM INT, V56, P431, DOI 10.1016/j.neuint.2009.11.017
   MILLER JW, 1994, AM J PATHOL, V145, P574
   Moss SE, 2008, OPTOMETRY VISION SCI, V85, P668, DOI 10.1097/OPX.0b013e318181a947
   Munoz B, 2000, ARCH OPHTHALMOL-CHIC, V118, P819, DOI 10.1001/archopht.118.6.819
   Nagase H, 2006, CARDIOVASC RES, V69, P562, DOI 10.1016/j.cardiores.2005.12.002
   Nakamura S, 2007, INVEST OPHTH VIS SCI, V48, P1552, DOI 10.1167/iovs.06-1027
   Narayanan D, 2010, CIRC RES, V107, P631, DOI 10.1161/CIRCRESAHA.110.224345
   Nichols KK, 2011, INVEST OPHTH VIS SCI, V52, P1922, DOI 10.1167/iovs.10-6997a
   Niedernhofer LJ, 2003, J BIOL CHEM, V278, P31426, DOI 10.1074/jbc.M212549200
   Nita M, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/3164734
   Nita M, 2014, MED SCI MONITOR, V20, P1003, DOI 10.12659/MSM.889887
   Niwa K, 2001, CIRC RES, V88, P600, DOI 10.1161/01.RES.88.6.600
   Noda K, 2012, J OPHTHALMOL, V2012, DOI 10.1155/2012/279037
   Nolan CJ, 2011, LANCET, V378, P169, DOI 10.1016/S0140-6736(11)60614-4
   Nowak Michal, 2005, Klin Oczna, V107, P715
   Ohia SE, 2005, MUTAT RES-FUND MOL M, V579, P22, DOI 10.1016/j.mrfmmm.2005.03.025
   Ohira Akihiro, 2008, Nippon Ganka Gakkai Zasshi, V112, P22
   Olofsson EM, 2007, MOL VIS, V13, P1285
   Osburn WO, 2006, ARCH BIOCHEM BIOPHYS, V454, P7, DOI 10.1016/j.abb.2006.08.005
   Pacher P, 2007, PHYSIOL REV, V87, P315, DOI 10.1152/physrev.00029.2006
   Pal PB, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056894
   Pal PB, 2012, AMINO ACIDS, V42, P1669, DOI 10.1007/s00726-011-0869-3
   Pande J, 2002, EXP EYE RES, V75, P359, DOI 10.1006/exer.2002.2038
   PARK JW, 1992, FREE RADICAL BIO MED, V12, P245, DOI 10.1016/0891-5849(92)90111-S
   Perry HD, 2008, AM J MANAG CARE, V14, P79
   Piarulli F, 2009, DIABETOLOGIA, V52, P1419, DOI 10.1007/s00125-009-1367-y
   Pinazo-Duran MD, 2013, CLIN INTERV AGING, V8, P139, DOI 10.2147/CIA.S40640
   Potau J M, 2000, Arch Soc Esp Oftalmol, V75, P159
   Potau J M, 2000, Arch Soc Esp Oftalmol, V75, P21
   PRASHAR S, 1993, ACTA OPHTHALMOL, V71, P214
   Quinlan CL, 2014, J BIOL CHEM, V289, P8312, DOI 10.1074/jbc.M113.545301
   Rada B, 2008, SEMIN IMMUNOPATHOL, V30, P237, DOI 10.1007/s00281-008-0126-3
   RAMSELL TG, 1969, BRIT J OPHTHALMOL, V53, P98, DOI 10.1136/bjo.53.2.98
   Ringvold A, 1998, ACTA OPHTHALMOL SCAN, V76, P149, DOI 10.1034/j.1600-0420.1998.760205.x
   Ringvold A, 2003, INVEST OPHTH VIS SCI, V44, P10, DOI 10.1167/iovs.02-0173
   Roehlecke C, 2009, MOL VIS, V15, P1929
   Roy Anandita, 2012, Pathophysiology, V19, P137, DOI 10.1016/j.pathophys.2012.05.001
   ROY MS, 1986, ARCH OPHTHALMOL-CHIC, V104, P225
   Sacca SC, 2008, PROG BRAIN RES, V173, P385, DOI 10.1016/S0079-6123(08)01127-8
   Sacca SC, 2005, ARCH OPHTHALMOL-CHIC, V123, P458, DOI 10.1001/archopht.123.4.458
   Sacca SC, 2007, EXP EYE RES, V84, P389, DOI 10.1016/j.exer.2006.10.008
   Sakai N, 1996, J AM CHEM SOC, V118, P1559, DOI 10.1021/ja953480g
   SanGiovanni JP, 2005, PROG RETIN EYE RES, V24, P87, DOI 10.1016/j.preteyeres.2004.06.002
   Santhanam AVR, 2012, J NEUROCHEM, V122, P1211, DOI 10.1111/j.1471-4159.2012.07872.x
   Santos JH, 2003, J BIOL CHEM, V278, P1728, DOI 10.1074/jbc.M208752200
   Sarkar MK, 2010, TOXICOL IN VITRO, V24, P1711, DOI 10.1016/j.tiv.2010.05.014
   Sawada H, 2009, CURR EYE RES, V34, P36, DOI 10.1080/02713680802500960
   Saxena S, 2004, OPHTHAL EPIDEMIOL, V11, P271, DOI 10.1080/09286580490510733
   Schafer M, 2008, PHARMACOL RES, V58, P165, DOI 10.1016/j.phrs.2008.06.004
   Schaumberg DA, 2003, AM J OPHTHALMOL, V136, P318, DOI 10.1016/S0002-9394(03)00218-6
   Schein OD, 1997, AM J OPHTHALMOL, V124, P723, DOI 10.1016/S0002-9394(14)71688-5
   Schmedt T, 2012, EXP EYE RES, V95, P24, DOI 10.1016/j.exer.2011.08.002
   Schmidt AM, 2000, BBA-MOL CELL RES, V1498, P99, DOI 10.1016/S0167-4889(00)00087-2
   Scott PA, 2009, EXP EYE RES, V89, P942, DOI 10.1016/j.exer.2009.08.002
   SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413
   Sherwin T, 2004, CLIN EXP OPHTHALMOL, V32, P211, DOI 10.1111/j.1442-9071.2004.00805.x
   Shin AH, 2006, ARCH PHARM RES, V29, P577, DOI 10.1007/BF02969268
   Shoham A, 2008, FREE RADICAL BIO MED, V45, P1047, DOI 10.1016/j.freeradbiomed.2008.07.021
   Sies H, 1997, EXP PHYSIOL, V82, P291, DOI 10.1113/expphysiol.1997.sp004024
   SMITH VA, 1995, EYE, V9, P429, DOI 10.1038/eye.1995.100
   SNODDERLY DM, 1995, AM J CLIN NUTR, V62, P1448
   SOHAL RS, 1981, AGE PIGMENTS
   SOKOL S, 1985, ARCH OPHTHALMOL-CHIC, V103, P51
   Sorkhabi R, 2011, MOL VIS, V17, P41
   SPECTOR A, 1995, FASEB J, V9, P1173, DOI 10.1096/fasebj.9.12.7672510
   Stadtman ER, 2006, FREE RADICAL RES, V40, P1250, DOI 10.1080/10715760600918142
   Sun W, 2005, DIABETES, V54, P3418, DOI 10.2337/diabetes.54.12.3418
   Szabo C, 2007, NAT REV DRUG DISCOV, V6, P662, DOI 10.1038/nrd2222
   Taarnhoj NCBB, 2005, INVEST OPHTH VIS SCI, V46, P3850, DOI 10.1167/iovs.05-0177
   Tamm ER, 1996, INVEST OPHTH VIS SCI, V37, P2402
   Tamm ER, 2007, SURV OPHTHALMOL, V52, pS101, DOI 10.1016/j.survophthal.2007.08.002
   Tavares FD, 2010, SEMIN OPHTHALMOL, V25, P84, DOI 10.3109/08820538.2010.488568
   Tektas OY, 2009, EXP EYE RES, V88, P769, DOI 10.1016/j.exer.2008.11.025
   Tezel G, 2004, INVEST OPHTH VIS SCI, V45, P4049, DOI 10.1167/iovs.04-0490
   Tezel G, 2006, PROG RETIN EYE RES, V25, P490, DOI 10.1016/j.preteyeres.2006.07.003
   Thomas DD, 2015, REDOX BIOL, V5, P225, DOI 10.1016/j.redox.2015.05.002
   Tian BH, 2000, INVEST OPHTH VIS SCI, V41, P619
   Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870
   Truscott RJW, 2005, EXP EYE RES, V80, P709, DOI 10.1016/j.exer.2004.12.007
   TUBERVILLE AW, 1986, CURR EYE RES, V5, P939, DOI 10.3109/02713688608995175
   TURRENS JF, 1980, BIOCHEM J, V191, P421, DOI 10.1042/bj1910421
   Uchino Y, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045805
   Valko M, 2004, MOL CELL BIOCHEM, V266, P37, DOI 10.1023/B:MCBI.0000049134.69131.89
   Valko M, 2016, ARCH TOXICOL, V90, P1, DOI 10.1007/s00204-015-1579-5
   VanDerMeid KR, 2011, MOL VIS, V17, P1056
   Varma SD, 2011, EYE CONTACT LENS, V37, P233, DOI 10.1097/ICL.0b013e31821ec4f2
   Vazquez-Torres A, 2000, J EXP MED, V192, P227, DOI 10.1084/jem.192.2.227
   Vujosevic S, 2016, ACTA OPHTHALMOL, V94, P56, DOI 10.1111/aos.12812
   Wassell J, 1998, INVEST OPHTH VIS SCI, V39, P1487
   Wenk J, 2001, CURR PROBL DERMATOL, V29, P83
   Wilkinson CP, 2003, OPHTHALMOLOGY, V110, P1677, DOI 10.1016/S0161-6420(03)00475-5
   Williams DL, 2008, VET CLIN N AM-SMALL, V38, P179, DOI 10.1016/j.cvsm.2007.10.006
   Winkler B S, 1999, Mol Vis, V5, P32
   WINKLER BS, 1994, FREE RADICAL BIO MED, V17, P333, DOI 10.1016/0891-5849(94)90019-1
   Wojcik KA, 2013, INT J MOL SCI, V14, P19294, DOI 10.3390/ijms140919294
   Wu JM, 2006, SURV OPHTHALMOL, V51, P461, DOI 10.1016/j.survophthal.2006.06.009
   Wu Y, 2014, OXID MED CELL LONGEV, V2014, DOI 10.1155/2014/752387
   Yadav UCS, 2011, CURR MED CHEM, V18, P931
   YAMADA M, 1991, DNA CELL BIOL, V10, P735, DOI 10.1089/dna.1991.10.735
   Yang JH, 2005, INVEST OPHTH VIS SCI, V46, P1039, DOI 10.1167/iovs.04-0325
   Yildirim Z, 2009, BIOL TRACE ELEM RES, V128, P135, DOI 10.1007/s12011-008-8258-9
   YOUNG RW, 1988, SURV OPHTHALMOL, V32, P252, DOI 10.1016/0039-6257(88)90174-9
   Yue BYJT, 1996, SURV OPHTHALMOL, V40, P379
   Zanon-Moreno V, 2008, J GLAUCOMA, V17, P263, DOI 10.1097/IJG.0b013e31815c3a7f
   Zhang XY, 2014, CELL BIOSCI, V4, DOI 10.1186/2045-3701-4-27
   Zhang Y, 2011, MOL VIS, V17, P2325
   Zhou LL, 1999, J CELL PHYSIOL, V180, P182, DOI 10.1002/(SICI)1097-4652(199908)180:2<182::AID-JCP6>3.0.CO;2-X
   Zierhut M., 2008, FREE RADICALS OPHTHA
NR 262
TC 24
Z9 25
U1 3
U2 15
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1381-6128
EI 1873-4286
J9 CURR PHARM DESIGN
JI Curr. Pharm. Design
PY 2018
VL 24
IS 40
BP 4726
EP 4741
DI 10.2174/1381612825666190115121531
PG 16
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA HO9JB
UT WOS:000461278900004
PM 30644339
DA 2022-11-30
ER

PT J
AU Baek, A
   Yoon, S
   Kim, J
   Baek, YM
   Park, H
   Lim, D
   Chung, H
   Kim, DE
AF Baek, Ahruem
   Yoon, Soojin
   Kim, Jean
   Baek, Yu Mi
   Park, Hanna
   Lim, Daehan
   Chung, Hyewon
   Kim, Dong-Eun
TI Autophagy and KRT8/keratin 8 protect degeneration of retinal pigment
   epithelium under oxidative stress
SO AUTOPHAGY
LA English
DT Article
DE age-related macular degeneration (AMD); apoptosis; autophagy; cell
   survival; epithelial-mesenchymal transition (EMT); KRT8 (keratin 8);
   mitogen-activated protein kinases 1 and 3 (MAPK1; 3)
ID N-TERMINAL KINASE; MACULAR DEGENERATION; INTERMEDIATE-FILAMENTS; KERATIN
   REORGANIZATION; CELL-SURVIVAL; PHOSPHORYLATION; DISEASE; MICE;
   ACTIVATION; APOPTOSIS
AB Contribution of autophagy and regulation of related proteins to the degeneration of retinal pigment epithelium (RPE) in age-related macular degeneration (AMD) remain unknown. We report that upregulation of KRT8 (keratin 8) as well as its phosphorylation are accompanied with autophagy and attenuated with the inhibition of autophagy in RPE cells under oxidative stress. KRT8 appears to have a dual role in RPE pathophysiology. While increased expression of KRT8 following autophagy provides a cytoprotective role in RPE, phosphorylation of KRT8 induces pathologic epithelial-mesenchymal transition (EMT) of RPE cells under oxidative stress, which is mediated by MAPK1/ERK2 (mitogen-activated protein kinase 1) and MAPK3/ERK1. Inhibition of autophagy further promotes EMT, which can be reversed by inhibition of MAPK. Thus, regulated enhancement of autophagy with concurrent increased expression of KRT8 and the inhibition of KRT8 phosphorylation serve to inhibit oxidative stress-induced EMT of RPE cells as well as to prevent cell death, suggesting that pharmacological manipulation of KRT8 upregulation through autophagy with combined inhibition of the MAPK1/3 pathway may be attractive therapeutic strategies for the treatment of AMD.
C1 [Baek, Ahruem; Yoon, Soojin; Baek, Yu Mi; Park, Hanna; Kim, Dong-Eun] Konkuk Univ, Dept Biosci & Biotechnol, 120 Neungdong Ro, Seoul 05902, South Korea.
   [Kim, Jean; Lim, Daehan; Chung, Hyewon] Konkuk Univ, Sch Med, Dept Ophthalmol, Seoul, South Korea.
C3 Konkuk University; Konkuk University; Konkuk University Medical Center
RP Kim, DE (通讯作者)，Konkuk Univ, Dept Biosci & Biotechnol, 120 Neungdong Ro, Seoul 05902, South Korea.; Chung, H (通讯作者)，Konkuk Univ, Sch Med, Med Ctr, Dept Ophthalmol, 120-1 Neungdong Ro, Seoul 05029, South Korea.
EM hchung@kuh.ac.kr; kimde@konkuk.ac.kr
RI Kim, Dong-Eun/D-8304-2011
OI Kim, Dong-Eun/0000-0001-6545-8387; Baek, Ahruem/0000-0001-6672-6339
FU National Research Foundation of Korea - Ministry of Science, ICT &
   Future Planning [NRF-2012M3A9B2028336, NRF-2015R1A2A2A01005591]
FX This research was supported by the National Research Foundation of Korea
   funded by the Ministry of Science, ICT & Future Planning
   (NRF-2012M3A9B2028336 and NRF-2015R1A2A2A01005591 to D.-E. K. and H. C.,
   respectively.).
CR Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   Anesti V, 2006, BBA-BIOENERGETICS, V1757, P692, DOI 10.1016/j.bbabio.2006.04.013
   Antony R, 2010, J BIOL CHEM, V285, P18301, DOI 10.1074/jbc.M109.095232
   Arjamaa O, 2009, AGEING RES REV, V8, P349, DOI 10.1016/j.arr.2009.06.002
   Bailey TA, 2004, INVEST OPHTH VIS SCI, V45, P675, DOI 10.1167/iovs.03-0351
   Bjorkoy G, 2009, METHOD ENZYMOL, V452, P181, DOI 10.1016/S0076-6879(08)03612-4
   Brantley MA, 2007, OPHTHALMOLOGY, V114, P2168, DOI 10.1016/j.ophtha.2007.09.008
   Bressler NM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1621
   Busch T, 2012, J CELL SCI, V125, P2148, DOI 10.1242/jcs.080127
   Caulin C, 2000, J CELL BIOL, V149, P17, DOI 10.1083/jcb.149.1.17
   Chung BM, 2013, CURR OPIN CELL BIOL, V25, P600, DOI 10.1016/j.ceb.2013.06.008
   Churchill AJ, 2006, HUM MOL GENET, V15, P2955, DOI 10.1093/hmg/ddl238
   Coulombe PA, 2002, CURR OPIN CELL BIOL, V14, P110, DOI 10.1016/S0955-0674(01)00301-5
   Feng L, 1999, J CELL SCI, V112, P2081
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   FUCHS E, 1994, ANNU REV BIOCHEM, V63, P345, DOI 10.1146/annurev.bi.63.070194.002021
   Gilbert S, 2001, J CELL BIOL, V154, P763, DOI 10.1083/jcb.200102130
   Girardot F, 2004, BMC GENOMICS, V5, DOI 10.1186/1471-2164-5-74
   Guo SJ, 2015, AUTOPHAGY, V11, P560, DOI 10.1080/15548627.2015.1017181
   Hara T, 2006, NATURE, V441, P885, DOI 10.1038/nature04724
   Harada M, 2008, HEPATOLOGY, V47, P2026, DOI 10.1002/hep.22294
   He T, 2002, J BIOL CHEM, V277, P10767, DOI 10.1074/jbc.M111436200
   Inada H, 2001, J CELL BIOL, V155, P415, DOI 10.1083/jcb.200103078
   Jaffe GJ, 2016, OPHTHALMOLOGY, V123, P78, DOI 10.1016/j.ophtha.2015.09.004
   Johansson I, 2015, AUTOPHAGY, V11, P1636, DOI 10.1080/15548627.2015.1061170
   Kaarniranta K, 2009, AGEING RES REV, V8, P128, DOI 10.1016/j.arr.2009.01.001
   Kang GY, 2014, J PROTEOME RES, V13, P581, DOI 10.1021/pr400751k
   Komatsu M, 2006, NATURE, V441, P880, DOI 10.1038/nature04723
   Ku NO, 1998, EMBO J, V17, P1892, DOI 10.1093/emboj/17.7.1892
   Ku NO, 2000, J CELL BIOL, V149, P547, DOI 10.1083/jcb.149.3.547
   Lau ATY, 2007, CANCER RES, V67, P2107, DOI 10.1158/0008-5472.CAN-06-3771
   Leopoldino AM, 2012, MOL CELL BIOCHEM, V363, P65, DOI 10.1007/s11010-011-1158-x
   Levine B, 2005, J CLIN INVEST, V115, P2679, DOI 10.1172/JCI26390
   Liao J, 1997, J BIOL CHEM, V272, P17565, DOI 10.1074/jbc.272.28.17565
   Lopez PF, 1996, INVEST OPHTH VIS SCI, V37, P855
   Mitter SK, 2014, AUTOPHAGY, V10, P1989, DOI 10.4161/auto.36184
   Mizushima N, 2001, J CELL BIOL, V152, P657, DOI 10.1083/jcb.152.4.657
   Mizushima N, 2010, CELL, V140, P313, DOI 10.1016/j.cell.2010.01.028
   Nussenblatt RB, 2010, RETINA-J RET VIT DIS, V30, P1579, DOI 10.1097/IAE.0b013e3181e7978e
   Park MK, 2011, BBA-MOL CELL BIOL L, V1811, P1021, DOI 10.1016/j.bbalip.2011.07.007
   Qi ZF, 2011, NEUROCHEM INT, V59, P572, DOI 10.1016/j.neuint.2011.03.023
   Ranchon I, 2003, J NEUROSCI, V23, P6050, DOI 10.1523/JNEUROSCI.23-14-06050.2003
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Ryhanen T, 2009, J CELL MOL MED, V13, P3616, DOI 10.1111/j.1582-4934.2008.00577.x
   Sabbah M, 2008, DRUG RESIST UPDATE, V11, P123, DOI 10.1016/j.drup.2008.07.001
   Scherz-Shouval R, 2007, EMBO J, V26, P1749, DOI 10.1038/sj.emboj.7601623
   Schmitz-Valckenberg S, 2009, SURV OPHTHALMOL, V54, P96, DOI 10.1016/j.survophthal.2008.10.004
   Snider NT, 2014, NAT REV MOL CELL BIO, V15, P163, DOI 10.1038/nrm3753
   Stahl A, 2008, FEBS LETT, V582, P3097, DOI 10.1016/j.febslet.2008.08.005
   Tamiya S, 2010, INVEST OPHTH VIS SCI, V51, P2755, DOI 10.1167/iovs.09-4725
   Tao GZ, 2009, J CELL SCI, V122, P3851, DOI 10.1242/jcs.051862
   Toops KA, 2015, MOL BIOL CELL, V26, P1, DOI 10.1091/mbc.E14-05-1028
   Valapala M, 2014, AUTOPHAGY, V10, P480, DOI 10.4161/auto.27292
   Wang AL, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004160
   Wang L, 2014, BBA-MOL CELL RES, V1843, P1248, DOI 10.1016/j.bbamcr.2014.03.016
   Wang ZH, 2013, CARCINOGENESIS, V34, P128, DOI 10.1093/carcin/bgs295
   Winkler BS, 1999, MOL VIS, V5
   Wu H, 2009, MECH DEVELOP, V126, P624, DOI 10.1016/j.mod.2009.06.1082
   YAMASHITA H, 1992, RETINA-J RET VIT DIS, V12, P59, DOI 10.1097/00006982-199212010-00012
   Yoon SY, 2008, J NEUROSCI RES, V86, P3230, DOI 10.1002/jnr.21760
   Yorimitsu T, 2009, AUTOPHAGY, V5, P616, DOI 10.4161/auto.5.5.8091
   Zanzottera EC, 2015, INVEST OPHTH VIS SCI, V56, P3269, DOI 10.1167/iovs.15-16432
   Zhao C, 2011, J CLIN INVEST, V121, P369, DOI 10.1172/JCI44303
NR 63
TC 41
Z9 43
U1 2
U2 12
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1554-8627
EI 1554-8635
J9 AUTOPHAGY
JI Autophagy
PY 2017
VL 13
IS 2
BP 248
EP 263
DI 10.1080/15548627.2016.1256932
PG 16
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA EM2CY
UT WOS:000395125200004
PM 28045574
OA Green Submitted, Bronze, Green Published
DA 2022-11-30
ER

PT J
AU Zhang, XH
   Das, SK
   Passi, SF
   Uehara, H
   Bohner, A
   Chen, M
   Tiem, M
   Archer, B
   Ambati, BK
AF Zhang, Xiaohui
   Das, Subrata K.
   Passi, Samuel F.
   Uehara, Hironori
   Bohner, Austin
   Chen, Marcus
   Tiem, Michelle
   Archer, Bonnie
   Ambati, Balamurali K.
TI AAV2 Delivery of Flt23k Intraceptors Inhibits Murine Choroidal
   Neovascularization
SO MOLECULAR THERAPY
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; RETINAL GANGLION-CELLS; MACULAR DEGENERATION;
   ADENOASSOCIATED VIRUS; IN-VITRO; TRANSGENE EXPRESSION; SURVIVAL FACTOR;
   GENE-THERAPY; VEGF; RANIBIZUMAB
AB Long-term inhibition of extracellular vascular endothelial growth factor (VEGF) in the treatment of age-related macular degeneration (AMD) may induce retinal neuronal toxicity and risk other side effects. We developed a novel strategy which inhibits retinal pigment epithelium (RPE)-derived VEGF, sparing other highly sensitive retinal tissues. Flt23k, an intraceptor inhibitor of VEGF, was able to inhibit VEGF in vitro. Adeno-associated virus type 2 (AAV2)-mediated expression of Flt23k was maintained for up to 6 months postsubretinal injection in mice. Flt23k was able to effectively inhibit laser-induced murine choroidal neovascularization (CNV). VEGF levels in the RPE/choroid complex decreased significantly in AAV2.Flt23k treated eyes. Neither retinal structure detected by Heidelberg Spectralis nor function measured by electroretinography (ERG) was adversely affected by treatment with AAV2.Flt23k. Hence AAV2.Flt23k can effectively maintain long-term expression and inhibit laser-induced CNV in mice through downregulation of VEGF while maintaining a sound retinal safety profile. These findings suggest a promising novel approach for the treatment of CNV.
C1 [Zhang, Xiaohui; Das, Subrata K.; Passi, Samuel F.; Uehara, Hironori; Bohner, Austin; Chen, Marcus; Tiem, Michelle; Archer, Bonnie; Ambati, Balamurali K.] Univ Utah, Moran Eye Ctr, Salt Lake City, UT 84112 USA.
C3 Utah System of Higher Education; University of Utah
RP Ambati, BK (通讯作者)，Univ Utah, Moran Eye Ctr, 65 Mario Capecchi Dr, Salt Lake City, UT 84112 USA.
EM bala.ambati@utah.edu
OI DAS, SUBRATA/0000-0001-8608-3270; zhang, xiaohui/0000-0001-7216-4256
FU RPB; NEI [5R01EY017182]; Research to Prevent Blindness, New York, NY;
   NATIONAL EYE INSTITUTE [R01EY017182] Funding Source: NIH RePORTER
FX The authors thank Ryan Watkins for his assistance with this study. This
   work was supported by the RPB Unrestricted Award and NEI 5R01EY017182
   and in part by an Unrestricted Grant from Research to Prevent Blindness,
   New York, NY, to the Department of Ophthalmonlogy & Visual Sciences,
   University of Utah. B.K.A. has patent rights related to this technology,
   but there are no other financial conflicts of interest among any of the
   authors.
CR Aesoy R, 2008, MOL CANCER RES, V6, P1630, DOI 10.1158/1541-7786.MCR-07-2172
   Askou AL, 2012, J GENE MED, V14, P632, DOI 10.1002/jgm.2678
   Bennett J, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3002865
   Byeon SH, 2010, INVEST OPHTH VIS SCI, V51, P1190, DOI 10.1167/iovs.09-4144
   Cheng Y, 2013, CURR GENE THER, V13, P182, DOI 10.2174/1566523211313030003
   Cho YK, 2012, INVEST OPHTH VIS SCI, V53, P2328, DOI 10.1167/iovs.11-8393
   Conlon TJ, 2013, HUM GENE THER CL DEV, V24, P23, DOI 10.1089/humc.2013.037
   Cronin T, 2012, PHARMACEUTICALS, V5, P447, DOI 10.3390/ph5050447
   Das B, 2005, CANCER RES, V65, P7267, DOI 10.1158/0008-5472.CAN-04-4575
   Deudero JJP, 2008, J BIOL CHEM, V283, P11435, DOI 10.1074/jbc.M703875200
   Dismuke DJ, 2013, CURR GENE THER
   Ford KM, 2011, INVEST OPHTH VIS SCI, V52, P9478, DOI 10.1167/iovs.11-8353
   Friedlander M, 2007, J CLIN INVEST, V117, P576, DOI 10.1172/JCI31030
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gerber HP, 1998, J BIOL CHEM, V273, P30336, DOI 10.1074/jbc.273.46.30336
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Grunwald JE, 2014, OPHTHALMOLOGY, V121, P150, DOI 10.1016/j.ophtha.2013.08.015
   Guy J, 2009, INVEST OPHTH VIS SCI, V50, P4205, DOI 10.1167/iovs.08-3214
   Guziewicz KE, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075666
   Hufnagel RB, 2012, GRAEF ARCH CLIN EXP, V250, P1117, DOI 10.1007/s00417-012-2028-2
   Igarashi T, 2010, HUM GENE THER, V21, P631, DOI 10.1089/hum.2009.153
   Jackson TL, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d5058
   Jacobson SG, 2006, HUM GENE THER, V17, P845, DOI 10.1089/hum.2006.17.845
   Jani PD, 2007, INVEST OPHTH VIS SCI, V48, P2030, DOI 10.1167/iovs.06-0853
   Ju WK, 2010, MOL VIS, V16, P1331
   Kay CN, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062097
   Klettner A, 2008, INVEST OPHTH VIS SCI, V49, P4523, DOI 10.1167/iovs.08-2055
   la Cour M, 2002, DRUG AGING, V19, P101, DOI 10.2165/00002512-200219020-00003
   LEON CS, 1991, J CATARACT REFR SURG, V17, P573
   Luo L, 2013, ELIFE, V2, DOI 10.7554/eLife.00324
   Luo L, 2013, ACS NANO, V7, P3264, DOI 10.1021/nn305958y
   MacLachlan TK, 2011, MOL THER, V19, P326, DOI 10.1038/mt.2010.258
   Nishijima K, 2007, AM J PATHOL, V171, P53, DOI 10.2353/ajpath.2007.061237
   Owen LA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033576
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Romano MR, 2012, BRAIN RES, V1478, P55, DOI 10.1016/j.brainres.2012.08.014
   Saint-Geniez M, 2009, P NATL ACAD SCI USA, V106, P18751, DOI 10.1073/pnas.0905010106
   Saint-Geniez M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003554
   Salmon F, 2014, EXPERT REV CLIN PHAR, V7, P53, DOI 10.1586/17512433.2014.852065
   Sarra GM, 2002, VISION RES, V42, P541, DOI 10.1016/S0042-6989(01)00230-9
   Sayanagi K, 2009, BRIT J OPHTHALMOL, V93, P622, DOI 10.1136/bjo.2008.151977
   Singh N, 2005, INVEST OPHTH VIS SCI, V46, P1647, DOI 10.1167/iovs.04-1172
   Singh N, 2006, INVEST OPHTH VIS SCI, V47, P4787, DOI 10.1167/iovs.06-0419
   Takeda A, 2009, NATURE, V460, P225, DOI 10.1038/nature08151
   Tarallo V, 2012, INVEST OPHTH VIS SCI, V53, P7989, DOI 10.1167/iovs.12-10658
   Testa F, 2013, OPHTHALMOLOGY, V120, P1283, DOI 10.1016/j.ophtha.2012.11.048
   Tuo JS, 2012, NEUROBIOL AGING, V33, DOI 10.1016/j.neurobiolaging.2011.01.009
   Welti J, 2013, J CLIN INVEST, V123, P3190, DOI 10.1172/JCI70212
   Yodoi Y, 2009, AM J OPHTHALMOL, V147, P816, DOI 10.1016/j.ajo.2008.11.020
   Zhang SH, 2012, INVEST OPHTH VIS SCI, V53, P2675, DOI 10.1167/iovs.11-8856
NR 50
TC 15
Z9 18
U1 0
U2 12
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 1525-0016
EI 1525-0024
J9 MOL THER
JI Mol. Ther.
PD FEB
PY 2015
VL 23
IS 2
BP 226
EP 234
DI 10.1038/mt.2014.199
PG 9
WC Biotechnology & Applied Microbiology; Genetics & Heredity; Medicine,
   Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Genetics & Heredity; Research &
   Experimental Medicine
GA CA2PT
UT WOS:000348750700004
PM 25306972
OA Green Published, hybrid
DA 2022-11-30
ER

PT J
AU Moisseiev, E
   Ben Ami, T
   Barak, A
AF Moisseiev, Elad
   Ben Ami, Tal
   Barak, Adiel
TI Vitrectomy and subretinal injection of tissue plasminogen activator for
   large submacular hemorrhage secondary to AMD
SO EUROPEAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; Counting fingers; Pars plana
   vitrectomy; Submacular hemorrhage; Tissue plasminogen activator; Visual
   acuity
ID CHOROIDAL NEOVASCULAR LESIONS; MACULAR DEGENERATION; NATURAL-HISTORY;
   VISUAL-ACUITY; GAS; MANAGEMENT; SURGERY
AB Purpose: To evaluate the efficacy and safety of pars plana vitrectomy (PPV) with subretinal injection of tissue plasminogen activator (tPA) for the treatment of large submacular hemorrhage (SMH) secondary to age-related macular degeneration (AMD), and identify parameters correlated with the visual prognosis.
   Methods: Thirty-one eyes that underwent PPV with subretinal tPA injection for large SMH secondary to AMD were included in this retrospective study. Main outcome measure was improvement in at least one line in visual acuity (VA).
   Results: Improvement in VA was achieved in 14 (45.2%) patients. These patients had a significantly worse VA at presentation than patients who did not improve (p = 0.05). Central retinal thickness and earlier intervention were not correlated with the final visual prognosis. Postoperative complications included retinal detachment (19.3%), recurrent SMH (6.4%), and elevated intraocular pressure (6.4%).
   Conclusions: The VA at presentation is the most significant preoperative parameter associated with improvement in VA. A cutoff value of counting fingers VA is suggested, as patients with better VA at presentation did not benefit from surgery.
C1 [Moisseiev, Elad; Ben Ami, Tal; Barak, Adiel] Tel Aviv Univ, Sackler Fac Med, Tel Aviv Sourasky Med Ctr, Dept Ophthalmol, IL-69978 Tel Aviv, Israel.
C3 Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv Sourasky
   Medical Center
RP Moisseiev, E (通讯作者)，Tel Aviv Med Ctr & Sch Med, Dept Ophthalmol, 6 Weitzman St, IL-64239 Tel Aviv, Israel.
EM elad_moi@netvision.net.il
RI Yiu, Glenn/AAF-2858-2020
CR Avery RL, 1996, RETINA-J RET VIT DIS, V16, P183, DOI 10.1097/00006982-199616030-00001
   BENNETT SR, 1990, AM J OPHTHALMOL, V109, P33, DOI 10.1016/S0002-9394(14)75575-8
   Bhisitkul RB, 2008, INVEST OPHTH VIS SCI, V49, P4071, DOI 10.1167/iovs.08-1892
   Bressler NM, 2004, OPHTHALMOLOGY, V111, P1993, DOI 10.1016/j.ophtha.2004.07.023
   Childs AL, 2004, OPHTHALMOLOGY, V111, P2007, DOI 10.1016/j.ophtha.2004.07.024
   ELBABA F, 1986, OPHTHALMOLOGY, V93, P1581
   Fang IM, 2009, EYE, V23, P397, DOI 10.1038/sj.eye.6703017
   GILLIES A, 1983, ANN OPHTHALMOL, V15, P1068
   GLATT H, 1982, AM J OPHTHALMOL, V94, P762, DOI 10.1016/0002-9394(82)90301-4
   Hattenbach LO, 2001, OPHTHALMOLOGY, V108, P1485, DOI 10.1016/S0161-6420(01)00648-0
   Hesse L, 1999, GRAEF ARCH CLIN EXP, V237, P273, DOI 10.1007/s004170050232
   Hillenkamp J, 2010, GRAEF ARCH CLIN EXP, V248, P5, DOI 10.1007/s00417-009-1158-7
   Holladay JT, 1997, J REFRACT SURG, V13, P388
   LEWIS H, 1994, AM J OPHTHALMOL, V118, P559, DOI 10.1016/S0002-9394(14)76571-7
   Rishi E, 2012, INDIAN J OPHTHALMOL, V60, P521, DOI 10.4103/0301-4738.103779
   Sandhu SS, 2010, CLIN OPHTHALMOL, V4, P637
   Schulze SD, 2002, GRAEF ARCH CLIN EXP, V240, P717, DOI 10.1007/s00417-002-0516-5
   Schulze-Bonsel K, 2006, INVEST OPHTH VIS SCI, V47, P1236, DOI 10.1167/iovs.05-0981
   Scupola A, 1999, OPHTHALMOLOGICA, V213, P97, DOI 10.1159/000027400
   Shienbaum G, 2013, AM J OPHTHALMOL, V155, P1009, DOI 10.1016/j.ajo.2013.01.012
   Shultz RW, 2011, SEMIN OPHTHALMOL, V26, P361, DOI 10.3109/08820538.2011.585368
   Steel DHW, 2011, BRIT J OPHTHALMOL, V95, P1051, DOI 10.1136/bjo.2010.182253
   TOTH CA, 1991, ARCH OPHTHALMOL-CHIC, V109, P723, DOI 10.1001/archopht.1991.01080050139046
   van Zeeburg EJT, 2013, OPHTHALMOLOGICA, V229, P1, DOI 10.1159/000343066
   Yang Po-Min, 2005, Chang Gung Med J, V28, P852
NR 25
TC 12
Z9 12
U1 0
U2 3
PU WICHTIG EDITORE
PI MILAN
PA 72/74 VIA FRIULI, 20135 MILAN, ITALY
SN 1120-6721
EI 1724-6016
J9 EUR J OPHTHALMOL
JI Eur. J. Ophthalmol.
PD NOV-DEC
PY 2014
VL 24
IS 6
BP 925
EP 931
DI 10.5301/ejo.5000500
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AX0FA
UT WOS:000346627400018
PM 24966031
DA 2022-11-30
ER

PT J
AU Vadlapatla, RK
   Vadlapudi, AD
   Mitra, AK
AF Vadlapatla, Ramya Krishna
   Vadlapudi, Aswani Dutt
   Mitra, Ashim K.
TI Hypoxia-Inducible Factor-1 (HIF-1): A Potential Target for Intervention
   in Ocular Neovascular Diseases
SO CURRENT DRUG TARGETS
LA English
DT Article
DE Age-related macular degeneration; diabetic retinopathy; hypoxia
   signaling; hypoxia-inducible factor-1 (HIF-1); ocular
   neovascularization; retinopathy of prematurity
ID ENDOTHELIAL GROWTH-FACTOR; ACTIVATED PROTEIN-KINASE; PAS DOMAIN
   PROTEIN-1; CHOROIDAL BLOOD-FLOW; DIABETIC-RETINOPATHY; FACTOR 1-ALPHA;
   MACULAR DEGENERATION; TRANSCRIPTIONAL ACTIVATION; GENE-EXPRESSION; VEGF
   EXPRESSION
AB Constant oxygen supply is essential for proper tissue development, homeostasis and function of all eukaryotic organisms. Cellular response to reduced oxygen levels is mediated by the transcriptional regulator hypoxia-inducible factor-1 (HIF-1). It is a heterodimeric complex protein consisting of an oxygen dependent subunit (HIF-1 alpha) and a constitutively expressed nuclear subunit (HIF-1 beta). In normoxic conditions, de novo synthesized cytoplasmic HIF-1 alpha is degraded by 26S proteasome. Under hypoxic conditions, HIF-1 alpha is stabilized, binds with HIF-1 beta and activates transcription of various target genes. These genes play a key role in regulating angiogenesis, cell survival, proliferation, chemotherapy, radiation resistance, invasion, metastasis, genetic instability, immortalization, immune evasion, metabolism and stem cell maintenance. This review highlights the importance of hypoxia signaling in development and progression of various vision threatening pathologies such as diabetic retinopathy, retinopathy of prematurity, age-related macular degeneration and glaucoma. Further, various inhibitors of HIF-1 pathway that may have a viable potential in the treatment of oxygen-dependent ocular diseases are also discussed.
C1 [Vadlapatla, Ramya Krishna; Vadlapudi, Aswani Dutt; Mitra, Ashim K.] Univ Missouri, Sch Pharm, Div Pharmaceut Sci, Kansas City, MO 64108 USA.
C3 University of Missouri System; University of Missouri Kansas City
RP Mitra, AK (通讯作者)，Univ Missouri, Sch Pharm, 2464 Charlotte St, Kansas City, MO 64108 USA.
EM mitraa@umkc.edu
FU NIH [R01EY09171, R01EY010659]; NATIONAL EYE INSTITUTE [R01EY010659,
   R01EY009171] Funding Source: NIH RePORTER
FX This study has been supported by NIH grants R01EY09171 and R01EY010659.
CR Abu El-Asrar AM, 2007, BRIT J OPHTHALMOL, V91, P822, DOI 10.1136/bjo.2006.109876
   Adams MKM, 2011, AM J EPIDEMIOL, V173, P1246, DOI 10.1093/aje/kwr005
   AIELLO LP, 1995, ARCH OPHTHALMOL-CHIC, V113, P1538, DOI 10.1001/archopht.1995.01100120068012
   AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203
   Algvere PV, 2003, ACTA OPHTHALMOL SCAN, V81, P427, DOI 10.1034/j.1600-0420.2003.00157.x
   Alqawi O, 2006, PROSTATE CANCER P D, V9, P126, DOI 10.1038/sj.pcan.4500852
   Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   AMES A, 1992, CAN J PHYSIOL PHARM, V70, pS158, DOI 10.1139/y92-257
   Arden GB, 2011, CURR DIABETES REV, V7, P291, DOI 10.2174/157339911797415620
   Arjamaa O, 2009, AGEING RES REV, V8, P349, DOI 10.1016/j.arr.2009.06.002
   Ayoub T, 2009, J ROY SOC MED, V102, P56, DOI 10.1258/jrsm.2009.080298
   Baccus SA, 2007, ANNU REV PHYSIOL, V69, P271, DOI 10.1146/annurev.physiol.69.120205.124451
   Bae MK, 2006, ONCOL REP, V15, P1557
   Barnhart BC, 2007, CANCER METAST REV, V26, P261, DOI 10.1007/s10555-007-9053-3
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Ben-Yosef Y, 2002, CIRC RES, V90, P784, DOI 10.1161/01.RES.0000015588.70132.DC
   Berra E, 2003, EMBO J, V22, P4082, DOI 10.1093/emboj/cdg392
   Berra E, 2001, EMBO REP, V2, P615, DOI 10.1093/embo-reports/kve130
   Berra E, 2000, BIOCHEM PHARMACOL, V60, P1171, DOI 10.1016/S0006-2952(00)00423-8
   Bhavsar AR, 2006, RETINA-J RET VIT DIS, V26, pS71, DOI 10.1097/00006982-200607001-00016
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Bindra RS, 2007, CANCER METAST REV, V26, P249, DOI 10.1007/s10555-007-9061-3
   Brahimi-Horn C, 2005, CELL SIGNAL, V17, P1, DOI 10.1016/j.cellsig.2004.04.010
   Bruick RK, 2001, SCIENCE, V294, P1337, DOI 10.1126/science.1066373
   Bruick RK, 2000, P NATL ACAD SCI USA, V97, P9082, DOI 10.1073/pnas.97.16.9082
   Buchler P, 2004, CANCER-AM CANCER SOC, V100, P201, DOI 10.1002/cncr.11873
   Bunn HF, 1996, PHYSIOL REV, V76, P839, DOI 10.1152/physrev.1996.76.3.839
   Bursell SE, 1996, INVEST OPHTH VIS SCI, V37, P886
   Campa C, 2011, CURR DRUG TARGETS, V12, P173, DOI 10.2174/138945011794182674
   Campochiaro PA, 2013, J MOL MED, V91, P311, DOI 10.1007/s00109-013-0993-5
   Caniggia I, 2000, J CLIN INVEST, V105, P577, DOI 10.1172/JCI8316
   Caprara C, 2012, PROG RETIN EYE RES, V31, P89, DOI 10.1016/j.preteyeres.2011.11.003
   Chan DA, 2007, CANCER METAST REV, V26, P333, DOI 10.1007/s10555-007-9063-1
   Chen Jing, 2007, Angiogenesis, V10, P133, DOI 10.1007/s10456-007-9066-0
   Chen P, 2012, MOL VIS, V18, P864
   Cockman ME, 2000, J BIOL CHEM, V275, P25733, DOI 10.1074/jbc.M002740200
   Comerford KM, 2002, CANCER RES, V62, P3387
   Conway EM, 2001, CARDIOVASC RES, V49, P507, DOI 10.1016/S0008-6363(00)00281-9
   Cook HL, 2008, BRIT MED BULL, V85, P127, DOI 10.1093/bmb/ldn012
   Cormier-Regard S, 1998, J BIOL CHEM, V273, P17787, DOI 10.1074/jbc.273.28.17787
   Crawford TN, 2009, CURR DIABETES REV, V5, P8, DOI 10.2174/157339909787314149
   Dahl KDC, 2005, MOL BIOL CELL, V16, P1901
   Dames SA, 2002, P NATL ACAD SCI USA, V99, P5271, DOI 10.1073/pnas.082121399
   Donoso LA, 2006, SURV OPHTHALMOL, V51, P137, DOI 10.1016/j.survophthal.2005.12.001
   Duyndam MCA, 2007, BIOCHEM PHARMACOL, V74, P191, DOI 10.1016/j.bcp.2007.04.003
   Eckhart AD, 1997, P NATL ACAD SCI USA, V94, P9487, DOI 10.1073/pnas.94.17.9487
   Ema M, 1997, P NATL ACAD SCI USA, V94, P4273, DOI 10.1073/pnas.94.9.4273
   ENGERMAN RL, 1995, DIABETES METAB REV, V11, P109, DOI 10.1002/dmr.5610110203
   Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4
   Famiglietti EV, 2003, BRAIN RES, V969, P195, DOI 10.1016/S0006-8993(02)03766-6
   Fang J, 2007, CARCINOGENESIS, V28, P858, DOI 10.1093/carcin/bgl205
   Feldser D, 1999, CANCER RES, V59, P3915
   Ferrara N, 2004, ENDOCR REV, V25, P581, DOI 10.1210/er.2003-0027
   Ferris FL, 1999, NEW ENGL J MED, V341, P667, DOI 10.1056/NEJM199908263410907
   Flammer J, 2002, PROG RETIN EYE RES, V21, P359, DOI 10.1016/S1350-9462(02)00008-3
   Flammer J, 2008, CAN J OPHTHALMOL, V43, P317, DOI 10.3129/i08-056
   FLYNN JT, 1992, NEW ENGL J MED, V326, P1050, DOI 10.1056/NEJM199204163261603
   Forsythe JA, 1996, MOL CELL BIOL, V16, P4604
   Frede S, 2007, METHOD ENZYMOL, V435, P405, DOI 10.1016/S0076-6879(07)35021-0
   Freedman SJ, 2002, P NATL ACAD SCI USA, V99, P5367, DOI 10.1073/pnas.082117899
   Fu LN, 2012, CARCINOGENESIS, V33, P1664, DOI 10.1093/carcin/bgs217
   Garcia-Maceira P, 2009, ONCOGENE, V28, P313, DOI 10.1038/onc.2008.398
   Gehrs KM, 2006, ANN MED, V38, P450, DOI 10.1080/07853890600946724
   Gerber HP, 1997, J BIOL CHEM, V272, P23659, DOI 10.1074/jbc.272.38.23659
   Giaccia AJ, 2004, GENE DEV, V18, P2183, DOI 10.1101/gad.1243304
   Gilbert C, 2008, EARLY HUM DEV, V84, P77, DOI 10.1016/j.earlhumdev.2007.11.009
   Giordano FJ, 2001, CURR OPIN GENET DEV, V11, P35, DOI 10.1016/S0959-437X(00)00153-2
   GOLDBERG MA, 1988, SCIENCE, V242, P1412, DOI 10.1126/science.2849206
   Gradin K, 2002, J BIOL CHEM, V277, P23508, DOI 10.1074/jbc.M201307200
   Greenberger LM, 2008, MOL CANCER THER, V7, P3598, DOI 10.1158/1535-7163.MCT-08-0510
   Greer SN, 2012, EMBO J, V31, P2448, DOI 10.1038/emboj.2012.125
   Grosfeld A, 2002, J BIOL CHEM, V277, P42953, DOI 10.1074/jbc.M206775200
   Groulx I, 2002, MOL CELL BIOL, V22, P5319, DOI 10.1128/MCB.22.15.5319-5336.2002
   Grunwald JE, 2005, INVEST OPHTH VIS SCI, V46, P1033, DOI 10.1167/iovs.04-1050
   Gu YZ, 1998, GENE EXPRESSION, V7, P205
   Hackett SF, 2000, J CELL PHYSIOL, V184, P275, DOI 10.1002/1097-4652(200009)184:3<275::AID-JCP1>3.0.CO;2-7
   Hara S, 2001, BIOCHEM BIOPH RES CO, V287, P808, DOI 10.1006/bbrc.2001.5659
   HARDY P, 1994, INVEST OPHTH VIS SCI, V35, P580
   Hardy P, 2000, CARDIOVASC RES, V47, P489, DOI 10.1016/S0008-6363(00)00084-5
   Harris A L, 2000, Oncologist, V5 Suppl 1, P32
   Hewitson KS, 2002, J BIOL CHEM, V277, P26351, DOI 10.1074/jbc.C200273200
   Hogenesch JB, 2000, J NEUROSCI, V20, part. no.
   Holekamp NM, 2006, AM J OPHTHALMOL, V141, P1027, DOI 10.1016/j.ajo.2006.01.016
   Hon WC, 2002, NATURE, V417, P975, DOI 10.1038/nature00767
   Hu J, 1998, BIOCHEM BIOPH RES CO, V245, P894, DOI 10.1006/bbrc.1998.8543
   Huang JH, 2002, J BIOL CHEM, V277, P39792, DOI 10.1074/jbc.M206955200
   Huang LE, 1996, J BIOL CHEM, V271, P32253, DOI 10.1074/jbc.271.50.32253
   Huang LE, 1998, P NATL ACAD SCI USA, V95, P7987, DOI 10.1073/pnas.95.14.7987
   Hur E, 2001, MOL PHARMACOL, V59, P1216, DOI 10.1124/mol.59.5.1216
   Inoue Y, 2007, BRIT J OPHTHALMOL, V91, P1720, DOI 10.1136/bjo.2006.111583
   Isaacs JS, 2002, J BIOL CHEM, V277, P29936, DOI 10.1074/jbc.M204733200
   Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817
   Ivan M, 2001, CURR OPIN GENET DEV, V11, P27, DOI 10.1016/S0959-437X(00)00152-0
   Iyer NV, 1998, GENE DEV, V12, P149, DOI 10.1101/gad.12.2.149
   Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796
   Jeong JW, 2002, CELL, V111, P709, DOI 10.1016/S0092-8674(02)01085-1
   Jiang BH, 2001, CELL GROWTH DIFFER, V12, P363
   Jiang BH, 1996, J BIOL CHEM, V271, P17771, DOI 10.1074/jbc.271.30.17771
   Jiang BH, 1997, J BIOL CHEM, V272, P19253, DOI 10.1074/jbc.272.31.19253
   Jiang J, 2009, J CELL PHYSIOL, V218, P66, DOI 10.1002/jcp.21566
   Josifova T, 2010, EPMA J, V1, P73, DOI 10.1007/s13167-010-0003-8
   Josko J, 2000, Med Sci Monit, V6, P1047
   Kallio PJ, 1997, P NATL ACAD SCI USA, V94, P5667, DOI 10.1073/pnas.94.11.5667
   Kallio PJ, 1998, EMBO J, V17, P6573, DOI 10.1093/emboj/17.22.6573
   Kamura T, 2000, P NATL ACAD SCI USA, V97, P10430, DOI 10.1073/pnas.190332597
   Kermorvant-Duchemin E, 2010, DOC OPHTHALMOL, V120, P51, DOI 10.1007/s10633-009-9201-x
   Kietzmann T, 1999, BLOOD, V94, P4177, DOI 10.1182/blood.V94.12.4177.424k14_4177_4185
   Kim JH, 2008, J CELL MOL MED, V12, P2407, DOI 10.1111/j.1582-4934.2008.00243.x
   Kim MS, 2001, NAT MED, V7, P437, DOI 10.1038/86507
   Kim WY, 2009, CANCER RES, V69, P1624, DOI 10.1158/0008-5472.CAN-08-0505
   Kimoto K, 2012, J OPHTHALMOL, V2012, DOI 10.1155/2012/852183
   Klein R, 2010, ARCH OPHTHALMOL-CHIC, V128, P750, DOI 10.1001/archophthalmol.2010.92
   Kocur I, 2002, BRIT J OPHTHALMOL, V86, P716, DOI 10.1136/bjo.86.7.716
   Koh MY, 2008, MOL CANCER THER, V7, P90, DOI 10.1158/1535-7163.MCT-07-0463
   Kong DH, 2005, CANCER RES, V65, P9047, DOI 10.1158/0008-5472.CAN-05-1235
   Koshiji M, 2005, MOL CELL, V17, P793, DOI 10.1016/j.molcel.2005.02.015
   Krieg M, 2000, ONCOGENE, V19, P5435, DOI 10.1038/sj.onc.1203938
   Krishnamachary B, 2003, CANCER RES, V63, P1138
   Krishnamurthy P, 2004, J BIOL CHEM, V279, P24218, DOI 10.1074/jbc.M313599200
   Kumar SM, 2007, CANCER RES, V67, P3177, DOI 10.1158/0008-5472.CAN-06-3312
   Kung AL, 2004, CANCER CELL, V6, P33, DOI 10.1016/j.ccr.2004.06.009
   Kurihara T, 2012, J CLIN INVEST, V122, P4213, DOI 10.1172/JCI65157
   Kuriyama H, 2001, OPHTHALMIC RES, V33, P196, DOI 10.1159/000055670
   Lando D, 2002, GENE DEV, V16, P1466, DOI 10.1101/gad.991402
   Lando D, 2003, EUR J BIOCHEM, V270, P781, DOI 10.1046/j.1432-1033.2003.03445.x
   Lando D, 2002, SCIENCE, V295, P858, DOI 10.1126/science.1068592
   Lashkari K, 2000, AM J PATHOL, V156, P1337, DOI 10.1016/S0002-9440(10)65004-3
   LeCouter J, 2001, NATURE, V412, P877, DOI 10.1038/35091000
   Lee K, 2009, P NATL ACAD SCI USA, V106, P2353, DOI 10.1073/pnas.0812801106
   Lee PJ, 1997, J BIOL CHEM, V272, P5375, DOI 10.1074/jbc.272.9.5375
   Lee YM, 2003, BIOCHEM BIOPH RES CO, V300, P241, DOI 10.1016/S0006-291X(02)02787-0
   LEVY AP, 1995, J BIOL CHEM, V270, P13333, DOI 10.1074/jbc.270.22.13333
   Li Y, 2010, CURR CANCER DRUG TAR, V10, P782, DOI 10.2174/156800910793605857
   Liao D, 2007, CANCER RES, V67, P563, DOI 10.1158/0008-5472.CAN-06-2701
   Lim JI, 2010, RETINA-J RET VIT DIS, V30, P1472, DOI 10.1097/IAE.0b013e3181d6df09
   Lin M, 2011, DIABETOLOGIA, V54, P1554, DOI 10.1007/s00125-011-2081-0
   Lin MK, 2012, INVEST OPHTH VIS SCI, V53, P6197, DOI 10.1167/iovs.11-8936
   Liu YT, 2011, EXP EYE RES, V93, P331, DOI 10.1016/j.exer.2011.08.007
   Loenarz C, 2011, EMBO REP, V12, P63, DOI 10.1038/embor.2010.170
   Lofstedt T, 2004, J BIOL CHEM, V279, P39223, DOI 10.1074/jbc.M402904200
   Lok CN, 1999, J BIOL CHEM, V274, P24147, DOI 10.1074/jbc.274.34.24147
   Lopez-Barneo J, 2001, ANNU REV PHYSIOL, V63, P259, DOI 10.1146/annurev.physiol.63.1.259
   Lukashev D, 2007, CANCER METAST REV, V26, P273, DOI 10.1007/s10555-007-9054-2
   Mabjeesh NJ, 2003, CANCER CELL, V3, P363, DOI 10.1016/S1535-6108(03)00077-1
   Mabuchi S, 2007, CLIN CANCER RES, V13, P4261, DOI 10.1158/1078-0432.CCR-06-2770
   Maeda M, 2006, BIOL PHARM BULL, V29, P1344, DOI 10.1248/bpb.29.1344
   Mahon PC, 2001, GENE DEV, V15, P2675, DOI 10.1101/gad.924501
   Makino Y, 2002, J BIOL CHEM, V277, P32405, DOI 10.1074/jbc.C200328200
   Makino Y, 2001, NATURE, V414, P550, DOI 10.1038/35107085
   Masson N, 2003, J CELL SCI, V116, P3041, DOI 10.1242/jcs.00655
   Masson N, 2001, EMBO J, V20, P5197, DOI 10.1093/emboj/20.18.5197
   MELILLO G, 1995, J EXP MED, V182, P1683, DOI 10.1084/jem.182.6.1683
   Metelitsina TI, 2008, INVEST OPHTH VIS SCI, V49, P358, DOI 10.1167/iovs.07-0526
   Metzen E, 2003, J CELL SCI, V116, P1319, DOI 10.1242/jcs.00318
   Min JH, 2002, SCIENCE, V296, P1886, DOI 10.1126/science.1073440
   Minet E, 2001, FREE RADICAL BIO MED, V31, P847, DOI 10.1016/S0891-5849(01)00657-8
   Moeller BJ, 2007, CANCER METAST REV, V26, P241, DOI 10.1007/s10555-007-9056-0
   Mohamed Q, 2007, JAMA-J AM MED ASSOC, V298, P902, DOI 10.1001/jama.298.8.902
   Morello CA, 2007, AM J HEALTH-SYST PH, V64, pS3, DOI 10.2146/ajhp070330
   Mowat FM, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011103
   Mukhopadhyay CK, 2000, J BIOL CHEM, V275, P21048, DOI 10.1074/jbc.M000636200
   Neckers L, 2007, J BIOSCIENCES, V32, P517, DOI 10.1007/s12038-007-0051-y
   Neufeld G, 1999, FASEB J, V13, P9, DOI 10.1096/fasebj.13.1.9
   Newcomb EW, 2005, NEURO-ONCOLOGY, V7, P225, DOI 10.1215/S1152851704000997
   Ng EWM, 2005, CAN J OPHTHALMOL, V40, P352, DOI 10.1016/S0008-4182(05)80078-X
   Nguyen SV, 1999, BIOCHEM BIOPH RES CO, V265, P382, DOI 10.1006/bbrc.1999.1674
   Oikawa M, 2001, BIOCHEM BIOPH RES CO, V289, P39, DOI 10.1006/bbrc.2001.5927
   Okawa H, 2008, CURR BIOL, V18, P1917, DOI 10.1016/j.cub.2008.10.029
   Olenyuk BZ, 2004, P NATL ACAD SCI USA, V101, P16768, DOI 10.1073/pnas.0407617101
   Osborne NN, 2001, BRIT J OPHTHALMOL, V85, P1252, DOI 10.1136/bjo.85.10.1252
   Pieramici DJ, 2008, EYE, V22, P1330, DOI 10.1038/eye.2008.88
   Pore N, 2006, CANCER RES, V66, P3197, DOI 10.1158/0008-5472.CAN-05-3090
   Pore N, 2006, CANCER RES, V66, P9252, DOI 10.1158/0008-5472.CAN-06-1239
   Pournaras CJ, 2008, PROG RETIN EYE RES, V27, P284, DOI 10.1016/j.preteyeres.2008.02.002
   PUGH CW, 1991, P NATL ACAD SCI USA, V88, P10553, DOI 10.1073/pnas.88.23.10553
   Quaggin SE, 2012, J CLIN INVEST, V122, P3849, DOI 10.1172/JCI65509
   Quigley HA, 2006, BRIT J OPHTHALMOL, V90, P262, DOI 10.1136/bjo.2005.081224
   Quigley HA, 2011, LANCET, V377, P1367, DOI 10.1016/S0140-6736(10)61423-7
   Rakic JM, 2003, INVEST OPHTH VIS SCI, V44, P3186, DOI 10.1167/iovs.02-1092
   Rapisarda A, 2002, CANCER RES, V62, P4316
   REYES H, 1992, SCIENCE, V256, P1193, DOI 10.1126/science.256.5060.1193
   Reynolds R, 2010, OPHTHALMOLOGY, V117, P1989, DOI 10.1016/j.ophtha.2010.07.009
   Richard DE, 1999, J BIOL CHEM, V274, P32631, DOI 10.1074/jbc.274.46.32631
   Rolfs A, 1997, J BIOL CHEM, V272, P20055, DOI 10.1074/jbc.272.32.20055
   Ruas JL, 2002, J BIOL CHEM, V277, P38723, DOI 10.1074/jbc.M205051200
   Saint-Geniez M, 2004, INT J DEV BIOL, V48, P1045, DOI 10.1387/ijdb.041895ms
   Sang NL, 2002, MOL CELL BIOL, V22, P2984, DOI 10.1128/MCB.22.9.2984-2992.2002
   Sapieha P, 2010, J CLIN INVEST, V120, P3022, DOI 10.1172/JCI42142
   Schlingemann RO, 2004, GRAEF ARCH CLIN EXP, V242, P91, DOI 10.1007/s00417-003-0828-0
   Schofield CJ, 1999, CURR OPIN STRUC BIOL, V9, P722, DOI 10.1016/S0959-440X(99)00036-6
   SEMENZA GL, 1991, P NATL ACAD SCI USA, V88, P5680, DOI 10.1073/pnas.88.13.5680
   SEMENZA GL, 1994, J BIOL CHEM, V269, P23757
   Semenza GL, 2007, SCIENCE, V318, P62, DOI 10.1126/science.1147949
   Semenza GL, 2010, WIRES SYST BIOL MED, V2, P336, DOI 10.1002/wsbm.69
   Seo MS, 2000, AM J PATHOL, V157, P995, DOI 10.1016/S0002-9440(10)64612-3
   Shankar S, 2009, MOL CANCER THER, V8, P1596, DOI 10.1158/1535-7163.MCT-08-1004
   Sheridan CM, 2009, GRAEF ARCH CLIN EXP, V247, P1361, DOI 10.1007/s00417-009-1133-3
   Shin DH, 2008, BLOOD, V111, P3131, DOI 10.1182/blood-2007-11-120576
   Silva RLE, 2007, FASEB J, V21, P3219, DOI 10.1096/fj.06-7359com
   Smith Lois E H, 2003, Semin Neonatol, V8, P469, DOI 10.1016/S1084-2756(03)00119-2
   Smith LEH, 2008, INVEST OPHTH VIS SCI, V49, P5177, DOI 10.1167/iovs.08-2584
   Sodhi A, 2000, CANCER RES, V60, P4873
   Srinivas V, 1999, BIOCHEM BIOPH RES CO, V260, P557, DOI 10.1006/bbrc.1999.0878
   STITT AW, 1994, BRIT J OPHTHALMOL, V78, P133, DOI 10.1136/bjo.78.2.133
   Stone J, 2008, BRAIN RES, V1189, P58, DOI 10.1016/j.brainres.2007.10.083
   Sullivan R, 2007, CANCER METAST REV, V26, P319, DOI 10.1007/s10555-007-9062-2
   Sung CH, 2010, J CELL BIOL, V190, P953, DOI 10.1083/jcb.201006020
   Suzuki H, 2001, ONCOGENE, V20, P5779, DOI 10.1038/sj.onc.1204742
   Swietach P, 2007, CANCER METAST REV, V26, P299, DOI 10.1007/s10555-007-9064-0
   Takagi H, 1996, DIABETES, V45, P1016, DOI 10.2337/diabetes.45.8.1016
   Takahashi Y, 2000, J BIOL CHEM, V275, P14139, DOI 10.1074/jbc.275.19.14139
   Tanimoto K, 2000, EMBO J, V19, P4298, DOI 10.1093/emboj/19.16.4298
   Taylor CT, 2008, J PHYSIOL-LONDON, V586, P4055, DOI 10.1113/jphysiol.2008.157669
   Tazuke SI, 1998, P NATL ACAD SCI USA, V95, P10188, DOI 10.1073/pnas.95.17.10188
   Terzuoli E, 2010, CANCER RES, V70, P6837, DOI 10.1158/0008-5472.CAN-10-1075
   Tezel G, 2004, ARCH OPHTHALMOL-CHIC, V122, P1348, DOI 10.1001/archopht.122.9.1348
   THIEME H, 1995, DIABETES, V44, P98, DOI 10.2337/diabetes.44.1.98
   Tian H, 1997, GENE DEV, V11, P72, DOI 10.1101/gad.11.1.72
   Tian H, 1998, GENE DEV, V12, P3320, DOI 10.1101/gad.12.21.3320
   Tolentino M, 2011, SURV OPHTHALMOL, V56, P95, DOI 10.1016/j.survophthal.2010.08.006
   Tolppanen AM, 2009, MOL VIS, V15, P762
   Tripathi RC, 1998, OPHTHALMOLOGY, V105, P232, DOI 10.1016/S0161-6420(98)92782-8
   van Leeuwen R, 2003, INVEST OPHTH VIS SCI, V44, P3771, DOI 10.1167/iovs.03-0121
   Wan XL, 2006, NEOPLASIA, V8, P394, DOI 10.1593/neo.05820
   Wang B, 2005, J OCUL PHARMACOL TH, V21, P107, DOI 10.1089/jop.2005.21.107
   WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510
   Wang W, 2009, DIGEST DIS SCI, V54, P2128, DOI 10.1007/s10620-008-0605-3
   Watkins PJ, 2003, BRIT MED J, V326, P924, DOI 10.1136/bmj.326.7395.924
   Welsh SJ, 2003, CURR CANCER DRUG TAR, V3, P391, DOI 10.2174/1568009033481732
   Welsh SJ, 2003, MOL CANCER THER, V2, P235
   Wenger Roland H, 2005, Sci STKE, V2005, pre12, DOI 10.1126/stke.3062005re12
   Wiesener MS, 1998, BLOOD, V92, P2260, DOI 10.1182/blood.V92.7.2260.2260_2260_2268
   Wilkinson-Berka JL, 2006, INT J BIOCHEM CELL B, V38, P752, DOI 10.1016/j.biocel.2005.08.002
   Wood SM, 1998, J BIOL CHEM, V273, P8360, DOI 10.1074/jbc.273.14.8360
   Wykoff CC, 2000, CANCER RES, V60, P7075
   Yang QC, 2006, J EXP CLIN CANC RES, V25, P593
   Yasui H, 2008, BRIT J CANCER, V99, P1442, DOI 10.1038/sj.bjc.6604720
   Yoshida T, 2010, FASEB J, V24, P1759, DOI 10.1096/fj.09-145664
   Young RM, 2008, J BIOL CHEM, V283, P16309, DOI 10.1074/jbc.M710079200
   Yu F, 2001, CANCER RES, V61, P4136
   Yuan F, 1996, P NATL ACAD SCI USA, V93, P14765, DOI 10.1073/pnas.93.25.14765
   Yuan G, 2008, J CELL PHYSIOL, V217, P674, DOI 10.1002/jcp.21537
   Zagzag D, 2006, LAB INVEST, V86, P1221, DOI 10.1038/labinvest.3700482
   Zhang HF, 2008, P NATL ACAD SCI USA, V105, P19579, DOI 10.1073/pnas.0809763105
   Zhang QZ, 2005, MOL CANCER THER, V4, P1465, DOI 10.1158/1535-7163.MCT-05-0198
   Zhao Q, 2007, PANCREAS, V34, P242, DOI 10.1097/01.mpa.0000250135.95144.b6
   Zimmet P, 2001, NATURE, V414, P782, DOI 10.1038/414782a
NR 247
TC 80
Z9 84
U1 0
U2 23
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1389-4501
EI 1873-5592
J9 CURR DRUG TARGETS
JI Curr. Drug Targets
PD JUL
PY 2013
VL 14
IS 8
BP 919
EP 935
DI 10.2174/13894501113149990015
PG 17
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA 161KF
UT WOS:000320191100011
PM 23701276
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Ito, Y
   Tanaka, H
   Hara, H
AF Ito, Yasushi
   Tanaka, Hirotaka
   Hara, Hideaki
TI The Potential Roles of Metallothionein as a Therapeutic Target for
   Cerebral Ischemia and Retinal Diseases
SO CURRENT PHARMACEUTICAL BIOTECHNOLOGY
LA English
DT Article
DE Age-related macular degeneration; cerebral ischemia; metallothionein;
   neuroprotection; oxidative stress; retinitis pigmentosa; zinc toxicity
ID GROWTH-INHIBITORY FACTOR; CONE CELL-DEATH; MACULAR DEGENERATION;
   OXIDATIVE DAMAGE; GENE-EXPRESSION; TRANSGENIC MICE; NITRIC-OXIDE;
   BINDING-ACTIVITY; BRAIN; ZINC
AB Methallothionein (MT) is a low molecular weight cysteine rich metalloprotein. In mammals, there are four isoforms (MT-1, -2, -3, and -4) and they have multiple roles, such as the detoxification of heavy metals, regulating essential metal homeostasis, and protecting against oxidative stress. Recently, accumulating studies have suggested that MTs (especially MT-1, -2, and -3) are an important neuroprotective substance for cerebral ischemia and retinal diseases, such as age-related macular degeneration (AMD) and retinitis pigmentosa (RP), that are characterized by a progressive retinal degeneration. Oxidative stress and/or zinc toxicity has been implicated as part of the common pathway in these diseases. Studying the expression patterns and functions of MTs may broaden our understanding of the endogenous molecular responses that these diseases trigger, and may help us to develop new therapeutic strategies to treat them. However, the precise roles of MTs within the brain and retina are not fully understood in terms of neuropathological conditions. In this review, we discuss the recent findings focusing on MTs' functions following cerebral ischemia, AMD, and RP.
C1 [Ito, Yasushi; Tanaka, Hirotaka; Hara, Hideaki] Gifu Pharmaceut Univ, Dept Biofunct Evaluat, Gifu 5011196, Japan.
C3 Gifu Pharmaceutical University
RP Hara, H (通讯作者)，Gifu Pharmaceut Univ, Dept Biofunct Evaluat, 1-25-4 Daigaku Nishi, Gifu 5011196, Japan.
EM hidehara@gifu-pu.ac.jp
CR Adler R, 1999, Mol Vis, V5, P31
   BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620
   BOUGHMAN JA, 1980, AM J HUM GENET, V32, P223
   BRESSLER NM, 1988, SURV OPHTHALMOL, V32, P375, DOI 10.1016/0039-6257(88)90052-5
   Buch H, 2004, OPHTHALMOLOGY, V111, P53, DOI 10.1016/j.ophtha.2003.05.010
   Cai JY, 2000, PROG RETIN EYE RES, V19, P205, DOI 10.1016/S1350-9462(99)00009-9
   Calderone A, 2004, J NEUROSCI, V24, P9903, DOI 10.1523/JNEUROSCI.1713-04.2004
   Campagne MV, 2000, J NEUROSCI, V20, P5200, DOI 10.1523/JNEUROSCI.20-14-05200.2000
   Campagne MV, 1999, P NATL ACAD SCI USA, V96, P12870
   Chan C. C., 2008, OPHTHAL RES, V40, p[3, 124]
   Chan PH, 1996, STROKE, V27, P1124, DOI 10.1161/01.STR.27.6.1124
   Chen L, 2004, EXP EYE RES, V79, P287, DOI 10.1016/j.exer.2004.05.004
   Chen L, 2004, EXP EYE RES, V79, P239, DOI 10.1016/j.exer.2004.05.002
   Chung RS, 2004, J NEUROCHEM, V88, P454, DOI 10.1046/j.1471-4159.2003.02193.x
   Ciulla TA, 2001, ACTA OPHTHALMOL SCAN, V79, P108, DOI 10.1034/j.1600-0420.2001.079002108.x
   Cuajungco MP, 1997, NEUROBIOL DIS, V4, P137, DOI 10.1006/nbdi.1997.0163
   Dalton T, 1996, J NUTR, V126, P825, DOI 10.1093/jn/126.4.825
   Dalton TP, 1996, J BIOL CHEM, V271, P26233, DOI 10.1074/jbc.271.42.26233
   Erickson JC, 1997, J NEUROSCI, V17, P1271
   Fitzgerald M, 2007, EXP BRAIN RES, V183, P171, DOI 10.1007/s00221-007-1032-y
   Galasso SL, 2007, MOL MED, V13, P380, DOI 10.2119/2007-00044.Galasso
   Ghoshal K, 2001, PROG NUCLEIC ACID RE, V66, P357
   Hartong DT, 2006, LANCET, V368, P1795, DOI 10.1016/S0140-6736(06)69740-7
   He J., 2012, NEUROL SCI
   Hidalgo J, 2001, BRAIN RES BULL, V55, P133, DOI 10.1016/S0361-9230(01)00452-X
   Howells C, 2010, FEBS J, V277, P2931, DOI 10.1111/j.1742-4658.2010.07718.x
   Iadecola C, 1997, J NEUROSCI, V17, P9157
   Jacobson SG, 2002, NAT GENET, V32, P215, DOI 10.1038/ng1002-215
   Kang YJ, 1997, J CLIN INVEST, V100, P1501, DOI 10.1172/JCI119672
   Klaassen CD, 1999, ANNU REV PHARMACOL, V39, P267, DOI 10.1146/annurev.pharmtox.39.1.267
   Komeima K, 2008, FREE RADICAL BIO MED, V45, P905, DOI 10.1016/j.freeradbiomed.2008.06.020
   Komeima K, 2007, J CELL PHYSIOL, V213, P809, DOI 10.1002/jcp.21152
   Komeima K, 2006, P NATL ACAD SCI USA, V103, P11300, DOI 10.1073/pnas.0604056103
   KONDO Y, 1995, CANCER RES, V55, P474
   Koumura A, 2009, BRAIN RES, V1292, P148, DOI 10.1016/j.brainres.2009.07.050
   LAZO JS, 1995, J BIOL CHEM, V270, P5506, DOI 10.1074/jbc.270.10.5506
   Lehotsky J, 2009, GEN PHYSIOL BIOPHYS, V28, pF104
   Lipton P, 1999, PHYSIOL REV, V79, P1431, DOI 10.1152/physrev.1999.79.4.1431
   Lobner D, 2000, CELL MOL BIOL, V46, P797
   Lu HS, 2002, EXP EYE RES, V74, P83, DOI 10.1006/exer.2001.1101
   MARGOSHES M, 1957, J AM CHEM SOC, V79, P4813, DOI 10.1021/ja01574a064
   Nachman-Clewner M, 2008, INVEST OPHTH VIS SCI, V49, P3207, DOI 10.1167/iovs.07-1039
   Nakka VP, 2008, MOL NEUROBIOL, V37, P7, DOI 10.1007/s12035-007-8013-9
   Nicolas MG, 1996, EXP EYE RES, V62, P399, DOI 10.1006/exer.1996.0045
   Noell W K, 1966, Invest Ophthalmol, V5, P450
   Nowak JZ, 2006, PHARMACOL REP, V58, P353
   Palmiter RD, 1998, P NATL ACAD SCI USA, V95, P8428, DOI 10.1073/pnas.95.15.8428
   Pankhurst MW, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-172
   Pedersen MO, 2009, BIOFACTORS, V35, P315, DOI 10.1002/biof.44
   Penkowa M, 1999, EXP NEUROL, V156, P149, DOI 10.1006/exnr.1998.7009
   Penkowa M, 1999, J NEUROSCI, V19, P2535
   Penkowa M, 2006, DAN MED BULL, V53, P105
   Pereira B M, 1990, Adv Neurol, V52, P97
   Potter EG, 2007, J NEUROTRAUM, V24, P28, DOI 10.1089/neu.2006.0056.R1
   QUAIFE CJ, 1994, BIOCHEMISTRY-US, V33, P7250, DOI 10.1021/bi00189a029
   Ramkumar HL, 2010, PROG RETIN EYE RES, V29, P169, DOI 10.1016/j.preteyeres.2010.02.002
   Sancho-Pelluz J, 2008, MOL NEUROBIOL, V38, P253, DOI 10.1007/s12035-008-8045-9
   Sato M, 2000, JPN J OPHTHALMOL, V44, P115, DOI 10.1016/S0021-5155(99)00198-7
   Schaller B, 2004, J CEREBR BLOOD F MET, V24, P351, DOI 10.1097/00004647-200404000-00001
   Schneider A, 2004, MOL BRAIN RES, V124, P20, DOI 10.1016/j.molbrainres.2004.02.002
   SCHWARZ MA, 1995, P NATL ACAD SCI USA, V92, P4452, DOI 10.1073/pnas.92.10.4452
   SEARLE PF, 1984, MOL CELL BIOL, V4, P1221, DOI 10.1128/MCB.4.7.1221
   Shen JK, 2007, HISTOL HISTOPATHOL, V22, P1301, DOI 10.14670/HH-22.1301
   Shen JK, 2005, J CELL PHYSIOL, V203, P457, DOI 10.1002/jcp.20346
   Sims NR, 2010, BBA-MOL BASIS DIS, V1802, P80, DOI 10.1016/j.bbadis.2009.09.003
   Suemori S, 2006, INVEST OPHTH VIS SCI, V47, P3975, DOI 10.1167/iovs.06-0275
   TAMAI KT, 1993, P NATL ACAD SCI USA, V90, P8013, DOI 10.1073/pnas.90.17.8013
   TATE DJ, 1993, INVEST OPHTH VIS SCI, V34, P2348
   Thiersch M, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-73
   Thirumoorthy N, 2007, WORLD J GASTROENTERO, V13, P993, DOI 10.3748/wjg.v13.i7.993
   Trendelenburg G, 2002, J NEUROSCI, V22, P5879
   Tuttolomondo A, 2009, CURR TOP MED CHEM, V9, P1240, DOI 10.2174/156802609789869619
   Tuttolomondo A, 2009, CURR TOP MED CHEM, V9, P1317, DOI 10.2174/156802609789869646
   UCHIDA Y, 1991, NEURON, V7, P337, DOI 10.1016/0896-6273(91)90272-2
   Uchida Y, 2002, J BIOL CHEM, V277, P32353, DOI 10.1074/jbc.M111263200
   Vallee B.L., 1979, Experientia Supplementum (Basel), V34, P19
   Vasak M, 2005, J TRACE ELEM MED BIO, V19, P13, DOI 10.1016/j.jtemb.2005.03.003
   Vaughan CJ, 1999, STROKE, V30, P1969, DOI 10.1161/01.STR.30.9.1969
   Victor Victor M., 2009, Infectious Disorders - Drug Targets, V9, P376
   Wakida K, 2007, NEUROSCIENCE, V148, P105, DOI 10.1016/j.neuroscience.2007.04.063
   Wakida K, 2006, BRAIN RES, V1116, P187, DOI 10.1016/j.brainres.2006.07.125
   Warner DS, 2004, J EXP BIOL, V207, P3221, DOI 10.1242/jeb.01022
   Wunderlich KA, 2010, INVEST OPHTH VIS SCI, V51, P4809, DOI 10.1167/iovs.09-5073
   Yanagitani S, 1999, LIFE SCI, V64, P707, DOI 10.1016/S0024-3205(98)00612-2
   You HJ, 2002, BBA-GEN SUBJECTS, V1573, P33, DOI 10.1016/S0304-4165(02)00325-2
   Youn J, 2002, CLIN EXP IMMUNOL, V129, P232, DOI 10.1046/j.1365-2249.2002.01922.x
   Yousuf S, 2009, BRAIN RES, V1250, P242, DOI 10.1016/j.brainres.2008.10.068
   Yuguchi T, 1997, J CEREBR BLOOD F MET, V17, P745
   Zarbin MA, 1998, EUR J OPHTHALMOL, V8, P199, DOI 10.1177/112067219800800401
   Zhu YA, 2010, MOL VIS, V16, P740
NR 90
TC 14
Z9 15
U1 0
U2 9
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1389-2010
EI 1873-4316
J9 CURR PHARM BIOTECHNO
JI Curr. Pharm. Biotechnol.
PD MAR
PY 2013
VL 14
IS 4
BP 400
EP 407
DI 10.2174/1389201011314040003
PG 8
WC Biochemistry & Molecular Biology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy
GA 252DU
UT WOS:000326986000003
PM 23590137
DA 2022-11-30
ER

PT J
AU Kim, JW
   Kang, KH
   Burrola, P
   Mak, TW
   Lemke, G
AF Kim, Jin Woo
   Kang, Kyung Hwa
   Burrola, Patrick
   Mak, Tak W.
   Lemke, Greg
TI Retinal degeneration triggered by inactivation of PTEN in the retinal
   pigment epithelium
SO GENES & DEVELOPMENT
LA English
DT Article
DE PI3K signaling; PTEN; retinal pigment epithelium (RPE);
   epithelial-to-mesenchymal transition (EMT); age-related macular
   degeneration (AMD)
ID LIPID PHOSPHATASE-ACTIVITY; TUMOR-SUPPRESSOR; SODIUM IODATE; MACULAR
   DEGENERATION; OXIDATIVE STRESS; ALPHA-CRYSTALLIN; PROTEIN;
   PHOSPHORYLATION; MORPHOGENESIS; 3-KINASE
AB Adhesion between epithelial cells mediates apical-basal polarization, cell proliferation, and survival, and defects in adhesion junctions are associated with abnormalities from degeneration to cancer. We found that the maintenance of specialized adhesions between cells of the retinal pigment epithelium (RPE) requires the phosphatase PTEN. RPE-specific deletion of the mouse pten gene results in RPE cells that fail to maintain basolateral adhesions, undergo an epithelial-to-mesenchymal transition (EMT), and subsequently migrate out of the retina entirely. These events in turn lead to the progressive death of photoreceptors. The C-terminal PSD-95/Dlg/ZO-1 (PDZ)-binding domain of PTEN is essential for the maintenance of RPE cell junctional integrity. Inactivation of PTEN, and loss of its interaction with junctional proteins, are also evident in RPE cells isolated from ccr2(-/-) mice and from mice subjected to oxidative damage, both of which display age-related macular degeneration (AMD). Together, these results highlight an essential role for PTEN in normal RPE cell function and in the response of these cells to oxidative stress.
C1 [Kim, Jin Woo; Kang, Kyung Hwa] Korea Adv Inst Sci & Technol, Dept Biol Sci, Taejon 305701, South Korea.
   [Burrola, Patrick; Lemke, Greg] Salk Inst Biol Studies, Mol Neurobiol Lab, La Jolla, CA 92037 USA.
   [Mak, Tak W.] Univ Hlth Network, Campbell Family Inst Breast Canc Res, Toronto, ON M5G 2C1, Canada.
C3 Korea Advanced Institute of Science & Technology (KAIST); Salk
   Institute; University of Toronto; University Toronto Affiliates;
   University Health Network Toronto
RP Kim, JW (通讯作者)，Korea Adv Inst Sci & Technol, Dept Biol Sci, Taejon 305701, South Korea.
EM jinwookim@kaist.ac.kr; lemke@salk.edu
RI KIM, JIN WOO/C-1655-2011
OI KIM, JIN WOO/0000-0003-0767-1918
FU Research Program for New Drug Target Discovery
   [M10748000222-08N4800-22210]; Stem Cell Research
   [M10641000055-07N410005510]; Korean Ministry of Science and Technology
   [CDA0004/2007-C]; HFSP Career Development Award
FX We thank Dr. Pierre Chambon for the generous gift of TRP1-Cre mice, Dr.
   Stefano Piccolo for BAT-gal mice, Dr. Nick Leslie for human PTEN and its
   mutant clones, Dr. Frank Furnari for pBabe-Puro-PTEN and mutant
   constructs, Dr. Masatoshi Takeichi for GST-E-cadherin, Dr. Benjamin
   Margolis for Crb3 antibody, and Joe Hash and Namsuk Kim for outstanding
   technical support. This work was supported by the Research Program for
   New Drug Target Discovery (M10748000222-08N4800-22210; J. W. K.) and
   Stem Cell Research (M10641000055-07N410005510; J. W. K.), grants from
   the Korean Ministry of Science and Technology (CDA0004/2007-C; J. W. K),
   an HFSP Career Development Award (J. W. K.), and the NIH G. L.).
CR Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797
   Adey NB, 2000, CANCER RES, V60, P35
   Adler R, 1999, MOL VIS, V5
   Ambati J, 2003, NAT MED, V9, P1390, DOI 10.1038/nm950
   Bailey TA, 2004, INVEST OPHTH VIS SCI, V45, P675, DOI 10.1167/iovs.03-0351
   Barbieri SS, 2008, ARTERIOSCL THROM VAS, V28, P732, DOI 10.1161/ATVBAHA.107.159434
   Barbieri SS, 2007, FASEB J, V21, P1831, DOI 10.1096/fj.06-7557com
   Barker N, 2000, BIOESSAYS, V22, P961
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   BOK D, 1993, J CELL SCI, P189
   Bonilha VL, 1999, J CELL BIOL, V147, P1533, DOI 10.1083/jcb.147.7.1533
   Bringmann A, 2001, FRONT BIOSCI-LANDMRK, V6, pE77, DOI 10.2741/Bringman
   Cai JY, 2000, PROG RETIN EYE RES, V19, P205, DOI 10.1016/S1350-9462(99)00009-9
   Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655
   CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0
   Das S, 2003, P NATL ACAD SCI USA, V100, P7491, DOI 10.1073/pnas.0932835100
   Decanini A, 2007, AM J OPHTHALMOL, V143, P607, DOI 10.1016/j.ajo.2006.12.006
   Defoe DM, 2004, EXP EYE RES, V79, P51, DOI 10.1016/j.exer.2004.02.017
   Doonan F, 2004, CURR NEUROVASC RES, V1, P41, DOI 10.2174/1567202043480215
   EDWARDS RB, 1977, SCIENCE, V197, P1001, DOI 10.1126/science.560718
   Enzmann V, 2006, EXP EYE RES, V82, P441, DOI 10.1016/j.exer.2005.08.002
   Furnari FB, 1997, P NATL ACAD SCI USA, V94, P12479, DOI 10.1073/pnas.94.23.12479
   Georgescu MM, 1999, P NATL ACAD SCI USA, V96, P10182, DOI 10.1073/pnas.96.18.10182
   Georgescu MM, 2000, CANCER RES, V60, P7033
   GRIERSON I, 1994, EYE, V8, P255, DOI 10.1038/eye.1994.54
   Hamdi HK, 2003, FRONT BIOSCI-LANDMRK, V8, pE305, DOI 10.2741/1019
   Horwitz J, 2000, SEMIN CELL DEV BIOL, V11, P53, DOI 10.1006/scdb.1999.0351
   Jamora C, 2002, NAT CELL BIOL, V4, pE101, DOI 10.1038/ncb0402-e101
   Jin ML, 2002, INVEST OPHTH VIS SCI, V43, P2782
   Kiuchi K, 2002, CURR EYE RES, V25, P373, DOI 10.1076/ceyr.25.6.373.14227
   Kotelevets L, 2004, FASEB J, V18, P115, DOI 10.1096/fj.04-1942fje
   Kotelevets L, 2001, J CELL BIOL, V155, P1129, DOI 10.1083/jcb.200105109
   Lee JM, 2006, J CELL BIOL, V172, P973, DOI 10.1083/jcb.200601018
   Lee JO, 1999, CELL, V99, P323, DOI 10.1016/S0092-8674(00)81663-3
   Lee SR, 2002, J BIOL CHEM, V277, P20336, DOI 10.1074/jbc.M111899200
   Leslie NR, 2007, CURR BIOL, V17, P115, DOI 10.1016/j.cub.2006.12.026
   Leslie NR, 2003, EMBO J, V22, P5501, DOI 10.1093/emboj/cdg513
   Leslie NR, 2000, BIOCHEM J, V346, P827, DOI 10.1042/0264-6021:3460827
   Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943
   Lilien J, 2005, CURR OPIN CELL BIOL, V17, P459, DOI 10.1016/j.ceb.2005.08.009
   Liu H, 2006, INVEST OPHTH VIS SCI, V47, P5088, DOI 10.1167/iovs.06-0403
   Livesey FJ, 2001, NAT REV NEUROSCI, V2, P109, DOI 10.1038/35053522
   Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375
   MALORNY U, 1986, CELL TISSUE RES, V243, P421
   Maretto S, 2003, P NATL ACAD SCI USA, V100, P3299, DOI 10.1073/pnas.0434590100
   Marmorstein AD, 1998, ANN NY ACAD SCI, V857, P1, DOI 10.1111/j.1749-6632.1998.tb10102.x
   Martin-Belmonte F, 2007, CELL, V128, P383, DOI 10.1016/j.cell.2006.11.051
   Mori M, 2002, INVEST OPHTH VIS SCI, V43, P1384
   Morrow EM, 1998, TRENDS CELL BIOL, V8, P353, DOI 10.1016/S0962-8924(98)01341-5
   Myers MP, 1997, P NATL ACAD SCI USA, V94, P9052, DOI 10.1073/pnas.94.17.9052
   Myers MP, 1998, P NATL ACAD SCI USA, V95, P13513, DOI 10.1073/pnas.95.23.13513
   Noell W K, 1966, Invest Ophthalmol, V5, P450
   Penna D, 1998, ONCOGENE, V17, P2601, DOI 10.1038/sj.onc.1202196
   Perez-Moreno M, 2003, CELL, V112, P535, DOI 10.1016/S0092-8674(03)00108-9
   Pinal N, 2006, CURR BIOL, V16, P140, DOI 10.1016/j.cub.2005.11.068
   Prasad D, 2006, MOL CELL NEUROSCI, V33, P96, DOI 10.1016/j.mcn.2006.06.011
   RINGVOLD A, 1981, EXP EYE RES, V33, P361, DOI 10.1016/S0014-4835(81)80088-7
   Rizzolo LJ, 1997, HISTOL HISTOPATHOL, V12, P1057
   Salmena L, 2008, CELL, V133, P403, DOI 10.1016/j.cell.2008.04.013
   Schraermeyer U, 1999, PIGM CELL RES, V12, P219, DOI 10.1111/j.1600-0749.1999.tb00755.x
   Sparrow JR, 2005, EXP EYE RES, V80, P595, DOI 10.1016/j.exer.2005.01.007
   Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356
   Suzuki A, 2001, IMMUNITY, V14, P523, DOI 10.1016/S1074-7613(01)00134-0
   Tamura M, 1998, SCIENCE, V280, P1614, DOI 10.1126/science.280.5369.1614
   Thiery JP, 2003, CURR OPIN CELL BIOL, V15, P740, DOI 10.1016/j.ceb.2003.10.006
   Tolkacheva T, 2001, CANCER RES, V61, P4985
   Vasioukhin V, 2000, CELL, V100, P209, DOI 10.1016/S0092-8674(00)81559-7
   Vazquez F, 2000, MOL CELL BIOL, V20, P5010, DOI 10.1128/MCB.20.14.5010-5018.2000
   Vazquez F, 2001, J BIOL CHEM, V276, P48627, DOI 10.1074/jbc.C100556200
   Vogelmann R, 2005, J CELL SCI, V118, P4901, DOI 10.1242/jcs.02594
   Wang KY, 2000, EUR J BIOCHEM, V267, P4705, DOI 10.1046/j.1432-1327.2000.01521.x
   Wenzel A, 2005, PROG RETIN EYE RES, V24, P275, DOI 10.1016/j.preteyeres.2004.08.002
   Winkler BS, 1999, MOL VIS, V5
   Yang P, 2006, INVEST OPHTH VIS SCI, V47, P4598, DOI 10.1167/iovs.06-0140
   Yook JI, 2006, NAT CELL BIOL, V8, P1398, DOI 10.1038/ncb1508
   YOUNG RW, 1969, J CELL BIOL, V42, P392, DOI 10.1083/jcb.42.2.392
   Zarbin MA, 1998, EUR J OPHTHALMOL, V8, P199, DOI 10.1177/112067219800800401
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
NR 78
TC 56
Z9 57
U1 0
U2 8
PU COLD SPRING HARBOR LAB PRESS, PUBLICATIONS DEPT
PI COLD SPRING HARBOR
PA 1 BUNGTOWN RD, COLD SPRING HARBOR, NY 11724 USA
SN 0890-9369
EI 1549-5477
J9 GENE DEV
JI Genes Dev.
PD NOV 15
PY 2008
VL 22
IS 22
BP 3147
EP 3157
DI 10.1101/gad.1700108
PG 11
WC Cell Biology; Developmental Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Developmental Biology; Genetics & Heredity
GA 378UJ
UT WOS:000261349400007
PM 18997061
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Matsumoto, Y
   Freund, KB
   Peiretti, E
   Cooney, MJ
   Ferrara, DCAC
   Yannuzzi, LA
AF Matsumoto, Yoko
   Freund, K. Bailey
   Peiretti, Enrico
   Cooney, Michael J.
   Ferrara, Daniela C. A. C.
   Yannuzzi, Lawrence A.
TI Rebound macular edema following bevacizumab (avastin) therapy for
   retinal venous occlusive disease
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE retinal vein occlusion; cystoid macular edema; bevacizumab (avastin);
   rebound
ID COHERENCE TOMOGRAPHY FINDINGS; CHOROIDAL NEOVASCULARIZATION;
   INTRAVITREAL INJECTION; VEIN OCCLUSION; DEGENERATION
AB Background: Bevacizumab, a humanized monoclonal antibody to vascular endothelial growth factor (VEGF), has been given via intravitreal injection as an off-label therapy for both neovascular age-related macular degeneration and for macular edema secondary to retinal vascular disease. The authors describe three patients with macular edema secondary to retinal venous occlusion whose edema initially responded to intravitreal bevacizumab but subsequently recurred in excess of that observed before treatment.
   Methods: This is a retrospective case series of three patients with macular edema secondary to retinal vein occlusion treated with intravitreal bevacizumab.
   Results: In all three patients, the rebound retinal edema observed was more pronounced than that present before treatment.
   Conclusion: These cases suggest a potential limitation of using relatively 'short-acting VEGF antagonists in retinal vascular disease of a chronic nature. Frequent repeated injections may be required to prevent a rebound effect with no clearly defined endpoint. Until the long-term safety of multiple injections of these agents is established, the authors recommend caution in using this treatment strategy.
C1 Vitreous Retina Macula Consultants New York, New York, NY 10022 USA.
   Manhattan Eye Ear & Throat Hosp, LuEsther T Mertz Retinal Res Ctr, New York, NY 10021 USA.
C3 Vitreous Retina Macula Consultants of New York; Manhattan Eye Ear &
   Throat Hospital
RP Freund, KB (通讯作者)，Vitreous Retina Macula Consultants New York, 460 Pk Ave,5th Floor, New York, NY 10022 USA.
EM VRMNY@AOL.com
RI Freund, K. Bailey/V-7488-2018
OI Freund, K. Bailey/0000-0002-7888-9773; Peiretti,
   Enrico/0000-0003-1088-0163
CR Adamis AP, 2006, OPHTHALMOLOGY, V113, P23, DOI 10.1016/j.ophtha.2005.10.012
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   FERRARA N, 2007, IN PRESS RETINA, V27
   Iturralde D, 2006, RETINA-J RET VIT DIS, V26, P279, DOI 10.1097/00006982-200603000-00005
   JACOB P, 1998, OPHTHALMOLOGY, V105, P412
   Mason JO, 2006, RETINA-J RET VIT DIS, V26, P356, DOI 10.1097/00006982-200603000-00018
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P336, DOI 10.3928/1542-8877-20050701-15
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
   Spaide RF, 2006, RETINA-J RET VIT DIS, V26, P383, DOI 10.1097/00006982-200604000-00001
   Spaide RF, 2006, RETINA-J RET VIT DIS, V26, P275, DOI 10.1097/00006982-200603000-00004
   Tong JP, 2006, AM J OPHTHALMOL, V141, P456, DOI 10.1016/j.ajo.2005.10.012
NR 11
TC 92
Z9 98
U1 0
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD APR-MAY
PY 2007
VL 27
IS 4
BP 426
EP 431
DI 10.1097/IAE.0b013e31804a7af2
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 171AA
UT WOS:000246706100004
PM 17420693
DA 2022-11-30
ER

PT J
AU Fattal, E
   Bochot, A
AF Fattal, Elias
   Bochot, Amelie
TI Ocular delivery of nucleic acids: antisense oligonucleotides, aptamers
   and siRNA
SO ADVANCED DRUG DELIVERY REVIEWS
LA English
DT Review
DE antisense oligonucleotides; aptamers; siRNA; intravitreal
   administration; cationic polymers; cationic lipids; nanoparticles;
   microparticles; liposomes; dendrimers; iontophoresis
ID ENDOTHELIAL GROWTH-FACTOR; PIGMENT EPITHELIAL-CELLS; NONVIRAL
   GENE-TRANSFER; EARLY MESSENGER RNA-4; ANTI-VEGF APTAMER; ANTIVIRAL
   ACTIVITY; PHOSPHOROTHIOATE OLIGONUCLEOTIDE; CHOROIDAL
   NEOVASCULARIZATION; IN-VITRO; DRUG-DELIVERY
AB Nucleic acids have gained a lot of interest for the treatment of ocular diseases. The first to enter in clinic has been Vitravene (R) an antisense oligonucleotide for the treatment of cytomegalovirus (CMV) infection and more recently, research on aptamers have led to the marketing of anti-vascular endothelial growth factor (VEGF) inhibitor (Macugen (R)) for the treatment of age-related macular degeneration (AMD). The siRNAs appear very promising as they are very potent inhibitors of protein expression. Despite their potential, nucleic acids therapeutic targets of nucleic acid-based drugs are mainly located in the posterior segment of the eye requiring invasive administration which can be harmful if repeated. Their intracellular penetration in some cases needs to be enhanced. This is the reason why adequate delivery systems were designed either to insure cellular penetration, protection against degradation or to allow long-term delivery. A combination of both effects was also developed for an implantable system. In conclusion, the intraocular administration of nucleic acids offers interesting perspectives for the treatment of ocular diseases. (c) 2006 Elsevier B.V. All rights reserved.
C1 Univ Paris Sud, CNRS, UMR 8612, Sch Pharm, F-92296 Chatenay Malabry, France.
C3 Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of
   Chemistry (INC); UDICE-French Research Universities; Universite Paris
   Saclay
RP Fattal, E (通讯作者)，Univ Paris Sud, CNRS, UMR 8612, Sch Pharm, 5 Rue Jean Baptiste Clement, F-92296 Chatenay Malabry, France.
EM elias.fattal@cep.u-psud.fr
RI Fattal, Elias/AAH-1769-2019
OI Fattal, Elias/0000-0002-3194-961X; Bochot, Amelie/0000-0001-9604-2376
CR Abul-Hassan K, 2000, CURR EYE RES, V20, P361, DOI 10.1076/0271-3683(200005)20:5;1-1;FT361
   ADAMIS AP, 1994, AM J OPHTHALMOL, V118, P445, DOI 10.1016/S0002-9394(14)75794-0
   Agrawal S, 1999, BBA-GENE STRUCT EXPR, V1489, P53, DOI 10.1016/S0167-4781(99)00141-4
   Al-Jamal KT, 2005, ADV DRUG DELIVER REV, V57, P2238, DOI 10.1016/j.addr.2005.09.015
   Ambati J, 2000, INVEST OPHTH VIS SCI, V41, P1181
   Ambati J, 2000, INVEST OPHTH VIS SCI, V41, P1186
   Anderson KP, 1996, ANTIMICROB AGENTS CH, V40, P2004, DOI 10.1128/AAC.40.9.2004
   Andresen JL, 1997, CURR EYE RES, V16, P605
   Arnedo A, 2000, J CHROMATOGR A, V871, P311, DOI 10.1016/S0021-9673(99)01193-0
   Arnedo A, 2004, J CONTROL RELEASE, V94, P217, DOI 10.1016/j.jconrel.2003.10.009
   Asahara T, 2001, JPN J OPHTHALMOL, V45, P31, DOI 10.1016/S0021-5155(00)00291-4
   AZAD RF, 1993, ANTIMICROB AGENTS CH, V37, P1945, DOI 10.1128/AAC.37.9.1945
   AZAD RF, 1995, ANTIVIR RES, V28, P101, DOI 10.1016/0166-3542(95)00035-K
   Bejjani R, 2005, MOL VIS, V11, P124
   Berdugo M, 2003, ANTISENSE NUCLEIC A, V13, P107, DOI 10.1089/108729003321629647
   Blind M, 1999, P NATL ACAD SCI USA, V96, P3606, DOI 10.1073/pnas.96.7.3606
   Bochot A, 1998, J DRUG TARGET, V6, P309, DOI 10.3109/10611869808996838
   Bochot A, 2002, INVEST OPHTH VIS SCI, V43, P253
   Bochot A, 2000, PROG RETIN EYE RES, V19, P131, DOI 10.1016/S1350-9462(99)00014-2
   Bourges JL, 2003, INVEST OPHTH VIS SCI, V44, P3562, DOI 10.1167/iovs.02-1068
   BOUSSIF O, 1995, P NATL ACAD SCI USA, V92, P7297, DOI 10.1073/pnas.92.16.7297
   Burmeister PE, 2005, CHEM BIOL, V12, P25, DOI 10.1016/j.chembiol.2004.10.017
   Carrasquillo KG, 2003, INVEST OPHTH VIS SCI, V44, P290, DOI 10.1167/iovs.01-1156
   Cordeiro MF, 2003, CLIN SCI, V104, P181, DOI 10.1042/CS20020150
   Cordeiro MF, 1999, BRIT J OPHTHALMOL, V83, P1219, DOI 10.1136/bjo.83.11.1219
   Cordeiro MF, 2003, GENE THER, V10, P59, DOI 10.1038/sj.gt.3301865
   Cunningham ET, 2005, OPHTHALMOLOGY, V112, P1747, DOI 10.1016/j.ophtha.2005.06.007
   Danis DP, 2003, CURR EYE RES, V26, P45, DOI 10.1076/ceyr.26.1.45.14252
   De Rosa G, 2002, INT J PHARM, V242, P225, DOI 10.1016/S0378-5173(02)00162-X
   De Rosa G, 2002, J PHARM SCI, V91, P790, DOI 10.1002/jps.10063
   De Rosa G, 2003, BIOMACROMOLECULES, V4, P529, DOI 10.1021/bm025684c
   De Rosa G, 2003, INT J PHARMACEUT, V254, P89, DOI 10.1016/S0378-5173(02)00689-0
   Delie F, 2001, INT J PHARM, V214, P25, DOI 10.1016/S0378-5173(00)00627-X
   Dennig Jorg, 2002, J Biotechnol, V90, P339
   Desire L, 2000, J NEUROCHEM, V75, P151, DOI 10.1046/j.1471-4159.2000.0750151.x
   Detrick B, 2001, INVEST OPHTH VIS SCI, V42, P163
   Dhalla MS, 2006, AM J OPHTHALMOL, V141, P752, DOI 10.1016/j.ajo.2005.10.053
   dos Santos ALG, 2006, PHARM RES-DORDR, V23, P770, DOI 10.1007/s11095-006-9748-0
   Drolet DW, 2000, PHARMACEUT RES, V17, P1503, DOI 10.1023/A:1007657109012
   Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107
   Far RKK, 2003, NUCLEIC ACIDS RES, V31, P4417, DOI 10.1093/nar/gkg649
   Ferrara N, 2004, ENDOCR REV, V25, P581, DOI 10.1210/er.2003-0027
   Fish G, 2003, OPHTHALMOLOGY, V110, P979, DOI 10.1016/S0161-6420(03)00085-X
   FITZGERALD P, 1987, J PHARM PHARMACOL, V39, P487, DOI 10.1111/j.2042-7158.1987.tb03428.x
   FloresAguilar M, 1997, J INFECT DIS, V175, P1308, DOI 10.1086/516461
   Garrett KL, 2001, J GENE MED, V3, P373, DOI 10.1002/jgm.197
   Gewirtz AM, 1998, BLOOD, V92, P712, DOI 10.1182/blood.V92.3.712.415a32_712_736
   GIORDANO GG, 1995, CURR EYE RES, V14, P761, DOI 10.3109/02713689508995797
   dos Santos ALG, 2006, J CONTROL RELEASE, V112, P369, DOI 10.1016/j.jconrel.2006.02.010
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Gryaznov S, 1996, NUCLEIC ACIDS RES, V24, P1508, DOI 10.1093/nar/24.8.1508
   GRYAZNOV SM, 1995, P NATL ACAD SCI USA, V92, P5798, DOI 10.1073/pnas.92.13.5798
   Halhal M, 2004, EXP EYE RES, V78, P751, DOI 10.1016/j.exer.2003.10.017
   Hamalainen KM, 1997, INVEST OPHTH VIS SCI, V38, P627
   HANVEY JC, 1992, SCIENCE, V258, P1481, DOI 10.1126/science.1279811
   Hariprasad SM, 2006, AM J OPHTHALMOL, V141, P200, DOI 10.1016/j.ajo.2005.07.053
   Healy JM, 2004, PHARM RES-DORDR, V21, P2234, DOI 10.1007/s11095-004-7676-4
   Hecquet C, 2002, INVEST OPHTH VIS SCI, V43, P3091
   Henry SP, 2001, INVEST OPHTH VIS SCI, V42, P2646
   Irache JM, 2005, MINI-REV MED CHEM, V5, P293, DOI 10.2174/1389557053175335
   Jaaskelainen I, 2000, EUR J PHARM SCI, V10, P187, DOI 10.1016/S0928-0987(00)00068-3
   Jaaskelainen I, 2004, METHOD ENZYMOL, V387, P210
   Jager RD, 2004, RETINA-J RET VIT DIS, V24, P676, DOI 10.1097/00006982-200410000-00002
   KEAN JM, 1995, BIOCHEMISTRY-US, V34, P14617, DOI 10.1021/bi00045a001
   Ketting RF, 2001, GENE DEV, V15, P2654, DOI 10.1101/gad.927801
   Khan A, 2000, J DRUG TARGET, V8, P319, DOI 10.3109/10611860008997909
   Kim B, 2004, AM J PATHOL, V165, P2177, DOI 10.1016/S0002-9440(10)63267-1
   Kitajima I, 1999, ANTISENSE NUCLEIC A, V9, P233, DOI 10.1089/oli.1.1999.9.233
   Kourlas H, 2006, CLIN THER, V28, P36, DOI 10.1016/j.clinthera.2006.01.009
   KULKA M, 1993, ANTIVIR RES, V20, P115, DOI 10.1016/0166-3542(93)90002-Z
   KULKA M, 1994, ANTIMICROB AGENTS CH, V38, P675, DOI 10.1128/AAC.38.4.675
   KULKA M, 1989, P NATL ACAD SCI USA, V86, P6868, DOI 10.1073/pnas.86.18.6868
   KULKA M, 1995, ANTISENSE RES DEV, V5, P243, DOI 10.1089/ard.1995.5.243
   Kurreck J, 2003, EUR J BIOCHEM, V270, P1628, DOI 10.1046/j.1432-1033.2003.03555.x
   Kvanta A, 1996, INVEST OPHTH VIS SCI, V37, P1929
   Larsen Michael, 2005, Ugeskr Laeger, V167, P3301
   LEONETTI JP, 1993, PROG NUCLEIC ACID RE, V44, P143, DOI 10.1016/S0079-6603(08)60219-6
   LOKE SL, 1989, P NATL ACAD SCI USA, V86, P3474, DOI 10.1073/pnas.86.10.3474
   Marano RJ, 2004, EXP EYE RES, V79, P525, DOI 10.1016/j.exer.2004.06.023
   Marano RJ, 2005, CLIN EXP OPHTHALMOL, V33, P81, DOI 10.1111/j.1442-9071.2005.00952.x
   Marano RJ, 2005, GENE THER, V12, P1544, DOI 10.1038/sj.gt.3302579
   Marano RJ, 2003, INVEST OPHTH VIS SCI, V44, pU291
   Martin DF, 2002, RETINA-J RET VIT DIS, V22, P143
   McCauley TG, 2006, PHARM RES-DORDR, V23, P303, DOI 10.1007/s11095-005-9305-2
   MORITERA T, 1991, INVEST OPHTH VIS SCI, V32, P1785
   Moshfeghi AA, 2005, ADV DRUG DELIVER REV, V57, P2047, DOI 10.1016/j.addr.2005.09.006
   Mulamba GB, 1998, ANTIMICROB AGENTS CH, V42, P971, DOI 10.1128/AAC.42.4.971
   Murata M, 2006, CURR EYE RES, V31, P171, DOI 10.1080/02713680500514636
   Myles ME, 2005, ADV DRUG DELIVER REV, V57, P2063, DOI 10.1016/j.addr.2005.08.006
   Nakamura H, 2004, MOL VIS, V10, P703
   Ng EWM, 2005, CAN J OPHTHALMOL, V40, P352, DOI 10.1016/S0008-4182(05)80078-X
   Ng EWM, 2006, NAT REV DRUG DISCOV, V5, P123, DOI 10.1038/nrd1955
   Nimjee SM, 2005, ANNU REV MED, V56, P555, DOI 10.1146/annurev.med.56.062904.144915
   Normand N, 2001, J BIOL CHEM, V276, P15042, DOI 10.1074/jbc.M010294200
   Normand N, 2005, MOL VIS, V11, P184
   Ogata N, 1999, CURR EYE RES, V18, P261, DOI 10.1076/ceyr.18.4.261.5358
   OLSEN TW, 1995, INVEST OPHTH VIS SCI, V36, P1893
   Opalinska JB, 2002, NAT REV DRUG DISCOV, V1, P503, DOI 10.1038/nrd837
   PARI GS, 1995, ANTIMICROB AGENTS CH, V39, P1157, DOI 10.1128/AAC.39.5.1157
   PARI GS, 1993, J VIROL, V67, P6979, DOI 10.1128/JVI.67.12.6979-6988.1993
   Peeters L, 2005, INVEST OPHTH VIS SCI, V46, P3553, DOI 10.1167/iovs.05-0165
   Perry CM, 1999, DRUGS, V57, P375, DOI 10.2165/00003495-199957030-00010
   Pestourie C, 2005, BIOCHIMIE, V87, P921, DOI 10.1016/j.biochi.2005.04.013
   PEYMAN A, 1995, BIOL CHEM H-S, V376, P195
   PIERCE EA, 1995, P NATL ACAD SCI USA, V92, P905, DOI 10.1073/pnas.92.3.905
   Pitkanen L, 2003, PHARM RES-DORDR, V20, P576, DOI 10.1023/A:1023238530504
   Pitkanen Leena, 2004, AAPS J, V6, pe25
   PODDEVIN B, 1994, ANTISENSE RES DEV, V4, P147, DOI 10.1089/ard.1994.4.147
   Proske D, 2005, APPL MICROBIOL BIOT, V69, P367, DOI 10.1007/s00253-005-0193-5
   Reich S, 2003, MOL VIS, V9, P210
   Remy JS, 1998, ADV DRUG DELIVER REV, V30, P85, DOI 10.1016/S0169-409X(97)00109-9
   Rho SH, 2001, OPHTHALMIC RES, V33, P24, DOI 10.1159/000055637
   Robinson GS, 1996, P NATL ACAD SCI USA, V93, P4851, DOI 10.1073/pnas.93.10.4851
   Roy S, 1999, NAT BIOTECHNOL, V17, P476, DOI 10.1038/8654
   Ruckman J, 1998, J BIOL CHEM, V273, P20556, DOI 10.1074/jbc.273.32.20556
   Ruponen M, 2001, J BIOL CHEM, V276, P33875, DOI 10.1074/jbc.M011553200
   Ruponen M, 2003, J CONTROL RELEASE, V93, P213, DOI 10.1016/j.jconrel.2003.08.004
   Ruponen M, 1999, BBA-BIOMEMBRANES, V1415, P331, DOI 10.1016/S0005-2736(98)00199-0
   SHAH M, 1995, J CELL SCI, V108, P985
   Shen WY, 2002, LAB INVEST, V82, P167, DOI 10.1038/labinvest.3780409
   Shuler RK, 2004, J OCUL PHARMACOL TH, V20, P159, DOI 10.1089/108076804773710830
   SMITH JA, 1995, J VIROL, V69, P1925, DOI 10.1128/JVI.69.3.1925-1931.1995
   Song QH, 2000, J CELL BIOCHEM, V77, P186, DOI 10.1002/(SICI)1097-4644(20000501)77:2<186::AID-JCB3>3.0.CO;2-M
   STEIN CA, 1993, SCIENCE, V261, P1004, DOI 10.1126/science.8351515
   STEIN CA, 1996, BIOTECHNOLOGY, V14, P47
   Summerton J, 1997, ANTISENSE NUCLEIC A, V7, P187, DOI 10.1089/oli.1.1997.7.187
   Summerton J, 1999, BBA-GENE STRUCT EXPR, V1489, P141, DOI 10.1016/S0167-4781(99)00150-5
   Tolentino MJ, 2004, RETINA-J RET VIT DIS, V24, P132, DOI 10.1097/00006982-200402000-00018
   Urban Ernst, 2003, Farmaco (Lausanne), V58, P243, DOI 10.1016/S0014-827X(03)00022-3
   Urtti A, 2000, J DRUG TARGET, V7, P413, DOI 10.3109/10611860009102216
   Vaucheret H, 2001, TRENDS GENET, V17, P29, DOI 10.1016/S0168-9525(00)02166-1
   Voigt M, 2002, BIOCHEM BIOPH RES CO, V295, P336, DOI 10.1016/S0006-291X(02)00656-3
   Wasmuth S, 2003, INVEST OPHTH VIS SCI, V44, P5228, DOI 10.1167/iovs.03-0312
   Wimmer N, 2002, BIOORG MED CHEM LETT, V12, P2635, DOI 10.1016/S0960-894X(02)00511-5
   Zavaglia D, 2003, MOL THER, V8, P840, DOI 10.1016/j.ymthe.2003.08.001
NR 135
TC 105
Z9 123
U1 4
U2 63
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0169-409X
EI 1872-8294
J9 ADV DRUG DELIVER REV
JI Adv. Drug Deliv. Rev.
PD NOV 15
PY 2006
VL 58
IS 11
BP 1203
EP 1223
DI 10.1016/j.addr.2006.07.020
PG 21
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA 118FL
UT WOS:000242927700006
PM 17097190
DA 2022-11-30
ER

PT J
AU Soucek, P
   Cihelkova, I
AF Soucek, P
   Cihelkova, I
TI Treatment of macular degeneration - (A controlled case)
SO NEUROENDOCRINOLOGY LETTERS
LA English
DT Article
DE age-related macular degeneration; choroidal neovascularization;
   verteporfin; photodynamic therapy; fluorescein angiography; optical
   coherence tomography
AB Our controlled case describes the drug possibility to stabilize the exudative form of Age-related Macular Degeneration. The new approach of selective destruction of choroidal neovascularization (CNV) can be applied in patients with subfoveal lesions. Photodynamic therapy (PDT) is based on the reaction of photoactivable drug with the light of low-energy laser beam. So far only verteporfin [Visudyne, Novartis] as sensitizer is marketed and laser with wavelength of 689 nm is used. But it is questionable whether to apply this very costly treatment to extremely old people. An example of treatment of 90-year old woman with AMD with classic form of CNV is presented. Her BCVA was 0.05 OD. She underwent four session of PDT At the last visit (eighteen months after initial and ten months after last session of PDT) the BCVA remained 0.05 OD. The patient is using a special magnifying lens for reading achieving near vision of 0.32.
   The presented example indicates the necessity of detailed study of every case to promote the therapeutic decisions for the benefit of progress in the field.
C1 Univ Hosp, Eye Dept, Prague 10034, Czech Republic.
C3 General University Hospital Prague
RP Soucek, P (通讯作者)，Univ Hosp, Eye Dept, Srobarova 50, Prague 10034, Czech Republic.
CR Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   FINE SL, 1982, ARCH OPHTHALMOL-CHIC, V100, P912
   Soucek P, 1997, Cesk Slov Oftalmol, V53, P94
   Soucek P, 2002, Cesk Slov Oftalmol, V58, P89
NR 4
TC 2
Z9 2
U1 0
U2 0
PU MAGHIRA & MAAS PUBLICATIONS
PI STOCKHOLM
PA PO BOX 26132, S-100 41 STOCKHOLM, SWEDEN
SN 0172-780X
J9 NEUROENDOCRINOL LETT
JI Neuroendocrinol. Lett.
PD AUG
PY 2002
VL 23
IS 4
BP 370
EP 372
AR PII NEL230402A12
PG 3
WC Endocrinology & Metabolism; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Endocrinology & Metabolism; Neurosciences & Neurology
GA 590CT
UT WOS:000177800800021
PM 12195243
DA 2022-11-30
ER

PT J
AU Valverde-Megias, A
   Rego-Lorca, D
   Fernandez-Vigo, JI
   Murciano-Cespedosa, A
   Megias-Fresno, A
   Garcia-Feijoo, J
AF Valverde-Megias, Alicia
   Rego-Lorca, Daniela
   Ignacio Fernandez-Vigo, Jose
   Murciano-Cespedosa, Antonio
   Megias-Fresno, Alicia
   Garcia-Feijoo, Julian
TI Effect of COVID-19 Lockdown in Spain on Structural and Functional
   Outcomes of Neovascular AMD Patients
SO JOURNAL OF CLINICAL MEDICINE
LA English
DT Article
DE COVID-19; nAMD; anti-VEGF
ID MACULAR DEGENERATION; RANIBIZUMAB
AB This is a retrospective single-center study of patients with neovascular age-related macular degeneration whose follow-up was delayed due to COVID-19 pandemic with at least three months between visits in Madrid, Spain. The purpose of the study was to evaluate best corrected visual acuity (BCVA) changes and try to identify features in optical coherence tomography (OCT) that could be related to more profound visual loss. It included 270 eyes. The two last visits before lockdown were used for comparison with the visit after lockdown. BCVA changed from 60.2 +/- 18.2 to 55.9 +/- 20.5 ETDRS letters. 29% of the eyes lost more than 5 letters. OCT was active in 67% of eyes before lockdown and in 80.4% after lockdown. Multiple lineal analysis showed that patients whose OCT before lockdown presented with a combination of intra and subretinal fluid were more likely to suffer a greater visual loss (p = 0.002). These patients should be encouraged to not miss any visits in case a new lockdown is imposed.
C1 [Valverde-Megias, Alicia; Rego-Lorca, Daniela; Ignacio Fernandez-Vigo, Jose; Garcia-Feijoo, Julian] San Carlos Clin Hosp, Dept Ophthalmol, Madrid 28040, Spain.
   [Rego-Lorca, Daniela; Ignacio Fernandez-Vigo, Jose; Garcia-Feijoo, Julian] IdISSC Inst Invest Sanitaria Hosp Clin San Carlos, Madrid 28040, Spain.
   [Ignacio Fernandez-Vigo, Jose] Ctr Int Oftalmol Avanzada, Madrid 28010, Spain.
   [Murciano-Cespedosa, Antonio] Univ Complutense Madrid, Fac Biol, Dept Biomath, Madrid 28040, Spain.
   [Megias-Fresno, Alicia] Univ Complutense Madrid, Fac Biol, Dept Biochem & Mol Biol, Madrid 28040, Spain.
   [Garcia-Feijoo, Julian] Univ Complutense Madrid, Fac Med, Dept Opthalmol, Madrid 28040, Spain.
C3 Complutense University of Madrid; Complutense University of Madrid;
   Complutense University of Madrid
RP Valverde-Megias, A (通讯作者)，San Carlos Clin Hosp, Dept Ophthalmol, Madrid 28040, Spain.
EM amegias@bio.ucm.es; dpregolorca@gmail.com; jfyigo@hotmail.com;
   murciano@ucm.es; alicia.valgreen@gmail.com; jgarciafeijoo@hotmail.com
RI ; Fernandez-Vigo, Jose Ignacio/G-9779-2017
OI Valverde-Megias, Alicia/0000-0002-6166-114X; MURCIANO CESPEDOSA,
   ANTONIO/0000-0001-6644-8420; Fernandez-Vigo, Jose
   Ignacio/0000-0001-8745-3464
CR Abraham P, 2010, AM J OPHTHALMOL, V150, P315, DOI 10.1016/j.ajo.2010.04.011
   Arruabarrena C, 2021, J CLIN MED, V10, DOI 10.3390/jcm10153281
   Borrelli E, 2021, J CLIN MED, V10, DOI 10.3390/jcm10061265
   Borrelli E, 2020, GRAEF ARCH CLIN EXP, V258, P2621, DOI 10.1007/s00417-020-04955-7
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Gillies MC, 2019, JAMA OPHTHALMOL, V137, P372, DOI 10.1001/jamaophthalmol.2018.6776
   Holz FG, 2016, BRIT J OPHTHALMOL, V100, P1623, DOI 10.1136/bjophthalmol-2015-308166
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Huang YJ, 2012, INVEST OPHTH VIS SCI, V53, P2133, DOI 10.1167/iovs.11-8755
   Maguire MG, 2016, OPHTHALMOLOGY, V123, P1751, DOI 10.1016/j.ophtha.2016.03.045
   Naravane AV, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0247161
   Ophthalmologists RCo, 2020, CLIN GUIDELINES HYDR
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schmidt-Erfurth U, 2014, BRIT J OPHTHALMOL, V98, P1144, DOI 10.1136/bjophthalmol-2014-305702
   Sekeroglu MA, 2022, EUR J OPHTHALMOL, V32, P1064, DOI 10.1177/11206721211010613
   Sevik MO, 2021, INT OPHTHALMOL, V41, P2951, DOI 10.1007/s10792-021-01854-6
   Stone LG, 2021, GRAEF ARCH CLIN EXP, V259, P1773, DOI 10.1007/s00417-021-05174-4
   Teo KYC, 2020, OPHTHALMOL RETINA, V4, P871, DOI 10.1016/j.oret.2020.03.017
   The Royal College of Ophthalmologists, 2020, MED RET MAN PLANS CO
   Yeter DY, 2021, J FR OPHTALMOL, V44, P299, DOI 10.1016/j.jfo.2021.02.001
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 21
TC 3
Z9 3
U1 3
U2 13
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2077-0383
J9 J CLIN MED
JI J. Clin. Med.
PD AUG
PY 2021
VL 10
IS 16
AR 3551
DI 10.3390/jcm10163551
PG 11
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA UG4NK
UT WOS:000689231100001
PM 34441845
OA Green Published, gold, Green Accepted
DA 2022-11-30
ER

PT J
AU Cheng, KJ
   Hsieh, CM
   Nepali, K
   Liou, JP
AF Cheng, Kuei-Ju
   Hsieh, Chien-Ming
   Nepali, Kunal
   Liou, Jing-Ping
TI Ocular Disease Therapeutics: Design and Delivery of Drugs for Diseases
   of the Eye
SO JOURNAL OF MEDICINAL CHEMISTRY
LA English
DT Article
ID OPEN-ANGLE GLAUCOMA; RETINOL-BINDING-PROTEIN; RHO-KINASE INHIBITOR;
   SELECTIVE LASER TRABECULOPLASTY; DIABETIC MACULAR EDEMA; DEXAMETHASONE
   INTRAVITREAL IMPLANT; LATANOPROSTENE BUNOD 0.024-PERCENT;
   CARBONIC-ANHYDRASE INHIBITORS; LOWERING INTRAOCULAR-PRESSURE; TIMOLOL
   MALEATE 0.5-PERCENT
AB The ocular drug discovery field has evidenced significant advancement in the past decade. The FDA approvals of Rhopressa, Vyzulta, and Roclatan for glaucoma, Brolucizumab for wet age-related macular degeneration (wet AMD), Luxturna for retinitis pigmentosa, Dextenza (0.4 mg dexamethasone intracanalicular insert) for ocular inflammation, ReSure sealant to seal corneal incisions, and Lifitegrast for dry eye represent some of the major developments in the field of ocular therapeutics. A literature survey also indicates that gene therapy, stem cell therapy, and target discovery through genomic research represent significant promise as potential strategies to achieve tissue repair or regeneration and to attain therapeutic benefits in ocular diseases. Overall, the emergence of new technologies coupled with first-in-class entries in ophthalmology are highly anticipated to restructure and boost the future trends in the field of ophthalmic drug discovery. This perspective focuses on various aspects of ocular drug discovery and the recent advances therein. Recent medicinal chemistry campaigns along with a brief overview of the structure-activity relationships of the diverse chemical classes and developments in ocular drug delivery (ODD) are presented.
C1 [Cheng, Kuei-Ju; Hsieh, Chien-Ming; Nepali, Kunal; Liou, Jing-Ping] Taipei Med Univ, Coll Pharm, Sch Pharm, Taipei 11031, Taiwan.
   [Cheng, Kuei-Ju] Taipei Med Univ, Taipei Municipal Wanfang Hosp, Dept Pharm, Taipei 11696, Taiwan.
C3 Taipei Medical University; Taipei Medical University; Taipei Municipal
   WanFang Hospital
RP Nepali, K; Liou, JP (通讯作者)，Taipei Med Univ, Coll Pharm, Sch Pharm, Taipei 11031, Taiwan.
EM nepali@tmu.edu.tw; jpl@tmu.edu.tw
OI Hsieh, Chien-Ming/0000-0002-7204-4681
FU MOST, Taiwan [107-2113-M-038-001, MOST108-2320-B-038-010-MY2 (2-1)]
FX The corresponding authors are supported by grants from MOST, Taiwan
   (grant no. 107-2113-M-038-001 and MOST108-2320-B-038-010-MY2 (2-1). We
   are grateful to the Springer Nature and ACS Publications for permitting
   the inclusion of Figures 2, 5 and 8 in this Perspective.
CR Abdelbary G, 2008, AAPS PHARMSCITECH, V9, P740, DOI 10.1208/s12249-008-9105-1
   Abdelkader H, 2011, J PHARM SCI-US, V100, P1833, DOI 10.1002/jps.22422
   Abidi A, 2016, J PHARMACOL PHARMACO, V7, P194, DOI 10.4103/0976-500X.195920
   Abrishami M, 2009, RETINA-J RET VIT DIS, V29, P699, DOI 10.1097/IAE.0b013e3181a2f42a
   Adams CM, 2018, J MED CHEM, V61, P1622, DOI 10.1021/acs.jmedchem.7b01731
   Aggarwal D, 2005, INT J PHARMACEUT, V290, P155, DOI 10.1016/j.ijpharm.2004.10.026
   Alam NM, 2015, DIS MODEL MECH, V8, P701, DOI 10.1242/dmm.020248
   Alezzandrini A., 2010, RETINA TODAY, P34
   Ali M., 2017, AL SHIFA J OPHTHALMO, V13, P163
   Ali Y, 2006, ADV DRUG DELIVER REV, V58, P1258, DOI 10.1016/j.addr.2006.07.022
   Aliancy J, 2017, OPHTHALMOL THER, V6, P221, DOI 10.1007/s40123-017-0094-6
   Almasieh M, 2012, PROG RETIN EYE RES, V31, P152, DOI 10.1016/j.preteyeres.2011.11.002
   Almeida H, 2015, CURR PHARM DESIGN, V21, P5212, DOI 10.2174/1381612821666150923095155
   Almeida H, 2014, J PHARM PHARM SCI, V17, P278, DOI 10.18433/J3DP43
   Alshamrani A. Z., 2018, EGYPT J HOSP MED, V70, P151, DOI DOI 10.12816/0042978
   Alvarez-Trabado J, 2017, INT J PHARMACEUT, V532, P204, DOI 10.1016/j.ijpharm.2017.09.017
   Alward WL, 1998, AM J OPHTHALMOL, V126, P498
   Ambati J, 2000, INVEST OPHTH VIS SCI, V41, P1181
   Ambati J, 2002, PROG RETIN EYE RES, V21, P145, DOI 10.1016/S1350-9462(01)00018-0
   An HC, 2018, J MED CHEM, V61, P9266, DOI 10.1021/acs.jmedchem.8b00971
   [Anonymous], 2015, DIABETES CARE, V38, pS1, DOI 10.2337/dc15-S001
   [Anonymous], 1978, Ophthalmology, V85, P82
   [Anonymous], 2018, SON LPATH
   [Anonymous], 2018, VYZ PAT GLAUC
   [Anonymous], 2020, KALVISTA DME
   [Anonymous], 2018, TREAT AG REL MAC DEG
   [Anonymous], 2019, NIC PRES 1 DAT PROM
   [Anonymous], 2020, DEXT
   [Anonymous], 2017, SEC GLAUC
   [Anonymous], 2020, NCX 667 NOVEL NITRIC
   [Anonymous], 2017, CLIN STUD INV SAF EF
   [Anonymous], 2018, DIABETIC RETINOPATHY
   [Anonymous], 2019, FACTS CAT
   [Anonymous], 2020, UN NEWS
   [Anonymous], 2016, OPSISPORIN LONG ACTI
   [Anonymous], 2016, SAF STUD INTR EBI 03
   [Anonymous], 2017, BUSINESS WIRE
   [Anonymous], 2019, DIABETIC RETINOPATHY
   [Anonymous], 2020, OZURDEX DEXAMETHASON
   [Anonymous], 2019, NOV OR PLASM KALL PK
   [Anonymous], 2020, RESURE SEAL
   [Anonymous], 2019, AB
   [Anonymous], 2019, TES MORPHOSYS
   [Anonymous], 2016, INTR OC NAN EM 505 B
   [Anonymous], 2019, OPT 302
   [Anonymous], 2018, ANT VASCULAR END GRO
   [Anonymous], 2020, KALVISTA PLANS CONT
   [Anonymous], 2017, GRAYB VIS IN PHAS 1
   [Anonymous], 2019, INVELTYS LOT ET OPHT
   [Anonymous], 2020, OPHTHALMIC DRUG DELI
   [Anonymous], 2018, RAN ED MAC DIAB PROT
   [Anonymous], 2019, MAC DEG TREATM
   [Anonymous], 2020, PIP OPHTH THER
   [Anonymous], 2019, AFL
   [Anonymous], 2019, DIAGN TREATM NORM TE
   [Anonymous], 2019, BUSINESS WIRE
   [Anonymous], 2019, NITR OX NO DON NIC E
   [Anonymous], 2019, MACULAR DEGENERATION
   [Anonymous], 2020, NCX 1741 NOV NO DON
   [Anonymous], 2019, ANT VEGF TREATM
   [Anonymous], 2019, GLAUCOMA SYMPTOMS TR
   [Anonymous], 2019, UPD CLIN TRIALS MAC
   [Anonymous], 2019, OPHTHALMIC DRUG DELI
   [Anonymous], 2019, LAMP GEN
   [Anonymous], 2019, STUD FAR RO6867461 P
   [Anonymous], 2018, OPHTH ANN RES 3 PHAS
   [Anonymous], 2019, TRIM
   [Anonymous], 2018, GLAUCOMA
   [Anonymous], 2020, AKST4290
   [Anonymous], 2016, ROCLATANTM MERCURY 2
   [Anonymous], 2019, EYEDR MED GLAUC
   [Anonymous], 2020, PROD PROD CAND
   [Anonymous], 2019, OR DRUG TREATM AMD
   [Anonymous], 2019, WHAT IS GLAUC
   [Anonymous], 2019, MEIB GLAND DYSF MGD
   [Anonymous], 2017, NIC ANN PRES NCX 667
   [Anonymous], 2014, J PHARM APPL SCI
   Gonzalez-Correa JA, 2018, J AGR FOOD CHEM, V66, P637, DOI 10.1021/acs.jafc.7b05063
   Araie M, 2015, ADV THER, V32, P1128, DOI 10.1007/s12325-015-0260-y
   Arber S, 1998, NATURE, V393, P805, DOI 10.1038/31729
   Arjamaa O, 2009, AGEING RES REV, V8, P349, DOI 10.1016/j.arr.2009.06.002
   Asbell PA, 2005, LANCET, V365, P599
   Atiyeh BS, 2010, INT J SURG, V8, P581, DOI 10.1016/j.ijsu.2010.07.291
   Avalanche Biotechnologies Inc, 2019, ANN POS TOP LIN PHAS
   Awwad S, 2017, BRIT J PHARMACOL, V174, P4205, DOI 10.1111/bph.14024
   Ayala M, 2011, CLIN OPHTHALMOL, V5, P1469, DOI 10.2147/OPTH.S25636
   Babic N, 2015, SRP ARK CELOK LEK, V143, P626, DOI 10.2298/SARH1510626B
   Bacharach J, 2015, OPHTHALMOLOGY, V122, P302, DOI 10.1016/j.ophtha.2014.08.022
   Bainbridge JWB, 2008, NEW ENGL J MED, V358, P2231, DOI 10.1056/NEJMoa0802268
   Basavarajappa HD, 2015, J MED CHEM, V58, P5015, DOI 10.1021/acs.jmedchem.5b00449
   Battaglia L, 2016, EXPERT OPIN DRUG DEL, V13, P1743, DOI 10.1080/17425247.2016.1201059
   Bhatwadekar AD, 2020, EXPERT OPIN INV DRUG, V29, P237, DOI 10.1080/13543784.2020.1723078
   Blangetti M, 2017, ACS MED CHEM LETT, V8, P1054, DOI 10.1021/acsmedchemlett.7b00264
   Blumenkranz MS, 2006, RETINA-J RET VIT DIS, V26, P370, DOI 10.1097/00006982-200603000-00024
   Bochot A, 2012, J CONTROL RELEASE, V161, P628, DOI 10.1016/j.jconrel.2012.01.019
   Boddu SHS, 2010, BIOANALYSIS, V2, P487, DOI 10.4155/BIO.10.2
   Boland S, 2013, BIOORG MED CHEM LETT, V23, P6442, DOI 10.1016/j.bmcl.2013.09.040
   Bollinger KE, 2008, CLEV CLIN J MED, V75, P193, DOI 10.3949/ccjm.75.3.193
   Bordet T, 2019, DRUG DISCOV TODAY, V24, P1685, DOI 10.1016/j.drudis.2019.05.038
   Borghi V, 2010, J OCUL PHARMACOL TH, V26, P125, DOI 10.1089/jop.2009.0120
   Boyer DS, 2014, OPHTHALMOLOGY, V121, P1904, DOI 10.1016/j.ophtha.2014.04.024
   Bozdag M, 2014, J MED CHEM, V57, P9673, DOI 10.1021/jm501497m
   Bozdag M, 2014, J MED CHEM, V57, P9152, DOI 10.1021/jm501314c
   Braga-Mele R, 2014, J CATARACT REFR SURG, V40, P2134, DOI 10.1016/j.jcrs.2014.10.010
   Bratton ML, 2014, J AAPOS, V18, P110, DOI 10.1016/j.jaapos.2013.11.014
   Bremond-Gignac D, 2014, EXPERT OPIN DRUG MET, V10, P905, DOI 10.1517/17425255.2014.915026
   Brownlee M, 2005, DIABETES, V54, P1615, DOI 10.2337/diabetes.54.6.1615
   Calton MA, 2018, INVEST OPHTH VIS SCI, V59
   Campochiaro PA, 2006, HUM GENE THER, V17, P167, DOI 10.1089/hum.2006.17.167
   Campochiaro PA, 2017, HUM GENE THER, V28, P99, DOI 10.1089/hum.2016.117
   Campochiaro PA, 2016, OPHTHALMOLOGY, V123, P1722, DOI 10.1016/j.ophtha.2016.04.025
   Campos-Sandoval JA, 2011, J MED CHEM, V54, P4378, DOI 10.1021/jm200256g
   Canning P, 2016, P NATL ACAD SCI USA, V113, P7213, DOI 10.1073/pnas.1514213113
   Cao JH, 2014, OPHTHALMOLOGY, V121, P1871, DOI 10.1016/j.ophtha.2014.04.012
   Carta F, 2015, J MED CHEM, V58, P4039, DOI 10.1021/acs.jmedchem.5b00383
   Carta F, 2013, J MED CHEM, V56, P4691, DOI 10.1021/jm400414j
   Carta F, 2012, J MED CHEM, V55, P1721, DOI 10.1021/jm300031j
   Carvalho IM, 2015, J CONTROL RELEASE, V202, P76, DOI 10.1016/j.jconrel.2015.01.023
   Cavet ME, 2015, INVEST OPHTH VIS SCI, V56, P4108, DOI 10.1167/iovs.14-16015
   Cavet ME, 2014, INVEST OPHTH VIS SCI, V55, P5005, DOI 10.1167/iovs.14-14515
   Chang DJ, 2012, J MED CHEM, V55, P10863, DOI 10.1021/jm301488q
   Chang KC, 2016, J NAT PROD, V79, P1439, DOI 10.1021/acs.jnatprod.6b00185
   Phan CM, 2013, EYE CONTACT LENS, V39, P162, DOI 10.1097/ICL.0b013e31827a7a07
   Chemerovski-Glikman M, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-27516-9
   Chen HH, 2014, BIOORG MED CHEM LETT, V24, P1875, DOI 10.1016/j.bmcl.2014.03.017
   Chen J, 2011, CLIN OPHTHALMOL, V5, P667, DOI 10.2147/OPTH.S15971
   Chen PP, 2003, OPHTHALMOLOGY, V110, P726, DOI 10.1016/S0161-6420(02)01974-7
   Chen X, 2016, J CATARACT REFR SURG, V42, P163, DOI 10.1016/j.jcrs.2015.12.005
   Chen YT, 2008, BIOORG MED CHEM LETT, V18, P6406, DOI 10.1016/j.bmcl.2008.10.080
   Cheng W. S., 2017, YIXUE YANJIU, V37, P121
   Chiou G, 2012, RETINA TODAY, P69
   Chiou GCY, 2001, J OCUL PHARMACOL TH, V17, P189, DOI 10.1089/10807680151125555
   Chircop Megan, 2014, Small GTPases, V5, DOI 10.4161/sgtp.29770
   Chou R, 2016, JAMA-J AM MED ASSOC, V315, P915, DOI 10.1001/jama.2016.0783
   Cioffi CL, 2015, J MED CHEM, V58, P5863, DOI 10.1021/acs.jmedchem.5b00423
   Cioffi CL, 2014, J MED CHEM, V57, P7731, DOI 10.1021/jm5010013
   Clark AF, 2003, NAT REV DRUG DISCOV, V2, P448, DOI 10.1038/nrd1106
   Clayton JA, 2018, NEW ENGL J MED, V378, P2212, DOI 10.1056/NEJMra1407936
   Constable IJ, 2017, AM J OPHTHALMOL, V177, P150, DOI 10.1016/j.ajo.2017.02.018
   Constable IJ, 2016, EBIOMEDICINE, V14, P168, DOI 10.1016/j.ebiom.2016.11.016
   Costa VP, 2014, ACTA OPHTHALMOL, V92, pe252, DOI 10.1111/aos.12298
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Cruysberg LPJ, 2002, J OCUL PHARMACOL TH, V18, P559, DOI 10.1089/108076802321021108
   Da Settimo F, 2005, J MED CHEM, V48, P6897, DOI 10.1021/jm050382p
   Damji KF, 1999, BRIT J OPHTHALMOL, V83, P718, DOI 10.1136/bjo.83.6.718
   Davis Geetha, 2016, Mo Med, V113, P58
   de Vries JW, 2018, BIOMATERIALS, V157, P98, DOI 10.1016/j.biomaterials.2017.11.046
   Dellabella A, 2015, US PHARM, V40, pHS19
   DELONG MA, 2012, INVEST OPHTH VIS SCI, V53, P3867
   Deng H, 2013, DYES PIGMENTS, V99, P930, DOI 10.1016/j.dyepig.2013.06.037
   Doe C, 2007, J PHARMACOL EXP THER, V320, P89, DOI 10.1124/jpet.106.110635
   Donaldson KE, 2013, J CATARACT REFR SURG, V39, P1753, DOI 10.1016/j.jcrs.2013.09.002
   Donegan RK, 2016, J MED CHEM, V59, P788, DOI 10.1021/acs.jmedchem.5b00828
   Dot C, 2015, J FR OPHTALMOL, V38, P656, DOI 10.1016/j.jfo.2015.03.002
   Dugel PU, 2020, OPHTHALMOLOGY, V127, P72, DOI 10.1016/j.ophtha.2019.04.017
   Duh EJ, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.93751
   Duvvuri S, 2003, EXPERT OPIN BIOL TH, V3, P45, DOI 10.1517/14712598.3.1.45
   Edmunds B, 2002, EYE, V16, P297, DOI 10.1038/sj.eye.6700148
   Ehara T, 2018, J MED CHEM, V61, P2552, DOI 10.1021/acs.jmedchem.8b00007
   Eisenberg DL, 2002, SURV OPHTHALMOL, V47, pS105, DOI 10.1016/S0039-6257(02)00327-2
   Eisenberg JS, 2013, OPHTHALMOLOGY MANAGE, V17, P36
   Eljarrat-Binstock E, 2006, J CONTROL RELEASE, V110, P479, DOI 10.1016/j.jconrel.2005.09.049
   Elman MJ, 2010, OPHTHALMOLOGY, V117, P1064, DOI 10.1016/j.ophtha.2010.02.031
   EPSTEIN DL, 1977, ARCH OPHTHALMOL-CHIC, V95, P1378, DOI 10.1001/archopht.1977.04450080088009
   Errera MH, 2019, OCUL IMMUNOL INFLAMM, V27, P319, DOI 10.1080/09273948.2018.1501492
   European Commission, 2019, EUR COMM APPR SPARK
   Fadamiro CO, 2017, NIGER J CLIN PRACT, V20, P783, DOI 10.4103/1119-3077.212451
   Fang XG, 2010, J MED CHEM, V53, P5727, DOI 10.1021/jm100579r
   Farkouh A, 2016, CLIN OPHTHALMOL, V10, P2433, DOI 10.2147/OPTH.S118409
   FAULDS D, 1993, DRUGS, V45, P953, DOI 10.2165/00003495-199345060-00007
   Feng YB, 2008, J MED CHEM, V51, P6642, DOI 10.1021/jm800986w
   Ferrara N, 2010, NAT MED, V16, P1107, DOI 10.1038/nm1010-1107
   FERRIS FL, 1987, OPHTHALMOLOGY, V94, P761
   Flores AM, 2016, FASEB J, V30, P1789, DOI 10.1096/fj.201500180
   Foureaux G, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0133149
   Francis BA, 2011, OPHTHALMOLOGY, V118, P1466, DOI 10.1016/j.ophtha.2011.03.028
   Fredholm BB, 2001, PHARMACOL REV, V53, P527
   Frey T, 2011, ANTIOXID REDOX SIGN, V15, P1271, DOI 10.1089/ars.2011.3906
   Gaafar PME, 2014, J LIPOSOME RES, V24, P204, DOI 10.3109/08982104.2014.881850
   Ganesh T, 2014, J MED CHEM, V57, P4454, DOI 10.1021/jm401431x
   Garcia GA, 2016, CLIN OPHTHALMOL, V10, DOI 10.2147/OPTH.S103985
   Garnock-Jones K, 2014, DRUGS, V74, P2211, DOI 10.1007/s40265-014-0333-2
   Garty S, 2011, INVEST OPHTH VIS SCI, V52, P6109, DOI 10.1167/iovs.10-6071
   Gaudana R, 2010, AAPS J, V12, P348, DOI 10.1208/s12248-010-9183-3
   Ge XM, 2019, PHARMACEUTICS, V11, DOI 10.3390/pharmaceutics11020055
   Gebka A, 2014, MEDIAT INFLAMM, V2014, DOI 10.1155/2014/131538
   Gedde SJ, 2012, AM J OPHTHALMOL, V153, P789, DOI 10.1016/j.ajo.2011.10.026
   Geneau R, 2008, SOC SCI MED, V66, P558, DOI 10.1016/j.socscimed.2007.09.016
   Geroski DH, 2000, INVEST OPHTH VIS SCI, V41, P961
   Gimbel HV, 2011, CURR OPIN OPHTHALMOL, V22, P28, DOI 10.1097/ICU.0b013e328341425d
   Ginn JD, 2010, BIOORG MED CHEM LETT, V20, P5153, DOI 10.1016/j.bmcl.2010.07.014
   Gordon K, 2019, NAT REV DRUG DISCOV, V18, P415, DOI 10.1038/d41573-018-00016-1
   Gote V, 2019, EC OPHTHALMOL, V10, P660
   Gote V, 2019, J PHARMACOL EXP THER, V370, P602, DOI 10.1124/jpet.119.256933
   Graw J, 2010, CURR TOP DEV BIOL, V90, P343, DOI 10.1016/S0070-2153(10)90010-0
   Greco A, 2016, AM J MED, V129, DOI 10.1016/j.amjmed.2016.03.038
   GREEN WR, 1985, OPHTHALMOLOGY, V92, P615
   Guler HA, 2018, BMC OPHTHALMOL, V18, DOI 10.1186/s12886-018-0905-0
   Guzman-Aranguez A, 2013, J OCUL PHARMACOL TH, V29, P189, DOI 10.1089/jop.2012.0212
   Haber SL, 2019, THER ADV OPHTHALMOL, V11, DOI 10.1177/2515841419870366
   Haddad S, 2006, SURV OPHTHALMOL, V51, P316, DOI 10.1016/j.survophthal.2006.05.001
   HAEFLIGER IO, 1994, SURV OPHTHALMOL, V39, P123, DOI 10.1016/0039-6257(94)90157-0
   Hammes HP, 2002, DIABETES, V51, P3107, DOI 10.2337/diabetes.51.10.3107
   Hanus J, 2016, BRIT J OPHTHALMOL, V100, P122, DOI 10.1136/bjophthalmol-2015-306972
   Harrison BA, 2015, ACS MED CHEM LETT, V6, P84, DOI 10.1021/ml500367g
   Harrison BA, 2009, J MED CHEM, V52, P6515, DOI 10.1021/jm901226j
   Hartstein I, 2005, CURR MED RES OPIN, V21, P255, DOI 10.1185/030079905X26252
   Heier JS, 2017, LANCET, V390, P50, DOI 10.1016/S0140-6736(17)30979-0
   Heier JS, 2016, OPHTHALMOLOGY, V123, P2376, DOI 10.1016/j.ophtha.2016.07.032
   Heijl A, 2002, ARCH OPHTHALMOL-CHIC, V120, P1268, DOI 10.1001/archopht.120.10.1268
   Hejtmancik JF, 2003, DEV OPHTHALMOL, V37, P67
   Henderson AJ, 2010, BIOORG MED CHEM LETT, V20, P1137, DOI 10.1016/j.bmcl.2009.12.012
   Henson DB, 2006, ARCH OPHTHALMOL-CHIC, V124, P1405, DOI 10.1001/archopht.124.10.1405
   Hernandez M, 2008, EXP EYE RES, V86, P798, DOI 10.1016/j.exer.2008.02.008
   Hessen Michelle, 2014, J Ophthalmic Vis Res, V9, P240
   Higashiyama M, 2006, J OCUL PHARMACOL TH, V22, P333, DOI 10.1089/jop.2006.22.333
   Hikichi T, 2000, RETINA-J RET VIT DIS, V20, P195, DOI 10.1097/00006982-200002000-00014
   Holekamp NM, 2010, AM J OPHTHALMOL, V149, P32, DOI 10.1016/j.ajo.2009.07.036
   Holz FG, 2014, OPHTHALMOLOGY, V121, P1079, DOI 10.1016/j.ophtha.2013.11.023
   Hong CH, 2005, SURV OPHTHALMOL, V50, P48, DOI 10.1016/j.survophthal.2004.10.006
   Honjo M, 2018, JPN J OPHTHALMOL, V62, P109, DOI 10.1007/s10384-018-0566-9
   Hornof M, 2005, EUR J PHARM BIOPHARM, V60, P207, DOI 10.1016/j.ejpb.2005.01.009
   Hosoya K, 2005, BIOL PHARM BULL, V28, P1, DOI 10.1248/bpb.28.1
   Hsu J, 2007, CURR OPIN OPHTHALMOL, V18, P235, DOI 10.1097/ICU.0b013e3281108000
   HUANG AJW, 1989, INVEST OPHTH VIS SCI, V30, P684
   HUANG HS, 1983, J PHARM SCI, V72, P1272, DOI 10.1002/jps.2600721109
   Huang QH, 2015, J MED CHEM, V58, P2821, DOI 10.1021/acs.jmedchem.5b00043
   Hussain RM, 2018, EXPERT OPIN PHARMACO, V19, P471, DOI 10.1080/14656566.2018.1448060
   Ibrahim MA, 2013, BMC PHARMACOL TOXICO, V14, DOI 10.1186/2050-6511-14-7
   Iglicki Matias, 2019, Retina, V39, P44, DOI 10.1097/IAE.0000000000002196
   Ilhan N, 2015, CUTAN OCUL TOXICOL, V34, P294, DOI 10.3109/15569527.2014.975242
   Impagnatiello F, 2011, EXP EYE RES, V93, P243, DOI 10.1016/j.exer.2011.02.006
   Impagnatiello F, 2019, BRIT J PHARMACOL, V176, P1079, DOI 10.1111/bph.14328
   Impagnatiello F, 2015, INVEST OPHTH VIS SCI, V56, P6558, DOI 10.1167/iovs.15-17190
   INAZAKI H, 2017, CLIN EXP OPHTHALMOL, V255, P2009, DOI DOI 10.1007/S00417-017-3727-5
   Inazaki H, 2017, J GLAUCOMA, V26, P96, DOI 10.1097/IJG.0000000000000552
   Inoue K, 2018, INT OPHTHALMOL, V38, P93, DOI 10.1007/s10792-016-0427-9
   Inoue T, 2013, BIOORGAN MED CHEM, V21, P3873, DOI 10.1016/j.bmc.2013.04.011
   Inoue T, 2013, BIOORGAN MED CHEM, V21, P1219, DOI 10.1016/j.bmc.2012.12.025
   Inoue T, 2015, ACTA OPHTHALMOL, V93, pE393, DOI 10.1111/aos.12641
   Iriyama A, 2009, J CELL PHYSIOL, V220, P469, DOI 10.1002/jcp.21792
   Iwamura R, 2018, J MED CHEM, V61, P6869, DOI 10.1021/acs.jmedchem.8b00808
   Jackson TL, 2003, INVEST OPHTH VIS SCI, V44, P2141, DOI 10.1167/iovs.02-1027
   Jacobson KA, 2006, NAT REV DRUG DISCOV, V5, P247, DOI 10.1038/nrd1983
   Jaffe G. J., 2005, ASS RES VIS OPHTH AN
   Jaffe GJ, 2017, OPHTHALMOLOGY, V124, P224, DOI 10.1016/j.ophtha.2016.10.010
   Janagam DR, 2017, ADV DRUG DELIVER REV, V122, P31, DOI 10.1016/j.addr.2017.04.001
   Janoria KG, 2007, EXPERT OPIN DRUG DEL, V4, P371, DOI 10.1517/17425247.4.4.371
   Jendza K, 2019, NAT CHEM BIOL, V15, P666, DOI 10.1038/s41589-019-0303-9
   Jin HX, 2010, J MED CHEM, V53, P1117, DOI 10.1021/jm901381j
   Johnson DH, 2001, J GLAUCOMA, V10, P55, DOI 10.1097/00061198-200102000-00011
   Johnson SC, 2013, NATURE, V493, P338, DOI 10.1038/nature11861
   Jokinen M, 2008, KEY ENG MATER, V377, P195, DOI 10.4028/www.scientific.net/KEM.377.195
   Jonas JB, 2017, LANCET, V390, P2183, DOI 10.1016/S0140-6736(17)31469-1
   Joshi D, 2013, J NAT PROD, V76, P450, DOI 10.1021/np300769c
   Joussen AM, 2019, BRIT J CLIN PHARMACO, V85, P347, DOI 10.1111/bcp.13794
   Kamei M, 1999, AM J OPHTHALMOL, V128, P739, DOI 10.1016/S0002-9394(99)00239-1
   Kammer JA, 2010, BRIT J OPHTHALMOL, V94, P74, DOI 10.1136/bjo.2009.158071
   KANAI M, 1968, J CLIN INVEST, V47, P2025, DOI 10.1172/JCI105889
   Kapoor KG, 2015, SEMIN OPHTHALMOL, V30, P475, DOI 10.3109/08820538.2014.889179
   Karahan Eyyup, 2014, Med Hypothesis Discov Innov Ophthalmol, V3, P45
   Karki RG, 2019, J MED CHEM, V62, P4656, DOI 10.1021/acs.jmedchem.9b00271
   Karn PR, 2014, INT J NANOMED, V9, P3791, DOI 10.2147/IJN.S65601
   Kassa E, 2019, EXPERT OPIN BIOL TH, V19, P335, DOI 10.1080/14712598.2019.1575358
   Katz ML, 2002, ARCH GERONTOL GERIAT, V34, P169, DOI 10.1016/S0167-4943(02)00005-5
   Kaur IP, 2004, INT J PHARMACEUT, V269, P1, DOI 10.1016/j.ijpharm.2003.09.016
   Kaur IP, 2002, DRUG DEV IND PHARM, V28, P353, DOI 10.1081/DDC-120002997
   Kaur IP, 2002, DRUG DEV IND PHARM, V28, P473
   Kawase K, 2016, ADV THER, V33, P1612, DOI 10.1007/s12325-016-0385-7
   Kels BD, 2015, CLIN DERMATOL, V33, P140, DOI 10.1016/j.clindermatol.2014.10.006
   KERWIN JF, 1994, MED RES REV, V14, P23, DOI 10.1002/med.2610140103
   Khan S, 2018, J OCUL PHARMACOL TH, V34, P287, DOI 10.1089/jop.2017.0079
   Khandelwal SS, 2019, GRAEF ARCH CLIN EXP, V257, P863, DOI 10.1007/s00417-018-04218-6
   Khandhadia S, 2012, IMMUNOBIOLOGY, V217, P127, DOI 10.1016/j.imbio.2011.07.019
   Khouri A. S., 2017, AM ACAD OPTOM ABST, pE351
   Khurana G, 2012, INT J PHARM INVESTIG, V2, P70, DOI 10.4103/2230-973X.100040
   Khurana RN, 2015, RETINA-J RET VIT DIS, V35, P1640, DOI 10.1097/IAE.0000000000000515
   Kim JH, 2009, NANOTECHNOLOGY, V20, DOI 10.1088/0957-4484/20/50/505101
   Kim SH, 2007, INVEST OPHTH VIS SCI, V48, P808, DOI 10.1167/iovs.06-0670
   Kim YC, 2014, J CONTROL RELEASE, V190, P172, DOI 10.1016/j.jconrel.2014.06.043
   Klein ML, 1998, ARCH OPHTHALMOL-CHIC, V116, P1082, DOI 10.1001/archopht.116.8.1082
   Kompella UB, 2010, THER DELIV, V1, P435, DOI 10.4155/TDE.10.40
   Kopczynski C., 2012, INVEST OPHTH VIS SCI, V53, P5080
   Kopczynski C, 2013, BRIT J OPHTHALMOL, V97, P567, DOI 10.1136/bjophthalmol-2012-302466
   Kortesuo P, 2000, BIOMATERIALS, V21, P193, DOI 10.1016/S0142-9612(99)00148-9
   Krauss AHP, 2011, EXP EYE RES, V93, P250, DOI 10.1016/j.exer.2011.03.001
   KRAUSS AH, 2002, INVEST OPHTHALMOL VI, V43
   KRUG J, 1995, AM J OPHTHALMOL, V120, P718
   Kubota R, 2012, RETINA-J RET VIT DIS, V32, P183, DOI 10.1097/IAE.0b013e318217369e
   Kuwada SK, 2007, CURR OPIN MOL THER, V9, P92
   Kwon YH, 2001, AM J OPHTHALMOL, V132, P47, DOI 10.1016/S0002-9394(01)00912-6
   Kwon YH, 2009, NEW ENGL J MED, V360, P1113, DOI 10.1056/NEJMra0804630
   Lai E, 2014, CURR OPIN OPHTHALMOL, V25, P35, DOI 10.1097/ICU.0000000000000016
   Lam D. S. C., 2015, GLAUCOMA, V2, P708
   Lamb LE, 2004, PHOTOCHEM PHOTOBIOL, V79, P127, DOI 10.1562/0031-8655(2004)079<0127:AACOOL>2.0.CO;2
   Lane SS, 2008, J CATARACT REFR SURG, V34, P1451, DOI 10.1016/j.jcrs.2008.05.034
   Langhals H, 2011, J MED CHEM, V54, P3903, DOI 10.1021/jm2001986
   Lee S, 2015, CHEM COMMUN, V51, P9026, DOI 10.1039/c5cc02215k
   Lee S, 2017, J MED CHEM, V60, P1210, DOI 10.1021/acs.jmedchem.6b01792
   Lee SS, 2019, J OCUL PHARMACOL TH, V35, P138, DOI 10.1089/jop.2018.0095
   Lee SS, 2010, PHARM RES-DORDR, V27, P2043, DOI 10.1007/s11095-010-0159-x
   Lee YB, 2014, INVEST OPHTH VIS SCI, V55, P3525, DOI 10.1167/iovs.14-13881
   Leibowitz H M, 1980, Surv Ophthalmol, V24, P335
   Lemp MA, 2007, OCUL SURF, V5, P75
   Levy B, 2015, AM J OPHTHALMOL, V159, P980, DOI 10.1016/j.ajo.2015.01.026
   Lewis RA, 2017, AM J OPHTHALMOL, V175, P137, DOI 10.1016/j.ajo.2016.11.020
   Lewis RA, 2016, BRIT J OPHTHALMOL, V100, P339, DOI 10.1136/bjophthalmol-2015-306778
   Li GR, 2016, EUR J PHARMACOL, V787, P20, DOI 10.1016/j.ejphar.2016.04.002
   Li RS, 2012, J MED CHEM, V55, P2474, DOI 10.1021/jm201289r
   Li SY, 2012, INVEST OPHTH VIS SCI, V53, P5976, DOI 10.1167/iovs.12-10007
   Li SY, 2009, INVEST OPHTH VIS SCI, V50, P836, DOI 10.1167/iovs.08-2310
   Lichter PR, 2003, AM J OPHTHALMOL, V136, P136, DOI 10.1016/S0002-9394(03)00143-0
   Lim A, 2015, TRENDS MOL MED, V21, P736, DOI 10.1016/j.molmed.2015.10.001
   Lin CW, 2018, J OCUL PHARMACOL TH, V34, P40, DOI 10.1089/jop.2017.0023
   Liu JHK, 2016, AM J OPHTHALMOL, V169, P249, DOI 10.1016/j.ajo.2016.04.019
   Liu YC, 2017, LANCET, V390, P600, DOI 10.1016/S0140-6736(17)30544-5
   Loftssona T, 1999, ADV DRUG DELIVER REV, V36, P59, DOI 10.1016/S0169-409X(98)00055-6
   London NJS, 2011, ADV THER, V28, P351, DOI 10.1007/s12325-011-0019-z
   Lorthiois E, 2017, J MED CHEM, V60, P5717, DOI 10.1021/acs.jmedchem.7b00425
   LOWDER CY, 2011, US OPHTHAL REV, V4, P107
   Lp J., 2016, J BIOEQUIV BIOAVAILA, V9, P320, DOI DOI 10.4172/JBB.1000318
   Ludwig A, 2005, ADV DRUG DELIVER REV, V57, P1595, DOI 10.1016/j.addr.2005.07.005
   Maibaum J, 2016, NAT CHEM BIOL, V12, P1105, DOI [10.1038/NCHEMBIO.2208, 10.1038/nchembio.2208]
   Makley LN, 2015, SCIENCE, V350, P674, DOI 10.1126/science.aac9145
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   Mandal A, 2017, J CONTROL RELEASE, V248, P96, DOI 10.1016/j.jconrel.2017.01.012
   MARMOR MF, 1985, EXP EYE RES, V40, P687, DOI 10.1016/0014-4835(85)90138-1
   Martens TF, 2015, J CONTROL RELEASE, V202, P83, DOI 10.1016/j.jconrel.2015.01.030
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Matonti F, 2016, EUR J OPHTHALMOL, V26, P454, DOI 10.5301/ejo.5000787
   Maulvi FA, 2016, DRUG DELIV, V23, P3017, DOI 10.3109/10717544.2016.1138342
   MAURICE DM, 1977, EXP EYE RES, V25, P577, DOI 10.1016/0014-4835(77)90136-1
   May JA, 2006, J MED CHEM, V49, P318, DOI 10.1021/jm050663x
   May JA, 2003, J MED CHEM, V46, P4188, DOI 10.1021/jm030205t
   May JA, 2015, J MED CHEM, V58, P8818, DOI 10.1021/acs.jmedchem.5b00857
   McAlinden C, 2014, EYE, V28, P249, DOI 10.1038/eye.2013.267
   Mcgoldrick K. E., 2007, DECISION MAKING ANES, P518
   Mcmonnies Charles W, 2017, J Optom, V10, P5, DOI 10.1016/j.optom.2016.06.002
   McVicar CM, 2011, DIABETES, V60, P2995, DOI 10.2337/db11-0026
   Medeiros FA, 2016, AM J OPHTHALMOL, V168, P250, DOI 10.1016/j.ajo.2016.05.012
   Mehran NA, 2020, EYE, V34, P72, DOI 10.1038/s41433-019-0671-0
   Melamed S, 2003, ARCH OPHTHALMOL-CHIC, V121, P957, DOI 10.1001/archopht.121.7.957
   Menezo M, 2019, CURR MED RES OPIN, V35, P2111, DOI 10.1080/03007995.2019.1652449
   Meredith EL, 2015, J MED CHEM, V58, P9273, DOI 10.1021/acs.jmedchem.5b01227
   Mitchell P, 2002, ARCH OPHTHALMOL-CHIC, V120, P1357, DOI 10.1001/archopht.120.10.1357
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Mitchell P, 2011, OPHTHALMOLOGY, V118, P615, DOI 10.1016/j.ophtha.2011.01.031
   Molnar KS, 2019, INVEST OPHTH VIS SCI, V60, P3320, DOI 10.1167/iovs.18-25647
   Moore NA, 2017, EXPERT OPIN BIOL TH, V17, P1235, DOI 10.1080/14712598.2017.1356817
   Motani A, 2009, J BIOL CHEM, V284, P7673, DOI 10.1074/jbc.M809654200
   Motiejunaite R, 2008, EXP EYE RES, V86, P171, DOI 10.1016/j.exer.2007.10.013
   Mukherjee B, 2007, INT J NANOMED, V2, P213
   MURUGESAN N, 2018, INVEST OPHTHAL VIS S, V59
   Myochin T, 2012, J AM CHEM SOC, V134, P13730, DOI 10.1021/ja303931b
   Nakagawa O, 1996, FEBS LETT, V392, P189, DOI 10.1016/0014-5793(96)00811-3
   Narayanaswamy A, 2015, JAMA OPHTHALMOL, V133, P206, DOI 10.1001/jamaophthalmol.2014.4893
   Natarajan JV, 2014, ACS NANO, V8, P419, DOI 10.1021/nn4046024
   Naylor HM, 1999, BIOCHEMISTRY-US, V38, P2647, DOI 10.1021/bi982291i
   Neubauer AS, 2013, CLIN OPHTHALMOL, V7, P121, DOI 10.2147/OPTH.S38559
   NEWTON DW, 1973, J PHARM SCI, V62, P1538, DOI 10.1002/jps.2600620936
   Nocentini A, 2016, J MED CHEM, V59, P10692, DOI 10.1021/acs.jmedchem.6b01389
   Nocentini A, 2018, J MED CHEM, V61, P5380, DOI 10.1021/acs.jmedchem.8b00625
   Ntsoane MD, 2010, AFR VIS EYE HEALTH J, V69, P182
   Ntsoane M. D., 2012, African Journal of Primary Health Care and Family Medicine, V4, P412
   Oh SH, 2007, J NATL CANCER I, V99, P949, DOI 10.1093/jnci/djm007
   Okamoto N, 2010, J OLEO SCI, V59, P423, DOI 10.5650/jos.59.423
   Okubo A, 1999, INVEST OPHTH VIS SCI, V40, P443
   Olivieri M, 2016, J MED CHEM, V59, P9960, DOI 10.1021/acs.jmedchem.6b01039
   Olsen TW, 1998, AM J OPHTHALMOL, V125, P237, DOI 10.1016/S0002-9394(99)80096-8
   Orzalesi N, 2006, OPHTHALMOLOGY, V113, P239, DOI 10.1016/j.ophtha.2005.10.045
   Pacchiano F, 2011, J MED CHEM, V54, P1896, DOI 10.1021/jm101541x
   Pacella F, 2016, INT J OPHTHALMOL-CHI, V9, P1427, DOI 10.18240/ijo.2016.10.10
   Palanki MSS, 2008, J MED CHEM, V51, P1546, DOI 10.1021/jm7011276
   Pan PC, 2013, DRUG DISCOV TODAY, V18, P1323, DOI 10.1016/j.drudis.2013.09.010
   Papadaki T, 2003, RETINA-J RET VIT DIS, V23, P800, DOI 10.1097/00006982-200312000-00010
   Papadopoulos KP, 2016, CLIN CANCER RES, V22, P1348, DOI 10.1158/1078-0432.CCR-15-1221
   Paradies G, 2009, CELL CALCIUM, V45, P643, DOI 10.1016/j.ceca.2009.03.012
   Pareja-Rios A, 2018, INT J OPHTHALMOL-CHI, V11, P77, DOI 10.18240/ijo.2018.01.14
   Park TK, 2017, MOL THER-NUCL ACIDS, V8, P26, DOI 10.1016/j.omtn.2017.05.012
   Patel Ashaben, 2013, World J Pharmacol, V2, P47
   Patel U, 2018, CADTH ISSUES EMERGIN, P1
   Peng CC, 2010, BIOMATERIALS, V31, P4032, DOI 10.1016/j.biomaterials.2010.01.113
   Pescina S, 2015, J PHARM SCI-US, V104, P2190, DOI 10.1002/jps.24465
   Phipps JA, 2009, HYPERTENSION, V53, P175, DOI 10.1161/HYPERTENSIONAHA.108.117663
   Phulke Sonia, 2017, J Curr Glaucoma Pract, V11, P67, DOI 10.5005/jp-journals-l0028-1226
   Pitkanen L, 2005, INVEST OPHTH VIS SCI, V46, P641, DOI 10.1167/iovs.04-1051
   Pons M, 2010, INVEST OPHTH VIS SCI, V51
   Prum Bruce E Jr, 2016, Ophthalmology, V123, pP1, DOI 10.1016/j.ophtha.2015.10.049
   Quigley HA, 2006, BRIT J OPHTHALMOL, V90, P262, DOI 10.1136/bjo.2005.081224
   Quigley HA, 2011, LANCET, V377, P1367, DOI 10.1016/S0140-6736(10)61423-7
   Rabiu MM, 2001, BRIT J OPHTHALMOL, V85, P776, DOI 10.1136/bjo.85.7.776
   Raghava Swita, 2004, Expert Opin Drug Deliv, V1, P99, DOI 10.1517/17425247.1.1.99
   Rakoczy EP, 2015, LANCET, V386, P2395, DOI 10.1016/S0140-6736(15)00345-1
   Ram J, 2016, NEW ENGL J MED, V374, pE22, DOI 10.1056/NEJMicm1507349
   Rattner A, 2006, NAT REV NEUROSCI, V7, P860, DOI 10.1038/nrn2007
   Ray P, 2011, BIOORG MED CHEM LETT, V21, P97, DOI 10.1016/j.bmcl.2010.11.060
   Reddy SC, 1999, EUR J OPHTHALMOL, V9, P134, DOI 10.1177/112067219900900211
   Regula JT, 2016, EMBO MOL MED, V8, P1265, DOI 10.15252/emmm.201505889
   Reimondez-Troitino S, 2015, EUR J PHARM BIOPHARM, V95, P279, DOI 10.1016/j.ejpb.2015.02.019
   Ren RY, 2016, INVEST OPHTH VIS SCI, V57, P6197, DOI 10.1167/iovs.16-20189
   Resch H, 2009, ACTA OPHTHALMOL, V87, P4, DOI 10.1111/j.1755-3768.2007.01167.x
   Riento K, 2003, NAT REV MOL CELL BIO, V4, P446, DOI 10.1038/nrm1128
   Risitano AM, 2015, BLOOD, V126, DOI 10.1182/blood.V126.23.2137.2137
   Rocha EM, 2000, BRIT J OPHTHALMOL, V84, P76, DOI 10.1136/bjo.84.1.76
   Romero-Aroca Pedro, 2016, J Diabetes Res, V2016, P2156273
   Rong XF, 2019, J CATARACT REFR SURG, V45, P732, DOI 10.1016/j.jcrs.2018.12.025
   Rosenfeld PJ, 2018, OPHTHALMOLOGY, V125, P1488, DOI 10.1016/j.ophtha.2018.06.002
   Runkle EA, 2011, METHODS MOL BIOL, V686, P133, DOI 10.1007/978-1-60761-938-3_5
   Sahoo SK, 2008, DRUG DISCOV TODAY, V13, P144, DOI 10.1016/j.drudis.2007.10.021
   Sall K, 2000, OPHTHALMOLOGY, V107, P631, DOI 10.1016/S0161-6420(99)00176-1
   Sasaki M, 2010, DIABETOLOGIA, V53, P971, DOI 10.1007/s00125-009-1655-6
   Sato S, 2016, ADV THER, V33, P1628, DOI 10.1007/s12325-016-0389-3
   Saxena V, 2003, J PHARM SCI, V92, P2090, DOI 10.1002/jps.10470
   Scaria A, 2016, MOL THER, V24, pS98, DOI 10.1016/S1525-0016(16)33058-1
   Schaumberg DA, 2009, ARCH OPHTHALMOL-CHIC, V127, P763, DOI 10.1001/archophthalmol.2009.103
   Schehlein EM, 2019, DRUGS, V79, P1031, DOI 10.1007/s40265-019-01130-z
   Schuster AK, 2015, J CATARACT REFR SURG, V41, P1088, DOI 10.1016/j.jcrs.2015.04.005
   Seal JR, 2019, J OCUL PHARMACOL TH, V35, P50, DOI 10.1089/jop.2018.0067
   Serle JB, 2018, AM J OPHTHALMOL, V186, P116, DOI 10.1016/j.ajo.2017.11.019
   Sharma A, 2020, EYE, V34, P1063, DOI 10.1038/s41433-019-0616-7
   SHE SC, 1990, INVEST OPHTH VIS SCI, V31, P1950
   Shen Y, 2007, AAPS J, V9, DOI 10.1208/aapsj0903044
   Shi CY, 2019, J OPHTHALMOL, V2019, DOI 10.1155/2019/4106893
   Shibuya M, 2005, J NEUROL SCI, V238, P31, DOI 10.1016/j.jns.2005.06.003
   Shim MS, 2017, BMB REP, V50, P60, DOI 10.5483/BMBRep.2017.50.2.200
   Shirasaki Y, 2008, J PHARM SCI-US, V97, P2462, DOI 10.1002/jps.21200
   SIEG JW, 1979, J PHARM SCI, V68, P724, DOI 10.1002/jps.2600680619
   Silva MM, 2017, MAR DRUGS, V15, DOI 10.3390/md15120370
   Simard B, 2013, PHOTOCH PHOTOBIO SCI, V12, P1824, DOI 10.1039/c3pp50118c
   Singh MS, 2018, INVEST OPHTH VIS SCI, V59, P78
   Smith JA, 2007, OCUL SURF, V5, P93
   Spiegel D, 2002, BRIT J OPHTHALMOL, V86, P1228, DOI 10.1136/bjo.86.11.1228
   Stanton CM, 2011, INVEST OPHTH VIS SCI, V52, P8828, DOI 10.1167/iovs.11-7933
   STEWART PA, 1994, J COMP NEUROL, V340, P566, DOI 10.1002/cne.903400409
   Stitt AW, 2016, PROG RETIN EYE RES, V51, P156, DOI 10.1016/j.preteyeres.2015.08.001
   Sturdivant JM, 2016, BIOORG MED CHEM LETT, V26, P2475, DOI 10.1016/j.bmcl.2016.03.104
   Sugimoto Y, 2007, J BIOL CHEM, V282, P11613, DOI 10.1074/jbc.R600038200
   Sultan MB, 2011, OPHTHALMOLOGY, V118, P1107, DOI 10.1016/j.ophtha.2011.02.045
   Sun Y, 2008, J LEUKOCYTE BIOL, V83, P1512, DOI 10.1189/jlb.0108076
   Tanihara H, 2008, ARCH OPHTHALMOL-CHIC, V126, P309, DOI 10.1001/archophthalmol.2007.76
   Tanihara H, 2016, ACTA OPHTHALMOL, V94, pE26, DOI 10.1111/aos.12829
   Tanihara H, 2015, JAMA OPHTHALMOL, V133, P755, DOI 10.1001/jamaophthalmol.2015.0525
   Tanihara H, 2015, ACTA OPHTHALMOL, V93, pE254, DOI 10.1111/aos.12599
   Tanihara H, 2013, JAMA OPHTHALMOL, V131, P1288, DOI 10.1001/jamaophthalmol.2013.323
   Tanihara H, 2013, AM J OPHTHALMOL, V156, P731, DOI 10.1016/j.ajo.2013.05.016
   Tanna AP, 2018, OPHTHALMOLOGY, V125, P1741, DOI 10.1016/j.ophtha.2018.04.040
   Tarr Joanna M, 2013, ISRN Ophthalmol, V2013, P343560, DOI 10.1155/2013/343560
   Taskintuna I, 2016, MIDDLE EAST AFR J OP, V23, P13, DOI 10.4103/0974-9233.173134
   Terao E, 2017, CURR EYE RES, V42, P738, DOI 10.1080/02713683.2016.1250276
   Teufel DP, 2018, J MED CHEM, V61, P2823, DOI 10.1021/acs.jmedchem.7b01625
   Than A, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06981-w
   Tien T, 2017, INVEST OPHTH VIS SCI, V58, P2915, DOI 10.1167/iovs.16-21355
   Toda R, 2011, J PHARM SCI-US, V100, P3904, DOI 10.1002/jps.22610
   Tokushige H, 2007, INVEST OPHTH VIS SCI, V48, P3216, DOI 10.1167/iovs.05-1617
   Tseng CL, 2013, J NANOMATER, V2013, DOI 10.1155/2013/238351
   Uddin MI, 2015, ACS MED CHEM LETT, V6, P445, DOI 10.1021/ml5005206
   van Kooten TG, 2019, ACTA OPHTHALMOL, V97, pE860, DOI 10.1111/aos.14096
   van Lier JE, 2009, J MED CHEM, V52, P4107, DOI 10.1021/jm900350f
   Villanueva M Teresa, 2019, Nat Rev Drug Discov, V18, P172, DOI 10.1038/d41573-019-00017-8
   Vujosevic S, 2013, CURR MED CHEM, V20, P3267, DOI 10.2174/09298673113209990030
   Vullo D, 2016, J MED CHEM, V59, P5857, DOI 10.1021/acs.jmedchem.6b00462
   Vulpetti A, 2018, ACS MED CHEM LETT, V9, P490, DOI 10.1021/acsmedchemlett.8b00104
   Vulpetti A, 2017, J MED CHEM, V60, P1946, DOI 10.1021/acs.jmedchem.6b01684
   Vyas SP, 1998, PHARMAZIE, V53, P466
   Wang JL, 2017, INT J NANOMED, V12, P8115, DOI 10.2147/IJN.S139436
   Wang J, 2013, INT J ONCOL, V43, P1357, DOI 10.3892/ijo.2013.2100
   Wang RF, 2015, J GLAUCOMA, V24, P51, DOI 10.1097/IJG.0b013e3182952213
   Wang SK, 2014, CLIN OPHTHALMOL, V8, P883, DOI 10.2147/OPTH.S41000
   Wang YC, 2014, BIOORG MED CHEM LETT, V24, P2885, DOI 10.1016/j.bmcl.2014.04.089
   WEBB RL, 1993, J PHARMACOL EXP THER, V267, P287
   Weinreb R., 2010, MED TREATMENT GLAUCO
   Weinreb RN, 2016, OPHTHALMOLOGY, V123, P965, DOI 10.1016/j.ophtha.2016.01.019
   Weinreb RN, 2015, BRIT J OPHTHALMOL, V99, P738, DOI 10.1136/bjophthalmol-2014-305908
   Wells JA, 2015, NEW ENGL J MED, V372, P1193, DOI 10.1056/NEJMoa1414264
   Whitlock NA, 2009, J OCUL PHARMACOL TH, V25, P187, DOI 10.1089/jop.2008.0142
   WHO, 2019, BLINDN VIS IMP
   Wilkinson BL, 2006, J MED CHEM, V49, P6539, DOI 10.1021/jm060967z
   Williams MA, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009300.pub2
   Williams RD, 2011, AM J OPHTHALMOL, V152, P834, DOI 10.1016/j.ajo.2011.04.012
   Wink DA, 1998, FREE RADICAL BIO MED, V25, P434, DOI 10.1016/S0891-5849(98)00092-6
   Wolkenberg SE, 2011, J MED CHEM, V54, P2351, DOI 10.1021/jm101501b
   Wong MOM, 2015, SURV OPHTHALMOL, V60, P36, DOI 10.1016/j.survophthal.2014.06.006
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Woodward DF, 2004, CARDIOVASC DRUG REV, V22, P103
   World Health Organization, 2019, PRIOR EYE DIS
   Wroblewski JJ, 2016, OSLI RETINA, V47, P914, DOI 10.3928/23258160-20161004-04
   Wu F, 2010, BIOORG MED CHEM LETT, V20, P3235, DOI 10.1016/j.bmcl.2010.04.070
   Xu WW, 2019, J DRUG DELIV SCI TEC, V54, DOI 10.1016/j.jddst.2019.101330
   Yadav M, 2019, MAT SCI ENG C-MATER, V103, DOI 10.1016/j.msec.2019.05.015
   Yamada H, 2017, J OCUL PHARMACOL TH, V33, P176, DOI 10.1089/jop.2016.0085
   Yamamoto K, 2014, INVEST OPHTH VIS SCI, V55, P7126, DOI 10.1167/iovs.13-13842
   Yasuda M, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0185305
   Ye TT, 2013, ASIAN J PHARM SCI, V8, P207, DOI 10.1016/j.ajps.2013.09.002
   Yehoshua Z, 2014, OPHTHALMOLOGY, V121, P693, DOI 10.1016/j.ophtha.2013.09.044
   Yin Y, 2013, J MED CHEM, V56, P3568, DOI 10.1021/jm400062r
   Yu JH, 2011, CORNEA, V30, P379, DOI 10.1097/ICO.0b013e3181f7f363
   Yuan XY, 2015, ACS NANO, V9, P1749, DOI 10.1021/nn506599f
   Yuuki T, 2001, J DIABETES COMPLICAT, V15, P257, DOI 10.1016/S1056-8727(01)00155-6
   Zaczek A, 1999, BRIT J OPHTHALMOL, V83, P1036, DOI 10.1136/bjo.83.9.1036
   Zahn G, 2009, ARCH OPHTHALMOL-CHIC, V127, P1329, DOI 10.1001/archophthalmol.2009.265
   Zhang J, 2015, J OPHTHALMOL, V2015, DOI 10.1155/2015/734527
   Zhang K, 2012, NAT REV DRUG DISCOV, V11, P541, DOI 10.1038/nrd3745
   Zhang M, 2012, ACS MED CHEM LETT, V3, P317, DOI 10.1021/ml300005w
   Zhang XY, 2014, CELL BIOSCI, V4, DOI 10.1186/2045-3701-4-27
   Zhong YS, 2013, BBA-GEN SUBJECTS, V1830, P2882, DOI 10.1016/j.bbagen.2013.01.005
NR 505
TC 21
Z9 21
U1 5
U2 27
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0022-2623
EI 1520-4804
J9 J MED CHEM
JI J. Med. Chem.
PD OCT 8
PY 2020
VL 63
IS 19
BP 10533
EP 10593
DI 10.1021/acs.jmedchem.9b01033
PG 61
WC Chemistry, Medicinal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA OE5GM
UT WOS:000580558700001
PM 32482069
DA 2022-11-30
ER

PT J
AU Mishra, SS
   Mandal, B
   Puhan, NB
AF Mishra, Sapna S.
   Mandal, Bappaditya
   Puhan, N. B.
TI Multi-Level Dual-Attention Based CNN for Macular Optical Coherence
   Tomography Classification
SO IEEE SIGNAL PROCESSING LETTERS
LA English
DT Article
DE Attention mechanism; age-related macular degeneration (AMD); diabetic
   macular edema (DME); multi-level dual-attention; optical coherence
   tomography (OCT)
ID IMAGES; EDEMA; DEGENERATION
AB In this letter, we propose a multi-level dual-attention model to classify two common macular diseases, age-related macular degeneration (AMD) and diabetic macular edema (DME) from normal macular eye conditions using optical coherence tomography (OCT) imaging technique. Our approach unifies the dual-attention mechanism at multi-levels of the pre-trained deep convolutional neural network (CNN). It provides a focused learning mechanism by taking into account both multi-level features based attention focusing on the salient coarser features and self-attention mechanism attending higher entropy regions of the finer features. Our proposed method enables the network to automatically focus on the relevant parts of the input images at different levels of feature subspaces. This leads to a more locally deformation-aware feature generation and classification. The proposed approach does not require pre-processing steps such as extraction of region of interest, denoising, and retinal flattening, making the network more robust and fully automatic. Experimental results on two macular OCT databases show the superior performance of our proposed approach as compared to the current state-of-the-art methodologies.
C1 [Mishra, Sapna S.; Puhan, N. B.] Indian Inst Technol Bhubaneswar, Sch Elect Sci, Bhubaneswar 752050, Odisha, India.
   [Mandal, Bappaditya] Keele Univ, Sch Comp & Math, Newcastle ST5 5BG, England.
C3 Indian Institute of Technology System (IIT System); Indian Institute of
   Technology Bhubaneswar; Keele University
RP Mandal, B (通讯作者)，Keele Univ, Sch Comp & Math, Newcastle ST5 5BG, England.
EM ssm14@iitbbs.ac.in; b.mandal@keele.ac.uk; nnbpuhan@iitbbs.ac.in
OI Mishra, Sapna/0000-0002-5304-7131; Mandal,
   Bappaditya/0000-0001-8417-1410
CR Anderson P., 2017, BOTTOMUP TOP DOWN AT
   Chen MY, 2018, IEEE SIGNAL PROC LET, V25, P1440, DOI 10.1109/LSP.2018.2860246
   Chen YP, 2018, ADV NEUR IN, V31
   De Fauw J, 2018, NAT MED, V24, P1342, DOI 10.1038/s41591-018-0107-6
   Fang LY, 2019, IEEE T MED IMAGING, V38, P1959, DOI 10.1109/TMI.2019.2898414
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Fu J, 2019, PROC CVPR IEEE, P3141, DOI 10.1109/CVPR.2019.00326
   Guan Q., 2018, DIAGNOSE RADIOLOGIST
   HUANG D, 1991, SCIENCE, V254, P1178, DOI 10.1126/science.1957169
   Huang LF, 2019, IEEE SIGNAL PROC LET, V26, P1026, DOI 10.1109/LSP.2019.2917779
   Ji QG, 2018, ALGORITHMS, V11, DOI 10.3390/a11060088
   Kaiming He, 2016, 2016 IEEE Conference on Computer Vision and Pattern Recognition (CVPR), P770, DOI 10.1109/CVPR.2016.90
   Kaiser L., 2017, P ADV NEURAL INFORM, P5998
   Karri SPK, 2017, BIOMED OPT EXPRESS, V8, P579, DOI 10.1364/BOE.8.000579
   Khagi B., 2018, P 2018 11 BIOM ENG I, P1
   Kim J, 2018, IEEE SIGNAL PROC LET, V25, P1181, DOI 10.1109/LSP.2018.2811740
   Liu YY, 2011, MED IMAGE ANAL, V15, P748, DOI 10.1016/j.media.2011.06.005
   Mehta S, 2015, PRIMARY CARE, V42, P377, DOI 10.1016/j.pop.2015.05.009
   Mishra D, 2019, IEEE T BIO-MED ENG, V66, P1637, DOI 10.1109/TBME.2018.2877577
   Nam H, 2017, PROC CVPR IEEE, P2156, DOI 10.1109/CVPR.2017.232
   Oktay, 2018, ATTENTION U NET LEAR, DOI DOI 10.48550/ARXIV.1804.03999
   Parkhi O. M., 2015, P BR MACH VIS, P1
   Pershing S, 2014, ANN INTERN MED, V160, P18, DOI 10.7326/M13-0768
   Rasti R, 2017, IRAN CONF MACH, P192, DOI 10.1109/IranianMVIP.2017.8342347
   Rasti R, 2018, IEEE T MED IMAGING, V37, P1024, DOI 10.1109/TMI.2017.2780115
   Rong YB, 2019, IEEE J BIOMED HEALTH, V23, P253, DOI 10.1109/JBHI.2018.2795545
   Russakovsky O, 2015, INT J COMPUT VISION, V115, P211, DOI 10.1007/s11263-015-0816-y
   Schlemper J., 2018, ATTENTION GATED NETW
   Simonyan K., 2015, ARXIV
   Srinivasan PP, 2014, BIOMED OPT EXPRESS, V5, P3568, DOI 10.1364/BOE.5.003568
   Sun YK, 2017, J BIOMED OPT, V22, DOI 10.1117/1.JBO.22.1.016012
   Wang Y, 2016, BIOMED OPT EXPRESS, V7, P4928, DOI 10.1364/BOE.7.004928
   Xiang Y, 2017, IEEE SIGNAL PROC LET, V24, P505, DOI 10.1109/LSP.2017.2673123
   Zizhao Zhang, 2017, Medical Image Computing and Computer Assisted Intervention - MICCAI 2017. 20th International Conference. Proceedings: LNCS 10435, P320, DOI 10.1007/978-3-319-66179-7_37
NR 34
TC 11
Z9 11
U1 1
U2 21
PU IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC
PI PISCATAWAY
PA 445 HOES LANE, PISCATAWAY, NJ 08855-4141 USA
SN 1070-9908
EI 1558-2361
J9 IEEE SIGNAL PROC LET
JI IEEE Signal Process. Lett.
PD DEC
PY 2019
VL 26
IS 12
BP 1793
EP 1797
DI 10.1109/LSP.2019.2949388
PG 5
WC Engineering, Electrical & Electronic
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Engineering
GA KC0KB
UT WOS:000506875000011
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Schwob, N
   Palmowski-Wolfe, A
AF Schwob, Noemie
   Palmowski-Wolfe, Anja
TI Objective measurement of visual acuity by optokinetic nystagmus
   suppression in children and adult patients
SO JOURNAL OF AAPOS
LA English
DT Article
AB PURPOSE To investigate the correlation between subjective and objective visual acuity as elicited with a new computerized optokinetic nystagmus (OKN) suppression test ("SpeedWheel") in adults and school-aged children.
   METHODS Fifteen children (6-12 years) and 27 adults with refractive errors, amblyopia, cataract, age-related macular degeneration, and thyroid-associated orbitopathy underwent testing of subjective visual acuity with E- and Landolt-C symbols (Freiburg Acuity and Contrast Test [FrACT]) and visual acuity as estimated with the SpeedWheel on an LCD screen. Statistical analysis: linear regression, Spearman correlation, and Bland-Altman plots.
   RESULTS Mean difference against the mean was -0.01 when SpeedWheel was compared to Landolt C, but -0.15 when compared to E-symbols. Overall, SpeedWheel correlated very strongly to FrACT ("E": r = 0.85; P < 0.001; Landolt-C: r = 0.81; P < 0.001). This also held true in children ("E": r = 0.74; P < 0.003; Landolt-C: r = 0.69; P < 0.005).
   CONCLUSIONS SpeedWheel enables estimation of visual acuity in a variety of conditions in both adults and school-aged children.
C1 [Schwob, Noemie; Palmowski-Wolfe, Anja] Univ Basel, Univ Eye Hosp Basel, Dept Neuroophthalmol, Basel, Switzerland.
C3 University of Basel
RP Schwob, N (通讯作者)，Univ Basel, Univ Eye Hosp Basel, Dept Neuroophthalmol, Basel, Switzerland.
RI Palmowski-Wolfe, Anja/S-9168-2019
OI Palmowski-Wolfe, Anja/0000-0003-4062-4814
CR Cetinkaya A, 2008, EYE, V22, P77, DOI 10.1038/sj.eye.6702529
   FUKAI S, 1990, JPN J OPHTHALMOL, V34, P239
   Han SB, 2011, INVEST OPHTH VIS SCI, V52, P7492, DOI 10.1167/iovs.11-7663
   Hyon JY, 2010, INVEST OPHTH VIS SCI, V51, P752, DOI 10.1167/iovs.09-4362
   Ohm J., 1954, AMA ARCH OPHTHALMOL, V51, P734
   Shin YJ, 2006, AM J OPHTHALMOL, V141, P327, DOI 10.1016/j.ajo.2005.09.025
   Wester ST, 2007, INVEST OPHTH VIS SCI, V48, P4542, DOI 10.1167/iovs.06-1206
NR 7
TC 4
Z9 4
U1 0
U2 4
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1091-8531
EI 1528-3933
J9 J AAPOS
JI J. AAPOS
PD OCT
PY 2019
VL 23
IS 5
BP 272
EP 274
DI 10.1016/j.jaapos.2019.05.016
PG 3
WC Ophthalmology; Pediatrics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Pediatrics
GA JR6WK
UT WOS:000499763000011
PM 31526857
DA 2022-11-30
ER

PT J
AU Su, F
   Spee, C
   Araujo, E
   Barron, E
   Wang, M
   Ghione, C
   Hinton, DR
   Nusinowitz, S
   Kannan, R
   Reddy, ST
   Farias-Eisner, R
AF Su, Feng
   Spee, Christine
   Araujo, Eduardo
   Barron, Eric
   Wang, Mo
   Ghione, Caleb
   Hinton, David R.
   Nusinowitz, Steven
   Kannan, Ram
   Reddy, Srinivasa T.
   Farias-Eisner, Robin
TI A Novel HDL-Mimetic Peptide HM-10/10 Protects RPE and Photoreceptors in
   Murine Models of Retinal Degeneration
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE retinal pigment epithelium (RPE); sodium iodate; geographic atrophy;
   retinitis pigmentosa; apoptosis; HDL-mimetic peptide; OCT; retinal
   function
ID METHYL-N-NITROSOUREA; INHIBIT TUMOR-DEVELOPMENT; MITOCHONDRIAL-DNA
   DAMAGE; SODIUM IODATE; APOA-I; MACULAR DEGENERATION; OXIDATIVE STRESS;
   SMALL-INTESTINE; CELL-DEATH; APOPTOSIS
AB Age-related macular degeneration (AMD) is a leading cause of blindness in the developed world. The retinal pigment epithelium (RPE) is a critical site of pathology in AMD. Oxidative stress plays a key role in the development of AMD. We generated a chimeric high-density lipoprotein (HDL), mimetic peptide named HM-10/10, with anti-oxidant properties and investigated its potential for the treatment of retinal disease using cell culture and animal models of RPE and photoreceptor (PR) degeneration. Treatment with HM-10/10 peptide prevented human fetal RPE cell death caused by tert-Butyl hydroperoxide (tBH)-induced oxidative stress and sodium iodate (NaIO3), which causes RPE atrophy and is a model of geographic atrophy in mice. We also show that HM-10/10 peptide ameliorated photoreceptor cell death and significantly improved retinal function in a mouse model of N-methyl-N-nitrosourea (MNU)-induced PR degeneration. Our results demonstrate that HM-10/10 protects RPE and retina from oxidant injury and can serve as a potential therapeutic agent for the treatment of retinal degeneration.
C1 [Su, Feng; Reddy, Srinivasa T.; Farias-Eisner, Robin] Univ Calif Los Angeles, David Geffen Sch Med, Dept Obstet & Gynecol, Los Angeles, CA 90095 USA.
   [Spee, Christine; Hinton, David R.] Univ Southern Calif, Keck Sch Med, Dept Pathol, Los Angeles, CA 90033 USA.
   [Araujo, Eduardo; Ghione, Caleb; Nusinowitz, Steven; Kannan, Ram] Univ Calif Los Angeles, Jules Stein Eye Inst, Los Angeles, CA 90095 USA.
   [Barron, Eric; Wang, Mo; Kannan, Ram] Doheny Eye Inst, Stephen J Ryan Initiat Macular Res, Los Angeles, CA 90033 USA.
   [Hinton, David R.] Univ Southern Calif, Dept Ophthalmol, Los Angeles, CA 90033 USA.
   [Reddy, Srinivasa T.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA.
   [Reddy, Srinivasa T.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Mol & Med Pharmacol, Los Angeles, CA 90095 USA.
   [Farias-Eisner, Robin] Creighton Univ, Sch Med, Dept Obstet & Gynecol, Omaha, NE 68178 USA.
C3 University of California System; University of California Los Angeles;
   University of California Los Angeles Medical Center; David Geffen School
   of Medicine at UCLA; University of Southern California; University of
   California System; University of California Los Angeles; Doheny Eye
   Institute; University of Southern California; University of California
   System; University of California Los Angeles; University of California
   Los Angeles Medical Center; David Geffen School of Medicine at UCLA;
   University of California System; University of California Los Angeles;
   University of California Los Angeles Medical Center; David Geffen School
   of Medicine at UCLA; Creighton University
RP Reddy, ST; Farias-Eisner, R (通讯作者)，Univ Calif Los Angeles, David Geffen Sch Med, Dept Obstet & Gynecol, Los Angeles, CA 90095 USA.; Reddy, ST (通讯作者)，Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA.; Reddy, ST (通讯作者)，Univ Calif Los Angeles, David Geffen Sch Med, Dept Mol & Med Pharmacol, Los Angeles, CA 90095 USA.; Farias-Eisner, R (通讯作者)，Creighton Univ, Sch Med, Dept Obstet & Gynecol, Omaha, NE 68178 USA.
EM fsu@mednet.ucla.edu; ChristineK.Spee@med.usc.edu; araujo@jsei.ucla.edu;
   ebarron2@doheny.org; mwang@doheny.org; CGhion@hotmail.com;
   dhinton@usc.edu; nusinowitz@jsei.ucla.edu; rkannan@doheny.org;
   sreddy@mednet.ucla.edu; robinFarias-Eisner@creighton.edu
RI kannan, ram/ABB-7154-2020
OI kannan, ram/0000-0002-1583-3414; Farias-Eisner,
   Robin/0000-0002-1856-3763
FU Annenberg Foundation; Carl and Roberta Deutsch Family Foundation; NIH
   [HL71776, EY01545]; Arnold Mabel Beckman Foundation [NEI EY00331];
   Research to Prevent Blindness
FX This work was supported by funds from the Annenberg Foundation, the Carl
   and Roberta Deutsch Family Foundation, NIH grants HL71776 (SR,), EY01545
   and the Arnold Mabel Beckman Foundation (DRH, RK,) NEI EY00331 (SN,) and
   an unrestricted grant to the Department of Ophthalmology from Research
   to Prevent Blindness.
CR Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   Bloedon LT, 2008, J LIPID RES, V49, P1344, DOI 10.1194/jlr.P800003-JLR200
   Chattopadhyay A, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-26755-0
   Chattopadhyay A, 2015, PHARMACOL RES PERSPE, V3, DOI 10.1002/prp2.154
   Chattopadhyay A, 2016, J LIPID RES, V57, P832, DOI 10.1194/jlr.M064352
   Chattopadhyay A, 2013, J LIPID RES, V54, P3220, DOI 10.1194/jlr.M033555ERR
   Dou GR, 2012, FREE RADICAL BIO MED, V53, P1111, DOI 10.1016/j.freeradbiomed.2012.06.042
   Dunbar RL, 2017, CTS-CLIN TRANSL SCI, V10, P455, DOI 10.1111/cts.12487
   Enzmann V, 2006, EXP EYE RES, V82, P441, DOI 10.1016/j.exer.2005.08.002
   Franco LM, 2009, INVEST OPHTH VIS SCI, V50, P4004, DOI 10.1167/iovs.08-2898
   Ganapathy E, 2012, INT J CANCER, V130, P1071, DOI 10.1002/ijc.26079
   Gao F, 2012, J PHARMACOL EXP THER, V342, P255, DOI 10.1124/jpet.112.191544
   Gao F, 2011, INTEGR BIOL-UK, V3, P479, DOI 10.1039/c0ib00147c
   Gao Y, 2010, EXP EYE RES, V90, P397, DOI 10.1016/j.exer.2009.11.017
   Hanus J, 2016, CELL DEATH DISCOV, V2, DOI 10.1038/cddiscovery.2016.54
   Hyttinen JMT, 2017, AGEING RES REV, V36, P64, DOI 10.1016/j.arr.2017.03.006
   Jarrett SG, 2008, PROG RETIN EYE RES, V27, P596, DOI 10.1016/j.preteyeres.2008.09.001
   Kannan R, 2006, MOL VIS, V12, P1649
   Kannan R, 2014, NEURAL REGEN RES, V9, P2044, DOI 10.4103/1673-5374.147927
   Karunadharma PP, 2010, INVEST OPHTH VIS SCI, V51, P5470, DOI 10.1167/iovs.10-5429
   Kim HL, 2018, NEUROCHEM RES, V43, P1010, DOI 10.1007/s11064-018-2508-9
   Kiuchi K, 2002, CURR EYE RES, V25, P373, DOI 10.1076/ceyr.25.6.373.14227
   Machalinska A, 2014, CURR EYE RES, V39, P1033, DOI 10.3109/02713683.2014.892996
   Mao XY, 2018, BIOMED PHARMACOTHER, V103, P517, DOI 10.1016/j.biopha.2018.04.038
   Mari M, 2013, BBA-GEN SUBJECTS, V1830, P3317, DOI 10.1016/j.bbagen.2012.10.018
   Matsunaga D, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0165150
   Mukherjee P, 2017, J LIPID RES, V58, P1636, DOI 10.1194/jlr.M076554
   Navab M, 2005, ARTERIOSCL THROM VAS, V25, P1932, DOI 10.1161/01.ATV.0000174589.70190.e2
   Navab M, 2015, J LIPID RES, V56, P871, DOI 10.1194/jlr.M056614
   Navab M, 2013, J LIPID RES, V54, P3403, DOI 10.1194/jlr.M042051
   Navab M, 2012, J LIPID RES, V53, P437, DOI 10.1194/jlr.M023523
   Navab M, 2011, J LIPID RES, V52, P1200, DOI 10.1194/jlr.M013144
   Navab M, 2009, J LIPID RES, V50, P1538, DOI 10.1194/jlr.M800539-JLR200
   Navab M, 2009, J LIPID RES, V50, pS145, DOI 10.1194/jlr.R800036-JLR200
   Navab M, 2006, CURR OPIN LIPIDOL, V17, P440, DOI 10.1097/01.mol.0000236371.27508.d4
   Pennington KL, 2016, EYE VISION, V3, DOI 10.1186/s40662-016-0063-5
   Qin SF, 2014, EXP EYE RES, V118, P100, DOI 10.1016/j.exer.2013.11.010
   Reisenhofer M, 2015, GRAEF ARCH CLIN EXP, V253, P721, DOI 10.1007/s00417-014-2906-x
   Sachdeva MM, 2014, EXP EYE RES, V119, P111, DOI 10.1016/j.exer.2013.10.024
   Sonoda S, 2009, NAT PROTOC, V4, P662, DOI 10.1038/nprot.2009.33
   Sreekumar PG, 2016, INVEST OPHTH VIS SCI, V57, P1238, DOI 10.1167/iovs.15-17053
   Sreekumar PG, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033420
   Sreekumar PG, 2009, EXP EYE RES, V88, P410, DOI 10.1016/j.exer.2008.10.009
   Su F, 2012, MOL CANCER THER, V11, P1311, DOI 10.1158/1535-7163.MCT-11-0905
   Su F, 2010, P NATL ACAD SCI USA, V107, P19997, DOI 10.1073/pnas.1009010107
   Tao Y, 2015, SCI REP-UK, V5, DOI 10.1038/srep18612
   Tarallo V, 2012, CELL, V149, P847, DOI 10.1016/j.cell.2012.03.036
   Terluk MR, 2015, J NEUROSCI, V35, P7304, DOI 10.1523/JNEUROSCI.0190-15.2015
   Tsubura A, 2010, HISTOL HISTOPATHOL, V25, P933, DOI 10.14670/HH-25.933
   Wang W, 2014, J CONTROL RELEASE, V191, P4, DOI 10.1016/j.jconrel.2014.04.028
   Watson CE, 2011, J LIPID RES, V52, P361, DOI 10.1194/jlr.M011098
   White CR, 2014, J LIPID RES, V55, P2007, DOI 10.1194/jlr.R051367
   Yoshizawa K, 1999, LAB INVEST, V79, P1359
   Zhao SG, 2011, HEPATO-GASTROENTEROL, V58, P2106, DOI 10.5754/hge11219
   Zhou P, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098275
   Zulliger R, 2011, GRAEF ARCH CLIN EXP, V249, P859, DOI 10.1007/s00417-010-1584-6
NR 56
TC 4
Z9 4
U1 0
U2 2
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1422-0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD OCT
PY 2019
VL 20
IS 19
AR 4807
DI 10.3390/ijms20194807
PG 17
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA JK4FF
UT WOS:000494798300148
PM 31569695
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Sasaki, F
   Yokomizo, T
AF Sasaki, Fumiyuki
   Yokomizo, Takehiko
TI The leukotriene receptors as therapeutic targets of inflammatory disease
SO INTERNATIONAL IMMUNOLOGY
LA English
DT Review
DE BLT1; CysLT1; CysLT2; GPR99
ID PROTEIN-COUPLED RECEPTOR; GENE DISRUPTION REVEALS; B-4 RECEPTOR;
   INSULIN-RESISTANCE; NEUTROPHIL RECRUITMENT; VASCULAR-PERMEABILITY;
   MACULAR DEGENERATION; CELL-MIGRATION; MURINE MODEL; IN-VITRO
AB Leukotrienes (LTs) are inflammatory mediators derived from arachidonic acid. LTs include the di-hydroxy acid LT (LTB 4) and the cysteinyl LTs (CysLTs; LTC4, LTD4 and LTE4), all of which are involved in both acute and chronic inflammation. We and other groups identified a high-affinity LTB4 receptor, BLT1; the LTC4 and LTD4 receptors, CysLT1 and CysLT2; and the LTE4 receptor, GPR99. Pharmacological studies have shown that BLT1 signaling stimulates degranulation, chemotaxis and phagocytosis of neutrophils, whereas CysLT1 and CysLT2 signaling induces airway inflammation by increasing vascular permeability and the contraction of bronchial smooth muscle. Recently, we and other groups suggested that the LTB 4-BLT1 axis and the cysteinyl LTs-CysLT1/2 axis are involved in chronic inflammatory diseases including asthma, atopic dermatitis, psoriasis, atherosclerosis, arthritis, obesity, cancer and age-related macular degeneration using animal models for disease and gene knockout mice. This review describes the classical and novel functions of LTs and their receptors in several inflammatory diseases and discusses the potential clinical applications of antagonists for LT receptors and inhibitors of LT biosynthesis.
C1 [Sasaki, Fumiyuki] Tokyo Med & Dent Univ, Grad Sch Med & Dent Sci, Dept Cell Signaling, Bunkyo Ku, Yushima 1-5-45, Tokyo 1138549, Japan.
   [Yokomizo, Takehiko] Juntendo Univ, Grad Sch Med, Dept Biochem, Bunkyo Ku, Hongo 2-1-1, Tokyo 1138421, Japan.
C3 Tokyo Medical & Dental University (TMDU); Juntendo University
RP Yokomizo, T (通讯作者)，Juntendo Univ, Grad Sch Med, Dept Biochem, Bunkyo Ku, Hongo 2-1-1, Tokyo 1138421, Japan.
EM yokomizo-tky@umin.ac.jp
RI Yokomizo, Takehiko/P-5673-2016
OI Yokomizo, Takehiko/0000-0002-5219-1553
FU Ministry of Education, Culture, Sports, Science, and Technology (MEXT)
   of the Japan Society for the Promotion of Science (JSPS) [22116001,
   22116002, 15H05897, 15H05904, 15H04708, 18H02627]; Naito Foundation; Ono
   Medical Research Foundation; Uehara Memorial Foundation; Mitsubishi
   Foundation; Takeda Science Foundation; Foundation for Strategic Research
   Projects in Private Universities of the MEXT [S1311011]; Institute for
   Environmental and Gender-Specific Medicine
FX This work is supported by Grants-in-Aid for Scientific Research
   (KAKENHI) from the Ministry of Education, Culture, Sports, Science, and
   Technology (MEXT) of the Japan Society for the Promotion of Science
   (JSPS) (grant numbers 22116001, 22116002, 15H05897, 15H05904, 15H04708
   and 18H02627 to T.Y.) and by grants from the Naito Foundation, the Ono
   Medical Research Foundation, the Uehara Memorial Foundation, the
   Mitsubishi Foundation and the Takeda Science Foundation. This study is
   also supported in part by a Grant-in-Aid (S1311011 to T.Y.) from the
   Foundation for Strategic Research Projects in Private Universities of
   the MEXT and by a grant from the Institute for Environmental and
   Gender-Specific Medicine.
CR Ambati J, 2013, NAT REV IMMUNOL, V13, P438, DOI 10.1038/nri3459
   Back M, 2005, P NATL ACAD SCI USA, V102, P17501, DOI 10.1073/pnas.0505845102
   Bankova LG, 2016, P NATL ACAD SCI USA, V113, P6242, DOI 10.1073/pnas.1605957113
   Barajas-Espinosa A, 2012, FASEB J, V26, P1100, DOI 10.1096/fj.11-195792
   Beller TC, 2004, J BIOL CHEM, V279, P46129, DOI 10.1074/jbc.M407057200
   Birke FW, 2001, J PHARMACOL EXP THER, V297, P458
   Boudaud M, 2018, J IMMUNOL, V201, P2787, DOI 10.4049/jimmunol.1701463
   Braga TT, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00602
   Butler CT, 2017, J BIOL CHEM, V292, P3552, DOI 10.1074/jbc.M116.747766
   Cahill KN, 2017, J ALLERGY CLIN IMMUN, V139, P764, DOI 10.1016/j.jaci.2016.09.025
   Chheda ZS, 2016, J IMMUNOL, V197, P2016, DOI 10.4049/jimmunol.1502376
   Chou RC, 2010, IMMUNITY, V33, P266, DOI 10.1016/j.immuni.2010.07.018
   CUTHBERT NJ, 1991, ANN NY ACAD SCI, V629, P402
   Czech MP, 2017, NAT MED, V23, P804, DOI 10.1038/nm.4350
   Dainichi T, 2018, NAT IMMUNOL, V19, P1286, DOI 10.1038/s41590-018-0256-2
   Duah E, 2013, SCI REP-UK, V3, DOI 10.1038/srep03274
   Falavarjani KG, 2013, EYE, V27, P787, DOI 10.1038/eye.2013.107
   Goodarzi K, 2003, NAT IMMUNOL, V4, P965, DOI 10.1038/ni972
   Graner M, 2008, NUTR METAB CARDIOVAS, V18, P271, DOI 10.1016/j.numecd.2007.01.003
   Grivennikov SI, 2010, CELL, V140, P883, DOI 10.1016/j.cell.2010.01.025
   Hashidate T, 2010, FASEB J, V24, P3500, DOI 10.1096/fj.10-156844
   He WH, 2004, NATURE, V429, P188, DOI 10.1038/nature02488
   Hegde B, 2018, J IMMUNOL, V200, P3556, DOI 10.4049/jimmunol.1701504
   Heise CE, 2000, J BIOL CHEM, V275, P30531, DOI 10.1074/jbc.M003490200
   Honda T, 2019, INT IMMUNOL, V31, P589, DOI 10.1093/intimm/dxy087
   Hori T, 2018, NAT CHEM BIOL, V14, P262, DOI [10.1038/NCHEMBIO.2547, 10.1038/nchembio.2547]
   Huang WW, 1998, J EXP MED, V188, P1063, DOI 10.1084/jem.188.6.1063
   Hui YQ, 2001, J BIOL CHEM, V276, P47489, DOI 10.1074/jbc.M107556200
   Ibarra-Soria X, 2018, NAT CELL BIOL, V20, P127, DOI 10.1038/s41556-017-0013-z
   Jala VR, 2017, ONCOIMMUNOLOGY, V6, DOI 10.1080/2162402X.2017.1361593
   Jiang Y, 2007, BLOOD, V110, P3263, DOI 10.1182/blood-2007-07-100453
   Jiang YF, 2006, J IMMUNOL, V177, P2755, DOI 10.4049/jimmunol.177.5.2755
   Johnson ZL, 2017, CELL, V168, P1075, DOI 10.1016/j.cell.2017.01.041
   JONES TR, 1995, CAN J PHYSIOL PHARM, V73, P191, DOI 10.1139/y95-028
   Kanaoka Y, 2013, J BIOL CHEM, V288, P10967, DOI 10.1074/jbc.C113.453704
   Kathiresan S, 2008, NEW ENGL J MED, V358, P1240, DOI 10.1056/NEJMoa0706728
   Kato K, 2000, J EXP MED, V192, P413, DOI 10.1084/jem.192.3.413
   Kerschner JE, 2013, INT J PEDIATR OTORHI, V77, P1, DOI 10.1016/j.ijporl.2012.11.038
   Ketelhuth DFJ, 2015, PROSTAG OTH LIPID M, V121, P105, DOI 10.1016/j.prostaglandins.2015.05.007
   Kihara Y, 2010, BIOCHEM BIOPH RES CO, V394, P673, DOI 10.1016/j.bbrc.2010.03.049
   Kim ND, 2006, J EXP MED, V203, P829, DOI 10.1084/jem.20052349
   KRELL RD, 1990, AM REV RESPIR DIS, V141, P978, DOI 10.1164/ajrccm/141.4_Pt_1.978
   LABAT C, 1992, J PHARMACOL EXP THER, V263, P800
   Lambert V, 2013, NAT PROTOC, V8, P2197, DOI 10.1038/nprot.2013.135
   Lambrecht BN, 2015, NAT IMMUNOL, V16, P45, DOI 10.1038/ni.3049
   LAWSON CF, 1989, J LIPID MEDIATOR, V1, P3
   Li PP, 2015, NAT MED, V21, P239, DOI 10.1038/nm.3800
   Liu T, 2018, J IMMUNOL, V200, P915, DOI 10.4049/jimmunol.1700603
   Lund SJ, 2017, J IMMUNOL, V199, P1096, DOI 10.4049/jimmunol.1601569
   Lynch KR, 1999, NATURE, V399, P789
   Maekawa A, 2001, P NATL ACAD SCI USA, V98, P2256, DOI 10.1073/pnas.041624398
   Maekawa A, 2002, J BIOL CHEM, V277, P20820, DOI 10.1074/jbc.M203163200
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Mindt BC, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00840
   Miyabe Y, 2017, SEMIN IMMUNOL, V33, P52, DOI 10.1016/j.smim.2017.09.009
   Miyahara N, 2005, AM J RESP CRIT CARE, V172, P161, DOI 10.1164/rccm.200502-205OC
   Miyahara N, 2008, J IMMUNOL, V181, P1170, DOI 10.4049/jimmunol.181.2.1170
   Mothe-Satney I, 2012, DIABETES, V61, P2311, DOI 10.2337/db11-1455
   MURPHY RC, 1979, P NATL ACAD SCI USA, V76, P4275, DOI 10.1073/pnas.76.9.4275
   Nakao S, 2011, AM J PATHOL, V178, P1913, DOI 10.1016/j.ajpath.2011.01.011
   Obata T, 1985, Adv Prostaglandin Thromboxane Leukot Res, V15, P229
   Obata T, 1987, Adv Prostaglandin Thromboxane Leukot Res, V17A, P540
   Okuno T, 2008, J EXP MED, V205, P759, DOI 10.1084/jem.20072329
   Ott VL, 2003, NAT IMMUNOL, V4, P974, DOI 10.1038/ni971
   Oyoshi MK, 2012, IMMUNITY, V37, P747, DOI 10.1016/j.immuni.2012.06.018
   Oyoshi MK, 2012, P NATL ACAD SCI USA, V109, P4992, DOI 10.1073/pnas.1203127109
   Paruchuri S, 2009, J EXP MED, V206, P2543, DOI 10.1084/jem.20091240
   Reynolds AL, 2016, J BIOL CHEM, V291, P7242, DOI 10.1074/jbc.M115.710665
   RICHARDS IM, 1989, AM REV RESPIR DIS, V140, P1712, DOI 10.1164/ajrccm/140.6.1712
   Rius M, 2008, J PHARMACOL EXP THER, V324, P86, DOI 10.1124/jpet.107.131342
   Salimi M, 2017, J ALLERGY CLIN IMMUN, V140, P1090, DOI 10.1016/j.jaci.2016.12.958
   Samuelsson B, 1979, Harvey Lect, V75, P1
   SAMUELSSON B, 1979, PROSTAGLANDINS, V17, P785, DOI 10.1016/0090-6980(79)90052-2
   Sasaki F, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.96902
   Sasaki F, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0185133
   Satpathy SR, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8064
   Sawada Y, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-30373-1
   Sawada Y, 2015, J EXP MED, V212, P1921, DOI 10.1084/jem.20150381
   SCHOORS DF, 1995, BRIT J CLIN PHARMACO, V40, P277, DOI 10.1111/j.1365-2125.1995.tb05785.x
   Sene A, 2015, TRENDS MOL MED, V21, P43, DOI 10.1016/j.molmed.2014.10.005
   Shao WH, 2006, J IMMUNOL, V176, P6254, DOI 10.4049/jimmunol.176.10.6254
   Shoelson SE, 2006, J CLIN INVEST, V116, P1793, DOI 10.1172/JCI29069
   Showell HJ, 1996, BRIT J PHARMACOL, V117, P1127, DOI 10.1111/j.1476-5381.1996.tb16706.x
   SMITH LJ, 1990, AM REV RESPIR DIS, V141, P988, DOI 10.1164/ajrccm/141.4_Pt_1.988
   Smolen JS, 2018, NAT REV DIS PRIMERS, V4, DOI 10.1038/nrdp.2018.1
   Spite M, 2011, J IMMUNOL, V187, P1942, DOI 10.4049/jimmunol.1100196
   Sumida H, 2014, J IMMUNOL, V192, P4361, DOI 10.4049/jimmunol.1302959
   Tager AM, 2003, NAT IMMUNOL, V4, P982, DOI 10.1038/ni970
   Terawaki K, 2005, J IMMUNOL, V175, P4217, DOI 10.4049/jimmunol.175.7.4217
   Toda A, 2010, BIOCHIMIE, V92, P682, DOI 10.1016/j.biochi.2009.12.002
   Todoric J, 2016, CANCER PREV RES, V9, P895, DOI 10.1158/1940-6207.CAPR-16-0209
   Weber C, 2011, NAT MED, V17, P1410, DOI 10.1038/nm.2538
   White AA, 2018, NEW ENGL J MED, V379, P1060, DOI 10.1056/NEJMra1712125
   Wijnholds J, 1997, NAT MED, V3, P1275, DOI 10.1038/nm1197-1275
   Wynn TA, 2016, IMMUNITY, V44, P450, DOI 10.1016/j.immuni.2016.02.015
   Ying W, 2017, J CLIN INVEST, V127, P1019, DOI 10.1172/JCI90350
   Yokomizo T, 2000, J EXP MED, V192, P421, DOI 10.1084/jem.192.3.421
   Yokomizo T, 1997, NATURE, V387, P620, DOI 10.1038/42506
   Zandi S, 2015, CELL REP, V10, P1173, DOI 10.1016/j.celrep.2015.01.050
   Zhang K, 2012, NAT REV DRUG DISCOV, V11, P541, DOI 10.1038/nrd3745
NR 100
TC 39
Z9 42
U1 1
U2 16
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0953-8178
EI 1460-2377
J9 INT IMMUNOL
JI Int. Immunol.
PD SEP
PY 2019
VL 31
IS 9
SI SI
BP 607
EP 615
DI 10.1093/intimm/dxz044
PG 9
WC Immunology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Immunology
GA JE1VB
UT WOS:000490482800007
PM 31135881
OA Bronze
DA 2022-11-30
ER

PT J
AU Hu, X
   Liang, YY
   Zhao, B
   Wang, YY
AF Hu, Xin
   Liang, Yuanyuan
   Zhao, Bo
   Wang, Yongyi
TI Thymoquinone protects human retinal pigment epithelial cells against
   hydrogen peroxide induced oxidative stress and apoptosis
SO JOURNAL OF CELLULAR BIOCHEMISTRY
LA English
DT Article
DE age-related macular degeneration (AMD); apoptosis; Nrf2/heme oxygenase 1
   (HO-1) signaling pathway; oxidative stress; retinal pigment epithelium
   (RPE) cells; thymoquinone (TQ)
ID ACTIVATION; PATHWAY; ACID
AB Oxidative stress in retinal pigment epithelium (RPE) cells may contribute to the progression of age-related macular degeneration. Thymoquinone (TQ), an active component derived from Nigella sativa, possesses antioxidative effect. However, the role of TQ in RPE cells under oxidative stress condition remains unclear. The present study aimed to examine the protective effect of TQ against hydrogen peroxide (H2O2)-induced oxidative stress in human RPE cells. Our results showed that TQ improved the cell viability and apoptosis in H2O2-induced ARPE cells. We also found that the levels of reactive oxygen species and malondialdehyde induced by H2O2 were reduced after the pretreatment of TQ. In addition, the inhibitory effect of H2O2 on the glutathione (GSH) level and superoxide dismutase activity was markedly attenuated by TQ pretreatment. Moreover, TQ enhanced the activation of Nrf2/heme oxygenase 1 (HO-1) signaling pathway in H2O2-induced ARPE cells. Knockdown of Nrf2 abolished the protective effect of TQ on H2O2-induced oxidative damage. These results suggested that TQ protected ARPE cells from H2O2-induced oxidative stress and apoptosis via the Nrf2/HO-1 signaling pathway.
C1 [Hu, Xin; Liang, Yuanyuan; Zhao, Bo; Wang, Yongyi] Henan Univ, Huaihe Hosp, Dept Ophthalmol, 8 Baobei Rd, Kaifeng 475000, Peoples R China.
C3 Henan University
RP Hu, X (通讯作者)，Henan Univ, Huaihe Hosp, Dept Ophthalmol, 8 Baobei Rd, Kaifeng 475000, Peoples R China.
EM huxin1981kf@163.com
CR Abdel-Wahab Wessam Mohamad, 2014, Pak J Biol Sci, V17, P1152
   Arslan J, 2018, PHARMACOGENOMICS, V19, P435, DOI 10.2217/pgs-2017-0183
   Aziz N, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19051355
   Bonilha VL, 2018, ADV EXP MED BIOL, V1074, P3, DOI 10.1007/978-3-319-75402-4_1
   Bonomini F, 2008, HISTOL HISTOPATHOL, V23, P381, DOI 10.14670/HH-23.381
   Buelow R, 2001, AM J TRANSPLANT, V1, P313, DOI 10.1034/j.1600-6143.2001.10404.x
   Chowdhury FA, 2018, BIOMED RES INT, V2018, DOI 10.1155/2018/4010629
   Dilber Y, 2016, ACTA HISTOCHEM, V118, P31, DOI 10.1016/j.acthis.2015.11.004
   DOREY CK, 1989, INVEST OPHTH VIS SCI, V30, P1691
   Droge W, 2008, ANTIOXID REDOX SIGN, V10, P661, DOI 10.1089/ars.2007.1953
   Fouad AA, 2015, ENVIRON TOXICOL PHAR, V40, P960, DOI 10.1016/j.etap.2015.09.010
   Guan D, 2018, J BIOL REG HOMEOS AG, V32, P225
   Halliwell B, 2007, BIOCHEM J, V401, P1, DOI 10.1042/BJ20061131
   Hytti M, 2015, SCI REP-UK, V5, DOI 10.1038/srep17645
   Jakaria M, 2018, OXID MED CELL LONGEV, V2018, DOI 10.1155/2018/1209801
   Kobayashi A, 2004, MOL CELL BIOL, V24, P7130, DOI 10.1128/MCB.24.16.7130-7139.2004
   Li ZR, 2013, MOL VIS, V19, P1656
   Liang FQ, 2003, EXP EYE RES, V76, P397, DOI 10.1016/S0014-4835(03)00023-X
   Loboda A, 2016, CELL MOL LIFE SCI, V73, P3221, DOI 10.1007/s00018-016-2223-0
   Lores-Motta L, 2018, MOL DIAGN THER, V22, P315, DOI 10.1007/s40291-018-0332-1
   Mabrouk A, 2015, GEN PHYSIOL BIOPHYS, V34, P65, DOI 10.4149/gpb_2014022
   Mehta S, 2015, PRIMARY CARE, V42, P377, DOI 10.1016/j.pop.2015.05.009
   Pimentel C, 2012, OXID MED CELL LONGEV
   Rajakumar D, 2013, NEUROCHEM RES, V38, P2009, DOI 10.1007/s11064-013-1107-z
   Romano Antonino D, 2010, J Nephrol, V23 Suppl 15, pS29
   SEDDON JM, 1994, ARCH OPHTHALMOL-CHIC, V112, P176, DOI 10.1001/archopht.1994.01090140052021
   Shao YY, 2017, TRANSL NEUROSCI, V8, P9, DOI 10.1515/tnsci-2017-0003
   Storz G, 1999, CURR OPIN MICROBIOL, V2, P188, DOI 10.1016/S1369-5274(99)80033-2
   Taysi S, 2015, CUTAN OCUL TOXICOL, V34, P101, DOI 10.3109/15569527.2014.910802
   Wihlmark U, 1996, APMIS, V104, P265, DOI 10.1111/j.1699-0463.1996.tb00716.x
   Zhang H, 2014, FREE RADICAL BIO MED, V69, P219, DOI 10.1016/j.freeradbiomed.2014.01.025
NR 31
TC 21
Z9 21
U1 1
U2 16
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0730-2312
EI 1097-4644
J9 J CELL BIOCHEM
JI J. Cell. Biochem.
PD MAR
PY 2019
VL 120
IS 3
BP 4514
EP 4522
DI 10.1002/jcb.27739
PG 9
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA HL1LP
UT WOS:000458459600181
PM 30269355
DA 2022-11-30
ER

PT J
AU Ben M'Barek, K
   Habeler, W
   Plancheron, A
   Jarraya, M
   Goureau, O
   Monville, C
AF Ben M'Barek, Karim
   Habeler, Walter
   Plancheron, Alexandra
   Jarraya, Mohamed
   Goureau, Olivier
   Monville, Christelle
TI Engineering Transplantation-suitable Retinal Pigment Epithelium Tissue
   Derived from Human Embryonic Stem Cells
SO JOVE-JOURNAL OF VISUALIZED EXPERIMENTS
LA English
DT Article
DE Developmental Biology; Issue 139; Pluripotent stem cells;
   differentiation; cell therapy; retinal pigment epithelium; retinal
   dystrophies; age-related macular degeneration
ID HUMAN IPS CELLS; MACULAR DEGENERATION; SUBRETINAL IMPLANTATION; AMNIOTIC
   MEMBRANE; HUMAN RPE; DISEASE; GENERATION; MONOLAYERS; SURVIVAL; SUPPORT
AB Several pathological conditions of the eye affect the functionality and/or the survival of the retinal pigment epithelium (RPE). These include some forms of retinitis pigmentosa (RP) and age-related macular degeneration (AMD). Cell therapy is one of the most promising therapeutic strategies proposed to cure these diseases, with already encouraging preliminary results in humans. However, the method of preparation of the graft has a significant impact on its functional outcomes in vivo. Indeed, RPE cells grafted as a cell suspension are less functional than the same cells transplanted as a retinal tissue. Herein, we describe a simple and reproducible method to engineer RPE tissue and its preparation for an in vivo implantation. RPE cells derived from human pluripotent stem cells are seeded on a biological support, the human amniotic membrane (hAM). Compared to artificial scaffolds, this support has the advantage of having a basement membrane that is close to the Bruch's membrane where endogenous RPE cells are attached. However, its manipulation is not easy, and we developed several strategies for its proper culturing and preparation for grafting in vivo.
C1 [Ben M'Barek, Karim; Habeler, Walter; Plancheron, Alexandra; Monville, Christelle] INSERM, AFM, U861, I Stem, Paris, France.
   [Ben M'Barek, Karim; Habeler, Walter; Plancheron, Alexandra; Monville, Christelle] UEVE, AFM, U861, I Stem, Evry, France.
   [Ben M'Barek, Karim; Habeler, Walter; Plancheron, Alexandra] CECS, AFM, I Stem, Evry, France.
   [Jarraya, Mohamed] Hop St Louis, AP HP, Banque Tissus Humain, Paris, France.
   [Goureau, Olivier] Sorbonne Univ, INSERM, CNRS, Inst Vis, F-75012 Paris, France.
C3 Institut National de la Sante et de la Recherche Medicale (Inserm);
   UDICE-French Research Universities; Universite Paris Saclay;
   UDICE-French Research Universities; Universite Paris Saclay;
   UDICE-French Research Universities; Universite Paris Saclay; Assistance
   Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis -
   APHP; UDICE-French Research Universities; Universite Paris Cite; Centre
   National de la Recherche Scientifique (CNRS); Institut National de la
   Sante et de la Recherche Medicale (Inserm); UDICE-French Research
   Universities; Sorbonne Universite; Universite Paris Cite
RP Monville, C (通讯作者)，INSERM, AFM, U861, I Stem, Paris, France.; Monville, C (通讯作者)，UEVE, AFM, U861, I Stem, Evry, France.
EM cmonville@istem.fr
RI GOUREAU, Olivier/ABH-9547-2020; GOUREAU, Olivier/F-2752-2017; M'BAREK,
   Karim BEN/K-1389-2019
OI GOUREAU, Olivier/0000-0001-7730-9143; GOUREAU,
   Olivier/0000-0001-7730-9143; M'BAREK, Karim BEN/0000-0002-2556-0325;
   Monville, Christelle/0000-0003-1256-5140; HABELER,
   Walter/0000-0003-4490-3669
FU ANR [GPiPS: ANR-2010-RFCS005, ANR-16-CE17-008-02]; Fondation pour la
   Recherche Medicale [Bio-engineering program] [DBS20140930777]; LABEX
   REVIVE [ANR-10-LABX-73]; NeurATRIS, a translational research
   infrastructure (Investissements d'Avenir) for biotherapies in
   Neurosciences [ANR-11-INBS-0011]; INGESTEM, the national infrastructure
   (Investissements d'Avenir) engineering for pluripotent and
   differentiated stem cells [ANR-11-INBS-000]; DIM Stempole; Association
   Francaise contre les Myopathies (AFM)-Telethon
FX This work was supported by grants from the ANR [GPiPS: ANR-2010-RFCS005;
   SightREPAIR: ANR-16-CE17-008-02], the Fondation pour la Recherche
   Medicale [Bio-engineering program - DBS20140930777] and from LABEX
   REVIVE [ANR-10-LABX-73] to Olivier Goureau and Christelle Monville. It
   was supported by NeurATRIS, a translational research infrastructure
   (Investissements d'Avenir) for biotherapies in Neurosciences
   [ANR-11-INBS-0011] and INGESTEM, the national infrastructure
   (Investissements d'Avenir) engineering for pluripotent and
   differentiated stem cells [ANR-11-INBS-000] to Christelle Monville.
   Karim Ben M'Barek was supported by fellowships from DIM Stempole and
   LABEX REVIVE [ANR-10-LABX-73]. I-Stem is part of the Biotherapies
   Institute for Rare Diseases supported by the Association Francaise
   contre les Myopathies (AFM)-Telethon.
CR Ben M'Barek K, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aai7471
   Ben M'Barek K, 2015, WORLD J STEM CELLS, V7, P596, DOI 10.4252/wjsc.v7.i3.596
   Binder S, 2007, PROG RETIN EYE RES, V26, P516, DOI 10.1016/j.preteyeres.2007.02.002
   Borooah S, 2013, PROG RETIN EYE RES, V37, P163, DOI 10.1016/j.preteyeres.2013.09.002
   Capeans C, 2003, ACTA OPHTHALMOL SCAN, V81, P271, DOI 10.1034/j.1600-0420.2003.00076.x
   da Cruz L, 2018, NAT BIOTECHNOL, V36, P1, DOI 10.1038/nbt.4114
   Daiger SP, 2013, CLIN GENET, V84, P132, DOI 10.1111/cge.12203
   Diniz B, 2013, INVEST OPHTH VIS SCI, V54, P5087, DOI 10.1167/iovs.12-11239
   Dunn KC, 1996, EXP EYE RES, V62, P155, DOI 10.1006/exer.1996.0020
   Gehrs KM, 2006, ANN MED, V38, P450, DOI 10.1080/07853890600946724
   Hartong DT, 2006, LANCET, V368, P1795, DOI 10.1016/S0140-6736(06)69740-7
   Hsiung J, 2015, STEM CELL TRANSL MED, V4, P10, DOI 10.5966/sctm.2014-0205
   Hu YT, 2012, OPHTHALMIC RES, V48, P186, DOI 10.1159/000338749
   Ilmarinen T, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0143669
   Kamao H, 2014, STEM CELL REP, V2, P205, DOI 10.1016/j.stemcr.2013.12.007
   Kashani AH, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aao4097
   Khandhadia S, 2012, ADV EXP MED BIOL, V724, P15, DOI 10.1007/978-1-4614-0653-2_2
   Kiilgaard Jens Folke, 2012, Stem Cells Int, V2012, P716968, DOI 10.1155/2012/716968
   Leach LL, 2015, STEM CELLS, V33, P2363, DOI 10.1002/stem.2010
   Lustremant C, 2013, CELL REPROGRAM, V15, P233, DOI 10.1089/cell.2012.0076
   Mandai M, 2017, NEW ENGL J MED, V376, P1038, DOI 10.1056/NEJMoa1608368
   Maruotti J, 2015, P NATL ACAD SCI USA, V112, P10950, DOI 10.1073/pnas.1422818112
   Ohno-Matsui K, 2005, MOL VIS, V11, P1
   Paolin A, 2016, CELL TISSUE BANK, V17, P51, DOI 10.1007/s10561-015-9520-y
   Pennington BO, 2016, J OCUL PHARMACOL TH, V32, P261, DOI 10.1089/jop.2015.0153
   Ramsden CM, 2013, DEVELOPMENT, V140, P2576, DOI 10.1242/dev.092270
   Reichman S, 2017, STEM CELLS, V35, P1176, DOI 10.1002/stem.2586
   Reichman S, 2014, P NATL ACAD SCI USA, V111, P8518, DOI 10.1073/pnas.1324212111
   Salero E, 2012, CELL STEM CELL, V10, P88, DOI 10.1016/j.stem.2011.11.018
   Schwartz SD, 2015, LANCET, V385, P509, DOI 10.1016/S0140-6736(14)61376-3
   Schwartz SD, 2012, LANCET, V379, P713, DOI 10.1016/S0140-6736(12)60028-2
   Song MJ, 2016, BRAIN RES, V1638, P2, DOI 10.1016/j.brainres.2015.12.011
   Stanzel BV, 2014, STEM CELL REP, V2, P64, DOI 10.1016/j.stemcr.2013.11.005
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Swaroop A, 2009, ANNU REV GENOM HUM G, V10, P19, DOI 10.1146/annurev.genom.9.081307.164350
   Thomas BB, 2016, INVEST OPHTH VIS SCI, V57, P2877, DOI 10.1167/iovs.16-19238
   Thumann G, 1997, CURR EYE RES, V16, P1236, DOI 10.1076/ceyr.16.12.1236.5031
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
NR 38
TC 4
Z9 4
U1 0
U2 12
PU JOURNAL OF VISUALIZED EXPERIMENTS
PI CAMBRIDGE
PA 1 ALEWIFE CENTER, STE 200, CAMBRIDGE, MA 02140 USA
SN 1940-087X
J9 JOVE-J VIS EXP
JI J. Vis. Exp.
PD SEP
PY 2018
IS 139
AR e58216
DI 10.3791/58216
PG 8
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA HI1MZ
UT WOS:000456210900044
PM 30247475
OA Green Published, Green Submitted
DA 2022-11-30
ER

PT J
AU Andres-Guerrero, V
   Perucho-Gonzalez, L
   Garcia-Feijoo, J
   Morales-Fernandez, L
   Saenz-Frances, F
   Herrero-Vanrell, R
   Julvez, LP
   Llorens, V
   Martinez-de-la-Casa, J
   Konstas, AG
AF Andres-Guerrero, Vanessa
   Perucho-Gonzalez, Lucia
   Garcia-Feijoo, Julian
   Morales-Fernandez, Laura
   Saenz-Frances, Federico
   Herrero-Vanrell, Rocio
   Pablo Julvez, Luis
   Polo Llorens, Vicente
   Maria Martinez-de-la-Casa, Jose
   Konstas, Anastasios-Georgios P.
TI Current Perspectives on the Use of Anti-VEGF Drugs as Adjuvant Therapy
   in Glaucoma
SO ADVANCES IN THERAPY
LA English
DT Review
DE Angiogenesis; Aflibercept; Bevacizumab; Glaucoma filtration surgery;
   Neovascular glaucoma; Ranibizumab; VEGF; Wound modulation
ID ENDOTHELIAL GROWTH-FACTOR; INTRAVITREAL BEVACIZUMAB AVASTIN; SINGLE-SITE
   PHACOTRABECULECTOMY; VASCULAR-PERMEABILITY FACTOR; WOUND-HEALING
   MODULATION; OFF-LABEL BEVACIZUMAB; PREVENT BLEB FAILURE; NEOVASCULAR
   GLAUCOMA; MITOMYCIN-C; INTRACAMERAL BEVACIZUMAB
AB The approval of one of the first anti-vascular endothelial growth factor (VEGF) agents for the treatment of neovascular age-related macular degeneration one decade ago marked the beginning of a new era in the management of several sight-threatening retinal diseases. Since then, emerging evidence has demonstrated the utility of these therapies for the treatment of other ocular conditions characterized by elevated VEGF levels. In this article we review current perspectives on the use of anti-VEGF drugs as adjuvant therapy in the management of neovascular glaucoma (NVG). The use of anti-VEGFs for modifying wound healing in glaucoma filtration surgery (GFS) is also reviewed. Selected studies investigating the use of anti-VEGF agents or antimetabolites in GFS or the management of NVG have demonstrated that these agents can improve surgical outcomes. However, anti-VEGF agents have yet to demonstrate specific advantages over the more established agents commonly used today. Further studies are needed to evaluate the duration of action, dosing intervals, and toxicity profile of these treatments.
C1 [Andres-Guerrero, Vanessa; Perucho-Gonzalez, Lucia; Garcia-Feijoo, Julian; Morales-Fernandez, Laura; Saenz-Frances, Federico; Herrero-Vanrell, Rocio; Pablo Julvez, Luis; Polo Llorens, Vicente; Maria Martinez-de-la-Casa, Jose] Inst Hlth Carlos III, Ocular Pathol Natl Net OFTARED, Madrid, Spain.
   [Andres-Guerrero, Vanessa; Perucho-Gonzalez, Lucia; Garcia-Feijoo, Julian; Morales-Fernandez, Laura; Saenz-Frances, Federico; Maria Martinez-de-la-Casa, Jose] Univ Complutense Madrid, Hosp Clin San Carlos, Dept Ophthalmol, Madrid, Spain.
   [Andres-Guerrero, Vanessa; Perucho-Gonzalez, Lucia; Garcia-Feijoo, Julian; Morales-Fernandez, Laura; Saenz-Frances, Federico; Herrero-Vanrell, Rocio; Maria Martinez-de-la-Casa, Jose] San Carlos Clin Hosp, Sanitary Res Inst, Madrid, Spain.
   [Herrero-Vanrell, Rocio] Univ Complutense Madrid, Dept Pharm & Pharmaceut Technol, Fac Pharm, Madrid, Spain.
   [Pablo Julvez, Luis; Polo Llorens, Vicente] Hosp Univ Miguel Servet, Dept Ophthalmol, Zaragoza, Spain.
   [Konstas, Anastasios-Georgios P.] Aristotle Univ Thessaloniki, AHEPA Hosp, Univ Dept Ophthalmol 1, 1 Kyriakidi St, Thessaloniki 54636, Greece.
   [Konstas, Anastasios-Georgios P.] Aristotle Univ Thessaloniki, AHEPA Hosp, Univ Dept Ophthalmol 3, 1 Kyriakidi St, Thessaloniki 54636, Greece.
C3 Complutense University of Madrid; Hospital Clinico San Carlos;
   Complutense University of Madrid; Miguel Servet University Hospital;
   Aristotle University of Thessaloniki; Ahepa University Hospital;
   Aristotle University of Thessaloniki; Ahepa University Hospital
RP Konstas, AG (通讯作者)，Aristotle Univ Thessaloniki, AHEPA Hosp, Univ Dept Ophthalmol 1, 1 Kyriakidi St, Thessaloniki 54636, Greece.; Konstas, AG (通讯作者)，Aristotle Univ Thessaloniki, AHEPA Hosp, Univ Dept Ophthalmol 3, 1 Kyriakidi St, Thessaloniki 54636, Greece.
EM konstas@med.auth.gr
RI Andrés-Guerrero, Vanessa/K-8077-2015; Herrero-Vanrell,
   Rocio/G-6849-2017; GARCIA FEIJOO, JULIAN/G-9762-2017; Saenz-Frances,
   Federico/A-3350-2012
OI Andrés-Guerrero, Vanessa/0000-0003-0157-1932; Herrero-Vanrell,
   Rocio/0000-0001-9764-7975; GARCIA FEIJOO, JULIAN/0000-0002-7772-5718;
   Polo Llorens, Vicente/0000-0002-1402-3129; Pablo,
   Luis/0000-0003-2389-8282; Martinez-de-la-Casa, Jose
   Maria/0000-0001-9441-0542; Saenz-Frances, Federico/0000-0002-3196-1491
FU Sanitary Research Institute of the San Carlos Clinical Hospital; Ocular
   Pathology National Net OFTARED of the Institute of Health Carlos III
   [RD12/0034]; Research Group UCM [920415, GR3/14]; Spanish Ministry of
   Economy and Competitiveness MICINN [MAT 2013-43127R]
FX All named authors meet the International Committee of Medical Journal
   Editors (ICMJE) criteria for authorship for this manuscript, take
   responsibility for the integrity of the work as a whole, and have given
   final approval for the version to be published. The authors would like
   to acknowledge the financial support from the Sanitary Research
   Institute of the San Carlos Clinical Hospital, the Ocular Pathology
   National Net OFTARED of the Institute of Health Carlos III (RD12/0034),
   the Research Group UCM 920415 (GR3/14), and the Spanish Ministry of
   Economy and Competitiveness MICINN (MAT 2013-43127R). No funding or
   sponsorship was received for the publication charges of this article.
CR Akkan JU, 2015, J GLAUCOMA, V24, P1, DOI 10.1097/IJG.0b013e318287abf3
   ALON T, 1995, NAT MED, V1, P1024, DOI 10.1038/nm1095-1024
   Andreoli CM, 2007, CURR OPIN OPHTHALMOL, V18, P502, DOI 10.1097/ICU.0b013e3282f0ca54
   Arroyo MVA, 1998, KIDNEY INT, V54, pS7
   Avery RL, 2006, OPHTHALMOLOGY, V113, P1695, DOI 10.1016/j.ophtha.2006.05.064
   Bakri SJ, 2007, OPHTHALMOLOGY, V114, P2179, DOI 10.1016/j.ophtha.2007.09.012
   Banks RE, 1998, BRIT J CANCER, V77, P956, DOI 10.1038/bjc.1998.158
   Bao P, 2009, J SURG RES, V153, P347, DOI 10.1016/j.jss.2008.04.023
   BERSE B, 1992, MOL BIOL CELL, V3, P211, DOI 10.1091/mbc.3.2.211
   Bochmann F, 2011, BMC OPHTHALMOL, V11, DOI 10.1186/1471-2415-11-1
   Brkovic A, 2007, J CELL BIOCHEM, V100, P727, DOI 10.1002/jcb.21124
   Cantor LB, 2003, J GLAUCOMA, V12, P266, DOI 10.1097/00061198-200306000-00015
   Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0
   Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220
   Chalam KV, 2014, JAMA OPHTHALMOL, V132, P1350, DOI 10.1001/jamaophthalmol.2014.2356
   Ciulla TA, 2009, CURR OPIN OPHTHALMOL, V20, P166, DOI 10.1097/ICU.0b013e328329d173
   COSTA VP, 1993, OPHTHALMIC SURG LAS, V24, P152
   Cui LJ, 2008, ACTA PHARMACOL SIN, V29, P1021, DOI 10.1111/j.1745-7254.2008.00833.x
   Daneshvar Ramin, 2013, J Ophthalmic Vis Res, V8, P182
   Duch S, 2009, J GLAUCOMA, V18, P140, DOI 10.1097/IJG.0b013e318170a747
   European Glaucoma Society, 2014, TERM GUID GLAUC
   Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669
   Fong DS, 2007, RETINA-J RET VIT DIS, V27, P816, DOI 10.1097/IAE.0b013e318042d32c
   Franco L, 2016, EUR J OPHTHALMOL, V26, P221, DOI 10.5301/ejo.5000688
   Gaudreault J, 2005, INVEST OPHTH VIS SCI, V46, P726, DOI 10.1167/iovs.04-0601
   Gaudreault J, 2007, RETINA-J RET VIT DIS, V27, P1260, DOI 10.1097/IAE.0b013e318134eecd
   Gaudry M, 1997, BLOOD, V90, P4153, DOI 10.1182/blood.V90.10.4153
   Georgalas Ilias, 2009, Ther Clin Risk Manag, V5, P17
   Georgoulas S, 2008, PROG BRAIN RES, V173, P237, DOI 10.1016/S0079-6123(08)01117-5
   Gluzman-Poltorak Z, 2000, J BIOL CHEM, V275, P18040, DOI 10.1074/jbc.M909259199
   Goishi K, 2004, CURR TOP DEV BIOL, V62, P127
   Grewal DS, 2008, OPHTHALMOLOGY, V115, P2141, DOI 10.1016/j.ophtha.2008.06.009
   Griffioen AW, 2000, PHARMACOL REV, V52, P237
   Grisanti S, 2006, AM J OPHTHALMOL, V142, P158, DOI 10.1016/j.ajo.2006.02.045
   Grisanti Salvatore, 2007, Indian Journal of Ophthalmology, V55, P417
   Grover S, 2009, BRIT J OPHTHALMOL, V93, P273, DOI 10.1136/bjo.2008.145714
   Gulati N, 2011, BRIT J OPHTHALMOL, V95, P162, DOI 10.1136/bjo.2009.177279
   Guo S, 2010, J DENT RES, V89, P219, DOI 10.1177/0022034509359125
   Gupta N, 2013, OPEN OPHTHALMOL J, V7, P4, DOI 10.2174/1874364101307010004
   Hasanreisoglu M, 2009, EUR J OPHTHALMOL, V19, P607, DOI 10.1177/112067210901900414
   Hau S, 2009, CURR OPIN OPHTHALMOL, V20, P131, DOI 10.1097/ICU.0b013e328325a54b
   Hayreh SS, 2007, PROG RETIN EYE RES, V26, P470, DOI 10.1016/j.preteyeres.2007.06.001
   Holash J, 2002, P NATL ACAD SCI USA, V99, P11393, DOI 10.1073/pnas.172398299
   Horsley MB, 2010, CURR OPIN OPHTHALMOL, V21, P112, DOI 10.1097/ICU.0b013e3283360aad
   Jampel HD, 2012, OPHTHALMOLOGY, V119, P712, DOI 10.1016/j.ophtha.2011.09.049
   Jurkowska-Dudzinska J, 2012, CLIN EXP OPHTHALMOL, V40, pE135, DOI 10.1111/j.1442-9071.2011.02608.x
   Kahook MY, 2010, AM J OPHTHALMOL, V150, P399, DOI 10.1016/j.ajo.2010.03.025
   Kahook MY, 2006, OPHTHAL SURG LAS IM, V37, P144, DOI 10.3928/1542-8877-20060301-11
   Kaiser PK, 2006, AM J OPHTHALMOL, V142, P660, DOI 10.1016/j.ajo.2006.05.061
   Kano MR, 2005, J CELL SCI, V118, P3759, DOI 10.1242/jcs.02483
   KECK PJ, 1989, SCIENCE, V246, P1309, DOI 10.1126/science.2479987
   KHAW PT, 1992, ARCH OPHTHALMOL-CHIC, V110, P1150, DOI 10.1001/archopht.1992.01080200130040
   Kim M, 2015, SURV OPHTHALMOL, V60, P524, DOI 10.1016/j.survophthal.2015.04.003
   Kirwan JF, 2013, OPHTHALMOLOGY, V120, P2532, DOI 10.1016/j.ophtha.2013.07.049
   Kitnarong N, 2015, OPHTHALMOL THER, V4, P33, DOI 10.1007/s40123-015-0033-3
   Lama PJ, 2003, SURV OPHTHALMOL, V48, P314, DOI 10.1016/S0039-6257(03)00038-9
   Lattanzio FA, 2005, J OCUL PHARMACOL TH, V21, P223, DOI 10.1089/jop.2005.21.223
   LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986
   Li ZQ, 2009, INVEST OPHTH VIS SCI, V50, P5217, DOI 10.1167/iovs.08-2662
   Liu XY, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000003223
   Luke J, 2013, GRAEF ARCH CLIN EXP, V251, P2403, DOI 10.1007/s00417-013-2428-y
   Magdelaine-Beuzelin C, 2010, MABS-AUSTIN, V2, P176, DOI 10.4161/mabs.2.2.11205
   Marey HM, 2011, CLIN OPHTHALMOL, V5, P841, DOI 10.2147/OPTH.S21453
   Mathew R, 2011, AM J OPHTHALMOL, V152, P10, DOI 10.1016/j.ajo.2011.03.013
   Memarzadeh F, 2009, INVEST OPHTH VIS SCI, V50, P3233, DOI 10.1167/iovs.08-2441
   Meyer T, 2009, J THROMB HAEMOST, V7, P171, DOI 10.1111/j.1538-7836.2008.03212.x
   Mietz H, 1996, Curr Opin Ophthalmol, V7, P72, DOI 10.1097/00055735-199604000-00013
   Mietz H, 2005, GRAEF ARCH CLIN EXP, V243, P1284, DOI 10.1007/s00417-005-1170-5
   Nilforushan N, 2012, AM J OPHTHALMOL, V153, P352, DOI 10.1016/j.ajo.2011.08.005
   Nissen NN, 1998, AM J PATHOL, V152, P1445
   Nomoto H, 2009, INVEST OPHTH VIS SCI, V50, P4807, DOI 10.1167/iovs.08-3148
   Ozgonul C, 2014, CURR EYE RES, V39, P451, DOI 10.3109/02713683.2013.851704
   Park HYL, 2012, ARCH OPHTHALMOL-CHIC, V130, P685, DOI 10.1001/archophthalmol.2011.2799
   Park SC, 2012, EXPERT OPIN BIOL TH, V12, P1641, DOI 10.1517/14712598.2012.721772
   Pralhad T, 2003, J PHARM PHARMACOL, V55, P1045, DOI 10.1211/0022357021819
   Presta LG, 1997, CANCER RES, V57, P4593
   Pro MJ, 2015, CURR EYE RES, V40, P510, DOI 10.3109/02713683.2014.935441
   Quigley HA, 2006, BRIT J OPHTHALMOL, V90, P262, DOI 10.1136/bjo.2005.081224
   Rich RM, 2006, RETINA-J RET VIT DIS, V26, P495, DOI 10.1097/01.iae.0000225766.75009.3a
   Rodrigues EB, 2009, PROG RETIN EYE RES, V28, P117, DOI 10.1016/j.preteyeres.2008.11.005
   Rudge JS, 2007, P NATL ACAD SCI USA, V104, P18363, DOI 10.1073/pnas.0708865104
   Saeedi OJ, 2014, J GLAUCOMA, V23, pE60, DOI 10.1097/IJG.0000000000000008
   Saito Y, 2010, AM J OPHTHALMOL, V149, P964, DOI 10.1016/j.ajo.2010.01.008
   Salim S, 2012, CURR OPIN OPHTHALMOL, V23, P89, DOI 10.1097/ICU.0b013e32834ff401
   Schmucker C, 2011, BRIT J OPHTHALMOL, V95, P308, DOI 10.1136/bjo.2009.178574
   Seibold LK, 2012, SURV OPHTHALMOL, V57, P530, DOI 10.1016/j.survophthal.2012.01.008
   Sengupta S, 2013, J GLAUCOMA, V22, P266, DOI 10.1097/IJG.0b013e3182877d1b
   Sengupta S, 2012, J GLAUCOMA, V21, P450, DOI 10.1097/IJG.0b013e31821826b2
   SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0
   Simha A, 2013, COCHRANE DB SYST REV, V10
   Sivak-Callcott JA, 2001, OPHTHALMOLOGY, V108, P1767, DOI 10.1016/S0161-6420(01)00775-8
   Soker S, 2002, J CELL BIOCHEM, V85, P357, DOI 10.1002/jcb.10140
   SooHoo JR, 2015, CLIN EXP OPHTHALMOL, V43, P803, DOI 10.1111/ceo.12559
   SooHoo JR, 2013, SEMIN OPHTHALMOL, V28, P165, DOI 10.3109/08820538.2012.730103
   STAVRI GT, 1995, CIRCULATION, V92, P11, DOI 10.1161/01.CIR.92.1.11
   Sugimoto Y, 2010, GRAEF ARCH CLIN EXP, V248, P1601, DOI 10.1007/s00417-010-1406-x
   Tai TYT, 2015, J GLAUCOMA, V24, P311, DOI 10.1097/IJG.0b013e31829f9bd3
   Tolentino M, 2011, SURV OPHTHALMOL, V56, P95, DOI 10.1016/j.survophthal.2010.08.006
   UCHIDA K, 1994, AM J PHYSIOL, V266, pF81, DOI 10.1152/ajprenal.1994.266.1.F81
   Van Bergen T, 2011, EXP EYE RES, V93, P689, DOI 10.1016/j.exer.2011.08.016
   Vandewalle E, 2014, BRIT J OPHTHALMOL, V98, P73, DOI 10.1136/bjophthalmol-2013-303966
   Waisbourd M, 2014, PHARMACOLOGY, V93, P108, DOI 10.1159/000358600
   Wakabayashi T, 2008, OPHTHALMOLOGY, V115, P1571, DOI 10.1016/j.ophtha.2008.02.026
   Wilkins M, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002897.pub2
   WONG J, 1994, EXP EYE RES, V58, P439, DOI 10.1006/exer.1994.1037
   Yazdani S, 2009, J GLAUCOMA, V18, P632, DOI 10.1097/IJG.0b013e3181997211
   Yoeruek E, 2008, ACTA OPHTHALMOL, V86, P322, DOI 10.1111/j.1600-0420.2007.01049.x
   Yoeruek E, 2007, CORNEA, V26, P977, DOI 10.1097/ICO.0b013e3180de1d0a
   Yoshida A, 1996, GROWTH FACTORS, V13, P57, DOI 10.3109/08977199609034566
   Yu DY, 2009, PROG RETIN EYE RES, V28, P303, DOI 10.1016/j.preteyeres.2009.06.004
   Yuzbasioglu E, 2009, J OCUL PHARMACOL TH, V25, P259, DOI 10.1089/jop.2008.0088
NR 111
TC 23
Z9 28
U1 0
U2 10
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0741-238X
EI 1865-8652
J9 ADV THER
JI Adv. Ther.
PD FEB
PY 2017
VL 34
IS 2
BP 378
EP 395
DI 10.1007/s12325-016-0461-z
PG 18
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA EM6SV
UT WOS:000395443300005
PM 28000166
OA hybrid, Green Published, Green Accepted
DA 2022-11-30
ER

PT J
AU Gorusupudi, A
   Liu, AH
   Hageman, GS
   Bernstein, PS
AF Gorusupudi, Aruna
   Liu, Aihua
   Hageman, Gregory S.
   Bernstein, Paul S.
TI Associations of human retinal very long-chain polyunsaturated fatty
   acids with dietary lipid biomarkers
SO JOURNAL OF LIPID RESEARCH
LA English
DT Article
DE eye; retina; diet and dietary lipids; omega-3 fatty acids; nutrition;
   mass spectrometry; elongation of very long-chain fatty acids elongase 4;
   age-related macular degeneration
ID DOCOSAHEXAENOIC ACID; MACULAR DYSTROPHY; ELOVL4; RISK; ADIPOSE;
   PHOSPHATIDYLCHOLINES; QUANTIFICATION; DEGENERATION; PROFILE; 22/6N-3
AB The human retina is well-known to have unique lipid profiles enriched in long-chain polyunsaturated fatty acids (LC-PUFAs) and very long-chain polyunsaturated fatty acids (VLC-PUFAs) that appear to promote normal retinal structure and function, but the influence of diet on retinal lipid profiles in health and disease remains controversial. In this study, we examined two independent cohorts of donor eyes and related their retinal lipid profiles with systemic biomarkers of lipid intake. We found that serum and red blood cell lipids, and to a lesser extent orbital fat, are indeed excellent biomarkers of retinal lipid content and n-3 / n-6 ratios in both the LC-PUFA and VLC-PUFA series. Eyes from age-related macular degeneration (AMD) donors have significantly decreased levels of VLC-PUFAs and low n-3 / n-6 ratios. These results are consistent with the protective role of dietary n-3 LC-PUFAs against AMD and emphasize the importance of monitoring systemic biomarkers of lipid intake when undertaking clinical trials of lipid supplements for prevention and treatment of retinal disease.
C1 [Gorusupudi, Aruna; Liu, Aihua; Hageman, Gregory S.; Bernstein, Paul S.] Univ Utah, Med Ctr, John E Moran Eye Ctr, Salt Lake City, UT 84132 USA.
   [Hageman, Gregory S.; Bernstein, Paul S.] Univ Utah, Med Ctr, Sharon Eccles Steele Ctr Translat Med, Salt Lake City, UT 84132 USA.
C3 Utah System of Higher Education; University of Utah; Utah System of
   Higher Education; University of Utah
RP Bernstein, PS (通讯作者)，Univ Utah, Med Ctr, John E Moran Eye Ctr, Salt Lake City, UT 84132 USA.; Bernstein, PS (通讯作者)，Univ Utah, Med Ctr, Sharon Eccles Steele Ctr Translat Med, Salt Lake City, UT 84132 USA.
EM paul.bernstein@hsc.utah.edu
FU Macula Vision Research Foundation (New York, NY); Beckman Initiative for
   Macular Research (Irvine, CA); National Eye Institute, National
   Institutes of Health [EY-14800]; NATIONAL EYE INSTITUTE [P30EY014800]
   Funding Source: NIH RePORTER
FX This work was supported by grants from the Macula Vision Research
   Foundation (New York, NY), the Beckman Initiative for Macular Research
   (Irvine, CA), and the National Eye Institute, National Institutes of
   Health (EY-14800). The content is solely the responsibility of the
   authors and does not necessarily represent the official views of the
   National Institutes of Health. The invaluable assistance of Chris
   Pappas, Lisa Nichols, Norma Miller, Kelly Nelson, Yumna K. Subhani, and
   the donor eye acquisition staff members of the Utah Lions Eye Bank and
   the Utah Center for Translational Medicine Donor Eye Repository is
   gratefully acknowledged
CR Acar N, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035102
   Agbaga MP, 2014, INVEST OPHTH VIS SCI, V55, P3669, DOI 10.1167/iovs.13-13099
   Agbaga MP, 2014, ADV EXP MED BIOL, V801, P631, DOI 10.1007/978-1-4614-3209-8_79
   Agbaga MP, 2010, J LIPID RES, V51, P1624, DOI 10.1194/jlr.R005025
   AVELDANO MI, 1987, J BIOL CHEM, V262, P1172
   Ayyagari R, 2001, Ophthalmic Genet, V22, P233, DOI 10.1076/opge.22.4.233.2219
   Barabas P, 2013, P NATL ACAD SCI USA, V110, P5181, DOI 10.1073/pnas.1214707110
   Baylin A, 2002, AM J CLIN NUTR, V76, P750, DOI 10.1093/ajcn/76.4.750
   Baylin A, 2006, CURR OPIN LIPIDOL, V17, P22, DOI 10.1097/01.mol.0000199814.46720.83
   Bazan NG, 2009, J LIPID RES, V50, pS400, DOI 10.1194/jlr.R800068-JLR200
   Berdeaux O, 2010, J CHROMATOGR A, V1217, P7738, DOI 10.1016/j.chroma.2010.10.039
   Bernstein PS, 2001, INVEST OPHTH VIS SCI, V42, P3331
   Bretillon L, 2008, EXP EYE RES, V87, P521, DOI 10.1016/j.exer.2008.08.010
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Cho E, 2001, AM J CLIN NUTR, V73, P209
   DeAngelis MM, 2007, ARCH OPHTHALMOL-CHIC, V125, P49, DOI 10.1001/archopht.125.1.49
   Dwyer JH, 2004, NEW ENGL J MED, V350, P29, DOI 10.1056/NEJMoa025079
   FLIESLER SJ, 1983, PROG LIPID RES, V22, P79
   Harkewicz R, 2012, J BIOL CHEM, V287, P11469, DOI 10.1074/jbc.M111.256073
   Hubbard AF, 2006, ARCH OPHTHALMOL-CHIC, V124, P257, DOI 10.1001/archopht.124.2.257
   Kaarniranta K, 2012, NEUROSCI LETT, V513, P233, DOI 10.1016/j.neulet.2012.02.050
   Liu AH, 2013, J CHROMATOGR A, V1307, P191, DOI 10.1016/j.chroma.2013.07.103
   Liu AH, 2011, CLIN LIPIDOL, V6, P593, DOI 10.2217/CLP.11.41
   Liu AH, 2010, J LIPID RES, V51, P3217, DOI 10.1194/jlr.M007518
   MAKRIDES M, 1994, AM J CLIN NUTR, V60, P189, DOI 10.1093/ajcn/60.2.189
   McMahon A, 2010, BRIT J OPHTHALMOL, V94, P1127, DOI 10.1136/bjo.2008.149286
   Merle BMJ, 2014, INVEST OPHTH VIS SCI, V55, P2010, DOI 10.1167/iovs.14-13916
   Patterson E, 2012, J NUTR METAB, V2012, DOI 10.1155/2012/539426
   Rice DS, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7228
   SanGiovanni JP, 2007, ARCH OPHTHALMOL-CHIC, V125, P671, DOI 10.1001/archopht.125.5.671
   SanGiovanni JP, 2005, PROG RETIN EYE RES, V24, P87, DOI 10.1016/j.preteyeres.2004.06.002
   SARKKINEN ES, 1994, AM J CLIN NUTR, V59, P364, DOI 10.1093/ajcn/59.2.364
   Schmitz G, 2008, PROG LIPID RES, V47, P147, DOI 10.1016/j.plipres.2007.12.004
   Seddon JM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1191, DOI 10.1001/archopht.119.8.1191
   Souied EH, 2013, OPHTHALMOLOGY, V120, P1619, DOI 10.1016/j.ophtha.2013.01.005
   Suh M, 2005, CURR EYE RES, V30, P959, DOI 10.1080/02713680500246957
   Suh M, 2000, PEDIATR RES, V48, P524, DOI 10.1203/00006450-200010000-00017
   van Leeuwen R, 2003, ARCH OPHTHALMOL-CHIC, V121, P519, DOI 10.1001/archopht.121.4.519
   Wang H, 2010, MOL PHARMACEUT, V7, P2185, DOI 10.1021/mp100199m
   Weiss GA, 2013, LIPIDS HEALTH DIS, V12, DOI 10.1186/1476-511X-12-89
   Yi JH, 2012, MOL MED REP, V6, P1045, DOI 10.3892/mmr.2012.1063
   Zhang K, 2001, NAT GENET, V27, P89, DOI 10.1038/83817
NR 42
TC 40
Z9 40
U1 0
U2 15
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0022-2275
EI 1539-7262
J9 J LIPID RES
JI J. Lipid Res.
PD MAR
PY 2016
VL 57
IS 3
BP 499
EP 508
DI 10.1194/jlr.P065540
PG 10
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA DF1JK
UT WOS:000371095500019
PM 26764040
OA Green Published, hybrid
DA 2022-11-30
ER

PT J
AU Chai, PW
   Ni, HY
   Zhang, H
   Fan, XQ
AF Chai, Peiwei
   Ni, Hongyan
   Zhang, He
   Fan, Xianqun
TI The Evolving Functions of Autophagy in Ocular Health: A Double-edged
   Sword
SO INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES
LA English
DT Review
DE Autophagy; age-related macular degeneration; cataracts; diabetic
   retinopathy; thyroid-associated ophthalmopathy; ocular tumours.
ID PIGMENT EPITHELIAL-CELLS; TOXOPLASMA-GONDII; DISEASE; GROWTH; AMPK; RPE;
   DEGENERATION; DEGRADATION; MECHANISMS; DIAGNOSIS
AB Autophagy plays an adaptive role in cell survival, development, differentiation and intracellular homeostasis. Autophagy is recognized as a 'self-cannibalizing' process that is active during stresses such as starvation, chemotherapy, infection, ageing, and oxygen shortage to protect organisms from various irritants and to regenerate materials and energy. However, autophagy can also lead to a form of programmed cell death distinct from apoptosis.
   Components of the autophagic pathway are constitutively expressed at a high level in the eye, including in the cornea, lens, retina, and orbit. In addition, the activation of autophagy is directly linked to the development of eye diseases such as age-related macular degeneration (ARMD), cataracts, diabetic retinopathy (DR), glaucoma, photoreceptor degeneration, ocular tumours, ocular infections and thyroid-associated ophthalmopathy (TAO). A high level of autophagy defends against external stress; however, excessive autophagy can result in deterioration, as observed in ocular diseases such as ARMD and DR.
   This review summarizes recent developments elucidating the relationship between autophagy and ocular diseases and the potential roles of autophagy in the pathogenesis and treatment of these diseases.
C1 [Chai, Peiwei; Ni, Hongyan; Zhang, He; Fan, Xianqun] Shanghai Jiao Tong Univ, Sch Med, Peoples Hosp 9, Dept Ophthalmol, Shanghai, Peoples R China.
C3 Shanghai Jiao Tong University
RP Zhang, H; Fan, XQ (通讯作者)，Shanghai Jiao Tong Univ, Sch Med, Peoples Hosp 9, Shanghai 200025, Peoples R China.
EM zhanghe@sjtu.edu.cn; drfanxianqun@126.com
RI Chai, Peiwei/W-9926-2019
FU Scientific Research Program of the National Health and Family Planning
   Commission of China [201402014]; National Natural Science Foundation of
   China [31470757]; Program for Professors of Special Appointment (Eastern
   Scholar) at the Shanghai Institutions of Higher Learning [1410000159];
   SMC-ChenXing Young Scholar Program (Class B); Shanghai Municipal
   Education Commission-Gaofeng Clinical Medicine Grant [2016-13]; Science
   and Technology Commission of Shanghai [14JC1404100, 14JC1404200,
   14430723100]
FX This work was supported by the Scientific Research Program of the
   National Health and Family Planning Commission of China (201402014), the
   National Natural Science Foundation of China (31470757), the Program for
   Professors of Special Appointment (Eastern Scholar) at the Shanghai
   Institutions of Higher Learning (1410000159), the SMC-ChenXing Young
   Scholar Program (2014, Class B), the Shanghai Municipal Education
   Commission-Gaofeng Clinical Medicine Grant (2016-13) and the Science and
   Technology Commission of Shanghai (14JC1404100, 14JC1404200, and
   14430723100). The funders of this research had no role in study design,
   data collection and analysis, the decision to publish, or the
   preparation of the manuscript.
CR Ambrosini G, 2013, MOL CANCER THER, V12, P768, DOI 10.1158/1535-7163.MCT-12-1020
   Bahn RS, 2010, NEW ENGL J MED, V362, P726, DOI 10.1056/NEJMra0905750
   Bifulco M, 2016, ENDOCRINE, V53, P649, DOI 10.1007/s12020-015-0762-z
   Boya P, 2013, NAT CELL BIOL, V15, P713, DOI 10.1038/ncb2788
   Cai X, 2016, J DIABETES RES, V2016, DOI 10.1155/2016/3789217
   Chang RT, 2016, ASIA-PAC J OPHTHALMO, V5, P32, DOI 10.1097/APO.0000000000000173
   Chen JJ, 2011, AM J HUM GENET, V88, P827, DOI 10.1016/j.ajhg.2011.05.008
   Chen Y, 2013, J BIOL CHEM, V288, P7506, DOI 10.1074/jbc.M112.439935
   Coffey EE, 2014, NEUROSCIENCE, V263, P111, DOI 10.1016/j.neuroscience.2014.01.001
   Criollo A, 2007, CELL DEATH DIFFER, V14, P1029, DOI 10.1038/sj.cdd.4402099
   de Jong PTVM, 2015, GRAEF ARCH CLIN EXP, V253, P2061, DOI 10.1007/s00417-015-3180-2
   Du M, 2013, DIABETOLOGIA, V56, P2318, DOI 10.1007/s00125-013-2986-x
   Ebneter A, 2016, ENDOCR DEV, V31, P84, DOI 10.1159/000439391
   Eckstein A, 2013, OPHTHALMOLOGE, V110, P1079, DOI 10.1007/s00347-013-2976-x
   El Fkih L, 2007, Tunis Med, V85, P1025
   Fan JY, 2015, GENOME BIOL
   Fu D, 2012, DIABETOLOGIA, V55, P3128, DOI 10.1007/s00125-012-2692-0
   Ganne P, 2015, JAMA OPHTHALMOL, V133, P603, DOI 10.1001/jamaophthalmol.2014.6127
   Giatromanolaki AN, 2011, MODERN PATHOL, V24, P1036, DOI 10.1038/modpathol.2011.63
   Guha S, 2014, EXP EYE RES, V126, P68, DOI 10.1016/j.exer.2014.05.013
   Guo L, 2013, MOL CELL BIOL, V33, P3180, DOI 10.1128/MCB.00193-13
   Harris J, 2009, VET IMMUNOL IMMUNOP, V128, P37, DOI 10.1016/j.vetimm.2008.10.293
   HORNUNG JP, 1989, J COMP NEUROL, V283, P425, DOI 10.1002/cne.902830310
   Kawashima M, 2013, EXP GERONTOL, V48, P1096, DOI 10.1016/j.exger.2013.04.002
   Kim J, 2011, NAT CELL BIOL, V13, P132, DOI 10.1038/ncb2152
   Kim KE, 2016, ASIA-PAC J OPHTHALMO, V5, P23, DOI 10.1097/APO.0000000000000177
   Knoferle J, 2010, P NATL ACAD SCI USA, V107, P6064, DOI 10.1073/pnas.0909794107
   Kundu M, 2008, ANNU REV PATHOL-MECH, V3, P427, DOI 10.1146/annurev.pathmechdis.2.010506.091842
   Lam D, 2016, ASIA-PAC J OPHTHALMO, V5, P2, DOI 10.1097/APO.0000000000000184
   Lee JH, 2010, CELL, V141, P1146, DOI 10.1016/j.cell.2010.05.008
   Leib DA, 2009, J VIROL, V83, P12164, DOI 10.1128/JVI.01676-09
   Levine B, 2008, CELL, V132, P27, DOI 10.1016/j.cell.2007.12.018
   Levine B, 2007, NAT REV IMMUNOL, V7, P767, DOI 10.1038/nri2161
   Little MP, 2013, RADIAT ENVIRON BIOPH, V52, P435, DOI 10.1007/s00411-013-0484-7
   Liu K, 2014, AUTOPHAGY, V10, P442, DOI 10.4161/auto.27418
   Lodder J, 2015, AUTOPHAGY, V11, P1280, DOI 10.1080/15548627.2015.1058473
   Fanjul-Moles ML, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/7420637
   Lum JJ, 2005, CELL, V120, P237, DOI 10.1016/j.cell.2004.11.046
   Maiuri MC, 2007, NAT REV MOL CELL BIO, V8, P741, DOI 10.1038/nrm2239
   Mallat A, 2014, BIOMED RES INT, V2014, P1
   McCannel CA, 1996, AM J OPHTHALMOL, V121, P35, DOI 10.1016/S0002-9394(14)70532-X
   Mihaylova MM, 2011, NAT CELL BIOL, V13, P1016, DOI 10.1038/ncb2329
   Mitter SK, 2014, AUTOPHAGY, V10, P1989, DOI 10.4161/auto.36184
   Mizushima N, 2008, NATURE, V451, P1069, DOI 10.1038/nature06639
   Mo J, 2014, MOL VIS, V20, P1161
   Morishita H, 2013, J BIOL CHEM, V288, P11436, DOI 10.1074/jbc.M112.437103
   Nixon RA, 2013, NAT MED, V19, P983, DOI 10.1038/nm.3232
   Orvedahl A, 2007, CELL HOST MICROBE, V1, P23, DOI 10.1016/j.chom.2006.12.001
   Pankiv S, 2010, J CELL BIOL, V188, P253, DOI 10.1083/jcb.200907015
   Park HYL, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.26
   Porter K, 2013, AUTOPHAGY, V9, P581, DOI 10.4161/auto.23568
   Porter KM, 2014, BBA-MOL CELL RES, V1843, P1054, DOI 10.1016/j.bbamcr.2014.02.010
   Portillo JAC, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0014472
   Rodriguez-Muela N, 2012, CELL DEATH DIFFER, V19, P162, DOI 10.1038/cdd.2011.88
   Shintani T, 2004, SCIENCE, V306, P990, DOI 10.1126/science.1099993
   Shoji-Kawata S, 2013, NATURE, V494, P201, DOI 10.1038/nature11866
   Sinha D, 2008, MOL CELL NEUROSCI, V37, P85, DOI 10.1016/j.mcn.2007.08.016
   Subauste CS, 2007, AUTOPHAGY, V3, P245, DOI 10.4161/auto.3717
   Subauste CS, 2006, INFECT IMMUN, V74, P1573, DOI 10.1128/IAI.74.3.1573-1579.2006
   Subauste CS, 1999, J IMMUNOL, V162, P6690
   Talloczy Z, 2006, AUTOPHAGY, V2, P24, DOI 10.4161/auto.2176
   Valapala M, 2014, AGING CELL, V13, P1091, DOI 10.1111/acel.12274
   Valapala M, 2014, AUTOPHAGY, V10, P480, DOI 10.4161/auto.27292
   Walker S, 2008, AUTOPHAGY, V4, P1093, DOI 10.4161/auto.7141
   Wang AL, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004160
   Wang Y, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/281912
   Ward C, 2016, BBA-MOL CELL BIOL L, V1861, P269, DOI 10.1016/j.bbalip.2016.01.006
   Weir E, 2004, CAN MED ASSOC J, V170, P463
   Wignes JA, 2013, EXP EYE RES, V115, P263, DOI 10.1016/j.exer.2013.06.026
   Xu SQ, 2016, CANCER LETT, V381, P41, DOI 10.1016/j.canlet.2016.07.024
   Yao J, 2014, CELL PHYSIOL BIOCHEM, V33, P107, DOI 10.1159/000356654
   Yoon JS, 2015, THYROID, V25, P445, DOI 10.1089/thy.2014.0300
   Yu L, 2004, SCIENCE, V304, P1500, DOI 10.1126/science.1096645
   Zhan J, 2016, CURR MOL MED, V16, P487, DOI 10.2174/1566524016666160429121606
   Zhang J, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.330
   Zhang Y, 2009, P NATL ACAD SCI USA, V106, P19860, DOI 10.1073/pnas.0906048106
   Zhao XY, 2015, J NANOMATER, V2015, DOI 10.1155/2015/104193
   Zoncu R, 2011, NAT REV MOL CELL BIO, V12, P21, DOI 10.1038/nrm3025
NR 78
TC 47
Z9 50
U1 2
U2 13
PU IVYSPRING INT PUBL
PI LAKE HAVEN
PA PO BOX 4546, LAKE HAVEN, NSW 2263, AUSTRALIA
SN 1449-2288
J9 INT J BIOL SCI
JI Int. J. Biol. Sci.
PY 2016
VL 12
IS 11
BP 1332
EP 1340
DI 10.7150/ijbs.16245
PG 9
WC Biochemistry & Molecular Biology; Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
   Topics
GA EC1DK
UT WOS:000387843500006
PM 27877085
OA Green Published, gold, Green Submitted
DA 2022-11-30
ER

PT J
AU Ord, LM
   Wright, J
   DeAngelis, MM
   Feehan, M
AF Ord, Lisa M.
   Wright, JoAnne
   DeAngelis, Margaret M.
   Feehan, Michael
TI Quality of Life with Macular Degeneration Is Not as Dark as It May Seem:
   Patients' Perceptions of the MacDQoL Questionnaire
SO JOURNAL OF CLINICAL MEDICINE
LA English
DT Article
DE age-related macular degeneration; quality of life; MacDQoL
   Questionnaire; visual impairment
ID DISEASE; IMPACT
AB To determine the perceived relevance and value of an individualized measure of the impact of macular degeneration on quality of life (QoL) for elderly people with Age-Related Macular Degeneration (AMD) in the USA, through the assessment of the suitability of the measure's domains and by gaining a deeper insight into the impact of AMD on patients' QoL vis-a-vis these domains, community-dwelling older adults in the metropolitan Salt Lake City, Utah area were interviewed using the macular degeneration on quality of life (MacDQoL) instrument. Participants felt that the MacDQoL was a relevant instrument for use in this US study population, though it could be improved by adding items pertaining to transportation, and independent driving, in particular, as an important QoL indicator. The emerging theme from analysis of the respondent's commentary was that, in spite of AMD, these respondents were committed to engage in, and enjoy life. This is an important concept for clinicians and those who offer support programs to integrate into their care planning and reinforce in messaging to patients with the condition.
C1 [Ord, Lisa M.; DeAngelis, Margaret M.] Univ Utah, Sch Med, John A Moran Eye Ctr, Salt Lake City, UT 84132 USA.
   [Wright, JoAnne] Univ Utah, Coll Hlth, Div Occupat Therapy, Salt Lake City, UT 84108 USA.
   [Wright, JoAnne] Salt Lake Community Coll, Sch Hlth Sci, W Jordan, UT 84088 USA.
   [Feehan, Michael] Univ Utah, Coll Pharm, Salt Lake City, UT 84112 USA.
C3 Utah System of Higher Education; University of Utah; Utah System of
   Higher Education; University of Utah; Utah System of Higher Education;
   University of Utah
RP Ord, LM (通讯作者)，Univ Utah, Sch Med, John A Moran Eye Ctr, Salt Lake City, UT 84132 USA.
EM lisa.ord@hsc.utah.edu; joanne@xmission.com; margaret.deangelis@utah.edu;
   mike.feehan@utah.edu
FU National Institutes of Health [EY014800]; Research to Prevent Blindness,
   Inc., New York, NY; ALSAM Foundation Award
FX Appreciation is expressed to student researchers: Amy Anderson, Cynthia
   Johnson, Alicia Miller, and Rachel Mitchell. This work was supported by
   National Institutes of Health (EY014800), and an Unrestricted Grant from
   Research to Prevent Blindness, Inc., New York, NY, to the Department of
   Ophthalmology & Visual Sciences, University of Utah. Also, Margaret M.
   DeAngelis is a recipient of an ALSAM Foundation Award.
CR Braun V., 2006, QUAL RES PSYCHOL, V3, P77, DOI [10.1191/1478088706qp063oa, DOI 10.1191/1478088706QP063OA]
   Crossland MD, 2005, OPTOMETRY VISION SCI, V82, P11
   Cunningham ST, 2000, COMMUNITY DENT ORAL, V28, P195, DOI 10.1034/j.1600-0528.2000.280305.x
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Finger RP, 2012, OPHTHALMOLOGY, V119, P2351, DOI 10.1016/j.ophtha.2012.05.031
   Fletcher D.C., 2008, SMITH KETTLEWELL REA
   Fletcher DC, 2006, OPTOMETRY VISION SCI, V83, P178, DOI 10.1097/01.opx.0000204510.08026.7f
   Leonard R., 2015, STAT VISION IMPAIRME
   Longworth L, 2014, HEALTH TECHNOL ASSES, V18, P1, DOI 10.3310/hta18090
   Mitchell Jan, 2005, Health Qual Life Outcomes, V3, P25, DOI 10.1186/1477-7525-3-25
   Mitchell J, 2004, QUAL LIFE RES, V13, P1548, DOI 10.1023/B:QURE.0000031348.51292.4a
   National Eye Institute, 2014, AG REL MAC DEG
   Scott IU, 1999, AM J OPHTHALMOL, V128, P54, DOI 10.1016/S0002-9394(99)00108-7
   Seiler Cotten, 2008, REPUBLIC DRIVERS CUL
   Tosh J, 2012, VALUE HEALTH, V15, P118, DOI 10.1016/j.jval.2011.08.002
   World Health Organization, 2010, GLOB DAT VIS IMP 201
   Yonekawa Y, 2015, J CLIN MED, V4, P343, DOI 10.3390/jcm4020343
   Yonekawa Y, 2015, CSH PERSPECT MED, V5, DOI 10.1101/cshperspect.a017178
   Yuzawa M, 2013, CLIN OPHTHALMOL, V7, P1325, DOI 10.2147/OPTH.S45248
NR 19
TC 6
Z9 7
U1 0
U2 6
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2077-0383
J9 J CLIN MED
JI J. Clin. Med.
PD SEP
PY 2015
VL 4
IS 9
BP 1841
EP 1852
DI 10.3390/jcm4091841
PG 12
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA CT9OK
UT WOS:000363146300011
PM 26402711
OA Green Submitted, gold, Green Published
DA 2022-11-30
ER

PT J
AU Fuhrmann, S
   Zou, CJ
   Levine, EM
AF Fuhrmann, Sabine
   Zou, ChangJiang
   Levine, Edward M.
TI Retinal pigment epithelium development, plasticity, and tissue
   homeostasis
SO EXPERIMENTAL EYE RESEARCH
LA English
DT Review
DE RPE; development; regeneration; retina; transdifferentiation;
   age-related macular degeneration; self-repair
ID BONE MORPHOGENETIC PROTEINS; VERTEBRATE EYE DEVELOPMENT; TRANSCRIPTION
   FACTOR MITF; COLI GENE DISRUPTION; NEURAL CREST CELLS; OPTIC VESICLE;
   HOMEOBOX GENE; XENOPUS-LAEVIS; TRANS-DIFFERENTIATION; CHICK-EMBRYOS
AB The retinal pigment epithelium (RPE) is a simple epithelium interposed between the neural retina and the choroid. Although only 1 cell-layer in thickness, the RPE is a virtual workhorse, acting in several capacities that are essential for visual function and preserving the structural and physiological integrities of neighboring tissues. Defects in RPE function, whether through chronic dysfunction or age-related decline, are associated with retinal degenerative diseases including age-related macular degeneration. As such, investigations are focused on developing techniques to replace RPE through stem cell-based methods, motivated primarily because of the seemingly limited regeneration or self-repair properties of mature RPE. Despite this, RPE cells have an unusual capacity to transdifferentiate into various cell types, with the particular fate choices being highly context-dependent. In this review, we describe recent findings elucidating the mechanisms and steps of RPE development and propose a developmental framework for understanding the apparent contradiction in the capacity for low self-repair versus high transdifferentiation. (C) 2013 Elsevier Ltd. All rights reserved.
C1 [Fuhrmann, Sabine; Zou, ChangJiang; Levine, Edward M.] Univ Utah, John A Moran Eye Ctr, Dept Ophthalmol & Visual Sci, Salt Lake City, UT 84132 USA.
C3 Utah System of Higher Education; University of Utah
RP Fuhrmann, S (通讯作者)，Univ Utah, John A Moran Eye Ctr, Dept Ophthalmol & Visual Sci, 65 Mario Capecchi Dr, Salt Lake City, UT 84132 USA.
EM sabine.fuhrmann@hsc.utah.edu; changjiang.zou@hci.utah.edu;
   ed.levine@utah.edu
RI Levine, Edward/N-3878-2015
OI Levine, Edward/0000-0003-1725-2805
FU NIH/NEI [EY014954, EY013760]; Research to Prevent Blindness, Inc.;
   NATIONAL EYE INSTITUTE [R01EY013760, R01EY014954] Funding Source: NIH
   RePORTER
FX Supported by NIH/NEI (EY014954 to S.F., EY013760 to E.M.L.) and by an
   unrestricted grant from Research to Prevent Blindness, Inc., to the
   Department of Ophthalmology, University of Utah. Our apologies to those
   authors whose work is not cited due to space limitations.
CR Adijanto J, 2012, J BIOL CHEM, V287, P20491, DOI 10.1074/jbc.M112.354761
   Adler R, 2002, DEVELOPMENT, V129, P3161
   Agathocleous M, 2009, DEVELOPMENT, V136, P3289, DOI 10.1242/dev.040451
   Al-Hussaini H, 2008, MOL VIS, V14, P1784
   Andoniadou CL, 2013, CELL MOL LIFE SCI, V70, P3739, DOI 10.1007/s00018-013-1269-5
   Araki M, 1998, DEV GROWTH DIFFER, V40, P167
   ARAKI M, 1977, DEV BIOL, V60, P278, DOI 10.1016/0012-1606(77)90124-5
   Araki M, 2002, DEV BIOL, V244, P358, DOI 10.1006/dbio.2002.0591
   Araki M, 2007, DEV GROWTH DIFFER, V49, P109, DOI 10.1111/j.1440-169x.2007.00911.x
   Arresta E, 2005, J EXP ZOOL PART A, V303A, P958, DOI 10.1002/jez.a.219
   Azuma N, 2005, HUM MOL GENET, V14, P1059, DOI 10.1093/hmg/ddi098
   Bailey TJ, 2004, INT J DEV BIOL, V48, P761, DOI 10.1387/ijdb.041878tb
   Barbosa-Sabanero K, 2012, BIOCHEM J, V447, P321, DOI 10.1042/BJ20120813
   Barker N, 2010, CELL STEM CELL, V7, P656, DOI 10.1016/j.stem.2010.11.016
   Baumer N, 2003, DEVELOPMENT, V130, P2903, DOI 10.1242/dev.00450
   Beby F, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011673
   Beccari L, 2013, MECH DEVELOP, V130, P95, DOI 10.1016/j.mod.2012.10.004
   Beccari L, 2012, DEVELOPMENT, V139, P151, DOI 10.1242/dev.067660
   Bedelbaeva K, 2010, P NATL ACAD SCI USA, V107, P5845, DOI 10.1073/pnas.1000830107
   Bharti K, 2008, DEVELOPMENT, V135, P1169, DOI 10.1242/dev.014142
   Bharti K, 2006, PIGM CELL RES, V19, P380, DOI 10.1111/j.1600-0749.2006.00318.x
   Bharti K, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002757
   Bielen H, 2012, DEV CELL, V23, P812, DOI 10.1016/j.devcel.2012.09.006
   Blankenhorn EP, 2009, MAMM GENOME, V20, P720, DOI 10.1007/s00335-009-9216-3
   BODENSTEIN L, 1987, DEV BIOL, V121, P192, DOI 10.1016/0012-1606(87)90152-7
   Boulton M.E., 2012, AGE RELATED MACULAR, P45
   Bovolenta P, 1997, J NEUROSCI, V17, P4243
   Brown KE, 2010, DEV BIOL, V339, P14, DOI 10.1016/j.ydbio.2009.12.003
   Bumsted KM, 2000, INVEST OPHTH VIS SCI, V41, P903
   Burke JM, 2005, MOL INTERV, V5, P241, DOI 10.1124/mi.5.4.7
   BUSE E, 1991, NEUROSCI LETT, V126, P63, DOI 10.1016/0304-3940(91)90372-Z
   Cai ZG, 2010, J NEUROSCI, V30, P4110, DOI 10.1523/JNEUROSCI.4364-09.2010
   Cavodeassi F, 2005, NEURON, V47, P43, DOI 10.1016/j.neuron.2005.05.026
   Chuang JC, 1999, MECH DEVELOP, V84, P195, DOI 10.1016/S0925-4773(99)00077-5
   COULOMBRE JL, 1965, DEV BIOL, V12, P79, DOI 10.1016/0012-1606(65)90022-9
   Dakubo GD, 2008, DEV BIOL, V320, P242, DOI 10.1016/j.ydbio.2008.05.528
   Danno H, 2008, P NATL ACAD SCI USA, V105, P5408, DOI 10.1073/pnas.0710954105
   Defoe DM, 2007, MOL VIS, V13, P273
   Del Priore LV, 2002, INVEST OPHTH VIS SCI, V43, P3312
   Deschet K, 1999, MECH DEVELOP, V83, P179, DOI 10.1016/S0925-4773(99)00037-4
   England SJ, 2006, DEVELOPMENT, V133, P4613, DOI 10.1242/dev.02678
   Fuhrmann S, 2000, DEVELOPMENT, V127, P4599
   Fuhrmann S, 2010, CURR TOP DEV BIOL, V93, P61, DOI [10.1016/S0070-2153(10)93003-2, 10.1016/B978-0-12-385044-7.00003-5]
   Fuhrmann Sabine, 2008, Organogenesis, V4, P60
   Fujimura N, 2009, DEV BIOL, V334, P31, DOI 10.1016/j.ydbio.2009.07.002
   Galy A, 2002, DEV BIOL, V248, P251, DOI 10.1006/dbio.2002.0736
   GAO H, 1992, INVEST OPHTH VIS SCI, V33, P1
   Georgiadis A, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015730
   Green ES, 2003, DEVELOPMENT, V130, P539, DOI 10.1242/dev.00275
   Grondona JM, 1996, DEVELOPMENT, V122, P2173
   GUILLEMOT F, 1992, DEVELOPMENT, V114, P743
   Harman AM, 1997, INVEST OPHTH VIS SCI, V38, P2016
   Heber-Katz E, 2004, PHILOS T ROY SOC B, V359, P785, DOI 10.1098/rstb.2004.1468
   Hiscott P, 1999, PROG RETIN EYE RES, V18, P167, DOI 10.1016/S1350-9462(98)00024-X
   HODGKINSON CA, 1993, CELL, V74, P395, DOI 10.1016/0092-8674(93)90429-T
   Horsford DJ, 2005, DEVELOPMENT, V132, P177, DOI 10.1242/dev.01571
   Housset M, 2013, J NEUROSCI, V33, P9890, DOI 10.1523/JNEUROSCI.1099-13.2013
   Hu GL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037224
   Huh SO, 1999, DEV BIOL, V211, P53, DOI 10.1006/dbio.1999.9303
   Hyer J, 2003, DEV BIOL, V259, P351, DOI 10.1016/S0012-1606(03)00205-7
   Ikegami Y, 2002, J NEUROBIOL, V50, P209, DOI 10.1002/neu.10031
   Ishii Y, 2009, DEVELOPMENT, V136, P2579, DOI 10.1242/dev.031344
   ITOH Y, 1976, DEV BIOL, V54, P157, DOI 10.1016/0012-1606(76)90295-5
   Kagiyama Y, 2005, DEV GROWTH DIFFER, V47, P523
   Kibardin A, 2006, DEVELOPMENT, V133, P2845, DOI 10.1242/dev.02445
   Kim CH, 2000, NATURE, V407, P913, DOI 10.1038/35038097
   Kim JW, 2008, GENE DEV, V22, P3147, DOI 10.1101/gad.1700108
   KNIGHT JK, 1995, J NEUROBIOL, V27, P447, DOI 10.1002/neu.480270402
   Kokkinopoulos I, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018921
   KONG Y, 1995, CELL MOL BIOL, V41, P171
   KONG Y, 1992, CELL MOL BIOL, V38, P263
   Kozlowski MR, 2012, MED HYPOTHESES, V78, P505, DOI 10.1016/j.mehy.2012.01.018
   Kuriyama F, 2009, DEV NEUROBIOL, V69, P950, DOI 10.1002/dneu.20745
   Kwan KM, 2012, DEVELOPMENT, V139, P359, DOI 10.1242/dev.071407
   Lagutin OV, 2003, GENE DEV, V17, P368, DOI 10.1101/gad.1059403
   Lamba D, 2008, CELL STEM CELL, V2, P538, DOI 10.1016/j.stem.2008.05.002
   Lanning JL, 2005, J INVEST DERMATOL, V125, P805, DOI 10.1111/j.0022-202X.2005.23819.x
   Lee CS, 2001, DEV BIOL, V236, P17, DOI 10.1006/dbio.2001.0280
   Lee HS, 2006, NAT CELL BIOL, V8, P55, DOI 10.1038/ncb1344
   Li HS, 1997, DEVELOPMENT, V124, P603
   Li WB, 2012, INVEST OPHTH VIS SCI, V53, P5334, DOI 10.1167/iovs.12-8303
   Liou GI, 2004, MOL VIS, V10, P383
   LIU ISC, 1994, NEURON, V13, P377, DOI 10.1016/0896-6273(94)90354-9
   Liu W, 2010, J CLIN INVEST, V120, P3568, DOI 10.1172/JCI43219
   Locker M, 2010, ARCH ITAL BIOL, V148, P59
   LOHNES D, 1994, DEVELOPMENT, V120, P2723
   Longbottom R, 2009, P NATL ACAD SCI USA, V106, P18728, DOI 10.1073/pnas.0902593106
   Lopashov GV, 1963, DEV MECH VERTEBRATE
   Ma WX, 2009, STEM CELLS, V27, P1376, DOI 10.1002/stem.48
   MACDONALD R, 1995, DEVELOPMENT, V121, P3267
   Machalinska A, 2013, EXP EYE RES, V112, P68, DOI 10.1016/j.exer.2013.04.004
   Marcus DM, 2000, MOL VIS, V6, P169
   Marcus DM, 1997, ARCH OPHTHALMOL-CHIC, V115, P645, DOI 10.1001/archopht.1997.01100150647013
   Marmorstein AD, 1998, ANN NY ACAD SCI, V857, P1, DOI 10.1111/j.1749-6632.1998.tb10102.x
   Martinez-De Luna RI, 2011, DEV BIOL, V353, P10, DOI 10.1016/j.ydbio.2011.02.008
   Martinez-Morales JR, 2004, BIOESSAYS, V26, P766, DOI 10.1002/bies.20064
   Martinez-Morales JR, 2003, J BIOL CHEM, V278, P21721, DOI 10.1074/jbc.M301708200
   Martinez-Morales JR, 2001, DEVELOPMENT, V128, P2019
   Mathers PH, 1997, NATURE, V387, P603, DOI 10.1038/42475
   Matt N, 2008, DEV BIOL, V320, P140, DOI 10.1016/j.ydbio.2008.04.039
   Maurus D, 2005, EMBO J, V24, P1181, DOI 10.1038/sj.emboj.7600603
   McBrearty BA, 1998, P NATL ACAD SCI USA, V95, P11792, DOI 10.1073/pnas.95.20.11792
   Mitsuda S, 2005, DEV BIOL, V280, P122, DOI 10.1016/j.ydbio.2005.01.009
   Moore KB, 2004, DEV CELL, V6, P55, DOI 10.1016/S1534-5807(03)00395-2
   Mort Richard L, 2012, Results Probl Cell Differ, V55, P357, DOI 10.1007/978-3-642-30406-4_19
   Muller F, 2007, DEVELOPMENT, V134, P3483, DOI 10.1242/dev.02884
   Mui SH, 2005, GENE DEV, V19, P1249, DOI 10.1101/gad.1276605
   Muranishi Y, 2012, DEV GROWTH DIFFER, V54, P341, DOI 10.1111/j.1440-169X.2012.01337.x
   Nabeshima A., 2013, GENESIS
   Nakamura K, 2007, BRAIN RES, V1136, P28, DOI 10.1016/j.brainres.2006.12.032
   Nakayama A, 1998, MECH DEVELOP, V70, P155, DOI 10.1016/S0925-4773(97)00188-3
   Nasonkin IO, 2013, DEVELOPMENT, V140, P1330, DOI 10.1242/dev.086603
   Nelson CM, 2012, ADV EXP MED BIOL, V723, P425, DOI 10.1007/978-1-4614-0631-0_54
   Nguyen MTT, 2000, DEVELOPMENT, V127, P3581
   Nishihara D, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048879
   Ohuchi H, 1999, MECH DEVELOP, V85, P193, DOI 10.1016/S0925-4773(99)00094-5
   Oliver G, 1995, DEVELOPMENT, V121, P4045
   Opas M, 2001, INT J DEV BIOL, V45, P633
   Ou JX, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059247
   Pai VP, 2012, DEVELOPMENT, V139, P313, DOI 10.1242/dev.073759
   Pan Y, 2011, NEUROCHEM RES, V36, P569, DOI 10.1007/s11064-010-0268-2
   PARK CM, 1989, DEV BIOL, V134, P201, DOI 10.1016/0012-1606(89)90089-4
   PARK CM, 1991, DEV BIOL, V148, P322, DOI 10.1016/0012-1606(91)90341-Y
   Pearson RA, 2005, NEURON, V46, P731, DOI 10.1016/j.neuron.2005.04.024
   PITTACK C, 1991, DEVELOPMENT, V113, P577
   Pittack C, 1997, DEVELOPMENT, V124, P805
   Porter FD, 1997, DEVELOPMENT, V124, P2935
   PRITCHARD DJ, 1978, J EMBRYOL EXP MORPH, V48, P1
   Range RC, 2013, PLOS BIOL, V11, DOI 10.1371/journal.pbio.1001467
   Rapaport DH, 1995, J COMP NEUROL, V363, P359, DOI 10.1002/cne.903630303
   Rasmussen JT, 2001, P NATL ACAD SCI USA, V98, P3861, DOI 10.1073/pnas.071586298
   RAYMOND SM, 1995, CURR BIOL, V5, P1286, DOI 10.1016/S0960-9822(95)00255-7
   REH TA, 1987, DEV BIOL, V122, P471, DOI 10.1016/0012-1606(87)90311-3
   REH TA, 1987, NATURE, V330, P68, DOI 10.1038/330068a0
   REH TA, 1995, SEMIN CELL BIOL, V6, P137, DOI 10.1006/scel.1995.0019
   Reh TA, 1998, J NEUROBIOL, V36, P206, DOI 10.1002/(SICI)1097-4695(199808)36:2<206::AID-NEU8>3.0.CO;2-5
   Rizzolo LJ, 2007, INT REV CYTOL, V258, P195, DOI 10.1016/S0074-7696(07)58004-6
   ROBB RM, 1985, INVEST OPHTH VIS SCI, V26, P614
   Rojas-Munoz A, 2005, DEV BIOL, V288, P348, DOI 10.1016/j.ydbio.2005.08.046
   Rowan S, 2004, DEVELOPMENT, V131, P5139, DOI 10.1242/dev.01300
   Sakaguchi DS, 1997, DEV DYNAM, V209, P387, DOI 10.1002/(SICI)1097-0177(199708)209:4<387::AID-AJA6>3.0.CO;2-E
   Sakami S, 2008, MECH DEVELOP, V125, P106, DOI 10.1016/j.mod.2007.10.001
   Salero E, 2012, CELL STEM CELL, V10, P88, DOI 10.1016/j.stem.2011.11.018
   SCHOLTZ CL, 1987, DEVELOPMENT, V99, P501
   Schouwey K, 2011, ONCOGENE, V30, P313, DOI 10.1038/onc.2010.428
   Sigulinsky CL, 2008, DEV BIOL, V317, P560, DOI 10.1016/j.ydbio.2008.02.055
   Spence JR, 2007, MOL VIS, V13, P57
   Spence JR, 2004, DEVELOPMENT, V131, P4607, DOI 10.1242/dev.01298
   Stenkamp DL, 2000, DEV BIOL, V220, P238, DOI 10.1006/dbio.2000.9629
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   STROEVA OG, 1960, J EMBRYOL EXP MORPH, V8, P349
   STROEVA OG, 1983, INT REV CYTOL, V83, P221, DOI 10.1016/S0074-7696(08)61689-7
   STROEVA OG, 1983, J EMBRYOL EXP MORPH, V75, P271
   SVOBODA KKH, 1987, DEVELOPMENT, V100, P185
   Swaroop A, 2009, ANNU REV GENOM HUM G, V10, P19, DOI 10.1146/annurev.genom.9.081307.164350
   Tang K, 2010, DEVELOPMENT, V137, P725, DOI 10.1242/dev.040568
   Teraoka ME, 2009, DEV BIOL, V330, P389, DOI 10.1016/j.ydbio.2009.04.008
   Tetreault N, 2009, DEV BIOL, V327, P541, DOI 10.1016/j.ydbio.2008.12.022
   Tibber MS, 2007, J COMP NEUROL, V503, P128, DOI 10.1002/cne.21388
   Toy J, 1998, P NATL ACAD SCI USA, V95, P10643, DOI 10.1073/pnas.95.18.10643
   TSO MOM, 1968, ARCH OPHTHALMOL-CHIC, V80, P214, DOI 10.1001/archopht.1968.00980050216012
   Umazume K, 2012, INVEST OPHTH VIS SCI, V53, P4910, DOI 10.1167/iovs.12-9768
   Visvader JE, 2011, COLD SPRING HARBOR P, V3
   Vogel-Hopker A, 2000, MECH DEVELOP, V94, P25, DOI 10.1016/S0925-4773(00)00320-8
   von Leithner PL, 2010, MOL VIS, V16, P570
   Voronina VA, 2004, HUM MOL GENET, V13, P315, DOI 10.1093/hmg/ddh025
   Wang FE, 2010, FASEB J, V24, P1552, DOI 10.1096/fj.08-125856
   Wang SZ, 2010, EXPERT OPIN BIOL TH, V10, P1227, DOI 10.1517/14712598.2010.495218
   Westenskow P, 2009, DEVELOPMENT, V136, P2505, DOI 10.1242/dev.032136
   Westenskow PD, 2010, INVEST OPHTH VIS SCI, V51, P5328, DOI 10.1167/iovs.09-5015
   Wilson SW, 2004, DEV CELL, V6, P167, DOI 10.1016/S1534-5807(04)00027-9
   Xia HM, 2011, EXP EYE RES, V93, P862, DOI 10.1016/j.exer.2011.09.020
   Yoshida K, 2004, ANAT EMBRYOL, V208, P145, DOI 10.1007/s00429-004-0382-5
   Yoshii C, 2007, DEV BIOL, V303, P45, DOI 10.1016/j.ydbio.2006.11.024
   Yun S, 2009, DEVELOPMENT, V136, P3895, DOI 10.1242/dev.041202
   Zhang XM, 2001, DEV BIOL, V233, P271, DOI 10.1006/dbio.2000.0195
   Zhao C, 2011, J CLIN INVEST, V121, P369, DOI 10.1172/JCI44303
   ZHAO SL, 1995, BRAIN RES, V677, P300, DOI 10.1016/0006-8993(95)00163-K
   Zhao SL, 1997, INT REV CYTOL, V171, P225
   Zou CJ, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002924
   Zuber ME, 2003, DEVELOPMENT, V130, P5155, DOI 10.1242/dev.00723
NR 181
TC 147
Z9 154
U1 0
U2 41
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0014-4835
EI 1096-0007
J9 EXP EYE RES
JI Exp. Eye Res.
PD JUN
PY 2014
VL 123
SI SI
BP 141
EP 150
DI 10.1016/j.exer.2013.09.003
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AJ0HY
UT WOS:000337332800016
PM 24060344
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Matsumoto, H
   Miller, JW
   Vavvas, DG
AF Matsumoto, Hidetaka
   Miller, Joan W.
   Vavvas, Demetrios G.
TI Retinal Detachment Model in Rodents by Subretinal Injection of Sodium
   Hyaluronate
SO JOVE-JOURNAL OF VISUALIZED EXPERIMENTS
LA English
DT Article
DE Medicine; Issue 79; Photoreceptor Cells; Rodentia; Retinal Degeneration;
   Retinal Detachment; animal models; Neuroscience; ophthalmology; retina;
   mouse; photoreceptor cell death; retinopathy; age-related macular
   degeneration (AMD)
AB Subretinal injection of sodium hyaluronate is a widely accepted method of inducing retinal detachment (RD). However, the height and duration of RD or the occurrence of subretinal hemorrhage can affect photoreceptor cell death in the detached retina. Hence, it is advantageous to create reproducible RDs without subretinal hemorrhage for evaluating photoreceptor cell death. We modified a previously reported method to create bullous and persistent RDs in a reproducible location with rare occurrence of subretinal hemorrhage. The critical step of this modified method is the creation of a self-sealing scleral incision, which can prevent leakage of sodium hyaluronate after injection into the subretinal space. To make the self-sealing scleral incision, a scleral tunnel is created, followed by scleral penetration into the choroid with a 30 G needle. Although choroidal hemorrhage may occur during this step, astriction with a surgical spear reduces the rate of choroidal hemorrhage. This method allows a more reproducible and reliable model of photoreceptor death in diseases that involve RD such as rhegmatogenous RD, retinopathy of prematurity, diabetic retinopathy, central serous chorioretinopathy, and age-related macular degeneration (AMD).
C1 [Matsumoto, Hidetaka; Miller, Joan W.; Vavvas, Demetrios G.] Harvard Univ, Sch Med, Massachusetts Eye & Ear Infirm, Retina Serv,Angiogenesis Lab,Dept Ophthalmol, Cambridge, MA 02138 USA.
C3 Harvard University; Massachusetts Eye & Ear Infirmary
RP Matsumoto, H (通讯作者)，Harvard Univ, Sch Med, Massachusetts Eye & Ear Infirm, Retina Serv,Angiogenesis Lab,Dept Ophthalmol, Cambridge, MA 02138 USA.
EM hide-m@gunma-u.ac.jp; Demetrios_Vavvas@meei.harvard.edu
FU Bausch & Lomb Vitreoretinal Fellowship; National Eye Institute
   [EY014104]; Research to Prevent Blindness Foundation; Lions Eye Research
   Fund; NATIONAL EYE INSTITUTE [P30EY014104] Funding Source: NIH RePORTER
FX We thank Wendy Chao for her support in critical review. This work was
   supported by Bausch & Lomb Vitreoretinal Fellowship (HM), National Eye
   Institute grant EY014104 (JWM), Research to Prevent Blindness Foundation
   (DGV), Lions Eye Research Fund (DGV), and a generous donation of the
   Yeatts family (JWM and DGV).
CR ANDERSON DH, 1986, INVEST OPHTH VIS SCI, V27, P168
   BENNER JD, 1994, OPHTHALMOLOGY, V101, P672
   Bhisitkul RB, 2008, INVEST OPHTH VIS SCI, V49, P4071, DOI 10.1167/iovs.08-1892
   Cebulla CM, 2010, EXP EYE RES, V90, P521, DOI 10.1016/j.exer.2010.01.008
   COOK B, 1995, INVEST OPHTH VIS SCI, V36, P990
   GLATT H, 1982, AM J OPHTHALMOL, V94, P762, DOI 10.1016/0002-9394(82)90301-4
   Hisatomi T, 2002, CURR EYE RES, V24, P161, DOI 10.1076/ceyr.24.3.161.8305
   Hisatomi T, 2001, AM J PATHOL, V158, P1271, DOI 10.1016/S0002-9440(10)64078-3
   Kong FS, 2010, EXP EYE RES, V90, P546, DOI 10.1016/j.exer.2010.01.011
   Leon S, 2000, J NEUROSCI, V20, P4615, DOI 10.1523/JNEUROSCI.20-12-04615.2000
   MACHEMER R, 1968, AM J OPHTHALMOL, V66, P1075, DOI 10.1016/0002-9394(68)90816-7
   Mantopoulos D, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024245
   Murakami Y, 2010, HUM GENE THER, V21, P199, DOI 10.1089/hum.2009.102
   Nakazawa T, 2007, P NATL ACAD SCI USA, V104, P2425, DOI 10.1073/pnas.0608167104
   Nakazawa T, 2006, MOL VIS, V12, P867
   Nakazawa T, 2011, INVEST OPHTH VIS SCI, V52, P1384, DOI 10.1167/iovs.10-6509
   Roh MI, 2011, INVEST OPHTH VIS SCI, V52, P3825, DOI 10.1167/iovs.10-6797
   Ross W, 2005, OPHTHALMOLOGY, V112, P1213, DOI 10.1016/j.ophtha.2005.01.040
   Secondi R, 2012, INVEST OPHTH VIS SCI, V53, P5190, DOI 10.1167/iovs.12-9672
   TOTH CA, 1991, ARCH OPHTHALMOL-CHIC, V109, P723, DOI 10.1001/archopht.1991.01080050139046
   Trichonas G, 2010, P NATL ACAD SCI USA, V107, P21695, DOI 10.1073/pnas.1009179107
   Yang L, 2004, INVEST OPHTH VIS SCI, V45, P648, DOI 10.1167/iovs.03-0827
   Zacks DN, 2006, INVEST OPHTH VIS SCI, V47, P1691, DOI 10.1167/iovs.05-1209
   Zacks DN, 2003, INVEST OPHTH VIS SCI, V44, P1262, DOI 10.1167/iovs.02-0492
   Zeng R, 2012, INVEST OPHTH VIS SCI, V53, P1685, DOI 10.1167/iovs.11-8241
NR 25
TC 20
Z9 21
U1 0
U2 2
PU JOURNAL OF VISUALIZED EXPERIMENTS
PI CAMBRIDGE
PA 1 ALEWIFE CENTER, STE 200, CAMBRIDGE, MA 02140 USA
SN 1940-087X
J9 JOVE-J VIS EXP
JI J. Vis. Exp.
PD SEP
PY 2013
IS 79
AR e50660
DI 10.3791/50660
PG 5
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA V36RI
UT WOS:000209228100038
OA Green Published, Bronze
DA 2022-11-30
ER

PT J
AU Kim, JH
   Lee, BJ
   Kim, JH
   Yu, YS
   Kim, KW
AF Kim, Jeong Hun
   Lee, Byung Joo
   Kim, Jin Hyoung
   Yu, Young Suk
   Kim, Kyu-Won
TI Anti-angiogenic effect of caffeic acid on retinal neovascularization
SO VASCULAR PHARMACOLOGY
LA English
DT Article
DE Anti-angiogenic; Anti-oxidant; Caffeic acid; Retinal neovascularization;
   Reactive oxygen species; Vascular endothelial growth factor
ID OXYGEN-INDUCED RETINOPATHY; ENDOTHELIAL GROWTH-FACTOR; PREMATURITY;
   EXPRESSION; DEGUELIN; CELLS
AB Pathological angiogenesis is the most common cause of vision loss at all ages including retinopathy of prematurity (ROP). diabetic retinopathy. and age-related macular degeneration. ROP is a proliferative disease of the retinal vasculature in premature infants. Herein, we demonstrated caffeic acid (CA) has the anti-angiogenic activity to retinal endothelial cells and retinal neovascularization in a mouse model of ROP. which might be related to the suppression of ROS-induced VEGF expression. CA effectively inhibited VEGF-induced proliferation of retinal endothelial cells in concentration-dependent manner. In addition, VEGF-induced migration and tube formation of retinal endothelial cells were completely inhibited This anti-angiogenic activity of CA on retinal endothelial cells was related to the anti-oxidant activity the inhibitory activity of CA to H2O2-induced reactive oxygen species production and VEGF expression. Interestingly, CA significantly suppressed retinal neovascularization in oxygen-induced retinopathy as the animal model of ROP without retinal cytotoxicity These data suggests that CA could be a potent anti-angiogenic agent for retinal neovascularization, and be applied in the treatment of other vaso-proliferative retinopathies Published by Elsevier Inc.
C1 [Kim, Jeong Hun; Lee, Byung Joo; Kim, Jin Hyoung; Yu, Young Suk] Seoul Natl Univ, Coll Med, Dept Ophthalmol, Seoul 110744, South Korea.
   [Kim, Jeong Hun; Lee, Byung Joo; Kim, Jin Hyoung; Yu, Young Suk] Seoul Natl Univ Hosp, Seoul Artificial Eye Ctr Clin Res Inst, Seoul 110744, South Korea.
   [Kim, Kyu-Won] Seoul Natl Univ, NeuroVasc Coordinat Res Ctr, Coll Pharm, Seoul 151742, South Korea.
   [Kim, Kyu-Won] Seoul Natl Univ, NeuroVasc Coordinat Res Ctr, Res Inst Pharmaceut Sci, Seoul 151742, South Korea.
C3 Seoul National University (SNU); Seoul National University (SNU); Seoul
   National University Hospital; Seoul National University (SNU); Seoul
   National University (SNU)
RP Yu, YS (通讯作者)，Seoul Natl Univ, Coll Med, Dept Ophthalmol, Seoul 110744, South Korea.
RI Kim, Kyu Won/AAJ-7213-2020; Kim, Jeong Hun/J-2748-2012; Yu, Young
   Suk/J-5551-2012
OI Kim, Jeong Hun/0000-0003-2957-1766
FU Ministry of Science and Technology (MOST) [M1064501001-06n4501-00110];
   Korea Science and Engineering Foundation (KOSEF)
FX Thanks to Mr. Chang Sik Cho and Sung Jin Cho for the technical
   assistance of animal experiments. This study was supported by the
   Bio-signal Analysis Technology Innovation Program
   (M1064501001-06n4501-00110) of the Ministry of Science and Technology
   (MOST) and Korea Science and Engineering Foundation (KOSEF).
CR Abran D, 1997, AM J PHYSIOL-REG I, V272, pR995, DOI 10.1152/ajpregu.1997.272.3.R995
   AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203
   Banskota AH, 2001, PHYTOTHER RES, V15, P561, DOI 10.1002/ptr.1029
   Buhimschi IA, 2003, AM J OBSTET GYNECOL, V189, P181, DOI 10.1067/mob.2003.357
   Chen Jing, 2007, Angiogenesis, V10, P133, DOI 10.1007/s10456-007-9066-0
   Folkman J, 2006, ANNU REV MED, V57, P1, DOI 10.1146/annurev.med.57.121304.131306
   Gariano RF, 2005, NATURE, V438, P960, DOI 10.1038/nature04482
   GIBSON DL, 1990, PEDIATRICS, V86, P405
   Jun HO, 2007, FEBS LETT, V581, P4977, DOI 10.1016/j.febslet.2007.09.034
   Jung JE, 2007, CARCINOGENESIS, V28, P1780, DOI 10.1093/carcin/bgm130
   Kim JH, 2008, J CELL MOL MED, V12, P2407, DOI 10.1111/j.1582-4934.2008.00243.x
   Kim JH, 2008, J PHARMACOL EXP THER, V324, P643, DOI 10.1124/jpet.107.132720
   Kim JH, 2007, BIOCHEM BIOPH RES CO, V362, P848, DOI 10.1016/j.bbrc.2007.08.100
   Kim JH, 2008, BIOPHYS J, V94, P4095, DOI 10.1529/biophysj.107.119800
   Lelkes PI, 1998, ADV EXP MED BIOL, V454, P295
   Min JK, 2007, BLOOD, V109, P1495, DOI 10.1182/blood-2006-06-029298
   ROTH AM, 1977, AM J OPHTHALMOL, V84, P636, DOI 10.1016/0002-9394(77)90377-4
   Ruef J, 1997, CIRC RES, V81, P24, DOI 10.1161/01.RES.81.1.24
   Shono T, 1996, MOL CELL BIOL, V16, P4231
   Siquet C, 2006, FREE RADICAL RES, V40, P433, DOI 10.1080/10715760500540442
   SMITH LEH, 1994, INVEST OPHTH VIS SCI, V35, P101
   SONDHEIMER E, 1958, ARCH BIOCHEM BIOPHYS, V74, P131, DOI 10.1016/0003-9861(58)90207-8
NR 22
TC 31
Z9 34
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1537-1891
EI 1879-3649
J9 VASC PHARMACOL
JI Vasc. Pharmacol.
PD OCT
PY 2009
VL 51
IS 4
BP 262
EP 267
DI 10.1016/j.vph.2009.06.010
PG 6
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA 512WY
UT WOS:000271283700006
PM 19589397
DA 2022-11-30
ER

PT J
AU Lee, PY
   Kim, KS
   Lee, WK
AF Lee, Phil Young
   Kim, Ki Seok
   Lee, Won Ki
TI Severe choroidal ischemia following Photodynamic Therapy for pigment
   epithelial detachment and chronic central serous chorioretinopathy
SO JAPANESE JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE central serous chorioretinopathy; choroidal ischemia; choroidal
   neovascularization; photodynamic therapy; pigment epithelial detachment
AB Photodynamic therapy (PDT) has proven beneficial in the treatment of central serous chorioretinopathy (CSC).
   Two patients with serous pigment epithelial detachments (PEDs) and one patient with chronic CSC developed an abrupt visual loss caused by severe choroidal ischemia following PDT. Serous PEDs in the two patients were regarded as a latent variant of CSC. PDT was performed in accordance with the Treatment of Age-Related Macular Degeneration with Photodynamic Therapy guidelines.
   Although following PDT, PEDs and serous sensory retinal detachments resolved in all patients, the laser-treated areas of the patients revealed severe choroidal ischemia and their visual acuity decreased. Only in case 1 did visual acuity recover to the pretreatment level 2 months after treatment. In case 2, visual acuity was still reduced 7 months after treatment. In case 3, secondary choroidal neovascularization developed in the treatment area 1 month after treatment.
   In the CSC variant associated with PED only or in chronic CSC, PDT performed by the standard procedure can increase the risk of severe choroidal ischemia. Further studies are needed to find safe and optimal PDT parameters.
C1 [Lee, Won Ki] Catholic Univ, Coll Med, Kangnam St Marys Hosp, Dept Ophthalmol & Visual Sci, Seoul 137701, South Korea.
   [Kim, Ki Seok] Saevit Eye Hosp, Seoul, South Korea.
   [Lee, Phil Young] Seoul Vet Hosp, Seoul, South Korea.
C3 Catholic University of Korea; Catholic University Korea Hospital; Seoul
   Veterans Hospital
RP Lee, WK (通讯作者)，Catholic Univ, Coll Med, Kangnam St Marys Hosp, Dept Ophthalmol & Visual Sci, 505 Banpo Dong, Seoul 137701, South Korea.
EM wklee@catholic.ac.kr
CR Giovannini A, 1997, RETINA-J RET VIT DIS, V17, P286, DOI 10.1097/00006982-199707000-00002
   Iida T, 1999, RETINA-J RET VIT DIS, V19, P508, DOI 10.1097/00006982-199911000-00005
   Lai TYY, 2006, BRIT J OPHTHALMOL, V90, P869, DOI 10.1136/bjo.2006.090282
   Piccolino FC, 2003, RETINA-J RET VIT DIS, V23, P752, DOI 10.1097/00006982-200312000-00002
   Yannuzzi LA, 2003, RETINA-J RET VIT DIS, V23, P288, DOI 10.1097/00006982-200306000-00002
NR 5
TC 70
Z9 77
U1 0
U2 1
PU SPRINGER JAPAN KK
PI TOKYO
PA CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065,
   JAPAN
SN 0021-5155
EI 1613-2246
J9 JPN J OPHTHALMOL
JI Jpn. J. Ophthalmol.
PD JAN
PY 2009
VL 53
IS 1
BP 52
EP 56
DI 10.1007/s10384-008-0613-z
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 402AL
UT WOS:000262986500011
PM 19184311
DA 2022-11-30
ER

PT J
AU Auricchio, A
   Rolling, F
AF Auricchio, A
   Rolling, F
TI Adeno-associated viral vectors for retinal gene transfer and treatment
   of retinal diseases
SO CURRENT GENE THERAPY
LA English
DT Review
DE retina; gene transfer; rAAV; retinal degeneration; retinitis pigmentosa;
   neovascular diseases
ID EPITHELIUM-DERIVED FACTOR; CILIARY NEUROTROPHIC FACTOR; AAV-MEDIATED
   DELIVERY; TRANSGENIC RAT MODEL; RETINITIS-PIGMENTOSA; LONG-TERM;
   OPTIC-NERVE; ANIMAL-MODELS; PHOTORECEPTOR DEGENERATION; LYSOSOMAL
   STORAGE
AB Retinal gene transfer holds big promises for the treatment of inherited and non-inherited blinding diseases, such as retinitis pigmentosa or age-related macular degeneration. Key to the development of successful gene-based therapies for the eye are efficient tools for retinal gene transfer. Vectors based on adeno-associated viruses (AAV) are able to transduce robustly and persistently different retinal cell types of animal models after a single intraocular administration. Recombinant AAV (rAAV) vectors are versatile gene transfer tools in that capsid proteins from dozens of AAV serotypes can be easily interchanged, resulting in the creation of recombinant vectors with unique transduction proper-ties. This has allowed successful proof-of-principle studies using rAAV-inediated gene transfer to restore retinal morphology and function in small and large animal models of retinal diseases. In addition, gene delivery using rAAV vectors in the eye seems to have appropriate biosafety characteristics to rapidly move it from bench to bedside. All the above aspects will be reviewed and discussed in detail below.
C1 CHU Hotel Dieu, INSERM, Lab Therapie Gen, U649, F-44035 Nantes, France.
   Telethon Inst Genet & Med, I-80131 Naples, Italy.
C3 Institut National de la Sante et de la Recherche Medicale (Inserm);
   Nantes Universite; CHU de Nantes; Fondazione Telethon; Telethon
   Institute of Genetics & Medicine (TIGEM)
RP Rolling, F (通讯作者)，CHU Hotel Dieu, INSERM, Lab Therapie Gen, U649, Bat J Monnet,30 Ave J Monnet, F-44035 Nantes, France.
EM fabienne.rolling@univ-nantes.fr
RI AURICCHIO, Alberto/AHE-7979-2022
OI AURICCHIO, Alberto/0000-0002-0832-2472
FU Telethon [TGM06C03, 371/B, TGM06S01] Funding Source: Medline
CR Acland GM, 2001, NAT GENET, V28, P92, DOI 10.1038/ng0501-92
   Ali RR, 1998, HUM GENE THER, V9, P81, DOI 10.1089/hum.1998.9.1-81
   Ali RR, 1996, HUM MOL GENET, V5, P591, DOI 10.1093/hmg/5.5.591
   Ali RR, 2000, NAT GENET, V25, P306, DOI 10.1038/77068
   Auricchio A, 2002, MOL THER, V6, P490, DOI 10.1006/mthe.2002.0702
   Auricchio A, 2001, HUM MOL GENET, V10, P3075, DOI 10.1093/hmg/10.26.3075
   Bainbridge JWB, 2003, GENE THER, V10, P1336, DOI 10.1038/sj.gt.3301990
   Bainbridge JWB, 2002, GENE THER, V9, P320, DOI 10.1038/sj.gt.3301680
   Behling KC, 2002, MOL VIS, V8, P449
   Bennett J, 1999, P NATL ACAD SCI USA, V96, P9920, DOI 10.1073/pnas.96.17.9920
   Bohl D, 2000, BLOOD, V95, P2793, DOI 10.1182/blood.V95.9.2793.009k07_2793_2798
   Bok D, 2002, EXP EYE RES, V74, P719, DOI 10.1006/exer.2002.1176
   Borras T, 2003, PROG RETIN EYE RES, V22, P435, DOI 10.1016/S1350-9462(03)00018-1
   Bosch A, 2000, MOL THER, V1, P63, DOI 10.1006/mthe.1999.0005
   Breaker RR, 2004, NATURE, V432, P838, DOI 10.1038/nature03195
   Cao W, 2001, INVEST OPHTH VIS SCI, V42, P1646
   Chader GJ, 2001, P NATL ACAD SCI USA, V98, P2122, DOI 10.1073/pnas.061024098
   CHANG GQ, 1993, NEURON, V11, P595, DOI 10.1016/0896-6273(93)90072-Y
   Chaum E, 2003, J CELL BIOCHEM, V88, P57, DOI 10.1002/jcb.10354
   Chiorini JA, 1997, J VIROL, V71, P6823, DOI 10.1128/JVI.71.9.6823-6833.1997
   Chiorini JA, 1999, J VIROL, V73, P1309, DOI 10.1128/JVI.73.2.1309-1319.1999
   Citti L, 2005, CURR GENE THER, V5, P11
   Ciulla TA, 1998, SURV OPHTHALMOL, V43, P134, DOI 10.1016/S0039-6257(98)00014-9
   Conrad CK, 1996, GENE THER, V3, P658
   Daly TM, 1999, P NATL ACAD SCI USA, V96, P2296, DOI 10.1073/pnas.96.5.2296
   Dawson DW, 1999, SCIENCE, V285, P245, DOI 10.1126/science.285.5425.245
   Dejneka NS, 2004, MOL THER, V9, P182, DOI 10.1016/j.ymthe.2003.11.013
   Dudus L, 1999, VISION RES, V39, P2545, DOI 10.1016/S0042-6989(98)00308-3
   Elliger SS, 1999, GENE THER, V6, P1175, DOI 10.1038/sj.gt.3300931
   Favre D, 2001, MOL THER, V4, P559, DOI 10.1006/mthe.2001.0494
   Folliot S, 2003, J GENE MED, V5, P493, DOI 10.1002/jgm.367
   Gal A, 2000, NAT GENET, V26, P270, DOI 10.1038/81555
   Gao GP, 2002, MOL THER, V5, P644, DOI 10.1006/mthe.2001.0591
   Green ES, 2001, MOL THER, V3, P507, DOI 10.1006/mthe.2001.0289
   Grimm C, 2002, NAT MED, V8, P718, DOI 10.1038/nm723
   Guy J, 1999, ARCH OPHTHALMOL-CHIC, V117, P929
   Hafezi F, 2000, BRIT J OPHTHALMOL, V84, P922, DOI 10.1136/bjo.84.8.922
   Hennig AK, 2003, J NEUROSCI, V23, P3302
   Jung SC, 2001, P NATL ACAD SCI USA, V98, P2676, DOI 10.1073/pnas.051634498
   Krzystolik MG, 2002, ARCH OPHTHALMOL-CHIC, V120, P338
   Lai YKY, 2002, GENE THER, V9, P804, DOI 10.1038/sj.gt.3301695
   Lau D, 2000, INVEST OPHTH VIS SCI, V41, P3622
   LaVail MM, 1998, INVEST OPHTH VIS SCI, V39, P592
   Lee D, 2003, ADV EXP MED BIOL, V533, P297
   LEMEUR G, ARCH OPHTHALMOL, V123, P500
   Lewin AS, 1998, NAT MED, V4, P967, DOI 10.1038/nm0898-967
   Liang FQ, 2001, MOL THER, V3, P241, DOI 10.1006/mthe.2000.0252
   Liang FQ, 2001, MOL THER, V4, P461, DOI 10.1006/mthe.2001.0473
   Lorenz B, 2000, INVEST OPHTH VIS SCI, V41, P2735
   Martin KRG, 2003, INVEST OPHTH VIS SCI, V44, P4357, DOI 10.1167/iovs.02-1332
   McKinnon SJ, 2002, MOL THER, V5, P780, DOI 10.1006/mthe.2002.0608
   Monahan PE, 2000, GENE THER, V7, P24, DOI 10.1038/sj.gt.3301109
   Mori K, 2002, INVEST OPHTH VIS SCI, V43, P1994
   Muramatsu S, 1996, VIROLOGY, V221, P208, DOI 10.1006/viro.1996.0367
   Narfstrom K, 2003, INVEST OPHTH VIS SCI, V44, P1663, DOI 10.1167/iovs.02-0595
   O'Reilly M S, 1997, EXS, V79, P273
   OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3
   Phelan JK, 2000, MOL VIS, V6, P116
   Provost N, 2005, MOL THER, V11, P275, DOI 10.1016/j.ymthe.2004.09.022
   Rabinowitz JE, 2002, J VIROL, V76, P791, DOI 10.1128/JVI.76.2.791-801.2002
   Raisler BJ, 2002, P NATL ACAD SCI USA, V99, P8909, DOI 10.1073/pnas.122247299
   Rasmussen H, 2001, Hum Gene Ther, V12, P2029
   Reich S, 2003, MOL VIS, V9, P210
   Rex TS, 2004, MOL THER, V10, P855, DOI 10.1016/j.ymthe.2004.07.027
   Rutledge EA, 1998, J VIROL, V72, P309, DOI 10.1128/JVI.72.1.309-319.1998
   Sanftner LHM, 2001, MOL THER, V4, P622, DOI 10.1006/mthe.2001.0498
   Sapieha PS, 2003, MOL CELL NEUROSCI, V24, P656, DOI 10.1016/S1044-7431(03)00228-8
   Sarra GM, 2001, HUM MOL GENET, V10, P2353, DOI 10.1093/hmg/10.21.2353
   Schlichtenbrede FC, 2004, MOL CELL NEUROSCI, V25, P103, DOI 10.1016/j.mcn.2003.09.020
   Schlichtenbrede FC, 2003, J GENE MED, V5, P757, DOI 10.1002/jgm.401
   Schlichtenbrede FC, 2003, GENE THER, V10, P523, DOI 10.1038/sj.gt.3301929
   Smith AJ, 2003, MOL THER, V8, P188, DOI 10.1016/S1525-0016(03)00144-8
   Snyder RO, 1999, J GENE MED, V1, P166
   Snyder RO, 1999, NAT MED, V5, P64, DOI 10.1038/4751
   Stellmach V, 2001, P NATL ACAD SCI USA, V98, P2593, DOI 10.1073/pnas.031252398
   Tao W, 2002, INVEST OPHTH VIS SCI, V43, P3292
   Thompson DA, 2003, PROG RETIN EYE RES, V22, P683, DOI 10.1016/S1350-9462(03)00051-X
   Thompson DA, 2000, INVEST OPHTH VIS SCI, V41, P4293
   Vollrath D, 2001, P NATL ACAD SCI USA, V98, P12584, DOI 10.1073/pnas.221364198
   Wang B, 2000, P NATL ACAD SCI USA, V97, P13714, DOI 10.1073/pnas.240335297
   Weber M, 2003, MOL THER, V7, P774, DOI 10.1016/S1525-0016(03)00098-4
   Witmer AN, 2002, INVEST OPHTH VIS SCI, V43, P849
   Xia HB, 2004, NAT MED, V10, P816, DOI 10.1038/nm1076
   Xiao WD, 1999, J VIROL, V73, P3994, DOI 10.1128/JVI.73.5.3994-4003.1999
   Xiao X, 2000, J VIROL, V74, P1436, DOI 10.1128/JVI.74.3.1436-1442.2000
   Yang HY, 2002, ACTA GEOL SIN-ENGL, V76, P1
   Zeng Y, 2004, INVEST OPHTH VIS SCI, V45, P3279, DOI 10.1167/iovs.04-0576
NR 87
TC 40
Z9 47
U1 1
U2 6
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1566-5232
EI 1875-5631
J9 CURR GENE THER
JI Curr. Gene Ther.
PD JUN
PY 2005
VL 5
IS 3
BP 339
EP 348
DI 10.2174/1566523054065020
PG 10
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA 939VI
UT WOS:000230100200009
PM 15975011
DA 2022-11-30
ER

PT J
AU Nakata, K
   Crabb, JW
   Hollyfield, JG
AF Nakata, K
   Crabb, JW
   Hollyfield, JG
TI Crystallin distribution in Bruch's membrane-choroid complex from AMD and
   age-matched donor eyes
SO EXPERIMENTAL EYE RESEARCH
LA English
DT Article
DE crystallins; drusen; Bruch's membrane; choroid; age-related macular
   degeneration
ID ALPHA-A-CRYSTALLIN; MACULAR DEGENERATION; B-CRYSTALLIN; DRUSEN;
   MACULOPATHY; EXPRESSION; PROTEINS
AB Crystallins were consistently found in a recent proteomic analysis of drusen from age-related macular degeneration (AMD) donor eyes. Here we compare the distribution of several crystallins in drusen, Bruch's membrane and choroid from AMD and non-AMD age-matched control eyes. Immunohistochernistry and Western blots of tissue samples were performed using antibodies to alpha A- and alpha B-crystallins. Bruch's membrane, drusen and the subjacent choroidal connective tissue from AMD tissues showed greater immunoreactivity for alpha A- and alpha B-crystallins than were observed in normal age-matched control tissues. Western blots also demonstrated more intense alpha A- and alpha B-crystallin signals from AMD tissues than were present in age-matched controls. These data indicate that alpha A- and alpha B-crystallins accumulate in Bruch's membrane and choroidal connective tissues to a greater degree in AMD than in normal aging. These findings suggest that the accumulation of these small heat shock proteins at this critical interface below the RPE reflects a disease-related stress response manifested during the progression of AMD. (c) 2005 Elsevier Ltd. All rights reserved.
C1 Cleveland Clin Fdn, Cole Eye Inst, Dept Ophthalm Res, Cleveland, OH 44195 USA.
C3 Cleveland Clinic Foundation
RP Hollyfield, JG (通讯作者)，Cleveland Clin Fdn, Cole Eye Inst, Dept Ophthalm Res, 9500 Euclid Ave,i-31, Cleveland, OH 44195 USA.
EM hollyj@ccf.org
FU NATIONAL EYE INSTITUTE [R01EY014239, R56EY014240, R24EY015638,
   R01EY014240] Funding Source: NIH RePORTER; NEI NIH HHS [EY 014240, EY
   015638, EY 014239] Funding Source: Medline
CR Abdelsalam A, 1999, SURV OPHTHALMOL, V44, P1, DOI 10.1016/S0039-6257(99)00072-7
   Andley UP, 2000, J BIOL CHEM, V275, P36823, DOI 10.1074/jbc.M004233200
   BLOEMENDAL H, 1991, PROG NUCLEIC ACID RE, V41, P259
   Boyle DL, 1996, CURR EYE RES, V15, P577, DOI 10.3109/02713689609000769
   BRESSLER NM, 1994, RETINA-J RET VIT DIS, V14, P130, DOI 10.1097/00006982-199414020-00006
   CHIESA R, 1987, J BIOL CHEM, V262, P1438
   Cobb BA, 2002, BIOCHEMISTRY-US, V41, P483, DOI 10.1021/bi0112457
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   de Jong WW, 1998, INT J BIOL MACROMOL, V22, P151, DOI 10.1016/S0141-8130(98)00013-0
   EAGLE RC, 1984, OPHTHALMOLOGY, V91, P613
   FITZGERALD PG, 1991, CURR EYE RES, V10, P417, DOI 10.3109/02713689109001750
   HOLLYFIELD JG, 2004, ARVO ABSTR, P2289
   Horwitz J, 2003, EXP EYE RES, V76, P145, DOI 10.1016/S0014-4835(02)00278-6
   Kamradt MC, 2001, J BIOL CHEM, V276, P16059, DOI 10.1074/jbc.C100107200
   Kapphahn RJ, 2003, BIOCHEMISTRY-US, V42, P15310, DOI 10.1021/bi034774e
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   Midena E, 1997, INVEST OPHTH VIS SCI, V38, P469
   Nagaraj RH, 2003, BIOCHEMISTRY-US, V42, P10746, DOI 10.1021/bi034541n
   Olsen TW, 2004, INVEST OPHTH VIS SCI, V45, P4484, DOI 10.1167/iovs.04-0342
   Sakaguchi H, 2003, EXP EYE RES, V76, P131, DOI 10.1016/S0014-4835(02)00249-X
   SARKS S, 1994, RETINA, P1071
   Spraul CW, 1997, ARCH OPHTHALMOL-CHIC, V115, P267, DOI 10.1001/archopht.1997.01100150269022
   VANDERSCHAFT TL, 1992, OPHTHALMOLOGY, V99, P278
   WISTOW GJ, 1988, ANNU REV BIOCHEM, V57, P479, DOI 10.1146/annurev.bi.57.070188.002403
   YANOFF M, 1992, OCULAR PATHOLOGY COL
NR 25
TC 70
Z9 74
U1 2
U2 4
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0014-4835
EI 1096-0007
J9 EXP EYE RES
JI Exp. Eye Res.
PD JUN
PY 2005
VL 80
IS 6
BP 821
EP 826
DI 10.1016/j.exer.2004.12.011
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 940RM
UT WOS:000230161700009
PM 15939038
DA 2022-11-30
ER

PT J
AU Parodi, MB
   Iacono, P
AF Parodi, MB
   Iacono, P
TI Photodynamic therapy with verteporfin for anterior segment
   neovascularizations in neovascular glaucoma
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID EXPERIMENTAL IRIS NEOVASCULARIZATION; GROWTH-FACTOR
AB PURPOSE: To evaluate photodynamic therapy (PDT) with verteporfin for iris and angle neovascularization in eyes with neovascular glaucoma.
   DESIGN: Interventional case series.
   METHODS: A prospective, noncomparative case series included four patients (four eyes) with neovascular glaucoma. PDT was performed following the parameters of treatment of age-related macular degeneration with photodynamic therapy Study Group (TAP). The laser was directed at the anterior chamber angle and iris surface using a Goldmann three-mirror contact lens. Iris and angle neovascularization were quantified using the number of clock hours involved. Outcome measures were obliteration of neovascularization and decrease of intraocular pressure (IOP).
   RESULTS: One week after PDT, we registered complete obliteration of angle neovascularization and partial occlusion of iris neovascularization. Subsequent reopening of angle neovascularization was detectable at 1 month. Intraocular pressure diminished considerably after 1 week, with a subsequent tendency toward stabilization.
   CONCLUSIONS: Photodynamic therapy can be used safely and effectively in the early phases of neovascular glaucoma to achieve angle neovascularization obliteration and IOP reduction. (C) 2004 by Elsevier Inc. All rights reserved.
C1 Univ Trieste, Osped Maggiore, Eye Clin, I-34129 Trieste, Italy.
C3 University of Trieste
RP Parodi, MB (通讯作者)，Univ Trieste, Osped Maggiore, Eye Clin, I-34129 Trieste, Italy.
EM maubp@yahoo.it
RI Parodi, Maurizio Battaglia/K-7876-2016; Iacono, Pierluigi/AAD-3158-2020
OI Battaglia Parodi, Maurizio/0000-0002-0385-7961
CR Husain D, 1997, OPHTHALMOLOGY, V104, P1242, DOI 10.1016/S0161-6420(97)30151-1
   LaMuraglia GM, 1997, J VASC SURG, V26, P294, DOI 10.1016/S0741-5214(97)70192-7
   MILLER JW, 1991, OPHTHALMOLOGY, V98, P1711
   Tripathi RC, 1998, OPHTHALMOLOGY, V105, P232, DOI 10.1016/S0161-6420(98)92782-8
   WAND M, 1978, AM J OPHTHALMOL, V86, P332, DOI 10.1016/0002-9394(78)90235-0
NR 5
TC 17
Z9 21
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD JUL
PY 2004
VL 138
IS 1
BP 157
EP 158
DI 10.1016/j.ajo.2004.02.015
PG 2
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 836PO
UT WOS:000222568200030
PM 15234305
DA 2022-11-30
ER

PT J
AU Tavakoli, S
   Puranen, J
   Bahrpeyma, S
   Lautala, VE
   Karumo, S
   Lajunen, T
   del Amo, EM
   Ruponen, M
   Urtti, A
AF Tavakoli, Shirin
   Puranen, Jooseppi
   Bahrpeyma, Sina
   Lautala, Veera E.
   Karumo, Suvi
   Lajunen, Tatu
   del Amo, Eva M.
   Ruponen, Marika
   Urtti, Arto
TI Liposomal sunitinib for ocular drug delivery: A potential treatment for
   choroidal neovascularization
SO INTERNATIONAL JOURNAL OF PHARMACEUTICS
LA English
DT Article
DE Liposome; Sunitinib; Choroidal neovascularization; Age-related macular
   degeneration; Cyclodextrin; Intravitreal injection
ID IN-VITRO; BARRIERS; KINASE; VEGF
AB Choroidal neovascularization (CNV) is a prevalent vision-threatening vascular disorder in aging population. CNV is associated with several diseases in the posterior segment of the eye such as age-related macular degeneration (AMD). In this study we developed sunitinib-loaded liposomes to block the neovascularization signalling pathway through inhibition of tyrosine kinase of vascular endothelial growth factor receptors (VEGFRs). Liposomal sunitinib formulations were prepared by thin film hydration method and studied for their encapsulation efficiency (EE), loading capacity (LC) and drug release profile in buffer andvitreous. Our finding showed that the liposomes (mean size 104 nm) could effectively entrap sunitinib (EE approximate to 95%) at relatively high loading capacity (LC approximate to 5%) and release sunitinib over at least 3 days. Intravitreal sunitinib-loaded liposomes revealed inhibitory effect on established neovascularization in laser-induced CNV mouse model while the intravitreal injection of sunitinib solubilized with cyclodextrin was inefficient in management of neovascularization. Accordingly, liposomal sunitinib is a promising drug delivery system that should be further studied to inhibit the CNV related to AMD.
C1 [Tavakoli, Shirin; Lautala, Veera E.; Karumo, Suvi; Lajunen, Tatu; Urtti, Arto] Univ Helsinki, Fac Pharm, Drug Res Program, Div Pharmaceut Biosci, Viikinkaari 5 E, FI-00790 Helsinki, Finland.
   [Puranen, Jooseppi; Bahrpeyma, Sina; Lajunen, Tatu; del Amo, Eva M.; Ruponen, Marika; Urtti, Arto] Univ Eastern Finland, Fac Hlth Sci, Sch Pharm, Yliopistonranta 1, Kuopio 70210, Finland.
   [Lajunen, Tatu] Tokyo Univ Pharm & Life Sci, Dept Pharmaceut Sci, Lab Pharmaceut Technol, 1432-1 Hachioji, Tokyo 1920392, Japan.
C3 University of Helsinki; University of Eastern Finland; Tokyo University
   of Pharmacy & Life Sciences
RP Urtti, A (通讯作者)，Univ Helsinki, Fac Pharm, Drug Res Program, Div Pharmaceut Biosci, Viikinkaari 5 E, FI-00790 Helsinki, Finland.; Urtti, A (通讯作者)，Univ Eastern Finland, Fac Hlth Sci, Sch Pharm, Yliopistonranta 1, Kuopio 70210, Finland.
EM arto.urtti@helsinki.fi
OI del Amo Paez, Eva Maria/0000-0002-5705-4515; Lajunen,
   Tatu/0000-0001-6234-9193
FU European Union; Finnish Pharmaceutical Society [676137]; Sokeain Ystavat
   grant; Business Finland; Orion Research Foundation [4208/31/2015];
   Phospholipid Research Center [9-8214-9]; Instrumentarium Science
   Foundation [TLA-2019-068/1-1]; Silmasaatioiden Tohtor-itutkijapooliand
   Eva del Amo from Orion Research Foundation; University of Eastern
   Finland
FX Shirin Tavakoli and Arto Urtti acknowledge the research support from
   European Union?s Horizon 2020 research and innovation program Marie
   Sklodowska-Curie Innovative Training Networks (ITN) Nanomed (grant no.
   676137) . Shirin Tavakoli also acknowledges Finnish Phar-maceutical
   Society and Sokeain Ysta?va?t grant. Tatu Lajunen and Arto Urtti
   acknowledge support from Business Finland (#4208/31/2015) . Tatu Lajunen
   received additional funding from Orion ResearchFoun-dation (#9-8214-9) ,
   Phospholipid Research Center (#TLA-2019-068/1-1) , Instrumentarium
   Science Foundation and Silma?sa?a?tio?iden Tohtor-itutkijapooli and Eva
   del Amo from Orion Research Foundation and the strategic funding of the
   University of Eastern Finland. Sina Bahrpeyma and Jooseppi Puranen
   acknowledge Doctoral School of the University of Eastern Finland. Sina
   Bahrpeyma is grateful to Kuopio Research Foun-dation, Eye and Tissue
   Bank Foundation (Silma?-ja kudospankkisa?a?tio?) , and Sokeain
   Ysta?va?t. We thank Timo Oksanen for his help in UPLC analysis. Ocular
   Drug Development Laboratory infrastructure, Univer-sity of Eastern
   Finland is acknowledged for supporting the in vivo experiments.
CR Al-Khersan H, 2019, EXPERT OPIN PHARMACO, V20, P1879, DOI 10.1080/14656566.2019.1636031
   [Anonymous], WORLD REPORT VISION
   Campochiaro PA, 2013, J MOL MED, V91, P311, DOI 10.1007/s00109-013-0993-5
   del Amo EM, 2017, PROG RETIN EYE RES, V57, P134, DOI 10.1016/j.preteyeres.2016.12.001
   del Amo EM, 2015, EUR J PHARM BIOPHARM, V95, P215, DOI 10.1016/j.ejpb.2015.01.003
   Ferrara N, 2016, TRANSL VIS SCI TECHN, V5, DOI 10.1167/tvst.5.2.10
   Ferrara N, 2016, NAT REV DRUG DISCOV, V15, P385, DOI 10.1038/nrd.2015.17
   Giddabasappa A, 2016, EXP EYE RES, V145, P373, DOI 10.1016/j.exer.2016.02.010
   Higuchi TA., 1965, ADV ANAL CHEM INSTRU, P117
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Jain A, 2016, CHEM PHYS LIPIDS, V201, P28, DOI 10.1016/j.chemphyslip.2016.10.005
   Janoria KG, 2007, EXPERT OPIN DRUG DEL, V4, P371, DOI 10.1517/17425247.4.4.371
   Kari OK, 2020, PHARMACEUTICS, V12, DOI 10.3390/pharmaceutics12080763
   Motzer R.J., 2006, SUNITINIB
   Nowak-Sliwinska P, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.4
   Peyman GA, 2009, RETINA-J RET VIT DIS, V29, P875, DOI 10.1097/IAE.0b013e3181a94f01
   Ramazani F., 2015, EUR J PHARMACOL
   Robbie S.J., 2013, INVESTIG
   Roskoski R, 2007, BIOCHEM BIOPH RES CO, V356, P323, DOI 10.1016/j.bbrc.2007.02.156
   Sakurai Y, 2005, P NATL ACAD SCI USA, V102, P1076, DOI 10.1073/pnas.0404984102
   Schmitt M, 2019, MOL PHARMACEUT, V16, P4399, DOI 10.1021/acs.molpharmaceut.9b00679
   Streets J, 2020, SCI PHARM, V88, DOI 10.3390/scipharm88030030
   Takahashi H, 2006, J OCUL PHARMACOL TH, V22, P213, DOI 10.1089/jop.2006.22.213
   Tavakoli S, 2020, J CONTROL RELEASE, V328, P952, DOI 10.1016/j.jconrel.2020.10.028
   Tavakoli S, 2021, MOL PHARMACEUT, V18, P699, DOI 10.1021/acs.molpharmaceut.0c00411
   Tsujinaka H, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-14340-x
   Urtti A, 2006, ADV DRUG DELIVER REV, V58, P1131, DOI 10.1016/j.addr.2006.07.027
   Varela-Fernandez R, 2020, PHARMACEUTICS, V12, DOI 10.3390/pharmaceutics12030269
   Welsbie DS, 2019, MOL NEURODEGENER, V14, DOI 10.1186/s13024-019-0345-1
   Welsbie DS, 2017, NEURON, V94, P1142, DOI 10.1016/j.neuron.2017.06.008
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Zhang T, 2008, DRUG METAB DISPOS, V36, P1300, DOI 10.1124/dmd.108.021121
NR 33
TC 3
Z9 3
U1 12
U2 18
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0378-5173
EI 1873-3476
J9 INT J PHARMACEUT
JI Int. J. Pharm.
PD MAY 25
PY 2022
VL 620
AR 121725
DI 10.1016/j.ijpharm.2022.121725
PG 6
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA 1H3XF
UT WOS:000796477900004
PM 35405282
OA Green Published, hybrid
DA 2022-11-30
ER

PT J
AU Li, J
   Du, L
   He, JN
   Chu, KO
   Guo, CL
   Wong, MOM
   Pang, CP
   Chu, WK
AF Li, Jian
   Du, Lin
   He, Jing Na
   Chu, Kai On
   Guo, Cosmos Liutao
   Wong, Mandy Oi Man
   Pang, Chi Pui
   Chu, Wai Kit
TI Anti-inflammatory Effects of GTE in Eye Diseases
SO FRONTIERS IN NUTRITION
LA English
DT Review
DE green tea; EGCG; ocular inflammation; pharmacokinetics; safety
ID GREEN TEA CATECHINS; HUMAN SJOGRENS-SYNDROME; FACTOR-H POLYMORPHISM;
   DRY-EYE; EPIGALLOCATECHIN-GALLATE; MACULAR DEGENERATION; MOUSE MODEL;
   RECEPTOR EXPRESSION; OCULAR HYPERTENSION; AUTOIMMUNE UVEITIS
AB Ocular inflammation is a common complication of various eye diseases with wide consequences from irritations to potentially sight-threatening complications. Green tea is a popular beverage throughout the world. One of the proven health benefits of consuming green tea extract (GTE) is anti-inflammation. Catechins are the biologically active constituents of GTE. In in vitro and in vivo studies, GTE and catechins present inhibition of inflammatory responses in the development of ocular inflammation including infectious, non-infectious or autoimmune, and oxidative-induced complications. Research on the ocular inflammation in animal models has made significant progress in the past decades and several key disease mechanisms have been identified. Here we review the experimental investigations on the effects of GTE and catechins on various ocular inflammation related diseases including glaucoma, age-related macular degeneration, uveitis and ocular surface inflammation. We also review the pharmacokinetics of GTE constituents and safety of green tea consumption. We discuss the insights and perspectives of these experimental results, which would be useful for future development of novel therapeutics in human.
C1 [Li, Jian] Zhejiang Univ, Affiliated Hangzhou Peoples Hosp 1, Dept Ophthalmol, Sch Med, Hangzhou, Peoples R China.
   [Li, Jian; Du, Lin; He, Jing Na; Chu, Kai On; Wong, Mandy Oi Man; Pang, Chi Pui; Chu, Wai Kit] Chinese Univ Hong Kong, Dept Ophthalmol & Visual Sci, Hong Kong, Peoples R China.
   [Guo, Cosmos Liutao] Chinese Univ Hong Kong, Med, Hong Kong, Peoples R China.
   [Guo, Cosmos Liutao] Chinese Univ Hong Kong, Surg Programme, Hong Kong, Peoples R China.
   [Wong, Mandy Oi Man] Hong Kong Eye Hosp, Hong Kong, Peoples R China.
C3 Zhejiang University; Chinese University of Hong Kong; Chinese University
   of Hong Kong; Chinese University of Hong Kong
RP Chu, WK (通讯作者)，Chinese Univ Hong Kong, Dept Ophthalmol & Visual Sci, Hong Kong, Peoples R China.
EM waikit@cuhk.edu.hk
OI Wong, Mandy Oi Man/0000-0002-5538-9143
CR Abboud PA, 2008, EUR J PHARMACOL, V579, P411, DOI 10.1016/j.ejphar.2007.10.053
   Ahmed S, 2008, P NATL ACAD SCI USA, V105, P14692, DOI 10.1073/pnas.0802675105
   Aktas O, 2004, J IMMUNOL, V173, P5794, DOI 10.4049/jimmunol.173.9.5794
   Alexander P, 2014, MOL VIS, V20, P1253
   Ambati J, 2013, NAT REV IMMUNOL, V13, P438, DOI 10.1038/nri3459
   Ames Philip, 2015, Clin Investig (Lond), V5, P267, DOI 10.4155/cli.14.135
   Anderson OA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067263
   Anonymous, 2005, International Ophthalmology Clinics, V45, P1, DOI 10.1097/01.iio.0000155938.83083.94
   Atkinson-Leadbeater K, 2016, DEV DYNAM, V245, P667, DOI [10.1002/DVDY.24406, 10.1002/dvdy.24406]
   Ayyildiz T, 2020, EYE CONTACT LENS, V46, pS39, DOI 10.1097/ICL.0000000000000640
   Babazadeh A, 2018, CURR DRUG TARGETS, V19, P170, DOI 10.2174/1389450118666170508095250
   Barthelman M, 1998, CARCINOGENESIS, V19, P2201, DOI 10.1093/carcin/19.12.2201
   Bettuzzi S, 2006, CANCER RES, V66, P1234, DOI 10.1158/0008-5472.CAN-05-1145
   BLOCHMICHEL E, 1987, AM J OPHTHALMOL, V103, P234, DOI 10.1016/S0002-9394(14)74235-7
   Caspi RR, 2011, INVEST OPHTH VIS SCI, V52, P1873, DOI 10.1167/iovs.10-6909
   Caspi RR, 2010, J CLIN INVEST, V120, P3073, DOI 10.1172/JCI42440
   CASPI RR, 1993, J NEUROIMMUNOL, V47, P177, DOI 10.1016/0165-5728(93)90028-W
   Cavet ME, 2011, MOL VIS, V17, P533
   Chauhan SK, 2009, J IMMUNOL, V182, P1247, DOI 10.4049/jimmunol.182.3.1247
   Chen SD, 2013, CHINESE MED J-PEKING, V126, P1567, DOI 10.3760/cma.j.issn.0366-6999.20123565
   Chen ZY, 2001, J AGR FOOD CHEM, V49, P477, DOI 10.1021/jf000877h
   Chow HHS, 2006, CANCER EPIDEM BIOMAR, V15, P2473, DOI 10.1158/1055-9965.EPI-06-0365
   Chow HHS, 2005, CLIN CANCER RES, V11, P4627, DOI 10.1158/1078-0432.CCR-04-2549
   Chu KO, 2007, HUM REPROD, V22, P280, DOI 10.1093/humrep/del353
   Chu KO, 2018, J AGR FOOD CHEM, V66, P12866, DOI 10.1021/acs.jafc.8b05998
   Chu KO, 2015, J NUTR BIOCHEM, V26, P1357, DOI 10.1016/j.jnutbio.2015.07.001
   Chu KO, 2010, J AGR FOOD CHEM, V58, P1523, DOI 10.1021/jf9032602
   Connors SK, 2012, NUTR CANCER, V64, P4, DOI 10.1080/01635581.2012.630158
   Coureta C, 2020, J FR OPHTALMOL, V43, P341, DOI 10.1016/j.jfo.2019.03.033
   Daiger SP, 2013, CLIN GENET, V84, P132, DOI 10.1111/cge.12203
   De Falco S, 2014, KOREAN J INTERN MED, V29, P1, DOI 10.3904/kjim.2014.29.1.1
   Dostal AM, 2017, J HUM NUTR DIET, V30, P166, DOI 10.1111/jhn.12408
   Doudevski I, 2014, INVEST OPHTH VIS SCI, V55, P2491, DOI 10.1167/iovs.13-12941
   Doyle SL, 2012, NAT MED, V18, P791, DOI 10.1038/nm.2717
   Dube A, 2010, EUR J PHARM SCI, V41, P219, DOI 10.1016/j.ejps.2010.06.010
   Dunkelberger JR, 2010, CELL RES, V20, P34, DOI 10.1038/cr.2009.139
   Durrani OM, 2004, BRIT J OPHTHALMOL, V88, P1159, DOI 10.1136/bjo.2003.037226
   Ecoiffier T, 2008, ARCH OPHTHALMOL-CHIC, V126, P1695, DOI 10.1001/archopht.126.12.1695
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Ergorul C, 2010, J MOL NEUROSCI, V42, P183, DOI 10.1007/s12031-010-9343-z
   Falsini B, 2009, GRAEF ARCH CLIN EXP, V247, P1223, DOI 10.1007/s00417-009-1064-z
   Friedman M, 2009, J FOOD SCI, V74, pH47, DOI 10.1111/j.1750-3841.2008.01033.x
   Fu Z, 2011, BRIT J NUTR, V105, P1218, DOI 10.1017/S0007114510004824
   Fukuda M, 1997, JPN J OPHTHALMOL, V41, P63, DOI 10.1016/S0021-5155(97)00009-9
   Ghosh S, 2012, CLIN EXP OPHTHALMOL, V40, P675, DOI 10.1111/j.1442-9071.2012.02781.x
   Gianfredi V, 2017, J NUTRIGENET NUTRIGE, V10, P126, DOI 10.1159/000480636
   Gillespie K, 2008, LIFE SCI, V83, P581, DOI 10.1016/j.lfs.2008.08.011
   Goyal S, 2009, ARCH OPHTHALMOL-CHIC, V127, P882, DOI 10.1001/archophthalmol.2009.125
   Gregory MS, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017659
   Gritz DC, 2004, OPHTHALMOLOGY, V111, P491, DOI 10.1016/j.ophtha.2003.06.014
   Guly CM, 2010, BMJ-BRIT MED J, V341, DOI 10.1136/bmj.c4976
   Haqqi TM, 1999, P NATL ACAD SCI USA, V96, P4524, DOI 10.1073/pnas.96.8.4524
   Hara Y, 2011, PHARMACOL RES, V64, P100, DOI 10.1016/j.phrs.2011.03.018
   Haratifar S, 2014, FOOD FUNCT, V5, P1160, DOI 10.1039/c3fo60343a
   Hong JG, 2001, BIOCHEM PHARMACOL, V62, P1175, DOI 10.1016/S0006-2952(01)00767-5
   Horai R, 2011, J INTERF CYTOK RES, V31, P733, DOI 10.1089/jir.2011.0042
   Howell GR, 2014, NEUROBIOL DIS, V71, P44, DOI 10.1016/j.nbd.2014.07.016
   Hsu SD, 2007, AUTOIMMUNITY, V40, P138, DOI 10.1080/08916930601167343
   Hu B, 2012, CARBOHYD POLYM, V89, P362, DOI 10.1016/j.carbpol.2012.03.015
   Hu J, 2018, REGUL TOXICOL PHARM, V95, P412, DOI 10.1016/j.yrtph.2018.03.019
   Huang HY, 2018, INT J NANOMED, V13, P7251, DOI 10.2147/IJN.S173198
   Hussain T, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/7432797
   Isbrucker RA, 2006, FOOD CHEM TOXICOL, V44, P636, DOI 10.1016/j.fct.2005.11.003
   Iso H, 2006, ANN INTERN MED, V144, P554, DOI 10.7326/0003-4819-144-8-200604180-00005
   Isomura T, 2016, EUR J CLIN NUTR, V70, P1340, DOI 10.1038/ejcn.2016.165
   Ito K, 2014, NAT REV UROL, V11, P197, DOI 10.1038/nrurol.2014.42
   Jung YD, 2001, BRIT J CANCER, V84, P844, DOI 10.1054/bjoc.2000.1691
   KADA T, 1985, MUTAT RES, V150, P127, DOI 10.1016/0027-5107(85)90109-5
   Kawano T, 2006, NAT MED, V12, P225, DOI 10.1038/nm1362
   Kim HR, 2008, J NUTR, V138, P2111, DOI 10.3945/jn.108.089912
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kolko M, 1996, J BIOL CHEM, V271, P32722, DOI 10.1074/jbc.271.51.32722
   Krishna U, 2017, POSTGRAD MED J, V93, P766, DOI 10.1136/postgradmedj-2017-134891
   Krizaj D, 2014, CURR EYE RES, V39, P105, DOI 10.3109/02713683.2013.836541
   Kuriyama S, 2006, AM J CLIN NUTR, V83, P355
   Lambert JD, 2010, FOOD CHEM TOXICOL, V48, P409, DOI 10.1016/j.fct.2009.10.030
   Larson T, 2011, EXPERT OPIN EMERG DR, V16, P309, DOI 10.1517/14728214.2011.537824
   LaVail MM, 2018, EXP EYE RES, V167, P56, DOI 10.1016/j.exer.2017.10.023
   Lee MJ, 2002, CANCER EPIDEM BIOMAR, V11, P1025
   Lemp MA, 2007, OCUL SURF, V5, P75
   Li GR, 2007, MOL VIS, V13, P2282
   Li J, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-38868-1
   Li J, 2017, INVEST OPHTH VIS SCI, V58, P4193, DOI 10.1167/iovs.17-22436
   Luo C, 2013, EXP EYE RES, V112, P93, DOI 10.1016/j.exer.2013.04.016
   Luo C, 2010, INVEST OPHTH VIS SCI, V51, P5697, DOI 10.1167/iovs.10-5407
   Luo LH, 2004, INVEST OPHTH VIS SCI, V45, P4293, DOI 10.1167/iovs.03-1145
   Marotte H, 2010, RHEUMATOLOGY, V49, P467, DOI 10.1093/rheumatology/kep397
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Masukawa Y, 2006, J CHROMATOGR B, V834, P26, DOI 10.1016/j.jchromb.2006.02.008
   Mazzanti G, 2009, EUR J CLIN PHARMACOL, V65, P331, DOI 10.1007/s00228-008-0610-7
   Mesquida M, 2014, CLIN EXP IMMUNOL, V176, P301, DOI 10.1111/cei.12295
   Nakagawa K, 1997, J NUTR SCI VITAMINOL, V43, P679, DOI 10.3177/jnsv.43.679
   Nejabat M, 2017, J CLIN DIAGN RES, V11, pNC5, DOI 10.7860/JCDR/2017/23336.9426
   Noguchi-Shinohara M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096013
   OKADA M, 1988, J IMMUNOL, V141, P1543
   Pae M, 2010, J NUTR, V140, P1509, DOI 10.3945/jn.110.124743
   Patel S, 2015, GRAEF ARCH CLIN EXP, V253, P1841, DOI 10.1007/s00417-015-3168-y
   Perdices L, 2020, ANTIOXIDANTS-BASEL, V9, DOI 10.3390/antiox9080718
   Perez VL, 2016, OCUL SURF, V14, P207, DOI 10.1016/j.jtos.2016.01.001
   Pisella PJ, 2003, J FR OPHTALMOL, V26, P675
   Qi SN, 2017, MOL VIS, V23, P171
   Qin YJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103995
   Rashidinejad A, 2021, FOOD RES INT, V142, DOI 10.1016/j.foodres.2021.110186
   Roszkowska AM, 2021, GENES-BASEL, V12, DOI 10.3390/genes12030365
   Sampath C, 2016, PHYTOMEDICINE, V23, P200, DOI 10.1016/j.phymed.2015.12.013
   Schaumberg DA, 2003, AM J OPHTHALMOL, V136, P318, DOI 10.1016/S0002-9394(03)00218-6
   Scheller J, 2014, SEMIN IMMUNOL, V26, P2, DOI 10.1016/j.smim.2013.11.002
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Senanayake SPJN, 2013, J FUNCT FOODS, V5, P1529, DOI 10.1016/j.jff.2013.08.011
   Shen CY, 2015, NEUROSCI LETT, V600, P132, DOI 10.1016/j.neulet.2015.06.002
   Soto I, 2014, CSH PERSPECT MED, V4, DOI 10.1101/cshperspect.a017269
   Stapleton F, 2017, OCUL SURF, V15, P334, DOI 10.1016/j.jtos.2017.05.003
   Stefani M, 2014, BIOFACTORS, V40, P482, DOI 10.1002/biof.1171
   Steinmann J, 2013, BRIT J PHARMACOL, V168, P1059, DOI 10.1111/bph.12009
   Sugioka K, 2019, INVEST OPHTH VIS SCI, V60, P2895, DOI 10.1167/iovs.19-27306
   Sun D, 2013, GLIA, V61, P1218, DOI 10.1002/glia.22507
   Tang GY, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20246196
   Thomas AS, 2019, CURR OPIN OPHTHALMOL, V30, P138, DOI 10.1097/ICU.0000000000000562
   Thurau SR, 2004, INT IMMUNOL, V16, P1573, DOI 10.1093/intimm/dxh158
   THYLEFORS B, 1994, B WORLD HEALTH ORGAN, V72, P323
   Tode J, 2017, CYTOKINE, V96, P8, DOI 10.1016/j.cyto.2017.02.023
   Toolsee NA, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/412379
   Valdes LM, 2020, DRUGS, V80, P765, DOI 10.1007/s40265-020-01314-y
   Van Veldhuisen PC, 2000, AM J OPHTHALMOL, V130, P429
   Vargas JLC, 2015, J NEUROSCI, V35, P12088, DOI 10.1523/JNEUROSCI.1273-15.2015
   Varilek GW, 2001, J NUTR, V131, P2034, DOI 10.1093/jn/131.7.2034
   Wang CC, 2013, ANGIOGENESIS, V16, P59, DOI 10.1007/s10456-012-9299-4
   Wang JJ, 2015, WORLD J DIABETES, V6, P726, DOI 10.4239/wjd.v6.i5.726
   Wang JP, 2012, AM J PATHOL, V180, P221, DOI 10.1016/j.ajpath.2011.09.007
   Wang L, 2019, EXP CELL RES, V380, P149, DOI 10.1016/j.yexcr.2019.04.014
   Wei X, 2019, J NEUROSCI RES, V97, P70, DOI 10.1002/jnr.24256
   Weinreb RN, 2004, AM J OPHTHALMOL, V138, P458, DOI 10.1016/j.ajo.2004.04.054
   WHITCUP SM, 1993, ANN NY ACAD SCI, V696, P307
   Williams PA, 2017, EXP EYE RES, V157, P20, DOI 10.1016/j.exer.2017.02.014
   Xing LJ, 2019, J AGR FOOD CHEM, V67, P1029, DOI 10.1021/acs.jafc.8b06146
   Xu CL, 2020, J DIABETES RES, V2020, DOI 10.1155/2020/1860452
   Xu JW, 2020, BIOMED PHARMACOTHER, V121, DOI 10.1016/j.biopha.2019.109606
   Yadav UCS, 2019, METHODS MOL BIOL, V1960, P161, DOI 10.1007/978-1-4939-9167-9_14
   Yan YT, 2018, INT J BIOL MACROMOL, V115, P600, DOI 10.1016/j.ijbiomac.2018.04.011
   Yang JJ, 2001, AM J OPHTHALMOL, V131, P421, DOI 10.1016/S0002-9394(00)00862-X
   Yang MM, 2014, RETINA-J RET VIT DIS, V34, P1, DOI 10.1097/IAE.0b013e31829f7415
   Yang YP, 2019, OXID MED CELL LONGEV, V2019, DOI 10.1155/2019/8407206
   Yang YP, 2016, SCI REP-UK, V6, DOI 10.1038/srep29546
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Yoon KC, 2007, INVEST OPHTH VIS SCI, V48, P2561, DOI 10.1167/iovs.07-0002
   Yu ZM, 2017, CANCER PREV RES, V10, P571, DOI [10.1158/1940-6207.CAPR-17-0160, 10.1158/1940-6207.capr-17-0160]
   Yuan JM, 2013, AM J CLIN NUTR, V98, p1676S, DOI 10.3945/ajcn.113.058271
   Zhang B, 2006, BRAIN RES, V1124, P176, DOI 10.1016/j.brainres.2006.09.067
   Zhang B, 2007, BRAIN RES, V1159, P40, DOI 10.1016/j.brainres.2007.05.029
   Zhao RJ, 2014, INT IMMUNOPHARMACOL, V22, P285, DOI 10.1016/j.intimp.2014.06.041
NR 150
TC 1
Z9 1
U1 2
U2 5
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 2296-861X
J9 FRONT NUTR
JI Front. Nutr.
PD DEC 13
PY 2021
VL 8
AR 753955
DI 10.3389/fnut.2021.753955
PG 12
WC Nutrition & Dietetics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Nutrition & Dietetics
GA XY8UL
UT WOS:000737240400001
PM 34966770
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Wu, LQ
   Liang, Y
   Song, N
   Wang, XY
   Jiang, C
   Chen, XX
   Qin, B
   Sun, XT
   Liu, GH
   Zhao, C
AF Wu, Lianqun
   Liang, Yu
   Song, Nan
   Wang, Xiying
   Jiang, Chao
   Chen, Xinxin
   Qin, Bing
   Sun, Xiantao
   Liu, Guohua
   Zhao, Chen
TI Differential expression and alternative splicing of transcripts in
   orbital adipose/connective tissue of thyroid-associated ophthalmopathy
SO EXPERIMENTAL BIOLOGY AND MEDICINE
LA English
DT Article
DE Thyroid-associated ophthalmopathy; alternative splicing; rMATS;
   adipogenesis; adipose; connective tissue
ID EXTRACELLULAR-MATRIX PROTEINS; GAMMA PPAR-GAMMA; THYROTROPIN RECEPTOR;
   ADIPOGENESIS; FIBROBLASTS; PATHOGENESIS; FIBROSIS; DISEASE; CELLS;
   IDENTIFICATION
AB Thyroid-associated ophthalmopathy is a typical autoimmune disease of orbital tissues. Alternative splicing significantly influences many diseases progression, including cancer, age-related macular degeneration, and multiple sclerosis, by modulating the expression of transcripts. However, its role in thyroid-associated ophthalmopathy is still unclear. In this study, differential expression transcripts and differential alternative splicing genes in orbital adipose/connective tissues of thyroid-associated ophthalmopathy patients were detected using RNA sequencing, Cuffdiff, and replicate multivariate analysis of transcript splicing. Three thousand ninety six differential expression transcripts and 2355 differential alternative splicing genes were screened out, while functional enrichment analysis indicated that differential expression transcript and differential alternative splicing genes were associated with immune modulation, extracellular matrix remodeling, and adipogenesis. The expression of the SORBS1, SEPT2, COL12A1, and VCAN gene transcripts was verified by qRT-PCR. In conclusion, prevalent alternative splicing is involved in the disease development in thyroid-associated ophthalmopathy. More attention should be paid to the mechanism of alternative splicing to explore more potential therapeutic targets in thyroid-associated ophthalmopathy.
C1 [Wu, Lianqun; Liang, Yu; Wang, Xiying; Jiang, Chao; Zhao, Chen] Fudan Univ, Eye & ENT Hosp, Eye Inst, Shanghai 200031, Peoples R China.
   [Wu, Lianqun; Liang, Yu; Wang, Xiying; Jiang, Chao; Zhao, Chen] Fudan Univ, Eye & ENT Hosp, Dept Ophthalmol, Shanghai 200031, Peoples R China.
   [Wu, Lianqun; Liang, Yu; Wang, Xiying; Jiang, Chao; Zhao, Chen] Fudan Univ, Chinese Acad Med Sci, Key Lab Myopia, NHC Key Lab Myopia, Shanghai 200031, Peoples R China.
   [Wu, Lianqun; Liang, Yu; Wang, Xiying; Jiang, Chao; Zhao, Chen] Shanghai Key Lab Visual Impairment & Restorat, Shanghai 200031, Peoples R China.
   [Song, Nan] Fudan Univ, Eye & ENT Hosp, Dept Facial Plast & Reconstruct Surg, Shanghai 200031, Peoples R China.
   [Chen, Xinxin] Second Mil Med Univ, Changzheng Hosp, Dept Ophthalmol, Shanghai 20003, Peoples R China.
   [Qin, Bing] Suqian First Hosp, Dept Ophthalmol, Suqian 223800, Peoples R China.
   [Sun, Xiantao] Zhengzhou Univ, Dept Ophthalmol, Childrens Hosp, Zhengzhou 450053, Peoples R China.
   [Liu, Guohua] Shandong Univ, Dept Ophthalmol, Qilu Childrens Hosp, Jinan 250022, Peoples R China.
C3 Fudan University; Fudan University; Chinese Academy of Medical Sciences
   - Peking Union Medical College; Fudan University; Fudan University;
   Naval Medical University; Zhengzhou University; Shandong University
RP Zhao, C (通讯作者)，Fudan Univ, Eye & ENT Hosp, Eye Inst, Shanghai 200031, Peoples R China.; Zhao, C (通讯作者)，Fudan Univ, Eye & ENT Hosp, Dept Ophthalmol, Shanghai 200031, Peoples R China.; Zhao, C (通讯作者)，Fudan Univ, Chinese Acad Med Sci, Key Lab Myopia, NHC Key Lab Myopia, Shanghai 200031, Peoples R China.; Zhao, C (通讯作者)，Shanghai Key Lab Visual Impairment & Restorat, Shanghai 200031, Peoples R China.
EM dr_zhaochen@fudan.edu.cn
FU Shanghai Natural Science Foundation [20ZR1409800]; National Natural
   Science Foundation of China [81600765, 81670864, 81730025]; Excellent
   Academic Leaders of Shanghai [18XD1401000]; Shanghai Municipal Health
   and Family Planning Commission [201640120]
FX This study was supported by Shanghai Natural Science Foundation
   (20ZR1409800 to L.Q.W), National Natural Science Foundation of China
   (81600765 to L.Q.W., 81670864 and 81730025 to C.Z.), Excellent Academic
   Leaders of Shanghai (18XD1401000 to C.Z.), Shanghai Municipal Health and
   Family Planning Commission (201640120 to L.Q.W.).
CR Anders Simon, 2010, Genome Biol, V11, pR106, DOI 10.1186/gb-2010-11-10-r106
   Anders S, 2015, BIOINFORMATICS, V31, P166, DOI 10.1093/bioinformatics/btu638
   Bahn RS, 2010, NEW ENGL J MED, V362, P726, DOI 10.1056/NEJMra0905750
   Bahn RS, 2002, THYROID, V12, P193, DOI 10.1089/105072502753600124
   Barquissau V, 2017, BIOCHIMIE, V136, P3, DOI 10.1016/j.biochi.2016.12.012
   BARTLEY GB, 1995, AM J OPHTHALMOL, V119, P792, DOI 10.1016/S0002-9394(14)72787-4
   Baumann CA, 2000, J BIOL CHEM, V275, P9131, DOI 10.1074/jbc.275.13.9131
   Bednarczuk T, 1999, THYROID, V9, P289, DOI 10.1089/thy.1999.9.289
   Bednarczuk T, 1998, AUTOIMMUNITY, V27, P221, DOI 10.3109/08916939808993834
   Bolger AM, 2014, BIOINFORMATICS, V30, P2114, DOI 10.1093/bioinformatics/btu170
   Cai H, 2016, TRENDS PHARMACOL SCI, V37, P303, DOI 10.1016/j.tips.2015.11.011
   Cao LQ, 2015, CANCER LETT, V359, P127, DOI 10.1016/j.canlet.2015.01.004
   Cardamone G, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18030576
   Eckstein AK, 2009, HORM METAB RES, V41, P456, DOI 10.1055/s-0029-1220935
   Fang SJ, 2017, J CLIN ENDOCR METAB, V102, P4273, DOI 10.1210/jc.2017-01349
   Fang SJ, 2016, J CLIN ENDOCR METAB, V101, P2955, DOI 10.1210/jc.2016-1882
   Farina AR, 2020, J EXP CLIN CANC RES, V39, DOI 10.1186/s13046-020-01616-9
   Farina F, 2016, NAT CELL BIOL, V18, P65, DOI 10.1038/ncb3285
   Feldon SE, 2005, INVEST OPHTH VIS SCI, V46, P3913, DOI 10.1167/iovs.05-0605
   Ferrari SM, 2019, AUTOIMMUN REV, V18, P673, DOI 10.1016/j.autrev.2019.05.004
   Gianoukakis AG, 2008, THYROID, V18, P953, DOI 10.1089/thy.2007.0405
   Gortz GE, 2016, ENDOCRINOLOGY, V157, P3771, DOI 10.1210/en.2016-1304
   Heufelder AE, 1996, EUR J ENDOCRINOL, V134, P51, DOI 10.1530/eje.0.1340051
   Khong JJ, 2015, INVEST OPHTH VIS SCI, V56, P6438, DOI 10.1167/iovs.15-17185
   Kim D, 2015, NAT METHODS, V12, P357, DOI [10.1038/NMETH.3317, 10.1038/nmeth.3317]
   Kloeckener-Gruissem B, 2013, EUR J HUM GENET, V21, P352, DOI 10.1038/ejhg.2012.137
   KOCH M, 1995, J CELL BIOL, V130, P1005, DOI 10.1083/jcb.130.4.1005
   Kumar S, 2004, J CLIN ENDOCR METAB, V89, P930, DOI 10.1210/jc.2003-031427
   Lee GR, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19030730
   Lin JC, 2015, INT J MOL SCI, V16, P22169, DOI 10.3390/ijms160922169
   Liu HF, 2018, NUCLEIC ACIDS RES, V46, P6069, DOI 10.1093/nar/gky401
   McGregor AM, 1998, LANCET, V352, P595, DOI 10.1016/S0140-6736(05)79573-8
   Moldovan LMY, 2019, J CELL PHYSIOL, V234, P3850, DOI 10.1002/jcp.27157
   Mourits MP, 1997, CLIN ENDOCRINOL, V47, P9, DOI 10.1046/j.1365-2265.1997.2331047.x
   Neubauer K, 2017, FRONT CELL DEV BIOL, V5, DOI 10.3389/fcell.2017.00003
   Padilla-Benavides T, 2016, J CELL BIOCHEM, V117, P2315, DOI 10.1002/jcb.25529
   Pujol-Lereis LM, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0200739
   Roberts A, 2011, BIOINFORMATICS, V27, P2325, DOI 10.1093/bioinformatics/btr355
   Rosen ED, 2000, GENE DEV, V14, P1293
   Shen SH, 2014, P NATL ACAD SCI USA, V111, pE5593, DOI 10.1073/pnas.1419161111
   Smith TJ, 2019, ENDOCR REV, V40, P236, DOI 10.1210/er.2018-00066
   Smith TJ, 2017, NEW ENGL J MED, V376, P1748, DOI 10.1056/NEJMoa1614949
   Tong BD, 2015, MOL VIS, V21, P324
   Trivanovic D, 2018, ARTIF CELL NANOMED B, V46, pS370, DOI 10.1080/21691401.2018.1494183
   Ueno T, 2011, FEBS J, V278, P2901, DOI 10.1111/j.1742-4658.2011.08213.x
   Valyasevi RW, 2002, J CLIN ENDOCR METAB, V87, P2352, DOI 10.1210/jc.87.5.2352
   Wall JR, 2010, ENDOKRYNOL POL, V61, P222
   Wang L, 2014, BMC PLANT BIOL, V14, DOI 10.1186/1471-2229-14-169
   Wang Y, 2015, BIOMED REP, V3, P152, DOI 10.3892/br.2014.407
   Wu LQ, 2020, EXP EYE RES, V196, DOI 10.1016/j.exer.2020.108036
   Yang HW, 2017, BIOSCIENCE REP, V37, DOI [10.1042/BSR20160440, 10.1042/bsr20160440]
   Zhang M, 2003, MOL MED, V9, P18, DOI 10.1007/BF03402103
   Zhao PQ, 2015, ENDOCR PATHOL, V26, P200, DOI 10.1007/s12022-015-9373-8
   Zhao PQ, 2013, EXP EYE RES, V107, P65, DOI 10.1016/j.exer.2012.11.014
NR 54
TC 1
Z9 1
U1 1
U2 11
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1535-3702
EI 1535-3699
J9 EXP BIOL MED
JI Exp. Biol. Med.
PD SEP
PY 2021
VL 246
IS 18
BP 1990
EP 2006
AR 15353702211017292
DI 10.1177/15353702211017292
EA JUN 2021
PG 17
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA UU4CZ
UT WOS:000682606400001
PM 34078122
OA Green Published
DA 2022-11-30
ER

PT J
AU Dong, CW
   Tran, LG
   Park, WT
AF Dong, Chao-Wei
   Tran, Le-Giang
   Park, Woo-Tae
TI A polymer membrane electrolysis micropump powered by a compact wireless
   power transmission system
SO JOURNAL OF MECHANICAL SCIENCE AND TECHNOLOGY
LA English
DT Article
DE Drug delivery; Electrolysis micropump; Wireless power transfer; Bio-MEMS
ID DRUG-DELIVERY; MEMS; WATER; EFFICIENCY; PRINCIPLE; HYDROGEN; INFUSION
AB In this study, a polydimethylsiloxane (PDMS) membrane electrolysis micropump activated by a miniaturized wireless power transfer (WPT) system is introduced. The micropump system has total dimensions of 20 x 14 x 8.2 mm(3). Combined with a compact WPT system, the micropump enables the delivery of drugs to the treatment area on demand. The WPT system consists of an impedance matching network and a two-stage voltage multiplier. Voltages ranging from 0.8 V to 1.3 V can be generated at different operating distance of 8 cm to 20 cm away from the RF source. The micropump is capable of delivering liquid continuously over a flow ranging from 0.11 mu L/min to 4.84 mu L/min. This micropump demonstrates a maximum cumulative released drug volume of up to 100.8 mu L and was able to produce a pressure that is higher than the intraocular pressure. The results can be used for the study of age-related macular degeneration, diabetic retinopathy, and other ophthalmic diseases.
C1 [Dong, Chao-Wei; Park, Woo-Tae] Seoul Natl Univ Sci & Technol, Dept Mech Engn, Seoul, South Korea.
   [Tran, Le-Giang; Park, Woo-Tae] Seoul Natl Univ Sci & Technol, Convergence Inst Biomed Engn & Biomat, Seoul, South Korea.
C3 Seoul National University of Science & Technology; Seoul National
   University of Science & Technology
RP Park, WT (通讯作者)，Seoul Natl Univ Sci & Technol, Dept Mech Engn, Seoul, South Korea.; Park, WT (通讯作者)，Seoul Natl Univ Sci & Technol, Convergence Inst Biomed Engn & Biomat, Seoul, South Korea.
EM wtpark@seoultech.ac.kr
FU Seoul National University of Science and Technology Internal Research
   Fund [2019-0497]
FX This research was sponsored by the Seoul National University of Science
   and Technology Internal Research Fund (2019-0497).
CR Ashraf MW, 2011, INT J MOL SCI, V12, P3648, DOI 10.3390/ijms12063648
   Awwad S, 2017, BRIT J PHARMACOL, V174, P4205, DOI 10.1111/bph.14024
   Cegielska O, 2019, POLYMERS-BASEL, V11, DOI 10.3390/polym11111742
   Chuang WC, 2010, SENSORS-BASEL, V10, P6149, DOI 10.3390/s100606149
   Cobo A, 2016, SENSOR ACTUAT A-PHYS, V239, P18, DOI 10.1016/j.sna.2016.01.001
   Di Tommaso C, 2012, EUR J PHARM BIOPHARM, V81, P257, DOI 10.1016/j.ejpb.2012.02.014
   Fallahi H, 2019, MICROMACHINES-BASEL, V10, DOI 10.3390/mi10120830
   Feng GH, 2005, J MICROELECTROMECH S, V14, P192, DOI 10.1109/JMEMS.2004.839331
   Fricke TR, 2018, OPHTHALMOLOGY, V125, P1492, DOI 10.1016/j.ophtha.2018.04.013
   Joseph RR, 2017, NANOMEDICINE-UK, V12, P683, DOI 10.2217/nnm-2016-0379
   Li PY, 2008, SENSOR ACTUAT A-PHYS, V143, P41, DOI 10.1016/j.sna.2007.06.034
   Li PY, 2010, J MICROELECTROMECH S, V19, P215, DOI 10.1109/JMEMS.2009.2032670
   LIN FN, 1985, INT J HYDROGEN ENERG, V10, P811, DOI 10.1016/0360-3199(85)90169-7
   Mazloomi K, 2012, INT J ELECTROCHEM SC, V7, P3314
   Meng E, 2012, ADV DRUG DELIVER REV, V64, P1628, DOI 10.1016/j.addr.2012.08.006
   Neagu C, 2000, MECHATRONICS, V10, P571, DOI 10.1016/S0957-4158(99)00066-5
   Neagu CR, 1996, J MICROELECTROMECH S, V5, P2, DOI 10.1109/84.485209
   Ou X, 2019, J SEP SCI, V43, P1
   Paddon CA, 2006, J APPL ELECTROCHEM, V36, P617, DOI 10.1007/s10800-006-9122-2
   Pagonis DN, 2012, MICROELECTRON ENG, V95, P65, DOI 10.1016/j.mee.2012.02.006
   Razzacki SZ, 2004, ADV DRUG DELIVER REV, V56, P185, DOI 10.1016/j.addr.2003.08.012
   Saati S, 2010, CURR EYE RES, V35, P192, DOI 10.3109/02713680903521936
   Sheybani R, 2015, BIOMED MICRODEVICES, V17, DOI 10.1007/s10544-015-9980-7
   Sheybani R, 2012, J MICROELECTROMECH S, V21, P1197, DOI 10.1109/JMEMS.2012.2203103
   Singh P, 2019, J CONTROL RELEASE, V315, P97, DOI 10.1016/j.jconrel.2019.10.022
   Szydzik C, 2019, ANAL CHEM, V91, P10830, DOI 10.1021/acs.analchem.9b02486
   Tran LG, 2019, SENSOR ACTUAT A-PHYS, V285, P386, DOI 10.1016/j.sna.2018.11.029
   Wang C, 2018, J CONTROL RELEASE, V283, P105, DOI 10.1016/j.jconrel.2018.05.030
   WHO, 2019, BLINDN VIS IMP
   Xie J, 2004, ANAL CHEM, V76, P3756, DOI 10.1021/ac035188u
   Yi Y, 2016, REMOTELY POWERED ELE
   Yi Y, 2015, J MICROMECH MICROENG, V25, DOI 10.1088/0960-1317/25/10/105011
   Yi Y, 2015, BIOMICROFLUIDICS, V9, DOI 10.1063/1.4927436
   Yi Y, 2015, LAB CHIP, V15, P3540, DOI 10.1039/c5lc00703h
   Zainal MA, 2017, BIOMED MICRODEVICES, V19, DOI 10.1007/s10544-017-0148-5
   Zhang XJ, 2019, ELECTROPHORESIS, V40, P865, DOI 10.1002/elps.201800494
   Zhou JW, 2016, PROC IEEE MICR ELECT, P349, DOI 10.1109/MEMSYS.2016.7421632
NR 37
TC 3
Z9 3
U1 6
U2 24
PU KOREAN SOC MECHANICAL ENGINEERS
PI SEOUL
PA KSTC NEW BLD. 7TH FLOOR, 635-4 YEOKSAM-DONG KANGNAM-KU, SEOUL 135-703,
   SOUTH KOREA
SN 1738-494X
EI 1976-3824
J9 J MECH SCI TECHNOL
JI J. Mech. Sci. Technol.
PD FEB
PY 2021
VL 35
IS 2
BP 697
EP 706
DI 10.1007/s12206-021-0130-2
EA JAN 2021
PG 10
WC Engineering, Mechanical
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Engineering
GA QF8UF
UT WOS:000612285500012
DA 2022-11-30
ER

PT J
AU Le, YZ
AF Le, Yun-Zheng
TI VEGF production production and signaling in Muller glia are critical to
   modulating vascular function and neuronal integrity in diabetic
   retinopathy and hypoxic retinal vascular diseases
SO VISION RESEARCH
LA English
DT Article
DE Muller glia; DR; ROP; AMD; VEGF; Hypoxia; BRB breakdown; Neurotrophin;
   Neuroprotection
ID ENDOTHELIAL GROWTH-FACTOR; HIPPOCAMPAL-NEURONS; PERMEABILITY FACTOR;
   SURVIVAL FACTOR; FACTOR RECEPTOR; RAT MODEL; IN-VIVO; EXPRESSION; CELLS;
   ACTIVATION
AB Muller glia (MG) are major retinal supporting cells that participate in retinal metabolism, function, maintenance, and protection. During the pathogenesis of diabetic retinopathy (DR), a neurovascular disease and a leading cause of blindness, MG modulate vascular function and neuronal integrity by regulating the production of angiogenic and trophic factors. In this article, I will (1) briefly summarize our work on delineating the role and mechanism of MG-modulated vascular function through the production of vascular endothelial growth factor (VEGF) and on investigating VEGF signaling-mediated MG viability and neural protection in diabetic animal models, (2) explore the relationship among VEGF and neurotrophins in protecting Muller cells in in vitro models of diabetes and hypoxia and its potential implication to neuroprotection in DR and hypoxic retinal diseases, and (3) discuss the relevance of our work to the effectiveness and safety of long-term anti-VEGF therapies, a widely used strategy to combat DR, diabetic macular edema, neovascular age-related macular degeneration, retinopathy of prematurity, and other hypoxic retinal vascular disorders. (C) 2017 Elsevier Ltd. All rights reserved.
C1 [Le, Yun-Zheng] Univ Oklahoma, Hlth Sci Ctr, Dept Med Endocrinol, Oklahoma City, OK 73104 USA.
   [Le, Yun-Zheng] Univ Oklahoma, Hlth Sci Ctr, Dept Cell Biol, Oklahoma City, OK 73104 USA.
   [Le, Yun-Zheng] Univ Oklahoma, Hlth Sci Ctr, Dept Ophthalmol, Oklahoma City, OK 73104 USA.
   [Le, Yun-Zheng] Univ Oklahoma, Hlth Sci Ctr, Harold Hamm Diabet Ctr, Oklahoma City, OK 73104 USA.
C3 University of Oklahoma System; University of Oklahoma Health Sciences
   Center; University of Oklahoma System; University of Oklahoma Health
   Sciences Center; University of Oklahoma System; University of Oklahoma
   Health Sciences Center; University of Oklahoma System; University of
   Oklahoma Health Sciences Center
RP Le, YZ (通讯作者)，941 SL Young Blvd,BSEB 302G, Oklahoma City, OK 73104 USA.
EM Yun-Le@ouhsc.edu
FU NIH [GM104934, EY020900, EY26970]; American Diabetes Association;
   International Retinal Research Foundation; Presbyterian Health
   Foundation; Oklahoma Center for the Advancement of Science and
   Technology; Oklahoma Center for Adult Stem Cell Research; Research to
   Prevent Blindness; NATIONAL EYE INSTITUTE [P30EY021725, R01EY026970,
   R01EY020900] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL
   MEDICAL SCIENCES [P20GM104934] Funding Source: NIH RePORTER
FX I thank Dr. V. P. Sarthy for providing rMC1 cells and Mei Zhu for
   technical assistance. Our work was supported by NIH grants GM104934,
   EY020900, EY26970, grants from American Diabetes Association, Research
   to Prevent Blindness, International Retinal Research Foundation,
   Presbyterian Health Foundation, Oklahoma Center for the Advancement of
   Science and Technology, and Oklahoma Center for Adult Stem Cell
   Research, and an endowment from Choctaw Nation.
CR AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203
   ALON T, 1995, NAT MED, V1, P1024, DOI 10.1038/nm1095-1024
   Arevalo JF, 2016, BRIT J OPHTHALMOL, V100, P1605, DOI 10.1136/bjophthalmol-2015-307950
   Arevalo JF, 2016, RETINA-J RET VIT DIS, V36, P859, DOI 10.1097/IAE.0000000000000827
   Bai YY, 2009, J PATHOL, V219, P446, DOI 10.1002/path.2611
   Bouzioukh F, 2006, EUR J NEUROSCI, V23, P2247, DOI 10.1111/j.1460-9568.2006.04783.x
   Cariboni A, 2007, J NEUROSCI, V27, P2387, DOI 10.1523/JNEUROSCI.5075-06.2007
   Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0
   Cepko CL, 1996, P NATL ACAD SCI USA, V93, P589, DOI 10.1073/pnas.93.2.589
   Copits BA, 2011, J NEUROSCI, V31, P7334, DOI 10.1523/JNEUROSCI.0100-11.2011
   Dong SQ, 2014, ADV EXP MED BIOL, V801, P139, DOI 10.1007/978-1-4614-3209-8_18
   Du YP, 2002, J NEUROCHEM, V80, P771, DOI 10.1046/j.0022-3042.2001.00737.x
   El-Asrar AM, 2001, AM J OPHTHALMOL, V132, P551, DOI 10.1016/S0002-9394(01)01127-8
   El-Remessy AB, 2007, FASEB J, V21, P2528, DOI 10.1096/fj.06-7854com
   El-Remessy AB, 2003, AM J PATHOL, V162, P1995, DOI 10.1016/S0002-9440(10)64332-5
   FERRARA N, 1989, BIOCHEM BIOPH RES CO, V161, P851, DOI 10.1016/0006-291X(89)92678-8
   Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669
   Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0
   Fu SH, 2015, DIABETES, V64, P3554, DOI 10.2337/db15-0180
   Fu S, 2014, ADV EXP MED BIOL, V801, P401, DOI 10.1007/978-1-4614-3209-8_51
   Gerber HP, 1999, DEVELOPMENT, V126, P1149
   Grunwald JE, 2015, OPHTHALMOLOGY, V122, P809, DOI 10.1016/j.ophtha.2014.11.007
   Haigh JJ, 2003, DEV BIOL, V262, P225, DOI 10.1016/S0012-1606(03)00356-7
   Hao TF, 2013, FREE RADICAL BIO MED, V63, P421, DOI 10.1016/j.freeradbiomed.2013.05.036
   He CY, 2013, AM J PATHOL, V183, P626, DOI 10.1016/j.ajpath.2013.04.028
   Herran E, 2013, EUR J PHARM BIOPHARM, V85, P1183, DOI 10.1016/j.ejpb.2013.03.034
   Hombrebueno JR, 2015, SCI REP-UK, V5, DOI 10.1038/srep18316
   Jeon CJ, 1998, J NEUROSCI, V18, P8936
   Jiang YC, 2014, INVEST OPHTH VIS SCI, V55, P824, DOI 10.1167/iovs.13-13755
   Karl Mike O, 2012, Methods Mol Biol, V884, P213, DOI 10.1007/978-1-61779-848-1_15
   Karl MO, 2008, P NATL ACAD SCI USA, V105, P19508, DOI 10.1073/pnas.0807453105
   Kilic U, 2006, J NEUROSCI, V26, P12439, DOI 10.1523/JNEUROSCI.0434-06.2006
   Kim BW, 2008, CELL SIGNAL, V20, P714, DOI 10.1016/j.cellsig.2007.12.009
   Kowluru RA, 2003, FREE RADICAL RES, V37, P1169, DOI 10.1080/10715760310001604189
   Kowluru RA, 2000, CURR EYE RES, V21, P814, DOI 10.1076/ceyr.21.4.814.5545
   Krakora D, 2013, MOL THER, V21, P1602, DOI 10.1038/mt.2013.108
   Kvanta A, 1996, INVEST OPHTH VIS SCI, V37, P1929
   LAVAIL MM, 1992, P NATL ACAD SCI USA, V89, P11249, DOI 10.1073/pnas.89.23.11249
   Le YZ, 2011, J OPHTHALMOL, V2011, DOI 10.1155/2011/806783
   Leal EC, 2007, INVEST OPHTH VIS SCI, V48, P5257, DOI 10.1167/iovs.07-0112
   Lee MY, 1999, NEUROSCI LETT, V265, P107, DOI 10.1016/S0304-3940(99)00219-0
   Lennmyr F, 1998, J NEUROPATH EXP NEUR, V57, P874, DOI 10.1097/00005072-199809000-00009
   Lopez PF, 1996, INVEST OPHTH VIS SCI, V37, P855
   Ma YH, 2012, J NEUROSCI RES, V90, P1873, DOI 10.1002/jnr.23088
   Maguire MG, 2016, OPHTHALMOLOGY, V123, P1751, DOI 10.1016/j.ophtha.2016.03.045
   McCloskey DP, 2008, BRAIN RES BULL, V76, P36, DOI 10.1016/j.brainresbull.2007.11.018
   McCloskey DP, 2005, J NEUROSCI, V25, P8889, DOI 10.1523/JNEUROSCI.2577-05.2005
   MILLER JW, 1994, AM J PATHOL, V145, P574
   Ng D, 2009, PLOS BIOL, V7, P278, DOI 10.1371/journal.pbio.1000041
   Nishijima K, 2007, AM J PATHOL, V171, P53, DOI 10.2353/ajpath.2007.061237
   Penn JS, 2008, PROG RETIN EYE RES, V27, P331, DOI 10.1016/j.preteyeres.2008.05.001
   PIERCE EA, 1995, P NATL ACAD SCI USA, V92, P905, DOI 10.1073/pnas.92.3.905
   Reichenbach A, 2013, GLIA, V61, P651, DOI 10.1002/glia.22477
   Robbins SG, 1997, GROWTH FACTORS, V14, P229, DOI 10.3109/08977199709021522
   Saint-Geniez M, 2009, P NATL ACAD SCI USA, V106, P18751, DOI 10.1073/pnas.0905010106
   Saint-Geniez M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003554
   Sapieha P, 2008, NAT MED, V14, P1067, DOI 10.1038/nm.1873
   Sarthy VP, 1998, INVEST OPHTH VIS SCI, V39, P212
   SMITH LEH, 1994, INVEST OPHTH VIS SCI, V35, P101
   Sun YJ, 2003, J CLIN INVEST, V111, P1843, DOI 10.1172/JCI200317977
   Ueki Y, 2009, VISION RES, V49, P615, DOI 10.1016/j.visres.2009.01.012
   Wang JJ, 2015, WORLD J DIABETES, V6, P726, DOI 10.4239/wjd.v6.i5.726
   Wang JJ, 2010, DIABETES, V59, P2297, DOI 10.2337/db09-1420
   Wecker T, 2017, BRIT J OPHTHALMOL, V101, P353, DOI 10.1136/bjophthalmol-2016-308668
   Wick A, 2002, J NEUROSCI, V22, P6401
   Xi X, 2005, BIOCHEM BIOPH RES CO, V326, P548, DOI 10.1016/j.bbrc.2004.11.064
   Yasuhara T, 2004, EUR J NEUROSCI, V19, P1494, DOI 10.1111/j.1460-9568.2004.03254.x
   Zheng C, 2007, BIOCHEM BIOPH RES CO, V363, P989, DOI 10.1016/j.bbrc.2007.09.088
NR 68
TC 60
Z9 65
U1 0
U2 9
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0042-6989
EI 1878-5646
J9 VISION RES
JI Vision Res.
PD OCT
PY 2017
VL 139
SI SI
BP 108
EP 114
DI 10.1016/j.visres.2017.05.005
PG 7
WC Neurosciences; Ophthalmology; Psychology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology; Ophthalmology; Psychology
GA FQ4FA
UT WOS:000418311900014
PM 28601428
OA Green Accepted, Bronze
DA 2022-11-30
ER

PT J
AU Ahmed, F
   Li, Y
   Fanning, K
   Netzel, M
   Schenk, PM
AF Ahmed, Faruq
   Li, Yan
   Fanning, Kent
   Netzel, Michael
   Schenk, Peer M.
TI Effect of drying, storage temperature and air exposure on astaxanthin
   stability from Haematococcus pluvialis
SO FOOD RESEARCH INTERNATIONAL
LA English
DT Article
DE Astaxanthin; Cost-benefit analysis; Freeze-drying; Haematococcus
   pluvialis; Spray-drying
ID CAROTENOIDS; DEGRADATION; MICROALGAE
AB Astaxanthin is a powerful antioxidant with various health benefits such as prevention of age-related macular degeneration and improvement of the immune system, liver and heart function. To improve the post-harvesting stability of astaxanthin used in food, feed and nutraceutical industries, the biomass of the high astaxanthin producing alga Haematococcus pluvialis was dried by spray- or freeze-drying and under vacuum or air at -20 degrees C to 37 degrees C for 20 weeks. Freeze-drying led to 41% higher astaxanthin recovery compared to commonly-used spray-drying. Low storage temperature (-20 degrees C, 4 degrees C) and vacuum-packing also showed higher astaxanthin stability with as little as 123 +/- 3.1% degradation during 20 weeks of storage. Cost-benefit analysis showed that freeze-drying followed by vacuum-packed storage at -20 degrees C can generate AUD$600 higher profit compared to spray-drying from 100 kg H. pluvialis powder. Therefore, freeze-drying can be suggested as a mild and more profitable method for ensuring longer shelf life of astaxanthin from H. pluvialis. (C) 2015 Elsevier Ltd. All rights reserved.
C1 [Ahmed, Faruq; Schenk, Peer M.] Univ Queensland, Algae Biotechnol Lab, Sch Agr & Food Sci, Brisbane, Qld 4072, Australia.
   [Li, Yan] James Cook Univ, Coll Marine & Environm Sci, Townsville, Qld 4811, Australia.
   [Fanning, Kent] DAFF, Coopers Plains, Qld 4108, Australia.
   [Netzel, Michael] Univ Queensland, Ctr Nutr & Food Sci, Queensland Alliance Agr & Food Innovat, Coopers Plains, Qld 4108, Australia.
C3 University of Queensland; James Cook University; Queensland Department
   of Agriculture & Fisheries; University of Queensland
RP Schenk, PM (通讯作者)，Univ Queensland, Algae Biotechnol Lab, Sch Agr & Food Sci, Brisbane, Qld 4072, Australia.
EM p.schenk@uq.edu.au
RI Li, Yan/A-5532-2008; Netzel, Michael/M-4050-2013; Schenk,
   Peer/B-7879-2016
OI Li, Yan/0000-0002-9102-0917; Netzel, Michael/0000-0002-3136-3926;
   Schenk, Peer/0000-0003-4878-3799; Li, Yan/0000-0002-9742-0081
FU James Cook University-The University of Queensland Collaborative
   Research [JCU20732]
FX We are grateful to the microalgae team at the James Cook University/MBD
   Research & Development Facility for culturing and harvesting microalgal
   cultures. This work was partially funded by James Cook University-The
   University of Queensland Collaborative Research (JCU20732).
CR Ahmed F, 2014, FOOD CHEM, V165, P300, DOI 10.1016/j.foodchem.2014.05.107
   Bhattacharjee M., 2014, J ALGAL BIOMASS UTIL, V5, P21
   Bjerkeng Bjorn, 2008, V4, P237, DOI 10.1007/978-3-7643-7499-0_12
   Borowitzka MA, 2013, J APPL PHYCOL, V25, P743, DOI 10.1007/s10811-013-9983-9
   Bustos-Garza C, 2013, FOOD RES INT, V54, P641, DOI 10.1016/j.foodres.2013.07.061
   Fanning KJ, 2010, J SCI FOOD AGR, V90, P91, DOI 10.1002/jsfa.3787
   Gouveia L., 2003, Innovative Food Science & Emerging Technologies, V4, P227, DOI 10.1016/S1466-8564(03)00002-X
   Lorenz R. T., 1999, NATUROSE TECHNICAL B, V60
   Miao FP, 2013, CHIN J OCEANOL LIMN, V31, P1181, DOI 10.1007/s00343-013-2105-3
   Niamnuy C, 2008, J FOOD ENG, V87, P591, DOI 10.1016/j.jfoodeng.2008.01.013
   Raposo MFJ, 2012, WORLD J MICROB BIOT, V28, P1253, DOI 10.1007/s11274-011-0929-6
   Spiller Gene A., 2003, Journal of Medicinal Food, V6, P51, DOI 10.1089/109662003765184741
   Tachaprutinun A, 2009, INT J PHARMACEUT, V374, P119, DOI 10.1016/j.ijpharm.2009.03.001
NR 13
TC 46
Z9 50
U1 2
U2 82
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0963-9969
EI 1873-7145
J9 FOOD RES INT
JI Food Res. Int.
PD AUG
PY 2015
VL 74
BP 231
EP 236
DI 10.1016/j.foodres.2015.05.021
PG 6
WC Food Science & Technology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Food Science & Technology
GA CO2FJ
UT WOS:000358971200025
PM 28411988
DA 2022-11-30
ER

PT J
AU Nakajima, E
   Hammond, KB
   Shearer, TR
   Azuma, M
AF Nakajima, E.
   Hammond, K. B.
   Shearer, T. R.
   Azuma, M.
TI Activation of the mitochondrial caspase pathway and subsequent calpain
   activation in monkey RPE cells cultured under zinc depletion
SO EYE
LA English
DT Article
DE calpain; caspase; monkey; non-human primate; AMD; zinc depletion
ID RETINAL-PIGMENT EPITHELIUM; MACULAR DEGENERATION; SUPEROXIDE-DISMUTASE;
   INTRACELLULAR ZINC; APOPTOSIS; AGE; CHELATION; PROTEASE; COPPER; DAMAGE
AB Purpose Decreased zinc levels in the macula are reported in patients with age-related macular degeneration, and the zinc chelator N,N,N', N'-tetrakis (2-pyridylmethyl) ethylenediamine) (TPEN) causes death of human retinal pigment epithelial (RPE) cells. The purpose of the present study was to investigate signal transduction pathways during cell death initiated by TPEN, using monkey RPE cells.
   Methods RPE cells were cultured with TPEN. Activation of calpains and caspases, and proteolysis of their substrates were detected by immunoblotting. Incubation of calpain inhibitor SNJ-1945 or caspase inhibitor z-VAD-fmk was used to confirm activation of specific proteases.
   Results TPEN caused a time-dependent decrease in viable RPE cells. Cell death was accompanied by activation of calpain-1, caspase-9, and caspase-3. SNJ-1945 inhibited calpain activation and slightly inhibited caspase-9 activation. z-VAD-fmk inhibited caspases and calpain-1 activation. TPEN did not activate caspase-12.
   Conclusions Relative zinc deficiency in RPE cells causes activation of cytosolic calpain and mitochondrial caspase pathways without ER stress.
C1 [Nakajima, E.; Hammond, K. B.; Azuma, M.] Senju Pharmaceut Corp Ltd, Senju Lab Ocular Sci, Portland, OR 97239 USA.
   [Nakajima, E.; Hammond, K. B.; Shearer, T. R.; Azuma, M.] Oregon Hlth & Sci Univ, Dept Integrat Biosci, Portland, OR 97201 USA.
C3 Senju Pharmaceutical Co. Ltd.; Oregon Health & Science University
RP Azuma, M (通讯作者)，Senju Pharmaceut Corp Ltd, 4640 SW Macadam Ave,Suite 200C, Portland, OR 97239 USA.
EM azumam@ohsu.edu
FU Senju Pharmaceutical Co, Ltd; NIH [RR00163]; NATIONAL CENTER FOR
   RESEARCH RESOURCES [P51RR000163] Funding Source: NIH RePORTER; OFFICE OF
   THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH [U42OD010426] Funding
   Source: NIH RePORTER
FX Dr Shearer is a paid consultant for Senju Pharmaceutical Co, Ltd, a
   company that may have a commercial interest in the results of this
   research and technology. Drs Azuma and Nakajima are employees of Senju
   Pharmaceutical Co, Ltd. This potential conflict of interest was
   reviewed, and a management plan approved by the OHSU Conflict of
   Interest in Research Committee was implemented. This research was
   supported in part by NIH grant RR00163 to the Oregon National Primate
   Research Center.
CR Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   Azuma M, 1997, EXP EYE RES, V64, P529, DOI 10.1006/exer.1996.0234
   Azuma M, 2010, J OCUL PHARMACOL TH, V26, P367, DOI 10.1089/jop.2010.0042
   Bayir H, 2008, CRIT CARE, V12, DOI 10.1186/cc6779
   Cregan SP, 2004, ONCOGENE, V23, P2785, DOI 10.1038/sj.onc.1207517
   Hyun HJ, 2001, INVEST OPHTH VIS SCI, V42, P460
   Julien S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0029245
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kitagaki H, 2000, BIOSCI BIOTECH BIOCH, V64, P689, DOI 10.1271/bbb.64.689
   Krampe B, 2010, CYTOTECHNOLOGY, V62, P175, DOI 10.1007/s10616-010-9274-0
   Mamballikalathil I, 2000, INVEST OPHTH VIS SCI, V41, P529
   MARKLUND SL, 1982, CANCER RES, V42, P1955
   MATSUMOTO B, 1990, INVEST OPHTH VIS SCI, V31, P879
   MCCABE MJ, 1993, LAB INVEST, V69, P101
   Nakajima E, 2011, INVEST OPHTH VIS SCI, V52, P7059, DOI 10.1167/iovs.11-7497
   Nakatani T, 2000, CHEM-BIOL INTERACT, V125, P151, DOI 10.1016/S0009-2797(99)00166-0
   Newsome DA, 1995, J TRACE ELEM EXP MED, V8, P193
   NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0
   Oliver FJ, 1998, J BIOL CHEM, V273, P33533, DOI 10.1074/jbc.273.50.33533
   PIGUET B, 1995, EYE, V9, P34, DOI 10.1038/eye.1995.5
   Sandbach JM, 2001, INVEST OPHTH VIS SCI, V42, P2173
   Sanges D, 2006, P NATL ACAD SCI USA, V103, P17366, DOI 10.1073/pnas.0606276103
   SATO M, 1993, FREE RADICAL BIO MED, V14, P325, DOI 10.1016/0891-5849(93)90029-T
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Tamada Y, 2007, CURR EYE RES, V32, P565, DOI 10.1080/02713680701359633
   Wang KKW, 2000, TRENDS NEUROSCI, V23, P20, DOI 10.1016/S0166-2236(99)01479-4
   Wood DE, 1999, J BIOL CHEM, V274, P8309, DOI 10.1074/jbc.274.12.8309
NR 27
TC 12
Z9 12
U1 0
U2 6
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-222X
EI 1476-5454
J9 EYE
JI Eye
PD JAN
PY 2014
VL 28
IS 1
BP 85
EP 92
DI 10.1038/eye.2013.239
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 286BS
UT WOS:000329440100014
PM 24202052
OA Bronze, Green Published
DA 2022-11-30
ER

PT J
AU Kuo, CN
   Chen, CY
   Lai, CH
   Lai, LJ
   Wu, PC
   Hung, CH
   Chen, CH
AF Kuo, Chien-Neng
   Chen, Chung-Yi
   Lai, Chen-Hsiung
   Lai, Li-Ju
   Wu, Pei-Chen
   Hung, Chia-Hui
   Chen, Ching-Hsein
TI Cell cycle regulation by bevacizumab in ARPE-19 human retinal pigment
   epithelial cells
SO MOLECULAR MEDICINE REPORTS
LA English
DT Article
DE bevacizumab; human retinal pigment epithelial cells; cell cycle; G1/S
   arrest; age-related macular degeneration
ID INTRAVITREAL INJECTION; ENDOTHELIAL-CELLS; DEPENDENT KINASES; GROWTH;
   INHIBITION; AVASTIN; TEARS; P53
AB Bevacizumab, a recombinant humanized monoclonal antibody, binds vascular endothelial growth factor (VEGF) and inhibits its interaction with receptors found on endothelial cells. Bevacizumab has been increasingly used as an off-label treatment for exudative age-related macular degeneration (A MD). Whether or not bevacizumab is capable of arresting the growth of human retinal pigment epithelial cells remains to be clarified. In this study, flow cytometry was used to evaluate whether bevacizumab markedly induced the G(1)/S phase arrest. The G(1)/S phase cycle-related protein analysis demonstrated that the expression of cyclin-dependent kinase (CDK)2, 4 and 6 and of cyclin D and E, as well as the phosphorylation of retinoblastoma tumor suppressor protein (ppRB) production were found to be markedly reduced by bevacizumab. By contrast, the protein levels of p53, p16, p21 and p27 were increased in bevacizumab-treated ARPE-19 cells (a human retinal pigment epithelial cell line). These events of G(1)/S arrest induced by bevacizumab in ARPE-19 cells suggest that a preventive effect of bevacizumab exists in AMD.
C1 [Chen, Ching-Hsein] Natl Chiayi Univ, Coll Life Sci, Dept Microbiol Immunol & Biopharmaceut, Chiayi 60004, Taiwan.
   [Kuo, Chien-Neng; Lai, Chen-Hsiung; Lai, Li-Ju; Wu, Pei-Chen] Chang Gung Mem Hosp, Dept Ophthalmol, Chiayi, Taiwan.
   [Kuo, Chien-Neng; Lai, Chen-Hsiung; Lai, Li-Ju; Wu, Pei-Chen; Hung, Chia-Hui] Chang Gung Univ, Coll Med, Gueishan, Taiwan.
   [Kuo, Chien-Neng; Lai, Chen-Hsiung; Lai, Li-Ju; Wu, Pei-Chen] Chang Gung Univ Sci & Technol, Gueishan, Taiwan.
   [Chen, Chung-Yi] Fooyin Univ, Sch Med & Hlth Sci, Dept Med Lab Sci & Biotechnol, Kaohsiung 83102, Taiwan.
   [Hung, Chia-Hui] Chang Gung Mem Hosp, Dept Dermatol, Chiayi, Taiwan.
C3 National Chiayi University; Chang Gung Memorial Hospital; Chang Gung
   University; Chang Gung University of Science & Technology; Fooyin
   University; Chang Gung Memorial Hospital
RP Chen, CH (通讯作者)，Natl Chiayi Univ, Coll Life Sci, Dept Microbiol Immunol & Biopharmaceut, 300 Syuefu Rd, Chiayi 60004, Taiwan.
EM chench@mail.ncyu.edu.tw
FU Chang Gung Memorial Hospital, ROC [CMRPG6B0041]
FX This study was supported by a grant from the Chang Gung Memorial
   Hospital, ROC: CMRPG6B0041.
CR Arias L, 2007, EUR J OPHTHALMOL, V17, P992, DOI 10.1177/112067210701700622
   Attar-Schneider O, 2012, LAB INVEST, V92, P178, DOI 10.1038/labinvest.2011.162
   Brar VS, 2009, J OCUL PHARMACOL TH, V25, P507, DOI 10.1089/jop.2009.0028
   Das SK, 2008, BBA-GEN SUBJECTS, V1780, P743, DOI 10.1016/j.bbagen.2008.01.003
   Forooghian F, 2008, CAN J OPHTHALMOL, V43, P246, DOI 10.3129/i08-017
   Garg S, 2008, CLIN EXP OPHTHALMOL, V36, P252, DOI 10.1111/j.1442-9071.2008.01710.x
   Jinno S, 1999, ONCOGENE, V18, P565, DOI 10.1038/sj.onc.1202347
   Luthra S, 2006, RETINA-J RET VIT DIS, V26, P512, DOI 10.1097/01.iae.0000222547.35820.52
   Masamha CP, 2009, CANCER RES, V69, P6565, DOI 10.1158/0008-5472.CAN-09-0913
   Mueller A, 1997, CANCER RES, V57, P5542
   Sherr CJ, 2000, CANCER RES, V60, P3689
   SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149
   Shima C, 2008, ACTA OPHTHALMOL, V86, P372, DOI 10.1111/j.1600-0420.2007.01067.x
   Spitzer MS, 2006, BRIT J OPHTHALMOL, V90, P1316, DOI 10.1136/bjo.2006.095190
   Subramanyam Anand, 2007, Indian J Ophthalmol, V55, P483
   Ukomadu C, 2003, J BIOL CHEM, V278, P43586, DOI 10.1074/jbc.M307194200
   Vivar OI, 2009, BIOCHEM PHARMACOL, V78, P469, DOI 10.1016/j.bcp.2009.05.008
   Yoo YA, 2005, MOL CELL BIOL, V25, P6603, DOI 10.1128/MCB.25.15.6603-6616.2005
   Yu QY, 2001, NATURE, V411, P1017, DOI 10.1038/35082500
NR 19
TC 5
Z9 6
U1 1
U2 6
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1791-2997
J9 MOL MED REP
JI Mol. Med. Rep.
PD OCT
PY 2012
VL 6
IS 4
BP 701
EP 704
DI 10.3892/mmr.2012.986
PG 4
WC Oncology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Research & Experimental Medicine
GA 006TD
UT WOS:000308841000003
PM 22798045
OA Bronze
DA 2022-11-30
ER

PT J
AU Lauridsen, LH
   Rothnagel, JA
   Veedu, RN
AF Lauridsen, Lasse H.
   Rothnagel, Joseph A.
   Veedu, Rakesh N.
TI Enzymatic Recognition of 2 '-Modified Ribonucleoside 5 '-Triphosphates:
   Towards the Evolution of Versatile Aptamers
SO CHEMBIOCHEM
LA English
DT Review
DE aptamers; nucleotides; polymerases; SELEX
ID T7 RNA-POLYMERASE; IN-VITRO SELECTION; LOCKED NUCLEIC-ACIDS; DIRECTED
   SYNTHESIS; MODIFIED OLIGONUCLEOTIDES; DNA-POLYMERASES; EMERGING CLASS;
   POLYMERIZATION; ANALOGS; NUCLEOTIDES
AB The quest for effective, selective and nontoxic nucleic-acid-based drugs has led to designing modifications of naturally occurring nucleosides. A number of modified nucleic acids have been made in the past decades in the hope that they would prove useful in target-validation studies and therapeutic applications involving antisense, RNAi, aptamer, and ribozyme-based technologies. Since their invention in the early 1990s, aptamers have emerged as a very promising class of therapeutics, with one drug entering the market for the treatment of age-related macular degeneration. To combat the limitations of aptamers containing naturally occurring nucleotides, chemically modified nucleotides have to be used. In order to apply modified nucleotides in aptamer drug development, their enzyme-recognition capabilities must be understood. For this purpose, several modified nucleoside 5'-triphosphates were synthesized and investigated as substrates for various enzymes. Herein, we review studies on the enzyme-recognition of various 2'-sugar-modified NTPs that were carried out with a view to their effective utilization in SELEX processes to generate versatile aptamers.
C1 [Lauridsen, Lasse H.; Rothnagel, Joseph A.; Veedu, Rakesh N.] Univ Queensland, Sch Chem & Mol Biosci, Brisbane, Qld 4072, Australia.
   [Lauridsen, Lasse H.] Tech Univ Denmark, Dept Micro & Nanotechnol, DK-2800 Lyngby, Denmark.
C3 University of Queensland; Technical University of Denmark
RP Veedu, RN (通讯作者)，Univ Queensland, Sch Chem & Mol Biosci, Brisbane, Qld 4072, Australia.
EM rakesh@uq.edu.au
RI Lauridsen, Lasse/E-3839-2012; Rothnagel, Joe/A-4874-2010
OI Rothnagel, Joe/0000-0002-6710-3165
FU University of Queensland; Novo Nordisk Fonden [NNF10CC1016517] Funding
   Source: researchfish
FX We greatly appreciate the financial support received from The University
   of Queensland (The UQ Fellowship and the Early Career Research
   Fellowship Schemes).
CR Ambros V, 2001, CELL, V107, P823, DOI 10.1016/S0092-8674(01)00616-X
   AURUP H, 1992, BIOCHEMISTRY-US, V31, P9636, DOI 10.1021/bi00155a016
   Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5
   Bera S, 2001, TETRAHEDRON LETT, V42, P5813, DOI 10.1016/S0040-4039(01)01118-2
   BROWN D, 1995, BIOCHEMISTRY-US, V34, P14765, DOI 10.1021/bi00045a018
   Burmeister PE, 2006, OLIGONUCLEOTIDES, V16, P337, DOI 10.1089/oli.2006.16.337
   Burmeister PE, 2005, CHEM BIOL, V12, P25, DOI 10.1016/j.chembiol.2004.10.017
   Carroll SS, 2003, J BIOL CHEM, V278, P11979, DOI 10.1074/jbc.M210914200
   Chelliserrykattil J, 2004, NAT BIOTECHNOL, V22, P1155, DOI 10.1038/nbt1001
   Chi GC, 2005, NUCLEOS NUCLEOT NUCL, V24, P1449, DOI 10.1080/15257770500265703
   CLARK JM, 1988, NUCLEIC ACIDS RES, V16, P9677, DOI 10.1093/nar/16.20.9677
   CONRAD F, 1995, NUCLEIC ACIDS RES, V23, P1845, DOI 10.1093/nar/23.11.1845
   Crooke S.T, 2008, ANTISENSE DRUG TECHN, P3
   Das SR, 2005, CURR OPIN CHEM BIOL, V9, P585, DOI 10.1016/j.cbpa.2005.10.009
   DEMESMAEKER A, 1995, ACCOUNTS CHEM RES, V28, P366, DOI 10.1021/ar00057a002
   Dutartre H, 2006, ANTIMICROB AGENTS CH, V50, P4161, DOI 10.1128/AAC.00433-06
   EATON BE, 1995, ANNU REV BIOCHEM, V64, P837, DOI 10.1146/annurev.bi.64.070195.004201
   ELLINGTON AD, 1990, NATURE, V346, P818, DOI 10.1038/346818a0
   Famulok M, 2007, CHEM REV, V107, P3715, DOI 10.1021/cr0306743
   Gopinath SCB, 2007, ANAL BIOANAL CHEM, V387, P171, DOI 10.1007/s00216-006-0826-2
   Hannon GJ, 2002, NATURE, V418, P244, DOI 10.1038/418244a
   Huang Y, 1997, BIOCHEMISTRY-US, V36, P13718, DOI 10.1021/bi971609o
   Ichida JK, 2005, J AM CHEM SOC, V127, P2802, DOI 10.1021/ja045364w
   IMAZAWA M, 1975, CHEM PHARM BULL, V23, P604
   Jayasena SD, 1999, CLIN CHEM, V45, P1628
   KAKEFUDA A, 1994, TETRAHEDRON, V50, P10167, DOI 10.1016/S0040-4020(01)81749-X
   Kalota A, 2006, NUCLEIC ACIDS RES, V34, P451, DOI 10.1093/nar/gkj455
   Karthikeyan G, 1999, NUCLEIC ACIDS RES, V27, P3851, DOI 10.1093/nar/27.19.3851
   Keefe AD, 2010, NAT REV DRUG DISCOV, V9, P537, DOI 10.1038/nrd3141
   Kempeneers V, 2005, NUCLEIC ACIDS RES, V33, P3828, DOI 10.1093/nar/gki695
   KLUG SJ, 1994, MOL BIOL REP, V20, P97, DOI 10.1007/BF00996358
   Kore AR, 2008, NUCLEOS NUCLEOT NUCL, V27, P1, DOI 10.1080/15257770701571693
   Koshkin AA, 1998, TETRAHEDRON, V54, P3607, DOI 10.1016/S0040-4020(98)00094-5
   Kuwahara M, 2008, NUCLEIC ACIDS RES, V36, P4257, DOI 10.1093/nar/gkn404
   MCCARTHY JR, 1991, J AM CHEM SOC, V113, P7439, DOI 10.1021/ja00019a061
   Mello CC, 2004, NATURE, V431, P338, DOI 10.1038/nature02872
   MILLIGAN JF, 1987, NUCLEIC ACIDS RES, V15, P8783, DOI 10.1093/nar/15.21.8783
   MONTGOMERY JA, 1978, J ORG CHEM, V43, P541, DOI 10.1021/jo00398a003
   NAIR V, 1992, J AM CHEM SOC, V114, P7951, DOI 10.1021/ja00046a074
   Nimjee SM, 2005, ANNU REV MED, V56, P555, DOI 10.1146/annurev.med.56.062904.144915
   Obika S, 1998, TETRAHEDRON LETT, V39, P5401, DOI 10.1016/S0040-4039(98)01084-3
   Ogino T., 2007, NUCL ACIDS S SER, V51, P355, DOI DOI 10.1093/NASS/NRM178
   Ogino T, 2010, CHEMBIOCHEM, V11, P2597, DOI 10.1002/cbic.201000449
   Ono T, 1997, NUCLEIC ACIDS RES, V25, P4581, DOI 10.1093/nar/25.22.4581
   Opalinska JB, 2002, NAT REV DRUG DISCOV, V1, P503, DOI 10.1038/nrd837
   Padilla R, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/gnf138
   Padilla R, 1999, NUCLEIC ACIDS RES, V27, P1561, DOI 10.1093/nar/27.6.1561
   Pavey JBJ, 2004, ORG BIOMOL CHEM, V2, P869, DOI 10.1039/b314348a
   Peng CG, 2007, J AM CHEM SOC, V129, P5310, DOI 10.1021/ja069100g
   Raines K, 1998, RNA, V4, P340
   Richardson FC, 2000, BIOCHEM PHARMACOL, V59, P1045, DOI 10.1016/S0006-2952(99)00414-1
   Rimmele M, 2003, CHEMBIOCHEM, V4, P963, DOI 10.1002/cbic.200300648
   Ruckman J, 1998, J BIOL CHEM, V273, P20556, DOI 10.1074/jbc.273.32.20556
   Singh SK, 1998, CHEM COMMUN, P455, DOI 10.1039/a708608c
   Sioud M, 1998, NAT BIOTECHNOL, V16, P556, DOI 10.1038/nbt0698-556
   Stoltenburg R, 2007, BIOMOL ENG, V24, P381, DOI 10.1016/j.bioeng.2007.06.001
   TABOR S, 1989, P NATL ACAD SCI USA, V86, P4076, DOI 10.1073/pnas.86.11.4076
   Trempe JF, 2001, J AM CHEM SOC, V123, P4896, DOI 10.1021/ja003859p
   TUERK C, 1990, SCIENCE, V249, P505, DOI 10.1126/science.2200121
   Veedu RN, 2007, NUCLEOS NUCLEOT NUCL, V26, P1207, DOI 10.1080/15257770701527844
   Veedu RN, 2007, CHEMBIOCHEM, V8, P490, DOI 10.1002/cbic.200600501
   Veedu RN, 2010, BIOORG MED CHEM LETT, V20, P6565, DOI 10.1016/j.bmcl.2010.09.044
   Veedu RN, 2010, NEW J CHEM, V34, P877, DOI 10.1039/b9nj00628a
   Veedu RN, 2009, ORG BIOMOL CHEM, V7, P1404, DOI 10.1039/b819946a
   Veedu RN, 2009, MOL BIOSYST, V5, P787, DOI 10.1039/b905513b
   Verma S, 1998, ANNU REV BIOCHEM, V67, P99, DOI 10.1146/annurev.biochem.67.1.99
   Viguera E, 2001, J MOL BIOL, V312, P323, DOI 10.1006/jmbi.2001.4943
   Zhou Y, 2002, MOL PHARMACOL, V61, P222, DOI 10.1124/mol.61.1.222
   Zinnen SP, 2002, RNA, V8, P214, DOI 10.1017/S1355838202014723
NR 69
TC 42
Z9 46
U1 3
U2 56
PU WILEY-V C H VERLAG GMBH
PI WEINHEIM
PA POSTFACH 101161, 69451 WEINHEIM, GERMANY
SN 1439-4227
EI 1439-7633
J9 CHEMBIOCHEM
JI ChemBioChem
PD JAN 2
PY 2012
VL 13
IS 1
BP 19
EP 25
DI 10.1002/cbic.201100648
PG 7
WC Biochemistry & Molecular Biology; Chemistry, Medicinal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy
GA 867VK
UT WOS:000298482700002
PM 22162282
DA 2022-11-30
ER

PT J
AU Brockmann, C
   Schulz, M
   Laube, T
AF Brockmann, Claudia
   Schulz, Marcus
   Laube, Thomas
TI Transmittance characteristics of ultraviolet and blue-light-filtering
   intralocular lenses
SO JOURNAL OF CATARACT AND REFRACTIVE SURGERY
LA English
DT Article
ID INTRAOCULAR-LENS; MACULAR DEGENERATION; CATARACT-SURGERY; CONTRAST
   SENSITIVITY; PIGMENT-EPITHELIUM; COLOR-VISION; DAMAGE; ABSORPTION;
   RADIATION; IMPLANTATION
AB PURPOSE: To record the spectral transmittance curves of various ultraviolet (UV) and blue-light-filtering intraocular lenses (IOLs), evaluate their UV and blue-light-radiation- absorption capacities, and compare them with those of the natural crystalline lens.
   SETTING: Department of Ophthalmology, Duisburg-Essen University, Essen, Germany.
   METHODS: Eight IOLs from 6 manufacturers were evaluated. The transmittance of wavelengths from 200 nm to 800 nm was measured using a high-performance spectrophotometer with a diffuse transmittance accessory through a 1.5 mm aperture.
   RESULTS: All assessed IOLs provided good UVC (200 to 280 nm) and UVB (280 to 320 nm) protection, but 2 IOLs lacked sufficient UVA (320 to 400 nm) protection. Major differences in the absorption capacities were observed in the blue-light range (400 to 500 nm).
   CONCLUSIONS: The absorption characteristics of some UV and blue-light-filtering IOLs resembled those of the crystalline lens, but some differed. Long-term clinical trials should be performed to determine how blue-blocking IOLs affect the risk for progression of age-related macular degeneration.
C1 [Brockmann, Claudia; Laube, Thomas] Duisburg Essen Univ, Dept Ophthalmol, D-45147 Essen, Germany.
   [Schulz, Marcus] Varian Inc, Darmstadt, Germany.
C3 University of Duisburg Essen
RP Brockmann, C (通讯作者)，Duisburg Essen Univ, Dept Ophthalmol, Hufelandstr 55, D-45147 Essen, Germany.
EM brockmann@zentrum-augenheilkunde.de
CR Bhattacharjee H, 2006, J CATARACT REFR SURG, V32, P451, DOI 10.1016/j.jcrs.2005.12.136
   BOETTNER EA, 1962, INVEST OPHTH VISUAL, V1, P776
   Cionni RJ, 2006, J CATARACT REFR SURG, V32, P236, DOI 10.1016/j.jcrs.2005.12.129
   Ernest PH, 2004, J CATARACT REFR SURG, V30, P1755, DOI 10.1016/j.jcrs.2003.12.054
   GROSSWEINER LI, 1984, CURR EYE RES, V3, P137, DOI 10.3109/02713688408997195
   HAM WT, 1979, PHOTOCHEM PHOTOBIOL, V29, P735, DOI 10.1111/j.1751-1097.1979.tb07759.x
   HAM WT, 1976, NATURE, V260, P153, DOI 10.1038/260153a0
   KRAFF MC, 1985, OPHTHALMOLOGY, V92, P366
   Laube T, 2004, OPHTHALMOLOGY, V111, P880, DOI 10.1016/j.ophtha.2003.08.031
   LINDSTROM RL, 1986, J CATARACT REFR SURG, V12, P285, DOI 10.1016/S0886-3350(86)80011-6
   Mainster MA, 2005, ARCH OPHTHALMOL-CHIC, V123, P550, DOI 10.1001/archopht.123.4.550
   Marshall J, 2005, J CATARACT REFR SURG, V31, P2319, DOI 10.1016/j.jcrs.2004.11.061
   PAUTLER EL, 1989, INHERITED ENV INDUCE, P555
   Pitts D G, 1989, J Am Optom Assoc, V60, P420
   Pollack A, 1998, OPHTHALMIC SURG LAS, V29, P286
   Pollack A, 1997, EYE, V11, P523, DOI 10.1038/eye.1997.138
   Pollack A, 1996, OPHTHALMOLOGY, V103, P1546, DOI 10.1016/S0161-6420(96)30464-8
   PUTTING BJ, 1994, EXP EYE RES, V58, P31, DOI 10.1006/exer.1994.1192
   RAPP LM, 1994, INVEST OPHTH VIS SCI, V35, P3540
   Roberts JE, 2001, J PHOTOCH PHOTOBIO B, V64, P136, DOI 10.1016/S1011-1344(01)00196-8
   Rodriguez-Galietero A, 2005, J CATARACT REFR SURG, V31, P1736, DOI 10.1016/j.jcrs.2005.02.039
   Shaban H, 2002, BIOL CHEM, V383, P537, DOI 10.1515/BC.2002.054
   Sparrow JR, 2004, J CATARACT REFR SURG, V30, P873, DOI 10.1016/j.jcrs.2004.01.031
   Sparrow JR, 2001, INVEST OPHTH VIS SCI, V42, P1356
   Sparrow JR, 2000, INVEST OPHTH VIS SCI, V41, P1981
   TAYLOR HR, 1992, ARCH OPHTHALMOL-CHIC, V110, P99, DOI 10.1001/archopht.1992.01080130101035
   Vuori ML, 2006, ACTA OPHTHALMOL SCAN, V84, P92, DOI 10.1111/j.1600-0420.2005.00579.x
   Wang JJ, 2003, OPHTHALMOLOGY, V110, P1960, DOI 10.1016/S0161-6420(03)00816-9
   Werner JS, 2005, BRIT J OPHTHALMOL, V89, P1518, DOI 10.1136/bjo.2005.073734
   Yanagi Y, 2006, J CATARACT REFR SURG, V32, P1540, DOI 10.1016/j.jcrs.2006.04.012
   Yuan ZX, 2004, AM J OPHTHALMOL, V138, P138, DOI 10.1016/j.ajo.2004.02.024
   ZUCLICH JA, 1989, HEALTH PHYS, V56, P671, DOI 10.1097/00004032-198905000-00012
NR 33
TC 51
Z9 52
U1 2
U2 17
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0886-3350
J9 J CATARACT REFR SURG
JI J. Cataract. Refract. Surg.
PD JUL
PY 2008
VL 34
IS 7
BP 1161
EP 1166
DI 10.1016/j.jcrs.2008.03.039
PG 6
WC Ophthalmology; Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Surgery
GA 323MI
UT WOS:000257449800026
PM 18571086
DA 2022-11-30
ER

PT J
AU Jonas, JB
AF Jonas, JB
TI Intraocular availability of triamcinolone acetonide after intravitreal
   injection
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
AB BACKGROUND: To evaluate the intraocular concentration of triamcinolone acetonide after intravitreal injection.
   METHODS: The prospective clinical interventional case series study included 17 patients who had received a 20 to 25 mg intravitreal injection of triamcinolone acetonide as treatment for exudative age-related macular degeneration, diffuse diabetic macular edema, or retinal vein occlusions. During a secondary intraocular surgery taking place 4.1 weeks to 25.7 months after the intravitreal injection, aqueous humor samples were obtained. None of the eyes were vitrectomized.
   RESULTS: In the aqueous humor samples, triamcinolone acetonide was in low, but measurable, concentrations detected up to 1.5 years after the intravitreal injection. Concentrations found in samples obtained during the first 6 months, or 7 to 12 months, respectively, after the injection ranged between 3.0 mug/l and 436 mug/l, and between 0.0 mug/l and 11.2 mug/l, respectively.
   CONCLUSIONS: After injection of triamcinolone acetonide, triamcinolone can be present in measurable concentrations up to 1.5 years after the application. (C) 2004 by Elsevier Inc. All rights reserved.
C1 Univ Heidelberg, Fac Clin Medicine Mannheim, Dept Ophthalmol, Heidelberg, Germany.
C3 Ruprecht Karls University Heidelberg
RP Jonas, JB (通讯作者)，Univ Augenklin, Theodor Kutzer Ufer 1-3, D-68167 Mannheim, Germany.
EM Jost.Jonas@augen.ma.uni-heidelberg.de
CR Beer PM, 2003, OPHTHALMOLOGY, V110, P681, DOI 10.1016/S0161-6420(02)01969-3
   Greenberg PB, 2002, BRIT J OPHTHALMOL, V86, P247, DOI 10.1136/bjo.86.2.247
   Jonas JB, 2003, ARCH OPHTHALMOL-CHIC, V121, P729, DOI 10.1001/archopht.121.5.729
   Jonas JB, 2002, BRIT J OPHTHALMOL, V86, P1066, DOI 10.1136/bjo.86.9.1066
   Machemer R, 1979, Trans Am Ophthalmol Soc, V77, P171
NR 5
TC 85
Z9 93
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD MAR
PY 2004
VL 137
IS 3
BP 560
EP 562
DI 10.1016/j.ajo.2003.08.012
PG 3
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 804VF
UT WOS:000220325500026
PM 15013884
DA 2022-11-30
ER

PT J
AU Borooah, S
   Jeganathan, VS
   Ambrecht, AM
   Oladiwura, D
   Gavin, M
   Dhillon, B
   Cackett, P
AF Borooah, S.
   Jeganathan, V. S.
   Ambrecht, A-M
   Oladiwura, D.
   Gavin, M.
   Dhillon, B.
   Cackett, P.
TI Long-term visual outcomes of intravitreal ranibizumab treatment for wet
   age-related macular degeneration and effect on blindness rates in
   south-east Scotland
SO EYE
LA English
DT Article
ID SUBFOVEAL CHOROIDAL NEOVASCULARIZATION; PHOTODYNAMIC THERAPY; LEGAL
   BLINDNESS; UNITED-STATES; IMPAIRMENT; VERTEPORFIN; TRIAL
AB Aims To evaluate patient visual acuity outcomes and blindness rates attributable to wet AMD with a potential 5-year follow-up from intravitreal ranibizumab treatment (IVTR) in south-east Scotland.
   Methods Data was analysed from 104 eyes of 96 patients who initiated treatment prior to September 2008. The main outcome measures were LogMAR visual acuity, number of clinic visits and the number of injections. Annual blind registration data in south-east Scotland were analysed using blind certifications recorded by the Royal National Institute of Blind People.
   Results Patients had a mean clinical follow-up of 4 years and 1 month and a mean loss of 5.5 letters over the study period. Of the treated eyes 9.6% gained >= 15 letters whilst 24.0% lost >= 15 letters during this period. An average of 9.56 injections were administered per patient. The age-sex standardised incidence of legal blindness attributable to wet AMD in south-east Scotland peaked at 9.1 cases per 100 000 of the population in 2006 in either eye. Following the introduction of IVTR there were annual decreases in the incidence of blindness attributable to AMD falling to a trough of 4.8 cases per 100 000 of the population in 2011.
   Conclusions This study demonstrates that the majority of patients in a south-east Scotland maintain their vision following IVTR in wet AMD in the real-world setting. Our study also suggests that the introduction of IVTR has had population wide benefits in reducing the blindness attributable to wet AMD in the south-east Scotland population.
C1 [Borooah, S.; Jeganathan, V. S.; Ambrecht, A-M; Dhillon, B.; Cackett, P.] Univ Edinburgh, Dept Ophthalmol, Edinburgh EH3 9HA, Midlothian, Scotland.
   [Oladiwura, D.; Gavin, M.] NHS Greater Glasgow & Clyde, Gartnavel Gen Hosp, Dept Ophthalmol, Glasgow, Lanark, Scotland.
C3 University of Edinburgh
RP Borooah, S (通讯作者)，Univ Edinburgh, Dept Ophthalmol, Princess Alexandra Eye Pavil,Chalmers St, Edinburgh EH3 9HA, Midlothian, Scotland.
EM shyamanga@aol.com
RI Borooah, Shyamanga/AAM-6581-2021
CR Abraham P, 2010, AM J OPHTHALMOL, V150, P315, DOI 10.1016/j.ajo.2010.04.011
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Barry RJ, 2005, BRIT J OPHTHALMOL, V89, P995, DOI 10.1136/bjo.2004.059915
   Bloch SB, 2012, AM J OPHTHALMOL, V153, P209, DOI 10.1016/j.ajo.2011.10.016
   Bressler NM, 2011, ARCH OPHTHALMOL-CHIC, V129, P709, DOI 10.1001/archophthalmol.2011.140
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Bunce C, 1998, BRIT J OPHTHALMOL, V82, P72, DOI 10.1136/bjo.82.1.72
   Cohen SY, 2007, BRIT J OPHTHALMOL, V91, P1173, DOI 10.1136/bjo.2007.115501
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Minassian DC, 2011, BRIT J OPHTHALMOL, V95, P1433, DOI 10.1136/bjo.2010.195370
   Olsen TW, 2004, OPHTHALMOLOGY, V111, P250, DOI 10.1016/j.ophtha.2003.05.030
   ROBINSON R, 1994, BRIT J OPHTHALMOL, V78, P736, DOI 10.1136/bjo.78.10.736
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Singer MA, 2012, OPHTHALMOLOGY, V119, P1175, DOI 10.1016/j.ophtha.2011.12.016
   Ying GS, 2013, OPHTHALMOLOGY, V120, P122, DOI 10.1016/j.ophtha.2012.07.042
NR 16
TC 28
Z9 28
U1 1
U2 2
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-222X
EI 1476-5454
J9 EYE
JI Eye
PD SEP
PY 2015
VL 29
IS 9
BP 1156
EP 1161
DI 10.1038/eye.2015.83
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CR0XD
UT WOS:000361046000005
PM 26043706
OA Green Published, Bronze
DA 2022-11-30
ER

PT J
AU Tawfik, M
   Chen, F
   Goldberg, JL
   Sabel, BA
AF Tawfik, Mohamed
   Chen, Fang
   Goldberg, Jeffrey L.
   Sabel, Bernhard A.
TI Nanomedicine and drug delivery to the retina: current status and
   implications for gene therapy
SO NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY
LA English
DT Review
DE Retinal drug delivery; Nanomedicine; Retina; Retinal diseases; Gene
   therapy; Nanoparticles
ID ENDOTHELIAL GROWTH-FACTOR; CONFOCAL NEUROIMAGING ICON; MACULAR
   DEGENERATION; CHOROIDAL NEOVASCULARIZATION; INTRAVITREAL INJECTION;
   GLOBAL PREVALENCE; POSTERIOR SEGMENT; MOUSE MODEL; LONG-TERM;
   NANOPARTICLE CARBOPLATIN
AB Blindness affects more than 60 million people worldwide. Retinal disorders, including age-related macular degeneration (AMD), diabetic retinopathy (DR), and glaucoma, are the leading causes of blindness. Finding means to optimize local and sustained delivery of drugs or genes to the eye and retina is one goal to advance the development of new therapeutics. Despite the ease of accessibility of delivering drugs via the ocular surface, the delivery of drugs to the retina is still challenging due to anatomic and physiologic barriers. Designing a suitable delivery platform to overcome these barriers should enhance drug bioavailability and provide a safe, controlled, and sustained release. Current inventions for posterior segment treatments include intravitreal implants and subretinal viral gene delivery that satisfy these criteria. Several other novel drug delivery technologies, including nanoparticles, micelles, dendrimers, microneedles, liposomes, and nanowires, are now being widely studied for posterior segment drug delivery, and extensive research on gene delivery using siRNA, mRNA, or aptamers is also on the rise. This review discusses the current state of retinal drug/gene delivery and highlights future therapeutic opportunities.
C1 [Tawfik, Mohamed; Sabel, Bernhard A.] Otto von Guericke Univ, Med Fac, Inst Med Psychol, Magdeburg, Germany.
   [Chen, Fang; Goldberg, Jeffrey L.] Stanford Univ, Sch Med, Spencer Ctr Vis Res, Byers Eye Inst, Palo Alto, CA 94304 USA.
C3 Otto von Guericke University; Stanford University
RP Sabel, BA (通讯作者)，Otto von Guericke Univ, Med Fac, Inst Med Psychol, Magdeburg, Germany.
EM bernhard.sabel@med.ovgu.de
OI Chen, Fang/0000-0002-6675-5508
FU Otto-v.-Guericke University of Magdeburg; Byers Eye Institute; Projekt
   DEAL
FX Open Access funding enabled and organized by Projekt DEAL. This study
   was funded by Otto-v.-Guericke University of Magdeburg and by Byers Eye
   Institute.
CR Ackland Peter, 2017, Community Eye Health, V30, P71
   ADAMIS AP, 1994, AM J OPHTHALMOL, V118, P445, DOI 10.1016/S0002-9394(14)75794-0
   Albertazzi L, 2013, MOL PHARMACEUT, V10, P249, DOI 10.1021/mp300391v
   Albrecht NE., 2020, BIOCHEMISTRY-US, V42, P18, DOI [10.1042/BIO20200058, DOI 10.1042/BIO20200058]
   Allocca M, 2008, J CLIN INVEST, V118, P1955, DOI 10.1172/JCI34316
   Almasieh M, 2012, PROG RETIN EYE RES, V31, P152, DOI 10.1016/j.preteyeres.2011.11.002
   Alshamrani M, 2019, AAPS PHARMSCITECH, V20, DOI 10.1208/s12249-019-1404-1
   Amadio M, 2016, PHARMACOL RES, V103, P253, DOI 10.1016/j.phrs.2015.11.027
   Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   Solinis MA, 2015, EUR J PHARM BIOPHARM, V95, P331, DOI 10.1016/j.ejpb.2014.12.022
   [Anonymous], 2014, EUR J PHARM BIOPHARM, V87, P19, DOI 10.1016/j.ejpb.2014.02.013
   Arslan OE, 2016, NANOBIOMATERIALS OPH, ppp57, DOI 10.1007/978-3-319-29346-2_4
   Arslan OE, 2018, DRUG DELIVERY RETINA, P3, DOI [10.1007/978-3-319-95807-1_1, DOI 10.1007/978-3-319-95807-1_1]
   Auricchio A, 2017, HUM GENE THER, V28, P982, DOI 10.1089/hum.2017.164
   Awwad S, 2017, BRIT J PHARMACOL, V174, P4205, DOI 10.1111/bph.14024
   Bachu RD, 2018, PHARMACEUTICS, V10, DOI 10.3390/pharmaceutics10010028
   Bajpai AK., 2016, SMART BIOMATERIAL DE, DOI [10.1201/9781315371559, DOI 10.1201/9781315371559]
   Barar Jaleh, 2009, J Ophthalmic Vis Res, V4, P238
   Bartholomae CC, 2011, MOL THER, V19, P703, DOI 10.1038/mt.2011.19
   Bemelmans AP, 2006, PLOS MED, V3, P1892, DOI 10.1371/journal.pmed.0030347
   Bennett L, 2016, OCULAR DRUG DELIVERY, ppp165, DOI [10.1007/978-3-319-47691-9_10, DOI 10.1007/978-3-319-47691-9_10]
   BENSINGER R, 1976, INVEST OPHTH VISUAL, V15, P1008
   Binley K, 2013, INVEST OPHTH VIS SCI, V54, P4061, DOI 10.1167/iovs.13-11871
   Binley K, 2012, HUM GENE THER, V23, P980, DOI 10.1089/hum.2012.008
   Bisht R, 2018, WIRES NANOMED NANOBI, V10, DOI 10.1002/wnan.1473
   BLOOMFIELD SE, 1978, ARCH OPHTHALMOL-CHIC, V96, P885
   Bochot A, 2012, J CONTROL RELEASE, V161, P628, DOI 10.1016/j.jconrel.2012.01.019
   Bordet T, 2019, DRUG DISCOV TODAY, V24, P1685, DOI 10.1016/j.drudis.2019.05.038
   Bourges JL, 2003, INVEST OPHTH VIS SCI, V44, P3562, DOI 10.1167/iovs.02-1068
   Bozzuto G, 2015, INT J NANOMED, V10, P975, DOI 10.2147/IJN.S68861
   Brandt JD, 2016, OPHTHALMOLOGY, V123, P1685, DOI 10.1016/j.ophtha.2016.04.026
   Bruining MJ, 1999, J BIOMED MATER RES, V47, P189, DOI 10.1002/(SICI)1097-4636(199911)47:2<189::AID-JBM8>3.0.CO;2-M
   Cai X, 2008, VISION RES, V48, P319, DOI 10.1016/j.visres.2007.07.012
   Campochiaro PA, 2012, OPHTHALMOLOGY, V119, P2125, DOI 10.1016/j.ophtha.2012.04.030
   Chan YJ, 2021, PART FIBRE TOXICOL, V18, DOI 10.1186/s12989-020-00395-7
   Chang M, 2005, EXPERT REV MED DEVIC, V2, P421, DOI 10.1586/17434440.2.4.421
   Chao JR, 2017, TRANSL VIS SCI TECHN, V6, DOI 10.1167/tvst.6.3.4
   Cheng CJ, 2015, NAT REV DRUG DISCOV, V14, P239, DOI 10.1038/nrd4503
   Chiang PPC, 2006, LANCET, V368, P365, DOI 10.1016/S0140-6736(06)69105-8
   Cholkar Kishore, 2012, Recent Pat Nanomed, V2, P82
   Chopra P, 2012, J CONTROL RELEASE, V160, P96, DOI 10.1016/j.jconrel.2012.01.032
   Chuang K, 2017, YALE J BIOL MED, V90, P635
   Cideciyan AV, 2021, NAT MED, V27, P785, DOI 10.1038/s41591-021-01297-7
   Ciolino JB, 2014, BIOMATERIALS, V35, P432, DOI 10.1016/j.biomaterials.2013.09.032
   Colthurst MJ, 2000, BIOMATERIALS, V21, P649, DOI 10.1016/S0142-9612(99)00220-3
   Crommelin DJA, 2020, J CONTROL RELEASE, V318, P256, DOI 10.1016/j.jconrel.2019.12.023
   Cunha-Vaz J, 2014, OPHTHALMOLOGY, V121, P1892, DOI 10.1016/j.ophtha.2014.04.019
   CUNHAVAZ JG, 1976, DOC OPHTHALMOL, V41, P287, DOI 10.1007/BF00146764
   Dagnelie G, 2012, CURR OPIN NEUROL, V25, P67, DOI 10.1097/WCO.0b013e32834f02c3
   DAVIS DV, 1986, J CATARACT REFR SURG, V12, P182, DOI 10.1016/S0886-3350(86)80040-2
   Dejneka NS, 2008, MOL VIS, V14, P997
   del Amo EM, 2017, PROG RETIN EYE RES, V57, P134, DOI 10.1016/j.preteyeres.2016.12.001
   Desai A, 2019, NOVEL DRUG DELIVERY TECHNOLOGIES, P335, DOI 10.1007/978-981-13-3642-3_10
   Ding XY, 2009, PROG RETIN EYE RES, V28, P1, DOI 10.1016/j.preteyeres.2008.10.001
   Dixon P, 2015, EXPERT OPIN THER PAT, V25, P1117, DOI 10.1517/13543776.2015.1057501
   Dua HS, 2013, OPHTHALMOLOGY, V120, P1778, DOI 10.1016/j.ophtha.2013.01.018
   Dugel PU., 2009, INVEST OPHTH VIS SCI, V50, P4332, DOI 10.1016/j.ajo.2015.03.017
   Dumbleton Kathy, 2002, Cont Lens Anterior Eye, V25, P137, DOI 10.1016/S1367-0484(02)00009-7
   Dundon NM, 2015, FRONT BEHAV NEUROSCI, V9, DOI 10.3389/fnbeh.2015.00192
   Edelhauser HF, 2010, INVEST OPHTH VIS SCI, V51, P5403, DOI 10.1167/iovs.10-5392
   Farjo KM, 2010, VASC CELL, V2, DOI 10.1186/2040-2384-2-21
   Fedorchak MV, 2016, NANOBIOMATERIALS OPH, ppp389, DOI [10.1007/978-3-319-29346-2_17, DOI 10.1007/978-3-319-29346-2_17]
   Ferrara N, 2010, NAT MED, V16, P1107, DOI 10.1038/nm1010-1107
   Fialho SL, 2008, EUR J PHARM BIOPHARM, V68, P637, DOI 10.1016/j.ejpb.2007.08.004
   Fonn D, 2007, OPTOMETRY VISION SCI, V84, P279, DOI 10.1097/OPX.0b013e31804636af
   Freddo TF, 2001, EXP EYE RES, V73, P581, DOI 10.1006/exer.2001.1056
   Fudalej E, 2021, OPHTHALMIC RES, V64, P345, DOI 10.1159/000514441
   Gaballa SA, 2021, DRUG DELIV TRANSL RE, V11, P866, DOI 10.1007/s13346-020-00843-z
   Gall C, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0156134
   Gaudana R, 2009, PHARM RES-DORDR, V26, P1197, DOI 10.1007/s11095-008-9694-0
   Gehrs KM, 2006, ANN MED, V38, P450, DOI 10.1080/07853890600946724
   Germain M, 2020, J CONTROL RELEASE, V326, P164, DOI 10.1016/j.jconrel.2020.07.007
   Ghazi NG, 2016, HUM GENET, V135, P327, DOI 10.1007/s00439-016-1637-y
   Giannaccini M, 2017, SCI REP-UK, V7, DOI 10.1038/srep43092
   Gokoffski KK, 2020, CURR OPIN NEUROL, V33, P93, DOI 10.1097/WCO.0000000000000777
   Gonzalez V, 2016, INVEST OPHTH VIS SCI, V57
   Gonzalez-Cordero A, 2013, NAT BIOTECHNOL, V31, P741, DOI 10.1038/nbt.2643
   Green W R, 1977, Trans Am Ophthalmol Soc, V75, P180
   Grishanin R, 2019, MOL THER, V27, P118, DOI 10.1016/j.ymthe.2018.11.003
   Gross N, 2013, MOL VIS, V19, P54
   Gu Y, 2019, MOL PHARMACEUT, V16, P2845, DOI 10.1021/acs.molpharmaceut.8b01136
   Gupta H, 2012, DRUG DISCOV TODAY, V17, P522, DOI 10.1016/j.drudis.2012.01.014
   Gupta SV, 2016, NANOBIOMATERIALS OPH, ppp131, DOI [10.1007/978-3-319-29346-2_7, DOI 10.1007/978-3-319-29346-2_7]
   Guzman-Aranguez A, 2013, BRIT J PHARMACOL, V170, P730, DOI 10.1111/bph.12330
   Haghjou Nahid, 2011, J Ophthalmic Vis Res, V6, P317
   Hamalainen KM, 1997, INVEST OPHTH VIS SCI, V38, P627
   Hambright D, 2012, MOL VIS, V18, P920
   Hashimoto T, 2007, GENE THER, V14, P584, DOI 10.1038/sj.gt.3302897
   Henrich-Noack P, 2012, ARCH TOXICOL, V86, P1099, DOI 10.1007/s00204-012-0832-4
   Hirani A, 2016, PHARM DEV TECHNOL, V21, P61, DOI 10.3109/10837450.2014.965326
   Hollyfield JG, 2008, NAT MED, V14, P194, DOI 10.1038/nm1709
   Hong Y, 1996, J BIOMED MATER RES, V30, P441, DOI 10.1002/(SICI)1097-4636(199604)30:4<441::AID-JBM2>3.0.CO;2-P
   Hsiao MH, 2014, ACTA BIOMATER, V10, P3188, DOI 10.1016/j.actbio.2014.03.016
   Hsu KH, 2015, DISSERTATION
   Hu B, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-0207-x
   Hyon SH, 2000, YONSEI MED J, V41, P720, DOI 10.3349/ymj.2000.41.6.720
   Ideta R, 2004, FEBS LETT, V557, P21, DOI 10.1016/S0014-5793(03)01315-2
   Iezzi R, 2012, BIOMATERIALS, V33, P979, DOI 10.1016/j.biomaterials.2011.10.010
   Ishikawa M, 2015, J OPHTHALMOL, V2015, DOI 10.1155/2015/138070
   Iwao K, 2007, J GLAUCOMA, V16, P251, DOI 10.1097/IJG.0b013e31802d696f
   Jiang J, 2007, INVEST OPHTH VIS SCI, V48, P4038, DOI 10.1167/iovs.07-0066
   Jiang JJ, 2021, FUND CLIN PHARMACOL, V35, P4, DOI 10.1111/fcp.12561
   Jo DH, 2015, NANOMED-NANOTECHNOL, V11, P1603, DOI 10.1016/j.nano.2015.04.015
   Jo DH, 2011, INT J MOL SCI, V12, P8288, DOI 10.3390/ijms12118288
   Johnson KS, 2010, AM J OPHTHALMOL, V149, P77, DOI 10.1016/j.ajo.2009.07.035
   Johnson LN, 2008, MOL THER, V16, P107, DOI 10.1038/sj.mt.6300324
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Joseph RR, 2017, NANOMEDICINE-UK, V12, P683, DOI 10.2217/nnm-2016-0379
   Kachi S, 2005, GENE THER, V12, P843, DOI 10.1038/sj.gt.3302475
   Kaemmerer WF, 2018, BIOENG TRANSL MED, V3, P166, DOI 10.1002/btm2.10090
   Kaiser PK, 2010, AM J OPHTHALMOL, V150, P33, DOI 10.1016/j.ajo.2010.02.006
   Kakoti BB, 2016, NANOBIOMATERIALS OPH, P495, DOI 10.1007/978-3-319-29346-2_22
   Kalita D, 2014, AM J OPHTHALMOL, V157, P1109, DOI 10.1016/j.ajo.2014.01.027
   Kalomiraki M, 2016, INT J NANOMED, V11, P1, DOI 10.2147/IJN.S93069
   Kang SJ, 2009, ARCH OPHTHALMOL-CHIC, V127, P1043, DOI 10.1001/archophthalmol.2009.185
   Kasala D, 2016, NANOMEDICINE-UK, V11, P1689, DOI 10.2217/nnm-2016-0060
   Kempen JH, 2011, OPHTHALMOLOGY, V118, P1916, DOI 10.1016/j.ophtha.2011.07.027
   Khiev D, 2021, NANOMATERIALS-BASEL, V11, DOI 10.3390/nano11010173
   Kim JH, 2009, NANOTECHNOLOGY, V20, DOI 10.1088/0957-4484/20/50/505101
   Kim MG, 2017, BIOCHEM BIOPH RES CO, V489, P35, DOI 10.1016/j.bbrc.2017.05.103
   Kokaz S.F., 2022, NANOENG BIOMATER, P215, DOI [10.1002/9783527832095.ch25, DOI 10.1002/9783527832095.CH25, 10.1002/ 9783527832095.CH25]
   Kong J, 2008, GENE THER, V15, P1311, DOI 10.1038/gt.2008.78
   Kong L, 2011, NEUROBIOL DIS, V42, P514, DOI 10.1016/j.nbd.2011.03.004
   Korb DR., 2002, TEAR FILM STRUCTURE, DOI [10.1016/b978-0-7506-4196-8.50002-x, DOI 10.1016/B978-0-7506-4196-8.50006-7]
   KREUTER J, 1995, BRAIN RES, V674, P171, DOI 10.1016/0006-8993(95)00023-J
   Kyosseva SV, 2015, WORLD J OPHTHALMOL, V1, DOI [10.5318/wjo.v5.i1.23, DOI 10.5318/WJO.V5.I1.23]
   Lahkar S, 2019, SURFACE MODIFICATION, P277, DOI [10.1007/978-3-030-06115-9_15, DOI 10.1007/978-3-030-06115-9_15]
   Lancina MG, 2017, ACS BIOMATER SCI ENG, V3, P1861, DOI 10.1021/acsbiomaterials.7b00319
   Lee IK, 2021, SCI ADV, V7, DOI 10.1126/sciadv.abf0344
   Lee SJ, 2008, INVEST OPHTH VIS SCI, V49, P4506, DOI 10.1167/iovs.08-1989
   Lee SS, 2010, PHARM RES-DORDR, V27, P2043, DOI 10.1007/s11095-010-0159-x
   Leggat PA, 2007, ANZ J SURG, V77, P209, DOI 10.1111/j.1445-2197.2007.04020.x
   Li V H, 1986, J Microencapsul, V3, P213, DOI 10.3109/02652048609031575
   Liao HW, 2007, BIOTECHNIQUES, V42, P285, DOI 10.2144/000112404
   Liu HA, 2011, INVEST OPHTH VIS SCI, V52, P4789, DOI 10.1167/iovs.10-5891
   Liu MM, 2011, BRIT J OPHTHALMOL, V95, P604, DOI 10.1136/bjo.2009.174912
   Liu S, 2016, NANOBIOMATERIALS OPH, ppp83, DOI [10.1007/978-3-319-29346-2_5, DOI 10.1007/978-3-319-29346-2_5]
   Lloyd AW, 2001, BIOMATERIALS, V22, P769, DOI 10.1016/S0142-9612(00)00237-4
   Lochmann D, 2005, EUR J PHARM BIOPHARM, V59, P419, DOI 10.1016/j.ejpb.2004.04.001
   Lv HT, 2006, J CONTROL RELEASE, V114, P100, DOI 10.1016/j.jconrel.2006.04.014
   Maeda Y, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0226118
   Mak KY, 2017, CURR GENE THER, V17, P4, DOI 10.2174/1566523217666170314141931
   Malhotra Manjusha, 2001, Indian Journal of Experimental Biology, V39, P11
   Mandal A, 2019, PHARM RES-DORDR, V36, DOI 10.1007/s11095-018-2556-5
   Manickavasagam D, 2016, EUR J PHARM BIOPHARM, V107, P56, DOI 10.1016/j.ejpb.2016.06.012
   Marano RJ, 2005, GENE THER, V12, P1544, DOI 10.1038/sj.gt.3302579
   Martinez T, 2014, MOL THER, V22, P81, DOI 10.1038/mt.2013.216
   Masland RH, 2001, NAT NEUROSCI, V4, P877, DOI 10.1038/nn0901-877
   Masuda I, 1996, INVEST OPHTH VIS SCI, V37, P1914
   Maurice D, 2001, J OCUL PHARMACOL TH, V17, P393, DOI 10.1089/108076801753162807
   Meyer CH, 2011, EYE, V25, P661, DOI 10.1038/eye.2011.66
   Meza-Rios A, 2020, OPHTHALMOL THER, DOI 10.1007/s40123-020-00257-7
   Mishra V, 2014, INT J PHARMACEUT, V461, P380, DOI 10.1016/j.ijpharm.2013.11.043
   Molokhia SA, 2007, INT J PHARMACEUT, V335, P46, DOI 10.1016/j.ijpharm.2006.11.001
   Moreno-Montanes J, 2014, MOL THER, V22, P226, DOI 10.1038/mt.2013.217
   Morrison C, 2018, NAT REV DRUG DISCOV, V17, P156, DOI 10.1038/nrd.2018.20
   Moshfeghi DM, 2002, AM J OPHTHALMOL, V134, P132, DOI 10.1016/S0002-9394(02)01426-5
   Murata N, 2008, J CONTROL RELEASE, V126, P246, DOI 10.1016/j.jconrel.2007.11.017
   Naik R, 2009, DRUG DISCOV TODAY, V14, P306, DOI 10.1016/j.drudis.2008.09.012
   Occhiutto Marcelo L, 2012, Pharmaceutics, V4, P252, DOI 10.3390/pharmaceutics4020252
   Ogura Y, 2019, OPHTHALMOLOGICA, V241, P161, DOI 10.1159/000492135
   Okada AA, 2003, BRIT J OPHTHALMOL, V87, P968, DOI 10.1136/bjo.87.8.968
   Oliveira AV, 2017, MAT SCI ENG C-MATER, V77, P1275, DOI 10.1016/j.msec.2017.04.068
   Olsen TW, 2011, INVEST OPHTH VIS SCI, V52, P4749, DOI 10.1167/iovs.10-6291
   Osswald CR, 2016, CURR EYE RES, V41, P1216, DOI 10.3109/02713683.2015.1101140
   Panda JJ, 2013, J CONTROL RELEASE, V172, P1151, DOI 10.1016/j.jconrel.2013.09.016
   Pang J, 2010, GENE THER, V17, P815, DOI 10.1038/gt.2010.29
   Pardue MT, 2018, PROG RETIN EYE RES, V65, P50, DOI 10.1016/j.preteyeres.2018.02.002
   Park K, 2019, J CONTROL RELEASE, V305, P221, DOI 10.1016/j.jconrel.2019.05.044
   Park K, 2009, DIABETES, V58, P1902, DOI 10.2337/db08-1327
   Patel Ashaben, 2013, World J Pharmacol, V2, P47
   Patel SR, 2012, INVEST OPHTH VIS SCI, V53, P4433, DOI 10.1167/iovs.12-9872
   Patel SR, 2011, PHARM RES-DORDR, V28, P166, DOI 10.1007/s11095-010-0271-y
   Patel S, 2008, CURR DIABETES REP, V8, P257, DOI 10.1007/s11892-008-0046-6
   PAUTLER SE, 1986, OPHTHALMIC SURG LAS, V17, P334
   Peng YQ, 2017, OPHTHALMIC RES, V58, P217, DOI 10.1159/000479157
   Prilloff S, 2010, EUR J NEUROSCI, V31, P521, DOI 10.1111/j.1460-9568.2010.07078.x
   Raghava Swita, 2004, Expert Opin Drug Deliv, V1, P99, DOI 10.1517/17425247.1.1.99
   Rai Uma Do J P, 2015, Drug Discov Today, V20, P491, DOI 10.1016/j.drudis.2014.10.010
   Rajagopal P, 2018, J GENE MED, V20, DOI 10.1002/jgm.3011
   Ramge P, 2000, EUR J NEUROSCI, V12, P1931, DOI 10.1046/j.1460-9568.2000.00078.x
   RAVIOLA G, 1977, EXP EYE RES, V25, P27, DOI 10.1016/S0014-4835(77)80009-2
   REIDY JJ, 1990, CORNEA, V9, P196
   Robinson B. V., 1990, PVP CRITICAL REV KIN, DOI [10.1201/9780203741672, DOI 10.1201/9780203741672]
   Robinson R, 2011, ACS NANO, V5, P4392, DOI 10.1021/nn103146p
   Rowe-Rendleman CL, 2014, INVEST OPHTH VIS SCI, V55, P2714, DOI 10.1167/iovs.13-13707
   Ruz V, 2014, INVEST OPHTH VIS SCI, V55
   Ryoo NK, 2017, NANOSCALE, V9, P15461, DOI 10.1039/c7nr03142d
   Saati S, 2010, CURR EYE RES, V35, P192, DOI 10.3109/02713680903521936
   Sabel BA, 2020, EPMA J, V11, P177, DOI 10.1007/s13167-020-00204-3
   Sabel BA, 1997, NAT MED, V3, P244, DOI 10.1038/nm0297-244
   Sabel BA, 2020, CLIN NEUROPHYSIOL, V131, P887, DOI 10.1016/j.clinph.2020.01.008
   Sabel Bernhard A, 2018, J Curr Glaucoma Pract, V12, P1, DOI 10.5005/jp-journals-10028-1237
   Sabel BA, 2014, JAMA OPHTHALMOL, V132, P381, DOI 10.1001/jamaophthalmol.2013.7963
   Sabel BA, 2011, PROG BRAIN RES, V192, P199, DOI 10.1016/B978-0-444-53355-5.00013-0
   Sakai T, 2006, EXP EYE RES, V82, P657, DOI 10.1016/j.exer.2005.09.003
   Salama HA, 2017, AAPS PHARMSCITECH, V18, P2517, DOI 10.1208/s12249-017-0710-8
   Schroeder U, 1998, PEPTIDES, V19, P777, DOI 10.1016/S0196-9781(97)00474-9
   Sharma A, 2011, NANOMED-NANOTECHNOL, V7, P505, DOI 10.1016/j.nano.2011.01.006
   Shen J, 2006, GENE THER, V13, P225, DOI 10.1038/sj.gt.3302641
   Shirai H, 2016, P NATL ACAD SCI USA, V113, pE81, DOI 10.1073/pnas.1512590113
   Simunovic MP, 2017, JAMA OPHTHALMOL, V135, P234, DOI 10.1001/jamaophthalmol.2016.5630
   Singh RB, 2020, THER ADV OPHTHALMOL, V12, DOI 10.1177/2515841420905740
   Singh SR, 2009, GENE THER, V16, P645, DOI 10.1038/gt.2008.185
   Solano ECR, 2014, NUCLEIC ACID THER, V24, P258, DOI 10.1089/nat.2014.0489
   Souza JG, 2014, J PHARM PHARMACOL, V66, P507, DOI 10.1111/jphp.12132
   Srivastava A, 2016, CURR OPIN VIROL, V21, P75, DOI 10.1016/j.coviro.2016.08.003
   Stieger K, 2008, MOL THER, V16, P916, DOI 10.1038/mt.2008.41
   Subrizi A, 2019, DRUG DISCOV TODAY, V24, P1446, DOI 10.1016/j.drudis.2019.02.001
   Taj SH, 2016, BIOMATERIALS, V91, P151, DOI 10.1016/j.biomaterials.2016.03.025
   Takahashi M, 1999, J VIROL, V73, P7812, DOI 10.1128/JVI.73.9.7812-7816.1999
   Tannebaum S, 1995, J Am Optom Assoc, V66, P652
   Tawfik M, 2021, J BIOMED NANOTECHNOL, V17, P846, DOI 10.1166/jbn.2021.3073
   Tawfik M, 2021, NEURAL REGEN RES, V16, P2534, DOI 10.4103/1673-5374.313068
   Thakur R, 2012, J DRUG DELIV THER, V2, P2, DOI [10.22270/jddt.v2i2.102, DOI 10.22270/JDDT.V2I2.102]
   Tham Yih-Chung, 2014, Ophthalmology, V121, P2081, DOI 10.1016/j.ophtha.2014.05.013
   Thomas M, 2003, P NATL ACAD SCI USA, V100, P9138, DOI 10.1073/pnas.1233634100
   Titze-de-Almeida R, 2017, PHARM RES-DORDR, V34, P1339, DOI 10.1007/s11095-017-2134-2
   Tolentino MJ, 2004, RETINA-J RET VIT DIS, V24, P132, DOI 10.1097/00006982-200402000-00018
   Trapani I, 2015, HUM GENE THER, V26, P193, DOI 10.1089/hum.2015.030
   Tsai CH, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19092830
   Tseng YS, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00009
   Tyagi P, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048188
   URTTI A, 1990, INT J PHARM, V61, P241, DOI 10.1016/0378-5173(90)90215-P
   Vadlapudi AD, 2014, J OCUL PHARMACOL TH, V30, P49, DOI 10.1089/jop.2013.0157
   Velagaleti PR., 2010, DRUG DELIV TECHNOL, V10, P42
   Venugopalan P, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10472
   Voigt N, 2014, J NANOPART RES, V16, DOI 10.1007/s11051-014-2379-1
   Vote BJT, 2000, CLIN EXP OPHTHALMOL, V28, P437, DOI 10.1046/j.1442-9071.2000.00351.x
   Waite D, 2017, THER DELIV, V8, P685, DOI 10.4155/tde-2017-0097
   Wang HJ, 2010, BIOMATERIALS, V31, P8741, DOI 10.1016/j.biomaterials.2010.07.082
   Wang HL, 2015, J MATER CHEM B, V3, P939, DOI 10.1039/c4tb01611d
   Weinreb RN, 2014, JAMA-J AM MED ASSOC, V311, P1901, DOI 10.1001/jama.2014.3192
   Wilkinson CP, 2003, OPHTHALMOLOGY, V110, P1677, DOI 10.1016/S0161-6420(03)00475-5
   Wilson B, 2009, NANOMEDICINE-UK, V4, P499, DOI [10.2217/nnm.09.29, 10.2217/NNM.09.29]
   Winter KN, 2010, MATH MED BIOL, V27, P211, DOI 10.1093/imammb/dqp019
   Wong FSY, 2017, NEURAL REGEN RES, V12, P576, DOI 10.4103/1673-5374.205093
   Wong TT, 2014, DRUG DELIV TRANSL RE, V4, P303, DOI 10.1007/s13346-014-0196-9
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wu ZG, 2018, SCI ADV, V4, DOI 10.1126/sciadv.aat4388
   Yadav D, 2018, DRUG DELIVERY RETINA, ppp51, DOI [10.1007/978-3-319-95807-1_3, DOI 10.1007/978-3-319-95807-1_3]
   Yasin MN, 2014, J CONTROL RELEASE, V196, P208, DOI 10.1016/j.jconrel.2014.09.030
   Yasukawa Tsutomu, 2006, Expert Opin Drug Deliv, V3, P261, DOI 10.1517/17425247.3.2.261
   Yau JWY, 2012, DIABETES CARE, V35, P556, DOI 10.2337/dc11-1909
   Yeh S, 2020, OPHTHALMOLOGY, V127, P948, DOI 10.1016/j.ophtha.2020.01.006
   Yenice I, 2008, EXP EYE RES, V87, P162, DOI 10.1016/j.exer.2008.04.002
   Yin HB, 2010, J BIOMED MATER RES B, V92B, P129, DOI 10.1002/jbm.b.31498
   You Q, 2019, MOL PHARMACEUT, V16, P5068, DOI 10.1021/acs.molpharmaceut.9b01046
   You Q, 2019, J DRUG TARGET, V27, P338, DOI 10.1080/1061186X.2018.1531416
   Yu C, 2021, ADV SCI, V8, DOI 10.1002/advs.202100540
   Yu Y, 2015, TRANSL VIS SCI TECHN, V4, DOI 10.1167/tvst.4.2.5
   Zhang EQ, 2020, EUR J PHARM BIOPHARM, V150, P131, DOI 10.1016/j.ejpb.2020.03.006
   Zhang K, 2012, NAT REV DRUG DISCOV, V11, P541, DOI 10.1038/nrd3745
   Zhang K, 2011, P NATL ACAD SCI USA, V108, P6241, DOI 10.1073/pnas.1018987108
   Zhang LH, 2009, INT J NANOMED, V4, P175
   Zhang N, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-92971-w
   Zhang X, 2020, RESTOR NEUROL NEUROS, V38, P131, DOI 10.3233/RNN-190941
   Zhang Y, 2010, INT J PHARMACEUT, V390, P198, DOI 10.1016/j.ijpharm.2010.01.035
NR 258
TC 0
Z9 0
U1 8
U2 8
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0028-1298
EI 1432-1912
J9 N-S ARCH PHARMACOL
JI Naunyn-Schmiedebergs Arch. Pharmacol.
PD DEC
PY 2022
VL 395
IS 12
BP 1477
EP 1507
DI 10.1007/s00210-022-02287-3
EA SEP 2022
PG 31
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA 5W8LZ
UT WOS:000854720300001
PM 36107200
OA hybrid, Green Published
DA 2022-11-30
ER

PT J
AU Smitha, A
   Jidesh, P
AF Smitha, A.
   Jidesh, P.
TI Detection of retinal disorders from OCT images using generative
   adversarial networks
SO MULTIMEDIA TOOLS AND APPLICATIONS
LA English
DT Article
DE Ophthalmic image analysis; Optical coherence tomography; Retinal
   disorder; Retinal image segmentation and classification; Age-related
   macular degeneration; Diabetic macular edema
ID OPTICAL COHERENCE TOMOGRAPHY; SEGMENTATION; LAYERS; CLASSIFICATION
AB Retinal image analysis has opened up a new window for prompt diagnosis and detection of various retinal disorders. Optical Coherence Tomography (OCT) is one of the major diagnostic tools to identify retinal abnormalities related to macular disorders like Age-Related Macular Degeneration (AMD) and Diabetic Macular Edema (DME). The clinical findings include retinal layer analysis to spot the abnormalities on OCT images. Though various models are proposed over the years to diagnose these disorders automatically, an end-to-end system that performs automatic denoising, segmentation, and classification does not exist to the best of our knowledge. This paper proposes a Generative Adversarial Network (GAN) based approach for automated segmentation and classification of OCT-B scans to diagnose AMD and DME. The proposed method incorporates the integration of handcrafted Gabor features to enhance the retina layer segmentation and non-local denoising to remove speckle noise. The classification metrics of GAN are compared with existing methods. The accuracy of up to 92.42% and F1-score of 0.79 indicates that the GANs can perform well for segmentation and classification of OCT images.
C1 [Smitha, A.; Jidesh, P.] Natl Inst Technol Karnataka, Dept Math & Computat Sci, Surathkal 575025, India.
C3 National Institute of Technology (NIT System); National Institute of
   Technology Karnataka
RP Jidesh, P (通讯作者)，Natl Inst Technol Karnataka, Dept Math & Computat Sci, Surathkal 575025, India.
EM jidesh@nitk.edu.in
FU Ministry of Education, Government of India; Department of Atomic Energy,
   Govt. of India [02011/17/2020NBHM(RP)/RDII/8073]
FX A. Smitha would like to acknowledge Prof. Vasudevan Lakshminarayanan,
   University of Waterloo, Canada, and Dr. J. Jothi Balaji, Medical
   Research Foundation, India, for their valuable suggestions regarding the
   research work. Smitha express her gratitude to the Ministry of
   Education, Government of India, for providing financial support (as
   fellowship) for carrying out the research at National Institute of
   Technology Karnataka, Surathkal. She also acknowledges the contribution
   of Mr. Abhinaba Hazarika, Master student at NITK, for assisting in the
   implementation and documentation of the proposed work. Dr. P. Jidesh
   thanks the Department of Atomic Energy, Govt. of India, for providing
   financial support under the research grant no.
   02011/17/2020NBHM(RP)/R&DII/8073.
CR Alqudah AM, 2020, MED BIOL ENG COMPUT, V58, P41, DOI 10.1007/s11517-019-02066-y
   Arjovsky M, 2017, PR MACH LEARN RES, V70
   Balasuriya BK, 2017, I C SOFTWARE KNOWL I
   Bandello F., 2019, DIABETIC MACULAR EDE, P97, DOI [10.1007/978-3-319-96157-6, DOI 10.1007/978-3-319-96157-6]
   Birch DG, 2007, INT J NANOMED, V2, P65, DOI 10.2147/nano.2007.2.1.65
   Brownlee J., 2019, MACHINE LEARNING MAS
   Chiu SJ, 2010, OPT EXPRESS, V18, P19413, DOI 10.1364/OE.18.019413
   Dai Z, 2017, ARXIVABS170509783
   Das V, 2020, IEEE SENSOR LETT, V4, DOI 10.1109/LSENS.2019.2963712
   Dodo BI, 2019, IEEE ACCESS, V7, P152388, DOI 10.1109/ACCESS.2019.2947761
   Febin IP, 2018, IMAGING SCI J, V66, P479, DOI 10.1080/13682199.2018.1518760
   Froment J, 2014, IMAGE PROCESS ON LIN, V4, P300, DOI 10.5201/ipol.2014.120
   Fuglede B, 2004, 2004 IEEE INTERNATIONAL SYMPOSIUM ON INFORMATION THEORY, PROCEEDINGS, P31
   Garcia-Layana, 2017, OPTICAL COHERENCE TO
   Girish GN, 2019, IEEE J BIOMED HEALTH, V23, P296, DOI 10.1109/JBHI.2018.2810379
   Glen S, 2014, P VALUE STAT HYPOTHE
   Goldman D.R, 2018, 15 1 DIABETIC MACULA
   Grandini M, 2020, ARXIV200805756
   He K., 2016, P IEEE COMPUTER SOC, P630, DOI DOI 10.1109/CVPR.2016.90
   Huang G, 2017, PROC CVPR IEEE, P2261, DOI 10.1109/CVPR.2017.243
   Huang LF, 2019, IEEE SIGNAL PROC LET, V26, P1026, DOI 10.1109/LSP.2019.2917779
   Gulrajani I, 2017, ADV NEUR IN, V30
   Jidesh P, 2018, COMPUT ELECTR ENG, V70, P631, DOI 10.1016/j.compeleceng.2017.09.013
   Li JX, 2021, BIOMED OPT EXPRESS, V12, P2204, DOI 10.1364/BOE.417212
   Li QL, 2020, TRANSL VIS SCI TECHN, V9, DOI 10.1167/tvst.9.2.61
   Li XC, 2019, IEEE ACCESS, V7, P33771, DOI 10.1109/ACCESS.2019.2891975
   Ma YS, 2021, J INNOV OPT HEAL SCI, V14, DOI 10.1142/S1793545821400113
   Minitab, 2020, GOODN FIT IND DISTR
   Mishra Z, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-66355-5
   Mittal A, 2012, IEEE T IMAGE PROCESS, V21, P4695, DOI 10.1109/TIP.2012.2214050
   Moreira Neto C A, 2018, ATLAS RETINAL OCT OP, P1
   Negi A, 2020, 2020 5TH IEEE INTERNATIONAL CONFERENCE ON RECENT ADVANCES AND INNOVATIONS IN ENGINEERING (IEEE - ICRAIE-2020), DOI 10.1109/ICRAIE51050.2020.9358337
   Paul D, 2020, COMP MED SY, P526, DOI 10.1109/CBMS49503.2020.00105
   Popescu Dan P, 2011, Biophys Rev, V3, P155, DOI 10.1007/s12551-011-0054-7
   Rasti R, 2018, IEEE T MED IMAGING, V37, P1024, DOI 10.1109/TMI.2017.2780115
   Roy AG, 2017, BIOMED OPT EXPRESS, V8, P3627, DOI 10.1364/BOE.8.003627
   Salimans T, 2016, ADV NEUR IN, V29
   Schmitt JM, 1999, J BIOMED OPT, V4, P95, DOI 10.1117/1.429925
   Sedai S, 2019, LECT NOTES COMPUT SC, V11764, P282, DOI 10.1007/978-3-030-32239-7_32
   Serener A, 2019, 2019 SCIENTIFIC MEETING ON ELECTRICAL-ELECTRONICS & BIOMEDICAL ENGINEERING AND COMPUTER SCIENCE (EBBT)
   Sharma S, 2019, ADV INTELL SYST COMP, V748, P423, DOI 10.1007/978-981-13-0923-6_37
   Sladojevic S, 2016, COMPUT INTEL NEUROSC, V2016, DOI 10.1155/2016/3289801
   Sudeep PV, 2016, BIOMED SIGNAL PROCES, V28, P1, DOI 10.1016/j.bspc.2016.03.001
   Sudeep PV, 2016, COMPUT BIOL MED, V71, P97, DOI 10.1016/j.compbiomed.2016.02.003
   Sunija AP, 2021, COMPUT METH PROG BIO, V200, DOI 10.1016/j.cmpb.2020.105877
   Szegedy C., 2016, 2016 IEEE C COMPUTER, P2818, DOI DOI 10.1109/CVPR.2016.308
   Wang DB, 2019, IEEE PHOTONICS J, V11, DOI 10.1109/JPHOT.2019.2926231
   Wang XJ, 2021, 2021 4TH INTERNATIONAL CONFERENCE ON INTELLIGENT AUTONOMOUS SYSTEMS (ICOIAS 2021), P260, DOI [10.1109/ICoIAS53694.2021.00053, 10.1109/ICBAIE52039.2021.9390034]
   Weldon TP, 1996, PATTERN RECOGN, V29, P2005, DOI 10.1016/S0031-3203(96)00047-7
   Yanagihara RT, 2020, TRANSL VIS SCI TECHN, V9, DOI 10.1167/tvst.9.2.11
NR 50
TC 0
Z9 0
U1 0
U2 1
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 1380-7501
EI 1573-7721
J9 MULTIMED TOOLS APPL
JI Multimed. Tools Appl.
PD AUG
PY 2022
VL 81
IS 20
BP 29609
EP 29631
DI 10.1007/s11042-022-12475-1
EA APR 2022
PG 23
WC Computer Science, Information Systems; Computer Science, Software
   Engineering; Computer Science, Theory & Methods; Engineering, Electrical
   & Electronic
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Computer Science; Engineering
GA 3E6IF
UT WOS:000778057700005
DA 2022-11-30
ER

PT J
AU Wei, CR
   Li, XQ
AF Wei, Changran
   Li, Xiangqi
TI The Role of Photoactivated and Non-Photoactivated Verteporfin on Tumor
SO FRONTIERS IN PHARMACOLOGY
LA English
DT Review
DE verteporfin; yes-associated protein; TEA domain inhibitor;
   non-photoactivated therapy; photodynamic therapy; hippo pathway
ID PHOTODYNAMIC THERAPY; SIGNALING PATHWAY; UVEAL MELANOMA; HIPPO PATHWAY;
   TARGETING YAP; CANCER; PROTEIN; EXPRESSION; CELL; PHOTOSENSITIZERS
AB Verteporfin (VP) has long been clinically used to treat age-related macular degeneration (AMD) through photodynamic therapy (PDT). Recent studies have reported a significant anti-tumor effect of VP as well. Yes-associated protein (YAP) is a pro-tumorigenic factor that is aberrantly expressed in various cancers and is a central effector of the Hippo signaling pathway that regulates organ size and tumorigenesis. VP can inhibit YAP without photoactivation, along with suppressing autophagy, and downregulating germinal center kinase-like kinase (GLK) and STE20/SPS1-related proline/alanine-rich kinase (SPAK). In addition, VP can induce mitochondrial damage and increase the production of reactive oxygen species (ROS) upon photoactivation, and is an effective photosensitizer (PS) in anti-tumor PDT. We have reviewed the direct and adjuvant therapeutic action of VP as a PS, and its YAP/TEA domain (TEAD)-dependent and independent pharmacological effects in the absence of light activation against cancer cells and solid tumors. Based on the present evidence, VP may be repositioned as a promising anti-cancer chemotherapeutic and adjuvant drug.
C1 [Wei, Changran; Li, Xiangqi] Shandong Univ Tradit Chinese Med, Dept Clin Med Sch 1, Jinan, Peoples R China.
   [Li, Xiangqi] Shandong First Med Univ, Affiliated Hosp 2, Dept Breast Surg, Tai An, Shandong, Peoples R China.
C3 Shandong University of Traditional Chinese Medicine; Shandong First
   Medical University & Shandong Academy of Medical Sciences
RP Li, XQ (通讯作者)，Shandong Univ Tradit Chinese Med, Dept Clin Med Sch 1, Jinan, Peoples R China.; Li, XQ (通讯作者)，Shandong First Med Univ, Affiliated Hosp 2, Dept Breast Surg, Tai An, Shandong, Peoples R China.
EM drlixqi@hotmail.com
FU National Natural Science Foundation of China [81473687]; Shandong
   Provincial Natural Science Foundation, China [ZR2009CM039, ZR2013HM038];
   High level project cultivation program of Shandong First Medical
   University, China [2018GCC14]; Academic promotion of Shandong First
   Medical University, China [2019QL017]
FX This work was supported by funds from the National Natural Science
   Foundation of China (No 81473687), Shandong Provincial Natural Science
   Foundation, China (No ZR2009CM039 and No ZR2013HM038). High level
   project cultivation program of Shandong First Medical University, China
   (No 2018GCC14). Academic promotion of Shandong First Medical University,
   China (grant no. 2019QL017).
CR Abrahamse H, 2016, BIOCHEM J, V473, P347, DOI 10.1042/BJ20150942
   Al-Moujahed A, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-07632-8
   AlAmri MA, 2018, CHEMBIOCHEM, V19, P2072, DOI 10.1002/cbic.201800272
   Bae SI, 2008, BIOCHEM PHARMACOL, V76, P1653, DOI 10.1016/j.bcp.2008.09.003
   Bakri SJ, 2004, EXPERT OPIN PHARMACO, V5, P195, DOI 10.1517/14656566.5.1.195
   Banerjee SM, 2020, J CLIN MED, V9, DOI 10.3390/jcm9020483
   Bang LG, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-40495-9
   Baskaran Rengarajan, 2018, Biomater Res, V22, P25, DOI 10.1186/s40824-018-0140-z
   Bazylinska U, 2019, PHARMACEUTICS, V11, DOI 10.3390/pharmaceutics11080405
   Bum-Erdene K, 2019, CELL CHEM BIOL, V26, P378, DOI 10.1016/j.chembiol.2018.11.010
   Canal-Fontcuberta I, 2012, RETINA-J RET VIT DIS, V32, P942, DOI 10.1097/IAE.0b013e31825097c1
   Chen B, 2008, INT J CANCER, V123, P695, DOI 10.1002/ijc.23538
   Chen JC, 2018, J AM SOC NEPHROL, V29, P2372, DOI 10.1681/ASN.2017121272
   Chen R., 2017, HEPATOLOGY, V67, P1823, DOI [10.1371/journal.pone.0190981, DOI 10.1371/JOURNAL.PONE.0190981]
   Cheng JC, 2018, MOL CANCER RES, V16, P1543, DOI 10.1158/1541-7786.MCR-17-0681
   Chu CK, 2018, CAN J OPHTHALMOL, V53, pE13, DOI 10.1016/j.jcjo.2017.06.012
   Chuang HC, 2019, J BIOMED SCI, V26, DOI 10.1186/s12929-019-0570-5
   Cohen SY, 2009, RETINA-J RET VIT DIS, V29, P1062, DOI 10.1097/IAE.0b013e3181b1bb1a
   Crommelin DJA, 2020, J CONTROL RELEASE, V318, P256, DOI 10.1016/j.jconrel.2019.12.023
   Curry A, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0171586
   Donohue E, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0114964
   Donohue E, 2013, J CANCER, V4, P585, DOI 10.7150/jca.7030
   Donohue E, 2011, J BIOL CHEM, V286, P7290, DOI 10.1074/jbc.M110.139915
   Eales KL, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-32727-1
   Garcia-Rendueles MER, 2015, CANCER DISCOV, V5, P1178, DOI 10.1158/2159-8290.CD-15-0330
   Gavini J, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1989-z
   Gibault F, 2018, CANCERS, V10, DOI 10.3390/cancers10050140
   Gibault F, 2018, J MED CHEM, V61, P5057, DOI 10.1021/acs.jmedchem.7b00879
   Gibault F, 2016, CURR MED CHEM, V23, P1171, DOI 10.2174/0929867323666160316125048
   Giraud J, 2020, INT J CANCER, V146, P2255, DOI 10.1002/ijc.32667
   He C, 2008, PHARM RES-DORDR, V25, P1873, DOI 10.1007/s11095-008-9604-5
   Hertig V, 2018, J CELL PHYSIOL, V233, P3218, DOI 10.1002/jcp.26165
   Hua G, 2016, ONCOGENE, V35, P2247, DOI 10.1038/onc.2015.288
   Huggett MT, 2014, BRIT J CANCER, V110, P1698, DOI 10.1038/bjc.2014.95
   Husari A, 2019, CELL SIGNAL, V63, DOI 10.1016/j.cellsig.2019.109382
   Hussain RN, 2015, OPHTHALMOLOGY, V122, P2361, DOI 10.1016/j.ophtha.2015.05.026
   Ichikawa K, 2004, CANCER LETT, V205, P39, DOI 10.1016/j.canlet.2003.10.001
   Isfort I, 2019, CLIN CANCER RES, V25, P3718, DOI 10.1158/1078-0432.CCR-17-3553
   Jiang D, 2019, ACTA BIOMATER, V88, P406, DOI 10.1016/j.actbio.2019.02.009
   Jin D, 2018, EBIOMEDICINE, V37, P188, DOI 10.1016/j.ebiom.2018.10.044
   Kaan HYK, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0178381
   Kandasamy S, 2020, MOL CANCER RES, V18, P343, DOI 10.1158/1541-7786.MCR-19-0914
   Kaneko K, 2020, COMMUN BIOL, V3, DOI 10.1038/s42003-020-0956-7
   Kang W, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-017-0134-0
   Khurana M, 2008, J BIOMED OPT, V13, DOI 10.1117/1.2965545
   Kim J, 2016, NATURE, V538, P114, DOI 10.1038/nature19771
   Kleinovink JW, 2017, CANCER IMMUNOL RES, V5, P832, DOI 10.1158/2326-6066.CIR-17-0055
   Konstantinou EK, 2017, SCI REP-UK, V7, DOI 10.1038/srep46581
   Kraus D, 2017, MOL CANCER THER, V16, P2422, DOI 10.1158/1535-7163.MCT-17-0326
   Kuramoto K, 2020, FEBS J, V287, P2023, DOI 10.1111/febs.15187
   Kurohane K, 2001, CANCER LETT, V167, P49, DOI 10.1016/S0304-3835(01)00475-X
   Kwiatkowski S, 2018, BIOMED PHARMACOTHER, V106, P1098, DOI 10.1016/j.biopha.2018.07.049
   Kydd J, 2018, PHARMACEUTICS, V10, DOI 10.3390/pharmaceutics10040226
   Li NS, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0962-5
   Li W, 2017, J EXP CLIN CANC RES, V36, DOI 10.1186/s13046-017-0612-3
   Li XS, 2020, NAT REV CLIN ONCOL, V17, P657, DOI 10.1038/s41571-020-0410-2
   Li Y, 2018, BIOCHEM J, V475, P2043, DOI 10.1042/BCJ20180225
   Li Y, 2019, CANCER SCI, V110, P561, DOI 10.1111/cas.13888
   Lin CH, 2015, MOL BIOL CELL, V26, P3946, DOI 10.1091/mbc.E15-07-0456
   Lin KC, 2017, TRENDS BIOCHEM SCI, V42, P862, DOI 10.1016/j.tibs.2017.09.003
   Liu-Chittenden Y, 2012, GENE DEV, V26, P1300, DOI 10.1101/gad.192856.112
   Madar-Balakirski N, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010282
   McCaughan JS, 1999, DRUG AGING, V15, P49, DOI 10.2165/00002512-199915010-00005
   Mellish K. J., 2001, EXPERT OPIN PHARMACO, V2, P351
   Meng ZP, 2016, GENE DEV, V30, P1, DOI 10.1101/gad.274027.115
   Michy T, 2019, CANCERS, V11, DOI 10.3390/cancers11111760
   Miller JW, 2019, OPHTHALMOL RETINA, V3, P900, DOI 10.1016/j.oret.2019.07.015
   Momma T, 1998, CANCER RES, V58, P5425
   Newman DK, 2016, EYE, V30, P202, DOI 10.1038/eye.2015.251
   Nouri K, 2019, CANCERS, V11, DOI 10.3390/cancers11101596
   Ooki A, 2018, CANCER RES, V78, P168, DOI 10.1158/0008-5472.CAN-17-0836
   Osaki T, 2007, CANCER LETT, V248, P47, DOI 10.1016/j.canlet.2006.05.021
   Pan W, 2016, CELL PHYSIOL BIOCHEM, V39, P481, DOI 10.1159/000445640
   Panciera T, 2017, NAT REV MOL CELL BIO, V18, P758, DOI 10.1038/nrm.2017.87
   Pavel M, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05388-x
   Pellosi DS, 2019, MOL PHARMACEUT, V16, P1009, DOI 10.1021/acs.molpharmaceut.8b01001
   Pellosi DS, 2017, MAT SCI ENG C-MATER, V71, P1, DOI 10.1016/j.msec.2016.09.064
   Pellosi DS, 2016, INT J NANOMED, V11, P4479, DOI 10.2147/IJN.S103344
   Rizzi M, 2017, J PHOTOCH PHOTOBIO B, V167, P1, DOI 10.1016/j.jphotobiol.2016.12.021
   Rundle P, 2014, BRIT J OPHTHALMOL, V98, P494, DOI 10.1136/bjophthalmol-2013-304432
   Santucci M, 2015, J MED CHEM, V58, P4857, DOI 10.1021/jm501615v
   Scott LJ, 2000, DRUG AGING, V16, P139, DOI 10.2165/00002512-200016020-00005
   Shibata M, 2019, CANCERS, V11, DOI 10.3390/cancers11050732
   Shrestha M, 2019, CARCINOGENESIS, V40, P1288, DOI 10.1093/carcin/bgz023
   Smith SA, 2019, J MED CHEM, V62, P1291, DOI 10.1021/acs.jmedchem.8b01402
   Sugiura K, 2019, AM J PATHOL, V189, P1863, DOI 10.1016/j.ajpath.2019.05.014
   Tang RX, 2016, BRIT J CANCER, V115, P243, DOI 10.1038/bjc.2016.186
   Tang ZX, 2019, FUTURE ONCOL, V15, P1535, DOI 10.2217/fon-2019-0035
   Tranchant R, 2018, LUNG CANCER, V126, P15, DOI 10.1016/j.lungcan.2018.10.015
   Trautmann M, 2019, EMBO MOL MED, V11, DOI 10.15252/emmm.201809889
   Turkoglu EB, 2019, RETINA-J RET VIT DIS, V39, P1319, DOI 10.1097/IAE.0000000000002169
   van Rijssen TJ, 2019, PROG RETIN EYE RES, V73, DOI 10.1016/j.preteyeres.2019.07.003
   Vassilev A, 2001, GENE DEV, V15, P1229, DOI 10.1101/gad.888601
   Wang C, 2017, CANCER RES, V77, P1637, DOI 10.1158/0008-5472.CAN-15-3084
   Wang C, 2016, AM J CANCER RES, V6, P996
   Wang C, 2016, AM J CANCER RES, V6, P27
   Wang J, 2019, MOL MED, V25, DOI 10.1186/s10020-019-0103-4
   Wang KJ, 2019, CLIN CANCER RES, V25, P1070, DOI 10.1158/1078-0432.CCR-18-0586
   Wang L, 2018, PROSTATE, V78, P390, DOI 10.1002/pros.23483
   Wang RC, 2012, SCIENCE, V338, P956, DOI 10.1126/science.1225967
   Wang YZ, 2019, TOXICOL APPL PHARM, V381, DOI 10.1016/j.taap.2019.114714
   Wei HL, 2017, CANCER SCI, V108, P478, DOI 10.1111/cas.13138
   Weiler SME, 2017, GASTROENTEROLOGY, V152, P2037, DOI 10.1053/j.gastro.2017.02.018
   Wu DW, 2018, THERANOSTICS, V8, P1256, DOI 10.7150/thno.22048
   Wu XQ, 2020, ONCOGENE, V39, P2568, DOI 10.1038/s41388-020-1166-y
   Xie LZ, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1217-9
   Xiong JX, 2019, INT J BIOL SCI, V15, P312, DOI 10.7150/ijbs.29135
   Yu FX, 2014, CANCER CELL, V25, P822, DOI 10.1016/j.ccr.2014.04.017
   Zhang JJ, 2019, AM J TRANSL RES, V11, P6965
   Zhang WQ, 2017, J CELL MOL MED, V21, P2663, DOI 10.1111/jcmm.13182
   Zhao B, 2010, GENE DEV, V24, P862, DOI 10.1101/gad.1909210
   Zhao LL, 2016, MAT SCI ENG C-MATER, V68, P317, DOI 10.1016/j.msec.2016.05.108
   Zhao W, 2019, FASEB J, V33, P1151, DOI 10.1096/fj.201800408R
   Zhao X, 2017, CANCER LETT, V402, P61, DOI 10.1016/j.canlet.2017.05.015
   Zhou W, 2019, ANAL BIOCHEM, V586, DOI 10.1016/j.ab.2019.113413
   Zhou Y, 2019, CANCER CELL INT, V19, DOI 10.1186/s12935-019-0898-7
   Ziemssen F, 2012, EXPERT OPIN DRUG MET, V8, P1023, DOI 10.1517/17425255.2012.701617
   Zucchini C, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1506-3
NR 118
TC 26
Z9 26
U1 6
U2 13
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1663-9812
J9 FRONT PHARMACOL
JI Front. Pharmacol.
PD OCT 15
PY 2020
VL 11
AR 557429
DI 10.3389/fphar.2020.557429
PG 15
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA OK6LU
UT WOS:000584760400001
PM 33178014
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Jiang, PF
   Choi, A
   Swindle-Reilly, KE
AF Jiang, Pengfei
   Choi, Andrew
   Swindle-Reilly, Katelyn E.
TI Controlled release of anti-VEGF by redox-responsive polydopamine
   nanoparticles
SO NANOSCALE
LA English
DT Article
ID DRUG-DELIVERY SYSTEMS; OXIDATIVE STRESS; MACULAR DEGENERATION; PLGA
   NANOPARTICLES; ARPE-19 CELLS; BEVACIZUMAB; ANGIOGENESIS; PATHOGENESIS;
   MECHANISMS; SECRETION
AB Reactive oxidative species (ROS) are the primary mediator of angiogenesis by upregulating the expression of vascular endothelial growth factor (VEGF) in the development of wet age-related macular degeneration (AMD). However, the current treatment of AMD currently relies on monthly intravitreal injection of anti-angiogenic therapeutics to inhibit new choroidal angiogenesis. However, repeated injections have been associated with side-effects, are costly, and may lower patient compliance. Moreover, the intraocular oxidative stress-dependent angiogenesis is not alleviated by current treatments, which limits the overall efficacy of the treatment strategy. Recently, nanoparticle-based devices present potential in sustained delivery of angiogenesis inhibitors and excellent capability of scavenging reactive oxygen species (ROS). Nevertheless, limited efforts have been dedicated to the treatment of oxidative stress-related diseasesviaa combined anti-angiogenesis and anti-oxidization pathway. For this purpose, we developed anti-angiogenetic protein-loaded polydopamine (PDA) nanoparticles for the enhanced treatment of AMD. Remarkably, the PDA nanoparticles could efficiently scavenge ROS to reduce the expression of angiogenic agents. In parallel, the particles were able to controllably release loaded anti-angiogenic drugs in response to oxidative stress.
C1 [Jiang, Pengfei; Swindle-Reilly, Katelyn E.] Ohio State Univ, William G Lowrie Dept Chem & Biomol Engn, 134-140 W Woodruff Ave, Columbus, OH 43210 USA.
   [Choi, Andrew; Swindle-Reilly, Katelyn E.] Ohio State Univ, Dept Biomed Engn, 1080 Carmack Rd, Columbus, OH 43210 USA.
   [Swindle-Reilly, Katelyn E.] Ohio State Univ, Dept Ophthalmol & Visual Sci, 915 Olentangy River Rd, Columbus, OH 43212 USA.
C3 University System of Ohio; Ohio State University; University System of
   Ohio; Ohio State University; University System of Ohio; Ohio State
   University
RP Swindle-Reilly, KE (通讯作者)，Ohio State Univ, William G Lowrie Dept Chem & Biomol Engn, 134-140 W Woodruff Ave, Columbus, OH 43210 USA.; Swindle-Reilly, KE (通讯作者)，Ohio State Univ, Dept Biomed Engn, 1080 Carmack Rd, Columbus, OH 43210 USA.; Swindle-Reilly, KE (通讯作者)，Ohio State Univ, Dept Ophthalmol & Visual Sci, 915 Olentangy River Rd, Columbus, OH 43212 USA.
EM reilly.198@osu.edu
OI Swindle-Reilly, Katelyn/0000-0003-1739-0263
FU Ohio Lions Eye Research Foundation Lois Hagelberger-Huebner Young
   Investigator Award; Ohio State University Institute for Materials
   Research
FX This research work was supported by the Ohio Lions Eye Research
   Foundation Lois Hagelberger-Huebner Young Investigator Award and in part
   funded by The Ohio State University Institute for Materials Research.
   The authors would like to thank the William G. Lowrie Department of
   Chemical and Biomolecular Engineering and Department of Biomedical
   Engineering for offering technical support. Also, the authors would like
   to thank Dr. Yi Zhao for providing help with using the fluorescent
   microscope and Dr. Matthew A. Reilly and Dr. Bharat Kumar for providing
   porcine eyes.
CR Ahsan H, 2003, CLIN EXP IMMUNOL, V131, P398, DOI 10.1046/j.1365-2249.2003.02104.x
   Amrite AC, 2005, J PHARM PHARMACOL, V57, P1555, DOI 10.1211/jpp.57.12.0005
   Atienzar-Aroca S, 2016, J CELL MOL MED, V20, P1457, DOI 10.1111/jcmm.12834
   Avery RL, 2014, BRIT J OPHTHALMOL, V98, P1636, DOI 10.1136/bjophthalmol-2014-305252
   Ball V, 2018, FRONT BIOENG BIOTECH, V6, DOI 10.3389/fbioe.2018.00109
   Ballinger SW, 1999, EXP EYE RES, V68, P765, DOI 10.1006/exer.1998.0661
   Bao XF, 2018, ACS NANO, V12, P8882, DOI 10.1021/acsnano.8b04022
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Bettinger CJ, 2009, BIOMATERIALS, V30, P3050, DOI 10.1016/j.biomaterials.2009.02.018
   Blasiak J, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/768026
   Cai X, 2016, ADV EXP MED BIOL, V854, P111, DOI 10.1007/978-3-319-17121-0_16
   Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220
   Cave AC, 2006, ANTIOXID REDOX SIGN, V8, P691, DOI 10.1089/ars.2006.8.691
   Charbgoo F, 2017, INT J NANOMED, V12, P1401, DOI 10.2147/IJN.S124855
   Cheng YY, 2017, SMALL, V13, DOI 10.1002/smll.201701942
   Rodriguez ARC, 2016, RSC ADV, V6, P40058, DOI 10.1039/c6ra03664c
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   DeCicco-Skinner KL, 2014, JOVE-J VIS EXP, DOI 10.3791/51312
   Dong A, 2009, J CELL PHYSIOL, V219, P544, DOI 10.1002/jcp.21698
   Dong ZL, 2016, THERANOSTICS, V6, P1031, DOI 10.7150/thno.14431
   Dreyer DR, 2013, CHEM SCI, V4, P3796, DOI 10.1039/c3sc51501j
   Folkman, 1984, BIOL ENDOTHELIAL CEL, DOI 10.1007/978-1-4613-2825-4_42
   Foroozandeh P, 2018, NANOSCALE RES LETT, V13, DOI 10.1186/s11671-018-2728-6
   Ho CC, 2013, J MATER SCI-MATER M, V24, P2381, DOI 10.1007/s10856-013-4994-2
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Jager RD, 2004, RETINA-J RET VIT DIS, V24, P676, DOI 10.1097/00006982-200410000-00002
   Jiang PF, 2020, MOL PHARMACEUT, V17, P2570, DOI 10.1021/acs.molpharmaceut.0c00260
   Jiang PF, 2020, J CONTROL RELEASE, V320, P442, DOI 10.1016/j.jconrel.2020.01.036
   Jin L, 2019, INFLAMMATION, V42, P658, DOI 10.1007/s10753-018-0923-3
   Kannan R, 2006, MOL VIS, V12, P1649
   Kauppinen A, 2012, IMMUNOL LETT, V147, P29, DOI 10.1016/j.imlet.2012.05.005
   Khandhadia S, 2010, EXPERT REV MOL MED, V12, DOI 10.1017/S146239941000164X
   Kim Min-Ho, 2003, Korean J Ophthalmol, V17, P19
   Lai JY, 2010, INT J MOL SCI, V11, P5257, DOI 10.3390/ijms11125256
   Li FF, 2012, OPEN OPHTHALMOL J, V6, P54, DOI 10.2174/1874364101206010054
   Li WQ, 2017, ACS APPL MATER INTER, V9, P16794, DOI 10.1021/acsami.7b01540
   Liu YL, 2014, CHEM REV, V114, P5057, DOI 10.1021/cr400407a
   de Redin IL, 2018, INT J PHARMACEUT, V541, P214, DOI 10.1016/j.ijpharm.2018.02.003
   Lynge ME, 2011, NANOSCALE, V3, P4916, DOI 10.1039/c1nr10969c
   Napoli A, 2004, NAT MATER, V3, P183, DOI 10.1038/nmat1081
   Nowak JZ, 2006, PHARMACOL REP, V58, P353
   Pezzella A, 1997, TETRAHEDRON, V53, P8281, DOI 10.1016/S0040-4020(97)00494-8
   Pulido JS, 2007, EYE, V21, P829, DOI 10.1038/sj.eye.6702514
   Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0
   Rose RC, 1998, P SOC EXP BIOL MED, V217, P397, DOI 10.3181/00379727-217-44250
   Sapieha P, 2010, INT J BIOCHEM CELL B, V42, P5, DOI 10.1016/j.biocel.2009.10.006
   Schieber M, 2014, CURR BIOL, V24, pR453, DOI 10.1016/j.cub.2014.03.034
   Shen SH, 2017, INT J NANOMED, V12, P4085, DOI 10.2147/IJN.S132780
   Shi HQ, 2015, BIOCHEM BIOPH RES CO, V463, P1071, DOI 10.1016/j.bbrc.2015.06.060
   SNODDERLY DM, 1995, AM J CLIN NUTR, V62, P1448
   Tao WH, 2018, ASIAN J PHARM SCI, V13, P101, DOI 10.1016/j.ajps.2017.11.002
   Thrimawithana TR, 2011, DRUG DISCOV TODAY, V16, P270, DOI 10.1016/j.drudis.2010.12.004
   Tiwari G, 2012, INT J PHARM INVESTIG, V2, P2, DOI 10.4103/2230-973X.96920
   van Leeuwen R, 2005, JAMA-J AM MED ASSOC, V294, P3101, DOI 10.1001/jama.294.24.3101
   Varshochian R, 2015, J BIOMED MATER RES A, V103, P3148, DOI 10.1002/jbm.a.35446
   Varshochian R, 2013, EUR J PHARM SCI, V50, P341, DOI 10.1016/j.ejps.2013.07.014
   Wang K, 2018, J BIOMED MATER RES A, V106, P2795, DOI 10.1002/jbm.a.36450
   Wang Q, 2017, BIOMACROMOLECULES, V18, P1333, DOI 10.1021/acs.biomac.7b00077
   Winkler BS, 1999, MOL VIS, V5
   Xian DH, 2019, OXID MED CELL LONGEV, V2019, DOI 10.1155/2019/2304018
   Yasukawa T, 2005, ADV DRUG DELIVER REV, V57, P2033, DOI 10.1016/j.addr.2005.09.005
   Zhao H, 2018, NANOSCALE, V10, P6981, DOI 10.1039/c8nr00838h
   Zhou XH, 2011, PLOS ONE, V6, DOI [10.1371/journal.pone.0016733, 10.1371/journal.pone.0017812]
NR 63
TC 15
Z9 15
U1 5
U2 63
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 2040-3364
EI 2040-3372
J9 NANOSCALE
JI Nanoscale
PD SEP 7
PY 2020
VL 12
IS 33
BP 17298
EP 17311
DI 10.1039/d0nr03710a
PG 14
WC Chemistry, Multidisciplinary; Nanoscience & Nanotechnology; Materials
   Science, Multidisciplinary; Physics, Applied
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Chemistry; Science & Technology - Other Topics; Materials Science;
   Physics
GA NF7NR
UT WOS:000563481700012
PM 32789323
DA 2022-11-30
ER

PT J
AU Sugano, E
   Edwards, G
   Saha, S
   Wilmott, LA
   Grambergs, RC
   Mondal, K
   Qi, H
   Stiles, M
   Tomita, H
   Mandal, N
AF Sugano, Eriko
   Edwards, Genea
   Saha, Saikat
   Wilmott, Lynda A.
   Grambergs, Richard C.
   Mondal, Koushik
   Qi, Hui
   Stiles, Megan
   Tomita, Hiroshi
   Mandal, Nawajes
TI Overexpression of acid ceramidase (ASAH1) protects retinal cells
   (ARPE19) from oxidative stress
SO JOURNAL OF LIPID RESEARCH
LA English
DT Article
DE N-acylsphingosine amidohydrolase 1; ceramide; hexosyl-ceramide;
   lysosome, retinal pigment epithelium; retinal degeneration; age-related
   macular degeneration
ID SYSTEMIC-LUPUS-ERYTHEMATOSUS; INDUCED APOPTOSIS; SPHINGOLIPID
   METABOLISM; GENE-EXPRESSION; CHAIN LENGTH; TEMPORAL EXPRESSION; PIGMENT
   EPITHELIUM; ER STRESS; ACTIVATION; INHIBITION
AB Over 11 million people in the United States alone have some form of age-related macular degeneration (AMD). Oxidative stress, cell death, and the degeneration of retinal pigment epithelial (RPE) cells contribute to AMD pathology. Recent evidence suggests that ceramide (Cer), a cellular sphingolipid mediator that acts as a second messenger to induce apoptosis, might play a role in RPE cell death. The lysosomal breakdown of Cer by acid ceramidase [N-acylsphingosine amidohydrolase (ASAH)1] into sphingosine (Sph) is the major source for Sph 1-phosphate production, which has an opposing role to Cer and provides cytoprotection. Here, we investigated the role of Cer in human RPE-derived ARPE19 cells under hydrogen peroxide-induced oxidative stress, and show that Cer and hexosyl-Cer levels increase in the oxidatively stressed ARPE19 cells, which can be prevented by overexpression of lysosomal ASAH1. This study demonstrates that oxidative stress generates sphingolipid death mediators in retinal cells and that induction of ASAH1 could rescue retinal cells from oxidative stress by hydrolyzing excess Cers.
C1 [Sugano, Eriko; Tomita, Hiroshi] Iwate Univ, Div Sci & Engn, Morioka, Iwate 0208551, Japan.
   [Edwards, Genea; Saha, Saikat; Wilmott, Lynda A.; Grambergs, Richard C.; Mondal, Koushik; Mandal, Nawajes] Univ Tennessee, Ctr Hlth Sci, Dept Ophthalmol, Memphis, TN 38163 USA.
   [Mandal, Nawajes] Univ Tennessee, Ctr Hlth Sci, Dept Anat & Neurobiol, Memphis, TN 38163 USA.
   [Qi, Hui; Stiles, Megan; Mandal, Nawajes] Univ Oklahoma, Hlth Sci Ctr, Dept Ophthalmol, Oklahoma City, OK 73104 USA.
C3 Iwate University; University of Tennessee System; University of
   Tennessee Health Science Center; University of Tennessee System;
   University of Tennessee Health Science Center; University of Oklahoma
   System; University of Oklahoma Health Sciences Center
RP Mandal, N (通讯作者)，Univ Tennessee, Ctr Hlth Sci, Dept Ophthalmol, Memphis, TN 38163 USA.; Mandal, N (通讯作者)，Univ Tennessee, Ctr Hlth Sci, Dept Anat & Neurobiol, Memphis, TN 38163 USA.; Mandal, N (通讯作者)，Univ Oklahoma, Hlth Sci Ctr, Dept Ophthalmol, Oklahoma City, OK 73104 USA.
EM nmandal@uthsc.edu
OI Edwards, Genea/0000-0002-5790-5391
FU National Eye Institute [EY022071, EY025256, EY021725]; Foundation
   Fighting Blindness; Research to Prevent Blindness; Ministry of
   Education, Culture, Sports, Science and Technology [16K11314, 16H05485,
   16K15729]; Virginia Commonwealth University Massey Cancer Center;
   National Institutes of Health [P30 CA016059]; NATIONAL CANCER INSTITUTE
   [P30CA016059] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE
   [R01EY022071, R21EY025256, P30EY021725] Funding Source: NIH RePORTER
FX This work was supported by National Eye Institute Grants EY022071,
   EY025256, and EY021725, and grants from the Foundation Fighting
   Blindness and Research to Prevent Blindness. Additional support was
   provided by Ministry of Education, Culture, Sports, Science and
   Technology Grants-in-Aid for Scientific Research 16K11314, 16H05485, and
   16K15729. The lipidomic services (Virginia Commonwealth University
   Lipidomics/Metabolomics Core) and products in support of the study were
   generated, in part, by the Virginia Commonwealth University Massey
   Cancer Center, with funding from National Institutes of Health Grant P30
   CA016059. The content is solely the responsibility of the authors and
   does not necessarily represent the official views of the National
   Institutes of Health, the Department of Veterans Affairs, or the US
   Government.
CR Abbott SK, 2014, MOVEMENT DISORD, V29, P518, DOI 10.1002/mds.25729
   Abe T, 1999, CELL TRANSPLANT, V8, P501, DOI 10.1177/096368979900800505
   Acharya U, 2003, SCIENCE, V299, P1740, DOI 10.1126/science.1080549
   Barak A, 2001, INVEST OPHTH VIS SCI, V42, P247
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Berdyshev EV, 2009, J BIOL CHEM, V284, P5467, DOI 10.1074/jbc.M805186200
   Bienias K, 2016, PHARMACOL REP, V68, P570, DOI 10.1016/j.pharep.2015.12.008
   Campochiaro PA, 2015, ANTIOXID REDOX SIGN, V23, P643, DOI 10.1089/ars.2015.6327
   Chalfant CE, 1999, J BIOL CHEM, V274, P20313, DOI 10.1074/jbc.274.29.20313
   Chatterjee M, 2001, MOL CELL BIOCHEM, V219, P21, DOI 10.1023/A:1011083818452
   Checa A, 2017, LUPUS, V26, P1023, DOI 10.1177/0961203316686707
   Chen H, 2014, SURV OPHTHALMOL, V59, P64, DOI 10.1016/j.survophthal.2013.02.005
   Chen H, 2013, J LIPID RES, V54, P1616, DOI 10.1194/jlr.M035048
   Chen H, 2012, MOL VIS, V18, P1325
   Chen H, 2012, ADV EXP MED BIOL, V723, P553, DOI 10.1007/978-1-4614-0631-0_70
   Chimin P, 2017, J LIPID RES, V58, P1797, DOI 10.1194/jlr.M074518
   Czabotar PE, 2014, NAT REV MOL CELL BIO, V15, P49, DOI 10.1038/nrm3722
   Czubowicz K, 2014, MOL NEUROBIOL, V50, P26, DOI 10.1007/s12035-013-8606-4
   Dbaibo GS, 2007, HAEMATOLOGICA, V92, P753, DOI 10.3324/haematol.10968
   Dbaibo GS, 2001, FEBS LETT, V503, P7, DOI 10.1016/S0014-5793(01)02625-4
   de la Monte SM, 2012, J ALZHEIMERS DIS, V30, pS217, DOI 10.3233/JAD-2012-111728
   Dumitru CA, 2007, ANTIOXID REDOX SIGN, V9, P1535, DOI 10.1089/ars.2007.1692
   Feng CY, 2017, MOL VIS, V23, P765
   Foresti R, 2013, PHARMACOL RES, V76, P132, DOI 10.1016/j.phrs.2013.07.010
   Galadari S, 2015, APOPTOSIS, V20, P689, DOI 10.1007/s10495-015-1109-1
   Galadari S, 2013, LIPIDS HEALTH DIS, V12, DOI 10.1186/1476-511X-12-98
   Garanto A, 2013, EXP EYE RES, V110, P96, DOI 10.1016/j.exer.2013.03.003
   German OL, 2006, INVEST OPHTH VIS SCI, V47, P1658, DOI 10.1167/iovs.05-1310
   Gomez-Munoz A, 2006, BBA-BIOMEMBRANES, V1758, P2049, DOI 10.1016/j.bbamem.2006.05.011
   Grosch S, 2012, PROG LIPID RES, V51, P50, DOI 10.1016/j.plipres.2011.11.001
   Hannun YA, 2008, NAT REV MOL CELL BIO, V9, P139, DOI 10.1038/nrm2329
   Hennessy BT, 2005, NAT REV DRUG DISCOV, V4, P988, DOI 10.1038/nrd1902
   HOGAN M J, 1972, Transactions of the American Academy of Ophthalmology and Oto-Laryngology, V76, P64
   Holz FG, 2001, INVEST OPHTH VIS SCI, V42, P1051
   Huwiler A, 2006, CURR PHARM DESIGN, V12, P4625, DOI 10.2174/138161206779010422
   Jarrett SG, 2012, MOL ASPECTS MED, V33, P399, DOI 10.1016/j.mam.2012.03.009
   Jarvis W. David, 1998, Current Opinion in Oncology, V10, P552, DOI 10.1097/00001622-199811000-00013
   Jiang PP, 2016, CELL PHYSIOL BIOCHEM, V40, P1391, DOI 10.1159/000453191
   Kannan R, 2004, FREE RADICAL BIO MED, V37, P166, DOI 10.1016/j.freeradbiomed.2004.04.011
   Katsel P, 2007, NEUROCHEM RES, V32, P845, DOI 10.1007/s11064-007-9297-x
   Kennedy CJ, 1995, EYE, V9, P763, DOI 10.1038/eye.1995.192
   Kitatani K, 2008, CELL SIGNAL, V20, P1010, DOI 10.1016/j.cellsig.2007.12.006
   Kizhakkayil J, 2012, FREE RADICAL BIO MED, V52, P1854, DOI 10.1016/j.freeradbiomed.2012.02.026
   Kowluru RA, 2007, EXP DIABETES RES, DOI 10.1155/2007/43603
   Lahiri S, 2009, J BIOL CHEM, V284, P16090, DOI 10.1074/jbc.M807438200
   LEVADE T, 1995, J NEUROL SCI, V134, P108, DOI 10.1016/0022-510X(95)00231-0
   Levy M, 2010, IUBMB LIFE, V62, P347, DOI 10.1002/iub.319
   Li CM, 1999, GENOMICS, V62, P223, DOI 10.1006/geno.1999.5940
   Liang FQ, 2003, EXP EYE RES, V76, P397, DOI 10.1016/S0014-4835(03)00023-X
   Maceyka M, 2002, BBA-MOL CELL BIOL L, V1585, P193, DOI 10.1016/S1388-1981(02)00341-4
   Mandal MNA, 2006, INVEST OPHTH VIS SCI, V47, P5514, DOI 10.1167/iovs.06-0449
   Mandal MNA, 2011, J BIOL CHEM, V286, P32491, DOI 10.1074/jbc.M111.255877
   Mandal MNA, 2009, FREE RADICAL BIO MED, V46, P672, DOI 10.1016/j.freeradbiomed.2008.12.006
   Mandal NA, 2006, INVEST OPHTH VIS SCI, V47, P4091, DOI 10.1167/iovs.05-1655
   Manning BD, 2007, CELL, V129, P1261, DOI 10.1016/j.cell.2007.06.009
   Merrill AH, 1997, TOXICOL APPL PHARM, V142, P208, DOI 10.1006/taap.1996.8029
   Mullen TD, 2012, BIOCHEM J, V441, P789, DOI 10.1042/BJ20111626
   Mysliwiec M, 2008, DIABETES RES CLIN PR, V79, P141, DOI 10.1016/j.diabres.2007.07.011
   OLIVERA A, 1993, NATURE, V365, P557, DOI 10.1038/365557a0
   Pettus BJ, 2002, BBA-MOL CELL BIOL L, V1585, P114, DOI 10.1016/S1388-1981(02)00331-1
   Qi H, 2017, J LIPID RES, V58, P636, DOI 10.1194/jlr.M067264
   Rath G, 2009, INT J BIOCHEM CELL B, V41, P1165, DOI 10.1016/j.biocel.2008.10.021
   Reme CE, 1998, PROG RETIN EYE RES, V17, P443, DOI 10.1016/S1350-9462(98)00009-3
   Salinas M, 2000, MOL CELL NEUROSCI, V15, P156, DOI 10.1006/mcne.1999.0813
   Sanvicens N, 2006, J NEUROCHEM, V98, P1432, DOI 10.1111/j.1471-4159.2006.03977.x
   SATOH S, 1994, IMMUNOLOGY, V82, P571
   Schmittgen TD, 2008, NAT PROTOC, V3, P1101, DOI 10.1038/nprot.2008.73
   Schubert KM, 2000, J BIOL CHEM, V275, P13330, DOI 10.1074/jbc.275.18.13330
   Spiegel S, 1996, FASEB J, V10, P1388, DOI 10.1096/fasebj.10.12.8903509
   Stiban J, 2010, ADV EXP MED BIOL, V688, P60
   Stiles M, 2016, J LIPID RES, V57, P818, DOI 10.1194/jlr.M063719
   Suzuki J, 2011, NEUROSCIENCE, V176, P188, DOI 10.1016/j.neuroscience.2010.11.035
   Takeda Y, 1999, J BIOL CHEM, V274, P10654, DOI 10.1074/jbc.274.15.10654
   Tan SF, 2016, ONCOTARGET, V7, P83208, DOI 10.18632/oncotarget.13079
   Tani M, 2007, CELL SIGNAL, V19, P229, DOI 10.1016/j.cellsig.2006.07.001
   Thayyullathil F, 2011, J CELL BIOCHEM, V112, P1138, DOI 10.1002/jcb.23033
   Tomita H, 2000, TOHOKU J EXP MED, V190, P223, DOI 10.1620/tjem.190.223
   Wijesinghe DS, 2014, J LIPID RES, V55, P1298, DOI 10.1194/jlr.M048207
   Wijesinghe DS, 2010, J LIPID RES, V51, P641, DOI 10.1194/jlr.D000430
   WOLFF RA, 1994, J BIOL CHEM, V269, P19605
   Wu BX, 2009, BBA-MOL CELL BIOL L, V1791, P730, DOI 10.1016/j.bbalip.2009.03.012
   Xing Y, 2016, J NEUROL SCI, V370, P82, DOI 10.1016/j.jns.2016.09.028
   Yao J, 2013, INT J MOL SCI, V14, P10355, DOI 10.3390/ijms140510355
   YOUNG RW, 1987, SURV OPHTHALMOL, V31, P291, DOI 10.1016/0039-6257(87)90115-9
   Young SA, 2012, BIOCHEM RES INT, V2012, DOI 10.1155/2012/248135
NR 85
TC 20
Z9 20
U1 1
U2 6
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0022-2275
EI 1539-7262
J9 J LIPID RES
JI J. Lipid Res.
PD JAN
PY 2019
VL 60
IS 1
BP 30
EP 43
DI 10.1194/jlr.M082198
PG 14
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA HF7EG
UT WOS:000454401500006
PM 30413652
OA Green Published, hybrid
DA 2022-11-30
ER

PT J
AU Tanetsugu, Y
   Tagami, T
   Terukina, T
   Ogawa, T
   Ohta, M
   Ozeki, T
AF Tanetsugu, Yusuke
   Tagami, Tatsuaki
   Terukina, Takayuki
   Ogawa, Takaya
   Ohta, Masato
   Ozeki, Tetsuya
TI Development of a Sustainable Release System for a Ranibizumab Biosimilar
   Using Poly(lactic-co-glycolic acid) Biodegradable Polymer-Based
   Microparticles as a Platform
SO BIOLOGICAL & PHARMACEUTICAL BULLETIN
LA English
DT Article
DE ranibizumab; poly(lactic-co-glycolic acid) (PLGA); controlled release;
   anti-vascular endothelial growth factor (VEGF) therapy; biosimilar;
   age-related macular degeneration (AMD)
ID DIABETIC MACULAR EDEMA; 2.0 MG RANIBIZUMAB; PLGA MICROPARTICLES;
   CO-ENCAPSULATION; DRUG-RELEASE; IN-VITRO; DEGENERATION; MICROSPHERES;
   DELIVERY; VERTEPORFIN
AB Ranibizumab is a humanized monoclonal antibody fragment against vascular endothelial growth factor (VEGF)-A and is widely used to treat age-related macular degeneration (AMD) caused by angiogenesis. Ranibizumab has a short half-life in the eye due to its low molecular weight and susceptibility to proteolysis. Monthly intravitreal injection of a large amount of ranibizumab formulation is a burden for both patients and medical staff. We therefore sought to develop a sustainable release system for treating the eye with ranibizumab using a drug carrier. A ranibizumab biosimilar (RB) was incorporated into microparticles of poly(lactic-co-glycolic acid) (PLGA) biodegradable polymer. Ranibizumab was sustainably released from PLGA microparticles (80+% after 3 weeks). Assay of tube formation by endothelial cells indicated that RB released from PLGA microparticles inhibited VEGF-induced tube formation and this tendency was confirmed by a cell proliferation assay. These results indicate that RB-loaded PLGA microparticles are useful for sustainable RB release and suggest the utility of intraocular sustainable release systems for delivering RB site-specifically to AMD patients.
C1 [Tanetsugu, Yusuke; Tagami, Tatsuaki; Terukina, Takayuki; Ozeki, Tetsuya] Nagoya City Univ, Grad Sch Pharmaceut Sci, Drug Delivery & Nano Pharmaceut, Mizuho Ku, 3-1 Tanabe Dori, Nagoya, Aichi 4678603, Japan.
   [Ogawa, Takaya; Ohta, Masato] Meiji Seika Pharma Co Ltd, Chem Mfg & Control Res Labs, Kohoku Ku, 760 Morooka Cho, Yokohama, Kanagawa 2228567, Japan.
C3 Nagoya City University; Meiji Seika Pharma
RP Ozeki, T (通讯作者)，Nagoya City Univ, Grad Sch Pharmaceut Sci, Drug Delivery & Nano Pharmaceut, Mizuho Ku, 3-1 Tanabe Dori, Nagoya, Aichi 4678603, Japan.
EM ozekit@phar.nagoya-cu.ac.jp
RI Ogawa, Takaya/ABB-4415-2020
OI Ogawa, Takaya/0000-0001-8273-964X
FU Meiji Seika Pharma Co., Ltd.
FX Tetsuya Ozeki received financial support from Meiji Seika Pharma Co.,
   Ltd.
CR Abraham P, 2010, AM J OPHTHALMOL, V150, P315, DOI 10.1016/j.ajo.2010.04.011
   Allison SD, 2008, EXPERT OPIN DRUG DEL, V5, P615, DOI 10.1517/17425247.5.6.615 
   Ba J, 2015, DRUG DES DEV THER, V9, DOI 10.2147/DDDT.S86269
   Bakri SJ, 2007, OPHTHALMOLOGY, V114, P2179, DOI 10.1016/j.ophtha.2007.09.012
   Blanco D, 1998, EUR J PHARM BIOPHARM, V45, P285, DOI 10.1016/S0939-6411(98)00011-3
   Boyer D, 2010, OPHTHALMOLOGY, V117, P1860, DOI 10.1016/j.ophtha.2010.02.022
   Boyer DS, 2011, RETINA-J RET VIT DIS, V31, P915, DOI 10.1097/IAE.0b013e318206d18c
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Busbee BG, 2013, OPHTHALMOLOGY, V120, P1046, DOI 10.1016/j.ophtha.2012.10.014
   Callanan DG, 2008, ARCH OPHTHALMOL-CHIC, V126, P1191, DOI 10.1001/archopht.126.9.1191
   Campochiaro PA, 2010, OPHTHALMOLOGY, V117, P1102, DOI 10.1016/j.ophtha.2010.02.021
   Dedania VS, 2015, CLIN OPHTHALMOL, V9, P533, DOI 10.2147/OPTH.S80049
   Eleryan MG, 2016, CLIN COSMET INVESTI, V9, P135, DOI 10.2147/CCID.S91691
   Elsaid N, 2016, MOL PHARMACEUT, V13, P2923, DOI 10.1021/acs.molpharmaceut.6b00335
   Fine SL, 2000, NEW ENGL J MED, V342, P483, DOI 10.1056/NEJM200002173420707
   Fredenberg S, 2011, INT J PHARMACEUT, V415, P34, DOI 10.1016/j.ijpharm.2011.05.049
   Giteau A, 2008, INT J PHARMACEUT, V350, P14, DOI 10.1016/j.ijpharm.2007.11.012
   Goncalves J, 2016, CLIN EXP RHEUMATOL, V34, P698
   Herrero-Vanrell R, 2001, ADV DRUG DELIVER REV, V52, P5, DOI 10.1016/S0169-409X(01)00200-9
   Ho AC, 2014, OPHTHALMOLOGY, V121, P2181, DOI 10.1016/j.ophtha.2014.05.009
   Iwata M, 1998, INT J PHARM, V160, P145, DOI 10.1016/S0378-5173(97)00306-2
   Johansen P, 1998, PHARMACEUT RES, V15, P1103, DOI 10.1023/A:1011998615267
   Lee DJ, 2015, J FUNCT BIOMATER, V6, P650, DOI 10.3390/jfb6030650
   Lee SS, 2010, PHARM RES-DORDR, V27, P2043, DOI 10.1007/s11095-010-0159-x
   Lowe J, 2007, EXP EYE RES, V85, P425, DOI 10.1016/j.exer.2007.05.008
   Makadia HK, 2011, POLYMERS-BASEL, V3, P1377, DOI 10.3390/polym3031377
   OKADA H, 1988, J PHARMACOL EXP THER, V244, P744
   Okada H, 1997, ADV DRUG DELIVER REV, V28, P43, DOI 10.1016/S0169-409X(97)00050-1
   Perez C, 2003, BIOTECHNOL BIOENG, V82, P825, DOI 10.1002/bit.10632
   Nguyen QD, 2012, OPHTHALMOLOGY, V119, P789, DOI 10.1016/j.ophtha.2011.12.039
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Tagami T, 2014, INT J PHARMACEUT, V468, P91, DOI 10.1016/j.ijpharm.2014.04.013
   Thaloor D, 1998, CELL GROWTH DIFFER, V9, P305
   van de Weert M, 2000, PHARM RES-DORDR, V17, P1159, DOI 10.1023/A:1026498209874
   Zhang LL, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0135608
NR 37
TC 16
Z9 16
U1 1
U2 21
PU PHARMACEUTICAL SOC JAPAN
PI TOKYO
PA 2-12-15 SHIBUYA, SHIBUYA-KU, TOKYO, 150-0002, JAPAN
SN 0918-6158
J9 BIOL PHARM BULL
JI Biol. Pharm. Bull.
PD FEB
PY 2017
VL 40
IS 2
BP 145
EP 150
DI 10.1248/bpb.b16-00437
PG 6
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA EJ3BO
UT WOS:000393086200004
PM 28154252
OA gold
DA 2022-11-30
ER

PT J
AU Foxton, RH
   Finkelstein, A
   Vijay, S
   Dahlmann-Noor, A
   Khaw, PT
   Morgan, JE
   Shima, DT
   Ng, YS
AF Foxton, Richard H.
   Finkelstein, Arthur
   Vijay, Sauparnika
   Dahlmann-Noor, Annegret
   Khaw, Peng T.
   Morgan, James E.
   Shima, David T.
   Ng, Yin-Shan
TI VEGF-A Is Necessary and Sufficient for Retinal Neuroprotection in Models
   of Experimental Glaucoma
SO AMERICAN JOURNAL OF PATHOLOGY
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; GANGLION-CELL DEATH; INDUCED APOPTOSIS;
   SURVIVAL; NEURONS; ACTIVATION; INHIBITORS; PRESSURE; SUSCEPTIBILITY;
   MECHANISMS
AB Vascular endothelial growth factor A (VEGF-A) is a validated therapeutic target in several angiogenic-and vascular permeability related pathological conditions, including certain cancers and potentially blinding diseases, such as age-related macular degeneration and diabetic retinopathy. We and others have shown that VEGF-A also plays an important role in neuronal development and neuroprotection, including in the neural retina. Antagonism of VEGF-A function might therefore present a risk to neuronal survival as a significant adverse effect. Herein, we demonstrate that VEGF-A acts directly on retinal ganglion cells (RGCs) to promote survival. VEGF receptor-2 signaling via the phosphoinositide-3-kinase/Akt pathway was required for the survival response in isolated RGCs. These results were confirmed in animal models of staurosporine-induced RGC death and experimental hypertensive glaucoma. Importantly, we observed that VEGF-A blockade significantly exacerbated neuronal cell death in the hypertensive glaucoma model. Our findings highlight the need to better define the risks associated with use of VEGF-A antagonists in the ocular setting.
C1 [Foxton, Richard H.; Finkelstein, Arthur; Vijay, Sauparnika; Dahlmann-Noor, Annegret; Khaw, Peng T.; Shima, David T.; Ng, Yin-Shan] Moorfields Eye Hosp, Biomed Res Ctr, Natl Inst Hlth Res, London, England.
   [Foxton, Richard H.; Finkelstein, Arthur; Vijay, Sauparnika; Dahlmann-Noor, Annegret; Khaw, Peng T.; Shima, David T.; Ng, Yin-Shan] UCL, Inst Ophthalmol, London WC1E 6BT, England.
   [Morgan, James E.] Cardiff Univ, Sch Optometry & Vis Sci, Cardiff CF10 3AX, S Glam, Wales.
   [Morgan, James E.] Cardiff Univ, Sch Med, Cardiff CF10 3AX, S Glam, Wales.
C3 University of London; University College London; Moorfields Eye Hospital
   NHS Foundation Trust; University of London; University College London;
   Cardiff University; Cardiff University
RP Ng, YS (通讯作者)，UCL, Inst Ophthalmol, Dept Ocular Biol & Therapeut, 11-43 Bath St, London EC1V 9EL, England.
EM yin-shan.ng@ucl.ac.uk
RI Morgan, James/GRO-2905-2022; Dahlmann-Noor, Annegret/A-2967-2017
OI Morgan, James/0000-0002-8920-1065; Khaw, Sir Peng
   Tee/0000-0002-8087-2268; Ng, Yin Shan/0000-0002-4982-1999;
   Dahlmann-Noor, Annegret/0000-0002-7402-4350
FU Medical Research Council [G0901303]; Medical Research Council Dorothy
   Hodgkin Postgraduate Award; Helen Hamlyn Trust; Fight for Sight;
   National Institute for Health Research Biomedical Research Centre
   Moorfields; University College London Institute of Ophthalmology;
   Medical Research Council [G0800946] Funding Source: researchfish;
   National Institute for Health Research [NF-SI-0512-10101] Funding
   Source: researchfish; MRC [G0800946, G0901303] Funding Source: UKRI
FX Supported by the Medical Research Council (G0901303), in part by the
   Medical Research Council Dorothy Hodgkin Postgraduate Award, the Helen
   Hamlyn Trust, Fight for Sight, the National Institute for Health
   Research Biomedical Research Centre Moorfields, and the University
   College London Institute of Ophthalmology.
CR Adler R, 1999, MOL VIS, V5
   Almasieh M, 2012, PROG RETIN EYE RES, V31, P152, DOI 10.1016/j.preteyeres.2011.11.002
   Azzouz M, 2004, NATURE, V429, P413, DOI 10.1038/nature02544
   Bhisitkul RB, 2012, ARVO M, V53, P3679
   Brockington A, 2010, BMC GENOMICS, V11, DOI 10.1186/1471-2164-11-203
   Caballero-Benitez A, 2003, J NEUROSCI RES, V71, P383, DOI 10.1002/jnr.10493
   Cariboni A, 2011, DEVELOPMENT, V138, P3723, DOI 10.1242/dev.063362
   Carmeliet P, 2005, NATURE, V436, P193, DOI 10.1038/nature03875
   Chauvier D, 2007, CELL DEATH DIFFER, V14, P387, DOI 10.1038/sj.cdd.4402044
   Chong V, 2012, OPHTHALMOLOGICA, V227, P2, DOI 10.1159/000337152
   Cui W, 2011, BRAIN RES, V1394, P14, DOI 10.1016/j.brainres.2011.02.006
   D'Amore PA, 2007, AM J PATHOL, V171, P14, DOI 10.2353/ajpath.2007.070385
   Erskine L, 2011, NEURON, V70, P951, DOI 10.1016/j.neuron.2011.02.052
   Ferrara N, 2005, BIOCHEM BIOPH RES CO, V333, P328, DOI 10.1016/j.bbrc.2005.05.132
   Fuchs C, 2005, INVEST OPHTH VIS SCI, V46, P2983, DOI 10.1167/iovs.04-1177
   GARCIAVALENZUELA E, 1995, EXP EYE RES, V61, P33, DOI 10.1016/S0014-4835(95)80056-5
   Gerber HP, 1998, J BIOL CHEM, V273, P30336, DOI 10.1074/jbc.273.46.30336
   Gomes E, 2007, MOL CELL BIOCHEM, V305, P179, DOI 10.1007/s11010-007-9542-2
   Guo L, 2006, INVEST OPHTH VIS SCI, V47, P626, DOI 10.1167/iovs.05-0754
   Hanninen VA, 2002, CURR EYE RES, V25, P389
   Horsley MB, 2010, CURR OPIN OPHTHALMOL, V21, P112, DOI 10.1097/ICU.0b013e3283360aad
   Ito K, 2007, J PHARMACOL EXP THER, V321, P1, DOI 10.1124/jpet.106.111674
   Jackson GR, 2010, CURR DIABETES REP, V10, P380, DOI 10.1007/s11892-010-0132-4
   Jakobs TC, 2005, J CELL BIOL, V171, P313, DOI 10.1083/jcb.200506099
   Jin K, 2001, NEUROSCIENCE, V108, P351, DOI 10.1016/S0306-4522(01)00154-3
   Jin KL, 2000, P NATL ACAD SCI USA, V97, P10242, DOI 10.1073/pnas.97.18.10242
   Kerrigan LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P1031, DOI 10.1001/archopht.1997.01100160201010
   Kerrigan-Baumrind LA, 2000, INVEST OPHTH VIS SCI, V41, P741
   Kilic U, 2006, J NEUROSCI, V26, P12439, DOI 10.1523/JNEUROSCI.0434-06.2006
   Kim HS, 2005, BRAIN RES, V1057, P17, DOI 10.1016/j.brainres.2005.07.005
   Kim I, 1999, INVEST OPHTH VIS SCI, V40, P2115
   Kitaoka Y, 2007, BRAIN RES, V1142, P247, DOI 10.1016/j.brainres.2007.01.097
   Kortuem K, 2000, INVEST OPHTH VIS SCI, V41, P3176
   Libby RT, 2005, PLOS GENET, V1, P17, DOI 10.1371/journal.pgen.0010004
   Ma YH, 2011, BRAIN RES BULL, V86, P441, DOI 10.1016/j.brainresbull.2011.07.007
   Mackenzie F, 2012, DEVELOPMENT, V139, P1371, DOI 10.1242/dev.072348
   Martinez-de-la-Casa JM, 2012, INVEST OPHTH VIS SCI, V53, P6214, DOI 10.1167/iovs.12-9875
   Matsuzaki H, 2001, FASEB J, V15, P1218, DOI 10.1096/fj.00-0495fje
   Nishijima K, 2007, AM J PATHOL, V171, P53, DOI 10.2353/ajpath.2007.061237
   Saint-Geniez M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003554
   Samsel PA, 2011, INVEST OPHTH VIS SCI, V52, P1671, DOI 10.1167/iovs.09-3921
   Sappington RM, 2006, INVEST OPHTH VIS SCI, V47, P2932, DOI 10.1167/iovs.05-1407
   Soker S, 1998, CELL, V92, P735, DOI 10.1016/S0092-8674(00)81402-6
   SOMMER A, 1991, ARCH OPHTHALMOL-CHIC, V109, P1090, DOI 10.1001/archopht.1991.01080080050026
   Sondell M, 1999, J NEUROSCI, V19, P5731, DOI 10.1523/JNEUROSCI.19-14-05731.1999
   Sun YJ, 2003, J CLIN INVEST, V111, P1843, DOI 10.1172/JCI200317977
   Tezel G, 2004, INVEST OPHTH VIS SCI, V45, P4049, DOI 10.1167/iovs.04-0490
   Tolosa L, 2008, J NEUROCHEM, V105, P1080, DOI 10.1111/j.1471-4159.2007.05206.x
   Ullian EM, 2004, MOL CELL NEUROSCI, V26, P544, DOI 10.1016/j.mcn.2004.05.002
   Wang XK, 2009, BMC NEUROSCI, V10, DOI 10.1186/1471-2202-10-12
   Wang X, 2010, NEUROSCI LETT, V468, P110, DOI 10.1016/j.neulet.2009.10.077
   Wax MB, 1998, ARCH OPHTHALMOL-CHIC, V116, P993, DOI 10.1001/archopht.116.8.993
   Wise LM, 2003, J BIOL CHEM, V278, P38004, DOI 10.1074/jbc.M301194200
   Wittstrom E, 2012, EUR J OPHTHALMOL, V22, P563, DOI 10.5301/ejo.5000089
   Wright AF, 2004, NAT GENET, V36, P1153, DOI 10.1038/ng1448
NR 55
TC 121
Z9 124
U1 0
U2 12
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9440
EI 1525-2191
J9 AM J PATHOL
JI Am. J. Pathol.
PD APR
PY 2013
VL 182
IS 4
BP 1379
EP 1390
DI 10.1016/j.ajpath.2012.12.032
PG 12
WC Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pathology
GA 165NY
UT WOS:000320491800036
PM 23416159
OA Green Accepted, Green Published, hybrid
DA 2022-11-30
ER

PT J
AU Blenkinsop, TA
   Corneo, B
   Temple, S
   Stern, JH
AF Blenkinsop, Timothy A.
   Corneo, Barbara
   Temple, Sally
   Stern, Jeffrey H.
TI Ophthalmologic stem cell transplantation therapies
SO REGENERATIVE MEDICINE
LA English
DT Article
DE bone marrow stem cell; eye disease; human embryonic stem cell; human
   neural stem cell; induced pluripotent stem cell; limbal stem cell;
   retinal pigment epithelial stem cell; umbilical cord stem cell
ID RETINAL-PIGMENT EPITHELIUM; MACULAR DEGENERATION; VISUAL FUNCTION;
   SUBRETINAL SPACE; RODENT MODEL; RPE; DISEASE; MOUSE; DIFFERENTIATION;
   RESCUE
AB Vision loss is a major social issue, with more than 20 million people over the age of 18 years affected in the USA alone. Loss of vision is feared more than premature death or cardiovascular disease, according to a recent Society for Consumer Research group survey. The annual direct cost of medical care for the most prevalent eye disease, age-related macular degeneration, was estimated at US$255 billion in 2010 with an additional economic impact of US$88 billion due to lost productivity and the burden of family and community care for visual disability. With the blossoming of human stem cell research, regenerative treatments are now being developed that can help reduce this burden. Positive results from animal studies demonstrate that stem cell-based transplants can preserve and potentially improve vision. This has led to new clinical trials for several eye diseases that are yielding encouraging results. In the next few years, additional trials and longer-term results are anticipated to further develop ocular regenerative therapies, with the potential to revolutionize our approach to ophthalmic disease and damage.
C1 [Blenkinsop, Timothy A.; Corneo, Barbara; Temple, Sally; Stern, Jeffrey H.] Regenerat Res Fdn, Neural Stem Cell Inst, Rensselaer, NY 12144 USA.
RP Stern, JH (通讯作者)，Regenerat Res Fdn, Neural Stem Cell Inst, 1 Discovery Dr, Rensselaer, NY 12144 USA.
EM jeffstern@nynsci.org
OI Corneo, Barbara/0000-0001-5189-6749
FU NATIONAL EYE INSTITUTE [R01EY022079] Funding Source: NIH RePORTER; NEI
   NIH HHS [R01 EY022079] Funding Source: Medline
CR Aboody K, 2011, NEURON, V70, P597, DOI 10.1016/j.neuron.2011.05.007
   Arnhold S, 2007, GRAEF ARCH CLIN EXP, V245, P414, DOI 10.1007/s00417-006-0382-7
   Arnhold S, 2004, INVEST OPHTH VIS SCI, V45, P4251, DOI 10.1167/iovs.03-1108
   Bharti K, 2011, PIGM CELL MELANOMA R, V24, P21, DOI 10.1111/j.1755-148X.2010.00772.x
   Binder S, 2007, PROG RETIN EYE RES, V26, P516, DOI 10.1016/j.preteyeres.2007.02.002
   Bonilha VL, 2006, ADV EXP MED BIOL, V572, P519
   Braunstein R, 2012, WORLD OPHTH C
   Carr AJ, 2009, MOL VIS, V15, P283
   Castellarin AA, 1998, RETINA-J RET VIT DIS, V18, P143, DOI 10.1097/00006982-199818020-00008
   Chaudhry GR, 2009, STEM CELLS DEV, V18, P247, DOI 10.1089/scd.2008.0057
   Corneo B, 2009, CELL STEM CELL, V5, P347, DOI 10.1016/j.stem.2009.09.011
   da Cruz L, 2007, PROG RETIN EYE RES, V26, P598, DOI 10.1016/j.preteyeres.2007.07.001
   Del Priore LV, 2006, PROG RETIN EYE RES, V25, P539, DOI 10.1016/j.preteyeres.2006.08.001
   Eiraku M, 2011, NATURE, V472, P51, DOI 10.1038/nature09941
   Friedlander Martin, 2007, Angiogenesis, V10, P89, DOI 10.1007/s10456-007-9070-4
   Hirami Y, 2009, NEUROSCI LETT, V458, P126, DOI 10.1016/j.neulet.2009.04.035
   Hynes SR, 2010, GRAEF ARCH CLIN EXP, V248, P763, DOI 10.1007/s00417-009-1263-7
   Idelson M, 2009, CELL STEM CELL, V5, P396, DOI 10.1016/j.stem.2009.07.002
   Jin ZB, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017084
   Klein R, 2011, ARCH OPHTHALMOL-CHIC, V129, P75, DOI 10.1001/archophthalmol.2010.318
   Klimanskaya I, 2004, CLONING STEM CELLS, V6, P217, DOI 10.1089/1536230042323420
   Kwan ASL, 1999, EXP NEUROL, V159, P21, DOI 10.1006/exnr.1999.7157
   Lamba DA, 2011, INVEST OPHTH VIS SCI, V52, P4897, DOI 10.1167/iovs.10-6504
   Lamba DA, 2009, CELL STEM CELL, V4, P73, DOI 10.1016/j.stem.2008.10.015
   Li Yongping, 2002, Yan Ke Xue Bao, V18, P37
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Lu B, 2009, STEM CELLS, V27, P2126, DOI 10.1002/stem.149
   Lund RD, 2007, STEM CELLS, V25, P602, DOI 10.1634/stemcells.2006-0308
   Lund RD, 2006, CLONING STEM CELLS, V8, P189, DOI 10.1089/clo.2006.8.189
   McGill TJ, 2012, EUR J NEUROSCI, V35, P468, DOI 10.1111/j.1460-9568.2011.07970.x
   McUsic AC, 2012, BIOMATERIALS, V33, P1396, DOI 10.1016/j.biomaterials.2011.10.083
   Meyer JS, 2011, STEM CELLS, V29, P1206, DOI 10.1002/stem.674
   MohandSaid S, 1997, OPHTHALMIC RES, V29, P290, DOI 10.1159/000268027
   MOORE AT, 1992, J MED GENET, V29, P289, DOI 10.1136/jmg.29.5.289
   Mostoslavsky G, 2012, STEM CELLS, V30, P28, DOI 10.1002/stem.742
   Nakano T, 2012, CELL STEM CELL, V10, P771, DOI 10.1016/j.stem.2012.05.009
   O'Callaghan AR, 2011, STEM CELLS, V29, P1923, DOI 10.1002/stem.756
   Osakada F, 2008, NAT BIOTECHNOL, V26, P215, DOI 10.1038/nbt1384
   Osakada F, 2009, J CELL SCI, V122, P3169, DOI 10.1242/jcs.050393
   Otani A, 2004, J CLIN INVEST, V114, P765, DOI 10.1172/JCI200421686
   Pellegrini G, 1997, LANCET, V349, P990, DOI 10.1016/S0140-6736(96)11188-0
   Phillips JB, 2011, DIS MODEL MECH, V4, P786, DOI 10.1242/dmm.006429
   Rama P, 2001, TRANSPLANTATION, V72, P1478, DOI 10.1097/00007890-200111150-00002
   Rama P, 2010, NEW ENGL J MED, V363, P147, DOI 10.1056/NEJMoa0905955
   Robinton DA, 2012, NATURE, V481, P295, DOI 10.1038/nature10761
   Rowland TJ, 2012, J CELL PHYSIOL, V227, P457, DOI 10.1002/jcp.22814
   Salero E, 2012, CELL STEM CELL, V10, P88, DOI 10.1016/j.stem.2011.11.018
   Schwartz SD, 2012, LANCET, V379, P713, DOI 10.1016/S0140-6736(12)60028-2
   SIMELL O, 1973, LANCET, V1, P1031
   Siqueira RC, 2011, RETINA-J RET VIT DIS, V31, P1207, DOI 10.1097/IAE.0b013e3181f9c242
   Sodha S, 2011, J BIOMAT SCI-POLYM E, V22, P443, DOI 10.1163/092050610X487738
   Sparrrow JR, 2010, CURR MOL MED, V10, P802
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Takahashi K, 2007, CELL, V131, P861, DOI 10.1016/j.cell.2007.11.019
   Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024
   Taylor AW, 2010, OCUL IMMUNOL INFLAMM, V18, P488, DOI 10.3109/09273948.2010.525730
   Tezel TH, 2007, AM J OPHTHALMOL, V143, P584, DOI 10.1016/j.ajo.2006.12.007
   Thieltges F, 2011, OPHTHALMIC RES, V46, P133, DOI 10.1159/000324045
   US FDA Cellular Tissue and Gene Therapies Advisory Committee, 2011, CTGTAC M
   van der Bogt KEA, 2006, CELL CYCLE, V5, P2748, DOI 10.4161/cc.5.23.3533
   Vugler A, 2008, EXP NEUROL, V214, P347, DOI 10.1016/j.expneurol.2008.09.007
   West EL, 2010, STEM CELLS, V28, P1997, DOI 10.1002/stem.520
   Wylegala E, 2008, EUR J OPHTHALMOL, V18, P886, DOI 10.1177/112067210801800605
   Yue FM, 2010, BIOCHEM BIOPH RES CO, V394, P877, DOI 10.1016/j.bbrc.2010.03.008
NR 64
TC 30
Z9 31
U1 0
U2 17
PU FUTURE MEDICINE LTD
PI LONDON
PA UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3
   1QB, ENGLAND
SN 1746-0751
EI 1746-076X
J9 REGEN MED
JI Regen. Med.
PY 2012
VL 7
IS 6
SU S
BP 32
EP 39
DI 10.2217/RME.12.77
PG 8
WC Cell & Tissue Engineering; Engineering, Biomedical
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Engineering
GA 058ED
UT WOS:000312616000009
PM 23210809
OA Green Accepted, Bronze
DA 2022-11-30
ER

PT J
AU Kaluzny, JJ
   Wojtkowski, M
   Sikorski, BL
   Szkulmowski, M
   Szkulmowska, A
   Bajraszewski, T
   Fujimoto, JG
   Duker, JS
   Schuman, JS
   Kowalczyk, A
AF Kaluzny, Jakub J.
   Wojtkowski, Maciej
   Sikorski, Bartosz L.
   Szkulmowski, Maciei
   Szkulmowska, Anna
   Bajraszewski, Tomasz
   Fujimoto, James G.
   Duker, Jay S.
   Schuman, Joel S.
   Kowalczyk, Andrzej
TI Analysis of the Outer Retina Reconstructed by High-Resolution,
   Three-Dimensional Spectral Domain Optical Coherence Tomography
SO OPHTHALMIC SURGERY LASERS & IMAGING
LA English
DT Article
ID ULTRAHIGH-RESOLUTION
AB BACKGROUND AND OBJECTIVE: A retrospective cross-sectional study was conducted to demonstrate an analysis of an outer retinal layer reconstructed by the three-dimensional and high-speed spectral domain optical coherence tomography (SD-OCT) instrument.
   PATIENTS AND METHODS: New measurement protocols for SD-OCT and methods of analysis and visualization of the individual segmented retinal layer reconstructed by SD-OCT were proposed. Three contour maps representing mutual distances between the basal part of the retinal pigment epithelium, the junction between the inner and outer segments of photoreceptors, and a reference contour representing the shape of a healthy retina were introduced.
   RESULTS: The analysis of the outer retina was performed on pathological eyes. Three cases of central serous chorioretinopathy, age-related macular degeneration, and acute zonal occult outer retinoparhy are demonstrated.
   CONCLUSION: Three contour maps reconstructed for clinical cases demonstrate high variability of observed patterns depending on analyzed pathology. The authors believe this can help to present OCT data stmultaneously in a more comprehensive and convenient way to assist in everyday clinical diagnosis. [Ophthalmic Surg Lasers Imaging 2009;40:102-108.]
C1 [Wojtkowski, Maciej; Szkulmowski, Maciei; Szkulmowska, Anna; Bajraszewski, Tomasz; Kowalczyk, Andrzej] Nicholas Copernicus Univ, Inst Phys, PL-87100 Torun, Poland.
   [Kaluzny, Jakub J.; Sikorski, Bartosz L.] Nicholas Copernicus Univ, Dept Ophthalmol, Coll Med, Bydgoszcz, Poland.
   [Fujimoto, James G.] MIT, Dept Elect Engn & Comp Sci, Cambridge, MA USA.
   [Fujimoto, James G.] MIT, Elect Res Lab, Cambridge, MA USA.
   [Duker, Jay S.] Tufts Univ, New England Eye Ctr, Tufts New England Med Ctr, Boston, MA 02111 USA.
   [Schuman, Joel S.] Univ Pittsburgh, Sch Med, Dept Ophthalmol, UPMC Eye Ctr, Pittsburgh, PA 15261 USA.
C3 Nicolaus Copernicus University; Nicolaus Copernicus University; Ludwik
   Rydygier Collegium Medicum; Massachusetts Institute of Technology (MIT);
   Massachusetts Institute of Technology (MIT); Tufts Medical Center; Tufts
   University; Pennsylvania Commonwealth System of Higher Education
   (PCSHE); University of Pittsburgh
RP Wojtkowski, M (通讯作者)，Nicholas Copernicus Univ, Inst Phys, Ul Grudziadzka 5, PL-87100 Torun, Poland.
RI Sikorski, Bartosz L/AHD-2057-2022; Szkulmowski, Maciej/D-6244-2014;
   Wojtkowski, Maciej/D-6822-2014; Schuman, Joel S/K-7304-2012; Maciej,
   Szkulmowski/B-7923-2009; Kowalczyk, Andrzej A/B-5741-2013; Schuman, Joel
   S/M-2389-2019
OI Sikorski, Bartosz L/0000-0001-5357-9560; Szkulmowski,
   Maciej/0000-0002-2006-0524; Schuman, Joel S/0000-0002-8885-3766;
   Kowalczyk, Andrzej A/0000-0002-0843-7587; Schuman, Joel
   S/0000-0002-8885-3766; Wojtkowski, Maciej/0000-0003-0599-0878;
   Szkulmowska, Anna/0000-0002-2939-0829; Kaluzny,
   Jakub/0000-0003-1908-2141
FU Polish Ministry of Science; Foundation for Polish Science (Homing 34
   project); Rector of NCU [504-F]; NATIONAL EYE INSTITUTE [R01EY011289,
   R01EY013178] Funding Source: NIH RePORTER
FX Supported by Polish Ministry of Science, grants for years 2006 to 2009.
   Dr Wojtkowski receives additional Support of Foundation for Polish
   Science (Homing 34 project) and Rector of NCU for the scientific grant
   504-F.
CR ANSI,, 2000, AM NAT STAND CENTR P
   Jiao SL, 2005, OPT EXPRESS, V13, P444, DOI 10.1364/OPEX.13.000444
   Ko TH, 2004, OPT EXPRESS, V12, P2112, DOI 10.1364/OPEX.12.002112
   Ko TH, 2004, OPHTHALMOLOGY, V111, P2033, DOI 10.1016/j.ophtha.2004.05.021
   POLSKIE N, 1992, PN91T06700
   Srinivasan VJ, 2006, OPHTHALMOLOGY, V113, P2054, DOI 10.1016/j.ophtha.2006.05.046
   Szkulmowski M, 2007, J BIOMED OPT, V12, DOI 10.1117/1.2771569
   Wojtkowski M, 2005, OPHTHALMOLOGY, V112, P1734, DOI 10.1016/j.ophtha.2005.05.023
NR 8
TC 11
Z9 11
U1 0
U2 7
PU SLACK INC
PI THOROFARE
PA 6900 GROVE RD, THOROFARE, NJ 08086 USA
SN 1542-8877
EI 1938-2375
J9 OPHTHAL SURG LAS IM
JI Ophthalmic Surg. Lasers Imaging
PD MAR-APR
PY 2009
VL 40
IS 2
BP 102
EP 108
DI 10.3928/15428877-20090301-10
PG 7
WC Ophthalmology; Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Surgery
GA 418SU
UT WOS:000264170000003
PM 19320297
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Pechan, P
   Rubin, H
   Lukason, M
   Ardinger, J
   DuFresne, E
   Hauswirth, WW
   Wadsworth, SC
   Scaria, A
AF Pechan, P.
   Rubin, H.
   Lukason, M.
   Ardinger, J.
   DuFresne, E.
   Hauswirth, W. W.
   Wadsworth, S. C.
   Scaria, A.
TI Novel anti-VEGF chimeric molecules delivered by AAV vectors for
   inhibition of retinal neovascularization
SO GENE THERAPY
LA English
DT Article
DE VEGF; VEGFR1; Flt-1; Fc fragment; retinal neovascularization;
   adeno-associated virus 2
ID ENDOTHELIAL GROWTH-FACTOR; ADENOASSOCIATED VIRAL VECTOR;
   IMMUNOGLOBULIN-LIKE DOMAIN; FACTOR RECEPTOR FLT-1; TYROSINE KINASE;
   GENE-TRANSFER; OCULAR NEOVASCULARIZATION; MACULAR DEGENERATION;
   THERAPEUTIC LEVELS; LIGAND-BINDING
AB Vascular endothelial growth factor (VEGF) is important in pathological neovascularization, which is a key component of diseases such as the wet form of age-related macular degeneration, proliferative diabetic retinopathy and cancer. One of the most potent naturally occurring VEGF binders is VEGF receptor Flt-1. We have generated two novel chimeric VEGF-binding molecules, sFLT01 and sFLT02, which consist of the second immunoglobulin (IgG)-like domain of Flt-1 fused either to a human IgG1 Fc or solely to the CH3 domain of IgG1 Fc through a polyglycine linker 9Gly. In vitro analysis showed that these novel molecules are high-affinity VEGF binders. We have demonstrated that adeno-associated virus serotype 2 (AAV2)-mediated intravitreal gene delivery of sFLT01 efficiently inhibits angiogenesis in the mouse oxygen-induced retinopathy model. There were no histological observations of toxicity upon persistent ocular expression of sFLT01 for up to 12 months following intravitreal AAV2-based delivery in the rodent eye. Our data suggest that AAV2-mediated intravitreal gene delivery of our novel molecules may be a safe and effective treatment for retinal neovascularization.
C1 [Pechan, P.; Rubin, H.; Lukason, M.; Ardinger, J.; DuFresne, E.; Wadsworth, S. C.; Scaria, A.] Genzyme Corp, Dept Mol Biol, Framingham, MA 01701 USA.
   [Hauswirth, W. W.] Univ Florida, Dept Ophthalmol, Gainesville, FL USA.
C3 Sanofi-Aventis; Genzyme Corporation; State University System of Florida;
   University of Florida
RP Scaria, A (通讯作者)，Genzyme Corp, Dept Mol Biol, 49 New York Ave,Room 4615, Framingham, MA 01701 USA.
EM abraham.scaria@genzyme.com
OI Pechan, Peter/0000-0001-9663-8743; hauswirth,
   william/0000-0002-3244-4947
CR ADAMIS AP, 1994, AM J OPHTHALMOL, V118, P445, DOI 10.1016/S0002-9394(14)75794-0
   AIELLO LP, 1995, P NATL ACAD SCI USA, V92, P10457, DOI 10.1073/pnas.92.23.10457
   Ali RR, 1997, BRIT J OPHTHALMOL, V81, P795, DOI 10.1136/bjo.81.9.795
   Ali RR, 1998, HUM GENE THER, V9, P81, DOI 10.1089/hum.1998.9.1-81
   Ali RR, 1996, HUM MOL GENET, V5, P591, DOI 10.1093/hmg/5.5.591
   Bainbridge JWB, 2002, GENE THER, V9, P320, DOI 10.1038/sj.gt.3301680
   Barleon B, 1997, J BIOL CHEM, V272, P10382
   Bennett J, 2006, HUM GENE THER, V17, P177, DOI 10.1089/hum.2006.17.177
   Cunningham SA, 1997, BIOCHEM BIOPH RES CO, V231, P596, DOI 10.1006/bbrc.1997.6156
   Davis-Smyth T, 1998, J BIOL CHEM, V273, P3216, DOI 10.1074/jbc.273.6.3216
   DavisSmyth T, 1996, EMBO J, V15, P4919, DOI 10.1002/j.1460-2075.1996.tb00872.x
   DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256
   Ferrara N, 2004, ENDOCR REV, V25, P581, DOI 10.1210/er.2003-0027
   FERRARA N, 1989, BIOCHEM BIOPH RES CO, V161, P851, DOI 10.1016/0006-291X(89)92678-8
   Gehlbach P, 2003, HUM GENE THER, V14, P129, DOI 10.1089/104303403321070829
   Holash J, 2002, P NATL ACAD SCI USA, V99, P11393, DOI 10.1073/pnas.172398299
   HUSTON JS, 1988, P NATL ACAD SCI USA, V85, P5879, DOI 10.1073/pnas.85.16.5879
   Jacobson SG, 2006, MOL THER, V13, P1074, DOI 10.1016/j.ymthe.2006.03.005
   KENDALL RL, 1993, P NATL ACAD SCI USA, V90, P10705, DOI 10.1073/pnas.90.22.10705
   Kvanta A, 1996, INVEST OPHTH VIS SCI, V37, P1929
   Lai CM, 2005, MOL THER, V12, P659, DOI 10.1016/j.ymthe.2005.04.022
   Lai YKY, 2002, GENE THER, V9, P804, DOI 10.1038/sj.gt.3301695
   QUINN TP, 1993, P NATL ACAD SCI USA, V90, P7533, DOI 10.1073/pnas.90.16.7533
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   SHIBUYA M, 1990, ONCOGENE, V5, P519
   SMITH LEH, 1994, INVEST OPHTH VIS SCI, V35, P101
   TERMAN BI, 1992, BIOCHEM BIOPH RES CO, V187, P1579, DOI 10.1016/0006-291X(92)90483-2
   Vincent KA, 1997, J VIROL, V71, P1897, DOI 10.1128/JVI.71.3.1897-1905.1997
   Wiesmann C, 1997, CELL, V91, P695, DOI 10.1016/S0092-8674(00)80456-0
   Willett CG, 2004, NAT MED, V10, P145, DOI 10.1038/nm988
   Xu LF, 2001, HUM GENE THER, V12, P563, DOI 10.1089/104303401300042500
   Ziegler RJ, 2004, MOL THER, V9, P231, DOI 10.1016/j.ymthe.2003.11.015
   Zolotukhin S, 2002, METHODS, V28, P158, DOI 10.1016/S1046-2023(02)00220-7
NR 33
TC 80
Z9 132
U1 0
U2 10
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0969-7128
EI 1476-5462
J9 GENE THER
JI Gene Ther.
PD JAN
PY 2009
VL 16
IS 1
BP 10
EP 16
DI 10.1038/gt.2008.115
PG 7
WC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Genetics & Heredity; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Genetics & Heredity; Research & Experimental Medicine
GA 392HN
UT WOS:000262293900003
PM 18633446
DA 2022-11-30
ER

PT J
AU Ito, YN
   Ito, M
   Takita, H
   Yoneya, S
   Peyman, GA
   Gehlbach, PL
   Mori, K
AF Ito, Yoko N.
   Ito, Mitsuteru
   Takita, Hiroyasu
   Yoneya, Shin
   Peyman, Gholam A.
   Gehlbach, Peter L.
   Mori, Keisuke
TI Transpupillary thermotherapy-induced modification of angiogenesis- and
   coagulation-related gene expression in the rat posterior fundus
SO MOLECULAR VISION
LA English
DT Article
ID PROTEIN-C RECEPTOR; HEAT-SHOCK; RETINAL NEOVASCULARIZATION; PLUS
   HYPERTHERMIA; RANDOMIZED-TRIAL; CELL-ADHESION; IN-VIVO; TUMOR;
   INDUCTION; GROWTH
AB PURPOSE: To study gene expression changes in the rat retina and choroid following transpupillary thermotherapy (TTT) and to identify molecular mechanisms that may enhance treatment of choroidal neovascularization, complicating age-related macular degeneration.
   METHODS: One fundus of Brown Norway rats was treated with an 810 nm diode laser while the contralateral fundus received no treatment. The mRNA was extracted and processed for cDNA microarray analysis. Genes with increased expression were validated by semiquantitative reverse transcription polymerase chain reaction (PCR) and quantitative real-time PCR (qRT-PCR).
   RESULTS: Of the 14,815 cDNA elements on the array, 12 genes were up-regulated in TTT treated eyes. Upregulation of eight of these 12 genes could be verified by semiquantitative RT-PCR. The eight verified genes were EPCR, IL-1 beta, MCP-1, TSP-1, Fgl, Asns, MT-2, and NMDMC, which included 4 angiogenesis- and coagulation-related genes.
   CONCLUSIONS: This study demonstrates upregulation of angiogenesis- and coagulation-related genes following TTT. The response profile and its temporal relationships provide insight into the molecular mechanisms that lead to vascular occlusion and antiangiogenesis induced by TTT.
C1 Saitama Med Univ, Dept Ophthalmol, Iruma, Saitama 3500495, Japan.
   Tulane Univ, Med Ctr, Dept Ophthalmol, New Orleans, LA 70118 USA.
   Johns Hopkins Univ, Sch Med, Dept Ophthalmol, Baltimore, MD 21205 USA.
C3 Saitama Medical University; Tulane University; Johns Hopkins University
RP Mori, K (通讯作者)，Saitama Med Univ, Dept Ophthalmol, 38 Morohongo, Iruma, Saitama 3500495, Japan.
EM keisuke@saitama-med.ac.jp
RI Murad, Masoud K/E-7715-2011
CR BAGAVANDOSS P, 1990, BIOCHEM BIOPH RES CO, V170, P867, DOI 10.1016/0006-291X(90)92171-U
   BECKMANN RP, 1990, SCIENCE, V248, P850, DOI 10.1126/science.2188360
   BROWN SL, 1992, INT J HYPERTHER, V8, P501, DOI 10.3109/02656739209037988
   Davidson AJ, 2003, NATURE, V425, P300, DOI 10.1038/nature01973
   Desmettre T, 2001, INVEST OPHTH VIS SCI, V42, P2976
   Dinarello CA, 1996, BLOOD, V87, P2095, DOI 10.1182/blood.V87.6.2095.bloodjournal8762095
   EICHEL E, 2005, ARVO ANN M MAY 1 5 F
   Esmon CT, 2003, CHEST, V124, p26S, DOI 10.1378/chest.124.3_suppl.26S
   FAJARDO LF, 1994, INT J HYPERTHER, V10, P347, DOI 10.3109/02656739409010278
   FUKUDOME K, 1994, J BIOL CHEM, V269, P26486
   Goede V, 1999, INT J CANCER, V82, P765, DOI 10.1002/(SICI)1097-0215(19990827)82:5<765::AID-IJC23>3.0.CO;2-F
   GOOD DJ, 1990, P NATL ACAD SCI USA, V87, P6624, DOI 10.1073/pnas.87.17.6624
   Hackam AS, 2004, MOL VIS, V10, P637
   Higgins GT, 2003, INVEST OPHTH VIS SCI, V44, P1775, DOI 10.1167/iovs.02-0742
   Hildebrandt B, 2002, CRIT REV ONCOL HEMAT, V43, P33, DOI 10.1016/S1040-8428(01)00179-2
   Hong KH, 2005, BLOOD, V105, P1405, DOI 10.1182/blood-2004-08-3178
   Ito Y, 2005, RETINA-J RET VIT DIS, V25, P1046, DOI 10.1097/00006982-200512000-00014
   Jimenez B, 2000, NAT MED, V6, P41, DOI 10.1038/71517
   JourneedeKorver JG, 1997, BRIT J OPHTHALMOL, V81, P234, DOI 10.1136/bjo.81.3.234
   Kurosawa S, 1997, J CLIN INVEST, V100, P411, DOI 10.1172/JCI119548
   Lanzetta P, 2002, OPHTHALMOLOGY, V109, P1098, DOI 10.1016/S0161-6420(02)01034-5
   Lawler J, 2002, J CELL MOL MED, V6, P1, DOI 10.1111/j.1582-4934.2002.tb00307.x
   LEUNG LLK, 1984, J CLIN INVEST, V74, P1764, DOI 10.1172/JCI111595
   Liaw PCY, 2000, J BIOL CHEM, V275, P5447, DOI 10.1074/jbc.275.8.5447
   Liaw PCY, 2001, J BIOL CHEM, V276, P8364, DOI 10.1074/jbc.M010572200
   Mainster MA, 2000, OPHTHALMIC SURG LAS, V31, P359
   Miyajima-Uchida H, 2000, INVEST OPHTH VIS SCI, V41, P561
   Newsom RSB, 2001, BRIT J OPHTHALMOL, V85, P505
   Ohta M, 2002, INT J CANCER, V102, P220, DOI 10.1002/ijc.10705
   OOSTERHUIS JA, 1995, ARCH OPHTHALMOL-CHIC, V113, P315, DOI 10.1001/archopht.1995.01100030071024
   Peyman GA, 2003, RETINA-J RET VIT DIS, V23, P378, DOI 10.1097/00006982-200306000-00015
   POLLA BS, 1995, INFLAMMATION, V19, P363, DOI 10.1007/BF01534393
   Reichel E, 1999, OPHTHALMOLOGY, V106, P1908, DOI 10.1016/S0161-6420(99)90400-1
   REINHOLD H S, 1986, International Journal of Hyperthermia, V2, P111, DOI 10.3109/02656738609012389
   Roca C, 2003, CANCER RES, V63, P2345
   Saijo Y, 2002, J IMMUNOL, V169, P469, DOI 10.4049/jimmunol.169.1.469
   Saji H, 2001, CANCER, V92, P1085, DOI 10.1002/1097-0142(20010901)92:5<1085::AID-CNCR1424>3.0.CO;2-K
   Saposnik B, 2004, BLOOD, V103, P1311, DOI 10.1182/blood-2003-07-2520
   Sawaji Y, 2002, BRIT J CANCER, V86, P1597, DOI 10.1038/sj.bjc.6600268
   Shields CL, 1998, OPHTHALMOLOGY, V105, P581, DOI 10.1016/S0161-6420(98)94008-8
   Shields CL, 1996, OPHTHALMOLOGY, V103, P1642, DOI 10.1016/S0161-6420(96)30451-X
   Sneed PK, 1998, INT J RADIAT ONCOL, V40, P287, DOI 10.1016/S0360-3016(97)00731-1
   SONG CW, 1980, JNCI-J NATL CANCER I, V64, P119
   TARABOLETTI G, 1990, J CELL BIOL, V111, P765, DOI 10.1083/jcb.111.2.765
   TISSIERES A, 1974, J MOL BIOL, V84, P389, DOI 10.1016/0022-2836(74)90447-1
   VALDAGNI R, 1994, INT J RADIAT ONCOL, V28, P163, DOI 10.1016/0360-3016(94)90154-6
   van der Zee J, 2000, LANCET, V355, P1119, DOI 10.1016/S0140-6736(00)02059-6
   Vernon CC, 1996, INT J RADIAT ONCOL, V35, P731
   Vidal-Vanaclocha F, 2000, P NATL ACAD SCI USA, V97, P734, DOI 10.1073/pnas.97.2.734
   VIDALVANACLOCHA F, 1994, CANCER RES, V54, P2667
   Voronov E, 2003, P NATL ACAD SCI USA, V100, P2645, DOI 10.1073/pnas.0437939100
   Yoshida S, 2004, GRAEF ARCH CLIN EXP, V242, P409, DOI 10.1007/s00417-004-0874-2
   Yoshida S, 2003, J LEUKOCYTE BIOL, V73, P137, DOI 10.1189/jlb.0302117
NR 53
TC 2
Z9 2
U1 0
U2 2
PU MOLECULAR VISION
PI ATLANTA
PA C/O JEFF BOATRIGHT, LAB B, 5500 EMORY EYE CENTER, 1327 CLIFTON RD, N E,
   ATLANTA, GA 30322 USA
SN 1090-0535
J9 MOL VIS
JI Mol. Vis.
PD JUL 20
PY 2006
VL 12
IS 88-90
BP 802
EP 810
PG 9
WC Biochemistry & Molecular Biology; Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Ophthalmology
GA 069QU
UT WOS:000239464100003
PM 16885923
DA 2022-11-30
ER

PT J
AU Michaelides, M
   Hunt, DM
   Moore, AT
AF Michaelides, M
   Hunt, DM
   Moore, AT
TI The genetics of inherited macular dystrophies
SO JOURNAL OF MEDICAL GENETICS
LA English
DT Review
ID SORSBYS-FUNDUS-DYSTROPHY; X-LINKED RETINOSCHISIS; AREOLAR CHOROIDAL
   DYSTROPHY; AGE-RELATED MACULOPATHY; RECESSIVE RETINITIS-PIGMENTOSA;
   BIFOCAL CHORIORETINAL ATROPHY; HUMAN RETINAL DEGENERATION;
   AUTOSOMAL-DOMINANT DRUSEN; LIGHT-INDUCED DAMAGE; CONE-ROD DYSTROPHY
AB The inherited macular dystrophies comprise a heterogeneous group of disorders characterised by central visual loss and atrophy of the macula and underlying retinal pigment epithelium (RPE). The different forms of macular degeneration encompass a wide range of clinical, psychophysical and histological findings. The complexity of the molecular basis of monogenic macular disease is now beginning to be elucidated with the identification of many of the disease-causing genes. Age related macular degeneration (ARMD), the leading cause of blind registration in the developed world, may also have a significant genetic component to its aetiology. Genes implicated in monogenic macular dystrophies are good candidate susceptibility genes for ARMD, although to date, with the possible exception of ABCA4, none of these genes have been shown to confer increased risk of ARMD. The aim of this paper is to review current knowledge relating to the monogenic macular dystrophies, with discussion of currently mapped genes, chromosomal loci and genotype-phenotype relationships. Inherited systemic disorders with a macular dystrophy component will not be discussed.
C1 UCL, Inst Ophthalmol, London EC1V 9EL, England.
C3 University of London; University College London
RP Moore, AT (通讯作者)，UCL, Inst Ophthalmol, 11-43 Bath St, London EC1V 9EL, England.
EM tony.moore@ucl.ac.uk
RI Hunt, David M/K-6024-2012
OI Hunt, David M/0000-0002-9264-3948
CR Ali RR, 2000, NAT GENET, V25, P306, DOI 10.1038/77068
   Allikmets R, 1997, NAT GENET, V15, P236, DOI 10.1038/ng0397-236
   Allikmets R, 1997, SCIENCE, V277, P1805, DOI 10.1126/science.277.5333.1805
   Bernstein PS, 2001, INVEST OPHTH VIS SCI, V42, P3331
   BIRD A, 1994, RETINA, V2, P1019
   BIRNBACH CD, 1994, OPHTHALMOLOGY, V101, P1211
   BRECHER R, 1990, EYE, V4, P210, DOI 10.1038/eye.1990.28
   Caldwell GM, 1999, GENOMICS, V58, P98, DOI 10.1006/geno.1999.5808
   CAPON MRC, 1989, OPHTHALMOLOGY, V96, P1769
   Chong NHV, 2000, INVEST OPHTH VIS SCI, V41, P898
   Cremers FPM, 1998, HUM MOL GENET, V7, P355, DOI 10.1093/hmg/7.3.355
   De La Paz MA, 1999, OPHTHALMOLOGY, V106, P1531, DOI 10.1016/S0161-6420(99)90449-9
   den Dunnen JT, 1998, HUM MOL GENET, V7, P1185
   DEUTMAN AF, 1969, ARCH OPHTHALMOL-CHIC, V81, P305, DOI 10.1001/archopht.1969.00990010307001
   DEUTMAN AF, 1976, AM J OPHTHALMOL, V82, P540, DOI 10.1016/0002-9394(76)90540-7
   Donoso LA, 2001, SURV OPHTHALMOL, V46, P149, DOI 10.1016/S0039-6257(01)00251-X
   DOREY CK, 1989, INVEST OPHTH VIS SCI, V30, P1691
   DOUGLAS AA, 1968, BRIT J OPHTHALMOL, V52, P742, DOI 10.1136/bjo.52.10.742
   Downes SM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1373, DOI 10.1001/archopht.117.10.1373
   EAGLE RC, 1980, OPHTHALMOLOGY, V87, P1189
   Eksandh LC, 2000, ARCH OPHTHALMOL-CHIC, V118, P1098, DOI 10.1001/archopht.118.8.1098
   FARRAR GJ, 1991, NATURE, V354, P478, DOI 10.1038/354478a0
   FELBOR U, 1995, HUM MOL GENET, V4, P2415, DOI 10.1093/hmg/4.12.2415
   Felbor U, 1997, HUM MUTAT, V10, P301, DOI 10.1002/(SICI)1098-1004(1997)10:4<301::AID-HUMU6>3.0.CO;2-J
   FISH G, 1981, BRIT J OPHTHALMOL, V65, P359, DOI 10.1136/bjo.65.5.359
   Fisher S K, 2001, Prog Brain Res, V131, P679
   FISHMAN GA, 1991, OPHTHALMOLOGY, V98, P957
   FISHMAN GA, 1987, OPHTHALMOLOGY, V94, P809, DOI 10.1016/s0161-6420(87)33533-x
   FORSMAN K, 1992, CLIN GENET, V42, P156
   Francis PJ, 2003, BRIT J OPHTHALMOL, V87, P893, DOI 10.1136/bjo.87.7.893
   FRANGIEH GT, 1982, ARCH OPHTHALMOL-CHIC, V100, P1115
   GEORGE NDL, 1995, BRIT J OPHTHALMOL, V79, P653, DOI 10.1136/bjo.79.7.653
   GEORGE NDL, 1995, BRIT J OPHTHALMOL, V79, P697, DOI 10.1136/bjo.79.7.697
   Gerth C, 2002, GRAEF ARCH CLIN EXP, V240, P628, DOI 10.1007/s00417-002-0502-y
   Godley BF, 1996, OPHTHALMOLOGY, V103, P893, DOI 10.1016/S0161-6420(96)30590-3
   GOTO Y, 1990, NATURE, V348, P651, DOI 10.1038/348651a0
   Grayson C, 2000, HUM MOL GENET, V9, P1873, DOI 10.1093/hmg/9.12.1873
   Griesinger IB, 2000, INVEST OPHTH VIS SCI, V41, P248
   Hamdi HK, 2002, BIOCHEM BIOPH RES CO, V295, P668, DOI 10.1016/S0006-291X(02)00728-3
   Hoyng CB, 1996, AM J OPHTHALMOL, V121, P623, DOI 10.1016/S0002-9394(14)70627-0
   Hoyng CB, 1996, GRAEF ARCH CLIN EXP, V234, P87, DOI 10.1007/BF00695246
   Hughes AE, 1998, J MED GENET, V35, P770, DOI 10.1136/jmg.35.9.770
   Jacobson SG, 2002, ARCH OPHTHALMOL-CHIC, V120, P376
   JACOBSON SG, 1995, NAT GENET, V11, P27, DOI 10.1038/ng0995-27
   KAJIWARA K, 1991, NATURE, V354, P480, DOI 10.1038/354480a0
   KAPLAN J, 1993, NAT GENET, V5, P308, DOI 10.1038/ng1193-308
   KELSELL RE, 1995, HUM MOL GENET, V4, P1653, DOI 10.1093/hmg/4.9.1653
   KEMP CM, 1994, INVEST OPHTH VIS SCI, V35, P3154
   Klaver CCW, 1998, AM J HUM GENET, V63, P200, DOI 10.1086/301901
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P1646, DOI 10.1001/archopht.116.12.1646
   Klein ML, 1998, ARCH OPHTHALMOL-CHIC, V116, P1082, DOI 10.1001/archopht.116.8.1082
   Kniazeva M, 2000, AM J OPHTHALMOL, V130, P197, DOI 10.1016/S0002-9394(00)00585-7
   Kniazeva M, 1999, AM J HUM GENET, V64, P1394, DOI 10.1086/302377
   KREMER H, 1994, HUM MOL GENET, V3, P299, DOI 10.1093/hmg/3.2.299
   Lois N, 2001, ARCH OPHTHALMOL-CHIC, V119, P359, DOI 10.1001/archopht.119.3.359
   Lois N, 1999, INVEST OPHTH VIS SCI, V40, P2668
   Lotery AJ, 2000, INVEST OPHTH VIS SCI, V41, P1291
   Lotery AJ, 1996, HUM MOL GENET, V5, P705, DOI 10.1093/hmg/5.5.705
   Majid MA, 2002, FEBS LETT, V529, P281, DOI 10.1016/S0014-5793(02)03359-8
   MANSCHOT WA, 1972, ARCH OPHTHALMOL-CHIC, V88, P131
   Marmorstein AD, 2000, P NATL ACAD SCI USA, V97, P12758, DOI 10.1073/pnas.220402097
   Marmorstein LHY, 2002, P NATL ACAD SCI USA, V99, P13067, DOI 10.1073/pnas.202491599
   Martinez-Mir A, 1998, NAT GENET, V18, P11, DOI 10.1038/ng0198-11
   MartinezMir A, 1997, GENOMICS, V40, P142, DOI 10.1006/geno.1996.4528
   MASSIN P, 1995, AM J OPHTHALMOL, V120, P247, DOI 10.1016/S0002-9394(14)72615-7
   Massin P, 1999, OPHTHALMOLOGY, V106, P1821, DOI 10.1016/S0161-6420(99)90356-1
   Mata NL, 2000, P NATL ACAD SCI USA, V97, P7154, DOI 10.1073/pnas.130110497
   Mata NL, 2001, INVEST OPHTH VIS SCI, V42, P1685
   Maugeri A, 2000, AM J HUM GENET, V67, P960, DOI 10.1086/303079
   Maugeri A, 1999, AM J HUM GENET, V64, P1024, DOI 10.1086/302323
   Maw MA, 2000, HUM MOL GENET, V9, P27, DOI 10.1093/hmg/9.1.27
   MEYERS SM, 1988, ARCH OPHTHALMOL-CHIC, V106, P651
   Michaelides M, 2003, INVEST OPHTH VIS SCI, V44, P1657, DOI 10.1167/iovs.02-0941
   Michaelides M, 2003, INVEST OPHTH VIS SCI, V44, P2178, DOI 10.1167/iovs.02-1094
   MOHLER CW, 1981, OPHTHALMOLOGY, V88, P688
   Molday LL, 2001, INVEST OPHTH VIS SCI, V42, P816
   Molday LL, 2000, NAT GENET, V25, P257, DOI 10.1038/77004
   NICHOLS BE, 1993, NAT GENET, V3, P202, DOI 10.1038/ng0393-202
   NICHOLS BE, 1993, HUM MOL GENET, V2, P601, DOI 10.1093/hmg/2.5.601
   Paloma E, 2002, HUM MUTAT, V20, DOI 10.1002/humu.9086
   Petrukhin K, 1998, NAT GENET, V19, P241, DOI 10.1038/915
   Pianta MJ, 2003, EXP EYE RES, V76, P203, DOI 10.1016/S0014-4835(02)00280-4
   PINCKERS A, 1983, OPHTHALMIC PAED GEN, V3, P157, DOI 10.3109/13816818309007833
   Poetsch A, 2001, J BIOL CHEM, V276, P48009, DOI 10.1074/jbc.M108941200
   Qi JH, 2003, NAT MED, V9, P407, DOI 10.1038/nm846
   Rabb MF, 1998, AM J OPHTHALMOL, V125, P502, DOI 10.1016/S0002-9394(99)80191-3
   Radu RA, 2003, P NATL ACAD SCI USA, V100, P4742, DOI 10.1073/pnas.0737855100
   REARDON W, 1992, LANCET, V340, P1376, DOI 10.1016/0140-6736(92)92560-3
   Reichel MB, 1998, BRIT J OPHTHALMOL, V82, P1162, DOI 10.1136/bjo.82.10.1162
   Rivera A, 2000, AM J HUM GENET, V67, P800, DOI 10.1086/303090
   Rozet JM, 1998, EUR J HUM GENET, V6, P291, DOI 10.1038/sj.ejhg.5200221
   Sarra GM, 2001, HUM MOL GENET, V10, P2353, DOI 10.1093/hmg/10.21.2353
   Sauer CG, 1997, NAT GENET, V17, P164, DOI 10.1038/ng1097-164
   Simonelli F, 2000, INVEST OPHTH VIS SCI, V41, P892
   Small K W, 1998, Trans Am Ophthalmol Soc, V96, P925
   Small KW, 1999, MOL VIS, V5
   Sparrow JR, 2002, INVEST OPHTH VIS SCI, V43, P1222
   Sparrow JR, 2000, INVEST OPHTH VIS SCI, V41, P1981
   SPARROW JR, 2003, IN PRESS J BIOL CHEM
   Stefko ST, 2000, AM J OPHTHALMOL, V130, P203, DOI 10.1016/S0002-9394(00)00562-6
   STEINMETZ RL, 1993, BRIT J OPHTHALMOL, V77, P549, DOI 10.1136/bjo.77.9.549
   Stone EM, 1999, NAT GENET, V22, P199, DOI 10.1038/9722
   Stone EM, 2001, HUM MOL GENET, V10, P2285, DOI 10.1093/hmg/10.20.2285
   STONE EM, 1994, ARCH OPHTHALMOL-CHIC, V112, P765, DOI 10.1001/archopht.1994.01090180063036
   Stone EM, 1998, NAT GENET, V20, P328, DOI 10.1038/3798
   Sun H, 2002, P NATL ACAD SCI USA, V99, P4008, DOI 10.1073/pnas.052692999
   Sun H, 2000, NAT GENET, V26, P242, DOI 10.1038/79994
   Sun H, 1999, J BIOL CHEM, V274, P8269, DOI 10.1074/jbc.274.12.8269
   Sun H, 1997, NAT GENET, V17, P15, DOI 10.1038/ng0997-15
   SWANN PG, 1990, OPHTHAL PHYSL OPT, V10, P149, DOI 10.1111/j.1475-1313.1990.tb00969.x
   Tarttelin EE, 2001, J MED GENET, V38, P381, DOI 10.1136/jmg.38.6.381
   TRAVIS GH, 1991, NEURON, V6, P61, DOI 10.1016/0896-6273(91)90122-G
   van Driel MA, 1998, OPHTHALMIC GENET, V19, P117, DOI 10.1076/opge.19.3.117.2187
   VANDENOUWELAND JMW, 1992, NAT GENET, V1, P368, DOI 10.1038/ng0892-368
   von Ruckmann A, 1999, GRAEF ARCH CLIN EXP, V237, P1, DOI 10.1007/s004170050186
   VONRUCKMANN A, 1995, BRIT J OPHTHALMOL, V79, P407, DOI 10.1136/bjo.79.5.407
   vonRuckmann A, 1997, INVEST OPHTH VIS SCI, V38, P478
   vonRuckmann A, 1997, ARCH OPHTHALMOL-CHIC, V115, P609, DOI 10.1001/archopht.1997.01100150611006
   WEBER BHF, 1994, J MED GENET, V31, P388, DOI 10.1136/jmg.31.5.388
   Weber BHF, 2002, P NATL ACAD SCI USA, V99, P6222, DOI 10.1073/pnas.092528599
   Weber BHF, 2002, INVEST OPHTH VIS SCI, V43, P2732
   WEBER BHF, 1994, NAT GENET, V8, P352, DOI 10.1038/ng1294-352
   Webster AR, 2001, INVEST OPHTH VIS SCI, V42, P1179
   Weeks DE, 2000, HUM MOL GENET, V9, P1329, DOI 10.1093/hmg/9.9.1329
   Weeks DE, 2001, AM J OPHTHALMOL, V132, P682, DOI 10.1016/S0002-9394(01)01214-4
   WEINGEIST TA, 1982, ARCH OPHTHALMOL-CHIC, V100, P1108
   WELEBER RG, 1993, ARCH OPHTHALMOL-CHIC, V111, P1531, DOI 10.1001/archopht.1993.01090110097033
   Weng J, 1999, CELL, V98, P13, DOI 10.1016/S0092-8674(00)80602-9
   YANOFF M, 1968, ARCH OPHTHALMOL-CHIC, V79, P49
   YOUNG RW, 1987, SURV OPHTHALMOL, V31, P291, DOI 10.1016/0039-6257(87)90115-9
   Zhang K, 2001, NAT GENET, V27, P89, DOI 10.1038/83817
NR 131
TC 122
Z9 125
U1 0
U2 11
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0022-2593
EI 1468-6244
J9 J MED GENET
JI J. Med. Genet.
PD SEP 1
PY 2003
VL 40
IS 9
BP 641
EP 650
DI 10.1136/jmg.40.9.641
PG 10
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA 718ZP
UT WOS:000185177700001
PM 12960208
OA Green Published, Bronze
DA 2022-11-30
ER

PT J
AU Fishkin, N
   Jang, YP
   Itagaki, Y
   Sparrow, JR
   Nakanishi, K
AF Fishkin, N
   Jang, YP
   Itagaki, Y
   Sparrow, JR
   Nakanishi, K
TI A2-Rhodopsin: a new fluorophore isolated from photoreceptor outer
   segments
SO ORGANIC & BIOMOLECULAR CHEMISTRY
LA English
DT Article
ID RETINAL-PIGMENT EPITHELIUM; STARGARDT MACULAR DYSTROPHY; FUNDUS
   AUTOFLUORESCENCE; GEOGRAPHIC ATROPHY; TRANSPORTER GENE; AGING RETINA;
   LIPOFUSCIN; ABCR; DEGENERATION; RHODOPSIN
AB A2E and iso-A2E are fluorescent amphiphilic pyridinium bisretinoids involved in age-related macular degeneration (AMD). It is now shown that the presence of high exogenous concentrations of all-trans-retinal in photoreceptor outer segments leads to the formation of A2-rhodopsin (A2-Rh), an unprecedented fluorescent rhodopsin adduct which consists of bisretinoids (A2) linked to each of three lysine residues in rhodopsin (Rh) and which exhibits an emission spectrum similar to A2E. The fluorophore to protein ratio was determined by MALDI-TOF-MS and UV-VIS spectroscopy. Enzymatic degradation with thermolysin and cathepsin D showed that two of the A2 moieties were located in the region of the third cytoplasmic loop and 8th helix of Rh. Examination of A2-Rh and A2-PE (the precursor of A2E) fluorescence in relation to all-trans-retinal concentration indicated that whereas A2-PE formation is favored over that of A2-Rh, for a single rhodopsin molecule only one phosphatidylethanolamine molecule is available to react with all-trans-retinal; this phosphatidylethanolamine is probably tightly associated with the protein.
C1 Columbia Univ, Dept Chem, New York, NY 10027 USA.
   Columbia Univ, Dept Ophthalmol, New York, NY 10027 USA.
C3 Columbia University; Columbia University
RP Nakanishi, K (通讯作者)，Columbia Univ, Dept Chem, New York, NY 10027 USA.
RI Jang, Young Pyo/AAJ-8782-2020
OI Jang, Young Pyo/0000-0001-5865-9228
FU NEI NIH HHS [EY 139933-01, EY 12951] Funding Source: Medline; NIGMS NIH
   HHS [GM 34509, GM 36564] Funding Source: Medline; NATIONAL EYE INSTITUTE
   [R01EY012951] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF
   GENERAL MEDICAL SCIENCES [R01GM036564, R01GM034509, R37GM034509] Funding
   Source: NIH RePORTER
CR Ablonczy Z, 2000, MOL VIS, V6, P109
   Ahn J, 2000, J BIOL CHEM, V275, P20399, DOI 10.1074/jbc.M000555200
   Allikmets R, 1997, NAT GENET, V15, P236, DOI 10.1038/ng0397-236
   Allikmets R, 1997, SCIENCE, V277, P1805, DOI 10.1126/science.277.5333.1805
   Beck M, 1998, FEBS LETT, V436, P304, DOI 10.1016/S0014-5793(98)01156-9
   Ben-Shabat S, 2002, ANGEW CHEM INT EDIT, V41, P814, DOI 10.1002/1521-3773(20020301)41:5<814::AID-ANIE814>3.0.CO;2-2
   Ben-Shabat S, 2002, J BIOL CHEM, V277, P7183, DOI 10.1074/jbc.M108981200
   Delori FC, 2001, INVEST OPHTH VIS SCI, V42, P1855
   DOREY CK, 1989, INVEST OPHTH VIS SCI, V30, P1691
   ELDRED GE, 1988, EXP EYE RES, V47, P71, DOI 10.1016/0014-4835(88)90025-5
   ELDRED GE, 1993, NATURE, V361, P724, DOI 10.1038/361724a0
   FEENEYBURNS L, 1984, INVEST OPHTH VIS SCI, V25, P195
   FUKADA Y, 1990, BIOCHEMISTRY-US, V29, P3133, DOI 10.1021/bi00464a033
   Holz FG, 2001, INVEST OPHTH VIS SCI, V42, P1051
   Holz FG, 1999, GRAEF ARCH CLIN EXP, V237, P145, DOI 10.1007/s004170050209
   Imamoto Y, 2000, BIOCHEMISTRY-US, V39, P15225, DOI 10.1021/bi0018685
   Kennedy CJ, 1995, EYE, V9, P763, DOI 10.1038/eye.1995.192
   Liu JH, 2000, J BIOL CHEM, V275, P29354, DOI 10.1074/jbc.M910191199
   Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739
   Parish CA, 1998, P NATL ACAD SCI USA, V95, P14609, DOI 10.1073/pnas.95.25.14609
   RABB MF, 1986, OPHTHALMOLOGY, V93, P1443
   Rando RR, 2001, CHEM REV, V101, P1881, DOI 10.1021/cr960141c
   REGAN CM, 1980, EXP EYE RES, V30, P183, DOI 10.1016/0014-4835(80)90112-8
   Ren RXF, 1997, J AM CHEM SOC, V119, P3619, DOI 10.1021/ja9700414
   Sachs K, 2000, J BIOL CHEM, V275, P6189, DOI 10.1074/jbc.275.9.6189
   Sakai N, 1996, J AM CHEM SOC, V118, P1559, DOI 10.1021/ja953480g
   SCHOCHET SS, 1980, ARCH OPHTHALMOL-CHIC, V98, P1083, DOI 10.1001/archopht.1980.01020031073013
   Shroyer NF, 1999, VISION RES, V39, P2537, DOI 10.1016/S0042-6989(99)00037-1
   Sparrow JR, 2001, INVEST OPHTH VIS SCI, V42, P1356
   Sparrow JR, 2000, INVEST OPHTH VIS SCI, V41, P1981
   Sun H, 1999, J BIOL CHEM, V274, P8269, DOI 10.1074/jbc.274.12.8269
   Tanaka K, 1999, TETRAHEDRON, V55, P1657, DOI 10.1016/S0040-4020(98)01197-1
   WALD G, 1952, J GEN PHYSIOL, V35, P797, DOI 10.1085/jgp.35.5.797
   Weng J, 1999, CELL, V98, P13, DOI 10.1016/S0092-8674(00)80602-9
NR 34
TC 51
Z9 53
U1 0
U2 2
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 1477-0520
J9 ORG BIOMOL CHEM
JI Org. Biomol. Chem.
PY 2003
VL 1
IS 7
BP 1101
EP 1105
DI 10.1039/b212213h
PG 5
WC Chemistry, Organic
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Chemistry
GA 661ZB
UT WOS:000181919400007
PM 12926382
DA 2022-11-30
ER

PT J
AU Moos, WH
   Faller, DV
   Glavas, IP
   Harpp, DN
   Kamperi, N
   Kanara, I
   Kodukula, K
   Mavrakis, AN
   Pernokas, J
   Pernokas, M
   Pinkert, CA
   Powers, WR
   Sampani, K
   Steliou, K
   Tamvakopoulos, C
   Vavvas, DG
   Zamboni, RJ
   Chen, XH
AF Moos, Walter H.
   V. Faller, Douglas
   Glavas, Ioannis P.
   Harpp, David N.
   Kamperi, Natalia
   Kanara, Iphigenia
   Kodukula, Krishna
   Mavrakis, Anastasios N.
   Pernokas, Julie
   Pernokas, Mark
   Pinkert, Carl A.
   Powers, Whitney R.
   Sampani, Konstantina
   Steliou, Kosta
   Tamvakopoulos, Constantin
   Vavvas, Demetrios G.
   Zamboni, Robert J.
   Chen, Xiaohong
TI Treatment and prevention of pathological mitochondrial dysfunction in
   retinal degeneration and in photoreceptor injury
SO BIOCHEMICAL PHARMACOLOGY
LA English
DT Review
DE Cuproptosis; Ferroptosis; ?-lipoic acid; Macular degeneration;
   Mitochondrial disease; Ophthalmology; Photoreceptor cells; Rare
   diseases; Retinal disease; Therapeutics
ID ALPHA-LIPOIC ACID; OXIDATIVE STRESS; EPIGENETIC TREATMENT; CELL-DEATH;
   L-CARNITINE; NEURODEGENERATIVE DISEASES; LIPID-PEROXIDATION; PIGMENT
   EPITHELIUM; VISUAL-SYSTEM; ANTIOXIDANT
AB Pathological deterioration of mitochondrial function is increasingly linked with multiple degenerative illnesses as a mediator of a wide range of neurologic and age-related chronic diseases, including those of genetic origin. Several of these diseases are rare, typically defined in the United States as an illness affecting fewer than 200,000 people in the U.S. population, or about one in 1600 individuals. Vision impairment due to mitochondrial dysfunction in the eye is a prominent feature evident in numerous primary mitochondrial diseases and is common to the pathophysiology of many of the familiar ophthalmic disorders, including age-related macular degeneration, diabetic retinopathy, glaucoma and retinopathy of prematurity - a collection of syndromes, diseases and disorders with significant unmet medical needs. Focusing on metabolic mitochondrial pathway mechanisms, including the possible roles of cuproptosis and ferroptosis in retinal mitochondrial dysfunction, we shed light on the potential of alpha-lipoyl-L-carnitine in treating eye diseases. alpha-Lipoyl-L-carnitine is a bioavailable mitochondria-targeting lipoic acid prodrug that has shown potential in protecting against retinal degeneration and photoreceptor cell loss in ophthalmic indications.
C1 [Moos, Walter H.] Univ Calif San Francisco, Sch Pharm, Dept Pharmaceut Chem, San Francisco, CA USA.
   [V. Faller, Douglas] Boston Univ, Sch Med, Dept Med, Boston, MA USA.
   [V. Faller, Douglas; Steliou, Kosta] Boston Univ, Sch Med, Canc Res Ctr, Boston, MA USA.
   [Glavas, Ioannis P.] New York Univ, Sch Med, Dept Ophthalmol, New York, NY USA.
   [Harpp, David N.; Zamboni, Robert J.] McGill Univ, Dept Chem, Montreal, PQ, Canada.
   [Kamperi, Natalia; Tamvakopoulos, Constantin] Biomed Res Fdn, Acad Athens, Ctr Clin Expt Surg & Translat Res Pharmacol Pharma, Athens, Greece.
   [Kanara, Iphigenia] Embassy Greece London, London, England.
   [Kodukula, Krishna] ShangPharma Innovat, South San Francisco, CA USA.
   [Mavrakis, Anastasios N.] Tufts Univ, Sch Med, St Elizabeths Med Ctr, Dept Med, Boston, MA USA.
   [Pernokas, Julie; Pernokas, Mark] Adv Dent Associates New England, Woburn, MA USA.
   [Pinkert, Carl A.] Auburn Univ, Coll Vet Med, Dept Pathobiol, Auburn, AL USA.
   [Powers, Whitney R.] Boston Univ, Dept Hlth Sci, Boston, MA USA.
   [Powers, Whitney R.] Boston Univ, Sch Med, Dept Anat, Boston, MA USA.
   [Sampani, Konstantina] Beetham Eye Inst, Joslin Diabet Ctr, Boston, MA USA.
   [Sampani, Konstantina] Harvard Med Sch, Dept Med, Boston, MA USA.
   [Steliou, Kosta] PhenoMatriX Inc, Natick, MA USA.
   [Vavvas, Demetrios G.; Chen, Xiaohong] Harvard Med Sch, Dept Ophthalmol, Boston, MA USA.
   [Vavvas, Demetrios G.; Chen, Xiaohong] Massachusetts Eye & Ear Infirm, Retina Serv, Angiogenesis Lab, Boston, MA USA.
   [Chen, Xiaohong] Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, State Key Lab Ophthalmol, Guangdong Prov Key Lab Ophthalmol & Visual Sci, Guangzhou, Peoples R China.
   [Moos, Walter H.] Univ Calif San Francisco UCSF, Sch Pharm, Dept Pharmaceut Chem, Box 2280,600 16th St,Genentech Hall S512B, San Francisco, CA 94143 USA.
   [Sampani, Konstantina] Joslin Diabet Ctr, Ophthalmol, One Joslin Pl, Boston, MA 02215 USA.
   [Chen, Xiaohong] Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, State Key Lab Ophthalmol, Guangdong Prov Key Lab Ophthalmol & Visual Sci, Guangzhou 510060, Peoples R China.
C3 University of California System; University of California San Francisco;
   Boston University; Boston University; New York University; McGill
   University; Academy of Athens; St. Elizabeth's Medical Center; Tufts
   University; Auburn University System; Auburn University; Boston
   University; Boston University; Harvard University; Joslin Diabetes
   Center, Inc.; Harvard University; Harvard Medical School; Harvard
   University; Harvard Medical School; Harvard University; Massachusetts
   Eye & Ear Infirmary; Sun Yat Sen University; University of California
   System; University of California San Francisco; Harvard University;
   Joslin Diabetes Center, Inc.; Sun Yat Sen University
RP Moos, WH (通讯作者)，Univ Calif San Francisco UCSF, Sch Pharm, Dept Pharmaceut Chem, Box 2280,600 16th St,Genentech Hall S512B, San Francisco, CA 94143 USA.; Sampani, K (通讯作者)，Joslin Diabet Ctr, Ophthalmol, One Joslin Pl, Boston, MA 02215 USA.; Chen, XH (通讯作者)，Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, State Key Lab Ophthalmol, Guangdong Prov Key Lab Ophthalmol & Visual Sci, Guangzhou 510060, Peoples R China.
EM walter.moos@ucsf.edu; konstantina.sampani@joslin.harvard.edu;
   chenxh327@sysu.edu.cn
CR Abbas F, 2022, NATURE, V606, P351, DOI 10.1038/s41586-022-04709-x
   Acevedo K, 2019, J BIOL INORG CHEM, V24, P1141, DOI 10.1007/s00775-019-01731-9
   Adashi EY, 2021, SCIENCE, V373, P1200, DOI 10.1126/science.abg0491
   Adeva-Andany MM, 2017, IUBMB LIFE, V69, P578, DOI 10.1002/iub.1646
   Ahmad R, 2021, DIABET METAB SYND OB, V14, P3001, DOI 10.2147/DMSO.S318972
   Ajith TA, 2020, CLIN EXP PHARMACOL P, V47, P1883, DOI 10.1111/1440-1681.13373
   Alfonso-Munoz EA, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22084020
   Anandhan A, 2020, CELL CHEM BIOL, V27, P436, DOI 10.1016/j.chembiol.2020.03.011
   [Anonymous], 2022, LANCET NEUROL, V21, P203, DOI 10.1016/S1474-4422(22)00046-1
   Aoyagi Y, 2022, CANCER DISCOV, V12, P250, DOI 10.1158/2159-8290.CD-21-0032
   Arjunan P, 2022, J CLIN MED, V11, DOI 10.3390/jcm11102938
   Arroyo JG, 2005, AM J OPHTHALMOL, V139, P605, DOI 10.1016/j.ajo.2004.11.046
   AttaAllah HR, 2021, GRAEF ARCH CLIN EXP, V259, P3283, DOI 10.1007/s00417-021-05275-0
   Augustine J, 2021, FRONT ENDOCRINOL, V11, DOI 10.3389/fendo.2020.621938
   Awwad S, 2017, BRIT J PHARMACOL, V174, P4205, DOI 10.1111/bph.14024
   Bacci A, 2022, PHARMACEUTICALS-BASE, V15, DOI 10.3390/ph15060688
   Bacci A, 2021, ANTIOXIDANTS-BASEL, V10, DOI 10.3390/antiox10030367
   Bacman SR, 2018, NAT MED, V24, P1696, DOI 10.1038/s41591-018-0166-8
   Banerjee M, 2021, THER ADV OPHTHALMOL, V13, DOI 10.1177/25158414211030418
   Barrasso AP, 2018, GENESIS, V56, DOI 10.1002/dvg.23087
   Bayar S.A., 2022, RET VIT, V31, P82, DOI [10.37845/ret.vit.2022.31.15, DOI 10.37845/RET.VIT.2022.31.15]
   Belmouhand M, 2021, BMC OPHTHALMOL, V21, DOI 10.1186/s12886-021-02030-1
   Ben-Arzi A, 2022, PHARMACEUTICS, V14, DOI 10.3390/pharmaceutics14050904
   Bigot K, 2020, PHARMACEUTICS, V12, DOI 10.3390/pharmaceutics12090836
   Birtel J, 2022, OPHTHALMOL RETINA, V6, P65, DOI 10.1016/j.oret.2021.02.017
   Bosch-Morell F, 2021, BIOMOLECULES, V11, DOI 10.3390/biom11040514
   Bottani E, 2020, PHARMACEUTICS, V12, DOI 10.3390/pharmaceutics12111083
   Bowder D., 1982, WHO WAS WHO GREEK WO
   Boyd P, 2022, EXP EYE RES, V216, DOI 10.1016/j.exer.2022.108947
   Bringer MA, 2022, EXP EYE RES, V214, DOI 10.1016/j.exer.2021.108867
   Brunetti D, 2021, STEM CELLS, V39, P1289, DOI 10.1002/stem.3425
   Brunton L.L., 2017, GOODMAN GILMANS PHAR, V13rd ed., DOI DOI 10.1016/J.GEOMORPH.2006.10.020
   Burton T C, 1982, Trans Am Ophthalmol Soc, V80, P475
   Cai ZY, 2021, INT J OPHTHALMOL-CHI, V14, P1260, DOI 10.18240/ijo.2021.08.19
   Camiolo G, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20030609
   Carlson DA, 2007, ALTERN MED REV, V12, P343
   Carota G, 2021, J CLIN MED, V10, DOI 10.3390/jcm10112306
   Carrella S, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.653522
   Casson RJ, 2021, PROG RETIN EYE RES, V81, DOI 10.1016/j.preteyeres.2020.100881
   Chan TCW, 2020, EXP EYE RES, V201, DOI 10.1016/j.exer.2020.108255
   Chang YH, 2022, INVEST OPHTH VIS SCI, V63, DOI 10.1167/iovs.63.5.5
   Charif M, 2021, MOL NEURODEGENER, V16, DOI 10.1186/s13024-021-00431-w
   Chen AX, 2021, EYE, V35, P74, DOI 10.1038/s41433-020-1110-y
   Chen GH, 2022, FREE RADICAL BIO MED, V180, P95, DOI 10.1016/j.freeradbiomed.2022.01.012
   Chen JY, 2022, CELL DEATH DIFFER, V29, P467, DOI 10.1038/s41418-022-00941-0
   Chen XH, 2020, AGING-US, V12, P24504, DOI 10.18632/aging.202453
   Chen XN, 2020, INVEST OPHTH VIS SCI, V61
   Cheng RY, 2022, NEUROTOXICOLOGY, V88, P88, DOI 10.1016/j.neuro.2021.11.003
   Chhetri J, 2016, EXPERT OPIN THER TAR, V20, P721, DOI 10.1517/14728222.2015.1134489
   Chinnery PF, 2020, NEW ENGL J MED, V382, P1855, DOI 10.1056/NEJMcibr2002015
   Chipuk JE, 2021, DEV CELL, V56, P1221, DOI 10.1016/j.devcel.2021.03.033
   Ciccone L, 2021, NEURAL REGEN RES, V16, P2353, DOI 10.4103/1673-5374.300981
   Cobine PA, 2021, BBA-MOL CELL RES, V1868, DOI 10.1016/j.bbamcr.2020.118867
   COOK B, 1995, INVEST OPHTH VIS SCI, V36, P990
   Dard L, 2020, MOL ASPECTS MED, V71, DOI 10.1016/j.mam.2019.100842
   Das S, 2021, PFLUG ARCH EUR J PHY, V473, P1411, DOI 10.1007/s00424-021-02556-9
   Dascalu AM, 2022, EXP THER MED, V23, DOI 10.3892/etm.2022.11253
   David S, 2022, ANTIOXID REDOX SIGN, V37, P150, DOI 10.1089/ars.2021.0218
   de Boer L., 2022, PHYS GUIDE DIAGNOSIS, P889
   Di Nottia M, 2021, GENES-BASEL, V12, DOI 10.3390/genes12020247
   Dieguez HH, 2021, CELL DEATH DIS, V12, DOI 10.1038/s41419-021-04412-1
   Dinah C, 2022, EYE, V36, P1121, DOI 10.1038/s41433-021-01591-1
   Dodson M, 2021, CELL CHEM BIOL, V28, P741, DOI 10.1016/j.chembiol.2021.05.013
   Dodson M, 2019, REDOX BIOL, V23, DOI 10.1016/j.redox.2019.101107
   Donabedian P, 2022, OPHTHALMIC RES, V65, P245, DOI 10.1159/000519457
   Dorn GW, 2022, CELLS-BASEL, V11, DOI 10.3390/cells11061049
   dos Santos SM, 2019, OXID MED CELL LONGEV, V2019, DOI 10.1155/2019/8409329
   Doyle E, 2007, EYE, V21, P534, DOI 10.1038/sj.eye.6702260
   Dunn D.A., 2018, MITOCHONDRIAL DYSFUN, P305
   Eells JT, 2019, BIOLOGY-BASEL, V8, DOI 10.3390/biology8020031
   Elango V., TNOA J OPHTHALMIC SC, V59, P286, DOI [10.4103/tjosr.tjosr_36_21, DOI 10.4103/TJOSR.TJOSR_36_21]
   Elsayed MEAA, 2019, GRAEF ARCH CLIN EXP, V257, P1353, DOI 10.1007/s00417-019-04294-2
   Exertier C, 2022, MOL ASPECTS MED, V84, DOI 10.1016/j.mam.2021.101055
   Falk MJ, 2021, J INHERIT METAB DIS, V44, P312, DOI 10.1002/jimd.12319
   Ferreira GC, 2017, NEUROCHEM RES, V42, P1661, DOI 10.1007/s11064-017-2288-7
   Finsterer Josef, 2019, Can J Ophthalmol, DOI 10.1016/j.jcjo.2018.10.019
   Formosa LE, 2022, P NATL ACAD SCI USA, V119, DOI 10.1073/pnas.2110357119
   Fowler MJ, 2008, CLIN DIABETES, V26, P77, DOI DOI 10.2337/DIACLIN.26.2.77
   Franco R, 2021, CURR ISSUES MOL BIOL, V43, P650, DOI 10.3390/cimb43020047
   Fu ZJ, 2021, J LIPID RES, V62, DOI 10.1194/jlr.TR120000618
   Fukuda S, 2021, SCI ADV, V7, DOI 10.1126/sciadv.abj3658
   Garcia-Garcia Julian, 2022, Ophthalmic Res, DOI 10.1159/000524942
   George SM, 2021, PROG RETIN EYE RES, V85, DOI 10.1016/j.preteyeres.2021.100969
   Ghosh Ritwik, 2022, Clin Case Rep, V10, pe05361, DOI 10.1002/ccr3.5361
   Giarmarco MM, 2020, P NATL ACAD SCI USA, V117, P28816, DOI 10.1073/pnas.2007827117
   Gomes TMB, 2021, HUM MOL GENET, V30, pR245, DOI 10.1093/hmg/ddab156
   Gore E, 2022, ANTIOXID REDOX SIGN, DOI 10.1089/ars.2021.0137
   Gorman GS, 2016, NAT REV DIS PRIMERS, V2, P1, DOI 10.1038/nrdp.2016.80
   Grabowska A, 2021, EYE, V35, P1035, DOI 10.1038/s41433-020-01154-w
   Green DR, 2019, CELL, V177, P1094, DOI 10.1016/j.cell.2019.04.024
   Greenwald EC, 2018, CHEM REV, V118, P11707, DOI 10.1021/acs.chemrev.8b00333
   Gruosso F, 2021, J CLIN MED, V10, DOI 10.3390/jcm10010094
   Gueven N, 2017, MITOCHONDRION, V36, P7, DOI 10.1016/j.mito.2016.07.013
   Gukasyan HJ, 2019, PHARM RES-DORDR, V36, DOI 10.1007/s11095-019-2606-7
   Guo J, 2022, IUBMB LIFE, V74, P296, DOI 10.1002/iub.2585
   Hadian K, 2021, NAT CHEM BIOL, V17, P1113, DOI 10.1038/s41589-021-00853-z
   Haines NR, 2018, J PROTEOME RES, V17, P2421, DOI 10.1021/acs.jproteome.8b00169
   Hasan N, 2021, EYE, V35, P3041, DOI 10.1038/s41433-021-01621-y
   Hass DT, 2021, PROG RETIN EYE RES, V83, DOI 10.1016/j.preteyeres.2021.100941
   Hassannia B, 2021, ANTIOXID REDOX SIGN, V35, P487, DOI 10.1089/ars.2020.8175
   Hernandez-Rabaza V, 2019, ANTIOXIDANTS-BASEL, V8, DOI 10.3390/antiox8030053
   Hirano M, 2018, ESSAYS BIOCHEM, V62, P467, DOI 10.1042/EBC20170114
   Hisatomi T, 2002, CURR EYE RES, V24, P161, DOI 10.1076/ceyr.24.3.161.8305
   Hoffman ME, 2019, CURR ANAL BIOTECHNOL, V2, P26
   Hosseinian Sina, 2022, Mitochondrion, V65, P33, DOI 10.1016/j.mito.2022.04.006
   Hu JZ, 2019, EXP EYE RES, V181, P223, DOI 10.1016/j.exer.2019.02.011
   Hu QY, 2019, SHOCK, V51, P52, DOI 10.1097/SHK.0000000000001190
   Hughes LD, 2021, ANNU REV IMMUNOL, V39, P791, DOI 10.1146/annurev-immunol-102819-072601
   Hunsaker EW, 2019, INORG CHEM, V58, P13528, DOI 10.1021/acs.inorgchem.9b01029
   Ideraabdullah FY, 2018, PHYSIOL REV, V98, P667, DOI 10.1152/physrev.00010.2017
   Irwin MH, 2016, DRUG DEVELOP RES, V77, P109, DOI 10.1002/ddr.21294
   Ito H, 2021, ARCH BIOCHEM BIOPHYS, V700, DOI 10.1016/j.abb.2020.108695
   Jakaria M, 2021, J NEUROCHEM, V159, P804, DOI 10.1111/jnc.15519
   Javadov S, 2022, CURR OPIN PHYSIOL, V25, DOI 10.1016/j.cophys.2022.100483
   Garcia-Medina JJ, 2020, ANTIOXIDANTS-BASEL, V9, DOI 10.3390/antiox9060561
   Ji MH, 2021, TRANSL VIS SCI TECHN, V10, DOI 10.1167/tvst.10.8.4
   Kahlson Martha A, 2022, Science, V375, P1231, DOI 10.1126/science.abo3959
   Kamerlin SCL, 2013, Q REV BIOPHYS, V46, P1, DOI 10.1017/S0033583512000157
   Kan E, 2017, INT OPHTHALMOL, V37, P1269, DOI 10.1007/s10792-016-0396-z
   Kanda P, 2022, EYE, V36, P941, DOI 10.1038/s41433-021-01808-3
   Kang QZ, 2020, REDOX BIOL, V37, DOI 10.1016/j.redox.2020.101799
   Kattamis A, 2022, LANCET, V399, P2310, DOI 10.1016/S0140-6736(22)00536-0
   Kattar A, 2021, EXPERT OPIN DRUG DEL, V18, P1589, DOI 10.1080/17425247.2021.1953466
   Katz JA, 2021, CLIN OPHTHALMOL, V15, P2167, DOI 10.2147/OPTH.S259011
   Kim BJ, 2020, OPHTHALMOL RETINA, V4, P889, DOI 10.1016/j.oret.2020.03.019
   Klopstock T, 2019, LANCET NEUROL, V18, P631, DOI 10.1016/S1474-4422(19)30142-5
   Kodukula K, 2017, BIORESEARCH OPEN ACC, V6, P123, DOI 10.1089/biores.2017.0020
   Kooragayala K, 2015, INVEST OPHTH VIS SCI, V56, P8428, DOI 10.1167/iovs.15-17901
   Korenfeld MS, 2021, EYE, V35, P3292, DOI 10.1038/s41433-020-01391-z
   Kowluru RA, 2022, METABOLISM, V126, DOI 10.1016/j.metabol.2021.154920
   Kowluru RA, 2021, ANTIOXIDANTS-BASEL, V10, DOI 10.3390/antiox10050783
   Lakkaraju A, 2020, PROG RETIN EYE RES, V78, DOI 10.1016/j.preteyeres.2020.100846
   Landowski M, 2022, SCI REP-UK, V12, DOI 10.1038/s41598-021-04644-3
   Latham LE, 2021, CHEM RES TOXICOL, V34, P1208, DOI 10.1021/acs.chemrestox.0c00479
   Leger-Charnay E, 2022, PLOS ONE, V17, DOI 10.1371/journal.pone.0264787
   Lenaers G, 2021, PROG RETIN EYE RES, V83, DOI 10.1016/j.preteyeres.2020.100935
   Li JQ, 2019, OPHTHALMOLOGICA, V242, P81, DOI 10.1159/000499489
   Li X, 2021, BIOLOGY-BASEL, V10, DOI 10.3390/biology10100944
   Liang DG, 2022, MOL CELL, V82, P2215, DOI 10.1016/j.molcel.2022.03.022
   Liao SY, 2022, BBA-MOL CELL RES, V1869, DOI 10.1016/j.bbamcr.2022.119233
   Lima-Fontes M, 2022, SURV OPHTHALMOL, V67, P883, DOI 10.1016/j.survophthal.2021.11.009
   Lin J.B., 2022, OPHTHALMOL SCI, DOI [10.1016/j.xops.2022.100192, DOI 10.1016/J.XOPS.2022.100192]
   Litts KM, 2018, RETINA-J RET VIT DIS, V38, P445, DOI 10.1097/IAE.0000000000001946
   Liu HH, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22073689
   Liu HL, 2022, EXP EYE RES, V217, DOI 10.1016/j.exer.2022.108979
   Liu L, 2021, CELL BIOL INT, V45, P422, DOI 10.1002/cbin.11505
   Liufu TL, 2021, REV NEUROSCIENCE, V32, P35, DOI 10.1515/revneuro-2020-0034
   Lopez AJ, 2022, CELL PROLIFERAT, V55, DOI 10.1111/cpr.13198
   Lu J, 2021, FOOD FUNCT, V12, P9583, DOI [10.1039/d1fo01036k, 10.1039/D1FO01036K]
   Luong A, 2021, J ORAL BIOSCI, V63, P360, DOI 10.1016/j.job.2021.10.006
   Lyamzaev KG, 2022, J CELL PHYSIOL, V237, P2345, DOI 10.1002/jcp.30711
   Madruga E, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22020740
   Maher P, 2020, CELL CHEM BIOL, V27, P1456, DOI 10.1016/j.chembiol.2020.10.010
   Mahmud M, 2022, FRONT CELL NEUROSCI, V16, DOI 10.3389/fncel.2022.800065
   Maidana DE, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-97947-4
   Malard E, 2021, ANTIOXID REDOX SIGN, V35, P1176, DOI 10.1089/ars.2020.8238
   Mendoza-Nunez VM, 2019, OXID MED CELL LONGEV, V2019, DOI 10.1155/2019/3276958
   Marco-Hernandez AV, 2022, CLIN GENET, V101, P233, DOI 10.1111/cge.14093
   Velazquez LAM, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms222111542
   Maxwell -Hyslop, 1986, DICT CLASSICAL MYTHO
   McDonald MB, 2022, OPHTHALMOL THER, V11, P1, DOI 10.1007/s40123-021-00410-w
   McLaughlin MD, 2017, OPHTHALMOLOGY, V124, P667, DOI 10.1016/j.ophtha.2017.01.001
   McWilliams TG, 2019, AUTOPHAGY, V15, P1296, DOI 10.1080/15548627.2019.1580509
   Mendes D, 2022, MITOCHONDRION, V65, P67, DOI 10.1016/j.mito.2022.05.001
   Metsla K, 2022, J ALZHEIMERS DIS, V85, P715, DOI 10.3233/JAD-215026
   Micera A, 2004, CYTOKINE GROWTH F R, V15, P411, DOI 10.1016/j.cytogfr.2004.09.003
   Miller DJ, 2020, ANTIOXIDANTS-BASEL, V9, DOI 10.3390/antiox9100905
   Miller Joan W, 2017, US Ophthalmic Rev, V10, P119, DOI 10.17925/USOR.2017.10.02.119
   Miller KN, 2021, CELL, V184, P5506, DOI 10.1016/j.cell.2021.09.034
   Miller WP, 2021, FREE RADICAL BIO MED, V165, P127, DOI 10.1016/j.freeradbiomed.2021.01.041
   Mirra S, 2021, NEUROBIOL DIS, V156, DOI 10.1016/j.nbd.2021.105405
   Mithal DS, 2021, NAT METAB, V3, P5, DOI 10.1038/s42255-020-00336-w
   Mitry D, 2011, BRIT J OPHTHALMOL, V95, P365, DOI 10.1136/bjo.2009.172296
   Moos WH, 2021, BIOCHEM PHARMACOL, V193, DOI 10.1016/j.bcp.2021.114809
   Moos WH, 2020, BIORESEARCH OPEN ACC, V9, P94, DOI 10.1089/biores.2020.0004
   Moos WH, 2018, BIORESEARCH OPEN ACC, V7, P107, DOI 10.1089/biores.2018.0017
   Moos WH, 2017, BIORESEARCH OPEN ACC, V6, P169, DOI 10.1089/biores.2017.0036
   Moos WH, 2017, DRUG DEVELOP RES, V78, P24, DOI 10.1002/ddr.21366
   Moos WH, 2016, DRUG DEVELOP RES, V77, P53, DOI 10.1002/ddr.21295
   Muench NA, 2021, CELLS-BASEL, V10, DOI 10.3390/cells10071593
   Mundae R, 2022, AM J OPHTHALMOL, V237, P49, DOI 10.1016/j.ajo.2021.11.017
   Nag TC, 2021, EYE, V35, P2917, DOI 10.1038/s41433-021-01602-1
   Newman EA, 2013, J CEREBR BLOOD F MET, V33, P1685, DOI 10.1038/jcbfm.2013.145
   Ni LH, 2021, OXID MED CELL LONGEV, V2021, DOI 10.1155/2021/8054817
   Ohman T, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-020-80005-w
   Olivares-Gonzalez L, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22042096
   Ong JX, 2022, EYE, V36, P319, DOI 10.1038/s41433-021-01825-2
   Ortolan D, 2022, P NATL ACAD SCI USA, V119, DOI 10.1073/pnas.2117553119
   Osama A, 2020, AGEING RES REV, V64, DOI 10.1016/j.arr.2020.101206
   Oshitari T, 2022, NEURAL REGEN RES, V17, P795, DOI 10.4103/1673-5374.322457
   Ozgen S, 2022, NEURAL REGEN RES, V17, P741, DOI 10.4103/1673-5374.322429
   Palikaras K, 2020, MECH AGEING DEV, V187, DOI 10.1016/j.mad.2020.111216
   Pallardo FV, 2021, TRANSL RES, V229, P135, DOI 10.1016/j.trsl.2020.08.009
   Pan CD, 2021, P NATL ACAD SCI USA, V118, DOI 10.1073/pnas.2100122118
   Panvini AR, 2022, EXP EYE RES, V219, DOI 10.1016/j.exer.2022.109013
   Papapanou PN, 2018, J CLIN PERIODONTOL, V45, pS162, DOI 10.1111/jcpe.12946
   Parameshwaran K, 2015, DRUG DEVELOP RES, V76, P72, DOI 10.1002/ddr.21242
   Parameshwaran K, 2012, PHARMACOL BIOCHEM BE, V101, P487, DOI 10.1016/j.pbb.2012.02.011
   Parameshwaran K, 2010, REJUV RES, V13, P729, DOI 10.1089/rej.2010.1020
   Pearce JMS, 2013, EUR NEUROL, V69, P292, DOI 10.1159/000346232
   Peng WJ, 2021, BRAIN RES BULL, V174, P250, DOI 10.1016/j.brainresbull.2021.06.014
   Picard E, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9030705
   Piccolino FC, 2005, AM J OPHTHALMOL, V139, P87, DOI 10.1016/j.ajo.2004.08.037
   Pikuleva IA, 2014, PROG RETIN EYE RES, V41, P64, DOI 10.1016/j.preteyeres.2014.03.002
   Pirih FQ, 2021, PERIODONTOL 2000, V87, P50, DOI 10.1111/prd.12379
   Pisoschi AM, 2021, EUR J MED CHEM, V209, DOI 10.1016/j.ejmech.2020.112891
   Pitceathly RDS, 2021, J INHERIT METAB DIS, V44, P22, DOI 10.1002/jimd.12281
   Potic J, 2018, GRAEF ARCH CLIN EXP, V256, P489, DOI 10.1007/s00417-017-3880-x
   Primiano G, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-65482-3
   Ptito M, 2021, CELLS-BASEL, V10, DOI 10.3390/cells10123269
   Qin QY, 2022, CELL DEATH DIS, V13, DOI 10.1038/s41419-022-04911-9
   Raman R, 2021, EYE, V35, P2913, DOI 10.1038/s41433-021-01623-w
   Ramon J, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22126447
   Rao SR, 2021, J LIPID RES, V62, DOI 10.1194/jlr.TR120000979
   Rein DB, 2022, OPHTHALMOLOGY, V129, P369, DOI 10.1016/j.ophtha.2021.09.010
   Rey F, 2022, NEURAL REGEN RES, V17, P754, DOI 10.4103/1673-5374.322430
   Rizzollo F, 2021, TRENDS BIOCHEM SCI, V46, P960, DOI 10.1016/j.tibs.2021.07.003
   Rolev KD, 2021, NEUROPHARMACOLOGY, V187, DOI 10.1016/j.neuropharm.2021.108498
   Rong R, 2022, ANN NY ACAD SCI, V1508, P78, DOI 10.1111/nyas.14716
   Rossmann MP, 2021, DIS MODEL MECH, V14, DOI 10.1242/dmm.048912
   Rowe JA, 1999, OPHTHALMOLOGY, V106, P154, DOI 10.1016/S0161-6420(99)90018-0
   Rubin Rita, 2021, JAMA, V326, P2000, DOI 10.1001/jama.2021.20455
   Russell OM, 2020, CELL, V181, P168, DOI 10.1016/j.cell.2020.02.051
   Saadane A, 2021, AM J PATHOL, V191, P1805, DOI 10.1016/j.ajpath.2021.06.006
   Sable A., 2019, WORLD J PHARM RES, V8, P793
   Saeedi P, 2019, DIABETES RES CLIN PR, V157, DOI 10.1016/j.diabres.2019.107843
   Saha A, 2022, CELL STEM CELL, V29, P460, DOI 10.1016/j.stem.2022.01.002
   Sanz-Gonzalez S M, 2020, Arch Soc Esp Oftalmol (Engl Ed), V95, P120, DOI 10.1016/j.oftal.2019.11.009
   Sarezky D, 2016, CLIN OPHTHALMOL, V10, P1899, DOI 10.2147/OPTH.S115900
   Sarzi-Puttini P, 2021, PHARMACOL RES, V173, DOI 10.1016/j.phrs.2021.105874
   Sas AR, 2020, NAT IMMUNOL, V21, P1496, DOI 10.1038/s41590-020-00813-0
   Sas KM, 2016, JCI INSIGHT, V1, DOI 10.1172/jci.insight.86976
   Savage N, 2021, NATURE, V597, pS24, DOI 10.1038/d41586-021-02629-w
   Schofield JH, 2021, ANTIOXID REDOX SIGN, V34, P517, DOI 10.1089/ars.2020.8058
   Scholl HPN, 2021, OPHTHALMIC RES, V64, P888, DOI 10.1159/000517794
   Sena DF, 2021, COCHRANE DB SYST REV, DOI [10.1002/14551858.CD008350.pub3, 10.1002/14651858.CD008350.pub3]
   Shah M, 2019, PHARM RES-DORDR, V36, DOI 10.1007/s11095-019-2588-5
   Shahandeh A, 2022, FRONT NEUROSCI-SWITZ, V15, DOI 10.3389/fnins.2021.794809
   Shamsi FA, 2007, CURR EYE RES, V32, P575, DOI 10.1080/02713680701363833
   Shinhmar H, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-02311-1
   Shu WT, 2018, PHARMACEUTICALS-BASE, V11, DOI 10.3390/ph11040112
   Shukal DK, 2022, HUM EXP TOXICOL, V41, DOI 10.1177/09603271211063165
   Skeie JM, 2021, INVEST OPHTH VIS SCI, V62, DOI 10.1167/iovs.62.3.22
   Slone J, 2020, NPJ GENOM MED, V5, DOI 10.1038/s41525-020-0116-5
   Smirnova J, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-19873-2
   Song SJ, 2017, ENDOCRINE, V56, P82, DOI 10.1007/s12020-016-1215-z
   Soriano-Castell D, 2021, FREE RADICAL BIO MED, V177, P313, DOI 10.1016/j.freeradbiomed.2021.11.003
   Standring S, 2016, J ANAT, V229, P32, DOI 10.1111/joa.12473
   Steliou K., 2014, US Patent, Patent No. [8,741,853, 8741853]
   Steliou K, 2015, DRUG DEVELOP RES, V76, P167, DOI 10.1002/ddr.21258
   Steliou K, 2009, DRUG DEVELOP RES, V70, P499, DOI 10.1002/ddr.20342
   Stenton SL, 2020, EBIOMEDICINE, V56, DOI 10.1016/j.ebiom.2020.102784
   Stockwell BR, 2022, CELL, V185, P2401, DOI 10.1016/j.cell.2022.06.003
   Stockwell BR, 2017, CELL, V171, P273, DOI 10.1016/j.cell.2017.09.021
   Suh JH, 2004, REDOX REP, V9, P57, DOI 10.1179/135100004225003923
   Sun S, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.6.42
   Sun Y, 2022, FRONT ENDOCRINOL, V13, DOI 10.3389/fendo.2022.858012
   Sweigard JH, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aab1482
   Tan LX, 2020, REDOX BIOL, V37, DOI 10.1016/j.redox.2020.101781
   Tang DL, 2022, CELL RES, V32, P417, DOI 10.1038/s41422-022-00653-7
   Tang DL, 2019, CELL RES, V29, P347, DOI 10.1038/s41422-019-0164-5
   Tang ZM, 2021, SMALL METHODS, V5, DOI 10.1002/smtd.202100848
   Tang ZM, 2021, REDOX BIOL, V43, DOI 10.1016/j.redox.2021.101971
   Tao Y, 2016, TOHOKU J EXP MED, V240, P209, DOI 10.1620/tjem.240.209
   Taormina G, 2019, FRONT ENDOCRINOL, V10, DOI 10.3389/fendo.2019.00673
   Tarnacka B, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22157820
   Taurone S, 2022, EXCLI J, V21, P544, DOI 10.17179/excli2022-4663
   Thomas CN, 2022, BRIT J PHARMACOL, V179, P1908, DOI 10.1111/bph.15459
   Tibullo D, 2017, INFLAMM RES, V66, P947, DOI 10.1007/s00011-017-1079-6
   Tinker RJ, 2021, MOL DIAGN THER, V25, P181, DOI 10.1007/s40291-020-00510-6
   Tonade D, 2021, PROG RETIN EYE RES, V83, DOI 10.1016/j.preteyeres.2020.100919
   Torrente L, 2022, ANNU REV PHARMACOL, V62, P279, DOI 10.1146/annurev-pharmtox-052220-104025
   Trichonas G, 2010, P NATL ACAD SCI USA, V107, P21695, DOI 10.1073/pnas.1009179107
   Tsang JKW, 2021, LIFE-BASEL, V11, DOI 10.3390/life11020079
   Tsantilas KA, 2021, INVEST OPHTH VIS SCI, V62, DOI 10.1167/iovs.62.14.20
   Tsoka P, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-28633-1
   Tsvetkov P, 2022, SCIENCE, V375, P1254, DOI 10.1126/science.abf0529
   Tsvetkov P, 2019, NAT CHEM BIOL, V15, P681, DOI 10.1038/s41589-019-0291-9
   Ugarte M, 2013, SURV OPHTHALMOL, V58, P585, DOI 10.1016/j.survophthal.2012.12.002
   Ulasov AV, 2022, LIFE SCI, V291, DOI 10.1016/j.lfs.2021.120111
   Vallabh NA, 2017, MITOCHONDRION, V36, P103, DOI 10.1016/j.mito.2017.05.009
   Van Gelder RN, 2022, NAT MED, V28, P1149, DOI 10.1038/s41591-022-01862-8
   Villarejo-Zori B, 2021, MOL ASPECTS MED, V82, DOI 10.1016/j.mam.2021.101038
   Vodickova A, 2022, MITOCHONDRION, V64, P1, DOI 10.1016/j.mito.2022.02.004
   VONSTADEN H, 1992, YALE J BIOL MED, V65, P223
   Wakabayashi T, 2009, OPHTHALMOLOGY, V116, P519, DOI 10.1016/j.ophtha.2008.10.001
   Walker MA, 2020, NEW ENGL J MED, V383, P1556, DOI 10.1056/NEJMoa2001265
   Wang P, 2021, CLIN OPHTHALMOL, V15, P1621, DOI 10.2147/OPTH.S307009
   Wang ZH, 2022, MITOCHONDRION, V65, P80, DOI 10.1016/j.mito.2022.05.002
   Weinberger Y, 2022, EUR J OPHTHALMOL, V32, P2840, DOI 10.1177/11206721211064035
   Weissig V, 2020, TRENDS MOL MED, V26, P40, DOI 10.1016/j.molmed.2019.09.002
   Wu H, 2021, LIFE-BASEL, V11, DOI 10.3390/life11030222
   Xu G, 2018, AUTOPHAGY, V14, P1818, DOI 10.1080/15548627.2018.1501251
   Yan HF, 2021, SIGNAL TRANSDUCT TAR, V6, DOI 10.1038/s41392-020-00428-9
   Yang YJ, 2022, EXP EYE RES, V218, DOI 10.1016/j.exer.2022.109006
   Yapa NMB, 2021, FEBS LETT, V595, P1184, DOI 10.1002/1873-3468.14077
   Yu B, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-16312-7
   Yumnamcha T, 2020, ANTIOXIDANTS-BASEL, V9, DOI 10.3390/antiox9121244
   Zacks DN, 2022, J CLIN MED, V11, DOI 10.3390/jcm11030592
   Zeviani M, 2022, CELLS-BASEL, V11, DOI 10.3390/cells11040637
   Zeviani M, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms23010210
   Zhang HX, 2021, SCI ADV, V7, DOI 10.1126/sciadv.abi5657
   Zhang J, 2022, FRONT NUTR, V9, DOI 10.3389/fnut.2022.844757
   Zhang SX, 2015, PROG RETIN EYE RES, V45, P111, DOI 10.1016/j.preteyeres.2014.12.001
   Zhang YH, 2018, REDOX BIOL, V14, P535, DOI 10.1016/j.redox.2017.11.001
   Zhang YS, 2020, J CLIN MED, V9, DOI 10.3390/jcm9113523
   Zhang Y, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.797110
   Zhang ZY, 2021, BRAIN RES BULL, V169, P51, DOI 10.1016/j.brainresbull.2021.01.004
   Zhao LL, 2014, INVEST OPHTH VIS SCI, V55, P5979, DOI 10.1167/iovs.14-15025
   Zhao TT, 2021, AGING DIS, V12, P529, DOI 10.14336/AD.2020.0912
   Zhu XY, 2021, ELIFE, V10, DOI 10.7554/eLife.64690
   Zollet P, 2021, OPHTHALMOLOGICA, V244, P408, DOI 10.1159/000513584
   Zong Y, 2021, INT J OPHTHALMOL-CHI, V14, P1610, DOI 10.18240/ijo.2021.10.20
NR 313
TC 0
Z9 0
U1 19
U2 19
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0006-2952
EI 1873-2968
J9 BIOCHEM PHARMACOL
JI Biochem. Pharmacol.
PD SEP
PY 2022
VL 203
AR 115168
DI 10.1016/j.bcp.2022.115168
PG 15
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA 3G0ZW
UT WOS:000831086500001
PM 35835206
OA hybrid
DA 2022-11-30
ER

PT J
AU Kim, D
   Webel, AD
   Blumenkranz, MS
   Kim, Y
   Yang, JH
   Yu, SY
   Kwak, HW
   Palanker, D
   Toy, B
   Myung, D
AF Kim, Do Gyun
   Webel, Aaron D.
   Blumenkranz, Mark S.
   Kim, Yonguk
   Yang, Ji Ho
   Yu, Seung Young
   Kwak, Hyung Woo
   Palanker, Daniel
   Toy, Brian
   Myung, David
TI A Smartphone-Based Near-Vision Testing System: Design, Accuracy, and
   Reproducibility Compared With Standard Clinical Measures
SO OPHTHALMIC SURGERY LASERS & IMAGING RETINA
LA English
DT Article
ID MACULAR DEGENERATION; MONITORING-SYSTEM; VISUAL FUNCTION
AB BACKGROUND AND OBJECTIVE: Ophthalmologic telemedicine has emerged during the COVID-19 pandemic. The objective of this study is to assess the accuracy and reproducibility of a smartphonebased home vision monitoring system (Sightbook) and to compare it with existing clinical standards.
   PATIENTS AND METHODS: Near Snellen visual acuity (VA) was measured with Sightbook and compared with conventional measurements for distance and near VA at an academic medical center ophthalmology clinic in 200 patients with a variety of different specified preexisting ocular conditions. Measurements of contrast sensitivity were also compared by using an existing commercially available chart system in 15 normal patients and 15 patients with age-related macular degeneration.
   RESULTS: Sightbook VA tests were reproducible (SD = +/- 0.054 logMAR), and correlation with standard VA methods was significant (R .001). Sightbook contrast sensitivity measurements were reproducible (SD/mean ratio, 0.02 to 0.04), yielding results similar to those of standard tests (R2 0.87 and P < .001).
   CONCLUSIONS: Smartphone-based VA and contrast sensitivity are highly correlated with standard charts and may be useful in augmenting limited in office care.
C1 [Kim, Do Gyun; Yang, Ji Ho] Hanyang Univ, Myungji Hosp, Dept Ophthalmol, Goyang, South Korea.
   [Webel, Aaron D.; Blumenkranz, Mark S.; Palanker, Daniel; Myung, David] Stanford Univ, Byers Eye Inst, Dept Ophthalmol, Stanford, CA 94303 USA.
   [Kim, Yonguk; Yu, Seung Young; Kwak, Hyung Woo] Kyung Hee Univ, Dept Ophthalmol, Seoul, South Korea.
   [Toy, Brian] Univ Southern Calif, Roski Eye Inst, Dept Ophthalmol, Los Angeles, CA 90007 USA.
C3 Hanyang University; Stanford University; Kyung Hee University;
   University of Southern California
RP Myung, D (通讯作者)，Stanford Univ, Byers Eye Inst, 2452 Watson Court,9, Palo Alto, CA 94303 USA.
EM djmyung@istanford.edu
OI Palanker, Daniel/0000-0002-0480-3025
FU National Eye Institute [P30-EY026877]; Research to Prevent Blindness
FX ADW, DP, and DM were supported by departmental core grants from the
   National Eye Institute (P30-EY026877) and Research to Prevent Blindness
   to the Department of Ophthalmology at Stanford University School of
   Medicine.
CR [Anonymous], 2020, ENFORCEMENT POLICY R
   Brucker J, 2019, OPHTHALMOL THER, V8, P461, DOI 10.1007/s40123-019-0203-9
   Chew EY, 2014, OPHTHALMOLOGY, V121, P535, DOI 10.1016/j.ophtha.2013.10.027
   Faes L, 2014, EYE, V28, P788, DOI 10.1038/eye.2014.104
   Hark LA, 2017, AM J OPHTHALMOL, V181, P114, DOI 10.1016/j.ajo.2017.06.024
   Kaiser PK, 2013, RETINA-J RET VIT DIS, V33, P1863, DOI 10.1097/IAE.0b013e3182899258
   Khurana RN, 2021, AM J OPHTHALMOL, V227, P222, DOI [10.1016/i.aio.2021.03.033, 10.1016/j.ajo.2021.03.033]
   Meyer CH, 2008, OPHTHALMOLOGICA, V222, P364, DOI 10.1159/000151246
   Ting DSW, 2020, NAT MED, V26, P459, DOI 10.1038/s41591-020-0824-5
   Toy BC, 2016, RETINA-J RET VIT DIS, V36, P1000, DOI 10.1097/IAE.0000000000000955
   Wang YZ, 2013, INVEST OPHTH VIS SCI, V54, P5497, DOI 10.1167/iovs.13-12037
   Yeung WK, 2019, NPJ DIGIT MED, V2, DOI [10.1038/s41746-019-0154-5, 10.1038/s41746-019-0195-9]
NR 12
TC 0
Z9 0
U1 1
U2 2
PU SLACK INC
PI THOROFARE
PA 6900 GROVE RD, THOROFARE, NJ 08086 USA
SN 2325-8160
EI 2325-8179
J9 OSLI RETINA
JI Ophthalmic Surg. Lasers Imag. Retin.
PD FEB
PY 2022
VL 53
IS 2
BP 79
EP 84
DI 10.3928/23258160-20220121-05
PG 6
WC Ophthalmology; Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Surgery
GA ZS9DS
UT WOS:000768759200002
PM 35148218
DA 2022-11-30
ER

PT J
AU Elsharkawy, M
   Elrazzaz, M
   Ghazal, M
   Alhalabi, M
   Soliman, A
   Mahmoud, A
   El-Daydamony, E
   Atwan, A
   Thanos, A
   Sandhu, HS
   Giridharan, G
   El-Baz, A
AF Elsharkawy, Mohamed
   Elrazzaz, Mostafa
   Ghazal, Mohammed
   Alhalabi, Marah
   Soliman, Ahmed
   Mahmoud, Ali
   El-Daydamony, Eman
   Atwan, Ahmed
   Thanos, Aristomenis
   Sandhu, Harpal Singh
   Giridharan, Guruprasad
   El-Baz, Ayman
TI Role of Optical Coherence Tomography Imaging in Predicting Progression
   of Age-Related Macular Disease: A Survey
SO DIAGNOSTICS
LA English
DT Article
DE optical coherence tomography (OCT); computer-aided diagnostic (CAD);
   age-related macular degeneration (AMD); dry AMD; wet AMD
ID RETICULAR PSEUDODRUSEN; AUTOMATED DETECTION; FUNDUS IMAGES;
   DEGENERATION; CLASSIFICATION; MACULOPATHY; PREVALENCE; SYSTEM; COLOR;
   RISK
AB In developed countries, age-related macular degeneration (AMD), a retinal disease, is the main cause of vision loss in the elderly. Optical Coherence Tomography (OCT) is currently the gold standard for assessing individuals for initial AMD diagnosis. In this paper, we look at how OCT imaging can be used to diagnose AMD. Our main aim is to examine and compare automated computer-aided diagnostic (CAD) systems for diagnosing and grading of AMD. We provide a brief summary, outlining the main aspects of performance assessment and providing a basis for current research in AMD diagnosis. As a result, the only viable alternative is to prevent AMD and stop both this devastating eye condition and unwanted visual impairment. On the other hand, the grading of AMD is very important in order to detect early AMD and prevent patients from reaching advanced AMD disease. In light of this, we explore the remaining issues with automated systems for AMD detection based on OCT imaging, as well as potential directions for diagnosis and monitoring systems based on OCT imaging and telemedicine applications.
C1 [Elsharkawy, Mohamed; Elrazzaz, Mostafa; Soliman, Ahmed; Mahmoud, Ali; Sandhu, Harpal Singh; Giridharan, Guruprasad; El-Baz, Ayman] Univ Louisville, Bioengn Dept, Louisville, KY 40292 USA.
   [Ghazal, Mohammed; Alhalabi, Marah] Abu Dhabi Univ, Coll Engn, Elect & Comp Engn Dept, Abu Dhabi 59911, U Arab Emirates.
   [El-Daydamony, Eman; Atwan, Ahmed] Mansoura Univ, Fac Comp & Informat, Mansoura 35516, Egypt.
   [Thanos, Aristomenis] Legacy Devers Eye Inst, Portland, OR 97210 USA.
C3 University of Louisville; Abu Dhabi University; Egyptian Knowledge Bank
   (EKB); Mansoura University; Devers Eye Institute
RP El-Baz, A (通讯作者)，Univ Louisville, Bioengn Dept, Louisville, KY 40292 USA.
EM mohamed.elsharkawy@louisville.edu; mgelra01@louisville.edu;
   mohammed.ghazal@adu.ac.ae; marah.alhalabi@adu.ac.ae;
   ahmed.soliman@louisville.edu; ahmahm01@louisville.edu;
   emane_daydamoni@mans.edu.eg; ahmed.atwan@nbu.edu.sa; athanos@lhs.org;
   harpal.sandhu@gmail.com; gagiri01@louisville.edu;
   aselba01@louisville.edu
RI El-Baz, Ayman/AAC-6689-2019; Elsharkawy, Mohamed/AAV-9439-2020; Soliman,
   Ahmed/I-1601-2013
OI El-Baz, Ayman/0000-0001-7264-1323; Elsharkawy,
   Mohamed/0000-0001-9242-9709; Alhalabi, Marah/0000-0001-8190-5263;
   Ghazal, Mohammed/0000-0002-9045-6698; atwan, ahmed/0000-0001-7031-9568;
   Soliman, Ahmed/0000-0002-1931-3416
FU ASPIRE Award for Research Excellence 2019 under the Advanced Technology
   Research Council-ASPIRE
FX This work is supported, in part, by ASPIRE Award for Research Excellence
   2019 under the Advanced Technology Research Council-ASPIRE.
CR Adams MKM, 2011, AM J EPIDEMIOL, V173, P1246, DOI 10.1093/aje/kwr005
   Ahlers C, 2010, INVEST OPHTH VIS SCI, V51, P2149, DOI 10.1167/iovs.09-3817
   Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   An GZ, 2019, IEEE ENG MED BIO, P2049, DOI 10.1109/EMBC.2019.8857468
   ARNOLD JJ, 1995, RETINA-J RET VIT DIS, V15, P183, DOI 10.1097/00006982-199515030-00001
   BAUDOIN CE, 1984, REV EPIDEMIOL SANTE, V32, P254
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Brar M, 2009, AM J OPHTHALMOL, V148, P439, DOI 10.1016/j.ajo.2009.04.022
   Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   Burlina PM, 2019, JAMA OPHTHALMOL, V137, P258, DOI 10.1001/jamaophthalmol.2018.6156
   Burlina PM, 2017, JAMA OPHTHALMOL, V135, P1170, DOI 10.1001/jamaophthalmol.2017.3782
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Chong EWT, 2008, AM J OPHTHALMOL, V145, P707, DOI 10.1016/j.ajo.2007.12.005
   Chou R, 2016, JAMA-J AM MED ASSOC, V315, P915, DOI 10.1001/jama.2016.0783
   Cohen SY, 2007, BRIT J OPHTHALMOL, V91, P354, DOI 10.1136/bjo.2006.101022
   Coleman HR, 2008, LANCET, V372, P1835, DOI 10.1016/S0140-6736(08)61759-6
   Dasari B, 2011, BMC OPHTHALMOL, V11, DOI 10.1186/1471-2415-11-22
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   de Carlo Talisa E, 2015, Int J Retina Vitreous, V1, P5
   Feskanich D, 2008, ARCH OPHTHALMOL-CHIC, V126, P519, DOI 10.1001/archopht.126.4.519
   Finger RP, 2010, RETINA-J RET VIT DIS, V30, P1455, DOI 10.1097/IAE.0b013e3181e09829
   Fraccaro P, 2015, BMC OPHTHALMOL, V15, DOI 10.1186/1471-2415-15-10
   Freeman SR, 2010, RETINA-J RET VIT DIS, V30, P431, DOI 10.1097/IAE.0b013e3181bd2f94
   Fujimoto JG, 2000, NEOPLASIA, V2, P9, DOI 10.1038/sj.neo.7900071
   Garcia-Floriano A, 2019, COMPUT ELECTR ENG, V75, P218, DOI 10.1016/j.compeleceng.2017.11.008
   Gass J D, 1974, Trans Am Ophthalmol Soc, V72, P139
   Gass J.D.M., 1997, DIAGN TREAT, P158
   Gopinath B, 2013, AM J CLIN NUTR, V98, P129, DOI 10.3945/ajcn.112.057091
   Gorczynska I, 2009, BRIT J OPHTHALMOL, V93, P603, DOI 10.1136/bjo.2007.136101
   Green W R, 1999, Mol Vis, V5, P27
   GREEN WR, 1993, OPHTHALMOLOGY, V100, P1519
   GREEN WR, 1991, RETINA-J RET VIT DIS, V11, P328, DOI 10.1097/00006982-199111030-00010
   Gregori G, 2011, OPHTHALMOLOGY, V118, P1373, DOI 10.1016/j.ophtha.2010.11.013
   Grossniklaus HE, 2004, AM J OPHTHALMOL, V137, P496, DOI 10.1016/j.ajo.2003.09.042
   Hassan T, 2018, J MED SYST, V42, DOI 10.1007/s10916-018-1078-3
   Hee MR, 1996, OPHTHALMOLOGY, V103, P1260, DOI 10.1016/S0161-6420(96)30512-5
   Holz FG, 2004, AM J OPHTHALMOL, V137, P504, DOI 10.1016/j.ajo.2003.11.026
   Huang W, 2011, IEEE T MED IMAGING, V30, P94, DOI 10.1109/TMI.2010.2062197
   Hwang DK, 2019, THERANOSTICS, V9, P232, DOI 10.7150/thno.28447
   Joachim N, 2015, OPHTHALMOLOGY, V122, P2482, DOI 10.1016/j.ophtha.2015.08.002
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Keane PA, 2012, SURV OPHTHALMOL, V57, P389, DOI 10.1016/j.survophthal.2012.01.006
   Khan JC, 2006, BRIT J OPHTHALMOL, V90, P29, DOI 10.1136/bjo.2005.073825
   Kim SG, 2003, YONSEI MED J, V44, P821, DOI 10.3349/ymj.2003.44.5.821
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein R, 2008, AM J OPHTHALMOL, V145, P317, DOI 10.1016/j.ajo.2007.09.008
   LeCun Y, 2015, NATURE, V521, P436, DOI 10.1038/nature14539
   Lee CS, 2017, OPHTHALMOL RETINA, V1, P322, DOI 10.1016/j.oret.2016.12.009
   Leibowitz H M, 1980, Surv Ophthalmol, V24, P335
   Leng T, 2009, RETINA-J RET VIT DIS, V29, P988, DOI 10.1097/IAE.0b013e3181ae7113
   Li F, 2019, GRAEF ARCH CLIN EXP, V257, P495, DOI 10.1007/s00417-018-04224-8
   Li HK, 1999, SURV OPHTHALMOL, V44, P61, DOI 10.1016/S0039-6257(99)00059-4
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Liu J, 2009, IFMBE PROC, V23, P559
   Liu YY, 2011, INVEST OPHTH VIS SCI, V52, P8316, DOI 10.1167/iovs.10-7012
   Lujan BJ, 2009, OPHTHAL SURG LAS IM, V40, P96, DOI 10.3928/15428877-20090301-16
   Ma J, 2017, OPHTHALMOL EYE DIS, V9, DOI 10.1177/1179172116686075
   MATSUI M, 1973, Nippon Ganka Gakkai Zasshi, V77, P907
   Millen AE, 2011, ARCH OPHTHALMOL-CHIC, V129, P481, DOI 10.1001/archophthalmol.2011.48
   Motozawa N, 2019, OPHTHALMOL THER, V8, P527, DOI 10.1007/s40123-019-00207-y
   Nagiel A, 2015, JAMA OPHTHALMOL, V133, P629, DOI 10.1001/jamaophthalmol.2015.0668
   Narasimha-Iyer H, 2006, IEEE T BIO-MED ENG, V53, P1084, DOI 10.1109/TBME.2005.863971
   Ooto S, 2011, INVEST OPHTH VIS SCI, V52, P8769, DOI 10.1167/iovs.11-8388
   Pascolini D, 2004, OPHTHAL EPIDEMIOL, V11, P67, DOI 10.1076/opep.11.2.67.28158
   Pieroni CG, 2006, BRIT J OPHTHALMOL, V90, P191, DOI 10.1136/bjo.2005.076612
   Podoleanu AG, 2013, WOODH PUB SER ELECT, P253, DOI 10.1533/9780857097545.3.253
   Quellec G, 2010, IEEE T MED IMAGING, V29, P1321, DOI 10.1109/TMI.2010.2047023
   Rahman N, 2020, BRIT J OPHTHALMOL, V104, P451, DOI 10.1136/bjophthalmol-2019-315086
   Saleem SM, 2020, AM J OPHTHALMOL, V216, P237, DOI 10.1016/j.ajo.2020.04.029
   SANDBERG MA, 1993, OPHTHALMOLOGY, V100, P1009
   Sandhu HS, 2020, AM J OPHTHALMOL, V216, P201, DOI 10.1016/j.ajo.2020.01.016
   Schmitz-Valckenberg S, 2010, OPHTHALMOLOGY, V117, P1169, DOI 10.1016/j.ophtha.2009.10.044
   Sharafeldeen A, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-83735-7
   Sikorski BL, 2011, OPHTHALMOLOGY, V118, P82, DOI 10.1016/j.ophtha.2010.04.017
   Sleman AA, 2021, MED PHYS, V48, P1584, DOI 10.1002/mp.14720
   Spaide RF, 2020, OPHTHALMOLOGY, V127, P616, DOI 10.1016/j.ophtha.2019.11.004
   Spaide RF, 2010, RETINA-J RET VIT DIS, V30, P1441, DOI 10.1097/IAE.0b013e3181ee5ce8
   Srinivasan PP, 2014, BIOMED OPT EXPRESS, V5, P3568, DOI 10.1364/BOE.5.003568
   Stahl A, 2020, DTSCH ARZTEBL INT, V117, P513, DOI 10.3238/arztebl.2020.0513
   Sunness JS, 1999, MOL VIS, V5
   Tan JH, 2018, FUTURE GENER COMP SY, V87, P127, DOI 10.1016/j.future.2018.05.001
   Tanna P, 2017, BRIT J OPHTHALMOL, V101, P25, DOI 10.1136/bjophthalmol-2016-308823
   Ting DSW, 2017, JAMA-J AM MED ASSOC, V318, P2211, DOI 10.1001/jama.2017.18152
   Treder M, 2018, GRAEF ARCH CLIN EXP, V256, P259, DOI 10.1007/s00417-017-3850-3
   Venhuizen FG, 2017, INVEST OPHTH VIS SCI, V58, P2318, DOI 10.1167/iovs.16-20541
   Victor A.A., 2019, VISUAL IMPAIRMENT BL
   Vitale S, 2020, JAMA OPHTHALMOL, V138, P610, DOI 10.1001/jamaophthalmol.2020.0824
   Wolf-Schnurrbusch UEK, 2008, INVEST OPHTH VIS SCI, V49, P3095, DOI 10.1167/iovs.07-1460
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yannuzzi LA, 2001, RETINA-J RET VIT DIS, V21, P416, DOI 10.1097/00006982-200110000-00003
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P303, DOI 10.1016/j.ophtha.2009.07.014
NR 92
TC 4
Z9 4
U1 4
U2 4
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2075-4418
J9 DIAGNOSTICS
JI Diagnostics
PD DEC
PY 2021
VL 11
IS 12
AR 2313
DI 10.3390/diagnostics11122313
PG 19
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA XY3SX
UT WOS:000736897600001
PM 34943550
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Anderson, AM
   Kirtadze, T
   Malanga, M
   Dinh, D
   Barnes, C
   Campo, A
   Clemens, DM
   Garcia-Fandino, R
   Pinero, A
   O'Connor, MS
AF Anderson, Amelia M.
   Kirtadze, Tamari
   Malanga, Milo
   Dinh, Darren
   Barnes, Carolyn
   Campo, Angielyn
   Clemens, Daniel M.
   Garcia-Fandino, Rebeca
   Pinero, Angel
   O'Connor, Matthew S.
TI Cyclodextrin dimers: A versatile approach to optimizing encapsulation
   and their application to therapeutic extraction of toxic oxysterols
SO INTERNATIONAL JOURNAL OF PHARMACEUTICS
LA English
DT Article
DE Aging; Oxysterols; Cyclodextrin; 7-ketocholesterol; Atherosclerosis
ID HYDROXYPROPYL-BETA-CYCLODEXTRIN; INCLUSION COMPLEXES; CHOLESTEROL;
   CYTOTOXICITY; DERIVATIVES; EXPRESSION; APOPTOSIS; CRYSTAL; EFFLUX; CD
AB We have developed a novel class of specifically engineered, dimerized cyclodextrin (CD) nanostructures for the encapsulation of toxic biomolecules such as 7-ketocholesterol (7KC). 7KC accumulates over time and causes dysfunction in many cell types, linking it to several age-related diseases including atherosclerosis and age-related macular degeneration (AMD). Presently, treatments for these diseases are invasive, expensive, and show limited benefits. CDs are cyclic glucose oligomers utilized to capture small, hydrophobic molecules. Here, a combination of in silico, in vitro, and ex vivo methods is used to implement a synergistic rational drug design strategy for developing CDs to remove atherogenic 7KC from cells and tissues. Mechanisms by which CDs encapsulate sterols are discussed, and we conclude that covalently linked head-to-head dimers of beta CDs have substantially improved affinity for 7KC compared to monomers. We find that inclusion complexes can be stabilized or destabilized in ways that allow the design of CD dimers with increased 7KC selectivity while maintaining an excellent safety profile. These CD dimers are being developed as therapeutics to treat atherosclerosis and other debilitating diseases of aging.
C1 [Anderson, Amelia M.; Kirtadze, Tamari; Dinh, Darren; Clemens, Daniel M.; Garcia-Fandino, Rebeca; Pinero, Angel; O'Connor, Matthew S.] Underdog Pharmaceut Inc, 110 Pioneer Way,Suite J, Mountain View, CA 94041 USA.
   [Anderson, Amelia M.; Barnes, Carolyn; Campo, Angielyn; O'Connor, Matthew S.] SENS Res Fdn, 110 Pioneer Way,Suite J, Mountain View, CA USA.
   [Malanga, Milo] Cyclolab Cyclodextrin Res & Dev Ltd, Illatos Ut 7, H-1097 Budapest, Hungary.
   [Garcia-Fandino, Rebeca; Pinero, Angel] MD USE Innovat Solut SL, Edificio Emprendia,Campus Vida, Santiago De Compostela 15782, A Coruna, Spain.
   [Garcia-Fandino, Rebeca] Univ Santiago de Compostela, Dept Quim Organ, Ctr Singular Invest Quim Biol & Mat Mol CIQUS, Santiago De Compostela 15782, Spain.
   [Pinero, Angel] Univ Santiago de Compostela, Fac Fis, Dept Fis Aplicada, Santiago De Compostela, Spain.
C3 CycloLab; Universidade de Santiago de Compostela; CiQUS; Universidade de
   Santiago de Compostela
RP O'Connor, MS (通讯作者)，Underdog Pharmaceut Inc, 110 Pioneer Way,Suite J, Mountain View, CA 94041 USA.
EM matthew.oconnor@underdogpharma.com
RI Fandino, Rebeca Garcia/M-1880-2014; Pineiro, Angel/C-1098-2009
OI Fandino, Rebeca Garcia/0000-0002-5274-3928; Anderson,
   Amelia/0000-0002-3846-472X; Pineiro, Angel/0000-0001-9350-8468
FU SENS Research Foundation (SRF); Forever Healthy Foundation; Michael
   Antonov Foundation; Underdog Pharmaceuticals
FX This work was supported by funding from Underdog Pharmaceuticals, SENS
   Research Foundation (SRF) , the Forever Healthy Foundation, and the
   Michael Antonov Foundation. The authors would also like to thank CESGA
   (University of Santiago de Compostela) for the computing time and
   services, as well as W. Gray Jerome (Vanderbilt University) , Lajos
   Szente (CycloLab LTD) , Aubrey de Grey (SRF) , Greg Chin (SRF) , and
   Alexandra Stolzing (SRF) for critical feedback and unwavering support on
   this project.
CR Agrawal S, 2002, MOL CELL BIOL, V22, P1981, DOI 10.1128/MCB.22.7.1981-1992.2002
   Aime S, 2009, ORG BIOMOL CHEM, V7, P370, DOI 10.1039/b812172a
   Alcalde MA, 2009, J INCL PHENOM MACRO, V63, P309, DOI 10.1007/s10847-008-9524-3
   Anderson A, 2020, REDOX BIOL, V29, DOI 10.1016/j.redox.2019.101380
   Atger VM, 1997, J CLIN INVEST, V99, P773, DOI 10.1172/JCI119223
   BERENDSEN HJC, 1995, COMPUT PHYS COMMUN, V91, P43, DOI 10.1016/0010-4655(95)00042-E
   Biswas A, 2019, BIOPHYS J, V116, P1456, DOI 10.1016/j.bpj.2019.03.016
   Bonnet P, 2001, J ORG CHEM, V66, P689, DOI 10.1021/jo0008284
   BRESLOW R, 1983, J AM CHEM SOC, V105, P1390, DOI 10.1021/ja00343a063
   Breslow R, 1996, J AM CHEM SOC, V118, P8495, DOI 10.1021/ja961567b
   Brewster ME, 2004, J DRUG DELIV SCI TEC, V14, P21, DOI 10.1016/S1773-2247(04)50002-3
   Brown A.J., CHOLESTEROL OXYSTERO, P11
   Bussi G, 2007, J CHEM PHYS, V126, DOI 10.1063/1.2408420
   Caira MR, 2015, BEILSTEIN J ORG CHEM, V11, P2616, DOI 10.3762/bjoc.11.281
   Choi Y.-H., 2000, MOL MODELING STUDIES
   Christoforides E, 2018, BEILSTEIN J ORG CHEM, V14, P838, DOI 10.3762/bjoc.14.69
   European Medicines Agency, 2017, CYCL US EXC
   Food and Drug Administration (FDA), 2020, SEARCH APPROVED SURV
   Freeman NE, 2005, J LIPID RES, V46, P1933, DOI 10.1194/jlr.M500101-JLR200
   Garrido PF, 2020, BIOMOLECULES, V10, DOI 10.3390/biom10030431
   Gelissen IC, 1996, J BIOL CHEM, V271, P17852, DOI 10.1074/jbc.271.30.17852
   Gould S, 2005, FOOD CHEM TOXICOL, V43, P1451, DOI 10.1016/j.fct.2005.03.007
   Guo JW, 2019, ADV MATER, V31, DOI 10.1002/adma.201904607
   Hamon F, 2014, BEILSTEIN J ORG CHEM, V10, P2874, DOI 10.3762/bjoc.10.304
   Hess B, 1997, J COMPUT CHEM, V18, P1463, DOI 10.1002/(SICI)1096-987X(199709)18:12<1463::AID-JCC4>3.3.CO;2-L
   IRIE T, 1982, J PHARMACOBIO-DYNAM, V5, P741
   IRIE T, 1992, J PHARM SCI, V81, P521, DOI 10.1002/jps.2600810609
   Irie T, 1997, J PHARM SCI-US, V86, P147, DOI 10.1021/js960213f
   Jansook P, 2018, INT J PHARMACEUT, V535, P272, DOI 10.1016/j.ijpharm.2017.11.018
   Jansook P, 2010, J PHARM SCI-US, V99, P719, DOI 10.1002/jps.21861
   Kalinowski H, 1984, 13C NMR SPEKTROSKOPI
   Kam JH, 2015, EXP EYE RES, V135, P59, DOI 10.1016/j.exer.2015.03.023
   Keating GM, 2016, DRUGS, V76, P1041, DOI 10.1007/s40265-016-0604-1
   Kim H, 2020, ACS NANO, V14, P6519, DOI 10.1021/acsnano.9b08216
   Kiss T, 2010, EUR J PHARM SCI, V40, P376, DOI 10.1016/j.ejps.2010.04.014
   Kritharides L, 1996, J BIOL CHEM, V271, P27450, DOI 10.1074/jbc.271.44.27450
   Kucakova K, 2020, STEROIDS, V155, DOI 10.1016/j.steroids.2019.108555
   Lemaire S, 1998, FEBS LETT, V440, P434, DOI 10.1016/S0014-5793(98)01496-3
   Liang Q, 2016, RSC ADV, V6, P3586, DOI 10.1039/c5ra19349d
   LINDNER K, 1978, ANGEW CHEM INT EDIT, V17, P694, DOI 10.1002/anie.197806941
   Linse B, 2014, J CHEM PHYS, V141, DOI 10.1063/1.4901119
   Loftsson T, 2007, INT J PHARMACEUT, V329, P1, DOI 10.1016/j.ijpharm.2006.10.044
   Lopez CA, 2013, SCI REP-UK, V3, DOI 10.1038/srep02071
   Lopez CA, 2011, PLOS COMPUT BIOL, V7, DOI 10.1371/journal.pcbi.1002020
   Machelart A, 2019, ACS NANO, V13, P3992, DOI 10.1021/acsnano.8b07902
   Maeda Y, 2019, NANOMATERIALS-BASEL, V9, DOI 10.3390/nano9050802
   Malanga M, 2016, J PHARM SCI-US, V105, P2921, DOI 10.1016/j.xphs.2016.04.034
   Malde AK, 2011, J CHEM THEORY COMPUT, V7, P4026, DOI 10.1021/ct200196m
   MANOR PC, 1974, J AM CHEM SOC, V96, P3630, DOI 10.1021/ja00818a042
   Mathieu JM, 2012, BIOTECHNOL BIOENG, V109, P2409, DOI 10.1002/bit.24506
   Messner M, 2010, INT J PHARMACEUT, V387, P199, DOI 10.1016/j.ijpharm.2009.11.035
   Mixcoha E, 2014, J PHYS CHEM B, V118, P6999, DOI 10.1021/jp412533b
   OConnor M.S., 2020, Patent No. [US20200216576A1, 20200216576]
   PARRINELLO M, 1981, J APPL PHYS, V52, P7182, DOI 10.1063/1.328693
   Patra D, 2013, ACS NANO, V7, P7674, DOI 10.1021/nn402173w
   Puglisi A, 2019, MACROMOL RAPID COMM, V40, DOI 10.1002/marc.201800557
   Ruebner A, 1996, J INCLUS PHENOM MOL, V25, P35, DOI 10.1007/BF01041531
   Santos CIAV, 2019, BIOMOLECULES, V9, DOI 10.3390/biom9050196
   Saokham P, 2018, MOLECULES, V23, DOI 10.3390/molecules23051161
   Scantlebery AML, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-53890-z
   Shibata N, 2010, CIRC J, V74, P2045, DOI 10.1253/circj.CJ-10-0860
   Sudo R, 2015, GENES CELLS, V20, P982, DOI 10.1111/gtc.12301
   Szejtli J, 1998, CHEM REV, V98, P1743, DOI 10.1021/cr970022c
   Szejtli J, 1983, J INCL PHENOM, V1, P135, DOI DOI 10.1007/BF00656816
   Szente L, 2018, MOLECULES, V23, DOI 10.3390/molecules23051228
   Testa G, 2018, BIOCHIMIE, V153, P220, DOI 10.1016/j.biochi.2018.06.006
   Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334
   Tsamaloukas A, 2005, BIOPHYS J, V89, P1109, DOI 10.1529/biophysj.105.061846
   UENO A, 1989, J AM CHEM SOC, V111, P6391, DOI 10.1021/ja00198a061
   Vejux A, 2009, J NUTR BIOCHEM, V20, P45, DOI 10.1016/j.jnutbio.2007.12.001
   Wang JM, 2004, J COMPUT CHEM, V25, P1157, DOI 10.1002/jcc.20035
   Wang JM, 2006, J MOL GRAPH MODEL, V25, P247, DOI 10.1016/j.jmgm.2005.12.005
   Wang YQ, 2018, ACS NANO, V12, P8943, DOI 10.1021/acsnano.8b02037
   Williams RO, 1998, EUR J PHARM BIOPHARM, V46, P355, DOI 10.1016/S0939-6411(98)00033-2
   Zidovetzki R, 2007, BBA-BIOMEMBRANES, V1768, P1311, DOI 10.1016/j.bbamem.2007.03.026
   Zimmer S, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aad6100
NR 76
TC 2
Z9 2
U1 3
U2 13
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0378-5173
EI 1873-3476
J9 INT J PHARMACEUT
JI Int. J. Pharm.
PD SEP 5
PY 2021
VL 606
AR 120522
DI 10.1016/j.ijpharm.2021.120522
EA SEP 2021
PG 15
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA UL7HO
UT WOS:000692818100003
PM 33839224
OA hybrid
DA 2022-11-30
ER

PT J
AU Lemaire, W
   Benhouria, M
   Koua, K
   Besrour, M
   Gauthier, LP
   Martin-Hardy, G
   Rossignol, T
   Roy, S
   Fontaine, R
AF Lemaire, William
   Benhouria, Maher
   Koua, Konin
   Besrour, Marwan
   Gauthier, Louis-Philippe
   Martin-Hardy, Gabriel
   Rossignol, Tommy
   Roy, Sebastien
   Fontaine, Rejean
TI Retinal Stimulator ASIC Architecture Based on a Joint Power and Data
   Optical Link
SO IEEE JOURNAL OF SOLID-STATE CIRCUITS
LA English
DT Article
DE Electrodes; Implants; Retina; Optical fiber communication; Laser beams;
   Computer architecture; Stimulated emission; Brain-machine interface;
   implantable electronics; neurostimulation; retinal prosthesis; VLSI
ID ELECTRICAL-STIMULATION; PRIMATE RETINA; PROSTHESIS; DESIGN; RESOLUTION;
   CELLS; TRIAL; SIGHT; CHIP
AB Retinal implants aim to partially restore vision to patients suffering from blindness caused by age-related macular degeneration (AMD) or retinitis pigmentosa (RP). Up until now, most prostheses were powered using an inductive link coupled with cables penetrating through the eyeball. Although they efficiently power the implant, they limit long-term reliability and cause postoperative complications. A fully wireless near-infrared power and data link entering the eye through the pupil alleviates these issues but limits the available power and causes energy supply interruptions during blinking. This article presents a retinal implant ASIC architecture optimized for optical operation despite these constraints. It contains 288 individually controlled electrode drivers, each connected to electrode pads with a pitch of 150 mu m. A digital controller with a stateless communication scheme allows flexible stimulation sequences and is capable of restoring stimulation within 3 ms after an eye blink. The prototype was fabricated using a CMOS 65-nm low-power technology and occupies an area of 2.8 x 3.1 mm(2) with a static power consumption of 3.1 mW.
C1 [Lemaire, William; Benhouria, Maher; Koua, Konin; Besrour, Marwan; Gauthier, Louis-Philippe; Martin-Hardy, Gabriel; Rossignol, Tommy; Roy, Sebastien; Fontaine, Rejean] Univ Sherbrooke, Interdisciplinary Inst Technol Innovat 3IT, Sherbrooke, PQ J1K 0A5, Canada.
C3 University of Sherbrooke
RP Lemaire, W (通讯作者)，Univ Sherbrooke, Interdisciplinary Inst Technol Innovat 3IT, Sherbrooke, PQ J1K 0A5, Canada.
EM william.lemaire@usherbrooke.ca
OI Roy, Sebastien/0000-0002-1262-9485; Rossignol,
   Tommy/0000-0002-9270-9193; Fontaine, Rejean/0000-0002-5453-0168
FU Natural Sciences and Engineering Research Council of Canada (NSERC)
   [NSERC-CRD 530093]; Prompt; CMC Microsystems, Canada
FX This work was supported in part by the Natural Sciences and Engineering
   Research Council of Canada (NSERC) through Collaborative Research and
   Development NSERC-CRD 530093, in part by Prompt, and in part by CMC
   Microsystems, Canada.
CR Ahnood A, 2018, ADV BIOSYST, V2, DOI 10.1002/adbi.201800043
   Ahuja AK, 2013, TRANSL VIS SCI TECHN, V2, DOI 10.1167/tvst.2.4.1
   [Anonymous], 2007, Z13612007 ANSI LAS I
   Asher A, 2007, IEEE T BIO-MED ENG, V54, P993, DOI 10.1109/TBME.2007.894828
   Batty E., 2019, P 5 INT C LEARN REPR
   Berry MJ, 1997, P NATL ACAD SCI USA, V94, P5411, DOI 10.1073/pnas.94.10.5411
   Bourne RRA, 2014, BRIT J OPHTHALMOL, V98, P629, DOI 10.1136/bjophthalmol-2013-304033
   Chang YC, 2019, J NEURAL ENG, V16, DOI 10.1088/1741-2552/aaf92b
   Chen KF, 2013, ISSCC DIG TECH PAP I, V56, P294, DOI 10.1109/ISSCC.2013.6487741
   Chow Alan Y, 2010, Trans Am Ophthalmol Soc, V108, P120
   Chun HS, 2014, IEEE T BIOMED CIRC S, V8, P108, DOI 10.1109/TBCAS.2013.2257171
   Daschner R, 2017, BIOMED MICRODEVICES, V19, DOI 10.1007/s10544-017-0147-6
   Delori FC, 2007, J OPT SOC AM A, V24, P1250, DOI 10.1364/JOSAA.24.001250
   Dumm G, 2014, INVEST OPHTH VIS SCI, V55, P8077, DOI 10.1167/iovs.14-15391
   Fafard S, 2016, APPL PHYS LETT, V108, DOI 10.1063/1.4941240
   Ferlauto L, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03386-7
   Firszt JB, 2007, OTOL NEUROTOL, V28, P629, DOI 10.1097/01.mao.0000281803.36574.bc
   Ganesan K, 2014, BIOMATERIALS, V35, P908, DOI 10.1016/j.biomaterials.2013.10.040
   Garrett DJ, 2012, J NEURAL ENG, V9, DOI 10.1088/1741-2560/9/1/016002
   Grosberg LE, 2017, J NEUROPHYSIOL, V118, P1457, DOI 10.1152/jn.00750.2016
   Ho AC, 2015, OPHTHALMOLOGY, V122, P1547, DOI 10.1016/j.ophtha.2015.04.032
   Humayun MS, 2012, OPHTHALMOLOGY, V119, P779, DOI 10.1016/j.ophtha.2011.09.028
   Humayun MS, 2003, VISION RES, V43, P2573, DOI 10.1016/S0042-6989(03)00457-7
   Jepson LH, 2013, J NEUROSCI, V33, P7194, DOI 10.1523/JNEUROSCI.4967-12.2013
   Lankaranian D, 2008, J GLAUCOMA, V17, P48, DOI 10.1097/IJG.0b013e318133fc49
   Lemaire W., 2020, ARXIV201012600
   Loizos K, 2016, HEALTHC TECHNOL LETT, V3, P93, DOI 10.1049/htl.2015.0043
   Lorach H, 2015, NAT MED, V21, P476, DOI 10.1038/nm.3851
   Loudin JD, 2007, J NEURAL ENG, V4, pS72, DOI 10.1088/1741-2560/4/1/S09
   Mathieson K, 2012, NAT PHOTONICS, V6, P391, DOI [10.1038/nphoton.2012.104, 10.1038/NPHOTON.2012.104]
   McIntosh LT, 2016, ADV NEUR IN, V29
   Moghaddam GK, 2014, COMPUT METH PROG BIO, V117, P334, DOI 10.1016/j.cmpb.2014.06.012
   Monge M, 2013, IEEE T BIOMED CIRC S, V7, P747, DOI 10.1109/TBCAS.2014.2298334
   Muratore DG, 2019, IEEE T BIOMED CIRC S, V13, P1128, DOI 10.1109/TBCAS.2019.2935468
   Tran N, 2014, IEEE J SOLID-ST CIRC, V49, P751, DOI 10.1109/JSSC.2014.2298037
   Opie NL, 2013, IEEE ENG MED BIO, P2760, DOI 10.1109/EMBC.2013.6610112
   Ortmanns M, 2007, IEEE J SOLID-ST CIRC, V42, P2946, DOI 10.1109/JSSC.2007.908693
   Palanker D, 2005, J NEURAL ENG, V2, pS105, DOI 10.1088/1741-2560/2/1/012
   Paraskevoudi N., 2019, FRONTIERS SYST NEURO, V12, P1
   Pepin E, 2016, PROC EUR SOLID-STATE, P229, DOI 10.1109/ESSCIRC.2016.7598284
   Sekirnjak C, 2008, J NEUROSCI, V28, P4446, DOI 10.1523/JNEUROSCI.5138-07.2008
   Shah NP, 2019, I IEEE EMBS C NEUR E, P714, DOI 10.1109/NER.2019.8716987
   Shun Bai, 2012, 2012 IEEE International Symposium on Circuits and Systems - ISCAS 2012, P2829, DOI 10.1109/ISCAS.2012.6271900
   Sit JJ, 2007, IEEE T BIOMED CIRC S, V1, P172, DOI 10.1109/TBCAS.2007.911631
   Sooksood K, 2009, ADV RADIO SCI, V7, P197, DOI 10.5194/ars-7-197-2009
   Sooksood K, 2010, IEEE T BIOMED CIRC S, V4, P162, DOI 10.1109/TBCAS.2010.2040277
   Stingl K, 2015, VISION RES, V111, P149, DOI 10.1016/j.visres.2015.03.001
   Suaning GJ, 2001, IEEE T BIO-MED ENG, V48, P248, DOI 10.1109/10.909646
   Wu CY, 2015, BIOMED CIRC SYST C, P161
NR 49
TC 4
Z9 4
U1 1
U2 3
PU IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC
PI PISCATAWAY
PA 445 HOES LANE, PISCATAWAY, NJ 08855-4141 USA
SN 0018-9200
EI 1558-173X
J9 IEEE J SOLID-ST CIRC
JI IEEE J. Solid-State Circuit
PD JUL
PY 2021
VL 56
IS 7
BP 2158
EP 2170
DI 10.1109/JSSC.2020.3045141
PG 13
WC Engineering, Electrical & Electronic
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Engineering
GA TC7ZH
UT WOS:000668857500016
DA 2022-11-30
ER

PT J
AU Ramya, J
   Rajakumar, MP
   Maheswari, BU
AF Ramya, J.
   Rajakumar, M. P.
   Maheswari, B. Uma
TI HPWO-LS-based deep learning approach with S-ROA-optimized optic cup
   segmentation for fundus image classification
SO NEURAL COMPUTING & APPLICATIONS
LA English
DT Article
DE Fundus image; Optic cup; Search and rescue optimization algorithm;
   Hybrid particle swarm optimization with local search; Deep neural
   network
AB Recently, automated retinal image processing has been considered a competitive field of research due to the low-accuracy results, complexity, and unacceptable outcomes associated with it. In this article, we proposed a novel approach for the classification of fundus images from different kinds of fundus disorders. The original images are preprocessed in terms of noise and contrast enhancement by using the contrast limited adaptive histogram equalization method. The optic cup segmentation from the fundus images is effectively handled via the search and rescue optimization algorithm. After that, the color, texture, and shape-based gray-level co-occurrence matrix features are extracted. The hybrid particle swarm optimization with local search strategy improves the DNN parameter and the newly developed method is named as optimal DNN. The optimal DNN is used to classify whether the image is diabetic retinopathy, glaucoma, or age-related macular degeneration. Experimentally, different kinds of datasets such as STARE, Drishti, and RIM-One datasets with performance measure are validated. Finally, the proposed approaches demonstrate higher classification performances in terms of accuracy, specificity, sensitivity, precision, recall, and f-measure.
C1 [Ramya, J.; Rajakumar, M. P.; Maheswari, B. Uma] St Josephs Coll Engn, Comp Sci & Engn, Chennai, Tamil Nadu, India.
C3 St. Joseph's College of Engineering, Chennai
RP Ramya, J (通讯作者)，St Josephs Coll Engn, Comp Sci & Engn, Chennai, Tamil Nadu, India.
EM ramsharsha@gmail.com
RI J, Ramya/AAR-5157-2020; Rajakumar, M P/AAR-5169-2020; B, UMA
   MAHESWARI/AAU-8265-2021
OI Rajakumar, M P/0000-0003-2821-7677; B, UMA MAHESWARI/0000-0001-9707-285X
CR Albert P, 2020, J CIRCUIT SYST COMP, V29, DOI 10.1142/S0218126620502539
   Badar M, 2020, COMPUT SCI REV, V35, DOI 10.1016/j.cosrev.2019.100203
   Badgujar RD, 2019, IRBM, V40, P69, DOI 10.1016/j.irbm.2019.02.003
   Choi D, 2018, TENCON IEEE REGION, P0651, DOI 10.1109/TENCON.2018.8650070
   Dorigo M., 2019, HDB METAHEURISTICS, V19, P311, DOI 10.1007/978-3-319-91086-4_10
   Fumero F., 2011, 2011 24 INT S COMP B, P1, DOI [DOI 10.1109/CBMS.2011.5999143, 10.1109/CBMS.2011.5999143]
   Ghani A, 2019, ELECTRONICS-SWITZ, V8, DOI 10.3390/electronics8121522
   Guo YH, 2017, SYMMETRY-BASEL, V9, DOI 10.3390/sym9100235
   Jang Y, 2018, J DIGIT IMAGING, V31, P923, DOI 10.1007/s10278-018-0099-2
   Jindal, 2020, MACH VISION APPL, V31, P1
   Kaur S, 2020, ENG APPL ARTIF INTEL, V90, DOI 10.1016/j.engappai.2020.103541
   Kaviriri DK, 2021, J FORESTRY RES, V32, P171, DOI 10.1007/s11676-019-01094-6
   Kavitha D, 2021, T EMERG TELECOMMUN T, V32, DOI 10.1002/ett.4132
   Kavitha M, 2014, J INTELL FUZZY SYST, V27, P2511, DOI 10.3233/IFS-141224
   Liu Z, 2020, ENG APPL ARTIF INTEL, V95, DOI 10.1016/j.engappai.2020.103771
   Martins J, 2020, COMPUT METH PROG BIO, V192, DOI 10.1016/j.cmpb.2020.105341
   Masoomi Z, 2013, INT J GEOGR INF SCI, V27, P542, DOI 10.1080/13658816.2012.698016
   Mateen M, 2019, SYMMETRY-BASEL, V11, DOI 10.3390/sym11010001
   Meng Q., 2019, AS C PATT REC, P469
   Neary, 2014, U.S. Patent, Patent No. [8,838,262, 8838262]
   Niu B, 2008, LECT NOTES COMPUT SC, V5227, P156
   Ongun G, 2001, IEEE IJCNN, P2461, DOI 10.1109/IJCNN.2001.938753
   Pan XQ, 2020, IEEE ACCESS, V8, P123726, DOI 10.1109/ACCESS.2020.3001299
   Popescu D, 2015, LECT NOTES COMPUT SC, V9492, P463, DOI 10.1007/978-3-319-26561-2_55
   Pruthi J, 2020, BIOMED SIGNAL PROCES, V60, DOI 10.1016/j.bspc.2020.102004
   Qureshi I, 2019, ALGORITHMS, V12, DOI 10.3390/a12010014
   Ravikumar S, 2021, J AMB INTEL HUM COMP, DOI 10.1007/s12652-020-02725-1
   Ravikumar S, 2021, J AMB INTEL HUM COMP, V12, P7475, DOI 10.1007/s12652-020-02424-x
   Rejeesh MR, 2019, MULTIMED TOOLS APPL, V78, P22691, DOI 10.1007/s11042-019-7577-5
   Sakaguchi A., 2019, P 2019 9 INT C BIOME, P190
   Sathya, 2020, J AMB INTEL HUM COMP, P1
   Shabani A, 2020, EXPERT SYST APPL, V161, DOI 10.1016/j.eswa.2020.113698
   Shankar K, 2020, IEEE ACCESS, V8, P118164, DOI 10.1109/ACCESS.2020.3005152
   Shen YX, 2020, MED IMAGE ANAL, V61, DOI 10.1016/j.media.2020.101654
   Sundararaj V., 2016, INT J INTELL ENG SYS, V9, P117, DOI DOI 10.22266/ijies2016.0930.12
   Sundararaj V, 2020, PROG PHOTOVOLTAICS, V28, P1128, DOI 10.1002/pip.3315
   Sundararaj V, 2019, INT J BIOMED ENG TEC, V31, P325, DOI 10.1504/IJBET.2019.103242
   Sundararaj V, 2019, WIRELESS PERS COMMUN, V104, P173, DOI 10.1007/s11277-018-6014-9
   Sundararaj V, 2018, COMPUT SECUR, V77, P277, DOI 10.1016/j.cose.2018.04.009
   Takahama T, 2006, IEEE C EVOL COMPUTAT, P1
   Xiang Z, 2020, INT CONF ACOUST SPEE, P3827, DOI 10.1109/ICASSP40776.2020.9054581
   Zapotecas MS, 2012, IEEE C EV COMP, P1, DOI DOI 10.1109/CEC.2012.6252990
NR 42
TC 0
Z9 0
U1 1
U2 2
PU SPRINGER LONDON LTD
PI LONDON
PA 236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND
SN 0941-0643
EI 1433-3058
J9 NEURAL COMPUT APPL
JI Neural Comput. Appl.
PD AUG
PY 2021
VL 33
IS 15
BP 9677
EP 9690
DI 10.1007/s00521-021-05732-1
EA FEB 2021
PG 14
WC Computer Science, Artificial Intelligence
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Computer Science
GA TG5EF
UT WOS:000617864100002
DA 2022-11-30
ER

PT J
AU Suarez-Barrio, C
   del Olmo-Aguado, S
   Garcia-Perez, E
   de la Fuente, M
   Muruzabal, F
   Anitua, E
   Baamonde-Arbaiza, B
   Fernandez-Vega-Cueto, L
   Fernandez-Vega, L
   Merayo-Lloves, J
AF Suarez-Barrio, Carlota
   del Olmo-Aguado, Susana
   Garcia-Perez, Eva
   de la Fuente, Maria
   Muruzabal, Francisco
   Anitua, Eduardo
   Baamonde-Arbaiza, Begona
   Fernandez-Vega-Cueto, Luis
   Fernandez-Vega, Luis
   Merayo-Lloves, Jesus
TI Antioxidant Role of PRGF on RPE Cells after Blue Light Insult as a
   Therapy for Neurodegenerative Diseases
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE age-related macular degeneration (AMD); neurodegenerative disease;
   retinal pigment epithelium (RPE); ARPE19; plasma rich in growth factors
   (PRGF); blue light; reactive oxygen species (ROS); antioxidant
ID PIGMENT EPITHELIAL-CELLS; 3 BLOOD DERIVATIVES; OXIDATIVE STRESS;
   GROWTH-FACTORS; PLASMA RICH; MACULAR DEGENERATION; HEME OXYGENASE-1;
   RETINAL DAMAGE; IN-VITRO; DEATH
AB Oxidative stress has a strong impact on the development of retinal diseases such as age-related macular degeneration (AMD). Plasma rich in growth factors (PRGF) is a novel therapeutic approach in ophthalmological pathologies. The aim of this study was to analyze the antioxidant effect of PRGF in retinal epithelial cells (EPR) in in vitro and ex vivo retinal phototoxicity models. In vitro analyses were performed on ARPE19 human cell line. Viability and mitochondrial status were assessed in order to test the primary effects of PRGF. GSH level, and protein and gene expression of the main antioxidant pathway (Keap1, Nrf2, GCL, HO-1, and NQO1) were also studied. Ex vivo analyses were performed on rat RPE, and HO-1 and Nrf2 gene and protein expression were evaluated. The results show that PRGF reduces light insult by stimulating the cell response against oxidative damage and modulates the antioxidant pathway. We conclude that PRGF's protective effect could prove useful as a new therapy for treating neurodegenerative disorders such as AMD.
C1 [Suarez-Barrio, Carlota; del Olmo-Aguado, Susana; Garcia-Perez, Eva; Baamonde-Arbaiza, Begona; Fernandez-Vega-Cueto, Luis; Fernandez-Vega, Luis; Merayo-Lloves, Jesus] Inst Univ Fernandez Vega, Fdn Invest Oftalmol, Oviedo 33012, Spain.
   [Suarez-Barrio, Carlota; del Olmo-Aguado, Susana; Garcia-Perez, Eva; Baamonde-Arbaiza, Begona; Fernandez-Vega-Cueto, Luis; Fernandez-Vega, Luis; Merayo-Lloves, Jesus] Univ Oviedo, Oviedo 33012, Spain.
   [Suarez-Barrio, Carlota; del Olmo-Aguado, Susana; Baamonde-Arbaiza, Begona; Fernandez-Vega-Cueto, Luis; Fernandez-Vega, Luis; Merayo-Lloves, Jesus] Inst Invest Sanit Principado Asturias, Ave Roma S-N, Oviedo 33011, Spain.
   [de la Fuente, Maria; Muruzabal, Francisco; Anitua, Eduardo] BTI Biotechnol Inst, Vitoria 01007, Spain.
   [de la Fuente, Maria; Muruzabal, Francisco; Anitua, Eduardo] Univ Inst Regenerat Med & Oral Implantol, UPV EHU, UIRMI, Fdn Eduardo Anitua, Vitoria 01007, Spain.
C3 University of Oviedo; Instituto de Investigacion Sanitaria del
   Principado de Asturias (ISPA); University of Basque Country
RP del Olmo-Aguado, S (通讯作者)，Inst Univ Fernandez Vega, Fdn Invest Oftalmol, Oviedo 33012, Spain.; del Olmo-Aguado, S (通讯作者)，Univ Oviedo, Oviedo 33012, Spain.; del Olmo-Aguado, S (通讯作者)，Inst Invest Sanit Principado Asturias, Ave Roma S-N, Oviedo 33011, Spain.
EM carlotasb.8@gmail.com; solmo@fio.as; evagp2002@gmail.com;
   maria.delafuente@bti-implant.es; francisco.muruzabal@bti-implant.es;
   dentalresearch@fundacioneduardoanitua.org; bbaamonde@yahoo.es;
   lfvc@fernandez-vega.com; prof.luis@fernandez-vega.com; merayo@fio.as
RI del Olmo Aguado, Susana/AAY-3497-2021; Merayo-Lloves,
   Jesús/ABG-8863-2020; Garcia, Eva/M-2382-2017; Anitua,
   Eduardo/O-1154-2018
OI del Olmo Aguado, Susana/0000-0002-2867-7254; Fernandez-Vega Cueto
   Felgueroso, Luis/0000-0001-9197-5847; Garcia, Eva/0000-0002-3594-9318;
   Anitua, Eduardo/0000-0002-8386-5303; Suarez Barrio,
   Carlota/0000-0003-0171-1851
FU "Accion Estrategica en Salud (AES)"Instituto de Salud Carlos III-of the
   Spanish Ministry of Economy and Competitiveness [PI17/01549]; European
   Union through the "Fondo Europeo de Desarrollo Regional (FEDER)"
FX This work was supported by the grant PI17/01549 from the "Accion
   Estrategica en Salud (AES)"Instituto de Salud Carlos III-of the Spanish
   Ministry of Economy and Competitiveness, and the European Union through
   the "Fondo Europeo de Desarrollo Regional (FEDER)".
CR Alaimo A, 2019, ARCH TOXICOL, V93, P1401, DOI 10.1007/s00204-019-02409-6
   Anitua E, 2012, KNEE SURG SPORT TR A, V20, P1657, DOI 10.1007/s00167-011-1697-4
   Anitua E, 2004, THROMB HAEMOSTASIS, V91, P4, DOI 10.1160/TH03-07-0440
   Anitua E, 2008, TRENDS PHARMACOL SCI, V29, P37, DOI 10.1016/j.tips.2007.10.010
   Anitua E, 2007, BIOMATERIALS, V28, P4551, DOI 10.1016/j.biomaterials.2007.06.037
   Argun M, 2014, EYE, V28, P752, DOI 10.1038/eye.2014.50
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Behar-Cohen F, 2011, PROG RETIN EYE RES, V30, P239, DOI 10.1016/j.preteyeres.2011.04.002
   Boulton M, 2001, EYE, V15, P384, DOI 10.1038/eye.2001.141
   Brown EE, 2019, REDOX BIOL, V24, DOI 10.1016/j.redox.2019.101201
   Datta S, 2017, PROG RETIN EYE RES, V60, P201, DOI 10.1016/j.preteyeres.2017.03.002
   del Olmo-Aguado S, 2016, NEUROCHEM RES, V41, P2324, DOI 10.1007/s11064-016-1946-5
   Detmer SA, 2007, NAT REV MOL CELL BIO, V8, P870, DOI 10.1038/nrm2275
   Drew VJ, 2018, FRONT MED-LAUSANNE, V5, DOI 10.3389/fmed.2018.00033
   El-Esawi M, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-13832-z
   Etxebarria J, 2017, ACTA OPHTHALMOL, V95, pe693, DOI 10.1111/aos.13371
   Fisher CR, 2018, INVEST OPHTH VIS SCI, V59, pAMD41, DOI 10.1167/iovs.18-24289
   Fleury C, 2002, BIOCHIMIE, V84, P131, DOI 10.1016/S0300-9084(02)01369-X
   Freire V, 2014, CORNEA, V33, P614, DOI 10.1097/ICO.0000000000000109
   Freire V, 2012, INVEST OPHTH VIS SCI, V53, P5571, DOI 10.1167/iovs.11-7340
   Gehrs KM, 2006, ANN MED, V38, P450, DOI 10.1080/07853890600946724
   Golestaneh N, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2016.453
   Haigler MC, 2018, J AM DENT ASSOC, V149, P940, DOI 10.1016/j.adaj.2018.07.025
   Hanus J, 2015, INVEST OPHTH VIS SCI, V56, P5048, DOI 10.1167/iovs.15-16401
   Holzman DC, 2010, ENVIRON HEALTH PERSP, V118, pA22, DOI 10.1289/ehp.118-a22
   Jaadane I, 2017, J CELL MOL MED, V21, P3453, DOI 10.1111/jcmm.13255
   Juan SH, 2005, BIOCHEM PHARMACOL, V69, P41, DOI 10.1016/j.bcp.2004.09.015
   Katsuragi Yoshinori, 2016, Current Opinion in Toxicology, V1, P54, DOI 10.1016/j.cotox.2016.09.005
   Kim CY, 2009, ARCH PHARM RES, V32, P869, DOI 10.1007/s12272-009-1609-z
   King A, 2004, PHOTOCHEM PHOTOBIOL, V79, P470, DOI 10.1562/LE-03-17.1
   Klein R, 2011, ARCH OPHTHALMOL-CHIC, V129, P75, DOI 10.1001/archophthalmol.2010.318
   Krigel A, 2016, NEUROSCIENCE, V339, P296, DOI 10.1016/j.neuroscience.2016.10.015
   Kumari A., 2018, SWEET BIOCH, P13, DOI 10.1016/B978-0-12-814453-4.00003-0
   la Cour M., 2005, ADV ORGAN BIOL, V10, P253, DOI [DOI 10.1016/S1569-2590(05)10009-3, 10.1016/S1569-2590(05)10009-3]
   Lee WH, 2014, ADV EXP MED BIOL, V801, P23, DOI 10.1007/978-1-4614-3209-8_4
   Lever JM, 2016, ANTIOXID REDOX SIGN, V25, P165, DOI 10.1089/ars.2016.6659
   Liang FQ, 2003, EXP EYE RES, V76, P397, DOI 10.1016/S0014-4835(03)00023-X
   Liu ZB, 2019, OXID MED CELL LONGEV, V2019, DOI 10.1155/2019/8948657
   Lockwood DB, 2005, DENT MATER, V21, P683, DOI 10.1016/j.dental.2004.07.022
   Lopez-Plandolit S, 2011, CORNEA, V30, P1312, DOI 10.1097/ICO.0b013e31820d86d6
   Lopez-Plandolit S, 2010, CORNEA, V29, P843, DOI 10.1097/ICO.0b013e3181a81820
   Lougheed T, 2014, ENVIRON HEALTH PERSP, V122, pA81, DOI 10.1289/ehp.122-A81
   Malone PE, 2007, EXP EYE RES, V84, P444, DOI 10.1016/j.exer.2006.10.020
   Moon J, 2017, INTEGR BIOL-UK, V9, P436, DOI 10.1039/c7ib00032d
   Moutray T, 2011, THER ADV CHRONIC DIS, V2, P325, DOI 10.1177/2040622311415895
   Nunez-Alvarez C, 2019, ACTA OPHTHALMOL, V97, pE103, DOI 10.1111/aos.13812
   Organisciak DT, 2010, PROG RETIN EYE RES, V29, P113, DOI 10.1016/j.preteyeres.2009.11.004
   Orrenius S, 2007, DRUG METAB REV, V39, P443, DOI 10.1080/03602530701468516
   Osborne NN, 2008, J NEUROCHEM, V105, P2013, DOI 10.1111/j.1471-4159.2008.05320.x
   Osborne NN, 2010, EXP EYE RES, V90, P750, DOI 10.1016/j.exer.2010.03.008
   Ott M, 2007, APOPTOSIS, V12, P913, DOI 10.1007/s10495-007-0756-2
   Roehlecke C, 2009, MOL VIS, V15, P1929
   Ryter SW, 2007, ANTIOXID REDOX SIGN, V9, P49, DOI 10.1089/ars.2007.9.49
   Sachdeva MM, 2014, EXP EYE RES, V119, P111, DOI 10.1016/j.exer.2013.10.024
   Sanchez-Avila RM, 2019, INT MED CASE REP J, V12, P229, DOI 10.2147/IMCRJ.S170329
   Shang YM, 2014, ENVIRON HEALTH PERSP, V122, P269, DOI 10.1289/ehp.1307294
   Suarez-Barrio C, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20071655
   Thoreson W.B., 2014, REFERENCE MODULE BIO
   Vu KT, 2017, EXP EYE RES, V164, P31, DOI 10.1016/j.exer.2017.08.001
   Youn HY, 2009, J PHOTOCH PHOTOBIO B, V95, P64, DOI 10.1016/j.jphotobiol.2009.01.001
   Zhu C, 2017, BIOMED PHARMACOTHER, V88, P124, DOI 10.1016/j.biopha.2016.11.089
   Zou X, 2012, J NUTR BIOCHEM, V23, P994, DOI 10.1016/j.jnutbio.2011.05.006
NR 62
TC 13
Z9 13
U1 0
U2 6
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1422-0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD FEB
PY 2020
VL 21
IS 3
AR 1021
DI 10.3390/ijms21031021
PG 17
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA KY4PQ
UT WOS:000522551606007
PM 32033116
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Ting, DSW
   Pasquale, LR
   Peng, L
   Campbell, JP
   Lee, AY
   Raman, R
   Tan, GSW
   Schmetterer, L
   Keane, PA
   Wong, TY
AF Ting, Daniel Shu Wei
   Pasquale, Louis R.
   Peng, Lily
   Campbell, John Peter
   Lee, Aaron Y.
   Raman, Rajiv
   Tan, Gavin Siew Wei
   Schmetterer, Leopold
   Keane, Pearse A.
   Wong, Tien Yin
TI Artificial intelligence and deep learning in ophthalmology
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Review
DE imaging; retina; glaucoma; telemedicine; public health
ID MAJOR RISK-FACTORS; DIABETIC-RETINOPATHY; MACULAR DEGENERATION; GLOBAL
   PREVALENCE; AUTOMATIC SEGMENTATION; INTRAOCULAR-PRESSURE; GLAUCOMA
   PROGRESSION; NEURAL-NETWORKS; RETINAL LAYER; PREMATURITY
AB Artificial intelligence (AI) based on deep learning (DL) has sparked tremendous global interest in recent years. DL has been widely adopted in image recognition, speech recognition and natural language processing, but is only beginning to impact on healthcare. In ophthalmology, DL has been applied to fundus photographs, optical coherence tomography and visual fields, achieving robust classification performance in the detection of diabetic retinopathy and retinopathy of prematurity, the glaucoma-like disc, macular oedema and age-related macular degeneration. DL in ocular imaging may be used in conjunction with telemedicine as a possible solution to screen, diagnose and monitor major eye diseases for patients in primary care and community settings. Nonetheless, there are also potential challenges with DL application in ophthalmology, including clinical and technical challenges, explainability of the algorithm results, medicolegal issues, and physician and patient acceptance of the AI 'black-box' algorithms. DL could potentially revolutionise how ophthalmology is practised in the future. This review provides a summary of the state-of-the-art DL systems described for ophthalmic applications, potential challenges in clinical deployment and the path forward.
C1 [Ting, Daniel Shu Wei; Tan, Gavin Siew Wei; Schmetterer, Leopold; Wong, Tien Yin] Natl Univ Singapore, Singapore Eye Res Inst, Singapore Natl Eye Ctr, Duke NUS Med Sch, Singapore, Singapore.
   [Pasquale, Louis R.] Mt Sinai Hosp, Dept Ophthalmol, New York, NY 10029 USA.
   [Peng, Lily] Google AI Healthcare, Mountain View, CA USA.
   [Campbell, John Peter] Oregon Hlth & Sci Univ, Casey Eye Inst, Portland, OR 97201 USA.
   [Lee, Aaron Y.] Univ Washington, Sch Med, Dept Ophthalmol, Seattle, WA 98195 USA.
   [Raman, Rajiv] Sankara Nethralaya, Vitreoretinal Dept, Chennai, Tamil Nadu, India.
   [Schmetterer, Leopold] Nanyang Technol Univ, Lee Kong Chian Sch Med, Dept Ophthalmol, Singapore, Singapore.
   [Schmetterer, Leopold] Med Univ Vienna, Dept Clin Pharmacol, Vienna, Austria.
   [Schmetterer, Leopold] Med Univ Vienna, Ctr Med Phys & Biomed Engn, Vienna, Austria.
   [Keane, Pearse A.] Moorfields Eye Hosp, Vitreoretinal Serv, London, England.
C3 National University of Singapore; Singapore National Eye Center; Icahn
   School of Medicine at Mount Sinai; Oregon Health & Science University;
   University of Washington; University of Washington Seattle; Nanyang
   Technological University & National Institute of Education (NIE)
   Singapore; Nanyang Technological University; Medical University of
   Vienna; Medical University of Vienna; University of London; University
   College London; Moorfields Eye Hospital NHS Foundation Trust
RP Ting, DSW (通讯作者)，Singapore Natl Eye Ctr, Duke NUS Med Sch, Ophthalmol, Singapore 168751, Singapore.
EM daniel.ting.s.w@singhealth.com.sg
RI Lee, Aaron/AAT-2839-2020; Keane, Pearse/AAE-5709-2019; Raman,
   Rajiv/A-7234-2009; Wong, Tien Yin/AAC-9724-2020
OI Keane, Pearse/0000-0002-9239-745X; Raman, Rajiv/0000-0001-5842-0233;
   Wong, Tien Yin/0000-0002-8448-1264; Schmetterer,
   Leopold/0000-0002-7189-1707; Ting, Daniel Shu Wei/0000-0003-2264-7174;
   Lee, Aaron/0000-0002-7452-1648; Bidwai, Pooja Vishal/0000-0002-3077-4395
FU National Medical Research Council (NMRC), Ministry of Health (MOH),
   Singapore National Health Innovation Center, Innovation to Develop Grant
   [NHIC-I2D-1409022]; SingHealth Foundation Research Grant
   [SHF/FG648S/2015]; Tanoto Foundation; Singapore Epidemiology of Eye
   Diseases; NMRC, MOH [0796/2003, IRG07nov013, IRG09nov014,
   STaR/0003/2008, STaR/2013, CG/SERI/2010]; Biomedical Research Council
   [08/1/35/19/550, 09/1/35/19/616]; Singapore Integrated Diabetic
   Retinopathy Programme (SiDRP); MOH, Singapore
   [AIC/RPDD/SIDRP/SERI/FY2013/0018, AIC/HPD/FY2016/0912]; National
   Institutes of Health [K12 EY027720, R01EY019474, P30EY10572,
   P41EB015896]; National Science Foundation [SCH-1622542, SCH-1622536,
   SCH-1622679]; Research to Prevent Blindness; UK National Institute for
   Health Research (NIHR) Clinician Scientist Award [NIHR-CS--2014-12-023];
   NATIONAL EYE INSTITUTE [P30EY010572, K12EY027720, R01EY019474] Funding
   Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND
   BIOENGINEERING [P41EB015896] Funding Source: NIH RePORTER
FX This project received funding from the National Medical Research Council
   (NMRC), Ministry of Health (MOH), Singapore National Health Innovation
   Center, Innovation to Develop Grant (NHIC-I2D-1409022), SingHealth
   Foundation Research Grant (SHF/FG648S/2015), and the Tanoto Foundation,
   and unrestricted donations to the Retina Division, Johns Hopkins
   University School of Medicine. For the Singapore Epidemiology of Eye
   Diseases (SEED) study, we received funding from NMRC, MOH (grants
   0796/2003, IRG07nov013, IRG09nov014, STaR/0003/2008 and STaR/2013;
   CG/SERI/2010) and Biomedical Research Council (grants 08/1/35/19/550 and
   09/1/35/19/616). The Singapore Integrated Diabetic Retinopathy Programme
   (SiDRP) received funding from the MOH, Singapore (grants
   AIC/RPDD/SIDRP/SERI/FY2013/0018 and AIC/HPD/FY2016/0912). In USA, it is
   supported by the National Institutes of Health (K12 EY027720,
   R01EY019474, P30EY10572, P41EB015896), by the National Science
   Foundation (SCH-1622542, SCH-1622536, SCH-1622679) and by unrestricted
   departmental funding from Research to Prevent Blindness. PAK is
   supported by a UK National Institute for Health Research (NIHR)
   Clinician Scientist Award (NIHR-CS--2014-12-023). The views expressed
   are those of the authors and not necessarily those of the NHS, the NIHR
   or the Department of Health.
CR Abramoff MD, 2018, NPJ DIGIT MED, V1, DOI 10.1038/s41746-018-0040-6
   Abramoff MD, 2016, INVEST OPHTH VIS SCI, V57, P5200, DOI 10.1167/iovs.16-19964
   [Anonymous], 2018, OCT ROLLOUT EVERY SP
   Bejnordi BE, 2017, JAMA-J AM MED ASSOC, V318, P2199, DOI 10.1001/jama.2017.14585
   Blencowe Hannah, 2016, Indian Pediatr, V53 Suppl 2, pS89
   Brown JM, 2018, PROC SPIE, V10579, DOI 10.1117/12.2295942
   Brown JM, 2018, JAMA OPHTHALMOL, V136, P803, DOI 10.1001/jamaophthalmol.2018.1934
   Buchan JC, 2017, EYE, V31, P1519, DOI 10.1038/eye.2017.114
   Burlina PM, 2017, JAMA OPHTHALMOL, V135, P1170, DOI 10.1001/jamaophthalmol.2017.3782
   Campbell J Peter, 2015, AMIA Annu Symp Proc, V2015, P366
   Centers for Medicare & Medicaid Services, 2018, CMS MED PROV UT PAYM
   Chen M, 2017, LECT NOTES COMPUT SC, V10554, P177, DOI 10.1007/978-3-319-67561-9_20
   Chew EY, 2015, JAMA-J AM MED ASSOC, V314, P791, DOI 10.1001/jama.2015.9677
   Christopher M, 2018, INVEST OPHTH VIS SCI, V59, P2748, DOI 10.1167/iovs.17-23387
   Daniel E, 2015, JAMA OPHTHALMOL, V133, P675, DOI 10.1001/jamaophthalmol.2015.0460
   De Fauw J, 2018, NAT MED, V24, P1342, DOI 10.1038/s41591-018-0107-6
   Elsas FJ, 2001, ARCH OPHTHALMOL-CHIC, V119, P1110
   Elze T, 2015, J R SOC INTERFACE, V12, DOI 10.1098/rsif.2014.1118
   Esteva A, 2017, NATURE, V542, P115, DOI 10.1038/nature21056
   Fang LY, 2017, BIOMED OPT EXPRESS, V8, P2732, DOI 10.1364/BOE.8.002732
   Fleck BW, 2018, EYE, V32, P74, DOI 10.1038/eye.2017.150
   Gargeya R, 2017, OPHTHALMOLOGY, V124, P962, DOI 10.1016/j.ophtha.2017.02.008
   Gilbert C, 1997, LANCET, V350, P12, DOI 10.1016/S0140-6736(97)01107-0
   Grassmann F, 2018, OPHTHALMOLOGY, V125, P1410, DOI 10.1016/j.ophtha.2018.02.037
   Gulshan V, 2016, JAMA-J AM MED ASSOC, V316, P2402, DOI 10.1001/jama.2016.17216
   Hamwood J, 2018, BIOMED OPT EXPRESS, V9, P3049, DOI 10.1364/BOE.9.003049
   Heijl A, 2002, ARCH OPHTHALMOL-CHIC, V120, P1268, DOI 10.1001/archopht.120.10.1268
   Hinton G, 2012, IEEE SIGNAL PROC MAG, V29, P82, DOI 10.1109/MSP.2012.2205597
   Hutchinson A, 2000, DIABETIC MED, V17, P495, DOI 10.1046/j.1464-5491.2000.00250.x
   JONAS JB, 1988, GRAEF ARCH CLIN EXP, V226, P213, DOI 10.1007/BF02181183
   Kass MA, 2002, ARCH OPHTHALMOL-CHIC, V120, P701
   Kazemian P, 2018, OPHTHALMOLOGY, V125, P569, DOI 10.1016/j.ophtha.2017.10.033
   Keel S, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-22612-2
   Kermany DS, 2018, CELL, V172, P1122, DOI 10.1016/j.cell.2018.02.010
   Krause J, 2018, OPHTHALMOLOGY, V125, P1264, DOI 10.1016/j.ophtha.2018.01.034
   Lakhani P, 2017, RADIOLOGY, V284, P574, DOI 10.1148/radiol.2017162326
   Lam C, 2018, INVEST OPHTH VIS SCI, V59, P590, DOI 10.1167/iovs.17-22721
   LeCun Y, 2015, NATURE, V521, P436, DOI 10.1038/nature14539
   Lee CS, 2017, OPHTHALMOL RETINA, V1, P322, DOI 10.1016/j.oret.2016.12.009
   Lee CS, 2017, BIOMED OPT EXPRESS, V8, P3440, DOI 10.1364/BOE.8.003440
   Li ZX, 2018, OPHTHALMOLOGY, V125, P1199, DOI 10.1016/j.ophtha.2018.01.023
   LICHTER PR, 2001, OPHTHALMOLOGY, V108, P1943, DOI [DOI 10.1016/S0161-6420(01)00873-9, 10.1016/S0161-6420(01)00873-9]
   Murray RB, 2005, MED J AUSTRALIA, V182, P520, DOI 10.5694/j.1326-5377.2005.tb00018.x
   Poplin R, 2018, NAT BIOMED ENG, V2, P158, DOI 10.1038/s41551-018-0195-0
   Prentasic P, 2016, J BIOMED OPT, V21, DOI 10.1117/1.JBO.21.7.075008
   Quellec G, 2017, MED IMAGE ANAL, V39, P178, DOI 10.1016/j.media.2017.04.012
   Ramanishka V, 2016, TOP DOWN VISUAL SALI
   ROBINSON R, 1992, BRIT J OPHTHALMOL, V76, P289, DOI 10.1136/bjo.76.5.289
   Ronneberger O, 2015, LECT NOTES COMPUT SC, V9351, P234, DOI 10.1007/978-3-319-24574-4_28
   Roy AG, 2017, BIOMED OPT EXPRESS, V8, P3627, DOI 10.1364/BOE.8.003627
   Scanlon PH, 2003, BRIT J OPHTHALMOL, V87, P1258, DOI 10.1136/bjo.87.10.1258
   Schulzer M, 1998, AM J OPHTHALMOL, V126, P487
   Shin HC, 2016, IEEE T MED IMAGING, V35, P1285, DOI 10.1109/TMI.2016.2528162
   Tanna AP, 2011, OPHTHALMOLOGY, V118, P60, DOI 10.1016/j.ophtha.2010.04.038
   Tham Yih-Chung, 2014, Ophthalmology, V121, P2081, DOI 10.1016/j.ophtha.2014.05.013
   Ting DSW, 2018, NAT MED, V24, P539, DOI 10.1038/s41591-018-0029-3
   Ting DSW, 2018, RADIOLOGY, V286, P729, DOI 10.1148/radiol.2017172407
   Ting DSW, 2011, OPHTHALMOLOGY, V118, P1588, DOI 10.1016/j.ophtha.2011.04.009
   Ting DSW, 2017, JAMA-J AM MED ASSOC, V318, P2211, DOI 10.1001/jama.2017.18152
   Ting DSW, 2016, CLIN EXP OPHTHALMOL, V44, P260, DOI 10.1111/ceo.12696
   Tompson J.J., 2014, ADV NEURAL INF PROCE, V27, P1799, DOI DOI 10.5555/2968826.2969027
   Treder M, 2018, GRAEF ARCH CLIN EXP, V256, P259, DOI 10.1007/s00417-017-3850-3
   Varadarajan AV, 2018, INVEST OPHTH VIS SCI, V59, P2861, DOI 10.1167/iovs.18-23887
   Venhuizen FG, 2018, BIOMED OPT EXPRESS, V9, P1545, DOI 10.1364/BOE.9.001545
   Viswanathan AC, 2003, BRIT J OPHTHALMOL, V87, P726, DOI 10.1136/bjo.87.6.726
   Wang MY, 2018, OPHTHALMOLOGY, V125, P352, DOI 10.1016/j.ophtha.2017.09.021
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   World Economic Forum, 2016, 4 IND REV WHAT IT ME
   Worrall D, 2016, AUTOMATED RETINOPATH
   Yau JWY, 2012, DIABETES CARE, V35, P556, DOI 10.2337/dc11-1909
   Yousefi S, 2018, AM J OPHTHALMOL, V193, P71, DOI 10.1016/j.ajo.2018.06.007
   Zhang XY, 2016, IEEE T PATTERN ANAL, V38, P1943, DOI 10.1109/TPAMI.2015.2502579
NR 72
TC 363
Z9 374
U1 39
U2 323
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD FEB
PY 2019
VL 103
IS 2
BP 167
EP 175
DI 10.1136/bjophthalmol-2018-313173
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA HL8YJ
UT WOS:000459028400003
PM 30361278
OA Green Published, hybrid
HC Y
HP N
DA 2022-11-30
ER

PT J
AU Barben, M
   Ail, D
   Storti, F
   Klee, K
   Schori, C
   Samardzija, M
   Michalakis, S
   Biel, M
   Meneau, I
   Blaser, F
   Barthelmes, D
   Grimm, C
AF Barben, Maya
   Ail, Divya
   Storti, Federica
   Klee, Katrin
   Schori, Christian
   Samardzija, Marijana
   Michalakis, Stylianos
   Biel, Martin
   Meneau, Isabelle
   Blaser, Frank
   Barthelmes, Daniel
   Grimm, Christian
TI Hif1a inactivation rescues photoreceptor degeneration induced by a
   chronic hypoxia-like stress
SO CELL DEATH AND DIFFERENTIATION
LA English
DT Article
ID CHOROIDAL BLOOD-FLOW; MACULAR DEGENERATION; INDUCIBLE FACTOR-1-ALPHA;
   PROTECTS PHOTORECEPTORS; RETINAL DEGENERATION; AGE; PATHOGENESIS;
   ACTIVATION; EXPRESSION; ERYTHROPOIETIN
AB Reduced choroidal blood flow and tissue changes in the ageing human eye impair oxygen delivery to photoreceptors and the retinal pigment epithelium. As a consequence, mild but chronic hypoxia may develop and disturb cell metabolism, function and ultimately survival, potentially contributing to retinal pathologies such as age-related macular degeneration (AMD). Here, we show that several hypoxia-inducible genes were expressed at higher levels in the aged human retina suggesting increased activity of hypoxia-inducible transcription factors (HIFs) during the physiological ageing process. To model chronically elevated HIF activity and investigate ensuing consequences for photoreceptors, we generated mice lacking von Hippel Lindau (VHL) protein in rods. This activated HIF transcription factors and led to a slowly progressing retinal degeneration in the ageing mouse retina. Importantly, this process depended mainly on HIF1 with only a minor contribution of HIF2. A gene therapy approach using AAV-mediated RNA interference through an anti-Hif1a shRNA significantly mitigated the degeneration suggesting a potential intervention strategy that may be applicable to human patients.
C1 [Barben, Maya; Ail, Divya; Storti, Federica; Klee, Katrin; Schori, Christian; Samardzija, Marijana; Grimm, Christian] Univ Zurich, Dept Ophthalmol, Lab Retinal Cell Biol, Zurich, Switzerland.
   [Barben, Maya; Grimm, Christian] Univ Zurich, Neurosci Ctr Zurich ZNZ, Zurich, Switzerland.
   [Klee, Katrin; Schori, Christian; Grimm, Christian] Univ Zurich, Ctr Integrat Human Physiol ZIHP, Zurich, Switzerland.
   [Michalakis, Stylianos; Biel, Martin] Ludwig Maximilians Univ Munchen, Munich Ctr Integrated Prot Sci, Dept Pharm, Ctr Drug Res, Munich, Germany.
   [Meneau, Isabelle; Blaser, Frank; Barthelmes, Daniel] Univ Hosp Zurich, Dept Ophthalmol, Zurich, Switzerland.
   [Barthelmes, Daniel] Univ Sydney, Save Sight Inst, Sydney, NSW, Australia.
   [Ail, Divya] Univ Paris Saclay, Univ Paris Sud, Paris Saclay Inst Neurosci, CNRS, Orsay, France.
C3 University of Zurich; University of Zurich; University of Zurich; Zurich
   Center Integrative Human Physiology (ZIHP); University of Munich;
   University of Zurich; University Zurich Hospital; University of Sydney;
   Centre National de la Recherche Scientifique (CNRS); UDICE-French
   Research Universities; Universite Paris Saclay
RP Grimm, C (通讯作者)，Univ Zurich, Dept Ophthalmol, Lab Retinal Cell Biol, Zurich, Switzerland.; Grimm, C (通讯作者)，Univ Zurich, Neurosci Ctr Zurich ZNZ, Zurich, Switzerland.; Grimm, C (通讯作者)，Univ Zurich, Ctr Integrat Human Physiol ZIHP, Zurich, Switzerland.
EM cgrimm@opht.uzh.ch
RI Ail, Divya/AAB-7567-2022; Samardzija, Marijana/B-9245-2008; Biel,
   Martin/G-1175-2014; Michalakis, Stylianos/W-2094-2018; Michalakis,
   Stylianos/M-4677-2019
OI Ail, Divya/0000-0002-9122-5998; Samardzija,
   Marijana/0000-0003-0991-4653; Biel, Martin/0000-0002-9974-3052;
   Michalakis, Stylianos/0000-0001-5092-9238; Michalakis,
   Stylianos/0000-0001-5092-9238; Grimm, Christian/0000-0001-9318-4352
FU Swiss National Science Foundation (SNF) [31003A_133043, 31003A_173008]
FX The authors thank Andrea Gubler, Cornelia Imsand, and Sarah Notzli for
   excellent technical support, Prof. Ian Frew (University Medical Center
   Freiburg, Germany) for advice on the Hif1a siRNA sequence and Prof.
   Roland Wenger (University of Zurich, Switzerland) for providing
   lentiviral vectors. Supported by the Swiss National Science Foundation
   (SNF #31003A_133043 and 31003A_173008).
CR Arjamaa O, 2009, AGEING RES REV, V8, P349, DOI 10.1016/j.arr.2009.06.002
   Becirovic E, 2016, FRONT NEUROSCI-SWITZ, V10, DOI 10.3389/fnins.2016.00356
   Berenberg TL, 2012, RETINA-J RET VIT DIS, V32, P25, DOI 10.1097/IAE.0b013e3182150483
   Burgi S, 2009, MOL VIS, V15, P1631
   Campochiaro PA, 2015, PROG RETIN EYE RES, V49, P67, DOI 10.1016/j.preteyeres.2015.06.002
   Caprara C, 2012, PROG RETIN EYE RES, V31, P89, DOI 10.1016/j.preteyeres.2011.11.003
   Caprara C, 2011, INVEST OPHTH VIS SCI, V52, P2109, DOI 10.1167/iovs.10-6222
   Ciulla TA, 1999, AM J OPHTHALMOL, V128, P75, DOI 10.1016/S0002-9394(99)00061-6
   Coleman DJ, 2013, BRIT J OPHTHALMOL, V97, P1020, DOI 10.1136/bjophthalmol-2013-303143
   Curcio CA, 1996, INVEST OPHTH VIS SCI, V37, P1236
   Dallinger S, 1998, J AM GERIATR SOC, V46, P484, DOI 10.1111/j.1532-5415.1998.tb02471.x
   Danciger M, 2000, MAMM GENOME, V11, P422, DOI 10.1007/s003350010081
   Feigl B, 2009, PROG RETIN EYE RES, V28, P63, DOI 10.1016/j.preteyeres.2008.11.004
   Geiger P, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.333
   Gordon EA, 2013, CELL SIGNAL, V25, P2518, DOI 10.1016/j.cellsig.2013.08.004
   Grimm C, 2002, NAT MED, V8, P718, DOI 10.1038/nm723
   Gruber M, 2007, P NATL ACAD SCI USA, V104, P2301, DOI 10.1073/pnas.0608382104
   Grunwald JE, 2005, INVEST OPHTH VIS SCI, V46, P1033, DOI 10.1167/iovs.04-1050
   Guo K, 2001, CELL DEATH DIFFER, V8, P367, DOI 10.1038/sj.cdd.4400810
   Haase VH, 2001, P NATL ACAD SCI USA, V98, P1583, DOI 10.1073/pnas.98.4.1583
   Heynen SR, 2011, MOL VIS, V17, P2934
   Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796
   Joly S, 2008, J NEUROSCI, V28, P13765, DOI 10.1523/JNEUROSCI.5114-08.2008
   Jung JE, 2008, EXP MOL MED, V40, P479, DOI 10.3858/emm.2008.40.5.479
   Kast B, 2016, EXP EYE RES, V146, P60, DOI 10.1016/j.exer.2015.12.008
   Kent DL, 2014, MOL VIS, V20, P46
   Klobucar M, 2016, BBA-MOL BASIS DIS, V1862, P1938, DOI 10.1016/j.bbadis.2016.07.014
   Kurihara T, 2016, ELIFE, V5, DOI 10.7554/eLife.14319
   Kurihara T, 2010, DEVELOPMENT, V137, P1563, DOI 10.1242/dev.049015
   Lam AKC, 2003, OPTOMETRY VISION SCI, V80, P305, DOI 10.1097/00006324-200304000-00008
   Lange C, 2011, INVEST OPHTH VIS SCI, V52, P5872, DOI 10.1167/iovs.11-7204
   Lange C, 2011, NEUROBIOL DIS, V41, P119, DOI 10.1016/j.nbd.2010.08.028
   Le YZ, 2006, MOL VIS, V12, P389
   Lewin AS, 1998, NAT MED, V4, P967, DOI 10.1038/nm0898-967
   Lin MK, 2012, INVEST OPHTH VIS SCI, V53, P6197, DOI 10.1167/iovs.11-8936
   Loboda A, 2010, MOL CELLS, V29, P435, DOI 10.1007/s10059-010-0067-2
   Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459
   Miao EA, 2011, IMMUNOL REV, V243, P206, DOI 10.1111/j.1600-065X.2011.01044.x
   Oczos J, 2014, INVEST OPHTH VIS SCI, V55, P4714, DOI 10.1167/iovs.14-14332
   Okawa H, 2008, CURR BIOL, V18, P1917, DOI 10.1016/j.cub.2008.10.029
   Pawlus MR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072358
   Ryan HE, 2000, CANCER RES, V60, P4010
   Samardzija M, 2006, FASEB J, V20, P2411, DOI 10.1096/fj.06-5895fje
   Samardzija M, 2006, INVEST OPHTH VIS SCI, V47, P5181, DOI 10.1167/iovs.06-0556
   Semenza GL, 2012, TRENDS MOL MED, V18, P534, DOI 10.1016/j.molmed.2012.08.001
   Shelby SJ, 2015, EXP EYE RES, V137, P84, DOI 10.1016/j.exer.2015.06.016
   Simo R, 2014, DIABETES CARE, V37, P893, DOI 10.2337/dc13-2002
   Sparrow JR, 2015, INVEST OPHTH VIS SCI, V56, P5029, DOI 10.1167/iovs.15-16763
   Stefansson E, 2011, PROG RETIN EYE RES, V30, P72, DOI 10.1016/j.preteyeres.2010.09.003
   Sun Q, 2016, J LEUKOCYTE BIOL, V100, P961, DOI 10.1189/jlb.3MR0516-224R
   Thiersch M, 2009, EUR J NEUROSCI, V29, P2291, DOI 10.1111/j.1460-9568.2009.06781.x
   Thiersch M, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-73
   Webb JD, 2009, CELL MOL LIFE SCI, V66, P3539, DOI 10.1007/s00018-009-0147-7
   Yokogami K, 2013, BRAIN TUMOR PATHOL, V30, P135, DOI 10.1007/s10014-012-0122-0
NR 54
TC 23
Z9 23
U1 0
U2 2
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1350-9047
EI 1476-5403
J9 CELL DEATH DIFFER
JI Cell Death Differ.
PD DEC
PY 2018
VL 25
IS 12
BP 2071
EP 2085
DI 10.1038/s41418-018-0094-7
PG 15
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA HB9TR
UT WOS:000451436300002
PM 29666476
OA Green Published, hybrid, Green Accepted
DA 2022-11-30
ER

PT J
AU Sallehudin, NJ
   Raus, RA
   Mustapa, M
   Othman, R
   Mel, M
AF Sallehudin, N. J.
   Raus, R. A.
   Mustapa, M.
   Othman, R.
   Mel, M.
TI Screening of lutein content in several fresh-water microalgae
SO INTERNATIONAL FOOD RESEARCH JOURNAL
LA English
DT Article
DE Freshwater microalgae; Chlorophycean microalgae; Chlorella; Scenedesmus;
   Ankistrodesmus; Desmodesmus; Growth rate; Lutein
ID TAGETES-ERECTA L.; MACULAR PIGMENT; CELL-SIZE; BIOMASS; FRUITS
AB Lutein is the most abundant xanthophylls in the photosynthetic organisms and its dietary intake is thought to protect against the development of age-related macular degeneration. Microalgae are predicted to be the major contributors of lutein in the future and to date, various species of microalgae has been analyzed for its lutein content. This study examined the lutein content of six chlorophycean microalgae species grown in the laboratory culture under the comparable environmental condition in which the population doubling time (t(d)) as well as the maximum growth rate (mu(max)) for each species was evaluated. Using batch culture operation grown under the heteroautotrophic condition, Scenedesmus dimorphus was observed to accumulate the highest lutein content (60.11 mg/g) with maximal biomass of 0.349 g/L culture. Based on the observations available, it appears that strains of unicellular microalgae of smaller size have appreciably higher intrinsic growth rates than algae of the larger size (Chlorella sp. B > Chlorella sp. TLL > Scenedesmus dimorphus > Scenedesmus obliquus TLL > Desmodesmus sp. TH > Ankistrodesmus sp. TH). (C) All Rights Reserved
C1 [Sallehudin, N. J.; Raus, R. A.; Mustapa, M.; Mel, M.] Int Islamic Univ Malaysia, Dept Biotechnol Engn, Kulliyyah Engn, Kuala Lumpur 50728, Malaysia.
   [Othman, R.] Int Islamic Univ Malaysia, Dept Landscape Architecture, Kulliyyah Architecture & Environm Design, Kuala Lumpur 50728, Malaysia.
C3 International Islamic University Malaysia; International Islamic
   University Malaysia
RP Raus, RA (通讯作者)，Int Islamic Univ Malaysia, Dept Biotechnol Engn, Kulliyyah Engn, Kuala Lumpur 50728, Malaysia.
EM rahaar@iium.edu.my
RI Mel, Maizirwan/W-6765-2019
FU RACE under the Ministry of Higher Education, Malaysia [14-005-0011];
   Biotechnology Engineering Department, Kulliyyah of Engineering,
   International Islamic University Malaysia, Gombak; Faculty of Pharmacy,
   University Teknologi MARA (UiTM) Puncak Alam Campus; Forest Research
   Institute Malaysia (FRIM)
FX This research is supported by RACE 14-005-0011 under the Ministry of
   Higher Education, Malaysia and by the Biotechnology Engineering
   Department, Kulliyyah of Engineering, International Islamic University
   Malaysia, Gombak. The utility for freeze dryer machine was supported by
   Faculty of Pharmacy, University Teknologi MARA (UiTM) Puncak Alam Campus
   and also by Forest Research Institute Malaysia (FRIM).
CR AGUSTI S, 1987, LIMNOL OCEANOGR, V32, P983, DOI 10.4319/lo.1987.32.4.0983
   Breithaupt DE, 2002, J AGR FOOD CHEM, V50, P66, DOI 10.1021/jf010970l
   Ceron MC, 2008, J AGR FOOD CHEM, V56, P11761, DOI 10.1021/jf8025875
   Chan MC, 2013, BIOCHEM ENG J, V78, P24, DOI 10.1016/j.bej.2012.11.017
   Chue KT, 2012, CHEM NAT COMPD+, V48, P141, DOI 10.1007/s10600-012-0183-7
   Cordero BF, 2011, MAR DRUGS, V9, P1607, DOI 10.3390/md9091607
   Dall'Osto L, 2006, BMC PLANT BIOL, V6, DOI 10.1186/1471-2229-6-32
   Del Campo JA, 2004, APPL MICROBIOL BIOT, V64, P848, DOI 10.1007/s00253-003-1510-5
   Kubola J, 2011, FOOD CHEM, V127, P1138, DOI 10.1016/j.foodchem.2011.01.115
   Landrum JT, 1997, EXP EYE RES, V65, P57, DOI 10.1006/exer.1997.0309
   Lopez-Sandoval DC, 2014, J EXP MAR BIOL ECOL, V457, P151, DOI 10.1016/j.jembe.2014.04.013
   MARAIS J, 1991, South African Journal for Enology and Viticulture, V12, P64
   Molina E, 2005, 10 INT C APPL PHYC K
   Monma M., 2014, BIOSCIENCE BIOTECHNO, V58, P926
   MUNK WH, 1952, J MAR RES, V11, P215
   Mustapa M., 2016, ARPN J ENG APPL SCI, V11, P104
   Nielsen SL, 2006, J PLANKTON RES, V28, P489, DOI 10.1093/plankt/fbi134
   Othman R., 1991, THESIS
   Sivel M, 2014, CZECH J FOOD SCI, V32, P521, DOI 10.17221/104/2014-CJFS
   Sommerburg O, 1998, BRIT J OPHTHALMOL, V82, P907, DOI 10.1136/bjo.82.8.907
   Straskraba M., 1976, DEV ANAL PHYTOPLANKT, P33
   VENKATAKRISHNA S, 1977, TEA QUART, V47, P28
NR 22
TC 0
Z9 0
U1 0
U2 3
PU UNIV PUTRA MALAYSIA PRESS
PI SELANGOR
PA SERDANG, SELANGOR, 00000, MALAYSIA
SN 1985-4668
EI 2231-7546
J9 INT FOOD RES J
JI Int. Food Res. J.
PD DEC
PY 2018
VL 25
IS 6
BP 2307
EP 2312
PG 6
WC Food Science & Technology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Food Science & Technology
GA HF9UA
UT WOS:000454586900011
DA 2022-11-30
ER

PT J
AU Palczewska, G
   Maeda, A
   Golczak, M
   Arai, E
   Dong, ZQ
   Perusek, L
   Kevany, B
   Palczewski, K
AF Palczewska, Grazyna
   Maeda, Akiko
   Golczak, Marcin
   Arai, Eisuke
   Dong, Zhiqian
   Perusek, Lindsay
   Kevany, Brian
   Palczewski, Krzysztof
TI Receptor MER Tyrosine Kinase Proto-oncogene (MERTK) Is Not Required for
   Transfer of Bis-retinoids to the Retinal Pigmented Epithelium
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID LEBER CONGENITAL AMAUROSIS; ROD OUTER SEGMENTS; VISUAL CYCLE; RCS RAT;
   MOUSE MODEL; FUNDUS AUTOFLUORESCENCE; ADIPONECTIN RECEPTORS; MACULAR
   DEGENERATION; DYSTROPHY PHENOTYPE; BINDING PROTEIN
AB Accumulation of bis-retinoids in the retinal pigmented epithelium (RPE) is a hallmark of aging and retinal disorders such as Stargardt disease and age-related macular degeneration. These aberrant fluorescent condensation products, including di-retinoid-pyridinium-ethanolamine (A2E), are thought to be transferred to RPE cells primarily through phagocytosis of the photoreceptor outer segments. However, we observed by two-photon microscopy that mouse retinas incapable of phagocytosis due to a deficiency of the c-Mer proto-oncogene tyrosine kinase (Mertk) nonetheless contained fluorescent retinoid condensation material in their RPE. Primary RPE cells from Mertk(-/-) mice also accumulated fluorescent products in vitro. Finally, quantification of A2E demonstrated the acquisition of retinal condensation products in Mertk(-/-) mouse RPE prior to retinal degeneration. In these mice, we identified activated microglial cells that likely were recruited to transport A2E-like condensation products to the RPE and dispose of the dying photoreceptor cells. These observations demonstrate a novel transport mechanism between photoreceptor cells and RPE that does not involve canonical Mertk-dependent phagocytosis.
C1 [Palczewska, Grazyna; Dong, Zhiqian] Polgenix Inc, Cleveland, OH USA.
   [Maeda, Akiko; Arai, Eisuke; Perusek, Lindsay] Case Western Reserve Univ, Sch Med, Dept Ophthalmol & Visual Sci, Cleveland, OH 44106 USA.
   [Golczak, Marcin; Kevany, Brian; Palczewski, Krzysztof] Case Western Reserve Univ, Sch Med, Dept Pharmacol, 10900 Euclid Ave, Cleveland, OH 44106 USA.
   [Golczak, Marcin; Kevany, Brian; Palczewski, Krzysztof] Case Western Reserve Univ, Sch Med, Cleveland Ctr Membrane & Struct Biol, Cleveland, OH 44106 USA.
C3 Case Western Reserve University; Case Western Reserve University; Case
   Western Reserve University
RP Maeda, A (通讯作者)，Case Western Reserve Univ, Sch Med, Dept Ophthalmol & Visual Sci, Cleveland, OH 44106 USA.; Palczewski, K (通讯作者)，Case Western Reserve Univ, Sch Med, Dept Pharmacol, 10900 Euclid Ave, Cleveland, OH 44106 USA.
EM aam19@case.edu; kxp65@case.edu
OI DONG, ZHIQIAN/0000-0002-8748-4532
FU National Institutes of Health [EY022326, U01 EY025451, R24 EY024864,
   EY022658, EY023948]; VSRC CORE Grant [P30 EY011373]; Arnold and Mabel
   Beckman Foundation; Foundation Fighting Blindness; NATIONAL EYE
   INSTITUTE [R01EY022658, R01EY023948, R01EY022326, R24EY024864,
   P30EY011373, U01EY025451] Funding Source: NIH RePORTER
FX This work was supported in part by National Institutes of Health Grants
   EY022326, U01 EY025451, and R24 EY024864 (to K. P.), EY022658 (to A.
   M.), and EY023948 (to M. G.), VSRC CORE Grant P30 EY011373, the Arnold
   and Mabel Beckman Foundation, and the Foundation Fighting Blindness. The
   authors declare that they have no conflicts of interest with the
   contents of this article. The content is solely the responsibility of
   the authors and does not necessarily represent the official views of the
   National Institutes of Health.
CR Batten ML, 2005, PLOS MED, V2, P1177, DOI 10.1371/journal.pmed.0020333
   Ben-Shabat S, 2002, J BIOL CHEM, V277, P7183, DOI 10.1074/jbc.M108981200
   BOK D, 1993, J CELL SCI, P189
   Bruban J, 2011, NEUROBIOL DIS, V42, P55, DOI 10.1016/j.nbd.2011.01.004
   CHAITIN MH, 1983, INVEST OPHTH VIS SCI, V24, P812
   D'Cruz PM, 2000, HUM MOL GENET, V9, P645, DOI 10.1093/hmg/9.4.645
   Delori FC, 2001, INVEST OPHTH VIS SCI, V42, P1855
   Duncan JL, 2003, INVEST OPHTH VIS SCI, V44, P826, DOI 10.1167/iovs.02-0438
   EDWARDS RB, 1977, SCIENCE, V197, P1001, DOI 10.1126/science.560718
   Fujioka H, 2014, ULTRASTRUCT PATHOL, V38, P204, DOI 10.3109/01913123.2014.888114
   Gal A, 2000, NAT GENET, V26, P270, DOI 10.1038/81555
   Gliem M, 2016, JAMA OPHTHALMOL, V134, P817, DOI 10.1001/jamaophthalmol.2016.1475
   Golczak M, 2010, J BIOL CHEM, V285, P9667, DOI 10.1074/jbc.M109.063941
   Holz FG, 2007, AM J OPHTHALMOL, V143, P463, DOI 10.1016/j.ajo.2006.11.041
   Hu SJ, 2015, J NEUROSCI, V35, P6987, DOI 10.1523/JNEUROSCI.3955-14.2015
   Imanishi Y, 2004, J CELL BIOL, V166, P447, DOI 10.1083/jcb.200405110
   Imanishi Y, 2004, J CELL BIOL, V164, P373, DOI 10.1083/jcb.200311079
   Johnson AC, 2008, J BIOL CHEM, V283, P3988, DOI 10.1074/jbc.M707264200
   Katz ML, 2001, INVEST OPHTH VIS SCI, V42, P3023
   Kevany BM, 2010, PHYSIOLOGY, V25, P8, DOI 10.1152/physiol.00038.2009
   Kim SR, 2006, EXP EYE RES, V82, P828, DOI 10.1016/j.exer.2005.10.004
   Kiser PD, 2014, CHEM REV, V114, P194, DOI 10.1021/cr400107q
   Kohno H, 2013, J BIOL CHEM, V288, P15326, DOI 10.1074/jbc.M112.448712
   LaVail MM, 2016, ADV EXP MED BIOL, V854, P487, DOI 10.1007/978-3-319-17121-0_65
   Lemke G, 2008, NAT REV IMMUNOL, V8, P327, DOI 10.1038/nri2303
   Liang Y, 2003, J BIOL CHEM, V278, P21655, DOI 10.1074/jbc.M302536200
   Lu QX, 1999, NATURE, V398, P723, DOI 10.1038/19554
   Ma WX, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007945
   Maeda A, 2005, J BIOL CHEM, V280, P18822, DOI 10.1074/jbc.M501757200
   Maeda A, 2008, J BIOL CHEM, V283, P26684, DOI 10.1074/jbc.M804505200
   Maeda A, 2014, P NATL ACAD SCI USA, V111, pE1428, DOI 10.1073/pnas.1317986111
   McBee JK, 2001, PROG RETIN EYE RES, V20, P469, DOI 10.1016/S1350-9462(01)00002-7
   Medzhitov R, 2008, NATURE, V454, P428, DOI 10.1038/nature07201
   Molday RS, 2015, PROG MOL BIOL TRANSL, V134, P415, DOI 10.1016/bs.pmbts.2015.06.008
   Mortazavi A, 2008, NAT METHODS, V5, P621, DOI 10.1038/nmeth.1226
   Mustafi D, 2011, FASEB J, V25, P3157, DOI 10.1096/fj.11-186767
   Palczewska G, 2014, NAT MED, V20, P785, DOI 10.1038/nm.3590
   Palczewska G, 2010, NAT MED, V16, P1444, DOI 10.1038/nm.2260
   Parish CA, 1998, P NATL ACAD SCI USA, V95, P14609, DOI 10.1073/pnas.95.25.14609
   Prasad D, 2006, MOL CELL NEUROSCI, V33, P96, DOI 10.1016/j.mcn.2006.06.011
   Redmond TM, 1998, NAT GENET, V20, P344, DOI 10.1038/3813
   Rice DS, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7228
   Saari JC, 2001, NEURON, V29, P739, DOI 10.1016/S0896-6273(01)00248-3
   Seitz HM, 2007, J IMMUNOL, V178, P5635, DOI 10.4049/jimmunol.178.9.5635
   Sennlaub F, 2013, EMBO MOL MED, V5, P1775, DOI 10.1002/emmm.201302692
   Sparrow JR, 2012, PROG RETIN EYE RES, V31, P121, DOI 10.1016/j.preteyeres.2011.12.001
   Stecher H, 1999, J BIOL CHEM, V274, P8577, DOI 10.1074/jbc.274.13.8577
   Stone J, 1999, PROG RETIN EYE RES, V18, P689, DOI 10.1016/S1350-9462(98)00032-9
   Tanabe H, 2015, NATURE, V520, P312, DOI 10.1038/nature14301
   Travis GH, 2007, ANNU REV PHARMACOL, V47, P469, DOI 10.1146/annurev.pharmtox.47.120505.105225
   Van Hooser JP, 2002, J BIOL CHEM, V277, P19173, DOI 10.1074/jbc.M112384200
   Vollrath D, 2001, P NATL ACAD SCI USA, V98, P12584, DOI 10.1073/pnas.221364198
   Vollrath D, 2015, PLOS GENET, V11, DOI 10.1371/journal.pgen.1005723
   Xu HP, 2009, PROG RETIN EYE RES, V28, P348, DOI 10.1016/j.preteyeres.2009.06.001
   Yamauchi T, 2003, NATURE, V423, P762, DOI 10.1038/nature01705
   YOUNG RW, 1969, J CELL BIOL, V42, P392, DOI 10.1083/jcb.42.2.392
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P303, DOI 10.1016/j.ophtha.2009.07.014
NR 57
TC 12
Z9 12
U1 0
U2 0
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
EI 1083-351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD DEC 23
PY 2016
VL 291
IS 52
BP 26937
EP 26949
DI 10.1074/jbc.M116.764563
PG 13
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA EH2BE
UT WOS:000391571400032
PM 27875314
OA hybrid, Green Published
DA 2022-11-30
ER

PT J
AU Nociari, MM
   Lehmann, GL
   Bay, AEP
   Radu, RA
   Jiang, ZC
   Goicochea, S
   Schreiner, R
   Warren, JD
   Shan, JF
   de Beaumais, SA
   Menand, M
   Sollogoub, M
   Maxfield, FR
   Rodriguez-Boulan, E
AF Nociari, Marcelo M.
   Lehmann, Guillermo L.
   Bay, Andres E. Perez
   Radu, Roxana A.
   Jiang, Zhichun
   Goicochea, Shelby
   Schreiner, Ryan
   Warren, J. David
   Shan, Jufang
   de Beaumais, Segolene Adam
   Menand, Mickael
   Sollogoub, Matthieu
   Maxfield, Frederick R.
   Rodriguez-Boulan, Enrique
TI Beta cyclodextrins bind, stabilize, and remove lipofuscin bisretinoids
   from retinal pigment epithelium
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
DE aging; retinopathy; lipofuscinosis; residual bodies
ID MACULAR DEGENERATION; RPE LIPOFUSCIN; A2E; CHOLESTEROL; COMPONENT;
   CELLS; INVOLVEMENT; FLUOROPHORE; MECHANISMS; DISEASE
AB Accumulation of lipofuscin bisretinoids (LBs) in the retinal pigment epithelium (RPE) is the alleged cause of retinal degeneration in genetic blinding diseases (e. g., Stargardt) and a possible etiological agent for age-related macular degeneration. Currently, there are no approved treatments for these diseases; hence, agents that efficiently remove LBs from RPE would be valuable therapeutic candidates. Here, we show that beta cyclodextrins (beta-CDs) bind LBs and protect them against oxidation. Computer modeling and biochemical data are consistent with the encapsulation of the retinoid arms of LBs within the hydrophobic cavity of beta-CD. Importantly, beta-CD treatment reduced by 73% and 48% the LB content of RPE cell cultures and of eyecups obtained from Abca4-Rdh8 double knock-out (DKO) mice, respectively. Furthermore, intravitreal administration of beta-CDs reduced significantly the content of bisretinoids in the RPE of DKO animals. Thus, our results demonstrate the effectiveness of beta-CDs to complex and remove LB deposits from RPE cells and provide crucial data to develop novel prophylactic approaches for retinal disorders elicited by LBs.
C1 [Nociari, Marcelo M.; Lehmann, Guillermo L.; Bay, Andres E. Perez; Goicochea, Shelby; Schreiner, Ryan; Rodriguez-Boulan, Enrique] Cornell Univ, Margaret Dyson Vis Res Inst, New York, NY 10065 USA.
   [Warren, J. David; Maxfield, Frederick R.] Cornell Univ, Dept Biochem, New York, NY 10065 USA.
   [Shan, Jufang] Cornell Univ, Weill Cornell Med Coll, Dept Physiol, New York, NY 10065 USA.
   [Radu, Roxana A.; Jiang, Zhichun] Univ Calif Los Angeles, Stein Eye Inst, Dept Ophthalmol, Los Angeles, CA 90095 USA.
   [de Beaumais, Segolene Adam; Menand, Mickael; Sollogoub, Matthieu] Univ Paris 06, Sorbonne Univ, CNRS, Inst Parisien Chim Mol,UMR 8232, F-75005 Paris, France.
C3 Cornell University; Cornell University; Cornell University; University
   of California System; University of California Los Angeles; Centre
   National de la Recherche Scientifique (CNRS); CNRS - Institute of
   Chemistry (INC); UDICE-French Research Universities; Sorbonne
   Universite; Universite Paris Cite
RP Nociari, MM (通讯作者)，Cornell Univ, Margaret Dyson Vis Res Inst, New York, NY 10065 USA.
EM mnociari@med.cornell.edu; boulan@med.cornell.edu
RI Sollogoub, Matthieu/Z-1594-2019; Lehmann, Guillermo/L-9530-2017; Ménand,
   Mickaël/X-2270-2019; Maxfield, Fred/M-6747-2019; Sollogoub,
   Matthieu/A-7102-2008; Radu, Roxana A./K-8924-2019; Warren, J
   David/B-5625-2008; Menand, Mickael/B-9648-2011
OI Sollogoub, Matthieu/0000-0003-0500-5946; Ménand,
   Mickaël/0000-0003-0174-9120; Maxfield, Fred/0000-0003-4396-8866;
   Sollogoub, Matthieu/0000-0003-0500-5946; Warren, J
   David/0000-0002-2833-2248; Menand, Mickael/0000-0003-0174-9120;
   Schreiner, Ryan/0000-0002-7457-6606; Radu, Roxana/0000-0002-5064-6403
FU Beckman Foundation; Research to Prevent Blindness Foundation; Dyson
   Foundation; National Institutes of Health [EY022165, EY08538]; Bright
   Focus Foundation; Pew International Postdoctoral Fellowship; NATIONAL
   EYE INSTITUTE [P30EY000331, R01EY008538, R21EY022165] Funding Source:
   NIH RePORTER
FX We thank Krzyzstof Palczewski (Case Western Reserve University) for
   providing Abca4-Rdh8 DKOs, Dr. Harel Weinstein (Weill Cornell Medical
   College) for molecular modeling and comments on the manuscript, and
   Kevin Lazo for his technical help. This work was supported by the
   Beckman, Research to Prevent Blindness, and Dyson Foundations; National
   Institutes of Health Grants EY022165 and EY08538 (to E. R. B.); and a
   Clinical Translational Scientific Center Pilot Award and a Macular
   Degeneration Research Standard Award from the Bright Focus Foundation
   (to M.M.N.). G. L. L. was supported in part by a Pew International
   Postdoctoral Fellowship.
CR Abi-Mosleh L, 2009, P NATL ACAD SCI USA, V106, P19316, DOI 10.1073/pnas.0910916106
   Allikmets R, 1997, NAT GENET, V15, P236, DOI 10.1038/ng0397-236
   Anderson OA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067263
   Baltazar GC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049635
   Ben-Shabat S, 2002, ANGEW CHEM INT EDIT, V41, P814, DOI 10.1002/1521-3773(20020301)41:5<814::AID-ANIE814>3.0.CO;2-2
   BENESI HA, 1949, J AM CHEM SOC, V71, P2703, DOI 10.1021/ja01176a030
   BRESLOW R, 1995, TETRAHEDRON, V51, P377, DOI 10.1016/0040-4020(94)00903-8
   Buschini E, 2011, PROG NEUROBIOL, V95, P14, DOI 10.1016/j.pneurobio.2011.05.011
   Crane NJ, 2002, J CHEM EDUC, V79, P1261
   Davidson CD, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006951
   De S, 2002, J GEN PHYSIOL, V120, P147, DOI 10.1085/jgp.20028566
   ELDRED GE, 1993, NATURE, V361, P724, DOI 10.1038/361724a0
   Girotti A W, 1985, J Free Radic Biol Med, V1, P87
   Godley BF, 2005, J BIOL CHEM, V280, P21061, DOI 10.1074/jbc.M502194200
   Holtkamp GM, 1998, CLIN EXP IMMUNOL, V112, P34
   Holz FG, 2001, INVEST OPHTH VIS SCI, V42, P1051
   Holz FG, 1999, INVEST OPHTH VIS SCI, V40, P737
   Iriyama A, 2009, J CELL PHYSIOL, V220, P469, DOI 10.1002/jcp.21792
   Jang YP, 2005, J BIOL CHEM, V280, P39732, DOI 10.1074/jbc.M504933200
   Jarrett SG, 2012, MOL ASPECTS MED, V33, P399, DOI 10.1016/j.mam.2012.03.009
   Kanda A, 2008, BRIT J OPHTHALMOL, V92, P448, DOI 10.1136/bjo.2007.131581
   Kim SR, 2008, EXP EYE RES, V86, P975, DOI 10.1016/j.exer.2008.03.016
   Lakkaraju A, 2007, P NATL ACAD SCI USA, V104, P11026, DOI 10.1073/pnas.0702504104
   Ma WX, 2013, NEUROBIOL AGING, V34, P943, DOI 10.1016/j.neurobiolaging.2012.06.010
   Maeda A, 2008, J BIOL CHEM, V283, P26684, DOI 10.1074/jbc.M804505200
   Maeda A, 2012, NAT CHEM BIOL, V8, P170, DOI 10.1038/nchembio.759
   Maeda A, 2009, J BIOL CHEM, V284, P15173, DOI 10.1074/jbc.M900322200
   Maeda T, 2012, PHOTOCHEM PHOTOBIOL, V88, P1309, DOI 10.1111/j.1751-1097.2012.01143.x
   Mondal M, 2009, MOL BIOL CELL, V20, P581, DOI 10.1091/mbc.E08-07-0785
   Ng KP, 2008, MOL CELL PROTEOMICS, V7, P1397, DOI 10.1074/mcp.M700525-MCP200
   Nilsson E, 1997, MECH AGEING DEV, V99, P61, DOI 10.1016/S0047-6374(97)00091-2
   Plazzo AP, 2012, CHEM PHYS LIPIDS, V165, P505, DOI 10.1016/j.chemphyslip.2012.03.007
   Radu RA, 2008, INVEST OPHTH VIS SCI, V49, P3821, DOI 10.1167/iovs.07-1470
   Ragauskaite L, 2001, PHOTOCHEM PHOTOBIOL, V74, P483, DOI 10.1562/0031-8655(2001)074<0483:EEOTPO>2.0.CO;2
   Rosenbaum AI, 2011, J NEUROCHEM, V116, P789, DOI 10.1111/j.1471-4159.2010.06976.x
   Rosenbaum AI, 2010, P NATL ACAD SCI USA, V107, P5477, DOI 10.1073/pnas.0914309107
   Schurig HPNV, 1990, ANGEW CHEM INT EDIT, V29, P939
   Schutt F, 2000, INVEST OPHTH VIS SCI, V41, P2303
   Sokolov VS, 2007, J PHOTOCH PHOTOBIO B, V86, P177, DOI 10.1016/j.jphotobiol.2006.09.006
   Sparrow JR, 2008, ADV EXP MED BIOL, V613, P393, DOI 10.1007/978-0-387-74904-4_46
   Sparrow JR, 2010, METHODS MOL BIOL, V652, P315, DOI 10.1007/978-1-60327-325-1_18
   Sparrow JR, 1999, INVEST OPHTH VIS SCI, V40, P2988
   Sparrow JR, 2005, EXP EYE RES, V80, P595, DOI 10.1016/j.exer.2005.01.007
   Sparrow JR, 2002, INVEST OPHTH VIS SCI, V43, P1222
   Sparrow JR, 2001, INVEST OPHTH VIS SCI, V42, P1356
   Sparrrow JR, 2010, CURR MOL MED, V10, P802
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Vance JE, 2011, CURR OPIN LIPIDOL, V22, P204, DOI 10.1097/MOL.0b013e3283453e69
   Wang Z, 2006, PHOTOCHEM PHOTOBIOL, V82, P1251, DOI 10.1562/2006-04-01-RA-864
   Washington I, 2005, ANGEW CHEM INT EDIT, V44, P7097, DOI 10.1002/anie.200501346
   Weng J, 1999, CELL, V98, P13, DOI 10.1016/S0092-8674(00)80602-9
   Wielgus AR, 2010, PHOTOCHEM PHOTOBIOL, V86, P781, DOI 10.1111/j.1751-1097.2010.00750.x
   Wu YL, 2011, J AM CHEM SOC, V133, P849, DOI 10.1021/ja107195u
   Yao JQ, 2012, J EXP MED, V209, P2501, DOI 10.1084/jem.20121239
   Yoon KD, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041309
   Zhou J, 2009, INVEST OPHTH VIS SCI, V50, P1392, DOI 10.1167/iovs.08-2868
NR 56
TC 42
Z9 50
U1 0
U2 21
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD APR 8
PY 2014
VL 111
IS 14
BP E1402
EP E1408
DI 10.1073/pnas.1400530111
PG 7
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA AE4VU
UT WOS:000333985200013
PM 24706818
OA Green Published, Bronze
DA 2022-11-30
ER

PT J
AU Feng, XL
   Zhou, CS
   Niu, DX
   Zhao, JH
   Yang, JJ
   He, L
   Li, C
AF Feng, Xiaolu
   Zhou, Chensheng
   Niu, Dongxiao
   Zhao, Jinghui
   Yang, Juanjuan
   He, Lin
   Li, Can
TI Yield Improving Strategy for SNP Detection on DNA Origami Chip by
   Employing Au Nanoparticles
SO CURRENT ORGANIC CHEMISTRY
LA English
DT Article
DE Age-related macular degeneration (AMD); atomic force microscope (AFM);
   Au nanoparticle (AuNP); DNA origami chips; single-nucleotide
   polymorphisms (SNPs)
ID HYBRIDIZATION
AB Detection of single nucleotide polymorphisms (SNPs) is critical for early stage diagnosis. However, available clinical methods for detecting SNPs require strict assay conditions or complicated enzyme reactions. DNA hybridization by Au nanoparticles is a new microscopic method for DNA detection, which offers many advantages over traditional ones. But currently, this method is limitedly used because of low yield of hybridization. Here we report novel strategies which use toehold-mediated strand displacement on DNA origami Chip by employing AuNPs, and we greatly improved the yield of hybridization to 80% from less than 10%. Based on the kinetic characteristic of toehold-mediated strand displacement reaction, DNA strands with unmatched sequences can be easily replaced by fully complementary ones, and the exchange rate depends on the length of the toehold region. Therefore, variation on ssDNA sequence can be differentiated by their different displacement time. With this approach we detect SNPs of age-related macular degeneration on DNA origami chip. This approach offers a new, simple and sensitive way to detect SNP.
C1 [Feng, Xiaolu; Zhou, Chensheng; Niu, Dongxiao; Zhao, Jinghui; Yang, Juanjuan; He, Lin; Li, Can] Shanghai Jiao Tong Univ, Bio X Inst, Key Lab Genet Dev & Neuropsychiatr Disorders, Minist Educ, Shanghai 200030, Peoples R China.
C3 Shanghai Jiao Tong University
RP Li, C (通讯作者)，Shanghai Jiao Tong Univ, Bio X Inst, Key Lab Genet Dev & Neuropsychiatr Disorders, Minist Educ, Shanghai 200030, Peoples R China.
EM lican@live.cn
FU 973 Program [2013CB967401, 2012CB93600, 2010CB529600]; National Key
   Technology RD Program [2012BAI01B09]; National Nature Science Foundation
   of China [81121001]
FX This work was support by the 973 Program (2013CB967401, 2012CB93600, and
   2010CB529600), the National Key Technology R&D Program (2012BAI01B09)
   and the National Nature Science Foundation of China (81121001). The
   funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Beyer S, 2005, NANO LETT, V5, P719, DOI 10.1021/nl050155a
   Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   Ding BQ, 2010, J AM CHEM SOC, V132, P3248, DOI 10.1021/ja9101198
   Hansen JA, 2006, J AM CHEM SOC, V128, P3860, DOI 10.1021/ja0574116
   He Y, 2006, J AM CHEM SOC, V128, P15978, DOI 10.1021/ja0665141
   Huang Y, 2009, J AM CHEM SOC, V131, P2478, DOI 10.1021/ja808700d
   Huh YS, 2009, J AM CHEM SOC, V131, P2208, DOI 10.1021/ja807526v
   Jones RPO, 2010, INVEST OPHTH VIS SCI, V51, P2356, DOI 10.1167/iovs.09-4620
   Kanda A, 2007, P NATL ACAD SCI USA, V104, P16227, DOI 10.1073/pnas.0703933104
   Ke YG, 2008, CHEM COMMUN, P5622, DOI 10.1039/b811332g
   Kolpashchikov DM, 2008, J AM CHEM SOC, V130, P2934, DOI 10.1021/ja711192e
   Nesterova IV, 2009, J AM CHEM SOC, V131, P2432, DOI 10.1021/ja8088247
   Qian L, 2006, CHINESE SCI BULL, V51, P2973, DOI 10.1007/s11434-006-2223-9
   Rosi NL, 2006, SCIENCE, V312, P1027, DOI 10.1126/science.1125559
   Rothemund PWK, 2006, NATURE, V440, P297, DOI 10.1038/nature04586
   Seferos DS, 2007, J AM CHEM SOC, V129, P15477, DOI 10.1021/ja0776529
   Sharma J, 2008, J AM CHEM SOC, V130, P7820, DOI 10.1021/ja802853r
   Somorjai GA, 2008, TOP CATAL, V47, P1, DOI 10.1007/s11244-007-9028-1
   Stewart ME, 2008, CHEM REV, V108, P494, DOI 10.1021/cr068126n
   WALLACE RB, 1979, NUCLEIC ACIDS RES, V6, P3543, DOI 10.1093/nar/6.11.3543
   Yan HL, 2009, J PHYS CHEM C, V113, P17326, DOI 10.1021/jp905408q
   Yin P, 2008, NATURE, V451, P318, DOI 10.1038/nature06451
   Yurke B, 2003, ABSTR PAP AM CHEM S, V226, pU470
   Zhang DY, 2007, SCIENCE, V318, P1121, DOI 10.1126/science.1148532
   Zhang Z, 2010, SMALL, V6, P1854, DOI 10.1002/smll.201000908
   Zhang Z, 2010, ADV MATER, V22, P2672, DOI 10.1002/adma.201000151
NR 26
TC 0
Z9 0
U1 1
U2 26
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1385-2728
EI 1875-5348
J9 CURR ORG CHEM
JI Curr. Org. Chem.
PY 2014
VL 18
IS 15
BP 2043
EP 2046
DI 10.2174/138527281815140916092815
PG 4
WC Chemistry, Organic
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Chemistry
GA AQ1WQ
UT WOS:000342575100011
DA 2022-11-30
ER

PT J
AU Kokkinopoulos, I
AF Kokkinopoulos, Ioannis
TI 670 nm LED ameliorates inflammation in the CFH-/- mouse neural retina
SO JOURNAL OF PHOTOCHEMISTRY AND PHOTOBIOLOGY B-BIOLOGY
LA English
DT Article
DE Retina; 670 nm; Mitochondria; Neuroinflammation; TLR; Complement
ID COMPLEMENT FACTOR-H; MIGRATION INHIBITORY FACTOR; AGE-RELATED
   MACULOPATHY; MACULAR DEGENERATION; INNATE IMMUNITY; MICE; RISK;
   POLYMORPHISM; ACTIVATION; ARMS2
AB Para-inflammation in the neural retina is thought to contribute to the onset of some age-related retinal diseases. Continuous innate immune system activation, manifests in progressive chronic inflammation, macrophage invasion and cell loss, resulting in visual loss.
   We have previously shown that mitochondrial function is augmented following 670 nm LED exposure, leading to reduced retinal inflammation. Here, it was asked whether 670 nm LED regulates para-inflammation in an aged-related macular degeneration mouse model. Mutant CFH-/- mice were exposed to four 90 s exposures over 2 days for 1 week and 8 weeks. These regimes significantly reduced activated macrophage number, TNF-alpha and MIF protein expression levels. Immuno-reactivity to C3, C3b and calcitonin, all markers of inflammatory status were also altered. Finally, innate immune proteins, TLR 2 and 4, showed a marked decrease in protein expression.
   These findings support the notion that 670 nm LED regulates innate immunity, alleviating inflammation in the neural retina of an age-related macular degeneration mouse model. (C) 2013 Elsevier B.V. All rights reserved.
C1 [Kokkinopoulos, Ioannis] Kings Coll London, Wolfson Ctr Age Related Dis, Sch Biomed & Hlth Sci, London SE1 1UL, England.
   [Kokkinopoulos, Ioannis] UCL, Inst Ophthalmol, London WC1E 6BT, England.
C3 University of London; King's College London; University of London;
   University College London
RP Kokkinopoulos, I (通讯作者)，Kings Coll London, Wolfson Ctr Age Related Dis, Guys Campus, London SE1 1UL, England.
EM ioannis.kokkinopoulos@kcl.ac.uk
FU MRC Grant [the Medical Research Council UK] [G03000341]
FX This work was supported by an MRC Grant [the Medical Research Council UK
   (G03000341)]. I would like to thank Prof. Alan Colman for his invaluable
   help, Prof. Pat Doherty for his support and Prof. Pete Coffey for
   providing the CFH<SUP>-/-</SUP> mice. Also, I would like to thank Dr.
   Jaimie Hoh-Kam and Ms. (soon to be Dr.) Vivian Lee, for their objective
   critique during data analysis.
CR Albarracin R, 2011, INVEST OPHTH VIS SCI, V52, P3582, DOI 10.1167/iovs.10-6664
   Bhutto IA, 2011, BRIT J OPHTHALMOL, V95, P1323, DOI 10.1136/bjo.2010.199216
   Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   Buschini E, 2011, PROG NEUROBIOL, V95, P14, DOI 10.1016/j.pneurobio.2011.05.011
   Chen M, 2007, EXP EYE RES, V84, P635, DOI 10.1016/j.exer.2006.11.015
   Chen M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022818
   Chen M, 2010, INVEST OPHTH VIS SCI, V51, P5888, DOI 10.1167/iovs.09-5103
   Coffey PJ, 2007, P NATL ACAD SCI USA, V104, P16651, DOI 10.1073/pnas.0705079104
   Despriet DDG, 2006, JAMA-J AM MED ASSOC, V296, P301, DOI 10.1001/jama.296.3.301
   Dong JW, 2010, AM J PHYSIOL-HEART C, V298, pH1079, DOI 10.1152/ajpheart.00306.2009
   Donoso LA, 2006, SURV OPHTHALMOL, V51, P137, DOI 10.1016/j.survophthal.2005.12.001
   Dvoriantchikova G, 2010, MOL VIS, V16, P1907
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Eells JT, 2003, P NATL ACAD SCI USA, V100, P3439, DOI 10.1073/pnas.0534746100
   Faber C, 2012, INVEST OPHTH VIS SCI, V53, P6324, DOI 10.1167/iovs.12-10385
   Fitzgerald M, 2010, J NEUROTRAUM, V27, P2107, DOI 10.1089/neu.2010.1426
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gibson DL, 2010, GASTROENTEROLOGY, V139, P1277, DOI 10.1053/j.gastro.2010.06.057
   GRECO M, 1989, BIOCHEM BIOPH RES CO, V163, P1428, DOI 10.1016/0006-291X(89)91138-8
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hayashi H, 2010, INVEST OPHTH VIS SCI, V51, P5914, DOI 10.1167/iovs.10-5554
   Kam JH, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013127
   Karl MO, 2007, GRAEF ARCH CLIN EXP, V245, P981, DOI 10.1007/s00417-006-0451-y
   Karu T, 1999, J PHOTOCH PHOTOBIO B, V49, P1, DOI 10.1016/S1011-1344(98)00219-X
   Kaur I, 2006, INVEST OPHTH VIS SCI, V47, P3729, DOI 10.1167/iovs.05-1430
   Kijlstra A, 2005, OCUL IMMUNOL INFLAMM, V13, P3, DOI 10.1080/09273940590909185
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kleinman ME, 2012, ADV EXP MED BIOL, V723, P3, DOI 10.1007/978-1-4614-0631-0_1
   Kokkinopoulos I, 2012, NEUROBIOL AGING
   Kokkinopoulos I, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018921
   Kuehn MH, 2006, EXP EYE RES, V83, P620, DOI 10.1016/j.exer.2006.03.002
   Kumar MV, 2004, J NEUROIMMUNOL, V153, P7, DOI 10.1016/j.jneuroim.2004.04.018
   Losse J, 2010, J IMMUNOL, V184, P912, DOI 10.4049/jimmunol.0901702
   Luhmann UFO, 2009, INVEST OPHTH VIS SCI, V50, P5934, DOI 10.1167/iovs.09-3462
   MANN HB, 1947, ANN MATH STAT, V18, P50, DOI 10.1214/aoms/1177730491
   Matsuda A, 1997, J NEUROIMMUNOL, V77, P85, DOI 10.1016/S0165-5728(97)00061-1
   Mattapallil MJ, 2012, INVEST OPHTH VIS SCI, V53, P2921, DOI 10.1167/iovs.12-9662
   Mitamura Y, 1999, AM J OPHTHALMOL, V128, P763, DOI 10.1016/S0002-9394(99)00368-2
   PANGBURN MK, 1980, J EXP MED, V152, P1102, DOI 10.1084/jem.152.4.1102
   PASSARELLA S, 1984, FEBS LETT, V175, P95, DOI 10.1016/0014-5793(84)80577-3
   Pastore D, 2000, INT J RADIAT BIOL, V76, P863
   Pickering MC, 2002, NAT GENET, V31, P424, DOI 10.1038/ng912
   Raychaudhuri S, 2011, NAT GENET, V43, P1232, DOI 10.1038/ng.976
   Ricci F, 2009, ARCH OPHTHALMOL-CHIC, V127, P1368, DOI 10.1001/archophthalmol.2009.237
   Roger T, 2003, J ENDOTOXIN RES, V9, P119, DOI 10.1179/096805103125001513
   Rutar M, 2011, INVEST OPHTH VIS SCI, V52, P5347, DOI 10.1167/iovs.10-7119
   Schorlemmer H.U., 1981, BLOOD TRANSFUS, V27, P59
   Seth A, 2008, INVEST OPHTH VIS SCI, V49, P743, DOI 10.1167/iovs.07-1072
   Sivakumaran TA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025598
   Smailhodzic D, 2012, OPHTHALMOLOGY, V119, P339, DOI 10.1016/j.ophtha.2011.07.056
   Soysal Y., 2011, DNA CELL BIOL
   Takase H, 2002, INVEST OPHTH VIS SCI, V43, P2691
   Tanaka K, 2011, INVEST OPHTH VIS SCI, V52, P7441, DOI 10.1167/iovs.11-7546
   Tashimo A, 2004, DIABETIC MED, V21, P1292, DOI 10.1111/j.1464-5491.2004.01334.x
   Walport MJ, 2001, NEW ENGL J MED, V344, P1058, DOI 10.1056/NEJM200104053441406
   Walport MJ, 2001, NEW ENGL J MED, V344, P1140, DOI 10.1056/NEJM200104123441506
   Whelan HT, 2001, J CLIN LASER MED SUR, V19, P305, DOI 10.1089/104454701753342758
   Wong-Riley MTT, 2001, NEUROREPORT, V12, P3033, DOI 10.1097/00001756-200110080-00011
   Wong-Riley MTT, 2005, J BIOL CHEM, V280, P4761, DOI 10.1074/jbc.M409650200
   Xu HP, 2008, AGING CELL, V7, P58, DOI 10.1111/j.1474-9726.2007.00351.x
   Xu HP, 2009, PROG RETIN EYE RES, V28, P348, DOI 10.1016/j.preteyeres.2009.06.001
   Xu YL, 2008, MOL VIS, V14, P1373
   Yang X, 2010, BRIT J OPHTHALMOL, V94, P1211, DOI 10.1136/bjo.2009.165811
   Zipfel PF, 2009, NAT REV IMMUNOL, V9, P729, DOI 10.1038/nri2620
   Ziskind A, 2008, OPHTHALMIC GENET, V29, P117, DOI 10.1080/13816810802216472
NR 66
TC 8
Z9 8
U1 0
U2 8
PU ELSEVIER SCIENCE SA
PI LAUSANNE
PA PO BOX 564, 1001 LAUSANNE, SWITZERLAND
SN 1011-1344
J9 J PHOTOCH PHOTOBIO B
JI J. Photochem. Photobiol. B-Biol.
PD MAY 5
PY 2013
VL 122
BP 24
EP 31
DI 10.1016/j.jphotobiol.2013.03.003
PG 8
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA 152MQ
UT WOS:000319536200004
PM 23584451
DA 2022-11-30
ER

PT J
AU Park, PJ
   Shukla, D
AF Park, Paul J.
   Shukla, Deepak
TI Role of heparan sulfate in ocular diseases
SO EXPERIMENTAL EYE RESEARCH
LA English
DT Review
DE heparan sulfate; herpetic keratitis; bacterial keratitis; age-related
   macular degeneration; choroidal neovascularization; proteoglycans
ID HERPES-SIMPLEX-VIRUS; COMPLEMENT FACTOR-H; FIBROBLAST-GROWTH-FACTOR;
   EXPERIMENTAL CHOROIDAL NEOVASCULARIZATION; MAMMARY EPITHELIAL-CELLS;
   MACULAR DEGENERATION; BRUCHS MEMBRANE; TYPE-1 ENTRY; MAMMALIAN
   HEPARANASE; ALTERNATIVE PATHWAY
AB Heparan sulfate (HS), a ubiquitous and structurally diverse cell surface polysaccharide and extracellular matrix component, is a factor common to several major eye pathologies. Its multitude of functions and variable distribution among the different ocular tissues makes it an important contributor to a variety of disease states. Although HS facilitates the pathogenesis of many disorders, its role in each varies. Unique functions of HS have been particularly noted in viral and bacterial keratitis and age-related macular degeneration. Combined, these pathologies comprise a large portion of conditions leading to visual impairment worldwide. Given this prevalence of diseases facilitated by HS, it is prudent to take an in-depth look at this compound in the context of these pathologic states. While the initial part of the review will discuss the pathogenic aspects of HS, it is also important to consider the wider implications of such roles for HS. The remainder of the article will specifically address one such implication, the possibility for future use of novel HS-based therapeutics to combat these eye pathologies. (C) 2013 Elsevier Ltd. All rights reserved.
C1 [Park, Paul J.; Shukla, Deepak] Univ Illinois, Coll Med, Dept Ophthalmol & Visual Sci, Chicago, IL 60612 USA.
   [Shukla, Deepak] Univ Illinois, Coll Med, Dept Microbiol & Immunol, Chicago, IL 60612 USA.
C3 University of Illinois System; University of Illinois Chicago;
   University of Illinois Chicago Hospital; University of Illinois System;
   University of Illinois Chicago; University of Illinois Chicago Hospital
RP Shukla, D (通讯作者)，Univ Illinois, Coll Med, Dept Microbiol & Immunol, 1855 W Taylor St M-C 648, Chicago, IL 60612 USA.
EM dshukla@uic.edu
OI Shukla, Deepak/0000-0002-3039-6953
FU National Institutes of Health [RO1 AI057860, AI081869, EY01792];
   Illinois Society for the Prevention of Blindness (ISPB); NATIONAL EYE
   INSTITUTE [P30EY001792] Funding Source: NIH RePORTER; NATIONAL INSTITUTE
   OF ALLERGY AND INFECTIOUS DISEASES [K02AI081869, R01AI057860] Funding
   Source: NIH RePORTER
FX This work was supported by National Institutes of Health grants RO1
   AI057860, AI081869 (both to D. Shukla), EY01792 (core grant) and an
   award from Illinois Society for the Prevention of Blindness (ISPB) to P.
   Park.
CR Ali MM, 2012, J VIROL, V86, P6434, DOI 10.1128/JVI.00433-12
   Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   Aquino RS, 2010, PROG MOL BIOL TRANSL, V93, P373, DOI 10.1016/S1877-1173(10)93016-0
   Bacsa S, 2011, J GEN VIROL, V92, P733, DOI 10.1099/vir.0.027052-0
   BAIRD A, 1990, NATURE, V348, P344, DOI 10.1038/348344a0
   Bartlett AH, 2007, MOL CELLS, V24, P153
   Bartlett AH, 2010, EXPERT REV MOL MED, V12, DOI 10.1017/S1462399409001367
   Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729
   Bourcier T, 2003, BRIT J OPHTHALMOL, V87, P834, DOI 10.1136/bjo.87.7.834
   Brickman YG, 1998, J BIOL CHEM, V273, P4350, DOI 10.1074/jbc.273.8.4350
   CALL TW, 1990, EXP EYE RES, V51, P451, DOI 10.1016/0014-4835(90)90158-Q
   Campochiaro PA, 2000, J CELL PHYSIOL, V184, P301, DOI 10.1002/1097-4652(200009)184:3<301::AID-JCP3>3.0.CO;2-H
   CASTELLOT JJ, 1985, AM J PATHOL, V120, P427
   Chen Y, 2008, MOL CELLS, V26, P415
   Chen YP, 1997, NAT MED, V3, P866, DOI 10.1038/nm0897-866
   Clark SJ, 2006, J BIOL CHEM, V281, P24713, DOI 10.1074/jbc.M605083200
   Clark SJ, 2011, INVEST OPHTH VIS SCI, V52, P6511, DOI 10.1167/iovs.11-7909
   Clark SJ, 2010, BIOCHEM SOC T, V38, P1342, DOI 10.1042/BST0381342
   Clark SJ, 2010, J BIOL CHEM, V285, P30192, DOI 10.1074/jbc.M110.103986
   Coleman HR, 2008, LANCET, V372, P1835, DOI 10.1016/S0140-6736(08)61759-6
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Crews JE, 2003, GENERATIONS, V27, P83
   de Cordoba SR, 2004, MOL IMMUNOL, V41, P355, DOI 10.1016/j.molimm.2004.02.005
   Despriet DDG, 2006, JAMA-J AM MED ASSOC, V296, P301, DOI 10.1001/jama.296.3.301
   Dreyfuss JL, 2010, J THROMB HAEMOST, V8, P1828, DOI 10.1111/j.1538-7836.2010.03916.x
   Dreyfuss JL, 2010, GROWTH FACTORS, V28, P24, DOI 10.3109/08977190903321819
   Dreyfuss JL, 2009, AN ACAD BRAS CIENC, V81, P409, DOI 10.1590/S0001-37652009000300007
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Esko JD, 2002, ANNU REV BIOCHEM, V71, P435, DOI 10.1146/annurev.biochem.71.110601.135458
   Esko JD, 2001, J CLIN INVEST, V108, P169, DOI 10.1172/JCI13530
   Feyzi E, 1998, J BIOL CHEM, V273, P13395, DOI 10.1074/jbc.273.22.13395
   GASS JDM, 1973, ARCH OPHTHALMOL-CHIC, V90, P206
   GOUREAU O, 1995, EUR J BIOCHEM, V230, P1046, DOI 10.1111/j.1432-1033.1995.tb20654.x
   Green M, 2008, CORNEA, V27, P22, DOI 10.1097/ICO.0b013e318156caf2
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hayashida A, 2011, J BIOL CHEM, V286, P3288, DOI 10.1074/jbc.M110.185165
   Hecker LA, 2010, HUM MOL GENET, V19, P209, DOI 10.1093/hmg/ddp472
   Hulett MD, 1999, NAT MED, V5, P803, DOI 10.1038/10525
   Inomata T, 2012, INVEST OPHTH VIS SCI, V53, P1277, DOI 10.1167/iovs.11-8742
   Iozzo RV, 2001, J CLIN INVEST, V108, P349, DOI 10.1172/JCI13738
   Iozzo RV, 2001, J CLIN INVEST, V108, P165, DOI 10.1172/JCI13560
   Ivers RQ, 2000, AM J EPIDEMIOL, V152, P633, DOI 10.1093/aje/152.7.633
   Jayson GC, 1998, J BIOL CHEM, V273, P51, DOI 10.1074/jbc.273.1.51
   Jett BD, 2002, DNA CELL BIOL, V21, P397, DOI 10.1089/10445490260099683
   Jiang XN, 2003, J HISTOCHEM CYTOCHEM, V51, P1393, DOI 10.1177/002215540305101101
   KANER RJ, 1990, SCIENCE, V248, P1410, DOI 10.1126/science.2162560
   KAWAGUCHI H, 1995, J CLIN INVEST, V96, P923, DOI 10.1172/JCI118140
   Kelly U, 2010, J IMMUNOL, V185, P5486, DOI 10.4049/jimmunol.0903596
   Kim B, 2006, CURR EYE RES, V31, P1021, DOI 10.1080/02713680601038824
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klein R, 2011, ARCH OPHTHALMOL-CHIC, V129, P75, DOI 10.1001/archophthalmol.2010.318
   Liesegang TJ, 2001, CORNEA, V20, P1, DOI 10.1097/00003226-200101000-00001
   LIMBERG M B, 1991, American Journal of Ophthalmology, V112, p2S
   Lindahl U, 1998, J BIOL CHEM, V273, P24979, DOI 10.1074/jbc.273.39.24979
   LINDAHL U, 1994, THROMB RES, V75, P1, DOI 10.1016/0049-3848(94)90136-8
   Loges S, 2009, J THROMB HAEMOST, V7, P21, DOI 10.1111/j.1538-7836.2008.03203.x
   Ly CN, 2006, CLIN EXP OPHTHALMOL, V34, P44, DOI 10.1111/j.1442-9071.2006.01143.x
   MARCUM JA, 1986, AM J PHYSIOL, V250, pH879, DOI 10.1152/ajpheart.1986.250.5.H879
   Mataveli FD, 2009, GROWTH FACTORS, V27, P22, DOI 10.1080/08977190802574765
   MIRDA DP, 1992, J VIROL, V66, P448, DOI 10.1128/JVI.66.1.448-457.1992
   Molist A, 1998, EUR J BIOCHEM, V254, P371, DOI 10.1046/j.1432-1327.1998.2540371.x
   Murphy PR, 2001, ENDOCRINOLOGY, V142, P81, DOI 10.1210/en.142.1.81
   Nadanaka S, 2008, J BIOCHEM, V144, P7, DOI 10.1093/jb/mvn040
   O'Donnell CD, 2006, VIROLOGY, V346, P452, DOI 10.1016/j.virol.2005.11.003
   O'Donnell CD, 2010, VIROLOGY, V397, P389, DOI 10.1016/j.virol.2009.11.011
   Oh MJ, 2010, BIOCHEM BIOPH RES CO, V391, P176, DOI 10.1016/j.bbrc.2009.11.027
   Oppermann M, 2006, CLIN EXP IMMUNOL, V144, P342, DOI 10.1111/j.1365-2249.2006.03071.x
   Park PW, 2004, J BIOL CHEM, V279, P251, DOI 10.1074/jbc.M308537200
   Perrimon N, 2000, NATURE, V404, P725, DOI 10.1038/35008000
   Rabenstein DL, 2002, NAT PROD REP, V19, P312, DOI 10.1039/b100916h
   RAPRAEGER A, 1985, J BIOL CHEM, V260, P1046
   Regatieri CV, 2010, BRAZ J MED BIOL RES, V43, P627, DOI 10.1590/S0100-879X2010007500043
   Regatieri CV, 2009, INVEST OPHTH VIS SCI, V50, P5487, DOI 10.1167/iovs.08-3171
   Rein DB, 2009, ARCH OPHTHALMOL-CHIC, V127, P533, DOI 10.1001/archophthalmol.2009.58
   Rein DB, 2006, ARCH OPHTHALMOL-CHIC, V124, P1754, DOI 10.1001/archopht.124.12.1754
   Saaddine JB, 2003, OPHTHALMOLOGY, V110, P253, DOI 10.1016/S0161-6420(02)01839-0
   Safaiyan F, 1998, EUR J BIOCHEM, V252, P576, DOI 10.1046/j.1432-1327.1998.2520576.x
   Salameh Sarah, 2012, Open Virol J, V6, P1, DOI 10.2174/1874357901206010001
   SAMPAIO LO, 2006, INSIGHTS CARBOHYDRAT, P1
   Sanderson RD, 2001, SEMIN CELL DEV BIOL, V12, P89, DOI 10.1006/scdb.2000.0241
   Sasisekharan R, 1997, Angiogenesis, V1, P45, DOI 10.1023/A:1018318914258
   Schaefer F, 2001, BRIT J OPHTHALMOL, V85, P842, DOI 10.1136/bjo.85.7.842
   Shukla D, 1999, CELL, V99, P13, DOI 10.1016/S0092-8674(00)80058-6
   SHWORAK NW, 1994, J BIOL CHEM, V269, P21204
   Shworak NW, 1999, J BIOL CHEM, V274, P5170, DOI 10.1074/jbc.274.8.5170
   Soler R, 2008, UROLOGY, V72, P937, DOI 10.1016/j.urology.2008.01.028
   Su G, 2007, J BIOL CHEM, V282, P14906, DOI 10.1074/jbc.M611739200
   TEETERS VW, 1973, AM J OPHTHALMOL, V76, P1
   Tezel G, 1999, ARCH OPHTHALMOL-CHIC, V117, P917
   Tiwari V, 2005, BIOCHEM BIOPH RES CO, V338, P930, DOI 10.1016/j.bbrc.2005.10.056
   Tiwari V, 2004, J GEN VIROL, V85, P805, DOI 10.1099/vir.0.19641-0
   Tiwari V, 2012, GLYCOBIOLOGY
   Tiwari V, 2006, J VIROL, V80, P8970, DOI 10.1128/JVI.00296-06
   Tiwari V, 2011, J BIOL CHEM, V286, P25406, DOI 10.1074/jbc.M110.201103
   Tkachenko E, 2005, CIRC RES, V96, P488, DOI 10.1161/01.RES.0000159708.71142.c8
   Turnbull J, 2001, TRENDS CELL BIOL, V11, P75, DOI 10.1016/S0962-8924(00)01897-3
   Vajpayee R B, 1996, Aust N Z J Ophthalmol, V24, P131, DOI 10.1111/j.1442-9071.1996.tb01567.x
   Varki A, 2009, ESSENTIALS GLYCOBIOL
   Vlodavsky I, 1999, NAT MED, V5, P793, DOI 10.1038/10518
   Wadstrom T, 1999, J MED MICROBIOL, V48, P223, DOI 10.1099/00222615-48-3-223
   Witmer AN, 2001, CURR EYE RES, V22, P190, DOI 10.1076/ceyr.22.3.190.5519
   Xia GQ, 2002, J BIOL CHEM, V277, P37912, DOI 10.1074/jbc.M204209200
   Xu D, 2005, BIOCHEM J, V385, P451, DOI 10.1042/BJ20040908
   Yabe T, 2001, BIOCHEM J, V359, P235, DOI 10.1042/0264-6021:3590235
   Zhang H, 2001, J LEUKOCYTE BIOL, V70, P225
NR 107
TC 23
Z9 23
U1 0
U2 21
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0014-4835
J9 EXP EYE RES
JI Exp. Eye Res.
PD MAY
PY 2013
VL 110
BP 1
EP 9
DI 10.1016/j.exer.2013.01.015
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 135YR
UT WOS:000318327100001
PM 23410824
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Marneros, AG
   Keene, DR
   Hansen, U
   Fukai, N
   Moulton, K
   Goletz, PL
   Moiseyev, G
   Pawlyk, BS
   Halfter, W
   Dong, SC
   Shibata, M
   Li, TS
   Crouch, RK
   Bruckner, P
   Olsen, BR
AF Marneros, AG
   Keene, DR
   Hansen, U
   Fukai, N
   Moulton, K
   Goletz, PL
   Moiseyev, G
   Pawlyk, BS
   Halfter, W
   Dong, SC
   Shibata, M
   Li, TS
   Crouch, RK
   Bruckner, P
   Olsen, BR
TI Collagen XVIII endostatin is essential for vision and retinal pigment
   epithelial function
SO EMBO JOURNAL
LA English
DT Article
DE age-related macular degeneration; collagen XVIII; endostatin; retinal
   pigment epithelium
ID ENDOGENOUS INHIBITOR; KNOBLOCH-SYNDROME; DEFICIENT MICE; TUMOR-GROWTH;
   MEMBRANE; ANGIOGENESIS; RPE65; ABNORMALITIES; DEGENERATION; MICROFIBRILS
AB Age-related macular degeneration (ARMD) with abnormal deposit formation under the retinal pigment epithelium (RPE) is the major cause of blindness in the Western world. basal laminar deposits are found in early ARMD and are composed of excess basement membrane material produced by the RPE. Here, we demonstrate that mice lacking the basement membrane component collagen XVIII/endostatin have massive accumulation of sub-RPE deposits with striking similarities to basal laminar deposits, abnormal RPE, and age-dependent loss of vision. The progressive attenuation of visual function results from decreased retinal rhodopsin content as a consequence of abnormal vitamin A metabolism in the RPE. In addition, aged mutant mice show photoreceptor abnormalities and increased expression of glial fibrillary acidic protein in the neural retina. Our data demonstrate that collagen XVIII/ endostatin is essential for RPE function, and suggest an important role of this collagen in Bruch's membrane. Consistent with such a role, the ultrastructural organization of collagen XVIII/ endostatin in basement membranes, including Bruch's membrane, shows that it is part of basement membrane molecular networks.
C1 Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA.
   Shriners Hosp Children, Portland Res Ctr, Portland, OR 97201 USA.
   Univ Munster, Dept Physiol Chem & Pathophysiol, D-4400 Munster, Germany.
   Childrens Hosp, Dept Surg, Boston, MA 02115 USA.
   Med Univ S Carolina, Dept Ophthalmol, Charleston, SC 29425 USA.
   Massachusetts Eye & Ear Infirm, Boston, MA 02114 USA.
   Univ Pittsburgh, Dept Neurobiol, Pittsburgh, PA USA.
   Med & Biol Labs Co, Ina, Saitama, Japan.
C3 Harvard University; Harvard Medical School; University of Munster;
   Harvard University; Boston Children's Hospital; Medical University of
   South Carolina; Harvard University; Massachusetts Eye & Ear Infirmary;
   Pennsylvania Commonwealth System of Higher Education (PCSHE); University
   of Pittsburgh
RP Marneros, AG (通讯作者)，Harvard Univ, Sch Med, Dept Cell Biol, 240 Longwood Ave, Boston, MA 02115 USA.
EM alexander_marneros@hms.harvard.edu
RI Bruckner, Peter/F-4817-2019
OI Bruckner, Peter/0000-0002-5566-5611; Marneros,
   Alexander/0000-0003-3866-020X
FU NEI NIH HHS [EY04939, R01 EY012231, R01 EY004939, EY12231] Funding
   Source: Medline; NHLBI NIH HHS [R01 HL067255] Funding Source: Medline;
   NIAMS NIH HHS [R37 AR036819, R01 AR036819, AR36820, AR36819, R01
   AR036820] Funding Source: Medline; NINDS NIH HHS [R01 NS033981,
   NS33981-02] Funding Source: Medline; NATIONAL EYE INSTITUTE
   [R01EY012231, R01EY004939] Funding Source: NIH RePORTER; NATIONAL HEART,
   LUNG, AND BLOOD INSTITUTE [R01HL067255] Funding Source: NIH RePORTER;
   NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES
   [R37AR036819, R01AR036819, R37AR036820, R01AR036820] Funding Source: NIH
   RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE
   [R01NS033981] Funding Source: NIH RePORTER
CR Brinker A, 2000, EUR J BIOCHEM, V267, P5085, DOI 10.1046/j.1432-1327.2000.01570.x
   Curcio CA, 1999, ARCH OPHTHALMOL-CHIC, V117, P329, DOI 10.1001/archopht.117.3.329
   Dithmar S, 2001, ARCH OPHTHALMOL-CHIC, V119, P1643, DOI 10.1001/archopht.119.11.1643
   Dithmar S, 2000, INVEST OPHTH VIS SCI, V41, P2035
   Felbor U, 2000, EMBO J, V19, P1187, DOI 10.1093/emboj/19.6.1187
   Fukai N, 2002, EMBO J, V21, P1535, DOI 10.1093/emboj/21.7.1535
   Guidry C, 2002, INVEST OPHTH VIS SCI, V43, P267
   Halfter W, 1998, J BIOL CHEM, V273, P25404, DOI 10.1074/jbc.273.39.25404
   Jahng WJ, 2003, BIOCHEMISTRY-US, V42, P6159, DOI 10.1021/bi034002i
   Kassner A, 2003, MATRIX BIOL, V22, P131, DOI 10.1016/S0945-053X(03)00008-8
   KATZ ML, 1993, EXP EYE RES, V56, P671, DOI 10.1006/exer.1993.1084
   Li TS, 1998, P NATL ACAD SCI USA, V95, P11933, DOI 10.1073/pnas.95.20.11933
   Ma JX, 2001, INVEST OPHTH VIS SCI, V42, P1429
   Marneros AG, 2003, INVEST OPHTH VIS SCI, V44, P2367, DOI 10.1167/iovs.02-1180
   MURAGAKI Y, 1995, P NATL ACAD SCI USA, V92, P8763, DOI 10.1073/pnas.92.19.8763
   OH SP, 1994, P NATL ACAD SCI USA, V91, P4229, DOI 10.1073/pnas.91.10.4229
   OH SP, 1994, GENOMICS, V19, P494, DOI 10.1006/geno.1994.1098
   OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6
   PASSOSBUENO MR, 1994, AM J MED GENET, V52, P170, DOI 10.1002/ajmg.1320520209
   Redmond TM, 1998, NAT GENET, V20, P344, DOI 10.1038/3813
   Rossi M, 2003, EMBO J, V22, P236, DOI 10.1093/emboj/cdg019
   SAKAI LY, 1994, METHOD ENZYMOL, V245, P29
   SARKS SH, 1976, BRIT J OPHTHALMOL, V60, P324, DOI 10.1136/bjo.60.5.324
   Sasaki T, 1998, EMBO J, V17, P4249, DOI 10.1093/emboj/17.15.4249
   SAWADA H, 1990, J CELL BIOL, V110, P219, DOI 10.1083/jcb.110.1.219
   Sertie AL, 2000, HUM MOL GENET, V9, P2051, DOI 10.1093/hmg/9.13.2051
   VANDERSCHAFT TL, 1994, GRAEF ARCH CLIN EXP, V232, P40, DOI 10.1007/BF00176436
NR 27
TC 97
Z9 100
U1 0
U2 8
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA
SN 0261-4189
J9 EMBO J
JI Embo J.
PD JAN 14
PY 2004
VL 23
IS 1
BP 89
EP 99
DI 10.1038/sj.emboj.7600014
PG 11
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA 773JW
UT WOS:000188921500009
PM 14685281
OA Green Published
DA 2022-11-30
ER

PT J
AU Huang, Z
   Deng, KY
   Deng, YM
   Hui, YN
   Song, YP
AF Huang, Zhen
   Deng, Kai-Yu
   Deng, Yu-Meng
   Hui, Yan-Nian
   Song, Yan-Ping
TI Long-term outcomes of drusenoid pigment epithelium detachment in
   intermediate AMD treated with 577 nm subthreshold micropulse laser: a
   preliminary clinical study
SO INTERNATIONAL JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE age-related macular degeneration; drusenoid pigment detachment; optical
   coherence tomography; retinal pigment epithelium; subthreshold
   micropulse laser
ID MACULAR DEGENERATION; THERAPY; PHOTOCOAGULATION; PROGRESSION; RETINA
AB AIM: To evaluate the long-term anatomical and visual outcomes of drusenoid pigment epithelial detachment (D-PED) in intermediate age-related macular degeneration (AMD) eyes treated with 577 nm yellow subthreshold micropulse laser (SML).
   METHODS: In this retrospective study, 21 eyes of 16 patients with D-PED in intermediate AMD were consecutively included and assessed. All the eyes were treated with 577 nm SML in several sessions according to D-PED growth status. The logarithm of the minimum angle of resolution (logMAR) best-corrected visual acuity (BCVA) were assessed at the initial visit and after treatment. Spectral-domain optical coherence tomography (SD-OCT) was performed to evaluate the D-PED lifecycle by volumetric calculations. Regression analysis was used to determine the breakpoint, growth, and collapse rate of the D-PED lesions. The progression to advanced AMD was also documented.
   RESULTS: All the eyes were treated with SML for 2.9 +/- 1.0 sessions. The mean follow-up period was 25.3 +/- 12.6mo. The BCVA was stable from the baseline to final visit. All the eyes were categorized into two groups according to the anatomical changes of the D-PED lesion: the collapse group (n=6, 28.6%) and non-collapse group (n=15, 71.4%). The change in logMAR BCVA did not differ significantly between the collapse group 0.00 (-0.31, 0.85) and non-collapse group 0.00 (0.00, 0.00; P=1). Regression analysis showed that the growth rate was significantly higher in the collapse group (0.090 +/- 0.095 mm(3)/mo) than in the non-collapse group (0.025 +/- 0.035 mm(3)/mo; P<0.001). One eye (4.8%) developed macular neovascularization at 11mo after SML treatment in the non-collapse group. Three eyes (14.3%) developed geographic atrophy (GA) in the collapse group.
   CONCLUSION: Compared to the natural course of D-PED reported by previous studies, our results preliminarily show that SML can alleviate visual loss and possibility of progression to advanced AMD in eyes with D-PED in intermediate AMD. A controlled clinical trial needs to further verify the benefit of the intervention.
C1 [Huang, Zhen; Song, Yan-Ping] Southern Med Univ, Sch Clin Med 1, 1838 Guangzhou Ave North, Guangzhou 510515, Guangdong, Peoples R China.
   [Huang, Zhen; Deng, Kai-Yu; Deng, Yu-Meng; Song, Yan-Ping] Gen Hosp Cent Theater Command, Dept Ophthalmol, Wuhan 430070, Hubei, Peoples R China.
   [Hui, Yan-Nian] Fourth Mil Med Univ, Dept Ophthalmol, Xijing Hosp, Xian 710032, Shaanxi, Peoples R China.
C3 Southern Medical University - China; Air Force Military Medical
   University
RP Song, YP (通讯作者)，Southern Med Univ, Sch Clin Med 1, 1838 Guangzhou Ave North, Guangzhou 510515, Guangdong, Peoples R China.
EM songyanping@medmail.com.cn
CR Arsan A, 2018, EYE, V32, P726, DOI 10.1038/eye.2017.293
   Balaratnasingam C, 2017, OPHTHALMOLOGY, V124, P644, DOI 10.1016/j.ophtha.2016.12.034
   Balaratnasingam C, 2016, INVEST OPHTH VIS SCI, V57, P5479, DOI 10.1167/iovs.16-19816
   Caballero S, 2017, INVEST OPHTH VIS SCI, V58, P5164, DOI 10.1167/iovs.16-20736
   Chew EY, 2014, JAMA OPHTHALMOL, V132, P142, DOI 10.1001/jamaophthalmol.2013.7376
   Cukras C, 2010, OPHTHALMOLOGY, V117, P489, DOI 10.1016/j.ophtha.2009.12.002
   Curcio CA, 2017, INVEST OPHTH VIS SCI, V58, P211, DOI 10.1167/iovs.17-21872
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   Garcia CAD, 2013, RETINA-J RET VIT DIS, V33, P1558, DOI 10.1097/IAE.0b013e318285cbd2
   Dorin Giorgio, 2003, Semin Ophthalmol, V18, P147, DOI 10.1076/soph.18.3.147.29812
   Guymer RH, 2019, OPHTHALMOLOGY, V126, P829, DOI 10.1016/j.ophtha.2018.09.015
   Hilely A, 2021, BRIT J OPHTHALMOL, V105, P1415, DOI 10.1136/bjophthalmol-2020-317326
   Hirabayashi K, 2020, GRAEF ARCH CLIN EXP, V258, P1039, DOI 10.1007/s00417-020-04638-3
   Kim HD, 2015, INVEST OPHTH VIS SCI, V56, P122, DOI 10.1167/iovs.14-15132
   Kim MS, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-71401-3
   Kim M, 2021, RETINA-J RET VIT DIS, V41, P402, DOI 10.1097/IAE.0000000000002844
   Koss MJ, 2012, EYE, V26, P307, DOI 10.1038/eye.2011.282
   Lains I, 2021, RETINA-J RET VIT DIS, V41, P2098, DOI 10.1097/IAE.0000000000003152
   Lavinsky D, 2016, INVEST OPHTH VIS SCI, V57, P2488, DOI 10.1167/iovs.15-18981
   Luttrull JK, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0202097
   Luttrull JK, 2016, INVEST OPHTH VIS SCI, V57, P265, DOI 10.1167/iovs.15-18163
   Luttrull JK, 2005, BRIT J OPHTHALMOL, V89, P74, DOI 10.1136/bjo.2004.051540
   Mao FF, 2019, INVEST OPHTH VIS SCI, V60, P4966, DOI 10.1167/iovs.19-27325
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Owens SL, 2003, EYE, V17, P623, DOI 10.1038/sj.eye.6700442
   Park DW, 2006, OPHTHALMOLOGY, V113, P1974, DOI 10.1016/j.ophtha.2006.08.015
   Roquet W, 2004, BRIT J OPHTHALMOL, V88, P638, DOI 10.1136/bjo.2003.017632
   Schlanitz FG, 2017, BRIT J OPHTHALMOL, V101, P198, DOI 10.1136/bjophthalmol-2016-308422
   Sitnilska V, 2020, OPHTHALMOLOGICA, V243, P444, DOI 10.1159/000507196
   Terashima H, 2019, RETINA-J RET VIT DIS, V39, P1377, DOI 10.1097/IAE.0000000000002165
   Tode J, 2019, TRANSL VIS SCI TECHN, V8, DOI 10.1167/tvst.8.6.11
   Tvenning AO, 2020, ACTA OPHTHALMOL, V98, P701, DOI 10.1111/aos.14423
   Wang J, 2017, INVEST OPHTH VIS SCI, V58, P4722, DOI 10.1167/iovs.17-21610
   Yu JJ, 2019, OPHTHALMOLOGY, V126, P261, DOI 10.1016/j.ophtha.2018.08.017
NR 34
TC 0
Z9 0
U1 4
U2 6
PU IJO PRESS
PI XI AN
PA NO 269 YOUYI EAST RD, XI AN, 710054, PEOPLES R CHINA
SN 2222-3959
EI 2227-4898
J9 INT J OPHTHALMOL-CHI
JI Int. J. Ophthalmol.
PD MAR 18
PY 2022
VL 15
IS 3
BP 474
EP 482
DI 10.18240/ijo.2022.03.16
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA ZS3HR
UT WOS:000768359800016
PM 35310065
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Chaouche, AB
   Rezaei, M
   Silvestre, D
   Arleo, A
   Allard, R
AF Braham Chaouche, Asma
   Rezaei, Maryam
   Silvestre, Daphne
   Arleo, Angelo
   Allard, Remy
TI Functionally Assessing the Age-Related Decline in the Detection Rate of
   Photons by Cone Photoreceptors
SO FRONTIERS IN AGING NEUROSCIENCE
LA English
DT Review
DE photoreceptors; cones; photon noise; contrast sensitivity; motion;
   noise; equivalent input noise; detection of photons
ID DENSITY; PHOTOPIGMENT; PIGMENTS; VISION; NOISE
AB Age-related decline in visual perception is usually attributed to optical factors of the eye and neural factors. However, the detection of light by cones converting light into neural signals is a crucial intermediate processing step of vision. Interestingly, a novel functional approach can evaluate many aspects of the visual system including the detection of photons by cones. This approach was used to investigate the underlying cause of age-related visual decline and found that the detection rate of cones was considerably affected with healthy aging. This functional test enabling to evaluate the detection of photons by cones could be particularly useful to screen for retinal pathologies affecting cones such as age-related macular degeneration. However, the paradigm used to functionally measure the detection of photons was complex as it was evaluating many other properties of the visual system. The aim of the current mini review is to clarify the underlying rationale of functionally evaluating the detection of photons by cones, describe a simpler approach to evaluate it, and review the impact of aging on the detection rate of cones.
C1 [Braham Chaouche, Asma; Rezaei, Maryam; Allard, Remy] Univ Montreal, Sch Optometry, Montreal, PQ, Canada.
   [Silvestre, Daphne] McGill Univ, Dept Educ & Counselling Psychol, Montreal, PQ, Canada.
   [Arleo, Angelo] Sorbonne Univ, Inst Vis, INSERM, CNRS, Paris, France.
C3 Universite de Montreal; McGill University; Centre National de la
   Recherche Scientifique (CNRS); Institut National de la Sante et de la
   Recherche Medicale (Inserm); UDICE-French Research Universities;
   Sorbonne Universite; Universite Paris Cite
RP Allard, R (通讯作者)，Univ Montreal, Sch Optometry, Montreal, PQ, Canada.
EM remy.allard@umontreal.ca
OI Arleo, Angelo/0000-0002-1990-1971
FU Fondation des Maladies de l'Oeil; Reseau de Recherche en Sante de la
   Vision; Fondation Antoine-Turmel; ANR -Essilor SilverSight Chair
   [ANR-14-CHIN-0001]
FX This research was supported by grants from the Fondation des Maladies de
   l'Oeil, the Reseau de Recherche en Sante de la Vision, and the Fondation
   Antoine-Turmel to RA and by ANR -Essilor SilverSight Chair
   ANR-14-CHIN-0001 to AA.
CR Allard R., 2017, J VISUAL-JAPAN, V17, P600, DOI [10.1167/17.10.600, DOI 10.1167/17.10.600]
   Angueyra JM, 2013, NAT NEUROSCI, V16, P1692, DOI 10.1038/nn.3534
   BURNS SA, 1987, INVEST OPHTH VIS SCI, V28, P711
   Chaouche AB, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-73322-7
   Cunea A, 2007, VISUAL NEUROSCI, V24, P151, DOI 10.1017/S0952523807070204
   CURCIO CA, 1993, INVEST OPHTH VIS SCI, V34, P3278
   De Vries H, 1943, PHYSICA, V10, P553, DOI 10.1016/S0031-8914(43)90575-0
   Elsner AE, 2002, J OPT SOC AM A, V19, P215, DOI 10.1364/JOSAA.19.000215
   Hecht S, 1942, J GEN PHYSIOL, V25, P819, DOI 10.1085/jgp.25.6.819
   KELLY DH, 1972, VISION RES, V12, P89, DOI 10.1016/0042-6989(72)90139-3
   KEUNEN JEE, 1987, INVEST OPHTH VIS SCI, V28, P985
   Lu ZL, 2008, PSYCHOL REV, V115, P44, DOI 10.1037/0033-295X.115.1.44
   Martinez-Roda JA, 2016, CLIN EXP OPTOM, V99, P518, DOI 10.1111/cxo.12369
   MUELLER CG, 1951, J GEN PHYSIOL, V34, P463, DOI 10.1085/jgp.34.4.463
   Owsley C, 2016, ANNU REV VIS SCI, V2, P255, DOI 10.1146/annurev-vision-111815-114550
   Owsley C, 2011, VISION RES, V51, P1610, DOI 10.1016/j.visres.2010.10.020
   PandaJonas S, 1995, OPHTHALMOLOGY, V102, P1853, DOI 10.1016/S0161-6420(95)30784-1
   Pelli D. G., 1990, VISION CODING EFFICI, P3
   Pelli D.G, 1981, EFFECTS VISUAL NOISE
   Pelli DG, 1999, J OPT SOC AM A, V16, P647, DOI 10.1364/JOSAA.16.000647
   Raghavan M., 1995, SOURCES VISUAL NOISE
   ROSE A, 1948, J OPT SOC AM, V38, P196, DOI 10.1364/JOSA.38.000196
   RUSHTON WAH, 1968, VISION RES, V8, P617, DOI 10.1016/0042-6989(68)90040-0
   Silvestre D, 2019, INVEST OPHTH VIS SCI, V60, P544, DOI 10.1167/iovs.18-25598
   Silvestre D, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-20619-3
   Swanson WH, 1996, VISION RES, V36, P2079, DOI 10.1016/0042-6989(95)00280-4
   Watson AB, 2013, J VISION, V13, DOI 10.1167/13.6.18
NR 27
TC 0
Z9 0
U1 0
U2 3
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1663-4365
J9 FRONT AGING NEUROSCI
JI Front. Aging Neurosci.
PD DEC 7
PY 2021
VL 13
AR 744444
DI 10.3389/fnagi.2021.744444
PG 6
WC Geriatrics & Gerontology; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Geriatrics & Gerontology; Neurosciences & Neurology
GA XS3ND
UT WOS:000732819000001
PM 34955808
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Sun, CJ
   Zhou, J
   Meng, XQ
AF Sun, Chunjiao
   Zhou, Jun
   Meng, Xiaoqian
TI Primary cilia in retinal pigment epithelium development and diseases
SO JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
LA English
DT Review
DE barrier; development; primary cilium; retinal disease; retinal pigment
   epithelium
ID IDENTIFICATION; PROTEIN; CELLS
AB Retinal pigment epithelium (RPE) is a highly polarized epithelial monolayer lying between the photoreceptor layer and the Bruch membrane. It is essential for vision through participating in many critical activities, including phagocytosis of photoreceptor outer segments, recycling the visual cycle-related compounds, forming a barrier to control the transport of nutrients, ions, and water, and the removal of waste. Primary cilia are conservatively present in almost all the vertebrate cells and acts as a sensory organelle to control tissue development and homeostasis maintenance. Numerous studies reveal that abnormalities in RPE lead to various retinal diseases, such as age-related macular degeneration and diabetic macular oedema, but the mechanism of primary cilia in these physiological and pathological activities remains to be elucidated. Herein, we summarize the functions of primary cilia in the RPE development and the mutations of ciliary genes identified in RPE-related diseases. By highlighting the significance of primary cilia in regulating the physiological and pathological processes of RPE, we aim to provide novel insights for the treatment of RPE-related retinal diseases.
C1 [Sun, Chunjiao; Zhou, Jun; Meng, Xiaoqian] Shandong Normal Univ, Inst Biomed Sci, Coll Life Sci, Shandong Prov Key Lab Anim Resistance Biol, Jinan, Peoples R China.
C3 Shandong Normal University
RP Meng, XQ (通讯作者)，Shandong Normal Univ, Coll Life Sci, 88 East Wenhua Rd, Jinan 250014, Peoples R China.
EM mengxiaoqian@sdnu.edu.cn
FU Taishan Scholars Program of Shandong Province [20161201]; Natural
   Science Foundation of Shandong Province [ZR2016CM28]
FX This work was supported by grants from the Taishan Scholars Program of
   Shandong Province (20161201) and Natural Science Foundation of Shandong
   Province (ZR2016CM28).
CR del Barrio JLA, 2018, EYE VISION, V5, DOI 10.1186/s40662-018-0122-1
   Alvarez-Satta M, 2019, AGEING RES REV, V52, P53, DOI 10.1016/j.arr.2019.04.004
   Brydon EM, 2019, MOL THER-METH CLIN D, V15, P392, DOI 10.1016/j.omtm.2019.10.014
   Buskin A, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06448-y
   Chawan-Saad J, 2019, TAIWAN J OPHTHALMOL, V9, P233, DOI 10.4103/tjo.tjo_68_19
   Collins M, 2015, P ROY SOC B-BIOL SCI, V282, DOI 10.1098/rspb.2014.3003
   da Cruz L, 2018, NAT BIOTECHNOL, V36, P1, DOI 10.1038/nbt.4114
   De Zoysa AS, 1999, J MED MICROBIOL, V48, P335, DOI 10.1099/00222615-48-4-335
   Dilan TL, 2018, HUM MOL GENET, V27, P283, DOI 10.1093/hmg/ddx399
   Drivas TG, 2013, J CLIN INVEST, V123, P4525, DOI 10.1172/JCI69448
   Gu JN, 2019, ACTA BIOMATER, V92, P115, DOI 10.1016/j.actbio.2019.05.017
   Lehmann GL, 2014, EXP EYE RES, V126, P5, DOI 10.1016/j.exer.2014.04.021
   Li GL, 2019, FRONT MOL NEUROSCI, V12, DOI 10.3389/fnmol.2019.00212
   May-Simera HL, 2018, CELL REP, V22, P189, DOI 10.1016/j.celrep.2017.12.038
   Nazlamova L, 2021, HUM GENET, V140, P593, DOI 10.1007/s00439-020-02228-1
   Pala R, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18112272
   Parfitt DA, 2016, CELL STEM CELL, V18, P769, DOI 10.1016/j.stem.2016.03.021
   Patnaik SR, 2019, CELL MOL LIFE SCI, V76, P757, DOI 10.1007/s00018-018-2966-x
   Ramsay E, 2019, EUR J PHARM BIOPHARM, V143, P18, DOI 10.1016/j.ejpb.2019.08.008
   Robert MA, 2017, BIOTECHNOL J, V12, DOI 10.1002/biot.201600193
   Ruan GX, 2017, MOL THER, V25, P331, DOI 10.1016/j.ymthe.2016.12.006
   Saini JS, 2016, ADV EXP MED BIOL, V854, P557, DOI 10.1007/978-3-319-17121-0_74
   Shang P, 2018, JOVE-J VIS EXP, DOI 10.3791/56997
   Shrestha R, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8010036
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Utz VM, 2018, OPHTHALMIC GENET, V39, P671, DOI 10.1080/13816810.2018.1533027
   Wheway G, 2015, NAT CELL BIOL, V17, P1074, DOI 10.1038/ncb3201
   Xia T, 2017, VISION RES, V139, P72, DOI 10.1016/j.visres.2017.02.006
   Yamashita T, 2009, J NEUROSCI, V29, P9748, DOI 10.1523/JNEUROSCI.5854-08.2009
   Zhang W, 2018, HUM GENE THER, V29, P42, DOI 10.1089/hum.2017.049
NR 30
TC 1
Z9 1
U1 1
U2 4
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1582-1838
EI 1582-4934
J9 J CELL MOL MED
JI J. Cell. Mol. Med.
PD OCT
PY 2021
VL 25
IS 19
BP 9084
EP 9088
DI 10.1111/jcmm.16882
EA AUG 2021
PG 5
WC Cell Biology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Research & Experimental Medicine
GA WD3SZ
UT WOS:000689676400001
PM 34448530
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Ng, DSC
   Chan, LKY
   Ng, CM
   Lai, TYY
AF Ng, Danny Siu-Chun
   Chan, Leo Ka-Yu
   Ng, Ching Man
   Lai, Timothy Y. Y.
TI Visualising the choriocapillaris: Histology, imaging modalities and
   clinical research - A review
SO CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Review
DE choriocapillaris; choroidal imaging; optical coherence tomography
   angiography
ID OPTICAL COHERENCE TOMOGRAPHY; QUANTITATIVE ASSESSMENT;
   MORPHOMETRIC-ANALYSIS; MACULAR DEGENERATION; ANGIOGRAPHY; FLOW;
   FEATURES; EYES; NEOVASCULARIZATION; MICROVASCULATURE
AB The choriocapillaris plays a considerable role in the normal physiology of the eye as well as in various diseases. Assessing the changes in the choriocapillaris can therefore provide important information about normal ageing and pathogenesis of visual impairment, and even some systemic diseases. In vivo imaging of the choriocapillaris has evolved from non-depth resolved, dye-based angiography to advanced, high-resolution optical coherence tomography angiography (OCTA). However, the intricate microvascular networks within the choriocapillaris are still beyond the resolving limits of most OCTA instruments. Knowledge of histology, meticulous image acquisition methods, recognition of artefact and post-acquisition processing techniques are necessary for optimising OCTA choriocapillaris images. Qualitative and quantitative analyses of the choriocapillaris provide clinical information in age-related macular degeneration (AMD), diabetic retinopathy (DR), pathologic myopia and central serous chorioretinopathy (CSC). Furthermore, studies have revealed choriocapillaris changes in posterior uveitis that are correlated with treatment outcome and have important prognostic significance. In addition to retinal diseases, choriocapillaris changes have been observed in systemic vascular diseases and complications associated with pregnancy.
C1 [Ng, Danny Siu-Chun; Chan, Leo Ka-Yu; Ng, Ching Man; Lai, Timothy Y. Y.] Chinese Univ Hong Kong, Dept Ophthalmol & Visual Sci, Hong Kong, Peoples R China.
   [Ng, Danny Siu-Chun; Chan, Leo Ka-Yu] Hong Kong Eye Hosp, Mong Kok, Hong Kong, Peoples R China.
   [Lai, Timothy Y. Y.] 2010 Retina & Macula Ctr, Kowloon, Hong Kong, Peoples R China.
C3 Chinese University of Hong Kong
RP Lai, TYY (通讯作者)，Chinese Univ Hong Kong, Dept Ophthalmol & Visual Sci, Hong Kong, Peoples R China.; Lai, TYY (通讯作者)，4-F Hong Kong Eye Hosp,147K Argyle St, Hong Kong, Peoples R China.
EM tyylai@cuhk.edu.hk
OI Lai, Timothy/0000-0002-7832-6428
CR Adhi M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0133080
   Al-Sheikh M, 2017, INVEST OPHTH VIS SCI, V58, P2063, DOI 10.1167/iovs.16-21289
   Alagorie AR, 2020, RETINA-J RET VIT DIS, V40, P2106, DOI 10.1097/IAE.0000000000002878
   ALM A, 1970, ACTA PHYSIOL SCAND, V80, P19, DOI 10.1111/j.1748-1716.1970.tb04765.x
   Arya M, 2018, EYE VISION, V5, DOI 10.1186/s40662-018-0118-x
   Borrelli E, 2019, OPHTHALMOL RETINA, V3, P979, DOI 10.1016/j.oret.2019.05.026
   Borrelli E, 2018, RETINA-J RET VIT DIS, V38, P1968, DOI 10.1097/IAE.0000000000002198
   Borrelli E, 2017, INVEST OPHTH VIS SCI, V58, P4792, DOI 10.1167/iovs.17-22360
   Branchini LA, 2013, OPHTHALMOLOGY, V120, P1901, DOI 10.1016/j.ophtha.2013.01.066
   Byon I, 2019, AM J OPHTHALMOL, V208, P397, DOI 10.1016/j.ajo.2019.08.026
   Cao JT, 1998, ARCH OPHTHALMOL-CHIC, V116, P589, DOI 10.1001/archopht.116.5.589
   Cheung CMG, 2019, EYE, V33, P14, DOI 10.1038/s41433-018-0158-4
   Choi W, 2015, OPHTHALMOLOGY, V122, P2532, DOI 10.1016/j.ophtha.2015.08.029
   Chu ZD, 2021, AM J OPHTHALMOL, V222, P92, DOI 10.1016/j.ajo.2020.08.045
   Chu ZD, 2020, AM J OPHTHALMOL, V218, P17, DOI 10.1016/j.ajo.2020.05.006
   Chu ZD, 2020, AM J OPHTHALMOL, V213, P161, DOI 10.1016/j.ajo.2020.02.003
   Chu ZD, 2019, AM J OPHTHALMOL, V208, P111, DOI 10.1016/j.ajo.2019.07.003
   Chu ZD, 2018, QUANT IMAG MED SURG, V8, P1102, DOI 10.21037/qims.2018.12.09
   Chu ZD, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-34826-5
   Chua J, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-84136-6
   Chua J, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-41917-4
   Corvi F, 2021, EYE, V35, P110, DOI 10.1038/s41433-020-01217-y
   Dodo Y, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-05663-9
   Ebrahimiadib N, 2021, SURV OPHTHALMOL, V66, P653, DOI 10.1016/j.survophthal.2020.12.006
   Ferrara D, 2014, OPHTHALMOLOGY, V121, P719, DOI 10.1016/j.ophtha.2013.10.014
   FLOWER RW, 1993, INVEST OPHTH VIS SCI, V34, P2720
   Gerl VB, 2002, INVEST OPHTH VIS SCI, V43, P1104
   Hanyuda Naoto, 2017, Invest Ophthalmol Vis Sci, V58, P5856, DOI 10.1167/iovs.17-22223
   Ho M, 2021, BRIT J OPHTHALMOL, V105, P555, DOI 10.1136/bjophthalmol-2020-316076
   Hogan MJ., 1971, HISTOLOGY HUMAN EYE
   Jia YL, 2014, OPHTHALMOLOGY, V121, P1435, DOI 10.1016/j.ophtha.2014.01.034
   Kaye R, 2020, PROG RETIN EYE RES, V79, DOI 10.1016/j.preteyeres.2020.100865
   Klufas MA, 2017, OPHTHALMOL RETINA, V1, P77, DOI 10.1016/j.oret.2016.08.008
   Kurokawa K, 2017, BIOMED OPT EXPRESS, V8, P1803, DOI 10.1364/BOE.8.001803
   Lane M, 2016, INVEST OPHTH VIS SCI, V57
   Lim HB, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-31321-9
   Lutty G, 1999, MOL VIS, V5
   Margolis R, 2009, AM J OPHTHALMOL, V147, P811, DOI 10.1016/j.ajo.2008.12.008
   Matet A, 2019, RETINA-J RET VIT DIS, V39, P2178, DOI 10.1097/IAE.0000000000002271
   McLeod DS, 2009, INVEST OPHTH VIS SCI, V50, P4982, DOI 10.1167/iovs.09-3639
   MELAMED S, 1980, BRIT J OPHTHALMOL, V64, P537, DOI 10.1136/bjo.64.7.537
   Moriyama M, 2011, OPHTHALMOLOGY, V118, P1626, DOI 10.1016/j.ophtha.2011.01.018
   Moult EM, 2020, RETINA-J RET VIT DIS, V40, P428, DOI 10.1097/IAE.0000000000002556
   Nassisi M, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0207638
   Nesper PL, 2017, INVEST OPHTH VIS SCI, V58, P307, DOI 10.1167/iovs.17-21787
   Nickla DL, 2010, PROG RETIN EYE RES, V29, P144, DOI 10.1016/j.preteyeres.2009.12.002
   OLVER JM, 1990, EYE, V4, P262, DOI 10.1038/eye.1990.38
   Onal S, 2018, RETINA-J RET VIT DIS, V38, P828, DOI 10.1097/IAE.0000000000001587
   Phansalkar Neerad, 2011, 2011 International Conference on Communications and Signal Processing (ICCSP), P218, DOI 10.1109/ICCSP.2011.5739305
   Pichi F, 2016, RETINA-J RET VIT DIS, V36, pS178, DOI 10.1097/IAE.0000000000001255
   Rahimy E, 2013, CAN J OPHTHALMOL, V48, P539, DOI 10.1016/j.jcjo.2013.07.006
   RAMRATTAN RS, 1994, INVEST OPHTH VIS SCI, V35, P2857
   Rispoli M, 2018, OSLI RETINA, V49, P918, DOI 10.3928/23258160-20181203-02
   Rochepeau C, 2018, AM J OPHTHALMOL, V194, P26, DOI 10.1016/j.ajo.2018.07.004
   Saito M, 2018, INT OPHTHALMOL, V38, P2205, DOI 10.1007/s10792-017-0705-1
   Seddon Johanna M, 2016, JAMA Ophthalmol, V134, P1272, DOI 10.1001/jamaophthalmol.2016.3519
   Spaide RF, 2016, AM J OPHTHALMOL, V170, P58, DOI 10.1016/j.ajo.2016.07.023
   Su L, 2020, TRANSL VIS SCI TECHN, V9, DOI 10.1167/tvst.9.9.24
   Su L, 2020, GRAEF ARCH CLIN EXP, V258, P1173, DOI 10.1007/s00417-020-04639-2
   Takayama K, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-33580-y
   Uji A, 2018, ACTA OPHTHALMOL, V96, pE820, DOI 10.1111/aos.13740
   Uji A, 2017, JAMA OPHTHALMOL, V135, P1197, DOI 10.1001/jamaophthalmol.2017.3904
   Uji A, 2017, OPHTHALMOLOGY, V124, P944, DOI 10.1016/j.ophtha.2017.02.006
   Waheed NK, 2016, DEV OPHTHALMOL, V56, P91, DOI 10.1159/000442784
   Wang JC, 2018, TRANSL VIS SCI TECHN, V7, DOI 10.1167/tvst.7.6.25
   Wei X, 2018, SURV OPHTHALMOL, V63, P646, DOI 10.1016/j.survophthal.2018.03.003
   Wirth MA, 2017, ACTA OPHTHALMOL, V95, P428, DOI 10.1111/aos.13226
   Yin X, 2014, J BIOMED OPT, V19, DOI 10.1117/1.JBO.19.8.086020
   YONEYA S, 1983, INT OPHTHALMOL, V6, P95, DOI 10.1007/BF00127637
   Zaki F, 2017, BIOMED OPT EXPRESS, V8, P2720, DOI 10.1364/BOE.8.002720
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
   Zhang QQ, 2018, INVEST OPHTH VIS SCI, V59, P203, DOI 10.1167/iovs.17-22953
   Zhang QQ, 2017, OPHTHALMOL RETINA, V1, P124, DOI 10.1016/j.oret.2016.08.005
   Zheng F, 2019, AM J OPHTHALMOL, V200, P110, DOI 10.1016/j.ajo.2018.12.025
   Zhou KH, 2019, BIOMED OPT EXPRESS, V10, P2847, DOI 10.1364/BOE.10.002847
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P1775, DOI 10.1016/j.ophtha.2010.01.027
NR 76
TC 1
Z9 1
U1 2
U2 5
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1442-6404
EI 1442-9071
J9 CLIN EXP OPHTHALMOL
JI Clin. Exp. Ophthalmol.
PD JAN
PY 2022
VL 50
IS 1
BP 91
EP 103
DI 10.1111/ceo.13984
EA AUG 2021
PG 13
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA YY5OZ
UT WOS:000687062000001
PM 34387023
DA 2022-11-30
ER

PT J
AU Popovic, N
   Hooker, E
   Barabino, A
   Flamier, A
   Provost, F
   Buscarlet, M
   Bernier, G
   Larrivee, B
AF Popovic, Natalija
   Hooker, Erika
   Barabino, Andrea
   Flamier, Anthony
   Provost, Frederic
   Buscarlet, Manuel
   Bernier, Gilbert
   Larrivee, Bruno
TI COCO/DAND5 inhibits developmental and pathological ocular angiogenesis
SO EMBO MOLECULAR MEDICINE
LA English
DT Article
DE angiogenesis; COCO; energy metabolism; ocular pathologies
AB Neovascularization contributes to multiple visual disorders including age-related macular degeneration (AMD) and retinopathy of prematurity. Current therapies for treating ocular angiogenesis are centered on the inhibition of vascular endothelial growth factor (VEGF). While clinically effective, some AMD patients are refractory or develop resistance to anti-VEGF therapies and concerns of increased risks of developing geographic atrophy following long-term treatment have been raised. Identification of alternative pathways to inhibit pathological angiogenesis is thus important. We have identified a novel inhibitor of angiogenesis, COCO, a member of the Cerberus-related DAN protein family. We demonstrate that COCO inhibits sprouting, migration and cellular proliferation of cultured endothelial cells. Intravitreal injections of COCO inhibited retinal vascularization during development and in models of retinopathy of prematurity. COCO equally abrogated angiogenesis in models of choroidal neovascularization. Mechanistically, COCO inhibited TGF beta and BMP pathways and altered energy metabolism and redox balance of endothelial cells. Together, these data show that COCO is an inhibitor of retinal and choroidal angiogenesis, possibly representing a therapeutic option for the treatment of neovascular ocular diseases.
C1 [Popovic, Natalija; Hooker, Erika; Bernier, Gilbert; Larrivee, Bruno] Univ Montreal, Fac Med, Montreal, PQ, Canada.
   [Popovic, Natalija; Hooker, Erika; Barabino, Andrea; Flamier, Anthony; Provost, Frederic; Buscarlet, Manuel; Bernier, Gilbert; Larrivee, Bruno] Hop Maisonneuve Rosemont Res Ctr, Montreal, PQ, Canada.
   [Barabino, Andrea; Flamier, Anthony; Bernier, Gilbert] Univ Montreal, Dept Neurosci, Montreal, PQ, Canada.
   [Larrivee, Bruno] Univ Montreal, Dept Ophthalmol, Montreal, PQ, Canada.
   [Flamier, Anthony] Whitehead Inst Biomed Res, 9 Cambridge Ctr, Cambridge, MA 02142 USA.
C3 Universite de Montreal; Universite de Montreal; Universite de Montreal;
   Massachusetts Institute of Technology (MIT); Whitehead Institute
RP Bernier, G; Larrivee, B (通讯作者)，Univ Montreal, Fac Med, Montreal, PQ, Canada.; Bernier, G; Larrivee, B (通讯作者)，Hop Maisonneuve Rosemont Res Ctr, Montreal, PQ, Canada.; Bernier, G (通讯作者)，Univ Montreal, Dept Neurosci, Montreal, PQ, Canada.; Larrivee, B (通讯作者)，Univ Montreal, Dept Ophthalmol, Montreal, PQ, Canada.
EM gbernier.hmr@ssss.gouv.qc.ca; bruno.larrivee@umontreal.ca
OI Provost, Frederic/0000-0002-2432-7580; Hooker,
   Erika/0000-0002-4515-4041; Popovic, Natalija/0000-0002-8324-4099;
   Larrivee, Bruno/0000-0003-1388-3108
FU Canadian Institutes of Health Research [FRN 363540]; Foundation Fighting
   Blindness; Fonds de Recherche en Ophtalmologie de l'Universite de
   Montreal; Hopital Maisonneuve-Rosemont Foundation; Suzanne
   Veronneau-Troutman scholarship; Heart and Stroke Foundation of Canada
FX The work described in this paper was supported by the Canadian
   Institutes of Health Research (FRN 363540; G.B, B.L.), the Foundation
   Fighting Blindness (G.B, B.L.), the Fonds de Recherche en Ophtalmologie
   de l'Universite de Montreal and Hopital Maisonneuve-Rosemont Foundation.
   N.P was supported by a Suzanne Veronneau-Troutman scholarship and Fonds
   de Recherche en Ophtalmologie de l'Universite de Montreal. B.L. was
   supported by a New Investigator Award from the Heart and Stroke
   Foundation of Canada. The authors wish to thank Houda Tahiri and Mikhail
   Sergeev for their help with the choroidal explant model and microscopy,
   respectively. The authors also thank Sergio Garcia-Crespo for his
   critical assessment of the manuscript. We kindly thank Ralf Adams and S.
   Paul Oh for Alk1 Delta EC mice.
CR Abe Y, 2013, AM J PHYSIOL-RENAL, V305, pF1477, DOI 10.1152/ajprenal.00182.2013
   Akla N, 2018, ARTERIOSCL THROM VAS, V38, P1821, DOI 10.1161/ATVBAHA.118.310733
   Amadio M, 2016, PHARMACOL RES, V103, P253, DOI 10.1016/j.phrs.2015.11.027
   Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   [Anonymous], 2021, EMBO MOL MED, pE11900
   Apte RS, 2019, CELL, V176, P1248, DOI 10.1016/j.cell.2019.01.021
   Araujo AC, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102716
   Aspalter IM, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8264
   Bell E, 2003, DEVELOPMENT, V130, P1381, DOI 10.1242/dev.00344
   Belo JA, 2017, J CARDIOVASC DEV DIS, V4, DOI 10.3390/jcdd4040023
   Bernard K, 2015, J BIOL CHEM, V290, P25427, DOI 10.1074/jbc.M115.646984
   Cantelmo AR, 2016, CANCER CELL, V30, P968, DOI 10.1016/j.ccell.2016.10.006
   Chen JJ, 2020, DNA CELL BIOL, V39, P661, DOI 10.1089/dna.2019.5151
   De Bock K, 2013, CELL, V154, P651, DOI 10.1016/j.cell.2013.06.037
   Draoui N, 2017, OPEN BIOL, V7, DOI 10.1098/rsob.170219
   Dutton LR, 2019, J BIOL CHEM, V294, P18041, DOI 10.1074/jbc.AC119.010148
   Eelen G, 2018, PHYSIOL REV, V98, P3, DOI 10.1152/physrev.00001.2017
   Esen E, 2013, CELL METAB, V17, P745, DOI 10.1016/j.cmet.2013.03.017
   Ferrara N, 2016, TRANSL VIS SCI TECHN, V5, DOI 10.1167/tvst.5.2.10
   Gerhardt H, 2008, ORGANOGENESIS, V4, P241, DOI [DOI 10.4161/0RG.4.4.7414, DOI 10.4161/org.4.4.7414]
   Gherghe CM, 2011, FASEB J, V25, P1836, DOI 10.1096/fj.10-172981
   Goumans MJ, 2018, CSH PERSPECT BIOL, V10, DOI 10.1101/cshperspect.a031989
   Grillo E, 2016, ONCOTARGET, V7, P35353, DOI 10.18632/oncotarget.9286
   Grunwald JE, 2014, OPHTHALMOLOGY, V121, P150, DOI 10.1016/j.ophtha.2013.08.015
   Jerkic M, 2012, OXID MED CELL LONGEV, V2012, DOI 10.1155/2012/686972
   KATO T, 1973, ANAL BIOCHEM, V53, P86, DOI 10.1016/0003-2697(73)90409-0
   Kattamuri C, 2017, BIOCHEM J, V474, P1093, DOI 10.1042/BCJ20161050
   Kieran MW, 2012, CSH PERSPECT MED, V2, DOI 10.1101/cshperspect.a006593
   Kim YW, 2014, BLOOD, V123, P625, DOI 10.1182/blood-2013-09-512749
   Kom C, 2015, DEV CELL, V34, P5, DOI 10.1016/j.devcel.2015.06.004
   Korn C, 2014, DEVELOPMENT, V141, P1757, DOI 10.1242/dev.104422
   Kudin AP, 2004, J BIOL CHEM, V279, P4127, DOI 10.1074/jbc.M310341200
   Kurihara T, 2012, J CLIN INVEST, V122, P4213, DOI 10.1172/JCI65157
   Kussmaul L, 2006, P NATL ACAD SCI USA, V103, P7607, DOI 10.1073/pnas.0510977103
   Lambert V, 2013, NAT PROTOC, V8, P2197, DOI 10.1038/nprot.2013.135
   Lange C, 2016, NAT REV NEUROL, V12, P439, DOI 10.1038/nrneurol.2016.88
   Larrivee B, 2012, DEV CELL, V22, P489, DOI 10.1016/j.devcel.2012.02.005
   Lee HW, 2017, ARTERIOSCL THROM VAS, V37, P657, DOI 10.1161/ATVBAHA.116.308422
   Lee SY, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-07316-5
   Lin SS, 2001, J BIOL CHEM, V276, P36000, DOI 10.1074/jbc.M103509200
   Lv BJ, 2014, INT J CLIN EXP PATHO, V7, P5717
   Marneros AG, 2005, AM J PATHOL, V167, P1451, DOI 10.1016/S0002-9440(10)61231-X
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Masckauchan T. Nestor H., 2005, Angiogenesis, V8, P43, DOI 10.1007/s10456-005-5612-9
   Mausner-Fainberg K, 2019, J NEUROIMMUNOL, V327, P36, DOI 10.1016/j.jneuroim.2019.01.009
   Miki A, 2010, J CELL PHYSIOL, V224, P262, DOI 10.1002/jcp.22129
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Mitola S, 2010, BLOOD, V116, P3677, DOI 10.1182/blood-2010-06-291930
   Nishijima K, 2007, AM J PATHOL, V171, P53, DOI 10.2353/ajpath.2007.061237
   Nolan K, 2014, PROTEIN SCI, V23, P999, DOI 10.1002/pro.2485
   Ntumba K, 2016, ONCOTARGET, V7, P55957, DOI 10.18632/oncotarget.11182
   Ogura M, 2012, BIOCHEM J, V447, P281, DOI 10.1042/BJ20120509
   Oubaha M, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aaf9440
   Parzych K, 2019, ONCOGENE, V38, P3216, DOI 10.1038/s41388-018-0651-z
   Pate KT, 2014, EMBO J, V33, P1454, DOI 10.15252/embj.201488598
   Potente M, 2011, CELL, V146, P873, DOI 10.1016/j.cell.2011.08.039
   Raftopoulou M, 2004, DEV BIOL, V265, P23, DOI 10.1016/j.ydbio.2003.06.003
   Rama N, 2015, NAT MED, V21, P483, DOI 10.1038/nm.3849
   Rodriguez-Garcia A, 2017, FEBS J, V284, P3437, DOI 10.1111/febs.14201
   Rothhammer T, 2007, ONCOGENE, V26, P4158, DOI 10.1038/sj.onc.1210182
   Saint-Geniez M, 2009, P NATL ACAD SCI USA, V106, P18751, DOI 10.1073/pnas.0905010106
   Saint-Geniez M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003554
   Schmucker C, 2004, VISION RES, V44, P1857, DOI 10.1016/j.visres.2004.03.011
   Shan WR, 2019, CELL MOL LIFE SCI, V76, P1381, DOI 10.1007/s00018-019-03007-6
   Shao Z, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069552
   Soukupova J, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-12837-y
   Stahl A, 2010, INVEST OPHTH VIS SCI, V51, P2813, DOI 10.1167/iovs.10-5176
   STAMBAUGH R, 1966, J BIOL CHEM, V241, P1462
   Thul PJ, 2017, SCIENCE, V356, DOI 10.1126/science.aal3321
   Tosi GM, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19113363
   Treps L, 2016, PHARMACOL REV, V68, P872, DOI 10.1124/pr.116.012492
   Tuder RM, 2013, CLIN CHEST MED, V34, P639, DOI 10.1016/j.ccm.2013.08.009
   Tumelty KE, 2018, J BIOL CHEM, V293, P3039, DOI 10.1074/jbc.M117.804021
   Ueno S, 2008, J CELL PHYSIOL, V217, P13, DOI 10.1002/jcp.21445
   Wang HW, 2019, ENVIRON POLLUT, V255, DOI 10.1016/j.envpol.2019.113359
   Wang PX, 2010, ISLETS, V2, P46, DOI 10.4161/isl.2.1.10017
   Xiao WS, 2018, ANTIOXID REDOX SIGN, V28, P251, DOI 10.1089/ars.2017.7216
   Xu JM, 2017, FREE RADICAL BIO MED, V106, P208, DOI 10.1016/j.freeradbiomed.2017.02.036
   Yang SQ, 2016, DRUG DES DEV THER, V10, P1857, DOI 10.2147/DDDT.S97653
   Zhang KZ, 2018, GASTROENTEROLOGY, V154, P224, DOI 10.1053/j.gastro.2017.09.010
   Zhou SF, 2015, DEVELOPMENT, V142, P3294, DOI 10.1242/dev.125385
   Zhou YL, 2014, J CLIN INVEST, V124, P3825, DOI 10.1172/JCI76431
   Zorov DB, 2014, PHYSIOL REV, V94, P909, DOI 10.1152/physrev.00026.2013
NR 83
TC 3
Z9 3
U1 0
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1757-4676
EI 1757-4684
J9 EMBO MOL MED
JI EMBO Mol. Med.
PD MAR 5
PY 2021
VL 13
IS 3
AR e12005
DI 10.15252/emmm.202012005
EA FEB 2021
PG 20
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA QT4QT
UT WOS:000618022500001
PM 33587337
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Cui, YT
   Li, Y
   Huang, N
   Xiong, Y
   Cao, RJ
   Meng, LJ
   Liu, JK
   Feng, ZH
AF Cui, Yuting
   Li, Yuan
   Huang, Na
   Xiong, Yue
   Cao, Ruijun
   Meng, Lingjie
   Liu, Jiankang
   Feng, Zhihui
TI Structure based modification of chalcone analogue activates Nrf2 in the
   human retinal pigment epithelial cell line ARPE-19
SO FREE RADICAL BIOLOGY AND MEDICINE
LA English
DT Article
DE Nrf2; Oxidative stress; Mitochondrial dysfunction; Acrolein; Macular
   degeneration
ID ANTIOXIDANT TRANSCRIPTION FACTOR; OXIDATIVE STRESS; MITOCHONDRIAL
   DYSFUNCTION; MACULAR DEGENERATION; MOLECULAR-MECHANISMS;
   CIGARETTE-SMOKING; SIGNALING PATHWAY; GSH SYNTHESIS; RPE; INDUCTION
AB Oxidative stress-induced degeneration of retinal pigment epithelial (RPE) cells is known to be a key contributor to the development of age-related macular degeneration (AMD). Activation of the nuclear factor-(erythroid-derived 2)-related factor-2 (Nrf2)-mediated cellular defense system is believed to be a valid therapeutic approach. In the present study, we designed and synthesized a novel chalcone analogue, 1-(2,3,4-trimethoxyphenyl)-2-(3,4,5-trimethoxyphenyl)-acrylketone (Tak), as a Nrf2 activator. The potency of Tak was measured in RPE cells by the induction of the Nrf2-dependent antioxidant genes HO-1, NQO-1, GCLc, and GCLm, which were regulated through the Erk pathway. We also showed that Tak could protect RPE cells against oxidative stress-induced cell death and mitochondrial dysfunction. Furthermore, by modifying the alpha, beta unsaturated carbonyl entity in Tak, we showed that the induction of antioxidant genes was abolished, indicating that this unique feature in Tak was responsible for the Nrf2 activation. These results suggest that Tak is a potential candidate for clinical application against AMD.
C1 [Cui, Yuting; Xiong, Yue; Liu, Jiankang; Feng, Zhihui] Xi An Jiao Tong Univ, Ctr Mitochondrial Biol & Med, Sch Life Sci & Technol, Key Lab Biomed Informat Engn,Minist Educ, Xian 710049, Peoples R China.
   [Li, Yuan] Xian Med Univ, Inst Basic Med Sci, Xian 710021, Peoples R China.
   [Huang, Na; Cao, Ruijun; Meng, Lingjie] Xi An Jiao Tong Univ, Sch Sci, MOE Key Lab Nonequilibrium Synth & Modulat Conden, Xian 710049, Peoples R China.
   [Liu, Jiankang; Feng, Zhihui] Xi An Jiao Tong Univ, Frontier Inst Sci & Technol, Xian 710049, Peoples R China.
C3 Xi'an Jiaotong University; Xi'an Medical University; Xi'an Jiaotong
   University; Xi'an Jiaotong University
RP Liu, JK; Feng, ZH (通讯作者)，Xi An Jiao Tong Univ, Ctr Mitochondrial Biol & Med, Sch Life Sci & Technol, Key Lab Biomed Informat Engn,Minist Educ, Xian 710049, Peoples R China.
EM j.liu@mail.xjtu.edu.cn; zhfeng@mail.xjtu.edu.cn
RI Feng, Zhihui/E-7408-2011
OI Feng, Zhihui/0000-0002-2448-6565
FU National Natural Science Foundation of China [81571050, 31770917,
   31570777, 91649106, 31701025]; China Postdoctoral Science Foundation
   [2017M613108]; Fundamental Research Funds for the Central Universities
   [Z201806073]
FX This work was supported by the National Natural Science Foundation of
   China (81571050; 31770917; 31570777; 91649106; and 31701025), the
   General Financial Grant from the China Postdoctoral Science Foundation
   (2017M613108) and the Fundamental Research Funds for the Central
   Universities (Z201806073).
CR Alam J, 1999, J BIOL CHEM, V274, P26071, DOI 10.1074/jbc.274.37.26071
   Bellezza I, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.01280
   Bennett BL, 2001, P NATL ACAD SCI USA, V98, P13681, DOI 10.1073/pnas.251194298
   Bhoiwala DL, 2015, INVEST OPHTH VIS SCI, V56, P5344, DOI 10.1167/iovs.15-17026
   Botta D, 2008, DRUG METAB REV, V40, P465, DOI [10.1080/03602530802186587, 10.1080/03602530802186587 ]
   Cano M, 2010, VISION RES, V50, P652, DOI 10.1016/j.visres.2009.08.018
   Alfredo SIC, 2018, PHARMACOL RES, V134, P92, DOI 10.1016/j.phrs.2018.06.013
   Chuang JI, 2015, FREE RADICAL BIO MED, V89, P274, DOI 10.1016/j.freeradbiomed.2015.08.011
   Datta S, 2017, PROG RETIN EYE RES, V60, P201, DOI 10.1016/j.preteyeres.2017.03.002
   Dhubhghaill SSN, 2010, ADV EXP MED BIOL, V664, P437, DOI 10.1007/978-1-4419-1399-9_50
   Feng ZH, 2010, J NUTR BIOCHEM, V21, P1222, DOI 10.1016/j.jnutbio.2009.10.010
   Filomeni G, 2012, BIOCHEM PHARMACOL, V83, P1349, DOI 10.1016/j.bcp.2012.02.003
   Fukui M, 2010, FREE RADICAL BIO MED, V49, P800, DOI 10.1016/j.freeradbiomed.2010.06.002
   Furukawa M, 2005, MOL CELL BIOL, V25, P162, DOI 10.1128/MCB.25.1.162-171.2005
   Gao XQ, 2004, P NATL ACAD SCI USA, V101, P10446, DOI 10.1073/pnas.0403886101
   Gehrs KM, 2006, ANN MED, V38, P450, DOI 10.1080/07853890600946724
   Gutteridge CE, 2011, PHARMACOLOGY, V87, P96, DOI 10.1159/000322532
   Itoh K, 1999, GENE DEV, V13, P76, DOI 10.1101/gad.13.1.76
   Jia LH, 2007, INVEST OPHTH VIS SCI, V48, P339, DOI 10.1167/iovs.06-0248
   Kachadourian R, 2012, J MED CHEM, V55, P1382, DOI 10.1021/jm2016073
   Kinnunen K, 2012, ACTA OPHTHALMOL, V90, P299, DOI 10.1111/j.1755-3768.2011.02179.x
   Kokotas H, 2011, CLIN CHEM LAB MED, V49, P601, DOI 10.1515/CCLM.2011.091
   Kozhevnikova OS, 2013, CELL CYCLE, V12, P1745, DOI 10.4161/cc.24825
   Lambros ML, 2016, ADV EXP MED BIOL, V854, P67, DOI 10.1007/978-3-319-17121-0_10
   Lee JA, 2018, NEUROCHEM INT, V112, P96, DOI 10.1016/j.neuint.2017.11.006
   Li WG, 2009, MOL CARCINOGEN, V48, P91, DOI 10.1002/mc.20465
   Li X, 2008, FREE RADICAL BIO MED, V44, P1465, DOI 10.1016/j.freeradbiomed.2008.01.004
   Li Y, 2013, TOXICOL APPL PHARM, V272, P726, DOI 10.1016/j.taap.2013.07.029
   Malhotra D, 2010, NUCLEIC ACIDS RES, V38, P5718, DOI 10.1093/nar/gkq212
   Nakagami Y, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/7469326
   Nakaso K, 2003, FEBS LETT, V546, P181, DOI 10.1016/S0014-5793(03)00517-9
   Nguyen T, 2009, J BIOL CHEM, V284, P13291, DOI 10.1074/jbc.R900010200
   Pavelic SK, 2015, BBA-MOL BASIS DIS, V1852, P1833, DOI 10.1016/j.bbadis.2015.06.006
   Pawlowska E, 2019, OXID MED CELL LONGEV, V2019, DOI 10.1155/2019/9682318
   Piippo N, 2018, CELL PHYSIOL BIOCHEM, V49, P359, DOI 10.1159/000492886
   Sachdeva MM, 2014, EXP EYE RES, V119, P111, DOI 10.1016/j.exer.2013.10.024
   Saint-Geniez M, 2009, P NATL ACAD SCI USA, V106, P18751, DOI 10.1073/pnas.0905010106
   Singh P, 2014, EUR J MED CHEM, V85, P758, DOI 10.1016/j.ejmech.2014.08.033
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Suh JH, 2004, P NATL ACAD SCI USA, V101, P3381, DOI 10.1073/pnas.0400282101
   Sulaiman RS, 2014, EXP EYE RES, V129, P161, DOI 10.1016/j.exer.2014.10.002
   Suzuki M, 2008, AM J RESP CELL MOL, V39, P673, DOI 10.1165/rcmb.2007-0424OC
   Suzuki T, 2013, TRENDS PHARMACOL SCI, V34, P340, DOI 10.1016/j.tips.2013.04.005
   Vari R, 2011, J NUTR BIOCHEM, V22, P409, DOI 10.1016/j.jnutbio.2010.03.008
   Venugopal R, 1996, P NATL ACAD SCI USA, V93, P14960, DOI 10.1073/pnas.93.25.14960
   VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yang SH, 1999, MOL CELL BIOL, V19, P4028
   Yang SY, 2019, BMC COMPLEM ALTERN M, V19, DOI 10.1186/s12906-019-2551-3
   Zhang DD, 2003, MOL CELL BIOL, V23, P8137, DOI 10.1128/MCB.23.22.8137-8151.2003
   Zhao ZY, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019456
   Zhong Q, 2013, INVEST OPHTH VIS SCI, V54, P3941, DOI 10.1167/iovs.13-11598
   Zipper LM, 2003, TOXICOL SCI, V73, P124, DOI 10.1093/toxsci/kfg083
   Zou X, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.190
   Zou X, 2012, J NUTR BIOCHEM, V23, P994, DOI 10.1016/j.jnutbio.2011.05.006
NR 55
TC 8
Z9 10
U1 4
U2 26
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0891-5849
EI 1873-4596
J9 FREE RADICAL BIO MED
JI Free Radic. Biol. Med.
PD FEB 20
PY 2020
VL 148
BP 52
EP 59
DI 10.1016/j.freeradbiomed.2019.12.033
PG 8
WC Biochemistry & Molecular Biology; Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Endocrinology & Metabolism
GA KK8IX
UT WOS:000512981100006
PM 31887452
DA 2022-11-30
ER

PT J
AU Khan, KB
   Khaliq, AA
   Jalil, A
   Iftikhar, MA
   Ullah, N
   Aziz, MW
   Ullah, K
   Shahid, M
AF Khan, Khan Bahadar
   Khaliq, Amir A.
   Jalil, Abdul
   Iftikhar, Muhammad Aksam
   Ullah, Najeeb
   Aziz, Muhammad Waqar
   Ullah, Kifayat
   Shahid, Muhammad
TI A review of retinal blood vessels extraction techniques: challenges,
   taxonomy, and future trends
SO PATTERN ANALYSIS AND APPLICATIONS
LA English
DT Review
DE Vessels segmentation; DRIVE; STARE; Retina images; Survey; Review
ID FUNDUS IMAGES; MATCHED-FILTER; LEVEL SET; DIABETIC-RETINOPATHY;
   MATHEMATICAL MORPHOLOGY; NEURAL-NETWORKS; COLOR IMAGES; BIT PLANES;
   OPTIC DISC; RED-FREE
AB The visual exploration of retinal blood vessels assists ophthalmologists in the diagnoses of different abnormalities of the eyes such as diabetic retinopathy, glaucoma, cardiovascular ailment, high blood pressure, arteriosclerosis, and age-related macular degeneration. The manual inspection of retinal vasculature is an extremely challenging and tedious task for medical experts due to the complex structure of an eye, tiny blood vessels, and variation in vessels width. Several automatic retinal vessels extraction techniques have been proposed in contemporary literature, which assist ophthalmologists in the timely identification of an eye disorders. However, due to the fast evolution of such techniques, a comprehensive survey is needed. This survey presents a comprehensive review of such techniques, strategies, and algorithms presented to date. The techniques are classified into logical groups based on the underlying methodology employed for retinal vessel extraction. The performance of existing techniques is reported on the publicly accessible datasets in term of various performance measures, providing a valuable comparison among the techniques. Thus, this survey presents a valuable resource for researchers working toward automatic extraction of retinal vessels.
C1 [Khan, Khan Bahadar] Islamia Univ, UCET, Dept Telecommun Engn, Bahawalpur, Pakistan.
   [Khan, Khan Bahadar; Khaliq, Amir A.; Jalil, Abdul] Int Islamic Univ, Dept Elect Engn, Islamabad, Pakistan.
   [Iftikhar, Muhammad Aksam] Comsats Inst Informat Technol, Dept Comp Sci, Lahore, Pakistan.
   [Khan, Khan Bahadar; Ullah, Najeeb; Aziz, Muhammad Waqar; Ullah, Kifayat] CECOS Univ, Dept Comp Sci, Peshawar, Kpk, Pakistan.
   [Shahid, Muhammad] IIT, PAVIS Pattern Anal & Comp Vis Lab, Genoa, Italy.
C3 International Islamic University, Pakistan; COMSATS University Islamabad
   (CUI); Istituto Italiano di Tecnologia - IIT
RP Khan, KB (通讯作者)，Islamia Univ, UCET, Dept Telecommun Engn, Bahawalpur, Pakistan.; Khan, KB (通讯作者)，Int Islamic Univ, Dept Elect Engn, Islamabad, Pakistan.; Khan, KB (通讯作者)，CECOS Univ, Dept Comp Sci, Peshawar, Kpk, Pakistan.
EM kb.khattak@gmail.com
RI Khan, Khan Bahadar/E-2289-2019
OI Khan, Khan Bahadar/0000-0003-1409-7571
CR Abramoff Michael D, 2010, IEEE Rev Biomed Eng, V3, P169, DOI 10.1109/RBME.2010.2084567
   AKITA K, 1982, PATTERN RECOGN, V15, P431, DOI 10.1016/0031-3203(82)90022-X
   Akram MU, 2013, ENG COMPUT-GERMANY, V29, P165, DOI 10.1007/s00366-011-0253-7
   Al-Diri B, 2009, IEEE T MED IMAGING, V28, P1488, DOI 10.1109/TMI.2009.2017941
   Al-Diri B, 2008, IEEE ENG MED BIO, P2262, DOI 10.1109/IEMBS.2008.4649647
   Al-Rawi M, 2007, COMPUT BIOL MED, V37, P262, DOI 10.1016/j.compbiomed.2006.03.003
   Alberti KGMM, 1998, DIABETIC MED, V15, P539, DOI 10.1002/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO;2-S
   Alonso-Montes C, 2008, INT J CIRC THEOR APP, V36, P641, DOI 10.1002/cta.512
   Alonso-Montes C., 2005, Proceedings. 9th IEEE International Workshop on Cellular Neural Networks and their Applications (IEEE Cat. No. 05TH8814), P61
   Alonso-Montes C, 2005, LECT NOTES COMPUT SC, V3687, P165
   Amin MA, 2011, SOFT COMPUT, V15, P1217, DOI 10.1007/s00500-010-0574-2
   Andersson T, 2013, IEEE T IMAGE PROCESS, V22, P621, DOI 10.1109/TIP.2012.2220148
   Anitha J, 2013, NEURAL NETW WORLD, V23, P149, DOI 10.14311/NNW.2013.23.011
   Annunziata R., 2015, J BIOMED HLTH INFORM, V20, P1129
   [Anonymous], 2016, AMBIENT AIR POLLUTIO
   [Anonymous], 2010, VICAVR DATABASE
   [Anonymous], 2006, ARIA ONLINE RETINAL
   [Anonymous], 2004, MESSIDOR METHODS EVA
   Anzalone A, 2008, COMPUT BIOL MED, V38, P913, DOI 10.1016/j.compbiomed.2008.05.006
   Arguello F, 2018, J REAL-TIME IMAGE PR, V14, P773, DOI 10.1007/s11554-014-0469-z
   Ayala G, 2005, IEEE T FUZZY SYST, V13, P384, DOI 10.1109/TFUZZ.2004.839667
   Azzopardi G, 2013, IEEE T PATTERN ANAL, V35, P490, DOI 10.1109/TPAMI.2012.106
   Bao XR, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/137024
   Bekkers E, 2014, J MATH IMAGING VIS, V49, P583, DOI 10.1007/s10851-013-0488-6
   Budai A., 2009, INVESTIG OPHTHALMOL, V50, P325
   Can A, 1999, IEEE Trans Inf Technol Biomed, V3, P125, DOI 10.1109/4233.767088
   Carmona EJ, 2008, ARTIF INTELL MED, V43, P243, DOI 10.1016/j.artmed.2008.04.005
   Ceylan M, 2016, TURK J ELECTR ENG CO, V24, P3212, DOI 10.3906/elk-1408-157
   Chakraborti T, 2015, MACH VISION APPL, V26, P55, DOI 10.1007/s00138-014-0636-z
   Chan TF, 2001, IEEE T IMAGE PROCESS, V10, P266, DOI 10.1109/83.902291
   CHAUDHURI S, 1989, IEEE T MED IMAGING, V8, P263, DOI 10.1109/42.34715
   Cheng EK, 2014, MACH VISION APPL, V25, P1779, DOI 10.1007/s00138-014-0638-x
   Cheng L, 2014, LECT NOTES COMPUT SC, V8673, P626, DOI 10.1007/978-3-319-10404-1_78
   Chutatape O, 1998, P ANN INT IEEE EMBS, V20, P3144, DOI 10.1109/IEMBS.1998.746160
   Cinsdikici MG, 2009, COMPUT METH PROG BIO, V96, P85, DOI 10.1016/j.cmpb.2009.04.005
   Condurache AP, 2012, COMPUT MED IMAG GRAP, V36, P325, DOI 10.1016/j.compmedimag.2012.02.002
   Da Chen, 2015, Scale Space and Variational Methods in Computer Vision. 5th International Conference, SSVM 2015. Proceedings: LNCS 9087, P270, DOI 10.1007/978-3-319-18461-6_22
   Dai PS, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0127748
   De J, 2013, LECT NOTES COMPUT SC, V7944, P277
   De J, 2014, BMC BIOINFORMATICS, V15, DOI 10.1186/1471-2105-15-20
   Delibasis KK, 2010, COMPUT METH PROG BIO, V100, P108, DOI 10.1016/j.cmpb.2010.03.004
   Dizdaroglu B, 2014, EURASIP J IMAGE VIDE, DOI 10.1186/1687-5281-2014-39
   DRIVE, 2004, DRIVE DIGITAL RETINA
   Dudek P, 2006, ELECTRON LETT, V42, P678, DOI 10.1049/el:20060352
   Emary E, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0158738
   Espona L, 2007, LECT NOTES COMPUT SC, V4478, P178
   Fadzil M. H. Ahmad, 2007, Journal of Medical Engineering & Technology, V31, P435, DOI 10.1080/03091900601111201
   Farnell DJJ, 2008, J FRANKLIN I, V345, P748, DOI 10.1016/j.jfranklin.2008.04.009
   Fathi A, 2013, BIOMED SIGNAL PROCES, V8, P71, DOI 10.1016/j.bspc.2012.05.005
   Faust O, 2012, J MED SYST, V36, P145, DOI 10.1007/s10916-010-9454-7
   FIELD C, 1994, INT STAT REV, V62, P405, DOI 10.2307/1403770
   Frangi AF, 1998, LECT NOTES COMPUT SC, V1496, P130, DOI 10.1007/bfb0056195
   Franklin SW, 2014, APPL SOFT COMPUT, V22, P94, DOI 10.1016/j.asoc.2014.04.024
   Franklin SW, 2014, BIOCYBERN BIOMED ENG, V34, P117, DOI 10.1016/j.bbe.2014.01.004
   Fraz MM, 2015, EXPERT SYST APPL, V42, P7221, DOI 10.1016/j.eswa.2015.05.022
   Fraz MM, 2013, J DIGIT IMAGING, V26, P274, DOI 10.1007/s10278-012-9513-3
   Fraz MM, 2013, COMPUT MED IMAG GRAP, V37, P48, DOI 10.1016/j.compmedimag.2013.01.004
   Fraz MM, 2012, COMPUT METH PROG BIO, V108, P600, DOI 10.1016/j.cmpb.2011.08.009
   Fraz MM, 2012, COMPUT METH PROG BIO, V108, P407, DOI 10.1016/j.cmpb.2012.03.009
   Fraz MM, 2012, LECT NOTES COMPUT SC, V7325, P380, DOI 10.1007/978-3-642-31298-4_45
   Fraz M. M., 2011, Advances in Visual Computing. Proceedings 7th International Symposium, ISVC 2011, P410
   Fraz MM, 2014, INT J COMPUT ASS RAD, V9, P795, DOI 10.1007/s11548-013-0965-9
   Fraz MM, 2012, IEEE T BIO-MED ENG, V59, P2538, DOI 10.1109/TBME.2012.2205687
   Fumero F., 2011, 2011 24 INT S COMP B, P1, DOI [DOI 10.1109/CBMS.2011.5999143, 10.1109/CBMS.2011.5999143]
   Gang L, 2002, IEEE T BIO-MED ENG, V49, P168, DOI 10.1109/10.979356
   Ganjee R, 2014, J MED SYST, V38, DOI 10.1007/s10916-014-0108-z
   Gao XH, 2001, 2001 INTERNATIONAL CONFERENCE ON IMAGE PROCESSING, VOL II, PROCEEDINGS, P881, DOI 10.1109/ICIP.2001.958635
   Garcia-Feijoo J, 2008, DRIONS DB
   Garhofer G, 2012, MEASUREMENT RETINAL, P101
   GeethaRamani R, 2016, BIOCYBERN BIOMED ENG, V36, P102, DOI 10.1016/j.bbe.2015.06.004
   Giancardo L, 2012, MED IMAGE ANAL, V16, P216, DOI 10.1016/j.media.2011.07.004
   Guo ZL, 2014, INVERSE PROBL IMAG, V8, P459, DOI 10.3934/ipi.2014.8.459
   Heijl A, 2002, ARCH OPHTHALMOL-CHIC, V120, P1268, DOI 10.1001/archopht.120.10.1268
   Hoover A, 2000, IEEE T MED IMAGING, V19, P203, DOI 10.1109/42.845178
   Huang Y, 2012, MICROVASC RES, V84, P169, DOI 10.1016/j.mvr.2012.05.005
   Hubbard LD, 1999, OPHTHALMOLOGY, V106, P2269, DOI 10.1016/S0161-6420(99)90525-0
   HUBER PJ, 1965, ANN MATH STAT, V36, P1753, DOI 10.1214/aoms/1177699803
   Orlando JI, 2017, IEEE T BIO-MED ENG, V64, P16, DOI 10.1109/TBME.2016.2535311
   Imani E, 2015, COMPUT METH PROG BIO, V118, P263, DOI 10.1016/j.cmpb.2015.01.004
   Jelinek HF, 2010, AUTOMATED IMAGE DETECTION OF RETINAL PATHOLOGY, P1
   Jiang H, 2013, J CONSTR ENG M, V139, DOI 10.1061/(ASCE)CO.1943-7862.0000729
   Jiang K, 2015, J MED IMAG HEALTH IN, V5, P1524, DOI 10.1166/jmihi.2015.1561
   Jiang XY, 2003, IEEE T PATTERN ANAL, V25, P131, DOI 10.1109/TPAMI.2003.1159954
   Jusoh F, 2016, OVERVIEW RETINAL BLO, P63
   Kaba Djibril, 2013, Health Information Science. Second International Conference, HIS 2013. Proceedings, P105, DOI 10.1007/978-3-642-37899-7_9
   Kar SS, 2016, COMPUT BIOL MED, V70, P174, DOI 10.1016/j.compbiomed.2015.12.018
   KASS M, 1987, INT J COMPUT VISION, V1, P321, DOI 10.1007/BF00133570
   Kauppi T, 2007, P MED IM UND AN MIUA, V1, P3
   Khan KB, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0162581
   Koukounis D, 2014, INTEGRATION, V47, P377, DOI 10.1016/j.vlsi.2013.11.005
   Kovacs G, 2016, MED IMAGE ANAL, V29, P24, DOI 10.1016/j.media.2015.12.003
   Kovesi P, 2003, AUSTR PATT REC SOC C
   Krause M, 2016, J REAL-TIME IMAGE PR, V11, P413, DOI 10.1007/s11554-013-0342-5
   Lalondey M, 2000, P C VIS INT, P61
   Lam BSY, 2010, IEEE T MED IMAGING, V29, P1369, DOI 10.1109/TMI.2010.2043259
   Lam BSY, 2008, IEEE T MED IMAGING, V27, P237, DOI 10.1109/TMI.2007.909827
   Lazar I, 2015, COMPUT BIOL MED, V66, P209, DOI 10.1016/j.compbiomed.2015.09.008
   Lerme N, 2014, LECT NOTES COMPUT SC, V8815, P311, DOI 10.1007/978-3-319-11755-3_35
   Li QL, 2016, IEEE T MED IMAGING, V35, P109, DOI 10.1109/TMI.2015.2457891
   Li Q, 2012, EXPERT SYST APPL, V39, P7600, DOI 10.1016/j.eswa.2011.12.046
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Liskowski P, 2016, IEEE T MED IMAGING, V35, P2369, DOI 10.1109/TMI.2016.2546227
   LIU IC, 1993, IEEE T MED IMAGING, V12, P334, DOI 10.1109/42.232264
   Lupascu CA, 2010, COMPUTATIONAL INTELL, P263
   Lupascu CA, 2010, IEEE T INF TECHNOL B, V14, P1267, DOI 10.1109/TITB.2010.2052282
   Mabrouk M.S., 2006, ICGST INT J GRAPH VI, V6, P1
   Mahadevan V, 2004, IEEE T INF TECHNOL B, V8, P360, DOI 10.1109/TITB.2004.834410
   Mapayi T, 2014, LECT NOTES COMPUT SC, V8509, P558, DOI 10.1007/978-3-319-07998-1_64
   Marin D, 2011, IEEE T MED IMAGING, V30, P146, DOI 10.1109/TMI.2010.2064333
   Martinez-Perez M., 1999, MED IMAGE COMPUTING, P90
   Martinez-Perez ME, 2007, MED IMAGE ANAL, V11, P47, DOI 10.1016/j.media.2006.11.004
   McInerney T, 2002, MED IMAGE ANAL, V6, P251, DOI 10.1016/S1361-8415(02)00083-X
   McInerney T, 2000, MED IMAGE ANAL, V4, P73, DOI 10.1016/S1361-8415(00)00008-6
   Mendonca AM, 2006, IEEE T MED IMAGING, V25, P1200, DOI 10.1109/TMI.2006.879955
   Miri MS, 2011, IEEE T BIO-MED ENG, V58, P1183, DOI 10.1109/TBME.2010.2097599
   Moghimirad E, 2012, COMPUT BIOL MED, V42, P50, DOI 10.1016/j.compbiomed.2011.10.008
   Mudassar A. A., 2013, J MED ENG, V2013
   Nain D, 2004, LECT NOTES COMPUT SC, V3216, P51
   Narasimha-Iyer H, 2008, IEEE T INF TECHNOL B, V12, P406, DOI 10.1109/TITB.2007.897782
   Narasimha-Iyer H, 2007, IEEE T BIO-MED ENG, V54, P1427, DOI 10.1109/TBME.2007.900804
   Nayebifar B, 2013, COMPUT BIOL MED, V43, P541, DOI 10.1016/j.compbiomed.2013.01.016
   NEKOVEI R, 1995, IEEE T NEURAL NETWOR, V6, P64, DOI 10.1109/72.363449
   Nguyen UTV, 2013, PATTERN RECOGN, V46, P703, DOI 10.1016/j.patcog.2012.08.009
   Niemeijer M, 2004, PROC SPIE, V5370, P648, DOI 10.1117/12.535349
   Niemeijer M, 2010, IEEE T MED IMAGING, V29, P185, DOI 10.1109/TMI.2009.2033909
   Nieto A, 2009, I C FIELD PROG LOGIC, P485, DOI 10.1109/FPL.2009.5272498
   Oliveira WS, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0149943
   Oloumi F, 2012, IEEE T INSTRUM MEAS, V61, P1825, DOI 10.1109/TIM.2012.2192339
   Ong GL, 2004, AM J OPHTHALMOL, V137, P445, DOI 10.1016/j.ajo.2003.10.021
   Osareh A, 2009, IRAN J SCI TECHNOL B, V33, P191
   Palomera-Perez MA, 2010, IEEE T INF TECHNOL B, V14, P500, DOI 10.1109/TITB.2009.2036604
   Panda R, 2016, BIOCYBERN BIOMED ENG, V36, P119, DOI 10.1016/j.bbe.2015.10.005
   Patton N, 2006, PROG RETIN EYE RES, V25, P99, DOI 10.1016/j.preteyeres.2005.07.001
   Perfetti R, 2007, IEEE T CIRCUITS-II, V54, P141, DOI 10.1109/TCSII.2006.886244
   Poletti E, 2014, OPHTHALMOLOGICAL IMAGING AND APPLICATIONS, P97
   Prentasic P, 2013, INT SYMP IMAGE SIG, P711
   Quek FKH, 2001, IEEE T MED IMAGING, V20, P117, DOI 10.1109/42.913178
   Rad AE, 2017, MULTIMED TOOLS APPL, V76, P2185, DOI 10.1007/s11042-015-3196-y
   Ravichandran CG, 2014, J MED IMAG HEALTH IN, V4, P567, DOI 10.1166/jmihi.2014.1289
   REAVEN GM, 1988, DIABETES, V37, P1595, DOI 10.2337/diabetes.37.12.1595
   Ricci E, 2007, IEEE T MED IMAGING, V26, P1357, DOI 10.1109/TMI.2007.898551
   RONCHETTI E, 1985, STAT PROBABIL LETT, V3, P21, DOI 10.1016/0167-7152(85)90006-9
   Rossant F, 2011, J MED IMAG HEALTH IN, V1, P42, DOI 10.1166/jmihi.2011.1006
   Rouchdy Y, 2013, COMP M BIO BIO E-IV, V1, P79, DOI 10.1080/21681163.2013.766019
   Roychowdhury S, 2015, IEEE J BIOMED HEALTH, V19, P1118, DOI 10.1109/JBHI.2014.2335617
   Salazar-Gonzalez A, 2014, IEEE J BIOMED HEALTH, V18, P1874, DOI 10.1109/JBHI.2014.2302749
   Shahbeig S, 2013, IET IMAGE PROCESS, V7, P392, DOI 10.1049/iet-ipr.2012.0472
   Shehhi RA, 2016, MATH PROBL ENG, V2016, P15
   Sigurosson EM, 2014, PATTERN RECOGN LETT, V47, P164, DOI 10.1016/j.patrec.2014.03.006
   Singh NP, 2016, COMPUT METH PROG BIO, V129, P40, DOI 10.1016/j.cmpb.2016.03.001
   Sinthanayothin C, 1999, BRIT J OPHTHALMOL, V83, P902, DOI 10.1136/bjo.83.8.902
   Sironi A, 2015, IEEE T PATTERN ANAL, V37, P94, DOI 10.1109/TPAMI.2014.2343229
   Soares JVB, 2006, IEEE T MED IMAGING, V25, P1214, DOI 10.1109/TMI.2006.879967
   Sofka M, 2006, IEEE T MED IMAGING, V25, P1531, DOI 10.1109/TMI.2006.884190
   Sossa H, 2014, NEUROCOMPUTING, V131, P132, DOI 10.1016/j.neucom.2013.10.031
   Staal J, 2004, IEEE T MED IMAGING, V23, P501, DOI 10.1109/TMI.2004.825627
   Sukkaew Lassada, 2007, Journal of the Medical Association of Thailand, V90, P1780
   Sum KW, 2008, IEEE T BIO-MED ENG, V55, P358, DOI 10.1109/TBME.2007.896587
   TIELSCH JM, 1991, AM J EPIDEMIOL, V134, P1102, DOI 10.1093/oxfordjournals.aje.a116013
   Tolias YA, 1998, IEEE T MED IMAGING, V17, P263, DOI 10.1109/42.700738
   Varnousfaderani Ehsan S, 2015, AMIA Annu Symp Proc, V2015, P1140
   Vazquez SG, 2013, MACH VISION APPL, V24, P919, DOI 10.1007/s00138-012-0442-4
   Vega Roberto, 2013, Advances in Artificial Intelligence and Its Applications. 12th Mexican International Conference on Artificial Intelligence, MICAI 2013. Proceedings: LNCS 8265, P532, DOI 10.1007/978-3-642-45114-0_42
   Vega R, 2015, COMPUT BIOL MED, V58, P20, DOI 10.1016/j.compbiomed.2014.12.016
   Vermeer KA, 2004, COMPUT BIOL MED, V34, P209, DOI 10.1016/S0010-4825(03)00055-6
   Vilarino DL, 2004, IEEE T CIRCUITS-I, V51, P885, DOI 10.1109/TCSI.2004.827637
   Villalobos-Castaldi FM, 2010, J VISUAL-JAPAN, V13, P263, DOI 10.1007/s12650-010-0037-y
   Vlachos M, 2010, COMPUT MED IMAG GRAP, V34, P213, DOI 10.1016/j.compmedimag.2009.09.006
   Wang L, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0143105
   Wang L, 2007, IEEE T MED IMAGING, V26, P137, DOI 10.1109/TMI.2006.889732
   Wang SL, 2015, NEUROCOMPUTING, V149, P708, DOI 10.1016/j.neucom.2014.07.059
   Wang YF, 2013, PATTERN RECOGN, V46, P2117, DOI 10.1016/j.patcog.2012.12.014
   Welikala RA, 2016, COMPUT BIOL MED, V71, P67, DOI 10.1016/j.compbiomed.2016.01.027
   Winder RJ, 2009, COMPUT MED IMAG GRAP, V33, P608, DOI 10.1016/j.compmedimag.2009.06.003
   Wong CW, 2016, PROG RETIN EYE RES, V53, P107, DOI 10.1016/j.preteyeres.2016.04.002
   Xu LL, 2010, BIOMED ENG ONLINE, V9, DOI 10.1186/1475-925X-9-14
   Xu XY, 2011, IEEE T MED IMAGING, V30, P1184, DOI 10.1109/TMI.2010.2103566
   Yang Y, 2008, INT J AP MAT COM-POL, V18, P399, DOI 10.2478/v10006-008-0036-5
   Yao C, 2009, J CENT SOUTH UNIV T, V16, P640, DOI 10.1007/s11771-009-0106-3
   Yin Y., 2013, COMP MATH MATH PHYS, V2013
   Yin Y, 2012, PATTERN RECOGN, V45, P1235, DOI 10.1016/j.patcog.2011.09.019
   You S., 2011, 2011 IEEE International Conference on Healthcare Informatics, Imaging and Systems Biology, P331, DOI 10.1109/HISB.2011.39
   You XG, 2011, PATTERN RECOGN, V44, P2314, DOI 10.1016/j.patcog.2011.01.007
   Yu H, 2012, SPIE MED IMAGING
   Zana F, 2001, IEEE T IMAGE PROCESS, V10, P1010, DOI 10.1109/83.931095
   Zhang B, 2010, COMPUT BIOL MED, V40, P438, DOI 10.1016/j.compbiomed.2010.02.008
   Zhang J, 2014, COMPUT MED IMAG GRAP, V38, P517, DOI 10.1016/j.compmedimag.2014.05.010
   Zhang J, 2015, LECT NOTES COMPUT SC, V9279, P537, DOI 10.1007/978-3-319-23231-7_48
   Zhang L, 2009, IEEE T INF TECHNOL B, V13, P528, DOI 10.1109/TITB.2008.2007201
   Zhang YP, 2009, J SIGNAL PROCESS SYS, V55, P103, DOI 10.1007/s11265-008-0179-5
   Zhang ZH, 2013, IEEE ASIAN SOLID STA, P393, DOI 10.1109/ASSCC.2013.6691065
   Zhao YT, 2015, IEEE T MED IMAGING, V34, P1797, DOI 10.1109/TMI.2015.2409024
   Zhao YQ, 2014, PATTERN RECOGN, V47, P2437, DOI 10.1016/j.patcog.2014.01.006
   ZHOU LA, 1994, IEEE T MED IMAGING, V13, P619, DOI 10.1109/42.363106
   Zhu CZ, 2016, CHINESE J ELECTRON, V25, P503, DOI 10.1049/cje.2016.05.016
   Zhu T, 2010, COMPUT MED IMAG GRAP, V34, P203, DOI 10.1016/j.compmedimag.2009.09.004
NR 196
TC 30
Z9 31
U1 3
U2 55
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1433-7541
EI 1433-755X
J9 PATTERN ANAL APPL
JI Pattern Anal. Appl.
PD AUG
PY 2019
VL 22
IS 3
BP 767
EP 802
DI 10.1007/s10044-018-0754-8
PG 36
WC Computer Science, Artificial Intelligence
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Computer Science
GA IF4XE
UT WOS:000473084300001
OA Green Published
DA 2022-11-30
ER

PT J
AU Mohammadpour, M
   Heidari, Z
   Mirghorbani, M
   Hashemi, H
AF Mohammadpour, Mehrdad
   Heidari, Zahra
   Mirghorbani, Masoud
   Hashemi, Hassan
TI Smartphones, tele-ophthalmology, and VISION 2020
SO INTERNATIONAL JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE smartphone; tele-ophthalmology; tele-retina; tele-glaucoma;
   tele-retinopathy of prematurity; patient satisfaction; policy making
ID SLIT-LAMP BIOMICROSCOPY; QUALITY-OF-LIFE; DIABETIC-RETINOPATHY;
   COST-EFFECTIVENESS; TELEOPHTHALMOLOGY SYSTEM; DIGITAL PHOTOGRAPHY;
   FUNDUS PHOTOGRAPHY; TELEMEDICINE; PREMATURITY; GLAUCOMA
AB Telemedicine is an emerging field in recent medical achievements with rapid development. The "smartphone" availability has increased in both developed and developing countries even among people in rural and remotes areas. Tele-based services can be used for screening ophthalmic diseases and also monitoring patients with known diseases. Electronic ophthalmologic records of the patients including captured images by smartphones from anterior and posterior segments of the eye will be evaluated by ophthalmologists, and if patients require further evaluations, they will be referred to experts in the relevant field. Eye diseases such as cataract, glaucoma, age-related macular degeneration, diabetic retinopathy, and retinopathy of prematurity are the most common causes of blindness in many countries and beneficial use of teleophthalmology with smartphones will be a good way to achieve the aim of VISION 2020 all over the world. Numerous studies have shown that teleophthalmology is similar to the conventional eye care system in clinical outcomes and even provides more patient satisfaction as it saves time and cost. This review explains how teleophthalmology helps to improve patient outcomes through smartphones.
C1 [Mohammadpour, Mehrdad; Mirghorbani, Masoud] Univ Tehran Med Sci, Dept Ophthalmol, Farabi Eye Hosp, Tehran 1336616351, Iran.
   [Mohammadpour, Mehrdad; Mirghorbani, Masoud] Univ Tehran Med Sci, Eye Res Ctr, Tehran 1336616351, Iran.
   [Mohammadpour, Mehrdad; Heidari, Zahra] Noor Eye Hosp, Noor Ophthalmol Res Ctr, Tehran 1968653111, Iran.
   [Heidari, Zahra] Mazandaran Univ Med Sci, Dept Rehabil Sci, Sari 4815733971, Iran.
   [Hashemi, Hassan] Noor Eye Hosp, Noor Res Ctr Ophthalm Epidemiol, Tehran 1968653111, Iran.
C3 Tehran University of Medical Sciences; Tehran University of Medical
   Sciences; Mazandaran University Medical Sciences
RP Heidari, Z (通讯作者)，Noor Eye Hosp, Ophthalmol Res Ctr, 96,Esfandiar Blvd,Valiasr Ave, Tehran, Iran.
EM zahra.heidari77@Yahoo.com
RI heidari, zahra/AAO-8370-2021; Mirghorbani, S.masoud/AAG-4223-2019;
   Heidari, Zahra/H-3096-2014; MOHAMMADPOUR, Mehrdad/E-8571-2011; Hashemi,
   Hassan/N-2293-2019
OI heidari, zahra/0000-0001-6468-2053; Mirghorbani,
   S.masoud/0000-0003-4295-2563; Heidari, Zahra/0000-0003-1838-9408;
   Hashemi, Hassan/0000-0002-6086-1537
CR Ackland P, 2012, INDIAN J OPHTHALMOL, V60, P380, DOI 10.4103/0301-4738.100531
   Amer Acad Pediat, 2008, PEDIATRICS, V122, P1401, DOI 10.1542/peds.2008-2624
   Andonegui J, 2010, J TELEMED TELECARE, V16, P429, DOI 10.1258/jtt.2010.091204
   [Anonymous], 1976, Am J Ophthalmol, V81, P383
   Aoki N, 2004, DIABETES CARE, V27, P1095, DOI 10.2337/diacare.27.5.1095
   Araci IE, 2014, NAT MED, V20, P1074, DOI 10.1038/nm.3621
   Ayatollahi Haleh, 2017, Open Med Inform J, V11, P20, DOI 10.2174/1874431101711010020
   Beck S, 2010, B WORLD HEALTH ORGAN, V88, P31, DOI 10.2471/BLT.08.062554
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Bursell SE, 2012, CLIN EXP OPTOM, V95, P311, DOI 10.1111/j.1444-0938.2012.00746.x
   Castillo-Riquelme MC, 2004, INT J TECHNOL ASSESS, V20, P201, DOI 10.1017/S0266462304000984
   Chakrabarti R, 2014, J MOB TECHNOL MED, V3, P1
   Chew EY, 2006, CURR OPIN OPHTHALMOL, V17, P519, DOI 10.1097/ICU.0b013e328010948d
   Chew EY, 2014, CONTEMP CLIN TRIALS, V37, P294, DOI 10.1016/j.cct.2014.02.003
   Chiang MF, 2012, OPHTHALMOLOGY, V119, P1272, DOI 10.1016/j.ophtha.2012.01.002
   Chiong HS, 2016, CLIN EXP OPTOM, V99, P580, DOI 10.1111/cxo.12381
   COGAN DG, 1961, ARCH OPHTHALMOL-CHIC, V66, P366, DOI 10.1001/archopht.1961.00960010368014
   Cook C, 2004, SAMJ S AFR MED J, V94, P750
   Coronado A., 2014, INVESTIG OPHTHALMOL, V55, P5330
   Court JH, 2015, CLIN OPHTHALMOL, V9, P745, DOI 10.2147/OPTH.S75000
   Dai SA, 2011, CLIN EXP OPHTHALMOL, V39, P23, DOI 10.1111/j.1442-9071.2010.02399.x
   De Bats F, 2014, OPHTHALMOLOGICA, V231, P172, DOI 10.1159/000356695
   de la Torre-Diez I, 2015, TELEMED E-HEALTH, V21, P81, DOI 10.1089/tmj.2014.0053
   Fierson WM, 2013, PEDIATRICS, V131, P189, DOI 10.1542/peds.2012-2996
   Fletcher D, 2016, United States patent application, Patent No. [US 15/094,750, 15094750]
   Foster A, 2005, EYE, V19, P1133, DOI 10.1038/sj.eye.6701973
   Gilbert C, 2005, PEDIATRICS, V115, pE518, DOI 10.1542/peds.2004-1180
   Hautala N, 2009, ACTA OPHTHALMOL, V87, P912, DOI 10.1111/j.1755-3768.2009.01570.x
   He MG, 2015, OPHTHAL EPIDEMIOL, V22, P237, DOI 10.3109/09286586.2015.1058958
   Hellstrom A, 2013, LANCET, V382, P1445, DOI 10.1016/S0140-6736(13)60178-6
   Jackson KM, 2008, ARCH OPHTHALMOL-CHIC, V126, P493, DOI 10.1001/archopht.126.4.493
   John S, 2012, TELEMED E-HEALTH, V18, P382, DOI 10.1089/tmj.2011.0190
   Jones S, 2010, DIABETIC MED, V27, P249, DOI 10.1111/j.1464-5491.2009.02870.x
   Kandasamy Y, 2013, J PAEDIATR CHILD H, V49, pE1, DOI 10.1111/j.1440-1754.2012.02557.x
   Kaur M, 2015, 2015 INTERNATIONAL CONFERENCE ON GREEN COMPUTING AND INTERNET OF THINGS (ICGCIOT), P1607, DOI 10.1109/ICGCIoT.2015.7380724
   Kelly SP, 2011, CLIN OPHTHALMOL, V5, P1673, DOI 10.2147/OPTH.S26753
   Khouri AS, 2008, TELEMED J E-HEALTH, V14, P261, DOI 10.1089/tmj.2007.0049
   Kiage Dan, 2013, Middle East Afr J Ophthalmol, V20, P150, DOI 10.4103/0974-9233.110604
   Kreatsoulas J., 2010, RETINA TODAY
   Kumar S, 2005, BRIT J OPHTHALMOL, V89, P1382, DOI 10.1136/bjo.2005.072579
   Kumar S, 2006, AM J OPHTHALMOL, V141, P429
   Kurji Khaliq, 2013, Middle East Afr J Ophthalmol, V20, P56, DOI 10.4103/0974-9233.106388
   Lamonaca F, 2015, MEASUREMENT, V73, P82, DOI 10.1016/j.measurement.2015.04.017
   Lau SL, 2015, 2015 IEEE C E LEARN
   Lee JY, 2010, GRAEF ARCH CLIN EXP, V248, P141, DOI 10.1007/s00417-009-1191-6
   Li Zhijian, 2012, Conn Med, V76, P85
   Liesenfeld B, 2000, DIABETES CARE, V23, P345, DOI 10.2337/diacare.23.3.345
   Linkous JD, 2004, TELEMED J E-HEALTH, V10, P469, DOI 10.1089/tmj.2004.10.469
   Litmanovitz I, 2010, ISR MED ASSOC J, V12, P301
   Livingstone I, 2014, INVEST OPHTH VIS SCI, V55
   Loewenstein A, 2012, OPHTHALMIC RES, V48, P11, DOI 10.1159/000339842
   Lord RK, 2010, OPHTHALMOLOGY, V117, P1274, DOI 10.1016/j.ophtha.2010.01.001
   Maamari RN, 2014, BRIT J OPHTHALMOL, V98, P438, DOI 10.1136/bjophthalmol-2013-303797
   Maberley D, 2003, CAN MED ASSOC J, V168, P160
   Maberley DAL, 2005, EYE, V19, P611, DOI 10.1038/sj.eye.6701584
   McKean-Cowdin R, 2007, AM J OPHTHALMOL, V143, P1013, DOI 10.1016/j.ajo.2007.02.022
   Mills T, 2009, DRUG AGING, V26, P933, DOI 10.2165/11316830-000000000-00000
   Mohammadpour M, 2016, CONTACT LENS ANTERIO, V39, P80, DOI 10.1016/j.clae.2015.09.005
   Mosa AM, 2012, BMC MED INFORM DECIS, V12, DOI 10.1186/1472-6947-12-67
   Mukamel D B, 1999, Ophthalmic Epidemiol, V6, P61
   Myung D., 2014, J MOB TECHNOL MED, V3, P2, DOI DOI 10.7309/JMTM.3.1.2
   Myung D., 2014, J MOB TECHNOL MED, V3, P9, DOI 10.7309/jmtm.3.1.3
   Ng Mancho, 2009, J Diabetes Sci Technol, V3, P289
   Nitzkin J L, 1997, Telemed J, V3, P141, DOI 10.1089/tmj.1.1997.3.141
   Paul PG, 2006, TELEMED J E-HEALTH, V12, P571, DOI 10.1089/tmj.2006.12.571
   Pirbhai A, 2005, AM J OPHTHALMOL, V139, P455, DOI 10.1016/j.ajo.2004.09.077
   Quigley HA, 2006, BRIT J OPHTHALMOL, V90, P262, DOI 10.1136/bjo.2005.081224
   Rachapelle S, 2013, OPHTHALMOLOGY, V120, P566, DOI 10.1016/j.ophtha.2012.09.002
   Ribeiro AG, 2014, ARQ BRAS OFTALMOL, V77, P214, DOI 10.5935/0004-2749.20140055
   Richter GM, 2009, SURV OPHTHALMOL, V54, P671, DOI 10.1016/j.survophthal.2009.02.020
   Rudnisky CJ, 2007, OPHTHALMOLOGY, V114, P1748, DOI 10.1016/j.ophtha.2006.12.010
   Russo A, 2016, J GLAUCOMA, V25, pE777, DOI 10.1097/IJG.0000000000000499
   Russo A, 2015, J OPHTHALMOL, V2015, DOI 10.1155/2015/823139
   Russo A, 2015, AM J OPHTHALMOL, V159, P360, DOI 10.1016/j.ajo.2014.11.008
   Salcone EM, 2010, SEMIN OPHTHALMOL, V25, P214, DOI 10.3109/08820538.2010.523671
   Sanguansak T, 2017, J TELEMED TELECARE, V23, P36, DOI 10.1177/1357633X15625400
   Scanlon PH, 2003, BRIT J OPHTHALMOL, V87, P1258, DOI 10.1136/bjo.87.10.1258
   Schoenfeld ER, 2001, OPHTHALMOLOGY, V108, P563, DOI 10.1016/S0161-6420(00)00600-X
   Shahid K, 2012, TELEMED E-HEALTH, V18, P95, DOI 10.1089/tmj.2011.0067
   Shaw JE, 2010, DIABETES RES CLIN PR, V87, P4, DOI 10.1016/j.diabres.2009.10.007
   Silva PS, 2011, ARCH OPHTHALMOL-CHIC, V129, P236, DOI 10.1001/archophthalmol.2010.365
   Sood S, 2007, TELEMED J E-HEALTH, V13, P573, DOI 10.1089/tmj.2006.0073
   Sreelatha OK, 2014, RURAL REMOTE HEALTH, V14
   Sreelatha OK, 2016, CLIN OPHTHALMOL, V10, P285, DOI 10.2147/OPTH.S80487
   Strouthidis NG, 2014, BRIT J OPHTHALMOL, V98, P1605, DOI 10.1136/bjophthalmol-2013-304133
   Surendran Thandalam Sundararajan, 2014, J Diabetes Sci Technol, V8, P262
   Thomas SM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0113779
   Trese MT, 2008, RETINA, V28, P1
   Tuulonen A, 1999, J GLAUCOMA, V8, P367
   Union IT, 2014, ICT FACTS FIG WORLD
   Varma R, 2011, AM J OPHTHALMOL, V152, P515, DOI 10.1016/j.ajo.2011.06.004
   Verma M, 2009, INDIAN J OPHTHALMOL, V57, P381, DOI 10.4103/0301-4738.55078
   Vinekar A, 2014, INDIAN J OPHTHALMOL, V62, P41, DOI 10.4103/0301-4738.126178
   Wang YZ, 2013, INVEST OPHTH VIS SCI, V54, P5497, DOI 10.1167/iovs.13-12037
   Weaver Daniel T, 2014, Int Ophthalmol Clin, V54, P9, DOI 10.1097/IIO.0000000000000036
   Weaver DT, 2012, J AAPOS, V16, P229, DOI 10.1016/j.jaapos.2012.01.007
   Whited JD, 2005, TELEMED J E-HEALTH, V11, P641, DOI 10.1089/tmj.2005.11.641
   Williams GA, 2004, OPHTHALMOLOGY, V111, P1055, DOI 10.1016/j.ophtha.2004.02.004
   Winther C, 2015, J OPHTHALMOL, V2015, DOI 10.1155/2015/285463
   Woodward MA, 2015, TELEMED E-HEALTH, V21, P271, DOI 10.1089/tmj.2014.0115
   World Health Organization, 2013, UN EYE HLTH GLOB ACT, V978, P4
   World Health Organization, 2000, PREV BLINDN DEAFN GL
   Wright HR, 2015, BRIT J OPHTHALMOL, V99, P313, DOI 10.1136/bjophthalmol-2014-305588
   Yu SY, 2014, INVEST OPHTH VIS SCI, V55
   Zimmer-Galler IE, 2005, OPHTHAL SURG LAS IM, V36, P228, DOI 10.3928/1542-8877-20050501-09
NR 105
TC 55
Z9 58
U1 1
U2 7
PU IJO PRESS
PI XI AN
PA NO 269 YOUYI EAST RD, XI AN, 710054, PEOPLES R CHINA
SN 2222-3959
EI 2227-4898
J9 INT J OPHTHALMOL-CHI
JI Int. J. Ophthalmol.
PD DEC 18
PY 2017
VL 10
IS 12
BP 1909
EP 1918
DI 10.18240/ijo.2017.12.19
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA FP9AB
UT WOS:000417937800019
PM 29259912
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Ouyang, H
   Goldberg, JL
   Chen, SY
   Li, W
   Xu, GT
   Li, W
   Zhang, K
   Nussenblatt, RB
   Liu, YZ
   Xie, T
   Chan, CC
   Zack, DJ
AF Ouyang, Hong
   Goldberg, Jeffrey L.
   Chen, Shuyi
   Li, Wei
   Xu, Guo-Tong
   Li, Wei
   Zhang, Kang
   Nussenblatt, Robert B.
   Liu, Yizhi
   Xie, Ting
   Chan, Chi-Chao
   Zack, Donald J.
TI Ocular Stem Cell Research from Basic Science to Clinical Application: A
   Report from Zhongshan Ophthalmic Center Ocular Stem Cell Symposium
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE age-related macular degeneration; glaucoma; limbal stem cell deficiency;
   regenerative medicine; stem cells; eye diseases
ID RETINAL-PIGMENT EPITHELIUM; MULLER GLIA DEDIFFERENTIATION; MACULAR
   DEGENERATION; NEURAL REGENERATION; NEURONAL PROGENITORS; IMMUNE
   PRIVILEGE; DIFFERENTIATION; SURFACE; MECHANISMS; TRANSPLANTATION
AB Stem cells hold promise for treating a wide variety of diseases, including degenerative disorders of the eye. The eye is an ideal organ for stem cell therapy because of its relative immunological privilege, surgical accessibility, and its being a self-contained system. The eye also has many potential target diseases amenable to stem cell-based treatment, such as corneal limbal stem cell deficiency, glaucoma, age-related macular degeneration (AMD), and retinitis pigmentosa (RP). Among them, AMD and glaucoma are the two most common diseases, affecting over 200 million people worldwide. Recent results on the clinical trial of retinal pigment epithelial (RPE) cells from human embryonic stem cells (hESCs) and induced pluripotent stem cells (iPSCs) in treating dry AMD and Stargardt's disease in the US, Japan, England, and China have generated great excitement and hope. This marks the beginning of the ocular stem cell therapy era. The recent Zhongshan Ophthalmic Center Ocular Stem Cell Symposium discussed the potential applications of various stem cell types in stem cell-based therapies, drug discoveries and tissue engineering for treating ocular diseases.
C1 [Ouyang, Hong; Chen, Shuyi; Liu, Yizhi; Chan, Chi-Chao] Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, State Key Lab Ophthalmol, Guangzhou 510060, Guangdong, Peoples R China.
   [Goldberg, Jeffrey L.] Stanford Univ, Dept Ophthalmol, Palo Alto, CA 94303 USA.
   [Li, Wei] NEI, Unit Retinal Neurophysiol, NIH, Bethesda, MD 20892 USA.
   [Xu, Guo-Tong] Tongji Univ, Dept Ophthalmol, Shanghai 200092, Peoples R China.
   [Li, Wei] Xiamen Univ, Dept Ophthalmol, Xiamen 361005, Peoples R China.
   [Zhang, Kang] Univ Calif San Diego, Dept Ophthalmol, San Diego, CA 92093 USA.
   [Nussenblatt, Robert B.; Chan, Chi-Chao] NEI, Immunol Lab, NIH, Bldg 10, Bethesda, MD 20892 USA.
   [Xie, Ting] Stowers Inst Med Res, Kansas City, MO 64110 USA.
   [Zack, Donald J.] Johns Hopkins Univ, Wilmer Ophthalmol Inst, Baltimore, MD 21231 USA.
C3 Sun Yat Sen University; Stanford University; National Institutes of
   Health (NIH) - USA; NIH National Eye Institute (NEI); Tongji University;
   Xiamen University; University of California System; University of
   California San Diego; National Institutes of Health (NIH) - USA; NIH
   National Eye Institute (NEI); Stowers Institute for Medical Research;
   Johns Hopkins University; Johns Hopkins Medicine
RP Chan, CC (通讯作者)，Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, State Key Lab Ophthalmol, Guangzhou 510060, Guangdong, Peoples R China.; Chan, CC (通讯作者)，NEI, Immunol Lab, NIH, Bldg 10, Bethesda, MD 20892 USA.; Xie, T (通讯作者)，Stowers Inst Med Res, Kansas City, MO 64110 USA.; Zack, DJ (通讯作者)，Johns Hopkins Univ, Wilmer Ophthalmol Inst, Baltimore, MD 21231 USA.
EM ouyhong3@mail.sysu.edu.cn; Jeffrey.Goldberg@Stanford.edu;
   chenshy23@mail.sysu.edu.cn; liwei2@nei.nih.gov; gtxu@tongji.edu.cn;
   liwei2@nei.nih.gov; k5zhang@ad.ucsd.edu; nussenblattr@nei.nih.gov;
   yzliu62@yahoo.com; tgx@stowers.org; chanc@nei.nih.gov; dzack@jhmi.edu
RI Zhang, Kang/Y-2740-2019; Li, Wei/P-8985-2015; liu, yi/GXE-9662-2022
OI Zhang, Kang/0000-0002-4549-1697; Li, Wei/0000-0001-7458-2590; Ouyang,
   Hong/0000-0002-7622-7733; Goldberg, Jeffrey/0000-0002-1390-7360
FU Zhongshan Ophthalmic Center (ZOC); NATIONAL EYE INSTITUTE [R01EY023754]
   Funding Source: NIH RePORTER
FX The Zhongshan Ophthalmic Center (ZOC) provided funding support to the
   Symposium and funds for covering the costs to publish in open access.
CR Ahmad S, 2008, STEM CELLS, V26, P1609, DOI 10.1634/stemcells.2007-0782
   BENSON JL, 1991, TRANSPLANTATION, V51, P834, DOI 10.1097/00007890-199104000-00018
   Bermingham-McDonogh O, 2011, NEURON, V71, P389, DOI 10.1016/j.neuron.2011.07.015
   Bernardos RL, 2007, J NEUROSCI, V27, P7028, DOI 10.1523/JNEUROSCI.1624-07.2007
   Blackshaw S, 2004, PLOS BIOL, V2, P1411, DOI 10.1371/journal.pbio.0020247
   Brandl C, 2015, J CLIN MED, V4, P282, DOI 10.3390/jcm4020282
   Burillon C, 2012, INVEST OPHTH VIS SCI, V53, P1325, DOI 10.1167/iovs.11-7744
   Cameron DA, 2000, VISUAL NEUROSCI, V17, P789, DOI 10.1017/S0952523800175121
   Cao XG, 2011, PATHOL INT, V61, P528, DOI 10.1111/j.1440-1827.2011.02695.x
   CHAN CC, 1986, ARCH OPHTHALMOL-CHIC, V104, P725
   Chen MF, 2015, AGING CELL, V14, P635, DOI 10.1111/acel.12346
   Chen S, 2012, NAT NEUROSCI, V15, P954, DOI 10.1038/nn.3128
   Chen YH, 2011, ARCH OPHTHALMOL-CHIC, V129, P344, DOI 10.1001/archophthalmol.2011.10
   COTSARELIS G, 1989, CELL, V57, P201, DOI 10.1016/0092-8674(89)90958-6
   Dahlmann-Noor AH, 2010, DRUG DISCOV TODAY, V15, P287, DOI 10.1016/j.drudis.2010.02.007
   Das AV, 2006, DEV BIOL, V299, P283, DOI 10.1016/j.ydbio.2006.07.029
   DAVANGER M, 1971, NATURE, V229, P560, DOI 10.1038/229560a0
   de Andrade GB, 2014, J COMP NEUROL, V522, P2609, DOI 10.1002/cne.23552
   DETRICK B, 1986, AM J OPHTHALMOL, V101, P584, DOI 10.1016/0002-9394(86)90949-9
   Du YQ, 2012, INVEST OPHTH VIS SCI, V53, P1566, DOI 10.1167/iovs.11-9134
   Dua HS, 2003, EYE, V17, P877, DOI 10.1038/sj.eye.6700573
   Dyer MA, 2000, NAT NEUROSCI, V3, P873, DOI 10.1038/78774
   EICHNER R, 1984, J CELL BIOL, V98, P1388, DOI 10.1083/jcb.98.4.1388
   Enzmann V, 1999, TRANSPL IMMUNOL, V7, P9, DOI 10.1016/S0966-3274(99)80013-6
   Fausett BV, 2008, J NEUROSCI, V28, P1109, DOI 10.1523/JNEUROSCI.4853-07.2008
   Fausett BV, 2006, J NEUROSCI, V26, P6303, DOI 10.1523/JNEUROSCI.0332-06.2006
   Fimbel SM, 2007, J NEUROSCI, V27, P1712, DOI 10.1523/JNEUROSCI.5317-06.2007
   Fischer AJ, 2001, NAT NEUROSCI, V4, P247, DOI 10.1038/85090
   Forrester JV, 2009, EYE, V23, P756, DOI 10.1038/eye.2008.259
   Fuller JA, 2014, ADV EXP MED BIOL, V801, P773, DOI 10.1007/978-1-4614-3209-8_97
   Goldman D, 2014, NAT REV NEUROSCI, V15, P431, DOI 10.1038/nrn3723
   Hamon A, 2016, DEV DYNAM, V245, P727, DOI [10.1002/DVDY.24375, 10.1002/dvdy.24375]
   Hannum G, 2013, MOL CELL, V49, P359, DOI 10.1016/j.molcel.2012.10.016
   Hayashi R, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045435
   Jadhav AP, 2009, PROG RETIN EYE RES, V28, P249, DOI 10.1016/j.preteyeres.2009.05.002
   Jha BS, 2015, CURR STEM CELL REP, V1, P79, DOI 10.1007/s40778-015-0014-4
   Kador KE, 2013, BIOMATERIALS, V34, P4242, DOI 10.1016/j.biomaterials.2013.02.027
   Kamao H, 2014, STEM CELL REP, V2, P205, DOI 10.1016/j.stemcr.2013.12.007
   Karl MO, 2013, CELL TISSUE RES, V353, P311, DOI 10.1007/s00441-013-1646-2
   Karl MO, 2008, P NATL ACAD SCI USA, V105, P19508, DOI 10.1073/pnas.0807453105
   KENYON KR, 1989, OPHTHALMOLOGY, V96, P709
   Knickelbein Jared E, 2015, Int Ophthalmol Clin, V55, P63, DOI 10.1097/IIO.0000000000000073
   Kolli S, 2014, STEM CELLS, V32, P2135, DOI 10.1002/stem.1694
   Ksander BR, 2014, NATURE, V511, P353, DOI 10.1038/nature13426
   LAND MF, 1992, ANNU REV NEUROSCI, V15, P1, DOI 10.1146/annurev.ne.15.030192.000245
   Lenkowski JR, 2014, PROG RETIN EYE RES, V40, P94, DOI 10.1016/j.preteyeres.2013.12.007
   Li C, 2011, J CELL PHYSIOL, V226, P2429, DOI 10.1002/jcp.22591
   Li TQ, 2013, CELL RES, V23, P788, DOI 10.1038/cr.2013.48
   Li W, 2008, J PATHOL, V214, P114, DOI 10.1002/path.2256
   Li W, 2008, INVEST OPHTH VIS SCI, V49, P154, DOI 10.1167/iovs.07-0883
   Li W, 2007, CELL RES, V17, P26, DOI 10.1038/sj.cr.7310137
   Li W, 2007, INVEST OPHTH VIS SCI, V48, P605, DOI 10.1167/iovs.06-0514
   Li WL, 2011, P NATL ACAD SCI USA, V108, P8299, DOI 10.1073/pnas.1014041108
   Li XM, 2010, INVEST OPHTH VIS SCI, V51, P516, DOI 10.1167/iovs.09-3822
   Light AC, 2012, J COMP NEUROL, V520, P2864, DOI 10.1002/cne.23068
   Maruotti J, 2015, P NATL ACAD SCI USA, V112, P10950, DOI 10.1073/pnas.1422818112
   Mehta B, 2013, NEURON, V77, P516, DOI 10.1016/j.neuron.2012.11.024
   Miyagishima KJ, 2014, VISUAL NEUROSCI, V31, P153, DOI 10.1017/S0952523813000308
   Mukhopadhyay M, 2006, DEVELOPMENT, V133, P2149, DOI 10.1242/dev.02381
   Nagashima M, 2013, DEVELOPMENT, V140, P4510, DOI 10.1242/dev.090738
   Nelson BR, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022817
   Niederkorn Jerry Y, 2007, Chem Immunol Allergy, V92, P27, DOI 10.1159/000099251
   Nishida K, 2004, NEW ENGL J MED, V351, P1187, DOI 10.1056/NEJMoa040455
   Ooto S, 2004, P NATL ACAD SCI USA, V101, P13654, DOI 10.1073/pnas.0402129101
   Osakada F, 2007, J NEUROSCI, V27, P4210, DOI 10.1523/JNEUROSCI.4193-06.2007
   Ouyang H, 2014, NATURE, V511, P358, DOI 10.1038/nature13465
   Pearson C, 2015, PROG BRAIN RES, V220, P241, DOI 10.1016/bs.pbr.2015.04.005
   Pellegrini G, 1999, TRANSPLANTATION, V68, P868, DOI 10.1097/00007890-199909270-00021
   PERCOPO CM, 1990, J IMMUNOL, V145, P4101
   Pollak J, 2013, DEVELOPMENT, V140, P2619, DOI 10.1242/dev.091355
   Qiao H, 2009, AM J PATHOL, V174, P414, DOI 10.2353/ajpath.2009.080766
   Qin Z, 2009, P NATL ACAD SCI USA, V106, P9310, DOI 10.1073/pnas.0811186106
   Qu ZP, 2015, STEM CELL RES THER, V6, DOI 10.1186/s13287-015-0207-x
   Rama P, 2001, TRANSPLANTATION, V72, P1478, DOI 10.1097/00007890-200111150-00002
   Ramachandran R, 2012, NAT CELL BIOL, V14, P1013, DOI 10.1038/ncb2586
   Ramachandran R, 2011, P NATL ACAD SCI USA, V108, P15858, DOI 10.1073/pnas.1107220108
   Ramachandran R, 2010, NAT CELL BIOL, V12, P1101, DOI 10.1038/ncb2115
   Roesch K, 2008, J COMP NEUROL, V509, P225, DOI 10.1002/cne.21730
   Sareen D, 2014, STEM CELL TRANSL MED, V3, P1002, DOI 10.5966/sctm.2014-0076
   Schlotzer-Schrehardt U, 2005, EXP EYE RES, V81, P247, DOI 10.1016/j.exer.2005.02.016
   Schwartz SD, 2012, LANCET, V379, P713, DOI 10.1016/S0140-6736(12)60028-2
   Sluch VM, 2015, SCI REP-UK, V5, DOI 10.1038/srep16595
   Sluch VM, 2014, DEV OPHTHALMOL, V53, P111, DOI 10.1159/000358409
   Stenkamp DL, 2007, INT REV CYTOL, V259, P173, DOI 10.1016/S0074-7696(06)59005-9
   Sun Y, 2015, SURV OPHTHALMOL, V60, P93, DOI 10.1016/j.survophthal.2014.07.001
   Takahashi K, 2007, CELL, V131, P861, DOI 10.1016/j.cell.2007.11.019
   Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024
   Trounson A, 2015, CELL STEM CELL, V17, P11, DOI 10.1016/j.stem.2015.06.007
   Ueki Y, 2015, P NATL ACAD SCI USA, V112, P13717, DOI 10.1073/pnas.1510595112
   Venugopalan P, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10472
   Vierbuchen T, 2010, NATURE, V463, P1035, DOI 10.1038/nature08797
   Wahlin KJ, 2014, ADV EXP MED BIOL, V801, P157, DOI 10.1007/978-1-4614-3209-8_20
   Wan J, 2012, DEV CELL, V22, P334, DOI 10.1016/j.devcel.2011.11.020
   Wei L, 2012, CELL REP, V2, P1151, DOI 10.1016/j.celrep.2012.10.013
   Welsbie DS, 2013, P NATL ACAD SCI USA, V110, P4045, DOI 10.1073/pnas.1211284110
   Xu J, 2015, CELL STEM CELL, V16, P119, DOI 10.1016/j.stem.2015.01.013
   Yan RT, 2013, INVEST OPHTH VIS SCI, V54, P4766, DOI 10.1167/iovs.13-11936
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Zhang K, 2012, NAT REV DRUG DISCOV, V11, P541, DOI 10.1038/nrd3745
   Zhang K, 2011, NEW ENGL J MED, V365, P370, DOI 10.1056/NEJMcibr1105280
   Zhao L, 2015, NATURE, V523, P607, DOI 10.1038/nature14650
   Zhao TB, 2011, NATURE, V474, P212, DOI 10.1038/nature10135
   Zhu SY, 2010, CELL STEM CELL, V7, P651, DOI 10.1016/j.stem.2010.11.015
NR 103
TC 8
Z9 9
U1 1
U2 23
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
SN 1422-0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD MAR
PY 2016
VL 17
IS 3
AR 415
DI 10.3390/ijms17030415
PG 15
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA DI7WN
UT WOS:000373712800084
PM 27102165
OA Green Published, Green Submitted, gold
DA 2022-11-30
ER

PT J
AU Pinazo-Duran, MD
   Zanon-Moreno, V
   Garcia-Medina, JJ
   Arevalo, JF
   Gallego-Pinazo, R
   Nucci, C
AF Pinazo-Duran, Maria D.
   Zanon-Moreno, Vicente
   Garcia-Medina, Jose J.
   Fernando Arevalo, J.
   Gallego-Pinazo, Roberto
   Nucci, Carlo
TI Eclectic Ocular Comorbidities and Systemic Diseases with Eye
   Involvement: A Review
SO BIOMED RESEARCH INTERNATIONAL
LA English
DT Review
ID MACULAR DEGENERATION; RETINAL DISEASE; DRY EYE; GLAUCOMA; RETINOPATHY;
   PREVALENCE; DEPRESSION; DISORDER; CHILDREN; OUTCOMES
AB Coexistence of several ocular diseases is more frequent than suspected. In spite of the refractive errors, one or more of the following can be detected simultaneously: glaucoma, cataracts, uveitis, age-related macular degeneration, and dry eyes. In addition, as people age, ocular comorbidities are much more usually seen. Specific diseases are openly acknowledged to affect the eyes and vision, such as diabetes mellitus, hypertension blood pressure, arthritis, hyperthyroidism, neurodegenerative disorders, hematologic malignancies, and/or systemic infections. Recent advances in early diagnosis and therapy of the ophthalmic pathologies have reinforced patient options to prevent visual impairment and blindness. Because of this, it is essential not to overlook sight-threatening conditions such as the ocular comorbidities and/or the eye involvement in the context of systemic disorders. Moreover, the important role of the multidisciplinary cooperation to improve and sustain management of patients affected with eclectic ocular comorbidities and/or systemic disorders with eye repercussion is specifically addressed. This review intends to shed light on these topics to help in making opportune diagnosis and appropriately managing the affected patients.
C1 [Pinazo-Duran, Maria D.; Zanon-Moreno, Vicente; Garcia-Medina, Jose J.; Gallego-Pinazo, Roberto] Fdn Invest Biomed & Sanitaria FISABIO, Ophthalm Res Unit Santiago Grisolia, Ave Gaspar Aguilar 90, Valencia 46017, Spain.
   [Pinazo-Duran, Maria D.; Zanon-Moreno, Vicente] Univ Valencia, Fac Med & Odontol, Dept Surg, Ophthalmol Res Unit, Ave Blasco Ibanez 15, Valencia 46010, Spain.
   [Pinazo-Duran, Maria D.; Garcia-Medina, Jose J.; Gallego-Pinazo, Roberto] Inst Salud Carlos III, Spanish Net Ophthalm Pathol OFTARED, C Sinesio Delgado 4, Madrid 28029, Spain.
   [Garcia-Medina, Jose J.] Univ Hosp Reina Sofia, Dept Ophthalmol, Ave Intendente Jorge Palacios 1, Murcia 30003, Spain.
   [Fernando Arevalo, J.] Johns Hopkins Univ, Sch Med, Wilmer Eye Inst, Retina Div, Nelson Bldg,600 N Wolf St, Baltimore, MD 21287 USA.
   [Gallego-Pinazo, Roberto] Univ & Polytech Hosp La Fe, Dept Ophthalmol, Ave Fernando Abril Martorell 106, Valencia 46026, Spain.
   [Nucci, Carlo] Univ Roma Tor Vergata, Dept Expt Med & Surg, Ophthalm Unit, 81 Oxford St, I-00133 Rome, Italy.
C3 University of Valencia; Instituto de Salud Carlos III; Johns Hopkins
   University; Johns Hopkins Medicine; University of Rome Tor Vergata
RP Pinazo-Duran, MD (通讯作者)，Fdn Invest Biomed & Sanitaria FISABIO, Ophthalm Res Unit Santiago Grisolia, Ave Gaspar Aguilar 90, Valencia 46017, Spain.; Pinazo-Duran, MD (通讯作者)，Univ Valencia, Fac Med & Odontol, Dept Surg, Ophthalmol Res Unit, Ave Blasco Ibanez 15, Valencia 46010, Spain.; Pinazo-Duran, MD (通讯作者)，Inst Salud Carlos III, Spanish Net Ophthalm Pathol OFTARED, C Sinesio Delgado 4, Madrid 28029, Spain.
EM dolores.pinazo@uv.es
RI Zanon-Moreno, Vicente/ABB-7328-2021; Zanon-Moreno, Vicente/B-8348-2009
OI Zanon-Moreno, Vicente/0000-0003-1179-1592; Pinazo-Duran, Maria
   Dolores/0000-0002-0118-7837; Arevalo Suarez, Fernando
   Antonio/0000-0002-4114-5949
CR Abbassi S, 2015, JAMA OPHTHALMOL, V133, DOI 10.1001/jamaophthalmol.2015.1494
   Ackland P, 2012, INDIAN J OPHTHALMOL, V60, P380, DOI 10.4103/0301-4738.100531
   Alanay Y, 2007, J INTELL DISABIL RES, V51, P151, DOI 10.1111/j.1365-2788.2006.00942.x
   Aptel F, 2015, JAMA OPHTHALMOL, V133, P797, DOI 10.1001/jamaophthalmol.2015.0893
   Austin SR, 2015, MED CARE, V53, pE65, DOI 10.1097/MLR.0b013e318297429c
   Avitzour M, 2014, STEM CELL REP, V3, P699, DOI 10.1016/j.stemcr.2014.09.001
   Battaglia S, 2014, DRUG AGING, V31, P787, DOI 10.1007/s40266-014-0213-1
   Baudouin C, 2014, BRIT J OPHTHALMOL, V98, P1168, DOI 10.1136/bjophthalmol-2013-304619
   Becker KN, 2014, DM-DIS MON, V60, P268, DOI 10.1016/j.disamonth.2014.03.007
   Bee YM, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/524754
   Bodenheimer T, 2002, JAMA-J AM MED ASSOC, V288, P1909, DOI 10.1001/jama.288.15.1909
   Cerami C, 2015, J NEUROL SCI, V354, P112, DOI 10.1016/j.jns.2015.04.026
   Cheung CMG, 2014, J INTERN MED, V276, P140, DOI 10.1111/joim.12227
   Christian CW, 2009, PEDIATRICS, V123, P1409, DOI 10.1542/peds.2009-0408
   Cimarolli VR, 2016, CLIN OPHTHALMOL, V10, P55, DOI 10.2147/OPTH.S80489
   Cremer A., 2015, J HUMAN HYPERTENSION
   Davis JC, 2012, BMC GERIATR, V12, DOI 10.1186/1471-2318-12-50
   Dick A. D., 2015, OPHTHALMOLOGY
   El-Mogy A., 2014, MIDDLE E CURRENT PSY, V21, P252
   Erden S, 2012, CLIN EXP HYPERTENS, V34, P397, DOI 10.3109/10641963.2012.663028
   Fernandez CA, 2013, INVEST OPHTH VIS SCI, V54, P3666, DOI 10.1167/iovs.13-11635
   Galbis-Estrada C, 2013, CLIN INTERV AGING, V8, P711, DOI 10.2147/CIA.S43191
   Gallego-Pinazo R, 2014, ARQ BRAS OFTALMOL, V77, P355, DOI 10.5935/0004-2749.20140089
   Gamidov A A, 2015, Vestn Oftalmol, V131, P64, DOI 10.17116/oftalma2015131364-70
   Garcia-Martin E, 2014, OPHTHALMOLOGY, V121, P573, DOI 10.1016/j.ophtha.2013.09.035
   Garg P, 2014, MIDDLE EAST AFR J OP, V21, P128, DOI 10.4103/0974-9233.129757
   Griffith JF, 2015, CLIN OPHTHALMOL, V9, P1275, DOI 10.2147/OPTH.S85851
   Gupta, 2015, OCUL IMMUNOL INFLAMM, V23, P1
   Hoang Q. V., 2014, PATHOLOGIC MYOPIA, P333
   Jeganathan VSE, 2008, DIABETES CARE, V31, P1905, DOI 10.2337/dc08-0342
   Jehangir N, 2016, CURR OPIN OPHTHALMOL, V27, P38, DOI 10.1097/ICU.0000000000000215
   Ji Hong, 2015, Zhonghua Yan Ke Za Zhi, V51, P581
   Kamiya K, 2015, AM J OPHTHALMOL, V160, P851, DOI 10.1016/j.ajo.2015.08.016
   Kanner EM, 2009, J GLAUCOMA, V18, P488, DOI 10.1097/IJG.0b013e31818fb44e
   Kassem IS, 2012, J AAPOS, V16, P437, DOI 10.1016/j.jaapos.2012.06.003
   Kesavamoorthy G., 2015, J CLIN DIAGNOSIS RES, V9, pLC10
   Konradsen TR, 2013, ACTA OPHTHALMOL, V91, P751, DOI 10.1111/aos.12068
   Kranjc BS, 2012, STRABISMUS, V20, P74, DOI 10.3109/09273972.2012.680234
   Kriszt A, 2015, INT J OPHTHALMOL-CHI, V8, P922, DOI 10.3980/j.issn.2222-3959.2015.05.12
   Lavric A., 2015, OCULAR IMMUNOLOGY IN, V2, P1
   Lin HC, 2010, OPHTHALMOLOGY, V117, P2088, DOI 10.1016/j.ophtha.2010.03.003
   Lin IC, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0108938
   Lin Michael K, 2015, Retin Physician, V12, P52
   Liu Yingpeng, 2007, Ophthalmology, V114, pe47, DOI 10.1016/j.ophtha.2007.07.013
   Marrie RA, 2015, MULT SCLER J, V21, P332, DOI 10.1177/1352458514564488
   Marsiglia M, 2016, RETINA-J RET VIT DIS, V36, P64, DOI 10.1097/IAE.0000000000000685
   Melo P, 2010, NEUROCHEM INT, V56, P431, DOI 10.1016/j.neuint.2009.11.017
   Mottet B, 2015, J FR OPHTALMOL, V38, P983, DOI 10.1016/j.jfo.2015.08.006
   Nucci C, 2015, PROG BRAIN RES, V221, P49, DOI 10.1016/bs.pbr.2015.04.010
   Pacheco-Cervera J, 2015, PEDIATR OBES, V10, P448, DOI 10.1111/ijpo.12005
   Papadaki TG, 2007, AM J OPHTHALMOL, V144, P62, DOI 10.1016/j.ajo.2007.03.013
   Qureshi M Babar, 2014, Community Eye Health, V27, P21
   Ranjan R, 2014, ASIA-PAC J OPHTHALMO, V3, P299, DOI 10.1097/APO.0000000000000021
   Rowe AK, 2005, LANCET, V366, P1026, DOI 10.1016/S0140-6736(05)67028-6
   Rowe F, 2016, DISABIL REHABIL, V38, P813, DOI 10.3109/09638288.2015.1061604
   Meirelles SHS, 2015, CLIN OPHTHALMOL, V9, P2139, DOI 10.2147/OPTH.S75384
   Schwartz SG, 2015, CURR PHARM DESIGN, V21, P4694, DOI 10.2174/1381612821666150909101621
   Shea S, 2009, J AM MED INFORM ASSN, V16, P446, DOI 10.1197/jamia.M3157
   Shi YH, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0115625
   Shorstein NH, 2015, OPHTHALMOLOGY, V122, P2450, DOI 10.1016/j.ophtha.2015.08.024
   Sidney Stephen, 2015, Am J Prev Med, V49, pe81, DOI 10.1016/j.amepre.2015.05.014
   Skegro Ivan, 2015, Coll Antropol, V39, P43
   Sobas EM, 2015, CLIN OPHTHALMOL, V9, P1625, DOI 10.2147/OPTH.S86812
   Sodhi A, 2015, JAMA OPHTHALMOL, V133, P1375, DOI 10.1001/jamaophthalmol.2015.3723
   Stromland K, 2002, ALCOHOL ALCOHOLISM, V37, P2, DOI 10.1093/alcalc/37.1.2
   Sykakis E, 2015, J OPHTHALMOL, V2015, DOI 10.1155/2015/172075
   Tan PEZ, 2014, INVEST OPHTH VIS SCI, V55, P8439, DOI 10.1167/iovs.14-15056
   Tanwar M, 2010, CASE REP MED, V2010, DOI 10.1155/2010/212656
   Tedeschi-Reiner E, 2005, AM J CARDIOL, V96, P1107, DOI 10.1016/j.amjcard.2005.05.070
   The PLoS Medicine Editors, 2005, PLOS MED, V2
   Thornton I. L., 2015, ORBIT, V35, P35
   Ting D. S. W., 2015, CLIN EXPT OPHTHALMOL
   Vanya M, 2015, ACTA MICROBIOL IMM H, V62, P403, DOI 10.1556/030.62.2015.4.5
   Villani E, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000001648
   Wang L, 2008, HYPERTENSION, V51, P119, DOI 10.1161/HYPERTENSIONAHA.107.098343
   Wang R, 2014, J PEDIAT OPHTH STRAB, V51, P201, DOI 10.3928/01913913-20140604-01
   Wang TJ, 2012, OPHTHAL EPIDEMIOL, V19, P137, DOI 10.3109/09286586.2012.680531
   Willens D, 2011, CLIN DIABETES, V29, P60, DOI DOI 10.2337/DIACLIN.29.2.60
   Wong TY, 2008, AM J EPIDEMIOL, V167, P51, DOI 10.1093/aje/kwm256
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   World Health Organization, 2010, VIS 2020 RIGHT SIGHT
NR 81
TC 12
Z9 12
U1 0
U2 5
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2314-6133
EI 2314-6141
J9 BIOMED RES INT
JI Biomed Res. Int.
PY 2016
VL 2016
AR 6215745
DI 10.1155/2016/6215745
PG 10
WC Biotechnology & Applied Microbiology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Research & Experimental Medicine
GA DH9AL
UT WOS:000373088100001
PM 27051666
OA gold, Green Published, Green Submitted
DA 2022-11-30
ER

PT J
AU Di Marco, F
   Di Paolo, M
   Romeo, S
   Colecchi, L
   Fiorani, L
   Spana, S
   Stone, J
   Bisti, S
AF Di Marco, Fabiana
   Di Paolo, Mattia
   Romeo, Stefania
   Colecchi, Linda
   Fiorani, Lavinia
   Spana, Sharon
   Stone, Jonathan
   Bisti, Silvia
TI Combining Neuroprotectants in a Model of Retinal Degeneration: No
   Additive Benefit
SO PLOS ONE
LA English
DT Article
ID SAFFRON SUPPLEMENTATION; LIGHT; PHOTOBIOMODULATION; DEATH; MECHANISMS;
   SURVIVAL; OXYGEN
AB The central nervous system undergoing degeneration can be stabilized, and in some models can be restored to function, by neuroprotective treatments. Photobiomodulation (PBM) and dietary saffron are distinctive as neuroprotectants in that they upregulate protective mechanisms, without causing measurable tissue damage. This study reports a first attempt to combine the actions of PBM and saffron. Our working hypothesis was that the actions of PBM and saffron in protecting retinal photoreceptors, in a rat light damage model, would be additive. Results confirmed the neuroprotective potential of each used separately, but gave no evidence that their effects are additive. Detailed analysis suggests that there is actually a negative interaction between PBM and saffron when given simultaneously, with a consequent reduction of the neuroprotection. Specific testing will be required to understand the mechanisms involved and to establish whether there is clinical potential in combining neuroprotectants, to improve the quality of life of people affected by retinal pathology, such as age-related macular degeneration, the major cause of blindness and visual impairment in older adults.
C1 [Di Marco, Fabiana; Di Paolo, Mattia; Romeo, Stefania; Colecchi, Linda; Fiorani, Lavinia; Bisti, Silvia] Univ Aquila, Dept Biotechnol & Appl Clin Sci, I-67100 Laquila, Italy.
   [Spana, Sharon; Stone, Jonathan] Univ Sydney, Discipline Physiol, Sydney, NSW 2006, Australia.
   [Spana, Sharon; Stone, Jonathan] Univ Sydney, Bosch Inst, Sydney, NSW 2006, Australia.
   [Stone, Jonathan; Bisti, Silvia] Australian Natl Univ, ARC Ctr Excellence Vis Sci, Canberra, ACT, Australia.
C3 University of L'Aquila; University of Sydney; University of Sydney;
   Australian National University
RP Di Marco, F (通讯作者)，Univ Aquila, Dept Biotechnol & Appl Clin Sci, I-67100 Laquila, Italy.
EM dm.fabiana@hotmail.it
FU Australian Research Council Centre of Excellence in Vision Science; Sir
   Zelman Cowen Universities Fund; Lord Mayor's Charitable Foundation;
   Australian Travel Awards for L'Aquila Researchers (ARIA); Ministero
   dell'Istruzione, dell'Universita e della Ricerca dedicato ai PRIN,
   Progetti di Ricerca di Interesse Nazionale (MIUR-PRIN)
FX This work was supported by the Australian Research Council Centre of
   Excellence in Vision Science, by the Sir Zelman Cowen Universities Fund
   and the Lord Mayor's Charitable Foundation, by Australian Travel Awards
   for L'Aquila Researchers (ARIA) to FDM and SR and by a Ministero
   dell'Istruzione, dell'Universita e della Ricerca dedicato ai PRIN,
   Progetti di Ricerca di Interesse Nazionale (MIUR-PRIN) (2010-2011)
   research grant to SB. The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Albarracin R, 2011, INVEST OPHTH VIS SCI, V52, P3582, DOI 10.1167/iovs.10-6664
   Begum R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057828
   Bisti S, 2014, VISUAL NEUROSCI, V12, P1
   Bowers F, 2001, INVEST OPHTH VIS SCI, V42, P804
   Di Marco F, 2013, AM J NEURODEGENER DI, V2, P208
   Eells JT, 2008, LECT NOTES ELECTR EN, V12, P39
   Falsini B, 2010, INVEST OPHTH VIS SCI, V51, P6118, DOI 10.1167/iovs.09-4995
   GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493
   Giaccio M, 2004, CRIT REV FOOD SCI, V44, P155, DOI 10.1080/10408690490441433
   Maccarone R, 2008, INVEST OPHTH VIS SCI, V49, P1254, DOI 10.1167/iovs.07-0438
   Marangoni D, 2013, J TRANSL MED, V11, DOI 10.1186/1479-5876-11-228
   Maslim J, 1997, INVEST OPHTH VIS SCI, V38, P1667
   Natoli R, 2010, MOL VIS, V16, P1801
   Organisciak DT, 2010, PROG RETIN EYE RES, V29, P113, DOI 10.1016/j.preteyeres.2009.11.004
   Purushothuman S, 2013, BRAIN RES, V1535, P61, DOI 10.1016/j.brainres.2013.08.047
   Rutar M, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-257
   Stone J, 1999, PROG RETIN EYE RES, V18, P689, DOI 10.1016/S1350-9462(98)00032-9
NR 17
TC 12
Z9 13
U1 0
U2 4
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUN 23
PY 2014
VL 9
IS 6
AR e100389
DI 10.1371/journal.pone.0100389
PG 7
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA AL1WV
UT WOS:000338917900046
PM 24955576
OA gold, Green Published, Green Submitted
DA 2022-11-30
ER

PT J
AU Zuber, AA
   Robinson, DE
   Short, RD
   Steele, DA
   Whittle, JD
AF Zuber, Agnieszka A.
   Robinson, David E.
   Short, Robert D.
   Steele, David A.
   Whittle, Jason D.
TI Development of a surface to increase retinal pigment epithelial cell
   (ARPE-19) proliferation under reduced serum conditions
SO JOURNAL OF MATERIALS SCIENCE-MATERIALS IN MEDICINE
LA English
DT Article
ID MACULAR DEGENERATION; HEPARAN-SULFATE; POLYMER-FILMS; PLASMA; BINDING;
   TRANSPLANTATION; IMMOBILIZATION; ALLYLAMINE; SHEETS
AB Age related macular degeneration of the eye is brought about by damage to the retinal pigment epithelium (RPE) and is a major cause of adult blindness. One potential treatment method is transplantation of RPE cells grown in vitro. Maintaining RPE cell viability and physiological function in vitro is a challenge, and this must also be achieved using materials that can be subsequently used to deliver an intact cell sheet into the eye. In this paper, plasma polymerisation has been used to develop a chemically modified surface for maintaining RPE cells in vitro. Multiwell plates modified with a plasma copolymer of allylamine and octadiene maintained RPE cell growth at a level similar to that of TCPS. However, the addition of bound glycosaminoglycans (GAGs) to the plasma polymerised surface significantly enhanced RPE proliferation. Simply adding GAG to the culture media had no positive effect. It is shown that a combination of plasma polymer and GAG is a promising method for developing suitable surfaces for cell growth and delivery, that can be applied to any substrate material.
C1 [Zuber, Agnieszka A.; Robinson, David E.; Short, Robert D.; Steele, David A.; Whittle, Jason D.] Univ S Australia, Mawson Inst, Adelaide, SA 5001, Australia.
C3 University of South Australia
RP Whittle, JD (通讯作者)，Univ S Australia, Mawson Inst, GPO Box 2471, Adelaide, SA 5001, Australia.
EM Jason.whittle@unisa.edu.au
RI Steele, David A/D-4051-2009; Whittle, Jason D/E-5842-2011
OI Whittle, Jason D/0000-0002-8250-1639; Short, Robert/0000-0001-9173-1180
FU Mawson Institute
FX AZZ would like to thank the Mawson Institute start up fund for funding
   of this research.
CR Alberdi E, 1999, J BIOL CHEM, V274, P31605, DOI 10.1074/jbc.274.44.31605
   Aramant RB, 2002, PROG RETIN EYE RES, V21, P57, DOI 10.1016/S1350-9462(01)00020-9
   BHATT NS, 1994, AM J OPHTHALMOL, V117, P214, DOI 10.1016/S0002-9394(14)73079-X
   Booij JC, 2010, PROG RETIN EYE RES, V29, P1, DOI 10.1016/j.preteyeres.2009.08.003
   Calderon JG, 1998, J BIOMED MATER RES, V42, P597, DOI 10.1002/(SICI)1097-4636(19981215)42:4<597::AID-JBM16>3.0.CO;2-R
   Coad BR, 2012, ACS APPL MATER INTER, V4, P2455, DOI 10.1021/am300128n
   COLE GJ, 1985, J CELL BIOL, V100, P1192, DOI 10.1083/jcb.100.4.1192
   Eriksson AS, 2012, J HISTOCHEM CYTOCHEM, V60, P936, DOI 10.1369/0022155412460242
   Gengenbach TR, 1996, SURF INTERFACE ANAL, V24, P611, DOI 10.1002/(SICI)1096-9918(19960916)24:9<611::AID-SIA169>3.0.CO;2-7
   Gengenbach TR, 1996, SURF INTERFACE ANAL, V24, P271, DOI 10.1002/(SICI)1096-9918(199604)24:4<271::AID-SIA116>3.0.CO;2-J
   Ghosh F, 1999, EXP EYE RES, V68, P67, DOI 10.1006/exer.1998.0582
   Hileman RE, 1998, BIOESSAYS, V20, P156, DOI 10.1002/(SICI)1521-1878(199802)20:2<156::AID-BIES8>3.3.CO;2-#
   Huang KF, 2012, BIOMATERIALS, V33, P2067, DOI 10.1016/j.biomaterials.2011.11.040
   Kociok N, 1998, EXP EYE RES, V67, P237, DOI 10.1006/exer.1998.0517
   Kubota A, 2006, BIOMATERIALS, V27, P3639, DOI 10.1016/j.biomaterials.2006.02.018
   Maguire MG, 2008, OPHTHALMOLOGY, V115, P1468, DOI 10.1016/j.ophtha.2008.02.028
   Marson A, 2009, GLYCOBIOLOGY, V19, P1537, DOI 10.1093/glycob/cwp132
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Meade KA, 2013, J BIOL CHEM, V288, P5530, DOI 10.1074/jbc.M112.423012
   Michelmore A, 2013, RSC ADV, V3, P13540, DOI 10.1039/c3ra41563e
   Michelmore A, 2013, ACS APPL MATER INTER, V5, P5387, DOI 10.1021/am401484b
   PAGE B, 1993, INT J ONCOL, V3, P473
   Pascolini D, 2012, BRIT J OPHTHALMOL, V96, P614, DOI 10.1136/bjophthalmol-2011-300539
   Robinson DE, 2012, BIOMATERIALS, V33, P1007, DOI 10.1016/j.biomaterials.2011.10.042
   Robinson DE, 2010, PLASMA PROCESS POLYM, V7, P102, DOI 10.1002/ppap.200900115
   Shadforth AMA, 2012, BIOMATERIALS, V33, P4110, DOI 10.1016/j.biomaterials.2012.02.040
   Siow KS, 2007, TISSUE ENG, V13, P890
   Siow KS, 2006, PLASMA PROCESS POLYM, V3, P392, DOI 10.1002/ppap.200600021
   Sirko S, 2010, STEM CELLS, V28, P775, DOI 10.1002/stem.309
   Sundback CA, 2005, BIOMATERIALS, V26, P5454, DOI 10.1016/j.biomaterials.2005.02.004
   Trowbridge JM, 2002, GLYCOBIOLOGY, V12, p117R, DOI 10.1093/glycob/cwf066
   Whittle JD, 2000, CHEM MATER, V12, P2664, DOI 10.1021/cm0002158
   Yaji N, 2009, BIOMATERIALS, V30, P797, DOI 10.1016/j.biomaterials.2008.10.045
   Zhang Z, 2005, SURF COAT TECH, V200, P993, DOI 10.1016/j.surfcoat.2005.02.001
NR 34
TC 5
Z9 6
U1 0
U2 14
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0957-4530
EI 1573-4838
J9 J MATER SCI-MATER M
JI J. Mater. Sci.-Mater. Med.
PD MAY
PY 2014
VL 25
IS 5
BP 1367
EP 1373
DI 10.1007/s10856-014-5163-y
PG 7
WC Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Engineering; Materials Science
GA AF1VZ
UT WOS:000334503300016
PM 24493476
DA 2022-11-30
ER

PT J
AU Sugano, E
   Murayama, N
   Takahashi, M
   Tabata, K
   Tamai, M
   Tomita, H
AF Sugano, Eriko
   Murayama, Namie
   Takahashi, Maki
   Tabata, Kitako
   Tamai, Makoto
   Tomita, Hiroshi
TI Essential Role of Thioredoxin 2 in Mitigating Oxidative Stress in
   Retinal Epithelial Cells
SO JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID TRANSCRIPTION FACTOR; HSP90 COMPLEX; APOPTOSIS; PHOTORECEPTORS;
   DETOXIFICATION; SPHINGOSINE; INHIBITION; ACTIVATION; EXPRESSION; GROWTH
AB The retina is constantly subjected to oxidative stress, which is countered by potent antioxidative systems present in retinal pigment epithelial (RPE) cells. Disruption of these systems leads to the development of age-related macular degeneration. Thioredoxin 2 (Trx2) is a potent antioxidant, which acts directly on mitochondria. In the present study, oxidative stress was induced in the human RPE cell line (ARPE-19) using 4-hydroxynonenal (4-HNE) or C2-ceramide. The protective effect of Trx2 against oxidative stress was investigated by assessing cell viability, the kinetics of cell death, mitochondrial metabolic activity, and expression of heat shock proteins (Hsps) in Trx2-overexpressing cell lines generated by transfecting ARPE cells with an adeno-associated virus vector encoding Trx2. We show that overexpression of Trx2 reduced cell death induced by both agents when they were present in low concentrations. Moreover, early after the induction of oxidative stress Trx2 played a key role in the maintenance of the cell viability through upregulation of mitochondrial metabolic activity and inhibition of Hsp70 expression.
C1 [Sugano, Eriko; Murayama, Namie; Takahashi, Maki; Tabata, Kitako; Tomita, Hiroshi] Iwate Univ, Dept Chem & Bioengn, Fac Engn, Grad Sch Engn, Morioka, Iwate 0208551, Japan.
   [Tamai, Makoto] Tohoku Univ, Sch Med, Sendai, Miyagi 9808574, Japan.
   [Tomita, Hiroshi] Tohoku Univ, Grad Sch Med, Sendai, Miyagi 9808574, Japan.
   [Tomita, Hiroshi] Tohoku Univ Hosp, Clin Res Innovat & Educ Ctr, Sendai, Miyagi 9808574, Japan.
   [Tomita, Hiroshi] Iwate Univ, Dept Chem & Bioengn, Fac Engn, Lab Visual Neurosci,Grad Sch Engn, Morioka, Iwate 0208551, Japan.
C3 Iwate University; Tohoku University; Tohoku University; Tohoku
   University; Iwate University
RP Tomita, H (通讯作者)，Iwate Univ, Dept Chem & Bioengn, Fac Engn, Grad Sch Engn, 4-3-5 Ueda, Morioka, Iwate 0208551, Japan.
EM htomita@iwate-u.ac.jp
RI Tomita, Hiroshi/O-2135-2018
OI Tomita, Hiroshi/0000-0003-1051-2301
FU Ministry of Education, Culture, Sports, Science and Technology of Japan
   [23791960, 24390393, 23659804]; Program for Promotion of Fundamental
   Studies in Health Sciences of the National Institute of Biomedical
   Innovation (NIBIO); Grants-in-Aid for Scientific Research [24791833]
   Funding Source: KAKEN
FX This work was supported in part by Grants-in-Aid for Scientific Research
   from the Ministry of Education, Culture, Sports, Science and Technology
   of Japan (nos. 23791960, 24390393, and 23659804) and from the Program
   for Promotion of Fundamental Studies in Health Sciences of the National
   Institute of Biomedical Innovation (NIBIO).
CR Abarikwu SO, 2012, BASIC CLIN PHARMACOL, V110, P441, DOI 10.1111/j.1742-7843.2011.00834.x
   Abe T, 2003, INVEST OPHTH VIS SCI, V44, P4097, DOI 10.1167/iovs.02-0867
   Abrahan CE, 2010, INVEST OPHTH VIS SCI, V51, P1171, DOI 10.1167/iovs.09-3909
   ABRAVAYA K, 1992, GENE DEV, V6, P1153, DOI 10.1101/gad.6.7.1153
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Choudhary S, 2005, TOXICOL APPL PHARM, V204, P122, DOI 10.1016/j.taap.2004.08.023
   Cuvillier O, 2002, BBA-MOL CELL BIOL L, V1585, P153, DOI 10.1016/S1388-1981(02)00336-0
   Dean DO, 2001, INVEST OPHTH VIS SCI, V42, P3031
   FAKTOROVICH EG, 1992, J NEUROSCI, V12, P3554
   Gouaze V, 2001, MOL PHARMACOL, V60, P488
   Grant CM, 2001, MOL MICROBIOL, V39, P533, DOI 10.1046/j.1365-2958.2001.02283.x
   Grimm D, 1999, GENE THER, V6, P1322, DOI 10.1038/sj.gt.3300946
   Gudz TI, 1997, J BIOL CHEM, V272, P24154, DOI 10.1074/jbc.272.39.24154
   HOLMGREN A, 1985, ANNU REV BIOCHEM, V54, P237, DOI 10.1146/annurev.bi.54.070185.001321
   HOLMGREN A, 1989, J BIOL CHEM, V264, P13963
   Jang YJ, 2009, ANN NY ACAD SCI, V1171, P176, DOI 10.1111/j.1749-6632.2009.04727.x
   Kaarniranta K, 2005, NEUROSCI LETT, V382, P185, DOI 10.1016/j.neulet.2005.03.009
   Kapphahn RJ, 2006, EXP EYE RES, V83, P165, DOI 10.1016/j.exer.2005.11.017
   LAURENT TC, 1964, J BIOL CHEM, V239, P3436
   LaVail MM, 1998, INVEST OPHTH VIS SCI, V39, P592
   Lillig CH, 2007, ANTIOXID REDOX SIGN, V9, P25, DOI 10.1089/ars.2007.9.25
   Louie JL, 2002, EXP EYE RES, V75, P271, DOI 10.1006/exer.2002.2022
   Lu LL, 2009, ANTIOXID REDOX SIGN, V11, P715, DOI 10.1089/ARS.2008.2171
   Miranda CL, 2009, CHEM RES TOXICOL, V22, P863, DOI 10.1021/tx900042u
   Morishima N, 2005, J BIOCHEM, V137, P449, DOI 10.1093/jb/mvi057
   Nakashima Izumi, 2003, Molecular Aspects of Medicine, V24, P231, DOI 10.1016/S0098-2997(03)00018-9
   Romero FJ, 1998, ENVIRON HEALTH PERSP, V106, P1229, DOI 10.2307/3433990
   Saari JC, 2012, ANNU REV NUTR, V32, P125, DOI 10.1146/annurev-nutr-071811-150748
   Salminen A, 2010, MOL MED, V16, P535, DOI 10.2119/molmed.2010.00070
   Scheibel T, 1998, BIOCHEM PHARMACOL, V56, P675, DOI 10.1016/S0006-2952(98)00120-8
   Sugano E, 2005, INVEST OPHTH VIS SCI, V46, P3341, DOI 10.1167/iovs.04-1351
   Sugano E, 2003, EXP EYE RES, V77, P203, DOI 10.1016/S0014-4835(03)00115-5
   Sugano E, 2006, CURR EYE RES, V31, P607, DOI 10.1080/02713680600744851
   Sugano E, 2013, CELL STRUCT FUNCT, V38, P81, DOI 10.1247/csf.12025
   Zou JY, 1998, CELL, V94, P471, DOI 10.1016/S0092-8674(00)81588-3
NR 35
TC 13
Z9 13
U1 0
U2 1
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2090-004X
EI 2090-0058
J9 J OPHTHALMOL
JI J. Ophthalmol.
PY 2013
VL 2013
AR 185825
DI 10.1155/2013/185825
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 303GT
UT WOS:000330663200001
PM 24319591
OA gold, Green Submitted, Green Published
DA 2022-11-30
ER

PT J
AU Cai, S
   Smith, ME
   Redenti, SM
   Wnek, GE
   Young, MJ
AF Cai, Sophie
   Smith, Meghan Elisabeth
   Redenti, Stephen Michael
   Wnek, Gary Edmund
   Young, Michael Joseph
TI Mouse Retinal Progenitor Cell Dynamics on Electrospun
   Poly(epsilon-Caprolactone)
SO JOURNAL OF BIOMATERIALS SCIENCE-POLYMER EDITION
LA English
DT Article
DE Progenitor cell; biocompatibility; electrospinning; scaffold;
   polycaprolactone; retina
ID STEM-CELLS; DIFFERENTIATION; SCAFFOLDS; SURVIVAL; TRANSPLANTATION;
   PHOTORECEPTORS; DEGRADATION; FABRICATION; INTEGRATION; NANOFIBERS
AB Age-related macular degeneration, retinitis pigmentosa and glaucoma are among the many retinal degenerative diseases where retinal cell death leads to irreversible vision loss and blindness. Working toward a cell-replacement-based therapy for such diseases, a number of research groups have recently evaluated the feasibility of using retinal progenitor cells (RPCs) cultured and transplanted on biodegradable polymer substrates to replace damaged retinal tissue. Appropriate polymer substrate design is essential to providing a three-dimensional environment that can facilitate cell adhesion, proliferation and post-transplantation migration into the host environment. In this study, we have designed and fabricated a novel, ultra-thin electrospun poly(epsilon-caprolactone) (PCL) scaffold with microscale fiber diameters, appropriate porosity for infiltration by RPCs, and biologically compatible mechanical characteristics. We have verified that our electrospun PCL scaffold supports robust mouse RPC proliferation, adhesion, and differentiation in vitro, as well as migration into mouse retinal explants. These promising results make PCL a strong candidate for further development as a cell transplantation substrate in retinal regenerative research. (C) Koninklijke Brill NV, Leiden, 2011
C1 [Cai, Sophie; Redenti, Stephen Michael; Young, Michael Joseph] Harvard Univ, Dept Ophthalmol, Schepens Eye Res Inst, Sch Med, Boston, MA 02114 USA.
   [Smith, Meghan Elisabeth] Case Western Reserve Univ, Dept Chem Engn, Cleveland, OH 44106 USA.
   [Redenti, Stephen Michael] CUNY Herbert H Lehman Coll, Dept Biol Sci, Bronx, NY 10468 USA.
   [Wnek, Gary Edmund] Case Western Reserve Univ, Dept Macromol Sci & Engn, Cleveland, OH 44106 USA.
C3 Harvard University; Harvard Medical School; Schepens Eye Research
   Institute; Case Western Reserve University; City University of New York
   (CUNY) System; Lehman College (CUNY); Case Western Reserve University
RP Young, MJ (通讯作者)，Harvard Univ, Dept Ophthalmol, Schepens Eye Res Inst, Sch Med, 20 Staniford St, Boston, MA 02114 USA.
EM michael.young@schepens.harvard.edu
FU National Eye Institute; Discovery Eye Foundation; Lincy Foundation
FX S. C. and M. E. S. contributed equally. We thank James Swift for
   assistance with SEM imaging and Randy Huang from the Schepens Flow
   Cytometry Facility for assistance with FACS enrichment. We would also
   like to thank the National Eye Institute, Discovery Eye Foundation, and
   Lincy Foundation for funding support.
CR Ballios BG, 2010, CAN J OPHTHALMOL, V45, P342, DOI 10.3129/i10-070
   Bhardwaj N, 2010, BIOTECHNOL ADV, V28, P325, DOI 10.1016/j.biotechadv.2010.01.004
   Bhatia B, 2010, OPEN OPHTHALMOL J, V4, P30, DOI 10.2174/1874364101004010030
   Bolgen N, 2005, J BIOMAT SCI-POLYM E, V16, P1537, DOI 10.1163/156856205774576655
   Bull ND, 2009, REGEN MED, V4, P855, DOI 10.2217/RME.09.59
   Cepko CL, 1996, P NATL ACAD SCI USA, V93, P589, DOI 10.1073/pnas.93.2.589
   Chacko DM, 2000, BIOCHEM BIOPH RES CO, V268, P842, DOI 10.1006/bbrc.2000.2153
   Cui WG, 2010, SCI TECHNOL ADV MAT, V11, DOI 10.1088/1468-6996/11/1/014108
   Han D, 2006, NANOMED-NANOTECHNOL, V2, P37, DOI 10.1016/j.nano.2006.01.002
   Hirami Y, 2009, NEUROSCI LETT, V458, P126, DOI 10.1016/j.neulet.2009.04.035
   Kohane DS, 2008, PEDIATR RES, V63, P487, DOI 10.1203/01.pdr.0000305937.26105.e7
   Lamba DA, 2009, CELL STEM CELL, V4, P73, DOI 10.1016/j.stem.2008.10.015
   Lavik EB, 2005, BIOMATERIALS, V26, P3187, DOI 10.1016/j.biomaterials.2004.08.022
   Lem J, 1999, P NATL ACAD SCI USA, V96, P736, DOI 10.1073/pnas.96.2.736
   Levine EM, 2000, CELL MOL LIFE SCI, V57, P224, DOI 10.1007/PL00000686
   Li WJ, 2006, ACTA BIOMATER, V2, P377, DOI 10.1016/j.actbio.2006.02.005
   Liang D, 2007, ADV DRUG DELIVER REV, V59, P1392, DOI 10.1016/j.addr.2007.04.021
   MacLaren RE, 2007, EYE, V21, P1352, DOI 10.1038/sj.eye.6702842
   MacLaren RE, 2006, NATURE, V444, P203, DOI 10.1038/nature05161
   Marchetti V, 2010, J CLIN INVEST, V120, P3012, DOI 10.1172/JCI42951
   Neeley WL, 2008, BIOMATERIALS, V29, P418, DOI 10.1016/j.biomaterials.2007.10.007
   Osakada F, 2008, NAT BIOTECHNOL, V26, P215, DOI 10.1038/nbt1384
   Osakada F, 2009, NAT PROTOC, V4, P811, DOI 10.1038/nprot.2009.51
   Pham QP, 2006, TISSUE ENG, V12, P1197, DOI 10.1089/ten.2006.12.1197
   Pritchard CD, 2010, BIOMATERIALS, V31, P7978, DOI 10.1016/j.biomaterials.2010.07.026
   Pritchard CD, 2010, BIOMATERIALS, V31, P2153, DOI 10.1016/j.biomaterials.2009.11.074
   Redenti Stephen, 2008, J Ocul Biol Dis Infor, V1, P19, DOI 10.1007/s12177-008-9005-3
   Sakaguchi DS, 2005, ANN NY ACAD SCI, V1049, P118, DOI 10.1196/annals.1334.012
   Sant S, 2011, J TISSUE ENG REGEN M, V5, P283, DOI 10.1002/term.313
   Schmitt S, 2009, INVEST OPHTH VIS SCI, V50, P5901, DOI 10.1167/iovs.08-3067
   Sill TJ, 2008, BIOMATERIALS, V29, P1989, DOI 10.1016/j.biomaterials.2008.01.011
   Sodha S, 2011, J BIOMAT SCI-POLYM E, V22, P443, DOI 10.1163/092050610X487738
   Sung HJ, 2004, BIOMATERIALS, V25, P5735, DOI 10.1016/j.biomaterials.2004.01.066
   Tao S, 2007, LAB CHIP, V7, P695, DOI 10.1039/b618583e
   Tomita M, 2005, STEM CELLS, V23, P1579, DOI 10.1634/stemcells.2005-0111
   Tucker BA, 2010, BIOMATERIALS, V31, P9, DOI 10.1016/j.biomaterials.2009.09.015
   Wollensak G, 2004, RETINA-J RET VIT DIS, V24, P967, DOI 10.1097/00006982-200412000-00021
NR 37
TC 15
Z9 15
U1 1
U2 18
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 0920-5063
EI 1568-5624
J9 J BIOMAT SCI-POLYM E
JI J. Biomater. Sci.-Polym. Ed.
PY 2012
VL 23
IS 11
BP 1451
EP 1465
DI 10.1163/092050611X584388
PG 15
WC Engineering, Biomedical; Materials Science, Biomaterials; Polymer
   Science
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Engineering; Materials Science; Polymer Science
GA 987VM
UT WOS:000307445900005
PM 21781383
DA 2022-11-30
ER

PT J
AU Korbolina, EE
   Kozhevnikova, OS
   Stefanova, NA
   Kolosova, NG
AF Korbolina, Elena E.
   Kozhevnikova, Ouyna S.
   Stefanova, Nataliya A.
   Kolosova, Natalia G.
TI Quantitative trait loci on chromosome 1 for cataract and AMD-like
   retinopathy in senescence-accelerated OXYS rats
SO AGING-US
LA English
DT Article
DE age-related macular degeneration; cataract; senescence-accelerated OXYS
   rats; QTL analysis; congenic strains
ID RETINAL-PIGMENT EPITHELIUM; MACULAR DEGENERATION; BLOOD-PRESSURE; MOUSE;
   MICE; HYPERTENSION; PREVALENCE; DISSECTION; BEHAVIOR; MODEL
AB Age-related macular degeneration (AMD) and cataract are common age-related diseases in humans. Previously we showed that senescence-accelerated OXYS rats develop retinopathy and cataract, which are comparable to human AMD and senile cataract. Here we focused on the identification of quantitative trait loci (QTLs), which affect early-onset cataract and retinopathy in OXYS rats, using F2 hybrids bred by a reciprocal cross (OXYSxWAG and WAGxOXYS). Chromosome 1 showed significant associations between retinopathy and loci in the regions of markers D1Rat30 and D1Rat219 (QTL1) as well as D1Rat219 and D1Rat81 (QTL2); and between early cataract development with the locus in the region of the markers D1Rat219 and D1Rat81 (QTL2). To determine the effects of these QTLs, we generated two congenic strains by transferring chromosome 1 regions from OXYS into WAG background. Both congenic strains (named WAG/OXYS-1.1 and WAG/OXYS-1.2, respectively) display early cataract and retinopathy development. Thus, we confirmed that genes located in the analyzed regions of chromosome 1 are associated with the development of these diseases in OXYS rats.
C1 [Korbolina, Elena E.; Kozhevnikova, Ouyna S.; Stefanova, Nataliya A.; Kolosova, Natalia G.] Inst Cytol & Genet SB RAS, Novosibirsk 630090, Russia.
C3 Russian Academy of Sciences; Institute of Cytology & Genetics ICG SB RAS
RP Kolosova, NG (通讯作者)，Inst Cytol & Genet SB RAS, Novosibirsk 630090, Russia.
EM kolosova@bionet.nsc.ru
RI Kolosova, Nataliya G/AAR-7409-2020; Kolosova, Nataliya G/P-3178-2015;
   Kozhevnikova, Oyuna S./H-3588-2016; Stefanova, Natalia/V-1530-2018
OI Kolosova, Nataliya G/0000-0003-2398-8544; Kolosova, Nataliya
   G/0000-0003-2398-8544; Kozhevnikova, Oyuna S./0000-0001-6475-4061;
   Stefanova, natalia/0000-0001-5127-5993
FU FASI [16.513.11.3107]; Russian Foundation for Basic Research
   [11-04-00666]; Presidium of RAS "Fundamental Sciences for Medicine"
   [21.13]
FX This work was supported by the following agencies: FASI state contracts
   16.513.11.3107, Russian Foundation for Basic Research (project
   11-04-00666) and Presidium of RAS "Fundamental Sciences for Medicine"
   (project 21.13).
CR Abd-El-Barr MM, 2007, VISION RES, V47, P3394, DOI 10.1016/j.visres.2007.09.016
   Anderson MG, 2001, BMC GENET, V2, DOI 10.1186/1471-2156-2-1
   Beavis WD, 1988, MOL ANAL COMPLEX TRA, P123
   Bouxsein ML, 2002, J BONE MINER RES, V17, P570, DOI 10.1359/jbmr.2002.17.4.570
   Carelli V, 2009, BBA-BIOENERGETICS, V1787, P518, DOI 10.1016/j.bbabio.2009.02.024
   Danciger M, 2003, INVEST OPHTH VIS SCI, V44, P2442, DOI 10.1167/iovs.02-1252
   Dubrovsky YV, 2010, AGING-US, V2, P936, DOI 10.18632/aging.100241
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P532
   Gusarevich OG, 2007, B SB RAMS, V1, P92
   He XQ, 2009, P NATL ACAD SCI USA, V106, P18545, DOI 10.1073/pnas.0907454106
   Izidio GS, 2011, MAMM GENOME, V22, P329, DOI 10.1007/s00335-011-9327-5
   Johnson MD, 2009, HYPERTENSION, V54, P639, DOI 10.1161/HYPERTENSIONAHA.108.126664
   Kolosova N G, 2003, Adv Gerontol, V12, P143
   Kolosova NG, 2003, B EXP BIOL MED+, V136, P415, DOI 10.1023/B:BEBM.0000010967.24302.78
   LANDER E, 1995, NAT GENET, V11, P241, DOI 10.1038/ng1195-241
   LANDER E S, 1987, Genomics, V1, P174, DOI 10.1016/0888-7543(87)90010-3
   LAVAIL MM, 1987, EXP EYE RES, V44, P465, DOI 10.1016/S0014-4835(87)80180-X
   Markovets AM, 2011, AGING-US, V3, P44
   Muraleva N A, 2011, Adv Gerontol, V24, P143
   Neroev VV, 2008, BIOCHEMISTRY-MOSCOW+, V73, P1317, DOI 10.1134/S0006297908120043
   Nijman IJ, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-95
   Obukhova LA, 2009, AGING-US, V1, P389, DOI 10.18632/aging.100043
   Oidopova O S, 2008, Adv Gerontol, V21, P499
   Rakoczy PE, 2006, EXP EYE RES, V82, P741, DOI 10.1016/j.exer.2005.10.012
   Rapp JP, 2000, PHYSIOL REV, V80, P135, DOI 10.1152/physrev.2000.80.1.135
   RAPP JP, 1995, HYPERTENSION, V25, P1121, DOI 10.1161/01.HYP.25.6.1121
   Redina O E, 2009, Neurosci Behav Physiol, V39, P57, DOI 10.1007/s11055-008-9100-8
   Rumyantseva Y, 2008, BIOCHEMISTRY-MOSCOW+, V73, P1176, DOI 10.1134/S0006297908110023
   Sacca SC, 2009, MUTAT RES-FUND MOL M, V667, P98, DOI 10.1016/j.mrfmmm.2008.11.002
   Sato H, 2010, MOL VIS, V16, P378
   Schrader WF, 2006, OPHTHALMOLOGE, V103, P742, DOI 10.1007/s00347-006-1418-4
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   SNELL GD, 1948, J GENET, V49, P87, DOI 10.1007/BF02986826
   Solberg LC, 2004, MAMM GENOME, V15, P648, DOI 10.1007/s00335-004-2326-z
   Stefanova NA, 2011, J ETHNOPHARMACOL, V138, P624, DOI 10.1016/j.jep.2011.10.017
   Strunnikova NV, 2010, HUM MOL GENET, V19, P2468, DOI 10.1093/hmg/ddq129
   Wolf N, 2004, INVEST OPHTH VIS SCI, V45, P1922, DOI 10.1167/iovs.03-0435
   Xiao QH, 2010, PFLUG ARCH EUR J PHY, V460, P559, DOI 10.1007/s00424-010-0821-5
   Zhdankina AA, 2008, B EXP BIOL MED+, V146, P455, DOI 10.1007/s10517-009-0298-4
   Zimdahl H, 2004, SCIENCE, V303, P807, DOI 10.1126/science.1092427
NR 40
TC 11
Z9 14
U1 0
U2 2
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
SN 1945-4589
J9 AGING-US
JI Aging-US
PD JAN
PY 2012
VL 4
IS 1
BP 49
EP 59
DI 10.18632/aging.100427
PG 11
WC Cell Biology; Geriatrics & Gerontology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Geriatrics & Gerontology
GA 931SM
UT WOS:000303239600007
PM 22300709
OA gold, Green Published, Green Submitted
DA 2022-11-30
ER

PT J
AU Wu, JCF
   Chruscinski, A
   Perez, VAD
   Singh, H
   Pitsiouni, M
   Rabinovitch, M
   Utz, PJ
   Cooke, JP
AF Wu, Jenny C. F.
   Chruscinski, Andrzej
   Perez, Vinicio A. De Jesus
   Singh, Harvir
   Pitsiouni, Maria
   Rabinovitch, Marlene
   Utz, Paul J.
   Cooke, John P.
TI Cholinergic Modulation of Angiogenesis: Role of the 7 Nicotinic
   Acetylcholine Receptor
SO JOURNAL OF CELLULAR BIOCHEMISTRY
LA English
DT Article
DE nAChR; siRNA; RPP
ID NITRIC-OXIDE; BETA-CATENIN; ENDOTHELIAL-CELLS; CA2+ PERMEABILITY;
   ALPHA-9; EXPRESSION; PATHWAY; GROWTH; INTERLEUKIN-1-BETA; PROLIFERATION
AB Pathological angiogenesis contributes to tobacco-related diseases such as malignancy, atherosclerosis and age-related macular degeneration. Nicotine acts on endothelial nicotinic acetylcholine receptors (nAChRs) to activate endothelial cells and to augment pathological angiogenesis. In the current study, we studied nAChR subunits involved in these actions. We detected mRNA for all mammalian nAChR subunits except alpha(2), alpha(4), gamma, and delta in four different types of ECs. Using siRNA methodology, we found that the alpha(7) nAChR plays a dominant role in nicotine-induced cell signaling (assessed by intracellular calcium and NO imaging, and studies of protein expression and phosphorylation), as well as nicotine-activated EC functions (proliferation, survival, migration, and tube formation). The alpha(9) and alpha(7) nAChRs have opposing effects on nicotine-induced cell proliferation and survival. Our studies reveal a critical role for the alpha(7) nAChR in mediating the effects of nicotine on the endothelium. Other subunits play a modulatory role. These findings may have therapeutic implications for diseases characterized by pathological angiogenesis. J. Cell. Biochem. 108: 433-446, 2009. (C) 2009 Wiley-Liss, Inc.
C1 [Cooke, John P.] Stanford Univ, Sch Med, Falk Cardiovasc Res Ctr, Dept Cardiovasc Med, Stanford, CA 94305 USA.
   [Chruscinski, Andrzej; Singh, Harvir; Utz, Paul J.] Stanford Univ, Dept Immunol, Stanford, CA 94305 USA.
   [Perez, Vinicio A. De Jesus; Rabinovitch, Marlene] Stanford Univ, Dept Med, Stanford, CA 94305 USA.
C3 Stanford University; Stanford University; Stanford University
RP Cooke, JP (通讯作者)，Stanford Univ, Sch Med, Falk Cardiovasc Res Ctr, Dept Cardiovasc Med, 300 Pasteur Dr, Stanford, CA 94305 USA.
EM john.cooke@stanford.edu
OI Cooke, John/0000-0003-0033-9138
FU National Institutes of Health [R01 HL-75774, R01 CA098303, R21 HL085743,
   IK12 HL087746, R21 DK073905]; California Tobacco Related Disease
   Research Program of the University of California [15IT-0257,
   1514RT-0169]; California Institute for Regenerative Medicine
   [RS1-00183]; NATIONAL CANCER INSTITUTE [R01CA098303] Funding Source: NIH
   RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K12HL087746,
   R21HL085743, R01HL075774] Funding Source: NIH RePORTER; NATIONAL
   INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R21DK073905]
   Funding Source: NIH RePORTER
FX This study was supported by grants from the National Institutes of
   Health (R01 HL-75774, R01 CA098303, R21 HL085743, IK12 HL087746 to Dr.
   Cooke, and R21DK073905 to P.J. Utz), the California Tobacco Related
   Disease Research Program of the University of California (15IT-0257 and
   1514RT-0169), and the California Institute for Regenerative Medicine
   (RS1-00183), and the Stanford Cardiovascular Institute. Dr. Cooke is the
   inventor of patents owned by Stardord University for diagnostic and
   therapeutic applications of the NOS pathway From which he receives
   royalties. Dr. Cooke and Dr. Wit are inventors on Stanford University
   patents related to therapeutic applications of the ITAChR pathway for
   therapeutic modulation of angiogenesis. Several of these patents have
   been licensed to CoMentis Inc., in which company Dr. Cooke has equity.
CR Barbieri SS, 2008, ARTERIOSCL THROM VAS, V28, P732, DOI 10.1161/ATVBAHA.107.159434
   Barbieri SS, 2007, FASEB J, V21, P1831, DOI 10.1096/fj.06-7557com
   Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0
   BOULTER J, 1987, P NATL ACAD SCI USA, V84, P7763, DOI 10.1073/pnas.84.21.7763
   Chan SM, 2004, NAT MED, V10, P1390, DOI 10.1038/nm1139
   Chan SM, 2007, BLOOD, V110, P278, DOI 10.1182/blood-2006-08-039883
   Chernyavsky AI, 2007, EXP CELL RES, V313, P3542, DOI 10.1016/j.yexcr.2007.07.011
   Cooke JP, 2007, LIFE SCI, V80, P2347, DOI 10.1016/j.lfs.2007.01.061
   Cooke JP, 2008, TRENDS CARDIOVAS MED, V18, P247, DOI 10.1016/j.tcm.2008.11.007
   Cooke JP, 2002, CIRCULATION, V105, P2133, DOI 10.1161/01.CIR.0000014928.45119.73
   Dasgupta P, 2006, CELL CYCLE, V5, P2324, DOI 10.4161/cc.5.20.3366
   Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905
   Dejana E, 2004, NAT REV MOL CELL BIO, V5, P261, DOI 10.1038/nrm1357
   Dimmeler S, 1999, NATURE, V399, P601, DOI 10.1038/21224
   ELGOYHEN AB, 1994, CELL, V79, P705, DOI 10.1016/0092-8674(94)90555-X
   FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27
   Frodin M, 1999, MOL CELL ENDOCRINOL, V151, P65, DOI 10.1016/S0303-7207(99)00061-1
   Fuchs P, 2002, AUDIOL NEURO-OTOL, V7, P40, DOI 10.1159/000046862
   Fucile S, 2006, CELL CALCIUM, V39, P349, DOI 10.1016/j.ceca.2005.12.002
   Fucile S, 2004, CELL CALCIUM, V35, P1, DOI 10.1016/j.ceca.2003.08.006
   Gee KR, 2000, CELL CALCIUM, V27, P97, DOI 10.1054/ceca.1999.0095
   Gotti C, 2007, BIOCHEM PHARMACOL, V74, P1102, DOI 10.1016/j.bcp.2007.05.023
   Grando SA, 2007, LIFE SCI, V80, P2181, DOI 10.1016/j.lfs.2007.03.015
   Guo MZ, 2004, J PHYSIOL-LONDON, V554, P78, DOI 10.1113/jphysiol.2003.051086
   Hay N, 2005, CANCER CELL, V8, P179, DOI 10.1016/j.ccr.2005.08.008
   Heeschen C, 2002, J CLIN INVEST, V110, P527, DOI 10.1172/JCI200214676
   Heeschen C, 2001, NAT MED, V7, P833, DOI 10.1038/89961
   HERMAN IM, 1993, J CARDIOVASC PHARM, V22, pS25, DOI 10.1097/00005344-199322004-00005
   Ilan N, 2003, LAB INVEST, V83, P1105, DOI 10.1097/01.LAB.0000083531.84403.8B
   Kiuchi K, 2008, INVEST OPHTH VIS SCI, V49, P1705, DOI 10.1167/iovs.07-0089
   Kojima H, 1998, ANAL CHEM, V70, P2446, DOI 10.1021/ac9801723
   Lips KS, 2002, NEUROSCIENCE, V115, P1, DOI 10.1016/S0306-4522(02)00274-9
   MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0
   Ng MKC, 2007, ARTERIOSCL THROM VAS, V27, P106, DOI 10.1161/01.ATV.0000251517.98396.4a
   Obaya AJ, 2002, CELL MOL LIFE SCI, V59, P126, DOI 10.1007/s00018-002-8410-1
   Peng HS, 2004, LIFE SCI, V76, P263, DOI 10.1016/j.lfs.2004.05.031
   Shesely EG, 1996, P NATL ACAD SCI USA, V93, P13176, DOI 10.1073/pnas.93.23.13176
   Verbitsky M, 2000, NEUROPHARMACOLOGY, V39, P2515, DOI 10.1016/S0028-3908(00)00124-6
   Villablanca AC, 1998, J APPL PHYSIOL, V84, P2089, DOI 10.1152/jappl.1998.84.6.2089
   Zhang B, 2007, J NEUROSCI, V27, P3968, DOI 10.1523/JNEUROSCI.4691-06.2007
   Zhu BQ, 2003, CANCER CELL, V4, P191, DOI 10.1016/S1535-6108(03)00219-8
NR 41
TC 44
Z9 45
U1 0
U2 5
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0730-2312
EI 1097-4644
J9 J CELL BIOCHEM
JI J. Cell. Biochem.
PD OCT 1
PY 2009
VL 108
IS 2
BP 433
EP 446
DI 10.1002/jcb.22270
PG 14
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA 502EM
UT WOS:000270438000012
PM 19623583
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Donati, MC
   Virgili, G
   Bini, A
   Giansanti, F
   Rapizzi, E
   Giacomelli, G
   Menchini, U
AF Donati, M. Carla
   Virgili, Gianni
   Bini, Alessandro
   Giansanti, Fabrizio
   Rapizzi, Emilio
   Giacomelli, Giovanni
   Menchini, Ugo
TI Intravitreal Bevacizumab (Avastin) for Choroidal Neovascularization in
   Angioid Streaks: A Case Series
SO OPHTHALMOLOGICA
LA English
DT Article
DE Angioid streaks; Bevacizumab; Choroidal neovascularization; Intravitreal
   injection
ID MACULAR DEGENERATION; PHOTODYNAMIC THERAPY; SECONDARY
AB Background: Intravitreal (IV) bevacizumab (Avastin (R), Roche), initially used for the off-label treatment of neovascular age-related macular degeneration (AMD), has extended itself to treat various ocular pathologies such as choroidal neovascularization not associated to AMD. Methods: IV bevacizumab 1,25 mg (Avastin) was used in the treatment of choroidal neovascularization (CNV) in 6 eyes of 5 patients with angioid streaks. All cases had a history of photodynamic treatment (PDT) or laser treatment and all showed progressive worsening despite the use of these therapies. Results: After injection patients were followed up at nearly 2- month intervals. IV Avastin was repeated in case of recurrence. Three eyes were treated combining PDT and IV Avastin. Cases were followed up for 7-14 months. All patients needed more IV injections. Five out of 6 eyes showed an improvement of BCVA and a slight reduction of leakage and size with FA. Conclusion: This small series suggests that IV Avastin might be useful in the treatment of CNV due to AS. Copyright (C) 2008 S. Karger AG, Basel
C1 [Donati, M. Carla; Virgili, Gianni; Bini, Alessandro; Giansanti, Fabrizio; Rapizzi, Emilio; Giacomelli, Giovanni; Menchini, Ugo] Univ Florence, Dept Otoneuroophthalmol Surg Sci, Florence, Italy.
C3 University of Florence
RP Bini, A (通讯作者)，Careggi Univ Hosp, Univ Studi Firenze, Viale Morgagni 85, IT-50134 Florence, Italy.
EM albin75po@yahoo.it
RI Giansanti, Fabrizio/I-2193-2012; giacomelli, giovanni/ABC-6173-2020;
   Virgili, Gianni/P-6607-2014
OI Giansanti, Fabrizio/0000-0002-4107-2807; Virgili,
   Gianni/0000-0002-9960-2989
FU Ente Cassa di Risparmio di Firenze
FX Supported by a grant from the Ente Cassa di Risparmio di Firenze.
CR Augustin AJ, 2007, RETINA-J RET VIT DIS, V27, P133, DOI 10.1097/IAE.0b013e3180323de7
   Bhatnagar P, 2007, RETINA-J RET VIT DIS, V27, P897, DOI 10.1097/IAE.0b013e31809ff5df
   HOLZ FG, 2007, ANN M ASS RES VIS OP
   Lommatzsch A, 2007, OPHTHALMOLOGE, V104, P325, DOI 10.1007/s00347-006-1456-y
   MANSOUR AM, 1988, OPHTHALMOLOGICA, V197, P36, DOI 10.1159/000309915
   Menchini U, 2004, RETINA-J RET VIT DIS, V24, P763, DOI 10.1097/00006982-200410000-00013
   Mennel S, 2007, OPHTHALMOLOGICA, V221, P216, DOI 10.1159/000101922
   Pece A, 1997, RETINA-J RET VIT DIS, V17, P12
   Piro PA, 1983, MANAGEMENT RETINAL V, P136
   Rinaldi M, 2007, ARCH OPHTHALMOL-CHIC, V125, P1422, DOI 10.1001/archopht.125.10.1422
   Sachdev Nishant, 2007, Indian J Ophthalmol, V55, P457
   Teixeira A, 2006, ACTA OPHTHALMOL SCAN, V84, P835, DOI 10.1111/j.1600-0420.2006.00762.x
NR 12
TC 17
Z9 18
U1 0
U2 1
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3755
EI 1423-0267
J9 OPHTHALMOLOGICA
JI Ophthalmologica
PY 2009
VL 223
IS 1
BP 24
EP 27
DI 10.1159/000161879
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 387VP
UT WOS:000261980000005
PM 18849633
DA 2022-11-30
ER

PT J
AU Gillies, MC
   Larsson, J
AF Gillies, Mark C.
   Larsson, Jorgen
TI The effect of intravitreal triamcinolone on foveal edema in exudative
   macular degeneration
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID CLINICAL-TRIAL; ACETONIDE
AB PURPOSE: To evaluate the effect of a single intravitreal injection of triamcinolone (IVTA) on central macular thickness and visual acuity in eyes with minimally classic exudative age-related macular degeneration (AMD). DESIGN- Retrospective, nonrandomized clinical interventional study.
   METHODS: Optical coherence tomography (OCT) and best,corrected logarithm of the minimum angle of resolution visual acuity were performed at baseline and one month after treatment.
   RESULTS: We identified I I eyes with foveal edema and minimally classic subfoveal neovascularization treated with an IVTA. Foveal edema decreased significantly from 401 98 mu m at baseline to 295 141 mu m (mean standard deviation; P = .004) at one month. There was, however, no significant change in visual acuity at one or three months after the intervention.
   CONCLUSIONS: This biological effect of IVTA does not support its clinical use, yet it does warrant further research to determine whether locally delivered cortico- steroids may be synergistic with other treatments. Reduction in foveal edema is not necessarily associated with improved visual function in exudative AMD.
C1 Univ Sydney, Save Sight Inst, Dept Clin Ophthalmol, Sydney, NSW 2001, Australia.
C3 University of Sydney
RP Gillies, MC (通讯作者)，Univ Sydney, Save Sight Inst, Dept Clin Ophthalmol, GPO Box 4337, Sydney, NSW 2001, Australia.
EM mark@eye.usyd.edu.au
RI gillies, mark c/B-3242-2012
CR Benhamou N, 2003, AM J OPHTHALMOL, V135, P246, DOI 10.1016/S0002-9394(02)01938-4
   Danis RP, 2000, RETINA-J RET VIT DIS, V20, P244, DOI 10.1097/00006982-200003000-00004
   Gillies MC, 2003, ARCH OPHTHALMOL-CHIC, V121, P667, DOI 10.1001/archopht.121.5.667
   Larsson J, 2005, AM J OPHTHALMOL, V139, P802, DOI 10.1016/j.ajo.2004.12.054
   Park CH, 2003, AM J OPHTHALMOL, V136, P419, DOI 10.1016/S0002-9394(03)00228-9
   Penfold PL, 1995, AUST NZ J OPHTHALMOL, V23, P293, DOI 10.1111/j.1442-9071.1995.tb00179.x
   Sutter FKP, 2004, OPHTHALMOLOGY, V111, P2044, DOI 10.1016/j.ophtha.2004.05.025
NR 7
TC 9
Z9 9
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD JUL
PY 2007
VL 144
IS 1
BP 134
EP 136
DI 10.1016/j.ajo.2007.03.019
PG 3
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 187SD
UT WOS:000247867800026
PM 17601437
DA 2022-11-30
ER

PT J
AU MacLaren, RE
   Aylward, GW
AF MacLaren, RE
   Aylward, GW
TI Delayed atrophy of the retinal pigment epithelium after submacular
   surgery
SO EUROPEAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE retina; CNV; Bruch's membrane; choriocapillaris; macular degeneration
ID SUBFOVEAL NEOVASCULAR MEMBRANES; SURGICAL REMOVAL
AB PURPOSE. We report a case of delayed atrophy of the retinal pigment epithelium (RPE) eighteen months after apparently successful excision of submacular choroidal new vessels (CNV) in a patient with age-related macular degeneration (AMD).
   METHODS. Case report.
   RESULTS. Submacular surgery for CNV was achieved without visible disturbance of the underlying RPE in an 83 year old man diagnosed with AMD. At the time of surgery the CNV displayed clinical features consistent with lying internal to Bruch's membrane (Type 2 configuration). There was no visible RPE defect at the fovea and vision improved during the subsequent 12 months follow-up. Eighteen months later, however, an atrophic central RPE defect appeared, with a similar shape to the CNV originally excised.
   CONCLUSIONS. This case demonstrates that submacular CNV with Type 2 configuration can occur in AMD and lead to an initially favourable outcome following submacular surgery. Atrophy of the RPE nevertheless did eventually occur and in a pattern consistent with damage during the original operation. It is important to consider results of longer term follow-up when interpreting success rates for surgery in AMD.
C1 Moorfields Eye Hosp, Vitreoretinal Serv, London EC1 2PD, England.
C3 University of London; University College London; Moorfields Eye Hospital
   NHS Foundation Trust
RP MacLaren, RE (通讯作者)，Moorfields Eye Hosp, Vitreoretinal Serv, City Rd, London EC1 2PD, England.
EM maclaren@herald.ox.ac.uk
OI MacLaren, Robert/0000-0002-3096-4682
CR BERGER AS, 1992, OPHTHALMOLOGY, V99, P969
   GASS JDM, 1994, AM J OPHTHALMOL, V118, P285, DOI 10.1016/S0002-9394(14)72951-4
   Stanga PE, 2002, OPHTHALMOLOGY, V109, P1492, DOI 10.1016/S0161-6420(02)01099-0
   THOMAS MA, 1991, AM J OPHTHALMOL, V111, P1, DOI 10.1016/S0002-9394(14)76888-6
NR 4
TC 3
Z9 3
U1 0
U2 0
PU WICHTIG EDITORE
PI MILAN
PA 72/74 VIA FRIULI, 20135 MILAN, ITALY
SN 1120-6721
J9 EUR J OPHTHALMOL
JI Eur. J. Ophthalmol.
PD JAN-FEB
PY 2005
VL 15
IS 1
BP 170
EP 172
DI 10.1177/112067210501500131
PG 3
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 900MR
UT WOS:000227219500031
PM 15751262
DA 2022-11-30
ER

PT J
AU Mei, CY
   Zhang, YY
   Pan, LT
   Dong, B
   Chen, XW
   Gao, QY
   Xu, H
   Xu, WJ
   Fang, H
   Liu, SY
   McAlinden, C
   Paschalis, EI
   Wang, QM
   Yang, M
   Huang, JH
   Yu, AY
AF Mei, ChenYang
   Zhang, Yuanyuan
   Pan, Luting
   Dong, Bin
   Chen, Xingwei
   Gao, Qingyi
   Xu, Hang
   Xu, Wenjin
   Fang, Hui
   Liu, Siyu
   McAlinden, Colm
   Paschalis, Eleftherios I.
   Wang, Qinmei
   Yang, Mei
   Huang, Jinhai
   Yu, A-Yong
TI A One-Step Electrochemical Aptasensor Based on Signal Amplification of
   Metallo Nanoenzyme Particles for Vascular Endothelial Growth Factor
SO FRONTIERS IN BIOENGINEERING AND BIOTECHNOLOGY
LA English
DT Article
DE electrochemical aptasensor; vascular endothelial growth factor;
   one-step; signal amplification; metallo nanoenzyme particles
ID TARGET; BIOSENSORS; APTAMERS; SENSORS
AB In this study, a one-step electrochemical aptasensor was developed to detect the biomarker vascular endothelial growth factor (VEGF), an important protein in the pathogenesis of many retinal diseases, including age-related macular degeneration, diabetic retinopathy, retinopathy of prematurity, and retinal vein occlusion. The aptamer has a good affinity and can rapidly identify and capture VEGF based on its unique structure. We designed a VEGF aptasensor based on the aptamer recognition and complex metallo nanoenzyme particles as an electron exchange center and bridge between capture DNA and electrode. The aptamers maintained the hairpin structure to avoid nonspecific surface adsorption and expose the capture sequence outwards when the target was inexistent. Conversely, the aptamers opened the hairpin structure to release space to accomplish binding between VEGF and DNA, resulting in increased impedance. The performance of the electrochemical aptasensor is detected by electrochemical impedance spectroscopy (EIS). The limit of detection by EIS was as low as 8.2 pg ml(-1), and the linear range was 10 pg ml(-1)-1 mu g ml(-1). The electrochemical aptasensor also showed high specificity and reproducibility.
C1 [Mei, ChenYang; Zhang, Yuanyuan; Pan, Luting; Dong, Bin; Chen, Xingwei; Gao, Qingyi; Xu, Hang; Xu, Wenjin; Fang, Hui; Liu, Siyu; Wang, Qinmei; Yang, Mei; Yu, A-Yong] Wenzhou Med Univ, Eye Hosp, Wenzhou, Peoples R China.
   [Mei, ChenYang; Zhang, Yuanyuan; Pan, Luting; Dong, Bin; Chen, Xingwei; Gao, Qingyi; Xu, Hang; Xu, Wenjin; Fang, Hui; Liu, Siyu; Wang, Qinmei; Yang, Mei; Yu, A-Yong] Wenzhou Med Univ, Sch Ophthalmol & Optometry, Wenzhou, Peoples R China.
   [McAlinden, Colm] Swansea Bay Univ Hlth Board, Singleton Hosp, Dept Ophthalmol, Swansea, W Glam, Wales.
   [Paschalis, Eleftherios I.] Harvard Med Sch, Boston, MA 02115 USA.
   [Paschalis, Eleftherios I.] Harvard Med Sch, Massachusetts Eye & Ear, Dept Ophthalmol, Disrupt Technol Lab DTL, Boston, MA 02115 USA.
   [Huang, Jinhai] Fudan Univ, Eye & ENT Hosp, Eye Inst, Shanghai, Peoples R China.
   [Huang, Jinhai] Fudan Univ, Eye & ENT Hosp, Dept Ophthalmol, Shanghai, Peoples R China.
   [Huang, Jinhai] Fudan Univ, Chinese Acad Med Sci, NHC Key Lab Myopia, Key Lab Myopia, Shanghai, Peoples R China.
   [Huang, Jinhai] Shanghai Res Ctr Ophthalmol & Optometry, Shanghai, Peoples R China.
C3 Wenzhou Medical University; Wenzhou Medical University; Singleton
   Hospital; Harvard University; Harvard Medical School; Harvard
   University; Harvard Medical School; Massachusetts Eye & Ear Infirmary;
   Fudan University; Fudan University; Chinese Academy of Medical Sciences
   - Peking Union Medical College; Fudan University
RP Yang, M; Yu, AY (通讯作者)，Wenzhou Med Univ, Eye Hosp, Wenzhou, Peoples R China.; Yang, M; Yu, AY (通讯作者)，Wenzhou Med Univ, Sch Ophthalmol & Optometry, Wenzhou, Peoples R China.; Huang, JH (通讯作者)，Fudan Univ, Eye & ENT Hosp, Eye Inst, Shanghai, Peoples R China.; Huang, JH (通讯作者)，Fudan Univ, Eye & ENT Hosp, Dept Ophthalmol, Shanghai, Peoples R China.; Huang, JH (通讯作者)，Fudan Univ, Chinese Acad Med Sci, NHC Key Lab Myopia, Key Lab Myopia, Shanghai, Peoples R China.; Huang, JH (通讯作者)，Shanghai Res Ctr Ophthalmol & Optometry, Shanghai, Peoples R China.
EM meiyang112686@wmu.edu.cn; vip999vip@163.com; yaybetter@hotmail.com
RI Liu, Siyu/GYV-4856-2022
FU Medical and Health Science and Technology Program of Zhejiang Province
   [2020KY652]; Zhejiang Provincial Natural Science Foundation of China
   [LY21H120003]; Zhejiang Provincial & Ministry of Health Research Fund
   for Medical Sciences [WKJ-ZJ-2134]; Project of Shanghai Science and
   Technology [22S11900200]; EYE & ENT Hospital of Fudan University
   High-level Talents Program [2021318]
FX This work was supported by the Medical and Health Science and Technology
   Program of Zhejiang Province (2020KY652); Zhejiang Provincial Natural
   Science Foundation of China under Grant LY21H120003; Zhejiang Provincial
   & Ministry of Health Research Fund for Medical Sciences (WKJ-ZJ-2134);
   Project of Shanghai Science and Technology (22S11900200); and EYE & ENT
   Hospital of Fudan University High-level Talents Program (2021318).
CR Bozal-Palabiyik B, 2019, ELECTROANAL, V31, P1475, DOI 10.1002/elan.201900185
   Chattaraj R, 2016, ACS APPL MATER INTER, V8, P802, DOI 10.1021/acsami.5b10036
   Cheng W, 2012, BIOSENS BIOELECTRON, V36, P12, DOI 10.1016/j.bios.2012.03.032
   Da HM, 2018, BIOSENS BIOELECTRON, V101, P213, DOI 10.1016/j.bios.2017.10.032
   Dang WY, 2019, TALANTA, V205, DOI 10.1016/j.talanta.2019.06.092
   Diaz-Fernandez A, 2021, BIOSENS BIOELECTRON, V175, DOI 10.1016/j.bios.2020.112872
   Duran BG, 2019, BIOSENS BIOELECTRON, V131, P171, DOI 10.1016/j.bios.2019.02.017
   Ferapontova EE, 2018, ANNU REV ANAL CHEM, V11, P197, DOI 10.1146/annurev-anchem-061417-125811
   Gao XS, 2020, BIOSENS BIOELECTRON, V147, DOI 10.1016/j.bios.2019.111778
   Hu LZ, 2018, ANAL CHEM, V90, P6247, DOI 10.1021/acs.analchem.8b00885
   Ilgu M, 2016, ANALYST, V141, P1551, DOI 10.1039/c5an01824b
   Jayasena SD, 1999, CLIN CHEM, V45, P1628
   JENISON RD, 1994, SCIENCE, V263, P1425, DOI 10.1126/science.7510417
   Kim M, 2019, FRONT CHEM, V7, DOI 10.3389/fchem.2019.00234
   Kumar S, 2017, RSC ADV, V7, P37568, DOI 10.1039/c7ra06973a
   Lange C, 2016, NAT REV NEUROL, V12, P439, DOI 10.1038/nrneurol.2016.88
   Long XY, 2018, ANAL CHEM, V90, P3563, DOI 10.1021/acs.analchem.8b00006
   Mahmoud AM, 2020, ANAL CHIM ACTA, V1133, P58, DOI 10.1016/j.aca.2020.08.001
   Mahmudunnabi RG, 2020, ANALYST, V145, P4398, DOI 10.1039/d0an00558d
   Mei CY, 2021, SENSOR ACTUAT B-CHEM, V345, DOI 10.1016/j.snb.2021.130398
   Mu XY, 2019, ACS NANO, V13, P1870, DOI 10.1021/acsnano.8b08045
   Nandhakumar P, 2020, ANGEW CHEM INT EDIT, V59, P22419, DOI 10.1002/anie.202009737
   Pan LH, 2017, BIOSENS BIOELECTRON, V89, P598, DOI 10.1016/j.bios.2016.01.077
   Roushani M, 2019, MICROCHIM ACTA, V186, DOI 10.1007/s00604-019-3858-y
   Shamsipur M, 2015, BIOSENS BIOELECTRON, V74, P369, DOI 10.1016/j.bios.2015.06.079
   Siew QY, 2021, BIOSENS BIOELECTRON, V176, DOI 10.1016/j.bios.2020.112895
   Lima HRS, 2018, BIOSENS BIOELECTRON, V108, P27, DOI 10.1016/j.bios.2018.02.034
   Stepanova V, 2019, SENSORS-BASEL, V19, DOI 10.3390/s19224962
   Wang XY, 2019, TALANTA, V205, DOI 10.1016/j.talanta.2019.120140
   Yao J, 2018, CHEM SCI, V9, P2927, DOI 10.1039/c7sc05476a
   Zhang GJ, 2021, BIOSENS BIOELECTRON, V173, DOI 10.1016/j.bios.2020.112785
   Zhang HG, 2017, ANALYST, V142, P2419, DOI 10.1039/c7an00541e
   Zhao Yue, 2018, Drugs Context, V7, P212532, DOI 10.7573/dic.212532
   Zhu CX, 2019, J COLLOID INTERF SCI, V546, P92, DOI 10.1016/j.jcis.2019.03.035
   Zhu JL, 2019, BIOSENS BIOELECTRON, V141, DOI 10.1016/j.bios.2019.111450
   Zhu X, 2019, BIOSENS BIOELECTRON, V146, DOI 10.1016/j.bios.2019.111756
NR 36
TC 0
Z9 0
U1 20
U2 21
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 2296-4185
J9 FRONT BIOENG BIOTECH
JI Front. Bioeng. Biotechnol.
PD MAY 9
PY 2022
VL 10
AR 850412
DI 10.3389/fbioe.2022.850412
PG 9
WC Biotechnology & Applied Microbiology; Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Science & Technology - Other
   Topics
GA 1L0LA
UT WOS:000798982900001
PM 35615476
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Othman, R
   Cagnone, G
   Joyal, JS
   Vaucher, E
   Couture, R
AF Othman, Rahmeh
   Cagnone, Gael
   Joyal, Jean-Sebastien
   Vaucher, Elvire
   Couture, Rejean
TI Kinins and Their Receptors as Potential Therapeutic Targets in Retinal
   Pathologies
SO CELLS
LA English
DT Review
DE kallikrein-kinin system; kinin receptors; diabetic retinopathy;
   age-related macular degeneration
ID ANGIOTENSIN-CONVERTING-ENZYME; ENDOTHELIAL-GROWTH-FACTOR; DIABETIC
   MACULAR EDEMA; NITRIC-OXIDE SYNTHASE; B-1 BRADYKININ RECEPTOR; II TYPE-2
   RECEPTOR; RENIN-ANGIOTENSIN; TISSUE KALLIKREIN; UP-REGULATION; RAT MODEL
AB The kallikrein-kinin system (KKS) contributes to retinal inflammation and neovascularization, notably in diabetic retinopathy (DR) and neovascular age-related macular degeneration (AMD). Bradykinin type 1 (B1R) and type 2 (B2R) receptors are G-protein-coupled receptors that sense and mediate the effects of kinins. While B2R is constitutively expressed and regulates a plethora of physiological processes, B1R is almost undetectable under physiological conditions and contributes to pathological inflammation. Several KKS components (kininogens, tissue and plasma kallikreins, and kinin receptors) are overexpressed in human and animal models of retinal diseases, and their inhibition, particularly B1R, reduces inflammation and pathological neovascularization. In this review, we provide an overview of the KKS with emphasis on kinin receptors in the healthy retina and their detrimental roles in DR and AMD. We highlight the crosstalk between the KKS and the renin-angiotensin system (RAS), which is known to be detrimental in ocular pathologies. Targeting the KKS, particularly the B1R, is a promising therapy in retinal diseases, and B1R may represent an effector of the detrimental effects of RAS (Ang II-AT1R).
C1 [Othman, Rahmeh; Vaucher, Elvire] Univ Montreal, Sch Optometry, Montreal, PQ H3T 1P1, Canada.
   [Othman, Rahmeh; Couture, Rejean] Univ Montreal, Fac Med, Dept Pharmacol & Physiol, Montreal, PQ H3T 1J4, Canada.
   [Cagnone, Gael; Joyal, Jean-Sebastien] Univ Montreal, Fac Med, Dept Pediatry, CHU St Justine, Montreal, PQ H3T 1J4, Canada.
C3 Universite de Montreal; Universite de Montreal; Universite de Montreal;
   Centre Hospitalier Universitaire Sainte-Justine
RP Othman, R; Vaucher, E (通讯作者)，Univ Montreal, Sch Optometry, Montreal, PQ H3T 1P1, Canada.; Othman, R; Couture, R (通讯作者)，Univ Montreal, Fac Med, Dept Pharmacol & Physiol, Montreal, PQ H3T 1J4, Canada.
EM rahmeh.othman@umontreal.ca; gael.cagnone@umontreal.ca;
   js.joyal@umontreal.ca; elyire.yaucher@umontreal.ca;
   rejean.couture@umontreal.ca
OI Vaucher, Elvire/0000-0001-7075-5263; Othman, Rahmeh/0000-0002-3323-145X;
   Cagnone, Gael/0000-0001-9664-3518
FU Canadian Institutes of Health Research [PJT-175061]; FRQS Vision Health
   Research Network; Antoine-Turmel Foundation; Graduate Program of
   Physiology; Faculty of Graduate and Postdoctoral Studies; Faculty of
   Medicine, Universite de Montreal
FX This research was funded by the Canadian Institutes of Health Research
   (PJT-175061) and the FRQS Vision Health Research Network, in partnership
   with the Antoine-Turmel Foundation, to E.V. and R.C. R.O. received PhD
   Studentship Awards from the Graduate Program of Physiology, the Faculty
   of Graduate and Postdoctoral Studies, and the Faculty of Medicine,
   Universite de Montreal.
CR Abassi Z, 2021, AM J PHYSIOL-LUNG C, V320, pL422, DOI 10.1152/ajplung.00548.2020
   Abdouh M, 2008, BRIT J PHARMACOL, V154, P136, DOI 10.1038/bjp.2008.48
   Abdouh M, 2003, BRIT J PHARMACOL, V140, P33, DOI 10.1038/sj.bjp.0705210
   Al-Shabrawey M, 2008, INVEST OPHTH VIS SCI, V49, P3239, DOI 10.1167/iovs.08-1755
   Al-Shabrawey M, 2008, INVEST OPHTH VIS SCI, V49, P3231, DOI 10.1167/iovs.08-1754
   Al-Shabrawey M, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/854593
   Albert-Weissenberger C, 2013, PROG NEUROBIOL, V101, P65, DOI 10.1016/j.pneurobio.2012.11.004
   Allred AJ, 2000, AM J PHYSIOL-RENAL, V279, pF841, DOI 10.1152/ajprenal.2000.279.5.F841
   Bas M, 2015, NEW ENGL J MED, V372, P418, DOI 10.1056/NEJMoa1312524
   Bascands JL, 2009, BIOCHEM BIOPH RES CO, V386, P407, DOI 10.1016/j.bbrc.2009.06.063
   Beavers CJ, 2011, ANN PHARMACOTHER, V45, P520, DOI 10.1345/aph.1P630
   Bezalel S, 2015, AM J MED, V128, P120, DOI 10.1016/j.amjmed.2014.07.011
   Bhat Menakshi, 2014, Prog Drug Res, V69, P111
   BHOOLA KD, 1992, PHARMACOL REV, V44, P1
   Binet F, 2020, SCIENCE, V369, P934, DOI 10.1126/science.aay5356
   Blaes N, 2013, EXPERT OPIN THER TAR, V17, P1145, DOI 10.1517/14728222.2013.827664
   Blais C, 1999, PEPTIDES, V20, P421, DOI 10.1016/S0196-9781(99)00020-0
   Borsook D, 2009, NAT REV NEUROL, V5, P306, DOI 10.1038/nrneurol.2009.73
   BRIGGS JP, 1984, AM J PHYSIOL, V247, pF480, DOI 10.1152/ajprenal.1984.247.3.F480
   Brovkovych V, 2011, J CELL MOL MED, V15, P258, DOI 10.1111/j.1582-4934.2009.00992.x
   Campbell DJ, 2003, INT J BIOCHEM CELL B, V35, P784, DOI 10.1016/S1357-2725(02)00262-5
   Campbell WD, 2002, MICROBIOL IMMUNOL, V46, P131, DOI 10.1111/j.1348-0421.2002.tb02669.x
   Campos MM, 1999, BRIT J PHARMACOL, V127, P1851, DOI 10.1038/sj.bjp.0702715
   Canto A, 2019, ANTIOXIDANTS-BASEL, V8, DOI 10.3390/antiox8110543
   Catanzaro O, 2012, PEPTIDES, V34, P349, DOI 10.1016/j.peptides.2012.02.008
   Chaturvedi N, 1998, LANCET, V351, P28, DOI 10.1016/S0140-6736(97)06209-0
   Chaturvedi N, 2001, DIABETIC MED, V18, P288, DOI 10.1046/j.1464-5491.2001.00441.x
   Cheung N, 2014, DIABETES CARE, V37, P900, DOI 10.2337/dc13-1990
   Choudhary M, 2019, ADV EXP MED BIOL, V1185, P9, DOI 10.1007/978-3-030-27378-1_2
   Choudhary R, 2017, J CURR OPHTHALMOL, V29, P7, DOI 10.1016/j.joco.2016.09.009
   Ciulla TA, 2003, DIABETES CARE, V26, P2653, DOI 10.2337/diacare.26.9.2653
   Clermont A, 2016, INVEST OPHTH VIS SCI, V57, P2390, DOI 10.1167/iovs.15-18272
   Clermont A, 2011, DIABETES, V60, P1590, DOI 10.2337/db10-1260
   Couture R, 2001, EUR J PHARMACOL, V429, P161, DOI 10.1016/S0014-2999(01)01318-8
   COUTURE R, 1981, CAN J PHYSIOL PHARM, V59, P621, DOI 10.1139/y81-096
   Couture R, 2014, CURR VASC PHARMACOL, V12, P223, DOI 10.2174/1570161112666140226121627
   da Costa PLN, 2018, BMC CANCER, V18, DOI 10.1186/s12885-018-4260-6
   Dagnino APA, 2020, PHARMACEUTICALS-BASE, V13, DOI 10.3390/ph13090215
   DANSER AHJ, 1989, J CLIN ENDOCR METAB, V68, P160, DOI 10.1210/jcem-68-1-160
   DANSER AHJ, 1994, INVEST OPHTH VIS SCI, V35, P1008
   de Miguel LS, 2008, CARDIOVASC RES, V80, P106, DOI 10.1093/cvr/cvn170
   Decarie A, 1996, AM J PHYSIOL-HEART C, V271, pH1340, DOI 10.1152/ajpheart.1996.271.4.H1340
   Desposito D, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-09721-0
   Desposito D, 2015, J PHARMACOL EXP THER, V352, P218, DOI 10.1124/jpet.114.219196
   Dias JP, 2012, J CARDIOVASC PHARM, V60, P61, DOI 10.1097/FJC.0b013e3182576277
   Duchene J, 2009, CURR OPIN PHARMACOL, V9, P125, DOI 10.1016/j.coph.2008.11.011
   Duka I, 2001, CIRC RES, V88, P275, DOI 10.1161/01.RES.88.3.275
   Ebrahimian TG, 2005, ARTERIOSCL THROM VAS, V25, P65, DOI 10.1161/01.ATV.0000149377.90852.d8
   El-Remessy AB, 2006, AM J PATHOL, V168, P235, DOI 10.2353/ajpath.2006.050500
   El-Remessy AB, 2005, J CELL SCI, V118, P243, DOI 10.1242/jcs.01612
   El-Remessy AB, 2003, INVEST OPHTH VIS SCI, V44, P3135, DOI 10.1167/iovs.02-1022
   Emanueli C, 2002, CIRCULATION, V105, P360, DOI 10.1161/hc0302.102142
   Emanueli C, 2001, TRENDS PHARMACOL SCI, V22, P478, DOI 10.1016/S0165-6147(00)01761-2
   Erdos E., 1979, HDB EXPT PHARM S, VXXV, P427
   Erdos EG, 2001, BIOL CHEM, V382, P43, DOI 10.1515/BC.2001.007
   Fernandes L, 2006, REGUL PEPTIDES, V136, P92, DOI 10.1016/j.regpep.2006.04.018
   Ferrario CM, 2006, J RENIN-ANGIO-ALDO S, V7, P3, DOI 10.3317/jraas.2006.003
   Forrester SJ, 2018, PHYSIOL REV, V98, P1627, DOI 10.1152/physrev.00038.2017
   Freeman EJ, 1996, HYPERTENSION, V28, P104, DOI 10.1161/01.HYP.28.1.104
   Fu ZJ, 2019, EMBO MOL MED, V11, DOI 10.15252/emmm.201910473
   Gao BB, 2008, J PROTEOME RES, V7, P2516, DOI 10.1021/pr800112g
   Gao G, 2003, DIABETOLOGIA, V46, P689, DOI 10.1007/s00125-003-1085-9
   Gao L, 2008, CHINESE MED J-PEKING, V121, P2129, DOI 10.1097/00029330-200811010-00004
   Ghazi NG, 2002, RETINA-J RET VIT DIS, V22, P509, DOI 10.1097/00006982-200208000-00023
   Gilbert RE, 2000, DIABETOLOGIA, V43, P1360, DOI 10.1007/s001250051539
   Girolami JP, 2021, PHARMACEUTICALS-BASE, V14, DOI 10.3390/ph14030240
   Gobel K, 2011, J AUTOIMMUN, V36, P106, DOI 10.1016/j.jaut.2010.11.004
   Guillonneau X, 2017, PROG RETIN EYE RES, V61, P98, DOI 10.1016/j.preteyeres.2017.06.002
   Hachana S, 2020, CURR EYE RES, V45, P965, DOI 10.1080/02713683.2020.1712730
   Hachana S, 2020, BRIT J PHARMACOL, V177, P1949, DOI 10.1111/bph.14962
   Hachana S, 2018, BRIT J PHARMACOL, V175, P968, DOI 10.1111/bph.14138
   Haddad Y, 2017, FRONT PHYSIOL, V8, DOI 10.3389/fphys.2017.00861
   Haddad Y, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00509
   Haddad Y, 2016, BRIT J PHARMACOL, V173, P1988, DOI 10.1111/bph.13491
   Hamid S, 2020, PHARMACEUTICALS-BASE, V13, DOI 10.3390/ph13110347
   Han ED, 2002, J CLIN INVEST, V109, P1057, DOI 10.1172/JCI200214211
   Hatcher HC, 1997, INVEST OPHTH VIS SCI, V38, P658
   Hess JF, 1996, IMMUNOPHARMACOLOGY, V33, P1, DOI 10.1016/0162-3109(96)00074-4
   Hilgenfeldt U, 2005, BRIT J PHARMACOL, V146, P958, DOI 10.1038/sj.bjp.0706409
   Hoang MV, 1997, BIOCHEM J, V327, P23, DOI 10.1042/bj3270023
   HUIE RE, 1993, FREE RADICAL RES COM, V18, P195, DOI 10.3109/10715769309145868
   Igic R, 2018, EXP EYE RES, V166, P74, DOI 10.1016/j.exer.2017.05.007
   Ikeda Y, 2004, CANCER RES, V64, P5178, DOI 10.1158/0008-5472.CAN-03-3589
   Ishihara K, 2002, INT IMMUNOPHARMACOL, V2, P499, DOI 10.1016/S1567-5769(01)00193-X
   Ishihara K, 2001, JPN J PHARMACOL, V87, P318, DOI 10.1254/jjp.87.318
   Ismael MA, 2008, EUR J PHARMACOL, V589, P66, DOI 10.1016/j.ejphar.2008.05.006
   Jalowy A, 1999, J AM SOC NEPHROL, V10, pS129
   Jeppesen P, 2002, INVEST OPHTH VIS SCI, V43, P1891
   Ji BY, 2017, BIOMED PHARMACOTHER, V94, P1057, DOI 10.1016/j.biopha.2017.08.042
   Kakoki M, 2004, P NATL ACAD SCI USA, V101, P13302, DOI 10.1073/pnas.0405449101
   Kakoki M, 2007, P NATL ACAD SCI USA, V104, P7576, DOI 10.1073/pnas.0701617104
   Kakoki M, 2009, KIDNEY INT, V75, P1019, DOI 10.1038/ki.2008.647
   Kaplan AP, 2002, J ALLERGY CLIN IMMUN, V109, P195, DOI 10.1067/mai.2002.121316
   Kern TS, 2007, DIABETES, V56, P373, DOI 10.2337/db05-1621
   Khan Z, 2017, OSLI RETINA, V48, P160, DOI 10.3928/23258160-20170130-10
   Kiire CA, 2013, SURV OPHTHALMOL, V58, P459, DOI 10.1016/j.survophthal.2012.10.002
   Kim T, 2007, PROTEOMICS, V7, P4203, DOI 10.1002/pmic.200700745
   Kintsurashvili E, 2001, AM J PHYSIOL-HEART C, V281, pH1778, DOI 10.1152/ajpheart.2001.281.4.H1778
   KLEIN R, 1984, ARCH OPHTHALMOL-CHIC, V102, P527, DOI 10.1001/archopht.1984.01040030405011
   KLEIN R, 1984, OPHTHALMOLOGY, V91, P1464
   KLEIN R, 1984, ARCH OPHTHALMOL-CHIC, V102, P520, DOI 10.1001/archopht.1984.01040030398010
   Klein R, 2020, OPHTHALMOLOGY, V127, pS122, DOI 10.1016/j.ophtha.2020.01.033
   Kolomeyer AM, 2019, RETINA-J RET VIT DIS, V39, P918, DOI 10.1097/IAE.0000000000002059
   Kuhr F, 2010, NEUROPEPTIDES, V44, P145, DOI 10.1016/j.npep.2009.12.004
   Lau J, 2020, PHARMACEUTICALS-BASE, V13, DOI 10.3390/ph13080199
   Le YZ, 2017, VISION RES, V139, P108, DOI 10.1016/j.visres.2017.05.005
   Leal EC, 2007, INVEST OPHTH VIS SCI, V48, P5257, DOI 10.1167/iovs.07-0112
   Lee H, 2019, YONSEI MED J, V60, P679, DOI 10.3349/ymj.2019.60.7.679
   Leeb-Lundberg LMF, 2005, PHARMACOL REV, V57, P27, DOI 10.1124/pr.57.1.2
   Li P, 2008, HYPERTENSION, V51, P252, DOI 10.1161/HYPERTENSIONAHA.107.097394
   LINZ W, 1995, PHARMACOL REV, V47, P25
   Llobet A, 1999, INVEST OPHTH VIS SCI, V40, P113
   Ma JX, 1996, EXP EYE RES, V63, P19, DOI 10.1006/exer.1996.0087
   Ma JX, 1996, CURR EYE RES, V15, P1117, DOI 10.3109/02713689608995143
   Marceau F, 2004, NAT REV DRUG DISCOV, V3, P845, DOI 10.1038/nrd1522
   Marceau F, 1998, PHARMACOL REV, V50, P357
   Marceau F, 2020, PHARMACEUTICALS-BASE, V13, DOI 10.3390/ph13090201
   Masuda T, 2014, EUR J PHARMACOL, V738, P74, DOI 10.1016/j.ejphar.2014.05.033
   Mauer M, 2009, NEW ENGL J MED, V361, P40, DOI 10.1056/NEJMoa0808400
   MCDONALD KM, 1995, CIRCULATION, V91, P2043, DOI 10.1161/01.CIR.91.7.2043
   Mejia AJ, 2015, ARCH DERMATOL RES, V307, P803, DOI 10.1007/s00403-015-1595-6
   MENKE JG, 1994, J BIOL CHEM, V269, P21583
   Molinaro G, 2002, J PHARMACOL EXP THER, V303, P232, DOI 10.1124/jpet.102.038067
   Morand-Contant M, 2010, AM J PHYSIOL-HEART C, V299, pH1625, DOI 10.1152/ajpheart.00735.2009
   Mugisho OO, 2020, CELL BIOL INT, V44, P343, DOI 10.1002/cbin.11232
   Mukherjee S, 2003, FRONT BIOSCI-LANDMRK, V8, pE410, DOI 10.2741/1103
   Nagai N, 2007, INVEST OPHTH VIS SCI, V48, P2321, DOI 10.1167/iovs.06-1296
   Naidoo S, 2006, METAB BRAIN DIS, V21, P253, DOI 10.1007/s11011-006-9008-3
   Nakamura S, 2011, ARTERIOSCL THROM VAS, V31, P1041, DOI 10.1161/ATVBAHA.111.223594
   Noda M, 2007, NEUROCHEM INT, V51, P185, DOI 10.1016/j.neuint.2007.06.017
   Nunes MA, 2020, PHARMACEUTICALS-BASE, V13, DOI 10.3390/ph13100288
   Orsenigo F, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms2199
   Othman R, 2020, PHARMACEUTICALS-BASE, V13, DOI 10.3390/ph13060130
   Othman R, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.00300
   Pacella F, 2016, INT J OPHTHALMOL-CHI, V9, P1427, DOI 10.18240/ijo.2016.10.10
   Pacher P, 2007, PHYSIOL REV, V87, P315, DOI 10.1152/physrev.00029.2006
   Parekh RU, 2020, CELL MOL NEUROBIOL, V40, P845, DOI 10.1007/s10571-019-00778-1
   Parenti A, 2001, FASEB J, V15, P1487, DOI 10.1096/fj.00-0503fje
   Ocaranza MP, 2020, NAT REV CARDIOL, V17, P116, DOI 10.1038/s41569-019-0244-8
   Penn JS, 2008, PROG RETIN EYE RES, V27, P331, DOI 10.1016/j.preteyeres.2008.05.001
   Phipps JA, 2008, KIDNEY INT, V73, P1114, DOI 10.1038/ki.2008.9
   Phipps JA, 2009, HYPERTENSION, V53, P175, DOI 10.1161/HYPERTENSIONAHA.108.117663
   Pinna A, 2004, OPHTHALMOLOGICA, V218, P260, DOI 10.1159/000078617
   Pouliot M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033864
   Pouliot M, 2011, EXP EYE RES, V92, P482, DOI 10.1016/j.exer.2011.03.007
   Qin L, 2019, ARTHRITIS RES THER, V21, DOI 10.1186/s13075-018-1774-x
   Regoli D, 2017, CAN J PHYSIOL PHARM, V95, P1117, DOI 10.1139/cjpp-2016-0619
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Rohlenova K, 2020, CELL METAB, V31, P862, DOI 10.1016/j.cmet.2020.03.009
   Santos RAS, 2013, J ENDOCRINOL, V216, pR1, DOI 10.1530/JOE-12-0341
   SARKS SH, 1976, BRIT J OPHTHALMOL, V60, P324, DOI 10.1136/bjo.60.5.324
   Sato M, 2000, CIRCULATION, V102, P346
   Satofuka S, 2008, AM J PATHOL, V173, P1911, DOI 10.2353/ajpath.2008.080457
   SCHWARTZ JC, 1990, LIFE SCI, V47, P1279, DOI 10.1016/0024-3205(90)90192-T
   Sharif NA, 1996, EXP EYE RES, V63, P631, DOI 10.1006/exer.1996.0157
   Sharif NA, 2014, DRUG DEVELOP RES, V75, P211, DOI 10.1002/ddr.21174
   SHEIKH IA, 1986, BIOCHEM PHARMACOL, V35, P1951, DOI 10.1016/0006-2952(86)90726-4
   Shen B, 2007, J AM SOC NEPHROL, V18, P1140, DOI 10.1681/ASN.2006101127
   Sikpa D, 2020, PHARMACEUTICALS-BASE, V13, DOI 10.3390/ph13100279
   Simo R, 2018, DIABETOLOGIA, V61, P1902, DOI 10.1007/s00125-018-4692-1
   Sjolie AK, 2011, DIABETIC MED, V28, P345, DOI 10.1111/j.1464-5491.2010.03210.x
   SKIDGEL RA, 1987, KIDNEY INT, V31, pS45
   SKIDGEL RA, 1984, PEPTIDES, V5, P769, DOI 10.1016/0196-9781(84)90020-2
   Sodhi CP, 2018, AM J PHYSIOL-LUNG C, V314, pL17, DOI 10.1152/ajplung.00498.2016
   Sriramula S, 2020, PHARMACOL RES, V155, DOI 10.1016/j.phrs.2020.104715
   Stadnicki A, 2005, AM J PHYSIOL-GASTR L, V289, pG361, DOI 10.1152/ajpgi.00369.2004
   Stauss H M, 1994, J Cardiovasc Risk, V1, P255
   Stearne MR, 1998, BMJ-BRIT MED J, V317, P703
   Sugiyama T, 2007, EXP EYE RES, V85, P406, DOI 10.1016/j.exer.2007.06.008
   Sun JK, 2019, OPHTHALMOL RETINA, V3, P1107, DOI 10.1016/j.oret.2019.07.006
   Tan Y, 2004, AM J PHYSIOL-HEART C, V286, pH926, DOI 10.1152/ajpheart.00757.2003
   Tan Y, 2007, AM J PHYSIOL-RENAL, V293, pF1026, DOI 10.1152/ajprenal.00203.2007
   Terzuoli E, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19020330
   Thomas AS, 2015, RETINA-J RET VIT DIS, V35, P1964, DOI 10.1097/IAE.0000000000000603
   Tidjane N, 2015, EUR J INFLAMM, V13, P40, DOI 10.1177/1721727X15577736
   Tidjane N, 2016, BIOL CHEM, V397, P323, DOI 10.1515/hsz-2015-0230
   Tomita H, 2012, KIDNEY INT, V81, P733, DOI 10.1038/ki.2011.499
   Tonussi CR, 1997, EUR J PHARMACOL, V326, P61, DOI 10.1016/S0014-2999(97)00153-2
   Tschope C, 1997, J Card Fail, V3, P133, DOI 10.1016/S1071-9164(97)90047-6
   Tsutsumi Y, 1999, J CLIN INVEST, V104, P925, DOI 10.1172/JCI7886
   ValdezGuerrero AS, 2021, CAN J DIABETES, V45, P504, DOI 10.1016/j.jcjd.2020.10.009
   van Buggenum IMH, 2002, DIABETOLOGIA, V45, P203, DOI 10.1007/s00125-001-0747-8
   VIJAYARAGHAVAN J, 1990, J BIOL CHEM, V265, P14150
   Voigt AP, 2019, P NATL ACAD SCI USA, V116, P24100, DOI 10.1073/pnas.1914143116
   Walker K, 1996, PAIN, V65, P211, DOI 10.1016/0304-3959(95)00195-6
   Wang B, 2015, LANCET DIABETES ENDO, V3, P263, DOI 10.1016/S2213-8587(14)70256-6
   Wang PHM, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003050
   Webb JG, 2009, EXP EYE RES, V89, P126, DOI 10.1016/j.exer.2009.02.016
   Webb JG, 2003, EXP EYE RES, V76, P283, DOI 10.1016/S0014-4835(02)00313-5
   Westermann D, 2009, DIABETES, V58, P1373, DOI 10.2337/db08-0329
   White AJR, 2015, J RENIN-ANGIO-ALDO S, V16, P59, DOI 10.1177/1470320314549791
   Wilkinson-Berka JL, 2019, EXP EYE RES, V187, DOI 10.1016/j.exer.2019.107766
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yamagishi S, 2005, FEBS LETT, V579, P4265, DOI 10.1016/j.febslet.2005.06.058
   YAMAMOTO K, 1992, HYPERTENSION, V19, P692, DOI 10.1161/01.HYP.19.6.692
   Yannuzzi LA, 2001, RETINA-J RET VIT DIS, V21, P416, DOI 10.1097/00006982-200110000-00003
   Yao YY, 2007, REGUL PEPTIDES, V140, P12, DOI 10.1016/j.regpep.2006.11.020
   Yilmaz T, 2009, OPHTHALMOLOGY, V116, P902, DOI 10.1016/j.ophtha.2009.02.002
   Yu HS, 2014, BIOCHEM PHARMACOL, V87, P243, DOI 10.1016/j.bcp.2013.10.016
   Zheng L, 2007, DIABETOLOGIA, V50, P1987, DOI 10.1007/s00125-007-0734-9
   Zimmerman D, 2012, CLIN SCI, V123, P333, DOI 10.1042/CS20120111
NR 201
TC 3
Z9 3
U1 2
U2 4
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2073-4409
J9 CELLS-BASEL
JI Cells
PD AUG
PY 2021
VL 10
IS 8
AR 1913
DI 10.3390/cells10081913
PG 21
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA UF9ZT
UT WOS:000688924700001
PM 34440682
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Ferrara, M
   Lugano, G
   Sandinha, MT
   Kearns, VR
   Geraghty, B
   Steel, DHW
AF Ferrara, Mariantonia
   Lugano, Gaia
   Sandinha, Maria Teresa
   Kearns, Victoria R.
   Geraghty, Brendan
   Steel, David H. W.
TI Biomechanical properties of retina and choroid: a comprehensive review
   of techniques and translational relevance
SO EYE
LA English
DT Review
ID INTERNAL LIMITING MEMBRANE; OPTICAL COHERENCE TOMOGRAPHY;
   MECHANICAL-PROPERTIES; BRUCHS MEMBRANE; ELASTIC PROPERTIES; MACULAR
   DEGENERATION; OCULAR BIOMECHANICS; HUMAN EYE; AGE; SCLERA
AB Studying the biomechanical properties of biological tissue is crucial to improve our understanding of disease pathogenesis. The biomechanical characteristics of the cornea, sclera and the optic nerve head have been well addressed with an extensive literature and an in-depth understanding of their significance whilst, in comparison, knowledge of the retina and choroid is relatively limited. Knowledge of these tissues is important not only to clarify the underlying pathogenesis of a wide variety of retinal and vitreoretinal diseases, including age-related macular degeneration, hereditary retinal dystrophies and vitreoretinal interface diseases but also to optimise the surgical handling of retinal tissues and, potentially, the design and properties of implantable retinal prostheses and subretinal therapies. Our aim with this article is to comprehensively review existing knowledge of the biomechanical properties of retina, internal limiting membrane (ILM) and the Bruch's membrane-choroidal complex (BMCC), highlighting the potential implications for clinical and surgical practice. Prior to this we review the testing methodologies that have been used both in vitro, and those starting to be used in vivo to aid understanding of their results and significance.
C1 [Ferrara, Mariantonia] Royal Victoria Infirm, Newcastle Eye Ctr, Newcastle Upon Tyne, Tyne & Wear, England.
   [Lugano, Gaia; Kearns, Victoria R.] Univ Liverpool, Inst Life Course & Med Sci, Dept Eye & Vis Sci, Liverpool, Merseyside, England.
   [Sandinha, Maria Teresa] Royal Liverpool Univ Hosp, St Pauls Eye Unit, Liverpool, Merseyside, England.
   [Geraghty, Brendan] Univ Liverpool, Inst Life Course & Med Sci, Musculoskeletal & Ageing Sci, Liverpool, Merseyside, England.
   [Steel, David H. W.] Sunderland Eye Infirm, Sunderland, Durham, England.
   [Steel, David H. W.] Newcastle Univ, Bioscience Inst, Newcastle Upon Tyne, Tyne & Wear, England.
C3 Newcastle University - UK; University of Liverpool; Royal Liverpool &
   Broadgreen University Hospitals NHS Trust; Royal Liverpool University
   Hospital; University of Liverpool; University of Liverpool; Newcastle
   University - UK
RP Geraghty, B (通讯作者)，Univ Liverpool, Inst Life Course & Med Sci, Musculoskeletal & Ageing Sci, Liverpool, Merseyside, England.; Steel, DHW (通讯作者)，Sunderland Eye Infirm, Sunderland, Durham, England.; Steel, DHW (通讯作者)，Newcastle Univ, Bioscience Inst, Newcastle Upon Tyne, Tyne & Wear, England.
EM B.Geraghty@liverpool.ac.uk; David.steel@ncl.ac.uk
RI Ferrara, Mariantonia/AEC-7557-2022; Steel, David/I-8053-2015
OI Ferrara, Mariantonia/0000-0002-1191-4989; Steel,
   David/0000-0001-8734-3089; Sandinha, Maria Teresa/0000-0001-5669-7159
CR Agladioglu K, 2016, BRIT J RADIOL, V89, DOI 10.1259/bjr.20150429
   Al Gwairi O, 2016, J OPHTHALMOL, V2016, DOI 10.1155/2016/2913612
   Alamouti B, 2003, BRIT J OPHTHALMOL, V87, P899, DOI 10.1136/bjo.87.7.899
   Angunawela RI, 2011, INVEST OPHTH VIS SCI, V52, P7046, DOI 10.1167/iovs.10-6872
   Ao J, 2018, CLIN EXP OPHTHALMOL, V46, P670, DOI 10.1111/ceo.13121
   Bhutto IA, 2008, ARCH OPHTHALMOL-CHIC, V126, P670, DOI 10.1001/archopht.126.5.670
   Boote C, 2020, PROG RETIN EYE RES, V74, DOI 10.1016/j.preteyeres.2019.100773
   Campagne MV, 2014, J PATHOL, V232, P151, DOI 10.1002/path.4266
   Campbell IC, 2014, J BIOMECH ENG-T ASME, V136, DOI 10.1115/1.4026286
   Candiello J, 2007, FEBS J, V274, P2897, DOI 10.1111/j.1742-4658.2007.05823.x
   Candiello J, 2010, MATRIX BIOL, V29, P402, DOI 10.1016/j.matbio.2010.03.004
   Chen KN, 2014, J BIOMED MATER RES A, V102, P2001, DOI 10.1002/jbm.a.34858
   Chen K, 2014, ANN BIOMED ENG, V42, P678, DOI 10.1007/s10439-013-0936-x
   Chen K, 2012, RETINA-J RET VIT DIS, V32, P844, DOI 10.1097/IAE.0b013e318225d0c9
   Chen K, 2010, J BIOMECH, V43, P1417, DOI 10.1016/j.jbiomech.2009.09.056
   Chen K, 2010, J BIOMED MATER RES A, V93A, P634, DOI 10.1002/jbm.a.32571
   Chirco KR, 2017, EYE, V31, P10, DOI 10.1038/eye.2016.216
   Ciasca G, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0220571
   Coudrillier B, 2012, INVEST OPHTH VIS SCI, V53, P1714, DOI 10.1167/iovs.11-8009
   Croft MA, 2013, INVEST OPHTH VIS SCI, V54, P5049, DOI 10.1167/iovs.12-10847
   Dalkara D, 2009, MOL THER, V17, P2096, DOI 10.1038/mt.2009.181
   DEGUILLEBON H, 1972, ARCH OPHTHALMOL-CHIC, V87, P545, DOI 10.1001/archopht.1972.01000020547012
   Djigo AD, 2019, ACTA BIOMATER, V84, P305, DOI 10.1016/j.actbio.2018.11.033
   Dorsey J. F., 1997, Investigative Ophthalmology and Visual Science, V38, pS661
   Downs JC, 2015, EXP EYE RES, V133, P19, DOI 10.1016/j.exer.2015.02.011
   Downs JC, 2003, J BIOMECH ENG-T ASME, V125, P124, DOI 10.1115/1.1536930
   Durig B. R., 1989, Proceedings of the SPIE - The International Society for Optical Engineering, V954, P438
   Eilaghi A, 2010, J BIOMECH, V43, P1696, DOI 10.1016/j.jbiomech.2010.02.031
   Elsheikh A, 2008, EXP EYE RES, V86, P783, DOI 10.1016/j.exer.2008.02.006
   Ethier CR, 2004, ANNU REV BIOMED ENG, V6, P249, DOI 10.1146/annurev.bioeng.6.040803.140055
   FlugelKoch C, 1996, OPHTHALMOLOGICA, V210, P296
   Franze K, 2011, SOFT MATTER, V7, P3147, DOI 10.1039/c0sm01017k
   Fratzl P, 1998, J STRUCT BIOL, V122, P119, DOI 10.1006/jsbi.1998.3966
   FRIBERG TR, 1988, EXP EYE RES, V47, P429, DOI 10.1016/0014-4835(88)90053-X
   Fung Y.C., 1993, BIOMECHANICS MECH PR, Vsecond, DOI [10.1007/978-1-4757-2257-4, DOI 10.1007/978-1-4757-2257-4]
   Geraghty B, 2020, J BIOMECH, V98, DOI 10.1016/j.jbiomech.2019.109438
   Girard MJA, 2015, CURR EYE RES, V40, P1, DOI 10.3109/02713683.2014.914543
   GRAEBEL WP, 1977, J BIOMECH ENG-T ASME, V99, P203, DOI 10.1115/1.3426291
   Haritoglou C, 2013, EYE, V27, P1308, DOI 10.1038/eye.2013.178
   He YM, 2019, IEEE J SEL TOP QUANT, V25, DOI [10.1109/jstqe.2018.2834435, 10.1109/JSTQE.2018.2834435]
   Henrich Paul B, 2012, Invest Ophthalmol Vis Sci, V53, P2561, DOI 10.1167/iovs.11-8502
   Hernandez Flora, 2014, J Ophthalmic Vis Res, V9, P251
   Jonas JB, 2017, RETINA-J RET VIT DIS, V37, P1428, DOI 10.1097/IAE.0000000000001464
   JONES IL, 1992, EYE, V6, P556, DOI 10.1038/eye.1992.121
   Karimi A, 2018, TECHNOL HEALTH CARE, V26, P483, DOI 10.3233/THC-160777
   Keenan TDL, 2014, INVEST OPHTH VIS SCI, V55, P5370, DOI 10.1167/iovs.14-14126
   Kenawy N, 2010, OPHTHALMOLOGY, V117, P320, DOI 10.1016/j.ophtha.2009.07.024
   Kennedy BF, 2014, BIOMED OPT EXPRESS, V5, P2113, DOI 10.1364/BOE.5.002113
   Kennedy KM, 2012, OPT LETT, V37, P2310, DOI 10.1364/OL.37.002310
   Kishan AU, 2011, SURV OPHTHALMOL, V56, P195, DOI 10.1016/j.survophthal.2010.08.008
   KITA M, 1992, INVEST OPHTH VIS SCI, V33, P1879
   Li CH, 2014, BIOMED OPT EXPRESS, V5, P1403, DOI 10.1364/BOE.5.001403
   MARMOR MF, 1994, RETINA-J RET VIT DIS, V14, P181, DOI 10.1097/00006982-199414020-00014
   Matsunaga N, 2005, RETINA-J RET VIT DIS, V25, P311, DOI 10.1097/00006982-200504000-00010
   Mcmonnies CW, 2016, CLIN EXP OPTOM, V99, P113, DOI 10.1111/cxo.12302
   MOSES ROBERT A., 1965, INVEST OPHTHALMOL, V4, P935
   Myers KM, 2010, ACTA BIOMATER, V6, P4327, DOI 10.1016/j.actbio.2010.06.007
   Nadarasa J, 2018, BIOMECH MODEL MECHAN, V17, P517, DOI 10.1007/s10237-017-0975-6
   Nickla DL, 2010, PROG RETIN EYE RES, V29, P144, DOI 10.1016/j.preteyeres.2009.12.002
   Owen Leah A, 2019, Invest Ophthalmol Vis Sci, V60, P1204, DOI 10.1167/iovs.18-24254
   Pekel G, 2015, OPTOMETRY VISION SCI, V92, P573, DOI 10.1097/OPX.0000000000000588
   Pekel G, 2015, CURR EYE RES, V40, P332, DOI 10.3109/02713683.2014.918151
   Pierscionek K, 2007, BRIT J OPHTHALMOL, V91, P801, DOI 10.1136/bjo.2006.110221
   Qi WJ, 2014, APPL PHYS LETT, V104, DOI 10.1063/1.4869562
   Qian XQ, 2015, BIO-MED MATER ENG, V26, pS287, DOI 10.3233/BME-151316
   Qu YQ, 2018, BIOMED OPT EXPRESS, V9, P4054, DOI 10.1364/BOE.9.004054
   Qu YQ, 2018, INVEST OPHTH VIS SCI, V59, P455, DOI 10.1167/iovs.17-22971
   REICHENBACH A, 1991, EXP EYE RES, V53, P241, DOI 10.1016/0014-4835(91)90080-X
   Reichenbach A, 2020, GLIA, V68, P768, DOI 10.1002/glia.23727
   Roberts MD, 2010, INVEST OPHTH VIS SCI, V51, P295, DOI 10.1167/iovs.09-4016
   Rohrbach D, 2015, J ACOUST SOC AM, V137, pEL381, DOI 10.1121/1.4916790
   Romano MR, 2019, GRAEF ARCH CLIN EXP, V257, P1, DOI 10.1007/s00417-018-4173-8
   Romano MR, 2018, GRAEF ARCH CLIN EXP, V256, P1573, DOI 10.1007/s00417-018-4029-2
   Romano MR, 2017, MECCANICA, V52, P603, DOI 10.1007/s11012-016-0416-0
   Romano MR, 2015, J OPHTHALMOL, V2015, DOI 10.1155/2015/372564
   Rossi T, 2011, INVEST OPHTH VIS SCI, V52, P3994, DOI 10.1167/iovs.10-6477
   Sarvazyan AP, 1998, ULTRASOUND MED BIOL, V24, P1419, DOI 10.1016/S0301-5629(98)00110-0
   SEBAG J, 1992, EYE, V6, P541, DOI 10.1038/eye.1992.119
   Shahbazi S, 2012, ULTRASONICS, V52, P208, DOI 10.1016/j.ultras.2011.08.004
   Slattery AD, 2013, ULTRAMICROSCOPY, V131, P46, DOI 10.1016/j.ultramic.2013.03.009
   Sousa-Martins D, 2015, INVEST OPHTH VIS SCI, V56, P1993, DOI 10.1167/iovs.14-16187
   Summers JA, 2013, EXP EYE RES, V114, P120, DOI 10.1016/j.exer.2013.03.008
   Tadi P, ANATOMY HEAD NECK EY
   To M, 2013, EXP EYE RES, V116, P298, DOI 10.1016/j.exer.2013.09.011
   Tsilibary EC, 2003, J PATHOL, V200, P537, DOI 10.1002/path.1439
   Ugarte M, 2006, BRIT J OPHTHALMOL, V90, P621, DOI 10.1136/bjo.2005.086579
   VANALPHEN GWHM, 1991, VISION RES, V31, P1417, DOI 10.1016/0042-6989(91)90061-9
   Vielmuth F, 2016, OPHTHALMOLOGICA, V235, P233, DOI 10.1159/000444508
   Voorhees AP, 2017, EXP EYE RES, V160, P85, DOI 10.1016/j.exer.2017.05.004
   Wang S, 2014, OPT LETT, V39, P41, DOI 10.1364/OL.39.000041
   Wang XF, 2018, INVEST OPHTH VIS SCI, V59, P2808, DOI 10.1167/iovs.17-22069
   Whitcomb JE, 2009, EXP EYE RES, V89, P456, DOI 10.1016/j.exer.2009.04.014
   Whitford C, 2015, J MECH BEHAV BIOMED, V42, P76, DOI 10.1016/j.jmbbm.2014.11.006
   Wollensak G, 2004, RETINA-J RET VIT DIS, V24, P967, DOI 10.1097/00006982-200412000-00021
   Wollensak G, 2004, OPHTHALMOLOGICA, V218, P278, DOI 10.1159/000078621
   Wollensak G, 2006, RETINA-J RET VIT DIS, V26, P965, DOI 10.1097/01.iae.0000250001.45661.95
   Worthington KS, 2014, EXP EYE RES, V121, P194, DOI 10.1016/j.exer.2014.02.020
   WU W, 1987, J BIOMECH ENG-T ASME, V109, P65, DOI 10.1115/1.3138644
   Zhou D, 2019, J R SOC INTERFACE, V16, DOI 10.1098/rsif.2018.0685
NR 100
TC 9
Z9 9
U1 1
U2 7
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
SN 0950-222X
EI 1476-5454
J9 EYE
JI Eye
PD JUL
PY 2021
VL 35
IS 7
BP 1818
EP 1832
DI 10.1038/s41433-021-01437-w
EA MAR 2021
PG 15
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA SY4HS
UT WOS:000623734900005
PM 33649576
OA Green Published, hybrid
DA 2022-11-30
ER

PT J
AU Shin, K
   Kent, JE
   Singh, C
   Fujimoto, LM
   Yu, JH
   Tian, Y
   Im, W
   Marassi, FM
AF Shin, Kyungsoo
   Kent, James E.
   Singh, Chandan
   Fujimoto, Lynn M.
   Yu, Jinghua
   Tian, Ye
   Im, Wonpil
   Marassi, Francesca M.
TI Calcium and hydroxyapatite binding site of human vitronectin provides
   insights to abnormal deposit formation
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
DE macular degeneration; deposit; drusen; NMR; solid state
ID SOLID-STATE NMR; OUTER-MEMBRANE PROTEIN; COMPLEMENT ACTIVATION; MACULAR
   DEGENERATION; CELL-SURFACE; DRUSEN; MODEL; IDENTIFICATION; POLARIZATION;
   RECOGNITION
AB The human blood protein vitronectin (Vn) is a major component of the abnormal deposits associated with age-related macular degeneration, Alzheimer's disease, and many other age-related disorders. Its accumulation with lipids and hydroxyapatite (HAP) has been demonstrated, but the precise mechanism for deposit formation remains unknown. Using a combination of solution and solid-state NMR experiments, cosedimentation assays, differential scanning fluorimetry (DSF), and binding energy calculations, we demonstrate that Vn is capable of binding both soluble ionic calcium and crystalline HAP, with high affinity and chemical specificity. Calcium ions bind preferentially at an external site, at the top of the hemopexin-like (HX) domain, with a group of four Asp carboxylate groups. The same external site is also implicated in HAP binding. Moreover, Vn acquires thermal stability upon association with either calcium ions or crystalline HAP. The data point to a mechanism whereby Vn plays an active role in orchestrating calcified deposit formation. They provide a platform for understanding the pathogenesis of macular degeneration and other related degenerative disorders, and the normal functions of Vn, especially those related to bone resorption.
C1 [Shin, Kyungsoo; Kent, James E.; Singh, Chandan; Fujimoto, Lynn M.; Yu, Jinghua; Tian, Ye; Marassi, Francesca M.] Sanford Burnham Prebys Med Discovery Inst, Canc Ctr, La Jolla, CA 92037 USA.
   [Im, Wonpil] Lehigh Univ, Dept Biol Sci Chem & Bioengn, Bethlehem, PA 18015 USA.
   [Singh, Chandan] Banaras Hindu Univ, Dept Biochem, Inst Sci, Varanasi 221005, Uttar Pradesh, India.
C3 Sanford Burnham Prebys Medical Discovery Institute; Lehigh University;
   Banaras Hindu University (BHU)
RP Marassi, FM (通讯作者)，Sanford Burnham Prebys Med Discovery Inst, Canc Ctr, La Jolla, CA 92037 USA.
EM fmarassi@sbp.edu
OI Shin, Kyungsoo/0000-0003-4836-8798; Singh, Dr.
   Chandan/0000-0001-8006-1329; Fujimoto, Lynn/0000-0002-7239-1501
FU NIH [GM 118186]; Canadian Institutes of Health Research Postdoctoral
   Fellowship;  [P30 CA030199]
FX We thank Bernhard Lechtenberg and Ian Pass for useful discussion. This
   study was supported by NIH Grant GM 118186 (to F.M.M.) and from a
   Canadian Institutes of Health Research Postdoctoral Fellowship (to
   K.S.). It utilized the Cancer Center Structural Biology Resource
   supported by Grant P30 CA030199.
CR Arya S, 2018, EXP EYE RES, V172, P21, DOI 10.1016/j.exer.2018.03.023
   Baldus M, 1998, MOL PHYS, V95, P1197, DOI 10.1080/002689798166215
   Bartra SS, 2015, MICROBIOL-SGM, V161, P2174, DOI 10.1099/mic.0.000179
   Bergen AA, 2019, PROG RETIN EYE RES, V70, P55, DOI 10.1016/j.preteyeres.2018.12.003
   Bertini I, 2011, P NATL ACAD SCI USA, V108, P10396, DOI 10.1073/pnas.1103854108
   Boskey AL, 2008, CHEM REV, V108, P4716, DOI 10.1021/cr0782473
   Brooks BR, 2009, J COMPUT CHEM, V30, P1545, DOI 10.1002/jcc.21287
   Carafoli E, 2016, J BIOL CHEM, V291, P20849, DOI 10.1074/jbc.R116.735894
   Cavanagh J, 2007, PROTEIN NMR SPECTROSCOPY: PRINCIPLES AND PRACTICE, 2ND EDITION, P1
   Cha HJ, 2002, J MOL BIOL, V320, P1065, DOI 10.1016/S0022-2836(02)00558-2
   Chambers TJ, 2011, ANN NY ACAD SCI, V1240, P1, DOI 10.1111/j.1749-6632.2011.06249.x
   CONLAN MG, 1988, BLOOD, V72, P185
   Csincsik L, 2018, OPHTHALMIC RES, V59, P182, DOI 10.1159/000487053
   Cummings LJ, 2009, METHOD ENZYMOL, V463, P387, DOI 10.1016/S0076-6879(09)63024-X
   Dey A, 2010, NAT MATER, V9, P1010, DOI [10.1038/nmat2900, 10.1038/NMAT2900]
   Ding Y, 2015, J BIOMOL NMR, V61, P275, DOI 10.1007/s10858-014-9893-4
   Dorozhkin SV, 2002, ANGEW CHEM INT EDIT, V41, P3130, DOI 10.1002/1521-3773(20020902)41:17<3130::AID-ANIE3130>3.0.CO;2-1
   Flinn JM, 2014, METALLOMICS, V6, P1223, DOI 10.1039/c4mt00058g
   Fung BM, 2000, J MAGN RESON, V142, P97, DOI 10.1006/jmre.1999.1896
   Gower LB, 2008, CHEM REV, V108, P4551, DOI 10.1021/cr800443h
   Hageman GS, 1999, FASEB J, V13, P477, DOI 10.1096/fasebj.13.3.477
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   HAYMAN EG, 1983, P NATL ACAD SCI-BIOL, V80, P4003, DOI 10.1073/pnas.80.13.4003
   Hoang QQ, 2003, NATURE, V425, P977, DOI 10.1038/nature02079
   Hu YY, 2010, P NATL ACAD SCI USA, V107, P22425, DOI 10.1073/pnas.1009219107
   Im W, 1998, COMPUT PHYS COMMUN, V111, P59, DOI 10.1016/S0010-4655(98)00016-2
   Jager C, 2006, MAGN RESON CHEM, V44, P573, DOI 10.1002/mrc.1774
   Jo S, 2008, J COMPUT CHEM, V29, P1859, DOI 10.1002/jcc.20945
   Jo S, 2008, NUCLEIC ACIDS RES, V36, pW270, DOI 10.1093/nar/gkn314
   Johnson LV, 2011, P NATL ACAD SCI USA, V108, P18277, DOI 10.1073/pnas.1109703108
   Khan KN, 2016, PROG RETIN EYE RES, V53, P70, DOI 10.1016/j.preteyeres.2016.04.008
   KUBOTA K, 1988, CELL STRUCT FUNCT, V13, P123, DOI 10.1247/csf.13.123
   Leavesley DI, 2013, IUBMB LIFE, V65, P807, DOI 10.1002/iub.1203
   Marassi FM, 1997, P NATL ACAD SCI USA, V94, P8551, DOI 10.1073/pnas.94.16.8551
   MCLAUGHLIN S, 1981, J GEN PHYSIOL, V77, P445, DOI 10.1085/jgp.77.4.445
   MORRIS GA, 1979, J AM CHEM SOC, V101, P760, DOI 10.1021/ja00497a058
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Mysliwy J, 2006, PROTEIN EXPRES PURIF, V46, P406, DOI 10.1016/j.pep.2005.08.020
   Noskov SY, 2004, NATURE, V431, P830, DOI 10.1038/nature02943
   PAUSAK S, 1973, J CHEM PHYS, V59, P591, DOI 10.1063/1.1680062
   Piccard H, 2007, J LEUKOCYTE BIOL, V81, P870, DOI 10.1189/jlb.1006629
   Preissner KT, 2011, SEMIN THROMB HEMOST, V37, P408, DOI 10.1055/s-0031-1276590
   PYTELA R, 1985, P NATL ACAD SCI USA, V82, P5766, DOI 10.1073/pnas.82.17.5766
   Rao Ashit, 2016, Biophys Rev, V8, P309, DOI 10.1007/s12551-016-0228-4
   Roux B, 2000, BIOCHEMISTRY-US, V39, P13295, DOI 10.1021/bi001567v
   Schultz R, 2018, INVEST OPHTH VIS SCI, V59
   Scudeller LA, 2017, BIOINTERPHASES, V12, DOI 10.1116/1.4983407
   SEIFFERT D, 1994, J BIOL CHEM, V269, P2659
   Shin K, 2019, SCI ADV, V5, DOI 10.1126/sciadv.aax5068
   Shin TM, 2008, MOL NEURODEGENER, V3, DOI 10.1186/1750-1326-3-16
   Singh B, 2010, MOL MICROBIOL, V78, P545, DOI 10.1111/j.1365-2958.2010.07373.x
   Tan ACS, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aat4544
   Thompson RB, 2015, P NATL ACAD SCI USA, V112, P1565, DOI 10.1073/pnas.1413347112
   Tomasini B R, 1991, Prog Hemost Thromb, V10, P269
   Uskokovic V, 2015, RSC ADV, V5, P36614, DOI 10.1039/c4ra17180b
   Vaisar T, 2007, J CLIN INVEST, V117, P746, DOI 10.1172/JCI26206
   Vranken WF, 2005, PROTEINS, V59, P687, DOI 10.1002/prot.20449
   Yoneda A, 1998, BIOCHEMISTRY-US, V37, P6351, DOI 10.1021/bi972247n
   Zheng H, 2017, ACTA CRYSTALLOGR D, V73, P223, DOI 10.1107/S2059798317001061
   Zhou AW, 2003, NAT STRUCT BIOL, V10, P541, DOI 10.1038/nsb943
NR 60
TC 2
Z9 2
U1 1
U2 11
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD AUG 4
PY 2020
VL 117
IS 31
BP 18504
EP 18510
DI 10.1073/pnas.2007699117
PG 7
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA NU5MD
UT WOS:000573684400024
PM 32699145
OA Green Published
DA 2022-11-30
ER

PT J
AU Jo, YD
   Kim, J
   Choung, SY
AF Jo, Ye-Dam
   Kim, Jun
   Choung, Se-Young
TI Protective effects of quercetin-3-O-alpha-L-arabinopyranoside against
   UVA induced apoptosis via regulating inflammatory pathways in ARPE-19
   cells and Balb/c mice
SO JOURNAL OF FUNCTIONAL FOODS
LA English
DT Article
DE Quercetin-3-O-alpha-L-arabinopyranoside; A2E; ARPE-19 cells; UVA
   exposure; Age-related macular degeneration
ID PIGMENT EPITHELIAL-CELLS; BLUE-LIGHT; MACULAR DEGENERATION; OXIDATIVE
   STRESS; INDUCED DAMAGE; CHLOROGENIC ACID; IN-VITRO; QUERCETIN;
   ANTIOXIDANT; EXPRESSION
AB Accumulation of N-retinylidene-N-retinylethanolamine (A2E) and light exposure are known to be intensely involved in the progression of age-related macular degeneration (AMD). It has been demonstrated that when A2E was exposed to light, oxidative byproducts of A2E (oxo-A2E) are generated, causing cell death. We aimed to investigate the effects of quercetin-3-O-alpha-L-arabinopyranoside (QA) on ultraviolet A (UVA) exposure in human retinal pigment epithelial cells (ARPE-19 cells) and retinas of balb/c mice. This study demonstrated that QA inhibited translocation of NF-kB and upregulations of inflammatory related genes such as IL-1 beta, IL-6, MCP-1, CXCL-2, and VEGF-A, significantly increased by UVA exposure. In addition, QA prevented UVA induced apoptosis through decreasing caspase 3 activation and PARP cleavage both in APRE-19 cells and in retinas. Taken together, our study demonstrated the protective effects of QA on UVA induced apoptosis, suggesting that QA could be a potential agent to prevent onset and progression of AMD.
C1 [Jo, Ye-Dam; Kim, Jun; Choung, Se-Young] Kyung Hee Univ, Grad Sch, Dept Life & Nanopharmaceut Sci, 26 Kyungheedae Ro, Seoul 02447, South Korea.
C3 Kyung Hee University
RP Choung, SY (通讯作者)，Kyung Hee Univ, Grad Sch, Dept Life & Nanopharmaceut Sci, 26 Kyungheedae Ro, Seoul 02447, South Korea.
EM sychoung@khu.ac.kr
RI Choung, Young/AAH-9208-2020
CR Afrin S, 2018, BIOTECHNOLOGY ADV
   Alge-Priglinger CS, 2009, INVEST OPHTH VIS SCI, V50, P5495, DOI 10.1167/iovs.08-3193
   Ba XQ, 2011, AM J PATHOL, V178, P946, DOI 10.1016/j.ajpath.2010.12.004
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Buschini E, 2011, PROG NEUROBIOL, V95, P14, DOI 10.1016/j.pneurobio.2011.05.011
   Chan CM, 2008, MOL VIS, V14, P2528
   Charles I, 2005, INVEST OPHTH VIS SCI, V46, P1330, DOI 10.1167/iovs.04-0363
   Cousins SW, 2004, ARCH OPHTHALMOL-CHIC, V122, P1013, DOI 10.1001/archopht.122.7.1013
   Dib B, 2015, BBA-MOL CELL RES, V1853, P2897, DOI 10.1016/j.bbamcr.2015.08.012
   Eichler W, 2002, INVEST OPHTH VIS SCI, V43, P2767
   Fang Y, 2016, SCI REP-UK, V6, DOI 10.1038/srep21018
   Ferlemi AV, 2016, EXP EYE RES, V145, P258, DOI 10.1016/j.exer.2016.01.012
   Gardi C, 2015, ARCH BIOCHEM BIOPHYS, V583, P150, DOI 10.1016/j.abb.2015.08.008
   Gasparrini M, 2017, NUTRIENTS, V9, DOI 10.3390/nu9060605
   Ghanta S, 2007, J AGR FOOD CHEM, V55, P10962, DOI 10.1021/jf071892q
   Grisanti S, 2008, PROG RETIN EYE RES, V27, P372, DOI 10.1016/j.preteyeres.2008.05.002
   Imai S, 2010, EUR J PHARMACOL, V642, P77, DOI 10.1016/j.ejphar.2010.05.057
   Jadhav Kavita, 2017, Liver Res, V1, P96, DOI 10.1016/j.livres.2017.08.001
   Jang YP, 2005, J BIOL CHEM, V280, P39732, DOI 10.1074/jbc.M504933200
   Kim J, 2018, J FUNCT FOODS, V40, P426, DOI 10.1016/j.jff.2017.11.021
   Kim J, 2018, FOOD FUNCT, V9, P2171, DOI 10.1039/c7fo01958k
   Klein R, 2002, OPHTHALMOLOGY, V109, P1767, DOI 10.1016/S0161-6420(02)01146-6
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Kool J, 2003, ONCOGENE, V22, P4235, DOI 10.1038/sj.onc.1206611
   KUPPNER MC, 1995, IMMUNOLOGY, V84, P265
   Lambert V, 2003, FASEB J, V17, P2290, DOI 10.1096/fj.03-0113fje
   Lee BL, 2016, NUTR RES, V36, P1402, DOI 10.1016/j.nutres.2016.11.008
   Lee YK, 2012, ARCH DERMATOL RES, V304, P73, DOI 10.1007/s00403-011-1176-2
   Maleki SJ, 2019, FOOD CHEM, V299, DOI 10.1016/j.foodchem.2019.125124
   Marie M, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0331-5
   Morgan MJ, 2011, CELL RES, V21, P103, DOI 10.1038/cr.2010.178
   Overman A, 2011, INT J OBESITY, V35, P1165, DOI 10.1038/ijo.2010.272
   Pennesi ME, 2012, MOL ASPECTS MED, V33, P487, DOI 10.1016/j.mam.2012.06.003
   Rodrigues M, 2013, DIABETES
   Schutt F, 2000, INVEST OPHTH VIS SCI, V41, P2303
   Silvan JM, 2016, FOOD FUNCT, V7, P1067, DOI [10.1039/c5fo01368b, 10.1039/C5FO01368B]
   Sparrow JR, 2005, EXP EYE RES, V80, P595, DOI 10.1016/j.exer.2005.01.007
   Sparrow JR, 2003, VISION RES, V43, P2983, DOI 10.1016/S0042-6989(03)00475-9
   Sparrow JR, 2003, J BIOL CHEM, V278, P18207, DOI 10.1074/jbc.M300457200
   Sparrow JR, 2000, INVEST OPHTH VIS SCI, V41, P1981
   Sun GY, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0141509
   Suzuki M, 2012, J CELL SCI JCS
   Thapliyal Ashish, 2014, Int J Cell Biol, V2014, P308535, DOI 10.1155/2014/308535
   Uetama T, 2003, J CELL PHYSIOL, V197, P77, DOI 10.1002/jcp.10342
   Vadlapatla RK, 2014, EYE, V28, P93, DOI 10.1038/eye.2013.240
   Wang H, 2010, J BIOL CHEM M, V109
   Wang Y, 2017, J FUNCT FOODS, V33, P103, DOI 10.1016/j.jff.2017.02.034
   Wenzel A, 2005, PROG RETIN EYE RES, V24, P275, DOI 10.1016/j.preteyeres.2004.08.002
   Wielgus AR, 2010, PHOTOCH PHOTOBIO SCI, V9, P1505, DOI 10.1039/c0pp00133c
   Yao J, 2013, INT J MOL SCI, V14, P10355, DOI 10.3390/ijms140510355
   Yin JG, 2011, J CELL PHYSIOL, V226, P2025, DOI 10.1002/jcp.22532
   Yoon SM, 2016, ARCH PHARM RES, V39, P21, DOI 10.1007/s12272-015-0683-7
   Zhong Q, 2013, DIABETES
NR 53
TC 3
Z9 3
U1 0
U2 7
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1756-4646
J9 J FUNCT FOODS
JI J. Funct. Food.
PD NOV
PY 2019
VL 62
AR 103541
DI 10.1016/j.jff.2019.103541
PG 10
WC Food Science & Technology; Nutrition & Dietetics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Food Science & Technology; Nutrition & Dietetics
GA JF2HW
UT WOS:000491207500016
DA 2022-11-30
ER

PT J
AU Ong, SR
   Crowston, JG
   Loprinzi, PD
   Ramulu, PY
AF Ong, Sharon R.
   Crowston, Jonathan G.
   Loprinzi, Paul D.
   Ramulu, Pradeep Y.
TI Physical activity, visual impairment, and eye disease
SO EYE
LA English
DT Review
ID INVALID ACCELEROMETRY DATA; INTRAOCULAR-PRESSURE; MACULAR DEGENERATION;
   AEROBIC EXERCISE; OLDER-ADULTS; NEUROTROPHIC FACTOR; PERFUSION-PRESSURE;
   LEISURE ACTIVITY; LIFE-STYLE; FIELD LOSS
AB Numerous studies have demonstrated physical activity is a strong factor in overall health and well-being, and a growing body of literature, reviewed herein, suggests that several eye conditions, including glaucoma, age-related macular degeneration, and diabetic retinopathy, are associated with lower activity levels. Likewise, physical activity levels are lower in persons with worse vision. Research in this area has utilized both self-reported physical activity measures as well as objective measures of activity (i.e., accelerometers), each of which have their own strengths and limitations. Putative mechanisms explaining the association of various eye conditions with physical activity are discussed. It is possible that activity restriction occurs as a downstream consequence of eye disease/visual impairment, that activity restriction causes eye disease/visual impairment, or that causality is bidirectional; evidence supporting each of these theories is put forth. An improved understanding of the relationship between physical activity and eye disease will highlight potential secondary health risks resulting from eye disease, and can help determine whether activity might serve as a readily available preventative measure to prevent specific eye conditions.
C1 [Ong, Sharon R.] Univ Maryland, Sch Med, Baltimore, MD 21201 USA.
   [Crowston, Jonathan G.] Univ Melbourne, Ctr Eye Res Australia, 32 Gisborne St East, Melbourne, Vic 3002, Australia.
   [Loprinzi, Paul D.] Univ Mississippi, Med Ctr, Jackson, MS 39216 USA.
   [Ramulu, Pradeep Y.] Johns Hopkins Univ, Baltimore, MD 21205 USA.
C3 University System of Maryland; University of Maryland Baltimore; Centre
   for Eye Research Australia; University of Melbourne; University of
   Mississippi; University of Mississippi Medical Center; Johns Hopkins
   University
RP Ramulu, PY (通讯作者)，Johns Hopkins Univ, Baltimore, MD 21205 USA.
EM pramulu@jhmi.edu
CR Aadahl M, 2003, MED SCI SPORT EXER, V35, P1196, DOI 10.1249/01.MSS.0000074446.02192.14
   AINSWORTH BE, 1993, MED SCI SPORT EXER, V25, P71, DOI 10.1249/00005768-199301000-00011
   Ainsworth BE, 2000, MED SCI SPORT EXER, V32, pS498, DOI 10.1097/00005768-200009001-00009
   Anuradha S, 2011, MED SCI SPORT EXER, V43, P280, DOI 10.1249/MSS.0b013e3181ea0f0d
   Aspinall PA, 2008, INVEST OPHTH VIS SCI, V49, P1907, DOI 10.1167/iovs.07-0559
   Atienza AA, 2011, MED SCI SPORT EXER, V43, P815, DOI 10.1249/MSS.0b013e3181fdfc32
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Black AA, 2008, OPTOMETRY VISION SCI, V85, P489, DOI 10.1097/OPX.0b013e31817882db
   Black AA, 2011, OPTOMETRY VISION SCI, V88, P1275, DOI 10.1097/OPX.0b013e31822f4d6a
   BLUMENTHAL JA, 1989, J GERONTOL, V44, pM147, DOI 10.1093/geronj/44.5.M147
   Broeder CE, 1997, MED SCI SPORT EXER, V29, P705, DOI 10.1097/00005768-199705000-00019
   CAMACHO TC, 1991, AM J EPIDEMIOL, V134, P220, DOI 10.1093/oxfordjournals.aje.a116074
   Catellier DJ, 2005, MED SCI SPORT EXER, V37, pS555, DOI 10.1249/01.mss.0000185651.59486.4e
   Chen K, 2016, INT J EXERC SCI, V9, P30
   Chrysostomou V, 2016, AGING CELL, V15, P1082, DOI 10.1111/acel.12512
   Chrysostomou V, 2014, NEUROBIOL AGING, V35, P1722, DOI 10.1016/j.neurobiolaging.2014.01.019
   Colcombe SJ, 2006, J GERONTOL A-BIOL, V61, P1166, DOI 10.1093/gerona/61.11.1166
   Coleman HR, 2008, LANCET, V372, P1835, DOI 10.1016/S0140-6736(08)61759-6
   Cornelissen VA, 2005, HYPERTENSION, V46, P667, DOI 10.1161/01.HYP.0000184225.05629.51
   Daussin FN, 2008, AM J PHYSIOL-REG I, V295, pR264, DOI 10.1152/ajpregu.00875.2007
   Di Francescomarino S, 2009, SPORTS MED, V39, P797, DOI 10.2165/11317750-000000000-00000
   DiLorenzo TM, 1999, PREV MED, V28, P75, DOI 10.1006/pmed.1998.0385
   Ding J, 2012, CURR DIABETES REP, V12, P346, DOI 10.1007/s11892-012-0283-6
   Ding J, 2012, CLIN EXP OPTOM, V95, P290, DOI 10.1111/j.1444-0938.2012.00725.x
   Ferguson T, 2015, INT J BEHAV NUTR PHY, V12, DOI 10.1186/s12966-015-0201-9
   Ghaffariyeh A, 2011, OPTOMETRY VISION SCI, V88, P80, DOI 10.1097/OPX.0b013e3181fc329f
   Gilbert J, 2004, DIABETES CARE, V27, P990, DOI 10.2337/diacare.27.4.990
   Gleiss AC, 2011, METHODS ECOL EVOL, V2, P23, DOI 10.1111/j.2041-210X.2010.00057.x
   Hallemans A, 2010, GAIT POSTURE, V32, P547, DOI 10.1016/j.gaitpost.2010.07.018
   He Z, 2006, INVEST OPHTH VIS SCI, V47, P4872, DOI 10.1167/iovs.06-0590
   Heijl A, 2002, ARCH OPHTHALMOL-CHIC, V120, P1268, DOI 10.1001/archopht.120.10.1268
   HEINEMANN AW, 1988, GERONTOLOGIST, V28, P181, DOI 10.1093/geront/28.2.181
   Hillman CH, 2008, NAT REV NEUROSCI, V9, P58, DOI 10.1038/nrn2298
   Hollewand AM, 2016, J AGING PHYS ACTIV, V24, P555, DOI 10.1123/japa.2014-0290
   Kasapis C, 2005, J AM COLL CARDIOL, V45, P1563, DOI 10.1016/j.jacc.2004.12.077
   Kasneci E, 2017, J OPHTHALMOL, V2017, DOI 10.1155/2017/6425913
   KING AC, 1993, HEALTH PSYCHOL, V12, P292, DOI 10.1037/0278-6133.12.4.292
   Knowler WC, 2002, NEW ENGL J MED, V346, P393, DOI 10.1056/NEJMoa012512
   Knudtson MD, 2006, BRIT J OPHTHALMOL, V90, P1461, DOI 10.1136/bjo.2006.103796
   Kokkinos PF, 1999, SPORTS MED, V28, P307, DOI 10.2165/00007256-199928050-00002
   Kramer AF, 2007, TRENDS COGN SCI, V11, P342, DOI 10.1016/j.tics.2007.06.009
   Kwon SJ, 2013, NEURAL REGEN RES, V8, P922, DOI 10.3969/j.issn.1673-5374.2013.10.007
   Lee IM, 2003, MED SCI SPORT EXER, V35, P1823, DOI 10.1249/01.MSS.0000093620.27893.23
   Loprinzi PD, 2016, PREV MED, V87, P18, DOI 10.1016/j.ypmed.2016.02.005
   Loprinzi PD, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125394
   Loprinzi PD, 2014, J AFFECT DISORDERS, V167, P8, DOI 10.1016/j.jad.2014.05.052
   Loprinzi PD, 2014, AM J HEALTH PROMOT, V28, P155, DOI 10.4278/ajhp.121116-ARB-563
   Loprinzi PD, 2013, BRAIN RES, V1539, P95, DOI 10.1016/j.brainres.2013.10.004
   Loprinzi PD, 2013, J PHYS ACT HEALTH, V10, P79, DOI 10.1123/jpah.10.1.79
   Loprinzi PD, 2012, RES Q EXERCISE SPORT, V83, P422
   Lynch BM, 2011, RECENT RESULTS CANC, V186, P13, DOI 10.1007/978-3-642-04231-7_2
   MACDOUGALL D, 1981, Canadian Journal of Applied Sport Sciences, V6, P93
   Maliszewska-Cyna E, 2017, CURR ALZHEIMER RES, V14, P47, DOI 10.2174/1567205013666160819125400
   Martin KRG, 2003, INVEST OPHTH VIS SCI, V44, P4357, DOI 10.1167/iovs.02-1332
   Mattson MP, 2012, CELL METAB, V16, P706, DOI 10.1016/j.cmet.2012.08.012
   Mazzeo RS, 1998, MED SCI SPORT EXER, V30, P992, DOI 10.1097/00005768-199806000-00033
   McArdle W., 1991, MED SCI SPORTS EXERC, V23, P1403, DOI [DOI 10.1249/00005768-199112000-00013, 10.1249/00005768-199112000-00013]
   McGuinness MB, 2016, BRIT J OPHTHALMOL, V100, P1353, DOI 10.1136/bjophthalmol-2015-307663
   Miles L, 2007, NUTR BULL, V32, P314, DOI 10.1111/j.1467-3010.2007.00668.x
   Munch IC, 2013, INVEST OPHTH VIS SCI, V54, P3932, DOI 10.1167/iovs.12-10785
   Munemasa Yasunari, 2012, Front Cell Neurosci, V6, P60, DOI 10.3389/fncel.2012.00060
   Nguyen AM, 2015, BMC GERIATR, V15, DOI 10.1186/s12877-015-0062-8
   Quigley HA, 2006, BRIT J OPHTHALMOL, V90, P262, DOI 10.1136/bjo.2005.081224
   Rasmussen P, 2009, EXP PHYSIOL, V94, P1062, DOI 10.1113/expphysiol.2009.048512
   Regnaux JP, 2012, COCHRANE DB SYST REV, P11
   Risner D, 2009, J GLAUCOMA, V18, P429, DOI 10.1097/IJG.0b013e31818fa5f3
   ROTH DL, 1987, PSYCHOSOM MED, V49, P355, DOI 10.1097/00006842-198707000-00004
   Rovner BW, 2002, AM J GERIAT PSYCHIAT, V10, P305
   Scarmeas N, 2001, NEUROLOGY, V57, P2236, DOI 10.1212/WNL.57.12.2236
   Schrack J, 2015, JAMA-J AM MED ASSOC, V313, P2079, DOI 10.1001/jama.2015.3877
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P785, DOI 10.1001/archopht.121.6.785
   Shephard RJ, 2003, BRIT J SPORT MED, V37, P197, DOI 10.1136/bjsm.37.3.197
   Sigal RJ, 2004, DIABETES CARE, V27, P2518, DOI 10.2337/diacare.27.10.2518
   Stevens GA, 2013, OPHTHALMOLOGY, V120, P2377, DOI 10.1016/j.ophtha.2013.05.025
   Strath SJ, 2012, MED SCI SPORT EXER, V44, pS77, DOI 10.1249/MSS.0b013e3182399eb1
   Strohle A, 2009, J NEURAL TRANSM, V116, P777, DOI 10.1007/s00702-008-0092-x
   Subhi Yousif, 2016, Dan Med J, V63
   Subhi Y, 2014, CLIN OPHTHALMOL, V8, P15, DOI 10.2147/OPTH.S55080
   Tang J, 2011, PROG RETIN EYE RES, V30, P343, DOI 10.1016/j.preteyeres.2011.05.002
   TIELSCH JM, 1995, ARCH OPHTHALMOL-CHIC, V113, P216, DOI 10.1001/archopht.1995.01100020100038
   Tikellis G, 2010, MICROCIRCULATION, V17, P381, DOI 10.1111/j.1549-8719.2010.00033.x
   Tuomilehto J, 2001, NEW ENGL J MED, V344, P1343, DOI 10.1056/NEJM200105033441801
   van Landingham SW, 2012, OPHTHALMOLOGY, V119, P2486, DOI 10.1016/j.ophtha.2012.06.034
   van Poppel MNM, 2010, SPORTS MED, V40, P565, DOI 10.2165/11531930-000000000-00000
   Varma R, 2016, JAMA OPHTHALMOL, V134, P802, DOI 10.1001/jamaophthalmol.2016.1284
   Vasudevan SK, 2011, INDIAN J OPHTHALMOL, V59, pS102, DOI 10.4103/0301-4738.73700
   Vaynman S, 2004, EUR J NEUROSCI, V20, P2580, DOI 10.1111/j.1460-9568.2004.03720.x
   Vieira GM, 2006, ARCH OPHTHALMOL-CHIC, V124, P1251, DOI 10.1001/archopht.124.9.1251
   Westerterp KR, 2009, EUR J APPL PHYSIOL, V105, P823, DOI 10.1007/s00421-009-1000-2
   Williams PT, 2009, MED SCI SPORT EXER, V41, P1566, DOI 10.1249/MSS.0b013e31819e420f
   Willis JR, 2013, JAMA OPHTHALMOL, V131, P1049, DOI 10.1001/jamaophthalmol.2013.316
   Yip JLY, 2011, INVEST OPHTH VIS SCI, V52, P8186, DOI 10.1167/iovs.11-8267
   Zebardast N, 2015, OPHTHALMOLOGY, V122, P1102, DOI 10.1016/j.ophtha.2015.02.024
   Zuhl M., 2012, IDEA FITNESS J, V9, P34
NR 94
TC 45
Z9 47
U1 0
U2 7
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
SN 0950-222X
EI 1476-5454
J9 EYE
JI Eye
PD AUG
PY 2018
VL 32
IS 8
BP 1296
EP 1303
DI 10.1038/s41433-018-0081-8
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Ophthalmology
GA GP8GQ
UT WOS:000441148700002
PM 29610523
OA Green Published, Bronze
DA 2022-11-30
ER

PT J
AU Li, W
AF Li, Wei
TI Phagocyte dysfunction, tissue aging and degeneration
SO AGEING RESEARCH REVIEWS
LA English
DT Review
DE Phagocytosis; Aging; Phagocyte dysfunction; Macrophage; Microglia;
   Retinal pigment epithelium
ID RETINAL-PIGMENT EPITHELIUM; GLYCATION END-PRODUCTS; RECEPTOR TYROSINE
   KINASES; MACULAR DEGENERATION; OXIDATIVE STRESS; ALZHEIMERS-DISEASE;
   MULTIPLE-SCLEROSIS; APOPTOTIC CELLS; PHOSPHATIDYLSERINE RECEPTOR;
   INFLAMMATORY RESPONSES
AB Immunologically-silent phagocytosis of apoptotic cells is critical to maintaining tissue homeostasis and innate immune balance. Aged phagocytes reduce their functional activity, leading to accumulation of unphagocytosed debris, chronic sterile inflammation and exacerbation of tissue aging and damage. Macrophage dysfunction plays an important role in immunosenescence. Microglial dysfunction has been linked to age-dependent neurodegenerations. Retinal pigment epithelial (RPE) cell dysfunction has been implicated in the pathogenesis of age-related macular degeneration (AMD). Despite several reports on the characterization of aged phagocytes, the role of phagocyte dysfunction in tissue aging and degeneration is yet to be fully appreciated. Lack of knowledge of molecular mechanisms by which aging reduces phagocyte function has hindered our capability to exploit the therapeutic potentials of phagocytosis for prevention or delay of tissue degeneration. This review summarizes our current knowledge of phagocyte dysfunction in aged tissues and discusses possible links to age-related diseases. We highlight the challenges to decipher the molecular mechanisms, present new research approaches and envisage future strategies to prevent phagocyte dysfunction, tissue aging and degeneration. (C) 2013 Elsevier B.V. All rights reserved.
C1 [Li, Wei] Univ Miami, Miller Sch Med, Bascom Palmer Eye Inst, Dept Microbiol & Immunol,Neurosci Program, Miami, FL 33136 USA.
C3 Bascom Palmer Eye Institute; University of Miami
RP Li, W (通讯作者)，1638 NW 10th Ave, Miami, FL 33136 USA.
EM wli@med.miami.edu
FU NIH [R01GM094449, R21HD075372]; Florida James & Esther King Biomedical
   Research Program [1KF-38241]; BrightFocus Foundation [M2012026];
   Juvenile Diabetes Research Foundation [5-2012-189]; Glaucoma Research
   Foundation; Florida Bankhead-Coley Cancer Research Program
   [2BF-04-46776]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD
   HEALTH & HUMAN DEVELOPMENT [R21HD075372] Funding Source: NIH RePORTER;
   NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM094449] Funding
   Source: NIH RePORTER
FX I thank Dr. Duco Hamasaki for manuscript review. This work is partially
   supported by NIH R01GM094449, R21HD075372 and grants from Florida James
   & Esther King Biomedical Research Program (1KF-38241), BrightFocus
   Foundation (M2012026), Juvenile Diabetes Research Foundation
   (5-2012-189), Glaucoma Research Foundation and Florida Bankhead-Coley
   Cancer Research Program (2BF-04-46776).
CR Agrawal A, 2007, J IMMUNOL, V178, P6912, DOI 10.4049/jimmunol.178.11.6912
   Ambati J, 2003, NAT MED, V9, P1390, DOI 10.1038/nm950
   Anwar A, 2009, J LEUKOCYTE BIOL, V86, P73, DOI [10.1189/JLB.0608334, 10.1189/jlb.0608334]
   Aprahamian T, 2008, CLIN EXP IMMUNOL, V152, P448, DOI 10.1111/j.1365-2249.2008.03658.x
   Aw D, 2007, IMMUNOLOGY, V120, P435, DOI 10.1111/j.1365-2567.2007.02555.x
   Baquer NZ, 2009, BIOGERONTOLOGY, V10, P377, DOI 10.1007/s10522-009-9226-2
   Bazan NG, 2006, TRENDS NEUROSCI, V29, P263, DOI 10.1016/j.tins.2006.03.005
   Bazan NG, 2010, J LIPID RES, V51, P2018, DOI 10.1194/jlr.R001131
   Binder MD, 2008, J NEUROSCI, V28, P5195, DOI 10.1523/JNEUROSCI.1180-08.2008
   Binder MD, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017727
   Buschini E, 2011, PROG NEUROBIOL, V95, P14, DOI 10.1016/j.pneurobio.2011.05.011
   Butcher SK, 2001, J LEUKOCYTE BIOL, V70, P881
   Caberoy NB, 2012, J NEUROIMMUNOL, V252, P40, DOI 10.1016/j.jneuroim.2012.07.009
   Caberoy NB, 2012, J CELL PHYSIOL, V227, P401, DOI 10.1002/jcp.22955
   Caberoy NB, 2010, EMBO J, V29, P3898, DOI 10.1038/emboj.2010.265
   Caberoy NB, 2010, EXP CELL RES, V316, P245, DOI 10.1016/j.yexcr.2009.10.008
   Cataldo AM, 1996, J NEUROSCI, V16, P186
   Chen GY, 2010, NAT REV IMMUNOL, V10, P826, DOI 10.1038/nri2873
   Chen H, 2009, INVEST OPHTH VIS SCI, V50, P1895, DOI 10.1167/iovs.08-2850
   Combadiere C, 2007, J CLIN INVEST, V117, P2920, DOI 10.1172/JCI31692
   CORRALDEBRINSKI M, 1992, NAT GENET, V2, P324, DOI 10.1038/ng1292-324
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   D'Cruz PM, 2000, HUM MOL GENET, V9, P645, DOI 10.1093/hmg/9.4.645
   De la Fuente M, 2004, CELL MOL BIOL, V50, P683, DOI 10.1170/82
   de la Rosa EJ, 2000, TRENDS NEUROSCI, V23, P454, DOI 10.1016/S0166-2236(00)01628-3
   Ding XY, 2009, PROG RETIN EYE RES, V28, P1, DOI 10.1016/j.preteyeres.2008.10.001
   DOWLING JE, 1962, J CELL BIOL, V14, P73, DOI 10.1083/jcb.14.1.73
   Erwig LP, 2007, AM J PATHOL, V171, P2, DOI 10.2353/ajpath.2007.070135
   Franceschi C, 2007, MECH AGEING DEV, V128, P92, DOI 10.1016/j.mad.2006.11.016
   Freeman GJ, 2010, IMMUNOL REV, V235, P172, DOI 10.1111/j.0105-2896.2010.00903.x
   Fricker M, 2012, J NEUROSCI, V32, P2657, DOI 10.1523/JNEUROSCI.4837-11.2012
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P532
   Gal A, 2000, NAT GENET, V26, P270, DOI 10.1038/81555
   Goronzy JJ, 2012, CELL MOL LIFE SCI, V69, P1615, DOI 10.1007/s00018-012-0970-0
   Grillo MA, 2008, AMINO ACIDS, V35, P29, DOI 10.1007/s00726-007-0606-0
   Guerreiro R, 2013, NEW ENGL J MED, V368, P117, DOI 10.1056/NEJMoa1211851
   Hagstrom SA, 1999, INVEST OPHTH VIS SCI, V40, P2795
   Hannum G, 2013, MOL CELL, V49, P359, DOI 10.1016/j.molcel.2012.10.016
   He M, 2011, EMBO REP, V12, P358, DOI 10.1038/embor.2011.28
   Hearps AC, 2012, AGING CELL
   Hickman SE, 2008, J NEUROSCI, V28, P8354, DOI 10.1523/JNEUROSCI.0616-08.2008
   Hsieh CL, 2009, J NEUROCHEM, V109, P1144, DOI 10.1111/j.1471-4159.2009.06042.x
   Huizinga R, 2012, GLIA, V60, P422, DOI 10.1002/glia.22276
   Ishibashi T, 1998, ARCH OPHTHALMOL-CHIC, V116, P1629, DOI 10.1001/archopht.116.12.1629
   Ivan E, 2006, HUM IMMUNOL, V67, P479, DOI 10.1016/j.humimm.2005.12.001
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Jiang MH, 2012, AGING CELL, V11, P29, DOI 10.1111/j.1474-9726.2011.00757.x
   Jonsson T, 2013, NEW ENGL J MED, V368, P107, DOI 10.1056/NEJMoa1211103
   KATZ ML, 1984, EXP EYE RES, V38, P137, DOI 10.1016/0014-4835(84)90098-8
   Kinnunen K, 2012, ACTA OPHTHALMOL, V90, P299, DOI 10.1111/j.1755-3768.2011.02179.x
   Lai AY, 2012, FUTUR NEUROL, V7, P165, DOI 10.2217/FNL.12.6
   Lee CYD, 2010, J NEURAL TRANSM, V117, P949, DOI 10.1007/s00702-010-0433-4
   Lemke G, 2008, NAT REV IMMUNOL, V8, P327, DOI 10.1038/nri2303
   Li W, 2012, METHODS, V58, P2, DOI 10.1016/j.ymeth.2012.07.013
   Li W, 2012, J CELL PHYSIOL, V227, P1291, DOI 10.1002/jcp.22815
   Luo XG, 2010, MOL NEURODEGENER, V5, DOI 10.1186/1750-1326-5-12
   Lyck L, 2009, J NEUROSCI METH, V182, P143, DOI 10.1016/j.jneumeth.2009.06.003
   Ma GZM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016964
   MEDA L, 1995, NATURE, V374, P647, DOI 10.1038/374647a0
   Miyanishi M, 2007, NATURE, V450, P435, DOI 10.1038/nature06307
   Morgan D, 2009, CNS NEUROL DISORD-DR, V8, P7, DOI 10.2174/187152709787601821
   Mukherjee PK, 2004, P NATL ACAD SCI USA, V101, P8491, DOI 10.1073/pnas.0402531101
   Mukherjee PK, 2007, P NATL ACAD SCI USA, V104, P13158, DOI 10.1073/pnas.0705963104
   Napoli I, 2009, NEUROSCIENCE, V158, P1030, DOI 10.1016/j.neuroscience.2008.06.046
   Napoli I, 2010, EXP NEUROL, V225, P24, DOI 10.1016/j.expneurol.2009.04.024
   Neumann H, 2007, J NEUROIMMUNOL, V184, P92, DOI 10.1016/j.jneuroim.2006.11.032
   Neumann H, 2013, NEW ENGL J MED, V368, P182, DOI 10.1056/NEJMe1213157
   Njie EG, 2012, NEUROBIOL AGING, V33, DOI 10.1016/j.neurobiolaging.2010.05.008
   NobenTrauth K, 1996, NATURE, V380, P534, DOI 10.1038/380534a0
   Paolicelli RC, 2011, SCIENCE, V333, P1456, DOI 10.1126/science.1202529
   Park D, 2007, NATURE, V450, P430, DOI 10.1038/nature06329
   Park SY, 2008, CELL DEATH DIFFER, V15, P192, DOI 10.1038/sj.cdd.4402242
   Pavese N, 2006, NEUROLOGY, V66, P1638, DOI 10.1212/01.wnl.0000222734.56412.17
   Plowden J, 2004, AGING CELL, V3, P161, DOI 10.1111/j.1474-9728.2004.00102.x
   SCHMIDT AM, 1995, J CLIN INVEST, V96, P1395, DOI 10.1172/JCI118175
   Schmidt AM, 2001, J CLIN INVEST, V108, P949, DOI 10.1172/JCI14002
   Scott RS, 2001, NATURE, V411, P207, DOI 10.1038/35075603
   Shiozawa Y., 2010, EXPT HEMATOLOGY, V38, P132
   Sim FJ, 2002, J NEUROSCI, V22, P2451, DOI 10.1523/JNEUROSCI.22-07-02451.2002
   Simell B, 2011, VACCINE, V29, P1929, DOI 10.1016/j.vaccine.2010.12.121
   Sims GP, 2010, ANNU REV IMMUNOL, V28, P367, DOI 10.1146/annurev.immunol.021908.132603
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Solana R, 2012, SEMIN IMMUNOL
   STITT TN, 1995, CELL, V80, P661, DOI 10.1016/0092-8674(95)90520-0
   Stubdal H, 2000, MOL CELL BIOL, V20, P878, DOI 10.1128/MCB.20.3.878-882.2000
   Takahashi K, 2007, PLOS MED, V4, P675, DOI 10.1371/journal.pmed.0040124
   Videla LA, 2001, REDOX REP, V6, P155, DOI 10.1179/135100001101536265
   Vives-Bauza C, 2008, J BIOL CHEM, V283, P24770, DOI 10.1074/jbc.M800706200
   VLASSARA H, 1995, MOL MED, V1, P634, DOI 10.1007/BF03401604
   von Bernhardi R, 2010, J NEUROCHEM, V112, P1099, DOI 10.1111/j.1471-4159.2009.06537.x
   Wang Y, 2013, ONCOGENE, V32, P872, DOI 10.1038/onc.2012.104
   Weinger JG, 2009, AM J PATHOL, V175, P283, DOI 10.2353/ajpath.2009.080807
   Wenisch C, 2000, J LEUKOCYTE BIOL, V67, P40, DOI 10.1002/jlb.67.1.40
   YEN TC, 1989, BIOCHEM BIOPH RES CO, V165, P994, DOI 10.1016/0006-291X(89)92701-0
   Zhao C, 2006, NEUROBIOL AGING, V27, P1298, DOI 10.1016/j.neurobiolaging.2005.06.008
   Zhao L, 2007, MOL VIS, V13, P873
NR 96
TC 65
Z9 69
U1 0
U2 22
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 1568-1637
EI 1872-9649
J9 AGEING RES REV
JI Ageing Res. Rev.
PD SEP
PY 2013
VL 12
IS 4
BP 1005
EP 1012
DI 10.1016/j.arr.2013.05.006
PG 8
WC Cell Biology; Geriatrics & Gerontology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Geriatrics & Gerontology
GA 278EQ
UT WOS:000328872400015
PM 23748186
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Synowiec, E
   Sliwinski, T
   Danisz, K
   Blasiak, J
   Sklodowska, A
   Romaniuk, D
   Watala, C
   Szaflik, J
   Szaflik, JP
AF Synowiec, Ewelina
   Sliwinski, Tomasz
   Danisz, Katarzyna
   Blasiak, Janusz
   Sklodowska, Anna
   Romaniuk, Dorota
   Watala, Cezary
   Szaflik, Jerzy
   Szaflik, Jacek P.
TI Association between polymorphism of the NQO1, NOS3 and NFE2L2 genes and
   AMD
SO FRONTIERS IN BIOSCIENCE-LANDMARK
LA English
DT Article
DE AMD; Reactive oxygen species; Iron; Gene polymorphism; NQO1; NOS3;
   NFE2L2 gene
ID AGE-RELATED MACULOPATHY; BLUE MOUNTAINS EYE; BEAVER DAM EYE; MACULAR
   DEGENERATION; NITRIC-OXIDE; OXIDOREDUCTASE 1; BREAST-CANCER; CHOROIDAL
   NEOVASCULARIZATION; FAMILIAL AGGREGATION; SUPEROXIDE-DISMUTASE
AB Oxidative stress may play a role in the pathogenesis of age-related macular degeneration (AMD). In this study we examined the association between AMD risk and polymorphisms of genes encoding enzymes involved in the generation and removal of iron-mediated oxidation: NQO1 (609C> T, rs1800566), NOS3 (894G>T, rs1799983) and NFE2L2 (28312647A>G, rs6726395). We found that the G/G genotype of the rs6726395 polymorphism was associated with a decreased risk of AMD wet form (OR 0.44) and on the other hand the T allele of the rs1799983 polymorphism increased such risk (OR 1.63). We also observed that the C/C-G/T combined genotype of the rs1800566 and rs1799983 polymorphisms was positively correlated with a reduced risk of AMD as well as of its dry form (OR 0.40 and 0.35). The presence of the G/T-G/G combined genotype of the rs1799983 and rs6726395 polymorphisms decreased the risk of this disease (OR 0.35). The results obtained in our study suggest a potential role of the rs1800566, rs1799983 and rs6726395 polymorphisms in the AMD pathogenesis.
C1 [Synowiec, Ewelina; Sliwinski, Tomasz; Danisz, Katarzyna; Blasiak, Janusz] Univ Lodz, Dept Mol Genet, PL-90236 Lodz, Poland.
   [Sklodowska, Anna; Szaflik, Jerzy; Szaflik, Jacek P.] Med Univ Warsaw, Dept Ophthalmol, PL-03709 Warsaw, Poland.
   [Sklodowska, Anna; Szaflik, Jerzy; Szaflik, Jacek P.] Samodzielny Publiczny Kliniczny Szpital Okulistyc, PL-03709 Warsaw, Poland.
   [Romaniuk, Dorota] Med Univ Silesia, Univ Hosp, Dept Ophthalmol, PL-40952 Katowice, Poland.
   [Watala, Cezary] Med Univ Lodz, Dept Haemostasis & Haemostat Disorders, PL-90549 Lodz, Poland.
C3 University of Lodz; Medical University of Warsaw; Medical University
   Silesia; Medical University Lodz
RP Szaflik, JP (通讯作者)，Med Univ Warsaw, Dept Ophthalmol, Sierakowskiego 13, PL-03709 Warsaw, Poland.
EM szaflik@ophthalmology.pl
RI Watala, Cezary/ABF-4863-2020
OI Watala, Cezary/0000-0002-5627-7872; Sliwinski,
   Tomasz/0000-0001-8385-7744; Blasiak, Janusz/0000-0001-9539-9584;
   Synowiec, Ewelina/0000-0002-0730-4491; Szaflik,
   Jerzy/0000-0002-7601-1326
FU Polish Ministry of Science and Higher Education [N N402 248 336];
   Novartis Poland
FX This work was supported by grant N N402 248 336 from Polish Ministry of
   Science and Higher Education. Publication of this article was supported
   by Novartis Poland.
CR Alp E, 2009, DNA CELL BIOL, V28, P343, DOI 10.1089/dna.2009.0866
   Arisawa T, 2007, INT J MOL MED, V20, P849
   Bianco NR, 2003, MOL ENDOCRINOL, V17, P1344, DOI 10.1210/me.2002-0382
   Brunk UT, 2002, FREE RADICAL BIO MED, V33, P611, DOI 10.1016/S0891-5849(02)00959-0
   Buch H, 2005, ACTA OPHTHALMOL SCAN, V83, P409, DOI 10.1111/J.1600-0420.2005.00492.x
   Conen D, 2008, J INTERN MED, V263, P376, DOI 10.1111/j.1365-2796.2007.01894.x
   Dhubhghaill SSN, 2010, ADV EXP MED BIOL, V664, P437, DOI 10.1007/978-1-4419-1399-9_50
   Drummond GR, 2000, CIRC RES, V86, P347, DOI 10.1161/01.RES.86.3.347
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Frank R N, 2000, Trans Am Ophthalmol Soc, V98, P109
   FREUND KB, 1993, AM J OPHTHALMOL, V115, P786, DOI 10.1016/S0002-9394(14)73649-9
   Gorbunov NV, 1997, J BIOL CHEM, V272, P12328, DOI 10.1074/jbc.272.19.12328
   Hadziahmetovic M, 2008, INVEST OPHTH VIS SCI, V49, P2728, DOI 10.1167/iovs.07-1472
   Hahn P, 2004, P NATL ACAD SCI USA, V101, P13850, DOI 10.1073/pnas.0405146101
   Hahn P, 2003, ARCH OPHTHALMOL-CHIC, V121, P1099, DOI 10.1001/archopht.121.8.1099
   Hahn P, 2006, NEUROREPORT, V17, P1803, DOI 10.1097/WNR.0b013e3280107776
   Hong CC, 2007, CANCER EPIDEM BIOMAR, V16, P1784, DOI 10.1158/1055-9965.EPI-07-0247
   Hu JY, 2011, OPHTHAL EPIDEMIOL, V18, P137, DOI 10.3109/09286586.2011.574335
   Hubackova M, 2009, PHARMACOGENET GENOM, V19, P505, DOI 10.1097/FPC.0b013e32832cf9cf
   Hyman Leslie, 2002, Curr Opin Ophthalmol, V13, P171
   HYMAN LG, 1983, AM J EPIDEMIOL, V118, P213, DOI 10.1093/oxfordjournals.aje.a113629
   Itoh K, 1997, BIOCHEM BIOPH RES CO, V236, P313, DOI 10.1006/bbrc.1997.6943
   Jaiswal AK, 2000, FREE RADICAL BIO MED, V29, P254, DOI 10.1016/S0891-5849(00)00306-3
   KANNER J, 1991, ARCH BIOCHEM BIOPHYS, V289, P130, DOI 10.1016/0003-9861(91)90452-O
   Kimura K, 2000, AM J OPHTHALMOL, V130, P769, DOI 10.1016/S0002-9394(00)00552-3
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P653, DOI 10.1001/archopht.116.5.653
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P1646, DOI 10.1001/archopht.116.12.1646
   Klein BEK, 1998, ARCH OPHTHALMOL-CHIC, V116, P219, DOI 10.1001/archopht.116.2.219
   Klein R, 2003, OPHTHALMOLOGY, V110, P636, DOI 10.1016/S0161-6420(02)01448-3
   Leveziel N, 2007, MOL VIS, V13, P2153
   Li N, 2006, ANTIOXID REDOX SIGN, V8, P88, DOI 10.1089/ars.2006.8.88
   Milton RC, 2005, OPHTHALMOLOGY, V112, P533, DOI 10.1016/j.ophtha.2004.10.047
   PIGUET B, 1993, BRIT J OPHTHALMOL, V77, P400, DOI 10.1136/bjo.77.7.400
   Rebbeck TR, 1999, CANCER-AM CANCER SOC, V86, P2493, DOI 10.1002/(SICI)1097-0142(19991201)86:11+<2493::AID-CNCR6>3.0.CO;2-Z
   Rosenfeld PJ, 1999, GENETICS, P69
   Ross D, 1996, BRIT J CANCER, V74, P995, DOI 10.1038/bjc.1996.477
   ROY D, 1988, J BIOL CHEM, V263, P3646
   SanGiovanni JP, 2007, ARCH OPHTHALMOL-CHIC, V125, P671, DOI 10.1001/archopht.125.5.671
   Schillinger M, 2002, J ENDOVASC THER, V9, P385, DOI 10.1583/1545-1550(2002)009<0385:HOGIAV>2.0.CO;2
   Scholl HPN, 2007, MOL VIS, V13, P196
   Seddon JM, 1997, AM J OPHTHALMOL, V123, P199, DOI 10.1016/S0002-9394(14)71036-0
   Seddon JM, 2006, ARCH OPHTHALMOL-CHIC, V124, P995, DOI 10.1001/archopht.124.7.995
   Sickenberg M, 2001, OPHTHALMOLOGICA, V215, P247, DOI 10.1159/000050869
   Siegel D, 1999, PHARMACOGENETICS, V9, P113, DOI 10.1097/00008571-199902000-00015
   SILVESTRI G, 1994, EYE, V8, P564, DOI 10.1038/eye.1994.138
   Smith W, 1998, AUST NZ J OPHTHALMOL, V26, P203, DOI 10.1111/j.1442-9071.1998.tb01311.x
   Spencer KL, 2008, HUM MOL GENET, V17, P1821, DOI 10.1093/hmg/ddn075
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   Toriello M, 2008, HEADACHE, V48, P1115, DOI 10.1111/j.1526-4610.2008.01181.x
   Veldman BA, 2002, J HYPERTENS, V20, P2023, DOI 10.1097/00004872-200210000-00022
   Vojnikovic B, 2007, COLLEGIUM ANTROPOL, V31, P43
   von Otter M, 2010, MECH AGEING DEV, V131, P105, DOI 10.1016/j.mad.2009.12.007
   Wang JJ, 2008, OPHTHALMOLOGY, V115, P693, DOI 10.1016/j.ophtha.2007.05.038
   Wang JJ, 2003, OPHTHALMOLOGY, V110, P1960, DOI 10.1016/S0161-6420(03)00816-9
   Wong RW, 2007, RETINA-J RET VIT DIS, V27, P997, DOI 10.1097/IAE.0b013e318074c290
   Wozniak K, 2009, J BIOMED BIOTECHNOL, DOI 10.1155/2009/827562
   Wyllie S, 1997, ARCH BIOCHEM BIOPHYS, V346, P180, DOI 10.1006/abbi.1997.0306
   Wysokinski D, 2011, TOHOKU J EXP MED, V223, P253, DOI 10.1620/tjem.223.253
   Yamada N, 2000, AM J HUM GENET, V66, P187, DOI 10.1086/302729
   Yang X, 2010, BRIT J OPHTHALMOL, V94, P1211, DOI 10.1136/bjo.2009.165811
   Yao L, 2010, BREAST CANCER RES TR, V124, P223, DOI 10.1007/s10549-010-0800-8
   Yates JRW, 2000, J MED GENET, V37, P83, DOI 10.1136/jmg.37.2.83
   Zai CC, 2010, PROG NEURO-PSYCHOPH, V34, P50, DOI 10.1016/j.pnpbp.2009.09.020
   Zerbib J, 2010, MOL VIS, V16, P1324
   Zhu F, 2009, BMC GASTROENTEROL, V9, DOI 10.1186/1471-230X-9-76
   Ziegler RG, 1996, J NATL CANCER I, V88, P650, DOI 10.1093/jnci/88.10.650
NR 66
TC 13
Z9 15
U1 1
U2 6
PU FRONTIERS IN BIOSCIENCE INC
PI IRVINE
PA 16471 SCIENTIFIC WAY, IRVINE, CA 92618 USA
SN 1093-9946
EI 1093-4715
J9 FRONT BIOSCI-LANDMRK
JI Front. Biosci.
PD JAN 1
PY 2013
VL 18
BP 80
EP 90
DI 10.2741/4088
PG 11
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA 171UK
UT WOS:000320954800005
PM 23276910
DA 2022-11-30
ER

PT J
AU Keane, PA
   Sadda, SR
AF Keane, Pearse A.
   Sadda, Srinivas R.
TI Development of Anti-VEGF Therapies for Intraocular Use: A Guide for
   Clinicians
SO JOURNAL OF OPHTHALMOLOGY
LA English
DT Review
ID ENDOTHELIAL GROWTH-FACTOR; VASCULAR-PERMEABILITY FACTOR; EXPERIMENTAL
   CHOROIDAL NEOVASCULARIZATION; OCCLUSION 12-MONTH OUTCOMES; PIGMENT
   EPITHELIAL-CELLS; MACULAR DEGENERATION; OCULAR NEOVASCULARIZATION; IRIS
   NEOVASCULARIZATION; INTRAVITREAL INJECTION; SUSTAINED BENEFITS
AB Angiogenesis is the process by which new blood vessels form from existing vessel networks. In the past three decades, significant progress has been made in our understanding of angiogenesis; progress driven in large part by the increasing realization that blood vessel growth can promote or facilitate disease. By the early 1990s, it had become clear that the recently discovered "vascular endothelial growth factor" (VEGF) was a powerful mediator of angiogenesis. As a result, several groups targeted this molecule as a potential mediator of retinal ischemia-induced neovascularization in disorders such as diabetic retinopathy and retinal vein occlusion. Around this time, it also became clear that increased intraocular VEGF production was not limited to ischemic retinal diseases but was also a feature of choroidal vascular diseases such as neovascular age-related macular degeneration (AMD). Thus, a new therapeutic era emerged, utilizing VEGF blockade for the management of chorioretinal diseases characterized by vascular hyperpermeability and/or neovascularization. In this review, we provide a guide for clinicians on the development of anti-VEGF therapies for intraocular use.
C1 [Sadda, Srinivas R.] Univ So Calif, Keck Sch Med, Doheny Eye Inst, Los Angeles, CA 90033 USA.
   [Sadda, Srinivas R.] Univ So Calif, Keck Sch Med, Dept Ophthalmol, Los Angeles, CA 90033 USA.
   [Keane, Pearse A.] Moorfields Eye Hosp NHS Fdn Trust, NIHR Biomed Res Ctr Ophthalmol, London EC1V 2PD, England.
   [Keane, Pearse A.] UCL Inst Ophthalmol, London EC1V 2PD, England.
C3 Doheny Eye Institute; University of Southern California; University of
   Southern California; University of London; University College London;
   Moorfields Eye Hospital NHS Foundation Trust; University of London;
   University College London
RP Sadda, SR (通讯作者)，Univ So Calif, Keck Sch Med, Doheny Eye Inst, Los Angeles, CA 90033 USA.
EM ssadda@doheny.org
RI Keane, Pearse/AAE-5709-2019
OI Keane, Pearse/0000-0002-9239-745X
FU Department of Health's NIHR Biomedical Research Centre for Ophthalmology
   at Moorfields Eye Hospital; UCL Institute of Ophthalmology; Carl Zeiss
   Meditec; Optos; Optovue, Inc.; Academy of Medical Sciences (AMS)
   [AMS-SGCL6-Keane] Funding Source: researchfish; National Institute for
   Health Research [CL-2010-18-004] Funding Source: researchfish
FX Dr Keane has received a proportion of his funding from the Department of
   Health's NIHR Biomedical Research Centre for Ophthalmology at Moorfields
   Eye Hospital and UCL Institute of Ophthalmology. The views expressed in
   the publication are those of the authors and not necessarily those of
   the Department of Health.; Dr Sadda is a co-inventor of Doheny
   intellectual property related to optical coherence tomography that has
   been licensed by Topcon Medical Systems, and is a member of the
   scientific advisory board for Heidelberg Engineering. Dr Sadda also
   receives research support from Carl Zeiss Meditec, Optos, and Optovue,
   Inc.
CR ABRAHAM JA, 1986, SCIENCE, V233, P545, DOI 10.1126/science.2425435
   ADAMIS AP, 1994, AM J OPHTHALMOL, V118, P445, DOI 10.1016/S0002-9394(14)75794-0
   Adamis AP, 1996, ARCH OPHTHALMOL-CHIC, V114, P66, DOI 10.1001/archopht.1996.01100130062010
   AIELLO LP, 1995, P NATL ACAD SCI USA, V92, P10457, DOI 10.1073/pnas.92.23.10457
   AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203
   ALGIRE GH, 1945, J NATL CANCER I, V6, P73, DOI 10.1093/jnci/6.1.73
   Apte RS, 2007, OPHTHALMOLOGY, V114, P1702, DOI 10.1016/j.ophtha.2007.02.021
   Bakri SJ, 2007, OPHTHALMOLOGY, V114, P2179, DOI 10.1016/j.ophtha.2007.09.012
   Bakri SJ, 2007, OPHTHALMOLOGY, V114, P855, DOI 10.1016/j.ophtha.2007.01.017
   Benjamin LE, 1999, J CLIN INVEST, V103, P159, DOI 10.1172/JCI5028
   Boyer D, 2010, OPHTHALMOLOGY, V117, P1860, DOI 10.1016/j.ophtha.2010.02.022
   Boyer DS, 2009, OPHTHALMOLOGY, V116, P1731, DOI 10.1016/j.ophtha.2009.05.024
   Brar VS, 2009, J OCUL PHARMACOL TH, V25, P507, DOI 10.1089/jop.2009.0028
   Bressler NM, 2009, OPHTHALMOLOGY, V116, pS15, DOI 10.1016/j.ophtha.2009.06.048
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2011, OPHTHALMOLOGY, V118, P1594, DOI 10.1016/j.ophtha.2011.02.022
   Campochiaro PA, 2011, OPHTHALMOLOGY, V118, P2041, DOI 10.1016/j.ophtha.2011.02.038
   Campochiaro PA, 2010, OPHTHALMOLOGY, V117, P1102, DOI 10.1016/j.ophtha.2010.02.021
   Cao JT, 2010, INVEST OPHTH VIS SCI, V51, P6009, DOI 10.1167/iovs.09-4956
   Carmeliet P, 2000, NAT MED, V6, P389, DOI 10.1038/74651
   Carmeliet P, 2011, NATURE, V473, P298, DOI 10.1038/nature10144
   Chen Y, 1999, J MOL BIOL, V293, P865, DOI 10.1006/jmbi.1999.3192
   CLAUSS M, 1990, J EXP MED, V172, P1535, DOI 10.1084/jem.172.6.1535
   DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256
   Dixon JA, 2009, EXPERT OPIN INV DRUG, V18, P1573, DOI 10.1517/13543780903201684
   Dor Y, 2001, AM J PHYSIOL-CELL PH, V280, pC1367, DOI 10.1152/ajpcell.2001.280.6.C1367
   Drolet DW, 2000, PHARMACEUT RES, V17, P1503, DOI 10.1023/A:1007657109012
   Eaton BE, 1997, CURR OPIN CHEM BIOL, V1, P10, DOI 10.1016/S1367-5931(97)80103-2
   Elman MJ, 2010, OPHTHALMOLOGY, V117, P1064, DOI 10.1016/j.ophtha.2010.02.031
   FERRARA N, 1989, BIOCHEM BIOPH RES CO, V161, P851, DOI 10.1016/0006-291X(89)92678-8
   Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669
   Ferrara N, 1997, ENDOCR REV, V18, P4, DOI 10.1210/er.18.1.4
   Ferrara N, 2005, NATURE, V438, P967, DOI 10.1038/nature04483
   Ferrara N, 2006, RETINA-J RET VIT DIS, V26, P859, DOI 10.1097/01.iae.0000242842.14624.e7
   Ferrara N, 2010, NAT MED, V16, P1107, DOI 10.1038/nm1010-1107
   FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182
   Gaudreault J, 2005, INVEST OPHTH VIS SCI, V46, P726, DOI 10.1167/iovs.04-0601
   Gaudreault J, 2007, RETINA-J RET VIT DIS, V27, P1260, DOI 10.1097/IAE.0b013e318134eecd
   Gerber HP, 1999, DEVELOPMENT, V126, P1149
   Gordon MS, 2005, ONCOLOGY-BASEL, V69, P25, DOI 10.1159/000088481
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Han YS, 2009, GRAEF ARCH CLIN EXP, V247, P541, DOI 10.1007/s00417-008-0976-3
   Holash J, 2002, P NATL ACAD SCI USA, V99, P11393, DOI 10.1073/pnas.172398299
   Iliopoulos O, 1996, P NATL ACAD SCI USA, V93, P10595, DOI 10.1073/pnas.93.20.10595
   Ishida S, 2003, J EXP MED, V198, P483, DOI 10.1084/jem.20022027
   Kaiser PK, 2006, AM J OPHTHALMOL, V142, P660, DOI 10.1016/j.ajo.2006.05.061
   Kaiser PK, 2010, AM J OPHTHALMOL, V150, P33, DOI 10.1016/j.ajo.2010.02.006
   Kaiser PK, 2010, BRIT J OPHTHALMOL, V94, P143, DOI 10.1136/bjo.2009.159863
   Karkkainen MJ, 2002, NAT CELL BIOL, V4, pE2, DOI 10.1038/ncb0102-e2
   KECK PJ, 1989, SCIENCE, V246, P1309, DOI 10.1126/science.2479987
   Keefe AD, 2010, NAT REV DRUG DISCOV, V9, P537, DOI 10.1038/nrd3141
   Keyt BA, 1996, J BIOL CHEM, V271, P5638, DOI 10.1074/jbc.271.10.5638
   Kim KJ, 1992, GROWTH FACTORS, V7, P53, DOI 10.3109/08977199209023937
   Krzystolik MG, 2002, ARCH OPHTHALMOL-CHIC, V120, P338
   KU DD, 1993, AM J PHYSIOL, V265, pH586, DOI 10.1152/ajpheart.1993.265.2.H586
   Kvanta A, 1996, INVEST OPHTH VIS SCI, V37, P1929
   Lamoreaux WJ, 1998, MICROVASC RES, V55, P29, DOI 10.1006/mvre.1997.2056
   Lee S, 2005, J CELL BIOL, V169, P681, DOI 10.1083/jcb.200409115
   LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986
   Liu L, 2011, INVEST OPHTH VIS SCI, V52, P1023, DOI 10.1167/iovs.10-6431
   Lopez PF, 1996, INVEST OPHTH VIS SCI, V37, P855
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Martin DF, 2002, RETINA-J RET VIT DIS, V22, P143
   Meyer CH, 2011, EYE, V25, P661, DOI 10.1038/eye.2011.66
   Meyer CH, 2011, RETINA-J RET VIT DIS, V31, P1877, DOI 10.1097/IAE.0b013e318217373c
   Michaelson IC., 1948, T OPHTHALMOL SOC, V68, P137
   Miller JW, 1997, AM J PATHOL, V151, P13
   Mitchell P, 2010, BRIT J OPHTHALMOL, V94, P2, DOI 10.1136/bjo.2009.159160
   Mitchell P, 2011, OPHTHALMOLOGY, V118, P615, DOI 10.1016/j.ophtha.2011.01.031
   Miyamoto K, 2000, AM J PATHOL, V156, P1733, DOI 10.1016/S0002-9440(10)65044-4
   Mordenti J, 1999, TOXICOL PATHOL, V27, P536, DOI 10.1177/019262339902700507
   Neufeld G, 1999, FASEB J, V13, P9, DOI 10.1096/fasebj.13.1.9
   Ng EWM, 2006, NAT REV DRUG DISCOV, V5, P123, DOI 10.1038/nrd1955
   Nishijima K, 2007, AM J PATHOL, V171, P53, DOI 10.2353/ajpath.2007.061237
   Nork TM, 2011, ARCH OPHTHALMOL-CHIC, V129, P1042, DOI 10.1001/archophthalmol.2011.210
   PARK JE, 1993, MOL BIOL CELL, V4, P1317, DOI 10.1091/mbc.4.12.1317
   Patel PJ, 2008, TRIALS, V9, DOI 10.1186/1745-6215-9-56
   Peters S, 2007, BRIT J OPHTHALMOL, V91, P827, DOI 10.1136/bjo.2006.109702
   PLOUET J, 1989, EMBO J, V8, P3801, DOI 10.1002/j.1460-2075.1989.tb08557.x
   Presta LG, 1997, CANCER RES, V57, P4593
   ROBERTS WG, 1995, J CELL SCI, V108, P2369
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Ruckman J, 1998, J BIOL CHEM, V273, P20556, DOI 10.1074/jbc.273.32.20556
   Saishin Y, 2003, J CELL PHYSIOL, V195, P241, DOI 10.1002/jcp.10246
   Semenza GL, 2002, BIOCHEM PHARMACOL, V64, P993, DOI 10.1016/S0006-2952(02)01168-1
   SENGER DR, 1983, SCIENCE, V219, P983, DOI 10.1126/science.6823562
   Shahar J, 2006, RETINA-J RET VIT DIS, V26, P262, DOI 10.1097/00006982-200603000-00002
   SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0
   Singer M, 2009, INVEST OPHTH VIS SCI, V50, P3093
   Singerman LJ, 2008, BRIT J OPHTHALMOL, V92, P1606, DOI 10.1136/bjo.2007.132597
   Soker S, 1998, CELL, V92, P735, DOI 10.1016/S0092-8674(00)81402-6
   Spaide RF, 2006, AM J OPHTHALMOL, V141, P149, DOI 10.1016/j.ajo.2005.07.025
   Sultan MB, 2011, OPHTHALMOLOGY, V118, P1107, DOI 10.1016/j.ophtha.2011.02.045
   Tatar O, 2008, ARCH OPHTHALMOL-CHIC, V126, P782, DOI 10.1001/archopht.126.6.782
   TISCHER E, 1991, J BIOL CHEM, V266, P11947
   Tolentino MJ, 1996, ARCH OPHTHALMOL-CHIC, V114, P964, DOI 10.1001/archopht.1996.01100140172010
   Tucker CE, 1999, J CHROMATOGR B, V732, P203, DOI 10.1016/S0378-4347(99)00285-6
   Tufail A, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c2459
   Ueta T, 2009, OPHTHALMOLOGY, V116, P362, DOI 10.1016/j.ophtha.2008.09.046
   Yuan F, 1996, P NATL ACAD SCI USA, V93, P14765, DOI 10.1073/pnas.93.25.14765
   Zarbin MA, 2010, RETINA-J RET VIT DIS, V30, P1350, DOI 10.1097/IAE.0b013e3181f57e30
NR 101
TC 43
Z9 45
U1 0
U2 7
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2090-004X
EI 2090-0058
J9 J OPHTHALMOL
JI J. Ophthalmol.
PY 2012
VL 2012
AR 483034
DI 10.1155/2012/483034
PG 13
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 979DE
UT WOS:000306794300001
PM 22220269
OA Green Submitted, gold, Green Published
DA 2022-11-30
ER

PT J
AU Garnock-Jones, KP
AF Garnock-Jones, Karly P.
TI Ranibizumab In Macular Oedema Following Retinal Vein Occlusion
SO DRUGS
LA English
DT Article
ID INTRAVITREAL RANIBIZUMAB; LUCENTIS; VEGF
AB Ranibizumab (Lucentis (R)), a recombinant humanized IgG(1) kappa isotype monoclonal antibody fragment, is approved in the US for the treatment of macular oedema following retinal vein occlusion (RVO). It binds to the receptor-binding site of active forms of vascular endothelial growth factor-A, inhibiting its biological activity.
   In two large, well designed, phase III trials in patients with macular oedema following branch RVO (BRVO) or central RVO (CRVO), monthly intravitreal injections of ranibizumab 0.5 mg were associated with significantly greater improvement from baseline in mean best-corrected visual acuity letter score (measured on the Early Treatment Diabetic Retinopathy Study chart) in the study eye at 6 months (primary endpoint) than sham injections.
   Moreover, ranibizumab was significantly more effective than sham injections with regard to improvements in central foveal thickness at 6 months, as well as several other visual acuity measures.
   Ranibizumab was generally well tolerated in patients with macular oedema following CRVO or BRVO. Overall, the most common adverse events with ranibizumab were consistent with the adverse event profile previously reported in patients with age-related macular degeneration.
C1 Adis, Auckland 0754, New Zealand.
C3 Adis International
RP Garnock-Jones, KP (通讯作者)，Adis, 41 Centorian Dr,Private Bag 65901,Mairangi Bay, Auckland 0754, New Zealand.
EM demail@adis.co.nz
OI Garnock-Jones, Karly/0000-0002-1109-9945
CR Blick SK, 2007, DRUGS, V67, P1207
   Blick SKA, 2007, DRUGS, V67, P1199, DOI 10.2165/00003495-200767080-00007
   Boyer D, 2010, OPHTHALMOLOGY, V117, P1860, DOI 10.1016/j.ophtha.2010.02.022
   Campochiaro PA, 2008, MOL THER, V16, P791, DOI 10.1038/mt.2008.10
   Campochiaro PA, 2010, OPHTHALMOLOGY, V117, P1102, DOI 10.1016/j.ophtha.2010.02.021
   *GEN INC, EXT STUD EV SAF TOL
   *GEN INC, LUC RAN INJ US PRESC
   Hamid S, 2009, WORLD APPL SCI J, V6, P94
   Ho AC, 2010, INVEST OPHTH VIS SCI, V51
   Karia N, 2010, CLIN OPHTHALMOL, V4, P809
   Kinge B, 2010, AM J OPHTHALMOL, V150, P310, DOI 10.1016/j.ajo.2010.03.028
   Lowe J, 2003, INVEST OPHTH VIS SCI, V44, pU423
   Pieramici Dante J, 2008, Ophthalmology, V115, pe47, DOI 10.1016/j.ophtha.2008.06.021
   Rehak J, 2008, CURR EYE RES, V33, P111, DOI 10.1080/02713680701851902
   Rouvas A, 2010, RETINA-J RET VIT DIS, V30, P893, DOI 10.1097/IAE.0b013e3181cd4894
   Rouvas A, 2009, GRAEF ARCH CLIN EXP, V247, P1609, DOI 10.1007/s00417-009-1138-y
   Spaide RF, 2009, AM J OPHTHALMOL, V147, P298, DOI 10.1016/j.ajo.2008.08.016
   SUNER IJ, 2010, ASS RES VIS OPHTH 20
   VARMA R, 2010, ASS RES VIS OPHTH 20
NR 19
TC 10
Z9 12
U1 0
U2 1
PU ADIS INT LTD
PI NORTHCOTE
PA 5 THE WAREHOUSE WAY, NORTHCOTE 0627, AUCKLAND, NEW ZEALAND
SN 0012-6667
EI 1179-1950
J9 DRUGS
JI Drugs
PY 2011
VL 71
IS 4
BP 455
EP 463
PG 9
WC Pharmacology & Pharmacy; Toxicology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy; Toxicology
GA 744XL
UT WOS:000289128400005
PM 21395358
DA 2022-11-30
ER

PT J
AU Macgregor, AM
   Eberhart, CG
   Fraig, M
   Lu, J
   Halushka, MK
AF Macgregor, Anne M.
   Eberhart, Charles G.
   Fraig, Mostafa
   Lu, Jie
   Halushka, Marc K.
TI Tissue Inhibitor of Matrix Metalloproteinase-3 Levels in the
   Extracellular Matrix of Lung, Kidney, and Eye Increase With Age
SO JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY
LA English
DT Article
DE tissue inhibitor of matrix metalloproteinase-3; extracellular matrix;
   immunohistochemistry
ID RETINAL-PIGMENT EPITHELIUM; BRUCHS MEMBRANE; VASCULAR-DISEASE; TIMP-3;
   EXPRESSION; OVEREXPRESSION; INVASION; PROTEIN; DEATH
AB Tissue inhibitor of matrix metalloproteinase-3 (TIMP-3) is an important regulator of matrix metalloproteinase activity in many types of disease, including atherosclerosis, neoplasia, and inflammatory conditions. Among TIMPs, TIMP-3 uniquely binds the extracellular matrix (ECM). We performed IHC staining on 17 tissue microarrays containing >1500 samples to determine the location of ECM TIMP-3 staining in a variety of predominantly vascular tissues. We found a unique pattern of TIMP-3 staining in the ECM of renal arterioles, small pulmonary vessels and parenchyma, and Bruch's membrane in the retina. There was no staining in larger caliber arteries including coronary and internal mammary arteries. TIMP-3 protein accumulation was found to be an age-dependent phenomenon, with staining appearing in all three tissues in early adulthood and becoming more robust among the elderly. These findings may help to explain the late onset of the TIMP-3-associated ocular diseases Sorsby fundus dystrophy and age-related macular degeneration and suggest a similar phenomenon could be at work in other age-related conditions. (J Histochem Cytochem 57:207-213, 2009)
C1 [Macgregor, Anne M.; Eberhart, Charles G.; Fraig, Mostafa; Lu, Jie; Halushka, Marc K.] Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21205 USA.
   [Eberhart, Charles G.] Johns Hopkins Univ, Sch Med, Dept Ophthalmol, Baltimore, MD 21205 USA.
C3 Johns Hopkins University; Johns Hopkins University
RP Halushka, MK (通讯作者)，Ross Bldg,RM 632L,720 Rutland Ave, Baltimore, MD 21205 USA.
EM mhalush1@jhmi.edu
RI Fraig, Mostafa M/I-1670-2016
OI Fraig, Mostafa M/0000-0003-1119-3672; Halushka, Marc/0000-0002-7112-7389
FU American Diabetes Association [1-05-JF-20]
FX This study was supported by a junior faculty award from the American
   Diabetes Association (1-05-JF-20 to MKH).; The authors thank Sonny Dike,
   MD, for assistance with IHC.
CR Airola K, 1998, J HISTOCHEM CYTOCHEM, V46, P437, DOI 10.1177/002215549804600403
   Amour A, 1998, FEBS LETT, V435, P39, DOI 10.1016/S0014-5793(98)01031-X
   Bailey TA, 2001, EXP EYE RES, V73, P851, DOI 10.1006/exer.2001.1089
   Baker AH, 1999, BRIT J CANCER, V79, P1347, DOI 10.1038/sj.bjc.6690217
   Baker AH, 1998, J CLIN INVEST, V101, P1478, DOI 10.1172/JCI1584
   Brew K, 2000, BBA-PROTEIN STRUCT M, V1477, P267, DOI 10.1016/S0167-4838(99)00279-4
   Della NG, 1996, INVEST OPHTH VIS SCI, V37, P1921
   Fariss RN, 1997, AM J PATHOL, V150, P323
   Gill SE, 2003, DEV BIOL, V261, P313, DOI 10.1016/S0012-1606(03)00318-X
   Gomez DE, 1997, EUR J CELL BIOL, V74, P111
   HALUSHKA MK, CARDIOVASC IN PRESS
   Hobeika MJ, 2007, J VASC SURG, V45, P849, DOI 10.1016/j.jvs.2006.09.066
   Janssen A, 2008, INVEST OPHTH VIS SCI, V49, P2812, DOI 10.1167/iovs.07-1444
   Kamei M, 1997, DEGENERATIVE RETINAL DISEASES, P11
   Kamei M, 1999, INVEST OPHTH VIS SCI, V40, P2367
   Leco KJ, 2001, J CLIN INVEST, V108, P817, DOI 10.1172/JCI200112067
   LECO KJ, 1994, J BIOL CHEM, V269, P9352
   Lee MH, 2007, J BIOL CHEM, V282, P6887, DOI 10.1074/jbc.M610490200
   Malemud CJ, 2006, FRONT BIOSCI-LANDMRK, V11, P1696, DOI 10.2741/1915
   Maleszewski J, 2007, J HISTOCHEM CYTOCHEM, V55, P597, DOI 10.1369/jhc.6A7152.2007
   Mohammed FF, 2003, ANN RHEUM DIS, V62, P43
   Monnier VM, 2006, REJUV RES, V9, P264, DOI 10.1089/rej.2006.9.264
   Raffetto JD, 2008, BIOCHEM PHARMACOL, V75, P346, DOI 10.1016/j.bcp.2007.07.004
   Ruiz A, 1996, BIOCHEM BIOPH RES CO, V226, P467, DOI 10.1006/bbrc.1996.1379
   Ryu J, 2005, THROMB HAEMOSTASIS, V94, P175, DOI 10.1160/TH04-10-0656
   Santos S, 2002, EUR RESPIR J, V19, P632, DOI 10.1183/09031936.02.00245902
   Selman M, 2000, AM J PHYSIOL-LUNG C, V279, pL562, DOI 10.1152/ajplung.2000.279.3.L562
   SORSBY A, 1949, BRIT J OPHTHALMOL, V33, P67, DOI 10.1136/bjo.33.2.67
   THOMPSON EM, 1988, J MED GENET, V25, P313, DOI 10.1136/jmg.25.5.313
   Visse R, 2003, CIRC RES, V92, P827, DOI 10.1161/01.RES.0000070112.80711.3D
   WEBER BHF, 1994, NAT GENET, V8, P352, DOI 10.1038/ng1294-352
NR 31
TC 26
Z9 27
U1 0
U2 1
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 0022-1554
EI 1551-5044
J9 J HISTOCHEM CYTOCHEM
JI J. Histochem. Cytochem.
PD MAR
PY 2009
VL 57
IS 3
BP 207
EP 213
DI 10.1369/jhc.2008.952531
PG 7
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA 409UH
UT WOS:000263530800003
PM 18955737
OA Green Published, Bronze
DA 2022-11-30
ER

PT J
AU Bantseev, V
   Horvath, J
   Barteselli, G
   Ranade, S
   Maia, M
   Yadav, DB
   Schuetz, C
   Shelton, A
   Booler, HS
AF Bantseev, Vladimir
   Horvath, Joshua
   Barteselli, Giulio
   Ranade, Shrirang
   Maia, Mauricio
   Yadav, Daniela Bumbaca
   Schuetz, Chris
   Shelton, Amy
   Booler, Helen S.
TI Nonclinical Toxicology and Biocompatibility Program Supporting Clinical
   Development and Registration of the Port Delivery System With
   Ranibizumab for Neovascular Age-Related Macular Degeneration
SO TOXICOLOGIC PATHOLOGY
LA English
DT Article
DE biocompatibility; clinical development; neovascular age-related macular
   degeneration; Port Delivery System with ranibizumab; toxicology
AB The Port Delivery System with ranibizumab (PDS) is an investigational drug delivery system designed to provide continuous intravitreal release of ranibizumab for extended durations. The PDS consists of a permanent, surgically placed, refillable intraocular implant; a customized formulation of ranibizumab; and ancillary devices to support surgery and refill procedures. A toxicology program was conducted to evaluate the ocular toxicology and biocompatibility of the PDS to support its clinical development program and product registrational activities. PDS safety studies included a 6-month chronic toxicology evaluation in minipigs as well as evaluation of nonfunctional surrogate implants (comprised of the same implant materials but without ranibizumab) in rabbits. Biocompatibility of the implant and ancillary devices was evaluated in both in vitro and in vivo studies. Implants and extracts from implants and ancillary devices were nongenotoxic, noncytotoxic, nonsensitizing, and nonirritating. Ocular findings were comparable between implanted and sham-operated eyes, and no systemic toxicity was observed. The results of this nonclinical toxicology program demonstrated that the PDS was biocompatible and that intravitreal delivery of ranibizumab via the PDS did not introduce any new toxicology-related safety concerns relative to intravitreal injections, supporting ongoing PDS clinical development and product registrational evaluation.
C1 [Bantseev, Vladimir; Horvath, Joshua; Barteselli, Giulio; Ranade, Shrirang; Maia, Mauricio; Yadav, Daniela Bumbaca; Schuetz, Chris; Shelton, Amy; Booler, Helen S.] Genentech Inc, One DNA Way,MS 441A, San Francisco, CA 94080 USA.
   [Yadav, Daniela Bumbaca] Merck, San Francisco, CA USA.
   [Booler, Helen S.] Roche, Basel, Switzerland.
C3 Roche Holding; Genentech; Merck & Company; Roche Holding
RP Bantseev, V (通讯作者)，Genentech Inc, One DNA Way,MS 441A, San Francisco, CA 94080 USA.
EM bantseev.vladimir@gene.com
OI Barteselli, Giulio/0000-0003-0533-1135; Ranade,
   Shrirang/0000-0002-9457-2477
CR Alimera Sciences Limited, ILUVIEN 190 MICR INT
   [Anonymous], 2014, LUC
   Bantseev V, 2020, RETINA-J RET VIT DIS, V40, P1520, DOI 10.1097/IAE.0000000000002614
   Campochiaro PA, 2019, OPHTHALMOLOGY, V126, P1141, DOI 10.1016/j.ophtha.2019.03.036
   Drugs.com, VITR
   European Medicines Agency, OZ SUMM PROD CHAR
   Gohil R, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0129361
   Ho AC, 2014, OPHTHALMOLOGY, V121, P2181, DOI 10.1016/j.ophtha.2014.05.009
   Holz FG, 2020, RETINA-J RET VIT DIS, V40, P1673, DOI 10.1097/IAE.0000000000002670
   Holz FG, 2015, BRIT J OPHTHALMOL, V99, P220, DOI 10.1136/bjophthalmol-2014-305327
   Krzystolik MG, 2002, ARCH OPHTHALMOL-CHIC, V120, P338
   Maguire MG, 2016, OPHTHALMOLOGY, V123, P1751, DOI 10.1016/j.ophtha.2016.03.045
   Nicoli S, 2009, MOL VIS, V15, P259
   Olsen TW, 2020, OPHTHALMOLOGY, V127, pP1, DOI 10.1016/j.ophtha.2019.09.024
   Pagliarini S, 2014, J OPHTHALMOL, V2014, DOI 10.1155/2014/857148
   Peden MC, 2015, OPHTHALMOLOGY, V122, P803, DOI 10.1016/j.ophtha.2014.11.018
   Prenner JL, 2015, AM J OPHTHALMOL, V160, P725, DOI 10.1016/j.ajo.2015.06.023
   Rakic JM, 2013, CLIN OPHTHALMOL, V7, P1849, DOI 10.2147/OPTH.S49385
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   van Meer PJK, 2013, MABS-AUSTIN, V5, P810, DOI 10.4161/mabs.25234
   Varano M, 2015, CLIN OPHTHALMOL, V9, P2243, DOI 10.2147/OPTH.S92548
   Vukicevic M, 2016, EYE, V30, P413, DOI 10.1038/eye.2015.235
   Wang YMC, 2016, AAPS J, V18, P395, DOI 10.1208/s12248-015-9857-y
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
NR 26
TC 5
Z9 5
U1 1
U2 4
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0192-6233
EI 1533-1601
J9 TOXICOL PATHOL
JI Toxicol. Pathol.
PD APR
PY 2021
VL 49
IS 3
SI SI
BP 663
EP 672
DI 10.1177/0192623320968079
PG 10
WC Pathology; Toxicology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pathology; Toxicology
GA QZ1JO
UT WOS:000630491300024
PM 33205714
DA 2022-11-30
ER

PT J
AU Nguyen, NX
   Besch, D
   Bartz-Schmidt, K
   Gelisken, F
   Trauzettel-Klosinski, S
AF Nguyen, Nhung X.
   Besch, Dorothea
   Bartz-Schmidt, Karl
   Gelisken, Faik
   Trauzettel-Klosinski, Susanne
TI Reading performance with low-vision aids and vision-related quality of
   life after macular translocation surgery in patients with age-related
   macular degeneration
SO ACTA OPHTHALMOLOGICA SCANDINAVICA
LA English
DT Article
DE reading ability; low-vision aid; vision-related quality of life;
   age-related macular degeneration; macular translocation with 360-degree
   peripheral retinectomy
ID 360-DEGREES PERIPHERAL RETINECTOMY; VISUAL FUNCTION; PHOTODYNAMIC
   THERAPY; RETINOTOMY; SATISFACTION; IMPROVEMENT
AB Purpose: The aim of the present study was to evaluate the power of magnification required, reading performance with low-vision aids and vision-related quality of life with reference to reading ability and ability to carry out day-to-day activities in patients after macular translocation.
   Methods: This study included 15 patients who had undergone macular translocation with 360-degree peripheral retinectomy. The mean length of follow-up was 19.2 +/- 10.8 months (median 11 months). At the final examination, the impact of visual impairment on reading ability and quality of life was assessed according to a modified 9-item questionnaire in conjunction with a comprehensive clinical examination, which included assessment of best corrected visual acuity (BCVA), the magnification power required for reading, use of low-vision aids and reading speed. Patients rated the extent to which low vision restricted their ability to read and participate in other activities that affect quality of life. Responses were scored on a scale of 1.0 (optimum self-evaluation) to 5.0 (very poor).
   Results: In the operated eye, overall mean postoperative BCVA (distance) was not significantly better than mean preoperative BCVA (0.11 +/- 0.06 and 0.15 +/- 0.08, respectively; p = 0.53). However, 53% of patients reported a subjective increase in visual function after treatment. At the final visit, the mean magnification required was x 7.7 +/- 6.7. A total of 60% of patients needed optical magnifiers for reading and in 40% of patients closed-circuit TV systems were necessary. All patients were able to read newspaper print using adapted low-vision aids at a mean reading speed of 71 +/- 40 words per minute. Mean self-reported scores were 3.2 +/- 1.1 for reading, 2.5 +/- 0.7 for day-to-day activities and 2.7 +/- 3.0 for outdoor walking and using steps or stairs. Patients' levels of dependency were significantly correlated with scores for reading (p = 0.01), day-to-day activities (p < 0.001) and outdoor walking and using steps (p = 0.001).
   Conclusions: The evaluation of self-reported visual function and vision-related quality of life in patients after macular translocation is necessary to obtain detailed information on treatment effects. Our results indicated improvement in patients' subjective evaluations of visual function, without significant improvement in visual acuity. The postoperative clinical benefits of treatment coincide with subjective benefits in terms of reading ability, quality of life and patient satisfaction. Our study confirms the importance and efficiency of visual rehabilitation with aids for low vision after surgery.
C1 Univ Eye Hosp, Dept Ophthalmol 2, Low Vis Clin, Res Lab, D-72076 Tubingen, Germany.
   Univ Eye Hosp, Dept Ophthalmol 1, Tubingen, Germany.
C3 Eberhard Karls University of Tubingen; Eberhard Karls University
   Hospital; Eberhard Karls University of Tubingen; Eberhard Karls
   University Hospital
RP Nguyen, NX (通讯作者)，Univ Eye Hosp, Dept Ophthalmol 2, Low Vis Clin, Res Lab, Schleichstr 12-16, D-72076 Tubingen, Germany.
EM nhung.nguyen@med.uni-tuebingen.de
CR Aisenbrey S, 2002, OPHTHALMOLOGE, V99, P164, DOI 10.1007/s00347-001-0582-9
   Aisenbrey S, 2002, ARCH OPHTHALMOL-CHIC, V120, P451
   AULHORN E, 1953, PFLUG ARCH GES PHYS, V257, P318, DOI 10.1007/BF00363531
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Cahill MT, 2005, OPHTHALMOLOGY, V112, P152, DOI 10.1016/j.ophtha.2004.06.036
   Cahill MT, 2005, OPHTHALMOLOGY, V112, P144, DOI 10.1016/j.ophtha.2004.06.035
   Eckardt C, 1999, GRAEF ARCH CLIN EXP, V237, P313, DOI 10.1007/s004170050239
   Falkner CI, 2007, GRAEF ARCH CLIN EXP, V245, P490, DOI 10.1007/s00417-005-0184-3
   Fujikado T, 2000, AM J OPHTHALMOL, V130, P525, DOI 10.1016/S0002-9394(00)00582-1
   Fujikado T, 2002, AM J OPHTHALMOL, V134, P849, DOI 10.1016/S0002-9394(02)01756-7
   GELISKEN F, 2007, GRAEFES ARCH CLIN EX
   Hahn GA, 2006, BRIT J OPHTHALMOL, V90, P480, DOI 10.1136/bjo.2005.087379
   HANSELL JB, 2006, BR J OPHTHALMOL, V90, P593
   Hewitt AW, 2006, GRAEF ARCH CLIN EXP, V244, P972, DOI 10.1007/s00417-005-0218-x
   Krummenauer F, 2005, EUR J OPHTHALMOL, V15, P74, DOI 10.1177/112067210501500112
   Krummenauer F, 2004, OPHTHALMOLOGE, V101, P688, DOI 10.1007/s00347-003-0961-5
   Lai JC, 2002, ARCH OPHTHALMOL-CHIC, V120, P1317, DOI 10.1001/archopht.120.10.1317
   Lesnoni G, 2005, EUR J OPHTHALMOL, V15, P102, DOI 10.1177/112067210501500116
   MACHEMER R, 1993, GRAEF ARCH CLIN EXP, V231, P635, DOI 10.1007/BF00921957
   Mruthyunjaya P, 2004, OPHTHALMOLOGY, V111, P1715, DOI 10.1016/j.ophtha.2004.03.022
   RAYNER K, 1975, COGNITIVE PSYCHOL, V7, P65, DOI 10.1016/0010-0285(75)90005-5
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Toth CA, 2004, GRAEF ARCH CLIN EXP, V242, P541, DOI 10.1007/s00417-004-0867-1
   Trauzettel-Klosinski S, 2000, Z PRAKT AUGENHEILKD, V21, P529
   Trauzettel-Klosinski S., 2003, VIS IMPAIR RES, V5, P83, DOI [10.1076/vimr.5.2.83.26264, DOI 10.1076/VIMR.5.2.83.26264]
   TRAUZETTELKLOSINSKI S, 1994, NEURO-OPHTHALMOLOGY, V14, P15, DOI 10.3109/01658109409019482
   WHITTAKER SG, 1993, OPTOMETRY VISION SCI, V70, P54, DOI 10.1097/00006324-199301000-00010
NR 27
TC 9
Z9 9
U1 0
U2 6
PU BLACKWELL PUBLISHING
PI OXFORD
PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND
SN 1395-3907
J9 ACTA OPHTHALMOL SCAN
JI Acta Ophthalmol. Scand.
PD DEC
PY 2007
VL 85
IS 8
BP 877
EP 882
DI 10.1111/j.1600-0420.2007.00963.x
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 232MY
UT WOS:000251025000014
PM 17651462
OA Bronze
DA 2022-11-30
ER

PT J
AU Xiao, A
   Li, HJ
   Li, QY
   Liang, RB
   Shu, HY
   Ge, QM
   Liao, XL
   Pan, YC
   Wu, JL
   Su, T
   Zhang, LJ
   Zhou, Q
   Shao, Y
AF Xiao, Ang
   Li, Hai-Jun
   Li, Qiu-Yu
   Liang, Rong-Bin
   Shu, Hui-Ye
   Ge, Qian-Min
   Liao, Xu-Lin
   Pan, Yi-Cong
   Wu, Jie-Li
   Su, Ting
   Zhang, Li-Juan
   Zhou, Qiong
   Shao, Yi
TI Functional Connectivity Hypointensity of Middle Cingulate Gyrus and
   Thalamus in Age-Related Macular Degeneration Patients: A Resting-State
   Functional Magnetic Resonance Imaging Study
SO FRONTIERS IN AGING NEUROSCIENCE
LA English
DT Article
DE age-related macular degeneration; rs-fMRI; functional connectivity;
   middle cingulate gyrus; thalamus
ID RETINAL MICROVASCULAR ABNORMALITIES; ATHEROSCLEROSIS RISK; BRAIN
   CONNECTIVITY; DISEASE; REORGANIZATION; FMRI; PROJECTION; NETWORKS;
   LESIONS; STROKE
AB ObjectiveAge-related macular degeneration (AMD) causes visual damage and blindness globally. The purpose of this study was to investigate changes in functional connectivity (FC) in AMD patients using resting-state functional magnetic resonance imaging (rs-fMRI). Subjects and MethodsA total of 23 patients (12 male, 11 female) with AMD were enrolled to the AMD patients group (AMDs), and 17 healthy age-, sex-, and education-matched controls (9 male, 8 female) to the healthy controls group (HCs). All participants underwent rs-fMRI and mean FC values were compared between the two groups. ResultsSignificantly higher FC values were found in the inferior frontal gyrus (IFG), superior frontal gyrus (SFG), inferior parietal lobule (IPL), rectal gyrus (RTG), and superior parietal lobule (SPL) in AMDs compared with HCs. Conversely, FC values in the cerebellum posterior lobe (CPL), middle cingulate gyrus (MCG), medulla (MDL), cerebellum anterior lobe (CAL), and thalamus (TLM) were significantly lower in AMDs than in HCs. ConclusionThis study demonstrated FC abnormalities in many specific cerebral regions in AMD patients, and may provide new insights for exploration of potential pathophysiological mechanism of AMD-induced functional cerebral changes.
C1 [Xiao, Ang; Li, Qiu-Yu; Liang, Rong-Bin; Shu, Hui-Ye; Ge, Qian-Min; Pan, Yi-Cong; Zhang, Li-Juan; Zhou, Qiong; Shao, Yi] Nanchang Univ, Affiliated Hosp 1, Dept Ophthalmol, Nanchang, Peoples R China.
   [Li, Hai-Jun] Nanchang Univ, Affiliated Hosp 1, Dept PET Ctr, Nanchang, Peoples R China.
   [Li, Hai-Jun] Nanchang Univ, Affiliated Hosp 1, Med Image Ctr, Nanchang, Peoples R China.
   [Liao, Xu-Lin] Chinese Univ Hong Kong, Dept Ophthalmol & Visual Sci, Shatin, Hong Kong, Peoples R China.
   [Wu, Jie-Li; Su, Ting] Xiamen Univ, Xiangan Hosp, Sch Med, Dept Ophthalmol,Eye Inst,Fujian Prov Key Lab Opht, Xiamen, Peoples R China.
   [Su, Ting] Harvard Med Sch, Dept Ophthalmol, Massachusetts Eye & Ear, Boston, MA USA.
C3 Nanchang University; Nanchang University; Nanchang University; Chinese
   University of Hong Kong; Xiamen University; Harvard University; Harvard
   Medical School; Massachusetts Eye & Ear Infirmary
RP Zhou, Q; Shao, Y (通讯作者)，Nanchang Univ, Affiliated Hosp 1, Dept Ophthalmol, Nanchang, Peoples R China.
EM qiongz-ms@126.com; freebee99@163.com
OI Li, Haijun/0000-0001-6631-123X
FU Jiangxi branch of National Clinical Research Center for ocular disease
   [20211ZDG02003]; Key Research Foundation of Jiangxi Province
   [20203BBG73058, 20192BBGL70033]; Excellent Talents Development Project
   of Jiangxi Province [20192BCBL23020]; Natural Science Foundation of
   Jiangxi Province [20181BAB205034]; Grassroots Health Appropriate
   Technology "Spark Promotion Plan" Project of Jiangxi Province
   [20188003]; Health Development Planning Commission Science Foundation of
   Jiangxi Province [20201032, 202130210]; Health Development Planning
   Commission Science TCM Foundation of Jiangxi Province [2018A060,
   2020A0087]; Education Department Foundation of Jiangxi Province
   [GJJ200157, GJJ200159, GJJ200169]
FX Jiangxi branch of National Clinical Research Center for ocular disease
   (No. 20211ZDG02003); Key Research Foundation of Jiangxi Province (Nos.
   20181BBG70004 and 20203BBG73059); Excellent Talents Development Project
   of Jiangxi Province (No. 20192BCBL23020); Natural Science Foundation of
   Jiangxi Province (No. 20181BAB205034); Grassroots Health Appropriate
   Technology "Spark Promotion Plan" Project of Jiangxi Province (No.
   20188003); Health Development Planning Commission Science Foundation of
   Jiangxi Province (Nos. 20201032 and 202130210); Health Development
   Planning Commission Science TCM Foundation of Jiangxi Province (Nos.
   2018A060 and 2020A0087); Education Department Foundation of Jiangxi
   Province (Nos. GJJ200157, GJJ200159, and GJJ200169); and Key Research
   Foundation of Jiangxi Province (Nos. 20203BBG73058 and 20192BBGL70033).
CR Calhoun VD, 2001, HUM BRAIN MAPP, V14, P140, DOI 10.1002/hbm.1048
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Critchley HD, 2004, NAT NEUROSCI, V7, P189, DOI 10.1038/nn1176
   Cugati S, 2006, OPHTHALMOLOGY, V113, P2020, DOI 10.1016/j.ophtha.2006.05.047
   Damoiseaux JS, 2006, P NATL ACAD SCI USA, V103, P13848, DOI 10.1073/pnas.0601417103
   DARIANSMITH C, 1995, J NEUROSCI, V15, P1631, DOI 10.1523/JNEUROSCI.15-03-01631.1995
   De Luca M, 2006, NEUROIMAGE, V29, P1359, DOI 10.1016/j.neuroimage.2005.08.035
   Ding JR, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026596
   Ding K, 2013, NEURAL PLAST, V2013, DOI 10.1155/2013/612086
   Douaud G, 2011, BRAIN, V134, P3467, DOI 10.1093/brain/awr279
   Fuller JH, 2001, DIABETOLOGIA, V44, pS54, DOI 10.1007/PL00002940
   Giannikopoulos DV, 2006, P NATL ACAD SCI USA, V103, P10805, DOI 10.1073/pnas.0604539103
   Haak KV, 2016, OPHTHAL PHYSL OPT, V36, P335, DOI 10.1111/opo.12279
   Hernowo AT, 2014, CORTEX, V56, P99, DOI 10.1016/j.cortex.2013.01.003
   Huang X, 2016, NEUROPSYCH DIS TREAT, V12, P1901, DOI 10.2147/NDT.S110541
   KAAS JH, 1990, SCIENCE, V248, P229, DOI 10.1126/science.2326637
   Kawasaki R, 2010, OPHTHALMOLOGY, V117, P921, DOI 10.1016/j.ophtha.2009.10.007
   Laude A, 2010, PROG RETIN EYE RES, V29, P19, DOI 10.1016/j.preteyeres.2009.10.001
   Li SH, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0170598
   Li XB, 2019, PSYCHIAT RES, V282, DOI 10.1016/j.psychres.2019.112608
   Liang ML, 2017, NEURORADIOLOGY, V59, P517, DOI 10.1007/s00234-017-1824-0
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Little DM, 2008, INVEST OPHTH VIS SCI, V49, P1728, DOI 10.1167/iovs.07-0372
   Liu Y, 2007, BRAIN, V130, P2085, DOI 10.1093/brain/awm121
   Lowe MJ, 1998, NEUROIMAGE, V7, P119, DOI 10.1006/nimg.1997.0315
   Masuda Y, 2008, CEREB CORTEX, V18, P2483, DOI 10.1093/cercor/bhm256
   Mayer AR, 2015, NEUROSCI BIOBEHAV R, V49, P8, DOI 10.1016/j.neubiorev.2014.11.016
   Pascual-Leone A, 2005, ANNU REV NEUROSCI, V28, P377, DOI 10.1146/annurev.neuro.27.070203.144216
   Patton N, 2005, J ANAT, V206, P319, DOI 10.1111/j.1469-7580.2005.00395.x
   Prins D, 2016, ACTA OPHTHALMOL, V94, P113, DOI 10.1111/aos.12825
   Prins D, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0146684
   Puig J, 2018, STROKE, V49, P2353, DOI 10.1161/STROKEAHA.118.021319
   Raichle ME, 2010, SCI AM, V302, P44, DOI 10.1038/scientificamerican0310-44
   Rosengarth K, 2013, FRONT PSYCHOL, V4, DOI 10.3389/fpsyg.2013.00428
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P785, DOI 10.1001/archopht.121.6.785
   Seddon JM, 1996, JAMA-J AM MED ASSOC, V276, P1141, DOI 10.1001/jama.276.14.1141
   Seiple W, 2005, INVEST OPHTH VIS SCI, V46, P2886, DOI 10.1167/iovs.04-1296
   Seitz RJ, 2006, NEUROPSYCHOLOGY, V20, P743, DOI 10.1037/0894-4105.20.6.743
   Spreng RN, 2010, J COGNITIVE NEUROSCI, V22, P1112, DOI 10.1162/jocn.2009.21282
   Szlyk JP, 2009, INVEST OPHTH VIS SCI, V50, P4487, DOI 10.1167/iovs.08-2258
   Whitson HE, 2015, BRAIN CONNECT, V5, P126, DOI 10.1089/brain.2014.0277
   Wong TY, 2002, JAMA-J AM MED ASSOC, V288, P67, DOI 10.1001/jama.288.1.67
   Wong TY, 2001, SURV OPHTHALMOL, V46, P59, DOI 10.1016/S0039-6257(01)00234-X
   Wong TY, 2001, LANCET, V358, P1134, DOI 10.1016/S0140-6736(01)06253-5
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yan CG, 2016, NEUROINFORMATICS, V14, P339, DOI 10.1007/s12021-016-9299-4
   Yan CG, 2010, FRONT SYST NEUROSCI, V4, DOI 10.3389/fnsys.2010.00013
   Yan XH, 2019, CURR EYE RES, V44, P316, DOI 10.1080/02713683.2018.1540642
   Yatsuya H, 2010, STROKE, V41, P1349, DOI 10.1161/STROKEAHA.110.580837
   Yoshimine S, 2018, BRAIN STRUCT FUNCT, V223, P3889, DOI 10.1007/s00429-018-1702-5
   Zhang DY, 2010, NAT REV NEUROL, V6, P15, DOI 10.1038/nrneurol.2009.198
   Zhao J, 2020, NEURAL REGEN RES, V15, P285, DOI 10.4103/1673-5374.265566
   Zhuang J, 2018, NEUROBIOL AGING, V63, P65, DOI 10.1016/j.neurobiolaging.2017.11.003
   Zuo XT, 2020, NEUROBIOL AGING, V95, P176, DOI 10.1016/j.neurobiolaging.2020.07.020
NR 54
TC 1
Z9 1
U1 5
U2 6
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1663-4365
J9 FRONT AGING NEUROSCI
JI Front. Aging Neurosci.
PD MAR 21
PY 2022
VL 14
AR 854758
DI 10.3389/fnagi.2022.854758
PG 13
WC Geriatrics & Gerontology; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Geriatrics & Gerontology; Neurosciences & Neurology
GA 0I4CO
UT WOS:000779369400001
PM 35391752
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Zarranz-Ventura, J
   Parrado-Carrillo, A
   Nguyen, V
   Sararols, L
   Garay-Aramburu, G
   Puzo, M
   Arruabarrena, C
   Figueras-Roca, M
   Gillies, MC
   Casaroli-Marano, RP
AF Zarranz-Ventura, Javier
   Parrado-Carrillo, Alba
   Nguyen, Vuong
   Sararols, Laura
   Garay-Aramburu, Gonzaga
   Puzo, Martin
   Arruabarrena, Carolina
   Figueras-Roca, Marc
   Gillies, Mark C.
   Casaroli-Marano, Ricardo P.
CA Writing Comm Fight Retinal Blindne
TI Creation of a neovascular age-related macular degeneration national
   database using a web-based platform: Fight Retinal Blindness Spain.
   Report 1: Visual outcomes
SO CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE aflibercept; age-related macular degeneration; audit; benchmark
   standard; bevacizumab; national database; national dataset; neovascular
   AMD; ranibizumab
ID TREAT-AND-EXTEND; DAILY CLINICAL-PRACTICE; ACUITY OUTCOMES; INTRAVITREAL
   RANIBIZUMAB; 2-YEAR OUTCOMES; AFLIBERCEPT; THERAPY; AMD; MANAGEMENT;
   EFFICACY
AB Background To study the visual outcomes of neovascular AMD (nAMD) treated with anti-vascular endothelial growth factor (VEGF) drugs at national level. Methods Multicenter national database of nAMD eyes treated with anti-VEGF intravitreal injections (ranibizumab, aflibercept, bevacizumab) in fixed bimonthly (FB) or treat-and-extend (TAE) regimens. Demographics, visual acuity (VA) in logarithm of the minimum angle of resolution (logMAR) ETDRS letters at baseline and subsequent visits, number of injections and visits data were collected using a validated web-based tool (Fight Retinal Blindness!). Results 1273 eyes (1014 patients) were included, 971 treatment naive (TN) and 302 previously treated (PT). Baseline VA (mean +/- SD) was 57.5 (+/- 19.5) and 62.2 (+/- 17) (p > 0.001), and 24 months final VA was 60.4 (+/- 21.2) and 58.8 (+/- 21.1) (p = 0.326), respectively. Mean VA change at 12/24 months was +4.2/+2.9 letters in TN eyes and +0.1/-3.4 letters in PT eyes (p < 0.001/p < 0.001). The percentage of >= 15 letters gainers/losers at 24 months was 24.8%/14.5% in TN, and 10.3%/15.7% in PT eyes. The median number of injections/visits at 12 months was 7/9 in TN and 6/8 in PT (p = 0.002/p < 0.001) and at 24 months was 11/16 in TN and 11/14 in PT (p = 0.329/p < 0.001). Study drugs included ranibizumab (39.5%), aflibercept (41.2%) and bevacizumab (19.3%). Conclusion Independent, large-scale national audits are feasible if committed health care professionals are provided with efficient information technology systems to do them. The results described here represent an adequate measurement of the quality of care delivered nationwide and benchmark the clinical management of nAMD at a country level compared to other real-world international cohorts.
C1 [Zarranz-Ventura, Javier; Parrado-Carrillo, Alba; Figueras-Roca, Marc; Casaroli-Marano, Ricardo P.] Hosp Clin Barcelona, C Sabino Arana 1, Barcelona 08028, Spain.
   [Zarranz-Ventura, Javier; Parrado-Carrillo, Alba; Figueras-Roca, Marc; Casaroli-Marano, Ricardo P.] Inst Investigac Biomed August Pi I Sunyer IDIBAPS, Barcelona, Spain.
   [Nguyen, Vuong; Gillies, Mark C.] Univ Sydney, Sydney Med Sch, Save Sight Inst, Sydney, NSW, Australia.
   [Sararols, Laura] Fundacio Privada Hosp Asil Granollers, Granollers, Spain.
   [Garay-Aramburu, Gonzaga] OSI Araba, Vitoria, ES, Brazil.
   [Puzo, Martin] Hosp Univ Miguel Servet, Zaragoza, Spain.
   [Arruabarrena, Carolina] Hosp Univ Principe Asturias, Madrid, Spain.
   [Casaroli-Marano, Ricardo P.] Univ Barcelona, Sch Med, Dept Surg, Barcelona, Spain.
C3 University of Barcelona; Hospital Clinic de Barcelona; University of
   Sydney; Miguel Servet University Hospital; Prince of Asturias University
   Hospital; University of Barcelona
RP Zarranz-Ventura, J (通讯作者)，Hosp Clin Barcelona, C Sabino Arana 1, Barcelona 08028, Spain.
EM zarranz@clinic.cat
RI Zarranz-Ventura, Javier/AAB-5390-2021; Casaroli-Marano, Ricardo
   Pedro/D-4535-2014
OI Zarranz-Ventura, Javier/0000-0003-2338-8143; Arruabarrena,
   Carolina/0000-0002-5312-8900; Asencio-Duran, Monica/0000-0002-6281-3109;
   Parrado-Carrillo, Alba/0000-0003-0182-7950; Carreno,
   Ester/0000-0002-0055-9547; Velazquez Villoria,
   Daniel/0000-0002-8677-6859; Gillies, mark/0000-0001-8580-0274; PUZO,
   MARTIN/0000-0002-5048-4846; Casaroli-Marano, Ricardo
   Pedro/0000-0003-1812-9323; Nguyen, Vuong/0000-0001-9070-9803;
   GARAY-ARAMBURU, GONZAGA/0000-0001-5255-8426; Zapata, Miguel
   Angel/0000-0002-0096-4569
CR Almuhtaseb H, 2017, EYE, V31, P1582, DOI 10.1038/eye.2017.108
   Arnold JJ, 2015, OPHTHALMOLOGY, V122, P1212, DOI 10.1016/j.ophtha.2015.02.009
   Barthelmes D, 2018, RETINA-J RET VIT DIS, V38, P20, DOI 10.1097/IAE.0000000000001496
   Casaroli-Marano R, 2014, J OPHTHALMOL, V2014, DOI 10.1155/2014/346360
   Castro-Navarro V, 2016, OPHTHALMOLOGICA, V236, P215, DOI 10.1159/000453281
   Cohen SY, 2013, RETINA-J RET VIT DIS, V33, P474, DOI 10.1097/IAE.0b013e31827b6324
   Figueras-Roca M, 2021, GRAEF ARCH CLIN EXP, V259, P1463, DOI 10.1007/s00417-020-05016-9
   Finger RP, 2013, ACTA OPHTHALMOL, V91, P540, DOI 10.1111/j.1755-3768.2012.02493.x
   Galvez MIL, 2020, ACTA OPHTHALMOL, V98, pE820, DOI 10.1111/aos.14399
   Garcia-Layana A, 2019, J OPHTHALMOL, V2019, DOI 10.1155/2019/9821509
   Gillies MC, 2014, RETINA-J RET VIT DIS, V34, P188, DOI 10.1097/IAE.0b013e318296b271
   Holz FG, 2016, EYE, V30, P1063, DOI 10.1038/eye.2016.90
   Holz FG, 2020, RETINA-J RET VIT DIS, V40, P1673, DOI 10.1097/IAE.0000000000002670
   Holz FG, 2016, BRIT J OPHTHALMOL, V100, P1623, DOI 10.1136/bjophthalmol-2015-308166
   Holz FG, 2015, BRIT J OPHTHALMOL, V99, P220, DOI 10.1136/bjophthalmol-2014-305327
   Hykin P, 2016, CLIN OPHTHALMOL, V10, P87, DOI 10.2147/OPTH.S92627
   Kertes PJ, 2020, JAMA OPHTHALMOL, V138, P244, DOI 10.1001/jamaophthalmol.2019.5540
   Kertes PJ, 2019, OPHTHALMOLOGY, V126, P841, DOI 10.1016/j.ophtha.2019.01.013
   Khanani AM, 2020, OPHTHALMOL RETINA, V4, P122, DOI 10.1016/j.oret.2019.09.009
   Lange C, 2009, GRAEF ARCH CLIN EXP, V247, P137, DOI 10.1007/s00417-008-0926-0
   Liew G, 2016, EYE, V30, P1462, DOI 10.1038/eye.2016.149
   Madhusudhana KC, 2016, BRIT J OPHTHALMOL, V100, P1617, DOI 10.1136/bjophthalmol-2015-308077
   Mehta H, 2018, PROG RETIN EYE RES, V65, P127, DOI 10.1016/j.preteyeres.2017.12.002
   Mehta H, 2018, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011599.pub2
   Mekjavic PJ, 2018, BMC OPHTHALMOL, V18, DOI 10.1186/s12886-018-1005-x
   Mitchell P, 2021, RETINA-J RET VIT DIS, V41, P1911, DOI 10.1097/IAE.0000000000003128
   Oca LuYzaro AI., 2019, ARCH SOC ESP OFTALMO, V94, P430, DOI DOI 10.1016/J.OFTAL.2019.05.007
   Ohji M, 2020, ADV THER, V37, P1173, DOI 10.1007/s12325-020-01236-x
   Rao P, 2018, OPHTHALMOLOGY, V125, P522, DOI 10.1016/j.ophtha.2017.10.010
   Ross AH, 2020, EYE, V34, P1825, DOI 10.1038/s41433-019-0747-x
   Schmidt-Erfurth U, 2014, BRIT J OPHTHALMOL, V98, P1144, DOI 10.1136/bjophthalmol-2014-305702
   Silva R, 2018, OPHTHALMOLOGY, V125, P57, DOI 10.1016/j.ophtha.2017.07.014
   Souied EH, 2015, RETINA-J RET VIT DIS, V35, P1743, DOI 10.1097/IAE.0000000000000548
   Tufail A, 2014, OPHTHALMOLOGY, V121, P1092, DOI 10.1016/j.ophtha.2013.11.031
   Udaondo P, 2016, OPHTHALMOLOGICA, V236, P29, DOI 10.1159/000445724
   van Asten F, 2019, ACTA OPHTHALMOL, V97, pE323, DOI 10.1111/aos.13946
   Westborg I, 2017, ACTA OPHTHALMOL, V95, P787, DOI 10.1111/aos.13539
   Wykoff CC, 2017, OPHTHALMOL RETINA, V1, P314, DOI 10.1016/j.oret.2016.12.004
   Wykoff CC, 2018, J MANAG CARE SPEC PH, V24, pS3, DOI 10.18553/jmcp.2018.24.2-a.s3
   Wykoff CC, 2015, OPHTHALMOLOGY, V122, P2514, DOI 10.1016/j.ophtha.2015.08.009
   Zarranz-Ventura J, 2014, OPHTHALMOLOGY, V121, P1966, DOI 10.1016/j.ophtha.2014.04.026
   Ziemssen F, 2015, OPHTHALMOLOGE, V112, P246, DOI 10.1007/s00347-014-3217-7
NR 42
TC 1
Z9 1
U1 0
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1442-6404
EI 1442-9071
J9 CLIN EXP OPHTHALMOL
JI Clin. Exp. Ophthalmol.
PD APR
PY 2022
VL 50
IS 3
BP 312
EP 324
DI 10.1111/ceo.14054
EA FEB 2022
PG 13
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 0F6RH
UT WOS:000757961500001
PM 35106882
OA Green Published
DA 2022-11-30
ER

PT J
AU Fusi-Rubiano, W
   Webb, R
   Narendran, N
   Yang, YC
AF Fusi-Rubiano, William
   Webb, Richard
   Narendran, Nirodhini
   Yang, Yit C.
TI Identifying early symptoms of choroidal neovascularisation in second
   eyes of patients with unilateral wet age related macular degeneration
   using a telephone evaluation method
SO EYE
LA English
DT Article
ID VISUAL IMPAIRMENT; MONITORING-SYSTEM; SUBGROUP ANALYSIS; LEGAL
   BLINDNESS; FELLOW EYE; RANIBIZUMAB; DEPRESSION; OUTCOMES; ANCHOR; MARINA
AB Background/Objectives Patients undergoing intravitreal injections for nAMD are often anxious about early detection of nAMD in their fellow eyes. The purpose of this study was to evaluate a home-based telephone method for helping patients to monitor for symptoms of second eye involvement.
   Subjects/Methods Using a five-staged evaluation tool, telephone-assisted evaluations were repeatedly performed on the patients' fellow eyes every 4 weeks for 1 year. A decision on presence or absence of nAMD was made after each telephone evaluation. Slitlamp examination and OCT scan were performed at 3, 6, 9 and 12 months or whenever nAMD was suspected from the telephone evaluation. The sensitivity and specificity values were calculated from the true and false positive and negative rates of each of the five composite stages.
   Results In total, 514 telephone episodes comprising 2570 evaluations were conducted on fellow eyes of 50 patients over one year. Three patients (6%) developed nAMD in fellow eyes. The sensitivity of all of the stages was low (33.3%). The specificity of the five stages ranged from 91.3% to 98.6%. The highest specificity was achieved by the near acuity component of the tool.
   Conclusions We were unable to demonstrate a high sensitivity for the five-staged tool but the near acuity component of this tool had a very high specificity. This could have potential for "ruling out" nAMD and reducing the burden of false positive episodes for a large group of patients who are at risk of developing nAMD in their second eyes.
C1 [Fusi-Rubiano, William; Webb, Richard; Narendran, Nirodhini; Yang, Yit C.] New Cross Hosp, Ophthalmol Dept, Wolverhampton WV10 0QP, England.
   [Narendran, Nirodhini; Yang, Yit C.] Aston Univ, Sch Life & Hlth Sci, Birmingham B4 7ET, W Midlands, England.
C3 New Cross Hospital; Aston University
RP Fusi-Rubiano, W (通讯作者)，New Cross Hosp, Ophthalmol Dept, Wolverhampton WV10 0QP, England.
EM William.fusi-rubiano@nhs.net
FU Tripartite grant from three charitable bodies South Staffordshire
   Medical Foundation; Rotha Abraham Bequest; Royal Wolverhampton Hospitals
   NHS Trust
FX Funded in part by the Tripartite grant from three charitable bodies
   South Staffordshire Medical FoundationReg. Charity No: 1075209 Rotha
   Abraham Bequest Reg. Charity No: 509234 The Royal Wolverhampton
   Hospitals NHS Trust Charity Reg. Charity No: 1059467.
CR Al-Zamil WM, 2017, CLIN INTERV AGING, V12, P1313, DOI 10.2147/CIA.S143508
   Bailey ST, 2019, OPHTHALMOL RETINA, V3, P629, DOI 10.1016/j.oret.2019.03.008
   Belkin M, 2013, AM J OPHTHALMOL, V155, P404, DOI 10.1016/j.ajo.2012.09.017
   Bloch SB, 2012, AM J OPHTHALMOL, V153, P209, DOI 10.1016/j.ajo.2011.10.016
   Boyer DS, 2007, OPHTHALMOLOGY, V114, P246, DOI 10.1016/j.ophtha.2006.10.045
   Bressler NM, 2011, ARCH OPHTHALMOL-CHIC, V129, P709, DOI 10.1001/archophthalmol.2011.140
   Brody BL, 2001, OPHTHALMOLOGY, V108, P1893, DOI 10.1016/S0161-6420(01)00754-0
   Bujang MA, 2016, J CLIN DIAGN RES, V10, pYE1, DOI 10.7860/JCDR/2016/18129.8744
   Canan H, 2014, CLIN INTERV AGING, V9, P141, DOI 10.2147/CIA.S56863
   Chew EY, 2014, OPHTHALMOLOGY, V121, P535, DOI 10.1016/j.ophtha.2013.10.027
   Cornish EE, 2021, RETINA-J RET VIT DIS, V41, P118, DOI 10.1097/IAE.0000000000002798
   Crossland M, 2007, BRIT J OPHTHALMOL, V91, P391, DOI 10.1136/bjo.2006.095315
   Kaiser PK, 2007, AM J OPHTHALMOL, V144, P850, DOI 10.1016/j.ajo.2007.08.012
   Kaiser PK, 2013, RETINA-J RET VIT DIS, V33, P1863, DOI 10.1097/IAE.0b013e3182899258
   Keane PA, 2015, CLIN OPHTHALMOL, V9, P353, DOI 10.2147/OPTH.S59012
   Lalkhen AG, 2008, BJA EDUC, V8, P221, DOI 10.1093/bjaceaccp/mkn041
   Maguire MG, 2013, OPHTHALMOLOGY, V120, P2035, DOI 10.1016/j.ophtha.2013.03.017
   Mitchell P, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101072
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Rovner BW, 2002, AM J GERIAT PSYCHIAT, V10, P305
   Schwartz Roy, 2015, Int J Retina Vitreous, V1, P20, DOI 10.1186/s40942-015-0022-7
   Uchida A, 2018, OPHTHALMOL RETINA, V2, P1107, DOI 10.1016/j.oret.2018.04.007
   Whillans J, 2014, BRIT J VISUAL IMPA, V32, P236, DOI 10.1177/0264619614543532
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
   Wong TY, 2020, RETINA-J RET VIT DIS, V40, P599, DOI 10.1097/IAE.0000000000002768
   Ying GS, 2013, OPHTHALMOLOGY, V120, P122, DOI 10.1016/j.ophtha.2012.07.042
   Zarranz-Ventura J, 2014, OPHTHALMOLOGY, V121, P1966, DOI 10.1016/j.ophtha.2014.04.026
NR 27
TC 0
Z9 0
U1 0
U2 1
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
SN 0950-222X
EI 1476-5454
J9 EYE
JI Eye
PD NOV
PY 2021
VL 35
IS 11
BP 3028
EP 3034
DI 10.1038/s41433-020-01364-2
EA JAN 2021
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA WJ3DG
UT WOS:000605863200006
PM 33414532
OA Green Published, Bronze
DA 2022-11-30
ER

PT J
AU Ramtohul, P
   Cabral, D
   Klancnik, JM
   Curcio, CA
   Freund, KB
AF Ramtohul, Prithvi
   Cabral, Diogo
   Klancnik, James M.
   Curcio, Christine A.
   Freund, K. Bailey
TI Soft drusen accumulation within a full-thickness macular hole: new
   insights into the mechanisms of lipid cycling pathways in age-related
   macular degeneration
SO EYE
LA English
DT Article
C1 [Ramtohul, Prithvi; Cabral, Diogo; Klancnik, James M.; Freund, K. Bailey] Vitreous Retina Macula Consultants New York, New York, NY 10027 USA.
   [Klancnik, James M.; Freund, K. Bailey] NYU, Dept Ophthalmol, Grossman Sch New York, New York, NY 10027 USA.
   [Curcio, Christine A.] Univ Alabama Birmingham, Sch Med, Dept Ophthalmol & Visual Sci, Birmingham, AL USA.
C3 Vitreous Retina Macula Consultants of New York; New York University;
   University of Alabama System; University of Alabama Birmingham
RP Freund, KB (通讯作者)，Vitreous Retina Macula Consultants New York, New York, NY 10027 USA.; Freund, KB (通讯作者)，NYU, Dept Ophthalmol, Grossman Sch New York, New York, NY 10027 USA.
EM kbfreund@gmail.com
OI Curcio, Christine/0000-0001-9769-1538
FU Macula Foundation, Inc., New York, NY; Fundacao Luso-Americana para o
   Desenvolvimento (FLAD, USA RD) [2020/0140]
FX This work was supported by The Macula Foundation, Inc., New York, NY.
   Diogo Cabral was supported in part by a studentship from Fundacao
   Luso-Americana para o Desenvolvimento (FLAD, USA R&D@PhD -Proj
   2020/0140).
CR Curcio Christine A, 2018, Invest Ophthalmol Vis Sci, V59, pAMD160, DOI 10.1167/iovs.18-24882
   HOGAN M J, 1972, Transactions of the American Academy of Ophthalmology and Oto-Laryngology, V76, P64
   Johnson LV, 2011, P NATL ACAD SCI USA, V108, P18277, DOI 10.1073/pnas.1109703108
   Pilgrim MG, 2017, INVEST OPHTH VIS SCI, V58, DOI 10.1167/iovs.16-21060
   Wang L, 2009, INVEST OPHTH VIS SCI, V50, P870, DOI 10.1167/iovs.08-2376
NR 5
TC 0
Z9 0
U1 0
U2 2
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
SN 0950-222X
EI 1476-5454
J9 EYE
JI Eye
PD DEC
PY 2022
VL 36
IS 12
BP 2346
EP 2347
DI 10.1038/s41433-022-02012-7
EA MAR 2022
PG 2
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 6H2ZZ
UT WOS:000769831700001
PM 35296802
DA 2022-11-30
ER

PT J
AU Framme, C
   Flucke, B
   Birngruber, R
AF Framme, C.
   Flucke, B.
   Birngruber, R.
TI Comparison of reduced and standard light application in photodynamic
   therapy of the eye in two rabbit models
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE PDT; AMD; choroidal neovascularization; radiant exposure; threshold
ID FLUENCE RATE; SUBRETINAL INJECTION; TUMOR; DIFFUSION; KINETICS
AB Current PDT treatment for age-related macular degeneration uses a standard radiant exposure of 50 J/cm(2) stop at an irradiance of 600 mW/cm(2) stop. However; there is a general problem with the unusually high irradiance; in fact, the rate of photochemical production of singlet oxygen may be limited by insufficiently oxygenized neovascular tissue. It was the aim of this study to evaluate the efficacy of verteporfin (Visudyne) photoactivation to induce thrombosis of choriocapillaries and in experimentally induced corneal neovascularizations in rabbits by varying irradiance and retinal radiant exposure.
   The light-dose threshold to induce micro-thrombosis in the choriocapillaries (seven eyes) and in corneal neovascularizations (eight eyes) of Chinchilla-Bastard rabbits using different retinal irradiances (100 and 600 mW/cm(2) stop) at different radiant exposures (20, 10, 5, 2.5, 1.25, 0.62, and 0.3 J/cm(2) stop) was evaluated. Induction of neovascularizations was performed 7 days prior to PDT treatment using intracorneal silk sutures. A dose of 2 mg/kg verteporfin was intravenously infused 10 min before standard PDT. The criterion for vascular thrombosis was vessel closure as determined by fluorescein angiography 1 h and 1 day post exposure.
   Experiments on the choroid revealed vessel closure 1 h after irradiation at ED50 = 10.8 J/cm(2) stop (both 600 and 100 mW/cm(2) stop) and after 24 h at ED50 = 2.4 J/cm(2) stop (600 mW/cm(2) stop) versus 1.8 J/cm(2) stop (100 mW/cm(2) stop). Vessel closure was enhanced at irradiation with 100 mW/cm(2) stop. Regarding corneal neovascularizations, vessel thrombosis was observable by dark appearance of irradiated clotted neovascular tissue and angiographically by a lack of leakage at ED50 thresholds of 0.62 J/cm(2) stop (1 h) and 0.41 J/cm(2) stop (1 day) for 100 mW/cm(2) stop and of 0.99 J/cm(2) stop (1 h), and 0.67 J/cm(2)supercript stop (1 day) for 600 mW/cm(2)supercript stop. Thus in both experiments thresholds for vessel closure were reduced by a factor of 1.5 for the lower intensity. Histology revealed more selective vessel occlusion without RPE and photoreceptor damage for 100 mW/cm(2) stop rather than 600 mW/cm(2) stop intensity at threshold irradiation.
   Low-intensity PDT with verteporfin for neovascular tissue seems to be more effective than regular high-intensity PDT. Future preclinical trials should address the issue of proper dosimetry for effective PDT in age-related macular degeneration.
C1 Univ Regensburg, Hosp Eye, D-93042 Regensburg, Germany.
   Med Laser Ctr Luebeck, Lubeck, Germany.
C3 University of Regensburg
RP Framme, C (通讯作者)，Univ Regensburg, Hosp Eye, Franz Josef Str Allee 11, D-93042 Regensburg, Germany.
EM carsten.framme@klinik.uni-regensburg.de
RI Birngruber, Reginald/Q-2342-2016
CR [Anonymous], 1971, PROBIT ANAL
   BIRNGRUBER R, 1983, HEALTH PHYS, V44, P519, DOI 10.1097/00004032-198305000-00006
   Blant SA, 1996, PHOTOCHEM PHOTOBIOL, V64, P963, DOI 10.1111/j.1751-1097.1996.tb01862.x
   CORRENT G, 1989, ARCH OPHTHALMOL-CHIC, V107, P1501, DOI 10.1001/archopht.1989.01070020575043
   Costa RA, 2003, RETINA-J RET VIT DIS, V23, P159, DOI 10.1097/00006982-200304000-00004
   FOSTER TH, 1991, RADIAT RES, V126, P296, DOI 10.2307/3577919
   FOSTER TH, 1993, CANCER RES, V53, P1249
   Gabel V. P., 1978, 23 CONCILIUM OPHTHAL, P658
   Georgakoudi I, 1997, PHOTOCHEM PHOTOBIOL, V65, P135, DOI 10.1111/j.1751-1097.1997.tb01889.x
   GIBSON SL, 1990, CANCER RES, V50, P7236
   HENDERSON BW, 1987, CANCER RES, V47, P3110
   HENDERSON BW, 1985, CANCER RES, V45, P572
   HENDERSON BW, 1992, PHOTOCHEM PHOTOBIOL, V55, P145, DOI 10.1111/j.1751-1097.1992.tb04222.x
   Michels S, 2003, INVEST OPHTH VIS SCI, V44, P2147, DOI 10.1167/iovs.02-0604
   NICHOLS MG, 1994, PHYS MED BIOL, V39, P2161, DOI 10.1088/0031-9155/39/12/003
   Schmidt-Erfurth U, 2002, ARCH OPHTHALMOL-CHIC, V120, P835
   SCHMIDTERFURTH U, 1995, LASER SURG MED, V17, P178, DOI 10.1002/lsm.1900170207
   Sitnik TM, 1998, BRIT J CANCER, V77, P1386, DOI 10.1038/bjc.1998.231
   Sitnik TM, 1998, PHOTOCHEM PHOTOBIOL, V67, P462, DOI 10.1111/j.1751-1097.1998.tb05228.x
   SLINEY DH, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   TROMBERG BJ, 1990, PHOTOCHEM PHOTOBIOL, V52, P375, DOI 10.1111/j.1751-1097.1990.tb04193.x
   ZHU ZR, 1988, ARCH OPHTHALMOL-CHIC, V106, P406
   ZHU ZR, 1988, OPHTHALMOLOGY, V95, P925
NR 23
TC 15
Z9 17
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD JUL
PY 2006
VL 244
IS 7
BP 773
EP 781
DI 10.1007/s00417-005-0221-2
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 065GO
UT WOS:000239148000002
PM 16440207
DA 2022-11-30
ER

PT J
AU Ucgul, AY
   Aktas, Z
   Ozgur, A
   Cubuk, MO
   Hasanreisoglu, M
   Ozdek, S
   Gurelik, G
AF Ucgul, Ahmet Y.
   Aktas, Zeynep
   Ozgur, Armagan
   Cubuk, Mehmet O.
   Hasanreisoglu, Murat
   Ozdek, Sengul
   Gurelik, Gokhan
TI Sustained Elevation of Intraocular Pressure After Administration of
   Intravitreal Anti-Vascular Endothelial Growth Factor Agents in Patients
   With and Without Pseudoexfoliation Syndrome
SO JOURNAL OF GLAUCOMA
LA English
DT Article
DE anti-VEGF; bevacizumab; pseudoexfoliation; ranibizumab; sustained IOP
   elevation
ID MACULAR DEGENERATION; NITRIC-OXIDE; BEVACIZUMAB AVASTIN; RANIBIZUMAB
   LUCENTIS; FACTOR THERAPY; INJECTION; EYES
AB Precis: Intravitreal anti-vascular endothelial growth factor therapy resulted in sustained elevation of intraocular pressure (IOP) in 18.6% of patients with coexisting age-related macular degeneration and pseudoexfoliation (PXF) syndrome. The development of sustained elevation of IOP after similar to 19 injections reflected the cumulative effect of anti-vascular endothelial growth factor injections on IOP.
   Purpose: The purpose of this study was to compare the long-term effect of intravitreal ranibizumab (IVR) and intravitreal bevacizumab (IVB) therapies on IOP in patients with and without PXF syndrome.
   Design: This was a retrospective comparative study.
   Patients and Methods: Data from 412 eyes of 206 patients diagnosed with unilateral neovascular age-related macular degeneration, treated with IVR or IVB, and followed-up for at least 6 months, were retrospectively reviewed. Seventy treated and 70 untreated fellow eyes of 70 patients with bilateral PXF syndrome, and 136 treated and 136 untreated fellow eyes of 136 patients without PXF syndrome were included in this study. Demographic information, clinical findings, total number of IVR and IVB injections, and IOP values at each visit were recorded. Sustained elevation of IOP (SE-IOP) was defined as either an IOP >21 mm Hg or a >= 5 mm Hg increase in IOP from baseline for at least 2 consecutive visits. Baseline and final IOP values in each group were compared using the paired samplettest, and IOP changes in the groups were compared using split-plot analysis of variance. Multivariate logistic regression analysis was used to evaluate the influence of variables on the development of SE-IOP.
   Results: The mean (+/- SD) age of the patients was 77.53 +/- 3.78 years (range, 70 to 83 y), and the mean follow-up was 28.50 +/- 16.51 months (range, 6 to 58 mo). The mean number of injections was 15.56 +/- 8.01 (range, 5 to 36). The mean baseline and final IOP in treated eyes were 14.82 +/- 3.08 and 16.50 +/- 3.11 mm Hg, respectively (P<0.001). A higher incidence of SE-IOP and higher final IOP values were observed in PXF-positive eyes receiving IVB compared with the other groups. Seven of the patients required antiglaucomatous treatment. Multivariate logistic regression analysis revealed an increased odds ratio (4.90;P=0.016) of SE-IOP in PXF-positive eyes compared with PXF-negative eyes.
   Conclusion: IVB therapy may cause greater increases in IOP in patients with PXF syndrome. The co-accumulation of PXF material and bevacizumab particles on the trabecular meshwork should be further investigated.
C1 [Ucgul, Ahmet Y.] Abant Izzet Baysal Univ, Izzet Baysal Training & Res Hosp, Dept Ophthalmol, Bolu, Turkey.
   [Aktas, Zeynep; Hasanreisoglu, Murat; Ozdek, Sengul; Gurelik, Gokhan] Gazi Univ, Dept Ophthalmol, Med Sch, Ankara, Turkey.
   [Ozgur, Armagan] Sanliurfa Training & Res Hosp, Dept Ophthalmol, Sanliurfa, Turkey.
   [Cubuk, Mehmet O.] Istanbul Training & Res Hosp, Dept Ophthalmol, Istanbul, Turkey.
C3 Abant Izzet Baysal University; AIBU Bolu Izzet Baysal Education &
   Research Hospital; Gazi University; Sanliurfa Training & Research
   Hospital; Istanbul Training & Research Hospital
RP Aktas, Z (通讯作者)，Bahcelievler Mah 172 Sokak 4, TR-06830 Ankara, Turkey.
EM drzeynep2000@yahoo.com
RI Cubuk, Mehmet Ozgur/GVU-1411-2022; Özdek, Şengül/CAF-5314-2022;
   Hasanreisoglu, Murat/K-3887-2012; ÜÇGÜL, Ahmet Yücel/ABH-8820-2020
OI Özdek, Şengül/0000-0002-7494-4106; Hasanreisoglu,
   Murat/0000-0001-9885-5653; ÜÇGÜL, Ahmet Yücel/0000-0001-9945-793X;
   Ozgur, Armagan/0000-0001-9111-8060
CR Adelman RA, 2010, J OCUL PHARMACOL TH, V26, P105, DOI 10.1089/jop.2009.0076
   Arevalo JF, 2009, GRAEF ARCH CLIN EXP, V247, P735, DOI 10.1007/s00417-008-1034-x
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Bakri SJ, 2008, GRAEF ARCH CLIN EXP, V246, P955, DOI 10.1007/s00417-008-0819-2
   Bakri SJ, 2014, OPHTHALMOLOGY, V121, P1102, DOI 10.1016/j.ophtha.2013.11.029
   Borazan M, 2010, J GLAUCOMA, V19, P207, DOI 10.1097/IJG.0b013e3181aae93e
   Borghi V, 2010, J OCUL PHARMACOL TH, V26, P125, DOI 10.1089/jop.2009.0120
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Choi DY, 2011, RETINA-J RET VIT DIS, V31, P1028, DOI 10.1097/IAE.0b013e318217ffde
   D'Amico DJ, 2006, OPHTHALMOLOGY, V113, P992, DOI 10.1016/j.ophtha.2006.02.027
   Dedania VS, 2015, RETINA-J RET VIT DIS, V35, P841, DOI 10.1097/IAE.0000000000000520
   Elhawy E, 2012, HUM GENOMICS, V6, DOI 10.1186/1479-7364-6-22
   Ferrara N, 2006, RETINA-J RET VIT DIS, V26, P859, DOI 10.1097/01.iae.0000242842.14624.e7
   GHARAGOZLOO NZ, 1992, AM J OPHTHALMOL, V114, P473
   Gismondi M, 2009, J GLAUCOMA, V18, P658, DOI 10.1097/IJG.0b013e31819c4893
   Good TJ, 2011, BRIT J OPHTHALMOL, V95, P1111, DOI 10.1136/bjo.2010.180729
   Helbig H, 1994, Ger J Ophthalmol, V3, P148
   Hoang QV, 2013, RETINA-J RET VIT DIS, V33, P179, DOI 10.1097/IAE.0b013e318261a6f7
   Hoang QV, 2012, OPHTHALMOLOGY, V119, P321, DOI 10.1016/j.ophtha.2011.08.011
   Hollands H, 2007, CAN J OPHTHALMOL, V42, P807, DOI 10.3129/i07-172
   Kahook MY, 2010, J GLAUCOMA, V19, P437, DOI 10.1097/IJG.0b013e3181ca74de
   Kahook MY, 2010, RETINA-J RET VIT DIS, V30, P887, DOI 10.1097/IAE.0b013e3181d50cea
   Kahook MY, 2009, OPHTHAL SURG LAS IM, V40, P293, DOI 10.3928/15428877-20090430-12
   Kernt M, 2007, OPHTHALMOLOGE, V104, P965, DOI 10.1007/s00347-007-1569-y
   Kim D, 2014, J GLAUCOMA, V23, P446, DOI 10.1097/IJG.0b013e3182946505
   Kim JE, 2008, AM J OPHTHALMOL, V146, P930, DOI 10.1016/j.ajo.2008.07.007
   Kim YJ, 2014, AM J OPHTHALMOL, V157, P1266, DOI 10.1016/j.ajo.2014.02.035
   Kotikoski H, 2002, J OCUL PHARMACOL TH, V18, P11, DOI 10.1089/108076802317233171
   Kvanta A, 1996, INVEST OPHTH VIS SCI, V37, P1929
   Liu L, 2011, INVEST OPHTH VIS SCI, V52, P1023, DOI 10.1167/iovs.10-6431
   Mathalone N, 2012, GRAEF ARCH CLIN EXP, V250, P1435, DOI 10.1007/s00417-012-1981-0
   Oubraham H, 2011, RETINA-J RET VIT DIS, V31, P26, DOI 10.1097/IAE.0b013e3181de5609
   Ricca AM, 2015, J OCUL PHARMACOL TH, V31, P2, DOI 10.1089/jop.2014.0062
   Ritch R, 2001, SURV OPHTHALMOL, V45, P265, DOI 10.1016/S0039-6257(00)00196-X
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schlotzer-Schrehardt U, 2006, AM J OPHTHALMOL, V141, P921, DOI 10.1016/j.ajo.2006.01.047
   SCHLOTZERSCHREHARDT U, 1995, INVEST OPHTH VIS SCI, V36, P1750
   Schmucker C, 2010, CURR OPIN OPHTHALMOL, V21, P218, DOI 10.1097/ICU.0b013e3283386783
   SCHUMAN JS, 1994, EXP EYE RES, V58, P99, DOI 10.1006/exer.1994.1199
   Segal O, 2013, ISR MED ASSOC J, V15, P352
   Shams Naveed, 2006, Ophthalmol Clin North Am, V19, P335
   Sniegowski M, 2010, OPEN OPHTHALMOL J, V4, P28, DOI 10.2174/1874364101004010028
   Tseng JJ, 2012, J GLAUCOMA, V21, P241, DOI 10.1097/IJG.0b013e31820d7d19
   Wehrli SJ, 2012, RETINA-J RET VIT DIS, V32, P1295, DOI 10.1097/IAE.0b013e31823f0c95
   Zenkel Matthias, 2014, J Glaucoma, V23, pS12, DOI 10.1097/IJG.0000000000000123
   Zhou YD, 2016, SCI REP-UK, V6, DOI 10.1038/srep39301
NR 46
TC 2
Z9 2
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1057-0829
EI 1536-481X
J9 J GLAUCOMA
JI J. Glaucoma
PD OCT
PY 2020
VL 29
IS 10
BP 981
EP 988
DI 10.1097/IJG.0000000000001600
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA OA9JC
UT WOS:000578094700027
PM 32649449
OA hybrid
DA 2022-11-30
ER

PT J
AU Bikbov, MM
   Kazakbaeva, GM
   Gilmanshin, TR
   Zainullin, RM
   Arslangareeva, II
   Salavatova, VF
   Bikbova, GM
   Panda-Jonas, S
   Nikitin, NA
   Zaynetdinov, AF
   Nuriev, IF
   Khikmatullin, RI
   Uzianbaeva, YV
   Yakupova, DF
   Aminev, SK
   Jonas, JB
AF Bikbov, Mukharram M.
   Kazakbaeva, Gyulli M.
   Gilmanshin, Timur R.
   Zainullin, Rinat M.
   Arslangareeva, Inga I.
   Salavatova, Venera F.
   Bikbova, Guzel M.
   Panda-Jonas, Songhomitra
   Nikitin, Nikolai A.
   Zaynetdinov, Artur F.
   Nuriev, Ildar F.
   Khikmatullin, Renat I.
   Uzianbaeva, Yulia V.
   Yakupova, Dilya F.
   Aminev, Said K.
   Jonas, Jost B.
TI Axial length and its associations in a Russian population: The Ural Eye
   and Medical Study
SO PLOS ONE
LA English
DT Article
ID OPEN-ANGLE GLAUCOMA; AGE-RELATED MACULOPATHY; OCULAR BIOMETRY;
   INTRAOCULAR-PRESSURE; ADULT-POPULATION; RISK-FACTORS; MACULAR
   DEGENERATION; VISION IMPAIRMENT; REFRACTIVE ERROR; SYSTEMIC FACTORS
AB Purpose
   To assess the normal distribution of axial length and its associations in a population of Russia.
   Methods
   The population-based Ural Eye and Medical Study included 5,899 (80.5%) individuals out of 7328 eligible individuals aged 40+ years. The participants underwent an ocular and systemic examination. Axial length was measured sonographically (Ultra-compact A/B/P ultrasound system, Quantel Medical, Cournon d'Auvergne, France).
   Results
   Biometric data were available for 5707 (96.7%) individuals with a mean age of 58.8 +/- 10.6 years (range: 40-94 years; 25%, 50%, 75% quartile: 51.0, 58.0, 66.0 years, respectively). Mean axial length was 23.30 +/- 1.10 mm (range: 19.02-32.87mm; 95% confidence interval (CI): 21.36-25.89; 25%, 50%, 75% quartile: 22.65mm, 23.23mm, 23.88mm, resp.). Prevalences of moderate myopia (axial length: 24.5-<26.5mm) and high myopia (axial length >26.5mm) were 555/5707 (8.7%; 95% CI: 9.0,10.5) and 78/5707 (1.4%; 95% CI: 1.1,1.7), respectively. Longer axial length (mean: 23.30 +/- 1.10mm) was associated (correlation coefficient r(2) :0.70) with older age (P<0.001; standardized regression coefficient beta:0.14), taller body height (P<0.001; beta: 0.07), higher level of education (P<0.001; beta:0.04), higher intraocular pressure (P<0.001; beta: 0.03), more myopic spherical refractive error (P<0.001; beta:-0.55), lower corneal refractive power (P<0.001; beta:-0.44), deeper anterior chamber depth (P<0.001; beta:0.20), wider anterior chamber angle (P<0.001; beta:0.05), thinner peripapillary retinal nerve fiber layer thickness (P<0.001; beta:-0.04), higher degree of macular fundus tessellation (P<0.001; beta:0.08), lower prevalence of epiretinal membranes (P = 0.01; beta-0.02) and pseudoexfoliation (P = 0.007; beta:-0.02) and higher prevalence of myopic maculopathy (P<0.001; beta:0.08). In that model, prevalence of age-related macular degeneration (any type: P = 0.84; early type: P = 0.46), diabetic retinopathy (P = 0.16), and region of habitation (P = 0.27) were not significantly associated with axial length.
   Conclusions
   Mean axial length in this typically multi-ethnic Russian study population was comparable with values from populations in Singapore and Beijing. In contrast to previous studies, axial length was not significantly related with the prevalences of age-related macular degeneration and diabetic retinopathy or region of habitation.
C1 [Bikbov, Mukharram M.; Kazakbaeva, Gyulli M.; Gilmanshin, Timur R.; Zainullin, Rinat M.; Arslangareeva, Inga I.; Salavatova, Venera F.; Bikbova, Guzel M.; Nikitin, Nikolai A.; Zaynetdinov, Artur F.; Nuriev, Ildar F.; Khikmatullin, Renat I.; Uzianbaeva, Yulia V.; Yakupova, Dilya F.; Aminev, Said K.] Ufa Eye Res Inst, Ufa, Bashkortostan, Russia.
   [Panda-Jonas, Songhomitra] Seegartenklinik, Augenpraxis, Heidelberg, Germany.
   [Jonas, Jost B.] Heidelberg Univ, Med Fac Mannheim, Dept Ophthalmol, Mannheim, Germany.
C3 Ufa Eye Research Institute; Ruprecht Karls University Heidelberg
RP Bikbov, MM (通讯作者)，Ufa Eye Res Inst, Ufa, Bashkortostan, Russia.; Jonas, JB (通讯作者)，Heidelberg Univ, Med Fac Mannheim, Dept Ophthalmol, Mannheim, Germany.
EM Bikbov.m@gmail.com; Jost.Jonas@medma.uni-heidelberg.de
RI Zainullin, Rinat/AAR-6362-2021; Bikbov, Mukharram/AAO-7624-2021;
   Bikbova, Guzel/B-1751-2018
OI Kazakbaeva, Gyulli/0000-0002-0569-1264; Bikbova,
   Guzel/0000-0002-7715-7466
FU Deutsche Forschungsgemeinschaft; Baden-Wurttemberg Ministry of Science,
   Research and the Arts; Ruprecht-Karls-Universitat Heidelberg
FX We acknowledge financial support by Deutsche Forschungsgemeinschaft
   within the funding program Open Access Publishing, by the
   Baden-Wurttemberg Ministry of Science, Research and the Arts and by
   Ruprecht-Karls-Universitat Heidelberg.
CR Aleksandrov A S, 2000, Vestn Oftalmol, V116, P29
   Aleksandrova L A, 1996, Vestn Oftalmol, V112, P39
   Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Bikbov M, 2018, OPHTHAL EPIDEMIOL, V25, P187, DOI 10.1080/09286586.2017.1384504
   Bikbov MM, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-25928-1
   Chaine G, 1998, BRIT J OPHTHALMOL, V82, P996, DOI 10.1136/bjo.82.9.996
   Chihara E, 1997, OPHTHALMOLOGICA, V211, P66, DOI 10.1159/000310760
   Eysteinsson T, 2005, ACTA OPHTHALMOL SCAN, V83, P734, DOI 10.1111/j.1600-0420.2005.00540.x
   Flaxman SR, 2017, LANCET GLOB HEALTH, V5, pE1221, DOI 10.1016/S2214-109X(17)30393-5
   George R, 2003, BRIT J OPHTHALMOL, V87, P399, DOI 10.1136/bjo.87.4.399
   Gololobov V T, 2009, Vestn Oftalmol, V125, P21
   Holden BA, 2016, OPHTHALMOLOGY, V123, P1036, DOI 10.1016/j.ophtha.2016.01.006
   Ikram MK, 2003, INVEST OPHTH VIS SCI, V44, P3778, DOI 10.1167/iovs.03-0120
   Jonas JB, 2002, AM J OPHTHALMOL, V134, P547, DOI 10.1016/S0002-9394(02)01644-6
   Jonas JB, 2007, OPHTHAL RES, V39, P139, DOI 10.1159/000102935
   Jonas JB, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0175120
   Jonas JB, 2012, ACTA OPHTHALMOL, V90, pe185, DOI 10.1111/j.1755-3768.2011.02316.x
   Kawase K, 2008, BRIT J OPHTHALMOL, V92, P1175, DOI 10.1136/bjo.2007.128819
   Kuzin AA, 2010, OPHTHALMOLOGY, V117, P1713, DOI 10.1016/j.ophtha.2010.01.035
   LESKE MC, 1995, ARCH OPHTHALMOL-CHIC, V113, P918, DOI 10.1001/archopht.1995.01100070092031
   Mamatkhuzhaeva G N, 2002, Vestn Oftalmol, V118, P47
   Memarzadeh F, 2008, AM J OPHTHALMOL, V146, P69, DOI 10.1016/j.ajo.2008.03.015
   Mitchell P, 1999, OPHTHALMOLOGY, V106, P2010, DOI 10.1016/S0161-6420(99)90416-5
   Morgan IG, 2012, LANCET, V379, P1739, DOI 10.1016/S0140-6736(12)60272-4
   Naidoo KS, 2016, OPTOMETRY VISION SCI, V93, P227, DOI 10.1097/OPX.0000000000000796
   Nangia V, 2010, OPHTHALMOLOGY, V117, P1360, DOI 10.1016/j.ophtha.2009.11.040
   Nowak Michal S, 2008, Klin Oczna, V110, P55
   Ohno-Matsui K, 2015, AM J OPHTHALMOL, V159, P877, DOI 10.1016/j.ajo.2015.01.022
   Shufelt C, 2005, INVEST OPHTH VIS SCI, V46, P4450, DOI 10.1167/iovs.05-0435
   Stevens GA, 2016, LANCET, V388, pE19, DOI 10.1016/S0140-6736(16)30388-9
   Tomoyose E, 2010, AM J OPHTHALMOL, V150, P279, DOI 10.1016/j.ajo.2010.03.009
   Weinreb RN, 2014, JAMA-J AM MED ASSOC, V311, P1901, DOI 10.1001/jama.2014.3192
   Wickremasinghe S, 2004, INVEST OPHTH VIS SCI, V45, P776, DOI 10.1167/iovs.03-0456
   Wong TY, 2003, OPHTHALMOLOGY, V110, P211, DOI 10.1016/S0161-6420(02)01260-5
   Wong TY, 2002, BRIT J OPHTHALMOL, V86, P963, DOI 10.1136/bjo.86.9.963
   Wong TY, 2001, INVEST OPHTH VIS SCI, V42, P73
   Wu HM, 2007, CLIN EXP OPHTHALMOL, V35, P834, DOI 10.1111/j.1442-9071.2007.01638.x
   Xu L, 2006, BRIT J OPHTHALMOL, V90, P1087, DOI 10.1136/bjo.2006.096123
   Xu L, 2007, ACTA OPHTHALMOL SCAN, V85, P914, DOI 10.1111/j.1600-0420.2007.00966.x
   Xu LA, 2007, OPHTHALMOLOGY, V114, P216, DOI 10.1016/j.ophtha.2006.06.050
   Xu L, 2006, OPHTHALMOLOGY, V113, P1134, DOI 10.1016/j.ophtha.2006.01.035
   Yan YN, 2015, OPHTHALMOLOGY, V122, P1873, DOI 10.1016/j.ophtha.2015.05.031
   Yin G, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043172
   Zhou Q, 2012, OPHTHAL EPIDEMIOL, V19, P278, DOI 10.3109/09286586.2012.708084
NR 44
TC 23
Z9 26
U1 0
U2 6
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD FEB 1
PY 2019
VL 14
IS 2
AR e0211186
DI 10.1371/journal.pone.0211186
PG 20
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA HK2LM
UT WOS:000457742900020
PM 30707718
OA Green Published, Green Submitted, gold
DA 2022-11-30
ER

PT J
AU Hong, T
   Mitchell, P
   Rochtchina, E
   Fong, CSU
   Chia, EM
   Wang, JJ
AF Hong, Thomas
   Mitchell, Paul
   Rochtchina, Elena
   Fong, Calvin Sze-un
   Chia, Ee-Munn
   Wang, Jie Jin
TI Long-term Changes in Visual Acuity in an Older Population over a 15-Year
   Period The Blue Mountains Eye Study
SO OPHTHALMOLOGY
LA English
DT Article
ID BEAVER DAM EYE; MACULAR DEGENERATION; RISK-FACTORS; IMPAIRMENT;
   PREVALENCE; MORTALITY; AUSTRALIA; SMOKING; ADULTS; COMMUNITY
AB Purpose: To describe the change in visual acuity (VA) and incidence of visual impairment (VI) in an older population over a 15-year period.
   Design: Population-based cohort.
   Participants: Of the 3654 participants of the Blue Mountains Eye Study (BMES) baseline examination from 1992 through 1994, 1149 were re-examined during the 15-year follow-up between 2007 and 2010.
   Methods: Best-corrected VA by means of subjective refraction was measured with a logarithm of the minimum angle of resolution chart using Early Treatment Diabetic Retinopathy Study methods at each examination.
   Main Outcome Measures: Unilateral VI was defined as VA worse than 20/40 and blindness was defined as VA worse than 20/200 in the worse eye. Incident bilateral VI and blindness were determined according to VA in the better eye at the 15-year visit. Doubling of the visual angle was defined as a loss of 15 letters or more from baseline to the 15-year visit. Halving of the visual angle was defined as a VA improvement of 15 letters or more over the same period. Causes of VI were determined at examination, by photographic grading, and from medical records.
   Results: Cumulative 15-year incidence of unilateral and bilateral VI was 12.3% (95% confidence interval [CI], 11.0-13.6) and 5.2% (95% CI, 4.3-6.1), respectively, and for unilateral and bilateral blindness, the cumulative incidence was 3.7% (95% CI, 3.0-4.4) and 0.9% (95% CI, 0.5-1.3), respectively. These incidence rates increased significantly with increasing age (P<0.01 for trend). Doubling and halving of the visual angle occurred in 6.9% (95% CI, 5.9-7.9) and 1.6% (95% CI, 1.0-2.2) of participants, respectively. Cataract accounted for 48.5% of unilateral and bilateral incident VI, followed by age-related macular degeneration (26.9%). Age-related macular degeneration accounted for 56.9% of unilateral and bilateral incident blindness cases, followed by cataract (20.7%).
   Conclusions: These data provide population-based estimates of long-term incidence of visual impairment among older persons. Our estimate for cumulative incidence of blindness, accounting for competing risk of death, was similar to that of the Beaver Dam Eye Study (BDES) after age standardization. However, our estimate for cumulative incidence of VI was lower compared with that observed in the BDES population. This difference may be explained in part by a higher mortality rate among our population. (C) 2013 by the American Academy of Ophthalmology.
C1 [Hong, Thomas; Mitchell, Paul; Rochtchina, Elena; Fong, Calvin Sze-un; Chia, Ee-Munn; Wang, Jie Jin] Univ Sydney, Ctr Vis Res, Dept Ophthalmol, Sydney, NSW 2006, Australia.
   [Hong, Thomas; Mitchell, Paul; Rochtchina, Elena; Fong, Calvin Sze-un; Chia, Ee-Munn; Wang, Jie Jin] Univ Sydney, Westmead Millennium Inst, Sydney, NSW 2006, Australia.
   [Wang, Jie Jin] Univ Melbourne, Ctr Eye Res Australia, Melbourne, Vic, Australia.
C3 University of Sydney; University of Sydney; Westmead Institute for
   Medical Research; Centre for Eye Research Australia; University of
   Melbourne
RP Wang, JJ (通讯作者)，Univ Sydney, Dept Ophthalmol, Ctr Vis Res, Westmead Hosp, Hawkesbury Rd, Westmead, NSW 2145, Australia.
EM jiejin.wang@sydney.edu.au
RI wang, jie/GRS-0942-2022; Wang, Jie Jin/P-1499-2014; Mitchell,
   Paul/P-1498-2014
OI Wang, Jie Jin/0000-0001-9491-4898; 
FU National Health and Medical Research Council, Canberra, ACT, Australia
   [932085, 974159, 211069, 457349]
FX Supported by the National Health and Medical Research Council (grant
   nos.: 932085, 974159, 211069, and 457349), Canberra, ACT, Australia
CR Attebo K, 1996, OPHTHALMOLOGY, V103, P357
   Australian Bureau of Statistics, POP PROJ AUSTR 2006
   Berry SD, 2010, J AM GERIATR SOC, V58, P783, DOI 10.1111/j.1532-5415.2010.02767.x
   Cedrone C, 2003, OPHTHALMOLOGY, V110, P584, DOI 10.1016/S0161-6420(02)01898-5
   Cedrone C, 2007, OPHTHAL EPIDEMIOL, V14, P320, DOI 10.1080/09286580701316116
   Chong EW, 2009, ARCH OPHTHALMOL-CHIC, V127, P1640, DOI 10.1001/archophthalmol.2009.298
   Evans JR, 2004, OPHTHALMOLOGY, V111, P513, DOI 10.1016/j.ophtha.2003.07.012
   Foong AWP, 2008, OPHTHALMOLOGY, V115, P802, DOI 10.1016/j.ophtha.2007.04.066
   Foran S, 2002, ARCH OPHTHALMOL-CHIC, V120, P613, DOI 10.1001/archopht.120.5.613
   Freeman EE, 2005, INVEST OPHTH VIS SCI, V46, P4040, DOI 10.1167/iovs.05-0687
   Hennis AJ, 2009, OPHTHALMOLOGY, V116, P1461, DOI 10.1016/j.ophtha.2009.02.017
   HILL DJ, 1982, MED J AUSTRALIA, V1, P23, DOI 10.5694/j.1326-5377.1982.tb132119.x
   Huang SS, 2009, ARCH OPHTHALMOL-CHIC, V127, P1362, DOI 10.1001/archophthalmol.2009.138
   Hyman L, 2001, OPHTHALMOLOGY, V108, P1751, DOI 10.1016/S0161-6420(01)00590-5
   Karpa MJ, 2009, ARCH OPHTHALMOL-CHIC, V127, P1347, DOI 10.1001/archophthalmol.2009.240
   Kawasaki R, 2010, OPHTHALMOLOGY, V117, P921, DOI 10.1016/j.ophtha.2009.10.007
   Klein BEK, 1998, ARCH OPHTHALMOL-CHIC, V116, P219, DOI 10.1001/archopht.116.2.219
   Klein R, 2001, OPHTHALMOLOGY, V108, P1757, DOI 10.1016/S0161-6420(01)00769-2
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1310
   Klein R, 2006, AM J OPHTHALMOL, V142, P539, DOI 10.1016/j.ajo.2006.06.015
   McCarty CA, 2001, BRIT J OPHTHALMOL, V85, P322, DOI 10.1136/bjo.85.3.322
   Mitchell P, 1997, OPHTHALMOLOGY, V104, P581, DOI 10.1016/S0161-6420(97)30266-8
   Nucci C, 2005, EYE, V19, P175, DOI 10.1038/sj.eye.6701444
   Racette L, 2003, SURV OPHTHALMOL, V48, P295, DOI 10.1016/S0039-6257(03)00028-6
   Schellini SA, 2009, BMC OPHTHALMOL, V9, DOI 10.1186/1471-2415-9-8
   Smith W, 1996, ARCH OPHTHALMOL-CHIC, V114, P1518, DOI 10.1001/archopht.1996.01100140716016
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Thornton J, 2005, EYE, V19, P935, DOI 10.1038/sj.eye.6701978
   TIELSCH JM, 1995, NEW ENGL J MED, V332, P1205, DOI 10.1056/NEJM199505043321806
   U. S. Census Bureau, 2002, CAL 2000 SUMM POP HO
   Varma R, 2010, AM J OPHTHALMOL, V149, P713, DOI 10.1016/j.ajo.2009.12.011
   Wang JJ, 2000, CLIN EXP OPHTHALMOL, V28, P268, DOI 10.1046/j.1442-9071.2000.00315.x
   Wang JJ, 1999, AUST NZ J PUBL HEAL, V23, P147, DOI 10.1111/j.1467-842X.1999.tb01225.x
   Zhao JL, 2010, OPHTHALMOLOGY, V117, P409, DOI 10.1016/j.ophtha.2009.11.023
NR 34
TC 26
Z9 26
U1 0
U2 15
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
J9 OPHTHALMOLOGY
JI Ophthalmology
PD OCT
PY 2013
VL 120
IS 10
BP 2091
EP 2099
DI 10.1016/j.ophtha.2013.03.032
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 227CQ
UT WOS:000325086400027
PM 23726666
DA 2022-11-30
ER

PT J
AU Wilson, M
   Chopra, R
   Wilson, MZ
   Cooper, C
   MacWilliams, P
   Liu, Y
   Wulczyn, E
   Florea, D
   Hughes, CO
   Karthikesalingam, A
   Khalid, H
   Vermeirsch, S
   Nicholson, L
   Keane, PA
   Balaskas, K
   Kelly, CJ
AF Wilson, Marc
   Chopra, Reena
   Wilson, Megan Z.
   Cooper, Charlotte
   MacWilliams, Patricia
   Liu, Yun
   Wulczyn, Ellery
   Florea, Daniela
   Hughes, Cian O.
   Karthikesalingam, Alan
   Khalid, Hagar
   Vermeirsch, Sandra
   Nicholson, Luke
   Keane, Pearse A.
   Balaskas, Konstantinos
   Kelly, Christopher J.
TI Validation and Clinical Applicability of Whole-Volume Automated
   Segmentation of Optical Coherence Tomography in Retinal Disease Using
   Deep Learning
SO JAMA OPHTHALMOLOGY
LA English
DT Article
ID MACULAR DEGENERATION; FLUID; OUTCOMES; QUANTIFICATION; RANIBIZUMAB;
   PREDICTORS; RELEVANT; THERAPY; EDEMA
AB IMPORTANCE Quantitative volumetric measures of retinal disease in optical coherence tomography (OCT) scans are infeasible to perform owing to the time required for manual grading. Expert-level deep learning systems for automatic OCT segmentation have recently been developed. However, the potential clinical applicability of these systems is largely unknown.
   OBJECTIVE To evaluate a deep learning model for whole-volume segmentation of 4 clinically important pathological features and assess clinical applicability.
   DESIGN, SETTING, PARTICIPANTS This diagnostic study used OCT data from 173 patients with a total of 15 558 B-scans, treated at Moorfields Eye Hospital. The data set included 2 common OCT devices and 2 macular conditions: wet age-related macular degeneration (107 scans) and diabetic macular edema (66 scans), covering the full range of severity, and from 3 points during treatment. Two expert graders performed pixel-level segmentations of intraretinal fluid, subretinal fluid, subretinal hyperreflective material, and pigment epithelial detachment, including all B-scans in each OCT volume, taking as long as 50 hours per scan. Quantitative evaluation of whole-volume model segmentations was performed. Qualitative evaluation of clinical applicability by 3 retinal experts was also conducted. Data were collected from June 1, 2012, to January 31, 2017, for set 1 and from January 1 to December 31, 2017, for set 2; graded between November 2018 and January 2020; and analyzed from February 2020 to November 2020.
   MAIN OUTCOMES AND MEASURES Rating and stack ranking for clinical applicability by retinal specialists, model-grader agreement for voxelwise segmentations, and total volume evaluated using Dice similarity coefficients, Bland-Altman plots, and intraclass correlation coefficients.
   RESULTS Among the 173 patients included in the analysis (92 [53%] women), qualitative assessment found that automated whole-volume segmentation ranked better than or comparable to at least 1 expert grader in 127 scans (73%; 95% CI, 66%-79%). A neutral or positive rating was given to 135 model segmentations (78%; 95% CI, 71%-84%) and 309 expert gradings (2 per scan) (89%; 95% CI, 86%-92%). The model was rated neutrally or positively in 86% to 92% of diabetic macular edema scans and 53% to 87% of age-related macular degeneration scans. Intraclass correlations ranged from 0.33 (95% CI, 0.08-0.96) to 0.96 (95% CI, 0.90-0.99). Dice similarity coefficients ranged from 0.43 (95% CI, 0.29-0.66) to 0.78 (95% CI, 0.57-0.85).
   CONCLUSIONS AND RELEVANCE This deep learning-based segmentation tool provided clinically useful measures of retinal disease that would otherwise be infeasible to obtain. Qualitative evaluation was additionally important to reveal clinical applicability for both care management and research.
C1 [Wilson, Marc; Chopra, Reena; Wilson, Megan Z.; Cooper, Charlotte; MacWilliams, Patricia; Hughes, Cian O.; Karthikesalingam, Alan; Kelly, Christopher J.] Google Hlth, 6 Pancras Sq, London N1C 4AG, England.
   [Chopra, Reena; Florea, Daniela; Khalid, Hagar; Vermeirsch, Sandra; Nicholson, Luke; Keane, Pearse A.; Balaskas, Konstantinos] Moorfields Eye Hosp NHS Natl Hlth Serv Fdn Trust, Natl Inst Hlth Res Biomed Res Ctr Ophthalmol, London, England.
   [Chopra, Reena; Florea, Daniela; Khalid, Hagar; Vermeirsch, Sandra; Nicholson, Luke; Keane, Pearse A.; Balaskas, Konstantinos] UCL, Inst Ophthalmol, London, England.
   [Liu, Yun; Wulczyn, Ellery] Google Hlth, Palo Alto, CA USA.
C3 University of London; University College London; Moorfields Eye Hospital
   NHS Foundation Trust; University of London; University College London
RP Kelly, CJ (通讯作者)，Google Hlth, 6 Pancras Sq, London N1C 4AG, England.
EM cjkelly@google.com
RI Balaskas, Konstantinos/ABD-5979-2020; Florea, Daniela I/J-9171-2016
OI Balaskas, Konstantinos/0000-0002-7690-6277; Keane,
   Pearse/0000-0002-9239-745X; Liu, Yun/0000-0003-4079-8275; Florea,
   Daniela/0000-0003-1006-0560
FU Google LLC; College of Optometrists, United Kingdom
FX This study was funded by Google LLC. Ms Chopra received scholarship
   support from the College of Optometrists, United Kingdom.
CR Anbeek P, 2004, MED IMAGE ANAL, V8, P205, DOI 10.1016/j.media.2004.06.019
   [Anonymous], 2017, RETOUCH RETINAL OCT
   Bogunovic H, 2019, IEEE T MED IMAGING, V38, P1858, DOI 10.1109/TMI.2019.2901398
   Chopra R, 2020, INVEST OPHTH VIS SCI, V61
   Costa RA, 2006, PROG RETIN EYE RES, V25, P325, DOI 10.1016/j.preteyeres.2006.03.001
   De Fauw J, 2018, NAT MED, V24, P1342, DOI 10.1038/s41591-018-0107-6
   DICE LR, 1945, ECOLOGY, V26, P297, DOI 10.2307/1932409
   Euser AM, 2008, J CLIN EPIDEMIOL, V61, P978, DOI 10.1016/j.jclinepi.2007.11.003
   Gerendas BS, 2018, BRIT J OPHTHALMOL, V102, P195, DOI 10.1136/bjophthalmol-2017-310483
   Giani A, 2010, RETINA-J RET VIT DIS, V30, P607, DOI 10.1097/IAE.0b013e3181c2e09d
   Gomez J, 2018, CURR CARDIOVASC IMAG, V11, DOI 10.1007/s12410-018-9443-7
   Gurney-Champion OJ, 2020, RADIOTHER ONCOL, V146, P66, DOI 10.1016/j.radonc.2020.01.026
   Guymer RH, 2019, OPHTHALMOLOGY, V126, P723, DOI 10.1016/j.ophtha.2018.11.025
   Information Commissioner's Office, 2015, AN MAN DAT PROT RISK
   Keane PA, 2012, SURV OPHTHALMOL, V57, P389, DOI 10.1016/j.survophthal.2012.01.006
   Keenan TDL, 2021, OPHTHALMOLOGY, V128, P100, DOI [10.1016/j.opatha.2020.06.038, 10.1016/j.ophtha.2020.06.038]
   Lee CS, 2017, BIOMED OPT EXPRESS, V8, P3440, DOI 10.1364/BOE.8.003440
   Lee H, 2018, AM J OPHTHALMOL, V191, P64, DOI 10.1016/j.ajo.2018.04.007
   Lu DH, 2019, MED IMAGE ANAL, V54, P100, DOI 10.1016/j.media.2019.02.011
   Man MY, 2015, MALAYS J MED SCI, V22, P9
   Mehta N, 2020, JAMA OPHTHALMOL, V138, P1017, DOI 10.1001/jamaophthalmol.2020.2769
   Monteiro M, 2020, LANCET DIGIT HEALTH, V2, pE314, DOI 10.1016/S2589-7500(20)30085-6
   Moraes G, 2021, OPHTHALMOLOGY, V128, P693, DOI 10.1016/j.ophtha.2020.09.025
   Oakley JD, AUTOMATED DEEP LEARN, DOI [10.1101/2020.09.01.278259, DOI 10.1101/2020.09.01.278259]
   Pokroy R, 2018, RETINA-J RET VIT DIS, V38, P1485, DOI 10.1097/IAE.0000000000001748
   Ritter M, 2014, BRIT J OPHTHALMOL, V98, P1629, DOI 10.1136/bjophthalmol-2014-305186
   Roberts PK, 2020, JAMA OPHTHALMOL, V138, P945, DOI 10.1001/jamaophthalmol.2020.2457
   Ronneberger O, 2015, LECT NOTES COMPUT SC, V9351, P234, DOI 10.1007/978-3-319-24574-4_28
   Rosenfeld PJ, 2016, INVEST OPHTH VIS SCI, V57, pOCT14, DOI 10.1167/iovs.16-19969
   Rosenkrantz AB, 2015, ACAD RADIOL, V22, P33, DOI 10.1016/j.acra.2014.08.011
   Sadda SR, 2006, OPHTHALMOLOGY, V113, P285, DOI 10.1016/j.ophtha.2005.10.005
   Schindelin J, 2012, NAT METHODS, V9, P676, DOI [10.1038/NMETH.2019, 10.1038/nmeth.2019]
   Schlegl T, 2018, OPHTHALMOLOGY, V125, P549, DOI 10.1016/j.ophtha.2017.10.031
   Schmidt-Erfurth U, 2020, OPHTHALMOLOGY, V127, P1211, DOI 10.1016/j.ophtha.2020.03.010
   Sophie R, 2015, OPHTHALMOLOGY, V122, P1395, DOI 10.1016/j.ophtha.2015.02.036
   Toth CA, 2015, RETINA-J RET VIT DIS, V35, P1303, DOI 10.1097/IAE.0000000000000483
   Waldstein SM, 2015, BRIT J OPHTHALMOL, V99, P794, DOI 10.1136/bjophthalmol-2014-305573
   Wilson EB, 1927, J AM STAT ASSOC, V22, P209, DOI 10.2307/2276774
   Wintergerst MWM, 2017, TRANSL VIS SCI TECHN, V6, DOI 10.1167/tvst.6.4.10
   World Med Assoc, 2013, JAMA-J AM MED ASSOC, V310, P2191, DOI 10.1001/jama.2013.281053
   Ying GS, 2013, OPHTHALMOLOGY, V120, P122, DOI 10.1016/j.ophtha.2012.07.042
NR 41
TC 6
Z9 6
U1 0
U2 5
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6165
EI 2168-6173
J9 JAMA OPHTHALMOL
JI JAMA Ophthalmol.
PD SEP
PY 2021
VL 139
IS 9
BP 964
EP 973
DI 10.1001/jamaophthalmol.2021.2273
EA JUL 2021
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA UR2VT
UT WOS:000672064400002
PM 34236406
OA hybrid, Green Published
DA 2022-11-30
ER

PT J
AU Jonas, JB
   Wei, WB
   Xu, L
   Rietschel, M
   Streit, F
   Wang, YX
AF Jonas, Jost B.
   Wei, Wen Bin
   Xu, Liang
   Rietschel, Marcella
   Streit, Fabian
   Wang, Ya Xing
TI Self-rated depression and eye diseases: The Beijing Eye Study
SO PLOS ONE
LA English
DT Article
ID QUALITY-OF-LIFE; DRY-EYE; TEAR FLUID; ANXIETY; PREVALENCE; SYMPTOMS;
   AGE; GLAUCOMA; ASSOCIATION; VALIDITY
AB Purpose
   To assess the prevalence of depression in the general population of Beijing and its association with ocular diseases.
   Methods
   The population-based Beijing Eye Study was conducted in a rural and an urban region of Greater Beijing. The study participants underwent a detailed ophthalmological examination and an interview including questions on the socioeconomic background. Depressive symptoms were evaluated using a Chinese depression scale adapted from Zung's self-rated depression scale. The total score of depression symptoms was 80. Depression was defined as having a depression score >44.
   Results
   Out of 3468 study participants, 3267 (94.2%) individuals (1419 men) with an age of 64.5 +/- 9.7 years (range: 50-93 years) participated in the interview and answered all questions on depression. The mean depression score was 25.0 +/- 5.9 (median: 23.3; range:20-64). Depression (depression score >44) was present in 66 individuals (2.0%; 95% confidence interval (CI): 1.5,2.5), and 5 individuals (0.2%; 95%CI: 0.02,0.3) had a depression score >= 59. In multivariate regression, analysis, a higher depression score was associated (regression coefficient r(2):0.22) with a higher number of days with dry eye feeling (P<0.001; standardized regression coefficient beta: 0.09; non-standardized regression coefficient B: 0.20; 95%CI: 0.12,0.29) and shorter corneal curvature radius (P = 0.03;beta:-0.04; B:1.01; 95%CI: -1.90,-0.12), after adjusting for age, gender, region of habitation, body mass index, cognitive function score, life quality score and blood concentration of triglycerides. Adding age-related macular degeneration (P = 0.10), glaucoma (P = 0.77), diabetic retinopathy (P = 0.77), nuclear cataract (P = 0.35), cortical cataract (P= 0.58) or posterior subcapsular cataract (P= 0.28) as single parameters to the model revealed no significant correlation with the depression score. Lower best corrected visual acuity showed a marginal significant association (P = 0.05; beta: 0.04; B: 1.56; 95%CI: -0.01, 3.13).
   Conclusions
   Dry eye feeling was the only common ocular disorder associated with an increased depression score, while the occurrence of age-related macular degeneration, any type of glaucoma, diabetic retinopathy, any type of cataract and keratoconus were not significantly associated with an increased depression score. Lower visual acuity was marginally associated. The prevalence of depression in the population aged 50+ years in Greater Beijing was 2.0% (96%CI: 1.5,2.5).
C1 [Jonas, Jost B.; Xu, Liang; Wang, Ya Xing] Capital Med Univ, Beijing Inst Ophthalmol, Beijing Tongren Eye Ctr, Beijing Tongren Hosp, Beijing, Peoples R China.
   [Jonas, Jost B.; Xu, Liang; Wang, Ya Xing] Beijing Key Lab Ophthalmol & Visual Sci, Beijing, Peoples R China.
   [Jonas, Jost B.] Heidelberg Univ, Med Fac Mannheim, Dept Ophthalmol, Mannheim, Germany.
   [Wei, Wen Bin] Capital Med Univ, Beijing Tongren Hosp, Beijing Tongren Eye Ctr, Beijing, Peoples R China.
   [Rietschel, Marcella; Streit, Fabian] Heidelberg Univ, Med Fac Mannheim, Cent Inst Mental Hlth, Dept Genet Epidemiol Psychiat, Mannheim, Germany.
C3 Capital Medical University; Ruprecht Karls University Heidelberg;
   Capital Medical University; Central Institute of Mental Health; Ruprecht
   Karls University Heidelberg
RP Wang, YX (通讯作者)，Capital Med Univ, Beijing Inst Ophthalmol, Beijing Tongren Eye Ctr, Beijing Tongren Hosp, Beijing, Peoples R China.; Wang, YX (通讯作者)，Beijing Key Lab Ophthalmol & Visual Sci, Beijing, Peoples R China.
EM xlbio1@163.com
RI wang, YA XING/K-9671-2016
OI wang, YA XING/0000-0003-2749-7793; Jonas, Jost/0000-0003-2972-5227
FU State Natural Sciences Fund [81041018]; Natural Sciences Fund of the
   Beijing Government [7092021, 7112031]
FX This work is supported by the State Natural Sciences Fund (81041018 to
   W.B.W.) and the Natural Sciences Fund of the Beijing Government
   (7092021; 7112031 to W.B.W.). The funders had no role in study design,
   data collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Augustin A, 2007, INVEST OPHTH VIS SCI, V48, P1498, DOI 10.1167/iovs.06-0761
   BIGGS JT, 1978, BRIT J PSYCHIAT, V132, P381, DOI 10.1192/bjp.132.4.381
   Brody BL, 2001, OPHTHALMOLOGY, V108, P1893, DOI 10.1016/S0161-6420(01)00754-0
   Cohen BE, 2015, AM J HYPERTENS, V28, P1295, DOI 10.1093/ajh/hpv047
   Dawson SR, 2014, BMC OPHTHALMOL, V14, DOI 10.1186/1471-2415-14-78
   de Salamanca AE, 2005, INVEST OPHTH VIS SCI, V46, P504, DOI 10.1167/iovs.04-0665
   Foster PJ, 2002, BRIT J OPHTHALMOL, V86, P238, DOI 10.1136/bjo.86.2.238
   Gu L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065356
   Hallak JA, 2015, CORNEA, V34, P1545, DOI 10.1097/ICO.0000000000000641
   Hilsenroth MJ, 2004, INT J PSYCHIAT CLIN, V8, P3, DOI 10.1080/13651500310004795
   Jie Y, 2009, EYE, V23, P688, DOI 10.1038/sj.eye.6703101
   Jivraj J, 2013, CAN J OPHTHALMOL, V48, P269, DOI 10.1016/j.jcjo.2013.03.007
   Jonas JB, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082284
   Kassoff A, 2001, AM J OPHTHALMOL, V131, P167
   Katon WJ, 2003, BIOL PSYCHIAT, V54, P216, DOI 10.1016/S0006-3223(03)00273-7
   Kim KW, 2011, INVEST OPHTH VIS SCI, V52, P7954, DOI 10.1167/iovs.11-8050
   KITAMURA T, 1994, ACTA PSYCHIAT SCAND, V90, P446, DOI 10.1111/j.1600-0447.1994.tb01622.x
   Labbe A, 2013, BRIT J OPHTHALMOL, V97, P1399, DOI 10.1136/bjophthalmol-2013-303838
   LEE HC, 1994, J GERIATR PSYCH NEUR, V7, P216, DOI 10.1177/089198879400700404
   Lee WJ, 2013, ASIA-PAC J OPHTHALMO, V2, P23, DOI 10.1097/APO.0b013e31827be8b1
   Lim NCS, 2016, J GLAUCOMA, V25, P605, DOI 10.1097/IJG.0000000000000393
   Mabuchi F, 2008, J GLAUCOMA, V17, P552, DOI 10.1097/IJG.0b013e31816299d4
   Martin J, 2017, PSYCHIAT GENET, V27, P187, DOI 10.1097/YPG.0000000000000182
   Mrugacz M, 2017, ADV MED SCI-POLAND, V62, P338, DOI 10.1016/j.advms.2017.03.003
   Munzer A, 2013, TOXINS, V5, P2227, DOI 10.3390/toxins5112227
   Pflugfelder SC, 1999, CURR EYE RES, V19, P201, DOI 10.1076/ceyr.19.3.201.5309
   Popescu ML, 2012, INVEST OPHTH VIS SCI, V53, P2308, DOI 10.1167/iovs.11-9330
   Qian Y, 2012, AM J OPHTHALMOL, V153, P370, DOI 10.1016/j.ajo.2011.06.028
   Schein OD, 1997, AM J OPHTHALMOL, V124, P723, DOI 10.1016/S0002-9394(14)71688-5
   Shen MX, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2016-012961
   Skalicky S, 2008, J GLAUCOMA, V17, P546, DOI 10.1097/IJG.0b013e318163bdd1
   Solomon A, 2001, INVEST OPHTH VIS SCI, V42, P2283
   van der Aa HPA, 2015, INVEST OPHTH VIS SCI, V56, P849, DOI 10.1167/iovs.14-15848
   Vos T, 2016, LANCET, V388, P1545, DOI [10.1016/S0140-6736(16)31012-1, 10.1016/S0140-6736(16)31678-6]
   Wan KH, 2016, EYE, V30, P1558, DOI 10.1038/eye.2016.186
   Wang SG, 2012, TRAC-TREND ANAL CHEM, V39, P3, DOI 10.1016/j.trac.2012.07.010
   Wang TJ, 2012, ACTA OPHTHALMOL, V90, P663, DOI 10.1111/j.1755-3768.2010.01993.x
   Wray NR, 2018, NAT GENET, V50, P668, DOI 10.1038/s41588-018-0090-3
   Xie XB, 2013, CRIT CARE, V17, DOI 10.1186/cc12841
   Xu J, 2013, OPHTHALMOLOGY, V120, P2023, DOI 10.1016/j.ophtha.2013.03.009
   Yan YN, 2015, OPHTHALMOLOGY, V122, P1873, DOI 10.1016/j.ophtha.2015.05.031
   Yochim BP, 2012, J GLAUCOMA, V21, P250, DOI 10.1097/IJG.0b013e3182071b7e
   Zhang XX, 2017, AM J OPHTHALMOL, V183, P37, DOI 10.1016/j.ajo.2017.07.021
   Zhang XZ, 2013, JAMA OPHTHALMOL, V131, P573, DOI 10.1001/jamaophthalmol.2013.2597
   Zheng YJ, 2017, SCI REP-UK, V7, DOI 10.1038/srep46453
   Zhou CD, 2013, J PSYCHOSOM RES, V75, P75, DOI 10.1016/j.jpsychores.2013.03.005
   ZUNG WWK, 1965, ARCH GEN PSYCHIAT, V12, P63, DOI 10.1001/archpsyc.1965.01720310065008
NR 47
TC 18
Z9 18
U1 0
U2 1
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD AUG 10
PY 2018
VL 13
IS 8
AR e0202132
DI 10.1371/journal.pone.0202132
PG 15
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA GQ0KU
UT WOS:000441308500052
PM 30096194
OA Green Submitted, Green Published, gold
DA 2022-11-30
ER

PT J
AU Marques, JP
   Farinha, C
   Costa, MA
   Ferrao, A
   Nunes, S
   Silva, R
AF Marques, Joao Pedro
   Farinha, Claudia
   Costa, Miguel Angelo
   Ferrao, Angela
   Nunes, Sandrina
   Silva, Rufino
TI Protocol for a randomised, double-masked, sham-controlled phase 4 study
   on the efficacy, safety and tolerability of intravitreal aflibercept
   monotherapy compared with aflibercept with adjunctive photodynamic
   therapy in polypoidal choroidal vasculopathy: the ATLANTIC study
SO BMJ OPEN
LA English
DT Article
ID MACULAR DEGENERATION; VEGF-TRAP; VERTEPORFIN; RANIBIZUMAB; ASSOCIATION;
   LAPTOP
AB Purpose The purpose of this study is to compare the efficacy and safety of intravitreal aflibercept (IVA) with sham photodynamic therapy (sPDT) versus IVA with verteporfin PDT (vPDT) in a Caucasian population with treatment-naive polypoidal choroidal vasculopathy (PCV), enrolling into a treat and extend (T&E) regimen.
   Methods and analysis Randomised, double-masked, sham-controlled, multicentre phase 4 investigator-driven clinical trial. The primary outcomes are (1) change in best-corrected visual acuity (BCVA) from baseline and (2) polyp regression at week 52, assessed by indocyanine green angiography (ICGA). Fifty patients with treatment-naive PCV will be recruited from Portuguese and Spanish clinical sites. Eligible patients will receive monthly IVA for 3 months (week 0, week 4 and week 8). At week 16, all patients will repeat ICGA and undergo central randomisation (1: 1 ratio) into one of the following groups: Group 1-IVA T&E + vPDT; Group 2-IVA T&E + sPDT. PDT will be performed at week 16, week 28 and week 40 in the presence of active polyps. After week 16, the presence of macular fluid on optical coherence tomography will determine the schedule of observations. When present, the interval between visits/injections will decrease 2 weeks (minimum 6 weeks). When not, the interval between visits/injections will increase 2 weeks (maximum 12 weeks). Efficacy will be evaluated based on BCVA, central retinal thickness and polyp regression. Safety parameters will include assessment of intraocular pressure, adverse events and serious adverse events.
   Ethics and dissemination This study was designed and shall be implemented and reported in accordance with the International Conference on Harmonisation (ICH) Harmonised Tripartite Guidelines for Good Clinical Practice, with applicable local regulations and with the ethical principles laid down in the Declaration of Helsinki. The study received approval from Comissao de Eticaca para a Investigacao Clinica and Comite Etica de investigacion Clinica del Hospital Universitari de Bellvitge.
C1 [Marques, Joao Pedro; Farinha, Claudia; Costa, Miguel Angelo; Ferrao, Angela; Nunes, Sandrina; Silva, Rufino] Assoc Invest & Biomed Res Light & Image AIBILI, Coimbra, Portugal.
   [Marques, Joao Pedro; Silva, Rufino] Univ Coimbra FMUC, Fac Med, Coimbra, Portugal.
   [Marques, Joao Pedro; Farinha, Claudia; Silva, Rufino] CHUG, Dept Ophthalmol, Coimbra, Portugal.
C3 Universidade de Coimbra
RP Marques, JP (通讯作者)，Assoc Invest & Biomed Res Light & Image AIBILI, Coimbra, Portugal.; Marques, JP (通讯作者)，Univ Coimbra FMUC, Fac Med, Coimbra, Portugal.; Marques, JP (通讯作者)，CHUG, Dept Ophthalmol, Coimbra, Portugal.
EM marquesjoaopedro@gmail.com
RI Marques, João Pedro/J-3584-2012; Farinha, Cláudia/R-1392-2017; Silva,
   Rufino M/J-2817-2012
OI Marques, João Pedro/0000-0002-1014-0483; Farinha,
   Cláudia/0000-0003-4596-0913; Silva, Rufino M/0000-0001-8676-0833; Nunes,
   Sandrina/0000-0001-5401-9637
FU Bayer HealthCare Pharmaceuticals Inc.; Bayer Portugal, SA; Bayer
   Hispania
FX This study was supported by Bayer HealthCare Pharmaceuticals Inc.; Bayer
   Portugal, SA; Bayer Hispania, S.L. Bayer or any of the subsidiaries had
   no role in the design or conduct of this research.
CR Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Chen HY, 2012, MOL VIS, V18, P816
   Gotoh N, 2008, CLIN EXP OPHTHALMOL, V36, P437, DOI 10.1111/j.1442-9071.2008.01791.x
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Holash J, 2002, P NATL ACAD SCI USA, V99, P11393, DOI 10.1073/pnas.172398299
   Honda S, 2014, OPHTHALMOLOGICA, V231, P59, DOI 10.1159/000355488
   Kikushima W, 2017, GRAEFES ARCH CLIN EX, V255
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Koh AHC, 2013, RETINA-J RET VIT DIS, V33, P686, DOI 10.1097/IAE.0b013e3182852446
   Lafaut BA, 2000, GRAEF ARCH CLIN EXP, V238, P752, DOI 10.1007/s004170000180
   Ma L, 2015, OPHTHALMOLOGY, V122, P1854, DOI 10.1016/j.ophtha.2015.05.012
   Oishi A, 2014, OPHTHALMOLOGY, V121, P1151, DOI 10.1016/j.ophtha.2013.12.037
   Oishi A, 2013, AM J OPHTHALMOL, V156, P644, DOI 10.1016/j.ajo.2013.05.024
   Peyman GA, 2009, RETINA-J RET VIT DIS, V29, P875, DOI 10.1097/IAE.0b013e3181a94f01
   Wang W, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0110667
   Wong CW, 2016, PROG RETIN EYE RES, V53, P107, DOI 10.1016/j.preteyeres.2016.04.002
   Zhang XZ, 2011, INVEST OPHTH VIS SCI, V52, P8063, DOI 10.1167/iovs.11-7820
NR 17
TC 6
Z9 6
U1 0
U2 0
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 2044-6055
J9 BMJ OPEN
JI BMJ Open
PD AUG
PY 2017
VL 7
IS 8
AR e015785
DI 10.1136/bmjopen-2016-015785
PG 14
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA FI2UT
UT WOS:000411802700100
PM 28851779
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Chia, EM
   Mitchell, P
   Rochtchina, E
   Foran, S
   Golding, M
   Wang, JJ
AF Chia, Ee-Munn
   Mitchell, Paul
   Rochtchina, Elena
   Foran, Suriya
   Golding, Maryanne
   Wang, Jie Jin
TI Association between vision and hearing impairments and their combined
   effects on quality of life
SO ARCHIVES OF OPHTHALMOLOGY
LA English
DT Article
ID AGE-RELATED MACULOPATHY; DISEASE RISK-FACTORS; BEAVER-DAM;
   CARDIOVASCULAR-DISEASE; VISUAL IMPAIRMENT; HEALTH SURVEY; EPIDEMIOLOGY;
   PREVALENCE; AUSTRALIA; CATARACT
AB Objectives: To assess associations between age-related vision and hearing impairments and whether combined sensory losses magnify effects on health-related quality of life.
   Methods: Seventy-five percent of survivors (n=2334) were reexamined at Blue Mountains Eye Study 5-year examinations and 86.3% (2015) attended hearing assessments. Visual impairment was defined as visual acuity less than 20/40 (better eye), and hearing impairment as average pure-tone air conduction threshold greater than 25 dB (500-4000 Hz, better ear).
   Results: Persons with visual impairment, compared with those without visual impairment, had lower mean audiometric thresholds across all frequencies (P <=. 05). For each 1-line (5-letter) reduction in best-corrected visual acuity and presenting visual acuity, hearing loss prevalence increased by 18% and 13%, respectively. Cataract and age-related maculopathy were also associated with hearing loss (respectively, multivariate-adjusted odds ratio, 1.3 and 1.6; 95% confidence interval, 1.0-1.7 and 1.1-3.1). The association between age-related maculopathy and hearing loss was stronger at younger ages (< 70 years). Combined impairments were associated with poorer health- related quality of life than were single impairments (multivariate- adjusted 36- Item Short- Form Health Survey mean physical and mental component scores; P-trend =. 001 and < .001, respectively).
   Conclusions: Older persons with visual impairment were also more likely to have hearing loss in this study, which suggests that these sensory impairments could share common risk factors or biologic aging markers. Combined sensory impairments also cumulatively affect health-related quality of life.
C1 Univ Sydney, Westmead Hosp, Ctr Vis Res, Dept Ophthalmol,FRANZCO, Westmead, NSW 2145, Australia.
   Natl Acoust Labs, Sydney, NSW, Australia.
C3 University of Sydney; National Acoustic Laboratories
RP Mitchell, P (通讯作者)，Univ Sydney, Westmead Hosp, Ctr Vis Res, Dept Ophthalmol,FRANZCO, Hawkesbury Rd, Westmead, NSW 2145, Australia.
EM paul_mitchell@wmi.usyd.edu.au
RI Wang, Jie Jin/P-1499-2014; Mitchell, Paul/P-1498-2014; wang,
   jie/GRS-0942-2022
OI Wang, Jie Jin/0000-0001-9491-4898; 
CR Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Appollonio I, 1996, AGE AGEING, V25, P89, DOI 10.1093/ageing/25.2.89
   Attebo K, 1996, OPHTHALMOLOGY, V103, P357
   Australian Bureau of Statistics, 1997, NAT HLTH SURV 1995 S
   BRESSLER NM, 1988, SURV OPHTHALMOL, V32, P375, DOI 10.1016/0039-6257(88)90052-5
   Campbell V A, 1999, MMWR CDC Surveill Summ, V48, P131
   Cruickshanks KJ, 1998, JAMA-J AM MED ASSOC, V279, P1715, DOI 10.1001/jama.279.21.1715
   Dalton DS, 1998, DIABETES CARE, V21, P1540, DOI 10.2337/diacare.21.9.1540
   Gale CR, 2001, OPHTHALMOLOGY, V108, P1992, DOI 10.1016/S0161-6420(01)00833-8
   GATES GA, 1993, ARCH OTOLARYNGOL, V119, P156
   Keller BK, 1999, J AM GERIATR SOC, V47, P1319, DOI 10.1111/j.1532-5415.1999.tb07432.x
   Klein BEK, 1998, AM J OPHTHALMOL, V126, P782, DOI 10.1016/S0002-9394(98)00280-3
   Klein BEK, 1997, AM J OPHTHALMOL, V123, P338, DOI 10.1016/S0002-9394(14)70129-1
   Klein BEK, 2001, AM J OPHTHALMOL, V132, P537, DOI 10.1016/S0002-9394(01)01126-6
   Klein R, 2003, OPHTHALMOLOGY, V110, P636, DOI 10.1016/S0161-6420(02)01448-3
   Klein R, 1996, OPHTHALMOLOGY, V103, P1169, DOI 10.1016/S0161-6420(96)30526-5
   Klein R, 1998, ARCH OPHTHALMOL-CHIC, V116, P360, DOI 10.1001/archopht.116.3.360
   KLEIN R, 1992, INT TXB DIABETES MEL, P1373
   Lee P, 1999, AM J OPHTHALMOL, V127, P447, DOI 10.1016/S0002-9394(98)00418-8
   Lupsakko T, 2002, INT J GERIATR PSYCH, V17, P808, DOI 10.1002/gps.689
   Mathers C., 1999, BURDEN DIS INJURY AU
   McCarty CA, 2001, ARCH OPHTHALMOL-CHIC, V119, P1455
   McCarty CA, 1999, AM J OPHTHALMOL, V128, P446, DOI 10.1016/S0002-9394(99)00218-4
   Mitchell P, 1997, OPHTHALMOLOGY, V104, P581, DOI 10.1016/S0161-6420(97)30266-8
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Popelka MM, 2000, J AM GERIATR SOC, V48, P1273, DOI 10.1111/j.1532-5415.2000.tb02601.x
   Reuben DB, 1999, J AM GERIATR SOC, V47, P930, DOI 10.1111/j.1532-5415.1999.tb01286.x
   Rowe N G, 2000, Ophthalmic Epidemiol, V7, P103
   Rubin GS, 2000, WOMEN HLTH, P1213, DOI [10.1016/B978-012288145-9/50111-X., DOI 10.1016/B978-012288145-9/50111-X]
   Sanson-Fisher RW, 1998, J CLIN EPIDEMIOL, V51, P961, DOI 10.1016/S0895-4356(98)00087-0
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Sperduto RD, 2001, OPHTHALMOLOGY, V108, P1400
   VandenLangenberg GM, 1998, AM J EPIDEMIOL, V148, P204, DOI 10.1093/oxfordjournals.aje.a009625
   WAHL HW, 2000, COMMUNICATION TECHNO
   WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002
   Ware JE., 1993, SCORING SF 36 SF 36
   Ware JE, 1994, SF 36 PHYS MENTAL HL
NR 37
TC 109
Z9 115
U1 3
U2 16
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0003-9950
EI 1538-3601
J9 ARCH OPHTHALMOL-CHIC
JI Arch. Ophthalmol.
PD OCT
PY 2006
VL 124
IS 10
BP 1465
EP 1470
DI 10.1001/archopht.124.10.1465
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 091VX
UT WOS:000241057500011
PM 17030715
DA 2022-11-30
ER

PT J
AU Lam, TC
   Chun, RK
   Li, KK
   To, CH
AF Lam, Thomas C.
   Chun, Rachel K. M.
   Li, King-Kit
   To, Chi-Ho
TI Application of proteomic technology in eye research: a mini review
SO CLINICAL AND EXPERIMENTAL OPTOMETRY
LA English
DT Review
DE electrophoresis; mass spectrometry; myopia; ocular diseases; proteomics
ID 2-DIMENSIONAL GEL-ELECTROPHORESIS; RETINAL-PIGMENT EPITHELIUM;
   IONIZATION MASS-SPECTROMETRY; MEIBOMIAN GLAND SECRETIONS; CODED AFFINITY
   TAGS; ALPHA-A-CRYSTALLIN; PROTEIN EXPRESSION; MACULAR DEGENERATION;
   VITREOUS PROTEINS; HUMAN LENS
AB Proteomics is a rapidly growing research area for the study of the protein cognate of genomic data. This review gives a brief overview of the modern proteomic technology. In addition to general applications of proteomics, we highlight its contribution to studying the physiology of different ocular tissues. We also summarise the published proteomic literature in the broad context of ophthalmic diseases, such as cataract, age-related maculopathy, diabetic retinopathy, glaucoma and myopia. The proteomic technology is a useful research tool and it will continue to advance our understanding of a variety of molecular processes in ocular tissues and diseases.
C1 Hong Kong Polytech Univ, Sch Optometry, Lab Expt Optometry, Ctr Myopia Res, Kowloon, Hong Kong, Peoples R China.
C3 Hong Kong Polytechnic University
RP To, CH (通讯作者)，Hong Kong Polytech Univ, Sch Optometry, Lab Expt Optometry, Ctr Myopia Res, Kowloon, Hong Kong, Peoples R China.
EM sochto@inet.polyu.edu.hk
RI Lam, Chuen/AAI-4020-2021
OI Lam, Chuen/0000-0002-3511-5620; To, Chi-ho/0000-0002-1938-8397; Chun,
   Rachel Ka Man/0000-0001-6978-0963
CR AKIBA J, 1993, OPHTHALMOLOGY, V100, P1384
   Alge CS, 2003, INVEST OPHTH VIS SCI, V44, P3629, DOI 10.1167/iovs.02-1225
   Allison WT, 2006, MOL VIS, V12, P655
   Azarian SM, 2006, J PROTEOME RES, V5, P521, DOI 10.1021/pr0502323
   Bahk SC, 2006, PROTEOMICS, V6, P3436, DOI 10.1002/pmic.200500779
   Baker GRC, 2006, ARCH OPHTHALMOL-CHIC, V124, P1451, DOI 10.1001/archopht.124.10.1451
   Ball LE, 2004, BIOCHEMISTRY-US, V43, P9856, DOI 10.1021/bi0496034
   BALSAMO J, 1986, J CELL BIOCHEM, V32, P125, DOI 10.1002/jcb.240320205
   BANGA JP, 1987, EXP EYE RES, V44, P199, DOI 10.1016/S0014-4835(87)80004-0
   Bertrand E, 2006, MOL CELL PROTEOMICS, V5, P2158, DOI 10.1074/mcp.M600073-MCP200
   Bhattacharya SK, 2005, J BIOL CHEM, V280, P6080, DOI 10.1074/jbc.M411233200
   Boeckmann B, 2003, NUCLEIC ACIDS RES, V31, P365, DOI 10.1093/nar/gkg095
   Bollag D M, 1994, Methods Mol Biol, V36, P1
   Bonilha VL, 2004, MOL CELL PROTEOMICS, V3, P1119, DOI 10.1074/mcp.M400106-MCP200
   Bresgen M., 1994, Ophthalmologe, V91, P758
   Buhimsehi CS, 2006, OBSTET GYNECOL SURV, V61, P481, DOI 10.1097/01.ogx.0000224617.11789.ab
   Butterfield DA, 2004, BRAIN RES, V1000, P1, DOI 10.1016/j.brainres.2003.12.012
   Celis JE, 1999, CURR OPIN BIOTECH, V10, P16, DOI 10.1016/S0958-1669(99)80004-4
   CELIS JE, 1991, FASEB J, V5, P2200, DOI 10.1096/fasebj.5.8.1827083
   Choe LH, 2000, ELECTROPHORESIS, V21, P993, DOI 10.1002/(SICI)1522-2683(20000301)21:5<993::AID-ELPS993>3.0.CO;2-9
   Clack JW, 2003, ELECTROPHORESIS, V24, P3493, DOI 10.1002/elps.200305520
   Coppe AM, 2005, OPHTHALMOLOGY, V112, P2103, DOI 10.1016/j.ophtha.2005.06.028
   COTTRELL JS, 1994, PEPTIDE RES, V7, P115
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   DATILES MB, 1992, CURR EYE RES, V11, P669, DOI 10.3109/02713689209000740
   de Souza GA, 2006, GENOME BIOL, V7, DOI 10.1186/gb-2006-7-8-r72
   Deeg CA, 2007, PROTEOMICS, V7, P1540, DOI 10.1002/pmic.200600795
   DERETIC D, 1994, J BIOL CHEM, V269, P16853
   Dixon DW, 2005, J INORG BIOCHEM, V99, P813, DOI 10.1016/j.jinorgbio.2004.12.013
   Dolnik V, 1999, ELECTROPHORESIS, V20, P3106, DOI 10.1002/(SICI)1522-2683(19991001)20:15/16<3106::AID-ELPS3106>3.0.CO;2-2
   Ethen CM, 2006, INVEST OPHTH VIS SCI, V47, P2280, DOI 10.1167/iovs.05-1395
   FENN JB, 1989, SCIENCE, V246, P64, DOI 10.1126/science.2675315
   FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800
   Fritz JS, 2004, J CHROMATOGR A, V1039, P3, DOI 10.1016/j.chroma.2003.12.068
   Fung KYC, 2004, PROTEOMICS, V4, P3953, DOI 10.1002/pmic.200300849
   Gao BB, 2007, NAT MED, V13, P181, DOI 10.1038/nm1534
   Gorg A, 2000, ELECTROPHORESIS, V21, P1037, DOI 10.1002/(SICI)1522-2683(20000401)21:6<1037::AID-ELPS1037>3.0.CO;2-V
   Granville CA, 2005, AM J RESP CELL MOL, V32, P169, DOI 10.1165/rcmb.F290
   Graves PR, 2003, RECENT PROG HORM RES, V58, P1, DOI 10.1210/rp.58.1.1
   Grus FH, 2005, INVEST OPHTH VIS SCI, V46, P863, DOI 10.1167/iovs.04-0448
   Hale John E., 2003, Briefings in Functional Genomics & Proteomics, V2, P185
   Ham BM, 2007, ANAL BIOANAL CHEM, V387, P889, DOI 10.1007/s00216-006-1018-9
   Ham BM, 2006, INVEST OPHTH VIS SCI, V47, P3330, DOI 10.1167/iovs.05-0756
   Hammack BN, 2004, MULT SCLER, V10, P245, DOI 10.1191/1352458504ms1023oa
   Han DK, 2001, NAT BIOTECHNOL, V19, P946, DOI 10.1038/nbt1001-946
   Han J, 2006, INVEST OPHTH VIS SCI, V47, P2990, DOI 10.1167/iovs.05-1529
   Hanash S, 2002, MOL CELL PROTEOMICS, V1, P413, DOI 10.1074/mcp.R200002-MCP200
   Hart C, 2004, ELECTROPHORESIS, V25, P2486, DOI 10.1002/elps.200406001
   Hathout Y, 2005, J PROTEOME RES, V4, P620, DOI 10.1021/pr049749p
   Hauck SM, 2003, GLIA, V44, P251, DOI 10.1002/glia.10292
   Haynes PA, 1998, ELECTROPHORESIS, V19, P1862, DOI 10.1002/elps.1150191104
   Hendrickson CL, 1999, ANNU REV PHYS CHEM, V50, P517, DOI 10.1146/annurev.physchem.50.1.517
   HILDEBRANDT JD, 1985, J BIOL CHEM, V260, P4867
   Hoehenwarter W, 2006, AMINO ACIDS, V30, P369, DOI 10.1007/s00726-005-0283-9
   Hollo B, 2006, INVEST OPHTH VIS SCI, V47, P235, DOI 10.1167/iovs.05-0945
   Irvine GB, 2003, J BIOCHEM BIOPH METH, V56, P233, DOI 10.1016/S0165-022X(03)00061-7
   Iwaki H, 2004, CANCER SCI, V95, P955, DOI 10.1111/j.1349-7006.2004.tb03183.x
   JANSSENBIENHOLD U, 1993, EUR J NEUROSCI, V5, P584, DOI 10.1111/j.1460-9568.1993.tb00524.x
   Jeffery DA, 2003, CURR OPIN BIOTECH, V14, P87, DOI 10.1016/S0958-1669(02)00010-1
   Johnson JR, 2004, J PROTEOME RES, V3, P296, DOI 10.1021/pr0340781
   JONES PS, 1987, J COMP NEUROL, V266, P112, DOI 10.1002/cne.902660109
   KARAS M, 1988, ANAL CHEM, V60, P2299, DOI 10.1021/ac00171a028
   Karring H, 2005, MOL CELL PROTEOMICS, V4, P1406, DOI 10.1074/mcp.D500003-MCP200
   Kathiresan T, 2006, FEBS J, V273, P3370, DOI 10.1111/j.1742-4658.2006.05344.x
   Kavallaris M, 2005, MED J AUSTRALIA, V182, P575, DOI 10.5694/j.1326-5377.2005.tb06817.x
   Kennedy S, 2002, BIOMARKERS, V7, P269, DOI 10.1080/13547500210127318
   Kersten B, 2002, PLANT MOL BIOL, V48, P133, DOI 10.1023/A:1013784205292
   Kim SJ, 2006, CURR EYE RES, V31, P231, DOI 10.1080/02713680600557030
   KLIFFEN M, 1995, LAB INVEST, V73, P267
   Kliffen M, 1996, ARCH OPHTHALMOL-CHIC, V114, P1009, DOI 10.1001/archopht.1996.01100140217021
   KLOSE J, 1975, HUMANGENETIK, V26, P231
   Kobayashi Naoyuki, 2004, Tanpakushitsu Kakusan Koso, V49, P1333
   Konig S, 2003, ELECTROPHORESIS, V24, P751, DOI 10.1002/elps.200390090
   Koo BS, 2005, J PROTEOME RES, V4, P719, DOI 10.1021/pr0498133
   LAICINE EM, 1994, EXP EYE RES, V59, P441, DOI 10.1006/exer.1994.1129
   Laiko VV, 2000, ANAL CHEM, V72, P5239, DOI 10.1021/ac000530d
   Lam TC, 2006, J PROTEOME RES, V5, P771, DOI 10.1021/pr050280n
   LAM TC, 2005, ASS RES VIS OPHTH AR
   LAM TC, 2006, 11 INT MYOP C SING
   Lampi KJ, 1998, EXP EYE RES, V67, P31, DOI 10.1006/exer.1998.0481
   Laub MT, 2000, SCIENCE, V290, P2144, DOI 10.1126/science.290.5499.2144
   Lauber WM, 2001, ELECTROPHORESIS, V22, P906, DOI 10.1002/1522-2683()22:5<906::AID-ELPS906>3.0.CO;2-9
   Lee WC, 2004, ANAL BIOCHEM, V324, P1, DOI 10.1016/j.ab.2003.08.031
   LEWIS GP, 1994, AM J OPHTHALMOL, V118, P368, DOI 10.1016/S0002-9394(14)72962-9
   LEWIS GP, 1995, INVEST OPHTH VIS SCI, V36, P2404
   LEWIS SE, 1988, J CELL BIOL, V107, P2689, DOI 10.1083/jcb.107.6.2689
   Li N, 2005, J PROTEOME RES, V4, P2052, DOI 10.1021/pr0501970
   Lim R, 1999, INVEST OPHTH VIS SCI, V40, P3021
   LINN T, 1976, CELL, V8, P103, DOI 10.1016/0092-8674(76)90191-4
   Loboda AV, 2000, RAPID COMMUN MASS SP, V14, P1047, DOI 10.1002/1097-0231(20000630)14:12<1047::AID-RCM990>3.0.CO;2-E
   Lopez MF, 2000, ELECTROPHORESIS, V21, P3673, DOI 10.1002/1522-2683(200011)21:17<3673::AID-ELPS3673>3.3.CO;2-D
   Lund LM, 2001, BIOCHEM BIOPH RES CO, V289, P1157, DOI 10.1006/bbrc.2001.6111
   Macri J, 2001, TRENDS CARDIOVAS MED, V11, P66, DOI 10.1016/S1050-1738(01)00088-3
   Maeda A, 1999, INVEST OPHTH VIS SCI, V40, P2788
   Martin RE, 2005, INVEST OPHTH VIS SCI, V46, P1147, DOI 10.1167/iovs.04-1207
   Maruska A, 2004, J BIOCHEM BIOPH METH, V59, P1, DOI 10.1016/j.jbbm.2003.12.003
   Maruyama I, 2000, INVEST OPHTH VIS SCI, V41, P1657
   McFarlane I, 2000, NEUROREPORT, V11, P1543, DOI 10.1097/00001756-200005150-00035
   Medzihradszky KF, 2000, ANAL CHEM, V72, P552, DOI 10.1021/ac990809y
   Missotten GS, 2003, MELANOMA RES, V13, P627, DOI 10.1097/00008390-200312000-00013
   Morel V, 2000, ELECTROPHORESIS, V21, P3460, DOI 10.1002/1522-2683(20001001)21:16<3460::AID-ELPS3460>3.0.CO;2-I
   Mulugeta S, 2000, J NEUROSCI RES, V59, P247
   Navas A, 2004, PROTEOMICS, V4, P299, DOI 10.1002/pmic.200300603
   Nawrot M, 2004, INVEST OPHTH VIS SCI, V45, P393, DOI 10.1167/iovs.03-0989
   Neal RE, 2005, EXP EYE RES, V80, P337, DOI 10.1016/j.exer.2004.09.015
   Nichols KK, 2007, INVEST OPHTH VIS SCI, V48, P34, DOI 10.1167/iovs.06-0753
   Nielsen K, 2006, EXP EYE RES, V82, P201, DOI 10.1016/j.exer.2005.06.009
   Nordgaard CL, 2006, INVEST OPHTH VIS SCI, V47, P815, DOI 10.1167/iovs.05-0976
   OFARRELL PH, 1975, J BIOL CHEM, V250, P4007
   Okumura N, 2006, J OCUL PHARMACOL TH, V22, P347, DOI 10.1089/jop.2006.22.347
   Organisciak D, 2006, PHOTOCHEM PHOTOBIOL, V82, P1088, DOI 10.1562/2005-06-30-RA-599
   Ouchi M, 2005, EXP EYE RES, V81, P176, DOI 10.1016/j.exer.2005.01.020
   PAPPIN DJC, 1993, CURR BIOL, V3, P327, DOI 10.1016/0960-9822(93)90195-T
   Patterson SD, 2000, CURR OPIN BIOTECH, V11, P413, DOI 10.1016/S0958-1669(00)00119-1
   Pierce JD, 2007, NURS HEALTH SCI, V9, P52, DOI 10.1111/j.1442-2018.2007.00295.x
   PIERRO L, 1992, RETINA-J RET VIT DIS, V12, P12, DOI 10.1097/00006982-199212010-00003
   Pineiro C, 2003, J PROTEOME RES, V2, P127, DOI 10.1021/pr0200083
   Posadas EM, 2004, CURR OPIN ONCOL, V16, P478, DOI 10.1097/00001622-200409000-00012
   Purcell AW, 2004, MOL CELL PROTEOMICS, V3, P193, DOI 10.1074/mcp.R300013-MCP200
   RAHBAR S, 1986, HEMOGLOBIN, V10, P379, DOI 10.3109/03630268608996869
   REEH S, 1977, J BACTERIOL, V129, P702, DOI 10.1128/JB.129.2.702-706.1977
   Robinson NE, 2005, MOL VIS, V11, P1211
   Robinson NE, 2006, MOL VIS, V12, P704
   Rogers MA, 2003, CANCER RES, V63, P6971
   RUSSELL P, 1991, EXP EYE RES, V52, P613, DOI 10.1016/0014-4835(91)90064-L
   Sakaguchi H, 2003, EXP EYE RES, V76, P131, DOI 10.1016/S0014-4835(02)00249-X
   Schaefer H, 2006, BBA-PROTEINS PROTEOM, V1764, P1948, DOI 10.1016/j.bbapap.2006.10.004
   SCHLOSSHAUER B, 1985, DEV BRAIN RES, V19, P237, DOI 10.1016/0165-3806(85)90195-6
   Schutt F, 2002, FEBS LETT, V528, P217, DOI 10.1016/S0014-5793(02)03312-4
   Secretan M, 1997, Eur J Ophthalmol, V7, P307
   Sellers TA, 2003, GENET EPIDEMIOL, V24, P83, DOI 10.1002/gepi.10226
   SEMPLEROWLAND SL, 1991, ELECTROPHORESIS, V12, P307, DOI 10.1002/elps.1150120414
   Senderowicz AM, 2004, CURR OPIN CELL BIOL, V16, P670, DOI 10.1016/j.ceb.2004.09.014
   Shadforth IP, 2005, BMC GENOMICS, V6, DOI 10.1186/1471-2164-6-145
   Shimizu Akira, 2002, Rinsho Byori, V50, P169
   Sineshchekova OO, 2004, VISUAL NEUROSCI, V21, P715, DOI 10.1017/S0952523804215061
   Smith JC, 2006, MOL BIOSYST, V2, P364, DOI 10.1039/b606798k
   Somiari RI, 2005, J CHROMATOGR B, V815, P215, DOI 10.1016/j.jchromb.2004.11.012
   Sparre T, 2003, EXPERT REV MOL DIAGN, V3, P743, DOI 10.1586/14737159.3.6.743
   Srivastava OP, 2006, MOL VIS, V12, P1615
   Steely H T Jr, 2000, Pharmacogenomics, V1, P267, DOI 10.1517/14622416.1.3.267
   Steinberg TH, 2001, PROTEOMICS, V1, P841, DOI 10.1002/1615-9861(200107)1:7<841::AID-PROT841>3.3.CO;2-5
   Steinert R, 2002, TECHNOL CANCER RES T, V1, P297, DOI 10.1177/153303460200100411
   Stults JT, 2005, METHOD ENZYMOL, V402, P245, DOI 10.1016/S0076-6879(05)02008-2
   Tanito M, 2006, FREE RADICAL BIO MED, V41, P1847, DOI 10.1016/j.freeradbiomed.2006.09.012
   Tew KD, 1996, MOL PHARMACOL, V50, P149
   Tezel G, 2005, INVEST OPHTH VIS SCI, V46, P3177, DOI 10.1167/iovs.05-0208
   Thompson LJ, 2003, PROTEOMICS, V3, P2258, DOI 10.1002/pmic.200300498
   Tonge R, 2001, PROTEOMICS, V1, P377
   Tsai PS, 2006, BRIT J OPHTHALMOL, V90, P372, DOI 10.1136/bjo.2005.080846
   Umeda S, 2005, FASEB J, V19, P1683, DOI 10.1096/fj.04-3525fje
   Unlu M, 1997, ELECTROPHORESIS, V18, P2071, DOI 10.1002/elps.1150181133
   Veenstra TD, 1999, BIOCHEM BIOPH RES CO, V257, P1, DOI 10.1006/bbrc.1998.0103
   Visintin M, 2004, J IMMUNOL METHODS, V290, P135, DOI 10.1016/j.jim.2004.04.014
   Watanabe K, 2001, Tanpakushitsu Kakusan Koso, V46, P80
   Wiechmann AF, 2002, J PINEAL RES, V32, P270, DOI 10.1034/j.1600-079X.2002.01878.x
   Wilkins MR, 1996, BIOTECHNOL GENET ENG, V13, P19, DOI 10.1080/02648725.1996.10647923
   Wilson KE, 2004, J NEUROL NEUROSUR PS, V75, P529, DOI 10.1136/jnnp.2003.026260
   Wodarczyk L, 1997, J NEUROCHEM, V68, P1114
   Wohabrebbi A, 2002, J NEUROSCI RES, V67, P298, DOI 10.1002/jnr.10106
   Wu CH, 2003, NUCLEIC ACIDS RES, V31, P345, DOI 10.1093/nar/gkg040
   Wu CW, 2004, AM J OPHTHALMOL, V137, P655, DOI 10.1016/j.ajo.2003.11.009
   Wu J, 2005, ELECTROPHORESIS, V26, P225, DOI 10.1002/elps.200406176
   Wu Y, 1999, Yan Ke Xue Bao, V15, P32
   Yamane K, 2003, MOL CELL PROTEOMICS, V2, P1177, DOI 10.1074/mcp.M300038-MCP200
   Yi R, 2004, PROTEOMICS, V4, P3477, DOI 10.1002/pmic.200400897
   Yip TTC, 2005, CLIN CHEM, V51, P47, DOI 10.1373/clinchem.2004.031229
   Zanello SB, 2006, CURR EYE RES, V31, P825, DOI 10.1080/02713680600878816
   Zhao XJ, 2004, INVEST OPHTH VIS SCI, V45, P4023, DOI 10.1167/iovs.04-0535
   Zhou L, 2003, RAPID COMMUN MASS SP, V17, P401, DOI 10.1002/rcm.925
NR 170
TC 15
Z9 17
U1 0
U2 6
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0816-4622
EI 1444-0938
J9 CLIN EXP OPTOM
JI Clin. Exp. Optom.
PD JAN
PY 2008
VL 91
IS 1
BP 23
EP 33
DI 10.1111/j.1444-0938.2007.00194.x
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 235QP
UT WOS:000251249700004
PM 18045249
OA Bronze
DA 2022-11-30
ER

PT J
AU Kim, JH
   Kim, JW
   Kim, CG
   Lee, DW
AF Kim, Jae Hui
   Kim, Jong Woo
   Kim, Chul Gu
   Lee, Dong Won
TI LONG-TERM CHANGES IN CHOROIDAL THICKNESS IN EYES WITH TYPE 3 MACULAR
   NEOVASCULARIZATION
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE Type 3 macular neovascularization; retinal angiomatous proliferation;
   age-related macular degeneration; choroidal thickness; anti-vascular
   endothelial growth factor
ID RETINAL ANGIOMATOUS PROLIFERATION; AFLIBERCEPT THERAPY; DEGENERATION;
   VASCULOPATHY; RANIBIZUMAB; SUBTYPES; RISK
AB Purpose: To evaluate the long-term changes in subfoveal choroidal thickness (SCT) in eyes with Type 3 macular neovascularization that underwent anti-vascular endothelial growth factor therapy. Methods: This retrospective study was performed with 47 patients diagnosed with Type 3 macular neovascularization and treated with anti-vascular endothelial growth factor therapy. All the patients initially received three loading injections. The SCT was compared at diagnosis, 3 months, 12 months, and at the final follow-up visit. The velocity of changes in SCT was also compared between each period. Results: The mean follow-up period was 52.1 +/- 11.0 months. The mean SCT was 143.3 +/- 51.2 mu m at diagnosis, and it had significantly decreased to 128.6 +/- 47.4 mu m at 3 months (P < 0.001), 123.2 +/- 45.7 mu m at 12 months (P < 0.001), and 110.0 +/- 43.0 mu m at the final follow-up (P < 0.001). The mean velocity of the decrease in SCT was 4.9 +/- 3.9 mu m per month during the first 3 months, 0.6 +/- 1.2 mu m per month between the 3rd and the 12th months, and 0.3 +/- 0.3 mu m per month between the 12th month and the final follow-up. The velocity of the decrease was significantly greater during the first 3 months than during the 3rd to 12th month (P < 0.001) and 12th month to final follow-up (P < 0.001) periods. The difference was not significant between the 3rd to 12th month and 12th months to final follow-up (P = 0.836) periods. Conclusion: Subfoveal choroidal thickness continuously decreased over time, with a significant decrease of 23% noted in eyes with Type 3 macular neovascularization. The thickness rapidly decreased during the initial loading phase. Subsequently, a continuous but gradual decrease in the thickness was noted.
C1 [Kim, Jae Hui; Kim, Jong Woo; Kim, Chul Gu; Lee, Dong Won] Konyang Univ, Kims Eye Hosp, Dept Ophthalmol, Coll Med, Seoul, South Korea.
C3 Konyang University; Konyang University Hospital
RP Kim, JH (通讯作者)，Kims Eye Hosp, Dept Ophthalmol, 156 Youngdeungpo Dong 4Ga, Seoul 150034, South Korea.
EM kimoph@gmail.com
FU Kim's Eye Hospital Research Center
FX Supported by Kim's Eye Hospital Research Center.
CR Arias L, 2020, RETINA-J RET VIT DIS, V40, P1234, DOI 10.1097/IAE.0000000000002582
   Bakri SJ, 2019, OPHTHALMOLOGY, V126, P55, DOI 10.1016/j.ophtha.2018.07.028
   Borrelli E, 2018, RETINA-J RET VIT DIS, V38, P1968, DOI 10.1097/IAE.0000000000002198
   Cho HJ, 2015, AM J OPHTHALMOL, V159, P285, DOI 10.1016/j.ajo.2014.10.035
   Freund KB, 2008, RETINA-J RET VIT DIS, V28, P201, DOI 10.1097/IAE.0b013e3181669504
   Gross NE, 2005, RETINA-J RET VIT DIS, V25, P713, DOI 10.1097/00006982-200509000-00005
   Jung JJ, 2014, AM J OPHTHALMOL, V158, P769, DOI 10.1016/j.ajo.2014.07.006
   Kim JH, 2019, RETINA-J RET VIT DIS, V39, P1672, DOI 10.1097/IAE.0000000000002239
   Kim JH, 2016, BRIT J OPHTHALMOL, V100, P1634, DOI 10.1136/bjophthalmol-2015-308074
   Kim JH, 2015, RETINA-J RET VIT DIS, V35, P2604, DOI 10.1097/IAE.0000000000000633
   Kim JH, 2015, AM J OPHTHALMOL, V160, P207, DOI 10.1016/j.ajo.2015.04.010
   Kim JH, 2013, AM J OPHTHALMOL, V155, P743, DOI 10.1016/j.ajo.2012.11.001
   Kim YK, 2016, RETINA-J RET VIT DIS, V36, P1516, DOI 10.1097/IAE.0000000000000952
   Koizumi H, 2016, OPHTHALMOLOGY, V123, P617, DOI 10.1016/j.ophtha.2015.10.039
   Liu Y, 2007, GRAEF ARCH CLIN EXP, V245, P1441, DOI 10.1007/s00417-007-0575-8
   Nagiel A, 2015, RETINA-J RET VIT DIS, V35, P638, DOI 10.1097/IAE.0000000000000488
   Palkovits S, 2017, RETINA-J RET VIT DIS, V37, P2262, DOI 10.1097/IAE.0000000000001480
   Rahman W, 2013, GRAEF ARCH CLIN EXP, V251, P1483, DOI 10.1007/s00417-012-2199-x
   Sizmaz S, 2014, EUR J OPHTHALMOL, V24, P904, DOI 10.5301/ejo.5000478
   Su D, 2016, RETINA-J RET VIT DIS, V36, pS40, DOI 10.1097/IAE.0000000000001268
   Ting DSW, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-08276-4
   Ting DSW, 2016, AM J OPHTHALMOL, V164, P128, DOI 10.1016/j.ajo.2015.12.024
   Yamazaki T, 2014, RETINA-J RET VIT DIS, V34, P1316, DOI 10.1097/IAE.0000000000000086
   Yamazaki T, 2012, OPHTHALMOLOGY, V119, P1621, DOI 10.1016/j.ophtha.2012.02.022
   Yannuzzi LA, 2001, RETINA-J RET VIT DIS, V21, P416, DOI 10.1097/00006982-200110000-00003
NR 25
TC 3
Z9 3
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD JUN
PY 2021
VL 41
IS 6
BP 1251
EP 1258
DI 10.1097/IAE.0000000000003010
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA SO2SL
UT WOS:000658826900015
PM 33136977
DA 2022-11-30
ER

PT J
AU Hammond, BR
   Johnson, MA
AF Hammond, BR
   Johnson, MA
TI The Age-related Eye Disease Study (AREDS)
SO NUTRITION REVIEWS
LA English
DT Review
ID MACULAR DEGENERATION; CATARACT-EXTRACTION; BETA-CAROTENE; ZINC INTAKE;
   ANTIOXIDANT; MACULOPATHY; SUPPLEMENTS; PIGMENT; LUTEIN; COPPER
AB Some of the earliest and best known manifestations of malnutrition involve visual disorders, such as blindness that results from vitamin A deficiency. Interest is now being focused on the role of nutrition in the prevention and treatment of chronic, age-related disorders. The Age-related Eye Disease. Study (AREDS) was conducted in order. to determine whether high-dose supplementation could influence the natural progression of eye disease in older Americans. AREDS found that prospective administration of purified vitamin C, vitamin E, beta-carotene, zinc, and copper had some benefits for age-related maculopathy, but had virtually no impact on the progression of cataracts.
C1 Univ Georgia, Dept Foods & Nutr, Vis Sci Lab, Athens, GA 30602 USA.
C3 University System of Georgia; University of Georgia
RP Hammond, BR (通讯作者)，Univ Georgia, Dept Foods & Nutr, Vis Sci Lab, Athens, GA 30602 USA.
OI Hammond, Billy/0000-0002-5762-0206
CR *AG REL EYE DIS ST, WISC CAT GRAD SYST A
   Age-Related Eye Disease Study Research Group, 2001, ARCH OPHTHALMOL-CHIC, V119, P1439
   AKYOL N, 1990, BRIT J OPHTHALMOL, V74, P661, DOI 10.1136/bjo.74.11.661
   [Anonymous], 2002, VIS PROBL US PREV AD
   BABIZHAYEV MA, 1994, BBA-MOL BASIS DIS, V1225, P326, DOI 10.1016/0925-4439(94)90014-0
   Beatty S, 1999, BRIT J OPHTHALMOL, V83, P867, DOI 10.1136/bjo.83.7.867
   BELPOLITI M, 1993, INVEST OPHTH VIS SCI, V34, P2843
   Brown L, 1999, AM J CLIN NUTR, V70, P517
   Cai JY, 2000, PROG RETIN EYE RES, V19, P205, DOI 10.1016/S1350-9462(99)00009-9
   Chasan-Taber L, 1999, EPIDEMIOLOGY, V10, P679, DOI 10.1097/00001648-199911000-00006
   Cho EY, 2001, ANN EPIDEMIOL, V11, P328, DOI 10.1016/S1047-2797(01)00217-4
   Christen WG, 1999, P ASSOC AM PHYSICIAN, V111, P16, DOI 10.1046/j.1525-1381.1999.09231.x
   Delcourt C, 1999, ARCH OPHTHALMOL-CHIC, V117, P1384, DOI 10.1001/archopht.117.10.1384
   FRIEDMAN DS, 2002, 2002 ANN M ABSTR PRO
   Hammond BR, 2002, INVEST OPHTH VIS SCI, V43, P47
   HEIBA IM, 1993, AM J MED GENET, V47, P1208, DOI 10.1002/ajmg.1320470816
   HEIBA IM, 1995, INVEST OPHTH VIS SCI, V36, P227
   *IT CAT STUD GROUP, 1991, AM J EPIDEMIOL, V133, P541
   Jacques PF, 1997, AM J CLIN NUTR, V66, P911, DOI 10.1093/ajcn/66.4.911
   Johnson MA, 1998, AM J CLIN NUTR, V67, p1035S, DOI 10.1093/ajcn/67.5.1035S
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   KOSTIC D, 1995, AM J CLIN NUTR, V62, P604, DOI 10.1093/ajcn/62.3.604
   Mares-Perlman J.A., 1999, CRC MOD NUT, P181
   MICOZZI MS, 1992, AM J CLIN NUTR, V55, P1120, DOI 10.1093/ajcn/55.6.1120
   *NAT AC SCI, 2001, DIET REF INT VIT C V
   National Academy of Science, 2002, DIET REF INT VIT A V
   NEWSOME DA, 1988, ARCH OPHTHALMOL-CHIC, V106, P192
   Olmedilla B, 2001, J SCI FOOD AGR, V81, P904, DOI 10.1002/jsfa.905
   Richer S, 1999, J Am Optom Assoc, V70, P24
   RICHER S, 2002, 2002 ANN M ABSTR PRO
   Rouhiainen P, 1996, AM J EPIDEMIOL, V144, P496, DOI 10.1093/oxfordjournals.aje.a008956
   Sharma S, 2001, CAN J OPHTHALMOL, V36, P7, DOI 10.1016/S0008-4182(01)80060-0
   Smith W, 1999, OPHTHALMOLOGY, V106, P761, DOI 10.1016/S0161-6420(99)90164-1
   TAYLOR A, 2001, OXIDAT STRESS DIS, V7, P457
   VandenLangenberg GM, 1998, AM J EPIDEMIOL, V148, P204, DOI 10.1093/oxfordjournals.aje.a009625
   Young R. W., 1991, AGE RELATED CATARACT
NR 36
TC 12
Z9 13
U1 0
U2 14
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0029-6643
EI 1753-4887
J9 NUTR REV
JI Nutr. Rev.
PD SEP
PY 2002
VL 60
IS 9
BP 283
EP 288
PG 6
WC Nutrition & Dietetics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Nutrition & Dietetics
GA 593TT
UT WOS:000178010100005
PM 12296455
DA 2022-11-30
ER

PT J
AU van Leeuwen, R
   Vingerling, JR
   Hofman, A
   de Jong, PTVM
   Stricker, BH
AF van Leeuwen, R
   Vingerling, JR
   Hofman, A
   de Jong, PTVM
   Stricker, BH
TI Cholesterol lowering drugs and risk of age related maculopathy:
   prospective cohort study with cumulative exposure measurement
SO BRITISH MEDICAL JOURNAL
LA English
DT Article
ID MACULAR DEGENERATION
C1 Erasmus Med Ctr Rotterdam, Dept Epidemiol & Biostat, NL-3000 DR Rotterdam, Netherlands.
   Erasmus Med Ctr Rotterdam, Dept Ophthalmol, NL-3000 CA Rotterdam, Netherlands.
C3 Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam;
   Erasmus MC
RP de Jong, PTVM (通讯作者)，Netherlands Ophthalm Res Inst, KNAW, Meibergdreef 47, NL-1105 BA Amsterdam, Netherlands.
CR Arnold JJ, 2000, BRIT MED J, V321, P741, DOI 10.1136/bmj.321.7263.741
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Hall NF, 2001, BRIT MED J, V323, P375, DOI 10.1136/bmj.323.7309.375
   in 't Veld BA, 2001, NEW ENGL J MED, V345, P1515, DOI 10.1056/NEJMoa010178
   McCarty CA, 2001, MED J AUSTRALIA, V175, P340, DOI 10.5694/j.1326-5377.2001.tb143604.x
NR 5
TC 60
Z9 61
U1 0
U2 3
PU BRITISH MED JOURNAL PUBL GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0959-535X
J9 BRIT MED J
JI Br. Med. J.
PD FEB 1
PY 2003
VL 326
IS 7383
BP 255
EP 256
DI 10.1136/bmj.326.7383.255
PG 2
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA 644FY
UT WOS:000180908300019
PM 12560276
OA Green Published, Bronze, Green Submitted
DA 2022-11-30
ER

PT J
AU Schaumberg, DA
   Christen, WG
   Kozlowski, P
   Miller, DT
   Ridker, PM
   Zee, RYL
AF Schaumberg, Debra A.
   Christen, William G.
   Kozlowski, Piotr
   Miller, David T.
   Ridker, Paul M.
   Zee, Robert Y. L.
TI A prospective assessment of the Y402H variant in complement factor H,
   genetic variants in C-reactive protein, and risk of age-related macular
   degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID HAPLOTYPE RECONSTRUCTION; CIGARETTE-SMOKING; PROMOTER REGION; COMMON;
   ASSOCIATION; SUSCEPTIBILITY; POLYMORPHISM; DRUSEN; INFLAMMATION;
   MACULOPATHY
AB PURPOSE. Two biologically related factors, complement factor H (CFH) and C-reactive protein (CRP), have been associated with AMD. The Y402H variant of CFH is located within the binding site of CFH for CRP. Although plasma CRP levels have been related to AMD and plasma CRP levels are partly determined by genetic variation, there is no information on whether genetic variants in CRP are associated with AMD.
   METHODS. A prospective analysis was performed of 111 men who eventually de,eloped AMD and 401 men who remained free of AMD, all participants in the Physicians' Health Study. Genotypes were determined for the common T -> C single nucleotide polymorphism (SNP) in exon 9 of CFH (rs 1061170; protein Y402H), as well as seven previously described CRP SNPs (rs3093059, rs2794521, rs3091244, rs1417938, rs1800947, rs1130864, and rs1205). Logistic regression analysis was used to evaluate individual SNPs, as well as six CRP haplotypes for association with AMD.
   RESULTS. The high-risk C allele of CFH was present in 45% of cases and 34% of controls. An odds ratio (OR) of 1.46 was observed for AMD (95% confidence interval [CI]: 1.05-2.04) for TC heterozygotes and an OR of 2.13 (95% CI: 1.10-4.16) for CC homozygotes, assuming a multiplicative (log-additive) model and attributable fraction of 25% (95% CI: 1% to 44%) was calculated. For CRP, single-marker or haplotype-based analysis failed to reveal any significant associations with a risk of AMD.
   CONCLUSIONS. These prospective data confirmed an association between the Y402H variant of CFH and a risk of AMD. In contrast, although a biologically plausible, genetic variation in CRP does not appear to be associated with a risk of AMD. Further prospective studies of a larger number of subjects are needed to substantiate available information on the genetic epidemiology of AMD.
C1 Brigham & Womens Hosp, Div Prevent Med, Boston, MA 02115 USA.
   Brigham & Womens Hosp, Div Hematol, Boston, MA 02115 USA.
   Brigham & Womens Hosp, Ctr Cardiovasc Dis Prevent, Boston, MA 02115 USA.
   Harvard Univ, Sch Med, Dept Ophthalmol, Boston, MA 02115 USA.
   Childrens Hosp, Div Genet, Boston, MA 02115 USA.
C3 Harvard University; Brigham & Women's Hospital; Harvard University;
   Brigham & Women's Hospital; Harvard University; Brigham & Women's
   Hospital; Harvard University; Harvard Medical School; Harvard
   University; Boston Children's Hospital
RP Schaumberg, DA (通讯作者)，900 Commonwealth Ave E,3rd Floor, Boston, MA 02215 USA.
EM dschaumberg@rics.bwh.harvard.edu
RI Kozlowski, Piotr/I-1860-2019
OI Kozlowski, Piotr/0000-0003-3770-7715
FU NCI NIH HHS [R01 CA034944, R01 CA040360, CA-34944, CA-40360] Funding
   Source: Medline; NEI NIH HHS [EY-013834, EY-06633, R01 EY013834, R01
   EY013834-01A1] Funding Source: Medline; NHLBI NIH HHS [R01 HL034595,
   HL-34595, HL-26490, R01 HL026490] Funding Source: Medline; NATIONAL
   CANCER INSTITUTE [R01CA040360] Funding Source: NIH RePORTER; NATIONAL
   EYE INSTITUTE [R01EY006633, R01EY013834] Funding Source: NIH RePORTER;
   NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL034595] Funding Source:
   NIH RePORTER
CR Ballou SP, 1997, CLIN GERIATR MED, V13, P653
   Bar H, 2005, HUM MOL GENET, V14, P1251, DOI 10.1093/hmg/ddi136
   Carlson CS, 2005, AM J HUM GENET, V77, P64, DOI 10.1086/431366
   Christen WG, 1999, AM J EPIDEMIOL, V149, P476, DOI 10.1093/oxfordjournals.aje.a009836
   Christen WG, 1996, JAMA-J AM MED ASSOC, V276, P1147, DOI 10.1001/jama.276.14.1147
   Conley YP, 2005, HUM MOL GENET, V14, P1991, DOI 10.1093/hmg/ddi204
   DEVLIN B, 1995, GENOMICS, V29, P311, DOI 10.1006/geno.1995.9003
   Du Clos TW, 2000, ANN MED, V32, P274, DOI 10.3109/07853890009011772
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Franceschi C, 2000, ANN NY ACAD SCI, V908, P244
   Giannakis E, 2003, EUR J IMMUNOL, V33, P962, DOI 10.1002/eji.200323541
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Johnson LV, 2000, EXP EYE RES, V70, P441, DOI 10.1006/exer.1999.0798
   Klein R, 2005, AM J OPHTHALMOL, V140, P35, DOI 10.1016/j.ajo.2005.01.051
   Klein R, 2003, OPHTHALMOLOGY, V110, P25, DOI 10.1016/S0161-6420(02)01565-8
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kovacs A, 2005, ATHEROSCLEROSIS, V178, P193, DOI 10.1016/j.atherosclerosis.2004.08.018
   Lavrovsky Y, 2000, EXP GERONTOL, V35, P521, DOI 10.1016/S0531-5565(00)00118-2
   Lohmueller KE, 2003, NAT GENET, V33, P177, DOI 10.1038/ng1071
   McGwin G, 2005, BRIT J OPHTHALMOL, V89, P1166, DOI 10.1136/bjo.2005.067397
   Miller DT, 2005, ANN HUM GENET, V69, P623, DOI 10.1111/j.1529-8817.2005.00210.x
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Rothman KJ, 1998, MODERN EPIDEMIOLOGY, P133
   Schaumberg DA, 2001, ARCH OPHTHALMOL-CHIC, V119, P1259
   Schaumberg DA, 2006, INVEST OPHTH VIS SCI, V47, P2336, DOI 10.1167/iovs.05-1456
   Schlesselman J.J., 1982, CASE CONTROL STUDIES
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P774, DOI 10.1001/archopht.123.6.774
   Seddon JM, 2004, JAMA-J AM MED ASSOC, V291, P704, DOI 10.1001/jama.291.6.704
   Seddon JM, 1996, JAMA-J AM MED ASSOC, V276, P1141, DOI 10.1001/jama.276.14.1141
   Stephens M, 2003, AM J HUM GENET, V73, P1162, DOI 10.1086/379378
   Stephens M, 2001, AM J HUM GENET, V68, P978, DOI 10.1086/319501
   Wallenstein S, 1998, GENET EPIDEMIOL, V15, P173, DOI 10.1002/(SICI)1098-2272(1998)15:2<173::AID-GEPI5>3.3.CO;2-8
   WALTER SD, 1976, BIOMETRICS, V32, P829, DOI 10.2307/2529268
   Winkler BS, 1999, MOL VIS, V5
   Zareparsi S, 2005, AM J HUM GENET, V77, P149, DOI 10.1086/431426
   ZEE RY, 2005, ATHEROSCLEROSIS 1013
NR 39
TC 61
Z9 67
U1 0
U2 4
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD JUN
PY 2006
VL 47
IS 6
BP 2336
EP 2340
DI 10.1167/iovs.05-1456
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 048LQ
UT WOS:000237949000012
PM 16723442
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Takashima, K
   Inoue, Y
   Tashiro, S
   Muto, K
AF Takashima, Kayo
   Inoue, Yusuke
   Tashiro, Shimon
   Muto, Kaori
TI Lessons for reviewing clinical trials using induced pluripotent stem
   cells: examining the case of a first-in-human trial for age-related
   macular degeneration
SO REGENERATIVE MEDICINE
LA English
DT Review
DE age-related macular degeneration; AMD; committee meeting minutes; direct
   benefit; first-in-human trial; induced pluripotent stem cell; iPSC;
   reasonable accommodation; protecting research participants; review
   committee; risk assessment; subject selection
C1 [Takashima, Kayo; Inoue, Yusuke; Muto, Kaori] Univ Tokyo, Inst Med Sci, Dept Publ Policy, Tokyo, Japan.
   [Tashiro, Shimon] Natl Canc Ctr, Ctr Publ Hlth Sci, Bioeth Sect, Tokyo, Japan.
C3 University of Tokyo; National Cancer Center - Japan
RP Takashima, K (通讯作者)，Univ Tokyo, Inst Med Sci, Dept Publ Policy, Tokyo, Japan.
EM kayot-tky@umin.ac.jp
RI Takashima, Kayo/ABA-2057-2020; Tashiro, Shimon/GNP-6380-2022; Takashima,
   Kayo/AAW-6904-2021
OI Takashima, Kayo/0000-0001-5891-6052; Inoue, Yusuke/0000-0003-4298-9737;
   Tashiro, Shimon/0000-0002-6734-9149
FU Highway Program for Realization of Regenerative Medicine from the Japan
   Agency for Medical Research and Development (AMED); AMED
FX This research was supported by the Highway Program for Realization of
   Regenerative Medicine from the Japan Agency for Medical Research and
   Development (AMED). The authors have no other relevant affiliations or
   financial involvement with any organization or entity with a financial
   interest in or financial conflict with the subject matter or materials
   discussed in the manuscript apart from those disclosed.; Funded writing
   assistance (English editing service) for this manuscript was supported
   by AMED.
CR [Anonymous], 2014, IPS RES EOPCH MAKING
   Benjaminy S, 2015, AM J OPHTHALMOL, V160, P408, DOI 10.1016/j.ajo.2015.05.026
   Committee for Science and Technology the Ministry of Health Labor and Welfare, 2012, HANDL CLIN RES AG RE
   Dresser R., 2002, SCI OFFERS SALVATION, P8
   Fox C., 2013, BIOSCIENCE TECHNOLOG
   Habets MGJL, 2014, REGEN MED, V9, P1, DOI [10.2217/RME.13.83, 10.2217/rme.13.83]
   International Society for Stem Cell Research, 2016, PHYT ROADM RES TRANS
   Kimmelman J., 2009, GENE TRANSFER ETHICS, P1
   King NMP, 2000, J LAW MED ETHICS, V28, P332, DOI 10.1111/j.1748-720X.2000.tb00685.x
   Lidz CW, 2015, CAMB Q HEALTHC ETHIC, V24, P231, DOI 10.1017/S096318011400053X
   Mandai M, 2017, NEW ENGL J MED, V376, P1038, DOI 10.1056/NEJMoa1608368
   Nakano-Okuno M, 2014, STEM CELL REV REP, V10, P743, DOI 10.1007/s12015-014-9536-x
   Peterson M, 2007, EMBO REP, V8, P305, DOI 10.1038/sj.embor.7400947
   Reardon S., 2014, NATURE NEWS
   Riken and Foundation for Biomedical Research and Innovation, PIL SAF STUD IPSC BA
   Takahashi M, 2014, COLLABORATION CLIN R
   UNCRPD, 2006, LAWS-BASEL
NR 17
TC 12
Z9 13
U1 0
U2 7
PU FUTURE MEDICINE LTD
PI LONDON
PA UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3
   1QB, ENGLAND
SN 1746-0751
EI 1746-076X
J9 REGEN MED
JI Regen. Med.
PD MAR
PY 2018
VL 13
IS 2
BP 125
EP 130
DI 10.2217/rme-2017-0130
PG 6
WC Cell & Tissue Engineering; Engineering, Biomedical
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Engineering
GA GC2OQ
UT WOS:000429622800002
PM 29210321
OA hybrid
DA 2022-11-30
ER

PT J
AU Wang, JY
   Ying, GS
AF Wang, Jianyong
   Ying, Gui-Shuang
TI Growth Rate of Geographic Atrophy Secondary to Age-Related Macular
   Degeneration: A Meta-Analysis of Natural History Studies and
   Implications for Designing Future Trials
SO OPHTHALMIC RESEARCH
LA English
DT Article
DE Sample size; Clinical trial; Geographic atrophy; Growth rate; Natural
   history
ID FUNDUS AUTOFLUORESCENCE PATTERNS; EYE DISEASE; PROGRESSION; ENLARGEMENT;
   AREA
AB Introduction: There is no effective treatment for geographic atrophy (GA). To help design future GA treatment trials, we conducted a meta-analysis for GA growth rate and its variability in natural history studies. Methods: Literatures were searched up to April 30, 2020. Data were extracted independently by 2 authors and analyzed using random-effects models. Results: The pooled mean GA growth rate was 1.66 mm(2)/year (SD = 1.27 mm(2)/year, I-2 = 97.0%, p < 0.001) from 23 studies (3,078 patients) reported with growth rate in mm(2)/year and 0.33 mm/year (SD = 0.17 mm/year, I-2 = 83.0%, p < 0.001) from 12 studies (1,808 patients) reported with growth rate in mm/year. Larger mean baseline GA area in mm(2) was associated with larger mean growth rate in both mm(2)/year and mm/year (p < 0.001). The sample size at 85% power for detecting 15% reduction in growth rate in a 2-arm GA trial is 464 and 209 patients per arm, respectively, for using mm(2)/year and mm/year as the primary outcome. Discussion/Conclusion: GA natural history studies had a pooled mean (SD) GA growth rate of 1.66 (1.27) mm(2)/year or 0.33 (0.17) mm/year. Because GA growth rate using mm/year requires smaller sample size than using mm(2)/year, GA growth rate in mm/year is recommended as the primary outcome measure for future GA trials.
C1 [Wang, Jianyong] Zhejiang Univ, Affiliated Hosp 1, Coll Med, Dept Ophthalmol, Hangzhou, Peoples R China.
   [Ying, Gui-Shuang] Univ Penn, Ctr Prevent Ophthalmol & Biostat, Perelman Sch Med, Dept Ophthalmol, Philadelphia, PA 19104 USA.
C3 Zhejiang University; University of Pennsylvania; Pennsylvania Medicine
RP Ying, GS (通讯作者)，Univ Penn, Ctr Prevent Ophthalmol & Biostat, Dept Ophthalmol, Philadelphia, PA 19104 USA.
EM gsying@pennmedicine.upenn.edu
CR Abdillahi H, 2014, OPHTHALMOLOGY, V121, P1734, DOI 10.1016/j.ophtha.2014.03.036
   Batioglu F, 2014, OPHTHALMIC RES, V52, P53, DOI 10.1159/000361077
   Biarnes M, 2015, AM J OPHTHALMOL, V160, P345, DOI 10.1016/j.ajo.2015.05.009
   Caire J, 2014, JAMA OPHTHALMOL, V132, P528, DOI 10.1001/jamaophthalmol.2013.8175
   Cheng QE, 2018, OPHTHALMOL RETINA, V2, P518, DOI 10.1016/j.oret.2017.08.018
   Feuer WJ, 2013, JAMA OPHTHALMOL, V131, P110, DOI 10.1001/jamaophthalmol.2013.572
   Fleckenstein M, 2018, OPHTHALMOLOGY, V125, P369, DOI 10.1016/j.ophtha.2017.08.038
   Grassmann F, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0126636
   Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186
   Holekamp N, 2020, OPHTHALMOLOGY, V127, P769, DOI 10.1016/j.ophtha.2019.12.009
   Holz FG, 2007, AM J OPHTHALMOL, V143, P463, DOI 10.1016/j.ajo.2006.11.041
   Holz FG, 2018, JAMA OPHTHALMOL, V136, P666, DOI 10.1001/jamaophthalmol.2018.1544
   Holz FG, 2014, OPHTHALMOLOGY, V121, P1079, DOI 10.1016/j.ophtha.2013.11.023
   Jaffe GJ, 2015, AM J OPHTHALMOL, V160, P1226, DOI 10.1016/j.ajo.2015.08.024
   Jeong YJ, 2014, EYE, V28, P209, DOI 10.1038/eye.2013.275
   Keenan TD, 2018, OPHTHALMOLOGY, V125, P1913, DOI 10.1016/j.ophtha.2018.05.028
   Kim BJ, 2020, OPHTHALMOL RETINA, V4, P889, DOI 10.1016/j.oret.2020.03.019
   Klein ML, 2010, OPHTHALMOLOGY, V117, P1554, DOI 10.1016/j.ophtha.2009.12.012
   Klein R, 2008, AM J OPHTHALMOL, V146, P692, DOI 10.1016/j.ajo.2008.05.050
   Kuppermann BD, 2020, PHASE 2 STUDY SAFETY
   Liao DS, 2020, OPHTHALMOLOGY, V127, P186, DOI 10.1016/j.ophtha.2019.07.011
   Lindblad AS, 2009, ARCH OPHTHALMOL-CHIC, V127, P1168, DOI 10.1001/archophthalmol.2009.198
   Marsiglia M, 2013, INVEST OPHTH VIS SCI, V54, P7362, DOI 10.1167/iovs.12-11073
   Mata NL, 2013, RETINA-J RET VIT DIS, V33, P498, DOI 10.1097/IAE.0b013e318265801d
   Mones J, 2018, TRANSL VIS SCI TECHN, V7, DOI 10.1167/tvst.7.6.40
   Nunes RP, 2013, OSLI RETINA, V44, P344, DOI 10.3928/23258160-20130715-06
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Sadda SR, 2016, RETINA-J RET VIT DIS, V36, P1806, DOI 10.1097/IAE.0000000000001283
   Schmitz-Valckenberg S, 2016, RETINA-J RET VIT DIS, V36, P2250, DOI 10.1097/IAE.0000000000001258
   Schmitz-Valckenberg S, 2016, OPHTHALMOLOGY, V123, P361, DOI 10.1016/j.ophtha.2015.09.036
   Shen LB, 2018, OPHTHALMOL RETINA, V2, P914, DOI 10.1016/j.oret.2018.01.019
   Shen LBL, 2019, OPHTHALMOL RETINA, V3, P305, DOI 10.1016/j.oret.2018.11.013
   Shen LL, 2019, RECLASSIFICATION FUN
   Simader C, 2014, AM J OPHTHALMOL, V158, P557, DOI 10.1016/j.ajo.2014.05.026
   Stetson PF, 2014, INVEST OPHTH VIS SCI, V55, P792, DOI 10.1167/iovs.13-13199
   Stroup DF, 2000, JAMA-J AM MED ASSOC, V283, P2008, DOI 10.1001/jama.283.15.2008
   Sunness JS, 2007, OPHTHALMOLOGY, V114, P271, DOI 10.1016/j.ophtha.2006.09.016
   Sunness JS, 1999, OPHTHALMOLOGY, V106, P1768, DOI 10.1016/S0161-6420(99)90340-8
   Wallace BC, 2009, BMC MED RES METHODOL, V9, DOI 10.1186/1471-2288-9-80
   Wan X, 2014, BMC MED RES METHODOL, V14, DOI 10.1186/1471-2288-14-135
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yaspan BL, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aaf1443
   Yehoshua Z, 2014, OPHTHALMOLOGY, V121, P693, DOI 10.1016/j.ophtha.2013.09.044
   Yehoshua Z, 2011, OPHTHALMOLOGY, V118, P679, DOI 10.1016/j.ophtha.2010.08.018
   Zhang K, 2011, P NATL ACAD SCI USA, V108, P6241, DOI 10.1073/pnas.1018987108
NR 45
TC 5
Z9 5
U1 0
U2 4
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3747
EI 1423-0259
J9 OPHTHALMIC RES
JI Ophthalmic Res.
PD MAR
PY 2021
VL 64
IS 2
BP 205
EP 215
DI 10.1159/000510507
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA QU7CX
UT WOS:000627438300005
PM 32721951
OA Bronze
DA 2022-11-30
ER

PT J
AU Fong, CSU
   Mitchell, P
   Rochtchina, E
   Cugati, S
   Hong, T
   Wang, JJ
AF Fong, Calvin Sze-Un
   Mitchell, Paul
   Rochtchina, Elena
   Cugati, Sudha
   Hong, Thomas
   Wang, Jie Jin
TI Three-Year Incidence and Factors Associated With Posterior Capsule
   Opacification After Cataract Surgery: The Australian Prospective
   Cataract Surgery and Age-related Macular Degeneration Study
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID ND-YAG CAPSULOTOMY; ACRYLIC INTRAOCULAR LENSES; SINGLE-PIECE;
   IMPLANTATION; 3-PIECE; ACRYSOF; PHACOEMULSIFICATION; RATES; PREVENTION;
   SILICONE
AB PURPOSE: To assess 3-year incidence and associated factors of posterior capsule opacification (PCO) after phacoemulsification surgery.
   DESIGN: Cohort study.
   METHODS: A total of 1934 consecutive patients aged 64 years undergoing phacoemulsification surgery at Westmead Hospital were recruited, of whom 1495 (77.3%) had retroillumination anterior segment images taken of the surgical eyes after 1 month and at a further postoperative visit within 3 years. Severe PCO was defined if the view of the optic disc was obscured, or neodymiumyttrium-aluminum-garnet capsulotomy was performed. Cumulative incidence of PCO was estimated using Kaplan-Meier methods. Associations of PCO with surgeon groups and different types of implanted intraocular lenses (IOLs) were assessed, adjusting for age, sex, diabetes, and ethnicity.
   RESULTS: Three-year cumulative incidence of PCO was 38.5% (95% confidence interval [CI] 36.1%40.9%) among the 1495 patients, including 4.7% (95% CI 3.5%-5.8%) with severe PCO. PCO incidence was higher (49%) in: (1) eyes operated on by junior trainees compared to those by senior ophthalmologist surgeons (36%) (adjusted odds ratio [OR] 1.6, 95% CI 1.2-2.0); and (2) eyes with hydrophobic, 3-piece (either square-edged [51%, OR 2.3, 95% CI 1.4-3.6] or partial-round-edged [39%, OR 1.5, 95% CI 1.1-2.1]), or hydrophilic IOLs (64%, OR 2.9, 95% CI 1.9-4.4) compared to those with single-piece, square-edged, hydrophobic IOLs (34%), after additional adjustment for surgeon group.
   CONCLUSIONS: Predominantly mild PCO occurred in one-third of eyes after phacoemulsification surgery. Possible predisposing factors associated with PCO development include surgery performed by ophthalmologic trainees and the use of hydrophilic or other hydrophobic IOLs apart from the single-piece, square-edged one. (C) 2014 by Elsevier Inc. All rights reserved.
C1 [Fong, Calvin Sze-Un; Mitchell, Paul; Rochtchina, Elena; Cugati, Sudha; Hong, Thomas; Wang, Jie Jin] Univ Sydney, Ctr Vis Res, Dept Ophthalmol, Westmead, NSW 2145, Australia.
   [Fong, Calvin Sze-Un; Mitchell, Paul; Rochtchina, Elena; Cugati, Sudha; Hong, Thomas; Wang, Jie Jin] Univ Sydney, Westmead Millennium Inst, Westmead, NSW 2145, Australia.
   [Cugati, Sudha] Flinders Univ S Australia, Flinders Med Ctr, Dept Ophthalmol, Adelaide, SA 5001, Australia.
   [Wang, Jie Jin] Univ Melbourne, Ctr Eye Res Australia, Melbourne, Vic, Australia.
C3 University of Sydney; University of Sydney; Westmead Institute for
   Medical Research; Flinders Medical Centre; Flinders University South
   Australia; Centre for Eye Research Australia; University of Melbourne
RP Wang, JJ (通讯作者)，Univ Sydney, Westmead Hosp, Ctr Vis Res, Dept Ophthalmol, Hawkesbury Rd, Westmead, NSW 2145, Australia.
EM jiejin.wang@sydney.edu.au
RI Mitchell, Paul/P-1498-2014; Cugati, Sudha/ABB-1331-2021; wang,
   jie/GRS-0942-2022; Wang, Jie Jin/P-1499-2014
OI Wang, Jie Jin/0000-0001-9491-4898
FU Abbott; Novartis; Bayer; National Health & Medical Research Council
   Senior Research Fellowship; National Health & Medical Research Council,
   Australia [302010]; Retina Australia; NHMRC Centres for Clinical
   Research Excellence [529923]
FX THE AUTHORS HAVE COMPLETED AND SUBMITTED THE ICMJE FORM FOR DISCLOSURE
   OF POTENTIAL CONFLICTS OF INTEREST. P.M. serves on Advisory Boards for
   Abbott, Novartis, Bayer, and Bausch & Lomb and has received consultancy
   fees and payment for lectures from Abbott, Novartis, and Bayer. J.J.W.
   is funded by a National Health & Medical Research Council Senior
   Research Fellowship (2005-2014). The Australian Prospective Cataract
   Surgery and Age-related Macular Degeneration study was supported by the
   National Health & Medical Research Council, Australia (Grant No
   302010,2004-2006), Retina Australia (2005), and NHMRC Centres for
   Clinical Research Excellence (Identification No 529923,2009-2013).
   Contributions of authors: study design (J.J.W., P.M.); conduct of the
   study (S.C., C.S.F.); data collection (S.C., C.S.F., T.H.); management
   of the study (J.J.W., P.M.); statistical analyses (E.R.); analysis and
   interpretation of data (E.R., J.J.W., C.S.F.); drafting the manuscript
   (C.S.F., J.J.W.); review of the article (J.J:W., P.M., E.R., S.C., T.H.,
   C.S.F.); and approval of the final version of the article, including
   changes made in the subsequent revision (J.J.W., P.M., E.R., S.C., T.H.,
   C.S.F.). The authors wish to thank Ms Tania de Loryn for managing the
   Australian Prospective Cataract Surgery and Age-related Macular
   Degeneration study, Ms Kirsten Jakobsen for editing the article and
   retinal photographs for publication, and Mr George Burlutsky for
   additional statistical analyses.
CR Ando H, 2003, J CATARACT REFR SURG, V29, P2148, DOI 10.1016/S0886-3350(03)00353-5
   [Anonymous], 1991, OPHTHALMOLOGY, V98, P786
   Auffarth GU, 2004, OPHTHAL EPIDEMIOL, V11, P319, DOI 10.1080/09286580490515116
   Bender LE, 2004, J CATARACT REFR SURG, V30, P786, DOI 10.1016/j.jcrs.2003.08.007
   Bilge AH, 2004, EUR J OPHTHALMOL, V14, P375, DOI 10.1177/112067210401400503
   Cleary G, 2009, J CATARACT REFR SURG, V35, P265, DOI 10.1016/j.jcrs.2008.10.048
   Congdon N, 2008, BRIT J OPHTHALMOL, V92, P598, DOI 10.1136/bjo.2007.126714
   Cugati S, 2007, OPHTHAL EPIDEMIOL, V14, P408, DOI 10.1080/09286580701316124
   DANGEL ME, 1994, OPHTHALMIC SURG LAS, V25, P82
   Elgohary MA, 2006, CLIN EXP OPHTHALMOL, V34, P526, DOI 10.1111/j.1442-9071.2006.1263.x
   Findl O, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003738.pub3
   Gooley TA, 1999, STAT MED, V18, P695, DOI 10.1002/(SICI)1097-0258(19990330)18:6<695::AID-SIM60>3.0.CO;2-O
   Greenberg PB, 2011, OPHTHALMOLOGY, V118, P507, DOI 10.1016/j.ophtha.2010.07.023
   Hancox J, 2007, J CATARACT REFR SURG, V33, P413, DOI 10.1016/j.jcrs.2006.10.056
   Hayashi K, 2005, OPHTHALMOLOGY, V112, P1550, DOI 10.1016/j.ophtha.2005.03.024
   Hayashi K, 2004, BRIT J OPHTHALMOL, V88, P182, DOI 10.1136/bjo.2003.023580
   Heatley CJ, 2005, J CATARACT REFR SURG, V31, P718, DOI 10.1016/j.jcrs.2004.08.060
   Hewitt A, 2002, CLIN EXP OPHTHALMOL, V30, P248, DOI 10.1046/j.1442-9071.2002.00531.x
   Hosmer DW., 1989, APPL LOGISTIC REGRES
   IONIDES A, 1994, EYE, V8, P535, DOI 10.1038/eye.1994.132
   Johansson B, 2010, BRIT J OPHTHALMOL, V94, P450, DOI 10.1136/bjo.2009.166181
   Kobayashi H, 2000, AM J OPHTHALMOL, V130, P310, DOI 10.1016/S0002-9394(00)00490-6
   Kohnen T, 2008, OPHTHALMOLOGY, V115, P1308, DOI 10.1016/j.ophtha.2008.01.002
   Kucuksumer Y, 2000, J CATARACT REFR SURG, V26, P1176, DOI 10.1016/S0886-3350(00)00583-6
   Kugelberg M, 2008, ACTA OPHTHALMOL, V86, P533, DOI 10.1111/j.1600-0420.2007.01094.x
   Leydolt C, 2007, OPHTHALMOLOGY, V114, P1663, DOI 10.1016/j.ophtha.2006.12.016
   Prajna NV, 2000, AM J OPHTHALMOL, V130, P304, DOI 10.1016/S0002-9394(00)00481-5
   Prakash G, 2009, CAN J OPHTHALMOL, V44, P284, DOI 10.3129/i09-051
   Ram J, 2009, CAN J OPHTHALMOL, V44, P160, DOI 10.3129/i09-042
   Stordahl PB, 2003, ACTA OPHTHALMOL SCAN, V81, P326, DOI 10.1034/j.1600-0420.2003.00091.x
   Suh Youngwoo, 2005, Korean J Ophthalmol, V19, P29
   Sundelin K, 2001, J CATARACT REFR SURG, V27, P1586, DOI 10.1016/S0886-3350(01)00998-1
   Vasavada AR, 2011, J CATARACT REFR SURG, V37, P1050, DOI 10.1016/j.jcrs.2010.12.060
   Wallin TR, 2003, AM J OPHTHALMOL, V136, P614, DOI 10.1016/S0002-9394(03)00418-5
   Wang JJ, 2012, OPHTHALMOLOGY, V119, P2298, DOI 10.1016/j.ophtha.2012.07.003
   Zaczek A, 1999, J CATARACT REFR SURG, V25, P233, DOI 10.1016/S0886-3350(99)80132-1
   Zemaitiene R, 2007, BRIT J OPHTHALMOL, V91, P644, DOI 10.1136/bjo.2006.103648
   Zemaitiene R, 2011, MED LITH, V47, P595
NR 38
TC 19
Z9 20
U1 0
U2 12
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD JAN
PY 2014
VL 157
IS 1
BP 171
EP 179
DI 10.1016/j.ajo.2013.08.016
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 283UR
UT WOS:000329273000025
PM 24112632
DA 2022-11-30
ER

PT J
AU Laiginhas, R
   Shi, YY
   Shen, MX
   Jiang, XS
   Feuer, W
   Gregori, G
   Rosenfeld, PJ
AF Laiginhas, Rita
   Shi, Yingying
   Shen, Mengxi
   Jiang, Xiaoshuang
   Feuer, William
   Gregori, Giovanni
   Rosenfeld, Philip J.
TI Persistent Hypertransmission Defects Detected on En Face Swept Source
   Optical Computed Tomography Images Predict the Formation of Geographic
   Atrophy in Age-Related Macular Degeneration
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID OCT; PROGRESSION
AB PURPOSE: To determine whether persistent hypertrans-mission defects (hyperTDs), previously shown to have a greatest linear dimension (GLD) =250 mu m on en face swept source OCT (SS-OCT) images, serve as a stand-alone early biomarker for the future formation geographic atrophy (GA).
   DESIGN: Post hoc cohort study using a subgroup of a prospective study.
   METHODS: Patients with intermediate age-related mac-ular degeneration (iAMD) underwent 6- x 6-mm SS-OCT raster scans at baseline and during their follow-up period. En face images were generated using a slab with segmentation boundaries positioned 64 mu m to 400 mu m be-neath the Bruch's membrane. Two graders independently evaluated all en face structural images for the presence of hyperTDs with a GLD >= 250 mu m and GA.
   RESULTS: A total of 190 eyes were included with a mean +/- SD follow-up of 31 +/- 13.2 months. At baseline, 31 eyes (16%) had at least 1 hyperTD >= 250 mu m, and 13 eyes (42%) progressed to GA. In those eyes without a hy-perTD >= 250 mu m at baseline, 42 (26%) developed hyperTDs >= 250 mu m during their follow-up, and 11 eyes (7%) progressed to GA. At the last available follow-up visit, 25 eyes (13%) progressed to GA and of these 25 eyes, a prior hyperTD >= 250 mu m was detected in 24 eyes before GA formed. A time-dependent Cox-survival regression anal-ysis estimated an 80-fold (95% CI, 10.7-614, P <.001) increased risk of developing GA once a hyperTD >= 250 mu m appeared.
   CONCLUSIONS: Persistent hyperTDs detected on en face OCT images were shown to serve as an early stand-alone OCT biomarker for the future formation of GA. (C) 2021 Elsevier Inc. All rights reserved.
C1 [Laiginhas, Rita; Shi, Yingying; Shen, Mengxi; Jiang, Xiaoshuang; Feuer, William; Gregori, Giovanni; Rosenfeld, Philip J.] Univ Miami, Miller Sch Med, Bascom Palmer Eye Inst, Dept Ophthalmol, Miami, FL USA.
C3 Bascom Palmer Eye Institute; University of Miami
RP Rosenfeld, PJ (通讯作者)，Bascom Palmer Eye Inst, 900 NW 17th St, Miami, FL 33136 USA.
EM prosenfeld@miami.edu
RI Shen, Mengxi/ABC-6941-2021
OI Shen, Mengxi/0000-0002-1336-1695; Rosenfeld, Philip/0000-0002-4068-6671;
   Laiginhas, Rita/0000-0001-7275-6470
FU Carl Zeiss Meditec, Inc; Salah Foundation; National Institutes of Health
   National Eye Institute Center Core Grant [P30EY014801]; Research to
   Prevent Blindness
FX This research was supported by grants from Carl Zeiss Meditec, Inc, the
   Salah Foundation, the National Institutes of Health National Eye
   Institute Center Core Grant (P30EY014801), and Research to Prevent
   Blindness (unrestricted grant) to the Department of Ophthalmology,
   University of Miami Miller School of Medicine. The funding organization
   had no role in the design or conduct of this research.
CR Gharibvand L, 2009, SAS GLOBAL FORUM
   Guymer RH, 2020, OPHTHALMOLOGY, V127, P394, DOI 10.1016/j.ophtha.2019.09.035
   Holz FG, 2014, OPHTHALMOLOGY, V121, P1079, DOI 10.1016/j.ophtha.2013.11.023
   Jaffe GJ, 2021, OPHTHALMOL RETINA, V5, P855, DOI 10.1016/j.oret.2020.12.009
   Jiang XS, 2021, TRANSL VIS SCI TECHN, V10, DOI 10.1167/tvst.10.4.11
   Sadda SR, 2018, OPHTHALMOLOGY, V125, P537, DOI 10.1016/j.ophtha.2017.09.028
   Schaal KB, 2017, AM J OPHTHALMOL, V174, P145, DOI 10.1016/j.ajo.2016.11.002
   Schaal KB, 2016, OPHTHALMOLOGY, V123, P1060, DOI 10.1016/j.ophtha.2016.01.034
   Shi YY, 2021, OPHTHALMOL RETINA, V5, P1214, DOI 10.1016/j.oret.2021.02.004
   Wang RK, 2010, OPT LETT, V35, P1467, DOI 10.1364/OL.35.001467
   Wu Z, 2021, CAM REPORT 6 OPHTHAL, DOI [10.1016/j.oret.2021.03.008, DOI 10.1016/J.ORET.2021.03.008]
   Wu ZC, 2021, OPHTHALMOL RETINA, V5, P118, DOI 10.1016/j.oret.2020.06.026
   Wu ZC, 2020, OPHTHALMOL RETINA, V4, P568, DOI 10.1016/j.oret.2019.12.011
   Wu ZC, 2014, OPHTHALMOLOGY, V121, P2415, DOI 10.1016/j.ophtha.2014.06.034
   Yehoshua Z, 2015, OSLI RETINA, V46, P413, DOI 10.3928/23258160-20150422-03
   Yehoshua Z, 2014, OPHTHALMOLOGY, V121, P693, DOI 10.1016/j.ophtha.2013.09.044
   Yehoshua Z, 2013, OSLI RETINA, V44, P127, DOI 10.3928/23258160-20130313-05
   Yehoshua Z, 2011, OPHTHALMOLOGY, V118, P2434, DOI 10.1016/j.ophtha.2011.05.008
   Yehoshua Z, 2011, OPHTHALMOLOGY, V118, P679, DOI 10.1016/j.ophtha.2010.08.018
   Zhang AQ, 2015, J BIOMED OPT, V20, DOI 10.1117/1.JBO.20.10.100901
NR 20
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD MAY
PY 2022
VL 237
BP 58
EP 70
DI 10.1016/j.ajo.2021.11.001
PG 13
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 3E8KI
UT WOS:000830227300007
PM 34785169
DA 2022-11-30
ER

PT J
AU Shiwani, HA
   Elfaki, MY
   Memon, D
   Ali, S
   Aziz, A
   Egom, EE
AF Shiwani, Haaris A.
   Elfaki, Mohammed Y.
   Memon, Danyal
   Ali, Suhayb
   Aziz, Abdul
   Egom, Emmanuel E.
TI Updates on sphingolipids: Spotlight on retinopathy
SO BIOMEDICINE & PHARMACOTHERAPY
LA English
DT Review
DE Ceramide; Sphingosine-1-phosphate; Sphingosine; Ceramide-1-phosphate;
   Photoreceptor; Retinal pigment epithelium; Age-related macular
   degeneration
ID 1-PHOSPHATE STIMULATES PROLIFERATION; BOVINE RETINAL PERICYTES;
   STRESS-INDUCED APOPTOSIS; PROTEIN-KINASE-C; SPHINGOSINE 1-PHOSPHATE;
   ACID SPHINGOMYELINASE; CATHEPSIN-D; MACULAR DEGENERATION;
   DIABETIC-RETINOPATHY; CERAMIDE METABOLISM
AB The sphingolipids ceramide (Cer), ceramide-1-phosphate (C1P), sphingosine (Sph), and sphingosine-1-phosphate (S1P)) are key signaling molecules that regulate many patho-biological processes. During the last decade, they have gained increasing attention since they may participate in important and numerous retinal processes, such as neuronal survival and death, proliferation and migration of neuronal and vascular cells, inflammation, and neovascularization. Cer for instance has emerged as a key mediator of inflammation and death of neuronal and retinal pigment epithelium cells in experimental models of retinopathies such as glaucoma, age-related macular degeneration (AMD), and retinitis pigmentosa. S1P may have opposite biological actions, preventing photoreceptor and ganglion cell degeneration but also promoting inflammation, fibrosis, and neovascularization in AMD, glaucoma, and pro-fibrotic disorders. Alterations in Cer, S1P, and ceramide 1-phosphate may also contribute to uveitis. Furthermore, use of inhibitors that either prevent Cer increase or modulate S1P signaling, such as Myriocin, desipramine, and Fingolimod (FTY720), have been shown to preserve neuronal viability and retinal function. Collectively, the expanding role for these sphingolipids in the modulation of vital processes in retina cell types and in their dysregulation in retinal degenerations makes them attractive therapeutic targets.
C1 [Shiwani, Haaris A.] Royal Preston Hosp, Dept Ophthalmol, Preston, England.
   [Elfaki, Mohammed Y.] Univ Coll Dublin, Sch Med, Dublin, Ireland.
   [Memon, Danyal] Childrens Hlth Ireland, Dept Cardiol, Dublin, Ireland.
   [Ali, Suhayb] Ulster Hosp, Dept Acute Med, Belfast, North Ireland.
   [Aziz, Abdul] Royal Liverpool Univ Hosp, Dept Resp Med, Liverpool, England.
   [Egom, Emmanuel E.] Univ Ottawa, Inst Savoir Montfort ISM, Hop Montfort, Ottawa, ON, Canada.
   [Egom, Emmanuel E.] Inst Med Res & Med Plants Studies IMPM, Lab Endocrinol & Radioisotopes, Yaounde, Cameroon.
C3 Royal Preston Hospital; University College Dublin; Royal Liverpool &
   Broadgreen University Hospitals NHS Trust; Royal Liverpool University
   Hospital; University of Liverpool; University of Ottawa
RP Shiwani, HA (通讯作者)，Royal Preston Hosp, Dept Ophthalmol, Preston, England.; Egom, EE (通讯作者)，Univ Ottawa, Inst Savoir Montfort, Montfort Hosp, Ottawa, ON, Canada.
EM SHIWANIH@tcd.ie; egomemmanuel@gmail.com
RI EGOM, EMMANUEL EROUME-A/ABG-1708-2021
OI EGOM, EMMANUEL EROUME-A/0000-0001-7142-5477
CR Abcouwer SF, 2002, INVEST OPHTH VIS SCI, V43, P2791
   Abrahan CE, 2010, INVEST OPHTH VIS SCI, V51, P1171, DOI 10.1167/iovs.09-3909
   Afsar E, 2020, REDOX BIOL, V30, DOI 10.1016/j.redox.2020.101430
   Andrieu-Abadie N, 2001, FREE RADICAL BIO MED, V31, P717, DOI 10.1016/S0891-5849(01)00655-4
   Avela K, 2018, ACTA OPHTHALMOL, V96, P183, DOI 10.1111/aos.13551
   Avila-Fernandez A, 2008, INVEST OPHTH VIS SCI, V49, P2709, DOI 10.1167/iovs.07-0865
   BAJJALIEH SM, 1989, J BIOL CHEM, V264, P14354
   Barber AJ, 2005, INVEST OPHTH VIS SCI, V46, P2210, DOI 10.1167/iovs.04-1340
   Barber AJ, 1998, J CLIN INVEST, V102, P783, DOI 10.1172/JCI2425
   Bertrand RE, 2021, GENET MED, V23, P488, DOI 10.1038/s41436-020-01003-x
   Bionda C, 2004, BIOCHEM J, V382, P527, DOI 10.1042/BJ20031819
   Blanco R, 2017, EXP EYE RES, V164, P37, DOI 10.1016/j.exer.2017.08.005
   Boini KM, 2011, AM J PATHOL, V179, P2210, DOI 10.1016/j.ajpath.2011.07.019
   Brown MM, 2005, CAN J OPHTHALMOL, V40, P277, DOI 10.1016/S0008-4182(05)80070-5
   Brush RS, 2010, INVEST OPHTH VIS SCI, V51, P4422, DOI 10.1167/iovs.09-5134
   Busik JV, 2009, J EXP MED, V206, P2897, DOI 10.1084/jem.20090889
   Caballero S, 2009, EXP EYE RES, V88, P367, DOI 10.1016/j.exer.2008.07.012
   Cabral Thiago, 2017, Int J Retina Vitreous, V3, P31, DOI 10.1186/s40942-017-0084-9
   Cacicedo JM, 2005, DIABETES, V54, P1838, DOI 10.2337/diabetes.54.6.1838
   CAMPOCHIARO PA, 1985, ARCH OPHTHALMOL-CHIC, V103, P434
   Canals D, 2018, CHEM PHYS LIPIDS, V216, P142, DOI 10.1016/j.chemphyslip.2018.09.013
   Castro BM, 2014, PROG LIPID RES, V54, P53, DOI 10.1016/j.plipres.2014.01.004
   Chakravarthy H, 2016, STEM CELLS, V34, P972, DOI 10.1002/stem.2259
   Colie S, 2009, CANCER RES, V69, P9346, DOI 10.1158/0008-5472.CAN-09-2198
   Cordis GA, 1998, J PHARMACEUT BIOMED, V16, P1189, DOI 10.1016/S0731-7085(97)00260-4
   Cuvillier O, 2002, BBA-MOL CELL BIOL L, V1585, P153, DOI 10.1016/S1388-1981(02)00336-0
   de Hoz R, 2016, BIOMED RES INT, V2016, DOI 10.1155/2016/2954721
   Denis U, 2002, FREE RADICAL BIO MED, V33, P236, DOI 10.1016/S0891-5849(02)00879-1
   Der P, 2006, J MOL CELL CARDIOL, V40, P313, DOI 10.1016/j.yjmcc.2005.10.005
   Domenech EB, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.8.14
   Eresch J, 2018, INVEST OPHTH VIS SCI, V59, P653, DOI 10.1167/iovs.17-22544
   Esche M, 2010, NEUROSCI LETT, V480, P101, DOI 10.1016/j.neulet.2010.06.014
   Fabiani C, 2017, N-S ARCH PHARMACOL, V390, P741, DOI 10.1007/s00210-017-1374-3
   Fan J, 2016, INVEST OPHTH VIS SCI, V57, P4476, DOI 10.1167/iovs.16-19717
   Fan LL, 2016, INVEST OPHTH VIS SCI, V57, P1254, DOI 10.1167/iovs.15-18658
   Feucht N, 2019, MULT SCLER J, V25, P224, DOI 10.1177/1352458517750009
   Fox TE, 2006, DIABETES, V55, P3573, DOI 10.2337/db06-0539
   Futerman AH, 2004, EMBO REP, V5, P777, DOI 10.1038/sj.embor.7400208
   Gangoiti P, 2008, CELL SIGNAL, V20, P726, DOI 10.1016/j.cellsig.2007.12.008
   Gangoiti P, 2012, BIOCHIMIE, V94, P597, DOI 10.1016/j.biochi.2011.09.009
   Gangoiti P, 2010, FEBS LETT, V584, P517, DOI 10.1016/j.febslet.2009.11.086
   German OL, 2006, INVEST OPHTH VIS SCI, V47, P1658, DOI 10.1167/iovs.05-1310
   GOMEZMUNOZ A, 1995, J BIOL CHEM, V270, P26318, DOI 10.1074/jbc.270.44.26318
   Granado MH, 2009, CELL SIGNAL, V21, P405, DOI 10.1016/j.cellsig.2008.11.003
   Gupta OP, 2007, CURR OPIN OPHTHALMOL, V18, P201, DOI 10.1097/ICU.0b013e32810c8df4
   Hait NC, 2009, SCIENCE, V325, P1254, DOI 10.1126/science.1176709
   HAMMES HP, 1995, MOL MED, V1, P527, DOI 10.1007/BF03401589
   Han XL, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021643
   Hannun YA, 2018, NAT REV MOL CELL BIO, V19, P175, DOI 10.1038/nrm.2017.107
   Hannun YA, 2011, J BIOL CHEM, V286, P27855, DOI 10.1074/jbc.R111.254359
   Hazra S, 2013, DIABETOLOGIA, V56, P644, DOI 10.1007/s00125-012-2781-0
   Healy SJM, 2009, EUR J PHARMACOL, V625, P234, DOI 10.1016/j.ejphar.2009.06.064
   Heinrich M, 1999, EMBO J, V18, P5252, DOI 10.1093/emboj/18.19.5252
   Hetz C, 2012, NAT REV MOL CELL BIO, V13, P89, DOI 10.1038/nrm3270
   Hinton DR, 1998, ARCH OPHTHALMOL-CHIC, V116, P203
   Hinze A, 2011, BMC CELL BIOL, V12, DOI 10.1186/1471-2121-12-35
   Hla T, 2004, SEMIN CELL DEV BIOL, V15, P513, DOI 10.1016/j.semcdb.2004.05.002
   Hoeferlin L Alexis, 2013, Handb Exp Pharmacol, P153, DOI 10.1007/978-3-7091-1368-4_8
   Igarashi N, 2003, J BIOL CHEM, V278, P46832, DOI 10.1074/jbc.M306577200
   Jain A, 2017, J CELL SCI, V130, P360, DOI 10.1242/jcs.194191
   Jasani Kirti Madhukar, 2017, BMJ Case Rep, V2017, DOI 10.1136/bcr-2016-218912
   Joly S, 2016, J NEUROCHEM, V138, P571, DOI 10.1111/jnc.13701
   Kagedal K, 2001, BIOCHEM J, V359, P335, DOI 10.1042/0264-6021:3590335
   Kannan R, 2004, FREE RADICAL BIO MED, V37, P166, DOI 10.1016/j.freeradbiomed.2004.04.011
   Karakucuk Y, 2020, CUTAN OCUL TOXICOL, V39, P281, DOI 10.1080/15569527.2020.1790591
   Khimani KS, 2018, J NEURO-OPHTHALMOL, V38, P337, DOI 10.1097/WNO.0000000000000592
   Kim M, 2017, J ALZHEIMERS DIS, V60, P809, DOI 10.3233/JAD-160645
   Kimura T, 2000, BIOCHEM J, V348, P71, DOI 10.1042/0264-6021:3480071
   Kitatani K, 2008, CELL SIGNAL, V20, P1010, DOI 10.1016/j.cellsig.2007.12.006
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein R, 2008, OPHTHALMOLOGY, V115, P1859, DOI 10.1016/j.ophtha.2008.08.023
   Koochekpour S, 1996, CANCER LETT, V102, P209, DOI 10.1016/0304-3835(96)04161-4
   KRUEGER DE, 1980, SURV OPHTHALMOL, V24, P614, DOI 10.1016/0039-6257(80)90122-8
   Lahiri S, 2007, CELL MOL LIFE SCI, V64, P2270, DOI 10.1007/s00018-007-7076-0
   Lanzillo R, 2018, MULT SCLER J, V24, P1706, DOI 10.1177/1352458517729463
   Lee R, 2015, EYE VISION, V2, DOI 10.1186/s40662-015-0026-2
   Li C, 2014, BBA-MOL BASIS DIS, V1842, P1121, DOI 10.1016/j.bbadis.2014.04.009
   Li GY, 2012, DIABETES, V61, P3294, DOI 10.2337/db11-1249
   Liu FY, 2016, ONCOTARGET, V7, P83907, DOI 10.18632/oncotarget.13438
   Liu H, 2003, J BIOL CHEM, V278, P40330, DOI 10.1074/jbc.M304455200
   LIU PS, 1995, J BIOL CHEM, V270, P27179, DOI 10.1074/jbc.270.45.27179
   Liu X, 2012, MOL CELL BIOCHEM, V363, P21, DOI 10.1007/s11010-011-1154-1
   Loomans CJM, 2004, DIABETES, V53, P195, DOI 10.2337/diabetes.53.1.195
   Maceyka M, 2005, J BIOL CHEM, V280, P37118, DOI 10.1074/jbc.M502207200
   Masson E, 2005, GLYCOBIOLOGY, V15, P585, DOI 10.1093/glycob/cwi039
   Mielke MM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073094
   Mielke MM, 2012, NEUROLOGY, V79, P633, DOI 10.1212/WNL.0b013e318264e380
   Milis DG, 2006, MOL CELL BIOCHEM, V283, P57, DOI 10.1007/s11010-006-2270-1
   Min KJ, 2004, GLIA, V48, P197, DOI 10.1002/glia.20069
   Min KJ, 2004, EXP MOL MED, V36, P461, DOI 10.1038/emm.2004.58
   Miranda GE, 2011, INVEST OPHTH VIS SCI, V52, P6580, DOI 10.1167/iovs.10-7065
   Miranda GE, 2009, INVEST OPHTH VIS SCI, V50, P4416, DOI 10.1167/iovs.09-3388
   Mullen TD, 2012, BIOCHEM J, V441, P789, DOI 10.1042/BJ20111626
   Nagahashi M, 2012, CANCER RES, V72, P726, DOI 10.1158/0008-5472.CAN-11-2167
   Norgaard TL, 2020, BASIC CLIN PHARMACOL, V126, P492, DOI 10.1111/bcpt.13381
   Novgorodov SA, 2011, J BIOL CHEM, V286, P25352, DOI 10.1074/jbc.M110.214866
   Ohtani R, 2004, BRAIN RES, V1023, P31, DOI 10.1016/j.brainres.2004.07.024
   Ollinger K, 2000, ARCH BIOCHEM BIOPHYS, V373, P346, DOI 10.1006/abbi.1999.1567
   Piano I, 2020, FRONT NEUROSCI-SWITZ, V14, DOI 10.3389/fnins.2020.00372
   Platania CBM, 2019, DRUG DELIV, V26, P237, DOI 10.1080/10717544.2019.1574936
   Porter H, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19123885
   Pujol-Lereis LM, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0200739
   PUSHKAREVA M, 1995, IMMUNOL TODAY, V16, P294, DOI 10.1016/0167-5699(95)80184-7
   Qi H, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-44047-z
   Qiao YB, 2012, INVEST OPHTH VIS SCI, V53, P8200, DOI 10.1167/iovs.12-10965
   Roberg K, 1998, AM J PATHOL, V152, P1151
   Roberg K, 1999, FREE RADICAL BIO MED, V27, P1228, DOI 10.1016/S0891-5849(99)00146-X
   Ruvolo PP, 1999, J BIOL CHEM, V274, P20296, DOI 10.1074/jbc.274.29.20296
   Sanvicens N, 2006, J NEUROCHEM, V98, P1432, DOI 10.1111/j.1471-4159.2006.03977.x
   Sawada N, 2000, CELL DEATH DIFFER, V7, P761, DOI 10.1038/sj.cdd.4400711
   Sawai H, 2004, BIOCHEM BIOPH RES CO, V319, P46, DOI 10.1016/j.bbrc.2004.04.152
   SCHRODER S, 1991, AM J PATHOL, V139, P81
   Schuppel M, 2008, J INVEST DERMATOL, V128, P1747, DOI 10.1038/sj.jid.5701259
   Sia PI, 2018, RETINA-J RET VIT DIS, V38, pE80, DOI 10.1097/IAE.0000000000002334
   Simon MV, 2021, J LIPID RES, V62, DOI 10.1194/jlr.TR120000972
   Simon MV, 2015, INVEST OPHTH VIS SCI, V56, P5808, DOI 10.1167/iovs.14-16195
   Skoura A, 2007, J CLIN INVEST, V117, P2506, DOI 10.1172/JCI31123
   Sonoda S, 2014, CYTOKINE, V68, P137, DOI 10.1016/j.cyto.2014.03.011
   Soulet D, 2008, CURR OPIN PHARMACOL, V8, P508, DOI 10.1016/j.coph.2008.04.002
   Spalm FHP, 2019, MOL NEUROBIOL, V56, P4760, DOI 10.1007/s12035-018-1402-4
   Stiles M, 2016, J LIPID RES, V57, P818, DOI 10.1194/jlr.M063719
   Strettoi E, 2010, P NATL ACAD SCI USA, V107, P18706, DOI 10.1073/pnas.1007644107
   Sugano E, 2019, J LIPID RES, V60, P30, DOI 10.1194/jlr.M082198
   Sugano E, 2013, J OPHTHALMOL, V2013, DOI 10.1155/2013/185825
   Takahashi H, 2021, HELIYON, V7, DOI 10.1016/j.heliyon.2021.e05902
   Terao R, 2019, PROSTAG OTH LIPID M, V145, DOI 10.1016/j.prostaglandins.2019.106365
   Terao R, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20153670
   Terao R, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19010112
   Thudichum J.L.W, 1884, BIOMED J DIGIT PROJ, V22
   Tuson M, 2004, AM J HUM GENET, V74, P128, DOI 10.1086/381055
   van Blitterswijk WJ, 2003, BIOCHEM J, V369, P199, DOI 10.1042/BJ20021528
   Vera MS, 2021, EXP EYE RES, V202, DOI 10.1016/j.exer.2020.108359
   Simon MV, 2019, FRONT CELL NEUROSCI, V13, DOI 10.3389/fncel.2019.00246
   von Haefen C, 2002, ONCOGENE, V21, P4009, DOI 10.1038/sj.onc.1205497
   Wang XG, 2014, BRIT J OPHTHALMOL, V98, P1368, DOI 10.1136/bjophthalmol-2013-304547
   Wilkerson JL, 2019, MOL NEUROBIOL, V56, P7188, DOI 10.1007/s12035-019-1599-x
   Wilmott LA, 2019, J DIABETES COMPLICAT, V33, P195, DOI 10.1016/j.jdiacomp.2018.12.005
   Wlodkowic D, 2009, LEUKEMIA RES, V33, P1440, DOI 10.1016/j.leukres.2009.05.025
   Wu BX, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0133032
   Xie B, 2009, J CELL PHYSIOL, V218, P192, DOI 10.1002/jcp.21588
   Xing Y, 2016, J ALZHEIMERS DIS, V52, P1029, DOI 10.3233/JAD-151158
   Yao J, 2013, INT J MOL SCI, V14, P10355, DOI 10.3390/ijms140510355
   Yonamine I, 2011, J CELL BIOL, V192, P557, DOI 10.1083/jcb.201004098
   You YY, 2014, INVEST OPHTH VIS SCI, V55, P3060, DOI 10.1167/iovs.13-13262
   Yu FPS, 2019, AM J PATHOL, V189, P320, DOI 10.1016/j.ajpath.2018.10.018
   Zager RA, 1998, KIDNEY INT, V53, P573, DOI 10.1046/j.1523-1755.1998.00772.x
   Zarbin MA, 2013, OPHTHALMOLOGY, V120, P1432, DOI 10.1016/j.ophtha.2012.12.040
   Zhang DX, 2001, BASIC RES CARDIOL, V96, P267, DOI 10.1007/s003950170057
   Zhu DH, 2010, VISION RES, V50, P643, DOI 10.1016/j.visres.2009.09.002
NR 149
TC 2
Z9 2
U1 5
U2 8
PU ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI ISSY-LES-MOULINEAUX
PA 65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY-LES-MOULINEAUX, FRANCE
SN 0753-3322
EI 1950-6007
J9 BIOMED PHARMACOTHER
JI Biomed. Pharmacother.
PD NOV
PY 2021
VL 143
AR 112197
DI 10.1016/j.biopha.2021.112197
EA SEP 2021
PG 11
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA WK1KE
UT WOS:000709491100003
PM 34560541
OA gold
DA 2022-11-30
ER

PT J
AU Xie, Y
   Mansouri, M
   Rizk, A
   Berger, P
AF Xie, Ye
   Mansouri, Maysam
   Rizk, Aurelien
   Berger, Philipp
TI Regulation of VEGFR2 trafficking and signaling by Rab GTPase-activating
   proteins
SO SCIENTIFIC REPORTS
LA English
DT Article
ID CELLS; IDENTIFICATION; MIGRATION; INSULIN; PHOSPHORYLATION;
   NEUROPILIN-1; ENDOCYTOSIS; SECRETION; MEMBRANE; EFFECTOR
AB Vascular endothelial growth factor receptor-2 (VEGFR2) and its ligands (VEGFs) are crucial players in vasculogenesis and angiogenesis. General blocking of this signaling system with antibodies or small molecule inhibitors is an established strategy to treat cancer and age-related macular degeneration. Nevertheless, the activated receptor can signal to discrete downstream signaling pathways and the equilibrium between these pathways is modulated by coreceptors and distinct isoforms of VEGF. Here we investigated the influence of Rab GTPase activating proteins (RabGAPs) on VEGFR2 signaling, tube formation, and migration of endothelial cells. We demonstrate that members of the TBC1D10 subfamily of RabGAPs have opposite effects. Whereas TBC1D10A leads to increased Erk1/2 signaling, TBC1D10B lowered Erk1/2 and p38 signaling and reduced tube formation in vitro. TBC1D10A is a RabGAP acting on RAB13 that was shown before to play a role in angiogenesis and we could indeed show colocalization of these two proteins with VEGFR2 in activated cells. In addition, we observed that cells expressing TBC1D10B show lower expression ofVEGFR2 and NRP1 on filopodia of activated cells. Taken together, our systematic analysis of influence of RabGAPs on VEGFR2 signaling identifies the TBC1D10 subfamily members as modulators of angiogenesis.
C1 [Xie, Ye; Mansouri, Maysam; Rizk, Aurelien; Berger, Philipp] Paul Scherrer Inst, Lab Nanoscale Biol, CH-5232 Villigen, Switzerland.
   [Mansouri, Maysam] Swiss Fed Inst Technol, Dept Biosyst Sci & Engn, CH-4058 Basel, Switzerland.
   [Rizk, Aurelien] InterAx Biotech AG, CH-5232 Villigen, Switzerland.
C3 Paul Scherrer Institute; ETH Zurich
RP Berger, P (通讯作者)，Paul Scherrer Inst, Lab Nanoscale Biol, CH-5232 Villigen, Switzerland.
EM Philipp.Berger@psi.ch
RI Berger, Philipp/AAV-1624-2021
OI Berger, Philipp/0000-0002-8147-1749
FU Swiss National Science Foundation [31003A-146975]
FX This work was supported by the Swiss National Science Foundation
   (31003A-146975 to P.B.). We would like to thank Dr. Lawrence Rajendran
   for the RabGAP plasmids, Dr. Kurt Ballmer-Hofer for helpful discussions,
   and Dr. Ned Mantei for his assistance with editing the manuscript.
CR Arnaoutova I, 2009, ANGIOGENESIS, V12, P267, DOI 10.1007/s10456-009-9146-4
   Ballmer-Hofer K, 2011, BLOOD, V118, P816, DOI 10.1182/blood-2011-01-328773
   Cebe-Suarez S, 2008, FASEB J, V22, P3078, DOI 10.1096/fj.08-107219
   Chen YN, 2017, PROTEIN SCI, V26, P834, DOI 10.1002/pro.3132
   DeCicco-Skinner KL, 2014, JOVE-J VIS EXP, DOI 10.3791/51312
   Dull T, 1998, J VIROL, V72, P8463, DOI 10.1128/JVI.72.11.8463-8471.1998
   Dumont DJ, 1998, SCIENCE, V282, P946, DOI 10.1126/science.282.5390.946
   Eichmann A, 2012, CURR OPIN CELL BIOL, V24, P188, DOI 10.1016/j.ceb.2012.02.002
   FOLKMAN J, 1980, NATURE, V288, P551, DOI 10.1038/288551a0
   FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0
   Fuchs E, 2007, J CELL BIOL, V177, P1133, DOI 10.1083/jcb.200612068
   Gampel A, 2006, BLOOD, V108, P2624, DOI 10.1182/blood-2005-12-007484
   Hayashi M, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2683
   Horowitz A, 2012, CELL SIGNAL, V24, P1810, DOI 10.1016/j.cellsig.2012.05.007
   Hoseini SJ, 2017, DNA CELL BIOL, V36, P401, DOI 10.1089/dna.2016.3546
   Hou YA, 2013, J BIOL CHEM, V288, P19548, DOI 10.1074/jbc.M113.472134
   Hsu C, 2010, J CELL BIOL, V189, P223, DOI 10.1083/jcb.200911018
   Huyghe JR, 2013, NAT GENET, V45, P197, DOI 10.1038/ng.2507
   Ishibashi K, 2009, GENES CELLS, V14, P41, DOI 10.1111/j.1365-2443.2008.01251.x
   Itoh T, 2006, J BIOL CHEM, V281, P31823, DOI 10.1074/jbc.M603808200
   Jonkman JEN, 2014, CELL ADHES MIGR, V8, P440, DOI 10.4161/cam.36224
   Jopling HM, 2009, ARTERIOSCL THROM VAS, V29, P1119, DOI 10.1161/ATVBAHA.109.186239
   Kawamura H, 2008, BLOOD, V112, P3638, DOI 10.1182/blood-2007-12-125856
   Koch S, 2014, DEV CELL, V28, P633, DOI 10.1016/j.devcel.2014.02.010
   KUBOTA Y, 1988, J CELL BIOL, V107, P1589, DOI 10.1083/jcb.107.4.1589
   Lamalice L, 2006, J BIOL CHEM, V281, P34009, DOI 10.1074/jbc.M603928200
   Lanahan AA, 2014, CIRCULATION, V130, P902, DOI 10.1161/CIRCULATIONAHA.114.009683
   Marubashi S, 2016, J BIOL CHEM, V291, P1427, DOI 10.1074/jbc.M115.684043
   Meyer RD, 2011, MOL CELL BIOL, V31, P2010, DOI 10.1128/MCB.01006-10
   NAKAOHAYASHI J, 1992, ATHEROSCLEROSIS, V92, P141, DOI 10.1016/0021-9150(92)90273-J
   Nakayama M, 2013, EXP CELL RES, V319, P1340, DOI 10.1016/j.yexcr.2013.03.008
   Nakayama M, 2013, NAT CELL BIOL, V15, P249, DOI 10.1038/ncb2679
   Nottingham RM, 2011, J BIOL CHEM, V286, P33213, DOI 10.1074/jbc.M111.261115
   PLUTNER H, 1991, J CELL BIOL, V115, P31, DOI 10.1083/jcb.115.1.31
   Ren B, 2010, J CLIN INVEST, V120, P1217, DOI 10.1172/JCI39837
   Sakane A, 2010, MOL CELL BIOL, V30, P1077, DOI 10.1128/MCB.01067-09
   Shalaby F, 1997, CELL, V89, P981, DOI 10.1016/S0092-8674(00)80283-4
   Sheff DR, 1999, J CELL BIOL, V145, P123, DOI 10.1083/jcb.145.1.123
   Sidjanin DJ, 2016, AUTOPHAGY, V12, P1759, DOI 10.1080/15548627.2016.1199300
   Simons M, 2012, J AM COLL CARDIOL, V60, P626, DOI 10.1016/j.jacc.2012.01.069
   Sklan EH, 2007, J BIOL CHEM, V282, P36354, DOI 10.1074/jbc.M705221200
   Stermann T, 2018, ENDOCRINOLOGY, V159, P1748, DOI 10.1210/en.2018-00087
   Stuttfeld E, 2009, IUBMB LIFE, V61, P915, DOI 10.1002/iub.234
   Sun ZY, 2012, J EXP MED, V209, P1363, DOI 10.1084/jem.20111343
   Takahashi T, 2001, EMBO J, V20, P2768, DOI 10.1093/emboj/20.11.2768
   Tisdale EJ, 1996, J BIOL CHEM, V271, P29372, DOI 10.1074/jbc.271.46.29372
   Udayar V, 2013, CELL REP, V5, P1536, DOI 10.1016/j.celrep.2013.12.005
   Wandinger-Ness A, 2014, CSH PERSPECT BIOL, V6, DOI 10.1101/cshperspect.a022616
   Wheeler DB, 2015, SCIENCE, V350, P211, DOI 10.1126/science.aaa4903
   Wu CS, 2011, J BIOL CHEM, V286, P23511, DOI 10.1074/jbc.M111.245209
NR 50
TC 11
Z9 11
U1 2
U2 6
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD SEP 16
PY 2019
VL 9
AR 13342
DI 10.1038/s41598-019-49646-4
PG 12
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA IX7KF
UT WOS:000485861500067
PM 31527750
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Terao, R
   Honjo, M
   Aihara, M
AF Terao, Ryo
   Honjo, Megumi
   Aihara, Makoto
TI Apolipoprotein M Inhibits Angiogenic and Inflammatory Response by
   Sphingosine 1-Phosphate on Retinal Pigment Epithelium Cells
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE sphingosine 1-phosphate; sphingolipids and inflammation; S1P-receptors;
   apolipoprotein M; high-density lipoprotein; choroidal
   neovascularization; age-related macular degeneration; vascular
   endothelial growth factor; hypoxia inducible factor; interleukin-8
ID MACULAR DEGENERATION; ENDOTHELIAL-CELLS; SPHINGOSINE-1-PHOSPHATE
   RECEPTOR-2; VEGF; METABOLISM; S1P; PHOSPHORYLATION; RANIBIZUMAB;
   EFFICACY; KINASE
AB Sphingosine 1-phosphate (S1P) is a potent lipid mediator that modulates inflammatory responses and proangiogenic factors. It has been suggested that S1P upregulates choroidal neovascularization (CNV) and may be deeply involved in the pathogenesis of exudative age-related macular degeneration (AMD). Recent studies have suggested that apolipoprotein M (ApoM), a carrier protein for S1P, modulates the biological properties of S1P in the pathogenesis of atherosclerosis. However, the role of ApoM/S1P in AMD has not been explored. We investigated the effect of S1P on proangiogenic factors in human retinal pigment epithelium (RPE) cell lines in vitro. S1P promoted the expression of vascular endothelial growth factor in RPE cells. Hypoxia inducible factor-1 expression was also upregulated. These S1P-induced enhancements in growth factors and chemotactic cytokines in RPE cells were significantly inhibited by ApoM treatment. Additionally, in vivo experiments using a laser-induced CNV murine model demonstrated that intravitreal ApoM injection significantly reduced the progression of CNV formation. Although the detailed mechanisms remain to be elucidated, the present results provide a novel potential therapeutic target for AMD, and demonstrate a suppressive role for ApoM and S1P in the pathology of CNV progression.
C1 [Terao, Ryo; Honjo, Megumi; Aihara, Makoto] Univ Tokyo, Grad Sch Med, Dept Ophthalmol, Tokyo 1138654, Japan.
C3 University of Tokyo
RP Aihara, M (通讯作者)，Univ Tokyo, Grad Sch Med, Dept Ophthalmol, Tokyo 1138654, Japan.
EM qqaf787c9@gmail.com; m_honjo@kuhp.kyoto-u.ac.jp; aihara-tky@umin.net
RI Terao, Ryo/AAV-3334-2020
OI Terao, Ryo/0000-0001-6182-4343
FU Grants-in-Aid for Scientific Research [15K10854] Funding Source: KAKEN
CR Aaltonen V., 2017, GRAEFES ARCH CLIN EX, DOI [10. 1007/s00417-017-3711-0 28631245, DOI 10.1007/S00417-017-3711-028631245]
   Aoki S, 2005, J BIOCHEM, V138, P47, DOI 10.1093/jb/mvi100
   Axler O, 2007, J LIPID RES, V48, P1772, DOI 10.1194/jlr.M700113-JLR200
   Blaauwgeers HGT, 1999, AM J PATHOL, V155, P421, DOI 10.1016/S0002-9440(10)65138-3
   Blaho VA, 2015, NATURE, V523, P342, DOI 10.1038/nature14462
   Bressler SB, 2009, OPHTHALMOLOGY, V116, pS1, DOI 10.1016/j.ophtha.2009.06.045
   Cabral Thiago, 2017, Int J Retina Vitreous, V3, P31, DOI 10.1186/s40942-017-0084-9
   Christensen PM, 2016, FASEB J, V30, P2351, DOI 10.1096/fj.201500064
   Christoffersen C, 2008, J BIOL CHEM, V283, P1839, DOI 10.1074/jbc.M704576200
   Christoffersen C, 2011, P NATL ACAD SCI USA, V108, P9613, DOI 10.1073/pnas.1103187108
   Chumanevich A, 2016, MEDIAT INFLAMM, V2016, DOI 10.1155/2016/1503206
   Dehne N, 2009, EXP CELL RES, V315, P1791, DOI 10.1016/j.yexcr.2009.03.019
   Dornonville de la Cour M, 1993, Acta Ophthalmol Suppl, P1
   Egom EE, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18081800
   Endo A, 2002, J BIOL CHEM, V277, P23747, DOI 10.1074/jbc.M111794200
   Fernandez-Robredo P, 2014, J OPHTHALMOL, V2014, DOI 10.1155/2014/510285
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Hait NC, 2006, BBA-BIOMEMBRANES, V1758, P2016, DOI 10.1016/j.bbamem.2006.08.007
   Hajny S, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18081636
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Hernandez-Coronado CG, 2016, GEN COMP ENDOCR, V236, P1, DOI 10.1016/j.ygcen.2016.06.029
   Hla T, 2004, SEMIN CELL DEV BIOL, V15, P513, DOI 10.1016/j.semcdb.2004.05.002
   Holtkamp GM, 2001, PROG RETIN EYE RES, V20, P29, DOI 10.1016/S1350-9462(00)00017-3
   Igarashi J, 2003, P NATL ACAD SCI USA, V100, P10664, DOI 10.1073/pnas.1934494100
   Kalhori V, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066189
   KLEIN R, 1995, INVEST OPHTH VIS SCI, V36, P182
   Kurano M, 2013, ATHEROSCLEROSIS, V229, P102, DOI 10.1016/j.atherosclerosis.2013.04.024
   Lambert V, 2013, NAT PROTOC, V8, P2197, DOI 10.1038/nprot.2013.135
   Lee JF, 2006, J BIOL CHEM, V281, P29190, DOI 10.1074/jbc.M604310200
   Li Guang-Yu, 2005, Zhonghua Yan Ke Za Zhi, V41, P312
   Lijekvist-Soltic I, 2008, BRAIN RES, V1227, P226, DOI 10.1016/j.brainres.2008.06.077
   Maines LW, 2006, INVEST OPHTH VIS SCI, V47, P5022, DOI 10.1167/iovs.05-1236
   Massin P, 2010, DIABETES CARE, V33, P2399, DOI 10.2337/dc10-0493
   Michaud MD, 2009, ARTERIOSCL THROM VAS, V29, P902, DOI 10.1161/ATVBAHA.109.185280
   Mintz-Hittner HA, 2011, NEW ENGL J MED, V364, P603, DOI 10.1056/NEJMoa1007374
   Murata N, 2000, BIOCHEM J, V352, P809, DOI 10.1042/0264-6021:3520809
   Nagineni CN, 2015, AGING DIS, V6, P444, DOI 10.14336/AD.2015.0323
   Nowak JZ, 2006, PHARMACOL REP, V58, P353
   O'Sullivan MJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0095566
   Pitson SM, 2005, J EXP MED, V201, P49, DOI 10.1084/jem.20040559
   Qiao YB, 2012, INVEST OPHTH VIS SCI, V53, P8200, DOI 10.1167/iovs.12-10965
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Ruiz M, 2017, LIPIDS HEALTH DIS, V16, DOI 10.1186/s12944-017-0429-2
   Ruiz M, 2017, ARTERIOSCL THROM VAS, V37, P118, DOI 10.1161/ATVBAHA.116.308435
   Sanchez T, 2004, J CELL BIOCHEM, V92, P913, DOI 10.1002/jcb.20127
   Sanchez T, 2007, ARTERIOSCL THROM VAS, V27, P1312, DOI 10.1161/ATVBAHA.107.143735
   SARKS SH, 1976, BRIT J OPHTHALMOL, V60, P324, DOI 10.1136/bjo.60.5.324
   Schmidt-Erfurth U, 2014, BRIT J OPHTHALMOL, V98, P1144, DOI 10.1136/bjophthalmol-2014-305702
   Skoura A, 2007, J CLIN INVEST, V117, P2506, DOI 10.1172/JCI31123
   Sparrrow JR, 2010, CURR MOL MED, V10, P802
   Spiegel S, 2003, NAT REV MOL CELL BIO, V4, P397, DOI 10.1038/nrm1103
   Stangos AN, 2010, AM J OPHTHALMOL, V150, P666, DOI 10.1016/j.ajo.2010.05.035
   STRIETER RM, 1992, AM J PATHOL, V141, P1279
   Swaney JS, 2008, EXP EYE RES, V87, P367, DOI 10.1016/j.exer.2008.07.005
   Takabe K, 2008, PHARMACOL REV, V60, P181, DOI 10.1124/pr.107.07113
   Tanimoto T, 2002, J BIOL CHEM, V277, P42997, DOI 10.1074/jbc.M204764200
   Terao R., 2017, JAPAN DATA PREPARATI
   Wilkerson BA, 2012, J BIOL CHEM, V287, P44645, DOI 10.1074/jbc.M112.423426
   Xie B, 2009, J CELL PHYSIOL, V218, P192, DOI 10.1002/jcp.21588
   Xu N, 1999, J BIOL CHEM, V274, P31286, DOI 10.1074/jbc.274.44.31286
NR 60
TC 17
Z9 17
U1 2
U2 3
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1422-0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD JAN
PY 2018
VL 19
IS 1
AR 112
DI 10.3390/ijms19010112
PG 14
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA FV2OI
UT WOS:000424407200109
PM 29301231
OA Green Published, Green Submitted, gold
DA 2022-11-30
ER

PT J
AU Campochiaro, PA
AF Campochiaro, P. A.
TI Gene transfer for ocular neovascularization and macular edema
SO GENE THERAPY
LA English
DT Review
DE age-related macular degeneration; angiogenesis; diabetic retinopathy;
   neovascularization; proliferative retinopathies
ID EPITHELIUM-DERIVED FACTOR; ENDOTHELIAL GROWTH-FACTOR; CHOROIDAL
   NEOVASCULARIZATION; RETINAL NEOVASCULARIZATION; TISSUE INHIBITOR;
   INCREASED EXPRESSION; SOLUBLE VEGF; PROLIFERATIVE RETINOPATHY;
   ANGIOGENESIS INHIBITOR; PERIOCULAR INJECTION
AB Diseases complicated by abnormal growth of vessels or excessive leakage are the most prevalent cause of moderate or severe vision loss in developed countries. Recent progress unraveling the molecular pathogenesis of several of these disease processes has led to new drug therapies that have provided major benefits to patients. However, those treatments often require frequent intraocular injections, and despite monthly injections, some patients have a suboptimal response. Gene transfer of antiangiogenic proteins is an alternative approach that has the potential to provide long-term suppression of neovascularization (NV) and/or excessive vascular leakage in the eye. Studies in animal models of ocular NV have demonstrated impressive results with a number of transgenes, and a clinical trial in patients with advanced neovascular age-related macular degeneration has provided proof-of-concept. Two ongoing clinical trials, one using an adeno-associated viral (AAV) vector to express a vascular endothelial growth factor-binding protein and another using a lentiviral vector to express endostatin and angiostatin, will provide valuable information that should help to inform future trials and provide a foundation on which to build. Gene Therapy (2012) 19, 121-126; doi:10.1038/gt.2011.164; published online 10 November 2011
C1 [Campochiaro, P. A.] Johns Hopkins Univ, Sch Med, Dept Ophthalmol, Baltimore, MD 21287 USA.
   [Campochiaro, P. A.] Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21287 USA.
C3 Johns Hopkins University; Johns Hopkins University
RP Campochiaro, PA (通讯作者)，Johns Hopkins Univ, Sch Med, Dept Ophthalmol, 600 N Wolfe St,Maumenee 719, Baltimore, MD 21287 USA.
EM pcampo@jhmi.edu
FU National Eye Institute [EY05951, EY12609, EY10017]; Juvenile Diabetes
   Research Foundation; NATIONAL EYE INSTITUTE [R01EY012609, R01EY010017]
   Funding Source: NIH RePORTER
FX This study was supported by grants EY05951, EY12609 and EY10017 from the
   National Eye Institute and a grant from the Juvenile Diabetes Research
   Foundation. PAC is the George S and Dolores Dore Eccles Professor of
   Ophthalmology.
CR AIELLO LP, 1995, P NATL ACAD SCI USA, V92, P10457, DOI 10.1073/pnas.92.23.10457
   APTE SS, 1995, J BIOL CHEM, V270, P14313, DOI 10.1074/jbc.270.24.14313
   Araki T, 1998, J NEUROSCI RES, V53, P7, DOI 10.1002/(SICI)1097-4547(19980701)53:1<7::AID-JNR2>3.0.CO;2-F
   Auricchio A, 2002, MOL THER, V6, P490, DOI 10.1006/mthe.2002.0702
   Bainbridge JWB, 2002, GENE THER, V9, P320, DOI 10.1038/sj.gt.3301680
   Balaggan KS, 2006, GENE THER, V13, P1153, DOI 10.1038/sj.gt.3302769
   Bilak MM, 1999, J NEUROPATH EXP NEUR, V58, P719, DOI 10.1097/00005072-199907000-00006
   Boyer D, 2010, OPHTHALMOLOGY, V117, P1860, DOI 10.1016/j.ophtha.2010.02.022
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Campochiaro PA, 2006, HUM GENE THER, V17, P167, DOI 10.1089/hum.2006.17.167
   Campochiaro PA, 2008, MOL THER, V16, P791, DOI 10.1038/mt.2008.10
   Campochiaro PA, 2010, OPHTHALMOLOGY, V117, P1102, DOI 10.1016/j.ophtha.2010.02.021
   Campochiaro PA, 2010, OPHTHALMOLOGY, V117, P2387, DOI 10.1016/j.ophtha.2010.03.060
   Cao W, 2001, INVEST OPHTH VIS SCI, V42, P1646
   Dawson DW, 1999, SCIENCE, V285, P245, DOI 10.1126/science.285.5425.245
   Della NG, 1996, INVEST OPHTH VIS SCI, V37, P1921
   Demetriades AM, 2008, J OCUL PHARMACOL TH, V24, P70, DOI 10.1089/jop.2007.0061
   Elman MJ, 2010, OPHTHALMOLOGY, V117, P1064, DOI 10.1016/j.ophtha.2010.02.031
   Fariss RN, 1998, BRIT J OPHTHALMOL, V82, P1329, DOI 10.1136/bjo.82.11.1329
   Fukai N, 2002, EMBO J, V21, P1535, DOI 10.1093/emboj/21.7.1535
   Gehlbach P, 2003, GENE THER, V10, P637, DOI 10.1038/sj.gt.3301931
   Gehlbach P, 2003, HUM GENE THER, V14, P129, DOI 10.1089/104303403321070829
   He YL, 1999, MOL ENDOCRINOL, V13, P537, DOI 10.1210/me.13.4.537
   Honda M, 2000, GENE THER, V7, P978, DOI 10.1038/sj.gt.3301203
   Igarashi T, 2003, GENE THER, V10, P219, DOI 10.1038/sj.gt.3301878
   Kachi S, 2009, HUM GENE THER, V20, P31, DOI 10.1089/hum.2008.046
   Kamei M, 1999, INVEST OPHTH VIS SCI, V40, P2367
   Kelly BD, 2003, CIRC RES, V93, P1074, DOI 10.1161/01.RES.0000102937.50486.1B
   Kendall RL, 1996, BIOCHEM BIOPH RES CO, V226, P324, DOI 10.1006/bbrc.1996.1355
   KLEIN R, 1984, ARCH OPHTHALMOL-CHIC, V102, P520, DOI 10.1001/archopht.1984.01040030398010
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Kwak N, 2000, INVEST OPHTH VIS SCI, V41, P3158
   Lai CC, 2001, INVEST OPHTH VIS SCI, V42, P2401
   Lai CM, 2005, MOL THER, V12, P659, DOI 10.1016/j.ymthe.2005.04.022
   Lai YKY, 2002, GENE THER, V9, P804, DOI 10.1038/sj.gt.3301695
   Lee S, 2007, CELL, V130, P691, DOI 10.1016/j.cell.2007.06.054
   Lukason M, 2011, MOL THER, V19, P260, DOI 10.1038/mt.2010.230
   MacLachlan TK, 2011, MOL THER, V19, P326, DOI 10.1038/mt.2010.258
   Miki A, 2010, J CELL PHYSIOL, V224, P262, DOI 10.1002/jcp.22129
   Mori K, 2002, INVEST OPHTH VIS SCI, V43, P1994
   Mori K, 2002, INVEST OPHTH VIS SCI, V43, P2428
   Mori K, 2001, J CELL PHYSIOL, V188, P253, DOI 10.1002/jcp.1114
   Mori K, 2001, AM J PATHOL, V159, P313, DOI 10.1016/S0002-9440(10)61697-5
   Nguyen QD, 2009, OPHTHALMOLOGY, V116, P2175, DOI 10.1016/j.ophtha.2009.04.023
   Nguyen QD, 2006, AM J OPHTHALMOL, V142, P961, DOI 10.1016/j.ajo.2006.06.068
   Nishijima K, 2007, AM J PATHOL, V171, P53, DOI 10.2353/ajpath.2007.061237
   Ohno-Matsui K, 2002, AM J PATHOL, V160, P711, DOI 10.1016/S0002-9440(10)64891-2
   Okamoto N, 1997, AM J PATHOL, V151, P281
   OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3
   OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6
   Oshima Y, 2005, FASEB J, V19, P963, DOI 10.1096/fj.04-2209fje
   Oshima Y, 2004, J CELL PHYSIOL, V201, P393, DOI 10.1002/jcp.20110
   Oshima Y, 2004, J CELL PHYSIOL, V199, P412, DOI 10.1002/jcp.10442
   Ozaki H, 2000, AM J PATHOL, V156, P697, DOI 10.1016/S0002-9440(10)64773-6
   Ozaki H, 1999, INVEST OPHTH VIS SCI, V40, P182
   Pechan P, 2009, GENE THER, V16, P10, DOI 10.1038/gt.2008.115
   Quan DN, 2010, OPHTHALMOLOGY, V117, P2146, DOI 10.1016/j.ophtha.2010.08.016
   Raisler BJ, 2002, P NATL ACAD SCI USA, V99, P8909, DOI 10.1073/pnas.122247299
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rota R, 2004, J GENE MED, V6, P992, DOI 10.1002/jgm.586
   Saint-Geniez M, 2009, P NATL ACAD SCI USA, V106, P18751, DOI 10.1073/pnas.0905010106
   Saint-Geniez M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003554
   Saishin Y, 2003, J CELL PHYSIOL, V195, P241, DOI 10.1002/jcp.10246
   Saishin Y, 2003, INVEST OPHTH VIS SCI, V44, P4989, DOI 10.1167/iovs.03-0600
   Seo MS, 1999, AM J PATHOL, V154, P1743, DOI 10.1016/S0002-9440(10)65430-2
   Shen JK, 2006, FASEB J, V20, P723, DOI 10.1096/fj.05-5046fje
   Shimizu K, 2005, BIOCHEM BIOPH RES CO, V327, P700, DOI 10.1016/j.bbrc.2004.12.073
   Soboleva G, 2003, J CELL PHYSIOL, V197, P149, DOI 10.1002/jcp.10361
   STEELE FR, 1993, P NATL ACAD SCI USA, V90, P1526, DOI 10.1073/pnas.90.4.1526
   Takahashi K, 2003, FASEB J, V17, P896, DOI 10.1096/fj.02-0824fje
   Takahashi T, 2000, AM J OPHTHALMOL, V130, P774, DOI 10.1016/S0002-9394(00)00772-8
   Tobe T, 1998, AM J PATHOL, V153, P1641, DOI 10.1016/S0002-9440(10)65753-7
   TOMBRANTINK J, 1991, EXP EYE RES, V53, P411, DOI 10.1016/0014-4835(91)90248-D
   Ueno S, 2008, J CELL PHYSIOL, V217, P13, DOI 10.1002/jcp.21445
   Watanabe K, 2004, J CLIN INVEST, V114, P898, DOI 10.1172/JC1200421152
   WEBER BHF, 1994, NAT GENET, V8, P352, DOI 10.1038/ng1294-352
   Yamada H, 2000, J CELL PHYSIOL, V185, P135, DOI 10.1002/1097-4652(200010)185:1<135::AID-JCP13>3.0.CO;2-Y
   Yannuzzi LA, 2001, RETINA-J RET VIT DIS, V21, P416, DOI 10.1097/00006982-200110000-00003
NR 78
TC 28
Z9 34
U1 1
U2 9
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0969-7128
EI 1476-5462
J9 GENE THER
JI Gene Ther.
PD FEB
PY 2012
VL 19
IS 2
SI SI
BP 121
EP 126
DI 10.1038/gt.2011.164
PG 6
WC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Genetics & Heredity; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Genetics & Heredity; Research & Experimental Medicine
GA 892VI
UT WOS:000300313300002
PM 22071973
DA 2022-11-30
ER

PT J
AU Hosomichi, J
   Yasui, N
   Koide, T
   Soma, K
   Morita, I
AF Hosomichi, J
   Yasui, N
   Koide, T
   Soma, K
   Morita, I
TI Involvement of the collagen I-binding motif in the anti-angiogenic
   activity of pigment epithelium-derived factor
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE pigment epithelium-derived factor; HeLa cell; tumor growth;
   anti-angiogenesis; collagen I
ID HEPATOCELLULAR-CARCINOMA; PLASMINOGEN-ACTIVATOR; PROSTATE-CANCER;
   MELANOMA-CELLS; FACTOR PEDF; SITE; MASPIN; SERPIN; EXPRESSION; INHIBITOR
AB Pigment epithelium-derived factor (PEDF) is the most potent endogenous inhibitor of angiogenesis in age-related macular degeneration and tumors. However, the molecular mechanism of the anti-angiogenic activity of PEDF is poorly understood. PEDF interacts with the extracellular matrix (ECM) in vitro. Here, we investigated the possible involvement of the motif for ECM interaction in the anti-angiogenic activity of PEDF. The growth rates of HeLa cells in culture were not affected by transfection of PEDF, indicating that PEDF did not suppress tumor cell growth directly. In tumor xenografts, the overexpression of wild-type PEDF significantly suppressed tumor growth, whereas a mutant of the collagen I-binding site of PEDF (Col-mut PEDF) did not inhibit tumor growth. A mutant of the heparin-binding site of PEDF (Hep-mut PEDF) suppressed tumor growth. Histological analysis showed that the density and area of microvasculatures in either PEDF or Hep-mut PEDF were suppressed when compared with those in either vector or Col-mut PEDF. Our data indicate that PEDF inhibits tumor growth via its anti-angiogenic activity, and the collagen I-binding motif of PEDF is involved in the biological activity. (C) 2005 Elsevier Inc. All rights reserved.
C1 Tokyo Med & Dent Univ, Grad Sch, Dept Cellular Physiol Chem, Tokyo, Japan.
   Tokyo Med & Dent Univ, Grad Sch, Dept Orthodont Sci, Tokyo, Japan.
   Osaka Univ, Inst Prot Res, Osaka, Japan.
   Niigata Univ Pharm & Appl Life Sci, Fac Pharmaceut Sci, Niigata, Japan.
   Ctr Excellence Program Frontie Res Mol Destruct &, Tokyo, Japan.
C3 Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental
   University (TMDU); Osaka University; Niigata University
RP Morita, I (通讯作者)，Tokyo Med & Dent Univ, Grad Sch, Dept Cellular Physiol Chem, Tokyo, Japan.
EM morita.cell@tmd.ac.jp
RI Yasui, Norihisa/V-8252-2019
OI Yasui, Norihisa/0000-0001-7117-3070
CR Abe R, 2004, AM J PATHOL, V164, P1225, DOI 10.1016/S0002-9440(10)63210-5
   Alberdi E, 1999, J BIOL CHEM, V274, P31605, DOI 10.1074/jbc.274.44.31605
   Alberdi E, 1998, BIOCHEMISTRY-US, V37, P10643, DOI 10.1021/bi9802317
   BECERRA SP, 1995, J BIOL CHEM, V270, P25992, DOI 10.1074/jbc.270.43.25992
   Blacque OE, 2002, J BIOL CHEM, V277, P10783, DOI 10.1074/jbc.M110992200
   Chan CF, 2004, CLIN CANCER RES, V10, P4140, DOI 10.1158/1078-0432.CCR-03-0574
   Cher ML, 2003, P NATL ACAD SCI USA, V100, P7847, DOI 10.1073/pnas.1331360100
   Dawson DW, 1999, SCIENCE, V285, P245, DOI 10.1126/science.285.5425.245
   Di Lullo GA, 2002, J BIOL CHEM, V277, P4223, DOI 10.1074/jbc.M110709200
   Doll JA, 2003, NAT MED, V9, P774, DOI 10.1038/nm870
   Filleur S, 2005, CANCER RES, V65, P5144, DOI 10.1158/0008-5472.CAN-04-3744
   Ge XK, 2002, CANCER LETT, V179, P133, DOI 10.1016/S0304-3835(02)00004-6
   Ibanez-Tallon I, 2002, BLOOD, V100, P3325, DOI 10.1182/blood.V100.9.3325
   Liu H, 2004, P NATL ACAD SCI USA, V101, P6605, DOI 10.1073/pnas.0308342101
   Matsumoto K, 2004, HEPATOLOGY, V40, P252, DOI 10.1002/hep.20259
   McGowen R, 2000, CANCER RES, V60, P4771
   Meyer C, 2002, J BIOL CHEM, V277, P45400, DOI 10.1074/jbc.M208339200
   Sweeney SM, 2003, J BIOL CHEM, V278, P30516, DOI 10.1074/jbc.M304237200
   TOMBRANTINK J, 1991, EXP EYE RES, V53, P411, DOI 10.1016/0014-4835(91)90248-D
   Volpert OV, 2002, NAT MED, V8, P349, DOI 10.1038/nm0402-349
   Yasui N, 2003, BIOCHEMISTRY-US, V42, P3160, DOI 10.1021/bi0206558
NR 21
TC 40
Z9 42
U1 0
U2 4
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0006-291X
EI 1090-2104
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD SEP 30
PY 2005
VL 335
IS 3
BP 756
EP 761
DI 10.1016/j.bbrc.2005.07.140
PG 6
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA 961LF
UT WOS:000231663200017
PM 16102727
DA 2022-11-30
ER

PT J
AU Skenduli-Bala, E
   de Voogd, S
   Wolfs, CW
   van Leeuwen, R
   Ikram, MK
   Jonas, JB
   Bakker, D
   Hofman, A
   de Jong, PTVM
AF Skenduli-Bala, E
   de Voogd, S
   Wolfs, CW
   van Leeuwen, R
   Ikram, MK
   Jonas, JB
   Bakker, D
   Hofman, A
   de Jong, PTVM
TI Causes of incident visual field loss in a general elderly population -
   The Rotterdam study
SO ARCHIVES OF OPHTHALMOLOGY
LA English
DT Article
ID BLUE MOUNTAINS EYE; CAUSE-SPECIFIC PREVALENCE; OPEN-ANGLE GLAUCOMA;
   IMPAIRMENT PROJECT; BARBADOS EYE; VISION; STUDY/; ASSOCIATION;
   AUSTRALIA; BLINDNESS
AB Objective: To determine the incidence and causes of visual field loss (VFL) in a general elderly population.
   Methods: Central visual fields of both eyes were examined with suprathreshold perimetry in 3761 persons aged 55 years or older and free of VFL at baseline from the population-based Rotterdam Study. Goldmann perimetry was performed to confirm suprathreshold VFL. Causes of incident VFL (iVFL) were assessed based on all available ophthalmologic and neurological examination data and medical records.
   Results: After a mean follow-up time of 6.3 years, 175 persons developed VFL. The overall incidence rate of iVFL was 7.4 per 1000 person-years, increasing to 21.1 per 1000 person-years in those aged 80 years and older. Glaucoma was the leading cause of iVFL in all age categories. The overall incidence of glaucomatous VFL was 2.0 per 1000 person-years.
   Conclusions: The incidence of all VFL increased 5-fold between 55 years and 80 years of age or older. After glaucoma, stroke was the second most common cause of iVFL in persons younger than 75 years, followed by age-related macular degeneration and retinal vascular occlusive disease.
C1 Royal Netherlands Acad Arts & Sci, KNAW, Netherlands Ophthalm Res Inst, NL-1105 BA Amsterdam, Netherlands.
   Erasmus Univ, Med Ctr, Dept Epidemiol & Biostat, Rotterdam, Netherlands.
   Erasmus Univ, Med Ctr, Dept Ophthalmol, Rotterdam, Netherlands.
   Univ Mannheim, Dept Ophthalmol, Mannheim, Germany.
   Univ Amsterdam, Acad Med Ctr, Dept Ophthalmol, NL-1105 AZ Amsterdam, Netherlands.
C3 Royal Netherlands Academy of Arts & Sciences; Netherlands Institute for
   Neuroscience (NIN-KNAW); Erasmus University Rotterdam; Erasmus MC;
   Erasmus University Rotterdam; Erasmus MC; University of Mannheim;
   University of Amsterdam; Academic Medical Center Amsterdam
RP de Jong, PTVM (通讯作者)，Royal Netherlands Acad Arts & Sci, KNAW, Netherlands Ophthalm Res Inst, Meibergdreef 47, NL-1105 BA Amsterdam, Netherlands.
EM p.dejong@ioi.knaw.nl
OI Ikram, Mohammad Kamran/0000-0003-0173-9571
CR Borger PH, 2003, OPHTHALMOLOGY, V110, P1292, DOI 10.1016/S0161-6420(03)00450-0
   Cedrone C, 2003, OPHTHALMOLOGY, V110, P584, DOI 10.1016/S0161-6420(02)01898-5
   Foran S, 2002, ARCH OPHTHALMOL-CHIC, V120, P613, DOI 10.1001/archopht.120.5.613
   Gilhotra JS, 2001, CLIN EXP OPHTHALMOL, V29, P104, DOI 10.1046/j.1442-9071.2001.00411.x
   HARRINGTON D, 1971, VISUAL FIELDS
   Hyman L, 2001, OPHTHALMOLOGY, V108, P1751, DOI 10.1016/S0161-6420(01)00590-5
   Ivers RQ, 1998, J AM GERIATR SOC, V46, P58
   JOHNSON CA, 1983, ARCH OPHTHALMOL-CHIC, V101, P371
   Klein R, 2001, OPHTHALMOLOGY, V108, P1757, DOI 10.1016/S0161-6420(01)00769-2
   Leske MC, 2001, ARCH OPHTHALMOL-CHIC, V119, P89
   Ott A, 1998, AM J EPIDEMIOL, V147, P574
   Rahmani B, 1996, OPHTHALMOLOGY, V103, P1721, DOI 10.1016/S0161-6420(96)30435-1
   Ramrattan RS, 2001, ARCH OPHTHALMOL-CHIC, V119, P1788, DOI 10.1001/archopht.119.12.1788
   Rodriguez J, 2002, OPHTHALMOLOGY, V109, P737, DOI 10.1016/S0161-6420(01)01008-9
   Rothman KJ., 2008, MODERN EPIDEMIOLOGY, V3
   Rubin GS, 2001, INVEST OPHTH VIS SCI, V42, P64
   Taylor HR, 1997, AM J OPHTHALMOL, V123, P328, DOI 10.1016/S0002-9394(14)70128-X
   VanNewkirk MR, 2001, OPHTHALMOLOGY, V108, P960, DOI 10.1016/S0161-6420(01)00554-1
   VINGERLING JR, 1995, AM J EPIDEMIOL, V142, P404, DOI 10.1093/oxfordjournals.aje.a117648
   Wolfs RCW, 2000, INVEST OPHTH VIS SCI, V41, P3309
NR 20
TC 30
Z9 31
U1 0
U2 3
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0003-9950
EI 1538-3601
J9 ARCH OPHTHALMOL-CHIC
JI Arch. Ophthalmol.
PD FEB
PY 2005
VL 123
IS 2
BP 233
EP 238
DI 10.1001/archopht.123.2.233
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 893XS
UT WOS:000226755000013
PM 15710821
OA Bronze
DA 2022-11-30
ER

PT J
AU Cetkovic, A
   Bellapianta, A
   Irimia-Vladu, M
   Hofinger, J
   Yumusak, C
   Corna, A
   Scharber, MC
   Zeck, G
   Sariciftci, NS
   Bolz, M
   Salti, A
AF Cetkovic, Ana
   Bellapianta, Alessandro
   Irimia-Vladu, Mihai
   Hofinger, Jakob
   Yumusak, Cigdem
   Corna, Andrea
   Scharber, Markus Clark
   Zeck, Gunther
   Sariciftci, Niyazi Serdar
   Bolz, Matthias
   Salti, Ahmad
TI In Vitro Cytotoxicity of D18 and Y6 as Potential Organic Photovoltaic
   Materials for Retinal Prostheses
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE retinal dystrophy; cytotoxicity; retinal prosthesis; D18; Y6; organic
   photovoltaic materials
ID STIMULATION; MODEL
AB Millions of people worldwide are diagnosed with retinal dystrophies such as retinitis pigmentosa and age-related macular degeneration. A retinal prosthesis using organic photovoltaic (OPV) semiconductors is a promising therapeutic device to restore vision to patients at the late onset of the disease. However, an appropriate cytotoxicity approach has to be employed on the OPV materials before using them as retinal implants. In this study, we followed ISO standards to assess the cytotoxicity of D18, Y6, PFN-Br and PDIN individually, and as mixtures of D18/Y6, D18/Y6/PFN-Br and D18/Y6/PDIN. These materials were proven for their high performance as organic solar cells. Human RPE cells were put in direct and indirect contact with these materials to analyze their cytotoxicity by the MTT assay, apoptosis by flow cytometry, and measurements of cell morphology and proliferation by immunofluorescence. We also assessed electrophysiological recordings on mouse retinal explants via microelectrode arrays (MEAs) coated with D18/Y6. In contrast to PFN-Br and PDIN, all in vitro experiments show no cytotoxicity of D18 and Y6 alone or as a D18/Y6 mixture. We conclude that D18/Y6 is safe to be subsequently investigated as a retinal prosthesis.
C1 [Cetkovic, Ana; Bellapianta, Alessandro; Bolz, Matthias; Salti, Ahmad] Johannes Kepler Univ Linz, Univ Clin Ophthalmol & Optometry, Ctr Med Res, A-4020 Linz, Austria.
   [Irimia-Vladu, Mihai; Hofinger, Jakob; Yumusak, Cigdem; Scharber, Markus Clark; Sariciftci, Niyazi Serdar] Johannes Kepler Univ Linz, Linz Inst Organ Solar Cells LIOS, Inst Phys Chem, Altenbergerstr 69, A-4040 Linz, Austria.
   [Corna, Andrea; Zeck, Gunther] Tech Univ TU Wien, Inst Biomed Elect, A-1040 Vienna, Austria.
C3 Johannes Kepler University Linz; Johannes Kepler University Linz
RP Salti, A (通讯作者)，Johannes Kepler Univ Linz, Univ Clin Ophthalmol & Optometry, Ctr Med Res, A-4020 Linz, Austria.
EM ahmad.salti@jku.at
RI Salti, Ahmad/AFR-7386-2022; Bolz, Matthias/HCI-0622-2022; Yumusak,
   Cigdem/F-4074-2015
OI Salti, Ahmad/0000-0002-7678-0125; Bellapianta,
   Alessandro/0000-0002-3375-9940; Zeck, Gunther/0000-0003-3998-9883;
   Yumusak, Cigdem/0000-0001-7207-1121
FU University Clinic for Ophthalmology and Optometry, Johannes Kepler
   University Linz, Finanzbuchhaltung Univ.-Prof. Dr. Matthias Bolz,
   Artificial Retina Project
FX This research and the APC were funded by the University Clinic for
   Ophthalmology and Optometry, Johannes Kepler University Linz,
   Finanzbuchhaltung Univ.-Prof. Dr. Matthias Bolz 161050, Artificial
   Retina Project.
CR Abdelhameed M, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-21181-8
   Ahuja AK, 2008, IEEE T BIO-MED ENG, V55, P1744, DOI 10.1109/TBME.2008.919126
   Allen PJ, 2021, CLIN EXP OPHTHALMOL, V49, P418, DOI 10.1111/ceo.13950
   [Anonymous], 2009, 109935 ONORM EN ISO
   [Anonymous], 2021, 1099312 ISO
   Antognazza MR, 2016, ADV HEALTHC MATER, V5, P2271, DOI 10.1002/adhm.201600318
   Ayton LN, 2020, CLIN NEUROPHYSIOL, V131, P1383, DOI 10.1016/j.clinph.2019.11.029
   Bellapianta A, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms23062922
   Bi SQ, 2019, ADV MATER, V31, DOI 10.1002/adma.201805708
   Biswas S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099075
   Cai CS, 2017, SOL ENERG MAT SOL C, V161, P52, DOI 10.1016/j.solmat.2016.11.027
   Castro-Galvez Z, 2019, TOXICOL IN VITRO, V61, DOI 10.1016/j.tiv.2019.104645
   Fan BB, 2019, SCI CHINA CHEM, V62, P746, DOI 10.1007/s11426-019-9457-5
   Ferlauto L, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03386-7
   Fujikado T, 2016, INVEST OPHTH VIS SCI, V57, P6147, DOI 10.1167/iovs.16-20367
   Ghezzi D, 2013, NAT PHOTONICS, V7, P400, DOI [10.1038/nphoton.2013.34, 10.1038/NPHOTON.2013.34]
   Ghezzi D, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1164
   Goo YS, 2011, KOREAN J PHYSIOL PHA, V15, P415, DOI 10.4196/kjpp.2011.15.6.415
   Hallum LE, 2021, TRANSL VIS SCI TECHN, V10, DOI 10.1167/tvst.10.10.8
   Heeger AJ., 2011, SEMICONDUCTING METAL, V21, P391
   Hofinger J, 2021, MATER ADV, V2, P4291, DOI 10.1039/d1ma00293g
   Hong JW, 2021, ISCIENCE, V24, DOI 10.1016/j.isci.2021.103550
   Irimia-Vladu M., 2017, GREEN MAT ELECT, P1, DOI [10.1002/9783527692958, DOI 10.1002/9783527692958]
   Leccardi MJIA, 2020, COMMUN MATER, V1, DOI 10.1038/s43246-020-0023-4
   Liu QS, 2020, SCI BULL, V65, P272, DOI 10.1016/j.scib.2020.01.001
   Liu ZR, 1996, ANAL BIOCHEM, V236, P139, DOI 10.1006/abio.1996.0142
   Lorach H, 2015, NAT MED, V21, P476, DOI 10.1038/nm.3851
   Maya-Vetencourt JF, 2020, FRONT BIOENG BIOTECH, V8, DOI 10.3389/fbioe.2020.579141
   Maya-Vetencourt JF, 2017, NAT MATER, V16, P681, DOI [10.1038/NMAT4874, 10.1038/nmat4874]
   Medagoda DI, 2021, COMMUN MATER, V2, DOI 10.1038/s43246-021-00217-z
   Meng LX, 2018, SCIENCE, V361, P1094, DOI 10.1126/science.aat2612
   Menzler J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0106047
   Menzler J, 2011, J NEUROSCI, V31, P2280, DOI 10.1523/JNEUROSCI.4238-10.2011
   Napoli D, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22105381
   Oosterhout SD, 2017, ORG ELECTRON, V47, P57, DOI 10.1016/j.orgel.2017.04.028
   Palanker D, 2020, OPHTHALMOLOGY, V127, P1097, DOI 10.1016/j.ophtha.2020.02.024
   Quiroga RQ, 2004, NEURAL COMPUT, V16, P1661, DOI 10.1162/089976604774201631
   Rand D, 2018, ADV MATER, V30, DOI 10.1002/adma.201707292
   Sahel JA, 2015, CSH PERSPECT MED, V5, DOI 10.1101/cshperspect.a017111
   Saltzman WM, 2014, PRINCIPLES OF TISSUE ENGINEERING, 4TH EDITION, P385, DOI 10.1016/B978-0-12-398358-9.00020-3
   Samba R, 2015, J NEURAL ENG, V12, DOI 10.1088/1741-2560/12/1/016014
   Sytnyk M, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00135-0
   Tong Y, 2020, SCI CHINA CHEM, V63, P758, DOI 10.1007/s11426-020-9726-0
   Vagni P, 2022, NAT COMMUN, V13, DOI 10.1038/s41467-022-31180-z
   Vazquez-Dominguez I, 2019, GENES-BASEL, V10, DOI 10.3390/genes10090654
   Verbakel SK, 2018, PROG RETIN EYE RES, V66, P157, DOI 10.1016/j.preteyeres.2018.03.005
   Wang ZQ, 2011, J PHOTON ENERGY, V1, DOI 10.1117/1.3606393
   Wu YJ, 2020, MATER CHEM FRONT, V4, P3444, DOI 10.1039/d0qm00279h
   Yan TT, 2019, ADV MATER, V31, DOI 10.1002/adma.201902210
   Yuan J, 2019, JOULE, V3, P1140, DOI 10.1016/j.joule.2019.01.004
   Zeck G, 2016, FRONT CELL NEUROSCI, V10, DOI 10.3389/fncel.2016.00025
   Zhang Y, 2018, SCI CHINA CHEM, V61, P1328, DOI 10.1007/s11426-018-9260-2
   Zrenner E, 2011, P ROY SOC B-BIOL SCI, V278, P1489, DOI 10.1098/rspb.2010.1747
NR 53
TC 0
Z9 0
U1 9
U2 9
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1422-0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD AUG
PY 2022
VL 23
IS 15
AR 8666
DI 10.3390/ijms23158666
PG 15
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA 3R4OF
UT WOS:000838893500001
PM 35955800
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Grover, S
   Sharma, M
AF Grover, Sandeep
   Sharma, Manu
CA Int Age-related Macular DegenerationGenomics Consortium IAMDGC
TI Sleep, Pain, and Neurodegeneration: A Mendelian Randomization Study
SO FRONTIERS IN NEUROLOGY
LA English
DT Article
DE Mendelian randomization; causal inference; neurodegenerative disorders;
   sleep; pain; chronotype
ID GENOME-WIDE ASSOCIATION; MACULAR DEGENERATION; CIRCADIAN-RHYTHMS; RISK
   LOCI; METAANALYSIS; DURATION; IDENTIFICATION; POPULATION; MELATONIN;
   DISEASE
AB Our aim was to determine whether the genetic liability to sleep and pain-related traits have a causal effect on risk of neurodegeneration in individuals of predominantly European ancestry. We selected five neurodegenerative disorders, namely, age-related macular degeneration (AMD), Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), and Parkinson's disease (PD). Sleep duration (SD), short sleep (SS), long sleep (LS), chronotype (CHR), morning person (MP), insomnia (INS), and multisite chronic pain (MCP) were considered as exposures. We conducted Mendelian randomization (MR) using an inverse-variance weighted (IVW) method to compute causal effect estimates using latest available GWAS data sets. The MP phenotype was observed as the strongest risk factor for genetic liability to AMD (ORIVW = 1.192; 95% CI 1.078, 1.318, P = 0.0007). We observed suggestive evidence of risky effects of CHR on AMD (P = 0.0034), SS on AD (P = 0.0044), and INS on ALS (P = 0.0123). However, we failed to observe any role of pain. The results were robust on sensitivity analyses. Our study highlighted the role of MP as a risk factor for AMD.
C1 [Grover, Sandeep; Sharma, Manu; Int Age-related Macular DegenerationGenomics Consortium IAMDGC] Univ Tubingen, Inst Clin Epidemiol & Appl Biometry, Ctr Genet Epidemiol, Tubingen, Germany.
C3 Eberhard Karls University of Tubingen
RP Sharma, M (通讯作者)，Univ Tubingen, Inst Clin Epidemiol & Appl Biometry, Ctr Genet Epidemiol, Tubingen, Germany.
EM manu.sharma@uni-tuebingen.de
FU International Genomics of Alzheimer's Patients (IGAP); EU [01ED1406];
   Michael J. Fox Foundation; USA Genetic Diversity in PD Program:
   GAP-India [17473]; German Research Council [DFG/SH 599/6-1]
FX This study was, in part, supported by the EU Joint
   Programme-Neurodegenerative Diseases Research (JPND) project under the
   aegis of JPND (www.jpnd.eu) through Germany, BMBF, funding code
   01ED1406. MS was further funded by the Michael J. Fox Foundation, USA
   Genetic Diversity in PD Program: GAP-India Grant ID: 17473 and supported
   by grants from the German Research Council (DFG/SH 599/6-1 to MS), and
   MSA Coalition.
CR Anastasopoulos E, 2018, OPHTHAL EPIDEMIOL, V25, P457, DOI 10.1080/09286586.2018.1512634
   Angrist JD, 1996, J AM STAT ASSOC, V91, P444, DOI 10.2307/2291629
   Augustin AJ, 2002, KLIN MONATSBL AUGENH, V219, P631, DOI 10.1055/s-2002-35164
   Bokenberger K, 2017, J GERONTOL A-BIOL, V72, P134, DOI 10.1093/gerona/glw127
   Bulik-Sullivan BK, 2015, NAT GENET, V47, P291, DOI 10.1038/ng.3211
   Cravello L, 2019, PAIN THER, V8, P53, DOI 10.1007/s40122-019-0111-7
   Cullell N, 2021, NEUROBIOL AGING, V106, DOI 10.1016/j.neurobiolaging.2021.05.008
   Dashti HS, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-08917-4
   de Tommaso M, 2016, BEHAV NEUROL, V2016, DOI 10.1155/2016/7576292
   de Tommaso M, 2016, BEHAV NEUROL, V2016, DOI 10.1155/2016/2949358
   Feustel AC, 2020, NEUROLOGY, V94, pE1, DOI 10.1212/WNL.0000000000008699
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Grover S, 2019, NEUROLOGY, V93, pE1412, DOI 10.1212/WNL.0000000000008245
   Grover S, 2017, METHODS MOL BIOL, V1666, P581, DOI 10.1007/978-1-4939-7274-6_29
   Gunther R, 2016, FRONT NEUROL, V7, DOI 10.3389/fneur.2016.00117
   Henry A, 2019, INT J EPIDEMIOL, V48, P849, DOI 10.1093/ije/dyz071
   Henry DE, 2011, PM&R, V3, P1116, DOI 10.1016/j.pmrj.2011.05.018
   Herzog ED, 2007, NAT REV NEUROSCI, V8, P790, DOI 10.1038/nrn2215
   Hooghiemstra AM, 2015, ALZ DIS ASSOC DIS, V29, P45, DOI 10.1097/WAD.0000000000000037
   Jansen IE, 2019, NAT GENET, V51, P404, DOI 10.1038/s41588-018-0311-9
   Jansen PR, 2019, NAT GENET, V51, P394, DOI 10.1038/s41588-018-0333-3
   Johnston KJA, 2019, PLOS GENET, V15, DOI 10.1371/journal.pgen.1008164
   Jones SE, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-018-08259-7
   Khurana RN, 2016, RETINA-J RET VIT DIS, V36, P255, DOI 10.1097/IAE.0000000000000706
   Krupp L, 2006, MULT SCLER J, V12, P367, DOI 10.1191/135248506ms1373ed
   Lambert JC, 2013, NAT GENET, V45, P1452, DOI 10.1038/ng.2802
   Leng Y, 2019, LANCET NEUROL, V18, P307, DOI 10.1016/S1474-4422(18)30461-7
   Leng Y, 2018, INT J EPIDEMIOL, V47, P1679, DOI 10.1093/ije/dyy098
   Lo Coco D, 2011, J NEUROL NEUROSUR PS, V82, P839, DOI 10.1136/jnnp.2010.228007
   May A, 2007, NEUROL SCI, V28, pS101, DOI 10.1007/s10072-007-0760-x
   Nalls MA, 2019, LANCET NEUROL, V18, P1091, DOI 10.1016/S1474-4422(19)30320-5
   Nalls MA, 2014, NAT GENET, V46, P989, DOI 10.1038/ng.3043
   Ohara T, 2018, J AM GERIATR SOC, V66, P1911, DOI 10.1111/jgs.15446
   Paladini A, 2015, PAIN PHYSICIAN, V18, pE863
   Panda S, 2018, NEUROL INDIA, V66, P700, DOI 10.4103/0028-3886.232327
   Patsopoulos NA, 2019, SCIENCE, V365, P1417, DOI 10.1126/science.aav7188
   Perez-Canales JL, 2016, OPHTHAL EPIDEMIOL, V23, P20, DOI 10.3109/09286586.2015.1119288
   Pinho-Ribeiro FA, 2017, TRENDS IMMUNOL, V38, P5, DOI 10.1016/j.it.2016.10.001
   Roberts JE, 2001, J PHOTOCH PHOTOBIO B, V64, P136, DOI 10.1016/S1011-1344(01)00196-8
   Robinson DG, 2018, INVEST OPHTH VIS SCI, V59, P4531, DOI 10.1167/iovs.18-24284
   Tomany SC, 2004, ARCH OPHTHALMOL-CHIC, V122, P750, DOI 10.1001/archopht.122.5.750
   Tosini G, 2012, EXP EYE RES, V103, P82, DOI 10.1016/j.exer.2012.08.009
   Tsai DC, 2020, ACTA OPHTHALMOL, V98, pE238, DOI 10.1111/aos.14238
   Valkovic P, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0136541
   van Rheenen W, 2016, NAT GENET, V48, P1043, DOI 10.1038/ng.3622
   Verbanck M, 2018, NAT GENET, V50, P693, DOI 10.1038/s41588-018-0099-7
   Videnovic A, 2014, NAT REV NEUROL, V10, P683, DOI 10.1038/nrneurol.2014.206
   Videnovic A, 2014, JAMA NEUROL, V71, P463, DOI 10.1001/jamaneurol.2013.6239
   Westwood AJ, 2017, NEUROLOGY, V88, P1172, DOI 10.1212/WNL.0000000000003732
   Winkler BS, 1999, MOL VIS, V5
   Zhang G, 2021, J NEUROL, V268, P4332, DOI 10.1007/s00415-021-10564-z
   Zhou HJ, 2018, BMC OPHTHALMOL, V18, DOI 10.1186/s12886-018-1004-y
NR 52
TC 0
Z9 0
U1 3
U2 3
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-2295
J9 FRONT NEUROL
JI Front. Neurol.
PD MAY 2
PY 2022
VL 13
AR 765321
DI 10.3389/fneur.2022.765321
PG 25
WC Clinical Neurology; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA 1I0JN
UT WOS:000796924200001
PM 35585838
OA Green Published, Green Submitted, gold
DA 2022-11-30
ER

PT J
AU Al-Ani, A
   Sunba, S
   Hafeez, B
   Toms, D
   Ungrin, M
AF Al-Ani, Abdullah
   Sunba, Saud
   Hafeez, Bilal
   Toms, Derek
   Ungrin, Mark
TI In Vitro Maturation of Retinal Pigment Epithelium Is Essential for
   Maintaining High Expression of Key Functional Genes
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE retinal pigment epithelium (RPE); maturation; differentiation; embryonic
   stem cells; pigment epithelium derived factor (PEDF); cell culture
ID EMBRYONIC STEM-CELLS; ENDOTHELIAL GROWTH-FACTOR; MACULAR DEGENERATION;
   SUBRETINAL IMPLANTATION; VISUAL IMPAIRMENT; BRUCHS MEMBRANE; RCS RAT;
   RPE; VEGF; RESCUE
AB Age-related macular degeneration (AMD) is the leading cause of blindness in the industrialized world. AMD is associated with dysfunction and atrophy of the retinal pigment epithelium (RPE), which provides critical support for photoreceptor survival and function. RPE transplantation is a promising avenue towards a potentially curative treatment for early stage AMD patients, with encouraging reports from animal trials supporting recent progression toward clinical treatments. Mature RPE cells have been reported to be superior, but a detailed investigation of the specific changes in the expression pattern of key RPE genes during maturation is lacking. To understand the effect of maturity on RPE, we investigated transcript levels of 19 key RPE genes using ARPE-19 cell line and human embryonic stem cell-derived RPE cultures. Mature RPE cultures upregulated PEDF, IGF-1, CNTF and BDNF-genes that code for trophic factors known to enhance the survival and function of photoreceptors. Moreover, the mRNA levels of these genes are maximized after 42 days of maturation in culture and lost upon dissociation to single cells. Our findings will help to inform future animal and human RPE transplantation efforts.
C1 [Al-Ani, Abdullah; Sunba, Saud; Hafeez, Bilal; Toms, Derek; Ungrin, Mark] Univ Calgary, Fac Vet Med, Dept Comparat Biol & Expt Med, Calgary, AB T2N 1N4, Canada.
   [Al-Ani, Abdullah; Toms, Derek; Ungrin, Mark] Univ Calgary, Alberta Childrens Hosp, Res Inst, Calgary, AB T2N 4N1, Canada.
   [Al-Ani, Abdullah; Ungrin, Mark] Univ Alberta, Alberta Diabet Inst, Edmonton, AB T6G 2E1, Canada.
   [Al-Ani, Abdullah; Ungrin, Mark] Univ Calgary, Biomed Engn Grad Program, Calgary, AB T2N 1N4, Canada.
   [Al-Ani, Abdullah] Univ Calgary, Cumming Sch Med, Med Program, Calgary, AB T2N 4N1, Canada.
C3 University of Calgary; Alberta Childrens Hospital; University of
   Calgary; University of Alberta; University of Calgary; University of
   Calgary
RP Toms, D (通讯作者)，Univ Calgary, Fac Vet Med, Dept Comparat Biol & Expt Med, Calgary, AB T2N 1N4, Canada.; Toms, D (通讯作者)，Univ Calgary, Alberta Childrens Hosp, Res Inst, Calgary, AB T2N 4N1, Canada.
EM aalani@ucalgary.ca; saud.sunba@ucalgary.ca; muhammad.hafeez@ucalgary.ca;
   derek.toms@ucalgary.ca; mdungrin@ucalgary.ca
OI Al-Ani, Abdullah/0000-0001-5057-7033; Ungrin, Mark/0000-0002-7410-1491;
   Toms, Derek/0000-0002-5114-7147
FU Brain Canada; Canadian National Institute for the Blind; Alberta
   Children's Hospital Research Institute; University of Calgary Biomedical
   Engineering Graduate Program; Canadian Institutes of Health Research
FX This work was funded by grants from Brain Canada (M.U.) and the Canadian
   National Institute for the Blind (D.T., M.U.). A.A.-A. and D.T. were
   supported by fellowships from the Alberta Children's Hospital Research
   Institute; A.A.-A. also received funding from the University of Calgary
   Biomedical Engineering Graduate Program and Canadian Institutes of
   Health Research.
CR Ablonczy Z, 2011, INVEST OPHTH VIS SCI, V52, P8614, DOI 10.1167/iovs.11-8021
   Al-Ani A, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0204269
   Algvere PV, 1997, GRAEF ARCH CLIN EXP, V235, P149, DOI 10.1007/BF00941722
   Arroba AI, 2011, INVEST OPHTH VIS SCI, V52, P9124, DOI 10.1167/iovs.11-7736
   Arroba AI, 2009, EUR J NEUROSCI, V30, P975, DOI 10.1111/j.1460-9568.2009.06902.x
   Azadi S, 2007, BRAIN RES, V1129, P116, DOI 10.1016/j.brainres.2006.10.031
   Barnstable CJ, 2004, PROG RETIN EYE RES, V23, P561, DOI 10.1016/j.preteyeres.2004.05.002
   Ben M'Barek K, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aai7471
   Bennis A, 2017, STEM CELL REV REP, V13, P659, DOI 10.1007/s12015-017-9754-0
   Bhutto IA, 2006, EXP EYE RES, V82, P99, DOI 10.1016/j.exer.2005.05.007
   Bird AC, 2010, J CLIN INVEST, V120, P3033, DOI 10.1172/JCI42437
   Bouck N, 2002, TRENDS MOL MED, V8, P330, DOI 10.1016/S1471-4914(02)02362-6
   Buchholz DE, 2009, STEM CELLS, V27, P2427, DOI 10.1002/stem.189
   Caffe AR, 2001, INVEST OPHTH VIS SCI, V42, P275
   Calton MA, 2018, MOL VIS, V24, P425
   CAMPOCHIARO PA, 1994, J CELL SCI, V107, P2459
   Castillo BV, 1997, EXP NEUROL, V146, P1, DOI 10.1006/exnr.1997.6534
   Chen HY, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002339
   Chou CF, 2013, AM J PREV MED, V45, P29, DOI 10.1016/j.amepre.2013.02.018
   Comitato A, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0613-y
   da Cruz L, 2018, NAT BIOTECHNOL, V36, P1, DOI 10.1038/nbt.4114
   Davis RJ, 2017, STEM CELL REP, V9, P42, DOI 10.1016/j.stemcr.2017.05.016
   Diniz B, 2013, INVEST OPHTH VIS SCI, V54, P5087, DOI 10.1167/iovs.12-11239
   DOMENICI E, 2017, JOJ OPHTHALMOL, V3, DOI DOI 10.19080/JOJO.2017.03.555620
   Donato L, 2020, ANTIOXIDANTS-BASEL, V9, DOI 10.3390/antiox9050416
   Dunn KC, 1996, EXP EYE RES, V62, P155, DOI 10.1006/exer.1996.0020
   Frick KD, 2007, ARCH OPHTHALMOL-CHIC, V125, P544, DOI 10.1001/archopht.125.4.544
   Geiger M., 2015, SERPIN FAMILY
   German OL, 2008, J NEUROSCI RES, V86, P3503, DOI 10.1002/jnr.21813
   Gogat K, 2004, INVEST OPHTH VIS SCI, V45, P7, DOI 10.1167/iovs.02-1096
   Hagglund AC, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023387
   Hall MO, 2002, EXP EYE RES, V75, P391, DOI 10.1006/exer.2002.2030
   Haurigot V, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041511
   Hettich C, 2014, GRAEF ARCH CLIN EXP, V252, P1747, DOI 10.1007/s00417-014-2742-z
   Hochmann S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030365
   Johnson AA, 2017, PROG RETIN EYE RES, V58, P45, DOI 10.1016/j.preteyeres.2017.01.006
   Jonas JB, 2010, ARCH OPHTHALMOL-CHIC, V128, P1281, DOI 10.1001/archophthalmol.2010.227
   Kamei M, 1999, INVEST OPHTH VIS SCI, V40, P2367
   Kaplan HJ, 1999, NAT MED, V5, P292, DOI 10.1038/6509
   Kashani AH, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aao4097
   Kim LA, 2012, AM J PATHOL, V181, P376, DOI 10.1016/j.ajpath.2012.06.006
   Kim YH, 2009, GRAEF ARCH CLIN EXP, V247, P651, DOI 10.1007/s00417-009-1049-y
   Klassen H, 2016, EXPERT OPIN BIOL TH, V16, P7, DOI 10.1517/14712598.2016.1093110
   Klimanskaya I, 2004, CLONING STEM CELLS, V6, P217, DOI 10.1089/1536230042323420
   Kopplin LJ, 2010, GENES IMMUN, V11, P609, DOI 10.1038/gene.2010.39
   Koss MJ, 2016, GRAEF ARCH CLIN EXP, V254, P1553, DOI 10.1007/s00417-016-3386-y
   LaVail MM, 2012, RETINAL DEGENERATIVE
   LI LX, 1988, EXP EYE RES, V47, P911, DOI 10.1016/0014-4835(88)90073-5
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Little CW, 1996, INVEST OPHTH VIS SCI, V37, P204
   Liu X, 2016, GENE, V580, P41, DOI 10.1016/j.gene.2016.01.001
   Lu B, 2009, STEM CELLS, V27, P2126, DOI 10.1002/stem.149
   Lund RD, 2006, CLONING STEM CELLS, V8, P189, DOI 10.1089/clo.2006.8.189
   Mandai M, 2017, NEW ENGL J MED, V376, P1038, DOI 10.1056/NEJMoa1608368
   Maruotti J, 2015, P NATL ACAD SCI USA, V112, P10950, DOI 10.1073/pnas.1422818112
   Masuda T, 2014, J BIOL CHEM, V289, P12908, DOI 10.1074/jbc.M114.556738
   Moiseyev G, 2005, P NATL ACAD SCI USA, V102, P12413, DOI 10.1073/pnas.0503460102
   Mori K, 2006, INVEST OPHTH VIS SCI, V43, P2001
   Nagineni CN, 2003, J CELL PHYSIOL, V197, P453, DOI 10.1002/jcp.10378
   Ohno-Matsui K, 2001, J CELL PHYSIOL, V189, P323, DOI 10.1002/jcp.10026
   R Core Team, 2018, R LANG ENV STAT COMP
   Raoul W, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-87
   Regent F, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-47123-6
   Rein DB, 2006, ARCH OPHTHALMOL-CHIC, V124, P1754, DOI 10.1001/archopht.124.12.1754
   Ren SW, 2010, MOL VIS, V16, P1076
   Ricci F, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066978
   Ruiz A, 1996, BIOCHEM BIOPH RES CO, V226, P467, DOI 10.1006/bbrc.1996.1379
   Sachdeva MM, 2016, SEMIN OPHTHALMOL, V31, P25, DOI 10.3109/08820538.2015.1115253
   Sadiq MA, 2015, SAUDI J OPHTHALMOL, V29, P287, DOI 10.1016/j.sjopt.2015.05.005
   Saint-Geniez M, 2009, P NATL ACAD SCI USA, V106, P18751, DOI 10.1073/pnas.0905010106
   Samuel W, 2017, MOL VIS, V23, P60
   Schwartz SD, 2016, INVEST OPHTH VIS SCI, V57, DOI 10.1167/iovs.15-18681
   Schwartz SD, 2015, LANCET, V385, P509, DOI 10.1016/S0140-6736(14)61376-3
   Schwartz SD, 2012, LANCET, V379, P713, DOI 10.1016/S0140-6736(12)60028-2
   Singer Michael, 2014, F1000Prime Rep, V6, P29, DOI 10.12703/P6-29
   Sparrrow JR, 2010, CURR MOL MED, V10, P802
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Strunnikova NV, 2010, HUM MOL GENET, V19, P2468, DOI 10.1093/hmg/ddq129
   Tan YSE, 2018, BRIT J OPHTHALMOL, V102, P1182, DOI 10.1136/bjophthalmol-2017-311390
   Tosi GM, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19113363
   Warwick A, 2016, EYE, V30, P488, DOI 10.1038/eye.2015.204
   WEBER BHF, 1994, NAT GENET, V8, P352, DOI 10.1038/ng1294-352
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Zajac-Pytrus HM, 2015, ADV CLIN EXP MED, V24, P1099, DOI 10.17219/acem/27093
   Zamiri P, 2005, INVEST OPHTH VIS SCI, V46, P908, DOI 10.1167/iovs.04-0362
   Zhang M, 2009, CURR EYE RES, V34, P791, DOI 10.1080/02713680903086018
NR 86
TC 2
Z9 2
U1 0
U2 3
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1422-0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD SEP
PY 2020
VL 21
IS 17
AR 6066
DI 10.3390/ijms21176066
PG 15
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA NQ7QJ
UT WOS:000571063900001
PM 32842471
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Rossato, FA
   Su, Y
   Mackey, A
   Ng, YSE
AF Rossato, Franco Aparecido
   Su, Yu
   Mackey, Ashley
   Ng, Yin Shan Eric
TI Fibrotic Changes and Endothelial-to-Mesenchymal Transition Promoted by
   VEGFR2 Antagonism Alter the Therapeutic Effects of VEGFA Pathway
   Blockage in a Mouse Model of Choroidal Neovascularization
SO CELLS
LA English
DT Article
DE endothelial-to-mesenchymal transition; choroidal neovascularization;
   age-related macular degeneration; VEGFA; VEGFA resistance
ID GROWTH-FACTOR; MACULAR DEGENERATION; FACTOR EXPRESSION; CELL-ADHESION;
   RANIBIZUMAB; INFLAMMATION; ANGIOGENESIS; INHIBITORS; EYE
AB Many patients with wet age-related macular degeneration do not respond well to anti- vascular endothelial growth factor A (VEGFA) therapy for choroidal neovascularization (CNV), and the efficacy of anti-VEGFA decreases over time. We investigated the hypothesis that fibrotic changes, in particular via endothelial-to-mesenchymal transition (EndoMT), play a role in CNV and alter the therapeutic effects of VEGFA pathway blockage. Induction of EndoMT of primary human retinal endothelial cells led to a significantly reduced response to VEGFA at the level of gene expression, cellular proliferation, migration, and tube formation. Suppression of EndoMT restored cell responsiveness to VEGFA. In a mouse model of spontaneous CNV, fibrotic changes and EndoMT persisted as the CNV lesions became more established over time. VEGFA receptor-2 (VEGFR2) antagonism further induced fibrosis and EndoMT in the CNV. The combination of VEGFR2 antagonism and fibrosis/EndoMT inhibition was more effective than either individual treatment in reducing CNV. Our data indicate that fibrosis and EndoMT are involved in the progression of CNV, are exacerbated by VEGFR2 inhibition, and could provide an explanation for the reduced efficacy of anti-VEGFA treatment over time.
C1 [Rossato, Franco Aparecido; Su, Yu; Mackey, Ashley; Ng, Yin Shan Eric] Schepens Eye Res Inst Mass Eye & Ear, Dept Ophthalmol, 20 Staniford St, Boston, MA 02114 USA.
   [Rossato, Franco Aparecido; Su, Yu; Mackey, Ashley; Ng, Yin Shan Eric] Harvard Med Sch, 20 Staniford St, Boston, MA 02114 USA.
   [Su, Yu] Wuhan Univ, Ophthalm Ctr, Renmin Hosp, Wuhan 430000, Peoples R China.
C3 Harvard University; Harvard Medical School; Wuhan University
RP Ng, YSE (通讯作者)，Schepens Eye Res Inst Mass Eye & Ear, Dept Ophthalmol, 20 Staniford St, Boston, MA 02114 USA.; Ng, YSE (通讯作者)，Harvard Med Sch, 20 Staniford St, Boston, MA 02114 USA.
EM rossatofap@gmail.com; sy_daisy1206@163.com; ashley.mackey@biogen.com;
   eric_ng@meei.harvard.edu
OI Reis, AlessanRSS/0000-0001-8486-7469; Ng, Yin Shan/0000-0002-4982-1999;
   Su, Yu/0000-0002-4159-1033
FU Grimshaw-Gudewicz Charitable Foundation; MALion's Eye Foundation AMD
   Research grant; BrightFocus Foundation AMD Research Grant [M2015214];
   CNPq, National Council of Scientific and Technological
   Development-Brazil [PDE 210477/2014-8]; NIH National Eye Institute Core
   Grant [P30EY003790]
FX This project was supported by the Grimshaw-Gudewicz Charitable
   Foundation (Y.S.E.N.), theMALion's Eye Foundation AMD Research grant
   (Y.S.E.N.), the BrightFocus Foundation AMD Research Grant M2015214
   (Y.S.E.N.), CNPq, National Council of Scientific and Technological
   Development-Brazil (PDE 210477/2014-8) (F.A.R.) and by the NIH National
   Eye Institute Core Grant P30EY003790.
CR Bain J, 2007, BIOCHEM J, V408, P297, DOI 10.1042/BJ20070797
   Bakri SJ, 2019, OPHTHALMOLOGY, V126, P55, DOI 10.1016/j.ophtha.2018.07.028
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Casalino G, 2018, OPHTHALMOL RETINA, V2, P451, DOI 10.1016/j.oret.2017.08.019
   Chen XY, 2016, ONCOTARGET, V7, P31053, DOI 10.18632/oncotarget.8842
   Cho JG, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00294
   Cuenda A, 2007, BBA-MOL CELL RES, V1773, P1358, DOI 10.1016/j.bbamcr.2007.03.010
   Daniel E, 2014, OPHTHALMOLOGY, V121, P656, DOI 10.1016/j.ophtha.2013.10.019
   Dejana E, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14361
   Detmar M, 1998, J INVEST DERMATOL, V111, P1, DOI 10.1046/j.1523-1747.1998.00262.x
   Doyle SL, 2015, INVEST OPHTH VIS SCI, V56, P5424, DOI 10.1167/iovs.15-17264
   Dubrac A, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05926-7
   Evrard SM, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11853
   Feng LL, 2017, AM J PATHOL, V187, P2208, DOI 10.1016/j.ajpath.2017.06.015
   Framme C, 2010, INVEST OPHTH VIS SCI, V51, P1671, DOI 10.1167/iovs.09-4496
   Good RB, 2015, AM J PATHOL, V185, P1850, DOI 10.1016/j.ajpath.2015.03.019
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Henderson WR, 2010, P NATL ACAD SCI USA, V107, P14309, DOI 10.1073/pnas.1001520107
   Hsu MY, 2016, SCI REP-UK, V6, DOI 10.1038/srep34631
   Hwang JC, 2011, OPHTHAL SURG LAS IM, V42, DOI 10.3928/15428877-20100924-01
   Illigens BMW, 2017, ANN THORAC SURG, V104, P932, DOI 10.1016/j.athoracsur.2017.01.112
   Kauppinen A, 2016, CELL MOL LIFE SCI, V73, P1765, DOI 10.1007/s00018-016-2147-8
   Kim I, 2001, J BIOL CHEM, V276, P7614, DOI 10.1074/jbc.M009705200
   Kuiper EJ, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002675
   Li SD, 2016, SCI REP-UK, V6, DOI 10.1038/srep33349
   Li XY, 2011, J CELL BIOL, V195, P729, DOI 10.1083/jcb.201105103
   Lin F, 2012, IUBMB LIFE, V64, P717, DOI 10.1002/iub.1059
   Liu TR, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05982-z
   Maguire MG, 2016, OPHTHALMOLOGY, V123, P1751, DOI 10.1016/j.ophtha.2016.03.045
   Mechtcheriakova D, 1999, BLOOD, V93, P3811, DOI 10.1182/blood.V93.11.3811.411k40_3811_3823
   Medici D, 2011, BIOCHEM J, V437, P515, DOI 10.1042/BJ20101500
   Melder RJ, 1996, NAT MED, V2, P992, DOI 10.1038/nm0996-992
   Mitchell TS, 2008, ANGIOGENESIS, V11, P141, DOI 10.1007/s10456-007-9085-x
   Nagai N, 2015, AM J PATHOL, V185, P2534, DOI 10.1016/j.ajpath.2015.04.029
   Nagai N, 2014, INVEST OPHTH VIS SCI, V55, P3709, DOI 10.1167/iovs.14-13989
   Piera-Velazquez S, 2011, AM J PATHOL, V179, P1074, DOI 10.1016/j.ajpath.2011.06.001
   Ratnapriya R, 2013, CLIN GENET, V84, P160, DOI 10.1111/cge.12206
   Regula JT, 2016, EMBO MOL MED, V8, P1265, DOI 10.15252/emmm.201505889
   Rieder F, 2011, AM J PATHOL, V179, P2660, DOI 10.1016/j.ajpath.2011.07.042
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sahlgren C, 2008, P NATL ACAD SCI USA, V105, P6392, DOI 10.1073/pnas.0802047105
   Sharili AS, 2013, CANCER LETT, V333, P170, DOI 10.1016/j.canlet.2013.01.027
   Shen JH, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-1049-0
   Sugiyama N, 2012, NEPHROL DIAL TRANSPL, V27, P1351, DOI 10.1093/ndt/gfr550
   Sung CO, 2011, AM J PATHOL, V179, P1827, DOI 10.1016/j.ajpath.2011.06.032
   Wang Y, 2011, EYE, V25, P127, DOI 10.1038/eye.2010.196
   Wang ZJ, 2016, BIOTECHNOL BIOENG, V113, P1403, DOI 10.1002/bit.25905
   Welch-Reardon KM, 2015, ARTERIOSCL THROM VAS, V35, P303, DOI 10.1161/ATVBAHA.114.303220
   Yang SQ, 2016, DRUG DES DEV THER, V10, P1857, DOI 10.2147/DDDT.S97653
   Zhang Y, 2016, SCI REP-UK, V6, DOI 10.1038/srep33787
NR 51
TC 8
Z9 8
U1 2
U2 4
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2073-4409
J9 CELLS-BASEL
JI Cells
PD SEP
PY 2020
VL 9
IS 9
AR 2057
DI 10.3390/cells9092057
PG 21
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA OF6UF
UT WOS:000581339300001
PM 32917003
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Coffey, AM
   Hutton, EK
   Combe, L
   Bhindi, P
   Gertig, D
   Constable, PA
AF Coffey, Alexandra M.
   Hutton, Emily K.
   Combe, Louise
   Bhindi, Pooja
   Gertig, Demi
   Constable, Paul A.
TI Optical coherence tomography angiography in primary eye care
SO CLINICAL AND EXPERIMENTAL OPTOMETRY
LA English
DT Review
DE foveal avascular zone; OCT-A; optical coherence tomography angiography;
   vessel density
ID VESSEL DENSITY; OCT ANGIOGRAPHY; CAPILLARY DENSITY; GLAUCOMA SUSPECT;
   SEVERITY; HEALTHY; MICROVASCULATURE; PARAMETERS; QUANTIFICATION;
   PERFUSION
AB Optical coherence tomography angiography (OCT-A) is a non-invasive imaging modality for assessing the vasculature within ocular structures including the retina, macula, choroid and optic nerve. OCT-A has a wide range of clinical applications in various optometric conditions which have been independently reported in the literature. This paper aims to present a review of the current literature on the clinical application of OCT-A in optometric practice as well as to analyse and evaluate the quality of the available evidence. This review included 78 articles from a literature search conducted on 26 May 2019 across the following databases: Cochrane Library of Systematic Reviews, Medline, Scopus and Web of Science. Primary ocular pathologies discussed in this review include glaucoma, diabetic retinopathy, age-related macular degeneration, myopia, acquired and congenital macular dystrophies, epiretinal membrane, retinal vein occlusion, retinitis pigmentosa, choroidal melanoma, uveitis, central serous chorioretinopathy, amblyopia and optic neuropathies. Primary outcome variables included vessel density, foveal avascular zone area and diameter, flow velocity and flow index. This review aims to evaluate the evidence available for OCT-A applications in diagnosis and prognosis of ocular conditions in an optometric setting.
C1 [Coffey, Alexandra M.; Hutton, Emily K.; Combe, Louise; Bhindi, Pooja; Gertig, Demi; Constable, Paul A.] Flinders Univ S Australia, Coll Nursing & Hlth Sci, Caring Futures Inst, Adelaide, SA, Australia.
C3 Flinders University South Australia
RP Constable, PA (通讯作者)，Flinders Univ S Australia, Coll Nursing & Hlth Sci, Caring Futures Inst, Adelaide, SA, Australia.
EM paul.constable@flinders.edu.au
RI constable, paul/AAF-7227-2019
OI constable, paul/0000-0002-3994-1700; Gertig, Demi/0000-0002-8031-4098
CR Akagi T, 2016, AM J OPHTHALMOL, V168, P237, DOI 10.1016/j.ajo.2016.06.009
   Alnawaiseh M, 2018, GRAEF ARCH CLIN EXP, V256, P589, DOI 10.1007/s00417-017-3865-9
   Arrigo A, 2018, AM J OPHTHALMOL, V195, P233, DOI 10.1016/j.ajo.2018.08.001
   Arya M, 2018, EXPERT REV MED DEVIC, V15, P875, DOI 10.1080/17434440.2018.1548932
   Ashraf M, 2018, INVEST OPHTH VIS SCI, V59, P4292, DOI 10.1167/iovs.18-24142
   Augstburger E, 2018, INVEST OPHTH VIS SCI, V59, P870, DOI 10.1167/iovs.17-22996
   Bhanushali D, 2016, INVEST OPHTH VIS SCI, V57, pOCT519, DOI 10.1167/iovs.15-18901
   Campbell JP, 2017, SCI REP-UK, V7, DOI 10.1038/srep42201
   Cennamo G, 2017, GRAEF ARCH CLIN EXP, V255, P1787, DOI 10.1007/s00417-017-3709-7
   Cennamo G, 2017, ACTA OPHTHALMOL, V95, pE36, DOI 10.1111/aos.13159
   Chen HSL, 2017, INVEST OPHTH VIS SCI, V58, P3637, DOI 10.1167/iovs.17-21846
   Chen QY, 2017, CLIN EXP OPHTHALMOL, V45, P884, DOI 10.1111/ceo.12986
   Choi J, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0184948
   Conti FF, 2019, BRIT J OPHTHALMOL, V103, P452, DOI 10.1136/bjophthalmol-2018-311903
   Dave VP, 2019, CAN J OPHTHALMOL, V54, P297, DOI 10.1016/j.jcjo.2018.06.009
   de Carlo Talisa E, 2015, Int J Retina Vitreous, V1, P5
   Dogan B, 2019, INT OPHTHALMOL, V39, P2245, DOI 10.1007/s10792-018-01060-x
   Elias C, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2017-016264
   Emre S, 2019, INT OPHTHALMOL, V39, P2391, DOI 10.1007/s10792-019-01080-1
   Fard MA, 2019, J NEURO-OPHTHALMOL, V39, P339, DOI 10.1097/WNO.0000000000000775
   Fard MA, 2019, INVEST OPHTH VIS SCI, V60, P168, DOI 10.1167/iovs.18-25453
   Faridi A, 2017, OPHTHALMOL RETINA, V1, P294, DOI 10.1016/j.oret.2017.02.007
   Feucht N, 2019, MULT SCLER J, V25, P224, DOI 10.1177/1352458517750009
   FORTE R, 2019, BR J OPHTHALMOL
   Gao SS, 2016, INVEST OPHTH VIS SCI, V57, pOCT27, DOI 10.1167/iovs.15-19043
   Goker YS, 2019, CURR EYE RES, V44, P311, DOI 10.1080/02713683.2018.1545912
   Hagag AM, 2019, AM J OPHTHALMOL, V204, P70, DOI 10.1016/j.ajo.2019.02.034
   Hollo G, 2018, J GLAUCOMA, V27, P302, DOI 10.1097/IJG.0000000000000868
   Hou HY, 2018, AM J OPHTHALMOL, V190, P69, DOI 10.1016/j.ajo.2018.03.026
   Kang JW, 2017, RETINA-J RET VIT DIS, V37, P1700, DOI 10.1097/IAE.0000000000001403
   Kiyota N, 2018, ACTA OPHTHALMOL, V96, pE485, DOI 10.1111/aos.13639
   Koyanagi Y, 2018, ACTA OPHTHALMOL, V96, pE59, DOI 10.1111/aos.13475
   Kromer R, 2019, ACTA OPHTHALMOL, V97, pE199, DOI 10.1111/aos.13914
   Kumar RS, 2016, INVEST OPHTH VIS SCI, V57, P6079, DOI 10.1167/iovs.16-19984
   Kurysheva NI, 2018, MEDICINE, V97, DOI 10.1097/MD.0000000000009744
   Kurysheva NI, 2016, RES J PHARM BIOL CHE, V7, P651
   Kwon J, 2017, J GLAUCOMA, V26, P1120, DOI 10.1097/IJG.0000000000000800
   Lee H, 2018, RETINA-J RET VIT DIS, V38, P976, DOI 10.1097/IAE.0000000000001618
   Leveque PM, 2016, J OPHTHALMOL, V2016, DOI 10.1155/2016/6956717
   Li L, 2019, ACTA OPHTHALMOL, V97, P240, DOI 10.1111/aos.14076
   Li ZJ, 2019, ACTA DIABETOL, V56, P531, DOI 10.1007/s00592-019-01288-8
   Lommatzsch C, 2018, GRAEF ARCH CLIN EXP, V256, P1499, DOI 10.1007/s00417-018-3965-1
   Lommatzsch C, 2018, INT J OPHTHALMOL-CHI, V11, P835, DOI 10.18240/ijo.2018.05.20
   Lupidi M, 2017, OPHTHALMIC RES, V58, P131, DOI 10.1159/000471885
   Lynch G, 2018, BIOMED OPT EXPRESS, V9, P5982, DOI 10.1364/BOE.9.005982
   Manalastas PIC, 2018, J GLAUCOMA, V27, P227, DOI 10.1097/IJG.0000000000000862
   Mansoori T, 2018, SAUDI J OPHTHALMOL, V32, P295, DOI 10.1016/j.sjopt.2018.09.006
   Mansoori T, 2017, J GLAUCOMA, V26, P438, DOI 10.1097/IJG.0000000000000649
   Matet A, 2019, RETINA-J RET VIT DIS, V39, P2178, DOI 10.1097/IAE.0000000000002271
   Milani P, 2018, GRAEF ARCH CLIN EXP, V256, P1419, DOI 10.1007/s00417-018-4012-y
   Muller PL, 2018, INVEST OPHTH VIS SCI, V59, pAMD122, DOI 10.1167/iovs.18-23819
   Nelis P, 2017, GRAEF ARCH CLIN EXP, V255, P1319, DOI 10.1007/s00417-017-3640-y
   Nesper PL, 2017, INVEST OPHTH VIS SCI, V58, P307, DOI 10.1167/iovs.17-21787
   Parodi MB, 2017, BRIT J OPHTHALMOL, V101, P428, DOI 10.1136/bjophthalmol-2016-308925
   Parodi MB, 2017, BRIT J OPHTHALMOL, V101, P780, DOI 10.1136/bjophthalmol-2016-308869
   Penteado RC, 2018, J GLAUCOMA, V27, P481, DOI 10.1097/IJG.0000000000000964
   Pichi F, 2018, ACTA OPHTHALMOL, V96, pE549, DOI 10.1111/aos.13602
   Rao HL, 2017, BRIT J OPHTHALMOL, V101, P1066, DOI 10.1136/bjophthalmol-2016-309377
   Rao HL, 2016, AM J OPHTHALMOL, V171, P75, DOI 10.1016/j.ajo.2016.08.030
   Richter GM, 2018, TRANSL VIS SCI TECHN, V7, DOI 10.1167/tvst.7.6.21
   Rochepeau C, 2018, AM J OPHTHALMOL, V194, P26, DOI 10.1016/j.ajo.2018.07.004
   Rosen RB, 2019, AM J OPHTHALMOL, V203, P103, DOI 10.1016/j.ajo.2019.01.012
   Samara WA, 2017, OPHTHALMOLOGY, V124, P235, DOI 10.1016/j.ophtha.2016.10.008
   Shen CY, 2018, BMC OPHTHALMOL, V18, DOI 10.1186/s12886-018-0778-2
   Sobral I, 2018, J AAPOS, V22, P286, DOI 10.1016/j.jaapos.2018.03.009
   Spaide RF, 2018, PROG RETIN EYE RES, V64, P1, DOI 10.1016/j.preteyeres.2017.11.003
   Spain RI, 2018, BRIT J OPHTHALMOL, V102, P520, DOI 10.1136/bjophthalmol-2017-310477
   Sugahara M, 2017, SCI REP-UK, V7, DOI 10.1038/srep46396
   Takeyama A, 2018, J OPHTHALMOL, V2018, DOI 10.1155/2018/1751857
   Takusagawa HL, 2017, OPHTHALMOLOGY, V124, P1589, DOI 10.1016/j.ophtha.2017.06.002
   Toto L, 2018, RETINA-J RET VIT DIS, V38, P731, DOI 10.1097/IAE.0000000000001615
   Triolo G, 2017, INVEST OPHTH VIS SCI, V58, P5705, DOI 10.1167/iovs.17-22865
   Valverde-Megias A, 2017, RETINA-J RET VIT DIS, V37, P731, DOI 10.1097/IAE.0000000000001233
   Vujosevic S, 2018, INVEST OPHTH VIS SCI, V59, P5074, DOI 10.1167/iovs.18-24891
   Wan KH, 2018, JAMA OPHTHALMOL, V136, P866, DOI 10.1001/jamaophthalmol.2018.1627
   Wang Q, 2018, GRAEF ARCH CLIN EXP, V256, P1615, DOI 10.1007/s00417-018-4038-1
   Wang XL, 2015, GRAEF ARCH CLIN EXP, V253, P1557, DOI 10.1007/s00417-015-3095-y
   Wintergerst MWM, 2018, AM J OPHTHALMOL, V194, P35, DOI 10.1016/j.ajo.2018.06.023
   Wu JH, 2019, CURR EYE RES, V44, P533, DOI 10.1080/02713683.2018.1563195
   Yarmohammadi A, 2016, OPHTHALMOLOGY, V123, P2498, DOI 10.1016/j.ophtha.2016.08.041
   Yarmohammadi A, 2016, INVEST OPHTH VIS SCI, V57, pOCT451, DOI 10.1167/iovs.15-18944
   Yip VCH, 2019, J GLAUCOMA, V28, P80, DOI 10.1097/IJG.0000000000001125
   Zhu L, 2018, J GLAUCOMA, V27, P322, DOI 10.1097/IJG.0000000000000900
   Zivkovic M, 2017, BIOMED RES INT, V2017, DOI 10.1155/2017/3079141
NR 84
TC 5
Z9 5
U1 2
U2 9
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 0816-4622
EI 1444-0938
J9 CLIN EXP OPTOM
JI Clin. Exp. Optom.
PD JAN 2
PY 2021
VL 104
IS 1
BP 3
EP 13
DI 10.1111/cxo.13068
EA APR 2020
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA QP1WS
UT WOS:000525934100001
PM 32285493
OA Green Submitted
DA 2022-11-30
ER

PT J
AU Xi, L
AF Xi, Lei
TI Pigment Epithelium-Derived Factor as a Possible Treatment Agent for
   Choroidal Neovascularization
SO OXIDATIVE MEDICINE AND CELLULAR LONGEVITY
LA English
DT Review
ID ENDOTHELIAL GROWTH-FACTOR; AQUEOUS-HUMOR CONCENTRATIONS; SERINE-PROTEASE
   INHIBITOR; FACTOR GENE POLYMORPHISMS; P38 MAP KINASE; MACULAR
   DEGENERATION; FACTOR PEDF; FACTOR VEGF; MET72THR POLYMORPHISM;
   CELL-DEATH
AB Choroidal neovascularization (CNV) is a sight-threatening disease and is characterized by the formation of pathological neovascularization in the choroid which extends into the subretinal space. Exudative age-related macular degeneration (AMD) is the formation of CNV in the macular area which leads to irreversible blindness. Continuous leakage and hemorrhage of the CNV lesion may eventually result in scarring or later fibrosis, which could result in photoreceptor cell atrophy. The current strategy for treating CNV is the use of antivascular endothelial growth factor (VEGF) agents. Many studies have demonstrated the efficacy of intravitreal anti-VEGF therapy. Other studies have also reported the side effects of single anti-VEGF treatment. And long-term inhibition of a single system may result in collateral damage to other visual elements. Pigment epithelium-derived factor (PEDF) is a 50 kDa protein that was first isolated from the conditioned medium of human RPE cells. PEDF has both antiangiogenesis and neuroprotective functions for photoreceptor cells. It may be a potential ocular antiangiogenic agent. This review outlines the distribution of PEDF in the eye, the mechanism of antiangiogenesis, the protective effect on the retina, and the relationship between PEDF and VEGF.
C1 [Xi, Lei] Univ Tubingen, Ctr Ophthalmol, Div Expt Vitreoretinal Surg, Schleichstr 12-1, D-72076 Tubingen, Germany.
C3 Eberhard Karls University of Tubingen; Eberhard Karls University
   Hospital
RP Xi, L (通讯作者)，Univ Tubingen, Ctr Ophthalmol, Div Expt Vitreoretinal Surg, Schleichstr 12-1, D-72076 Tubingen, Germany.
EM everydayxilei@163.com
CR Ablonczy Z, 2009, J BIOL CHEM, V284, P30177, DOI 10.1074/jbc.M109.032391
   Akuffo KO, 2015, BRIT J OPHTHALMOL, V99, P1037, DOI 10.1136/bjophthalmol-2014-305768
   Alberdi E, 1998, BIOCHEMISTRY-US, V37, P10643, DOI 10.1021/bi9802317
   Amano S, 2005, MICROVASC RES, V69, P45, DOI 10.1016/j.mvr.2004.11.001
   Amaral J, 2005, INVEST OPHTH VIS SCI, V46, P4383, DOI 10.1167/iovs.05-0492
   Amaral J, 2010, INVEST OPHTH VIS SCI, V51, P1318, DOI 10.1167/iovs.09-4455
   Askou AL, 2019, MOL THER-NUCL ACIDS, V16, P38, DOI 10.1016/j.omtn.2019.01.012
   Askou AL, 2015, MOL THER-METH CLIN D, V2, DOI 10.1038/mtm.2014.64
   Baffi J, 2000, INVEST OPHTH VIS SCI, V41, P3582
   Bernard A, 2009, J BIOL CHEM, V284, P10480, DOI 10.1074/jbc.M809259200
   Bessho H, 2009, MOL VIS, V15, P1107
   Bhutto IA, 2006, EXP EYE RES, V82, P99, DOI 10.1016/j.exer.2005.05.007
   Breslin JW, 2003, AM J PHYSIOL-HEART C, V284, pH92, DOI 10.1152/ajpheart.00330.2002
   Cai J, 2006, J BIOL CHEM, V281, P3604, DOI 10.1074/jbc.M507401200
   Cai J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021164
   Cao W, 2001, INVEST OPHTH VIS SCI, V42, P1646
   Cayouette M, 1999, NEUROBIOL DIS, V6, P523, DOI 10.1006/nbdi.1999.0263
   Chen LL, 2006, BIOCHEM BIOPH RES CO, V348, P1288, DOI 10.1016/j.bbrc.2006.07.188
   Chen W, 2015, FRONTIERS OF MANUFACTURING SCIENCE AND MEASURING TECHNOLOGY V, P6
   Chen Y, 2019, DIS MODEL MECH, V12, DOI 10.1242/dmm.035642
   Cohen SY, 1996, OPHTHALMOLOGY, V103, P1241, DOI 10.1016/S0161-6420(96)30515-0
   Comitato A, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0613-y
   Connolly E, 2018, BRIT J OPHTHALMOL, V102, P1691, DOI 10.1136/bjophthalmol-2017-311673
   Costagliola C, 2015, BRIT J OPHTHALMOL, V99, P1004, DOI 10.1136/bjophthalmol-2014-306465
   DOBI ET, 1989, ARCH OPHTHALMOL-CHIC, V107, P264, DOI 10.1001/archopht.1989.01070010270035
   Ferrara N, 1997, ENDOCR REV, V18, P4, DOI 10.1210/er.18.1.4
   Fields MA, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0177763
   FRANK RN, 1989, CURR EYE RES, V8, P239, DOI 10.3109/02713688908997565
   Gao GQ, 2001, FEBS LETT, V489, P270, DOI 10.1016/S0014-5793(01)02110-X
   Gao S, 2017, SCI REP-UK, V7, DOI 10.1038/srep42846
   Grossniklaus HE, 2004, AM J OPHTHALMOL, V137, P496, DOI 10.1016/j.ajo.2003.09.042
   Hamilton MM, 2008, MOL VIS, V14, P2535
   Hanhart J, 2018, GRAEF ARCH CLIN EXP, V256, P651, DOI 10.1007/s00417-018-3917-9
   Hao XL, 2018, MEDICINE, V97, DOI [10.1097/md.0000000000011981, 10.1097/MD.0000000000011981]
   Haribalaganesh R, 2010, EXP EYE RES, V90, P726, DOI 10.1016/j.exer.2010.03.005
   He XM, 2017, KIDNEY INT, V91, P642, DOI 10.1016/j.kint.2016.09.036
   He Y, 2014, INVEST OPHTH VIS SCI, V55, DOI 10.1167/iovs.14-14696
   Ho TC, 2006, BIOCHEM BIOPH RES CO, V342, P372, DOI 10.1016/j.bbrc.2006.01.164
   Ho TC, 2010, AM J PATHOL, V177, P1798, DOI 10.2353/ajpath.2010.091085
   Holekamp NM, 2002, AM J OPHTHALMOL, V134, P220, DOI 10.1016/S0002-9394(02)01549-0
   Imai Daisuke, 2010, J Ocul Biol Dis Infor, V3, P53, DOI 10.1007/s12177-010-9055-1
   Issbrucker K, 2002, FASEB J, V16, P262, DOI 10.1096/fj.02-0329fje
   Jablonski MM, 2000, J NEUROSCI, V20, P7149
   Johnston EK, 2015, IN VITRO CELL DEV-AN, V51, P730, DOI 10.1007/s11626-015-9884-0
   Julien S, 2013, BRIT J OPHTHALMOL, V97, P511, DOI 10.1136/bjophthalmol-2012-302308
   Kanemura H, 2013, SCI REP-UK, V3, DOI 10.1038/srep02334
   Karakousis PC, 2001, MOL VIS, V7, P154
   Kwak N, 2000, INVEST OPHTH VIS SCI, V41, P3158
   Lin JM, 2008, AM J OPHTHALMOL, V145, P716, DOI 10.1016/j.ajo.2007.11.006
   Liu H, 2004, P NATL ACAD SCI USA, V101, P6605, DOI 10.1073/pnas.0308342101
   Ma L, 2015, SCI REP-UK, V5, DOI 10.1038/srep09497
   Maminishkis A, 2006, INVEST OPHTH VIS SCI, V47, P3612, DOI 10.1167/iovs.05-1622
   Matsuoka M, 2004, BRIT J OPHTHALMOL, V88, P809, DOI 10.1136/bjo.2003.032466
   Mattes D, 2009, MOL VIS, V15, P343
   Meyer C, 2002, J BIOL CHEM, V277, P45400, DOI 10.1074/jbc.M208339200
   Minkevich NI, 2016, EXP EYE RES, V152, P1, DOI 10.1016/j.exer.2016.08.017
   Miyake M, 2013, INVEST OPHTH VIS SCI, V54, P4208, DOI 10.1167/iovs.13-12280
   Mori K, 2002, INVEST OPHTH VIS SCI, V43, P1994
   Mori K, 2001, J CELL PHYSIOL, V188, P253, DOI 10.1002/jcp.1114
   Nadal-Nicolas FM, 2018, ADV EXP MED BIOL, V1074, P457, DOI 10.1007/978-3-319-75402-4_56
   Ogata N, 2002, INVEST OPHTH VIS SCI, V43, P1168
   Park K, 2011, AM J PATHOL, V178, P688, DOI 10.1016/j.ajpath.2010.10.014
   Principe DR, 2016, ONCOTARGET, V7, P28218, DOI 10.18632/oncotarget.8587
   Qu Y, 2011, CURR EYE RES, V36, P60, DOI 10.3109/02713683.2010.524343
   Renno RZ, 2002, INVEST OPHTH VIS SCI, V43, P1574
   Saishin Y, 2005, HUM GENE THER, V16, P473, DOI 10.1089/hum.2005.16.473
   Schraermeyer U, 2012, GRAEF ARCH CLIN EXP, V250, P1303, DOI 10.1007/s00417-012-2055-z
   Schwesinger C, 2001, AM J PATHOL, V158, P1161, DOI 10.1016/S0002-9440(10)64063-1
   Sekiya A, 2011, J BIOL CHEM, V286, P26364, DOI 10.1074/jbc.M111.252684
   Semkova I, 2002, P NATL ACAD SCI USA, V99, P13090, DOI 10.1073/pnas.202486199
   Shin YJ, 2012, MOL VIS, V18, P2265
   Spilsbury K, 2000, AM J PATHOL, V157, P135, DOI 10.1016/S0002-9440(10)64525-7
   STEELE FR, 1993, P NATL ACAD SCI USA, V90, P1526, DOI 10.1073/pnas.90.4.1526
   Stellmach V, 2001, P NATL ACAD SCI USA, V98, P2593, DOI 10.1073/pnas.031252398
   Subramanian P, 2016, INVEST OPHTH VIS SCI, V57, P4581, DOI 10.1167/iovs.15-19039
   Tombran-Tink J, 2010, CURR MOL MED, V10, P267, DOI 10.2174/156652410791065336
   TOMBRANTINK J, 1995, J NEUROSCI, V15, P4992
   TOMBRANTINK J, 1989, INVEST OPHTH VIS SCI, V30, P1700
   Tong JP, 2006, AM J OPHTHALMOL, V141, P456, DOI 10.1016/j.ajo.2005.10.012
   Tsai TH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0095443
   Unterlauft JD, 2014, EXP EYE RES, V127, P206, DOI 10.1016/j.exer.2014.08.004
   Vigneswara V, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1379-6
   Vigneswara V, 2013, INVEST OPHTH VIS SCI, V54, P2624, DOI 10.1167/iovs.13-11803
   Volpert OV, 2002, NAT MED, V8, P349, DOI 10.1038/nm0402-349
   Wang FH, 2007, CHINESE MED J-PEKING, V120, P1534, DOI 10.1097/00029330-200709010-00013
   Wang JJ, 2005, DIABETES, V54, P243, DOI 10.2337/diabetes.54.1.243
   Wang JJ, 2006, DIABETES, V55, P1678, DOI 10.2337/db05-1448
   Wang YJ, 2013, ASN NEURO, V5, DOI 10.1042/AN20130028
   Wynn TA, 2008, J PATHOL, V214, P199, DOI 10.1002/path.2277
   Yamagishi S, 2005, MED HYPOTHESES, V64, P1202, DOI 10.1016/j.mehy.2005.01.017
   Yamagishi S, 2002, BIOCHEM BIOPH RES CO, V296, P877, DOI 10.1016/S0006-291X(02)00940-3
   Yamagishi S, 2006, J BIOL CHEM, V281, P20213, DOI 10.1074/jbc.M602110200
   Yang JL, 2010, INVEST OPHTH VIS SCI, V51, P3273, DOI 10.1167/iovs.08-2878
   Yasui N, 2003, BIOCHEMISTRY-US, V42, P3160, DOI 10.1021/bi0206558
   Yu YJ, 2016, INT J OPHTHALMOL-CHI, V9, P1112, DOI 10.18240/ijo.2016.08.05
   Yun JH, 2018, BIOCHEM BIOPH RES CO, V503, P2792, DOI 10.1016/j.bbrc.2018.08.041
   Yun JH, 2018, FASEB J, V32, P2324, DOI 10.1096/fj.201700570RR
   Zha WJ, 2016, ALLERGY ASTHMA IMMUN, V8, P161, DOI 10.4168/aair.2016.8.2.161
   Zhang H, 2017, SCI REP-UK, V7, DOI 10.1038/srep41932
   Zhang SX, 2006, J MOL ENDOCRINOL, V37, P1, DOI 10.1677/jme.1.02008
NR 100
TC 8
Z9 8
U1 1
U2 3
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1942-0900
EI 1942-0994
J9 OXID MED CELL LONGEV
JI Oxidative Med. Cell. Longev.
PD MAR 6
PY 2020
VL 2020
AR 8941057
DI 10.1155/2020/8941057
PG 11
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA KY0MW
UT WOS:000522269500006
PM 32215180
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Terao, R
   Honjo, M
   Ueta, T
   Obinata, H
   Izumi, T
   Kurano, M
   Yatomi, Y
   Koso, H
   Watanabe, S
   Aihara, M
AF Terao, Ryo
   Honjo, Megumi
   Ueta, Takashi
   Obinata, Hideru
   Izumi, Takashi
   Kurano, Makoto
   Yatomi, Yutaka
   Koso, Hideto
   Watanabe, Sumiko
   Aihara, Makoto
TI Light Stress-Induced Increase of Sphingosine 1-Phosphate in
   Photoreceptors and Its Relevance to Retinal Degeneration
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE sphingosine 1-phosphate; sphingolipids and inflammation; light-induced
   retinal degeneration; choroidal neovascularization; age-related macular
   degeneration; visual cycle; sphingosine kinase
ID KERATINOCYTE PROLIFERATION; MACULAR DEGENERATION;
   SPHINGOSINE-1-PHOSPHATE; PROTECTS; INVOLVEMENT; INHIBITION; MECHANISMS;
   OXIDATION; DISEASE; FTY720
AB Sphingosine 1-phosphate (S1P) is a potent lipid mediator that modulates inflammation and angiogenesis. In this study, we investigated the possible involvement of S1P in the pathology of light-induced retinal degeneration in vivo and in vitro. The intracellular S1P and sphingosine kinase (SphK) activity in a photoreceptor cell line (661W cells) was significantly increased by exposure to light. The enhancement of SphK1 expression was dependent on illumination, and all-trans-retinal significantly promoted SphK1 expression. S1P treatment reduced protein kinase B (Akt) phosphorylation and increased the protein expression of cleaved caspase-3, and induced photoreceptor cell apoptosis. In vivo, light exposure enhanced the expression of SphK1 in the outer segments of photoreceptors. Intravitreal injection of a SphK inhibitor significantly suppressed the thinning of the outer nuclear layer and ameliorated the attenuation of the amplitudes of a-waves and b-waves of electroretinograms during light-induced retinal degeneration. These findings imply that light exposure induces the synthesis of S1P in photoreceptors by upregulating SphK1, which is facilitated by all-trans-retinal, causing retinal degeneration. Inhibition of this enhancement may be a therapeutic target of outer retinal degeneration, including age-related macular degeneration.
C1 [Terao, Ryo; Honjo, Megumi; Ueta, Takashi; Aihara, Makoto] Univ Tokyo, Grad Sch Med, Dept Ophthalmol, Tokyo 1138654, Japan.
   [Obinata, Hideru] Gunma Univ, Initiat Adv Res GIAR, 3-39-22 Showa Machi, Maebashi, Gunma 3718511, Japan.
   [Izumi, Takashi] Gunma Univ, Grad Sch Med, Dept Biochem, 3-39-22 Showa Machi, Maebashi, Gunma 3718511, Japan.
   [Kurano, Makoto; Yatomi, Yutaka] Univ Tokyo, Dept Clin Lab Med, Bunkyo Ku, 7-3-1,Hongo, Tokyo 1138654, Japan.
   [Koso, Hideto; Watanabe, Sumiko] Univ Tokyo, Inst Med Sci, Div Mol & Dev Biol, Minato Ku, 4-6-1 Shirokanedai, Tokyo 1088639, Japan.
C3 University of Tokyo; Gunma University; Gunma University; University of
   Tokyo; University of Tokyo
RP Aihara, M (通讯作者)，Univ Tokyo, Grad Sch Med, Dept Ophthalmol, Tokyo 1138654, Japan.
EM aihara-tky@umin.net
RI Terao, Ryo/AAV-3334-2020
OI Terao, Ryo/0000-0001-6182-4343; Yatomi, Yutaka/0000-0003-1719-4297;
   Aihara, Makoto/0000-0001-6810-0583
CR Allikmets R, 1997, NAT GENET, V15, P236, DOI 10.1038/ng0397-236
   Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   Chen H, 2013, J LIPID RES, V54, P1616, DOI 10.1194/jlr.M035048
   Chen Y, 2012, J BIOL CHEM, V287, P5059, DOI 10.1074/jbc.M111.315432
   CRUICKSHANKS KJ, 1993, ARCH OPHTHALMOL-CHIC, V111, P514, DOI 10.1001/archopht.1993.01090040106042
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   Fabiani C, 2017, N-S ARCH PHARMACOL, V390, P741, DOI 10.1007/s00210-017-1374-3
   Frej C, 2015, ANAL BIOANAL CHEM, V407, P8533, DOI 10.1007/s00216-015-9008-4
   Goldberg AFX, 2016, PROG RETIN EYE RES, V55, P52, DOI 10.1016/j.preteyeres.2016.05.003
   Gu RP, 2017, INVEST OPHTH VIS SCI, V58, P3656, DOI 10.1167/iovs.17-22116
   Guzel Y, 2018, EUR J OBSTET GYN R B, V222, P19, DOI 10.1016/j.ejogrb.2018.01.001
   Igarashi N, 2003, J BIOL CHEM, V278, P46832, DOI 10.1074/jbc.M306577200
   Izawa H, 2015, INVEST OPHTH VIS SCI, V56, P6914, DOI 10.1167/iovs.15-16748
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kim DS, 2004, CELL SIGNAL, V16, P89, DOI 10.1016/S0898-6568(03)00114-1
   Lee JF, 2006, J BIOL CHEM, V281, P29190, DOI 10.1074/jbc.M604310200
   Liu H, 2003, J BIOL CHEM, V278, P40330, DOI 10.1074/jbc.M304455200
   Maeda A, 2009, J BIOL CHEM, V284, P15173, DOI 10.1074/jbc.M900322200
   Masutomi K, 2012, PHOTOCHEM PHOTOBIOL, V88, P1356, DOI 10.1111/j.1751-1097.2012.01129.x
   McBee JK, 2001, PROG RETIN EYE RES, V20, P469, DOI 10.1016/S1350-9462(01)00002-7
   Miranda GE, 2009, INVEST OPHTH VIS SCI, V50, P4416, DOI 10.1167/iovs.09-3388
   Nowak JZ, 2013, PHARMACOL REP, V65, P288, DOI 10.1016/S1734-1140(13)71005-3
   Ohkawa R, 2015, CLIN BIOCHEM, V48, P690, DOI 10.1016/j.clinbiochem.2015.03.019
   ORGANISCIAK DT, 1992, INVEST OPHTH VIS SCI, V33, P1599
   Porter H, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19123885
   Rozanowska M, 2012, PHOTOCHEM PHOTOBIOL, V88, P1362, DOI 10.1111/j.1751-1097.2012.01161.x
   Saigusa Daisuke, 2014, Mass Spectrom (Tokyo), V3, pS0046, DOI 10.5702/massspectrometry.S0046
   Sanchez T, 2004, J CELL BIOCHEM, V92, P913, DOI 10.1002/jcb.20127
   Schuppel M, 2008, J INVEST DERMATOL, V128, P1747, DOI 10.1038/sj.jid.5701259
   Spiegel S, 2003, NAT REV MOL CELL BIO, V4, P397, DOI 10.1038/nrm1103
   Stiles M, 2016, J LIPID RES, V57, P818, DOI 10.1194/jlr.M063719
   Takabe K, 2008, PHARMACOL REV, V60, P181, DOI 10.1124/pr.107.07113
   Terao R., PROSTAGLANDINS LIPID
   Terao R, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19010112
   Wilkerson JL, 2019, MOL NEUROBIOL, V56, P7188, DOI 10.1007/s12035-019-1599-x
   Xu YQ, 2013, CNS NEUROSCI THER, V19, P170, DOI 10.1111/cns.12053
   Zeng Y, 2019, PROG BIOPHYS MOL BIO, V148, P32, DOI 10.1016/j.pbiomolbio.2017.11.006
   Zhang QJ, 2005, HUM GENET, V118, P356, DOI 10.1007/s00439-005-0054-4
NR 38
TC 5
Z9 5
U1 0
U2 2
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1422-0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD AUG
PY 2019
VL 20
IS 15
AR 3670
DI 10.3390/ijms20153670
PG 20
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA IS8ET
UT WOS:000482383000063
PM 31357484
OA gold, Green Published, Green Submitted
DA 2022-11-30
ER

PT J
AU Yu, Y
   Lin, XY
   Wang, QL
   He, MG
   Chau, Y
AF Yu, Yu
   Lin, Xingyan
   Wang, Qilin
   He, Mingguang
   Chau, Ying
TI Long-term therapeutic effect in nonhuman primate eye from a single
   injection of anti-VEGF controlled release hydrogel
SO BIOENGINEERING & TRANSLATIONAL MEDICINE
LA English
DT Article
DE anti-VEGF; controlled release; drug delivery; hydrogel
ID ENDOTHELIAL GROWTH-FACTOR; OPEN-LABEL EXTENSION; MACULAR DEGENERATION;
   CHOROIDAL NEOVASCULARIZATION; INTRAVITREAL INJECTION; PROLONGED
   BLOCKADE; VISUAL IMPAIRMENT; GLOBAL PREVALENCE; CLINICAL-TRIAL;
   RANIBIZUMAB
AB Wet age-related macular degeneration (wet-AMD) is a leading cause of irreversible blindness. Current treatment of AMD requires monthly intravitreal injection, which is difficult to be implemented in many parts of the world. In recent years, controlled release of anti-vascular endothelial growth factor (VEGF) therapeutics has attracted intense research interest aiming to reduce the injection frequency to one or two times per year. In this study, we evaluated the in vivo pharmacokinetics and the long-term therapeutic efficacy of an in situ hydrogel encapsulating an anti-VEGF antibody in nonhuman primates. We show that after a single injection of anti-VEGF controlled release hydrogel, a relatively constant concentration of drug can be maintained in the monkey eye for at least 5 months and the dose was sufficient for the treatment of recurrent choroidal neovascularization induced by repeat laser photocoagulation in monkeys. Our result suggested that when formulated into a controlled release formulation, a single dose of anti-VEGF may be sufficient for a half-year treatment and controlled release may be a suitable strategy to reduce the injection frequency in the treatment of AMD in human.
C1 [Yu, Yu; Chau, Ying] Hong Kong Univ Sci & Technol, Dept Chem & Biol Engn, Kowloon, Clear Water Bay, Hong Kong, Peoples R China.
   [Lin, Xingyan; Wang, Qilin; He, Mingguang] Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, State Key Lab Ophthalmol, Guangzhou, Guangdong, Peoples R China.
   [Chau, Ying] Hong Kong Univ Sci & Technol, Shenzhen Res Inst, Shenzhen, Peoples R China.
C3 Hong Kong University of Science & Technology; Sun Yat Sen University;
   Hong Kong University of Science & Technology
RP Chau, Y (通讯作者)，Hong Kong Univ Sci & Technol, Dept Chem & Biol Engn, Kowloon, Clear Water Bay, Hong Kong, Peoples R China.
EM keychau@ust.hk
RI He, Mingguang/AAY-5239-2020
OI He, Mingguang/0000-0002-6912-2810; Yu, Yu/0000-0002-4845-3637; Wang,
   Qilin/0000-0001-6967-6197
FU Hong Kong General Research Fund [GRF16322016]; Science and Technology
   Plan of Shenzhen [JCY20170818114038319]
FX Hong Kong General Research Fund, Grant/Award Number: GRF16322016;
   Science and Technology Plan of Shenzhen, Grant/Award Number:
   JCY20170818114038319
CR Adamson P, 2016, J CONTROL RELEASE, V244, P1, DOI 10.1016/j.jconrel.2016.10.026
   Amadio M, 2016, PHARMACOL RES, V103, P253, DOI 10.1016/j.phrs.2015.11.027
   Antoszyk AN, 2008, AM J OPHTHALMOL, V145, P862, DOI 10.1016/j.ajo.2007.12.029
   Balazs EA, 2008, CURR PHARM BIOTECHNO, V9, P236, DOI 10.2174/138920108785161596
   Bressler NM, 2002, ARCH OPHTHALMOL-CHIC, V120, P1307
   Dong N, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125329
   Feng J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068149
   Glassman AR, 2017, JAMA OPHTHALMOL, V135, P685, DOI 10.1001/jamaophthalmol.2017.1652
   Goody RJ, 2011, EXP EYE RES, V92, P464, DOI 10.1016/j.exer.2011.03.006
   Heier JS, 2017, LANCET, V390, P50, DOI 10.1016/S0140-6736(17)30979-0
   Hillier RJ, 2017, RETINA-J RET VIT DIS, V37, P761, DOI 10.1097/IAE.0000000000001210
   Hwang YS, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067495
   Jonas JB, 2014, LANCET GLOB HEALTH, V2, pE65, DOI 10.1016/S2214-109X(13)70163-3
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   KORTUEM KU, 2018, INVEST OPHTH VIS SCI, V59
   Lau CML, 2018, ADV DRUG DELIVER REV, V126, P145, DOI 10.1016/j.addr.2018.03.013
   Maguire MG, 2016, OPHTHALMOLOGY, V123, P1751, DOI 10.1016/j.ophtha.2016.03.045
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   McCulloch DL, 2015, DOC OPHTHALMOL, V130, P1, DOI 10.1007/s10633-014-9473-7
   Mengxi Shen T, 2018, INVEST OPHTHALMOL, V59, P809
   Miki A, 2010, J CELL PHYSIOL, V224, P262, DOI 10.1002/jcp.22129
   Miyake T, 2010, INVEST OPHTH VIS SCI, V51, P1606, DOI 10.1167/iovs.09-4140
   Noma H, 2008, EYE, V22, P42, DOI 10.1038/sj.eye.6702498
   Osswald CR, 2016, CURR EYE RES, V41, P1216, DOI 10.3109/02713683.2015.1101140
   Oyster CW., 1999, HUMAN EYE STRUCTURE
   Pascolini D, 2012, BRIT J OPHTHALMOL, V96, P614, DOI 10.1136/bjophthalmol-2011-300539
   Peden MC, 2015, OPHTHALMOLOGY, V122, P803, DOI 10.1016/j.ophtha.2014.11.018
   Peden MC, 2015, RETIN PHYS
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
   Singer MA, 2012, OPHTHALMOLOGY, V119, P1175, DOI 10.1016/j.ophtha.2011.12.016
   Ueno S, 2008, J CELL PHYSIOL, V217, P13, DOI 10.1002/jcp.21445
   Weir E, 2004, CAN MED ASSOC J, V170, P463
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yu Y, 2015, TRANSL VIS SCI TECHN, V4, DOI 10.1167/tvst.4.2.5
   Yu Y, 2015, BIOMACROMOLECULES, V16, P56, DOI 10.1021/bm501063n
   Yu Y, 2012, BIOMACROMOLECULES, V13, P937, DOI 10.1021/bm2014476
   Zhang K, 2012, NAT REV DRUG DISCOV, V11, P541, DOI 10.1038/nrd3745
NR 40
TC 14
Z9 14
U1 1
U2 13
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
EI 2380-6761
J9 BIOENG TRANSL MED
JI Bioeng. Transl. Med.
PD MAY
PY 2019
VL 4
IS 2
SI SI
AR e10128
DI 10.1002/btm2.10128
PG 9
WC Biotechnology & Applied Microbiology; Engineering, Biomedical;
   Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Engineering; Pharmacology &
   Pharmacy
GA IE2FU
UT WOS:000472200700004
PM 31249878
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Korhonen, E
   Piippo, N
   Hytti, M
   Hyttinen, JMT
   Kaarniranta, K
   Kauppinen, A
AF Korhonen, Eveliina
   Piippo, Niina
   Hytti, Maria
   Hyttinen, Juha M. T.
   Kaarniranta, Kai
   Kauppinen, Anu
TI SQSTM1/p62 regulates the production of IL-8 and MCP-1 in IL-1
   beta-stimulated human retinal pigment epithelial cells
SO CYTOKINE
LA English
DT Article
DE SQSTM1/p62; Interleukin-8; Monocyte chemoattractant protein-1;
   Inflammasome; Retinal pigment epithelium
ID MACULAR DEGENERATION; AUTOPHAGY; P62; PROTEIN; INFLAMMATION;
   AGGREGATION; ACTIVATION; PHYSIOLOGY; PATHWAY; STRESS
AB Age-related macular degeneration (AMD) is a complex eye disease in which decline in autophagy leads to the accumulation of sequestosome 1/p62 (SQSTM1/p62)-labeled waste material inside the retinal pigment epithelial (RPE) cells, and the condition results in activation of the inflammasome signaling and IL-1 beta secretion. Here, we have studied the role of SQSTM1/p62 in the production of IL-6, IL-8, and MCP-1 in the presence or absence of IL-1 beta. SQSTM1/p62 was either overexpressed or silenced in ARPE-19 cells, which were then exposed to IL-1 beta. Alternatively, bafilomycin A was used to demonstrate the functional decline of autophagy with increased SQSTM1/p62 levels. The protein concentration of SQSTM1/p62 was measured using the western blot technique, and interleukin levels were determined by ELISA. In IL-1 beta-loaded RPE cells, SQSTM1/p62 depletion and overexpression increased the production of MCP-1 and IL-8, respectively. Neither knock-down nor over expression of SQSTM1/p62 induced the release of IL-6. Our data suggest that SQSTM1/p62 is a significant factor in inflammatory responses, especially following the inflammasome activation.
C1 [Korhonen, Eveliina; Piippo, Niina; Hytti, Maria; Kauppinen, Anu] Univ Eastern Finland, Fac Hlth Sci, Sch Pharm, POB 1627, FI-70211 Kuopio, Finland.
   [Hyttinen, Juha M. T.; Kaarniranta, Kai] Univ Eastern Finland, Inst Clin Med, Dept Ophthalmol, POB 1627, FI-70211 Kuopio, Finland.
   [Kaarniranta, Kai] Kuopio Univ Hosp, Dept Ophthalmol, POB 100, FI-70029 Kuopio, Finland.
C3 University of Eastern Finland; University of Eastern Finland; Kuopio
   University Hospital; University of Eastern Finland
RP Korhonen, E (通讯作者)，Univ Eastern Finland, Fac Hlth Sci, Sch Pharm, POB 1627, FI-70211 Kuopio, Finland.
EM eveliina.korhonen@uef.fi
RI Hytti, Maria/AAE-4016-2019
OI Hytti, Maria/0000-0003-2150-6847; Korhonen,
   Eveliina/0000-0002-5360-7258; Hyttinen, Juha/0000-0002-3414-4032
FU Finnish Cultural Foundation (Central and North-Savo Regional Fund); Emil
   Aaltonen Foundation; Academy of Finland (Health Research Council)
   [AK297267, AK307341]; Sokeain ystavat ry; Silma-ja kudospankkisaatio
FX We warmly acknowledge Dr. Ewen MacDonald for the language revision, and
   Res. Dir. Emeritus Antero Salminen for his valuable collaboration,
   discussions, and critical review of the manuscript. This study was
   financially supported by Finnish Cultural Foundation (Central and
   North-Savo Regional Fund), Emil Aaltonen Foundation, the Academy of
   Finland (Health Research Council projects AK297267 and AK307341),
   Sokeain ystavat ry, and Silma-ja kudospankkisaatio.
CR BAGGIOLINI M, 1995, INT J IMMUNOPHARMACO, V17, P103, DOI 10.1016/0192-0561(94)00088-6
   Chen M, 2015, J LEUKOCYTE BIOL, V98, P713, DOI 10.1189/jlb.3RI0615-239R
   Deshmane SL, 2009, J INTERF CYTOK RES, V29, P313, DOI 10.1089/jir.2008.0027
   INOUE H, 1990, GENE, V96, P23, DOI 10.1016/0378-1119(90)90336-P
   Into T, 2010, J BIOL CHEM, V285, P35759, DOI 10.1074/jbc.M110.126904
   Jang CH, 2006, RHEUMATOLOGY, V45, P703, DOI 10.1093/rheumatology/kei282
   Jin ZY, 2009, CELL, V137, P721, DOI 10.1016/j.cell.2009.03.015
   Johansson I, 2015, AUTOPHAGY, V11, P1636, DOI 10.1080/15548627.2015.1061170
   Kaarniranta K, 2013, AUTOPHAGY, V9, P973, DOI 10.4161/auto.24546
   Katsuragi Y, 2015, FEBS J, V282, P4672, DOI 10.1111/febs.13540
   Kauppinen A, 2016, CELL MOL LIFE SCI, V73, P1765, DOI 10.1007/s00018-016-2147-8
   Kawai K, 2008, J BIOCHEM, V143, P765, DOI 10.1093/jb/mvn027
   Kim JY, 2009, J IMMUNOL, V182, P2131, DOI 10.4049/jimmunol.0802755
   Komatsu M, 2012, PHARMACOL RES, V66, P457, DOI 10.1016/j.phrs.2012.07.004
   Komatsu M, 2010, NAT CELL BIOL, V12, P213, DOI 10.1038/ncb2021
   Lamark Trond, 2012, Int J Cell Biol, V2012, P736905, DOI 10.1155/2012/736905
   Lee HM, 2011, J IMMUNOL, V186, P1248, DOI 10.4049/jimmunol.1001954
   Lin XL, 2013, DNA CELL BIOL, V32, P220, DOI 10.1089/dna.2012.1915
   Liu WJ, 2016, CELL MOL BIOL LETT, V21, DOI 10.1186/s11658-016-0031-z
   MARSHALL J, 1987, EYE-T OPHTH SOC UK, V1, P282, DOI 10.1038/eye.1987.47
   Moscat J, 2007, TRENDS BIOCHEM SCI, V32, P95, DOI 10.1016/j.tibs.2006.12.002
   Pankiv S, 2007, J BIOL CHEM, V282, P24131, DOI 10.1074/jbc.M702824200
   Piippo N, 2014, BBA-MOL CELL RES, V1843, P3038, DOI 10.1016/j.bbamcr.2014.09.015
   Sambrook J, 1990, MOL CLONING LAB MANU, P125
   Scott MG, 2007, NAT BIOTECHNOL, V25, P465, DOI 10.1038/nbt1288
   Sudo T, 2000, BIOCHEM BIOPH RES CO, V269, P521, DOI 10.1006/bbrc.2000.2333
   Swirski FK, 2013, CIRC RES, V112, P744, DOI 10.1161/CIRCRESAHA.113.300867
   Velez-Montoya R, 2014, RETINA-J RET VIT DIS, V34, P423, DOI 10.1097/IAE.0000000000000036
   Viiri J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069563
   Viiri J, 2010, MOL VIS, V16, P1399
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yang S, 2017, J BIOL CHEM, V292, P3379, DOI 10.1074/jbc.M116.756536
   Yang ZF, 2010, NAT CELL BIOL, V12, P814, DOI 10.1038/ncb0910-814
   Yu HB, 2009, J BIOL CHEM, V284, P36007, DOI 10.1074/jbc.C109.073627
NR 34
TC 12
Z9 12
U1 0
U2 11
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 1043-4666
EI 1096-0023
J9 CYTOKINE
JI Cytokine
PD APR
PY 2019
VL 116
BP 70
EP 77
DI 10.1016/j.cyto.2018.12.015
PG 8
WC Biochemistry & Molecular Biology; Cell Biology; Immunology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology; Immunology
GA HQ8SM
UT WOS:000462695600009
PM 30685605
DA 2022-11-30
ER

PT J
AU Mao, XY
   Pan, T
   Shen, H
   Xi, HY
   Yuan, ST
   Liu, QH
AF Mao, Xiying
   Pan, Ting
   Shen, Han
   Xi, Huiyu
   Yuan, Songtao
   Liu, Qinghuai
TI The rescue effect of mesenchymal stem cell on sodium iodate-induced
   retinal pigment epithelial cell death through deactivation of NF-kappa
   B-mediated NLRP3 inflammasome
SO BIOMEDICINE & PHARMACOTHERAPY
LA English
DT Article
DE Age-Related macular degeneration; Mesenchymal stem cell; Retinal pigment
   epithelium; Caspase; Inflammasome; NF-kappa B pathway
ID MACULAR DEGENERATION; RETINITIS-PIGMENTOSA; OXIDATIVE STRESS;
   ACTIVATION; APOPTOSIS; AMD; RPE
AB Age-related macular degeneration (AMD) is a multifactorial disease resulting in the gradual loss of retinal pigment epithelium (RPE) and the permanent visual damage. Various risk factors, including oxidative stress, form a complex network at the confluence of inflammation. Mesenchymal stem cell (MSC) is a well-studied population of adult stem cell with strong neuroprotective and immunoregulatory properties. Here, we reported the protective effect of MSC on sodium iodate (NaIO3)-triggered RPE degeneration. Sodium iodate (NaIO3)induced RPE cell death was remarkably reduced when cocultured with MSC. Inhibition of several cell death pathways mediated by mitochondrial instability and its subsequent caspase-1/3/8 activation was implicated in this process. In addition, NLRP3 inflammasome, the upstream of caspase-1 activation, was also found down-regulated via suppressing its priming signal NF-kappa B pathway. Taken together, MSC protected against NaIO3-triggered RPE death via deactivating NF-kappa B-mediated NLRP3 inflammasome and maintaining mitochondrial integrity. This study highlights the significant role of MSC in modulating the proinflammatory environment of AMD, and suggests the clinical value of MSC in treating AMD as well as RPE replacement therapy.
C1 [Mao, Xiying; Pan, Ting; Shen, Han; Xi, Huiyu; Yuan, Songtao; Liu, Qinghuai] Nanjing Med Univ, Affiliated Hosp 1, Dept Ophthalmol, 300 Guangzhou Rd, Nanjing 210029, Jiangsu, Peoples R China.
C3 Nanjing Medical University
RP Yuan, ST; Liu, QH (通讯作者)，Nanjing Med Univ, Affiliated Hosp 1, Dept Ophthalmol, 300 Guangzhou Rd, Nanjing 210029, Jiangsu, Peoples R China.
EM yuansongtao@vip.163.com; liuqh@njmu.edu.cn
OI Liu, Qinghuai/0000-0003-1605-1964
FU National Key Research and Development Program of China [2017YFA0104100];
   National Basic Research Program ("973" Program) of China [2013CB967500]
FX This research was supported by grants from National Key Research and
   Development Program of China (2017YFA0104100) and the National Basic
   Research Program ("973" Program) of China (2013CB967500)
CR Anderson OA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067263
   Binder S, 2007, PROG RETIN EYE RES, V26, P516, DOI 10.1016/j.preteyeres.2007.02.002
   Celkova L, 2015, J CLIN MED, V4, P172, DOI 10.3390/jcm4010172
   Chung H, 2016, CELL DEATH DIFFER, V23, P1331, DOI 10.1038/cdd.2016.14
   Czabotar PE, 2014, NAT REV MOL CELL BIO, V15, P49, DOI 10.1038/nrm3722
   Doyle SL, 2012, NAT MED, V18, P791, DOI 10.1038/nm.2717
   Fink SL, 2005, INFECT IMMUN, V73, P1907, DOI 10.1128/IAI.73.4.1907-1916.2005
   Giono LE, 2006, J CELL PHYSIOL, V209, P13, DOI 10.1002/jcp.20689
   He YX, 2014, INT J MOL SCI, V15, P14456, DOI 10.3390/ijms150814456
   Kim Y, 2014, P NATL ACAD SCI USA, V111, P16082, DOI 10.1073/pnas.1403814111
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Liu RT, 2013, INVEST OPHTH VIS SCI, V54, P2225, DOI 10.1167/iovs.12-10849
   Marneros AG, 2013, CELL REP, V4, P945, DOI 10.1016/j.celrep.2013.08.002
   Ng Tsz Kin, 2014, World J Stem Cells, V6, P111, DOI 10.4252/wjsc.v6.i2.111
   Nita M, 2014, MEDIAT INFLAMM, V2014, DOI 10.1155/2014/930671
   Oner A, 2016, STEM CELL RES THER, V7, DOI 10.1186/s13287-016-0432-y
   Schieber M, 2014, CURR BIOL, V24, pR453, DOI 10.1016/j.cub.2014.03.034
   Shaw PX, 2016, AIMS MOL SCI, V3, P196, DOI 10.3934/molsci.2016.2.196
   Tarallo V, 2012, CELL, V149, P847, DOI 10.1016/j.cell.2012.03.036
   Zhang SX, 2014, EXP EYE RES, V125, P30, DOI 10.1016/j.exer.2014.04.015
   Zhou RB, 2011, NATURE, V469, P221, DOI 10.1038/nature09663
NR 21
TC 16
Z9 16
U1 0
U2 8
PU ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI ISSY-LES-MOULINEAUX
PA 65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY-LES-MOULINEAUX, FRANCE
SN 0753-3322
EI 1950-6007
J9 BIOMED PHARMACOTHER
JI Biomed. Pharmacother.
PD JUL
PY 2018
VL 103
BP 517
EP 523
DI 10.1016/j.biopha.2018.04.038
PG 7
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA GH3UW
UT WOS:000433328800063
PM 29677537
DA 2022-11-30
ER

PT J
AU Liu, CS
   Lin, CH
   Sun, YN
   Ho, CL
   Hsu, CC
AF Liu, Chien-Sheng
   Lin, Cheng-Hsien
   Sun, Yung-Nien
   Ho, Chung-Liang
   Hsu, Chung-Chi
TI True color blood flow imaging using a high-speed laser photography
   system
SO OPTICAL ENGINEERING
LA English
DT Article
DE blood flow imaging; laser photography; color laser photography;
   high-speed imaging
ID OPTICAL COHERENCE TOMOGRAPHY; MATING OPTIMIZATION; CONE PHOTORECEPTORS;
   PROJECTION DISPLAYS; MUTUAL INFORMATION; SPECKLE REDUCTION; HBMO
   ALGORITHM; RESOLUTION OCT; HUMAN RETINA; OPHTHALMOSCOPE
AB Physiological changes in the retinal vasculature are commonly indicative of such disorders as diabetic retinopathy, glaucoma, and age-related macular degeneration. Thus, various methods have been developed for noninvasive clinical evaluation of ocular hemodynamics. However, to the best of our knowledge, current ophthalmic instruments do not provide a true color blood flow imaging capability. Accordingly, we propose a new method for the true color imaging of blood flow using a high-speed pulsed laser photography system. In the proposed approach, monochromatic images of the blood flow are acquired using a system of three cameras and three color lasers (red, green, and blue). A high-quality true color image of the blood flow is obtained by assembling the monochromatic images by means of image realignment and color calibration processes. The effectiveness of the proposed approach is demonstrated by imaging the flow of mouse blood within a microfluidic channel device. The experimental results confirm the proposed system provides a high-quality true color blood flow imaging capability, and therefore has potential for noninvasive clinical evaluation of ocular hemodynamics. (C) 2012 Society of Photo-Optical Instrumentation Engineers (SPIE). [DOI: 10.1117/1.OE.51.10.103201]
C1 [Liu, Chien-Sheng] Natl Chung Cheng Univ, Dept Mech Engn, Chiayi 62102, Taiwan.
   [Lin, Cheng-Hsien] Chung Shan Inst Sci & Technol, Flight Testing Div, Tao Yuan 325, Taiwan.
   [Sun, Yung-Nien] Natl Cheng Kung Univ, Dept Comp Sci & Informat Engn, Tainan 70101, Taiwan.
   [Ho, Chung-Liang] Natl Cheng Kung Univ, Coll Med, Dept Pathol, Tainan 70101, Taiwan.
   [Hsu, Chung-Chi] Natl Cheng Kung Univ, Inst Basic Med Sci, Tainan 70101, Taiwan.
C3 National Chung Cheng University; Chung-Shan Institute of Science &
   Technology; National Cheng Kung University; National Cheng Kung
   University; National Cheng Kung University
RP Liu, CS (通讯作者)，Natl Chung Cheng Univ, Dept Mech Engn, Chiayi 62102, Taiwan.
EM imecsl@ccu.edu.tw
FU National Science Council of Taiwan [NSC 100-2218-E-194-008]; Ministry of
   Economic Affairs of Taiwan [8301XS3E10]
FX The authors gratefully acknowledge the financial support provided to
   this study by the National Science Council of Taiwan under Grant No. NSC
   100-2218-E-194-008 and the Ministry of Economic Affairs of Taiwan under
   Grant No. 8301XS3E10.
CR Afshar A, 2007, J FRANKLIN I, V344, P452, DOI 10.1016/j.jfranklin.2006.06.001
   Aguirre AD, 2010, OPT EXPRESS, V18, P4222, DOI 10.1364/OE.18.004222
   Ashman RA, 2001, LASER MED SCI, V16, P52, DOI 10.1007/PL00011337
   Baskin JS, 2001, J CHEM EDUC, V78, P737, DOI 10.1021/ed078p737
   Berisha F, 2009, GRAEF ARCH CLIN EXP, V247, P303, DOI 10.1007/s00417-008-0963-8
   Bozorg-Haddad O, 2006, WATER RESOUR MANAG, V20, P661, DOI 10.1007/s11269-005-9001-3
   Bub G, 2010, NAT METHODS, V7, P209, DOI [10.1038/nmeth.1429, 10.1038/NMETH.1429]
   Cover T.M., 2006, ELEMENTS INFORM THEO
   Day D., 2006, INT J BIOMED IMAG, V2006, P93438
   Dogariu A, 2008, J BIOMED OPT, V13, DOI 10.1117/1.2978064
   Duwel I., 2004, ILASS EUR 19 ANN C
   Egge SV, 2011, OPT ENG, V50, DOI 10.1117/1.3613937
   Eom KB, 2011, OPT ENG, V50, DOI 10.1117/1.3577699
   Erdogan T., 2006, BIOPHOTON INT
   FAIRCHILD MD, 1998, COLOR APPEARANCE MOD
   Fathian M, 2007, APPL MATH COMPUT, V190, P1502, DOI 10.1016/j.amc.2007.02.029
   Flusberg BA, 2008, NAT METHODS, V5, P935, DOI 10.1038/nmeth.1256
   Furukawa A., 2008, P SOC PHOTO-OPT INS, V6911
   Garbin V, 2007, APPL PHYS LETT, V90, DOI 10.1063/1.2713164
   Gargesha M, 2009, OPT EXPRESS, V17, P10786, DOI 10.1364/OE.17.010786
   Gilmore ED, 2005, AM J PHYSIOL-HEART C, V288, pH2912, DOI 10.1152/ajpheart.01037.2004
   Gora M, 2009, OPT EXPRESS, V17, P14880, DOI 10.1364/OE.17.014880
   Hirata T, 2007, ANAL CHEM, V79, P147, DOI 10.1021/ac0612473
   Hood DC, 2009, OPT EXPRESS, V17, P3997, DOI 10.1364/OE.17.003997
   Horng MH, 2010, APPL MATH COMPUT, V215, P3302, DOI 10.1016/j.amc.2009.10.018
   Immonen P., 2006, INT WORKSH IM SYST T, P190
   Jiang N, 2008, OPT LETT, V33, P2236, DOI 10.1364/OL.33.002236
   Jonnal RS, 2007, OPT EXPRESS, V15, P16141, DOI 10.1364/OE.15.016141
   Klein S, 2007, IEEE T IMAGE PROCESS, V16, P2879, DOI 10.1109/TIP.2007.909412
   Ko HS, 2010, FLOW MEAS INSTRUM, V21, P443, DOI 10.1016/j.flowmeasinst.2010.06.001
   Kuratomi Y, 2010, J OPT SOC AM A, V27, P1812, DOI 10.1364/JOSAA.27.001812
   Liao ZJ, 2008, P SOC PHOTO-OPT INS, V6622, P62229, DOI 10.1117/12.790954
   Maes F, 1997, IEEE T MED IMAGING, V16, P187, DOI 10.1109/42.563664
   Makita S, 2008, OPT EXPRESS, V16, P8406, DOI 10.1364/OE.16.008406
   Manivannan A, 2001, ARCH OPHTHALMOL-CHIC, V119, P819
   Manivannan A, 1998, BRIT J OPHTHALMOL, V82, P342, DOI 10.1136/bjo.82.4.342
   Mujat M, 2010, OPT EXPRESS, V18, P11607, DOI 10.1364/OE.18.011607
   Oddos S, 2008, BIOPHYS J, V95, pL66, DOI 10.1529/biophysj.108.143198
   Peng Q, 2008, REP PROG PHYS, V71, DOI 10.1088/0034-4885/71/5/056701
   Petty HR, 2004, OPT PHOTONICS NEWS, V15, P40, DOI 10.1364/OPN.15.1.000040
   Pircher M, 2007, OPT EXPRESS, V15, P16922, DOI 10.1364/OE.15.016922
   Reinholz F, 1999, CYTOMETRY, V37, P165, DOI 10.1002/(SICI)1097-0320(19991101)37:3<165::AID-CYTO1>3.0.CO;2-A
   Reza AW, 2009, J MED SYST, V33, P73, DOI 10.1007/s10916-008-9166-4
   Rha J, 2006, OPT EXPRESS, V14, P4552, DOI 10.1364/OE.14.004552
   Sharp PF, 1999, BRIT J OPHTHALMOL, V83, P1241, DOI 10.1136/bjo.83.11.1241
   Sharp PF, 2004, PHYS MED BIOL, V49, P1085, DOI 10.1088/0031-9155/49/7/001
   Son DVT, 2010, SENSORS-BASEL, V10, P16, DOI 10.3390/s100100016
   Sourice A, 2005, MEAS SCI TECHNOL, V16, P2229, DOI 10.1088/0957-0233/16/11/014
   Srinivasan VJ, 2009, OPT EXPRESS, V17, P3861, DOI 10.1364/OE.17.003861
   Thoroddsen ST, 2008, ANNU REV FLUID MECH, V40, P257, DOI 10.1146/annurev.fluid.40.111406.102215
   Trisnadi JI, 2002, P SOC PHOTO-OPT INS, V4657, P131, DOI 10.1117/12.463781
   Vajda I, 1989, THEORY STAT INFERENC
   Vieira P, 2002, PHYSIOL MEAS, V23, P1, DOI 10.1088/0967-3334/23/1/301
   Vrhel MJ, 1999, IEEE T IMAGE PROCESS, V8, P1796, DOI 10.1109/83.806624
   Wang LL, 2000, OPT ENG, V39, P1659, DOI 10.1117/1.602543
   Wang M, 2009, OPT LETT, V34, P1955, DOI 10.1364/OL.34.001955
   White BR, 2003, OPT EXPRESS, V11, P3490, DOI 10.1364/OE.11.003490
   Wurzbacher T, 2008, MED IMAGE ANAL, V12, P300, DOI 10.1016/j.media.2007.12.007
   Yazdanfar S, 2000, OPT LETT, V25, P1448, DOI 10.1364/OL.25.001448
   Zhang Y, 2005, OPT EXPRESS, V13, P4792, DOI 10.1364/OPEX.13.004792
   Zhang Y, 2006, OPT EXPRESS, V14, P4380, DOI 10.1364/OE.14.004380
NR 61
TC 4
Z9 4
U1 0
U2 14
PU SPIE-SOC PHOTO-OPTICAL INSTRUMENTATION ENGINEERS
PI BELLINGHAM
PA 1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98225 USA
SN 0091-3286
EI 1560-2303
J9 OPT ENG
JI Opt. Eng.
PD OCT
PY 2012
VL 51
IS 10
AR 103201
DI 10.1117/1.OE.51.10.103201
PG 9
WC Optics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Optics
GA 021WF
UT WOS:000309915400016
DA 2022-11-30
ER

PT J
AU Shinojima, A
   Lee, DK
   Tsubota, K
   Negishi, K
   Kurihara, T
AF Shinojima, Ari
   Lee, Deokho
   Tsubota, Kazuo
   Negishi, Kazuno
   Kurihara, Toshihide
TI Retinal Diseases Regulated by Hypoxia-Basic and Clinical Perspectives: A
   Comprehensive Review
SO JOURNAL OF CLINICAL MEDICINE
LA English
DT Review
DE age-related macular degeneration; angiography; auto-fluorescence;
   central serous chorioretinopathy; choroidal neovascularization;
   hypofluorescent; hypoxia-inducible factor; indocyanine green; optical
   coherence tomography; vascular endothelial growth factor
ID ENDOTHELIAL GROWTH-FACTOR; CENTRAL SEROUS CHORIORETINOPATHY; INDOCYANINE
   GREEN ANGIOGRAPHY; OPTICAL COHERENCE TOMOGRAPHY; MACULAR DEGENERATION;
   PIGMENT EPITHELIUM; FACTOR EXPRESSION; VEGF EXPRESSION; LATE-PHASE; AGE
AB In recent years, the number of patients with age-related macular degeneration (AMD) is increasing worldwide along with increased life expectancy. Currently, the standard treatment for wet-AMD is intravitreal injection of anti-vascular endothelial growth factor (VEGF) drugs. The upstream of VEGF is hypoxia-inducible factor (HIF), a master regulator of hypoxia-responsive genes responsive to acute and chronic hypoxia. HIF activation induces various pathological pro-angiogenic gene expressions including VEGF under retinal hypoxia, ultimately leading to the development of ocular ischemic neovascular diseases. In this regard, HIF is considered as a promising therapeutic target in ocular ischemic diseases. In clinical ophthalmology, abnormal hypofluorescent areas have been detected in the late-phase of indocyanine green angiography, which are thought to be lipid deposits at the level of Bruch's membrane to choriocapillaris in vitreoretinal diseases. These deposits may interfere with the oxygen and nutrients that should be supplied to the retinal pigment epithelium, and that HIF/VEGF is highly suspected to be expressed in the hypoxic retinal pigment epithelium, leading to neovascularization. In this review, we comprehensively summarize pathophysiology of AMD-related ocular diseases with the HIF/VEGF pathway from basic and clinic researches with recent findings.
C1 [Shinojima, Ari; Lee, Deokho; Kurihara, Toshihide] Keio Univ, Lab Photobiol, Sch Med, Tokyo 1608582, Japan.
   [Shinojima, Ari; Lee, Deokho; Tsubota, Kazuo; Negishi, Kazuno; Kurihara, Toshihide] Keio Univ, Dept Ophthalmol, Sch Med, Tokyo 1608582, Japan.
   [Tsubota, Kazuo] Tsubota Lab Inc, Tokyo 1600016, Japan.
C3 Keio University; Keio University
RP Kurihara, T (通讯作者)，Keio Univ, Lab Photobiol, Sch Med, Tokyo 1608582, Japan.; Kurihara, T (通讯作者)，Keio Univ, Dept Ophthalmol, Sch Med, Tokyo 1608582, Japan.
EM ari.shinojima@keio.jp; deokholee@keio.jp; tsubota@tsubota-lab.com;
   kazunonegishi@keio.jp; kurihara@z8.keio.jp
RI ; Tsubota, Kazuo/M-1915-2013
OI Kurihara, Toshihide/0000-0002-5457-2720; Tsubota,
   Kazuo/0000-0002-8874-7111; Lee, Deokho/0000-0002-5992-9039; Negishi,
   Kazuno/0000-0002-2892-9810; Shinojima, Ari/0000-0003-2322-0332
FU Ministry of Education, Culture, Sports, Science and Technology (MEXT)
   [15K10881, 18K09424]
FX FundingThis work is supported by Grants-in-Aid for Scientific Research
   (KAKENHI, number 15K10881, and 18K09424) from the Ministry of Education,
   Culture, Sports, Science and Technology (MEXT) to T.K.
CR [Anonymous], EYLEA SOLUTION IVT I
   [Anonymous], LUCENTIS SOLUTION IN
   Appelhoff RJ, 2004, J BIOL CHEM, V279, P38458, DOI 10.1074/jbc.M406026200
   Avery RL, 2017, RETINA-J RET VIT DIS, V37, P1847, DOI 10.1097/IAE.0000000000001493
   Balaratnasingam C, 2018, OPHTHALMOLOGY, V125, P100, DOI 10.1016/j.ophtha.2017.08.033
   Parodi MB, 2020, PHARMACEUTICALS-BASE, V13, DOI 10.3390/ph13110359
   Berra E, 2003, EMBO J, V22, P4082, DOI 10.1093/emboj/cdg392
   Bird AC, 2003, EYE, V17, P457, DOI 10.1038/sj.eye.6700562
   Blaauwgeers HGT, 1999, AM J PATHOL, V155, P421, DOI 10.1016/S0002-9440(10)65138-3
   Bressler NM, 2012, RETINA-J RET VIT DIS, V32, P1821, DOI 10.1097/IAE.0b013e31825db6ba
   Bujarborua D, 2005, RETINA-J RET VIT DIS, V25, P422, DOI 10.1097/00006982-200506000-00005
   Castro-Navarro V, 2021, GRAEF ARCH CLIN EXP, V259, P1385, DOI 10.1007/s00417-020-04940-0
   Chen W, 2010, P NATL ACAD SCI USA, V107, P7401, DOI 10.1073/pnas.0912702107
   Daruich A, 2015, PROG RETIN EYE RES, V48, P82, DOI 10.1016/j.preteyeres.2015.05.003
   Dengler VL, 2014, CRIT REV BIOCHEM MOL, V49, P1, DOI 10.3109/10409238.2013.838205
   Dugel PU, 2020, OPHTHALMOLOGY, V127, P72, DOI 10.1016/j.ophtha.2019.04.017
   Ema M, 1997, P NATL ACAD SCI USA, V94, P4273, DOI 10.1073/pnas.94.9.4273
   Fallah J, 2019, CURR ONCOL REP, V21, DOI 10.1007/s11912-019-0752-z
   Fine SL, 2000, NEW ENGL J MED, V342, P483, DOI 10.1056/NEJM200002173420707
   Flamme I, 1998, AM J PATHOL, V153, P25, DOI 10.1016/S0002-9440(10)65541-1
   Forsythe JA, 1996, MOL CELL BIOL, V16, P4604
   Fujita K, 2015, OPHTHALMOLOGY, V122, P555, DOI 10.1016/j.ophtha.2014.09.034
   Fung AT, 2012, RETINA-J RET VIT DIS, V32, P1829, DOI 10.1097/IAE.0b013e3182680a66
   GASS JDM, 1967, AM J OPHTHALMOL, V63, P573
   GILBERT CM, 1984, BRIT J OPHTHALMOL, V68, P815, DOI 10.1136/bjo.68.11.815
   Gorin M B, 1992, Semin Ophthalmol, V7, P182, DOI 10.3109/08820539209065107
   Hage R, 2015, AM J OPHTHALMOL, V159, P890, DOI 10.1016/j.ajo.2015.02.002
   Hanumunthadu D, 2019, J OPHTHAL VIS RES, V14, P164, DOI 10.4103/jovr.jovr_152_17
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Ibuki M, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21238940
   Ibuki M, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.00174
   Ibuki M, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20205049
   Imamura Y, 2009, RETINA-J RET VIT DIS, V29, P1469, DOI 10.1097/IAE.0b013e3181be0a83
   Imanaga N, 2021, OPHTHALMOL RETINA, V5, P285, DOI 10.1016/j.oret.2020.07.011
   Iwai K, 1999, P NATL ACAD SCI USA, V96, P12436, DOI 10.1073/pnas.96.22.12436
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kawagishi H, 2019, P JPN ACAD B-PHYS, V95, P29, DOI 10.2183/pjab.95.003
   Kishi S, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0206646
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   Koivunen P, 2007, J BIOL CHEM, V282, P30544, DOI 10.1074/jbc.M704988200
   Koo T, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04175-y
   Kubota Y, 2008, J CLIN INVEST, V118, P2393, DOI 10.1172/JCI34882
   Kunimi H, 2021, FASEB J, V35, DOI 10.1096/fj.202100572R
   Kunimi H, 2019, PEERJ, V7, DOI 10.7717/peerj.7849
   Kunimi H, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20133171
   Kurihara T, 2015, GANKA OPHTHALMOL, V57, P1027
   Kurihara T, 2016, ELIFE, V5, DOI 10.7554/eLife.14319
   Kurihara T, 2014, ADV EXP MED BIOL, V801, P275, DOI 10.1007/978-1-4614-3209-8_35
   Kurihara T, 2012, J CLIN INVEST, V122, P4213, DOI 10.1172/JCI65157
   Kurihara T, 2010, DEVELOPMENT, V137, P1563, DOI 10.1242/dev.049015
   Landazuri MO, 2006, BIOCHEM BIOPH RES CO, V351, P313, DOI 10.1016/j.bbrc.2006.09.170
   LANG R, 1994, DEVELOPMENT, V120, P3395
   LATIF F, 1993, SCIENCE, V260, P1317, DOI 10.1126/science.8493574
   Lee CS, 2015, YONSEI MED J, V56, P1678, DOI 10.3349/ymj.2015.56.6.1678
   Lee D, 2020, BIOMOLECULES, V10, DOI 10.3390/biom10101405
   Lores-Motta L, 2021, AM J HUM GENET, V108, P1367, DOI 10.1016/j.ajhg.2021.06.002
   Marneros AG, 2005, AM J PATHOL, V167, P1451, DOI 10.1016/S0002-9440(10)61231-X
   Mitchinson A., 2014, NATURE, V505, P298, DOI DOI 10.1038/505298A
   Miwa Y, 2019, NEUROCHEM INT, V128, P21, DOI 10.1016/j.neuint.2019.03.008
   Mori K, 2002, RETINA-J RET VIT DIS, V22, P309, DOI 10.1097/00006982-200206000-00009
   Nakamura-Ishizu A, 2012, DEV BIOL, V363, P106, DOI 10.1016/j.ydbio.2011.12.027
   Neale BM, 2010, P NATL ACAD SCI USA, V107, P7395, DOI 10.1073/pnas.0912019107
   NEUMANN HPH, 1995, BRAIN PATHOL, V5, P181, DOI 10.1111/j.1750-3639.1995.tb00592.x
   Nita M, 2020, EXCLI J, V19, P1353, DOI 10.17179/excli2020-2915
   Pawlus MR, 2013, CELL SIGNAL, V25, P1895, DOI 10.1016/j.cellsig.2013.05.018
   RAMRATTAN RS, 1994, INVEST OPHTH VIS SCI, V35, P2857
   Rim TH, 2017, BRIT J OPHTHALMOL, V101, P1367, DOI 10.1136/bjophthalmol-2016-309952
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Ross A, 2011, CURR OPIN OPHTHALMOL, V22, P166, DOI 10.1097/ICU.0b013e3283459826
   Sadda, 2017, SPECTRAL DOMAIN OPTI
   Schlingemann RO, 2004, GRAEF ARCH CLIN EXP, V242, P91, DOI 10.1007/s00417-003-0828-0
   Schodel J, 2011, BLOOD, V117, pE207, DOI 10.1182/blood-2010-10-314427
   Sehnal D, 2021, NUCLEIC ACIDS RES, V49, pW431, DOI 10.1093/nar/gkab314
   SEMENZA GL, 1992, MOL CELL BIOL, V12, P5447, DOI 10.1128/MCB.12.12.5447
   Shinojima A, 2021, J CLIN MED, V10, DOI 10.3390/jcm10102178
   Shinojima A, 2020, BRIT J OPHTHALMOL, V104, P852, DOI 10.1136/bjophthalmol-2019-314970
   Shinojima A, 2016, OPHTHALMOLOGICA, V236, P108, DOI 10.1159/000448436
   Shinojima A, 2016, OPHTHALMOLOGICA, V236, P100, DOI 10.1159/000448342
   Shoda C, 2020, NUTRIENTS, V12, DOI 10.3390/nu12041055
   Spaide RF, 2022, PROG RETIN EYE RES, V86, DOI 10.1016/j.preteyeres.2021.100973
   Tadayoni R, 2019, P 19 EURETINA
   Tadayoni R, 2018, P 18 EURETINA VIENN
   Tian H, 1997, GENE DEV, V11, P72, DOI 10.1101/gad.11.1.72
   Usui V, 2015, J CLIN INVEST, V125, P2335, DOI 10.1172/JCI80297
   Vives-Bauza C, 2008, J BIOL CHEM, V283, P24770, DOI 10.1074/jbc.M800706200
   Wakatsuki Y, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0144156
   WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510
   Wang SS, 2014, P NATL ACAD SCI USA, V111, P16538, DOI 10.1073/pnas.1414789111
   Weidemann A, 2010, GLIA, V58, P1177, DOI 10.1002/glia.20997
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Zhang J, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.330
NR 92
TC 2
Z9 2
U1 2
U2 3
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2077-0383
J9 J CLIN MED
JI J. Clin. Med.
PD DEC
PY 2021
VL 10
IS 23
AR 5496
DI 10.3390/jcm10235496
PG 16
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA XV6NX
UT WOS:000735057600001
PM 34884197
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Flores-Bellver, M
   Mighty, J
   Aparicio-Domingo, S
   Li, KV
   Shi, C
   Zhou, J
   Cobb, H
   McGrath, P
   Michelis, G
   Lenhart, P
   Bilousova, G
   Heissel, S
   Rudy, MJ
   Coughlan, C
   Goodspeed, AE
   Becerra, SP
   Redenti, S
   Canto-Soler, MV
AF Flores-Bellver, Miguel
   Mighty, Jason
   Aparicio-Domingo, Silvia
   Li, Kang, V
   Shi, Cui
   Zhou, Jing
   Cobb, Hannah
   McGrath, Patrick
   Michelis, German
   Lenhart, Patricia
   Bilousova, Ganna
   Heissel, Soren
   Rudy, Michael J.
   Coughlan, Christina
   Goodspeed, Andrew E.
   Becerra, S. Patricia
   Redenti, Stephen
   Canto-Soler, M. Valeria
TI Extracellular vesicles released by human retinal pigment epithelium
   mediate increased polarised secretion of drusen proteins in response to
   AMD stressors
SO JOURNAL OF EXTRACELLULAR VESICLES
LA English
DT Article
DE AMD; drusen; exosomes; extracellular vesicles; microvesicles;
   proteomics; RPE; stem cells
ID MACULAR DEGENERATION; OXIDATIVE STRESS; APOLIPOPROTEIN-E; AMYLOID-BETA;
   EXOSOME SECRETION; EYE DEVELOPMENT; VISUAL CYCLE; RPE; EXPRESSION; CELLS
AB Age-related macular degeneration (AMD) is a leading cause of blindness worldwide. Drusen are key contributors to the etiology of AMD and the ability to modulate drusen biogenesis could lead to therapeutic strategies to slow or halt AMD progression. The mechanisms underlying drusen biogenesis, however, remain mostly unknown. Here we demonstrate that under homeostatic conditions extracellular vesicles (EVs) secreted by retinal pigment epithelium (RPE) cells are enriched in proteins associated with mechanisms involved in AMD pathophysiology, including oxidative stress, immune response, inflammation, complement system and drusen composition. Furthermore, we provide first evidence that drusen-associated proteins are released as cargo of extracellular vesicles secreted by RPE cells in a polarised apical:basal mode. Notably, drusen-associated proteins exhibited distinctive directional secretion modes in homeostatic conditions and, differential modulation of this directional secretion in response to AMD stressors. These observations underpin the existence of a finely-tuned mechanism regulating directional apical:basal sorting and secretion of drusen-associated proteins via EVs, and its modulation in response to mechanisms involved in AMD pathophysiology. Collectively, our results strongly support an active role of RPE-derived EVs as a key source of drusen proteins and important contributors to drusen development and growth.
C1 [Flores-Bellver, Miguel; Aparicio-Domingo, Silvia; Li, Kang, V; Cobb, Hannah; Lenhart, Patricia; Canto-Soler, M. Valeria] Univ Colorado, Sue Anschutz Rodgers Eye Ctr, Sch Med, Dept Ophthalmol,CellSight Ocular Stem Cell & Rege, Aurora, CO 80045 USA.
   [Mighty, Jason; Shi, Cui; Zhou, Jing; Redenti, Stephen] Lehman Coll, Bronx, NY USA.
   [Mighty, Jason; Shi, Cui; Redenti, Stephen] CUNY, Grad Sch, Biol Doctoral Program, New York, NY USA.
   [Mighty, Jason; Shi, Cui; Redenti, Stephen] CUNY, Univ Ctr, New York, NY 10021 USA.
   [McGrath, Patrick; Bilousova, Ganna] Univ Colorado, Sch Med, Dept Dermatol, Aurora, CO USA.
   [Michelis, German; Becerra, S. Patricia] NEI, Sect Prot Struct & Funct, NIH, Bethesda, MD 20892 USA.
   [Bilousova, Ganna; Canto-Soler, M. Valeria] Univ Colorado, Charles C Gates Ctr Regenerat Med, Sch Med, Aurora, CO USA.
   [Bilousova, Ganna] Univ Colorado, Sch Med, Linda Crnic Inst Syndrome, Aurora, CO USA.
   [Heissel, Soren] Rockefeller Univ, Prote Resource Ctr, 1230 York Ave, New York, NY 10021 USA.
   [Coughlan, Christina] Univ Colorado, Alzheimers & Cognit Ctr, Linda Crnic Inst Syndrome, Dept Neurol, Anschutz Med Campus, Aurora, CO USA.
   [Goodspeed, Andrew E.] Univ Colorado, Dept Pharmacol, Anschutz Med Campus, Aurora, CO USA.
   [Goodspeed, Andrew E.] Univ Colorado, Canc Ctr, Anschutz Med Campus, Aurora, CO USA.
   [Redenti, Stephen] CUNY, Grad Sch, Biochem Doctoral Program, New York, NY USA.
   [Rudy, Michael J.] Univ Colorado, Sch Med, Dept Neurol, Aurora, CO USA.
C3 University of Colorado System; University of Colorado Anschutz Medical
   Campus; City University of New York (CUNY) System; Lehman College
   (CUNY); City University of New York (CUNY) System; City University of
   New York (CUNY) System; University of Colorado System; University of
   Colorado Anschutz Medical Campus; National Institutes of Health (NIH) -
   USA; NIH National Eye Institute (NEI); University of Colorado System;
   University of Colorado Anschutz Medical Campus; University of Colorado
   System; University of Colorado Anschutz Medical Campus; Rockefeller
   University; University of Colorado System; University of Colorado
   Anschutz Medical Campus; University of Colorado System; University of
   Colorado Anschutz Medical Campus; University of Colorado System;
   University of Colorado Anschutz Medical Campus; City University of New
   York (CUNY) System; University of Colorado System; University of
   Colorado Anschutz Medical Campus
RP Flores-Bellver, M; Canto-Soler, MV (通讯作者)，Univ Colorado, Sue Anschutz Rodgers Eye Ctr, Sch Med, Dept Ophthalmol,CellSight Ocular Stem Cell & Rege, Aurora, CO 80045 USA.
EM m.flores-bellver@cuanschutz.edu; valeria.canto-soler@cuanschutz.edu
RI Li, Kang/Q-4855-2017
OI Li, Kang/0000-0003-0355-4255; Flores-Bellver, Miguel/0000-0003-3421-3699
FU National Eye Institute [5R21EY026752-02]; National Institute of General
   Medical Sciences [5SC3GM113782]; Maryland Stem Cell Research Fund
   [123914]; Research to Prevent Blindness; CellSight Development Fund;
   Gates Frontiers Fund; Bright Focus Foundation [M2016119]
FX National Eye Institute, Grant/Award Number: 5R21EY026752-02; National
   Institute of General Medical Sciences, Grant/Award Number: 5SC3GM113782;
   Maryland Stem Cell Research Fund, Grant/Award Number: 123914; Research
   to Prevent Blindness; CellSight Development Fund; The Solich Fund; Gates
   Frontiers Fund; Bright Focus Foundation, Grant/Award Number: M2016119
CR Adler R, 2007, DEV BIOL, V305, P1, DOI 10.1016/j.ydbio.2007.01.045
   Alvarez-Erviti L, 2011, NEUROBIOL DIS, V42, P360, DOI 10.1016/j.nbd.2011.01.029
   Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   Anderson DH, 2004, EXP EYE RES, V78, P243, DOI 10.1016/j.exer.2003.10.011
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Anderson DH, 2001, AM J OPHTHALMOL, V131, P767, DOI 10.1016/S0002-9394(00)00961-2
   Andreu Z, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00442
   Atienzar-Aroca S, 2016, J CELL MOL MED, V20, P1457, DOI 10.1111/jcmm.12834
   Baixauli F, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00403
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Becerra SP, 2004, EXP EYE RES, V78, P223, DOI 10.1016/j.exer.2003.10.013
   Beebe DC, 2013, INVEST OPHTH VIS SCI, V54, P5720, DOI 10.1167/iovs.13-12873
   Behndig A, 1998, INVEST OPHTH VIS SCI, V39, P471
   Bergen AA, 2019, PROG RETIN EYE RES, V70, P55, DOI 10.1016/j.preteyeres.2018.12.003
   Bhutto IA, 2006, EXP EYE RES, V82, P99, DOI 10.1016/j.exer.2005.05.007
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Bianchi E, 2013, INT J MOL MED, V31, P232, DOI 10.3892/ijmm.2012.1164
   Biasutto L, 2013, EXP CELL RES, V319, P2113, DOI 10.1016/j.yexcr.2013.05.005
   Blaauwgeers HGT, 1999, AM J PATHOL, V155, P421, DOI 10.1016/S0002-9440(10)65138-3
   Blenkinsop TA, 2015, INVEST OPHTH VIS SCI, V56, P7085, DOI 10.1167/iovs.14-16246
   Bok D, 2005, P NATL ACAD SCI USA, V102, P7053, DOI 10.1073/pnas.0502819102
   Bonilha VL, 2014, EXP EYE RES, V126, P38, DOI 10.1016/j.exer.2013.09.015
   Bonilha VL, 1999, J CELL BIOL, V147, P1533, DOI 10.1083/jcb.147.7.1533
   Boya P, 2016, PROG RETIN EYE RES, V55, P206, DOI 10.1016/j.preteyeres.2016.08.001
   BROWNING PJ, 1994, J EXP MED, V180, P1949, DOI 10.1084/jem.180.5.1949
   Buchholz DE, 2009, STEM CELLS, V27, P2427, DOI 10.1002/stem.189
   Bullock J, 2021, INVEST OPHTH VIS SCI, V62, DOI 10.1167/iovs.62.2.30
   Burridge PW, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018293
   Cai X, 2009, OPHTHALMIC GENET, V30, P57, DOI 10.1080/13816810802626399
   Canto-Soler V, 2016, INVEST OPHTH VIS SCI, V57, DOI 10.1167/iovs.16-19127
   Capowski EE, 2019, DEVELOPMENT, V146, DOI 10.1242/dev.171686
   Chang YG, 2007, J CELL SCI, V120, P3053, DOI 10.1242/jcs.006361
   Colombo M, 2014, ANNU REV CELL DEV BI, V30, P255, DOI 10.1146/annurev-cellbio-101512-122326
   Cook C., 1994, PRENATAL DEV EYE ITS, V1
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Croze RH, 2014, STEM CELL TRANSL MED, V3, P1066, DOI 10.5966/sctm.2014-0079
   Dai J, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-00261-0
   Dalvi S, 2019, CELL DEATH DISCOV, V5, DOI 10.1038/s41420-019-0171-9
   Datta S, 2017, PROG RETIN EYE RES, V60, P201, DOI 10.1016/j.preteyeres.2017.03.002
   Faber Carsten, 2008, Ugeskr Laeger, V170, P2953
   FRAMBACH DA, 1990, INVEST OPHTH VIS SCI, V31, P1767
   Fu B, 2017, INT J OPHTHALMOL-CHI, V10, P535, DOI 10.18240/ijo.2017.04.06
   Fuhrmann S, 2014, EXP EYE RES, V123, P141, DOI 10.1016/j.exer.2013.09.003
   Galloway CA, 2017, P NATL ACAD SCI USA, V114, pE8214, DOI 10.1073/pnas.1710430114
   Gangalum RK, 2016, J BIOL CHEM, V291, P12930, DOI 10.1074/jbc.M115.698530
   Gangalum RK, 2011, J BIOL CHEM, V286, P3261, DOI 10.1074/jbc.M110.160135
   Gao GQ, 2001, FEBS LETT, V489, P270, DOI 10.1016/S0014-5793(01)02110-X
   Geisen P, 2006, CURR EYE RES, V31, P739, DOI 10.1080/02713680600837408
   Gimeno-Hernandez R, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.590572
   Golestaneh N, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2016.453
   Green RW, 1999, MOL VIS, V5
   Hageman GS, 1999, FASEB J, V13, P477, DOI 10.1096/fasebj.13.3.477
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hill AF, 2019, J NEUROSCI, V39, P9269, DOI 10.1523/JNEUROSCI.0147-18.2019
   Hockemeyer D, 2009, NAT BIOTECHNOL, V27, P851, DOI 10.1038/nbt.1562
   Horsford DJ, 2005, DEVELOPMENT, V132, P177, DOI 10.1242/dev.01571
   Hoshino A, 2020, CELL, V182, P1044, DOI 10.1016/j.cell.2020.07.009
   Hosokawa K, 2020, BIOL PHARM BULL, V43, P540, DOI 10.1248/bpb.b19-01097
   Hu J, 2001, MOL VIS, V7, P14
   Hu XY, 2009, P NATL ACAD SCI USA, V106, P20324, DOI 10.1073/pnas.0911281106
   Jha P, 2006, ADV EXP MED BIOL, V586, P53
   Kanekiyo T, 2014, NEURON, V81, P740, DOI 10.1016/j.neuron.2014.01.045
   Katschke KJ, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-25557-8
   Keerthikumar S, 2016, J MOL BIOL, V428, P688, DOI 10.1016/j.jmb.2015.09.019
   KELLY ME, 1994, CELL IMMUNOL, V159, P124, DOI 10.1006/cimm.1994.1302
   Kim JH, 2010, INVEST OPHTH VIS SCI, V51, P561, DOI 10.1167/iovs.09-3774
   Kliffen M, 1997, BRIT J OPHTHALMOL, V81, P154, DOI 10.1136/bjo.81.2.154
   Klimanskaya I, 2004, CLONING STEM CELLS, V6, P217, DOI 10.1089/1536230042323420
   Klingeborn M, 2018, ADV EXP MED BIOL, V1074, P539, DOI 10.1007/978-3-319-75402-4_65
   Klingeborn M, 2017, PROG RETIN EYE RES, V59, P158, DOI 10.1016/j.preteyeres.2017.04.004
   Klingeborn M, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-05102-9
   Knickelbein JE, 2016, INVEST OPHTH VIS SCI, V57, P4101, DOI 10.1167/iovs.15-18353
   Kogut I, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03190-3
   Lakkaraju A, 2020, PROG RETIN EYE RES, V78, DOI 10.1016/j.preteyeres.2020.100846
   Lamark Trond, 2012, Int J Cell Biol, V2012, P736905, DOI 10.1155/2012/736905
   Lee Y, 2012, HUM MOL GENET, V21, pR125, DOI 10.1093/hmg/dds317
   Levy O, 2015, J NEUROSCI, V35, P13568, DOI 10.1523/JNEUROSCI.2468-15.2015
   Li J, 2012, J BIOL CHEM, V287, P44593, DOI 10.1074/jbc.M112.420224
   Liberzon A, 2011, BIOINFORMATICS, V27, P1739, DOI 10.1093/bioinformatics/btr260
   Locke CJ, 2014, EXP EYE RES, V129, P1, DOI 10.1016/j.exer.2014.10.010
   Lueck K, 2011, EYE, V25, P1074, DOI 10.1038/eye.2011.109
   Mali P, 2013, SCIENCE, V339, P823, DOI 10.1126/science.1232033
   Maminishkis A, 2006, INVEST OPHTH VIS SCI, V47, P3612, DOI 10.1167/iovs.05-1622
   Martin G, 2004, GRAEF ARCH CLIN EXP, V242, P321, DOI 10.1007/s00417-003-0838-y
   Mathivanan S, 2012, NUCLEIC ACIDS RES, V40, pD1241, DOI 10.1093/nar/gkr828
   McKechnie NM, 2003, INVEST OPHTH VIS SCI, V44, P2650, DOI 10.1167/iovs.02-0765
   Mclaughlin L, 2000, J CLIN INVEST, V106, P1105, DOI 10.1172/JCI9037
   Mitter SK, 2014, AUTOPHAGY, V10, P1989, DOI 10.4161/auto.36184
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Nguyen MTT, 2000, DEVELOPMENT, V127, P3581
   Nita M, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/3164734
   Noren Hooten Nicole, 2020, Transl Med Aging, V4, P96, DOI 10.1016/j.tma.2020.07.006
   ORAHILLY R, 1975, EXP EYE RES, V21, P93, DOI 10.1016/0014-4835(75)90075-5
   Pathan M, 2019, NUCLEIC ACIDS RES, V47, pD516, DOI 10.1093/nar/gky1029
   Pathan M, 2015, PROTEOMICS, V15, P2597, DOI 10.1002/pmic.201400515
   Peng KY, 2019, BRAIN, V142, P163, DOI 10.1093/brain/awy289
   Rajendran L, 2006, P NATL ACAD SCI USA, V103, P11172, DOI 10.1073/pnas.0603838103
   Ranganathan V, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5516
   Ratajczak MZ, 2020, LEUKEMIA, V34, P3126, DOI 10.1038/s41375-020-01041-z
   Reyes-Reveles J, 2017, J BIOL CHEM, V292, P8038, DOI 10.1074/jbc.M116.770784
   Riva P, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20174113
   Saari JC, 2001, NEURON, V29, P739, DOI 10.1016/S0896-6273(01)00248-3
   Sakaguchi H, 2002, EXP EYE RES, V74, P547, DOI 10.1006/exer.2002.1186
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   Schertler GFX, 2000, METHOD ENZYMOL, V315, P91
   Shah N, 2018, BBA-MOL BASIS DIS, V1864, P2610, DOI 10.1016/j.bbadis.2018.04.016
   Singh R, 2015, MOL THER, V23, P1700, DOI 10.1038/mt.2015.141
   Singh R, 2013, INVEST OPHTH VIS SCI, V54, P6767, DOI 10.1167/iovs.13-11943
   Sinha MS, 2018, ACTA NEUROPATHOL, V136, P41, DOI 10.1007/s00401-018-1868-1
   Sonoda S, 2009, NAT PROTOC, V4, P662, DOI 10.1038/nprot.2009.33
   Sreekumar PG, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012578
   Stahl PD, 2019, PHYSIOLOGY, V34, P169, DOI 10.1152/physiol.00045.2018
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Su HR, 1996, INT ARCH ALLERGY IMM, V110, P314, DOI 10.1159/000237322
   Sugano E, 2013, CELL STRUCT FUNCT, V38, P81, DOI 10.1247/csf.12025
   Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024
   Tangirala RK, 2001, J BIOL CHEM, V276, P261, DOI 10.1074/jbc.M003324200
   Thery C, 2018, J EXTRACELL VESICLES, V7, DOI 10.1080/20013078.2018.1535750
   Thornton J, 2005, EYE, V19, P935, DOI 10.1038/sj.eye.6701978
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   Vaajasaari H, 2011, MOL VIS, V17, P558
   Van Deun J, 2017, NAT METHODS, V14, P228, DOI 10.1038/nmeth.4185
   van Niel G, 2011, DEV CELL, V21, P708, DOI 10.1016/j.devcel.2011.08.019
   Vargas A, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0182389
   Vergara MN, 2017, DEVELOPMENT, V144, P3698, DOI 10.1242/dev.146290
   Wang AL, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004160
   Wang L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010329
   Wang L, 2014, FREE RADICAL BIO MED, V70, P155, DOI 10.1016/j.freeradbiomed.2014.01.015
   Wasmuth S, 2009, INVEST OPHTH VIS SCI, V50, P5304, DOI 10.1167/iovs.08-3326
   Watt B, 2013, PIGM CELL MELANOMA R, V26, P300, DOI 10.1111/pcmr.12067
   Whitcup SM, 2013, INT J INFLAMM, V2013, DOI 10.1155/2013/724648
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wu W, 2016, ONCOTARGET, V7, P22819, DOI 10.18632/oncotarget.8185
   Xu J, 2018, J CELL SCI, V131, DOI 10.1242/jcs.215210
   Yoshida T, 2005, J CLIN INVEST, V115, P2793, DOI 10.1172/JCI24635
   YOUNG RW, 1987, SURV OPHTHALMOL, V31, P291, DOI 10.1016/0039-6257(87)90115-9
   Yu GC, 2012, OMICS, V16, P284, DOI 10.1089/omi.2011.0118
   Zhong XF, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5047
NR 140
TC 8
Z9 8
U1 6
U2 17
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
EI 2001-3078
J9 J EXTRACELL VESICLES
JI J. Extracell. Vesicles
PD NOV
PY 2021
VL 10
IS 13
AR e12165
DI 10.1002/jev2.12165
PG 27
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA WT0HK
UT WOS:000715554600001
PM 34750957
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Seo, S
   Kim, KL
   Yeo, Y
   Kim, RI
   Jeong, H
   Kim, JO
   Song, SH
   An, MJ
   Kim, JW
   Hong, HK
   Ham, MH
   Woo, SJ
   Sung, JH
   Park, SG
   Suh, W
AF Seo, Songyi
   Kim, Koung Li
   Yeo, Yeongju
   Kim, Ryul-, I
   Jeong, Hayoung
   Kim, Jin-Ock
   Song, Sun-Hwa
   An, Mi-Jin
   Kim, Jung-Woong
   Hong, Hye Kyoung
   Ham, Min Hee
   Woo, Se Joon
   Sung, Jong-Hyuk
   Park, Sang Gyu
   Suh, Wonhee
TI A Fully Human Monoclonal Antibody Targeting cKIT Is a Potent Inhibitor
   of Pathological Choroidal Neovascularization in Mice
SO PHARMACEUTICS
LA English
DT Article
DE age-related macular degeneration; choroidal neovascularization; cKIT;
   fully human monoclonal antibody; stem cell factor
ID ENDOTHELIAL GROWTH-FACTOR; STEM-CELL FACTOR; MACULAR DEGENERATION;
   EXPRESSION; ATROPHY; MODEL
AB Stem cell factor (SCF) and its receptor, cKIT, are novel regulators of pathological neovascularization in the eye, which suggests that inhibition of SCF/cKIT signaling may be a novel pharmacological strategy for treating neovascular age-related macular degeneration (AMD). This study evaluated the therapeutic potential of a newly developed fully human monoclonal antibody targeting cKIT, NN2101, in a murine model of neovascular AMD. In hypoxic human endothelial cells, NN2101 substantially inhibited the SCF-induced increase in angiogenesis and activation of the cKIT signaling pathway. In a murine model of neovascular AMD, intravitreal injection of NN2101 substantially inhibited the SCF/cKIT-mediated choroidal neovascularization (CNV), with efficacy comparable to aflibercept, a vascular endothelial growth factor inhibitor. A combined intravitreal injection of NN2101 and aflibercept resulted in an additive therapeutic effect on CNV. NN2101 neither caused ocular toxicity nor interfered with the early retinal vascular development in mice. Ocular pharmacokinetic analysis in rabbits indicated that NN2101 demonstrated a pharmacokinetic profile suitable for intravitreal injection. These findings provide the first evidence of the potential use of the anti-cKIT blocking antibody, NN2101, as an alternative or additive therapeutic for the treatment of neovascular AMD.
C1 [Seo, Songyi; Yeo, Yeongju; Kim, Ryul-, I; Jeong, Hayoung; Suh, Wonhee] Chung Ang Univ, Dept Global Innovat Drug, Grad Sch, Seoul 06974, South Korea.
   [Seo, Songyi; Kim, Koung Li; Yeo, Yeongju; Kim, Ryul-, I; Jeong, Hayoung; Kim, Jin-Ock; Suh, Wonhee] Chung Ang Univ, Coll Pharm, Seoul 06974, South Korea.
   [Kim, Jin-Ock; Song, Sun-Hwa; Park, Sang Gyu] Ajou Univ, Coll Pharm, Suwon 16499, South Korea.
   [An, Mi-Jin; Kim, Jung-Woong] Chung Ang Univ, Dept Life Sci, Seoul 06974, South Korea.
   [Hong, Hye Kyoung; Ham, Min Hee] Seoul Natl Univ, Bundang Hosp, Dept Ophthalmol, Coll Med, Seongnam 13620, South Korea.
   [Sung, Jong-Hyuk] Yonsei Univ, Coll Pharm, Incheon 21983, South Korea.
C3 Chung Ang University; Chung Ang University; Ajou University; Chung Ang
   University; Seoul National University (SNU); Yonsei University
RP Suh, W (通讯作者)，Chung Ang Univ, Dept Global Innovat Drug, Grad Sch, Seoul 06974, South Korea.; Suh, W (通讯作者)，Chung Ang Univ, Coll Pharm, Seoul 06974, South Korea.; Park, SG (通讯作者)，Ajou Univ, Coll Pharm, Suwon 16499, South Korea.
EM ssi4053@naver.com; crux777@hanmail.net; mh8541@naver.com;
   ous3@naver.com; gkdud8160@naver.com; kjo8909@ajou.ac.kr;
   thdtjsghk@daum.net; dksalwls333@gmail.com; jungkim@cau.ac.kr;
   alpaomega@hanmail.net; miniham@naver.com; sejoonwoo@gmail.com;
   brian99@yonsei.ac.kr; sgpark@ajou.ac.kr; wsuh@cau.ac.kr
RI Woo, Se Joon/I-7357-2013
OI Woo, Se Joon/0000-0003-3692-7169; suh, wonhee/0000-0001-5811-0833; Park,
   Sang Gyu/0000-0002-4870-2242; Kim, Jung-Woong/0000-0003-4458-7213
FU National Research Foundation - Korea (NRF) - Korea government
   [2020R1A4A4079817, 2018M3A9H2019045, 2020R1A2C1012930]
FX This work was supported by the National Research Foundation funded by
   the Korea (NRF) grant funded by the Korea government (2020R1A4A4079817,
   2018M3A9H2019045, 2020R1A2C1012930).
CR Abu El-Asrar AM, 2013, J DIABETES RES, V2013, DOI 10.1155/2013/539658
   Abu El-Asrar AM, 2010, MOL VIS, V16, P1098
   Bhisitkul RB, 2015, AM J OPHTHALMOL, V159, P915, DOI 10.1016/j.ajo.2015.01.032
   Broudy VC, 1997, BLOOD, V90, P1345, DOI 10.1182/blood.V90.4.1345.1345_1345_1364
   Campochiaro PA, 2015, PROG RETIN EYE RES, V49, P67, DOI 10.1016/j.preteyeres.2015.06.002
   Chou TC, 2006, PHARMACOL REV, V58, P621, DOI 10.1124/pr.58.3.10
   Christoforidis JB, 2012, CURR EYE RES, V37, P1171, DOI 10.3109/02713683.2012.727521
   Ford KM, 2011, INVEST OPHTH VIS SCI, V52, P9478, DOI 10.1167/iovs.11-8353
   Garcia-Quintanilla L, 2019, PHARMACEUTICS, V11, DOI 10.3390/pharmaceutics11080365
   Grisanti S, 2008, PROG RETIN EYE RES, V27, P372, DOI 10.1016/j.preteyeres.2008.05.002
   Grunwald JE, 2017, OPHTHALMOLOGY, V124, P97, DOI 10.1016/j.ophtha.2016.09.012
   Holz FG, 2014, J CLIN INVEST, V124, P1430, DOI 10.1172/JCI71029
   Kim JO, 2020, INT J BIOL MACROMOL, V159, P66, DOI 10.1016/j.ijbiomac.2020.05.045
   Kim KL, 2019, ARTERIOSCL THROM VAS, V39, P2120, DOI 10.1161/ATVBAHA.119.313179
   Kim KL, 2017, INVEST OPHTH VIS SCI, V58, P3592, DOI 10.1167/iovs.17-21416
   Kurihara T, 2012, J CLIN INVEST, V122, P4213, DOI 10.1172/JCI65157
   Lambert V, 2013, NAT PROTOC, V8, P2197, DOI 10.1038/nprot.2013.135
   Meyer CH, 2016, DEV OPHTHALMOL, V55, P63, DOI 10.1159/000431143
   Park SJ, 2016, INVEST OPHTH VIS SCI, V57, P2612, DOI 10.1167/iovs.16-19204
   Sadda SR, 2018, OPHTHALMOLOGY, V125, P878, DOI 10.1016/j.ophtha.2017.12.026
   Sette C, 2000, INT J DEV BIOL, V44, P599
   Spitzer MS, 2006, BRIT J OPHTHALMOL, V90, P1316, DOI 10.1136/bjo.2006.095190
   Usui-Ouchi A, 2019, J CLIN INVEST, V129, P3032, DOI 10.1172/JCI129862
   Varela-Fernandez R, 2020, PHARMACEUTICS, V12, DOI 10.3390/pharmaceutics12030269
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yoshida H, 2001, J INVEST DERM SYMP P, V6, P1, DOI 10.1046/j.0022-202x.2001.00006.x
NR 26
TC 0
Z9 0
U1 1
U2 2
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1999-4923
J9 PHARMACEUTICS
JI Pharmaceutics
PD AUG
PY 2021
VL 13
IS 8
AR 1308
DI 10.3390/pharmaceutics13081308
PG 14
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA UH4KM
UT WOS:000689902000001
PM 34452268
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Lai, KY
   Pathipati, MP
   Blumenkranz, MS
   Leung, LS
   Moshfeghi, DM
   Toy, BC
   Myung, D
AF Lai, Krystal Y.
   Pathipati, Mythili P.
   Blumenkranz, Mark S.
   Leung, Loh-Shan
   Moshfeghi, Darius M.
   Toy, Brian C.
   Myung, David
TI Assessment of Eye Disease and Visual Impairment in the Nursing Home
   Population Using Mobile Health Technology
SO OPHTHALMIC SURGERY LASERS & IMAGING RETINA
LA English
DT Article
ID QUALITY-OF-LIFE; VISION IMPAIRMENT; OLDER-PEOPLE; RESIDENTS; PREVALENCE;
   ADULTS; IMPACT; DEPRESSION; DISABILITY
AB BACKGROUND AND OBJECTIVE: To characterize the burden of eye disease and the utility of teleophthalmology in nursing home patients, a population with ophthalmic needs not commensurate with care received.
   PATIENTS AND METHODS: Informed consent was obtained from 78 California Bay Area skilled nursing facility patients. Near visual acuity (VA) and anterior/posterior segment photographs were taken with a smartphone-based VA app and ophthalmic camera system. The Nursing Home Vision-Targeted Health-Related Quality of Life questionnaire was also administered. Risk factors for visual impairment were assessed. Institutional review board approval was obtained from Stanford University.
   RESULTS: Cataracts (51%), diabetic retinopathy (DR) (12%), optic neuropathy (12%), and age-related macular degeneration (AMD) (10%) were common findings; 11.7% had other referral-warranted findings. AMD and DR correlated with a higher risk of poor VA, with adjusted odds ratios of 22 (P = .01) and 43 (P = .004).
   CONCLUSIONS: This study demonstrated a high prevalence of poor VA and ophthalmic disease in the nursing home population impacting quality of life. Smartphone-based teleophthalmology platforms have the potential to increase access to eye care for nursing home patients.
C1 [Lai, Krystal Y.; Pathipati, Mythili P.; Blumenkranz, Mark S.; Leung, Loh-Shan; Moshfeghi, Darius M.; Myung, David] Stanford Univ, Byers Eye Inst, 2452 Watson Court,9, Palo Alto, CA 94303 USA.
   [Leung, Loh-Shan; Myung, David] VA Palo Alto Hlth Care Syst, Palo Alto, CA USA.
   [Toy, Brian C.] Univ Southern Calif, Dept Ophthalmol, Roski Eye Inst, Los Angeles, CA 90007 USA.
C3 Stanford University; US Department of Veterans Affairs; Veterans Health
   Administration (VHA); VA Palo Alto Health Care System; University of
   Southern California
RP Myung, D (通讯作者)，Stanford Univ, Byers Eye Inst, 2452 Watson Court,9, Palo Alto, CA 94303 USA.; Toy, BC (通讯作者)，USC Sch Med, Roski Eye Inst, 1450 San Pablo St,4th Floor, Los Angeles, CA 90033 USA.
EM brian.toy@med.usc.edu; djmyung@stanford.edu
OI Toy, Brian/0000-0002-9612-5697; Moshfeghi, Darius
   Mohammad/0000-0003-2254-292X; Leung, Loh-Shan/0000-0001-8496-0698
FU Research to Prevent Blindness (RPB), New York, New York; National Eye
   Institute [P30-EY026877]
FX Supported by unrestricted grants to the Departments of Ophthalmology at
   both Stanford and USC from Research to Prevent Blindness (RPB), New
   York, New York, and a departmental P30-EY026877 core grant to Stanford
   from the National Eye Institute.
CR AAO Hoskins Center for Quality Eye Care, FREQ OC EX 2015
   Chia EM, 2004, INVEST OPHTH VIS SCI, V45, P71, DOI 10.1167/iovs.03-0661
   Dev MK, 2014, CURR EYE RES, V39, P232, DOI 10.3109/02713683.2013.838973
   Dreer LE, 2007, AGING MENT HEALTH, V11, P722, DOI 10.1080/13607860701366186
   Elliott AF, 2013, J AGING HEALTH, V25, P364, DOI 10.1177/0898264312472538
   FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Friedman DS, 2005, ARCH OPHTHALMOL-CHIC, V123, P1581, DOI 10.1001/archopht.123.11.1581
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P532
   Gray LC, 2012, J TELEMED TELECARE, V18, P142, DOI 10.1258/jtt.2012.SFT105
   HOROWITZ A, 1994, GERONTOLOGIST, V34, P316, DOI 10.1093/geront/34.3.316
   Ip SPS, 2000, INT J GERIATR PSYCH, V15, P1120, DOI 10.1002/1099-1166(200012)15:12<1120::AID-GPS256>3.0.CO;2-X
   Keller B K, 2001, J Am Med Dir Assoc, V2, P15, DOI 10.1097/00130535-200101000-00004
   Knudtson MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P807, DOI 10.1001/archopht.123.6.807
   Lamoureux EL, 2009, INVEST OPHTH VIS SCI, V50, P4103, DOI 10.1167/iovs.08-3294
   Mitchell P, 1997, MED J AUSTRALIA, V166, P73, DOI 10.5694/j.1326-5377.1997.tb138724.x
   Myung D., 2014, J MOB TECHNOL MED, V3, P2, DOI DOI 10.7309/JMTM.3.1.2
   Myung D., 2014, J MOB TECHNOL MED, V3, P9, DOI 10.7309/jmtm.3.1.3
   Owsley C, 2007, ARCH OPHTHALMOL-CHIC, V125, P925, DOI 10.1001/archopht.125.7.925
   Rokicki W, 2016, ARCH MED SCI, V12, P1232, DOI 10.5114/aoms.2015.55146
   RUBIN GS, 1994, OPTOMETRY VISION SCI, V71, P750, DOI 10.1097/00006324-199412000-00005
   TIELSCH JM, 1995, NEW ENGL J MED, V332, P1205, DOI 10.1056/NEJM199505043321806
   Toy BC, 2016, RETINA-J RET VIT DIS, V36, P1000, DOI 10.1097/IAE.0000000000000955
   Tsui Irena, 2014, J Diabetes Sci Technol, V8, P845, DOI 10.1177/1932296814529637
   U.S. Census Bureau, QUICKFACTS SAN MAT C
   US Census Bureau, QUICKFACTS SANT CLAR
   West SK, 2003, OPHTHALMIC EPIDEMIOL, V10, P193, DOI 10.1076/opep.10.3.193.15081
   World Health Organization, BLINDN VIS IMP
NR 28
TC 3
Z9 3
U1 0
U2 2
PU SLACK INC
PI THOROFARE
PA 6900 GROVE RD, THOROFARE, NJ 08086 USA
SN 2325-8160
EI 2325-8179
J9 OSLI RETINA
JI Ophthalmic Surg. Lasers Imag. Retin.
PD MAY
PY 2020
VL 51
IS 5
BP 262
EP 270
DI 10.3928/23258160-20200501-03
PG 9
WC Ophthalmology; Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Surgery
GA LW7HW
UT WOS:000539315500003
PM 32511729
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Wei, X
   Balne, PK
   Meissner, KE
   Barathi, VA
   Schmetterer, L
   Agrawal, R
AF Wei, Xin
   Balne, Praveen Kumar
   Meissner, Kenith E.
   Barathi, Velucharny A.
   Schmetterer, Leopold
   Agrawal, Rupesh
TI Assessment of flow dynamics in retinal and choroidal microcirculation
SO SURVEY OF OPHTHALMOLOGY
LA English
DT Review
DE retinal blood flow; choroidal blood flow; optic nerve head blood flow;
   diabetic retinopathy; glaucoma; age-related macular degeneration
ID OCULAR BLOOD-FLOW; OPTIC-NERVE HEAD; COHERENCE TOMOGRAPHY ANGIOGRAPHY;
   OPEN-ANGLE GLAUCOMA; SCANNING LASER OPHTHALMOSCOPE; WAVE-FORM ANALYSIS;
   INTRAVITREAL BEVACIZUMAB AVASTIN(R); PROLIFERATIVE DIABETIC-RETINOPATHY;
   FLUORESCEIN LEUKOCYTE ANGIOGRAPHY; INTRAOCULAR-PRESSURE REDUCTION
AB Alterations in ocular blood flow have been implicated in mechanisms that lead to vision loss in patients with various ocular disorders such as diabetic retinopathy, glaucoma, and age-related macular degeneration. Assessment of retinal and choroidal blood flow is also a window to evaluate systemic diseases that affect microvasculature. Quantification and qualification of the blood flow in the retina and choroid help us understand pathophysiology, stratify disease risk, and monitor disease progression in these disorders. Multiple methods are used by researchers for assessment of blood flow, but a gold standard is lacking. We review commonly used methods, both invasive and noninvasive, for evaluation of blood flow, including intravital microscopy, laser Doppler velocimetry, laser Doppler flowmetry, laser interferometry, confocal scanning laser Doppler flowmetry, laser speckle flowgraphy, Doppler optical coherence tomography, blue-field entoptic simulation, retinal vessel caliber assessment, optical coherence tomography angiography, retinal function imaging, color Doppler imaging, and scanning laser ophthalmoscope angiogram. As technology evolves, better evaluation of blood flow in various ocular and systemic diseases will likely bring new perspectives into clinical practice and translate to better diagnosis and treatment. (C) 2018 Elsevier Inc. All rights reserved.
C1 [Wei, Xin; Agrawal, Rupesh] Tan Tock Seng Hosp, Natl Healthcare Grp, Eye Inst, Singapore 308433, Singapore.
   [Balne, Praveen Kumar; Barathi, Velucharny A.; Schmetterer, Leopold; Agrawal, Rupesh] Singapore Eye Res Inst, Singapore, Singapore.
   [Meissner, Kenith E.] Swansea Univ, Dept Phys, Swansea, W Glam, Wales.
   [Schmetterer, Leopold; Agrawal, Rupesh] Nanyang Technol Univ, Lee Kong Chian Sch Med, Singapore, Singapore.
   [Schmetterer, Leopold] Med Univ Vienna, Dept Clin Pharmacol, Vienna, Austria.
   [Schmetterer, Leopold] Med Univ Vienna, Ctr Med Phys & Biomed Engn, Vienna, Austria.
C3 Tan Tock Seng Hospital; National University of Singapore; Singapore
   National Eye Center; Swansea University; Nanyang Technological
   University & National Institute of Education (NIE) Singapore; Nanyang
   Technological University; Medical University of Vienna; Medical
   University of Vienna
RP Agrawal, R (通讯作者)，Tan Tock Seng Hosp, Natl Healthcare Grp, Eye Inst, Singapore 308433, Singapore.
EM rupesh_agrawal@ttsh.com.sg
RI Balne, Praveen Kumar/X-7075-2019
OI Balne, Praveen Kumar/0000-0001-8365-9991; Agrawal,
   Rupesh/0000-0002-6662-5850; Schmetterer, Leopold/0000-0002-7189-1707;
   Wei, Xin/0000-0001-8865-1956
CR Arai T, 1998, J ULTRAS MED, V17, P675, DOI 10.7863/jum.1998.17.11.675
   Arbel Y, 2014, ATHEROSCLEROSIS, V232, P149, DOI 10.1016/j.atherosclerosis.2013.10.033
   Arend O, 2002, BRIT J OPHTHALMOL, V86, P429, DOI 10.1136/bjo.86.4.429
   BEHRENDT T, 1965, AM J OPHTHALMOL, V59, P1079, DOI 10.1016/0002-9394(65)93427-6
   BENNETT AG, 1994, GRAEF ARCH CLIN EXP, V232, P361, DOI 10.1007/BF00175988
   Berenberg TL, 2012, RETINA-J RET VIT DIS, V32, P25, DOI 10.1097/IAE.0b013e3182150483
   Berisha F, 2005, BRIT J OPHTHALMOL, V89, P185, DOI 10.1136/bjo.2004.048173
   Boehm AG, 1999, GRAEF ARCH CLIN EXP, V237, P484, DOI 10.1007/s004170050266
   Boltz A, 2010, INVEST OPHTH VIS SCI, V51, P4220, DOI 10.1167/iovs.09-4968
   BONNER R, 1981, APPL OPTICS, V20, P2097, DOI 10.1364/AO.20.002097
   Bosch AJ, 2017, BMC CARDIOVASC DISOR, V17, DOI 10.1186/s12872-017-0732-x
   Burgansky-Eliash Z, 2016, CURR EYE RES, V41, P965, DOI 10.3109/02713683.2015.1080278
   Burgansky-Eliash Z, 2014, CURR EYE RES, V39, P304, DOI 10.3109/02713683.2013.840384
   Burgansky-Eliash Z, 2013, OSLI RETINA, V44, P51, DOI 10.3928/23258160-20121221-13
   Burgansky-Eliash Z, 2012, RETINA-J RET VIT DIS, V32, P112, DOI 10.1097/IAE.0b013e31821ba2c4
   Burgansky-Eliash Z, 2010, RETINA-J RET VIT DIS, V30, P765, DOI 10.1097/IAE.0b013e3181c596c6
   BURSELL SE, 1992, CURR EYE RES, V11, P287, DOI 10.3109/02713689209001782
   Cekic O, 2011, CURR EYE RES, V36, P149, DOI 10.3109/02713683.2010.533809
   Chalam K V, 2016, J Ophthalmic Vis Res, V11, P84, DOI 10.4103/2008-322X.180709
   Chamot SR, 1999, MICROVASC RES, V57, P153, DOI 10.1006/mvre.1998.2136
   Chen CL, 2017, JAMA OPHTHALMOL, V135, P461, DOI 10.1001/jamaophthalmol.2017.0261
   Cheng CY, 2001, OPHTHALMOLOGY, V108, P1445, DOI 10.1016/S0161-6420(01)00603-0
   Cheng RW, 2016, J PHYSIOL-LONDON, V594, P625, DOI 10.1113/JP271182
   Cheung N, 2008, DIABETES CARE, V31, P1842, DOI 10.2337/dc08-0189
   Chhablani J, 2013, GRAEF ARCH CLIN EXP, V251, P2665, DOI 10.1007/s00417-013-2360-1
   Chin YC, 2014, OPHTHAL EPIDEMIOL, V21, P224, DOI 10.3109/09286586.2014.926941
   Choi W, 2012, BIOMED OPT EXPRESS, V3, P1047, DOI 10.1364/BOE.3.001047
   Chung HS, 1999, BRIT J OPHTHALMOL, V83, P466, DOI 10.1136/bjo.83.4.466
   Ciancaglini M, 2001, GRAEF ARCH CLIN EXP, V239, P549, DOI 10.1007/s004170100305
   Cicinelli MV, 2018, SURV OPHTHALMOL, V63, P236, DOI 10.1016/j.survophthal.2017.06.005
   Ciulla TA, 1999, AM J OPHTHALMOL, V128, P75, DOI 10.1016/S0002-9394(99)00061-6
   Ciulla TA, 2002, BRIT J OPHTHALMOL, V86, P209, DOI 10.1136/bjo.86.2.209
   Ciulla TA, 2001, ACTA OPHTHALMOL SCAN, V79, P108, DOI 10.1034/j.1600-0420.2001.079002108.x
   Couturier A, 2015, RETINA-J RET VIT DIS, V35, P2384, DOI 10.1097/IAE.0000000000000859
   Cuypers MHM, 2000, GRAEF ARCH CLIN EXP, V238, P935, DOI 10.1007/s004170000207
   Dai CX, 2013, INVEST OPHTH VIS SCI, V54, P7998, DOI 10.1167/iovs.13-12318
   de Carlo TE, 2016, OSLI RETINA, V47, P108, DOI 10.3928/23258160-20160126-02
   de Carlo TE, 2015, OPHTHALMOLOGY, V122, P1228, DOI 10.1016/j.ophtha.2015.01.029
   Dimitrova G, 2001, EYE, V15, P602, DOI 10.1038/eye.2001.193
   Doblhoff-Dier V, 2014, BIOMED OPT EXPRESS, V5, P630, DOI 10.1364/BOE.5.000630
   Elsner AE, 1997, PRACTICAL ATLAS RETI
   Evans DW, 1997, BRIT J OPHTHALMOL, V81, P279, DOI 10.1136/bjo.81.4.279
   FALLON TJ, 1985, T OPHTHAL SOC UK, V104, P857
   FALLON TJ, 1987, OPHTHALMOLOGY, V94, P1410
   FEKE GT, 1987, IEEE T BIO-MED ENG, V34, P673, DOI 10.1109/TBME.1987.325992
   FEKE GT, 1989, INVEST OPHTH VIS SCI, V30, P58
   FERCHER AF, 1981, OPT COMMUN, V37, P326, DOI 10.1016/0030-4018(81)90428-4
   Figueroa M, 2006, AM J OPHTHALMOL, V141, P863, DOI 10.1016/j.ajo.2005.11.049
   Findl O, 2000, AM J OPHTHALMOL, V130, P589, DOI 10.1016/S0002-9394(00)00636-X
   Findl O, 2000, BRIT J OPHTHALMOL, V84, P493, DOI 10.1136/bjo.84.5.493
   Findl O, 1997, CURR EYE RES, V16, P1024, DOI 10.1076/ceyr.16.10.1024.9024
   Flammer J, 1994, Surv Ophthalmol, V38 Suppl, pS3, DOI 10.1016/0039-6257(94)90041-8
   Flammer J, 1998, PROG RETIN EYE RES, V17, P267, DOI 10.1016/S1350-9462(97)00006-2
   Flammer J, 2002, PROG RETIN EYE RES, V21, P359, DOI 10.1016/S1350-9462(02)00008-3
   FLOWER RW, 1993, INVEST OPHTH VIS SCI, V34, P2720
   Fontaine O, 2011, INVEST OPHTH VIS SCI, V52, P7400, DOI 10.1167/iovs.10-6646
   FRIEDMAN E, 1995, OPHTHALMOLOGY, V102, P640, DOI 10.1016/S0161-6420(95)30974-8
   Fuchsjager-Mayrl G, 2004, INVEST OPHTH VIS SCI, V45, P834, DOI 10.1167/iovs.03-0461
   Fuchsjager-Mayrl G, 2002, INVEST OPHTH VIS SCI, V43, P1520
   Funatsu H, 2006, JPN J OPHTHALMOL, V50, P25, DOI 10.1007/s10384-005-0266-0
   Galassi F, 2003, ARCH OPHTHALMOL-CHIC, V121, P1711, DOI 10.1001/archopht.121.12.1711
   Garcia JPS, 2002, OPHTHALMIC RES, V34, P295, DOI 10.1159/000065600
   Garhofer G, 2012, INVEST OPHTH VIS SCI, V53, P698, DOI 10.1167/iovs.11-8624
   Geyer O, 1999, ACTA OPHTHALMOL SCAN, V77, P522, DOI 10.1034/j.1600-0420.1999.770507.x
   Gilmore ED, 2007, INVEST OPHTH VIS SCI, V48, P1744, DOI 10.1167/iovs.06-1016
   GOEBEL W, 1995, INVEST OPHTH VIS SCI, V36, P864
   Grunwald JE, 1998, INVEST OPHTH VIS SCI, V39, P2329
   GRUNWALD JE, 1995, BRIT J OPHTHALMOL, V79, P735, DOI 10.1136/bjo.79.8.735
   Grunwald JE, 1998, INVEST OPHTH VIS SCI, V39, P385
   Grunwald JE, 2005, INVEST OPHTH VIS SCI, V46, P1033, DOI 10.1167/iovs.04-1050
   GRUNWALD JE, 1989, OPHTHALMOLOGY, V96, P1518
   Grunwald JE, 1999, AM J OPHTHALMOL, V127, P516, DOI 10.1016/S0002-9394(99)00028-8
   GRUNWALD JE, 1984, OPHTHALMOLOGY, V91, P1690
   GRUNWALD JE, 1986, ARCH OPHTHALMOL-CHIC, V104, P991
   GUTHOFF RF, 1991, ARCH OPHTHALMOL-CHIC, V109, P532, DOI 10.1001/archopht.1991.01080040100037
   Hafez AS, 2003, AM J OPHTHALMOL, V136, P1022, DOI 10.1016/S0002-9394(03)00632-9
   Hafez AS, 2003, OPHTHALMOLOGY, V110, P201, DOI 10.1016/S0161-6420(02)01716-5
   HAMARD P, 1994, BRIT J OPHTHALMOL, V78, P449, DOI 10.1136/bjo.78.6.449
   Harris A, 1996, J GLAUCOMA, V5, P258
   Harris A, 1999, PROG RETIN EYE RES, V18, P669
   Harris NR, 2013, JOVE-J VIS EXP, DOI 10.3791/51110
   HICKAM JOHN B., 1965, INVEST OPHTHALMOL, V4, P876
   Nguyen HT, 2016, BMC ENDOCR DISORD, V16, DOI 10.1186/s12902-016-0105-y
   Hommer A, 2008, INVEST OPHTH VIS SCI, V49, P4046, DOI 10.1167/iovs.07-1342
   Hosal BM, 1998, EUR J OPHTHALMOL, V8, P234, DOI 10.1177/112067219800800406
   Hossain P, 1998, INVEST OPHTH VIS SCI, V39, P1879
   Huang D, 2016, DEV OPHTHALMOL, V56, P6, DOI 10.1159/000442770
   Hubbard LD, 1999, OPHTHALMOLOGY, V106, P2269, DOI 10.1016/S0161-6420(99)90525-0
   Hwang JC, 2012, INVEST OPHTH VIS SCI, V53, P3020, DOI 10.1167/iovs.11-8552
   Hwang TS, 2015, RETINA-J RET VIT DIS, V35, P2371, DOI 10.1097/IAE.0000000000000716
   Ikram MK, 2005, OPHTHALMOLOGY, V112, P548, DOI 10.1016/j.ophtha.2004.10.038
   Ino-ue M, 2000, ACTA OPHTHALMOL SCAN, V78, P173, DOI 10.1034/j.1600-0420.2000.078002173.x
   Ishikawa M, 1998, MICROVASC RES, V56, P166, DOI 10.1006/mvre.1998.2100
   Iwase T, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0174427
   Izhaky D, 2009, JPN J OPHTHALMOL, V53, P345, DOI 10.1007/s10384-009-0689-0
   Jeganathan VSE, 2008, AM J OPHTHALMOL, V146, P954, DOI 10.1016/j.ajo.2008.07.006
   Jensen PS, 1998, INVEST OPHTH VIS SCI, V39, P407
   Jiang H, 2016, MULT SCLER J, V22, P1812, DOI 10.1177/1352458516631035
   Jiang H, 2016, OPHTHALMOLOGY, V123, P437, DOI 10.1016/j.ophtha.2015.07.026
   JONAS JB, 1989, INVEST OPHTH VIS SCI, V30, P1599
   Justesen BL, 2010, ACTA OPHTHALMOL, V88, P453, DOI 10.1111/j.1755-3768.2009.01557.x
   Kagemann L, 1998, BRIT J OPHTHALMOL, V82, P131, DOI 10.1136/bjo.82.2.131
   Kashani AH, 2017, PROG RETIN EYE RES, V60, P66, DOI 10.1016/j.preteyeres.2017.07.002
   Kerr J, 1998, AM J OPHTHALMOL, V126, P42, DOI 10.1016/S0002-9394(98)00074-9
   Khoobehi B, 1999, OPHTHALMIC SURG LAS, V30, P140
   Khoobehi B, 1997, OPHTHALMIC SURG LAS, V28, P937
   KHOOBEHI B, 1994, OPHTHALMOLOGY, V101, P1716
   Khuu LA, 2017, ACTA OPHTHALMOL, V95, pE206, DOI 10.1111/aos.13230
   KIMURA H, 1995, CURR EYE RES, V14, P223, DOI 10.3109/02713689509033518
   Kiss B, 2001, MICROVASC RES, V61, P1, DOI 10.1006/mvre.2000.2269
   Klein R, 2004, AM J OPHTHALMOL, V137, P435, DOI 10.1016/j.ajo.2003.10.020
   Klein R, 2012, ARCH OPHTHALMOL-CHIC, V130, P749, DOI 10.1001/archophthalmol.2011.2560
   Kochkorov A, 2010, GRAEF ARCH CLIN EXP, V248, P833, DOI 10.1007/s00417-009-1277-1
   KOHNER EM, 1976, DIABETES, V25, P839
   Konishi N, 2002, OPT REV, V9, P163, DOI 10.1007/s10043-002-0163-4
   Konno S, 1996, INVEST OPHTH VIS SCI, V37, P1140
   Krepler K, 2003, RETINA-J RET VIT DIS, V23, P192, DOI 10.1097/00006982-200304000-00009
   Kur J, 2012, PROG RETIN EYE RES, V31, P377, DOI 10.1016/j.preteyeres.2012.04.004
   Lee JC, 2013, INVEST OPHTH VIS SCI, V54, P6104, DOI 10.1167/iovs.13-12255
   Leitgeb RA, 2014, PROG RETIN EYE RES, V41, P26, DOI 10.1016/j.preteyeres.2014.03.004
   LIEB WE, 1991, ARCH OPHTHALMOL-CHIC, V109, P527, DOI 10.1001/archopht.1991.01080040095036
   Liew G, 2008, CIRC-CARDIOVASC IMAG, V1, P156, DOI 10.1161/CIRCIMAGING.108.784876
   LOEBL M, 1978, OPHTHALMOLOGY, V85, P911
   Lorenzi M, 2008, DIABETOLOGIA, V51, P361, DOI 10.1007/s00125-007-0872-0
   LOTFI K, 1991, INVEST OPHTH VIS SCI, V32, P3028
   Loukovaara S, 2003, INVEST OPHTH VIS SCI, V44, P1486, DOI 10.1167/iovs.02-0293
   Luft N, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0168190
   LUTTY GA, 1992, ARCH OPHTHALMOL-CHIC, V110, P267, DOI 10.1001/archopht.1992.01080140123039
   Maar N, 2009, ACTA OPHTHALMOL, V87, P631, DOI 10.1111/j.1755-3768.2008.01311.x
   MacKinnon JR, 1997, ACTA OPHTHALMOL SCAN, V75, P661
   MacKinnon JR, 2000, ACTA OPHTHALMOL SCAN, V78, P386, DOI 10.1034/j.1600-0420.2000.078004386.x
   Marinier JA, 2000, OPTOMETRY VISION SCI, V77, P231
   Matsunaga DR, 2015, OSLI RETINA, V46, P796, DOI 10.3928/23258160-20150909-03
   MAUMENEE AE, 1983, OPHTHALMOLOGY, V90, P741
   McGeechan K, 2008, AM J CARDIOL, V102, P58, DOI 10.1016/j.amjcard.2008.02.094
   MENDIVIL A, 1995, BRIT J OPHTHALMOL, V79, P413, DOI 10.1136/bjo.79.5.413
   Mendivil A, 1995, Eur J Ophthalmol, V5, P259
   Meng NN, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062723
   Mete A, 2012, OPHTHALMIC RES, V47, P141, DOI 10.1159/000330509
   Mete A, 2010, J CLIN ULTRASOUND, V38, P66, DOI 10.1002/jcu.20650
   Metelitsina TI, 2008, INVEST OPHTH VIS SCI, V49, P358, DOI 10.1167/iovs.07-0526
   Metelitsina TI, 2010, BRIT J OPHTHALMOL, V94, P1629, DOI 10.1136/bjo.2009.176859
   Metelitsina TI, 2006, BRIT J OPHTHALMOL, V90, P342, DOI 10.1136/bjo.2005.082974
   Michelson G, 1998, GRAEF ARCH CLIN EXP, V236, P80, DOI 10.1007/s004170050046
   Michelson G, 1996, J GLAUCOMA, V5, P91
   Michelson G, 1995, BRIT J OPHTHALMOL, V79, P1126, DOI 10.1136/bjo.79.12.1126
   Michelson G, 1996, J GLAUCOMA, V5, P99
   Micieli JA, 2012, ACTA OPHTHALMOL, V90, pE13, DOI 10.1111/j.1755-3768.2011.02209.x
   Moore NA, 2017, BRIT J OPHTHALMOL, V101, P305, DOI 10.1136/bjophthalmol-2016-308460
   Moreau-Gaudry VV, 2010, EYE, V24, P706, DOI 10.1038/eye.2009.130
   Nagaoka T, 2005, INVEST OPHTH VIS SCI, V46, P720, DOI 10.1167/iovs.04-0906
   Nagaoka T, 2004, BRIT J OPHTHALMOL, V88, P1060, DOI 10.1136/bjo.2003.035345
   Nagaoka T, 2010, INVEST OPHTH VIS SCI, V51, P6729, DOI 10.1167/iovs.10-5364
   Newman EA, 2013, J CEREBR BLOOD F MET, V33, P1685, DOI 10.1038/jcbfm.2013.145
   Nicolela MT, 1996, AM J OPHTHALMOL, V122, P775, DOI 10.1016/S0002-9394(14)70373-3
   NISHIWAKI H, 1995, INVEST OPHTH VIS SCI, V36, P123
   Nitta F, 2014, CLIN OPHTHALMOL, V8, P1119, DOI 10.2147/OPTH.S62022
   Noonan JE, 2015, CLIN EXP OPHTHALMOL, V43, P673, DOI 10.1111/ceo.12530
   Novais EA, 2016, DEV OPHTHALMOL, V56, P132, DOI 10.1159/000442805
   NOVOTNY HR, 1961, CIRCULATION, V24, P82, DOI 10.1161/01.CIR.24.1.82
   Okamoto M, 2016, RETINA-J RET VIT DIS, V36, P805, DOI 10.1097/IAE.0000000000000800
   ORMEROD LD, 1995, EYE, V9, P605, DOI 10.1038/eye.1995.148
   Palkovits S, 2013, GRAEF ARCH CLIN EXP, V251, P1475, DOI 10.1007/s00417-012-2193-3
   Patel A, 2008, NEW ENGL J MED, V358, P2560, DOI 10.1056/NEJMoa0802987
   PATEL V, 1992, BMJ-BRIT MED J, V305, P678, DOI 10.1136/bmj.305.6855.678
   Patton N, 2006, PROG RETIN EYE RES, V25, P99, DOI 10.1016/j.preteyeres.2005.07.001
   Pedersen L, 2014, GRAEF ARCH CLIN EXP, V252, P1561, DOI 10.1007/s00417-014-2614-6
   Pemp B, 2009, BRIT J OPHTHALMOL, V93, P486, DOI 10.1136/bjo.2008.148676
   Pemp B, 2008, CAN J OPHTHALMOL, V43, P295, DOI 10.3129/i08-049
   Pemp B, 2013, ACTA OPHTHALMOL, V91, pE348, DOI 10.1111/aos.12069
   Pemp B, 2010, DIABETES CARE, V33, P2038, DOI 10.2337/dc10-0502
   Pichi F, 2017, PROG RETIN EYE RES, V59, P178, DOI 10.1016/j.preteyeres.2017.04.005
   Piltz-Seymour IR, 2001, AM J OPHTHALMOL, V132, P63, DOI 10.1016/S0002-9394(01)00871-6
   Pittman RN, 1987, OXYGEN DELIVERY TRAN
   Plange N, 2003, BRIT J OPHTHALMOL, V87, P731, DOI 10.1136/bjo.87.6.731
   Polska E, 2004, BRIT J OPHTHALMOL, V88, P533, DOI 10.1136/bjo.2003.028480
   Polska E, 2002, CURR EYE RES, V24, P318, DOI 10.1076/ceyr.24.4.318.8413
   Polska E, 2001, AM J PHYSIOL-HEART C, V280, pH1442, DOI 10.1152/ajpheart.2001.280.4.H1442
   Portmann N, 2011, INVEST OPHTH VIS SCI, V52, P7068, DOI 10.1167/iovs.11-7758
   Pournaras CJ, 2006, INVEST OPHTH VIS SCI, V47, P1581, DOI 10.1167/iovs.05-0434
   Pournaras CJ, 2004, EUR J OPHTHALMOL, V14, P226, DOI 10.1177/112067210401400307
   Pournaras CJ, 2008, PROG RETIN EYE RES, V27, P284, DOI 10.1016/j.preteyeres.2008.02.002
   Pournaras CJ, 2013, OPHTHALMOLOGICA, V229, P61, DOI 10.1159/000338186
   Prada D, 2016, SURV OPHTHALMOL, V61, P164, DOI 10.1016/j.survophthal.2015.10.004
   PREUSSNER PR, 1983, GRAEF ARCH CLIN EXP, V221, P110, DOI 10.1007/BF02133848
   Resch H, 2011, ACTA OPHTHALMOL, V89, pE544, DOI 10.1111/j.1755-3768.2011.02175.x
   Rina M, 2015, GRAEF ARCH CLIN EXP, V253, P2285, DOI 10.1007/s00417-015-3123-y
   RIVA C, 1972, INVEST OPHTH VISUAL, V11, P936
   RIVA CE, 1985, INVEST OPHTH VIS SCI, V26, P1124
   RIVA CE, 1992, EXP EYE RES, V55, P499, DOI 10.1016/0014-4835(92)90123-A
   RIVA CE, 1979, APPL OPTICS, V18, P2301, DOI 10.1364/AO.18.002301
   Riva CE, 2001, INVEST OPHTH VIS SCI, V42, P756
   RIVA CE, 1980, J OPT SOC AM, V70, P1234, DOI 10.1364/JOSA.70.001234
   RIVA CE, 1994, INVEST OPHTH VIS SCI, V35, P4273
   Riva CE, 2010, ACTA OPHTHALMOL, V88, P622, DOI 10.1111/j.1755-3768.2009.01621.x
   ROBINSON F, 1985, OPHTHALMOLOGY, V92, P1130
   Rogers SL, 2008, DIABETES CARE, V31, P761, DOI 10.2337/dc07-1622
   Roisman L, 2016, OPHTHALMOLOGY, V123, P1309, DOI 10.1016/j.ophtha.2016.01.044
   Rosenfeld PJ, 2016, DEV OPHTHALMOL, V56, P18, DOI 10.1159/000442773
   Roy MS, 2011, ARCH OPHTHALMOL-CHIC, V129, P8, DOI 10.1001/archophthalmol.2010.340
   Saidha S, 2013, JAMA NEUROL, V70, P34, DOI 10.1001/jamaneurol.2013.573
   Sakalar YB, 2013, J CLIN ULTRASOUND, V41, P32, DOI 10.1002/jcu.21989
   Sakata K, 2006, OPHTHALMOLOGY, V113, P1385, DOI 10.1016/j.ophtha.2006.04.023
   Savage HI, 2004, INVEST OPHTH VIS SCI, V45, P4504, DOI 10.1167/iovs.04-0077
   Schmetterer L, 1996, BRIT J OPHTHALMOL, V80, P217, DOI 10.1136/bjo.80.3.217
   Schmetterer L, 2000, EYE, V14, P39, DOI 10.1038/eye.2000.9
   Schmetterer L, 1998, GRAEF ARCH CLIN EXP, V236, P160, DOI 10.1007/s004170050058
   Schmetterer L, 2007, SURV OPHTHALMOL, V52, pS134, DOI 10.1016/j.survophthal.2007.08.008
   SCHMETTERER LF, 1995, OPT ENG, V34, P711, DOI 10.1117/12.193292
   Schmidl D, 2012, INVEST OPHTH VIS SCI, V53, P4337, DOI 10.1167/iovs.11-9055
   Schmidl D, 2011, EXP EYE RES, V93, P141, DOI 10.1016/j.exer.2010.09.002
   Schocket Lisa S., 2004, International Ophthalmology, V25, P89, DOI 10.1023/B:INTE.0000031744.93778.60
   Sehi M, 2014, OPHTHALMOLOGY, V121, P750, DOI 10.1016/j.ophtha.2013.10.022
   Shao Q, 2016, EUR J OPHTHALMOL, V26, P342, DOI 10.5301/ejo.5000694
   Shepherd A. P., 1990, LASER DOPPLER BLOOD, P17
   Shiga Y, 2016, CURR EYE RES, V41, P1447, DOI 10.3109/02713683.2015.1127974
   Shiga Y, 2014, INVEST OPHTH VIS SCI, V55, P3899, DOI 10.1167/iovs.14-14116
   Shiga Y, 2013, INVEST OPHTH VIS SCI, V54, P7699, DOI 10.1167/iovs.13-12930
   Silver D M, 1994, Surv Ophthalmol, V38 Suppl, pS72, DOI 10.1016/0039-6257(94)90049-3
   SINCLAIR SH, 1991, OPHTHALMOLOGY, V98, P1580
   SINCLAIR SH, 1982, OPHTHALMOLOGY, V89, P748, DOI 10.1016/s0161-6420(82)34720-x
   Sousa DC, 2018, ACTA OPHTHALMOL, V96, pE315, DOI 10.1111/aos.13622
   Spaide RF, 2018, PROG RETIN EYE RES, V64, P1, DOI 10.1016/j.preteyeres.2017.11.003
   Spaide RF, 2015, RETINA-J RET VIT DIS, V35, P2163, DOI 10.1097/IAE.0000000000000765
   Spaide RF, 2015, JAMA OPHTHALMOL, V133, P45, DOI 10.1001/jamaophthalmol.2014.3616
   SPONSEL WE, 1990, AM J OPHTHALMOL, V109, P49, DOI 10.1016/S0002-9394(14)75578-3
   Srinivas S, 2017, RETINA-J RET VIT DIS, V37, P2001, DOI 10.1097/IAE.0000000000001479
   Stalmans I, 2011, ACTA OPHTHALMOL, V89, pe609, DOI 10.1111/j.1755-3768.2011.02178.x
   Stanga PE, 2016, DEV OPHTHALMOL, V56, P13, DOI 10.1159/000442771
   STERN MD, 1977, AM J PHYSIOL, V232, pH441, DOI 10.1152/ajpheart.1977.232.4.H441
   Sugiyama T, 2010, ACTA OPHTHALMOL, V88, P723, DOI 10.1111/j.1755-3768.2009.01586.x
   Sullu Y, 2005, CLIN EXP OPHTHALMOL, V33, P246, DOI 10.1111/j.1442-9071.2005.01013.x
   Sun C, 2008, INVEST OPHTH VIS SCI, V49, P1784, DOI 10.1167/iovs.07-1450
   Takahashi A, 2008, BRIT J OPHTHALMOL, V92, P1369, DOI 10.1136/bjo.2007.136028
   Takasago Y, 2019, RETINA-J RET VIT DIS, V39, P296, DOI 10.1097/IAE.0000000000001980
   TAMAKI Y, 1993, JPN J OPHTHALMOL, V37, P385
   Tamaki Y, 1997, JPN J OPHTHALMOL, V41, P49, DOI 10.1016/S0021-5155(96)00008-1
   TAMAKI Y, 1994, INVEST OPHTH VIS SCI, V35, P3825
   TAMAKI Y, 1995, EXP EYE RES, V60, P373, DOI 10.1016/S0014-4835(05)80094-6
   Tamaki Y, 2001, OPHTHALMOLOGY, V108, P627, DOI 10.1016/S0161-6420(00)00541-8
   TANAKA T, 1991, OPHTHALMOLOGY, V98, P1824
   Tayyari F, 2015, INVEST OPHTH VIS SCI, V56, P6796, DOI 10.1167/iovs.15-17481
   Tobe LA, 2015, BRIT J OPHTHALMOL, V99, P609, DOI 10.1136/bjophthalmol-2014-305780
   Toklu Y, 2011, ACTA OPHTHALMOL, V89, pE41, DOI 10.1111/j.1755-3768.2010.02075.x
   Told R, 2016, INVEST OPHTH VIS SCI, V57, P1432, DOI 10.1167/iovs.16-19140
   Tsai ASH, 2011, DIABETES RES CLIN PR, V94, P291, DOI 10.1016/j.diabres.2011.07.032
   Tsuda S, 2014, CURR EYE RES, V39, P1207, DOI 10.3109/02713683.2014.905608
   Uretmen O, 2003, OPHTHALMOLOGICA, V217, P137, DOI 10.1159/000068559
   Venkataraman ST, 2010, MICROCIRCULATION, V17, P568, DOI 10.1111/j.1549-8719.2010.00045.x
   Wajer SD, 2000, MICROVASC RES, V60, P281, DOI 10.1006/mvre.2000.2270
   Wang Y, 2009, BRIT J OPHTHALMOL, V93, P634, DOI 10.1136/bjo.2008.150276
   Wang YM, 2007, J BIOMED OPT, V12, DOI 10.1117/1.2772871
   Wang YM, 2011, INVEST OPHTH VIS SCI, V52, P840, DOI 10.1167/iovs.10-5985
   Wang YM, 2009, OPT EXPRESS, V17, P4061, DOI 10.1364/OE.17.004061
   Weigert G, 2005, OPHTHALMOLOGY, V112, P1337, DOI 10.1016/j.ophtha.2005.03.016
   Wise G.N., 1975, RETINAL CIRCULATION
   WOLF S, 1993, OPHTHALMOLOGY, V100, P1561
   WOLF S, 1991, OPHTHALMOLOGY, V98, P996
   WOLF S, 1989, GRAEF ARCH CLIN EXP, V227, P145, DOI 10.1007/BF02169788
   Wong T, 2007, LANCET, V369, P425, DOI 10.1016/S0140-6736(07)60198-6
   Wong TY, 2004, NEW ENGL J MED, V351, P2310, DOI 10.1056/NEJMra032865
   Wong TY, 2004, ANN INTERN MED, V140, P248, DOI 10.7326/0003-4819-140-4-200402170-00006
   Wong TY, 2002, JAMA-J AM MED ASSOC, V287, P1153, DOI 10.1001/jama.287.9.1153
   Wong TY, 2002, JAMA-J AM MED ASSOC, V287, P2528, DOI 10.1001/jama.287.19.2528
   Wong TY, 2001, LANCET, V358, P1134, DOI 10.1016/S0140-6736(01)06253-5
   Xu LA, 2006, AM J OPHTHALMOL, V142, P688, DOI 10.1016/j.ajo.2006.05.028
   Yang K, 2012, GRAEF ARCH CLIN EXP, V250, P741, DOI 10.1007/s00417-011-1824-4
   Yang Y, 1997, GRAEF ARCH CLIN EXP, V235, P27, DOI 10.1007/BF01007834
   Yang YS, 1997, OPHTHALMOLOGY, V104, P1670, DOI 10.1016/S0161-6420(97)30080-3
   Yaoeda K, 2003, ACTA OPHTHALMOL SCAN, V81, P253, DOI 10.1034/j.1600-0420.2003.00073.x
   Yoshida A, 1996, OPHTHALMIC RES, V28, P343, DOI 10.1159/000267926
   YOSHITOMI T, 1990, JPN J OPHTHALMOL, V34, P57
NR 272
TC 36
Z9 37
U1 3
U2 28
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0039-6257
EI 1879-3304
J9 SURV OPHTHALMOL
JI Surv. Ophthalmol.
PD SEP-OCT
PY 2018
VL 63
IS 5
BP 646
EP 664
DI 10.1016/j.survophthal.2018.03.003
PG 19
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA GR1TS
UT WOS:000442335200005
PM 29577954
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Madeira, MH
   Rashid, K
   Ambrosio, AF
   Santiago, AR
   Langmann, T
AF Madeira, M. H.
   Rashid, K.
   Ambrosio, A. F.
   Santiago, A. R.
   Langmann, T.
TI Blockade of microglial adenosine A2A receptor impacts inflammatory
   mechanisms, reduces ARPE-19 cell dysfunction and prevents photoreceptor
   loss in vitro
SO SCIENTIFIC REPORTS
LA English
DT Article
ID RETINAL-PIGMENT EPITHELIUM; COMPLEMENT ACTIVATION; MACULAR DEGENERATION;
   NLRP3 INFLAMMASOME; LYSOSOMAL DESTABILIZATION; GANGLION-CELLS;
   AUTOPHAGY; DEATH; NEUROINFLAMMATION; SUSCEPTIBILITY
AB Age-related macular degeneration (AMD) is characterized by pathological changes in the retinal pigment epithelium (RPE) and loss of photoreceptors. Growing evidence has demonstrated that reactive microglial cells trigger RPE dysfunction and loss of photoreceptors, and inflammasome pathways and complement activation contribute to AMD pathogenesis. We and others have previously shown that adenosine A(2A) receptor (A(2A)R) blockade prevents microglia-mediated neuroinflammatory processes and mediates protection to the retina. However, it is still unknown whether blocking A(2A)R in microglia protects against the pathological features of AMD. Herein, we show that an A(2A)R antagonist, SCH58261, prevents the upregulation of the expression of pro-inflammatory mediators and the alterations in the complement system triggered by an inflammatory challenge in human microglial cells. Furthermore, blockade of A(2A)R in microglia decreases the inflammatory response, as well as complement and inflammasome activation, in ARPE-19 cells exposed to conditioned medium of activated microglia. Finally, we also show that blocking A(2A)R in human microglia increases the clearance of apoptotic photoreceptors. This study opens the possibility of using selective A(2A)R antagonists in therapy for AMD, by modulating the interplay between microglia, RPE and photoreceptors.
C1 [Madeira, M. H.; Ambrosio, A. F.; Santiago, A. R.] Univ Coimbra, Inst Biomed Imaging & Life Sci IBILI, Fac Med, Coimbra, Portugal.
   [Madeira, M. H.; Ambrosio, A. F.; Santiago, A. R.] Univ Coimbra, CNC IBILI Consortium, Coimbra, Portugal.
   [Madeira, M. H.; Rashid, K.; Langmann, T.] Univ Cologne, Dept Ophthalmol, Lab Expt Immunol Eye, Cologne, Germany.
   [Ambrosio, A. F.; Santiago, A. R.] Assoc Innovat & Biomed Res Light & Image AIBILI, Coimbra, Portugal.
C3 Universidade de Coimbra; Universidade de Coimbra; University of Cologne;
   Universidade de Coimbra
RP Langmann, T (通讯作者)，Univ Cologne, Dept Ophthalmol, Lab Expt Immunol Eye, Cologne, Germany.
EM thomas.langmann@uk-koeln.de
RI Madeira, Maria H./AAD-4755-2019; Ambrósio, António F/I-3722-2012;
   Santiago, Ana Raquel/I-6566-2013
OI Madeira, Maria H./0000-0001-6282-3553; Ambrósio, António
   F/0000-0002-0477-1641; Santiago, Ana Raquel/0000-0002-7541-7041
FU Federation of European Biochemical Societies (FEBS); DFG [FOR2240];
   Foundation for Science and Technology [PEst UID/NEU/04539/2013];
   COMPETE-FEDER [POCI-01-0145-FEDER-007440]; Centro 2020 Regional
   Operational Program [CENTRO-01-0145-FEDER-000008]
FX M.H. Madeira was a recipient of a short-term fellowship from the
   Federation of European Biochemical Societies (FEBS). The work was
   supported by DFG research unit FOR2240 (Lymph) Angiogenesis and cellular
   immunity in inflammatory diseases of the eye, Foundation for Science and
   Technology (PEst UID/NEU/04539/2013), COMPETE-FEDER
   (POCI-01-0145-FEDER-007440), and Centro 2020 Regional Operational
   Program (CENTRO-01-0145-FEDER-000008: BrainHealth 2020).
CR Ablonczy Z, 2011, INVEST OPHTH VIS SCI, V52, P8614, DOI 10.1167/iovs.11-8021
   Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   Aslanidis A, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0296-6
   Black JRM, 2016, GENET MED, V18, P283, DOI 10.1038/gim.2015.70
   Boia R, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.451
   Brandstetter C, 2016, J PHOTOCH PHOTOBIO B, V161, P177, DOI 10.1016/j.jphotobiol.2016.05.018
   Brandstetter C, 2015, J MOL MED, V93, P905, DOI 10.1007/s00109-015-1275-1
   Celkova L, 2015, J CLIN MED, V4, P172, DOI 10.3390/jcm4010172
   Chen M, 2015, J LEUKOCYTE BIOL, V98, P713, DOI 10.1189/jlb.3RI0615-239R
   Cipriani V, 2012, IMMUNOBIOLOGY, V217, P158, DOI 10.1016/j.imbio.2011.09.002
   Cunha RA, 2016, J NEUROCHEM, V139, P1019, DOI 10.1111/jnc.13724
   Dunaief JL, 2002, ARCH OPHTHALMOL-CHIC, V120, P1435, DOI 10.1001/archopht.120.11.1435
   Dunn KC, 1998, INVEST OPHTH VIS SCI, V39, P2744
   Franchi L, 2009, NAT IMMUNOL, V10, P241, DOI 10.1038/ni.1703
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Fronk AH, 2016, J TISSUE ENG, V7, DOI 10.1177/2041731416650838
   Gao JY, 2015, MEDIAT INFLAMM, V2015, DOI 10.1155/2015/690243
   Harrigan TJ, 2008, J NEUROCHEM, V106, P2449, DOI 10.1111/j.1471-4159.2008.05553.x
   Iannaccone A, 2017, EXP EYE RES, V155, P64, DOI 10.1016/j.exer.2016.12.006
   Iannaccone A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0145323
   Kaarniranta K, 2017, CELL BIOL TOXICOL, V33, P113, DOI 10.1007/s10565-016-9371-8
   Karlstetter M, 2017, EMBO MOL MED, V9, P154, DOI 10.15252/emmm.201606627
   Karlstetter M, 2015, PROG RETIN EYE RES, V45, P30, DOI 10.1016/j.preteyeres.2014.11.004
   Karlstetter M, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-3
   Katschke KJ, 2012, J BIOL CHEM, V287, P12886, DOI 10.1074/jbc.M112.345082
   Kauppinen A, 2016, CELL MOL LIFE SCI, V73, P1765, DOI 10.1007/s00018-016-2147-8
   Kim S. Y., 2015, MACROPHAGE HOUST, V2, DOI [10.14800/macrophage.698, DOI 10.14800/MACROPHAGE.698]
   Kohno H, 2013, J BIOL CHEM, V288, P15326, DOI 10.1074/jbc.M112.448712
   Lechner J, 2016, IMMUN AGEING, V13, DOI 10.1186/s12979-016-0060-5
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Luckoff A, 2017, NAT PROTOC, V12, P1136, DOI 10.1038/nprot.2017.032
   Ma WX, 2013, NEUROBIOL AGING, V34, P943, DOI 10.1016/j.neurobiolaging.2012.06.010
   Ma WX, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007945
   Madeira MH, 2016, SCI REP-UK, V6, DOI 10.1038/srep27532
   Madeira MH, 2016, TRANSL RES, V169, P112, DOI 10.1016/j.trsl.2015.11.005
   Madeira MH, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0333-5
   Madeira MH, 2015, MEDIAT INFLAMM, V2015, DOI 10.1155/2015/673090
   Nakahira K, 2011, NAT IMMUNOL, V12, P222, DOI 10.1038/ni.1980
   Natoli R, 2017, INVEST OPHTH VIS SCI, V58, P2977, DOI 10.1167/iovs.17-21672
   Natoli R, 2017, MOL NEURODEGENER, V12, DOI 10.1186/s13024-017-0175-y
   Nebel C, 2017, BIOCHEM BIOPH RES CO, V484, P681, DOI 10.1016/j.bbrc.2017.01.176
   Nozaki M, 2006, P NATL ACAD SCI USA, V103, P2328, DOI 10.1073/pnas.0408835103
   Orsini F, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00380
   Ouyang XS, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3909
   Piippo N, 2014, BBA-MOL CELL RES, V1843, P3038, DOI 10.1016/j.bbamcr.2014.09.015
   Rutar M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093343
   Rutar M, 2011, INVEST OPHTH VIS SCI, V52, P5347, DOI 10.1167/iovs.10-7119
   Santiago AR, 2014, MEDIAT INFLAMM, V2014, DOI 10.1155/2014/465694
   Saura J, 2005, J NEUROCHEM, V95, P919, DOI 10.1111/j.1471-4159.2005.03395.x
   Schick T, 2017, EYE, V31, P810, DOI 10.1038/eye.2016.328
   Sierra A, 2013, FRONT CELL NEUROSCI, V7, DOI 10.3389/fncel.2013.00006
   Smith ME, 1998, NEUROCHEM RES, V23, P427, DOI 10.1023/A:1022478005243
   Sweet MJ, 1996, J LEUKOCYTE BIOL, V60, P8, DOI 10.1002/jlb.60.1.8
   Tseng WA, 2013, INVEST OPHTH VIS SCI, V54, P110, DOI 10.1167/iovs.12-10655
   Wagner E, 2010, NAT REV DRUG DISCOV, V9, P43, DOI 10.1038/nrd3011
   Wang YJ, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17010073
   Wolf SA, 2017, ANNU REV PHYSIOL, V79, P619, DOI 10.1146/annurev-physiol-022516-034406
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wu L, 2013, INVEST OPHTH VIS SCI, V54, P170, DOI 10.1167/iovs.12-10453
   Xu HP, 2016, EUR J PHARMACOL, V787, P94, DOI 10.1016/j.ejphar.2016.03.001
   Yang LP, 2007, MOL VIS, V13, P2048
   Yao JY, 2015, AUTOPHAGY, V11, P939, DOI 10.1080/15548627.2015.1041699
   Yu LQ, 2008, ANN NEUROL, V63, P338, DOI 10.1002/ana.21313
   Zhang C, 2005, MOL VIS, V11, P887
   Zhong Z, 2016, CLIN EXP RHEUMATOL, V34, pS12
   Zhou JL, 2006, P NATL ACAD SCI USA, V103, P16182, DOI 10.1073/pnas.0604255103
NR 67
TC 31
Z9 33
U1 0
U2 2
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD FEB 2
PY 2018
VL 8
AR 2272
DI 10.1038/s41598-018-20733-2
PG 15
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA HN4ZZ
UT WOS:000460193500001
PM 29396515
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Zhang, GS
   Li, Y
   Teng, XL
   Wu, Q
   Gong, H
   Ren, FM
   Guo, YX
   Liu, L
   Zhang, H
AF Zhang, Guisen
   Li, Yan
   Teng, Xuelong
   Wu, Qiang
   Gong, Hui
   Ren, Fengmei
   Guo, Yuxia
   Liu, Lei
   Zhang, Han
TI Prevalence and causes of low vision and blindness in Baotou: A
   cross-sectional study
SO MEDICINE
LA English
DT Article
DE blindness; low vision; prevalence
ID VISUAL IMPAIRMENT; RURAL-POPULATION; PROVINCE; ADULTS; CHINA
AB The aim of this study was to investigate the prevalence and causes of low vision and blindness in Baotou, Inner Mongolia.A cross-sectional study was carried out. Multistage sampling was used to select samples. The visual acuity was estimated using LogMAR and corrected by pinhole as best-corrected visual acuity.There were 7000 samples selected and 5770 subjects included in this investigation. The overall bilateral prevalence rates of low vision and blindness were 3.66% (95% CI: 3.17-4.14) and 0.99% (95% CI: 0.73-1.24), respectively. The prevalence of bilateral low vision, blindness, and visual impairment increased with age and decreased with education level. The main leading cause of low vision and blindness was cataract. Diabetic retinopathy and age-related macular degeneration were found to be the second leading causes of blindness in Baotou.The low vision and blindness were more prevalent in elderly people and subjects with low education level in Baotou. Cataract was the main cause for visual impairment and more attention should be paid to fundus diseases. In order to prevent blindness, much more eye care programs should be established.
C1 [Zhang, Guisen; Gong, Hui; Ren, Fengmei] Hohhot Chao Ju Eye Hosp, Dept Ophthalmol, Hohhot, Peoples R China.
   [Li, Yan] China Med Univ, Sch Fundamental Sci, Dept English, Shenyang, Peoples R China.
   [Teng, Xuelong] Hebei Xinji Fuming Eye Hosp, Dept Ophthalmol, Shijiazhuang, Peoples R China.
   [Wu, Qiang; Guo, Yuxia] Baotou Chao Ju Eye Hosp, Dept Ophthalmol, Baotou, Peoples R China.
   [Liu, Lei; Zhang, Han] China Med Univ, Affiliated Hosp 1, Dept Ophthalmol, 155 Nanjing North St, Shenyang 110001, Liaoning, Peoples R China.
C3 China Medical University; China Medical University
RP Liu, L; Zhang, H (通讯作者)，China Med Univ, Affiliated Hosp 1, Dept Ophthalmol, 155 Nanjing North St, Shenyang 110001, Liaoning, Peoples R China.
EM liuleijiao@163.com; Zhanghan0614@139.com
OI Zhang, Han/0000-0002-9338-0051
CR Chen TT, 2015, INVEST OPHTH VIS SCI, V56, P1283, DOI 10.1167/iovs.14-16263
   Cheng F, 2016, ACTA OPHTHALMOL, V94, P407, DOI 10.1111/aos.12808
   Cheng JW, 2013, OPHTHALMIC RES, V49, P1, DOI 10.1159/000327144
   Hashemi H, 2015, IRAN J PUBLIC HEALTH, V44, P855
   Li J, 2012, INVEST OPHTH VIS SCI, V53, P4498, DOI 10.1167/iovs.12-9429
   Li XF, 2012, OPHTHAL EPIDEMIOL, V19, P272, DOI 10.3109/09286586.2012.700081
   Liu Ju-ping, 2011, Zhonghua Yan Ke Za Zhi, V47, P791
   Lu Hong, 2012, Zhonghua Yan Ke Za Zhi, V48, P205
   Mai Dina Na Bijiang, 2012, Zhonghua Yi Xue Za Zhi, V92, P743
   Marmamula S, 2011, BMC OPHTHALMOL, V11, DOI 10.1186/1471-2415-11-26
   Pascolini D, 2012, BRIT J OPHTHALMOL, V96, P614, DOI 10.1136/bjophthalmol-2011-300539
   Pizzarello L, 2004, ARCH OPHTHALMOL-CHIC, V122, P615, DOI 10.1001/archopht.122.4.615
   Swanson MW, 2004, OPHTHAL EPIDEMIOL, V11, P227, DOI 10.1080/09286580490514540
   Tang YT, 2015, OPHTHALMOLOGY, V122, P1480, DOI 10.1016/j.ophtha.2015.03.022
   Tong Xiao-wei, 2011, Zhonghua Yan Ke Za Zhi, V47, P785
   Wang GQ, 2013, INT J OPHTHALMOL-CHI, V6, P237, DOI 10.3980/j.issn.2222-3959.2013.02.24
   Wang Li-Hua, 2012, Zhonghua Yan Ke Za Zhi, V48, P226
   Wei M, 2010, INT J OPHTHALMOL-CHI, V3, P83, DOI 10.3980/j.issn.2222-3959.2010.01.20
   Wong TY, 2014, BRIT J OPHTHALMOL, V98, P599, DOI 10.1136/bjophthalmol-2013-304047
   Xu L, 2006, OPHTHALMOLOGY, V113, P1134, DOI 10.1016/j.ophtha.2006.01.035
   Yang WY, 2016, SCI REP-UK, V6, DOI 10.1038/srep22590
   Yao Y, 2013, PAK J MED SCI, V29, P1203
   Zhang YG, 2012, CLIN EXP OPHTHALMOL, V40, P484, DOI 10.1111/j.1442-9071.2011.02682.x
   Zhou Jing, 2012, Zhonghua Yan Ke Za Zhi, V48, P908
   Zhu MM, 2014, BMC OPHTHALMOL, V14, DOI 10.1186/1471-2415-14-3
NR 25
TC 9
Z9 10
U1 0
U2 10
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0025-7974
EI 1536-5964
J9 MEDICINE
JI Medicine (Baltimore)
PD SEP
PY 2016
VL 95
IS 37
AR e4905
DI 10.1097/MD.0000000000004905
PG 6
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA DX5ZO
UT WOS:000384461600069
PM 27631267
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Song, JF
   Li, DJ
   He, MJ
   Chen, JQ
   Liu, CQ
AF Song, Jiangfeng
   Li, Dajing
   He, Meijuan
   Chen, Jieqiong
   Liu, Chunquan
TI Comparsion of Carotenoid Composition in Immature and Mature Grains of
   Corn (Zea Mays L.) Varieties
SO INTERNATIONAL JOURNAL OF FOOD PROPERTIES
LA English
DT Article
DE Carotenoids; HPLC-DAD-MS; MS; Corn; Discrepancy
ID ISOMERS; PIGMENTS; KERNELS
AB The objective of this study was to compare the carotenoid composition of sweet and waxy corn grains at the stage of milk and dough by reversed-phase high-performance liquid chromatography, using a C(30) column, connected to diode array detector and mass spectrometry. In the reverse phase 21 carotenoids were found, the major identified carotenoids were all-trans-lutein, all-trans-zeaxanthin, and all-trans-- cryptoxanthin. Waxy corn grains showed significantly lower contents for total carotenoids ranging from 1.52 to 3.68 g/g dry weight in three varieties, whereas sweet corn grains had higher carotenoid contents from 8.42 to 39.71 g/g dry weight. The composition of the carotenoid pattern was somewhat different compared to literature data; this could be the results of genetic or environmental differences. Taking into account the usage of all-trans lutein and all-trans-zeaxanthin for the prevention of several pathologies, especially the age related macular degeneration, the immature sweet corn (e.g., Jingtian 5 and Jingtian 3) might be interesting sources of a lutein and/or zeaxanthin extract that could add value to an underutilized biomass.
C1 [Song, Jiangfeng; Li, Dajing; He, Meijuan; Chen, Jieqiong; Liu, Chunquan] Jiangsu Acad Agr Sci, Inst Farm Prod Proc, Nanjing 210014, Jiangsu, Peoples R China.
   [Liu, Chunquan] Natl Res & Dev Ctr Vegetable Proc, Nanjing, Jiangsu, Peoples R China.
   [Chen, Jieqiong] Nanjing Agr Univ, Coll Food Sci & Technol, Nanjing, Jiangsu, Peoples R China.
C3 Jiangsu Academy of Agricultural Sciences; Nanjing Agricultural
   University
RP Song, JF (通讯作者)，Jiangsu Acad Agr Sci, Inst Farm Prod Proc, 50 Zhongling St, Nanjing 210014, Jiangsu, Peoples R China.
EM lidajing@163.com
OI Liu, Chunquan/0000-0002-8502-9317
FU Jiangsu Agricultural Science and Technology Innovation Fund [CX14(2055)]
FX This work was supported by the Jiangsu Agricultural Science and
   Technology Innovation Fund [Project No. CX14(2055)].
CR Abushita AA, 2000, J AGR FOOD CHEM, V48, P2075, DOI 10.1021/jf990715p
   Burt AJ, 2010, J AGR FOOD CHEM, V58, P8286, DOI 10.1021/jf100161r
   Emenhiser C, 1996, J AGR FOOD CHEM, V44, P3887, DOI 10.1021/jf960104m
   Hackett MM, 2004, J FOOD SCI, V69, pC536, DOI 10.1111/j.1365-2621.2004.tb13647.x
   Hu QP, 2011, J AGR FOOD CHEM, V59, P2026, DOI 10.1021/jf104149q
   Humphries JM, 2003, J AGR FOOD CHEM, V51, P1322, DOI 10.1021/jf026073e
   Kean EG, 2007, J AGR FOOD CHEM, V55, P2619, DOI 10.1021/jf062939v
   Khoo HE, 2011, MOLECULES, V16, P1710, DOI 10.3390/molecules16021710
   Kurilich AC, 1999, J AGR FOOD CHEM, V47, P1948, DOI 10.1021/jf981029d
   Li DJ, 2015, INT J FOOD PROP, V18, P178, DOI 10.1080/10942912.2013.828748
   Lima VLAG, 2005, FOOD CHEM, V90, P565, DOI 10.1016/j.foodchem.2004.04.014
   Liu FG, 2013, FOOD BIOPROCESS TECH, V6, P2800, DOI 10.1007/s11947-012-0996-1
   Lozano-Alejo N, 2007, INNOV FOOD SCI EMERG, V8, P385, DOI 10.1016/j.ifset.2007.03.015
   Newilah GN, 2009, FRUITS, V64, P197, DOI 10.1051/fruits/2009015
   Perera CO, 2007, INT J FOOD PROP, V10, P201, DOI 10.1080/10942910601045271
   Scott CE, 2005, J FOOD COMPOS ANAL, V18, P551, DOI 10.1016/j.jfca.2004.04.001
   WEBER EJ, 1987, J AM OIL CHEM SOC, V64, P1129, DOI 10.1007/BF02612988
   Xu JG, 2010, J AGR FOOD CHEM, V58, P5751, DOI 10.1021/jf100364k
   Ying SW, 2013, INT J FOOD PROP, V16, P826, DOI 10.1080/10942912.2011.567431
NR 19
TC 18
Z9 18
U1 2
U2 44
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1094-2912
EI 1532-2386
J9 INT J FOOD PROP
JI Int. J. Food Prop.
PD FEB 1
PY 2016
VL 19
IS 2
BP 351
EP 358
DI 10.1080/10942912.2015.1031245
PG 8
WC Food Science & Technology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Food Science & Technology
GA CW2XF
UT WOS:000364855700008
DA 2022-11-30
ER

PT J
AU Takeyama, M
   Yoneda, M
   Gosho, M
   Iwaki, M
   Zako, M
AF Takeyama, Masayuki
   Yoneda, Masahiko
   Gosho, Masahiko
   Iwaki, Masayoshi
   Zako, Masahiro
TI Decreased VEGF-A and sustained PEDF expression in a human retinal
   pigment epithelium cell line cultured under hypothermia
SO BIOLOGICAL RESEARCH
LA English
DT Article
DE Age-related macular degeneration (AMD); Hypothermia; Pigment
   epithelium-derived factor (PEDF); Retinal pigment epithelium (RPE);
   Vascular endothelial growth factor (VEGF); Vitrectomy
ID ENDOTHELIAL GROWTH-FACTOR; MACULAR DEGENERATION; VITREOMACULAR ADHESION;
   VITRECTOMY; ANGIOGENESIS; PHYSIOLOGY; SECRETION; SURGERY
AB Background: Previous reports have described a decrease in retinal temperature and clinical improvement of wet age-related macular degeneration (AMD) after vitrectomy. We hypothesized that the retinal temperature decrease after vitrectomy plays a part in the suppression of wet AMD development. To test this hypothesis, we evaluated the temperature dependence of the expression of vascular endothelial growth factor-A (VEGF-A) and in vitro angiogenesis in retinal pigment epithelium (RPE).
   Results: We cultured ARPE-19 cells at 37, 35, 33 and 31 degrees C and measured the expression of VEGF-A, VEGF-A splicing variants, and pigment epithelium-derived factor (PEDF). We performed an in vitro tube formation assay. The dehydrogenase activity was also evaluated at each temperature. Expression of VEGF-A significantly decreased with decreased temperature while PEDF expression did not. VEGF165 expression and in vitro angiogenesis also were temperature dependent. The dehydrogenase activity significantly decreased as the culture temperature decreased.
   Conclusions: RPE cultured under hypothermia that decreased cellular metabolism also had decreased VEGF-A and sustained PEDF expression, creating an anti-angiogenic environment. This mechanism may be associated with a beneficial effect after vitrectomy in patients with wet AMD.
C1 [Takeyama, Masayuki; Iwaki, Masayoshi; Zako, Masahiro] Aichi Med Univ, Dept Ophthalmol, Nagakute, Aichi 4801195, Japan.
   [Yoneda, Masahiko] Aichi Prefectural Univ, Sch Nursing & Hlth, Dept Biochem & Mol Biol, Nagoya, Aichi 4638502, Japan.
   [Gosho, Masahiko] Univ Tsukuba, Fac Med, Dept Clin Trial & Clin Epidemiol, Tsukuba, Ibaraki 3058575, Japan.
C3 Aichi Medical University; University of Tsukuba
RP Zako, M (通讯作者)，Aichi Med Univ, Dept Ophthalmol, Nagakute, Aichi 4801195, Japan.
EM zako@aichi-med-u.ac.jp
FU JSPS KAKENHI [25861659]; Strategic Research Foundation Grant-Aided
   Project for Private Universities from Ministry of Education, Culture,
   Sports, Science, and Technology, Japan (MEXT) [S1101027]
FX This study was supported by JSPS KAKENHI Grant Number 25861659, and
   Strategic Research Foundation Grant-Aided Project for Private
   Universities from the Ministry of Education, Culture, Sports, Science,
   and Technology, Japan (MEXT), 2011-2015 (S1101027). The authors thank
   Yoshiko Takahashi for excellent technical help and Takuya Kataoka for
   valuable suggestions on this study.
CR Ablonczy Z, 2009, J BIOL CHEM, V284, P30177, DOI 10.1074/jbc.M109.032391
   Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   Barnstable CJ, 2004, PROG RETIN EYE RES, V23, P561, DOI 10.1016/j.preteyeres.2004.05.002
   Becerra SP, 2004, EXP EYE RES, V78, P223, DOI 10.1016/j.exer.2003.10.013
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Coassin M, 2010, BRIT J OPHTHALMOL, V94, P1678, DOI 10.1136/bjo.2009.168864
   Dawson DW, 1999, SCIENCE, V285, P245, DOI 10.1126/science.285.5425.245
   Frank RN, 1996, AM J OPHTHALMOL, V122, P393, DOI 10.1016/S0002-9394(14)72066-5
   Ikeda T, 2000, ACTA OPHTHALMOL SCAN, V78, P460, DOI 10.1034/j.1600-0420.2000.078004460.x
   Landers MB, 2012, RETINA-J RET VIT DIS, V32, P172, DOI 10.1097/IAE.0b013e31821c3ee0
   Maminishkis A, 2006, INVEST OPHTH VIS SCI, V47, P3612, DOI 10.1167/iovs.05-1622
   Mojana F, 2008, AM J OPHTHALMOL, V146, P218, DOI 10.1016/j.ajo.2008.04.027
   Ohno-Matsui K, 2001, J CELL PHYSIOL, V189, P323, DOI 10.1002/jcp.10026
   Roller AB, 2010, OPHTHALMOLOGY, V117, P1381, DOI 10.1016/j.ophtha.2009.11.007
   Romano MR, 2013, CURR EYE RES, V38, P371, DOI 10.3109/02713683.2012.745160
   Sakamoto T, 2010, RETINA-J RET VIT DIS, V30, P856, DOI 10.1097/IAE.0b013e3181c969cb
   Schulze S, 2008, ACTA OPHTHALMOL, V86, P470, DOI 10.1111/j.1755-3768.2008.01210.x
   Schulze S, 2012, ACTA OPHTHALMOL, V90, P244, DOI 10.1111/j.1755-3768.2010.01929.x
   Simpson ARH, 2012, SURV OPHTHALMOL, V57, P498, DOI 10.1016/j.survophthal.2012.01.011
   Stefansson E, 2009, GRAEF ARCH CLIN EXP, V247, P147, DOI 10.1007/s00417-008-0980-7
   Tombran-Tink J, 2010, CURR MOL MED, V10, P267, DOI 10.2174/156652410791065336
   Tombran-Tink J, 1995, BIOCHEM J, V15, P4992
NR 22
TC 14
Z9 14
U1 0
U2 3
PU SOC BIOLGIA CHILE
PI SANTIAGO
PA CASILLA 16164, SANTIAGO 9, CHILE
SN 0716-9760
EI 0717-6287
J9 BIOL RES
JI Biol. Res.
PD JUL 30
PY 2015
VL 48
AR 42
DI 10.1186/s40659-015-0034-7
PG 8
WC Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Life Sciences & Biomedicine - Other Topics
GA CN7TS
UT WOS:000358637500001
PM 26223306
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Skerka, C
   Chen, Q
   Fremeaux-Bacchi, V
   Roumenina, LT
AF Skerka, Christine
   Chen, Qian
   Fremeaux-Bacchi, Veronique
   Roumenina, Lubka T.
TI Complement factor H related proteins (CFHRs)
SO MOLECULAR IMMUNOLOGY
LA English
DT Review
ID HEMOLYTIC-UREMIC SYNDROME; SHORT CONSENSUS REPEAT; DENSE DEPOSIT
   DISEASE; C-REACTIVE-PROTEIN; GENOME-WIDE ASSOCIATION; REGULATORS
   FACTOR-H; BORRELIA-BURGDORFERI; CANDIDA-ALBICANS; IMMUNE EVASION;
   PSEUDOMONAS-AERUGINOSA
AB Factor H related proteins comprise a group of five plasma proteins: CFHR1, CFHR2, CFHR3, CFHR4 and CFHR5, and each member of this group binds to the central complement component C3b. Mutations, genetic deletions, duplications or rearrangements in the individual CFHR genes are associated with a number of diseases including atypical hemolytic uremic syndrome (aHUS), C3 glomerulopathies (C3 glomerulonephritis (C3GN), dense deposit disease (DDD) and CFHR5 nephropathy), IgA nephropathy, age related macular degeneration (AMD) and systemic lupus erythematosus (SLE). Although complement regulatory functions were attributed to most of the members of the CFHR protein family, the precise role of each CFHR protein in complement activation and the exact contribution to disease pathology is still unclear. Recent publications show that CFHR proteins form homo- as well as heterodimers. Genetic abnormalities within the CFHR gene locus can result in hybrid proteins with affected dimerization or recognition domains which cause defective functions. Here we summarize the recent data about CFHR genes and proteins in order to better understand the role of CFHR proteins in complement activation and in complement associated diseases. (C) 2013 Elsevier Ltd. All rights reserved.
C1 [Skerka, Christine; Chen, Qian] Leibniz Inst Nat Prod Res & Infect Biol, Dept Infect Biol, D-07745 Jena, Germany.
   [Fremeaux-Bacchi, Veronique; Roumenina, Lubka T.] INSERM, Ctr Rech Cordeliers, UMRS 872, Paris, France.
   [Fremeaux-Bacchi, Veronique] Hop Europeen Georges Pompidou, Serv Immunol Biol, Paris, France.
   [Roumenina, Lubka T.] Univ Paris Descartes Sorbonne Paris Cite, Paris, France.
   [Roumenina, Lubka T.] Univ Paris 06, Paris, France.
C3 Hans Knoll Institute (HKI); Institut National de la Sante et de la
   Recherche Medicale (Inserm); UDICE-French Research Universities;
   Sorbonne Universite; Universite Paris Cite; Assistance Publique Hopitaux
   Paris (APHP); Hopital Universitaire Europeen Georges-Pompidou - APHP;
   UDICE-French Research Universities; Universite Paris Cite; UDICE-French
   Research Universities; Universite Paris Cite; UDICE-French Research
   Universities; Sorbonne Universite
RP Skerka, C (通讯作者)，Hans Knoell Inst, Leibniz Inst Nat Prod Res & Infect Biol, Dept Infect Biol, Beutenbergstr 11, D-07745 Jena, Germany.
EM christine.skerka@hki-jena.de
RI Roumenina, Lubka/P-5906-2019; Roumenina, Lubka/L-2638-2017
OI Roumenina, Lubka/0000-0002-9940-0324; 
FU 'Deutsche Forschungsgemeinschaft' (DFG) Germany [Sk 46]; EU
   [2012-305608]
FX This work was supported by the 'Deutsche Forschungsgemeinschaft' (DFG,
   Sk 46) Germany and by EU FP7 grant 2012-305608 (EURenOmics). We thank
   Heiko Richter and Nadine Flach for Western blot analysis for the
   detailed characterization of the factor H/CFHR gene locus. QC is a
   doctoral researcher at the International Leibniz Research School (ILRS),
   part of the Jena school of Microbial Communication (JSMC), Jena,
   Germany.
CR Abarrategui-Garrido C, 2009, BLOOD, V114, P4261, DOI 10.1182/blood-2009-05-223834
   Abrera-Abeleda MA, 2006, J MED GENET, V43, P582, DOI 10.1136/jmg.2005.038315
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Athanasiou Y, 2011, CLIN J AM SOC NEPHRO, V6, P1436, DOI 10.2215/CJN.09541010
   Behnsen J, 2008, INFECT IMMUN, V76, P820, DOI 10.1128/IAI.01037-07
   BHAKDI S, 1988, PROG ALLERGY, V40, P1
   Bienaime F, 2010, KIDNEY INT, V77, P339, DOI 10.1038/ki.2009.472
   Blackmore TK, 1998, INFECT IMMUN, V66, P1427, DOI 10.1128/IAI.66.4.1427-1431.1998
   Blanc C, 2012, J IMMUNOL, V189, P3528, DOI 10.4049/jimmunol.1200679
   Castiblanco-Valencia MM, 2012, J INFECT DIS, V205, P995, DOI 10.1093/infdis/jir875
   Chen Q, 2012, IMMUNOBIOLOGY, V217, P1131, DOI 10.1016/j.imbio.2012.08.009
   Chen Q, 2011, NEW ENGL J MED, V365, P2340, DOI 10.1056/NEJMc1107484
   Davila S, 2010, NAT GENET, V42, P772, DOI 10.1038/ng.640
   de Jorge EG, 2013, P NATL ACAD SCI USA, V110, P4685, DOI 10.1073/pnas.1219260110
   de Jorge EG, 2012, IMMUNOBIOLOGY, V217, P1205, DOI 10.1016/j.imbio.2012.08.219
   Deltas C, 2013, ADV EXP MED BIOL, V735, P189, DOI 10.1007/978-1-4614-4118-2_12
   Delvaeye M, 2009, NEW ENGL J MED, V361, P345, DOI 10.1056/NEJMoa0810739
   Diaz-Guillen MA, 1999, IMMUNOGENETICS, V49, P549, DOI 10.1007/s002510050534
   Dragon-Durey MA, 2009, J MED GENET, V46, P447, DOI 10.1136/jmg.2008.064766
   Dragon-Durey MA, 2005, J AM SOC NEPHROL, V16, P555, DOI 10.1681/ASN.2004050380
   Eberhardt HE, 2011, MOL IMMUNOL, V48, P1674, DOI 10.1016/j.molimm.2011.06.245
   Eberhardt H. U., 2009, MED INT P 2 EUR C IM
   Eberhardt HU, 2012, IMMUNOBIOLOGY, V217, P1143, DOI 10.1016/j.imbio.2012.08.043
   Fakhouri F, 2010, NAT REV NEPHROL, V6, P494, DOI 10.1038/nrneph.2010.85
   Francis NJ, 2012, BLOOD, V119, P591, DOI 10.1182/blood-2011-03-339903
   Fremeaux-Bacchi V, 2013, CLIN J AM SOC NEPHRO, V8, P554, DOI 10.2215/CJN.04760512
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Fritsche LG, 2010, HUM MOL GENET, V19, P4694, DOI 10.1093/hmg/ddq399
   Gale DP, 2010, LANCET, V376, P794, DOI 10.1016/S0140-6736(10)60670-8
   Gharavi AG, 2011, NAT GENET, V43, P321, DOI 10.1038/ng.787
   Haapasalo K, 2009, INFECT IMMUN, V77, P3886, DOI 10.1128/IAI.01583-08
   Hallstrom T, 2012, J IMMUNOL, V189, P4939, DOI 10.4049/jimmunol.1200386
   Haupt K, 2007, J INFECT DIS, V196, P124, DOI 10.1086/518509
   Hebecker M, 2010, MOL IMMUNOL, V47, P1347, DOI 10.1016/j.molimm.2009.12.005
   Heinen Stefan, 2006, Hum Mutat, V27, P292, DOI 10.1002/humu.9408
   Heinen S, 2009, BLOOD, V114, P2439, DOI 10.1182/blood-2009-02-205641
   Hellwage J, 1999, FEBS LETT, V462, P345, DOI 10.1016/S0014-5793(99)01554-9
   Hellwage J, 2001, J BIOL CHEM, V276, P8427, DOI 10.1074/jbc.M007994200
   Herbert AP, 2007, J BIOL CHEM, V282, P18960, DOI 10.1074/jbc.M609636200
   Herbert AP, 2012, BIOCHEMISTRY-US, V51, P1874, DOI 10.1021/bi201689j
   Holmes LV, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060352
   Huber-Lang M, 2006, NAT MED, V12, P682, DOI 10.1038/nm1419
   Hughes AE, 2006, NAT GENET, V38, P1173, DOI 10.1038/ng1890
   Jozsi M, 2005, EUR J HUM GENET, V13, P321, DOI 10.1038/sj.ejhg.5201324
   Jozsi M, 2008, BLOOD, V111, P1512, DOI 10.1182/blood-2007-09-109876
   Jozsi M, 2007, BLOOD, V110, P1516, DOI 10.1182/blood-2007-02-071472
   Kemper C, 2007, NAT REV IMMUNOL, V7, P9, DOI 10.1038/nri1994
   Kopp A, 2012, J IMMUNOL, V189, P1858, DOI 10.4049/jimmunol.1200357
   Kotarsky H, 1998, J IMMUNOL, V160, P3349
   Kraiczy P, 2004, INT J MED MICROBIOL, V293, P152, DOI 10.1016/S1433-1128(04)80029-9
   Kraiczy P, 2004, J BIOL CHEM, V279, P2421, DOI 10.1074/jbc.M308343200
   Krid S, 2012, AM J TRANSPLANT, V12, P1938, DOI 10.1111/j.1600-6143.2012.04051.x
   Kunert A, 2007, J IMMUNOL, V179, P2979, DOI 10.4049/jimmunol.179.5.2979
   Leban N, 2012, INT J IMMUNOGENET, V39, P110, DOI 10.1111/j.1744-313X.2011.01071.x
   Lehtinen MJ, 2009, J BIOL CHEM, V284, P15650, DOI 10.1074/jbc.M900814200
   Lemaire M, 2013, NAT GENET, V45, P531, DOI 10.1038/ng.2590
   Licht C, 2006, KIDNEY INT, V70, P42, DOI 10.1038/sj.ki.5000269
   Losse J, 2010, J IMMUNOL, V184, P912, DOI 10.4049/jimmunol.0901702
   Luo SS, 2011, J BIOL CHEM, V286, P8021, DOI 10.1074/jbc.M110.130138
   Luo SS, 2010, J IMMUNOL, V185, P2164, DOI 10.4049/jimmunol.1001011
   Maga TK, 2011, NEPHROL DIAL TRANSPL, V26, P739, DOI 10.1093/ndt/gfq658
   Maga TK, 2010, HUM MUTAT, V31, pE1445, DOI 10.1002/humu.21256
   Male DA, 2000, MOL IMMUNOL, V37, P41, DOI 10.1016/S0161-5890(00)00024-9
   Malik TH, 2012, J AM SOC NEPHROL, V23, P1155, DOI 10.1681/ASN.2012020166
   Manuelian T, 2003, J CLIN INVEST, V111, P1181, DOI 10.1172/JCI200316651
   Martinez-Barricarte R, 2012, INVEST OPHTH VIS SCI, V53, P1087, DOI 10.1167/iovs.11-8709
   Martinez-Barricarte R, 2010, J CLIN INVEST, V120, P3702, DOI 10.1172/JCI43343
   McRae JL, 2005, J IMMUNOL, V174, P6250, DOI 10.4049/jimmunol.174.10.6250
   Meri T, 2005, MICROB PATHOGENESIS, V39, P139, DOI 10.1016/j.micpath.2005.07.003
   Meri T, 2002, INFECT IMMUN, V70, P5185, DOI 10.1128/IAI.70.9.5185-5192.2002
   Mihlan M, 2009, MOL IMMUNOL, V46, P335, DOI 10.1016/j.molimm.2008.10.029
   Miller JW, 2013, AM J OPHTHALMOL, V155, P1, DOI 10.1016/j.ajo.2012.10.018
   Moore I, 2010, BLOOD, V115, P379, DOI 10.1182/blood-2009-05-221549
   Morgan BP, 1999, CRIT REV IMMUNOL, V19, P173
   Morgan HP, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032187
   MULLEREBERHARD HJ, 1986, ANNU REV IMMUNOL, V4, P503, DOI 10.1146/annurev.iy.04.040186.002443
   Murphy B, 2002, AM J KIDNEY DIS, V39, P24, DOI 10.1053/ajkd.2002.29873
   Nester C, 2011, CLIN J AM SOC NEPHRO, V6, P1488, DOI 10.2215/CJN.10181110
   Ngampasutadol J, 2008, J IMMUNOL, V180, P3426, DOI 10.4049/jimmunol.180.5.3426
   Noris M, 2009, NEW ENGL J MED, V361, P1676, DOI 10.1056/NEJMra0902814
   Oliver MA, 2007, J ANTIMICROB CHEMOTH, V60, P450, DOI 10.1093/jac/dkm174
   Pandiripally V, 2003, INFECT IMMUN, V71, P7119, DOI 10.1128/IAI.71.12.7119-7128.2003
   Park CT, 1996, J BIOL CHEM, V271, P18054, DOI 10.1074/jbc.271.30.18054
   Perez-Caballero D, 2004, J IMMUNOL, V173, P6899, DOI 10.4049/jimmunol.173.11.6899
   Ram S, 1999, MOL IMMUNOL, V36, P915, DOI 10.1016/S0161-5890(99)00114-5
   Raychaudhuri S, 2011, NAT GENET, V43, P1232, DOI 10.1038/ng.976
   Reuter M, 2010, J BIOL CHEM, V285, P38473, DOI 10.1074/jbc.M110.143727
   Ricklin D, 2010, NAT IMMUNOL, V11, P785, DOI 10.1038/ni.1923
   de Cordoba SR, 2012, IMMUNOBIOLOGY, V217, P1034, DOI 10.1016/j.imbio.2012.07.021
   Roumenina LT, 2011, J IMMUNOL METHODS, V365, P8, DOI 10.1016/j.jim.2010.12.020
   Servais A, 2012, KIDNEY INT, V82, P454, DOI 10.1038/ki.2012.63
   Sethi S, 2011, SEMIN NEPHROL, V31, P341, DOI 10.1016/j.semnephrol.2011.06.005
   SKERKA C, 1991, J BIOL CHEM, V266, P12015
   SKERKA C, 1992, J IMMUNOL, V148, P3313
   SKERKA C, 1993, J BIOL CHEM, V268, P2904
   Skerka C, 1997, J BIOL CHEM, V272, P5627, DOI 10.1074/jbc.272.9.5627
   Skerka C., 2008, THROMB HAEMOSTASIS, V100, P1
   Stevenson B, 2002, INFECT IMMUN, V70, P5307, DOI 10.1128/IAI.70.9.5307-5311.2002
   Susukida R, 2007, ELECTROPHORESIS, V28, P309, DOI 10.1002/elps.200600287
   TIMMANN C, 1991, J IMMUNOL, V146, P1265
   Tortajada A., 2013, J CLIN INVE IN PRESS
   Venables JP, 2006, PLOS MED, V3, P1957, DOI 10.1371/journal.pmed.0030431
   Verma A, 2006, INFECT IMMUN, V74, P2659, DOI 10.1128/IAI.74.5.2659-2666.2006
   Vernon KA, 2012, AM J KIDNEY DIS, V60, P121, DOI 10.1053/j.ajkd.2012.02.329
   Vogl G, 2008, MOL IMMUNOL, V45, P1485, DOI 10.1016/j.molimm.2007.08.011
   Walport MJ, 2001, NEW ENGL J MED, V344, P1058, DOI 10.1056/NEJM200104053441406
   Walport MJ, 2001, NEW ENGL J MED, V344, P1140, DOI 10.1056/NEJM200104123441506
   Wang L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010329
   Ward PA, 2009, J MOL MED, V87, P375, DOI 10.1007/s00109-009-0442-7
   Weismann D, 2011, NATURE, V478, P76, DOI 10.1038/nature10449
   Westra D, 2012, J HUM GENET, V57, P459, DOI 10.1038/jhg.2012.57
   Zhao J, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002079
   Zipfel PF, 2007, PLOS GENET, V3, P387, DOI 10.1371/journal.pgen.0030041
   Zipfel PF, 2010, PEDIATR NEPHROL, V25, P2009, DOI 10.1007/s00467-010-1446-9
   Zipfel PF, 2009, NAT REV IMMUNOL, V9, P729, DOI 10.1038/nri2620
NR 115
TC 159
Z9 171
U1 2
U2 152
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0161-5890
J9 MOL IMMUNOL
JI Mol. Immunol.
PD DEC 15
PY 2013
VL 56
IS 3
SI SI
BP 170
EP 180
DI 10.1016/j.molimm.2013.06.001
PG 11
WC Biochemistry & Molecular Biology; Immunology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Immunology
GA 199TZ
UT WOS:000323019700004
PM 23830046
OA hybrid
DA 2022-11-30
ER

PT J
AU Cao, L
   Liu, C
   Wang, F
   Wang, H
AF Cao, L.
   Liu, C.
   Wang, F.
   Wang, H.
TI SIRT1 negatively regulates amyloid-beta-induced inflammation via the
   NF-kappa B pathway
SO BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH
LA English
DT Article
DE Amyloid-beta; SRT1720; Age-related macular degeneration; Barrier
   integrity; Tight junction; Matrix metalloproteinase-9
ID RETINAL-PIGMENT EPITHELIUM; BLOOD-BRAIN-BARRIER; MACULAR DEGENERATION;
   COMPLEMENT ACTIVATION; OXIDATIVE STRESS; GENE-EXPRESSION; DRUSEN
   DEPOSITS; TIGHT JUNCTIONS; MATRIX-METALLOPROTEINASE-9; TRANSCRIPTION
AB Chronic inflammation induced by amyloid-beta (A beta) plays a key role in the development of age-related macular degeneration (AMD), and matrix metalloproteinase-9 (MMP-9), interleukin (IL)-6, and IL-8 may be associated with chronic inflammation in AMD. Sirtuin 1 (SIRT1) regulates inflammation via inhibition of nuclear factor-kappa B (NF-kappa B) signaling, and resveratrol has been reported to prevent A beta-induced retinal degeneration; therefore, we investigated whether this action was mediated via activation of SIRT1 signaling. Human adult retinal pigment epithelial (RPE) cells were exposed to A beta, and overactivation and knockdown of SIRT1 were performed to investigate whether SIRT1 is required for abrogating A beta-induced inflammation. We found that A beta-induced RPE barrier disruption and expression of IL-6, IL-8, and MMP-9 were abrogated by the SIRT1 activator SRT1720, whereas alterations induced by A beta in SIRT1-silenced RPE cells were not attenuated by SRT1720. In addition, SRT1720 inhibited A beta-mediated NF-kappa B activation and decrease of the NF-kappa B inhibitor, I kappa B alpha. Our findings suggest a protective role for SIRT1 signaling in A beta-dependent retinal degeneration and inflammation in AMD.
C1 [Cao, L.; Liu, C.; Wang, H.] Tongji Univ, Peoples Hosp 10, Sch Med, Dept Ophthalmol, Shanghai 200092, Peoples R China.
   [Wang, F.] Shanghai Tenth Peoples Hosp, Dept Ophthalmol, Shanghai 200072, Peoples R China.
C3 Tongji University
RP Wang, F (通讯作者)，Shanghai Tenth Peoples Hosp, Dept Ophthalmol, 301 Middle Yan Chang Rd, Shanghai 200072, Peoples R China.
EM milwang_122@msn.com
FU Science and Technology Commission of Shanghai [11JC1409900]; National
   High Technology Research and Development Program of China (863 Program)
   [S2010GR0002]
FX We thank the Biochemistry and Molecular Biology Institute of Shanghai
   Tenth People's Hospital and are grateful for their technological
   support. Research supported by the Science and Technology Commission of
   Shanghai (#11JC1409900) and the National High Technology Research and
   Development Program of China (863 Program, #S2010GR0002).
CR Bailey TA, 2004, INVEST OPHTH VIS SCI, V45, P675, DOI 10.1167/iovs.03-0351
   Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649
   Bauer AT, 2010, J CEREBR BLOOD F MET, V30, P837, DOI 10.1038/jcbfm.2009.248
   Bruban J, 2009, AGING CELL, V8, P162, DOI 10.1111/j.1474-9726.2009.00456.x
   Brunet A, 2004, SCIENCE, V303, P2011, DOI 10.1126/science.1094637
   Buschini E, 2011, PROG NEUROBIOL, V95, P14, DOI 10.1016/j.pneurobio.2011.05.011
   Canevari L, 2004, NEUROCHEM RES, V29, P637, DOI 10.1023/B:NERE.0000014834.06405.af
   Cao LN, 2013, INT J MOL MED, V31, P1105, DOI 10.3892/ijmm.2013.1310
   Capiralla H, 2012, J NEUROCHEM, V120, P461, DOI 10.1111/j.1471-4159.2011.07594.x
   Chen LF, 2001, SCIENCE, V293, P1653, DOI 10.1126/science.1062374
   Chen LF, 2003, J MOL MED, V81, P549, DOI 10.1007/s00109-003-0469-0
   Cunha-Vaz J, 2011, EUR J OPHTHALMOL, V21, pS3, DOI 10.5301/EJO.2010.6049
   Feng SR, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020599
   Feng XW, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0059888, 10.1371/journal.pone.0078846]
   Howitz KT, 2003, NATURE, V425, P191, DOI 10.1038/nature01960
   Isas JM, 2010, INVEST OPHTH VIS SCI, V51, P1304, DOI 10.1167/iovs.09-4207
   Jo DH, 2010, ARCH PHARM RES, V33, P1557, DOI 10.1007/s12272-010-1007-6
   Johnson LV, 2011, P NATL ACAD SCI USA, V108, P18277, DOI 10.1073/pnas.1109703108
   Johnson LV, 2002, P NATL ACAD SCI USA, V99, P11830, DOI 10.1073/pnas.192203399
   Jonas JB, 2012, ACTA OPHTHALMOL, V90, pe381, DOI 10.1111/j.1755-3768.2012.02414.x
   Kayed R, 2003, SCIENCE, V300, P486, DOI 10.1126/science.1079469
   Kivela T, 2000, CELL TISSUE RES, V301, P217, DOI 10.1007/s004410000225
   Kook SY, 2012, J NEUROSCI, V32, P8845, DOI 10.1523/JNEUROSCI.6102-11.2012
   Kurji KH, 2010, INVEST OPHTH VIS SCI, V51, P1151, DOI 10.1167/iovs.09-3622
   Li F, 2012, CURR PHARM DESIGN, V18, P27, DOI 10.2174/138161212798919075
   Lowin B, 1995, Curr Top Microbiol Immunol, V198, P1
   Luibl V, 2006, J CLIN INVEST, V116, P378, DOI 10.1172/JCI25843
   Martins T, 2011, BRAIN RES, V1411, P28, DOI 10.1016/j.brainres.2011.07.013
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Nakamaru Y, 2009, FASEB J, V23, P2810, DOI 10.1096/fj.08-125468
   NATHAN CF, 1987, J CLIN INVEST, V80, P1550, DOI 10.1172/JCI113241
   Park SY, 2012, INT IMMUNOPHARMACOL, V14, P13, DOI 10.1016/j.intimp.2012.06.003
   Peng SM, 2012, INVEST OPHTH VIS SCI, V53, P5016, DOI 10.1167/iovs.11-8311
   Tilstra JS, 2011, AGING DIS, V2, P449
   Villalba JM, 2012, BIOFACTORS, V38, P349, DOI 10.1002/biof.1032
   Walker DG, 2001, NEUROBIOL AGING, V22, P957, DOI 10.1016/S0197-4580(01)00306-2
   Wang JY, 2008, J IMMUNOL, V181, P712, DOI 10.4049/jimmunol.181.1.712
   Yeung F, 2004, EMBO J, V23, P2369, DOI 10.1038/sj.emboj.7600244
NR 38
TC 47
Z9 50
U1 1
U2 34
PU ASSOC BRAS DIVULG CIENTIFICA
PI SAO PAULO
PA FACULDADE MEDICINA, SALA 21, 14049 RIBEIRAO PRETO, SAO PAULO, 00, BRAZIL
SN 0100-879X
EI 1678-4510
J9 BRAZ J MED BIOL RES
JI Brazilian J. Med. Biol. Res.
PD AUG
PY 2013
VL 46
IS 8
BP 659
EP 669
DI 10.1590/1414-431X20132903
PG 11
WC Biology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Life Sciences & Biomedicine - Other Topics; Research & Experimental
   Medicine
GA 220HP
UT WOS:000324573800003
PM 24036938
OA Green Submitted, Green Published, gold
DA 2022-11-30
ER

PT J
AU Parmeggiani, F
   Costagliola, C
   Incorvaia, C
   Sebastiani, A
   Gemmati, D
AF Parmeggiani, Francesco
   Costagliola, Ciro
   Incorvaia, Carlo
   Sebastiani, Adolfo
   Gemmati, Donato
TI Pharmacogenetic Aspects in Therapeutic Management of Subfoveal Choroidal
   Neovascularisation: Role of Factor XIII-A 185 T-Allele
SO CURRENT DRUG TARGETS
LA English
DT Review
DE Macular degenerations; choroidal neovascularization; pharmacogenetics;
   photodynamic therapy with verteporfin; fibrin-clot stability; factor
   XIII-A G185T gene polymorphism; anti-thrombophilia
ID COMPLEMENT FACTOR-H; ENDOTHELIAL GROWTH-FACTOR; RANDOMIZED
   CLINICAL-TRIAL; VERTEPORFIN PHOTODYNAMIC THERAPY; SINGLE-NUCLEOTIDE
   POLYMORPHISMS; COAGULATION-FACTOR-XIII; FIBRIN CLOT STRUCTURE;
   METHYLENETETRAHYDROFOLATE REDUCTASE GENE; INTRAVITREAL BEVACIZUMAB
   INJECTION; CORONARY-ARTERY-DISEASE
AB In Western Countries, the occurrence of choroidal neovascularization (CNV) secondary to different forms of macular degeneration represents a common cause of blindness. Particularly, age-related macular degeneration (AMD) and pathologic myopia (PM) are the most frequent diseases related to CNV development. At present, the combined employment of drugs acting against vascular endothelial growth factor (anti-VEGF) and photodynamic therapy with verteporfin (PDT-V) is a promising therapeutic strategy for neovascular macular degenerations. However, this approach inevitably leads to an increase in health-resource utilization. In several clusters of patients treated for CNV, correlations among common gene polymorphisms implicated in coagulation-or complement-cascade and different levels of, respectively, post-PDT-V or post-anti-VEGF benefit have been reported. Factor XIII-A G185T substitution (rs5985), a frequent anti-thrombophilic genetic variant of Caucasian ethnic groups, unequivocally influences a worsening of the CNV responsiveness to PDT-V in patients affected by either AMD- or PM-related CNV. These coherent pharmacogenetic findings point out the opportunities to: i. optimize the eligibility criteria of PDT-V and, ii. customize the interventional strategy against CNV, for finally minimizing the socio-economic burden of neovascular macular degenerations.
C1 [Parmeggiani, Francesco; Incorvaia, Carlo; Sebastiani, Adolfo] Univ Ferrara, Dept Ophthalmol, I-44100 Ferrara, Italy.
   [Costagliola, Ciro] Univ Molise, Dept Hlth Sci, Campobasso, Italy.
   [Gemmati, Donato] Univ Ferrara, Dept Hematol, Ctr Study Hemostasis & Thrombosis, I-44100 Ferrara, Italy.
C3 University of Ferrara; University of Molise; University of Ferrara
RP Parmeggiani, F (通讯作者)，Univ Ferrara, Sez Clin Oculist, Dipartimento Discipline Medchirurg Comunicaz & Co, Corso Giovecca 203, I-44100 Ferrara, Italy.
EM francesco.parmeggiani@unife.it
RI Costagliola, Ciro/G-5707-2012
OI Costagliola, Ciro/0000-0001-8477-6188; Gemmati,
   Donato/0000-0001-6213-6120
CR Abugreen S, 2003, BRIT J OPHTHALMOL, V87, P307, DOI 10.1136/bjo.87.3.307
   Antoszyk AN, 2008, AM J OPHTHALMOL, V145, P862, DOI 10.1016/j.ajo.2007.12.029
   Anwar R, 1999, BLOOD, V93, P897, DOI 10.1182/blood.V93.3.897.403k02_897_905
   Arias L, 2005, BRIT J OPHTHALMOL, V89, P312, DOI 10.1136/bjo.2004.050997
   Ariens RAS, 2000, BLOOD, V96, P988, DOI 10.1182/blood.V96.3.988.015k57_988_995
   Ariens RAS, 2002, BLOOD, V100, P743, DOI 10.1182/blood.V100.3.743
   Arnold J, 2001, OPHTHALMOLOGY, V108, P841
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Attie-Castro FA, 2000, THROMB HAEMOSTASIS, V84, P601, DOI 10.1055/s-0037-1614074
   Augustin A, 2009, RETINA-J RET VIT DIS, V29, pS5
   Axer-Siegel R, 2004, AM J OPHTHALMOL, V137, P258, DOI 10.1016/j.ajo.2003.08.009
   Bakri SJ, 2009, RETINA-J RET VIT DIS, V29, P573, DOI 10.1097/IAE.0b013e3181a46a8a
   Bashshur ZF, 2008, AM J OPHTHALMOL, V145, P249, DOI 10.1016/j.ajo.2007.09.031
   Bereczky Z, 2003, PATHOPHYSIOL HAEMO T, V33, P430, DOI 10.1159/000083841
   Bergeron-Sawitzke J, 2009, EUR J HUM GENET, V17, P1190, DOI 10.1038/ejhg.2009.23
   Blinder KJ, 2003, AM J OPHTHALMOL, V136, P407, DOI 10.1016/S0002-9394(03)00223-X
   Blinder KJ, 2003, OPHTHALMOLOGY, V110, P667, DOI 10.1016/S0161-6420(02)01998-X
   BLOMBACK B, 1994, THROMB RES, V75, P521, DOI 10.1016/0049-3848(94)90227-5
   Bradley John, 2007, Angiogenesis, V10, P141, DOI 10.1007/s10456-007-9069-x
   Brantley MA, 2009, EYE, V23, P626, DOI 10.1038/eye.2008.28
   Brantley MA, 2007, OPHTHALMOLOGY, V114, P2168, DOI 10.1016/j.ophtha.2007.09.008
   Brantley MA, 2007, AM J OPHTHALMOL, V144, P404, DOI 10.1016/j.ajo.2007.05.018
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown GC, 2007, OPHTHALMOLOGY, V114, P1170, DOI 10.1016/j.ophtha.2006.09.019
   Brown GC, 2005, AM J OPHTHALMOL, V140, P679, DOI 10.1016/j.ajo.2005.04.061
   Brown MM, 2008, OPHTHALMOLOGY, V115, P1039, DOI 10.1016/j.ophtha.2007.08.033
   CARR ME, 1995, BLOOD COAGUL FIBRIN, V6, P567, DOI 10.1097/00001721-199509000-00011
   Casas JP, 2005, LANCET, V365, P224, DOI 10.1016/S0140-6736(05)70152-5
   Castoldi E, 2004, CURR OPIN HEMATOL, V11, P176, DOI 10.1097/01.moh.0000130315.41033.32
   Castro R, 2006, J INHERIT METAB DIS, V29, P3, DOI 10.1007/s10545-006-0106-5
   Chakravarthy U, 2006, BRIT J OPHTHALMOL, V90, P1188, DOI 10.1136/bjo.2005.082255
   Chan WM, 2009, BRIT J OPHTHALMOL, V93, P150, DOI 10.1136/bjo.2008.145797
   Chan WM, 2006, JPN J OPHTHALMOL, V50, P161, DOI 10.1007/s10384-005-0259-z
   Chan WM, 2005, BRIT J OPHTHALMOL, V89, P1522, DOI 10.1136/bjo.2005.074716
   Chappelow AV, 2008, DRUGS, V68, P1029, DOI 10.2165/00003495-200868080-00002
   Chowers I, 2008, MOL VIS, V14, P2263
   Chowers I, 2008, MOL VIS, V14, P1829
   Ciulla TA, 2009, CURR OPIN OPHTHALMOL, V20, P166, DOI 10.1097/ICU.0b013e328329d173
   COLLET JP, 1993, BLOOD, V82, P2462
   Collet JP, 2003, J BIOL CHEM, V278, P21331, DOI 10.1074/jbc.M212734200
   Collet JP, 2000, ARTERIOSCL THROM VAS, V20, P1354, DOI 10.1161/01.ATV.20.5.1354
   Colquitt JL, 2008, HEALTH TECHNOL ASSES, V12, P1
   Coppola A, 2000, SEMIN THROMB HEMOST, V26, P243, DOI 10.1055/s-2000-8469
   Costagliola C, 2008, EUR J OPHTHALMOL, V18, P955, DOI 10.1177/112067210801800616
   Costagliola C, 2009, RETINA-J RET VIT DIS, V29, P1227, DOI 10.1097/IAE.0b013e3181b773e1
   Costagliola C, 2009, GRAEF ARCH CLIN EXP, V247, P1031, DOI 10.1007/s00417-009-1081-y
   Cruess AF, 2008, PHARMACOECONOMICS, V26, P57, DOI 10.2165/00019053-200826010-00006
   D'Angelo A, 2003, PATHOPHYSIOL HAEMO T, V33, P337, DOI 10.1159/000083824
   Dadgostar H, 2008, EYE, V22, P761, DOI 10.1038/eye.2008.86
   Danckwardt S, 2006, ACTA HAEMATOL-BASEL, V115, P192, DOI 10.1159/000090934
   Dardik R, 2006, J THROMB HAEMOST, V4, P19, DOI 10.1111/j.1538-7836.2005.01473.x
   Dardik R, 2003, ARTERIOSCL THROM VAS, V23, P1472, DOI 10.1161/01.ATV.0000081636.25235.C6
   de Lange M, 2006, ARTERIOSCL THROM VAS, V26, P1914, DOI 10.1161/01.ATV.0000231538.60223.92
   Doggen CJM, 2003, J THROMB HAEMOST, V1, P2056, DOI 10.1046/j.1538-7836.2003.00352.x
   Dougherty TJ, 1998, JNCI-J NATL CANCER I, V90, P889, DOI 10.1093/jnci/90.12.889
   Droz I, 2008, BRIT J OPHTHALMOL, V92, P513, DOI 10.1136/bjo.2007.127811
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Fatah K, 1996, THROMB HAEMOSTASIS, V76, P535
   Feng XF, 2009, OPHTHALMOLOGY, V116, P1908, DOI 10.1016/j.ophtha.2009.03.011
   Ferrara N, 2004, ENDOCR REV, V25, P581, DOI 10.1210/er.2003-0027
   Ferrara N, 2007, ANNU REV MED, V58, P491, DOI 10.1146/annurev.med.58.061705.145635
   Francis PJ, 2008, MOL VIS, V14, P1395
   Garattini S, 2008, EUR J CLIN PHARMACOL, V64, P115, DOI 10.1007/s00228-007-0411-4
   Gemmati D, 2004, WOUND REPAIR REGEN, V12, P512, DOI 10.1111/j.1067-1927.2004.012503.x
   Gemmati D, 2001, AM J HEMATOL, V67, P183, DOI 10.1002/ajh.1104
   Gemmati D, 2007, MOL MED, V13, P112, DOI 10.2119/2006-00049.Gemmati
   Giansanti F, 2009, COCHRANE DB SYST REV, V2
   Gohil R, 2009, THROMB HAEMOSTASIS, V102, P360, DOI 10.1160/TH09-01-0013
   Gotoh N, 2008, CLIN EXP OPHTHALMOL, V36, P437, DOI 10.1111/j.1442-9071.2008.01791.x
   Goverdhan SV, 2008, EYE, V22, P849, DOI 10.1038/sj.eye.6702830
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Greve MDJ, 2005, ARCH OPHTHALMOL-CHIC, V123, P448
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hasan T., 1997, CANC MED, P739
   HAWKINS BS, 1993, ARCH OPHTHALMOL-CHIC, V111, P1200
   HENDERSON BW, 1992, PHOTOCHEM PHOTOBIOL, V55, P145, DOI 10.1111/j.1751-1097.1992.tb04222.x
   Ichinose A, 2001, THROMB HAEMOSTASIS, V86, P57
   Incorvaia C, 2008, RETINA-J RET VIT DIS, V28, P289, DOI 10.1097/IAE.0b013e31813ffe90
   Jambor C, 2009, ANESTH ANALG, V109, P1023, DOI 10.1213/ANE.0b013e3181b5a263
   Jiang H, 2009, RETINA-J RET VIT DIS, V29, P974, DOI 10.1097/IAE.0b013e3181a3b90e
   Kaiser PK, 2006, AM J OPHTHALMOL, V142, P660, DOI 10.1016/j.ajo.2006.05.061
   Kaiser PK, 2009, OPHTHALMOLOGY, V116, P747, DOI 10.1016/j.ophtha.2008.12.057
   Kaur I, 2008, INVEST OPHTH VIS SCI, V49, P1771, DOI 10.1167/iovs.07-0560
   Kim IK, 2008, MOL VIS, V14, P1487
   Kim NR, 2008, INVEST OPHTH VIS SCI, V49, P2071, DOI 10.1167/iovs.07-1195
   Klein ML, 2008, OPHTHALMOLOGY, V115, P1019, DOI 10.1016/j.ophtha.2008.01.036
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klein R, 2008, OPHTHALMOLOGY, V115, P1742, DOI 10.1016/j.ophtha.2008.03.021
   Kobbervig C, 2004, BIOPHYS CHEM, V112, P223, DOI 10.1016/j.bpc.2004.07.023
   Kohler HP, 1998, THROMB HAEMOSTASIS, V79, P8, DOI 10.1055/s-0037-1614250
   Kohler HP, 1998, THROMB HAEMOSTASIS, V80, P704
   Krebs I, 2005, AM J OPHTHALMOL, V140, P416, DOI 10.1016/j.ajo.2005.03.050
   Lai TYY, 2009, RETINA-J RET VIT DIS, V29, P750, DOI 10.1097/IAE.0b013e31819ed6bd
   Lam DSC, 2004, BRIT J OPHTHALMOL, V88, P1315, DOI 10.1136/bjo.2004.041624
   Landa G, 2009, OPHTHALMOLOGICA, V223, P370, DOI 10.1159/000227783
   Lane DA, 2000, BLOOD, V95, P1517, DOI 10.1182/blood.V95.5.1517.005k48_1517_1532
   Lazic R, 2007, OPHTHALMOLOGY, V114, P1179, DOI 10.1016/j.ophtha.2007.03.006
   Lee AY, 2009, BRIT J OPHTHALMOL, V93, P610, DOI 10.1136/bjo.2008.150995
   Lee AY, 2008, PHARMACOGENOMICS, V9, P1547, DOI 10.2217/14622416.9.10.1547
   Leveziel N, 2008, INVEST OPHTH VIS SCI, V49, P3090, DOI 10.1167/iovs.07-1540
   Lim BCB, 2003, LANCET, V361, P1424, DOI 10.1016/S0140-6736(03)13135-2
   Maguire MG, 1999, AGE RELATED MACULAR, P17
   Manku KK, 2007, CLIN EXP OPHTHALMOL, V35, P330, DOI 10.1111/j.1442-9071.2007.01482.x
   Mannucci PM, 2003, CIRCULATION, V107, P1117, DOI 10.1161/01.CIR.0000051465.94572.D0
   Mao RF, 2008, CELL BIOCHEM FUNCT, V26, P352, DOI 10.1002/cbf.1450
   Marioli DI, 2009, GRAEF ARCH CLIN EXP, V247, P1547, DOI 10.1007/s00417-009-1129-z
   Martini CH, 2005, J THROMB HAEMOST, V3, P177, DOI 10.1111/j.1538-7836.2004.01080.x
   Matthews RG, 2007, CLIN CHEM LAB MED, V45, P1700, DOI 10.1515/CCLM.2007.324
   Maurer MC, 2006, ARCH BIOCHEM BIOPHYS, V445, P36, DOI 10.1016/j.abb.2005.11.009
   Michels S, 2003, INVEST OPHTH VIS SCI, V44, P2147, DOI 10.1167/iovs.02-0604
   Miller JW, 1999, ARCH OPHTHALMOL-CHIC, V117, P1161
   Mosesson MW, 2005, J THROMB HAEMOST, V3, P1894, DOI 10.1111/j.1538-7836.2005.01365.x
   Navea A, 2009, RETINA-J RET VIT DIS, V29, P13, DOI 10.1097/IAE.0b013e31818a1fd3
   Okumura T, 2003, J THROMB HAEMOST, V1, P1856, DOI 10.1046/j.1538-7836.2003.00339.x
   Parmeggiani F, 2006, OPHTHALMOLOGY, V113, P157
   Parmeggiani F, 2008, INVEST OPHTH VIS SCI, V49, P3100, DOI 10.1167/iovs.07-1654
   Parmeggiani F, 2007, PHARMACOGENET GENOM, V17, P1039, DOI 10.1097/FPC.0b013e3282f12a4e
   Parmeggiani Francesco, 2009, Recent Pat DNA Gene Seq, V3, P114
   Parmeggiani F, 2010, OPHTHALMOLOGY, V117, P517, DOI 10.1016/j.ophtha.2009.08.028
   Parmeggiani F, 2009, PHARMACOGENOMICS, V10, P81, DOI 10.2217/14622416.10.1.81
   PAULEIKHOFF D, 1990, AM J OPHTHALMOL, V109, P38, DOI 10.1016/S0002-9394(14)75576-X
   Peng FY, 2001, INT J MOL MED, V8, P509
   Pieramici DJ, 2006, ARCH OPHTHALMOL-CHIC, V124, P660
   Polito A, 2006, ANN ACAD MED SINGAP, V35, P145
   Raftery J, 2007, BRIT J OPHTHALMOL, V91, P1244, DOI 10.1136/bjo.2007.116616
   Ranchod TM, 2008, RETINA-J RET VIT DIS, V28, P711, DOI 10.1097/IAE.0b013e31816079c3
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Rosenberg N, 2002, AM J HUM GENET, V70, P758, DOI 10.1086/338932
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schlotzer-Schrehardt U, 2002, GRAEF ARCH CLIN EXP, V240, P748, DOI 10.1007/s00417-002-0517-4
   Schmidt-Erfurth U, 2000, SURV OPHTHALMOL, V45, P195, DOI 10.1016/S0039-6257(00)00158-2
   Schmidt-Erfurth U, 2005, OPHTHALMOLOGY, V112, P2061, DOI 10.1016/j.ophtha.2005.09.007
   Schmidt-Erfurth U, 1999, ARCH OPHTHALMOL-CHIC, V117, P1177
   Schmidt-Erfurth U, 2002, INVEST OPHTH VIS SCI, V43, P830
   Schmidt-Erfurth U, 1998, GRAEF ARCH CLIN EXP, V236, P365, DOI 10.1007/s004170050092
   Schmidt-Erfurth U, 2009, PROG RETIN EYE RES, V28, P145, DOI 10.1016/j.preteyeres.2009.01.001
   Schmidt-Erfurth UM, 2007, ACTA OPHTHALMOL SCAN, V85, P486, DOI 10.1111/j.1600-0420.2007.00979.x
   Schmidt-Erfurth UM, 2007, PROG RETIN EYE RES, V26, P437, DOI 10.1016/j.preteyeres.2007.03.002
   Schroder V, 2000, THROMB HAEMOSTASIS, V84, P1128
   Schwahn B, 2001, Am J Pharmacogenomics, V1, P189, DOI 10.2165/00129785-200101030-00004
   Seddon JM, 2007, JAMA-J AM MED ASSOC, V297, P1793, DOI 10.1001/jama.297.16.1793
   Seitsonen SP, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003833
   Shah GK, 2009, RETINA-J RET VIT DIS, V29, P133, DOI 10.1097/IAE.0b013e3181960a28
   Shastry B, 2010, GRAEF ARCH CLIN EXP, V248, P1057, DOI 10.1007/s00417-010-1333-x
   SHEMIRANI AH, THROMB RES IN PRESS
   Shemirani AH, 2006, BBA-PROTEINS PROTEOM, V1764, P1420, DOI 10.1016/j.bbapap.2006.06.007
   Shima C, 2009, GRAEF ARCH CLIN EXP, V247, P899, DOI 10.1007/s00417-009-1067-9
   Shuler RK, 2008, OPHTHALMOLOGY, V115, P520, DOI 10.1016/j.ophtha.2007.06.021
   Shuler RK, 2008, AM J OPHTHALMOL, V145, P303, DOI 10.1016/j.ajo.2007.09.027
   Soubrane G, 2008, SURV OPHTHALMOL, V53, P121, DOI 10.1016/j.survophthal.2007.12.004
   Spaide RF, 2006, AM J OPHTHALMOL, V141, P149, DOI 10.1016/j.ajo.2005.07.025
   Stepien KE, 2009, RETINA-J RET VIT DIS, V29, P1067, DOI 10.1097/IAE.0b013e3181b1bb06
   Stevens TS, 1997, ARCH OPHTHALMOL-CHIC, V115, P345, DOI 10.1001/archopht.1997.01100150347006
   Subramanian ML, 2009, AM J OPHTHALMOL, V148, P875, DOI 10.1016/j.ajo.2009.07.009
   Trumbo TA, 2000, J BIOL CHEM, V275, P20627, DOI 10.1074/jbc.M000209200
   Undas A, 2007, J THROMB HAEMOST, V5, P1988, DOI 10.1111/j.1538-7836.2007.02637.x
   Undas A, 2006, J THROMB HAEMOST, V4, P1029, DOI 10.1111/j.1538-7836.2006.01882.x
   Undas A, 2006, J THROMB HAEMOST, V4, P973, DOI 10.1111/j.1538-7836.2006.01903.x
   Undas A, 2003, CIRCULATION, V107, P17, DOI 10.1161/01.CIR.0000047062.03282.A3
   Undas A, 2006, ARTERIOSCL THROM VAS, V26, P1397, DOI 10.1161/01.ATV.0000219688.43572.75
   Virgili G, 2007, COCHRANE DB SYST REV, V3
   Waisbourd M, 2007, DRUG AGING, V24, P643, DOI 10.2165/00002512-200724080-00003
   Warner D, 2001, THROMB HAEMOSTASIS, V85, P408
   Wartiovaara U, 1999, ATHEROSCLEROSIS, V142, P295, DOI 10.1016/S0021-9150(98)00241-X
   Wegscheider BJ, 2007, OPHTHALMOLOGY, V114, P738, DOI 10.1016/j.ophtha.2006.07.048
   Wickens J, 2006, DRUG SAFETY, V29, P189, DOI 10.2165/00002018-200629030-00003
   Wolberg AS, 2007, BLOOD REV, V21, P131, DOI 10.1016/j.blre.2006.11.001
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
   Wright C, 2008, ANN NY ACAD SCI, V1141, P284, DOI 10.1196/annals.1441.026
   Xu YL, 2008, MOL VIS, V14, P1373
   Yang N, 2006, EYE, V20, P523, DOI 10.1038/sj.eye.6701991
   Ye Z, 2006, LANCET, V367, P651, DOI 10.1016/S0140-6736(06)68263-9
   Yip PP, 2009, BRIT J OPHTHALMOL, V93, P754, DOI 10.1136/bjo.2008.150987
   Zuluaga MF, 2007, INVEST OPHTH VIS SCI, V48, P1767, DOI 10.1167/iovs.06-1224
   2005, RETINA, V25, P119
NR 178
TC 11
Z9 11
U1 0
U2 6
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y26, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1389-4501
J9 CURR DRUG TARGETS
JI Curr. Drug Targets
PD FEB
PY 2011
VL 12
IS 2
BP 138
EP 148
DI 10.2174/138945011794182773
PG 11
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA 720RX
UT WOS:000287299000002
PM 20887247
OA Green Published
DA 2022-11-30
ER

PT J
AU Lakshminarayana, R
   Raju, M
   Krishnakantha, TP
   Baskaran, V
AF Lakshminarayana, Rangaswamy
   Raju, Marisiddaiah
   Krishnakantha, Thirumalai Parthasarathy
   Baskaran, Vallikannan
TI Lutein and zeaxanthin in leafy greens and their bioavailability: Olive
   oil influences the absorption of dietary lutein and its accumulation in
   adult rats
SO JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY
LA English
DT Article
DE lutein; leafy greens; bioavailability; carotenoids
ID PERFORMANCE LIQUID-CHROMATOGRAPHY; BETA-CAROTENE ABSORPTION;
   INTESTINAL-ABSORPTION; MASS-SPECTROMETRY; VEGETABLES; SERUM; INDIA;
   ACID; PHOSPHOLIPIDS; EMULSIONS
AB This study determined the lutein level in various green leafy vegetables (GLVs) and the influence of olive and sunflower oils on the postprandial plasma and eye response of dietary lutein in adult rats, previously induced with lutein depletion (LD). Fresh GLVs (n = 35) were assessed for lutein (L) and its isomer zeaxanthin (Z) levels by high-performance liquid chromatography and liquid chromatography-mass spectrometry. Among GLVs analyzed, Commelina benghalensis L. contained a higher level of L + Z (183 mg/100 g dry wt) and was used as a lutein source for feeding studies. Rats with LD were fed a diet containing powdered C. benghalensis (2.69 mg lutein/kg diet) with either olive oil (OO group), sunflower oil (SFO group), or groundnut oil (GNO group) for 16 days. The L + Z levels of the OO group were markedly (p > 0.05) higher than those of SFO and GNO groups, in plasma (37.6 and 40.9%) and eyes (22.7 and 30.8%), respectively. These results suggest that oleic acid or OO can be used as a suitable fat source to modulate the absorption of dietary lutein to manage age-related macular degeneration.
C1 Cent Food Technol Res Inst, Dept Biochem, Mysore 570020, Karnataka, India.
C3 Council of Scientific & Industrial Research (CSIR) - India; CSIR -
   Central Food Technological Research Institute (CFTRI)
RP Baskaran, V (通讯作者)，Cent Food Technol Res Inst, Dept Biochem, Mysore 570020, Karnataka, India.
EM basrev@yahoo.co.in
RI Lakshminarayana, Rangaswamy/AAC-5824-2019; VALLIKANNAN,
   BASKARAN/G-1120-2010
CR Ahuja KDK, 2006, NUTRITION, V22, P259, DOI 10.1016/j.nut.2005.07.015
   Baskaran V, 2003, LIPIDS, V38, P705, DOI 10.1007/s11745-003-1118-5
   Borel P, 1996, J LIPID RES, V37, P250
   Breithaupt DE, 2002, J AGR FOOD CHEM, V50, P66, DOI 10.1021/jf010970l
   CHEN BH, 1992, FOOD CHEM, V45, P129, DOI 10.1016/0308-8146(92)90023-U
   Clark RM, 2000, LIPIDS, V35, P803, DOI 10.1007/s11745-000-0589-8
   Gartner C, 1996, INT J VITAM NUTR RES, V66, P119
   GRANADO F, 1992, J AGR FOOD CHEM, V40, P2135, DOI 10.1021/jf00023a019
   Grover JK, 2002, J ETHNOPHARMACOL, V81, P81, DOI 10.1016/S0378-8741(02)00059-4
   Grover JK, 2001, ASIA PACIFIC BIOTECH, V8, P28, DOI DOI 10.1142/S0219030301001811
   HANDELMAN GJ, 1988, INVEST OPHTH VIS SCI, V29, P850
   Handelman GJ, 1999, AM J CLIN NUTR, V70, P247
   HART DJ, 1995, FOOD CHEM, V54, P101, DOI 10.1016/0308-8146(95)92669-B
   HEINONEN MI, 1990, J AGR FOOD CHEM, V38, P609, DOI 10.1021/jf00093a005
   Hollander D., 1978, AM J PHYSIOL, V235, P686
   Ismail Amin, 2003, Malays J Nutr, V9, P31
   Jackson KG, 2002, AM J CLIN NUTR, V76, P942, DOI 10.1093/ajcn/76.5.942
   JACQUES PF, 1991, AM J CLIN NUTR, V53, P352
   KOSTIC D, 1995, AM J CLIN NUTR, V62, P604, DOI 10.1093/ajcn/62.3.604
   Krinsky NI, 2003, ANNU REV NUTR, V23, P171, DOI 10.1146/annurev.nutr.23.011702.073307
   Lakshminarayana R, 2006, MOL CELL BIOCHEM, V281, P103, DOI 10.1007/s11010-006-1337-3
   Lakshminarayana R, 2005, J AGR FOOD CHEM, V53, P2838, DOI 10.1021/jf0481711
   Landrum JT, 1997, EXP EYE RES, V65, P57, DOI 10.1006/exer.1997.0309
   Mares-Perlman JA, 2001, AM J EPIDEMIOL, V153, P424, DOI 10.1093/aje/153.5.424
   MERCADANTE AZ, 1991, J AGR FOOD CHEM, V39, P1094, DOI 10.1021/jf00006a018
   Morrison M.R., 1964, J LIPID RES, V5, P600
   Nambiar VS, 1998, J FOOD SCI TECH MYS, V35, P365
   O'Neill ME, 2001, BRIT J NUTR, V85, P499, DOI 10.1079/BJN2000284
   Rahman MH, 2000, NUTR METAB CARDIOVAS, V10, P121
   Raju M, 2006, MOL CELL BIOCHEM, V288, P7, DOI 10.1007/s11010-005-9091-5
   Raju M, 2005, J NUTR SCI VITAMINOL, V51, P216, DOI 10.3177/jnsv.51.216
   Rajyalakshmi P, 2001, PLANT FOOD HUM NUTR, V56, P225, DOI 10.1023/A:1011125232097
   Singh G, 2001, PLANT FOOD HUM NUTR, V56, P359, DOI 10.1023/A:1011873119620
   Unlu NZ, 2005, J NUTR, V135, P431, DOI 10.1093/jn/135.3.431
   VANVLIET T, 1995, AM J CLIN NUTR, V62, P110, DOI 10.1093/ajcn/62.1.110
   West C. E., 1993, CAROTENOID CONTENT F
   Wingerath T, 1996, J AGR FOOD CHEM, V44, P2006, DOI 10.1021/jf960057y
   1977, J NUTR, V170, P1340
NR 38
TC 39
Z9 40
U1 2
U2 28
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0021-8561
EI 1520-5118
J9 J AGR FOOD CHEM
JI J. Agric. Food Chem.
PD JUL 26
PY 2007
VL 55
IS 15
BP 6395
EP 6400
DI 10.1021/jf070482z
PG 6
WC Agriculture, Multidisciplinary; Chemistry, Applied; Food Science &
   Technology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Agriculture; Chemistry; Food Science & Technology
GA 190UE
UT WOS:000248085300070
PM 17602649
DA 2022-11-30
ER

PT J
AU Deng, YH
   Ge, XF
   Li, Y
   Zou, B
   Wen, XF
   Chen, WR
   Lu, L
   Zhang, MF
   Zhang, XM
   Li, CM
   Zhao, C
   Lin, XF
   Zhang, XL
   Huang, XH
   Li, XR
   Jin, M
   Peng, GH
   Wang, DN
   Wang, X
   Lai, WY
   Liang, JR
   Li, JJ
   Liang, QX
   Yang, L
   Zhang, QF
   Li, YY
   Lu, P
   Hu, X
   Li, XF
   Deng, XL
   Liu, Y
   Zou, YL
   Guo, SX
   Chen, TT
   Qin, YL
   Yang, FH
   Miao, L
   Chen, W
   Chan, CC
   Lin, HT
   Liu, YZ
   Lee, RWJ
   Wei, L
AF Deng, Yuhua
   Ge, Xiaofei
   Li, Yan
   Zou, Bin
   Wen, Xiaofeng
   Chen, Weirong
   Lu, Lin
   Zhang, Meifen
   Zhang, Xiaomin
   Li, Chunmei
   Zhao, Chan
   Lin, Xiaofeng
   Zhang, Xiulan
   Huang, Xinhua
   Li, Xiaorong
   Jin, Ming
   Peng, Guang-Hua
   Wang, Dongni
   Wang, Xun
   Lai, Weiyi
   Liang, Juanran
   Li, Jing Jing
   Liang, Qiaoxing
   Yang, Liu
   Zhang, Qinfen
   Li, Yinyin
   Lu, Ping
   Hu, Xiao
   Li, Xifang
   Deng, Xiuli
   Liu, Yu
   Zou, Yanli
   Guo, Shixin
   Chen, Tingting
   Qin, Yali
   Yang, Fuhua
   Miao, Li
   Chen, Wei
   Chan, Chi-Chao
   Lin, Haotian
   Liu, Yizhi
   Lee, Richard W. J.
   Wei, Lai
TI Identification of an intraocular microbiota
SO CELL DISCOVERY
LA English
DT Article
AB The current dogma in ophthalmology and vision research presumes the intraocular environment to be sterile. However, recent evidence of intestinal bacterial translocation into the bloodstream and many other internal organs including the eyes, found in healthy and diseased animal models, suggests that the intraocular cavity may also be inhabited by a microbial community. Here, we tested intraocular samples from over 1000 human eyes. Using quantitative PCR, negative staining transmission electron microscopy, direct culture, and high-throughput sequencing technologies, we demonstrated the presence of intraocular bacteria. The possibility that the microbiome from these low-biomass communities could be a contamination from other tissues and reagents was carefully evaluated and excluded. We also provide preliminary evidence that a disease-specific microbial signature characterized the intraocular environment of patients with age-related macular degeneration and glaucoma, suggesting that either spontaneous or pathogenic bacterial translocation may be associated with these common sight-threatening conditions. Furthermore, we revealed the presence of an intraocular microbiome in normal eyes from non-human mammals and demonstrated that this varied across species (rat, rabbit, pig, and macaque) and was established after birth. These findings represent the first-ever evidence of intraocular microbiota in humans.
C1 [Deng, Yuhua; Ge, Xiaofei; Li, Yan; Zou, Bin; Wen, Xiaofeng; Chen, Weirong; Lu, Lin; Li, Chunmei; Lin, Xiaofeng; Zhang, Xiulan; Huang, Xinhua; Wang, Dongni; Wang, Xun; Lai, Weiyi; Liang, Juanran; Li, Jing Jing; Liang, Qiaoxing; Yang, Liu; Hu, Xiao; Li, Xifang; Deng, Xiuli; Liu, Yu; Zou, Yanli; Guo, Shixin; Chen, Tingting; Qin, Yali; Miao, Li; Chan, Chi-Chao; Lin, Haotian; Liu, Yizhi; Wei, Lai] Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, State Key Lab Ophthalmol, Guangzhou 510060, Guangdong, Peoples R China.
   [Zhang, Meifen; Zhao, Chan] Chinese Acad Med Sci, Peking Union Med Coll Hosp, Dept Ophthalmol, Beijing 100730, Peoples R China.
   [Zhang, Xiaomin; Li, Xiaorong; Yang, Fuhua] Tianjin Med Univ, Eye Hosp, Eye Inst, Tianjin 300384, Peoples R China.
   [Zhang, Xiaomin; Li, Xiaorong; Yang, Fuhua] Sch Optometry & Ophthalmol, Tianjin 300384, Peoples R China.
   [Jin, Ming] China Japan Friendship Hosp, Dept Ophthalmol, Beijing 100029, Peoples R China.
   [Peng, Guang-Hua] Zhengzhou Univ, Basic Med Coll, Dept Pathophysiol, Zhengzhou 450001, Henan, Peoples R China.
   [Peng, Guang-Hua] Gen Hosp Chinese Peoples Liberat Army, Dept Ophthalmol, Beijing 100853, Peoples R China.
   [Zhang, Qinfen; Li, Yinyin; Lu, Ping] Sun Yat Sen Univ, Sch Life Sci, Inst Aquat Econ Anim, State Key Lab Biocontrol,MOE Key Lab Aquat Prod S, Guangzhou 510275, Guangdong, Peoples R China.
   [Zhang, Qinfen; Li, Yinyin; Lu, Ping] Sun Yat Sen Univ, Sch Life Sci, Guangdong Prov Key Lab Aquat Econ Anim, Guangzhou 510275, Guangdong, Peoples R China.
   [Chen, Wei] Univ Pittsburgh, Dept Biostat, Pittsburgh, PA 15261 USA.
   [Chen, Wei] UPMC, Childrens Hosp Pittsburgh, Dept Pediat, Div Pulm Med Allergy & Immunol, Pittsburgh, PA 15224 USA.
   [Lee, Richard W. J.] Univ Bristol, Translat Hlth Sci, Bristol, Avon, England.
   [Lee, Richard W. J.] Moorfields Eye Hosp NHS Fdn Trust, Biomed Res Ctr, Natl Inst Hlth Res, London, England.
   [Lee, Richard W. J.] UCL Inst Ophthalmol, London, England.
C3 Sun Yat Sen University; Chinese Academy of Medical Sciences - Peking
   Union Medical College; Peking Union Medical College Hospital; Tianjin
   Medical University; China-Japan Friendship Hospital; Zhengzhou
   University; Sun Yat Sen University; Sun Yat Sen University; Pennsylvania
   Commonwealth System of Higher Education (PCSHE); University of
   Pittsburgh; Pennsylvania Commonwealth System of Higher Education
   (PCSHE); University of Pittsburgh; University of Bristol; University of
   London; University College London; Moorfields Eye Hospital NHS
   Foundation Trust; University of London; University College London
RP Liu, YZ; Wei, L (通讯作者)，Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, State Key Lab Ophthalmol, Guangzhou 510060, Guangdong, Peoples R China.; Lee, RWJ (通讯作者)，Univ Bristol, Translat Hlth Sci, Bristol, Avon, England.; Lee, RWJ (通讯作者)，Moorfields Eye Hosp NHS Fdn Trust, Biomed Res Ctr, Natl Inst Hlth Res, London, England.; Lee, RWJ (通讯作者)，UCL Inst Ophthalmol, London, England.
EM yzliu62@yahoo.com; richard.lee16@nhs.net; weil9@mail.sysu.edu.cn
RI liu, yi/GXE-9662-2022; Chen, Wei/GZK-7348-2022
OI Zhang, Xiaomin/0000-0003-4898-4152; Hu, Xiao/0000-0001-7589-2769; Lee,
   Richard/0000-0002-9480-6843
FU National Basic Research Program of China [2015CB964601]; Li Foundation
   Heritage Prize; National Natural Science Foundation of China [81530028,
   81570828, 81721003]; Guangdong Province Science & Technology Plan
   [2014B020228002]; National Key Basic Research [2015CB964600]; 973
   Development Program of China [2015CB964600]; Local Innovative and
   Research Teams Project of Guangdong Pearl River Talents Program,
   Clinical Innovation Research Program of Guangzhou Regenerative Medicine
   and Health Guangdong Laboratory [2018GZR0201001]
FX This work was supported by the National Basic Research Program of China
   (2015CB964601), the Li Foundation Heritage Prize, the National Natural
   Science Foundation of China (81570828 to L.W.), and by the National
   Natural Science Foundation of China (81530028; 81721003), the Guangdong
   Province Science & Technology Plan (2014B020228002), the National Key
   Basic Research and 973 Development Program of China (2015CB964600), and
   Local Innovative and Research Teams Project of Guangdong Pearl River
   Talents Program, Clinical Innovation Research Program of Guangzhou
   Regenerative Medicine and Health Guangdong Laboratory (2018GZR0201001 to
   Yizhi L.).
CR Aagaard K, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3008599
   Abubucker S, 2012, PLOS COMPUT BIOL, V8, DOI 10.1371/journal.pcbi.1002358
   Asouith M, 2018, ANN RHEUM DIS, V77, P618, DOI 10.1136/annrheumdis-2018-eular.7487
   Aykut B, 2019, NATURE, V574, P264, DOI 10.1038/s41586-019-1608-2
   Berthelot JM, 2020, JOINT BONE SPINE, V87, P31, DOI 10.1016/j.jbspin.2019.01.004
   Berthelot JM, 2015, JOINT BONE SPINE, V82, P8, DOI 10.1016/j.jbspin.2014.07.011
   Blumberg J, 2010, J CLIN INVEST, V120, P3054, DOI 10.1172/JCI42161
   Clifford RJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048558
   Davis NM, 2018, MICROBIOME, V6, DOI 10.1186/s40168-018-0605-2
   de Goffau MC, 2019, NATURE, V572, P329, DOI 10.1038/s41586-019-1451-5
   de Goffau MC, 2018, NAT MICROBIOL, V3, P851, DOI 10.1038/s41564-018-0202-y
   Eisenhofer R, 2019, TRENDS MICROBIOL, V27, P105, DOI 10.1016/j.tim.2018.11.003
   Fine RL, 2020, GUT MICROBES, V11, P217, DOI 10.1080/19490976.2019.1629236
   Franzosa EA, 2015, NAT REV MICROBIOL, V13, P360, DOI 10.1038/nrmicro3451
   Kell Douglas, 2015, F1000Res, V4, P179, DOI 10.12688/f1000research.6709.2
   Kim D, 2015, NAT METHODS, V12, P357, DOI [10.1038/NMETH.3317, 10.1038/nmeth.3317]
   Kugadas A, 2016, OCUL SURF, V14, P342, DOI 10.1016/j.jtos.2016.04.004
   Minich JJ, 2019, MSYSTEMS, V4, DOI 10.1128/mSystems.00186-19
   Nagpal Ravinder, 2018, Nutr Healthy Aging, V4, P267, DOI 10.3233/NHA-170030
   Nejman D, 2020, SCIENCE, V368, P973, DOI 10.1126/science.aay9189
   O'Keeffe KM, 2015, INFECT IMMUN, V83, P3445, DOI 10.1128/IAI.00358-15
   Oh J, 2014, NATURE, V514, P59, DOI 10.1038/nature13786
   Ottman N, 2012, FRONT CELL INFECT MI, V2, DOI 10.3389/fcimb.2012.00104
   Perez VL, 2015, TRENDS IMMUNOL, V36, P354, DOI 10.1016/j.it.2015.04.003
   Poore GD, 2020, NATURE, V579, P567, DOI 10.1038/s41586-020-2095-1
   Rooks MG, 2016, NAT REV IMMUNOL, V16, P341, DOI 10.1038/nri.2016.42
   Schmieder R, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017288
   Schmieder R, 2011, BIOINFORMATICS, V27, P863, DOI 10.1093/bioinformatics/btr026
   Segata N, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-6-r60
   St Leger AJ, 2017, IMMUNITY, V47, P148, DOI 10.1016/j.immuni.2017.06.014
   Vieira SM, 2018, SCIENCE, V359, P1156, DOI 10.1126/science.aar7201
   Wen XF, 2018, PROG RETIN EYE RES, V64, P84, DOI 10.1016/j.preteyeres.2018.01.001
   Wood DE, 2014, GENOME BIOL, V15, DOI 10.1186/gb-2014-15-3-r46
NR 33
TC 8
Z9 8
U1 6
U2 12
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
EI 2056-5968
J9 CELL DISCOV
JI Cell Discov.
PD MAR 9
PY 2021
VL 7
IS 1
AR 13
DI 10.1038/s41421-021-00245-6
PG 12
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA QT9YZ
UT WOS:000626943900001
PM 33750767
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Samardzija, M
   Barben, M
   Todorova, V
   Klee, K
   Storti, F
   Grimm, C
AF Samardzija, Marijana
   Barben, Maya
   Todorova, Vyara
   Klee, Katrin
   Storti, Federica
   Grimm, Christian
TI Hif1a and Hif2a can be safely inactivated in cone photoreceptors
SO SCIENTIFIC REPORTS
LA English
DT Article
ID HYPOXIA-INDUCIBLE FACTOR-1-ALPHA; RETINAL-PIGMENT EPITHELIUM; OXYGEN
   DISTRIBUTION; HIF-1-ALPHA; DEGENERATION; MECHANISMS; PROTECTS; DELETION;
   CELLS; HIF-1
AB Impaired tissue oxygenation results in hypoxia and leads to the activation of hypoxia-inducible transcription factors (HIF). A chronic, HIF-triggered molecular response to hypoxia may be an important factor in the etiology of age-related macular degeneration (AMD) and is likely activated before any clinical manifestation of the disease. Thus, HIF1 and HIF2 recently emerged as potential therapeutic targets for AMD. To address and evaluate potential consequences of anti-HIF therapies for retinal physiology and function, we generated mouse lines that have Hif1a, or both Hif1a and Hif2a ablated specifically in cone photoreceptors. The knockdown of Hifs in cones did not cause detectable pathological alterations such as loss of cone photoreceptors, retinal degeneration or abnormalities of the retinal vasculature, had no impact on retinal function and resulted in a similar tolerance to hypoxic exposure. Our data indicate that HIF transcription factors are dispensable for maintaining normal cone function and survival in retinas of adult mice. This study provides the groundwork necessary to establish safety profiles for strategies aiming at antagonizing HIF1A and HIF2A function in cone photoreceptors for the treatment of retinal degenerative diseases that involve a hypoxic component such as AMD.
C1 [Samardzija, Marijana; Barben, Maya; Todorova, Vyara; Klee, Katrin; Storti, Federica; Grimm, Christian] Univ Zurich, Dept Ophthalmol, Lab Retinal Cell Biol, CH-8952 Schlieren, Switzerland.
   [Grimm, Christian] Univ Zurich, Ctr Integrat Human Physiol ZIHP, CH-8006 Zurich, Switzerland.
   [Grimm, Christian] Univ Zurich, Neurosci Ctr Zurich, CH-8006 Zurich, Switzerland.
C3 University of Zurich; Zurich Center Integrative Human Physiology (ZIHP);
   University of Zurich
RP Samardzija, M (通讯作者)，Univ Zurich, Dept Ophthalmol, Lab Retinal Cell Biol, CH-8952 Schlieren, Switzerland.
EM marijana.samardzija@usz.uzh.ch
RI Samardzija, Marijana/B-9245-2008
OI Samardzija, Marijana/0000-0003-0991-4653; Todorova,
   Vyara/0000-0002-3120-110X; Grimm, Christian/0000-0001-9318-4352
FU Swiss National Science Foundation [31003A_173008]
FX We thank Coni Imsand, Sarah Notzli, Andrea Gubler, and Adrian Urwyler
   for their excellent technical assistance. This work was supported by the
   Swiss National Science Foundation (31003A_173008).
CR Akimoto M, 2004, INVEST OPHTH VIS SCI, V45, P42, DOI 10.1167/iovs.03-0804
   Arjamaa O, 2009, AGEING RES REV, V8, P349, DOI 10.1016/j.arr.2009.06.002
   Arya M, 2018, EYE VISION, V5, DOI 10.1186/s40662-018-0118-x
   Barben M., 2018, CELL DEATH DIFFER
   Barben M, 2018, MOL NEURODEGENER, V13, DOI 10.1186/s13024-018-0243-y
   Blasiak J, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/768026
   Caprara C, 2011, INVEST OPHTH VIS SCI, V52, P2109, DOI 10.1167/iovs.10-6222
   Chan DA, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002394
   Cramer T, 2003, CELL, V112, P645, DOI 10.1016/S0092-8674(03)00154-5
   Del Rey MJ, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-03921-4
   Dengler VL, 2014, CRIT REV BIOCHEM MOL, V49, P1, DOI 10.3109/10409238.2013.838205
   Grimm C, 2002, NAT MED, V8, P718, DOI 10.1038/nm723
   Gruber M, 2007, P NATL ACAD SCI USA, V104, P2301, DOI 10.1073/pnas.0608382104
   Grunwald JE, 2005, INVEST OPHTH VIS SCI, V46, P1033, DOI 10.1167/iovs.04-1050
   Heynen SR, 2011, MOL VIS, V17, P2934
   Huang Y, 2004, FASEB J, V18, P1138, DOI 10.1096/fj.04-1510fje
   Iyer NV, 1998, GENE DEV, V12, P149, DOI 10.1101/gad.12.2.149
   Jacobs GH, 2007, DOC OPHTHALMOL, V115, P137, DOI 10.1007/s10633-007-9055-z
   Kaelin WG, 2008, MOL CELL, V30, P393, DOI 10.1016/j.molcel.2008.04.009
   Kast B, 2016, EXP EYE RES, V146, P60, DOI 10.1016/j.exer.2015.12.008
   Keith B, 2012, NAT REV CANCER, V12, P9, DOI 10.1038/nrc3183
   Koh MY, 2012, TRENDS BIOCHEM SCI, V37, P364, DOI 10.1016/j.tibs.2012.06.004
   Kurihara T, 2016, ELIFE, V5, DOI 10.7554/eLife.14319
   Kurihara T, 2012, J CLIN INVEST, V122, P4213, DOI 10.1172/JCI65157
   Lange C, 2011, INVEST OPHTH VIS SCI, V52, P5872, DOI 10.1167/iovs.11-7204
   Lin MK, 2012, INVEST OPHTH VIS SCI, V53, P6197, DOI 10.1167/iovs.11-8936
   LINSENMEIER RA, 1992, J GEN PHYSIOL, V99, P177, DOI 10.1085/jgp.99.2.177
   Linsenmeier RA, 2000, INVEST OPHTH VIS SCI, V41, P3117
   Madisen L, 2010, NAT NEUROSCI, V13, P133, DOI 10.1038/nn.2467
   Magistretti PJ, 1996, ANN NY ACAD SCI, V777, P380, DOI 10.1111/j.1749-6632.1996.tb34449.x
   McHugh KJ, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0216215
   Mears AJ, 2001, NAT GENET, V29, P447, DOI 10.1038/ng774
   Okawa H, 2008, CURR BIOL, V18, P1917, DOI 10.1016/j.cub.2008.10.029
   Provot S, 2007, J CELL BIOL, V177, P451, DOI 10.1083/jcb.200612023
   Roberts PA, 2016, PROG RETIN EYE RES, V53, P48, DOI 10.1016/j.preteyeres.2016.04.001
   Roberts PA, 2016, J MATH BIOL, V73, P1, DOI 10.1007/s00285-015-0931-y
   Rudolf M, 2013, OPHTHALMOLOGY, V120, P821, DOI 10.1016/j.ophtha.2012.10.007
   Ryan HE, 2000, CANCER RES, V60, P4010
   Ryan HE, 1998, EMBO J, V17, P3005, DOI 10.1093/emboj/17.11.3005
   Samardzija M, 2008, HUM MOL GENET, V17, P281, DOI 10.1093/hmg/ddm304
   Samardzija M, 2014, INVEST OPHTH VIS SCI, V55, P5304, DOI 10.1167/iovs.14-14789
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   Schlingemann RO, 2004, GRAEF ARCH CLIN EXP, V242, P91, DOI 10.1007/s00417-003-0828-0
   Semenza GL, 2001, CURR OPIN CELL BIOL, V13, P167, DOI 10.1016/S0955-0674(00)00194-0
   Semenza GL, 2014, ANNU REV PATHOL-MECH, V9, P47, DOI 10.1146/annurev-pathol-012513-104720
   Semenza GL, 2013, J CLIN INVEST, V123, P3664, DOI 10.1172/JCI67230
   Sundermeier TR, 2017, J BIOL CHEM, V292, P3366, DOI 10.1074/jbc.M116.770024
   Thiersch M, 2009, EUR J NEUROSCI, V29, P2291, DOI 10.1111/j.1460-9568.2009.06781.x
   Thiersch M, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-73
   Vukovic M, 2016, BLOOD, V127, P2841, DOI 10.1182/blood-2015-10-677138
   Weidemann A, 2008, CELL DEATH DIFFER, V15, P621, DOI 10.1038/cdd.2008.12
   Yu DY, 2005, EXP EYE RES, V80, P745, DOI 10.1016/j.exer.2005.01.018
   Zhao J, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2014.565
NR 53
TC 6
Z9 6
U1 0
U2 2
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD NOV 6
PY 2019
VL 9
AR 16121
DI 10.1038/s41598-019-52508-8
PG 14
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA JK1VZ
UT WOS:000494636500010
PM 31695081
OA Green Published, gold, Green Accepted
DA 2022-11-30
ER

PT J
AU Scuderi, L
   Davinelli, S
   Iodice, CM
   Bartollino, S
   Scapagnini, G
   Costagliola, C
   Scuderi, G
AF Scuderi, Luca
   Davinelli, Sergio
   Iodice, Clemente Maria
   Bartollino, Silvia
   Scapagnini, Giovanni
   Costagliola, Ciro
   Scuderi, Gianluca
TI Melatonin: Implications for Ocular Disease and Therapeutic Potential
SO CURRENT PHARMACEUTICAL DESIGN
LA English
DT Review
DE Melatonin; aging; aged-related ocular diseases; uveitis; cataract;
   glaucoma; age-related macular degeneration; diabetic retinopathy
ID ENDOTOXIN-INDUCED UVEITIS; OXIDATIVE STRESS; CIRCADIAN CLOCK;
   ANTIOXIDATIVE PROTECTION; INTRAOCULAR-PRESSURE; DIABETIC-RETINOPATHY;
   AQUEOUS-HUMOR; EXPRESSION; RETINA; CELLS
AB Melatonin, an indoleamine secreted mainly by the pineal gland, is known to modulate a wide range of circadian functions. However, this neurohormone is also synthesized within the eye and acts directly on ocular structures to mediate a variety of physiological processes. This review is focused on the role and therapeutic potential of melatonin in ocular diseases. We summarize data indicating that melatonin may represent a powerful tool to counteract ocular dysfunctions such as uveitis, glaucoma, age-related macular degeneration, and diabetic retinopathy. A search strategy was conducted to identify studies in PubMed (January 1990 to September 2017). In particular, we included experimental studies, clinical trials, and reviews to provide suitable insights and elucidations regarding the action of melatonin on age-related ocular disorders. Literature data suggest that melatonin could potentially protect ocular tissues by decreasing the production of free radicals and pro-inflammatory mediators. Additionally, melatonin appears to be safe and well-tolerated, even at high doses, and no adverse/side effects were reported. Although this topic remains under intense investigation, we can conclude that melatonin, as a single agent or in combination with other drugs, is an attractive pharmacological candidate for age-related ocular diseases.
C1 [Scuderi, Luca; Iodice, Clemente Maria; Scuderi, Gianluca] Univ Roma La Sapienza, Fac Med & Psychol, Neurosci Mental Hlth & Sense Organs Dept, Rome, Italy.
   [Davinelli, Sergio; Bartollino, Silvia; Scapagnini, Giovanni; Costagliola, Ciro] Univ Molise, Dept Med & Hlth Sci V Tiberio, Via Francesco De Sanctis 1, I-86100 Campobasso, Italy.
C3 Sapienza University Rome; University of Molise
RP Davinelli, S (通讯作者)，Univ Molise, Dept Med & Hlth Sci V Tiberio, Via Francesco De Sanctis 1, I-86100 Campobasso, Italy.
EM sergio.davinelli@unimol.it
RI Iodice, Clemente M./GLU-4013-2022; Bartollino, Silvia/M-6271-2019;
   Davinelli, Sergio/U-1545-2017; Costagliola, Ciro/G-5707-2012
OI Iodice, Clemente M./0000-0003-1688-6646; Bartollino,
   Silvia/0000-0001-7105-6392; Davinelli, Sergio/0000-0003-2578-7199;
   Scuderi, Gianluca/0000-0003-0744-0722; Costagliola,
   Ciro/0000-0001-8477-6188
FU Polifarma SpA
FX The authors would like to express their appreciation and gratitude to
   the Polifarma SpA for intellectual assistance and financial support.
CR Acuna-Castroviejo D, 2014, CELL MOL LIFE SCI, V71, P2997, DOI 10.1007/s00018-014-1579-2
   Alcantara-Contreras S, 2011, NEUROSCI LETT, V494, P61, DOI 10.1016/j.neulet.2011.02.056
   Alkozi H, 2017, ACTA OPHTHALMOL, V95, pE185, DOI 10.1111/aos.13253
   Aranda ML, 2017, CURR NEUROPHARMACOL, V15, P951, DOI 10.2174/1570159X15666170113122120
   Alkozi HA, 2015, EXP EYE RES, V136, P34, DOI 10.1016/j.exer.2015.04.019
   Ayoub MA, 2004, MOL PHARMACOL, V66, P312, DOI 10.1124/mol.104.000398
   Baba K, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004302
   Baba K, 2009, P NATL ACAD SCI USA, V106, P15043, DOI 10.1073/pnas.0904400106
   Bandello F, 2010, DEV OPHTHALMOL, V47, P73, DOI 10.1159/000320075
   Bek T, 2017, MITOCHONDRION, V36, P4, DOI 10.1016/j.mito.2016.07.011
   Bellot JL, 1996, INFLAMM RES, V45, P203, DOI 10.1007/BF02285162
   Blasiak J, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/6819736
   Bondy SC, 2007, NEUROCHEM INT, V50, P571, DOI 10.1016/j.neuint.2006.12.014
   Buffa A., 1993, Bollettino Societa Italiana Biologia Sperimentale, V69, P767
   CAHILL GM, 1993, NEURON, V10, P573, DOI 10.1016/0896-6273(93)90160-S
   Cai J, 2002, EYE, V16, P242, DOI 10.1038/sj.eye.6700133
   Campagne MV, 2014, J PATHOL, V232, P151, DOI 10.1002/path.4266
   Cheung CMG, 2019, EYE, V33, P14, DOI 10.1038/s41433-018-0158-4
   Ciuffi M, 2003, J PHOTOCH PHOTOBIO B, V71, P59, DOI 10.1016/j.jphotobiol.2003.07.004
   Civan MM, 2004, EXP EYE RES, V78, P625, DOI 10.1016/j.exer.2003.09.021
   Civan MM, 1998, CURR TOP MEMBR, V45, P1
   Cohen LP, 2014, COLD SPRING HARB PER, V4
   Crooke A, 2012, CURR MED CHEM, V19, P3508, DOI 10.2174/092986712801323234
   Crooke A, 2015, CURR EYE RES, V40, P56, DOI 10.3109/02713683.2014.914540
   Crooke A, 2012, EXPERT OPIN DRUG DIS, V7, P989, DOI 10.1517/17460441.2012.714769
   Cunea A, 2007, VISUAL NEUROSCI, V24, P151, DOI 10.1017/S0952523807070204
   CURCIO CA, 1993, INVEST OPHTH VIS SCI, V34, P3278
   Davinelli S, 2014, J NUTR HEALTH AGING, V18, P800, DOI [10.1007/s12603-014-0552-y, 10.1007/s12603-014-0520-6]
   Davinelli S, 2018, J NUTR BIOCHEM, V61, P33, DOI 10.1016/j.jnutbio.2018.07.011
   Davinelli S, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/2825703
   Davinelli S, 2016, HIGH BLOOD PRESS CAR, V23, P197, DOI 10.1007/s40292-016-0149-0
   Davinelli S, 2016, IMMUN AGEING, V13, DOI 10.1186/s12979-016-0070-3
   Davinelli S, 2015, J AM COLL NUTR, V34, P28, DOI 10.1080/07315724.2015.1080108
   DEVOS AF, 1994, INVEST OPHTH VIS SCI, V35, P3873
   Djordjevic B, 2018, EUR J PHARMACOL, V833, P290, DOI 10.1016/j.ejphar.2018.06.011
   Doganlar ZB, 2019, CURR EYE RES, V44, P1157, DOI 10.1080/02713683.2019.1619778
   DOUGHTY MJ, 1990, AM J ANAT, V189, P316, DOI 10.1002/aja.1001890404
   Feher J, 2018, INT J IMMUNOPATH PH, V31, DOI 10.1177/0394632017748841
   Fischer TW, 2013, J PINEAL RES, V54, P303, DOI 10.1111/jpi.12018
   Fukuhara C, 2004, J NEUROSCI, V24, P1803, DOI 10.1523/JNEUROSCI.4988-03.2004
   Fukuhara C, 2001, NEUROREPORT, V12, P3833, DOI 10.1097/00001756-200112040-00046
   Gianesini C, 2016, INVEST OPHTH VIS SCI, V57, P94, DOI 10.1167/iovs.15-18235
   Gramajo AL, 2015, EYE, V29, P1037, DOI 10.1038/eye.2015.104
   HARDELAND R, 1993, NEUROSCI BIOBEHAV R, V17, P347, DOI 10.1016/S0149-7634(05)80016-8
   Hardeland R, 2005, ENDOCRINE, V27, P119, DOI 10.1385/ENDO:27:2:119
   Hesselink JMK, 2016, DRUG DES DEV THER, V10, P3133, DOI 10.2147/DDDT.S112389
   Sande PH, 2008, AM J PATHOL, V173, P1702, DOI 10.2353/ajpath.2008.080518
   Huete-Toral F, 2015, J PHARMACOL EXP THER, V352, P119, DOI 10.1124/jpet.114.218263
   Ismail SA, 2009, ANESTH ANALG, V108, P1146, DOI 10.1213/ane.0b013e3181907ebe
   Jahanban-Esfahlan R, 2018, BRIT J PHARMACOL, V175, P3230, DOI 10.1111/bph.13898
   Jan JE, 2000, J PINEAL RES, V29, P34, DOI 10.1034/j.1600-079X.2000.290105.x
   Jenwitheesuk A, 2014, INT J MOL SCI, V15, P16848, DOI 10.3390/ijms150916848
   Del Sole MJ, 2012, J PINEAL RES, V52, P29, DOI 10.1111/j.1600-079X.2011.00913.x
   Jung KH, 2009, J PINEAL RES, V47, P173, DOI 10.1111/j.1600-079X.2009.00698.x
   Kaur C, 2007, J PATHOL, V212, P429, DOI 10.1002/path.2195
   Kowluru RA, 2001, DIABETES, V50, P1938, DOI 10.2337/diabetes.50.8.1938
   Lambiase A, 2014, DRUG TODAY, V50, P239, DOI [10.1358/dot.2014.050.03.2103755, 10.1358/dot.2014.50.3.2103755]
   Mauriz JL, 2013, J PINEAL RES, V54, P1, DOI 10.1111/j.1600-079X.2012.01014.x
   Meyer P, 2002, BRIT J OPHTHALMOL, V86, P1053, DOI 10.1136/bjo.86.9.1053
   Murphy MP, 2009, BIOCHEM J, V417, P1, DOI 10.1042/BJ20081386
   Nguyen QD, 2006, RETINA-J RET VIT DIS, P1
   OSBORNE NN, 1991, VISUAL NEUROSCI, V7, P637, DOI 10.1017/S0952523800010427
   Ostrin LA, 2019, CLIN EXP OPTOM, V102, P99, DOI 10.1111/cxo.12824
   Ozdemir G, 2014, EYE, V28, P1020, DOI 10.1038/eye.2014.127
   Rada JAS, 2006, INVEST OPHTH VIS SCI, V47, P25, DOI 10.1167/iovs.05-0195
   Ratay ML, 2017, ADV HEALTHC MATER, V6, P6
   Reiter RJ, 2000, J BIOMED SCI, V7, P444, DOI 10.1159/000025480
   Rodriguez C, 2004, J PINEAL RES, V36, P1, DOI 10.1046/j.1600-079X.2003.00092.x
   Rosenstein RE, 2010, J PINEAL RES, V49, P1, DOI 10.1111/j.1600-079X.2010.00764.x
   Saenz DA, 2002, J PINEAL RES, V33, P31, DOI 10.1034/j.1600-079X.2002.01880.x
   Salido EM, 2013, J PINEAL RES, V54, P179, DOI 10.1111/jpi.12008
   Sande PH, 2014, BRIT J PHARMACOL, V171, P5696, DOI 10.1111/bph.12873
   SANDVIG KU, 1994, CHRONOBIOL INT, V11, P173, DOI 10.3109/07420529409057237
   SASAKI M, 1995, J COMP PHYSIOL A, V176, P465
   Scarpulla RC, 2012, BBA-GENE REGUL MECH, V1819, P1088, DOI 10.1016/j.bbagrm.2011.10.011
   Schmid-Kubista KE, 2009, ACTA OPHTHALMOL, V87, P89, DOI 10.1111/j.1755-3768.2008.01173.x
   Scuderi G, 2016, J OPHTHALMOL, V2016, DOI 10.1155/2016/6935086
   Semeraro F, 2019, DIABETES METAB, V45, P517, DOI 10.1016/j.diabet.2019.04.002
   Shamsi FA, 2001, INVEST OPHTH VIS SCI, V42, P3041
   Shan GG, 2016, BMC MED RES METHODOL, V16, DOI 10.1186/s12874-016-0194-3
   Shi DB, 2012, J PINEAL RES, V53, P154, DOI 10.1111/j.1600-079X.2012.00982.x
   Sparrow JR, 2005, EXP EYE RES, V80, P595, DOI 10.1016/j.exer.2005.01.007
   Srinivasan V, 2005, NEUROTOX RES, V7, P293, DOI 10.1007/BF03033887
   Sundelin S, 1998, CURR EYE RES, V17, P851, DOI 10.1076/ceyr.17.8.851.5146
   Tosini Gianluca, 2013, J Glaucoma, V22 Suppl 5, pS49, DOI 10.1097/IJG.0b013e3182934bb4
   Tosini G, 2012, EXP EYE RES, V103, P82, DOI 10.1016/j.exer.2012.08.009
   Wahl C, 2011, J ANAT, V219, P766, DOI 10.1111/j.1469-7580.2011.01429.x
   Wang M, 2008, ACTA OPHTHALMOL, V86, P126, DOI 10.1111/j.1600-0420.2007.00889.x
   Wiechmann AF, 2003, EXP EYE RES, V77, P219, DOI 10.1016/S0014-4835(03)00126-X
   Wilkinson CP, 2003, OPHTHALMOLOGY, V110, P1677, DOI 10.1016/S0161-6420(03)00475-5
   Yap EY, 1996, ARCH OPHTHALMOL-CHIC, V114, P689, DOI 10.1001/archopht.1996.01100130681007
   Yau JWY, 2012, DIABETES CARE, V35, P556, DOI 10.2337/dc11-1909
   Yi CX, 2005, ANN NY ACAD SCI, V1057, P384, DOI 10.1196/annals.1356.029
   Zhdanova IV, 2001, BRAIN RES, V903, P263, DOI 10.1016/S0006-8993(01)02444-1
NR 94
TC 8
Z9 8
U1 2
U2 12
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1381-6128
EI 1873-4286
J9 CURR PHARM DESIGN
JI Curr. Pharm. Design
PY 2019
VL 25
IS 39
BP 4185
EP 4191
DI 10.2174/1381612825666191113110225
PG 7
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA JY8HG
UT WOS:000504648800009
PM 31724508
DA 2022-11-30
ER

PT J
AU Wawrzyniak, O
   Zarebska, Z
   Rolle, K
   Gotz-Wieckowska, A
AF Wawrzyniak, Olga
   Zarebska, Zaneta
   Rolle, Katarzyna
   Gotz-Wieckowska, Anna
TI Circular and long non-coding RNAs and their role in ophthalmologic
   diseases
SO ACTA BIOCHIMICA POLONICA
LA English
DT Review
DE ophthalmologic diseases; neovascularization; retinopathy; AMD; ocular
   malignancy; long non-coding RNAs; circRNAs
ID MESSENGER-RNA; RETINOBLASTOMA PROGRESSION; CANCER PROGRESSION;
   IDENTIFICATION; PROLIFERATION; TRANSLATION; EXPRESSION; KNOCKDOWN;
   LNCRNAS; NEOVASCULARIZATION
AB Long non-coding RNAs are >200-nucleotide-long RNA molecules which lack or have limited protein-coding potential. They can regulate protein formation through several different mechanisms. Similarly, circular RNAs are reported to play a critical role in post-transcriptional gene regulation. Changes in the expression pattern of these molecules are known to underlie various diseases, including cancer, cardiovascular, neurological and immunological disorders (Rinn & Chang, 2012; Sun & Kraus, 2015). Recent studies suggest that they are differentially expressed both in healthy ocular tissues as well as in eye pathologies, such as neovascularization, proliferative vit-reoretinopathy, glaucoma, cataract, ocular malignancy or even strabismus (Li et al., 2016). Aetiology of ocular diseases is multifactorial and combines genetic and environmental factors, including epigenetic and non-coding RNAs. In addition, disorders like diabetic retinopathy or age-related macular degeneration lack biomarkers for early detection as well as effective treatment methods that would allow controlling the disease progression at its early stages. The newly discovered non-coding RNAs seem to be the ideal candidates for novel molecular markers and therapeutic strategies. In this review, we summarized the current knowledge about gene expression regulators - long non-coding and circular RNA molecules in eye diseases.
C1 [Wawrzyniak, Olga; Gotz-Wieckowska, Anna] Poznan Univ Med Sci, Dept Ophthalmol, Poznan, Poland.
   [Zarebska, Zaneta; Rolle, Katarzyna] Polish Acad Sci, Inst Bioorgan Chem, Dept Mol Neurooncol, Poznan, Poland.
   [Rolle, Katarzyna] Adam Mickiewicz Univ, Ctr Adv Technol, Poznan, Poland.
C3 Poznan University of Medical Sciences; Polish Academy of Sciences;
   Institute of Bioorganic Chemistry of the Polish Academy of Sciences;
   Adam Mickiewicz University
RP Gotz-Wieckowska, A (通讯作者)，Poznan Univ Med Sci, Dept Ophthalmol, Poznan, Poland.; Rolle, K (通讯作者)，Polish Acad Sci, Inst Bioorgan Chem, Dept Mol Neurooncol, Poznan, Poland.; Rolle, K (通讯作者)，Adam Mickiewicz Univ, Ctr Adv Technol, Poznan, Poland.
EM kbug@ibch.poznan.pl; a.gotzwieckowska@gmail.com
RI Wawrzyniak, Olga/GZH-3296-2022; Wawrzyniak, Olga/AAK-2035-2020
OI Wawrzyniak, Olga/0000-0002-5550-3276; Zarebska,
   Zaneta/0000-0003-4811-7470
CR Abu-Amero K, 2015, INT J MOL SCI, V16, P28886, DOI 10.3390/ijms161226135
   Ashwal-Fluss R, 2014, MOL CELL, V56, P55, DOI 10.1016/j.molcel.2014.08.019
   Ayupe AC, 2015, RNA BIOL, V12, P877, DOI 10.1080/15476286.2015.1062960
   Bachmayr-Heyda A, 2015, SCI REP-UK, V5, DOI 10.1038/srep08057
   Beermann J, 2016, PHYSIOL REV, V96, P1297, DOI 10.1152/physrev.00041.2015
   Biswas S, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-24907-w
   Bond CS, 2009, J CELL BIOL, V186, P637, DOI 10.1083/jcb.200906113
   Chen B, 2018, MOL MED REP, V18, P16, DOI 10.3892/mmr.2018.8987
   Chen LL, 2015, RNA BIOL, V12, P381, DOI 10.1080/15476286.2015.1020271
   Chen X, 2017, BRIEF BIOINFORM, V18, P558, DOI 10.1093/bib/bbw060
   Chen X, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.382
   Colombo T, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/304208
   Conn SJ, 2015, CELL, V160, P1125, DOI 10.1016/j.cell.2015.02.014
   Dong N, 2018, INFLAMM RES, V67, P913, DOI 10.1007/s00011-018-1184-1
   Du Z, 2013, NAT STRUCT MOL BIOL, V20, P908, DOI 10.1038/nsmb.2591
   Fan JY, 2015, GENOME BIOL, V16, DOI 10.1186/s13059-015-0705-2
   Furney SJ, 2013, CANCER DISCOV, V3, P1122, DOI 10.1158/2159-8290.CD-13-0330
   Gao YL, 2016, TUMOR BIOL, V37, P1461, DOI 10.1007/s13277-015-4564-y
   Gauthier AC, 2017, BIOMED RES INT, V2017, DOI 10.1155/2017/5712341
   Gong QY, 2017, BIOSCIENCE REP, V37, DOI 10.1042/BSR20171157
   Guo JU, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0409-z
   Hao FQ, 2018, BIOSCIENCE REP, V38, DOI 10.1042/BSR20180384
   Hu CM, 2018, BIOMED PHARMACOTHER, V107, P547, DOI 10.1016/j.biopha.2018.08.020
   Hu JH, 2018, BIOCHEM BIOPH RES CO, V505, P222, DOI 10.1016/j.bbrc.2018.09.060
   Huang J, 2015, CORNEA, V34, P580, DOI 10.1097/ICO.0000000000000389
   Jeck WR, 2013, RNA, V19, P141, DOI 10.1261/rna.035667.112
   Jia Y, 2018, EXP THER MED, V15, P4277, DOI 10.3892/etm.2018.5949
   Kaarniranta K, 2009, EXP GERONTOL, V44, P685, DOI 10.1016/j.exger.2009.09.002
   Kaneko H, 2017, TRANSL VIS SCI TECHN, V6, DOI 10.1167/tvst.6.4.5
   Kellner S, 2010, RNA BIOL, V7, P237, DOI 10.4161/rna.7.2.11468
   Khandelwal A, 2015, MOL CARCINOGEN, V54, P1235, DOI 10.1002/mc.22362
   Kim J, 2016, BBA-GENE REGUL MECH, V1859, P209, DOI 10.1016/j.bbagrm.2015.06.013
   Li CP, 2017, CELL MOL NEUROBIOL, V37, P361, DOI 10.1007/s10571-016-0380-1
   Li F, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17040478
   Li GX, 2017, EXP CELL RES, V356, P20, DOI 10.1016/j.yexcr.2017.04.002
   Li L, 2018, ONCOL LETT, V15, P8424, DOI 10.3892/ol.2018.8385
   Li LJ, 2017, EXP CELL RES, V361, P1, DOI 10.1016/j.yexcr.2017.10.010
   Li SH, 2018, ONCOTARGETS THER, V11, P3215, DOI 10.2147/OTT.S160428
   Liu C, 2016, BIOCHEM BIOPH RES CO, V479, P198, DOI 10.1016/j.bbrc.2016.09.032
   Long YC, 2017, SCI ADV, V3, DOI 10.1126/sciadv.aao2110
   Ma WX, 2018, MOL MED REP, V17, P7737, DOI 10.3892/mmr.2018.8832
   Memczak S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0141214
   Memczak S, 2013, NATURE, V495, P333, DOI 10.1038/nature11928
   Meola N, 2012, RNA, V18, P111, DOI 10.1261/rna.029454.111
   Mercer TR, 2013, NAT STRUCT MOL BIOL, V20, P300, DOI 10.1038/nsmb.2480
   Mercer TR, 2010, BMC NEUROSCI, V11, DOI 10.1186/1471-2202-11-14
   Mercer TR, 2009, NAT REV GENET, V10, P155, DOI 10.1038/nrg2521
   Michalik KM, 2014, CIRC RES, V114, P1389, DOI 10.1161/CIRCRESAHA.114.303265
   Nakano M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033389
   Neely KA, 1998, AM J PATHOL, V153, P665, DOI 10.1016/S0002-9440(10)65607-6
   Pamudurti NR, 2017, MOL CELL, V66, P9, DOI 10.1016/j.molcel.2017.02.021
   Pastori C, 2012, RNA BIOL, V9, P860, DOI 10.4161/rna.20482
   Pradhan Priya, 2016, New Front Ophthalmol, V2, P192, DOI 10.15761/NFO.1000145
   Qiu GZ, 2016, BIOCHEM BIOPH RES CO, V471, P135, DOI 10.1016/j.bbrc.2016.01.164
   Rapicavoli NA, 2010, BMC DEV BIOL, V10, DOI 10.1186/1471-213X-10-49
   Rasool Mahmood, 2016, Noncoding RNA Res, V1, P69, DOI 10.1016/j.ncrna.2016.11.001
   Ren GL, 2019, J CELL PHYSIOL, V234, P2266, DOI 10.1002/jcp.27203
   Rinn JL, 2012, ANNU REV BIOCHEM, V81, P145, DOI 10.1146/annurev-biochem-051410-092902
   Robertson AG, 2017, CANCER CELL, V32, P204, DOI 10.1016/j.ccell.2017.07.003
   Rong DW, 2017, ONCOTARGET, V8, P73271, DOI 10.18632/oncotarget.19154
   Sallam T, 2018, CIRC RES, V122, P155, DOI 10.1161/CIRCRESAHA.117.311802
   Salzman J, 2016, TRENDS GENET, V32, P309, DOI 10.1016/j.tig.2016.03.002
   Salzman J, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003777
   Salzman J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030733
   Shan K, 2017, CIRCULATION, V136, P1629, DOI 10.1161/CIRCULATIONAHA.117.029004
   Shang YM, 2018, BIOMED PHARMACOTHER, V106, P1243, DOI 10.1016/j.biopha.2018.07.052
   Shen Y, 2016, J CELL MOL MED, V20, P537, DOI 10.1111/jcmm.12755
   Sheng LJ, 2018, GENE, V668, P140, DOI 10.1016/j.gene.2018.05.065
   Shiga Y, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0186678
   Su SZ, 2015, TUMOR BIOL, V36, P7205, DOI 10.1007/s13277-015-3413-3
   Sun M, 2015, ENDOCR REV, V36, P25, DOI 10.1210/er.2014-1034
   Taheri Mohammad, 2018, Biophys Rev, V10, P1205, DOI 10.1007/s12551-017-0379-y
   Tan GC, 2014, MED HLTH, V9, P2
   Tang YJ, 2017, NAT REV RHEUMATOL, V13, P657, DOI 10.1038/nrrheum.2017.162
   Tessier CR, 2004, CANCER RES, V64, P209, DOI 10.1158/0008-5472.CAN-03-2927
   Wan PX, 2017, J MED GENET, V54, P450, DOI 10.1136/jmedgenet-2016-104266
   Wang CG, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18122659
   Wang JJ, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0597-7
   Wang MN, 2018, BIOCHEM BIOPH RES CO, V504, P283, DOI 10.1016/j.bbrc.2018.08.175
   Wang SN, 2018, IUBMB LIFE, V70, P969, DOI 10.1002/iub.1886
   Wang Y, 2015, RNA, V21, P172, DOI 10.1261/rna.048272.114
   Wang Y, 2017, BIOMED PHARMACOTHER, V87, P548, DOI 10.1016/j.biopha.2016.12.040
   Xu XD, 2014, MOL BIOL REP, V41, P4493, DOI 10.1007/s11033-014-3320-5
   Xu Y, 2018, EUR REV MED PHARMACO, V22, P896, DOI 10.26355/eurrev_201802_14367
   Yan B, 2014, J CELL PHYSIOL, V229, P825, DOI 10.1002/jcp.24522
   Yan B, 2012, DNA CELL BIOL, V31, pS34, DOI 10.1089/dna.2011.1544
   Yang CD, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0771-7
   Yang G, 2018, J CELL MOL MED, V22, P5083, DOI 10.1111/jcmm.13796
   Yang T, 2016, PLOS ONE, V11, DOI [10.1371/journal.pone.0166177, 10.1371/journal.pone.0152687]
   Yang Y, 2018, INT J OPHTHALMOL-CHI, V11, P773, DOI 10.18240/ijo.2018.05.09
   Yang Y, 2017, CELL RES, V27, P626, DOI 10.1038/cr.2017.31
   Yonekawa Y, 2015, J CLIN MED, V4, P343, DOI 10.3390/jcm4020343
   Young TL, 2005, CURR BIOL, V15, P501, DOI 10.1016/j.cub.2005.02.027
   Yue YY, 2018, INVEST OPHTH VIS SCI, V59, P1158, DOI 10.1167/iovs.17-23247
   Zhang HD, 2018, EPIGENOMICS-UK, V10, P1229, DOI 10.2217/epi-2018-0002
   Zhang JY, 2017, BIOSCIENCE REP, V37, DOI 10.1042/BSR20170036
   Zhang SJ, 2017, INVEST OPHTH VIS SCI, V58, P6500, DOI 10.1167/iovs.17-22698
   Zhang XO, 2014, CELL, V159, P134, DOI 10.1016/j.cell.2014.09.001
   Zhang Y, 2017, THERANOSTICS, V7, P3155, DOI 10.7150/thno.19646
   Zhang Y, 2013, MOL CELL, V51, P792, DOI 10.1016/j.molcel.2013.08.017
   Zhang YH, 2017, MOL MED REP, V16, P5113, DOI 10.3892/mmr.2017.7304
   Zhong YX, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0827-8
   Zhou RM, 2015, BIOCHEM BIOPH RES CO, V465, P324, DOI 10.1016/j.bbrc.2015.07.120
   Zhu W, 2017, INT J NANOMED, V12, P7589, DOI 10.2147/IJN.S140275
NR 104
TC 28
Z9 30
U1 2
U2 13
PU ACTA BIOCHIMICA POLONICA
PI WARSAW
PA PASTEURA 3, 02-093 WARSAW, POLAND
SN 0001-527X
EI 1734-154X
J9 ACTA BIOCHIM POL
JI Acta Biochim. Pol.
PY 2018
VL 65
IS 4
BP 497
EP 508
DI 10.18388/abp.2018_2639
PG 12
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA HI0XY
UT WOS:000456169400003
PM 30428483
OA Green Submitted, gold
DA 2022-11-30
ER

PT J
AU Zafar, S
   Siddiqui, MAR
   Shahzad, R
   Shahzad, MH
AF Zafar, Sidra
   Siddiqui, M. A. Rehman
   Shahzad, Rida
   Shahzad, Masroor H.
TI Swept-source optical coherence tomography to screen for macular
   pathology in eyes having routine cataract surgery
SO JOURNAL OF CATARACT AND REFRACTIVE SURGERY
LA English
DT Article
AB Purpose: To determine the incremental benefit of swept-source optical coherence tomography (SS-OCT) in identifying occult macular disease preoperatively in patients scheduled for routine cataract surgery.
   Setting: Shahzad Eye Hospital, Karachi, Pakistan.
   Design: Prospective case series.
   Methods: Preoperative SS-OCT scans were performed in all patients scheduled to have cataract surgery between January and March 2016. Scans were subsequently reviewed for the presence of macular abnormalities. Patients with clinically detectable retinal pathologies were excluded.
   Results: Of the 179 eligible patients, 155 were included in the study. Macular pathology was noted in 17 patients (10.9%). The most commonly identified conditions were age-related macular degeneration (n = 5), idiopathic epiretinal membrane (n = 4), and vitreomacular interface abnormalities (n = 4). Other abnormalities included cystoid macular edema (n = 2) and ellipsoid zone abnormalities (n = 2). Media opacities precluded interpretation of 9 scans (4.7%).
   Conclusions: Swept-source OCT was an effective noninvasive modality for detecting macular structural abnormalities, especially in the presence media opacities. Optical coherence tomography imaging should be considered as an adjunct to routine dilated fundus examination for macular evaluation, particularly if premium intraocular lenses are being considered. (C) 2017 ASCRS and ESCRS
C1 [Zafar, Sidra; Shahzad, Rida] Aga Khan Univ Hosp, Med Coll, Karachi, Pakistan.
   [Siddiqui, M. A. Rehman; Shahzad, Masroor H.] Shahzad Eye Hosp, Karachi, Pakistan.
   [Siddiqui, M. A. Rehman] South City Hosp, Karachi, Pakistan.
C3 Aga Khan University
RP Siddiqui, MAR (通讯作者)，B-2,Block 16, Karachi, Pakistan.
EM rehman.siddiqui@gmail.com
RI Siddiqui, M.A. Rehman/AAB-4931-2021
OI Siddiqui, M. A. Rehman/0000-0001-5100-3189
CR [Anonymous], 2000, Community Eye Health, V13, P17
   [Anonymous], 2016, J CATARACT REFRACT S, V42, P530
   Baker CW, 2013, JAMA OPHTHALMOL, V131, P870, DOI 10.1001/jamaophthalmol.2013.2313
   Davis Geetha, 2016, Mo Med, V113, P58
   Eleftheriadis H, 2003, BRIT J OPHTHALMOL, V87, P960, DOI 10.1136/bjo.87.8.960
   Henderson BA, 2007, J CATARACT REFR SURG, V33, P1550, DOI 10.1016/j.jcrs.2007.05.013
   Klein BR, 2016, J CATARACT REFR SURG, V42, P537, DOI 10.1016/j.jcrs.2016.01.036
   Michalewski J, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/639160
   Neto CAM, 2015, ARQ BRAS OFTALMOL, V78, P241, DOI 10.5935/0004-2749.20150062
   Piasecka K, 2014, EUR OPHTHALMIC REV, V8, P132
   Ruiz-Medrano J, 2014, INVEST OPHTH VIS SCI, V55, P3532, DOI 10.1167/iovs.14-13868
NR 11
TC 17
Z9 18
U1 0
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0886-3350
EI 1873-4502
J9 J CATARACT REFR SURG
JI J. Cataract. Refract. Surg.
PD MAR
PY 2017
VL 43
IS 3
BP 324
EP 327
DI 10.1016/j.jcrs.2016.12.022
PG 4
WC Ophthalmology; Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Surgery
GA ES9HJ
UT WOS:000399867000006
PM 28410712
DA 2022-11-30
ER

PT J
AU Fine, SL
   Goldberg, MF
   Tasman, W
AF Fine, Stuart L.
   Goldberg, Morton F.
   Tasman, William
TI Historical Perspectives on the Management of Macular Degeneration,
   Diabetic Retinopathy, and Retinal Detachment Personal Reminiscences
SO OPHTHALMOLOGY
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; PARS-PLANA VITRECTOMIES; RANIBIZUMAB;
   THERAPY; EDEMA; EYES
AB We were challenged and delighted when Dr. Sharon Solomon, guest editor of this Retina Supplement, invited us to reminisce about caring for patients with common retinal disorders before there was access to the diagnostic and therapeutic tools that are readily available today. We agreed to confine our remarks to 3 common, but serious, conditions: age-related macular degeneration (Dr. Fine), diabetic retinopathy (Dr. Goldberg), and retinal detachment (Dr. Tasman). Each of us completed our ophthalmology training about half a century ago. At that time, a patient who received any 1 of the 3 diagnoses was at considerable risk of severe and irreversible loss of vision. Most readers today will have little if any experience in evaluating and treating such patients without access to a plethora of diagnostic and therapeutic technologies, including intravenous fluorescein angiography, laser photocoagulation, optical coherence tomography, ophthalmic ultrasound, angioinhibitory drugs, vitrectomy, intraocular gases, and many others. We are both pleased and privileged that each of us has practiced our profession long enough to enjoy what the enormous technological developments of the past half century, as described in this article, have meant for our patients. (C) 2016 by the American Academy of Ophthalmology.
C1 [Fine, Stuart L.] Univ Colorado, Sch Med, Ophthalmol, Boulder, CO 80309 USA.
   [Fine, Stuart L.] Univ Penn, Sch Med, Scheie Eye Inst, Ophthalmol, Philadelphia, PA 19104 USA.
   [Fine, Stuart L.] Univ Penn, Sch Med, Scheie Eye Inst, Philadelphia, PA 19104 USA.
   [Goldberg, Morton F.] Johns Hopkins Sch Med, Wilmer Eye Inst, Baltimore, MD USA.
   [Goldberg, Morton F.] Johns Hopkins Sch Med, Ophthalmol, Baltimore, MD USA.
   [Tasman, William] Johns Hopkins Univ Hosp, Baltimore, MD 21287 USA.
   [Tasman, William] Thomas Jefferson Univ, Sidney Kimmel Coll, Dept Ophthalmol, Philadelphia, PA 19107 USA.
   [Tasman, William] Wills Eye Hosp & Res Inst, Philadelphia, PA USA.
C3 University of Colorado System; University of Colorado Anschutz Medical
   Campus; University of Colorado Boulder; University of Pennsylvania;
   Pennsylvania Medicine; University of Pennsylvania; Pennsylvania
   Medicine; Johns Hopkins University; Johns Hopkins Medicine; Johns
   Hopkins University; Johns Hopkins Medicine; Johns Hopkins University;
   Johns Hopkins Medicine; Jefferson University; Jefferson University
RP Fine, SL (通讯作者)，Univ Penn, Scheie Eye Inst, 51 North 39th St, Philadelphia, PA 19104 USA.
EM stuart.fine@ucdenver.edu
OI Tasman, William/0000-0002-9662-9078
CR AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203
   Albert DM, 2015, OPHTHALMOLOGY, V122, P1955, DOI 10.1016/j.ophtha.2015.05.037
   [Anonymous], 1990, Arch Ophthalmol, V108, P958
   [Anonymous], 1976, Am J Ophthalmol, V81, P383
   Avery RL, 2016, JAMA OPHTHALMOL, V134, P21, DOI 10.1001/jamaophthalmol.2015.4070
   Bauer O., 1911, TEUERUNG EINFUHRUNG
   Ben-Noun LL, 2002, GERONTOLOGY, V48, P52, DOI 10.1159/000048925
   BIRD AC, 1974, BRIT J OPHTHALMOL, V58, P367, DOI 10.1136/bjo.58.4.367
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   BRESSLER SB, 1982, AM J OPHTHALMOL, V93, P157, DOI 10.1016/0002-9394(82)90410-X
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Coccius A., 1853, UEBER ANWENDUNG AUGE, P131
   Cunha-Vaz JG, 1979, BLOOD RETINAL BARRIE
   Desmarres LA, 1847, TRAITE THEORIQUE PRA, P710
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   FINE SL, 1982, ARCH OPHTHALMOL-CHIC, V100, P912
   GASS JDM, 1967, AM J OPHTHALMOL, V64, P612
   GASS JDM, 1966, ARCH OPHTHALMOL-CHIC, V76, P646, DOI 10.1001/archopht.1966.03850010648005
   GOLDBERG MF, 1987, OPHTHALMOLOGY, V94, P741
   GOLDBERG MF, 1973, ARCH OPHTHALMOL-CHIC, V89, P311, DOI 10.1001/archopht.1973.01000040313011
   Goldberg MF, 1969, USPHS PUBLICATION, V1890
   GONIN J, 1934, DECOLLEMENT RETINE P
   Gullstrand A., 1911, ARCH AUGENHEILKD, V68, P101
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Helmholtz H., 1851, BESCHREIBUNG AUGEN S
   HYMAN LG, 1983, AM J EPIDEMIOL, V118, P213, DOI 10.1093/oxfordjournals.aje.a113629
   Junius P, 1926, SCHEIBERFORMIGE ENTA
   KAHN HA, 1977, AM J EPIDEMIOL, V106, P17, DOI 10.1093/oxfordjournals.aje.a112428
   L'Esperance F A Jr, 1969, Trans Am Acad Ophthalmol Otolaryngol, V73, P1077
   la Hire de, 1709, HIST ACAD R SCI 0330, P95
   LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986
   Little H L, 1970, Trans Am Acad Ophthalmol Otolaryngol, V74, P85
   Machemer R, 1971, Trans Am Acad Ophthalmol Otolaryngol, V75, P813
   Maitre-Jan A., 1722, TRAITE MALADIES OEIL, P241
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Mery, 1704, HIST ACAD R SCI 1112, P261
   Meyer-Schwickerath G., 1960, LIGHT COAGULATION
   Michaelson I.C, 1954, BRIT J OPHTHALMOL, V38, P441, DOI [10.1136/bjo.38.7.441, DOI 10.1136/BJO.38.7.441]
   Michaelson IC, 1980, TXB FUNDUS EYE
   Morax DV, 1913, PRECIS OPHTALMOLOGIE
   Morgagni JB, 1766, SEDIBUS CAUSIS MORBO, V1, P182
   PATZ A, 1985, ARCH OPHTHALMOL-CHIC, V103, P1796, DOI 10.1001/archopht.1985.01050120030015
   Patz A, 1971, T AM ACAD OPHTHALMOL, V755, P69
   PEYMAN GA, 1971, ARCH OPHTHALMOL-CHIC, V86, P548, DOI 10.1001/archopht.1971.01000010550011
   PEYMAN GA, 1976, BRIT J OPHTHALMOL, V60, P752, DOI 10.1136/bjo.60.11.752
   PEYMAN GA, 1978, ARCH OPHTHALMOL-CHIC, V96, P45
   PEYMAN GA, 1976, AM J OPHTHALMOL, V81, P263, DOI 10.1016/0002-9394(76)90239-7
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   SCHATZ H, 1973, ARCH OPHTHALMOL-CHIC, V90, P183, DOI 10.1001/archopht.1973.01000050185003
   SCHEPENS C L, 1947, Trans Am Acad Ophthalmol Otolaryngol, V51, P298
   SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401
   Sichel J., 1841, ANN OCUL, V5, P225
   Stockton J., 1722, NEW TREATISE DIS EYE, V1741, P285
   Writing Committee for the Diabetic Retinopathy Clinical Research Network, 2015, JAMA-J AM MED ASSOC, V314, P2137, DOI DOI 10.1001/JAMA.2015.15217
NR 54
TC 3
Z9 3
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD OCT
PY 2016
VL 123
IS 10
SU S
BP S64
EP S77
DI 10.1016/j.ophtha.2016.04.058
PG 14
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA EE3QJ
UT WOS:000389509400003
PM 27664288
DA 2022-11-30
ER

PT J
AU Hariri, A
   Diniz, B
   Fou, LV
   Lam, LA
   Nittala, MG
   Sadda, SR
AF Hariri, Amirhossein
   Diniz, Bruno
   Fou, Lyndsey V.
   Lam, Linda A.
   Nittala, Muneeswar Gupta
   Sadda, SriniVas R.
TI Quantitative OCT Subanalysis of Eyes With Choroidal Neovascularization
   Switched From Multiple Injections of Bevacizumab or Ranibizumab to
   Intravitreal Aflibercept
SO OPHTHALMIC SURGERY LASERS & IMAGING RETINA
LA English
DT Article
ID MACULAR DEGENERATION; GROWTH-FACTOR; VEGF; TACHYPHYLAXIS
AB BACKGROUND AND OBJECTIVE: To assess the early therapeutic response after switching from multiple injections of bevacizumab or ranibizumab to aflibercept in eyes with neovascular age-related macular degeneration (AMD).
   PATIENTS AND METHODS: SD-OCT scans of patients with neovascular AMD that was suboptimally responsive to multiple injections of bevacizumab or ranibizumab who were switched to aflibercept were analyzed. After segmenting these scans, the relevant volumes were computed and compared at the various time points by Student's t test.
   RESULTS: After switching to aflibercept, converse to the outcome of the last injection of bevacizumab or ranibizumab, statistically significant decreases of 0.32 mm(3) in neurosensory retinal volume, 0.08 mm(3) in subretinal fluid, and 0.56 mm(3) in pigment epithelial detachment were observed (P =.01, .04, and .001, respectively). The mean ETDRS visual acuity increased from 62 to 65 letters after switching (P = .04). These favorable outcomes were sustained after three monthly injections of the new drug.
   CONCLUSION: Switching to aflibercept therapy in eyes with persistent fluid after multiple intravitreal injections of bevacizumab or ranibizumab was associated with an early reduction in all fluid compartments and improvement in visual acuity.
C1 [Hariri, Amirhossein; Diniz, Bruno; Fou, Lyndsey V.; Nittala, Muneeswar Gupta; Sadda, SriniVas R.] Doheny Eye Inst, Los Angeles, CA 90033 USA.
   [Hariri, Amirhossein; Lam, Linda A.; Sadda, SriniVas R.] Univ So Calif, Keck Sch Med, Dept Ophthalmol, Los Angeles, CA 90033 USA.
C3 Doheny Eye Institute; University of Southern California
RP Sadda, SR (通讯作者)，Doheny Eye Inst, 1355 San Pablo St, Los Angeles, CA 90033 USA.
RI Nittala, Muneeswar/AAT-7533-2020
FU Beckman Macular Degeneration Research Center; Research to Prevent
   Blindness Physician Scientist Award
FX Supported by the Beckman Macular Degeneration Research Center and a
   Research to Prevent Blindness Physician Scientist Award.
CR Baranano AE, 2012, ACTA OPHTHALMOL, V90, pE274, DOI 10.1111/j.1755-3768.2012.02398.x
   Blick SK, 2007, DRUGS, V67, P1207
   Blick SKA, 2007, DRUGS, V67, P1199, DOI 10.2165/00003495-200767080-00007
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Cho H, 2013, BRIT J OPHTHALMOL, V97, P1032, DOI 10.1136/bjophthalmol-2013-303344
   Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669
   Forooghian F, 2009, RETINA-J RET VIT DIS, V29, P723, DOI 10.1097/IAE.0b013e3181a2c1c3
   Frampton JE, 2012, DRUG AGING, V29, P839, DOI 10.1007/s40266-012-0015-2
   Gaudreault J, 2005, INVEST OPHTH VIS SCI, V46, P726, DOI 10.1167/iovs.04-0601
   Gregori NZ, RETINA, V30, P1046
   Guber J, 2014, OPEN OPHTHALMOL J, V8, P3, DOI 10.2174/1874364101408010003
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Joeres S, 2007, INVEST OPHTH VIS SCI, V48, P4300, DOI 10.1167/iovs.07-0179
   Keane PA, 2008, OPHTHALMOLOGY, V115, P2206, DOI 10.1016/j.ophtha.2008.08.016
   Papadopoulos N, 2012, ANGIOGENESIS, V15, P171, DOI 10.1007/s10456-011-9249-6
   Rakic JM, 2003, INVEST OPHTH VIS SCI, V44, P3186, DOI 10.1167/iovs.02-1092
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sadda SR, 2007, INVEST OPHTH VIS SCI, V48, P839, DOI 10.1167/iovs.06-0554
   Schaal S, 2008, OPHTHALMOLOGY, V115, P2199, DOI 10.1016/j.ophtha.2008.07.007
   Takahashi H, 2005, CLIN SCI, V109, P227, DOI 10.1042/CS20040370
   Tozer K, 2013, OPHTHALMOLOGY, V120, P2029, DOI 10.1016/j.ophtha.2013.03.016
   Zhang F, 2009, P NATL ACAD SCI USA, V106, P6152, DOI 10.1073/pnas.0813061106
   Zhu Q, 2008, OPHTHALMOLOGY, V115, P1750, DOI 10.1016/j.ophtha.2008.04.023
NR 23
TC 8
Z9 8
U1 0
U2 1
PU SLACK INC
PI THOROFARE
PA 6900 GROVE RD, THOROFARE, NJ 08086 USA
SN 2325-8160
EI 2325-8179
J9 OSLI RETINA
JI Ophthalmic Surg. Lasers Imag. Retin.
PD FEB
PY 2015
VL 46
IS 2
BP 195
EP 200
DI 10.3928/23258160-20150213-18
PG 6
WC Ophthalmology; Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Surgery
GA CG5TZ
UT WOS:000353360100006
PM 25707044
DA 2022-11-30
ER

PT J
AU Cimarolli, VR
   Boerner, K
   Brennan-Ing, M
   Reinhardt, JP
   Horowitz, A
AF Cimarolli, Verena R.
   Boerner, Kathrin
   Brennan-Ing, Mark
   Reinhardt, Joann P.
   Horowitz, Amy
TI Challenges faced by older adults with vision loss: a qualitative study
   with implications for rehabilitation
SO CLINICAL REHABILITATION
LA English
DT Article
DE Ageing; disability; qualitative study; rehabilitation; visual impairment
ID SERVICES; PROGRAM
AB Objective: To provide an in-depth assessment of challenges faced by older adults with recent vision loss and to determine changes in the nature of these challenges over time for the purpose of informing the design of vision rehabilitation services.
   Design: Longitudinal, qualitative study with three time points.
   Setting: Vision rehabilitation agency.
   Subjects: Three hundred and sixty-four older adults aged 65 with significant vision impairment due to age-related macular degeneration.
   Interventions: In-person interviews conducted at baseline, one year and two years and coded using a qualitative analytical approach.
   Main measures: Open-ended questions assessing challenges faced due to vision loss in functional, social and psychological life domains.
   Results: Almost all participants reported a wide variety of challenges across all three domains with the most variety in the functional domain. Over a two-year period, functional challenges (e. g. using transportation) increased, social challenges (e. g. recognizing people) remained stable, and psychological challenges (e. g. negative affect) decreased overall.
   Conclusions: Although functional challenges are predominant, social and psychological challenges are quite common and need to be addressed in vision rehabilitation. Rehabilitation planning should also consider that vision-related challenges can change over time.
C1 [Cimarolli, Verena R.; Boerner, Kathrin; Reinhardt, Joann P.] Jewish Home Lifecare, Res Inst Aging, Guild Ctr Res Vis & Aging, PH, New York, NY 10025 USA.
   [Brennan-Ing, Mark] AIDS Community Res Initiat Amer, New York, NY USA.
   [Horowitz, Amy] Fordham Univ, Grad Sch Social Serv, New York, NY 10023 USA.
C3 Fordham University
RP Cimarolli, VR (通讯作者)，Jewish Home Lifecare, Res Inst Aging, Guild Ctr Res Vis & Aging, PH, 120 W 106th St, New York, NY 10025 USA.
EM vcimarolli@jewishhome.org
RI Boerner, Kathrin/M-1504-2019
FU United States National Institute of Mental Health [R01 MH64437];
   NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH064437] Funding Source: NIH
   RePORTER
FX Study participants were drawn from a longitudinal study on coping with
   vision loss in late life, which was funded by the United States National
   Institute of Mental Health (R01 MH64437; A. Horowitz, PI). The study was
   conducted at Lighthouse International, New York, NY, USA.
CR Agency for Healthcare Research and Quality (AHRQ), 2004, TECHN ASS
   Agency for Healthcare Research and Quality (AHRQ), 2002, LIT REV
   AMD Alliance International, FACT SHEET
   ARDITI A, 1993, INVEST OPHTH VIS SCI, V34, P120
   Boerner K, 2006, CODING MANUAL EXPLIC
   Burmedi D., 2002, VISUAL IMPAIRMENT RE, V4, P47
   Casten Robin J, 2004, Curr Opin Ophthalmol, V15, P181, DOI 10.1097/01.icu.0000120710.35941.3f
   Horowitz A, 2005, AM J GERIAT PSYCHIAT, V13, P180, DOI 10.1176/appi.ajgp.13.3.180
   Horowitz A, 2006, DEPRESSION DISABILIT
   Ivanoff SD, 1996, DISABIL REHABIL, V18, P515, DOI 10.3109/09638289609166038
   Massof RW, 2007, INVEST OPHTH VIS SCI, V48, P4955, DOI 10.1167/iovs.06-0566
   Massof RW, 1998, OPTOMETRY VISION SCI, V75, P349, DOI 10.1097/00006324-199805000-00025
   Matthews FE, 2004, BMC PUBLIC HEALTH, V27, P4
   Muhr T., 1997, ATLAS TI WINDOWS VIS
   Owsley C, 2009, ARCH OPHTHALMOL-CHIC, V127, P681, DOI 10.1001/archophthalmol.2009.55
   Rees G, 2010, DISABIL REHABIL, V32, P808, DOI 10.3109/09638280903304193
   Reinhardt JP, 2003, PSYCHOL AGING, V18, P770, DOI 10.1037/0882-7974.18.4.770
   *WHO, MAGN CAUS VIS IMP
NR 18
TC 43
Z9 44
U1 0
U2 9
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 0269-2155
EI 1477-0873
J9 CLIN REHABIL
JI Clin. Rehabil.
PD AUG
PY 2012
VL 26
IS 8
BP 748
EP 757
DI 10.1177/0269215511429162
PG 10
WC Rehabilitation
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Rehabilitation
GA 975CN
UT WOS:000306484500010
PM 22169832
DA 2022-11-30
ER

PT J
AU Pelle, G
   Shweke, N
   Van Huyen, JPD
   Tricot, L
   Hessaine, S
   Fremeaux-Bacchi, V
   Hiesse, C
   Delahousse, M
AF Pelle, Gaelle
   Shweke, Nasim
   Van Huyen, Jean-Paul Duong
   Tricot, Leila
   Hessaine, Sadika
   Fremeaux-Bacchi, Veronique
   Hiesse, Christian
   Delahousse, Michel
TI Systemic and Kidney Toxicity of Intraocular Administration of Vascular
   Endothelial Growth Factor Inhibitors
SO AMERICAN JOURNAL OF KIDNEY DISEASES
LA English
DT Article
DE Thrombotic microangiopathy; age-related macular degeneration;
   intravitreal anti-vascular endothelial growth factor therapy; complement
   factor H
ID ANTI-VEGF THERAPY; THROMBOTIC MICROANGIOPATHY; MACULAR DEGENERATION;
   RANIBIZUMAB; PROTEINURIA
AB Intravenous injection of angiogenesis-inhibitor drugs is used widely to treat cancers. Associated renal complications primarily involve proteinuria and hypertension, and thrombotic microangiopathies also have been described. Intravitreal anti-vascular endothelial growth factor (VEGF) therapy currently is used by ophthalmologists to treat neovascularization in age-related macular degeneration. However, there is some evidence that intravitreal anti-VEGF injections may result in systemic absorption, with the potential for injury in organs that are reliant on VEGF, such as the kidney. We report the first case to our knowledge of a patient who developed an acute decrease in kidney function, nonimmune microangiopathic hemolytic anemia with schistocytes, and thrombocytopenia after 4 intravitreal injections of ranibizumab. Light microscopy of a kidney biopsy specimen showed segmental duplications of glomerular basement membranes with endothelial swelling and several recanalized arteriolar thrombi. Because of the increasing use of intravitreal anti-VEGF agents, ophthalmologists and nephrologists should be aware of the associated risk of kidney disease. Early detection is crucial so that intravitreal injections can be stopped before severe kidney disease occurs. Am J Kidney Dis. 57(5): 756-759. (C) 2011 by the National Kidney Foundation, Inc.
C1 [Pelle, Gaelle; Shweke, Nasim; Tricot, Leila; Hiesse, Christian; Delahousse, Michel] Hop Foch, Serv Nephrol Transplantat Renale, F-92151 Suresnes, France.
   [Van Huyen, Jean-Paul Duong] Hop Europeen Georges Pompidou, AP HP, Serv Anatomopathol, Paris, France.
   [Hessaine, Sadika] Hop Europeen Georges Pompidou, AP HP, Ctr Reg Pharmacovigilance, Paris, France.
   [Fremeaux-Bacchi, Veronique] Hop Europeen Georges Pompidou, AP HP, Serv Immunol Biol, Paris, France.
C3 Hospital Foch; Assistance Publique Hopitaux Paris (APHP); Hopital
   Universitaire Europeen Georges-Pompidou - APHP; UDICE-French Research
   Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris
   (APHP); Hopital Universitaire Europeen Georges-Pompidou - APHP;
   UDICE-French Research Universities; Universite Paris Cite; Assistance
   Publique Hopitaux Paris (APHP); Hopital Universitaire Europeen
   Georges-Pompidou - APHP; UDICE-French Research Universities; Universite
   Paris Cite
RP Pelle, G (通讯作者)，Hop Foch, Serv Nephrol Transplantat Renale, 40 Rue Worth, F-92151 Suresnes, France.
EM g.pelle@hopital-foch.org
CR Benz K, 2010, CURR OPIN NEPHROL HY, V19, P242, DOI 10.1097/MNH.0b013e3283378f25
   Bollee G, 2009, NEPHROL DIAL TRANSPL, V24, P682, DOI 10.1093/ndt/gfn657
   Boon CJF, 2009, MOL IMMUNOL, V46, P1573, DOI 10.1016/j.molimm.2009.02.013
   Bressler NM, 2009, OPHTHALMOLOGY, V116, pS15, DOI 10.1016/j.ophtha.2009.06.048
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Csaky K, 2009, AM J OPHTHALMOL, V148, P647, DOI 10.1016/j.ajo.2009.06.014
   Eremina V, 2008, NEW ENGL J MED, V358, P1129, DOI 10.1056/NEJMoa0707330
   Frangie C, 2007, LANCET ONCOL, V8, P177, DOI 10.1016/S1470-2045(07)70037-2
   Gurevich F, 2009, AM J MED, V122, P322, DOI 10.1016/j.amjmed.2008.11.025
   Izzedine H, 2007, NEPHROL DIAL TRANSPL, V22, P1481, DOI 10.1093/ndt/gfl565
   Jardeleza MSR, 2009, SEMIN OPHTHALMOL, V24, P87, DOI 10.1080/08820530902800330
   Noris M, 2009, NEW ENGL J MED, V361, P1676, DOI 10.1056/NEJMra0902814
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Roncone D, 2007, NAT CLIN PRACT NEPHR, V3, P287, DOI 10.1038/ncpneph0476
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Stokes MB, 2008, KIDNEY INT, V74, P1487, DOI 10.1038/ki.2008.256
   Zakarija A, 2009, KIDNEY INT, V75, pS20, DOI 10.1038/ki.2008.613
   Zhu XL, 2007, AM J KIDNEY DIS, V49, P186, DOI 10.1053/j.ajkd.2006.11.039
NR 18
TC 55
Z9 57
U1 0
U2 6
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0272-6386
EI 1523-6838
J9 AM J KIDNEY DIS
JI Am. J. Kidney Dis.
PD MAY
PY 2011
VL 57
IS 5
BP 756
EP 759
DI 10.1053/j.ajkd.2010.11.030
PG 4
WC Urology & Nephrology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Urology & Nephrology
GA 749ZW
UT WOS:000289513600019
PM 21295897
DA 2022-11-30
ER

PT J
AU Gilbert, M
   Mousa, S
   Mousa, SA
AF Gilbert, Mark
   Mousa, Shaymaa
   Mousa, Shaker A.
TI Current status of anti-vascular endothelial growth factor (VEGF)
   strategies and future directions
SO DRUGS OF THE FUTURE
LA English
DT Review
ID TYROSINE KINASE INHIBITOR; PHASE-II TRIAL; VASCULAR-PERMEABILITY FACTOR;
   FACTOR EXPRESSION; TRANSCRIPTIONAL REGULATION; MULTIKINASE INHIBITOR;
   MACULAR DEGENERATION; FACTOR RECEPTOR-2; PROGNOSTIC VALUE;
   CLINICAL-TRIALS
AB Angiogenesis, or the process by which new vessels are created from preexisting vasculature, has become the subject of intense research in recent years. Increased rates of angiogenesis are associated with several disease states, including cancer, age-related macular degeneration (AMD), psoriasis, rheumatoid arthritis and diabetic retinopathy. Numerous growth factors, including vascular endothelial growth factor (VEGF), are able to induce angiogenesis. Overexpression of VEGF has been correlated with increased metastasis of tumors and is a marker of poor prognosis in many carcinomas. Various therapies have been designed to target VEGF and inhibit angiogenesis, including monoclonal antibodies, soluble receptor decoys, tyrosine kinase receptor (TKR) inhibitors and other therapies targeting the mRNA that codes VEGF. Clinical trials have shown VEGF inhibitors to be effective in increasing overall survival rates, time to tumor progression, partial response rates and duration of response in cancer patients. In AMD patients, these therapies slow the rate of vision loss and in some cases increase visual acuity. Although these therapies are a milestone in the treatment of these disease states, several concerns need to be addressed before their impact can be fully understood.
C1 [Gilbert, Mark; Mousa, Shaymaa; Mousa, Shaker A.] Albany Coll Pharm, Pharmaceut Res Inst, Rensselaer, NY 12144 USA.
C3 Albany College of Pharmacy & Health Sciences
RP Mousa, SA (通讯作者)，Albany Coll Pharm, Pharmaceut Res Inst, 1 Discovery Dr, Rensselaer, NY 12144 USA.
EM mousas@acp.edu
RI Mousa, Shaker A/A-7151-2017
OI Mousa, Shaker A/0000-0002-9294-015X
CR Abou-Alfa GK, 2006, J CLIN ONCOL, V24, P4293, DOI 10.1200/JCO.2005.01.3441
   Arnold AM, 2007, J CLIN ONCOL, V25, P4278, DOI 10.1200/JCO.2007.12.3083
   Awada A, 2005, BRIT J CANCER, V92, P1855, DOI 10.1038/sj.bjc.6602584
   Borre M, 2000, CLIN CANCER RES, V6, P1882
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   BROWN LF, 1997, EXS, V79, P233
   Byrne AT, 2003, CLIN CANCER RES, V9, P5721
   Carter P, 2001, NAT REV CANCER, V1, P118, DOI 10.1038/35101072
   Casa Douglas J, 2005, Curr Sports Med Rep, V4, P309
   CASCINU S, 2007, CLIN CANCER RES, V6, P2803
   Chakravarthy U, 2006, OPHTHALMOLOGY, V113, P1508, DOI 10.1016/j.ophtha.2006.02.064
   Ciardiello F, 2003, CLIN CANCER RES, V9, P1546
   CLAUSS M, 1990, J EXP MED, V172, P1535, DOI 10.1084/jem.172.6.1535
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   Demetri GD, 2006, LANCET, V368, P1329, DOI 10.1016/S0140-6736(06)69446-4
   Drevs J, 2007, J CLIN ONCOL, V25, P3045, DOI 10.1200/JCO.2006.07.2066
   Dvorak HF, 1999, CURR TOP MICROBIOL, V237, P97
   Escudier B, 2007, NEW ENGL J MED, V356, P125, DOI 10.1056/NEJMoa060655
   ESKENS FA, 2006, J CLIN ONCOL S, V24
   Faivre S, 2006, J CLIN ONCOL, V24, P25, DOI 10.1200/JCO.2005.02.2194
   Ferrara N, 1999, J MOL MED, V77, P527, DOI 10.1007/s001099900019
   Ferrara N, 1999, NAT MED, V5, P1359, DOI 10.1038/70928
   Fink AM, 2007, CLIN EXP RHEUMATOL, V25, P305
   Foekens JA, 2001, CANCER RES, V61, P5407
   FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182
   Forsythe JA, 1996, MOL CELL BIOL, V16, P4604
   Gerber HP, 1997, J BIOL CHEM, V272, P23659, DOI 10.1074/jbc.272.38.23659
   GIANTONIO B, 2005, 41 ANN M AM SOC CLIN
   GIANTONIO BJ, 2003, P AM SOC CLIN ONCOL, V22
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Hainsworth JD, 2005, J CLIN ONCOL, V23, P7889, DOI 10.1200/JCO.2005.01.8234
   HAINSWORTH JD, 2005, 41 ANN M AM SOC CLIN
   Heffelfinger SC, 1999, CLIN CANCER RES, V5, P2867
   Heier JS, 2006, OPHTHALMOLOGY, V113, P633, DOI 10.1016/j.ophtha.2005.10.052
   Hirawat S, 2007, J CLIN ONCOL, V25
   Holash J, 2002, P NATL ACAD SCI USA, V99, P11393, DOI 10.1073/pnas.172398299
   Hurwitz H, 2004, NEW ENGL J MED, V350, P2335, DOI 10.1056/NEJMoa032691
   HUTSON TE, 2007, J CLIN ONCOL S, V25
   Inoue K, 2000, CLIN CANCER RES, V6, P4866
   Johnson DH, 2004, J CLIN ONCOL, V22, P2184, DOI 10.1200/JCO.2004.11.022
   Joukov V, 1997, J CELL PHYSIOL, V173, P211, DOI 10.1002/(SICI)1097-4652(199711)173:2<211::AID-JCP23>3.0.CO;2-H
   Kaya M, 2000, CLIN CANCER RES, V6, P572
   Kerbel R, 2002, NAT REV CANCER, V2, P727, DOI 10.1038/nrc905
   Kindler HL, 2005, J CLIN ONCOL, V23, P8033, DOI 10.1200/JCO.2005.01.9661
   Kuniyasu H, 2000, CLIN CANCER RES, V6, P2295
   LEVY AP, 1995, J BIOL CHEM, V270, P13333, DOI 10.1074/jbc.270.22.13333
   Linderholm B, 1999, BRIT J CANCER, V81, P727, DOI 10.1038/sj.bjc.6690755
   Llovet J, 2007, J CLIN ONCOL, V25
   Marx J, 2002, SCIENCE, V295, P1444
   Miller K, 2005, 28 ANN SAN ANT BREAS
   Miller KD, 2005, CLIN CANCER RES, V11, P3369, DOI 10.1158/1078-0432.CCR-04-1923
   Mineta H, 2000, BRIT J CANCER, V83, P775, DOI 10.1054/bjoc.2000.1357
   Murakami M, 2006, BLOOD, V108, P1849, DOI 10.1182/blood-2006-04-016030
   Nakamura K, 2006, CANCER RES, V66, P9134, DOI 10.1158/0008-5472.CAN-05-4290
   Nemunaitis J, 2006, J CLIN ONCOL, V24, P4721, DOI 10.1200/JCO.2005.05.5335
   Pettersson A, 2000, LAB INVEST, V80, P99, DOI 10.1038/labinvest.3780013
   Polverino A, 2006, CANCER RES, V66, P8715, DOI 10.1158/0008-5472.CAN-05-4665
   Raez LE, 2004, J CLIN ONCOL, V22, P2800, DOI 10.1200/JCO.2004.10.197
   RATAIN MJ, 2005, 41 ANN M AM SOC CLIN
   Relf M, 1997, CANCER RES, V57, P963
   Ribatti D, 2007, LEUKEMIA, V21, P44, DOI 10.1038/sj.leu.2404402
   Riely G, 2007, CLIN CANCER RES, V13, p4623S, DOI 10.1158/1078-0432.CCR-07-0544
   Rixe O, 2007, LANCET ONCOL, V8, P975, DOI 10.1016/S1470-2045(07)70285-1
   Rosen LS, 2007, J CLIN ONCOL, V25, P2369, DOI 10.1200/JCO.2006.07.8170
   ROSEN R, 2005, 41 ANN M AM SOC CLIN
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Saltz LB, 2007, J CLIN ONCOL, V25, P4557, DOI 10.1200/JCO.2007.12.0949
   Sandler A, 2006, NEW ENGL J MED, V355, P2542, DOI 10.1056/NEJMoa061884
   Scott EN, 2007, EXPERT OPIN INV DRUG, V16, P367, DOI 10.1517/13543784.16.3.367
   SENGER DR, 1993, CANCER METAST REV, V12, P303, DOI 10.1007/BF00665960
   Shih CH, 2000, CLIN CANCER RES, V6, P1161
   Spilsbury K, 2000, AM J PATHOL, V157, P135, DOI 10.1016/S0002-9440(10)64525-7
   Strumberg D, 2005, J CLIN ONCOL, V23, P965, DOI 10.1200/JCO.2005.06.124
   SUTTLE AB, 2004, P AM SOC CLIN ONCOL, V23
   Suzuki E, 2004, CLIN CANCER RES, V10, P5907, DOI 10.1158/1078-0432.CCR-03-0611
   Thomas AL, 2007, ANN ONCOL, V18, P782, DOI 10.1093/annonc/mdl469
   TISCHER E, 1991, J BIOL CHEM, V266, P11947
   Traxler P, 2004, CANCER RES, V64, P4931, DOI 10.1158/0008-5472.CAN-03-3681
   Tyagi Preeta, 2005, Clin Colorectal Cancer, V5, P24
   VANCRUIJSEN H, 2003, 41 ANN M AM SOC CLIN
   Wedge SR, 2005, CANCER RES, V65, P4389, DOI 10.1158/0008-5472.CAN-04-4409
   Wolowacz SE, 2007, PHARMACOECONOMICS, V25, P863, DOI 10.2165/00019053-200725100-00005
   Yang JC, 2003, NEW ENGL J MED, V349, P427, DOI 10.1056/NEJMoa021491
   Zhang P, 2007, OPHTHALMOLOGICA, V221, P411, DOI 10.1159/000107502
NR 84
TC 6
Z9 6
U1 0
U2 3
PU PROUS SCIENCE, SAU-THOMSON REUTERS
PI BARCELONA
PA 398 PROVENCA, 08025 BARCELONA, SPAIN
SN 0377-8282
EI 2013-0368
J9 DRUG FUTURE
JI Drug Future
PD JUN
PY 2008
VL 33
IS 6
BP 515
EP 525
DI 10.1358/dof.2008.033.06.1221918
PG 11
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA 328UN
UT WOS:000257823800006
DA 2022-11-30
ER

PT J
AU Badadhe, JD
   Roh, H
   Lee, BC
   Kim, JH
   Im, M
AF Badadhe, Jaya Dilip
   Roh, Hyeonhee
   Lee, Byung Chul
   Kim, Jae Hun
   Im, Maesoon
TI Ultrasound stimulation for non-invasive visual prostheses
SO FRONTIERS IN CELLULAR NEUROSCIENCE
LA English
DT Review
DE ultrasound stimulation; neuromodulation; artificial vision; vision
   restoration; visual prosthesis
ID INTENSITY FOCUSED ULTRASOUND; PHASED-ARRAY SYSTEM; RESPONSES; CHANNELS;
   VISION; CORTEX; CELLS
AB Globally, it is estimated there are more than 2.2 billion visually impaired people. Visual diseases such as retinitis pigmentosa, age-related macular degeneration, glaucoma, and optic neuritis can cause irreversible profound vision loss. Many groups have investigated different approaches such as microelectronic prostheses, optogenetics, stem cell therapy, and gene therapy to restore vision. However, these methods have some limitations such as invasive implantation surgery and unknown long-term risk of genetic manipulation. In addition to the safety of ultrasound as a medical imaging modality, ultrasound stimulation can be a viable non-invasive alternative approach for the sight restoration because of its ability to non-invasively control neuronal activities. Indeed, recent studies have demonstrated ultrasound stimulation can successfully modulate retinal/brain neuronal activities without causing any damage to the nerve cells. Superior penetration depth and high spatial resolution of focused ultrasound can open a new avenue in neuromodulation researches. This review summarizes the latest research results about neural responses to ultrasound stimulation. Also, this work provides an overview of technical viewpoints in the future design of a miniaturized ultrasound transducer for a non-invasive acoustic visual prosthesis for non-surgical and painless restoration of vision.
C1 [Badadhe, Jaya Dilip; Roh, Hyeonhee; Lee, Byung Chul; Im, Maesoon] Korea Inst Sci & Technol KIST, Brain Sci Inst, Seoul, South Korea.
   [Badadhe, Jaya Dilip; Lee, Byung Chul; Im, Maesoon] Univ Sci & Technol UST, KIST Sch, Div Biomed Sci & Technol, Seoul, South Korea.
   [Roh, Hyeonhee] Korea Univ, Coll Engn, Sch Elect Engn, Seoul, South Korea.
   [Lee, Byung Chul] Kyung Hee Univ, KHU KIST Dept Converging Sci & Technol, Seoul, South Korea.
   [Kim, Jae Hun] Korea Inst Sci & Technol KIST, Sensor Syst Res Ctr, Seoul, South Korea.
C3 Korea Institute of Science & Technology (KIST); Korea Institute of
   Science & Technology (KIST); University of Science & Technology (UST);
   Korea University; Kyung Hee University; Korea Institute of Science &
   Technology (KIST)
RP Im, M (通讯作者)，Korea Inst Sci & Technol KIST, Brain Sci Inst, Seoul, South Korea.; Im, M (通讯作者)，Univ Sci & Technol UST, KIST Sch, Div Biomed Sci & Technol, Seoul, South Korea.
EM maesoon.im@kist.re.kr
RI Im, Maesoon/AFO-1812-2022
OI Im, Maesoon/0000-0003-1152-4398
FU KIST (Korea Institute of Science and Technology) [2E31821]; National
   Research Foundation of Korea (NRF) - Ministry of Science and ICT
   [2020R1C1C1006065, 2021M3F3A2A01037366, 2022M3E5E8017395]; Korea Medical
   Device Development Fund - Korean government (Ministry of Science and
   ICT) [202011D01]; Korea Medical Device Development Fund -Korean
   government(Ministry of Trade, Industry and Energy) [202011D01]; Korea
   Medical Device Development Fund - Korean government(Ministry of Health
   and Welfare) [202011D01]; Korea Medical Device Development Fund - Korean
   government(Ministry of Food and Drug Safety) [202011D01]
FX This work was supported in part by the KIST (Korea Institute of Science
   and Technology) institutional grant (2E31821) and National R&D Program
   through the National Research Foundation of Korea (NRF) funded by the
   Ministry of Science and ICT (Nos. 2020R1C1C1006065, 2021M3F3A2A01037366,
   and 2022M3E5E8017395). Also, this work was supported in part by the
   Korea Medical Device Development Fund grant funded by the Korean
   government (Ministry of Science and ICT, Ministry of Trade, Industry and
   Energy, Ministry of Health and Welfare, Ministry of Food and Drug
   Safety) (Project Number: 202011D01).
CR Baek H, 2017, BIOMED ENG LETT, V7, P135, DOI 10.1007/s13534-016-0007-y
   Barrett JM, 2014, VISUAL NEUROSCI, V31, P345, DOI 10.1017/S0952523814000212
   Beauchamp MS, 2020, CELL, V181, P774, DOI 10.1016/j.cell.2020.04.033
   Berry MH, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09124-x
   Blackmore J, 2019, ULTRASOUND MED BIOL, V45, P1509, DOI 10.1016/j.ultrasmedbio.2018.12.015
   Cadoni S., 2021, BIORXIV, DOI [10.1101/2021.11.07.467597, DOI 10.1101/2021.11.07.467597]
   Cafarelli A, 2021, ACS NANO, V15, P11066, DOI 10.1021/acsnano.1c03087
   Dalecki D, 2004, ANNU REV BIOMED ENG, V6, P229, DOI 10.1146/annurev.bioeng.6.040803.140126
   di Biase L, 2019, FRONT NEUROL, V10, DOI 10.3389/fneur.2019.00549
   Duque M, 2022, NAT COMMUN, V13, DOI 10.1038/s41467-022-28205-y
   Fan H, 2021, BIORXIV, DOI [10.1101/2021.09.11.458049, DOI 10.1101/2021.09.11.458049]
   Farvardin M, 2018, FRONT NEUROSCI-SWITZ, V12, DOI 10.3389/fnins.2018.00584
   Fernandez Eduardo, 2018, Bioelectron Med, V4, P12, DOI 10.1186/s42234-018-0013-8
   Fomenko A, 2018, BRAIN STIMUL, V11, P1209, DOI 10.1016/j.brs.2018.08.013
   Gao MD, 2017, IEEE T NEUR SYS REH, V25, P1605, DOI 10.1109/TNSRE.2017.2682923
   Ghezzi D, 2015, FRONT NEUROSCI-SWITZ, V9, DOI 10.3389/fnins.2015.00290
   Hsiao YH, 2016, J CANCER, V7, P225, DOI 10.7150/jca.13906
   Humayun MS, 2009, IEEE ENG MED BIO, P4566, DOI 10.1109/IEMBS.2009.5332695
   Ibsen S, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9264
   Im M, 2020, J NEURAL ENG, V17, DOI 10.1088/1741-2552/ab8ca9
   Im M, 2018, J NEURAL ENG, V15, DOI 10.1088/1741-2552/aaadc1
   Im M, 2015, J PHYSIOL-LONDON, V593, P3577, DOI 10.1113/JP270606
   Jackson GR, 2002, AGEING RES REV, V1, P381, DOI 10.1016/S1568-1637(02)00007-7
   Jiang LM, 2022, NAT COMMUN, V13, DOI 10.1038/s41467-022-31599-4
   Jiang QJ, 2018, IEEE T NEUR SYS REH, V26, P969, DOI 10.1109/TNSRE.2018.2821194
   Jiang XX, 2019, IEEE T BIO-MED ENG, V66, P2704, DOI 10.1109/TBME.2018.2889669
   Johns LD, 2002, J ATHL TRAINING, V37, P293
   Jones BW, 2016, EXP EYE RES, V150, P149, DOI 10.1016/j.exer.2016.03.018
   Kang JH, 2021, IEEE T NEUR SYS REH, V29, P300, DOI 10.1109/TNSRE.2020.3048973
   Kim H, 2015, NEUROREPORT, V26, P211, DOI 10.1097/WNR.0000000000000330
   Kim S, 2022, FRONT CELL NEUROSCI, V16, DOI 10.3389/fncel.2022.911754
   Kim S, 2021, BRAIN STIMUL, V14, P290, DOI 10.1016/j.brs.2021.01.002
   Krasovitski B, 2011, P NATL ACAD SCI USA, V108, P3258, DOI 10.1073/pnas.1015771108
   Kubanek J, 2018, J NEUROSCI, V38, P3081, DOI 10.1523/JNEUROSCI.1458-17.2018
   Kubanek J, 2016, SCI REP-UK, V6, DOI 10.1038/srep24170
   Leary Brendan Vaezy and Shahram., 2008, MARKETING CLEARANCE
   Lee JI, 2019, IEEE T NEUR SYS REH, V27, P2015, DOI 10.1109/TNSRE.2019.2939012
   Lee W, 2016, SCI REP-UK, V6, DOI 10.1038/srep34026
   Lee W, 2015, SCI REP-UK, V5, DOI 10.1038/srep08743
   Legon W, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-28320-1
   Legon W, 2014, NAT NEUROSCI, V17, P322, DOI 10.1038/nn.3620
   Li GF, 2018, IEEE T ULTRASON FERR, V65, P1583, DOI 10.1109/TUFFC.2018.2847252
   Lo PA, 2020, MICROMACHINES-BASEL, V11, DOI 10.3390/mi11100929
   Lu GX, 2021, IEEE T ULTRASON FERR, V68, P21, DOI 10.1109/TUFFC.2020.3005670
   Maingret F, 1999, J BIOL CHEM, V274, P1381, DOI 10.1074/jbc.274.3.1381
   Marino A, 2017, NANO TODAY, V14, P9, DOI 10.1016/j.nantod.2016.12.005
   Marino A, 2015, ACS NANO, V9, P7678, DOI 10.1021/acsnano.5b03162
   Menz M. D., 2017, BIORXIV, DOI [10.1101/231449, DOI 10.1101/231449]
   Menz MD, 2013, J NEUROSCI, V33, P4550, DOI 10.1523/JNEUROSCI.3521-12.2013
   Menz MD, 2019, J NEUROSCI, V39, P6251, DOI 10.1523/JNEUROSCI.2394-18.2019
   MORRIS CE, 1990, J MEMBRANE BIOL, V113, P93, DOI 10.1007/BF01872883
   Naor O, 2016, J NEURAL ENG, V13, DOI 10.1088/1741-2560/13/3/031003
   Naor O, 2012, J NEURAL ENG, V9, DOI 10.1088/1741-2560/9/2/026006
   O'Brien WD, 2007, PROG BIOPHYS MOL BIO, V93, P212, DOI 10.1016/j.pbiomolbio.2006.07.010
   Palanker D, 2020, OPHTHALMOLOGY, V127, P1097, DOI 10.1016/j.ophtha.2020.02.024
   Park B, 2018, ADV MATER, V30, DOI 10.1002/adma.201706764
   Plaksin M, 2016, ENEURO, V3, DOI 10.1523/ENEURO.0136-15.2016
   Qian X., 2022, BME FRONT, V2022, DOI [10.34133/2022/9829316, DOI 10.34133/2022/9829316]
   Qiu Z., 2019, BRAIN STIMUL, V12, DOI [10.1016/j.brs.2018.12.549, DOI 10.1016/J.BRS.2018.12.549]
   Qiu ZH, 2019, ISCIENCE, V21, P448, DOI 10.1016/j.isci.2019.10.037
   Rivnay J, 2017, SCI ADV, V3, DOI 10.1126/sciadv.1601649
   Rousou C, 2021, PHARMACEUTICS, V13, DOI 10.3390/pharmaceutics13111782
   Sakai T, 2006, J OPTOELECTRON ADV M, V8, P1435
   Sarica C, 2022, BRAIN STIMUL, V15, P376, DOI 10.1016/j.brs.2021.12.012
   Seok C, 2021, IEEE T BIOMED CIRC S, V15, P705, DOI 10.1109/TBCAS.2021.3105064
   Seok C, 2021, IEEE T BIOMED CIRC S, V15, P692, DOI 10.1109/TBCAS.2021.3100458
   Shepherd RK, 2013, TRENDS BIOTECHNOL, V31, P562, DOI 10.1016/j.tibtech.2013.07.001
   Sorum B, 2021, P NATL ACAD SCI USA, V118, DOI 10.1073/pnas.2006980118
   Steiss J.E., 2004, CANINE REHABIL PHYS, V880, P324, DOI [10.1016/b978-0-7216-9555-6.50023-1, DOI 10.1016/B978-0-7216-9555-6.50023-1]
   Stingl K, 2015, VISION RES, V111, P149, DOI 10.1016/j.visres.2015.03.001
   Sukharev Sergei, 2004, Sci STKE, V2004, pre4, DOI 10.1126/stke.2192004re4
   Tochitsky I, 2016, NEURON, V92, P100, DOI 10.1016/j.neuron.2016.08.038
   Toosy AT, 2014, LANCET NEUROL, V13, P83, DOI 10.1016/S1474-4422(13)70259-X
   Tsui PH, 2005, ULTRASONICS, V43, P560, DOI 10.1016/j.ultras.2004.12.003
   Tufail Y, 2011, NAT PROTOC, V6, P1453, DOI 10.1038/nprot.2011.371
   Tyler WJ, 2018, CURR OPIN NEUROBIOL, V50, P222, DOI 10.1016/j.conb.2018.04.011
   Tyler WJ, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003511
   Wang SY, 2020, FRONT PHYSIOL, V11, DOI 10.3389/fphys.2020.00787
   Wells PNT, 2006, PHYS MED BIOL, V51, pR83, DOI 10.1088/0031-9155/51/13/R06
   Yang Y., 2020, BIORXIV, DOI [10.1101/2020.01.28.919910, DOI 10.1101/2020.01.28.919910]
   Ye J, 2018, NANO LETT, V18, P4148, DOI 10.1021/acs.nanolett.8b00935
   Yoo S, 2022, NAT COMMUN, V13, DOI 10.1038/s41467-022-28040-1
   Yu YY, 2019, SENSORS-BASEL, V19, DOI 10.3390/s19081825
   Yuan Y, 2019, CEREB CORTEX, V29, P3220, DOI 10.1093/cercor/bhy187
   Yue L, 2016, PROG RETIN EYE RES, V53, P21, DOI 10.1016/j.preteyeres.2016.05.002
   Zhao L, 2017, ULTRASOUND MED BIOL, V43, P1986, DOI 10.1016/j.ultrasmedbio.2017.04.020
   Zhuo SY, 2022, J NEURAL ENG, V19, DOI 10.1088/1741-2552/ac7d75
   Zrenner E, 2011, P ROY SOC B-BIOL SCI, V278, P1489, DOI 10.1098/rspb.2010.1747
NR 88
TC 0
Z9 0
U1 6
U2 6
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
EI 1662-5102
J9 FRONT CELL NEUROSCI
JI Front. Cell. Neurosci.
PD AUG 3
PY 2022
VL 16
AR 971148
DI 10.3389/fncel.2022.971148
PG 9
WC Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA 3U9RX
UT WOS:000841301300001
PM 35990889
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Bellapianta, A
   Cetkovic, A
   Bolz, M
   Salti, A
AF Bellapianta, Alessandro
   Cetkovic, Ana
   Bolz, Matthias
   Salti, Ahmad
TI Retinal Organoids and Retinal Prostheses: An Overview
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE retinal dystrophy; retinal organoids; iPSCs; 3D models; retinal
   prosthesis; photovoltaic polymers; organic semiconductors; blindness;
   restore vision
ID PLURIPOTENT STEM-CELLS; OPTIC-CUP MORPHOGENESIS; HUMAN IPS CELLS; OUTER
   SEGMENT; NEURAL RETINA; DIRECTED DIFFERENTIATION; CONE PHOTORECEPTORS;
   CEREBRAL ORGANOIDS; EYE DEVELOPMENT; VISION
AB Despite the progress of modern medicine in the last decades, millions of people diagnosed with retinal dystrophies (RDs), such as retinitis pigmentosa, or age-related diseases, such as age-related macular degeneration, are suffering from severe visual impairment or even legal blindness. On the one hand, the reprogramming of somatic cells into induced pluripotent stem cells (iPSCs) and the progress of three-dimensional (3D) retinal organoids (ROs) technology provide a great opportunity to study, understand, and even treat retinal diseases. On the other hand, research advances in the field of electronic retinal prosthesis using inorganic photovoltaic polymers and the emergence of organic semiconductors represent an encouraging therapeutical strategy to restore vision to patients at the late onset of the disease. This review will provide an overview of the latest advancement in both fields. We first describe the retina and the photoreceptors, briefly mention the most used RD animal models, then focus on the latest RO differentiation protocols, carry out an overview of the current technology on inorganic and organic retinal prostheses to restore vision, and finally summarize the potential utility and applications of ROs.
C1 [Bellapianta, Alessandro; Cetkovic, Ana; Bolz, Matthias; Salti, Ahmad] Johannes Kepler Univ Linz, Univ Clin Ophthalmol & Optometry, Fac Med, Ctr Med Res, A-4020 Linz, Austria.
C3 Johannes Kepler University Linz
RP Salti, A (通讯作者)，Johannes Kepler Univ Linz, Univ Clin Ophthalmol & Optometry, Fac Med, Ctr Med Res, A-4020 Linz, Austria.
EM alessandro.bellapianta@jku.at; ana.cetkovic@jku.at;
   matthias.bolz@jku.at; ahmad.salti@jku.at
RI Salti, Ahmad/AFR-7386-2022; Bolz, Matthias/HCI-0622-2022
OI Salti, Ahmad/0000-0002-7678-0125; Bellapianta,
   Alessandro/0000-0002-3375-9940
FU University Clinic for Ophthalmology and Optometry, Johannes Kepler
   University Linz, Finanzbuchhaltung Univ. Matthias Bolz, Artificial
   Retina Project
FX This review and the APC were funded by the University Clinic for
   Ophthalmology and Optometry, Johannes Kepler University Linz,
   Finanzbuchhaltung Univ. Matthias Bolz 161050, Artificial Retina Project.
CR Abbott CJ, 2018, INVEST OPHTH VIS SCI, V59, P1410, DOI 10.1167/iovs.17-23086
   Achberger K, 2019, ELIFE, V8, DOI 10.7554/eLife.46188
   Ahmad KM, 2003, VISUAL NEUROSCI, V20, P189, DOI 10.1017/S0952523803202091
   Ahuja AK, 2008, IEEE T BIO-MED ENG, V55, P1744, DOI 10.1109/TBME.2008.919126
   Alfonsetti M, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms221910334
   Allen PJ, 2021, CLIN EXP OPHTHALMOL, V49, P418, DOI 10.1111/ceo.13950
   ANDERSON DH, 1976, J ULTRA MOL STRUCT R, V55, P119, DOI 10.1016/S0022-5320(76)80087-1
   Antognazza MR, 2009, APPL PHYS LETT, V94, DOI 10.1063/1.3153846
   Antognazza MR, 2016, ADV HEALTHC MATER, V5, P2271, DOI 10.1002/adhm.201600318
   Aparicio JG, 2017, EXP EYE RES, V154, P177, DOI 10.1016/j.exer.2016.11.013
   Castro AA, 2019, STEM CELLS, V37, P1496, DOI 10.1002/stem.3089
   Aumuller G., 2017, DUALE REIHE ANATOMIE, DOI [10.1055/B-005-143674, DOI 10.1055/B-005-143674]
   Ayton LN, 2020, CLIN NEUROPHYSIOL, V131, P1383, DOI 10.1016/j.clinph.2019.11.029
   Benfenati F, 2018, LAB ANIMAL, V47, P71, DOI 10.1038/s41684-018-0003-1
   Bloch E., 2019, PROSTHESIS, DOI [10.5772/intechopen.84947, DOI 10.5772/INTECHOPEN.84947, 10.5772/INTECHOPEN.84947]
   BOWMAKER JK, 1980, J PHYSIOL-LONDON, V298, P501, DOI 10.1113/jphysiol.1980.sp013097
   BOWMAKER JK, 1980, J PHYSIOL-LONDON, V298, P131, DOI 10.1113/jphysiol.1980.sp013071
   Cameron DE, 2014, NAT REV MICROBIOL, V12, P381, DOI 10.1038/nrmicro3239
   Capowski EE, 2019, DEVELOPMENT, V146, DOI 10.1242/dev.171686
   CHA K, 1992, VISION RES, V32, P1367, DOI 10.1016/0042-6989(92)90229-C
   Chauhan BK, 2009, DEVELOPMENT, V136, P3657, DOI 10.1242/dev.042242
   Chen GK, 2010, CELL STEM CELL, V7, P240, DOI 10.1016/j.stem.2010.06.017
   Chenais NAL, 2021, COMMUN MATER, V2, DOI 10.1038/s43246-021-00133-2
   Chichagova V, 2020, STEM CELLS, V38, P195, DOI 10.1002/stem.3116
   Chow RL, 1999, DEVELOPMENT, V126, P4213
   Collin RWJ, 2017, CURR OPIN OPHTHALMOL, V28, P260, DOI 10.1097/ICU.0000000000000363
   Compagnucci C, 2016, STEM CELL TRANSL MED, V5, P860, DOI 10.5966/sctm.2015-0303
   Cooke Jessica A, 2015, Curr Ophthalmol Rep, V3, P200
   Corna A, 2018, J NEURAL ENG, V15, DOI 10.1088/1741-2552/aac1c8
   Corral-Serrano JC, 2020, P NATL ACAD SCI USA, V117, P9922, DOI 10.1073/pnas.1903125117
   Cowan CS, 2020, CELL, V182, P1623, DOI 10.1016/j.cell.2020.08.013
   CURCIO CA, 1990, J COMP NEUROL, V292, P497, DOI 10.1002/cne.902920402
   da Cruz L, 2013, BRIT J OPHTHALMOL, V97, P632, DOI 10.1136/bjophthalmol-2012-301525
   DE ROBERTIS E., 1960, JOUR GEN PHYSIOL, V43, P1
   Dekkers JF, 2013, NAT MED, V19, P939, DOI 10.1038/nm.3201
   Eiraku M, 2008, CELL STEM CELL, V3, P519, DOI 10.1016/j.stem.2008.09.002
   Eiraku M, 2011, NATURE, V472, P51, DOI 10.1038/nature09941
   Eldred KC, 2018, SCIENCE, V362, P200, DOI 10.1126/science.aau6348
   Ericsson Aaron C, 2013, Mo Med, V110, P201
   Faber H, 2020, ACTA OPHTHALMOL, V98, pE998, DOI 10.1111/aos.14435
   Fan NN, 2013, J GENET GENOMICS, V40, P67, DOI 10.1016/j.jgg.2012.07.014
   Ferlauto L, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03386-7
   Fernando M., 2021, BIORXIV, V7, DOI [10.1101/2021.05.16.444356, DOI 10.1101/2021.05.16.444356]
   Finger RP, 2011, BRIT J OPHTHALMOL, V95, P1061, DOI 10.1136/bjo.2010.194712
   Fligor CM, 2020, METHOD CELL BIOL, V159, P279, DOI 10.1016/bs.mcb.2020.02.005
   Frederick J, 2000, METHOD ENZYMOL, V316, P515
   Frings S., 2010, DUALE REIHE PHYSL
   Fuhrmann S, 2010, CURR TOP DEV BIOL, V93, P61, DOI [10.1016/S0070-2153(10)93003-2, 10.1016/B978-0-12-385044-7.00003-5]
   Fujikado T, 2016, INVEST OPHTH VIS SCI, V57, P6147, DOI 10.1167/iovs.16-20367
   Gabriel E, 2021, CELL STEM CELL, V28, P1740, DOI 10.1016/j.stem.2021.07.010
   Garcia JM, 2015, WORLD J STEM CELLS, V7, P160, DOI 10.4252/wjsc.v7.i1.160
   Garg SJ, 2013, CURR OPIN OPHTHALMOL, V24, P407, DOI 10.1097/ICU.0b013e328363829b
   Gautam V, 2014, ADV MATER, V26, P1751, DOI 10.1002/adma.201304368
   Ghezzi D, 2013, NAT PHOTONICS, V7, P400, DOI [10.1038/nphoton.2013.34, 10.1038/NPHOTON.2013.34]
   Ghezzi D, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1164
   Gonzalez-Cordero A, 2017, STEM CELL REP, V9, P820, DOI 10.1016/j.stemcr.2017.07.022
   Gregory P, 2000, J PORPHYR PHTHALOCYA, V4, P432, DOI 10.1002/(SICI)1099-1409(200006/07)4:4<432::AID-JPP254>3.3.CO;2-E
   Gupta N, 2006, BRIT J OPHTHALMOL, V90, P674, DOI 10.1136/bjo.2005.086769
   Hallam D, 2018, STEM CELLS, V36, P1535, DOI 10.1002/stem.2883
   Hallum LE, 2021, TRANSL VIS SCI TECHN, V10, DOI 10.1167/tvst.10.10.8
   Haynes T, 2007, P NATL ACAD SCI USA, V104, P20380, DOI 10.1073/pnas.0708202104
   Hecht S, 1942, J GEN PHYSIOL, V25, P819, DOI 10.1085/jgp.25.6.819
   Hiler D, 2015, CELL STEM CELL, V17, P101, DOI 10.1016/j.stem.2015.05.015
   Hong JW, 2021, ISCIENCE, V24, DOI 10.1016/j.isci.2021.103550
   Horsford DJ, 2005, DEVELOPMENT, V132, P177, DOI 10.1242/dev.01571
   Huang J, 2015, DEV BIOL, V402, P119, DOI 10.1016/j.ydbio.2015.03.006
   Huang TW, 2021, J NEURAL ENG, V18, DOI 10.1088/1741-2552/abe6b8
   Humayun MS, 2012, OPHTHALMOLOGY, V119, P779, DOI 10.1016/j.ophtha.2011.09.028
   Hunt NC, 2017, ACTA BIOMATER, V49, P329, DOI 10.1016/j.actbio.2016.11.016
   Hyer J, 2003, DEV BIOL, V259, P351, DOI 10.1016/S0012-1606(03)00205-7
   Irimia-Vladu M, 2019, CHEM MATER, V31, P6315, DOI 10.1021/acs.chemmater.9b01405
   Jayakody SA, 2015, PROG RETIN EYE RES, V46, P31, DOI 10.1016/j.preteyeres.2015.01.003
   Jones BW, 2005, EXP EYE RES, V81, P123, DOI 10.1016/j.exer.2005.03.006
   Kaya KD, 2019, MOL VIS, V25, P663
   Kim H, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18102093
   Konig H, 2013, CURR GENOMICS, V14, P11, DOI 10.2174/1389202911314010003
   Kolb H., 2012, SIMPLE ANATOMY RETIN
   Kruczek K, 2020, STEM CELLS, V38, P1206, DOI 10.1002/stem.3239
   Kuwahara A, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7286
   Lamba DA, 2006, P NATL ACAD SCI USA, V103, P12769, DOI 10.1073/pnas.0601990103
   Lancaster MA, 2017, NAT BIOTECHNOL, V35, P659, DOI 10.1038/nbt.3906
   Lancaster MA, 2014, NAT PROTOC, V9, P2329, DOI 10.1038/nprot.2014.158
   Lancaster MA, 2013, NATURE, V501, P373, DOI 10.1038/nature12517
   Lane A, 2020, STEM CELL REP, V15, P67, DOI 10.1016/j.stemcr.2020.05.007
   Leccardi MJIA, 2020, COMMUN MATER, V1, DOI 10.1038/s43246-020-0023-4
   Lee DY, 2016, OSLI RETINA, V47, P171, DOI 10.3928/23258160-20160126-11
   Li XJ, 2019, STEM CELL RES, V41, DOI 10.1016/j.scr.2019.101655
   Lin TC, 2015, J CHIN MED ASSOC, V78, P501, DOI 10.1016/j.jcma.2015.05.010
   Lorach H, 2015, NAT MED, V21, P476, DOI 10.1038/nm.3851
   Low JH, 2019, CELL STEM CELL, V25, P373, DOI 10.1016/j.stem.2019.06.009
   Lowe A, 2016, STEM CELL REP, V6, P743, DOI 10.1016/j.stemcr.2016.03.011
   Luo YHL, 2014, BRIT MED BULL, V109, P31, DOI 10.1093/bmb/ldu002
   Madrakhimov SB, 2020, MOL THER-METH CLIN D, V17, P647, DOI 10.1016/j.omtm.2020.03.018
   Maeda A, 2019, ANNU REV GENOM HUM G, V20, P201, DOI 10.1146/annurev-genom-083118-015043
   Martinez-Morales JR, 2004, BIOESSAYS, V26, P766, DOI 10.1002/bies.20064
   Mathers PH, 1997, NATURE, V387, P603, DOI 10.1038/42475
   Maya-Vetencourt JF, 2020, NAT NANOTECHNOL, V15, P698, DOI 10.1038/s41565-020-0696-3
   Maya-Vetencourt JF, 2017, NAT MATER, V16, P681, DOI [10.1038/NMAT4874, 10.1038/nmat4874]
   Medagoda DI, 2021, COMMUN MATER, V2, DOI 10.1038/s43246-021-00217-z
   Mellough CB, 2015, STEM CELLS, V33, P2416, DOI 10.1002/stem.2023
   Meyer JS, 2009, P NATL ACAD SCI USA, V106, P16698, DOI 10.1073/pnas.0905245106
   Miller JD, 2013, CELL STEM CELL, V13, P691, DOI 10.1016/j.stem.2013.11.006
   Nakano T, 2012, CELL STEM CELL, V10, P771, DOI 10.1016/j.stem.2012.05.009
   NATHANS J, 1986, SCIENCE, V232, P193, DOI 10.1126/science.2937147
   Nguyen D, 2021, FRONT NEUROSCI-SWITZ, V15, DOI 10.3389/fnins.2021.615256
   Nguyen MTT, 2000, DEVELOPMENT, V127, P3581
   O'Hara-Wright M, 2020, DEVELOPMENT, V147, DOI 10.1242/dev.189746
   Ohgushi M, 2010, CELL STEM CELL, V7, P225, DOI 10.1016/j.stem.2010.06.018
   Osakada F, 2008, NAT BIOTECHNOL, V26, P215, DOI 10.1038/nbt1384
   Osakada F, 2009, NAT PROTOC, V4, P811, DOI 10.1038/nprot.2009.51
   Palanker D, 2022, NAT COMMUN, V13, DOI 10.1038/s41467-022-28125-x
   Palanker D, 2020, OPHTHALMOLOGY, V127, P1097, DOI 10.1016/j.ophtha.2020.02.024
   PAPERMASTER DS, 1985, INVEST OPHTH VIS SCI, V26, P1386
   Parmeggiani F, 2011, CURR GENOMICS, V12, P236, DOI 10.2174/138920211795860080
   Pearson RA, 2012, NATURE, V485, P99, DOI 10.1038/nature10997
   Pearson RA, 2014, VISUAL NEUROSCI, V31, P333, DOI 10.1017/S0952523814000200
   PEPPERBERG DR, 1984, VISION RES, V24, P357, DOI 10.1016/0042-6989(84)90061-0
   Peterson SM, 2019, EXP EYE RES, V189, DOI 10.1016/j.exer.2019.107825
   Phillips MJ, 2012, INVEST OPHTH VIS SCI, V53, P2007, DOI 10.1167/iovs.11-9313
   Quadrato G, 2017, NATURE, V545, P48, DOI 10.1038/nature22047
   Rand D, 2018, ADV MATER, V30, DOI 10.1002/adma.201707292
   Reichman S, 2014, P NATL ACAD SCI USA, V111, P8518, DOI 10.1073/pnas.1324212111
   Roska B, 2018, NATURE, V557, P359, DOI 10.1038/s41586-018-0076-4
   Sahel JA, 2015, CSH PERSPECT MED, V5, DOI 10.1101/cshperspect.a017111
   Schnichels S, 2021, PROG RETIN EYE RES, V81, DOI 10.1016/j.preteyeres.2020.100880
   Scholl HPN, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aaf2838
   Schwank G, 2013, CELL STEM CELL, V13, P653, DOI 10.1016/j.stem.2013.11.002
   Seiler MJ, 2012, PROG RETIN EYE RES, V31, P661, DOI 10.1016/j.preteyeres.2012.06.003
   Shim S, 2020, MICROMACHINES-BASEL, V11, DOI 10.3390/mi11050535
   Shirai H, 2016, P NATL ACAD SCI USA, V113, pE81, DOI 10.1073/pnas.1512590113
   Simone G, 2018, ADV MATER, V30, DOI 10.1002/adma.201804678
   Singh RK, 2015, STEM CELLS DEV, V24, P2778, DOI 10.1089/scd.2015.0144
   Sinn R, 2013, MECH DEVELOP, V130, P347, DOI 10.1016/j.mod.2013.05.001
   Smith C, 2015, MOL THER, V23, P570, DOI 10.1038/mt.2014.226
   Sridhar A, 2020, CELL REP, V30, P1644, DOI 10.1016/j.celrep.2020.01.007
   STEINBERG RH, 1980, J COMP NEUROL, V190, P501, DOI 10.1002/cne.901900307
   Stern JH, 2011, NEUROTHERAPEUTICS, V8, P736, DOI 10.1007/s13311-011-0077-6
   Stiles NRB, 2021, VISION RES, V182, P58, DOI 10.1016/j.visres.2021.01.008
   Stingl K, 2017, FRONT NEUROSCI-SWITZ, V11, DOI 10.3389/fnins.2017.00445
   Sytnyk M, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00135-0
   Sytnyk M, 2014, J AM CHEM SOC, V136, P16522, DOI 10.1021/ja5073965
   Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024
   Tang ZM, 2017, J TRANSL MED, V15, DOI 10.1186/s12967-017-1183-y
   Thomson JA, 1998, SCIENCE, V282, P1145, DOI 10.1126/science.282.5391.1145
   Utz VM, 2018, OPHTHALMIC GENET, V39, P671, DOI 10.1080/13816810.2018.1533027
   Vazquez-Dominguez I, 2019, GENES-BASEL, V10, DOI 10.3390/genes10090654
   Verbakel SK, 2018, PROG RETIN EYE RES, V66, P157, DOI 10.1016/j.preteyeres.2018.03.005
   Verra DM, 2020, PROG RETIN EYE RES, V74, DOI 10.1016/j.preteyeres.2019.100776
   VILLEGAS GM, 1964, J ANAT, V98, P501
   Volkner M, 2016, STEM CELL REP, V6, P525, DOI 10.1016/j.stemcr.2016.03.001
   Vu HTV, 2005, BRIT J OPHTHALMOL, V89, P360, DOI 10.1136/bjo.2004.047498
   Wagstaff PE, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-020-79651-x
   Wahlin KJ, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-00774-9
   Wang XB, 2015, BIOMATERIALS, V53, P40, DOI 10.1016/j.biomaterials.2015.02.065
   Watanabe K, 2005, NAT NEUROSCI, V8, P288, DOI 10.1038/nn1402
   Wong AP, 2012, NAT BIOTECHNOL, V30, P876, DOI 10.1038/nbt.2328
   Wu YJ, 2020, MATER CHEM FRONT, V4, P3444, DOI 10.1039/d0qm00279h
   Zerti D, 2021, STEM CELLS, V39, P458, DOI 10.1002/stem.3331
   Zhang Xiao, 2021, Cell Regen, V10, P33, DOI 10.1186/s13619-021-00097-1
   Zhong XF, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5047
   Zhou SF, 2015, DEVELOPMENT, V142, P3294, DOI 10.1242/dev.125385
   Zhu ZR, 2014, METHOD ENZYMOL, V546, P215, DOI 10.1016/B978-0-12-801185-0.00011-8
   Zrenner E, 2011, P ROY SOC B-BIOL SCI, V278, P1489, DOI 10.1098/rspb.2010.1747
NR 163
TC 1
Z9 1
U1 6
U2 9
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1422-0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD MAR
PY 2022
VL 23
IS 6
AR 2922
DI 10.3390/ijms23062922
PG 22
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA 0C4TZ
UT WOS:000775308900001
PM 35328339
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Lohia, A
   Sahel, DK
   Salman, M
   Singh, V
   Mariappan, I
   Mittal, A
   Chitkara, D
AF Lohia, Aayushi
   Sahel, Deepak Kumar
   Salman, Mohd
   Singh, Vivek
   Mariappan, Indumathi
   Mittal, Anupama
   Chitkara, Deepak
TI Delivery strategies for CRISPR/Cas genome editing tool for retinal
   dystrophies: challenges and opportunities
SO ASIAN JOURNAL OF PHARMACEUTICAL SCIENCES
LA English
DT Review
DE CRISPR/Cas9; Gene editing; Retinal dystrophies; Non-viral nanocarriers
ID LINKED RETINITIS-PIGMENTOSA; LEBER CONGENITAL AMAUROSIS; MEDIATED
   DNA-TRANSFECTION; GENE-THERAPY; DRUG-DELIVERY; CRISPR-CAS9 NUCLEASES;
   EFFICIENT DELIVERY; HIGHLY EFFICIENT; USHER-SYNDROME; MOUSE MODEL
AB CRISPR/Cas, an adaptive immune system in bacteria, has been adopted as an efficient and precise tool for site-specific gene editing with potential therapeutic opportunities. It has been explored for a variety of applications, including gene modulation, epigenome editing, diagnosis, mRNA editing, etc. It has found applications in retinal dystrophic conditions including progressive cone and cone-rod dystrophies, congenital stationary night blindness, X-linked juvenile retinoschisis, retinitis pigmentosa, age-related macular degeneration, leber's congenital amaurosis, etc. Most of the therapies for retinal dystrophic conditions work by regressing symptoms instead of reversing the gene mutations. CRISPR/Cas9 through indel could impart beneficial effects in the reversal of gene mutations in dystrophic conditions. Recent research has also consolidated on the approaches of using CRISPR systems for retinal dystrophies but their delivery to the posterior part of the eye is a major concern due to high molecular weight, negative charge, and in vivo stability of CRISPR components. Recently, non-viral vectors have gained interest due to their potential in tissue-specific nucleic acid (miRNA/siRNA/CRISPR) delivery. This review highlights the opportunities of retinal dystrophies management using CRISPR/Cas nanomedicine. (C) 2022 Shenyang Pharmaceutical University. Published by Elsevier B.V.
C1 [Lohia, Aayushi; Sahel, Deepak Kumar; Mittal, Anupama; Chitkara, Deepak] Birla Inst Technol & Sci, Pilani BITS Pilani, Dept Pharm, Vidya Vihar Campus, Pilani 333031, Rajasthan, India.
   [Salman, Mohd; Singh, Vivek; Mariappan, Indumathi] LV Prasad Eye Inst, Champalimaud Translat Ctr Eye Res, Prof Brien Holden Eye Res Ctr, Kallam Anji Reddy Campus, Hyderabad 500034, India.
C3 Birla Institute of Technology & Science Pilani (BITS Pilani); L. V.
   Prasad Eye Institute
RP Chitkara, D (通讯作者)，Birla Inst Technol & Sci, Pilani BITS Pilani, Dept Pharm, Vidya Vihar Campus, Pilani 333031, Rajasthan, India.
EM deepak.chitkara@pilani.bits-pilani.ac.in
OI Salman, Mohd/0000-0001-5200-5274
FU Indian Council of Medical Research (ICMR) [45/66/2019-Nan/BMS,
   3/1/3/JRF-2019/HRD]; Department of Biotechnology, Ministry of Science
   and Technology (DBT) , Government of India [BT/PR26897/NNT/28/1489/2017]
FX We sincerely acknowledge the Indian Council of Medical Research (ICMR)
   for financial support through senior research fellowship (SRF) to DKS
   (file no. 45/66/2019-Nan/BMS) and junior research fellow to MS (file no.
   3/1/3/JRF-2019/HRD (LS) ) . The funding support from the Department of
   Biotechnology, Ministry of Science and Technology (DBT) , Government of
   India to DC through project grant (BT/PR26897/NNT/28/1489/2017) is duly
   acknowledged.
CR Abu-Safieh L, 2013, GENOME RES, V23, P236, DOI 10.1101/gr.144105.112
   Abudayyeh OO, 2017, NATURE, V550, P280, DOI 10.1038/nature24049
   Agrahari V, 2016, DRUG DELIV TRANSL RE, V6, P735, DOI 10.1007/s13346-016-0339-2
   Akinc A, 2005, J GENE MED, V7, P657, DOI 10.1002/jgm.696
   Aleman TS, 2004, INVEST OPHTH VIS SCI, V45, P1259, DOI 10.1167/iovs.03-1230
   Alkan F, 2018, GENOME BIOL, V19, DOI 10.1186/s13059-018-1534-x
   Azhar M, 2021, BIOSENS BIOELECTRON, V183, DOI 10.1016/j.bios.2021.113207
   Bainbridge JWB, 2015, NEW ENGL J MED, V372, P1887, DOI 10.1056/NEJMoa1414221
   Bainbridge JWB, 2008, NEW ENGL J MED, V358, P2231, DOI 10.1056/NEJMoa0802268
   Bainbridge JWB, 2002, GENE THER, V9, P320, DOI 10.1038/sj.gt.3301680
   Bakondi B, 2016, MOL THER, V24, P556, DOI 10.1038/mt.2015.220
   Balaggan KS, 2006, J GENE MED, V8, P275, DOI 10.1002/jgm.845
   Barrangou R, 2016, NAT BIOTECHNOL, V34, P933, DOI 10.1038/nbt.3659
   Bassuk AG, 2016, SCI REP-UK, V6, DOI 10.1038/srep19969
   Berger W, 2010, PROG RETIN EYE RES, V29, P335, DOI 10.1016/j.preteyeres.2010.03.004
   Boycott KM, 2001, HUM GENET, V108, P91, DOI 10.1007/s004390100461
   Bulcha JT, 2021, SIGNAL TRANSDUCT TAR, V6, DOI 10.1038/s41392-021-00487-6
   Burmistrz M, 2015, POL J MICROBIOL, V64, P193, DOI 10.5604/01.3001.0009.2114
   Burnight ER, 2018, PROG RETIN EYE RES, V65, P28, DOI 10.1016/j.preteyeres.2018.03.003
   Burnight ER, 2017, MOL THER, V25, P1999, DOI 10.1016/j.ymthe.2017.05.015
   Carroll D, 2014, ANNU REV BIOCHEM, V83, P409, DOI 10.1146/annurev-biochem-060713-035418
   Celea Christiana, 2015, Maedica (Bucur), V10, P61
   Chan L, 2017, YALE J BIOL MED, V90, P523
   Chang J, 2019, ACCOUNTS CHEM RES, V52, P665, DOI 10.1021/acs.accounts.8b00493
   Chavez A, 2015, NAT METHODS, V12, P326, DOI [10.1038/NMETH.3312, 10.1038/nmeth.3312]
   Chen D, 2018, FRONT MOL NEUROSCI, V10, DOI 10.3389/fnmol.2017.00453
   Chen GJ, 2019, NAT NANOTECHNOL, V14, P974, DOI 10.1038/s41565-019-0539-2
   Chen Y, 2006, INVEST OPHTH VIS SCI, V47, P1177, DOI 10.1167/iovs.05-0965
   Chew WL, 2016, NAT METHODS, V13, P868, DOI 10.1038/nmeth.3993
   Cho SW, 2014, GENOME RES, V24, P132, DOI 10.1101/gr.162339.113
   Choi JS, 2004, J CONTROL RELEASE, V99, P445, DOI 10.1016/j.jconrel.2004.07.027
   Cholkar K, 2013, J OCUL PHARMACOL TH, V29, P106, DOI 10.1089/jop.2012.0200
   Churchill JD, 2013, INVEST OPHTH VIS SCI, V54, P1411, DOI 10.1167/iovs.12-11541
   Colella P, 2012, HUM GENE THER, V23, P796, DOI 10.1089/hum.2012.123
   Cong L, 2013, SCIENCE, V339, P819, DOI 10.1126/science.1231143
   den Hollander AI, 2008, PROG RETIN EYE RES, V27, P391, DOI 10.1016/j.preteyeres.2008.05.003
   Deng WL, 2015, P NATL ACAD SCI USA, V112, P11870, DOI 10.1073/pnas.1515692112
   Dias MF, 2018, PROG RETIN EYE RES, V63, P107, DOI 10.1016/j.preteyeres.2017.10.004
   DiCarlo JE, 2018, J CLIN INVEST, V128, P2177, DOI 10.1172/JCI120429
   Edelhauser HF, 2010, INVEST OPHTH VIS SCI, V51, P5403, DOI 10.1167/iovs.10-5392
   Esvelt KM, 2013, NAT METHODS, V10, P1116, DOI [10.1038/NMETH.2681, 10.1038/nmeth.2681]
   Feehan JM, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-07153-4
   FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413
   Fogli S, 2018, EYE, V32, P1010, DOI 10.1038/s41433-018-0021-7
   Francis PJ, 2006, J ROY SOC MED, V99, P189, DOI 10.1258/jrsm.99.4.189
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Fry LE, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21030777
   Fu YF, 2013, NAT BIOTECHNOL, V31, P822, DOI 10.1038/nbt.2623
   Fuster-Garcia C, 2017, MOL THER-NUCL ACIDS, V8, P529, DOI 10.1016/j.omtn.2017.08.003
   Garrood WT, 2021, P NATL ACAD SCI USA, V118, DOI 10.1073/pnas.2004838117
   Gaudelli NM, 2017, NATURE, V551, P464, DOI 10.1038/nature24644
   Giannelli SG, 2018, HUM MOL GENET, V27, P761, DOI 10.1093/hmg/ddx438
   Gilbert LA, 2013, CELL, V154, P442, DOI 10.1016/j.cell.2013.06.044
   Gonzalez-Avila LU, 2021, FRONT MICROBIOL, V12, DOI 10.3389/fmicb.2021.657981
   Hacein-Bey-Abina S, 2008, J CLIN INVEST, V118, P3132, DOI 10.1172/JCI35700
   Haeussler M, 2016, GENOME BIOL, V17, DOI 10.1186/s13059-016-1012-2
   Hartong DT, 2006, LANCET, V368, P1795, DOI 10.1016/S0140-6736(06)69740-7
   Hashimoto T, 2007, GENE THER, V14, P584, DOI 10.1038/sj.gt.3302897
   Hauswirth WW, 2008, HUM GENE THER, V19, P979, DOI 10.1089/hum.2008.107
   Hejtmancik JF, 2020, P NATL ACAD SCI USA, V117, P3904, DOI 10.1073/pnas.1922925117
   Hoffman LM, 1997, INVEST OPHTH VIS SCI, V38, P2224
   Holmgaard A, 2017, MOL THER-NUCL ACIDS, V9, P89, DOI 10.1016/j.omtn.2017.08.016
   Hong DH, 2002, INVEST OPHTH VIS SCI, V43, P3373
   Hu S, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.4.31
   Huang KC, 2019, STEM CELL REP, V13, P906, DOI 10.1016/j.stemcr.2019.09.010
   Hui Sek-Wen, 2008, V423, P91, DOI 10.1007/978-1-59745-194-9_6
   Hung KL, 2018, MOL THER, V26, P456, DOI 10.1016/j.ymthe.2017.11.012
   Issa PC, 2015, P NATL ACAD SCI USA, V112, P8415, DOI 10.1073/pnas.1506960112
   Jacobson SG, 2006, INVEST OPHTH VIS SCI, V47, P4113, DOI 10.1167/iovs.06-0424
   Javed MR, 2018, CURR MICROBIOL, V75, P1675, DOI 10.1007/s00284-018-1547-4
   Jo DH, 2019, SCI ADV, V5, DOI 10.1126/sciadv.aax1210
   Jo DH, 2019, MOL THER, V27, P130, DOI 10.1016/j.ymthe.2018.10.009
   Julien S, 2008, MOL VIS, V14, P1358
   Kasdorf BT, 2015, BIOPHYS J, V109, P2171, DOI 10.1016/j.bpj.2015.10.002
   Kariko K, 2008, MOL THER, V16, P1833, DOI 10.1038/mt.2008.200
   Kim EH, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14964
   Kim K, 2017, GENOME RES, V27, P419, DOI 10.1101/gr.219089.116
   Kleinstiver BP, 2016, NATURE, V529, P490, DOI 10.1038/nature16526
   Kleinstiver BP, 2015, NATURE, V523, P481, DOI 10.1038/nature14592
   Koo T, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04175-y
   Kremer H, 2006, HUM MOL GENET, V15, pR262, DOI 10.1093/hmg/ddl205
   Ksantini M, 2012, EUR J OPHTHALMOL, V22, P647, DOI 10.5301/ejo.5000096
   Latella MC, 2016, MOL THER-NUCL ACIDS, V5, P1, DOI 10.1038/mtna.2016.92
   Lee M, 2005, PHARM RES-DORDR, V22, P1, DOI 10.1007/s11095-004-9003-5
   Lei Y, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms16026
   Lheriteau E, 2014, MOL THER, V22, P265, DOI 10.1038/mt.2013.232
   Li L, 2018, BIOMATERIALS, V171, P207, DOI 10.1016/j.biomaterials.2018.04.031
   Li L, 2015, HUM GENE THER, V26, P452, DOI 10.1089/hum.2015.069
   Li L, 2015, J BIOMED NANOTECHNOL, V11, P739, DOI 10.1166/jbn.2015.2069
   Li PJ, 2018, CRISPR J, V1, P55, DOI 10.1089/crispr.2017.0009
   Liang FQ, 2001, METH MOLEC MED, V47, P125, DOI 10.1385/1-59259-085-3:125
   Linari M, 1999, P NATL ACAD SCI USA, V96, P1315, DOI 10.1073/pnas.96.4.1315
   Lino CA, 2018, DRUG DELIV, V25, P1234, DOI 10.1080/10717544.2018.1474964
   Liu CY, 2019, SCI ADV, V5, DOI 10.1126/sciadv.aaw8922
   Liu MJ, 2019, FRONT GENET, V9, DOI 10.3389/fgene.2018.00691
   Ma YW, 2014, FEBS J, V281, P5186, DOI 10.1111/febs.13110
   Mackay DS, 2010, MOL VIS, V16, P369
   MacLaren RE, 2014, LANCET, V383, P1129, DOI 10.1016/S0140-6736(13)62117-0
   Madaan K, 2014, J PHARM BIOALLIED SC, V6, P139, DOI 10.4103/0975-7406.130965
   Maguire AM, 2008, NEW ENGL J MED, V358, P2240, DOI 10.1056/NEJMoa0802315
   Makarova KS, 2011, NAT REV MICROBIOL, V9, P467, DOI 10.1038/nrmicro2577
   Maruyama A, 1998, BIOCONJUGATE CHEM, V9, P292, DOI 10.1021/bc9701510
   Matsoukas IG, 2018, FRONT GENET, V9, DOI 10.3389/fgene.2018.00134
   McCarty DM, 2001, GENE THER, V8, P1248, DOI 10.1038/sj.gt.3301514
   Meindl A, 1996, NAT GENET, V13, P35, DOI 10.1038/ng0596-35
   Modrzejewski D, 2020, FRONT PLANT SCI, V11, DOI 10.3389/fpls.2020.574959
   Mojica FJM, 2009, MICROBIOL-SGM, V155, P733, DOI 10.1099/mic.0.023960-0
   Mout R, 2017, BIOCONJUGATE CHEM, V28, P880, DOI 10.1021/acs.bioconjchem.7b00057
   Mout R, 2017, ACS NANO, V11, P2452, DOI 10.1021/acsnano.6b07600
   Naeem M, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9071608
   Nakai H, 2001, J VIROL, V75, P6969, DOI 10.1128/JVI.75.15.6969-6976.2001
   Nandrot EE, 2004, J EXP MED, V200, P1539, DOI 10.1084/jem.20041447
   Nandrot EF, 2007, P NATL ACAD SCI USA, V104, P12005, DOI 10.1073/pnas.0704756104
   Neefjes J, 2011, NAT REV IMMUNOL, V11, P823, DOI 10.1038/nri3084
   Nickla DL, 2010, PROG RETIN EYE RES, V29, P144, DOI 10.1016/j.preteyeres.2009.12.002
   Noel NCL, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9102214
   Pacione LR, 2003, ANNU REV NEUROSCI, V26, P657, DOI 10.1146/annurev.neuro.26.041002.131416
   Palfi S, 2014, LANCET, V383, P1138, DOI 10.1016/S0140-6736(13)61939-X
   Pang JJ, 2006, MOL THER, V13, P565, DOI 10.1016/j.ymthe.2005.09.001
   Patel Ashaben, 2013, World J Pharmacol, V2, P47
   Patel N, 2016, GENET MED, V18, P554, DOI 10.1038/gim.2015.127
   Patra JK, 2018, J NANOBIOTECHNOL, V16, DOI 10.1186/s12951-018-0392-8
   Peer D, 2007, NAT NANOTECHNOL, V2, P751, DOI 10.1038/nnano.2007.387
   Qi LS, 2013, CELL, V152, P1173, DOI 10.1016/j.cell.2013.02.022
   Ramakrishna S, 2014, GENOME RES, V24, P1020, DOI 10.1101/gr.171264.113
   Ramirez-Acosta CM, 2020, PHARMACEUTICS, V12, DOI 10.3390/pharmaceutics12060561
   Ran FA, 2015, NATURE, V520, P186, DOI 10.1038/nature14299
   Roosing S, 2014, PROG RETIN EYE RES, V42, P1, DOI 10.1016/j.preteyeres.2014.05.001
   Saha SK, 2019, MOL THER-NUCL ACIDS, V14, P212, DOI 10.1016/j.omtn.2018.11.016
   Sahel DK, 2019, J PHARMACOL EXP THER, V370, P725, DOI 10.1124/jpet.119.257287
   Samson JE, 2013, NAT REV MICROBIOL, V11, P675, DOI 10.1038/nrmicro3096
   Sanjurjo-Soriano C, 2020, MOL THER-METH CLIN D, V17, P156, DOI 10.1016/j.omtm.2019.11.016
   Sanjurjo-Soriano C, 2018, NEURAL PLAST, V2018, DOI 10.1155/2018/5056279
   Schimmer J, 2015, HUM GENE THER CL DEV, V26, P144, DOI 10.1089/humc.2015.29001.sch
   SELLON DC, 1992, J VIROL, V66, P5906, DOI 10.1128/JVI.66.10.5906-5913.1992
   Sengillo JD, 2017, GENES-BASEL, V8, DOI 10.3390/genes8020053
   Shah N, 2011, J PEPT SCI, V17, P470, DOI 10.1002/psc.1347
   Shikari H, 2014, SEMIN OPHTHALMOL, V29, P276, DOI 10.3109/08820538.2014.962167
   Shin J, 2018, METHODS MOL BIOL, V1772, P151, DOI 10.1007/978-1-4939-7795-6_8
   Simonelli F, 2007, INVEST OPHTH VIS SCI, V48, P4284, DOI 10.1167/iovs.07-0068
   Sinha D, 2020, AM J HUM GENET, V107, P278, DOI 10.1016/j.ajhg.2020.06.011
   Slaymaker IM, 2016, SCIENCE, V351, P84, DOI 10.1126/science.aad5227
   Smith DW, 2020, PROG RETIN EYE RES, V78, DOI 10.1016/j.preteyeres.2020.100845
   Souto EB, 2019, PHARMACEUTICS, V11, DOI 10.3390/pharmaceutics11090460
   Stone EM, 2017, OPHTHALMOLOGY, V124, P1314, DOI 10.1016/j.ophtha.2017.04.008
   Subrizi A, 2019, DRUG DISCOV TODAY, V24, P1446, DOI 10.1016/j.drudis.2019.02.001
   Sun WJ, 2015, ANGEW CHEM INT EDIT, V54, P12029, DOI 10.1002/anie.201506030
   Sundaramurthi H, 2019, ADV EXP MED BIOL, V1185, P263, DOI 10.1007/978-3-030-27378-1_43
   Tavakoli S, 2021, MOL PHARMACEUT, V18, P699, DOI 10.1021/acs.molpharmaceut.0c00411
   Thiadens AAHJ, 2012, OPHTHALMOLOGY, V119, P819, DOI 10.1016/j.ophtha.2011.10.011
   Tsai CH, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19092830
   Tsai YT, 2018, OPHTHALMOLOGY, V125, P1421, DOI 10.1016/j.ophtha.2018.04.001
   Uddin F, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.01387
   Ueyama K, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0108071
   van Genderen MM, 2009, AM J HUM GENET, V85, P730, DOI 10.1016/j.ajhg.2009.10.012
   Varela-Fernandez R, 2020, PHARMACEUTICS, V12, DOI 10.3390/pharmaceutics12030269
   Vazquez-Dominguez I, 2019, GENES-BASEL, V10, DOI 10.3390/genes10090654
   Walters BJ, 2016, FRONT GENET, V6, DOI [10.3389/fphys.2015.00362, 10.3389/fgene.2015.00362]
   Wang D, 2015, HUM GENE THER, V26, P432, DOI 10.1089/hum.2015.087
   Wang HP, 2013, INT J MOL MED, V31, P377, DOI 10.3892/ijmm.2012.1197
   Wang M, 2016, P NATL ACAD SCI USA, V113, P2868, DOI 10.1073/pnas.1520244113
   Wei T, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-17029-3
   Wilbie D, 2019, ACCOUNTS CHEM RES, V52, P1555, DOI 10.1021/acs.accounts.9b00106
   Wu WH, 2016, MOL THER, V24, P1388, DOI 10.1038/mt.2016.107
   Xu WH, 2019, METHODS MOL BIOL, V1874, P1, DOI 10.1007/978-1-4939-8831-0_1
   Xu XY, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-30227-w
   Yang Y, 1996, GENE THER, V3, P137
   Yanik M, 2017, PROG RETIN EYE RES, V56, P1, DOI 10.1016/j.preteyeres.2016.09.001
   Ye GJ, 2016, HUM GENE THER, V27, P72, DOI 10.1089/hum.2015.130
   Yin H, 2014, NAT REV GENET, V15, P541, DOI 10.1038/nrg3763
   Yu HZ, 2020, FRONT BIOENG BIOTECH, V8, DOI 10.3389/fbioe.2020.601246
   Yu TZ, 2012, ANGEW CHEM INT EDIT, V51, P8478, DOI 10.1002/anie.201203920
   Yu WH, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14716
   Zaneveld J, 2013, SCI CHINA LIFE SCI, V56, P125, DOI 10.1007/s11427-013-4443-y
   Zetsche B, 2015, NAT BIOTECHNOL, V33, P139, DOI 10.1038/nbt.3149
   Zhan TZ, 2019, SEMIN CANCER BIOL, V55, P106, DOI 10.1016/j.semcancer.2018.04.001
   Zhang QJ, 2016, ASIA-PAC J OPHTHALMO, V5, P265, DOI 10.1097/APO.0000000000000227
   Zhang Z, 2019, MACROMOL RAPID COMM, V40, DOI 10.1002/marc.201800068
   Zincarelli C, 2008, MOL THER, V16, P1073, DOI 10.1038/mt.2008.76
   Zinkernagel MS, 2015, CLIN OPHTHALMOL, V9, P2195, DOI 10.2147/OPTH.S65732
   Zinshteyn B, 2009, WIRES SYST BIOL MED, V1, P202, DOI 10.1002/wsbm.10
NR 181
TC 2
Z9 2
U1 6
U2 6
PU SHENYANG PHARMACEUTICAL UNIV
PI SHENYANG
PA SHENYANG PHARMACEUTICAL UNIV, NO 103, WENHUA RD, SHENYANG, 110016,
   PEOPLES R CHINA
SN 1818-0876
J9 ASIAN J PHARM SCI
JI Asian J. Pharm. Sci.
PD MAR
PY 2022
VL 17
IS 2
BP 153
EP 176
DI 10.1016/j.ajps.2022.02.001
PG 24
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA 1K2IX
UT WOS:000798432200001
PM 36320315
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Demir, F
   Tasci, B
AF Demir, Fatih
   Tasci, Burak
TI An Effective and Robust Approach Based on R-CNN+LSTM Model and NCAR
   Feature Selection for Ophthalmological Disease Detection from Fundus
   Images
SO JOURNAL OF PERSONALIZED MEDICINE
LA English
DT Article
DE ophthalmological disease; fundus images; R-CNN+LSTM; NCAR feature
   selection
ID DIAGNOSIS
AB Changes in and around anatomical structures such as blood vessels, optic disc, fovea, and macula can lead to ophthalmological diseases such as diabetic retinopathy, glaucoma, age-related macular degeneration (AMD), myopia, hypertension, and cataracts. If these diseases are not diagnosed early, they may cause partial or complete loss of vision in patients. Fundus imaging is the primary method used to diagnose ophthalmologic diseases. In this study, a powerful R-CNN+LSTM-based approach is proposed that automatically detects eight different ophthalmologic diseases from fundus images. Deep features were extracted from fundus images with the proposed R-CNN+LSTM structure. Among the deep features extracted, those with high representative power were selected with an approach called NCAR, which is a multilevel feature selection algorithm. In the classification phase, the SVM algorithm, which is a powerful classifier, was used. The proposed approach is evaluated on the eight-class ODIR dataset. The accuracy (main metric), sensitivity, specificity, and precision metrics were used for the performance evaluation of the proposed approach. Besides, the performance of the proposed approach was compared with the existing approaches using the ODIR dataset.
C1 [Demir, Fatih; Tasci, Burak] Firat Univ, Vocat Sch Tech Sci, TR-23119 Elazig, Turkey.
C3 Firat University
RP Tasci, B (通讯作者)，Firat Univ, Vocat Sch Tech Sci, TR-23119 Elazig, Turkey.
EM fatihdemir@firat.edu.tr; btasci@firat.edu.tr
RI Demir, Fatih/M-3012-2017; TAŞCI, Burak/L-7100-2018
OI TAŞCI, Burak/0000-0002-4490-0946; Demir, Fatih/0000-0003-3210-3664
CR Abramoff Michael D, 2010, IEEE Rev Biomed Eng, V3, P169, DOI 10.1109/RBME.2010.2084567
   Agarap A.F.M., 2019, ARXIV180308375
   Almazroa A, 2015, J OPHTHALMOL, V2015, DOI 10.1155/2015/180972
   Ashraf MN, 2014, 2014 11TH INTERNATIONAL CONFERENCE ON COMPUTER GRAPHICS, IMAGING AND VISUALIZATION (CGIV): NEW TECHNIQUES AND TRENDS, P57, DOI 10.1109/CGiV.2014.29
   Baygin M, 2021, BIOMED SIGNAL PROCES, V70, DOI 10.1016/j.bspc.2021.102936
   Buduma N., 2017, FUNDAMENTALS DEEP LE
   Chai YD, 2018, KNOWL-BASED SYST, V161, P147, DOI 10.1016/j.knosys.2018.07.043
   Deepak S, 2019, COMPUT BIOL MED, V111, DOI 10.1016/j.compbiomed.2019.103345
   Demir F, 2021, IEEE SENS J, V21, P14923, DOI 10.1109/JSEN.2021.3070373
   Elloumi Yaroub, 2021, Artificial Intelligence in Medicine. 19th International Conference on Artificial Intelligence in Medicine, AIME 2021. Proceedings. Lecture Notes in Artificial Intelligence, Subseries of Lecture Notes in Computer Science (LNCS 12721), P355, DOI 10.1007/978-3-030-77211-6_40
   Gagnon L, 2001, PROC SPIE, V4322, P1218, DOI 10.1117/12.430999
   Gour M., 2020, ARXIV200613817
   Gour N, 2021, BIOMED SIGNAL PROCES, V66, DOI 10.1016/j.bspc.2020.102329
   He JJ, 2021, BIOMED SIGNAL PROCES, V67, DOI 10.1016/j.bspc.2021.102491
   Hochreiter S., 1997, STUD COMPUT INTELL, V9, P1735, DOI DOI 10.1007/978-3-642-24797-2
   Ioffe S, 2015, PR MACH LEARN RES, V37, P448
   Islam Md Tariqul, 2019, 2019 IEEE International Conference on Signal Processing, Information, Communication & Systems (SPICSCON), P59, DOI 10.1109/SPICSCON48833.2019.9065162
   Ismael AM, 2021, EXPERT SYST APPL, V164, DOI 10.1016/j.eswa.2020.114054
   Jin J., 2014, ARXIV14125474
   Jordi C.C., 2019, OCULAR DIS INTELLIGE
   Kanski J.J., 2011, CLIN OPHTHALMOLOGY S, V7th
   Kaur T, 2020, MACH VISION APPL, V31, DOI 10.1007/s00138-020-01069-2
   Khan IA, 2020, PROCEEDINGS OF 2020 11TH INTERNATIONAL CONFERENCE ON ELECTRICAL AND COMPUTER ENGINEERING (ICECE), P491, DOI 10.1109/ICECE51571.2020.9393050
   Khan MSM, 2021, 2021 IEEE WORLD AI IOT CONGRESS (AIIOT), P209, DOI [10.1109/AIIoT52608.2021.9454244, 10.1109/AIIOT52608.2021.9454244]
   Khare SK, 2021, IEEE T INSTRUM MEAS, V70, DOI 10.1109/TIM.2021.3070608
   Krizhevsky A, 2017, COMMUN ACM, V60, P84, DOI 10.1145/3065386
   Li F, 2019, GRAEF ARCH CLIN EXP, V257, P495, DOI 10.1007/s00417-018-04224-8
   Ning Li, 2021, Benchmarking, and Optimizing Measuring. Third BenchCouncil International Symposium, Bench 2020. Revised Selected Papers. Lecture Notes in Computer Science (LNCS 12614), P177, DOI 10.1007/978-3-030-71058-3_11
   Orfao J, 2021, LECT NOTES COMPUT SC, V12722, P30, DOI 10.1007/978-3-030-80432-9_3
   Raghavendra U, 2018, INFORM SCIENCES, V441, P41, DOI 10.1016/j.ins.2018.01.051
   Reza AW, 2011, J MED SYST, V35, P17, DOI 10.1007/s10916-009-9337-y
   Robnik-Sikonja M, 2003, MACH LEARN, V53, P23, DOI 10.1023/A:1025667309714
   Santurkar S, 2018, ADV NEUR IN, V31
   Simonyan K., 2014, PREPRINT, DOI DOI 10.48550/ARXIV.1409.1556
   Singh TP, 2020, P I MECH ENG C-J MEC, V234, P544, DOI 10.1177/0954406219880209
   Srivastava N, 2014, J MACH LEARN RES, V15, P1929
   Sun T., TELEAEYE LOW COST AU
   Togacar M, 2020, COMPUT BIOL MED, V121, DOI 10.1016/j.compbiomed.2020.103805
   Tuncer T, 2021, BIOMED SIGNAL PROCES, V68, DOI 10.1016/j.bspc.2021.102591
   Turkoglu M, 2021, APPL INTELL, V51, P1213, DOI 10.1007/s10489-020-01888-w
   Wang J, 2020, IEEE ACCESS, V8, P212499, DOI 10.1109/ACCESS.2020.3040275
   Weng TW, 2018, PR MACH LEARN RES, V80
   Yang W, 2012, J COMPUT, V7, P161, DOI 10.4304/jcp.7.1.161-168
   Yannuzzi LA, 2004, AM J OPHTHALMOL, V137, P511, DOI 10.1016/j.ajo.2003.12.035
NR 44
TC 3
Z9 3
U1 3
U2 4
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2075-4426
J9 J PERS MED
JI J. Pers. Med.
PD DEC
PY 2021
VL 11
IS 12
AR 1276
DI 10.3390/jpm11121276
PG 18
WC Health Care Sciences & Services; Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Health Care Sciences & Services; General & Internal Medicine
GA XZ6KT
UT WOS:000737759400001
PM 34945747
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Lopez-Cuenca, I
   de Hoz, R
   Alcantara-Rey, C
   Salobrar-Garcia, E
   Elvira-Hurtado, L
   Fernandez-Albarral, JA
   Barabash, A
   Ramirez-Torano, F
   de Frutos-Lucas, J
   Salazar, JJ
   Ramirez, AI
   Ramirez, JM
AF Lopez-Cuenca, Ines
   de Hoz, Rosa
   Alcantara-Rey, Celia
   Salobrar-Garcia, Elena
   Elvira-Hurtado, Lorena
   Fernandez-Albarral, Jose A.
   Barabash, Ana
   Ramirez-Torano, Federico
   de Frutos-Lucas, Jaisalmer
   Salazar, Juan J.
   Ramirez, Ana I.
   Ramirez, Jose M.
TI Foveal Avascular Zone and Choroidal Thickness Are Decreased in Subjects
   with Hard Drusen and without High Genetic Risk of Developing Alzheimer's
   Disease
SO BIOMEDICINES
LA English
DT Article
DE Alzheimer's; family history; ApoE e4; AMD; choroid; foveal avascular
   zone; hard drusen; retina; OCT; OCTA
ID CEREBRAL AMYLOID ANGIOPATHY; APOLIPOPROTEIN-E; MACULAR DEGENERATION;
   RETINAL MICROVASCULATURE; MOUSE MODEL; BLOOD-FLOW; AGE; ASSOCIATION;
   NEUROPATHOLOGY; ANGIOGRAPHY
AB A family history (FH+) of Alzheimer's disease (AD) and epsilon 4 allele of the ApoE gene are the main genetic risk factors for developing AD, whereas epsilon 4 allele plays a protective role in age-related macular degeneration. Ocular vascular changes have been reported in both pathologies. We analyzed the choroidal thickness using optical coherence tomography (OCT) and the foveal avascular zone (FAZ) using OCT-angiography and compared the results with ApoE gene expression, AD FH+, and the presence or absence of hard drusen (HD) in 184 cognitively healthy subjects. Choroidal thickness was statistically significantly different in the (FH-, epsilon 4-, HD+) group compared with (i) both the (FH-, epsilon 4-, HD-) and the (FH+, epsilon 4+, HD+) groups in the superior and inferior points at 1500 mu m, and (ii) the (FH+, epsilon 4-, HD+) group in the superior point at 1500 mu m. There were statistically significant differences in the superficial FAZ between the (FH+, epsilon 4-, HD+) group and (i) the (FH+, epsilon 4-, HD-) group and (ii) the (FH+, epsilon 4+, HD-) group. In conclusion, ocular vascular changes are not yet evident in participants with a genetic risk of developing AD.
C1 [Lopez-Cuenca, Ines; de Hoz, Rosa; Alcantara-Rey, Celia; Salobrar-Garcia, Elena; Elvira-Hurtado, Lorena; Fernandez-Albarral, Jose A.; Salazar, Juan J.; Ramirez, Ana I.; Ramirez, Jose M.] Univ Complutense Madrid UCM, Inst Investigaci Oftalmolog Ramon Castroviejo, IdISSC, Madrid 28040, Spain.
   [Lopez-Cuenca, Ines; de Hoz, Rosa; Salobrar-Garcia, Elena; Salazar, Juan J.; Ramirez, Ana I.; Ramirez, Jose M.] OFTARED Inst Salud Carlos 3, Madrid 28029, Spain.
   [de Hoz, Rosa; Salobrar-Garcia, Elena; Salazar, Juan J.; Ramirez, Ana I.] Univ Complutense Madrid, Fac Opt & Optometria, Dept Inmunol Oftalmol & ORL, Madrid 28037, Spain.
   [Barabash, Ana] Hosp Clin Univ San Carlos, Inst Invest Sanitaria, Endocrinol & Nutr Dept, Madrid 28040, Spain.
   [Barabash, Ana] Inst Salud Carlos 3, Centro Investigac Biomed Red Diabet Enfermedades, Madrid 28029, Spain.
   [Ramirez-Torano, Federico; de Frutos-Lucas, Jaisalmer] Tech Univ Madrid, Ctr Biomed Technol, Lab Cognit & Computat Neurosci, Madrid 28233, Spain.
   [Ramirez-Torano, Federico; de Frutos-Lucas, Jaisalmer] Univ Complutense Madrid, Dept Expt Psychol, Madrid 28223, Spain.
   [de Frutos-Lucas, Jaisalmer] Edith Cowan Univ, Ctr Precis Hlth, Joondalup, WA, Australia.
   [de Frutos-Lucas, Jaisalmer] Univ Antonio Nebrija, Fac Ciencias Vida Naturaleza, Dept Psicologia, Madrid 28015, Spain.
   [Ramirez, Jose M.] Univ Complutense Madrid, Fac Med, Dept Inmunol, Madrid 28040, Spain.
C3 Complutense University of Madrid; Complutense University of Madrid;
   Instituto de Salud Carlos III; Universidad Politecnica de Madrid;
   Complutense University of Madrid; Edith Cowan University; Universidad
   Antonio de Nebrija; Complutense University of Madrid
RP Ramirez, JM (通讯作者)，Univ Complutense Madrid UCM, Inst Investigaci Oftalmolog Ramon Castroviejo, IdISSC, Madrid 28040, Spain.; Ramirez, JM (通讯作者)，OFTARED Inst Salud Carlos 3, Madrid 28029, Spain.; Ramirez, JM (通讯作者)，Univ Complutense Madrid, Fac Med, Dept Inmunol, Madrid 28040, Spain.
EM inelopez@ucm.es; rdehoz@med.ucm.es; celiaalc@ucm.es;
   elenasalobrar@med.ucm.es; marelvir@ucm.es; joseaf08@ucm.es;
   ana.barabash@gmail.com; federico.ramirez@ctb.upm.es;
   jaisamer.defrutos@ctb.upm.es; jjsalazar@med.ucm.es;
   airamirez@med.ucm.es; ramirezs@med.ucm.es
RI Ramírez, Ana I/ABF-4789-2021; Salobrar-Garcia, Elena/I-6908-2019;
   Barabash, Ana M/B-1612-2012; Barabash, Ana/AAD-2141-2020;
   Fernández-Albarral, Jose A./AAG-4357-2020; Salazar, Juan J/L-6887-2014
OI Ramírez, Ana I/0000-0002-2656-4723; Salobrar-Garcia,
   Elena/0000-0001-5939-5551; Barabash, Ana M/0000-0003-2383-1563;
   Barabash, Ana/0000-0003-2383-1563; Fernández-Albarral, Jose
   A./0000-0003-0399-7996; Salazar, Juan J/0000-0001-5480-5902
FU Ophthalmological Network OFTARED of the Institute of Health of Carlos
   III of the Spanish Ministry of Science and Innovation [RD16/0008/0005];
   Research Network RETIBRAIN of the Spanish Ministry of Science and
   Innovation [RED2018-102499-T]; Spanish Ministry of Economy and
   Competitiveness [PSI2015-68793-C3-1-R]; Complutense University of Madrid
   [CT42/18-CT43/18]; Spanish Ministry of Science, Innovation, and
   Universities [FPU17/01023]
FX This research was funded by the Ophthalmological Network OFTARED
   (RD16/0008/0005) of the Institute of Health of Carlos III of the Spanish
   Ministry of Science and Innovation; the Research Network RETIBRAIN
   (RED2018-102499-T) of the Spanish Ministry of Science and Innovation;
   and the Spanish Ministry of Economy and Competitiveness (Grant
   PSI2015-68793-C3-1-R). I.L.-C. is currently supported by a Predoctoral
   Fellowship (CT42/18-CT43/18) from the Complutense University of Madrid.
   J.A.F.-A. is currently supported by a Predoctoral Fellowship
   (FPU17/01023) from the Spanish Ministry of Science, Innovation, and
   Universities. The sponsor or funding organization had no role in the
   design or conduct of this research. Approval date: 17 December 2018.
CR Anderson DH, 2001, AM J OPHTHALMOL, V131, P767, DOI 10.1016/S0002-9394(00)00961-2
   Arvanitakis Z, 2011, ANN NEUROL, V69, P320, DOI 10.1002/ana.22112
   Baird PN, 2006, HUM MUTAT, V27, P337, DOI 10.1002/humu.20288
   Bayhan HA, 2015, CLIN EXP OPHTHALMOL, V43, P145, DOI 10.1111/ceo.12386
   Bendlin BB, 2010, MATURITAS, V65, P131, DOI 10.1016/j.maturitas.2009.12.014
   Berenberg TL, 2012, RETINA-J RET VIT DIS, V32, P25, DOI 10.1097/IAE.0b013e3182150483
   Bertram L, 2010, NEURON, V68, P270, DOI 10.1016/j.neuron.2010.10.013
   Boker T, 1993, Ger J Ophthalmol, V2, P10
   Boon CJF, 2013, PROG RETIN EYE RES, V37, P90, DOI 10.1016/j.preteyeres.2013.08.003
   Boyle PA, 2015, NEUROLOGY, V85, P1930, DOI 10.1212/WNL.0000000000002175
   Brown WR, 2011, NEUROPATH APPL NEURO, V37, P56, DOI 10.1111/j.1365-2990.2010.01139.x
   Bulut M, 2018, BRIT J OPHTHALMOL, V102, P233, DOI 10.1136/bjophthalmol-2017-310476
   Bulut M, 2016, J OPHTHALMOL, V2016, DOI 10.1155/2016/7291257
   CHEN JC, 1992, INVEST OPHTH VIS SCI, V33, P334
   Cheung CY, 2019, CURR OPIN NEUROL, V32, P82, DOI 10.1097/WCO.0000000000000645
   Chua J, 2020, ALZHEIMERS RES THER, V12, DOI 10.1186/s13195-020-00724-0
   Chung SE, 2011, OPHTHALMOLOGY, V118, P840, DOI 10.1016/j.ophtha.2010.09.012
   Conrath J, 2005, EYE, V19, P322, DOI 10.1038/sj.eye.6701456
   Cunha Joao Paulo, 2017, Alzheimers Dement (Amst), V8, P11, DOI 10.1016/j.dadm.2017.03.004
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   Delaey C, 2000, OPHTHALMIC RES, V32, P249, DOI 10.1159/000055622
   Donix M, 2012, NEUROPSYCHOL REV, V22, P298, DOI 10.1007/s11065-012-9193-2
   Edwards GA, 2019, FRONT AGING NEUROSCI, V11, DOI 10.3389/fnagi.2019.00146
   Feke Gilbert T, 2015, Alzheimers Dement (Amst), V1, P144, DOI 10.1016/j.dadm.2015.01.004
   FOSTER NL, 1984, ANN NEUROL, V16, P649, DOI 10.1002/ana.410160605
   FRIEDMAN E, 1989, OPHTHALMOLOGY, V96, P104
   Frost S, 2013, TRANSL PSYCHIAT, V3, DOI 10.1038/tp.2012.150
   Gharbiya M, 2014, J ALZHEIMERS DIS, V40, P907, DOI 10.3233/JAD-132039
   GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4
   Grewal DS, 2018, OSLI RETINA, V49, P440, DOI 10.3928/23258160-20180601-09
   HOLZ FG, 1994, OPHTHALMOLOGY, V101, P1522
   Jayadev S, 2008, ARCH NEUROL-CHICAGO, V65, P373, DOI 10.1001/archneurol.2007.61
   Jiang H, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0192154
   Johnson NA, 2005, RADIOLOGY, V234, P851, DOI 10.1148/radiol.2343040197
   Kaarniranta K, 2011, J ALZHEIMERS DIS, V24, P615, DOI 10.3233/JAD-2011-101908
   Kimbrough IF, 2015, BRAIN, V138, P3716, DOI 10.1093/brain/awv327
   Klaver CCW, 1998, AM J HUM GENET, V63, P200, DOI 10.1086/301901
   Koh LHL, 2017, ACTA OPHTHALMOL, V95, pE597, DOI 10.1111/aos.13399
   Koronyo Y, 2015, BRAIN, V138, P2399, DOI 10.1093/brain/awv150
   Lopez-de-Eguileta A, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0239484
   Louveau A, 2017, J CLIN INVEST, V127, P3210, DOI 10.1172/JCI90603
   Lutty GA, 2020, EXP EYE RES, V192, DOI 10.1016/j.exer.2020.107939
   Marz W, 2004, EUR HEART J, V25, P2109, DOI 10.1016/j.ehj.2004.08.024
   McKay GJ, 2011, HUM MUTAT, V32, P1407, DOI 10.1002/humu.21577
   Mullins RE, 2011, INVEST OPHTH VIS SCI, V52, P1606, DOI 10.1167/iovs.10-6476
   NAMBA Y, 1991, BRAIN RES, V541, P163, DOI 10.1016/0006-8993(91)91092-F
   Nickla DL, 2010, PROG RETIN EYE RES, V29, P144, DOI 10.1016/j.preteyeres.2009.12.002
   O'Bryhim BE, 2018, JAMA OPHTHALMOL, V136, P1242, DOI 10.1001/jamaophthalmol.2018.3556
   PAULEIKHOFF D, 1990, AM J OPHTHALMOL, V109, P211, DOI 10.1016/S0002-9394(14)75989-6
   Perl DP, 2010, MT SINAI J MED, V77, P32, DOI 10.1002/msj.20157
   PRUNTE C, 1988, GRAEF ARCH CLIN EXP, V226, P55, DOI 10.1007/BF02172719
   Ramirez J.M., 2005, DEGENERACION MACULAR, P1
   Ramirez J.M., 2014, CARDIOVASCULAR DIS 2, P123
   Ramirez JM, 2001, EXP EYE RES, V73, P601, DOI 10.1006/exer.2001.1061
   Ravi Teja Karru Venkata, 2017, J Gerontol Geriatr Res, V6, DOI 10.4172/2167-7182.1000447
   Ribalta J, 2003, CURR OPIN CLIN NUTR, V6, P177, DOI 10.1097/00075197-200303000-00006
   ROHER AE, 1993, P NATL ACAD SCI USA, V90, P10836, DOI 10.1073/pnas.90.22.10836
   Salobrar-Garcia E, 2020, J PERS MED, V10, DOI 10.3390/jpm10040231
   Savva GM, 2009, NEW ENGL J MED, V360, P2302, DOI 10.1056/NEJMoa0806142
   Schultz N, 2020, J ALZHEIMERS DIS, V73, P1201, DOI 10.3233/JAD-190868
   Shi HS, 2020, ACTA NEUROPATHOL, V139, P813, DOI 10.1007/s00401-020-02134-w
   Shin JY, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-020-80892-z
   Smyth LCD, 2018, J CHEM NEUROANAT, V92, P48, DOI 10.1016/j.jchemneu.2018.06.001
   SNODDERLY DM, 1992, J NEUROSCI, V12, P1169
   Souied EH, 1998, AM J OPHTHALMOL, V125, P353, DOI 10.1016/S0002-9394(99)80146-9
   Sperling RA, 2011, ALZHEIMERS DEMENT, V7, P280, DOI 10.1016/j.jalz.2011.03.003
   Tekirian TL, 1998, J NEUROPATH EXP NEUR, V57, P76, DOI 10.1097/00005072-199801000-00009
   Thal DR, 2008, ACTA NEUROPATHOL, V115, P599, DOI 10.1007/s00401-008-0366-2
   Toops KA, 2016, ADV EXP MED BIOL, V854, P3, DOI 10.1007/978-3-319-17121-0_1
   Trebbastoni A, 2017, ALZ DIS ASSOC DIS, V31, P128, DOI 10.1097/WAD.0000000000000176
   Trivino A, 2005, HISTOL HISTOPATHOL, V20, P393, DOI 10.14670/HH-20.393
   Trivino A, 2002, ANAT EMBRYOL, V205, P417, DOI 10.1007/s00429-002-0257-6
   van de Kreeke JA, 2020, BRIT J OPHTHALMOL, V104, P157, DOI 10.1136/bjophthalmol-2019-314127
   Wang X, 2021, FRONT AGING NEUROSCI, V12, DOI 10.3389/fnagi.2020.572484
   Williams Michael A, 2015, Alzheimers Dement (Amst), V1, P229
   Wylegala A, 2018, CURR NEUROL NEUROSCI, V18, DOI 10.1007/s11910-018-0911-x
   Yoon SP, 2019, OPHTHALMOL RETINA, V3, P489, DOI 10.1016/j.oret.2019.02.002
   Zabel P, 2019, INVEST OPHTH VIS SCI, V60, P3447, DOI 10.1167/iovs.19-27028
   Zareparsi S, 2004, INVEST OPHTH VIS SCI, V45, P1306, DOI 10.1167/iovs.03-1253
   Zhang YS, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0214685
NR 80
TC 3
Z9 3
U1 3
U2 5
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2227-9059
J9 BIOMEDICINES
JI Biomedicines
PD JUN
PY 2021
VL 9
IS 6
AR 638
DI 10.3390/biomedicines9060638
PG 14
WC Biochemistry & Molecular Biology; Medicine, Research & Experimental;
   Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Research & Experimental Medicine;
   Pharmacology & Pharmacy
GA SX9OK
UT WOS:000665526100001
PM 34199664
OA Green Accepted, gold, Green Published
DA 2022-11-30
ER

PT J
AU Nashine, S
   Kenney, MC
AF Nashine, Sonali
   Kenney, M. Cristina
TI Role of Citicoline in an in vitro AMD model
SO AGING-US
LA English
DT Article
DE Citicoline; age-related macular degeneration (AMD); neuroprotection;
   RPE; mitochondria
ID CDP-CHOLINE; CYTIDINE-5'-DIPHOSPHOCHOLINE CITICOLINE; EXPRESSION;
   APOPTOSIS; CASPASE-3; EFFICACY; GLAUCOMA; SAFETY
AB Citicoline is the exogenous form of the nootropic, Cytidine 5'-diphosphate-choline that exerts its neuroprotective effects in the brain as well as in the eye. The current study characterized the cytoprotective effects of purified Citicoline in transmitochondrial AMD (Age-related Macular Degeneration) RPE cybrid cells which carry diseased mitochondria from clinically characterized AMD patients. The effects of Citicoline were examined via flow cytometry analysis of AnnexinV/PI-stained cells, IncuCyte live-cell imaging analysis to quantify cells undergoing caspase-3/7-mediated apoptosis, analyses of gene expression profiles of apoptosis, hypoxia, and angiogenesis markers, and measurement of ROS levels and cell viability. Our results demonstrated that Citicoline when added exogenously alleviates apoptotic effects as evidenced by diminished AnnexinV/PI and Caspase-3/7 staining, downregulation of apoptosis genes, enhanced cell viability, and reduced oxidative stress in AMD RPE cybrid cells. In conclusion, our study identified Citicoline as a protector in AMD RPE cybrid cells in vitro. However, further studies are required to establish the merit of Citicoline as a cytoprotective molecule in AMD and to decipher the molecular underpinnings of its mechanism of action in AMD.
C1 [Nashine, Sonali; Kenney, M. Cristina] Univ Calif Irvine, Gavin Herbert Eye Inst, Dept Ophthalmol, Irvine, CA 92697 USA.
   [Kenney, M. Cristina] Univ Calif Irvine, Dept Pathol & Lab Med, Irvine, CA 92697 USA.
C3 University of California System; University of California Irvine;
   University of California System; University of California Irvine
RP Kenney, MC (通讯作者)，Univ Calif Irvine, Gavin Herbert Eye Inst, Dept Ophthalmol, Irvine, CA 92697 USA.; Kenney, MC (通讯作者)，Univ Calif Irvine, Dept Pathol & Lab Med, Irvine, CA 92697 USA.
EM mkenney@uci.edu
FU Arnold and Mabel Beckman Foundation; Discovery Eye Foundation; Polly and
   Michael Smith; Edith and Roy Carver; Iris and B. Gerald Cantor
   Foundation; Unrestricted Departmental Grant from Research to Prevent
   Blindness; NEI [R01 EY0127363]; UCI School of Medicine; Institute for
   Clinical and Translational Science (ICTS) at University of California
   Irvine; 2017 Genentech/ARVO AMD Translational Research Fellowship; 2016
   RPB pilot research grant
FX This research was funded by Arnold and Mabel Beckman Foundation,
   Discovery Eye Foundation, Polly and Michael Smith, Edith and Roy Carver,
   Iris and B. Gerald Cantor Foundation, Unrestricted Departmental Grant
   from Research to Prevent Blindness and NEI R01 EY0127363, UCI School of
   Medicine, and support of the Institute for Clinical and Translational
   Science (ICTS) at University of California Irvine. S.N. is a recipient
   of the 2017 Genentech/ARVO AMD Translational Research Fellowship and the
   2016 RPB pilot research grant.
CR Adibhatla RM, 2003, J NEUROSCI RES, V73, P308, DOI 10.1002/jnr.10672
   Alvarez XA, 1999, METHOD FIND EXP CLIN, V21, P535, DOI 10.1358/mf.1999.21.8.794835
   Bogdanov P, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19082458
   Cho HJ, 2009, METHOD FIND EXP CLIN, V31, P171, DOI 10.1358/mf.2009.31.3.1364241
   Conant Richard, 2004, Altern Med Rev, V9, P17
   Cotroneo AM, 2013, CLIN INTERV AGING, V8, P131, DOI 10.2147/CIA.S38420
   EBERHARDT R, 1990, CLIN THER, V12, P489
   El-Assaad F, 2014, ANTIMICROB AGENTS CH, V58, P602, DOI 10.1128/AAC.02591-12
   Fagone P, 2013, BBA-MOL CELL BIOL L, V1831, P523, DOI 10.1016/j.bbalip.2012.09.009
   Gareri P, 2015, CLIN INTERV AGING, V10, P1421, DOI 10.2147/CIA.S87886
   Grieb P, 2014, CNS DRUGS, V28, P185, DOI 10.1007/s40263-014-0144-8
   Hurtado O, 2013, J NEUROCHEM, V126, P819, DOI 10.1111/jnc.12269
   Ju LP, 2018, BIOCHEM BIOPH RES CO, V506, P485, DOI 10.1016/j.bbrc.2018.10.034
   Kay JG, 2011, SENSORS-BASEL, V11, P1744, DOI 10.3390/s110201744
   Krupinski J, 2002, NEUROPHARMACOLOGY, V42, P846, DOI 10.1016/S0028-3908(02)00032-1
   Kuida K, 2000, INT J BIOCHEM CELL B, V32, P121, DOI 10.1016/S1357-2725(99)00024-2
   Matteucci A, 2014, INT J MOL SCI, V15, P6286, DOI 10.3390/ijms15046286
   Nashine S, 2019, AGING-US, V11, P6691, DOI 10.18632/aging.102179
   Nashine S, 2019, AGING-US, V11, P1177, DOI 10.18632/aging.101820
   Nashine S, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-33290-5
   Nashine S, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.348
   Nashine S, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0159828
   Ottobelli L, 2013, OPHTHALMOLOGICA, V229, P219, DOI 10.1159/000350496
   Parisi V, 2005, DOC OPHTHALMOL, V110, P91, DOI 10.1007/s10633-005-7348-7
   Parisi V, 1999, OPHTHALMOLOGY, V106, P1126, DOI 10.1016/S0161-6420(99)90269-5
   Parisi V, 2008, PROG BRAIN RES, V173, P541, DOI 10.1016/S0079-6123(08)01137-0
   Park CH, 2006, BRAIN RES, V1081, P203, DOI 10.1016/j.brainres.2005.12.128
   Porter AG, 1999, CELL DEATH DIFFER, V6, P99, DOI 10.1038/sj.cdd.4400476
   Shamas-Din A, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a008714
   Sobrado M, 2003, NEUROSCIENCE, V118, P107, DOI 10.1016/S0306-4522(02)00912-0
   TROVARELLI G, 1981, NEUROCHEM RES, V6, P821, DOI 10.1007/BF00965041
   WEISS GB, 1995, LIFE SCI, V56, P637, DOI 10.1016/0024-3205(94)00427-T
NR 32
TC 7
Z9 8
U1 0
U2 3
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
SN 1945-4589
J9 AGING-US
JI Aging-US
PD MAY 31
PY 2020
VL 12
IS 10
BP 9031
EP 9040
DI 10.18632/aging.103164
PG 10
WC Cell Biology; Geriatrics & Gerontology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Geriatrics & Gerontology
GA LU4HS
UT WOS:000537718700017
PM 32470946
OA Green Published, gold, Green Submitted
DA 2022-11-30
ER

PT J
AU Gorin, MB
   daSilva, MJ
AF Gorin, Michael B.
   daSilva, Michael J.
TI Predictive genetics for AMD: Hype and hopes for genetics-based
   strategies for treatment and prevention
SO EXPERIMENTAL EYE RESEARCH
LA English
DT Article
DE Predictive genetics; Age-related macular degeneration
ID COMPLEMENT FACTOR-H; AGE-RELATED MACULOPATHY; GROWTH-FACTOR TREATMENT;
   MEDIATED DARK-ADAPTATION; GENOME-WIDE ASSOCIATION; ANTI-VEGF TREATMENT;
   MACULAR DEGENERATION; NEOVASCULAR AMD; COMMON VARIANTS; VISUAL FUNCTION
AB Age-related macular degeneration (AMD) is a complex disease with multiple genetic and environmental risk factors. In the age of molecular genetics, many investigators have established a link between genes and development or progression of the disease. This later evolved to determine whether phenotypic features of AMD have distinct genetic profiles. Molecular genetics have subsequently been introduced as factors in risk assessment models, increasing the predictive value of these tools. Models seek to predict either development or progression of disease, and different AMD-related genes aid our understanding of these respective features. Several investigators have attempted to link molecular genetics with treatment response, but results and their clinical significance vary. Ocular and systemic biomarkers may interact with established genes, promising future routes of ongoing clinical assessment. Our understanding of AMD molecular genetics is not yet sufficient to recommend routine testing, despite its utility in the research setting. Clinicians must be wary of misusing population-based risk models from genetic and biomarker associations, as they are not necessarily relevant for individual counseling. This review addresses the known uses of predictive genetics, and suggests future directions.
C1 [Gorin, Michael B.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Ophthalmol, Div Retinal Disorders & Ophthalm Genet,UCLA Stein, Los Angeles, CA 90095 USA.
   [Gorin, Michael B.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Human Genet, Los Angeles, CA 90095 USA.
   [daSilva, Michael J.] Univ Calif Los Angeles, UCLA Stein Eye Inst, Dept Ophthalmol, David Geffen Sch Med, Los Angeles, CA 90095 USA.
C3 University of California System; University of California Los Angeles;
   University of California Los Angeles Medical Center; David Geffen School
   of Medicine at UCLA; University of California System; University of
   California Los Angeles; University of California Los Angeles Medical
   Center; David Geffen School of Medicine at UCLA; University of
   California System; University of California Los Angeles; University of
   California Los Angeles Medical Center; David Geffen School of Medicine
   at UCLA
RP Gorin, MB (通讯作者)，Univ Calif Los Angeles, David Geffen Sch Med, Dept Ophthalmol, Div Retinal Disorders & Ophthalm Genet,UCLA Stein, Los Angeles, CA 90095 USA.
EM gorin@jsei.ucla.edu
CR Assel MJ, 2018, OPHTHALMOLOGY, V125, P391, DOI 10.1016/j.ophtha.2017.09.008
   Awh CC, 2015, OPHTHALMOLOGY, V122, pE62, DOI 10.1016/j.ophtha.2015.03.028
   Awh CC, 2013, OPHTHALMOLOGY, V120, P2317, DOI 10.1016/j.ophtha.2013.07.039
   Barral S, 2006, INVEST OPHTH VIS SCI, V47, P5453, DOI 10.1167/iovs.06-0655
   Canter JA, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002091
   Chavali VRM, 2015, J CLIN MED, V4, P304, DOI 10.3390/jcm4020304
   Chen GH, 2015, SCI REP-UK, V5, DOI 10.1038/srep14517
   Chen W, 2010, P NATL ACAD SCI USA, V107, P7401, DOI 10.1073/pnas.0912702107
   Cheng CY, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7063
   Chew EY, 2015, OPHTHALMOLOGY, V122, P212, DOI 10.1016/j.ophtha.2014.10.012
   Chew EY, 2014, OPHTHALMOLOGY, V121, P2173, DOI 10.1016/j.ophtha.2014.05.008
   Chiu CJ, 2007, AM J CLIN NUTR, V86, P1210, DOI 10.1093/ajcn/86.4.1210
   Colijn JM, 2019, OPHTHALMOLOGY, V126, P393, DOI 10.1016/j.ophtha.2018.09.045
   Curcio CA, 2019, OPHTHALMOLOGY, V126, P866, DOI 10.1016/j.ophtha.2018.12.024
   Delcourt C, 2011, INVEST OPHTH VIS SCI, V52, P5955, DOI 10.1167/iovs.10-6235
   Despriet DDG, 2006, JAMA-J AM MED ASSOC, V296, P301, DOI 10.1001/jama.296.3.301
   Duvvari MR, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0152047
   Duvvari MR, 2015, MOL VIS, V21, P285
   Ebrahimi KB, 2014, ADV EXP MED BIOL, V801, P259, DOI 10.1007/978-1-4614-3209-8_33
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Elshelmani H, 2017, METHODS MOL BIOL, V1509, P93, DOI 10.1007/978-1-4939-6524-3_10
   Esteban O, 2019, ACTA OPHTHALMOL, V97, pE133, DOI 10.1111/aos.13865
   Fagerness JA, 2009, EUR J HUM GENET, V17, P100, DOI 10.1038/ejhg.2008.140
   Fan Q, 2017, INT J EPIDEMIOL, V46, P1891, DOI 10.1093/ije/dyx189
   Fauser S, 2015, SURV OPHTHALMOL, V60, P138, DOI 10.1016/j.survophthal.2014.11.002
   Fauser S, 2011, INVEST OPHTH VIS SCI, V52, P5525, DOI 10.1167/iovs.10-6827
   Finger RP, 2016, OPHTHALMOLOGY, V123, P599, DOI 10.1016/j.ophtha.2015.10.029
   Finger RP, 2014, SURV OPHTHALMOL, V59, P1, DOI 10.1016/j.survophthal.2013.03.009
   Flynn OJ, 2018, INVEST OPHTH VIS SCI, V59, P2411, DOI 10.1167/iovs.17-22874
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Geerlings MJ, 2017, MOL IMMUNOL, V84, P65, DOI 10.1016/j.molimm.2016.11.016
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Gorin MB, 2014, J CLIN MED, V3, P1335, DOI 10.3390/jcm3041335
   Grassmann F., 2019, JAMA OPHTHALMOL, DOI DOI 10.1001/JAMAOPHTHALMO1.2019.1318
   Guymer RH, 2005, SURV OPHTHALMOL, V50, P194, DOI 10.1016/j.survophthal.2004.12.002
   Hageman GS, 2006, ANN MED, V38, P592, DOI 10.1080/07853890601097030
   Hageman Gregory S., 2011, Human Genomics, V5, P420
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Hagstrom SA, 2015, OPHTHALMOLOGY, V122, P1563, DOI 10.1016/j.ophtha.2015.04.024
   Haines JL, 2006, INVEST OPHTH VIS SCI, V47, P329, DOI 10.1167/iovs.05-0116
   Heesterbeek TJ, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-43144-3
   Ho L, 2011, ARCH OPHTHALMOL-CHIC, V129, P758, DOI 10.1001/archophthalmol.2011.141
   Hoffman JD, 2014, INVEST OPHTH VIS SCI, V55, P4455, DOI 10.1167/iovs.13-13684
   Hogg RE, 2012, RETINA-J RET VIT DIS, V32, P1950, DOI 10.1097/IAE.0b013e31824dadf1
   Hollborn M, 2018, MOL VIS, V24, P518
   Hong N, 2016, ACTA OPHTHALMOL, V94, P334, DOI 10.1111/aos.13049
   Hughes AE, 2007, PLOS MED, V4, P1993, DOI 10.1371/journal.pmed.0040355
   Hughes AE, 2016, ACTA OPHTHALMOL, V94, pE247, DOI 10.1111/aos.12822
   Iyengar SK, 2004, AM J HUM GENET, V74, P20, DOI 10.1086/380912
   Joachim N, 2015, OPHTHALMOLOGY, V122, P2482, DOI 10.1016/j.ophtha.2015.08.002
   Kavanagh D, 2015, HUM MOL GENET, V24, P3861, DOI 10.1093/hmg/ddv091
   Keir LS, 2017, J CLIN INVEST, V127, P199, DOI 10.1172/JCI86418
   Kenealy SJ, 2004, MOL VIS, V10, P57
   Kersten E, 2018, CLIN GENET, V94, P569, DOI 10.1111/cge.13447
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kloeckener-Gruissem B, 2011, INVEST OPHTH VIS SCI, V52, P4694, DOI 10.1167/iovs.10-6080
   Kondo N, 2008, INVEST OPHTH VIS SCI, V49, P1101, DOI 10.1167/iovs.07-1145
   Kortvely E, 2010, INVEST OPHTH VIS SCI, V51, P79, DOI 10.1167/iovs.09-3850
   Kremlitzka M, 2018, HUM MOL GENET, V27, P2678, DOI 10.1093/hmg/ddy178
   Kubicka-Trzaska Agnieszka, 2016, Klin Oczna, V118, P114
   Lau LI, 2011, INVEST OPHTH VIS SCI, V52, P6832, DOI 10.1167/iovs.11-7815
   LEVEILLARD T, 2019, INT J MOL SCI, V20
   Lin JM, 2008, AM J OPHTHALMOL, V145, P1045, DOI 10.1016/j.ajo.2008.01.027
   Lores-Motta L, 2018, JAMA OPHTHALMOL, V136, P875, DOI 10.1001/jamaophthalmol.2018.2019
   Lu FT, 2018, GENET TEST MOL BIOMA, V22, P526, DOI 10.1089/gtmb.2018.0110
   Marazita MC, 2016, REDOX BIOL, V7, P78, DOI 10.1016/j.redox.2015.11.011
   Martinez-Barricarte R, 2012, INVEST OPHTH VIS SCI, V53, P1087, DOI 10.1167/iovs.11-8709
   McGwin G, 2005, OPHTHALMOLOGY, V112, P488, DOI 10.1016/j.ophtha.2004.10.027
   McKay GJ, 2017, OPHTHALMOLOGY, V124, P90, DOI 10.1016/j.ophtha.2016.09.007
   Medina FM, 2019, OPHTHALMIC RES, V61, P168, DOI 10.1159/000475995
   Merle BMJ, 2019, OPHTHALMOLOGY, V126, P381, DOI 10.1016/j.ophtha.2018.08.006
   Millen AE, 2015, JAMA OPHTHALMOL, V133, P1171, DOI 10.1001/jamaophthalmol.2015.2715
   Momozawa Y, 2016, HUM MOL GENET, V25, P5027, DOI 10.1093/hmg/ddw335
   Mori K, 2010, OPHTHALMOLOGY, V117, P928, DOI 10.1016/j.ophtha.2009.10.001
   Morrison Margaux A., 2011, Human Genomics, V5, P538
   Nakata I, 2011, OPHTHALMOLOGY, V118, P1408, DOI 10.1016/j.ophtha.2010.12.011
   Neale BM, 2010, P NATL ACAD SCI USA, V107, P7395, DOI 10.1073/pnas.0912019107
   Neely D, 2017, RETINA-J RET VIT DIS, V37, P1329, DOI 10.1097/IAE.0000000000001454
   Orlin A, 2012, RETINA-J RET VIT DIS, V32, P4, DOI 10.1097/IAE.0b013e31822a2c7c
   Owen LA, 2014, INVEST OPHTH VIS SCI, V55, P3543, DOI 10.1167/iovs.14-14047
   Owsley C, 2016, INVEST OPHTH VIS SCI, V57, P1782, DOI 10.1167/iovs.15-18962
   Owsley C, 2016, CURR EYE RES, V41, P266, DOI 10.3109/02713683.2015.1011282
   Owsley C, 2016, OPHTHALMOLOGY, V123, P344, DOI 10.1016/j.ophtha.2015.09.041
   Park DH, 2017, INT OPHTHALMOL, V37, P1205, DOI 10.1007/s10792-016-0391-4
   Park UC, 2017, BMC OPHTHALMOL, V17, DOI 10.1186/s12886-017-0631-z
   Park UC, 2014, MOL VIS, V20, P1680
   Parmeggiani F, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-38919-7
   Pauer GJT, 2010, AM J OPHTHALMOL, V149, P513, DOI 10.1016/j.ajo.2009.09.024
   Pearlman J, 2015, OPHTHALMOLOGY, V122, pE60, DOI 10.1016/j.ophtha.2015.01.031
   Peter I, 2011, AM J OPHTHALMOL, V152, P1005, DOI 10.1016/j.ajo.2011.05.016
   Pietraszkiewicz A, 2018, OPHTHALMOLOGY, V125, P398, DOI 10.1016/j.ophtha.2017.10.027
   Ratnapriya R, 2014, HUM MOL GENET, V23, P5827, DOI 10.1093/hmg/ddu276
   Raychaudhuri S, 2011, NAT GENET, V43, P1232, DOI 10.1038/ng.976
   Restrepo NA, 2014, INVEST OPHTH VIS SCI, V55, DOI 10.1167/iovs.14-14246
   Reynolds R., 2010, ARVO M, V51, P4532
   Riaz M, 2016, SCI REP-UK, V6, DOI 10.1038/srep37924
   Rohrer B, 2019, MOL VIS, V25, P79
   Rojas-Fernandez CH, 2017, ANN PHARMACOTHER, V51, P264, DOI 10.1177/1060028016680643
   Rowan S, 2016, ADV EXP MED BIOL, V854, P95, DOI 10.1007/978-3-319-17121-0_14
   SanGiovanni JP, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005508
   SanGiovanni John Paul, 2009, V99, P105, DOI 10.1159/000193002
   Sardell RJ, 2016, MOL VIS, V22, P1062
   Sauer L., 2018, INVESTIG OPHTHALMOL, V59, pAMD65
   Schaumberg DA, 2007, ARCH OPHTHALMOL-CHIC, V125, P55, DOI 10.1001/archopht.125.1.55
   Schaumberg DA, 2010, ARCH OPHTHALMOL-CHIC, V128, P1462, DOI 10.1001/archophthalmol.2010.261
   Schick JH, 2003, AM J HUM GENET, V72, P1412, DOI 10.1086/375500
   Schweitzer D, 2005, BIOMED TECH, V50, P263, DOI 10.1515/BMT.2005.038
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P774, DOI 10.1001/archopht.123.6.774
   Seddon JM, 2003, AM J HUM GENET, V73, P780, DOI 10.1086/378505
   Seddon JM, 1996, JAMA-J AM MED ASSOC, V276, P1141, DOI 10.1001/jama.276.14.1141
   Seddon JM, 2016, BRIT J OPHTHALMOL, V100, P1731, DOI 10.1136/bjophthalmol-2016-308624
   Seddon JM, 2011, OPHTHALMOLOGY, V118, P2203, DOI 10.1016/j.ophtha.2011.04.029
   Seddon JM, 2009, INVEST OPHTH VIS SCI, V50, P2044, DOI 10.1167/iovs.08-3064
   Seddon JM, 2009, INVEST OPHTH VIS SCI, V50, P586, DOI 10.1167/iovs.08-2514
   Shah AR, 2016, AM J OPHTHALMOL, V163, P154, DOI 10.1016/j.ajo.2015.11.033
   Silveira AC, 2010, VISION RES, V50, P698, DOI 10.1016/j.visres.2009.09.016
   Spencer KL, 2007, HUM MOL GENET, V16, P1986, DOI 10.1093/hmg/ddm146
   Szemraj M, 2015, MED SCI MONITOR, V21, P2734, DOI 10.12659/MSM.893697
   Tong Y, 2016, INT J OPHTHALMOL-CHI, V9, P1028, DOI 10.18240/ijo.2016.07.16
   Triebwasser MP, 2015, INVEST OPHTH VIS SCI, V56, P6873, DOI 10.1167/iovs.15-17432
   Vierkotten S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022959
   Wagner EK, 2016, SCI REP-UK, V6, DOI 10.1038/srep31531
   Wang Y.F., 2015, SCI REP, V5, P112
   Warwick A, 2016, EYE, V30, P488, DOI 10.1038/eye.2015.204
   Weeks DE, 2004, AM J HUM GENET, V75, P174, DOI 10.1086/422476
   Weeks DE, 2001, AM J OPHTHALMOL, V132, P682, DOI 10.1016/S0002-9394(01)01214-4
   Wu MX, 2017, BRIT J OPHTHALMOL, V101, P976, DOI 10.1136/bjophthalmol-2016-309418
   Yamashiro K, 2011, INVEST OPHTH VIS SCI, V52, P8780, DOI 10.1167/iovs.11-8205
   Yan Q, 2018, HUM MOL GENET, V27, P929, DOI 10.1093/hmg/ddy002
   Yang P, 2009, INVEST OPHTH VIS SCI, V50, P3473, DOI 10.1167/iovs.08-3202
   Yaspan BL, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aaf1443
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Yu Y, 2016, HUM MOL GENET, V25, P5276, DOI 10.1093/hmg/ddw336
   Yu Y, 2011, HUM MOL GENET, V20, P3699, DOI 10.1093/hmg/ddr270
   Zhao L, 2013, CURR MOL MED, V13, P929, DOI 10.2174/15665240113139990048
   Zhao ZN, 2017, BMC OPHTHALMOL, V17, DOI 10.1186/s12886-017-0529-9
NR 137
TC 6
Z9 6
U1 1
U2 3
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0014-4835
EI 1096-0007
J9 EXP EYE RES
JI Exp. Eye Res.
PD FEB
PY 2020
VL 191
AR 107894
DI 10.1016/j.exer.2019.107894
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA KM9UV
UT WOS:000514487100020
PM 31862397
DA 2022-11-30
ER

PT J
AU Park, DH
   Connor, KM
   Lambris, JD
AF Park, Dong Ho
   Connor, Kip M.
   Lambris, John D.
TI The Challenges and Promise of Complement Therapeutics for Ocular
   Diseases
SO FRONTIERS IN IMMUNOLOGY
LA English
DT Review
DE age-related macular degeneration; complement system; immune modulation;
   ocular inflammation; therapeutics
ID MEMBRANE ATTACK COMPLEX; FACTOR-H POLYMORPHISM; MACULAR-DEGENERATION;
   ALTERNATIVE PATHWAY; FACTOR-I; GENETIC VARIANT; BRUCHS MEMBRANE;
   INFLUENCES RISK; FACTOR-B; AGE
AB Ocular inflammation is a defining feature of sight threating diseases and its dysregulation can catalyze and or propagate ocular neurodegenerative maladies such as age-related macular degeneration (AMD). The complement system, an intrinsic component of the innate immunity, has an integral role in maintaining immune-surveillance and homeostasis in the ocular microenvironment; however, overstimulation can drive ocular inflammatory diseases. The mechanism for complement disease propagation in AMD is not fully understood, although there is accumulating evidence showing that targeted modulation of complement-specific proteins has the potential to become a viable therapeutic approach. To date, a major focus of complement therapeutics has been on targeting the alternative complement system in AMD. Recent studies have outlined potential complement cascade inhibitors that might mitigate AMD disease progression. First-in-class complement inhibitors target the modulation of complement proteins C3, C5, factor B, factor D, and properdin. Herein, we will summarize ocular inflammation in the context of AMD disease progression, current clinical outcomes and complications of complement-mediated therapeutics. Given the need for additional therapeutic approaches for ocular inflammatory diseases, targeted complement modulation has emerged as a leading candidate for eliminating inflammation-driven ocular maladies.
C1 [Park, Dong Ho] Kyungpook Natl Univ, Sch Med, Dept Ophthalmol, Kyungpook Natl Univ Hosp, Daegu, South Korea.
   [Connor, Kip M.] Massachusetts Eye & Ear Infirm, Dept Ophthalmol, Angiogenesis Lab, Boston, MA 02114 USA.
   [Connor, Kip M.] Harvard Med Sch, Dept Ophthalmol, Boston, MA 02115 USA.
   [Lambris, John D.] Univ Penn, Dept Pathol & Lab Med, Pereian Sch Med, Stellar Chance Labs, Philadelphia, PA 19104 USA.
C3 Kyungpook National University; Kyungpook National University Hospital;
   Harvard University; Massachusetts Eye & Ear Infirmary; Harvard
   University; Harvard Medical School; University of Pennsylvania
RP Connor, KM (通讯作者)，Massachusetts Eye & Ear Infirm, Dept Ophthalmol, Angiogenesis Lab, Boston, MA 02114 USA.; Connor, KM (通讯作者)，Harvard Med Sch, Dept Ophthalmol, Boston, MA 02115 USA.
EM Kip_Connor@meel.harvard.edu
FU National Institute of Health/National Eye Institute [R01EY027303,
   R01EY029269, AI068730]; Department of Ophthalmology, Harvard University;
   Basic Science Research Program of the National Research Foundation of
   Korea (NRF) - Ministry of Education [NRF-2017R1D1A1B03027966]; Korea
   Health Technology R&D Project of the Korea Health Industry Development
   Institute (KHIDI) - Ministry of Health & Welfare, Republic of Korea
   [HI16C1501]; Massachusetts Eye and Ear Infirmary; American Macular
   Degeneration Foundation Prevention Award; NATIONAL EYE INSTITUTE
   [R01EY029269, R01EY027303] Funding Source: NIH RePORTER; NATIONAL
   INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI068730] Funding
   Source: NIH RePORTER
FX This study was supported by the National Institute of Health/National
   Eye Institute: Grant R01EY027303 and R01EY029269 (to KC); and AI068730
   (to JL) and the American Macular Degeneration Foundation Prevention
   Award (KC). Special thanks go to Department of Ophthalmology, Harvard
   University, and Massachusetts Eye and Ear Infirmary for supporting this
   research (KC). DP is financially supported by the Basic Science Research
   Program of the National Research Foundation of Korea (NRF), funded by
   the Ministry of Education (NRF-2017R1D1A1B03027966), and the Korea
   Health Technology R&D Project of the Korea Health Industry Development
   Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic
   of Korea (HI16C1501).
CR Alcon, 2013, EV AL 78898A EX AG R
   Alexion, 2018, AL RES DEV PIP
   Alexion, 2017, COMPL INH EC TREATM
   Amyndas Pharmaceuticals Inc, 2019, AM PRIOR CLIN PROGR
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   Apellis Pharmaceuticals Inc, 2018, STUD COMP EFF SAF IN
   Apellis Pharmaceuticals Inc, 2017, STUD APL 2 THER PAT
   Apellis Pharmaceuticals Inc, 2018, FILLY PHAS 2 STUD AP
   Apellis Pharmaceuticals Inc, 2018, APL 2 NEOV AMD
   Apellis Pharmaceuticals Inc, 2018, APL 2 GEOGRPH ATR PR
   Cao XG, 2011, PATHOL INT, V61, P528, DOI 10.1111/j.1440-1827.2011.02695.x
   Cashman SM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019078
   CATTERALL CF, 1987, BIOCHEM J, V242, P849, DOI 10.1042/bj2420849
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Chi ZL, 2010, ADV EXP MED BIOL, V703, P127, DOI 10.1007/978-1-4419-5635-4_9
   Clark SJ, 2018, SEMIN IMMUNOPATHOL, V40, P65, DOI 10.1007/s00281-017-0649-6
   Clark SJ, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01778
   Clark SJ, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00412
   Clark SJ, 2013, J IMMUNOL, V190, P2049, DOI 10.4049/jimmunol.1201751
   Clark SJ, 2010, BIOCHEM SOC T, V38, P1342, DOI 10.1042/BST0381342
   Clark SJ, 2010, J BIOL CHEM, V285, P30192, DOI 10.1074/jbc.M110.103986
   Clemons Traci E, 2005, Ophthalmology, V112, P533
   Cousins SW, 2010, INVEST OPHTH VIS SCI, V51, P1
   DAY AJ, 1988, IMMUNOGENETICS, V27, P211, DOI 10.1007/BF00346588
   Garcia CAD, 2014, OSLI RETINA, V45, P18, DOI 10.3928/23258160-20131217-01
   Do DV, 2014, RETINA-J RET VIT DIS, V34, P313, DOI 10.1097/IAE.0b013e3182979ddd
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Fagerness JA, 2009, EUR J HUM GENET, V17, P100, DOI 10.1038/ejhg.2008.140
   Ferrara D, 2015, JAMA OPHTHALMOL, V133, P785, DOI 10.1001/jamaophthalmol.2015.0814
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Forneris F, 2016, EMBO J, V35, P1133, DOI 10.15252/embj.201593673
   Forneris F, 2010, SCIENCE, V330, P1816, DOI 10.1126/science.1195821
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Fritsche LG, 2010, HUM MOL GENET, V19, P4694, DOI 10.1093/hmg/ddq399
   Gehrs KM, 2006, ANN MED, V38, P450, DOI 10.1080/07853890600946724
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Hageman GS, 2006, ANN MED, V38, P592, DOI 10.1080/07853890601097030
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   HAMILTON KK, 1990, BLOOD, V76, P2572
   Harboe M, 2008, J CELL MOL MED, V12, P1074, DOI 10.1111/j.1582-4934.2008.00350.x
   HARRIMAN GR, 1981, J IMMUNOL, V127, P2386
   Harris CL, 2012, TRENDS IMMUNOL, V33, P513, DOI 10.1016/j.it.2012.06.001
   Hebecker M, 2012, J BIOL CHEM, V287, P19528, DOI 10.1074/jbc.M112.364471
   Hecker LA, 2010, HUM MOL GENET, V19, P209, DOI 10.1093/hmg/ddp472
   Hemera, 2017, TREATM ADV DRY AG RE
   Herbert AP, 2007, J BIOL CHEM, V282, P18960, DOI 10.1074/jbc.M609636200
   Heurich M, 2011, P NATL ACAD SCI USA, V108, P8761, DOI 10.1073/pnas.1019338108
   Hillmen P, 2006, NEW ENGL J MED, V355, P1233, DOI 10.1056/NEJMoa061648
   Holers VM, 2008, IMMUNOL REV, V223, P300, DOI 10.1111/j.1600-065X.2008.00641.x
   Howard JF, 2017, LANCET NEUROL, V16, P976, DOI 10.1016/S1474-4422(17)30369-1
   Hughes AE, 2006, NAT GENET, V38, P1173, DOI 10.1038/ng1890
   Irmscher S, 2018, J INNATE IMMUN, V10, P94, DOI 10.1159/000484257
   Katschke KJ, 2012, J BIOL CHEM, V287, P12886, DOI 10.1074/jbc.M112.345082
   Kaushal S., 2009, INVESTIG OPHTHALMOL, V50, P1
   Keenan TDL, 2015, INVEST OPHTH VIS SCI, V56, P4870, DOI 10.1167/iovs.15-17009
   Kevany BM, 2010, PHYSIOLOGY, V25, P8, DOI 10.1152/physiol.00038.2009
   Kijlstra A, 2015, OPHTHALMIC RES, V54, P64, DOI 10.1159/000432401
   Kim C, 2016, FASEB J, V30, P1300, DOI 10.1096/fj.15-280834
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Laine M, 2007, J IMMUNOL, V178, P3831, DOI 10.4049/jimmunol.178.6.3831
   Langford-Smith A, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00025
   Langford-Smith A, 2014, J INNATE IMMUN, V6, P407, DOI 10.1159/000356513
   Lyzogubov VV, 2011, J BIOL CHEM, V286, DOI 10.1074/jbc.M110.204701
   Maga TK, 2010, HUM MUTAT, V31, pE1445, DOI 10.1002/humu.21256
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   Maller JB, 2007, NAT GENET, V39, P1200, DOI 10.1038/ng2131
   Markiewski MM, 2007, AM J PATHOL, V171, P715, DOI 10.2353/ajpath.2007.070166
   Mastellos DC, 2018, SEMIN HEMATOL, V55, P167, DOI 10.1053/j.seminhematol.2018.02.002
   Mastellos DC, 2017, TRENDS IMMUNOL, V38, P383, DOI 10.1016/j.it.2017.03.003
   Mastellos DC, 2015, EUR J CLIN INVEST, V45, P423, DOI 10.1111/eci.12419
   Montes T, 2009, P NATL ACAD SCI USA, V106, P4366, DOI 10.1073/pnas.0812584106
   Mullins RF, 2014, AM J PATHOL, V184, P3142, DOI 10.1016/j.ajpath.2014.07.017
   Nishiguchi KM, 2012, INVEST OPHTH VIS SCI, V53, P508, DOI 10.1167/iovs.11-8425
   Novartis, 2016, SAF TOL INTR LFG316
   Novartis, 2016, SAF EFF INTR LFG316
   Novartis, 2016, INTR LFG316 PAT AG R
   Novartis, 2017, CLG561 PROOF CONC ST
   Ophthotech, 2018, ZIMURA COMB EYL PAT
   Ophthotech, 2017, STUD ARC1905 ANTI C5
   Ophthotech, 2018, ZIM SUBJ GEOGR ATR S
   Ophthotech, 2018, ZIMURA COMP SHAM PAT
   Ophthotech, 2018, ZIMURA COMB LUCENTIS
   Ophthotech, 2018, OPHTH ANN RES PHAS 2
   PODACK ER, 1982, J EXP MED, V156, P268, DOI 10.1084/jem.156.1.268
   Raychaudhuri S, 2011, NAT GENET, V43, P1232, DOI 10.1038/ng.976
   Ricklin D, 2008, ADV EXP MED BIOL, V632, P273, DOI 10.1007/978-0-387-78952-1_20
   Ricklin D, 2016, IMMUNOL REV, V274, P33, DOI 10.1111/imr.12500
   Ricklin D, 2016, SEMIN IMMUNOL, V28, P208, DOI 10.1016/j.smim.2016.06.001
   Ricklin D, 2010, NAT IMMUNOL, V11, P785, DOI 10.1038/ni.1923
   Roche, 2018, STUD INV EFF SAF LAM
   ROLLINS SA, 1990, J IMMUNOL, V144, P3478
   Rudnicka AR, 2012, OPHTHALMOLOGY, V119, P571, DOI 10.1016/j.ophtha.2011.09.027
   Sahu A, 1996, J IMMUNOL, V157, P884
   Scholl HPN, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002593
   Seddon JM, 2013, NAT GENET, V45, P1366, DOI 10.1038/ng.2741
   Seddon JM, 2009, INVEST OPHTH VIS SCI, V50, P2044, DOI 10.1167/iovs.08-3064
   Sjoberg AP, 2007, J BIOL CHEM, V282, P10894, DOI 10.1074/jbc.M610256200
   Sofat R, 2012, INT J EPIDEMIOL, V41, P250, DOI 10.1093/ije/dyr204
   Spark Therapeutics Inc, 2018, LUXT
   Sparrrow JR, 2010, CURR MOL MED, V10, P802
   Stanton CM, 2011, INVEST OPHTH VIS SCI, V52, P8828, DOI 10.1167/iovs.11-7933
   Sui GY, 2013, BRIT J OPHTHALMOL, V97, P389, DOI 10.1136/bjophthalmol-2012-302281
   Sweigard JH, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aab1482
   Sweigard JH, 2014, FASEB J, V28, P3171, DOI 10.1096/fj.14-251041
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   Toomey CB, 2015, P NATL ACAD SCI USA, V112, pE3040, DOI 10.1073/pnas.1424391112
   Volanakis JE, 1996, PROTEIN SCI, V5, P553
   VYSE TJ, 1994, GENOMICS, V24, P90, DOI 10.1006/geno.1994.1585
   Walport MJ, 2001, NEW ENGL J MED, V344, P1058, DOI 10.1056/NEJM200104053441406
   Walport MJ, 2001, NEW ENGL J MED, V344, P1140, DOI 10.1056/NEJM200104123441506
   Whitcup SM, 2013, INT J INFLAMM, V2013, DOI 10.1155/2013/348092
   Whitmore SS, 2015, PROG RETIN EYE RES, V45, P1, DOI 10.1016/j.preteyeres.2014.11.005
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wu J, 2009, NAT IMMUNOL, V10, P728, DOI 10.1038/ni.1755
   Xue XG, 2017, NAT STRUCT MOL BIOL, V24, P643, DOI 10.1038/nsmb.3427
   Yaspan BL, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aaf1443
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Yehoshua Z, 2014, OPHTHALMOLOGY, V121, P693, DOI 10.1016/j.ophtha.2013.09.044
   Yu Y, 2014, HUM MOL GENET, V23, P5283, DOI 10.1093/hmg/ddu226
   2013, NAT GENET, V45, P813, DOI DOI 10.1038/NG.2640
   1999, OPHTHALMOLOGY, V106, P910, DOI DOI 10.1016/S0161-6420(99)00509-6
   2014, J OPHTHALMOL
   2018, JAMA OPHTHALMOL, V136, P666, DOI DOI 10.1001/JAMAOPHTHALMOL.2018.1544
NR 126
TC 51
Z9 52
U1 0
U2 11
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-3224
J9 FRONT IMMUNOL
JI Front. Immunol.
PD MAY 15
PY 2019
VL 10
AR 1007
DI 10.3389/fimmu.2019.01007
PG 14
WC Immunology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Immunology
GA HY2SA
UT WOS:000467972000001
PM 31156618
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Saadane, A
   Petrov, A
   Mast, N
   El-Darzi, N
   Dao, T
   Alnemri, A
   Song, Y
   Dunaief, JL
   Pikuleva, IA
AF Saadane, Aicha
   Petrov, Alexey
   Mast, Natalia
   El-Darzi, Nicole
   Dao, Tung
   Alnemri, Ahab
   Song, Ying
   Dunaief, Joshua L.
   Pikuleva, Irina A.
TI Mechanisms that minimize retinal impact of apolipoprotein E absence
SO JOURNAL OF LIPID RESEARCH
LA English
DT Article
DE cholesterol; retina; lipoproteins; iron; cytoskeleton; vesicular traffic
ID RECEPTOR-RELATED PROTEIN-1; LIPOPROTEIN-LIKE PARTICLES; MACULAR
   DEGENERATION; LIPID TRANSPORT; BRUCHS MEMBRANE; CHOLESTEROL-METABOLISM;
   ALZHEIMERS-DISEASE; EPSILON-4 ALLELE; LRP-1 EXPRESSION; MOUSE RETINA
AB Apolipoprotein E (APOE) is a component of lipid-transporting particles and a recognition ligand for receptors, which bind these particles. The APOE isoform epsilon 2 is a risk factor for age-related macular degeneration; nevertheless, APOE absence in humans and mice does not significantly affect the retina. We found that retinal cholesterol biosynthesis and the levels of retinal cholesterol were increased in Apoe(-/-) mice, whereas cholesterol elimination by metabolism was decreased. No focal cholesterol deposits were observed in the Apoe(-/-) retina. Retinal proteomics identified the most abundant cholesterol-related proteins in WT mice and revealed that, of these cholesterol-related proteins, only APOA4 had increased expression in the Apoe(-/-) retina. In addition, there were changes in retinal abundance of proteins involved in proinflammatory and antiinflammatory responses, cellular cytoskeleton maintenance, vesicular traffic, and retinal iron homeostasis. The data obtained indicate that when APOE is absent, particles containing APOA1, APOA4, and APOJ still transport cholesterol in the intraretinal space, but these particles are not taken up by retinal cells. Therefore, cholesterol biosynthesis inside retinal cells increase, whereas metabolism to oxysterols decreases to prevent cells from cholesterol depletion. These and other compensatory changes underlie only a minor retinal phenotype in Apoe(-/-) mice.
C1 [Saadane, Aicha; Petrov, Alexey; Mast, Natalia; El-Darzi, Nicole; Dao, Tung; Pikuleva, Irina A.] Case Western Reserve Univ, Dept Ophthalmol & Visual Sci, Cleveland, OH 44106 USA.
   [Alnemri, Ahab; Song, Ying; Dunaief, Joshua L.] Univ Penn, Scheie Eye Inst, FM Kirby Ctr Mol Ophthalmol, Perelman Sch Med, Philadelphia, PA 19104 USA.
C3 Case Western Reserve University; University of Pennsylvania;
   Pennsylvania Medicine
RP Pikuleva, IA (通讯作者)，Case Western Reserve Univ, Dept Ophthalmol & Visual Sci, Cleveland, OH 44106 USA.
EM iap8@case.edu
RI Petrov, Alexey/O-4500-2017
OI Petrov, Alexey/0000-0002-1432-3455; Saadane, Aicha/0000-0001-9985-2147;
   Alnemri, Ahab/0000-0002-2130-1238; Pikuleva, Irina/0000-0001-9742-6232
FU National Institutes of Health [P30 EY11373, EY018383, EY11373,
   EY015240]; Research to Prevent Blindness; F. M. Kirby Foundation;
   NATIONAL EYE INSTITUTE [R01EY015240, P30EY011373, P30EY001583,
   R01EY018383] Funding Source: NIH RePORTER
FX The authors thank the Visual Sciences Research Center Core Facilities
   (supported by National Institutes of Health Grant P30 EY11373) for
   assistance with mouse breeding (Heather Butler and Kathryn Franke),
   animal genotyping (John Denker), tissue sectioning (Catherine Doller),
   and microscopy (Anthony Gardella). The authors also thank Dr. Hisashi
   Fujioka (Electron Microscopy Core Facility) for help with studies of
   retinal ultrastructure and Danie Schlatzer (Proteomics and Small
   Molecule Mass Spectrometry Core) for conducting retinal label-free
   analysis.; This work was supported in part by National Institutes of
   Health Grants EY018383, EY11373, (both to I.A.P.) and EY015240; Research
   to Prevent Blindness; and the F. M. Kirby Foundation (J.L.D). The
   content is solely the responsibility of the authors and does not
   necessarily represent the official views of the National Institutes of
   Health.
CR Dato VA, 2018, BIOCHEM J, V475, P1669, DOI 10.1042/BCJ20170891
   Aldahmesh MA, 2013, AM J HUM GENET, V93, P313, DOI 10.1016/j.ajhg.2013.06.002
   Amaratunga A, 1996, J BIOL CHEM, V271, P5628, DOI 10.1074/jbc.271.10.5628
   Anderson DH, 2001, AM J OPHTHALMOL, V131, P767, DOI 10.1016/S0002-9394(00)00961-2
   Antonny B, 2018, ANNU REV BIOCHEM, V87, P809, DOI 10.1146/annurev-biochem-061516-044924
   Azzam S, 2016, OPEN FORUM INFECT DI, V3, DOI 10.1093/ofid/ofw037
   Barcelona PF, 2010, EXP EYE RES, V91, P264, DOI 10.1016/j.exer.2010.05.017
   Barcelona PF, 2013, FASEB J, V27, P3181, DOI 10.1096/fj.12-221598
   Bhisitkul RB, 2008, INVEST OPHTH VIS SCI, V49, P4071, DOI 10.1167/iovs.08-1892
   Blasiole DA, 2008, J BIOL CHEM, V283, P11374, DOI 10.1074/jbc.M710457200
   Blum CB, 2016, PROG CARDIOVASC DIS, V59, P119, DOI 10.1016/j.pcad.2016.07.007
   Bretillon L, 2000, J LIPID RES, V41, P840
   BU GJ, 1995, EMBO J, V14, P2269, DOI 10.1002/j.1460-2075.1995.tb07221.x
   Bu GJ, 2009, NAT REV NEUROSCI, V10, P333, DOI 10.1038/nrn2620
   Charvet CD, 2013, J BIOL CHEM, V288, P34054, DOI 10.1074/jbc.A113.498832
   Chen XP, 2016, CELL BIOL TOXICOL, V32, P347, DOI 10.1007/s10565-016-9339-8
   CORDER EH, 1994, NAT GENET, V7, P180, DOI 10.1038/ng0694-180
   CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Curcio CA, 2013, RETINA-J RET VIT DIS, V33, P265, DOI 10.1097/IAE.0b013e31827e25e0
   Curcio CA, 2010, J LIPID RES, V51, P451, DOI 10.1194/jlr.R002238
   Dentchev T, 2005, ARCH OPHTHALMOL-CHIC, V123, P1745, DOI 10.1001/archopht.123.12.1745
   Dithmar S, 2000, INVEST OPHTH VIS SCI, V41, P2035
   Duncan KG, 2009, BRIT J OPHTHALMOL, V93, P1116, DOI 10.1136/bjo.2008.144006
   Elliott DA, 2010, CLIN LIPIDOL, V5, P555, DOI 10.2217/CLP.10.37
   Elner Victor M, 2002, Trans Am Ophthalmol Soc, V100, P301
   Emonard H, 2014, PATHOL BIOL, V62, P84, DOI 10.1016/j.patbio.2014.02.002
   Fleming LM, 1996, EXP NEUROL, V138, P252, DOI 10.1006/exnr.1996.0064
   FLIESLER SJ, 1993, FEBS LETT, V335, P234, DOI 10.1016/0014-5793(93)80736-E
   Fliesler SJ, 2010, ADV EXP MED BIOL, V664, P481, DOI 10.1007/978-1-4419-1399-9_55
   Gao AB, 2017, DNA CELL BIOL, V36, P1050, DOI 10.1089/dna.2017.3853
   Gil SY, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2896
   Gustafsen C, 2014, CELL METAB, V19, P310, DOI 10.1016/j.cmet.2013.12.006
   GUYTON JR, 1988, J HISTOCHEM CYTOCHEM, V36, P1319, DOI 10.1177/36.10.2458408
   Hahn P, 2004, P NATL ACAD SCI USA, V101, P13850, DOI 10.1073/pnas.0405146101
   Hahn P, 2004, MOL VIS, V10, P598
   Hayashi H, 2012, J BIOL CHEM, V287, P25395, DOI 10.1074/jbc.M112.370130
   Heckenlively JR, 2003, RETINA-J RET VIT DIS, V23, P518, DOI 10.1097/00006982-200308000-00012
   HENTZE MW, 1987, P NATL ACAD SCI USA, V84, P6730, DOI 10.1073/pnas.84.19.6730
   Hoshi T, 2013, FEBS LETT, V587, P3749, DOI 10.1016/j.febslet.2013.10.001
   Houssier M, 2008, PLOS MED, V5, P323, DOI 10.1371/journal.pmed.0050039
   JOMARY C, 1993, MOL BRAIN RES, V20, P274, DOI 10.1016/0169-328X(93)90052-Q
   KEMPEN HJM, 1988, J LIPID RES, V29, P1149
   Kentala H, 2016, INT REV CEL MOL BIO, V321, P299, DOI 10.1016/bs.ircmb.2015.09.006
   KIM D, 1987, CIRC RES, V60, P185, DOI 10.1161/01.RES.60.2.185
   Klaver CCW, 1998, AM J HUM GENET, V63, P200, DOI 10.1086/301901
   Klein R, 2014, AM J OPHTHALMOL, V158, P513, DOI 10.1016/j.ajo.2014.05.027
   Kliffen M, 2000, BRIT J OPHTHALMOL, V84, P1415, DOI 10.1136/bjo.84.12.1415
   Leeb C, 2014, J BIOL CHEM, V289, P4161, DOI 10.1074/jbc.M113.529271
   Levy O, 2015, J NEUROSCI, V35, P13568, DOI 10.1523/JNEUROSCI.2468-15.2015
   Levy O, 2015, EMBO MOL MED, V7, P211, DOI 10.15252/emmm.201404524
   Lewis GP, 2003, INT REV CYTOL, V230, P263, DOI 10.1016/S0074-7696(03)30005-1
   Li CM, 2006, INVEST OPHTH VIS SCI, V47, P3119, DOI 10.1167/iovs.05-1446
   Li CM, 2005, INVEST OPHTH VIS SCI, V46, P2576, DOI 10.1167/iovs.05-0034
   Li CM, 2005, J LIPID RES, V46, P628, DOI 10.1194/jlr.M400428-JLR200
   Lin JB, 2016, J LIPID RES, V57, P258, DOI 10.1194/jlr.M064469
   Lu WY, 2010, BIOCHEMISTRY-US, V49, P4635, DOI 10.1021/bi1001486
   Mahley RW, 2000, ANNU REV GENOM HUM G, V1, P507, DOI 10.1146/annurev.genom.1.1.507
   MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935
   Mak ACY, 2014, JAMA NEUROL, V71, P1228, DOI 10.1001/jamaneurol.2014.2011
   Malek G, 2005, P NATL ACAD SCI USA, V102, P11900, DOI 10.1073/pnas.0503015102
   Mast N, 2018, DRUG METAB DISPOS, V46, P1528, DOI 10.1124/dmd.118.083345
   Mast N, 2011, INVEST OPHTH VIS SCI, V52, P594, DOI 10.1167/iovs.10-6021
   MAYEUX R, 1993, ANN NEUROL, V34, P752, DOI 10.1002/ana.410340527
   McKay GJ, 2011, HUM MUTAT, V32, P1407, DOI 10.1002/humu.21577
   Miyara N, 2008, JPN J OPHTHALMOL, V52, P84, DOI 10.1007/s10384-007-0507-5
   Moreira EF, 2001, J BIOL CHEM, V276, P18570, DOI 10.1074/jbc.M011259200
   Omarova S, 2012, J CLIN INVEST, V122, P3012, DOI 10.1172/JCI63816
   Ong JM, 2003, CURR EYE RES, V27, P15, DOI 10.1076/ceyr.27.2.15.15460
   Ong JM, 2001, INVEST OPHTH VIS SCI, V42, P1891
   Ostos MA, 2001, ARTERIOSCL THROM VAS, V21, P1023, DOI 10.1161/01.ATV.21.6.1023
   Pascolini D, 2004, OPHTHAL EPIDEMIOL, V11, P67, DOI 10.1076/opep.11.2.67.28158
   Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45
   Pfrieger FW, 2011, PROG LIPID RES, V50, P357, DOI 10.1016/j.plipres.2011.06.002
   PLUMP AS, 1992, CELL, V71, P343, DOI 10.1016/0092-8674(92)90362-G
   Qin XF, 1998, AM J PHYSIOL-HEART C, V274, pH1836, DOI 10.1152/ajpheart.1998.274.5.H1836
   Raffai RL, 2001, P NATL ACAD SCI USA, V98, P11587, DOI 10.1073/pnas.201279298
   Roses AD, 1996, ANN NY ACAD SCI, V777, P146, DOI 10.1111/j.1749-6632.1996.tb34413.x
   Rudolf M, 2005, BRIT J OPHTHALMOL, V89, P1627, DOI 10.1136/bjo.2005.071183
   Saadane A, 2014, AM J PATHOL, V184, P2403, DOI 10.1016/j.ajpath.2014.05.024
   Sanchez MC, 2006, EXP EYE RES, V83, P1378, DOI 10.1016/j.exer.2006.07.016
   Santos AM, 2008, J COMP NEUROL, V506, P224, DOI 10.1002/cne.21538
   Schratzberger P, 1996, NEUROSCI LETT, V214, P208, DOI 10.1016/0304-3940(96)12947-5
   Scott BL, 1998, NEUROSCI LETT, V245, P105, DOI 10.1016/S0304-3940(98)00180-3
   Shanmugaratnam J, 1997, MOL BRAIN RES, V50, P113, DOI 10.1016/S0169-328X(97)00176-9
   Simo R, 2009, AM J OPHTHALMOL, V147, P319, DOI 10.1016/j.ajo.2008.08.009
   SOTO C, 1995, FEBS LETT, V371, P110, DOI 10.1016/0014-5793(95)00863-5
   Souied EH, 1998, AM J OPHTHALMOL, V125, P353, DOI 10.1016/S0002-9394(99)80146-9
   Sridharan Gokul, 2012, J Oral Maxillofac Pathol, V16, P251, DOI 10.4103/0973-029X.99081
   Storch MK, 1996, NEUROSCIENCE, V71, P885, DOI 10.1016/0306-4522(95)00476-9
   Tomechko SE, 2015, PROTEOMICS, V15, P3797, DOI 10.1002/pmic.201400496
   Toops KA, 2016, ADV EXP MED BIOL, V854, P3, DOI 10.1007/978-3-319-17121-0_1
   Trotter JH, 2011, J NEUROSCI, V31, P14413, DOI 10.1523/JNEUROSCI.3135-11.2011
   Tserentsoodol N, 2006, MOL VIS, V12, P1319
   Tserentsoodol N, 2006, MOL VIS, V12, P1306
   Vowinkel T, 2004, J CLIN INVEST, V114, P260, DOI 10.1172/JCI200421233
   Wang L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010329
   Willnow TE, 1996, EMBO J, V15, P2632, DOI 10.1002/j.1460-2075.1996.tb00623.x
   WILLNOW TE, 1995, P NATL ACAD SCI USA, V92, P4537, DOI 10.1073/pnas.92.10.4537
   WINDLER E, 1980, J BIOL CHEM, V255, P8303
   Wisniewski JR, 2009, NAT METHODS, V6, P359, DOI [10.1038/nmeth.1322, 10.1038/NMETH.1322]
   Yang XY, 2018, FASEB J, V32, P3264, DOI 10.1096/fj.201701118R
   Zelcer N, 2009, SCIENCE, V325, P100, DOI 10.1126/science.1168974
   Zheng WC, 2015, J LIPID RES, V56, P81, DOI 10.1194/jlr.M053439
   Zheng WC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037926
NR 105
TC 13
Z9 13
U1 3
U2 5
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0022-2275
EI 1539-7262
J9 J LIPID RES
JI J. Lipid Res.
PD DEC
PY 2018
VL 59
IS 12
BP 2368
EP 2382
DI 10.1194/jlr.M090043
PG 15
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA HB7PT
UT WOS:000451273000012
PM 30333155
OA Green Published, hybrid
DA 2022-11-30
ER

PT J
AU Kubo, Y
   Akanuma, S
   Hosoya, K
AF Kubo, Yoshiyuki
   Akanuma, Shin-ichi
   Hosoya, Ken-ichi
TI Influx Transport of Cationic Drug at the Blood Retinal Barrier: Impact
   on the Retinal Delivery of Neuroprotectants
SO BIOLOGICAL & PHARMACEUTICAL BULLETIN
LA English
DT Review
DE cation transport; membrane transporter; blood-retinal barrier; diabetic
   retinopathy; age-related macular degeneration; neuroprotectant
ID OXYGEN-INDUCED RETINOPATHY; TAURINE TRANSPORT; P-GLYCOPROTEIN; MOUSE
   MODEL; CELL-LINES; RAT; INVOLVEMENT; PERMEABILITY; CARRIER; BRAIN
AB The retina is a tissue essential for vision, and the blood-retina barrier (BRB) helps to maintain an optimal microenvironment for the neural system in the retina. Recent findings concerning the BRB showed the involvement of transporters at the inner and outer BRB in drug and nutrient transport, suggesting their utility in the development of novel drug delivery systems to the retina. An in vitro-in vivo relationship study of permeability suggested the influx transport of verapamil, a cationic drug, across the BRB, and further in vivo and in vitro studies of cationic drugs, such as verapamil, propranolol and clonidine, revealed the involvement of carrier-mediated process in their influx transport at the BRB. Studies on substrate specificity in TR-iBRB2 cells, an in vitro model cell line of the inner BRB, suggests the involvement of novel organic cation transporter in the influx transport of cationic drugs at the inner BRB. Considering the neuroprotective effect previously reported for several cationic drugs, such as propranolol and clonidine, the study of cation transport at the BRB is widely expected to improve the treatment of retinal diseases, such as diabetic retinopathy and age-related macular degeneration.
C1 [Kubo, Yoshiyuki; Akanuma, Shin-ichi; Hosoya, Ken-ichi] Univ Toyama, Grad Sch Med & Pharmaceut Sci, Dept Pharmaceut, 2630 Sugitani, Toyama 9300194, Japan.
C3 University of Toyama
RP Kubo, Y (通讯作者)，Univ Toyama, Grad Sch Med & Pharmaceut Sci, Dept Pharmaceut, 2630 Sugitani, Toyama 9300194, Japan.
EM kuboyosh@pha.u-toyama.ac.jp
RI Kubo, Yoshiyuki/Q-6069-2019
FU Japan Society for the Promotion of Science (JSPS KAKENHI) [17K08409,
   16H05110]; Uehara Memorial Foundation; Tamura Science and Technology
   Foundation; Takeda Science Foundation; Suzuki Memorial Foundation;
   Nakatomi Foundation; Mochida Memorial Foundation for Medical and
   Pharmaceutical Research; Grants-in-Aid for Scientific Research
   [16H05110] Funding Source: KAKEN
FX This review was based upon work supported in part by Grants-in-Aid from
   the Japan Society for the Promotion of Science (JSPS KAKENHI Grant
   Number 17K08409 and 16H05110), the Uehara Memorial Foundation, the
   Tamura Science and Technology Foundation, the Takeda Science Foundation,
   the Suzuki Memorial Foundation, the Nakatomi Foundation, and the Mochida
   Memorial Foundation for Medical and Pharmaceutical Research.
CR ALM A, 1981, ACTA PHYSIOL SCAND, V113, P73, DOI 10.1111/j.1748-1716.1981.tb06864.x
   Chapy H, 2016, BRIT J PHARMACOL, V173, P497, DOI 10.1111/bph.13376
   Cunha-Vaz JG, 2004, EXP EYE RES, V78, P715, DOI 10.1016/S0014-4835(03)00213-6
   Fujii S, 2014, INVEST OPHTH VIS SCI, V55, P4650, DOI 10.1167/iovs.13-13819
   Hosoya K, 2005, BIOL PHARM BULL, V28, P1, DOI 10.1248/bpb.28.1
   Hosoya K, 2001, EXP EYE RES, V72, P163, DOI 10.1006/exer.2000.0941
   Hosoya K, 2013, ADV EXP MED BIOL, V763, P85
   Hosoya K, 2010, PHARM RES-DORDR, V27, P2715, DOI 10.1007/s11095-010-0272-x
   Kubo Y, 2016, BIOL PHARM BULL, V39, P1903, DOI 10.1248/bpb.b16-00597
   Kubo Y, 2016, BIOL PHARM BULL, V39, P1319, DOI 10.1248/bpb.b16-00140
   Kubo Y, 2014, MOL PHARMACEUT, V11, P3747, DOI 10.1021/mp500516j
   Kubo Y, 2013, J PHARM SCI-US, V102, P3332, DOI 10.1002/jps.23535
   Kubo Y, 2013, PHARM RES-DORDR, V30, P847, DOI 10.1007/s11095-012-0926-y
   Kubo Y, 2012, J PHARM SCI-US, V101, P2596, DOI 10.1002/jps.23171
   Martini D, 2011, J NEUROCHEM, V119, P1317, DOI 10.1111/j.1471-4159.2011.07530.x
   Molinuevo Jose L, 2005, Am J Alzheimers Dis Other Demen, V20, P77, DOI 10.1177/153331750502000206
   Nagase K, 2006, BBA-BIOMEMBRANES, V1758, P13, DOI 10.1016/j.bbamem.2006.01.011
   Ohkura Y, 2010, EXP EYE RES, V91, P387, DOI 10.1016/j.exer.2010.06.010
   Schnaudigel O., 1913, GRAEFE ARCH OPHTHAL, V86, P93
   Shen J, 2003, PHARM RES-DORDR, V20, P1357, DOI 10.1023/A:1025789606885
   STEWART PA, 1994, J COMP NEUROL, V340, P566, DOI 10.1002/cne.903400409
   Tagami M, 2009, BRAIN RES, V1283, P186, DOI 10.1016/j.brainres.2009.05.095
   TAKATA K, 1992, INVEST OPHTH VIS SCI, V33, P377
   Tomi M, 2005, INVEST OPHTH VIS SCI, V46, P2522, DOI 10.1167/iovs.04-1175
   Tomi M, 2007, MICROVASC RES, V73, P100, DOI 10.1016/j.mvr.2006.10.003
   Tomi M, 2009, J NEUROCHEM, V111, P716, DOI 10.1111/j.1471-4159.2009.06367.x
   Yoles E, 1999, INVEST OPHTH VIS SCI, V40, P65
NR 27
TC 6
Z9 6
U1 0
U2 7
PU PHARMACEUTICAL SOC JAPAN
PI TOKYO
PA 2-12-15 SHIBUYA, SHIBUYA-KU, TOKYO, 150-0002, JAPAN
SN 0918-6158
J9 BIOL PHARM BULL
JI Biol. Pharm. Bull.
PD AUG
PY 2017
VL 40
IS 8
BP 1139
EP 1145
DI 10.1248/bpb.b17-00090
PG 7
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA FC4OZ
UT WOS:000406821600003
PM 28768994
OA gold
DA 2022-11-30
ER

PT J
AU Hongisto, H
   Jylha, A
   Nattinen, J
   Rieck, J
   Ilmarinen, T
   Vereb, Z
   Aapola, U
   Beuerman, R
   Petrovski, G
   Uusitalo, H
   Skottman, H
AF Hongisto, Heidi
   Jylha, Antti
   Nattinen, Janika
   Rieck, Jochen
   Ilmarinen, Tanja
   Vereb, Zoltan
   Aapola, Ulla
   Beuerman, Roger
   Petrovski, Goran
   Uusitalo, Hannu
   Skottman, Heli
TI Comparative proteomic analysis of human embryonic stem cell-derived and
   primary human retinal pigment epithelium
SO SCIENTIFIC REPORTS
LA English
DT Article
ID MACULAR DEGENERATION; RPE CELLS; PROTEIN EXPRESSION; PROGRESSIVE STAGES;
   VISUAL FUNCTION; PHAGOCYTOSIS; DIFFERENTIATION; DERIVATION; SECRETION;
   INTEGRIN
AB Human embryonic stem cell-derived retinal pigment epithelial cells (hESC-RPE) provide an unlimited cell source for retinal cell replacement therapies. Clinical trials using hESC-RPE to treat diseases such as age-related macular degeneration (AMD) are currently underway. Human ESC-RPE cells have been thoroughly characterized at the gene level but their protein expression profile has not been studied at larger scale. In this study, proteomic analysis was used to compare hESC-RPE cells differentiated from two independent hESC lines, to primary human RPE (hRPE) using Isobaric tags for relative quantitation (iTRAQ). 1041 common proteins were present in both hESC-RPE cells and native hRPE with majority of the proteins similarly regulated. The hESC-RPE proteome reflected that of normal hRPE with a large number of metabolic, mitochondrial, cytoskeletal, and transport proteins expressed. No signs of increased stress, apoptosis, immune response, proliferation, or retinal degeneration related changes were noted in hESC-RPE, while important RPE specific proteins involved in key RPE functions such as visual cycle and phagocytosis, could be detected in the hESC-RPE. Overall, the results indicated that the proteome of the hESC-RPE cells closely resembled that of their native counterparts.
C1 [Hongisto, Heidi; Nattinen, Janika; Rieck, Jochen; Ilmarinen, Tanja; Skottman, Heli] Univ Tampere, BioMediTech Inst, Fac Med & Life Sci, Tampere, Finland.
   [Jylha, Antti; Nattinen, Janika; Aapola, Ulla; Beuerman, Roger; Uusitalo, Hannu] Univ Tampere, Fac Med & Life Sci, Dept Ophthalmol, Tampere, Finland.
   [Vereb, Zoltan; Petrovski, Goran] Univ Szeged, Dept Ophthalmol, Stem Cells & Eye Res Lab, Fac Med, Szeged, Hungary.
   [Beuerman, Roger] Singapore Eye Res Inst, Singapore, Singapore.
   [Beuerman, Roger] Duke NUS Sch Med, Singapore, Singapore.
   [Petrovski, Goran] Oslo Univ Hosp, Dept Ophthalmol, Ctr Eye Res, Oslo, Norway.
   [Petrovski, Goran] Univ Oslo, Oslo, Norway.
   [Uusitalo, Hannu] Univ Tampere, Tampere Univ Hosp, Eye Ctr, Tampere, Finland.
C3 Tampere University; Tampere University; Szeged University; National
   University of Singapore; Singapore National Eye Center; University of
   Oslo; University of Oslo; Tampere University; Tampere University
   Hospital
RP Hongisto, H (通讯作者)，Univ Tampere, BioMediTech Inst, Fac Med & Life Sci, Tampere, Finland.
EM heidi.m.hongisto@staff.uta.fi
RI Vereb, Zoltan/I-6356-2019; Vereb, Zoltan/AAR-4092-2020
OI Vereb, Zoltan/0000-0002-9518-2155; Nattinen, Janika/0000-0002-7844-079X;
   Aapola, Ulla/0000-0001-7691-3170; Hongisto, Heidi/0000-0002-2416-5673;
   Petrovski, Goran/0000-0003-2905-9252; Skottman,
   Heli/0000-0002-4127-8792; Ilmarinen, Tanja/0000-0002-4609-8897
FU Academy of Finland [218050, 133879, 304909]; Elsemay Bjorn Fund;
   Paivikki and Sakari Sohlberg foundation; National Brain Research Program
   [KTIA_NAP_13-A_III/9]
FX Outi Heikkila, Outi Melin and Hanna Pekkanen are thanked for commenting
   the manuscript. The study was supported by Academy of Finland (grant
   numbers 218050, 133879, and 304909), Elsemay Bjorn Fund, and Paivikki
   and Sakari Sohlberg foundation. GP and the Stem Cells and Eye Research
   Laboratory, Department of Ophthalmology, Faculty of Medicine, University
   of Szeged, Hungary, have been supported by the National Brain Research
   Program (KTIA_NAP_13-A_III/9). The funding sources were not involved in
   study design, data collection and analysis, decision to publish, or
   preparation of the article. Results of this study were presented in part
   at the International Society for Stem Cell Research (ISSCR) Annual
   Meeting in Stockholm, Sweden, June 24-27,2015.
CR Alge CS, 2006, J PROTEOME RES, V5, P862, DOI 10.1021/pr050420t
   Alge CS, 2003, INVEST OPHTH VIS SCI, V44, P3629, DOI 10.1167/iovs.02-1225
   Ambati J, 2013, NAT REV IMMUNOL, V13, P438, DOI 10.1038/nri3459
   An E, 2006, J PROTEOME RES, V5, P2599, DOI 10.1021/pr060121j
   Arnouk H, 2011, J PROTEOMICS, V74, P254, DOI 10.1016/j.jprot.2010.11.004
   Bourassa S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125934
   Carr AJ, 2009, MOL VIS, V15, P283
   Chen FK, 2010, BRIT J OPHTHALMOL, V94, P1337, DOI 10.1136/bjo.2009.172593
   Chen MJ, 2014, INT J ONCOL, V45, P1515, DOI 10.3892/ijo.2014.2554
   Coffey PJ, 2002, NAT NEUROSCI, V5, P53, DOI 10.1038/nn782
   Coghlan A., 2015, NEW SCI
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Cyranoski D, 2014, NATURE, DOI [10.1038/nature.2014.15915, DOI 10.1038/NATURE.2014.15915]
   Evans C, 2012, ANAL BIOANAL CHEM, V404, P1011, DOI 10.1007/s00216-012-5918-6
   Fang IM, 2009, EXP EYE RES, V88, P12, DOI 10.1016/j.exer.2008.09.019
   Ferrer M, 2014, STEM CELL TRANSL MED, V3, P911, DOI 10.5966/sctm.2013-0192
   Finnemann SC, 1997, P NATL ACAD SCI USA, V94, P12932, DOI 10.1073/pnas.94.24.12932
   Garcia JM, 2015, WORLD J STEM CELLS, V7, P160, DOI 10.4252/wjsc.v7.i1.160
   Graves PR, 2002, MICROBIOL MOL BIOL R, V66, P39, DOI 10.1128/MMBR.66.1.39-63.2002
   Hadziahmetovic M, 2012, INVEST OPHTH VIS SCI, V53, P5231, DOI 10.1167/iovs.12-10204
   Hubmacher D, 2006, CURR TOP DEV BIOL, V75, P93, DOI 10.1016/S0070-2153(06)75004-9
   Iannaccone A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0145323
   Ilmarinen T, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0143669
   Juuti-Uusitalo K, 2013, INVEST OPHTH VIS SCI, V54, P3510, DOI 10.1167/iovs.13-11800
   Kamao H, 2014, STEM CELL REP, V2, P205, DOI 10.1016/j.stemcr.2013.12.007
   Kay P, 2014, INVEST OPHTH VIS SCI, V55, P926, DOI 10.1167/iovs.13-13239
   Kevany BM, 2010, PHYSIOLOGY, V25, P8, DOI 10.1152/physiol.00038.2009
   Klimanskaya I, 2004, CLONING STEM CELLS, V6, P217, DOI 10.1089/1536230042323420
   Lee H, 2010, INT J BIOL MACROMOL, V47, P685, DOI 10.1016/j.ijbiomac.2010.08.018
   Little CW, 1998, EXP NEUROL, V149, P151, DOI 10.1006/exnr.1997.6642
   Lund RD, 2006, CLONING STEM CELLS, V8, P189, DOI 10.1089/clo.2006.8.189
   Maruotti J, 2015, P NATL ACAD SCI USA, V112, P10950, DOI 10.1073/pnas.1422818112
   Mikhailova A, 2015, SCI REP-UK, V5, DOI 10.1038/srep14684
   Muniz A, 2014, INVEST OPHTH VIS SCI, V55, P198, DOI 10.1167/iovs.13-11740
   Murad N, 2014, FEBS J, V281, P5251, DOI 10.1111/febs.13066
   Nordgaard CL, 2006, INVEST OPHTH VIS SCI, V47, P815, DOI 10.1167/iovs.05-0976
   Nordgaard CL, 2008, INVEST OPHTH VIS SCI, V49, P2848, DOI 10.1167/iovs.07-1352
   Novak A, 2012, STEM CELL REV REP, V8, P137, DOI 10.1007/s12015-011-9286-y
   Ow SY, 2009, J PROTEOME RES, V8, P5347, DOI 10.1021/pr900634c
   Pilat A, 2013, INVEST OPHTH VIS SCI, V54, P47, DOI 10.1167/iovs.12-11153
   Priglinger CS, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070011
   Rabin DM, 2013, AGING-US, V5, P51
   Schwartz SD, 2016, INVEST OPHTH VIS SCI, V57, DOI 10.1167/iovs.15-18681
   Sheridan C, 2005, ESSENT OPHTHALMOL, P101
   Skeie JM, 2014, JAMA OPHTHALMOL, V132, P1271, DOI 10.1001/jamaophthalmol.2014.2065
   Skottman H, 2010, IN VITRO CELL DEV-AN, V46, P206, DOI 10.1007/s11626-010-9286-2
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Strunnikova NV, 2010, HUM MOL GENET, V19, P2468, DOI 10.1093/hmg/ddq129
   Tucker BA, 2013, STEM CELL TRANSL MED, V2, P16, DOI 10.5966/sctm.2012-0040
   Vaajasaari H, 2011, MOL VIS, V17, P558
   Vugler A, 2008, EXP NEUROL, V214, P347, DOI 10.1016/j.expneurol.2008.09.007
   Wang SM, 2005, INVEST OPHTH VIS SCI, V46, P2552, DOI 10.1167/iovs.05-0279
   West KA, 2003, MOL CELL PROTEOMICS, V2, P37, DOI 10.1074/mcp.D200001-MCP200
   Yuan XL, 2010, MOL CELL PROTEOMICS, V9, P1031, DOI 10.1074/mcp.M900523-MCP200
   Zhang PB, 2016, PROTEOMICS, V16, P1146, DOI 10.1002/pmic.201500188
   Zheng QX, 2015, J OPHTHALMOL, V2015, DOI 10.1155/2015/918473
   Zhou P, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098275
NR 57
TC 16
Z9 16
U1 0
U2 3
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD JUL 20
PY 2017
VL 7
AR 6016
DI 10.1038/s41598-017-06233-9
PG 12
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA FB1MN
UT WOS:000405907800070
PM 28729539
OA gold, Green Accepted, Green Published
DA 2022-11-30
ER

PT J
AU Theodoropoulou, S
   Copland, DA
   Liu, J
   Wu, JH
   Gardner, PJ
   Ozaki, E
   Doyle, SL
   Campbell, M
   Dick, AD
AF Theodoropoulou, Sofia
   Copland, David A.
   Liu, Jian
   Wu, Jiahui
   Gardner, Peter J.
   Ozaki, Ema
   Doyle, Sarah L.
   Campbell, Matthew
   Dick, Andrew D.
TI Interleukin-33 regulates tissue remodelling and inhibits angiogenesis in
   the eye
SO JOURNAL OF PATHOLOGY
LA English
DT Article
DE IL-33; AMD; RPE; angiogenesis; wound healing
ID EPITHELIAL-CELL LINE; MACULAR DEGENERATION; INDUCED ARTHRITIS;
   MAST-CELLS; IN-VITRO; IL-33; ST2; CYTOKINE; INFLAMMATION; CONTRACTION
AB Age-related macular degeneration (AMD) is the leading cause of central vision loss worldwide. Loss of retinal pigment epithelium (RPE) is a major pathological hallmark in AMD with or without pathological neovascularization. Although activation of the immune system is implicated in disease progression, pathological pathways remain diverse and unclear. Here, we report an unexpected protective role of a pro-inflammatory cytokine, interleukin-33 (IL-33), in ocular angiogenesis. IL-33 and its receptor (ST2) are expressed constitutively in human and murine retina and choroid. When RPE was activated, IL-33 expression was markedly elevated in vitro. We found that IL-33 regulated tissue remodelling by attenuating wound-healing responses, including reduction in the migration of choroidal fibroblasts and retinal microvascular endothelial cells, and inhibition of collagen gel contraction. In vivo, local administration of recombinant IL-33 inhibited murine choroidal neovascularization (CNV) formation, a surrogate of human neovascular AMD, and this effect was ST2-dependent. Collectively, these data demonstrate IL-33 as a potential immunotherapy and distinguishes pathways for subverting AMD pathology. (c) 2016 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of Pathological Society of Great Britain and Ireland.
C1 [Theodoropoulou, Sofia; Copland, David A.; Liu, Jian; Wu, Jiahui; Dick, Andrew D.] Univ Bristol, Acad Unit Ophthalmol, Sch Clin Sci, Bristol, Avon, England.
   [Gardner, Peter J.; Dick, Andrew D.] UCL, Inst Ophthalmol, London, England.
   [Ozaki, Ema; Doyle, Sarah L.] Trinity Coll Dublin, Sch Med, Dept Clin Med, Dublin, Ireland.
   [Campbell, Matthew] Trinity Coll Dublin, Smurfit Inst Genet, Dublin, Ireland.
   [Dick, Andrew D.] Moorfields Eye Hosp, Biomed Res Ctr, NIHR, London, England.
C3 University of Bristol; University of London; University College London;
   Trinity College Dublin; Trinity College Dublin; University of London;
   King's College London; University College London; Moorfields Eye
   Hospital NHS Foundation Trust
RP Dick, AD (通讯作者)，Univ Bristol, Bristol Eye Hosp, Sch Clin Sci, Acad Unit Ophthalmol, Bristol BS1 2LX, Avon, England.
EM a.dick@bristol.ac.uk
RI Campbell, Matthew/AAZ-2997-2021; Copland, David/AAE-5334-2020; Copland,
   David/AAG-2368-2019
OI Copland, David/0000-0002-2257-4270; Theodoropoulou,
   Sofia/0000-0003-3038-5354; Campbell, Matthew/0000-0001-5883-5041; Doyle,
   Sarah/0000-0002-6294-9380; Dick, Andrew/0000-0002-0742-3159; Gardner,
   Pete/0000-0002-4940-2639
FU National Eye Research Centre, UK [RJ6056]; National Institute for Health
   Research, UK; National Institute for Health Research (NIHR) Biomedical
   Research Centre based at Moorfields Eye Hospital NHS Foundation Trust;
   University College London Institute of Ophthalmology; Science Foundation
   Ireland (SFI); Health Research Board of Ireland (HRB); Bright Focus
   Foundation; Academy of Medical Sciences (AMS) [SGL017\\1042] Funding
   Source: researchfish; National Institute for Health Research
   [CL-2015-25-502, ACF-2013-25-003] Funding Source: researchfish
FX Research was funded through the National Eye Research Centre, UK
   (RJ6056). ADD and ST were supported in part through the National
   Institute for Health Research, UK. Additional support was received from
   the National Institute for Health Research (NIHR) Biomedical Research
   Centre based at Moorfields Eye Hospital NHS Foundation Trust and
   University College London Institute of Ophthalmology. SD is supported by
   grants from Science Foundation Ireland (SFI), The Health Research Board
   of Ireland (HRB), and the Bright Focus Foundation. MC was supported by
   grants from Science Foundation Ireland (SFI), The Health Research Board
   of Ireland (HRB) and the Bright Focus Foundation. The views expressed
   are those of the authors and not necessarily those of the National
   Health Service, the NIHR or the Department of Health. We would like to
   thank Costanza Emanueli (School of Clinical Sciences, Bristol Heart
   Institute, University of Bristol, Bristol, UK) for providing the ST2
   knock-out (St2-/-) C57BL/6 mice. Additionally, we would like to thank
   Professor Seamus Martin and Dr Graeme Sullivan for providing human
   recombinant IL-33. We would also like to acknowledge the assistance of
   the Flow Cytometry Facility and the Wolfson Bioimaging Facility at the
   University of Bristol.
CR Allakhverdi Z, 2007, J IMMUNOL, V179, P2051, DOI 10.4049/jimmunol.179.4.2051
   Barbour M, 2014, EUR J IMMUNOL, V44, P3320, DOI 10.1002/eji.201444671
   BELL E, 1979, P NATL ACAD SCI USA, V76, P1274, DOI 10.1073/pnas.76.3.1274
   Campbell M, 2014, EXPERT REV CLIN IMMU, V10, P1273, DOI 10.1586/1744666X.2014.950231
   Carriere V, 2007, P NATL ACAD SCI USA, V104, P282, DOI 10.1073/pnas.0606854104
   CARVER W, 1995, J CELL PHYSIOL, V165, P425, DOI 10.1002/jcp.1041650224
   Cayrol C, 2009, P NATL ACAD SCI USA, V106, P9021, DOI 10.1073/pnas.0812690106
   Chackerian AA, 2007, J IMMUNOL, V179, P2551, DOI 10.4049/jimmunol.179.4.2551
   Chen M, 2008, INVEST OPHTH VIS SCI, V49, P3699, DOI 10.1167/iovs.07-1522
   Chen WY, 2015, P NATL ACAD SCI USA, V112, P7249, DOI 10.1073/pnas.1424236112
   Choi YS, 2009, BLOOD, V114, P3117, DOI 10.1182/blood-2009-02-203372
   Daniels JT, 2003, INVEST OPHTH VIS SCI, V44, P1104, DOI 10.1167/iovs.02-0412
   Demyanets S, 2011, ARTERIOSCL THROM VAS, V31, P2080, DOI 10.1161/ATVBAHA.111.231431
   Dick AD, 2015, INVEST OPHTH VIS SCI, V56, P5431, DOI 10.1167/iovs.15-17613
   Doyle SL, 2015, INVEST OPHTH VIS SCI, V56, P5424, DOI 10.1167/iovs.15-17264
   Doyle SL, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3007616
   Doyle SL, 2012, NAT MED, V18, P791, DOI 10.1038/nm.2717
   Dunn KC, 1996, EXP EYE RES, V62, P155, DOI 10.1006/exer.1996.0020
   Forrester JV, 2008, MUCOSAL IMMUNOL, V1, P372, DOI 10.1038/mi.2008.27
   Friedlander M, 2007, J CLIN INVEST, V117, P576, DOI 10.1172/JCI31030
   Fu AKY, 2016, P NATL ACAD SCI USA, V113, pE2705, DOI 10.1073/pnas.1604032113
   GUIDRY C, 1986, COLLAGEN REL RES, V6, P515
   Kakkar R, 2012, J BIOL CHEM, V287, P6941, DOI 10.1074/jbc.M111.298703
   Kuchler AM, 2008, AM J PATHOL, V173, P1229, DOI 10.2353/ajpath.2008.080014
   Lamkanfi M, 2011, NAT REV IMMUNOL, V11, P213, DOI 10.1038/nri2936
   Lamkanfi M, 2009, IMMUNITY, V31, P5, DOI 10.1016/j.immuni.2009.06.011
   Lavalette S, 2011, AM J PATHOL, V178, P2416, DOI 10.1016/j.ajpath.2011.01.013
   Lefrancais E, 2012, P NATL ACAD SCI USA, V109, P1673, DOI 10.1073/pnas.1115884109
   Leung BP, 2004, J IMMUNOL, V173, P145, DOI 10.4049/jimmunol.173.1.145
   Liew FY, 2010, NAT REV IMMUNOL, V10, P103, DOI 10.1038/nri2692
   Liu J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072935
   Luthi AU, 2009, IMMUNITY, V31, P84, DOI 10.1016/j.immuni.2009.05.007
   Martin NT, 2016, NAT IMMUNOL, V17, P122, DOI 10.1038/ni.3370
   McMenamin PG, 1997, EYE, V11, P183, DOI 10.1038/eye.1997.49
   Miller AM, 2008, J EXP MED, V205, P339, DOI 10.1084/jem.20071868
   Nussenblatt RB, 2014, AM J OPHTHALMOL, V158, P5, DOI 10.1016/j.ajo.2014.03.014
   Oboki K, 2010, P NATL ACAD SCI USA, V107, P18581, DOI 10.1073/pnas.1003059107
   Pichery M, 2012, J IMMUNOL, V188, P3488, DOI 10.4049/jimmunol.1101977
   Rein DB, 2009, ARCH OPHTHALMOL-CHIC, V127, P533, DOI 10.1001/archophthalmol.2009.58
   Schmitz J, 2005, IMMUNITY, V23, P479, DOI 10.1016/j.immuni.2005.09.015
   Wei JX, 2015, J INVEST MED, V63, P806, DOI 10.1097/JIM.0000000000000213
   Wu WK, 2015, AM J PATHOL, V185, P2324, DOI 10.1016/j.ajpath.2015.04.013
   Xi HK, 2016, J EXP MED, V213, P189, DOI 10.1084/jem.20150894
   Xu D, 1998, J EXP MED, V187, P787, DOI 10.1084/jem.187.5.787
   Xu D, 2008, P NATL ACAD SCI USA, V105, P10913, DOI 10.1073/pnas.0801898105
   Xu HP, 2009, PROG RETIN EYE RES, V28, P348, DOI 10.1016/j.preteyeres.2009.06.001
   Xu LN, 2015, RETINA-J RET VIT DIS, V35, P176, DOI 10.1097/IAE.0000000000000374
   YANAGISAWA K, 1992, FEBS LETT, V302, P51, DOI 10.1016/0014-5793(92)80282-L
NR 48
TC 35
Z9 36
U1 0
U2 13
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0022-3417
EI 1096-9896
J9 J PATHOL
JI J. Pathol.
PD JAN
PY 2017
VL 241
IS 1
BP 45
EP 56
DI 10.1002/path.4816
PG 12
WC Oncology; Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Pathology
GA EI9QO
UT WOS:000392844000006
PM 27701734
OA Green Published, hybrid, Green Accepted
DA 2022-11-30
ER

PT J
AU Xi, HK
   Katschke, KJ
   Li, Y
   Truong, T
   Lee, WP
   Diehl, L
   Rangell, L
   Tao, JH
   Arceo, R
   Eastham-Anderson, J
   Hackney, JA
   Iglesias, A
   Cote-Sierra, J
   Elstrott, J
   Weimer, RM
   Campagne, MV
AF Xi, Hongkang
   Katschke, Kenneth J., Jr.
   Li, Yun
   Tom Truong
   Lee, Wyne P.
   Diehl, Lauri
   Rangell, Linda
   Tao, Jianhua
   Arceo, Rommel
   Eastham-Anderson, Jeffrey
   Hackney, Jason A.
   Iglesias, Antonio
   Cote-Sierra, Javier
   Elstrott, Justin
   Weimer, Robby M.
   Campagne, Menno van Lookeren
TI IL-33 amplifies an innate immune response in the degenerating retina
SO JOURNAL OF EXPERIMENTAL MEDICINE
LA English
DT Article
ID INFLAMMATORY CYTOKINE PRODUCTION; MACULAR DEGENERATION; MULLER CELLS;
   PIGMENT EPITHELIUM; MICROGLIA; INSIGHTS; DISEASE; T1/ST2; STRESS; NLRP3
AB Age-related macular degeneration (AMD), a leading cause of vision impairment in the ageing population, is characterized by irreversible loss of retinal pigment epithelial (RPE) cells and photoreceptors and can be associated with choroidal neovascularization. Mononuclear phagocytes are often present in AMD lesions, but the processes that direct myeloid cell recruitment remain unclear. Here, we identify IL-33 as a key regulator of inflammation and photoreceptor degeneration after retina stress or injury. IL-33(+) Muller cells were more abundant and IL-33 cytokine was elevated in advanced AMD cases compared with age-matched controls with no AMD. In rodents, retina stress resulted in release of bioactive IL-33 that in turn increased inflammatory chemokine and cytokine expression in activated Muller cells. Deletion of ST2, the IL-33 receptor a chain, or treatment with a soluble IL-33 decoy receptor significantly reduced release of inflammatory mediators from Muller cells, inhibited accumulation of mononuclear phagocytes in the outer retina, and protected photoreceptor rods and cones after a retina insult. This study demonstrates a central role for IL-33 in regulating mononuclear phagocyte recruitment to the photoreceptor layer and positions IL-33 signaling as a potential therapeutic target in macular degenerative diseases.
C1 [Xi, Hongkang; Katschke, Kenneth J., Jr.; Li, Yun; Tom Truong; Lee, Wyne P.; Campagne, Menno van Lookeren] Genencor Inc, Dept Immunol, San Francisco, CA 94080 USA.
   [Diehl, Lauri; Rangell, Linda; Tao, Jianhua; Arceo, Rommel; Eastham-Anderson, Jeffrey] Genencor Inc, Dept Pathol, San Francisco, CA 94080 USA.
   [Hackney, Jason A.] Genencor Inc, Dept Bioinformat & Computat Biol, San Francisco, CA 94080 USA.
   [Elstrott, Justin; Weimer, Robby M.] Genencor Inc, Dept Biomed Imaging, San Francisco, CA 94080 USA.
   [Iglesias, Antonio; Cote-Sierra, Javier] Roche Innovat Ctr Basel, Roche Pharmaceut Res & Early Dev, Pharmacol Sci, CH-4070 Basel, Switzerland.
   [Cote-Sierra, Javier] Pfizer Inc, Worldwide Res & Dev, External R&D Innovat Immunol & Inflammat, Cambridge, MA 02139 USA.
C3 Roche Holding; Pfizer
RP Campagne, MV (通讯作者)，Genencor Inc, Dept Immunol, San Francisco, CA 94080 USA.
EM menno@gene.com
OI Elstrott, Justin/0000-0001-6694-5929; Hackney, Jason/0000-0002-5922-563X
CR Alves JC, 2010, NAT MED, V16, P708, DOI 10.1038/nm.2156
   Baekkevold ES, 2003, AM J PATHOL, V163, P69, DOI 10.1016/S0002-9440(10)63631-0
   Barbour M, 2014, EUR J IMMUNOL, V44, P3320, DOI 10.1002/eji.201444671
   Bessa J, 2014, J AUTOIMMUN, V55, P33, DOI 10.1016/j.jaut.2014.02.012
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Bourgon R, 2010, P NATL ACAD SCI USA, V107, P9546, DOI 10.1073/pnas.0914005107
   Bringmann A, 2006, PROG RETIN EYE RES, V25, P397, DOI 10.1016/j.preteyeres.2006.05.003
   Bringmann A, 2009, PROG RETIN EYE RES, V28, P423, DOI 10.1016/j.preteyeres.2009.07.001
   Carido M, 2014, INVEST OPHTH VIS SCI, V55, P5431, DOI 10.1167/iovs.14-14325
   Chovatiya R, 2014, MOL CELL, V54, P281, DOI 10.1016/j.molcel.2014.03.030
   Combadiere C, 2007, J CLIN INVEST, V117, P2920, DOI 10.1172/JCI31692
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   Doyle SL, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3007616
   Doyle SL, 2012, NAT MED, V18, P791, DOI 10.1038/nm.2717
   Durinck S, 2015, NAT GENET, V47, P13, DOI 10.1038/ng.3146
   Espinassous Q, 2009, J IMMUNOL, V183, P1446, DOI 10.4049/jimmunol.0803067
   Falcon S, 2007, BIOINFORMATICS, V23, P257, DOI 10.1093/bioinformatics/btl567
   Gadani SP, 2015, NEURON, V85, P703, DOI 10.1016/j.neuron.2015.01.013
   Gadina Massimo, 2007, Sci STKE, V2007, ppe31, DOI 10.1126/stke.3902007pe31
   Guo CR, 2012, EXP EYE RES, V104, P39, DOI 10.1016/j.exer.2012.08.013
   HOCHBERG Y, 1990, STAT MED, V9, P811, DOI 10.1002/sim.4780090710
   Hu SJ, 2015, J NEUROSCI, V35, P6987, DOI 10.1523/JNEUROSCI.3955-14.2015
   Hueber AJ, 2011, EUR J IMMUNOL, V41, P2229, DOI 10.1002/eji.201041360
   Jarrett SG, 2012, MOL ASPECTS MED, V33, P399, DOI 10.1016/j.mam.2012.03.009
   Jones LA, 2010, EUR J IMMUNOL, V40, P426, DOI 10.1002/eji.200939705
   Kearley J, 2015, IMMUNITY, V42, P566, DOI 10.1016/j.immuni.2015.02.011
   Kim J, 2014, J IMMUNOL, V193, P3792, DOI 10.4049/jimmunol.1400176
   LAVAIL MM, 1992, P NATL ACAD SCI USA, V89, P11249, DOI 10.1073/pnas.89.23.11249
   Lavalette S, 2011, AM J PATHOL, V178, P2416, DOI 10.1016/j.ajpath.2011.01.013
   Lefrancais E, 2012, P NATL ACAD SCI USA, V109, P1673, DOI 10.1073/pnas.1115884109
   Lingel A, 2009, STRUCTURE, V17, P1398, DOI 10.1016/j.str.2009.08.009
   Liu X, 2013, P NATL ACAD SCI USA, V110, P14918, DOI 10.1073/pnas.1308651110
   Liu XC, 2012, INFLAMMATION, V35, P776, DOI 10.1007/s10753-011-9379-4
   Lugt BV, 2014, NAT IMMUNOL, V15, P161, DOI 10.1038/ni.2795
   Maeda A, 2014, P NATL ACAD SCI USA, V111, pE1428, DOI 10.1073/pnas.1317986111
   Merchant AM, 1998, NAT BIOTECHNOL, V16, P677, DOI 10.1038/nbt0798-677
   Nakazawa T, 2007, P NATL ACAD SCI USA, V104, P2425, DOI 10.1073/pnas.0608167104
   Oliphant CJ, 2011, IMMUNOLOGY, V134, P378, DOI 10.1111/j.1365-2567.2011.03499.x
   Pichery M, 2012, J IMMUNOL, V188, P3488, DOI 10.4049/jimmunol.1101977
   Rivera JC, 2013, ARTERIOSCL THROM VAS, V33, P1881, DOI 10.1161/ATVBAHA.113.301331
   Rutar M, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-014-0224-1
   Rutar M, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-221
   Rutar M, 2011, INVEST OPHTH VIS SCI, V52, P2379, DOI 10.1167/iovs.10-6010
   Sarthy VP, 1998, INVEST OPHTH VIS SCI, V39, P212
   Schmitz J, 2005, IMMUNITY, V23, P479, DOI 10.1016/j.immuni.2005.09.015
   Sennlaub F, 2013, EMBO MOL MED, V5, P1775, DOI 10.1002/emmm.201302692
   Smyth, 2004, STAT APPL GENET MOL, V3, P1, DOI DOI 10.2202/1544-6115.1027
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Tarallo V, 2012, CELL, V149, P847, DOI 10.1016/j.cell.2012.03.036
   Townsend MJ, 2000, J EXP MED, V191, P1069, DOI 10.1084/jem.191.6.1069
   Villarreal DO, 2014, CANCER RES, V74, P1789, DOI 10.1158/0008-5472.CAN-13-2729
   Wu TD, 2010, BIOINFORMATICS, V26, P873, DOI 10.1093/bioinformatics/btq057
NR 52
TC 51
Z9 52
U1 2
U2 14
PU ROCKEFELLER UNIV PRESS
PI NEW YORK
PA 950 THIRD AVE, 2ND FLR, NEW YORK, NY 10022 USA
SN 0022-1007
EI 1540-9538
J9 J EXP MED
JI J. Exp. Med.
PD FEB 8
PY 2016
VL 213
IS 2
BP 189
EP 207
DI 10.1084/jem.20150894
PG 19
WC Immunology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Immunology; Research & Experimental Medicine
GA DI3FK
UT WOS:000373383700007
PM 26755704
OA Green Published, Green Submitted, Bronze
DA 2022-11-30
ER

PT J
AU Lu, AT
   Hannon, E
   Levine, ME
   Hao, K
   Crimmins, EM
   Lunnon, K
   Kozlenkov, A
   Mill, J
   Dracheva, S
   Horvath, S
AF Lu, Ake T.
   Hannon, Eilis
   Levine, Morgan E.
   Hao, Ke
   Crimmins, Eileen M.
   Lunnon, Katie
   Kozlenkov, Alexey
   Mill, Jonathan
   Dracheva, Stella
   Horvath, Steve
TI Genetic variants near MLST8 and DHX57 affect the epigenetic age of the
   cerebellum
SO NATURE COMMUNICATIONS
LA English
DT Article
ID GENOME-WIDE ASSOCIATION; DNA METHYLATION AGE; HUMAN LONGEVITY; HUMAN
   BRAIN; ALZHEIMERS-DISEASE; PREFRONTAL CORTEX; LIFE-SPAN; HUMAN TISSUES;
   CELL-TYPES; CLOCK
AB DNA methylation (DNAm) levels lend themselves for defining an epigenetic biomarker of aging known as the 'epigenetic clock'. Our genome-wide association study (GWAS) of cerebellar epigenetic age acceleration identifies five significant (P<5.0 x 10(-8)) SNPs in two loci: 2p22.1 (inside gene DHX57) and 16p13.3 near gene MLST8 (a subunit of mTOR complex 1 and 2). We find that the SNP in 16p13.3 has a cis-acting effect on the expression levels of MLST8 (P = 6.9 x 10(-18)) in most brain regions. In cerebellar samples, the SNP in 2p22.1 has a cis-effect on DHX57 (P = 4.4 x 10(-5)). Gene sets found by our GWAS analysis of cerebellar age acceleration exhibit significant overlap with those of Alzheimer's disease (P = 4.4 x 10(-15)), age-related macular degeneration (P = 6.4 x 10(-6)), and Parkinson's disease (P = 2.6 x 10(-4)). Overall, our results demonstrate the utility of a new paradigm for understanding aging and age-related diseases: it will be fruitful to use epigenetic tissue age as endophenotype in GWAS.
C1 [Lu, Ake T.; Levine, Morgan E.; Horvath, Steve] Univ Calif Los Angeles, David Geffen Sch Med, Dept Human Genet, Los Angeles, CA 90095 USA.
   [Hannon, Eilis; Lunnon, Katie; Mill, Jonathan] Univ Exeter, Sch Med, Exeter EX2 5DW, Devon, England.
   [Hao, Ke] Icahn Sch Med Mt Sinai, Friedman Brain Inst, Dept Genet & Genom Sci, New York, NY 10029 USA.
   [Crimmins, Eileen M.] Univ So Calif, Davis Sch Gerontol, Ethel Percy Andrus Gerontol Ctr, 3715 McClintock Ave, Los Angeles, CA 90089 USA.
   [Kozlenkov, Alexey; Dracheva, Stella] Icahn Sch Med Mt Sinai, Dept Psychiat, New York, NY 10029 USA.
   [Kozlenkov, Alexey; Dracheva, Stella] Icahn Sch Med Mt Sinai, Friedman Brain Inst, New York, NY 10029 USA.
   [Kozlenkov, Alexey; Dracheva, Stella] James J Peters VA Med Ctr, Bronx, NY 10468 USA.
   [Mill, Jonathan] Kings Coll London, Inst Psychiat, London SE5 8AF, England.
   [Horvath, Steve] Univ Calif Los Angeles, Sch Publ Hlth, Biostat, Los Angeles, CA 90095 USA.
C3 University of California System; University of California Los Angeles;
   University of California Los Angeles Medical Center; David Geffen School
   of Medicine at UCLA; University of Exeter; Icahn School of Medicine at
   Mount Sinai; University of Southern California; Icahn School of Medicine
   at Mount Sinai; Icahn School of Medicine at Mount Sinai; US Department
   of Veterans Affairs; Veterans Health Administration (VHA); James J.
   Peters VA Medical Center; University of London; King's College London;
   University of California System; University of California Los Angeles
RP Horvath, S (通讯作者)，Univ Calif Los Angeles, David Geffen Sch Med, Dept Human Genet, Los Angeles, CA 90095 USA.; Horvath, S (通讯作者)，Univ Calif Los Angeles, Sch Publ Hlth, Biostat, Los Angeles, CA 90095 USA.
EM shorvath@mednet.ucla.edu
RI Mill, Jonathan S/B-3276-2010; Lunnon, Katie/C-4638-2012; Hannon,
   Eilis/T-1349-2019; Mill, Jonathan/B-5678-2014
OI Mill, Jonathan S/0000-0003-1115-3224; Lunnon, Katie/0000-0001-7570-6065;
   Hannon, Eilis/0000-0001-6840-072X; Mill, Jonathan/0000-0003-1115-3224
FU National Institutes of Health [NIA/NIH 5R01AG042511-02]; Medical
   Research Council [MR/K013807/1] Funding Source: researchfish; MRC
   [MR/K013807/1] Funding Source: UKRI; NATIONAL INSTITUTE OF NEUROLOGICAL
   DISORDERS AND STROKE [T32NS048004] Funding Source: NIH RePORTER;
   NATIONAL INSTITUTE ON AGING [U01AG009740, R01AG042511, U34AG051425]
   Funding Source: NIH RePORTER; Veterans Affairs [I01BX001829] Funding
   Source: NIH RePORTER
FX The study was supported by the National Institutes of Health (NIA/NIH
   5R01AG042511-02).
CR Alisch RS, 2012, GENOME RES, V22, P623, DOI 10.1101/gr.125187.111
   Benayoun BA, 2015, NAT REV MOL CELL BIO, V16, P593, DOI 10.1038/nrm4048
   Christensen K, 2006, NAT REV GENET, V7, P436, DOI 10.1038/nrg1871
   Christiansen L, 2016, AGING CELL, V15, P149, DOI 10.1111/acel.12421
   Deelen J, 2014, HUM MOL GENET, V23, P4420, DOI 10.1093/hmg/ddu139
   Deelen J, 2011, AGING CELL, V10, P686, DOI 10.1111/j.1474-9726.2011.00705.x
   Di Narzo AF, 2014, HUM MOL GENET, V23, P4801, DOI 10.1093/hmg/ddu195
   Dunham I, 2012, NATURE, V489, P57, DOI 10.1038/nature11247
   Ernst J, 2015, NAT BIOTECHNOL, V33, P364, DOI 10.1038/nbt.3157
   Ernst J, 2011, NATURE, V473, P43, DOI 10.1038/nature09906
   Flachsbart F, 2009, P NATL ACAD SCI USA, V106, P2700, DOI 10.1073/pnas.0809594106
   Fraga MF, 2007, TRENDS GENET, V23, P413, DOI 10.1016/j.tig.2007.05.008
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Gibbs JR, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000952
   Harrison DE, 2009, NATURE, V460, P392, DOI 10.1038/nature08221
   Hernandez DG, 2011, HUM MOL GENET, V20, P1164, DOI 10.1093/hmg/ddq561
   Horvath S, 2015, AGING-US, V7, P1159, DOI 10.18632/aging.100861
   Horvath S, 2015, AGING-US, V7, P1130, DOI 10.18632/aging.100859
   Horvath S, 2015, J INFECT DIS, V212, P1563, DOI 10.1093/infdis/jiv277
   Horvath S, 2015, AGING-US, V7, P294, DOI 10.18632/aging.100742
   Horvath S, 2015, AGING CELL, V14, P491, DOI 10.1111/acel.12325
   Horvath S, 2014, P NATL ACAD SCI USA, V111, P15538, DOI 10.1073/pnas.1412759111
   Horvath S, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-10-r115
   Howie B, 2012, NAT GENET, V44, P955, DOI 10.1038/ng.2354
   Howie BN, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000529
   Johansson A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067378
   Johnson SC, 2013, NATURE, V493, P338, DOI 10.1038/nature11861
   Kaeberlein M, 2005, SCIENCE, V310, P1193, DOI 10.1126/science.1115535
   Kundaje A, 2015, NATURE, V518, P317, DOI 10.1038/nature14248
   Lambert JC, 2013, NAT GENET, V45, P1452, DOI 10.1038/ng.2802
   Lamming DW, 2013, J CLIN INVEST, V123, P980, DOI 10.1172/JCI64099
   Langfelder P, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-559
   Lee SH, 2011, AM J HUM GENET, V88, P294, DOI 10.1016/j.ajhg.2011.02.002
   Levine ME, 2015, AGING-US, V7, P1198, DOI 10.18632/aging.100864
   Lunnon K, 2014, NAT NEUROSCI, V17, P1164, DOI 10.1038/nn.3782
   Marioni RE, 2015, INT J EPIDEMIOL, V44, P1388, DOI 10.1093/ije/dyu277
   Marioni RE, 2015, GENOME BIOL, V16, DOI 10.1186/s13059-015-0584-6
   Morris BJ, 2015, GERONTOLOGY, V61, P515, DOI 10.1159/000375235
   Numata S, 2012, AM J HUM GENET, V90, P260, DOI 10.1016/j.ajhg.2011.12.020
   O'Connell J, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004234
   Pidsley R, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0483-2
   Price AL, 2006, NAT GENET, V38, P904, DOI 10.1038/ng1847
   Pruim RJ, 2010, BIOINFORMATICS, V26, P2336, DOI 10.1093/bioinformatics/btq419
   Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795
   Rakyan VK, 2010, GENOME RES, V20, P434, DOI 10.1101/gr.103101.109
   Ramasamy A, 2014, NAT NEUROSCI, V17, P1418, DOI 10.1038/nn.3801
   Rando TA, 2012, CELL, V148, P46, DOI 10.1016/j.cell.2012.01.003
   Segre AV, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1001058
   Simon-Sanchez J, 2009, NAT GENET, V41, P1308, DOI 10.1038/ng.487
   Spiers H, 2015, GENOME RES, V25, P338, DOI 10.1101/gr.180273.114
   Teschendorff AE, 2010, GENOME RES, V20, P440, DOI 10.1101/gr.103606.109
   Vellai T, 2003, NATURE, V426, P620, DOI 10.1038/426620a
   Visscher PM, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004269
   Wilicox BJ, 2008, P NATL ACAD SCI USA, V105, P13987, DOI 10.1073/pnas.0801030105
   Willer CJ, 2010, BIOINFORMATICS, V26, P2190, DOI 10.1093/bioinformatics/btq340
   Zhang DD, 2010, AM J HUM GENET, V86, P411, DOI 10.1016/j.ajhg.2010.02.005
NR 56
TC 45
Z9 46
U1 2
U2 11
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2041-1723
J9 NAT COMMUN
JI Nat. Commun.
PD FEB
PY 2016
VL 7
AR 10561
DI 10.1038/ncomms10561
PG 9
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA DF0FM
UT WOS:000371014500003
PM 26830004
OA gold, Green Published, Green Submitted
DA 2022-11-30
ER

PT J
AU Jeung, IC
   Jee, D
   Rho, CR
   Kang, S
AF Jeung, In Cheul
   Jee, Donghyun
   Rho, Chang-Rae
   Kang, Seungbum
TI Melissa Officinalis L. Extracts Protect Human Retinal Pigment Epithelial
   Cells against Oxidative Stress-Induced Apoptosis
SO INTERNATIONAL JOURNAL OF MEDICAL SCIENCES
LA English
DT Article
DE ALS-L1023; apoptosis
ID CARDIOVASCULAR-DISEASE; MACULAR DEGENERATION; HUMAN HEALTH;
   PATHOGENESIS; POLYPHENOLS; ACTIVATION; PREVENTION; MECHANISMS
AB Background: We evaluated the protective effect of ALS-L1023, an extract of Melissa officinalis L. (Labiatae; lemon balm) against oxidative stress-induced apoptosis in human retinal pigment epithelial cells (ARPE-19 cells).
   Methods: ARPE-19 cells were incubated with ALS-L1023 for 24 h and then treated with hydrogen peroxide (H2O2). Oxidative stress-induced apoptosis and intracellular generation of reactive oxygen species (ROS) were assessed by flow cytometry. Caspase-3/7 activation and cleaved poly ADP-ribose polymerase (PARP) were measured to investigate the protective role of ALS-L1023 against apoptosis. The protective effect of ALS-L1023 against oxidative stress through activation of the phosphatidylinositol 3-kinase/protein kinase B (PI3K/Akt) was evaluated by Western blot analysis.
   Results: ALS-L1023 clearly reduced H2O2-induced cell apoptosis and intracellular production of ROS. H2O2-induced oxidative stress increased caspase-3/7 activity and apoptotic PARP cleavage, which were significantly inhibited by ALS-L1023. Activation of the PI3K/Akt pathway was associated with the protective effect of ALS-L1023 on ARPE-19 cells.
   Conclusions: ALS-L1023 protected human RPE cells against oxidative damage. This suggests that ALS-L1023 has therapeutic potential for the prevention of dry age-related macular degeneration.
C1 [Jeung, In Cheul; Rho, Chang-Rae; Kang, Seungbum] Catholic Univ Korea, Coll Med, Daejeon St Marys Hosp, Clin Res Inst, Daejeon 301012, South Korea.
   [Jeung, In Cheul] Catholic Univ Korea, Dept Obstet & Gynecol, Coll Med, Seoul 137701, South Korea.
   [Jee, Donghyun; Rho, Chang-Rae; Kang, Seungbum] Catholic Univ Korea, Dept Ophthalmol & Visual Sci, Coll Med, Seoul 137701, South Korea.
C3 Catholic University of Korea; Catholic University of Korea; Catholic
   University of Korea
RP Kang, S (通讯作者)，Catholic Univ Korea, Dept Ophthalmol & Visual Sci, Daejeon St Marys Hosp, Coll Med, 64 Daeheung Ro, Daejeon 301012, South Korea.
EM john0730@catholic.ac.kr
FU Clinical Research Institute grant - Catholic University of Korea,
   Daejeon St. Mary's Hospital [CMCDJ-P-2013-024]; Korea Health Industry
   Development Institute [5-2013-A0094-00030]
FX This study was supported by Clinical Research Institute grant funded by
   the Catholic University of Korea, Daejeon St. Mary's Hospital
   (CMCDJ-P-2013-024) and by the Korea Health Industry Development
   Institute (5-2013-A0094-00030).
CR Allahverdiyev A, 2004, PHYTOMEDICINE, V11, P657, DOI 10.1016/j.phymed.2003.07.014
   Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Arts ICW, 2005, AM J CLIN NUTR, V81, p317S, DOI 10.1093/ajcn/81.1.317S
   Ballinger SW, 1999, EXP EYE RES, V68, P765, DOI 10.1006/exer.1998.0661
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Cai JY, 1999, INVEST OPHTH VIS SCI, V40, P959
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Dastmalchi K, 2000, LEBENSM WISSEN TECNO, V41, P391
   de Sousa AC, 2004, J PHARM PHARMACOL, V56, P677, DOI 10.1211/0022357023321
   Dugas B, 2010, EUR J NUTR, V49, P435, DOI 10.1007/s00394-010-0102-2
   Garcia-Lafuente A, 2009, INFLAMM RES, V58, P537, DOI 10.1007/s00011-009-0037-3
   Harman D, 2006, ANN NY ACAD SCI, V1067, P10, DOI 10.1196/annals.1354.003
   Hawkins BS, 1999, MOL VIS, V5
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kennedy DO, 2002, PHARMACOL BIOCHEM BE, V72, P953, DOI 10.1016/S0091-3057(02)00777-3
   Kennedy DO, 2006, PHYTOTHER RES, V20, P96, DOI 10.1002/ptr.1787
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Kuriyama S, 2006, JAMA-J AM MED ASSOC, V296, P1255, DOI 10.1001/jama.296.10.1255
   Lee EK, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0110109
   Li ZR, 2013, MOL VIS, V19, P1656
   Liang FQ, 2003, EXP EYE RES, V76, P397, DOI 10.1016/S0014-4835(03)00023-X
   Lopez V, 2009, NEUROCHEM RES, V34, P1955, DOI 10.1007/s11064-009-9981-0
   Matsiu T, 2002, J AGR FOOD CHEM, V50, P7244, DOI 10.1021/jf025913m
   Nowak JZ, 2006, PHARMACOL REP, V58, P353
   Pandey KB, 2009, OXID MED CELL LONGEV, V2, P270, DOI 10.4161/oxim.2.5.9498
   Pereira RP, 2009, NEUROCHEM RES, V34, P973, DOI 10.1007/s11064-008-9861-z
   Perron NR, 2011, J INORG BIOCHEM, V105, P745, DOI 10.1016/j.jinorgbio.2011.02.009
   Perron NR, 2009, CELL BIOCHEM BIOPHYS, V53, P75, DOI 10.1007/s12013-009-9043-x
   Peters U, 2001, AM J EPIDEMIOL, V154, P495, DOI 10.1093/aje/154.6.495
   Scalbert A, 2005, CRIT REV FOOD SCI, V45, P287, DOI 10.1080/1040869059096
   Song G, 2005, J CELL MOL MED, V9, P59, DOI 10.1111/j.1582-4934.2005.tb00337.x
   SOULIMANI R, 1991, PLANTA MED, V57, P105, DOI 10.1055/s-2006-960042
   Vauzour D, 2010, NUTRIENTS, V2, P1106, DOI 10.3390/nu2111106
   Yang P, 2006, INVEST OPHTH VIS SCI, V47, P4598, DOI 10.1167/iovs.06-0140
   Youdim KA, 2000, BBA-GEN SUBJECTS, V1523, P117, DOI 10.1016/S0304-4165(00)00109-4
NR 36
TC 15
Z9 17
U1 0
U2 6
PU IVYSPRING INT PUBL
PI LAKE HAVEN
PA PO BOX 4546, LAKE HAVEN, NSW 2263, AUSTRALIA
SN 1449-1907
J9 INT J MED SCI
JI Int. J. Med. Sci.
PY 2016
VL 13
IS 2
BP 139
EP 146
DI 10.7150/ijms.13861
PG 8
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA DF4GO
UT WOS:000371306200008
PM 26941573
OA Green Submitted, Green Published, gold
DA 2022-11-30
ER

PT J
AU Kim, KS
   Park, JM
   Kong, T
   Kim, C
   Bae, SH
   Kim, HW
   Moon, J
AF Kim, Kyung-Sul
   Park, Ji-Min
   Kong, TaeHo
   Kim, Chul
   Bae, Sang-hun
   Kim, Han Wool
   Moon, Jisook
TI Retinal Angiogenesis Effects of TGF-beta 1 and Paracrine Factors
   Secreted From Human Placental Stem Cells in Response to a Pathological
   Environment
SO CELL TRANSPLANTATION
LA English
DT Article
DE Retina; Angiogenesis; Placenta; Mesenchymal stem cells (MSCs); Systemic
   delivery; Transforming growth factor-beta (TGF-beta 1)
ID MESENCHYMAL STROMAL CELLS; BONE-MARROW; AMNIOTIC MEMBRANE; IN-VIVO;
   NEOVASCULARIZATION; TRANSPLANTATION; RETINOPATHY; BLOOD; BETA;
   PROLIFERATION
AB Abnormal angiogenesis is a primary cause of many eye diseases, including diabetic retinopathy, age-related macular degeneration, and retinopathy of prematurity. Mesenchymal stem cells (MSCs) are currently being investigated as a treatment for several such retinal diseases based on their neuroprotective and angiogenic potentials. In this study, we evaluated the role of systemically injected human placental amniotic membrane derived MSCs (AMSCs) on pathological neovascularization of proliferative retinopathy. We determined that AMSCs secrete higher levels of transforming growth factor-beta (TGF-beta 1) than other MSCs, and the secreted TGF-beta 1 directly suppresses the proliferation of endothelial cells under pathological conditions in vitro. Moreover, in a mouse model of oxygen-induced retinopathy, intraperitoneally injected AMSCs migrated into the retina and suppressed excessive neovascularization of the vasculature via expression of TGF-beta 1, and the antineovascular effect of AMSCs was blocked by treatment with TGF-beta 1 siRNA. These findings are the first to demonstrate that TGF-beta 1 secreted from AMSCs is one of the key factors to suppress retinal neovascularization in proliferative retinopathy and further elucidate the therapeutic function of AMSCs for the treatment of retinal neovascular diseases.
C1 [Kim, Kyung-Sul; Park, Ji-Min; Kong, TaeHo; Kim, Chul; Bae, Sang-hun; Moon, Jisook] CHA Univ, Dept Biotechnol, Coll Life Sci, Seoul, South Korea.
   [Park, Ji-Min; Kong, TaeHo; Kim, Chul; Bae, Sang-hun; Kim, Han Wool] Gangnam CHA Gen Hosp, Gen Res Inst, Seoul, South Korea.
C3 Pochon Cha University
RP Moon, J (通讯作者)，CHA Univ, Dept Biotechnol, Pangyo Ro 335, Songnam 463400, Gyeonggi Do, South Korea.
EM jmoon@cha.ac.kr
FU Korea Institute for the Advancement of Technology (KIAT) [16-006]; KOSEF
   of South Korea [2015R1C1A2A01055144]
FX This study was supported by The Korea Institute for the Advancement of
   Technology (KIAT, 16-006) and KOSEF (2015R1C1A2A01055144) of South
   Korea. The authors declare no conflicts of interest.
CR Abdulrazzak H, 2010, J R SOC INTERFACE, V7, pS689, DOI 10.1098/rsif.2010.0347.focus
   Adamis AP, 2006, OPHTHALMOLOGY, V113, P23, DOI 10.1016/j.ophtha.2005.10.012
   Bacenkova D, 2011, CYTOTHERAPY, V13, P1047, DOI 10.3109/14653249.2011.592522
   Blobe GC, 2000, NEW ENGL J MED, V342, P1350, DOI 10.1056/NEJM200005043421807
   Chang CJ, 2006, STEM CELLS, V24, P2466, DOI 10.1634/stemcells.2006-0071
   Chang YJ, 2010, CELLS TISSUES ORGANS, V192, P93, DOI 10.1159/000295774
   Cheung CMG, 2012, MOL VIS, V18, P830
   Darland D. C., 2001, Angiogenesis, V4, P11, DOI 10.1023/A:1016611824696
   English K, 2007, IMMUNOL LETT, V110, P91, DOI 10.1016/j.imlet.2007.04.001
   Fang TC, 2005, J AM SOC NEPHROL, V16, P1723, DOI 10.1681/ASN.2004121089
   FRATERSCHRODER M, 1986, BIOCHEM BIOPH RES CO, V137, P295, DOI 10.1016/0006-291X(86)91209-X
   Gao GQ, 2001, FEBS LETT, V489, P270, DOI 10.1016/S0014-5793(01)02110-X
   Goumans MJ, 2003, MOL CELL, V12, P817, DOI 10.1016/S1097-2765(03)00386-1
   HIRAI R, 1992, EXP CELL RES, V201, P119, DOI 10.1016/0014-4827(92)90355-C
   Hirschi KK, 1998, J CELL BIOL, V141, P805, DOI 10.1083/jcb.141.3.805
   Huang YM, 2011, STEM CELL REV REP, V7, P434, DOI 10.1007/s12015-010-9192-8
   Jang MJ, 2013, ACTA HAEMATOL-BASEL, V129, P197, DOI 10.1159/000345267
   Jonas JB, 2005, PROG RETIN EYE RES, V24, P587, DOI 10.1016/j.preteyeres.2005.01.004
   Kim J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032350
   Kim KS, 2013, NEUROBIOL AGING, V34, P2408, DOI 10.1016/j.neurobiolaging.2013.03.029
   Kinnaird T, 2004, CIRC RES, V94, P678, DOI 10.1161/01.RES.0000118601.37875.AC
   KLEIN R, 1984, ARCH OPHTHALMOL-CHIC, V102, P520, DOI 10.1001/archopht.1984.01040030398010
   Lee JM, 2012, INT IMMUNOPHARMACOL, V13, P219, DOI 10.1016/j.intimp.2012.03.024
   Liu YH, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035758
   Marongiu Fabio, 2010, Curr Protoc Stem Cell Biol, VChapter 1, DOI 10.1002/9780470151808.sc01e05s12
   Miki T, 2011, STEM CELL RES THER, V2, DOI 10.1186/scrt66
   Moodley Y, 2010, AM J RESP CRIT CARE, V182, P643, DOI 10.1164/rccm.201001-0014OC
   Nambu H, 2004, GENE THER, V11, P865, DOI 10.1038/sj.gt.3302230
   Otani A, 2002, NAT MED, V8, P1004, DOI 10.1038/nm744
   Ozerdem U, 2005, INVEST OPHTH VIS SCI, V46, P3502, DOI 10.1167/iovs.05-0309
   Park KS, 2010, TRANSPLANTATION, V89, P509, DOI 10.1097/TP.0b013e3181c7dc99
   Parolini O, 2008, STEM CELLS, V26, P300, DOI 10.1634/stemcells.2007-0594
   Pepper Michael S., 1997, Cytokine and Growth Factor Reviews, V8, P21, DOI 10.1016/S1359-6101(96)00048-2
   Portmann-Lanz CB, 2010, AM J OBSTET GYNECOL, V202, DOI 10.1016/j.ajog.2009.10.893
   Psaltis PJ, 2008, STEM CELLS, V26, P2201, DOI 10.1634/stemcells.2008-0428
   Rao MS, 2001, MECH AGEING DEV, V122, P713, DOI 10.1016/S0047-6374(01)00224-X
   RUBINSTEIN P, 1993, BLOOD, V81, P1679
   Seay U, 2005, J PHARMACOL EXP THER, V315, P1005, DOI 10.1124/jpet.105.091249
   Serrati S, 2009, BIOCHEM PHARMACOL, V77, P813, DOI 10.1016/j.bcp.2008.10.036
   Shih SC, 2003, P NATL ACAD SCI USA, V100, P15859, DOI 10.1073/pnas.2136855100
   Sieveking DP, 2009, VASC MED, V14, P153, DOI 10.1177/1358863X08098698
   Simo R, 2006, CURR DIABETES REV, V2, P71, DOI 10.2174/157339906775473671
   SMITH LEH, 1994, INVEST OPHTH VIS SCI, V35, P101
   Wolbank S, 2010, ADV BIOCHEM ENG BIOT, V123, P1, DOI 10.1007/10_2010_71
   Yamagishi S, 2008, CURR DRUG TARGETS, V9, P1025, DOI 10.2174/138945008786786154
   Yarygin KN, 2009, B EXP BIOL MED+, V148, P862, DOI 10.1007/s10517-010-0837-z
NR 46
TC 30
Z9 33
U1 0
U2 7
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0963-6897
EI 1555-3892
J9 CELL TRANSPLANT
JI Cell Transplant.
PY 2016
VL 25
IS 6
BP 1145
EP 1157
DI 10.3727/096368915X688263
PG 13
WC Cell & Tissue Engineering; Medicine, Research & Experimental;
   Transplantation
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Research & Experimental Medicine; Transplantation
GA DO5UG
UT WOS:000377847700011
PM 26065854
OA Bronze
DA 2022-11-30
ER

PT J
AU Liu, EM
   Shah, G
   Blinder, KJ
   Smith, BT
   Thomas, MA
AF Liu, Enchun M.
   Shah, Gaurav
   Blinder, Kevin J.
   Smith, Bradley T.
   Thomas, Matthew A.
TI Intravitreal Aflibercept for Neovascular AMD: Short-Term Clinical
   Effects of Intravitreal Aflibercept Injection as a Predictor of
   Long-Term Results
SO OPHTHALMIC SURGERY LASERS & IMAGING RETINA
LA English
DT Article
ID MACULAR DEGENERATION; ANATOMICAL OUTCOMES; RANIBIZUMAB; BEVACIZUMAB;
   EYES; RESISTANT; THERAPY; FLUID; VEGF
AB BACKGROUND AND OBJECTIVE: To study the relationship between early response to intravitreal aflibercept injection (IAI) for neovascular age-related macular degeneration (nAMD) and long-term visual outcomes
   PATIENTS AND METHODS: Seventeen patients with nAMD participated in this prospective clinical trial. All patients received three initial monthly IAIs, followed by IAIs at 8-week intervals. Study visits were scheduled at 1 week, followed by every 2 weeks for the first 3 months and then every 4 weeks until the conclusion of the study at 48 weeks.
   RESULTS: Eight eyes (47%) were dry on spectral-domain optical coherence tomography by week 2 (early responders), and the remaining nine eyes took an average of 7.5 weeks for fluid resolution (late responders). The mean change in best-corrected visual acuity (BCVA) at the final visit was + 11.9 letters from baseline (P = .002). Average BCVA gain in early responders was + 11.6 letters compared to + 12.2 letters in late responders (P = .7).
   CONCLUSIONS: Although there was not a statistically significant correlation between early response to IAI and better long-term outcomes, both early and late responders maintained excellent visual outcomes at 48 weeks.
C1 [Liu, Enchun M.; Shah, Gaurav; Blinder, Kevin J.; Smith, Bradley T.; Thomas, Matthew A.] Retina Inst, 1600 S Brentwood Blvd,Suite 800, St Louis, MO 63144 USA.
   [Blinder, Kevin J.; Smith, Bradley T.; Thomas, Matthew A.] Washington Univ, Sch Med, Dept Ophthalmol & Visual Sci, St Louis, MO 63110 USA.
   [Liu, Enchun M.] Retina Associates South Texas, San Antonio, TX USA.
C3 Washington University (WUSTL)
RP Shah, G (通讯作者)，Retina Inst, 1600 S Brentwood Blvd,Suite 800, St Louis, MO 63144 USA.
EM gkshah1@gmail.com
RI Smith, Bradley/ABB-2596-2021
FU investigator-initiated research grant - Regeneron Pharmaceuticals,
   Tarrytown, NY
FX Supported by the investigator-initiated research grant support provided
   by Regeneron Pharmaceuticals, Tarrytown, NY; the clinical trial is
   registered with ClinicalTrials. gov (identifier no. NCT01657669).
CR Bakall B, 2013, AM J OPHTHALMOL, V156, P15, DOI 10.1016/j.ajo.2013.02.017
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Chang AA, 2014, OPHTHALMOLOGY, V121, P188, DOI 10.1016/j.ophtha.2013.08.035
   Cho H, 2013, BRIT J OPHTHALMOL, V97, P1032, DOI 10.1136/bjophthalmol-2013-303344
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Fassnacht-Riederle H, 2014, GRAEF ARCH CLIN EXP, V252, P1705, DOI 10.1007/s00417-014-2589-3
   Gamulescu MA, 2007, GRAEF ARCH CLIN EXP, V245, P1037, DOI 10.1007/s00417-007-0551-3
   Grewal DS, 2014, EYE, V28, P895, DOI 10.1038/eye.2014.101
   Ho VY, 2013, AM J OPHTHALMOL, V156, P23, DOI 10.1016/j.ajo.2013.02.009
   Kumar N, 2013, RETINA-J RET VIT DIS, V33, P1605, DOI 10.1097/IAE.0b013e31828e8551
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Papadopoulos N, 2012, ANGIOGENESIS, V15, P171, DOI 10.1007/s10456-011-9249-6
   Patel KH, EYE LOND, V27, P663
   Pauleikhoff D, 2002, GRAEF ARCH CLIN EXP, V240, P533, DOI 10.1007/s00417-002-0505-8
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Saito M, 2013, CLIN OPHTHALMOL, V7, P1287, DOI 10.2147/OPTH.S47735
   Sarraf David, 2014, Trans Am Ophthalmol Soc, V112, P142
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Stone TW, 2014, ASRS 2014 PREFERENCE
   Yonekawa Y, 2013, AM J OPHTHALMOL, V156, P29, DOI 10.1016/j.ajo.2013.03.030
NR 20
TC 1
Z9 1
U1 0
U2 3
PU SLACK INC
PI THOROFARE
PA 6900 GROVE RD, THOROFARE, NJ 08086 USA
SN 2325-8160
EI 2325-8179
J9 OSLI RETINA
JI Ophthalmic Surg. Lasers Imag. Retin.
PD NOV-DEC
PY 2015
VL 46
IS 10
BP 1021
EP 1027
DI 10.3928/23258160-20151027-06
PG 7
WC Ophthalmology; Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Surgery
GA DP9UH
UT WOS:000378842400007
PM 26599244
DA 2022-11-30
ER

PT J
AU Solinis, MA
   del Pozo-Rodriguez, A
   Apaolaza, PS
   Rodriguez-Gascon, A
AF Angeles Solinis, M.
   del Pozo-Rodriguez, Ana
   Apaolaza, Paola S.
   Rodriguez-Gascon, Alicia
TI Treatment of ocular disorders by gene therapy
SO EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS
LA English
DT Review
DE Ocular disorder; Gene therapy; Viral vector; Non-viral vector; Clinical
   trial; Retina; Cornea
ID SOLID LIPID NANOPARTICLES; REGULATED TRANSGENE EXPRESSION;
   GLUCOCORTICOID-INDUCIBLE MMP1; PIGMENT EPITHELIAL-CELLS; X-LINKED
   RETINOSCHISIS; ORGAN-CULTURED HUMAN; ADENOASSOCIATED VIRUS; MACULAR
   DEGENERATION; IN-VITRO; STARGARDT-DISEASE
AB Gene therapy to treat ocular disorders is still starting, and current therapies are primarily experimental, with most human clinical trials still in research state, although beginning to show encouraging results. Currently 33 clinical trials have been approved, are in progress, or have been completed. The most promising results have been obtained in clinical trials of ocular gene therapy for Leber Congenital Amaurosis, which have prompted the study of several ocular diseases that are good candidates to be treated with gene therapy: glaucoma, age-related macular degeneration, retinitis pigmentosa, or choroideremia. The success of gene therapy relies on the efficient delivery of the genetic material to target cells, achieving optimum long-term gene expression. Although viral vectors have been widely used, their potential risk associated mainly with immunogenicity and mutagenesis has promoted the design of non-viral vectors. In this review, the main administration routes and the most studied delivery systems, viral and non-viral, for ocular gene therapy are presented. The primary ocular disease candidates to be treated with gene therapy have been also reviewed, including the genetic basis and the most relevant preclinical and clinical studies. (C) 2014 Elsevier B.V. All rights reserved.
C1 [Angeles Solinis, M.; del Pozo-Rodriguez, Ana; Apaolaza, Paola S.; Rodriguez-Gascon, Alicia] Univ Basque Country UPV EHU, Fac Pharm, Centro Invest Lascaray Ikergunea, Pharmacokinet Nanotechnol & Gene Therapy Grp Phar, Vitoria 01006, Spain.
C3 University of Basque Country
RP Rodriguez-Gascon, A (通讯作者)，Univ Basque Country UPV EHU, Fac Pharm, Pharm & Pharmaceut Technol Lab, Paseo Univ 7, Vitoria 01006, Spain.
EM alicia.rodriguez@ehu.es
RI Solinís, María Ángeles/S-1712-2018
OI Solinís, María Ángeles/0000-0001-9127-0775; del Pozo-Rodriguez,
   Ana/0000-0003-2478-0884; Apaolaza, Paola/0000-0002-7550-054X;
   Rodriguez-Gascon, Alicia/0000-0002-3195-6385
FU Basque Government's Department of Education, Universities and
   Investigation [IT-341-10]; Spanish Ministry of Economy and
   Competitiveness [SAF2010-19862]; University of Basque country (UPV-EHU)
FX This work was supported by the Basque Government's Department of
   Education, Universities and Investigation (IT-341-10) and by the Spanish
   Ministry of Economy and Competitiveness (SAF2010-19862). We thank the
   University of Basque country (UPV-EHU) for the grant awarded to Paola S.
   Apaolaza.
CR Abul-Hassan K, 2000, CURR EYE RES, V20, P361, DOI 10.1076/0271-3683(200005)20:5;1-1;FT361
   Al-Saikhan FI, 2013, SAUDI J OPHTHALMOL, V27, P107, DOI 10.1016/j.sjopt.2013.02.001
   Ali RR, 1998, HUM GENE THER, V9, P81, DOI 10.1089/hum.1998.9.1-81
   Allikmets R, 1997, NAT GENET, V15, P236, DOI 10.1038/ng0397-236
   Alqawlaq S., 2014, NANOMEDICINE
   Amrite AC, 2005, J PHARM PHARMACOL, V57, P1555, DOI 10.1211/jpp.57.12.0005
   Angella GJ, 2000, INVEST OPHTH VIS SCI, V41, P4158
   Arnedo A, 2004, J CONTROL RELEASE, V94, P217, DOI 10.1016/j.jconrel.2003.10.009
   Bainbridge JWB, 2008, NEW ENGL J MED, V358, P2231, DOI 10.1056/NEJMoa0802268
   Bainbridge JWB, 2003, GENE THER, V10, P1049, DOI 10.1038/sj.gt.3301945
   Balaggan KS, 2006, J GENE MED, V8, P275, DOI 10.1002/jgm.845
   Balaggan KS, 2012, GENE THER, V19, P145, DOI 10.1038/gt.2011.153
   Banin E, 2010, HUM GENE THER, V21, P1749, DOI 10.1089/hum.2010.047
   Bejjani R, 2005, MOL VIS, V11, P124
   Bemelmans AP, 2006, PLOS MED, V3, P1892, DOI 10.1371/journal.pmed.0030347
   Bennett J, 1999, P NATL ACAD SCI USA, V96, P9920, DOI 10.1073/pnas.96.17.9920
   Bennett J, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3002865
   Berger W, 2010, PROG RETIN EYE RES, V29, P335, DOI 10.1016/j.preteyeres.2010.03.004
   Berkowitz R, 2001, J VIROL, V75, P3371, DOI 10.1128/JVI.75.7.3371-3382.2001
   Bessis N, 2004, GENE THER, V11, pS10, DOI 10.1038/sj.gt.3302364
   Bettin P, 2013, OPHTHALMIC RES, V50, P197, DOI 10.1159/000348736
   Binley K, 2013, INVEST OPHTH VIS SCI, V54, P4061, DOI 10.1167/iovs.13-11871
   Binley K, 2012, HUM GENE THER, V23, P980, DOI 10.1089/hum.2012.008
   Bloquel C, 2006, ADV DRUG DELIVER REV, V58, P1224, DOI 10.1016/j.addr.2006.07.023
   Boye SE, 2012, HUM GENE THER, V23, P1101, DOI 10.1089/hum.2012.125
   Bucolo C, 2013, CURR OPIN PHARMACOL, V13, P50, DOI 10.1016/j.coph.2012.09.012
   Burnight ER, 2014, GENE THER, V21, P662, DOI 10.1038/gt.2014.39
   Byrne LC, 2014, GENE THER, V21, P585, DOI 10.1038/gt.2014.31
   Cai X, 2008, VISION RES, V48, P319, DOI 10.1016/j.visres.2007.07.012
   Campagne MV, 2014, J PATHOL, V232, P151, DOI 10.1002/path.4266
   Campochiaro PA, 2006, HUM GENE THER, V17, P167, DOI 10.1089/hum.2006.17.167
   Carrasquillo KG, 2003, INVEST OPHTH VIS SCI, V44, P290, DOI 10.1167/iovs.01-1156
   Cashman M.S., 2011, PLOS ONE, V6
   Chen CW, 2013, INT J NANOMED, V8, P2613, DOI 10.2147/IJN.S39622
   Chen Y, 2006, INVEST OPHTH VIS SCI, V47, P1177, DOI 10.1167/iovs.05-0965
   Cheung LK, 2013, PHARMACOTHERAPY, V33, P838, DOI 10.1002/phar.1264
   Cideciyan AV, 2013, P NATL ACAD SCI USA, V110, pE517, DOI 10.1073/pnas.1218933110
   Cideciyan AV, 2008, P NATL ACAD SCI USA, V105, P15112, DOI 10.1073/pnas.0807027105
   Colella P, 2009, TRENDS MOL MED, V15, P23, DOI 10.1016/j.molmed.2008.11.003
   Collin RWJ, 2012, MOL THER-NUCL ACIDS, V1, DOI 10.1038/mtna.2012.3
   Conley SM, 2010, PROG RETIN EYE RES, V29, P376, DOI 10.1016/j.preteyeres.2010.04.004
   Cremers FPM, 1998, HUM MOL GENET, V7, P355, DOI 10.1093/hmg/7.3.355
   Dalkara D, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005708
   de la Fuente M, 2008, INVEST OPHTH VIS SCI, V49, P2016, DOI 10.1167/iovs.07-1077
   Dejneka NS, 2008, MOL VIS, V14, P997
   del Amo EM, 2008, DRUG DISCOV TODAY, V13, P135, DOI 10.1016/j.drudis.2007.11.002
   del Pozo-Rodriguez A, 2008, INT J PHARM, V360, P177, DOI 10.1016/j.ijpharm.2008.04.023
   del Pozo-Rodriguez A, 2009, J CONTROL RELEASE, V133, P52, DOI 10.1016/j.jconrel.2008.09.004
   del Pozo-Rodriguez A, 2013, J OCUL PHARMACOL TH, V29, P173, DOI 10.1089/jop.2012.0128
   Delgado D, 2013, EUR J PHARM SCI, V50, P484, DOI 10.1016/j.ejps.2013.08.013
   Delgado D, 2012, HUM GENE THER, V23, P345, DOI 10.1089/hum.2011.115
   Delgado D, 2012, INT J PHARMACEUT, V425, P35, DOI 10.1016/j.ijpharm.2011.12.052
   Delgado D, 2011, EUR J PHARM BIOPHARM, V79, P495, DOI 10.1016/j.ejpb.2011.06.005
   Deng WT, 2012, INVEST OPHTH VIS SCI, V53, P1895, DOI 10.1167/iovs.11-8831
   dos Santos ALG, 2006, PHARM RES-DORDR, V23, P770, DOI 10.1007/s11095-006-9748-0
   Elbadawy HM, 2014, GENE THER, V21, P272, DOI 10.1038/gt.2013.82
   Elbadawy HM, 2012, J OPHTHALMOL, V2012, DOI 10.1155/2012/594869
   Elouahabi A, 2005, MOL THER, V11, P336, DOI 10.1016/j.ymthe.2004.12.006
   Enrico M.S., 2008, VISION RES, V48, P353
   Felt O, 1999, INT J PHARM, V180, P185, DOI 10.1016/S0378-5173(99)00003-4
   Feret A, 2007, GERIATR NURS, V28, P387, DOI 10.1016/j.gerinurse.2007.03.003
   Folliot S, 2003, J GENE MED, V5, P493, DOI 10.1002/jgm.367
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Furukawa A, 2002, J NEUROSCI, V22, P1640, DOI 10.1523/JNEUROSCI.22-05-01640.2002
   Gabelt BT, 2006, EXP EYE RES, V82, P935, DOI 10.1016/j.exer.2005.12.002
   Gan L, 2013, BIOMATERIALS, V34, P5978, DOI 10.1016/j.biomaterials.2013.04.035
   Gerometta R, 2010, INVEST OPHTH VIS SCI, V51, P3042, DOI 10.1167/iovs.09-4920
   Gong N, 2007, GENE THER, V14, P484, DOI 10.1038/sj.gt.3302884
   Gong NQ, 2007, INVEST OPHTH VIS SCI, V48, P1043, DOI 10.1167/iovs.06-1084
   Gordiyenko NV, 2010, INVEST OPHTH VIS SCI, V51, P1143, DOI 10.1167/iovs.09-4117
   Guzman-Aranguez A, 2013, BRIT J PHARMACOL, V170, P730, DOI 10.1111/bph.12330
   Hacein-Bey-Abina S, 2008, J CLIN INVEST, V118, P3132, DOI 10.1172/JCI35700
   Hamel C, 2006, ORPHANET J RARE DIS, V1, DOI 10.1186/1750-1172-1-40
   Han ZC, 2014, ADV EXP MED BIOL, V801, P719, DOI 10.1007/978-1-4614-3209-8_90
   Han ZC, 2012, J CLIN INVEST, V122, P3221, DOI 10.1172/JCI64833
   Herzog RW, 2010, MOL THER, V18, P1891, DOI 10.1038/mt.2010.228
   Hornof M, 2008, J GENE MED, V10, P70, DOI 10.1002/jgm.1125
   Jacobson SG, 2006, INVEST OPHTH VIS SCI, V47, P4113, DOI 10.1167/iovs.06-0424
   Jager L, 2007, CURR GENE THER, V7, P272
   Janssen A, 2008, MOL THER, V16, P1010, DOI 10.1038/mt.2008.57
   Jooss K, 2003, GENE THER, V10, P955, DOI 10.1038/sj.gt.3302037
   Kalatzis V, 2013, AM J OPHTHALMOL, V156, P433, DOI 10.1016/j.ajo.2013.05.009
   Kaur I.P., 2014, J CONTROL RELEASE
   Kay CN, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062097
   Khani SC, 2007, INVEST OPHTH VIS SCI, V48, P3954, DOI 10.1167/iovs.07-0257
   Kim LS, 2007, DOC OPHTHALMOL, V114, P21, DOI 10.1007/s10633-006-9034-9
   Klausner EA, 2012, J GENE MED, V14, P100, DOI 10.1002/jgm.1634
   Koirala A, 2014, ADV EXP MED BIOL, V801, P703, DOI 10.1007/978-1-4614-3209-8_88
   Koirala A, 2013, HUM MOL GENET, V22, P1632, DOI 10.1093/hmg/ddt013
   Kompella UB, 2013, PROG RETIN EYE RES, V36, P172, DOI 10.1016/j.preteyeres.2013.04.001
   Kong J, 2008, GENE THER, V15, P1311, DOI 10.1038/gt.2008.78
   Kuo CN, 2005, CURR EYE RES, V30, P1015, DOI 10.1080/02713680500330512
   Kurosaki T, 2013, BIOL PHARM BULL, V36, P96, DOI 10.1248/bpb.b12-00728
   Ladas ID, 2009, RETINA-J RET VIT DIS, V29, P313, DOI 10.1097/IAE.0b013e31819a5f98
   Lamartina S, 2007, J GENE MED, V9, P862, DOI 10.1002/jgm.1083
   Lheriteau E, 2014, MOL THER, V22, P265, DOI 10.1038/mt.2013.232
   Liang FQ, 2001, MOL THER, V4, P461, DOI 10.1006/mthe.2001.0473
   Liu MM, 2011, BRIT J OPHTHALMOL, V95, P604, DOI 10.1136/bjo.2009.174912
   MacLaren RE, 2014, LANCET, V383, P1129, DOI 10.1016/S0140-6736(13)62117-0
   Maguire AM, 2008, NEW ENGL J MED, V358, P2240, DOI 10.1056/NEJMoa0802315
   Manfredi A, 2013, HUM GENE THER, V24, P982, DOI 10.1089/hum.2013.154
   Mannermaa E, 2005, CURR EYE RES, V30, P345, DOI 10.1080/02713680590934058
   Mannisto M, 2002, J CONTROL RELEASE, V83, P169, DOI 10.1016/S0168-3659(02)00178-5
   Marano RJ, 2004, EXP EYE RES, V79, P525, DOI 10.1016/j.exer.2004.06.023
   Martin Molina F, 2013, GENE THERAPY TOOLS P, P3
   Martinez-Mir A, 1998, NAT GENET, V18, P11, DOI 10.1038/ng0198-11
   Masuda I, 1996, INVEST OPHTH VIS SCI, V37, P1914
   Meng F, 2013, NEUROSCIENCE, V250, P381, DOI 10.1016/j.neuroscience.2013.07.001
   Mevel M, 2010, J CONTROL RELEASE, V143, P222, DOI 10.1016/j.jconrel.2009.12.001
   Michalakis S, 2014, ADV EXP MED BIOL, V801, P733, DOI 10.1007/978-1-4614-3209-8_92
   MillingtonWard S, 1997, HUM MOL GENET, V6, P1415, DOI 10.1093/hmg/6.9.1415
   Min SH, 2005, MOL THER, V12, P644, DOI 10.1016/j.ymthe.2005.06.002
   Mohan RR, 2005, PROG RETIN EYE RES, V24, P537, DOI 10.1016/j.preteyeres.2005.04.001
   Molina RP, 2004, HUM GENE THER, V15, P865, DOI 10.1089/hum.2004.15.865
   Moreno-Montanes J, 2014, MOL THER, V22, P226, DOI 10.1038/mt.2013.217
   Mowat FM, 2014, GENE THER, V21, P96, DOI 10.1038/gt.2013.64
   Mussolino C, 2011, GENE THER, V18, P637, DOI 10.1038/gt.2011.3
   Naik R, 2009, DRUG DISCOV TODAY, V14, P306, DOI 10.1016/j.drudis.2008.09.012
   Nguyen QD, 2012, EYE, V26, P1099, DOI 10.1038/eye.2012.106
   O'Reilly M, 2007, AM J HUM GENET, V81, P127, DOI 10.1086/519025
   Olsen TW, 2011, INVEST OPHTH VIS SCI, V52, P4749, DOI 10.1167/iovs.10-6291
   Park TK, 2009, GENE THER, V16, P916, DOI 10.1038/gt.2009.61
   Parker DGA, 2007, GENE THER, V14, P760, DOI 10.1038/sj.gt.3302921
   Parker DGA, 2009, BRIT J OPHTHALMOL, V93, P1255, DOI 10.1136/bjo.2009.159137
   Parker DG, 2010, CLIN EXP OPHTHALMOL, V38, P405, DOI 10.1111/j.1442-9071.2010.02261.x
   Peden MC, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017140
   Peeters L, 2005, INVEST OPHTH VIS SCI, V46, P3553, DOI 10.1167/iovs.05-0165
   Peng CH, 2011, BIOMATERIALS, V32, P9077, DOI 10.1016/j.biomaterials.2011.08.008
   Petrs-Silva H, 2014, CLIN OPHTHALMOL, V8, P127, DOI 10.2147/OPTH.S38041
   Pitkanen L, 2003, PHARM RES-DORDR, V20, P576, DOI 10.1023/A:1023238530504
   Prentice HM, 2011, INVEST OPHTH VIS SCI, V52, P8562, DOI 10.1167/iovs.10-6835
   Provost N, 2005, MOL THER, V11, P275, DOI 10.1016/j.ymthe.2004.09.022
   Qazi Y, 2013, SEMIN OPHTHALMOL, V28, P287, DOI 10.3109/08820538.2013.825297
   Qin B., 2012, ADV OCULAR DRUG DELI, P87
   Rajiv R.M., 2012, PROG RETIN EYE RES, V31, P43
   Rittenhouse KD, 2014, INVEST OPHTH VIS SCI, V55, P1232, DOI 10.1167/iovs.13-13449
   Ritter T, 2007, TRANSPL IMMUNOL, V18, P101, DOI 10.1016/j.trim.2007.05.004
   Rivera VM, 2005, BLOOD, V105, P1424, DOI 10.1182/blood-2004-06-2501
   Rodriguez-Gascon A, 2014, INT J NANOMED, V9, P1833, DOI 10.2147/IJN.S39810
   Saghizadeh M, 2010, INVEST OPHTH VIS SCI, V51, P1970, DOI 10.1167/iovs.09-4569
   Serratrice N, 2014, J CONTROL RELEASE, V181, P22, DOI 10.1016/j.jconrel.2014.02.022
   Sharma A, 2010, EXP EYE RES, V91, P440, DOI 10.1016/j.exer.2010.06.020
   Sharma A, 2010, BRAIN RES BULL, V81, P273, DOI 10.1016/j.brainresbull.2009.07.005
   Shen J, 2006, GENE THER, V13, P225, DOI 10.1038/sj.gt.3302641
   Sieving PA, 2006, P NATL ACAD SCI USA, V103, P3896, DOI 10.1073/pnas.0600236103
   Sikkink SK, 2007, J MED GENET, V44, P225, DOI 10.1136/jmg.2006.047340
   Silva G.A., 2008, ARVO 2008 ANN M 2008
   Smith JS, 2002, J INFECT DIS, V186, pS3, DOI 10.1086/343739
   Spiga MG, 2010, INVEST OPHTH VIS SCI, V51, P3029, DOI 10.1167/iovs.09-4918
   Apaolaza PS, 2014, INT J PHARMACEUT, V465, P413, DOI 10.1016/j.ijpharm.2014.02.038
   Takahashi M, 1999, J VIROL, V73, P7812, DOI 10.1128/JVI.73.9.7812-7816.1999
   Tang XL, 2010, MOL VIS, V16, P2354
   Tantri A, 2004, SURV OPHTHALMOL, V49, P214, DOI 10.1016/j.survophthal.2003.12.007
   Testa F, 2013, OPHTHALMOLOGY, V120, P1283, DOI 10.1016/j.ophtha.2012.11.048
   Thumann G, 2012, CURR GENOMICS, V13, P350, DOI 10.2174/138920212801619214
   Tiyaboonchai W, 2003, EUR J PHARM SCI, V19, P191, DOI 10.1016/S0928-0987(03)00102-7
   Tong YC, 2007, J GENE MED, V9, P956, DOI 10.1002/jgm.1093
   Touchard E, 2012, MOL THER, V20, P1559, DOI 10.1038/mt.2011.304
   Tsybovsky Y, 2010, ADV EXP MED BIOL, V703, P105, DOI 10.1007/978-1-4419-5635-4_8
   Urtti A, 2006, ADV DRUG DELIVER REV, V58, P1131, DOI 10.1016/j.addr.2006.07.027
   Williams KA, 2010, CLIN EXP OPHTHALMOL, V38, P93, DOI 10.1111/j.1442-9071.2009.02179.x
   Xu HZ, 2012, OPHTHALMIC RES, V47, P163, DOI 10.1159/000331428
   Yanez-Munoz RJ, 2006, NAT MED, V12, P348, DOI 10.1038/nm1365
   Young S, 2001, CLIN EXP OPHTHALMOL, V29, P2, DOI 10.1046/j.1442-9071.2001.00360.x
   Zhong L, 2008, P NATL ACAD SCI USA, V105, P7827, DOI 10.1073/pnas.0802866105
NR 165
TC 60
Z9 63
U1 2
U2 49
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0939-6411
EI 1873-3441
J9 EUR J PHARM BIOPHARM
JI Eur. J. Pharm. Biopharm.
PD SEP
PY 2015
VL 95
BP 331
EP 342
DI 10.1016/j.ejpb.2014.12.022
PN B
PG 12
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA CU8WH
UT WOS:000363824300017
PM 25536112
DA 2022-11-30
ER

PT J
AU Kambhampati, SP
   Mishra, MK
   Mastorakos, P
   Oh, Y
   Lutty, GA
   Kannan, RM
AF Kambhampati, Siva P.
   Mishra, Manoj K.
   Mastorakos, Panagiotis
   Oh, Yumin
   Lutty, Gerard A.
   Kannan, Rangaramanujam M.
TI Intracellular delivery of dendrimer triamcinolone acetonide conjugates
   into microglial and human retinal pigment epithelial cells
SO EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS
LA English
DT Article
DE Dendrimer; Ocular drug delivery; Triamcinolone acetonide;
   Anti-inflammatory; Anti-VEGF; Microglial cells; Human retinal pigment
   epithelium
ID DIABETIC MACULAR EDEMA; INDUCED ANGIOGENESIS; ENDOTHELIAL-CELLS;
   DRUG-DELIVERY; ARPE-19 CELLS; GENE DELIVERY; EXPRESSION; DEGENERATION;
   INFLAMMATION; PERMEABILITY
AB Triamcinolone acetonide (TA) is a potent, intermediate-acting, steroid that has anti-inflammatory and anti-angiogenic activity. Intravitreal administration of TA has been used for diabetic macular edema, proliferative diabetic retinopathy and exudative age-related macular degeneration (AMD). However, the hydrophobicity, lack of solubility, and the side effects limit its effectiveness in the treatment of retinal diseases. In this study, we explore a PAMAM dendrimer-TA conjugate (D-TA) as a potential strategy to improve intracellular delivery and efficacy of TA to target cells. The conjugates were prepared with a high drug payload (similar to 21%) and were readily soluble in saline. Compared to free TA, D-TA demonstrated a significantly improved toxicity profile in two important target [microglial and human retinal pigment epithelium (RPE)] cells. The D-TA was similar to 100-fold more effective than free TA in its anti-inflammatory activity (measured in microglia), and in suppressing VEGF production (in hypoxic RPE cells). Dendrimer-based delivery may improve the efficacy of TA towards both its key targets of inflammation and VEGF production, with significant clinical implications. (C) 2015 Elsevier B.V. All rights reserved.
C1 [Kambhampati, Siva P.; Mishra, Manoj K.; Mastorakos, Panagiotis; Oh, Yumin; Lutty, Gerard A.; Kannan, Rangaramanujam M.] Johns Hopkins Univ, Sch Med, Dept Ophthalmol, Ctr Nanomed,Wilmer Eye Inst, Baltimore, MD 21231 USA.
   [Kambhampati, Siva P.; Mishra, Manoj K.; Kannan, Rangaramanujam M.] Wayne State Univ, Dept Biomed Engn, Detroit, MI USA.
C3 Johns Hopkins University; Johns Hopkins Medicine; Wayne State University
RP Kannan, RM (通讯作者)，Johns Hopkins Univ, Sch Med, Dept Ophthalmol, Ctr Nanomed,Wilmer Eye Inst, 400 North Broadway, Baltimore, MD 21231 USA.
EM krangar1@jhmi.edu
RI Kambhampati, Siva Pramodh/AAK-6269-2020; OH, YUMIN/M-6312-2017;
   Mastorakos, Panagiotis/ABG-1157-2021; Oh, Yumin/AAU-1302-2021
OI OH, YUMIN/0000-0003-1456-4045; Oh, Yumin/0000-0003-1456-4045
FU Wilmer Pooled Professor grant, NIH NIBIB [RO1EB018306-01]; Research to
   prevent blindness; Wilmer core facility and imaging center
   [P30EY001765]; NATIONAL EYE INSTITUTE [R01EY025304, P30EY001765] Funding
   Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND
   BIOENGINEERING [R01EB018306] Funding Source: NIH RePORTER
FX This study was supported by funds from Wilmer Pooled Professor grant,
   NIH NIBIB RO1EB018306-01-(RMK) and Research to prevent blindness (RPB).
   We also acknowledge Wilmer core facility and imaging center (core grant:
   P30EY001765) for flow cytometry and confocal microscopy facilities.
CR Ambati J, 2013, NAT REV IMMUNOL, V13, P438, DOI 10.1038/nri3459
   Ayalasomayajula SP, 2009, J OCUL PHARMACOL TH, V25, P97, DOI 10.1089/jop.2008.0090
   Becerra EM, 2011, CURR DRUG TARGETS, V12, P149
   Benson W.B., 2010, EVIDENCE BASED OPHTH, V11, P22
   Blaauwgeers HGT, 1999, AM J PATHOL, V155, P421, DOI 10.1016/S0002-9440(10)65138-3
   Bosnjakovic A, 2011, NANOMED-NANOTECHNOL, V7, P284, DOI 10.1016/j.nano.2010.10.008
   Sauvage MAD, 2013, CELL DEATH DIFFER, V20, P1546, DOI 10.1038/cdd.2013.108
   Chang YS, 2011, INVEST OPHTH VIS SCI, V52, P4214, DOI 10.1167/iovs.10-6058
   Chaplot SP, 2014, J PHARM PHARMACOL, V66, P542, DOI 10.1111/jphp.12104
   Chung H, 2007, INVEST OPHTH VIS SCI, V48, P5742, DOI 10.1167/iovs.07-0566
   Durairaj C, 2010, INVEST OPHTH VIS SCI, V51, P5804, DOI 10.1167/iovs.10-5388
   Ebrahem Q, 2006, INVEST OPHTH VIS SCI, V47, P4935, DOI 10.1167/iovs.05-1651
   Elman MJ, 2010, OPHTHALMOLOGY, V117, P1064, DOI 10.1016/j.ophtha.2010.02.031
   Felinski EA, 2005, CURR EYE RES, V30, P949, DOI 10.1080/02713680500263598
   Glybina IV, 2009, INVEST OPHTH VIS SCI, V50, P4847, DOI 10.1167/iovs.08-2831
   Gopal Lekha, 2007, Indian Journal of Ophthalmology, V55, P431
   Gruneich JA, 2004, GENE THER, V11, P668, DOI 10.1038/sj.gt.3302214
   Henn A, 2009, EUR J CELL BIOL, V88, P72
   Holden CA, 2012, NANOMED-NANOTECHNOL, V8, P776, DOI 10.1016/j.nano.2011.08.018
   Hong J, 2012, IMMUNOPHARM IMMUNOT, V34, P912, DOI 10.3109/08923973.2012.671332
   Iezzi R, 2012, BIOMATERIALS, V33, P979, DOI 10.1016/j.biomaterials.2011.10.010
   Kambhampati SP, 2013, J OCUL PHARMACOL TH, V29, P151, DOI 10.1089/jop.2012.0232
   Kannan S, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003162
   Kiernan DF, 2009, EXPERT OPIN PHARMACO, V10, P2511, DOI 10.1517/14656560903160671
   Kleinman ME, 2010, OPHTHALMOLOGY, V117, P1654, DOI 10.1016/j.ophtha.2010.01.052
   Krieglstein CF, 2001, AM J HYPERTENS, V14, p44S, DOI 10.1016/S0895-7061(01)02069-6
   Lesniak WG, 2013, MOL PHARMACEUT, V10, P4560, DOI 10.1021/mp400371r
   Li WC, 2014, INT OPHTHALMOL, V34, P465, DOI 10.1007/s10792-013-9829-0
   Ma K, 2009, BIOMATERIALS, V30, P6109, DOI 10.1016/j.biomaterials.2009.07.036
   Ma WX, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007945
   Macky TA, 2002, J MED CHEM, V45, P1122, DOI 10.1021/jm010511b
   Mansoor S, 2009, PHARM RES-DORDR, V26, P770, DOI 10.1007/s11095-008-9812-z
   Mastorakos P., 2014, NANOSCALE
   Matsuda S, 2005, INVEST OPHTH VIS SCI, V46, P1062, DOI 10.1167/iovs.04-0761
   McCarthy CA, 2013, CLIN EXP PHARMACOL P, V40, P571, DOI 10.1111/1440-1681.12099
   Mishra MK, 2014, ACS NANO, V8, P2134, DOI 10.1021/nn404872e
   Narayanan R, 2006, INVEST OPHTH VIS SCI, V47, P722, DOI 10.1167/iovs.05-0772
   Nauck M, 1998, EUR J PHARMACOL, V341, P309, DOI 10.1016/S0014-2999(97)01464-7
   Paulo CSO, 2011, NANOTECHNOLOGY, V22, DOI 10.1088/0957-4484/22/49/494002
   Penfold PL, 2000, CLIN EXP IMMUNOL, V121, P458, DOI 10.1046/j.1365-2249.2000.01316.x
   Penfold PL, 2002, INVEST OPHTH VIS SCI, V43, P3125
   Penfold PL, 2001, CLIN EXP OPHTHALMOL, V29, P188, DOI 10.1046/j.1442-9071.2001.00407.x
   Pereira A.D., 2012, INT J PHARM PHARM SC, V4, P132
   Salek SS, 2013, OCUL IMMUNOL INFLAMM, V21, P257, DOI 10.3109/09273948.2013.767353
   Sk UH, 2013, BIOMACROMOLECULES, V14, P801, DOI 10.1021/bm3018615
   Szurman P, 2006, EXP EYE RES, V83, P584, DOI 10.1016/j.exer.2006.02.012
   Valamanesh F, 2009, MOL VIS, V15, P2634
   Vandamme TF, 2005, J CONTROL RELEASE, V102, P23, DOI 10.1016/j.jconrel.2004.09.015
   Wang B, 2009, INT J PHARMACEUT, V377, P159, DOI 10.1016/j.ijpharm.2009.04.050
   Wang Y, 2011, EYE, V25, P127, DOI 10.1038/eye.2010.196
   Wang YS, 2002, GRAEF ARCH CLIN EXP, V240, P42, DOI 10.1007/s00417-001-0398-y
   Yeung CK, 2003, INVEST OPHTH VIS SCI, V44, P5293, DOI 10.1167/iovs.03-0490
   Zhang K, 2012, NAT REV DRUG DISCOV, V11, P541, DOI 10.1038/nrd3745
   Zhang X, 2014, CURR MOL MED, V14, P376, DOI 10.2174/1566524014666140128114414
   Zhang XY, 2008, DIABETES, V57, P1026, DOI 10.2337/db07-0982
NR 55
TC 49
Z9 49
U1 1
U2 21
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0939-6411
EI 1873-3441
J9 EUR J PHARM BIOPHARM
JI Eur. J. Pharm. Biopharm.
PD SEP
PY 2015
VL 95
BP 239
EP 249
DI 10.1016/j.ejpb.2015.02.013
PN B
PG 11
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA CU8WH
UT WOS:000363824300009
PM 25701805
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Hu, SJ
   Calippe, B
   Lavalette, S
   Roubeix, C
   Montassar, F
   Housset, M
   Levy, O
   Delarasse, C
   Paques, M
   Sahel, JA
   Sennlaub, F
   Guillonneau, X
AF Hu, Shulong J.
   Calippe, Bertrand
   Lavalette, Sophie
   Roubeix, Christophe
   Montassar, Fadoua
   Housset, Michael
   Levy, Olivier
   Delarasse, Cecile
   Paques, Michel
   Sahel, jose-Alain
   Sennlaub, Florian
   Guillonneau, Xavier
TI Upregulation of P2RX7 in Cx3cr1-Deficient Mononuclear Phagocytes Leads
   to Increased Interleukin-1 beta Secretion and Photoreceptor
   Neurodegeneration
SO JOURNAL OF NEUROSCIENCE
LA English
DT Article
DE IL-1; inflammasome; monocytes; P2RX7; retina
ID CELL-DEATH; P2X(7) RECEPTORS; RETINAL DEGENERATION; NEURONAL DEATH;
   ACTIVATION; MICROGLIA; INFLAMMASOME; DISEASE; INJURY; MODEL
AB Photoreceptor degeneration in age-related macular degeneration (AMD) is associated with an infiltration and chronic accumulation of mononuclear phagocytes (MPs). We have previously shown that Cx3cr1-deficient mice develop age- and stress- related subretinal accumulation of MPs, which is associated with photoreceptor degeneration. Cx3cr1-deficient MPs have been shown to increase neuronal apoptosis through IL-1 beta in neuroinflammation of the brain. The reason for increased IL-1 beta secretion from Cx3cr1-deficient MPs, and whether IL-1 beta is responsible for increased photoreceptor apoptosis in Cx3cr1-deficient mice, has not been elucidated. Here we show that Cx3cr1-deficient MPs express increased surface P2X7 receptor (P2RX7), which stimulates IL-1 beta maturation and secretion. P2RX7 and IL-1 beta inhibition efficiently blunted Cx3cr1-MP-dependent photoreceptor apoptosis in a monocyte/retina coculture system and in light-induced subretinal inflammation of Cx3cr1-deficient mice in vivo. Our results provide an explanation for increased CX3CR1-dependent IL-1 beta secretion and suggest that IL-1 beta or P2RX7 inhibition can help inhibit the inflammation-associated photoreceptor cell loss in late AMD, including geographic atrophy, for which no efficient treatment currently exists.
C1 [Hu, Shulong J.; Calippe, Bertrand; Lavalette, Sophie; Roubeix, Christophe; Montassar, Fadoua; Housset, Michael; Levy, Olivier; Paques, Michel; Sahel, jose-Alain; Sennlaub, Florian; Guillonneau, Xavier] INSERM, U 968, F-75012 Paris, France.
   [Hu, Shulong J.; Calippe, Bertrand; Lavalette, Sophie; Roubeix, Christophe; Montassar, Fadoua; Housset, Michael; Levy, Olivier; Paques, Michel; Sahel, jose-Alain; Sennlaub, Florian; Guillonneau, Xavier] Univ Paris 06, Sorbonne Univ, Inst Vis, UMR S 968, F-75012 Paris, France.
   [Hu, Shulong J.; Calippe, Bertrand; Lavalette, Sophie; Roubeix, Christophe; Montassar, Fadoua; Housset, Michael; Levy, Olivier; Paques, Michel; Sahel, jose-Alain; Sennlaub, Florian; Guillonneau, Xavier] CNRS, UMR 7210, F-75012 Paris, France.
   [Delarasse, Cecile] Univ Paris 06, Univ Paris 04, CNRS, INSERM,ICM,UMR S 1127,UMR 7225,U 1127, F-75013 Paris, France.
   [Paques, Michel; Sahel, jose-Alain] Ctr Hosp Natl Ophtalmol Quinze Vingts, DHU ViewMaintain, INSERM DHOS, CIC 1423, F-75012 Paris, France.
C3 Institut National de la Sante et de la Recherche Medicale (Inserm);
   UDICE-French Research Universities; Sorbonne Universite; Centre National
   de la Recherche Scientifique (CNRS); CNRS - National Institute for
   Biology (INSB); UDICE-French Research Universities; Universite Paris
   Cite; Centre National de la Recherche Scientifique (CNRS); CNRS -
   National Institute for Biology (INSB); Institut National de la Sante et
   de la Recherche Medicale (Inserm); UDICE-French Research Universities;
   Sorbonne Universite; Universite Paris Cite; CHNO des Quinze-Vingts;
   Institut National de la Sante et de la Recherche Medicale (Inserm);
   UDICE-French Research Universities; Sorbonne Universite
RP Guillonneau, X (通讯作者)，Inst Vis, F-75012 Paris, France.
EM xavier.guillonneau@inserm.fr
RI Sennlaub, Florian/F-2756-2017; guillonneau, xavier/AAF-9495-2021; Sahel,
   Jose-Alain/F-3172-2017; Guillonneau, xavier/E-3995-2017; Delarasse,
   Cecile/K-8234-2017
OI Sennlaub, Florian/0000-0003-4412-1341; guillonneau,
   xavier/0000-0001-7379-3935; Sahel, Jose-Alain/0000-0002-4831-1153;
   Guillonneau, xavier/0000-0001-7379-3935; Delarasse,
   Cecile/0000-0001-9739-4306
FU INSERM; ANR "blanc" [AO5120DD]; ANR Maladies Neurologiques et
   Psychiatriques [ANR-08-MNPS-003]; ANRGeno [R09099DS]; Labex Lifesenses;
   Carnot; ADPS-ALLIANZ; ERC starting Grant (ERC St.G.) [210345]
FX This work was supported by grants from INSERM, ANR "blanc" (AO5120DD),
   ANR Maladies Neurologiques et Psychiatriques (ANR-08-MNPS-003), ANRGeno
   2009 (R09099DS), Labex Lifesenses, Carnot, ADPS-ALLIANZ, and ERC
   starting Grant (ERC-2007 St.G. 210345).
CR Allan SM, 2005, NAT REV IMMUNOL, V5, P629, DOI 10.1038/nri1664
   Arbeloa J, 2012, NEUROBIOL DIS, V45, P954, DOI 10.1016/j.nbd.2011.12.014
   Bartlett R, 2013, MEDIAT INFLAMM, V2013, DOI 10.1155/2013/271813
   Bond SR, 2014, FRONT PHYSIOL, V5, DOI 10.3389/fphys.2014.00058
   Brandle U, 1998, MOL BRAIN RES, V62, P106, DOI 10.1016/S0169-328X(98)00254-X
   Cardona AE, 2006, NAT NEUROSCI, V9, P917, DOI 10.1038/nn1715
   Chow A, 2011, NAT REV IMMUNOL, V11, P788, DOI 10.1038/nri3087
   Chu KT, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-69
   Combadiere C, 2007, J CLIN INVEST, V117, P2920, DOI 10.1172/JCI31692
   Conductier G, 2010, J NEUROIMMUNOL, V224, P93, DOI 10.1016/j.jneuroim.2010.05.010
   Cruz-Guilloty F, 2013, INT J INFLAMM, V2013, DOI 10.1155/2013/503725
   Diaz-Hernandez M, 2009, FASEB J, V23, P1893, DOI 10.1096/fj.08-122275
   Dinarello CA, 1996, BLOOD, V87, P2095, DOI 10.1182/blood.V87.6.2095.bloodjournal8762095
   Fadok VA, 1998, J CLIN INVEST, V101, P890, DOI 10.1172/JCI1112
   Fu WX, 2012, PLOS ONE, V7, DOI [10.1371/journal.pone.0032127, 10.1371/journal.pone.0040003, 10.1371/journal.pone.0036949, 10.1186/1746-1596-7-49]
   Galea I, 2007, TRENDS IMMUNOL, V28, P12, DOI 10.1016/j.it.2006.11.004
   Geissmann F, 2003, IMMUNITY, V19, P71, DOI 10.1016/S1074-7613(03)00174-2
   Guo CR, 2012, EXP EYE RES, V104, P39, DOI 10.1016/j.exer.2012.08.013
   Gupta N, 2003, EXP EYE RES, V76, P463, DOI 10.1016/S0014-4835(02)00332-9
   HANGAI M, 1995, INVEST OPHTH VIS SCI, V36, P571
   Huynh MLN, 2002, J CLIN INVEST, V109, P41, DOI 10.1172/JCI200211638
   Kerur N, 2013, INVEST OPHTH VIS SCI, V54, P7395, DOI 10.1167/iovs.13-12500
   Kido N, 2001, BRAIN RES, V910, P153, DOI 10.1016/S0006-8993(01)02706-8
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Kohno H, 2013, J BIOL CHEM, V288, P15326, DOI 10.1074/jbc.M112.448712
   Kraft AD, 2011, INT J ENV RES PUB HE, V8, P2980, DOI 10.3390/ijerph8072980
   Lavalette S, 2011, AM J PATHOL, V178, P2416, DOI 10.1016/j.ajpath.2011.01.013
   Lee SJ, 2002, SCIENCE, V295, P1898, DOI 10.1126/science.1069540
   Levy O, 2015, EMBO MOL MED, V7, P211, DOI 10.15252/emmm.201404524
   Mantovani A, 2004, TRENDS IMMUNOL, V25, P677, DOI 10.1016/j.it.2004.09.015
   Mariathasan S, 2006, NATURE, V440, P228, DOI 10.1038/nature04515
   MILJANICH GP, 1981, J MEMBRANE BIOL, V60, P249, DOI 10.1007/BF01992562
   MOLDAY LL, 1987, BIOCHIM BIOPHYS ACTA, V897, P335, DOI 10.1016/0005-2736(87)90430-5
   Murakami Y, 2013, PROG RETIN EYE RES, V37, P114, DOI 10.1016/j.preteyeres.2013.08.001
   Nakazawa T, 2007, P NATL ACAD SCI USA, V104, P2425, DOI 10.1073/pnas.0608167104
   Nakazawa T, 2011, INVEST OPHTH VIS SCI, V52, P1384, DOI 10.1167/iovs.10-6509
   Niyadurupola N, 2013, INVEST OPHTH VIS SCI, V54, P2163, DOI 10.1167/iovs.12-10968
   Notomi S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053338
   Pelegrin P, 2006, EMBO J, V25, P5071, DOI 10.1038/sj.emboj.7601378
   Praetorius HA, 2009, PURINERG SIGNAL, V5, P433, DOI 10.1007/s11302-009-9146-2
   Puthussery T, 2004, J COMP NEUROL, V472, P13, DOI 10.1002/cne.20045
   Puthussery T, 2009, J COMP NEUROL, V513, P430, DOI 10.1002/cne.21964
   Qu Y, 2011, J IMMUNOL, V186, P6553, DOI 10.4049/jimmunol.1100478
   Ransohoff RM, 2009, IMMUNITY, V31, P711, DOI 10.1016/j.immuni.2009.09.010
   Rutar M, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-221
   SARKS SH, 1976, BRIT J OPHTHALMOL, V60, P324, DOI 10.1136/bjo.60.5.324
   Schroder K, 2010, CELL, V140, P821, DOI 10.1016/j.cell.2010.01.040
   Sennlaub F, 2013, EMBO MOL MED, V5, P1775, DOI 10.1002/emmm.201302692
   Shaftel SS, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-7
   Simi A, 2007, NEUROPHARMACOLOGY, V52, P1563, DOI 10.1016/j.neuropharm.2007.02.011
   Skaper SD, 2006, GLIA, V54, P234, DOI 10.1002/glia.20379
   Srinivasan B, 2004, J BIOL CHEM, V279, P41839, DOI 10.1074/jbc.M402872200
   Streilein JW, 2003, NAT REV IMMUNOL, V3, P879, DOI 10.1038/nri1224
   Sugiyama T, 2010, INVEST OPHTH VIS SCI, V51, P3236, DOI 10.1167/iovs.09-4192
   Wolf Y, 2013, FRONT CELL NEUROSCI, V7, DOI 10.3389/fncel.2013.00026
   Wu GS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043089
   Yoneda S, 2001, EXP EYE RES, V73, P661, DOI 10.1006/exer.2001.1072
   Yu Q, 2013, PURINERG SIGNAL, V9, P663, DOI 10.1007/s11302-013-9379-y
   Zieger M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0106562
NR 59
TC 58
Z9 59
U1 0
U2 13
PU SOC NEUROSCIENCE
PI WASHINGTON
PA 11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA
SN 0270-6474
J9 J NEUROSCI
JI J. Neurosci.
PD MAY 6
PY 2015
VL 35
IS 18
BP 6987
EP 6996
DI 10.1523/JNEUROSCI.3955-14.2015
PG 10
WC Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA CL0YG
UT WOS:000356668400002
PM 25948251
OA Green Published, Bronze
DA 2022-11-30
ER

PT J
AU El Sanharawi, M
   Touchard, E
   Benard, R
   Bigey, P
   Escriou, V
   Mehanna, C
   Naud, MC
   Berdugo, M
   Jeanny, JC
   Behar-Cohen, F
AF El Sanharawi, M.
   Touchard, E.
   Benard, R.
   Bigey, P.
   Escriou, V.
   Mehanna, C.
   Naud, M-C
   Berdugo, M.
   Jeanny, J-C
   Behar-Cohen, F.
TI Long-term efficacy of ciliary muscle gene transfer of three sFlt-1
   variants in a rat model of laser-induced choroidal neovascularization
SO GENE THERAPY
LA English
DT Article
DE gene therapy; anti-VEGF; choroidal neovascularization
ID ENDOTHELIAL GROWTH-FACTOR; DIABETIC MACULAR EDEMA; OCULAR
   NEOVASCULARIZATION; ANTI-VEGF; SOLUBLE VEGF; TYROSINE KINASE; TRANSGENIC
   MICE; FACTOR RECEPTOR; INHIBITION; EXPRESSION
AB Inhibition of vascular endothelial growth factor (VEGF) has become the standard of care for patients presenting with wet age-related macular degeneration. However, monthly intravitreal injections are required for optimal efficacy. We have previously shown that electroporation enabled ciliary muscle gene transfer results in sustained protein secretion into the vitreous for up to 9 months. Here, we evaluated the long-term efficacy of ciliary muscle gene transfer of three soluble VEGF receptor-1 (sFlt-1) variants in a rat model of laser-induced choroidal neovascularization (CNV). All three sFlt-1 variants significantly diminished vascular leakage and neovascularization as measured by fluorescein angiography (FA) and flatmount choroid at 3 weeks. FA and infracyanine angiography demonstrated that inhibition of CNV was maintained for up to 6 months after gene transfer of the two shortest sFlt-1 variants. Throughout, clinical efficacy was correlated with sustained VEGF neutralization in the ocular media. Interestingly, treatment with sFlt-1 induced a 50% downregulation of VEGF messenger RNA levels in the retinal pigment epithelium and the choroid. We demonstrate for the first time that non-viral gene transfer can achieve a long-term reduction of VEGF levels and efficacy in the treatment of CNV.
C1 [El Sanharawi, M.; Mehanna, C.; Naud, M-C; Berdugo, M.; Jeanny, J-C; Behar-Cohen, F.] INSERM, UMRS Physiopathol Ocular Dis Therapeut Innovat 87, Paris, France.
   [El Sanharawi, M.; Mehanna, C.; Naud, M-C; Berdugo, M.; Jeanny, J-C; Behar-Cohen, F.] Univ Paris 06, Ctr Rech Cordeliers, UMRS 872, F-75006 Paris, France.
   [El Sanharawi, M.; Mehanna, C.; Naud, M-C; Berdugo, M.; Jeanny, J-C; Behar-Cohen, F.] Univ Paris 05, UMRS 872, Paris, France.
   [Touchard, E.; Benard, R.] Eyevensys, Paris, France.
   [Bigey, P.; Escriou, V.] INSERM, U1022, Paris, France.
   [Bigey, P.; Escriou, V.] CNRS, UMR8151, Paris, France.
   [Bigey, P.; Escriou, V.] ENSCP Chim ParisTech, Paris, France.
   [Behar-Cohen, F.] Hotel Dieu Paris, Dept Ophthalmol, Paris, France.
C3 Institut National de la Sante et de la Recherche Medicale (Inserm);
   Institut National de la Sante et de la Recherche Medicale (Inserm);
   UDICE-French Research Universities; Sorbonne Universite; Universite
   Paris Cite; UDICE-French Research Universities; Universite Paris Cite;
   Institut National de la Sante et de la Recherche Medicale (Inserm);
   UDICE-French Research Universities; Universite Paris Cite; Centre
   National de la Recherche Scientifique (CNRS); UDICE-French Research
   Universities; Universite Paris Cite; UDICE-French Research Universities;
   PSL Research University Paris; Chimie ParisTech; Assistance Publique
   Hopitaux Paris (APHP); Hopital Universitaire Hotel-Dieu - APHP;
   UDICE-French Research Universities; Universite Paris Cite
RP El Sanharawi, M (通讯作者)，Univ Paris 06, Ctr Rech Cordeliers, UMRS 872, Equipe 17, 15 Rue Ecole Med, F-75006 Paris, France.
EM mohamed.elsanharawi@gmail.com
OI Escriou, Virginie/0000-0001-5686-9301; bigey, pascal/0000-0002-6795-8569
FU Fondation pour la Recherche Medicale (FRM)
FX This work was funded in part by Fondation pour la Recherche Medicale
   (FRM).
CR Ali G, 2009, BRIT J CANCER, V101, P1869, DOI 10.1038/sj.bjc.6605438
   Antonetti DA, 2012, NEW ENGL J MED, V366, P1227, DOI 10.1056/NEJMra1005073
   Bainbridge JWB, 2002, GENE THER, V9, P320, DOI 10.1038/sj.gt.3301680
   Barleon B, 1997, J BIOL CHEM, V272, P10382
   Basile DP, 2008, AM J PHYSIOL-RENAL, V294, pF928, DOI 10.1152/ajprenal.00596.2007
   Browning DJ, 2012, AM J OPHTHALMOL, V154, P222, DOI 10.1016/j.ajo.2012.04.020
   Campochiaro PA, 2012, OPHTHALMOLOGICA, V227, P30, DOI 10.1159/000337157
   Cideciyan AV, 2010, PROG RETIN EYE RES, V29, P398, DOI 10.1016/j.preteyeres.2010.04.002
   Cunningham SA, 1997, BIOCHEM BIOPH RES CO, V231, P596, DOI 10.1006/bbrc.1997.6156
   Rocha FGD, 2011, J GENE MED, V13, P148, DOI 10.1002/jgm.1547
   DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256
   Dhoot DS, 2012, EXPERT OPIN BIOL TH, V12, P371, DOI 10.1517/14712598.2012.660523
   Drechsler F, 2012, OPHTHALMIC RES, V47, P157, DOI 10.1159/000330279
   Edelman JL, 2000, EXP EYE RES, V71, P523, DOI 10.1006/exer.2000.0907
   El Sanharawi M, 2010, PROG RETIN EYE RES, V29, P443, DOI 10.1016/j.preteyeres.2010.04.001
   Gehlbach P, 2003, HUM GENE THER, V14, P129, DOI 10.1089/104303403321070829
   Girard S, 2008, NEUROREPORT, V19, P997, DOI 10.1097/WNR.0b013e3283036e88
   He YL, 1999, MOL ENDOCRINOL, V13, P537, DOI 10.1210/me.13.4.537
   Ho AC, 2012, OPHTHALMOLOGY, V119, P2179, DOI 10.1016/j.ophtha.2012.07.058
   Hufnagel RB, 2012, GRAEF ARCH CLIN EXP, V250, P1117, DOI 10.1007/s00417-012-2028-2
   Ideno J, 2007, INT J MOL MED, V19, P75
   Igarashi T, 2010, HUM GENE THER, V21, P631, DOI 10.1089/hum.2009.153
   Kaiser Peter K, 2009, Retina, V29, pS15, DOI 10.1097/IAE.0b013e3181ad240c
   KENDALL RL, 1993, P NATL ACAD SCI USA, V90, P10705, DOI 10.1073/pnas.90.22.10705
   Kendall RL, 1996, BIOCHEM BIOPH RES CO, V226, P324, DOI 10.1006/bbrc.1996.1355
   Khoury M, 2006, J GENE MED, V8, P1027, DOI 10.1002/jgm.922
   Kovach JL, 2012, J OPHTHALMOL, V2012, DOI 10.1155/2012/786870
   Kowalczuk L, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017462
   Lai CM, 2005, MOL THER, V12, P659, DOI 10.1016/j.ymthe.2005.04.022
   Lai YKY, 2002, GENE THER, V9, P804, DOI 10.1038/sj.gt.3301695
   Lois N, 2013, RETINA-J RET VIT DIS, V33, P13, DOI 10.1097/IAE.0b013e3182657fff
   Lukason M, 2011, MOL THER, V19, P260, DOI 10.1038/mt.2010.230
   Mao YX, 2011, HUM GENE THER, V22, P1525, DOI 10.1089/hum.2011.090
   Marano RJ, 2005, GENE THER, V12, P1544, DOI 10.1038/sj.gt.3302579
   Miyamoto N, 2008, OPHTHALMIC RES, V40, P203, DOI 10.1159/000119877
   Miyamoto N, 2007, DIABETOLOGIA, V50, P461, DOI 10.1007/s00125-006-0539-2
   Muether PS, 2012, OPHTHALMOLOGY, V119, P2082, DOI 10.1016/j.ophtha.2012.07.041
   MUSTONEN T, 1995, J CELL BIOL, V129, P895, DOI 10.1083/jcb.129.4.895
   Ohno-Matsui K, 2002, AM J PATHOL, V160, P711, DOI 10.1016/S0002-9440(10)64891-2
   Ohr M, 2012, EXPERT OPIN PHARMACO, V13, P585, DOI 10.1517/14656566.2012.658368
   Okamoto N, 1997, AM J PATHOL, V151, P281
   Pechan P, 2009, GENE THER, V16, P10, DOI 10.1038/gt.2008.115
   Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45
   Provost N, 2005, MOL THER, V11, P275, DOI 10.1016/j.ymthe.2004.09.022
   Roh MI, 2009, RETINA-J RET VIT DIS, V29, P523, DOI 10.1097/IAE.0b013e318195cb15
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Ryu JK, 2009, J NEUROSCI, V29, P3, DOI 10.1523/JNEUROSCI.2888-08.2009
   Saint-Geniez M, 2009, P NATL ACAD SCI USA, V106, P18751, DOI 10.1073/pnas.0905010106
   SHIBUYA M, 1990, ONCOGENE, V5, P519
   Smith AJ, 2012, GENE THER, V19, P154, DOI 10.1038/gt.2011.161
   Stieger K, 2009, MOL THER, V17, P516, DOI 10.1038/mt.2008.283
   Tao Weng, 2006, Expert Opin Biol Ther, V6, P717, DOI 10.1517/14712598.6.7.717
   Touchard E, 2012, GENE THER, V19, P886, DOI 10.1038/gt.2011.154
   Touchard E, 2009, GENE THER, V16, P862, DOI 10.1038/gt.2009.43
   Touchard E, 2010, J GENE MED, V12, P904, DOI 10.1002/jgm.1517
   Vinores SA, 2003, HISTOL HISTOPATHOL, V18, P797, DOI 10.14670/HH-18.797
   Wiesmann C, 1997, CELL, V91, P695, DOI 10.1016/S0092-8674(00)80456-0
   Xu B, 2009, HYPERTENS PREGNANCY, V28, P448, DOI 10.3109/10641950902777721
   Yamada E, 2001, HISTOL HISTOPATHOL, V16, P87, DOI 10.14670/HH-16.87
   Zechmeister-Koss I, 2012, BRIT J OPHTHALMOL, V96, P167, DOI 10.1136/bjophthalmol-2011-300674
NR 60
TC 9
Z9 9
U1 0
U2 5
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0969-7128
EI 1476-5462
J9 GENE THER
JI Gene Ther.
PD NOV
PY 2013
VL 20
IS 11
BP 1093
EP 1103
DI 10.1038/gt.2013.36
PG 11
WC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Genetics & Heredity; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Genetics & Heredity; Research & Experimental Medicine
GA 251DL
UT WOS:000326907900009
PM 23804076
DA 2022-11-30
ER

PT J
AU Lund, RD
   Ono, SJ
   Keegan, DJ
   Lawrence, JM
AF Lund, RD
   Ono, SJ
   Keegan, DJ
   Lawrence, JM
TI Retinal transplantation: progress and problems in clinical application
SO JOURNAL OF LEUKOCYTE BIOLOGY
LA English
DT Review
DE photoreceptor degeneration; grafting; immune rejection
ID EPITHELIAL-CELL TRANSPLANTATION; EMBRYONIC DOPAMINE NEURONS; PUPILLARY
   LIGHT REFLEX; DYSTROPHIC RCS RAT; NEURAL STEM-CELLS; MACULAR
   DEGENERATION; PIGMENT-EPITHELIUM; IMMUNE PRIVILEGE; SUBRETINAL SPACE;
   ANTERIOR-CHAMBER
AB There is currently no real treatment for blinding disorders that stem from the degeneration of cells in the retina and affect at least 50 million individuals worldwide. The excitement that accompanied the first studies showing the potential of retinal cell transplantation to alleviate the progress of blindness in such diseases as retinitis pigmentosa and age-related macular degeneration has lost some of its momentum, as attempts to apply research to the clinic have failed so far to provide effective treatments. What these studies have shown, however, is not that the approach is flawed but rather that the steps that need to be taken to achieve a viable., clinical treatment are many. This review summarizes the course of retinal transplant studies and points to obstacles that still need to be overcome to improve graft survival and efficacy and to develop a protocol that is effective in a clinical setting. Emphasis is given particularly to the consequences of introducing transplants to sites that have been considered immunologically privileged and to the role of the major histocompatibility complex classes I and 11 molecules in graft survival and rejection.
C1 Univ Utah, Hlth Sci Ctr, Moran Eye Ctr, Salt Lake City, UT 84132 USA.
   UCL, Inst Ophthalmol, Transplantat Unit, London, England.
   UCL, Dept Ocular Immunol, London, England.
C3 Utah System of Higher Education; University of Utah; University of
   London; University College London; University of London; University
   College London
RP Lund, RD (通讯作者)，Univ Utah, Hlth Sci Ctr, Moran Eye Ctr, N Med Dr, Salt Lake City, UT 84132 USA.
EM raymond.lund@hsc.utah.edu
CR Abe T, 2000, TOHOKU J EXP MED, V191, P7, DOI 10.1620/tjem.191.7
   Abe T, 1999, TOHOKU J EXP MED, V189, P295, DOI 10.1620/tjem.189.295
   Akimoto M, 1999, INVEST OPHTH VIS SCI, V40, P273
   Algvere PV, 1999, EUR J OPHTHALMOL, V9, P217, DOI 10.1177/112067219900900310
   Algvere PV, 1997, GRAEF ARCH CLIN EXP, V235, P149, DOI 10.1007/BF00941722
   ALGVERE PV, 1994, GRAEF ARCH CLIN EXP, V232, P707, DOI 10.1007/BF00184273
   Aramant RB, 1999, INVEST OPHTH VIS SCI, V40, P1557
   ARAMANT RB, 1995, EXP NEUROL, V133, P244, DOI 10.1006/exnr.1995.1027
   Aramant RB, 2002, PROG RETIN EYE RES, V21, P57, DOI 10.1016/S1350-9462(01)00020-9
   BANERJEE R, 1993, NEUROSCIENCE, V56, P939, DOI 10.1016/0306-4522(93)90140-B
   Barker R, 1993, Rev Neurosci, V4, P113
   Binder S, 2002, AM J OPHTHALMOL, V133, P215, DOI 10.1016/S0002-9394(01)01373-3
   BJORKLUND A, 1979, BRAIN RES, V177, P555, DOI 10.1016/0006-8993(79)90472-4
   Bjorklund L, 1997, EXP NEUROL, V148, P324, DOI 10.1006/exnr.1997.6655
   BOK D, 1993, INVEST OPHTH VIS SCI, V34, P473
   Boonman Z, 1999, EXP NEUROL, V156, P1, DOI 10.1006/exnr.1999.7056
   Bradbury EJ, 2002, NATURE, V416, P636, DOI 10.1038/416636a
   Clarkson ED, 1998, BRAIN RES, V806, P60, DOI 10.1016/S0006-8993(98)00717-3
   COFFEY PJ, 1990, PROG BRAIN RES, V82, P269
   Coffey PJ, 2002, NAT NEUROSCI, V5, P53, DOI 10.1038/nn782
   Crafoord S, 2000, ACTA OPHTHALMOL SCAN, V78, P122, DOI 10.1034/j.1600-0420.2000.078002122.x
   D'Cruz PM, 2000, HUM MOL GENET, V9, P645, DOI 10.1093/hmg/9.4.645
   D'Orazio TJ, 1998, J IMMUNOL, V160, P2089
   DAIGER SP, 1996, RETNET
   Del Priore LV, 2001, AM J OPHTHALMOL, V131, P472, DOI 10.1016/S0002-9394(00)00850-3
   delCerro M, 1997, MICROSC RES TECHNIQ, V36, P130, DOI 10.1002/(SICI)1097-0029(19970115)36:2<130::AID-JEMT6>3.0.CO;2-T
   Dobrossy MD, 2001, NAT REV NEUROSCI, V2, P871, DOI 10.1038/35104055
   Edgerton VR, 2001, J PHYSIOL-LONDON, V533, P15, DOI 10.1111/j.1469-7793.2001.0015b.x
   Fawcett J, 2002, SPINAL CORD, V40, P615, DOI 10.1038/sj.sc.3101328
   Freed CR, 2001, NEW ENGL J MED, V344, P710, DOI 10.1056/NEJM200103083441002
   GAZE RM, 1970, BRAIN RES, V21, P183, DOI 10.1016/0006-8993(70)90362-8
   Ghosh F, 2002, RETINA-J RET VIT DIS, V22, P478, DOI 10.1097/00006982-200208000-00013
   Ghosh F, 1999, INVEST OPHTH VIS SCI, V40, P133
   Ghosh F, 1999, INVEST OPHTH VIS SCI, V40, P126
   Ghosh F, 2000, GRAEF ARCH CLIN EXP, V238, P589, DOI 10.1007/s004170000138
   GILL TJ, 1989, JAMA-J AM MED ASSOC, V261, P2674, DOI 10.1001/jama.261.18.2674
   GOURAS P, 1992, INVEST OPHTH VIS SCI, V33, P2579
   Gouras P, 1996, VISION RES, V36, P4121, DOI 10.1016/S0042-6989(96)00180-0
   GOURAS P, 1985, CURR EYE RES, V4, P253, DOI 10.3109/02713688509000857
   Gouras P, 1989, Prog Clin Biol Res, V314, P659
   GRIFFITH TS, 1995, SCIENCE, V270, P1189, DOI 10.1126/science.270.5239.1189
   Grisanti S, 1997, INVEST OPHTH VIS SCI, V38, P1619
   Gullapalli VK, 2002, INVEST OPHTH VIS SCI, V43, pU971
   HALL BM, 1991, TRANSPLANTATION, V51, P1141, DOI 10.1097/00007890-199106000-00001
   Hattar S, 2002, SCIENCE, V295, P1065, DOI 10.1126/science.1069609
   Hicks D, 1999, INVEST OPHTH VIS SCI, V40, P3071
   JIANG LQ, 1991, TRANSPLANTATION, V52, P513, DOI 10.1097/00007890-199109000-00025
   JIANG LQ, 1995, TRANSPLANTATION, V59, P1201, DOI 10.1097/00007890-199504270-00021
   JIANG LQ, 1994, EXP EYE RES, V58, P719, DOI 10.1006/exer.1994.1069
   JIANG LQ, 1993, INVEST OPHTH VIS SCI, V34, P3347
   Jorgensen A, 1998, INVEST OPHTH VIS SCI, V39, P1590
   Kaplan H J, 1999, Chem Immunol, V73, P207
   Kaplan HJ, 1998, RETINA-J RET VIT DIS, V18, P99
   Karlsson J, 1999, BRAIN RES, V821, P546, DOI 10.1016/S0006-8993(99)01176-2
   KLASSEN H, 1988, EXP NEUROL, V102, P102, DOI 10.1016/0014-4886(88)90082-9
   KLASSEN H, 1987, P NATL ACAD SCI USA, V84, P6958, DOI 10.1073/pnas.84.19.6958
   Kohen L, 1997, OPHTHALMIC RES, V29, P298, DOI 10.1159/000268028
   Kreppel F, 2002, INVEST OPHTH VIS SCI, V43, P1965
   KSANDER BR, 1989, TRANSPLANTATION, V47, P661, DOI 10.1097/00007890-198904000-00018
   Kurimoto Y, 2001, NEUROSCI LETT, V306, P57, DOI 10.1016/S0304-3940(01)01857-2
   Kwan ASL, 1999, EXP NEUROL, V159, P21, DOI 10.1006/exnr.1999.7157
   Larsson J, 1999, GRAEF ARCH CLIN EXP, V237, P82, DOI 10.1007/s004170050199
   LAVAIL MM, 1992, P NATL ACAD SCI USA, V89, P11249, DOI 10.1073/pnas.89.23.11249
   LaVail MM, 1998, INVEST OPHTH VIS SCI, V39, P592
   Lawrence JM, 2002, INVEST OPHTH VIS SCI, V43, pU636
   Lawrence JM, 2000, INVEST OPHTH VIS SCI, V41, P518
   LAWRENCE JM, 1990, NEUROSCIENCE, V37, P431, DOI 10.1016/0306-4522(90)90413-X
   LAWRENCE JM, 2003, INVEST OPHTHALMOL VI, V44
   LI LX, 1988, EXP EYE RES, V47, P911, DOI 10.1016/0014-4835(88)90073-5
   Litchfield TM, 1997, EXP EYE RES, V64, P655, DOI 10.1006/exer.1996.0253
   Lu B, 2002, BRAIN RES, V943, P292, DOI 10.1016/S0006-8993(02)02906-2
   Lucas RJ, 2003, SCIENCE, V299, P245, DOI 10.1126/science.1077293
   Lund RD, 2001, P NATL ACAD SCI USA, V98, P9942, DOI 10.1073/pnas.171266298
   Lund RD, 2001, PROG RETIN EYE RES, V20, P415, DOI 10.1016/S1350-9462(01)00003-9
   LUND RD, 1988, TRANSPLANTATION, V46, P216, DOI 10.1097/00007890-198808000-00006
   LUND RD, 1991, TRENDS NEUROSCI, V14, P358, DOI 10.1016/0166-2236(91)90163-O
   LUND RD, 1994, EYE, V8, P263, DOI 10.1038/eye.1994.55
   Ma NL, 1998, INVEST OPHTH VIS SCI, V39, P2384
   Masli S, 2002, J IMMUNOL, V168, P2264, DOI 10.4049/jimmunol.168.5.2264
   MCLOON SC, 1980, EXP BRAIN RES, V40, P273
   Modo M, 2002, BRAIN RES, V958, P70, DOI 10.1016/S0006-8993(02)03463-7
   Mohand-Said S, 2000, ARCH OPHTHALMOL-CHIC, V118, P807, DOI 10.1001/archopht.118.6.807
   Mohand-Said S, 2001, PROG RETIN EYE RES, V20, P451, DOI 10.1016/S1350-9462(01)00006-4
   MUNRO NS, 1982, J EMBRYOL EXP MORPH, V71, P97
   NAKAO N, 1994, P NATL ACAD SCI USA, V91, P12408, DOI 10.1073/pnas.91.26.12408
   Othberg A, 1997, EXP NEUROL, V147, P498, DOI 10.1006/exnr.1997.6594
   Piccini P, 1999, NAT NEUROSCI, V2, P1137, DOI 10.1038/16060
   Piccotti JR, 1997, TRANSPLANTATION, V63, P619, DOI 10.1097/00007890-199703150-00001
   POLLACK IF, 1990, PROG BRAIN RES, V82, P129
   POLLACK IF, 1990, EXP NEUROL, V108, P114, DOI 10.1016/0014-4886(90)90017-M
   PRUSKY GT, 2002, SOC NEUR ABSTR
   Radner W, 2002, INVEST OPHTH VIS SCI, V43, P3053
   RAO K, 1988, PROG BRAIN RES, V78, P281
   RAO K, 1989, TRANSPLANTATION, V48, P1018, DOI 10.1097/00007890-198912000-00025
   RAO K, 1989, BRAIN RES, V488, P332, DOI 10.1016/0006-8993(89)90725-7
   Reichel MB, 1998, GENE THER, V5, P1038, DOI 10.1038/sj.gt.3300691
   Rezai KA, 1997, GRAEF ARCH CLIN EXP, V235, P558, DOI 10.1007/BF00947084
   Rosenblad C, 1996, NEUROSCIENCE, V75, P979
   Sanftner LHM, 2001, MOL THER, V4, P622, DOI 10.1006/mthe.2001.0498
   Sauve Y, 2002, NEUROSCIENCE, V114, P389, DOI 10.1016/S0306-4522(02)00271-3
   SAUVE Y, 2003, INVEST OPHTHALMOL VI, V44
   Schierle GS, 1999, NAT MED, V5, P97, DOI 10.1038/4785
   Schraermeyer U, 1999, INVEST OPHTH VIS SCI, V40, P1545
   Seiler MJ, 1998, INVEST OPHTH VIS SCI, V39, P2121
   Semkova I, 2002, P NATL ACAD SCI USA, V99, P13090, DOI 10.1073/pnas.202486199
   SHEEDLO HJ, 1992, INT REV CYTOL, V138, P1, DOI 10.1016/S0074-7696(08)61586-7
   SIMONS DJ, 1985, DEV BRAIN RES, V21, P156, DOI 10.1016/0165-3806(85)90036-7
   SMETANKA AM, 1990, BRAIN RES, V521, P343, DOI 10.1016/0006-8993(90)91564-W
   SO KF, 1985, BRAIN RES, V328, P349, DOI 10.1016/0006-8993(85)91047-9
   SPERRY RW, 1963, P NATL ACAD SCI USA, V50, P703, DOI 10.1073/pnas.50.4.703
   Streilein JW, 1999, PROG RETIN EYE RES, V18, P357, DOI 10.1016/S1350-9462(98)00022-6
   STREILEIN JW, 1980, J EXP MED, V152, P1121, DOI 10.1084/jem.152.4.1121
   STREILEIN JW, 1985, J IMMUNOL, V134, P1381
   STREILEIN JW, 1990, SURV OPHTHALMOL, V35, P67, DOI 10.1016/0039-6257(90)90048-Z
   STREILEIN JW, 1995, EYE, V9, P236, DOI 10.1038/eye.1995.46
   SUBRAMANIAN T, 1995, EXP NEUROL, V131, P157, DOI 10.1016/0014-4886(95)90017-9
   Takeuchi M, 1998, J IMMUNOL, V160, P1589
   TANSLEY K, 1946, J EXP BIOL, V22, P221
   Tezel TH, 1999, INVEST OPHTH VIS SCI, V40, P767
   Tropepe V, 2000, SCIENCE, V287, P2032, DOI 10.1126/science.287.5460.2032
   VanBuskirk AM, 1997, JAMA-J AM MED ASSOC, V278, P1993, DOI 10.1001/jama.278.22.1993
   Villegas-Perez MP, 1998, J COMP NEUROL, V392, P58, DOI 10.1002/(SICI)1096-9861(19980302)392:1<58::AID-CNE5>3.0.CO;2-O
   Wang SM, 2000, INVEST OPHTH VIS SCI, V41, P537
   WEKERLE H, 1987, J EXP BIOL, V132, P43
   Weller M, 1997, GER J OPHTHALMOL, V5, P332
   Wenkel H, 1998, INVEST OPHTH VIS SCI, V39, P1823
   Whiteley SJO, 1996, EXP NEUROL, V140, P100, DOI 10.1006/exnr.1996.0120
   WIDNER H, 1988, BRAIN RES REV, V13, P287, DOI 10.1016/0165-0173(88)90010-0
   WINTON HL, 2000, INVEST OPHTHALMOL VI, V41
   Woch G, 2001, INVEST OPHTH VIS SCI, V42, P1669
   YEE KT, 1990, BRAIN RES, V530, P121, DOI 10.1016/0006-8993(90)90667-Z
   Young MJ, 2000, MOL CELL NEUROSCI, V16, P197, DOI 10.1006/mcne.2000.0869
   Yu DY, 2001, PROG RETIN EYE RES, V20, P175, DOI 10.1016/S1350-9462(00)00027-6
   Zawada WM, 1998, BRAIN RES, V786, P96, DOI 10.1016/S0006-8993(97)01408-X
   Zhang XY, 1998, INVEST OPHTH VIS SCI, V39, P1021
   Zhang YQ, 2003, INVEST OPHTH VIS SCI, V44, P324, DOI 10.1167/iovs.02-0132
NR 136
TC 45
Z9 90
U1 0
U2 4
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0741-5400
EI 1938-3673
J9 J LEUKOCYTE BIOL
JI J. Leukoc. Biol.
PD AUG
PY 2003
VL 74
IS 2
BP 151
EP 160
DI 10.1189/jlb.0103041
PG 10
WC Cell Biology; Hematology; Immunology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Hematology; Immunology
GA 755FC
UT WOS:000187392000002
PM 12885930
DA 2022-11-30
ER

PT J
AU Santos, FM
   Mesquita, J
   Castro-de-Sousa, JP
   Ciordia, S
   Paradela, A
   Tomaz, CT
AF Santos, Fatima Milhano
   Mesquita, Joana
   Castro-de-Sousa, Joao Paulo
   Ciordia, Sergio
   Paradela, Alberto
   Tomaz, Candida Teixeira
TI Vitreous Humor Proteome: Targeting Oxidative Stress, Inflammation, and
   Neurodegeneration in Vitreoretinal Diseases
SO ANTIOXIDANTS
LA English
DT Article
DE age-related macular degeneration; inflammation; neurodegeneration;
   oxidative stress; proliferative diabetic retinopathy; proliferative
   vitreoretinopathy; vitreous proteomics
ID NITRIC-OXIDE SYNTHASE; EPITHELIUM-DERIVED FACTOR; RHEGMATOGENOUS
   RETINAL-DETACHMENT; PROLIFERATIVE DIABETIC-RETINOPATHY; TOTAL
   ANTIOXIDANT CAPACITY; ENDOTHELIAL GROWTH-FACTOR; BETA-AMYLOID
   STIMULATION; AGE-RELATED MACULOPATHY; NF-KAPPA-B; MACULAR DEGENERATION
AB Oxidative stress is defined as an unbalance between pro-oxidants and antioxidants, as evidenced by an increase in reactive oxygen and reactive nitrogen species production over time. It is important in the pathophysiology of retinal disorders such as diabetic retinopathy, age-related macular degeneration, retinal detachment, and proliferative vitreoretinopathy, which are the focus of this article. Although the human organism's defense mechanisms correct autoxidation caused by endogenous or exogenous factors, this may be insufficient, causing an imbalance in favor of excessive ROS production or a weakening of the endogenous antioxidant system, resulting in molecular and cellular damage. Furthermore, modern lifestyles and environmental factors contribute to increased chemical exposure and stress induction, resulting in oxidative stress. In this review, we discuss the current information about oxidative stress and the vitreous proteome with a special focus on vitreoretinal diseases. Additionally, we explore therapies using antioxidants in an attempt to rescue the body from oxidation, restore balance, and maximize healthy body function, as well as new investigational therapies that have shown significant therapeutic potential in preclinical studies and clinical trial outcomes, along with their goals and strategic approaches to combat oxidative stress.
C1 [Santos, Fatima Milhano; Mesquita, Joana; Castro-de-Sousa, Joao Paulo; Tomaz, Candida Teixeira] Univ Beira Interior, CICS UBI Ctr Invest Ciencias Saude, P-6201001 Covilha, Portugal.
   [Santos, Fatima Milhano; Ciordia, Sergio; Paradela, Alberto] CSIC, Ctr Nacl Biotecnol, Unidad Proteom, Campus Cantoblanco, Madrid 28049, Spain.
   [Santos, Fatima Milhano; Tomaz, Candida Teixeira] Univ Beira Interior, Cloud Comp Competence Ctr, C4 UBI, P-6200501 Covilha, Portugal.
   [Castro-de-Sousa, Joao Paulo] Ctr Hosp Leiria, Dept Ophthalmol, P-2410197 Leiria, Portugal.
   [Tomaz, Candida Teixeira] Univ Beira Interior, Fac Sci, Chem Dept, P-6201001 Covilha, Portugal.
C3 Universidade da Beira Interior; Consejo Superior de Investigaciones
   Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB);
   Universidade da Beira Interior; Universidade da Beira Interior
RP Santos, FM; Tomaz, CT (通讯作者)，Univ Beira Interior, CICS UBI Ctr Invest Ciencias Saude, P-6201001 Covilha, Portugal.; Santos, FM (通讯作者)，CSIC, Ctr Nacl Biotecnol, Unidad Proteom, Campus Cantoblanco, Madrid 28049, Spain.; Santos, FM; Tomaz, CT (通讯作者)，Univ Beira Interior, Cloud Comp Competence Ctr, C4 UBI, P-6200501 Covilha, Portugal.; Tomaz, CT (通讯作者)，Univ Beira Interior, Fac Sci, Chem Dept, P-6201001 Covilha, Portugal.
EM fr.milhano@cnb.csic.es; joanamesquita3@gmail.com;
   jpcastrosousa@netcabo.pt; sciordia@cnb.csic.es;
   alberto.paradela@cnb.csic.es; ctomaz@ubi.pt
RI ; Tomaz, Candida/F-9367-2014
OI Ciordia, Sergio/0000-0002-5726-853X; Tomaz, Candida/0000-0002-0927-2331
FU CICS-UBI [UIDB/00709/2020, UIDP/00709/2020]; national funds through the
   Portuguese Foundation for Science and Technology/MCTES - European
   Regional Development Fund
FX This work was developed within the scope of the CICS-UBI projects
   UIDB/00709/2020 and UIDP/00709/2020, financed by national funds through
   the Portuguese Foundation for Science and Technology/MCTES. It was also
   funded by the European Regional Development Fund through the "Programa
   Operacional Regional do Centro (Centro 2020)-Sistema de Apoio a
   Investigacao Cientifica e Tecnologica-Programas Integrados de IC&DT",
   Centro-01-0145-FEDER-000019-C4-Centro de Competencias em Cloud
   Computing.
CR Abu El-Asrar AM, 2013, J DIABETES RES, V2013, DOI 10.1155/2013/539658
   Abu El-Asrar AM, 2010, MOL VIS, V16, P1098
   Akama KT, 2000, J BIOL CHEM, V275, P7918, DOI 10.1074/jbc.275.11.7918
   Ambati J, 2013, NAT REV IMMUNOL, V13, P438, DOI 10.1038/nri3459
   An E, 2006, J PROTEOME RES, V5, P2599, DOI 10.1021/pr060121j
   Ankamah E, 2020, ANTIOXIDANTS-BASEL, V9, DOI 10.3390/antiox9010007
   Apte RS, 2021, NEW ENGL J MED, V385, P539, DOI 10.1056/NEJMcp2102061
   Araujo RS, 2021, GENE, V791, DOI 10.1016/j.gene.2021.145724
   Armento A, 2021, CELL MOL LIFE SCI, V78, P4487, DOI 10.1007/s00018-021-03796-9
   Arner ESJ, 2000, EUR J BIOCHEM, V267, P6102, DOI 10.1046/j.1432-1327.2000.01701.x
   Awata T, 2004, DIABETES CARE, V27, P2184, DOI 10.2337/diacare.27.9.2184
   Domenech EB, 2020, ANTIOXIDANTS-BASEL, V9, DOI 10.3390/antiox9040347
   BAGGIO E, 1993, CLIN INVESTIGATOR, V71, pS145
   Baillie JK, 2007, CHEST, V131, P1473, DOI 10.1378/chest.06-2235
   Balaiya Sankarathi, 2017, Proteomics Insights, V8, p1178641816686078, DOI 10.1177/1178641816686078
   Bhosale P, 2004, J BIOL CHEM, V279, P49447, DOI 10.1074/jbc.M405334200
   Blasiak J, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/768026
   Bokhary K, 2021, OPHTHALMIC RES, V64, P613, DOI 10.1159/000514722
   Bonilha VL, 2018, ADV EXP MED BIOL, V1074, P3, DOI 10.1007/978-3-319-75402-4_1
   Bonilha VL, 2017, FREE RADICAL BIO MED, V104, P226, DOI 10.1016/j.freeradbiomed.2017.01.018
   Bonilha VL, 2015, EXP EYE RES, V139, P22, DOI 10.1016/j.exer.2015.07.014
   Brown EE, 2019, REDOX BIOL, V24, DOI 10.1016/j.redox.2019.101201
   Brzovic-Saric V, 2015, MOL VIS, V21, P649
   Cai WT, 2016, BMC OPHTHALMOL, V16, DOI 10.1186/s12886-016-0373-3
   Cano M, 2021, AGING CELL, V20, DOI 10.1111/acel.13444
   Pastor JC, 2016, PROG RETIN EYE RES, V51, P125, DOI 10.1016/j.preteyeres.2015.07.005
   Carmo A, 2000, NITRIC OXIDE-BIOL CH, V4, P590, DOI 10.1006/niox.2000.0312
   Cecilia OM, 2019, J DIABETES RES, V2019, DOI 10.1155/2019/8562408
   Cederlund M, 2013, GRAEF ARCH CLIN EXP, V251, P725, DOI 10.1007/s00417-012-2113-6
   Chaudhary R, 2020, TRANSL VIS SCI TECHN, V9, DOI 10.1167/tvst.9.3.23
   Chelikani P, 2004, CELL MOL LIFE SCI, V61, P192, DOI 10.1007/s00018-003-3206-5
   Chen W, 2017, CLIN EXP OPHTHALMOL, V45, P379, DOI 10.1111/ceo.12891
   Chen WH, 1998, EXP EYE RES, V67, P83, DOI 10.1006/exer.1998.0494
   Colak E, 2019, HANDBOOK OF NUTRITION, DIET, AND THE EYE, 2ND EDITION, P85, DOI 10.1016/B978-0-12-815245-4.00006-5
   Colak E, 2018, CURR EYE RES, V43, P659, DOI 10.1080/02713683.2018.1437452
   Combs CK, 2001, J NEUROSCI, V21, P1179
   Constable I. J., 2013, RETINA-J RET VIT DIS, V5th, P1806
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   DANSER AHJ, 1994, INVEST OPHTH VIS SCI, V35, P1008
   Datta S, 2017, PROG RETIN EYE RES, V60, P201, DOI 10.1016/j.preteyeres.2017.03.002
   Davies MJ, 2020, ANTIOXID REDOX SIGN, V32, P957, DOI 10.1089/ars.2020.8030
   de Campos TDP, 2021, MOL BIOL REP, V48, P4637, DOI 10.1007/s11033-021-06419-5
   de Jong S, 2021, PROG RETIN EYE RES, V84, DOI 10.1016/j.preteyeres.2021.100952
   Delgadillo A.T., CLINICALTRIALS GOV I
   Deliyanti D, 2018, INVEST OPHTH VIS SCI, V59, P815, DOI 10.1167/iovs.17-22920
   Di Lorenzo A, 2014, J CELL SCI, V127, P2120, DOI 10.1242/jcs.153601
   Di Meo S, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/1245049
   Diederen RMH, 2006, GRAEF ARCH CLIN EXP, V244, P683, DOI 10.1007/s00417-005-0141-1
   Dixit S, 2020, EXP EYE RES, V198, DOI 10.1016/j.exer.2020.108121
   Pinazo-Duran MD, 2014, CLIN INTERV AGING, V9, P637, DOI 10.2147/CIA.S52662
   Du XL, 1999, FREE RADICAL BIO MED, V27, P752, DOI 10.1016/S0891-5849(99)00079-9
   Du Y, 2013, P NATL ACAD SCI USA, V110, P16586, DOI 10.1073/pnas.1314575110
   Duh EJ, 2004, AM J OPHTHALMOL, V137, P668, DOI 10.1016/j.ajo.2003.11.015
   Duh EJ, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.93751
   El-Asrar AM, 2001, AM J OPHTHALMOL, V132, P551, DOI 10.1016/S0002-9394(01)01127-8
   El-Sohemy A, 2002, AM J CLIN NUTR, V76, P172, DOI 10.1093/ajcn/76.1.172
   Ellis EA, 2002, NITRIC OXIDE-BIOL CH, V6, P295, DOI 10.1006/niox.2001.0419
   Erdogan C, 2003, OPHTHALMIC RES, V35, P251, DOI 10.1159/000072145
   Evelson P, 2001, ARCH BIOCHEM BIOPHYS, V388, P261, DOI 10.1006/abbi.2001.2292
   Feltgen N, 2014, DTSCH ARZTEBL INT, V111, P12, DOI 10.3238/arztebl.2014.0012
   Feng L, 2019, DISCOV MED, V27, P153
   Feng LW, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0227048
   Hernandez-Zimbron LF, 2018, OXID MED CELL LONGEV, V2018, DOI 10.1155/2018/8374647
   Figueira J, 2021, CLIN OPHTHALMOL, V15, P3221, DOI 10.2147/OPTH.S318026
   Fini ME, 2016, EXP EYE RES, V147, P57, DOI 10.1016/j.exer.2016.04.019
   Forman HJ, 2021, NAT REV DRUG DISCOV, V20, P689, DOI 10.1038/s41573-021-00233-1
   Fort PE, 2011, EXP EYE RES, V92, P98, DOI 10.1016/j.exer.2010.11.008
   Fu ZJ, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21041503
   Fu ZJ, 2018, DIABETES, V67, P974, DOI 10.2337/db17-0830
   Ganea E, 2006, CURR EYE RES, V31, P1, DOI 10.1080/02713680500477347
   Gao BB, 2008, J PROTEOME RES, V7, P2516, DOI 10.1021/pr800112g
   Garcia-Ramirez M, 2007, DIABETOLOGIA, V50, P1294, DOI 10.1007/s00125-007-0627-y
   Gardner TW, 2017, VISION RES, V139, P153, DOI 10.1016/j.visres.2017.03.006
   Garweg JG, 2013, SURV OPHTHALMOL, V58, P321, DOI 10.1016/j.survophthal.2012.12.004
   Gaspar LM, 2017, J CHROMATOGR B, V1061, P334, DOI 10.1016/j.jchromb.2017.07.049
   Geerlings MJ, 2017, MOL IMMUNOL, V84, P65, DOI 10.1016/j.molimm.2016.11.016
   Gehl Z, 2016, REDOX BIOL, V9, P100, DOI 10.1016/j.redox.2016.07.003
   Gharibyan AL, 2020, BIOMOLECULES, V10, DOI 10.3390/biom10010134
   Ghosh S, 2021, COMMUN BIOL, V4, DOI 10.1038/s42003-021-01763-5
   Golestaneh N, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2016.453
   Guariguata L, 2014, DIABETES RES CLIN PR, V103, P137, DOI 10.1016/j.diabres.2013.11.002
   Gupta V, 2016, CELL MOL LIFE SCI, V73, P4279, DOI 10.1007/s00018-016-2295-x
   Hamadmad S, 2019, EXP EYE RES, V189, DOI 10.1016/j.exer.2019.107811
   Hatters DM, 2002, EUR J BIOCHEM, V269, P2789, DOI 10.1046/j.1432-1033.2002.02957.x
   Haugstad M, 2017, ACTA OPHTHALMOL, V95, P247, DOI 10.1111/aos.13295
   Herrera E, 2001, J PHYSIOL BIOCHEM, V57, P43, DOI 10.1007/BF03179812
   Hoerster R, 2017, GRAEF ARCH CLIN EXP, V255, P1721, DOI 10.1007/s00417-017-3707-9
   Holappa M, 2017, OPEN OPHTHALMOL J, V11, P122, DOI 10.2174/1874364101711010122
   Holekamp NM, 2002, AM J OPHTHALMOL, V134, P220, DOI 10.1016/S0002-9394(02)01549-0
   Hsu MY, 2021, ANTIOXIDANTS-BASEL, V10, DOI 10.3390/antiox10071125
   Hyttinen JMT, 2017, AGEING RES REV, V36, P64, DOI 10.1016/j.arr.2017.03.006
   Idrees Sana, 2019, Int Ophthalmol Clin, V59, P221, DOI 10.1097/IIO.0000000000000258
   Imamura Y, 2006, P NATL ACAD SCI USA, V103, P11282, DOI 10.1073/pnas.0602131103
   Imlay JA, 2003, ANNU REV MICROBIOL, V57, P395, DOI 10.1146/annurev.micro.57.030502.090938
   Inagaki Y, 2003, DIABETOLOGIA, V46, P284, DOI 10.1007/s00125-002-1013-4
   Izuta H, 2010, MOL VIS, V16, P130
   Jabbehdari S, 2021, SURV OPHTHALMOL, V66, P423, DOI 10.1016/j.survophthal.2020.09.002
   Jing-Xu, 2018, CELL PHYSIOL BIOCHEM, V48, P705, DOI 10.1159/000491897
   Johnson LV, 2002, P NATL ACAD SCI USA, V99, P11830, DOI 10.1073/pnas.192203399
   Kaludercic N, 2020, FRONT CARDIOVASC MED, V7, DOI 10.3389/fcvm.2020.00012
   Kang GY, 2014, J PROTEOME RES, V13, P581, DOI 10.1021/pr400751k
   Kang MK, 2018, NUTRIENTS, V10, DOI 10.3390/nu10081046
   Kang QZ, 2020, REDOX BIOL, V37, DOI 10.1016/j.redox.2020.101799
   Kannan R, 2012, PROG RETIN EYE RES, V31, P576, DOI 10.1016/j.preteyeres.2012.06.001
   Kase S, 2011, INT J MOL MED, V28, P505, DOI 10.3892/ijmm.2011.708
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Katagiri M, 2018, INT OPHTHALMOL, V38, P607, DOI 10.1007/s10792-017-0499-1
   Kawa MP, 2014, J IMMUNOL RES, V2014, DOI 10.1155/2014/483960
   Kayama M, 2011, AM J PATHOL, V178, P1080, DOI 10.1016/j.ajpath.2010.11.072
   Kern TS, 2017, VISION RES, V139, P65, DOI 10.1016/j.visres.2017.03.011
   Kim JH, 2010, INVEST OPHTH VIS SCI, V51, P561, DOI 10.1167/iovs.09-3774
   Kim K, 2010, J PROTEOME RES, V9, P689, DOI 10.1021/pr901013d
   Kim SJ, 2006, CURR EYE RES, V31, P231, DOI 10.1080/02713680600557030
   Klaassen I, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0187304
   KLIFFEN M, 1995, LAB INVEST, V73, P267
   Klocker N, 1998, J NEUROSCI, V18, P1038
   Ko JA, 2017, CELL BIOCHEM FUNCT, V35, P426, DOI 10.1002/cbf.3292
   Kon CH, 1998, INVEST OPHTH VIS SCI, V39, P1524
   Koskela UE, 2013, OPHTHALMIC RES, V49, P108, DOI 10.1159/000342977
   Koss MJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096895
   Kowluru RA, 2004, BRIT J OPHTHALMOL, V88, P1343, DOI 10.1136/bjo.2003.038133
   Krohne TU, 2010, EXP EYE RES, V90, P465, DOI 10.1016/j.exer.2009.12.011
   Kuhn F, 2014, OPHTHALMIC RES, V51, P15, DOI 10.1159/000355077
   Kumita JR, 2007, J MOL BIOL, V369, P157, DOI 10.1016/j.jmb.2007.02.095
   Kwon OW, 2016, DEV OPHTHALMOL, V55, P154, DOI 10.1159/000438972
   Kwon YH, 2017, AUTOPHAGY: CANCER, OTHER PATHOLOGIES, INFLAMMATION, IMMUNITY, INFECTION, AND AGING, VOL 11, P105, DOI 10.1016/B978-0-12-805420-8.00003-2
   Lechner J, 2017, VISION RES, V139, P7, DOI 10.1016/j.visres.2017.04.003
   Lee SM, 2002, FREE RADICAL BIO MED, V32, P1185, DOI 10.1016/S0891-5849(02)00815-8
   Lee WH, 2014, ADV EXP MED BIOL, V801, P23, DOI 10.1007/978-1-4614-3209-8_4
   Lei H, 2010, AM J PATHOL, V177, P132, DOI 10.2353/ajpath.2010.090604
   Leveillard T, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20030762
   Li C, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/9702820
   Li JQ, 2019, OPHTHALMOLOGICA, V242, P81, DOI 10.1159/000499489
   Liang FQ, 2005, EXP EYE RES, V80, P113, DOI 10.1016/j.exer.2004.08.017
   Liu HT, 2016, INVEST OPHTH VIS SCI, V57, P4272, DOI 10.1167/iovs.16-19415
   Liu QY, 2016, INT J CLIN EXP PATHO, V9, P2998
   Lo ACY, 2011, OPHTHALMOLOGICA, V226, P10, DOI 10.1159/000328206
   Losiewicz MK, 2011, INVEST OPHTH VIS SCI, V52, P5034, DOI 10.1167/iovs.10-6931
   Loukovaara S, 2015, J PROTEOME RES, V14, P5131, DOI 10.1021/acs.jproteome.5b00900
   Luibl V, 2006, J CLIN INVEST, V116, P378, DOI 10.1172/JCI25843
   Lumi X, 2015, AGEING RES REV, V21, P71, DOI 10.1016/j.arr.2015.03.006
   Lushchak VI, 2014, CHEM-BIOL INTERACT, V224, P164, DOI 10.1016/j.cbi.2014.10.016
   Maeno A, 2016, ACTA OPHTHALMOL, V94, pE515, DOI 10.1111/aos.13002
   Mahajan N, 2019, OXID MED CELL LONGEV, V2019, DOI 10.1155/2019/8458472
   Mancino R, 2011, MOL VIS, V17, P1298
   Mantopoulos D, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024245
   Marmorstein LHY, 2002, P NATL ACAD SCI USA, V99, P13067, DOI 10.1073/pnas.202491599
   Masuda T, 2015, EUR J PHARMACOL, V749, P161, DOI 10.1016/j.ejphar.2014.10.007
   MEISTER A, 1983, ANNU REV BIOCHEM, V52, P711, DOI 10.1146/annurev.bi.52.070183.003431
   Milani P, 2013, OXID MED CELL LONGEV, V2013, DOI 10.1155/2013/836760
   Miller DJ, 2020, ANTIOXIDANTS-BASEL, V9, DOI 10.3390/antiox9100905
   Minamoto Atsushi, 2007, P495, DOI 10.1007/978-1-59745-432-2_23
   Mishra A, 2010, GLIA, V58, P1996, DOI 10.1002/glia.21068
   Mitry D, 2010, BRIT J OPHTHALMOL, V94, P678, DOI 10.1136/bjo.2009.157727
   Moran EP, 2016, AM J PHYSIOL-HEART C, V311, pH738, DOI 10.1152/ajpheart.00005.2016
   Murakami Y, 2013, PROG RETIN EYE RES, V37, P114, DOI 10.1016/j.preteyeres.2013.08.001
   Nagai N, 2017, TOXICOLOGY, V381, P19, DOI 10.1016/j.tox.2017.02.014
   Nagai N, 2007, INVEST OPHTH VIS SCI, V48, P4342, DOI 10.1167/iovs.06-1473
   Nakagami Y, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/7469326
   Nakamura T, 2020, ANTIOXID REDOX SIGN, V32, P817, DOI 10.1089/ars.2019.7916
   Nawaz IM, 2019, PROG RETIN EYE RES, V72, DOI 10.1016/j.preteyeres.2019.03.002
   Nemet A, 2017, J OPHTHALMOL, V2017, DOI 10.1155/2017/4310643
   Nielsen BR, 2020, ACTA OPHTHALMOL, V98, P603, DOI 10.1111/aos.14380
   Nita M, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/3164734
   Nobl M, 2016, EXP EYE RES, V146, P107, DOI 10.1016/j.exer.2016.01.001
   Notomi S, 2019, P NATL ACAD SCI USA, V116, P23724, DOI 10.1073/pnas.1906643116
   Ohman T, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-020-80005-w
   Okamoto T, 1997, ARCH BIOCHEM BIOPHYS, V342, P261, DOI 10.1006/abbi.1997.0127
   Olson KR, 2020, J EXP BIOL, V223, DOI 10.1242/jeb.196352
   Opatrilova R, 2018, ACTA OPHTHALMOL, V96, P222, DOI 10.1111/aos.13384
   Ozawa Y, 2020, REDOX BIOL, V37, DOI 10.1016/j.redox.2020.101779
   Paraoan L, 2020, PROG RETIN EYE RES, V79, DOI 10.1016/j.preteyeres.2020.100859
   Park K, 2011, AM J PATHOL, V178, P688, DOI 10.1016/j.ajpath.2010.10.014
   Parvez S, 2018, CHEM REV, V118, P8798, DOI 10.1021/acs.chemrev.7b00698
   Payne AJ, 2014, INT J MOL SCI, V15, P1865, DOI 10.3390/ijms15021865
   Phipps JA, 2019, EXP EYE RES, V187, DOI 10.1016/j.exer.2019.107753
   Pietras-Baczewska A, 2021, LIFE-BASEL, V11, DOI 10.3390/life11050453
   Pillar S, 2020, J DIABETES RES, V2020, DOI 10.1155/2020/5728674
   Pisoschi AM, 2021, EUR J MED CHEM, V209, DOI 10.1016/j.ejmech.2020.112891
   Powell SR, 2000, J NUTR, V130, p1447S, DOI 10.1093/jn/130.5.1447S
   Ramasamy R, 2011, ANN NY ACAD SCI, V1243, P88, DOI 10.1111/j.1749-6632.2011.06320.x
   Ratnayaka JA, 2015, EYE, V29, P1013, DOI 10.1038/eye.2015.100
   Ren LL, 2019, FREE RADICAL BIO MED, V145, P357, DOI 10.1016/j.freeradbiomed.2019.10.008
   Rhee SG, 2005, FREE RADICAL BIO MED, V38, P1543, DOI 10.1016/j.freeradbiomed.2005.02.026
   Richer S., 2016, ADV OPHTHALMOL OPTOM, V1, P335, DOI [10.1016/j.yaoo.2016.03.018, DOI 10.1016/J.YAOO.2016.03.018]
   Rinaldi C, 2021, LIFE-BASEL, V11, DOI 10.3390/life11080767
   Rinsky B, 2021, INVEST OPHTH VIS SCI, V62, DOI 10.1167/iovs.62.10.18
   Rivera JC, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/3940241
   Rodriguez ML, 2019, OXID MED CELL LONGEV, V2019, DOI 10.1155/2019/4940825
   Roh MI, 2011, INVEST OPHTH VIS SCI, V52, P3825, DOI 10.1167/iovs.10-6797
   Rohowetz LJ, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19113362
   Romero-Vazquez S, 2021, BIOMEDICINES, V9, DOI 10.3390/biomedicines9070763
   Rossino MG, 2019, FRONT NEUROSCI-SWITZ, V13, DOI 10.3389/fnins.2019.01172
   Ruan Y, 2020, ANTIOXIDANTS-BASEL, V9, DOI 10.3390/antiox9080761
   Ruebsam A, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.97919
   Sakaguchi H, 2002, EXP EYE RES, V74, P547, DOI 10.1006/exer.2002.1186
   Macarro MS, 2021, ANTIOXIDANTS-BASEL, V10, DOI 10.3390/antiox10020323
   SanGiovanni JP, 2008, ARCH OPHTHALMOL-CHIC, V126, P1274, DOI 10.1001/archopht.126.9.1274
   Santiago AR, 2018, FRONT PHYSIOL, V9, DOI 10.3389/fphys.2018.00820
   Santos FM, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19041157
   Schiapaccassa A, 2019, DIABETOL METAB SYNDR, V11, DOI 10.1186/s13098-019-0466-2
   Schmaier AH, 2003, AM J PHYSIOL-REG I, V285, pR1, DOI 10.1152/ajpregu.00535.2002
   Schmaier AH, 2002, J CLIN INVEST, V109, P1007, DOI 10.1172/JCI200215490
   Schori C, 2018, INVEST OPHTH VIS SCI, V59, DOI 10.1167/iovs.18-24122
   Scimone C, 2021, EXP EYE RES, V209, DOI 10.1016/j.exer.2021.108641
   Sebag J, 2020, PROG RETIN EYE RES, V79, DOI 10.1016/j.preteyeres.2020.100847
   Seddon JM, 2006, ARCH OPHTHALMOL-CHIC, V124, P995, DOI 10.1001/archopht.124.7.995
   Seider N, 2003, AM J OPHTHALMOL, V136, P911, DOI 10.1016/S0002-9394(03)00575-0
   Sethi CS, 2000, BRIT J OPHTHALMOL, V84, P654, DOI 10.1136/bjo.84.6.654
   Sharifi-Rad M, 2020, FRONT PHYSIOL, V11, DOI 10.3389/fphys.2020.00694
   Sharma T, 2016, CLIN EXP OPHTHALMOL, V44, P340, DOI 10.1111/ceo.12752
   Shea TB, 2002, FREE RADICAL BIO MED, V33, P1115, DOI 10.1016/S0891-5849(02)01001-8
   Shitama T, 2008, PROTEOM CLIN APPL, V2, P1265, DOI 10.1002/prca.200800017
   Shu YY, 2021, FRONT MOL BIOSCI, V8, DOI 10.3389/fmolb.2021.763002
   Sies H, 1997, EXP PHYSIOL, V82, P291, DOI 10.1113/expphysiol.1997.sp004024
   Sies H, 2020, ANTIOXIDANTS-BASEL, V9, DOI 10.3390/antiox9090852
   Sies Helmut, 2018, Current Opinion in Toxicology, V7, P122, DOI 10.1016/j.cotox.2018.01.002
   Simo-Servat O, 2019, OPHTHALMIC RES, V62, P211, DOI 10.1159/000499541
   Sinha D, 2016, EXP EYE RES, V144, P46, DOI 10.1016/j.exer.2015.08.018
   Smirnoff N, 2001, VITAM HORM, V61, P241
   Smith W, 1999, OPHTHALMOLOGY, V106, P761, DOI 10.1016/S0161-6420(99)90164-1
   Sreekumar PG, 2021, ANTIOXIDANTS-BASEL, V10, DOI 10.3390/antiox10050661
   Srividya G, 2018, EYE, V32, P820, DOI 10.1038/eye.2017.285
   Starkov AA, 2008, ANN NY ACAD SCI, V1147, P37, DOI 10.1196/annals.1427.015
   Sultan ZN, 2020, BMJ OPEN OPHTHALMOL, V5, DOI 10.1136/bmjophth-2020-000474
   Supuran CT, 2019, EXPERT OPIN THER PAT, V29, P761, DOI 10.1080/13543776.2019.1671353
   Suzuki Y, 2011, JPN J OPHTHALMOL, V55, P256, DOI 10.1007/s10384-011-0004-8
   Suzuki Y, 2019, GRAEF ARCH CLIN EXP, V257, P1519, DOI 10.1007/s00417-019-04343-w
   Symeonidis C, 2007, RETINA-J RET VIT DIS, V27, P1279, DOI 10.1097/IAE.0b013e3180592c00
   Symeonidis C, 2007, GRAEF ARCH CLIN EXP, V245, P560, DOI 10.1007/s00417-006-0386-3
   Symeonidis C, 2011, ACTA OPHTHALMOL, V89, P339, DOI 10.1111/j.1755-3768.2009.01701.x
   Szklarczyk D, 2019, NUCLEIC ACIDS RES, V47, pD607, DOI 10.1093/nar/gky1131
   Takahashi S., 2017, J CLIN EXP OPHTHALMO, V6, P682, DOI [10.4172/2155-9570.1000682, DOI 10.4172/2155-9570.1000682]
   Tamiya S, 2010, INVEST OPHTH VIS SCI, V51, P2755, DOI 10.1167/iovs.09-4725
   Tan DX, 2007, J PINEAL RES, V42, P28, DOI 10.1111/j.1600-079X.2006.00407.x
   TEICHERT J, 1992, INT J CLIN PHARM TH, V30, P511
   Tinggi Ujang, 2008, Environmental Health and Preventive Medicine, V13, P102, DOI 10.1007/s12199-007-0019-4
   Toda N, 2007, PROG RETIN EYE RES, V26, P205, DOI 10.1016/j.preteyeres.2007.01.004
   Toma C, 2021, ANTIOXIDANTS-BASEL, V10, DOI 10.3390/antiox10050653
   Toomey CB, 2018, PROG RETIN EYE RES, V62, P38, DOI 10.1016/j.preteyeres.2017.09.001
   Trinity J.D., CLINICALTRIALS GOV I
   Tsai T, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0194603
   Tsao YP, 2006, LIFE SCI, V79, P545, DOI 10.1016/j.lfs.2006.01.041
   Tseng CF, 2004, PROTEOMICS, V4, P2221, DOI 10.1002/pmic.200300787
   Urbak Larke, 2010, Int J Proteomics, V2010, P479571, DOI 10.1155/2010/479571
   Ursini F, 2016, REDOX BIOL, V8, P205, DOI 10.1016/j.redox.2016.01.010
   Van Lint P, 2006, CYTOKINE GROWTH F R, V17, P217, DOI 10.1016/j.cytogfr.2006.04.001
   VandenLangenberg GM, 1998, AM J EPIDEMIOL, V148, P204, DOI 10.1093/oxfordjournals.aje.a009625
   Verges B., CLINICALTRIALS GOV I
   Vielma AH, 2012, BRAIN RES, V1430, P112, DOI 10.1016/j.brainres.2011.10.045
   Villarejo-Zori B, 2021, MOL ASPECTS MED, V82, DOI 10.1016/j.mam.2021.101038
   Villegas-Rivera G, 2015, OXID MED CELL LONGEV, V2015, DOI 10.1155/2015/756294
   Wan PX, 2017, CLIN SCI, V131, P2363, DOI 10.1042/CS20171182
   Wang AL, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004160
   Wang H, 2013, EXP EYE RES, V108, P110, DOI 10.1016/j.exer.2012.11.023
   Wang H, 2012, PROTEOME SCI, V10, DOI 10.1186/1477-5956-10-15
   Wang JY, 2008, J IMMUNOL, V181, P712, DOI 10.4049/jimmunol.181.1.712
   Wang L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010329
   Wang W, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19061816
   Wang X, 2019, MOL MED REP, V19, P59, DOI 10.3892/mmr.2018.9645
   Wang X, 2019, INT OPHTHALMOL, V39, P2303, DOI 10.1007/s10792-018-01071-8
   Wang ZQ, 2011, ANN NEUROL, V70, P591, DOI 10.1002/ana.22514
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   World Health Organization, 2019, WORLD REP VIS, V214
   Wu KC, 2011, TOXICOL SCI, V123, P590, DOI 10.1093/toxsci/kfr183
   Wu ZF, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17122052
   Xiao JH, 2021, EXP EYE RES, V205, DOI 10.1016/j.exer.2021.108492
   Xie XL, 2019, BIOMED RES INT, V2019, DOI 10.1155/2019/9732325
   Xu HP, 2009, PROG RETIN EYE RES, V28, P348, DOI 10.1016/j.preteyeres.2009.06.001
   Yamagishi S, 2006, J BIOL CHEM, V281, P20213, DOI 10.1074/jbc.M602110200
   Yamane K, 2003, MOL CELL PROTEOMICS, V2, P1177, DOI 10.1074/mcp.M300038-MCP200
   Yamashita S, 2010, J NEUROCHEM, V113, P860, DOI 10.1111/j.1471-4159.2010.06658.x
   Yang IH, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-60785-x
   Yaung J, 2007, MOL VIS, V13, P566
   Yerbury JJ, 2007, FASEB J, V21, P2312, DOI 10.1096/fj.06-7986com
   Yilmaz G, 2000, AM J OPHTHALMOL, V130, P87, DOI 10.1016/S0002-9394(00)00398-6
   Yokoi M, 2007, BRIT J OPHTHALMOL, V91, P885, DOI 10.1136/bjo.2006.110890
   Yonekawa Y, 2015, J CLIN MED, V4, P343, DOI 10.3390/jcm4020343
   Yu B, 2018, SCI SIGNAL, V11, DOI 10.1126/scisignal.aag3315
   Yu J, 2008, PROTEOMICS, V8, P3667, DOI 10.1002/pmic.200700824
   Yu J, 2014, CLIN EXP OPTOM, V97, P72, DOI 10.1111/cxo.12088
   Yu J, 2012, INVEST OPHTH VIS SCI, V53, P8146, DOI 10.1167/iovs.12-10079
   Yuan XL, 2010, MOL CELL PROTEOMICS, V9, P1031, DOI 10.1074/mcp.M900523-MCP200
   Yuasa I, 2008, JPN J OPHTHALMOL, V52, P314, DOI 10.1007/s10384-008-0542-x
   Yumnamcha T, 2020, ANTIOXIDANTS-BASEL, V9, DOI 10.3390/antiox9121244
   Zelko IN, 2002, FREE RADICAL BIO MED, V33, P337, DOI 10.1016/S0891-5849(02)00905-X
   Zhang M, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-59244-4
   Zhang X, 2013, CURR MOL MED, V13, P946
   Zhang ZY, 2020, OXID MED CELL LONGEV, V2020, DOI 10.1155/2020/2896036
   Zhao C, 2011, J CLIN INVEST, V121, P369, DOI 10.1172/JCI44303
   Zhao ZY, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019456
   Zhong Q, 2013, INVEST OPHTH VIS SCI, V54, P3941, DOI 10.1167/iovs.13-11598
   Zhou P, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098275
   Zhu YF, 2019, INVEST OPHTH VIS SCI, V60, P3740, DOI 10.1167/iovs.19-27212
   Zou C, 2018, CLIN PROTEOM, V15, DOI 10.1186/s12014-018-9187-z
NR 297
TC 2
Z9 2
U1 12
U2 12
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2076-3921
J9 ANTIOXIDANTS-BASEL
JI Antioxidants
PD MAR
PY 2022
VL 11
IS 3
AR 505
DI 10.3390/antiox11030505
PG 36
WC Biochemistry & Molecular Biology; Chemistry, Medicinal; Food Science &
   Technology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Food Science
   & Technology
GA 0D2VF
UT WOS:000775857800001
PM 35326156
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Bede-Ojimadu, O
   Orish, CN
   Bocca, B
   Ruggieri, F
   Frazzoli, C
   Orisakwe, OE
AF Bede-Ojimadu, Onyinyechi
   Orish, Chinna N.
   Bocca, Beatrice
   Ruggieri, Flavia
   Frazzoli, Chiara
   Orisakwe, Orish E.
TI Trace elements exposure and risk in age-related eye diseases: a
   systematic review of epidemiological evidence
SO JOURNAL OF ENVIRONMENTAL SCIENCE AND HEALTH PART C-TOXICOLOGY AND
   CARCINOGENESIS
LA English
DT Review
DE Age-related eye diseases; blindness; metals; risk assessment; public
   health
ID RETINAL-PIGMENT EPITHELIUM; SERUM ZINC LEVEL; MACULAR DEGENERATION;
   UNITED-STATES; CADMIUM ACCUMULATION; LEAD-EXPOSURE; VITAMIN-E; DIETARY
   ANTIOXIDANTS; DIABETIC-RETINOPATHY; CATARACT FORMATION
AB This systematic review aimed to evaluate existing evidence on the associations between trace elements exposure and age-related eye diseases. PubMed and Google scholar databases were searched for epidemiological and postmortem studies on the relationship between exposure to trace elements and Age-related eye diseases such as age-related macular degeneration (AMD), cataract, glaucoma and diabetic retinopathy (DR), in population groups aged 40years and above. Available evidence suggests that cadmium (Cd) exposure may be positively associated with the risks of AMD and cataract. There is also evidence that exposure to lead (Pb) may be positively associated with higher risk of cataract and glaucoma. There is limited number of relevant studies and lack of prospective studies for most of the investigated associations. Evidence for other trace elements is weak and inconsistent, and the number of available studies is small. Likewise, there are very few relevant studies on the role of trace elements in DR. Chemical elements that affect the distribution and absorption of other trace elements have never been investigated. The suggestive but limited evidence motivates large and quality prospective studies to fully characterize the impact of exposure to trace (toxic and essential) elements on age-related eye diseases.
C1 [Bede-Ojimadu, Onyinyechi] Nnamdi Azikiwe Univ, Fac Med, Dept Chem Pathol, Nnewi, Nigeria.
   [Orish, Chinna N.] Univ Port Harcourt, Coll Hlth Sci, Fac Basic Med Sci, Dept Anat, Port Harcourt, Choba, Nigeria.
   [Bocca, Beatrice; Ruggieri, Flavia] Ist Super Sanita, Dept Environm & Hlth, Rome, Italy.
   [Frazzoli, Chiara] Ist Super Sanita, Dept Cardiovasc & Endocrine Metabol Dis & Ageing, Rome, Italy.
   [Orisakwe, Orish E.] Univ Port Harcourt, African Ctr Excellence Publ Hlth & Toxicol Res AC, Port Harcourt, Rivers, Nigeria.
C3 University of Port Harcourt; Istituto Superiore di Sanita (ISS);
   Istituto Superiore di Sanita (ISS); University of Port Harcourt
RP Orisakwe, OE (通讯作者)，Univ Port Harcourt, World Bank Africa, Ctr Excellence Publ Hlth & Toxicol Res PUTOR, PMB 5323, Port Harcourt, Rivers, Nigeria.
EM orishebere@gmail.com
RI ORISAKWE, ORISH EBERE/X-5852-2019; Bede-Ojimadu,
   Onyinyechi/ABC-7982-2021; Bede-Ojimadu, Onyinyechi/AAS-6849-2021;
   Frazzoli, Chiara/F-4395-2015
OI ORISAKWE, ORISH EBERE/0000-0002-5806-9858; Bede-Ojimadu,
   Onyinyechi/0000-0002-2049-8315; Ruggieri, Flavia/0000-0002-5161-8615;
   Frazzoli, Chiara/0000-0001-6802-2861
CR Abbafati C., 2018, Lancet, V392, P1789, DOI 10.1016/s0140-6736(18)32279-7
   Aberami S, 2019, EXP EYE RES, V186, DOI 10.1016/j.exer.2019.107718
   Aguirre JD, 2012, J BIOL CHEM, V287, P13541, DOI 10.1074/jbc.R111.312181
   Anyanwu BO, 2018, TOXICS, V6, DOI 10.3390/toxics6040065
   Aoki A, 2016, SCI REP-UK, V6, DOI 10.1038/srep20723
   Araujo JA, 2012, FRONT PHARMACOL, V3, DOI 10.3389/fphar.2012.00119
   Avunduk AM, 1999, CURR EYE RES, V18, P403, DOI 10.1076/ceyr.18.6.403.5268
   Bailey RL, 2015, ANN NUTR METAB, V66, P22, DOI 10.1159/000371618
   Bastawrous A, 2017, JAMA OPHTHALMOL, V135, P631, DOI 10.1001/jamaophthalmol.2017.1109
   Bede-Ojimadu O, 2018, FRONT PUBLIC HEALTH, V6, DOI 10.3389/fpubh.2018.00367
   Biesemeier A, 2015, EXP EYE RES, V137, P39, DOI 10.1016/j.exer.2015.05.019
   Bocca B, 2020, J TRACE ELEM MED BIO, V61, DOI 10.1016/j.jtemb.2020.126560
   Bourne RRA, 2018, BRIT J OPHTHALMOL, V102, P575, DOI 10.1136/bjophthalmol-2017-311258
   Cabrera Marcela P, 2011, Vet Med Int, V2011, P905153, DOI 10.4061/2011/905153
   Cekic O, 1998, OPHTHALMIC RES, V30, P49, DOI 10.1159/000055454
   Cekic O, 1999, OPHTHALMIC RES, V31, P332, DOI 10.1159/000055555
   Ceylan OM, 2013, BIOL TRACE ELEM RES, V153, P28, DOI 10.1007/s12011-013-9644-5
   Chakraborty I, 2007, INDIAN J CLIN BIOCHE, V22, P109, DOI 10.1007/BF02913326
   Chan EW, 2016, BRIT J OPHTHALMOL, V100, P78, DOI 10.1136/bjophthalmol-2014-306102
   Chang L, 2018, ANN TRANSL MED, V6, DOI 10.21037/atm.2018.08.09
   Chen HY, 2009, NEUROBIOL AGING, V30, P1865, DOI 10.1016/j.neurobiolaging.2008.01.002
   Cheng A. C. K., 2000, Hong Kong Medical Journal, V6, P195
   Chong EWT, 2007, BMJ-BRIT MED J, V335, P755, DOI 10.1136/bmj.39350.500428.47
   Christen WG, 2015, JAMA OPHTHALMOL, V133, P17, DOI 10.1001/jamaophthalmol.2014.3478
   Colak E, 2018, CURR EYE RES, V43, P659, DOI 10.1080/02713683.2018.1437452
   Colijn JM, 2017, OPHTHALMOLOGY, V124, P1753, DOI 10.1016/j.ophtha.2017.05.035
   Cruickshanks KJ, 2017, JAMA OPHTHALMOL, V135, P1417, DOI 10.1001/jamaophthalmol.2017.5001
   Dai J, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17020231
   Dignam T, 2019, J PUBLIC HEALTH MAN, V25, pS13, DOI 10.1097/PHH.0000000000000889
   Ding N, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0161472
   Dunaief JL, 2006, INVEST OPHTH VIS SCI, V47, P4660, DOI 10.1167/iovs.06-0568
   Elhaj MSM., 2016, SMJ, V52, P75, DOI [10.12816/0030341, DOI 10.12816/0030341]
   Elis A, 2004, ENDOCR RES, V30, P141, DOI 10.1081/ERC-200027354
   Elmorsy E, 2020, TOXICOL ENV HEALTH, V12, P91, DOI 10.1007/s13530-020-00046-6
   Elmorsy EM, 2019, PAK J MED HEALTH SCI, V13, P1037
   Ericson B, 2018, ENVIRON INT, V121, P461, DOI 10.1016/j.envint.2018.08.047
   Erie JC, 2007, AM J OPHTHALMOL, V144, P414, DOI 10.1016/j.ajo.2007.05.020
   Erie JC, 2009, AM J OPHTHALMOL, V148, P890, DOI 10.1016/j.ajo.2009.07.001
   Erie JC, 2009, AM J OPHTHALMOL, V147, P276, DOI 10.1016/j.ajo.2008.08.014
   Erie JC, 2005, AM J OPHTHALMOL, V139, P888, DOI 10.1016/j.ajo.2004.12.007
   Evans J, 2008, EYE, V22, P751, DOI 10.1038/eye.2008.100
   Evans JR, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000254.pub4
   Fernandez-Silva A, 2020, PEERJ, V8, DOI 10.7717/peerj.9178
   Firat PG, 2018, ANEMIA, V2018, DOI 10.1155/2018/1456323
   Flaxman SR, 2017, LANCET GLOB HEALTH, V5, pE1221, DOI 10.1016/S2214-109X(17)30393-5
   Flohe L, 2005, DEV OPHTHALMOL, V38, P89, DOI 10.1159/000082770
   Forsyth JE, 2018, ENVIRON RES, V166, P1, DOI 10.1016/j.envres.2018.04.019
   Frazzoli C, 2020, FOOD CHEM TOXICOL, V146, DOI 10.1016/j.fct.2020.111789
   Fuller-Thomson E, 2018, JAMA OPHTHALMOL, V136, P958, DOI 10.1001/jamaophthalmol.2018.2163
   Garcia-Castineiras S, 2010, EXP EYE RES, V90, P664, DOI 10.1016/j.exer.2010.03.003
   Garner B, 1999, REDOX REP, V4, P313, DOI 10.1179/135100099101535007
   Gilbert R, 2019, MOL NUTR FOOD RES, V63, DOI 10.1002/mnfr.201801049
   Gleim S, 2009, BIOCHEMISTRY-US, V48, P1793, DOI 10.1021/bi800968w
   Glynn RJ, 2009, OPHTHAL EPIDEMIOL, V16, P98, DOI 10.1080/09286580902737532
   Gorusupudi A, 2017, ADV NUTR, V8, P40, DOI 10.3945/an.116.013177
   Grahn BH, 2001, J AM COLL NUTR, V20, P106, DOI 10.1080/07315724.2001.10719022
   Grashow R, 2015, NEUROTOXICOLOGY, V49, P158, DOI 10.1016/j.neuro.2015.06.006
   GRUBB BR, 1986, EXP EYE RES, V43, P259, DOI 10.1016/S0014-4835(86)80094-X
   Guedes Guilherme, 2011, Curr Aging Sci, V4, P110
   Gungor ED, 2018, J TRACE ELEM MED BIO, V48, P16, DOI 10.1016/j.jtemb.2018.02.019
   Guo LY, 2014, EXP EYE RES, V129, P31, DOI 10.1016/j.exer.2014.10.012
   Hahn P, 2004, P NATL ACAD SCI USA, V101, P13850, DOI 10.1073/pnas.0405146101
   Hahn P, 2006, NEUROREPORT, V17, P1803, DOI 10.1097/WNR.0b013e3280107776
   Hamdan HZ, 2015, BIOL TRACE ELEM RES, V165, P30, DOI 10.1007/s12011-015-0236-4
   He XN, 2007, PROG RETIN EYE RES, V26, P649, DOI 10.1016/j.preteyeres.2007.07.004
   Ho L, 2011, ARCH OPHTHALMOL-CHIC, V129, P758, DOI 10.1001/archophthalmol.2011.141
   Hohberger B, 2018, J TRACE ELEM MED BIO, V45, P150, DOI 10.1016/j.jtemb.2017.10.003
   Hou XL, 1996, BIOL TRACE ELEM RES, V55, P89, DOI 10.1007/BF02784171
   Hu H, 2007, ENVIRON HEALTH PERSP, V115, P455, DOI 10.1289/ehp.9783
   Hwang HS, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0134338
   Hyun HJ, 2001, INVEST OPHTH VIS SCI, V42, P460
   Jaishankar Monisha, 2014, Interdiscip Toxicol, V7, P60, DOI 10.2478/intox-2014-0009
   Jan AT, 2015, INT J MOL SCI, V16, P29592, DOI 10.3390/ijms161226183
   Jarup L, 2003, BRIT MED BULL, V68, P167, DOI 10.1093/bmb/ldg032
   Jayashree MP, 2019, J CLIN RES OPHTHALMO, V6, P07
   Junemann AGM, 2018, J TRACE ELEM MED BIO, V50, P67, DOI 10.1016/j.jtemb.2018.06.010
   Junemann AGM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056734
   Kalariya NM, 2010, TOXICOL LETT, V198, P56, DOI 10.1016/j.toxlet.2010.04.021
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Khan JC, 2006, BRIT J OPHTHALMOL, V90, P75, DOI 10.1136/bjo.2005.073643
   Khoo HE, 2019, ANTIOXIDANTS-BASEL, V8, DOI 10.3390/antiox8040085
   Kim EC, 2014, INVEST OPHTH VIS SCI, V55, P5702, DOI 10.1167/iovs.14-14774
   Kim MH, 2016, J EXPO SCI ENV EPID, V26, P214, DOI 10.1038/jes.2014.75
   King JC, 2016, J NUTR, V146, p858S, DOI 10.3945/jn.115.220079
   Konerirajapuram N Sulochana, 2004, Indian J Ophthalmol, V52, P145
   Kyari F, 2015, BMC OPHTHALMOL, V15, DOI 10.1186/s12886-015-0160-6
   Landrum JT, 2002, INVEST OPHTH VIS SCI, V43, pU157
   Langford-Smith A, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0147576
   Lee SR, 2018, OXID MED CELL LONGEV, V2018, DOI 10.1155/2018/9156285
   Lemire M, 2010, ENVIRON HEALTH PERSP, V118, P1584, DOI 10.1289/ehp.0901284
   Lengyel I, 2007, EXP EYE RES, V84, P772, DOI 10.1016/j.exer.2006.12.015
   Lengyel I, 2008, EXPERT REV OPHTHALMO, V3, P1, DOI 10.1586/17469899.3.1.1
   Li YQ, 2017, P NATL ACAD SCI USA, V114, pE209, DOI 10.1073/pnas.1616811114
   Loh A, 2009, BBA-GEN SUBJECTS, V1790, P637, DOI 10.1016/j.bbagen.2008.11.001
   Luo YY, 2015, CHINESE MED J-PEKING, V128, P3276, DOI 10.4103/0366-6999.171357
   Lynch S, 2018, J NUTR, V148, p1001S, DOI 10.1093/jn/nxx036
   Marreiro DD, 2017, ANTIOXIDANTS-BASEL, V6, DOI 10.3390/antiox6020024
   Mayer MJ, 1998, ACTA OPHTHALMOL SCAN, V76, P62, DOI 10.1034/j.1600-0420.1998.760111.x
   Naka KS, 2020, SCI TOTAL ENVIRON, V698, DOI 10.1016/j.scitotenv.2019.134309
   Neal R, 2005, TOXICOLOGY, V212, P1, DOI 10.1016/j.tox.2005.03.015
   Nigra Anne E, 2016, Curr Environ Health Rep, V3, P416, DOI 10.1007/s40572-016-0117-9
   Nizami AA., 2020, STATPEARLS STATPEARLS
   Nuertey BD, 2019, J OPHTHALMOL, V2019, DOI 10.1155/2019/1717464
   O'Dell BL, 2000, J NUTR, V130, p1432S, DOI 10.1093/jn/130.5.1432S
   Pamphlett R, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0203627
   Park SJ, 2015, OPHTHALMOLOGY, V122, P129, DOI 10.1016/j.ophtha.2014.07.039
   Pico C, 2019, NUTRIENTS, V11, DOI 10.3390/nu11051092
   Post M, 2018, J TRACE ELEM MED BIO, V25, P443
   Prasad AS, 2019, ANTIOXIDANTS-BASEL, V8, DOI 10.3390/antiox8060164
   Quintanar L, 2016, ACS CHEM BIOL, V11, P263, DOI 10.1021/acschembio.5b00919
   Rai PSK., 2017, INT J RES MED SCI, V5, P3697, DOI [10.18203/2320-6012.ijrms20173588, DOI 10.18203/2320-6012.IJRMS20173588]
   Ramkumar S, 2018, BBA-MOL BASIS DIS, V1864, P3595, DOI 10.1016/j.bbadis.2018.08.021
   Ratnayaka JA, 2015, EYE, V29, P1013, DOI 10.1038/eye.2015.100
   Reddy VN, 2001, INVEST OPHTH VIS SCI, V42, P3247
   Redenti S, 2007, EXP EYE RES, V85, P580, DOI 10.1016/j.exer.2007.07.017
   Rudnicka AR, 2015, AM J OPHTHALMOL, V160, P85, DOI 10.1016/j.ajo.2015.04.003
   Ruiz-Hernandez A, 2017, INT J EPIDEMIOL, V46, P1903, DOI 10.1093/ije/dyx176
   Satarug S, 2008, EXP EYE RES, V87, P587, DOI 10.1016/j.exer.2008.09.014
   Saxena R, 2003, ACTA OPHTHALMOL SCAN, V81, P491, DOI 10.1034/j.1600-0420.2003.00119.x
   Schaumberg DA, 2004, JAMA-J AM MED ASSOC, V292, P2750, DOI 10.1001/jama.292.22.2750
   Sehgal M, 2014, GLOBAL HEALTH ACTION, V7, DOI 10.3402/gha.v7.25326
   Shin J, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17249231
   Shubhrica P., 2013, INDIAN J CLIN PRACT, V24, P381
   Shukla N, 1996, SCI TOTAL ENVIRON, V181, P161, DOI 10.1016/0048-9697(95)05006-X
   Song PG, 2017, J GLOB HEALTH, V7, DOI 10.7189/jogh.07.020705
   Stein JD, 2011, OPHTHALMOLOGY, V118, P1031, DOI 10.1016/j.ophtha.2010.10.024
   Tchounwou PB., 2012, EXP S, V101, P133, DOI [10.1007/978-3-7643-8340-4_6, DOI 10.1007/978-3-7643-8340-4_6]
   Tellez-Plaza M, 2012, ENVIRON HEALTH PERSP, V120, P204, DOI 10.1289/ehp.1104020
   Thornton J, 2005, EYE, V19, P935, DOI 10.1038/sj.eye.6701978
   Trakhtenberg EF, 2018, EXP NEUROL, V300, P22, DOI 10.1016/j.expneurol.2017.10.025
   Tsoi MF, 2016, AM J MED, V129, P1213, DOI 10.1016/j.amjmed.2016.05.042
   Ugarte M, 2014, METALLOMICS, V6, P189, DOI 10.1039/c3mt00291h
   Ugarte M, 2013, SURV OPHTHALMOL, V58, P585, DOI 10.1016/j.survophthal.2012.12.002
   VanderBeek BL, 2011, AM J OPHTHALMOL, V152, P273, DOI 10.1016/j.ajo.2011.02.004
   Vishwanathan R, 2013, INVEST OPHTH VIS SCI, V54, P3985, DOI 10.1167/iovs.12-11552
   Wang WY, 2018, ENVIRON HEALTH PERSP, V126, DOI [10.1289/EHP3442, 10.1289/ehp3442]
   Wang WY, 2016, INT J HYG ENVIR HEAL, V219, P850, DOI 10.1016/j.ijheh.2016.07.012
   Welp A., 2016, MAKING EYE HLTH POPU, P587
   Wessells KR, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050568
   Wieringa FT, 2015, NUTRIENTS, V7, P3252, DOI 10.3390/nu7053252
   Wills NK, 2008, EXP EYE RES, V87, P80, DOI 10.1016/j.exer.2008.04.013
   Wills NK, 2008, EXP EYE RES, V86, P41, DOI 10.1016/j.exer.2007.09.005
   Wills NK, 2009, EXP EYE RES, V89, P79, DOI 10.1016/j.exer.2009.02.014
   World Health Organisation, 2019, WORLD REP VIS
   Wu EW, 2014, ENVIRON RES, V133, P178, DOI 10.1016/j.envres.2014.05.023
   Wysokinski D, 2015, ACTA BIOCHIM POL, V62, P177, DOI 10.18388/abp.2014_843
   Yuki K, 2009, BIOL TRACE ELEM RES, V132, P1, DOI 10.1007/s12011-009-8376-z
   Zhou FK, 2018, ECOTOX ENVIRON SAFE, V163, P674, DOI 10.1016/j.ecoenv.2018.07.116
NR 148
TC 1
Z9 1
U1 3
U2 6
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 2689-6583
EI 2689-6591
J9 J ENV SCI HEAL C-TOX
JI J. Environ. Sci. Health Part C-Toxicol. Carcinogen.
PD JUL 20
PY 2021
VL 39
IS 3
BP 293
EP 339
DI 10.1080/26896583.2021.1916331
PG 47
WC Oncology; Environmental Sciences; Toxicology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Environmental Sciences & Ecology; Toxicology
GA TM2HF
UT WOS:000675371800001
PM 34114934
DA 2022-11-30
ER

PT J
AU Monemian, M
   Rabbani, H
AF Monemian, Maryam
   Rabbani, Hossein
TI Analysis of a Novel Segmentation Algorithm for Optical Coherence
   Tomography Images Based on Pixels Intensity Correlations
SO IEEE TRANSACTIONS ON INSTRUMENTATION AND MEASUREMENT
LA English
DT Article
DE Boundary pixel; intraretinal layer segmentation; optical coherence
   tomography (OCT)
ID RETINAL LAYER SEGMENTATION; AUTOMATIC SEGMENTATION; OCT IMAGES;
   BOUNDARIES; CLASSIFICATION
AB One of the newest important medical imaging modalities is optical coherence tomography (OCT) providing the possibility of taking pictures from optical scattering tissues such as retina. With the help of accurate verification and analysis of OCT images, it is possible to identify and treat irreversible retinal diseases like glaucoma. Therefore, to suggest novel high-performance segmentation methods is of significant importance. In this article, a novel algorithm is proposed for the segmentation of OCT B-scans. The proposed method uses the intensity information of pixels to find a distinguishing feature for boundary pixels which are located on the retinal layer boundaries. Also, a nonparametric mathematical model is provided and analyzed for the segmentation algorithm. Such a novel model is also capable of determining boundary pixels. The performance of the proposed algorithm is evaluated for both normal and age-related macular degeneration (AMD) cases. The comparisons are performed from complexity and accuracy points of view. We show that the proposed algorithm has an outstanding performance in terms of values of mean signed and unsigned errors for both cases. Also, the results of mathematical analysis and execution of the algorithm match with good approximation.
C1 [Monemian, Maryam; Rabbani, Hossein] Isfahan Univ Med Sci, Med Image & Signal Proc Res Ctr, Sch Adv Technol Med, Esfahan 8174673461, Iran.
C3 Isfahan University Medical Science
RP Rabbani, H (通讯作者)，Isfahan Univ Med Sci, Med Image & Signal Proc Res Ctr, Sch Adv Technol Med, Esfahan 8174673461, Iran.
EM rabbani.h@ieee.org
RI monemian, maryam/AAD-3326-2022
OI monemian, maryam/0000-0002-3449-2408
FU Vice Chancellery for Research and Technology of Isfahan University of
   Medical Sciences [299028]
FX This work was supported in part by the Vice Chancellery for Research and
   Technology of Isfahan University of Medical Sciences under Grant 299028.
CR [Anonymous], IOW REF ALG
   Chiu SJ, 2010, OPT EXPRESS, V18, P19413, DOI 10.1364/OE.18.019413
   de Sisternes L, 2017, BIOMED OPT EXPRESS, V8, P1926, DOI 10.1364/BOE.8.001926
   Dodo BI, 2019, IEEE ACCESS, V7, P152388, DOI 10.1109/ACCESS.2019.2947761
   DuBose TB, 2018, IEEE T MED IMAGING, V37, P1978, DOI 10.1109/TMI.2017.2772963
   Fang LY, 2017, BIOMED OPT EXPRESS, V8, P2732, DOI 10.1364/BOE.8.002732
   Fang LY, 2017, IEEE T MED IMAGING, V36, P407, DOI 10.1109/TMI.2016.2611503
   Fang LY, 2013, IEEE T MED IMAGING, V32, P2034, DOI 10.1109/TMI.2013.2271904
   Farsiu S, 2014, OPHTHALMOLOGY, V121, P162, DOI 10.1016/j.ophtha.2013.07.013
   Fernandez DC, 2005, IEEE T MED IMAGING, V24, P929, DOI 10.1109/TMI.2005.848655
   Fujimoto JG, 2009, OPT EXPRESS, V17, P3978, DOI 10.1364/OE.17.003978
   Garvin MK, 2008, IEEE T MED IMAGING, V27, P1495, DOI 10.1109/TMI.2008.923966
   Ghorbel I, 2011, PATTERN RECOGN, V44, P1590, DOI 10.1016/j.patcog.2011.01.012
   HUANG D, 1991, SCIENCE, V254, P1178, DOI 10.1126/science.1957169
   Hussain MA, 2017, IEEE T BIO-MED ENG, V64, P1638, DOI 10.1109/TBME.2016.2619120
   Kafieh Raheleh, 2013, J Med Signals Sens, V3, P45
   Kafieh R, 2013, MED IMAGE ANAL, V17, P907, DOI 10.1016/j.media.2013.05.006
   Keller B, 2016, J BIOMED OPT, V21, DOI 10.1117/1.JBO.21.7.076015
   Kugelman J, 2018, BIOMED OPT EXPRESS, V9, P5759, DOI 10.1364/BOE.9.005759
   Lee K, 2010, IEEE T MED IMAGING, V29, P159, DOI 10.1109/TMI.2009.2031324
   Liu XM, 2019, IEEE J BIOMED HEALTH, V23, P1404, DOI 10.1109/JBHI.2018.2856276
   Lv HL, 2018, OPT EXPRESS, V26, P11804, DOI 10.1364/OE.26.011804
   McLean JP, 2017, OPT EXPRESS, V25, P25819, DOI 10.1364/OE.25.025819
   Mishra A, 2009, OPT EXPRESS, V17, P23719, DOI 10.1364/OE.17.023719
   Monemian M, 2019, IEEE ENG MED BIO, P4750, DOI 10.1109/EMBC.2019.8856610
   Ogiela MR, 2005, IEEE T INSTRUM MEAS, V54, P2149, DOI 10.1109/TIM.2005.858566
   Ramzan A, 2019, IET IMAGE PROCESS, V13, P409, DOI 10.1049/iet-ipr.2018.5396
   Rashno A, 2018, IEEE T BIO-MED ENG, V65, P989, DOI 10.1109/TBME.2017.2734058
   Shah A, 2018, BIOMED OPT EXPRESS, V9, P4509, DOI 10.1364/BOE.9.004509
   Shi F, 2015, IEEE T MED IMAGING, V34, P441, DOI 10.1109/TMI.2014.2359980
   Stoitsis J, 2006, IEEE T INSTRUM MEAS, V55, P1944, DOI 10.1109/TIM.2006.884348
   Wang J, 2019, BIOMED OPT EXPRESS, V10, P2639, DOI 10.1364/BOE.10.002639
   Yazdanpanah A, 2011, IEEE T MED IMAGING, V30, P484, DOI 10.1109/TMI.2010.2087390
NR 33
TC 7
Z9 7
U1 2
U2 5
PU IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC
PI PISCATAWAY
PA 445 HOES LANE, PISCATAWAY, NJ 08855-4141 USA
SN 0018-9456
EI 1557-9662
J9 IEEE T INSTRUM MEAS
JI IEEE Trans. Instrum. Meas.
PY 2021
VL 70
DI 10.1109/TIM.2020.3017037
PG 12
WC Engineering, Electrical & Electronic; Instruments & Instrumentation
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Engineering; Instruments & Instrumentation
GA OZ4PT
UT WOS:000594910700045
DA 2022-11-30
ER

PT J
AU Tosi, GM
   Neri, G
   Barbera, S
   Mundo, L
   Parolini, B
   Lazzi, S
   Lugano, R
   Poletto, E
   Leoncini, L
   Pertile, G
   Mongiat, M
   Dimberg, A
   Galvagni, F
   Orlandini, M
AF Tosi, Gian Marco
   Neri, Giovanni
   Barbera, Stefano
   Mundo, Lucia
   Parolini, Barbara
   Lazzi, Stefano
   Lugano, Roberta
   Poletto, Evelina
   Leoncini, Lorenzo
   Pertile, Grazia
   Mongiat, Maurizio
   Dimberg, Anna
   Galvagni, Federico
   Orlandini, Maurizio
TI The Binding of CD93 to Multimerin-2 Promotes Choroidal
   Neovascularization
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE choriocapillaris; age-related macular degeneration; angiogenesis;
   neovascularization; retinal degeneration
ID MACULAR DEGENERATION; ELEVATED EXPRESSION; TUMOR ANGIOGENESIS;
   CELL-ADHESION; MORPHOGENESIS; UNVEILS; GROWTH; MODEL
AB PURPOSE. The purpose of this study was to investigate the involvement of CD93 and Multimerin-2 in three choroidal neovascularization (CNV) models and to evaluate their contribution in the neovascular progression of age-related macular degeneration (AMD).
   METHODS. Choroidal neovascular membranes collected during surgery from AMD patients were analyzed by microscopy methods. Laser-induced CNV mouse models and choroid sprouting assays (CSAs) were carried out using the CD93 knockout mouse model. An original ex vivo CSA of vascular angiogenesis, employing choroid tissues isolated from human donors, was developed.
   RESULTS. In contrast to healthy choroid endothelium, hyperproliferative choroidal endothelial cells (ECs) of AMD patients expressed high levels of CD93, and Multimerin-2 was abundantly deposited along the choroidal neovasculature. CD93 knockout mice showed a significant reduced neovascularization after laser photocoagulation, and their choroidal ECs displayed a decreased ability to produce sprouts in ex vivo angiogenesis assays. Moreover, the presence of an antibody able to hamper the CD93/Multimerin-2 interaction reduced vascular sprouting in the human CSA.
   CONCLUSIONS. Our results demonstrate that CD93 and its interaction with Multimerin-2 play an important role in pathological vascularization of the choroid, disclosing new possibilities for therapeutic intervention to neovascular AMD.
C1 [Tosi, Gian Marco; Neri, Giovanni] Univ Siena, Dept Med Surg & Neurosci, Ophthalmol Unit, Siena, Italy.
   [Barbera, Stefano; Galvagni, Federico; Orlandini, Maurizio] Univ Siena, Dept Biotechnol Chem & Pharm, Via Aldo Moro 2, I-53100 Siena, Italy.
   [Mundo, Lucia; Lazzi, Stefano; Leoncini, Lorenzo] Univ Siena, Sect Pathol, Dept Med Biotechnol, Siena, Italy.
   [Parolini, Barbara] St Anna Hosp, Vitroretinal Unit, Brescia, Italy.
   [Lugano, Roberta; Dimberg, Anna] Uppsala Univ, Sci Life Lab, Rudbeck Lab, Dept Immunol Genet & Pathol, Uppsala, Sweden.
   [Poletto, Evelina; Mongiat, Maurizio] IRCCS, Ctr Riferimento Oncol Aviano, Div Mol Oncol, Dept Res & Diag, Aviano, Italy.
   [Pertile, Grazia] IRCCS Sacro Cuore Don Calabria Hosp, Negrar, VR, Italy.
C3 University of Siena; University of Siena; University of Siena;
   University of Ferrara; Arcispedale Sant'Anna; Uppsala University; IRCCS
   Aviano (CRO); IRCCS Sacro Cuore Don Calabria
RP Galvagni, F; Orlandini, M (通讯作者)，Univ Siena, Dept Biotechnol Chem & Pharm, Via Aldo Moro 2, I-53100 Siena, Italy.
EM federico.galvagni@unisi.it; maurizio.orlandini@unisi.it
RI Pertile, Grazia/AAC-4956-2022; Lazzi, Stefano/P-8265-2018; Mundo,
   Lucia/ABE-8599-2021; Poletto, Evelina/AAW-3671-2020; LEONCINI,
   Lorenzo/P-8361-2018
OI Lazzi, Stefano/0000-0002-2218-3771; Poletto,
   Evelina/0000-0001-5675-3026; Barbera, Stefano/0000-0001-9544-455X;
   LEONCINI, Lorenzo/0000-0002-7457-300X; Lugano,
   Roberta/0000-0002-7294-345X; Parolini, Barbara/0000-0002-7838-6834
FU Grant Dipartimento di Eccellenza (2018-2022) grant; I.Ri.Fo.R Onlus
   (Institute for Research, Training, and Rehabilitation); Italian
   Association for the Blind and Visually Impaired; Italian Association for
   Cancer Research [IG23643]; Italian Ministry of Health [RF-201812365425]
FX Supported by a Grant Dipartimento di Eccellenza (2018-2022) grant;
   I.Ri.Fo.R Onlus (Institute for Research, Training, and Rehabilitation);
   Italian Association for the Blind and Visually Impaired; Italian
   Association for Cancer Research (grant IG23643, MM); and the Italian
   Ministry of Health (grant RF-201812365425, MM).
CR Andreuzzi E, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19123983
   Bao LL, 2016, BIOCHEM BIOPH RES CO, V476, P467, DOI 10.1016/j.bbrc.2016.05.146
   Barbera S, 2019, CELL COMMUN SIGNAL, V17, DOI 10.1186/s12964-019-0375-x
   Bressler SB, 2009, OPHTHALMOLOGY, V116, pS1, DOI 10.1016/j.ophtha.2009.06.045
   Coleman HR, 2008, LANCET, V372, P1835, DOI 10.1016/S0140-6736(08)61759-6
   Colladel R, 2016, ONCOTARGET, V7, P2022, DOI 10.18632/oncotarget.6515
   Eelen G, 2018, PHYSIOL REV, V98, P3, DOI 10.1152/physrev.00001.2017
   Flaxman SR, 2017, LANCET GLOB HEALTH, V5, pE1221, DOI 10.1016/S2214-109X(17)30393-5
   Galvagni F, 2017, MATRIX BIOL, V64, P112, DOI 10.1016/j.matbio.2017.08.003
   Galvagni F, 2016, ONCOTARGET, V7, P10090, DOI 10.18632/oncotarget.7136
   Galvagni F, 2012, HISTOCHEM CELL BIOL, V138, P419, DOI 10.1007/s00418-012-0965-9
   Handa JT, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11262-1
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   KARLSSON S, 2002, AM J PHYSIOL-CELL PH, V282, pR28
   Khan KA, 2017, ONCOGENE, V36, P6097, DOI 10.1038/onc.2017.214
   Khan KA, 2019, FEBS J, V286, P3299, DOI 10.1111/febs.14985
   Lambert V, 2013, NAT PROTOC, V8, P2197, DOI 10.1038/nprot.2013.135
   Langenkamp E, 2015, CANCER RES, V75, P4504, DOI 10.1158/0008-5472.CAN-14-3636
   Li SQ, 2011, MOL VIS, V17, P3566
   Loeven MA, 2018, INVEST OPHTH VIS SCI, V59, P722, DOI 10.1167/iovs.IOVS-17-22893
   Lorenzon E, 2012, ONCOGENE, V31, P3136, DOI 10.1038/onc.2011.487
   Lu F, 2009, GRAEF ARCH CLIN EXP, V247, P171, DOI 10.1007/s00417-008-0936-y
   Lugano R, 2018, J CLIN INVEST, V128, P3280, DOI 10.1172/JCI97459
   Mammadzada P, 2020, CELL MOL LIFE SCI, V77, P819, DOI 10.1007/s00018-019-03422-9
   Masiero M, 2013, CANCER CELL, V24, P229, DOI 10.1016/j.ccr.2013.06.004
   Norsworthy PJ, 2004, J IMMUNOL, V172, P3406, DOI 10.4049/jimmunol.172.6.3406
   Olsen RS, 2015, INT J COLORECTAL DIS, V30, P883, DOI 10.1007/s00384-015-2247-1
   Orlandini M, 2008, FEBS LETT, V582, P2542, DOI 10.1016/j.febslet.2008.06.025
   Orlandini M, 2014, ONCOTARGET, V5, P2750, DOI 10.18632/oncotarget.1887
   Pellicani R, 2020, MATRIX BIOL, V87, P11, DOI 10.1016/j.matbio.2019.08.002
   Pennesi ME, 2012, MOL ASPECTS MED, V33, P487, DOI 10.1016/j.mam.2012.06.003
   Shao Z, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069552
   Slaga D, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aat5775
   Solomon SD, 2019, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005139.pub4
   Tosi GM, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-26442-0
   Tosi GM, 2017, J CELL PHYSIOL, V232, P1767, DOI 10.1002/jcp.25689
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yardeni T, 2011, LAB ANIMAL, V40, P155, DOI 10.1038/laban0511-155
   Zanivan S, 2013, MOL CELL PROTEOMICS, V12, P3599, DOI 10.1074/mcp.M113.031344
   Zhang MY, 2005, IMMUNOLOGY, V115, P63, DOI 10.1111/j.1365-2567.2005.02120.x
NR 40
TC 3
Z9 3
U1 1
U2 4
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD JUL
PY 2020
VL 61
IS 8
AR 30
DI 10.1167/iovs.61.8.30
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA MS8BL
UT WOS:000554499000033
PM 32697305
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Kiel, C
   Lastrucci, C
   Luthert, PJ
   Serrano, L
AF Kiel, Christina
   Lastrucci, Claire
   Luthert, Philip J.
   Serrano, Luis
TI Simple and complex retinal dystrophies are associated with profoundly
   different disease networks
SO SCIENTIFIC REPORTS
LA English
DT Article
ID DOMINANT RETINITIS-PIGMENTOSA; LEBER CONGENITAL AMAUROSIS;
   BARDET-BIEDL-SYNDROME; USHER PROTEIN NETWORK; MACULAR DEGENERATION;
   OXIDATIVE STRESS; PHOTORECEPTOR CILIA; MUTATIONS; RHODOPSIN; CELLS
AB Retinopathies are a group of monogenetic or complex retinal diseases associated with high unmet medical need. Monogenic disorders are caused by rare genetic variation and usually arise early in life. Other diseases, such as age-related macular degeneration (AMD), develop late in life and are considered to be of complex origin as they develop from a combination of genetic, ageing, environmental and lifestyle risk factors. Here, we contrast the underlying disease networks and pathological mechanisms of monogenic as opposed to complex retinopathies, using AMD as an example of the latter. We show that, surprisingly, genes associated with the different forms of retinopathies in general do not overlap despite their overlapping retinal phenotypes. Further, AMD risk genes participate in multiple networks with interaction partners that link to different ubiquitous pathways affecting general tissue integrity and homeostasis. Thus AMD most likely represents an endophenotype with differing underlying pathogenesis in different subjects. Localising these pathomechanisms and processes within and across different retinal anatomical compartments provides a novel representation of AMD that may be extended to complex disease in general. This approach may generate improved treatment options that target multiple processes with the aim of restoring tissue homeostasis and maintaining vision.
C1 [Kiel, Christina; Lastrucci, Claire; Serrano, Luis] Barcelona Inst Sci & Technol, Ctr Genom Regulat CRG, EMBL CRG Syst Biol Res Unit, Dr Aiguader 88, Barcelona 08003, Spain.
   [Kiel, Christina; Lastrucci, Claire; Serrano, Luis] Univ Pompeu Fabra, Barcelona 08003, Spain.
   [Luthert, Philip J.] UCL, UCL Inst Ophthalmol, Dept Ocular Biol & Therapeut, 11-43 Bath St, London EC1V 9EL, England.
   [Luthert, Philip J.] UCL, NIHR Biomed Res Ctr, 11-43 Bath St, London EC1V 9EL, England.
   [Serrano, Luis] Pg Lluis Co 23, ICREA, Barcelona 08010, Spain.
C3 Barcelona Institute of Science & Technology; Pompeu Fabra University;
   Centre de Regulacio Genomica (CRG); Pompeu Fabra University; University
   of London; University College London; University of London; University
   College London; ICREA
RP Kiel, C (通讯作者)，Barcelona Inst Sci & Technol, Ctr Genom Regulat CRG, EMBL CRG Syst Biol Res Unit, Dr Aiguader 88, Barcelona 08003, Spain.; Kiel, C (通讯作者)，Univ Pompeu Fabra, Barcelona 08003, Spain.
EM christina.kiel@crg.eu
RI Serrano, Luis/B-3355-2013
OI Serrano, Luis/0000-0002-5276-1392; Luthert, Philip/0000-0001-7276-6898;
   Kiel, Christina/0000-0001-8454-6008
FU European Union [634479]; Spanish Ministerio de Economia y
   Competitividad, Plan Nacional [BIO2012-39754]; European Fund for
   Regional Development; Spanish Ministry of Economy and Competitiveness,
   'Centro de Excelencia Severo Ochoa'; CERCA Programme/Generalitat de
   Catalunya; ICREA Funding Source: Custom
FX We thank Harald H.H.W. Schmidt for critical reading and suggestions
   about the manuscript. This project has received funding from the
   European Union's Horizon 2020 research and innovation programme under
   grant agreement No. 634479 (EYE-RISK). This work was supported by the
   Spanish Ministerio de Economia y Competitividad, Plan Nacional
   BIO2012-39754 and the European Fund for Regional Development. We
   acknowledge the support of the Spanish Ministry of Economy and
   Competitiveness, 'Centro de Excelencia Severo Ochoa 2013-2017'. We
   acknowledge the support of the CERCA Programme/Generalitat de Catalunya.
CR Adam M. P., 1993, GENEREVIEWS R
   Ait-Ali N, 2015, CELL, V161, P817, DOI 10.1016/j.cell.2015.03.023
   Ambati J, 2013, NAT REV IMMUNOL, V13, P438, DOI 10.1038/nri3459
   Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   An G, 2009, WIRES SYST BIOL MED, V1, P159, DOI 10.1002/wsbm.45
   Ansley SJ, 2003, NATURE, V425, P628, DOI 10.1038/nature02030
   Ayuso C, 2010, GENOME MED, V2, DOI 10.1186/gm155
   Barabasi AL, 2011, NAT REV GENET, V12, P56, DOI 10.1038/nrg2918
   Barber AC, 2013, P NATL ACAD SCI USA, V110, P354, DOI 10.1073/pnas.1212677110
   Boldt K, 2011, J CLIN INVEST, V121, P2169, DOI 10.1172/JCI45627
   Campagne MV, 2014, J PATHOL, V232, P151, DOI 10.1002/path.4266
   Cao Y, 2012, P NATL ACAD SCI USA, V109, P7905, DOI 10.1073/pnas.1202332109
   Chowbina SR, 2009, BMC BIOINFORMATICS, V10, DOI 10.1186/1471-2105-10-S11-S5
   Ferrara N, 2016, NAT REV DRUG DISCOV, V15, P385, DOI 10.1038/nrd.2015.17
   Ferrari S, 2011, CURR GENOMICS, V12, P238, DOI 10.2174/138920211795860107
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Fritsche LG, 2014, ANNU REV GENOM HUM G, V15, P151, DOI 10.1146/annurev-genom-090413-025610
   Gerard X, 2015, MOL THER-NUCL ACIDS, V4, DOI 10.1038/mtna.2015.24
   Gerard X, 2012, MOL THER-NUCL ACIDS, V1, DOI 10.1038/mtna.2012.21
   Ghazi NG, 2016, HUM GENET, V135, P327, DOI 10.1007/s00439-016-1637-y
   Ghiassian SD, 2016, SCI REP-UK, V6, DOI 10.1038/srep27414
   Goh KI, 2007, P NATL ACAD SCI USA, V104, P8685, DOI 10.1073/pnas.0701361104
   Gosens I, 2007, HUM MOL GENET, V16, P1993, DOI 10.1093/hmg/ddm147
   Guo DF, 2011, TRENDS ENDOCRIN MET, V22, P286, DOI 10.1016/j.tem.2011.02.009
   Issa PC, 2015, P NATL ACAD SCI USA, V112, P8415, DOI 10.1073/pnas.1506960112
   Jin H, 2010, CELL, V141, P1208, DOI 10.1016/j.cell.2010.05.015
   Joyal JS, 2016, NAT MED, V22, P439, DOI 10.1038/nm.4059
   KAUSHAL S, 1994, BIOCHEMISTRY-US, V33, P6121, DOI 10.1021/bi00186a011
   Kiel C, 2011, MOL SYST BIOL, V7, DOI 10.1038/msb.2011.83
   Kurtz A, 2012, PREV MED, V54, pS50, DOI 10.1016/j.ypmed.2012.01.003
   Li C, 2014, BBA-MOL BASIS DIS, V1842, P1121, DOI 10.1016/j.bbadis.2014.04.009
   Licastro Federico, 2005, Immun Ageing, V2, P8
   Liquori A, 2016, HUM MUTAT, V37, P184, DOI 10.1002/humu.22926
   Maerker T, 2008, HUM MOL GENET, V17, P71, DOI 10.1093/hmg/ddm285
   Morimura H, 1998, P NATL ACAD SCI USA, V95, P3088, DOI 10.1073/pnas.95.6.3088
   Nakajima Y, 2008, J PHARM PHARMACOL, V60, P1365, DOI 10.1211/jpp/60.10.0013
   Nemet I, 2015, PROG MOL BIOL TRANSL, V132, P39, DOI 10.1016/bs.pmbts.2015.02.007
   Nishimura DY, 2004, P NATL ACAD SCI USA, V101, P16588, DOI 10.1073/pnas.0405496101
   Pellissier LP, 2015, HUM MOL GENET, V24, P3104, DOI 10.1093/hmg/ddv062
   Rakoczy EP, 2011, J MOL BIOL, V405, P584, DOI 10.1016/j.jmb.2010.11.003
   RAMRATTAN RS, 1994, INVEST OPHTH VIS SCI, V35, P2857
   Rao KN, 2016, HUM MOL GENET, V25, P1345, DOI 10.1093/hmg/ddw017
   Reimand J, 2011, NUCLEIC ACIDS RES, V39, pW307, DOI 10.1093/nar/gkr378
   Reimand J, 2016, NUCLEIC ACIDS RES, V44, pW83, DOI 10.1093/nar/gkw199
   Riazuddin SA, 2010, AM J HUM GENET, V86, P805, DOI 10.1016/j.ajhg.2010.04.001
   Roepman Ronald, 2007, V43, P209, DOI 10.1007/978-1-4020-5943-8_10
   Sanders AAWM, 2015, GENOME BIOL, V16, DOI 10.1186/s13059-015-0858-z
   Sreekumar PG, 2016, INVEST OPHTH VIS SCI, V57, P1238, DOI 10.1167/iovs.15-17053
   SUNG CH, 1991, P NATL ACAD SCI USA, V88, P8840, DOI 10.1073/pnas.88.19.8840
   SUNG CH, 1993, J BIOL CHEM, V268, P26645
   Toomey MB, 2015, J R SOC INTERFACE, V12, DOI 10.1098/rsif.2015.0563
   Vidal M, 2011, CELL, V144, P986, DOI 10.1016/j.cell.2011.02.016
   Viringipurampeer IA, 2016, HUM MOL GENET, V25, P1501, DOI 10.1093/hmg/ddw029
   WELL D, 1995, NATURE, V374, P60, DOI 10.1038/374060a0
   Whitmore SS, 2014, EXP EYE RES, V129, P93, DOI 10.1016/j.exer.2014.11.001
   Winograd-Katz SE, 2014, NAT REV MOL CELL BIO, V15, P273, DOI 10.1038/nrm3769
   Xu H., 2016, EUR J PHARMACOL, P30112
NR 57
TC 8
Z9 9
U1 0
U2 8
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD JAN 31
PY 2017
VL 7
AR 41835
DI 10.1038/srep41835
PG 10
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA EJ2ZZ
UT WOS:000393081400001
PM 28139756
OA Green Published, gold, Green Submitted
DA 2022-11-30
ER

PT J
AU Agrahari, V
   Agrahari, V
   Mandal, A
   Pal, D
   Mitra, AK
AF Agrahari, Vibhuti
   Agrahari, Vivek
   Mandal, Abhirup
   Pal, Dhananjay
   Mitra, Ashim K.
TI How are we improving the delivery to back of the eye? Advances and
   challenges of novel therapeutic approaches
SO EXPERT OPINION ON DRUG DELIVERY
LA English
DT Review
DE Ocular barriers; posterior eye diseases; age-related macular
   degeneration; drug delivery; stimuli-responsive; stem cell
   transplantation; encapsulated cell technology; nanocarriers;
   nanotechnology
ID OCULAR DRUG-DELIVERY; ENDOTHELIAL GROWTH-FACTOR; ANTI-VEGF AGENTS;
   POSTERIOR SEGMENT; MACULAR DEGENERATION; INTRAVITREAL INJECTION;
   SUSTAINED DELIVERY; OXIDATIVE STRESS; EXTENDED-RELEASE; TUNABLE RELEASE
AB Introduction: Drug delivery to the back of the eye requires strategic approaches that guarantee the long-term therapeutic effect with patient compliance. Current treatments for posterior eye diseases suffer from significant challenges including frequent intraocular injections of anti-VEGF agents and related adverse effects in addition to the high cost of the therapy.
   Areas covered: Treatment challenges and promising drug delivery approaches for posterior segment eye diseases, such as age-related macular degeneration (AMD) are summarized. Advances in the development of several nanotechnology-based systems, including stimuli-responsive approaches to enhance drug bioavailability and overcome existing barriers for effective ocular delivery are discussed. Stem cell transplantation and encapsulated cell technology (ECT) approaches to treat posterior eye diseases are elaborated.
   Expert opinion: There are several drug delivery systems demonstrating promising results. However, a better understanding of ocular barriers, disease pathophysiology, and drug clearance mechanisms is required for better therapeutic outcomes. The stem cell transplantation strategy and ECT approach provide positive results in AMD therapy, but there are a number of challenges that must be overcome for long-term efficiency. Ultimately, there are numerous multidimensional challenges to cure vision problems and a collaborative approach among scientists is required.
C1 [Agrahari, Vibhuti; Agrahari, Vivek; Mandal, Abhirup; Pal, Dhananjay; Mitra, Ashim K.] Univ Missouri, Sch Pharm, Kansas City, MO 64110 USA.
C3 University of Missouri System; University of Missouri Kansas City
RP Mitra, AK (通讯作者)，Univ Missouri, Sch Pharm, Kansas City, MO 64110 USA.
EM mitraa@umkc.edu
RI Agrahari, Vibhuti/U-5495-2019; Mandal, Abhirup/I-9536-2019; AGRAHARI,
   VIVEK/K-9972-2015
OI Mandal, Abhirup/0000-0002-2543-4994; 
FU NIH [R01EY09171, R01EY10659]; NATIONAL EYE INSTITUTE [R01EY010659,
   R01EY009171] Funding Source: NIH RePORTER
FX This study is supported by NIH R01EY09171 and NIH R01EY10659.
CR Abrishami M, 2009, RETINA-J RET VIT DIS, V29, P699, DOI 10.1097/IAE.0b013e3181a2f42a
   Agarwal A, 2015, CLIN OPHTHALMOL, V9, P1001, DOI [10.2147/OPTH.S59725, 10.2147/OPTH.S74959]
   Agrahari V, 2016, MOL PHARMACEUT, V13, P2912, DOI 10.1021/acs.molpharmaceut.5b00828
   Agrahari V, 2016, THER DELIV, V7, P257, DOI 10.4155/tde-2015-0012
   Agrahari V, 2016, NANOMEDICINE-UK, V11, P2935, DOI 10.2217/nnm-2016-0103
   Agrahari V, 2014, AAPS J, V16, P181, DOI 10.1208/s12248-013-9546-7
   Agrawal AK, 2012, EXPERT OPIN DRUG DEL, V9, P383, DOI 10.1517/17425247.2012.665367
   Akbarzadeh A, 2013, NANOSCALE RES LETT, V8, DOI 10.1186/1556-276X-8-102
   Amadio M, 2016, PHARMACOL RES, V103, P253, DOI 10.1016/j.phrs.2015.11.027
   Ambati J, 2013, NAT REV IMMUNOL, V13, P438, DOI 10.1038/nri3459
   Bansal P, 2016, J OCUL PHARMACOL TH, V32, P135, DOI 10.1089/jop.2015.0133
   Barar J, 2016, BIOIMPACTS, V6, P49, DOI 10.15171/bi.2016.07
   Bertolotti E, 2014, PROG RETIN EYE RES, V42, P130, DOI 10.1016/j.preteyeres.2014.06.002
   Bochot A, 2012, J CONTROL RELEASE, V161, P628, DOI 10.1016/j.jconrel.2012.01.019
   Boddu Sai H S, 2014, Recent Pat Drug Deliv Formul, V8, P27
   Bourges JL, 2006, ADV DRUG DELIVER REV, V58, P1182, DOI 10.1016/j.addr.2006.07.026
   Buwalda SJ, 2014, J CONTROL RELEASE, V190, P254, DOI 10.1016/j.jconrel.2014.03.052
   Canto-Soler V, 2016, INVEST OPHTH VIS SCI, V57, DOI 10.1167/iovs.16-19127
   Carr AJF, 2013, TRENDS NEUROSCI, V36, P385, DOI 10.1016/j.tins.2013.03.006
   Chen XW, 2012, J BIOMATER APPL, V27, P391, DOI 10.1177/0885328211406563
   Cholkar Kishore, 2012, Recent Pat Nanomed, V2, P82
   Christie JG, 2008, DRUG DISCOV TODAY, V13, P124, DOI 10.1016/j.drudis.2007.12.005
   Coursey TG, 2015, J CONTROL RELEASE, V213, P168, DOI 10.1016/j.jconrel.2015.07.007
   Das A, 2015, OPHTHALMOLOGY, V122, P1375, DOI 10.1016/j.ophtha.2015.03.024
   Davis BM, 2014, SMALL, V10, P1575, DOI 10.1002/smll.201303433
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   Delplace V, 2015, J CONTROL RELEASE, V219, P652, DOI 10.1016/j.jconrel.2015.09.065
   Eandi CM, 2016, EUR J PHARMACOL, V787, P78, DOI 10.1016/j.ejphar.2016.03.002
   Eljarrat-Binstock E, 2010, PHARM RES-DORDR, V27, P530, DOI 10.1007/s11095-009-0042-9
   Elsaid N, 2016, MOL PHARMACEUT, V13, P2923, DOI 10.1021/acs.molpharmaceut.6b00335
   Emerich DF, 2014, ADV DRUG DELIVER REV, V67-68, P131, DOI 10.1016/j.addr.2013.07.008
   Falavarjani KG, 2013, EYE, V27, P787, DOI 10.1038/eye.2013.107
   Gaudana R, 2010, AAPS J, V12, P348, DOI 10.1208/s12248-010-9183-3
   Gooch N, 2013, J FUNCT BIOMATER, V4, P14, DOI 10.3390/jfb4010014
   Gower NJD, 2016, BMC OPHTHALMOL, V16, DOI 10.1186/s12886-016-0188-2
   Gullapalli VK, 2005, EXP EYE RES, V80, P235, DOI 10.1016/j.exer.2004.09.006
   Gupta S, 2010, AAPS PHARMSCITECH, V11, P322, DOI 10.1208/s12249-010-9388-x
   Haghjou Nahid, 2011, J Ophthalmic Vis Res, V6, P317
   Heller JP, 2014, TRANSL VIS SCI TECHN, V3, DOI 10.1167/tvst.3.4.4
   Herrero-Vanrell R, 2014, PROG RETIN EYE RES, V42, P27, DOI 10.1016/j.preteyeres.2014.04.002
   Hirani A, 2016, PHARM DEV TECHNOL, V21, P61, DOI 10.3109/10837450.2014.965326
   Holz FG, 2016, OPHTHALMOLOGY, V123, P1080, DOI 10.1016/j.ophtha.2015.12.030
   Hu QR, 2010, STEM CELLS, V28, P1981, DOI 10.1002/stem.531
   Huang D, 2014, EUR J PHARM BIOPHARM, V88, P104, DOI 10.1016/j.ejpb.2014.04.011
   Jaffe GJ, 2016, OPHTHALMOLOGY, V123, P78, DOI 10.1016/j.ophtha.2015.09.004
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Jarrett SG, 2012, MOL ASPECTS MED, V33, P399, DOI 10.1016/j.mam.2012.03.009
   Kang-Mieler JJ, 2014, EXPERT OPIN DRUG DEL, V11, P1647, DOI 10.1517/17425247.2014.935338
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kaur IP, 2014, J CONTROL RELEASE, V193, P100, DOI 10.1016/j.jconrel.2014.05.031
   Kim YC, 2014, J CONTROL RELEASE, V190, P172, DOI 10.1016/j.jconrel.2014.06.043
   Kinnunen K, 2012, ACTA OPHTHALMOL, V90, P299, DOI 10.1111/j.1755-3768.2011.02179.x
   Klassen H, 2016, EXPERT OPIN BIOL TH, V16, P7, DOI 10.1517/14712598.2016.1093110
   Kompella UB, 2013, PROG RETIN EYE RES, V36, P172, DOI 10.1016/j.preteyeres.2013.04.001
   Kundu J, 2014, DEV OPHTHALMOL, V53, P143, DOI 10.1159/000357369
   Lafond M, 2016, EXPERT OPIN DRUG DEL, V27, P1
   Lee SS, 2010, PHARM RES-DORDR, V27, P2043, DOI 10.1007/s11095-010-0159-x
   Li Y, 2012, MOL MED, V18, P1312, DOI 10.2119/molmed.2012.00242
   Lo R, 2008, LAB CHIP, V8, P1027, DOI 10.1039/b804690e
   Lo R, 2009, BIOMED MICRODEVICES, V11, P959, DOI 10.1007/s10544-009-9313-9
   Lu XM, 2015, DRUG DES DEV THER, V9, DOI 10.2147/DDDT.S67536
   Ma FY, 2015, EUR J PHARM BIOPHARM, V89, P271, DOI 10.1016/j.ejpb.2014.12.010
   Mahlumba P, 2016, MOLECULES, V21, DOI 10.3390/molecules21081002
   Mandal A, 2016, EXPERT OPIN DRUG DEL, V5, P1
   Matanovic MR, 2014, INT J PHARMACEUT, V472, P262, DOI 10.1016/j.ijpharm.2014.06.029
   Mead B, 2015, STEM CELL RES, V14, P243, DOI 10.1016/j.scr.2015.02.003
   Meng E, 2012, ADV DRUG DELIVER REV, V64, P1628, DOI 10.1016/j.addr.2012.08.006
   Meng J, 2016, J NEUROIMMUNE PHARM
   Mitra AK, 2015, J CONTROL RELEASE, V219, P248, DOI 10.1016/j.jconrel.2015.09.067
   Moore DJ, 2001, INVEST OPHTH VIS SCI, V42, P2970
   Nabili Marjan, 2014, J Ther Ultrasound, V2, P6, DOI 10.1186/2050-5736-2-6
   Nazari H, 2015, PROG RETIN EYE RES, V48, P1, DOI 10.1016/j.preteyeres.2015.06.004
   Osswald CR, 2015, ANN BIOMED ENG, V43, P2609, DOI 10.1007/s10439-015-1314-7
   Ozkiris A, 2010, EXPERT OPIN THER PAT, V20, P103, DOI 10.1517/13543770902762885
   Park SH, 2016, ACTA BIOMATER, V44, P286, DOI 10.1016/j.actbio.2016.08.011
   Patel Ashaben, 2013, World J Pharmacol, V2, P47
   Patel S, 2015, J OCUL PHARMACOL TH, V31, P215, DOI 10.1089/jop.2014.0152
   Patel SP, 2016, J MICROENCAPSUL, V33, P103, DOI 10.3109/02652048.2015.1134685
   Peptu CA, 2015, CURR PHARM DESIGN, V21, P6055, DOI 10.2174/1381612821666151027151847
   Porta-i-Batalla M, 2016, NANOSCALE RES LETT, V11, DOI 10.1186/s11671-016-1585-4
   Pozarowska D, 2016, CENT EUR J IMMUNOL, V41, P311, DOI 10.5114/ceji.2016.63132
   Rai Uma Do J P, 2015, Drug Discov Today, V20, P491, DOI 10.1016/j.drudis.2014.10.010
   Ramtin A, 2016, DRUG DELIV TRANSL RE, V6, P793, DOI 10.1007/s13346-016-0284-0
   Rauck BM, 2014, INVEST OPHTH VIS SCI, V55, P469, DOI 10.1167/iovs.13-13120
   Rishi Ekta, 2016, Oman J Ophthalmol, V9, P87, DOI 10.4103/0974-620X.184511
   Villanueva JR, 2016, INT J PHARMACEUT, V511, P359, DOI 10.1016/j.ijpharm.2016.07.031
   Rowe-Rendleman CL, 2014, INVEST OPHTH VIS SCI, V55, P2714, DOI 10.1167/iovs.13-13707
   Sadiq MA, 2016, DEV OPHTHALMOL, V55, P310, DOI 10.1159/000438953
   Santos E, 2013, J CONTROL RELEASE, V170, P1, DOI 10.1016/j.jconrel.2013.04.015
   Shadforth AMA, 2012, BIOMATERIALS, V33, P4110, DOI 10.1016/j.biomaterials.2012.02.040
   Sharma OP, 2016, DRUG DELIV TRANSL RE, V6, P399, DOI 10.1007/s13346-016-0292-0
   Shaw PX, 2016, AIMS MOL SCI, V3, P196, DOI 10.3934/molsci.2016.2.196
   Singh RP, 2016, EXPERT OPIN DRUG DEL, P1, DOI [10.1177/1464420716657370, DOI 10.1177/1464420716657370]
   Smith AG, 2014, EXPERT OPIN EMERG DR, V19, P157, DOI 10.1517/14728214.2014.884559
   Souied EH, 2014, AM J OPHTHALMOL, V158, P724, DOI 10.1016/j.ajo.2014.05.037
   Sun K, 2007, MOL VIS, V13, P2310
   Svirskis D, 2010, J CONTROL RELEASE, V146, P6, DOI 10.1016/j.jconrel.2010.03.023
   Takashima Y, 2012, YAKUGAKU ZASSHI, V132, P1365, DOI 10.1248/yakushi.12-00234-3
   Tao Weng, 2006, Expert Opin Biol Ther, V6, P717, DOI 10.1517/14712598.6.7.717
   Tetz M, 2012, OPHTHALMOLOGICA, V227, P183, DOI 10.1159/000336045
   Thrimawithana TR, 2011, DRUG DISCOV TODAY, V16, P270, DOI 10.1016/j.drudis.2010.12.004
   Treharne AJ, 2012, J BIOMED MATER RES A, V100A, P2358, DOI 10.1002/jbm.a.34178
   Tuomela A, 2014, INT J PHARMACEUT, V467, P34, DOI 10.1016/j.ijpharm.2014.03.048
   Tyagi P, 2013, MOL PHARMACEUT, V10, P2858, DOI 10.1021/mp300716t
   Vaishya RD, 2014, WIRES NANOMED NANOBI, V6, P422, DOI 10.1002/wnan.1272
   Varshochian R, 2015, J BIOMED MATER RES A, V103, P3148, DOI 10.1002/jbm.a.35446
   Huu VAN, 2015, J CONTROL RELEASE, V200, P71, DOI 10.1016/j.jconrel.2015.01.001
   Villegas VM, 2016, EXPERT OPIN DRUG DEL, V2, P1
   Wang CH, 2012, BIOMACROMOLECULES, V13, P40, DOI 10.1021/bm2009558
   Wang JL, 2013, MEDIAT INFLAMM, V2013, DOI 10.1155/2013/780634
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wu XM, 2014, ACS NANO, V8, P153, DOI 10.1021/nn4054107
   Xiang P, 2014, BIOMATERIALS, V35, P9777, DOI 10.1016/j.biomaterials.2014.08.040
   Xie BB, 2015, INT J PHARMACEUT, V490, P375, DOI 10.1016/j.ijpharm.2015.05.071
   Xu QH, 2016, MACROMOL BIOSCI, V16, P635, DOI 10.1002/mabi.201500440
   Xu X, 2013, INT J BIOL MACROMOL, V60, P272, DOI 10.1016/j.ijbiomac.2013.05.034
   Yandrapu SK, 2013, MOL PHARMACEUT, V10, P4676, DOI 10.1021/mp400487f
   Yang SQ, 2016, DRUG DES DEV THER, V10, P1857, DOI 10.2147/DDDT.S97653
   Yasin MN, 2014, J CONTROL RELEASE, V196, P208, DOI 10.1016/j.jconrel.2014.09.030
   Yavuz B, 2015, J PHARM SCI-US, V104, P3814, DOI 10.1002/jps.24588
   Ye Z, 2015, INT J OPHTHALMOL-CHI, V8, P653, DOI 10.3980/j.issn.2222-3959.2015.04.02
   Yin HB, 2010, J BIOMED MATER RES B, V92B, P129, DOI 10.1002/jbm.b.31498
   Ying L, 2013, INT J PHARMACEUT, V453, P329, DOI 10.1016/j.ijpharm.2013.06.024
   Yuan X, 2015, ACS NANO, V9, P1749
   Zarbin M, 2016, TRENDS MOL MED, V22, P115, DOI 10.1016/j.molmed.2015.12.007
   Zhang LL, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0135608
   Zhang T, 2013, ANTIVIR RES, V97, P334, DOI 10.1016/j.antiviral.2012.12.019
   Zhou B, 2006, EXP EYE RES, V83, P615, DOI 10.1016/j.exer.2006.02.010
NR 128
TC 26
Z9 29
U1 0
U2 20
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1742-5247
EI 1744-7593
J9 EXPERT OPIN DRUG DEL
JI Expert Opin. Drug Deliv.
PY 2017
VL 14
IS 10
BP 1145
EP 1161
DI 10.1080/17425247.2017.1272569
PG 17
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA FF9MW
UT WOS:000409341600002
PM 27967247
DA 2022-11-30
ER

PT J
AU Dib, B
   Lin, HJ
   Maidana, DE
   Tian, B
   Miller, JB
   Bouzika, P
   Miller, JW
   Vavvas, DG
AF Dib, Bernard
   Lin, Haijiang
   Maidana, Daniel E.
   Tian, Bo
   Miller, John B.
   Bouzika, Peggy
   Miller, Joan W.
   Vavvas, Demetrios G.
TI Mitochondrial DNA has a pro-inflammatory role in AMD
SO BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH
LA English
DT Article
DE Age-related macular degeneration; Retinal pigment epithelium;
   Mitochondrial DNA; Inflammation; NLRP3 inflammasome
ID NF-KAPPA-B; RETINAL-PIGMENT EPITHELIUM; ENDOTHELIAL GROWTH-FACTOR;
   MACULAR DEGENERATION; NLRP3 INFLAMMASOME; CHOROIDAL NEOVASCULARIZATION;
   OXIDATIVE STRESS; ARPE-19 CELLS; MALATTIA LEVENTINESE; AQUEOUS-HUMOR
AB Age-related macular degeneration (AMD) is the leading cause of irreversible blindness in the elderly of industrialized nations, and there is increasing evidence to support a role for chronic inflammation in its pathogenesis. Mitochondrial DNA (mtDNA) has been recently reported to be pro-inflammatory in various diseases such as Alzheimer's and heart failure. Here, we report that intracellular mtDNA induces ARPE-19 cells to secrete inflammatory cytokines IL-6 and IL-8, which have been consistently associated with AMD onset and progression. The induction was dependent on the size of mtDNA, but not on specific sequence. Oxidative stress plays a major role in the development of AMD, and our findings indicate that mtDNA induces IL-6 and IL-8 more potently when oxidized. Cytokine induction was mediated by STING (Stimulator of Interferon Genes) and NF-kappa B as evidenced by abrogation of the cytokine response with the use of specific inhibitors (siRNA and BAY 11-7082, respectively). Finally, mtDNA primed the NLRP3 inflammasome. This study contributes to our understanding of the potential pro-inflammatory role of mtDNA in the pathogenesis of AMD. (C) 2015 Elsevier B.V. All rights reserved.
C1 [Dib, Bernard; Lin, Haijiang; Maidana, Daniel E.; Tian, Bo; Miller, John B.; Bouzika, Peggy; Miller, Joan W.; Vavvas, Demetrios G.] Harvard Univ, Sch Med, Massachusetts Eye & Ear Infirm, Dept Ophthalmol,Retina Serv,Angiogenesis Lab, Boston, MA 02114 USA.
C3 Harvard University; Harvard Medical School; Massachusetts Eye & Ear
   Infirmary
RP Vavvas, DG (通讯作者)，Harvard Univ, Massachusetts Eye & Ear Infirm, 243 Charles St, Boston, MA 02114 USA.
EM vavvas@meei.harvard.edu
RI Miller, John J/GZG-5663-2022
OI Lin, Haijiang/0000-0003-2931-468X; Vavvas,
   Demetrios/0000-0002-8622-6478; Dib, Bernard/0000-0001-8973-9503
FU NEI [R21EY023079-01A1, EY014104]; Yeatts Family Foundation; Loefflers
   Family Fund; research to prevent blindness foundation; Bayer Healthcare
   Global Ophthalmology Award; Macula Society Research Grant; NATIONAL EYE
   INSTITUTE [R21EY023079, P30EY014104, R01EY025362] Funding Source: NIH
   RePORTER
FX The authors would like to thank Mien Hoang and Keiko Kataoka for their
   technical support. This work was supported by: NEI R21EY023079-01A1
   (DGV); the Yeatts Family Foundation (DGV, JWM); the Loefflers Family
   Fund (DGV, JWM); the 2013 Macula Society Research Grant award (DGV); a
   Physician Scientist Award (DGV), an unrestricted grant (JWM) from the
   research to prevent blindness foundation; NEI grant EY014104 (Meei Core
   Grant); and Bayer Healthcare 2013 Global Ophthalmology Award (DEM).
CR Abe T, 2014, J VIROL, V88, P5328, DOI 10.1128/JVI.00037-14
   Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   Anderson OA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067263
   Bannwarth S, 2006, NAT PROTOC, V1, P2037, DOI 10.1038/nprot.2006.318
   Bauernfeind FG, 2009, J IMMUNOL, V183, P787, DOI 10.4049/jimmunol.0901363
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Blaauboer SM, 2014, J IMMUNOL, V192, P492, DOI 10.4049/jimmunol.1301812
   Blasiak J, 2013, INT J MOL SCI, V14, P2996, DOI 10.3390/ijms14022996
   Burdette DL, 2013, NAT IMMUNOL, V14, P19, DOI 10.1038/ni.2491
   Cao HD, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0113179
   Chen Y, 2011, MOL VIS, V17, P3072
   Cohen T, 1996, J BIOL CHEM, V271, P736, DOI 10.1074/jbc.271.2.736
   Collins LV, 2004, J LEUKOCYTE BIOL, V75, P995, DOI 10.1189/jlb.0703328
   Currais A, 2015, AGEING RES REV, V21, P30, DOI 10.1016/j.arr.2015.02.001
   Darzynkiewicz Z, 2007, CYTOM PART A, V71A, P536, DOI 10.1002/cyto.a.20425
   Doyle SL, 2012, NAT MED, V18, P791, DOI 10.1038/nm.2717
   Ebihara N, 2007, OPHTHAL RES, V39, P155, DOI 10.1159/000103235
   Feher J, 2006, NEUROBIOL AGING, V27, P983, DOI 10.1016/j.neurobiolaging.2005.05.012
   Fu L, 2007, HUM MOL GENET, V16, P2411, DOI 10.1093/hmg/ddm198
   Garg AD, 2010, BBA-REV CANCER, V1805, P53, DOI 10.1016/j.bbcan.2009.08.003
   Goverdhan SV, 2008, BRIT J OPHTHALMOL, V92, P537, DOI 10.1136/bjo.2007.123190
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Heidemann J, 2003, J BIOL CHEM, V278, P8508, DOI 10.1074/jbc.M208231200
   Hu YJ, 2014, DISCOV MED, V18, P7
   Izumi-Nagai K, 2008, INVEST OPHTH VIS SCI, V49, P1679, DOI 10.1167/iovs.07-1426
   Izumi-Nagai K, 2007, ARTERIOSCL THROM VAS, V27, P2555, DOI 10.1161/ATVBAHA.107.151431
   Izumi-Nagai K, 2007, AM J PATHOL, V170, P2149, DOI 10.2353/ajpath.2007.061018
   Jarrett SG, 2010, OPHTHALMIC RES, V44, P179, DOI 10.1159/000316480
   Kan MY, 2014, DIAGN PATHOL, V9, DOI 10.1186/1746-1596-9-73
   Karunadharma PP, 2010, INVEST OPHTH VIS SCI, V51, P5470, DOI 10.1167/iovs.10-5429
   Kauppinen A, 2012, IMMUNOL LETT, V147, P29, DOI 10.1016/j.imlet.2012.05.005
   Kenney MC, 2014, HUM MOL GENET, V23, P3537, DOI 10.1093/hmg/ddu065
   Kenney MC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054339
   Kerur N, 2013, INVEST OPHTH VIS SCI, V54, P7395, DOI 10.1167/iovs.13-12500
   Kimura K, 2000, AM J OPHTHALMOL, V130, P769, DOI 10.1016/S0002-9394(00)00552-3
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klein R, 2014, JAMA OPHTHALMOL, V132, P446, DOI 10.1001/jamaophthalmol.2013.7671
   Krysko DV, 2011, TRENDS IMMUNOL, V32, P157, DOI 10.1016/j.it.2011.01.005
   Lamkanfi M, 2014, CELL, V157, P1013, DOI 10.1016/j.cell.2014.04.007
   Latz E, 2004, NAT IMMUNOL, V5, P190, DOI 10.1038/ni1028
   Leifer CA, 2004, J IMMUNOL, V173, P1179, DOI 10.4049/jimmunol.173.2.1179
   Lin HJ, 2011, INVEST OPHTH VIS SCI, V52, P3521, DOI 10.1167/iovs.10-6163
   Liu XC, 2012, INFLAMMATION, V35, P776, DOI 10.1007/s10753-011-9379-4
   Marmorstein LHY, 2002, P NATL ACAD SCI USA, V99, P13067, DOI 10.1073/pnas.202491599
   Marneros AG, 2013, CELL REP, V4, P945, DOI 10.1016/j.celrep.2013.08.002
   Marques PE, 2012, HEPATOLOGY, V56, P1971, DOI 10.1002/hep.25801
   Martin D, 2009, J BIOL CHEM, V284, P6038, DOI 10.1074/jbc.C800207200
   Mathew A, 2012, J ALZHEIMERS DIS, V30, P617, DOI 10.3233/JAD-2012-120145
   Medzhitov R, 2008, NATURE, V454, P428, DOI 10.1038/nature07201
   Miao H, 2012, MOL VIS, V18, P574
   Mitter SK, 2014, AUTOPHAGY, V10, P1989, DOI 10.4161/auto.36184
   Muller F, 2000, J AM AGING ASSOC, V23, P227, DOI 10.1007/s11357-000-0022-9
   Nakahira K, 2011, NAT IMMUNOL, V12, P222, DOI 10.1038/ni.1980
   Nordgaard CL, 2006, INVEST OPHTH VIS SCI, V47, P815, DOI 10.1167/iovs.05-0976
   Oka T, 2012, NATURE, V490, P292, DOI 10.1038/nature11515
   Okamoto H, 2006, MOL VIS, V12, P156
   Paludan SR, 2013, IMMUNITY, V38, P870, DOI 10.1016/j.immuni.2013.05.004
   Patel M, 2008, SEMIN IMMUNOPATHOL, V30, P97, DOI 10.1007/s00281-008-0112-9
   Pazmandi K, 2014, FREE RADICAL BIO MED, V77, P281, DOI 10.1016/j.freeradbiomed.2014.09.028
   Piippo N, 2014, BBA-MOL CELL RES, V1843, P3038, DOI 10.1016/j.bbamcr.2014.09.015
   Pinti M, 2014, EUR J IMMUNOL, V44, P1552, DOI 10.1002/eji.201343921
   Puskarich MA, 2012, SHOCK, V38, P337, DOI 10.1097/SHK.0b013e318266a169
   Qiao Y, 2012, FEBS LETT, V586, P1022, DOI 10.1016/j.febslet.2012.02.045
   Reeve AK, 2008, ANN NY ACAD SCI, V1147, P21, DOI 10.1196/annals.1427.016
   Ricci F, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066978
   Ries M, 2013, J LEUKOCYTE BIOL, V94, P123, DOI 10.1189/jlb.0612278
   Roh MI, 2009, RETINA-J RET VIT DIS, V29, P523, DOI 10.1097/IAE.0b013e318195cb15
   SARKS SH, 1976, BRIT J OPHTHALMOL, V60, P324, DOI 10.1136/bjo.60.5.324
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P774, DOI 10.1001/archopht.123.6.774
   Shi G., 2015, INVEST OPHTHALMOL VI
   Shimada K, 2012, IMMUNITY, V36, P401, DOI 10.1016/j.immuni.2012.01.009
   Stone EM, 1999, NAT GENET, V22, P199, DOI 10.1038/9722
   Tarallo V, 2012, CELL, V149, P847, DOI 10.1016/j.cell.2012.03.036
   Terluk MR, 2015, J NEUROSCI, V35, P7304, DOI 10.1523/JNEUROSCI.0190-15.2015
   Tsai YY, 2008, INVEST OPHTH VIS SCI, V49, P693, DOI 10.1167/iovs.07-0125
   Tseng WA, 2013, INVEST OPHTH VIS SCI, V54, P110, DOI 10.1167/iovs.12-10655
   Tzeng HE, 2013, BIOCHEM PHARMACOL, V85, P531, DOI 10.1016/j.bcp.2012.11.021
   Udar N, 2009, INVEST OPHTH VIS SCI, V50, P2966, DOI 10.1167/iovs.08-2646
   Wilkins HM, 2014, J ALZHEIMERS DIS
   Xu HP, 2009, PROG RETIN EYE RES, V28, P348, DOI 10.1016/j.preteyeres.2009.06.001
   Yanagisawa S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028847
   Yoshida T, 2007, MOL VIS, V13, P545
   Zhang JZ, 2014, INT J MOL MED, V33, P817, DOI 10.3892/ijmm.2014.1650
   Zhang Q, 2010, NATURE, V464, P104, DOI 10.1038/nature08780
NR 84
TC 35
Z9 38
U1 0
U2 29
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0167-4889
EI 0006-3002
J9 BBA-MOL CELL RES
JI Biochim. Biophys. Acta-Mol. Cell Res.
PD NOV
PY 2015
VL 1853
IS 11
BP 2897
EP 2906
DI 10.1016/j.bbamcr.2015.08.012
PN A
PG 10
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA CT8LV
UT WOS:000363069000005
PM 26305120
OA Green Accepted, Bronze
DA 2022-11-30
ER

PT J
AU Cheung, N
   Wong, IY
   Wong, TY
AF Cheung, Ning
   Wong, Ian Y.
   Wong, Tien Y.
TI Ocular Anti-VEGF Therapy for Diabetic Retinopathy: Overview of Clinical
   Efficacy and Evolving Applications
SO DIABETES CARE
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; COHERENCE TOMOGRAPHIC PATTERNS; MACULAR
   EDEMA; INTRAVITREAL BEVACIZUMAB; DEFERRED LASER; RISK-FACTORS;
   RANIBIZUMAB; SAFETY; TRIAMCINOLONE; DEGENERATION
AB Ocular anti-vascular endothelial growth factor (VEGF) therapy represents one of the most significant advances in modern medicine. The introduction and widespread use of ocular anti-VEGF therapy for age-related macular degeneration heralded a new era in the treatment of vascular and exudative diseases of the retina. Its expanding indications now include diabetic macular edema and proliferative diabetic retinopathy, two vision-threatening forms of diabetic retinopathy. It is widely anticipated that ocular anti-VEGF therapy could spark a dramatic shift in the treatment paradigm for diabetic retinopathy. However, despite its clear efficacy shown in clinical trials, the dynamic landscape of evolving medical, ethical, and economic issues related to this new treatment suggests significant challenges ahead. In this article, we provide a discussion of this topic as part of this two-part Bench to Clinic narrative. Here, our Clinic contribution provides an overview of the current evidence from clinical trials on anti-VEGF therapy for diabetic retinopathy, and highlights the hopes and fears of this new treatment from clinical and public health standpoints. In the Bench narrative that precedes this contribution, Simo et al. provide an overview of the role of VEGF in the pathogenesis of diabetic retinopathy.
C1 [Cheung, Ning; Wong, Ian Y.] Univ Hong Kong, Inst Eye, Dept Ophthalmol, Hong Kong, Hong Kong, Peoples R China.
   [Cheung, Ning; Wong, Tien Y.] Natl Univ Singapore, Singapore Natl Eye Ctr, Singapore Eye Res Inst, Singapore 117548, Singapore.
   [Cheung, Ning; Wong, Tien Y.] Univ Melbourne, Royal Victorian Eye & Ear Hosp, Ctr Eye Res Australia, Melbourne, Vic, Australia.
C3 University of Hong Kong; National University of Singapore; Singapore
   National Eye Center; Centre for Eye Research Australia; Royal Victorian
   Eye & Ear Hospital; University of Melbourne
RP Cheung, N (通讯作者)，Univ Hong Kong, Inst Eye, Dept Ophthalmol, Hong Kong, Hong Kong, Peoples R China.
EM dannycheung@hotmail.com
RI Wong, Tien Yin/AAC-9724-2020
OI Wong, Tien Yin/0000-0002-8448-1264
FU Bayer; Pfizer; Novartis; Alcon; Allergan
FX N.C. has received grants from Bayer and Pfizer. I.Y.W. has received
   consultant fees from Bayer; grants from Novartis, Alcon, Allergan, and
   Bayer; and lecture honorarium from Global Vision China. T.Y.W. is on
   advisory boards for Abbott, Allergan, Bayer, Novartis, Pfizer, and
   Solvay and has received travel, honorarium, and research support from
   these companies. He has no stocks, equity, contracts of employment, or
   named positions on company boards. No other potential conflicts of
   interest relevant to this article were reported.
CR Aiello LP, 2010, OPHTHALMOLOGY, V117, P946, DOI 10.1016/j.ophtha.2009.10.002
   Antonetti DA, 2012, NEW ENGL J MED, V366, P1227, DOI 10.1056/NEJMra1005073
   Bandello F, 2012, EYE, V26, P485, DOI 10.1038/eye.2011.337
   Bressler SB, 2013, JAMA OPHTHALMOL, V131, P1033, DOI 10.1001/jamaophthalmol.2013.4154
   Brown DM, 2013, OPHTHALMOLOGY, V120, P2013, DOI 10.1016/j.ophtha.2013.02.034
   Chan JCN, 2009, JAMA-J AM MED ASSOC, V301, P2129, DOI 10.1001/jama.2009.726
   Cheung CMG, 2013, LANCET, V382, P1230, DOI 10.1016/S0140-6736(13)61580-9
   Cheung N, 2008, PROG RETIN EYE RES, V27, P161, DOI 10.1016/j.preteyeres.2007.12.001
   Cheung N, 2012, AM J OPHTHALMOL, V153, P193, DOI 10.1016/j.ajo.2011.11.022
   Cheung N, 2010, LANCET, V376, P124, DOI 10.1016/S0140-6736(09)62124-3
   Curtis LH, 2010, ARCH OPHTHALMOL-CHIC, V128, P1273, DOI 10.1001/archophthalmol.2010.223
   Department of Health and Human Services, 2011, REV MED PART B AV LU
   Diabetic Retinopathy Clinical Research Network*, 2013, JAMA Ophthalmol, V131, P283, DOI 10.1001/jamaophthalmol.2013.2015
   Do DV, 2013, JAMA OPHTHALMOL, V131, P139, DOI 10.1001/2013.jamaophthalmol.91
   Do DV, 2012, OPHTHALMOLOGY, V119, P1658, DOI 10.1016/j.ophtha.2012.02.010
   Elman MJ, 2012, OPHTHALMOLOGY, V119, P2312, DOI 10.1016/j.ophtha.2012.08.022
   Elman MJ, 2011, OPHTHALMOLOGY, V118, P609, DOI 10.1016/j.ophtha.2010.12.033
   International Diabetes Federation, 2011, IDF DIABETES ATLAS
   Ip MS, 2012, ARCH OPHTHALMOL-CHIC, V130, P1145, DOI 10.1001/archophthalmol.2012.1043
   Kim NR, 2009, BRIT J OPHTHALMOL, V93, P901, DOI 10.1136/bjo.2008.152553
   KLEIN R, 1995, OPHTHALMOLOGY, V102, P7
   Lang GE, 2013, OPHTHALMOLOGY, V120, P2004, DOI 10.1016/j.ophtha.2013.02.019
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Lim LS, 2011, AM J OPHTHALMOL, V152, P329, DOI 10.1016/j.ajo.2011.05.040
   Maia OO, 2009, AM J OPHTHALMOL, V147, P291, DOI 10.1016/j.ajo.2008.08.024
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Massin P, 2010, DIABETES CARE, V33, P2399, DOI 10.2337/dc10-0493
   Mitchell P, 2011, OPHTHALMOLOGY, V118, P615, DOI 10.1016/j.ophtha.2011.01.031
   Nepomuceno AB, 2013, AM J OPHTHALMOL, V156, P502, DOI 10.1016/j.ajo.2013.04.026
   Nguyen QD, 2012, OPHTHALMOLOGY, V119, P789, DOI 10.1016/j.ophtha.2011.12.039
   Quan DN, 2010, OPHTHALMOLOGY, V117, P2146, DOI 10.1016/j.ophtha.2010.08.016
   Rajendram R, 2012, ARCH OPHTHALMOL-CHIC, V130, P972, DOI 10.1001/archophthalmol.2012.393
   Schmucker C, 2011, BRIT J OPHTHALMOL, V95, P308, DOI 10.1136/bjo.2009.178574
   Simo R, 2014, DIABETES CARE, V37, P893, DOI 10.2337/dc13-2002
   Smiddy WE, 2012, OPHTHALMOLOGY, V119, P2558, DOI 10.1016/j.ophtha.2012.09.015
   Smith JM, 2011, COCHRANE DB SYST REV, V5
   Stein JD, 2013, OPHTHALMOLOGY, V120, P1835, DOI 10.1016/j.ophtha.2013.02.002
   Sultan MB, 2011, OPHTHALMOLOGY, V118, P1107, DOI 10.1016/j.ophtha.2011.02.045
   Van Geest RJ, 2012, BRIT J OPHTHALMOL, V96, P587, DOI 10.1136/bjophthalmol-2011-301005
   Virgili G, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008081.pub2
   Wirostko B, 2008, PROG RETIN EYE RES, V27, P608, DOI 10.1016/j.preteyeres.2008.09.002
   Wu PC, 2012, J OCUL PHARMACOL TH, V28, P59, DOI 10.1089/jop.2011.0070
   Yau JWY, 2012, DIABETES CARE, V35, P556, DOI 10.2337/dc11-1909
   Zechmeister-Koss I, 2012, BRIT J OPHTHALMOL, V96, P167, DOI 10.1136/bjophthalmol-2011-300674
   Zehetner C, 2013, BRIT J OPHTHALMOL, V97, P454, DOI 10.1136/bjophthalmol-2012-302451
   Zhang XZ, 2010, JAMA-J AM MED ASSOC, V304, P649, DOI 10.1001/jama.2010.1111
NR 46
TC 88
Z9 93
U1 0
U2 18
PU AMER DIABETES ASSOC
PI ALEXANDRIA
PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA
SN 0149-5992
EI 1935-5548
J9 DIABETES CARE
JI Diabetes Care
PD APR
PY 2014
VL 37
IS 4
BP 900
EP 905
DI 10.2337/dc13-1990
PG 6
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Endocrinology & Metabolism
GA AD7BB
UT WOS:000333414700016
PM 24652721
OA hybrid
DA 2022-11-30
ER

PT J
AU Arden, GB
   Sidman, RL
   Arap, W
   Schlingemann, RO
AF Arden, GB
   Sidman, RL
   Arap, W
   Schlingemann, RO
TI Spare the rod and spoil the eye
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Review
ID ENDOTHELIAL GROWTH-FACTOR; RETINAL-PIGMENT EPITHELIUM; OXYGEN-INDUCED
   RETINOPATHY; GLYCATION END-PRODUCTS; MACULAR DEGENERATION;
   DIABETIC-RETINOPATHY; DARK-ADAPTATION; BRUCHS MEMBRANE; LASER TREATMENT;
   POSSIBLE PARTICIPATION
AB This review presents a new unified view of the pathogenesis of three common causes of acquired retinal degenerative disease - diabetic retinopathy, age related macular degeneration, and retinopathy of prematurity. In these three conditions, angiogenesis has a predominant role in the development of sight threatening pathology. Angiogenesis is controlled by among other factors the expression of vascular endothelial growth factor (VEGF), which in turn is regulated by absolute and relative lack of oxygen. The severe pathological manifestations of these three conditions are not part of a general underlying disease process because they are peculiar to the eye, and the profound hypoxia that develops in normal retina during dark adaptation (rod driven hypoxia) is an adequate and elegant additional factor to explain their pathogenesis. A large number of experimental reports support this conclusion, although rod driven anoxia is not generally considered as a causal factor in ocular disease. However, the hypothesis can be critically tested, and also suggests novel methods of treatment and prevention of these conditions that may be simpler and more inexpensive than current therapies and that have a smaller potential for adverse effects.
C1 City Univ London, Henry Wellcome Labs, Appl Vis Res Ctr, Dept Optometry & Visual Sci, London EC1V 0HB, England.
   Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Neurol, Boston, MA USA.
   Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA.
   Acad Med Ctr, Dept Ophthalmol, Med Retina Unit, NL-1100 DE Amsterdam, Netherlands.
C3 City University London; Harvard University; Beth Israel Deaconess
   Medical Center; Harvard Medical School; University of Texas System; UTMD
   Anderson Cancer Center; University of Amsterdam; Academic Medical Center
   Amsterdam
RP Arden, GB (通讯作者)，City Univ London, Henry Wellcome Labs, Appl Vis Res Ctr, Dept Optometry & Visual Sci, Northampton Sq, London EC1V 0HB, England.
EM g.arden@city.ac.uk
OI Arden, Geoffrey/0000-0001-7334-2026
CR Abdelsalam A, 1999, SURV OPHTHALMOL, V44, P1, DOI 10.1016/S0039-6257(99)00072-7
   Adler R, 1999, MOL VIS, V5
   Amin RH, 1997, INVEST OPHTH VIS SCI, V38, P36
   [Anonymous], 1993, Arch Ophthalmol, V111, P1200
   Arden GB, 2004, BRIT J OPHTHALMOL, V88, P1180, DOI 10.1136/bjo.2003.033480
   Arden GB, 2001, BRIT J OPHTHALMOL, V85, P366, DOI 10.1136/bjo.85.3.366
   Arden GB, 2003, INVEST OPHTH VIS SCI, V44, P3226, DOI 10.1167/iovs.02-0998
   ARDEN GB, 2005, INVEST OPHTHALMOL VI
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Blaauwgeers HGT, 1999, AM J PATHOL, V155, P421, DOI 10.1016/S0002-9440(10)65138-3
   BRAUN RD, 1995, INVEST OPHTH VIS SCI, V36, P542
   BROWN B, 1986, OPHTHAL PHYSL OPT, V6, P81, DOI 10.1111/j.1475-1313.1986.tb00704.x
   Brownlee M, 2001, NATURE, V414, P813, DOI 10.1038/414813a
   Cai JY, 2000, PROG RETIN EYE RES, V19, P205, DOI 10.1016/S1350-9462(99)00009-9
   CHENG AS, 1993, OPTOMETRY VISION SCI, V70, P89, DOI 10.1097/00006324-199302000-00001
   Ciulla TA, 2002, BRIT J OPHTHALMOL, V86, P209, DOI 10.1136/bjo.86.2.209
   Curcio CA, 2001, EYE, V15, P376, DOI 10.1038/eye.2001.140
   DAMORE PA, 1994, INVEST OPHTH VIS SCI, V35, P3974
   Darzins P, 1997, OPHTHALMOLOGY, V104, P770, DOI 10.1016/S0161-6420(97)30235-8
   Dean FM, 1997, BRIT J OPHTHALMOL, V81, P27, DOI 10.1136/bjo.81.1.27
   DEUTMAN AF, 2004, OPHTHALMIC RES S
   Dowling JE, 1987, RETINA APPROACHABLE, P282
   Drasdo N, 2002, LANCET, V359, P2251, DOI 10.1016/S0140-6736(02)09265-6
   Ebrey T, 2001, PROG RETIN EYE RES, V20, P49, DOI 10.1016/S1350-9462(00)00014-8
   EISNER A, 1987, INVEST OPHTH VIS SCI, V28, P1832
   Ferrara N, 1999, CURR TOP MICROBIOL, V237, P1
   Frennesson C, 1998, BRIT J OPHTHALMOL, V82, P1169, DOI 10.1136/bjo.82.10.1169
   Frennesson I C, 1996, Eur J Ophthalmol, V6, P307
   Gardner TW, 2002, SURV OPHTHALMOL, V47, pS253, DOI 10.1016/S0039-6257(02)00387-9
   Gilbert RE, 1998, LAB INVEST, V78, P1017
   Green W R, 1999, Mol Vis, V5, P27
   Gu XR, 2003, J BIOL CHEM, V278, P42027, DOI 10.1074/jbc.M305460200
   Guymer RH, 1997, ARCH OPHTHALMOL-CHIC, V115, P595, DOI 10.1001/archopht.1997.01100150597004
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   HAGINS WA, 1989, P NATL ACAD SCI USA, V86, P1224, DOI 10.1073/pnas.86.4.1224
   Haimovici R, 2002, GRAEF ARCH CLIN EXP, V240, P90, DOI 10.1007/s00417-001-0417-z
   Hammes HP, 1998, DIABETES, V47, P401, DOI 10.2337/diabetes.47.3.401
   Harris A, 1996, BRIT J OPHTHALMOL, V80, P209, DOI 10.1136/bjo.80.3.209
   HAUGHSCHEIDT LM, 1995, EXP EYE RES, V61, P73, DOI 10.1016/S0014-4835(95)80060-3
   Havelius U, 1997, NEUROLOGY, V49, P1360, DOI 10.1212/WNL.49.5.1360
   Havelius U, 1997, NEUROLOGY, V49, P1353, DOI 10.1212/WNL.49.5.1353
   Havelius U, 2000, ACTA OPHTHALMOL SCAN, V78, P53, DOI 10.1034/j.1600-0420.2000.078001053.x
   Ho AC, 1999, OPHTHALMOLOGY, V106, P1367, DOI 10.1016/S0161-6420(99)00735-6
   Hofman P, 2001, ARCH OPHTHALMOL-CHIC, V119, P861
   Hofman P, 2001, OPHTHALMIC RES, V33, P156, DOI 10.1159/000055663
   Holmes-Walker DJ, 1998, DIABETIC MED, V15, P946, DOI 10.1002/(SICI)1096-9136(1998110)15:11<946::AID-DIA707>3.0.CO;2-L
   HOLTZ FG, 1985, GER J OPHTHALMOL, V4, P336
   Holz F G, 1995, Ger J Ophthalmol, V4, P336
   HOLZ FG, 1994, ARCH OPHTHALMOL-CHIC, V112, P402, DOI 10.1001/archopht.1994.01090150132035
   Hurley JB, 2002, J GEN PHYSIOL, V119, P125, DOI 10.1085/jgp.119.2.125
   Jackson GR, 2002, AGEING RES REV, V1, P381, DOI 10.1016/S1568-1637(02)00007-7
   Joussen AM, 2002, AM J PATHOL, V160, P501, DOI 10.1016/S0002-9440(10)64869-9
   Kent D, 2000, BRIT J OPHTHALMOL, V84, P542, DOI 10.1136/bjo.84.5.542
   Kern TS, 1996, ARCH OPHTHALMOL-CHIC, V114, P306, DOI 10.1001/archopht.1996.01100130302013
   Kondo T, 2003, J CLIN INVEST, V111, P1835, DOI 10.1172/JCI200317455
   Lahdenranta J, 2001, P NATL ACAD SCI USA, V98, P10368, DOI 10.1073/pnas.181329198
   LEYS A, 2004, OPHTHALMIC RES S, P2163
   Linsenmeier RA, 1998, INVEST OPHTH VIS SCI, V39, P1647
   LINSENMEIER RA, 1986, J GEN PHYSIOL, V88, P521, DOI 10.1085/jgp.88.4.521
   Little HL, 1997, OPHTHALMOLOGY, V104, P623, DOI 10.1016/S0161-6420(97)30261-9
   Lu M, 1998, J CLIN INVEST, V101, P1219, DOI 10.1172/JCI1277
   Lutty G, 1999, MOL VIS, V5
   Mackenzie PJ, 2002, OPHTHALMOLOGY, V109, P720, DOI 10.1016/S0161-6420(01)01021-1
   Malek G, 2003, AM J PATHOL, V162, P413, DOI 10.1016/S0002-9440(10)63836-9
   Marmorstein AD, 1998, ANN NY ACAD SCI, V857, P1, DOI 10.1111/j.1749-6632.1998.tb10102.x
   Marsh S, 2000, DIABETES CARE, V23, P1375, DOI 10.2337/diacare.23.9.1375
   McFarland RA, 1939, AM J PHYSIOL, V127, P37, DOI 10.1152/ajplegacy.1939.127.1.37
   MITZUTANI M, 1996, J CLIN INVEST, V97, P2883
   Murata T, 1996, LAB INVEST, V74, P819
   Nguyen QD, 2004, INVEST OPHTH VIS SCI, V45, P617, DOI 10.1167/iovs.03-0557
   Nguyen-Legros J, 2000, INT REV CYTOL, V196, P245
   NOMURA M, 1995, J BIOL CHEM, V270, P28316
   Owsley C, 2000, INVEST OPHTH VIS SCI, V41, P267
   Pugh EN, 1999, CURR OPIN NEUROBIOL, V9, P410, DOI 10.1016/S0959-4388(99)80062-2
   Qaum T, 2001, INVEST OPHTH VIS SCI, V42, P2408
   RAMRATTAN RS, 1994, INVEST OPHTH VIS SCI, V35, P2857
   REME CE, 1998, RETINAL PIGMENT EPIT, V29, P563
   Reynolds JD, 1998, NEW ENGL J MED, V338, P1572, DOI 10.1056/NEJM199805283382202
   Sarks SH, 1996, AUST NZ J OPHTHALMOL, V24, P15, DOI 10.1111/j.1442-9071.1996.tb01546.x
   Schlingemann RO, 2004, GRAEF ARCH CLIN EXP, V242, P91, DOI 10.1007/s00417-003-0828-0
   Segawa Y, 1998, OPHTHALMIC RES, V30, P333, DOI 10.1159/000055493
   SHARMA NK, 1985, AM J OPHTHALMOL, V100, P51, DOI 10.1016/S0002-9394(14)74982-7
   SMITH LEH, 1994, INVEST OPHTH VIS SCI, V35, P101
   SMITH PR, 1999, ADV EXP MED BIOL, V169, P661
   SMITH VC, 1988, J OPT SOC AM A, V5, P2113, DOI 10.1364/JOSAA.5.002113
   Sone H, 1997, DIABETOLOGIA, V40, P726, DOI 10.1007/s001250050740
   Spilsbury K, 2000, AM J PATHOL, V157, P135, DOI 10.1016/S0002-9440(10)64525-7
   Spraul CW, 1996, INVEST OPHTH VIS SCI, V37, P2724
   Sue CM, 1997, NEUROLOGY, V49, P1013, DOI 10.1212/WNL.49.4.1013
   Tolentino MJ, 1996, OPHTHALMOLOGY, V103, P1820, DOI 10.1016/S0161-6420(96)30420-X
   Voutilainen-Kaunisto RM, 2000, DIABETES CARE, V23, P1672, DOI 10.2337/diacare.23.11.1672
   WEITZIG PC, 1994, T AM OPHTHAL SOC, V92, P299
   WESOLOWSKI E, 1994, INVEST OPHTH VIS SCI, V35, P112
   WILLIAMSON JR, 1993, DIABETES, V42, P801, DOI 10.2337/diabetes.42.6.801
   Witmer AN, 2003, PROG RETIN EYE RES, V22, P1, DOI 10.1016/S1350-9462(02)00043-5
   YOUNG RW, 1969, J CELL BIOL, V42, P392, DOI 10.1083/jcb.42.2.392
   Yu DY, 2001, PROG RETIN EYE RES, V20, P175, DOI 10.1016/S1350-9462(00)00027-6
   Zack DJ, 1999, MOL VIS, V5, pU37
   Zarbin MA, 1998, EUR J OPHTHALMOL, V8, P199, DOI 10.1177/112067219800800401
   Zylbermann R, 1997, EYE, V11, P872, DOI 10.1038/eye.1997.224
NR 100
TC 127
Z9 133
U1 0
U2 17
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD JUN
PY 2005
VL 89
IS 6
BP 764
EP 769
DI 10.1136/bjo.2004.062547
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 930RP
UT WOS:000229434300026
PM 15923516
OA Green Published, Bronze, Green Submitted
DA 2022-11-30
ER

PT J
AU Terasaki, H
   Miyake, Y
   Niwa, T
   Ito, Y
   Suzuki, T
   Kikuchi, M
   Kondo, M
AF Terasaki, H
   Miyake, Y
   Niwa, T
   Ito, Y
   Suzuki, T
   Kikuchi, M
   Kondo, M
TI Focal macular electroretinograms before and after removal of choroidal
   neovascular lesions
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID TRANSLOCATION SURGERY; PHOTODYNAMIC THERAPY; DEGENERATION; VERTEPORFIN
AB PURPOSE. To evaluate the changes in focal macular electroretinograms (fmERGs) after surgical removal of choroidal neovascular (CNV) lesions.
   METHODS. Fourteen patients (14 eyes) with subfoveal or juxtafoveal CNV associated with age-related macular degeneration and 1 patient with idiopathic CNV underwent vitrectomy and removal of the lesions, fmERGs elicited by a 15degrees stimulus were recorded before and 3 months after surgery. Optical coherence tomography (OCT) was performed to measure the foveal and parafoveal thickness before and 3 months after surgery.
   RESULTS. Preoperative fmERGs were markedly reduced in all eyes. The mean amplitude of the b-wave in 15 eyes recorded 3 months after surgery increased significantly (P = 0.0022, Wilcoxon signed rank test). In all eyes except two with nearly nonrecordable a- and b- waves, the mean b-wave-to-a-wave ratio after surgery increased significantly in all eyes (P = 0.0330, Wilcoxon signed rank test). The percentage increase in the b-wave amplitude correlated significantly with the percentage decrease in the mean parafoveal retinal thickness (r = 0.088, P = 0.0076).
   CONCLUSIONS. The decreased macular ERGs were partially recoverable in the early postoperative period. The decreased retinal edema after surgery, may have contributed to this recovery.
C1 Nagoya Univ, Sch Med, Dept Ophthalmol, Showa Ku, Nagoya, Aichi 466, Japan.
C3 Nagoya University
RP Terasaki, H (通讯作者)，Nagoya Univ, Sch Med, Dept Ophthalmol, Showa Ku, 65 Tsuruma Cho, Nagoya, Aichi 466, Japan.
EM terasaki@med.nagoya-u.ac.jp
RI Terasaki, Hiroko/M-5054-2014; Ito, Yasuki/M-4876-2014
OI Ito, Yasuki/0000-0001-9219-9261
CR ALEXANDER MF, 1988, ARCH OPHTHALMOL-CHIC, V106, P1543, DOI 10.1001/archopht.1988.01060140711040
   *AM AC OPHTH, 2000, OPHTHALMOLOGY, V107, P1015
   BIERSDORF WR, 1990, DOC OPHTHALMOL, V73, P313
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Bressler NM, 2000, INVEST OPHTH VIS SCI, V41, P624
   BUSH RA, 1994, INVEST OPHTH VIS SCI, V35, P635
   Cekic O, 1999, LANCET, V354, P340, DOI 10.1016/S0140-6736(05)75249-1
   Giovannini A, 1999, BRIT J OPHTHALMOL, V83, P438, DOI 10.1136/bjo.83.4.438
   GREEN WR, 1993, OPHTHALMOLOGY, V100, P1519
   HAYASHI H, 1997, J JPN OPHTHALMOL SOC, V101, P417
   Hee MR, 1996, OPHTHALMOLOGY, V103, P1260, DOI 10.1016/S0161-6420(96)30512-5
   Kretschmann U, 1996, OPHTHALMIC RES, V28, P303, DOI 10.1159/000267919
   Merrill PT, 1999, OPHTHALMOLOGY, V106, P782, DOI 10.1016/S0161-6420(99)90167-7
   MIYAKE Y, 1988, AM J OPHTHALMOL, V106, P546, DOI 10.1016/0002-9394(88)90583-1
   MIYAKE Y, 1988, INVEST OPHTH VIS SCI, V29, P1631
   MIYAKE Y, 1988, ACTA SOC OPHTHALMOL, V92, P1418
   Pieramici DJ, 2000, AM J OPHTHALMOL, V130, P419, DOI 10.1016/S0002-9394(00)00533-X
   Potter MJ, 2000, AM J OPHTHALMOL, V129, P547, DOI 10.1016/S0002-9394(99)00480-8
   Reichel E, 1999, OPHTHALMOLOGY, V106, P1908, DOI 10.1016/S0161-6420(99)90400-1
   THOMAS MA, 1992, OPHTHALMOLOGY, V99, P952
NR 20
TC 14
Z9 14
U1 0
U2 0
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD MAY
PY 2002
VL 43
IS 5
BP 1540
EP 1545
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 548FN
UT WOS:000175378100038
PM 11980872
DA 2022-11-30
ER

PT J
AU Schweitzer, D
   Lang, GE
   Beuermann, B
   Remsch, H
   Hammer, M
   Thamm, E
   Spraul, CW
   Lang, GK
AF Schweitzer, D
   Lang, GE
   Beuermann, B
   Remsch, H
   Hammer, M
   Thamm, E
   Spraul, CW
   Lang, GK
TI Objective determination of the optical density of xanthophyll after
   supplementation of lutein
SO OPHTHALMOLOGE
LA English
DT Article
DE xanthophyll; lutein; age-related macular degeneration; imaging
   spectrometry; laser scanning ophthalmoscopy
ID HUMAN MACULAR PIGMENT; OXYGEN-SATURATION; PRIMATE RETINAS
AB Background. It is thought that a high optical density of xanthophyll has a protective effect against the development of agerelated macular degeneration, The aim of this study was to investigate whether an increase of the optical density of xanthophyll in the macula after a supplementation of lutein can be proven by objective methods. Most methods applied for the determination of the macular pigment require the co-operation of the proband and the ability for foveal fixation.
   Method. Imaging spectrometry and the evaluation of laser scanner images taken at 488 nm will be presented. In contrast to psychophysical methods, both methods are independent of the patients ability for foveal fixation.
   Results. Even by evaluation of laser scanner images taken as in fluorescence angiography but without inserting the blocking filter, the 2-dimensional distribution of xanthophyll can be determined. In 10 probands taking 6 mg lutein daily over 40 days,an increase of the optical density could be determined at least in some probands. The optical density reached a plateau 30 days after starting the supplementation of lutein.
   Conclusion. The assumed protective effect of xanthophyll against age-related macular degeneration can be influenced by supplementation of lutein under objective control.
C1 Univ Jena, Augenklin, Bereich Expt Ophthalmol, D-07740 Jena, Germany.
   Univ Ulm, Augenklin, D-89069 Ulm, Germany.
C3 Friedrich Schiller University of Jena; University of Hamburg; University
   Medical Center Hamburg-Eppendorf; Ulm University; University of Hamburg;
   University Medical Center Hamburg-Eppendorf
RP Schweitzer, D (通讯作者)，Univ Jena, Augenklin, Bereich Expt Ophthalmol, Bachstr 18, D-07740 Jena, Germany.
EM Dietrich.Schweitzer@med.uni-jena.de
CR Berendschot TTJM, 2000, INVEST OPHTH VIS SCI, V41, P3322
   BONE RA, 1985, VISION RES, V25, P1531, DOI 10.1016/0042-6989(85)90123-3
   BONE RA, 1996, INVEST OPHTH VIS SCI, V37, P112
   BROSIUS GG, 1995, SPSS BASE SYSTEM PRO, P690
   Edwards R. B., 1996, Investigative Ophthalmology and Visual Science, V37, pS914
   ELSNER AE, 1990, LASER SCANNING OPHTH, P109
   Hammer M, 1997, J Biomed Opt, V2, P418, DOI 10.1117/12.285093
   Hammond BR, 1997, INVEST OPHTH VIS SCI, V38, P1795
   HUPFER U, 1998, THESIS F SCHILLER U
   KONIGSDORFFER E, 1994, MAPPING SPEKTROMETRI
   Landrum JT, 1997, EXP EYE RES, V65, P57, DOI 10.1006/exer.1997.0309
   Schweitzer D, 1996, OPHTHALMIC RES, V28, P37, DOI 10.1159/000267955
   Schweitzer D, 1991, Fortschr Ophthalmol, V88, P554
   Schweitzer D, 1999, IEEE T BIO-MED ENG, V46, P1454, DOI 10.1109/10.804573
   Schweitzer D, 2000, OPHTHALMOLOGE, V97, P84, DOI 10.1007/s003470050017
   SCHWEITZER D, 1996, INVEST OPHTH VIS SCI, V37, P115
   SCHWEITZER D, 1998, LASER LIGHT, V8, P153
   SNODDERLY DM, 1984, INVEST OPHTH VIS SCI, V25, P660
   SNODDERLY DM, 1995, AM J CLIN NUTR, V62, P1448
   SNODDERLY DM, 1984, INVEST OPHTH VIS SCI, V25, P674
NR 20
TC 16
Z9 17
U1 0
U2 4
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0941-293X
EI 1433-0423
J9 OPHTHALMOLOGE
JI Ophthalmologe
PD APR
PY 2002
VL 99
IS 4
BP 270
EP +
DI 10.1007/s003470100533
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 555LA
UT WOS:000175794500004
PM 12058502
DA 2022-11-30
ER

PT J
AU El-Darzi, N
   Mast, N
   Buchner, DA
   Saadane, A
   Dailey, B
   Trichonas, G
   Pikuleva, IA
AF El-Darzi, Nicole
   Mast, Natalia
   Buchner, David A.
   Saadane, Aicha
   Dailey, Brian
   Trichonas, Georgios
   Pikuleva, Irina A.
TI Low-Dose Anti-HIV Drug Efavirenz Mitigates Retinal Vascular Lesions in a
   Mouse Model of Alzheimer's Disease
SO FRONTIERS IN PHARMACOLOGY
LA English
DT Article
DE retina; retinal angiomatous proliferation; efavirenz; retinal-choroidal
   anastomosis
ID LIVER-X RECEPTORS; SUBRETINAL DRUSENOID DEPOSITS; CHOLESTEROL
   24-HYDROXYLASE; MACULAR DEGENERATION; CHOROIDAL NEOVASCULARIZATION;
   TYPE-3 NEOVASCULARIZATION; CYTOCHROME-P450 46A1; READ ALIGNMENT; BASAL
   DEPOSITS; CELL-ADHESION
AB A small dose of the anti-HIV drug efavirenz (EFV) was previously discovered to activate CYP46A1, a cholesterol-eliminating enzyme in the brain, and mitigate some of the manifestation of Alzheimer's disease in 5XFAD mice. Herein, we investigated the retina of these animals, which were found to have genetically determined retinal vascular lesions associated with deposits within the retinal pigment epithelium and subretinal space. We established that EFV treatment activated CYP46A1 in the retina, enhanced retinal cholesterol turnover, and diminished the lesion frequency >5-fold. In addition, the treatment mitigated fluorescein leakage from the aberrant blood vessels, deposit size, activation of retinal macrophages/microglia, and focal accumulations of amyloid beta plaques, unesterified cholesterol, and Oil Red O-positive lipids. Studies of retinal transcriptomics and proteomics identified biological processes enriched with differentially expressed genes and proteins. We discuss the mechanisms of the beneficial EFV effects on the retinal phenotype of 5XFAD mice. As EFV is an FDA-approved drug, and we already tested the safety of small-dose EFV in patients with Alzheimer's disease, our data support further clinical investigation of this drug in subjects with retinal vascular lesions or neovascular age-related macular degeneration.
C1 [El-Darzi, Nicole; Mast, Natalia; Saadane, Aicha; Dailey, Brian; Trichonas, Georgios; Pikuleva, Irina A.] Dept Ophthalmol, Cleveland Hts, OH 44106 USA.
   [Buchner, David A.] Case Western Reserve Univ, Dept Genome Sci, Cleveland Hts, OH USA.
   [El-Darzi, Nicole; Mast, Natalia; Saadane, Aicha; Dailey, Brian; Trichonas, Georgios; Pikuleva, Irina A.] Dept Visual Sci, Cleveland Hts, OH 44106 USA.
   [Buchner, David A.] Case Western Reserve Univ, Dept Genet, Cleveland Hts, OH USA.
C3 Case Western Reserve University; Case Western Reserve University
RP Pikuleva, IA (通讯作者)，Dept Ophthalmol, Cleveland Hts, OH 44106 USA.; Pikuleva, IA (通讯作者)，Dept Visual Sci, Cleveland Hts, OH 44106 USA.
EM iap8@case.edu
CR Ali T, 2021, ACTA NEUROPATHOL COM, V9, DOI 10.1186/s40478-021-01162-1
   Amado-Azevedo J, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-10392-0
   Ambati BK, 2007, BRIT J OPHTHALMOL, V91, P505, DOI 10.1136/bjo.2006.107417
   Ambati BK, 2006, NATURE, V443, P993, DOI 10.1038/nature05249
   Apte RS, 2006, PLOS MED, V3, P1371, DOI 10.1371/journal.pmed.0030310
   Banerjee S, 2021, ISCIENCE, V24, DOI 10.1016/j.isci.2021.102718
   Berg J.M., 2002, BIOCHEMISTRY-US, V5th, P722
   Boussicault L, 2016, BRAIN, V139, P953, DOI 10.1093/brain/awv384
   Breazzano MP, 2020, RETINA-J RET VIT DIS, V40, pE55, DOI 10.1097/IAE.0000000000002892
   Bretillon L, 2007, CURR EYE RES, V32, P361, DOI 10.1080/02713680701231857
   Burlot MA, 2015, HUM MOL GENET, V24, P5965, DOI 10.1093/hmg/ddv268
   Calkin AC, 2012, NAT REV MOL CELL BIO, V13, P213, DOI 10.1038/nrm3312
   Campos M, 2006, INVEST OPHTH VIS SCI, V47, P5163, DOI 10.1167/iovs.06-0156
   Cao GQ, 2004, DRUG NEWS PERSPECT, V17, P35, DOI 10.1358/dnp.2004.17.1.829024
   Chappell JC, 2019, J DEV BIOL, V7, DOI 10.3390/jdb7030018
   Checchin D, 2006, INVEST OPHTH VIS SCI, V47, P3595, DOI 10.1167/iovs.05-1522
   Chen KC, 2016, AM J OPHTHALMOL, V164, P89, DOI 10.1016/j.ajo.2016.02.002
   Chen WL, 2007, CELL METAB, V5, P73, DOI 10.1016/j.cmet.2006.11.012
   Choudhary M, 2020, JCI INSIGHT, V5, DOI 10.1172/jci.insight.131928
   Cingolani P, 2012, FLY, V6, P80, DOI 10.4161/fly.19695
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Cui HX, 2014, J BIOL CHEM, V289, P34871, DOI 10.1074/jbc.M114.571000
   Curcio CA, 2005, EXP EYE RES, V81, P731, DOI 10.1016/j.exer.2005.04.012
   Curcio CA, 1999, ARCH OPHTHALMOL-CHIC, V117, P329, DOI 10.1001/archopht.117.3.329
   Curcio Christine A, 2018, Invest Ophthalmol Vis Sci, V59, pAMD160, DOI 10.1167/iovs.18-24882
   Curcio Christine A, 2018, Invest Ophthalmol Vis Sci, V59, pAMD182, DOI 10.1167/iovs.18-24883
   Curcio CA, 2009, METHODS MOL BIOL, V580, P267, DOI 10.1007/978-1-60761-325-1_15
   Darche M, 2020, FASEB J, V34, P5851, DOI 10.1096/fj.201901876R
   DePristo MA, 2011, NAT GENET, V43, P491, DOI 10.1038/ng.806
   Dickson DW, 1997, J NEUROPATH EXP NEUR, V56, P321, DOI 10.1097/00005072-199704000-00001
   Doebele RC, 2009, BLOOD, V114, P4592, DOI 10.1182/blood-2009-04-217042
   Dorrell MI, 2009, J CLIN INVEST, V119, P611, DOI 10.1172/JCI35977
   El-Darzi N, 2021, BIOLOGY-BASEL, V10, DOI 10.3390/biology10101003
   El-Darzi N, 2021, CELL MOL LIFE SCI, V78, P963, DOI 10.1007/s00018-020-03546-3
   Ernst C, 2006, J NEUROSCI METH, V150, P138, DOI 10.1016/j.jneumeth.2005.06.018
   Evans IM, 2011, IUBMB LIFE, V63, P258, DOI 10.1002/iub.456
   Evrard SM, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11853
   Fowler BJ, 2014, SCIENCE, V346, P1000, DOI 10.1126/science.1261754
   Frasa MAM, 2010, CURR BIOL, V20, P198, DOI 10.1016/j.cub.2009.12.053
   Freund KB, 2008, RETINA-J RET VIT DIS, V28, P201, DOI 10.1097/IAE.0b013e3181669504
   Freund KB, 2010, RETINA-J RET VIT DIS, V30, P1333, DOI 10.1097/IAE.0b013e3181e7976b
   Gadea G, 2014, EUR J CELL BIOL, V93, P466, DOI 10.1016/j.ejcb.2014.06.003
   Glass CK, 2006, NAT REV IMMUNOL, V6, P44, DOI 10.1038/nri1748
   Hammer SS, 2017, EBIOMEDICINE, V22, P181, DOI 10.1016/j.ebiom.2017.07.008
   Han MZ, 2020, EMBO MOL MED, V12, DOI 10.15252/emmm.201910924
   Hazra S, 2012, DIABETES, V61, P3270, DOI 10.2337/db11-1596
   Huang YM, 2021, FRONT AGING NEUROSCI, V13, DOI 10.3389/fnagi.2021.651638
   Hudry E, 2010, MOL THER, V18, P44, DOI 10.1038/mt.2009.175
   Jakobsson T, 2012, TRENDS PHARMACOL SCI, V33, P394, DOI 10.1016/j.tips.2012.03.013
   Janowski BA, 1996, NATURE, V383, P728, DOI 10.1038/383728a0
   Jiang ZH, 2020, BIOL TRACE ELEM RES, V196, P454, DOI 10.1007/s12011-019-01945-7
   Johnson LV, 2002, P NATL ACAD SCI USA, V99, P11830, DOI 10.1073/pnas.192203399
   Johnson V, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132013
   Jonsson NN, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.675979
   Jun GG, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025775
   Kacher R, 2019, BRAIN, V142, P2432, DOI 10.1093/brain/awz174
   Kalaany NY, 2006, ANNU REV PHYSIOL, V68, P159, DOI 10.1146/annurev.physiol.68.033104.152158
   Kam JH, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013127
   Kim HK, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20246144
   Lee JW, 2006, EXP EYE RES, V83, P465, DOI 10.1016/j.exer.2005.11.018
   Lee SD, 2015, ATHEROSCLEROSIS, V242, P29, DOI 10.1016/j.atherosclerosis.2015.06.042
   Lei CY, 2017, NEUROSCIENCE, V360, P48, DOI 10.1016/j.neuroscience.2017.07.053
   Li H, 2010, BIOINFORMATICS, V26, P589, DOI 10.1093/bioinformatics/btp698
   Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324
   Li ML, 2018, OPHTHALMOLOGY, V125, P276, DOI 10.1016/j.ophtha.2017.08.019
   Lim JKH, 2020, FRONT NEUROSCI-SWITZ, V14, DOI 10.3389/fnins.2020.00862
   Liu CY, 2015, ONCOTARGET, V6, P15966, DOI 10.18632/oncotarget.3862
   Luibl V, 2006, J CLIN INVEST, V116, P378, DOI 10.1172/JCI25843
   Lund EG, 1999, P NATL ACAD SCI USA, V96, P7238, DOI 10.1073/pnas.96.13.7238
   Lund EG, 2003, J BIOL CHEM, V278, P22980, DOI 10.1074/jbc.M303415200
   Lutjohann D, 1996, P NATL ACAD SCI USA, V93, P9799, DOI 10.1073/pnas.93.18.9799
   Malek G, 2003, AM J PATHOL, V162, P413, DOI 10.1016/S0002-9440(10)63836-9
   Mast N, 2021, NEUROTHERAPEUTICS, V18, P2040, DOI 10.1007/s13311-021-01079-6
   Mast N, 2020, BRAIN COMMUN, V2, DOI 10.1093/braincomms/fcaa180
   Mast N, 2018, DRUG METAB DISPOS, V46, P1528, DOI 10.1124/dmd.118.083345
   Mast N, 2017, NEUROPHARMACOLOGY, V123, P465, DOI 10.1016/j.neuropharm.2017.06.026
   Mast N, 2014, J BIOL CHEM, V289, P3529, DOI 10.1074/jbc.M113.532846
   Mast N, 2011, INVEST OPHTH VIS SCI, V52, P594, DOI 10.1167/iovs.10-6021
   McKenna A, 2010, GENOME RES, V20, P1297, DOI 10.1101/gr.107524.110
   Mi HY, 2019, NAT PROTOC, V14, P703, DOI 10.1038/s41596-019-0128-8
   Mitroi DN, 2019, EMBO REP, V20, DOI 10.15252/embr.201948143
   Mizutani T, 2015, INVEST OPHTH VIS SCI, V56, P7122, DOI 10.1167/iovs.15-17440
   Mori T, 2001, J NEUROPATH EXP NEUR, V60, P778, DOI 10.1093/jnen/60.8.778
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Namekata K, 2020, J BIOL CHEM, V295, P6710, DOI 10.1074/jbc.RA119.010438
   Narendran S, 2021, SIGNAL TRANSDUCT TAR, V6, DOI 10.1038/s41392-021-00537-z
   Nieweg K, 2009, J NEUROCHEM, V109, P125, DOI 10.1111/j.1471-4159.2009.05917.x
   Nobrega C, 2019, ACTA NEUROPATHOL, V138, P837, DOI 10.1007/s00401-019-02019-7
   Oak ASW, 2014, RETINA-J RET VIT DIS, V34, P825, DOI 10.1097/IAE.0000000000000121
   Oakley H, 2006, J NEUROSCI, V26, P10129, DOI 10.1523/JNEUROSCI.1202-06.2006
   Omarova S, 2012, J CLIN INVEST, V122, P3012, DOI 10.1172/JCI63816
   Park SW, 2017, ONCOTARGET, V8, P40006, DOI 10.18632/oncotarget.16967
   Park SW, 2014, NEUROBIOL AGING, V35, P2013, DOI 10.1016/j.neurobiolaging.2014.03.008
   Parthasarathy R, 2015, EXP EYE RES, V138, P134, DOI 10.1016/j.exer.2015.06.027
   Patel TK, 2017, PHARMACOL REP, V69, P1082, DOI 10.1016/j.pharep.2017.04.018
   Perez-Alvarez MJ, 2008, J NEUROSCI RES, V86, P1871, DOI 10.1002/jnr.21623
   Pesheva P, 1997, J NEUROSCI, V17, P4642
   PESHEVA P, 1993, NEURON, V10, P69, DOI 10.1016/0896-6273(93)90243-K
   Petrov AM, 2020, BRAIN COMMUN, V2, DOI 10.1093/braincomms/fcaa043
   Petrov AM, 2019, FASEB J, V33, P8782, DOI 10.1096/fj.201900092R
   Petrov AM, 2019, NEUROTHERAPEUTICS, V16, P710, DOI 10.1007/s13311-019-00737-0
   Piera-Velazquez S, 2019, PHYSIOL REV, V99, P1281, DOI 10.1152/physrev.00021.2018
   Pietrocola F, 2015, CELL METAB, V21, P805, DOI 10.1016/j.cmet.2015.05.014
   Pikuleva Irina A, 2021, Explor Neuroprotective Ther, V1, P159, DOI 10.37349/ent.2021.00013
   Pikuleva IA, 2021, FRONT AGING NEUROSCI, V13, DOI 10.3389/fnagi.2021.696778
   Pikuleva IA, 2014, PROG RETIN EYE RES, V41, P64, DOI 10.1016/j.preteyeres.2014.03.002
   Probstmeier R, 2000, BRAIN RES, V863, P42, DOI 10.1016/S0006-8993(00)02075-8
   Querques G, 2012, GRAEF ARCH CLIN EXP, V250, P165, DOI 10.1007/s00417-011-1804-8
   Quiroz-Mercado J, 2016, GRAEF ARCH CLIN EXP, V254, P1753, DOI 10.1007/s00417-016-3409-8
   Ramirez DMO, 2008, J COMP NEUROL, V507, P1676, DOI 10.1002/cne.21605
   Rathnasamy G, 2019, PROG NEUROBIOL, V173, P18, DOI 10.1016/j.pneurobio.2018.05.006
   ROZEMULLER JM, 1989, J NEUROPATH EXP NEUR, V48, P674, DOI 10.1097/00005072-198911000-00009
   Rudolf M, 2008, EXP EYE RES, V87, P402, DOI 10.1016/j.exer.2008.07.010
   Saadane A, 2019, AM J PATHOL, V189, P405, DOI 10.1016/j.ajpath.2018.10.013
   Saadane A, 2018, J LIPID RES, V59, P2368, DOI 10.1194/jlr.M090043
   Saadane A, 2014, AM J PATHOL, V184, P2403, DOI 10.1016/j.ajpath.2014.05.024
   Santos AM, 2008, J COMP NEUROL, V506, P224, DOI 10.1002/cne.21538
   Sarks S, 2007, INVEST OPHTH VIS SCI, V48, P968, DOI 10.1167/iovs.06-0443
   Shibata N, 2010, CIRC J, V74, P2045, DOI 10.1253/circj.CJ-10-0860
   Shu DY, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21124271
   Silveira AC, 2010, VISION RES, V50, P698, DOI 10.1016/j.visres.2009.09.016
   Singh N, 2006, INVEST OPHTH VIS SCI, V47, P4787, DOI 10.1167/iovs.06-0419
   Spaide RF, 2018, RETINA-J RET VIT DIS, V38, P891, DOI 10.1097/IAE.0000000000001732
   Spann NJ, 2013, NAT IMMUNOL, V14, P893, DOI 10.1038/ni.2681
   Steinberg SF, 2021, MOL PHARMACOL, V100, P558, DOI 10.1124/molpharm.121.000341
   Sun Y, 2015, P NATL ACAD SCI USA, V112, P10401, DOI 10.1073/pnas.1504387112
   Tual-Chalot S, 2013, JOVE-J VIS EXP, DOI 10.3791/50546
   Wang L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010329
   Westerterp M, 2018, CIRCULATION, V138, P898, DOI 10.1161/CIRCULATIONAHA.117.032636
   Winblad B, 2016, LANCET NEUROL, V15, P455, DOI 10.1016/S1474-4422(16)00062-4
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Worthmuller J, 2021, CELLS-BASEL, V10, DOI 10.3390/cells10061494
   Yan XH, 2014, HUM MOL GENET, V23, P5597, DOI 10.1093/hmg/ddu274
   Yu SX, 2017, CYTOKINE, V91, P30, DOI 10.1016/j.cyto.2016.12.003
   Zelcer N, 2006, J CLIN INVEST, V116, P607, DOI 10.1172/JCI27883
   Zhang J, 2012, MOL CELL PROTEOMICS, V11, DOI [10.1074/mcp.M111.010587, 10.1074/mcp.M111.015032]
   Zhang XB, 2021, P NATL ACAD SCI USA, V118, DOI [10.1073/pnas.2107682118j1of11, 10.1073/pnas.2107682118]
   Zheng WC, 2015, J LIPID RES, V56, P81, DOI 10.1194/jlr.M053439
   Zheng WC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037926
   Zhou YQ, 2020, EMBO MOL MED, V12, DOI 10.15252/emmm.201810233
NR 140
TC 0
Z9 0
U1 0
U2 0
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
EI 1663-9812
J9 FRONT PHARMACOL
JI Front. Pharmacol.
PD JUN 1
PY 2022
VL 13
AR 902254
DI 10.3389/fphar.2022.902254
PG 19
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA 2D6HO
UT WOS:000811645800001
PM 35721135
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Ziemssen, F
   Agostini, H
   Feltgen, N
   Finger, RP
   Haritoglou, C
   Hoerauf, H
   Iwersen, M
   Porstner, M
   Clemens, A
   Gmeiner, B
AF Ziemssen, Focke
   Agostini, Hansjuergen
   Feltgen, Nicolas
   Finger, Robert P.
   Haritoglou, Christos
   Hoerauf, Hans
   Iwersen, Matthias
   Porstner, Martina
   Clemens, Andreas
   Gmeiner, Benjamin
TI A model to quantify the influence of treatment patterns and optimize
   outcomes in nAMD
SO SCIENTIFIC REPORTS
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; 2.0 MG RANIBIZUMAB; MACULAR DEGENERATION;
   REGIMEN; EFFICACY; SAFETY
AB Neovascular age-related macular degeneration (nAMD) is a progressive retinal disease that often leads to severe and permanent vision loss. Early initiation of anti-vascular endothelial growth factor (anti-VEGF) therapy has been shown to preserve vision in nAMD patients. Concurrently, treatment outcomes in real-world are inferior to those reported in clinical trials. The most likely reasons observed are fewer treatment-intensity in routine clinical practice than in clinical trials. The other possibility could be the delay in starting treatment and the re-treatment interval. Although a negative impact of aforementioned parameters seems obvious, quantitative impact measures remain elusive in a real-world setting due to a lack of an 'optimal treatment' control group. To overcome this shortcoming, we developed, validated, and applied a model to assess and quantify the impact of anti-VEGF administration variables on visual acuity development in a prospective nAMD patient cohort. The model was further applied to probe the impact of the COVID-19 pandemic on visual progressions in nAMD patients. The presented model paves the way to systematically explore and evaluate realistic interventions in the current treatment paradigm, that can be adopted in routine clinical care.
C1 [Ziemssen, Focke] Univ Hosp Leipzig, Dept Ophthalmol, Leipzig, Germany.
   [Ziemssen, Focke] Univ Eye Hosp Tubingen, Ctr Ophthalmol, Tubingen, Germany.
   [Agostini, Hansjuergen] Univ Freiburg, Fac Med, Eye Ctr, Med Ctr, Freiburg, Germany.
   [Feltgen, Nicolas; Hoerauf, Hans] Univ Med Ctr Goettingen, Dept Ophthalmol, Gottingen, Germany.
   [Finger, Robert P.] Univ Bonn, Dept Ophthalmol, Bonn, Germany.
   [Haritoglou, Christos] Herzog Carl Theodor Eye Hosp, Munich, Germany.
   [Iwersen, Matthias; Porstner, Martina; Gmeiner, Benjamin] Novartis Pharma GmbH, Roonstr 25, D-90429 Nurnberg, Germany.
   [Clemens, Andreas] Novartis Pharma AG, Basel, Switzerland.
   [Clemens, Andreas] Univ Freiburg, Heart Ctr Freiburg Univ, Fac Med, Dept Cardiol & Angiol 1, Freiburg, Germany.
   [Gmeiner, Benjamin] Harvard Univ, Dept Chem & Chem Biol, Cambridge, MA 02138 USA.
C3 Leipzig University; Eberhard Karls University of Tubingen; Eberhard
   Karls University Hospital; University of Freiburg; University of
   Gottingen; University of Bonn; Novartis; Novartis; Universitats
   Herzzentrum Freiburg; University of Freiburg; Harvard University
RP Gmeiner, B (通讯作者)，Novartis Pharma GmbH, Roonstr 25, D-90429 Nurnberg, Germany.; Gmeiner, B (通讯作者)，Harvard Univ, Dept Chem & Chem Biol, Cambridge, MA 02138 USA.
EM benjamin.gmeiner@novartis.com
OI Gmeiner, Benjamin/0000-0002-1517-8528
CR Agostini H, 2020, CURR EYE RES, V45, P1298, DOI 10.1080/02713683.2020.1731832
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Busbee BG, 2013, OPHTHALMOLOGY, V120, P1046, DOI 10.1016/j.ophtha.2012.10.014
   Ciulla TA, 2020, OPHTHALMOL RETINA, V4, P19, DOI 10.1016/j.oret.2019.05.017
   Dugel PU, 2020, OPHTHALMOLOGY, V127, P72, DOI 10.1016/j.ophtha.2019.04.017
   GERMAN SOCIETY OF OPHTHALMOLOGY, 2020, OPHTHALMOLOGE, V117, P218
   Gianniou C, 2015, EYE, V29, P342, DOI 10.1038/eye.2014.258
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Ho AC, 2014, OPHTHALMOLOGY, V121, P2181, DOI 10.1016/j.ophtha.2014.05.009
   Holz FG, 2020, RETINA-J RET VIT DIS, V40, P1673, DOI 10.1097/IAE.0000000000002670
   Holz FG, 2010, INVEST OPHTH VIS SCI, V51, P405, DOI 10.1167/iovs.09-3813
   Khanna S, 2019, BMJ OPEN OPHTHALMOL, V4, DOI 10.1136/bmjophth-2019-000398
   Khoramnia R, 2021, INVEST OPHTH VIS SCI, V62
   Lim JH, 2012, AM J OPHTHALMOL, V153, P678, DOI 10.1016/j.ajo.2011.09.013
   Ludtke L, 2019, MED SCI MONITOR, V25, P6383, DOI 10.12659/MSM.915493
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Mehta H, 2018, PROG RETIN EYE RES, V65, P127, DOI 10.1016/j.preteyeres.2017.12.002
   Mones J, 2020, OPHTHALMOLOGICA, V243, P1, DOI 10.1159/000502747
   Mulyukov Z, 2018, CPT-PHARMACOMET SYST, V7, P660, DOI 10.1002/psp4.12322
   Naravane AV, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0247161
   Okada M, 2021, JAMA OPHTHALMOL, V139, P769, DOI 10.1001/jamaophthalmol.2021.1660
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sagkriotis A, 2021, CONTEMP CLIN TRIALS, V104, DOI 10.1016/j.cct.2021.106364
   Schmidt-Erfurth U, 2014, BRIT J OPHTHALMOL, V98, P1144, DOI 10.1136/bjophthalmol-2014-305702
   Silva R, 2018, OPHTHALMOLOGY, V125, P57, DOI 10.1016/j.ophtha.2017.07.014
   Sim PY, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2017-017771
   Sindal MD, 2021, INDIAN J OPHTHALMOL, V69, P730, DOI 10.4103/ijo.IJO_2807_20
   Song WL, 2021, OPHTHALMOL RETINA, V5, P975, DOI 10.1016/j.oret.2020.12.020
   Wachtlin J, 2020, J OPHTHALMOL, V2020, DOI 10.1155/2020/8024258
NR 29
TC 1
Z9 1
U1 1
U2 3
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD FEB 18
PY 2022
VL 12
IS 1
AR 2789
DI 10.1038/s41598-022-06362-w
PG 10
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA ZD0MB
UT WOS:000757901500038
PM 35181697
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Tong, Y
   Wang, SS
AF Tong, Yao
   Wang, Shusheng
TI Not All Stressors Are Equal: Mechanism of Stressors on RPE Cell
   Degeneration
SO FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
LA English
DT Review
DE AMD; RPE; oxidative stress; senescence; cell death
ID RETINAL-PIGMENT EPITHELIUM; AGE-RELATED MACULOPATHY; FACTOR-H
   POLYMORPHISM; ALU RNA ACCUMULATION; NF-KAPPA-B; OXIDATIVE STRESS;
   LIPID-PEROXIDATION; MACULAR DEGENERATION; AMYLOID-BETA; FREE-RADICALS
AB Age-related macular degeneration (AMD) is a major cause of irreversible blindness among the elderly population. Dysfunction and degeneration of the retinal pigment epithelial (RPE) layer in the retina underscore the pathogenesis of both dry and wet AMD. Advanced age, cigarette smoke and genetic factors have been found to be the prominent risk factors for AMD, which point to an important role for oxidative stress and aging in AMD pathogenesis. However, the mechanisms whereby oxidative stress and aging lead to RPE cell degeneration are still unclear. As cell senescence and cell death are the major outcomes from oxidative stress and aging, here we review the mechanisms of RPE cell senescence and different kinds of cell death, including apoptosis, necroptosis, pyroptosis, ferroptosis, with an aim to clarify how RPE cell degeneration could occur in response to AMD-related stresses, including H2O2, 4-Hydroxynonenal (4-HNE), N-retinylidene-N-retinyl-ethanolamine (A2E), Alu RNA and amyloid beta (A beta). Besides those, sodium iodate (NaIO3) induced RPE cell degeneration is also discussed in this review. Although NaIO3 itself is not related to AMD, this line of study would help understand the mechanism of RPE degeneration.
C1 [Tong, Yao; Wang, Shusheng] Tulane Univ, Dept Cell & Mol Biol, New Orleans, LA 70118 USA.
   [Wang, Shusheng] Tulane Univ, Dept Ophthalmol, New Orleans, LA 70118 USA.
C3 Tulane University; Tulane University
RP Wang, SS (通讯作者)，Tulane Univ, Dept Cell & Mol Biol, New Orleans, LA 70118 USA.; Wang, SS (通讯作者)，Tulane Univ, Dept Ophthalmol, New Orleans, LA 70118 USA.
EM swang1@tulane.edu
FU American Federation for Aging Research (AFAR) Scholarship; Tulane
   University; BrightFocus Foundation Grant in AMD; NIH [EY021862,
   EY026069]
FX YT was supported by American Federation for Aging Research (AFAR)
   Scholarship. SW was supported by a Startup fund from Tulane University,
   BrightFocus Foundation Grant in AMD, and NIH Grants EY021862 and
   EY026069. The fundings are not responsible for the content of the
   manuscript.
CR Alaimo A, 2019, ARCH TOXICOL, V93, P1401, DOI 10.1007/s00204-019-02409-6
   Alge CS, 2002, INVEST OPHTH VIS SCI, V43, P3575
   Anderson OA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067263
   Annis RP, 2016, FEBS J, V283, P4569, DOI 10.1111/febs.13944
   Arthur JR, 2000, CELL MOL LIFE SCI, V57, P1825
   ASHBURN FS, 1980, INVEST OPHTH VIS SCI, V19, P1427
   Ayala A, 2014, OXID MED CELL LONGEV, V2014, DOI 10.1155/2014/360438
   Baas DC, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013786
   BAICH A, 1992, PIGM CELL RES, V5, P394, DOI 10.1111/j.1600-0749.1992.tb00568.x
   Barak A, 2001, INVEST OPHTH VIS SCI, V42, P247
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Beckman KB, 1998, PHYSIOL REV, V78, P547, DOI 10.1152/physrev.1998.78.2.547
   Bedard K, 2007, PHYSIOL REV, V87, P245, DOI 10.1152/physrev.00044.2005
   Bergsbaken T, 2009, NAT REV MICROBIOL, V7, P99, DOI 10.1038/nrmicro2070
   Bernstein E, 2001, NATURE, V409, P363, DOI 10.1038/35053110
   BERNSTEIN PS, 1987, P NATL ACAD SCI USA, V84, P1849, DOI 10.1073/pnas.84.7.1849
   Bersuker K, 2019, NATURE, V575, P688, DOI 10.1038/s41586-019-1705-2
   Birben E, 2012, WORLD ALLERGY ORGAN, V5, P9, DOI 10.1097/WOX.0b013e3182439613
   Bohr V, 1998, TOXICOL LETT, V103, P47
   Bohr VA, 2007, NEUROSCIENCE, V145, P1183, DOI 10.1016/j.neuroscience.2007.03.015
   BOK D, 1985, INVEST OPHTH VIS SCI, V26, P1659
   Bonilha VL, 2008, CLIN OPHTHALMOL, V2, P413
   Brand MD, 2016, FREE RADICAL BIO MED, V100, P14, DOI 10.1016/j.freeradbiomed.2016.04.001
   Brentnall M, 2013, BMC CELL BIOL, V14, DOI 10.1186/1471-2121-14-32
   Bressler Neil M, 2002, J Am Board Fam Pract, V15, P142
   Brigelius-Flohe R, 2013, BBA-GEN SUBJECTS, V1830, P3289, DOI 10.1016/j.bbagen.2012.11.020
   Brion M, 2011, ACTA OPHTHALMOL, V89, pE12, DOI 10.1111/j.1755-3768.2010.02040.x
   Burke JM, 2008, PROG RETIN EYE RES, V27, P579, DOI 10.1016/j.preteyeres.2008.08.002
   Butterfield DA, 2013, ANTIOXID REDOX SIGN, V19, P823, DOI 10.1089/ars.2012.5027
   Canli O, 2016, BLOOD, V127, P139, DOI 10.1182/blood-2015-06-654194
   Cerbone A, 2007, FREE RADICAL BIO MED, V42, P1661, DOI 10.1016/j.freeradbiomed.2007.02.009
   Chatterjee S, 2016, OXIDATIVE STRESS AND BIOMATERIALS, P35, DOI 10.1016/B978-0-12-803269-5.00002-4
   Chen C, 2014, ANTIOXID REDOX SIGN, V20, P2091, DOI 10.1089/ars.2013.5240
   Chen GF, 2017, ACTA PHARMACOL SIN, V38, P1205, DOI 10.1038/aps.2017.28
   Chen QM, 2000, BIOCHEM J, V347, P543, DOI 10.1042/0264-6021:3470543
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Childs BG, 2015, NAT MED, V21, P1424, DOI 10.1038/nm.4000
   Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001
   Collado M, 2010, NAT REV CANCER, V10, P51, DOI 10.1038/nrc2772
   Cordaux R, 2009, NAT REV GENET, V10, P691, DOI 10.1038/nrg2640
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Curcio CA, 2017, INVEST OPHTH VIS SCI, V58, P211, DOI 10.1167/iovs.17-21872
   Dahlgren KN, 2002, J BIOL CHEM, V277, P32046, DOI 10.1074/jbc.M201750200
   Datta S, 2017, PROG RETIN EYE RES, V60, P201, DOI 10.1016/j.preteyeres.2017.03.002
   Davalli P, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/3565127
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363
   Ding JJ, 2016, NATURE, V535, P111, DOI 10.1038/nature18590
   Dixon SJ, 2012, CELL, V149, P1060, DOI 10.1016/j.cell.2012.03.042
   Doll S, 2019, NATURE, V575, P693, DOI 10.1038/s41586-019-1707-0
   Dondelinger Y, 2014, CELL REP, V7, P971, DOI 10.1016/j.celrep.2014.04.026
   Droge W, 2002, PHYSIOL REV, V82, P47, DOI 10.1152/physrev.00018.2001
   Du JH, 2016, P NATL ACAD SCI USA, V113, P14710, DOI 10.1073/pnas.1604572113
   Dunaief JL, 2002, ARCH OPHTHALMOL-CHIC, V120, P1435, DOI 10.1001/archopht.120.11.1435
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Eguchi Y, 1997, CANCER RES, V57, P1835
   Elmore S, 2007, TOXICOL PATHOL, V35, P495, DOI 10.1080/01926230701320337
   ESTERBAUER H, 1991, FREE RADICAL BIO MED, V11, P81, DOI 10.1016/0891-5849(91)90192-6
   Ethen CM, 2007, INVEST OPHTH VIS SCI, V48, P3469, DOI 10.1167/iovs.06-1058
   Fang XX, 2019, P NATL ACAD SCI USA, V116, P2672, DOI 10.1073/pnas.1821022116
   Ferrington DA, 2016, PROG RETIN EYE RES, V51, P69, DOI 10.1016/j.preteyeres.2015.09.002
   Fritsch M, 2019, NATURE, V575, P683, DOI 10.1038/s41586-019-1770-6
   Gao JY, 2018, J NEUROINFLAMM, V15, DOI 10.1186/s12974-018-1062-3
   GARDNER HW, 1989, FREE RADICAL BIO MED, V7, P65, DOI 10.1016/0891-5849(89)90102-0
   Giddabasappa A, 2010, INVEST OPHTH VIS SCI, V51, P5278, DOI 10.1167/iovs.10-5316
   Gil L, 2006, FREE RADICAL RES, V40, P495, DOI 10.1080/10715760600592962
   Gong YN, 2017, CELL, V169, P286, DOI 10.1016/j.cell.2017.03.020
   Gray DC, 2010, CELL, V142, P637, DOI 10.1016/j.cell.2010.07.014
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   HALLIWELL B, 1993, AM J CLIN NUTR, V57, P715
   HALLIWELL B, 1986, ARCH BIOCHEM BIOPHYS, V246, P501, DOI 10.1016/0003-9861(86)90305-X
   Hampel B, 2004, EXP GERONTOL, V39, P1713, DOI 10.1016/j.exger.2004.05.010
   Hanus J, 2016, CELL DEATH DISCOV, V2, DOI 10.1038/cddiscovery.2016.54
   Hanus J, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.478
   HAYFLICK L, 1965, EXP CELL RES, V37, P614, DOI 10.1016/0014-4827(65)90211-9
   He WT, 2015, CELL RES, V25, P1285, DOI 10.1038/cr.2015.139
   Herbig U, 2004, MOL CELL, V14, P501, DOI 10.1016/S1097-2765(04)00256-4
   Hitomi J, 2004, J CELL BIOL, V165, P347, DOI 10.1083/jcb.200310015
   Hollyfield JG, 2008, NAT MED, V14, P194, DOI 10.1038/nm1709
   Holtkamp GM, 2001, PROG RETIN EYE RES, V20, P29, DOI 10.1016/S1350-9462(00)00017-3
   Hwang YE, 2019, BMB REP, V52, P196, DOI 10.5483/BMBRep.2019.52.3.146
   Igney FH, 2002, NAT REV CANCER, V2, P277, DOI 10.1038/nrc776
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Jarrett SG, 2012, MOL ASPECTS MED, V33, P399, DOI 10.1016/j.mam.2012.03.009
   Jonasson F, 2011, OPHTHALMOLOGY, V118, P825, DOI 10.1016/j.ophtha.2010.08.044
   Kaneko H, 2011, NATURE, V471, P325, DOI 10.1038/nature09830
   Kang TB, 2013, IMMUNITY, V38, P27, DOI 10.1016/j.immuni.2012.09.015
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kayagaki N, 2011, NATURE, V479, P117, DOI 10.1038/nature10558
   KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33
   Khandhadia S, 2010, EXPERT REV MOL MED, V12, DOI 10.1017/S146239941000164X
   Khosla S, 2020, NAT REV ENDOCRINOL, V16, P263, DOI 10.1038/s41574-020-0335-y
   KILINC A, 1988, NEUROSCI LETT, V87, P307, DOI 10.1016/0304-3940(88)90467-3
   Kim Min-Ho, 2003, Korean J Ophthalmol, V17, P19
   Kim Y, 2014, P NATL ACAD SCI USA, V111, P16082, DOI 10.1073/pnas.1403814111
   KLEIN R, 1993, AM J EPIDEMIOL, V137, P190, DOI 10.1093/oxfordjournals.aje.a116659
   Klein R, 1998, AM J EPIDEMIOL, V147, P103
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   KONDA BR, 1994, INVEST OPHTH VIS SCI, V35, P40
   KORTE GE, 1984, INVEST OPHTH VIS SCI, V25, P1135
   Kovacs SB, 2017, TRENDS CELL BIOL, V27, P673, DOI 10.1016/j.tcb.2017.05.005
   Kuilman T, 2010, GENE DEV, V24, P2463, DOI 10.1101/gad.1971610
   Laurora S, 2005, FREE RADICAL BIO MED, V38, P215, DOI 10.1016/j.freeradbiomed.2004.10.014
   Lee BY, 2006, AGING CELL, V5, P187, DOI 10.1111/j.1474-9726.2006.00199.x
   Li GY, 2010, BIOMED ENVIRON SCI, V23, P371, DOI 10.1016/S0895-3988(10)60078-5
   Li J, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-2298-2
   Liu CQ, 2015, INT J MOL MED, V35, P169, DOI 10.3892/ijmm.2014.1993
   Liu RZT, 2014, EXP EYE RES, V127, P49, DOI 10.1016/j.exer.2014.07.003
   Liu RT, 2013, INVEST OPHTH VIS SCI, V54, P2225, DOI 10.1167/iovs.12-10849
   Liu X, 2017, ADV IMMUNOL, V135, P81, DOI 10.1016/bs.ai.2017.02.002
   Liu X, 2016, NATURE, V535, P153, DOI 10.1038/nature18629
   Luo X, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00240
   Ma HW, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-019-2216-7
   Mao XY, 2018, BIOMED PHARMACOTHER, V103, P517, DOI 10.1016/j.biopha.2018.04.038
   Marazita MC, 2016, REDOX BIOL, V7, P78, DOI 10.1016/j.redox.2015.11.011
   Martin-Sanchez D, 2017, J AM SOC NEPHROL, V28, P218, DOI 10.1681/ASN.2015121376
   Masuda N, 2019, BMC OPHTHALMOL, V19, DOI 10.1186/s12886-019-1076-3
   McCord JM, 2000, AM J MED, V108, P652, DOI 10.1016/S0002-9343(00)00412-5
   Mettu PS, 2012, MOL ASPECTS MED, V33, P376, DOI 10.1016/j.mam.2012.04.006
   Micklisch S, 2017, J NEUROINFLAMM, V14, DOI 10.1186/s12974-016-0776-3
   Moriguchi M, 2018, INVEST OPHTH VIS SCI, V59, P3476, DOI 10.1167/iovs.17-23532
   Muller T, 2017, CELL MOL LIFE SCI, V74, P3631, DOI 10.1007/s00018-017-2547-4
   Murakami Y, 2014, CELL DEATH DIFFER, V21, P270, DOI 10.1038/cdd.2013.109
   Nair U, 2007, FREE RADICAL BIO MED, V43, P1109, DOI 10.1016/j.freeradbiomed.2007.07.012
   Negre-Salvayre A, 2008, BRIT J PHARMACOL, V153, P6, DOI 10.1038/sj.bjp.0707395
   Nelson G, 2012, AGING CELL, V11, P345, DOI 10.1111/j.1474-9726.2012.00795.x
   Ngai LY, 2011, EYE, V25, P784, DOI 10.1038/eye.2011.56
   Niki E, 2009, FREE RADICAL BIO MED, V47, P469, DOI 10.1016/j.freeradbiomed.2009.05.032
   NOELL WK, 1953, AM J OPHTHALMOL, V36, P103, DOI 10.1016/0002-9394(53)90159-7
   Nunan J, 2000, FEBS LETT, V483, P6, DOI 10.1016/S0014-5793(00)02076-7
   Ogryzko VV, 1996, MOL CELL BIOL, V16, P5210
   Ohno-Matsui K, 2011, PROG RETIN EYE RES, V30, P217, DOI 10.1016/j.preteyeres.2011.02.004
   Olsson F, 2014, J BIOL CHEM, V289, P1540, DOI 10.1074/jbc.M113.498246
   Pandey R, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-11-r117
   PANNING B, 1994, VIROLOGY, V202, P408, DOI 10.1006/viro.1994.1357
   Pascolini D, 2012, BRIT J OPHTHALMOL, V96, P614, DOI 10.1136/bjophthalmol-2011-300539
   Phaniendra A, 2015, INDIAN J CLIN BIOCHE, V30, P11, DOI 10.1007/s12291-014-0446-0
   PIZZINO G, 2017, OXID MED CELL LONGEV, V2017, DOI DOI 10.1155/2017/8416763
   Rajendran P, 2014, CLIN CHIM ACTA, V436, P332, DOI 10.1016/j.cca.2014.06.004
   Richter C, 1996, FEBS LETT, V378, P107, DOI 10.1016/0014-5793(95)01431-4
   Rodriguez DA, 2016, CELL DEATH DIFFER, V23, P76, DOI 10.1038/cdd.2015.70
   Rosenfeld PJ, 2018, OPHTHALMOL RETINA, V2, P1028, DOI 10.1016/j.oret.2018.03.001
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   Schaur RJ, 2015, BIOMOLECULES, V5, P2247, DOI 10.3390/biom5042247
   Schutt F, 2003, INVEST OPHTH VIS SCI, V44, P3663, DOI 10.1167/iovs.03-0172
   Shaban H, 2002, EXP EYE RES, V75, P99, DOI 10.1006/exer.2001.1192
   Shaban H, 2001, ARCH BIOCHEM BIOPHYS, V394, P111, DOI 10.1006/abbi.2001.2535
   Sharma A, 2008, ARCH BIOCHEM BIOPHYS, V480, P85, DOI 10.1016/j.abb.2008.09.016
   Shi JJ, 2014, NATURE, V514, P187, DOI 10.1038/nature13683
   Shoeb M, 2014, CURR MED CHEM, V21, P230
   SIES H, 1970, FEBS LETT, V11, P172, DOI 10.1016/0014-5793(70)80521-X
   Simon JD, 2008, J PHYS CHEM B, V112, P13201, DOI 10.1021/jp804248h
   Skoumalova A, 2012, J CELL MOL MED, V16, P2291, DOI 10.1111/j.1582-4934.2012.01585.x
   Sparrow JR, 2005, EXP EYE RES, V80, P595, DOI 10.1016/j.exer.2005.01.007
   Sparrow JR, 2003, VISION RES, V43, P2983, DOI 10.1016/S0042-6989(03)00475-9
   Sparrow JR, 2003, J BIOL CHEM, V278, P18207, DOI 10.1074/jbc.M300457200
   Sparrow JR, 2001, INVEST OPHTH VIS SCI, V42, P1356
   Sparrrow JR, 2010, CURR MOL MED, V10, P802
   Spiteller P, 2001, BBA-MOL CELL BIOL L, V1531, P188, DOI 10.1016/S1388-1981(01)00100-7
   Sreekumar PG, 2005, BIOCHEM BIOPH RES CO, V334, P245, DOI 10.1016/j.bbrc.2005.06.081
   Stadtman ER, 2000, ANN NY ACAD SCI, V899, P191
   Sun LM, 2012, CELL, V148, P213, DOI 10.1016/j.cell.2011.11.031
   Suzuki M, 2007, MOL VIS, V13, P772
   Szabo C, 2007, NAT REV DRUG DISCOV, V6, P662, DOI 10.1038/nrd2222
   Takami M, 2009, J NEUROSCI, V29, P13042, DOI 10.1523/JNEUROSCI.2362-09.2009
   Tang PH, 2013, PROG RETIN EYE RES, V32, P48, DOI 10.1016/j.preteyeres.2012.09.002
   Tarallo V, 2012, CELL, V149, P847, DOI 10.1016/j.cell.2012.03.036
   Therond P., 2006, Annales Pharmaceutiques Francaises, V64, P383, DOI 10.1016/S0003-4509(06)75333-0
   Tuo JS, 2004, PROG RETIN EYE RES, V23, P229, DOI 10.1016/j.preteyeres.2004.02.001
   Valko M, 2007, INT J BIOCHEM CELL B, V39, P44, DOI 10.1016/j.biocel.2006.07.001
   van Deursen JM, 2014, NATURE, V509, P439, DOI 10.1038/nature13193
   Wang J, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-017-0200-7
   Wang W, 2016, MOL CELL ENDOCRINOL, V426, P91, DOI 10.1016/j.mce.2016.02.008
   Wang YY, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00971
   Weinlich R, 2017, NAT REV MOL CELL BIO, V18, P127, DOI 10.1038/nrm.2016.149
   WEITER JJ, 1986, INVEST OPHTH VIS SCI, V27, P145
   Wielgus AR, 2010, PHOTOCH PHOTOBIO SCI, V9, P1505, DOI 10.1039/c0pp00133c
   Wimmers S, 2007, PROG RETIN EYE RES, V26, P263, DOI 10.1016/j.preteyeres.2006.12.002
   Winkler BS, 1999, MOL VIS, V5
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Xie XB, 2017, MOL VIS, V23, P520
   Xu YJ, 2018, CLIN CHIM ACTA, V476, P28, DOI 10.1016/j.cca.2017.11.005
   Yagoda N, 2007, NATURE, V447, P864, DOI 10.1038/nature05859
   Yamada K, 2020, TRANSL VIS SCI TECHN, V9, DOI 10.1167/tvst.9.8.1
   Yang P, 2007, INVEST OPHTH VIS SCI, V48, P3341, DOI 10.1167/iovs.06-1340
   Yang WS, 2008, CHEM BIOL, V15, P234, DOI 10.1016/j.chembiol.2008.02.010
   Ye Z, 2018, INT J OPHTHALMOL-CHI, V11, P929, DOI 10.18240/ijo.2018.06.06
   Yin HY, 2011, CHEM REV, V111, P5944, DOI 10.1021/cr200084z
   YOUNG RW, 1968, J CELL BIOL, V39, P169, DOI 10.1083/jcb.39.1.169
   Zhao HL, 2019, INT J MOL MED, V43, P936, DOI 10.3892/ijmm.2018.4027
NR 190
TC 14
Z9 14
U1 3
U2 17
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 2296-634X
J9 FRONT CELL DEV BIOL
JI Front. Cell. Dev. Biol.
PD NOV 19
PY 2020
VL 8
AR 591067
DI 10.3389/fcell.2020.591067
PG 14
WC Cell Biology; Developmental Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Developmental Biology
GA OZ7RC
UT WOS:000595117600001
PM 33330470
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Tohari, AM
   Alhasani, RH
   Biswas, L
   Patnaik, SR
   Reilly, J
   Zeng, ZH
   Shu, XH
AF Tohari, Ali Mohammad
   Alhasani, Reem Hasaballah
   Biswas, Lincoln
   Patnaik, Sarita Rani
   Reilly, James
   Zeng, Zhihong
   Shu, Xinhua
TI Vitamin D Attenuates Oxidative Damage and Inflammation in Retinal
   Pigment Epithelial Cells
SO ANTIOXIDANTS
LA English
DT Article
DE vitamin D; oxidative stress; inflammation; retinal pigment epithelial
   cells; age-related macular degeneration
ID MACULAR DEGENERATION; IMMUNE-RESPONSE; AMYLOID-BETA; D METABOLISM;
   IL-33; STRESS; INJURY; D-3; ACTIVATION; PROTECTION
AB Age-related macular degeneration (AMD), the most common visual disorder in elderly people, is characterized by the formation of deposits beneath the retinal pigment epithelium (RPE) and by dysfunction of RPE and photoreceptor cells. The biologically active form of vitamin D, 1,25-(OH)2D3 (VITD), is categorized as a multifunctional steroid hormone that modulates many transcriptional processes of different genes and is involved in a broad range of cellular functions. Epidemiological and genetic association studies demonstrate that VITD may have a protective role in AMD, while single nucleotide polymorphisms in the vitamin D metabolism gene (CYP24A1) increase the risk of AMD. However, the functional mechanisms of VITD in AMD are not fully understood. In the current study, we investigated the impact of VITD on H2O2-induced oxidative stress and inflammation in human RPE cells. We demonstrate that exposure to H2O2 caused significantly reduced cell viability, increased production of reactive oxygen species (ROS), lowered expression of antioxidant enzymes and enhanced inflammation. VITD exposure notably counteracted the above H2O2-induced effects. Our data suggest that VITD protects the RPE from oxidative damage and elucidate molecular mechanisms of VITD deficiency in the development of AMD.
C1 [Tohari, Ali Mohammad] King Fahad Hosp, Dept Clin Biochem, POB 204, Jazan 91991, Saudi Arabia.
   [Tohari, Ali Mohammad; Alhasani, Reem Hasaballah; Biswas, Lincoln; Patnaik, Sarita Rani; Reilly, James; Shu, Xinhua] Glasgow Caledonian Univ, Dept Biol & Biomed Sci, Glasgow G4 0BA, Lanark, Scotland.
   [Zeng, Zhihong] Changsha Univ, Dept Bioengn & Environm Sci, Changsha 410022, Hunan, Peoples R China.
   [Shu, Xinhua] Glasgow Caledonian Univ, Dept Vis Sci, Glasgow G4 0BA, Lanark, Scotland.
C3 Glasgow Caledonian University; Changsha University; Glasgow Caledonian
   University
RP Shu, XH (通讯作者)，Glasgow Caledonian Univ, Dept Biol & Biomed Sci, Glasgow G4 0BA, Lanark, Scotland.; Zeng, ZH (通讯作者)，Changsha Univ, Dept Bioengn & Environm Sci, Changsha 410022, Hunan, Peoples R China.; Shu, XH (通讯作者)，Glasgow Caledonian Univ, Dept Vis Sci, Glasgow G4 0BA, Lanark, Scotland.
EM z20181201@ccsu.edu.cn; Xinhua.Shu@gcu.ac.uk
RI Zeng, Zhihong/HEV-8703-2022
OI Shu, Xinhua/0000-0003-3760-3019; Biswas, Lincoln/0000-0002-2288-341X
FU Saudi Arabia Government [A826]; Rosetrees Trust [M160, M160-F1,
   M160-F2]; National Eye Research Centre [SAC037]
FX This work was supported by a PhD scholarship (A826) from Saudi Arabia
   Government. The work was also supported by the Rosetrees Trust (M160,
   M160-F1, M160-F2) and National Eye Research Centre (SAC037).
CR Alsalem JA, 2014, INVEST OPHTH VIS SCI, V55, P2140, DOI 10.1167/iovs.13-13019
   Bao BY, 2008, INT J CANCER, V122, P2699, DOI 10.1002/ijc.23460
   Barbour M, 2014, EUR J IMMUNOL, V44, P3320, DOI 10.1002/eji.201444671
   Berridge MJ, 2015, BIOCHEM SOC T, V43, P349, DOI 10.1042/BST20140279
   Bhat AH, 2015, BIOMED PHARMACOTHER, V74, P101, DOI 10.1016/j.biopha.2015.07.025
   Bikle DD, 2014, CHEM BIOL, V21, P319, DOI 10.1016/j.chembiol.2013.12.016
   Cascella R, 2014, J OPHTHALMOL, V2014, DOI 10.1155/2014/582842
   Chen Y, 2013, J BIOL CHEM, V288, P19450, DOI 10.1074/jbc.M113.467670
   Christakos S, 2007, J STEROID BIOCHEM, V103, P405, DOI 10.1016/j.jsbmb.2006.12.079
   Du LX, 2018, NEUROSCIENCE, V369, P222, DOI 10.1016/j.neuroscience.2017.11.028
   Dwyer MA, 2011, MOL ENDOCRINOL, V25, P360, DOI 10.1210/me.2010-0392
   Eelen G, 2013, J STEROID BIOCHEM, V136, P112, DOI 10.1016/j.jsbmb.2012.09.011
   Eshaq RS, 2014, REDOX BIOL, V2, P661, DOI 10.1016/j.redox.2014.04.006
   Fernandes de Abreu D A, 2009, Psychoneuroendocrinology, V34 Suppl 1, pS265, DOI 10.1016/j.psyneuen.2009.05.023
   Gadani SP, 2015, NEURON, V85, P703, DOI 10.1016/j.neuron.2015.01.013
   Layana AG, 2017, NUTRIENTS, V9, DOI 10.3390/nu9101120
   Graffe A, 2014, INVEST OPHTH VIS SCI, V55, P5298, DOI 10.1167/iovs.14-13918
   Hamden K, 2009, J NUTR SCI VITAMINOL, V55, P215, DOI 10.3177/jnsv.55.215
   Holz FG, 2014, J CLIN INVEST, V124, P1430, DOI 10.1172/JCI71029
   Huang YN, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0370-0
   Itty S, 2014, RETINA-J RET VIT DIS, V34, P1779, DOI 10.1097/IAE.0000000000000178
   Krishnan AV, 2011, ANNU REV PHARMACOL, V51, P311, DOI 10.1146/annurev-pharmtox-010510-100611
   Lee V, 2012, NEUROBIOL AGING, V33, P2382, DOI 10.1016/j.neurobiolaging.2011.12.002
   Liew FY, 2010, NAT REV IMMUNOL, V10, P103, DOI 10.1038/nri2692
   Liu XC, 2012, INFLAMMATION, V35, P776, DOI 10.1007/s10753-011-9379-4
   Middleton RP, 2015, VET COMP ONCOL, V13, P452, DOI 10.1111/vco.12066
   Millen AE, 2011, ARCH OPHTHALMOL-CHIC, V129, P481, DOI 10.1001/archophthalmol.2011.48
   Morrison Margaux A., 2011, Human Genomics, V5, P538
   Nakai K, 2014, AM J HYPERTENS, V27, P586, DOI 10.1093/ajh/hpt160
   Parekh N, 2007, ARCH OPHTHALMOL-CHIC, V125, P661, DOI 10.1001/archopht.125.5.661
   Peng XJ, 2010, J CELL BIOCHEM, V110, P1324, DOI 10.1002/jcb.22646
   Polidoro L, 2013, J CARDIOVASC TRANSL, V6, P221, DOI 10.1007/s12265-012-9436-x
   Priya RR, 2012, OPHTHALMOLOGY, V119, P2526, DOI 10.1016/j.ophtha.2012.06.042
   Redza-Dutordoir M, 2016, BBA-MOL CELL RES, V1863, P2977, DOI 10.1016/j.bbamcr.2016.09.012
   Ren ZG, 2012, DIABETES RES CLIN PR, V98, P474, DOI 10.1016/j.diabres.2012.09.028
   Rui T, 2012, CARDIOVASC RES, V94, P370, DOI 10.1093/cvr/cvs015
   Samuel S, 2008, NUTR REV, V66, pS116, DOI 10.1111/j.1753-4887.2008.00094.x
   Seki K, 2009, CIRC-HEART FAIL, V2, P684, DOI 10.1161/CIRCHEARTFAILURE.109.873240
   Singh A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070948
   Theodoropoulou S, 2017, J PATHOL, V241, P45, DOI 10.1002/path.4816
   Tohari AM, 2016, CELL BIOCHEM FUNCT, V34, P82, DOI 10.1002/cbf.3167
   Toomey CB, 2015, P NATL ACAD SCI USA, V112, pE3040, DOI 10.1073/pnas.1424391112
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Xi HK, 2016, J EXP MED, V213, P189, DOI 10.1084/jem.20150894
   Yu JT, 2012, NEUROBIOL AGING, V33, DOI 10.1016/j.neurobiolaging.2010.07.003
   Zella LA, 2006, MOL ENDOCRINOL, V20, P1231, DOI 10.1210/me.2006-0015
   Zhang HF, 2012, J TRANSL MED, V10, DOI 10.1186/1479-5876-10-120
NR 47
TC 28
Z9 30
U1 1
U2 9
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2076-3921
J9 ANTIOXIDANTS-BASEL
JI Antioxidants
PD SEP
PY 2019
VL 8
IS 9
AR 341
DI 10.3390/antiox8090341
PG 14
WC Biochemistry & Molecular Biology; Chemistry, Medicinal; Food Science &
   Technology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Food Science
   & Technology
GA JA6MU
UT WOS:000487957300050
PM 31450606
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Radhakrishnan, K
   Vincent, A
   Joseph, RR
   Moreno, M
   Dickescheid, A
   Agrawal, R
   Venkatraman, S
AF Radhakrishnan, Krishna
   Vincent, Anita
   Joseph, Rini Rachel
   Moreno, Miguel
   Dickescheid, Andreas
   Agrawal, Rupesh
   Venkatraman, Subbu
TI Hollow Microcapsules as Periocular Drug Depot for Sustained Release of
   Anti-VEGF Protein
SO PHARMACEUTICS
LA English
DT Article
DE protein delivery; controlled release; anti-VEGF; microparticles; drug
   delivery; layer by layer microcapsules; age related macular
   degeneration; back of the eye
ID POSTERIOR SEGMENT; INTRAVITREAL INJECTION; DELIVERY; EYE; NANOPARTICLES;
   LIPOPHILICITY; DISPOSITION; TRANSPORT; BARRIERS; PORCINE
AB Diseases affecting the posterior segment of the eye such as age-related macular degeneration and diabetic retinopathy are leading causes of blindness all over the world. The current treatment regimen for such diseases involves repeated intravitreal injections of anti- Vascular Endothelial Growth Factor (VEGF) proteins. This method is highly invasive and can lead to severe complications. In an attempt to develop less invasive alternatives, we propose the use of a controlled release system consisting of anti-VEGF loaded hollow microcapsules that can be administered periocularly to form drug eluting depots on the episcleral surface. The microcapsules with either positive or negative surface charge were prepared by a layer by layer approach and showed pH responsive permeability switching. An ex vivo experiment using porcine sclera indicated positively charged microcapsules remained on the episcleral surface over four days while the negatively charged microcapsules were washed away. These positively charged microcapsules were then loaded with anti-VEGF protein ranibizumab using pH dependent permeability switching and protein release from the microcapsules were studied using an in vitro setup. An ex vivo experiment utilizing porcine sclera demonstrated sustained release of ranibizumab over seven days with zero-order kinetics.
C1 [Radhakrishnan, Krishna; Vincent, Anita; Joseph, Rini Rachel; Moreno, Miguel; Dickescheid, Andreas; Venkatraman, Subbu] Nanyang Technol Univ, Sch Mat Sci & Engn, NTU Northwestern Inst Nanomed NNIN, 50 Nanyang Ave, Singapore 639798, Singapore.
   [Agrawal, Rupesh] Tan Tock Seng Hosp, Singapore 308433, Singapore.
C3 Nanyang Technological University & National Institute of Education (NIE)
   Singapore; Nanyang Technological University; Tan Tock Seng Hospital
RP Radhakrishnan, K; Venkatraman, S (通讯作者)，Nanyang Technol Univ, Sch Mat Sci & Engn, NTU Northwestern Inst Nanomed NNIN, 50 Nanyang Ave, Singapore 639798, Singapore.
EM krishna.r@ntu.edu.sg; assubbu@ntu.edu.sg
RI Agrawal, Rupesh/AAR-3910-2020
OI Agrawal, Rupesh/0000-0002-6662-5850; Radhakrishnan,
   Krishna/0000-0003-3259-8150
FU NTU-Northwestern Institute for Nanotechnology (NNIN), Northwestern
   University, USA; Nanyang Technological University, Singapore
FX The authors gratefully acknowledge support from the NTU-Northwestern
   Institute for Nanotechnology (NNIN), Northwestern University, USA and
   the Nanyang Technological University, Singapore.
CR Abrishami M, 2009, RETINA-J RET VIT DIS, V29, P699, DOI 10.1097/IAE.0b013e3181a2f42a
   Amrite AC, 2005, J PHARM PHARMACOL, V57, P1555, DOI 10.1211/jpp.57.12.0005
   Amrite AC, 2008, MOL VIS, V14, P150
   Ando T., 1973, MOL BIOL BIOCH BIOPH
   Cardillo, 2006, INVEST OPHTH VIS SCI, V47, P3886
   Caruso F, 1999, MACROMOLECULES, V32, P2317, DOI 10.1021/ma980674i
   Cheruvu NPS, 2006, INVEST OPHTH VIS SCI, V47, P4513, DOI 10.1167/iovs.06-0404
   Falavarjani KG, 2013, EYE, V27, P787, DOI 10.1038/eye.2013.107
   Geroski DH, 2000, INVEST OPHTH VIS SCI, V41, P961
   Hartnett TE, 2015, EXPERT OPIN DRUG DEL, V12, P1513, DOI 10.1517/17425247.2015.1021680
   Joseph RR, 2017, NANOMEDICINE-UK, V12, P683, DOI 10.2217/nnm-2016-0379
   Kadam RS, 2010, J PHARMACOL EXP THER, V332, P1107, DOI 10.1124/jpet.109.161570
   Kim SH, 2007, OPHTHALMIC RES, V39, P244, DOI 10.1159/000108117
   Lee TWY, 2001, J OCUL PHARMACOL TH, V17, P565, DOI 10.1089/10807680152729257
   Loch C, 2012, EUR J PHARM SCI, V47, P131, DOI 10.1016/j.ejps.2012.05.007
   Miao H, 2013, ACTA OPHTHALMOL, V91, pe1, DOI 10.1111/j.1755-3768.2012.02557.x
   Moisseiev E, 2017, DEV OPHTHALMOL, V58, P87, DOI 10.1159/000455276
   Nirmal J, 2016, EXPERT OPIN DRUG DEL, V13, P1625, DOI 10.1080/17425247.2016.1188800
   Radhakrishnan K, 2017, DRUG DISCOV TODAY, V22, P416, DOI 10.1016/j.drudis.2016.10.015
   Radhakrishnan K, 2012, CHEM COMMUN, V48, P2307, DOI 10.1039/c2cc17344a
   Raghava Swita, 2004, Expert Opin Drug Deliv, V1, P99, DOI 10.1517/17425247.1.1.99
   Shelke NB, 2011, DRUG DELIV TRANSL RE, V1, P76, DOI 10.1007/s13346-010-0009-8
   Stevens RE, 2015, AAPS J, V17, P301, DOI 10.1208/s12248-015-9723-y
   van Wijngaarden P, 2005, JAMA-J AM MED ASSOC, V293, P1509, DOI 10.1001/jama.293.12.1509
   Wen H, 2010, PHARM RES-DORDR, V27, P2446, DOI 10.1007/s11095-010-0237-0
   Zhang LH, 2009, INT J NANOMED, V4, P175
   Zhang Y, 2010, AAPS J, V12, P263, DOI 10.1208/s12248-010-9185-1
   Zhao QH, 2006, J BIOMAT SCI-POLYM E, V17, P997, DOI 10.1163/156856206778366031
NR 28
TC 5
Z9 5
U1 2
U2 16
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1999-4923
J9 PHARMACEUTICS
JI Pharmaceutics
PD JUL
PY 2019
VL 11
IS 7
AR 330
DI 10.3390/pharmaceutics11070330
PG 17
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA IN9JM
UT WOS:000478995100032
PM 31336771
OA Green Published, gold, Green Submitted
DA 2022-11-30
ER

PT J
AU Atilano, SR
   Malik, D
   Chwa, M
   Caceres-Del-Carpio, J
   Nesburn, AB
   Boyer, DS
   Kuppermann, BD
   Jazwinski, SM
   Miceli, MV
   Wallace, DC
   Udar, N
   Kenney, MC
AF Atilano, Shari R.
   Malik, Deepika
   Chwa, Marilyn
   Caceres-Del-Carpio, Javier
   Nesburn, Anthony B.
   Boyer, David S.
   Kuppermann, Baruch D.
   Jazwinski, S. Michal
   Miceli, Michael V.
   Wallace, Douglas C.
   Udar, Nitin
   Kenney, M. Cristina
TI Mitochondrial DNA variants can mediate methylation status of
   inflammation, angiogenesis and signaling genes
SO HUMAN MOLECULAR GENETICS
LA English
DT Article
ID HEREDITARY OPTIC NEUROPATHY; NON-CPG METHYLATION; CYBRID CELL-LINES;
   MACULAR DEGENERATION; TRANSMITOCHONDRIAL CYBRIDS; ABERRANT ACCUMULATION;
   EPIGENETIC REGULATION; MALATTIA LEVENTINESE; HISTONE ACETYLATION;
   OXIDATIVE STRESS
AB Mitochondrial (mt) DNA can be classified into haplogroups representing different geographic and/or racial origins of populations. The H haplogroup is protective against age-related macular degeneration (AMD), while the J haplogroup is high risk for AMD. In the present study, we performed comparison analyses of human retinal cell cybrids, which possess identical nuclei, but mtDNA from subjects with either the H or J haplogroups, and demonstrate differences in total global methylation, and expression patterns for two genes related to acetylation and five genes related to methylation. Analyses revealed that untreated-H and -J cybrids have different expression levels for nuclear genes (CFH, EFEMP1, VEGFA and NFkB2). However, expression levels for these genes become equivalent after treatment with a methylation inhibitor, 5-aza-2'-deoxycytidine. Moreover, sequencing of the entire mtDNA suggests that differences in epigenetic status found in cybrids are likely due to single nucleotide polymorphisms (SNPs) within the haplogroup profiles rather than rare variants or private SNPs. In conclusion, our findings indicate that mtDNA variants can mediate methylation profiles and transcription for inflammation, angiogenesis and various signaling pathways, which are important in several common diseases.
C1 [Atilano, Shari R.; Malik, Deepika; Chwa, Marilyn; Caceres-Del-Carpio, Javier; Nesburn, Anthony B.; Kuppermann, Baruch D.; Udar, Nitin; Kenney, M. Cristina] Univ Calif Irvine, Gavin Herbert Eye Inst, Irvine, CA 92697 USA.
   [Kenney, M. Cristina] Univ Calif Irvine, Dept Pathol & Lab Med, Irvine, CA 92697 USA.
   [Nesburn, Anthony B.] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA.
   [Boyer, David S.] Retina Vitreous Associates, Med Grp, Beverly Hills, CA 90211 USA.
   [Jazwinski, S. Michal; Miceli, Michael V.] Tulane Univ, Tulane Ctr Aging, New Orleans, LA 70118 USA.
   [Jazwinski, S. Michal; Miceli, Michael V.] Tulane Univ, Dept Med, New Orleans, LA 70118 USA.
   [Wallace, Douglas C.] Childrens Hosp Philadelphia, Ctr Mitochondrial & Epigen Med, Philadelphia, PA 19104 USA.
C3 University of California System; University of California Irvine;
   University of California System; University of California Irvine; Cedars
   Sinai Medical Center; Retina Vitreous Associates Medical Group; Tulane
   University; Tulane University; University of Pennsylvania; Pennsylvania
   Medicine; Childrens Hospital of Philadelphia
RP Kenney, MC (通讯作者)，Univ Calif Irvine, Gavin Herbert Eye Inst, Ophthalmol Res Lab, Hewitt Hall,Room 2028,843 Hlth Sci Rd, Irvine, CA 92697 USA.
EM mkenney@uci.edu
OI Udar, Nitin/0000-0001-8533-9190; Atilano, Shari/0000-0002-7729-7864;
   CACERES DEL CARPIO, JAVIER/0000-0001-5673-5709
FU Discovery Eye Foundation; Guenther Foundation; Beckman Initiative for
   Macular Research; Polly and Michael Smith Foundation; Max Factor Family
   Foundation; Iris and B. Gerald Cantor Foundation; National Institute on
   Aging [R37 AG006168]; David & Julianna Pyott Pan-American-Retina
   Research Fellowship; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL
   SCIENCES [UL1TR001414] Funding Source: NIH RePORTER; NATIONAL INSTITUTE
   OF NEUROLOGICAL DISORDERS AND STROKE [R01NS021328] Funding Source: NIH
   RePORTER; NATIONAL INSTITUTE ON AGING [R37AG006168] Funding Source: NIH
   RePORTER
FX This work was supported by Discovery Eye Foundation, Guenther
   Foundation, Beckman Initiative for Macular Research, Polly and Michael
   Smith Foundation, Max Factor Family Foundation, Iris and B. Gerald
   Cantor Foundation, and the National Institute on Aging (S.M.J., R37
   AG006168). J.C.d.C. is the David & Julianna Pyott Pan-American-Retina
   Research fellow. D.M. was the recipient of the David & Julianna Pyott
   Pan-American-Retina Research Fellowship (2012-2014).
CR Albig AR, 2006, CANCER RES, V66, P2621, DOI 10.1158/0008-5472.CAN-04-4096
   Amado FM, 2014, EXPERT REV PROTEOMIC, V11, P383, DOI 10.1586/14789450.2014.899470
   Bause AS, 2013, EXP GERONTOL, V48, P634, DOI 10.1016/j.exger.2012.08.007
   Bellizzi D, 2009, CELL STRESS CHAPERON, V14, P265, DOI 10.1007/s12192-008-0081-x
   Bellizzi D, 2006, GENES CELLS, V11, P883, DOI 10.1111/j.1365-2443.2006.00986.x
   Bellizzi D, 2013, DNA RES, V20, P537, DOI 10.1093/dnares/dst029
   Bellizzi D, 2012, EPIGENOMICS-UK, V4, P17, DOI [10.2217/EPI.11.109, 10.2217/epi.11.109]
   Bhattacharya SK, 1999, NATURE, V397, P579, DOI 10.1038/17533
   Canter JA, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002091
   Carelli V, 2002, BBA-MOL BASIS DIS, V1588, P7, DOI 10.1016/S0925-4439(02)00097-2
   Chestnut BA, 2011, J NEUROSCI, V31, P16619, DOI 10.1523/JNEUROSCI.1639-11.2011
   Chomyn A., 1996, PLATELET MEDIATED TR
   Cress WD, 2000, J CELL PHYSIOL, V184, P1, DOI 10.1002/(SICI)1097-4652(200007)184:1<1::AID-JCP1>3.0.CO;2-7
   Czarnecka AM, 2011, J AGING RES, V2011, DOI DOI 10.4061/2011/136435
   D'Aquila P, 2012, GENE, V497, P323, DOI 10.1016/j.gene.2012.01.042
   Deng HX, 2013, GENE, V518, P351, DOI 10.1016/j.gene.2012.12.103
   Ghosh SS, 1999, ANN NY ACAD SCI, V893, P176, DOI 10.1111/j.1749-6632.1999.tb07825.x
   Gomez-Duran A, 2012, BBA-MOL BASIS DIS, V1822, P1216, DOI 10.1016/j.bbadis.2012.04.014
   Gomez-Duran A, 2010, HUM MOL GENET, V19, P3343, DOI 10.1093/hmg/ddq246
   Guo WL, 2014, NUCLEIC ACIDS RES, V42, P3009, DOI 10.1093/nar/gkt1306
   Hammes HP, 1999, INVEST OPHTH VIS SCI, V40, P1855
   Hu YJ, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-123
   Hutchins AS, 2005, J IMMUNOL, V175, P5606, DOI 10.4049/jimmunol.175.9.5606
   Hwang CF, 2010, J PATHOL, V222, P367, DOI 10.1002/path.2776
   Hwang S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022116
   Iacobazzi V, 2013, MOL GENET METAB, V110, P25, DOI 10.1016/j.ymgme.2013.07.012
   Jones MM, 2007, ARCH OPHTHALMOL-CHIC, V125, P1235, DOI 10.1001/archopht.125.9.1235
   Jun AS, 1996, MOL CELL BIOL, V16, P771
   Kadiyala CSR, 2012, J BIOL CHEM, V287, P25869, DOI 10.1074/jbc.M112.375204
   Kaipparettu BA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061747
   Katta S, 2009, J GENET, V88, P425, DOI 10.1007/s12041-009-0064-4
   Kenney MC, 2014, HUM MOL GENET, V23, P3537, DOI 10.1093/hmg/ddu065
   Kenney MC, 2014, BBA-MOL BASIS DIS, V1842, P208, DOI 10.1016/j.bbadis.2013.10.016
   Kenney MC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054339
   Kenney MC, 2013, BMC MED GENET, V14, DOI 10.1186/1471-2350-14-4
   Kim YJ, 2011, CLIN CANCER RES, V17, P4523, DOI 10.1158/1078-0432.CCR-10-2817
   KOGA Y, 1995, MUSCLE NERVE, pS119
   Linton KM, 2008, BRIT J CANCER, V98, P1403, DOI 10.1038/sj.bjc.6604316
   Liu MM, 2012, HUM GENOMICS, V6, DOI 10.1186/1479-7364-6-13
   Lo TF, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075628
   Mahlknecht U, 2000, MOL MED, V6, P623, DOI 10.1007/BF03402044
   Malik D, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099003
   Moreno-Navarrete JM, 2010, DIABETES, V59, P200, DOI 10.2337/db09-0700
   Marmorstein LHY, 2002, P NATL ACAD SCI USA, V99, P13067, DOI 10.1073/pnas.202491599
   Miceli MV, 2005, INVEST OPHTH VIS SCI, V46, P1765, DOI 10.1167/iovs.04-1327
   Montezuma Sandra R, 2007, Semin Ophthalmol, V22, P229, DOI 10.1080/08820530701745140
   Mueller EE, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030874
   Naviaux RK, 2008, CANCER BIOL THER, V7, P1191, DOI 10.4161/cbt.7.8.6741
   Nomoto S, 2010, ANN SURG ONCOL, V17, P923, DOI 10.1245/s10434-009-0790-0
   Osborne B, 2014, BBA-GEN SUBJECTS, V1840, P1295, DOI 10.1016/j.bbagen.2013.08.016
   Pacheu-Grau D, 2013, HUM MOL GENET, V22, P1132, DOI 10.1093/hmg/dds517
   Parry Lee, 2011, Genes Cancer, V2, P618, DOI 10.1177/1947601911418499
   Ratnapriya R, 2013, CLIN GENET, V84, P160, DOI 10.1111/cge.12206
   REIS RJS, 1983, J BIOL CHEM, V258, P9078
   Rollins B, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004913
   Roybal CN, 2005, INVEST OPHTH VIS SCI, V46, P3973, DOI 10.1167/iovs.05-0070
   Sadr-Nabavi A, 2009, INT J CANCER, V124, P1727, DOI 10.1002/ijc.24108
   SanGiovanni JP, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005508
   Shock LS, 2011, P NATL ACAD SCI USA, V108, P3630, DOI 10.1073/pnas.1012311108
   Smiraglia DJ, 2008, CANCER BIOL THER, V7, P1182, DOI 10.4161/cbt.7.8.6215
   Song EL, 2011, GYNECOL ONCOL, V121, P174, DOI 10.1016/j.ygyno.2010.11.004
   Song EL, 2010, GYNECOL ONCOL, V117, P417, DOI 10.1016/j.ygyno.2009.12.016
   Stone EM, 1999, NAT GENET, V22, P199, DOI 10.1038/9722
   Timmermann S, 2001, CELL MOL LIFE SCI, V58, P728, DOI 10.1007/PL00000896
   Tu YF, 2011, BBA-BIOENERGETICS, V1807, P1125, DOI 10.1016/j.bbabio.2011.04.015
   Udar N, 2009, INVEST OPHTH VIS SCI, V50, P2966, DOI 10.1167/iovs.08-2646
   Vithayathil SA, 2012, METHODS MOL BIOL, V837, P219, DOI 10.1007/978-1-61779-504-6_15
   Wallace D, 2007, EMERY RIMOINS PRINCI
   Wallace DC, 2010, MITOCHONDRION, V10, P12, DOI 10.1016/j.mito.2009.09.006
   Weng SW, 2013, MITOCHONDRION, V13, P888, DOI 10.1016/j.mito.2013.08.001
   Yang JD, 2011, J KOREAN MED SCI, V26, P1428, DOI 10.3346/jkms.2011.26.11.1428
   Yang TT, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067458
   Yue W, 2007, CLIN CANCER RES, V13, P4336, DOI 10.1158/1078-0432.CCR-07-0015
   Zhang YW, 2011, CANCER LETT, V303, P21, DOI 10.1016/j.canlet.2010.12.011
NR 74
TC 44
Z9 45
U1 0
U2 11
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0964-6906
EI 1460-2083
J9 HUM MOL GENET
JI Hum. Mol. Genet.
PD AUG 15
PY 2015
VL 24
IS 16
BP 4491
EP 4503
DI 10.1093/hmg/ddv173
PG 13
WC Biochemistry & Molecular Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA CR4OU
UT WOS:000361315400002
PM 25964427
OA Green Published
DA 2022-11-30
ER

PT J
AU Park, SW
   Kim, JH
   Mook-Jung, I
   Kim, KW
   Park, WJ
   Park, KH
   Kim, JH
AF Park, Sung Wook
   Kim, Jin Hyoung
   Mook-Jung, Inhee
   Kim, Kyu-Won
   Park, Woo Jin
   Park, Kyu Hyung
   Kim, Jeong Hun
TI Intracellular amyloid beta alters the tight junction of retinal pigment
   epithelium in 5XFAD mice
SO NEUROBIOLOGY OF AGING
LA English
DT Article
DE Aging; Alzheimer's disease; A beta; Age-related macular degeneration;
   Outer blood retinal barrier; Tight junction; Retina; Retinal pigment
   epithelium; Transgenic mice
ID BLOOD-BRAIN-BARRIER; MACULAR DEGENERATION; ALZHEIMERS-DISEASE;
   END-PRODUCTS; RAGE; RECEPTOR; MODEL; NEURODEGENERATION; ACCUMULATION;
   PATHOGENESIS
AB Extracellular deposit of amyloid beta (A beta) is a common pathologic feature in both age-related macular degeneration (AMD) and Alzheimer's disease, but the role of intracellular A beta on the tight junction of the retinal pigment epithelium (RPE) is unknown. In this study, we investigated the intracellular A beta expression and its role on the outer blood retinal barrier in the retina of 5XFAD mice, a mouse model of Alzheimer's disease. The retina of 5XFAD mice showed the pathologic features of AMD with intracellular A beta in the RPE. As intracellular A beta accumulated, zonular occludens-1 and occludin were markedly attenuated and lost their integrity as tight junctions in the RPE of 5XFAD mice. Also, A beta(42) uptake by ARPE-19 cells induced the tight junction breakdown of zonular occludens-1 and occludin without cell death. These results implicate that intracellular A beta(42) could play a role in the breakdown of the outer blood retinal barrier in 5XFAD mice. Thus, we suggested that 5XFAD mice could be a mouse model of dry AMD with regard to the A beta(42) related pathology. (C) 2014 Elsevier Inc. All rights reserved.
C1 [Park, Sung Wook; Kim, Jin Hyoung; Kim, Jeong Hun] Seoul Natl Univ Hosp, Biomed Res Inst, Fight Angiogenesis Related Blindness Lab, Seoul 110744, South Korea.
   [Park, Sung Wook; Mook-Jung, Inhee; Kim, Jeong Hun] Seoul Natl Univ, Coll Med, Dept Biomed Sci, Seoul, South Korea.
   [Kim, Kyu-Won] Seoul Natl Univ, Coll Pharm, SNU Harvard NeuroVasc Protect Res Ctr, Seoul, South Korea.
   [Kim, Kyu-Won] Seoul Natl Univ, Res Inst Pharmaceut Sci, Seoul, South Korea.
   [Park, Woo Jin] Life Sci Concentrat GIST Gwangju Inst Sci & Techn, Dept Life Sci, Kwangju, South Korea.
   [Park, Kyu Hyung; Kim, Jeong Hun] Seoul Natl Univ, Coll Med, Dept Ophthalmol, Seoul, South Korea.
   [Park, Kyu Hyung] Seoul Natl Univ, Bundang Hosp, Dept Ophthalmol, Songnam 463707, Gyeonggi Do, South Korea.
C3 Seoul National University (SNU); Seoul National University Hospital;
   Seoul National University (SNU); Seoul National University (SNU); Seoul
   National University (SNU); Gwangju Institute of Science & Technology
   (GIST); Seoul National University (SNU); Seoul National University (SNU)
RP Park, KH (通讯作者)，Seoul Natl Univ, Bundang Hosp, Coll Med, Dept Ophthalmol, 166 Gumiro, Songnam 463707, Gyeonggi Do, South Korea.
EM jiani4@snu.ac.kr; steph25@snu.ac.kr
RI Park, Sung Wook/D-5541-2012; Kim, Kyu Won/AAJ-7213-2020
OI Park, Sung Wook/0000-0001-8151-6663; Kim, Jeong Hun/0000-0003-2957-1766
FU Bio-Signal Analysis Technology Innovation Program [2009-0090895];
   Pioneer Research Program [2012-0009544]; Global Research Laboratory
   Program of NRF/MEST of NRF/MEST [2011-0021874]; Seoul National
   University Research Grant [800-20130338]
FX This work was supported by the Bio-Signal Analysis Technology Innovation
   Program (2009-0090895), the Pioneer Research Program (2012-0009544), the
   Global Research Laboratory Program of NRF/MEST (2011-0021874) of
   NRF/MEST, and the Seoul National University Research Grant
   (800-20130338).
CR Adams MKM, 2012, AM J EPIDEMIOL, V175, P511, DOI 10.1093/aje/kwr329
   Alexandrov PN, 2011, NEUROREPORT, V22, P623, DOI 10.1097/WNR.0b013e3283497334
   Bornhorst J, 2012, J BIOL CHEM, V287, P17140, DOI 10.1074/jbc.M112.344093
   Bruban J, 2009, AGING CELL, V8, P162, DOI 10.1111/j.1474-9726.2009.00456.x
   Cotel MC, 2012, NEUROBIOL AGING, V33, P96, DOI 10.1016/j.neurobiolaging.2010.02.012
   Deane R, 2003, NAT MED, V9, P907, DOI 10.1038/nm890
   Dentchev T, 2003, MOL VIS, V9, P184
   Howes KA, 2004, INVEST OPHTH VIS SCI, V45, P3713, DOI 10.1167/iovs.04-0404
   Johnson LV, 2002, P NATL ACAD SCI USA, V99, P11830, DOI 10.1073/pnas.192203399
   Kook SY, 2012, J NEUROSCI, V32, P8845, DOI 10.1523/JNEUROSCI.6102-11.2012
   LaFerla FM, 2007, NAT REV NEUROSCI, V8, P499, DOI 10.1038/nrn2168
   Le Fur I, 2010, NEUROBIOL AGING, V31, P165, DOI 10.1016/j.neurobiolaging.2008.03.003
   Lue LF, 2001, EXP NEUROL, V171, P29, DOI 10.1006/exnr.2001.7732
   Luibl V, 2006, J CLIN INVEST, V116, P378, DOI 10.1172/JCI25843
   Mackic JB, 1998, J CLIN INVEST, V102, P734, DOI 10.1172/JCI2029
   Malek G, 2005, P NATL ACAD SCI USA, V102, P11900, DOI 10.1073/pnas.0503015102
   Moon M, 2012, J ALZHEIMERS DIS, V29, P615, DOI 10.3233/JAD-2011-111778
   Moon M, 2011, J ALZHEIMERS DIS, V23, P147, DOI 10.3233/JAD-2010-101263
   NEEPER M, 1992, J BIOL CHEM, V267, P14998
   Ning A, 2008, INVEST OPHTH VIS SCI, V49, P5136, DOI 10.1167/iovs.08-1849
   Oakley H, 2006, J NEUROSCI, V26, P10129, DOI 10.1523/JNEUROSCI.1202-06.2006
   Ohno-Matsui K, 2011, PROG RETIN EYE RES, V30, P217, DOI 10.1016/j.preteyeres.2011.02.004
   Omtri RS, 2012, MOL PHARMACEUT, V9, P1887, DOI 10.1021/mp200530q
   Pennesi ME, 2012, MOL ASPECTS MED, V33, P487, DOI 10.1016/j.mam.2012.06.003
   Proitsi P, 2012, NEUROBIOL AGING, V33, DOI 10.1016/j.neurobiolaging.2011.12.036
   Rosvall L, 2009, NEUROBIOL AGING, V30, P1545, DOI 10.1016/j.neurobiolaging.2007.12.003
   Schmidt AM, 2001, J CLIN INVEST, V108, P949, DOI 10.1172/JCI14002
   Strohmeyer R, 2000, MOL BRAIN RES, V81, P7, DOI 10.1016/S0169-328X(00)00149-2
   Tai LM, 2010, J CELL MOL MED, V14, P1101, DOI 10.1111/j.1582-4934.2009.00717.x
   Takuma K, 2009, P NATL ACAD SCI USA, V106, P20021, DOI 10.1073/pnas.0905686106
   Yoshida T, 2005, J CLIN INVEST, V115, P2793, DOI 10.1172/JCI24635
   Zhou JL, 2005, EXP EYE RES, V80, P567, DOI 10.1016/j.exer.2004.11.009
NR 32
TC 50
Z9 51
U1 0
U2 20
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0197-4580
EI 1558-1497
J9 NEUROBIOL AGING
JI Neurobiol. Aging
PD SEP
PY 2014
VL 35
IS 9
BP 2013
EP 2020
DI 10.1016/j.neurobiolaging.2014.03.008
PG 8
WC Geriatrics & Gerontology; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Geriatrics & Gerontology; Neurosciences & Neurology
GA AK1SB
UT WOS:000338195100010
PM 24709310
DA 2022-11-30
ER

PT J
AU Irons, J
   McKone, E
   Dumbleton, R
   Barnes, N
   He, XM
   Provis, J
   Ivanovici, C
   Kwa, A
AF Irons, Jessica
   McKone, Elinor
   Dumbleton, Rachael
   Barnes, Nick
   He, Xuming
   Provis, Jan
   Ivanovici, Callin
   Kwa, Alisa
TI A new theoretical approach to improving face recognition in disorders of
   central vision: Face caricaturing
SO JOURNAL OF VISION
LA English
DT Article
DE face recognition; age-related macular degeneration (AMD); caricature;
   face-space; blur
ID PREFERRED RETINAL LOCUS; MACULAR DEGENERATION; CONTRAST SENSITIVITY;
   VISUAL-ACUITY; FACIAL DISTINCTIVENESS; PERIPHERAL-VISION; SHAPE
   INFORMATION; DISEASE; SPACE; REORGANIZATION
AB Damage to central vision, of which age-related macular degeneration (AMD) is the most common cause, leaves patients with only blurred peripheral vision. Previous approaches to improving face recognition in AMD have employed image manipulations designed to enhance early-stage visual processing (e. g., magnification, increased HSF contrast). Here, we argue that further improvement may be possible by targeting known properties of mid- and/or high-level face processing. We enhance identity-related shape information in the face by caricaturing each individual away from an average face. We simulate early- through late-stage AMD-blur by filtering spatial frequencies to mimic the amount of blurring perceived at approximately 108 through 308 into the periphery (assuming a face seen premagnified on a tablet computer). We report caricature advantages for all blur levels, for face viewpoints from front view to semiprofile, and in tasks involving perceiving differences in facial identity between pairs of people, remembering previously learned faces, and rejecting new faces as unknown. Results provide a proof of concept that caricaturing may assist in improving face recognition in AMD and other disorders of central vision.
C1 [Irons, Jessica; McKone, Elinor; Dumbleton, Rachael; Ivanovici, Callin; Kwa, Alisa] Australian Natl Univ, Res Sch Psychol, Canberra, ACT, Australia.
   [Irons, Jessica; McKone, Elinor] Australian Natl Univ, ARC Ctr Excellence Cognit & Its Disorders, Canberra, ACT, Australia.
   [Barnes, Nick; He, Xuming] NICTA, Canberra, ACT, Australia.
   [Barnes, Nick; He, Xuming] Australian Natl Univ, Coll Engn & Comp Sci, Canberra, ACT, Australia.
   [Barnes, Nick] Bion Vis Australia, Carlton, Vic, Australia.
   [Provis, Jan] Australian Natl Univ, John Curtin Sch Med Res, Canberra, ACT 2601, Australia.
   [Provis, Jan] Australian Natl Univ, Sch Med, Canberra, ACT, Australia.
C3 Australian National University; Australian National University;
   Australian National University; Australian National University;
   Australian National University; John Curtin School of Medical Research;
   Australian National University
RP McKone, E (通讯作者)，Australian Natl Univ, Res Sch Psychol, Canberra, ACT, Australia.
EM elinor.mckone@anu.edu.au
RI Barnes, Nick/Y-2744-2018; Provis, Jan/C-9529-2009
OI Barnes, Nick/0000-0002-9343-9535; Provis, Jan/0000-0002-6405-2868;
   McKone, Elinor/0000-0003-1655-4297; Irons, Jessica/0000-0002-0671-5168
FU Australian Research Council (ARC) Queen Elizabeth II Fellowship
   [DP0984558]; ARC Centre of Excellence in Cognition and Its Disorders
   [CE110001021]; Australian Government as represented by Department of
   Broadband, Communications, and the Digital Economy; ARC Information and
   Commu-nication Technologies Centre of Excellence Program; ARC Special
   Research Initiative in Bionic Vision Science and Technology
FX Thanks to Alexandra Boeing for help with using FantaMorph, and Emma
   Cumming for testing some participants in Experiment 2 and some
   preliminary data extraction in Experiments 2 and 3. Funding from
   Australian Research Council (ARC) Queen Elizabeth II Fellowship to EM
   (DP0984558); ARC Centre of Excellence in Cognition and Its Disorders
   (CE110001021); Australian Government as represented by Department of
   Broadband, Communications, and the Digital Economy; ARC Information and
   Communication Technologies Centre of Excellence Program; ARC Special
   Research Initiative in Bionic Vision Science and Technology grant to
   Bionic Vision Australia.
CR Anderson R, 2012, PROCEEDINGS OF THE BRITISH MACHINE VISION CONFERENCE 2012, DOI 10.5244/C.26.131
   Anderson RS, 1999, J OPT SOC AM A, V16, P2321, DOI 10.1364/JOSAA.16.002321
   ANSTIS SM, 1974, VISION RES, V14, P589, DOI 10.1016/0042-6989(74)90049-2
   Baker CI, 2008, VISION RES, V48, P1910, DOI 10.1016/j.visres.2008.05.020
   BENSON P J, 1991, European Journal of Cognitive Psychology, V3, P105, DOI 10.1080/09541449108406222
   BENSON PJ, 1994, PERCEPTION, V23, P75, DOI 10.1068/p230075
   Blacharski P.A., 1988, RETINAL DYSTROPHY DE, P135
   Blank I, 2011, J VISION, V11, DOI 10.1167/11.8.15
   Brody BL, 2001, OPHTHALMOLOGY, V108, P1893, DOI 10.1016/S0161-6420(01)00754-0
   BULLIMORE MA, 1991, INVEST OPHTH VIS SCI, V32, P2020
   Byatt G, 1998, VISION RES, V38, P2455, DOI 10.1016/S0042-6989(97)00469-0
   Calder AJ, 2000, COGNITION, V76, P105, DOI 10.1016/S0010-0277(00)00074-3
   Calder AJ, 1996, BRIT J PSYCHOL, V87, P141, DOI 10.1111/j.2044-8295.1996.tb02581.x
   Chang PPW, 2002, DEV PSYCHOL, V38, P1038, DOI 10.1037//0012-1649.38.6.1038
   Cheung SH, 2005, VISUAL NEUROSCI, V22, P187, DOI 10.1017/S0952523805222071
   Crossland MD, 2005, OPHTHALMOLOGY, V112, P1579, DOI 10.1016/j.ophtha.2005.03.027
   Dagnelie G, 2008, ANNU REV BIOMED ENG, V10, P339, DOI 10.1146/annurev.bioeng.10.061807.160529
   Davis JM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028800
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   DeGutis J, 2013, COGNITION, V126, P87, DOI 10.1016/j.cognition.2012.09.004
   Deloitte Access Economics, 2011, EYES FUT CLEAR OUTL
   Dilks DD, 2009, J NEUROSCI, V29, P2768, DOI 10.1523/JNEUROSCI.5258-08.2009
   FIORENTINI A, 1983, PERCEPTION, V12, P195, DOI 10.1068/p120195
   Freiwald WA, 2009, NAT NEUROSCI, V12, P1187, DOI 10.1038/nn.2363
   Guo G., 2010, IEEE INT WORKSH AN M
   Guo G. -D., 2009, 12 IEEE INT C COMP V
   HE X, 2012, ANN INT C IEEE ENG M
   Jiang F, 2006, PSYCHOL SCI, V17, P493, DOI 10.1111/j.1467-9280.2006.01734.x
   Johnston RA, 1997, VIS COGN, V4, P59, DOI 10.1080/713756748
   Kanwisher N, 2014, NEW VISUAL NEUROSCIENCES, P733
   Kaufmann JM, 2013, NEUROPSYCHOLOGIA, V51, P1310, DOI 10.1016/j.neuropsychologia.2013.03.015
   KLEINER RC, 1988, ARCH OPHTHALMOL-CHIC, V106, P55
   LANGLOIS JH, 1990, PSYCHOL SCI, V1, P115, DOI 10.1111/j.1467-9280.1990.tb00079.x
   Lee K, 2000, PSYCHOL SCI, V11, P379, DOI 10.1111/1467-9280.00274
   Lee KJ, 2000, PERCEPTION, V29, P1291, DOI 10.1068/p2792
   Leopold DA, 2006, NATURE, V442, P572, DOI 10.1038/nature04951
   Li Jingguang, 2010, Commun Integr Biol, V3, P295
   LIGHT LL, 1979, J EXP PSYCHOL-HUM L, V5, P212, DOI 10.1037/0278-7393.5.3.212
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Lowe JB, 2000, OPTOMETRY VISION SCI, V77, P260, DOI 10.1097/00006324-200005000-00013
   MANDELBAUM J, 1947, AM J OPHTHALMOL, V30, P581, DOI 10.1016/0002-9394(47)92311-8
   Marmor DJ, 2010, ARCH OPHTHALMOL-CHIC, V128, P117, DOI 10.1001/archophthalmol.2009.366
   McKone E, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047956
   McKone E, 2009, VISION RES, V49, P268, DOI 10.1016/j.visres.2008.10.020
   MILLODOT M, 1966, BRIT J PHYSIOL OPT, V23, P75
   PELI E, 1991, INVEST OPHTH VIS SCI, V32, P2337
   PELI E, 1991, J OPT SOC AM A, V8, P1762, DOI 10.1364/JOSAA.8.001762
   PELI E, 1989, TECHNICAL DIGEST SER, V7, P64
   Pitcher D, 2007, CURR BIOL, V17, P1568, DOI 10.1016/j.cub.2007.07.063
   Rhodes G, 1997, PERCEPTION, V26, P207, DOI 10.1068/p260207
   RHODES G, 1987, COGNITIVE PSYCHOL, V19, P473, DOI 10.1016/0010-0285(87)90016-8
   RHODES G, 1994, VIS COGN, V1, P275, DOI DOI 10.1080/13506289408402303
   Rossion B, 2013, VIS COGN, V21, P139, DOI 10.1080/13506285.2013.772929
   ROVAMO J, 1978, NATURE, V271, P54, DOI 10.1038/271054a0
   Russell R, 2009, PSYCHON B REV, V16, P252, DOI 10.3758/PBR.16.2.252
   Schmier JK, 2006, OPHTHAL EPIDEMIOL, V13, P137, DOI 10.1080/09286580600573049
   Schumacher EH, 2008, RESTOR NEUROL NEUROS, V26, P391
   Seiple W, 2013, OPTOMETRY VISION SCI, V90, P45, DOI 10.1097/OPX.0b013e3182794775
   Shan CF, 2012, PATTERN RECOGN LETT, V33, P431, DOI 10.1016/j.patrec.2011.05.016
   SJOSTRAND J, 1977, ACTA OPHTHALMOL, V55, P507
   STEVENAGE SV, 1995, BRIT J PSYCHOL, V86, P127, DOI 10.1111/j.2044-8295.1995.tb02550.x
   Sunness JS, 1999, OPHTHALMOLOGY, V106, P1768, DOI 10.1016/S0161-6420(99)90340-8
   Susilo T, 2010, VISION RES, V50, P300, DOI 10.1016/j.visres.2009.11.016
   Tejeria L, 2002, BRIT J OPHTHALMOL, V86, P1019, DOI 10.1136/bjo.86.9.1019
   Townsend J.T., 1983, STOCHASTIC MODELING
   VALENTINE T, 1986, PERCEPTION, V15, P525, DOI 10.1068/p150525
   VALENTINE T, 1991, Q J EXP PSYCHOL-A, V43, P161, DOI 10.1080/14640749108400966
   van Rheede JJ, 2010, J VISION, V10, DOI 10.1167/10.14.32
   WERTHEIM T, 1980, AM J OPTOM PHYS OPT, V57, P915
   Wilmer JB, 2010, P NATL ACAD SCI USA, V107, P5238, DOI 10.1073/pnas.0913053107
   Yardley L, 2008, J PSYCHOSOM RES, V65, P445, DOI 10.1016/j.jpsychores.2008.03.013
   YOUNG AW, 1987, PERCEPTION, V16, P747, DOI 10.1068/p160747
   Zhu X., 2012, IEEE C COMP VIS PATT
   2010, GLOB EC COST VIS IMP
NR 74
TC 19
Z9 19
U1 0
U2 16
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 1534-7362
J9 J VISION
JI J. Vision
PY 2014
VL 14
IS 2
AR 12
DI 10.1167/14.2.12
PG 29
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Ophthalmology
GA AE5YE
UT WOS:000334064400012
PM 24534882
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Nolan, JM
   Meagher, K
   Kashani, S
   Beatty, S
AF Nolan, J. M.
   Meagher, K.
   Kashani, S.
   Beatty, S.
TI What is meso-zeaxanthin, and where does it come from?
SO EYE
LA English
DT Review
DE Meso-zeaxanthin; Lutein; Zeaxanthin; Macular Pigment; Vision
ID HUMAN MACULAR PIGMENT; PRIMATE RETINAS; OXIDATION-PRODUCTS;
   BINDING-PROTEIN; OCULAR-TISSUES; HUMAN PLASMA; CAROTENOIDS; LUTEIN;
   SUPPLEMENTATION; IDENTIFICATION
AB The carotenoids lutein (L), zeaxanthin (Z), and meso-zeaxanthin (MZ) accumulate in the central retina, where they are collectively known as macular pigment (MP). Each of these three compounds exhibit a regional dominance, with MZ, Z, and L being the dominant carotenoids at the epicentre, mid-periphery, and periphery of the macula, respectively. There is a growing and evidence-based consensus that MP is important for optimal visual performance, because of its blue light-filtering properties and consequential attenuation of chromatic aberration, veiling luminance, and blue haze. It has also been hypothesised that MP may protect against age-related macular degeneration because of the same optical properties and also because of the antioxidant capacity of the three macular carotenoids. Challenges inherent in the separation and quantification of MZ have resulted in a paucity of data on the content of this carotenoid in foodstuffs, and have rendered the study of tissue concentrations of this compound problematic. As a consequence, the few studies that have investigated MZ have, perhaps, been disproportionately influential in the ongoing debate about the origins of this macular carotenoid. Certainly, the narrative that retinal MZ is derived wholly and solely from retinal L needs to be revisited.
C1 [Nolan, J. M.; Meagher, K.; Kashani, S.; Beatty, S.] Waterford Inst Technol, Vis Res Ctr, Macular Pigment Res Grp, Waterford, Ireland.
C3 South East Technological University (SETU)
RP Nolan, JM (通讯作者)，Waterford Inst Technol, Vis Res Ctr, Macular Pigment Res Grp, Carriganore House,West Campus, Waterford, Ireland.
EM jmnolan@wit.ie
RI Nolan, John/N-4921-2014
OI Nolan, John/0000-0002-5503-7084
FU European Research Council (ERC)
FX JMN is funded by the European Research Council (ERC).
CR Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Bhosale P, 2005, BBA-MOL BASIS DIS, V1740, P116, DOI 10.1016/j.bbadis.2005.02.002
   Bhosale P, 2004, J BIOL CHEM, V279, P49447, DOI 10.1074/jbc.M405334200
   Bhosale P, 2007, BIOCHEMISTRY-US, V46, P9050, DOI 10.1021/bi700558f
   Billsten HH, 2003, PHOTOCHEM PHOTOBIOL, V78, P138, DOI 10.1562/0031-8655(2003)078<0138:PPOXIC>2.0.CO;2
   Bone RA, 1997, EXP EYE RES, V64, P211, DOI 10.1006/exer.1996.0210
   BONE RA, 1993, INVEST OPHTH VIS SCI, V34, P2033
   Bone RA, 2007, NUTR METAB, V4, DOI 10.1186/1743-7075-4-12
   Britton G, 1995, FASEB J, V9, P1551, DOI 10.1096/fasebj.9.15.8529834
   Britton G., 1995, CAROTENOIDS B, V1B, P13
   Cantrell A, 2003, ARCH BIOCHEM BIOPHYS, V412, P47, DOI 10.1016/S0003-9861(03)00014-6
   Chang C.J.G., 2006, 13 WEEK ORAL GAVAGE
   Connolly EE, 2011, INVEST OPHTH VIS SCI, V52, P9207, DOI 10.1167/iovs.11-8025
   Connolly EE, 2010, CURR EYE RES, V35, P335, DOI 10.3109/02713680903521951
   Davies B.H., 1976, CAROTENOIDS, P138
   HIRSCH J, 1989, VISION RES, V29, P1095, DOI 10.1016/0042-6989(89)90058-8
   Johnson EJ, 2005, INVEST OPHTH VIS SCI, V46, P692, DOI 10.1167/iovs.02-1192
   Junghans A, 2001, ARCH BIOCHEM BIOPHYS, V391, P160, DOI 10.1006/abbi.2001.2411
   Khachik F, 1997, INVEST OPHTH VIS SCI, V38, P1802
   Khachik F, 2002, INVEST OPHTH VIS SCI, V43, P3383
   KHACHIK F, 1992, METHOD ENZYMOL, V213, P347
   KHACHIK F, 1991, PURE APPL CHEM, V63, P71, DOI 10.1351/pac199163010071
   KHACHIK F, 1992, ANAL CHEM, V64, P2111, DOI 10.1021/ac00042a016
   Li BX, 2011, BIOCHEMISTRY-US, V50, P2541, DOI 10.1021/bi101906y
   Li BX, 2010, ARCH BIOCHEM BIOPHYS, V504, P56, DOI 10.1016/j.abb.2010.07.024
   Loughman J, 2013, J OPTOM, V3, P74
   MAOKA T, 1986, COMP BIOCHEM PHYS B, V83, P121, DOI 10.1016/0305-0491(86)90341-X
   MEAGHER KA, 2012, BR J NUTR, P1, DOI DOI 10.1017/S0007114512004837
   Nolan JM, 2012, EXP EYE RES, V101, P9, DOI 10.1016/j.exer.2012.05.006
   Nolan JM, 2011, VISION RES, V51, P459, DOI 10.1016/j.visres.2010.12.016
   PEASE PL, 1987, VISION RES, V27, P705, DOI 10.1016/0042-6989(87)90067-8
   Perry A, 2009, J FOOD COMPOS ANAL, V22, P9, DOI 10.1016/j.jfca.2008.07.006
   Pintea A, 2011, J FOOD COMPOS ANAL, V24, P830, DOI 10.1016/j.jfca.2011.03.007
   Rasmussen HM, 2012, J FOOD COMPOS ANAL, V27, P139, DOI 10.1016/j.jfca.2012.04.009
   SNODDERLY DM, 1984, INVEST OPHTH VIS SCI, V25, P660
   SNODDERLY DM, 1984, INVEST OPHTH VIS SCI, V25, P674
   Stringham JM, 2011, INVEST OPHTH VIS SCI, V52, P7406, DOI 10.1167/iovs.10-6699
   Sujak A, 1999, ARCH BIOCHEM BIOPHYS, V371, P301, DOI 10.1006/abbi.1999.1437
   Thurnham DI, 2008, BRIT J NUTR, V100, P1307, DOI 10.1017/S0007114508971336
   Trevithick-Sutton CC, 2006, MOL VIS, V12, P1127
   Trieschmann M, 2008, EYE, V22, P132, DOI 10.1038/sj.eye.6702780
   Walls G L, 1933, Br J Ophthalmol, V17, P705, DOI 10.1136/bjo.17.12.705
   Xu XD, 2013, FOOD CONTROL, V32, P678, DOI 10.1016/j.foodcont.2013.02.007
NR 43
TC 47
Z9 49
U1 0
U2 16
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-222X
EI 1476-5454
J9 EYE
JI Eye
PD AUG
PY 2013
VL 27
IS 8
BP 899
EP 905
DI 10.1038/eye.2013.98
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 198AC
UT WOS:000322893000001
PM 23703634
OA Bronze, Green Published, Green Accepted
DA 2022-11-30
ER

PT J
AU Kawakami, K
   Ebara, M
   Izawa, H
   Sanchez-Ballester, NM
   Hill, JP
   Ariga, K
AF Kawakami, K.
   Ebara, M.
   Izawa, H.
   Sanchez-Ballester, N. M.
   Hill, J. P.
   Ariga, K.
TI Supramolecular Approaches for Drug Development
SO CURRENT MEDICINAL CHEMISTRY
LA English
DT Review
DE Drug delivery; emulsion; microemulsion; hybrid; micelle; polymer
   micelle; layer-by-layer; liposome; molecular conjugate; cyclodextrin;
   self-assembly; supramolecular chemistry
ID POORLY SOLUBLE DRUGS; AIR-WATER-INTERFACE; MESOPOROUS SILICA
   NANOPARTICLES; SOLID LIPID NANOPARTICLES; APPENDED ALPHA-CYCLODEXTRIN;
   PORE-ENGINEERED NANOCARBON; DYNAMIC CAVITY ARRAY; CONTROLLED-RELEASE;
   MOLECULAR RECOGNITION; CARBON NANOCAGE
AB Various supramolecular systems can be used as drug carriers to alter physicochemical and pharmacokinetic characteristics of drugs. Representative supramolecular systems that can be used for this purpose include surfactant/polymer micelles, (micro) emulsions, liposomes, layer-by-layer assemblies, and various molecular conjugates. Notably, liposomes are established supramolecular drug carriers, which have already been marketed in formulations including AmBisome (R) (for treatment of fungal infection), Doxil (R) (for Kaposi's sarcoma), and Visudyne (R) (for age-related macular degeneration and choroidal neovascularization). Microemulsions have been used oral drug delivery of poorly soluble drugs due to improvements in bioavailability and predictable of absorption behavior. Neoral (R), an immunosuppressant used after transplant operations, is one of the most famous microemulsion-based drugs. Polymer micelles are being increasingly investigated as novel drug carriers and some formulations have already been tested in clinical trials. Supramolecular systems can be functionalized by designing the constituent molecules to achieve efficient delivery of drugs to desired sites in the body. In this review, representative supramolecular drug delivery systems, that may improve usability of candidate drugs or add value to existing drugs, are introduced.
C1 [Kawakami, K.; Ebara, M.; Izawa, H.; Sanchez-Ballester, N. M.; Hill, J. P.; Ariga, K.] Natl Inst Mat Sci NIMS, World Premier Int WPI Res Ctr Mat Nanoarchitecton, Tsukuba, Ibaraki 3050044, Japan.
   [Kawakami, K.; Ebara, M.; Hill, J. P.; Ariga, K.] CREST, Japan Sci & Technol Agcy JST, Tsukuba, Ibaraki 3050044, Japan.
C3 National Institute for Materials Science; Japan Science & Technology
   Agency (JST)
RP Kawakami, K (通讯作者)，Natl Inst Mat Sci NIMS, World Premier Int WPI Res Ctr Mat Nanoarchitecton, 1-1 Namiki, Tsukuba, Ibaraki 3050044, Japan.
EM KAWAKAMI.Kohsaku@nims.go.jp; ARIGA.Katsuhiko@nims.go.jp
RI ARIGA, Katsuhiko/H-2695-2011; Sanchez Ballester, Noelia
   Maria/K-1031-2014; Hill, Jonathan P/B-9332-2011
OI ARIGA, Katsuhiko/0000-0002-2445-2955; Sanchez Ballester, Noelia
   Maria/0000-0003-1614-4773; Hill, Jonathan P/0000-0002-4229-5842;
   Kawakami, Kohsaku/0000-0002-3466-9365
FU World Premier International Research Center (WPI) Initiative on
   Materials Nanoarchitectonics, MEXT, Japan; Japan Science and Technology
   Agency (JST), Japan
FX The authors declare that there is no conflict of interest upon
   preparation of this manuscript. This work was in part supported by World
   Premier International Research Center (WPI) Initiative on Materials
   Nanoarchitectonics, MEXT, Japan and the Core Research for Evolutional
   Science and Technology (CREST) program of Japan Science and Technology
   Agency (JST), Japan.
CR Abdullayev E, 2011, ACS APPL MATER INTER, V3, P4040, DOI 10.1021/am200896d
   Acharya S, 2009, ADV MATER, V21, P2959, DOI 10.1002/adma.200802648
   Agarwal A, 2008, J CONTROL RELEASE, V128, P255, DOI 10.1016/j.jconrel.2008.03.017
   AHMAD I, 1993, CANCER RES, V53, P1484
   Alam S, 2009, ANGEW CHEM INT EDIT, V48, P7358, DOI 10.1002/anie.200901570
   Allen C, 2002, BIOSCIENCE REP, V22, P225, DOI 10.1023/A:1020186505848
   ALLEN TM, 1991, BIOCHIM BIOPHYS ACTA, V1066, P29, DOI 10.1016/0005-2736(91)90246-5
   Almeida AJ, 2007, ADV DRUG DELIVER REV, V59, P478, DOI 10.1016/j.addr.2007.04.007
   ANTENUCCI RN, 1984, J AGR FOOD CHEM, V32, P1316, DOI 10.1021/jf00126a025
   Ariga K, 2000, J AM CHEM SOC, V122, P7835, DOI 10.1021/ja000924m
   Ariga K, 2005, SOFT MATTER, V1, P132, DOI 10.1039/b501945a
   Ariga K, 2005, LANGMUIR, V21, P976, DOI 10.1021/la0477845
   Ariga K, 2008, SCI TECHNOL ADV MAT, V9, DOI 10.1088/1468-6996/9/1/014109
   Ariga K, 2008, ANGEW CHEM INT EDIT, V47, P7254, DOI 10.1002/anie.200802820
   Ariga K, 2007, COORDIN CHEM REV, V251, P2562, DOI 10.1016/j.ccr.2007.02.024
   Ariga K, 2008, CURR OPIN COLLOID IN, V13, P23, DOI 10.1016/j.cocis.2007.08.010
   Ariga K, 2007, J AM CHEM SOC, V129, P11022, DOI 10.1021/ja074870t
   Ariga K, 2007, PHYS CHEM CHEM PHYS, V9, P2319, DOI 10.1039/b700410a
   Ariga K, 2006, SOFT MATTER, V2, P465, DOI 10.1039/b602732f
   Ariga K, 2006, J POROUS MAT, V13, P427, DOI 10.1007/s10934-006-8041-2
   Ariga K, 2012, B CHEM SOC JPN, V85, P1, DOI 10.1246/bcsj.20110162
   Ariga K, 2012, ADV MATER, V24, P158, DOI 10.1002/adma.201102617
   Ariga K, 2012, SOFT MATTER, V8, P15, DOI 10.1039/c1sm06832f
   Ariga K, 2011, ADV DRUG DELIVER REV, V63, P762, DOI 10.1016/j.addr.2011.03.016
   Ariga K, 2011, SUPRAMOL CHEM, V23, P183, DOI 10.1080/10610278.2010.521830
   Ariga K, 2011, EXPERT OPIN DRUG DEL, V8, P633, DOI 10.1517/17425247.2011.566268
   Ariga K, 2011, PHYS CHEM CHEM PHYS, V13, P4802, DOI 10.1039/c0cp02040k
   Ariga K, 2011, J NANOSCI NANOTECHNO, V11, P1, DOI 10.1166/jnn.2011.3839
   Ariga K, 2011, CHEM SCI, V2, P195, DOI 10.1039/c0sc00300j
   Ariga K, 2010, ADV POLYM SCI, V229, P51, DOI 10.1007/12_2009_42
   Ariga K, 2010, ADV COLLOID INTERFAC, V154, P20, DOI 10.1016/j.cis.2010.01.005
   Ariga K, 2009, SOFT MATTER, V5, P3562, DOI 10.1039/b909397d
   Ariga K, 2008, MACROMOL BIOSCI, V8, P981, DOI 10.1002/mabi.200800102
   Balas F, 2006, J AM CHEM SOC, V128, P8116, DOI 10.1021/ja062286z
   Balzani V, 1998, ACCOUNTS CHEM RES, V31, P405, DOI 10.1021/ar970340y
   Becker AL, 2009, LANGMUIR, V25, P14079, DOI 10.1021/la901687a
   Benoit DSW, 2011, BIOMACROMOLECULES, V12, P2708, DOI 10.1021/bm200485b
   Blasi P, 2007, ADV DRUG DELIVER REV, V59, P454, DOI 10.1016/j.addr.2007.04.011
   Chang C, 2008, J POLYM SCI POL CHEM, V46, P3048, DOI 10.1002/pola.22645
   Convertine AJ, 2010, BIOMACROMOLECULES, V11, P2904, DOI 10.1021/bm100652w
   Datta KKR, 2011, J NANOSCI NANOTECHNO, V11, P3959, DOI 10.1166/jnn.2011.4138
   Datta KKR, 2011, J NANOSCI NANOTECHNO, V11, P3084, DOI 10.1166/jnn.2011.4155
   Datta KKR, 2010, ANGEW CHEM INT EDIT, V49, P5961, DOI 10.1002/anie.201001699
   Davis ME, 2002, NATURE, V417, P813, DOI 10.1038/nature00785
   Decher G, 1997, SCIENCE, V277, P1232, DOI 10.1126/science.277.5330.1232
   DECHER G, 1991, MAKROMOL CHEM-M SYMP, V46, P321, DOI 10.1002/masy.19910460145
   Du L, 2009, J AM CHEM SOC, V131, P15136, DOI 10.1021/ja904982j
   Ferris DP, 2009, J AM CHEM SOC, V131, P1686, DOI 10.1021/ja807798g
   Fujii N, 2010, MACROMOLECULES, V43, P3947, DOI 10.1021/ma100473j
   Fundueanu G, 2008, BIOMATERIALS, V29, P2767, DOI 10.1016/j.biomaterials.2008.03.025
   Gao H, 2005, J CONTROL RELEASE, V107, P158, DOI 10.1016/j.jconrel.2005.06.010
   Gao H, 2006, J CONTROL RELEASE, V112, P301, DOI 10.1016/j.jconrel.2006.02.016
   GHOSH P, 1981, ARCH BIOCHEM BIOPHYS, V206, P454, DOI 10.1016/0003-9861(81)90113-2
   Hamaguchi T, 2007, BRIT J CANCER, V97, P170, DOI 10.1038/sj.bjc.6603855
   Han DH, 2011, MACROMOLECULES, V44, P437, DOI 10.1021/ma102778d
   Harada A, 2001, ACCOUNTS CHEM RES, V34, P456, DOI 10.1021/ar000174l
   Hartmann M, 2005, CHEM MATER, V17, P4577, DOI 10.1021/cm0485658
   Hernandez R, 2004, J AM CHEM SOC, V126, P3370, DOI 10.1021/ja039424u
   Hong CY, 2004, J POLYM SCI POL CHEM, V42, P4873, DOI 10.1002/pola.20248
   ILER RK, 1966, J COLLOID INTERF SCI, V21, P569, DOI 10.1016/0095-8522(66)90018-3
   Immordino ML, 2006, INT J NANOMED, V1, P297
   Irie T, 1999, ADV DRUG DELIVER REV, V36, P101, DOI 10.1016/S0169-409X(98)00057-X
   Ishihara S., CURR ORG SY IN PRESS, DOI [10.2174/1570211700120911794, DOI 10.2174/1570211700120911794]
   Ishihara S, 2011, J AM CHEM SOC, V133, P16119, DOI 10.1021/ja2056165
   Ji Q, 2008, J AM CHEM SOC, V130, P2376, DOI 10.1021/ja076139s
   Ji QM, 2010, ANGEW CHEM INT EDIT, V49, P9737, DOI 10.1002/anie.201004929
   Ji QM, 2009, ADV FUNCT MATER, V19, P1792, DOI 10.1002/adfm.200801762
   Kamada M, 2002, J CONTROL RELEASE, V82, P407, DOI 10.1016/S0168-3659(02)00171-2
   KATAOKA K, 1993, J CONTROL RELEASE, V24, P119
   Kawakami K, 2006, EUR J PHARM SCI, V28, P7, DOI 10.1016/j.ejps.2005.11.012
   Kawakami K, 2004, J PHARM SCI-US, V93, P1471, DOI 10.1002/jps.20067
   Kawakami K, 2002, J CONTROL RELEASE, V81, P75, DOI 10.1016/S0168-3659(02)00050-0
   Kawakami K, 2002, J CONTROL RELEASE, V81, P65, DOI 10.1016/S0168-3659(02)00049-4
   Kawakami K, 2012, ADV DRUG DELIVER REV, V64, P480, DOI 10.1016/j.addr.2011.10.009
   Kawakami K, 2009, J PHARM SCI-US, V98, P2875, DOI 10.1002/jps.21816
   Khashab NM, 2009, EUR J ORG CHEM, V2009, P1669, DOI 10.1002/ejoc.200801300
   Kinbara K, 2005, CHEM REV, V105, P1377, DOI 10.1021/cr030071r
   Kotsuchibashi Y, 2008, J POLYM SCI POL CHEM, V46, P6142, DOI 10.1002/pola.22925
   Kotsuchibashi Y, 2010, J POLYM SCI POL CHEM, V48, P4393, DOI 10.1002/pola.24226
   Kotsuchibashi Y, 2009, J COLLOID INTERF SCI, V336, P67, DOI 10.1016/j.jcis.2009.03.093
   KOVARIK JM, 1994, J PHARM SCI-US, V83, P444, DOI 10.1002/jps.2600830336
   Kratz F, 2008, J CONTROL RELEASE, V132, P171, DOI 10.1016/j.jconrel.2008.05.010
   Krishnan V, 2011, CURR OPIN COLLOID IN, V16, P459, DOI 10.1016/j.cocis.2011.08.005
   Kwon GS, 2003, CRIT REV THER DRUG, V20, P357, DOI 10.1615/CritRevTherDrugCarrierSyst.v20.i5.20
   Lawrence MJ, 2000, ADV DRUG DELIVER REV, V45, P89, DOI 10.1016/S0169-409X(00)00103-4
   Lee J, 1999, CHEM COMMUN, P2177, DOI 10.1039/a906872d
   LEHN JM, 1988, ANGEW CHEM INT EDIT, V27, P89, DOI 10.1002/anie.198800891
   LEHN JM, 1990, ANGEW CHEM INT EDIT, V29, P1304, DOI 10.1002/anie.199013041
   Li GY, 2008, J POLYM SCI POL CHEM, V46, P5028, DOI 10.1002/pola.22831
   Li J, 2003, J BIOMED MATER RES A, V65A, P196, DOI 10.1002/jbm.a.10444
   Li M, 2011, J AM CHEM SOC, V133, P7348, DOI 10.1021/ja202768k
   Lindsey JS, 2011, ACCOUNTS CHEM RES, V44, P638, DOI 10.1021/ar200107x
   Lvov Y., 2008, PHARM FOCUS ASIA, V7, P36
   Ma YJ, 2006, NAT MATER, V5, P724, DOI 10.1038/nmat1716
   Maeda H, 2001, ADV DRUG DELIVER REV, V46, P169, DOI 10.1016/S0169-409X(00)00134-4
   Mal NK, 2003, NATURE, V421, P350, DOI 10.1038/nature01362
   Mandal S, 2010, J AM CHEM SOC, V132, P14415, DOI 10.1021/ja107589m
   MATSUMURA Y, 1986, CANCER RES, V46, P6387
   Matsumura Y, 2004, BRIT J CANCER, V91, P1775, DOI 10.1038/sj.bjc.6602204
   Meng HA, 2010, J AM CHEM SOC, V132, P12690, DOI 10.1021/ja104501a
   Michinobu T, 2006, J AM CHEM SOC, V128, P14478, DOI 10.1021/ja066429t
   Michinobu T, 2011, PHYS CHEM CHEM PHYS, V13, P4895, DOI 10.1039/c0cp01990a
   Mizukami S, 2010, J AM CHEM SOC, V132, P9524, DOI 10.1021/ja102167m
   Mori T, 2011, NANOSCALE RES LETT, V6, DOI 10.1186/1556-276X-6-304
   Mori T, 2010, J AM CHEM SOC, V132, P12868, DOI 10.1021/ja106653a
   Murakami M, 2007, SOLID STATE NUCL MAG, V31, P193, DOI 10.1016/j.ssnmr.2007.04.003
   Needham D, 2000, CANCER RES, V60, P1197
   Ohno T, 2011, NAT MATER, V10, P591, DOI [10.1038/nmat3054, 10.1038/NMAT3054]
   Mellet CO, 2011, CHEM SOC REV, V40, P1586, DOI 10.1039/c0cs00019a
   Otsuka H, 2003, ADV DRUG DELIVER REV, V55, P403, DOI 10.1016/S0169-409X(02)00226-0
   Pargaonkar N, 2005, PHARM RES-DORDR, V22, P826, DOI 10.1007/s11095-005-2600-0
   Patel K, 2008, J AM CHEM SOC, V130, P2382, DOI 10.1021/ja0772086
   Pellegrin Y, 2011, COORDIN CHEM REV, V255, P2578, DOI 10.1016/j.ccr.2010.12.017
   Peng K, 2010, CHEM COMMUN, V46, P4094, DOI 10.1039/c002565h
   Plummer R, 2011, BRIT J CANCER, V104, P593, DOI 10.1038/bjc.2011.6
   Price RR, 2001, J MICROENCAPSUL, V18, P713
   Qin SH, 2006, ADV MATER, V18, P2905, DOI 10.1002/adma.200601019
   Ruiz-Hitzky E, 2010, ADV MATER, V22, P323, DOI 10.1002/adma.200901134
   Ryoo R, 2001, ADV MATER, V13, P677, DOI 10.1002/1521-4095(200105)13:9<677::AID-ADMA677>3.3.CO;2-3
   SAENGER W, 1980, ANGEW CHEM INT EDIT, V19, P344, DOI 10.1002/anie.198003441
   Sakakibara K, 2011, SMALL, V7, P1288, DOI 10.1002/smll.201002350
   Schilli CM, 2004, MACROMOLECULES, V37, P7861, DOI 10.1021/ma035838w
   Shi GF, 2002, J CONTROL RELEASE, V80, P309, DOI 10.1016/S0168-3659(02)00017-2
   Slowing II, 2008, ADV DRUG DELIVER REV, V60, P1278, DOI 10.1016/j.addr.2008.03.012
   Srinivasu P, 2008, MICROPOR MESOPOR MAT, V108, P340, DOI 10.1016/j.micromeso.2007.03.048
   Srinivasu P, 2007, J NANOSCI NANOTECHNO, V7, P3250, DOI 10.1166/jnn.2007.919
   Strickley RG, 2004, PHARM RES-DORDR, V21, P201, DOI 10.1023/B:PHAM.0000016235.32639.23
   Ta T, 2010, BIOMACROMOLECULES, V11, P1915, DOI 10.1021/bm1004993
   Tadokoro M, 2009, J NANOSCI NANOTECHNO, V9, P391, DOI 10.1166/jnn.2009.J042
   Takai A, 2009, CHEM MATER, V21, P3414, DOI 10.1021/cm9011926
   Takashima Y, 2004, CHEM LETT, V33, P890, DOI 10.1246/cl.2004.890
   Tamesue S, 2010, ANGEW CHEM INT EDIT, V49, P7461, DOI 10.1002/anie.201003567
   Tomatsu I, 2006, J AM CHEM SOC, V128, P2226, DOI 10.1021/ja058345a
   Trewyn BG, 2004, NANO LETT, V4, P2139, DOI 10.1021/nl048774r
   Uekama K, 1998, CHEM REV, V98, P2045, DOI 10.1021/cr970025p
   Uekama K, 1997, J MED CHEM, V40, P2755, DOI 10.1021/jm970130r
   Vallet-Regi M, 2007, ANGEW CHEM INT EDIT, V46, P7548, DOI 10.1002/anie.200604488
   Veerabadran NG, 2007, NANO, V2, P115, DOI 10.1142/S1793292007000441
   Veerabadran NG, 2009, MACROMOL RAPID COMM, V30, P99, DOI 10.1002/marc.200800510
   Vinu A, 2005, J MATER CHEM, V15, P5122, DOI 10.1039/b507456h
   Vinu A, 2005, CHEM MATER, V17, P5887, DOI 10.1021/cm051780j
   Vinu A, 2005, ADV MATER, V17, P1648, DOI 10.1002/adma.200401643
   Vinu A, 2006, SCI TECHNOL ADV MAT, V7, P753, DOI 10.1016/j.stam.2006.10.007
   Vinu A, 2006, J POROUS MAT, V13, P379, DOI 10.1007/s10934-006-8034-1
   Vistoli G, 2008, DRUG DISCOV TODAY, V13, P285, DOI 10.1016/j.drudis.2007.11.007
   Wissing SA, 2004, ADV DRUG DELIVER REV, V56, P1257, DOI 10.1016/j.addr.2003.12.002
   Wong HL, 2007, ADV DRUG DELIVER REV, V59, P491, DOI 10.1016/j.addr.2007.04.008
   Wu SM, 2011, ADV FUNCT MATER, V21, P93, DOI 10.1002/adfm.201001520
   Xue M, 2011, J AM CHEM SOC, V133, P8798, DOI 10.1021/ja201252e
   Yamaguchi T, 1996, ADV DRUG DELIVER REV, V20, P117, DOI 10.1016/0169-409X(95)00115-N
   Yamauchi Y, 2008, CHEM MATER, V20, P1004, DOI 10.1021/cm701985f
   Yano H, 2001, J PHARM SCI-US, V90, P493, DOI 10.1002/1520-6017(200104)90:4<493::AID-JPS1007>3.3.CO;2-N
   Yano H, 2001, J PHARM SCI, V90, P2103, DOI 10.1002/jps.1161
   ZANA R, 1995, ADV COLLOID INTERFAC, V57, P1, DOI 10.1016/0001-8686(95)00235-I
   Zhao JP, 2009, J POLYM SCI POL CHEM, V47, P4099, DOI 10.1002/pola.23470
   Zhao YL, 2010, J AM CHEM SOC, V132, P13016, DOI 10.1021/ja105371u
   Zheng ZG, 2010, LANGMUIR, V26, P7679, DOI 10.1021/la101246a
NR 157
TC 21
Z9 21
U1 2
U2 102
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 0929-8673
EI 1875-533X
J9 CURR MED CHEM
JI Curr. Med. Chem.
PD MAY
PY 2012
VL 19
IS 15
BP 2388
EP 2398
DI 10.2174/092986712800269254
PG 11
WC Biochemistry & Molecular Biology; Chemistry, Medicinal; Pharmacology &
   Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy
GA 930IE
UT WOS:000303130200008
PM 22455591
DA 2022-11-30
ER

PT J
AU Heurich, M
   Martinez-Barricarte, R
   Francis, NJ
   Roberts, DL
   de Cordoba, SR
   Morgan, BP
   Harris, CL
AF Heurich, Meike
   Martinez-Barricarte, Ruben
   Francis, Nigel J.
   Roberts, Dawn L.
   Rodriguez de Cordoba, Santiago
   Morgan, B. Paul
   Harris, Claire L.
TI Common polymorphisms in C3, factor B, and factor H collaborate to
   determine systemic complement activity and disease risk
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
DE inflammation; infection
ID HEMOLYTIC-UREMIC SYNDROME; DECAY-ACCELERATING FACTOR; MACULAR
   DEGENERATION; ALTERNATIVE PATHWAY; MOLECULAR ANALYSIS;
   RHEUMATOID-ARTHRITIS; ACTIVATION; ALLOTYPES; CONVERTASE; SUSCEPTIBILITY
AB Common polymorphisms in complement alternative pathway (AP) proteins C3 (C3(R102G)), factor B (fB(R32Q)), and factor H (fH(V62I)) are associated with age-related macular degeneration (AMD) and other pathologies. Our published work showed that fB(R32Q) influences C3 convertase formation, whereas fH(V62I) affects factor I cofactor activity. Here we show how C3(R102G) (C3S/F) influences AP activity. In hemolysis assays, C3(102G) activated AP more efficiently (EC50 C3(102G): 157 nM; C3(102R): 191 nM; P < 0.0001). fB binding kinetics and convertase stability were identical, but native and recombinant fH bound more strongly to C3b(102R) (K-D C3b(102R): 1.0 mu M; C3b(102G): 1.4 mu M; P < 0.0001). Accelerated decay was unaltered, but fH cofactor activity was reduced for C3b(102G), favoring AP amplification. Combining disease "risk" variants (C3(102G), fB(32R), and fH(62V)) in add-back assays yielded sixfold higher hemolytic activity compared with "protective" variants (C3(102R), fB(32Q), and fH(62I); P < 0.0001). These data introduce the concept of a functional complotype (combination of polymorphisms) defining complement activity in an individual, thereby influencing susceptibility to AP-driven disease.
C1 [Heurich, Meike; Francis, Nigel J.; Roberts, Dawn L.; Morgan, B. Paul; Harris, Claire L.] Cardiff Univ, Sch Med, Dept Infect Immun & Biochem, Cardiff CF14 4XN, S Glam, Wales.
   [Martinez-Barricarte, Ruben; Rodriguez de Cordoba, Santiago] CSIC, Ctr Invest Biol, Madrid 28040, Spain.
C3 Cardiff University; Consejo Superior de Investigaciones Cientificas
   (CSIC); CSIC - Centro de Investigaciones Biologicas (CIB)
RP Harris, CL (通讯作者)，Cardiff Univ, Sch Med, Dept Infect Immun & Biochem, Cardiff CF14 4XN, S Glam, Wales.
EM harriscl@cardiff.ac.uk
RI de Cordoba, Santiago Rodriguez/K-6727-2014; Barricarte, Ruben
   Martinez/W-8695-2019
OI de Cordoba, Santiago Rodriguez/0000-0001-6401-1874; Barricarte, Ruben
   Martinez/0000-0001-7925-449X; Francis, Nigel/0000-0002-4706-4795;
   Heurich, Dr Meike/0000-0003-0105-2702; Morgan, Paul/0000-0003-4075-7676
FU Medical Research Council, United Kingdom [G0701298]; Spanish Ministerio
   de Educacion y Cultura [SAF2008-00226]; Ciber de Enfermedades Raras;
   Fundacion Renal Inigo Alvarez de Toledo; Medical Research Council
   [G0701298] Funding Source: researchfish; MRC [G0701298] Funding Source:
   UKRI
FX We thank Dr. David Cole (Cardiff University, Cardiff, United Kingdom)
   for advice on refolding rfH1-4 and Prof. Susan Lea (Oxford University,
   Oxford, United Kingdom) for sMCP and sDAF. This work was supported by
   the Medical Research Council, United Kingdom (G0701298 to C. L. H. and
   B. P. M.), the Spanish Ministerio de Educacion y Cultura (SAF2008-00226
   to S.R.deC.) and the Ciber de Enfermedades Raras and the Fundacion Renal
   Inigo Alvarez de Toledo (S.R.deC.).
CR Andrews PA, 1995, TRANSPLANTATION, V60, P1342
   Atkinson JP, 2005, ANN NY ACAD SCI, V1056, P144, DOI 10.1196/annals.1352.032
   BOTTO M, 1990, J EXP MED, V172, P1011, DOI 10.1084/jem.172.4.1011
   de Cordoba SR, 2004, MOL IMMUNOL, V41, P355, DOI 10.1016/j.molimm.2004.02.005
   de Jorge EG, 2007, P NATL ACAD SCI USA, V104, P240, DOI 10.1073/pnas.0603420103
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Esparza-Gordillo J, 2005, HUM MOL GENET, V14, P703, DOI 10.1093/hmg/ddi066
   Fagerness JA, 2009, EUR J HUM GENET, V17, P100, DOI 10.1038/ejhg.2008.140
   FEARON DT, 1978, P NATL ACAD SCI USA, V75, P1971, DOI 10.1073/pnas.75.4.1971
   FINN JE, 1993, CLIN EXP IMMUNOL, V91, P410
   FINN JE, 1994, NEPHROL DIAL TRANSPL, V9, P1564
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   GORDON DL, 1995, J IMMUNOL, V155, P348
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   HAGGLOF B, 1986, HUM HERED, V36, P201, DOI 10.1159/000153627
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Harris C L, 2000, Methods Mol Biol, V150, P83
   Harris CL, 2005, J BIOL CHEM, V280, P2569, DOI 10.1074/jbc.M410179200
   Harris CL, 2007, J IMMUNOL, V178, P352, DOI 10.4049/jimmunol.178.1.352
   Hecker LA, 2010, HUM MOL GENET, V19, P209, DOI 10.1093/hmg/ddp472
   Hepburn NJ, 2007, J BIOL CHEM, V282, P8292, DOI 10.1074/jbc.M609858200
   Herbert AP, 2007, J BIOL CHEM, V282, P18960, DOI 10.1074/jbc.M609636200
   Holers VM, 2008, IMMUNOL REV, V223, P300, DOI 10.1111/j.1600-065X.2008.00641.x
   Janssen BJC, 2009, EMBO J, V28, P2469, DOI 10.1038/emboj.2009.184
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kuhn S, 1996, EUR J IMMUNOL, V26, P2383, DOI 10.1002/eji.1830261017
   Kurreeman FAS, 2008, ARTHRITIS RHEUM-US, V58, P2670, DOI 10.1002/art.23793
   LACHMANN PJ, 1984, SPRINGER SEMIN IMMUN, V7, P143, DOI 10.1007/BF01893018
   Messias-Reason IJ, 2003, TISSUE ANTIGENS, V62, P308, DOI 10.1034/j.1399-0039.2003.00101.x
   Montes T, 2009, P NATL ACAD SCI USA, V106, P4366, DOI 10.1073/pnas.0812584106
   MORGAN BP, 1994, SPRINGER SEMIN IMMUN, V15, P369, DOI 10.1007/BF01837366
   Nishimoto K, 2010, ANN RHEUM DIS, V69, P368, DOI 10.1136/ard.2008.104315
   PAPIHA SS, 1991, HUM HERED, V41, P397, DOI 10.1159/000154033
   Pickering MC, 2007, J EXP MED, V204, P1249, DOI 10.1084/jem.20070301
   Prosser BE, 2007, J EXP MED, V204, P2277, DOI 10.1084/jem.20071069
   RAMBAUSEK M, 1987, Nephrology Dialysis Transplantation, V2, P208
   Reynolds R, 2009, INVEST OPHTH VIS SCI, V50, P5818, DOI 10.1167/iovs.09-3928
   de Cordoba S, 2011, BBA-MOL BASIS DIS, V1812, P12, DOI 10.1016/j.bbadis.2010.09.002
   Scholl HPN, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002593
   Sobrin L, 2010, EUR J HUM GENET, V18, P496, DOI 10.1038/ejhg.2009.185
   Spencer KL, 2008, HUM MOL GENET, V17, P1821, DOI 10.1093/hmg/ddn075
   Torreira E, 2009, P NATL ACAD SCI USA, V106, P882, DOI 10.1073/pnas.0810860106
   Tortajada A, 2009, HUM MOL GENET, V18, P3452, DOI 10.1093/hmg/ddp289
   VRIES RRPD, 1979, J IMMUNOGENET, V6, P271
   Walport MJ, 2001, NEW ENGL J MED, V344, P1058, DOI 10.1056/NEJM200104053441406
   Wu J, 2009, NAT IMMUNOL, V10, P728, DOI 10.1038/ni.1755
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Zipfel PF, 2007, PLOS GENET, V3, P387, DOI 10.1371/journal.pgen.0030041
   Zipfel PF, 2006, MOL IMMUNOL, V43, P97, DOI 10.1016/j.molimm.2005.06.015
NR 49
TC 161
Z9 174
U1 0
U2 13
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD MAY 24
PY 2011
VL 108
IS 21
BP 8761
EP 8766
DI 10.1073/pnas.1019338108
PG 6
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 768CB
UT WOS:000290908000050
PM 21555552
OA Green Submitted, Bronze, Green Published
DA 2022-11-30
ER

PT J
AU Picard, E
   Houssier, M
   Bujold, K
   Sapieha, P
   Lubell, W
   Dorfman, A
   Racine, J
   Hardy, P
   Febbraio, M
   Lachapelle, P
   Ong, H
   Sennlaub, F
   Chemtob, S
AF Picard, Emilie
   Houssier, Marianne
   Bujold, Kim
   Sapieha, Przemyslaw
   Lubell, William
   Dorfman, Allison
   Racine, Julie
   Hardy, Pierre
   Febbraio, Maria
   Lachapelle, Pierre
   Ong, Huy
   Sennlaub, Florian
   Chemtob, Sylvain
TI CD36 plays an important role in the clearance of oxLDL and associated
   age-dependent sub-retinal deposits
SO AGING-US
LA English
DT Article
DE CD36; oxidized lipids; Bruch's membrane; age-related macular
   degeneration
ID LOW-DENSITY-LIPOPROTEIN; E-DEFICIENT MICE; OXYGEN-INDUCED RETINOPATHY;
   PIGMENT EPITHELIAL-CELLS; MACULAR BRUCHS MEMBRANE;
   QUICK-FREEZE/DEEP-ETCH; APOLIPOPROTEIN-E; SCAVENGER RECEPTORS;
   RISK-FACTORS; ULTRASTRUCTURAL-CHANGES
AB Age-related macular degeneration (AMD) represents the major cause of vision loss in industrialized nations. Laminar deposits in Bruch's membrane (BM) are among the first prominent histopathologic features, along with drusen formation, and have been found to contain oxidized lipids. Increases in concentrations of oxidized LDL (oxLDL) in plasma are observed with age and high fat high (HFHC) cholesterol diet. CD36 is the principal receptor implicated in uptake of oxLDL, and is expressed in the retinal pigment epithelium (RPE). We determined if CD36 participates in oxLDL uptake in RPE and correspondingly in clearance of sub-retinal deposits. Uptake of oxLDL by RPE in vitro and in vivo was CD36-dependent. CD36 deficiency in mice resulted in age-associated accumulation of oxLDL and sub-retinal BM thickening, despite fed a regular diet. Conversely, treatment of HFHC-fed ApoE null mice with a CD36 agonist, EP80317 (300 mu g/kg/day), markedly diminished thickening of BM, and partially preserved (in part) photoreceptor function. In conclusion, our data uncover a new role for CD36 in the clearance of oxidized lipids from BM and in the prevention of age-dependent sub-retinal laminar deposits.
C1 [Picard, Emilie; Sapieha, Przemyslaw; Hardy, Pierre; Chemtob, Sylvain] Univ Montreal, Dept Pediat, Hosp Ste Justine, Res Ctr, Montreal, PQ H3C 3J7, Canada.
   [Picard, Emilie; Sapieha, Przemyslaw; Hardy, Pierre; Chemtob, Sylvain] Univ Montreal, Dept Ophthalmol, Hosp Ste Justine, Res Ctr, Montreal, PQ H3C 3J7, Canada.
   [Picard, Emilie; Sapieha, Przemyslaw; Hardy, Pierre; Chemtob, Sylvain] Univ Montreal, Dept Pharmacol, Hosp Ste Justine, Res Ctr, Montreal, PQ H3C 3J7, Canada.
   [Picard, Emilie; Sapieha, Przemyslaw; Hardy, Pierre; Chemtob, Sylvain] Univ Montreal, Dept Pediat, Hosp Maisonneuve Rosemont, Res Ctr, Montreal, PQ H3C 3J7, Canada.
   [Picard, Emilie; Sapieha, Przemyslaw; Hardy, Pierre; Chemtob, Sylvain] Univ Montreal, Dept Ophthalmol, Hosp Maisonneuve Rosemont, Res Ctr, Montreal, PQ H3C 3J7, Canada.
   [Picard, Emilie; Sapieha, Przemyslaw; Hardy, Pierre; Chemtob, Sylvain] Univ Montreal, Dept Pharmacol, Hosp Maisonneuve Rosemont, Res Ctr, Montreal, PQ H3C 3J7, Canada.
   [Houssier, Marianne; Sennlaub, Florian] INSERM, U872, F-75006 Paris, France.
   [Houssier, Marianne; Sennlaub, Florian] Univ Paris 06, Ctr Rech Cordeliers, UMR S 872, F-75006 Paris, France.
   [Houssier, Marianne; Sennlaub, Florian] Univ Paris 05, UMR S 872, F-75006 Paris, France.
   [Bujold, Kim; Ong, Huy] Univ Montreal, Fac Pharm, Montreal, PQ H3C 3J7, Canada.
   [Lubell, William] Univ Montreal, Dept Chem, Montreal, PQ H3C 3J7, Canada.
   [Dorfman, Allison; Racine, Julie; Lachapelle, Pierre] McGill Univ, Dept Ophthalmol, Montreal, PQ H3A 2T5, Canada.
   [Febbraio, Maria] Cleveland Clin Fdn, Lerner Res Inst, Dept Cell Biol, Cleveland, OH USA.
   [Sennlaub, Florian] Hop Hotel Dieu, APHP, Dept Ophthalmol, Paris, France.
C3 Universite de Montreal; Universite de Montreal; Universite de Montreal;
   Universite de Montreal; Universite de Montreal; Universite de Montreal;
   Institut National de la Sante et de la Recherche Medicale (Inserm);
   UDICE-French Research Universities; Universite Paris Cite; Institut
   National de la Sante et de la Recherche Medicale (Inserm); UDICE-French
   Research Universities; Sorbonne Universite; Universite Paris Cite;
   UDICE-French Research Universities; Universite Paris Cite; Universite de
   Montreal; Universite de Montreal; McGill University; Cleveland Clinic
   Foundation; Assistance Publique Hopitaux Paris (APHP); Hopital
   Universitaire Ambroise-Pare - APHP; Hopital Universitaire Hotel-Dieu -
   APHP; UDICE-French Research Universities; Universite Paris Cite
RP Chemtob, S (通讯作者)，Univ Montreal, Dept Pediat, Hosp Ste Justine, Res Ctr, Montreal, PQ H3C 3J7, Canada.
EM sylvain.chemtob@umontreal.ca
RI Sennlaub, Florian/F-2756-2017; picard, Emilie/A-6919-2013
OI Sennlaub, Florian/0000-0003-4412-1341; picard,
   Emilie/0000-0002-2689-0510; Lachapelle, Pierre/0000-0002-7792-1102;
   Houssier, Marianne/0000-0002-5329-4597; Lubell,
   William/0000-0002-3080-2712
FU Canadian Institutes of Health Research; Agence Nationale de Recherche:
   Genopat [ANR-Geno-031-03]; Agence Nationale de Recherche: Maladies
   Neurologiques et Psychiatriques [ANR- 08-MNPS -003,]; European Research
   Council [ERC-StG- 210345]
FX This work was supported by grants from the Canadian Institutes of Health
   Research and from Agence Nationale de Recherche: Genopat:
   ANR-Geno-031-03, Agence Nationale de Recherche: Maladies Neurologiques
   et Psychiatriques: ANR- 08-MNPS -003, European Research Council Starting
   Grant: ERC-StG- 210345. The funding agencies had no role in study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript. S Chemtob is a recipient of a Canada
   Research Chair (perinatology) and of the Leopoldine Wolfe Chair in
   translational vision research.
CR Anderson DH, 2004, EXP EYE RES, V78, P243, DOI 10.1016/j.exer.2003.10.011
   Anderson DH, 2001, AM J OPHTHALMOL, V131, P767, DOI 10.1016/S0002-9394(00)00961-2
   Collot-Teixeira S, 2007, CARDIOVASC RES, V75, P468, DOI 10.1016/j.cardiores.2007.03.010
   Curcio CA, 2001, INVEST OPHTH VIS SCI, V42, P265
   Dasch B, 2005, OPHTHALMOLOGE, V102, P1057, DOI 10.1007/s00347-005-1225-3
   Dembinska O, 2001, INVEST OPHTH VIS SCI, V42, P1111
   Dembinska O, 2002, INVEST OPHTH VIS SCI, V43, P2481
   Dithmar S, 2000, INVEST OPHTH VIS SCI, V41, P2035
   Dorfman AL, 2006, INVEST OPHTH VIS SCI, V47, P1101, DOI 10.1167/iovs.05-0727
   Duncan KG, 2002, BIOCHEM BIOPH RES CO, V292, P1017, DOI 10.1006/bbrc.2002.6756
   ENDEMANN G, 1993, J BIOL CHEM, V268, P11811
   Febbraio M, 1999, J BIOL CHEM, V274, P19055, DOI 10.1074/jbc.274.27.19055
   Febbraio M, 2000, J CLIN INVEST, V105, P1049, DOI 10.1172/JCI9259
   FRASER GE, 1994, AM J CLIN NUTR, V59, p1117S, DOI 10.1093/ajcn/59.5.1117S
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gordiyenko N, 2004, INVEST OPHTH VIS SCI, V45, P2822, DOI 10.1167/iovs.04-0074
   GREEN WR, 1993, OPHTHALMOLOGY, V100, P1519
   Guymer RH, 2006, MED J AUSTRALIA, V184, P455, DOI 10.5694/j.1326-5377.2006.tb00318.x
   HOLZ FG, 1994, ARCH OPHTHALMOL-CHIC, V112, P402, DOI 10.1001/archopht.1994.01090150132035
   Houssier M, 2008, PLOS MED, V5, P323, DOI 10.1371/journal.pmed.0050039
   Huang JD, 2008, INVEST OPHTH VIS SCI, V49, P2721, DOI 10.1167/iovs.07-1196
   Huang JD, 2007, EXP EYE RES, V85, P202, DOI 10.1016/j.exer.2007.03.011
   Ishida BY, 2006, BRIT J OPHTHALMOL, V90, P616, DOI 10.1136/bjo.2005.085076
   Ishigaki Y, 2008, CIRCULATION, V118, P75, DOI 10.1161/CIRCULATIONAHA.107.745174
   Johnson LV, 2002, P NATL ACAD SCI USA, V99, P11830, DOI 10.1073/pnas.192203399
   Johnson PT, 2005, INVEST OPHTH VIS SCI, V46, P4788, DOI 10.1167/iovs.05-0767
   Kamei M, 2007, INVEST OPHTH VIS SCI, V48, P1801, DOI 10.1167/iovs.06-0699
   Klaver CCW, 1998, AM J HUM GENET, V63, P200, DOI 10.1086/301901
   Kondo N, 2009, AGING-US, V1, P266, DOI 10.18632/aging.100006
   Kunjathoor VV, 2002, J BIOL CHEM, V277, P49982, DOI 10.1074/jbc.M209649200
   LEWIS H, 1986, OPHTHALMOLOGY, V93, P1098
   Li CM, 2007, EXP EYE RES, V85, P192, DOI 10.1016/j.exer.2007.04.002
   Li CM, 2006, INVEST OPHTH VIS SCI, V47, P3119, DOI 10.1167/iovs.05-1446
   Li CM, 2005, INVEST OPHTH VIS SCI, V46, P2576, DOI 10.1167/iovs.05-0034
   Malek G, 2003, AM J PATHOL, V162, P413, DOI 10.1016/S0002-9440(10)63836-9
   Marleau Sylvie, 2005, FASEB J, V19, P1869
   MOORE DJ, 1995, INVEST OPHTH VIS SCI, V36, P1290
   Nakamura YK, 2004, LIFE SCI, V74, P1265, DOI 10.1016/j.lfs.2003.08.007
   Ong JM, 2003, CURR EYE RES, V27, P15, DOI 10.1076/ceyr.27.2.15.15460
   Ong JM, 2001, INVEST OPHTH VIS SCI, V42, pS79
   Parekh N, 2009, ARCH OPHTHALMOL-CHIC, V127, P1483, DOI 10.1001/archophthalmol.2009.130
   PAULEIKHOFF D, 1990, OPHTHALMOLOGY, V97, P171
   Rodriguez IR, 2004, INVEST OPHTH VIS SCI, V45, P2830, DOI 10.1167/iovs.04-0075
   Ruberti JW, 2003, INVEST OPHTH VIS SCI, V44, P1753, DOI 10.1167/iovs.02-0496
   Rudolf M, 2004, OPHTHALMOLOGE, V101, P715, DOI 10.1007/s00347-003-0942-8
   Ryeom SW, 1996, J CELL SCI, V109, P387
   Saint-Geniez M, 2009, P NATL ACAD SCI USA, V106, P18751, DOI 10.1073/pnas.0905010106
   SARKS SH, 1976, BRIT J OPHTHALMOL, V60, P324, DOI 10.1136/bjo.60.5.324
   SHERAIDAH G, 1993, OPHTHALMOLOGY, V100, P47
   Starita C, 1996, EXP EYE RES, V62, P565, DOI 10.1006/exer.1996.0066
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   Trivino A, 2006, EXP EYE RES, V83, P357, DOI 10.1016/j.exer.2005.12.020
   Tserentsoodol N, 2006, MOL VIS, V12, P1306
   Wang L, 2009, INVEST OPHTH VIS SCI, V50, P870, DOI 10.1167/iovs.08-2376
   Wang L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010329
   ZHAO J, 1995, INT OPHTHALMOL, V19, P1, DOI 10.1007/BF00156412
NR 56
TC 60
Z9 60
U1 2
U2 10
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
SN 1945-4589
J9 AGING-US
JI Aging-US
PD DEC
PY 2010
VL 2
IS 12
BP 981
EP 989
DI 10.18632/aging.100218
PG 9
WC Cell Biology; Geriatrics & Gerontology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Geriatrics & Gerontology
GA 705PI
UT WOS:000286148000015
PM 21098885
OA Green Submitted, Green Published, gold
DA 2022-11-30
ER

PT J
AU Kernt, M
   Neubauer, AS
   Liegl, RG
   Hirneiss, C
   Alge, CS
   Wolf, A
   Ulbig, MW
   Kampik, A
AF Kernt, M.
   Neubauer, A. S.
   Liegl, R. G.
   Hirneiss, C.
   Alge, C. S.
   Wolf, A.
   Ulbig, M. W.
   Kampik, A.
TI Sorafenib prevents human retinal pigment epithelium cells from
   light-induced overexpression of VEGF, PDGF and PlGF
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; AGE-RELATED MACULOPATHY; MACULAR
   DEGENERATION; RAF/MEK/ERK PATHWAY; BAY 43-9006; PHASE-II; IN-VIVO;
   NEOVASCULARIZATION; INHIBITION; RANIBIZUMAB
AB Background Cumulative light exposure is significantly associated with progression of age-related macular degeneration (AMD). Inhibition of vascular endothelial growth factor is the main target of current antiangiogenic treatment strategies in AMD. However, other growth factors, such as platelet-derived growth factor (PDGF) and placenta growth factor (PlGF), have a substantial impact on development of AMD. Previous reports indicate that sorafenib, an oral multikinase inhibitor, might have beneficial effects on exudative AMD. This study investigates the effects of sorafenib on light-induced overexpression of growth factors in human retinal pigment epithelial (RPE) cells.
   Methods Primary human RPE cells were exposed to white light and incubated with sorafenib. Viability, expression, and secretion of VEGF-A, PDGF-BB, and PlGF and their mRNA were determined by reverse transcription-polymerase chain reactions, immunohistochemistry and enzyme-linked immunosorbent assays.
   Results Light exposure decreased cell viability and increased expression and secretion of VEGF-A, PDGF-BB and PlGF. These light-induced effects were significantly reduced when cells were treated with sorafenib at a dose of 1 mu g/ml.
   Conclusion The results show that sorafenib has promising properties as a potential antiangiogenic treatment for AMD.
C1 [Kernt, M.; Neubauer, A. S.; Liegl, R. G.; Hirneiss, C.; Alge, C. S.; Wolf, A.; Ulbig, M. W.; Kampik, A.] Univ Munich, Dept Ophthalmol, D-80336 Munich, Germany.
C3 University of Munich
RP Kernt, M (通讯作者)，Univ Munich, Dept Ophthalmol, Mathilden St 8, D-80336 Munich, Germany.
EM marcus.kernt@med.uni-muenchen.de
CR Abou-Alfa GK, 2006, J CLIN ONCOL, V24, P4293, DOI 10.1200/JCO.2005.01.3441
   Adnane L, 2006, METHOD ENZYMOL, V407, P597, DOI 10.1016/S0076-6879(05)07047-3
   Aiello LP, 2008, NEW ENGL J MED, V359, P967, DOI 10.1056/NEJMcibr0804551
   AIELLO LP, 1995, P NATL ACAD SCI USA, V92, P10457, DOI 10.1073/pnas.92.23.10457
   Algvere PV, 2006, ACTA OPHTHALMOL SCAN, V84, P4, DOI 10.1111/j.1600-0420.2005.00627.x
   Algvere PV, 2002, ACTA OPHTHALMOL SCAN, V80, P136, DOI 10.1034/j.1600-0420.2002.800204.x
   BARISHAK Y. ROBERT, 1960, ACTA OPHTHALMOL, V38, P339
   Bhutto IA, 2006, EXP EYE RES, V82, P99, DOI 10.1016/j.exer.2005.05.007
   Carlomagno F, 2006, JNCI-J NATL CANCER I, V98, P326, DOI 10.1093/jnci/djj069
   CROCKER DJ, 1970, EXP MOL PATHOL, V13, P51, DOI 10.1016/0014-4800(70)90084-5
   CRUICKSHANKS KJ, 1993, ARCH OPHTHALMOL-CHIC, V111, P514, DOI 10.1001/archopht.1993.01090040106042
   Cruickshanks KJ, 2001, ARCH OPHTHALMOL-CHIC, V119, P246
   Diago T, 2008, MAYO CLIN PROC, V83, P231
   Ehrlich R, 2008, CLIN INTERV AGING, V3, P473
   Erber R, 2003, FASEB J, V17, P338, DOI 10.1096/fj.03-0271fje
   Escudier B, 2007, NEW ENGL J MED, V356, P125, DOI 10.1056/NEJMoa060655
   Fine SL, 2000, NEW ENGL J MED, V342, P483, DOI 10.1056/NEJM200002173420707
   FLOOD MT, 1980, INVEST OPHTH VIS SCI, V19, P1309
   Freyberger H, 2000, EXP CLIN ENDOCR DIAB, V108, P106, DOI 10.1055/s-2000-5803
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Holz FG, 2004, AM J OPHTHALMOL, V137, P504, DOI 10.1016/j.ajo.2003.11.026
   Holz FG, 1999, GRAEF ARCH CLIN EXP, V237, P145, DOI 10.1007/s004170050209
   Houben R, 2009, MOL CANCER THER, V8, P433, DOI 10.1158/1535-7163.MCT-08-1051
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Jo N, 2006, AM J PATHOL, V168, P2036, DOI 10.2353/ajpath.2006.050588
   Kernt M, 2010, OPHTHALMOLOGE, V107, P150, DOI 10.1007/s00347-009-1945-x
   Kernt M, 2008, ACTA OPHTHALMOL, V86, P456, DOI 10.1111/j.1600-0420.2007.01014.x
   Kernt M, 2009, J CATARACT REFR SURG, V35, P354, DOI 10.1016/j.jcrs.2008.10.052
   Kliffen M, 1997, MICROSC RES TECHNIQ, V36, P106, DOI 10.1002/(SICI)1097-0029(19970115)36:2<106::AID-JEMT4>3.0.CO;2-N
   Kupsch Petra, 2005, Clin Colorectal Cancer, V5, P188, DOI 10.3816/CCC.2005.n.030
   Liu L, 2006, CANCER RES, V66, P11851, DOI 10.1158/0008-5472.CAN-06-1377
   Moshfeghi DM, 2007, RETINA-J RET VIT DIS, V27, P269, DOI 10.1097/IAE.0b013e31802e3e9b
   MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4
   Nilsson SEG, 2003, DOC OPHTHALMOL, V106, P13, DOI 10.1023/A:1022419606629
   Peyman Gholam A, 2009, Retina, V29, pS18, DOI 10.1097/IAE.0b013e3181ad22fa
   Ratain MJ, 2006, J CLIN ONCOL, V24, P2505, DOI 10.1200/JCO.2005.03.6723
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   ROBBINS SG, 1994, INVEST OPHTH VIS SCI, V35, P3649
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P336, DOI 10.3928/1542-8877-20050701-15
   Roth F, 2004, GRAEF ARCH CLIN EXP, V242, P710, DOI 10.1007/s00417-004-0976-x
   Schlingemann RO, 2004, GRAEF ARCH CLIN EXP, V242, P91, DOI 10.1007/s00417-003-0828-0
   Schlingemann RO, 1996, J PATHOL, V179, P436
   Schutt F, 2002, GRAEF ARCH CLIN EXP, V240, P983, DOI 10.1007/s00417-002-0558-8
   Spaide Richard F, 2009, Retina, V29, pS5, DOI 10.1097/IAE.0b013e3181ad237a
   Starita C, 1997, INVEST OPHTH VIS SCI, V38, P762
   Tomany SC, 2004, ARCH OPHTHALMOL-CHIC, V122, P750, DOI 10.1001/archopht.122.5.750
   van Wijngaarden P, 2005, JAMA-J AM MED ASSOC, V293, P1509, DOI 10.1001/jama.293.12.1509
   Wells JA, 1996, BRIT J OPHTHALMOL, V80, P363, DOI 10.1136/bjo.80.4.363
   Werner S, 2003, PHYSIOL REV, V83, P835, DOI 10.1152/physrev.2003.83.3.835
   Wilhelm SM, 2008, MOL CANCER THER, V7, P3129, DOI 10.1158/1535-7163.MCT-08-0013
   Wilhelm SM, 2004, CANCER RES, V64, P7099, DOI 10.1158/0008-5472.CAN-04-1443
   Witmer AN, 2003, PROG RETIN EYE RES, V22, P1, DOI 10.1016/S1350-9462(02)00043-5
   Yanagi Y, 2006, J CATARACT REFR SURG, V32, P1540, DOI 10.1016/j.jcrs.2006.04.012
   Zhou JL, 2005, EXP EYE RES, V80, P567, DOI 10.1016/j.exer.2004.11.009
NR 55
TC 29
Z9 36
U1 1
U2 7
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD NOV
PY 2010
VL 94
IS 11
BP 1533
EP 1539
DI 10.1136/bjo.2010.182162
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 668GI
UT WOS:000283256200025
PM 20962354
OA Green Accepted, Green Submitted
DA 2022-11-30
ER

PT J
AU Abdel-Aal, EM
   Young, JC
   Akhtar, H
   Rabalski, I
AF Abdel-Aal, El-Sayed M.
   Young, J. Christopher
   Akhtar, Humayoun
   Rabalski, Iwona
TI Stability of Lutein in Wholegrain Bakery Products Naturally High in
   Lutein or Fortified with Free Lutein
SO JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY
LA English
DT Article
DE Lutein; zeaxanthin; stability of lutein; bread; cookie; muffin
ID SSP MONOCOCCUM; CAROTENOIDS; EINKORN; RISK; L.; QUANTIFICATION;
   IDENTIFICATION; CATARACTS; ISOMERS; STORAGE
AB Lutein is a yellow pigment found in common foods that promotes the health of eyes and skin and is associated with reduced risk of age-related macular degeneration and cataracts. In the present study, selected high-lutein wheat and corn were milled into wholegrain flours by two mills to improve flour uniformity. The high-lutein and lutein-fortified wholegrain flours were processed into breads, cookies, and muffins to study lutein stability during baking and subsequent storage. Lutein and its isomers were separated, identified, and quantified by LC-UV/vis and LC-MS following extraction with water-saturated 1-butanol. Baking resulted in a significant reduction in all-trans-lutein and the formation of cis-lutein and cis-zeaxanthin isomers. Subsequent storage at ambient temperature had a slight impact on the content of all-trans-lutein. Effects of processing were more pronounced in lutein-fortified products, and the degradation rate of lutein was influenced by concentration and baking recipe. Fortified cookies and muffins showed greater lutein reduction compared with bread. Despite the significant reduction in lutein, the fortified bakery products still possessed reasonable amounts per serving that would enhance daily intake and consumption of wholegrain foods.
C1 [Abdel-Aal, El-Sayed M.; Young, J. Christopher; Akhtar, Humayoun; Rabalski, Iwona] Agr & Agri Food Canada, Guelph Food Res Ctr, Guelph, ON N1G 5C9, Canada.
C3 Agriculture & Agri Food Canada
RP Abdel-Aal, EM (通讯作者)，Agr & Agri Food Canada, Guelph Food Res Ctr, 93 Stone Rd W, Guelph, ON N1G 5C9, Canada.
EM elsayed.abdelaal@agr.gc.ca
CR Abdel-Aal ESM, 2007, J AGR FOOD CHEM, V55, P787, DOI 10.1021/jf062764p
   Abdel-Aal ESM, 2002, CEREAL CHEM, V79, P455, DOI 10.1094/CCHEM.2002.79.3.455
   ABDELAAL ESM, 1993, PLANT FOOD HUM NUTR, V44, P227, DOI 10.1007/BF01088317
   AbdelAal ESM, 1997, J CEREAL SCI, V26, P363, DOI 10.1006/jcrs.1997.0139
   Alves-Rodrigues A, 2004, TOXICOL LETT, V150, P57, DOI 10.1016/j.toxlet.2003.10.031
   American Association of Cereal Chemists, 2000, APPR METH AACC
   Boileau AC, 1999, J NUTR, V129, P1176, DOI 10.1093/jn/129.6.1176
   Bone RA, 2001, INVEST OPHTH VIS SCI, V42, P235
   Borghi B, 1996, CEREAL CHEM, V73, P208
   FARRINGTON WHH, 1981, J SCI FOOD AGR, V32, P948, DOI 10.1002/jsfa.2740320913
   Handelman GJ, 2001, NUTRITION, V17, P818, DOI 10.1016/S0899-9007(01)00640-2
   Hidalgo A, 2008, J AGR FOOD CHEM, V56, P11300, DOI 10.1021/jf802448t
   Hidalgo A, 2006, J CEREAL SCI, V44, P182, DOI 10.1016/j.jcs.2006.06.002
   Hidalgo A, 2010, FOOD CHEM, V121, P746, DOI 10.1016/j.foodchem.2010.01.034
   Kean EG, 2008, J AGR FOOD CHEM, V56, P9918, DOI 10.1021/jf8018613
   Krinsky NI, 2003, ANNU REV NUTR, V23, P171, DOI 10.1146/annurev.nutr.23.011702.073307
   Leeners B, 2006, HYPERTENS PREGNANCY, V25, P170
   Leenhardt F, 2006, J AGR FOOD CHEM, V54, P1710, DOI 10.1021/jf052243m
   Ma QX, 2008, INT J FOOD SCI TECH, V43, P1763, DOI 10.1111/j.1365-2621.2007.01694.x
   Mercadante AZ, 2008, CHEM FUNCT PROP FOOD, P213
   Michaud DS, 2000, AM J CLIN NUTR, V72, P990
   Olmedilla B, 2003, NUTRITION, V19, P21, DOI 10.1016/S0899-9007(02)00861-4
   Olmedilla B, 2001, J SCI FOOD AGR, V81, P904, DOI 10.1002/jsfa.905
   Osganian SK, 2003, AM J CLIN NUTR, V77, P1390, DOI 10.1093/ajcn/77.6.1390
   Scott CE, 2005, J FOOD COMPOS ANAL, V18, P551, DOI 10.1016/j.jfca.2004.04.001
   SPERLING HG, 1980, VISION RES, V20, P1117, DOI 10.1016/0042-6989(80)90049-8
   Tsao R, 2004, J CHROMATOGR A, V1045, P65, DOI 10.1016/j.chroma.2004.06.020
   Updike AA, 2003, J AGR FOOD CHEM, V51, P6184, DOI 10.1021/jf030350f
   Young JC, 2007, J AGR FOOD CHEM, V55, P4965, DOI 10.1021/jf070357n
NR 29
TC 39
Z9 44
U1 5
U2 35
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0021-8561
EI 1520-5118
J9 J AGR FOOD CHEM
JI J. Agric. Food Chem.
PD SEP 22
PY 2010
VL 58
IS 18
BP 10109
EP 10117
DI 10.1021/jf102400t
PG 9
WC Agriculture, Multidisciplinary; Chemistry, Applied; Food Science &
   Technology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Agriculture; Chemistry; Food Science & Technology
GA 649AB
UT WOS:000281736000034
PM 20734986
DA 2022-11-30
ER

PT J
AU Huang, TL
   Hsu, SY
   Tsai, RK
   Sheu, MM
AF Huang, Tzu-Lun
   Hsu, Sheng-Yao
   Tsai, Rong-Kung
   Sheu, Min-Muh
TI Etiology of ocular diseases in elderly Amis aborigines in Eastern Taiwan
   (The Amis Eye Study)
SO JAPANESE JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Amis elderly aborigines in Taiwan; Austronesian; etiology of ocular
   diseases
ID AGE-RELATED MACULOPATHY; MACULAR DEGENERATION; POPULATION; PREVALENCE;
   CLASSIFICATION; WISCONSIN; BLINDNESS; CATARACT; EXPOSURE; REGION
AB To determine the incidence of and risk factors associated with major ocular diseases in the elderly Amis population of Taiwan.
   This population-based cross-sectional study is the most current survey of ocular diseases among elderly Amis. The overall response rate was 61.2%, with 2316 participants screened. All ocular examinations were performed using a mobile ophthalmology setup staffed by an ophthalmologist with 30 years of experience.
   The mean age of the participants was 71.65 years. Cataracts were the most common ocular disease (82.6%), followed by pterygium (44.1%), arteriosclerotic changes in retinal vessels (35.7%), hypertensive retinopathy (18.5 %), age-related macular degeneration (5.2%), optic neuropathy (4.6%), corneal opacity (4.6%), and diabetic retinopathy (3.3%). Glaucoma (1.0%) and high myopia (0.39%) were minor ocular diseases among elderly Amis. The prevalence of diabetes was 15.4% and that of hypertension was 40.0%.
   Treatable diseases such as cataracts and pterygium were the most common ocular diseases in the Amis tribes. The relatively low incidence of glaucoma was likely due to the unique genetic background of this population.
C1 [Huang, Tzu-Lun; Hsu, Sheng-Yao; Tsai, Rong-Kung; Sheu, Min-Muh] Tzu Chi Univ, Buddhist Tzu Chi Gen Hosp, Dept Ophthalmol, Hualien 97002, Taiwan.
   [Hsu, Sheng-Yao; Tsai, Rong-Kung; Sheu, Min-Muh] Tzu Chi Univ, Dept Ophthalmol & Visual Sci, Hualien 97002, Taiwan.
C3 Buddhist Tzu Chi General Hospital; Hualien Tzu Chi Hospital; Tzu Chi
   University; Tzu Chi University
RP Sheu, MM (通讯作者)，Tzu Chi Univ, Buddhist Tzu Chi Gen Hosp, Dept Ophthalmol, 700,Sect 3,Chung Yang Rd, Hualien 97002, Taiwan.
EM hsuhung@mail.tcu.edu.tw
RI huang, tzulun/G-5829-2015
OI huang, tzulun/0000-0003-0984-3525
CR BELLWOOD P, 1991, SCI AM, V265, P70
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   CHANG HC, 1999, T SOC OPHTHALMOL SIN, V38, P313
   CHANG WH, 1989, AMIS VILLAGE LIGATES, P6
   CHEN CW, 1976, T SOC OPHTHALMOL SIN, V15, P27
   CHEN CW, 1962, T SOC OPHTHALMOL SIN, V12, P12
   Chen HD, 1997, DIABETES RES CLIN PR, V38, P199, DOI 10.1016/S0168-8227(97)00104-6
   CHEN NY, 1984, T SOC OPHTH SINICAE, V23, P14
   CHEN ST, 1996, INT S CULT WELL BIOL
   CHYLACK LT, 1993, ARCH OPHTHALMOL-CHIC, V111, P831, DOI 10.1001/archopht.1993.01090060119035
   Cruickshanks KJ, 1997, ARCH OPHTHALMOL-CHIC, V115, P242, DOI 10.1001/archopht.1997.01100150244015
   Genuth S, 2003, DIABETES CARE, V26, P3160
   GOLDBERG J, 1988, AM J EPIDEMIOL, V128, P700, DOI 10.1093/oxfordjournals.aje.a115023
   HEATH SA, 1973, AM J OPHTHALMOL, V75, P121, DOI 10.1016/0002-9394(73)90661-2
   HOLLOWS F, 1981, LANCET, V2, P1249
   HSU M, 2001, HIST FORMOSAN ABORIG, P19
   HSU M, 1991, CULTURE SELF ADAPTAT, P32
   Hu DN, 2008, PHOTOCHEM PHOTOBIOL, V84, P639, DOI 10.1111/j.1751-1097.2008.00316.x
   Hyman L, 2000, ARCH OPHTHALMOL-CHIC, V118, P351, DOI 10.1001/archopht.118.3.351
   Jaross N, 2005, CLIN EXP OPHTHALMOL, V33, P26, DOI 10.1111/j.1442-9071.2005.00939.x
   KINOSHIT.JH, 1974, INVEST OPHTH VISUAL, V13, P713
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Ko Ying-Chin, 1994, Kaohsiung Journal of Medical Sciences, V10, P352
   Lin LLK, 1988, T SOC OPHTH SINICAE, V185, P34
   Lin LLK, 1999, OPTOMETRY VISION SCI, V76, P1
   Lin M, 2000, TISSUE ANTIGENS, V55, P1, DOI 10.1034/j.1399-0039.2000.550101.x
   Lin SF, 2006, TZU CHI MED J, V18, P283
   MACKENZIE FD, 1992, OPHTHALMOLOGY, V99, P1056, DOI 10.1016/s0161-6420(92)31850-0
   MANN I, 1969, AM J OPHTHALMOL, V67, P358, DOI 10.1016/0002-9394(69)92045-5
   MANN I, 1972, ACTA OPHTHALMOL, V50, P543
   MAO WS, 2006, CHIN MED J, V95, P813
   MARTINEZ GS, 1982, AM J OPHTHALMOL, V94, P181, DOI 10.1016/0002-9394(82)90073-3
   MOTEGI A, 1945, J FORMOS MED ASSOC, V44, P71
   MOTEGI A, 1945, J FORMOS MED ASSOC, V44, P1
   MOTEGI A, 1944, J FORMOS MED ASSOC, V43, P778
   MOTEGI AJ, 1944, J FORMOS MED ASSOC, V43, P826
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Taylor H R, 1989, Trans Am Ophthalmol Soc, V87, P802
   Tenkate TD, 1998, J ENVIRON HEALTH, V61, P9
   Thomson I, 1997, BRIT J OPHTHALMOL, V81, P578, DOI 10.1136/bjo.81.7.578
   Threlfall TJ, 1999, AM J OPHTHALMOL, V128, P280, DOI 10.1016/S0002-9394(99)00161-0
   TIELSCH JM, 1990, ARCH OPHTHALMOL-CHIC, V108, P286, DOI 10.1001/archopht.1990.01070040138048
   Trejaut JA, 2005, PLOS BIOL, V3, P1362, DOI 10.1371/journal.pbio.0030247
   Tsai CY, 2005, JPN J OPHTHALMOL, V49, P166, DOI 10.1007/s10384-004-0164-x
NR 44
TC 12
Z9 13
U1 0
U2 5
PU SPRINGER JAPAN KK
PI TOKYO
PA SHIROYAMA TRUST TOWER 5F, 4-3-1 TORANOMON, MINATO-KU, TOKYO, 105-6005,
   JAPAN
SN 0021-5155
EI 1613-2246
J9 JPN J OPHTHALMOL
JI Jpn. J. Ophthalmol.
PD JUL
PY 2010
VL 54
IS 4
BP 266
EP 271
DI 10.1007/s10384-010-0817-x
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 637IS
UT WOS:000280811400002
PM 20700791
DA 2022-11-30
ER

PT J
AU Salzmann, J
   Linderholm, OP
   Guyomard, JL
   Paques, M
   Simonutti, M
   Lecchi, M
   Sommerhalder, J
   Dubus, E
   Pelizzone, M
   Bertrand, D
   Sahel, J
   Renaud, P
   Safran, AB
   Picaud, S
AF Salzmann, J.
   Linderholm, O. P.
   Guyomard, J-L
   Paques, M.
   Simonutti, M.
   Lecchi, M.
   Sommerhalder, J.
   Dubus, E.
   Pelizzone, M.
   Bertrand, D.
   Sahel, J.
   Renaud, P.
   Safran, A. B.
   Picaud, S.
TI Subretinal electrode implantation in the P23H rat for chronic
   stimulations
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID ELECTRICAL-STIMULATION; MORPHOMETRIC ANALYSIS; ARTIFICIAL VISION;
   VISUAL-PERCEPTION; HUMAN RETINA; PHOTORECEPTORS; MICROPHOTODIODES;
   PROSTHESIS; SIMULATION; MACULA
AB Background: In age related macular degeneration and inherited dystrophies, preservation of retinal ganglion cells has been demonstrated. This finding has led to the development of various models of subretinal or epiretinal implant in order to restore vision. This study addresses the development of a polyimide subretinal electrode platform in the dystrophic P23H rat in vivo.
   Methods: A technique was developed for implanting a subretinal electrode into the subretinal space and stabilising the distal extremity of the cabling on the rat cranium in order to allow future electrical stimulations of the retina.
   Results: In vivo imaging of the retina with the scanning laser ophthalmoscope demonstrated reabsorption of the surgically induced retinal detachment and the absence of major tissue reactions. These in vivo observations were confirmed by retinal histology. The extraocular fixation system on the rat cranium was effective in stabilising the distal connector for in vivo stimulation.
   Conclusion: This study demonstrates that a retinal implant can be introduced into the subretinal space of a dystrophic rat with a stable external connection for repeatable electrical measurements and stimulation. This in vivo model should therefore allow us to evaluate the safety and efficacy of electrical stimulations on dystrophic retina.
C1 INSERM, U592, Lab Physiopathol Cellulaire & Mol Retine, F-75571 Paris 12, France.
   Hop Cantonal Univ Geneva, Serv Ophthalmol, CH-1205 Geneva, Switzerland.
   Ecole Polytech Fed Lausanne, Microsyst Unit, Lausanne, Switzerland.
   Univ Paris 06, Paris, France.
   Fdn Ophthalmol A Rothschild, Paris, France.
   Univ Geneva, Ctr Med, Dept Neurosci, CH-1211 Geneva, Switzerland.
   Hop Cantonal Univ Geneva, Ctr Romand Implants Cochleaires, CH-1211 Geneva, Switzerland.
C3 Institut National de la Sante et de la Recherche Medicale (Inserm);
   University of Geneva; Swiss Federal Institutes of Technology Domain;
   Ecole Polytechnique Federale de Lausanne; UDICE-French Research
   Universities; Sorbonne Universite; University of Geneva; University of
   Geneva
RP Picaud, S (通讯作者)，INSERM, U592, Lab Physiopathol Cellulaire & Mol Retine, Batiment Kourilsky,184 Rue Faubourg St Antoine, F-75571 Paris 12, France.
EM picaud@st-antoine.inserm.fr
RI Sahel, Jose-Alain/F-3172-2017; Picaud, Serge/H-4012-2014; Renaud,
   P/A-6994-2011; Renaud, Philippe/AAQ-6205-2021
OI Sahel, Jose-Alain/0000-0002-4831-1153; Picaud,
   Serge/0000-0002-0548-5145; Renaud, P/0000-0001-5199-1252; Renaud,
   Philippe/0000-0001-5199-1252; Paques, Michel/0000-0002-9102-9196
CR Baig-Silva MS, 2005, J NEURAL ENG, V2, pS29, DOI 10.1088/1741-2560/2/1/005
   Banisadr G, 2002, J NEUROCHEM, V81, P257, DOI 10.1046/j.1471-4159.2002.00809.x
   Chow AY, 2004, ARCH OPHTHALMOL-CHIC, V122, P460, DOI 10.1001/archopht.122.4.460
   Chow AY, 1997, NEUROSCI LETT, V225, P13, DOI 10.1016/S0304-3940(97)00185-7
   Chow AY, 2002, J REHABIL RES DEV, V39, P313
   Chow AY, 2001, IEEE T NEUR SYS REH, V9, P86, DOI 10.1109/7333.918281
   D'Cruz PM, 2000, HUM MOL GENET, V9, P645, DOI 10.1093/hmg/9.4.645
   Delbeke J, 2003, VISION RES, V43, P1091, DOI 10.1016/S0042-6989(03)00013-0
   Eckmiller R, 1997, OPHTHALMIC RES, V29, P281, DOI 10.1159/000268026
   Frasson M, 1999, INVEST OPHTH VIS SCI, V40, P2724
   Grimmes S, 2000, BIOIMPEDANCE BIOELEC, P3
   Hammerle H, 2002, BIOMATERIALS, V23, P797, DOI 10.1016/S0142-9612(01)00185-5
   Humayun M S, 2001, Trans Am Ophthalmol Soc, V99, P271
   Humayun MS, 1999, VISION RES, V39, P2569, DOI 10.1016/S0042-6989(99)00052-8
   Humayun MS, 1996, ARCH OPHTHALMOL-CHIC, V114, P40, DOI 10.1001/archopht.1996.01100130038006
   Humayun MS, 2003, VISION RES, V43, P2573, DOI 10.1016/S0042-6989(03)00457-7
   HUMAYUN MS, 1996, INVEST OPHTH VIS SCI, V40, P143
   Kerdraon YA, 2002, CLIN EXP OPHTHALMOL, V30, P36, DOI 10.1046/j.1442-9071.2002.00485.x
   Kim SY, 2002, RETINA-J RET VIT DIS, V22, P471, DOI 10.1097/00006982-200208000-00012
   Kim SY, 2002, RETINA-J RET VIT DIS, V22, P464, DOI 10.1097/00006982-200208000-00011
   Machida S, 2000, INVEST OPHTH VIS SCI, V41, P3200
   Metz S, 2004, BIOSENS BIOELECTRON, V19, P1309, DOI 10.1016/j.bios.2003.11.021
   Pardue Machelle T., 2001, Documenta Ophthalmologica, V103, P155, DOI 10.1023/A:1012202410144
   Pardue MT, 2005, INVEST OPHTH VIS SCI, V46, P674, DOI 10.1167/iovs.04-0515
   Pardue MT, 2001, EXP EYE RES, V73, P333, DOI 10.1006/exer.2001.1041
   Rizzo JF, 2003, INVEST OPHTH VIS SCI, V44, P5362, DOI 10.1167/iovs.02-0817
   Rizzo JF, 2003, INVEST OPHTH VIS SCI, V44, P5355, DOI 10.1167/iovs.02-0819
   Sachs HG, 2005, GRAEF ARCH CLIN EXP, V243, P464, DOI 10.1007/s00417-004-1049-x
   Santos A, 1997, ARCH OPHTHALMOL-CHIC, V115, P511, DOI 10.1001/archopht.1997.01100150513011
   SCHANZE T, 2005, EXP EYE RES
   Schwahn HN, 2001, GRAEF ARCH CLIN EXP, V239, P961, DOI 10.1007/s004170100368
   Sommerhalder J, 2004, VISION RES, V44, P1693, DOI 10.1016/j.visres.2004.01.017
   Sommerhalder J, 2003, VISION RES, V43, P269, DOI 10.1016/S0042-6989(02)00481-9
   STONE JL, 1992, ARCH OPHTHALMOL-CHIC, V110, P1634, DOI 10.1001/archopht.1992.01080230134038
   Tamai M, 2002, OPHTHALMOLOGICA, V216, P52
   Veraart C, 1998, BRAIN RES, V813, P181, DOI 10.1016/S0006-8993(98)00977-9
   Ziegler D, 2004, SENSOR ACTUAT A-PHYS, V110, P11, DOI 10.1016/j.sna.2003.09.040
   Zrenner E, 1999, VISION RES, V39, P2555, DOI 10.1016/S0042-6989(98)00312-5
   Zrenner E, 1997, OPHTHALMIC RES, V29, P269, DOI 10.1159/000268025
   Zrenner E, 2002, OPHTHALMOLOGICA, V216, P8, DOI 10.1159/000064650
NR 40
TC 30
Z9 31
U1 1
U2 8
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD SEP
PY 2006
VL 90
IS 9
BP 1183
EP 1187
DI 10.1136/bjo.2005.089110
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 076ZP
UT WOS:000239997700031
PM 16754649
OA Green Published, Green Submitted
DA 2022-11-30
ER

PT J
AU Bhattacharyya, A
AF Bhattacharyya, Anwesha
TI The detrimental effects of progression of retinal degeneration in the
   visual cortex
SO FRONTIERS IN CELLULAR NEUROSCIENCE
LA English
DT Review
DE primary visual cortex; retina; retinal degeneration; electrophysiology;
   morphology; rodents; humans
ID MACULAR DEGENERATION; GANGLION-CELLS; PLASTICITY; RESPONSES; PATHWAYS
AB The leading cause of blindness in inherited and age-related retinal degeneration (RD) is the death of retinal photoreceptors such as rods and cones. The most prevalent form of RD is age-related macular degeneration (AMD) which affects the macula resulting in an irreversible loss of vision. The other is a heterogenous group of inherited disorders known as Retinitis Pigmentosa (RP) caused by the progressive loss of photoreceptors. Several approaches have been developed in recent years to artificially stimulate the remaining retinal neurons using optogenetics, retinal prostheses, and chemical photoswitches. However, the outcome of these strategies has been limited. The success of these treatments relies on the morphology, physiology, and proper functioning of the remaining intact structures in the downstream visual pathway. It is not completely understood what all alterations occur in the visual cortex during RD. In this review, I will discuss the known information in the literature about morphological and functional changes that occur in the visual cortex in rodents and humans during RD. The aim is to highlight the changes in the visual cortex that will be helpful for developing tools and strategies directed toward the restoration of high-resolution vision in patients with visual impairment.
C1 [Bhattacharyya, Anwesha] Amity Univ, Amity Inst Neuropsychol & Neurosci, Noida, UP, India.
C3 Amity University Noida
RP Bhattacharyya, A (通讯作者)，Amity Univ, Amity Inst Neuropsychol & Neurosci, Noida, UP, India.
EM abhattacharyya@amity.edu
FU Ramanujan Fellowship of Science and Engineering Research Board (SERB),
   Department of Science and Technology (DST), Govt. of India
   [RJF/2019/000040]; Core Research Grant (CRG) of SERB, DST
   [CRG/2021/003472]
FX AB was supported by the Ramanujan Fellowship of Science and Engineering
   Research Board (SERB), Department of Science and Technology (DST), Govt.
   of India (Grant: RJF/2019/000040), and the Core Research Grant (CRG) of
   SERB, DST (CRG/2021/003472).
CR Alahmadi BO, 2018, BMC OPHTHALMOL, V18, DOI 10.1186/s12886-018-0982-0
   Anderson EE, 2016, CELL TISSUE RES, V364, P263, DOI 10.1007/s00441-015-2337-y
   Baseler HA, 2011, NAT NEUROSCI, V14, P649, DOI 10.1038/nn.2793
   Begenisic T, 2020, NEUROSCIENCE, V424, P205, DOI 10.1016/j.neuroscience.2019.10.045
   Bhattacharyya A, 2013, BMC NEUROSCI, V14, DOI 10.1186/1471-2202-14-55
   Boucard CC, 2009, BRAIN, V132, P1898, DOI 10.1093/brain/awp119
   Bovolenta P, 2009, NAT NEUROSCI, V12, P5, DOI 10.1038/nn0109-5
   Breitenseher M, 1998, NEURORADIOLOGY, V40, P424, DOI 10.1007/s002340050616
   Burge WK, 2016, SCI REP-UK, V6, DOI 10.1038/srep23268
   Busskamp V, 2010, SCIENCE, V329, P413, DOI 10.1126/science.1190897
   Castaldi E, 2016, PLOS BIOL, V14, DOI 10.1371/journal.pbio.1002569
   Chang B, 2002, VISION RES, V42, P517, DOI 10.1016/S0042-6989(01)00146-8
   Chen K, 2020, VISION RES, V177, P6, DOI 10.1016/j.visres.2020.08.007
   Chen K, 2016, SCI REP-UK, V6, DOI 10.1038/srep26793
   Chung C.Y, 2017, J OPHTHALMIC RES OCU, V1, P19, DOI [10.36959/936/562, DOI 10.36959/936/562]
   Cunningham SI, 2015, VISION RES, V111, P197, DOI 10.1016/j.visres.2014.10.015
   Damiani D, 2012, J COMP NEUROL, V520, P1406, DOI 10.1002/cne.22802
   Ferreira S, 2017, NEUROIMAGE-CLIN, V13, P428, DOI 10.1016/j.nicl.2016.12.013
   Fine I, 2018, ANNU REV VIS SCI, V4, P337, DOI 10.1146/annurev-vision-102016-061241
   Garcia-Ayuso D, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20184649
   Gias C, 2011, VISION RES, V51, P2176, DOI 10.1016/j.visres.2011.08.012
   Hanson RLW, 2019, INVEST OPHTH VIS SCI, V60, P5045, DOI 10.1167/iovs.18-25823
   Hernowo AT, 2014, CORTEX, V56, P99, DOI 10.1016/j.cortex.2013.01.003
   Himmelhan DK, 2018, MECH DEVELOP, V151, P1, DOI 10.1016/j.mod.2018.03.002
   HUBEL DH, 1964, N-S ARCH EX PATH PH, V248, P492, DOI 10.1007/BF00348878
   Jones B.W., 1995, WEBVISION ORG RETINA
   Lin B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068084
   Lunghi C, 2019, INVEST OPHTH VIS SCI, V60, P2753, DOI 10.1167/iovs.18-25750
   Machado AR, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-11317-7
   Mancebo-Azor R, 2020, EUR J INVEST HEALTH, V10, P1010, DOI 10.3390/ejihpe10040071
   Marc RE, 2003, PROG RETIN EYE RES, V22, P607, DOI 10.1016/S1350-9462(03)00039-9
   Marc RE, 2007, INVEST OPHTH VIS SCI, V48, P3364, DOI 10.1167/iovs.07-0032
   McClements ME, 2020, FRONT NEUROSCI-SWITZ, V14, DOI 10.3389/fnins.2020.570909
   Moore SM, 2020, J CLIN MED, V9, DOI 10.3390/jcm9072224
   Nuzzi R, 2021, EYE BRAIN, V13, P159, DOI 10.2147/EB.S307551
   Nuzzi R, 2020, FRONT NEUROSCI-SWITZ, V14, DOI 10.3389/fnins.2020.00755
   Pandi SPS, 2021, EXP EYE RES, V203, DOI 10.1016/j.exer.2020.108404
   Pennesi ME, 2012, MOL ASPECTS MED, V33, P487, DOI 10.1016/j.mam.2012.06.003
   Pietra G, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22179412
   Polosukhina A, 2012, NEURON, V75, P271, DOI 10.1016/j.neuron.2012.05.022
   Ramanoel S, 2018, VISUAL NEUROSCI, V35, DOI 10.1017/S0952523817000372
   Ramsden CM, 2013, DEVELOPMENT, V140, P2576, DOI 10.1242/dev.092270
   Sahel JA, 2021, NAT MED, V27, P1223, DOI 10.1038/s41591-021-01351-4
   Shao YB, 2013, EUR J NEUROSCI, V38, P3456, DOI 10.1111/ejn.12349
   Shim S, 2020, MICROMACHINES-BASEL, V11, DOI 10.3390/mi11050535
   TranTrung Kien, 2012, International Journal of Modern Physics: Conference Series, V9, P209, DOI 10.1142/S2010194512005272
   Tritsch NX, 2007, NATURE, V450, P50, DOI 10.1038/nature06233
   van Wyk M, 2015, PLOS BIOL, V13, DOI 10.1371/journal.pbio.1002143
   Wandell BA, 2009, NAT REV NEUROSCI, V10, P873, DOI 10.1038/nrn2741
   Wang Y, 2012, BBA-MOL BASIS DIS, V1822, P423, DOI 10.1016/j.bbadis.2011.08.002
   Wang Y, 2018, NEUROSCIENCE, V383, P84, DOI 10.1016/j.neuroscience.2018.05.006
   Wang Y, 2017, IEEE ENG MED BIO, P3632, DOI 10.1109/EMBC.2017.8037644
   Wang Y, 2016, NEUROSCI LETT, V623, P42, DOI 10.1016/j.neulet.2016.04.062
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wosniack ME, 2021, ELIFE, V10, DOI 10.7554/eLife.61619
   Yoshimine S, 2018, BRAIN STRUCT FUNCT, V223, P3889, DOI 10.1007/s00429-018-1702-5
NR 56
TC 0
Z9 0
U1 0
U2 0
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
EI 1662-5102
J9 FRONT CELL NEUROSCI
JI Front. Cell. Neurosci.
PD JUL 29
PY 2022
VL 16
AR 904175
DI 10.3389/fncel.2022.904175
PG 8
WC Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA 3U0BM
UT WOS:000840635000001
PM 35966197
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Chan, HN
   Zhang, XJ
   Ling, XT
   Bui, CHT
   Wang, YM
   Ip, P
   Chu, WK
   Chen, LJ
   Tham, CC
   Yam, JC
   Pang, CP
AF Chan, Hei-Nga
   Zhang, Xiu-Juan
   Ling, Xiang-Tian
   Bui, Christine Huyen-Trang
   Wang, Yu-Meng
   Ip, Patrick
   Chu, Wai-Kit
   Chen, Li-Jia
   Tham, Clement C.
   Yam, Jason C.
   Pang, Chi-Pui
TI Vitamin D and Ocular Diseases: A Systematic Review
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Review
DE vitamin D; ocular disease; vitamin D receptor; myopia; age-related
   macular degeneration; glaucoma; dry eye syndrome; thyroid eye disease;
   uveitis; retinoblastoma
ID SERUM 25-HYDROXYVITAMIN D; NUTRITION EXAMINATION SURVEY; OPEN-ANGLE
   GLAUCOMA; TYPE-2 DIABETES-MELLITUS; GLYCATION END-PRODUCTS; DRY EYE
   DISEASE; D DEFICIENCY; MACULAR DEGENERATION; MICROVASCULAR
   COMPLICATIONS; D-RECEPTOR
AB The contributory roles of vitamin D in ocular and visual health have long been discussed, with numerous studies pointing to the adverse effects of vitamin D deficiency. In this paper, we provide a systematic review of recent findings on the association between vitamin D and different ocular diseases, including myopia, age-related macular degeneration (AMD), glaucoma, diabetic retinopathy (DR), dry eye syndrome (DES), thyroid eye disease (TED), uveitis, retinoblastoma (RB), cataract, and others, from epidemiological, clinical and basic studies, and briefly discuss vitamin D metabolism in the eye. We searched two research databases for articles examining the association between vitamin D deficiency and different ocular diseases. One hundred and sixty-two studies were found. There is evidence on the association between vitamin D and myopia, AMD, DR, and DES. Overall, 17 out of 27 studies reported an association between vitamin D and AMD, while 48 out of 54 studies reported that vitamin D was associated with DR, and 25 out of 27 studies reported an association between vitamin D and DES. However, the available evidence for the association with other ocular diseases, such as glaucoma, TED, and RB, remains limited.
C1 [Chan, Hei-Nga; Zhang, Xiu-Juan; Ling, Xiang-Tian; Bui, Christine Huyen-Trang; Wang, Yu-Meng; Chu, Wai-Kit; Chen, Li-Jia; Tham, Clement C.; Yam, Jason C.; Pang, Chi-Pui] Chinese Univ Hong Kong, Dept Ophthalmol & Visual Sci, Hong Kong, Peoples R China.
   [Ip, Patrick] Univ Hong Kong, Dept Paediat & Adolescent Med, Hong Kong, Peoples R China.
   [Chu, Wai-Kit; Chen, Li-Jia; Tham, Clement C.; Yam, Jason C.; Pang, Chi-Pui] Chinese Univ Hong Kong, Hong Kong Hub Paediat Excellence, Hong Kong, Peoples R China.
   [Chen, Li-Jia; Tham, Clement C.; Yam, Jason C.] Prince Wales Hosp, Dept Ophthalmol & Visual Sci, Hong Kong, Peoples R China.
   [Tham, Clement C.; Yam, Jason C.] Hong Kong Childrens Hosp, Dept Ophthalmol, Hong Kong, Peoples R China.
   [Tham, Clement C.; Yam, Jason C.] Hong Kong Eye Hosp, Hong Kong, Peoples R China.
C3 Chinese University of Hong Kong; University of Hong Kong; Chinese
   University of Hong Kong; Chinese University of Hong Kong; Prince of
   Wales Hospital
RP Yam, JC; Pang, CP (通讯作者)，Chinese Univ Hong Kong, Dept Ophthalmol & Visual Sci, Hong Kong, Peoples R China.; Yam, JC; Pang, CP (通讯作者)，Chinese Univ Hong Kong, Hong Kong Hub Paediat Excellence, Hong Kong, Peoples R China.; Yam, JC (通讯作者)，Prince Wales Hosp, Dept Ophthalmol & Visual Sci, Hong Kong, Peoples R China.; Yam, JC (通讯作者)，Hong Kong Childrens Hosp, Dept Ophthalmol, Hong Kong, Peoples R China.; Yam, JC (通讯作者)，Hong Kong Eye Hosp, Hong Kong, Peoples R China.
EM hnrubychan@cuhk.edu.hk; zhangxiujuan@cuhk.edu.hk;
   lingxt@link.cuhk.edu.hk; huyentrangbui@cuhk.edu.hk;
   yumengwang@cuhk.edu.hk; patricip@hku.hk; waikit@cuhk.edu.hk;
   lijia_chen@cuhk.edu.hk; clemtham@cuhk.edu.hk; yamcheuksing@cuhk.edu.hk;
   cppang@cuhk.edu.hk
RI Chen, Li Jia/I-5078-2014
OI Chen, Li Jia/0000-0003-3500-5840; Ip, Patrick/0000-0002-6797-6898; Tham,
   Chee Yung Clement/0000-0003-4407-6907; Yam, Jason C./0000-0002-2156-1486
FU General Research Fund (GRF), Research Grants Council, Hong Kong
   [14111515, 14103419]; Collaborative Research Fund [C7149-20G]; Health
   and Medical Research Fund (HMRF), Hong Kong [5160836, 07180826]; Chinese
   University of Hong Kong [4054193, 4054121, 4054199, 4054634]; Innovation
   and Technology Fund [7010590]; UBS Optimus Foundation [8984]; CUHK
   Jockey Club Children's Eye Care Programme; CUHK Jockey Club Myopia
   Prevention Programme; Centaline Myopia Fund
FX This study was supported in part by the General Research Fund (GRF),
   Research Grants Council, Hong Kong (14111515 and 14103419 [JCY]);
   Collaborative Research Fund (C7149-20G [JCY]); Health and Medical
   Research Fund (HMRF), Hong Kong (5160836, [LJC] and 07180826 [XJZ]), and
   the Direct Grants of the Chinese University of Hong Kong, (4054193 [LJC]
   and 4054121 & 4054199 [JCY] and 4054634 [XJZ]), the Innovation and
   Technology Fund (7010590 [JCY]), the UBS Optimus Foundation Grant 8984
   (JCY); the Centaline Myopia Fund [JCY]; the CUHK Jockey Club Children's
   Eye Care Programme; and the CUHK Jockey Club Myopia Prevention
   Programme.
CR Abdellah MM, 2019, J OPHTHALMOL, V2019, DOI 10.1155/2019/9312929
   Adamczak M, 2020, CURR HYPERTENS REP, V22, DOI 10.1007/s11906-020-01059-9
   Afarid M, 2020, J OPHTHAL VIS RES, V15, P172, DOI 10.18502/jovr.v15i2.6734
   Ahmadieh Hala, 2013, ISRN Endocrinol, V2013, P641098, DOI 10.1155/2013/641098
   Ahmed LHM, 2021, BIOMED REP, V14, DOI 10.3892/br.2020.1394
   Ahmed LHM, 2020, BMC ENDOCR DISORD, V20, DOI 10.1186/s12902-020-00549-w
   Aidenloo NS, 2022, IMMUNOPATHOL PERSA, V8, DOI 10.34172/ipp.2022.16
   Akkaya S, 2020, OCUL IMMUNOL INFLAMM, V28, P348, DOI 10.1080/09273948.2019.1604002
   Aksoy H, 2000, CLIN BIOCHEM, V33, P47, DOI 10.1016/S0009-9120(99)00085-5
   Al-Barry MA, 2016, BMC OPHTHALMOL, V16, DOI 10.1186/s12886-016-0354-6
   Al-Ishaq RK, 2021, ARCH PHYSIOL BIOCHEM, V127, P195, DOI 10.1080/13813455.2019.1628064
   Alam U, 2016, J DIABETES RES, V2016, DOI 10.1155/2016/6156217
   Albert DM, 2007, INVEST OPHTH VIS SCI, V48, P2327, DOI 10.1167/iovs.06-1210
   Albert DM, 2004, ARCH OPHTHALMOL-CHIC, V122, P1357, DOI 10.1001/archopht.122.9.1357
   Alcubierre N, 2015, J DIABETES RES, V2015, DOI 10.1155/2015/374178
   Alele JD, 2013, ATHEROSCLEROSIS, V228, P502, DOI 10.1016/j.atherosclerosis.2013.03.024
   Almoosa A, 2019, BAHRAIN MED B, V41, P238
   Alsalem JA, 2014, INVEST OPHTH VIS SCI, V55, P2140, DOI 10.1167/iovs.13-13019
   Alswailmi FK, 2021, IIUM MED J MALAYSIA, V20, P72, DOI 10.31436/imjm.v20i3.1756
   Aoki A, 2016, SCI REP-UK, V6, DOI 10.1038/srep20723
   Apte RS, 2021, NEW ENGL J MED, V385, P539, DOI 10.1056/NEJMcp2102061
   Arar ZV, 2016, ACTA CLIN CROAT, V55, P203, DOI 10.20471/acc.2016.55.02.04
   Arikan S, 2022, CLIN EXP OPTOM, V105, P733, DOI 10.1080/08164622.2021.1969212
   Arita R, 2017, BMC OPHTHALMOL, V17, DOI 10.1186/s12886-017-0482-7
   Arman A, 2020, ANN CLIN ANAL MED, V11, P91, DOI 10.4328/ACAM.6157
   Ashinne B, 2018, DIABETES RES CLIN PR, V139, P308, DOI 10.1016/j.diabres.2018.02.040
   Aslan MG, 2021, CORNEA, V40, P334, DOI 10.1097/ICO.0000000000002475
   Atalay K, 2020, ACTA ENDOCRINOL-BUCH, V16, P178, DOI 10.4183/aeb.2020.178
   Atalay K, 2019, J FR OPHTALMOL, V42, P730, DOI 10.1016/j.jfo.2019.01.002
   Audo I, 2003, INVEST OPHTH VIS SCI, V44, P4192, DOI 10.1167/iovs.02-1198
   Aydemir GA, 2022, INT OPHTHALMOL, V42, P1875, DOI 10.1007/s10792-021-02185-2
   Aydemir GA, 2022, CORNEA, V41, P1412, DOI 10.1097/ICO.0000000000002908
   Ayyagari R, 2019, MOL VIS, V25, P438
   Bae SH, 2016, SCI REP-UK, V6, DOI 10.1038/srep33083
   Bajaj Sarita, 2014, Indian J Endocrinol Metab, V18, P537, DOI 10.4103/2230-8210.137512
   Balbaba M, 2021, EUR J OPHTHALMOL, V31, P638, DOI 10.1177/1120672119894847
   Bang B, 1999, SCAND J RHEUMATOL, V28, P180
   Bascom A, 2019, INVEST OPHTH VIS SCI, V60
   Beauchet O, 2011, J AM GERIATR SOC, V59, P568, DOI 10.1111/j.1532-5415.2010.03299.x
   Bener A, 2018, BIOMED RES INT, V2018, DOI 10.1155/2018/2714590
   Bikle DD, 2014, CHEM BIOL, V21, P319, DOI 10.1016/j.chembiol.2013.12.016
   Bonakdaran S, 2015, INT J OPHTHALMOL-CHI, V8, P326, DOI 10.3980/j.issn.2222-3959.2015.02.20
   Boyuk B, 2017, EURASIAN J MED ONCOL, V1, P190, DOI 10.14744/ejmo.2017.69775
   Bozkurt B, 2018, OCUL IMMUNOL INFLAMM, V26, P435, DOI 10.1080/09273948.2016.1235714
   Brown CJ, 2015, CLIN OPHTHALMOL, V9, P1093, DOI 10.2147/OPTH.S84790
   BROWN EM, 1993, NATURE, V366, P575, DOI 10.1038/366575a0
   BURGESS ED, 1990, AM J HYPERTENS, V3, P903, DOI 10.1093/ajh/3.12.903
   Butler AE, 2020, THER ADV CHRONIC DIS, V11, DOI 10.1177/2040622320924159
   Cabuk KS, 2020, GRAEF ARCH CLIN EXP, V258, P1293, DOI 10.1007/s00417-020-04650-7
   CADE C, 1986, ENDOCRINOLOGY, V119, P84, DOI 10.1210/endo-119-1-84
   Cankaya C, 2018, INDIAN J OPHTHALMOL, V66, P1256, DOI 10.4103/ijo.IJO_238_18
   Carbone LD, 2021, J INVEST MED, V69, P843, DOI 10.1136/jim-2020-001645
   Castillo-Oti JM, 2022, NUTRIENTS, V14, DOI 10.3390/nu14010084
   Chaurasia A, 2017, J EVOL MED DENT SCI-, V6, P2735, DOI 10.14260/jemds/2017/590
   Chen L, 2014, AM J OPHTHALMOL, V157, P1103, DOI 10.1016/j.ajo.2014.02.020
   Chen M, 2010, INVEST OPHTH VIS SCI, V51, P5888, DOI 10.1167/iovs.09-5103
   Chiu ZK, 2020, OPHTHALMOLOGY, V127, P230, DOI 10.1016/j.ophtha.2019.06.030
   Cho MC, 2020, BMC OPHTHALMOL, V20, DOI 10.1186/s12886-019-1293-9
   Cho Y, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-98342-9
   Choi JA, 2014, INVEST OPHTH VIS SCI, V55, P2041, DOI [10.1167/iovs.13-12853, 10.1167/IOVS.13-12853]
   Chou HD, 2021, BRIT J OPHTHALMOL, V105, P468, DOI 10.1136/bjophthalmol-2019-315663
   Christen WG, 2020, JAMA OPHTHALMOL, V138, P1280, DOI 10.1001/jamaophthalmol.2020.4409
   Clark E, 2009, J EVAL CLIN PRACT, V15, P1054, DOI 10.1111/j.1365-2753.2009.01314.x
   Comes N, 2009, PHYSIOL GENOMICS, V38, P205, DOI 10.1152/physiolgenomics.90261.2008
   CONSTAD WH, 1988, AM J OPHTHALMOL, V105, P674, DOI 10.1016/0002-9394(88)90063-3
   Cooper JD, 2011, DIABETES, V60, P1624, DOI 10.2337/db10-1656
   Coppe AM, 2005, OPHTHALMOLOGY, V112, P2103, DOI 10.1016/j.ophtha.2005.06.028
   Cougnard-Greoire A, 2015, J NUTR, V145, P1865, DOI 10.3945/jn.115.214387
   Cuellar-Partida G, 2017, INT J EPIDEMIOL, V46, P1882, DOI 10.1093/ije/dyx068
   Dadaci Z, 2017, OCUL IMMUNOL INFLAMM, V25, P492, DOI 10.3109/09273948.2016.1139735
   Dadaci Z, 2014, ACTA OPHTHALMOL, V92, pE443, DOI 10.1111/aos.12398
   Daldal H, 2021, CUREUS, V13, DOI 10.7759/cureus.15159
   Day S, 2012, ARCH OPHTHALMOL-CHIC, V130, P1070, DOI 10.1001/archophthalmol.2012.439
   Delcourt C, 2014, INVEST OPHTH VIS SCI, V55, P7619, DOI 10.1167/iovs.14-14471
   Demirci G, 2018, EYE CONTACT LENS, V44, pS62, DOI 10.1097/ICL.0000000000000325
   Dikci S, 2020, INT OPHTHALMOL, V40, P1687, DOI 10.1007/s10792-020-01336-1
   Diker-Cohen T, 2006, APOPTOSIS, V11, P519, DOI 10.1007/s10495-006-5115-1
   Dirani M, 2009, BRIT J OPHTHALMOL, V93, P997, DOI 10.1136/bjo.2008.150979
   Dolgin E, 2015, NATURE, V519, P276, DOI 10.1038/519276a
   Dominguez LJ, 2021, METABOLITES, V11, DOI 10.3390/metabo11040255
   Droutsas K, 2010, OPHTHALMOLOGE, V107, P511, DOI 10.1007/s00347-009-2101-3
   Durusoy Gonul Karatas, 2020, Beyoglu Eye J, V5, P102, DOI 10.14744/bej.2020.75047
   Ekiz T, 2016, J CLIN DENSITOM, V19, P419, DOI 10.1016/j.jocd.2016.03.011
   Engelen L, 2015, CARDIOVASC DIABETOL, V14, DOI 10.1186/s12933-015-0231-2
   Epstein D, 2017, CURR EYE RES, V42, P448, DOI 10.1080/02713683.2016.1188117
   Ertek S, 2012, ARCH MED SCI, V8, P47, DOI 10.5114/aoms.2012.27280
   Eslampoor A, 2022, CLIN EXP OPTOM, DOI 10.1080/08164622.2022.2033601
   Ezhilarasi K, 2018, INT J BIOL MACROMOL, V116, P346, DOI 10.1016/j.ijbiomac.2018.05.026
   Fan Q, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11008
   Fang J, 2014, AM J OPHTHALMOL, V157, P488, DOI 10.1016/j.ajo.2013.10.010
   Faralli JA, 2009, EXP EYE RES, V88, P689, DOI 10.1016/j.exer.2008.08.019
   FATTORI E, 1994, J EXP MED, V180, P1243, DOI 10.1084/jem.180.4.1243
   Froicu M, 2003, MOL ENDOCRINOL, V17, P2386, DOI 10.1210/me.2003-0281
   Fukuoka S, 2021, J CLIN MED, V10, DOI 10.3390/jcm10020350
   Galor A, 2014, CORNEA, V33, P437, DOI 10.1097/ICO.0000000000000089
   Gao F, 2021, MEDICINE, V100, DOI 10.1097/MD.0000000000026570
   Gao MC, 2019, J CLIN NEUROSCI, V61, P22, DOI 10.1016/j.jocn.2018.11.024
   Layana AG, 2017, NUTRIENTS, V9, DOI 10.3390/nu9101120
   Ghiglioni DG, 2019, INT J IMMUNOPATH PH, V33, DOI 10.1177/2058738419833468
   Girard E, 2021, NUTRIENTS, V13, DOI 10.3390/nu13124302
   Goksugur SB, 2015, ALLERGOL IMMUNOPATH, V43, P533, DOI 10.1016/j.aller.2014.10.004
   Golan S, 2011, EYE, V25, P1122, DOI 10.1038/eye.2011.174
   Goncalves A, 2015, MATURITAS, V81, P470, DOI 10.1016/j.maturitas.2015.05.008
   Gonzalez MM, 2018, J OPHTHALMIC INFLAMM, V8, DOI 10.1186/s12348-018-0148-5
   Graffe A, 2014, INVEST OPHTH VIS SCI, V55, P5298, DOI 10.1167/iovs.14-13918
   Graffe A, 2012, J AM GERIATR SOC, V60, P1367, DOI 10.1111/j.1532-5415.2012.04015.x
   Grotting LA, 2017, JAMA OPHTHALMOL, V135, P150, DOI 10.1001/jamaophthalmol.2016.4888
   Guggenheim JA, 2014, INVEST OPHTH VIS SCI, V55, P8550, DOI 10.1167/iovs.14-15839
   Gungor A, 2015, INVEST OPHTH VIS SCI, V56, P6433, DOI 10.1167/iovs.15-16872
   Han SB, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0211204
   Harb EN, 2021, OPTOMETRY VISION SCI, V98, P458, DOI 10.1097/OPX.0000000000001694
   Harris A, 1999, J OCUL PHARMACOL TH, V15, P189, DOI 10.1089/jop.1999.15.189
   Hashemi R, 2018, INTERV MED APPL SCI, V10, P127, DOI 10.1556/1646.10.2018.22
   He MG, 2015, JAMA-J AM MED ASSOC, V314, P1142, DOI 10.1001/jama.2015.10803
   He R, 2014, DIABETIC MED, V31, P1657, DOI 10.1111/dme.12581
   Heisel CJ, 2020, OPHTHAL PLAST RECONS, V36, P17, DOI 10.1097/IOP.0000000000001437
   Herrmann M, 2015, DIABETES CARE, V38, P521, DOI 10.2337/dc14-0180
   Hewison M, 2012, RHEUM DIS CLIN N AM, V38, P125, DOI 10.1016/j.rdc.2012.03.012
   Hirooka K, 2007, CLIN OPHTHALMOL, V1, P217
   Holick MF, 2011, J CLIN ENDOCR METAB, V96, P1911, DOI 10.1210/jc.2011-0385
   Holick MF, 2009, ANN EPIDEMIOL, V19, P73, DOI 10.1016/j.annepidem.2007.12.001
   Hwang HS, 2018, CURR EYE RES, V43, P1052, DOI 10.1080/02713683.2018.1472286
   Hwang JS, 2019, CORNEA, V38, P304, DOI 10.1097/ICO.0000000000001822
   Itty S, 2014, RETINA-J RET VIT DIS, V34, P1779, DOI 10.1097/IAE.0000000000000178
   Jacob J, 2021, OPHTHALMOL THER, V10, P299, DOI 10.1007/s40123-021-00335-4
   Jain N, 2022, INDIAN J OPHTHALMOL, V70, P500, DOI 10.4103/ijo.IJO_1921_21
   Jamali N, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0190131
   Jani R, 2021, NUTR METAB CARDIOVAS, V31, P3282, DOI 10.1016/j.numecd.2021.09.003
   Jee D, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0157501
   Jee D, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0149294
   Jee D, 2015, J CATARACT REFR SURG, V41, P1705, DOI 10.1016/j.jcrs.2014.12.052
   Jee DY, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0115199
   Jeon Da-Hye, 2017, J Prev Med Public Health, V50, P369, DOI 10.3961/jpmph.17.089
   Jeon SM, 2018, EXP MOL MED, V50, DOI 10.1038/s12276-018-0038-9
   Jeremy M, 2019, MOL REPROD DEV, V86, P1951, DOI 10.1002/mrd.23280
   Jha P, 2015, DIABETES CARE, V38, P1551, DOI 10.2337/dc15-0111
   Jin KW, 2017, ACTA OPHTHALMOL, V95, pE230, DOI 10.1111/aos.13241
   Jitprapaikulsan J, 2016, J NEUROIMMUNOL, V295, P75, DOI 10.1016/j.jneuroim.2016.03.016
   Joergensen C, 2011, DIABETES CARE, V34, P1081, DOI 10.2337/dc10-2459
   Jones LA, 2007, INVEST OPHTH VIS SCI, V48, P3524, DOI 10.1167/iovs.06-1118
   Jung BJ, 2020, INDIAN J OPHTHALMOL, V68, P15, DOI 10.4103/ijo.IJO_760_19
   Jung CH, 2016, NUTR RES, V36, P117, DOI 10.1016/j.nutres.2015.11.008
   Kabatas EU, 2017, SCOT MED J, V62, P129, DOI 10.1177/0036933017701867
   Kabatas N, 2022, ARQ BRAS OFTALMOL, V85, P7, DOI 10.5935/0004-2749.20220002
   Kan Emrah, 2020, Oman Med J, V35, pe83, DOI 10.5001/omj.2020.01
   Kanellopoulos AJ, 2016, EYE VISION, V3, DOI 10.1186/s40662-015-0032-4
   Kara N, 2017, ARQ BRAS OFTALMOL, V80, P229, DOI 10.5935/0004-2749.20170056
   Karabulut Müjdat, 2022, Arq. Bras. Oftalmol., V85, P584, DOI 10.5935/0004-2749.20220089
   Karaca EE, 2020, ARQ BRAS OFTALMOL, V83, P312, DOI 10.5935/0004-2749.20200043
   Karimi S, 2021, J OPHTHAL VIS RES, V16, P34, DOI 10.18502/jovr.v16i1.8249
   Kastelan S, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/309723
   Kaur H, 2011, DIABETES CARE, V34, P1400, DOI 10.2337/dc11-0103
   Khamar P, 2019, INVEST OPHTH VIS SCI, V60, P2532, DOI 10.1167/iovs.19-26914
   Khandhadia S, 2012, IMMUNOBIOLOGY, V217, P127, DOI 10.1016/j.imbio.2011.07.019
   Kim EC, 2014, INVEST OPHTH VIS SCI, V55, P4823, DOI 10.1167/iovs.14-14763
   Kim Hyun Tae, 2016, Korean J Ophthalmol, V30, P426
   Kim KL, 2018, MEDICINE, V97, DOI [10.1097/MD.0000000000011908, 10.1097/md.0000000000011908]
   Kim MJ, 2017, KOREAN J FAM MED, V38, P81, DOI 10.4082/kjfm.2017.38.2.81
   Kim S, 2005, J BONE MINER RES, V20, P305, DOI 10.1359/JBMR.041112
   Kizilgu M, 2018, SEMIN OPHTHALMOL, V33, P589, DOI 10.1080/08820538.2017.1358752
   Kocaturk T, 2020, INT OPHTHALMOL, V40, P697, DOI 10.1007/s10792-019-01230-5
   Krefting EA, 2014, ACTA OPHTHALMOL, V92, P345, DOI 10.1111/aos.12125
   Kurtul BE, 2015, EYE, V29, P1081, DOI 10.1038/eye.2015.96
   Kusumadewi W, 2018, MULT SCLER RELAT DIS, V25, P329, DOI 10.1016/j.msard.2018.08.030
   Kutuzova GD, 2012, ARCH BIOCHEM BIOPHYS, V518, P53, DOI 10.1016/j.abb.2011.10.022
   Kutuzova GD, 2004, ARCH BIOCHEM BIOPHYS, V432, P152, DOI 10.1016/j.abb.2004.09.004
   Kwon JW, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000005012
   Lam DSC, 2008, INVEST OPHTH VIS SCI, V49, P873, DOI 10.1167/iovs.06-1097
   Lee JH, 2020, CORNEA, V39, P702, DOI 10.1097/ICO.0000000000002234
   Lee V, 2012, NEUROBIOL AGING, V33, P2382, DOI 10.1016/j.neurobiolaging.2011.12.002
   Lee YB, 2017, MEDICINE, V96, DOI [10.1097/MD.0000000000006343, 10.1097/md.0000000000006343]
   Li XM, 2022, FRONT MED-LAUSANNE, V9, DOI 10.3389/fmed.2022.809787
   Li YC, 2002, J CLIN INVEST, V110, P229, DOI [10.1172/JCI200215219, 10.1172/JCI0215219]
   Lingham G, 2021, ACTA OPHTHALMOL, V99, P679, DOI 10.1111/aos.14709
   Lingham G, 2019, TRANSL VIS SCI TECHN, V8, DOI 10.1167/tvst.8.1.13
   Liu YC, 2017, LANCET, V390, P600, DOI 10.1016/S0140-6736(17)30544-5
   Llop SM, 2019, OCUL IMMUNOL INFLAMM, V27, P602, DOI 10.1080/09273948.2018.1434208
   Long M, 2017, NUTR DIABETES, V7, DOI 10.1038/nutd.2017.30
   Lopes M, 2020, ACTA MEDICA PORT, V33, P459, DOI 10.20344/amp.12890
   Low W, 2010, BRIT J OPHTHALMOL, V94, P1012, DOI 10.1136/bjo.2009.173187
   Lu L, 2021, FRONT MED-LAUSANNE, V8, DOI 10.3389/fmed.2021.736316
   Lu L, 2018, J DIABETES RES, V2018, DOI 10.1155/2018/8193523
   Lv YJ, 2016, BMC OPHTHALMOL, V16, DOI 10.1186/s12886-016-0289-y
   Ma LL, 2020, MILITARY MED RES, V7, DOI 10.1186/s40779-020-00238-8
   Mahgoub MY, 2020, OPEN ACCESS RHEUMATO, V12, P35, DOI 10.2147/OARRR.S244838
   Malabanan A, 1998, LANCET, V351, P805, DOI 10.1016/S0140-6736(05)78933-9
   Mantell DJ, 2000, CIRC RES, V87, P214, DOI 10.1161/01.RES.87.3.214
   Mantravadi AV, 2015, PRIMARY CARE, V42, P437, DOI 10.1016/j.pop.2015.05.008
   Maxia C, 2017, EUR J HISTOCHEM, V61, P257, DOI 10.4081/ejh.2017.2837
   McKay GJ, 2017, OPHTHALMOLOGY, V124, P90, DOI 10.1016/j.ophtha.2016.09.007
   Mejia-Rodriguez F, 2021, NUTRIENTS, V13, DOI 10.3390/nu13082510
   Meng YF, 2019, MED SCI MONITOR, V25, P4759, DOI 10.12659/MSM.915434
   Meng YF, 2017, MED SCI MONITOR, V23, P2211, DOI 10.12659/MSM.901857
   Merle BMJ, 2017, INVEST OPHTH VIS SCI, V58, P4569, DOI 10.1167/iovs.17-21673
   Millen AE, 2017, J NUTR HEALTH AGING, V21, P772, DOI 10.1007/s12603-016-0827-6
   Millen AE, 2019, INVEST OPHTH VIS SCI, V60, P1362, DOI 10.1167/iovs.18-25945
   Millen AE, 2016, CARDIOVASC DIABETOL, V15, DOI 10.1186/s12933-016-0434-1
   Millen AE, 2015, JAMA OPHTHALMOL, V133, P1171, DOI 10.1001/jamaophthalmol.2015.2715
   Millen AE, 2011, ARCH OPHTHALMOL-CHIC, V129, P481, DOI 10.1001/archophthalmol.2011.48
   Milne R, 2013, AMINO ACIDS, V44, P1397, DOI 10.1007/s00726-011-1071-3
   Mitulescu T C, 2016, J Med Life, V9, P26
   Moher D, 2009, PLOS MED, V6, DOI [10.1136/bmj.b4037, 10.1371/journal.pmed.1000097]
   Morrison Margaux A., 2011, Human Genomics, V5, P538
   Mutlu U, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000005477
   Mutti DO, 2011, INVEST OPHTH VIS SCI, V52, P3818, DOI 10.1167/iovs.10-6534
   Mutti DO, 2011, OPTOMETRY VISION SCI, V88, P377, DOI 10.1097/OPX.0b013e31820b0385
   Nadri G, 2021, JEMDSA, V26, P82, DOI 10.1080/16089677.2021.1903170
   Nadri G, 2019, INT J RETINA VITR, V5, DOI 10.1186/s40942-019-0181-z
   Nagpal S, 2005, ENDOCR REV, V26, P662, DOI 10.1210/er.2004-0002
   Nian H, 2012, INVEST OPHTH VIS SCI, V53, P897, DOI 10.1167/iovs.11-8297
   NORMAN AW, 1980, SCIENCE, V209, P823, DOI 10.1126/science.6250216
   Oktem C, 2021, OPHTHALMIC RES, V64, P116, DOI 10.1159/000509602
   Oli A, 2017, SAUDI J OPHTHALMOL, V31, P76, DOI 10.1016/j.sjopt.2017.03.005
   Omidian M, 2019, DIABETOL METAB SYNDR, V11, DOI 10.1186/s13098-019-0479-x
   Oncul H, 2020, CAN J OPHTHALMOL, V55, P486, DOI 10.1016/j.jcjo.2020.06.014
   Orjuela-Grimm M, 2021, CANCER REP-US, V4, DOI 10.1002/cnr2.1409
   Ornek N, 2021, OPTOMETRY VISION SCI, V98, P170, DOI 10.1097/OPX.0000000000001640
   Ozturk E, 2020, CURR EYE RES, V45, P1619, DOI 10.1080/02713683.2020.1781194
   Papas EB, 2021, OPHTHAL PHYSL OPT, V41, P1254, DOI 10.1111/opo.12888
   Parekh N, 2007, ARCH OPHTHALMOL-CHIC, V125, P661, DOI 10.1001/archopht.125.5.661
   Park S, 2017, OPHTHAL EPIDEMIOL, V24, P281, DOI 10.1080/09286586.2017.1281427
   Park YG, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22136851
   Parravano M, 2019, ADV THER, V36, P2493, DOI 10.1007/s12325-019-01016-2
   Patrick PA, 2012, ARCH OPHTHALMOL-CHIC, V130, P756, DOI 10.1001/archophthalmol.2011.2749
   Payne JF, 2012, ENDOCR PRACT, V18, P185, DOI 10.4158/EP11147.OR
   Peng XJ, 2010, J CELL BIOCHEM, V110, P1324, DOI 10.1002/jcb.22646
   Serena AP, 2022, INT J RETINA VITR, V8, DOI 10.1186/s40942-022-00368-2
   Pillar S, 2022, SURV OPHTHALMOL, V67, P321, DOI 10.1016/j.survophthal.2021.07.006
   Planck T, 2018, EUR THYROID J, V7, P27, DOI 10.1159/000484521
   Plum LA, 2010, NAT REV DRUG DISCOV, V9, P941, DOI 10.1038/nrd3318
   Poon M, 2013, J DIABETES RES, V2013, DOI 10.1155/2013/280691
   Rai V, 2017, ENDOCRIN METAB CLIN, V46, P1039, DOI 10.1016/j.ecl.2017.07.009
   Ramin Shahrokh, 2015, Med Hypothesis Discov Innov Ophthalmol, V4, P39
   Rao P, 2015, INVEST OPHTH VIS SCI, V56, P4221, DOI 10.1167/iovs.15-16835
   Reddy GB, 2015, NUTRITION, V31, P959, DOI 10.1016/j.nut.2015.01.012
   Reheem RNAMA, 2013, ALEX J MED, V49, P119, DOI 10.1016/j.ajme.2012.08.006
   Reins RY, 2015, EXP EYE RES, V134, P101, DOI 10.1016/j.exer.2015.02.019
   Ren ZG, 2012, DIABETES RES CLIN PR, V98, P474, DOI 10.1016/j.diabres.2012.09.028
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Richter J, 2019, J DIET SUPPL, V16, P369, DOI 10.1080/19390211.2018.1458769
   Riek AE, 2012, J BIOL CHEM, V287, P38482, DOI 10.1074/jbc.M112.386912
   Rohmer J, 2020, OCUL IMMUNOL INFLAMM, V28, P341, DOI 10.1080/09273948.2018.1537399
   Rose KA, 2008, OPHTHALMOLOGY, V115, P1279, DOI 10.1016/j.ophtha.2007.12.019
   Rudnicka AR, 2006, INVEST OPHTH VIS SCI, V47, P4254, DOI 10.1167/iovs.06-0299
   Rullo J, 2020, J STEROID BIOCHEM, V197, DOI 10.1016/j.jsbmb.2019.105536
   Sabbaghi H, 2020, ARCH IRAN MED, V23, P445, DOI 10.34172/aim.2020.41
   Sadaka A, 2019, NEURO-OPHTHALMOLOGY, V43, P291, DOI 10.1080/01658107.2019.1566382
   Sawcer S, 2011, NATURE, V476, P214, DOI 10.1038/nature10251
   Schleithoff SS, 2006, AM J CLIN NUTR, V83, P754, DOI 10.1093/ajcn/83.4.754
   Schundeln MM, 2015, PEDIATR HEMAT ONCOL, V32, P455, DOI 10.3109/08880018.2015.1048912
   Seddon JM, 2011, OPHTHALMOLOGY, V118, P1386, DOI 10.1016/j.ophtha.2010.12.020
   Sengler C, 2018, ARTHRITIS RES THER, V20, DOI 10.1186/s13075-018-1765-y
   Senyigit A, 2019, DIABETES METAB SYND, V13, P1381, DOI 10.1016/j.dsx.2019.01.043
   Seshadri KG, 2011, J ENDOCRINOL METAB, V1, P47, DOI 10.4021/jem23w
   Seyhan D, 2019, ENDOCR METAB IMMUNE, V19, P166, DOI 10.2174/1871530319666181128105911
   Shab-Bidar S, 2011, BMC MED, V9, DOI 10.1186/1741-7015-9-125
   Shetty R, 2016, TRANSL VIS SCI TECHN, V5, DOI 10.1167/tvst.5.6.16
   Shetty R, 2016, BIOMED RES INT, V2016, DOI 10.1155/2016/4369750
   Shimo N, 2014, DIABETES RES CLIN PR, V106, pE41, DOI 10.1016/j.diabres.2014.08.005
   Singh A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070948
   Singh Sanjay Kumar, 2017, Community Eye Health, V30, pS5
   Sinha A, 2013, J CLIN ENDOCR METAB, V98, pE509, DOI 10.1210/jc.2012-3592
   Skowron Kamil, 2018, Folia Med Cracov, V58, P103
   Sobrin L, 2018, JAMA OPHTHALMOL, V136, P548, DOI [10.1001/jamaophthalmo1.2018.0642, 10.1001/jamaophthalmol.2018.0642]
   Song WS, 2018, J KOR OPHTHALMOL SOC, V59, P1024, DOI 10.3341/jkos.2018.59.11.1024
   Sorkhabi R, 2021, EUR J OPHTHALMOL, V31, P3259, DOI 10.1177/1120672120978886
   Specht IO, 2020, ACTA OPHTHALMOL, V98, P500, DOI 10.1111/aos.14349
   Sugden JA, 2008, DIABETIC MED, V25, P320, DOI 10.1111/j.1464-5491.2007.02360.x
   Suzuki A, 2006, ENDOCR J, V53, P503, DOI 10.1507/endocrj.K06-001
   Talmor Y, 2008, AM J PHYSIOL-RENAL, V294, pF1059, DOI 10.1152/ajprenal.00051.2008
   Tang J, 2009, J IMMUNOL, V182, P4624, DOI 10.4049/jimmunol.0801543
   Tang SM, 2019, BRIT J OPHTHALMOL, V103, P8, DOI 10.1136/bjophthalmol-2018-312159
   Tian B, 2009, EXP EYE RES, V88, P713, DOI 10.1016/j.exer.2008.08.008
   Tideman JWL, 2016, EUR J EPIDEMIOL, V31, P491, DOI 10.1007/s10654-016-0128-8
   Tohari AM, 2020, EXP CELL RES, V392, DOI 10.1016/j.yexcr.2020.112023
   Tohari AM, 2019, ANTIOXIDANTS-BASEL, V8, DOI 10.3390/antiox8090341
   Tohari AM, 2016, CELL BIOCHEM FUNCT, V34, P82, DOI 10.1002/cbf.3167
   Tomic M, 2022, DIABETES METAB SYND, V16, DOI 10.1016/j.dsx.2021.102355
   Torii H, 2017, EBIOMEDICINE, V15, P210, DOI 10.1016/j.ebiom.2016.12.007
   Uro M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0130879
   Usluogullari CA, 2015, BMC ENDOCR DISORD, V15, DOI 10.1186/s12902-015-0029-y
   van der Wijk AE, 2017, J LEUKOCYTE BIOL, V102, P993, DOI 10.1189/jlb.3RU0417-139
   VERSTAPPEN A, 1986, OPHTHALMIC RES, V18, P209, DOI 10.1159/000265436
   Vinson Joe A, 2006, Pathophysiology, V13, P151, DOI 10.1016/j.pathophys.2006.05.006
   Vural E, 2021, EUR J OPHTHALMOL, V31, P578, DOI 10.1177/1120672120902025
   Wahyudi D, 2020, PAK J MED HEALTH SCI, V14, P1588
   Wan H, 2019, ENDOCR PRACT, V25, P809, DOI 10.4158/EP-2019-0015
   Wan TT, 2015, BIOMED PHARMACOTHER, V74, P145, DOI 10.1016/j.biopha.2015.08.002
   Wang TJ, 2008, CIRCULATION, V117, P503, DOI 10.1161/CIRCULATIONAHA.107.706127
   Watts P, 2020, INDIAN J OPHTHALMOL, V68, P1020, DOI 10.4103/ijo.IJO_1492_19
   Williams KM, 2017, JAMA OPHTHALMOL, V135, P47, DOI 10.1001/jamaophthalmol.2016.4752
   Xiao Y, 2020, FRONT ENDOCRINOL, V11, DOI 10.3389/fendo.2020.564738
   Yang CH, 2018, CONTACT LENS ANTERIO, V41, P69, DOI 10.1016/j.clae.2017.09.007
   Yazar S, 2014, INVEST OPHTH VIS SCI, V55, P4552, DOI 10.1167/iovs.14-14589
   Ye XC, 2017, BIOCHEM BIOPH RES CO, V485, P499, DOI 10.1016/j.bbrc.2017.02.019
   Yenigun A, 2015, AM J RHINOL ALLERGY, V29, pE46, DOI 10.2500/ajra.2015.29.4164
   Yi XL, 2016, IUBMB LIFE, V68, P445, DOI 10.1002/iub.1501
   Yi XL, 2011, MOL VIS, V17, P673
   Yildirim P, 2016, INT J RHEUM DIS, V19, P49, DOI 10.1111/1756-185X.12727
   Yin ZH, 2011, INVEST OPHTH VIS SCI, V52, P7359, DOI 10.1167/iovs.11-7605
   Yonekawa Y, 2015, J CLIN MED, V4, P343, DOI 10.3390/jcm4020343
   Yoo TK, 2014, PUBLIC HEALTH NUTR, V17, P833, DOI 10.1017/S1368980013003492
   Yoon SY, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0147847
   Yu JM, 2016, INT J OPHTHALMOL-CHI, V9, P610, DOI 10.18240/ijo.2016.04.23
   Yuan J, 2019, HORM METAB RES, V51, P729, DOI 10.1055/a-1010-6449
   Yuan YF, 2018, J DIABETES RES, V2018, DOI 10.1155/2018/1757925
   ZADNIK K, 1994, JAMA-J AM MED ASSOC, V271, P1323, DOI 10.1001/jama.271.17.1323
   Zarei-Ghanavati S, 2020, J CURR OPHTHALMOL, V32, P26, DOI 10.1016/j.joco.2019.06.003
   Zavorkova Martina, 2018, Open Biochem J, V12, P36, DOI 10.2174/1874091X01812010036
   Zhang JS, 2017, CAN J OPHTHALMOL, V52, P219, DOI 10.1016/j.jcjo.2016.10.004
   Zhang R, 2010, NUTR J, V9, DOI 10.1186/1475-2891-9-65
   Zhang Y, 2016, BIOMED RES INT, V2016, DOI 10.1155/2016/5305282
   Zhao WJ, 2021, CHINESE MED J-PEKING, V134, P814, DOI 10.1097/CM9.0000000000001364
   Zhao X, 2021, J DIABETES RES, V2021, DOI 10.1155/2021/8853622
   Zhu M, 2015, J EPIDEMIOL, V25, P57, DOI 10.2188/jea.JE20140017
   Zicari AM, 2017, CURR MED RES OPIN, V33, P269, DOI 10.1080/03007995.2016.1254602
   Zmijewski MA, 2020, EXP DERMATOL, V29, P876, DOI 10.1111/exd.14147
   Zmijewski MA, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20010145
   Zoppini G, 2015, BMJ OPEN DIAB RES CA, V3, DOI 10.1136/bmjdrc-2014-000058
NR 319
TC 0
Z9 0
U1 16
U2 19
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1422-0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD APR
PY 2022
VL 23
IS 8
AR 4226
DI 10.3390/ijms23084226
PG 58
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA 0T4IP
UT WOS:000786932300001
PM 35457041
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Touhami, S
   Beguier, F
   Yang, TX
   Augustin, S
   Roubeix, C
   Blond, F
   Conart, JB
   Sahel, JA
   Bodaghi, B
   Delarasse, C
   Guillonneau, X
   Sennlaub, F
AF Touhami, Sara
   Beguier, Fanny
   Yang, Tianxiang
   Augustin, Sebastien
   Roubeix, Christophe
   Blond, Frederic
   Conart, Jean Baptiste
   Sahel, Jose Alain
   Bodaghi, Bahram
   Delarasse, Cecile
   Guillonneau, Xavier
   Sennlaub, Florian
TI Hypoxia Inhibits Subretinal Inflammation Resolution Thrombospondin-1
   Dependently
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE age-related macular degeneration; hypoxia; macrophages; mononuclear
   phagocytes; choroidal neovascularization; thrombospondin 1
ID OBSTRUCTIVE SLEEP-APNEA; CHOROIDAL NEOVASCULARIZATION; DEGENERATION;
   DISEASE; MACROPHAGES; EXPRESSION; INFILTRATE; DEFICIENT; RESPONSES; MICE
AB Hypoxia is potentially one of the essential triggers in the pathogenesis of wet age-related macular degeneration (wetAMD), characterized by choroidal neovascularization (CNV) which is driven by the accumulation of subretinal mononuclear phagocytes (MP) that include monocyte-derived cells. Here we show that systemic hypoxia (10% O-2) increased subretinal MP infiltration and inhibited inflammation resolution after laser-induced subretinal injury in vivo. Accordingly, hypoxic (2% O-2) human monocytes (Mo) resisted elimination by RPE cells in co-culture. In Mos from hypoxic mice, Thrombospondin 1 mRNA (Thbs1) was most downregulated compared to normoxic animals and hypoxia repressed Thbs-1 expression in human monocytes in vitro. Hypoxic ambient air inhibited MP clearance during the resolution phase of laser-injury in wildtype animals, but had no effect on the exaggerated subretinal MP infiltration observed in normoxic Thbs1(-/-)-mice. Recombinant Thrombospondin 1 protein (TSP-1) completely reversed the pathogenic effect of hypoxia in Thbs1(-/-)-mice, and accelerated inflammation resolution and inhibited CNV in wildtype mice. Together, our results demonstrate that systemic hypoxia disturbs TSP-1-dependent subretinal immune suppression and promotes pathogenic subretinal inflammation and can be therapeutically countered by local recombinant TSP-1.
C1 [Touhami, Sara; Beguier, Fanny; Yang, Tianxiang; Augustin, Sebastien; Roubeix, Christophe; Blond, Frederic; Conart, Jean Baptiste; Sahel, Jose Alain; Delarasse, Cecile; Guillonneau, Xavier; Sennlaub, Florian] Sorbonne Univ, CNRS, Inst Vis, INSERM, F-75012 Paris, France.
   [Touhami, Sara; Bodaghi, Bahram] Sorbonne Univ, Dept Ophthalmol, Pitie Salpetriere Univ Hosp, AP HP, F-75013 Paris, France.
   [Conart, Jean Baptiste] Univ Hosp, Dept Ophthalmol, F-54000 Nancy, France.
   [Sahel, Jose Alain] CHNO Quinze Vingts, INSERM DGOS CIC 1423, F-75012 Paris, France.
C3 Centre National de la Recherche Scientifique (CNRS); Institut National
   de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research
   Universities; Sorbonne Universite; Universite Paris Cite; Assistance
   Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere
   - APHP; UDICE-French Research Universities; Sorbonne Universite; CHNO
   des Quinze-Vingts; UDICE-French Research Universities; Sorbonne
   Universite
RP Guillonneau, X; Sennlaub, F (通讯作者)，Sorbonne Univ, CNRS, Inst Vis, INSERM, F-75012 Paris, France.
EM saratouhami@gmail.com; fanny.beguier@gmail.com;
   tianxiang.yang@inserm.fr; sebastien.augustin@inserm.fr;
   chris.roubeix@gmail.com; frederic.blond@inserm.fr; jbconart@hotmail.com;
   j.sahel@gmail.com; bahram.bodaghi@aphp.fr;
   cecile.delarasse@sorbonne-universite.fr; xavier.guillonneau@inserm.fr;
   florian.sennlaub@inserm.fr
RI Delarasse, Cecile/K-8234-2017; guillonneau, xavier/AAF-9495-2021;
   Guillonneau, xavier/E-3995-2017
OI Delarasse, Cecile/0000-0001-9739-4306; guillonneau,
   xavier/0000-0001-7379-3935; Guillonneau, xavier/0000-0001-7379-3935;
   Blond, Frederic/0000-0002-2314-0570
CR AUSSERER WA, 1994, MOL CELL BIOL, V14, P5032, DOI 10.1128/MCB.14.8.5032
   Beguier F, 2020, IMMUNITY, V53, P429, DOI 10.1016/j.immuni.2020.07.021
   Blasiak J, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/768026
   Caicedo A, 2005, EXP EYE RES, V81, P38, DOI 10.1016/j.exer.2005.01.013
   Calippe B, 2017, IMMUNITY, V46, P261, DOI 10.1016/j.immuni.2017.01.006
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Charles-Messance H, 2020, J NEUROINFLAMM, V17, DOI 10.1186/s12974-019-1655-5
   Daulatzai MA, 2015, J NEUROSCI RES, V93, P1778, DOI 10.1002/jnr.23634
   Dyer NP, 2019, PEERJ, V7, DOI 10.7717/peerj.6222
   Feigl B, 2009, PROG RETIN EYE RES, V28, P63, DOI 10.1016/j.preteyeres.2008.11.004
   Guillonneau X, 2017, PROG RETIN EYE RES, V61, P98, DOI 10.1016/j.preteyeres.2017.06.002
   Jurado-Gamez B, 2012, J SLEEP RES, V21, P139, DOI 10.1111/j.1365-2869.2011.00955.x
   Keenan TDL, 2017, BRIT J OPHTHALMOL, V101, P155, DOI 10.1136/bjophthalmol-2015-308278
   Kim D, 2015, NAT METHODS, V12, P357, DOI [10.1038/NMETH.3317, 10.1038/nmeth.3317]
   Klein Ronald, 2003, Ophthalmology, V110, P1273, DOI 10.1016/S0161-6420(03)00599-2
   Lavalette S, 2011, AM J PATHOL, V178, P2416, DOI 10.1016/j.ajpath.2011.01.013
   Levy O, 2015, J NEUROSCI, V35, P13568, DOI 10.1523/JNEUROSCI.2468-15.2015
   Levy O, 2015, EMBO MOL MED, V7, P211, DOI 10.15252/emmm.201404524
   Lewis JS, 1999, J LEUKOCYTE BIOL, V66, P889, DOI 10.1002/jlb.66.6.889
   Liu J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072935
   Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8
   Luhmann UFO, 2009, INVEST OPHTH VIS SCI, V50, P5934, DOI 10.1167/iovs.09-3462
   Mathis T, 2017, AGING CELL, V16, P173, DOI 10.1111/acel.12540
   METTOUCHI A, 1994, EMBO J, V13, P5668, DOI 10.1002/j.1460-2075.1994.tb06905.x
   Murdoch C, 2005, J IMMUNOL, V175, P6257, DOI 10.4049/jimmunol.175.10.6257
   Ng TF, 2009, INVEST OPHTH VIS SCI, V50, P5472, DOI 10.1167/iovs.08-2877
   Pack AI, 2009, PROG CARDIOVASC DIS, V51, P434, DOI 10.1016/j.pcad.2009.01.002
   Rahat MA, 2011, FRONT IMMUNOL, V2, DOI 10.3389/fimmu.2011.00045
   Robbie SJ, 2016, NEUROBIOL AGING, V40, P110, DOI 10.1016/j.neurobiolaging.2015.12.019
   Sakurai E, 2003, INVEST OPHTH VIS SCI, V44, P2743, DOI 10.1167/iovs.02-1246
   Sakurai E, 2003, INVEST OPHTH VIS SCI, V44, P3578, DOI 10.1167/iovs.03-0097
   SARKS SH, 1976, BRIT J OPHTHALMOL, V60, P324, DOI 10.1136/bjo.60.5.324
   Semenza GL, 2012, CELL, V148, P399, DOI 10.1016/j.cell.2012.01.021
   Sennlaub F, 2013, EMBO MOL MED, V5, P1775, DOI 10.1002/emmm.201302692
   Stefansson E, 2011, PROG RETIN EYE RES, V30, P72, DOI 10.1016/j.preteyeres.2010.09.003
   Touhami S, 2018, J NEUROINFLAMM, V15, DOI 10.1186/s12974-018-1106-8
   Tsutsumi C, 2003, J LEUKOCYTE BIOL, V74, P25, DOI 10.1189/jlb.0902436
   Wang SJ, 2012, ARCH OPHTHALMOL-CHIC, V130, P615, DOI 10.1001/archopthalmol.2011.1892
   Yu AY, 1999, J CLIN INVEST, V103, P691, DOI 10.1172/JCI5912
NR 39
TC 1
Z9 1
U1 1
U2 3
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1422-0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD JAN
PY 2022
VL 23
IS 2
AR 681
DI 10.3390/ijms23020681
PG 12
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA YP8KE
UT WOS:000748867900001
PM 35054863
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Li, L
   Zhu, MH
   Wu, WL
   Qin, B
   Gu, JY
   Tu, YY
   Chen, JN
   Liu, D
   Shi, YW
   Liu, XJ
   Sang, AM
   Ding, DM
AF Li, Lele
   Zhu, Manhui
   Wu, Wenli
   Qin, Bai
   Gu, Jiayi
   Tu, Yuanyuan
   Chen, Jianing
   Liu, Dong
   Shi, Yunwei
   Liu, Xiaojuan
   Sang, Aimin
   Ding, Dongmei
TI Brivanib, a multitargeted small-molecule tyrosine kinase inhibitor,
   suppresses laser-induced CNV in a mouse model of neovascular AMD
SO JOURNAL OF CELLULAR PHYSIOLOGY
LA English
DT Article
DE age-related macular degeneration; choroidal neovascularization;
   fibroblast growth factor receptor 1; receptor tyrosine kinase inhibitor;
   vascular endothelial growth factor receptor 2
ID ADVANCED HEPATOCELLULAR-CARCINOMA; GROWTH-FACTOR RECEPTOR-2; ANTI-VEGF
   AGENTS; CHOROIDAL NEOVASCULARIZATION; INTRAVITREAL INJECTION; SIGNALING
   PATHWAYS; ENDOTHELIAL-CELLS; DUAL INHIBITOR; FACTOR THERAPY; FGF
   RECEPTOR
AB In age-related macular degeneration (AMD), choroidal neovascularization (CNV), a major pathologic feature of neovascular AMD (nAMD), affects 10% of patients, potentially causing serious complications, including vision loss. Vascular endothelial growth factor receptor 2 (VEGFR2) and fibroblast growth factor receptor 1 (FGFR1) contribute to the pathogenesis of CNV. Brivanib is an oral selective dual receptor tyrosine kinase (RTK) inhibitor of FGFRs and VEGFRs, especially VEGFR2 and FGFR1. In this study, brivanib inhibited zebrafish embryonic angiogenesis without impairing neurodevelopment. In a mouse CNV model, brivanib intravitreal injection blocked phosphorylation of FGFR1 and VEGFR2 and reduced CNV leakage, area, and formation without causing intraocular toxicity. Moreover, brivanib oral gavage reduced CNV leakage and area. Accordingly, brivanib remained at high concentrations (above 14,000 ng/ml) in retinal/choroidal/scleral tissues following intravitreal injection. Similarly, brivanib remained at high concentrations (over 10,000 ng/ml) in retinal/choroidal/scleral tissues following oral gavage. Finally, in vitro cell experiments demonstrated that brivanib inhibited the proliferation, migration and tube formation of microvascular endothelial cells. In conclusion, our study suggested that brivanib treatment could be a novel therapeutic strategy for nAMD.
C1 [Li, Lele; Qin, Bai; Gu, Jiayi; Tu, Yuanyuan; Sang, Aimin] Nantong Univ, Affiliated Hosp, Dept Ophthalmol, Nantong 226001, Jiangsu, Peoples R China.
   [Zhu, Manhui] Soochow Univ, Lixiang Eye Hosp, Dept Ophthalmol, Suzhou, Jiangsu, Peoples R China.
   [Wu, Wenli; Chen, Jianing] Nantong Univ, Coll Med, Nantong, Jiangsu, Peoples R China.
   [Liu, Dong; Shi, Yunwei] Nantong Univ, Jiangsu Key Lab Neuroregenerat, Coinnovat Ctr Neuroregenerat, Nantong, Peoples R China.
   [Liu, Xiaojuan] Nantong Univ, Coll Med, Dept Pathogen Biol, Nantong, Jiangsu, Peoples R China.
   [Ding, Dongmei] Laizhou City Peoples Hosp, Dept Ophthalmol, Yantai 264000, Shandong, Peoples R China.
C3 Nantong University; Soochow University - China; Nantong University;
   Nantong University; Nantong University
RP Sang, AM (通讯作者)，Nantong Univ, Affiliated Hosp, Dept Ophthalmol, Nantong 226001, Jiangsu, Peoples R China.; Ding, DM (通讯作者)，Laizhou City Peoples Hosp, Dept Ophthalmol, Yantai 264000, Shandong, Peoples R China.
EM sangam@ntu.edu.cn; dingdm2005@aliyun.com
RI 涂, 园园/AGE-3991-2022
FU Graduate Technology Innovation Program of of Jiangsu Province
   [SJCX18_0829]; Suzhou Science and Technology Bureau [SYS2018005]; Suzhou
   Commission of Health and Family Planning [KJXW2018076]; 14th Six Talents
   Peak Project of Jiangsu Province [SWYY-058]; major project of Nantong
   city. [MS22018009]
FX Graduate Technology Innovation Program of of Jiangsu Province,
   Grant/Award Number: SJCX18_0829; Suzhou Science and Technology Bureau,
   Grant/Award Number: SYS2018005; Suzhou Commission of Health and Family
   Planning, Grant/Award Number: KJXW2018076; the 14th Six Talents Peak
   Project of Jiangsu Province, Grant/Award Number: SWYY-058; major project
   of Nantong city., Grant/Award Number: No. MS22018009
CR AIELLO LP, 1995, P NATL ACAD SCI USA, V92, P10457, DOI 10.1073/pnas.92.23.10457
   Amadio M, 2016, PHARMACOL RES, V103, P253, DOI 10.1016/j.phrs.2015.11.027
   Andreoli CM, 2007, CURR OPIN OPHTHALMOL, V18, P502, DOI 10.1097/ICU.0b013e3282f0ca54
   Ayers M, 2007, CANCER RES, V67, P6899, DOI 10.1158/0008-5472.CAN-06-4555
   Ba-Sang DZ, 2016, ONCOTARGET, V7, P84468, DOI 10.18632/oncotarget.12994
   Bergers G, 2008, NAT REV CANCER, V8, P592, DOI 10.1038/nrc2442
   Bhide RS, 2010, MOL CANCER THER, V9, P369, DOI 10.1158/1535-7163.MCT-09-0472
   Cao RH, 2012, P NATL ACAD SCI USA, V109, P15894, DOI 10.1073/pnas.1208324109
   Chan JK, 2017, GYNECOL ONCOL, V146, P554, DOI 10.1016/j.ygyno.2017.05.033
   Chiodelli P, 2017, ONCOGENE, V36, P6531, DOI 10.1038/onc.2017.243
   Choi YJ, 2018, CANCER RES TREAT, V50, P1252, DOI 10.4143/crt.2017.438
   Crespo-Garcia Sergio, 2017, Invest Ophthalmol Vis Sci, V58, P4997, DOI 10.1167/iovs.16-21283
   Cross MJ, 2001, TRENDS PHARMACOL SCI, V22, P201, DOI 10.1016/S0165-6147(00)01676-X
   Cucchetti A, 2017, LIVER CANCER, V6, P337, DOI 10.1159/000481314
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Diaz-Padilla I, 2011, EXPERT OPIN INV DRUG, V20, P577, DOI 10.1517/13543784.2011.565329
   Falavarjani KG, 2013, EYE, V27, P787, DOI 10.1038/eye.2013.107
   Feng SC, 2015, HISTOL HISTOPATHOL, V30, P13, DOI 10.14670/HH-30.13
   Ferguson FM, 2018, NAT REV DRUG DISCOV, V17, P353, DOI 10.1038/nrd.2018.21
   Gaumann AKA, 2016, INT J CANCER, V138, P540, DOI 10.1002/ijc.29499
   Gouaze-Andersson V, 2016, CANCER RES, V76, P3036, DOI 10.1158/0008-5472.CAN-15-2058
   Grant MB, 2004, EXPERT OPIN INV DRUG, V13, P1275, DOI 10.1517/13543784.13.10.1275
   Gschwind A, 2004, NAT REV CANCER, V4, P361, DOI 10.1038/nrc1360
   Hoch W, 2001, NAT MED, V7, P365, DOI 10.1038/85520
   Hueber A, 1997, INT OPHTHALMOL, V20, P345
   Huynh H, 2008, CLIN CANCER RES, V14, P6146, DOI 10.1158/1078-0432.CCR-08-0509
   Izumi-Nagai K, 2008, INVEST OPHTH VIS SCI, V49, P1679, DOI 10.1167/iovs.07-1426
   Johnson PJ, 2013, J CLIN ONCOL, V31, P3517, DOI 10.1200/JCO.2012.48.4410
   Kudo M, 2014, HEPATOLOGY, V60, P1697, DOI 10.1002/hep.27290
   Lemmon MA, 2010, CELL, V141, P1117, DOI 10.1016/j.cell.2010.06.011
   Li M, 2018, BIOCHEM BIOPH RES CO, V495, P2085, DOI [10.1016/ibbrc.2017.12.049, 10.1016/j.bbrc.2017.12.049]
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Maier P, 2005, GRAEF ARCH CLIN EXP, V243, P593, DOI 10.1007/s00417-004-1021-9
   Matsushima M, 1996, JPN J OPHTHALMOL, V40, P329
   Mei XY, 2018, VASC PHARMACOL, V101, P29, DOI 10.1016/j.vph.2017.11.002
   Munk MR, 2016, EXPERT OPIN BIOL TH, V16, P477, DOI 10.1517/14712598.2016.1132696
   Nakamura I, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092273
   Ng DSC, 2017, ASIA-PAC J OPHTHALMO, V6, P554, DOI 10.22608/APO.2017308
   Oladipupo SS, 2014, P NATL ACAD SCI USA, V111, P13379, DOI 10.1073/pnas.1324235111
   Papa A, 2016, EXPERT OPIN INV DRUG, V25, P31, DOI 10.1517/13543784.2016.1116517
   Rosenthal R, 2005, BIOCHEM BIOPH RES CO, V337, P241, DOI 10.1016/j.bbrc.2005.09.028
   Ryu JK, 2009, J NEUROSCI, V29, P3, DOI 10.1523/JNEUROSCI.2888-08.2009
   Schlumberger M, 2015, NEW ENGL J MED, V372, P621, DOI 10.1056/NEJMoa1406470
   Shah CP, 2011, OPHTHALMOLOGY, V118, P2028, DOI 10.1016/j.ophtha.2011.02.034
   Sourdon J, 2017, THERANOSTICS, V7, P2757, DOI 10.7150/thno.19551
   Sun HJ, 2017, BIOMED PHARMACOTHER, V95, P144, DOI 10.1016/j.biopha.2017.08.059
   Sun WJ, 2018, J GASTROINTEST CANC, V49, P107, DOI 10.1007/s12029-018-0065-8
   Tovar V, 2017, GUT, V66, P530, DOI 10.1136/gutjnl-2015-309501
   Tsimafeyeu I, 2016, EUR J CANCER, V61, P20, DOI 10.1016/j.ejca.2016.03.068
   Van de Veire S, 2010, CELL, V141, P178, DOI 10.1016/j.cell.2010.02.039
   Wei X, 2018, EXP EYE RES, V168, P2, DOI 10.1016/j.exer.2017.12.009
   WILLIAMS RL, 1989, CELL, V57, P1053, DOI 10.1016/0092-8674(89)90343-7
   Wu XY, 2015, ONCOTARGET, V6, P44563, DOI 10.18632/oncotarget.6310
   Yu HG, 2008, INVEST OPHTH VIS SCI, V49, P2599, DOI 10.1167/iovs.07-1508
   Yu X, 2019, OSTEOARTHR CARTILAGE, V27, P526, DOI 10.1016/j.joca.2018.12.007
   Zhang Wenbo, 2011, J Cardiovasc Dis Res, V2, P96, DOI 10.4103/0975-3583.83035
   Zhang Y, 2015, DRUG DES DEV THER, V9, P3413, DOI 10.2147/DDDT.S87920
   Zubilewicz A, 2001, ONCOGENE, V20, P1403, DOI 10.1038/sj.onc.1204231
NR 58
TC 14
Z9 14
U1 2
U2 9
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0021-9541
EI 1097-4652
J9 J CELL PHYSIOL
JI J. Cell. Physiol.
PD FEB
PY 2020
VL 235
IS 2
BP 1259
EP 1273
DI 10.1002/jcp.29041
EA JUL 2019
PG 15
WC Cell Biology; Physiology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Physiology
GA JQ2GV
UT WOS:000476148900001
PM 31270802
DA 2022-11-30
ER

PT J
AU Kumar, A
   Li, XR
AF Kumar, Anil
   Li, Xuri
TI PDGF-C and PDGF-D in ocular diseases
SO MOLECULAR ASPECTS OF MEDICINE
LA English
DT Review
DE Platelet-derived growth factor (PDGF); Proliferative vitreoretinopathy;
   Neovascular age-related macular degeneration; Retinal pathology;
   Angiogenesis; Ischemia-induced retinopathy; Inflammation
ID ENDOTHELIAL GROWTH-FACTOR; AGE-RELATED MACULOPATHY; GANGLION-CELL
   NEUROPROTECTION; PROTEASE-ACTIVATED LIGAND; ANTI-VEGF APTAMER; MACULAR
   DEGENERATION; PROLIFERATIVE VITREORETINOPATHY; CHOROIDAL
   NEOVASCULARIZATION; MESENCHYMAL TRANSITION; EPIRETINAL MEMBRANES
AB PDGFs and their receptors are critical regulators of numerous tissues and organs, including the eye. Extensive studies have shown that PDGFs and their receptors play critical roles in many ocular neo-vascular diseases, such as neovascular age-related macular degeneration, retinopathy of prematurity, and proliferative vitreoretinopathy. In addition, PDGFs and PDGFRs are also important players in ocular diseases involving the degeneration of retinal neuronal and vascular cells, such as glaucoma and retinitis pigmentosa. Due to their critical roles in the pathogenesis of many blinding ocular diseases, the PDGFs and PDGFRs have been considered as important target molecules for the treatment of eye diseases. PDGF-C and PDGF-D are relatively new members of the PDGF family and are potent angiogenic and survival factors. Recent studies have demonstrated their important roles in different types of eye diseases. Thus, modulating PDGF-C and PDGF-D activities may have therapeutic values for the treatment of ocular neovascular and degenerative diseases. This review mainly summarizes the recent advances on PDGF-C and PDGF-D biology in relationship to some major ocular diseases. (C) 2017 Elsevier Ltd. All rights reserved.
C1 [Kumar, Anil; Li, Xuri] Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, State Key Lab Ophthalmol, 54 South Xianlie Rd, Guangzhou 510060, Guangdong, Peoples R China.
C3 Sun Yat Sen University
RP Li, XR (通讯作者)，Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, State Key Lab Ophthalmol, 54 South Xianlie Rd, Guangzhou 510060, Guangdong, Peoples R China.
EM lixr6@mail.sysu.edu.cn
FU State Key Laboratory of Ophthalmology (SKLO) at the Zhongshan Ophthalmic
   Center (ZOC), Sun Yat-Sen University (SYSU), Guangzhou, China; Key
   Program of the National Natural Science Foundation of China (NSFC)
   [81330021]; NSFC [81670855]; NSFC-Swedish Research Foundation (VR)
   International Collaboration grant [81611130082]; Guangdong Province
   Leading Expert Program grant
FX This work is supported by the State Key Laboratory of Ophthalmology
   (SKLO) at the Zhongshan Ophthalmic Center (ZOC), Sun Yat-Sen University
   (SYSU), Guangzhou, China; a Key Program of the National Natural Science
   Foundation of China (NSFC, 81330021) to X. Li; an NSFC grant (81670855)
   to X. Li; an NSFC-Swedish Research Foundation (VR) International
   Collaboration grant (81611130082) to X. Li; and a Guangdong Province
   Leading Expert Program grant to X. Li.
CR Adamus G, 2012, MOL VIS, V18, P2323
   Akiyama H, 2006, J CELL PHYSIOL, V207, P407, DOI 10.1002/jcp.20583
   Ali MU, 2017, 3 BIOTECH, V7, DOI 10.1007/s13205-017-0878-3
   Alward WLM, 1998, NEW ENGL J MED, V339, P1298, DOI 10.1056/NEJM199810293391808
   Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Ambati J, 2013, NAT REV IMMUNOL, V13, P438, DOI 10.1038/nri3459
   Anand-Apte B., 2010, DEV ANATOMY RETINAL
   Andrae J, 2008, GENE DEV, V22, P1276, DOI 10.1101/gad.1653708
   Andrews A, 1999, INVEST OPHTH VIS SCI, V40, P2683
   [Anonymous], 1986, Arch Ophthalmol, V104, P694
   Bastiaans J, 2013, GRAEF ARCH CLIN EXP, V251, P1723, DOI 10.1007/s00417-013-2335-2
   Berger W, 2010, PROG RETIN EYE RES, V29, P335, DOI 10.1016/j.preteyeres.2010.03.004
   Bergsten E, 2001, NAT CELL BIOL, V3, P512, DOI 10.1038/35074588
   BETSHOLTZ C, 1986, NATURE, V320, P695, DOI 10.1038/320695a0
   Bird AC, 2010, J CLIN INVEST, V120, P3033, DOI 10.1172/JCI42437
   Biswas SK, 2008, INVEST OPHTH VIS SCI, V49, P3687, DOI 10.1167/iovs.07-1455
   Borkham-Kamphorst E, 2015, BIOCHEM BIOPH RES CO, V457, P307, DOI 10.1016/j.bbrc.2014.12.106
   Bowes Rickman C., 2013, INVEST OPHTH VIS SCI, V54
   Bressler NM, 2010, OPHTHALMOLOGY, V117, P747, DOI 10.1016/j.ophtha.2009.09.002
   Brucker Alexander J, 2009, Retina, V29, pS2, DOI 10.1097/IAE.0b013e3181ad255f
   Burgoyne CF, 2005, PROG RETIN EYE RES, V24, P39, DOI 10.1016/j.preteyeres.2004.06.001
   Cai Y, 2016, J CELL BIOL, V215, P245, DOI 10.1083/jcb.201605065
   Capitao M, 2016, J CELL BIOCHEM, V117, P2443, DOI 10.1002/jcb.25575
   Pastor JC, 2016, PROG RETIN EYE RES, V51, P125, DOI 10.1016/j.preteyeres.2015.07.005
   Cayabyab R, 2016, NEONATOLOGY, V109, P369, DOI 10.1159/000444901
   Charteris DG, 1998, BRIT J OPHTHALMOL, V82, P106, DOI 10.1136/bjo.82.2.106
   Charteris DG, 2004, OPHTHALMOLOGY, V111, P2240, DOI 10.1016/j.ophtha.2004.05.036
   Cheema RA, 2007, OPHTHAL SURG LAS IM, V38, P365, DOI 10.3928/15428877-20070901-02
   Chovatiya R, 2014, MOL CELL, V54, P281, DOI 10.1016/j.molcel.2014.03.030
   Chung HT, 2008, METHOD ENZYMOL, V441, P329, DOI 10.1016/S0076-6879(08)01218-4
   Claes C, 2014, DEV OPHTHALMOL, V54, P188, DOI 10.1159/000360466
   Coffee Robert E, 2014, Int Ophthalmol Clin, V54, P91, DOI 10.1097/IIO.0000000000000023
   Colak D, 2012, INVEST OPHTH VIS SCI, V53, P5899, DOI 10.1167/iovs.12-9634
   Crawford Y, 2009, TRENDS PHARMACOL SCI, V30, P624, DOI 10.1016/j.tips.2009.09.004
   Crawford Y, 2009, CANCER CELL, V15, P21, DOI 10.1016/j.ccr.2008.12.004
   Cui J, 2009, EXP EYE RES, V88, P438, DOI 10.1016/j.exer.2008.10.020
   Curcio CA, 2005, EXP EYE RES, V80, P761, DOI 10.1016/j.exer.2004.09.017
   Curcio CA, 2011, BRIT J OPHTHALMOL, V95, P1638, DOI 10.1136/bjophthalmol-2011-300344
   Dai XY, 2017, DIABETES, V66, P2424, DOI 10.2337/db17-0132
   Daiger SP, 2007, ARCH OPHTHALMOL-CHIC, V125, P151, DOI 10.1001/archopht.125.2.151
   Dejda A, 2016, INVEST OPHTH VIS SCI, V57, P1530, DOI 10.1167/iovs.15-18598
   Dong A, 2014, ANGIOGENESIS, V17, P553, DOI 10.1007/s10456-013-9402-5
   DOOLITTLE RF, 1983, SCIENCE, V221, P275, DOI 10.1126/science.6304883
   Dunn EN, 2017, OSLI RETINA, V48, P100, DOI 10.3928/23258160-20170130-02
   Eichten A, 2016, CANCER RES, V76, P2327, DOI 10.1158/0008-5472.CAN-15-1443
   Feist RM, 2014, GRAEF ARCH CLIN EXP, V252, P347, DOI 10.1007/s00417-013-2531-0
   Ferrara N, 2016, TRANSL VIS SCI TECHN, V5, DOI 10.1167/tvst.5.2.10
   Ferrari S, 2011, CURR GENOMICS, V12, P238, DOI 10.2174/138920211795860107
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Foster PJ, 2002, BRIT J OPHTHALMOL, V86, P238, DOI 10.1136/bjo.86.2.238
   Fredriksson L, 2004, CYTOKINE GROWTH F R, V15, P197, DOI 10.1016/j.cytogfr.2004.03.007
   Fritsche LG, 2014, ANNU REV GENOM HUM G, V15, P151, DOI 10.1146/annurev-genom-090413-025610
   Gelfand BD, 2016, TRENDS MOL MED, V22, P656, DOI 10.1016/j.molmed.2016.06.009
   Gilbertson DG, 2001, J BIOL CHEM, V276, P27406, DOI 10.1074/jbc.M101056200
   Guerrero AH, 2000, INT OPHTHALMOL CLIN, V40, P149, DOI 10.1097/00004397-200040010-00015
   Hamada T, 2002, MECH DEVELOP, V112, P161, DOI 10.1016/S0925-4773(01)00625-6
   Hammond CJ, 2002, OPHTHALMOLOGY, V109, P730, DOI 10.1016/S0161-6420(01)01049-1
   Harada C, 2006, PROG RETIN EYE RES, V25, P149, DOI 10.1016/j.preteyeres.2005.09.001
   Hartnett ME, 2017, CURR OPIN OPHTHALMOL, V28, P282, DOI 10.1097/ICU.0000000000000360
   HARTNETT ME, 1992, GRAEF ARCH CLIN EXP, V230, P11, DOI 10.1007/BF00166756
   Hartnett ME, 2003, RETINA-J RET VIT DIS, V23, P322, DOI 10.1097/00006982-200306000-00006
   Hartong DT, 2006, LANCET, V368, P1795, DOI 10.1016/S0140-6736(06)69740-7
   He C, 2014, P NATL ACAD SCI USA, V111, P14806, DOI 10.1073/pnas.1404140111
   HELDIN CH, 1986, NATURE, V319, P511, DOI 10.1038/319511a0
   Hou HY, 2015, INVEST OPHTH VIS SCI, V56, P2755, DOI 10.1167/iovs.15-16526
   Hou X, 2010, P NATL ACAD SCI USA, V107, P12216, DOI 10.1073/pnas.1004143107
   Jaffe GJ, 2017, OPHTHALMOLOGY, V124, P224, DOI 10.1016/j.ophtha.2016.10.010
   Jaffe GJ, 2016, OPHTHALMOLOGY, V123, P78, DOI 10.1016/j.ophtha.2015.09.004
   Ji JZ, 2004, EUR J NEUROSCI, V19, P265, DOI 10.1111/j.0953-816X.2003.03107.x
   Jin E., 2017, RETINA, V17, P188
   JOHNSSON A, 1982, BIOCHEM BIOPH RES CO, V104, P66, DOI 10.1016/0006-291X(82)91941-6
   Kanamoto T, 2011, CURR EYE RES, V36, P336, DOI 10.3109/02713683.2011.556301
   Kandasamy Y, 2017, BRIT J OPHTHALMOL, V101, P21, DOI 10.1136/bjophthalmol-2016-308828
   Kapetanakis VV, 2016, BRIT J OPHTHALMOL, V100, P86, DOI 10.1136/bjophthalmol-2015-307223
   Karvinen H, 2009, EUR J CLIN INVEST, V39, P320, DOI 10.1111/j.1365-2362.2009.02095.x
   Kazlauskas A, 2017, GENE, V614, P1, DOI 10.1016/j.gene.2017.03.003
   Kingman S, 2004, B WORLD HEALTH ORGAN, V82, P887
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein R, 2010, ARCH OPHTHALMOL-CHIC, V128, P750, DOI 10.1001/archophthalmol.2010.92
   Ko ML, 2001, NEUROSCI LETT, V305, P139, DOI 10.1016/S0304-3940(01)01830-4
   KOHLER N, 1974, EXP CELL RES, V87, P297, DOI 10.1016/0014-4827(74)90484-4
   Ku CA, 2015, HUM MOL GENET, V24, P670, DOI 10.1093/hmg/ddu487
   Kumar A, 2014, INVEST OPHTH VIS SCI, V55, P1787, DOI 10.1167/iovs.13-13522
   Kumar A, 2010, J BIOL CHEM, V285, P15500, DOI 10.1074/jbc.M110.113787
   LaRochelle WJ, 2001, NAT CELL BIOL, V3, P517, DOI 10.1038/35074593
   Lee C, 2013, TRENDS MOL MED, V19, P474, DOI 10.1016/j.molmed.2013.04.006
   Lei H, 2008, EXP EYE RES, V86, P711, DOI 10.1016/j.exer.2007.08.007
   Lei H, 2008, INVEST OPHTH VIS SCI, V49, P42, DOI 10.1167/iovs.07-0776
   Lei HT, 2007, INVEST OPHTH VIS SCI, V48, P2335, DOI 10.1167/iovs.06-0965
   Lei HT, 2014, MOL CELL BIOL, V34, P110, DOI 10.1128/MCB.00839-13
   Lei HT, 2011, MOL CELL BIOL, V31, P1788, DOI 10.1128/MCB.01321-10
   Li R, 2007, INVEST OPHTH VIS SCI, V48, P5722, DOI 10.1167/iovs.07-0327
   Li XR, 2000, NAT CELL BIOL, V2, P302, DOI 10.1038/35010579
   Li XR, 2003, CYTOKINE GROWTH F R, V14, P91, DOI 10.1016/S1359-6101(02)00090-4
   Li XR, 2010, ONCOTARGET, V1, P309, DOI 10.18632/oncotarget.141
   Liegl R, 2016, EYE BRAIN, V8, P91, DOI 10.2147/EB.S99038
   LIMB G A, 1991, Eye (London), V5, P686
   Liu BY, 2018, SURV OPHTHALMOL, V63, P56, DOI 10.1016/j.survophthal.2017.06.007
   Liu HT, 2016, INVEST OPHTH VIS SCI, V57, P4272, DOI 10.1167/iovs.16-19415
   Long C A, 1989, Pediatr Nurs, V15, P269
   Ma WX, 2016, ADV EXP MED BIOL, V854, P73, DOI 10.1007/978-3-319-17121-0_11
   MCNAMARA JA, 1991, OPHTHALMOLOGY, V98, P576
   Miao H, 2012, MOL VIS, V18, P574
   Miller JW, 2013, OPHTHALMOLOGY, V120, P106, DOI 10.1016/j.ophtha.2012.07.038
   Miller JW, 2013, AM J OPHTHALMOL, V155, P1, DOI 10.1016/j.ajo.2012.10.018
   Moran EP, 2016, AM J PHYSIOL-HEART C, V311, pH738, DOI 10.1152/ajpheart.00005.2016
   Mori K, 2002, INVEST OPHTH VIS SCI, V43, P2001
   Mowat FM, 2017, FRONT NEUROSCI-SWITZ, V11, DOI 10.3389/fnins.2017.00342
   Muhl L, 2017, J CELL SCI, V130, P1365, DOI 10.1242/jcs.200493
   Narayanan R, 2017, CURR PHARM DESIGN, V23, P542, DOI 10.2174/1381612822666161221154424
   Ng EWM, 2006, ANN NY ACAD SCI, V1082, P151, DOI 10.1196/annals.1348.062
   Ng EWM, 2006, NAT REV DRUG DISCOV, V5, P123, DOI 10.1038/nrd1955
   Ohira S, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0147080
   Parmeggiani F, 2011, CURR GENOMICS, V12, P250, DOI 10.2174/138920211795860125
   Patel JR, 2016, CURR OPIN OPHTHALMOL, V27, P387, DOI 10.1097/ICU.0000000000000286
   Peng FW, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047572
   Peng HM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0014750
   Peng YT, 2017, BMC OPHTHALMOL, V17, DOI 10.1186/s12886-017-0481-8
   Pennock S, 2014, PROG RETIN EYE RES, V40, P16, DOI 10.1016/j.preteyeres.2013.12.006
   Pennock S, 2011, AM J PATHOL, V179, P2931, DOI 10.1016/j.ajpath.2011.08.043
   Ponten A, 2005, CIRC RES, V97, P1036, DOI 10.1161/01.RES.0000190590.31545.d4
   Powers MR, 2005, CURR EYE RES, V30, P299, DOI 10.1080/02713680590923276
   Quigley HA, 1996, BRIT J OPHTHALMOL, V80, P389, DOI 10.1136/bjo.80.5.389
   Ray S, 2005, J BIOL CHEM, V280, P8494, DOI 10.1074/jbc.M413570200
   Reigstad LJ, 2005, FEBS J, V272, P5723, DOI 10.1111/j.1742-4658.2005.04989.x
   Rivera JC, 2017, J NEUROINFLAMM, V14, DOI 10.1186/s12974-017-0943-1
   ROBBINS SG, 1994, INVEST OPHTH VIS SCI, V35, P3649
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   ROSENQUIST R, 1989, CURR EYE RES, V8, P1233, DOI 10.3109/02713688909013902
   Rudnicka AR, 2015, AM J OPHTHALMOL, V160, P85, DOI 10.1016/j.ajo.2015.04.003
   Rutar M, 2016, ADV EXP MED BIOL, V854, P11, DOI 10.1007/978-3-319-17121-0_2
   Sadaka A, 2012, CLIN OPHTHALMOL, V6, P1325, DOI 10.2147/OPTH.S27896
   Sankar MJ, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009734.pub2
   Sato T, 2009, OPHTHALMOLOGY, V116, P2165, DOI 10.1016/j.ophtha.2009.04.026
   Savikko J, 2001, TRANSPLANT P, V33, P2307, DOI 10.1016/S0041-1345(01)02001-2
   SEIFERT RA, 1984, NATURE, V311, P669, DOI 10.1038/311669a0
   Si YF, 2013, J OCUL PHARMACOL TH, V29, P310, DOI 10.1089/jop.2012.0137
   Smith CL, 2011, CIRC RES, V108, pE15, DOI 10.1161/CIRCRESAHA.110.235531
   SMITH LEH, 1994, INVEST OPHTH VIS SCI, V35, P101
   Smith LEH, 2004, GROWTH HORM IGF RES, V14, pS140, DOI 10.1016/j.ghir.2004.03.030
   Sobrin L, 2014, PROG RETIN EYE RES, V40, P1, DOI 10.1016/j.preteyeres.2013.12.004
   Son D, 2014, J BIOL CHEM, V289, P6225, DOI 10.1074/jbc.M113.508994
   SUNDBERG C, 1993, AM J PATHOL, V143, P1377
   Sunness JS, 1999, OPHTHALMOLOGY, V106, P910, DOI 10.1016/S0161-6420(99)00509-6
   Takahama S, 2017, INVEST OPHTH VIS SCI, V58, P4703, DOI 10.1167/iovs.21783
   Tang ZS, 2010, J EXP MED, V207, P867, DOI 10.1084/jem.20091704
   Tolentino MJ, 2009, CURR MOL MED, V9, P973, DOI 10.2174/156652409789712783
   Uutela M, 2004, BLOOD, V104, P3198, DOI 10.1182/blood-2004-04-1485
   Venugopalan P, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10472
   Villegas VM, 2017, EXPERT OPIN DRUG DEL, V14, P273, DOI 10.1080/17425247.2016.1213240
   VINORES SA, 1995, EXP EYE RES, V60, P607, DOI 10.1016/S0014-4835(05)80003-X
   Wagsater D, 2009, ATHEROSCLEROSIS, V202, P415, DOI 10.1016/j.atherosclerosis.2008.04.050
   Wang L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010329
   Wegiel B, 2014, ANTIOXID REDOX SIGN, V20, P1709, DOI 10.1089/ars.2013.5667
   WESTERMARK B, 1976, EXP CELL RES, V98, P170, DOI 10.1016/0014-4827(76)90476-6
   Wilkinson-Berka JL, 2004, AM J PATHOL, V164, P1263, DOI 10.1016/S0002-9440(10)63214-2
   Wilson AM, 2012, GENE THER, V19, P127, DOI 10.1038/gt.2011.142
   Wiradjaja F, 2013, DIS MODEL MECH, V6, P1426, DOI 10.1242/dmm.013748
   Witmer AN, 2003, PROG RETIN EYE RES, V22, P1, DOI 10.1016/S1350-9462(02)00043-5
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wubben TJ, 2016, OPHTHALMOLOGY, V123, P1553, DOI 10.1016/j.ophtha.2016.02.040
   Xu YL, 2017, BMC OPHTHALMOL, V17, DOI 10.1186/s12886-017-0554-8
   Yang J, 2010, BLOOD, V115, P51, DOI 10.1182/blood-2009-06-223719
   Yang LQ, 2006, CELL, V127, P139, DOI 10.1016/j.cell.2006.08.036
   Zeng HY, 2008, ARCH OPHTHALMOL-CHIC, V126, P227, DOI 10.1001/archophthalmol.2007.65
   Zin A, 2013, CLIN PERINATOL, V40, P185, DOI 10.1016/j.clp.2013.02.001
NR 166
TC 16
Z9 16
U1 3
U2 15
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0098-2997
EI 1872-9452
J9 MOL ASPECTS MED
JI Mol. Asp. Med.
PD AUG
PY 2018
VL 62
BP 33
EP 43
DI 10.1016/j.mam.2017.10.002
PG 11
WC Biochemistry & Molecular Biology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Research & Experimental Medicine
GA GJ2FQ
UT WOS:000435085900004
PM 29079201
DA 2022-11-30
ER

PT J
AU Sun, JX
   Chang, TF
   Li, MH
   Sun, LJ
   Yan, XC
   Yang, ZY
   Liu, Y
   Xu, WQ
   Lv, Y
   Su, JB
   Liang, L
   Han, H
   Dou, GR
   Wang, YS
AF Sun, Jia-Xing
   Chang, Tian-Fang
   Li, Man-Hong
   Sun, Li-Juan
   Yan, Xian-Chun
   Yang, Zi-Yan
   Liu, Yuan
   Xu, Wen-Qin
   Lv, Yang
   Su, Jing-Bo
   Liang, Liang
   Han, Hua
   Dou, Guo-Rui
   Wang, Yu-Sheng
TI SNAI1, an endothelial-mesenchymal transition transcription factor,
   promotes the early phase of ocular neovascularization
SO ANGIOGENESIS
LA English
DT Article
DE Angiogenesis; SNAI1; Choroidal neovascularization; Oxygen-induced
   retinopathy; Endothelial-mesenchymal transition
ID DIRECT TARGET; GROWTH-FACTOR; CELL; ANGIOGENESIS; EXPRESSION; ASSAY;
   VASCULATURE; MECHANISMS; FIBROSIS; MOUSE
AB Ocular neovascularization is a comprehensive process involved in retinal vascular development and several blinding diseases such as age-related macular degeneration and retinopathy of prematurity, with vascular endothelial growth factor (VEGF) regarded as the master regulator. However, the qualified effect of anti-VEGF therapy reveals that the underlying mechanisms are still not clearly identified. To initialize angiogenesis, endothelial cells undergo a phenotype switching to generate highly migratory and invasive cells. This process shares certain similar characters observed in endothelial-mesenchymal transition (EndMT). Here, we found that SNAI1, an EndMT transcription factor, was expressed by endothelial cells in both physiological and pathological ocular neovascularization. SNAI1 overexpression triggered cell morphological change and enhanced cell motility, while loss of SNAI1 attenuated migration, invasion and sprouting. RNA sequence analysis further revealed that SNAI1 knockdown decreased the expression of genes related to cytoskeleton rearrangement and ECM remodeling. Moreover, intravitreal injection of small interfering RNA of SNAI1 suppressed new vessel formation in developing retina as well as mice model of choroidal neovascularization and oxygen-induced retinopathy. Therefore, we propose that the EndMT transcription factor SNAI1 promotes the early phase of ocular neovascularization and may provide a potential therapeutic target.
C1 [Sun, Jia-Xing; Chang, Tian-Fang; Li, Man-Hong; Sun, Li-Juan; Xu, Wen-Qin; Lv, Yang; Su, Jing-Bo; Dou, Guo-Rui; Wang, Yu-Sheng] Fourth Mil Med Univ, Xijing Hosp, Eye Inst Chinese PLA, Dept Ophthalmol, Xian 710032, Shaanxi, Peoples R China.
   [Yan, Xian-Chun; Yang, Zi-Yan; Liu, Yuan; Liang, Liang; Han, Hua] Fourth Mil Med Univ, Dept Genet & Dev Biol, State Key Lab Canc Biol, Xian 710032, Shaanxi, Peoples R China.
   [Han, Hua] Fourth Mil Med Univ, Dept Biochem & Mol Biol, Xian 710032, Shaanxi, Peoples R China.
C3 Air Force Military Medical University; Air Force Military Medical
   University; Air Force Military Medical University
RP Dou, GR; Wang, YS (通讯作者)，Fourth Mil Med Univ, Xijing Hosp, Eye Inst Chinese PLA, Dept Ophthalmol, Xian 710032, Shaanxi, Peoples R China.
EM fierywang@126.com; wangys003@126.com
RI Sun, Jiaxing/GWM-4417-2022
OI Yang, Ziyan/0000-0002-9030-2074; Sun, Jiaxing/0000-0001-8372-5784;
   Xianchun, yan/0000-0001-5649-5012
FU National Natural Science Foundation of China [81770936, 81670863]; Youth
   Science and Technology Nova Program of Shaanxi Province [2016KJXX-19];
   Foundation for the Author of National Excellent Doctoral Dissertation of
   the People's Republic of China [201481]
FX This study was funded by National Natural Science Foundation of China
   (Nos. 81770936, 81670863), Youth Science and Technology Nova Program of
   Shaanxi Province (No. 2016KJXX-19) and Foundation for the Author of
   National Excellent Doctoral Dissertation of the People's Republic of
   China (No. 201481).
CR Amerongen GPV, 2003, ARTERIOSCL THROM VAS, V23, P211, DOI 10.1161/01.ATV.0000054198.68894.88
   Bahramsoltani M, 2014, ANAT HISTOL EMBRYOL, V43, P103, DOI 10.1111/ahe.12052
   Baker M, 2012, NAT PROTOC, V7, P89, DOI 10.1038/nprot.2011.435
   Campochiaro PA, 2015, PROG RETIN EYE RES, V49, P67, DOI 10.1016/j.preteyeres.2015.06.002
   Campochiaro PA, 2013, J MOL MED, V91, P311, DOI 10.1007/s00109-013-0993-5
   Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025
   Cobaleda C, 2007, ANNU REV GENET, V41, P41, DOI 10.1146/annurev.genet.41.110306.130146
   Connor KM, 2009, NAT PROTOC, V4, P1565, DOI 10.1038/nprot.2009.187
   De Wever O, 2014, METHODS MOL BIOL, V1070, P13, DOI 10.1007/978-1-4614-8244-4_2
   Dou GR, 2008, FASEB J, V22, P1606, DOI 10.1096/fj.07-9998com
   Dou GR, 2016, SCI REP-UK, V6, DOI 10.1038/srep28617
   Dou GR, 2012, MOL MED, V18, P47, DOI 10.2119/molmed.2011.00256
   Eilken HM, 2010, CURR OPIN CELL BIOL, V22, P617, DOI 10.1016/j.ceb.2010.08.010
   Fruttiger Marcus, 2007, Angiogenesis, V10, P77, DOI 10.1007/s10456-007-9065-1
   Gonzalez DM, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2005189
   Gras B, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092254
   Hall DMS, 2014, METHODS MOL BIOL, V1070, P1, DOI 10.1007/978-1-4614-8244-4_1
   Jonkman JEN, 2014, CELL ADHES MIGR, V8, P440, DOI 10.4161/cam.36224
   Lambert V, 2013, NAT PROTOC, V8, P2197, DOI 10.1038/nprot.2013.135
   Lamouille S, 2014, NAT REV MOL CELL BIO, V15, P178, DOI 10.1038/nrm3758
   Lee SW, 2013, MOL THER, V21, P1767, DOI 10.1038/mt.2013.146
   LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986
   Li H, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023322
   Medici D, 2012, SEMIN CANCER BIOL, V22, P379, DOI 10.1016/j.semcancer.2012.04.004
   Medici D, 2010, NAT MED, V16, P1400, DOI 10.1038/nm.2252
   Neve A, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/756078
   Nieto MA, 2002, NAT REV MOL CELL BIO, V3, P155, DOI 10.1038/nrm757
   Park JA, 2015, PLOS GENET, V11, DOI 10.1371/journal.pgen.1005324
   Pepper MS, 2001, ARTERIOSCL THROM VAS, V21, P1104, DOI 10.1161/hq0701.093685
   Pitulescu ME, 2010, NAT PROTOC, V5, P1518, DOI 10.1038/nprot.2010.113
   Rubio RG, 2016, DEV OPHTHALMOL, V55, P28, DOI 10.1159/000431129
   She XW, 2009, BMC GENOMICS, V10, DOI 10.1186/1471-2164-10-269
   Soga N, 2001, EXP CELL RES, V269, P73, DOI 10.1006/excr.2001.5295
   Tao G, 2011, DEV BIOL, V359, P209, DOI 10.1016/j.ydbio.2011.08.022
   Grande MT, 2015, NAT MED, V21, P989, DOI 10.1038/nm.3901
   Trapnell C, 2012, NAT PROTOC, V7, P562, DOI 10.1038/nprot.2012.016
   van Buul JD, 2014, CELL ADHES MIGR, V8, P108, DOI 10.4161/cam.27599
   Villarejo A, 2014, J BIOL CHEM, V289, P930, DOI 10.1074/jbc.M113.528026
   Wang K, 2010, NUCLEIC ACIDS RES, V38, DOI 10.1093/nar/gkq603
   Welch-Reardon KM, 2015, ARTERIOSCL THROM VAS, V35, P303, DOI 10.1161/ATVBAHA.114.303220
   Welch-Reardon KM, 2014, J CELL SCI, V127, P2017, DOI 10.1242/jcs.143420
   Wu ZQ, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4998
   Xu WQ, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-07978-z
   Xu XB, 2015, J BIOL CHEM, V290, P16653, DOI 10.1074/jbc.M115.636944
   Yan XC, 2016, J AM HEART ASSOC, V5, DOI 10.1161/JAHA.115.003042
   Yan XC, 2015, SCI CHINA LIFE SCI, V58, P425, DOI 10.1007/s11427-015-4834-3
   Zhao XC, 2013, NEOPLASIA, V15, P815, DOI 10.1593/neo.13550
   Zhou BHP, 2004, NAT CELL BIOL, V6, P931, DOI 10.1038/ncb1173
NR 48
TC 25
Z9 26
U1 0
U2 9
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0969-6970
EI 1573-7209
J9 ANGIOGENESIS
JI Angiogenesis
PD AUG
PY 2018
VL 21
IS 3
BP 635
EP 652
DI 10.1007/s10456-018-9614-9
PG 18
WC Peripheral Vascular Disease
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cardiovascular System & Cardiology
GA GN0HX
UT WOS:000438644400009
PM 29675549
OA hybrid
DA 2022-11-30
ER

PT J
AU Masuzzo, A
   Dinet, V
   Cavanagh, C
   Mascarelli, F
   Krantic, S
AF Masuzzo, Ambra
   Dinet, Virginie
   Cavanagh, Chelsea
   Mascarelli, Frederic
   Krantic, Slavica
TI Amyloidosis in Retinal Neurodegenerative Diseases
SO FRONTIERS IN NEUROLOGY
LA English
DT Review
DE Alzheimer's disease; age-related macular degeneration; glaucoma;
   neurodegeneration; synaptic and mitochondrial dysfunction;
   micoangiopathy; neuroinflammation
ID NECROSIS-FACTOR-ALPHA; FACTOR-H POLYMORPHISM; TGCRND8 MOUSE MODEL;
   GANGLION-CELL LOSS; A-BETA-PEPTIDE; ALZHEIMERS-DISEASE; MACULAR
   DEGENERATION; PRECURSOR PROTEIN; PARKINSONS-DISEASE; IN-VIVO
AB As a part of the central nervous system, the retina may reflect both physiological processes and abnormalities related to pathologies that affect the brain. Amyloidosis due to the accumulation of amyloid-beta (A beta) was initially regarded as a specific and exclusive characteristic of neurodegenerative alterations seen in the brain of Alzheimer's disease (AD) patients. More recently, it was discovered that amyloidosis-related alterations, similar to those seen in the brain of Alzheimer's patients, also occur in the retina. Remarkably, these alterations were identified not only in primary retinal pathologies, such as age-related macular degeneration (AMD) and glaucoma, but also in the retinas of Alzheimer's patients. In this review, we first briefly discuss the biogenesis of A beta, a peptide involved in amyloidosis. We then discuss some pathological aspects (synaptic dysfunction, mitochondrial failure, glial activation, and vascular abnormalities) related to the neurotoxic effects of A beta. We finally highlight common features shared by AD, AMD, and glaucoma in the context of A beta amyloidosis and further discuss why the retina, due to the transparency of the eye, can be considered as a "window" to the brain.
C1 [Masuzzo, Ambra; Dinet, Virginie; Mascarelli, Frederic; Krantic, Slavica] Univ Paris 06, Sorbonne Univ, Univ Paris Descartes, Ctr Rech Cordeliers,INSERM,Sorbonne Paris Cite,UM, INSERM,Sorbonne Paris Cite,UMR S 1138, Paris, France.
   [Cavanagh, Chelsea] Douglas Hosp, Res Ctr, Dept Neurosci, Montreal, PQ, Canada.
C3 Institut National de la Sante et de la Recherche Medicale (Inserm);
   UDICE-French Research Universities; Sorbonne Universite; Universite
   Paris Cite; McGill University
RP Krantic, S (通讯作者)，Univ Paris 06, Sorbonne Univ, Univ Paris Descartes, Ctr Rech Cordeliers,INSERM,Sorbonne Paris Cite,UM, INSERM,Sorbonne Paris Cite,UMR S 1138, Paris, France.
EM slavica.krantic@crc.jussieu.fr
RI Mascarelli, Frederic/L-8916-2018; Krantic, Slavica/AAZ-5156-2021;
   Krantic, Slavica/E-4802-2019
OI Krantic, Slavica/0000-0002-0785-4549; Krantic,
   Slavica/0000-0002-0785-4549; Dinet, virginie/0000-0002-5458-0253
FU Fondation pour la Recherche Medicale FRM [DVS20131228910]; Service de
   Cooperation et d'Action Culturelle du Consulat General de France a
   Quebec [65 502]
FX The research leading to this review has received funding from the
   Fondation pour la Recherche Medicale FRM DVS20131228910 and the Service
   de Cooperation et d'Action Culturelle du Consulat General de France a
   Quebec 65 502 (Cooperation France-Quebec) to SK.
CR Abramov E, 2009, NAT NEUROSCI, V12, P1567, DOI 10.1038/nn.2433
   Albuquerque MS, 2015, FRONT AGING NEUROSCI, V7, DOI [10.3389/Thagi.2015.00030, 10.3389/fnagi.2015.00030]
   Anandatheerthavarada HK, 2003, J CELL BIOL, V161, P41, DOI 10.1083/jcb.200207030
   Anderson DH, 2004, EXP EYE RES, V78, P243, DOI 10.1016/j.exer.2003.10.011
   Andreasen N, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0098153
   Apelt J, 2001, BRAIN RES, V894, P21, DOI 10.1016/S0006-8993(00)03176-0
   Apelt J, 1997, INT J DEV NEUROSCI, V15, P95, DOI 10.1016/S0736-5748(96)00073-1
   Arends YM, 2000, NEUROBIOL AGING, V21, P39, DOI 10.1016/S0197-4580(00)00094-4
   Aruoma OI, 2009, TOXICOLOGY, V256, P92, DOI 10.1016/j.tox.2008.11.007
   Asai M, 2003, BIOCHEM BIOPH RES CO, V301, P231, DOI 10.1016/S0006-291X(02)02999-6
   BEACH TG, 1989, GLIA, V2, P420, DOI 10.1002/glia.440020605
   Berisha F, 2007, INVEST OPHTH VIS SCI, V48, P2285, DOI 10.1167/iovs.06-1029
   Bertrand E, 2008, FOLIA NEUROPATHOL, V46, P255
   Biron KE, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023789
   BLANKS JC, 1989, BRAIN RES, V501, P364, DOI 10.1016/0006-8993(89)90653-7
   Blanks JC, 1996, NEUROBIOL AGING, V17, P377, DOI 10.1016/0197-4580(96)00010-3
   Brion JP, 1998, ACTA NEUROL BELG, V98, P165
   Brouillette J, 2014, CURR PHARM DESIGN, V20, P2506, DOI 10.2174/13816128113199990498
   Bruban J, 2011, NEUROBIOL DIS, V42, P55, DOI 10.1016/j.nbd.2011.01.004
   Bruban J, 2009, AGING CELL, V8, P162, DOI 10.1111/j.1474-9726.2009.00456.x
   Bubber P, 2005, ANN NEUROL, V57, P695, DOI 10.1002/ana.20474
   CACERES A, 1990, NATURE, V343, P461, DOI 10.1038/343461a0
   Cagnin A, 2001, LANCET, V358, P461, DOI 10.1016/S0140-6736(01)05625-2
   Cai J, 2012, EMBO MOL MED, V4, P980, DOI 10.1002/emmm.201101084
   Calkins MJ, 2011, BBA-MOL BASIS DIS, V1812, P507, DOI 10.1016/j.bbadis.2011.01.007
   Cavanagh C, 2013, J ALZHEIMERS DIS, V36, P233, DOI 10.3233/JAD-122131
   Chen JX, 2007, J ALZHEIMERS DIS, V12, P177
   Chen ST, 1996, J NEUROPATH EXP NEUR, V55, P1073, DOI 10.1097/00005072-199655100-00007
   Cheng X, 2014, NEUROLOGY, V82, P1707, DOI 10.1212/WNL.0000000000000403
   Chin YC, 2014, OPHTHAL EPIDEMIOL, V21, P224, DOI 10.3109/09286586.2014.926941
   Chiu K, 2012, AGE, V34, P633, DOI 10.1007/s11357-011-9260-2
   Chorostecki J, 2015, J NEUROL SCI, V355, P44, DOI 10.1016/j.jns.2015.05.007
   Chow VW, 2010, NEUROMOL MED, V12, P1, DOI 10.1007/s12017-009-8104-z
   CLARRIS HJ, 1995, DEV BRAIN RES, V88, P87, DOI 10.1016/0165-3806(95)00083-P
   Coffey PJ, 2007, P NATL ACAD SCI USA, V104, P16651, DOI 10.1073/pnas.0705079104
   Couturier J, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-72
   Cunvong K, 2013, INVEST OPHTH VIS SCI, V54, P1516, DOI 10.1167/iovs.12-10821
   CURCIO CA, 1993, INVEST OPHTH VIS SCI, V34, P3278
   Danesh-Meyer HV, 2006, NEUROLOGY, V67, P1852, DOI 10.1212/01.wnl.0000244490.07925.8b
   Dawkins E, 2014, J NEUROCHEM, V129, P756, DOI 10.1111/jnc.12675
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   De Strooper B, 2000, J CELL SCI, V113, P1857
   De Strooper B, 2016, CELL, V164, P603, DOI 10.1016/j.cell.2015.12.056
   DELACOURTE A, 1990, NEUROLOGY, V40, P33, DOI 10.1212/WNL.40.1.33
   Dentchev T, 2003, MOL VIS, V9, P184
   deSilva HAR, 1997, MOL BRAIN RES, V47, P147
   Despriet DDG, 2006, JAMA-J AM MED ASSOC, V296, P301, DOI 10.1001/jama.296.3.301
   Devraj K, 2016, J CEREBR BLOOD F MET, V36, P1281, DOI 10.1177/0271678X15606463
   Dineley KT, 2002, J BIOL CHEM, V277, P25056, DOI 10.1074/jbc.M200066200
   Dinet V, 2012, AGING CELL, V11, P683, DOI 10.1111/j.1474-9726.2012.00834.x
   Dinet V, 2011, ACTA NEUROPATHOL, V121, P351, DOI 10.1007/s00401-010-0762-2
   Ding JD, 2008, VISION RES, V48, P339, DOI 10.1016/j.visres.2007.07.025
   Dutescu RM, 2009, GRAEF ARCH CLIN EXP, V247, P1213, DOI 10.1007/s00417-009-1060-3
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   El Khoury JB, 2003, J EXP MED, V197, P1657, DOI 10.1084/jem.20021546
   El-Agnaf OMA, 2000, BIOCHEM BIOPH RES CO, V273, P1003, DOI 10.1006/bbrc.2000.3051
   Fahrenholz F, 2000, ANN NY ACAD SCI, V920, P215
   Feke Gilbert T, 2015, Alzheimers Dement (Amst), V1, P144, DOI 10.1016/j.dadm.2015.01.004
   Fernandez-Perez EJ, 2016, CURR PHARM DESIGN, V22, P1295, DOI 10.2174/138161282210160304111702
   Forloni G, 2016, MOVEMENT DISORD, V31, P771, DOI 10.1002/mds.26624
   FREDERIKSE PH, 1994, NUCLEIC ACIDS RES, V22, P5686, DOI 10.1093/nar/22.25.5686
   FUKUCHI K, 1992, BIOCHEM BIOPH RES CO, V182, P165, DOI 10.1016/S0006-291X(05)80126-3
   Glabe CG, 2006, NEUROBIOL AGING, V27, P570, DOI 10.1016/j.neurobiolaging.2005.04.017
   Glotin AL, 2008, FREE RADICAL BIO MED, V44, P1348, DOI 10.1016/j.freeradbiomed.2007.12.023
   Goldstein LE, 2003, LANCET, V361, P1258, DOI 10.1016/S0140-6736(03)12981-9
   Gomez-Ramos P, 2007, J ALZHEIMERS DIS, V11, P53
   Grimm MO, 2007, TRENDS MOL MED, V13, P337, DOI 10.1016/j.molmed.2007.06.004
   Grimm MOW, 2005, NAT CELL BIOL, V7, P1118, DOI 10.1038/ncb1313
   Guo L, 2007, P NATL ACAD SCI USA, V104, P13444, DOI 10.1073/pnas.0703707104
   Haass C, 2007, NAT REV MOL CELL BIO, V8, P101, DOI 10.1038/nrm2101
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hainsworth AH, 2015, BRAIN PATHOL, V25, P44, DOI 10.1111/bpa.12224
   Hardy J, 2002, SCIENCE, V297, P353, DOI 10.1126/science.1072994
   HARDY JA, 1992, SCIENCE, V256, P184, DOI 10.1126/science.1566067
   He P, 2007, J CELL BIOL, V178, P829, DOI 10.1083/jcb.200705042
   Heneka MT, 2007, J NEUROIMMUNOL, V184, P69, DOI 10.1016/j.jneuroim.2006.11.017
   Heneka MT, 2015, LANCET NEUROL, V14, P388, DOI 10.1016/S1474-4422(15)70016-5
   Ho CY, 2014, BRAIN PATHOL, V24, P25, DOI 10.1111/bpa.12070
   Ho T, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029892
   Hou XR, 2015, ACTA OPHTHALMOL, V93, pE100, DOI 10.1111/aos.12510
   Hsia AY, 1999, P NATL ACAD SCI USA, V96, P3228, DOI 10.1073/pnas.96.6.3228
   Hsieh H, 2006, NEURON, V52, P831, DOI 10.1016/j.neuron.2006.10.035
   Huang HM, 2003, BBA-MOL BASIS DIS, V1637, P119, DOI 10.1016/S0925-4439(02)00222-3
   Huang YM, 2011, MED HYPOTHESES, V76, P194, DOI 10.1016/j.mehy.2010.09.016
   Izzotti A, 2006, MUTAT RES-REV MUTAT, V612, P105, DOI 10.1016/j.mrrev.2005.11.001
   Jacobsen KT, 2009, CELL MOL LIFE SCI, V66, P2299, DOI 10.1007/s00018-009-0020-8
   Jain Sachin, 2015, J Ophthalmic Vis Res, V10, P178, DOI 10.4103/2008-322X.163766
   Janelsins MC, 2005, J NEUROINFLAMM, V2, DOI 10.1186/1742-2094-2-23
   Ji K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056293
   Jimenez S, 2008, J NEUROSCI, V28, P11650, DOI 10.1523/JNEUROSCI.3024-08.2008
   Jindal V, 2015, MOL NEUROBIOL, V51, P885, DOI 10.1007/s12035-014-8733-6
   Johnson LV, 2002, P NATL ACAD SCI USA, V99, P11830, DOI 10.1073/pnas.192203399
   Johnson PT, 2003, INVEST OPHTH VIS SCI, V44, P4481, DOI 10.1167/iovs.03-0436
   Kam JH, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013127
   Kamenetz F, 2003, NEURON, V37, P925, DOI 10.1016/S0896-6273(03)00124-7
   Kettenmann H, 2011, PHYSIOL REV, V91, P461, DOI 10.1152/physrev.00011.2010
   Khan SS, 2016, FRONT NEUROSCI-SWITZ, V10, DOI 10.3389/fnins.2016.00031
   King ME, 2006, J CELL BIOL, V175, P541, DOI 10.1083/jcb.200605187
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Koizumi K, 2016, CELL MOL NEUROBIOL, V36, P155, DOI 10.1007/s10571-015-0256-9
   Kook SY, 2013, TISSUE BARRIERS, V1, DOI 10.4161/tisb.23993
   Koronyo-Hamaoui M, 2011, NEUROIMAGE, V54, pS204, DOI 10.1016/j.neuroimage.2010.06.020
   Krantic S, 2014, J ALZHEIMERS DIS, V40, P237, DOI 10.3233/JAD-132105
   Kumar A, 2015, FRONT PHARMACOL, V6, DOI 10.3389/fphar.2015.00206
   Lai AY, 2015, BRAIN, V138, P1046, DOI 10.1093/brain/awv023
   Lee CYD, 2010, J NEURAL TRANSM, V117, P949, DOI 10.1007/s00702-010-0433-4
   Leske MC, 2003, ARCH OPHTHALMOL-CHIC, V121, P48
   Lesne S, 2006, NATURE, V440, P352, DOI 10.1038/nature04533
   Li SM, 2009, NEURON, V62, P788, DOI 10.1016/j.neuron.2009.05.012
   Lian H, 2016, J NEUROSCI, V36, P577, DOI 10.1523/JNEUROSCI.2117-15.2016
   Lian H, 2015, NEURON, V85, P101, DOI 10.1016/j.neuron.2014.11.018
   Liao YF, 2004, J BIOL CHEM, V279, P49523, DOI 10.1074/jbc.M402034200
   Liew G, 2006, OPHTHALMOLOGY, V113, P1481, DOI 10.1016/j.ophtha.2006.03.051
   LILLIEN L, 1994, PERSPECT DEV NEUROBI, V2, P175
   Liu SJ, 2010, J ALZHEIMERS DIS, V21, P655, DOI 10.3233/JAD-2010-091654
   Liu X, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-271
   Liu Y, 2005, BRAIN, V128, P1778, DOI 10.1093/brain/awh531
   Lo P, 2016, MICROVASC RES, V105, P109, DOI 10.1016/j.mvr.2016.02.002
   LOFFLER KU, 1995, INVEST OPHTH VIS SCI, V36, P24
   Lue LF, 2001, GLIA, V35, P72, DOI 10.1002/glia.1072
   Luibl V, 2006, J CLIN INVEST, V116, P378, DOI 10.1172/JCI25843
   Lustbader JW, 2004, SCIENCE, V304, P448, DOI 10.1126/science.1091230
   Ma KR, 2011, NEUROSCI LETT, V492, P5, DOI 10.1016/j.neulet.2011.01.035
   Mailankody P, 2015, PARKINSONISM RELAT D, V21, P1164, DOI 10.1016/j.parkreldis.2015.08.002
   Manczak M, 2011, HUM MOL GENET, V20, P2495, DOI 10.1093/hmg/ddr139
   Marcinkiewicz M, 2000, J NEUROCHEM, V75, P2133, DOI 10.1046/j.1471-4159.2000.0752133.x
   Mc Donald JM, 2010, BRAIN, V133, P1328, DOI 10.1093/brain/awq065
   McKinnon SJ, 2002, INVEST OPHTH VIS SCI, V43, P1077
   McLeod DS, 2002, INVEST OPHTH VIS SCI, V43, P1986
   Minkeviciene R, 2009, J NEUROSCI, V29, P3453, DOI 10.1523/JNEUROSCI.5215-08.2009
   Minter MR, 2016, J NEUROCHEM, V136, P457, DOI 10.1111/jnc.13411
   More SS, 2015, ACS CHEM NEUROSCI, V6, P306, DOI 10.1021/cn500242z
   Moreira PI, 2010, BBA-MOL BASIS DIS, V1802, P2, DOI 10.1016/j.bbadis.2009.10.006
   MORIN PJ, 1993, J NEUROCHEM, V61, P464
   Nalivaeva NN, 2014, FRONT AGING NEUROSCI, V6, DOI [10.3389/tnagi.2014.00235, 10.3389/fnagi.2014.00235]
   Nicoll JAR, 2003, NAT MED, V9, P448, DOI 10.1038/nm840
   Niederwolfsgruber E, 1998, J GERONTOL A-BIOL, V53, pB186, DOI 10.1093/gerona/53A.3.B186
   Ning A, 2008, INVEST OPHTH VIS SCI, V49, P5136, DOI 10.1167/iovs.08-1849
   Nozaki M, 2006, P NATL ACAD SCI USA, V103, P2328, DOI 10.1073/pnas.0408835103
   Nucci C, 2013, CURR OPIN PHARMACOL, V13, P128, DOI 10.1016/j.coph.2012.08.004
   Ohyagi Y, 2005, FASEB J, V19, P255, DOI 10.1096/fj.04-2637fje
   Oliver JE, 2002, AM J OPHTHALMOL, V133, P764, DOI 10.1016/S0002-9394(02)01403-4
   Ono K, 2009, P NATL ACAD SCI USA, V106, P14745, DOI 10.1073/pnas.0905127106
   Osborn LM, 2016, PROG NEUROBIOL, V144, P121, DOI 10.1016/j.pneurobio.2016.01.001
   Palop JJ, 2007, NEURON, V55, P697, DOI 10.1016/j.neuron.2007.07.025
   Palop JJ, 2010, NAT NEUROSCI, V13, P812, DOI 10.1038/nn.2583
   Paquet C, 2007, NEUROSCI LETT, V420, P97, DOI 10.1016/j.neulet.2007.02.090
   Parisi V, 2001, CLIN NEUROPHYSIOL, V112, P1860, DOI 10.1016/S1388-2457(01)00620-4
   Parnell Miles, 2012, Int J Alzheimers Dis, V2012, P786494, DOI 10.1155/2012/786494
   Patel M, 2008, SEMIN IMMUNOPATHOL, V30, P97, DOI 10.1007/s00281-008-0112-9
   Patel NS, 2005, J NEUROINFLAMM, V2, DOI 10.1186/1742-2094-2-9
   Perez SE, 2009, INVEST OPHTH VIS SCI, V50, P793, DOI 10.1167/iovs.08-2384
   Picone P, 2014, OXID MED CELL LONGEV, V2014, DOI 10.1155/2014/780179
   Pihlaja R, 2011, GLIA, V59, P1643, DOI 10.1002/glia.21212
   Pinazo-Duran MD, 2015, PROG BRAIN RES, V220, P127, DOI 10.1016/bs.pbr.2015.06.001
   Pinho CM, 2014, BBA-BIOENERGETICS, V1837, P1069, DOI 10.1016/j.bbabio.2014.02.007
   Puzzo D, 2008, J NEUROSCI, V28, P14537, DOI 10.1523/JNEUROSCI.2692-08.2008
   Ratnayaka JA, 2015, EYE, V29, P1013, DOI 10.1038/eye.2015.100
   Ren HG, 2011, J BIOL CHEM, V286, P35308, DOI 10.1074/jbc.M110.207134
   Rhein V, 2009, P NATL ACAD SCI USA, V106, P20057, DOI 10.1073/pnas.0905529106
   Ring S, 2007, J NEUROSCI, V27, P7817, DOI 10.1523/JNEUROSCI.1026-07.2007
   Russo R, 2016, EUR J PHARMACOL, V787, P134, DOI 10.1016/j.ejphar.2016.03.064
   SADUN AA, 1990, OPHTHALMOLOGY, V97, P9
   Saido T, 2012, CSH PERSPECT MED, V2, DOI 10.1101/cshperspect.a006379
   Salinaro AT, 2014, FRONT PHARMACOL, V5, DOI 10.3389/fphar.2014.00129
   Satue M, 2014, BRIT J OPHTHALMOL, V98, P350, DOI 10.1136/bjophthalmol-2013-304152
   Selkoe DJ, 2016, EMBO MOL MED, V8, P595, DOI 10.15252/emmm.201606210
   Shankar GM, 2008, NAT MED, V14, P837, DOI 10.1038/nm1782
   Shankar GM, 2007, J NEUROSCI, V27, P2866, DOI 10.1523/JNEUROSCI.4970-06.2007
   Shields MB, 2008, CURR OPIN OPHTHALMOL, V19, P85, DOI 10.1097/ICU.0b013e3282f3919b
   Sipe JD, 2000, J STRUCT BIOL, V130, P88, DOI 10.1006/jsbi.2000.4221
   Sivak JM, 2013, INVEST OPHTH VIS SCI, V54, P871, DOI 10.1167/iovs.12-10827
   Snyder EM, 2005, NAT NEUROSCI, V8, P1051, DOI 10.1038/nn1503
   Solodkin A, 1996, J NEUROSCI, V16, P3311
   Sonkusare SK, 2005, PHARMACOL RES, V51, P1, DOI 10.1016/j.phrs.2004.05.005
   Sorrentino G, 2007, NEUROL SCI, V28, P63, DOI 10.1007/s10072-007-0789-x
   Sparrow JR, 2010, ADV EXP MED BIOL, V703, P63, DOI 10.1007/978-1-4419-5635-4_5
   Stewart CR, 2010, NAT IMMUNOL, V11, P155, DOI 10.1038/ni.1836
   Sullivan RKP, 2007, INVEST OPHTH VIS SCI, V48, P2782, DOI 10.1167/iovs.06-1283
   Sun LH, 2015, J NEUROCHEM, V134, P1139, DOI 10.1111/jnc.13212
   Sunderland T, 2003, JAMA-J AM MED ASSOC, V289, P2094, DOI 10.1001/jama.289.16.2094
   Suo Z, 2007, NEUROBIOL AGING, V28, P1873, DOI 10.1016/j.neurobiolaging.2006.08.013
   Surguchev A, 2010, BRAIN RES BULL, V81, P12, DOI 10.1016/j.brainresbull.2009.09.015
   Swerdlow RH, 2010, J ALZHEIMERS DIS, V20, pS265, DOI 10.3233/JAD-2010-100339
   Takahashi H, 2010, BRAIN STRUCT FUNCT, V214, P145, DOI 10.1007/s00429-010-0242-4
   Tamagnini F, 2015, HIPPOCAMPUS, V25, P786, DOI 10.1002/hipo.22403
   Tanabe C, 2007, BIOCHEM BIOPH RES CO, V352, P111, DOI 10.1016/j.bbrc.2006.10.181
   Thinakaran G, 2008, J BIOL CHEM, V283, P29615, DOI 10.1074/jbc.R800019200
   Van Nostrand WE, 2016, BBA-MOL BASIS DIS, V1862, P1018, DOI 10.1016/j.bbadis.2015.10.020
   Vargas JLC, 2015, J NEUROSCI, V35, P12088, DOI 10.1523/JNEUROSCI.1273-15.2015
   Venkataraman ST, 2010, MICROCIRCULATION, V17, P568, DOI 10.1111/j.1549-8719.2010.00045.x
   Vezzani A, 2005, EPILEPSIA, V46, P1724, DOI 10.1111/j.1528-1167.2005.00298.x
   Vinters HV, 2015, ANNU REV PATHOL-MECH, V10, P291, DOI 10.1146/annurev-pathol-020712-163927
   Volz C, 2015, EUR J PHARM BIOPHARM, V95, P158, DOI 10.1016/j.ejpb.2015.02.020
   Walsh DM, 2002, NATURE, V416, P535, DOI 10.1038/416535a
   Walsh DT, 2005, NEUROPATH APPL NEURO, V31, P491, DOI 10.1111/j.1365-2990.2005.00666.x
   Walsh DT, 2002, NEUROBIOL DIS, V10, P20, DOI 10.1006/nbdi.2002.0485
   Williams Michael A, 2015, Alzheimers Dement (Amst), V1, P229
   Wirths O, 2001, NEUROSCI LETT, V306, P116, DOI 10.1016/S0304-3940(01)01876-6
   Wolfe MS, 2008, NEUROTHERAPEUTICS, V5, P391, DOI 10.1016/j.nurt.2008.05.010
   Wright AL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059586
   Xiong K, 2007, EXP BRAIN RES, V181, P435, DOI 10.1007/s00221-007-0943-y
   Yamada M, 2015, J STROKE, V17, P17, DOI 10.5853/jos.2015.17.1.17
   Yamamoto M, 2007, AM J PATHOL, V170, P680, DOI 10.2353/ajpath.2007.060378
   Yamazaki T, 1996, J CELL SCI, V109, P999
   Yao ZX, 2002, FASEB J, V16, P1677, DOI 10.1096/fj.02-0285fje
   Yoneda S, 2005, JPN J OPHTHALMOL, V49, P106, DOI 10.1007/s10384-004-0156-x
   Yoshida T, 2005, J CLIN INVEST, V115, P2793, DOI 10.1172/JCI24635
   Yucel YH, 2003, PROG RETIN EYE RES, V22, P465, DOI 10.1016/S1350-9462(03)00026-0
   Yucel YH, 2000, ARCH OPHTHALMOL-CHIC, V118, P378
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
   Zetterberg M, 2008, AM J MED GENET B, V147B, P720, DOI 10.1002/ajmg.b.30668
   Zhang DF, 2016, NEUROPSYCHOPHARMACOL, V41, P1034, DOI 10.1038/npp.2015.232
   Zhang W, 2012, NEUROBIOL AGING, V33, P2661, DOI 10.1016/j.neurobiolaging.2011.12.023
NR 215
TC 25
Z9 26
U1 1
U2 23
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015,
   SWITZERLAND
SN 1664-2295
J9 FRONT NEUROL
JI Front. Neurol.
PD AUG 8
PY 2016
VL 7
AR 127
DI 10.3389/fneur.2016.00127
PG 17
WC Clinical Neurology; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA DS9AD
UT WOS:000381073300001
PM 27551275
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Prunty, MC
   Aung, MH
   Hanif, AM
   Allen, RS
   Chrenek, MA
   Boatright, JH
   Thule, PM
   Kundu, K
   Murthy, N
   Pardue, MT
AF Prunty, Megan C.
   Aung, Moe H.
   Hanif, Adam M.
   Allen, Rachael S.
   Chrenek, Micah A.
   Boatright, Jeffrey H.
   Thule, Peter M.
   Kundu, Kousik
   Murthy, Niren
   Pardue, Machelle T.
TI In Vivo Imaging of Retinal Oxidative Stress Using a Reactive Oxygen
   Species-Activated Fluorescent Probe
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE oxidative stress; fluorescent probes; retinal degeneration
ID BIOMATERIAL-ASSOCIATED INFLAMMATION; OCULAR BIOMARKERS; CORNEAL LESIONS;
   DAMAGE; LIGHT; SUPEROXIDE; ANTIOXIDANTS; DYSFUNCTION; MECHANISMS;
   DEFICITS
AB PURPOSE. In vivo methods for detecting oxidative stress in the eye would improve screening and monitoring of the leading causes of blindness: diabetic retinopathy, glaucoma, and age-related macular degeneration.
   METHODS. To develop an in vivo biomarker for oxidative stress in the eye, we tested the efficacy of a reactive oxygen species (ROS)-activated, near-infrared hydrocyanine-800CW (H-800CW) fluorescent probe in light-induced retinal degeneration (LIRD) mouse models. After intravitreal delivery in LIRD rats, fluorescent microscopy was used to confirm that the oxidized H-800CW appeared in the same retinal layers as an established ROS marker (dichlorofluorescein).
   RESULTS. Dose-response curves of increasing concentrations of intravenously injected H-800CW demonstrated linear increases in both intensity and total area of fundus hyperfluorescence in LIRD mice, as detected by scanning laser ophthalmoscopy. Fundus hyperfluorescence also correlated with the duration of light damage and functional deficits in vision after LIRD. In LIRD rats with intravitreal injections of H-800CW, fluorescent labeling was localized to photoreceptor inner segments, similar to dichlorofluorescein.
   CONCLUSIONS. Hydrocyanine-800CW detects retinal ROS in vivo and shows potential as a novel biomarker for ROS levels in ophthalmic diseases.
C1 [Prunty, Megan C.; Aung, Moe H.; Chrenek, Micah A.; Boatright, Jeffrey H.; Pardue, Machelle T.] Emory Univ, Dept Ophthalmol, Atlanta, GA 30322 USA.
   [Hanif, Adam M.; Allen, Rachael S.; Boatright, Jeffrey H.; Pardue, Machelle T.] Atlanta VA Ctr Visual & Neurocognit Rehabil, Atlanta, GA USA.
   [Thule, Peter M.] Atlanta VA Med Ctr, Biomed Res, Atlanta, GA USA.
   [Thule, Peter M.] Emory Univ, Dept Med, Atlanta, GA 30322 USA.
   [Kundu, Kousik] LI COR, Lincoln, NE USA.
   [Murthy, Niren] Univ Calif Berkeley, Dept Bioengn, Berkeley, CA 94720 USA.
C3 Emory University; US Department of Veterans Affairs; Veterans Health
   Administration (VHA); Atlanta VA Health Care System; Atlanta VA Medical
   Center; Emory University; University of California System; University of
   California Berkeley
RP Pardue, MT (通讯作者)，Atlanta VA Med Ctr, Res Serv Oph 151, Clairmont Rd, Decatur, GA 30033 USA.
EM mpardue@emory.edu
RI Pardue, Machelle T/N-9795-2013
FU Department of Veterans Affairs Rehab RD Merit Award [E0951-R];
   Department of Veterans Affairs Research Career Scientist Award [C6774S];
   National Institutes of Health (NIH) [EY016435]; NIH [R01 EY014026, P30
   EY006360]; Research to Prevent Blindness; Abraham J. and Phyllis Katz
   Foundation; NATIONAL EYE INSTITUTE [R01EY014026, R01EY016435,
   P30EY006360] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL
   MEDICAL SCIENCES [T32GM008169] Funding Source: NIH RePORTER; Veterans
   Affairs [I01RX000951] Funding Source: NIH RePORTER
FX Supported by Department of Veterans Affairs Rehab R&D Merit Award
   E0951-R (MTP) and Research Career Scientist Award C6774S (MTP), National
   Institutes of Health (NIH) EY016435 (MTP), NIH R01 EY014026 (JHB), NIH
   P30 EY006360, departmental grant from Research to Prevent Blindness, and
   a grant from the Abraham J. and Phyllis Katz Foundation (JHB).
CR Allen RS, 2014, EXP NEUROL, V254, P206, DOI 10.1016/j.expneurol.2014.02.005
   Arden GB, 2012, DOC OPHTHALMOL, V124, P15, DOI 10.1007/s10633-011-9305-y
   Aung MH, 2014, J NEUROSCI, V34, P726, DOI 10.1523/JNEUROSCI.3483-13.2014
   Aung MH, 2013, INVEST OPHTH VIS SCI, V54, P1370, DOI 10.1167/iovs.12-10927
   Blake R, 2014, BBA-GEN SUBJECTS, V1840, P1404, DOI 10.1016/j.bbagen.2013.11.007
   Blasiak J, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/768026
   Boatright JH, 2006, MOL VIS, V12, P1706
   Demontis GC, 2002, INVEST OPHTH VIS SCI, V43, P2421
   Dinjaski N, 2014, BIOMATERIALS, V35, P14, DOI 10.1016/j.biomaterials.2013.09.059
   Pinazo-Duran MD, 2014, CLIN INTERV AGING, V9, P637, DOI 10.2147/CIA.S52662
   Du Y, 2013, P NATL ACAD SCI USA, V110, P16586, DOI 10.1073/pnas.1314575110
   Elahy M, 2014, J ENDOCRINOL, V222, pR129, DOI 10.1530/JOE-14-0065
   Frost S, 2010, J ALZHEIMERS DIS, V22, P1, DOI 10.3233/JAD-2010-100819
   Frost SM, 2014, MED J AUSTRALIA, V201, P128, DOI 10.5694/mja14.00924
   Giorgio M, 2007, NAT REV MOL CELL BIO, V8, p722A
   Goodson P, 2012, AM J PHYSIOL-LUNG C, V302, pL410, DOI 10.1152/ajplung.00260.2011
   GUILLET R, 1988, INVEST OPHTH VIS SCI, V29, P949
   Kevany BM, 2010, PHYSIOLOGY, V25, P8, DOI 10.1152/physiol.00038.2009
   Kiang AS, 2014, ADV EXP MED BIOL, V801, P783, DOI 10.1007/978-1-4614-3209-8_98
   Kim JY, 2011, J CONTROL RELEASE, V156, P398, DOI 10.1016/j.jconrel.2011.07.017
   Komeima K, 2007, J CELL PHYSIOL, V213, P809, DOI 10.1002/jcp.21152
   Kundu K, 2010, ANGEW CHEM INT EDIT, V49, P6134, DOI 10.1002/anie.201002228
   Kundu K, 2009, ANGEW CHEM INT EDIT, V48, P299, DOI 10.1002/anie.200804851
   KUTTY RK, 1995, P NATL ACAD SCI USA, V92, P1177, DOI 10.1073/pnas.92.4.1177
   Lawson EC, 2014, J NEUROSCI, V34, P2406, DOI 10.1523/JNEUROSCI.2062-13.2014
   Lee D, 2014, APOPTOSIS, V19, P603, DOI 10.1007/s10495-013-0956-x
   Lin PW, 2009, FREE RADICAL BIO MED, V47, P1205, DOI 10.1016/j.freeradbiomed.2009.07.033
   Liu Q, 2007, INVEST OPHTH VIS SCI, V48, P4580, DOI 10.1167/iovs.07-0170
   Magalotti S, 2013, MOL IMAGING BIOL, V15, P423, DOI 10.1007/s11307-013-0614-2
   Maleki S, 2013, J BIOMED OPT, V18, DOI 10.1117/1.JBO.18.1.016004
   Marshall MV, 2010, MOL IMAGING BIOL, V12, P583, DOI 10.1007/s11307-010-0317-x
   Mocko JA, 2011, INVEST OPHTH VIS SCI, V52, P4223, DOI 10.1167/iovs.10-6750
   Munzel T, 2002, ARTERIOSCL THROM VAS, V22, P1761, DOI 10.1161/01.ATV.0000034022.11764.EC
   Noell W K, 1966, Invest Ophthalmol, V5, P450
   Organisciak DT, 2010, PROG RETIN EYE RES, V29, P113, DOI 10.1016/j.preteyeres.2009.11.004
   Osborne NN, 2013, CURR OPIN PHARMACOL, V13, P16, DOI 10.1016/j.coph.2012.09.002
   Park SW, 2012, INVEST OPHTH VIS SCI, V53, P7718, DOI 10.1167/iovs.11-8790
   Payne AJ, 2014, INT J MOL SCI, V15, P1865, DOI 10.3390/ijms15021865
   Pinazo-Duran MD, 2013, CURR OPIN PHARMACOL, V13, P98, DOI 10.1016/j.coph.2012.10.007
   Pitocco D, 2013, INT J MOL SCI, V14, P21525, DOI 10.3390/ijms141121525
   PRITSOS CA, 1985, ANAL BIOCHEM, V150, P294, DOI 10.1016/0003-2697(85)90513-5
   Prusky GT, 2000, VISION RES, V40, P2201, DOI 10.1016/S0042-6989(00)00081-X
   Prusky GT, 2004, INVEST OPHTH VIS SCI, V45, P4611, DOI 10.1167/iovs.04-0541
   Rayner CL, 2014, EXP EYE RES, V129, P48, DOI 10.1016/j.exer.2014.10.013
   Schoknecht K, 2014, J CEREBR BLOOD F MET, V34, P1791, DOI 10.1038/jcbfm.2014.147
   Seeliger MW, 2005, VISION RES, V45, P3512, DOI 10.1016/j.visres.2005.08.014
   Selvam S, 2011, BIOMATERIALS, V32, P7785, DOI 10.1016/j.biomaterials.2011.07.020
   Suri S, 2015, J BIOMED MATER RES A, V103, P76, DOI 10.1002/jbm.a.35162
   Tas A, 2015, ACTA OPHTHALMOL, V93, pE507, DOI 10.1111/aos.12614
   Turner PV, 2005, COMPARATIVE MED, V55, P175
   Willett NJ, 2011, ANTIOXID REDOX SIGN, V15, P1369, DOI 10.1089/ars.2010.3550
   Williams M, 2013, CURR DIABETES REP, V13, P481, DOI 10.1007/s11892-013-0384-x
   Xie LQ, 2012, ARTHRITIS RHEUM-US, V64, P1899, DOI 10.1002/art.34370
   Zarebski M, 2014, PHOTOCHEM PHOTOBIOL, V90, P709, DOI 10.1111/php.12216
   Zielonka J, 2008, NAT PROTOC, V3, P8, DOI 10.1038/nprot.2007.473
NR 55
TC 30
Z9 30
U1 0
U2 25
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD SEP
PY 2015
VL 56
IS 10
BP 5862
EP 5870
DI 10.1167/iovs.15-16810
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DB3QL
UT WOS:000368426300020
PM 26348635
OA Green Published
DA 2022-11-30
ER

PT J
AU Nakamura, S
   Hayashi, K
   Takizawa, H
   Murase, T
   Tsuruma, K
   Shimazawa, M
   Kakuta, H
   Nagasawa, H
   Hara, H
AF Nakamura, Shinsuke
   Hayashi, Kei
   Takizawa, Haruka
   Murase, Tetsuji
   Tsuruma, Kazuhiro
   Shimazawa, Masamitsu
   Kakuta, Hiroki
   Nagasawa, Hideko
   Hara, Hideaki
TI An Arylidene-Thiazolidinedione Derivative, GPU-4, without PPAR gamma
   Activation, Reduces Retinal Neovascularization
SO CURRENT NEUROVASCULAR RESEARCH
LA English
DT Article
DE Anti-oxidative effect; human retinal microvascular endothelial cell;
   oxygen-induced retinopathy model; reactive oxygen species;
   thiazolidinedione; vascular endothelial growth factor
ID ENDOTHELIAL GROWTH-FACTOR; OXIDATIVE STRESS; DIABETIC-RETINOPATHY;
   OXIDASE ACTIVITY; NAD(P)H OXIDASE; NADPH OXIDASE; NITRIC-OXIDE;
   IN-VITRO; ANGIOGENESIS; OXYGEN
AB Retinal angiogenesis is a leading cause of blindness, including retinopathy of prematurity, diabetic retinopathy, and age-related macular degeneration. Vascular endothelial growth factor (VEGF) is one of the major angiogenesis factors, and induces endothelial cell proliferation and migration. VEGF stimulates NADPH oxidase to produce reactive oxygen species (ROS), and ROS induce the transcription factors and genes involved in angiogenesis. In the present study, we demonstrated that GPU-4, 5-arylidene-2,4-thiazolidinedione derivative, demonstrates anti-angiogenic activity regarding human retinal microvascular endothelial cells (HRMECs) and retinal neovascularization in a mouse model of retinopathy of prematurity. GPU-4 inhibited the VEGF-induced radicals, proliferation, and migration in HRMECs without a PPAR.-mediated effect. Furthermore, systemic administration of GPU-4 inhibited the development of retinal neovascularization in a murine oxygen-induced retinopathy model but did not exert revascularization of the capillary-free area, which shows normal physiological revascularization. These findings indicate that GPU-4 suppressed in vitro and in vivo retinal neovascularization partly by a radical scavenging effect, suggesting that GPU-4 might be a potential therapeutic agent candidate for proliferative diseases of the retinal vasculature.
C1 [Nakamura, Shinsuke; Takizawa, Haruka; Tsuruma, Kazuhiro; Shimazawa, Masamitsu; Hara, Hideaki] Gifu Pharmaceut Univ, Dept Biofunct Evaluat, Gifu 5011196, Japan.
   [Hayashi, Kei; Murase, Tetsuji; Nagasawa, Hideko] Gifu Pharmaceut Univ, Dept Organ Chem, Gifu 5011196, Japan.
   [Kakuta, Hiroki] Okayama Univ, Div Pharmaceut Sci, Grad Sch Med Dent & Pharmaceut Sci, Okayama, Japan.
C3 Gifu Pharmaceutical University; Gifu Pharmaceutical University; Okayama
   University
RP Hara, H (通讯作者)，Gifu Pharmaceut Univ, Dept Biofunct Evaluat, 1-25-4 Daigaku Nishi, Gifu 5011196, Japan.
EM hidehara@gifu-pu.ac.jp
RI Kakuta, Hiroki/X-6328-2018; Kakuta, Hiroki/F-8066-2011; Kakuta,
   Hiroki/AAF-3991-2019
OI Kakuta, Hiroki/0000-0002-3633-8121; Kakuta, Hiroki/0000-0002-3633-8121
CR Abid MR, 2001, FASEB J, V15, P2548, DOI 10.1096/fj.01-0338fje
   AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203
   Al-Shabrawey M, 2005, AM J PATHOL, V167, P599, DOI 10.1016/S0002-9440(10)63001-5
   Alvarez Y, 2007, BMC DEV BIOL, V7, DOI 10.1186/1471-213X-7-114
   Asikainen TM, 2001, PEDIATR PULM, V32, P193, DOI 10.1002/ppul.1108
   Baba T, 2001, DIABETES CARE, V24, P953, DOI 10.2337/diacare.24.5.953
   Biscetti F, 2009, NUTR METAB CARDIOVAS, V19, P751, DOI 10.1016/j.numecd.2009.04.011
   Caldwell RB, 2005, CURR DRUG TARGETS, V6, P511, DOI 10.2174/1389450054021981
   CHANLING TL, 1995, INVEST OPHTH VIS SCI, V36, P1201
   Chikaraishi Y, 2007, EXP EYE RES, V84, P529, DOI 10.1016/j.exer.2006.11.007
   Chua CC, 1998, BBA-MOL CELL RES, V1405, P29, DOI 10.1016/S0167-4889(98)90093-3
   Colavitti R, 2002, J BIOL CHEM, V277, P3101, DOI 10.1074/jbc.M107711200
   Ellis EA, 1998, FREE RADICAL BIO MED, V24, P111, DOI 10.1016/S0891-5849(97)00202-5
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Folkman J, 2006, ANNU REV MED, V57, P1, DOI 10.1146/annurev.med.57.121304.131306
   Fruttiger M, 2002, INVEST OPHTH VIS SCI, V43, P522
   Fuchtenbusch M, 2000, EXP CLIN ENDOCR DIAB, V108, P151, DOI 10.1055/s-2000-7737
   Gariano RF, 2005, NATURE, V438, P960, DOI 10.1038/nature04482
   Goetze S, 1999, FEBS LETT, V452, P277, DOI 10.1016/S0014-5793(99)00624-9
   Harfouche R, 2005, FASEB J, V19, P1728, DOI 10.1096/fj.04-3621fje
   Hartnett ME, 2010, DOC OPHTHALMOL, V120, P25, DOI 10.1007/s10633-009-9181-x
   Higuchi A, 2010, ARTERIOSCL THROM VAS, V30, P46, DOI 10.1161/ATVBAHA.109.198465
   Hirsch IB, 1999, ARCH INTERN MED, V159, P1811, DOI 10.1001/archinte.159.15.1811
   Hossain SU, 2007, BIOORG MED CHEM LETT, V17, P1149, DOI 10.1016/j.bmcl.2006.12.040
   Ikeda S, 2005, CIRC RES, V96, P467, DOI 10.1161/01.RES.0000158286.51045.16
   Iwaki M, 2003, DIABETES, V52, P1655, DOI 10.2337/diabetes.52.7.1655
   Jeong TS, 2004, BIOORGAN MED CHEM, V12, P4017, DOI 10.1016/j.bmc.2004.06.001
   Kroll J, 1997, J BIOL CHEM, V272, P32521, DOI 10.1074/jbc.272.51.32521
   Lelkes PI, 1998, ADV EXP MED BIOL, V454, P295
   Lin MT, 2003, MOL PHARMACOL, V64, P1029, DOI 10.1124/mol.64.5.1029
   Luczak K, 2004, CELL BIOL INT, V28, P483, DOI 10.1016/j.cellbi.2004.03.004
   Maeda N, 2001, DIABETES, V50, P2094, DOI 10.2337/diabetes.50.9.2094
   Miller TW, 2009, CHEM REV, V109, P3099, DOI 10.1021/cr8005125
   Murata T, 2001, ARCH OPHTHALMOL-CHIC, V119, P709, DOI 10.1001/archopht.119.5.709
   Nakajima Y, 2008, J PHARM PHARMACOL, V60, P1365, DOI 10.1211/jpp/60.10.0013
   Nakamura S, 2010, EXP EYE RES, V90, P137, DOI 10.1016/j.exer.2009.09.022
   Nissen SE, 2007, NEW ENGL J MED, V356, P2457, DOI 10.1056/NEJMoa072761
   Nolte RT, 1998, NATURE, V395, P137, DOI 10.1038/25931
   Parenti A, 1998, J BIOL CHEM, V273, P4220, DOI 10.1074/jbc.273.7.4220
   Penn JS, 1997, FREE RADICAL BIO MED, V22, P977, DOI 10.1016/S0891-5849(96)00479-0
   Shono T, 1996, MOL CELL BIOL, V16, P4231
   Stone JR, 2002, ENDOTHELIUM-J ENDOTH, V9, P231, DOI 10.1080/10623320214733
   Thomas ML, 2001, ANN PHARMACOTHER, V35, P123
   Ushio-Fukai M, 2002, CIRC RES, V91, P1160, DOI 10.1161/01.RES.0000046227.65158.F8
   Ushio-Fukai M, 2006, CARDIOVASC RES, V71, P226, DOI 10.1016/j.cardiores.2006.04.015
   Vartanian AA, 2007, MELANOMA RES, V17, P370, DOI 10.1097/CMR.0b013e3282f1d2ec
   Yamaoka-Tojo M, 2004, CIRC RES, V95, P276, DOI 10.1161/01.RES.0000136522.58649.60
   Yi JH, 2008, BRAIN RES, V1244, P164, DOI 10.1016/j.brainres.2008.09.074
NR 48
TC 5
Z9 5
U1 0
U2 3
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1567-2026
EI 1875-5739
J9 CURR NEUROVASC RES
JI Curr. Neurovasc. Res.
PD FEB
PY 2011
VL 8
IS 1
BP 25
EP 34
DI 10.2174/156720211794520224
PG 10
WC Clinical Neurology; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA 720SM
UT WOS:000287300900003
PM 21208163
DA 2022-11-30
ER

PT J
AU Francis, PJ
   Appukuttan, B
   Simmons, E
   Landauer, N
   Stoddard, J
   Hamon, S
   Ott, J
   Ferguson, B
   Klein, M
   Stout, JT
   Neuringer, M
AF Francis, Peter J.
   Appukuttan, Binoy
   Simmons, Emily
   Landauer, Noelle
   Stoddard, Jonathan
   Hamon, Sara
   Ott, Jurg
   Ferguson, Betsy
   Klein, Michael
   Stout, J. Timothy
   Neuringer, Martha
TI Rhesus monkeys and humans share common susceptibility genes for
   age-related macular disease
SO HUMAN MOLECULAR GENETICS
LA English
DT Article
ID DEGENERATION; VARIANT; HTRA1; MACULOPATHY; DRUSEN
AB Age-related macular degeneration (AMD), a complex multigenic disorder and the most common cause of vision loss in the elderly, is associated with polymorphisms in the LOC387715/ARMS2 and HTRA1 genes on 10q26. Like humans, macaque monkeys possess a macula and develop age-related macular pathologies including drusen, the phenotypic hallmark of AMD. We genotyped a cohort of 137 unrelated rhesus macaques with and without macular drusen. As in humans, one variant within LOC387715/ARMS2 and one in HTRA1 were significantly associated with affected status. HTRA1 and the predicted LOC387715/ARMS2 gene were both transcribed in rhesus and human retina and retinal pigment epithelium. Among several primate species, orthologous exons for the human LOC387715/ARMS2 gene were present only in Old World monkeys and apes. In functional analyses, the disease-associated HTRA1 polymorphism resulted in a 2-fold increase in gene expression, supporting a role in pathogenesis. These results demonstrate that two genes associated with AMD in humans are also associated with macular disease in rhesus macaques and that one of these genes is specific to higher primates. This is the first evidence that humans and macaques share the same genetic susceptibility factors for a common complex disease.
C1 [Francis, Peter J.; Appukuttan, Binoy; Simmons, Emily; Stoddard, Jonathan; Klein, Michael; Stout, J. Timothy; Neuringer, Martha] Oregon Hlth & Sci Univ, Casey Eye Inst, Portland, OR 97239 USA.
   [Landauer, Noelle; Ferguson, Betsy; Neuringer, Martha] Oregon Hlth & Sci Univ, Oregon Natl Primate Res Ctr, Beaverton, OR USA.
   [Hamon, Sara; Ott, Jurg] Rockefeller Univ, Lab Stat Genet, New York, NY 10021 USA.
   [Ott, Jurg] Chinese Acad Sci, Beijing Inst Genom, Beijing, Peoples R China.
C3 Oregon Health & Science University; Oregon Health & Science University;
   Oregon National Primate Research Center; Rockefeller University; Chinese
   Academy of Sciences; Beijing Institute of Genomics, CAS
RP Francis, PJ (通讯作者)，Oregon Hlth & Sci Univ, Casey Eye Inst, 3375 SW Terwilliger Blvd, Portland, OR 97239 USA.
EM francisp@ohsu.edu
OI Blum, Emily/0000-0002-3110-9944
FU The Foundation Fighting Blindness, Owing Mills; National Institutes of
   Health (NIH) National Eye Institute [R01-EY12203]; National Center for
   Research Resources [RR-00163]; Clayton Foundation; Macular Degeneration
   Center Research Fund of the Casey Eye Institute; Research to Prevent
   Blindness, New York, NY; China NSF [30730057]; NATIONAL CENTER FOR
   RESEARCH RESOURCES [P51RR000163] Funding Source: NIH RePORTER; NATIONAL
   EYE INSTITUTE [R01EY012203] Funding Source: NIH RePORTER
FX This work was supported by grants from The Foundation Fighting
   Blindness, Owing Mills, MD (M.N., P.J.F.); the National Institutes of
   Health (NIH) National Eye Institute R01-EY12203 (M.K.) and National
   Center for Research Resources RR-00163 (M.N., N.L., B.F.); the Clayton
   Foundation (J.T.S.); the Macular Degeneration Center Research Fund of
   the Casey Eye Institute (M.K., P.J.F.), Research to Prevent Blindness,
   New York, NY (P.J.F.) and China NSF grant no. 30730057 (J.O.).
CR Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   ELMOFTY A, 1978, EXP EYE RES, V27, P499, DOI 10.1016/0014-4835(78)90027-1
   FERGUSON B, 2007, BMC GENOMICS, V8
   Francis PJ, 2007, HUM HERED, V63, P212, DOI 10.1159/000100046
   HOPE GM, 1992, BRIT J OPHTHALMOL, V76, P11, DOI 10.1136/bjo.76.1.11
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Kanda A, 2007, P NATL ACAD SCI USA, V104, P16227, DOI 10.1073/pnas.0703933104
   Kassoff A, 1999, CONTROL CLIN TRIALS, V20, P573
   Klein Michael L, 2003, Ophthalmol Clin North Am, V16, P567, DOI 10.1016/S0896-1549(03)00063-4
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   Seddon JM, 2007, JAMA-J AM MED ASSOC, V297, P1793, DOI 10.1001/jama.297.16.1793
   STAFFORD TJ, 1984, OPHTHALMOLOGY, V91, P513
   Touriol C, 2003, BIOL CELL, V95, P169, DOI 10.1016/S0248-4900(03)00033-9
   Umeda S, 2005, FASEB J, V19, P1683, DOI 10.1096/fj.04-3525fje
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
NR 16
TC 72
Z9 72
U1 0
U2 6
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0964-6906
J9 HUM MOL GENET
JI Hum. Mol. Genet.
PD SEP 1
PY 2008
VL 17
IS 17
BP 2673
EP 2680
DI 10.1093/hmg/ddn167
PG 8
WC Biochemistry & Molecular Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA 343PW
UT WOS:000258867000009
PM 18535016
OA Green Published, Bronze
DA 2022-11-30
ER

PT J
AU Potter, MJ
   Szabo, SM
   Ho, T
AF Potter, Michael J.
   Szabo, Shelagh M.
   Ho, Terrence
TI Combined photodynamic therapy and intravitreal triamcinolone for the
   treatment of myopic choroidal neovascularization in a 13-year-old girl
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE pathologic myopia; photodynamic therapy; verteporfin; intravitreal
   triamcinolone
ID AGE; VERTEPORFIN
AB Combination photodynamic therapy with verteporfin (PDT) and intravitreal triamcinolone acetonide (IVT) is currently being investigated as a treatment for choroidal neovascularization (CNV) due to age-related macular degeneration. However, PDT with triamcinolone has never previously been described in the treatment of CNV secondary to pathologic myopia, or in a young person. We describe the case of a young girl treated with combination PDT and IVT for a myopic subfoveal CNV membrane.
   This study was an interventional case report. The medical chart of a 13-year-old child treated with combination PDT with IVT was reviewed for changes in visual acuity on the ETDRS chart, CNV leakage on fluorescein angiography, and adverse events reported.
   ETDRS visual acuity improved from 20/80-2 to 20/25 in the right eye over 7 months following two treatments of a myopic CNV lesion with combination PDT and IVT. Following treatment, an inactive scar with no further leakage was visible on fluorescein angiography. An increase in intraocular pressure was associated with the second IVT treatment, and successfully treated with topical therapy.
   Combination PDT with IVT may be considered under appropriate circumstances to treat children with CNV.
C1 Univ British Columbia, Dept Ophthalmol & Visual Sci, VH Eye Care Ctr, Vancouver, BC V5Z 3N9, Canada.
C3 University of British Columbia
RP Potter, MJ (通讯作者)，Univ British Columbia, Dept Ophthalmol & Visual Sci, VH Eye Care Ctr, Sect B,2550 Willow St, Vancouver, BC V5Z 3N9, Canada.
EM mpotter@interchange.ubc.ca
CR Axer-Siegel R, 2004, AM J OPHTHALMOL, V138, P602, DOI 10.1016/j.ajo.2004.05.074
   Blinder K, 2003, RETINA-J RET VIT DIS, V23, P14
   Blinder KJ, 2003, OPHTHALMOLOGY, V110, P667, DOI 10.1016/S0161-6420(02)01998-X
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Mimouni KF, 2003, AM J OPHTHALMOL, V135, P900, DOI 10.1016/S0002-9394(02)02224-9
   Rechtman E, 2004, BRIT J OPHTHALMOL, V88, P344, DOI 10.1136/bjo.2003.027177
   Spaide RF, 2003, OPHTHALMOLOGY, V110, P1517, DOI 10.1016/S0161-6420(03)00544-X
   Yoshida T, 2002, OPHTHALMOLOGY, V109, P712, DOI 10.1016/S0161-6420(01)01007-7
NR 8
TC 18
Z9 21
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD MAY
PY 2006
VL 244
IS 5
BP 639
EP 641
DI 10.1007/s00417-005-0115-3
PG 3
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 044HH
UT WOS:000237662500016
PM 16175378
DA 2022-11-30
ER

PT J
AU Lee, CJ
   Blumenkranz, MS
   Fishman, HA
   Bent, SF
AF Lee, CJ
   Blumenkranz, MS
   Fishman, HA
   Bent, SF
TI Controlling cell adhesion on human tissue by soft lithography
SO LANGMUIR
LA English
DT Article
ID SELF-ASSEMBLED MONOLAYERS; MICROFABRICATION; TRANSPLANTATION; BIOLOGY
AB Soft lithographic techniques are widely used for fundamental biological applications. This study investigates the extension of soft lithography for use on human tissue to create a biological implant by systematically studying the effect of pattern size on cellular morphology. We focus on mimicking a key layer of the physiological retina with an organized monolayer of epithelial cells to act as a new treatment for age-related macular degeneration. We show that epithelial cells can be confined to cytophilic islands defined on lens capsule by the inhibitory polymer poly(vinyl alcohol). In addition, as the size of the cytophilic islands grows, both the fraction of islands with cells attached and the number of cells adhered to each island increase. High densities of cell adhesion and single cell attachment per island were achieved with a 25 mum pattern size. Over time, the cells spread over the 5 mum wide barriers to form a confluent monolayer that may eventually serve as a functional retinal implant. With the ability to apply soft lithography to tissue samples, human tissue may become a universal membrane substrate for other ocular diseases or in tissue engineering applications elsewhere in the body.
C1 Stanford Univ, Dept Chem Engn, Stanford, CA 94305 USA.
   Stanford Univ, Sch Med, Dept Ophthalmol, Stanford, CA 94305 USA.
C3 Stanford University; Stanford University
RP Bent, SF (通讯作者)，Stanford Univ, Dept Chem Engn, Stanford, CA 94305 USA.
OI Bent, Stacey/0000-0002-1084-5336
CR Branch DW, 2000, IEEE T BIO-MED ENG, V47, P290, DOI 10.1109/10.827289
   Folch A, 2000, ANNU REV BIOMED ENG, V2, P227, DOI 10.1146/annurev.bioeng.2.1.227
   GIUSTI P, 1993, J MATER SCI-MATER M, V4, P538, DOI 10.1007/BF00125590
   Hui CY, 2002, LANGMUIR, V18, P1394, DOI 10.1021/la0113567
   Ikada Y, 2000, MACROMOL RAPID COMM, V21, P117, DOI 10.1002/(SICI)1521-3927(20000201)21:3<117::AID-MARC117>3.3.CO;2-O
   Ito Y, 1999, BIOMATERIALS, V20, P2333, DOI 10.1016/S0142-9612(99)00162-3
   Kane RS, 1999, BIOMATERIALS, V20, P2363, DOI 10.1016/S0142-9612(99)00165-9
   KLEIN R, 1999, AGE RELATED MACULAR, P31
   Lee CJ, 2002, ARCH OPHTHALMOL-CHIC, V120, P1714
   Lu LC, 1999, BIOMATERIALS, V20, P2351, DOI 10.1016/S0142-9612(99)00164-7
   Luk YY, 2000, LANGMUIR, V16, P9604, DOI 10.1021/la0004653
   MARMOR MF, 1998, RETINAL PIGMENT EPIT, P6
   Mitchell P, 2001, NAT BIOTECHNOL, V19, P717, DOI 10.1038/90754
   Quake SR, 2000, SCIENCE, V290, P1536, DOI 10.1126/science.290.5496.1536
   SINGHVI R, 1994, SCIENCE, V264, P696, DOI 10.1126/science.8171320
   STJOHN PM, 1997, J NEUROSCI METHODS, V75
   SUGAWARA T, 1995, J BIOMED MATER RES, V29, P1047, DOI 10.1002/jbm.820290904
   Thumann G, 2000, ARCH OPHTHALMOL-CHIC, V118, P1350
   Wheeler BC, 1999, J BIOMECH ENG-T ASME, V121, P73, DOI 10.1115/1.2798045
   Whitesides GM, 2001, ANNU REV BIOMED ENG, V3, P335, DOI 10.1146/annurev.bioeng.3.1.335
   Wilbur JL, 1996, NANOTECHNOLOGY, V7, P452, DOI 10.1088/0957-4484/7/4/028
   ZARBIN MA, 1999, AGE RELATED MACULAR, P363
NR 22
TC 36
Z9 40
U1 0
U2 4
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0743-7463
J9 LANGMUIR
JI Langmuir
PD MAY 11
PY 2004
VL 20
IS 10
BP 4155
EP 4161
DI 10.1021/la035467c
PG 7
WC Chemistry, Multidisciplinary; Chemistry, Physical; Materials Science,
   Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Chemistry; Materials Science
GA 819MQ
UT WOS:000221319400049
PM 15969410
DA 2022-11-30
ER

PT J
AU Ermakov, I
   Ermakova, M
   Gellermann, W
   Bernstein, PS
AF Ermakov, I
   Ermakova, M
   Gellermann, W
   Bernstein, PS
TI Macular pigment Raman detector for clinical applications
SO JOURNAL OF BIOMEDICAL OPTICS
LA English
DT Article
DE age-related macular degeneration; macular pigments; lutein; zeaxanthin;
   Raman spectroscopy; noninvasive detector
ID CAROTENOID-PIGMENTS; DEGENERATION
AB Clinical studies of carotenoid macular pigments (MP) have been limited by the lack of noninvasive, objective instruments. We introduce a novel noninvasive optical instrument, an MP Raman detector, for assessment of the carotenoid status of the human retina in vivo. The instrument uses resonant excitation of carotenoid molecules in the visible wavelength range, and quantitatively measures the highly specific Raman signals that originate from the single- and double-bond stretch vibrations of the pi-conjugated carotenoid molecule's carbon backbone. The instrument is a robust, compact device and suitable for routine measurements of MP concentrations in a clinical setting. We characterized and tested the instrument in clinical studies of human subjects to validate its function and to begin to establish its role as a possible screening test for macular pathologies. We also show that the MP Raman spectroscopy technology has potential as a novel, highly specific method for rapid screening of carotenoid antioxidant levels in large populations at risk for vision loss from age-related macular degeneration, the leading cause of blindness of the elderly in the developed world. (C) 2004 Society of Photo-Optical Instrumentation Engineers.
C1 Univ Utah, Dept Phys, Salt Lake City, UT 84112 USA.
   Dixon Laser Inst, Salt Lake City, UT 84112 USA.
   Moran Eye Ctr, Dept Ophthalmol & Visual Sci, Salt Lake City, UT 84132 USA.
C3 Utah System of Higher Education; University of Utah
RP Ermakov, I (通讯作者)，Univ Utah, Dept Phys, Salt Lake City, UT 84112 USA.
EM werner@physics.utah.edu
FU NATIONAL EYE INSTITUTE [R41EY012324, R29EY011600] Funding Source: NIH
   RePORTER; NEI NIH HHS [R29 EY011600, R41 EY012324-01] Funding Source:
   Medline
CR *AM NAT STAND I, 2000, Z13612000 AM NAT STA
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Beatty S, 2001, INVEST OPHTH VIS SCI, V42, P439
   Bernstein PS, 2002, OPHTHALMOLOGY, V109, P1780, DOI 10.1016/S0161-6420(02)01173-9
   Born M., 1964, PRINCIPLES OPTICS, DOI 10.1017/CBO9781139644181
   Britton G., 1995, CAROTENOIDS B
   Delori FC, 2001, J OPT SOC AM A, V18, P1212, DOI 10.1364/JOSAA.18.001212
   Ermakov I. V., 1999, Proceedings of the International Conference on LASERS'98, P641
   Ermakov IV, 2001, OPT LETT, V26, P202, DOI 10.1364/OL.26.000202
   Ermakov IV, 2001, OPT LETT, V26, P1179, DOI 10.1364/OL.26.001179
   Gellermann W, 2000, PROC SPIE, V3917, P102, DOI 10.1117/12.382721
   Gellermann W, 2002, J OPT SOC AM A, V19, P1172, DOI 10.1364/JOSAA.19.001172
   Hammond BR, 1997, J OPT SOC AM A, V14, P1187, DOI 10.1364/JOSAA.14.001187
   HANDELMAN GJ, 1992, METHOD ENZYMOL, V213, P220
   Hata TR, 2000, J INVEST DERMATOL, V115, P441, DOI 10.1046/j.1523-1747.2000.00060.x
   KILBRIDE PE, 1989, VISION RES, V29, P663, DOI 10.1016/0042-6989(89)90028-X
   KOYAMA Y, 1988, J RAMAN SPECTROSC, V19, P37, DOI 10.1002/jrs.1250190107
   Mata NL, 2000, P NATL ACAD SCI USA, V97, P7154, DOI 10.1073/pnas.130110497
   READING VM, 1974, J OPT SOC AM, V64, P231, DOI 10.1364/JOSA.64.000231
   SCHALCH W, 1999, CRC MOD NUT, P215
   SHREVE AP, 1991, CHEM PHYS LETT, V178, P89, DOI 10.1016/0009-2614(91)85058-5
   Smith G., 1997, EYE VISUAL OPTICAL I
   SNODDERLY DM, 1999, CRC MOD NUT, P251
   WEBB RH, 1987, APPL OPTICS, V26, P1492, DOI 10.1364/AO.26.001492
   Werner JS, 2000, J OPT SOC AM A, V17, P1918, DOI 10.1364/JOSAA.17.001918
NR 25
TC 29
Z9 29
U1 0
U2 5
PU SPIE-SOC PHOTO-OPTICAL INSTRUMENTATION ENGINEERS
PI BELLINGHAM
PA 1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98225 USA
SN 1083-3668
EI 1560-2281
J9 J BIOMED OPT
JI J. Biomed. Opt.
PD JAN-FEB
PY 2004
VL 9
IS 1
BP 139
EP 148
DI 10.1117/1.1627776
PG 10
WC Biochemical Research Methods; Optics; Radiology, Nuclear Medicine &
   Medical Imaging
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Optics; Radiology, Nuclear Medicine &
   Medical Imaging
GA 765BR
UT WOS:000188247700014
PM 14715066
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Goenka, S
   Simon, SR
AF Goenka, Shilpi
   Simon, Sanford R.
TI Effects of E-Cigarette Refill Liquid Flavorings with and without
   Nicotine on Human Retinal Pigment Epithelial Cells: A Preliminary Study
SO INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH
LA English
DT Article
DE retinal pigment epithelial cells; e-cigarettes; e-liquid; flavorings;
   nicotine; cytotoxicity
ID ELECTRONIC CIGARETTE; OXIDATIVE STRESS; MACULAR DEGENERATION; ARPE-19;
   EXPRESSION; LINE; MECHANISMS; CHEMICALS; PROFILES; TOXICITY
AB Smoking is an etiologic factor for age-related macular degeneration (AMD). Although cigarette smoke has been extensively researched for retinal pigment epithelial (RPE) cell degeneration, the potential for adverse effects on the retinal epithelium following exposure to flavored e-cigarette refill liquid has never been explored. In this preliminary study, we have examined the effects of 20 e-liquids (10 different flavored nicotine-free and 10 nicotine-rich e-liquids) used in e-cigarettes on the metabolic activity, membrane integrity, and mitochondrial membrane potential of RPE cells. Our results showed that of the flavors studied over the concentration range: 0.5, 1, and 2% v/v for a duration of 48 h, cinnamon was the most toxic and menthol was the second most toxic, while other flavors showed lesser or no cytotoxicity. The presence of nicotine augmented cytotoxicity for cinnamon, menthol, strawberry, vanilla, and banana while for other flavors there was no synergism. Together, our results demonstrate that exposure of RPE to flavored e-cigarette refill liquids caused significant cytotoxicity and may be a risk factor for the development of retinal pathogenesis, although further in-depth studies are necessary.
C1 [Goenka, Shilpi; Simon, Sanford R.] SUNY Stony Brook, Dept Biomed Engn, Stony Brook, NY 11794 USA.
   [Goenka, Shilpi; Simon, Sanford R.] SUNY Stony Brook, Dept Biochem & Cellular Biol, Stony Brook, NY 11794 USA.
   [Simon, Sanford R.] SUNY Stony Brook, Dept Pathol, Stony Brook, NY 11794 USA.
C3 State University of New York (SUNY) System; SUNY Community College;
   State University of New York (SUNY) Stony Brook; State University of New
   York (SUNY) System; SUNY Community College; State University of New York
   (SUNY) Stony Brook; State University of New York (SUNY) System; SUNY
   Community College; State University of New York (SUNY) Stony Brook
RP Goenka, S (通讯作者)，SUNY Stony Brook, Dept Biomed Engn, Stony Brook, NY 11794 USA.; Goenka, S (通讯作者)，SUNY Stony Brook, Dept Biochem & Cellular Biol, Stony Brook, NY 11794 USA.
EM shilpi.goenka@stonybrook.edu; sanford.simon@stonybrook.edu
OI Goenka, Shilpi/0000-0001-5760-6669
CR Ablonczy Z, 2011, INVEST OPHTH VIS SCI, V52, P8614, DOI 10.1167/iovs.11-8021
   Adijanto J, 2014, EXP EYE RES, V126, P77, DOI 10.1016/j.exer.2014.01.015
   Ahmado A, 2011, INVEST OPHTH VIS SCI, V52, P7148, DOI 10.1167/iovs.10-6374
   Alakayak J., 2008, ETHNIC DIS, V18, pS145
   Alge CS, 2006, J PROTEOME RES, V5, P862, DOI 10.1021/pr050420t
   Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   Amrock SM, 2016, PEDIATRICS, V138, DOI 10.1542/peds.2015-4306
   Armento A, 2021, CELL MOL LIFE SCI, V78, P4487, DOI 10.1007/s00018-021-03796-9
   Armento A, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-67292-z
   Bahl V, 2012, REPROD TOXICOL, V34, P529, DOI 10.1016/j.reprotox.2012.08.001
   Bailey TA, 2004, INVEST OPHTH VIS SCI, V45, P675, DOI 10.1167/iovs.03-0351
   Behar RZ, 2014, TOXICOL IN VITRO, V28, P198, DOI 10.1016/j.tiv.2013.10.006
   Behar RZ, 2018, TOB CONTROL, V27, P325, DOI 10.1136/tobaccocontrol-2016-053472
   Behar RZ, 2016, TOB CONTROL, V25, pii94, DOI 10.1136/tobaccocontrol-2016-053224
   Bekki K, 2014, INT J ENV RES PUB HE, V11, P11192, DOI 10.3390/ijerph111111192
   Bengalli R, 2017, INT J ENV RES PUB HE, V14, DOI 10.3390/ijerph14101254
   Bitzer ZT, 2018, FREE RADICAL BIO MED, V120, P72, DOI 10.1016/j.freeradbiomed.2018.03.020
   Brunzell Darlene H, 2015, Curr Addict Rep, V2, P33
   Chan Francis Ka-Ming, 2013, Methods Mol Biol, V979, P65, DOI 10.1007/978-1-62703-290-2_7
   Chen JC, 2018, DRUG ALCOHOL DEPEN, V191, P279, DOI 10.1016/j.drugalcdep.2018.07.020
   Cheung CMG, 2014, J INTERN MED, V276, P140, DOI 10.1111/joim.12227
   Choudhury R, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-93708-5
   Clapp PW, 2019, AM J PHYSIOL-LUNG C, V316, pL470, DOI 10.1152/ajplung.00304.2018
   Dunn KC, 1998, INVEST OPHTH VIS SCI, V39, P2744
   Dunn KC, 1996, EXP EYE RES, V62, P155, DOI 10.1006/exer.1996.0020
   Erythropel HC, 2019, NICOTINE TOB RES, V21, P1248, DOI 10.1093/ntr/nty192
   Farsalinos KE, 2015, INT J ENV RES PUB HE, V12, P5215, DOI 10.3390/ijerph120505215
   Farsalinos KE, 2013, INT J ENV RES PUB HE, V10, P2500, DOI 10.3390/ijerph10062500
   Ferrington DA, 2017, REDOX BIOL, V13, P255, DOI 10.1016/j.redox.2017.05.015
   Goldenson NI, 2019, CURR ADDICT REP, V6, P98, DOI 10.1007/s40429-019-00244-4
   Goniewicz ML, 2013, NICOTINE TOB RES, V15, P158, DOI 10.1093/ntr/nts103
   Goniewicz ML, 2019, TOB CONTROL, V28, P676, DOI 10.1136/tobaccocontrol-2018-054565
   Gorukanti A, 2017, PREV MED, V94, P65, DOI 10.1016/j.ypmed.2016.10.019
   Gray N., 2021, J ANAL TOXICOL, V45, P337
   Gray N, 2019, INT J ENV RES PUB HE, V16, DOI 10.3390/ijerph16224450
   Harrell M B, 2017, Prev Med Rep, V5, P33
   Hazim RA, 2019, EXP EYE RES, V179, P18, DOI 10.1016/j.exer.2018.10.009
   He Yuan, 2010, J Ocul Biol Dis Infor, V3, P92, DOI 10.1007/s12177-011-9061-y
   Heesterbeek TJ, 2020, OPHTHAL PHYSL OPT, V40, P140, DOI 10.1111/opo.12675
   Helen GS, 2017, DRUG ALCOHOL DEPEN, V178, P391, DOI 10.1016/j.drugalcdep.2017.05.042
   Hess CA, 2017, ENVIRON RES, V152, P221, DOI 10.1016/j.envres.2016.09.026
   Inana G, 2018, J TRANSL MED, V16, DOI 10.1186/s12967-018-1434-6
   Jabba SV, 2020, NICOTINE TOB RES, V22, pS25, DOI 10.1093/ntr/ntaa185
   Jiang XR, 1999, NAT GENET, V21, P111, DOI 10.1038/5056
   Kaarniranta K, 2020, PROG RETIN EYE RES, V79, DOI 10.1016/j.preteyeres.2020.100858
   Kalayci M, 2020, PHOTODIAGN PHOTODYN, V32, DOI 10.1016/j.pdpdt.2020.102068
   Kendig DM, 2007, TOXICOL IN VITRO, V21, P125, DOI 10.1016/j.tiv.2006.08.004
   Kerasioti E, 2020, TOXICOL REP, V7, P1095, DOI 10.1016/j.toxrep.2020.08.029
   Kuntic M, 2020, EUR HEART J, V41, P2472, DOI 10.1093/eurheartj/ehz772
   Lamb T, 2020, TOXICOL LETT, V333, P303, DOI 10.1016/j.toxlet.2020.08.003
   LARSSON B, 1978, ACTA PHYSIOL SCAND, V104, P479, DOI 10.1111/j.1748-1716.1978.tb06303.x
   Lee HW, 2018, P NATL ACAD SCI USA, V115, pE1560, DOI 10.1073/pnas.1718185115
   Leigh NJ, 2016, TOB CONTROL, V25, pii81, DOI 10.1136/tobaccocontrol-2016-053205
   Leveziel N, 2011, OPHTHALMOLOGICA, V226, DOI 10.1159/000328981
   Lueck K, 2015, OPHTHALMIC RES, V54, P195, DOI 10.1159/000439596
   Mayyas F, 2020, LIFE SCI, V251, DOI 10.1016/j.lfs.2020.117644
   Merecz-Sadowska A, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21020652
   Moodie C, 2019, TOB CONTROL, V28, P595, DOI 10.1136/tobaccocontrol-2018-054711
   Morean ME, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0189015
   Moustafa MT, 2017, J OCUL PHARMACOL TH, V33, P610, DOI 10.1089/jop.2016.0129
   O'Farrell HE, 2021, TOXICOL IN VITRO, V75, DOI 10.1016/j.tiv.2021.105204
   Omaiye EE, 2019, CHEM RES TOXICOL, V32, P1058, DOI 10.1021/acs.chemrestox.8b00381
   Omaiye EE, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-39550-2
   Patil AJ, 2009, TOXICOLOGY, V259, P69, DOI 10.1016/j.tox.2009.02.004
   Pepper JK, 2016, TOB CONTROL, V25, pii62, DOI 10.1136/tobaccocontrol-2016-053174
   Plafker SM, 2012, INT REV CEL MOL BIO, V298, P135, DOI 10.1016/B978-0-12-394309-5.00004-3
   Reilly SM, 2019, NICOTINE TOB RES, V21, P1274, DOI 10.1093/ntr/nty221
   Rowell TR, 2017, AM J PHYSIOL-LUNG C, V313, pL52, DOI 10.1152/ajplung.00392.2016
   Rozing MP, 2020, PROG RETIN EYE RES, V76, DOI 10.1016/j.preteyeres.2019.100825
   Russell C, 2020, NICOTINE TOB RES, V22, P713, DOI 10.1093/ntr/ntz183
   Samuel W, 2017, MOL VIS, V23, P60
   Sapkal AU, 2018, J OPHTHAL VIS RES, V13, P419, DOI 10.4103/jovr.jovr_16_18
   Seiler-Ramadas R, 2021, WIEN KLIN WOCHENSCHR, V133, P1020, DOI 10.1007/s00508-020-01711-z
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Son Y, 2019, CHEM RES TOXICOL, V32, P1087, DOI 10.1021/acs.chemrestox.8b00400
   Soneji S, 2017, JAMA PEDIATR, V171, P788, DOI 10.1001/jamapediatrics.2017.1488
   Stevens EM, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17134755
   Thangboonjit W, 2015, EUR RESPIR J, V46, DOI 10.1183/13993003.congress-2015.PA909
   Wagener TL, 2017, TOB CONTROL, V26, pE23, DOI 10.1136/tobaccocontrol-2016-053041
   Wang AL, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005304
   Wang F, 2021, J MOL MED, V99, P1459, DOI 10.1007/s00109-021-02108-9
   Wang L, 2014, FREE RADICAL BIO MED, V70, P155, DOI 10.1016/j.freeradbiomed.2014.01.015
   Wavreil FDM, 2020, TOXICOL REP, V7, P23, DOI 10.1016/j.toxrep.2019.11.019
   Williams M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057987
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yang S, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.727870
   Yingst JM, 2017, NICOTINE TOB RES, V19, P1381, DOI 10.1093/ntr/ntw383
   Zhang XY, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-03283-x
   Zhu SH, 2014, TOB CONTROL, V23, P3, DOI 10.1136/tobaccocontrol-2014-051670
NR 89
TC 0
Z9 0
U1 2
U2 4
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1660-4601
J9 INT J ENV RES PUB HE
JI Int. J. Environ. Res. Public Health
PD NOV
PY 2021
VL 18
IS 21
AR 11655
DI 10.3390/ijerph182111655
PG 15
WC Environmental Sciences; Public, Environmental & Occupational Health
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Environmental Sciences & Ecology; Public, Environmental & Occupational
   Health
GA WZ5VF
UT WOS:000720033800001
PM 34770169
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Shigdar, S
   Schrand, B
   Giangrande, PH
   de Franciscis, V
AF Shigdar, Sarah
   Schrand, Brett
   Giangrande, Paloma H.
   de Franciscis, Vittorio
TI Aptamers: Cutting edge of cancer therapies
SO MOLECULAR THERAPY
LA English
DT Review
ID TARGETED DRUG-DELIVERY; BLOOD-BRAIN-BARRIER; IN-VITRO SELECTION;
   IPILIMUMAB PLUS DACARBAZINE; CELL ADHESION MOLECULE; SMALL ACTIVATING
   RNA; BIFUNCTIONAL APTAMER; TRANSFERRIN RECEPTOR; CURRENT CHALLENGES;
   GENE-EXPRESSION
AB The development of an aptamer-based therapeutic has rapidly progressed following the first two reports in the 1990s, underscoring the advantages of aptamer drugs associated with their unique binding properties. In 2004, the US Food and Drug Administration (FDA) approved the first therapeutic aptamer for the treatment of neovascular age-related macular degeneration, Macugen developed by NeXstar. Since then, eleven aptamers have successfully entered clinical trials for various therapeutic indications. Despite some of the pre-clinical and clinical successes of aptamers as therapeutics, no aptamer has been approved by the FDA for the treatment of cancer. This review highlights the most recent and cutting-edge approaches in the development of aptamers for the treatment of cancer types most refractory to conventional therapies. Herein, we will review (1) the development of aptamers to enhance anti-cancer immunity and as delivery tools for inducing the expression of immunogenic neoantigens; (2) the development of the most promising therapeutic aptamers designed to target the hardto-treat cancers such as brain tumors; and (3) the development of "carrier" aptamers able to target and penetrate tumors and metastasis, delivering RNA therapeutics to the cytosol and nucleus.
C1 [Shigdar, Sarah] Deakin Univ, Sch Med, 75 Pigdons Rd, Waurn Ponds, Vic 3216, Australia.
   [Shigdar, Sarah] Deakin Univ, Ctr Mol & Med Res, 75 Pigdons Rd, Waurn Ponds, Vic 3216, Australia.
   [Schrand, Brett] TCR2 Therapeut Inc, 100 Binney St, Cambridge, MA 02142 USA.
   [Giangrande, Paloma H.] Univ Iowa, Internal Med, Iowa City, IA 52242 USA.
   [Giangrande, Paloma H.] VP Platform Discovery Sci Biol Wave Life Sci, Cambridge, MA 02138 USA.
   [de Franciscis, Vittorio] Natl Res Council CNR, Inst Genet & Biomed Res IRGB, UOS Milan Via Rita Levi Montalcini, I-20090 Milan, Italy.
   [de Franciscis, Vittorio] Harvard Med Sch, Initiat RNA Med, Boston, MA 02115 USA.
C3 Deakin University; Deakin University; University of Iowa; Consiglio
   Nazionale delle Ricerche (CNR); Istituto di Ricerca Genetica e Biomedica
   (IRGB-CNR); Harvard University; Harvard Medical School
RP de Franciscis, V (通讯作者)，Natl Res Council CNR, Inst Genet & Biomed Res IRGB, UOS Milan Via Rita Levi Montalcini, I-20090 Milan, Italy.
EM vittorio.defranciscis@irgb.cnr.it
RI Shigdar, Sarah/AFR-0438-2022; Giangrande, Paloma/Q-3649-2018
OI de Franciscis, Vittorio/0000-0001-6601-1181; Shigdar,
   Sarah/0000-0001-8084-8447; Giangrande, Paloma/0000-0002-6559-3308
CR Ababneh N, 2013, NUCLEIC ACID THER, V23, P401, DOI 10.1089/nat.2013.0423
   Affinito A, 2020, MOL THER-NUCL ACIDS, V20, P176, DOI 10.1016/j.omtn.2020.02.005
   Affinito A, 2019, MOL THER-NUCL ACIDS, V18, P99, DOI 10.1016/j.omtn.2019.08.015
   Alnylam Pharmaceuticals, 2019, ALN ANN APPR GIVLAAR
   Alnylam Pharmaceuticals, 2019, INTR GIVLAARI GIV NO
   Alshaer W, 2018, ADV DRUG DELIVER REV, V134, P122, DOI 10.1016/j.addr.2018.09.011
   Alshaer W, 2018, J CONTROL RELEASE, V271, P98, DOI 10.1016/j.jconrel.2017.12.022
   Alshaer W, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0189558
   Amero P, 2021, J AM CHEM SOC, V143, P7655, DOI 10.1021/jacs.9b10460
   Amero P, 2020, CANCERS, V12, DOI 10.3390/cancers12102889
   Apolloni E, 2000, J IMMUNOL, V165, P6723, DOI 10.4049/jimmunol.165.12.6723
   Bagalkot V, 2006, ANGEW CHEM INT EDIT, V45, P8149, DOI 10.1002/anie.200602251
   Bao SD, 2006, NATURE, V444, P756, DOI 10.1038/nature05236
   Bates PJ, 2017, BBA-GEN SUBJECTS, V1861, P1414, DOI 10.1016/j.bbagen.2016.12.015
   Bauer M, 2019, MOLECULES, V24, DOI 10.3390/molecules24234377
   Berger H, 2017, FRONT CELL DEV BIOL, V5, DOI 10.3389/fcell.2017.00031
   Biswas S, 2013, PHARMACEUTICALS-BASE, V6, P161, DOI 10.3390/ph6020161
   Bruno JG, 2018, PHARMACEUTICALS-BASE, V11, DOI 10.3390/ph11030062
   Bukari B, 2020, BIOMEDICINES, V8, DOI 10.3390/biomedicines8050120
   Carro MS, 2010, NATURE, V463, P318, DOI 10.1038/nature08712
   Catuogno S, 2021, METHODS MOL BIOL, V2282, P31, DOI 10.1007/978-1-0716-1298-9_3
   Cheng CS, 2013, MOL THER-NUCL ACIDS, V2, DOI 10.1038/mtna.2012.59
   CONRY RM, 1995, CANCER RES, V55, P1397
   Corey DR, 2017, ADV EXP MED BIOL, V983, P161, DOI 10.1007/978-981-10-4310-9_11
   Damase TR, 2018, ACS COMB SCI, V20, P45, DOI 10.1021/acscombsci.7b00138
   Dassie JP, 2009, NAT BIOTECHNOL, V27, P839, DOI 10.1038/nbt.1560
   de Franciscis V, 2018, BIOCHIMIE, V145, P45, DOI 10.1016/j.biochi.2017.09.014
   De La Fuente A, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.aav9760
   Doorduijn EM, 2018, ONCOIMMUNOLOGY, V7, DOI 10.1080/2162402X.2017.1382793
   Doorduijn EM, 2016, J CLIN INVEST, V126, P784, DOI 10.1172/JCI83671
   Esposito CL, 2016, J CONTROL RELEASE, V238, P43, DOI 10.1016/j.jconrel.2016.07.032
   Esposito CL, 2020, CANCERS, V12, DOI 10.3390/cancers12061434
   Esposito CL, 2018, MOL THER-NUCL ACIDS, V10, P398, DOI 10.1016/j.omtn.2017.12.021
   Eulberg D, 2003, CHEMBIOCHEM, V4, P979, DOI 10.1002/cbic.200300663
   Fattal E, 2018, ADV DRUG DELIVER REV, V134, P1, DOI 10.1016/j.addr.2018.11.001
   Garrido G, 2020, CANCER IMMUNOL RES, V8, P856, DOI 10.1158/2326-6066.CIR-20-0020
   Garrido G, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11728-2
   Goto H, 2015, BLOOD, V126
   Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
   Haslam A, 2019, JAMA NETW OPEN, V2, DOI 10.1001/jamanetworkopen.2019.2535
   Haubner S, 2019, LEUKEMIA, V33, P64, DOI 10.1038/s41375-018-0180-3
   Hays EM, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18122576
   Hoellenriegel J, 2014, BLOOD, V123, P1032, DOI 10.1182/blood-2013-03-493924
   Hosney M, 2017, EXP THER MED, V13, P2235, DOI 10.3892/etm.2017.4291
   Huang YF, 2009, CHEMBIOCHEM, V10, P862, DOI 10.1002/cbic.200800805
   Imrich S, 2012, CELL ADHES MIGR, V6, P30, DOI 10.4161/cam.18953
   Janowski BA, 2007, NAT CHEM BIOL, V3, P166, DOI 10.1038/nchembio860
   Jiang F, 2015, INT J MOL SCI, V16, P23784, DOI 10.3390/ijms161023784
   JIRIKOWSKI GF, 1992, SCIENCE, V255, P996, DOI 10.1126/science.1546298
   Kaur H, 2018, THERANOSTICS, V8, P4016, DOI 10.7150/thno.25958
   Khalid U, 2019, PHARMACEUTICALS-BASE, V12, DOI 10.3390/ph12010002
   Kotula JW, 2012, NUCLEIC ACID THER, V22, P187, DOI 10.1089/nat.2012.0347
   Kristen AV, 2019, NEURODEGENER DIS MAN, V9, P5, DOI 10.2217/nmt-2018-0033
   Kryza D, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0149387
   Kwok A, 2019, THER DELIV, V10, P151, DOI 10.4155/tde-2018-0061
   Larkin J, 2019, NEW ENGL J MED, V381, P1535, DOI 10.1056/NEJMoa1910836
   Lathia JD, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024807
   Le JQ, 2020, CHEM ENG J, V388, DOI 10.1016/j.cej.2020.124170
   Lebedev A., 2017, CONSIDERATIONS DESIG
   Lemery S, 2017, NEW ENGL J MED, V377, P1409, DOI 10.1056/NEJMp1709968
   Li CL, 2016, ONCOTARGET, V7, P22893, DOI 10.18632/oncotarget.8290
   Li H, 2019, MOL THER-NUCL ACIDS, V18, P727, DOI 10.1016/j.omtn.2019.10.005
   Li XW, 2020, J AM CHEM SOC, V142, P3862, DOI 10.1021/jacs.9b11490
   Li X, 2019, BIOMED PHARMACOTHER, V117, DOI 10.1016/j.biopha.2019.109072
   Lv C, 2019, ANAL CHEM, V91, P13818, DOI 10.1021/acs.analchem.9b03281
   Macdonald J, 2020, NUCLEIC ACID THER, V30, P117, DOI 10.1089/nat.2019.0807
   Macdonald J, 2018, CANCERS, V10, DOI 10.3390/cancers10010019
   Macdonald J, 2017, ACS CHEM NEUROSCI, V8, P777, DOI 10.1021/acschemneuro.6b00369
   Maio M, 2015, J CLIN ONCOL, V33, P1191, DOI 10.1200/JCO.2014.56.6018
   Maldonado EB, 2020, FUTUR SCI OA, V6, DOI 10.2144/fsoa-2020-0024
   Mannironi C, 1997, BIOCHEMISTRY-US, V36, P9726, DOI 10.1021/bi9700633
   Marijt KA, 2018, J EXP MED, V215, P2325, DOI 10.1084/jem.20180577
   Marquart J, 2018, JAMA ONCOL, V4, P1093, DOI 10.1001/jamaoncol.2018.1660
   Soldevilla MM, 2019, MOL THER, V27, P1878, DOI 10.1016/j.ymthe.2019.07.013
   Soldevilla MM, 2016, ONCOTARGET, V7, P23182, DOI 10.18632/oncotarget.8095
   McConnell EM, 2019, ACS CHEM NEUROSCI, V10, P371, DOI 10.1021/acschemneuro.8b00292
   Ming X, 2010, NUCLEIC ACIDS RES, V38, P6567, DOI 10.1093/nar/gkq534
   Mol AA, 2019, NUCLEIC ACIDS RES, V47, DOI 10.1093/nar/gkz753
   Moses JE, 2007, CHEM SOC REV, V36, P1249, DOI 10.1039/b613014n
   Munz M, 2010, CANCER CELL INT, V10, DOI 10.1186/1475-2867-10-44
   Nakamara N, 2017, MOL MED, V23, P295, DOI 10.2119/molmed.2017.00099
   Ng EWM, 2006, NAT REV DRUG DISCOV, V5, P123, DOI 10.1038/nrd1955
   Nimjee SM, 2017, ANNU REV PHARMACOL, V57, P61, DOI 10.1146/annurev-pharmtox-010716-104558
   Nuzzo S, 2020, CANCERS, V12, DOI 10.3390/cancers12082173
   Ojima A, 2014, LAB INVEST, V94, P422, DOI 10.1038/labinvest.2014.5
   Paluncic J, 2016, BBA-MOL CELL RES, V1863, P770, DOI 10.1016/j.bbamcr.2016.01.025
   Pastor F, 2018, NAT REV DRUG DISCOV, V17, P751, DOI 10.1038/nrd.2018.132
   Pastor F, 2013, MOL THER-NUCL ACIDS, V2, DOI 10.1038/mtna.2013.26
   Pastor F, 2010, NATURE, V465, P227, DOI 10.1038/nature08999
   Povsic TJ, 2016, J ALLERGY CLIN IMMUN, V138, P1712, DOI 10.1016/j.jaci.2016.04.058
   Reebye V, 2014, HEPATOLOGY, V59, P216, DOI 10.1002/hep.26669
   Santos T, 2021, BIOCHEM PHARMACOL, V189, DOI 10.1016/j.bcp.2020.114208
   Schrand B, 2014, CANCER IMMUNOL RES, V2, P867, DOI 10.1158/2326-6066.CIR-14-0007
   Serrone L, 2000, J EXP CLIN CANC RES, V19, P21
   Shangguan D, 2008, J PROTEOME RES, V7, P2133, DOI 10.1021/pr700894d
   Shangguan D, 2007, CHEMBIOCHEM, V8, P603, DOI 10.1002/cbic.200600532
   Shangguan D, 2006, P NATL ACAD SCI USA, V103, P11838, DOI 10.1073/pnas.0602615103
   Shen XL, 2018, NUCLEIC ACIDS RES, V46, P1584, DOI 10.1093/nar/gkx1239
   Sherry MM, 2009, STEM CELLS, V27, P2383, DOI 10.1002/stem.185
   Shi NY, 2001, PHARMACEUT RES, V18, P1091, DOI 10.1023/A:1010910523202
   Shi NY, 2000, P NATL ACAD SCI USA, V97, P7567, DOI 10.1073/pnas.130187497
   Shigdar S, 2013, SENSORS-BASEL, V13, P13624, DOI 10.3390/s131013624
   Shigdar S, 2013, CANCER LETT, V330, P84, DOI 10.1016/j.canlet.2012.11.032
   Shigdar S, 2012, THER DELIV, V3, P227, DOI 10.4155/TDE.11.148
   Shigdar S, 2011, CANCER SCI, V102, P991, DOI 10.1111/j.1349-7006.2011.01897.x
   Shin H, 2018, ADV THER-GERMANY, V1, DOI 10.1002/adtp.201800065
   Shu D, 2021, MOL THER-NUCL ACIDS, V24, P426, DOI 10.1016/j.omtn.2021.03.007
   Sicco E, 2020, CANCER BIOTHER RADIO, V35, P262, DOI 10.1089/cbr.2019.3402
   Song YL, 2013, ANAL CHEM, V85, P4141, DOI 10.1021/ac400366b
   STEPHENSON ML, 1978, P NATL ACAD SCI USA, V75, P285, DOI 10.1073/pnas.75.1.285
   Tacar O, 2013, J PHARM PHARMACOL, V65, P157, DOI 10.1111/j.2042-7158.2012.01567.x
   Taghdisi SM, 2010, J DRUG TARGET, V18, P277, DOI 10.3109/10611860903434050
   Tapia-Alveal C, 2020, COMMUN BIOL, V3, DOI 10.1038/s42003-020-01515-x
   Ugurel S, 2013, J INVEST DERMATOL, V133, P289, DOI 10.1038/jid.2012.341
   Ulmer JB, 2016, CURR OPIN IMMUNOL, V41, P18, DOI 10.1016/j.coi.2016.05.008
   Vater A, 2015, DRUG DISCOV TODAY, V20, P147, DOI 10.1016/j.drudis.2014.09.004
   Vigneron N, 2018, J IMMUNOL, V201, P1875, DOI 10.4049/jimmunol.1701479
   Wang HM, 2001, MOL CELL, V8, P817, DOI 10.1016/S1097-2765(01)00366-5
   Wojtuszkiewicz A, 2015, J HEMATOL ONCOL, V8, DOI 10.1186/s13045-015-0158-9
   Wolf DMC, 2019, FRONT PEDIATR, V7, DOI 10.3389/fped.2019.00314
   WOLFF JA, 1990, SCIENCE, V247, P1465, DOI 10.1126/science.1690918
   Wrobel S, 2019, J CLIN MED, V8, DOI 10.3390/jcm8030368
   Xiang DX, 2017, THERANOSTICS, V7, P4071, DOI 10.7150/thno.20168
   Xiang DX, 2015, THERANOSTICS, V5, P1083, DOI 10.7150/thno.11711
   Xiao ZY, 2008, CHEM-EUR J, V14, P1769, DOI 10.1002/chem.200701330
   Yamazaki N, 2015, CANCER CHEMOTH PHARM, V76, P969, DOI 10.1007/s00280-015-2870-0
   Yang SH, 2018, MOL THER-NUCL ACIDS, V13, P164, DOI 10.1016/j.omtn.2018.08.023
   Yarchoan M, 2017, NAT REV CANCER, V17, DOI 10.1038/nrc.2017.74
   Yazdian-Robati R, 2020, INT J BIOL MACROMOL, V155, P1420, DOI 10.1016/j.ijbiomac.2019.11.118
   Yoon S, 2019, MOL THER-NUCL ACIDS, V18, P142, DOI 10.1016/j.omtn.2019.08.017
   Yoon S, 2019, MOL THER-NUCL ACIDS, V14, P131, DOI 10.1016/j.omtn.2018.11.012
   Yoon S, 2018, ADV DRUG DELIVER REV, V134, P22, DOI 10.1016/j.addr.2018.07.003
   Yoon S, 2016, MOL THER, V24, P1106, DOI 10.1038/mt.2016.60
   Yu YJ, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002230
   Zhang HJ, 2020, TALANTA, V219, DOI 10.1016/j.talanta.2020.121209
   Zhang MR, 2018, J NUCL MED, V59
   Zhang Y, 2021, P NATL ACAD SCI USA, V118, DOI 10.1073/pnas.2022830118
   Zhao NX, 2015, BIOMATERIALS, V67, P42, DOI 10.1016/j.biomaterials.2015.07.025
   Zheng JY, 2017, THERANOSTICS, V7, P1373, DOI 10.7150/thno.17826
   Zhou G, 2021, CANCER LETT, V501, P124, DOI 10.1016/j.canlet.2020.12.022
   Zhou JH, 2017, NAT REV DRUG DISCOV, V16, P181, DOI 10.1038/nrd.2016.199
   Zhu GZ, 2015, BIOCONJUGATE CHEM, V26, P2186, DOI 10.1021/acs.bioconjchem.5b00291
   Zuchero YJY, 2016, NEURON, V89, P70, DOI 10.1016/j.neuron.2015.11.024
   Zugazagoitia J, 2016, CLIN THER, V38, P1551, DOI 10.1016/j.clinthera.2016.03.026
NR 145
TC 17
Z9 17
U1 7
U2 32
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 1525-0016
EI 1525-0024
J9 MOL THER
JI Mol. Ther.
PD AUG 4
PY 2021
VL 29
IS 8
BP 2396
EP 2411
DI 10.1016/j.ymthe.2021.06.010
PG 16
WC Biotechnology & Applied Microbiology; Genetics & Heredity; Medicine,
   Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Genetics & Heredity; Research &
   Experimental Medicine
GA UD5YV
UT WOS:000687283200007
PM 34146729
OA hybrid, Green Published
DA 2022-11-30
ER

PT J
AU Su, D
   Garg, S
AF Su, Daniel
   Garg, Sunir
TI The retinal function imager and clinical applications
SO EYE AND VISION
LA English
DT Review
DE Retinal function imager; Retinal blood flow; Blood flow velocity;
   Oximetry; Noninvasive imaging; Retina
ID BLOOD-FLOW-VELOCITY; FLUORESCEIN ANGIOGRAPHY
AB Background: The Retinal Function Imager (RFI) provides in vivo and noninvasive imaging of both the retinal structure and function.
   Review: The RFI can create capillary perfusion maps, measure blood flow velocity, and determine metabolic function including blood oximetry. It can aid clinical diagnosis as well as assess treatment response in several retinal vascular diseases including diabetic retinopathy. Blood flow velocity abnormalities have also been implicated in disease such as age-related macular degeneration and require further investigation. Compared with optical coherence tomography angiography, the RFI produces capillary maps of comparable image quality and wider field of view but it is unable to provide depth-resolved information and has longer image acquisition time. Currently, functional imaging using blood oximetry has limited applications and additional research is required.
   Conclusion: The RFI offers noninvasive, high-resolution imaging of retinal microvasculature by creating capillary perfusion maps. In addition, it is capable of measuring retinal blood velocity directly and performs functional imaging with retinal blood oximetry. Its clinical applications are broad and additional research with functional imaging may potentially lead to diagnosis of diseases and their progression before anatomic abnormalities become evident, but longer image acquisition times may limit its clinical adoption.
C1 [Su, Daniel; Garg, Sunir] Mid Atlantic Retina, Wills Eye Hosp, Retina Serv, 840 Walnut St,Suite 1020, Philadelphia, PA 19107 USA.
C3 Jefferson University
RP Garg, S (通讯作者)，Mid Atlantic Retina, Wills Eye Hosp, Retina Serv, 840 Walnut St,Suite 1020, Philadelphia, PA 19107 USA.
EM sgarg@midatlanticretina.com
CR Arbel Y, 2014, ATHEROSCLEROSIS, V232, P149, DOI 10.1016/j.atherosclerosis.2013.10.033
   Barak A, 2012, EUR J OPHTHALMOL, V22, P423, DOI 10.5301/ejo.5000074
   Birger Y, 2011, GRAEF ARCH CLIN EXP, V249, P1587, DOI 10.1007/s00417-011-1716-7
   Bohni SC, 2015, EYE LOND, V29, P630
   Brancato R, 1998, Semin Ophthalmol, V13, P189, DOI 10.3109/08820539809056052
   Burgansky-Eliash Z, 2014, CURR EYE RES, V39, P304, DOI 10.3109/02713683.2013.840384
   Burgansky-Eliash Z, 2012, RETINA-J RET VIT DIS, V32, P112, DOI 10.1097/IAE.0b013e31821ba2c4
   Burgansky-Eliash Z, 2010, RETINA-J RET VIT DIS, V30, P765, DOI 10.1097/IAE.0b013e3181c596c6
   Chhablani J, 2013, GRAEF ARCH CLIN EXP, V251, P2665, DOI 10.1007/s00417-013-2360-1
   Ganekal S, 2013, NEPAL J OPHTHALMOL, V5, P250, DOI 10.3126/nepjoph.v5i2.8738
   Gutfreund S, 2013, GRAEF ARCH CLIN EXP, V251, P1507, DOI 10.1007/s00417-013-2325-4
   Izhaky D, 2009, JPN J OPHTHALMOL, V53, P345, DOI 10.1007/s10384-009-0689-0
   KWITEROVICH KA, 1991, OPHTHALMOLOGY, V98, P1139
   Linsenmeier RA, 2017, PROG RETIN EYE RES, V58, P115, DOI 10.1016/j.preteyeres.2017.01.003
   Liu GJ, 2017, J BIOPHOTONICS, V10, P1464, DOI 10.1002/jbio.201600325
   Nelson DA, 2005, OPHTHAL SURG LAS IM, V36, P57
   Nelson DA, 2011, CLIN OPHTHALMOL, V5, P1095, DOI 10.2147/OPTH.S20103
   Spaide RF, 2015, JAMA OPHTHALMOL, V133, P45, DOI 10.1001/jamaophthalmol.2014.3616
   Wang L, 2018, CURR EYE RES, V43, P273, DOI 10.1080/02713683.2017.1414853
   Witkin AJ, 2012, AM J OPHTHALMOL, V154, P901, DOI 10.1016/j.ajo.2012.03.052
   YANNUZZI LA, 1986, OPHTHALMOLOGY, V93, P611
NR 21
TC 10
Z9 10
U1 1
U2 3
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2326-0254
J9 EYE VISION
JI Eye Vis.
PD AUG 12
PY 2018
VL 5
AR 20
DI 10.1186/s40662-018-0114-1
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA HJ6NI
UT WOS:000457306900001
PM 30123814
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Kaarniranta, K
   Kajdanek, J
   Morawiec, J
   Pawlowska, E
   Blasiak, J
AF Kaarniranta, Kai
   Kajdanek, Jakub
   Morawiec, Jan
   Pawlowska, Elzbieta
   Blasiak, Janusz
TI PGC-1 Protects RPE Cells of the Aging Retina against Oxidative
   Stress-Induced Degeneration through the Regulation of Senescence and
   Mitochondrial Quality Control. The Significance for AMD Pathogenesis
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Review
DE PGC-1; age-related macular degeneration; AMD; senescence; mitochondrial
   quality control; mitochondria; oxidative stress
ID PIGMENT EPITHELIAL-CELLS; RECEPTOR-GAMMA COACTIVATOR-1-ALPHA; OUTER
   SEGMENT PHAGOCYTOSIS; ENDOTHELIAL GROWTH-FACTOR; SKELETAL-MUSCLE;
   TRANSCRIPTIONAL COACTIVATOR; DNA-DAMAGE; PGC-1-RELATED COACTIVATOR;
   MACULAR DEGENERATION; CELLULAR SENESCENCE
AB PGC-1 (peroxisome proliferator-activated receptor gamma coactivator 1-alpha) is a transcriptional coactivator of many genes involved in energy management and mitochondrial biogenesis. PGC-1 expression is associated with cellular senescence, organismal aging, and many age-related diseases, including AMD (age-related macular degeneration), an important global issue concerning vision loss. We and others have developed a model of AMD pathogenesis, in which stress-induced senescence of retinal pigment epithelium (RPE) cells leads to AMD-related pathological changes. PGC-1 can decrease oxidative stress, a key factor of AMD pathogenesis related to senescence, through upregulation of antioxidant enzymes and DNA damage response. PGC-1 is an important regulator of VEGF (vascular endothelial growth factor), which is targeted in the therapy of wet AMD, the most devastating form of AMD. Dysfunction of mitochondria induces cellular senescence associated with AMD pathogenesis. PGC-1 can improve mitochondrial biogenesis and negatively regulate senescence, although this function of PGC-1 in AMD needs further studies. Post-translational modifications of PGC-1 by AMPK (AMP kinase) and SIRT1 (sirtuin 1) are crucial for its activation and important in AMD pathogenesis.
C1 [Kaarniranta, Kai] Univ Eastern Finland, Dept Ophthalmol, Kuopio 70211, Finland.
   [Kaarniranta, Kai] Kuopio Univ Hosp, Dept Ophthalmol, Kuopio 70029, Finland.
   [Kajdanek, Jakub; Blasiak, Janusz] Univ Lodz, Fac Biol & Environm Protect, Dept Mol Genet, Pomorska 141-143, PL-90236 Lodz, Poland.
   [Morawiec, Jan] Med Univ Lodz, Dept Gen & Colorectal Surg, Pl Hallera 1, PL-90647 Lodz, Poland.
   [Pawlowska, Elzbieta] Med Univ Lodz, Dept Orthodont, Pomorska 251, PL-92216 Lodz, Poland.
C3 University of Eastern Finland; Kuopio University Hospital; University of
   Eastern Finland; University of Lodz; Medical University Lodz; Medical
   University Lodz
RP Blasiak, J (通讯作者)，Univ Lodz, Fac Biol & Environm Protect, Dept Mol Genet, Pomorska 141-143, PL-90236 Lodz, Poland.
EM kai.kaarniranta@kuh.fi; jakub.kajdanek@unilodz.eu; jmorawiec@op.pl;
   elzbieta.pawlowska@umed.lodz.pl; janusz.blasiak@biol.uni.lodz.pl
OI Blasiak, Janusz/0000-0001-9539-9584; Pawlowska,
   Elzbieta/0000-0002-5373-4783
FU National Science Centre, Poland [2017/27/B/NZ3/00872]
FX This research was funded by National Science Centre, Poland grant number
   2017/27/B/NZ3/00872.
CR Al-Hussaini H, 2008, MOL VIS, V14, P1784
   Barnstable CJ, 2006, ADV EXP MED BIOL, V572, P291
   Barot M, 2011, CURR EYE RES, V36, P1069, DOI 10.3109/02713683.2011.607536
   Bian ZM, 2018, EXP EYE RES, V170, P29, DOI 10.1016/j.exer.2018.02.014
   Blasiak J, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/5293258
   Blasiak J, 2012, INT J MOL SCI, V13, P13378, DOI 10.3390/ijms131013378
   Blasiak J, 2011, FRONT BIOSCI-LANDMRK, V16, P1291, DOI 10.2741/3789
   Borniquel S, 2006, FASEB J, V20, P1889, DOI 10.1096/fj.05-5189fje
   Bringold F, 2000, EXP GERONTOL, V35, P317, DOI 10.1016/S0531-5565(00)00083-8
   Brown EE, 2018, ADV EXP MED BIOL, V1074, P11, DOI 10.1007/978-3-319-75402-4_2
   Canto C, 2009, CURR OPIN LIPIDOL, V20, P98, DOI 10.1097/MOL.0b013e328328d0a4
   Cartoni R, 2005, J PHYSIOL-LONDON, V567, P349, DOI 10.1113/jphysiol.2005.092031
   Chen JQ, 2009, BBA-MOL CELL RES, V1793, P1540, DOI 10.1016/j.bbamcr.2009.06.001
   Cherry AD, 2015, ANTIOXID REDOX SIGN, V22, P965, DOI 10.1089/ars.2014.6200
   Cherry AD, 2014, J BIOL CHEM, V289, P41, DOI 10.1074/jbc.M113.512483
   Cristofalo VJ, 2004, MECH AGEING DEV, V125, P827, DOI 10.1016/j.mad.2004.07.010
   Cui LB, 2006, CELL, V127, P59, DOI 10.1016/j.cell.2006.09.015
   Dai DF, 2009, CIRCULATION, V119, P2789, DOI 10.1161/CIRCULATIONAHA.108.822403
   De Jong P., 2018, EYE
   DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363
   Egger A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031272
   Eisele PS, 2015, BIOCHEM BIOPH RES CO, V464, P692, DOI 10.1016/j.bbrc.2015.06.166
   Eiyama A, 2015, CURR OPIN CELL BIOL, V33, P95, DOI 10.1016/j.ceb.2015.01.002
   Esterbauer H, 1999, GENOMICS, V62, P98, DOI 10.1006/geno.1999.5977
   Feher J, 2006, NEUROBIOL AGING, V27, P983, DOI 10.1016/j.neurobiolaging.2005.05.012
   Fernandez-Marcos PJ, 2011, AM J CLIN NUTR, V93, p884S, DOI 10.3945/ajcn.110.001917
   Ferrington DA, 2017, REDOX BIOL, V13, P255, DOI 10.1016/j.redox.2017.05.015
   Ferrington DA, 2016, EXP EYE RES, V145, P269, DOI 10.1016/j.exer.2016.01.018
   Finneman SC, 2001, J EXP MED, V194, P1289, DOI 10.1084/jem.194.9.1289
   Finnemann SC, 2003, EMBO J, V22, P4143, DOI 10.1093/emboj/cdg416
   Franceschi C, 2000, ANN NY ACAD SCI, V908, P244
   Franceschi C, 2014, J GERONTOL A-BIOL, V69, pS4, DOI 10.1093/gerona/glu057
   Gerhart-Hines Z, 2007, EMBO J, V26, P1913, DOI 10.1038/sj.emboj.7601633
   Gleyzer N, 2005, MOL CELL BIOL, V25, P1354, DOI 10.1128/MCB.25.4.1354-1366.2005
   Golestaneh N, 2016, J TRANSL MED, V14, DOI 10.1186/s12967-016-1101-8
   Housley MP, 2009, J BIOL CHEM, V284, P5148, DOI 10.1074/jbc.M808890200
   Hyttinen JMT, 2018, CELL MOL LIFE SCI, V75, P2991, DOI 10.1007/s00018-018-2843-7
   Hyttinen JMT, 2017, AGEING RES REV, V36, P64, DOI 10.1016/j.arr.2017.03.006
   Iacovelli J, 2016, INVEST OPHTH VIS SCI, V57, P1038, DOI 10.1167/iovs.15-17758
   Jager S, 2007, P NATL ACAD SCI USA, V104, P12017, DOI 10.1073/pnas.0705070104
   Jeyapalan JC, 2008, MECH AGEING DEV, V129, P467, DOI 10.1016/j.mad.2008.04.001
   Kaarniranta K, 2017, CELL BIOL TOXICOL, V33, P113, DOI 10.1007/s10565-016-9371-8
   Kaarniranta K, 2013, AUTOPHAGY, V9, P973, DOI 10.4161/auto.24546
   Kauppinen A, 2016, CELL MOL LIFE SCI, V73, P1765, DOI 10.1007/s00018-016-2147-8
   Knutti D, 2001, P NATL ACAD SCI USA, V98, P9713, DOI 10.1073/pnas.171184698
   Korolchuk VI, 2017, EBIOMEDICINE, V21, P7, DOI 10.1016/j.ebiom.2017.03.020
   Kosmidou C, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-017-17634-1
   Kowald Axel, 2011, Commun Integr Biol, V4, P627, DOI 10.4161/cib.4.5.17110
   Kozlowski MR, 2012, MED HYPOTHESES, V78, P505, DOI 10.1016/j.mehy.2012.01.018
   Li J, 2015, TOXICOL SCI, V143, P196, DOI 10.1093/toxsci/kfu223
   Li XH, 2007, NATURE, V447, P1012, DOI 10.1038/nature05861
   Liu C, 2007, NATURE, V447, P477, DOI 10.1038/nature05767
   Lopez-Otin C, 2013, CELL, V153, P1194, DOI 10.1016/j.cell.2013.05.039
   Maeda A, 2009, J BIOL CHEM, V284, P15173, DOI 10.1074/jbc.M900322200
   Mailloux RJ, 2011, FREE RADICAL BIO MED, V51, P1106, DOI 10.1016/j.freeradbiomed.2011.06.022
   Martin OJ, 2014, CIRC RES, V114, P626, DOI 10.1161/CIRCRESAHA.114.302562
   Mattiasson G, 2003, NAT MED, V9, P1062, DOI 10.1038/nm903
   Mihaylova MM, 2011, NAT CELL BIOL, V13, P1016, DOI 10.1038/ncb2329
   Mimura T, 2013, EXP EYE RES, V116, P17, DOI 10.1016/j.exer.2013.07.017
   Mitter SK, 2014, AUTOPHAGY, V10, P1989, DOI 10.4161/auto.36184
   Miura S, 2008, ENDOCRINOLOGY, V149, P4527, DOI 10.1210/en.2008-0466
   Molusky MM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047970
   Mukherjee PK, 2007, P NATL ACAD SCI USA, V104, P13158, DOI 10.1073/pnas.0705963104
   Nandrot EE, 2004, J EXP MED, V200, P1539, DOI 10.1084/jem.20041447
   Nashine S, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.348
   Nordgaard CL, 2006, INVEST OPHTH VIS SCI, V47, P815, DOI 10.1167/iovs.05-0976
   Nordgaard CL, 2008, INVEST OPHTH VIS SCI, V49, P2848, DOI 10.1167/iovs.07-1352
   Olson BL, 2008, GENE DEV, V22, P252, DOI 10.1101/gad.1624208
   Patrushev N, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033211
   Pfluger PT, 2008, P NATL ACAD SCI USA, V105, P9793, DOI 10.1073/pnas.0802917105
   Popov DV, 2015, J MOL ENDOCRINOL, V55, P159, DOI 10.1530/JME-15-0150
   Puigserver P, 1999, SCIENCE, V286, P1368, DOI 10.1126/science.286.5443.1368
   Puigserver P, 1998, CELL, V92, P829, DOI 10.1016/S0092-8674(00)81410-5
   Puigserver P, 2001, MOL CELL, V8, P971, DOI 10.1016/S1097-2765(01)00390-2
   Qin WP, 2009, ARCH NEUROL-CHICAGO, V66, P352, DOI 10.1001/archneurol.2008.588
   Riazi-Esfahani Mohammad, 2017, J Ophthalmic Vis Res, V12, P424, DOI 10.4103/jovr.jovr_182_17
   Rickman CB, 2013, INVEST OPHTH VIS SCI, V54, pORSF68, DOI 10.1167/iovs.13-12757
   Rigoulet M, 2011, ANTIOXID REDOX SIGN, V14, P459, DOI 10.1089/ars.2010.3363
   Roggia MF, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0134870
   Sahin E, 2011, NATURE, V470, P359, DOI 10.1038/nature09787
   Saint-Geniez M, 2013, AM J PATHOL, V182, P255, DOI 10.1016/j.ajpath.2012.09.003
   SanGiovanni JP, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053155
   Sawada O, 2014, EXP EYE RES, V123, P27, DOI 10.1016/j.exer.2014.04.003
   Schmidt-Erfurth U, 2014, BRIT J OPHTHALMOL, V98, P1144, DOI 10.1136/bjophthalmol-2014-305702
   Schriner SE, 2005, SCIENCE, V308, P1909, DOI 10.1126/science.1106653
   Sen N, 2011, MOL CELL, V44, P621, DOI 10.1016/j.molcel.2011.08.044
   Shin JH, 2011, CELL, V144, P689, DOI 10.1016/j.cell.2011.02.010
   Sikora E, 2016, CURR DRUG TARGETS, V17, P377, DOI 10.2174/1389450116666151019094724
   Sikora E, 2011, AGEING RES REV, V10, P146, DOI 10.1016/j.arr.2010.10.002
   Sin TK, 2014, J PHYSIOL-LONDON, V592, P2535, DOI 10.1113/jphysiol.2014.271387
   Sparrow JR, 2012, PROG RETIN EYE RES, V31, P121, DOI 10.1016/j.preteyeres.2011.12.001
   Srivastava S, 2009, HUM MOL GENET, V18, P1805, DOI 10.1093/hmg/ddp093
   STONE J, 1995, J NEUROSCI, V15, P4738, DOI 10.1523/jneurosci.15-07-04738.1995
   Suliman HB, 2016, PHARMACOL REV, V68, P20, DOI 10.1124/pr.115.011502
   Sun MJ, 2006, J BIOL CHEM, V281, P4222, DOI 10.1074/jbc.M509769200
   Tsunemi T, 2012, PROG NEUROBIOL, V97, P142, DOI 10.1016/j.pneurobio.2011.10.004
   Ueta T, 2012, ARTERIOSCL THROM VAS, V32, P1366, DOI 10.1161/ATVBAHA.112.248021
   Valapala M, 2014, AUTOPHAGY, V10, P480, DOI 10.4161/auto.27292
   Valle I, 2005, CARDIOVASC RES, V66, P562, DOI 10.1016/j.cardiores.2005.01.026
   Vercauteren K, 2008, J BIOL CHEM, V283, P12102, DOI 10.1074/jbc.M710150200
   Vercauteren K, 2006, MOL CELL BIOL, V26, P7409, DOI 10.1128/MCB.00585-06
   Wallberg AE, 2003, MOL CELL, V12, P1137, DOI 10.1016/S1097-2765(03)00391-5
   Wu H, 2002, SCIENCE, V296, P349, DOI 10.1126/science.1071163
   Wu ZD, 1999, CELL, V98, P115, DOI 10.1016/S0092-8674(00)80611-X
   Xia HM, 2011, EXP EYE RES, V93, P862, DOI 10.1016/j.exer.2011.09.020
   Xiong SQ, 2015, CELL REP, V12, P1391, DOI 10.1016/j.celrep.2015.07.047
   Xiong SQ, 2013, ARTERIOSCL THROM VAS, V33, P988, DOI 10.1161/ATVBAHA.112.301019
   Yoshioka T, 2009, BIOCHEM BIOPH RES CO, V381, P537, DOI 10.1016/j.bbrc.2009.02.077
   Yu DY, 2001, PROG RETIN EYE RES, V20, P175, DOI 10.1016/S1350-9462(00)00027-6
   Zhang JZ, 2014, INT J MOL MED, V33, P817, DOI 10.3892/ijmm.2014.1650
   Zhang M, 2018, DIS MODEL MECH, V11, DOI 10.1242/dmm.032698
   Zhang YB, 2009, J BIOL CHEM, V284, P32813, DOI 10.1074/jbc.M109.037556
   Zhu L, 2010, J NUTR BIOCHEM, V21, P1089, DOI 10.1016/j.jnutbio.2009.09.006
   Zhu X, 2016, EXP CELL RES, V348, P87, DOI 10.1016/j.yexcr.2016.09.002
NR 114
TC 64
Z9 65
U1 1
U2 12
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1422-0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD AUG
PY 2018
VL 19
IS 8
AR 2317
DI 10.3390/ijms19082317
PG 20
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA GR7LE
UT WOS:000442869800169
PM 30087287
OA Green Submitted, Green Published, gold
DA 2022-11-30
ER

PT J
AU Fan, YT
   Huang, ZX
   Long, CD
   Ning, J
   Zhang, H
   Kuang, XL
   Zhang, QJ
   Shen, HX
AF Fan, Yuting
   Huang, Zixin
   Long, Chongde
   Ning, Jie
   Zhang, Han
   Kuang, Xielan
   Zhang, Qingjiong
   Shen, Huangxuan
TI ID2 protects retinal pigment epithelium cells from oxidative damage
   through p-ERK1/2/ID2/NRF2
SO ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS
LA English
DT Article
DE Age-related macular degeneration; Oxidative stress; Retinal pigment
   epithelium; Inhibitor of DNA binding protein 2
ID MACULAR DEGENERATION; UP-REGULATION; STEM-CELLS; STRESS; PROTEINS;
   ANTIOXIDANT; NRF2; MECHANISMS; TISSUE; ERK
AB Age-related macular degeneration (AMD) is the leading cause of blindness during aging. The degeneration of retinal pigment epithelium (RPE) is the main pathologic characteristic of AMD. ID2 is a member of the Inhibitor of DNA binding proteins (ID) family and is involved in regulation of cell proliferation and differentiation. However, currently the role of ID2 in oxidative injury response in RPE cells remains unknown. Here we showed that oxidative stress increased ID2 expression in RPE cells. Knockdown of ID2 promoted cell apoptosis and increased ROS level in RPE cells that were subjected to oxidative damage. In addition, over-expression of ID2 attenuated the oxidative damage response in RPE cells. Mechanistically, ID2 protected RPE cells from oxidative damage through activating NRF2. Furthermore, phosphorylation of ERK1/2 positively regulated the protective function of ID2. Finally, we confirmed that the oxidative damage increased Id2 expression and over-expression of Id2 elevated Nrf2 expression in primary mouse RPE cells. Therefore, ID2 protects RPE cells from oxidative damage through the p-ERK1/2/ID2/NRF2 pathway. Our study contributes to a better understanding of the mechanisms underlying oxidative stress in AMD and may present a new strategy for AMD treatment.
C1 [Fan, Yuting; Huang, Zixin; Long, Chongde; Ning, Jie; Zhang, Han; Kuang, Xielan; Zhang, Qingjiong; Shen, Huangxuan] Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, State Key Lab Ophthalmol, 54 Xianlie Rd, Guangzhou 510060, Guangdong, Peoples R China.
   [Kuang, Xielan; Shen, Huangxuan] Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, State Key Lab Ophthalmol, Biobank Eye, 54 Xianlie Rd, Guangzhou 510060, Guangdong, Peoples R China.
C3 Sun Yat Sen University; Sun Yat Sen University
RP Shen, HX (通讯作者)，Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, 54 Xianlie Rd, Guangzhou 510060, Guangdong, Peoples R China.
EM shenhx@mail.sysu.edu.cn
RI Zhang, Qingjiong/AAR-6331-2021
OI Zhang, Qingjiong/0000-0001-7508-848X
FU National Natural Science Foundation of China [81670874]; Fundamental
   Research Funds of the State Key Laboratory of Ophthalmology
   [3030902113057]
FX This study was supported by the National Natural Science Foundation of
   China (81670874) and the Fundamental Research Funds of the State Key
   Laboratory of Ophthalmology (3030902113057). We thank Associated
   Professor Lizi Wu (UF Genetics Institute, University of Florida) and
   Doctor Shuibin Lin (Department of Biological Chemistry and Molecular
   Pharmacology, Harvard Medical School) for helping us revising our
   language.
CR Bai J, 2014, MOL MED REP, V10, P491, DOI 10.3892/mmr.2014.2154
   Bensellam M, 2015, DIABETOLOGIA, V58, P758, DOI 10.1007/s00125-015-3503-1
   Bresciani A, 2017, ARCH BIOCHEM BIOPHYS, V631, P31, DOI 10.1016/j.abb.2017.08.003
   Campagne MV, 2014, J PATHOL, V232, P151, DOI 10.1002/path.4266
   Carvajal-Yepes M, 2011, J BIOL CHEM, V286, P8941, DOI 10.1074/jbc.M110.186684
   Datta S, 2017, PROG RETIN EYE RES, V60, P201, DOI 10.1016/j.preteyeres.2017.03.002
   Fei F, 2015, CELL MOL NEUROBIOL, V35, P1039, DOI 10.1007/s10571-015-0198-2
   Feng YL, 2017, ONCOTARGET, V8, P113002, DOI 10.18632/oncotarget.22949
   Fernandez-Godino R, 2016, NAT PROTOC, V11, P1206, DOI 10.1038/nprot.2016.065
   Ferrington DA, 2016, PROG RETIN EYE RES, V51, P69, DOI 10.1016/j.preteyeres.2015.09.002
   Galan A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101349
   Gao YR, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.311
   Ghisi M, 2016, CANCER CELL, V30, P59, DOI 10.1016/j.ccell.2016.05.019
   Gordois A, 2012, GLOB PUBLIC HEALTH, V7, P465, DOI 10.1080/17441692.2011.634815
   Gorrini C, 2013, NAT REV DRUG DISCOV, V12, P931, DOI 10.1038/nrd4002
   Hamanaka RB, 2010, TRENDS BIOCHEM SCI, V35, P505, DOI 10.1016/j.tibs.2010.04.002
   Hayes JD, 2014, TRENDS BIOCHEM SCI, V39, P199, DOI 10.1016/j.tibs.2014.02.002
   HE J, 2017, BIOMED RES INT, V2017, DOI DOI 10.1155/2017/3681707
   Helfenberger KE, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0193022
   Hirotsu Y, 2012, NUCLEIC ACIDS RES, V40, P10228, DOI 10.1093/nar/gks827
   Hussain RM, 2016, J INTEGR MED-JIM, V14, P456, DOI 10.1016/S2095-4964(16)60279-0
   Khan KN, 2016, PROG RETIN EYE RES, V53, P70, DOI 10.1016/j.preteyeres.2016.04.008
   Kobayashi M, 2005, ANTIOXID REDOX SIGN, V7, P385, DOI 10.1089/ars.2005.7.385
   Lasorella A, 2014, NAT REV CANCER, V14, P77, DOI 10.1038/nrc3638
   Lee JY, 2017, J UROLOGY, V197, P1539, DOI 10.1016/j.juro.2016.12.009
   Lu ZY, 2016, MOL MED REP, V14, P643, DOI 10.3892/mmr.2016.5314
   Fanjul-Moles ML, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/7420637
   Luo X, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00240
   Ma Q, 2013, ANNU REV PHARMACOL, V53, P401, DOI 10.1146/annurev-pharmtox-011112-140320
   Masuda T, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/9208489
   Mitsuishi Y, 2012, FRONT ONCOL, V2, DOI 10.3389/fonc.2012.00200
   Moiseyev G, 2005, P NATL ACAD SCI USA, V102, P12413, DOI 10.1073/pnas.0503460102
   Nigmatullina L, 2017, EMBO J, V36, P869, DOI 10.15252/embj.201694959
   Sun MX, 2017, IMMUNITY, V47, P389, DOI 10.1016/j.immuni.2017.08.019
   Wang JP, 2018, EXP PHYSIOL, V103, P461, DOI 10.1113/EP086650
   Williams DL, 2008, VET CLIN N AM-SMALL, V38, P179, DOI 10.1016/j.cvsm.2007.10.006
   Yang J, 2014, CARDIOVASC RES, V104, P388, DOI 10.1093/cvr/cvu215
   Zhao Y, 2014, J BIOL CHEM, V289, P29112, DOI 10.1074/jbc.M114.571679
   Zhou JLX, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0131043
   Zhou X, 2017, CURR MOL MED, V17, P312, DOI 10.2174/1566524017666171106115655
NR 40
TC 11
Z9 11
U1 1
U2 9
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0003-9861
EI 1096-0384
J9 ARCH BIOCHEM BIOPHYS
JI Arch. Biochem. Biophys.
PD JUL 15
PY 2018
VL 650
BP 1
EP 13
DI 10.1016/j.abb.2018.05.008
PG 13
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA GJ5MK
UT WOS:000435425400001
PM 29753724
DA 2022-11-30
ER

PT J
AU Hong, HS
   Kim, S
   Nam, S
   Um, J
   Kim, YH
   Son, Y
AF Hong, Hyun Sook
   Kim, Suna
   Nam, Seungwoo
   Um, Jihyun
   Kim, Yeong Hoon
   Son, Youngsook
TI Effect of substance P on recovery from laser-induced retinal
   degeneration
SO WOUND REPAIR AND REGENERATION
LA English
DT Article
ID ENDOTHELIAL PROGENITOR CELLS; BONE-MARROW; STEM-CELLS; PIGMENT
   EPITHELIUM; CHOROIDAL NEOVASCULARIZATION; MACULAR DEGENERATION; RAT
   MODEL; TRANSPLANTATION; INJURY; VEGF
AB Retinal degeneration is caused by neovascularization and persistent inflammation in the retinal pigment epithelium (RPE) and choroid, and causes serious eye disease including age-related macular degeneration (AMD). Thus, inhibiting inflammation and neovascularization may be a primary approach to protect the retina from degeneration. The purpose of this study was to determine whether substance P (SP), which can suppress inflammation and mobilize stem cells, can protect the RPE from degeneration. The effect of SP was evaluated by analyzing systemic inflammation, cell survival, and neovascularization within the argon laser-injured retina of mice. At 1 week postinjury, the SP-treated group had lower tumor necrosis factor-alpha and higher interleukin-10 serum concentrations, and a more intact retinal structure compared to the vehicle-treated group. In mice administered SP repeatedly for 4 weeks, the retinal structure appeared normal and showed sparse neovascularization, whereas the vehicle-treated group showed severe retinal destruction and dense neovascularization. Moreover, the efficacy of SP was identical to that of mesenchymal stem cells that were transplanted into the vitreous after retinal injury. This study highlights the potential for the endogenous neuropeptide SP as a treatment for retinal damage to prevent conditions such as AMD.
C1 [Hong, Hyun Sook] Kyung Hee Univ, Coll Med, East West Med Res Inst, Seoul, South Korea.
   [Kim, Suna; Nam, Seungwoo; Um, Jihyun; Son, Youngsook] Kyung Hee Univ, Coll Life Sci, Dept Genet Engn, Seoul, South Korea.
   [Kim, Suna; Nam, Seungwoo; Um, Jihyun; Son, Youngsook] Kyung Hee Univ, Grad Sch Biotechnol, Seoul, South Korea.
   [Kim, Yeong Hoon] Catholic Univ Korea, St Pauls Hosp, Coll Med, Dept Ophthalmol, Seoul, South Korea.
C3 Kyung Hee University; Kyung Hee University; Kyung Hee University;
   Catholic University of Korea
RP Son, Y (通讯作者)，Kyung Hee Univ, Dept Genet Engn, Seoul, South Korea.
EM ysson@khu.ac.kr
RI HONG, HYUN SOOK/AAI-3017-2020
OI HONG, HYUN SOOK/0000-0003-3659-1386
FU Korean Health Technology R&D Project grant from the Ministry of Health
   and Welfare (Sejong, Republic of Korea, Republic of Korea). [A120627,
   HI13C1479]
FX This study was supported by a Korean Health Technology R&D Project grant
   (A120627, HI13C1479) from the Ministry of Health and Welfare (Sejong,
   Republic of Korea, Republic of Korea).
CR ALGVERE PV, 1994, GRAEF ARCH CLIN EXP, V232, P707, DOI 10.1007/BF00184273
   Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   An YS, 2011, J CELL PHYSIOL, V226, P1204, DOI 10.1002/jcp.22447
   [Anonymous], 2010, SUMMARY PRODUCT CHAR
   Asahara T, 1999, CIRC RES, V85, P221, DOI 10.1161/01.RES.85.3.221
   Asahara T, 1999, EMBO J, V18, P3964, DOI 10.1093/emboj/18.14.3964
   Binder S, 2007, PROG RETIN EYE RES, V26, P516, DOI 10.1016/j.preteyeres.2007.02.002
   Carmeliet P, 2002, SEMIN CELL DEV BIOL, V13, P39, DOI 10.1006/scdb.2001.0290
   Dang PMC, 2006, FASEB J, V20, P1504, DOI 10.1096/fj.05-5395fje
   Engelmann K, 2004, GRAEF ARCH CLIN EXP, V242, P65, DOI 10.1007/s00417-003-0811-9
   Enzmann V, 2009, ARCH OPHTHALMOL-CHIC, V127, P563, DOI 10.1001/archophthalmol.2009.65
   Ferrari G, 1998, SCIENCE, V279, P1528, DOI 10.1126/science.279.5356.1528
   Harris JR, 2009, STEM CELLS, V27, P457, DOI 10.1634/stemcells.2008-0836
   Harris JR, 2006, INVEST OPHTH VIS SCI, V47, P2108, DOI 10.1167/iovs.05-0928
   Hong HS, 2014, BIOCHEM BIOPH RES CO, V453, P179, DOI 10.1016/j.bbrc.2014.09.090
   Hong HS, 2014, J TOXICOL SCI, V39, P391, DOI 10.2131/jts.39.391
   Hong HS, 2009, NAT MED, V15, P425, DOI 10.1038/nm.1909
   Jiang MH, 2012, NEUROREPORT, V23, P786, DOI 10.1097/WNR.0b013e3283572206
   Kang MH, 2009, WOUND REPAIR REGEN, V17, P216, DOI 10.1111/j.1524-475X.2009.00456.x
   Kim JH, 2013, BIOMATERIALS, V34, P1657, DOI 10.1016/j.biomaterials.2012.11.008
   Kocher AA, 2001, NAT MED, V7, P430, DOI 10.1038/86498
   Koon HW, 2004, J BIOL CHEM, V279, P45519, DOI 10.1074/jbc.M408523200
   Lee JY, 2014, BURNS, V40, P127, DOI 10.1016/j.burns.2013.06.008
   Machalinska A, 2009, CURR EYE RES, V34, P748, DOI 10.1080/02713680903050592
   Meyer JS, 2006, STEM CELLS, V24, P274, DOI 10.1634/stemcells.2005-0059
   Munoz M, 2008, INVEST NEW DRUG, V26, P111, DOI 10.1007/s10637-007-9087-y
   Palmer JM, 2013, EYE, V27, P1090, DOI 10.1038/eye.2013.139
   Quartara L, 1997, NEUROPEPTIDES, V31, P537, DOI 10.1016/S0143-4179(97)90001-9
   Robinson GS, 2001, FASEB J, V15, P1215, DOI 10.1096/fj.00-0598fje
   Sheridan CM, 2006, INVEST OPHTH VIS SCI, V47, P1642, DOI 10.1167/iovs.05-0779
   Toma HS, 2010, MICROVASC RES, V80, P295, DOI 10.1016/j.mvr.2010.05.011
   Tzameret A, 2014, EXP EYE RES, V118, P135, DOI 10.1016/j.exer.2013.10.023
   Wang HC, 2010, VISION RES, V50, P665, DOI 10.1016/j.visres.2009.09.003
   Wang SM, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009200
   Weinstock JV, 2003, J IMMUNOL, V171, P3762, DOI 10.4049/jimmunol.171.7.3762
   Yeung CK, 2004, JPN J OPHTHALMOL, V48, P236, DOI 10.1007/s10384-003-0053-8
NR 36
TC 18
Z9 19
U1 0
U2 6
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1067-1927
EI 1524-475X
J9 WOUND REPAIR REGEN
JI Wound Repair Regen.
PD MAR-APR
PY 2015
VL 23
IS 2
BP 268
EP 277
DI 10.1111/wrr.12264
PG 10
WC Cell Biology; Dermatology; Medicine, Research & Experimental; Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Dermatology; Research & Experimental Medicine; Surgery
GA CK7YE
UT WOS:000356452000176
PM 25682893
DA 2022-11-30
ER

PT J
AU Hsu, J
AF Hsu, Jason
TI Drug delivery methods for posterior segment disease
SO CURRENT OPINION IN OPHTHALMOLOGY
LA English
DT Article
DE dexamethasone; drug delivery; fluocinolone acetonide; uveitis
ID INTRAVITREAL BEVACIZUMAB AVASTIN; FLUOCINOLONE ACETONIDE IMPLANT;
   RELEASE GANCICLOVIR IMPLANT; CYTOMEGALO-VIRUS RETINITIS; RETINAL VEIN
   OCCLUSION; MACULAR EDEMA; UVEITIS; IONTOPHORESIS; TRIAL; TERM
AB Purpose of review
   New pharmacotherapies for posterior segment diseases of the eye have been recently introduced which use novel drug delivery methods. the various current and potential future methods will be discussed.
   Recent findings
   Drug delivery systems have been developed which can provided controlled release of drug for potentially long periods of time. Ideal candidates for these devices are chronic conditions that require repeated local administration of drug, such as noninfectious intermediate or posterior uveitis neovascular age-related macular degeneration and persistent macular edema due to diabetic retinopathy or venous occlusive disease. Recently Retisert (Bausch & Lomb, Rochester, New York, USA) a nonbiodegradable fluocinolone acetonide implant, was approved for use in noninfectious vitis affecting the posterior segment and is currently in clinical trial for the treatment of macular edema. A biodegradable dexamethasone implant is currently in clinical trials for the treatment of uveitis and diabetic macular edema.
   Summary
   With the development of therapeutic agents that require repeated administration comes a need for new strategies to improve safety and maximize efficacy. Novel drug delivery systems involving nonbiodegradable or biodegradable implants microparticulates or nanoparticulates liposomes, or transscleral iontophoresis may provide the solution.
C1 Wills Eye Inst, Retina Serv, Philadelphia, PA 19107 USA.
C3 Jefferson University
RP Hsu, J (通讯作者)，Wills Eye Inst, Retina Serv, 840 Walnut St,Suite 1020, Philadelphia, PA 19107 USA.
EM jasonhsu.md@comcast.net
CR Ambati J, 2000, INVEST OPHTH VIS SCI, V41, P1181
   Ambati J, 2000, INVEST OPHTH VIS SCI, V41, P1186
   ANGLADE E, 1995, DRUGS, V49, P213, DOI 10.2165/00003495-199549020-00006
   Antcliff RJ, 2001, OPHTHALMOLOGY, V108, P765, DOI 10.1016/S0161-6420(00)00658-8
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   BeharCohen FF, 1997, EXP EYE RES, V65, P533, DOI 10.1006/exer.1997.0364
   Bochot A, 2000, PROG RETIN EYE RES, V19, P131, DOI 10.1016/S1350-9462(99)00014-2
   Bourges JL, 2006, ADV DRUG DELIVER REV, V58, P1182, DOI 10.1016/j.addr.2006.07.026
   Bourges JL, 2003, INVEST OPHTH VIS SCI, V44, P3562, DOI 10.1167/iovs.02-1068
   CANTRILL HL, 1989, OPHTHALMOLOGY, V96, P367, DOI 10.1016/S0161-6420(89)32900-9
   Carrasquillo KG, 2003, INVEST OPHTH VIS SCI, V44, P290, DOI 10.1167/iovs.01-1156
   de Kozak Y, 2004, EUR J IMMUNOL, V34, P3702, DOI 10.1002/eji.200425022
   Driot JY, 2004, J OCUL PHARMACOL TH, V20, P269, DOI 10.1089/1080768041223611
   Dunn JP, 2004, RETINA-J RET VIT DIS, V24, P41, DOI 10.1097/00006982-200402000-00007
   Ebrahim S, 2005, SURV OPHTHALMOL, V50, P167, DOI 10.1016/j.survophthal.2004.12.006
   Gritz DC, 2004, OPHTHALMOLOGY, V111, P491, DOI 10.1016/j.ophtha.2003.06.014
   Haupert CL, 2000, INT OPHTHALMOL CLIN, V40, P205, DOI 10.1097/00004397-200004000-00015
   HOLLAND GN, 1983, OPHTHALMOLOGY, V90, P859
   Ip MS, 2004, ARCH OPHTHALMOL-CHIC, V122, P1131, DOI 10.1001/archopht.122.8.1131
   Iturralde D, 2006, RETINA-J RET VIT DIS, V26, P279, DOI 10.1097/00006982-200603000-00005
   JABS DA, 1987, OPHTHALMOLOGY, V94, P824
   JABS DA, 1989, ARCH OPHTHALMOL-CHIC, V107, P75, DOI 10.1001/archopht.1989.01070010077031
   Jabs DA, 2000, AM J OPHTHALMOL, V130, P492, DOI 10.1016/S0002-9394(00)00659-0
   Jaffe GJ, 2006, OPHTHALMOLOGY, V113, P1020, DOI 10.1016/j.ophtha.2006.02.021
   Jaffe GJ, 2005, OPHTHALMOLOGY, V112, P1192, DOI 10.1016/j.ophtha.2005.03.013
   Jaffe GJ, 2000, OPHTHALMOLOGY, V107, P2024, DOI 10.1016/S0161-6420(00)00466-8
   Jaffe GJ, 2000, INVEST OPHTH VIS SCI, V41, P3569
   Kuppermann BD, 1996, J INFECT DIS, V173, P18, DOI 10.1093/infdis/173.1.18
   KUPPERMANN BD, 2006, INVEST OPHTHALMOL VI, V47
   Kurz Daryl, 2002, Ophthalmol Clin North Am, V15, P405, DOI 10.1016/S0896-1549(02)00034-2
   Lim JI, 1999, AM J OPHTHALMOL, V127, P288, DOI 10.1016/S0002-9394(98)00443-7
   MARTIN DF, 1994, ARCH OPHTHALMOL-CHIC, V112, P1531, DOI 10.1001/archopht.1994.01090240037023
   Martin DF, 1999, AM J OPHTHALMOL, V127, P329
   MORITERA T, 1992, INVEST OPHTH VIS SCI, V33, P3125
   Moshfeghi AA, 2005, ADV DRUG DELIVER REV, V57, P2047, DOI 10.1016/j.addr.2005.09.006
   Musch DC, 1997, NEW ENGL J MED, V337, P83, DOI 10.1056/NEJM199707103370203
   Myles ME, 2005, ADV DRUG DELIVER REV, V57, P2063, DOI 10.1016/j.addr.2005.08.006
   Parkinson TM, 2003, J OCUL PHARMACOL TH, V19, P145, DOI 10.1089/108076803321637672
   PEARSON P, 2006, INVEST OPHTHALMOL VI, V47
   PEYMAN GA, 1987, RETINA-J RET VIT DIS, V7, P227, DOI 10.1097/00006982-198707040-00005
   RAMCHANDRAN RS, 2006, INVEST OPHTHALMOL VI, V47
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rothova A, 1996, BRIT J OPHTHALMOL, V80, P332, DOI 10.1136/bjo.80.4.332
   Shane TS, 2003, AM J OPHTHALMOL, V136, P649, DOI 10.1016/S0002-9394(03)00333-7
   WEINER A, 1991, AM J OPHTHALMOL, V112, P151, DOI 10.1016/S0002-9394(14)76694-2
   Yasukawa T, 2004, PROG RETIN EYE RES, V23, P253, DOI 10.1016/j.preteyeres.2004.02.003
   Yoshizumi MO, 1997, J OCUL PHARMACOL TH, V13, P529, DOI 10.1089/jop.1997.13.529
NR 47
TC 70
Z9 73
U1 1
U2 14
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1040-8738
J9 CURR OPIN OPHTHALMOL
JI Curr. Opin. Ophthalmol.
PD MAY
PY 2007
VL 18
IS 3
BP 235
EP 239
DI 10.1097/ICU.0b013e3281108000
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 162BL
UT WOS:000246061200010
PM 17435432
DA 2022-11-30
ER

PT J
AU Ishida, BY
   Duncan, KG
   Bailey, KR
   Kane, JP
   Schwartz, DM
AF Ishida, BY
   Duncan, KG
   Bailey, KR
   Kane, JP
   Schwartz, DM
TI High density lipoprotein mediated lipid efflux from retinal pigment
   epithelial cells in culture
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID CARDIOVASCULAR-DISEASE; APOLIPOPROTEIN-E; RISK-FACTORS; AGE; DRUSEN;
   ASSOCIATION; MACULOPATHY; DEPOSITS; BINDING; PROTEIN
AB Backgound/aim: The transport of radiolabelled photoreceptor outer segments (POS) lipids was investigated by cultured retinal pigment epithelial cells (RPE). Phagocytosis of POS by the RPE is essential to maintain the health and function of the photoreceptors in vivo. POS are phagocytised at the apical cell surface of RPE cells. Phagocytised POS lipids may be either recycled to the photoreceptors for reincorporation into new POS or they may be transported to the basolateral surface for efflux into the circulation.
   Results: The authors have demonstrated that high density lipoprotein (HDL) stimulates efflux of radiolabelled lipids, of POS origin, from the basal surface of RPE cells in culture. Effluxed lipids bind preferentially to HDL species of low and high molecular weight. Effluxed radiolabelled phosphotidyl choline was the major phospholipid bound to HDL, with lesser amounts of phosphatidyl ethanolamine, phosphatidyl inosotol. Effluxed radiolabelled triglycerides, cholesterol, and cholesterol esters also bound to HDL. Lipid free apolipoprotein A-I (apoA-I) and apoA-I containing vesicles also stimulate lipid efflux.
   Conclusion: The findings suggest a role for HDL and apoA-I in regulating lipid and cholesterol transport from RPE cells that may influence the pathological lipid accumulation associated with age related macular degeneration.
C1 Univ Calif San Francisco, Dept Ophthalmol, San Francisco, CA 94143 USA.
   Univ Calif San Francisco, Inst Cardiovasc Res, San Francisco, CA 94143 USA.
   Vet Affairs Med Ctr, San Francisco, CA 94121 USA.
C3 University of California System; University of California San Francisco;
   University of California System; University of California San Francisco;
   US Department of Veterans Affairs; Veterans Health Administration (VHA)
RP Schwartz, DM (通讯作者)，Univ Calif San Francisco, Dept Ophthalmol, Box 0730, San Francisco, CA 94143 USA.
EM schwartz7@mindspring.com
FU NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL031210] Funding Source:
   NIH RePORTER; NHLBI NIH HHS [R01 HL31210] Funding Source: Medline
CR Abalain JH, 2002, CLIN CHIM ACTA, V326, P97, DOI 10.1016/S0009-8981(02)00288-7
   Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Anderson DH, 2001, AM J OPHTHALMOL, V131, P767, DOI 10.1016/S0002-9394(00)00961-2
   Assmann G, 2003, ANNU REV MED, V54, P321, DOI 10.1146/annurev.med.54.101601.152409
   BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911
   BLUMENKRANZ MS, 1986, OPHTHALMOLOGY, V93, P552
   BRESSLER NM, 1988, SURV OPHTHALMOL, V32, P375, DOI 10.1016/0039-6257(88)90052-5
   Curcio CA, 1999, ARCH OPHTHALMOL-CHIC, V117, P329, DOI 10.1001/archopht.117.3.329
   Delcourt C, 2001, Ophthalmic Epidemiol, V8, P237, DOI 10.1076/opep.8.4.237.1613
   Duncan KG, 2002, BIOCHEM BIOPH RES CO, V292, P1017, DOI 10.1006/bbrc.2002.6756
   Evans JR, 2001, PROG RETIN EYE RES, V20, P227, DOI 10.1016/S1350-9462(00)00023-9
   GIUSTO NM, 1986, BIOCHIM BIOPHYS ACTA, V860, P137, DOI 10.1016/0005-2736(86)90508-0
   Gordiyenko N, 2004, INVEST OPHTH VIS SCI, V45, P2822, DOI 10.1167/iovs.04-0074
   GREEN WR, 1993, OPHTHALMOLOGY, V100, P1519
   HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182
   HOLZ FG, 1994, ARCH OPHTHALMOL-CHIC, V112, P402, DOI 10.1001/archopht.1994.01090150132035
   Hyman L, 2000, ARCH OPHTHALMOL-CHIC, V118, P351, DOI 10.1001/archopht.118.3.351
   Ishida BY, 2004, J LIPID RES, V45, P263, DOI 10.1194/jlr.M300306-JLR200
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Klein R, 2003, OPHTHALMOLOGY, V110, P636, DOI 10.1016/S0161-6420(02)01448-3
   Leibowitz H M, 1980, Surv Ophthalmol, V24, P335
   Li CM, 2005, J LIPID RES, V46, P628, DOI 10.1194/jlr.M400428-JLR200
   Li HH, 2001, J LIPID RES, V42, P2084
   Malek G, 2003, AM J PATHOL, V162, P413, DOI 10.1016/S0002-9440(10)63836-9
   MOORE DJ, 1995, INVEST OPHTH VIS SCI, V36, P1290
   Moore DJ, 2001, INVEST OPHTH VIS SCI, V42, P2970
   Morgan John, 2004, Curr Atheroscler Rep, V6, P359
   *NAT AV EYE COUNC, 1999, NIH PUBL
   Nofer JR, 2002, ATHEROSCLEROSIS, V161, P1, DOI 10.1016/S0021-9150(01)00651-7
   Rader DJ, 2003, AM J CARDIOL, V92, p42J, DOI 10.1016/S0002-9149(03)00615-5
   REID DM, 1992, EXP EYE RES, V54, P775, DOI 10.1016/0014-4835(92)90033-O
   Rosenberg T, 1996, ACTA OPHTHALMOL SCAN, V74, P399
   Ruberti JW, 2003, INVEST OPHTH VIS SCI, V44, P1753, DOI 10.1167/iovs.02-0496
   SCANU AM, 1971, ANAL BIOCHEM, V44, P576, DOI 10.1016/0003-2697(71)90247-8
   Seddon JM, 2004, JAMA-J AM MED ASSOC, V291, P704, DOI 10.1001/jama.291.6.704
   SHERAIDAH G, 1993, OPHTHALMOLOGY, V100, P47
   Snow K K, 1999, Ophthalmic Epidemiol, V6, P125, DOI 10.1076/opep.6.2.125.1558
   SONG MK, 1990, J CELL PHYSIOL, V143, P196, DOI 10.1002/jcp.1041430127
   Spaide RF, 1999, RETINA-J RET VIT DIS, V19, P141, DOI 10.1097/00006982-199902000-00010
   STEWART JM, 2003, 1711 ASS RES VIS OPH
   Wang N, 2003, ARTERIOSCL THROM VAS, V23, P1178, DOI 10.1161/01.ATV.0000075912.83860.26
   Wang N, 2003, J CLIN INVEST, V111, P99, DOI 10.1172/JCI200316808
   Wilson HL, 2004, AM J OPHTHALMOL, V137, P615, DOI 10.1016/j.ajo.2003.10.025
   YANNUZZI LA, 1992, ARCH OPHTHALMOL-CHIC, V110, P1701
   YOUNG RW, 1987, SURV OPHTHALMOL, V31, P291, DOI 10.1016/0039-6257(87)90115-9
NR 45
TC 39
Z9 42
U1 1
U2 4
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD MAY
PY 2006
VL 90
IS 5
BP 616
EP 620
DI 10.1136/bjo.2005.085076
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 033ZG
UT WOS:000236892900026
PM 16622093
OA Green Published
DA 2022-11-30
ER

PT J
AU Ermakov, IV
   Ermakova, MR
   Gellermann, W
AF Ermakov, IV
   Ermakova, MR
   Gellermann, W
TI Simple Raman instrument for in vivo detection of macular pigments
SO APPLIED SPECTROSCOPY
LA English
DT Article
DE noninvasive detection; Raman spectroscopy; retina; macular pigments;
   lutein; zeaxanthin
ID BETA-CAROTENE; DEGENERATION
AB Raman spectroscopy holds promise as a novel noninvasive technology for the quantification of the macular pigments (NIP) lutein and zeaxanthin. These compounds, which are members of the carotenoid family, are thought to prevent or delay the onset of age-related macular degeneration, the leading cause of irreversible blindness in the elderly. It is highly likely that they achieve this protection through their function as optical filters and/or antioxidants. Using resonant excitation in the visible region, we measure and quantify the Raman signals that originate from the carbon double bond (C=C) stretch vibrations of the pi-conjugated molecule backbone. In this manuscript we describe the construction and performance of a novel compact NIP Raman instrument utilizing dielectric angle-tuned band-pass filters for wavelength selection and a single-channet photo-multiplier for the detection of NIP Raman responses. NIP concentration measurements are fast and accurate, as seen in our experiments with model eyes and living human eyes. The ease and rapidity of Raman NIP measurements, the simplicity of the instrumentation, the high accuracy of the measurements, and the lack of significant systematic errors should make this technology attractive for widespread clinical research.
C1 Univ Utah, Dept Phys, Salt Lake City, UT 84112 USA.
C3 Utah System of Higher Education; University of Utah
RP Gellermann, W (通讯作者)，Univ Utah, Dept Phys, Salt Lake City, UT 84112 USA.
EM werner@physics.utah.edu
FU NEI NIH HHS [5 R42 EY 12324-03, R42 EY012324-03] Funding Source:
   Medline; NATIONAL EYE INSTITUTE [R42EY012324] Funding Source: NIH
   RePORTER
CR American National Standards Institute, 2000, Z13612000 ANSI LAS I
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Beatty S, 2001, INVEST OPHTH VIS SCI, V42, P439
   Bernstein PS, 2002, OPHTHALMOLOGY, V109, P1780, DOI 10.1016/S0161-6420(02)01173-9
   Ermakov I, 2004, J BIOMED OPT, V9, P139, DOI 10.1117/1.1627776
   Ermakov IV, 2004, J BIOMED OPT, V9, P332, DOI 10.1117/1.1646172
   Ermakov IV, 2001, OPT LETT, V26, P202, DOI 10.1364/OL.26.000202
   Ermakov IV, 2001, OPT LETT, V26, P1179, DOI 10.1364/OL.26.001179
   Gellermann W, 2002, J OPT SOC AM A, V19, P1172, DOI 10.1364/JOSAA.19.001172
   KOYAMA Y, 1988, J RAMAN SPECTROSC, V19, P37, DOI 10.1002/jrs.1250190107
   NEELAM K, 2005, IN PRESS INVEST OPHT
   READING VM, 1974, J OPT SOC AM, V64, P231, DOI 10.1364/JOSA.64.000231
   SCHALCH W, 1999, CRC MOD NUT, P215
   SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413
   SHREVE AP, 1991, CHEM PHYS LETT, V178, P89, DOI 10.1016/0009-2614(91)85058-5
NR 15
TC 26
Z9 26
U1 0
U2 1
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0003-7028
EI 1943-3530
J9 APPL SPECTROSC
JI Appl. Spectrosc.
PD JUL
PY 2005
VL 59
IS 7
BP 861
EP 867
DI 10.1366/0003702054411616
PG 7
WC Instruments & Instrumentation; Spectroscopy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Instruments & Instrumentation; Spectroscopy
GA 945AS
UT WOS:000230473300003
PM 16053555
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Peters, F
   Ebner, LJA
   Atac, D
   Maggi, J
   Berger, W
   den Hollander, AI
   Grimm, C
AF Peters, Florian
   Ebner, Lynn J. A.
   Atac, David
   Maggi, Jordi
   Berger, Wolfgang
   den Hollander, Anneke, I
   Grimm, Christian
TI Regulation of ABCA1 by AMD-Associated Genetic Variants and Hypoxia in
   iPSC-RPE
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE ABCA1; lipid accumulation; hypoxia; iPSC-RPE; reverse cholesterol
   transport; age-related macular degeneration; LXR agonist
ID RETINAL PIGMENTED EPITHELIUM; IMPAIRED CHOLESTEROL EFFLUX; GENOME-WIDE
   ASSOCIATION; LOW-DENSITY-LIPOPROTEIN; CHOROIDAL BLOOD-FLOW; MACULAR
   DEGENERATION; LIPID-METABOLISM; TANGIER-DISEASE; AGE; PHOSPHORYLATION
AB Age-related macular degeneration (AMD) is a progressive disease of the macula characterized by atrophy of the retinal pigment epithelium (RPE) and photoreceptor degeneration, leading to severe vision loss at advanced stages in the elderly population. Impaired reverse cholesterol transport (RCT) as well as intracellular lipid accumulation in the RPE are implicated in AMD pathogenesis. Here, we focus on ATP-binding cassette transporter A1 (ABCA1), a major cholesterol transport protein in the RPE, and analyze conditions that lead to ABCA1 dysregulation in induced pluripotent stem cell (iPSC)-derived RPE cells (iRPEs). Our results indicate that the risk-conferring alleles rs1883025 (C) and rs2740488 (A) in ABCA1 are associated with increased ABCA1 mRNA and protein levels and reduced efficiency of cholesterol efflux from the RPE. Hypoxia, an environmental risk factor for AMD, reduced expression of ABCA1 and increased intracellular lipid accumulation. Treatment with a liver X receptor (LXR) agonist led to an increase in ABCA1 expression and reduced lipid accumulation. Our data strengthen the homeostatic role of cholesterol efflux in the RPE and suggest that increasing cellular cholesterol export by stimulating ABCA1 expression might lessen lipid load, improving RPE survival and reducing the risk of developing AMD.
C1 [Peters, Florian; Ebner, Lynn J. A.; Grimm, Christian] Univ Zurich, Univ Hosp Zurich, Dept Ophthalmol, Lab Retinal Cell Biol, CH-8952 Zurich, Switzerland.
   [Atac, David; Maggi, Jordi; Berger, Wolfgang] Univ Zurich, Inst Med Mol Genet, CH-8952 Zurich, Switzerland.
   [den Hollander, Anneke, I] Radboud Univ Nijmegen Med Ctr, Dept Ophthalmol, NL-6525 Nijmegen, Netherlands.
   [den Hollander, Anneke, I] AbbVie, Genom Res Ctr, 200 Sidney St, Cambridge, MA 02139 USA.
C3 University of Zurich; University Zurich Hospital; University of Zurich;
   Radboud University Nijmegen; AbbVie
RP Peters, F; Grimm, C (通讯作者)，Univ Zurich, Univ Hosp Zurich, Dept Ophthalmol, Lab Retinal Cell Biol, CH-8952 Zurich, Switzerland.
EM florian.peters@usz.ch; lynn.ebner@usz.ch; grubichatac@medmolgen.uzh.ch;
   maggi@medmolgen.uzh.ch; berger@medmolgen.uzh.ch;
   anneke.denHollander@radboudumc.nl; cgrimm@opht.uzh.ch
OI Peters, Florian/0000-0002-8529-2326; Berger,
   Wolfgang/0000-0002-0370-3815; Grubich Atac, David/0000-0001-6537-8627;
   Maggi, Jordi/0000-0002-9906-8739; Ebner, Lynn Jenny
   Alix/0000-0002-9665-9197; Grimm, Christian/0000-0001-9318-4352; den
   Hollander, Anneke/0000-0003-0634-5408
FU Vontobel Foundation; OPOS Foundation; Forschungs-kredit of the
   University of Zurich [FK-20-028]; SNF [31003A 122359, 31003A_173008,
   310030_200798]; Velux Foundation [1371]; Dutch Research Council
   [016.Vici.170.024]
FX Supported by the Vontobel Foundation and the OPOS Foundation (F.P.),
   Forschungs-kredit of the University of Zurich (grant no.: FK-20-028)
   (L.J.A.E.), SNF (31003A 122359) (W.B.), the Velux Foundation (1371)
   (W.B.), the Dutch Research Council (grant no.: 016.Vici.170.024
   (A.I.d.H.) and SNF (31003A_173008 and 310030_200798) (C.G.).
CR Anderson DH, 2001, AM J OPHTHALMOL, V131, P767, DOI 10.1016/S0002-9394(00)00961-2
   ANDERSON DH, 1978, INVEST OPHTH VIS SCI, V17, P117
   Apte RS, 2016, EBIOMEDICINE, V5, P26, DOI 10.1016/j.ebiom.2016.02.003
   Berenberg TL, 2012, RETINA-J RET VIT DIS, V32, P25, DOI 10.1097/IAE.0b013e3182150483
   BIRD AC, 1992, BRIT J OPHTHALMOL, V76, P166, DOI 10.1136/bjo.76.3.166
   Chen W, 2010, P NATL ACAD SCI USA, V107, P7401, DOI 10.1073/pnas.0912702107
   Chertov AO, 2011, J BIOL CHEM, V286, P34700, DOI 10.1074/jbc.M111.279752
   Coleman DJ, 2013, BRIT J OPHTHALMOL, V97, P1020, DOI 10.1136/bjophthalmol-2013-303143
   Curcio CA, 2001, INVEST OPHTH VIS SCI, V42, P265
   Curcio CA, 2013, RETINA-J RET VIT DIS, V33, P265, DOI 10.1097/IAE.0b013e31827e25e0
   Ebeling MC, 2021, CELLS-BASEL, V10, DOI 10.3390/cells10040789
   Ebner LJA, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-96150-9
   Ershov AV, 2000, J NEUROSCI RES, V60, P328, DOI 10.1002/(SICI)1097-4547(20000501)60:3<328::AID-JNR7>3.0.CO;2-5
   Fauser S, 2011, INVEST OPHTH VIS SCI, V52, P5525, DOI 10.1167/iovs.10-6827
   Fliesler SJ, 2010, J LIPID RES, V51, P3399, DOI 10.1194/jlr.R010538
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Gnanaguru G, 2021, MOL THER, V29, P2281, DOI 10.1016/j.ymthe.2021.03.014
   Grunwald JE, 2005, INVEST OPHTH VIS SCI, V46, P1033, DOI 10.1167/iovs.04-1050
   Hallam D, 2017, STEM CELLS, V35, P2305, DOI 10.1002/stem.2708
   Kopitz J, 2004, BIOCHIMIE, V86, P825, DOI 10.1016/j.biochi.2004.09.029
   Kurihara T, 2016, ELIFE, V5, DOI 10.7554/eLife.14319
   Lakkaraju A, 2007, P NATL ACAD SCI USA, V104, P11026, DOI 10.1073/pnas.0702504104
   Liang B, 2017, BBA-MOL CELL BIOL L, V1862, P929, DOI 10.1016/j.bbalip.2017.06.002
   Lin SC, 2012, J CLIN ENDOCR METAB, V97, pE1515, DOI 10.1210/jc.2012-1450
   Maggi J, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22041508
   NEWSOME DA, 1987, CURR EYE RES, V6, P1211, DOI 10.3109/02713688709025231
   Oram JF, 2000, BBA-MOL CELL BIOL L, V1529, P321, DOI 10.1016/S1388-1981(00)00157-8
   Parathath S, 2011, CIRC RES, V109, P1141, DOI 10.1161/CIRCRESAHA.111.246363
   Parinot C, 2014, JOVE-J VIS EXP, DOI 10.3791/52100
   Pennington KL, 2016, EYE VISION, V3, DOI 10.1186/s40662-016-0063-5
   Peter I, 2011, AM J OPHTHALMOL, V152, P1005, DOI 10.1016/j.ajo.2011.05.016
   Ranalletta M, 2006, ARTERIOSCL THROM VAS, V26, P2308, DOI 10.1161/01.ATV.0000242275.92915.43
   Regent F, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-47123-6
   Reichman S, 2017, STEM CELLS, V35, P1176, DOI 10.1002/stem.2586
   Repa JJ, 2000, SCIENCE, V289, P1524, DOI 10.1126/science.289.5484.1524
   Ristau T, 2014, INVEST OPHTH VIS SCI, V55, P210, DOI 10.1167/iovs.13-13248
   Rodriguez IR, 2004, INVEST OPHTH VIS SCI, V45, P2830, DOI 10.1167/iovs.04-0075
   Saini JS, 2017, CELL STEM CELL, V20, P635, DOI 10.1016/j.stem.2016.12.015
   Schaefer EJ, 2016, PROG CARDIOVASC DIS, V59, P97, DOI 10.1016/j.pcad.2016.08.006
   Schmitz G, 2005, BBA-MOL CELL BIOL L, V1735, P1, DOI 10.1016/j.bbalip.2005.04.004
   See RH, 2002, J BIOL CHEM, V277, P41835, DOI 10.1074/jbc.M204923200
   Sene A, 2013, CELL METAB, V17, P549, DOI 10.1016/j.cmet.2013.03.009
   Stefansson E, 2011, PROG RETIN EYE RES, V30, P72, DOI 10.1016/j.preteyeres.2010.09.003
   Storti F, 2019, ELIFE, V8, DOI 10.7554/eLife.45100
   Tabas I, 2002, J CLIN INVEST, V110, P905, DOI 10.1172/JCI200216452
   Tsai YT, 2021, AM J HUM GENET, V108, P903, DOI 10.1016/j.ajhg.2021.04.006
   van Leeuwen EM, 2018, PROG RETIN EYE RES, V67, P56, DOI 10.1016/j.preteyeres.2018.04.006
   Vedhachalam C, 2007, J BIOL CHEM, V282, P25123, DOI 10.1074/jbc.M704590200
   Wang X, 2007, J CLIN INVEST, V117, P2216, DOI 10.1172/JCI32057
   Wang YF, 2016, GRAEF ARCH CLIN EXP, V254, P323, DOI 10.1007/s00417-015-3211-z
   Westerterp M, 2013, CIRC RES, V112, P1456, DOI 10.1161/CIRCRESAHA.113.301086
   Winder AF, 1996, J CLIN PATHOL, V49, P407, DOI 10.1136/jcp.49.5.407
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yang J, 2014, HUM MOL GENET, V23, P3445, DOI 10.1093/hmg/ddu053
   Yu Y, 2011, INVEST OPHTH VIS SCI, V52, P4663, DOI 10.1167/iovs.10-7070
   Zekavat SM, 2017, J LIPID RES, V58, P1325, DOI 10.1194/jlr.M074088
   Zimmer AD, 2016, HYPOXIA, V4, P135, DOI 10.2147/HP.S99044
NR 57
TC 3
Z9 3
U1 3
U2 4
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1422-0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD MAR
PY 2022
VL 23
IS 6
AR 3194
DI 10.3390/ijms23063194
PG 20
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA 0C5IC
UT WOS:000775345700001
PM 35328615
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Losada, PG
   Rousseau, L
   Grzeskowiak, M
   Valet, M
   Nguyen, D
   Degardin, J
   Dubus, E
   Picaud, S
   Lissorgues, G
AF Losada, Pedro Gonzalez
   Rousseau, Lionel
   Grzeskowiak, Marjorie
   Valet, Manon
   Nguyen, Diep
   Degardin, Julie
   Dubus, Elisabeth
   Picaud, Serge
   Lissorgues, Gaelle
TI Protuberant Electrode Structures for Subretinal Electrical Stimulation:
   Modeling, Fabrication and in vivo Evaluation
SO FRONTIERS IN NEUROSCIENCE
LA English
DT Article
DE retinal prostheses; microfabrication; 3D microelectrode; FEM;
   subretinal; electrical stimulation
ID RETINAL PROSTHESIS; FUTURE; ARRAYS
AB Many neural interfaces used for therapeutic applications are based on extracellular electrical stimulation to control cell polarization and thus functional activity. Amongst them, retinal implants have been designed to restore visual perception in blind patients affected by photoreceptor degeneration diseases, such as age-related macular degeneration (AMD) or retinitis pigmentosa (RP). While designing such a neural interface, several aspects must be taken into account, like the stimulation efficiency related to the current distribution within the tissue, the bio-interface optimization to improve resolution and tissue integration, and the material biocompatibility associated with longterm aging. In this study, we investigate the use of original microelectrode geometries for subretinal stimulation. The proposed structures combine the use of 3D wells with protuberant mushroom shaped electrode structures in the bottom, implemented on a flexible substrate that allows the in vivo implantation of the devices. These 3D microelectrode structures were first modeled using finite element analysis. Then, a specific microfabrication process compatible with flexible implants was developed to create the 3D microelectrode structures. These structures were tested in vivo to check the adaptation of the retinal tissue to them. Finally, preliminary in vivo stimulation experiments were performed.
C1 [Losada, Pedro Gonzalez; Rousseau, Lionel; Grzeskowiak, Marjorie; Lissorgues, Gaelle] Univ Paris Est ESIEE MLV, Lab ESYCOM, Noisy Le Grand, France.
   [Valet, Manon; Nguyen, Diep; Degardin, Julie; Dubus, Elisabeth; Picaud, Serge] Sorbonne Univ, CNRS, INSERM, Inst Vis, Paris, France.
C3 Universite Gustave-Eiffel; Centre National de la Recherche Scientifique
   (CNRS); Institut National de la Sante et de la Recherche Medicale
   (Inserm); UDICE-French Research Universities; Sorbonne Universite;
   Universite Paris Cite
RP Lissorgues, G (通讯作者)，Univ Paris Est ESIEE MLV, Lab ESYCOM, Noisy Le Grand, France.
EM gaelle.lissorgues@esiee.fr
RI ; Picaud, Serge/H-4012-2014
OI Nguyen, Diep/0000-0002-8860-046X; Picaud, Serge/0000-0002-0548-5145;
   Gonzalez-Losada, Pedro/0000-0003-4950-2290
FU French Research Agency [15-CE19-006-04-NEUROMEDDLE]; laboratory ESYCOM
   through doctoral school MSTIC of University Paris Est
FX This work was partly supported by the French Research Agency under grant
   number 15-CE19-006-04-NEUROMEDDLE, and by the laboratory ESYCOM through
   the doctoral funding of the Ph.D. student PL in doctoral school MSTIC of
   University Paris Est.
CR Bendali A, 2015, BIOMATERIALS, V67, P73, DOI 10.1016/j.biomaterials.2015.07.018
   Butterwick A, 2009, EXP EYE RES, V88, P22, DOI 10.1016/j.exer.2008.09.018
   Deuschl G, 2006, NEW ENGL J MED, V355, P896, DOI 10.1056/NEJMoa060281
   Djilas M, 2011, J NEURAL ENG, V8, DOI 10.1088/1741-2560/8/4/046020
   Edwards TL, 2018, OPHTHALMOLOGY, V125, P432, DOI 10.1016/j.ophtha.2017.09.019
   Eshraghi AA, 2012, ANAT REC, V295, P1967, DOI 10.1002/ar.22580
   Fendyur Anna, 2012, Front Neuroeng, V5, P21, DOI 10.3389/fneng.2012.00021
   Flores T, 2016, J NEURAL ENG, V13, DOI 10.1088/1741-2560/13/3/036010
   Hornig R., 2017, ARTIFICIAL VISION
   Huys R, 2008, SOLID STATE ELECTRON, V52, P533, DOI 10.1016/j.sse.2007.10.025
   Joucla S, 2014, FRONT COMPUT NEUROSC, V8, DOI 10.3389/fncom.2014.00013
   Joucla S, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004828
   Kim ET, 2008, SENSORS-BASEL, V8, P5845, DOI 10.3390/s8095845
   Koo KI, 2006, SENSOR ACTUAT A-PHYS, V130, P609, DOI 10.1016/j.sna.2005.11.070
   Luo YHL, 2016, PROG RETIN EYE RES, V50, P89, DOI 10.1016/j.preteyeres.2015.09.003
   Machida S, 2000, INVEST OPHTH VIS SCI, V41, P3200
   Mathieson K, 2012, NAT PHOTONICS, V6, P391, DOI [10.1038/nphoton.2012.104, 10.1038/NPHOTON.2012.104]
   Roux S, 2016, ELIFE, V5, DOI 10.7554/eLife.12687
   Sasso L, 2010, SENSORS-BASEL, V10, P10986, DOI 10.3390/s101210986
   Schwalb JM, 2008, NEUROTHERAPEUTICS, V5, P3, DOI 10.1016/j.nurt.2007.11.003
   Wang LL, 2012, J NEURAL ENG, V9, DOI 10.1088/1741-2560/9/4/046014
NR 21
TC 3
Z9 3
U1 0
U2 7
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
EI 1662-453X
J9 FRONT NEUROSCI-SWITZ
JI Front. Neurosci.
PD AUG 27
PY 2019
VL 13
AR 885
DI 10.3389/fnins.2019.00885
PG 14
WC Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA IT4LB
UT WOS:000482831300003
PM 31507363
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Chintalapudi, SR
   Wang, XD
   Wang, XF
   Shi, YF
   Kocak, M
   Palamoor, M
   Davis, RN
   Hollingsworth, TJ
   Jablonski, MM
AF Chintalapudi, Sumana R.
   Wang, XiangDi
   Wang, XiaoFei
   Shi, Yunfeng
   Kocak, Mehmet
   Palamoor, Mallika
   Davis, Raven N.
   Hollingsworth, T. J.
   Jablonski, Monica M.
TI NA3 glycan: a potential therapy for retinal pigment epithelial
   deficiency
SO FEBS JOURNAL
LA English
DT Article
DE atrophic age-related macular degeneration; glycan; retinal structure;
   RPE insufficiency; small molecule therapeutics
ID XENOPUS-LAEVIS; RAT MODEL; IN-VIVO; PROLIFERATION; DEGENERATION;
   PRESERVATION; EXPRESSION; SUPPORT; ABSENCE; FETUIN
AB Atrophic age-related macular degeneration (AMD) is the most common type of AMD, yet there is no United States Food and Drug Administration (FDA)-approved therapy. This disease is characterized by retinal pigment epithelial (RPE) insufficiency, primarily in the macula, which affects the structure and physiology of photoreceptors and ultimately, visual function. In this study, we evaluated the protective effects of a naturally derived small molecule glycan therapeutic-asialo-, tri-antennary complex-type N-glycan (NA3)-in two distinct preclinical models of atrophic AMD. In RPE-deprived Xenopus laevis tadpole eyes, NA3 supported normal retinal ultrastructure. In RCS rats, NA3 supported fully functioning visual integrity. Furthermore, structural analyses revealed that NA3 prevented photoreceptor outer segment degeneration, pyknosis of the outer nuclear layer, and reactive gliosis of Muller cells (MCs). It also promoted maturation of adherens junctions between MC and photoreceptors. Our results demonstrate the neuroprotective effects of a naturally derived small molecular glycan therapeutic-NA3-in two unique preclinical models with RPE insufficiency. These data suggest that NA3 glycan therapy may provide a new therapeutic avenue in the prevention and/or treatment of retinal diseases such as atrophic AMD.
C1 [Chintalapudi, Sumana R.; Wang, XiangDi; Wang, XiaoFei; Shi, Yunfeng; Palamoor, Mallika; Davis, Raven N.; Jablonski, Monica M.] Univ Tennessee, Hlth Sci Ctr, Hamilton Eye Inst, Dept Ophthalmol, 930 Madison Ave,Suite 758, Memphis, TN 38163 USA.
   [Chintalapudi, Sumana R.; Jablonski, Monica M.] Univ Tennessee, Hlth Sci Ctr, Dept Anat & Neurobiol, Memphis, TN 38163 USA.
   [Kocak, Mehmet] Univ Tennessee, Hlth Sci Ctr, Dept Prevent Med, Memphis, TN 38163 USA.
   [Hollingsworth, T. J.] Univ Tennessee, Hlth Sci Ctr, Neurosci Inst, Memphis, TN 38163 USA.
   [Jablonski, Monica M.] Univ Tennessee, Hlth Sci Ctr, Dept Pharmaceut Sci, Memphis, TN 38163 USA.
C3 University of Tennessee System; University of Tennessee Health Science
   Center; University of Tennessee System; University of Tennessee Health
   Science Center; University of Tennessee System; University of Tennessee
   Health Science Center; University of Tennessee System; University of
   Tennessee Health Science Center; University of Tennessee System;
   University of Tennessee Health Science Center
RP Jablonski, MM (通讯作者)，Univ Tennessee, Hlth Sci Ctr, Hamilton Eye Inst, Dept Ophthalmol, 930 Madison Ave,Suite 758, Memphis, TN 38163 USA.
EM mjablonski@uthsc.edu
RI Chintalapudi, Sumana Rameshbabu/AAJ-4008-2021; Hollingsworth,
   T.J./AAD-2814-2022
OI Chintalapudi, Sumana Rameshbabu/0000-0003-1079-0950; Hollingsworth,
   T.J./0000-0002-2119-521X; Jablonski, Monica/0000-0002-4021-3559
FU International Retinal Research Foundation; William and Ella Owens
   Medical Research Foundation; Research to Prevent Blindness
FX We thank Dr Vincent Ciavatta (Emory University) for generously providing
   the RCS rats. This study was funded by The International Retinal
   Research Foundation (MMJ), The William and Ella Owens Medical Research
   Foundation (MMJ) and an unrestricted grant from Research to Prevent
   Blindness (MMJ).
CR BEZOUSKA K, 1993, EUR J BIOCHEM, V213, P1303, DOI 10.1111/j.1432-1033.1993.tb17882.x
   Chintalapudi SR, 2016, FRONT AGING NEUROSCI, V8, DOI 10.3389/fnagi.2016.00093
   FISHER SK, 1991, INVEST OPHTH VIS SCI, V32, P1739
   Forest DL, 2015, DIS MODEL MECH, V8, P421, DOI 10.1242/dmm.017236
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gopinath B, 2014, BRIT J NUTR, V111, P1673, DOI 10.1017/S000711451300408X
   GUPTA D, 1994, GLYCOCONJUGATE J, V11, P558, DOI 10.1007/BF00731307
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hayase T, 1992, BIOCHEMISTRY-US, V9, P897
   Jablonski M, 2001, MOL VIS, V7, P27
   Jablonski MM, 1999, MOL VIS, V5
   Jablonski MM, 2003, ADV EXP MED BIOL, V533, P189
   Jablonski MM, 2001, EXP EYE RES, V72, P573, DOI 10.1006/exer.2001.0987
   Jablonski MM, 2000, ANAT RECORD, V259, P205, DOI 10.1002/(SICI)1097-0185(20000601)259:2<205::AID-AR10>3.0.CO;2-4
   Jacobson AG, 1967, METHODS DEV BIOL, P531
   Kitchener PD, 1999, INT J DEV NEUROSCI, V17, P21, DOI 10.1016/S0736-5748(98)00054-9
   LEWIS GP, 1994, AM J OPHTHALMOL, V118, P368, DOI 10.1016/S0002-9394(14)72962-9
   Miyamoto Y, 2015, CELL ADHES MIGR, V9, P183, DOI 10.1080/19336918.2015.1005466
   MULLEN RJ, 1976, SCIENCE, V192, P799, DOI 10.1126/science.1265483
   Pascolini D, 2004, OPHTHAL EPIDEMIOL, V11, P67, DOI 10.1076/opep.11.2.67.28158
   Reddy GB, 2009, INVEST OPHTH VIS SCI, V50, P3456, DOI 10.1167/iovs.08-2498
   Reiner A, 2015, INT J MOL SCI, V16, P758, DOI 10.3390/ijms16010758
   Ryals RC, 2017, INVEST OPHTH VIS SCI, V58, P1378, DOI 10.1167/iovs.16-20363
   Sato Y, 1999, BBA-GEN SUBJECTS, V1472, P344, DOI 10.1016/S0304-4165(99)00140-3
   Sauve Y, 2006, VISION RES, V46, P1459, DOI 10.1016/j.visres.2005.11.009
   Seddon Johanna M., 2004, International Ophthalmology Clinics, V44, P17, DOI 10.1097/00004397-200404440-00004
   Sheedlo HJ, 1999, CURR EYE RES, V19, P465, DOI 10.1076/ceyr.19.6.465.5274
   STIEMKE MM, 1994, DEV BIOL, V162, P169, DOI 10.1006/dbio.1994.1076
   STIEMKE MM, 1994, DEV BRAIN RES, V80, P285, DOI 10.1016/0165-3806(94)90115-5
   Stiemke MM, 1995, DEGENERATIVE DISEASES OF THE RETINA, P129
   TOWNSEND RR, 1989, ANAL BIOCHEM, V182, P1
   Tschernutter M, 2005, GENE THER, V12, P694, DOI 10.1038/sj.gt.3302460
   Wang XF, 2003, MOL VIS, V9, P701
   Wang XF, 2010, DEV NEUROBIOL, V70, P623, DOI 10.1002/dneu.20798
   Wang Xiaofei, 2005, Neuron Glia Biol, V1, P1
NR 35
TC 4
Z9 4
U1 0
U2 3
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1742-464X
EI 1742-4658
J9 FEBS J
JI FEBS J.
PD DEC
PY 2019
VL 286
IS 24
BP 4876
EP 4888
DI 10.1111/febs.15006
EA JUL 2019
PG 13
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA OB9NK
UT WOS:000478413800001
PM 31322324
DA 2022-11-30
ER

PT J
AU Moody, KJ
   Tinklepaugh, J
   Obert, E
   Grohn, K
   DeRosa, JR
   Lumen, E
   Moyer, BS
   Campbell, S
   Wolfe, AJ
   Sleeper, MB
   Bianchi, AH
   Fisher, C
   Applegate, J
   Leary, E
   LeClair, N
   Wortel, D
   Doyle, RP
   Rohrer, B
   Blanden, AR
AF Moody, Kelsey J.
   Tinklepaugh, Jay
   Obert, Elisabeth
   Grohn, Kris
   DeRosa, Jennifer R.
   Lumen, Ellie
   Moyer, Brandon S.
   Campbell, Scott
   Wolfe, Aaron J.
   Sleeper, Meegan B.
   Bianchi, Anthony H.
   Fisher, Cheyanne
   Applegate, Justin
   Leary, Emily
   LeClair, Nicholas
   Wortel, Danique
   Doyle, Robert P.
   Rohrer, Baerbel
   Blanden, Adam R.
TI Recombinant Manganese Peroxidase Reduces A2E Burden in Age-Related and
   Stargardt's Macular Degeneration Models
SO REJUVENATION RESEARCH
LA English
DT Article
DE A2E; macular degeneration; Stargardt's disease; enzyme replacement
   therapy; ophthalmology
ID MANNOSE RECEPTOR; MOUSE MODEL; LIPOFUSCIN; INFLAMMATION; EXPRESSION;
   PHENOTYPE; RETINA
AB Macular degeneration is hallmarked by retinal accumulation of toxic retinoid species (e.g., A2E) for which there is no endogenous mechanism to eliminate it. This ultimately results in progressive dysfunction and loss of vision either in advanced age for genetically normal patients (age-related macular degeneration) or in adolescence for those with inherited genetic mutations (Stargardt's disease). In this article, we present a proof-of-concept study for an enzyme-based therapy to remove these retinoids, modeled on traditional enzyme replacement therapy. Recombinant manganese peroxidase (rMnP) is produced in Pichia pastoris. In vitro, we demonstrate that rMnP breaks down A2E and other lipofuscin fluorophores with limited cellular toxicity, and as this enzyme is mannosylated, it can be taken up into cells through mannose receptor-dependent endocytosis. In vivo, we demonstrate that rMnP can significantly reduce the A2E burden when administered by intravitreal injections. Together, these data provide encouraging results toward the development of an enzyme-based therapy for macular degeneration and indicate the need for additional work to characterize the molecular mechanism of A2E breakdown and to improve the pharmacological parameters of the enzyme.
C1 [Moody, Kelsey J.; Grohn, Kris; DeRosa, Jennifer R.; Lumen, Ellie; Moyer, Brandon S.; Campbell, Scott; Wolfe, Aaron J.; Sleeper, Meegan B.; Bianchi, Anthony H.; Fisher, Cheyanne; Applegate, Justin; Leary, Emily; LeClair, Nicholas; Wortel, Danique; Blanden, Adam R.] Ichor Therapeut Inc, 2521 US-11, La Fayette, NY 13084 USA.
   [Moody, Kelsey J.; Grohn, Kris; DeRosa, Jennifer R.; Lumen, Ellie; Moyer, Brandon S.; Campbell, Scott; Wolfe, Aaron J.; Sleeper, Meegan B.; Bianchi, Anthony H.; Fisher, Cheyanne; Applegate, Justin; Leary, Emily; LeClair, Nicholas; Wortel, Danique; Blanden, Adam R.] Lysoclear Inc, La Fayette, NY USA.
   [Tinklepaugh, Jay; Doyle, Robert P.] Syracuse Univ, Dept Chem, Syracuse, NY 13244 USA.
   [Obert, Elisabeth; Rohrer, Baerbel] Med Univ South Carolina, Dept Ophthalmol, 171 Ashley Ave, Charleston, SC 29425 USA.
C3 Syracuse University; Medical University of South Carolina
RP Blanden, AR (通讯作者)，Ichor Therapeut Inc, 2521 US-11, La Fayette, NY 13084 USA.
EM adam.blanden@ichortherapeutics.com
RI Doyle, Robert P/W-1921-2018
OI Wolfe, Aaron/0000-0001-5287-8710
CR Ahn J, 2000, J BIOL CHEM, V275, P20399, DOI 10.1074/jbc.M000555200
   BOYLE D, 1991, INVEST OPHTH VIS SCI, V32, P1464
   Cox TM, 2015, LANCET, V385, P2355, DOI 10.1016/S0140-6736(14)61841-9
   Dunn KC, 1996, EXP EYE RES, V62, P155, DOI 10.1006/exer.1996.0020
   Greaton CJ, 2003, OPHTHALMIC RES, V35, P42, DOI 10.1159/000068198
   Gresh J, 2003, VISUAL NEUROSCI, V20, P211, DOI 10.1017/S0952523803202108
   Gu L, 2003, BIOTECHNOL PROGR, V19, P1403, DOI 10.1021/bp025781h
   HETH CA, 1991, EXP EYE RES, V52, P75, DOI 10.1016/0014-4835(91)90130-7
   Issa PC, 2015, P NATL ACAD SCI USA, V112, P8415, DOI 10.1073/pnas.1506960112
   Issa PC, 2013, INVEST OPHTH VIS SCI, V54, P5602, DOI 10.1167/iovs.13-11688
   Kauppinen A, 2016, CELL MOL LIFE SCI, V73, P1765, DOI 10.1007/s00018-016-2147-8
   Kimura M, 2014, FRONT PLANT SCI, V5, DOI 10.3389/fpls.2014.00285
   Liu JH, 2000, J BIOL CHEM, V275, P29354, DOI 10.1074/jbc.M910191199
   Ma L, 2011, J BIOL CHEM, V286, P7966, DOI 10.1074/jbc.M110.178657
   Maiti P, 2006, BIOCHEMISTRY-US, V45, P852, DOI 10.1021/bi0518545
   Morishima S, 2003, J ENDOCRINOL, V176, P285, DOI 10.1677/joe.0.1760285
   Parish CA, 1998, P NATL ACAD SCI USA, V95, P14609, DOI 10.1073/pnas.95.25.14609
   Park SJ, 2015, EYE, V29, P561, DOI 10.1038/eye.2014.329
   Perlee LT, 2013, OPHTHALMOLOGY, V120, P1880, DOI 10.1016/j.ophtha.2013.02.007
   Radu RA, 2011, J BIOL CHEM, V286, P18593, DOI 10.1074/jbc.M110.191866
   Reinboth JJ, 1997, EXP EYE RES, V65, P639, DOI 10.1006/exer.1997.0367
   Schloendorn J, 2009, REJUV RES, V12, P411, DOI 10.1089/rej.2009.0917
   SHEPHERD VL, 1991, INVEST OPHTH VIS SCI, V32, P1779
   Tanna P, 2017, BRIT J OPHTHALMOL, V101, P25, DOI 10.1136/bjophthalmol-2016-308823
   TARNOWSKI BI, 1988, INVEST OPHTH VIS SCI, V29, P742
   Verdegem PJE, 1997, TETRAHEDRON LETT, V38, P5355, DOI 10.1016/S0040-4039(97)01171-4
   Wang J, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-017-0200-7
   Wolf G, 2003, NUTR REV, V61, P342, DOI 10.1301/nr.2003.oct.342-346
   Wright CB, 2017, HANDB EXP PHARMACOL, V242, P321, DOI 10.1007/164_2016_36
   Wu YL, 2011, J AM CHEM SOC, V133, P849, DOI 10.1021/ja107195u
   Yogalingam G, 2018, SENS RES FOUND RES R, V2013, P3
   Yogalingam G, 2017, J BIOL CHEM, V292, P4255, DOI 10.1074/jbc.M116.739441
   Zhou JL, 2006, P NATL ACAD SCI USA, V103, P16182, DOI 10.1073/pnas.0604255103
   Zhou Ru, 2010, F1000 Biol Rep, V2, DOI 10.3410/B2-3
NR 34
TC 7
Z9 7
U1 0
U2 12
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1549-1684
EI 1557-8577
J9 REJUV RES
JI Rejuv. Res.
PD DEC 1
PY 2018
VL 21
IS 6
BP 560
EP 571
DI 10.1089/rej.2018.2146
PG 12
WC Geriatrics & Gerontology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Geriatrics & Gerontology
GA HF0OH
UT WOS:000453860900010
PM 30516450
DA 2022-11-30
ER

PT J
AU Long, D
   Kanan, Y
   Shen, JK
   Hackett, SF
   Liu, YY
   Hafiz, Z
   Khan, M
   Lu, LL
   Campochiaro, PA
AF Long, Da
   Kanan, Yogita
   Shen, Jikui
   Hackett, Sean F.
   Liu, Yuanyuan
   Hafiz, Zibran
   Khan, Mahmood
   Lu, Lili
   Campochiaro, Peter A.
TI VEGF/VEGFR2 blockade does not cause retinal atrophy in AMD-relevant
   models'
SO JCI INSIGHT
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; CONE CELL-DEATH; MACULAR DEGENERATION;
   RETINITIS-PIGMENTOSA; CHOROIDAL NEOVASCULARIZATION; PHOTORECEPTOR
   DEGENERATION; INCREASED EXPRESSION; GEOGRAPHIC ATROPHY; PROLONGED
   BLOCKADE; OXIDATIVE DAMAGE
AB Intraocular injections of VEGF-neutralizing proteins provide tremendous benefits in patients with choroidal neovascularization (NV) due to age-related macular degeneration (AMD), but during treatment some patients develop retinal atrophy. Suggesting that VEGF is a survival factor for retinal neurons, a clinical trial group attributed retinal atrophy to VEGF suppression and cautioned against frequent anti-VEGF injections. This recommendation may contribute to poor outcomes in clinical practice from insufficient treatment. Patients with type 3 choroidal NV have particularly high risk of retinal atrophy, an unexplained observation. Herein we show in mouse models that VEGF signaling does not contribute to photoreceptor survival and functioning: (a) neutralization of VEGFR2 strongly suppresses choroidal NV without compromising photoreceptor function or survival; (b) VEGF does not slow loss of photoreceptor function or death in mice with inherited retinal degeneration, and there is no exacerbation by VEGF suppression; and (c) mice with type 3 choroidal NV develop retinal atrophy due to oxidative damage with no contribution from VEGF suppression. Intraocular injections of VEGF-neutralizing proteins, a highly effective treatment in patients with neovascular AMD, should not be withheld or reduced due to concern that they may contribute to long-term visual loss from retinal atrophy.
C1 Johns Hopkins Univ, Sch Med, Dept Ophthalmol, Baltimore, MD 21205 USA.
   Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA.
   [Long, Da] Hunan Univ Chinese Med, Hosp 1, Dept Ophthalmol, Changsha, Hunan, Peoples R China.
   [Liu, Yuanyuan] Tianjin Med Univ, Gen Hosp, Dept Ophthalmol, Tianjin, Peoples R China.
C3 Johns Hopkins University; Johns Hopkins University; Hunan University of
   Chinese Medicine; Tianjin Medical University
RP Campochiaro, PA (通讯作者)，Johns Hopkins Univ, Sch Med, Wilmer Eye Inst, 815 Maumenee,600 N Wolfe St, Baltimore, MD 21205 USA.
EM pcampo@jhmi.edu
RI liu, yuanyuan/GWZ-5838-2022
FU Biostatistics Core Grant [EY01765]; NATIONAL EYE INSTITUTE [P30EY001765]
   Funding Source: NIH RePORTER
FX The authors thank Kadmon Corporation for providing the antibody directed
   against human VEGFR2 that cross-reacts with rat VEGFR2 and Jiangxia Wang
   of the Johns Hopkins Biostatistics Center, Department of Biostatistics,
   Johns Hopkins Bloomberg School of Public Health, Baltimore, MD for
   statistics consultation. This work was supported by Biostatistics Core
   Grant EY01765 to the Wilmer Eye Institute and unrestricted grants from
   Andrew and Yvette Marriott, Per Bang-Jensen, Jean Lake, and Conrad and
   Lois Aschenbach. PAC is the George S. and Dolores Dore Eccles Professor
   of Ophthalmology and Neuroscience.
CR ALON T, 1995, NAT MED, V1, P1024, DOI 10.1038/nm1095-1024
   BENEDETTI A, 1980, BIOCHIM BIOPHYS ACTA, V620, P281, DOI 10.1016/0005-2760(80)90209-X
   BRAUN RD, 1995, INVEST OPHTH VIS SCI, V36, P542
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Buss H, 1997, FREE RADICAL BIO MED, V23, P361, DOI 10.1016/S0891-5849(97)00104-4
   Byrne LC, 2015, J CLIN INVEST, V125, P105, DOI 10.1172/JCI65654
   Campochiaro PA, 1996, J NEUROSCI, V16, P1679
   Campochiaro PA, 2016, OPHTHALMOLOGY, V123, pS78, DOI 10.1016/j.ophtha.2016.04.056
   Chang B, 2002, VISION RES, V42, P517, DOI 10.1016/S0042-6989(01)00146-8
   Curcio CA, 1996, INVEST OPHTH VIS SCI, V37, P1236
   Dong A, 2007, J NEUROCHEM, V103, P1041, DOI 10.1111/j.1471-4159.2007.04839.x
   ESTERBAUER H, 1991, FREE RADICAL BIO MED, V11, P81, DOI 10.1016/0891-5849(91)90192-6
   FAKTOROVICH EG, 1990, NATURE, V347, P83, DOI 10.1038/347083a0
   Fleckenstein M, 2018, OPHTHALMOLOGY, V125, P369, DOI 10.1016/j.ophtha.2017.08.038
   Gargini C, 2007, J COMP NEUROL, V500, P222, DOI 10.1002/cne.21144
   Heier JS, 2017, LANCET, V390, P50, DOI 10.1016/S0140-6736(17)30979-0
   Holz FG, 2015, BRIT J OPHTHALMOL, V99, P220, DOI 10.1136/bjophthalmol-2014-305327
   Hombrebueno JR, 2015, SCI REP-UK, V5, DOI 10.1038/srep18316
   Kamba T, 2007, BRIT J CANCER, V96, P1788, DOI 10.1038/sj.bjc.6603813
   Kamba T, 2006, AM J PHYSIOL-HEART C, V290, pH560, DOI 10.1152/ajpheart.00133.2005
   Klein R, 2006, OPHTHALMOLOGY, V113, P373, DOI 10.1016/j.ophtha.2005.12.013
   Komeima K, 2007, J CELL PHYSIOL, V213, P809, DOI 10.1002/jcp.21152
   Komeima K, 2006, P NATL ACAD SCI USA, V103, P11300, DOI 10.1073/pnas.0604056103
   Krzystolik MG, 2002, ARCH OPHTHALMOL-CHIC, V120, P338
   Kurihara T, 2012, J CLIN INVEST, V122, P4213, DOI 10.1172/JCI65157
   Kwak N, 2000, INVEST OPHTH VIS SCI, V41, P3158
   LAVAIL MM, 1992, P NATL ACAD SCI USA, V89, P11249, DOI 10.1073/pnas.89.23.11249
   LaVail MM, 1998, INVEST OPHTH VIS SCI, V39, P592
   Lee SY, 2011, J CELL PHYSIOL, V226, P1843, DOI 10.1002/jcp.22508
   LEVINE RL, 1990, METHOD ENZYMOL, V186, P464
   Maguire MG, 2016, OPHTHALMOLOGY, V123, P1751, DOI 10.1016/j.ophtha.2016.03.045
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   MCLAUGHLIN ME, 1993, NAT GENET, V4, P130, DOI 10.1038/ng0693-130
   Miki A, 2010, J CELL PHYSIOL, V224, P262, DOI 10.1002/jcp.22129
   Ohnaka M, 2012, J NEUROCHEM, V122, P1047, DOI 10.1111/j.1471-4159.2012.07842.x
   Okabe K, 2014, CELL, V159, P584, DOI 10.1016/j.cell.2014.09.025
   Okamoto N, 1997, AM J PATHOL, V151, P281
   Peden MC, 2015, OPHTHALMOLOGY, V122, P803, DOI 10.1016/j.ophtha.2014.11.018
   Nguyen QD, 2012, OPHTHALMOLOGY, V119, P789, DOI 10.1016/j.ophtha.2011.12.039
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Saint-Geniez M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003554
   Sanftner LHM, 2001, MOL THER, V4, P622, DOI 10.1006/mthe.2001.0498
   Shen JK, 2005, J CELL PHYSIOL, V203, P457, DOI 10.1002/jcp.20346
   Singer MA, 2012, OPHTHALMOLOGY, V119, P1175, DOI 10.1016/j.ophtha.2011.12.016
   Sophie R, 2014, OPHTHALMOLOGY, V121, pE34, DOI 10.1016/j.ophtha.2013.12.043
   Tobe T, 1998, INVEST OPHTH VIS SCI, V39, P180
   Ueno S, 2008, J CELL PHYSIOL, V217, P13, DOI 10.1002/jcp.21445
   Uppu RM, 1996, ARCH BIOCHEM BIOPHYS, V327, P335, DOI 10.1006/abbi.1996.0131
   Yannuzzi LA, 2001, RETINA-J RET VIT DIS, V21, P416, DOI 10.1097/00006982-200110000-00003
   Yu DY, 2000, INVEST OPHTH VIS SCI, V41, P3999
NR 50
TC 16
Z9 16
U1 3
U2 5
PU AMER SOC CLINICAL INVESTIGATION INC
PI ANN ARBOR
PA 2015 MANCHESTER RD, ANN ARBOR, MI 48104 USA
SN 2379-3708
J9 JCI INSIGHT
JI JCI Insight
PD MAY 17
PY 2018
VL 3
IS 10
AR e120231
DI 10.1172/jci.insight.120231
PG 14
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA GG7GC
UT WOS:000432865500001
PM 29769445
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Han, S
   Lu, QJ
   Wang, NL
AF Han, Song
   Lu, Qingjun
   Wang, Ningli
TI Apr3 accelerates the senescence of human retinal pigment epithelial
   cells
SO MOLECULAR MEDICINE REPORTS
LA English
DT Article
DE apoptosis related protein 3; senescence; retinal pigment epithelium;
   oxidative stress; p53; p21
ID MACULAR DEGENERATION; CELLULAR SENESCENCE; OXIDATIVE STRESS;
   GENE-EXPRESSION; MECHANISMS; INSIGHTS; DISEASE; ACID; PEDF; PCR
AB Senescence of retinal pigment epithelium (RPE) cells is a major contributor to age-related macular degeneration (AMD). However, the molecular mechanisms underlying RPE dysfunction are not well understood. Apoptosis related protein 3 (Apr3) was originally cloned from HL-60 cells induced by all-trans retinoic acid (ATRA). Preliminary data revealed elevated Apr3 expression in the tissues of aged mice, suggesting that it is involved in the aging process. The present study demonstrated that Apr3 mRNA and protein levels were markedly increased in aged mouse RPE cells. Elevated Apr3 expression was also observed during premature senescence induced by oxidative stress (H2O2 and tert-BHP) in ARPE-19 cells. Moreover, Apr3 overexpression promoted cellular senescence in ARPE-19 cells, as characterized by enhanced senescence-associated beta-galactosidase activity, reduced cell proliferation and increased expression of the senescence markers p53 and p21. In addition, it was demonstrated that overexpression of Apr3-N, a truncated counterpart of Apr3, abrogated Apr3-induced phenotypes. It was concluded that Apr3 expression was induced in replicative and premature senescence of RPE cells and its overexpression accelerated senescence of ARPE-19 cells, which provides important insights into the function of Apr3 in senescence-associated diseases.
C1 [Han, Song; Lu, Qingjun; Wang, Ningli] Capital Med Univ, Beijing Tongren Hosp, Beijing Tongren Eye Ctr, Beijing Ophthalmol & Visual Sci Key Lab, 1 Dong Jiao Min Xiang, Beijing 100730, Peoples R China.
C3 Capital Medical University
RP Wang, NL (通讯作者)，Capital Med Univ, Beijing Tongren Hosp, Beijing Tongren Eye Ctr, Beijing Ophthalmol & Visual Sci Key Lab, 1 Dong Jiao Min Xiang, Beijing 100730, Peoples R China.
EM ningliw63@163.com
CR Ablonczy Z, 2014, FASEB J, V28, P2369, DOI 10.1096/fj.13-248021
   Bartke A, 2008, AGING CELL, V7, P285, DOI 10.1111/j.1474-9726.2008.00387.x
   Cao SJ, 2013, MOL VIS, V19, P718
   Chen JT, 2005, J OCUL PHARMACOL TH, V21, P413, DOI 10.1089/jop.2005.21.413
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   Dvashi Z, 2014, INVEST OPHTH VIS SCI, V55, P5679, DOI 10.1167/iovs.14-14349
   He Y, 2014, INVEST OPHTH VIS SCI, V55, DOI 10.1167/iovs.14-14696
   Hjelmeland LM, 1999, MOL VIS, V5
   Jeyapalan JC, 2007, MECH AGEING DEV, V128, P36, DOI 10.1016/j.mad.2006.11.008
   Kammula EC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051578
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Makarev E, 2014, AGING-US, V6, P1064, DOI 10.18632/aging.100711
   Plafker SM, 2012, INT REV CEL MOL BIO, V298, P135, DOI 10.1016/B978-0-12-394309-5.00004-3
   Salama R, 2014, GENE DEV, V28, P99, DOI 10.1101/gad.235184.113
   Sharma K, 2014, FRONT AGING NEUROSCI, V6, DOI 10.3389/fnagi.2014.00151
   Tombran-Tink J, 2004, EXP EYE RES, V78, P945, DOI 10.1016/j.exer.2003.12.013
   Yu F, 2007, BIOCHEM BIOPH RES CO, V358, P1041, DOI 10.1016/j.bbrc.2007.05.049
   Zhu F, 2000, BIOTECHNIQUES, V29, P310, DOI 10.2144/00292st06
   Zou X, 2011, FEBS LETT, V585, P2410, DOI 10.1016/j.febslet.2011.06.024
NR 19
TC 9
Z9 9
U1 1
U2 9
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1791-2997
EI 1791-3004
J9 MOL MED REP
JI Mol. Med. Rep.
PD APR
PY 2016
VL 13
IS 4
BP 3121
EP 3126
DI 10.3892/mmr.2016.4926
PG 6
WC Oncology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Research & Experimental Medicine
GA DI6AR
UT WOS:000373582100022
PM 26934949
OA Bronze
DA 2022-11-30
ER

PT J
AU Brandl, C
   Grassmann, F
   Riolfi, J
   Weber, BHF
AF Brandl, Caroline
   Grassmann, Felix
   Riolfi, Julia
   Weber, Bernhard H. F.
TI Tapping Stem Cells to Target AMD: Challenges and Prospects
SO JOURNAL OF CLINICAL MEDICINE
LA English
DT Review
DE stem cells; induced pluripotent stem cells (iPSCs); retinal pigment
   epithelium (RPE); age-related macular degeneration (AMD); disease
   modelling; drug screening; cell-based transplantation therapy;
   RNA-sequencing
ID RETINAL-PIGMENT EPITHELIUM; HUMAN SOMATIC-CELLS; MACULAR DEGENERATION;
   DIRECTED DIFFERENTIATION; X-INACTIVATION; AGE; DISEASE; GENERATION;
   REPAIR; IPSC
AB Human pluripotent stem cells (hPSCs) are increasingly gaining attention in biomedicine as valuable resources to establish patient-derived cell culture models of the cell type known to express the primary pathology. The idea of "a patient in a dish" aims at basic, but also clinical, applications with the promise to mimic individual genetic and metabolic complexities barely reflected in current invertebrate or vertebrate animal model systems. This may particularly be true for the inherited and complex diseases of the retina, as this tissue has anatomical and physiological aspects unique to the human eye. For example, the complex age-related macular degeneration (AMD), the leading cause of blindness in Western societies, can be attributed to a large number of genetic and individual factors with so far unclear modes of mutual interaction. Here, we review the current status and future prospects of utilizing hPSCs, specifically induced pluripotent stem cells (iPSCs), in basic and clinical AMD research, but also in assessing potential treatment options. We provide an outline of concepts for disease modelling and summarize ongoing and projected clinical trials for stem cell-based therapy in late-stage AMD.
C1 [Brandl, Caroline; Grassmann, Felix; Riolfi, Julia; Weber, Bernhard H. F.] Univ Regensburg, Inst Human Genet, Franz Josef Strauss Allee 11, D-93053 Regensburg, Germany.
   [Brandl, Caroline] Univ Hosp Regensburg, Dept Ophthalmol, D-93042 Regensburg, Germany.
C3 University of Regensburg; University of Regensburg
RP Weber, BHF (通讯作者)，Univ Regensburg, Inst Human Genet, Franz Josef Strauss Allee 11, D-93053 Regensburg, Germany.
EM Caroline.Brandl@klinik.uni-regensburg.de;
   Felix.Grassmann@klinik.uni-regensburg.de;
   Julia.Riolfi@stud.uni-regensburg.de; bweb@klinik.uni-regensburg.de
OI Grassmann, Felix/0000-0003-1390-7528; Brandl,
   Caroline/0000-0001-8223-6137; Weber, Bernhard H.F./0000-0002-8808-7723
FU Novartis Pharma GmbH, Nurnberg, Germany [3625340]
FX RNA-Seq analysis was in part supported by a grant from Novartis Pharma
   GmbH, Nurnberg, Germany (Reference No. 3625340).
CR Adams WJ, 2013, STEM CELL REP, V1, P105, DOI 10.1016/j.stemcr.2013.06.007
   Adhi M, 2013, CURR OPIN OPHTHALMOL, V24, P213, DOI 10.1097/ICU.0b013e32835f8bf8
   Anguera MC, 2012, CELL STEM CELL, V11, P75, DOI 10.1016/j.stem.2012.03.008
   Aoki T, 2010, TISSUE ENG PT A, V16, P2197, DOI [10.1089/ten.tea.2009.0747, 10.1089/ten.TEA.2009.0747]
   Augood CA, 2006, ARCH OPHTHALMOL-CHIC, V124, P529, DOI 10.1001/archopht.124.4.529
   Baglio SR, 2012, FRONT PHYSIOL, V3, DOI 10.3389/fphys.2012.00359
   Bharti K, 2011, PIGM CELL MELANOMA R, V24, P21, DOI 10.1111/j.1755-148X.2010.00772.x
   Birch DG, 2007, INT J NANOMED, V2, P65, DOI 10.2147/nano.2007.2.1.65
   Brandl C, 2014, NEUROMOL MED, V16, P551, DOI 10.1007/s12017-014-8308-8
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Buchholz DE, 2013, STEM CELL TRANSL MED, V2, P384, DOI 10.5966/sctm.2012-0163
   Buitendijk GHS, 2013, OPHTHALMOLOGY, V120, P2644, DOI 10.1016/j.ophtha.2013.07.053
   Cano M, 2010, VISION RES, V50, P652, DOI 10.1016/j.visres.2009.08.018
   Carr AJF, 2013, TRENDS NEUROSCI, V36, P385, DOI 10.1016/j.tins.2013.03.006
   Carroll J, 2013, CURR EYE RES, V38, P709, DOI 10.3109/02713683.2013.784792
   Chakraborty S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064342
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Chang YC, 2014, FRONT AGING NEUROSCI, V6, DOI 10.3389/fnagi.2014.00191
   Chew EY, 2014, JAMA OPHTHALMOL, V132, P142, DOI 10.1001/jamaophthalmol.2013.7376
   Chew EY, 2013, OPHTHALMOLOGY, V120, P1604, DOI 10.1016/j.ophtha.2013.01.021
   Chung Y, 2008, CELL STEM CELL, V2, P113, DOI 10.1016/j.stem.2007.12.013
   Cramer AO, 2013, CURR GENE THER, V13, P139
   Croze RH, 2014, STEM CELL TRANSL MED, V3, P1066, DOI 10.5966/sctm.2014-0079
   Dardik R, 2010, INVEST OPHTH VIS SCI, V51, P6188, DOI 10.1167/iovs.09-5095
   Das Ani M, 2005, Semin Ophthalmol, V20, P3, DOI 10.1080/08820530590921882
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   Dhamodaran K, 2014, STEM CELL RES THER, V5, DOI 10.1186/scrt445
   Du HJ, 2011, SEMIN OPHTHALMOL, V26, P216, DOI 10.3109/08820538.2011.577498
   Dunn KC, 1996, EXP EYE RES, V62, P155, DOI 10.1006/exer.1996.0020
   Eter N, 2010, BRIT J OPHTHALMOL, V94, P1420, DOI 10.1136/bjo.2009.158105
   Frenette PS, 2013, ANNU REV IMMUNOL, V31, P285, DOI 10.1146/annurev-immunol-032712-095919
   Fritsche LG, 2014, ANNU REV GENOM HUM G, V15, P151, DOI 10.1146/annurev-genom-090413-025610
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Fusaki N, 2009, P JPN ACAD B-PHYS, V85, P348, DOI 10.2183/pjab.85.348
   Gimble JM, 2007, CIRC RES, V100, P1249, DOI 10.1161/01.RES.0000265074.83288.09
   Gore A, 2011, NATURE, V471, P63, DOI 10.1038/nature09805
   Grassmann F, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037979
   Gullapalli VK, 2005, EXP EYE RES, V80, P235, DOI 10.1016/j.exer.2004.09.006
   Hall LL, 2008, J CELL PHYSIOL, V216, P445, DOI 10.1002/jcp.21411
   Heng BC, 2008, MINIM INVASIV THER, V17, P326, DOI 10.1080/13645700802390061
   Heng BC, 2014, METHODS MOL BIOL, V1151, P75, DOI 10.1007/978-1-4939-0554-6_6
   Hu Kejin, 2013, Methods Mol Biol, V997, P163, DOI 10.1007/978-1-62703-348-0_13
   Huang K, 2014, STEM CELL REP, V2, P36, DOI 10.1016/j.stemcr.2013.11.003
   Inoue H, 2014, EMBO J, V33, P409, DOI 10.1002/embj.201387098
   Ji JF, 2012, STEM CELLS, V30, P435, DOI 10.1002/stem.1011
   Jin ZB, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017084
   Jung DW, 2014, ACS CHEM BIOL, V9, P80, DOI 10.1021/cb400754f
   Kamao H, 2014, STEM CELL REP, V2, P205, DOI 10.1016/j.stemcr.2013.12.007
   Kim C, 2014, BLOOD RES, V49, P7, DOI 10.5045/br.2014.49.1.7
   Kim DH, 2011, SEMIN CELL DEV BIOL, V22, P336, DOI 10.1016/j.semcdb.2011.02.025
   Kim D, 2009, CELL STEM CELL, V4, P472, DOI 10.1016/j.stem.2009.05.005
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Klimanskaya I, 2004, CLONING STEM CELLS, V6, P217, DOI 10.1089/1536230042323420
   Koch P, 2009, LANCET NEUROL, V8, P819, DOI 10.1016/S1474-4422(09)70202-9
   Korbling M, 2003, NEW ENGL J MED, V349, P570, DOI 10.1056/NEJMra022361
   Krohne TU, 2012, STEM CELL TRANSL MED, V1, P96, DOI 10.5966/sctm.2011-0057
   Langmead B, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-3-r25
   Li De-Quan, 2014, J Stem Cells, V9, P79
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Marchetto MCN, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007076
   Mayer EJ, 2005, BRIT J OPHTHALMOL, V89, P102, DOI 10.1136/bjo.2004.057687
   McGill TJ, 2012, EUR J NEUROSCI, V35, P468, DOI 10.1111/j.1460-9568.2011.07970.x
   Medical Advisory Secretariat, 2008, Ont Health Technol Assess Ser, V8, P1
   Nakano-Okuno M, 2014, STEM CELL REV REP, V10, P743, DOI 10.1007/s12015-014-9536-x
   Narsinh KH, 2011, NAT PROTOC, V6, P78, DOI 10.1038/nprot.2010.173
   Nazor KL, 2012, CELL STEM CELL, V10, P620, DOI 10.1016/j.stem.2012.02.013
   Oliveira PH, 2014, STEM CELLS, V32, P2824, DOI 10.1002/stem.1796
   Parameswaran S, 2010, STEM CELLS, V28, P695, DOI 10.1002/stem.320
   Park SS, 2012, INVEST OPHTH VIS SCI, V53, P986, DOI 10.1167/iovs.11-8833
   Pennesi ME, 2012, MOL ASPECTS MED, V33, P487, DOI 10.1016/j.mam.2012.06.003
   Pons M, 2011, INVEST OPHTH VIS SCI, V52, P3842, DOI 10.1167/iovs.10-6254
   Ramsden CM, 2013, DEVELOPMENT, V140, P2576, DOI 10.1242/dev.092270
   Reh TA, 2006, METHOD ENZYMOL, V419, P52, DOI 10.1016/S0076-6879(06)19003-5
   Rosenfeld PJ, 2011, NEW ENGL J MED, V364, P1966, DOI 10.1056/NEJMe1103334
   Rowland TJ, 2013, J TISSUE ENG REGEN M, V7, P642, DOI 10.1002/term.1458
   Ruiz S, 2012, P NATL ACAD SCI USA, V109, P16196, DOI 10.1073/pnas.1202352109
   Schwartz SD, 2015, LANCET, V385, P509, DOI 10.1016/S0140-6736(14)61376-3
   Schwartz SD, 2012, LANCET, V379, P713, DOI 10.1016/S0140-6736(12)60028-2
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P321, DOI 10.1001/archopht.123.3.321
   Shen Y, 2008, P NATL ACAD SCI USA, V105, P4709, DOI 10.1073/pnas.0712018105
   Silva SS, 2008, P NATL ACAD SCI USA, V105, P4820, DOI 10.1073/pnas.0712136105
   Singh R, 2013, INVEST OPHTH VIS SCI, V54, P6767, DOI 10.1167/iovs.13-11943
   Singh R, 2013, HUM MOL GENET, V22, P593, DOI 10.1093/hmg/dds469
   Singhal S, 2012, STEM CELL TRANSL MED, V1, P188, DOI 10.5966/sctm.2011-0005
   Siqueira RC, 2011, STEM CELL RES THER, V2, DOI 10.1186/scrt91
   Stein-Streilein J, 2013, INT REV IMMUNOL, V32, P42, DOI 10.3109/08830185.2012.740535
   Sterneckert JL, 2014, NAT REV GENET, V15, P625, DOI 10.1038/nrg3764
   Sugino IK, 2011, INVEST OPHTH VIS SCI, V52, P9598, DOI 10.1167/iovs.11-8400
   Takahashi K, 2007, CELL, V131, P861, DOI 10.1016/j.cell.2007.11.019
   Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024
   Thomson JA, 1998, SCIENCE, V282, P1145, DOI 10.1126/science.282.5391.1145
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   Trapnell C, 2009, BIOINFORMATICS, V25, P1105, DOI 10.1093/bioinformatics/btp120
   Tucker BA, 2014, HUM MOL GENET, V23, pR9, DOI 10.1093/hmg/ddu124
   Tucker BA, 2013, ELIFE, V2, DOI 10.7554/eLife.00824
   Vazin T, 2010, RESTOR NEUROL NEUROS, V28, P589, DOI 10.3233/RNN-2010-0543
   Vitaloni M, 2014, J BIOL CHEM, V289, P2084, DOI 10.1074/jbc.M113.538702
   Vogel G, 2010, SCIENCE, V330, P1172, DOI 10.1126/science.330.6008.1172
   Vugler A, 2008, EXP NEUROL, V214, P347, DOI 10.1016/j.expneurol.2008.09.007
   Wang JJ, 2014, OPHTHALMOLOGY, V121, P667, DOI 10.1016/j.ophtha.2013.10.017
   Warren L, 2010, CELL STEM CELL, V7, P618, DOI 10.1016/j.stem.2010.08.012
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wright LS, 2014, EXP EYE RES, V123, P161, DOI 10.1016/j.exer.2013.12.001
   Yamanaka S, 2012, CELL STEM CELL, V10, P678, DOI 10.1016/j.stem.2012.05.005
   Ying QL, 2002, NATURE, V416, P545, DOI 10.1038/nature729
   Young MA, 2012, CELL STEM CELL, V10, P570, DOI 10.1016/j.stem.2012.03.002
   Yu AL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048501
   Yu JY, 2007, SCIENCE, V318, P1917, DOI 10.1126/science.1151526
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
   Zhang F, 2014, HUM MOL GENET, V23, pR40, DOI 10.1093/hmg/ddu125
   Zhou Ru, 2010, F1000 Biol Rep, V2, DOI 10.3410/B2-3
   Zhou T, 2012, NAT PROTOC, V7, P2080, DOI 10.1038/nprot.2012.115
   Zhou Yi-ye, 2013, Genomics Proteomics & Bioinformatics, V11, P284, DOI 10.1016/j.gpb.2013.09.008
   Zhu Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054552
   Zipfel PF, 2010, ADV EXP MED BIOL, V703, P9, DOI 10.1007/978-1-4419-5635-4_2
NR 115
TC 17
Z9 17
U1 0
U2 16
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
SN 2077-0383
J9 J CLIN MED
JI J. Clin. Med.
PD FEB
PY 2015
VL 4
IS 2
BP 282
EP 303
DI 10.3390/jcm4020282
PG 22
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA CT9IY
UT WOS:000363131700005
PM 26239128
OA gold, Green Submitted, Green Published
DA 2022-11-30
ER

PT J
AU Scripsema, NK
   Hu, DN
   Rosen, RB
AF Scripsema, Nicole K.
   Hu, Dan-Ning
   Rosen, Richard B.
TI Lutein, Zeaxanthin, and meso-Zeaxanthin in the Clinical Management of
   Eye Disease
SO JOURNAL OF OPHTHALMOLOGY
LA English
DT Review
ID PIGMENT OPTICAL-DENSITY; AGE-RELATED MACULOPATHY; MACULAR PIGMENT;
   RISK-FACTORS; VITAMIN-E; VISUAL FUNCTION; SINGLET OXYGEN; DOUBLE-BLIND;
   DIABETIC COMPLICATIONS; DIETARY ANTIOXIDANTS
AB Lutein, zeaxanthin, and meso-zeaxanthin are xanthophyll carotenoids found within the retina and throughout the visual system. The retina is one of the most metabolically active tissues in the body. The highest concentration of xanthophylls is found within the retina, and this selective presence has generated many theories regarding their role in supporting retinal function. Subsequently, the effect of xanthophylls in the prevention and treatment of various eye diseases has been examined through epidemiological studies, animal studies, and clinical trials. This paper attempts to review the epidemiological studies and clinical trials investigating the effects of xanthophylls on the incidence and progression of various eye diseases. Observational studies have reported that increased dietary intake and higher serum levels of lutein and zeaxanthin are associated with lower risk of age-related macular degeneration (AMD), especially late AMD. Randomized, placebo-controlled clinical trials have demonstrated that xanthophyll supplementation increases macular pigment levels, improves visual function, and decreases the risk of progression to late AMD, especially neovascular AMD. Current publications on the preventive and therapeutic effects of lutein and zeaxanthin on cataracts, diabetic retinopathy, and retinopathy of prematurity have reported encouraging results.
C1 [Scripsema, Nicole K.; Hu, Dan-Ning; Rosen, Richard B.] New York Eye & Ear Infirm Mt Sinai, Dept Ophthalmol, New York, NY 10003 USA.
   [Hu, Dan-Ning] New York Eye & Ear Infirm Mt Sinai, Dept Pathol, New York, NY 10003 USA.
   [Hu, Dan-Ning; Rosen, Richard B.] Icahn Sch Med Mt Sinai, New York, NY 10029 USA.
C3 New York Eye & Ear Infirmary of Mount Sinai; New York Eye & Ear
   Infirmary of Mount Sinai; Icahn School of Medicine at Mount Sinai
RP Rosen, RB (通讯作者)，New York Eye & Ear Infirm Mt Sinai, Dept Ophthalmol, New York, NY 10003 USA.
EM rrosen@nyee.edu
FU Dennis Gierhart Charitable Fund
FX Funding for the submission of this paper was generously donated by the
   Dennis Gierhart Charitable Fund.
CR Acar N, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035102
   Akuffo KO, 2015, EYE, V29, P902, DOI 10.1038/eye.2015.64
   Arnal E, 2009, CURR EYE RES, V34, P928, DOI 10.3109/02713680903205238
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Beatty S, 2001, INVEST OPHTH VIS SCI, V42, P439
   Beatty S, 2013, OPHTHALMOLOGY, V120, P600, DOI 10.1016/j.ophtha.2012.08.040
   Berendschot TTJM, 2002, ARCH OPHTHALMOL-CHIC, V120, P1732, DOI 10.1001/archopht.120.12.1732
   Bernstein PS, 2002, OPHTHALMOLOGY, V109, P1780, DOI 10.1016/S0161-6420(02)01173-9
   Bernstein PS, 2001, EXP EYE RES, V72, P215, DOI 10.1006/exer.2000.0954
   Berrow EJ, 2013, BRIT J NUTR, V109, P2008, DOI 10.1017/S0007114512004187
   Bertram JS, 1999, NUTR REV, V57, P182, DOI 10.1111/j.1753-4887.1999.tb06941.x
   BIRCH EE, 1992, INVEST OPHTH VIS SCI, V33, P3242
   Bone RA, 1997, EXP EYE RES, V64, P211, DOI 10.1006/exer.1996.0210
   BONE RA, 1985, VISION RES, V25, P1531, DOI 10.1016/0042-6989(85)90123-3
   Bone RA, 2001, INVEST OPHTH VIS SCI, V42, P235
   BONE RA, 1988, INVEST OPHTH VIS SCI, V29, P843
   BONE RA, 1993, INVEST OPHTH VIS SCI, V34, P2033
   Bone RA, 2007, NUTR METAB, V4, DOI 10.1186/1743-7075-4-12
   Bovier ER, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0108178
   Brazionis L, 2009, BRIT J NUTR, V101, P270, DOI 10.1017/S0007114508006545
   BROWN ED, 1989, AM J CLIN NUTR, V49, P1258, DOI 10.1093/ajcn/49.6.1258
   Brown L, 1999, AM J CLIN NUTR, V70, P517
   Brownlee M, 2001, NATURE, V414, P813, DOI 10.1038/414813a
   Brownlee M, 2005, DIABETES, V54, P1615, DOI 10.2337/diabetes.54.6.1615
   Cavallaro G, 2014, ACTA OPHTHALMOL, V92, P2, DOI 10.1111/aos.12049
   Chasan-Taber L, 1999, AM J CLIN NUTR, V70, P509
   Chew EY, 2014, JAMA OPHTHALMOL, V132, P142, DOI 10.1001/jamaophthalmol.2013.7376
   Chew EY, 2013, OPHTHALMOLOGY, V120, P1604, DOI 10.1016/j.ophtha.2013.01.021
   Cho EY, 2008, AM J CLIN NUTR, V87, P1837, DOI 10.1093/ajcn/87.6.1837
   Christen WG, 2008, ARCH OPHTHALMOL-CHIC, V126, P102, DOI 10.1001/archopht.126.1.102
   COGDELL RJ, 1975, BIOCHIM BIOPHYS ACTA, V408, P189, DOI 10.1016/0005-2728(75)90122-X
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Craft N E, 2004, J Nutr Health Aging, V8, P156
   Dani Carlo, 2012, J Matern Fetal Neonatal Med, V25, P523, DOI 10.3109/14767058.2011.629252
   Dawczynski J, 2013, GRAEF ARCH CLIN EXP, V251, P2711, DOI 10.1007/s00417-013-2376-6
   Delcourt C, 2006, INVEST OPHTH VIS SCI, V47, P2329, DOI 10.1167/iovs.05-1235
   DI MASCIO P, 1989, ARCH BIOCHEM BIOPHYS, V274, P532, DOI 10.1016/0003-9861(89)90467-0
   Feeney J, 2013, NEUROBIOL AGING, V34, P2449, DOI 10.1016/j.neurobiolaging.2013.05.007
   FEENEYBURNS L, 1984, INVEST OPHTH VIS SCI, V25, P195
   Fukuzawa K, 1998, LIPIDS, V33, P751, DOI 10.1007/s11745-998-0266-y
   Gale CR, 2003, INVEST OPHTH VIS SCI, V44, P2461, DOI 10.1167/iovs.02-0929
   Gale CR, 2001, OPHTHALMOLOGY, V108, P1992, DOI 10.1016/S0161-6420(01)00833-8
   Gong XM, 2015, ARCH BIOCHEM BIOPHYS, V572, P40, DOI 10.1016/j.abb.2015.02.004
   Granado F, 2003, BRIT J NUTR, V90, P487, DOI 10.1079/BJN2003927
   HAM WT, 1976, NATURE, V260, P153, DOI 10.1038/260153a0
   Hammond BR, 2006, APPL SPECTROSC, V60, P1348, DOI 10.1366/000370206778999067
   Hammond BR, 2014, INVEST OPHTH VIS SCI, V55, P8583, DOI 10.1167/iovs.14-15573
   Hammond BR, 2005, OPHTHAL PHYSL OPT, V25, P315, DOI 10.1111/j.1475-1313.2005.00271.x
   Hammond BR, 1996, VISION RES, V36, P2001, DOI 10.1016/0042-6989(95)00290-1
   Hammond BR, 1997, OPTOMETRY VISION SCI, V74, P499, DOI 10.1097/00006324-199707000-00017
   HANDELMAN GJ, 1988, INVEST OPHTH VIS SCI, V29, P850
   HANDELMAN GJ, 1992, METHOD ENZYMOL, V213, P220
   Hellstrom A, 2013, LANCET, V382, P1445, DOI 10.1016/S0140-6736(13)60178-6
   Ho L, 2011, ARCH OPHTHALMOL-CHIC, V129, P758, DOI 10.1001/archophthalmol.2011.141
   Hu BJ, 2011, INT J OPHTHALMOL-CHI, V4, P303, DOI 10.3980/j.issn.2222-3959.2011.03.19
   Jacques PF, 2001, ARCH OPHTHALMOL-CHIC, V119, P1009, DOI 10.1001/archopht.119.7.1009
   Johnson EJ, 2000, AM J CLIN NUTR, V71, P1555
   Johnson EJ, 2008, NUTR NEUROSCI, V11, P75, DOI 10.1179/147683008X301450
   Johnson Elizabeth J, 2002, Nutr Clin Care, V5, P56, DOI 10.1046/j.1523-5408.2002.00004.x
   JORGENSEN K, 1993, Z LEBENSM UNTERS FOR, V196, P423, DOI 10.1007/BF01190806
   Junghans A, 2001, ARCH BIOCHEM BIOPHYS, V391, P160, DOI 10.1006/abbi.2001.2411
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1439, DOI 10.1001/archopht.119.10.1439
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kaur C, 2009, INVEST OPHTH VIS SCI, V50, P5364, DOI 10.1167/iovs.09-3552
   KIM CBY, 1994, J OPT SOC AM A, V11, P1958, DOI 10.1364/JOSAA.11.001958
   Kim SR, 2006, EXP EYE RES, V82, P828, DOI 10.1016/j.exer.2005.10.004
   Kowluru RA, 2008, INVEST OPHTH VIS SCI, V49, P1645, DOI 10.1167/iovs.07-0764
   KRINSKY NI, 1982, J NATL CANCER I, V69, P205
   KRINSKY NI, 1979, PURE APPL CHEM, V51, P649, DOI 10.1351/pac197951030649
   Kuzniarz M, 2001, AM J OPHTHALMOL, V132, P19, DOI 10.1016/S0002-9394(01)00922-9
   LaRowe TL, 2008, OPHTHALMOLOGY, V115, P876, DOI 10.1016/j.ophtha.2007.06.015
   LESKE MC, 1991, ARCH OPHTHALMOL-CHIC, V109, P244, DOI 10.1001/archopht.1991.01080020090051
   Leske MC, 1998, OPHTHALMOLOGY, V105, P831, DOI 10.1016/S0161-6420(98)95021-7
   LIM BP, 1992, BIOCHIM BIOPHYS ACTA, V1126, P178
   Lima VC, 2010, INVEST OPHTH VIS SCI, V51, P5840, DOI 10.1167/iovs.09-4695
   Liu R, 2015, INVEST OPHTH VIS SCI, V56, P252, DOI 10.1167/iovs.14-15553
   Lyle BJ, 1999, AM J EPIDEMIOL, V149, P801, DOI 10.1093/oxfordjournals.aje.a009895
   Ma L., 2012, AM J OPHTHALMOL, V154
   Ma L, 2012, OPHTHALMOLOGY, V119, P2290, DOI 10.1016/j.ophtha.2012.06.014
   Ma L, 2012, BRIT J NUTR, V107, P350, DOI 10.1017/S0007114511004260
   Manzoni P, 2013, AM J PERINAT, V30, P25, DOI 10.1055/s-0032-1321494
   Mares-Perlman JA, 2000, ARCH OPHTHALMOL-CHIC, V118, P1556, DOI 10.1001/archopht.118.11.1556
   MARESPERLMAN JA, 1995, ARCH OPHTHALMOL-CHIC, V113, P1518, DOI 10.1001/archopht.1995.01100120048007
   Miranda M., 2006, Arch Soc Esp Oftalmol, V81, P27
   Moeller SM, 2006, ARCH OPHTHALMOL-CHIC, V124, P1151, DOI 10.1001/archopht.124.8.1151
   Muriach M, 2006, FREE RADICAL BIO MED, V41, P979, DOI 10.1016/j.freeradbiomed.2006.06.023
   Murray IJ, 2013, INVEST OPHTH VIS SCI, V54, P1781, DOI 10.1167/iovs.12-10715
   Niesman MR, 1997, NEUROCHEM RES, V22, P597, DOI 10.1023/A:1022474120512
   Nilsson SEG, 2003, DOC OPHTHALMOL, V106, P13, DOI 10.1023/A:1022419606629
   Nitti M, 2005, FREE RADICAL BIO MED, V38, P846, DOI 10.1016/j.freeradbiomed.2004.12.002
   Nitti M, 2007, NEUROSCI LETT, V416, P261, DOI 10.1016/j.neulet.2007.02.013
   Nolan JM, 2007, EXP EYE RES, V84, P61, DOI 10.1016/j.exer.2006.08.016
   Nolan JM, 2011, VISION RES, V51, P459, DOI 10.1016/j.visres.2010.12.016
   Nolan JM, 2010, OPHTHALMIC RES, V44, P131, DOI 10.1159/000315531
   Obrosova IG, 2005, DIABETES, V54, P3435, DOI 10.2337/diabetes.54.12.3435
   Olmedilla B, 2003, NUTRITION, V19, P21, DOI 10.1016/S0899-9007(02)00861-4
   Pacher P, 2005, ANTIOXID REDOX SIGN, V7, P1568, DOI 10.1089/ars.2005.7.1568
   Penn JS, 1997, FREE RADICAL BIO MED, V22, P977, DOI 10.1016/S0891-5849(96)00479-0
   Perrone S, 2014, OXID MED CELL LONGEV, V2014, DOI 10.1155/2014/781454
   Picone S, 2012, CLIN BIOCHEM, V45, P1558, DOI 10.1016/j.clinbiochem.2012.07.109
   Piermarocchi S, 2012, EUR J OPHTHALMOL, V22, P216, DOI 10.5301/ejo.5000069
   Rasmussen HM, 2012, J FOOD COMPOS ANAL, V27, P139, DOI 10.1016/j.jfca.2012.04.009
   Renzi LM, 2014, NEUROBIOL AGING, V35, P1695, DOI 10.1016/j.neurobiolaging.2013.12.024
   Renzi LM, 2010, EXP EYE RES, V91, P896, DOI 10.1016/j.exer.2010.09.015
   Richer Stuart, 2004, Optometry, V75, P216, DOI 10.1016/S1529-1839(04)70049-4
   Rivera JC, 2011, NEONATOLOGY, V100, P343, DOI 10.1159/000330174
   Romagnoli C, 2011, J MATERN-FETAL NEO M, V24, P147, DOI 10.3109/14767058.2011.607618
   Rubin LP, 2012, J PERINATOL, V32, P418, DOI 10.1038/jp.2011.87
   SanGiovanni JP, 2007, ARCH OPHTHALMOL-CHIC, V125, P1225, DOI 10.1001/archopht.125.9.1225
   Sasaki M, 2010, DIABETOLOGIA, V53, P971, DOI 10.1007/s00125-009-1655-6
   Schalch W, 1992, EXS, V62, P280
   SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413
   SEDDON JM, 1994, AM J PUBLIC HEALTH, V84, P788, DOI 10.2105/AJPH.84.5.788
   Sies H, 1997, INT J VITAM NUTR RES, V67, P364
   Smith LE, 2013, CLIN PERINATOL, V40, P201, DOI 10.1016/j.clp.2013.02.002
   SNODDERLY DM, 1991, INVEST OPHTH VIS SCI, V32, P268
   SNODDERLY DM, 1984, INVEST OPHTH VIS SCI, V25, P674
   Sommerburg O, 1998, BRIT J OPHTHALMOL, V82, P907, DOI 10.1136/bjo.82.8.907
   Sommerburg O, 1999, CURR EYE RES, V19, P491, DOI 10.1076/ceyr.19.6.491.5276
   SPERDUTO RD, 1993, ARCH OPHTHALMOL-CHIC, V111, P1246, DOI 10.1001/archopht.1993.01090090098027
   Stahl W, 1997, CARCINOGENESIS, V18, P89, DOI 10.1093/carcin/18.1.89
   Stahl W., 2002, HDB ANTIOXIDANTS, P223
   Stringham JM, 2008, OPTOMETRY VISION SCI, V85, P82, DOI 10.1097/OPX.0b013e318162266e
   Stringham JM, 2007, OPTOMETRY VISION SCI, V84, P859, DOI 10.1097/OPX.0b013e3181559c2b
   Stringham JM, 2011, INVEST OPHTH VIS SCI, V52, P7406, DOI 10.1167/iovs.10-6699
   Stringham JM, 2010, J FOOD SCI, V75, pR24, DOI 10.1111/j.1750-3841.2009.01447.x
   Stringham JM, 2004, INVEST OPHTH VIS SCI, V45, P3838, DOI 10.1167/iovs.04-0038
   Stringham JM, 2003, J OPT SOC AM A, V20, P1852, DOI 10.1364/JOSAA.20.001852
   Sujak A, 1999, ARCH BIOCHEM BIOPHYS, V371, P301, DOI 10.1006/abbi.1999.1437
   Tan JSL, 2008, OPHTHALMOLOGY, V115, P334, DOI 10.1016/j.ophtha.2007.03.083
   Thurnham DI, 2015, GRAEF ARCH CLIN EXP, V253, P1231, DOI 10.1007/s00417-014-2811-3
   van der Veen RLP, 2009, J BIOMED OPT, V14, DOI 10.1117/1.3275481
   van Leeuwen R, 2005, JAMA-J AM MED ASSOC, V294, P3101, DOI 10.1001/jama.294.24.3101
   VandenLangenberg GM, 1998, AM J EPIDEMIOL, V148, P204, DOI 10.1093/oxfordjournals.aje.a009625
   Vishwanathan R, 2014, AGE AGEING, V43, P271, DOI 10.1093/ageing/aft210
   Vishwanathan R, 2013, NUTR NEUROSCI, V16, P21, DOI 10.1179/1476830512Y.0000000024
   Vu HTV, 2006, INVEST OPHTH VIS SCI, V47, P3783, DOI 10.1167/iovs.05-0587
   Weigert G, 2011, INVEST OPHTH VIS SCI, V52, P8174, DOI 10.1167/iovs.11-7522
   Wenzel AJ, 2006, VISION RES, V46, P4615, DOI 10.1016/j.visres.2006.09.019
   WING GL, 1978, INVEST OPHTH VIS SCI, V17, P601
   YEUM KJ, 1995, INVEST OPHTH VIS SCI, V36, P2756
   Yeum KJ, 1999, CURR EYE RES, V19, P502, DOI 10.1076/ceyr.19.6.502.5282
NR 142
TC 54
Z9 57
U1 0
U2 24
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2090-004X
EI 2090-0058
J9 J OPHTHALMOL
JI J. Ophthalmol.
PY 2015
VL 2015
AR 865179
DI 10.1155/2015/865179
PG 13
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DA2BA
UT WOS:000367599100001
PM 26819755
OA Green Published, Green Submitted, gold
DA 2022-11-30
ER

PT J
AU Kotwal, GJ
   Fernando, N
   Zhou, JH
   Valter, K
AF Kotwal, Girish J.
   Fernando, Nilisha
   Zhou, Jianhua
   Valter, Krisztina
TI Exploring the potential benefits of vaccinia virus complement control
   protein in controlling complement activation in pathogenesis of the
   central nervous system diseases
SO MOLECULAR IMMUNOLOGY
LA English
DT Review
ID FACTOR-H POLYMORPHISM; MACULAR DEGENERATION; ALZHEIMERS-DISEASE;
   IMMUNE-SYSTEM; MOUSE MODEL; NEUROINFLAMMATION; COMPSTATIN; INHIBITION;
   INJURY; BRAIN
AB Aging is a major risk factor for the development of diseases related to the central nervous system (CNS), such as Alzheimer's disease (AD) and age-related macular degeneration (AMD). In both cases, linkage studies and genome-wide association studies found strong links with complement regulatory genes and disease risk. In AD, both CLU and CR1 genes were implicated in the late-onset form of the disease. In AMD, polymorphisms in CFH, CFB and C2 were similarly implicated. The cost of caring for patients with AD or AMD is approaching billions of dollars, and with the baby boomers reaching their 60's, this amount is likely to increase further. Intervention using complement inhibitors for individuals in their early 50s who are at a higher risk of disease development, (testing positive for genetic risk factors), could slow the progression of AD or AMD and possibly prevent the severity of late stage symptoms. Although we have used the vaccinia virus complement control protein (VCP) to elucidate the role of complement in CNS diseases, it has merely been an investigational tool but not the only possible potential therapeutic agent. (C) 2014 Elsevier Ltd. All rights reserved.
C1 [Kotwal, Girish J.] Univ Massachusetts, Sch Med, Dept Med, Worcester, MA USA.
   [Kotwal, Girish J.; Zhou, Jianhua] Inflamed Inc, Louisville, KY USA.
   [Fernando, Nilisha; Valter, Krisztina] Australian Natl Univ, John Curtin Sch Med Res, Canberra, ACT 2601, Australia.
   [Valter, Krisztina] Australian Natl Univ, Sch Med, Canberra, ACT, Australia.
C3 University of Massachusetts System; University of Massachusetts
   Worcester; Australian National University; John Curtin School of Medical
   Research; Australian National University
RP Kotwal, GJ (通讯作者)，Univ Massachusetts, Sch Med, Dept Med, 4664 Shenandoah Dr, Louisville, KY 40241 USA.
EM gjkotw0l@gmail.com
RI Valter, Krisztina/L-3015-2016
OI Fernando, Nilisha/0000-0002-8488-1348; Valter,
   Krisztina/0000-0002-2033-0408
CR Ager RR, 2010, J NEUROCHEM, V113, P389, DOI 10.1111/j.1471-4159.2010.06595.x
   Alexander JJ, 2008, J NEUROCHEM, V107, P1169, DOI 10.1111/j.1471-4159.2008.05668.x
   Anderson JB, 2002, TRANSPLANT P, V34, P1083, DOI 10.1016/S0041-1345(02)02805-1
   Bagyinszky E, 2014, CLIN INTERV AGING, V9, P535, DOI 10.2147/CIA.S51571
   Bohlson SS, 2007, MOL IMMUNOL, V44, P33, DOI 10.1016/j.molimm.2006.06.021
   Choi Sung S, 2014, Exp Neurobiol, V23, P45, DOI 10.5607/en.2014.23.1.45
   Crehan H, 2012, INT J ALZHEIMERS DIS, V2012
   Cullen KM, 2006, NEUROBIOL AGING, V27, P1786, DOI 10.1016/j.neurobiolaging.2005.10.016
   Daly J, 1998, NEUROBIOL AGING, V19, P619, DOI 10.1016/S0197-4580(98)00100-6
   Dong Y, 2007, INT J PHARMACEUT, V342, P208, DOI 10.1016/j.ijpharm.2007.04.031
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Fan R, 2007, J NEUROINFLAMM, V4, DOI 10.1186/1742-2094-4-22
   Fonseca MI, 2009, J IMMUNOL, V183, P1375, DOI 10.4049/jimmunol.0901005
   Francois C., 2006, Unites States Patent Application Publication Pub., Patent No. [US 2006/0142191 Al, 20060142191]
   Gasque P, 2000, IMMUNOPHARMACOLOGY, V49, P171, DOI 10.1016/S0162-3109(00)80302-1
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Gorham RD, 2013, EXP EYE RES, V116, P96, DOI 10.1016/j.exer.2013.07.023
   Gorin MB, 2005, EUR J HUM GENET, V13, P793, DOI 10.1038/sj.ejhg.5201431
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hicks RR, 2002, J NEUROTRAUM, V19, P705, DOI 10.1089/08977150260139093
   Kahn D, 2003, TRANSPLANT P, V35, P1606, DOI 10.1016/S0041-1345(03)00485-8
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Knerr PJ, 2011, ACS CHEM BIOL, V6, P753, DOI 10.1021/cb2000378
   Kotwal G J, 1994, Am Biotechnol Lab, V12, P76
   Kotwal GJ, 2011, CURR ALZHEIMER RES, V8, P32
   KOTWAL GJ, 1988, NATURE, V335, P176, DOI 10.1038/335176a0
   KOTWAL GJ, 1990, SCIENCE, V250, P827, DOI 10.1126/science.2237434
   Kotwal GJ, 1997, J LEUKOCYTE BIOL, V62, P415, DOI 10.1002/jlb.62.4.415
   Kuehn BM, 2005, JAMA-J AM MED ASSOC, V293, P1841, DOI 10.1001/jama.293.15.1841
   Kulkarni AP, 2011, CURR ALZHEIMER RES, V8, P95
   Kulkarni A, 2008, BIOGERONTOLOGY, V9, P405, DOI 10.1007/s10522-008-9161-7
   Kulkarni Amod P, 2012, Methods Mol Biol, V890, P305, DOI 10.1007/978-1-61779-876-4_18
   Leung E, 2013, EXPERT REV CLIN PHAR, V6, P565, DOI 10.1586/17512433.2013.829645
   Liu CC, 2013, NAT REV NEUROL, V26, P32, DOI DOI 10.1038/NRNEUR01.2012.263
   Lukiw WJ, 2012, MOL NEUROBIOL, V46, P11, DOI 10.1007/s12035-012-8234-4
   Mahley RW, 2012, NEURON, V76, P871, DOI 10.1016/j.neuron.2012.11.020
   McGeer PL, 1997, BRAIN RES, V749, P135, DOI 10.1016/S0006-8993(96)01324-8
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Murthy KHM, 2001, CELL, V104, P301, DOI 10.1016/S0092-8674(01)00214-8
   Pillay NS, 2008, BEHAV BRAIN RES, V192, P173, DOI 10.1016/j.bbr.2008.03.038
   Pillay NS, 2007, BRAIN RES, V1153, P158, DOI 10.1016/j.brainres.2007.03.056
   Pillay Nirvana S., 2004, Current Alzheimer Research, V1, P295, DOI 10.2174/1567205043331965
   Reynolds DN, 2004, ANN NY ACAD SCI, V1035, P165, DOI 10.1196/annals.1332.011
   Ricklin D, 2008, ADV EXP MED BIOL, V632, P273, DOI 10.1007/978-0-387-78952-1_20
   ROGERS J, 1992, P NATL ACAD SCI USA, V89, P10016, DOI 10.1073/pnas.89.21.10016
   Rutar M, 2011, INVEST OPHTH VIS SCI, V52, P5347, DOI 10.1167/iovs.10-7119
   Rutar M, 2011, INVEST OPHTH VIS SCI, V52, P2379, DOI 10.1167/iovs.10-6010
   Rutar M, 2010, CURR EYE RES, V35, P631, DOI 10.3109/02713681003682925
   Selkoe DJ, 2013, CELL, V154, P468, DOI 10.1016/j.cell.2013.07.003
   Selkoe DJ, 2001, NEURON, V32, P177, DOI 10.1016/S0896-6273(01)00475-5
   Shen Y, 2001, NEUROSCI LETT, V305, P165, DOI 10.1016/S0304-3940(01)01842-0
   Singhrao SK, 1999, EXP NEUROL, V159, P362, DOI 10.1006/exnr.1999.7170
   Smith SA, 2000, J VIROL, V74, P5659, DOI 10.1128/JVI.74.12.5659-5666.2000
   Smith SA, 2002, BBA-PROTEINS PROTEOM, V1598, P55, DOI 10.1016/S0167-4838(02)00339-4
   Stephan AH, 2013, J NEUROSCI, V33, P13460, DOI 10.1523/JNEUROSCI.1333-13.2013
   Tamamis P, 2012, CHEM BIOL DRUG DES, V79, P703, DOI 10.1111/j.1747-0285.2012.01324.x
   Veerhuis R, 2011, CURR ALZHEIMER RES, V8, P34, DOI 10.2174/156720511794604589
   Zhou J, 2008, J NEUROCHEM, V106, P2080, DOI 10.1111/j.1471-4159.2008.05558.x
   Zlokovic BV, 2013, JAMA NEUROL, V70, P440, DOI 10.1001/jamaneurol.2013.2152
NR 60
TC 5
Z9 5
U1 0
U2 9
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0161-5890
J9 MOL IMMUNOL
JI Mol. Immunol.
PD OCT
PY 2014
VL 61
IS 2
SI SI
BP 204
EP 209
DI 10.1016/j.molimm.2014.06.022
PG 6
WC Biochemistry & Molecular Biology; Immunology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Immunology
GA AP7NZ
UT WOS:000342265300018
PM 25052409
OA Green Published
DA 2022-11-30
ER

PT J
AU Treharne, AJ
   Thomson, HAJ
   Grossel, MC
   Lotery, AJ
AF Treharne, Andrew J.
   Thomson, Heather A. J.
   Grossel, Martin C.
   Lotery, Andrew J.
TI Developing methacrylate-based copolymers as an artificial Bruch's
   membrane substitute
SO JOURNAL OF BIOMEDICAL MATERIALS RESEARCH PART A
LA English
DT Article
DE copolymer; ophthalmology; retina; RGD peptide; scaffold;
   polymethylmethacrylate
ID RETINAL-PIGMENT EPITHELIUM; MACULAR DEGENERATION; CELL TRANSPLANTATION;
   IN-VITRO; ADHESION; BIOMATERIALS; COLLAGEN; PEPTIDE; RPE; SCAFFOLDS
AB Age-related macular degeneration (AMD) is the most common cause of blindness in the developed world. There is currently no treatment for the cellular loss, which is characteristic of AMD. Transplantation of retinal pigment epithelium (RPE) cells represents a potential therapy. Because of AMD-related pathology in the native support, Bruch's membrane, transplanted RPE cells require a scaffold to reside on. We present here the development of an electrospun fibrous scaffold derived from methyl methacrylate and poly(ethylene glycol) (PEG) methacrylate for novel application as an RPE scaffold. Scaffolds were chemically modified to improve cell adhesion by functionalization not previously reported for this type of copolymer system. A human RPE cell line was used to investigate cell-scaffold interactions for up to two weeks in vitro. Scanning electron microscopy was used to characterize the fibrous scaffolds and confirm cell attachment. By day 15, cell area was significantly (p < 0.001) enhanced on scaffolds with chemical modification of the PEG chain terminus. In addition, significantly, less-apoptotic cell death was demonstrable on these modified surfaces. (c) 2012 Wiley Periodicals, Inc. J Biomed Mater Res Part A: 100A: 23582364, 2012.
C1 [Thomson, Heather A. J.; Lotery, Andrew J.] Univ Southampton, Southampton Gen Hosp, Clin Neurosci Res Grp, Fac Med, Southampton SO16 6YD, Hants, England.
   [Treharne, Andrew J.; Grossel, Martin C.] Univ Southampton, Fac Nat & Environm Sci, Southampton SO17 1BJ, Hants, England.
C3 University of Southampton; University of Southampton
RP Lotery, AJ (通讯作者)，Univ Southampton, Southampton Gen Hosp, Clin Neurosci Res Grp, Fac Med, South Block,Mailpoint 806, Southampton SO16 6YD, Hants, England.
EM a.j.lotery@soton.ac.uk
RI , Martin/AAV-9496-2021
OI , Martin/0000-0001-7869-037X; Lotery, Andrew/0000-0001-5541-4305
FU Foresight RP; National Institute for Health Research [NF-SI-0507-10094]
   Funding Source: researchfish
FX Contract grant sponsors: Foresight RP; the Gift of Sight Appeal, and RP
   Fighting Blindness
CR Afshari FT, 2009, EYE, V23, P1890, DOI 10.1038/eye.2008.411
   Binder S, 2007, PROG RETIN EYE RES, V26, P516, DOI 10.1016/j.preteyeres.2007.02.002
   Booij JC, 2010, PROG RETIN EYE RES, V29, P1, DOI 10.1016/j.preteyeres.2009.08.003
   Cruess AF, 2008, PHARMACOECONOMICS, V26, P57, DOI 10.2165/00019053-200826010-00006
   Del Priore LV, 2006, PROG RETIN EYE RES, V25, P539, DOI 10.1016/j.preteyeres.2006.08.001
   Duan XD, 2007, BIOMATERIALS, V28, P78, DOI 10.1016/j.biomaterials.2006.08.034
   Fang IM, 2009, EXP EYE RES, V88, P12, DOI 10.1016/j.exer.2008.09.019
   Fittkau MH, 2005, BIOMATERIALS, V26, P167, DOI 10.1016/j.biomaterials.2004.02.012
   Franzco FKC, 2009, CLIN EXP OPHTHALMOL, V37, P275, DOI 10.1111/j.1442-9071.2009.01915.x
   HAUTANEN A, 1989, J BIOL CHEM, V264, P1437
   Heath DE, 2010, J BIOMED MATER RES A, V94A, P1294, DOI 10.1002/jbm.a.32811
   Hersel U, 2003, BIOMATERIALS, V24, P4385, DOI 10.1016/S0142-9612(03)00343-0
   Huang YC, 2007, J BIOMED MATER RES A, V82A, P842, DOI 10.1002/jbm.a.31036
   Hynes SR, 2010, GRAEF ARCH CLIN EXP, V248, P763, DOI 10.1007/s00417-009-1263-7
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Krishna Y, 2011, BRIT J OPHTHALMOL, V95, P569, DOI 10.1136/bjo.2009.169953
   Krishna Y, 2007, J BIOMED MATER RES A, V80A, P669, DOI 10.1002/jbm.a.30953
   Lateef SS, 2002, BIOMATERIALS, V23, P3159, DOI 10.1016/S0142-9612(02)00062-5
   MacLaren RE, 2007, OPHTHALMOLOGY, V114, P561, DOI 10.1016/j.ophtha.2006.06.049
   Place ES, 2009, NAT MATER, V8, P457, DOI [10.1038/NMAT2441, 10.1038/nmat2441]
   Scholl HPN, 2007, MOL VIS, V13, P196
   Singh S, 2001, BIOMATERIALS, V22, P3337, DOI 10.1016/S0142-9612(01)00171-5
   Sistiabudi R, 2009, BIOTECHNOL BIOENG, V102, P1723, DOI 10.1002/bit.22215
   Sonoda S, 2010, AGING-US, V2, P28, DOI 10.18632/aging.100111
   Tezcaner A, 2003, BIOMATERIALS, V24, P4573, DOI 10.1016/S0142-9612(03)00302-8
   Tezel TH, 1997, GRAEF ARCH CLIN EXP, V235, P41, DOI 10.1007/BF01007836
   Thumann G, 1997, CURR EYE RES, V16, P1236, DOI 10.1076/ceyr.16.12.1236.5031
   Thumann G, 2009, BIOMATERIALS, V30, P287, DOI 10.1016/j.biomaterials.2008.09.039
   Treharne AJ, 2011, BRIT J OPHTHALMOL, V95, P768, DOI 10.1136/bjo.2010.184002
   Turowski P, 2004, INVEST OPHTH VIS SCI, V45, P2786, DOI 10.1167/iovs.03-0943
   Williams RL, 2005, J MATER SCI-MATER M, V16, P1087, DOI 10.1007/s10856-005-4710-y
NR 31
TC 34
Z9 36
U1 0
U2 11
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1549-3296
EI 1552-4965
J9 J BIOMED MATER RES A
JI J. Biomed. Mater. Res. Part A
PD SEP
PY 2012
VL 100A
IS 9
BP 2358
EP 2364
DI 10.1002/jbm.a.34178
PG 7
WC Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Engineering; Materials Science
GA 980VJ
UT WOS:000306922000018
PM 22528296
DA 2022-11-30
ER

PT J
AU Carroll, MV
   Sim, RB
AF Carroll, Maria V.
   Sim, Robert B.
TI Complement in health and disease
SO ADVANCED DRUG DELIVERY REVIEWS
LA English
DT Review
DE Complement; Innate immunity; Blood plasma; Collectins; Inflammation;
   Phagocytosis; Opsonisation; Autoimmunity; Infection; Disease
ID MANNOSE-BINDING PROTEIN; PATTERN-RECOGNITION MOLECULES;
   SYSTEMIC-LUPUS-ERYTHEMATOSUS; HUMAN FACTOR-H; LECTIN PATHWAY ACTIVATION;
   GUINEA-PIG SERUM; L-FICOLIN; 1ST COMPONENT; ALTERNATIVE-PATHWAY; SERINE
   PROTEASES
AB The complement system consists of about 35-40 proteins and glycoproteins present in blood plasma or on cell surfaces. Its main biological function is to recognise "foreign" particles and macromolecules, and to promote their elimination either by opsonisation or lysis. Although historically complement has been studied as a system for immune defence against bacteria, it has an important homeostatic role in which it recognises damaged or altered "self" components. Thus complement has major roles in both immune defence against microorganisms, and in clearance of damaged or "used" host components.
   Since complement proteins opsonise or lyse cells, complement can damage healthy host cells and tissues. The system is regulated by many endogenous regulatory proteins. Regulation is sometimes imperfect and both too much and too little complement activation is associated with many diseases. Excessive or inappropriate activation can cause tissue damage in diseases such as rheumatoid arthritis, age-related macular degeneration (AMD), multiple sclerosis, ischemia-reperfusion injury (e.g. ischemic stroke). Insufficient complement activity is associated with susceptibility to infection (mainly bacterial) and development of autoimmune disease, like SLE (systemic lupus erythematosus). (C) 2011 Elsevier B.V. All rights reserved.
C1 [Carroll, Maria V.; Sim, Robert B.] Univ Oxford, Dept Pharmacol, Oxford OX1 3QT, England.
C3 University of Oxford
RP Sim, RB (通讯作者)，Univ Oxford, Dept Pharmacol, Mansfield Rd, Oxford OX1 3QT, England.
EM maria.carroll@pharm.ox.ac.uk; bob.sim@pharm.ox.ac.uk
RI Sim, Bob/A-1354-2008
OI Sim, Bob/0000-0002-2855-7455
CR Alchi B, 2010, PEDIATR NEPHROL, V25, P1409, DOI 10.1007/s00467-009-1322-7
   Alper CA, 1998, EXP CLIN IMMUNOGENET, V15, P203, DOI 10.1159/000019074
   Aoyagi Y, 2005, J IMMUNOL, V174, P418, DOI 10.4049/jimmunol.174.1.418
   Arlaud GJ, 2007, MOL IMMUNOL, V44, P3809, DOI 10.1016/j.molimm.2007.06.147
   Arlaud GJ, 2002, BIOCHEM SOC T, V30, P1001, DOI 10.1042/bst0301001
   Arnold JN, 2007, ANNU REV IMMUNOL, V25, P21, DOI 10.1146/annurev.immunol.25.022106.141702
   Ben Nasr A, 2006, J LEUKOCYTE BIOL, V80, P774, DOI 10.1189/jlb.1205755
   BHAKDI S, 1991, IMMUNOL TODAY, V12, P318, DOI 10.1016/0167-5699(91)90007-G
   Birmingham DJ, 2001, IMMUNOL REV, V180, P100, DOI 10.1034/j.1600-065X.2001.1800109.x
   Blackmore TK, 1996, J IMMUNOL, V157, P5422
   Blackmore TK, 1998, J IMMUNOL, V160, P3342
   CAMPBELL RD, 1988, ANNU REV IMMUNOL, V6, P161, DOI 10.1146/annurev.iy.06.040188.001113
   Carroll M C, 2000, Adv Immunol, V74, P61
   Carroll MV, 2009, MOL IMMUNOL, V46, P3367, DOI 10.1016/j.molimm.2009.07.015
   Cestari ID, 2009, MOL IMMUNOL, V47, P426, DOI 10.1016/j.molimm.2009.08.030
   Chen CB, 2004, J BIOL CHEM, V279, P26058, DOI 10.1074/jbc.M401318200
   CHINA B, 1993, INFECT IMMUN, V61, P3129, DOI 10.1128/IAI.61.8.3129-3136.1993
   Clark SJ, 2006, J BIOL CHEM, V281, P24713, DOI 10.1074/jbc.M605083200
   Clark SJ, 2010, BIOCHEM SOC T, V38, P1342, DOI 10.1042/BST0381342
   Clark SJ, 2010, J BIOL CHEM, V285, P30192, DOI 10.1074/jbc.M110.103986
   CLAS F, 1981, INFECT IMMUN, V31, P1138, DOI 10.1128/IAI.31.3.1138-1144.1981
   COLTEN HR, 1992, ANNU REV IMMUNOL, V10, P809, DOI 10.1146/annurev.iy.10.040192.004113
   Dave S, 2001, INFECT IMMUN, V69, P3435, DOI 10.1128/IAI.69.5.3435-3437.2001
   DAY AJ, 1988, IMMUNOGENETICS, V27, P211, DOI 10.1007/BF00346588
   de Cordoba SR, 2008, CLIN EXP IMMUNOL, V151, P1, DOI 10.1111/j.1365-2249.2007.03574.x
   de Cordoba SR, 1999, MOL IMMUNOL, V36, P803, DOI 10.1016/S0161-5890(99)00100-5
   Dempsey PW, 1996, SCIENCE, V271, P348, DOI 10.1126/science.271.5247.348
   Diaz A, 1997, J IMMUNOL, V158, P3779
   DODDS AW, 1978, BIOCHEM J, V175, P383, DOI 10.1042/bj1750383
   DRICKAMER K, 1993, ANNU REV CELL BIOL, V9, P237, DOI 10.1146/annurev.cb.09.110193.001321
   Endo Y, 2007, IMMUNOBIOLOGY, V212, P371, DOI 10.1016/j.imbio.2006.11.014
   ESSER AF, 1991, IMMUNOL TODAY, V12, P316, DOI 10.1016/0167-5699(91)90006-F
   FARRIES TC, 1988, BIOCHEM J, V253, P667, DOI 10.1042/bj2530667
   Fearon DT, 2000, NAT IMMUNOL, V1, P102, DOI 10.1038/77773
   FEARON DT, 1975, J EXP MED, V142, P856, DOI 10.1084/jem.142.4.856
   Fearon DT, 1998, SEMIN IMMUNOL, V10, P355, DOI 10.1006/smim.1998.0137
   FEARON DT, 1980, J EXP MED, V152, P20, DOI 10.1084/jem.152.1.20
   FIGUEROA JE, 1991, CLIN MICROBIOL REV, V4, P359, DOI 10.1128/CMR.4.3.359-395.1991
   Flores-Langarica A, 2009, J IMMUNOL, V182, P1305, DOI 10.4049/jimmunol.182.3.1305
   FRANK MM, 1991, IMMUNOL TODAY, V12, P322, DOI 10.1016/0167-5699(91)90009-I
   Frederiksen PD, 2005, SCAND J IMMUNOL, V62, P462, DOI 10.1111/j.1365-3083.2005.01685.x
   Garlatti V, 2007, J BIOL CHEM, V282, P35814, DOI 10.1074/jbc.M705741200
   Garred P, 2006, GENES IMMUN, V7, P85, DOI 10.1038/sj.gene.6364283
   GEERTSMA MF, 1994, AM J PHYSIOL-LUNG C, V267, pL578, DOI 10.1152/ajplung.1994.267.5.L578
   GORDON DL, 1995, J IMMUNOL, V155, P348
   Gordon J, 1926, BIOCHEM J, V20, P1028, DOI 10.1042/bj0201028
   Gordon J, 1929, BIOCHEM J, V23, P730, DOI 10.1042/bj0230730
   Gros P, 2008, NAT REV IMMUNOL, V8, P48, DOI 10.1038/nri2231
   Gulla KC, 2010, IMMUNOLOGY, V129, P482, DOI 10.1111/j.1365-2567.2009.03200.x
   Hallstrom T, 2008, J IMMUNOL, V181, P537, DOI 10.4049/jimmunol.181.1.537
   Hansen S, 2010, J IMMUNOL, V185, P6096, DOI 10.4049/jimmunol.1002185
   Hellwage J, 1999, FEBS LETT, V462, P345, DOI 10.1016/S0014-5793(99)01554-9
   Hellwage J, 1997, BIOCHEM J, V326, P321, DOI 10.1042/bj3260321
   Hellwage J, 2001, J BIOL CHEM, V276, P8427, DOI 10.1074/jbc.M007994200
   Helmy KY, 2006, CELL, V124, P915, DOI 10.1016/j.cell.2005.12.039
   HOLMSKOV U, 1994, IMMUNOL TODAY, V15, P67, DOI 10.1016/0167-5699(94)90136-8
   HORSTMANN RD, 1988, P NATL ACAD SCI USA, V85, P1657, DOI 10.1073/pnas.85.5.1657
   HOURCADE D, 1989, ADV IMMUNOL, V45, P381, DOI 10.1016/S0065-2776(08)60697-5
   Hourcade DE, 2006, J BIOL CHEM, V281, P2128, DOI 10.1074/jbc.M508928200
   HUGHESJONES NC, 1979, MOL IMMUNOL, V16, P697, DOI 10.1016/0161-5890(79)90010-5
   IKEDA K, 1987, J BIOL CHEM, V262, P7451
   Jack DL, 1998, J IMMUNOL, V160, P1346
   Jokiranta TS, 2000, J BIOL CHEM, V275, P27657
   Kang YH, 2009, ADV EXP MED BIOL, V653, P117
   KAWASAKI N, 1989, J BIOCHEM-TOKYO, V106, P483, DOI 10.1093/oxfordjournals.jbchem.a122878
   Kim DD, 2006, CLIN IMMUNOL, V118, P127, DOI 10.1016/j.clim.2005.10.014
   Koroleva IV, 1998, FEMS IMMUNOL MED MIC, V20, P11, DOI 10.1016/S0928-8244(97)00101-6
   Krarup A, 2005, INFECT IMMUN, V73, P1052, DOI 10.1128/IAI.73.2.1052-1060.2005
   Krarup A, 2004, J BIOL CHEM, V279, P47513, DOI 10.1074/jbc.M407161200
   Krarup A, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000623
   KUHLMAN M, 1989, J EXP MED, V169, P1733, DOI 10.1084/jem.169.5.1733
   Kuraya M, 2005, IMMUNOBIOLOGY, V209, P689, DOI 10.1016/j.imbio.2004.11.001
   LATSCH M, 1990, FEBS LETT, V276, P201, DOI 10.1016/0014-5793(90)80542-Q
   Le Y, 1998, FEBS LETT, V425, P367, DOI 10.1016/S0014-5793(98)00267-1
   LEVITZ SM, 1993, INFECT IMMUN, V61, P4891, DOI 10.1128/IAI.61.11.4891-4893.1993
   LEVY NJ, 1986, J IMMUNOL, V136, P4157
   LEVY NJ, 1985, INFECT IMMUN, V49, P19, DOI 10.1128/IAI.49.1.19-24.1985
   Liu Y, 2005, J IMMUNOL, V175, P3150, DOI 10.4049/jimmunol.175.5.3150
   Lu JH, 2002, BBA-GEN SUBJECTS, V1572, P387, DOI 10.1016/S0304-4165(02)00320-3
   Lynch NJ, 2004, J IMMUNOL, V172, P1198, DOI 10.4049/jimmunol.172.2.1198
   Ma YG, 2004, J BIOL CHEM, V279, P25307, DOI 10.1074/jbc.M400701200
   MALHOTRA R, 1995, NAT MED, V1, P237, DOI 10.1038/nm0395-237
   Malhotra R, 1994, Clin Exp Immunol, V97 Suppl 2, P4
   Markiewski MM, 2007, AM J PATHOL, V171, P715, DOI 10.2353/ajpath.2007.070166
   Matsushita M, 1996, J BIOL CHEM, V271, P2448, DOI 10.1074/jbc.271.5.2448
   Matsushita M, 2002, J IMMUNOL, V168, P3502, DOI 10.4049/jimmunol.168.7.3502
   Matsushita M, 2010, J INNATE IMMUN, V2, P24, DOI 10.1159/000228160
   Mayilyan KR, 2008, DRUG NEWS PERSPECT, V21, P200, DOI 10.1358/dnp.2008.21.4.1213349
   McRae JL, 2001, J BIOL CHEM, V276, P6747, DOI 10.1074/jbc.M007495200
   MERI S, 1990, P NATL ACAD SCI USA, V87, P3982, DOI 10.1073/pnas.87.10.3982
   Morgan BP, 2003, MOL IMMUNOL, V40, P159, DOI 10.1016/S0161-5890(03)00111-1
   Morley B.J., 2000, COMPLEMENT FACTS BOO
   MULLEREBERHARD HJ, 1988, ANNU REV BIOCHEM, V57, P321, DOI 10.1146/annurev.bi.57.070188.001541
   MULLEREBERHARD HJ, 1975, ANNU REV BIOCHEM, V44, P697, DOI 10.1146/annurev.bi.44.070175.003405
   NELSON DAVID S., 1959, YALE JOUR BIOL AND MED, V31, P185
   NELSON RA, 1966, IMMUNOCHEMISTRY, V3, P111, DOI 10.1016/0019-2791(66)90292-8
   Neth O, 2000, INFECT IMMUN, V68, P688, DOI 10.1128/IAI.68.2.688-693.2000
   Ng PML, 2007, EMBO J, V26, P3431, DOI 10.1038/sj.emboj.7601762
   Nilsson S.C., 2011, MOL IMMUNOL     0428
   Ormsby RJ, 2006, MOL IMMUNOL, V43, P1624, DOI 10.1016/j.molimm.2005.09.012
   PEPYS MB, 1974, J EXP MED, V140, P126, DOI 10.1084/jem.140.1.126
   Perry VH, 2008, NAT REV NEUROSCI, V9, P807, DOI 10.1038/nrn2394
   Petersen SV, 2000, MOL IMMUNOL, V37, P803, DOI 10.1016/S0161-5890(01)00004-9
   Pickering MC, 2000, RHEUMATOLOGY, V39, P133, DOI 10.1093/rheumatology/39.2.133
   Pillemer L, 1941, J EXP MED, V74, P297, DOI 10.1084/jem.74.4.297
   Polotsky VY, 1997, J INFECT DIS, V175, P1159, DOI 10.1086/520354
   PORTER RR, 1978, NATURE, V275, P699, DOI 10.1038/275699a0
   PREISSNER KT, 1991, ANNU REV CELL BIOL, V7, P275, DOI 10.1146/annurev.cellbio.7.1.275
   Presanis JS, 2004, MOL IMMUNOL, V40, P921, DOI 10.1016/j.molimm.2003.10.013
   Qu HC, 2011, MOL IMMUNOL, V48, P481, DOI 10.1016/j.molimm.2010.10.004
   Ram S, 1998, J EXP MED, V187, P743, DOI 10.1084/jem.187.5.743
   REID KBM, 1976, BIOCHEM J, V155, P19, DOI 10.1042/bj1550019
   RIPOCHE J, 1988, BIOCHEM J, V249, P593, DOI 10.1042/bj2490593
   Rooryck C, 2011, NAT GENET, V43, P197, DOI 10.1038/ng.757
   Rosen AM, 2010, ADV EXP MED BIOL, V703, P75, DOI 10.1007/978-1-4419-5635-4_6
   Rybak-Smith MJ, 2011, CARBON NANOSTRUCT, P183, DOI 10.1007/978-3-642-14802-6_10
   Salvador-Morales C, 2006, MOL IMMUNOL, V43, P193, DOI 10.1016/j.molimm.2005.02.006
   Saunders RE, 2007, HUM MUTAT, V28, P222, DOI 10.1002/humu.20435
   Schneider MC, 2006, J IMMUNOL, V176, P7566, DOI 10.4049/jimmunol.176.12.7566
   Schneider MC, 2009, NATURE, V458, P890, DOI 10.1038/nature07769
   Schwaeble W, 2002, IMMUNOBIOLOGY, V205, P455, DOI 10.1078/0171-2985-00146
   Schwaeble WJ, 2011, P NATL ACAD SCI USA, V108, P7523, DOI 10.1073/pnas.1101748108
   SIM E, 1984, LANCET, V2, P422
   SIM RB, 1981, BIOCHEM J, V193, P115, DOI 10.1042/bj1930115
   SIM RB, 1982, BIOCHEM J, V205, P285, DOI 10.1042/bj2050285
   Sim RB, 1998, IMMUNOBIOLOGY, V199, P208, DOI 10.1016/S0171-2985(98)80028-4
   SIM RB, 1979, BIOCHEM J, V179, P449, DOI 10.1042/bj1790449a
   SIM RB, 1993, METHOD ENZYMOL, V223, P13
   Sim Robert B., 2008, P84, DOI 10.1039/9781847558848-00084
   SIM RS, 1994, BIOCHEM SOC T, V22, P106, DOI 10.1042/bst0220106
   Sjoberg AP, 2009, TRENDS IMMUNOL, V30, P83, DOI 10.1016/j.it.2008.11.003
   Skjoedt MO, 2011, IMMUNOBIOLOGY, V216, P625, DOI 10.1016/j.imbio.2010.09.011
   Spitzer D, 2007, J IMMUNOL, V179, P2600, DOI 10.4049/jimmunol.179.4.2600
   SUPER M, 1989, LANCET, V2, P1236
   Tan LA, 2011, PROTEIN CELL, V2, P320, DOI 10.1007/s13238-011-1029-y
   Tan LA, 2010, PROTEIN CELL, V1, P1033, DOI 10.1007/s13238-010-0125-8
   Teh C, 2000, IMMUNOLOGY, V101, P225, DOI 10.1046/j.1365-2567.2000.00099.x
   TENNER AJ, 1984, J IMMUNOL, V133, P886
   Thiel S, 2006, MOL IMMUNOL, V43, P86, DOI 10.1016/j.molimm.2005.06.018
   Thiel S, 2007, MOL IMMUNOL, V44, P3875, DOI 10.1016/j.molimm.2007.06.005
   TSCHOPP J, 1993, J IMMUNOL, V151, P2159
   Vandivier RW, 2002, J IMMUNOL, V169, P3978, DOI 10.4049/jimmunol.169.7.3978
   VANEMMERIK LC, 1994, CLIN EXP IMMUNOL, V97, P411
   Wallis R, 2002, IMMUNOBIOLOGY, V205, P433, DOI 10.1078/0171-2985-00144
   Wallis R, 2000, J BIOL CHEM, V275, P30962, DOI 10.1074/jbc.M004030200
   Wallis R, 2010, IMMUNOBIOLOGY, V215, P1, DOI 10.1016/j.imbio.2009.08.006
   Walport MJ, 1998, IMMUNOBIOLOGY, V199, P265, DOI 10.1016/S0171-2985(98)80032-6
   WEDGWOOD R. J., 1958, ACTA HAEMATOL, V20, P253
   Weitz M., 2011, PEDIAT NEPHROL  0510
   Whitehead HR, 1925, BIOCHEM J, V19, P618, DOI 10.1042/bj0190618
   WILSON JG, 1987, IMMUNOL RES, V6, P192, DOI 10.1007/BF02918091
   Woodruff T.M., 2011, MOL IMMUNOL
   Xu W, 2008, J IMMUNOL, V180, P7613, DOI 10.4049/jimmunol.180.11.7613
   Zipfel PF, 2002, BIOCHEM SOC T, V30, P971, DOI 10.1042/bst0300971
   Zundel S, 2004, J IMMUNOL, V172, P4342, DOI 10.4049/jimmunol.172.7.4342
NR 155
TC 146
Z9 154
U1 0
U2 45
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0169-409X
EI 1872-8294
J9 ADV DRUG DELIVER REV
JI Adv. Drug Deliv. Rev.
PD SEP 16
PY 2011
VL 63
IS 12
BP 965
EP 975
DI 10.1016/j.addr.2011.06.005
PG 11
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA 833DI
UT WOS:000295861600002
PM 21704094
DA 2022-11-30
ER

PT J
AU Resnikoff, S
   Pascolini, D
   Etya'ale, D
   Kocur, I
   Pararajasegaram, R
   Pokharel, GP
   Mariotti, SP
AF Resnikoff, S
   Pascolini, D
   Etya'ale, D
   Kocur, I
   Pararajasegaram, R
   Pokharel, GP
   Mariotti, SP
TI Global data on visual impairment in the year 2002
SO BULLETIN OF THE WORLD HEALTH ORGANIZATION
LA English
DT Article
DE vision, low/epidemiology; blindness/epidemiology; vision, low/etiology;
   blindness/etiology; cataract/complications; glaucoma/complications;
   macular degeneration/complications; refractive errors/complications;
   cost of illness; age factors; sex factors
ID CATARACT BLINDNESS; REFRACTIVE ERROR; CHILDREN; POPULATION; PREVALENCE;
   DISTRICT
AB This paper presents estimates of the prevalence of visual impairment and its causes in 2002, based on the best available evidence derived from recent studies. Estimates were determined from data on low vision and blindness as defined in the International statistical classification of diseases, injuries and causes of death, 10th revision. The number of people with visual impairment worldwide in 2002 was in excess of 161 million, of whom about 37 million were blind.
   The burden of visual impairment is not distributed uniformly throughout the world: the least developed regions carry the largest share. Visual impairment is also unequally distributed across age groups, being largely Confined to adults 50 years of age and older A distribution imbalance is also found with regard to gender throughout the world: females have a significantly higher risk of having visual impairment than males.
   Notwithstanding the progress in surgical intervention that has been made in many countries over the last few decades, cataract remains the leading cause of visual impairment in all regions of the world, except in the most developed countries. Other major causes of visual impairment are, in order of importance, glaucoma, age-related macular degeneration, diabetic retinopathy and trachoma.
C1 WHO, Programme Prevent Blindness & Deafness, CH-1211 Geneva 27, Switzerland.
C3 World Health Organization
RP Resnikoff, S (通讯作者)，WHO, Programme Prevent Blindness & Deafness, 20 Ave Appia, CH-1211 Geneva 27, Switzerland.
EM resnikoffs@who.int
RI Resnikoff, Serge/N-2355-2019; Mitchell, Paul/P-1498-2014
OI Resnikoff, Serge/0000-0002-5866-4446; 
CR Amansakhatov S, 2002, BRIT J OPHTHALMOL, V86, P1207, DOI 10.1136/bjo.86.11.1207
   Dandona R, 2002, INVEST OPHTH VIS SCI, V43, P615
   Dineen BP, 2003, BRIT J OPHTHALMOL, V87, P820, DOI 10.1136/bjo.87.7.820
   Duerksen R, 2003, OPHTHAL EPIDEMIOL, V10, P349, DOI 10.1076/opep.10.5.349.17326
   Gilbert C E, 1999, Ophthalmic Epidemiol, V6, P73
   Limburg H, 1998, Ophthalmic Epidemiol, V5, P211, DOI 10.1076/opep.5.4.211.4193
   Limburg H, 1997, INT J EPIDEMIOL, V26, P1049, DOI 10.1093/ije/26.5.1049
   Limburg Hans, 1999, Indian Journal of Ophthalmology, V47, P135
   Michon JJ, 2002, BRIT J OPHTHALMOL, V86, P133, DOI 10.1136/bjo.86.2.133
   MURRAY CJL, 1996, 36 WORLD HLTH ORG
   Murthy GVS, 2002, INVEST OPHTH VIS SCI, V43, P623
   *NAT PROGR CONTR B, 2002, RIGHT SIGHT IN CAT S, V2
   *NAT PROGR CONTR B, 2002, NAT SURV BLINDN VIS
   Nirmalan PK, 2002, BRIT J OPHTHALMOL, V86, P505, DOI 10.1136/bjo.86.5.505
   Pascolini D, 2004, OPHTHAL EPIDEMIOL, V11, P67, DOI 10.1076/opep.11.2.67.28158
   Pokharel GP, 2000, AM J OPHTHALMOL, V129, P436, DOI 10.1016/S0002-9394(99)00453-5
   THYLEFORS B, 1995, B WORLD HEALTH ORGAN, V73, P115
   *UN NAT, 2003, WORLD POP PROSP 2002
   VanNewkirk MR, 2000, OPHTHALMOLOGY, V107, P2203, DOI 10.1016/S0161-6420(00)00459-0
   *WHO, 1990, PBL9018 WHO
   World Health Organization, 1993, INT STAT CLASS DIS I
   *WORLD HLTH ORG, 1988, PBL881 WHO
   *WORLD HLTH ORG, 2003, WORLD HLTH REP 2003
   *WORLD HLTH ORG, 1999, WHOPBL0077
   *WORLD HLTH ORG, 2000, WHOPBL9761
   Zhao JL, 2000, AM J OPHTHALMOL, V129, P427, DOI 10.1016/S0002-9394(99)00452-3
NR 26
TC 2761
Z9 2900
U1 5
U2 220
PU WORLD HEALTH ORGANIZATION
PI GENEVA 27
PA MARKETING AND DISSEMINATION, CH-1211 GENEVA 27, SWITZERLAND
SN 0042-9686
EI 1564-0604
J9 B WORLD HEALTH ORGAN
JI Bull. World Health Organ.
PD NOV
PY 2004
VL 82
IS 11
BP 844
EP 851
PG 8
WC Public, Environmental & Occupational Health
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Public, Environmental & Occupational Health
GA 873WZ
UT WOS:000225313500008
PM 15640920
DA 2022-11-30
ER

PT J
AU Alshaikh, RA
   Waeber, C
   Ryan, KB
AF Alshaikh, Rasha A.
   Waeber, Christian
   Ryan, Katie B.
TI Polymer based sustained drug delivery to the ocular posterior segment:
   barriers and future opportunities for the treatment of neovascular
   pathologies
SO ADVANCED DRUG DELIVERY REVIEWS
LA English
DT Review
DE Neovascular; Age related Macular Degeneration; Anti-VEGF;
   Corticosteroids; Dendrimer; Diabetic retinopathy; Responsive hydrogel;
   Intravitreal injection; Ocular barrier; Ocular implants; Sustained
   release
ID REVERSE THERMAL GEL; CONTROLLED-RELEASE; INTRAVITREAL INJECTION;
   BIOMEDICAL APPLICATIONS; FLUOCINOLONE ACETONIDE; INJECTABLE IMPLANTS;
   PROTEIN INSTABILITY; PLGA NANOPARTICLES; MOLECULAR-WEIGHT; CLICK
   HYDROGELS
AB There is an increasing momentum in research and pharmaceutical industry communities to design sustained, non-invasive delivery systems to treat chronic neovascular ocular diseases that affect the posterior segment of the eye including age-related macular degeneration and diabetic retinopathy. Current treatments include VEGF blockers, which have revolutionized the standard of care for patients, but their maximum therapeutic benefit is hampered by the need for recurrent and invasive administration procedures. Currently approved delivery systems intended to address these limitations exploit polymer technology to regulate drug release in a sustained manner.Here, we critically review sustained drug delivery approaches for the treatment of chronic neovascular diseases affecting the ocular posterior segment, with a special emphasis on novel and polymeric technologies spanning the spectrum of preclinical and clinical investigation, and those approved for treatment. The mechanism by which each formulation imparts sustained release, the impact of formulation characteristics on release and foreign body reaction, and special considerations related to the translation of these systems are discussed.(C) 2022 The Author(s). Published by Elsevier B.V. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
C1 [Alshaikh, Rasha A.; Waeber, Christian; Ryan, Katie B.] Univ Coll Cork, Sch Pharm, Cork, Ireland.
   [Waeber, Christian] Univ Coll Cork, Dept Pharmacol & Therapeut, Cork, Ireland.
   [Ryan, Katie B.] Univ Coll Cork, SSPC SFI Res Ctr Pharmaceut, Sch Pharm, Cork, Ireland.
   [Ryan, Katie B.] Univ Coll Cork, Sch Pharm, Coll Rd, Cork T12 YN60, Ireland.
C3 University College Cork; University College Cork; University College
   Cork; University College Cork
RP Ryan, KB (通讯作者)，Univ Coll Cork, Sch Pharm, Coll Rd, Cork T12 YN60, Ireland.
EM Katie.Ryan@ucc.ie
OI Ryan, Katie/0000-0002-6236-2977; Alshaikh, Rasha/0000-0003-2747-5084
FU Irish Research Council (IRC) [GOIPG/2020/971]
FX Funding This work was supported by the Irish Research Council (IRC) ,
   project ID: GOIPG/2020/971.
CR Abbasi E, 2014, NANOSCALE RES LETT, V9, DOI 10.1186/1556-276X-9-247
   Agrahari V, 2016, DRUG DELIV TRANSL RE, V6, P735, DOI 10.1007/s13346-016-0339-2
   Akash MSH, 2015, J CONTROL RELEASE, V209, P120, DOI 10.1016/j.jconrel.2015.04.032
   Alonso JM, 2021, POLYMERS-BASEL, V13, DOI 10.3390/polym13040650
   Altomare L, 2018, INT J ARTIF ORGANS, V41, P337, DOI 10.1177/0391398818765323
   Amrite AC, 2005, J PHARM PHARMACOL, V57, P1555, DOI 10.1211/jpp.57.12.0005
   Amselem L., 2010, RETINAL PHARMACOTHER, P297, DOI [10.1016/B978-1-4377-0603- 1.00048-X, DOI 10.1016/B978-1-4377-0603-1.00048-X]
   [Anonymous], 2019, GRAYBUG VISION INITI
   [Anonymous], 2010, ENCY EYE, DOI DOI 10.1016/B978-0-12-374203-2.00080-4
   Anwary M, 2018, ARTIF CELL NANOMED B, V46, P1074, DOI 10.1080/21691401.2018.1478845
   Arranz-Romera A, 2019, J CONTROL RELEASE, V297, P26, DOI 10.1016/j.jconrel.2019.01.012
   Balachandra A, 2019, DRUG DELIV, V26, P343, DOI 10.1080/10717544.2019.1587042
   Barrett CJ, 2007, SOFT MATTER, V3, P1249, DOI 10.1039/b705619b
   Beer PM, 2003, OPHTHALMOLOGY, V110, P681, DOI 10.1016/S0161-6420(02)01969-3
   Bernards DA, 2012, NANO LETT, V12, P5355, DOI 10.1021/nl302747y
   Bhatt P, 2020, AAPS PHARMSCITECH, V21, DOI 10.1208/s12249-020-01836-4
   Bilati U, 2005, EUR J PHARM BIOPHARM, V59, P375, DOI 10.1016/j.ejpb.2004.10.006
   Birch DG, 2013, AM J OPHTHALMOL, V156, P283, DOI 10.1016/j.ajo.2013.03.021
   Bisht R, 2017, J DRUG DELIV SCI TEC, V40, P142, DOI 10.1016/j.jddst.2017.06.006
   Bisht R, 2016, EXPERT OPIN DRUG DEL, V13, P953, DOI 10.1517/17425247.2016.1163334
   Booler H, 2021, TOXICOL PATHOL, V49, P656, DOI 10.1177/0192623320948851
   Bouas-Laurent H, 2001, CHEM SOC REV, V30, P248, DOI 10.1039/b006013p
   Busbee BG, 2013, OPHTHALMOLOGY, V120, P1046, DOI 10.1016/j.ophtha.2012.10.014
   Caccavo D, 2019, INT J PHARMACEUT, V560, P175, DOI 10.1016/j.ijpharm.2019.01.076
   Calo E, 2015, EUR POLYM J, V65, P252, DOI 10.1016/j.eurpolymj.2014.11.024
   Campochiaro PA, 2021, INVEST OPHTH VIS SCI, V62
   Castro-Navarro V, 2019, BMC OPHTHALMOL, V19, DOI 10.1186/s12886-018-1022-9
   Champion JA, 2009, PHARM RES-DORDR, V26, P244, DOI 10.1007/s11095-008-9626-z
   Chandrasekaran PR, 2021, THER ADV OPHTHALMOL, V13, DOI 10.1177/25158414211027708
   Chang D, 2019, DRUG DISCOV TODAY, V24, P1470, DOI 10.1016/j.drudis.2019.05.037
   Chang-Lin JE, 2011, INVEST OPHTH VIS SCI, V52, P80, DOI 10.1167/iovs.10-5285
   Chen ER, 2020, CLIN OPHTHALMOL, V14, P1349, DOI 10.2147/OPTH.S194234
   Chen H, 2013, INVEST OPHTH VIS SCI, V54, P2178, DOI 10.1167/iovs.12-11460
   Chen L, 2009, LYMPHOLOGY, V42, P66
   Cholkar K, 2012, WOODH PUB SER BIOMED, P1, DOI 10.1533/9781908818317.1
   Christie JG, 2008, DRUG DISCOV TODAY, V13, P124, DOI 10.1016/j.drudis.2007.12.005
   Coudrillier B, 2015, J BIOMECH ENG-T ASME, V137, DOI 10.1115/1.4029430
   Crowell SR, 2019, TRANSL VIS SCI TECHN, V8, DOI 10.1167/tvst.8.6.1
   Cwiklik L, 2016, BBA-BIOMEMBRANES, V1858, P2421, DOI 10.1016/j.bbamem.2016.02.020
   DAVIDORF FH, 1990, RETINA-J RET VIT DIS, V10, P297, DOI 10.1097/00006982-199010000-00013
   de Guimaraes TAC, 2022, BRIT J OPHTHALMOL, V106, P297, DOI 10.1136/bjophthalmol-2020-318452
   de Smet MD, 2013, OPHTHALMOLOGICA, V230, P165, DOI 10.1159/000353447
   del Amo EM, 2017, PROG RETIN EYE RES, V57, P134, DOI 10.1016/j.preteyeres.2016.12.001
   del Amo EM, 2015, EUR J PHARM BIOPHARM, V95, P215, DOI 10.1016/j.ejpb.2015.01.003
   Ding SY, 2016, NAT REV MATER, V1, DOI [10.1038/natrevmats.2016.21, 10.1038/natrevmats.2016.71]
   Doberenz F, 2020, J MATER CHEM B, V8, P607, DOI 10.1039/c9tb02052g
   Doshi RR, 2011, SEMIN OPHTHALMOL, V26, P104, DOI 10.3109/08820538.2010.541318
   Drapala PW, 2014, PHARM RES-DORDR, V31, P742, DOI 10.1007/s11095-013-1195-0
   Driot JY, 2004, J OCUL PHARMACOL TH, V20, P269, DOI 10.1089/1080768041223611
   Duvvuri S, 2004, CURR DRUG METAB, V5, P507, DOI 10.2174/1389200043335342
   El Sanharawi M, 2010, PROG RETIN EYE RES, V29, P443, DOI 10.1016/j.preteyeres.2010.04.001
   Elhayek RF, 2017, INVEST OPHTH VIS SCI, V58
   Elsaid N, 2016, MOL PHARMACEUT, V13, P2923, DOI 10.1021/acs.molpharmaceut.6b00335
   Falavarjani KG, 2013, EYE, V27, P787, DOI 10.1038/eye.2013.107
   Famili A, 2014, MACROMOL BIOSCI, V14, P1719, DOI 10.1002/mabi.201400250
   Fialho SL, 2008, EUR J PHARM BIOPHARM, V68, P637, DOI 10.1016/j.ejpb.2007.08.004
   Flaxman SR, 2017, LANCET GLOB HEALTH, V5, pE1221, DOI 10.1016/S2214-109X(17)30393-5
   Fraunfelder FW, 2006, CORNEA, V25, P1133, DOI 10.1097/01.ico.0000240084.27663.fd
   Gandhi A, 2015, ASIAN J PHARM SCI, V10, P99, DOI 10.1016/j.ajps.2014.08.010
   GBD 2019 Blindness and Vision Impairment Collaborators, 2021, LANCET GLOB HEALTH, V9, P144, DOI [10.1016/S2214-109X(20)30489-7, DOI 10.1016/S2214-109X(20)30489-7, 10.1016/S2214-109X(20)30489, DOI 10.1016/S2214-109X(20)30489]
   Gopferich A, 1996, BIOMATERIALS, V17, P103, DOI 10.1016/0142-9612(96)85755-3
   Haghjou Nahid, 2011, J Ophthalmic Vis Res, V6, P317
   Heller J, 1984, Crit Rev Ther Drug Carrier Syst, V1, P39
   Hoare TR, 2008, POLYMER, V49, P1993, DOI 10.1016/j.polymer.2008.01.027
   Hosseini K, 2008, J OCUL PHARMACOL TH, V24, P301, DOI 10.1089/jop.2007.0117
   Houchin ML, 2008, J PHARM SCI-US, V97, P2395, DOI 10.1002/jps.21176
   Huang D, 2018, BIOMATERIALS, V168, P10, DOI 10.1016/j.biomaterials.2018.03.034
   Huang XN, 2019, EXP EYE RES, V186, DOI 10.1016/j.exer.2019.107711
   Hughes PM, 2005, ADV DRUG DELIVER REV, V57, P2010, DOI 10.1016/j.addr.2005.09.004
   Iezzi R, 2012, BIOMATERIALS, V33, P979, DOI 10.1016/j.biomaterials.2011.10.010
   ILUVIEN, SUMMARY PRODUCT CHAR
   Irigoyen C, 2012, GRAEF ARCH CLIN EXP, V250, P499, DOI 10.1007/s00417-011-1851-1
   Lopez-Cano JJ, 2021, PHARMACEUTICS, V13, DOI 10.3390/pharmaceutics13020234
   Jeon O, 2009, BIOMATERIALS, V30, P2724, DOI 10.1016/j.biomaterials.2009.01.034
   Jeong JH, 2016, INT J NANOMED, V11, P3101, DOI 10.2147/IJN.S108452
   Jiang PF, 2020, J CONTROL RELEASE, V320, P442, DOI 10.1016/j.jconrel.2020.01.036
   Jiang WL, 2001, PHARM RES-DORDR, V18, P878, DOI 10.1023/A:1011009117586
   Jiang YJ, 2014, BIOMATERIALS, V35, P4969, DOI 10.1016/j.biomaterials.2014.03.001
   Jorgensen L, 2009, EXPERT OPIN DRUG DEL, V6, P1219, DOI 10.1517/17425240903199143
   Kasdorf BT, 2015, BIOPHYS J, V109, P2171, DOI 10.1016/j.bpj.2015.10.002
   Kageyama Y, 2013, CHEM COMMUN, V49, P9386, DOI 10.1039/c3cc43488e
   Kambhampati SP, 2015, EUR J PHARM BIOPHARM, V95, P239, DOI 10.1016/j.ejpb.2015.02.013
   Kambhampati SP, 2013, J OCUL PHARMACOL TH, V29, P151, DOI 10.1089/jop.2012.0232
   Kane FE, 2008, EXPERT OPIN DRUG DEL, V5, P1039, DOI 10.1517/17425247.5.9.1039 
   Kang Derwent Jennifer J, 2008, Trans Am Ophthalmol Soc, V106, P206
   Kharkar PM, 2016, ACS BIOMATER SCI ENG, V2, P165, DOI 10.1021/acsbiomaterials.5b00420
   Kim H, 2004, INVEST OPHTH VIS SCI, V45, P2722, DOI 10.1167/iovs.04-0091
   Kim HM, 2020, TRANSL VIS SCI TECHN, V9, DOI 10.1167/tvst.9.6.20
   Kim H, 2010, J CONTROL RELEASE, V142, P286, DOI 10.1016/j.jconrel.2009.10.031
   Kim J, 2019, ACTA BIOMATER, V97, P451, DOI 10.1016/j.actbio.2019.07.054
   Kim KE, 2015, INVEST OPHTH VIS SCI, V56, P5641, DOI 10.1167/iovs.15-16538
   Kim S, 2020, TRANSL VIS SCI TECHN, V9, DOI 10.1167/tvst.9.3.30
   Kim SH, 2008, PHARM RES-DORDR, V25, P512, DOI 10.1007/s11095-007-9408-z
   Koetting MC, 2015, MAT SCI ENG R, V93, P1, DOI 10.1016/j.mser.2015.04.001
   Kompella UB, 2010, THER DELIV, V1, P435, DOI 10.4155/TDE.10.40
   Koo H, 2012, BIOMATERIALS, V33, P3485, DOI 10.1016/j.biomaterials.2012.01.030
   Kowluru RA, 2011, INVEST OPHTH VIS SCI, V52, P8665, DOI 10.1167/iovs.10-6768
   Larson N, 2012, CHEM MATER, V24, P840, DOI 10.1021/cm2031569
   Lau CML, 2018, ADV DRUG DELIVER REV, V126, P145, DOI 10.1016/j.addr.2018.03.013
   LEE B, 1994, BIORHEOLOGY, V31, P339
   Lee J, 2016, DRUG METAB DISPOS, V44, P1675, DOI 10.1124/dmd.116.069369
   Lee SS, 2010, PHARM RES-DORDR, V27, P2043, DOI 10.1007/s11095-010-0159-x
   Li E, 2020, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD012208.pub2
   Li XM, 2018, FRONT CHEM, V6, DOI 10.3389/fchem.2018.00499
   Li XY, 2012, J MATER SCI-MATER M, V23, P2857, DOI 10.1007/s10856-012-4757-5
   Lim JI, 1999, AM J OPHTHALMOL, V127, P288, DOI 10.1016/S0002-9394(98)00443-7
   Lima LH, 2016, J OPHTHALMOL, V2016, DOI 10.1155/2016/5356371
   Lin CC, 2006, ADV DRUG DELIVER REV, V58, P1379, DOI 10.1016/j.addr.2006.09.004
   Liu JX, 2019, INT J NANOMED, V14, P8819, DOI 10.2147/IJN.S217038
   Liu WQ, 2019, CURR EYE RES, V44, P264, DOI 10.1080/02713683.2018.1533983
   Loftsson T, 2008, PHARMAZIE, V63, P171, DOI 10.1691/ph.2008.7322
   Lu Y, 2014, INT J OPHTHALMOL-CHI, V7, P1, DOI 10.3980/j.issn.2222-3959.2014.01.01
   Marano RJ, 2005, GENE THER, V12, P1544, DOI 10.1038/sj.gt.3302579
   Martens TF, 2015, J CONTROL RELEASE, V202, P83, DOI 10.1016/j.jconrel.2015.01.030
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Masuda T, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/9208489
   Mathew R, 2014, EYE, V28, P318, DOI 10.1038/eye.2013.287
   Maurice D, 2001, J OCUL PHARMACOL TH, V17, P393, DOI 10.1089/108076801753162807
   Maurice D., 1984, PHARM EYE, P19, DOI [10.1007/978-3-642-69222-2_2, DOI 10.1007/978-3-642-69222-2_2]
   Mietzner R, 2020, PHARMACEUTICS, V12, DOI 10.3390/pharmaceutics12080706
   Mochimaru H, 2009, INVEST OPHTH VIS SCI, V50, P4410, DOI 10.1167/iovs.08-3044
   Modaresifar K, 2018, ARTIF CELL NANOMED B, V46, P1799, DOI 10.1080/21691401.2017.1392970
   Moisseiev E, 2020, EYE, V34, P605, DOI 10.1038/s41433-019-0584-y
   Nair HA, 2018, DRUG TARGETING AND STIMULI SENSITIVE DRUG DELIVERY SYSTEMS, P303, DOI 10.1016/B978-0-12-813689-8.00008-2
   Naylor A, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21010211
   Nimmo CM, 2011, BIOCONJUGATE CHEM, V22, P2199, DOI 10.1021/bc200281k
   Nirmal J, 2020, EXP EYE RES, V199, DOI 10.1016/j.exer.2020.108187
   ocutx, OTX TKI AXITINIB INT
   Organization WH, 2019, WORLD REP VIS
   Osswald CR, 2017, CURR EYE RES, V42, P1293, DOI 10.1080/02713683.2017.1302590
   Osswald CR, 2016, CURR EYE RES, V41, P1216, DOI 10.3109/02713683.2015.1101140
   Ozerdem U, 2000, AM J OPHTHALMOL, V130, P240, DOI 10.1016/S0002-9394(00)00501-8
   Papadopoulos Z, 2020, CURR MED SCI, V40, P851, DOI 10.1007/s11596-020-2253-6
   Parhi R, 2017, ADV PHARM BULL, V7, P515, DOI 10.15171/apb.2017.064
   Park D, 2013, MACROMOL BIOSCI, V13, P464, DOI 10.1002/mabi.201200384
   Park D, 2011, BIOMATERIALS, V32, P777, DOI 10.1016/j.biomaterials.2010.09.044
   Patel P, 2019, J POLYM RES, V26, DOI 10.1007/s10965-019-1771-z
   Peeters L, 2005, INVEST OPHTH VIS SCI, V46, P3553, DOI 10.1167/iovs.05-0165
   Peng K, 2010, CHEM COMMUN, V46, P4094, DOI 10.1039/c002565h
   Perez VL, 2015, TRENDS IMMUNOL, V36, P354, DOI 10.1016/j.it.2015.04.003
   Peters T, 2017, BIOMATERIALS, V124, P157, DOI 10.1016/j.biomaterials.2017.02.006
   Peynshaert K, 2019, CURR EYE RES, V44, P465, DOI 10.1080/02713683.2019.1565890
   Peynshaert K, 2017, DRUG DELIV, V24, P1384, DOI 10.1080/10717544.2017.1375578
   Pitkanen L, 2005, INVEST OPHTH VIS SCI, V46, P641, DOI 10.1167/iovs.04-1051
   Prausnitz MR, 1998, J PHARM SCI, V87, P1479, DOI 10.1021/js9802594
   Puras G, 2013, EUR J PHARM BIOPHARM, V83, P131, DOI 10.1016/j.ejpb.2012.09.010
   Qu J, 2010, EXP EYE RES, V91, P48, DOI 10.1016/j.exer.2010.04.002
   Radhakrishnan K, 2017, DRUG DISCOV TODAY, V22, P416, DOI 10.1016/j.drudis.2016.10.015
   Raghava Swita, 2004, Expert Opin Drug Deliv, V1, P99, DOI 10.1517/17425247.1.1.99
   Raju HB, 2012, CLIN EXP OPHTHALMOL, V40, P100, DOI 10.1111/j.1442-9071.2011.02651.x
   Raju HB, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017452
   Ramos T, 2015, STEM CELLS INT, V2015, DOI 10.1155/2015/601731
   Ranta VP, 2010, J CONTROL RELEASE, V148, P42, DOI 10.1016/j.jconrel.2010.08.028
   Ratanji KD, 2014, J IMMUNOTOXICOL, V11, P99, DOI 10.3109/1547691X.2013.821564
   Rauck BM, 2014, INVEST OPHTH VIS SCI, V55, P469, DOI 10.1167/iovs.13-13120
   Regula JT, 2016, EMBO MOL MED, V8, P1265, DOI 10.15252/emmm.201505889
   Reis CP, 2006, NANOMED-NANOTECHNOL, V2, P8, DOI 10.1016/j.nano.2005.12.003
   Rezzola S, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.581288
   Rimpela AK, 2019, PHARMACEUTICS, V11, DOI 10.3390/pharmaceutics11010009
   Robinson MR, 2006, EXP EYE RES, V82, P479, DOI 10.1016/j.exer.2005.08.007
   Rodrigues GA, 2018, INVEST OPHTH VIS SCI, V59, P5836, DOI 10.1167/iovs.18-25307
   Rosenberg AS, 2006, AAPS J, V8, pE501, DOI 10.1208/aapsj080359
   Ruckman J, 1998, J BIOL CHEM, V273, P20556, DOI 10.1074/jbc.273.32.20556
   Ryan KB, 2012, RSC DRUG DISCOV, V22, P63, DOI 10.1039/9781849735292-00063
   Sadiq MA, 2015, EXPERT OPIN DRUG SAF, V14, P1147, DOI 10.1517/14740338.2015.1041916
   Sakai T, 2011, INVEST OPHTH VIS SCI, V52, P1516, DOI 10.1167/iovs.10-5676
   Sakurai E, 2001, OPHTHALMIC RES, V33, P31, DOI 10.1159/000055638
   Sampat KM, 2010, CURR OPIN OPHTHALMOL, V21, P178, DOI 10.1097/ICU.0b013e328338679a
   Schoenwald RD, 1997, J OCUL PHARMACOL TH, V13, P41, DOI 10.1089/jop.1997.13.41
   Seal J, 2018, INVEST OPHTH VIS SCI, V59
   Shatz W, 2016, MOL PHARMACEUT, V13, P2996, DOI 10.1021/acs.molpharmaceut.6b00345
   Shin SW, 2015, NANOMATERIALS-BASEL, V5, P1351, DOI 10.3390/nano5031351
   Shmueli RB, 2013, BIOMATERIALS, V34, P7544, DOI 10.1016/j.biomaterials.2013.06.044
   Siepmann J, 2001, ADV DRUG DELIVER REV, V48, P229, DOI 10.1016/S0169-409X(01)00116-8
   Sieving PA, 2006, P NATL ACAD SCI USA, V103, P3896, DOI 10.1073/pnas.0600236103
   Silva-Cunha A, 2009, INVEST OPHTH VIS SCI, V50, P2312, DOI 10.1167/iovs.08-2969
   Stewart MW, 2016, WORLD J DIABETES, V7, P333, DOI 10.4239/wjd.v7.i16.333
   Stitt AW, 2016, PROG RETIN EYE RES, V51, P156, DOI 10.1016/j.preteyeres.2015.08.001
   Sukhanova A, 2018, NANOSCALE RES LETT, V13, DOI 10.1186/s11671-018-2457-x
   Tabibian D, 2015, SURV OPHTHALMOL, V60, P51, DOI 10.1016/j.survophthal.2014.07.002
   Tao W, 2002, INVEST OPHTH VIS SCI, V43, P3292
   Teekamp N, 2015, EXPERT OPIN DRUG DEL, V12, P1311, DOI 10.1517/17425247.2015.1003807
   Tesar D, 2017, MABS-AUSTIN, V9, P1297, DOI 10.1080/19420862.2017.1372078
   Thackaberry EA, 2019, DRUG DISCOV TODAY, V24, P1539, DOI 10.1016/j.drudis.2019.05.032
   Thackaberry EA, 2017, INVEST OPHTH VIS SCI, V58, P4274, DOI 10.1167/iovs.16-21334
   Thakur A., 2013, TREATISE OCULAR DRUG, P114
   Thakur SS, 2014, EXPERT OPIN DRUG DEL, V11, P1575, DOI 10.1517/17425247.2014.927864
   Thrimawithana TR, 2011, DRUG DISCOV TODAY, V16, P270, DOI 10.1016/j.drudis.2010.12.004
   Tsujinaka H, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-14340-x
   Tyagi P, 2013, MOL PHARMACEUT, V10, P2858, DOI 10.1021/mp300716t
   Urtti A, 2006, ADV DRUG DELIVER REV, V58, P1131, DOI 10.1016/j.addr.2006.07.027
   van de Weert M, 2000, PHARM RES-DORDR, V17, P1159, DOI 10.1023/A:1026498209874
   Varela-Fernandez R, 2020, PHARMACEUTICS, V12, DOI 10.3390/pharmaceutics12030269
   Varshochian R, 2013, EUR J PHARM SCI, V50, P341, DOI 10.1016/j.ejps.2013.07.014
   Veronese FM, 2008, BIODRUGS, V22, P315, DOI 10.2165/00063030-200822050-00004
   Vigata M, 2020, PHARMACEUTICS, V12, DOI 10.3390/pharmaceutics12121188
   Vihola H, 2005, BIOMATERIALS, V26, P3055, DOI 10.1016/j.biomaterials.2004.09.008
   Waite D, 2017, THER DELIV, V8, P685, DOI 10.4155/tde-2017-0097
   Wang CY, 2014, EXP EYE RES, V129, P74, DOI 10.1016/j.exer.2014.11.002
   Wang DS, 2018, CHEMPHOTOCHEM, V2, P403, DOI 10.1002/cptc.201700233
   Wang MZ, 2012, RETINA-J RET VIT DIS, V32, P2158, DOI 10.1097/IAE.0b013e3182576d1d
   Watson PG, 2004, EXP EYE RES, V78, P609, DOI 10.1016/S0014-4835(03)00212-4
   Weissleder R, 2001, NAT BIOTECHNOL, V19, P316, DOI 10.1038/86684
   Wells LA, 2011, MACROMOL BIOSCI, V11, P988, DOI 10.1002/mabi.201100001
   Wells LA, 2011, BIOMACROMOLECULES, V12, P923, DOI 10.1021/bm101233m
   Woo SJ, 2021, JAMA OPHTHALMOL, V139, P68, DOI 10.1001/jamaophthalmol.2020.5053
   Xie BB, 2015, INT J PHARMACEUT, V490, P375, DOI 10.1016/j.ijpharm.2015.05.071
   Xu JP, 2019, MOLECULES, V24, DOI 10.3390/molecules24163005
   Xu QG, 2013, J CONTROL RELEASE, V167, P76, DOI 10.1016/j.jconrel.2013.01.018
   Xu X, 2013, INT J BIOL MACROMOL, V60, P272, DOI 10.1016/j.ijbiomac.2013.05.034
   Yandrapu SK, 2013, MOL PHARMACEUT, V10, P4676, DOI 10.1021/mp400487f
   Yang M, 2016, INVEST OPHTH VIS SCI, V57
   Yasin H., 2019, SYNTHESIS HYDROGELS
   Yasukawa Tsutomu, 2010, Handb Exp Pharmacol, P469, DOI 10.1007/978-3-642-00477-3_16
   Yavuz B, 2016, J PHARM PHARMACOL, V68, P1010, DOI 10.1111/jphp.12587
   Yu J, 2014, INT J PHARMACEUT, V470, P151, DOI 10.1016/j.ijpharm.2014.04.053
   Yu Y, 2015, TRANSL VIS SCI TECHN, V4, DOI 10.1167/tvst.4.2.5
   Yue K, 2015, BIOMATERIALS, V73, P254, DOI 10.1016/j.biomaterials.2015.08.045
   Zacharias LC, 2013, RETINA-J RET VIT DIS, V33, P522, DOI 10.1097/IAE.0b013e3182647f69
   Zarzycki R, 2010, ECOL CHEM ENG S, V17, P9
   Zeiss CJ, 2018, COMP ANATOMY HISTOLO, P445, DOI [10.1016/B978-0-12-802900-8, DOI 10.1016/B978-0-12-802900-8, DOI 10.1016/B978-0-12-802900-8.00021-X]
   Zhou Ru, 2010, F1000 Biol Rep, V2, DOI 10.3410/B2-3
NR 222
TC 2
Z9 2
U1 31
U2 32
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0169-409X
EI 1872-8294
J9 ADV DRUG DELIVER REV
JI Adv. Drug Deliv. Rev.
PD AUG
PY 2022
VL 187
AR 114342
DI 10.1016/j.addr.2022.114342
PG 24
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA 2A9SS
UT WOS:000809836800009
PM 35569559
OA hybrid
DA 2022-11-30
ER

PT J
AU Gupta, IK
   Choubey, A
   Choubey, S
AF Gupta, Indresh Kumar
   Choubey, Abha
   Choubey, Siddhartha
TI Artifical intelligence with optimal deep learning enabled automated
   retinal fundus image classification model
SO EXPERT SYSTEMS
LA English
DT Article
DE computer aided diagnosis; deep learning; fundus images; retinal
   diseases; RMSProp optimizer
AB Diabetic retinopathy (DR) and age related macular degeneration (AMD) becomes widespread microvascular illness among diabetic patients. Traditional retinal fundus image classification requires visual inspection by the professionals, which is time consuming and requires expert's knowledge. Earlier identification of retinal diseases is essential to delay or avoid vision deterioration and vision loss. The recently developed artificial intelligence (AI) and deep learning (DL) models can be employed for accurate retinal image classification. With this motivation, this study designs a new artificial intelligence with optimal deep convolutional neural network (AI-ODCNN) technique for retinal fundus image classification. Primarily, the proposed model uses the Gaussian Blur based noise removal and contrast enhancement technique (CLAHE) based contrast enhancement technique to pre-process the retinal fundus image. In addition, morphology and contour based image segmentation is performed. Moreover, the deep CNN with RMSProp Optimizer is employed for retinal fundus image classification. A wide range of simulations was performed on the automated retinal image analysis and structured analysis of the retina and the outcomes are examined with respect to various measures. The simulation outcomes ensured the better performance of the proposed approach related to other recent algorithms with maximum accuracy of 96.47%.
C1 [Gupta, Indresh Kumar; Choubey, Abha; Choubey, Siddhartha] Shri Shanakaracharya Tech Campus, Comp Sci & Engn, Bhilai, India.
RP Gupta, IK (通讯作者)，Shri Shanakaracharya Tech Campus, Comp Sci & Engn, Bhilai, India.
EM indresh.gupta345@gmail.com
CR [Anonymous], 2012, Wkly Epidemiol Rec, V87, P1
   Asiri N, 2019, ARTIF INTELL MED, V99, DOI 10.1016/j.artmed.2019.07.009
   Babu D. Vijendra, 2020, IOP Conference Series: Materials Science and Engineering, V993, DOI 10.1088/1757-899X/993/1/012080
   Chang Y, 2018, IEEE ACCESS, V6, P11782, DOI 10.1109/ACCESS.2018.2797872
   Chea N, 2021, CMC-COMPUT MATER CON, V67, P411, DOI 10.32604/cmc.2021.013390
   Devapriya W., 2016, 2016 WORLD C FUT TRE, P1
   Gonzalez-Gonzalo C, 2020, ACTA OPHTHALMOL, V98, P368, DOI 10.1111/aos.14306
   Hoover A, 2000, IEEE T MED IMAGING, V19, P203, DOI 10.1109/42.845178
   Jiang HY, 2020, IEEE ENG MED BIO, P1560, DOI 10.1109/EMBC44109.2020.9175884
   Koh JEW, 2018, APPL INTELL, V48, P1379, DOI 10.1007/s10489-017-1048-3
   Lakshminarayanan V, 2021, J IMAGING, V7, DOI 10.3390/jimaging7090165
   Li F, 2022, EYE, V36, P1433, DOI 10.1038/s41433-021-01552-8
   Liu YP, 2019, ARTIF INTELL MED, V99, DOI 10.1016/j.artmed.2019.07.002
   Masud M, 2022, ACM T MULTIM COMPUT, V18, DOI 10.1145/3470976
   Saranya P, 2020, J AMB INTEL HUM COMP, DOI 10.1007/s12652-020-02518-6
   Sarhan MH, 2020, IEEE J BIOMED HEALTH, V24, P3338, DOI 10.1109/JBHI.2020.3012134
   Septiarini A, 2020, SCI HORTIC-AMSTERDAM, V261, DOI 10.1016/j.scienta.2019.108939
   Sharafeldeen A, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-83735-7
   Shrivastava A., 2021, INVEST OPHTH VIS SCI, V62, P39
   Stevenson CH, 2019, CLIN EXP OPHTHALMOL, V47, P484, DOI 10.1111/ceo.13433
   Tamim N, 2021, APPL SCI-BASEL, V11, DOI 10.3390/app11136178
   Vijayan T., 2020, MICROPROCESSORS
   Wang J, 2020, IEEE ACCESS, V8, P212499, DOI 10.1109/ACCESS.2020.3040275
   Wu JH, 2021, J MED INTERNET RES, V23, DOI 10.2196/23863
   Yin H, 2020, COMPLEXITY, V2020, DOI 10.1155/2020/6843869
NR 25
TC 1
Z9 1
U1 9
U2 9
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0266-4720
EI 1468-0394
J9 EXPERT SYST
JI Expert Syst.
PD DEC
PY 2022
VL 39
IS 10
SI SI
AR e13028
DI 10.1111/exsy.13028
EA MAY 2022
PG 14
WC Computer Science, Artificial Intelligence; Computer Science, Theory &
   Methods
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Computer Science
GA 5Y8YW
UT WOS:000800304700001
DA 2022-11-30
ER

PT J
AU Wei, Y
   Wang, XJ
   Chew, EY
   Ding, Y
AF Wei, Yue
   Wang, Xinjun
   Chew, Emily Y.
   Ding, Ying
TI Confident identification of subgroups from SNP testing in RCTs with
   binary outcomes
SO BIOMETRICAL JOURNAL
LA English
DT Article
DE binary outcome; multiple testing; simultaneous confidence intervals;
   single nucleotide polymorphism; subgroup identification; treatment
   efficacy
ID INFERENCE
AB In modern drug development, genotype information becomes more frequently collected in randomized controlled trials (RCTs) for individualized risk prediction and personalized medicine development. Finding single nucleotide polymorphisms (SNPs) that are predictive of differential treatment efficacy, measured by a clinical outcome, is fundamentally different and more challenging than the traditional association test for a quantitative trait. With the objective to confidently identify and infer genetic subgroups with enhanced treatment efficacy from a large RCT for an eye disease, age-related macular degeneration (AMD), where the clinical endpoint is binary (progressed or not), we propose a novel SNP-testing procedure for binary clinical outcomes. Specifically, we formulate four contrasts to simultaneously assess all possible genetic effects on a logic-respecting efficacy measure, the relative risk (between treatment and control). Our method controls both within- and across-SNP multiplicity rigorously. We then use real genotype data to perform chromosome-wide simulations to evaluate our method performance and to provide practical recommendations. Finally, we apply the proposed method to perform a genome-wide SNP testing for the AMD trial and successfully identify multiple gene regions with genetic subgroups exhibiting enhanced efficacy in terms of decreasing the AMD progression rate.
C1 [Wei, Yue; Wang, Xinjun; Ding, Ying] Univ Pittsburgh, Dept Biostat, Pittsburgh, PA 15261 USA.
   [Chew, Emily Y.] NEI, NIH, Bethesda, MD 20892 USA.
C3 Pennsylvania Commonwealth System of Higher Education (PCSHE); University
   of Pittsburgh; National Institutes of Health (NIH) - USA; NIH National
   Eye Institute (NEI)
RP Ding, Y (通讯作者)，Univ Pittsburgh, Dept Biostat, Pittsburgh, PA 15261 USA.
EM yingding@pitt.edu
CR Chen WS, 2018, BMC MED RES METHODOL, V18, DOI 10.1186/s12874-018-0519-5
   Chew Emily Y, 2013, Ophthalmology, V120, P1604, DOI 10.1016/j.ophtha.2013.01.021
   Ding Y., 2020, ARXIV200310528
   Ding Y, 2018, ANN APPL STAT, V12, P1727, DOI 10.1214/17-AOAS1128
   Ding Y, 2016, STAT MED, V35, P1580, DOI 10.1002/sim.6822
   Flaherty KT, 2011, NAT REV DRUG DISCOV, V10, P811, DOI 10.1038/nrd3579
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Genz A., 2020, PACKAGE MVTNORM VERS
   Greenland S, 1999, STAT SCI, V14, P29
   Gumbel E.J., 2012, STAT EXTREMES
   Halekoh U, 2006, J STAT SOFTW, V15, P1, DOI 10.18637/jss.v015.i02
   Hernan MA., 2020, CAUSAL INFERENCE WHA
   HILL W G, 1968, Theoretical and Applied Genetics, V38, P226, DOI 10.1007/BF01245622
   Hothorn LA, 2009, BIOMETRICAL J, V51, P659, DOI 10.1002/bimj.200800203
   Hsu JC, 1999, J AM STAT ASSOC, V94, P468
   Huitfeldt A, 2019, EMERG THEMES EPIDEMI, V16, DOI 10.1186/s12982-018-0083-9
   Kassoff A, 1999, CONTROL CLIN TRIALS, V20, P573
   LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.1093/biomet/73.1.13
   Lin HM, 2019, BIOMETRICAL J, V61, P8, DOI 10.1002/bimj.201800002
   Neuberg LG, 2003, ECONOMET THEOR, V19, P675, DOI 10.1017/S026646603004109
   Romond EH, 2005, NEW ENGL J MED, V353, P1673, DOI 10.1056/NEJMoa052122
   Shaw AT, 2011, LANCET ONCOL, V12, P1004, DOI 10.1016/S1470-2045(11)70232-7
   So HC, 2011, BEHAV GENET, V41, P768, DOI 10.1007/s10519-011-9450-9
   Touloumis A., 2019, SIMULATING CORRELATE
   Warnes G., 2021, GENETICS POPULATION
   Williamson T, 2013, EMERG THEMES EPIDEMI, V10, DOI 10.1186/1742-7622-10-14
   Yelland LN, 2011, AM J EPIDEMIOL, V174, P984, DOI 10.1093/aje/kwr183
   Zou GY, 2004, AM J EPIDEMIOL, V159, P702, DOI 10.1093/aje/kwh090
NR 29
TC 0
Z9 0
U1 0
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0323-3847
EI 1521-4036
J9 BIOMETRICAL J
JI Biom. J.
PD FEB
PY 2022
VL 64
IS 2
SI SI
BP 256
EP 271
DI 10.1002/bimj.202000170
EA MAR 2021
PG 16
WC Mathematical & Computational Biology; Statistics & Probability
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Mathematical & Computational Biology; Mathematics
GA YX8VO
UT WOS:000626858200001
PM 33751636
DA 2022-11-30
ER

PT J
AU Bhatwadekar, AD
   Kansara, V
   Luo, QY
   Ciulla, T
AF Bhatwadekar, Ashay D.
   Kansara, Viral
   Luo, Qianyi
   Ciulla, Thomas
TI Anti-integrin therapy for retinovascular diseases
SO EXPERT OPINION ON INVESTIGATIONAL DRUGS
LA English
DT Review
DE Age-related macular degeneration; diabetic retinopathy; diabetic macular
   edema; vitreomacular traction; angiogenesis; integrin; extracellular
   matrix; Risuteganib; THR-687; SF-0166; SB-267268; AXT-107; JNJ-26076713;
   Cilengitide; Lebecetin
ID C-TYPE LECTIN; DIABETIC MACULAR EDEMA; GROWTH-FACTOR THERAPY; CHOROIDAL
   NEOVASCULARIZATION; RETINAL NEOVASCULARIZATION; TENASCIN-C; PRECLINICAL
   EVALUATION; IN-VITRO; ANTAGONIST; ALPHA-5-BETA-1
AB Introduction Integrins are a family of multi-functional cell-adhesion molecules, heterodimeric receptors that connect extracellular matrix (ECM) to actin cytoskeleton in the cell cortex, thus regulating cellular adhesion, migration, proliferation, invasion, survival, and apoptosis. Consequently, integrins play a role in inflammation, angiogenesis and fibrosis. Areas covered This review examines individual anti-integrin agents in terms of their chemical nature, route of administration, and anti-integrin action. It also provides a summary of preclinical and clinical studies. Current clinical candidates include risuteganib, THR-687, and SF-0166, which have shown promise in treating diabetic macular edema (DME) and/or age-related macular degeneration (AMD) in early clinical studies. Preclinical candidates include SB-267268, AXT-107, JNJ-26076713, Cilengitide and Lebecetin, which exhibit a decrease in retinal permeability, angiogenesis and/or choroidal neovascularization (CNV). Expert opinion Anti-integrin therapies show potential in treating retinal diseases. Anti-integrin agents tackle the multi-factorial nature of diabetic retinopathy (DR) and AMD and show promise as injectable and topical agents in preclinical and early clinical studies. Integrin inhibition has potential to serve as primary therapy, adjunctive therapy to anti-vascular endothelial growth factor agents, or secondary therapy in refractory cases.
C1 [Bhatwadekar, Ashay D.; Luo, Qianyi; Ciulla, Thomas] Indiana Univ, Dept Ophthalmol, Eugene & Marilyn Glick Eye Inst, Indianapolis, IN 46202 USA.
   [Kansara, Viral; Ciulla, Thomas] Clearside Biomed Inc, Preclin Dev Dept, Alpharetta, GA USA.
   [Ciulla, Thomas] Midwest Eye Inst, Retina Dept, Indianapolis, IN USA.
C3 Indiana University System; Indiana University-Purdue University
   Indianapolis
RP Ciulla, T (通讯作者)，Indiana Univ, Dept Ophthalmol, Eugene & Marilyn Glick Eye Inst, Indianapolis, IN 46202 USA.
EM thomasciulla@gmail.com
RI Ciulla, Thomas/AAA-1299-2020
OI Ciulla, Thomas/0000-0001-5557-6777; Kansara, Viral/0000-0003-0910-8686
FU NIH-National Eye Institute [R01EY027779]; Center for Diabetes and
   Metabolic Diseases, Indiana University
FX Research in the Bhatwadekar laboratory is supported by funding from
   NIH-National Eye Institute (R01EY027779) and by Pilot and Feasibility
   award from the Center for Diabetes and Metabolic Diseases, Indiana
   University.
CR Adamis AP, 2002, BRIT J OPHTHALMOL, V86, P363, DOI 10.1136/bjo.86.4.363
   Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   [Anonymous], 2020, AG REL MAC DEG AMD D
   [Anonymous], 2020, AREDS AREDS2 CLIN TR
   [Anonymous], 2020, SB 267268 ADISINSIGH
   [Anonymous], 2020, PHAS 1 SF STUD SINGL
   [Anonymous], 2020, DIV DIAB TRANSL
   [Anonymous], 2018, OPHTHALMIC INNOVATIO
   [Anonymous], 2020, SAFETY EXPLORATORY E
   [Anonymous], 2020, SAF EFF STUD ALG 100
   [Anonymous], 2020, PHAS 1 ASC PAR GROUP
   [Anonymous], 2020, RETINAL PHYS RISUTEG
   [Anonymous], 2015, ALLEGRO OPHTHALMICS
   [Anonymous], 2020, PHASE 1 STUDY THR 68
   Askew BC, 2018, J PHARMACOL EXP THER, V366, P244, DOI 10.1124/jpet.118.248427
   Barouch FC, 2000, INVEST OPHTH VIS SCI, V41, P1153
   BROOKS PC, 1994, SCIENCE, V264, P569, DOI 10.1126/science.7512751
   Calderwood DA, 2004, J CELL SCI, V117, P657, DOI 10.1242/jcs.01014
   Cantrell RA, 2020, OPHTHALMOLOGY, V127, P427, DOI 10.1016/j.ophtha.2019.10.019
   Chappelow AV, 2008, DRUGS, V68, P1029, DOI 10.2165/00003495-200868080-00002
   Ciulla TA, 2021, BRIT J OPHTHALMOL, V105, P216, DOI 10.1136/bjophthalmol-2020-315933
   Ciulla TA, 2020, OPHTHALMOL RETINA, V4, P19, DOI 10.1016/j.oret.2019.05.017
   Ciulla TA, 2018, OPHTHALMOL RETINA, V2, P1179, DOI 10.1016/j.oret.2018.06.004
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Cuilla TA, 2015, OPHTHALMOLOGY, V122, P1203, DOI 10.1016/j.ophtha.2015.02.031
   FRIEDLANDER M, 1995, SCIENCE, V270, P1500, DOI 10.1126/science.270.5241.1500
   Friedlander M, 1996, P NATL ACAD SCI USA, V93, P9764, DOI 10.1073/pnas.93.18.9764
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Fu YL, 2007, INVEST OPHTH VIS SCI, V48, P5184, DOI 10.1167/iovs.07-0469
   Gerhardinger C, 2009, DIABETES, V58, P1659, DOI 10.2337/db08-1008
   Holz FG, 2015, BRIT J OPHTHALMOL, V99, P220, DOI 10.1136/bjophthalmol-2014-305327
   Hu TT, 2019, EXP EYE RES, V180, P43, DOI 10.1016/j.exer.2018.11.022
   HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S
   Joussen AM, 2001, AM J PATHOL, V158, P147, DOI 10.1016/S0002-9440(10)63952-1
   Kaiser PK, 2016, RETINA TODAY
   Kapp TG, 2017, SCI REP-UK, V7, DOI 10.1038/srep39805
   Kechagia JZ, 2019, NAT REV MOL CELL BIO, V20, P457, DOI 10.1038/s41580-019-0134-2
   Kobayashi Y, 2016, LAB INVEST, V96, P1178, DOI 10.1038/labinvest.2016.99
   Kobayashi Y, 2016, MOL VIS, V22, P436
   KOHNO T, 1987, INVEST OPHTH VIS SCI, V28, P506
   Krebs I, 2007, AM J OPHTHALMOL, V144, P741, DOI 10.1016/j.ajo.2007.07.024
   KUPPERMANN BD, 2010, INVEST OPHTHALMOL VI, V51
   Luna J, 1996, LAB INVEST, V75, P563
   Maier AKB, 2007, CURR EYE RES, V32, P801, DOI 10.1080/02713680701553052
   MARANO RPC, 1995, EXP EYE RES, V60, P5, DOI 10.1016/S0014-4835(05)80079-X
   Mirando AC, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.122043
   Miyamoto K, 1999, P NATL ACAD SCI USA, V96, P10836, DOI 10.1073/pnas.96.19.10836
   Miyamoto K, 1998, INVEST OPHTH VIS SCI, V39, P2190
   Montassar F, 2017, FASEB J, V31, P1107, DOI 10.1096/fj.201600351R
   Nandrot EE, 2004, J EXP MED, V200, P1539, DOI 10.1084/jem.20041447
   Nebbioso M, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20071693
   Nicolo M, 2000, GRAEF ARCH CLIN EXP, V238, P107, DOI 10.1007/s004170050018
   Oliveira LB, 2002, CURR EYE RES, V25, P333, DOI 10.1076/ceyr.25.6.333.14234
   Oxurion NV, 2020, EXP PRES POS TOPL DA
   Patel PJ, 2008, INVEST OPHTH VIS SCI, V49, P1084, DOI 10.1167/iovs.07-1203
   Pilorget A, 2007, J CELL PHYSIOL, V211, P307, DOI 10.1002/jcp.20935
   Plow EF, 2000, J BIOL CHEM, V275, P21785, DOI 10.1074/jbc.R000003200
   Preissner KT, 1997, HORM METAB RES, V29, P643, DOI 10.1055/s-2007-979118
   Ramakrishnan V, 2006, J EXP THER ONCOL, V5, P273
   Rao P, 2018, OPHTHALMOLOGY, V125, P522, DOI 10.1016/j.ophtha.2017.10.010
   ROTH T, 1993, P NATL ACAD SCI USA, V90, P9640, DOI 10.1073/pnas.90.20.9640
   Roy S, 2015, EXP EYE RES, V133, P58, DOI 10.1016/j.exer.2014.08.011
   Santulli RJ, 2008, J PHARMACOL EXP THER, V324, P894, DOI 10.1124/jpet.107.131656
   Sarray S, 2003, BBA-PROTEINS PROTEOM, V1651, P30, DOI 10.1016/S1570-9639(03)00232-2
   Sarray S, 2007, MATRIX BIOL, V26, P306, DOI 10.1016/j.matbio.2007.01.001
   SEBAG J, 1989, INVEST OPHTH VIS SCI, V30, P1867
   SEBAG J, 1992, EYE, V6, P541, DOI 10.1038/eye.1992.119
   Sebag J., 2014, VITREOUS
   Stitt AW, 2010, INVEST OPHTH VIS SCI, V51, P4867, DOI 10.1167/iovs.10-5881
   Sui AL, 2018, MED SCI MONITOR, V24, P5860, DOI 10.12659/MSM.907446
   Sui AL, 2018, GRAEF ARCH CLIN EXP, V256, P951, DOI 10.1007/s00417-018-3940-x
   Tiwari S, 2011, J CELL SCI, V124, P1672, DOI 10.1242/jcs.084483
   Tsui I, 2012, BIOMED RES INT, V2012
   Umeda N, 2006, MOL PHARMACOL, V69, P1820, DOI 10.1124/mol.105.020941
   Wilkinson-Berka JL, 2006, INVEST OPHTH VIS SCI, V47, P1600, DOI 10.1167/iovs.05-1314
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   YANG P, 2019, INVEST OPHTHALMOL VI, V60
   Yasukawa T, 2004, CURR EYE RES, V28, P359, DOI 10.1076/ceyr.28.5.359.28678
   Yoshida T, 2012, EXP EYE RES, V94, P41, DOI 10.1016/j.exer.2011.11.003
   Zahn G, 2010, INVEST OPHTH VIS SCI, V51, P1028, DOI 10.1167/iovs.09-3575
   Zahn G, 2009, ARCH OPHTHALMOL-CHIC, V127, P1329, DOI 10.1001/archophthalmol.2009.265
   Zarbin Marco A, 2003, Trans Am Ophthalmol Soc, V101, P499
NR 82
TC 14
Z9 15
U1 2
U2 13
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1354-3784
EI 1744-7658
J9 EXPERT OPIN INV DRUG
JI Expert Opin. Investig. Drugs
PD SEP 1
PY 2020
VL 29
IS 9
BP 935
EP 945
DI 10.1080/13543784.2020.1795639
EA SEP 2020
PG 11
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA OC3GQ
UT WOS:000567606100001
PM 32657172
OA Green Submitted
DA 2022-11-30
ER

PT J
AU Caputi, AP
   Navarra, P
AF Caputi, Achille Patrizio
   Navarra, Pierluigi
TI Beyond antibodies: ankyrins and DARPins. From basic research to drug
   approval
SO CURRENT OPINION IN PHARMACOLOGY
LA English
DT Review
ID REPEAT PROTEINS DARPINS; MACULAR DEGENERATION; ABICIPAR-PEGOL;
   INTRAVITREAL AFLIBERCEPT; RANIBIZUMAB; VEGF; INHIBITORS; SELECTION;
   MEMBRANE; EFFICACY
AB This Pharmacological Perspective describes the pathway that, starting from the deep understanding of ankyrins - a family of proteins with high variability-binding and high specificity-binding characteristics - led to the development of a new class of recombinant-binding proteins, the DARPins (designed ankyrin repeat proteins). These are envisaged as alternatives to mAbs and related biologics, with the potential to overcome certain shortcomings of mAbs. DARPins have relatively low molecular weights (14-21 kDas) and more favorable PK profiles than mAbs, are stable proteins that can be easily produced in Escherichia coli and can be used in their monovalent form or conjugated to other moieties, for example, polyethylene glycol (PEG) to enhance their half-life. DARPins can also be engineered to produce bi-specific or tri-specific compounds that bind different epitopes of the same target or two different targets. Abicipar, a first-in-class anti-VEGF-A DARPin had similar efficacy compared to anti-VEGF biologics (bevacizumab, ranibizumab) in preclinical studies and was not inferior to ranibizumab in the treatment of age-related macular degeneration (AMD) with a reduced number of intravitreal injections. Abicipar has recently been submitted for regulatory approval for use in AMD.
C1 [Caputi, Achille Patrizio] Univ Messina, Sch Med, Dept Pharmacol, Messina, Italy.
   [Navarra, Pierluigi] Univ Cattolica Sacro Cuore, Dept Healthcare Surveillance & Bioeth, Sect Pharmacol, Fdn Policlin Univ A,Gemelli IRCCS Roma, Largo F Vito 1, I-00168 Rome, Italy.
C3 University of Messina; Catholic University of the Sacred Heart; IRCCS
   Policlinico Gemelli
RP Navarra, P (通讯作者)，Univ Cattolica Sacro Cuore, Dept Healthcare Surveillance & Bioeth, Sect Pharmacol, Fdn Policlin Univ A,Gemelli IRCCS Roma, Largo F Vito 1, I-00168 Rome, Italy.
EM pierluigi.navarra@unicatt.it
CR Amstutz P, 2006, PROTEIN ENG DES SEL, V19, P219, DOI 10.1093/protein/gzl004
   Amstutz P, 2005, J BIOL CHEM, V280, P24715, DOI 10.1074/jbc.M501746200
   Arnold JJ, 2015, OPHTHALMOLOGY, V122, P1212, DOI 10.1016/j.ophtha.2015.02.009
   Azaro A, 2018, J CLIN ONCOL, V36, DOI 10.1200/JCO.2018.36.15_suppl.2520
   Bansal DG, 2018, SCIENTIST
   BENNETT V, 1992, J BIOL CHEM, V267, P8703
   BENNETT V, 1982, J CELL BIOCHEM, V18, P49, DOI 10.1002/jcb.1982.240180106
   Binz HK, 2017, MABS-AUSTIN, V9, P1262, DOI 10.1080/19420862.2017.1305529
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Busbee BG, 2013, OPHTHALMOLOGY, V120, P1046, DOI 10.1016/j.ophtha.2012.10.014
   Callanan D, 2018, J OCUL PHARMACOL TH, V34, P700, DOI 10.1089/jop.2018.0062
   Carrasco J, 2020, ADV THER, V37, P300, DOI 10.1007/s12325-019-01147-6
   Dugel PU, 2020, OPHTHALMOLOGY, V127, P72, DOI 10.1016/j.ophtha.2019.04.017
   Fiedler U, 2017, ONCOTARGET, V8, P98371, DOI 10.18632/oncotarget.21738
   Gillies MC, 2019, JAMA OPHTHALMOL, V137, P372, DOI 10.1001/jamaophthalmol.2018.6776
   Gillies MC, 2016, OPHTHALMOLOGY, V123, P2545, DOI 10.1016/j.ophtha.2016.08.016
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Kertes PJ, 2019, OPHTHALMOLOGY, V126, P841, DOI 10.1016/j.ophtha.2019.01.013
   Koh A, 2020, RETINA-J RET VIT DIS, V40, P1529, DOI 10.1097/IAE.0000000000002624
   Kunimoto D, 2019, OSLI RETINA, V50, pE10, DOI 10.3928/23258160-20190129-13
   Luu KT, 2020, J PHARMACOL EXP THER, V373, P184, DOI 10.1124/jpet.119.263178
   LUX SE, 1990, NATURE, V345, P736, DOI 10.1038/345736a0
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Michaely P, 2002, EMBO J, V21, P6387, DOI 10.1093/emboj/cdf651
   Moisseiev E, 2020, EYE, V34, P605, DOI 10.1038/s41433-019-0584-y
   Pancer Z, 2004, NATURE, V430, P174, DOI 10.1038/nature02740
   Pardridge WM, 2010, J DRUG TARGET, V18, P157, DOI 10.3109/10611860903548354
   Parizek P, 2012, ACS CHEM BIOL, V7, P1356, DOI 10.1021/cb3001167
   Pecen PE, 2015, CURR OPIN OPHTHALMOL, V26, P188, DOI 10.1097/ICU.0000000000000147
   Pluckthun A, 2015, ANNU REV PHARMACOL, V55, P489, DOI 10.1146/annurev-pharmtox-010611-134654
   Rao Luigia, 2018, Oncotarget, V9, P13366, DOI 10.18632/oncotarget.24351
   Rodrigues GA, 2018, INVEST OPHTH VIS SCI, V59, P5836, DOI 10.1167/iovs.18-25307
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sharma A, 2020, EYE, V34, P797, DOI 10.1038/s41433-019-0607-8
   Sharma A, 2020, EYE, V34, P611, DOI 10.1038/s41433-019-0583-z
   Silva R, 2018, OPHTHALMOLOGY, V125, P57, DOI 10.1016/j.ophtha.2017.07.014
   SRINIVASAN Y, 1988, NATURE, V333, P177, DOI 10.1038/333177a0
   Steiner D, 2008, J MOL BIOL, V382, P1211, DOI 10.1016/j.jmb.2008.07.085
   Stumpp MT, 2008, DRUG DISCOV TODAY, V13, P695, DOI 10.1016/j.drudis.2008.04.013
   Tufail A, 2014, OPHTHALMOLOGY, V121, P1092, DOI 10.1016/j.ophtha.2013.11.031
   Vigano MA, 2018, BIOL OPEN, V7, DOI 10.1242/bio.040832
NR 42
TC 11
Z9 12
U1 4
U2 7
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1471-4892
EI 1471-4973
J9 CURR OPIN PHARMACOL
JI Curr. Opin. Pharmacol.
PD APR
PY 2020
VL 51
BP 93
EP 101
DI 10.1016/j.coph.2020.05.004
PG 9
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA OH6VG
UT WOS:000582733200013
PM 32674998
DA 2022-11-30
ER

PT J
AU Figueroa, AG
   McKay, BS
AF Figueroa, Anna G.
   McKay, Brian S.
TI A G-Protein Coupled Receptor and Macular Degeneration
SO CELLS
LA English
DT Review
DE GPR143; melanin; RPE; G-protein; OA1; L-DOPA; macular degeneration; AMD
ID RETINAL-PIGMENT EPITHELIUM; OCULAR ALBINISM; L-DOPA; EXOSOME RELEASE;
   PEDF; EXPRESSION; GENE; CELL; OA1; TRANSPORTER
AB Age-related macular degeneration (AMD) is a leading cause of irreversible blindness in the world. The risk of AMD increases with age and is most common among the white population. Here, we discuss the convergence of factors related to race, pigmentation, and susceptibility to AMD, where the primary defect occurs in retinal support cells, the retinal pigment epithelium (RPE). We explore whether the observed racial bias in AMD incidence is related to innate differences in the basal level of pigmentation between races, and whether the pigmentation pathway activity in the RPE might protect from retinal degeneration. More specifically, we explore whether the downstream signaling activity of GPR143, a G-protein coupled receptor in the pigmentation pathway, might underly the racial bias of AMD and be a target to prevent the disease. Lastly, we summarize the past findings of a large retrospective study that investigated the relationship between the stimulation of GPR143 with L-DOPA, the pigmentation pathway, and AMD, to potentially help develop new ways to prevent or treat AMD. The reader of this review will come to understand the racial bias of AMD, which is related to the function of the RPE.
C1 [Figueroa, Anna G.; McKay, Brian S.] Univ Arizona, Dept Ophthalmol & Vis Sci, Tucson, AZ 85724 USA.
C3 University of Arizona
RP McKay, BS (通讯作者)，Univ Arizona, Dept Ophthalmol & Vis Sci, Tucson, AZ 85724 USA.
EM afigueroa@email.arizona.edu; bsmckay@eyes.arizona.edu
OI Figueroa, Anna G./0000-0002-5047-6942
FU National Institute of Health [EY026544-01]
FX The work is funded by a grant from the National Institute of Health to
   Brian S. McKay, EY026544-01.
CR Adler R, 1999, MOL VIS, V5
   ANDERSON DH, 1978, INVEST OPHTH VIS SCI, V17, P117
   Arias Elizabeth, 2017, Natl Vital Stat Rep, V66, P1
   Baba K, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-05394-x
   Bang C, 2012, INT J BIOCHEM CELL B, V44, P2060, DOI 10.1016/j.biocel.2012.08.007
   BARBEAU A, 1969, Canadian Medical Association Journal, V101, P59
   Bastide MF, 2015, PROG NEUROBIOL, V132, P96, DOI 10.1016/j.pneurobio.2015.07.002
   Bergen AA, 2019, PROG RETIN EYE RES, V70, P55, DOI 10.1016/j.preteyeres.2018.12.003
   Bharti K, 2006, PIGM CELL RES, V19, P380, DOI 10.1111/j.1600-0749.2006.00318.x
   BOK D, 1993, J CELL SCI, P189
   Boulton M, 2001, EYE, V15, P384, DOI 10.1038/eye.2001.141
   Brilliant MH, 2016, AM J MED, V129, P292, DOI 10.1016/j.amjmed.2015.10.015
   Burgoyne T, 2013, J CELL SCI, V126, P5143, DOI 10.1242/jcs.128561
   CREEL DJ, 1990, OPHTHALMIC PAED GEN, V11, P193, DOI 10.3109/13816819009020979
   d'Addio M, 2000, HUM MOL GENET, V9, P3011, DOI 10.1093/hmg/9.20.3011
   Doudet DJ, 2004, EXP NEUROL, V189, P361, DOI 10.1016/j.expneurol.2004.06.009
   DUTTON J, 1993, CLIN CHEM, V39, P629
   Falk T, 2012, J BIOMED BIOTECHNOL, DOI 10.1155/2012/278932
   Falk T, 2010, INT J MOL SCI, V11, P2875, DOI 10.3390/ijms11082875
   Fraga S, 2002, EUR J PHARMACOL, V441, P127, DOI 10.1016/S0014-2999(02)01416-4
   Fronk AH, 2016, J TISSUE ENG, V7, DOI 10.1177/2041731416650838
   Gracies J-M, 2002, NEUROPSYCHOPHARMACOL, P1795
   Hardy KM, 2005, J BIOL CHEM, V280, P28917, DOI 10.1074/jbc.M504803200
   He XM, 2015, CLIN SCI, V128, P805, DOI 10.1042/CS20130463
   Huang Q, 2008, EXP EYE RES, V87, P226, DOI 10.1016/j.exer.2008.06.003
   Jackson CR, 2011, EUR J NEUROSCI, V34, P57, DOI 10.1111/j.1460-9568.2011.07734.x
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Jin NG, 2015, J PHYSIOL-LONDON, V593, P1597, DOI 10.1113/jphysiol.2014.284919
   Klein R, 2013, AM J OPHTHALMOL, V156, P1010, DOI 10.1016/j.ajo.2013.06.004
   Klein R, 2011, ARCH OPHTHALMOL-CHIC, V129, P75, DOI 10.1001/archophthalmol.2010.318
   Klingeborn M, 2018, ADV EXP MED BIOL, V1074, P539, DOI 10.1007/978-3-319-75402-4_65
   Klingeborn M, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-05102-9
   Lee H, 2019, PIGM CELL MELANOMA R, V32, P657, DOI 10.1111/pcmr.12782
   Locke CJ, 2014, EXP EYE RES, V129, P1, DOI 10.1016/j.exer.2014.10.010
   Lopez VM, 2008, PLOS BIOL, V6, P1861, DOI 10.1371/journal.pbio.0060236
   McAllister JT, 2010, VISION RES, V50, P810, DOI 10.1016/j.visres.2010.02.003
   McKay BS, 2006, EXP NEUROL, V201, P234, DOI 10.1016/j.expneurol.2006.04.016
   Mckay BS, 2019, J NEUROSCI RES, V97, P77, DOI 10.1002/jnr.24246
   McKay BS, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082301
   MCKAY BS, 1994, EXP CELL RES, V213, P85, DOI 10.1006/excr.1994.1176
   Mitchell P, 2010, BRIT J OPHTHALMOL, V94, P2, DOI 10.1136/bjo.2009.159160
   Mohammad S, 2011, OPHTHALMOLOGY, V118, P1645, DOI 10.1016/j.ophtha.2011.01.037
   ODONNELL FE, 1976, ARCH OPHTHALMOL-CHIC, V94, P1883, DOI 10.1001/archopht.1976.03910040593001
   Ohyashiki JH, 2016, CURR OPIN HEMATOL, V23, P268, DOI 10.1097/MOH.0000000000000235
   Pant S, 2012, BIOCHEM PHARMACOL, V83, P1484, DOI 10.1016/j.bcp.2011.12.037
   Perkumas KM, 2007, EXP EYE RES, V84, P209, DOI 10.1016/j.exer.2006.09.020
   Rajan PD, 2000, CURR EYE RES, V20, P195, DOI 10.1076/0271-3683(200003)20:3;1-9;FT195
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Roffler-Tarlov S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057184
   Rosenfeld Philip J, 2006, Ophthalmol Clin North Am, V19, P361
   Sahebi R, 2020, J CELL BIOCHEM, V121, P7, DOI 10.1002/jcb.29120
   Satoh M., 2015, RES REV J PHARM PHAR, V4, P88
   Schiaffino MV, 1996, P NATL ACAD SCI USA, V93, P9055, DOI 10.1073/pnas.93.17.9055
   SCHMIDT SY, 1986, INVEST OPHTH VIS SCI, V27, P1063
   Schorey JS, 2008, TRAFFIC, V9, P871, DOI 10.1111/j.1600-0854.2008.00734.x
   STEELE FR, 1993, P NATL ACAD SCI USA, V90, P1526, DOI 10.1073/pnas.90.4.1526
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Summers CG, 2014, CLIN EXP OPHTHALMOL, V42, P713, DOI 10.1111/ceo.12325
   Surace EM, 2000, INVEST OPHTH VIS SCI, V41, P4333
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   Tombran-Tink J, 2003, NAT REV NEUROSCI, V4, P628, DOI 10.1038/nrn1176
   TOMBRANTINK J, 1995, J NEUROSCI, V15, P4992
   TOMBRANTINK J, 1991, EXP EYE RES, V53, P411, DOI 10.1016/0014-4835(91)90248-D
   Vautrot V, 2019, J ONCOL, V2019, DOI 10.1155/2019/8585276
   WEITER JJ, 1986, INVEST OPHTH VIS SCI, V27, P145
   Zhang J, 2015, GENOM PROTEOM BIOINF, V13, P17, DOI 10.1016/j.gpb.2015.02.001
NR 66
TC 4
Z9 4
U1 2
U2 5
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2073-4409
J9 CELLS-BASEL
JI Cells
PD APR
PY 2020
VL 9
IS 4
AR 910
DI 10.3390/cells9040910
PG 13
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA LR2XW
UT WOS:000535559500121
PM 32276449
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Yeo, NJY
   Chan, EJJ
   Cheung, C
AF Yeo, Natalie Jia Ying
   Chan, Ebenezer Jia Jun
   Cheung, Christine
TI Choroidal Neovascularization: Mechanisms of Endothelial Dysfunction
SO FRONTIERS IN PHARMACOLOGY
LA English
DT Review
DE choroidal neovascularization; endothelial; vascular mechanisms;
   age-related macular degeneration; disease models
ID RETINAL-PIGMENT EPITHELIUM; MARROW-DERIVED CELLS; COMPLEMENT FACTOR-H;
   CARDIOVASCULAR RISK-FACTORS; SMOOTH-MUSCLE-CELLS; C-REACTIVE PROTEIN;
   MACULAR DEGENERATION; GROWTH-FACTOR; ALZHEIMERS-DISEASE; OXIDATIVE
   STRESS
AB Many conditions affecting the heart, brain, and even the eyes have their origins in blood vessel pathology, underscoring the role of vascular regulation. In age-related macular degeneration (AMD), there is excessive growth of abnormal blood vessels in the eye (choroidal neovascularization), eventually leading to vision loss due to detachment of retinal pigmented epithelium. As the advanced stage of this disease involves loss of retinal pigmented epithelium, much less attention has been given to early vascular events such as endothelial dysfunction. Although current gold standard therapy using inhibitors of vascular endothelial growth factor (VEGF) have achieved initial successes, some drawbacks include the lack of long-term restoration of visual acuity, as well as a subset of the patients being refractory to existing treatment, alluding us and others to hypothesize upon VEGF-independent mechanisms. Against this backdrop, we present here a nonexhaustive review on the vascular underpinnings of AMD, implications with genetic and systemic factors, experimental models for studying choroidal neovascularization, and interestingly, on both endothelial-centric pathways and noncell autonomous mechanisms. We hope to shed light on future research directions in improving vascular function in ocular disorders.
C1 [Yeo, Natalie Jia Ying; Cheung, Christine] Nanyang Technol Univ, Lee Kong Chian Sch Med, Singapore, Singapore.
   [Chan, Ebenezer Jia Jun] Nanyang Technol Univ, Sch Social Sci, Div Psychol, Coll Humanities Arts & Social Sci, Singapore, Singapore.
   [Chan, Ebenezer Jia Jun] Natl Univ Singapore, Duke NUS Med Sch, Singapore, Singapore.
   [Cheung, Christine] Agcy Sci Technol & Res, Inst Mol & Cell Biol, Singapore, Singapore.
C3 Nanyang Technological University & National Institute of Education (NIE)
   Singapore; Nanyang Technological University; Nanyang Technological
   University & National Institute of Education (NIE) Singapore; Nanyang
   Technological University; National University of Singapore; Agency for
   Science Technology & Research (A*STAR); A*STAR - Institute of Molecular
   & Cell Biology (IMCB)
RP Cheung, C (通讯作者)，Nanyang Technol Univ, Lee Kong Chian Sch Med, Singapore, Singapore.; Cheung, C (通讯作者)，Agcy Sci Technol & Res, Inst Mol & Cell Biol, Singapore, Singapore.
EM ccheung@ntu.edu.sg
RI Cheung, Christine/J-9721-2017
OI Cheung, Christine/0000-0001-7127-9107; Yeo, Natalie/0000-0002-1158-1432
FU Academic Research Fund (AcRF) Tier 2 grant from the Ministry of
   Education, Singapore [MOE2018-T2-1-042]; SERI-IMCB Program in Retinal
   Angiogenic Diseases (SIPRAD) [SPF2014/002]; A-STAR (Agency for Science
   Technology and Research, Singapore)
FX We are grateful for the funding support of an Academic Research Fund
   (AcRF) Tier 2 grant (MOE2018-T2-1-042) from the Ministry of Education,
   Singapore, as well as support from the SERI-IMCB Program in Retinal
   Angiogenic Diseases (SIPRAD) grant number SPF2014/002, a grant from
   A-STAR (Agency for Science Technology and Research, Singapore).
CR Ablonczy Z, 2011, INVEST OPHTH VIS SCI, V52, P8614, DOI 10.1167/iovs.11-8021
   Akaza E, 2007, JPN J OPHTHALMOL, V51, P270, DOI 10.1007/s10384-007-0452-3
   Akpek EK, 2013, AM J MANAG CARE, V19, pS67
   Ambati J, 2013, NAT REV IMMUNOL, V13, P438, DOI 10.1038/nri3459
   Anand-Apte B., 2010, RETINA ITS DISORDERS, P179, DOI [10.1016/B978-0-12-374203-2.00169-X, DOI 10.1016/B978-0-12-374203-2.00169-X]
   Arvanitakis Z, 2016, LANCET NEUROL, V15, P934, DOI 10.1016/S1474-4422(16)30029-1
   Asahara T, 1997, SCIENCE, V275, P964, DOI 10.1126/science.275.5302.964
   Asahara T, 1999, CIRC RES, V85, P221, DOI 10.1161/01.RES.85.3.221
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Berenberg TL, 2012, RETINA-J RET VIT DIS, V32, P25, DOI 10.1097/IAE.0b013e3182150483
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Biesemeier A, 2014, NEUROBIOL AGING, V35, P2562, DOI 10.1016/j.neurobiolaging.2014.05.003
   Blaauwgeers HGT, 1999, AM J PATHOL, V155, P421, DOI 10.1016/S0002-9440(10)65138-3
   Boos CJ, 2006, J AM COLL CARDIOL, V48, P1538, DOI 10.1016/j.jacc.2006.02.078
   Bora PS, 2005, J IMMUNOL, V174, P491, DOI 10.4049/jimmunol.174.1.491
   Bora PS, 2003, P NATL ACAD SCI USA, V100, P2679, DOI 10.1073/pnas.0438014100
   Bouras C, 2006, J NEUROPATH EXP NEUR, V65, P235, DOI 10.1097/01.jnen.0000203077.53080.2c
   Boyle EA, 2017, CELL, V169, P1177, DOI 10.1016/j.cell.2017.05.038
   Bracha P, 2017, EXPERT OPIN BIOL TH, V17, P1113, DOI 10.1080/14712598.2017.1346079
   BUEE L, 1994, ACTA NEUROPATHOL, V87, P469
   Cai H, 2000, CIRC RES, V87, P840, DOI 10.1161/01.RES.87.10.840
   Chan Chi-Chao, 2007, Trans Am Ophthalmol Soc, V105, P92
   Chan-Ling T, 2006, AM J PATHOL, V168, P1031, DOI 10.2353/ajpath.2006.050697
   Cheng CY, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7063
   Cheng HC, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0110818
   Cheung CMG, 2014, J INTERN MED, V276, P140, DOI 10.1111/joim.12227
   Cheung N, 2007, BRIT J OPHTHALMOL, V91, P430, DOI 10.1136/bjo.2006.106054
   Chichagova V, 2018, EYE, V32, P946, DOI 10.1038/s41433-018-0061-z
   Chirco KR, 2017, EYE, V31, P10, DOI 10.1038/eye.2016.216
   Chirco KR, 2016, EXP EYE RES, V146, P393, DOI 10.1016/j.exer.2015.09.003
   Cho HJ, 2012, EYE, V26, P426, DOI 10.1038/eye.2011.324
   Chung SD, 2014, AM J OPHTHALMOL, V157, P464, DOI 10.1016/j.ajo.2013.09.026
   Chung SE, 2013, RETINA-J RET VIT DIS, V33, P834, DOI 10.1097/IAE.0b013e31826af540
   Clark SJ, 2013, J IMMUNOL, V190, P2049, DOI 10.4049/jimmunol.1201751
   Clark SJ, 2010, J BIOL CHEM, V285, P30192, DOI 10.1074/jbc.M110.103986
   Couch SM, 2011, SEMIN OPHTHALMOL, V26, P114, DOI 10.3109/08820538.2011.577130
   Davignon J, 2004, CIRCULATION, V109, P27, DOI 10.1161/01.CIR.0000131515.03336.f8
   De Luca A, 2003, J HISTOCHEM CYTOCHEM, V51, P1279, DOI 10.1177/002215540305101004
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   DOBI ET, 1989, ARCH OPHTHALMOL-CHIC, V107, P264, DOI 10.1001/archopht.1989.01070010270035
   Dong A, 2009, J CELL PHYSIOL, V219, P544, DOI 10.1002/jcp.21698
   Dunn EN, 2017, OSLI RETINA, V48, P100, DOI 10.3928/23258160-20170130-02
   Dutescu RM, 2009, GRAEF ARCH CLIN EXP, V247, P1213, DOI 10.1007/s00417-009-1060-3
   Ehrlich R, 2009, GRAEF ARCH CLIN EXP, V247, P583, DOI 10.1007/s00417-008-1018-x
   El Assar M, 2012, FRONT PHYSIOL, V3, DOI 10.3389/fphys.2012.00132
   Else Holly, 2019, Nature, V569, P612, DOI 10.1038/d41586-019-01685-7
   Erdbruegger U, 2006, CLIN CHIM ACTA, V373, P17, DOI 10.1016/j.cca.2006.05.016
   Espinosa-Heidmann DG, 2005, EXP EYE RES, V80, P369, DOI 10.1016/j.exer.2004.10.005
   Espinosa-Heidmann DG, 2003, INVEST OPHTH VIS SCI, V44, P4914, DOI 10.1167/iovs.03-0371
   Fernandez-Robredo P, 2014, J OPHTHALMOL, V2014, DOI 10.1155/2014/510285
   FERRARA N, 1991, J CELL BIOCHEM, V47, P211, DOI 10.1002/jcb.240470305
   Ferreira VP, 2009, J IMMUNOL, V182, P7009, DOI 10.4049/jimmunol.0804031
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Fiedler U, 2006, NAT MED, V12, P235, DOI 10.1038/nm1351
   FISCHER VW, 1990, ACTA NEUROPATHOL, V79, P672, DOI 10.1007/BF00294246
   Fogli S, 2018, EYE, V32, P1010, DOI 10.1038/s41433-018-0021-7
   Foxton RH, 2019, EMBO MOL MED, V11, DOI 10.15252/emmm.201810204
   Franco M, 2011, BLOOD, V118, P2906, DOI 10.1182/blood-2011-01-331694
   FRANK RN, 1989, CURR EYE RES, V8, P239, DOI 10.3109/02713688908997565
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Gahn Greggory M, 2018, Vision (Basel), V2, DOI 10.3390/vision2010015
   Gao F, 2016, ANGIOGENESIS, V19, P107, DOI 10.1007/s10456-016-9497-6
   Garber K., 2015, RIKEN SUSPENDS 1 CLI, DOI [10.1038/nbt0915-890, DOI 10.1038/NBT0915-890]
   Giacalone JC, 2019, MICROVASC RES, V123, P50, DOI 10.1016/j.mvr.2018.12.002
   GIMBRONE MA, 1995, AM J CARDIOL, V75, pB67, DOI 10.1016/0002-9149(95)80016-L
   Golbaz I, 2011, INVEST OPHTH VIS SCI, V52, P1599, DOI 10.1167/iovs.09-5018
   Golde TE, 2002, NAT MED, V8, P936, DOI 10.1038/nm0902-936
   Gomi F, 2008, BRIT J OPHTHALMOL, V92, P70, DOI 10.1136/bjo.2007.122283
   Gong Y, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132643
   Gordois A, 2012, GLOB PUBLIC HEALTH, V7, P465, DOI 10.1080/17441692.2011.634815
   Gottesman RF, 2017, JAMA-J AM MED ASSOC, V317, P1443, DOI 10.1001/jama.2017.3090
   Grant MB, 2002, NAT MED, V8, P607, DOI 10.1038/nm0602-607
   Grau S, 2006, J BIOL CHEM, V281, P6124, DOI 10.1074/jbc.M500361200
   Grossniklaus HE, 2010, PROG RETIN EYE RES, V29, P500, DOI 10.1016/j.preteyeres.2010.05.003
   Grunewald M, 2006, CELL, V124, P175, DOI 10.1016/j.cell.2005.10.036
   Grunwald JE, 2005, INVEST OPHTH VIS SCI, V46, P1033, DOI 10.1167/iovs.04-1050
   HAGEMAN GS, 1991, P NATL ACAD SCI USA, V88, P2716, DOI 10.1073/pnas.88.7.2716
   Hardy J, 2002, SCIENCE, V297, P353, DOI 10.1126/science.1072994
   Hasdai D, 1997, CIRCULATION, V96, P3390
   Ho M, 2016, SCI REP-UK, V6, DOI 10.1038/srep36870
   Hogg RE, 2008, OPHTHALMOLOGY, V115, P1046, DOI 10.1016/j.ophtha.2007.07.031
   Hollyfield JG, 2008, NAT MED, V14, P194, DOI 10.1038/nm1709
   Holmes C, 2008, LANCET, V372, P216, DOI 10.1016/S0140-6736(08)61075-2
   Hou HY, 2006, CURR EYE RES, V31, P1051, DOI 10.1080/02713680601100459
   Huang LL, 2016, NAT GENET, V48, P640, DOI 10.1038/ng.3546
   Huang WB, 2014, INVEST OPHTH VIS SCI, V55, P5380, DOI 10.1167/iovs.14-15231
   ISHIBASHI T, 1987, INVEST OPHTH VIS SCI, V28, P1116
   Ishida S, 2003, J EXP MED, V198, P483, DOI 10.1084/jem.20022027
   Jaffe GJ, 2017, OPHTHALMOLOGY, V124, P224, DOI 10.1016/j.ophtha.2016.10.010
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Jiang J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046058
   Jiao J, 2017, INT J CLIN EXP PATHO, V10, P1104
   Jonas JB, 2017, ASIA-PAC J OPHTHALMO, V6, P493, DOI 10.22608/APO.2017251
   Jones A, 2011, P NATL ACAD SCI USA, V108, P14578, DOI 10.1073/pnas.1102853108
   Jones CA, 2008, NAT MED, V14, P448, DOI 10.1038/nm1742
   Kaarniranta K, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19082317
   Kaarniranta K, 2011, J ALZHEIMERS DIS, V24, P615, DOI 10.3233/JAD-2011-101908
   Kam JH, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013127
   Karran E, 2011, NAT REV DRUG DISCOV, V10, P698, DOI 10.1038/nrd3505
   Khandhadia S, 2012, IMMUNOBIOLOGY, V217, P127, DOI 10.1016/j.imbio.2011.07.019
   Kinnunen K, 2012, ANN MED, V44, P1, DOI 10.3109/07853890.2010.532150
   Kisler K, 2017, NAT REV NEUROSCI, V18, P419, DOI 10.1038/nrn.2017.48
   Klein R, 2014, JAMA OPHTHALMOL, V132, P446, DOI 10.1001/jamaophthalmol.2013.7671
   Klein R, 2013, OPHTHALMOLOGY, V120, P1012, DOI 10.1016/j.ophtha.2012.11.003
   KORTE GE, 1984, INVEST OPHTH VIS SCI, V25, P1135
   Kramer M, 2000, AM J OPHTHALMOL, V129, P495, DOI 10.1016/S0002-9394(99)00388-8
   Krebs I, 2013, BRIT J OPHTHALMOL, V97, P1443, DOI 10.1136/bjophthalmol-2013-303513
   Kurihara T, 2012, J CLIN INVEST, V122, P4213, DOI 10.1172/JCI65157
   Kuroiwa S, 2004, CLIN EXP OPHTHALMOL, V32, P297, DOI 10.1111/j.1442-9071.2004.00827.x
   Kvanta A, 1996, INVEST OPHTH VIS SCI, V37, P1929
   Kwak N, 2000, INVEST OPHTH VIS SCI, V41, P3158
   Lai TYY, 2008, BRIT J OPHTHALMOL, V92, P661, DOI 10.1136/bjo.2007.135103
   Lai TYY, 2004, AM J OPHTHALMOL, V137, P826, DOI 10.1016/j.ajo.2003.11.079
   Lally DR, 2012, CURR OPIN OPHTHALMOL, V23, P182, DOI 10.1097/ICU.0b013e328352411c
   Lambert V, 2013, NAT PROTOC, V8, P2197, DOI 10.1038/nprot.2013.135
   Lee CS, 2019, ALZHEIMERS DEMENT, V15, P34, DOI 10.1016/j.jalz.2018.06.2856
   Lee WK, 2008, JPN J OPHTHALMOL, V52, P108, DOI 10.1007/s10384-007-0501-y
   LEISHMAN R, 1957, Br J Ophthalmol, V41, P641, DOI 10.1136/bjo.41.11.641
   Lim JKH, 2016, FRONT NEUROSCI-SWITZ, V10, DOI 10.3389/fnins.2016.00536
   Lin MT, 2006, NATURE, V443, P787, DOI 10.1038/nature05292
   Lip PL, 2001, OPHTHALMOLOGY, V108, P705, DOI 10.1016/S0161-6420(00)00663-1
   Liu K, 2014, OPHTHALMOLOGY, V121, P911, DOI 10.1016/j.ophtha.2013.10.042
   Liu R, 2016, RETINA-J RET VIT DIS, V36, P778, DOI 10.1097/IAE.0000000000000794
   London A, 2013, NAT REV NEUROL, V9, P44, DOI 10.1038/nrneurol.2012.227
   LOU DA, 1987, IN VITRO CELL DEV B, V23, P75, DOI 10.1007/BF02623586
   LUTTY G, 2009, INVEST OPHTH VIS SCI, V50, P3518, DOI DOI 10.1167/IOVS.09-3639
   Machalinska A, 2012, ACTA OPHTHALMOL, V90, P695, DOI 10.1111/j.1755-3768.2011.02295.x
   Machalinska A, 2011, INVEST OPHTH VIS SCI, V52, P93, DOI 10.1167/iovs.10-5756
   Makin RD, 2018, INVEST OPHTH VIS SCI, V59, P5795, DOI 10.1167/iovs.18-25215
   Malek G, 2018, EXPERT OPIN DRUG DIS, V13, P359, DOI 10.1080/17460441.2018.1430136
   Manuelian T, 2003, J CLIN INVEST, V111, P1181, DOI 10.1172/JCI200316651
   Marazita MC, 2016, REDOX BIOL, V7, P78, DOI 10.1016/j.redox.2015.11.011
   Marneros AG, 2005, AM J PATHOL, V167, P1451, DOI 10.1016/S0002-9440(10)61231-X
   Marneros AG, 2013, CELL REP, V4, P945, DOI 10.1016/j.celrep.2013.08.002
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Mathura JR, 2000, INVEST OPHTH VIS SCI, V41, P592
   Maugeri A, 2018, BIOMED RES INT, V2018, DOI 10.1155/2018/7532507
   Miller JW, 1997, DIABETES METAB REV, V13, P37, DOI 10.1002/(SICI)1099-0895(199703)13:1<37::AID-DMR174>3.0.CO;2-K
   Mok SS, 2006, J NEUROCHEM, V96, P53, DOI 10.1111/j.1471-4159.2005.03539.x
   Mudau M, 2012, CARDIOVASC J AFR, V23, DOI 10.5830/CVJA-2011-068
   Mullins RF, 2014, ADV EXP MED BIOL, V801, P283, DOI 10.1007/978-1-4614-3209-8_36
   Naito H, 2012, EMBO J, V31, P842, DOI 10.1038/emboj.2011.465
   Nakashizuka H, 2008, INVEST OPHTH VIS SCI, V49, P4729, DOI 10.1167/iovs.08-2134
   Nation DA, 2019, NAT MED, V25, P270, DOI 10.1038/s41591-018-0297-y
   Ng DS, 2017, SCI REP-UK, V7, DOI 10.1038/srep45081
   Nishida N, 2006, P NATL ACAD SCI USA, V103, P19737, DOI 10.1073/pnas.0609791104
   Nitsch D, 2009, OPHTHAL EPIDEMIOL, V16, P181, DOI 10.1080/09286580902863064
   Nortley R, 2019, SCIENCE, V365, P250, DOI 10.1126/science.aav9518
   Nozaki M, 2006, P NATL ACAD SCI USA, V103, P2328, DOI 10.1073/pnas.0408835103
   Ohno-Matsui K, 2011, PROG RETIN EYE RES, V30, P217, DOI 10.1016/j.preteyeres.2011.02.004
   Oka C, 2004, DEVELOPMENT, V131, P1041, DOI 10.1242/dev.00999
   Okubo A, 2002, BRIT J OPHTHALMOL, V86, P1093, DOI 10.1136/bjo.86.10.1093
   Okuno Y, 2011, BLOOD, V117, P5264, DOI 10.1182/blood-2011-01-330720
   Pachydaki SI, 2012, J OPHTHALMIC INFLAMM, V2, P29, DOI 10.1007/s12348-011-0050-x
   Papadopoulos N, 2012, ANGIOGENESIS, V15, P171, DOI 10.1007/s10456-011-9249-6
   Pascolini D, 2012, BRIT J OPHTHALMOL, V96, P614, DOI 10.1136/bjophthalmol-2011-300539
   Pennesi ME, 2012, MOL ASPECTS MED, V33, P487, DOI 10.1016/j.mam.2012.06.003
   Pennington KL, 2016, EYE VISION, V3, DOI 10.1186/s40662-016-0063-5
   Poor SH, 2014, INVEST OPHTH VIS SCI, V55, P6525, DOI 10.1167/iovs.14-15067
   Purhonen S, 2008, P NATL ACAD SCI USA, V105, P6620, DOI 10.1073/pnas.0710516105
   Qian TW, 2018, EUR J CLIN INVEST, V48, DOI 10.1111/eci.12840
   Ratnayaka JA, 2015, EYE, V29, P1013, DOI 10.1038/eye.2015.100
   Reinmuth N, 2001, FASEB J, V15, P1239, DOI 10.1096/fj.00-0693fje
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Rong SS, 2019, BRIT J OPHTHALMOL, V103, P1777, DOI 10.1136/bjophthalmol-2018-313277
   Rops AL, 2004, KIDNEY INT, V66, P2193, DOI 10.1111/j.1523-1755.2004.66009.x
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2018, OPHTHALMOLOGY, V125, P1488, DOI 10.1016/j.ophtha.2018.06.002
   Ryan S J, 1979, Trans Am Ophthalmol Soc, V77, P707
   Saini JS, 2017, CELL STEM CELL, V20, P635, DOI 10.1016/j.stem.2016.12.015
   Saint-Geniez M, 2004, INT J DEV BIOL, V48, P1045, DOI 10.1387/ijdb.041895ms
   Schaumberg DA, 2007, ARCH OPHTHALMOL-CHIC, V125, P300, DOI 10.1001/archopht.125.3.300
   Schiattarella GG, 2019, NATURE, V568, P351, DOI 10.1038/s41586-019-1100-z
   Schlingemann RO, 2009, PROG BRAIN RES, V175, P253, DOI 10.1016/S0079-6123(09)17517-9
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P321, DOI 10.1001/archopht.123.3.321
   Seddon JM, 2004, JAMA-J AM MED ASSOC, V291, P704, DOI 10.1001/jama.291.6.704
   Seddon JM, 2016, JAMA OPHTHALMOL, V134, P1272, DOI 10.1001/jamaophthalmol.2016.3519
   Sengupta N, 2003, INVEST OPHTH VIS SCI, V44, P4908, DOI 10.1167/iovs.03-0342
   Sheridan CM, 2006, INVEST OPHTH VIS SCI, V47, P1642, DOI 10.1167/iovs.05-0779
   Siedlecki J, 2017, GRAEF ARCH CLIN EXP, V255, P963, DOI 10.1007/s00417-017-3595-z
   Silva R, 2013, OPHTHALMOLOGY, V120, P130, DOI 10.1016/j.ophtha.2012.07.026
   Singer MA, 2012, OPHTHALMOLOGY, V119, P1175, DOI 10.1016/j.ophtha.2011.12.016
   Snyder HM, 2015, ALZHEIMERS DEMENT, V11, P710, DOI 10.1016/j.jalz.2014.10.008
   Songstad AE, 2017, STEM CELL TRANSL MED, V6, P1533, DOI 10.1002/sctm.16-0399
   Stan RV, 2004, MOL BIOL CELL, V15, P3615, DOI 10.1091/mbc.E03-08-0593
   Stauffer BL, 2008, CURR OPIN CARDIOL, V23, P350, DOI 10.1097/HCO.0b013e328302f3c6
   Supanji, 2013, EXP EYE RES, V112, P79, DOI 10.1016/j.exer.2013.04.013
   Sweeney MD, 2018, NAT REV NEUROL, V14, P133, DOI 10.1038/nrneurol.2017.188
   Takahashi H, 2004, BIOCHEM BIOPH RES CO, V320, P372, DOI 10.1016/j.bbrc.2004.05.177
   Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024
   Tan JSL, 2008, BRIT J OPHTHALMOL, V92, P509, DOI 10.1136/bjo.2007.131706
   Tan JSL, 2007, OPHTHALMOLOGY, V114, P1143, DOI 10.1016/j.ophtha.2006.09.033
   Tedeschi-Reiner E, 2005, AM J CARDIOL, V96, P1107, DOI 10.1016/j.amjcard.2005.05.070
   Teo KYC, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19092611
   Thomas J, 2015, SOUTH MED J, V108, P502, DOI 10.14423/SMJ.0000000000000329
   Tobe T, 1998, INVEST OPHTH VIS SCI, V39, P180
   Tolentino MJ, 2004, RETINA-J RET VIT DIS, V24, P132, DOI 10.1097/00006982-200402000-00018
   Tomita M, 2004, STEM CELLS, V22, P21, DOI 10.1634/stemcells.22-1-21
   Tong JP, 2006, AM J OPHTHALMOL, V141, P456, DOI 10.1016/j.ajo.2005.10.012
   Tosi GM, 2017, INVEST OPHTH VIS SCI, V58, P162, DOI 10.1167/iovs.16-20922
   Totan Yϋksel, 2015, J Ophthalmic Vis Res, V10, P151, DOI 10.4103/2008-322X.163765
   Tsujikawa A, 2010, JPN J OPHTHALMOL, V54, P310, DOI 10.1007/s10384-010-0813-1
   van de Haar HJ, 2016, NEUROBIOL AGING, V45, P190, DOI 10.1016/j.neurobiolaging.2016.06.006
   Veckeneer M, 2017, EYE, V31, P1274, DOI 10.1038/eye.2017.137
   Vierkotten S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022959
   VINGERLING JR, 1995, AM J EPIDEMIOL, V142, P404, DOI 10.1093/oxfordjournals.aje.a117648
   Vogel RN, 2017, RETINA-J RET VIT DIS, V37, P257, DOI 10.1097/IAE.0000000000001150
   Wakabayashi T, 2013, INVEST OPHTH VIS SCI, V54, P6686, DOI 10.1167/iovs.13-12342
   Wang HB, 2016, MOL VIS, V22, P189
   Wang JQ, 2011, ANAT REC, V294, P1401, DOI 10.1002/ar.21438
   Wang XL, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-10124-4
   Wang YF, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-08690-4
   Weismann D, 2011, NATURE, V478, P76, DOI 10.1038/nature10449
   Wimmer RA, 2019, NATURE, V565, P505, DOI 10.1038/s41586-018-0858-8
   Wolf A, 2019, EMBO MOL MED, V11, DOI 10.15252/emmm.201910362
   Wong CW, 2016, PROG RETIN EYE RES, V53, P107, DOI 10.1016/j.preteyeres.2016.04.002
   Wong TY, 2006, ANN INTERN MED, V145, P98, DOI 10.7326/0003-4819-145-2-200607180-00007
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wu J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089600
   Xu HP, 2016, EUR J PHARMACOL, V787, P94, DOI 10.1016/j.ejphar.2016.03.001
   Yan ZZ, 2018, MOL VIS, V24, P83
   Yang K, 2014, RETINA-J RET VIT DIS, V34, P1539, DOI 10.1097/IAE.0000000000000118
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Yoneyama S, 2016, RETINA-J RET VIT DIS, V36, P1535, DOI 10.1097/IAE.0000000000000964
   Yoon SP, 2019, OPHTHALMOL RETINA, V3, P489, DOI 10.1016/j.oret.2019.02.002
   Yu Y, 2014, HUM MOL GENET, V23, P5283, DOI 10.1093/hmg/ddu226
   Yu Y, 2011, HUM MOL GENET, V20, P3699, DOI 10.1093/hmg/ddr270
   Zhang J, 2018, BMC OPHTHALMOL, V18, DOI 10.1186/s12886-018-0945-5
   Zhang L, 2012, J BIOL CHEM, V287, P1520, DOI 10.1074/jbc.M111.275990
   Zhang XY, 2018, BIOMED RES INT, V2018, DOI 10.1155/2018/9640131
   Zhang ZX, 2011, CURR EYE RES, V36, P838, DOI 10.3109/02713683.2011.593107
   Zipfel PF, 2009, IMMUNOL LETT, V126, P1, DOI 10.1016/j.imlet.2009.07.005
NR 234
TC 26
Z9 27
U1 1
U2 8
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1663-9812
J9 FRONT PHARMACOL
JI Front. Pharmacol.
PD NOV 29
PY 2019
VL 10
AR 1363
DI 10.3389/fphar.2019.01363
PG 19
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA JW0JK
UT WOS:000502745500001
PM 31849644
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Zhu, Q
   Liu, MX
   He, YX
   Yang, B
AF Zhu, Qi
   Liu, Mingxi
   He, Yuxi
   Yang, Bo
TI Quercetin protect cigarette smoke extracts induced inflammation and
   apoptosis in RPE cells
SO ARTIFICIAL CELLS NANOMEDICINE AND BIOTECHNOLOGY
LA English
DT Article
DE Quercetin; age-related macular degeneration; Keap1; Nrf2; ARE
ID ACTIVATION
AB Background: Age-related macular degeneration (AMD) is the leading cause of blindness in elderly population in the developed world. Dysfunction of retinal pigment epithelium (RPE) likely triggers early AMD stages. The effect of Quercetin on the early AMD in-vitro model remained unclear.
   Methods: The effect of Quercetin in the cell viability was detected with CCK8 methods in control, CSE treated, and CSE with Quercetin treatment group. The apoptotic status in each group was detected with tunnel assay. The oxidative and inflammation biomarkers were detected by ELISA. The expression levels of Keap1/Nrf2/ARE in RPE cells were measured by western blot after pretreatment of Quercetin followed by CSE treatment.
   Results: It was found that Quercetin could improve the cell viability and decrease cellular apoptotic rate in the CSE treated RPE group. The expressions of inflammatory and apoptotic biomarkers were significantly decreased in Quercetin treatment group. Furthermore, Quercetin exerts protective effects via activation Keap1/Nrf2/ARE pathway in CSE treated RPE cells.
   Conclusions: Quercetin demonstrated significant protective effects in an in-vitro model of early AMD and it might be a new therapeutic strategy for the management of early AMD.
C1 [Zhu, Qi; He, Yuxi; Yang, Bo] Jilin Univ, Hosp 2, Dept Ophthalmol, 218 Ziqiang Rd, Changchun 130041, Jilin, Peoples R China.
   [Liu, Mingxi] Jilin Univ, Hosp 1, Dept Orthoped Traumatol, Changchun, Jilin, Peoples R China.
C3 Jilin University; Jilin University
RP Yang, B (通讯作者)，Jilin Univ, Hosp 2, Dept Ophthalmol, 218 Ziqiang Rd, Changchun 130041, Jilin, Peoples R China.
EM yang660573@163.com
CR Arslan S, 2018, J AM COLL NUTR, V20, P1
   Bergen AA, 2018, PROG RETIN EYE RES, V17
   Gemenetzi M, 2017, EYE, V31, P1, DOI 10.1038/eye.2016.208
   Gonzalez-Bosch C, 2018, FREE RADICAL BIO MED, V122, P171, DOI 10.1016/j.freeradbiomed.2017.12.028
   Huang KP, 2017, EXP CELL RES, V361, P63, DOI 10.1016/j.yexcr.2017.09.042
   Juranova J, 2019, MOLECULES, V24, DOI 10.3390/molecules24010123
   Kim J, 2018, FOOD FUNCT, V9, P2171, DOI 10.1039/c7fo01958k
   Kunchithapautham K, 2014, J BIOL CHEM, V289, P14534, DOI 10.1074/jbc.M114.564674
   Lee M, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18112497
   Pandey MK, 2018, BIOTECHNOL ADV, V36, P1633, DOI 10.1016/j.biotechadv.2018.03.014
   Park GB, 2018, MOL MED REP, V17, P3563, DOI 10.3892/mmr.2017.8355
   Rodrigues GA, 2019, PHARM RES-DORDR, V36, DOI 10.1007/s11095-018-2554-7
   Tressera-Rimbau A, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/7467962
   Wedel S, 2018, MOLECULES, V23, DOI 10.3390/molecules23051219
   Wei B, 2019, DRUG DEV RES
   Xu XR, 2016, EUR J PHARMACOL, V770, P1, DOI 10.1016/j.ejphar.2015.11.050
   Yi YS, 2018, MOL NUTR FOOD RES, V62, DOI 10.1002/mnfr.201800147
   Yousefian M, 2019, PHYTOMEDICINE, V55, P200, DOI 10.1016/j.phymed.2018.08.002
   Zhao YS, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/1459497
   Zhu W, 2017, INT J NANOMED, V12, P7589, DOI 10.2147/IJN.S140275
   Zhu W, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058821
NR 21
TC 18
Z9 21
U1 2
U2 16
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 2169-1401
EI 2169-141X
J9 ARTIF CELL NANOMED B
JI Artif. Cell. Nanomed. Biotechnol.
PY 2019
VL 47
IS 1
BP 2010
EP 2015
DI 10.1080/21691401.2019.1608217
PG 6
WC Biotechnology & Applied Microbiology; Engineering, Biomedical; Materials
   Science, Biomaterials
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Engineering; Materials Science
GA HZ5FF
UT WOS:000468876300001
PM 31122072
OA gold
DA 2022-11-30
ER

PT J
AU Fernandez-Godino, R
   Pierce, EA
AF Fernandez-Godino, Rosario
   Pierce, Eric A.
TI C3a triggers formation of sub-retinal pigment epithelium deposits via
   the ubiquitin proteasome pathway
SO SCIENTIFIC REPORTS
LA English
DT Article
ID COMPLEMENT ACTIVATION; APOLIPOPROTEIN-B; BRUCHS MEMBRANE; HUMAN RETINA;
   DRUSEN; MODEL; PATHOGENESIS; INHIBITION; RECEPTOR; SYSTEM
AB The mechanisms that connect complement system activation and basal deposit formation in early stages of age-related macular degeneration (AMD) are insufficiently understood, which complicates the design of efficient therapies to prevent disease progression. Using human fetal (hf) retinal pigment epithelial (RPE) cells, we have established an in vitro model to investigate the effect of complement C3a on RPE cells and its role in the formation of sub-RPE deposits. The results of these studies revealed that C3a produced after C3 activation is sufficient to induce the formation of sub-RPE deposits via complement-driven proteasome inhibition. C3a binds the C3a receptor (C3aR), stimulates deposition of collagens IV and VI underneath the RPE, and impairs the extracellular matrix (ECM) turnover by increased MMP-2 activity, all mediated by downregulation of the ubiquitin proteasome pathway (UPP). The formation of basal deposits can be prevented by the addition of a C3aR antagonist, which restores the UPP activity and ECM turnover. These findings indicate that the cell-based model can be used to test potential therapeutic agents in vitro. The data suggest that modulation of C3aR-mediated events could be a therapeutic approach for treatment of early AMD.
C1 [Fernandez-Godino, Rosario; Pierce, Eric A.] Harvard Med Sch, Ocular Genom Inst, Dept Ophthalmol, Massachusetts Eye & Ear Infirm, Boston, MA 02114 USA.
C3 Harvard University; Harvard Medical School; Massachusetts Eye & Ear
   Infirmary
RP Fernandez-Godino, R (通讯作者)，Harvard Med Sch, Ocular Genom Inst, Dept Ophthalmol, Massachusetts Eye & Ear Infirm, Boston, MA 02114 USA.
EM rosario_godino@meei.harvard.edu
OI FERNANDEZ GODINO, ROSARIO/0000-0002-8831-7189
FU Ocular Genomics Institute, Department of Ophthalmology, Harvard Medical
   School, Boston, MA; Inflammatory Bowel Disease Grant [DK043351]; Boston
   Area Diabetes and Endocrinology Research Center (BADERC) [DK057521];
   NATIONAL EYE INSTITUTE [P30EY014104] Funding Source: NIH RePORTER
FX The authors thank Dr. Overkleeft and Dr. Florea for providing the
   proteasome probes and protocols. This work was supported by the Ocular
   Genomics Institute, Department of Ophthalmology, Harvard Medical School,
   Boston, MA 02114. Electron microscopy was performed by Diane Capen in
   the Microscopy Core of the Center for Systems Biology/Program in
   Membrane Biology, which is partially supported by an Inflammatory Bowel
   Disease Grant DK043351 and a Boston Area Diabetes and Endocrinology
   Research Center (BADERC) Award DK057521.
CR Ames RS, 1996, J BIOL CHEM, V271, P20231, DOI 10.1074/jbc.271.34.20231
   Ames RS, 2001, J IMMUNOL, V166, P6341, DOI 10.4049/jimmunol.166.10.6341
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   Bexborn F, 2008, MOL IMMUNOL, V45, P2370, DOI 10.1016/j.molimm.2007.11.003
   BRYAN JA, 1986, ARCH OPHTHALMOL-CHIC, V104, P422
   Busch C, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00703
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Curcio C.A., 2013, RETINA-J RET VIT DIS, VVolume 1, P465
   Curcio CA, 2010, J LIPID RES, V51, P451, DOI 10.1194/jlr.R002238
   Dahlmann B, 2000, J MOL BIOL, V303, P643, DOI 10.1006/jmbi.2000.4185
   Dawson TM, 2003, SCIENCE, V302, P819, DOI 10.1126/science.1087753
   Garcia CAD, 2014, OSLI RETINA, V45, P18, DOI 10.3928/23258160-20131217-01
   de Bruin G, 2016, ANGEW CHEM INT EDIT, V55, P4199, DOI 10.1002/anie.201509092
   de Carvalho JER, 2013, INVEST OPHTH VIS SCI, V54, P6489, DOI 10.1167/iovs.13-12374
   Deryugina EI, 1998, CANCER RES, V58, P3743
   Fernandez-Godino R, 2018, HUM MOL GENET, V27, P147, DOI 10.1093/hmg/ddx392
   Fernandez-Godino R, 2016, NAT PROTOC, V11, P1206, DOI 10.1038/nprot.2016.065
   Fernandez-Godino R, 2016, ADV EXP MED BIOL, V854, P53, DOI 10.1007/978-3-319-17121-0_8
   Fernandez-Godino R, 2015, HUM MOL GENET, V24, P5555, DOI 10.1093/hmg/ddv287
   Ferrington DA, 2008, J NEUROCHEM, V106, P158, DOI 10.1111/j.1471-4159.2008.05345.x
   Ferrington DA, 2016, PROG RETIN EYE RES, V51, P69, DOI 10.1016/j.preteyeres.2015.09.002
   Fu L, 2007, HUM MOL GENET, V16, P2411, DOI 10.1093/hmg/ddm198
   Garland DL, 2014, HUM MOL GENET, V23, P52, DOI 10.1093/hmg/ddt395
   Gu HM, 2016, FASEB J, V30, P2336, DOI 10.1096/fj.201500044
   Guo L, 1999, INVEST OPHTH VIS SCI, V40, P2676
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Hawlisch H, 1998, J IMMUNOL, V160, P2947
   Holland M Claire H, 2004, Curr Opin Investig Drugs, V5, P1164
   Hope AD, 2003, J NEUROCHEM, V86, P394, DOI 10.1046/j.1471-4159.2003.01844.x
   Hutamekalin P, 2010, J PHARMACOL SCI, V112, P56, DOI 10.1254/jphs.09180FP
   Johnson LV, 2000, EXP EYE RES, V70, P441, DOI 10.1006/exer.1999.0798
   Johnson LV, 2002, P NATL ACAD SCI USA, V99, P11830, DOI 10.1073/pnas.192203399
   Kapphahn RJ, 2007, EXP EYE RES, V84, P646, DOI 10.1016/j.exer.2006.12.002
   Kisselev AF, 2001, CHEM BIOL, V8, P739, DOI 10.1016/S1074-5521(01)00056-4
   Knupp C, 2002, J STRUCT BIOL, V139, P181, DOI 10.1016/S1047-8477(02)00534-8
   Kunchithapautham K, 2014, J BIOL CHEM, V289, P14534, DOI 10.1074/jbc.M114.564674
   Li L, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0113639
   Li N, 2013, NAT PROTOC, V8, P1155, DOI 10.1038/nprot.2013.065
   Lian H, 2015, NEURON, V85, P101, DOI 10.1016/j.neuron.2014.11.018
   Lim J, 2013, FASEB J, V27, P822, DOI 10.1096/fj.12-220582
   Loeffler KU, 1997, GRAEF ARCH CLIN EXP, V235, P248, DOI 10.1007/BF00941767
   Lohman RJ, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00414-w
   Malek G, 2003, AM J PATHOL, V162, P413, DOI 10.1016/S0002-9440(10)63836-9
   Maminishkis A, 2006, INVEST OPHTH VIS SCI, V47, P3612, DOI 10.1167/iovs.05-1622
   Maminishkis Arvydas, 2010, J Vis Exp, DOI 10.3791/2032
   Marin-Castano ME, 2005, INVEST OPHTH VIS SCI, V46, P3331, DOI 10.1167/iovs.04-1224
   Morrison CJ, 2009, CURR OPIN CELL BIOL, V21, P645, DOI 10.1016/j.ceb.2009.06.006
   Mullins RF, 2014, AM J PATHOL, V184, P3142, DOI 10.1016/j.ajpath.2014.07.017
   NORGAUER J, 1993, EUR J BIOCHEM, V217, P289, DOI 10.1111/j.1432-1033.1993.tb18245.x
   Nozaki M, 2006, P NATL ACAD SCI USA, V103, P2328, DOI 10.1073/pnas.0408835103
   Proctor LM, 2004, BRIT J PHARMACOL, V142, P756, DOI 10.1038/sj.bjp.0705819
   Ratajczak J, 2004, BLOOD, V103, P2071, DOI 10.1182/blood-2003-06-2099
   Reale E, 2001, MATRIX BIOL, V20, P37, DOI 10.1016/S0945-053X(00)00132-3
   Ricklin D, 2010, NAT IMMUNOL, V11, P785, DOI 10.1038/ni.1923
   Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089
   Scholl HPN, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002593
   Seddon JM, 2013, NAT GENET, V45, P1366, DOI 10.1038/ng.2741
   Shang F, 2012, MOL ASPECTS MED, V33, P446, DOI 10.1016/j.mam.2012.04.001
   Skandalis SS, 2012, CURR MOL MED, V12, P1068
   Soriano GP, 2017, METHODS MOL BIOL, V1491, P205, DOI 10.1007/978-1-4939-6439-0_15
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Syggelos SA, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/230805
   Toomey CB, 2018, INVEST OPHTH VIS SCI, V59, P662, DOI 10.1167/iovs.17-23134
   Verdoes M, 2006, CHEM BIOL, V13, P1217, DOI 10.1016/j.chembiol.2006.09.013
   Yang P, 2014, INVEST OPHTH VIS SCI, V55, P3012, DOI 10.1167/iovs.13-13554
   Yehoshua Z, 2014, OPHTHALMOLOGY, V121, P693, DOI 10.1016/j.ophtha.2013.09.044
   Zhang XY, 2008, INVEST OPHTH VIS SCI, V49, P3622, DOI 10.1167/iovs.07-1559
NR 69
TC 34
Z9 34
U1 0
U2 3
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD JUN 26
PY 2018
VL 8
AR 9679
DI 10.1038/s41598-018-28143-0
PG 14
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA GK5RH
UT WOS:000436233600007
PM 29946065
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Kim, GN
   Shin, MH
   Ahn, JY
   Han, YS
   Chung, IY
   Seo, SW
   Park, JM
   Yoo, JM
   Kim, SJ
AF Kim, Gyu-Nam
   Shin, Min-Ho
   Ahn, Ja-Young
   Han, Yong-Seop
   Chung, In-Young
   Seo, Seong-Wook
   Park, Jong-Moon
   Yoo, Ji-Myong
   Kim, Seong-Jae
TI Extensive Submacular Hemorrhage After Trabeculectomy With Mitomycin C
SO JOURNAL OF GLAUCOMA
LA English
DT Article
DE age-related macular degeneration; submacular hemorrhage; trabeculectomy
ID SUBRETINAL HEMORRHAGE
AB Purpose: We report the occurrence of an extensive submacular hemorrhage after trabeculectomy with mitomycin C in a patient with an occult choroidal neovascular membrane (CNVM).
   Patients and Methods: A 66-year-old man had a 3-year history of primary open-angle glaucoma in the left eye, which had been treated with topical antiglaucoma medication. The patient had age-related macular degeneration with an occult CNVM, for which he had received 5 intravitreal injections of ranibizumab and 5 intravitreal injections of bevacizumab in the left eye over a 3-year period. As intraocular pressure was not under control in the left eye over a 2-month period, trabeculectomy with mitomycin C was performed.
   Results: On the first postoperative day, intraocular pressure was 8 mm Hg with a well-formed bleb in the left eye. However, extensive subretinal hemorrhage was observed, and the patient underwent pneumatic displacement and pars plana vitrectomy to remove the hemorrhage. After 7 months, extensive subretinal fibrosis was observed and visual acuity was low (hand movement only).
   Conclusions: To our knowledge, this is the first report of an extensive submacular hemorrhage after trabeculectomy with mitomycin C in a patient with an occult CNVM.
C1 [Kim, Gyu-Nam; Shin, Min-Ho; Ahn, Ja-Young; Han, Yong-Seop; Chung, In-Young; Seo, Seong-Wook; Park, Jong-Moon; Yoo, Ji-Myong; Kim, Seong-Jae] Gyeongsang Natl Univ Hosp, Sch Med, Dept Ophthalmol, Jinju, South Korea.
   [Kim, Gyu-Nam; Shin, Min-Ho; Ahn, Ja-Young; Han, Yong-Seop; Chung, In-Young; Seo, Seong-Wook; Park, Jong-Moon; Yoo, Ji-Myong; Kim, Seong-Jae] Gyeongsang Natl Univ, Inst Hlth Sci, Jinju, South Korea.
   [Park, Jong-Moon] Gyeongsang Natl Univ, Changwon Hosp, Dept Ophthalmol, Chang Won, South Korea.
C3 Gyeongsang National University; Gyeongsang National University Hospital;
   Gyeongsang National University; Gyeongsang National University
RP Kim, SJ (通讯作者)，Univ Hosp, Dept Ophthalmol, Gyeongsang Natl, 79 Gangnam Ro, Jinju 52727, South Korea.
EM maya12kim@naver.com
OI chung, inyoung/0000-0002-4524-6771
FU Basic Science Research Program through the National Research Foundation
   of Korea (NRF) - Ministry of Science, ICT & Future Planning
   [NRF-2015R1C1A1A02037702]
FX Supported by the Basic Science Research Program through the National
   Research Foundation of Korea (NRF) funded by the Ministry of Science,
   ICT & Future Planning (NRF-2015R1C1A1A02037702).
CR Avery RL, 1996, RETINA-J RET VIT DIS, V16, P183, DOI 10.1097/00006982-199616030-00001
   BRUBAKER RF, 1983, SURV OPHTHALMOL, V27, P281, DOI 10.1016/0039-6257(83)90228-X
   GLATT H, 1982, AM J OPHTHALMOL, V94, P762, DOI 10.1016/0002-9394(82)90301-4
   Kara N, 2013, EYE, V27, P940, DOI 10.1038/eye.2013.116
   Seah S K, 1995, J Glaucoma, V4, P73
   TOTH CA, 1991, ARCH OPHTHALMOL-CHIC, V109, P723, DOI 10.1001/archopht.1991.01080050139046
NR 6
TC 0
Z9 0
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1057-0829
EI 1536-481X
J9 J GLAUCOMA
JI J. Glaucoma
PD MAY
PY 2018
VL 27
IS 5
BP E92
EP E94
DI 10.1097/IJG.0000000000000923
PG 3
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA GE8XV
UT WOS:000431515400001
PM 29485475
DA 2022-11-30
ER

PT J
AU Bretz, CA
   Divoky, V
   Prchal, J
   Kunz, E
   Simmons, AB
   Wang, HB
   Hartnett, ME
AF Bretz, Colin A.
   Divoky, Vladimir
   Prchal, Josef
   Kunz, Eric
   Simmons, Aaron B.
   Wang, Haibo
   Hartnett, Mary Elizabeth
TI Erythropoietin Signaling Increases Choroidal Macrophages and Cytokine
   Expression, and Exacerbates Choroidal Neovascularization
SO SCIENTIFIC REPORTS
LA English
DT Article
ID MACULAR DEGENERATION; BRUCHS MEMBRANE; RECEPTOR GENE; CELLS; ACTIVATION;
   ANGIOGENESIS; ACCUMULATION; BIOMARKERS; ANTIBODIES; CAPACITY
AB Erythropoietin (EPO) is recognized for neuroprotective and angiogenic effects and has been associated with aging and neovascular age-related macular degeneration (AMD). We hypothesized that systemic EPO facilitates the development of choroidal neovascularization (CNV). Wild type mice expressed murine EPOR (mWtEPOR) in RPE/choroids at baseline and had significantly increased serum EPO after laser treatment. To test the role of EPO signaling, we used human EPOR knock-in mice with the mWtEPOR gene replaced by either the human EPOR gene (hWtEPOR) or a mutated human EPOR gene (hMtEPOR) in a laser-induced choroidal neovascularization (LCNV) model. Loss-of-function hWtEPOR mice have reduced downstream activation, whereas gain-of-function hMtEPOR mice have increased EPOR signaling. Compared to littermate controls (mWtEPOR), hMtEPOR with increased EPOR signaling developed larger CNV lesions. At baseline, hMtEPOR mice had increased numbers of macrophages, greater expression of macrophage markers F4/80 and CD206, and following laser injury, had greater expression of cytokines CCL2, CXCL10, CCL22, IL-6, and IL-10 than mWtEPOR controls. These data support a hypothesis that injury from age-and AMD-related changes in the RPE/choroid leads to choroidal neovascularization through EPOR-mediated cytokine production.
C1 [Bretz, Colin A.; Kunz, Eric; Simmons, Aaron B.; Wang, Haibo; Hartnett, Mary Elizabeth] Univ Utah, John A Moran Eye Ctr, Salt Lake City, UT 84112 USA.
   [Divoky, Vladimir] Palacky Univ, Dept Biol, Olomouc, Czech Republic.
   [Prchal, Josef] Univ Utah, Dept Hematol, Salt Lake City, UT USA.
C3 Utah System of Higher Education; University of Utah; Palacky University
   Olomouc; Utah System of Higher Education; University of Utah
RP Hartnett, ME (通讯作者)，Univ Utah, John A Moran Eye Ctr, Salt Lake City, UT 84112 USA.
EM ME.Hartnett@hsc.utah.edu
OI Bretz, Colin/0000-0001-5296-9399
FU National Institutes of Health [EY014800]; Research to Prevent Blindness,
   Inc., New York, NY; (NEI/NIH) Mechanisms of Angiogenesis in Retinopathy
   of Prematurity [R01 EY015130]; (NEI/NIH) Endothelial Transmigration in
   Neovascular Age-related Macular Degeneration (MEH-PI) [R01 EY017011];
   CORE Vision Research Grant, University of Utah [T32 EY024234]; Czech
   Republic Program KONTAKT II [LH15223];  [GP14-10687P]; NATIONAL EYE
   INSTITUTE [R01EY017011, P30EY014800, T32EY024234, R01EY015130] Funding
   Source: NIH RePORTER
FX This work was supported by National Institutes of Health (EY014800), and
   an Unrestricted Grant from Research to Prevent Blindness, Inc., New
   York, NY, to the Department of Ophthalmology & Visual Sciences,
   University of Utah. R01 EY015130 (NEI/NIH) Mechanisms of Angiogenesis in
   Retinopathy of Prematurity (MEH-PI). R01 EY017011 (NEI/NIH) Endothelial
   Transmigration in Neovascular Age-related Macular Degeneration (MEH-PI).
   T32 EY024234 CORE Vision Research Grant, University of Utah. VD
   laboratory is supported by Czech Republic Program KONTAKT II (LH15223)
   and GP14-10687P.
CR Apte RS, 2006, PLOS MED, V3, P1371, DOI 10.1371/journal.pmed.0030310
   Bhutto IA, 2016, BRIT J OPHTHALMOL, V100, P720, DOI 10.1136/bjophthalmol-2015-308290
   Brines M, 2006, KIDNEY INT, V70, P246, DOI 10.1038/sj.ki.5001546
   Cao XG, 2011, PATHOL INT, V61, P528, DOI 10.1111/j.1440-1827.2011.02695.x
   Chan KK, 2017, ONCOTARGET, V8, P38251, DOI 10.18632/oncotarget.16368
   Cherepanoff S, 2010, BRIT J OPHTHALMOL, V94, P918, DOI 10.1136/bjo.2009.165563
   Combadiere C, 2007, J CLIN INVEST, V117, P2920, DOI 10.1172/JCI31692
   Ding SLS, 2016, EYE, V30, P1293, DOI 10.1038/eye.2016.94
   Divoky V, 2002, BLOOD, V99, P3873, DOI 10.1182/blood-2002-01-0301
   Divoky V, 2001, P NATL ACAD SCI USA, V98, P986, DOI 10.1073/pnas.98.3.986
   Divoky V, 2016, J MOL MED, V94, P597, DOI 10.1007/s00109-015-1375-y
   Ebie AZ, 2007, J MOL BIOL, V366, P517, DOI 10.1016/j.jmb.2006.11.035
   Elliott S, 2006, BLOOD, V107, P1892, DOI 10.1182/blood-2005-10-4066
   Ershler WB, 2005, J AM GERIATR SOC, V53, P1360, DOI 10.1111/j.1532-5415.2005.53416.x
   Grimm C, 2002, NAT MED, V8, P718, DOI 10.1038/nm723
   He LZ, 2013, AM J PATHOL, V182, P2407, DOI 10.1016/j.ajpath.2013.02.032
   Hoch M, 2011, CELL STEM CELL, V9, P131, DOI 10.1016/j.stem.2011.07.001
   Kang J, 2014, CARDIOVASC RES, V104, P171, DOI 10.1093/cvr/cvu180
   Kelly J, 2007, J CLIN INVEST, V117, P3421, DOI 10.1172/JCI32430
   KILLINGSWORTH MC, 1990, EYE, V4, P613, DOI 10.1038/eye.1990.86
   Kirkeby A, 2007, J NEUROSCI METH, V164, P50, DOI 10.1016/j.jneumeth.2007.03.026
   Lifshitz L, 2010, HAEMATOL-HEMATOL J, V95, P1823, DOI 10.3324/haematol.2010.025015
   Liu JY, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0050719, 10.1371/journal.pone.0064143, 10.1371/journal.pone.0057473]
   Luhmann UFO, 2009, INVEST OPHTH VIS SCI, V50, P5934, DOI 10.1167/iovs.09-3462
   Maralani HG, 2015, RETINA-J RET VIT DIS, V35, P459, DOI 10.1097/IAE.0000000000000338
   McCloskey M, 2013, INVEST OPHTH VIS SCI, V54, P2020, DOI 10.1167/iovs.13-11625
   McLeod DS, 2016, INVEST OPHTH VIS SCI, V57, P5843, DOI 10.1167/iovs.16-20049
   Mo FM, 2010, INVEST OPHTH VIS SCI, V51, P4226, DOI 10.1167/iovs.09-3910
   Nakamura R, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8847
   PENFOLD PL, 1985, GRAEF ARCH CLIN EXP, V223, P69, DOI 10.1007/BF02150948
   Rezar-Dreindl S, 2016, INVEST OPHTH VIS SCI, V57, P4144, DOI 10.1167/iovs.16-19772
   Robbie SJ, 2016, NEUROBIOL AGING, V40, P110, DOI 10.1016/j.neurobiolaging.2015.12.019
   Sakurada Y, 2015, OPHTHALMIC RES, V53, P2, DOI 10.1159/000365487
   Sakurai E, 2003, INVEST OPHTH VIS SCI, V44, P3578, DOI 10.1167/iovs.03-0097
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P774, DOI 10.1001/archopht.123.6.774
   Shah Shaival S, 2009, BMC Res Notes, V2, P234, DOI 10.1186/1756-0500-2-234
   Tankiewicz-Kwedlo A, 2016, MOL CELL BIOCHEM, V421, P1, DOI 10.1007/s11010-016-2779-x
   Tsutsumi C, 2003, J LEUKOCYTE BIOL, V74, P25, DOI 10.1189/jlb.0902436
   Wang HB, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0157748
   Wang HB, 2012, AM J PATHOL, V180, P1243, DOI 10.1016/j.ajpath.2011.11.031
   Wang HB, 2011, INVEST OPHTH VIS SCI, V52, P8271, DOI 10.1167/iovs.11-8230
   Wang SSS, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.18
   Wang ZY, 2009, MED HYPOTHESES, V72, P448, DOI 10.1016/j.mehy.2008.09.055
   WEN DY, 1994, J BIOL CHEM, V269, P22839
   Yang Y, 2016, SCI REP-UK, V6, DOI 10.1038/srep30933
   Yang ZH, 2014, AM J PATHOL, V184, P1230, DOI 10.1016/j.ajpath.2013.12.023
   Yodoi Y, 2007, INVEST OPHTH VIS SCI, V48, P5464, DOI 10.1167/iovs.07-0093
   Yu XB, 2001, BLOOD, V98, P475, DOI 10.1182/blood.V98.2.475
   Zajac E, 2013, BLOOD, V122, P4054, DOI 10.1182/blood-2013-05-501494
NR 49
TC 14
Z9 16
U1 0
U2 4
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD FEB 1
PY 2018
VL 8
AR 2161
DI 10.1038/s41598-018-20520-z
PG 12
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA FU3YD
UT WOS:000423787500136
PM 29391474
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Zarrouk, A
   Vejux, A
   Mackrill, J
   O'Callaghan, Y
   Hammami, M
   O'Brien, N
   Lizard, G
AF Zarrouk, Amira
   Vejux, Anne
   Mackrill, John
   O'Callaghan, Yvonne
   Hammami, Mohamed
   O'Brien, Nora
   Lizard, Gerard
TI Involvement of oxysterols in age-related diseases and ageing processes
SO AGEING RESEARCH REVIEWS
LA English
DT Review
DE Oxysterols; Ageing; Age-related diseases
ID PIGMENT EPITHELIAL-CELLS; AMYLOID PRECURSOR PROTEIN;
   SMOOTH-MUSCLE-CELLS; 158N MURINE OLIGODENDROCYTES; MARROW STROMAL CELLS;
   CHOLESTEROL OXIDATION-PRODUCTS; REGULATE GENE-EXPRESSION; OXYGEN SPECIES
   FORMATION; VASCULAR RISK-FACTORS; HUMAN MONOCYTIC CELLS
AB Ageing is accompanied by increasing vulnerability to major pathologies (atherosclerosis, Alzheimer's disease, age-related macular degeneration, cataract, and osteoporosis) which can have similar underlying pathoetiologies. All of these diseases involve oxidative stress, inflammation and/or cell death processes, which are triggered by cholesterol oxide derivatives, also named oxysterols. These oxidized lipids result either from spontaneous and/or enzymatic oxidation of cholesterol on the steroid nucleus or on the side chain. The ability of oxysterols to induce severe dysfunctions in organelles (especially mitochondria) plays key roles in RedOx homeostasis, inflammatory status, lipid metabolism, and in the control of cell death induction, which may at least in part contribute to explain the potential participation of these molecules in ageing processes and in age related diseases. As no efficient treatments are currently available for most of these diseases, which are predicted to become more prevalent due to the increasing life expectancy and average age, a better knowledge of the biological activities of the different oxysterols is of interest, and constitutes an important step toward identification of pharmacological targets for the development of new therapeutic strategies. (C) 2014 Elsevier B.V. All rights reserved.
C1 [Zarrouk, Amira; Vejux, Anne; Lizard, Gerard] Univ Bourgogne, INSERM, Inflammat & Lipid Metab EA 7270, Team Biochem Peroxisome, Dijon, France.
   [Zarrouk, Amira; O'Callaghan, Yvonne; O'Brien, Nora] Natl Univ Ireland Univ Coll Cork, Sch Food & Nutr Sci, Cork, Ireland.
   [Zarrouk, Amira; Hammami, Mohamed] Univ Monastir, Fac Med, LR12ES05, Lab NAFS Nutr Funct Food & Vasc Hlth, Monastir, Tunisia.
   [Zarrouk, Amira; Mackrill, John] Natl Univ Ireland Univ Coll Cork, BioSci Inst, Dept Physiol, Cork, Ireland.
C3 Institut National de la Sante et de la Recherche Medicale (Inserm);
   Universite de Bourgogne; University College Cork; Universite de
   Monastir; University College Cork
RP Lizard, G (通讯作者)，Univ Bourgogne, INSERM, Inflammat & Lipid Metab EA 7270, Team Biochem Peroxisome, Dijon, France.
EM gerard.lizard@u-bourgogne.fr
RI Vejux, Anne/C-1509-2019; Lizard, Gerard/B-2439-2012
FU Universite de Bourgogne (Ecole Doctorale Environnements-Sante); Erasmus
   program (Universite de Bourgogne, Dijon/University College of Cork
   (UCC), Cork); Campus France (ULYSSES program)
FX This work was supported by grants from the Universite de Bourgogne
   (Ecole Doctorale Environnements-Sante), Erasmus program (Universite de
   Bourgogne, Dijon/University College of Cork (UCC), Cork), Campus France
   (ULYSSES program) and the French Embassy in Irlande via Dr Claude Detrez
   for his efficient support.
CR Abad-Rodriguez J, 2004, J CELL BIOL, V167, P953, DOI 10.1083/jcb.200404149
   Abuznait AH, 2012, ACS CHEM NEUROSCI, V3, P820, DOI 10.1021/cn300077c
   Aghaloo TL, 2007, J ORTHOP RES, V25, P1488, DOI 10.1002/jor.20437
   Alexandrov P, 2005, NEUROREPORT, V16, P909, DOI 10.1097/00001756-200506210-00007
   Amantea CM, 2008, J CELL BIOCHEM, V105, P424, DOI 10.1002/jcb.21840
   Bartzokis G, 2011, NEUROBIOL AGING, V32, P1341, DOI 10.1016/j.neurobiolaging.2009.08.007
   Berzelius J.J., 1925, LEHRBUCH CHEMIE, p[1825, 525]
   Bjorkhem I, 2006, J INTERN MED, V260, P493, DOI 10.1111/j.1365-2796.2006.01725.x
   Bjorkhem I, 2004, ARTERIOSCL THROM VAS, V24, P806, DOI 10.1161/01.ATV.0000120374.59826.1b
   Bjorkhem I, 1998, J LIPID RES, V39, P1594
   BJORKHEM I, 1968, ACTA CHEM SCAND, V22, P1595, DOI 10.3891/acta.chem.scand.22-1595
   Bjorkhem I, 2009, J LIPID RES, V50, pS213, DOI 10.1194/jlr.R800025-JLR200
   Blennow K, 2006, LANCET, V368, P387, DOI 10.1016/S0140-6736(06)69113-7
   Boccardi V, 2014, AGEING RES REV, V15, P1, DOI 10.1016/j.arr.2013.12.006
   Bodovitz S, 1996, J BIOL CHEM, V271, P4436
   Bogdanovica N, 2001, NEUROSCI LETT, V314, P45, DOI 10.1016/S0304-3940(01)02277-7
   Boitard C, 2002, DIABETES METAB, V28, pS33
   Boumhras M., 2012, THESIS U BOURGOGNE D
   Bretillon L, 2000, NEUROSCI LETT, V293, P87, DOI 10.1016/S0304-3940(00)01466-X
   Bretillon L, 2007, CURR EYE RES, V32, P361, DOI 10.1080/02713680701231857
   Brian G, 2001, B WORLD HEALTH ORGAN, V79, P249
   Brown AJ, 1999, ATHEROSCLEROSIS, V142, P1, DOI 10.1016/S0021-9150(98)00196-8
   Brown J, 2004, J BIOL CHEM, V279, P34674, DOI 10.1074/jbc.M402324200
   Bu GJ, 2009, NAT REV NEUROSCI, V10, P333, DOI 10.1038/nrn2620
   Burns M, 2002, ANN NY ACAD SCI, V977, P367, DOI 10.1111/j.1749-6632.2002.tb04839.x
   Buttari B, 2013, BIOCHEM PHARMACOL, V86, P130, DOI 10.1016/j.bcp.2013.04.008
   Catarino S, 2012, ACTA OPHTHALMOL, V90, pE255, DOI 10.1111/j.1755-3768.2011.02350.x
   Cenedella RJ, 1996, SURV OPHTHALMOL, V40, P320, DOI 10.1016/S0039-6257(96)82007-8
   Cheng YW, 2005, FOOD CHEM TOXICOL, V43, P617, DOI 10.1016/j.fct.2005.01.007
   Curcio CA, 2005, EXP EYE RES, V81, P731, DOI 10.1016/j.exer.2005.04.012
   Dasari B, 2011, BMC OPHTHALMOL, V11, DOI 10.1186/1471-2415-11-22
   Dasari B, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-22
   Daugvilaite V, 2014, EUR J IMMUNOL, V44, P1904, DOI 10.1002/eji.201444493
   De Boussac H, 2013, EXPERT OPIN THER TAR, V17, P1029, DOI 10.1517/14728222.2013.820708
   de Boussac H, 2013, AM J CANCER RES, V3, P58
   de Medina P, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2835
   de Medina P, 2011, CHEM PHYS LIPIDS, V164, P432, DOI 10.1016/j.chemphyslip.2011.05.005
   Deckert V, 2002, BRIT J PHARMACOL, V137, P655, DOI 10.1038/sj.bjp.0704920
   Deckert V, 1997, CIRCULATION, V95, P723, DOI 10.1161/01.CIR.95.3.723
   Dentchev T, 2003, MOL VIS, V9, P184
   DI FRISCO S, 1953, Boll Soc Ital Biol Sper, V29, P1351
   Di Paolo G, 2011, NAT REV NEUROSCI, V12, P284, DOI 10.1038/nrn3012
   Diczfalusy U, 2013, BIOCHIMIE, V95, P455, DOI 10.1016/j.biochi.2012.06.016
   Ding XY, 2009, PROG RETIN EYE RES, V28, P1, DOI 10.1016/j.preteyeres.2008.10.001
   Dreyfus MA, 2005, J PHYS CHEM A, V109, P6242, DOI 10.1021/jp050606f
   Dufour J, 2012, CURR OPIN PHARMACOL, V12, P724, DOI 10.1016/j.coph.2012.06.012
   Dugas B, 2010, EUR J NUTR, V49, P435, DOI 10.1007/s00394-010-0102-2
   Duran M.J., 2010, CELL MOL BIOL NOISY, V56, P1434
   DuSell CD, 2010, ENDOCRINOLOGY, V151, P3675, DOI 10.1210/en.2010-0080
   Ehehalt R, 2003, J CELL BIOL, V160, P113, DOI 10.1083/jcb.200207113
   Ehrlich D, 2012, J NEUROL SCI, V322, P92, DOI 10.1016/j.jns.2012.07.002
   Famer D, 2007, BIOCHEM BIOPH RES CO, V359, P46, DOI 10.1016/j.bbrc.2007.05.033
   Fassbender K, 2001, P NATL ACAD SCI USA, V98, P5856, DOI 10.1073/pnas.081620098
   FELDMAN GERALD L., 1965, INVEST OPHTHAL MOL, V4, P162
   Fiolaki A, 2014, INT J NEUROSCI, V124, P1, DOI 10.3109/00207454.2013.821988
   Fiorenza MT, 2013, J BIOL REG HOMEOS AG, V27, P23
   Fotenos AF, 2005, NEUROLOGY, V64, P1032, DOI 10.1212/01.WNL.0000154530.72969.11
   Fourgeux C, 2014, BIOCHEM BIOPH RES CO, V446, P775, DOI 10.1016/j.bbrc.2014.01.118
   Freeman MR, 2004, J CELL BIOCHEM, V91, P54, DOI 10.1002/jcb.10724
   Galea E, 2012, BBA-MOL BASIS DIS, V1822, P1475, DOI 10.1016/j.bbadis.2012.02.005
   Gamba P, 2014, AGING CELL, V13, P561, DOI 10.1111/acel.12206
   Gao C, 2012, REV NEUROSCIENCE, V23, P1, DOI [10.1515/rns.2011.061, 10.1515/RNS.2011.061]
   Gargiulo S, 2014, CURR PHARM DESIGN, V20, P2993, DOI 10.2174/13816128113196660701
   Gargiulo S, 2011, FREE RADICAL BIO MED, V51, P844, DOI 10.1016/j.freeradbiomed.2011.05.030
   Gatto D, 2013, TRENDS IMMUNOL, V34, P336, DOI 10.1016/j.it.2013.01.007
   Geyeregger R, 2006, CELL MOL LIFE SCI, V63, P524, DOI 10.1007/s00018-005-5398-3
   Ghribi O, 2006, EXP NEUROL, V200, P460, DOI 10.1016/j.expneurol.2006.03.019
   Girao H, 1998, EXP EYE RES, V66, P645, DOI 10.1006/exer.1998.0465
   Gramajo AL, 2010, INVEST OPHTH VIS SCI, V51, P1164, DOI 10.1167/iovs.09-3443
   Hannedouche S, 2011, NATURE, V475, P524, DOI 10.1038/nature10280
   Harman D, 2003, ANTIOXID REDOX SIGN, V5, P557, DOI 10.1089/152308603770310202
   Hayden JM, 2002, J LIPID RES, V43, P26
   He CY, 2013, AM J PATHOL, V183, P626, DOI 10.1016/j.ajpath.2013.04.028
   Helmschrodt C, 2013, CLIN CHIM ACTA, V425, P3, DOI 10.1016/j.cca.2013.06.022
   Heverin M, 2004, J LIPID RES, V45, P186, DOI 10.1194/jlr.M300320-JLR200
   Hoang JJ, 2013, BIOCHEM PHARMACOL, V86, P168, DOI 10.1016/j.bcp.2013.04.005
   Hu HL, 2005, DEVELOPMENT, V132, P49, DOI 10.1242/dev.01564
   Huang JD, 2012, BBA-MOL CELL BIOL L, V1821, P637, DOI 10.1016/j.bbalip.2012.01.013
   Hudry E, 2010, MOL THER, V18, P44, DOI 10.1038/mt.2009.175
   Iuliano L, 2011, CHEM PHYS LIPIDS, V164, P457, DOI 10.1016/j.chemphyslip.2011.06.006
   Jack CR, 2010, LANCET NEUROL, V9, P119, DOI 10.1016/S1474-4422(09)70299-6
   Jack CR, 2009, BRAIN, V132, P1355, DOI 10.1093/brain/awp062
   Javitt NB, 2009, CURR OPIN OPHTHALMOL, V20, P151, DOI 10.1097/ICU.0b013e32832af468
   Jenny NS, 2012, DISCOV MED, V13, P451
   Jia GH, 2007, AUTOPHAGY, V3, P63, DOI 10.4161/auto.3427
   Joffre C, 2007, CURR EYE RES, V32, P271, DOI 10.1080/02713680601187951
   Johnson ML, 2004, J BONE MINER RES, V19, P1749, DOI 10.1359/JBMR.040816
   Joseph SB, 2003, NAT MED, V9, P213, DOI 10.1038/nm820
   Jusakul A, 2011, LIPIDS HEALTH DIS, V10, DOI 10.1186/1476-511X-10-44
   Kahn E, 2006, ANAL QUANT CYTOL, V28, P316
   Kha HT, 2004, J BONE MINER RES, V19, P830, DOI 10.1359/JBMR.040115
   Khalifa SAM, 2014, BIOCHEM BIOPH RES CO, V446, P681, DOI 10.1016/j.bbrc.2013.12.134
   Khatib S, 2014, BIOCHEM BIOPH RES CO, V446, P709, DOI 10.1016/j.bbrc.2013.12.116
   Kim DH, 2008, BIOPHYS J, V95, P620, DOI 10.1529/biophysj.107.114983
   Kim WK, 2007, J BONE MINER RES, V22, P1711, DOI 10.1359/JBMR.070710
   Kim WS, 2009, J ALZHEIMERS DIS, V16, P121, DOI 10.3233/JAD-2009-0944
   Kolsch H, 2004, NEUROSCI LETT, V368, P303, DOI 10.1016/j.neulet.2004.07.031
   Koschack J, 2009, NEUROBIOL AGING, V30, P898, DOI 10.1016/j.neurobiolaging.2007.10.010
   Kristofikova Z., 2012, NEUROCHEM RES, V37, P604
   Larrayoz IM, 2010, INVEST OPHTH VIS SCI, V51, P4942, DOI 10.1167/iovs.09-4854
   Larsson H, 2007, FREE RADICAL BIO MED, V43, P695, DOI 10.1016/j.freeradbiomed.2007.04.033
   Leduc V, 2010, TRENDS MOL MED, V16, P469, DOI 10.1016/j.molmed.2010.07.008
   Lee CS, 2007, NEUROCHEM RES, V32, P87, DOI 10.1007/s11064-006-9230-8
   Lemaire S, 1998, FEBS LETT, V440, P434, DOI 10.1016/S0014-5793(98)01496-3
   Lemaire-Ewing S, 2005, CELL BIOL TOXICOL, V21, P97, DOI 10.1007/s10565-005-0141-2
   Lemaire-Ewing S, 2009, CELL BIOL TOXICOL, V25, P127, DOI 10.1007/s10565-008-9063-0
   Leonarduzzi G, 2006, ANTIOXID REDOX SIGN, V8, P375, DOI 10.1089/ars.2006.8.375
   Leonarduzzi G, 2010, MOL NUTR FOOD RES, V54, pS31, DOI 10.1002/mnfr.200900493
   Leoni V, 2011, CHEM PHYS LIPIDS, V164, P515, DOI 10.1016/j.chemphyslip.2011.04.002
   Li W, 2011, BIOCHEM BIOPH RES CO, V409, P711, DOI 10.1016/j.bbrc.2011.05.071
   Lichtstein D, 2000, HYPERTENS RES, V23, pS51, DOI 10.1291/hypres.23.Supplement_S51
   Liochev SI, 2013, FREE RADICAL BIO MED, V60, P1, DOI 10.1016/j.freeradbiomed.2013.02.011
   Liu HM, 2005, J CELL BIOCHEM, V96, P198, DOI 10.1002/jcb.20510
   Liu HM, 2004, LIFE SCI, V76, P533, DOI 10.1016/j.lfs.2004.06.025
   Liu Y, 2009, CURR OPIN IMMUNOL, V21, P431, DOI 10.1016/j.coi.2009.05.011
   Lizard G, 1996, AM J PATHOL, V148, P1625
   Lopez-Otin C, 2013, CELL, V153, P1194, DOI 10.1016/j.cell.2013.05.039
   Lordan S, 2009, J NUTR BIOCHEM, V20, P321, DOI 10.1016/j.jnutbio.2009.01.001
   Lubos E, 2008, FRONT BIOSCI-LANDMRK, V13, P5323, DOI 10.2741/3084
   Lund EG, 1999, P NATL ACAD SCI USA, V96, P7238, DOI 10.1073/pnas.96.13.7238
   Lund EG, 1998, J BIOL CHEM, V273, P34316, DOI 10.1074/jbc.273.51.34316
   Luthra S, 2006, INVEST OPHTH VIS SCI, V47, P5569, DOI 10.1167/iovs.06-0333
   Lutjohann D, 2000, J LIPID RES, V41, P195
   Luu Bang, 1995, Comptes Rendus des Seances de la Societe de Biologie et de ses Filiales, V189, P827
   Malvitte L, 2008, CURR EYE RES, V33, P769, DOI 10.1080/02713680802337397
   Marchant NL, 2013, JAMA NEUROL, V70, P488, DOI 10.1001/2013.jamaneurol.405
   Martin M, 2010, BBA-MOL CELL BIOL L, V1801, P934, DOI 10.1016/j.bbalip.2010.03.011
   Martin MG, 2008, MOL BIOL CELL, V19, P2101, DOI 10.1091/mbc.E07-09-0897
   Martin MG, 2014, EMBO MOL MED, V6, P902, DOI 10.15252/emmm.201303711
   Mast N, 2008, P NATL ACAD SCI USA, V105, P9546, DOI 10.1073/pnas.0803717105
   Matsui H, 1997, CAN J CARDIOL, V13, P373
   Maulik M, 2013, MOL NEUROBIOL, V47, P37, DOI 10.1007/s12035-012-8337-y
   McGowan MH, 1999, J PHARMACOL EXP THER, V289, P1559
   Garcia ANM, 2009, J MOL NEUROSCI, V39, P342, DOI 10.1007/s12031-009-9227-2
   Menendez-Carreno M, 2011, NUTR HOSP, V26, P144, DOI 10.3305/nh.2011.26.1.4690
   Miguet C, 2001, CELL DEATH DIFFER, V8, P83, DOI 10.1038/sj.cdd.4400792
   Min SW, 2013, FRONT AGING NEUROSCI, V5, DOI 10.3389/fnagi.2013.00053
   Mintzer E, 2010, CHEM PHYS LIPIDS, V163, P586, DOI 10.1016/j.chemphyslip.2010.05.001
   Monier S, 2003, BIOCHEM BIOPH RES CO, V303, P814, DOI 10.1016/S0006-291X(03)00412-1
   Monte MJ, 2009, WORLD J GASTROENTERO, V15, P804, DOI 10.3748/wjg.15.804
   Neekhra A, 2007, INVEST OPHTH VIS SCI, V48, P1362, DOI 10.1167/iovs.06-0900
   Negre-Salvayre A, 2010, FREE RADICAL RES, V44, P1125, DOI 10.3109/10715762.2010.498478
   Nelson ER, 2013, BONE, V53, P42, DOI 10.1016/j.bone.2012.11.011
   Nury T, 2014, BIOCHEM BIOPH RES CO, V446, P714, DOI 10.1016/j.bbrc.2013.11.081
   Nury T, 2013, EUR J MED CHEM, V70, P558, DOI 10.1016/j.ejmech.2013.09.028
   Odermatt A, 2014, J STEROID BIOCH MOL
   Okabe A, 2014, REDOX BIOL, V2, P28, DOI 10.1016/j.redox.2013.11.007
   Olkkonen VM, 2013, PROG LIPID RES, V52, P529, DOI 10.1016/j.plipres.2013.06.004
   Otaegui-Arrazola A, 2010, FOOD CHEM TOXICOL, V48, P3289, DOI 10.1016/j.fct.2010.09.023
   Papassotiropoulos A, 2003, ARCH NEUROL-CHICAGO, V60, P29, DOI 10.1001/archneur.60.1.29
   Papassotiropoulos A, 2000, NEUROREPORT, V11, P1959, DOI 10.1097/00001756-200006260-00030
   Pedruzzi E, 2004, MOL CELL BIOL, V24, P10703, DOI 10.1128/MCB.24.24.10703-10717.2004
   Petit-Paitel A, 2010, M S-MED SCI, V26, P516, DOI 10.1051/medsci/2010265516
   Phan HTT, 2013, BBA-BIOMEMBRANES, V1828, P2487, DOI 10.1016/j.bbamem.2013.06.021
   Pikuleva IA, 2006, DRUG METAB DISPOS, V34, P513, DOI 10.1124/dmd.105.008789
   Pikuleva IA, 2014, PROG RETIN EYE RES, V41, P64, DOI 10.1016/j.preteyeres.2014.03.002
   Poli G, 2013, REDOX BIOL, V1, P125, DOI 10.1016/j.redox.2012.12.001
   Pommier AJC, 2010, ONCOGENE, V29, P2712, DOI 10.1038/onc.2010.30
   Prasanthi JRP, 2009, MOL NEURODEGENER, V4, DOI 10.1186/1750-1326-4-1
   Prunet C, 2006, PATHOL BIOL, V54, P22, DOI 10.1016/j.patbio.2004.11.002
   Prunet C, 2006, CYTOM PART A, V69A, P359, DOI 10.1002/cyto.a.20272
   Pulfer MK, 2005, J PHARMACOL EXP THER, V312, P256, DOI 10.1124/jpet.104.073437
   Ragot K, 2013, BIOCHEM PHARMACOL, V86, P67, DOI 10.1016/j.bcp.2013.02.028
   Ragot K, 2011, CHEM PHYS LIPIDS, V164, P469, DOI 10.1016/j.chemphyslip.2011.04.014
   Reddy B.S., 1997, CANCER RES, V37, P1697
   REDDY BS, 1979, CANCER RES, V39, P1521
   Reed B, 2014, JAMA NEUROL, V71, P195, DOI 10.1001/jamaneurol.2013.5390
   Richardson JA, 2007, J CELL BIOCHEM, V100, P1131, DOI 10.1002/jcb.21112
   RIGGS BL, 1992, NEW ENGL J MED, V327, P620
   Robbins DJ, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2002906
   Roher AE, 2002, BIOCHEMISTRY-US, V41, P11080, DOI 10.1021/bi026173d
   Romeo GR, 2008, J BIOL CHEM, V283, P9595, DOI 10.1074/jbc.M710092200
   Royer MC, 2009, J BIOL CHEM, V284, P15826, DOI 10.1074/jbc.M808641200
   Rudkowska I, 2010, MATURITAS, V66, P158, DOI 10.1016/j.maturitas.2009.12.015
   Rudolf M, 2009, J HISTOCHEM CYTOCHEM, V57, P731, DOI 10.1369/jhc.2009.953448
   Ruiz JLM, 2013, BIOCHEM PHARMACOL, V86, P80, DOI 10.1016/j.bcp.2013.02.033
   Rujoi M, 2003, INVEST OPHTH VIS SCI, V44, P1634, DOI 10.1167/iovs.02-0786
   Russell DW, 2000, BBA-MOL CELL BIOL L, V1529, P126, DOI 10.1016/S1388-1981(00)00142-6
   Savouret JF, 2001, J BIOL CHEM, V276, P3054, DOI 10.1074/jbc.M005988200
   SCHENCK GO, 1957, LIEBIGS ANN CHEM, V603, P46
   Schmitz G, 2008, REV PHYSIOL BIOCH P, V160, P93, DOI 10.1007/112_2008_802
   SCHMITZ G, 1991, J LIPID RES, V32, P1539
   Schmitz G, 2009, BBA-MOL CELL BIOL L, V1791, P524, DOI 10.1016/j.bbalip.2008.12.007
   Schreurs BG, 2013, NEUROSCIENCE, V254, P61, DOI 10.1016/j.neuroscience.2013.09.015
   Schroepfer GJ, 2000, PHYSIOL REV, V80, P361, DOI 10.1152/physrev.2000.80.1.361
   Schweizer RAS, 2004, J BIOL CHEM, V279, P18415, DOI 10.1074/jbc.M313615200
   Sharma K, 2014, FRONT AGING NEUROSCI, V6, DOI 10.3389/fnagi.2014.00151
   Shibata N, 2010, CIRC J, V74, P2045, DOI 10.1253/circj.CJ-10-0860
   Silva J, 2003, J BIOL CHEM, V278, P25376, DOI 10.1074/jbc.M301233200
   Silvente-Poirot S, 2014, SCIENCE, V343, P1445, DOI 10.1126/science.1252787
   Simons M, 1998, P NATL ACAD SCI USA, V95, P6460, DOI 10.1073/pnas.95.11.6460
   Slevin M, 2009, VASC CELL, V1, DOI 10.1186/2040-2384-1-4
   Smiljanic K, 2013, LIPIDS, V48, P1069, DOI 10.1007/s11745-013-3836-9
   SMITH LL, 1987, CHEM PHYS LIPIDS, V44, P87, DOI 10.1016/0009-3084(87)90046-6
   SMITH LL, 1979, MUTAT RES, V68, P23, DOI 10.1016/0165-1218(79)90074-0
   SODERBERG M, 1990, J NEUROCHEM, V54, P415, DOI 10.1111/j.1471-4159.1990.tb01889.x
   Solomon A, 2009, NEUROSCI LETT, V462, P89, DOI 10.1016/j.neulet.2009.06.073
   Spann NJ, 2013, NAT IMMUNOL, V14, P893, DOI 10.1038/ni.2681
   SPARKS DL, 1994, EXP NEUROL, V126, P88, DOI 10.1006/exnr.1994.1044
   Stocker R, 2004, PHYSIOL REV, V84, P1381, DOI 10.1152/physrev.00047.2003
   SVENNERHOLM L, 1994, J NEUROCHEM, V63, P1802
   Terlecky SR, 2006, BBA-MOL CELL RES, V1763, P1749, DOI 10.1016/j.bbamcr.2006.08.017
   Testa G, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096795
   Thirumangalakudi L, 2008, J NEUROCHEM, V106, P475, DOI 10.1111/j.1471-4159.2008.05415.x
   Titorenko VI, 2011, TRAFFIC, V12, P252, DOI 10.1111/j.1600-0854.2010.01144.x
   Tosato M, 2007, CLIN INTERV AGING, V2, P401
   Tousoulis D, 2012, CURR VASC PHARMACOL, V10, P4, DOI 10.2174/157016112798829760
   Trousson A, 2009, J NEUROCHEM, V109, P945, DOI 10.1111/j.1471-4159.2009.06009.x
   Vaya J, 2007, J NEUROCHEM, V102, P1727, DOI 10.1111/j.1471-4159.2007.04689.x
   Vaya J, 2011, CHEM PHYS LIPIDS, V164, P438, DOI 10.1016/j.chemphyslip.2011.03.005
   Vejux A, 2005, CYTOM PART A, V64A, P87, DOI 10.1002/cyto.a.20124
   Vejux A, 2009, J NUTR BIOCHEM, V20, P45, DOI 10.1016/j.jnutbio.2007.12.001
   Vejux A, 2011, J OPHTHALMOL, V2011, DOI 10.1155/2011/471947
   Vejux A, 2009, MOL ASPECTS MED, V30, P153, DOI 10.1016/j.mam.2009.02.006
   Vrensen GFJM, 2009, ACTA OPHTHALMOL, V87, P602, DOI 10.1111/j.1755-3768.2009.01674.x
   Vuorinen M, 2011, DEMENT GERIATR COGN, V31, P119, DOI 10.1159/000323810
   Vurusaner B., 2014, FREE RADICAL BIOL ME
   Wang JW, 2004, BIOCHEMISTRY-US, V43, P1010, DOI 10.1021/bi035696y
   Wang SF, 2013, BIOCHEM PHARMACOL, V86, P548, DOI 10.1016/j.bcp.2013.06.006
   Wentworth P, 2003, SCIENCE, V302, P1053, DOI 10.1126/science.1089525
   Wood WG, 2014, J NEUROCHEM, V129, P559, DOI 10.1111/jnc.12637
   Woodruff-Pak DS, 2007, J ALZHEIMERS DIS, V11, P371
   Yoon JH, 2004, HEPATOLOGY, V39, P732, DOI 10.1002/hep.20125
   Yuan XM, 2000, FREE RADICAL BIO MED, V28, P208, DOI 10.1016/S0891-5849(99)00220-8
   ZIGMAN S, 1984, CURR EYE RES, V3, P887, DOI 10.3109/02713688409167206
   Zonta B., 2013, FRONT SYNAPTIC NEURO, V5
   Zuliani G, 2011, BMC NEUROL, V11, DOI 10.1186/1471-2377-11-121
NR 227
TC 116
Z9 118
U1 0
U2 51
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 1568-1637
EI 1872-9649
J9 AGEING RES REV
JI Ageing Res. Rev.
PD NOV
PY 2014
VL 18
BP 148
EP 162
DI 10.1016/j.arr.2014.09.006
PG 15
WC Cell Biology; Geriatrics & Gerontology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Geriatrics & Gerontology
GA AY7XK
UT WOS:000347769000012
PM 25305550
DA 2022-11-30
ER

PT J
AU Stancanelli, R
   Lojkner, LD
   Larsen, KL
   Guardo, M
   Cannava, C
   Tommasini, S
   Ventura, CA
   Calabro, ML
   Micali, N
   Villari, V
   Mazzaglia, A
AF Stancanelli, Rosanna
   Lojkner, Lars Damgaard
   Larsen, Kim Lambertsen
   Guardo, Marta
   Cannava, Carmela
   Tommasini, Silvana
   Ventura, Cinzia Anna
   Calabro, Maria Luisa
   Micali, Norberto
   Villari, Valentina
   Mazzaglia, Antonino
TI Structural and spectroscopic features of
   lutein/butanoyl-beta-cyclodextrin nanoassemblies
SO JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS
LA English
DT Article
DE Nanoassemblies; UV-vis spectroscopy; Light scattering (dynamic); Light
   scattering (static); Zeta-potential
ID AMPHIPHILIC CYCLODEXTRINS; MACULAR DEGENERATION; LIGHT-SCATTERING; GENE
   DELIVERY; LUTEIN; ESTERS; CELLS; SUPPLEMENTATION; NANOPARTICLES; SYSTEMS
AB Lutein, the primary carotenoid present in the central area of the retina of eye appears to be associated with the protection against age-related macular degeneration (the leading cause of blindness in older adults). Its lipophilicity and consequently its scarce water solubility (1.3 x 10(-9) M) represent a drawback for bioavailability. To circumvent these unfavorable characteristics, in this work lutein (Lut) have been encapsulated in amphiphilic cyclodextrin (ACyD) by following the well-established strategy of entrapping a lipophilic drug in CyD carriers. Primary face butyrate modified beta-cyclodextrins (C-4:7) form in water nanoaggregates with a average size of 250 nm and a zeta-potential of about -6 mV. They are able to entrap lutein at 1:6 Lut/ACyD molar ratio by yielding nanoassemblies of vesicular aspect (320 nm and -8 mV) such as observed by static, dynamic and electrophoretic light-scattering. UV-vis measurements revealed that electronic properties of lutein were maintained when interact with ACyD nanoaggregates. The monitoring of the entapped carotenoid leaking from ACyD nanostructures was investigated suggesting the potential of Lut/ACyD nanoassemblies in drug delivery. Published by Elsevier B.V.
C1 [Stancanelli, Rosanna; Guardo, Marta; Cannava, Carmela; Tommasini, Silvana; Ventura, Cinzia Anna; Calabro, Maria Luisa] Univ Messina, Dipartimento Farmacochim, I-98168 Messina, Italy.
   [Lojkner, Lars Damgaard; Larsen, Kim Lambertsen] Aalborg Univ, Dept Chem Biotechnol & Environm Engn, DK-9000 Aalborg, Denmark.
   [Micali, Norberto; Villari, Valentina] CNR IPCF Ist Proc Chimicofis, I-98158 Messina, Italy.
   [Mazzaglia, Antonino] Univ Messina, CNR Inst Studio Mat Nanostrut, Dipartimento Chim Inorgan Chim Analit Chim Fis, I-98166 Messina, Italy.
C3 University of Messina; Aalborg University; Consiglio Nazionale delle
   Ricerche (CNR); Istituto per i Processi Chimico-Fisici (IPCF-CNR);
   University of Messina
RP Stancanelli, R (通讯作者)，Univ Messina, Dipartimento Farmacochim, Vle Annunziata, I-98168 Messina, Italy.
EM rstancanelli@unime.it; antonino.mazzaglia@ismn.cnr.it;
   antonino.mazzaglia@ismn.cnr.it
RI Micali, Norberto/G-7373-2012; Ventura, Cinzia Anna/J-3240-2012; Villari,
   Valentina/N-6695-2015; Larsen, Kim Lambertsen/T-7844-2018
OI Micali, Norberto/0000-0002-0350-2108; Villari,
   Valentina/0000-0002-7907-842X; VENTURA, Cinzia Anna/0000-0002-8743-2046;
   STANCANELLI, Rosanna/0000-0002-8670-7685; Larsen, Kim
   Lambertsen/0000-0003-2172-7519
FU MIUR (Ministero dell'Istruzione, dell'Universita e della Ricerca)
   [2009Z8YTYC]
FX This study was financially supported by MIUR (Ministero dell'Istruzione,
   dell'Universita e della Ricerca), PRIN2009 grant no. 2009Z8YTYC.
CR Adabi SHG, 2010, ARCH GEFLUGELKD, V74, P158
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Berne B.J., 2000, DYNAMIC LIGHT SCATTE
   Bilensoy E., 2002, J PHARM SCI, V91, P1214
   Chew BP, 1996, ANTICANCER RES, V16, P3689
   Chiu CJ, 2007, EXP EYE RES, V84, P229, DOI 10.1016/j.exer.2006.05.015
   Choisnard L, 2007, INT J PHARM, V344, P26, DOI 10.1016/j.ijpharm.2007.06.026
   Choisnard L, 2006, BIOMACROMOLECULES, V7, P515, DOI 10.1021/bm0507655
   Chu B, 1991, LASER LIGHT SCATTERI
   Delgado AV, 2005, PURE APPL CHEM, V77, P1753, DOI 10.1351/pac200577101753
   Diaz-Moscoso A, 2008, CHEM COMMUN, P2001, DOI 10.1039/b718672j
   Diaz-Moscoso A, 2011, BIOMATERIALS, V32, P7263, DOI 10.1016/j.biomaterials.2011.06.025
   Falvey P, 2005, CHEM-EUR J, V11, P1171, DOI 10.1002/chem.200400905
   Gallois-Montbrun D, 2007, J INCL PHENOM MACRO, V57, P131, DOI 10.1007/s10847-006-9208-9
   Glasstone S., 1948, TXB PHYS CHEM
   HUNTER RJ, 1986, FDN COLLOID SCI, V1
   Johnsson M, 2003, J AM CHEM SOC, V125, P757, DOI 10.1021/ja028195t
   Lakshminarayana R, 2010, FOOD CHEM TOXICOL, V48, P1811, DOI 10.1016/j.fct.2010.04.011
   Loane E, 2008, SURV OPHTHALMOL, V53, P68, DOI 10.1016/j.survophthal.2007.10.008
   Mallick S, 2007, DRUG DEV IND PHARM, V33, P865, DOI 10.1080/03639040701429333
   Mazzaglia A, 2003, CHEM-EUR J, V9, P5762, DOI 10.1002/chem.200304861
   McNeil-Watson F, 1998, COLLOID SURFACE A, V140, P53, DOI 10.1016/S0927-7757(97)00267-7
   Micali N, 2006, PHYS REV E, V73, DOI 10.1103/PhysRevE.73.051904
   Munoz-Botella S, 2002, ANAL CHIM ACTA, V468, P161, DOI 10.1016/S0003-2670(02)00629-3
   Olmedilla B, 2003, NUTRITION, V19, P21, DOI 10.1016/S0899-9007(02)00861-4
   Pedersen NR, 2005, TETRAHEDRON-ASYMMETR, V16, P615, DOI 10.1016/j.tetasy.2004.12.009
   Pfitzner I, 2000, BBA-GEN SUBJECTS, V1474, P163, DOI 10.1016/S0304-4165(00)00014-3
   Polyakov NE, 2004, J PHOTOCH PHOTOBIO A, V161, P261, DOI 10.1016/j.nainr.2003.08.007
   PROVENCHER SW, 1982, COMPUT PHYS COMMUN, V27, P229, DOI 10.1016/0010-4655(82)90174-6
   Quaglia F, 2009, BIOMATERIALS, V30, P374, DOI 10.1016/j.biomaterials.2008.09.035
   Richer Stuart, 2004, Optometry, V75, P216, DOI 10.1016/S1529-1839(04)70049-4
   Roux M, 2007, EUR BIOPHYS J BIOPHY, V36, P861, DOI 10.1007/s00249-007-0207-6
   Stancanelli R, 2010, J PHARM SCI-US, V99, P3141, DOI 10.1002/jps.22065
   Stepanek P., 1993, DYNAMIC LIGHT SCATTE, P177
   Villari V, 2008, J PHARM SCI-US, V97, P1703, DOI 10.1002/jps.21067
   ZHANG LX, 1991, CARCINOGENESIS, V12, P2109, DOI 10.1093/carcin/12.11.2109
   ZHANG P, 1991, TETRAHEDRON LETT, V32, P2769, DOI 10.1016/0040-4039(91)85081-F
   Zsila F, 2001, J PHYS CHEM B, V105, P9413, DOI 10.1021/jp011626u
NR 38
TC 18
Z9 18
U1 2
U2 70
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0731-7085
J9 J PHARMACEUT BIOMED
JI J. Pharm. Biomed. Anal.
PD DEC
PY 2012
VL 71
BP 214
EP 218
DI 10.1016/j.jpba.2012.07.034
PG 5
WC Chemistry, Analytical; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Chemistry; Pharmacology & Pharmacy
GA 020BI
UT WOS:000309783200032
PM 22938801
DA 2022-11-30
ER

PT J
AU Narasimhan, A
   Vishnampet, R
AF Narasimhan, Arunn
   Vishnampet, Ramanathan
TI Effect of choroidal blood flow on transscleral retinal drug delivery
   using a porous medium model
SO INTERNATIONAL JOURNAL OF HEAT AND MASS TRANSFER
LA English
DT Article
DE Drug delivery; Biofluids; Human eye; Porous medium; Numerical; Choroidal
   blood flow; Transscleral; Anecortave acetate
ID PHARMACOKINETIC MODEL; POSTERIOR SEGMENT; EYE; PERMEABILITY; DIAMETER;
   ANTERIOR; FINITE; SHAPE
AB Transscleral drug delivery is one of the methods of depositing drug in the posterior segment (comprising retina, choroid, sclera and macula) of the human eye, to treat diseases such as age related macular degeneration (AMD). In this study, the effect of choroidal blood flow on transscleral drug delivery to the retina is investigated using a porous medium model of the sclera and the choroid. A two-dimensional geometrical model of the human eye is constructed from available measurements and determination of physicochemical properties of the sclera and the choroid, such as their effective diffusivity D and porous medium permeability K. Position and time dependent concentrations of the drug in the sclera and the choroid are predicted and the relative magnitudes of the periocular, vitreous and circulation losses are compared for various blood flow velocities U-b. The simulations also predict the transient mean plasma concentration (C) over bar of the drug anecortave desacetate in the choroid and the effect of choroidal blood flow on the peak mean plasma concentration (C) over bar (max). Comparison of predicted (C) over bar with available experimental results is good. (c) 2012 Elsevier Ltd. All rights reserved.
C1 [Narasimhan, Arunn; Vishnampet, Ramanathan] Indian Inst Technol, Dept Mech Engn, Heat Transfer & Thermal Power Lab, Madras 600036, Tamil Nadu, India.
C3 Indian Institute of Technology System (IIT System); Indian Institute of
   Technology (IIT) - Madras
RP Narasimhan, A (通讯作者)，Indian Inst Technol, Dept Mech Engn, Heat Transfer & Thermal Power Lab, Madras 600036, Tamil Nadu, India.
EM arunn@iitm.ac.in
CR Ambati J, 2002, PROG RETIN EYE RES, V21, P145, DOI 10.1016/S1350-9462(01)00018-0
   Atchison DA, 2006, VISION RES, V46, P2236, DOI 10.1016/j.visres.2006.01.004
   Balachandran RK, 2008, PHARM RES-DORDR, V25, P2685, DOI 10.1007/s11095-008-9691-3
   Barza M, 1989, Infect Dis Clin North Am, V3, P533
   Dahlin DC, 2007, SURV OPHTHALMOL, V52, pS49, DOI 10.1016/j.survophthal.2006.11.002
   Dubbelman M, 2006, VISION RES, V46, P993, DOI 10.1016/j.visres.2005.09.021
   Edwards A, 1998, AICHE J, V44, P214, DOI 10.1002/aic.690440123
   FATT I, 1970, EXP EYE RES, V10, P243, DOI 10.1016/S0014-4835(70)80035-5
   Friedrich S, 1997, ANN BIOMED ENG, V25, P303, DOI 10.1007/BF02648045
   HAYREH SS, 1983, INT OPHTHALMOL, V6, P85, DOI 10.1007/BF00127636
   Kaiser PK, 2007, SURV OPHTHALMOL, V52, pS62, DOI 10.1016/j.survophthal.2006.10.015
   KANAI A, 1972, INVEST OPHTH VISUAL, V11, P816
   Kim H, 2004, INVEST OPHTH VIS SCI, V45, P2722, DOI 10.1167/iovs.04-0091
   KOMAI Y, 1991, INVEST OPHTH VIS SCI, V32, P2244
   Lee TWY, 2004, J OCUL PHARMACOL TH, V20, P43, DOI 10.1089/108076804772745455
   Lee TWY, 2004, J OCUL PHARMACOL TH, V20, P55, DOI 10.1089/108076804772745464
   Margolis R, 2009, AM J OPHTHALMOL, V147, P811, DOI 10.1016/j.ajo.2008.12.008
   MARSHALL GE, 1995, BRIT J OPHTHALMOL, V79, P57, DOI 10.1136/bjo.79.1.57
   Missel PJ, 2002, ANN BIOMED ENG, V30, P1128, DOI 10.1114/1.1521417
   Nagaoka T, 2004, ARCH OPHTHALMOL-CHIC, V122, P1477, DOI 10.1001/archopht.122.10.1477
   Norman RE, 2010, EXP EYE RES, V90, P277, DOI 10.1016/j.exer.2009.11.001
   OLSEN TW, 1995, INVEST OPHTH VIS SCI, V36, P1893
   Pinero DP, 2008, J CATARACT REFR SURG, V34, P126, DOI 10.1016/j.jcrs.2007.10.010
   Pitkanen L, 2005, INVEST OPHTH VIS SCI, V46, P641, DOI 10.1167/iovs.04-1051
   Pospisil H, 2001, ATLA-ALTERN LAB ANIM, V29, P347, DOI 10.1177/026119290102900318
   QUIGLEY HA, 1990, ARCH OPHTHALMOL-CHIC, V108, P51, DOI 10.1001/archopht.1990.01070030057028
   Ranta VP, 2006, ADV DRUG DELIVER REV, V58, P1164, DOI 10.1016/j.addr.2006.07.025
   Shamshad MA, 2010, INDIAN J OPHTHALMOL, V58, P189, DOI 10.4103/0301-4738.62641
   Tojo K, 2004, CHEM PHARM BULL, V52, P1290, DOI 10.1248/cpb.52.1290
   Tsuji A., 1988, OPHTHAL RES, V20, P3143
   Urtti A., 2006, ADV DRUG DELIVERY RE, V58
   Watanabe A, 2008, J NEUROSURG, V109, P255, DOI 10.3171/JNS/2008/109/8/0255
   Watson PG, 2004, EXP EYE RES, V78, P609, DOI 10.1016/S0014-4835(03)00212-4
NR 33
TC 7
Z9 7
U1 0
U2 10
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0017-9310
EI 1879-2189
J9 INT J HEAT MASS TRAN
JI Int. J. Heat Mass Transf.
PD OCT
PY 2012
VL 55
IS 21-22
BP 5665
EP 5672
DI 10.1016/j.ijheatmasstransfer.2012.05.060
PG 8
WC Thermodynamics; Engineering, Mechanical; Mechanics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Thermodynamics; Engineering; Mechanics
GA 998SO
UT WOS:000308260900028
DA 2022-11-30
ER

PT J
AU Silva, RM
   Cachulo, ML
   Figueira, J
   De Abreu, JRF
   Cunha-Vaz, JG
AF Silva, Rufino M.
   Cachulo, M. Luz
   Figueira, Joao
   De Abreu, Jose R. Faria
   Cunha-Vaz, J. G.
TI Chorioretinal anastomosis and photodynamic therapy: a two-year follow-up
   study
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE AMD; chorioretinal anastomoses; PDT; photodynamic therapy; RAL-retinal
   anastomosis to the lesion; RAP; visudyne
ID RETINAL ANGIOMATOUS PROLIFERATION; SUBFOVEAL CHOROIDAL
   NEOVASCULARIZATION; INDOCYANINE GREEN ANGIOGRAPHY; MACULAR DEGENERATION;
   INTRAVITREAL TRIAMCINOLONE; CLINICAL-TRIALS; VERTEPORFIN; OCCULT;
   LESIONS
AB Background To evaluate the two-year efficacy of photodynamic therapy with Visudyne (PDT) in neovascular age-related macular degeneration (AMD) eyes with chorioretinal anastomosis (CRA).
   Methods A non-randomized, institutional, prospective study, of 28 consecutive eyes of 23 patients, with CRA, treated with PDT. Masked best corrected visual acuity ( VA) and angiographic features at baseline and during the period of two years were evaluated.
   Results Twenty eight eyes completed one year and 19 eyes completed two years of follow-up. The number of treatments was 3 in the first year, and 0.8 in the second year. A VA loss < 3 lines occurred in 53% of the eyes, at two years. Treated eyes lost 0.5 lines in the first year and 2.4 lines in the second (p < 0,01). Recurrence with additional significant VA loss occurred in four eyes (21%) during the second year. Fourteen eyes (74%) showed no fluorescein leakage at two years.
   Conclusion AMD eyes with chorioretinal anastomosis can benefit from PDT with Verteporfin at two years. However, during the second year significant additional VA loss occurs mainly due to recurrence. New modalities of treatment are necessary to achieve VA improvement in CRA eyes.
C1 Univ Hosp Coimbra, Dept Ophthalmol, P-3000 Coimbra, Portugal.
   Univ Coimbra, Fac Med, Ctr Ophthalmol, Inst Biomed Res Light & Image, Coimbra, Portugal.
   AIBILI, Coimbra, Portugal.
C3 Universidade de Coimbra; Centro Hospitalar e Universitario de Coimbra
   (CHUC); Universidade de Coimbra; Universidade de Coimbra
RP Silva, RM (通讯作者)，Univ Hosp Coimbra, Dept Ophthalmol, P-3000 Coimbra, Portugal.
EM rufino.silva@oftalmologia.co.pt
RI Silva, Rufino M/J-2817-2012
OI Silva, Rufino M/0000-0001-8676-0833; Figueira, Joao
   P/0000-0002-3511-1515; Cunha-Vaz, Jose/0000-0002-0947-9850; Cachulo,
   Maria Luz/0000-0002-0900-4548
CR Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Axer-Siegel R, 2002, OPHTHALMOLOGY, V109, P1726, DOI 10.1016/S0161-6420(02)01149-1
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Borrillo JL, 2003, ARCH OPHTHALMOL-CHIC, V121, P558, DOI 10.1001/archopht.121.4.558
   Boscia F, 2004, AM J OPHTHALMOL, V138, P1077, DOI 10.1016/j.ajo.2004.06.072
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Criswell MH, 2005, INVEST OPHTH VIS SCI, V46, P2168, DOI 10.1167/iovs.04-1442
   Fernandes LHS, 2002, RETINA-J RET VIT DIS, V22, P557, DOI 10.1097/00006982-200210000-00005
   Freund KB, 2006, ARCH OPHTHALMOL-CHIC, V124, P487, DOI 10.1001/archopht.124.4.487
   Hartnett ME, 1996, OPHTHALMOLOGY, V103, P2042, DOI 10.1016/S0161-6420(96)30389-8
   HAWKINS BS, 1993, ARCH OPHTHALMOL-CHIC, V111, P1200
   KUHN D, 1995, ARCH OPHTHALMOL-CHIC, V113, P1392, DOI 10.1001/archopht.1995.01100110052025
   Kuroiwa S, 2003, RETINA-J RET VIT DIS, V23, P417, DOI 10.1097/00006982-200306000-00027
   Kusserow C, 2003, OPHTHALMOLOGE, V100, P197, DOI 10.1007/s00347-002-0673-2
   Lafaut BA, 2000, BRIT J OPHTHALMOL, V84, P1269, DOI 10.1136/bjo.84.11.1269
   NICOLO M, 2006, GRAEFES ARCH CLIN EX
   Pece A, 2001, RETINA-J RET VIT DIS, V21, P661, DOI 10.1097/00006982-200112000-00017
   Silva RM, 2004, GRAEF ARCH CLIN EXP, V242, P368, DOI 10.1007/s00417-003-0844-0
   Slakter JS, 2000, OPHTHALMOLOGY, V107, P742, DOI 10.1016/S0161-6420(00)00009-9
   SOLOMON SD, 2005, ARVO 2005 ANN M 1 5
   Spaide RF, 2003, OPHTHALMOLOGY, V110, P1517, DOI 10.1016/S0161-6420(03)00544-X
   Yannuzzi LA, 2001, RETINA-J RET VIT DIS, V21, P416, DOI 10.1097/00006982-200110000-00003
NR 22
TC 25
Z9 26
U1 0
U2 2
PU SPRINGER
PI NEW YORK
PA 233 SPRING STREET, NEW YORK, NY 10013 USA
SN 0721-832X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD AUG
PY 2007
VL 245
IS 8
BP 1131
EP 1139
DI 10.1007/s00417-006-0532-y
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 186MY
UT WOS:000247784000007
PM 17226019
OA Green Submitted
DA 2022-11-30
ER

PT J
AU Shang, P
   Stepicheva, NA
   Liu, HT
   Chowdhury, O
   Franks, J
   Sun, M
   Hose, S
   Ghosh, S
   Yazdankhah, M
   Strizhakova, A
   Stolz, DB
   Zigler, JS
   Sinha, D
AF Shang, Peng
   Stepicheva, Nadezda A.
   Liu, Haitao
   Chowdhury, Olivia
   Franks, Jonathan
   Sun, Ming
   Hose, Stacey
   Ghosh, Sayan
   Yazdankhah, Meysam
   Strizhakova, Anastasia
   Stolz, Donna Beer
   Zigler, J. Samuel, Jr.
   Sinha, Debasish
TI A Novel Method of Mouse RPE Explant Culture and Effective Introduction
   of Transgenes Using Adenoviral Transduction for In Vitro Studies in AMD
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE retina pigment epithelium; explant culture; RPE flatmount; adenoviral
   transduction
ID VISUAL CYCLE
AB Degeneration of retinal pigment epithelium (RPE) is one of the most critical phenotypic changes of age-related macular degeneration (AMD), the leading cause of vision loss in the elderly. While cultured polarized RPE cells with original properties are valuable in in vitro models to study RPE biology and the consequences of genetic and/or pharmacological manipulations, the procedure to establish mouse primary PRE cell culture or pluripotent stem cell-derived RPE cells is time-consuming and yields a limited number of cells. Thus, establishing a mouse in situ RPE culture system is highly desirable. Here we describe a novel and efficient method for RPE explant culture that allows for obtaining biologically relevant RPE cells in situ. These RPE explants (herein referred to as RPE flatmounts) are viable in culture for at least 7 days, can be efficiently transduced with adenoviral constructs, and/or treated with a variety of drugs/chemicals followed by downstream analysis of the signaling pathways/biological processes of interest, such as assessment of the autophagy flux, inflammatory response, and receptor tyrosine kinases stimulation. This method of RPE explant culture is highly beneficial for pharmacological and mechanistic studies in the field of RPE biology and AMD research.
C1 [Shang, Peng; Stepicheva, Nadezda A.; Liu, Haitao; Chowdhury, Olivia; Hose, Stacey; Ghosh, Sayan; Yazdankhah, Meysam; Strizhakova, Anastasia; Sinha, Debasish] Univ Pittsburgh, Dept Ophthalmol, Childrens Hosp, Sch Med, One Childrens Hosp Dr,4401 Penn Ave, Pittsburgh, PA 15224 USA.
   [Franks, Jonathan; Sun, Ming; Stolz, Donna Beer] Univ Pittsburgh, Dept Cell Biol, Sch Med, Pittsburgh, PA 15261 USA.
   [Franks, Jonathan; Sun, Ming; Stolz, Donna Beer] Univ Pittsburgh, Ctr Biol Imaging, Sch Med, Pittsburgh, PA 15261 USA.
   [Zigler, J. Samuel, Jr.] Johns Hopkins Univ, Wilmer Eye Inst, Sch Med, Baltimore, MD 21287 USA.
C3 Pennsylvania Commonwealth System of Higher Education (PCSHE); University
   of Pittsburgh; Pennsylvania Commonwealth System of Higher Education
   (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of
   Higher Education (PCSHE); University of Pittsburgh; Johns Hopkins
   University; Johns Hopkins Medicine
RP Shang, P (通讯作者)，Univ Pittsburgh, Dept Ophthalmol, Childrens Hosp, Sch Med, One Childrens Hosp Dr,4401 Penn Ave, Pittsburgh, PA 15224 USA.
EM shangpeng@pitt.edu; nstepich@pitt.edu; hal140@pitt.edu;
   CHOWDHUR@pitt.edu; jonnysax@gmail.com; mis23@pitt.edu;
   stacey.hose@pitt.edu; sayang@pitt.edu; meysam_yazdankhah@yahoo.com;
   strizhak@pitt.edu; donna.stolz@pitt.edu; szigler45@gmail.com;
   Debasish@pitt.edu
RI han, wei/ABG-2691-2021; Liu, Haitao/AAY-3944-2021
OI Liu, Haitao/0000-0002-3757-779X; Chowdhury, Olivia/0000-0002-3176-7832
FU Chair Professorship in Ophthalmology; National Institutes of Health
   [R01EY031594]
FX This work was supported by The Jennifer Salvitti Davis, MD, Chair
   Professorship in Ophthalmology (DS) and National Institutes of Health
   R01EY031594 (DS).
CR Bjorkoy G, 2009, METHOD ENZYMOL, V452, P181, DOI 10.1016/S0076-6879(08)03612-4
   Blenkinsop Timothy A, 2013, Methods Mol Biol, V945, P45, DOI 10.1007/978-1-62703-125-7_4
   Cai X, 2009, OPHTHALMIC GENET, V30, P57, DOI 10.1080/13816810802626399
   Datta S, 2017, PROG RETIN EYE RES, V60, P201, DOI 10.1016/j.preteyeres.2017.03.002
   Dejos C, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-24357-4
   Foltz LP, 2017, JOVE-J VIS EXP, DOI 10.3791/56274
   Gandhi J, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.00538
   Ghosh S, 2017, J PATHOL, V241, P583, DOI 10.1002/path.4870
   Hazim RA, 2019, EXP EYE RES, V179, P18, DOI 10.1016/j.exer.2018.10.009
   Hazim RA, 2017, STEM CELL RES THER, V8, DOI 10.1186/s13287-017-0652-9
   Kuznetsova AV, 2014, J OPHTHALMOL, V2014, DOI 10.1155/2014/801787
   Lakkaraju A, 2020, PROG RETIN EYE RES, V78, DOI 10.1016/j.preteyeres.2020.100846
   Liu T, 2017, SIGNAL TRANSDUCT TAR, V2, DOI 10.1038/sigtrans.2017.23
   Maruotti J, 2015, P NATL ACAD SCI USA, V112, P10950, DOI 10.1073/pnas.1422818112
   Shang P, 2021, COMMUN BIOL, V4, DOI 10.1038/s42003-021-02386-6
   Shang P, 2018, JOVE-J VIS EXP, DOI 10.3791/56997
   Shang P, 2017, AGING CELL, V16, P349, DOI 10.1111/acel.12561
   Shrestha A, 2019, MBIO, V10, DOI 10.1128/mBio.02985-19
   Strunnikova NV, 2010, HUM MOL GENET, V19, P2468, DOI 10.1093/hmg/ddq129
   Ueno T, 2020, BIOESSAYS, V42, DOI 10.1002/bies.202000122
   Umapathy A, 2019, ADV EXP MED BIOL, V1185, P389, DOI 10.1007/978-3-030-27378-1_64
   Velazquez AFC, 2018, MOL CELL BIOL, V38, DOI 10.1128/MCB.00303-18
   Wang J, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03856-y
   Xiang JM, 2016, BIOMED RES INT, V2016, DOI 10.1155/2016/7343965
   Xue YL, 2015, J CLIN INVEST, V125, P727, DOI 10.1172/JCI79651
   Yan YM, 2016, SCI REP-UK, V6, DOI 10.1038/srep37052
   Yang S, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.727870
   Yao CJ, 2005, IMMUNOLOGY, V116, P213, DOI 10.1111/j.1365-2567.2005.02212.x
NR 28
TC 1
Z9 1
U1 0
U2 4
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1422-0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD NOV
PY 2021
VL 22
IS 21
AR 11979
DI 10.3390/ijms222111979
PG 13
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA WX0SG
UT WOS:000718314300001
PM 34769409
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Lee, H
   Kim, S
   Kim, MA
   Jo, YJ
   Lee, WH
   Kim, HC
   Chung, H
AF Lee, Hyungwoo
   Kim, Seungmin
   Kim, Myung Ae
   Jo, Young Joon
   Lee, Woo Hyuk
   Kim, Hyung Chan
   Chung, Hyewon
TI Integrative analysis of the choroid by quantifying Haller vessel and
   choriocapillaris parameters in different drusen subtypes
SO SCIENTIFIC REPORTS
LA English
DT Article
ID GEOGRAPHIC-ATROPHY; RETICULAR PSEUDODRUSEN; MACULAR DEGENERATION;
   PROGRESSION; PREVALENCE; THICKNESS; RISK; EYES
AB This study aimed to quantify the Haller vessel and choriocapillaris (CC) parameters in drusen subtypes in nonexudative age-related macular degeneration (AMD) and pachydrusen. Ninety-five eyes of 80 patients and 28 control eyes were categorized into soft drusen, subretinal drusenoid deposit (SDD), soft drusen plus SDD, pachydrusen, and control groups. The diameter, length and intersections of Haller vessels and the total area, size and number of CC flow voids were quantified using en face optical coherence tomography (OCT) or OCT angiography. The pachydrusen group showed the largest Haller vessel area and diameter and shortest total length but similar CC parameters to those in the control group. The soft drusen plus SDD group showed the largest CC flow void area and size, while the Haller parameters were similar to those in the control group. The area and size of the flow voids in the SDD group were smaller than those in the soft drusen plus SDD group. Based on unsupervised machine learning, the eyes were classified into 4 clusters-the control, pachydrusen, soft drusen plus SDD and soft drusen plus SDD groups. Cluster 3 showed a larger diameter and shorter total length of the Haller vessels than cluster 4.
C1 [Lee, Hyungwoo; Kim, Seungmin; Kim, Myung Ae; Kim, Hyung Chan; Chung, Hyewon] Konkuk Univ, Sch Med, Dept Ophthalmol, Med Ctr, 120-1 Neungdong Ro, Seoul 05030, South Korea.
   [Jo, Young Joon; Lee, Woo Hyuk] Chungnam Natl Univ, Chungnam Natl Univ Hosp, Dept Ophthalmol, Coll Med, Daejeon, South Korea.
C3 Konkuk University; Konkuk University Medical Center; Chungnam National
   University; Chungnam National University Hospital
RP Chung, H (通讯作者)，Konkuk Univ, Sch Med, Dept Ophthalmol, Med Ctr, 120-1 Neungdong Ro, Seoul 05030, South Korea.
EM hchung@kuh.ac.kr
FU Konkuk University [2020-A019-0403]
FX This paper was supported by Konkuk University in 2020 [Grant Number
   2020-A019-0403]. The authors thank the statistician of Konkuk University
   Medical Center for the consultation concerning clustering analyses.
CR Abramoff M.D., 2004, BIOPHOTONICS INT, V11, P36, DOI DOI 10.1117/1.3589100
   Agrawal R, 2016, SCI REP-UK, V6, DOI 10.1038/srep21090
   Baek J, 2018, GRAEF ARCH CLIN EXP, V256, P2309, DOI 10.1007/s00417-018-4143-1
   Borrelli E, 2018, RETINA-J RET VIT DIS, V38, P1968, DOI 10.1097/IAE.0000000000002198
   Chatziralli I, 2018, INT OPHTHALMOL, V38, P1887, DOI 10.1007/s10792-017-0671-7
   Chu ZD, 2020, AM J OPHTHALMOL, V213, P161, DOI 10.1016/j.ajo.2020.02.003
   Cohen SY, 2007, BRIT J OPHTHALMOL, V91, P354, DOI 10.1136/bjo.2006.101022
   Corvi F, 2021, GRAEF ARCH CLIN EXP, V259, P2887, DOI 10.1007/s00417-021-05167-3
   Corvi F, 2021, RETINA-J RET VIT DIS, V41, P686, DOI 10.1097/IAE.0000000000002990
   Corvi F, 2017, BRIT J OPHTHALMOL, V101, P348, DOI 10.1136/bjophthalmol-2016-308548
   Curtin K, 2019, HYPERTENS PREGNANCY, V38, P141, DOI 10.1080/10641955.2019.1597107
   Ding C., 2004, P 21 INT C MACH LEAR, P29, DOI DOI 10.1145/1015330.1015408
   Finger RP, 2014, OPHTHALMOLOGY, V121, P1252, DOI 10.1016/j.ophtha.2013.12.034
   Fleckenstein M, 2018, OPHTHALMOLOGY, V125, P369, DOI 10.1016/j.ophtha.2017.08.038
   Cheung CM, 2018, OPHTHALMOL RETINA, V2, P1196, DOI 10.1016/j.oret.2018.06.014
   Hosoda Y, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-75451-5
   Hotaling NA, 2015, BIOMATERIALS, V61, P327, DOI 10.1016/j.biomaterials.2015.05.015
   Joachim N, 2013, OPHTHALMOLOGY, V120, P2042, DOI 10.1016/j.ophtha.2013.03.029
   Kaufman L, 2009, FINDING GROUPS DATA
   Keenan TD, 2020, RETINA-J RET VIT DIS, V40, P632, DOI 10.1097/IAE.0000000000002434
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Kodinariya T., 2013, INT J-TORONTO, V1, P90
   Lee H, 2020, RETINA-J RET VIT DIS, V40, P1704, DOI 10.1097/IAE.0000000000002678
   Lee J, 2019, AM J OPHTHALMOL, V208, P103, DOI 10.1016/j.ajo.2019.07.013
   Moult EM, 2020, RETINA-J RET VIT DIS, V40, P428, DOI 10.1097/IAE.0000000000002556
   Nassisi M, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0212563
   Spaide RF, 2018, RETINA-J RET VIT DIS, V38, P708, DOI 10.1097/IAE.0000000000001689
   SUTERA SP, 1993, ANNU REV FLUID MECH, V25, P1, DOI 10.1146/annurev.fl.25.010193.000245
   Thulliez M, 2019, OPHTHALMOL RETINA, V3, P478, DOI 10.1016/j.oret.2019.01.024
   Ting DSW, 2016, AM J OPHTHALMOL, V164, P128, DOI 10.1016/j.ajo.2015.12.024
   Velaga SB, 2020, RETINA-J RET VIT DIS, V40, P612, DOI 10.1097/IAE.0000000000002667
   Vujosevic S, 2019, ACTA OPHTHALMOL, V97, pE919, DOI 10.1111/aos.14088
   Wang JJ, 2003, ARCH OPHTHALMOL-CHIC, V121, P658, DOI 10.1001/archopht.121.5.658
   Zhang QQ, 2018, INVEST OPHTH VIS SCI, V59, P203, DOI 10.1167/iovs.17-22953
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P1775, DOI 10.1016/j.ophtha.2010.01.027
NR 35
TC 2
Z9 2
U1 0
U2 1
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD JUL 30
PY 2021
VL 11
IS 1
AR 15509
DI 10.1038/s41598-021-94627-1
PG 11
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA TX8DY
UT WOS:000683318500003
PM 34330991
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Telegina, DV
   Kozhevnikova, OS
   Antonenko, AK
   Kolosova, NG
AF Telegina, Darya V.
   Kozhevnikova, Oyuna S.
   Antonenko, Anna K.
   Kolosova, Nataliya G.
TI Features of Retinal Neurogenesis as a Key Factor of Age-Related
   Neurodegeneration: Myth or Reality?
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Review
DE retina; neurodegeneration; AMD; aging; neurogenesis; development;
   transcription factor
ID OPTICAL COHERENCE TOMOGRAPHY; CELL FATE SPECIFICATION; MULLER GLIA;
   MACULAR DEGENERATION; DEVELOPMENTAL ORIGINS; TRANSCRIPTION FACTORS;
   PIGMENT EPITHELIUM; HORIZONTAL CELLS; BIRTH-WEIGHT; MOUSE MODEL
AB Age-related macular degeneration (AMD) is a complex multifactorial neurodegenerative disease that constitutes the most common cause of irreversible blindness in the elderly in the developed countries. Incomplete knowledge about its pathogenesis prevents the search for effective methods of prevention and treatment of AMD, primarily of its "dry" type which is by far the most common (90% of all AMD cases). In the recent years, AMD has become "younger": late stages of the disease are now detected in relatively young people. It is known that AMD pathogenesis-according to the age-related structural and functional changes in the retina-is linked with inflammation, hypoxia, oxidative stress, mitochondrial dysfunction, and an impairment of neurotrophic support, but the mechanisms that trigger the conversion of normal age-related changes to the pathological process as well as the reason for early AMD development remain unclear. In the adult mammalian retina, de novo neurogenesis is very limited. Therefore, the structural and functional features that arise during its maturation and formation can exert long-term effects on further ontogenesis of this tissue. The aim of this review was to discuss possible contributions of the changes/disturbances in retinal neurogenesis to the early development of AMD.
C1 [Telegina, Darya V.; Kozhevnikova, Oyuna S.; Antonenko, Anna K.; Kolosova, Nataliya G.] Russian Acad Sci, Inst Cytol & Genet, Siberian Branch, Novosibirsk 630090, Russia.
   [Antonenko, Anna K.] Novosibirsk State Univ, Dept Nat Sci, Novosibirsk 630090, Russia.
C3 Russian Academy of Sciences; Institute of Cytology & Genetics ICG SB
   RAS; Novosibirsk State University
RP Telegina, DV (通讯作者)，Russian Acad Sci, Inst Cytol & Genet, Siberian Branch, Novosibirsk 630090, Russia.
EM telegina@bionet.nsc.ru; kolosova@bionet.nsc.ru; antonenko@bionet.nsc.ru;
   oidopova@bionet.nsc.ru
RI Kozhevnikova, Oyuna S./H-3588-2016; Kolosova, Nataliya G/P-3178-2015
OI Kozhevnikova, Oyuna S./0000-0001-6475-4061; Kolosova, Nataliya
   G/0000-0003-2398-8544; Antonenko, Anna/0000-0003-0675-8499; Telegina,
   Darya/0000-0001-8096-0519
FU Russian Science Foundation [21-15-00047]
FX This research was funded by the Russian Science Foundation, grant number
   21-15-00047.
CR Aldiri I, 2017, NEURON, V94, P550, DOI 10.1016/j.neuron.2017.04.022
   Allegra A, 2021, MECH AGEING DEV, V195, DOI 10.1016/j.mad.2021.111461
   Andreazzoli M, 2009, BIRTH DEFECTS RES C, V87, P284, DOI 10.1002/bdrc.20161
   Ardeljan D, 2013, PROG RETIN EYE RES, V37, P68, DOI 10.1016/j.preteyeres.2013.07.003
   Assawachananont J, 2018, HUM MOL GENET, V27, P3555, DOI 10.1093/hmg/ddy272
   Bachleda AR, 2016, INVEST OPHTH VIS SCI, V57, P1488, DOI 10.1167/iovs.15-17994
   Bandello Francesco, 2017, F1000Res, V6, P245, DOI 10.12688/f1000research.10664.1
   Barker DJP, 2007, J INTERN MED, V261, P412, DOI 10.1111/j.1365-2796.2007.01809.x
   Barker DJP, 2012, PUBLIC HEALTH, V126, P185, DOI 10.1016/j.puhe.2011.11.014
   Beby F, 2013, EXP EYE RES, V111, P9, DOI 10.1016/j.exer.2013.03.007
   Beby F, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011673
   Begum R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057828
   Bernard C, 2014, HUM MOL GENET, V23, P1742, DOI 10.1093/hmg/ddt562
   Bertolotti E, 2014, PROG RETIN EYE RES, V42, P130, DOI 10.1016/j.preteyeres.2014.06.002
   Bessant DAR, 1999, NAT GENET, V21, P355, DOI 10.1038/7678
   Bhansali P, 2014, NEURAL DEV, V9, DOI 10.1186/1749-8104-9-11
   Blasiak J, 2020, CELL MOL LIFE SCI, V77, P789, DOI 10.1007/s00018-019-03420-x
   Blasiak J, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20010210
   Bora PS, 2003, P NATL ACAD SCI USA, V100, P2679, DOI 10.1073/pnas.0438014100
   Bowl W, 2016, INVEST OPHTH VIS SCI, V57, pOCT235, DOI 10.1167/iovs.15-18843
   BRAEKEVELT CR, 1970, AM J ANAT, V127, P281, DOI 10.1002/aja.1001270305
   Bringmann A, 2018, PROG RETIN EYE RES, V66, P49, DOI 10.1016/j.preteyeres.2018.03.006
   Brown AM, 2009, OPTOMETRY VISION SCI, V86, P572, DOI 10.1097/OPX.0b013e3181a72980
   Brzezinski JA, 2015, DEVELOPMENT, V142, P3263, DOI 10.1242/dev.127043
   Casarosa S., 2011, EMBRYONIC STEM CELLS, P211
   Cepko C, 2014, NAT REV NEUROSCI, V15, P615, DOI 10.1038/nrn3767
   Cepko CL, 2015, ANNU REV VIS SCI, V1, P211, DOI 10.1146/annurev-vision-090814-121657
   Crump C, 2020, EARLY HUM DEV, V150, DOI 10.1016/j.earlhumdev.2020.105187
   D'Souza S, 2020, DEVELOPMENT, V147, DOI 10.1242/dev.196535
   de Melo J, 2011, DEVELOPMENT, V138, P2325, DOI 10.1242/dev.061846
   Del Debbio CB, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0152025
   Di Nardo AA, 2018, PHYSIOL REV, V98, P1943, DOI 10.1152/physrev.00018.2017
   Engerer P, 2017, EMBO J, V36, P1134, DOI 10.15252/embj.201694230
   Faigle R, 2013, BBA-GEN SUBJECTS, V1830, P2435, DOI 10.1016/j.bbagen.2012.09.002
   Fan WJ, 2016, NEURAL REGEN RES, V11, P312, DOI 10.4103/1673-5374.177743
   Felszeghy S, 2019, REDOX BIOL, V20, P1, DOI 10.1016/j.redox.2018.09.011
   Feng L, 2016, DISCOV MED, V21, P149
   Fiess A, 2019, INVEST OPHTH VIS SCI, V60, P4943, DOI 10.1167/iovs.19-27964
   Fiess A, 2017, GRAEF ARCH CLIN EXP, V255, P1433, DOI 10.1007/s00417-017-3662-5
   Fletcher EL, 2014, OPTOMETRY VISION SCI, V91, P878, DOI 10.1097/OPX.0000000000000322
   Furukawa T, 2000, NEURON, V26, P383, DOI 10.1016/S0896-6273(00)81171-X
   Garcia TB, 2017, CYTOKINE GROWTH F R, V34, P43, DOI 10.1016/j.cytogfr.2016.11.005
   Grigoryan EN, 2020, BIOMEDICINES, V8, DOI 10.3390/biomedicines8070208
   Grunert U, 2020, PROG RETIN EYE RES, V78, DOI 10.1016/j.preteyeres.2020.100844
   Hall NF, 2002, INVEST OPHTH VIS SCI, V43, P3641
   Hamel CP, 2007, ORPHANET J RARE DIS, V2, DOI 10.1186/1750-1172-2-7
   Harding P, 2019, J DEV BIOL, V7, DOI 10.3390/jdb7030016
   Hendrickson A, 2016, AM J OPHTHALMOL, V161, P29, DOI 10.1016/j.ajo.2015.09.023
   Hendrickson A, 2012, AM J OPHTHALMOL, V154, P767, DOI 10.1016/j.ajo.2012.05.007
   Hennig AK, 2008, BRAIN RES, V1192, P114, DOI 10.1016/j.brainres.2007.06.036
   Hoon M, 2014, PROG RETIN EYE RES, V42, P44, DOI 10.1016/j.preteyeres.2014.06.003
   Hoshino A, 2017, DEV CELL, V43, P763, DOI 10.1016/j.devcel.2017.10.029
   Huang L, 2012, BIOCHEM BIOPH RES CO, V426, P498, DOI 10.1016/j.bbrc.2012.08.110
   Huang X., 2020, SYNAP DEV MATURATION, P213, DOI [10.1016/B978-0-12-823672-7.00009-0, DOI 10.1016/B978-0-12-823672-7.00009-0]
   Jin KX, 2017, MOL NEUROBIOL, V54, P3565, DOI 10.1007/s12035-016-9899-x
   Joly S, 2011, GLIA, V59, P1033, DOI 10.1002/glia.21174
   Jorstad NL, 2017, NATURE, V548, P103, DOI 10.1038/nature23283
   Jun SJ, 2019, EXP EYE RES, V181, P346, DOI 10.1016/j.exer.2018.09.023
   Kaarniranta K, 2020, PROG RETIN EYE RES, V79, DOI 10.1016/j.preteyeres.2020.100858
   Karl MO, 2008, P NATL ACAD SCI USA, V105, P19508, DOI 10.1073/pnas.0807453105
   Kautzman AG, 2018, GLIA, V66, P623, DOI 10.1002/glia.23269
   Kautzmann MAI, 2011, J BIOL CHEM, V286, P28247, DOI 10.1074/jbc.M111.257246
   Nguyen-Ba-Charvet KT, 2014, CR BIOL, V337, P153, DOI 10.1016/j.crvi.2013.11.010
   Lalitha S, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-72828-4
   Lang HN, 2015, SCI REP-UK, V5, DOI 10.1038/srep13383
   Laranjeiro R, 2014, DEVELOPMENT, V141, P2644, DOI 10.1242/dev.104380
   Le TT, 2006, DEV BIOL, V295, P764, DOI 10.1016/j.ydbio.2006.03.055
   Li SG, 2004, NEURON, V43, P795, DOI 10.1016/j.neuron.2004.08.041
   Liew G, 2008, OPHTHAL EPIDEMIOL, V15, P56, DOI 10.1080/09286580701613769
   Lin C., 2019, DEVELOPMENT, DOI [10.1101/2019.12.19.882969, DOI 10.1101/2019.12.19.882969]
   Liu H, 2008, J NEUROSCI, V28, P749, DOI 10.1523/JNEUROSCI.4832-07.2008
   Louvi A, 2006, NAT REV NEUROSCI, V7, P93, DOI 10.1038/nrn1847
   Manuel M, 2008, BMC DEV BIOL, V8, DOI 10.1186/1471-213X-8-59
   Martinez-Gimeno M, 2001, Hum Mutat, V17, P520, DOI 10.1002/humu.1135
   Meng QH, 2014, INVEST OPHTH VIS SCI, V55, P7652, DOI 10.1167/iovs.14-15155
   Monsoro-Burq AH, 2015, SEMIN CELL DEV BIOL, V44, P87, DOI 10.1016/j.semcdb.2015.09.015
   Moreno-Cugnon Leire, 2018, Oncotarget, V9, P36684, DOI 10.18632/oncotarget.26393
   Mu XQ, 2005, DEV BIOL, V280, P467, DOI 10.1016/j.ydbio.2005.01.028
   Nakhai H, 2007, DEVELOPMENT, V134, P1151, DOI 10.1242/dev.02781
   Narayan DS, 2019, FRONT NEUROSCI-SWITZ, V13, DOI 10.3389/fnins.2019.01234
   Nelson BR, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022817
   Ohsawa R, 2008, BRAIN RES, V1192, P90, DOI 10.1016/j.brainres.2007.04.014
   Omori Y, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019685
   Ortin-Martinez A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102392
   Otteson DC, 2017, NEUROSCIENCE, V346, P447, DOI 10.1016/j.neuroscience.2017.01.022
   Park KA, 2012, INVEST OPHTH VIS SCI, V53, P7201, DOI 10.1167/iovs.12-10599
   Park SW, 2017, ONCOTARGET, V8, P40006, DOI 10.18632/oncotarget.16967
   Pennington KL, 2016, EYE VISION, V3, DOI 10.1186/s40662-016-0063-5
   Peynshaert K, 2019, CURR EYE RES, V44, P465, DOI 10.1080/02713683.2019.1565890
   Pfeiffer RL, 2020, PROG RETIN EYE RES, V74, DOI 10.1016/j.preteyeres.2019.07.004
   Pirmardan ER, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-35884-5
   Quinn PMJ, 2019, GENES-BASEL, V10, DOI 10.3390/genes10120987
   Ramkumar HL, 2010, PROG RETIN EYE RES, V29, P169, DOI 10.1016/j.preteyeres.2010.02.002
   Rapaport DH, 2004, J COMP NEUROL, V474, P304, DOI 10.1002/cne.20134
   Ringuette R, 2016, DEV BIOL, V411, P85, DOI 10.1016/j.ydbio.2016.01.006
   Roger JE, 2014, J CLIN INVEST, V124, P631, DOI 10.1172/JCI72722
   Salminen A, 2019, CELL MOL LIFE SCI, V76, P1901, DOI 10.1007/s00018-019-03048-x
   Savaskan E, 2002, J HISTOCHEM CYTOCHEM, V50, P519, DOI 10.1177/002215540205000408
   Schnichels S, 2021, PROG RETIN EYE RES, V81, DOI 10.1016/j.preteyeres.2020.100880
   Seo JH, 2007, OPHTHALMOLOGY, V114, P1547, DOI 10.1016/j.ophtha.2006.10.054
   Shah M, 2019, PHARM RES-DORDR, V36, DOI 10.1007/s11095-019-2588-5
   Shah Parag K, 2016, World J Clin Pediatr, V5, P35, DOI 10.5409/wjcp.v5.i1.35
   Stanescu D, 2007, EYE, V21, P90, DOI 10.1038/sj.eye.6702166
   Stanescu-Segall D, 2015, J GLAUCOMA, V24, P426, DOI 10.1097/IJG.0b013e318207069b
   Surzenko N, 2013, DEVELOPMENT, V140, P1445, DOI 10.1242/dev.071878
   Swaroop A, 2010, NAT REV NEUROSCI, V11, P563, DOI 10.1038/nrn2880
   Taranova OV, 2006, GENE DEV, V20, P1187, DOI 10.1101/gad.1407906
   Tekin MI, 2018, INVEST OPHTH VIS SCI, V59, P2833, DOI 10.1167/iovs.18-24030
   Telegina DV, 2018, BIOCHEMISTRY-MOSCOW+, V83, P1009, DOI 10.1134/S000629791809002X
   Telegina DV, 2017, SCI REP-UK, V7, DOI 10.1038/srep41533
   Hoang T, 2020, SCIENCE, V370, P934, DOI 10.1126/science.abb8598
   Ueki Y, 2015, P NATL ACAD SCI USA, V112, P13717, DOI 10.1073/pnas.1510595112
   Van Cruchten S, 2017, BIRTH DEFECTS RES, V109, P1540, DOI 10.1002/bdr2.1100
   Van Lieshout RJ, 2021, PEDIATRICS, V147, DOI 10.1542/peds.2020-001230
   VandenBosch LS, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-70334-1
   Vergara MN, 2013, EXP EYE RES, V109, P40, DOI 10.1016/j.exer.2013.01.010
   Vessey KA, 2017, AM J PATHOL, V187, P1670, DOI 10.1016/j.ajpath.2017.04.016
   Wang K, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-51151-7
   Warre-Cornish K, 2014, STEM CELLS DEV, V23, P941, DOI 10.1089/scd.2013.0471
   Webster MK, 2019, INVEST OPHTH VIS SCI, V60, P570, DOI 10.1167/iovs.18-25722
   Webster MK, 2017, NEUROSCIENCE, V346, P437, DOI 10.1016/j.neuroscience.2017.01.029
   Whitaker D.T., 2019, 753012 BIORXIV, P753012, DOI [10.1101/753012, DOI 10.1101/753012]
   Wilk MA, 2014, INVEST OPHTH VIS SCI, V55, P4186, DOI 10.1167/iovs.13-13217
   Wilken MS, 2016, CURR OPIN GENET DEV, V40, P57, DOI 10.1016/j.gde.2016.05.028
   Wu JL, 2019, DRUG DES DEV THER, V13, P2413, DOI 10.2147/DDDT.S206355
   Xia XH, 2016, INT J STEM CELLS, V9, P169, DOI 10.15283/ijsc16020
   Xiang MQ, 2013, CELL MOL LIFE SCI, V70, P2519, DOI 10.1007/s00018-012-1183-2
   Yamamoto H, 2020, CELL REP, V30, P658, DOI 10.1016/j.celrep.2019.12.072
   Yanni SE, 2012, BRIT J OPHTHALMOL, V96, P961, DOI 10.1136/bjophthalmol-2012-301612
   Zagozewski JL, 2014, CLIN GENET, V86, P453, DOI 10.1111/cge.12493
   Zagozewski JL, 2014, DEV BIOL, V393, P195, DOI 10.1016/j.ydbio.2014.07.004
   Zhang X, 2011, BIOINFORM BIOL INSIG, V5, P99, DOI 10.4137/BBI.S6930
   Zhou HB, 2020, CELL, V181, P590, DOI 10.1016/j.cell.2020.03.024
NR 133
TC 1
Z9 1
U1 2
U2 8
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1422-0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD JUL
PY 2021
VL 22
IS 14
AR 7373
DI 10.3390/ijms22147373
PG 18
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA TO3EC
UT WOS:000676798500001
PM 34298993
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Muthuswamy, A
   Chen, H
   Hu, Y
   Turner, OC
   Aina, OH
AF Muthuswamy, Anantharaman
   Chen, Henry
   Hu, Ying
   Turner, Oliver C.
   Aina, Olulanu H.
TI Mammalian Retinal Cell Quantification
SO TOXICOLOGIC PATHOLOGY
LA English
DT Article
DE retina; retinal ganglion cells; immunohistochemistry; quantification;
   image analysis
AB Normal retina and its cell layers are essential for processing visual stimuli, and loss of its integrity has been documented in many disease processes. The numbers and the axonal processes of retinal ganglion cells are reduced substantially in glaucoma, leading to vision loss and blindness. Similarly, selective loss of photoreceptors in age-related macular degeneration and hereditary retinal dystrophies also results in the compromise of visual acuity. Development of genetically modified mice has led to increased understanding of the pathogenesis of many retinal diseases. Similarly, in this digital era, usage of modalities to quantify the retinal cell loss has grown exponentially leading to a better understanding of the suitability of animal models to study human retinal diseases. These quantification modalities provide valuable quantifiable data in studying pathogenesis and disease progression. This review will discuss the immunohistochemical markers for various retinal cells, available automated tools to quantify retinal cells, and present an example of retinal ganglion cell quantification using HALO image analysis platform. Additionally, we briefly review retinal cell types and subtypes, salient features of retina in various laboratory animal species, and a few of the main disease processes that affect retinal cell numbers in humans.
C1 [Muthuswamy, Anantharaman; Chen, Henry; Hu, Ying] Regeneron Pharmaceut, Tarrytown, NY USA.
   [Turner, Oliver C.] Novartis, Preclin Safety, Novartis Inst BioMed Res, E Hanover, NJ USA.
   [Aina, Olulanu H.] Johnson & Johnson, Janssen Pharmaceut Co, Spring House, PA USA.
C3 Regeneron; Novartis; Johnson & Johnson; Janssen Pharmaceuticals; Johnson
   & Johnson USA
RP Muthuswamy, A (通讯作者)，Regeneron Pharmaceut, 304 Boulder Ridge Rd, South Salem, NY 10591 USA.
EM mananth@gmail.com
OI Turner, Oliver/0000-0003-0512-1170
CR Abramoff Michael D, 2010, IEEE Rev Biomed Eng, V3, P169, DOI 10.1109/RBME.2010.2084567
   Acs B, 2019, LAB INVEST, V99, P107, DOI 10.1038/s41374-018-0123-7
   Aeffner Famke, 2019, J Pathol Inform, V10, P9, DOI 10.4103/jpi.jpi_82_18
   Ahnelt PK, 2000, PROG RETIN EYE RES, V19, P711, DOI 10.1016/S1350-9462(00)00012-4
   Al-Hussaini H, 2008, MOL VIS, V14, P1784
   Ammary-Risch NJC., 2016, NIH NAT EYE I
   [Anonymous], 2008, OCULAR ANATOMY VARIA
   [Anonymous], 2014, NEW POLL PLACES FEAR
   [Anonymous], 2019, GLOBAL DISTRIBUTION
   [Anonymous], 2020, PHOTORECEPTOR CELL, V19
   Balasubramanian Revathi, 2014, Curr Ophthalmol Rep, V2, P100
   Beltran WA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090390
   BERKELAAR M, 1994, J NEUROSCI, V14, P4368, DOI 10.1523/jneurosci.14-07-04368.1994
   Boije Henrik, 2016, Front Neuroanat, V10, P77, DOI 10.3389/fnana.2016.00077
   Bolon, 2020, TOXICOL PATHOL, V26, p192623320967279
   Bringmann A, 2006, PROG RETIN EYE RES, V25, P397, DOI 10.1016/j.preteyeres.2006.05.003
   Bringmann A, 2012, OPHTHALMOLOGICA, V227, P1, DOI 10.1159/000328979
   Brown DL, 2017, VET PATHOL, V54, P358, DOI 10.1177/0300985817695781
   Brugmann A, 2012, BREAST CANCER RES TR, V132, P41, DOI 10.1007/s10549-011-1514-2
   BURKE JM, 1988, INVEST OPHTH VIS SCI, V29, P1784
   Chang B, 2002, VISION RES, V42, P517, DOI 10.1016/S0042-6989(01)00146-8
   Chen CS, 2008, INVEST OPHTH VIS SCI, V49, P2985, DOI 10.1167/iovs.07-1651
   Chen Liwen, 2016, Vision (Basel), V1, DOI 10.3390/vision1010004
   Chidlow G, 2011, J HISTOCHEM CYTOCHEM, V59, P884, DOI 10.1369/0022155411418115
   Chinnery HR, 2017, PFLUG ARCH EUR J PHY, V469, P501, DOI 10.1007/s00424-017-1947-5
   Chowers G, 2017, INVEST OPHTH VIS SCI, V58, P2239, DOI 10.1167/iovs.16-21255
   Cordeiro MF, 2017, BRAIN, V140, P1757, DOI 10.1093/brain/awx088
   CURCIO CA, 1990, J COMP NEUROL, V300, P5, DOI 10.1002/cne.903000103
   Daiger SP, 2013, CLIN GENET, V84, P132, DOI 10.1111/cge.12203
   Danias J, 2002, INVEST OPHTH VIS SCI, V43, P587
   de Gracia P, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0143278
   de Hoz R, 2016, BIOMED RES INT, V2016, DOI 10.1155/2016/2954721
   De Los Reyes RAR., 2020, ARTERITIC ANTERIOR I
   Guimaraes RPD, 2018, FRONT CELL NEUROSCI, V12, DOI 10.3389/fncel.2018.00410
   DESCHAEPDRIJVER L, 1989, RES VET SCI, V47, P34
   DRAGER UC, 1981, INVEST OPHTH VIS SCI, V20, P285
   Dubielzig R.R., 2010, VET OCULAR PATHOLOGY
   Ether J, 2017, QUANTITATIVE HUMAN P
   Fileta JB, 2008, J NEUROSCI METH, V170, P1, DOI 10.1016/j.jneumeth.2007.12.008
   Fritsche LG, 2014, ANNU REV GENOM HUM G, V15, P151, DOI 10.1146/annurev-genom-090413-025610
   FUKUDA Y, 1977, BRAIN RES, V119, P327, DOI 10.1016/0006-8993(77)90314-6
   GAASTERLAND D, 1974, INVEST OPHTH VISUAL, V13, P455
   Gallego A., 1986, PROG RET RES, V5, P165, DOI [10.1016/0278-4327(86)90010-6, DOI 10.1016/0278-4327(86)90010-6]
   Gauthier BE, 2019, TOXICOL PATHOL, V47, P436, DOI 10.1177/0192623319827485
   Goldberg MF, 2018, OPHTHALMOL RETINA, V2, P360, DOI 10.1016/j.oret.2017.08.001
   Grunert U, 2020, PROG RETIN EYE RES, V78, DOI 10.1016/j.preteyeres.2020.100844
   Guo Y, 2016, JOVE-J VIS EXP, DOI 10.3791/54504
   Guymer C, 2020, TRANSL VIS SCI TECHN, V9, DOI 10.1167/tvst.9.6.28
   Haverkamp S, 2000, J COMP NEUROL, V424, P1
   Hoon M, 2014, PROG RETIN EYE RES, V42, P44, DOI 10.1016/j.preteyeres.2014.06.003
   Huang W, 2006, CURR EYE RES, V31, P265, DOI 10.1080/02713680500545671
   Inman DM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065389
   Jeon CJ, 1998, J NEUROSCI, V18, P8936
   Jin KX, 2015, MOL BRAIN, V8, DOI 10.1186/s13041-015-0118-x
   JOHNSON LN, 1994, J NEURO-OPHTHALMOL, V14, P38
   Kokona D, 2017, INVEST OPHTH VIS SCI, V58, P2160, DOI 10.1167/iovs.16-20916
   KOONTZ MA, 1993, VISION RES, V33, P2617, DOI 10.1016/0042-6989(93)90220-Q
   Kozlowski C, 2018, TOXICOL PATHOL, V46, P324, DOI 10.1177/0192623318766457
   Kwong JMK, 2011, INVEST OPHTH VIS SCI, V52, P9694, DOI 10.1167/iovs.11-7869
   Lamb TD, 2007, NAT REV NEUROSCI, V8, P960, DOI 10.1038/nrn2283
   Lee YH., 2017, PLOS ONE, V12
   Levkovitch-Verbin H, 2002, INVEST OPHTH VIS SCI, V43, P402
   Liang YX, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0128718
   Libby RT, 2005, VISUAL NEUROSCI, V22, P637, DOI 10.1017/S0952523805225130
   LINDEN R, 1987, VISION RES, V27, P1071, DOI 10.1016/0042-6989(87)90021-6
   LINDEN R, 1983, BRAIN RES, V272, P145, DOI 10.1016/0006-8993(83)90371-2
   Lueck K, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-03493-3
   Ma WX, 2016, ADV EXP MED BIOL, V854, P73, DOI 10.1007/978-3-319-17121-0_11
   Magharious MM, 2011, JOVE-J VIS EXP, DOI 10.3791/2241
   Mantopoulos D, 2016, CURR EYE RES, V41, P1498, DOI 10.3109/02713683.2015.1135960
   Marc RE, 2014, FRONT NEURAL CIRCUIT, V8, DOI 10.3389/fncir.2014.00104
   Markand S, 2015, INVEST OPHTH VIS SCI, V56, P2684, DOI 10.1167/iovs.14-16190
   Masland RH, 2001, NAT NEUROSCI, V4, P877, DOI 10.1038/nn0901-877
   May CA, 2008, OPEN OPHTHALMOL J, V2, P94, DOI 10.2174/1874364100802010094
   Mazzoni F, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-018-38363-z
   McNeill DS, 2008, P NATL ACAD SCI USA, V105, P12645, DOI 10.1073/pnas.0806878105
   Mead B, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0110612
   Mecklenburg L, 2007, TOXICOL PATHOL, V35, P252, DOI 10.1080/01926230601178199
   Mukai R, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0208713
   Muller LPD, 2017, FRONT NEUROANAT, V11, DOI 10.3389/fnana.2017.00039
   Nadal-Nicolas FM, 2009, INVEST OPHTH VIS SCI, V50, P3860, DOI 10.1167/iovs.08-3267
   Newman NJ, 2002, AM J OPHTHALMOL, V134, P317, DOI 10.1016/S0002-9394(02)01639-2
   O'Koren EG, 2019, IMMUNITY, V50, P723, DOI 10.1016/j.immuni.2019.02.007
   O'Neal TB, 2020, RETINITIS PIGMENTOSA
   Olivares AM, 2017, CURR DIABETES REP, V17, DOI 10.1007/s11892-017-0913-0
   Ollivier FJ, 2004, VET OPHTHALMOL, V7, P11, DOI 10.1111/j.1463-5224.2004.00318.x
   Pardue MT, 2018, PROG RETIN EYE RES, V65, P50, DOI 10.1016/j.preteyeres.2018.02.002
   PEICHL L, 1994, VISUAL NEUROSCI, V11, P501, DOI 10.1017/S095252380000242X
   Peichl L, 1998, NATO ADV SCI I A-LIF, V299, P147
   Pennesi ME, 2012, MOL ASPECTS MED, V33, P487, DOI 10.1016/j.mam.2012.06.003
   Muniz JAPC, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0115291
   Poche RA, 2009, DEVELOPMENT, V136, P2141, DOI 10.1242/dev.033175
   Provis Jan M, 2005, Clin Exp Optom, V88, P269
   Purves D, 2001, NEUROSCIENCE, V2nd
   Ramirez AI, 2010, INVEST OPHTH VIS SCI, V51, P5690, DOI 10.1167/iovs.10-5248
   Rashid Khalid, 2019, Front Immunol, V10, P1975, DOI 10.3389/fimmu.2019.01975
   Salinas-Navarro M, 2009, VISION RES, V49, P637, DOI 10.1016/j.visres.2009.01.010
   Salinas-Navarro M, 2009, VISION RES, V49, P115, DOI 10.1016/j.visres.2008.09.029
   Sanes JR, 2015, ANNU REV NEUROSCI, V38, P221, DOI 10.1146/annurev-neuro-071714-034120
   Sappington RM, 2010, INVEST OPHTH VIS SCI, V51, P207, DOI 10.1167/iovs.09-3947
   Schlamp CL, 2001, MOL VIS, V7, P192
   Schnitzer J., 1988, Progress in Retinal Research, V7, P209, DOI 10.1016/0278-4327(88)90009-0
   SCHNITZER J, 1985, J COMP NEUROL, V240, P128, DOI 10.1002/cne.902400203
   SHAREEF SR, 1995, EXP EYE RES, V61, P379, DOI 10.1016/S0014-4835(05)80131-9
   Shrader SM, 2018, TOXICOL PATHOL, V46, P403, DOI 10.1177/0192623318770379
   Sjostrand J, 1999, VISION RES, V39, P2987, DOI 10.1016/S0042-6989(99)00030-9
   Smith CA, 2017, EYE, V31, P209, DOI 10.1038/eye.2016.295
   Sonntag S, 2012, J NEUROSCI, V32, P10713, DOI 10.1523/JNEUROSCI.0442-12.2012
   Soto I, 2008, J NEUROSCI, V28, P548, DOI 10.1523/JNEUROSCI.3714-07.2008
   Sparrrow JR, 2010, CURR MOL MED, V10, P802
   Stern J, 2015, EXP BIOL MED, V240, P1079, DOI 10.1177/1535370215587530
   Stradleigh TW, 2015, PROG RETIN EYE RES, V48, P181, DOI 10.1016/j.preteyeres.2015.04.001
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Strauss O, 2011, ADLERS PHYSL EYE, P325
   Surgucheva I, 2008, MOL VIS, V14, P1540
   Tham YC, 2014, OPHTHALMOLOGY, V121, P2081, DOI 10.1016/j.ophtha.2014.05.013
   Thoreson WB, 2019, PHYSIOL REV, V99, P1527, DOI 10.1152/physrev.00027.2018
   Trivino A, 1997, VISION RES, V37, P1707, DOI 10.1016/S0042-6989(97)00021-7
   Tsukamoto Y, 2017, FRONT NEUROANAT, V11, DOI 10.3389/fnana.2017.00092
   Tufford AR, 2018, CELL REP, V23, P2416, DOI 10.1016/j.celrep.2018.04.086
   Ullmann JFP, 2012, BRAIN BEHAV EVOLUT, V79, P26, DOI 10.1159/000332802
   van der Merwe I, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0202106
   Vecino E, 2016, PROG RETIN EYE RES, V51, P1, DOI 10.1016/j.preteyeres.2015.06.003
   Volland S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125631
   Wang JM, 2014, INVEST OPHTH VIS SCI, V55, P1941, DOI 10.1167/iovs.13-13075
   Wang MH, 2014, ADV EXP MED BIOL, V801, P333, DOI 10.1007/978-1-4614-3209-8_42
   Wang X, 2016, J NEUROSCI, V36, P2827, DOI 10.1523/JNEUROSCI.3575-15.2016
   WASSLE H, 1989, NATURE, V341, P643, DOI 10.1038/341643a0
   Watson AB, 2014, J VISION, V14, DOI 10.1167/14.7.15
   Wilsey LJ, 2016, INVEST OPHTH VIS SCI, V57, P1892, DOI 10.1167/iovs.15-18119
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yanoff MS., 2018, J OCULAR PATHOLOGY, V8
   Zeiss CJ, 2010, VET PATHOL, V47, P396, DOI 10.1177/0300985809359598
NR 133
TC 0
Z9 0
U1 0
U2 9
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0192-6233
EI 1533-1601
J9 TOXICOL PATHOL
JI Toxicol. Pathol.
PD APR
PY 2021
VL 49
IS 3
SI SI
BP 505
EP 520
DI 10.1177/0192623320976375
PG 16
WC Pathology; Toxicology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pathology; Toxicology
GA QZ1JO
UT WOS:000630491300007
PM 33380270
DA 2022-11-30
ER

PT J
AU Chen, RY
   Lee, C
   Lin, XC
   Zhao, C
   Li, XR
AF Chen, Rongyuan
   Lee, Chunsik
   Lin, Xianchai
   Zhao, Chen
   Li, Xuri
TI Novel function of VEGF-B as an antioxidant and therapeutic implications
SO PHARMACOLOGICAL RESEARCH
LA English
DT Review
DE VEGF-B; Oxidative stress; Antioxidant; Degenerative diseases; Ocular
   disorders; Apoptosis
ID ENDOTHELIAL GROWTH-FACTOR; MILD COGNITIVE IMPAIRMENT; HIGH-DOSE
   SUPPLEMENTATION; GENOME-WIDE ASSOCIATION; OXIDATIVE STRESS; IN-VIVO;
   VITAMIN-E; MACULAR DEGENERATION; INDUCED INFLAMMATION; IDENTIFIES
   VARIANTS
AB Oxidative stress, due to insufficiency of antioxidants or over-production of oxidants, can lead to severe cell and tissue damage. Oxidative stress occurs constantly and has been shown to be involved in innumerable diseases, such as degenerative, cardiovascular, neurological, and metabolic disorders, cancer, and aging, thus highlighting the vital need of antioxidant defense mechanisms. Vascular endothelial growth factor B (VEGF-B) was discovered a long time ago, and is abundantly expressed in most types of cells and tissues. VEGF-B remained functionally mysterious for many years and later on has been shown to be minimally angiogenic. Recently, VEGF-B is reported to be a potent antioxidant by boosting the expression of key antioxidant enzymes. Thus, one major role of VEGF-B lies in safeguarding tissues and cells from oxidative stress-induced damage. VEGF-B may therefore have promising therapeutic utilities in treating oxidative stress-related diseases. In this review, we discuss the current knowledge on the newly discovered antioxidant function of VEGF-B and the related molecular mechanisms, particularly, in relationship to some oxidative stress-related diseases, such as retinitis pigmentosa, age-related macular degeneration, diabetic retinopathy, glaucoma, amyotrophic lateral sclerosis, Alzheimer's disease, and Parkinson's disease.
C1 [Chen, Rongyuan; Lee, Chunsik; Lin, Xianchai; Li, Xuri] Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, State Key Lab Ophthalmol, Guangzhou 510060, Guangdong, Peoples R China.
   [Zhao, Chen] Fudan Univ, Eye & ENT Hosp, Shanghai Med Coll, Eye Inst, Shanghai, Peoples R China.
   [Zhao, Chen] Fudan Univ, State Hlth Minist, Key Lab Myopia, Shanghai 200023, Peoples R China.
   [Zhao, Chen] Shanghai Key Lab Visual Impairment & Restorat, Shanghai 200023, Peoples R China.
C3 Sun Yat Sen University; Fudan University; Fudan University
RP Li, XR (通讯作者)，Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, State Key Lab Ophthalmol, Guangzhou 510060, Guangdong, Peoples R China.; Zhao, C (通讯作者)，Fudan Univ, Eye & ENT Hosp, Shanghai Med Coll, Eye Inst, Shanghai, Peoples R China.
EM dr_zhaochen@163.com; lixr6@mail.sysu.edu.cn
FU State Key Laboratory of Ophthalmology (SKLO) at the Zhongshan Ophthalmic
   Center (ZOC), Sun Yat-Sen University (SYSU), Guangzhou, China; National
   Natural Science Foundation of China [81670855]; Guangzhou Science and
   Development Key Program [201804020010]; China Postdoctoral Science
   Foundation [2018M633240]
FX This work is supported by the State Key Laboratory of Ophthalmology
   (SKLO) at the Zhongshan Ophthalmic Center (ZOC), Sun Yat-Sen University
   (SYSU), Guangzhou, China; a grant from the National Natural Science
   Foundation of China (81670855) to X. Li; a grant from the Guangzhou
   Science and Development Key Program (201804020010) to X. Li; and a China
   Postdoctoral Science Foundation grant (2018M633240) to R. Chen.
CR Aase K, 2001, CIRCULATION, V104, P358, DOI 10.1161/01.CIR.104.3.358
   Abe K, 2017, LANCET NEUROL, V16, P505, DOI 10.1016/S1474-4422(17)30115-1
   Abraham D, 2002, TRANSPLANTATION, V73, P1703, DOI 10.1097/00007890-200206150-00003
   Abu-Amero KK, 2016, NUTRIENTS, V8, DOI 10.3390/nu8040200
   Agrawal M, 2018, J CONTROL RELEASE, V281, P139, DOI 10.1016/j.jconrel.2018.05.011
   Ak T, 2008, CHEM-BIOL INTERACT, V174, P27, DOI 10.1016/j.cbi.2008.05.003
   Al-Chalabi A, 2017, AMYOTROPH LAT SCL FR, V18, P471, DOI 10.1080/21678421.2017.1369125
   Allen RG, 2000, FREE RADICAL BIO MED, V28, P463, DOI 10.1016/S0891-5849(99)00242-7
   Ambati J, 2013, NAT REV IMMUNOL, V13, P438, DOI 10.1038/nri3459
   Anisimov A, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2003905
   Annabi B, 2012, DRUG TARGET INSIGHT, V6, P1, DOI 10.4137/DTI.S9442
   Arjunan P, 2018, P NATL ACAD SCI USA, V115, P10351, DOI 10.1073/pnas.1801379115
   Ataie A, 2010, PHARMACOL BIOCHEM BE, V96, P378, DOI 10.1016/j.pbb.2010.06.009
   Barabash A, 2009, NEUROBIOL AGING, V30, P1254, DOI 10.1016/j.neurobiolaging.2007.11.003
   Barber AJ, 1998, J CLIN INVEST, V102, P783, DOI 10.1172/JCI2425
   Bellezza I, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.01280
   Bellomo D, 2000, CIRC RES, V86, pE29, DOI 10.1161/01.RES.86.2.e29
   Bola C, 2014, GRAEF ARCH CLIN EXP, V252, P699, DOI 10.1007/s00417-014-2604-8
   Brkovic A, 2007, J CELL BIOCHEM, V100, P727, DOI 10.1002/jcb.21124
   Bry M, 2014, PHYSIOL REV, V94, P779, DOI 10.1152/physrev.00028.2013
   Bry M, 2010, CIRCULATION, V122, P1725, DOI 10.1161/CIRCULATIONAHA.110.957332
   Buttner S, 2013, EMBO J, V32, P3041, DOI 10.1038/emboj.2013.228
   Butterfield DA, 2002, NEUROBIOL AGING, V23, P655
   Cai H, 2000, CIRC RES, V87, P840, DOI 10.1161/01.RES.87.10.840
   Campochiaro PA, 2018, PROG RETIN EYE RES, V62, P24, DOI 10.1016/j.preteyeres.2017.08.004
   Campochiaro PA, 2015, ANTIOXID REDOX SIGN, V23, P643, DOI 10.1089/ars.2015.6327
   Carmeliet P, 2001, NAT MED, V7, P575, DOI 10.1038/87904
   Carri MT, 2015, FRONT CELL NEUROSCI, V9, DOI 10.3389/fncel.2015.00041
   Chen M, 2018, NEURAL REGEN RES, V13, P742, DOI 10.4103/1673-5374.230303
   Chew EY, 2013, JAMA OPHTHALMOL, V131, P843, DOI 10.1001/jamaophthalmol.2013.4412
   Daw EW, 2000, AM J HUM GENET, V66, P196, DOI 10.1086/302710
   Dhalla NS, 2000, J HYPERTENS, V18, P655, DOI 10.1097/00004872-200018060-00002
   Di GH, 2017, SCI REP-UK, V7, DOI 10.1038/srep40582
   Dogan S, 2011, EXP EYE RES, V93, P387, DOI 10.1016/j.exer.2011.05.008
   Dorst J, 2017, THER ADV NEUROL DISO, V11, P1, DOI 10.1177/1756285617734734
   DVORAK HF, 1995, AM J PATHOL, V146, P1029
   Falk T, 2011, NEUROSCI LETT, V496, P43, DOI 10.1016/j.neulet.2011.03.088
   Falk T, 2009, MOL NEURODEGENER, V4, DOI 10.1186/1750-1326-4-49
   Faustini G, 2017, GENES-BASEL, V8, DOI 10.3390/genes8120377
   Federico A, 2007, INT J CANCER, V121, P2381, DOI 10.1002/ijc.23192
   Gabrieli JDE, 1996, P NATL ACAD SCI USA, V93, P13534, DOI 10.1073/pnas.93.24.13534
   Gelfand BD, 2016, TRENDS MOL MED, V22, P656, DOI 10.1016/j.molmed.2016.06.009
   Giulia N, 2017, CURR TOP MED CHEM, V17, P3062, DOI 10.2174/1568026617666170607114232
   Gorusupudi A, 2017, ADV NUTR, V8, P40, DOI 10.3945/an.116.013177
   Grimmond S, 1996, GENOME RES, V6, P124, DOI 10.1101/gr.6.2.124
   Gugliandolo A, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18122504
   Hagberg CE, 2012, NATURE, V490, P426, DOI 10.1038/nature11464
   Hagberg CE, 2010, NATURE, V464, P917, DOI 10.1038/nature08945
   Hamaguchi T, 2009, AM J PATHOL, V175, P2557, DOI 10.2353/ajpath.2009.090417
   Hamel C, 2006, ORPHANET J RARE DIS, V1, DOI 10.1186/1750-1172-1-40
   Hammes HP, 1997, DIABETOLOGIA, V40, P629, DOI 10.1007/s001250050726
   Handa JT, 2012, MOL ASPECTS MED, V33, P418, DOI 10.1016/j.mam.2012.03.006
   Harada C, 2006, AM J PATHOL, V168, P261, DOI 10.2353/ajpath.2006.050765
   Harold D, 2009, NAT GENET, V41, P1088, DOI 10.1038/ng.440
   Hartong DT, 2006, LANCET, V368, P1795, DOI 10.1016/S0140-6736(06)69740-7
   Hayashi M, 2012, ADV EXP MED BIOL, V724, P278, DOI 10.1007/978-1-4614-0653-2_21
   Hinchcliffe M, 2017, DEGENER NEUROL NEURO, V7, P61, DOI 10.2147/DNND.S135748
   Hollyfield JG, 2008, NAT MED, V14, P194, DOI 10.1038/nm1709
   Huang DL, 2016, SCI REP-UK, V6, DOI 10.1038/srep26059
   Huang WJ, 2016, BIOMED REP, V4, P519, DOI 10.3892/br.2016.630
   Imamura Y, 2006, P NATL ACAD SCI USA, V103, P11282, DOI 10.1073/pnas.0602131103
   Iyer S, 2010, J BIOL CHEM, V285, P23779, DOI 10.1074/jbc.M110.130658
   Izzotti A, 2006, MUTAT RES-REV MUTAT, V612, P105, DOI 10.1016/j.mrrev.2005.11.001
   Jaiswal MK, 2019, MED RES REV, V39, P733, DOI 10.1002/med.21528
   Jankovic J, 2005, MOVEMENT DISORD, V20, pS11, DOI 10.1002/mds.20458
   Jarrett SG, 2012, MOL ASPECTS MED, V33, P399, DOI 10.1016/j.mam.2012.03.009
   Jensen LD, 2015, P NATL ACAD SCI USA, V112, pE5944, DOI 10.1073/pnas.1510245112
   Johnson EJ, 2010, CURR OPIN CLIN NUTR, V13, P28, DOI 10.1097/MCO.0b013e32833308ff
   Joukov V, 1997, EMBO J, V16, P3898, DOI 10.1093/emboj/16.13.3898
   Justilien V, 2007, INVEST OPHTH VIS SCI, V48, P4407, DOI 10.1167/iovs.07-0432
   Kanda M, 2008, J SURG ONCOL, V98, P190, DOI 10.1002/jso.21095
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1439, DOI 10.1001/archopht.119.10.1439
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kim YH, 2012, ACTA OPHTHALMOL, V90, pE31, DOI 10.1111/j.1755-3768.2011.02243.x
   Kisler K, 2017, NAT NEUROSCI, V20, P406, DOI 10.1038/nn.4489
   Kivela R, 2014, EMBO MOL MED, V6, P307, DOI 10.1002/emmm.201303147
   Komeima K, 2007, J CELL PHYSIOL, V213, P809, DOI 10.1002/jcp.21152
   Kowluru RA, 2001, EXPERT OPIN INV DRUG, V10, P1665, DOI 10.1517/13543784.10.9.1665
   Lambert JC, 2009, NAT GENET, V41, P1094, DOI 10.1038/ng.439
   Lees AJ, 2009, LANCET, V373, P2055, DOI 10.1016/S0140-6736(09)60492-X
   Leoni V, 2011, CLIN CHEM LAB MED, V49, P375, DOI 10.1515/CCLM.2011.088
   Levin Leonard A, 2005, Ophthalmol Clin North Am, V18, P585
   Li XR, 2001, GROWTH FACTORS, V19, P49, DOI 10.3109/08977190109001075
   Li X, 2008, ARTERIOSCL THROM VAS, V28, P1614, DOI 10.1161/ATVBAHA.107.158725
   Li XR, 2012, TRENDS MOL MED, V18, P119, DOI 10.1016/j.molmed.2011.11.006
   Li Y, 2008, J CLIN INVEST, V118, P913, DOI 10.1172/JCI33673
   Lin L, 2006, CELL MOL IMMUNOL, V3, P351
   Losso JN, 2010, J AGR FOOD CHEM, V58, P8246, DOI 10.1021/jf1012067
   Louzier V, 2003, AM J PHYSIOL-LUNG C, V284, pL926, DOI 10.1152/ajplung.00247.2002
   Makinen T, 1999, J BIOL CHEM, V274, P21217, DOI 10.1074/jbc.274.30.21217
   Mattson MP, 2004, NATURE, V430, P631, DOI 10.1038/nature02621
   Moreno ML, 2018, FRONT PHYSIOL, V9, DOI 10.3389/fphys.2018.01008
   Moreno MC, 2005, FASEB J, V19, P1161, DOI 10.1096/fj.04-3313fje
   Moreno MC, 2004, FREE RADICAL BIO MED, V37, P803, DOI 10.1016/j.freeradbiomed.2004.06.001
   Morrison JH, 1997, SCIENCE, V278, P412, DOI 10.1126/science.278.5337.412
   Mould AW, 2005, CIRC RES, V97, P60, DOI 10.1161/01.RES.0000182631.33638.77
   Nishida Y, 2006, BIOCHEM BIOPH RES CO, V350, P530, DOI 10.1016/j.bbrc.2006.09.083
   Nishida Y, 2009, J BIOL CHEM, V284, P33400, DOI 10.1074/jbc.M109.054056
   Nutt JG, 2005, NEW ENGL J MED, V353, P1021, DOI 10.1056/NEJMcp043908
   Ogawa S, 1998, J BIOL CHEM, V273, P31273, DOI 10.1074/jbc.273.47.31273
   Olofsson B, 1998, P NATL ACAD SCI USA, V95, P11709, DOI 10.1073/pnas.95.20.11709
   Olofsson B, 1996, P NATL ACAD SCI USA, V93, P2576, DOI 10.1073/pnas.93.6.2576
   Osborne NN, 2008, PROG BRAIN RES, V173, P339, DOI 10.1016/S0079-6123(08)01124-2
   Ozdemir G, 2009, J GLAUCOMA, V18, P662, DOI 10.1097/IJG.0b013e31819c46b1
   Poesen K, 2008, J NEUROSCI, V28, P10451, DOI 10.1523/JNEUROSCI.1092-08.2008
   Pollari E, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00131
   Potkin SG, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006501
   Puspita L, 2017, MOL BRAIN, V10, DOI 10.1186/s13041-017-0340-9
   Reichelt M, 2003, CLIN EXP OPHTHALMOL, V31, P61, DOI 10.1046/j.1442-9071.2003.00602.x
   Reitz C, 2010, J ALZHEIMERS DIS, V19, P229, DOI 10.3233/JAD-2010-1255
   Rissanen TT, 2003, CIRC RES, V92, P1098, DOI 10.1161/01.RES.0000073584.46059.E3
   Robciuc MR, 2016, CELL METAB, V23, P712, DOI 10.1016/j.cmet.2016.03.004
   Rogaeva E, 2007, NAT GENET, V39, P168, DOI 10.1038/ng1943
   Roy P, 2009, PHARM RES-DORDR, V26, P211, DOI 10.1007/s11095-008-9723-z
   Selley ML, 2002, NEUROBIOL AGING, V23, P383, DOI 10.1016/S0197-4580(01)00327-X
   SHIBUYA M, 1990, ONCOGENE, V5, P519
   Shoshan-Barmatz V, 2018, PHARMACOL RES, V131, P87, DOI 10.1016/j.phrs.2018.03.010
   Silvestre JS, 2003, CIRC RES, V93, P114, DOI 10.1161/01.RES.0000081594.21764.44
   Soto IC, 2012, CELL METAB, V16, P801, DOI 10.1016/j.cmet.2012.10.018
   Tai LM, 2014, J BIOL CHEM, V289, P30538, DOI 10.1074/jbc.M114.600833
   Takei K, 2017, AMYOTROPH LAT SCL FR, V18, P5, DOI 10.1080/21678421.2017.1353101
   Ung L, 2017, CLIN SCI, V131, P2865, DOI 10.1042/CS20171246
   van Leeuwen R, 2005, JAMA-J AM MED ASSOC, V294, P3101, DOI 10.1001/jama.294.24.3101
   Vemuri P, 2017, ANN NEUROL, V82, P706, DOI 10.1002/ana.25071
   Wright AF, 2010, NAT REV GENET, V11, P273, DOI 10.1038/nrg2717
   Wu MY, 2018, OXID MED CELL LONGEV, V2018, DOI 10.1155/2018/3420187
   Yang FS, 2005, J BIOL CHEM, V280, P5892, DOI 10.1074/jbc.M404751200
   Yang L, 2012, CELL MOL NEUROBIOL, V32, P1275, DOI 10.1007/s10571-012-9852-0
   Yue X, 2014, NEUROSCIENCE, V258, P385, DOI 10.1016/j.neuroscience.2013.11.038
   Zhang F, 2009, P NATL ACAD SCI USA, V106, P6152, DOI 10.1073/pnas.0813061106
   Zhao ZY, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019456
   Zou ZY, 2017, J NEUROL NEUROSUR PS, V88, P540, DOI 10.1136/jnnp-2016-315018
   2014, P NATL ACAD SCI USA, V111, P1727, DOI DOI 10.1073/PNAS.1407227111
   1996, J BIOL CHEM, V271, P1931, DOI DOI 10.1074/JBC.271.32.19310
   2016, AGEING RES REV, V29, P26, DOI DOI 10.1016/J.ARR.2016.05.012
   2008, J CLIN PSYCHOPHARM, V28, P110, DOI DOI 10.1097/JCP.OB013E318160862C
   2009, J NEUROCHEM, V110, P1028, DOI DOI 10.1111/J.1471-4159.2009.06195.X.
   2001, DIABETES, V50, P1938, DOI DOI 10.2337/DIABETES.50.8.1938.
   2009, CIRCULATION, V119, P845, DOI DOI 10.1161/CIRCULATIONAHA.108.816454
   2017, LANCET NEUROL, V16, P772, DOI DOI 10.1016/S1474-4422(17)30290-9
   2018, J NEUROCHEM, V144, P617, DOI DOI 10.1111/JNC.14271
   2010, CIRC RES, V106, P1893, DOI DOI 10.1161/CIRCRESAHA.110.220855
NR 142
TC 12
Z9 15
U1 5
U2 22
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 1043-6618
EI 1096-1186
J9 PHARMACOL RES
JI Pharmacol. Res.
PD MAY
PY 2019
VL 143
BP 33
EP 39
DI 10.1016/j.phrs.2019.03.002
PG 7
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA HW6VC
UT WOS:000466827800004
PM 30851357
DA 2022-11-30
ER

PT J
AU Behroozi, F
   Abdkhodaie, MJ
   Abandansari, HS
   Satarian, L
   Ashtiani, MK
   Jaafari, MR
   Baharvand, H
AF Behroozi, Farnaz
   Abdkhodaie, Mohammad-Jafar
   Abandansari, Hamid Sadeghi
   Satarian, Leila
   Ashtiani, Mohammad Kazemi
   Jaafari, Mahmoud Reza
   Baharvand, Hossein
TI Smart liposomal drug delivery for treatment of oxidative stress model in
   human embryonic stem cell-derived retinal pigment epithelial cells
SO INTERNATIONAL JOURNAL OF PHARMACEUTICS
LA English
DT Article
DE Redox sensitive; Liposome; Diselenide; Drug delivery; Human embryonic
   stem cells; Retinal pigment epithelium cells; Age macular degeneration
ID MACULAR DEGENERATION; GENE-EXPRESSION; NANOTECHNOLOGY; ANTIOXIDANT;
   RELEASE; DISEASE
AB Oxidative stress has been implicated in the progression of age-related macular degeneration (AMD). Treatment with antioxidants seems to delay progression of AMD. In this study, we suggested an antioxidant delivery system based on redox-sensitive liposome composed of phospholipids and a diselenide centered alkyl chain. Dynamic light scattering assessment indicated that the liposomes had an average size of 140 nm with a polydispersity index below 0.2. The percentage of encapsulation efficiency of the liposomes was calculated by high-performance liquid chromatography. The carriers were loaded with N-acetyl cysteine as a model antioxidant drug. We demonstrated responsiveness of the nanocarrier and its efficiency in drug delivery in an oxidative stress model of human embryonic stem cell-derived retinal pigment epithelial (hESC-RPE) cells. The modeled cells treated with diselenide containing liposomes loaded with 10mM NAC, showed a better therapeutic effect with a cell metabolic activity of 90%, which was significantly higher compared to insensitive liposomes or NAC treated groups (P < 0.05). In addition, the expression of oxidative-sensitive gene markers in diselenide containing liposomes groups were improved. Our results demonstrated fabricated smart liposomes opens new opportunity for targeted treatment of retinal degeneration.
C1 [Behroozi, Farnaz; Abdkhodaie, Mohammad-Jafar] Sharif Univ Technol, Dept Chem & Petr Engn, Tehran, Iran.
   [Abandansari, Hamid Sadeghi; Ashtiani, Mohammad Kazemi] ACECR, Dept Cell Engn, Cell Sci Res Ctr, Royan Inst Stem Cell Biol & Technol, Tehran, Iran.
   [Satarian, Leila; Baharvand, Hossein] ACECR, Dept Stem Cells & Dev Biol, Cell Sci Res Ctr, Royan Inst Stem Cell Biol & Technol, Tehran, Iran.
   [Jaafari, Mahmoud Reza] Mashhad Univ Med Sci, Nanotechnol Res Ctr, Pharmaceut Technol Inst, Mashhad, Iran.
   [Jaafari, Mahmoud Reza] Mashhad Univ Med Sci, Dept Pharmaceut Nanotechnol, Sch Pharm, Mashhad, Iran.
   [Baharvand, Hossein] Univ Sci & Culture, Dept Dev Biol, Tehran, Iran.
C3 Sharif University of Technology; Academic Center for Education, Culture
   & Research (ACECR); Academic Center for Education, Culture & Research
   (ACECR); Mashhad University Medical Science; Mashhad University Medical
   Science
RP Abdkhodaie, MJ (通讯作者)，Sharif Univ Technol, Dept Chem & Petr Engn, Tehran, Iran.; Baharvand, H (通讯作者)，ACECR, Dept Stem Cells & Dev Biol, Cell Sci Res Ctr, Royan Inst Stem Cell Biol & Technol, Tehran, Iran.; Jaafari, MR (通讯作者)，Mashhad Univ Med Sci, Nanotechnol Res Ctr, Pharmaceut Technol Inst, Mashhad, Iran.
EM abdmj@sharif.edu; JafariMR@mums.ac.ir; Baharvand@Royaninstitute.org
RI Satarian, Leila/M-3835-2017; Sadeghi Abandansari, Hamid/M-2374-2018
OI Satarian, Leila/0000-0002-5068-5031; Jaafari, Mahmoud
   Reza/0000-0003-3908-6828; Sadeghi Abandansari, Hamid/0000-0002-3548-168X
FU Royan Institute; Iran National Science Foundation (INSF); Iran Science
   Elites Federation
FX This work was supported by grants from Royan Institute, the Iran
   National Science Foundation (INSF), and Iran Science Elites Federation
   to H. B.
CR ANDERSON D, 1994, MUTAT RES, V307, P261, DOI 10.1016/0027-5107(94)90300-X
   Anthony C., 2005, PHARMACOPEIAL FORUM, V31, P726
   Arouri A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125508
   Baharvand H, 2006, DEV GROWTH DIFFER, V48, P117, DOI 10.1111/j.1440-169x.2006.00851.x
   Cai JY, 2000, PROG RETIN EYE RES, V19, P205, DOI 10.1016/S1350-9462(99)00009-9
   Damico FM, 2012, ARQ BRAS OFTALMOL, V75, P71, DOI 10.1590/S0004-27492012000100016
   Davidsen J, 2003, BBA-BIOMEMBRANES, V1609, P95, DOI 10.1016/S0005-2736(02)00659-4
   Delplace V, 2015, J CONTROL RELEASE, V219, P652, DOI 10.1016/j.jconrel.2015.09.065
   Farokhzad OC, 2009, ACS NANO, V3, P16, DOI 10.1021/nn900002m
   Gerona G, 2010, J OCUL PHARMACOL TH, V26, P309, DOI 10.1089/jop.2009.0101
   Goldenbogen B, 2011, LANGMUIR, V27, P10820, DOI 10.1021/la201160y
   Hanus J, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.478
   Hathout RM, 2007, AAPS PHARMSCITECH, V8
   Hsu KH, 2014, J DRUG DELIV SCI TEC, V24, P123, DOI 10.1016/S1773-2247(14)50021-4
   Kaczara P, 2010, FREE RADICAL BIO MED, V48, P1064, DOI 10.1016/j.freeradbiomed.2010.01.022
   Kasdorf BT, 2015, BIOPHYS J, V109, P2171, DOI 10.1016/j.bpj.2015.10.002
   Kodama T, 2010, J ELECTRON MICROSC, V59, P187, DOI 10.1093/jmicro/dfp056
   Lin TC, 2015, J CHIN MED ASSOC, V78, P635, DOI 10.1016/j.jcma.2015.07.008
   Mandai M., 2017, NEW ENGL J MED, V11, P376
   Mlochowski J, 2015, MOLECULES, V20, P10205, DOI 10.3390/molecules200610205
   Nogueira CW, 2003, INFLAMM RES, V52, P56, DOI 10.1007/s000110300001
   Parvini M, 2014, MOL NEUROBIOL, V50, P597, DOI 10.1007/s12035-014-8684-y
   Rafique J, 2015, MOLECULES, V20, P10095, DOI 10.3390/molecules200610095
   Raich PC, 2001, CANCER INVEST, V19, P540, DOI 10.1081/CNV-100103851
   Roth F, 2004, GRAEF ARCH CLIN EXP, V242, P710, DOI 10.1007/s00417-004-0976-x
   Sahoo SK, 2008, DRUG DISCOV TODAY, V13, P144, DOI 10.1016/j.drudis.2007.10.021
   SCHEWE T, 1995, GEN PHARMACOL-VASC S, V26, P1153, DOI 10.1016/0306-3623(95)00003-J
   Schwartz S. D., 2015, LANCET, V16, P385
   Sharman WM, 1999, DRUG DISCOV TODAY, V4, P507, DOI 10.1016/S1359-6446(99)01412-9
   Shen Y, 2007, AAPS J, V9, DOI 10.1208/aapsj0903044
   Song CC, 2014, J MATER CHEM B, V2, P3413, DOI 10.1039/c3tb21725f
   TATE DJ, 1995, INVEST OPHTH VIS SCI, V36, P1271
   Thrimawithana TR, 2011, DRUG DISCOV TODAY, V16, P270, DOI 10.1016/j.drudis.2010.12.004
   Torchilin VP, 2014, NAT REV DRUG DISCOV, V13, P813, DOI 10.1038/nrd4333
   Zahabi A, 2012, STEM CELLS DEV, V21, P2262, DOI 10.1089/scd.2011.0599
   Zalipsky S, 1999, BIOCONJUGATE CHEM, V10, P703, DOI 10.1021/bc990031n
NR 36
TC 6
Z9 6
U1 0
U2 26
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0378-5173
EI 1873-3476
J9 INT J PHARMACEUT
JI Int. J. Pharm.
PD SEP
PY 2018
VL 548
IS 1
BP 62
EP 72
DI 10.1016/j.ijpharm.2018.05.056
PG 11
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA GP1CZ
UT WOS:000440552100007
PM 29802900
DA 2022-11-30
ER

PT J
AU Gharahkhani, P
   Burdon, KP
   Bailey, JNC
   Hewitt, AW
   Law, MH
   Pasquale, LR
   Kang, JH
   Haines, JL
   Souzeau, E
   Zhou, T
   Siggs, OM
   Landers, J
   Awadalla, M
   Sharma, S
   Mills, RA
   Ridge, B
   Lynn, D
   Casson, R
   Graham, SL
   Goldberg, I
   White, A
   Healey, PR
   Grigg, J
   Lawlor, M
   Mitchell, P
   Ruddle, J
   Coote, M
   Walland, M
   Best, S
   Vincent, A
   Gale, J
   RadfordSmith, G
   Whiteman, DC
   Montgomery, GW
   Martin, NG
   Mackey, DA
   Wiggs, JL
   MacGregor, S
   Craig, JE
AF Gharahkhani, Puya
   Burdon, Kathryn P.
   Bailey, Jessica N. Cooke
   Hewitt, Alex W.
   Law, Matthew H.
   Pasquale, Louis R.
   Kang, Jae H.
   Haines, Jonathan L.
   Souzeau, Emmanuelle
   Zhou, Tiger
   Siggs, Owen M.
   Landers, John
   Awadalla, Mona
   Sharma, Shiwani
   Mills, Richard A.
   Ridge, Bronwyn
   Lynn, David
   Casson, Robert
   Graham, Stuart L.
   Goldberg, Ivan
   White, Andrew
   Healey, Paul R.
   Grigg, John
   Lawlor, Mitchell
   Mitchell, Paul
   Ruddle, Jonathan
   Coote, Michael
   Walland, Mark
   Best, Stephen
   Vincent, Andrea
   Gale, Jesse
   RadfordSmith, Graham
   Whiteman, David C.
   Montgomery, Grant W.
   Martin, Nicholas G.
   Mackey, David A.
   Wiggs, Janey L.
   MacGregor, Stuart
   Craig, Jamie E.
CA NEIGHBORHOOD Consortium
TI Analysis combining correlated glaucoma traits identifies five new risk
   loci for open-angle glaucoma
SO SCIENTIFIC REPORTS
LA English
DT Article
ID GENOME-WIDE ASSOCIATION; TO-DISC RATIO; SUSCEPTIBILITY LOCI; TRABECULAR
   MESHWORK; GENOTYPE IMPUTATION; COMMON VARIANTS; RETINOIC ACID; PROTEIN;
   DEGENERATION; MULTIPLE
AB Open-angle glaucoma (OAG) is a major cause of blindness worldwide. To identify new risk loci for OAG, we performed a genome-wide association study in 3,071 OAG cases and 6,750 unscreened controls, and meta-analysed the results with GWAS data for intraocular pressure (IOP) and optic disc parameters (the overall meta-analysis sample size varying between 32,000 to 48,000 participants), which are glaucoma-related traits. We identified and independently validated four novel genome-wide significant associations within or near MYOF and CYP26A1, LINC02052 and CRYGS, LMX1B, and LMO7 using single variant tests, one additional locus (C9) using gene-based tests, and two genetic pathways - "response to fluid shear stress" and "abnormal retina morphology" - in pathway-based tests. Interestingly, some of the new risk loci contribute to risk of other genetically-correlated eye diseases including myopia and age-related macular degeneration. To our knowledge, this study is the first integrative study to combine genetic data from OAG and its correlated traits to identify new risk variants and genetic pathways, highlighting the future potential of combining genetic data from genetically-correlated eye traits for the purpose of gene discovery and mapping.
C1 [Gharahkhani, Puya; Law, Matthew H.; RadfordSmith, Graham; Whiteman, David C.; Montgomery, Grant W.; Martin, Nicholas G.; MacGregor, Stuart] QIMR Berghofer Med Res Inst, Brisbane, Qld, Australia.
   [Burdon, Kathryn P.; Hewitt, Alex W.; Mackey, David A.] Univ Tasmania, Hobart, Tas, Australia.
   [Bailey, Jessica N. Cooke; Haines, Jonathan L.] Case Western Reserve Univ, Sch Med, Inst Computat Biol, Populat & Quantitat Hlth Sci, Cleveland, OH USA.
   [Pasquale, Louis R.; Wiggs, Janey L.] Harvard Med Sch, Massachusetts Eye & Ear Infirm, Dept Ophthalmol, Boston, MA USA.
   [Pasquale, Louis R.; Kang, Jae H.] Harvard Med Sch, Brigham & Womens Hosp, Channing Div Network Med, Boston, MA USA.
   [Souzeau, Emmanuelle; Zhou, Tiger; Siggs, Owen M.; Landers, John; Awadalla, Mona; Sharma, Shiwani; Mills, Richard A.; Ridge, Bronwyn; Craig, Jamie E.] Flinders Univ S Australia, Dept Ophthalmol, Adelaide, SA, Australia.
   [Lynn, David] Flinders Univ S Australia, Sch Med, South Australian Hlth & Med Res Inst, Adelaide, SA, Australia.
   [Casson, Robert] Univ Adelaide, South Australian Inst Ophthalmol, Adelaide, SA, Australia.
   [Graham, Stuart L.] Macquarie Univ, Ophthalmol & Vis Sci, Sydney, NSW, Australia.
   [Goldberg, Ivan; White, Andrew; Healey, Paul R.; Grigg, John; Lawlor, Mitchell] Univ Sydney, Dept Ophthalmol, Sydney, NSW, Australia.
   [White, Andrew; Healey, Paul R.; Mitchell, Paul] Univ Sydney, Westmead Inst Med Res, Ctr Vis Res, Westmead, NSW, Australia.
   [Ruddle, Jonathan; Coote, Michael; Walland, Mark] Univ Melbourne, Royal Victorian Eye & Ear Hosp, CERA, Melbourne, Vic, Australia.
   [Best, Stephen; Vincent, Andrea] Univ Auckland, Dept Ophthalmol, Auckland, New Zealand.
   [Gale, Jesse] Univ Otago, Dept Ophthalmol, Dunedin, Otago, New Zealand.
   [RadfordSmith, Graham] Univ Queensland, Sch Med, Herston Campus, Brisbane, Qld, Australia.
   [Montgomery, Grant W.] Univ Queensland, Inst Mol Biosci, Brisbane, Qld, Australia.
   [Mackey, David A.] Univ Western Australia, Lions Eye Inst, Ctr Ophthalmol & Visual Sci, Perth, WA, Australia.
C3 QIMR Berghofer Medical Research Institute; University of Tasmania; Case
   Western Reserve University; Harvard University; Harvard Medical School;
   Massachusetts Eye & Ear Infirmary; Harvard University; Brigham & Women's
   Hospital; Harvard Medical School; Flinders University South Australia;
   Flinders University South Australia; South Australian Health & Medical
   Research Institute (SAHMRI); University of Adelaide; Macquarie
   University; University of Sydney; University of Sydney; Westmead
   Institute for Medical Research; Royal Victorian Eye & Ear Hospital;
   University of Melbourne; University of Auckland; University of Otago;
   University of Queensland; University of Queensland; Lions Eye Institute;
   University of Western Australia
RP Gharahkhani, P (通讯作者)，QIMR Berghofer Med Res Inst, Brisbane, Qld, Australia.; Craig, JE (通讯作者)，Flinders Univ S Australia, Dept Ophthalmol, Adelaide, SA, Australia.
EM Puya.Gharahkhani@qimrberghofer.edu.au; jamie.craig@flinders.edu.au
RI Bailey, Jessica Cooke/Q-5062-2019; Whiteman, David C/P-2728-2014;
   Macgregor, Stuart/C-6442-2009; Grigg, John/A-6851-2013; Montgomery,
   Grant W/B-7148-2008; Souzeau, Emmanuelle/AAB-5608-2022; Mackey, David
   A/H-5340-2014; Fingert, John/F-8787-2012; Law, Matthew H./AAJ-4066-2021;
   Haines, Jonathan/C-3374-2012; Burdon, Kathryn/A-5026-2009;
   Radford-Smith, Graham/H-2792-2013; Gharahkhani, Puya/AAA-6912-2020;
   Fingert, John/AAX-4750-2021; Cooke Bailey, Jessica Nicole/AFQ-5925-2022;
   White, Andrew JR/E-8462-2013; Burdon, Kathryn/AAD-2334-2022; Gale,
   Jesse/AAB-7406-2019; Schuman, Joel/K-7304-2012
OI Bailey, Jessica Cooke/0000-0002-4001-8702; Whiteman, David
   C/0000-0003-2563-9559; Macgregor, Stuart/0000-0001-6731-8142; Grigg,
   John/0000-0002-6763-8119; Montgomery, Grant W/0000-0002-4140-8139;
   Souzeau, Emmanuelle/0000-0002-2015-6577; Mackey, David
   A/0000-0001-7914-4709; Fingert, John/0000-0002-0377-0479; Law, Matthew
   H./0000-0002-4303-8821; Haines, Jonathan/0000-0002-4351-4728; Burdon,
   Kathryn/0000-0001-8217-1249; Radford-Smith, Graham/0000-0002-2047-6239;
   Gharahkhani, Puya/0000-0002-4203-5952; Fingert,
   John/0000-0002-0377-0479; Cooke Bailey, Jessica
   Nicole/0000-0002-4001-8702; Burdon, Kathryn/0000-0001-8217-1249; Gale,
   Jesse/0000-0002-6616-445X; Graham, Stuart/0000-0001-7519-969X; Pasquale,
   Louis/0000-0002-5835-3496; Kang, Jae/0000-0003-4812-0557; Lichter,
   Paul/0000-0001-8394-4813; Sharma, Shiwani/0000-0002-0828-025X; Siggs,
   Owen/0000-0003-2840-4851; Kraft, Peter/0000-0002-4472-8103; Schuman,
   Joel/0000-0002-8885-3766; Mills, Richard/0000-0002-7386-2571; Scott,
   William/0000-0001-9336-6404; Hewitt, Alex/0000-0002-5123-5999; Craig,
   Jamie/0000-0001-9955-9696; Lynn, David/0000-0003-4664-1404; Moroi,
   Sayoko E/0000-0002-0418-0657
FU NHMRC Medical Genomics Grant; National Institutes of Health (NIH) Center
   for Inherited Research (CIDR) as part of an NIH/National Eye Institute
   (NEI) [1RO1EY018246]; Queensland Cancer Fund; Royal Australian;
   NCATS/NIH grant [UL1TR000427]; National Heart, Lung, and Blood Institute
   [HL043851, HL080467]; National Health and Medical Research Council of
   Australia [535074, 1023911]; NIH/NEI [R01EY022305, P30 EY014104];
   National Cancer Institute [CA047988]; National Eye Institute
   [HG005259-01]; GENEVA project [HG004728, U01-HG004424]; Donald W.
   Reynolds Foundation; Fondation Leducq; US National Cancer Institute [R01
   CA136725, 5 R01 CA 001833]; National Eye Institute through ARRA grants
   [3R01EY015872-05S1, 3R01EY019126-02S1]; Amgen; NIH grants [EY015543,
   EY006827, HL73042, HL073389, EY13315, CA87969, CA49449, UM1 CA186107,
   UM1 CA167552, EY009149, HG004608, EY008208, EY015473, EY012118,
   EY015682, EY011671, EY09580, EY013178, RR015574, EY015872, EY010886,
   EY009847, EY011008, EY144428, EY144448, EY18660]; Cooperative Research
   Centre for Discovery of Genes for Common Human Diseases (CRC); Cerylid
   Biosciences (Melbourne); Harvard Glaucoma Center for Excellence;
   Research to Prevent Blindness; NHMRC [1031362, 1037838, 1048037,
   1009844, 1031920]; Harvard Medical School Distinguished Scholar award;
   Alcon Research Institute grant; BrightFocus Foundation; Barrett's and
   Esophageal Adenocarcinoma Genetic Susceptibility Study (BEAGESS);
   Ramaciotti Establishment Grant; New Zealand College of Ophthalmology
   (RANZCO) Eye Foundation; Allergan; National Health and Medical Research
   Council (NHMRC) of Australia [199600, 552429, 241944, 339462, 389927,
   389875, 389891, 389892, 389938, 443036, 442915, 442981, 496610, 496739,
   552485, 552498, 1049472, 1050208]; Endometriosis Associations; 
   [U01HG004446];  [1U02HG004608-01];  [5U01HG006389-02];  [R01 CA131332]; 
   [3R01 EY15473-5S1]; NATIONAL CANCER INSTITUTE [UM1CA186107, UM1CA167552]
   Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R21EY028671,
   R01EY022305, R01EY023512, P30EY014104] Funding Source: NIH RePORTER
FX ANZRAG: Support for recruitment of ANZRAG was provided by the Royal
   Australian and New Zealand College of Ophthalmology (RANZCO) Eye
   Foundation. Genotyping was funded by the National Health and Medical
   Research Council of Australia (#535074 and #1023911). This work was also
   supported by funding from NHMRC #1031362 awarded to J.E.C., NHMRC
   #1037838 awarded to A.W.H., NHMRC #1048037 awarded to S.L.G., NHMRC
   #1009844 awarded to R.J.C. and I.G., NHMRC #1031920 and Alcon Research
   Institute grant awarded to D.A.M., Allergan Unrestricted grant awarded
   to A.J.W., and the BrightFocus Foundation and a Ramaciotti Establishment
   Grant. The authors acknowledge the support of Ms Bronwyn Usher-Ridge in
   patient recruitment and data collection, and Dr Patrick Danoy and Dr
   Johanna Hadler for genotyping. Controls for the ANZRAG cohort were drawn
   from the Australian Cancer Study, the Study of Digestive Health, a study
   of inflammatory bowel diseases, a study of endometriosis, and QIMR
   Berghofer twin study. The Australian Cancer Study was supported by the
   Queensland Cancer Fund and the National Health and Medical Research
   Council (NHMRC) of Australia (Program no. 199600, awarded to David C.
   Whiteman, Adele C. Green, Nicholas K. Hayward, Peter G. Parsons, David
   M. Purdie, and Penelope M. Webb; and program no. 552429 awarded to David
   C. Whiteman). The Study of Digestive Health was supported by grant
   number 5 R01 CA 001833 from the US National Cancer Institute (awarded to
   David C. Whiteman). The Barrett's and Esophageal Adenocarcinoma Genetic
   Susceptibility Study (BEAGESS) sponsored the genotyping of oesophageal
   cancer and Barrett's oesophagus cases, which were used as unscreened
   controls in the ANZRAG cohort. BEAGESS was funded by grant R01 CA136725
   from the US National Cancer Institute. Genotyping for part of the
   Australian twin control samples included in the ANZRAG cohort was funded
   by an NHMRC Medical Genomics Grant. Genotyping for the remainder of twin
   controls was performed by the National Institutes of Health (NIH) Center
   for Inherited Research (CIDR) as part of an NIH/National Eye Institute
   (NEI) grant 1RO1EY018246, and we are grateful to Dr Camilla Day and
   staff. We acknowledge with appreciation all women who participated in
   the QIMR Berghofer endometriosis study. We thank Endometriosis
   Associations for supporting study recruitment. We thank Sullivan
   Nicolaides and Queensland Medical Laboratory for pro bono collection and
   delivery of blood samples and other pathology services for assistance
   with blood collection. The QIMR twin and endometriosis studies were
   supported by grants from the National Health and Medical Research
   Council (NHMRC) of Australia (241944, 339462, 389927, 389875, 389891,
   389892, 389938, 443036, 442915, 442981, 496610, 496739, 552485, 552498,
   1049472 and 1050208), the Cooperative Research Centre for Discovery of
   Genes for Common Human Diseases (CRC), Cerylid Biosciences (Melbourne),
   and donations from Neville and Shirley Hawkins. We thank Matthew A.
   Brown, Margaret J. Wright, Megan J. Campbell, Anthony Caracella, Scott
   Gordon, Dale R Nyholt, Anjali K Henders, B. Haddon, D. Smyth, H. Beeby,
   O. Zheng, B. Chapman for their input into project management, databases,
   sample processing, and genotyping. We are grateful to the many research
   assistants and interviewers for assistance with the studies contributing
   to the QIMR Berghofer twin collection. NEIGHBORHOOD: The NEIGHBORHOOD
   data collection and analysis is supported by NIH/NEI R01EY022305 (JL
   Wiggs) and NIH/NEI P30 EY014104 Wiggs).; Support for collection of
   cases, controls and analysis for individual datasets is as follows.r
   Genotyping services for the NEIGHBOR study were provided by the Center
   for Inherited Disease Research (CIDR) and were supported by the National
   Eye Institute through grant HG005259-01 (JL Wiggs). Genotyping for the
   MEEI dataset and some NHS and HPFS cases (GLAUGEN) was completed at the
   Broad Institute and supported by GENEVA project grant HG004728 (LR
   Pasquale) and U01-HG004424 (Broad Institute). Genotype data cleaning and
   analysis for the GLAUGEN study was supported by U01HG004446 (C Laurie).
   Collecting and processing samples for the NEIGHBOR dataset was supported
   by the National Eye Institute through ARRA grants 3R01EY015872-05S1 (JL
   Wiggs) and 3R01EY019126-02S1 (MA Hauser). Funding for the collection of
   NEIGHBOR cases and controls was provided by NIH grants: EY015543 (RR
   Allingham), EY006827 (D Gaasterland); HL73042, HL073389, EY13315 (MA
   Hauser); CA87969, CA49449, UM1 CA186107, UM1 CA167552, EY009149 (PR
   Lichter), HG004608 (C McCarty), EY008208 (FA Medeiros), EY015473 (LR
   Pasquale), EY012118 (M Pericak-Vance), EY015682 (A Realini), EY011671
   (JE Richards), EY09580 (JE Richards), EY013178 (JS Schuman), RR015574,
   EY015872 Wiggs), EY010886 (JL Wiggs), EY009847 (JL Wiggs), EY011008,
   EY144428 (K Zhang), EY144448 (K Zhang), EY18660 (K Zhang). The
   collection of Marshfield clinic cases and controls was supported by
   1U02HG004608-01, 5U01HG006389-02 and NCATS/NIH grant UL1TR000427. In
   addition some NHS/HPFS cases and controls and analysis of GWAS data was
   supported by R01 CA131332. The WGHS is supported by HL043851 and
   HL080467 from the National Heart, Lung, and Blood Institute and CA047988
   from the National Cancer Institute, the Donald W. Reynolds Foundation
   and the Fondation Leducq, with collaborative scientific support and
   funding for genotyping provided by Amgen. POAG case identification in
   WGHS was supported by 3R01 EY15473-5S1 (LR Pasquale). JL Wiggs and LR
   Pasquale are supported by the Harvard Glaucoma Center for Excellence and
   an unrestricted grant from Research to Prevent Blindness. Dr. Pasquale
   is also supported by a Harvard Medical School Distinguished Scholar
   award.
CR Bailey JNC, 2016, NAT GENET, V48, P189, DOI 10.1038/ng.3482
   Bakshi A, 2016, SCI REP-UK, V6, DOI 10.1038/srep32894
   Barbeira A. N., 2017, BIORXIV
   BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x
   Boyle AP, 2012, GENOME RES, V22, P1790, DOI 10.1101/gr.137323.112
   Bulik-Sullivan B, 2015, NAT GENET, V47, P1236, DOI 10.1038/ng.3406
   Bulik-Sullivan BK, 2015, NAT GENET, V47, P291, DOI 10.1038/ng.3211
   Bullard JH, 2010, BMC BIOINFORMATICS, V11, DOI 10.1186/1471-2105-11-94
   Burdon KP, 2011, NAT GENET, V43, P574, DOI 10.1038/ng.824
   Burton PR, 2007, NATURE, V447, P661, DOI 10.1038/nature05911
   Cashman SM, 2011, INVEST OPHTH VIS SCI, V52, P3436, DOI 10.1167/iovs.10-6002
   Casson RJ, 2012, CLIN EXP OPHTHALMOL, V40, P341, DOI 10.1111/j.1442-9071.2012.02773.x
   Chang CC, 2015, GIGASCIENCE, V4, DOI 10.1186/s13742-015-0047-8
   Charlesworth J, 2010, INVEST OPHTH VIS SCI, V51, P3509, DOI 10.1167/iovs.09-4786
   Cross SH, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004359
   Cuellar-Partida G, 2016, SCI REP-UK, V6, DOI 10.1038/srep26885
   Das S, 2016, NAT GENET, V48, P1284, DOI 10.1038/ng.3656
   Delaneau O, 2012, NAT METHODS, V9, P179, DOI [10.1038/NMETH.1785, 10.1038/nmeth.1785]
   Dunham I, 2012, NATURE, V489, P57, DOI 10.1038/nature11247
   Fan BJ, 2011, INVEST OPHTH VIS SCI, V52, P1788, DOI 10.1167/iovs.10-6339
   Ferreira MAR, 2017, J ALLERGY CLIN IMMUN, V139, P1148, DOI 10.1016/j.jaci.2016.07.017
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Gamazon ER, 2015, NAT GENET, V47, P1091, DOI 10.1038/ng.3367
   Gharahkhani P, 2014, NAT GENET, V46, P1120, DOI 10.1038/ng.3079
   Goncalves J, 2010, EMBO REP, V11, P194, DOI 10.1038/embor.2010.5
   Jonas JB, 2004, INVEST OPHTH VIS SCI, V45, P2613, DOI 10.1167/iovs.03-1274
   Kim D, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-4-r36
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Liu P, 2010, DEV DYNAM, V239, P2161, DOI 10.1002/dvdy.22347
   Lonsdale J, 2013, NAT GENET, V45, P580, DOI 10.1038/ng.2653
   Luo TL, 2006, J NEUROBIOL, V66, P677, DOI 10.1002/neu.20239
   Marchini J, 2010, NAT REV GENET, V11, P499, DOI 10.1038/nrg2796
   McCarthy S, 2016, NAT GENET, V48, P1279, DOI 10.1038/ng.3643
   Meire F, 2011, MOL VIS, V17, P2072
   Mimiwati Z, 2006, BRIT J OPHTHALMOL, V90, P1505, DOI 10.1136/bjo.2006.092619
   Nikolskaya T, 2009, BMC MED GENOMICS, V2, DOI 10.1186/1755-8794-2-24
   Pers TH, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms6890
   Pruim RJ, 2010, BIOINFORMATICS, V26, P2336, DOI 10.1093/bioinformatics/btq419
   Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795
   Quigley HA, 2006, BRIT J OPHTHALMOL, V90, P262, DOI 10.1136/bjo.2005.081224
   Ramdas WD, 2011, OPHTHAL EPIDEMIOL, V18, P211, DOI 10.3109/09286586.2011.595038
   Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616
   Ross AC, 2011, ANNU REV NUTR, V31, P65, DOI 10.1146/annurev-nutr-072610-145127
   Sakai Y, 2004, DEV BIOL, V276, P143, DOI 10.1016/j.ydbio.2004.08.032
   Schwarz N, 2012, HUM MOL GENET, V21, P863, DOI 10.1093/hmg/ddr520
   Seddon JM, 2013, NAT GENET, V45, P1366, DOI 10.1038/ng.2741
   Semenova E, 2003, HUM MOL GENET, V12, P1301, DOI 10.1093/hmg/ddg140
   Souzeau E, 2012, CLIN EXP OPHTHALMOL, V40, P569, DOI 10.1111/j.1442-9071.2011.02742.x
   Springelkamp H, 2017, HUM MOL GENET, V26, P438, DOI 10.1093/hmg/ddw399
   Springelkamp H, 2015, HUM MOL GENET, V24, P2689, DOI 10.1093/hmg/ddv027
   Sun H, 2005, J MED GENET, V42, P706, DOI 10.1136/jmg.2004.028274
   Thorleifsson G, 2010, NAT GENET, V42, P906, DOI 10.1038/ng.661
   Tomarev SI, 2003, INVEST OPHTH VIS SCI, V44, P2588, DOI 10.1167/iovs.02-1099
   Trapnell C, 2009, BIOINFORMATICS, V25, P1105, DOI 10.1093/bioinformatics/btp120
   van Koolwijk LME, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002611
   Veltel S, 2008, NAT STRUCT MOL BIOL, V15, P373, DOI 10.1038/nsmb.1396
   Verhoeven VJM, 2013, NAT GENET, V45, P314, DOI 10.1038/ng.2554
   Ward LD, 2012, NUCLEIC ACIDS RES, V40, pD930, DOI 10.1093/nar/gkr917
   Westra HJ, 2013, NAT GENET, V45, P1238, DOI 10.1038/ng.2756
   Wiggs JL, 2012, PLOS GENET, V8, P413, DOI 10.1371/journal.pgen.1002654
   Willer CJ, 2010, BIOINFORMATICS, V26, P2190, DOI 10.1093/bioinformatics/btq340
   Wistow G, 2012, HUM GENOMICS, V6, DOI 10.1186/1479-7364-6-26
   Wolfs RCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P1640, DOI 10.1001/archopht.116.12.1640
   Yazar S, 2013, MOL VIS, V19, P1238
   Zhu XF, 2015, AM J HUM GENET, V96, P21, DOI 10.1016/j.ajhg.2014.11.011
NR 65
TC 22
Z9 23
U1 0
U2 6
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD FEB 15
PY 2018
VL 8
AR 3124
DI 10.1038/s41598-018-20435-9
PG 12
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA FW3EX
UT WOS:000425190500028
PM 29449654
OA Green Accepted, Green Published, gold
DA 2022-11-30
ER

PT J
AU Katsanos, A
   Gorgoli, K
   Mikropoulos, DG
   Arranz-Marquez, E
   Athanasopoulos, GP
   Teus, MA
   Konstas, AGP
AF Katsanos, Andreas
   Gorgoli, Kostantina
   Mikropoulos, Dimitrios G.
   Arranz-Marquez, Esther
   Athanasopoulos, Georgios P.
   Teus, Miguel A.
   Konstas, Anastasios G. P.
TI Assessing the role of ranibizumab in improving the outcome of glaucoma
   filtering surgery and neovascular glaucoma
SO EXPERT OPINION ON BIOLOGICAL THERAPY
LA English
DT Article
DE Glaucoma surgery; neovascular glaucoma; ranibizumab; bevacizumab;
   Lucentis; VEGF; anti-VEGF; trabeculectomy; wound healing
ID ENDOTHELIAL GROWTH-FACTOR; ANTI-VEGF THERAPY; INTRAOCULAR-PRESSURE;
   INTRAVITREAL INJECTION; MACULAR DEGENERATION; MITOMYCIN-C;
   TRABECULECTOMY; PHARMACOKINETICS; ANGIOGENESIS; DRUGS
AB Introduction: Ranibizumab was the first anti-vascular endothelial growth factor (VEGF) agent approved for the treatment of neovascular age-related macular degeneration. The use of ranibizumab and other anti-VEGF medications in recent years has revolutionized the treatment of several sight-threatening retinal disorders. Emerging evidence has demonstrated that anti-VEGF treatment can offer advantages in the management of other ocular conditions where VEGFs play a key role: ocular scarring following glaucoma filtering surgery and neovascular glaucoma (NVG).Areas covered: We critically review available evidence on the use of ranibizumab as a wound healing modulator in glaucoma filtering surgery and as an adjunct in the management of NVG.Expert opinion: Based on the available evidence and the authors' clinical experience, ranibizumab is a valuable adjunct in the management of NVG. In glaucoma filtering surgery, however, the role of ranibizumab is less clear and does not provide a significant advantage over mitomycin C. Drawbacks for its use in glaucoma include cost, its off-label use, uncertainty and limited evidence on the various routes of administration, the optimal dosing schemes and its toxicity profile. Future advances in ranibizumab delivery systems allowing less frequent dosing may change this treatment paradigm.
C1 [Katsanos, Andreas] Univ Ioannina, Dept Ophthalmol, Ioannina 45500, Greece.
   [Gorgoli, Kostantina] Brighton & Sussex Univ Hosp NHS Trust, Sussex Eye Hosp, Brighton, E Sussex, England.
   [Mikropoulos, Dimitrios G.; Konstas, Anastasios G. P.] AHEPA Hosp, Univ Dept Ophthalmol 3, Thessaloniki, Greece.
   [Arranz-Marquez, Esther; Teus, Miguel A.] Clin Novovis, Madrid, Spain.
   [Arranz-Marquez, Esther] Rey Juan Carlos Univ Hosp, Dept Ophthalmol, Madrid, Spain.
   [Athanasopoulos, Georgios P.; Konstas, Anastasios G. P.] Aristotle Univ Thessaloniki, Univ Dept Ophthalmol 1, Thessaloniki, Greece.
   [Teus, Miguel A.] Univ Alcala, Hosp Univ Principe Asturias, Dept Ophthalmol, Alcala De Henares, Spain.
C3 University of Ioannina; Brighton and Sussex University Hospitals NHS
   Trust; University of Brighton; Aristotle University of Thessaloniki;
   Ahepa University Hospital; Aristotle University of Thessaloniki; Prince
   of Asturias University Hospital; Universidad de Alcala
RP Katsanos, A (通讯作者)，Univ Ioannina, Dept Ophthalmol, Ioannina 45500, Greece.
EM katsanos@cc.uoi.gr
RI Teus, Miguel A./AAW-1835-2020; MIKROPOULOS, DIMITRIOS/AAD-3533-2019
OI Teus, Miguel A./0000-0002-3835-9882; MIKROPOULOS,
   DIMITRIOS/0000-0003-0931-5853
CR Andres-Guerrero V, 2017, ADV THER, V34, P378, DOI 10.1007/s12325-016-0461-z
   [Anonymous], 2017, EYLEA AFL FULL PRESC
   [Anonymous], 2017, LUCENTIS RAN FULL PR
   Atchison EA, 2018, OPHTHALMOLOGY, V125, P676, DOI 10.1016/j.ophtha.2017.11.027
   Bates David O, 2003, Int J Low Extrem Wounds, V2, P107, DOI 10.1016/j.jss.2008.04.023
   Cantor LB, 2003, J GLAUCOMA, V12, P266, DOI 10.1097/00061198-200306000-00015
   Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220
   Chen SD, 2015, ACTA OPHTHALMOL, V93, pE556, DOI 10.1111/aos.12624
   Costagliola C, 2012, EXPERT OPIN BIOL TH, V12, P1299, DOI 10.1517/14712598.2012.707176
   Daneshvar Ramin, 2013, J Ophthalmic Vis Res, V8, P182
   Elmekawey H, 2014, J GLAUCOMA, V23, P437, DOI 10.1097/IJG.0b013e3182946398
   European Glaucoma Society, 2014, TERM GUID GLAUC
   Garway-Heath DF, 2015, LANCET, V385, P1295, DOI 10.1016/S0140-6736(14)62111-5
   Gaudreault J, 2005, INVEST OPHTH VIS SCI, V46, P726, DOI 10.1167/iovs.04-0601
   Georgalas Ilias, 2009, Ther Clin Risk Manag, V5, P17
   Georgoulas S, 2008, PROG BRAIN RES, V173, P237, DOI 10.1016/S0079-6123(08)01117-5
   Hayreh SS, 2007, PROG RETIN EYE RES, V26, P470, DOI 10.1016/j.preteyeres.2007.06.001
   Heijl A, 2002, ARCH OPHTHALMOL-CHIC, V120, P1268, DOI 10.1001/archopht.120.10.1268
   Hollo G, 2017, DEV OPHTHALMOL, V59, P80, DOI 10.1159/000458488
   Horsley MB, 2010, CURR OPIN OPHTHALMOL, V21, P112, DOI 10.1097/ICU.0b013e3283360aad
   Kahook MY, 2010, AM J OPHTHALMOL, V150, P399, DOI 10.1016/j.ajo.2010.03.025
   Kaiser PK, 2006, AM J OPHTHALMOL, V142, P660, DOI 10.1016/j.ajo.2006.05.061
   Kitnarong N, 2015, OPHTHALMOL THER, V4, P33, DOI 10.1007/s40123-015-0033-3
   Krohne TU, 2012, AM J OPHTHALMOL, V154, P682, DOI 10.1016/j.ajo.2012.03.047
   Lama PJ, 2003, SURV OPHTHALMOL, V48, P314, DOI 10.1016/S0039-6257(03)00038-9
   Liu L, 2016, BMC OPHTHALMOL, V16, DOI 10.1186/s12886-016-0248-7
   Lu QY, 2016, ACTA OPHTHALMOL, V94, P414, DOI 10.1111/aos.13019
   Luke J, 2013, GRAEF ARCH CLIN EXP, V251, P2403, DOI 10.1007/s00417-013-2428-y
   Magdelaine-Beuzelin C, 2010, MABS-AUSTIN, V2, P176, DOI 10.4161/mabs.2.2.11205
   Mathew R, 2011, AM J OPHTHALMOL, V152, P10, DOI 10.1016/j.ajo.2011.03.013
   Matuskova V, 2018, OPHTHALMIC GENET, V39, P4, DOI 10.1080/13816810.2017.1326508
   Nissen NN, 1998, AM J PATHOL, V152, P1445
   Palmer BF, 2014, MOL CELL ENDOCRINOL, V397, P51, DOI 10.1016/j.mce.2014.08.001
   Park HYL, 2012, ARCH OPHTHALMOL-CHIC, V130, P685, DOI 10.1001/archophthalmol.2011.2799
   Park SC, 2012, EXPERT OPIN BIOL TH, V12, P1641, DOI 10.1517/14712598.2012.721772
   Pralhad T, 2003, J PHARM PHARMACOL, V55, P1045, DOI 10.1211/0022357021819
   Pro MJ, 2015, CURR EYE RES, V40, P510, DOI 10.3109/02713683.2014.935441
   Quigley HA, 2006, BRIT J OPHTHALMOL, V90, P262, DOI 10.1136/bjo.2005.081224
   Rodrigues EB, 2009, PROG RETIN EYE RES, V28, P117, DOI 10.1016/j.preteyeres.2008.11.005
   Salim S, 2012, CURR OPIN OPHTHALMOL, V23, P89, DOI 10.1097/ICU.0b013e32834ff401
   Seibold LK, 2012, SURV OPHTHALMOL, V57, P530, DOI 10.1016/j.survophthal.2012.01.008
   Tang M, 2016, BMC OPHTHALMOL, V16, DOI 10.1186/s12886-016-0183-7
   Tham Yih-Chung, 2014, Ophthalmology, V121, P2081, DOI 10.1016/j.ophtha.2014.05.013
   Thulliez M, 2014, JAMA OPHTHALMOL, V132, P1317, DOI 10.1001/jamaophthalmol.2014.2333
   Van Bergen T, 2011, EXP EYE RES, V93, P689, DOI 10.1016/j.exer.2011.08.016
   Weinreb RN, 2004, LANCET, V363, P1711, DOI 10.1016/S0140-6736(04)16257-0
   Xu L, 2013, INVEST OPHTH VIS SCI, V54, P1616, DOI 10.1167/iovs.12-10260
   Yu DY, 2009, PROG RETIN EYE RES, V28, P303, DOI 10.1016/j.preteyeres.2009.06.004
NR 48
TC 2
Z9 2
U1 0
U2 9
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1471-2598
EI 1744-7682
J9 EXPERT OPIN BIOL TH
JI Expert Opin. Biol. Ther.
PY 2018
VL 18
IS 6
BP 719
EP 724
DI 10.1080/14712598.2018.1479395
PG 6
WC Biotechnology & Applied Microbiology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Research & Experimental Medicine
GA GI5WU
UT WOS:000434442100011
PM 29781319
DA 2022-11-30
ER

PT J
AU Wang, J
   Zhang, M
   Hwang, TS
   Bailey, ST
   Huang, D
   Wilson, DJ
   Jia, YL
AF Wang, Jie
   Zhang, Miao
   Hwang, Thomas S.
   Bailey, Steven T.
   Huang, David
   Wilson, David J.
   Jia, Yali
TI Reflectance-based projection-resolved optical coherence tomography
   angiography [Invited]
SO BIOMEDICAL OPTICS EXPRESS
LA English
DT Article
ID CHOROIDAL NEOVASCULARIZATION; DIABETIC-RETINOPATHY; MACULAR
   DEGENERATION; RETINAL PLEXUSES; ARTIFACTS
AB Optical coherence tomography angiography (OCTA) is limited by projection artifacts from the superficial blood vessels onto deeper layers. We have recently described projection-resolved (PR) OCTA that solves the ambiguity between in situ flow and flow projection along each axial scan and suppresses the artifact on both en face and cross-sectional angiograms. While this method significantly improved the depth resolution of OCTA, the vascular integrity of the deeper layers was not fully preserved. In this study, we propose a novel reflectance-based projection-resolved (rbPR) OCTA algorithm which uses OCT reflectance to enhance the flow signal and suppress the projection artifacts in 3-dimensional OCTA. We demonstrated quantitatively that rbPR improved the vascular connectivity and improved the discrimination of the deeper plexus angiograms in healthy eyes, compared to prior PR-OCTA method. We also demonstrated qualitatively that rbPR removes flow projection artifacts more completely from the outer retinal slab in the eyes with age-related macular degeneration, and preserves vascular integrity of the intermediate and deep capillary plexuses in the eyes with diabetic retinopathy. Additionally, this method improves the resolution of the choriocapillaris and demonstrates details comparable to scanning electron microscopy. (C) 2017 Optical Society of America
C1 [Wang, Jie; Zhang, Miao; Hwang, Thomas S.; Bailey, Steven T.; Huang, David; Wilson, David J.; Jia, Yali] Oregon Hlth & Sci Univ, Casey Eye Inst, Portland, OR 97239 USA.
C3 Oregon Health & Science University
RP Jia, YL (通讯作者)，Oregon Hlth & Sci Univ, Casey Eye Inst, Portland, OR 97239 USA.
EM jiaya@ohsu.edu
RI Zhang, Miao/F-6574-2017; Hwang, Thomas S./AAW-6618-2020; Hwang,
   Thomas/AAV-5146-2020
OI Zhang, Miao/0000-0002-3242-5957; Hwang, Thomas S./0000-0002-0535-4823;
   Jia, Yali/0000-0002-2784-1905; Bailey, Steven/0000-0003-4949-1464
FU National Institutes of Health (Bethesda, MD) [DP3 DK104397, R01
   EY024544, R01 EY023285, P30 EY010572]; Research to Prevent Blindness
   (New York, NY); Oregon Health & Science University (OHSU); NATIONAL EYE
   INSTITUTE [R01EY023285, P30EY010572, R01EY024544] Funding Source: NIH
   RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY
   DISEASES [DP3DK104397] Funding Source: NIH RePORTER
FX This work was supported by grant DP3 DK104397, R01 EY024544, R01
   EY023285, P30 EY010572 from the National Institutes of Health (Bethesda,
   MD), and by unrestricted departmental funding from Research to Prevent
   Blindness (New York, NY). Oregon Health & Science University (OHSU),
   David Huang and Yali Jia, have a significant financial interest in
   Optovue, Inc. These potential conflicts of interest have been reviewed
   and managed by OHSU.
CR Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Chan G, 2012, INVEST OPHTH VIS SCI, V53, P5502, DOI 10.1167/iovs.12-10265
   Gao SS, 2016, J BIOMED OPT, V21, DOI 10.1117/1.JBO.21.7.076010
   Gao SS, 2016, INVEST OPHTH VIS SCI, V57, pOCT27, DOI 10.1167/iovs.15-19043
   Huang D., 2015, CLIN OCT ANGIOGRAPHY, P3
   Huang D, 2015, RETINA-J RET VIT DIS, V35, P2260, DOI 10.1097/IAE.0000000000000846
   Hwang TS, 2016, JAMA OPHTHALMOL, V134, P1411, DOI 10.1001/jamaophthalmol.2016.4272
   Jia YL, 2015, P NATL ACAD SCI USA, V112, pE2395, DOI 10.1073/pnas.1500185112
   Jia YL, 2014, OPHTHALMOLOGY, V121, P1435, DOI 10.1016/j.ophtha.2014.01.034
   LAM L, 1992, IEEE T PATTERN ANAL, V14, P869, DOI 10.1109/34.161346
   Liu L, 2015, BIOMED OPT EXPRESS, V6, P3564, DOI 10.1364/BOE.6.003564
   Lutty GA, 2013, INVEST OPHTH VIS SCI, V54, DOI 10.1167/iovs.13-12979
   McClintic S, 2015, JAMA OPHTHALMOL, V133, P1212, DOI 10.1001/jamaophthalmol.2015.2126
   OLVER JM, 1990, EYE, V4, P262, DOI 10.1038/eye.1990.38
   Singh K, 2014, PATTERN RECOGN LETT, V36, P10, DOI 10.1016/j.patrec.2013.08.024
   Spaide RF, 2015, RETINA-J RET VIT DIS, V35, P2163, DOI 10.1097/IAE.0000000000000765
   Zhang AQ, 2015, BIOMED OPT EXPRESS, V6, P4130, DOI 10.1364/BOE.6.004130
   Zhang M, 2016, INVEST OPHTH VIS SCI, V57, P5101, DOI 10.1167/iovs.16-19776
   Zhang M, 2016, BIOMED OPT EXPRESS, V7, P816, DOI 10.1364/BOE.7.000816
   Zhang M, 2015, BIOMED OPT EXPRESS, V6, P4661, DOI 10.1364/BOE.6.004661
NR 20
TC 61
Z9 62
U1 0
U2 5
PU OPTICAL SOC AMER
PI WASHINGTON
PA 2010 MASSACHUSETTS AVE NW, WASHINGTON, DC 20036 USA
SN 2156-7085
J9 BIOMED OPT EXPRESS
JI Biomed. Opt. Express
PD MAR 1
PY 2017
VL 8
IS 3
BP 1536
EP 1548
DI 10.1364/BOE.8.001536
PG 13
WC Biochemical Research Methods; Optics; Radiology, Nuclear Medicine &
   Medical Imaging
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Optics; Radiology, Nuclear Medicine &
   Medical Imaging
GA EN3YA
UT WOS:000395942600022
PM 28663848
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Kim, TK
   Park, CS
   Na, HJ
   Lee, K
   Yoon, A
   Chung, J
   Lee, S
AF Kim, Taek-Keun
   Park, Chang Sik
   Na, Hee-Jun
   Lee, Kangseung
   Yoon, Aerin
   Chung, Junho
   Lee, Sukmook
TI Ig-like domain 6 of VCAM-1 is a potential therapeutic target in TNF
   alpha-induced angiogenesis
SO EXPERIMENTAL AND MOLECULAR MEDICINE
LA English
DT Article
ID CELL-ADHESION MOLECULE-1; RHEUMATOID-ARTHRITIS; MACULAR DEGENERATION;
   CANCER; ANTIBODY; GROWTH; BEVACIZUMAB; RESISTANCE; LEUKOCYTE; INTEGRIN
AB Tumor necrosis factor alpha (TNF alpha)-induced angiogenesis plays important roles in the progression of various diseases, including cancer, wet age-related macular degeneration, and rheumatoid arthritis. However, the relevance and role of vascular cell adhesion molecule-1 (VCAM-1) in angiogenesis have not yet been clearly elucidated. In this study, VCAM-1 knockdown shows VCAM-1 involvement in TNFa-induced angiogenesis. Through competitive blocking experiments with VCAM-1 Ig-like domain 6 (VCAM-1-D6) protein, we identified VCAM-1-D6 as a key domain regulating TNFa-induced vascular tube formation. We demonstrated that a monoclonal antibody specific to VCAM-1-D6 suppressed TNFa-induced endothelial cell migration and tube formation and TNFa-induced vessel sprouting in rat aortas. We also found that the antibody insignificantly affected endothelial cell viability, morphology and activation. Finally, the antibody specifically blocked VCAM-1-mediated cell-cell contacts by directly inhibiting VCAM-1-D6-mediated interaction between VCAM-1 molecules. These findings suggest that VCAM-1-D6 may be a potential novel therapeutic target in TNFa-induced angiogenesis and that antibody-based modulation of VCAM-1-D6 may be an effective strategy to suppress TNFa-induced angiogenesis.
C1 [Kim, Taek-Keun; Park, Chang Sik; Na, Hee-Jun; Lee, Kangseung; Lee, Sukmook] Scripps Korea Antibody Inst, Res Ctr, Lab Mol Canc Therapeut, 1 Kangwondaehak Gil, Chunchon 200701, Gangwon Do, South Korea.
   [Yoon, Aerin; Chung, Junho] Seoul Natl Univ, Dept Biochem & Mol Biol, Coll Med, Seoul 110799, South Korea.
C3 Seoul National University (SNU)
RP Lee, S (通讯作者)，Scripps Korea Antibody Inst, Res Ctr, Lab Mol Canc Therapeut, 1 Kangwondaehak Gil, Chunchon 200701, Gangwon Do, South Korea.; Chung, J (通讯作者)，Seoul Natl Univ, Dept Biochem & Mol Biol, Coll Med, Seoul 110799, South Korea.
EM jjhchung@snu.ac.kr; Lees@skai.or.kr
FU Scripps Korea Antibody Institute [10TS03]; Bio & Medical Technology
   Development Program of the National Research Foundation-Korean
   government (Ministry of Science, ICT and Future Planning)
   [2015M3A9D9074279]
FX This work was supported by a research grant (10TS03) from the Scripps
   Korea Antibody Institute and partly by the Bio & Medical Technology
   Development Program of the National Research Foundation funded by the
   Korean government (Ministry of Science, ICT and Future Planning)
   (2015M3A9D9074279).
CR Aref AA, 2016, CURR OPIN OPHTHALMOL, V27, P140, DOI 10.1097/ICU.0000000000000239
   Barreiro O, 2002, J CELL BIOL, V157, P1233, DOI 10.1083/jcb.200112126
   CARLOS TM, 1990, BLOOD, V76, P965
   Carter RA, 2002, CLIN EXP IMMUNOL, V128, P44, DOI 10.1046/j.1365-2249.2002.01794.x
   Chong V, 2016, EYE, V30, P270, DOI 10.1038/eye.2015.217
   Cybulsky MI, 2001, J CLIN INVEST, V107, P1255, DOI 10.1172/JCI11871
   DeBusk LM, 2003, ARTHRITIS RHEUM-US, V48, P2461, DOI 10.1002/art.11213
   Ecker DM, 2015, MABS-AUSTIN, V7, P9, DOI 10.4161/19420862.2015.989042
   Elshabrawy HA, 2015, ANGIOGENESIS, V18, P433, DOI 10.1007/s10456-015-9477-2
   Folkman Judah, 1993, Comptes Rendus de l'Academie des Sciences Serie III Sciences de la Vie, V316, P909
   Gorcyznski R M, 1995, Transpl Immunol, V3, P55, DOI 10.1016/0966-3274(95)80007-7
   Hammam Olfat, 2013, Gastrointest Cancer Res, V6, P107
   Hsu JY, 2009, BIODRUGS, V23, P289, DOI 10.2165/11317600-000000000-00000
   Kanwar JR, 2000, IMMUNOL CELL BIOL, V78, P641, DOI 10.1046/j.1440-1711.2000.00947.x
   Kelly KA, 2007, J LEUKOCYTE BIOL, V81, P748, DOI 10.1189/jlb.1105664
   Ki MK, 2013, ONCOGENE, V32, P5449, DOI 10.1038/onc.2013.156
   Kim TK, 2016, BIOCHEM BIOPH RES CO, V469, P222, DOI 10.1016/j.bbrc.2015.11.125
   Kim TK, 2015, BIOCHEM BIOPH RES CO, V468, P774, DOI 10.1016/j.bbrc.2015.11.031
   Klemke M, 2007, J CELL PHYSIOL, V212, P368, DOI 10.1002/jcp.21029
   Kopetz S, 2010, J CLIN ONCOL, V28, P453, DOI 10.1200/JCO.2009.24.8252
   Lai KC, 2016, CANCER LETT, V370, P207, DOI 10.1016/j.canlet.2015.10.016
   Lee S, 2002, J BIOL CHEM, V277, P6542, DOI 10.1074/jbc.M108047200
   Lee S.-K., 2007, IEEE INT S ELECTROMA, V1, P1, DOI DOI 10.1002/MED.20079
   Lee S, 2012, J NANOMATER, V2012, DOI 10.1155/2012/582531
   Lichtlen P, 2010, INVEST OPHTH VIS SCI, V51, P4738, DOI 10.1167/iovs.09-4890
   Lucio-Eterovic AK, 2009, CLIN CANCER RES, V15, P4589, DOI 10.1158/1078-0432.CCR-09-0575
   Nowak JZ, 2006, PHARMACOL REP, V58, P353
   POLTE T, 1991, DNA CELL BIOL, V10, P349, DOI 10.1089/dna.1991.10.349
   Potente M, 2011, CELL, V146, P873, DOI 10.1016/j.cell.2011.08.039
   Solomon SD, 2016, OPHTHALMOLOGY, V123, P70, DOI 10.1016/j.ophtha.2015.09.002
   Stegall MD, 2001, TRANSPLANTATION, V71, P1549, DOI 10.1097/00007890-200106150-00011
   Syed BA, 2012, NAT REV DRUG DISCOV, V11, P827, DOI 10.1038/nrd3790
   Theodossiadis PG, 2009, AM J OPHTHALMOL, V147, P825, DOI 10.1016/j.ajo.2008.12.004
   Ulbrich H, 2003, TRENDS PHARMACOL SCI, V24, P640, DOI 10.1016/j.tips.2003.10.004
   Welti J, 2013, J CLIN INVEST, V123, P3190, DOI 10.1172/JCI70212
   Xiao ZZ, 2011, INT J MOL SCI, V12, P4165, DOI 10.3390/ijms12064165
   Yazdi MH, 2015, EXPERT OPIN BIOL TH, V15, P1349, DOI 10.1517/14712598.2015.1057565
NR 37
TC 15
Z9 17
U1 0
U2 5
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1226-3613
EI 2092-6413
J9 EXP MOL MED
JI Exp. Mol. Med.
PD FEB
PY 2017
VL 49
AR e294
DI 10.1038/emm.2016.147
PG 11
WC Biochemistry & Molecular Biology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Research & Experimental Medicine
GA EO9NI
UT WOS:000397015000005
PM 28209985
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Sreekumar, PG
   Hinton, DR
   Kannan, R
AF Sreekumar, Parameswaran G.
   Hinton, David R.
   Kannan, Ram
TI Endoplasmic reticulum-mitochondrial crosstalk: a novel role for the
   mitochondrial peptide humanin
SO NEURAL REGENERATION RESEARCH
LA English
DT Review
DE endoplasmic reticulum; mitochondria; mitochondrial-derived peptide;
   antioxidants; retinal pigment epithelium; age-related macular
   degeneration
ID STRESS; DEGENERATION; DYSFUNCTION; APOPTOSIS; CELLS; AGE
AB In this review, the interactive mechanisms of mitochondria with the endoplasmic reticulum (ER) are discussed with emphasis on the potential protective role of the mitochondria derived peptide humanin (HN) in ER stress. The ER and mitochondria are dynamic organelles capable of modifying their structure and function in response to changing environmental conditions. The ER and mitochondria join together at multiple sites and form mitochondria-ER associated membranes that participate in signal transduction pathways that are under active investigation. Our laboratory previously showed that HN protects cells from oxidative stress induced cell death and more recently, described the beneficial role of HN on ER stress-induced apoptosis in retinal pigment epithelium cells and the involvement of ER-mitochondrial cross-talk in cellular protection. The protection was achieved, in part, by the restoration of mitochondrial glutathione that was depleted by ER stress. Thus, HN may be a promising candidate for therapy for diseases that involve both oxidative and ER stress. Developing novel approaches for retinal delivery of HN, its analogues as well as small molecular weight ER stress inhibitors would prove to be a valuable approach in the treatment of age-related macular degeneration.
C1 [Sreekumar, Parameswaran G.; Kannan, Ram] Doheny Eye Inst, Arnold & Mabel Beckman Macular Res Ctr, 1355 San Pablo St, Los Angeles, CA 90033 USA.
   [Hinton, David R.] Univ Southern Calif, Keck Sch Med, USC Roski Inst, Dept Pathol & Ophthalmol, Los Angeles, CA 90033 USA.
C3 Doheny Eye Institute; University of Southern California
RP Hinton, DR (通讯作者)，Univ Southern Calif, Keck Sch Med, USC Roski Inst, Dept Pathol & Ophthalmol, Los Angeles, CA 90033 USA.
EM dhinton@usc.edu
RI kannan, ram/ABB-7154-2020
OI kannan, ram/0000-0002-1583-3414; /0000-0002-9425-3986
FU Arnold and Mabel Beckman Foundation; Research to Prevent Blindness,
   Inc.;  [EY01545]
FX This work was supported in part by Grants EY01545 (DRH), the Arnold and
   Mabel Beckman Foundation (DRH, RK) and an unrestricted grant to the
   Department of Ophthalmology from Research to Prevent Blindness, Inc.
CR Bronner DN, 2015, IMMUNITY, V43, P451, DOI 10.1016/j.immuni.2015.08.008
   Dou GR, 2012, FREE RADICAL BIO MED, V53, P1111, DOI 10.1016/j.freeradbiomed.2012.06.042
   Giacomello M, 2016, CELL DEATH DIFFER, V23, P1417, DOI 10.1038/cdd.2016.52
   Marchi S, 2014, BBA-BIOENERGETICS, V1837, P461, DOI 10.1016/j.bbabio.2013.10.015
   Matsunaga D, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0165150
   Oakes SA, 2015, ANNU REV PATHOL-MECH, V10, P173, DOI 10.1146/annurev-pathol-012513-104649
   Ribas V, 2014, FRONT PHARMACOL, V5, DOI 10.3389/fphar.2014.00151
   Salminen A, 2010, MOL MED, V16, P535, DOI 10.2119/molmed.2010.00070
   Sreekumar PG, 2016, INVEST OPHTH VIS SCI, V57, P1238, DOI 10.1167/iovs.15-17053
   Wang W, 2014, J CONTROL RELEASE, V191, P4, DOI 10.1016/j.jconrel.2014.04.028
   Yen K, 2013, J MOL ENDOCRINOL, V50, pR11, DOI 10.1530/JME-12-0203
   Zhang SX, 2014, EXP EYE RES, V125, P30, DOI 10.1016/j.exer.2014.04.015
NR 12
TC 18
Z9 18
U1 0
U2 7
PU MEDKNOW PUBLICATIONS & MEDIA PVT LTD
PI MUMBAI
PA B-9, KANARA BUSINESS CENTRE, OFF LINK RD, GHAKTOPAR-E, MUMBAI, 400075,
   INDIA
SN 1673-5374
EI 1876-7958
J9 NEURAL REGEN RES
JI Neural Regen. Res.
PD JAN
PY 2017
VL 12
IS 1
BP 35
EP 38
DI 10.4103/1673-5374.198970
PG 4
WC Cell Biology; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Neurosciences & Neurology
GA EM9VW
UT WOS:000395660400008
PM 28250736
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Sunkireddy, P
   Kanwar, RK
   Ram, J
   Kanwar, JR
AF Sunkireddy, Pavan
   Kanwar, Rupinder Kaur
   Ram, Jagat
   Kanwar, Jagat Rakesh
TI Ultra-small algal chitosan ocular nanoparticles with iron-binding milk
   protein prevents the toxic effects of carbendazim pesticide
SO NANOMEDICINE
LA English
DT Article
DE apoptosis; bovine lactoferrin; carbendazim; nanoencapsulation; ocular
   drug delivery; oxidative stress; topical administration; ultra-small
   algal chitosan nanoparticles
ID DELIVERY-SYSTEM; LACTOFERRIN; APOPTOSIS; CELLS
AB Aim: To fabricate ultra-small algal chitosan nanoparticles (US CS NPs) for efficient delivery of bovine lactoferrin (bLf) to ocular tissues through topical administration to prevent carbendazim-induced toxicity. Materials & methods: Rat eye model was used to evaluate the in vivo biodistribution the US CS NPs and bovine eye model was used for evaluating ex vivo biodistribution. Human lens epithelial cell line (HLEB-3) model was used to evaluate the in vitro toxicity, uptake mechanism and in vitro efficacy of the synthesized bLf-US CS NPs over carbendazim-induced ocular toxicity. Results: The in vivo and ex vivo biodistribution results suggest that the ultra-small CS NPs efficiently internalize into the ocular tissues within 1 h after administering topically. Ultra-small algal nanocarriers to encapsulate bioactive antioxidant bLf protein and evaluated its potential in inhibiting carbendazim-induced human lens cell apoptosis and oxidative stress. bLf-encapsulated ultra-small algal US CS NPs prevented carbendazim-induced human lens cell apoptosis and oxidative stress. Conclusion: US CS NPs could be explored for their potential for delivering various ocular drugs through topical administration for other eye diseases including cataract, glaucoma and age-related macular degeneration.
C1 [Sunkireddy, Pavan; Kanwar, Rupinder Kaur; Kanwar, Jagat Rakesh] Deakin Univ, NLIMBR, Sch Med SoM, C MMR,Sch Med,Fac Hlth, Pigdons Rd,Waurn Ponds, Geelong, Vic 3216, Australia.
   [Sunkireddy, Pavan] India Habitat Ctr, Energy & Resources Inst, Biotechnol & Management Bioresources Div, Darbari Seth Block,Lodhi Rd, New Delhi 110003, India.
   [Ram, Jagat] PGIMER, Dept Ophthalmol, Adv Eye Ctr, Chandigarh 160012, India.
C3 Deakin University; TERI University; Post Graduate Institute of Medical
   Education & Research (PGIMER), Chandigarh
RP Kanwar, JR (通讯作者)，Deakin Univ, NLIMBR, Sch Med SoM, C MMR,Sch Med,Fac Hlth, Pigdons Rd,Waurn Ponds, Geelong, Vic 3216, Australia.
EM jagat.kanwar@deakin.edu.au
FU Australia-India Strategic Research Fund (AISRF) [BF030016, BF060042];
   National Health and Medical Research Council (NHMRC) [APP1050286];
   TERI-DEAKIN Nanobiotechnology Centre
FX The authors would like to thank the Australia-India Strategic Research
   Fund (AISRF, BF030016, BF060042) and National Health and Medical
   Research Council (NHMRC, APP1050286) for providing the funding for this
   project. The authors also would like to thank TERI-DEAKIN
   Nanobiotechnology Centre for financial support to Pavan Sunkireddy. The
   authors have no other relevant affiliations or financial involvement
   with any organization or entity with a financial interest in or
   financial conflict with the subject matter or materials discussed in the
   manuscript apart from those disclosed.
CR Ahmad A, 2003, COLLOID SURFACE B, V28, P313, DOI 10.1016/S0927-7765(02)00174-1
   Alonso MJ, 2003, J PHARM PHARMACOL, V55, P1451, DOI 10.1211/0022357022476
   Amidi M, 2006, J CONTROL RELEASE, V111, P107, DOI 10.1016/j.jconrel.2005.11.014
   Bhasker S, 2015, TOXICOL IN VITRO, V29, P917, DOI 10.1016/j.tiv.2015.01.007
   Bonferoni MC, 2009, EXPERT OPIN DRUG DEL, V6, P923, DOI 10.1517/17425240903114142
   Burrow H, 2011, MED CHEM, V7, P224, DOI 1573-4064/11 $58.00+.00
   Calvo P, 1997, J APPL POLYM SCI, V63, P125, DOI 10.1002/(SICI)1097-4628(19970103)63:1<125::AID-APP13>3.0.CO;2-4
   Chen F, 2007, INT J PHARMACEUT, V336, P166, DOI 10.1016/j.ijpharm.2006.11.027
   De Campos AM, 2001, INT J PHARM, V224, P159, DOI 10.1016/S0378-5173(01)00760-8
   Eizatahry AA, 2008, POLYM ADVAN TECHNOL, V19, P1787, DOI 10.1002/pat.1195
   Fan W, 2012, COLLOID SURFACE B, V90, P21, DOI 10.1016/j.colsurfb.2011.09.042
   Gawel Stefan, 2004, Wiad Lek, V57, P453
   Gibbons JA, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1441-4
   GREAVES JL, 1993, ADV DRUG DELIVER REV, V11, P349, DOI 10.1016/0169-409X(93)90016-W
   Hagens WI, 2007, REGUL TOXICOL PHARM, V49, P217, DOI 10.1016/j.yrtph.2007.07.006
   Hu YL, 2011, INT J NANOMED, V6, P3351, DOI 10.2147/IJN.S25853
   Kanwar JR, 2015, MOLECULES, V20, P9703, DOI 10.3390/molecules20069703
   Kumar A., 2011, EUR J APPL SCI, V3, P86
   Malhotra M, 2009, DRUG DEV IND PHARM, V35, P719, DOI 10.1080/03639040802526789
   Meng W, 2006, J CONTROL RELEASE, V116, P314, DOI 10.1016/j.jconrel.2006.09.014
   Nagarwal RC, 2009, J CONTROL RELEASE, V136, P2, DOI 10.1016/j.jconrel.2008.12.018
   Nagavarma BV, 2012, ASIAN J PHARM CLIN R, V5, P16
   Nakai M, 1997, ANAT REC, V247, P379
   Rajeswary S, 2007, REPROD TOXICOL, V24, P371, DOI 10.1016/j.reprotox.2007.03.010
   Roy K, 2015, INT J NANOMED, V10, P1019, DOI 10.2147/IJN.S73916
   Sakr SA, 2014, TOXICOL IND HEALTH, V30, P259, DOI 10.1177/0748233712456059
   Samarasinghe RM, 2014, BIOMATERIALS, V35, P7522, DOI 10.1016/j.biomaterials.2014.04.109
   Santra S., 2011, (19)United States (12) Patent Application Publication (10) Pub., Patent No. [US20110021745A1, 20110021745, 2011/0021745]
   Santra S, 2010, [No title captured], Patent No. [US20110158901 A1, 20110158901]
   Soppimath KS, 2001, J CONTROL RELEASE, V70, P1, DOI 10.1016/s0168-3659(00)00339-4
   Sriramoju B, 2014, INT J NANOMED, V9, P3279, DOI 10.2147/IJN.S60169
   Tallury P, 2009, CHEM COMMUN, P2347, DOI 10.1039/b901729a
   Taranejoo S, 2014, J APPL POLYM SCI, V131, DOI 10.1002/app.39648
   Wang XM, 2008, EUR J PHARM BIOPHARM, V70, P735, DOI 10.1016/j.ejpb.2008.07.005
   Wu Y, 2005, INT J PHARMACEUT, V295, P235, DOI 10.1016/j.ijpharm.2005.01.042
   Zhang Y, 2011, MOL VIS, V17, P2325
   Zhou HY, 2013, INT J OPHTHALMOL-CHI, V6, P390, DOI 10.3980/j.issn.2222-3959.2013.03.25
NR 37
TC 14
Z9 14
U1 2
U2 20
PU FUTURE MEDICINE LTD
PI LONDON
PA UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3
   1QB, ENGLAND
SN 1743-5889
EI 1748-6963
J9 NANOMEDICINE-UK
JI Nanomedicine
PY 2016
VL 11
IS 5
BP 495
EP 511
DI 10.2217/nnm.15.205
PG 17
WC Biotechnology & Applied Microbiology; Nanoscience & Nanotechnology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Science & Technology - Other
   Topics
GA DG5WA
UT WOS:000372148800006
PM 26700462
DA 2022-11-30
ER

PT J
AU Hanus, J
   Anderson, C
   Wang, SS
AF Hanus, Jakub
   Anderson, Chastain
   Wang, Shusheng
TI RPE necroptosis in response to oxidative stress and in AMD
SO AGEING RESEARCH REVIEWS
LA English
DT Review
DE Apoptosis; Age-related macular degeneration; Geographic atrophy;
   Necroptosis; Necrosis; Oxidative stress; RPE
ID RETINAL-PIGMENT EPITHELIUM; COMPLEMENT FACTOR-H; MITOCHONDRIAL
   PERMEABILITY TRANSITION; RECEPTOR-INTERACTING PROTEIN; SENILE MACULAR
   DEGENERATION; MIXED LINEAGE KINASE; DOMAIN-LIKE PROTEIN; C-REACTIVE
   PROTEIN; INDUCED CELL-DEATH; PROGRAMMED NECROSIS
AB Age-related macular degeneration (AMD) is the leading cause of irreversible blindness in the elderly. The underlying mechanism of non-neovascular AMD (dry AMD), also named geographic atrophy (GA) remains unclear and the mechanism of retinal pigment epithelial (RPE) cell death in AMD is controversial. We review the history and recent progress in understanding the mechanism of RPE cell death induced by oxidative stress, in AMD mouse models, and in AMD patients. Due to the limitation of toolsets to distinguish between apoptosis and necroptosis (or necrosis), most previous research concludes that apoptosis is a major mechanism for RPE cell death in response to oxidative stress and in AMD. Recent studies suggest necroptosis as a major mechanism of RPE cell death in response to oxidative stress. Moreover, ultrastructural and histopathological studies support necrosis as major mechanism of RPE cells death in AMD. In this review, we discuss the mechanism of RPE cell death in response to oxidative stress, in AMD mouse models, and in human AMD patients. Based on the literature, we hypothesize that necroptosis is a major mechanism for RPE cell death in response to oxidative stress and in AMD. (C) 2015 Elsevier B.V. All rights reserved.
C1 [Hanus, Jakub; Anderson, Chastain; Wang, Shusheng] Tulane Univ, Dept Cell & Mol Biol, New Orleans, LA 70118 USA.
   [Wang, Shusheng] Tulane Univ, Dept Ophthalmol, New Orleans, LA 70118 USA.
C3 Tulane University; Tulane University
RP Wang, SS (通讯作者)，Tulane Univ, Dept Cell & Mol Biol & Ophthalmol, 2000 Percival Stern Hall,6400 Freret St, New Orleans, LA 70118 USA.
EM swang1@tulane.edu
FU NEI NIH HHS [R01 EY021862] Funding Source: Medline; NATIONAL EYE
   INSTITUTE [R01EY021862] Funding Source: NIH RePORTER
CR Alge CS, 2002, INVEST OPHTH VIS SCI, V43, P3575
   Ambati J, 2003, NAT MED, V9, P1390, DOI 10.1038/nm950
   BAICH A, 1992, PIGM CELL RES, V5, P394, DOI 10.1111/j.1600-0749.1992.tb00568.x
   Baines CP, 2005, NATURE, V434, P658, DOI 10.1038/nature03434
   Baird PN, 2006, HUM MUTAT, V27, P337, DOI 10.1002/humu.20288
   Barak A, 2001, INVEST OPHTH VIS SCI, V42, P247
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Behnam JI, 2006, BIOCHEM J, V394, P409, DOI 10.1042/BJ20051397
   Biarnes M, 2011, OPTOMETRY VISION SCI, V88, P881, DOI 10.1097/OPX.0b013e31821988c1
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Cai JY, 1999, INVEST OPHTH VIS SCI, V40, P959
   Cai X, 2012, FRONT BIOSCI-LANDMRK, V17, P1976, DOI 10.2741/4033
   Chen X, 2014, CELL RES, V24, P105, DOI 10.1038/cr.2013.171
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Cho Y, 2009, CELL, V137, P1112, DOI 10.1016/j.cell.2009.05.037
   Christofferson DE, 2010, CURR OPIN CELL BIOL, V22, P263, DOI 10.1016/j.ceb.2009.12.003
   Christofferson DE, 2013, ANN REV PHYSL
   Chu XK, 2013, BIOENGINEERED, V4, P130, DOI 10.4161/bioe.22949
   Coffey PJ, 2007, P NATL ACAD SCI USA, V104, P16651, DOI 10.1073/pnas.0705079104
   Combadiere C, 2007, J CLIN INVEST, V117, P2920, DOI 10.1172/JCI31692
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Declercq W, 2009, CELL, V138, P229, DOI 10.1016/j.cell.2009.07.006
   Dithmar S, 2000, INVEST OPHTH VIS SCI, V41, P2035
   Donoso LA, 2010, SURV OPHTHALMOL, V55, P227, DOI 10.1016/j.survophthal.2009.11.001
   Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8
   Dunaief JL, 2002, ARCH OPHTHALMOL-CHIC, V120, P1435, DOI 10.1001/archopht.120.11.1435
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Ellerman JE, 2007, CLIN CANCER RES, V13, P2836, DOI 10.1158/1078-0432.CCR-06-1953
   Enzmann V, 2006, EXP EYE RES, V82, P441, DOI 10.1016/j.exer.2005.08.002
   Eskes R, 2000, MOL CELL BIOL, V20, P929, DOI 10.1128/MCB.20.3.929-935.2000
   FARKAS TG, 1971, AM J OPHTHALMOL, V71, P1196, DOI 10.1016/0002-9394(71)90963-9
   Fink SL, 2005, INFECT IMMUN, V73, P1907, DOI 10.1128/IAI.73.4.1907-1916.2005
   Fink SL, 2006, CELL MICROBIOL, V8, P1812, DOI 10.1111/j.1462-5822.2006.00751.x
   Flores-Bellver M, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.288
   Franco LM, 2009, INVEST OPHTH VIS SCI, V50, P4004, DOI 10.1167/iovs.08-2898
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gallagher-Colombo S, 2010, INVEST OPHTH VIS SCI, V51, P5343, DOI 10.1167/iovs.09-5028
   Giani A, 2013, CELL DEATH DIFFER
   Glotin AL, 2006, INVEST OPHTH VIS SCI, V47, P4614, DOI 10.1167/iovs.06-0297
   Green DR, 2000, CELL, V102, P1, DOI 10.1016/S0092-8674(00)00003-9
   Gu XR, 2003, J BIOL CHEM, V278, P42027, DOI 10.1074/jbc.M305460200
   Hadziahmetovic M, 2008, INVEST OPHTH VIS SCI, V49, P2728, DOI 10.1167/iovs.07-1472
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hahn P, 2004, P NATL ACAD SCI USA, V101, P13850, DOI 10.1073/pnas.0405146101
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hanus J, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.478
   Hanus J, 2008, APOPTOSIS, V13, P377, DOI 10.1007/s10495-008-0183-z
   Harper N, 2003, J BIOL CHEM, V278, P44338, DOI 10.1074/jbc.M307376200
   Hashizume K, 2008, AM J PATHOL, V172, P1325, DOI 10.2353/ajpath.2008.070730
   Hildebrand JM, 2014, P NATL ACAD SCI USA, V111, P15072, DOI 10.1073/pnas.1408987111
   Ho TC, 2006, APOPTOSIS, V11, P1899, DOI 10.1007/s10495-006-9403-6
   Hollyfield JG, 2008, NAT MED, V14, P194, DOI 10.1038/nm1709
   Jacobson MD, 1997, CELL, V88, P347, DOI 10.1016/S0092-8674(00)81873-5
   Jarrett SG, 2012, MOL ASPECTS MED, V33, P399, DOI 10.1016/j.mam.2012.03.009
   Juel HB, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064619
   Justilien V, 2007, INVEST OPHTH VIS SCI, V48, P4407, DOI 10.1167/iovs.07-0432
   Kaarniranta K, 2005, NEUROSCI LETT, V382, P185, DOI 10.1016/j.neulet.2005.03.009
   Kaldarar-Pedotti S, 1979, Adv Ophthalmol, V39, P37
   Kaneko H, 2011, NATURE, V471, P325, DOI 10.1038/nature09830
   Karch J, 2013, ELIFE, V2, DOI 10.7554/eLife.00772
   Kasahara E, 2005, INVEST OPHTH VIS SCI, V46, P3426, DOI 10.1167/iovs.05-0344
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33
   Khandhadia S, 2010, EXPERT REV MOL MED, V12, DOI 10.1017/S146239941000164X
   Kim Min-Ho, 2003, Korean J Ophthalmol, V17, P19
   Kiuchi K, 2002, CURR EYE RES, V25, P373, DOI 10.1076/ceyr.25.6.373.14227
   Klaver CCW, 1998, AM J HUM GENET, V63, P200, DOI 10.1086/301901
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Krysko DV, 2008, METHODS, V44, P205, DOI 10.1016/j.ymeth.2007.12.001
   Lauer N, 2011, J IMMUNOL, V187, P4374, DOI 10.4049/jimmunol.1002488
   Li GY, 2010, BIOMED ENVIRON SCI, V23, P371, DOI 10.1016/S0895-3988(10)60078-5
   Li JX, 2012, CELL, V150, P339, DOI 10.1016/j.cell.2012.06.019
   Lin Y, 1999, GENE DEV, V13, P2514, DOI 10.1101/gad.13.19.2514
   Machalinska A, 2010, NEUROCHEM RES, V35, P1819, DOI 10.1007/s11064-010-0248-6
   Malek G, 2005, P NATL ACAD SCI USA, V102, P11900, DOI 10.1073/pnas.0503015102
   Mandal NA, 2006, INVEST OPHTH VIS SCI, V47, P4091, DOI 10.1167/iovs.05-1655
   Mattapallil MJ, 2012, INVEST OPHTH VIS SCI, V53, P2921, DOI 10.1167/iovs.12-9662
   Mettu PS, 2012, MOL ASPECTS MED, V33, P376, DOI 10.1016/j.mam.2012.04.006
   Murakami Y, 2014, CELL DEATH DIFFER, V21, P270, DOI 10.1038/cdd.2013.109
   Murrow L, 2013, ANNU REV PATHOL-MECH, V8, P105, DOI 10.1146/annurev-pathol-020712-163918
   Nagata S, 2003, CELL DEATH DIFFER, V10, P108, DOI 10.1038/sj.cdd.4401161
   Nakagawa T, 2005, NATURE, V434, P652, DOI 10.1038/nature03317
   NOELL WK, 1953, AM J OPHTHALMOL, V36, P103, DOI 10.1016/0002-9394(53)90159-7
   O'Donnell MA, 2011, NAT CELL BIOL, V13, P1437, DOI 10.1038/ncb2362
   PENFOLD PL, 1986, INVEST OPHTH VIS SCI, V27, P364
   PENFOLD PL, 1985, GRAEF ARCH CLIN EXP, V223, P69, DOI 10.1007/BF02150948
   Poldelski V, 2001, AM J KIDNEY DIS, V38, P339, DOI 10.1053/ajkd.2001.26099
   Qin S, 2008, J INFLAMM RES, V1, P49
   Rakoczy PE, 1997, BIOCHEM J, V324, P935, DOI 10.1042/bj3240935
   Rakoczy PE, 2002, AM J PATHOL, V161, P1515, DOI 10.1016/S0002-9440(10)64427-6
   Ramkumar HL, 2010, PROG RETIN EYE RES, V29, P169, DOI 10.1016/j.preteyeres.2010.02.002
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rossi D, 2003, HAEMATOLOGICA, V88, P212
   Rudolf M, 2013, OPHTHALMOLOGY, V120, P821, DOI 10.1016/j.ophtha.2012.10.007
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   SARKS SH, 1976, BRIT J OPHTHALMOL, V60, P324, DOI 10.1136/bjo.60.5.324
   Scaffidi P, 2002, NATURE, V418, P191, DOI 10.1038/nature00858
   Scholl HPN, 2005, OPHTHALMOLOGE, V102, P1029, DOI 10.1007/s00347-005-1270-y
   Seddon JM, 2004, JAMA-J AM MED ASSOC, V291, P704, DOI 10.1001/jama.291.6.704
   Sharma A, 2008, ARCH BIOCHEM BIOPHYS, V480, P85, DOI 10.1016/j.abb.2008.09.016
   Shen HM, 2004, MOL CELL BIOL, V24, P5914, DOI 10.1128/MCB.24.13.5914-5922.2004
   Sjoberg AP, 2007, J BIOL CHEM, V282, P10894, DOI 10.1074/jbc.M610256200
   Sreekumar PG, 2005, BIOCHEM BIOPH RES CO, V334, P245, DOI 10.1016/j.bbrc.2005.06.081
   Strunnikova N, 2004, INVEST OPHTH VIS SCI, V45, P3767, DOI 10.1167/iovs.04-0311
   Sun LM, 2012, CELL, V148, P213, DOI 10.1016/j.cell.2011.11.031
   Suzuki M, 2007, MOL VIS, V13, P772
   Tarallo V, 2012, CELL, V149, P847, DOI 10.1016/j.cell.2012.03.036
   Tian W, 2013, INT J ONCOL, V42, P1654, DOI 10.3892/ijo.2013.1863
   Tou JS, 2004, FASEB J, V18, P1297, DOI 10.1096/fj.04-1862fje
   Trichonas G, 2010, P NATL ACAD SCI USA, V107, P21695, DOI 10.1073/pnas.1009179107
   Tuo JS, 2007, INVEST OPHTH VIS SCI, V48, P3827, DOI 10.1167/iovs.07-0051
   Ufret-Vincenty RL, 2010, INVEST OPHTH VIS SCI, V51, P5878, DOI 10.1167/iovs.09-4457
   Wajant H, 2003, CELL DEATH DIFFER, V10, P45, DOI 10.1038/sj.cdd.4401189
   Wang JM, 2014, INVEST OPHTH VIS SCI, V55, P1941, DOI 10.1167/iovs.13-13075
   Wang ZG, 2012, CELL, V148, P228, DOI 10.1016/j.cell.2011.11.030
   Weismann D, 2011, NATURE, V478, P76, DOI 10.1038/nature10449
   Widlak P, 2005, J CELL BIOCHEM, V94, P1078, DOI 10.1002/jcb.20409
   Wright KM, 2006, CELL CYCLE, V5, P1616, DOI 10.4161/cc.5.15.3129
   Xu G Z, 1996, Trans Am Ophthalmol Soc, V94, P411
   Yang P., 2011, INVEST OPHTH VIS SCI, V52, P894
   Yang P, 2007, INVEST OPHTH VIS SCI, V48, P3341, DOI 10.1167/iovs.06-1340
   Yu DY, 2005, EXP EYE RES, V80, P745, DOI 10.1016/j.exer.2005.01.018
   Zampros I, 2012, J OPHTHALMOL, V2012, DOI 10.1155/2012/319728
   Zenkov NK, 2013, BIOCHEMISTRY-MOSCOW+, V78, P19, DOI 10.1134/S0006297913010033
   Zhang CX, 2003, J CELL SCI, V116, P1915, DOI 10.1242/jcs.00390
   Zhang D, 2005, INVEST OPHTH VIS SCI, V46, P3031, DOI 10.1167/iovs.04-1510
   Zhang DW, 2009, SCIENCE, V325, P332, DOI 10.1126/science.1172308
   Zhang JH, 2000, CELL RES, V10, P205, DOI 10.1038/sj.cr.7290049
   Zhao ZY, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019456
   Zhou P, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098275
   Zitvogel L, 2010, CELL, V140, P798, DOI 10.1016/j.cell.2010.02.015
NR 131
TC 126
Z9 132
U1 6
U2 41
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 1568-1637
EI 1872-9649
J9 AGEING RES REV
JI Ageing Res. Rev.
PD NOV
PY 2015
VL 24
BP 286
EP 298
DI 10.1016/j.arr.2015.09.002
PN B
PG 13
WC Cell Biology; Geriatrics & Gerontology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Geriatrics & Gerontology
GA CZ0AY
UT WOS:000366768700015
PM 26369358
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Knerr, PJ
   Tzekou, A
   Ricklin, D
   Qu, HC
   Chen, H
   van der Donk, WA
   Lambris, JD
AF Knerr, Patrick J.
   Tzekou, Apostolia
   Ricklin, Daniel
   Qu, Hongchang
   Chen, Hui
   van der Donk, Wilfred A.
   Lambris, John D.
TI Synthesis and Activity of Thioether-Containing Analogues of the
   Complement Inhibitor Compstatin
SO ACS CHEMICAL BIOLOGY
LA English
DT Article
ID SOLID-PHASE SYNTHESIS; BIOLOGICAL-ACTIVITIES; PROTECTED LANTHIONINES;
   DISULFIDE BRIDGE; AMINO-ACIDS; PEPTIDES; POTENT; PHARMACEUTICALS;
   SOMATOSTATIN; GLUTATHIONE
AB Disulfide bonds are essential for the structural stability and biological activity of many bioactive peptides. However, these bonds are labile to reducing agents, which can limit the therapeutic utility of such peptides. Substitution of a disulfide bond with a reduction-resistant cystathionine bridge is an attractive means of improving stability while imposing minimal structural perturbation to the peptide. We have applied this approach to the therapeutic complement inhibitor compstatin, a disulfide-containing peptide currently in clinical trials for age-related macular degeneration, in an effort to maintain its potent activity while improving its biological stability. Thioether-containing compstatin analogues were produced via solid phase peptide synthesis utilizing orthogonally protected cystathionine amino acid building blocks and solid supported peptide cyclization. Overall, the affinity of these analogues for their biological target and potent inhibition of complement activation were largely maintained when compared to those of the parent disulfide-containing peptides: Thus, the improved stability to reduction conferred by the thioether bond makes this new class of compstatin peptides a promising alternative for therapeutic applications. Additionally, the versatility of this synthesis allows for exploration of disulfide-to-thioether substitution in a variety of other therapeutic peptides.
C1 [Knerr, Patrick J.; van der Donk, Wilfred A.] Univ Illinois, Dept Chem, Urbana, IL 61801 USA.
   [van der Donk, Wilfred A.] Univ Illinois, Howard Hughes Med Inst, Urbana, IL 61801 USA.
   [Tzekou, Apostolia; Ricklin, Daniel; Qu, Hongchang; Chen, Hui; Lambris, John D.] Univ Penn, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA.
C3 University of Illinois System; University of Illinois Urbana-Champaign;
   Howard Hughes Medical Institute; University of Illinois System;
   University of Illinois Urbana-Champaign; University of Pennsylvania
RP van der Donk, WA (通讯作者)，Univ Illinois, Dept Chem, 600 S Mathews Ave, Urbana, IL 61801 USA.
EM vddonk@illinois.edu; lambris@upenn.edu
RI van der Donk, Wilfred/K-2961-2015; Lambris, John/Q-5633-2018; Ricklin,
   Daniel/F-5104-2011
OI van der Donk, Wilfred/0000-0002-5467-7071; Lambris,
   John/0000-0002-9370-5776; Ricklin, Daniel/0000-0001-6140-0233
FU Robert C. and Carolyn J. Springborn Endowment; Howard Hughes Medical
   Institute; National Institutes of Health [T32 GM070421, GM062134,
   AI068730]; NATIONAL EYE INSTITUTE [R01EY020633] Funding Source: NIH
   RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
   [P01AI068730] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF
   GENERAL MEDICAL SCIENCES [T32GM070421, R01GM062134] Funding Source: NIH
   RePORTER
FX We thank Dr. Deborah McClellan for editorial assistance. This work was
   supported by the Robert C. and Carolyn J. Springborn Endowment (PJ.K.),
   the Howard Hughes Medical Institute (W.A.V.). and National Institutes of
   Health grants T32 GM070421 (P.J.K.), GM062134 (J.D.L.), and AI068730
   (J.D.L.).
CR Armishaw CJ, 2006, J BIOL CHEM, V281, P14136, DOI 10.1074/jbc.M512419200
   Boakes S, 2009, MOL MICROBIOL, V72, P1126, DOI 10.1111/j.1365-2958.2009.06708.x
   Bondebjerg J, 2003, CHEMBIOCHEM, V4, P186, DOI 10.1002/cbic.200390030
   Bregant S, 2005, J ORG CHEM, V70, P2430, DOI 10.1021/jo048222t
   Burrage S, 2000, CHEM-EUR J, V6, P1455, DOI 10.1002/(SICI)1521-3765(20000417)6:8<1455::AID-CHEM1455>3.0.CO;2-M
   Craik DJ, 2006, CURR OPIN DRUG DISC, V9, P251
   Daly NL, 2009, ADV DRUG DELIVER REV, V61, P918, DOI 10.1016/j.addr.2009.05.003
   Davies MJ, 2005, BBA-PROTEINS PROTEOM, V1703, P93, DOI 10.1016/j.bbapap.2004.08.007
   Derksen DJ, 2006, J AM CHEM SOC, V128, P14252, DOI 10.1021/ja066203q
   Elaridi J, 2006, J ORG CHEM, V71, P7538, DOI 10.1021/jo0606913
   Fotouhi N, 2000, BIOORG MED CHEM LETT, V10, P1167, DOI 10.1016/S0960-894X(00)00175-X
   Ganz T, 2003, NAT REV IMMUNOL, V3, P710, DOI 10.1038/nri1180
   Gehrmann J, 1998, J MOL BIOL, V278, P401, DOI 10.1006/jmbi.1998.1701
   Giustarini D, 2004, FREE RADICAL RES, V38, P1101, DOI 10.1080/10715760400008854
   Hargittai B, 2000, J MED CHEM, V43, P4787, DOI 10.1021/jm990635c
   Janssen BJC, 2007, J BIOL CHEM, V282, P29241, DOI 10.1074/jbc.M704587200
   Jones DS, 1998, TETRAHEDRON LETT, V39, P6107, DOI 10.1016/S0040-4039(98)01292-1
   JOST K, 1974, COLLECT CZECH CHEM C, V39, P2835, DOI 10.1135/cccc19742835
   Karlsson R, 2006, ANAL BIOCHEM, V349, P136, DOI 10.1016/j.ab.2005.09.034
   Katragadda M, 2004, J BIOL CHEM, V279, P54987, DOI 10.1074/jbc.M409963200
   Katragadda M, 2006, J MED CHEM, V49, P4616, DOI 10.1021/jm0603419
   Katsara M, 2006, CURR MED CHEM, V13, P2221, DOI 10.2174/092986706777935113
   Kluskens LD, 2009, J PHARMACOL EXP THER, V328, P849, DOI 10.1124/jpet.108.146431
   Kourtzelis I, 2010, BLOOD, V116, P631, DOI 10.1182/blood-2010-01-264051
   KUSTERS E, 1984, CHROMATOGRAPHIA, V18, P287, DOI 10.1007/BF02259079
   LABOISSIERE MCA, 1995, J BIOL CHEM, V270, P28006
   Leaver SK, 2010, INTENS CARE MED, V36, P336, DOI 10.1007/s00134-009-1640-z
   Magotti P, 2009, J MOL RECOGNIT, V22, P495, DOI 10.1002/jmr.972
   Mallik B, 2005, J MED CHEM, V48, P274, DOI 10.1021/jm0495531
   Manning MC, 2010, PHARM RES-DORDR, V27, P544, DOI 10.1007/s11095-009-0045-6
   Matteucci M, 2004, TETRAHEDRON LETT, V45, P1399, DOI 10.1016/j.tetlet.2003.12.074
   MAYER JP, 1995, TETRAHEDRON LETT, V36, P7387, DOI 10.1016/0040-4039(95)01548-5
   Muttenthaler M, 2010, J AM CHEM SOC, V132, P3514, DOI 10.1021/ja910602h
   Osapay G, 1997, J MED CHEM, V40, P2241, DOI 10.1021/jm960850i
   Pattabiraman VR, 2008, ANGEW CHEM INT EDIT, V47, P9472, DOI 10.1002/anie.200802919
   Paul M, 2005, MINI-REV ORG CHEM, V2, P23, DOI 10.2174/1570193052774108
   Qu HC, 2011, MOL IMMUNOL, V48, P481, DOI 10.1016/j.molimm.2010.10.004
   Rabenstein DL, 1996, J ORG CHEM, V61, P7391, DOI 10.1021/jo960917+
   Rew Y, 2002, J MED CHEM, V45, P3746, DOI 10.1021/jm020108k
   Ricklin D, 2008, ADV EXP MED BIOL, V632, P273, DOI 10.1007/978-0-387-78952-1_20
   Ricklin D, 2007, NAT BIOTECHNOL, V25, P1265, DOI 10.1038/nbt1342
   Rink R, 2010, J PHARMACOL TOX MET, V61, P210, DOI 10.1016/j.vascn.2010.02.010
   Ross AC, 2010, J AM CHEM SOC, V132, P462, DOI 10.1021/ja9095945
   Sahu A, 1996, J IMMUNOL, V157, P884
   Sahu A, 2000, J IMMUNOL, V165, P2491, DOI 10.4049/jimmunol.165.5.2491
   Sarrias MR, 2001, J IMMUNOL, V167, P1490, DOI 10.4049/jimmunol.167.3.1490
   Serru V, 2001, CLIN CHEM, V47, P1321
   Silasi-Mansat R, 2010, BLOOD, V116, P1002, DOI 10.1182/blood-2010-02-269746
   Soulika AM, 2006, MOL IMMUNOL, V43, P2023, DOI 10.1016/j.molimm.2005.12.002
   SPINELLA MJ, 1991, P NATL ACAD SCI USA, V88, P7443, DOI 10.1073/pnas.88.16.7443
   Stevenson CL, 2009, CURR PHARM BIOTECHNO, V10, P122, DOI 10.2174/138920109787048634
   Stymiest JL, 2005, J ORG CHEM, V70, P7799, DOI 10.1021/jo050539l
   Terlau H, 2004, PHYSIOL REV, V84, P41, DOI 10.1152/physrev.00020.2003
   Vlieghe P, 2010, DRUG DISCOV TODAY, V15, P40, DOI 10.1016/j.drudis.2009.10.009
   Willey JM, 2007, ANNU REV MICROBIOL, V61, P477, DOI 10.1146/annurev.micro.61.080706.093501
   Wilson-Stanford S, 2009, APPL ENVIRON MICROB, V75, P1381, DOI 10.1128/AEM.01864-08
   Woycechowsky KJ, 2000, CURR OPIN CHEM BIOL, V4, P533, DOI 10.1016/S1367-5931(00)00128-9
   Zhou H, 2002, ORG LETT, V4, P1335, DOI 10.1021/ol025629g
   Zhu XM, 2003, EUR J ORG CHEM, V2003, P4069, DOI 10.1002/ejoc.200300336
   2009, NAT REV DRUG DISCOVE, V8, P922
NR 60
TC 70
Z9 74
U1 2
U2 28
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1554-8929
EI 1554-8937
J9 ACS CHEM BIOL
JI ACS Chem. Biol.
PD JUL
PY 2011
VL 6
IS 7
BP 753
EP 760
DI 10.1021/cb2000378
PG 8
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA 793VB
UT WOS:000292850900011
PM 21520911
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Sarks, J
   Arnold, J
   Ho, IV
   Sarks, S
   Killingsworth, M
AF Sarks, John
   Arnold, Jennifer
   Ho, I-Van
   Sarks, Shirley
   Killingsworth, Murray
TI Evolution of reticular pseudodrusen
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID SUBRETINAL DRUSENOID DEPOSITS; AGE-RELATED MACULOPATHY; CHOROIDAL
   NEOVASCULARIZATION; FUNDUS AUTOFLUORESCENCE; MACULAR DEGENERATION; RISK;
   DISEASE; ATROPHY
AB Aims To report observations relating to the clinical recognition and possible basis of reticular pseudodrusen (RPD).
   Methods This retrospective study reports the evolution of RPD in 166 patients who had follow-up of over 1 year using multiple imaging techniques. Mean age when first seen was 73.3 years and the mean period of observation was 4.9 years (range 1-18 years). Associated macular changes were recorded.
   Results RPD were first identified in the upper fundus as a reticular network, which then became less obvious, developing a diffuse yellowish appearance. RPD also faded around choroidal neovascularisation (CNV). RPD therefore could be transient but the pattern often remained visible outside the macula or nasal to the discs. Manifestations of age-related macular degeneration (AMD) were present in nearly all eyes and there was a particularly high association with CNV (52.1%). In one clinicopathological case abnormal material was found in the subretinal space.
   Conclusions The prevalence of RPD may be underestimated because their recognition depends upon the imaging method used, the area of fundus examined and the confusion with typical drusen. The pathology of one eye suggests that RPD may correspond to material in the subretinal space.
C1 [Sarks, John; Sarks, Shirley] Prince Wales Hosp, Dept Ophthalmol, Sydney, NSW, Australia.
   [Arnold, Jennifer] Marsden Eye Ctr, Sydney, NSW, Australia.
   [Ho, I-Van] Retina Associates, Sydney, NSW, Australia.
   [Killingsworth, Murray] S Western Area Pathol Serv, Sydney, NSW, Australia.
RP Sarks, J (通讯作者)，15 Parnell St, Strathfield, NSW 2135, Australia.
EM jssarks@bigpond.net.au
RI Killingsworth, Murray/O-3736-2019; Killingsworth, Murray C/G-5908-2015
OI Killingsworth, Murray/0000-0002-6125-1183; Ho, I-Van/0000-0002-7215-1233
CR ARNOLD JJ, 1995, RETINA-J RET VIT DIS, V15, P183, DOI 10.1097/00006982-199515030-00001
   Bindewald A, 2005, INVEST OPHTH VIS SCI, V46, P3309, DOI 10.1167/iovs.04-0430
   Cohen SY, 2007, BRIT J OPHTHALMOL, V91, P354, DOI 10.1136/bjo.2006.101022
   Curcio CA, 2009, PROG RETIN EYE RES, V28, P393, DOI 10.1016/j.preteyeres.2009.08.001
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein R, 2008, AM J OPHTHALMOL, V145, P317, DOI 10.1016/j.ajo.2007.09.008
   Lois N, 2002, AM J OPHTHALMOL, V133, P341, DOI 10.1016/S0002-9394(01)01404-0
   MIMOUN G, 1990, J FR OPHTALMOL, V13, P511
   Prenner JL, 2003, RETINA-J RET VIT DIS, V23, P307, DOI 10.1097/00006982-200306000-00004
   Rudolf M, 2008, EXP EYE RES, V87, P402, DOI 10.1016/j.exer.2008.07.010
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   Smith RT, 2009, AM J OPHTHALMOL, V148, P733, DOI 10.1016/j.ajo.2009.06.028
   Zarbin MA, 2006, BRIT J OPHTHALMOL, V90, P396, DOI 10.1136/bjo.2005.086041
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P303, DOI 10.1016/j.ophtha.2009.07.014
NR 14
TC 102
Z9 107
U1 0
U2 5
PU B M J PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD JUL
PY 2011
VL 95
IS 7
BP 979
EP 985
DI 10.1136/bjo.2010.194977
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 778PX
UT WOS:000291717700018
PM 21109695
OA Green Submitted, hybrid
DA 2022-11-30
ER

PT J
AU Cunha-Vaz, J
   Bernardes, R
   Lobo, C
AF Cunha-Vaz, Jose
   Bernardes, Rui
   Lobo, Conceicao
TI Blood-retinal barrier
SO EUROPEAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Blood-retinal barrier; Macular edema; Optical coherence tomography;
   Retinal pigment epithelium; Retinal vessels; Vitreous fluorometry
ID FLUORESCEIN; PERMEABILITY; BREAKDOWN; VESSELS
AB The blood-ocular barrier system is formed by 2 main barriers: the blood-aqueous barrier and the blood-retinal barrier (BRB). The BRB is particularly tight and restrictive and is a physiologic barrier that regulates ion, protein, and water flux into and out of the retina. The BRB consists of inner and outer components, the inner BRB being formed of tight junctions between retinal capillary endothelial cells and the outer BRB of tight junctions between retinal pigment epithelial cells. The BRB is essential to maintaining the eye as a privileged site and is essential for normal visual function. Methods of clinical evaluation of the BRB are reviewed and new directions using optical coherence tomography are presented. Alterations of the BRB play a crucial role in the development of retinal diseases. The 2 most frequent and relevant retinal diseases, diabetic retinopathy and age-related macular degeneration (AMD), are directly associated with alterations of the BRB. Diabetic retinopathy is initiated by an alteration of the inner BRB and neovascular AMD is a result of an alteration of the outer BRB. Macular edema is a direct result of alterations of the BRB.
C1 [Cunha-Vaz, Jose; Bernardes, Rui; Lobo, Conceicao] AIBILI, P-3000548 Coimbra, Portugal.
C3 Universidade de Coimbra
RP Cunha-Vaz, J (通讯作者)，AIBILI, P-3000548 Coimbra, Portugal.
EM cunhavaz@aibili.pt
RI Lobo, Conceição/ABB-8609-2021; Bernardes, Rui/M-4231-2013; Lobo,
   Conceicao/B-4122-2016
OI Bernardes, Rui/0000-0002-6677-2754; Lobo, Conceicao/0000-0001-5831-7711;
   Cunha-Vaz, Jose/0000-0002-0947-9850
CR Bernardes R, 2005, IEEE T BIO-MED ENG, V52, P106, DOI 10.1109/TBME.2004.839801
   Bernardes R, 2009, IFMBE PROC, V25, P316, DOI 10.1007/978-3-642-03891-4_84
   Coca-Prados M, 2007, PROG RETIN EYE RES, V26, P239, DOI 10.1016/j.preteyeres.2007.01.002
   CUNHAVAZ J, 1979, SURV OPHTHALMOL, V23, P279, DOI 10.1016/0039-6257(79)90158-9
   CUNHAVAZ J, 1969, DOC OPHTHALMOL, V26, P61, DOI 10.1007/BF00943962
   CUNHAVAZ J, 1975, BRIT J OPHTHALMOL, V59, P649, DOI 10.1136/bjo.59.11.649
   CUNHAVAZ JG, 1967, J PHYSIOL-LONDON, V191, P467, DOI 10.1113/jphysiol.1967.sp008262
   CUNHAVAZ JG, 1966, BRIT J OPHTHALMOL, V50, P441, DOI 10.1136/bjo.50.8.441
   CUNHAVAZ JG, 1984, SURV OPHTHALMOL, V28, P485, DOI 10.1016/0039-6257(84)90230-3
   Lobo CL, 1999, ARCH OPHTHALMOL-CHIC, V117, P631
   Lobo CL, 2000, ARCH OPHTHALMOL-CHIC, V118, P1364
   PARDRIDGE WM, 1998, INTRO BLOOD BRAIN BA, P1
   PEYMAN GA, 1972, INVEST OPHTH VISUAL, V11, P35
   Phillips B. E., 2007, RETINAL VASCULAR DIS, P139
   SHAKIB M, 1966, EXP EYE RES, V5, P229, DOI 10.1016/S0014-4835(66)80011-8
NR 15
TC 264
Z9 269
U1 1
U2 49
PU WICHTIG EDITORE
PI MILAN
PA 72/74 VIA FRIULI, 20135 MILAN, ITALY
SN 1120-6721
J9 EUR J OPHTHALMOL
JI Eur. J. Ophthalmol.
PD JAN-FEB
PY 2011
VL 21
SU 6
BP S3
EP S9
DI 10.5301/EJO.2010.6049
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 768FB
UT WOS:000290916000002
PM 23264323
DA 2022-11-30
ER

PT J
AU Ferrannini, M
   Vischini, G
   Staffolani, E
   Scaccia, F
   Miani, N
   Parravano, MC
   Louis, MM
   Splendiani, G
   Di Daniele, N
AF Ferrannini, M.
   Vischini, G.
   Staffolani, E.
   Scaccia, F.
   Miani, N.
   Parravano, M. C.
   Louis, M. M.
   Splendiani, G.
   Di Daniele, N.
TI Rheopheresis in vascular diseases
SO INTERNATIONAL JOURNAL OF ARTIFICIAL ORGANS
LA English
DT Article
DE rheopheresis; membrane differential filtration; AMD; PAOD
ID MACULAR DEGENERATION; ADHESION MOLECULES; ARTERIAL-DISEASE; APHERESIS;
   MECHANISM; SELECTIN
AB Background: Endothelial dysfunction is a common condition in many microvascular diseases, such as Age-related Macular Degeneration (AMD) and Peripheral Arterial Occlusive Disease (PAOD). Rheopheresis therapy improves ematic viscosity, shear stress and endothelial function while decreasing fibrinogen, LDL-cholesterol and alpha-2-macroglobulin levels.
   Objective: To evaluate the therapeutic efficacy of rheopheresis in patients with microcirculatory diseases.
   Materials and Methods: Eight patients (7 male and 1 female) were treated with rheopheresis: 3 males were affected by AMD, 4 male and 1 female by uremia and PAOD. We used Membrane Differential Filtration (MDF) with an ethinylvinylalcohol copolymer membrane as plasmafiltrator Patients with AMD were treated once a week for ten weeks. Patients affected with PAOD were treated twice weekly for 3 weeks and then were placed on a once-a-week program.
   Results: In all treated patients with AMD, visual acuity improved. In all patients affected with PAOD, we observed a complete resolution of pain; 3 out of 5 had a complete remission of ulcers. There was partial reduction of ulcers in the other patients and no adverse effects were observed.
   Conclusion: Rheopheresis is a safe, effective form of hemorheotherapy.
C1 Univ Roma Tor Vergata, Nephrol & Dialysis Unit, Rome, Italy.
   Umberto 1 Hosp, Nephrol & Dialysis Unit, Frosinone, Italy.
   Univ Roma Tor Vergata, Ophthalmol Unit, Rome, Italy.
C3 University of Rome Tor Vergata; University of Rome Tor Vergata
RP Ferrannini, M (通讯作者)，Policlin Univ Tor Vergata, Nephrol & Dialysis Unit, Viale Oxford 81, I-00133 Rome, Italy.
EM m.ferrannini@inwind.it
RI Vischini, Gisella/N-9980-2019; Blaha, Vladimir/C-1151-2016
OI Vischini, Gisella/0000-0001-5829-4396; Blaha,
   Vladimir/0000-0001-8088-9919
CR Arroyo JG, 2006, JAMA-J AM MED ASSOC, V295, P2394, DOI 10.1001/jama.295.20.2394
   DupuyFons C, 1996, J MAL VASCUL, V21, P165
   Empen K, 2002, J CLIN APHERESIS, V17, P38, DOI 10.1002/jca.10010
   KANNEL WB, 1987, AM HEART J, V113, P1006, DOI 10.1016/0002-8703(87)90063-9
   Klingel R, 2000, Ther Apher, V4, P348, DOI 10.1046/j.1526-0968.2000.004005348.x
   LECHNER P, 1994, CLIN HEMORHEOL, V14, P181
   LECHNER P, 1994, CLIN HEMORHEOL, V2, P181
   Motohashi K, 2003, THER APHER DIAL, V7, P425, DOI 10.1046/j.1526-0968.2003.00079.x
   Pulawski E, 2002, THER APHER, V6, P229, DOI 10.1046/j.1526-0968.2002.00405.x
   Pulido J, 2005, J CLIN APHERESIS, V20, P185, DOI 10.1002/jca.20047
   Pulido JS, 2005, CAN J OPHTHALMOL, V40, P332, DOI 10.1016/S0008-4182(05)80076-6
   Schuff-Werner P., 1997, JPN J APHERESIS, V16, P25
NR 12
TC 10
Z9 11
U1 0
U2 0
PU WICHTIG EDITORE
PI MILAN
PA 72/74 VIA FRIULI, 20135 MILAN, ITALY
SN 0391-3988
J9 INT J ARTIF ORGANS
JI Int. J. Artif. Organs
PD OCT
PY 2007
VL 30
IS 10
BP 923
EP 929
DI 10.1177/039139880703001010
PG 7
WC Engineering, Biomedical; Transplantation
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Engineering; Transplantation
GA 239JF
UT WOS:000251513900010
PM 17992654
DA 2022-11-30
ER

PT J
AU Alizadeh, P
   Smit-McBride, Z
   Oltjen, SL
   Hjelmeland, LM
AF Alizadeh, Parvaneh
   Smit-McBride, Zeljka
   Oltjen, Sharon L.
   Hjelmeland, Leonard M.
TI Regulation of cysteine cathepsin expression by oxidative stress in the
   retinal pigment epithelium/choroid of the mouse
SO EXPERIMENTAL EYE RESEARCH
LA English
DT Article
DE cathepsins; cystatins; retinal pigment epithelium; oxidative stress;
   mouse
ID C GENE POLYMORPHISM; CYSTATIN-C; COLLAGEN-XVIII; RAT; LOCALIZATION;
   ENDOSTATIN; ASSOCIATION; INHIBITOR; SEQUENCE; CELLS
AB Cystatin C is the major inhibitor of the cysteine cathepsins. Polymorphisms in the cystatin C gene have recently been associated with the risk of developing Age-related Macular Degeneration (AMD). Oxidative stress is also thought to play a key role in the pathogenesis of AMD. We surveyed the retinal pigment epithelium (RPE) and choroid of the C57BL/6J mouse for the expression of the cysteine cathepsins under normoxic and hyperoxic (75% O-2) conditions. Microarray analysis of RPE/choroid mRNA revealed the expression of cathepsins B and L, as well as cystatin C under all experimental conditions. The microarray results were confirmed by real-time quantitative polymerase chain reaction (PCR). Localization of the mRNA species for cystatin C and cathepsin B, as well as, localization of protein species for cystatin C, cathepsins B and L were performed to evaluate the tissue distribution of these species. Our results indicate that cystatin C is largely synthesized in the RPE and secreted from the basal side. Cathepsin B is the major cysteine protease in the RPE and choroid. The expression of all mRNAs and proteins was elevated by exposure to oxidative stress. (c) 2006 Elsevier Ltd. All rights reserved.
C1 Univ Calif Davis, Sch Med, Dept Ophthalmol, Vitreoretinal Res Lab, Davis, CA 95616 USA.
C3 University of California System; University of California Davis
RP Hjelmeland, LM (通讯作者)，Univ Calif Davis, Sch Med, Dept Ophthalmol, Vitreoretinal Res Lab, 1 Shields Ave, Davis, CA 95616 USA.
EM lmhjelmeland@ucdavis.edu
RI Smit-McBride, Zeljka/F-5524-2010
OI Smit-McBride, Zeljka/0000-0003-0275-8088
FU NATIONAL EYE INSTITUTE [R01EY006473, P30EY012576] Funding Source: NIH
   RePORTER; NEI NIH HHS [P30 EY012576, R01 EY006473, P30 EY 12576, R01 EY
   06473] Funding Source: Medline
CR BARKA T, 1994, ANAT REC, V239, P343, DOI 10.1002/ar.1092390312
   BERNSTEIN HG, 1989, NEUROSCI LETT, V98, P135, DOI 10.1016/0304-3940(89)90498-9
   Bhutto IA, 2004, INVEST OPHTH VIS SCI, V45, P1544, DOI 10.1167/iovs.03-0862
   Braissant O, 1998, ENDOCRINOLOGY, V139, P2748, DOI 10.1210/en.139.6.2748
   BRZIN J, 1984, BIOCHEM BIOPH RES CO, V118, P103, DOI 10.1016/0006-291X(84)91073-8
   CARUSO JA, 2006, J BIOL CHEM
   Ferreras M, 2000, FEBS LETT, V486, P247, DOI 10.1016/S0014-5793(00)02249-3
   Finckh U, 2000, ARCH NEUROL-CHICAGO, V57, P1579, DOI 10.1001/archneur.57.11.1579
   Frohlich E, 2001, GRAEF ARCH CLIN EXP, V239, P25, DOI 10.1007/s004170000218
   Im E, 2005, MOL BIOL CELL, V16, P3488, DOI 10.1091/mbc.E04-11-1029
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kirsner JB., 1995, INFLAMM BOWEL DIS, V1, P2, DOI DOI 10.1002/ibd.3780010103
   Lin C, 2003, CHINESE J PHYSIOL, V46, P111
   Marneros AG, 2004, EMBO J, V23, P89, DOI 10.1038/sj.emboj.7600014
   Niedergethmann M, 2004, PANCREAS, V29, P204, DOI 10.1097/00006676-200410000-00005
   Nishio C, 2000, BRAIN RES, V873, P252, DOI 10.1016/S0006-8993(00)02540-3
   Paraoan L, 2004, TRAFFIC, V5, P884, DOI 10.1111/j.1600-0854.2004.00230.x
   Paraoan L, 2003, EXP EYE RES, V76, P753, DOI 10.1016/S0014-4835(03)00061-7
   Paraoan L, 2001, MOL MEMBR BIOL, V18, P229
   Rheinhardt JM, 2001, J HISTOCHEM CYTOCHEM, V49, P923, DOI 10.1177/002215540104900714
   Wasselius J, 2004, ACTA OPHTHALMOL SCAN, V82, P68, DOI 10.1046/j.1600-0420.2003.00178.x
   Wasselius J, 2003, GRAEF ARCH CLIN EXP, V241, P934, DOI 10.1007/s00417-003-0782-x
   Wasselius J, 2001, INVEST OPHTH VIS SCI, V42, P1901
   Wistow G, 2002, MOL VIS, V8, P196
   Yamada H, 2001, AM J PATHOL, V159, P1113, DOI 10.1016/S0002-9440(10)61787-7
   Zatterstrom UK, 2000, CELL STRUCT FUNCT, V25, P97
NR 26
TC 19
Z9 20
U1 1
U2 4
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0014-4835
EI 1096-0007
J9 EXP EYE RES
JI Exp. Eye Res.
PD SEP
PY 2006
VL 83
IS 3
BP 679
EP 687
DI 10.1016/j.exer.2006.03.009
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 073OD
UT WOS:000239751600026
PM 16684524
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Ivert, L
   Keldbye, H
   Gouras, P
AF Ivert, L
   Keldbye, H
   Gouras, P
TI Age-related changes in the basement membrane of the retinal pigment
   epithelium of Rpe65-/- and wild-type mice
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
ID BASAL LAMINAR DEPOSIT; HIGH-FAT DIET; MACULAR DEGENERATION; FUNDUS
   FLAVIMACULATUS; BRUCHS MEMBRANE; MACACA-MULATTA; ANIMAL-MODEL; MOUSE
   MODEL; MACULOPATHY; DRUSEN
AB Purpose: To investigate unusual changes in the basal surface of the retinal pigment epithelium (RPE) cell layer in aging Rpe65 -/- and wild-type mice. Methods: The retinas of Rpe65 -/- and wild-type mice of different ages - 6 weeks and 3, 6, 12 - 13 and 16 months - were examined by electron microscopy. Results: There was an age-related increase in the width of the basement membrane of both Rpe65 -/- and wild-type mice which was associated with loss of basal infoldings of the plasma membrane of the RPE cells and protrusions of basement membrane material deep into the cytoplasm of these cells. These changes were evident at 6 months of age in RPE65 -/- mice and became extensive at 1 year of age. Similar changes occurred in wild-type mice but were less extensive and were only evident after 1 year of age. Conclusions: There is an age-dependent abnormality that develops at the basal surface of murine RPE cells, which resembles some of the changes observed in human age-related macular degeneration. These changes occur earlier in life and are more extensive in Rpe65 mutant mice.
C1 Karolinska Inst, St Eriks Eye Hosp, Dept Ophthalmol, S-11282 Stockholm, Sweden.
   Columbia Univ, Dept Ophthalmol, New York, NY 10027 USA.
C3 Karolinska Institutet; Columbia University
RP Ivert, L (通讯作者)，Karolinska Inst, St Eriks Eye Hosp, Dept Ophthalmol, Polhemsgatan 50, S-11282 Stockholm, Sweden.
EM lena.ivert@sankterik.se
CR Allikmets R, 1997, SCIENCE, V277, P1805, DOI 10.1126/science.277.5333.1805
   BARNETT KC, 1972, J COMP PATHOL, V82, P117, DOI 10.1016/0021-9975(72)90052-7
   BIRNBACH CD, 1994, OPHTHALMOLOGY, V101, P1211
   Cousins SW, 2003, INVEST OPHTH VIS SCI, V44, P1221, DOI 10.1167/iovs.02-0285
   Cousins SW, 2002, EXP EYE RES, V75, P543, DOI 10.1006/exer.2002.2047
   Curcio CA, 1999, ARCH OPHTHALMOL-CHIC, V117, P329, DOI 10.1001/archopht.117.3.329
   Curcio CA, 2001, INVEST OPHTH VIS SCI, V42, P265
   Dithmar S, 2001, ARCH OPHTHALMOL-CHIC, V119, P1643, DOI 10.1001/archopht.119.11.1643
   EAGLE RC, 1980, OPHTHALMOLOGY, V87, P1189
   ELMOFTY A, 1978, EXP EYE RES, V27, P499, DOI 10.1016/0014-4835(78)90027-1
   ELMOFTY AAM, 1980, EXP EYE RES, V31, P147, DOI 10.1016/0014-4835(80)90075-5
   Engbring JA, 2003, J PATHOL, V200, P465, DOI 10.1002/path.1396
   Erickson AC, 2000, J HISTOCHEM CYTOCHEM, V48, P1291, DOI 10.1177/002215540004801001
   FINE BS, 1978, INVEST OPHTH VIS SCI, V17, P1059
   GOTTSCH JD, 1993, ARCH OPHTHALMOL-CHIC, V111, P126, DOI 10.1001/archopht.1993.01090010130039
   GREEN WR, 1993, OPHTHALMOLOGY, V100, P1519
   GRIMES PA, 1980, EXP EYE RES, V30, P631, DOI 10.1016/0014-4835(80)90062-7
   Hamel CP, 2001, BRIT J OPHTHALMOL, V85, P424, DOI 10.1136/bjo.85.4.424
   Katz ML, 2001, INVEST OPHTH VIS SCI, V42, P3023
   KATZ ML, 1984, EXP EYE RES, V38, P137, DOI 10.1016/0014-4835(84)90098-8
   KLEIN BA, 1967, AM J OPHTHALMOL, V64, P3
   Kliffen M, 2000, BRIT J OPHTHALMOL, V84, P1415, DOI 10.1136/bjo.84.12.1415
   LOEFFLER KU, 1992, ARCH OPHTHALMOL-CHIC, V110, P15
   Loeffler KU, 1998, BRIT J OPHTHALMOL, V82, P1104, DOI 10.1136/bjo.82.10.1104
   LOEFFLER KU, 1986, GRAEFES ARCH CLIN EX, V224, P493
   LOPEZ PF, 1990, OPHTHALMOLOGY, V97, P798
   Majji AB, 2000, INVEST OPHTH VIS SCI, V41, P3936
   MCDONNELL PJ, 1986, OPHTHALMOLOGY, V93, P116
   Miceli MV, 2000, CURR EYE RES, V20, P8, DOI 10.1076/0271-3683(200001)20:1;1-H;FT008
   MISHIMA H, 1981, EXP EYE RES, V33, P75, DOI 10.1016/S0014-4835(81)80083-8
   MISHIMA H, 1978, GRAEFES ARCH CLIN EX, V209, P1
   Rakoczy PE, 2002, AM J PATHOL, V161, P1515, DOI 10.1016/S0002-9440(10)64427-6
   Redmond TM, 1998, NAT GENET, V20, P344, DOI 10.1038/3813
   SARKS SH, 1973, BRIT J OPHTHALMOL, V57, P951, DOI 10.1136/bjo.57.12.951
   Sarks SH, 1999, BRIT J OPHTHALMOL, V83, P358, DOI 10.1136/bjo.83.3.358
   SCHMIDT RE, 1971, VET PATHOL, V8, P28, DOI 10.1177/030098587100800105
   Spraul CW, 1996, INVEST OPHTH VIS SCI, V37, P2724
   Stafford T J, 1974, Mod Probl Ophthalmol, V12, P214
   STEINMETZ RL, 1991, OPHTHALMOLOGY, V98, P953
   VAINISI SJ, 1971, AM J OPHTHALMOL, V78, P279
   VANDERSCHAFT TL, 1991, ARCH OPHTHALMOL-CHIC, V109, P420, DOI 10.1001/archopht.1991.01080030122052
   Zhang D, 2002, BIOGERONTOLOGY, V3, P61, DOI 10.1023/A:1015259413857
NR 42
TC 7
Z9 6
U1 1
U2 2
PU SPRINGER
PI NEW YORK
PA 233 SPRING STREET, NEW YORK, NY 10013 USA
SN 0721-832X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD MAR
PY 2005
VL 243
IS 3
BP 250
EP 256
DI 10.1007/s00417-004-0967-y
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 914LA
UT WOS:000228227900011
PM 15378383
DA 2022-11-30
ER

EF